PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23553037-7	2013	Strikingly, combining anastrozole with the highly selective and allosteric Akt inhibitor MK-2206 or with the mTOR inhibitor rapamycin increased sensitivity to this AI in the control cells and was sufficient to overcome resistance and restore sensitivity to endocrine therapy in the resistant cells.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	109-113
23108404-5	2013	The endoplasmic reticulum Ca(2+) sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin.	Sirolimus	161-170	stromal interaction molecule 1	Homo sapiens	41-71
23924694-7	2013	Map4k4 silencing in cultured adipocytes elevates both the total protein expression and cleavage of sterol-regulated element binding protein-1 (Srebp-1) in a rapamycin-sensitive manner, consistent with Map4k4 signaling via mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	mitogen-activated protein kinase kinase kinase kinase 4	Homo sapiens	0-6
23938603-8	2013	Rapamycin fully inhibited mTORC1 and partially inhibited mTORC2 activities, including the phosphorylation of Akt (serine 473) and PKCalpha, in vascular tumor cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	109-112
23938603-8	2013	Rapamycin fully inhibited mTORC1 and partially inhibited mTORC2 activities, including the phosphorylation of Akt (serine 473) and PKCalpha, in vascular tumor cells.	Sirolimus	0-9	protein kinase C alpha	Homo sapiens	130-138
23918799-8	2013	Moreover, expression of RhoA suppressed axon overelongation mediated by autophagy inhibition, whereas inhibition of the RhoA signaling pathway by Y-27632 recovered rapamycin-mediated suppression of axon growth.	Sirolimus	164-173	ras homolog family member A	Homo sapiens	120-124
23266287-8	2013	The inhibition of GSK-3beta phosphorylation and mTOR was achieved with LY294002 and rapamycin, respectively.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	48-52
23756767-4	2013	In a number of rodent models, the mTOR inhibitor rapamycin induces increased food intake, which is accompanied by increased body weight.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	34-38
23981724-1	2013	Clinical immunosuppression protocols use calcineurin inhibitors, such as cyclosporine A (CsA) or tacrolimus (FK506), or mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (rapamycin).	Sirolimus	177-186	mechanistic target of rapamycin kinase	Homo sapiens	120-149
23981724-1	2013	Clinical immunosuppression protocols use calcineurin inhibitors, such as cyclosporine A (CsA) or tacrolimus (FK506), or mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (rapamycin).	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	151-155
23108404-5	2013	The endoplasmic reticulum Ca(2+) sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin.	Sirolimus	161-170	stromal interaction molecule 1	Homo sapiens	73-78
24044547-3	2013	As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for TSC patients.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	13-17
24044547-3	2013	As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for TSC patients.	Sirolimus	37-46	TSC complex subunit 1	Homo sapiens	113-116
23773767-5	2013	This review explores the relevance of the mTOR pathway to epileptogenesis and its potential as a therapeutic target in epilepsy treatment by presenting the current results on mTOR inhibitors, in particular, rapamycin, in animal models of diverse types of epilepsy.	Sirolimus	207-216	mechanistic target of rapamycin kinase	Homo sapiens	42-46
23773767-5	2013	This review explores the relevance of the mTOR pathway to epileptogenesis and its potential as a therapeutic target in epilepsy treatment by presenting the current results on mTOR inhibitors, in particular, rapamycin, in animal models of diverse types of epilepsy.	Sirolimus	207-216	mechanistic target of rapamycin kinase	Homo sapiens	175-179
24034707-8	2013	Thus, lack of inhibitory NK cell function during allo-specific T cell activation by human ICC + IFN-gamma-stimulated RAPA-DC may represent an unwanted effector mechanism that may underlie RAPA-induced inflammatory events in transplant patients undergoing microbial infection or allograft rejection.	Sirolimus	117-121	interferon gamma	Homo sapiens	96-105
23989949-5	2013	Moreover, PTEN-deficient bladder cancer cells were less sensitive to rapamycin than cells expressing wild-type PTEN, and rapamycin strikingly induced Akt activation in the absence of functional PTEN.	Sirolimus	121-130	AKT serine/threonine kinase 1	Homo sapiens	150-153
24010830-6	2013	We hypothesized that after intercrossing these mice, rapamycin treatment would induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in CGRP+ DRG neurons.	Sirolimus	53-62	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	149-153
23978538-9	2013	Rapamycin nullified the CoCl2-induced up-regulation of RTP801 and attenuated cell death.	Sirolimus	0-9	DNA-damage-inducible transcript 4	Mus musculus	55-61
24023300-1	2013	BACKGROUND: Mammalian Target of Rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have been shown to reduce cutaneous carcinogenesis in organ-transplant recipients requiring for immunosuppressive treatment to prevent from allograft rejection.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	12-41
24023300-1	2013	BACKGROUND: Mammalian Target of Rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have been shown to reduce cutaneous carcinogenesis in organ-transplant recipients requiring for immunosuppressive treatment to prevent from allograft rejection.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	43-47
24265855-1	2013	Functional intracellular Ca(2+) signaling is essential for the upregulation of the canonical mTOR-controlled autophagy pathway triggered by rapamycin or by nutrient deprivation.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	93-97
23971829-4	2013	Ridaforolimus is a non-prodrug analog of rapamycin (sirolimus) with conserved affinity for mTOR but improved solubility, stability and bioavailability when compared with sirolimus.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	91-95
23668915-3	2013	Yet AD, PD, HD and SCA3 are chronic degenerative diseases, and chronic administration of rapamycin at advanced clinical stages may result in deleterious systemic effects due to chronic inhibition of mammalian target of rapamycin (mTOR).	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	199-228
23668915-3	2013	Yet AD, PD, HD and SCA3 are chronic degenerative diseases, and chronic administration of rapamycin at advanced clinical stages may result in deleterious systemic effects due to chronic inhibition of mammalian target of rapamycin (mTOR).	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	230-234
23971829-4	2013	Ridaforolimus is a non-prodrug analog of rapamycin (sirolimus) with conserved affinity for mTOR but improved solubility, stability and bioavailability when compared with sirolimus.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	91-95
23978644-2	2013	Sirolimus, an inhibitor of mTOR, has been reported to decrease the size of angiomyolipomas and stabilize pulmonary function in patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	129-132
24027431-7	2013	Rapamycin, an mTOR inhibitor, induces cell cycle arrest of PCa cells and enhances chemotherapeutic resistance of PCa cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	interleukin 4	Homo sapiens	40-44
23161184-8	2013	Rapamycin, an inhibitor of mTOR, also reversed the effect of citrate in human umbilical vein endothelial cells and sprouting of aortic rings suggesting that the angiogenic effect of citrate involves activation of PI3K-Akt-mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
23161184-8	2013	Rapamycin, an inhibitor of mTOR, also reversed the effect of citrate in human umbilical vein endothelial cells and sprouting of aortic rings suggesting that the angiogenic effect of citrate involves activation of PI3K-Akt-mTOR pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	218-221
23161184-8	2013	Rapamycin, an inhibitor of mTOR, also reversed the effect of citrate in human umbilical vein endothelial cells and sprouting of aortic rings suggesting that the angiogenic effect of citrate involves activation of PI3K-Akt-mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	222-226
23787763-12	2013	Rapamycin in combination with Mino produced synergistic effects on LC3 conversion, reduction of the Akt/mTOR/p70S6K pathway, and glioma cell death.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	100-103
23838998-12	2013	Expression of CD80/CD86 was up-regulated on galectin-9-treated bone marrow-derived DCs, which was reversed by rapamycin.	Sirolimus	110-119	CD80 antigen	Mus musculus	14-18
23838998-12	2013	Expression of CD80/CD86 was up-regulated on galectin-9-treated bone marrow-derived DCs, which was reversed by rapamycin.	Sirolimus	110-119	CD86 antigen	Mus musculus	19-23
23838998-12	2013	Expression of CD80/CD86 was up-regulated on galectin-9-treated bone marrow-derived DCs, which was reversed by rapamycin.	Sirolimus	110-119	lectin, galactose binding, soluble 9	Mus musculus	44-54
23991087-5	2013	Augmentation of T cell replete allografts with manufactured rapamycin resistant Th9 cells markedly reduced both CD4(+) and CD8(+) T cell engraftment and strongly inhibited allo-specific T cell secretion of IFN-gamma.	Sirolimus	60-69	interferon gamma	Mus musculus	206-215
23603434-3	2013	This study revealed that over-expression of ABCG2 in Jurkat and HL60 cells led to an increased SP fraction, up-regulated levels of phosphorylated-PI3K and phosphorylated-Akt, and enhanced drug resistance, all of which could be attenuated by treatment with either the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin.	Sirolimus	313-322	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	44-49
24009738-6	2013	We also show that blocking PLD activity enhanced the sensitivity of PKD cells to rapamycin and that combining PLD inhibitors and rapamycin synergistically inhibited PKD cell proliferation.	Sirolimus	81-90	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	27-30
24009772-5	2013	Additionally rapamycin, a known inhibitor of mTOR-dependent protein synthesis, rescued cells from metformin-induced apoptosis and down-regulated CHOP expression.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	45-49
24009772-5	2013	Additionally rapamycin, a known inhibitor of mTOR-dependent protein synthesis, rescued cells from metformin-induced apoptosis and down-regulated CHOP expression.	Sirolimus	13-22	DNA damage inducible transcript 3	Homo sapiens	145-149
23991179-1	2013	Mammalian target of rapamycin complex 1 and 2 (mTORC1/2) are overactive in colorectal carcinomas; however, the first generation of mTOR inhibitors such as rapamycin have failed to show clinical benefits in treating colorectal carcinoma in part due to their effects only on mTORC1.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	47-51
23648089-4	2013	We find that rapamycin treatment leads to glucose intolerance in both young and old HET3 mice, but in contrast to the previously reported effect of injected rapamycin in C57BL/6 mice, HET3 mice treated with dietary rapamycin responded normally in an insulin tolerance test.	Sirolimus	13-22	insulin	Homo sapiens	250-257
23863152-3	2013	On the other hand, the rapamycin-insensitive mTORC2 responds to the presence of growth factors such as insulin by phosphorylating Akt to promote its maturation and allosteric activation.	Sirolimus	23-32	insulin	Homo sapiens	103-110
23841834-5	2013	Resistance to RAPA treatment correlated with high levels of Akt phosphorylation.	Sirolimus	14-18	AKT serine/threonine kinase 1	Homo sapiens	60-63
23839048-2	2013	For rapamycin, this is achieved by inducing inhibitory ternary complexes with the kinase mTOR.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Homo sapiens	89-93
23668243-3	2013	Studies on a number of ATP-competitive mTOR inhibitors have suggested that these inhibitors have a therapeutic superiority to rapalogs (rapamycin analogs) in a number of cancers.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	39-43
23881200-6	2013	This Review describes the complex mTOR signaling pathways, which control vital cellular functions including mRNA translation, cell proliferation, cell growth, differentiation, angiogenesis, and apoptosis, and examines molecular mechanisms for rapamycin toxicity in beta-cells.	Sirolimus	243-252	mechanistic target of rapamycin kinase	Homo sapiens	34-38
23835553-3	2013	Using a co-culture system of human lipopolysaccharide (LPS)-matured moDCs and allogeneic naive CD4(+) T cells, we show that inhibition of mTOR by the immunosuppressive drug rapamycin reduced moDC maturation and promoted Th2 skewing.	Sirolimus	173-182	CD4 molecule	Homo sapiens	95-98
23480027-2	2013	The aim of this study was to investigate the effect and mechanisms of sirolimus, an inhibitor of the mammalian target of rapamycin, on immune responses in a murine model of Crohn"s disease.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	101-130
23480027-7	2013	The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-alpha, IL-6 and IL-17A.	Sirolimus	27-36	interleukin 6	Mus musculus	136-140
24137226-7	2013	The qPCR assay showed that in the combination group the level of von Willebrand factor (vWF) mRNA was downregulated, while platelet endothelial cell adhesion molecule (PECAM-1) and endothelial nitric oxide synthase (eNOS) mRNAs were upregulated in HCAECs compared with the rapamycin group (P<0.05).	Sirolimus	273-282	von Willebrand factor	Homo sapiens	65-86
24137226-7	2013	The qPCR assay showed that in the combination group the level of von Willebrand factor (vWF) mRNA was downregulated, while platelet endothelial cell adhesion molecule (PECAM-1) and endothelial nitric oxide synthase (eNOS) mRNAs were upregulated in HCAECs compared with the rapamycin group (P<0.05).	Sirolimus	273-282	von Willebrand factor	Homo sapiens	88-91
23835553-3	2013	Using a co-culture system of human lipopolysaccharide (LPS)-matured moDCs and allogeneic naive CD4(+) T cells, we show that inhibition of mTOR by the immunosuppressive drug rapamycin reduced moDC maturation and promoted Th2 skewing.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	138-142
23812052-8	2013	Increased understanding of the genetic cause of the disease and the underlying dysregulation of the mTOR pathway has led to clinical trials of mTOR inhibitors including sirolimus and everolimus.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	100-104
23812052-8	2013	Increased understanding of the genetic cause of the disease and the underlying dysregulation of the mTOR pathway has led to clinical trials of mTOR inhibitors including sirolimus and everolimus.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	143-147
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	Sirolimus	250-259	eukaryotic translation initiation factor 4A1	Homo sapiens	135-140
23884207-0	2013	Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content.	Sirolimus	65-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-128
23884207-1	2013	Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-58
23884207-1	2013	Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	60-64
23702336-6	2013	Similar results were obtained by treatment with the mTOR inhibitor rapamycin.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	52-56
24252673-6	2013	RESULTS: Compared with pre-ITBL optical density (OD) values, there was a significantly increase in IL-2 OD(0.138 +- 0.050 in control group and 0.141 +- 0.052 in sirolimus group), but not FoxP3 and IL-10 OD in both groups at the time ITBLs were diagnosed.	Sirolimus	161-170	interleukin 2	Homo sapiens	99-103
24252673-12	2013	CONCLUSIONS: Sirolimus can downregulate IL-2 expression and upregulate FoxP3 and IL-10 expression, thereby stimulating FoxP3+ Treg cells, suppressing immunopathological damage, and promoting epithelial repair in bile ducts.	Sirolimus	13-22	interleukin 2	Homo sapiens	40-44
23879512-4	2013	The mTOR inhibitor sirolimus is reported to produce resolution of lymphatic abnormalities in LAM, but the efficiacy of the mTOR inhibitor everolimus has not been assessed.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
23722550-2	2013	The mTOR inhibitor rapamycin activates autophagy but paradoxically it also enhances radiosensitivity.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22890326-0	2013	The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBalpha isoform signaling.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
23395884-3	2013	Following the identification and characterization of mTOR-promoting activity in gliomagenesis, data from preclinical studies suggested the targeting of mTOR by rapamycin or its analogs (rapalogs) as a promising therapeutic approach.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	152-156
22890326-0	2013	The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBalpha isoform signaling.	Sirolimus	19-28	AKT serine/threonine kinase 1	Homo sapiens	71-75
22890326-0	2013	The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBalpha isoform signaling.	Sirolimus	19-28	AKT serine/threonine kinase 1	Homo sapiens	76-84
22890326-3	2013	We show that rapamycin selectively upregulates epidermal Akt1, while failing to upregulate epidermal Akt2.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	57-61
22890326-4	2013	Rapamycin increases epidermal Akt1 phosphorylation via inhibition of the mTOR complex 1-dependent regulation of insulin receptor substrate-1.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	30-34
22890326-4	2013	Rapamycin increases epidermal Akt1 phosphorylation via inhibition of the mTOR complex 1-dependent regulation of insulin receptor substrate-1.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-77
22890326-8	2013	We show in skin culture that rapamycin does enhance restoration of Akt1 phosphorylation in skin recovering from UV radiation, suggesting a mechanism for rapamycin"s antitumor activity in epidermis in spite of its efficient immunosuppressive properties.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	67-71
23716625-9	2013	Two weeks after the chemical burn injury, a significant elevation in the corneal IL-6 levels of the positive control group was observed, compared to the levels in the negative control group or the rapamycin group (P < 0.05).	Sirolimus	197-206	interleukin 6	Mus musculus	81-85
23716625-13	2013	Rapamycin protected the cornea from chemical damage via reduction of IL-6 and TGF-beta1 expression.	Sirolimus	0-9	interleukin 6	Mus musculus	69-73
23876886-9	2013	Overexpression of KLF2 strongly reversed rapamycin-induced effects on KLF2, eNOS, TM, TF and PAI-1 expression.	Sirolimus	41-50	Kruppel like factor 2	Homo sapiens	18-22
23580233-9	2013	Moreover, the effect of Mono-Pt involved the AKT1-MTOR-RPS6KB1 pathway and MAPK1 (ERK2)/MAPK3 (ERK1) signaling, since the MTOR inhibitor rapamycin increased, while the MAPK1/3 inhibitor U0126 decreased Mono-Pt-induced autophagic cell death.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	122-126
23580233-9	2013	Moreover, the effect of Mono-Pt involved the AKT1-MTOR-RPS6KB1 pathway and MAPK1 (ERK2)/MAPK3 (ERK1) signaling, since the MTOR inhibitor rapamycin increased, while the MAPK1/3 inhibitor U0126 decreased Mono-Pt-induced autophagic cell death.	Sirolimus	137-146	mitogen-activated protein kinase 1	Homo sapiens	168-173
23876886-9	2013	Overexpression of KLF2 strongly reversed rapamycin-induced effects on KLF2, eNOS, TM, TF and PAI-1 expression.	Sirolimus	41-50	Kruppel like factor 2	Homo sapiens	70-74
23876886-11	2013	CONCLUSIONS: Rapamycin induced an inhibition of KLF2 expression and an imbalance of anti- and pro-thrombotic gene expression, which promoted arterial thrombosis in vivo.	Sirolimus	13-22	Kruppel like factor 2	Homo sapiens	48-52
26120590-5	2013	Interestingly, pharmacological activation of AMPK can prevent activation of mTOR/p70S6K and insulin resistance, while inhibition of mTOR with rapamycin prevents insulin resistance, but not AMPK downregulation.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Homo sapiens	132-136
23300026-0	2013	Rapamycin induces apoptosis when autophagy is inhibited in T-47D mammary cells and both processes are regulated by Phlda1.	Sirolimus	0-9	pleckstrin homology like domain family A member 1	Homo sapiens	115-121
23566837-7	2013	Western blotting showed decreased expression of phosphorylated mTOR and phosphorylated p70S6K in the rapamycin-treated group, and increased the expression of both SIRT1 and SIRT6 compared to the control group (P<0.05).	Sirolimus	101-110	sirtuin 1	Rattus norvegicus	163-168
23499726-4	2013	A pilot trial in 16 ADPKD patients demonstrated that sirolimus, an mTOR inhibitor, reduced PLD volume by 26%.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	67-71
23759595-6	2013	Of note, Rapamycin treatment significantly delayed hepatocarcinogenesis in AKT/Ras mice.	Sirolimus	9-18	thymoma viral proto-oncogene 1	Mus musculus	75-78
23759595-7	2013	However, some microscopic lesions persisted in the livers of AKT/Ras mice despite the treatment and rapidly gave rise to HCC following Rapamycin withdrawal.	Sirolimus	135-144	thymoma viral proto-oncogene 1	Mus musculus	61-64
26120590-5	2013	Interestingly, pharmacological activation of AMPK can prevent activation of mTOR/p70S6K and insulin resistance, while inhibition of mTOR with rapamycin prevents insulin resistance, but not AMPK downregulation.	Sirolimus	142-151	insulin	Homo sapiens	161-168
23478858-9	2013	Either systemic administration or intra-PFC infusion of the mTOR inhibitor rapamycin completely blocked the behavioral effects produced by PCMS in adolescence.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	60-64
23619386-1	2013	Rapamycin is a canonical allosteric inhibitor of the mammalian tarpet of rapamycin (mTOR) kinase with immunosuppressive and proapoptotic activities.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	84-88
23607966-5	2013	The clinically available adenosine monophosphate-activated protein kinase activator, metformin, which is an antidiabetic drug, prevents rapamycin-induced ERK activation and the development of mechanical hypersensitivity and spontaneous pain.	Sirolimus	136-145	mitogen-activated protein kinase 1	Homo sapiens	154-157
24494524-8	2013	Findings provide compelling evidence for beneficial effects of prolonged RPM provision on feed intake, milk production, and reproduction of Holstein cows under concurrent metabolic pressures of early lactation and stressful high ambient temperatures.	Sirolimus	73-76	Weaning weight-maternal milk	Bos taurus	103-107
23739000-5	2013	Preliminary studies in patients affected by tuberous sclerosis and treated with rapamycin or everolimus demonstrated potential benefits in seizure frequency reduction, suggesting that mTOR inhibition could be a promising treatment option for mTORopathies-related epilepsy.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	184-188
23762265-4	2013	Forced expression of miR-99a or rapamycin treatment blocked insulin-induced PKM2 and HIF-1alpha expression, and glucose consumption and lactate production.	Sirolimus	32-41	insulin	Homo sapiens	60-67
23762265-4	2013	Forced expression of miR-99a or rapamycin treatment blocked insulin-induced PKM2 and HIF-1alpha expression, and glucose consumption and lactate production.	Sirolimus	32-41	hypoxia inducible factor 1 subunit alpha	Homo sapiens	85-95
23578333-3	2013	Everolimus is a synthetic, orally available analogue of rapamycin that inhibits the activation of mTOR.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	98-102
23636418-1	2013	Rapamycin is a selective inhibitor of the mammalian target of rapamycin (mTOR), a regulator kinase that integrates growth factors signaling via the phosphoinositide-3-kinase pathway and that has emerged as a novel therapeutic modality in breast cancer (BC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	42-71
23636418-1	2013	Rapamycin is a selective inhibitor of the mammalian target of rapamycin (mTOR), a regulator kinase that integrates growth factors signaling via the phosphoinositide-3-kinase pathway and that has emerged as a novel therapeutic modality in breast cancer (BC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-77
23313213-14	2013	Rapamycin decreased the obstruction induced expression of Col1a1, Col3a1, Eln and Mmp7.	Sirolimus	0-9	collagen type I alpha 1 chain	Rattus norvegicus	58-64
23532091-9	2013	Curcumin induced autophagy and apoptosis in SKN and SK-UT-1 cells, whereas rapamycin, a specific mTOR inhibitor, did not.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	97-101
23730210-6	2013	Rapamycin alone inhibited mTOR signaling of all cancer cell lines tested in vitro and in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	26-30
23730416-2	2013	The goal of this study was to compare the radiosensitizing activities of the allosteric mTOR inhibitor rapamycin with that of the competitive mTOR inhibitor PP242.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	88-92
23730416-3	2013	On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	80-84
23666574-0	2013	Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.	Sirolimus	31-40	neurofibromin 1	Homo sapiens	68-92
23666574-3	2013	The objectives of this study were to estimate sirolimus clearance in a cohort of children with NF1 using data collected in a concentration-guided trial, to evaluate the effect of treatment duration on clearance and dose requirements, and to evaluate the association of sirolimus clearance with patient-specific factors, including age, weight, body surface area (BSA), race, and sex.	Sirolimus	46-55	neurofibromin 1	Homo sapiens	95-98
23666574-4	2013	METHODS: Sirolimus concentration-time data were collected from an ongoing prospective trial in children with NF1.	Sirolimus	9-18	neurofibromin 1	Homo sapiens	109-112
23666574-11	2013	CONCLUSIONS: Sirolimus clearance in children with NF1 is comparable with that in pediatric transplant patients.	Sirolimus	13-22	neurofibromin 1	Homo sapiens	50-53
23666574-15	2013	The updated model will allow PK-guided individualized dosing of sirolimus in patients with NF1.	Sirolimus	64-73	neurofibromin 1	Homo sapiens	91-94
23730416-3	2013	On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	96-100
23730416-3	2013	On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	96-100
23585566-1	2013	Previous evidence from post-mortem Alzheimer disease (AD) brains and drug (especially rapamycin)-oriented in vitro and in vivo models implicated an aberrant accumulation of the mammalian target of rapamycin (mTor) in tangle-bearing neurons in AD brains and its role in the formation of abnormally hyperphosphorylated tau.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	177-206
23585566-1	2013	Previous evidence from post-mortem Alzheimer disease (AD) brains and drug (especially rapamycin)-oriented in vitro and in vivo models implicated an aberrant accumulation of the mammalian target of rapamycin (mTor) in tangle-bearing neurons in AD brains and its role in the formation of abnormally hyperphosphorylated tau.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	208-212
23689085-9	2013	CONCLUSION: A sirolimus-based, CNI-free immunosuppressive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, was associated with high rates of biopsy-confirmed acute rejection compared with CsA-based immunosuppression and is not recommended.	Sirolimus	14-23	interleukin 2	Homo sapiens	131-144
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	64-75
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	175-179
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	175-179
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	227-238
23705901-4	2013	RESULTS: AML cells treated with rapamycin shows a significant decrease in mRNA and protein expression as well as in promoter transcriptional activity of alpha-smooth muscle actin (alpha-SMA) compared to untreated cells.	Sirolimus	32-41	actin alpha 1, skeletal muscle	Homo sapiens	180-189
23724051-9	2013	Unexpectedly, we found that pretreatment with rapamycin, a potent mTOR inhibitor, gradually (i) sensitized animals to KA treatment and (ii) induced gross anatomical changes in the brain.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	66-70
23693095-7	2013	The in vitro and in vivo effect of the mTOR inhibitor rapamycin was also examined in human Hodgkin-lymphoma cell lines.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	39-43
23705901-5	2013	In addition, cells treated with rapamycin significantly decreased the protein expression of the transcription factor YY1.	Sirolimus	32-41	YY1 transcription factor	Homo sapiens	117-120
23705901-6	2013	Rapamycin treatment also results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells.	Sirolimus	0-9	YY1 transcription factor	Homo sapiens	58-61
23705901-7	2013	Moreover, cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the alphaSMA promoter element in nuclear extracts of AML cells.	Sirolimus	29-38	YY1 transcription factor	Homo sapiens	86-89
23705901-7	2013	Moreover, cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the alphaSMA promoter element in nuclear extracts of AML cells.	Sirolimus	29-38	actin alpha 1, skeletal muscle	Homo sapiens	97-105
23686371-5	2013	We observed an association between G6P accumulation, mTOR activation, endoplasmic reticulum (ER) stress, and impaired contractile function, all of which were prevented by pretreating animals with rapamycin (mTOR inhibition) or metformin (AMPK activation).	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	53-57
23536185-0	2013	Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	100-103
23663564-14	2013	Furthermore, the mTOR inhibitor, rapamycin, suppressed BCSCs in vitro and in vivo.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	17-21
24252508-5	2013	This dysregulation of the mTOR downstream signaling cascade is not restricted to the brain but appears to be systemic and can be detected in peripheral lymphocytes as a reduced Rapamycin response.	Sirolimus	177-186	mechanistic target of rapamycin kinase	Homo sapiens	26-30
23536185-5	2013	Inhibition of mammalian target of rapamycin complex 1 (mTORC1), for example with rapamycin, increases Akt phosphorylation while inhibiting mTORC1 signaling.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	102-105
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	125-134	AKT serine/threonine kinase 1	Homo sapiens	143-146
23536185-9	2013	Chemical inhibition of DNA-PK, knockdown or deficiency of DNA-PK catalytic subunit (DNA-PKcs), or knock-out of the DNA-PK component Ku86 inhibited rapamycin-induced Akt phosphorylation.	Sirolimus	147-156	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	23-29
23536185-9	2013	Chemical inhibition of DNA-PK, knockdown or deficiency of DNA-PK catalytic subunit (DNA-PKcs), or knock-out of the DNA-PK component Ku86 inhibited rapamycin-induced Akt phosphorylation.	Sirolimus	147-156	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	58-82
24252508-6	2013	CONCLUSIONS: The dysfunction of the signaling pathways downstream of mTOR may represent a risk factor for Alzheimer"s disease and is independent of the ApoE status of the patients.We have also identified the molecular substrates of the beneficial effects of Rapamycin on the nervous system.	Sirolimus	258-267	mechanistic target of rapamycin kinase	Homo sapiens	69-73
23536185-9	2013	Chemical inhibition of DNA-PK, knockdown or deficiency of DNA-PK catalytic subunit (DNA-PKcs), or knock-out of the DNA-PK component Ku86 inhibited rapamycin-induced Akt phosphorylation.	Sirolimus	147-156	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	84-92
23667674-0	2013	Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury.	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	55-59
23536185-9	2013	Chemical inhibition of DNA-PK, knockdown or deficiency of DNA-PK catalytic subunit (DNA-PKcs), or knock-out of the DNA-PK component Ku86 inhibited rapamycin-induced Akt phosphorylation.	Sirolimus	147-156	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	58-64
23536185-9	2013	Chemical inhibition of DNA-PK, knockdown or deficiency of DNA-PK catalytic subunit (DNA-PKcs), or knock-out of the DNA-PK component Ku86 inhibited rapamycin-induced Akt phosphorylation.	Sirolimus	147-156	AKT serine/threonine kinase 1	Homo sapiens	165-168
23536185-10	2013	Exposure of cancer cells to rapamycin increased DNA-PK activity, and gene silencing-mediated PP2A inhibition attenuated rapamycin-induced DNA-PK activity.	Sirolimus	28-37	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	48-54
23536185-10	2013	Exposure of cancer cells to rapamycin increased DNA-PK activity, and gene silencing-mediated PP2A inhibition attenuated rapamycin-induced DNA-PK activity.	Sirolimus	28-37	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	138-144
23536185-10	2013	Exposure of cancer cells to rapamycin increased DNA-PK activity, and gene silencing-mediated PP2A inhibition attenuated rapamycin-induced DNA-PK activity.	Sirolimus	120-129	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	138-144
23536185-11	2013	Collectively these results suggest that rapamycin induces PP2A-dependent and DNA-PK-mediated Akt phosphorylation.	Sirolimus	40-49	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	77-83
23536185-11	2013	Collectively these results suggest that rapamycin induces PP2A-dependent and DNA-PK-mediated Akt phosphorylation.	Sirolimus	40-49	AKT serine/threonine kinase 1	Homo sapiens	93-96
23558291-5	2013	mTOR inhibition by rapamycin suppresses FBXW7 loss-driven EMT, invasion and stemness.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
23558291-5	2013	mTOR inhibition by rapamycin suppresses FBXW7 loss-driven EMT, invasion and stemness.	Sirolimus	19-28	F-box and WD repeat domain containing 7	Homo sapiens	40-45
23667674-7	2013	These in vivo and in vitro experiments demonstrate that podocyte injury is associated with changes in autophagy levels, and that rapamycin can reduce podocyte injury by increasing autophagy levels via inhibition of the mTOR-ULK1 pathway.	Sirolimus	129-138	unc-51 like autophagy activating kinase 1	Rattus norvegicus	224-228
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	AKT serine/threonine kinase 1	Rattus norvegicus	137-140
23470622-5	2013	Treatment with rapamycin (0.5 muM) or the Akt inhibitor, A-443654 (0.5 muM), reduced FCS-stimulated growth of PA-SMCs from MCT-PH rats to the level in control rats while inhibiting Akt, GSK3, and S6K activation.	Sirolimus	15-24	AKT serine/threonine kinase 1	Rattus norvegicus	181-184
23561805-12	2013	Based on immunohistochemical analyses, populations of alpha-SMA-positive (alpha-SMA(+)) cells, neutrophils, CD3(+) T cells, and macrophages were all decreased in rapamycin-treated allografts versus DMSO controls.	Sirolimus	162-171	actin alpha 2, smooth muscle, aorta	Mus musculus	54-63
23561805-12	2013	Based on immunohistochemical analyses, populations of alpha-SMA-positive (alpha-SMA(+)) cells, neutrophils, CD3(+) T cells, and macrophages were all decreased in rapamycin-treated allografts versus DMSO controls.	Sirolimus	162-171	actin alpha 2, smooth muscle, aorta	Mus musculus	74-83
23403125-11	2013	The induction of S6K2/YY1 complex formation in response to serum stimulation is abolished by pre-treatment of cells with the mTOR inhibitor, rapamycin.	Sirolimus	141-150	ribosomal protein S6 kinase B2	Homo sapiens	17-21
23611130-0	2013	Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	136-140
23611130-0	2013	Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.	Sirolimus	0-9	nuclear receptor subfamily 3 group C member 1	Homo sapiens	189-212
23479136-4	2013	However, SK-Sora cells were more sensitive to rapamycin analogs (>=1 muM) than SK-HEP1 cells.	Sirolimus	46-55	latexin	Homo sapiens	72-75
23479136-7	2013	Second-generation drugs induced more potent growth inhibition than rapamycin analogs at concentrations >0.03 muM in parental cells, SK-Sora, and 786-Suni cells.	Sirolimus	67-76	latexin	Homo sapiens	112-115
23493289-2	2013	We investigated whether rapamycin, an inhibitor of the cell growth regulator mammalian target of rapamycin (mTOR) and effective against other SMC proliferative disorders, is of therapeutic benefit in experimental models of elastin deficiency.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	77-106
23493289-2	2013	We investigated whether rapamycin, an inhibitor of the cell growth regulator mammalian target of rapamycin (mTOR) and effective against other SMC proliferative disorders, is of therapeutic benefit in experimental models of elastin deficiency.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	108-112
23493289-4	2013	Increased mTOR signaling was detected in elastin-deficient aortas of newborn pups that was inhibited by maternal administration of rapamycin.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	10-14
23453973-6	2013	We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	128-132
23403125-11	2013	The induction of S6K2/YY1 complex formation in response to serum stimulation is abolished by pre-treatment of cells with the mTOR inhibitor, rapamycin.	Sirolimus	141-150	YY1 transcription factor	Homo sapiens	22-25
23403125-11	2013	The induction of S6K2/YY1 complex formation in response to serum stimulation is abolished by pre-treatment of cells with the mTOR inhibitor, rapamycin.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	125-129
23515290-11	2013	Rapamycin completely blocked the effects of TGF-beta and PGE2 on phosphorylation of p70S6K and S6 but not on AKT phosphorylation.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	44-52
23305067-2	2013	It has been reported that autophagic flux is altered in patients with AD, and application of the autophagy enhancer rapamycin may alleviate the cognitive impairment and amyloid-beta (Abeta) neuropathology in transgenic animal model of AD.	Sirolimus	116-125	amyloid beta precursor protein	Homo sapiens	169-181
23515290-13	2013	Pretreatment with L161982 or AH23848 blocked the stimulatory effects of PGE2 and TGF-beta on cell migration, whereas LY294002 or rapamycin completely eliminated PGE2, TGF-beta, and epidermal growth factor-induced migration in PC3 cells.	Sirolimus	129-138	transforming growth factor beta 1	Homo sapiens	167-175
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	tumor necrosis factor	Mus musculus	77-86
23557796-4	2013	This is supported by the findings that intracellular Ca(2+) chelator (BAPTA/AM) or mTOR inhibitor (rapamycin) abolished the events.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	83-87
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	thymoma viral proto-oncogene 1	Mus musculus	176-179
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	mono-ADP ribosylhydrolase 1	Mus musculus	183-188
23492884-0	2013	Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.	Sirolimus	146-155	gastrin releasing peptide receptor	Homo sapiens	48-82
23395818-5	2013	Rapamycin effectively inhibits mTOR in all phases of CML, but does not reduce number of LSC-enriched CD34(+) blast crisis (BC) cells, neither alone nor in combination with imatinib in CML-BC cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-35
23577651-2	2013	Furthermore, as mTOR is widely expressed, rapamycin (a macrolide antibiotic produced by Streptomyces hygroscopicus) is recommended in patients presenting neoplasia due to its antiproliferative actions.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	16-20
23492884-7	2013	RESULTS: Stable expression of GRPr was maintained after rapamycin treatment with doses up to 4 mg/kg in vivo.	Sirolimus	56-65	gastrin releasing peptide receptor	Homo sapiens	30-34
23443316-2	2013	Rapamycin and TGF-beta synergistically induce G1 cell-cycle arrest in several cell lines with intact TGF-beta signaling pathway, which protects cells from the apoptotic effects of rapamycin during S-phase of the cell cycle.	Sirolimus	180-189	transforming growth factor beta 1	Homo sapiens	101-109
23426956-10	2013	Rosuvastatin alone did not alter phosphorylation of S6 and extracellular signal-regulated kinase (ERK), and at the higher concentration, rosuvastatin and rapamycin slightly decreased ERK phosphorylation.	Sirolimus	154-163	mitogen-activated protein kinase 1	Homo sapiens	183-186
23434829-11	2013	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	Sirolimus	127-136	ATP binding cassette subfamily B member 1	Homo sapiens	153-157
23443316-4	2013	However, if TGF-beta signaling is defective, rapamycin induced apoptosis in both the presence and absence of serum/TGF-beta in colon and breast cancer cell lines.	Sirolimus	45-54	transforming growth factor beta 1	Homo sapiens	12-20
23443316-4	2013	However, if TGF-beta signaling is defective, rapamycin induced apoptosis in both the presence and absence of serum/TGF-beta in colon and breast cancer cell lines.	Sirolimus	45-54	transforming growth factor beta 1	Homo sapiens	115-123
23443316-0	2013	Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	15-18
23443316-2	2013	Rapamycin and TGF-beta synergistically induce G1 cell-cycle arrest in several cell lines with intact TGF-beta signaling pathway, which protects cells from the apoptotic effects of rapamycin during S-phase of the cell cycle.	Sirolimus	180-189	transforming growth factor beta 1	Homo sapiens	14-22
23443316-5	2013	Because genetic dysregulation of TGF-beta signaling is commonly observed in pancreatic cancers-with defects in the Smad4 gene being most prevalent, we hypothesized that pancreatic cancers would display a synthetic lethality to rapamycin in the presence of serum/TGF-beta.	Sirolimus	227-236	transforming growth factor beta 1	Homo sapiens	33-41
23443316-7	2013	Rapamycin also induced elevated phosphorylation of the survival kinase Akt at Ser473.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	71-74
23443316-8	2013	Suppression of rapamycin-induced Akt phosphorylation restored rapamycin sensitivity in Smad4-null, but not Smad4 wild-type pancreatic cancer cells.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	33-36
23443316-8	2013	Suppression of rapamycin-induced Akt phosphorylation restored rapamycin sensitivity in Smad4-null, but not Smad4 wild-type pancreatic cancer cells.	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	33-36
23443316-9	2013	This study shows that the synthetic lethality to rapamycin in pancreatic cancers with defective TGF-beta signaling is masked by rapamycin-induced increases in Akt phosphorylation.	Sirolimus	49-58	transforming growth factor beta 1	Homo sapiens	96-104
23443316-9	2013	This study shows that the synthetic lethality to rapamycin in pancreatic cancers with defective TGF-beta signaling is masked by rapamycin-induced increases in Akt phosphorylation.	Sirolimus	49-58	AKT serine/threonine kinase 1	Homo sapiens	159-162
23443316-9	2013	This study shows that the synthetic lethality to rapamycin in pancreatic cancers with defective TGF-beta signaling is masked by rapamycin-induced increases in Akt phosphorylation.	Sirolimus	128-137	transforming growth factor beta 1	Homo sapiens	96-104
23443316-9	2013	This study shows that the synthetic lethality to rapamycin in pancreatic cancers with defective TGF-beta signaling is masked by rapamycin-induced increases in Akt phosphorylation.	Sirolimus	128-137	AKT serine/threonine kinase 1	Homo sapiens	159-162
23548622-1	2013	PURPOSE: To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA).	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	80-84
23601105-2	2013	Switching from cyclosporine to the mTOR inhibitor rapamycin is reported to promote KS regression without allograft rejection.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
23601105-3	2013	Examining the underlying molecular basis for this clinical observation, we find that KSHV infection selectively upregulates mTOR signaling in primary human lymphatic endothelial cells (LECs), but not blood endothelial cells (BECs), and sensitizes LECs to rapamycin-induced apoptosis.	Sirolimus	255-264	mechanistic target of rapamycin kinase	Homo sapiens	124-128
23595747-8	2013	Axonal application of LY294002, a phosphoinositide3-kinase inhibitor, or rapamycin, an mTOR inhibitor, abolished axonal outgrowth enhanced by overexpression of the miR-17-92 cluster.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	87-91
23593290-6	2013	A cohort of FC PIK3ca mice were treated with rapamycin at a dose of 6 mg/kg/day or placebo for 14 days.	Sirolimus	45-54	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	15-21
23426943-2	2013	To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4(+) Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy.	Sirolimus	82-91	CD4 molecule	Homo sapiens	108-111
23562079-5	2013	As a consequence, both genetic and pharmacological inhibition of ERRalpha activity exacerbates hepatic hyperlipidemia observed in rapamycin-treated mice.	Sirolimus	130-139	estrogen related receptor, alpha	Mus musculus	65-73
23591341-9	2013	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P<0.01).	Sirolimus	293-302	mechanistic target of rapamycin kinase	Homo sapiens	53-57
23461852-8	2013	Treatment with sirolimus significantly decreased the arthritic lesions (P<0.001) and paw swelling (P<0.05), alleviated the histological features in the metacarpophalangeal joint, resulted in antihyperalgesic and antiallodynic effects without affecting the locomotor activity and prevented the increased spinal cord TNF-alpha level (P<0.05).	Sirolimus	15-24	tumor necrosis factor	Rattus norvegicus	321-330
23461852-9	2013	It seems that prevention of the increased TNF-alpha expression in the spinal cord may partially contribute to the antihyperalgesic effect of sirolimus in adjuvant arthritic rats and sirolimus could be a promising immunosupressive agent in the treatment of arthritic pain.	Sirolimus	141-150	tumor necrosis factor	Rattus norvegicus	42-51
23274896-8	2013	The mammalian target of rapamycin (mTOR) kinase inhibitor Torin1 mimicked the rapamycin effects on autophagy and stress, indicating that the beneficial effects of rapamycin are indeed mediated via inhibition of mTOR.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
23403511-5	2013	Under normoxia, we found that rapamycin (100 nM) induced an increase of pCREB that was prevented by mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or cAMP-dependent protein kinase (PKA) inhibitor H89.	Sirolimus	30-39	mitogen-activated protein kinase kinase 7	Homo sapiens	100-132
23403511-5	2013	Under normoxia, we found that rapamycin (100 nM) induced an increase of pCREB that was prevented by mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or cAMP-dependent protein kinase (PKA) inhibitor H89.	Sirolimus	30-39	mitogen-activated protein kinase kinase 7	Homo sapiens	134-137
23403511-5	2013	Under normoxia, we found that rapamycin (100 nM) induced an increase of pCREB that was prevented by mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126 or cAMP-dependent protein kinase (PKA) inhibitor H89.	Sirolimus	30-39	mitogen-activated protein kinase 1	Homo sapiens	178-181
23403511-9	2013	Under hypoxia, rapamycin effectively prevented the hypoxia-induced increase of pCREB, Bcl-2, and VEGF-A.	Sirolimus	15-24	BCL2 apoptosis regulator	Homo sapiens	86-91
23403511-9	2013	Under hypoxia, rapamycin effectively prevented the hypoxia-induced increase of pCREB, Bcl-2, and VEGF-A.	Sirolimus	15-24	vascular endothelial growth factor A	Homo sapiens	97-103
23403511-10	2013	Our study demonstrated that rapamycin might be less effective in treating OSA cells under normoxia and provided the rationale for a combination of rapamycin and MEK/ERK inhibitor in the treatment of OSA.	Sirolimus	28-37	mitogen-activated protein kinase kinase 7	Homo sapiens	161-164
23403511-10	2013	Our study demonstrated that rapamycin might be less effective in treating OSA cells under normoxia and provided the rationale for a combination of rapamycin and MEK/ERK inhibitor in the treatment of OSA.	Sirolimus	28-37	mitogen-activated protein kinase 1	Homo sapiens	165-168
23416162-8	2013	When treated with the PI3K/AKT/mTOR pathway inhibitor rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responded with increased lipid content and a more differentiated gene expression profile.	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	27-30
23416162-8	2013	When treated with the PI3K/AKT/mTOR pathway inhibitor rapamycin alone or in combination with the multikinase inhibitor sorafenib, all xenografts responded with increased lipid content and a more differentiated gene expression profile.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	31-35
23274896-8	2013	The mammalian target of rapamycin (mTOR) kinase inhibitor Torin1 mimicked the rapamycin effects on autophagy and stress, indicating that the beneficial effects of rapamycin are indeed mediated via inhibition of mTOR.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	211-215
22927055-4	2013	Preliminary reports have indicated that the mTOR inhibitors sirolimus and related drugs have activity in some patients with non-TSC-associated PEComa.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	44-48
22927055-4	2013	Preliminary reports have indicated that the mTOR inhibitors sirolimus and related drugs have activity in some patients with non-TSC-associated PEComa.	Sirolimus	60-69	TSC complex subunit 1	Homo sapiens	128-131
23523459-1	2013	OBJECTIVES: This study sought to compare the efficacy and safety results after coronary implantation of a combined sirolimus-eluting CD34 antibody coated Combo stent (OrbusNeich Medical, Ft. Lauderdale, Florida) with the paclitaxel-eluting Taxus Liberte stent (PES) (Boston Scientific, Natick, Massachusetts).	Sirolimus	115-124	CD34 molecule	Homo sapiens	133-137
23532775-9	2013	While ND-huCASMCs exhibited the normal increase in p27(Kip1) in response to rapamycin treatment, the DM-huCASMCs did not.	Sirolimus	76-85	dynactin subunit 6	Homo sapiens	51-54
23404111-0	2013	Hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells.	Sirolimus	26-35	chromosome 2 open reading frame 68	Homo sapiens	0-7
23404111-2	2013	The effect of rapamycin treatment on hcrcn81 expression was evaluated by examining the mRNA and protein expression of hcrcn81 in rapamycin-treated human colon carcinoma cell lines, SW480 and LoVo, using real-time PCR and western blot analysis, respectively.	Sirolimus	14-23	chromosome 2 open reading frame 68	Homo sapiens	37-44
23404111-2	2013	The effect of rapamycin treatment on hcrcn81 expression was evaluated by examining the mRNA and protein expression of hcrcn81 in rapamycin-treated human colon carcinoma cell lines, SW480 and LoVo, using real-time PCR and western blot analysis, respectively.	Sirolimus	14-23	chromosome 2 open reading frame 68	Homo sapiens	118-125
23404111-2	2013	The effect of rapamycin treatment on hcrcn81 expression was evaluated by examining the mRNA and protein expression of hcrcn81 in rapamycin-treated human colon carcinoma cell lines, SW480 and LoVo, using real-time PCR and western blot analysis, respectively.	Sirolimus	129-138	chromosome 2 open reading frame 68	Homo sapiens	37-44
23404111-2	2013	The effect of rapamycin treatment on hcrcn81 expression was evaluated by examining the mRNA and protein expression of hcrcn81 in rapamycin-treated human colon carcinoma cell lines, SW480 and LoVo, using real-time PCR and western blot analysis, respectively.	Sirolimus	129-138	chromosome 2 open reading frame 68	Homo sapiens	118-125
23404111-3	2013	The results demonstrated that mRNA and protein levels of hcrcn81 were elevated following rapamycin treatment in these cell lines, indicating that hcrcn81 expression is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells.	Sirolimus	89-98	chromosome 2 open reading frame 68	Homo sapiens	57-64
23404111-3	2013	The results demonstrated that mRNA and protein levels of hcrcn81 were elevated following rapamycin treatment in these cell lines, indicating that hcrcn81 expression is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells.	Sirolimus	89-98	chromosome 2 open reading frame 68	Homo sapiens	146-153
23358420-7	2013	FKBP51 could also enable the rapamycin-induced hyperphosphorylation of Akt, which depended on higher FKBP levels than rapamycin-induced inhibition of S6K phosphorylation.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	71-74
23512499-9	2013	As with rapamycin, cardamonin inhibited the activity of the mammalian target of rapamycin and S6 kinase 1, decreased the Ser 636/639 phosphorylation of insulin receptor substrate-1 and increased the activation of protein kinase B.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	60-89
23662044-2	2013	Rapamycin (RPM), a specific inhibitor of mTOR, exhibits potent and broad in vitro and in vivo antitumor activity against leukemia, breast cancer, and melanoma.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	41-45
23662044-2	2013	Rapamycin (RPM), a specific inhibitor of mTOR, exhibits potent and broad in vitro and in vivo antitumor activity against leukemia, breast cancer, and melanoma.	Sirolimus	11-14	mechanistic target of rapamycin kinase	Homo sapiens	41-45
23482748-0	2013	Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	46-50
23479645-9	2013	Application of the mTOR inhibitor rapamycin prevented post-hypoxic seizure impairment of homeostasis, suggesting that homeostatic plasticity mechanisms may be potentially modifiable therapeutic targets in epileptogenesis.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
23312829-3	2013	Everolimus, a rapamycin derivative, inhibits the mTOR pathway by acting on the mTOR complex 1.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	49-53
23312829-3	2013	Everolimus, a rapamycin derivative, inhibits the mTOR pathway by acting on the mTOR complex 1.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	79-83
23555162-7	2013	Additionally, involvement of the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway was also detected by Western blotting.	Sirolimus	98-107	AKT serine/threonine kinase 1	Homo sapiens	70-73
23555162-7	2013	Additionally, involvement of the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway was also detected by Western blotting.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	109-113
23228564-7	2013	FK506 and rapamycin reduced the association between TRPC1 and Orai1 with FK506 binding protein (52) (FKBP52) in human platelets, and between TRPC1 and the type II IP(3)R, which association is known to be crucial for the maintenance of SOCE in human platelets.	Sirolimus	10-19	FKBP prolyl isomerase 4	Homo sapiens	101-107
23644232-6	2013	mTOR inhibitors, such as rapamycin and its analogs, may represent novel, rational therapies for a variety of neurological disorders.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
23080369-7	2013	Rapamycin also inhibited the RB of healthy PMNs, which was associated with impaired phosphorylation of the NOX2 component, p47phox (phox: phagocyte oxidase), on its mitogen-activated protein kinase (MAPK) site (S345) as well as a preferential inhibition of p38-MAPK relative to p44/42-MAPK.	Sirolimus	0-9	mitogen-activated protein kinase 14	Homo sapiens	257-260
23297825-2	2013	The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is in sensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	232-261
23252795-2	2013	The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR signaling, including rapalogs (sirolimus, temsirolimus, everolimus and deforolimus), which complex with FK506-binding protein 12 (FK-BP12) to inhibit mTOR complex 1 (MTORC1) activity in an allosteric manner, or the more recent ATP-competitive mTOR inhibitors (mTORi), which target the catalytic site of the enzyme.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	99-103
23252795-2	2013	The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR signaling, including rapalogs (sirolimus, temsirolimus, everolimus and deforolimus), which complex with FK506-binding protein 12 (FK-BP12) to inhibit mTOR complex 1 (MTORC1) activity in an allosteric manner, or the more recent ATP-competitive mTOR inhibitors (mTORi), which target the catalytic site of the enzyme.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	99-103
23252795-2	2013	The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR signaling, including rapalogs (sirolimus, temsirolimus, everolimus and deforolimus), which complex with FK506-binding protein 12 (FK-BP12) to inhibit mTOR complex 1 (MTORC1) activity in an allosteric manner, or the more recent ATP-competitive mTOR inhibitors (mTORi), which target the catalytic site of the enzyme.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	99-103
23395931-11	2013	Inhibition of mTOR with rapamycin decreased NF-kappaB activation resulting in increased Bnip3 expression and cell death.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
23395931-11	2013	Inhibition of mTOR with rapamycin decreased NF-kappaB activation resulting in increased Bnip3 expression and cell death.	Sirolimus	24-33	BCL2 interacting protein 3	Homo sapiens	88-93
23044764-7	2013	Therefore, the inhibition of mTOR kinase activity in glial cells results in anti-inflammatory actions, suggesting possible beneficial effects of mTOR inhibitors (like rapamycin) in the treatment of inflammatory-based pathologies of the central nervous system.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	29-33
23044764-7	2013	Therefore, the inhibition of mTOR kinase activity in glial cells results in anti-inflammatory actions, suggesting possible beneficial effects of mTOR inhibitors (like rapamycin) in the treatment of inflammatory-based pathologies of the central nervous system.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	145-149
23879996-8	2013	RT-PCR showed that the expression of mTOR mRNA was lower in OSCs treated with 100 nmol/L rapamycin (0.961 +- 0.060) than that with 0 nmol/L rapamycin (1.654 +- 0.246, P < 0.05).	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	37-41
23121022-2	2013	We recently showed that rapamycin halts the progression of Alzheimer"s (AD)-like deficits, reduces amyloid-beta (Abeta) and induces autophagy in the human amyloid precursor protein (PDAPP) mouse model.	Sirolimus	24-33	amyloid beta precursor protein	Homo sapiens	99-111
23121022-2	2013	We recently showed that rapamycin halts the progression of Alzheimer"s (AD)-like deficits, reduces amyloid-beta (Abeta) and induces autophagy in the human amyloid precursor protein (PDAPP) mouse model.	Sirolimus	24-33	amyloid beta precursor protein	Homo sapiens	155-180
23283642-0	2013	Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	23-27
23283642-1	2013	We previously demonstrated in prostate cancer cells that a phytochemical-perillyl alcohol-and the mechanistic target of rapamycin (mTOR) inhibitor rapamycin rapidly attenuated telomerase activity.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	131-135
23283642-7	2013	Perillyl alcohol or rapamycin caused rapid dissociation of the captured hTERT-mTOR-RAPTOR complex, establishing an additional mechanism by which these agents decrease telomerase activity.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	78-82
23555298-4	2013	Expectedly, our subjects exhibited a marked range of hypertrophic responses (3% to +28%), and when applying Ingenuity Pathway Analysis (IPA) up-stream analysis to ~580 genes that co-varied with gain in lean mass, we identified rapamycin (mTOR) signaling associating with growth (P = 1.4 x 10(-30)).	Sirolimus	227-236	mechanistic target of rapamycin kinase	Homo sapiens	238-242
23328844-9	2013	The impact of TGF-beta/Smad3 signals on T-cell activation was similar to that of the mTOR inhibitor Rapamycin.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	85-89
23357480-7	2013	The above effects of rapamycin were prevented by pretreatment with the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126.	Sirolimus	21-30	mitogen-activated protein kinase kinase 7	Homo sapiens	71-103
23357480-7	2013	The above effects of rapamycin were prevented by pretreatment with the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) inhibitor U0126.	Sirolimus	21-30	mitogen-activated protein kinase kinase 7	Homo sapiens	105-108
23426399-2	2013	For in vitro experiments, NCI-H358, a human lung adenocarcinoma cell line, was co-cultured with immortalized astrocytes, and treated with rapamycin, an mTOR inhibitor.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	152-156
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	interleukin 3	Mus musculus	6-10
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	interleukin 6	Mus musculus	12-16
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	tumor necrosis factor	Mus musculus	18-27
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	mast cell protease 1	Mus musculus	45-50
23364979-5	2013	Furthermore, we also found that TGF-beta1-induced mTOR and p70S6K phosphorylation were significantly down-regulated by rapamycin.	Sirolimus	119-128	transforming growth factor beta 1	Homo sapiens	32-41
23364979-5	2013	Furthermore, we also found that TGF-beta1-induced mTOR and p70S6K phosphorylation were significantly down-regulated by rapamycin.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	50-54
23364979-7	2013	CONCLUSION: These results indicate that rapamycin effectively suppresses TGF-beta1-induced type III collagen and fibronectin levels in primary human lung fibroblasts partly through the mTOR/p70S6K pathway.	Sirolimus	40-49	transforming growth factor beta 1	Homo sapiens	73-82
23364979-7	2013	CONCLUSION: These results indicate that rapamycin effectively suppresses TGF-beta1-induced type III collagen and fibronectin levels in primary human lung fibroblasts partly through the mTOR/p70S6K pathway.	Sirolimus	40-49	fibronectin 1	Homo sapiens	113-124
23364979-7	2013	CONCLUSION: These results indicate that rapamycin effectively suppresses TGF-beta1-induced type III collagen and fibronectin levels in primary human lung fibroblasts partly through the mTOR/p70S6K pathway.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	185-189
23879996-8	2013	RT-PCR showed that the expression of mTOR mRNA was lower in OSCs treated with 100 nmol/L rapamycin (0.961 +- 0.060) than that with 0 nmol/L rapamycin (1.654 +- 0.246, P < 0.05).	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	37-41
23361299-6	2013	Using an ex vivo platform, we identified putative responders to rapamycin, an mTOR inhibitor in these tumors.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	78-82
23261661-2	2013	Rapamycin is a powerful mTOR inhibitor and strong autophagy inducer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	24-28
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	F-box and WD-40 domain protein 7	Mus musculus	193-198
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	F-box and WD-40 domain protein 7	Mus musculus	193-198
23393364-1	2013	BACKGROUND: Sirolimus is a potent blocker of mammalian target of Rapamycin (MTOR), with anti proliferative activity.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	45-74
23393364-1	2013	BACKGROUND: Sirolimus is a potent blocker of mammalian target of Rapamycin (MTOR), with anti proliferative activity.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	76-80
23153588-6	2013	An mTOR inhibitor, rapamycin also inhibited ABCA1, with IC(50) of 18.8muM.	Sirolimus	19-28	phospholipid-transporting ATPase ABCA1	Mesocricetus auratus	44-49
23446718-8	2013	Antagonism of the mTOR pathway with rapamycin and everolimus may provide new therapeutic options for these TSC patients.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	18-22
23446718-8	2013	Antagonism of the mTOR pathway with rapamycin and everolimus may provide new therapeutic options for these TSC patients.	Sirolimus	36-45	TSC complex subunit 1	Homo sapiens	107-110
23261705-4	2013	Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	Sirolimus	42-51	insulin	Homo sapiens	66-73
23261705-6	2013	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin.	Sirolimus	150-159	insulin	Homo sapiens	13-20
23261705-6	2013	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin.	Sirolimus	150-159	cyclin D3	Homo sapiens	114-119
23108236-3	2013	We have recently shown that rapamycin administration at the early pathological stage of a mouse model with frontotemporal lobar dementia (FTLD-U) characterized with cytoplasmic TARDBP/TDP-43(+)/ubiquitin(+) inclusions (UBIs) in the diseased neurons could rescue the learning/memory deficiency and the abnormal motor function disorder of the mice.	Sirolimus	28-37	TAR DNA binding protein	Mus musculus	177-183
23108236-3	2013	We have recently shown that rapamycin administration at the early pathological stage of a mouse model with frontotemporal lobar dementia (FTLD-U) characterized with cytoplasmic TARDBP/TDP-43(+)/ubiquitin(+) inclusions (UBIs) in the diseased neurons could rescue the learning/memory deficiency and the abnormal motor function disorder of the mice.	Sirolimus	28-37	TAR DNA binding protein	Mus musculus	184-190
23361299-7	2013	However, rapamycin did not induce antitumor effect in the majority of tumors with activated mTOR, potentially attributable to the observation that rapamycin induces feedback activation of AKT.	Sirolimus	147-156	AKT serine/threonine kinase 1	Homo sapiens	188-191
22875246-0	2013	Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	62-67
23305836-4	2013	Although FKBP12 was first identified as the principal intracellular target for the immunosuppressive drugs, FK506 and rapamycin, new insights into the role of FKBPs have since emerged.	Sirolimus	118-127	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	9-15
22875246-3	2013	We investigated the activation of the AKT/mTOR pathway in CC cell lines with different degrees of dedifferentiation and found that rapamycin could suppress the motility and the peritoneal dissemination of sarcomatoid SCK cells.	Sirolimus	131-140	thymoma viral proto-oncogene 1	Mus musculus	38-41
22875246-7	2013	The overexpression of STAT3 S727A lacking the phosphorylation site resulted in significantly less sensitivity to rapamycin than the overexpression of STAT3 WT.	Sirolimus	113-122	signal transducer and activator of transcription 3	Mus musculus	22-27
23255002-0	2013	Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	32-35
23255002-3	2013	Activated Akt induced by rapamycin has been suggested to attenuate the growth-inhibitory effects of rapamycin, serving as a negative feedback mechanism.	Sirolimus	25-34	AKT serine/threonine kinase 1	Homo sapiens	10-13
23255002-4	2013	In this study, we found that cotylenin A could suppress rapamycin-induced phosphorylation of Akt (Ser473) in MCF-7 cells and lung carcinoma A549 cells and that cotylenin A also enhanced the rapamycin-induced growth inhibition of MCF-7 and A549 cells.	Sirolimus	56-65	AKT serine/threonine kinase 1	Homo sapiens	93-96
23255002-4	2013	In this study, we found that cotylenin A could suppress rapamycin-induced phosphorylation of Akt (Ser473) in MCF-7 cells and lung carcinoma A549 cells and that cotylenin A also enhanced the rapamycin-induced growth inhibition of MCF-7 and A549 cells.	Sirolimus	190-199	AKT serine/threonine kinase 1	Homo sapiens	93-96
23255002-6	2013	We also found that the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) or arsenic trioxide (ATO) in combination with rapamycin markedly inhibited the growth of MCF-7 cells and 17-AAG or ATO suppressed rapamycin-induced phosphorylation of Akt.	Sirolimus	133-142	AKT serine/threonine kinase 1	Homo sapiens	254-257
23255002-7	2013	The PI3K inhibitor LY294002 also suppressed rapamycin-induced phosphorylation of Akt and combined treatment showed synergistic growth inhibition of MCF-7 cells.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	81-84
23255002-8	2013	Rapamycin inhibited growth more significantly in Akt siRNA-transfected MCF-7 cells than in control siRNA-transfected MCF-7 cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	49-52
23215724-8	2013	Rapamycin derivatives have been studied in Phase II / III clinical trials in breast cancer, and these derivatives achieved positive results in the treatment of metastatic breast cancer when combined with endocrine therapy or HER2-targeted therapies.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	225-229
22930581-5	2013	We proposed that the use of dual inhibitors of PI3K and mTOR could be a promising approach to more efficiently inhibit the PI3K/Akt pathway than rapamycin or PI3K inhibitor alone and produce better treatment outcome.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	56-60
22930581-5	2013	We proposed that the use of dual inhibitors of PI3K and mTOR could be a promising approach to more efficiently inhibit the PI3K/Akt pathway than rapamycin or PI3K inhibitor alone and produce better treatment outcome.	Sirolimus	145-154	AKT serine/threonine kinase 1	Homo sapiens	128-131
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	histone deacetylase 2	Homo sapiens	197-202
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	histone deacetylase 6	Homo sapiens	204-209
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	sirtuin 4	Homo sapiens	253-258
23160140-1	2013	Cyclosporin A (CsA), tacrolimus and rapamycin are immunosuppressive agents (IAs) associated with insulin resistance and dyslipidemia, although their molecular effects on lipid metabolism in adipose tissue are unknown.	Sirolimus	36-45	insulin	Homo sapiens	97-104
23160140-7	2013	These findings suggest that CsA, tacrolimus and rapamycin enhance lipolysis, inhibit lipid storage and expression of lipogenic genes in adipose tissue, which may contribute to the development of dyslipidemia and insulin resistance associated with immunosuppressive therapy.	Sirolimus	48-57	insulin	Homo sapiens	212-219
22370634-0	2013	MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.	Sirolimus	46-55	ATPase, Cu++ transporting, alpha polypeptide	Mus musculus	0-3
23222818-11	2013	Furthermore, the mTOR inhibitor sirolimus strongly inhibited alloresponses in vitro, whereas it did not affect CMV-specific responses.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	17-21
23222894-6	2013	Rapamycin, but not tacrolimus, induced a pro-antitumor phenotypic shift from CD62LCD44 effector memory Tc cells to CD62LCD44 central memory Tc cells, which featured up-regulated levels of T-bet and Eomes and preserved levels of interferon-gamma and perforin.	Sirolimus	0-9	interferon gamma	Mus musculus	228-244
23184930-8	2013	Furthermore, in contrast to Gln3, rapamycin-elicited Ure2 dephosphorylation occurred independently of Sit4 and Pph21/22 (PP2A) as well as Siw14, Ptc1, and Ppz1.	Sirolimus	34-43	patched 1	Homo sapiens	145-149
23079231-0	2013	Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	45-49
23079231-2	2013	Whereas the antiproliferative effect of sirolimus is mainly mediated by inhibition of mTOR, curcumin is described to affect many molecular targets which makes it unpredictable to appraise if the effects of these both substances on cell proliferation and especially on immunosuppression are additive or synergistic.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	86-90
24319682-4	2013	The noncoding RNA growth arrest specific transcript 5 (GAS5) has recently been shown to play a key role in growth arrest induced by several mechanisms, including serum withdrawal and treatment with the mTOR inhibitor rapamycin.	Sirolimus	217-226	mechanistic target of rapamycin kinase	Homo sapiens	202-206
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Sirolimus	208-217	solute carrier family 8 member A1	Homo sapiens	76-80
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Sirolimus	208-217	solute carrier family 8 member A3	Homo sapiens	281-285
23224887-6	2013	Rapamycin reduces NCX2 and NCX3 transport activity but has no effect on their surface expression or total cell NCX protein expression suggesting that, although it shares a common receptor FKBP with FK506, its mode of action follows a different pathway.We are showing now that the large cytosolic loop of NCX1, NCX2, and NCX3 is involved in acquisition of immunosuppressive drug specificity: truncation of the large cytosolic loop of NCX1 renders the protein sensitive to FK506.	Sirolimus	0-9	solute carrier family 8 member A3	Homo sapiens	27-31
23370361-10	2013	Pristimerin inhibited migration and invasion of cells, and co-treatment with the mTOR inhibitor rapamycin additionally suppressed these activities.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	81-85
23117620-4	2013	The dephosphorylating activity of ferulic acid was almost comparable to that of rapamycin, an established mTor inhibitor (TORC1).	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	106-110
22762560-3	2013	By doing so, rapamycin interferes with the phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis that controls several cellular functions involving cell growth, proliferation and angiogenesis.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	76-79
22762560-3	2013	By doing so, rapamycin interferes with the phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis that controls several cellular functions involving cell growth, proliferation and angiogenesis.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	80-84
24093774-3	2013	However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	28-32
23127588-0	2013	Low-dose rapamycin unmasks the protective potential of targeting intragraft NF-kappaB for islet transplants.	Sirolimus	9-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-85
23127588-9	2013	This result suggested that the effect of the NF-kappaB blockade might synergize with regulatory T-cell-sparing rapamycin.	Sirolimus	111-120	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	45-54
23127588-11	2013	In conclusion, rapamycin unmasks the protective potential of intragraft NF-kappaB blockade, which can, in some cases, permit permanent allograft survival without continuous systemic immunosuppression.	Sirolimus	15-24	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	72-81
23492649-3	2013	Several mTOR inhibitors (sirolimus, everolimus, temsirolimus, and ridaforolimus) have demonstrated antitumor activity in breast cancer cells.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	8-12
24151517-1	2013	The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in renal transplantation.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	4-33
24151517-1	2013	The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in renal transplantation.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	46-50
24093774-3	2013	However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	73-77
23439391-1	2013	Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	166-195
22234876-2	2013	However, mammalian target of rapamycin inhibitors (e.g., sirolimus; SRL) appear to be more immunoregulatory and might promote a tolerant state for withdrawal.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	9-38
23439391-1	2013	Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	200-204
23439391-1	2013	Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	166-195
23439391-1	2013	Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	200-204
23712219-1	2013	INTRODUCTION: mTOR (mammalian target of rapamycin) inhibitors sirolimus and everolimus, used as immunosuppressants in solid organ transplantation, may cause severe adverse effects, such as interstitial pneumonitis.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	14-18
23259423-2	2013	mTOR inhibitors, such as sirolimus (SRL), display immunosuppressive and antiproliferative properties, and the use of SRL in kidney transplant recipients reduces the risk of post-transplant cancer.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
24096474-6	2013	ChIMP is potentially extendable to small-molecule drug discovery, as engineering FK506-binding protein into intracellular sites within CaV1.2-alpha1C permits heterodimerization-initiated channel inhibition with rapamycin.	Sirolimus	211-220	caveolin 1	Homo sapiens	135-139
23712219-1	2013	INTRODUCTION: mTOR (mammalian target of rapamycin) inhibitors sirolimus and everolimus, used as immunosuppressants in solid organ transplantation, may cause severe adverse effects, such as interstitial pneumonitis.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	20-49
22711601-5	2013	An mTOR inhibitor, rapamycin, suppressed lactic acid production in lymphoma cell line cultures and also diminished steady-state lactate levels in xenotransplants.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	3-7
23255914-0	2013	Rapamycin induces autophagy in the melanoma cell line M14 via regulation of the expression levels of Bcl-2 and Bax.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	101-106
23255914-0	2013	Rapamycin induces autophagy in the melanoma cell line M14 via regulation of the expression levels of Bcl-2 and Bax.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	111-114
23255914-5	2013	We revealed that rapamycin induced autophagy and inhibited the proliferation of M14 cells in a concentration-dependent manner, Furthermore, western blot analysis revealed an upregulated expression of Bcl-2 and downregulated expression of Bax in M14 cells.	Sirolimus	17-26	BCL2 apoptosis regulator	Homo sapiens	200-205
23255914-5	2013	We revealed that rapamycin induced autophagy and inhibited the proliferation of M14 cells in a concentration-dependent manner, Furthermore, western blot analysis revealed an upregulated expression of Bcl-2 and downregulated expression of Bax in M14 cells.	Sirolimus	17-26	BCL2 associated X, apoptosis regulator	Homo sapiens	238-241
23116613-8	2013	This effect was abated by pathway blockers: the AMPK activator AICAR and the mTOR inhibitor rapamycin.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	77-81
23879172-3	2013	Phosphorus-containing sirolimus (FIM-A), which targets mTOR signaling, inhibits cancer cell growth in vitro.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	55-59
23555865-4	2013	The mTOR inhibitor, Rapamycin, stabilizes lung function in LAM and decreases the volume of renal angiomyolipomas, but lung function declines and angiomyolipomas regrow when treatment is discontinued, suggesting that factors induced by mTORC1 inhibition may promote the survival of TSC2-deficient cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
23326514-6	2013	To study the functional and pathological roles of elevated mTORC1 signaling in the oocytes, we treated the Pten-mutant mice with the specific mTORC1 inhibitor rapamycin.	Sirolimus	159-168	phosphatase and tensin homolog	Mus musculus	107-111
23565163-3	2013	The phosphorylation is inhibited by rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) in complex with raptor (mTORC1).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	71-100
23565163-3	2013	The phosphorylation is inhibited by rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) in complex with raptor (mTORC1).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	102-106
23437362-0	2013	Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.	Sirolimus	69-78	AKT serine/threonine kinase 1	Homo sapiens	22-25
23437362-5	2013	Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	40-43
23437362-5	2013	Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	154-157
23560047-7	2013	Rapamycin, an inhibitor of mTOR signalling, previously observed to prevent bladder strain induced de-differentiation of fully differentiated smooth muscle cells in vitro, inhibits FBS-induced smooth muscle cell differentiation of undifferentiated SKPs.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
23536771-9	2013	Rapamycin decreased the SE-induced mTOR activation and attenuated microgliosis which was mostly localized within the CA1 area.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
23308138-7	2013	Analyzing the impact of sirolimus introduction on cytokine microenvironment, we observed an increase of IL6 and TNFalpha without compensation of the negative feedback loops dependent on IL10 and soluble TNF receptors.	Sirolimus	24-33	interleukin 6	Homo sapiens	104-107
23308138-7	2013	Analyzing the impact of sirolimus introduction on cytokine microenvironment, we observed an increase of IL6 and TNFalpha without compensation of the negative feedback loops dependent on IL10 and soluble TNF receptors.	Sirolimus	24-33	tumor necrosis factor	Homo sapiens	112-120
23476113-8	2013	Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro.	Sirolimus	13-22	bone morphogenetic protein 2	Mus musculus	41-69
23476113-8	2013	Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro.	Sirolimus	13-22	bone morphogenetic protein 2	Mus musculus	71-75
22902509-3	2012	However, mTOR inhibition with rapamycin analogs or kinase inhibitors reduces cell growth but does not induce apoptosis, and the clinical benefit of rapamycin analogs has been modest.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	9-13
23165214-6	2013	The expression of HVEM on T cells and CD4+ T-cell subgroup decreased (p<0.05) while that on CD8+ T-cell subgroup remained roughly normal (p>0.05).The expression of HVEM on CD4+ Tregs increased significantly (p<0.05) in allo-renal recipients receiving Sirolimus regimen (p<0.05).	Sirolimus	260-269	TNF receptor superfamily member 14	Homo sapiens	18-22
23165214-6	2013	The expression of HVEM on T cells and CD4+ T-cell subgroup decreased (p<0.05) while that on CD8+ T-cell subgroup remained roughly normal (p>0.05).The expression of HVEM on CD4+ Tregs increased significantly (p<0.05) in allo-renal recipients receiving Sirolimus regimen (p<0.05).	Sirolimus	260-269	TNF receptor superfamily member 14	Homo sapiens	170-174
23165214-6	2013	The expression of HVEM on T cells and CD4+ T-cell subgroup decreased (p<0.05) while that on CD8+ T-cell subgroup remained roughly normal (p>0.05).The expression of HVEM on CD4+ Tregs increased significantly (p<0.05) in allo-renal recipients receiving Sirolimus regimen (p<0.05).	Sirolimus	260-269	CD4 molecule	Homo sapiens	178-181
23165214-7	2013	Though regulating the expression of HVEM/BTLA/CD160/LIGHT costimulatory system, Sirolimus-based regimen promotes inhibitory costimulatory signal in T cells and enhances the function of CD4+ Tregs in allo-renal recipients, which are in benefit of the control of transplant rejection as well as the induction and maintenance of transplant tolerance.	Sirolimus	80-89	TNF receptor superfamily member 14	Homo sapiens	36-40
23165214-7	2013	Though regulating the expression of HVEM/BTLA/CD160/LIGHT costimulatory system, Sirolimus-based regimen promotes inhibitory costimulatory signal in T cells and enhances the function of CD4+ Tregs in allo-renal recipients, which are in benefit of the control of transplant rejection as well as the induction and maintenance of transplant tolerance.	Sirolimus	80-89	CD4 molecule	Homo sapiens	185-188
22875481-8	2013	Moreover, inhibition of mTOR by rapamycin reversed the antidepressant effects of ketamine.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	24-28
23165214-0	2013	Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.	Sirolimus	0-9	TNF receptor superfamily member 14	Homo sapiens	68-72
23127854-6	2012	Notably, rapamycin augmented the OA-induced hyperphosphorylation of Akt by suppressing a negative feedback loop of Akt activation through VEGFR2 and its downstream target phosphatidylinositol 3-kinase (PI3K).	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	68-71
23127854-6	2012	Notably, rapamycin augmented the OA-induced hyperphosphorylation of Akt by suppressing a negative feedback loop of Akt activation through VEGFR2 and its downstream target phosphatidylinositol 3-kinase (PI3K).	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	115-118
23127854-9	2012	Moreover, the exacerbation of OA-induced events by rapamycin suggests that mTOR and PP2A work in concert to regulate cell survival, activated Akt and the levels of ubiquitinated proteins.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	75-79
23127854-9	2012	Moreover, the exacerbation of OA-induced events by rapamycin suggests that mTOR and PP2A work in concert to regulate cell survival, activated Akt and the levels of ubiquitinated proteins.	Sirolimus	51-60	AKT serine/threonine kinase 1	Homo sapiens	142-145
22954701-7	2012	Additionally, we find that in cells highly resistant to EGFR-TKI, autophagy is not robustly activated and that co-treatment of these cells with rapamycin, a known inducer of autophagy, can partially restore sensitivity to EGFR-TKI.	Sirolimus	144-153	epidermal growth factor receptor	Homo sapiens	56-64
22627923-8	2012	The genetic perturbation of the autophagy pathway through the regulation of the expression level of Beclin-1, an important autophagy regulator, resulted in a delayed autophagy induction and apoptosis inhibition in response to the rapamycin treatment in the DG44 host cell line.	Sirolimus	230-239	beclin-1	Cricetulus griseus	100-108
22983984-5	2012	We also investigated changes in sensitivity to the mTOR inhibitor, rapamycin, in inhibitor miR-144-transfected cells.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	51-55
23887441-1	2012	Sirolimus, the prototypical inhibitor of the mammalian target of rapamycin, has substantial antitumor activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	45-74
22921929-7	2012	In addition, the sustained effect of MPEP in the NSF test was partially abolished by pretreatment with a mammalian target of rapamycin (mTOR) antagonist, rapamycin.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	136-140
23085766-8	2012	In contrast, rapamycin increased Akt activity and failed to reduce the phosphorylation of 4E-BP1, PRAS40, and NDRG1.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	33-36
22983984-5	2012	We also investigated changes in sensitivity to the mTOR inhibitor, rapamycin, in inhibitor miR-144-transfected cells.	Sirolimus	67-76	microRNA 144	Homo sapiens	91-98
22954701-7	2012	Additionally, we find that in cells highly resistant to EGFR-TKI, autophagy is not robustly activated and that co-treatment of these cells with rapamycin, a known inducer of autophagy, can partially restore sensitivity to EGFR-TKI.	Sirolimus	144-153	epidermal growth factor receptor	Homo sapiens	222-230
22689677-8	2012	On days 30 and 90 post-transplant, sirolimus-treated patients had a significantly greater proportion of regulatory T cells among the CD4(+) cells in the peripheral blood, and isolated regulatory T cells were functional.	Sirolimus	35-44	CD4 molecule	Homo sapiens	133-136
22901235-6	2012	In addition, rapamycin preconditioning decreased the production of NF-kappaB, TNF-alpha, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area.	Sirolimus	13-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	67-76
22901235-6	2012	In addition, rapamycin preconditioning decreased the production of NF-kappaB, TNF-alpha, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area.	Sirolimus	13-22	tumor necrosis factor	Mus musculus	78-87
23089982-5	2012	Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235.	Sirolimus	153-162	AKT serine/threonine kinase 1	Homo sapiens	57-60
23089982-5	2012	Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	174-178
23089982-5	2012	Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	211-215
23730262-3	2012	As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for patients with TSC.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	13-17
23730262-3	2012	As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for patients with TSC.	Sirolimus	37-46	TSC complex subunit 1	Homo sapiens	127-130
22999860-0	2012	Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	79-84
22999860-12	2012	In situ knock-down of STAT3 attenuated rapamycin-induced protection against I/R injury.	Sirolimus	39-48	signal transducer and activator of transcription 3	Mus musculus	22-27
22999860-13	2012	Rapamycin triggered unique cardioprotective signaling including phosphorylation of ERK, STAT3, eNOS and glycogen synthase kinase-3ss in concert with increased prosurvival Bcl-2 to Bax ratio.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	88-93
22999860-13	2012	Rapamycin triggered unique cardioprotective signaling including phosphorylation of ERK, STAT3, eNOS and glycogen synthase kinase-3ss in concert with increased prosurvival Bcl-2 to Bax ratio.	Sirolimus	0-9	B cell leukemia/lymphoma 2	Mus musculus	171-176
22999860-15	2012	We propose that rapamycin is a novel and clinically relevant pharmacological strategy to target STAT3 activation for treatment of myocardial infarction.	Sirolimus	16-25	signal transducer and activator of transcription 3	Mus musculus	96-101
23271044-3	2012	Preclinical data also suggest that allosteric mTOR inhibition with rapamycin impaired leukemia initiating cells (LICs) function.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	46-50
22982730-8	2012	However, after pre-treatment with rapamycin, the level of Akt phosphorylation was decreased in primary cultures of CECs but could still be restored by ALA, whereas the levels of mTOR, S6K and 4E-BP1 phosphorylation were significantly decreased and could not be restored.	Sirolimus	34-43	thymoma viral proto-oncogene 1	Mus musculus	58-61
23215723-8	2012	In preclinical settings, dual PI3K/mTOR inhibitors displayed a much stronger cytotoxicity against leukemic cells than either PI3K inhibitors or allosteric mTOR inhibitors, such as rapamycin and its derivatives (rapalogs).	Sirolimus	180-189	mechanistic target of rapamycin kinase	Homo sapiens	35-39
23136410-2	2012	Although hyperactivation of mTOR has been strongly linked to the development of epilepsy and, conversely, inhibition of mTOR by rapamycin treatment is protective against seizures in several models, the downstream epileptic mechanisms have remained elusive.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	120-124
22917563-5	2012	Transfection of SH-SY5Y cells with AMPK or LC3beta shRNA, as well as treatment with pharmacological autophagy inhibitors suppressed, while mTOR inhibitor rapamycin potentiated 6-OHDA-induced oxidative stress and apoptotic cell death.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	139-143
22960125-7	2012	We propose a relevant role for Mtl1 O-mannosylation mediated by both Pmt1 and Pmt2 in the response to oxidative stress and in rapamycin treatment.	Sirolimus	126-135	metallothionein 1X pseudogene 1	Homo sapiens	31-35
22689083-6	2012	Activation of autophagy with rapamycin resulted in increased wogonin-mediated autophagy via inhibition of mTOR/P70S6K pathway.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	106-110
23073467-0	2012	Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.	Sirolimus	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
22923157-7	2012	Conversely in PC3 but not in LNCaP cells, rapamycin stimulated TNF-alpha-dependent apoptosis; such effect was associated with reduced c-Flip promoter activity and FoxO3a activation.	Sirolimus	42-51	tumor necrosis factor	Homo sapiens	63-72
22923157-7	2012	Conversely in PC3 but not in LNCaP cells, rapamycin stimulated TNF-alpha-dependent apoptosis; such effect was associated with reduced c-Flip promoter activity and FoxO3a activation.	Sirolimus	42-51	CASP8 and FADD like apoptosis regulator	Homo sapiens	134-140
22923157-7	2012	Conversely in PC3 but not in LNCaP cells, rapamycin stimulated TNF-alpha-dependent apoptosis; such effect was associated with reduced c-Flip promoter activity and FoxO3a activation.	Sirolimus	42-51	forkhead box O3	Homo sapiens	163-169
23053656-8	2012	Subsequent studies revealed that NDGA may also direct target mTORC1 complex because NDGA suppressed amino acids- and insulin-stimulated mTORC1 and acted like rapamycin to disrupt mTOR-Raptor interaction.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	61-65
22895070-8	2012	Proliferative inhibition correlated loosely with the presence of activating PIK3CA mutations and was strengthened in combination with the mTOR inhibitor rapamycin.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	138-142
22307455-0	2012	Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	25-29
23098083-0	2012	Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation.	Sirolimus	66-75	CD34 molecule	Homo sapiens	41-45
24710534-5	2012	mTOR inhibition via rapamycin decreases TAZ levels in HepG2 but not MCF7 cells and increases TEAD1 levels in MCF7 but not HepG2 cells, suggesting a selective role of the mTOR pathway in regulating these Hippo targets in a cell type-specific manner.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	0-4
24710534-5	2012	mTOR inhibition via rapamycin decreases TAZ levels in HepG2 but not MCF7 cells and increases TEAD1 levels in MCF7 but not HepG2 cells, suggesting a selective role of the mTOR pathway in regulating these Hippo targets in a cell type-specific manner.	Sirolimus	20-29	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	40-43
24710534-5	2012	mTOR inhibition via rapamycin decreases TAZ levels in HepG2 but not MCF7 cells and increases TEAD1 levels in MCF7 but not HepG2 cells, suggesting a selective role of the mTOR pathway in regulating these Hippo targets in a cell type-specific manner.	Sirolimus	20-29	TEA domain transcription factor 1	Homo sapiens	93-98
23762622-5	2012	mTOR inhibitors, such as rapamycin and its derivatives temsirolimus and everolimus, exhibit inhibitory effects on head and neck cancer in both in vitro cell line model and in vivo xenograft model.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22995302-10	2012	The mTOR inhibitor, rapamycin, abolishes Sirtinol-induced inflammation and NF-kappaB activation associated with p62/Sqstm1 accumulation.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22913509-0	2012	Preventive and therapeutic effects of rapamycin, a mammalian target of rapamycin inhibitor, on food allergy in mice.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	51-80
22913509-9	2012	Spontaneous and IL-9-dependent survival and IgE-induced IL-13 secretion, but not degranulation, of BMMCs were reduced by rapamycin.	Sirolimus	121-130	interleukin 13	Mus musculus	56-61
23027611-5	2012	Linking this signalling event to cognitive impairment, the mTOR inhibitor rapamycin prevented deficits in social cognition and novel object discrimination induced by 5-HT(6)  agonists.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	59-63
23342262-5	2012	In vitro studies prove that while Sirolimus (25 nmol/L) affects the signal downstream to mammalian target of rapamycin (mTOR), Nimotuzumab (83 nmol/L) downregulates pTYR, pMAPK and pSTAT3 by 40%, 20% and 30%, respectively.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	89-118
23342262-5	2012	In vitro studies prove that while Sirolimus (25 nmol/L) affects the signal downstream to mammalian target of rapamycin (mTOR), Nimotuzumab (83 nmol/L) downregulates pTYR, pMAPK and pSTAT3 by 40%, 20% and 30%, respectively.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	120-124
22859719-11	2012	In 2cKO HNSCC tongue tumors, rapamycin treatment induced apoptosis, inhibited cell proliferation and phosphorylation of Akt and S6, and decreased survivin expression.	Sirolimus	29-38	thymoma viral proto-oncogene 1	Mus musculus	120-123
22859719-12	2012	CONCLUSIONS: These findings indicate that tumorigenesis in 2cKO HNSCC is associated with activation of the Akt/mTOR/survivin pathway, and inhibition of this pathway by rapamycin treatment successfully ameliorates the onset and progression of tumorigenesis.	Sirolimus	168-177	thymoma viral proto-oncogene 1	Mus musculus	107-110
23384908-3	2012	The expressions of mTOR, 4E-BP1 and p70S6K at protein and mRNA level in K562 cells with rapamycin treatment were detected by Western blot and RT-PCR.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	19-23
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	AKT serine/threonine kinase 1	Homo sapiens	30-33
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	34-38
22285179-8	2012	In conclusion, we demonstrate that rapamycin effectively inhibits HB growth both in vitro and in vivo by blocking AKT/mTOR signalling at the level of p70S6K and that rapamycin should be considered to treat HB patients especially those to be indicated for liver transplantation to benefit from its anti-tumourigenic and immunosuppressive properties.	Sirolimus	35-44	AKT serine/threonine kinase 1	Homo sapiens	114-117
22285179-8	2012	In conclusion, we demonstrate that rapamycin effectively inhibits HB growth both in vitro and in vivo by blocking AKT/mTOR signalling at the level of p70S6K and that rapamycin should be considered to treat HB patients especially those to be indicated for liver transplantation to benefit from its anti-tumourigenic and immunosuppressive properties.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	118-122
22992293-6	2012	These effects were intensified by combined treatment of AST with the mTOR inhibitor rapamycin.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	69-73
22840496-7	2012	RESULTS: We observed that IL-22 induced significant proliferation of NHEK and FLS which was effectively inhibited by dual kinase (PI3K/mTOR) inhibitor, NVP-BEZ235 and specific mTOR inhibitor, Rapamycin.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Homo sapiens	176-180
22840496-8	2012	In NHEK and FLS, IL-22 significantly induced phosphorylation of Akt and mTOR which was effectively blocked by Rapamycin and NVP-BEZ235.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	64-67
22840496-8	2012	In NHEK and FLS, IL-22 significantly induced phosphorylation of Akt and mTOR which was effectively blocked by Rapamycin and NVP-BEZ235.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	72-76
22863900-0	2012	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.	Sirolimus	15-24	RAR related orphan receptor C	Homo sapiens	48-51
22863900-1	2012	BACKGROUND: The mammalian target of rapamycin (m-TOR) inhibitor sirolimus is an immunosuppressive drug used in kidney transplantation.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	16-45
22863900-1	2012	BACKGROUND: The mammalian target of rapamycin (m-TOR) inhibitor sirolimus is an immunosuppressive drug used in kidney transplantation.	Sirolimus	64-73	RAR related orphan receptor C	Homo sapiens	49-52
23369601-4	2012	RAPA-DC are generated through inhibition of the integrative kinase mammalian target of rapamycin (mTOR) by the immunosuppressive macrolide rapamycin during propagation of monocyte-derived DC.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	98-102
22941182-4	2012	When mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus) became available, these findings were observed increasingly, particularly in direct comparisons with inosine 5"-monophosphate dehydrogenase inhibitors.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	5-34
22941182-4	2012	When mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus) became available, these findings were observed increasingly, particularly in direct comparisons with inosine 5"-monophosphate dehydrogenase inhibitors.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	36-40
23384908-8	2012	The phosphorylation of mTOR was decreased after rapamycin treatment, as well as the expressions of 4E-BP1 and p70S6K at protein and mRNA level (P < 0.05).	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	23-27
22037511-3	2012	A key factor in the inter-individual variability for tacrolimus, and probably sirolimus, is whether an individual is genetically predicted to express the drug metabolising enzyme cytochrome P450 3A5 (CYP3A5).	Sirolimus	78-87	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	179-198
22932872-3	2012	We have tested the therapeutic potential of rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) and three other autophagy activators (spermidine, carbamazepine, and tamoxifen) in a FTLD-U mouse model with TDP-43 proteinopathies.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	75-104
22932872-3	2012	We have tested the therapeutic potential of rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) and three other autophagy activators (spermidine, carbamazepine, and tamoxifen) in a FTLD-U mouse model with TDP-43 proteinopathies.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	106-110
22932872-9	2012	These changes in TDP-43 metabolism are accompanied by rapamycin-induced decreases in mTOR-regulated phospho-p70 S6 kinase (P-p70) and the p62 protein, as well as increases in the autophagic marker LC3.	Sirolimus	54-63	TAR DNA binding protein	Mus musculus	17-23
22973301-0	2012	Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2.	Sirolimus	0-9	insulin	Homo sapiens	35-42
22973301-1	2012	Rapamycin, an inhibitor of mTOR complex 1 (mTORC1), improves insulin sensitivity in acute studies in vitro and in vivo by disrupting a negative feedback loop mediated by S6 kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
22973301-1	2012	Rapamycin, an inhibitor of mTOR complex 1 (mTORC1), improves insulin sensitivity in acute studies in vitro and in vivo by disrupting a negative feedback loop mediated by S6 kinase.	Sirolimus	0-9	insulin	Homo sapiens	61-68
22973301-2	2012	We find that rapamycin has a clear biphasic effect on insulin sensitivity in C2C12 myotubes, with enhanced responsiveness during the first hour that declines to almost complete insulin resistance by 24-48 h. We and others have recently observed that chronic rapamycin treatment induces insulin resistance in rodents, at least in part due to disruption of mTORC2, an mTOR-containing complex that is not acutely sensitive to the drug.	Sirolimus	13-22	insulin	Homo sapiens	54-61
22973301-2	2012	We find that rapamycin has a clear biphasic effect on insulin sensitivity in C2C12 myotubes, with enhanced responsiveness during the first hour that declines to almost complete insulin resistance by 24-48 h. We and others have recently observed that chronic rapamycin treatment induces insulin resistance in rodents, at least in part due to disruption of mTORC2, an mTOR-containing complex that is not acutely sensitive to the drug.	Sirolimus	13-22	insulin	Homo sapiens	177-184
22973301-2	2012	We find that rapamycin has a clear biphasic effect on insulin sensitivity in C2C12 myotubes, with enhanced responsiveness during the first hour that declines to almost complete insulin resistance by 24-48 h. We and others have recently observed that chronic rapamycin treatment induces insulin resistance in rodents, at least in part due to disruption of mTORC2, an mTOR-containing complex that is not acutely sensitive to the drug.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	355-359
22973301-8	2012	Thus, mTORC2 disruption, rather than inhibition of mitochondria, causes insulin resistance in rapamycin-treated myotubes, and this system may serve as a useful model to understand the effects of rapamycin on mTOR signaling in vivo.	Sirolimus	94-103	insulin	Homo sapiens	72-79
22973301-8	2012	Thus, mTORC2 disruption, rather than inhibition of mitochondria, causes insulin resistance in rapamycin-treated myotubes, and this system may serve as a useful model to understand the effects of rapamycin on mTOR signaling in vivo.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	6-10
22037511-3	2012	A key factor in the inter-individual variability for tacrolimus, and probably sirolimus, is whether an individual is genetically predicted to express the drug metabolising enzyme cytochrome P450 3A5 (CYP3A5).	Sirolimus	78-87	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	200-206
22776430-3	2012	Intent-to-treat analysis showed the 1-year adjusted mean change from baseline in creatinine clearance (Cockcroft-Gault) was significantly higher with sirolimus versus CNI treatment (+3.0 vs. -1.4 mL/min/1.73 m(2) , respectively; p = 0.004).	Sirolimus	150-159	CD59 molecule (CD59 blood group)	Homo sapiens	199-204
22958927-3	2012	In normal tissues, rapamycin prevents epithelial stem cell senescence by reducing oxidative stress through increased MnSOD.	Sirolimus	19-28	superoxide dismutase 2, mitochondrial	Mus musculus	117-122
22613737-3	2012	Because the mammalian target of rapamycin (mTOR) pathway regulates neurite outgrowth, synaptic plasticity and cell survival, thereby influencing brain development, we tested if exposure of the immature brain to the mTOR inhibitor rapamycin changes seizure susceptibility to neurological insults.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	43-47
22613737-3	2012	Because the mammalian target of rapamycin (mTOR) pathway regulates neurite outgrowth, synaptic plasticity and cell survival, thereby influencing brain development, we tested if exposure of the immature brain to the mTOR inhibitor rapamycin changes seizure susceptibility to neurological insults.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	215-219
22564264-3	2012	As posaconazole strongly inhibits CYP3A4, concurrent administration of sirolimus, a CYP3A4 substrate, and posaconazole has been reported to increase sirolimus drug exposure substantially.	Sirolimus	71-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
22564264-3	2012	As posaconazole strongly inhibits CYP3A4, concurrent administration of sirolimus, a CYP3A4 substrate, and posaconazole has been reported to increase sirolimus drug exposure substantially.	Sirolimus	71-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
22564264-3	2012	As posaconazole strongly inhibits CYP3A4, concurrent administration of sirolimus, a CYP3A4 substrate, and posaconazole has been reported to increase sirolimus drug exposure substantially.	Sirolimus	149-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
22564264-3	2012	As posaconazole strongly inhibits CYP3A4, concurrent administration of sirolimus, a CYP3A4 substrate, and posaconazole has been reported to increase sirolimus drug exposure substantially.	Sirolimus	149-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
22825337-5	2012	Moreover, we show that perifosine, as an Akt inhibitor, decreases rapamycin-induced phosphorylation of GSK3beta and elevated p-GSK3beta levels in rapamycin-resistant cell lines.	Sirolimus	66-75	thymoma viral proto-oncogene 1	Mus musculus	41-44
22787122-2	2012	Here we show that rapamycin-induced phosphorylation of Akt can occur in an IGF-1R-independent manner.	Sirolimus	18-27	AKT serine/threonine kinase 1	Homo sapiens	55-58
22787122-3	2012	Analysis of synovial sarcoma cell lines showed that either IGF-1R or the PDGF receptor alpha (PDGFRA) can mediate intrinsic resistance to rapamycin.	Sirolimus	138-147	platelet derived growth factor receptor alpha	Homo sapiens	94-100
22872575-1	2012	PURPOSE: Sirolimus is the eponymous inhibitor of the mTOR; however, only its analogs have been approved as cancer therapies.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	53-57
22842983-2	2012	While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer, mTOR inhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERalpha+) compared to ERalpha negative (ERalpha-) tumors.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	82-86
22842983-2	2012	While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer, mTOR inhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERalpha+) compared to ERalpha negative (ERalpha-) tumors.	Sirolimus	6-15	estrogen receptor 1	Homo sapiens	260-283
22842983-2	2012	While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer, mTOR inhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERalpha+) compared to ERalpha negative (ERalpha-) tumors.	Sirolimus	6-15	estrogen receptor 1	Homo sapiens	294-301
22842983-2	2012	While rapamycin and its derivatives (e.g., everolimus) have been shown to inhibit mTOR signaling and cell proliferation in preclinical models of breast cancer, mTOR inhibition has demonstrated variable clinical efficacy with a trend toward better responses in estrogen receptor alpha positive (ERalpha+) compared to ERalpha negative (ERalpha-) tumors.	Sirolimus	6-15	estrogen receptor 1	Homo sapiens	316-343
22842983-5	2012	We investigated the effect of rapamycin on the growth of several ERalpha+ and ERalpha- breast cancer cell lines and examined differences in the phosphorylation of mTOR substrates (SGK1, p70S6K, and Akt) that might account for the differing sensitivity of these cell lines to rapamycin.	Sirolimus	275-284	mechanistic target of rapamycin kinase	Homo sapiens	163-167
22842983-8	2012	We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERalpha+ MCF-7 and T47D cells, but not in ERalpha- MDA-MB-231 or MCF10A-Myc cells.	Sirolimus	27-36	insulin	Homo sapiens	84-91
22842983-8	2012	We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERalpha+ MCF-7 and T47D cells, but not in ERalpha- MDA-MB-231 or MCF10A-Myc cells.	Sirolimus	27-36	estrogen receptor 1	Homo sapiens	132-139
22842983-11	2012	Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERalpha- breast cancer.	Sirolimus	63-72	estrogen receptor 1	Homo sapiens	109-116
22696593-0	2012	Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.	Sirolimus	47-56	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	108-114
22696593-4	2012	In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance.	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	101-104
22696593-4	2012	In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance.	Sirolimus	185-194	AKT serine/threonine kinase 1	Homo sapiens	101-104
22696593-7	2012	CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib.	Sirolimus	86-95	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	35-41
22696593-7	2012	CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib.	Sirolimus	173-182	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	35-41
22696593-9	2012	We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA.	Sirolimus	65-74	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	177-183
22696593-10	2012	The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations.	Sirolimus	57-66	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	195-201
22861825-2	2012	Temsirolimus is an inhibitor of mTOR, and is a unique ester derivative of sirolimus, a macrocyclic lactone, with improved pharmaceutical properties, including stability and solubility.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	32-36
22710790-0	2012	Rapamycin induces p53-independent apoptosis through the mitochondrial             pathway in non-small cell lung cancer cells.	Sirolimus	0-9	tumor protein p53	Homo sapiens	18-21
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	Sirolimus	97-106	toll like receptor 2	Homo sapiens	39-43
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	Sirolimus	97-106	mitogen-activated protein kinase 1	Homo sapiens	126-130
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	Sirolimus	97-106	mitogen-activated protein kinase 1	Homo sapiens	131-134
22617154-8	2012	Furthermore, the antiviral activity of TLR2 ligands was abolished by pretreatment with U0126 and rapamycin, inhibitors of the MAPK/ERK and PI3K/Akt pathways, respectively.	Sirolimus	97-106	AKT serine/threonine kinase 1	Homo sapiens	144-147
22759736-8	2012	Kaposi"s sarcoma may regress with the use of the mammalian target of rapamycin inhibitor sirolimus.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	49-78
22710790-2	2012	Rapamycin,             a specific inhibitor of mTOR, results predominately in G1 cell cycle arrest through             translation control and occasionally, cell type-dependent apoptosis by an unknown             mechanism.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	47-51
22710790-5	2012	The apoptotic effect of             rapamycin was measured by caspase-3 activation and flow cytometric analysis of             Annexin V binding.	Sirolimus	36-45	caspase 3	Homo sapiens	62-71
22710790-7	2012	We found that rapamycin induced             apoptosis in NSCLC cell lines with p53 mutations.	Sirolimus	14-23	tumor protein p53	Homo sapiens	79-82
22710790-8	2012	Western blot analysis demonstrated             that rapamycin downregulates the expression levels of Bcl-2, which leads to increased             cytochrome c release from mitochondria and subsequent activation of caspase cascades.	Sirolimus	52-61	BCL2 apoptosis regulator	Homo sapiens	101-106
22710790-8	2012	Western blot analysis demonstrated             that rapamycin downregulates the expression levels of Bcl-2, which leads to increased             cytochrome c release from mitochondria and subsequent activation of caspase cascades.	Sirolimus	52-61	cytochrome c, somatic	Homo sapiens	145-157
22527536-4	2012	The role of sirolimus, an mTOR inhibitor with immunomodulatory and anti-proliferative properties, has been less well-defined.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	26-30
23105977-7	2012	Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively.	Sirolimus	11-20	mast cell protease 1	Mus musculus	37-42
26894018-5	2012	mTOR inhibition with sirolimus or everolimus decreases cysts in most animal models of PKD including Pkd1 and Pkd2 gene deficient orthologous models of human disease.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26894018-5	2012	mTOR inhibition with sirolimus or everolimus decreases cysts in most animal models of PKD including Pkd1 and Pkd2 gene deficient orthologous models of human disease.	Sirolimus	21-30	polycystin 2, transient receptor potential cation channel	Homo sapiens	109-113
23105977-7	2012	Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively.	Sirolimus	11-20	interleukin 6	Mus musculus	50-54
23105977-7	2012	Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively.	Sirolimus	11-20	interferon gamma	Mus musculus	60-68
22820188-6	2012	To introduce a constitutively active Akt (CA-Akt) in cultured RPE cells increased MMP-9 expression, and to block mTORC1 activation by rapamycin inhibited its effect.	Sirolimus	134-143	AKT serine/threonine kinase 1	Homo sapiens	37-40
22895726-3	2012	In addition, rapamycin, a clinically important immunosuppressant, is a specific and potent inhibitor of mTOR signaling.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	104-108
22895726-5	2012	We therefore performed an electrophysiological and morphological comparison of glutamatergic and GABAergic neurons in which mTOR signaling was either increased by loss of the repressor Pten or decreased by treatment with rapamycin.	Sirolimus	221-230	mechanistic target of rapamycin kinase	Homo sapiens	124-128
22500984-8	2012	Interestingly, CD4(+) but not CD8(+) T lymphocytes were sensitive to T(reg) and rapamycin-induced apoptosis in vitro.	Sirolimus	80-89	CD4 molecule	Homo sapiens	15-18
22579465-7	2012	Interestingly, sirolimus preserved renal epithelial cell expression of E-cadherin in TgS.	Sirolimus	15-24	cadherin 1	Mus musculus	71-81
22447639-0	2012	Rapamycin inhibits the invasive ability of thyroid cancer cells by down-regulating the expression of VEGF-C in vitro.	Sirolimus	0-9	vascular endothelial growth factor C	Homo sapiens	101-107
22447639-9	2012	We found the expression of VEGF-C was high in SW579 cells and decreased slightly when the cells were treated with 5 nm rapamycin.	Sirolimus	119-128	vascular endothelial growth factor C	Homo sapiens	27-33
22447639-12	2012	No obvious changes observed in the expression of AKT indicated that there might be a feedback loop effect by the mTOR inhibition induced by rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	113-117
22845908-8	2012	Systemic administration of rapamycin or PD98059 also attenuated MSC recruitment and neointimal formation in the aortic allografts.	Sirolimus	27-36	musculin	Rattus norvegicus	64-67
22447639-11	2012	Rapamycin could inhibit the proliferation and induce the apoptosis of human thyroid cancer cells in vitro by mTOR inhibition.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	109-113
22544534-6	2012	Clinical studies of rapamycin in human epilepsy are limited, but suggest that mTOR inhibitors at least have antiseizure effects in tuberous sclerosis patients.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	78-82
22579465-8	2012	Since sirolimus attenuated renal cell ZEB expression (a repressor of E-cadherin transcription), it appears that sirolimus may be attenuating renal cell EMT by preserving epithelial cell E-cadherin expression.	Sirolimus	6-15	zinc finger E-box binding homeobox 1	Mus musculus	38-41
21631587-1	2012	The mTOR inhibitors (ImTORs) sirolimus (SRL) and everolimus (EVR) have been increasingly used in renal transplantation as part of calcineurin inhibitor (CNI) sparing or avoidance regimens.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22579465-8	2012	Since sirolimus attenuated renal cell ZEB expression (a repressor of E-cadherin transcription), it appears that sirolimus may be attenuating renal cell EMT by preserving epithelial cell E-cadherin expression.	Sirolimus	6-15	cadherin 1	Mus musculus	69-79
22579465-8	2012	Since sirolimus attenuated renal cell ZEB expression (a repressor of E-cadherin transcription), it appears that sirolimus may be attenuating renal cell EMT by preserving epithelial cell E-cadherin expression.	Sirolimus	112-121	cadherin 1	Mus musculus	186-196
22522471-5	2012	Treatment with rapamycin, a potent mTOR (mammalian target of rapamycin pathway)-pathway inhibitor, markedly diminished aggressive behavior.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	35-39
22261591-11	2012	PKI-587 is a potent inhibitor of AKT (Ser473), mTOR (Ser2448), and S6K (Thr389) phosphorylation; in contrast, rapamycin stimulated mTOR complex 2 substrate AKT(Ser473) phosphorylation although it inhibited mTOR complex 1 substrate S6K phosphorylation.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	131-135
22261591-11	2012	PKI-587 is a potent inhibitor of AKT (Ser473), mTOR (Ser2448), and S6K (Thr389) phosphorylation; in contrast, rapamycin stimulated mTOR complex 2 substrate AKT(Ser473) phosphorylation although it inhibited mTOR complex 1 substrate S6K phosphorylation.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	156-159
22261591-11	2012	PKI-587 is a potent inhibitor of AKT (Ser473), mTOR (Ser2448), and S6K (Thr389) phosphorylation; in contrast, rapamycin stimulated mTOR complex 2 substrate AKT(Ser473) phosphorylation although it inhibited mTOR complex 1 substrate S6K phosphorylation.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	131-135
22696643-8	2012	Giant cells are associated with constitutive mammalian target of rapamycin (mTOR) activation, and we found that both giant LECs and LEC permeability were sensitive to rapamycin, an mTOR inhibitor, and VEGF-C addition.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	76-80
22329629-4	2012	The mTOR inhibitor rapamycin was found to restore both mitophagy and mitochondrial function in these cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22117756-6	2012	We evaluated the effect of the mTOR inhibitor rapamycin, which has been previously shown to block hypoxia-inducible factor (HIF) 1alpha.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	31-35
22117756-6	2012	We evaluated the effect of the mTOR inhibitor rapamycin, which has been previously shown to block hypoxia-inducible factor (HIF) 1alpha.	Sirolimus	46-55	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-135
22117756-11	2012	In primary mesothelial cell culture, rapamycin had no effect on TGFbeta-induced vascular endothelial growth factor (VEGF) but did suppress hypoxia-induced VEGF.	Sirolimus	37-46	vascular endothelial growth factor A	Homo sapiens	155-159
22117756-15	2012	The hypoxic response is mediated partly through HIF1alpha and the mTOR inhibitor rapamycin blocks the hypoxic-induced angiogenic effects but does not affect the direct TGFbeta-mediated fibrosis and angiogenesis.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	66-70
21763036-4	2012	Interestingly, in mice expressing this mutant SOD1 protein, DR significantly delays disease onset and extends lifespan, while Rapa has no effect.	Sirolimus	126-130	superoxide dismutase 1, soluble	Mus musculus	46-50
22522471-5	2012	Treatment with rapamycin, a potent mTOR (mammalian target of rapamycin pathway)-pathway inhibitor, markedly diminished aggressive behavior.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	41-70
21900343-7	2012	In conclusion, rapamycin inhibited t-PA and induced PAI-1 expression in HUVECs.	Sirolimus	15-24	plasminogen activator, tissue type	Homo sapiens	35-39
22496407-4	2012	The activity of mTOR complex 1 (mTORC1) is necessary for renal regeneration and repair after AKI, and inhibition of mTORC1 by rapamycin has been shown to delay recovery from ischemic AKI in animal studies, and to prolong delayed graft function in humans who have received a kidney transplant.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	16-20
22698676-0	2012	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.	Sirolimus	97-106	caveolin 1	Homo sapiens	0-10
22698676-9	2012	Systemic rapamycin treatment of mammary tumors grown in a Cav-1-deficient microenvironment significantly inhibited their tumor growth, decreased their stromal content, and reduced the levels of both vimentin and phospho-S6 in Cav-1-deficient cancer-associated fibroblasts.	Sirolimus	9-18	caveolin 1	Homo sapiens	58-63
22698676-10	2012	Since stromal loss of Cav-1 is a marker of a lethal tumor microenvironment in breast tumors, these high-risk patients might benefit from treatment with mTOR inhibitors, such as rapamycin or other rapamycin-related compounds (rapalogues).	Sirolimus	177-186	caveolin 1	Homo sapiens	22-27
24358826-1	2012	The recent development of mammalian target of rapamycin (mTOR) kinase domain inhibitors and genetic dissection of rapamycin-sensitive and -insensitive mTOR protein complexes (mTORC1 and mTORC2) have revealed that phosphorylation of the mTOR substrate 4E-BP1 on amino acids Thr37 and/or Thr46 represents a rapamycin-insensitive activity of mTORC1.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	57-61
22532572-3	2012	Hamartin and tuberin form a heterodimer that inhibits the mammalian target of rapamycin complex 1 (mTORC1) kinase, a major cellular regulator of protein translation, cell growth and proliferation.	Sirolimus	78-87	TSC complex subunit 1	Homo sapiens	0-8
22532572-4	2012	Hyperactivated mTORC1 signaling, an important feature of TSC, has prompted a number of preclinical and clinical studies with the mTORC1 inhibitor rapamycin.	Sirolimus	146-155	TSC complex subunit 1	Homo sapiens	57-60
22532572-6	2012	We hypothesized that low-dose rapamycin given prenatally and/or postnatally in a well-established neuroglial (Tsc2-hGFAP) model of TSC would rescue brain developmental defects.	Sirolimus	30-39	TSC complex subunit 1	Homo sapiens	131-134
22532572-12	2012	These results have important translational implications in the optimization of the timing and dosage of rapamycin treatment in TSC affected children.	Sirolimus	104-113	TSC complex subunit 1	Homo sapiens	127-130
22645144-3	2012	We found that leucine-induced insulin secretion was inhibited by both the mTOR inhibitor rapamycin as well as the adrenergic alpha2 receptor agonist clonidine.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	74-78
22645144-7	2012	The role of the mTOR pathway in metabolic homeostasis led us to a second important finding in this study; retrospective analysis of clinical data showed that co-administration of rapamycin and clonidine was associated with an increased incidence of new-onset diabetes in renal transplantation patients over those receiving rapamycin alone.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	16-20
22645144-7	2012	The role of the mTOR pathway in metabolic homeostasis led us to a second important finding in this study; retrospective analysis of clinical data showed that co-administration of rapamycin and clonidine was associated with an increased incidence of new-onset diabetes in renal transplantation patients over those receiving rapamycin alone.	Sirolimus	323-332	mechanistic target of rapamycin kinase	Homo sapiens	16-20
22698676-10	2012	Since stromal loss of Cav-1 is a marker of a lethal tumor microenvironment in breast tumors, these high-risk patients might benefit from treatment with mTOR inhibitors, such as rapamycin or other rapamycin-related compounds (rapalogues).	Sirolimus	177-186	mechanistic target of rapamycin kinase	Homo sapiens	152-156
22698676-10	2012	Since stromal loss of Cav-1 is a marker of a lethal tumor microenvironment in breast tumors, these high-risk patients might benefit from treatment with mTOR inhibitors, such as rapamycin or other rapamycin-related compounds (rapalogues).	Sirolimus	196-205	caveolin 1	Homo sapiens	22-27
22698676-10	2012	Since stromal loss of Cav-1 is a marker of a lethal tumor microenvironment in breast tumors, these high-risk patients might benefit from treatment with mTOR inhibitors, such as rapamycin or other rapamycin-related compounds (rapalogues).	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	152-156
22550167-0	2012	Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.	Sirolimus	69-78	thymoma viral proto-oncogene 1	Mus musculus	29-32
22751858-1	2012	Iatrogenic Kaposi sarcomas (KS) in organ transplant recipients are often treated by switching immunosuppressive therapy to an mTOR inhibitor, such as sirolimus or everolimus, as these have immunosuppressive as well as anti-tumor effects.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	126-130
23018254-1	2012	BACKGROUND: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors (sirolimus, SRL) - immunosuppressants used to prevent allograft rejection after renal transplantation - have a narrow therapeutic index and show considerable inter-individual pharmacokinetic differences.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	58-62
22575459-8	2012	The notion that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK-AKT-mTOR pathway was further suggested by the finding that rapamycin completely abolished the effect of IGF-1 on the 10-pS Cl channels in the TAL.	Sirolimus	154-163	AKT serine/threonine kinase 1	Rattus norvegicus	95-98
22544908-0	2012	Functional analysis of the single Est1/Ebs1 homologue in Kluyveromyces lactis reveals roles in both telomere maintenance and rapamycin resistance.	Sirolimus	125-134	Ebs1p	Saccharomyces cerevisiae S288C	39-43
22578218-7	2012	In the multiple-hit model of infantile spasms, pulse high-dose rapamycin administration can reduce the cortical overactivation of the mTOR pathway, suppresses spasms, and has disease-modifying effects by partially improving cognitive deficits.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	134-138
22550167-12	2012	CONCLUSION: Akt inhibition by MK-2206 increased the efficacy of etoposide or rapamycin.	Sirolimus	77-86	thymoma viral proto-oncogene 1	Mus musculus	12-15
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	epidermal growth factor receptor	Homo sapiens	102-106
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Homo sapiens	153-157
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	AKT serine/threonine kinase 1	Homo sapiens	296-299
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Homo sapiens	301-305
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	mitogen-activated protein kinase 1	Homo sapiens	322-363
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	mitogen-activated protein kinase 3	Homo sapiens	365-371
21861169-9	2012	Rapamycin (50 nM; a potent inhibitor of mTOR) attenuated the stimulatory effect of AKG on protein synthesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Sus scrofa	40-44
21940156-4	2012	The incidence of BK-related events may be reduced in patients receiving mTOR inhibitors (everolimus or sirolimus) with cyclosporine vs a calcineurin inhibitor with mycophenolic acid.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	72-76
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	CD4 molecule	Homo sapiens	133-136
22544507-6	2012	Specific inhibitors of mTOR are in clinical use, including sirolimus, everolimus, temsirolimus, and deforolimus.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	23-27
22421346-6	2012	Treatment of osteoblast precursor cells with rapamycin or FK-506, either alone, or synergistically with BMP-2, increased levels of phospho-Smad 1/5/8 protein and transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblast differentiation.	Sirolimus	45-54	RUNX family transcription factor 2	Homo sapiens	179-185
22421346-6	2012	Treatment of osteoblast precursor cells with rapamycin or FK-506, either alone, or synergistically with BMP-2, increased levels of phospho-Smad 1/5/8 protein and transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblast differentiation.	Sirolimus	45-54	SMAD family member 7	Homo sapiens	195-201
22421346-8	2012	When osteoblast differentiation was suppressed with exogenous TGF-beta1 treatment, rapamycin (but not FK-506) was able to rescue expression of differentiation markers, indicating distinct but overlapping activity of these compounds.	Sirolimus	83-92	transforming growth factor beta 1	Homo sapiens	62-71
22488882-6	2012	This striking myelin pathology, with features of human CMT type 4B1 and HNPP, is dependent on AKT/mTOR signalling, as evidenced by a significant amelioration of the pathology in mice treated with rapamycin.	Sirolimus	196-205	AKT serine/threonine kinase 1	Homo sapiens	94-97
22488882-6	2012	This striking myelin pathology, with features of human CMT type 4B1 and HNPP, is dependent on AKT/mTOR signalling, as evidenced by a significant amelioration of the pathology in mice treated with rapamycin.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	98-102
22788941-4	2012	At present, inhibitors of mammalian target of rapamycin such as sirolimus appear to be the most promising therapeutic agents, although drug toxicity and development of resistance are potential problems.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	26-55
22333157-0	2012	mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22344941-4	2012	Inhibition of mTOR by rapamycin improves cognitive deficits and rescues Abeta pathology and NFTs by increasing autophagy.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
22420007-2	2012	The aim of this study was to evaluate the effects of the mTOR inhibitors sirolimus and temsirolimus on human ACC cell growth and cortisol production.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	57-61
22391948-12	2012	Ghrelin receptor antagonism and Ghsr1a knockout blocked the upregulation of JNK activity and downregulation of GLUT4 levels and translocation in the gastrocnemius muscle induced by rapamycin.	Sirolimus	181-190	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	111-116
22758368-1	2012	Treatment with rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) can increase mammalian life span.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	42-71
22758368-2	2012	However, extended treatment with rapamycin results in increased hepatic gluconeogenesis concomitant with glucose and insulin insensitivity through inhibition of mTOR complex 2 (C2).	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	161-165
22428559-4	2012	Rapamycin inhibits some mTORC1 functions, whereas mTOR-KIs (mTOR kinase inhibitors) interfere with all of them.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	24-28
22333157-7	2012	This is the first study to show that rapamycin reduces glucose uptake in human adipocytes through impaired insulin signalling and this may contribute to the development of insulin resistance associated with rapamycin therapy.	Sirolimus	37-46	insulin	Homo sapiens	107-114
22483750-9	2012	Coexpression of mTOR significantly increased I(glu), an effect reversed by rapamycin (100 nM).	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	16-20
22455398-3	2012	Rapamycin and FK506 are two macrocyclic natural products, which tightly bind to most FKBP family members, including FKBP51 and FKBP52.	Sirolimus	0-9	FKBP prolyl isomerase 4	Homo sapiens	127-133
22338016-4	2012	EXPERIMENTAL DESIGN: We sought to identify a GEP of mTOR inhibitor resistance by stratification of eight DLBCL cell lines with respect to response to rapamycin.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	52-56
22559167-7	2012	The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR.	Sirolimus	15-24	BCL2 apoptosis regulator	Homo sapiens	94-99
22559167-12	2012	The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib.	Sirolimus	178-187	B cell leukemia/lymphoma 2	Mus musculus	108-113
22577264-10	2012	Furthermore, rapamycin and wortmannin, inhibitors of mTOR and PI3K, respectively, have co-stimulatory effects with alpha-MSH in enhancing melanogenesis in melanocyte cells.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	53-57
22577264-10	2012	Furthermore, rapamycin and wortmannin, inhibitors of mTOR and PI3K, respectively, have co-stimulatory effects with alpha-MSH in enhancing melanogenesis in melanocyte cells.	Sirolimus	13-22	proopiomelanocortin	Homo sapiens	115-124
22559167-3	2012	However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin.	Sirolimus	38-47	thymoma viral proto-oncogene 1	Mus musculus	89-92
22559167-3	2012	However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin.	Sirolimus	96-105	thymoma viral proto-oncogene 1	Mus musculus	89-92
22559167-7	2012	The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR.	Sirolimus	15-24	tumor protein p53	Homo sapiens	76-79
22560223-5	2012	Rapamycin triggers a similar protective response in C. elegans and mice, but increases worm life span dependent upon SKN-1 and not DAF-16, apparently by interfering with TORC2 along with TORC1.	Sirolimus	0-9	skin antigen 1	Mus musculus	117-122
22364775-0	2012	Effects of rapamycin-induced oligomerization of parvalbumin, Stim1 and Orai1 in puncta formation.	Sirolimus	11-20	stromal interaction molecule 1	Homo sapiens	61-66
22364775-5	2012	Here we made fusion proteins of Stim1 and Orai1 with FRB and FKBP12 domains that associate in the presence of rapamycin.	Sirolimus	110-119	stromal interaction molecule 1	Homo sapiens	32-37
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	stromal interaction molecule 1	Homo sapiens	30-35
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	stromal interaction molecule 1	Homo sapiens	39-44
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	stromal interaction molecule 1	Homo sapiens	39-44
22364775-7	2012	Rapamycin was then used to recruit the cytosolic Ca2+ buffer protein parvalbumin (Pav) to Stim1 in order to buffer the local cytosolic Ca2+ near the ER membrane.	Sirolimus	0-9	stromal interaction molecule 1	Homo sapiens	90-95
22409888-8	2012	The preclinical efficacy of mTOR inhibition by rapamycin and RAD001 was explored in HPV(+) HNSCC and CCSCC tumor xenografts.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22343118-0	2012	Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	39-43
22450807-5	2012	We therefore hypothesized that the mTOR inhibitor rapamycin would increase LPS-induced apoptosis and lung injury in vivo.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
22419707-14	2012	CONCLUSION: Our findings provide strong evidence for a direct effect of TSH on angiogenesis through its receptor, via cAMP-mammalian target of rapamycin signaling and indicate that this effect is VEGF dependent.	Sirolimus	143-152	vascular endothelial growth factor A	Homo sapiens	196-200
22466652-5	2012	Mouse models of obesity also exhibit increased hepatic activity of mammalian target of rapamycin complex 1 (mTORC1) and ER stress, and we found that administration of the mTOR inhibitor rapamycin to ob/ob mice reduced ER stress and increased hepatic sortilin-1 levels.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	108-112
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	0-9	caspase 3	Homo sapiens	241-250
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	111-120	caspase 3	Homo sapiens	241-250
22449574-4	2012	Here we demonstrate that besides inhibiting their respective target kinases, the pharmacological PI3-kinase inhibitor LY294002 and the downstream mTOR kinase inhibitor rapamycin also directly inhibit ABCG2 function.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Homo sapiens	146-150
22520346-7	2012	Increased understanding of the genetic cause of the disease and underlying dysregulation of the mammalian target of rapamycin pathway has led to clinical trials of mammalian target of rapamycin inhibitors, including sirolimus and everolimus.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	96-125
22520346-7	2012	Increased understanding of the genetic cause of the disease and underlying dysregulation of the mammalian target of rapamycin pathway has led to clinical trials of mammalian target of rapamycin inhibitors, including sirolimus and everolimus.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	164-193
22275355-6	2012	Although mycobacterial infection potently induces mTOR activity, we confirm that bacterial viability can be reduced by rapamycin treatment.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	50-54
22399302-4	2012	By fluorescence confocal microscopy, inactivation of mTOR with rapamycin promoted the nuclear translocation of unphosphorylated STAT1, but not that of a STAT1 mutant incapable of binding its nuclear import adaptor karyopherin-alpha1 (KPNA1).	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	53-57
22399302-4	2012	By fluorescence confocal microscopy, inactivation of mTOR with rapamycin promoted the nuclear translocation of unphosphorylated STAT1, but not that of a STAT1 mutant incapable of binding its nuclear import adaptor karyopherin-alpha1 (KPNA1).	Sirolimus	63-72	karyopherin subunit alpha 1	Homo sapiens	214-232
22399302-4	2012	By fluorescence confocal microscopy, inactivation of mTOR with rapamycin promoted the nuclear translocation of unphosphorylated STAT1, but not that of a STAT1 mutant incapable of binding its nuclear import adaptor karyopherin-alpha1 (KPNA1).	Sirolimus	63-72	karyopherin subunit alpha 1	Homo sapiens	234-239
22399302-5	2012	By immunoprecipitation, KPNA1 was physically associated with mTOR and STAT1 in a complex that translocated to the nucleus in response to rapamycin.	Sirolimus	137-146	karyopherin subunit alpha 1	Homo sapiens	24-29
22399302-5	2012	By immunoprecipitation, KPNA1 was physically associated with mTOR and STAT1 in a complex that translocated to the nucleus in response to rapamycin.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	61-65
22399302-7	2012	KPNA1, or its interaction with STAT1, was required for the nuclear import of latent STAT1, transcriptional induction of the STAT1 gene, and caspase-3 activation under conditions of reduced mTOR activity (i.e. rapamycin, glucose starvation, serum withdrawal).	Sirolimus	209-218	karyopherin subunit alpha 1	Homo sapiens	0-5
22449574-4	2012	Here we demonstrate that besides inhibiting their respective target kinases, the pharmacological PI3-kinase inhibitor LY294002 and the downstream mTOR kinase inhibitor rapamycin also directly inhibit ABCG2 function.	Sirolimus	168-177	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	200-205
22034068-12	2012	Rapamycin also protected against cell death induced by sodium nitroprusside and TNFalpha plus actinomycin D and prevented sGAG loss induced by IL-1alpha.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	80-88
22212527-0	2012	Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling.	Sirolimus	9-18	interleukin 1 beta	Mus musculus	91-99
22482732-4	2012	Importantly, skeletal muscle-specific YY1 knockout mice were protected from rapamycin-induced diabetic-like symptoms.	Sirolimus	76-85	YY1 transcription factor	Mus musculus	38-41
22482732-6	2012	Mechanistically, rapamycin induced YY1 dephosphorylation and recruitment to promoters of insulin/IGF genes, which promoted interaction with the polycomb protein-2 corepressor.	Sirolimus	17-26	YY1 transcription factor	Mus musculus	35-38
22084394-10	2012	Rapamycin treatment also maintained cartilage cellularity and decreased ADAMTS-5 and interleukin-1beta expression in articular cartilage.	Sirolimus	0-9	interleukin 1 beta	Mus musculus	85-102
22014210-2	2012	However, new-onset diabetes is a frequent complication occurring in patients treated with mTOR inhibitors such as rapamycin (Sirolimus).	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	90-94
22014210-2	2012	However, new-onset diabetes is a frequent complication occurring in patients treated with mTOR inhibitors such as rapamycin (Sirolimus).	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	90-94
22014210-12	2012	At the molecular level, long-term Sirolimus administration attenuated glucose uptake and metabolism in skeletal muscle by preventing full insulin-induced Akt activation and altering the expression and translocation of glucose transporters to the plasma membrane.	Sirolimus	34-43	AKT serine/threonine kinase 1	Rattus norvegicus	154-157
22017667-7	2012	KEY RESULTS: Rapamycin induced the expression of KLF4 in vitro and in vivo.	Sirolimus	13-22	Kruppel like factor 4	Rattus norvegicus	49-53
22017667-10	2012	Furthermore, knockdown of KLF4 attenuated the anti-proliferative effect of rapamycin both in vitro and in vivo.	Sirolimus	75-84	Kruppel like factor 4	Rattus norvegicus	26-30
21701901-11	2012	Sirolimus, a specific inhibitor of mTOR pathway, inhibited MHV68-induced hepatic expression of serine p-IRS-1, increased total IRS-1 levels and improved MHV68-induced hepatic insulin resistance.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
22311674-2	2012	mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22311674-2	2012	mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	0-4
22287562-7	2012	Inhibition of the AKT-mTOR pathway with rapamycin significantly reduced the size of high-grade papillary UCB but hyperactivated mitogen-activated protein kinase (MAPK).	Sirolimus	40-49	AKT serine/threonine kinase 1	Homo sapiens	18-21
22287562-7	2012	Inhibition of the AKT-mTOR pathway with rapamycin significantly reduced the size of high-grade papillary UCB but hyperactivated mitogen-activated protein kinase (MAPK).	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	22-26
21618507-10	2012	We also found that treatment of cells with mTOR inhibitor rapamycin and mTOR-siRNA caused decrease in phosphorylation of mTOR and its target proteins which were further downregulated on treatment with fisetin, suggesting that these effects are mediated in part, through mTOR signaling.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	43-47
22385271-10	2012	The pharmacological inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt axis reduced the neuroprotective effect of rapamycin without affecting autophagy.	Sirolimus	122-131	AKT serine/threonine kinase 1	Homo sapiens	75-78
22227406-11	2012	Rapamycin, a specific inhibitor of mammalian TOR signaling attenuated PTTH-stimulated phosphorylation of 4E-BP and S6K of the glands, and greatly inhibited PTTH-stimulated ecdysteroidogenesis.	Sirolimus	0-9	RAR related orphan receptor C	Homo sapiens	45-48
22328519-9	2012	FKBP interactions with RyR2 are very strong and resistant to drug (FK506, rapamycin and cyclic ADPribose) and redox (H(2)O(2) and diamide) treatment.	Sirolimus	74-83	ryanodine receptor 2	Homo sapiens	23-27
22366291-12	2012	A 2.5-fold expansion in CD4(+)CD25(+) lymphocytes occurred in recipients treated with fusion proteins and sirolimus that was not observed in the recipient treated with sirolimus alone.	Sirolimus	106-115	CD4 molecule	Homo sapiens	24-27
22366291-12	2012	A 2.5-fold expansion in CD4(+)CD25(+) lymphocytes occurred in recipients treated with fusion proteins and sirolimus that was not observed in the recipient treated with sirolimus alone.	Sirolimus	168-177	CD4 molecule	Homo sapiens	24-27
22366291-13	2012	CONCLUSIONS: Although IL-2/Fc, mIL-15/Fc, and sirolimus administered in this manner permitted modest prolongation of graft survival and expansion of CD4(+)CD25(+) T cells, tolerance was not achieved.	Sirolimus	46-55	CD4 molecule	Homo sapiens	149-152
22246168-8	2012	The PI3K/AKT inhibitor, LY294002,             and the mTOR inhibitor, rapamycin, largely neutralized the protective effects             of niacin, suggesting that AKT and downstream signaling mTOR/S6 activation are             necessary for the niacin-induced protective effects against UV-induced cell death             and cell apoptosis.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	54-58
22246168-8	2012	The PI3K/AKT inhibitor, LY294002,             and the mTOR inhibitor, rapamycin, largely neutralized the protective effects             of niacin, suggesting that AKT and downstream signaling mTOR/S6 activation are             necessary for the niacin-induced protective effects against UV-induced cell death             and cell apoptosis.	Sirolimus	70-79	AKT serine/threonine kinase 1	Homo sapiens	163-166
22379028-4	2012	Strikingly, a short course of high-dose, but not low-dose, rapamycin treatment transiently blocks viral vaccination-induced mammalian target of rapamycin activity in CD8(+) T cells favoring persistence and Ag-recall responses over type 1 effector maturation; however, prolonged high-dose rapamycin administration abrogated memory responses.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	124-153
22385271-8	2012	Rapamycin, that enhances autophagy by inhibition of mTOR and previously shown to be neuroprotective in our animal model of HI when administered before the ischemic insult, was used to study the potential interaction between autophagy and survival pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	52-56
22385271-9	2012	Rapamycin, besides inducing autophagy, also increased Akt and CREB (cAMP response element-binding protein) phosphorylation in the same cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	54-57
22167413-0	2012	Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	131-135
22564882-9	2012	At variance with rapamycin, dual PI3K/mTOR inhibitors targeted both mTOR complex 1 and mTOR complex 2, and inhibited the rapamycin-resistant phosphorylation of eukaryotic initiation factor 4E-binding protein 1, resulting in a marked inhibition of oncogenic protein translation.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	38-42
22564882-9	2012	At variance with rapamycin, dual PI3K/mTOR inhibitors targeted both mTOR complex 1 and mTOR complex 2, and inhibited the rapamycin-resistant phosphorylation of eukaryotic initiation factor 4E-binding protein 1, resulting in a marked inhibition of oncogenic protein translation.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	38-42
22364741-4	2012	As a part of this response, we found that the LAMMER kinase Kns1 is differentially expressed and hyperphosphorylated and accumulates in the nucleus after rapamycin treatment, whereupon it primes the phosphorylation of the RNA polymerase III subunit Rpc53 by a specific GSK-3 family member, Mck1.	Sirolimus	154-163	serine/threonine protein kinase KNS1	Saccharomyces cerevisiae S288C	60-64
22364741-4	2012	As a part of this response, we found that the LAMMER kinase Kns1 is differentially expressed and hyperphosphorylated and accumulates in the nucleus after rapamycin treatment, whereupon it primes the phosphorylation of the RNA polymerase III subunit Rpc53 by a specific GSK-3 family member, Mck1.	Sirolimus	154-163	DNA-directed RNA polymerase III subunit C53	Saccharomyces cerevisiae S288C	249-254
22364741-4	2012	As a part of this response, we found that the LAMMER kinase Kns1 is differentially expressed and hyperphosphorylated and accumulates in the nucleus after rapamycin treatment, whereupon it primes the phosphorylation of the RNA polymerase III subunit Rpc53 by a specific GSK-3 family member, Mck1.	Sirolimus	154-163	serine/threonine/tyrosine protein kinase MCK1	Saccharomyces cerevisiae S288C	290-294
22457328-2	2012	By assembling with unique and shared partner proteins, mTOR forms the catalytic core of at least two complexes, mTOR complex 1 (mTORC1) and mTORC2, that show differential sensitivity to the allosteric mTOR inhibitor rapamycin and that phosphorylate distinct substrates to modulate cell growth, proliferation, survival, and metabolism in response to diverse environmental cues.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	55-59
22457328-2	2012	By assembling with unique and shared partner proteins, mTOR forms the catalytic core of at least two complexes, mTOR complex 1 (mTORC1) and mTORC2, that show differential sensitivity to the allosteric mTOR inhibitor rapamycin and that phosphorylate distinct substrates to modulate cell growth, proliferation, survival, and metabolism in response to diverse environmental cues.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	112-116
22457328-2	2012	By assembling with unique and shared partner proteins, mTOR forms the catalytic core of at least two complexes, mTOR complex 1 (mTORC1) and mTORC2, that show differential sensitivity to the allosteric mTOR inhibitor rapamycin and that phosphorylate distinct substrates to modulate cell growth, proliferation, survival, and metabolism in response to diverse environmental cues.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	112-116
22167413-3	2012	The mTOR signaling pathway is frequently activated in acute myelogenous leukemia (AML) and we previously showed the safety of combining the mTOR inhibitor, sirolimus, with mitoxantrone, etoposide, and cytarabine (MEC) chemotherapy.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	4-8
22167413-3	2012	The mTOR signaling pathway is frequently activated in acute myelogenous leukemia (AML) and we previously showed the safety of combining the mTOR inhibitor, sirolimus, with mitoxantrone, etoposide, and cytarabine (MEC) chemotherapy.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	140-144
22394614-3	2012	By inhibiting the growth-promoting mTOR pathway, rapamycin decelerates geroconversion of the arrested cells.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	35-39
22422409-1	2012	PURPOSE: We sought to determine whether phosphoinositide 3-kinase (PI3K) pathway mutation or activation state and rapamycin-induced feedback loop activation of Akt is associated with rapamycin sensitivity or resistance.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	160-163
22422409-1	2012	PURPOSE: We sought to determine whether phosphoinositide 3-kinase (PI3K) pathway mutation or activation state and rapamycin-induced feedback loop activation of Akt is associated with rapamycin sensitivity or resistance.	Sirolimus	183-192	AKT serine/threonine kinase 1	Homo sapiens	160-163
22422409-8	2012	Rapamycin and everolimus significantly increased Akt phosphorylation but inhibited growth in an in vivo NET model (BON).	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	49-52
22433289-5	2012	With the use of rapamycin-mediated FKBP-FRB heterodimerization, we have developed a method for rapidly inducible activation or inactivation of small GTPases including Rac(4), Cdc42(4), RhoA(4) and Ras(5), in which rapamycin induces translocation of FKBP-fused GTPases, or their activators, to the plasma membrane where FRB is anchored.	Sirolimus	16-25	Rac family small GTPase 1 pseudogene 4	Homo sapiens	167-173
22266730-0	2012	Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes.	Sirolimus	0-9	solute carrier family 1 member 2	Rattus norvegicus	52-57
22266730-10	2012	Treatment with the autophagy stimulator rapamycin (0.2 mg/mL) significantly reduced the accumulation of mutant Htt-552, and reversed the changes in GLT-1 expression and [(3)H]glutamate uptake in the astrocytes.	Sirolimus	40-49	solute carrier family 1 member 2	Rattus norvegicus	148-153
22190165-0	2012	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	111-115
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sirolimus	10-19	BCL2 like 1	Homo sapiens	114-120
22416776-3	2012	The first identified mTOR inhibitor was rapamycin (sirolimus).	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	21-25
22351078-11	2012	Rapamycin, an inhibitor of mTOR suppressed TNF-alpha protein levels without any significant effect on its mRNA expression or global protein synthesis.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	43-52
22416776-3	2012	The first identified mTOR inhibitor was rapamycin (sirolimus).	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	21-25
22170729-6	2012	Everolimus is a rapamycin analog that inhibits mTOR, but it is more soluble than rapamycin and can be administered orally.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	47-51
22193387-6	2012	Similarly, human podocytes treated with the MTOR inhibitor rapamycin accumulated autophagosomes and autophagolysosomes.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	44-48
22144101-8	2012	These in vitro findings correlate with our in vivo data showing that inhibition of mTOR by rapamycin injection attenuated the onset of myelination in the early postnatal brain.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	83-87
22496622-3	2012	Here we show that rapamycin suppressed insulin-like growth factor 1 (IGF-1)- or fetal bovine serum (FBS)-stimulated lymphatic endothelial cell (LEC) tube formation, an in vitro model of lymphangiogenesis.	Sirolimus	18-27	insulin like growth factor 1	Homo sapiens	39-67
22357207-8	2012	Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	197-200
22357207-8	2012	Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	201-205
22357207-8	2012	Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	46-50
22496622-3	2012	Here we show that rapamycin suppressed insulin-like growth factor 1 (IGF-1)- or fetal bovine serum (FBS)-stimulated lymphatic endothelial cell (LEC) tube formation, an in vitro model of lymphangiogenesis.	Sirolimus	18-27	insulin like growth factor 1	Homo sapiens	69-74
22496622-4	2012	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	54-58
22496622-4	2012	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
22496622-4	2012	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
22496622-4	2012	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
22496622-4	2012	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of LEC tube formation, suggesting that rapamycin inhibition of LEC tube formation is mTOR kinase activity dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
22496622-7	2012	Down-regulation of VEGFR-3 mimicked the effect of rapamycin, inhibiting IGF-1- or FBS-stimulated tube formation, whereas over-expression of VEGFR-3 conferred high resistance to rapamycin inhibition of LEC tube formation.	Sirolimus	50-59	insulin like growth factor 1	Homo sapiens	72-77
22089196-10	2012	We found that knockdown of Atg7 (autophagy-related gene 7) exaggerates, whereas preincubation of rapamycin (an autophagy inducer) diminishes tumor necrosis factor alpha-induced cell death.	Sirolimus	97-106	tumor necrosis factor	Rattus norvegicus	141-168
22171948-4	2012	Treatment with the mTOR inhibitor rapamycin blocked activation of P70S6K and S6, but it also increased activation of AKT and failed to induce cell death.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
22171948-4	2012	Treatment with the mTOR inhibitor rapamycin blocked activation of P70S6K and S6, but it also increased activation of AKT and failed to induce cell death.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	117-120
22171948-5	2012	Combined treatment with rapamycin and PX-866, a PI3K inhibitor, blocked the activation of S6 and AKT and resulted in marked cell death when combined with PLX4720.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	97-100
22281494-0	2012	Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes.	Sirolimus	32-41	insulin	Homo sapiens	9-16
22239125-7	2012	Sirolimus was associated with a reduction in plasma interleukin (IL)-1beta and tumour necrosis factor (TNF)-alpha and higher levels of catalase and total antioxidant status.	Sirolimus	0-9	interleukin 1 beta	Rattus norvegicus	52-74
22239125-7	2012	Sirolimus was associated with a reduction in plasma interleukin (IL)-1beta and tumour necrosis factor (TNF)-alpha and higher levels of catalase and total antioxidant status.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	79-113
22497512-9	2012	2-fold increase in enrichment of CD4(+) CD25(+) FoxP3(+) Treg cells from CD4(+) cells was observed with rapamycin compared to cultures without rapamycin.	Sirolimus	104-113	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Papio anubis	33-36
22497512-9	2012	2-fold increase in enrichment of CD4(+) CD25(+) FoxP3(+) Treg cells from CD4(+) cells was observed with rapamycin compared to cultures without rapamycin.	Sirolimus	104-113	forkhead box protein P3	Papio anubis	48-53
22497512-9	2012	2-fold increase in enrichment of CD4(+) CD25(+) FoxP3(+) Treg cells from CD4(+) cells was observed with rapamycin compared to cultures without rapamycin.	Sirolimus	104-113	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Papio anubis	73-76
22497512-9	2012	2-fold increase in enrichment of CD4(+) CD25(+) FoxP3(+) Treg cells from CD4(+) cells was observed with rapamycin compared to cultures without rapamycin.	Sirolimus	143-152	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Papio anubis	33-36
22497512-9	2012	2-fold increase in enrichment of CD4(+) CD25(+) FoxP3(+) Treg cells from CD4(+) cells was observed with rapamycin compared to cultures without rapamycin.	Sirolimus	143-152	forkhead box protein P3	Papio anubis	48-53
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	27-31
22281494-5	2012	Interestingly, inhibition of mTOR by rapamycin did not affect ER stress markers such as PERK and JNK activity under the ER stress condition.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	29-33
22281494-8	2012	Taken together, these results suggest that rapamycin improved ER stress-induced insulin resistance via inhibition of mTOR/S6K1 hyperphosphorylation in L6 myotubes.	Sirolimus	43-52	insulin	Homo sapiens	80-87
22281494-8	2012	Taken together, these results suggest that rapamycin improved ER stress-induced insulin resistance via inhibition of mTOR/S6K1 hyperphosphorylation in L6 myotubes.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	117-121
22121221-9	2012	While rapamycin has no effect on overall nucleolar morphology or its proteome, it does induce loss of mTOR and raptor from them.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	102-106
22070140-5	2012	Treatment with the specific mTORC1 [mTOR (mammalian target of rapamycin) complex 1] inhibitor rapamycin or siRNA (small interfering RNA) knockdown of mTOR destabilized the ODC mRNA, but rapamycin had only a minor effect on ODC translation initiation.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22070140-5	2012	Treatment with the specific mTORC1 [mTOR (mammalian target of rapamycin) complex 1] inhibitor rapamycin or siRNA (small interfering RNA) knockdown of mTOR destabilized the ODC mRNA, but rapamycin had only a minor effect on ODC translation initiation.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	36-40
22281494-0	2012	Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	74-78
21742593-3	2012	Rapamycin is an antibiotic inhibiting mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
22043997-7	2012	Pharmacologic inhibition of mTOR using rapamycin or ridaforolimus increased lapatinib sensitivity and reduced phospho-Akt levels in cells that showed poor response to single-agent lapatinib, including those transfected with hyperactive Akt.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	28-32
22043997-7	2012	Pharmacologic inhibition of mTOR using rapamycin or ridaforolimus increased lapatinib sensitivity and reduced phospho-Akt levels in cells that showed poor response to single-agent lapatinib, including those transfected with hyperactive Akt.	Sirolimus	39-48	AKT serine/threonine kinase 1	Homo sapiens	118-121
22043997-7	2012	Pharmacologic inhibition of mTOR using rapamycin or ridaforolimus increased lapatinib sensitivity and reduced phospho-Akt levels in cells that showed poor response to single-agent lapatinib, including those transfected with hyperactive Akt.	Sirolimus	39-48	AKT serine/threonine kinase 1	Homo sapiens	236-239
22354768-4	2012	Recent work has shown that treatment with rapamycin, an inhibitor of the mTOR pathway, reduced nuclear blebbing in HGPS fibroblasts.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	73-77
22262166-1	2012	ATP-competitive mTOR kinase inhibitors (mTorKIs) are a new generation of mTOR-targeted agents with more potent anticancer activity than rapamycin in several tumor models.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	16-20
21779001-2	2012	We found that rapamycin, an inhibitor of mTOR complex 1 (mTORC1), attenuated endoplasmic reticulum (ER) stress-induced apoptosis.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	41-45
21779001-3	2012	Among three major branches of the unfolded protein response, rapamycin selectively suppressed the IRE1-JNK signaling without affecting PERK and ATF6 pathways.	Sirolimus	61-70	mitogen-activated protein kinase 8	Homo sapiens	103-106
22084168-0	2012	Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2-overexpressing human mammary epithelial cell lines.	Sirolimus	51-60	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-88
22214523-2	2012	Efficacy varies not so much with drug action, but with tumor type, as different cancer types (and different pre-clinical models) exhibit widely differing susceptibilities to mTOR inhibitors, such as rapamycin.	Sirolimus	199-208	mechanistic target of rapamycin kinase	Homo sapiens	174-178
20890785-10	2012	Based on these results, neuroblastoma tumor cells are sensitive to treatment with inhibitors of glycolysis, and the demonstrated synergy with rapamycin suggests that the combination of glycolysis and mTOR inhibitors represents a novel therapeutic approach for neuroblastoma that warrants further investigation.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Homo sapiens	200-204
22084168-2	2012	Here, we investigated whether rapamycin, an mTOR inhibitor, increased the sensitivity to doxorubicin therapy in two HER-2-overexpressing cell lines: C5.2, which was derived from the parental HB4a by transfection with HER-2 and SKBR3, which exhibits HER-2 amplification.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	44-48
22084168-5	2012	Rapamycin increased the sensitivity to doxorubicin in HER-2-overexpressing cells by approximately 2-fold, suggesting that the combination displayed a more effective antiproliferative action.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-59
22084168-9	2012	Altogether, our data showed a subset of genes that might be more robust than individual markers in predicting the response of HER-2-overexpressing breast cancers to doxorubicin and rapamycin combination.	Sirolimus	181-190	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-131
22353876-3	2012	Inhibition of protein synthesis by rapamycin or cycloheximide resulted in the phosphorylation of BiP on threonine residues while ER stress induced by tunicamycin or heat shock caused the fast dephosphorylation of the protein.	Sirolimus	35-44	heat shock protein family A (Hsp70) member 5	Homo sapiens	97-100
21993902-7	2012	Moreover, treatment of             CML cell line (K562) with rapamycin resulted in a decrease of phosphorylation             of mTOR, 4E-BP1 and p70S6K.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	128-132
21567173-3	2012	We show for the first time that in THP-1-derived macrophages and human monocytes, mTOR inhibition by rapamycin reversed L. donovani-induced IL-12 and IL-10 modulation.	Sirolimus	101-110	GLI family zinc finger 2	Homo sapiens	35-40
21567173-3	2012	We show for the first time that in THP-1-derived macrophages and human monocytes, mTOR inhibition by rapamycin reversed L. donovani-induced IL-12 and IL-10 modulation.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	82-86
21567173-5	2012	This increase in P70S6K phosphorylation was completely blocked by rapamycin (mTOR inhibitor) and partially by wortmannin (PI3K inhibitor).	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	77-81
22841839-7	2012	Future directions for developing TOR-based therapy include assessing the long-term benefits of rapamycin as a candidate drug for heart failure patients, defining the dynamic activity of TOR, exploring the impacts of TOR signaling manipulation in different models of cardiomyopathies, and elucidating the downstream signaling branches that confer the therapeutic effects of TOR signaling inhibition.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Danio rerio	33-36
22134914-4	2012	Surprisingly, rapamycin effectively inhibits Arabidopsis TOR-S6K1 signaling and retards glucose-mediated root and leaf growth, mimicking estradiol-inducible tor mutants.	Sirolimus	14-23	target of rapamycin	Arabidopsis thaliana	57-60
22134914-4	2012	Surprisingly, rapamycin effectively inhibits Arabidopsis TOR-S6K1 signaling and retards glucose-mediated root and leaf growth, mimicking estradiol-inducible tor mutants.	Sirolimus	14-23	target of rapamycin	Arabidopsis thaliana	157-160
22134914-7	2012	Rapamycin exerts TOR inhibition by inducing direct interaction between the TOR-FRB (FKP-rapamycin binding) domain and FKP12 in plant cells.	Sirolimus	0-9	target of rapamycin	Arabidopsis thaliana	17-20
22134914-7	2012	Rapamycin exerts TOR inhibition by inducing direct interaction between the TOR-FRB (FKP-rapamycin binding) domain and FKP12 in plant cells.	Sirolimus	0-9	target of rapamycin	Arabidopsis thaliana	75-78
22080480-2	2012	Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	16-20
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	angiotensinogen	Homo sapiens	48-54
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	angiotensinogen	Homo sapiens	163-169
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	insulin	Homo sapiens	180-187
21903859-4	2012	Herein, it is demonstrated that the mammalian target of rapamycin (mTOR) inhibitors rapamycin (sirolimus) and temsirolimus limit both hormone therapy (HT)-sensitive and castration-resistant PCa (CRPC) cell proliferation as single agents and have a profound radiosensitization effect when used in combination with IR.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	36-65
22156591-8	2012	TGF-beta induced high levels of Foxp3, but no suppressor activity, which emerged only in the presence of rapamycin.	Sirolimus	105-114	transforming growth factor beta 1	Homo sapiens	0-8
22301052-7	2012	Oral rapamycin had been reported to be effective for the treatment of various tumors, apparently because of its action of inhibiting the m-TOR complex.	Sirolimus	5-14	RAR related orphan receptor C	Homo sapiens	139-142
21903859-4	2012	Herein, it is demonstrated that the mammalian target of rapamycin (mTOR) inhibitors rapamycin (sirolimus) and temsirolimus limit both hormone therapy (HT)-sensitive and castration-resistant PCa (CRPC) cell proliferation as single agents and have a profound radiosensitization effect when used in combination with IR.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	67-71
22250258-0	2012	A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	70-74
22214188-8	2012	In contrast, the mTOR inhibitor rapamycin enhanced both COX-2 and mPGES-1 immunoreactivity and the release of PGE2 and PGD2.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	17-21
22214188-8	2012	In contrast, the mTOR inhibitor rapamycin enhanced both COX-2 and mPGES-1 immunoreactivity and the release of PGE2 and PGD2.	Sirolimus	32-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	56-61
22787661-2	2012	In animal models of TSC and cortical dysplasia, hyperactivation of the mTOR pathway promotes epileptogenesis and neuropathological abnormalities, and the mTOR inhibitor, rapamycin, prevents epilepsy and associated cellular and molecular phenotypes in these models.	Sirolimus	170-179	mechanistic target of rapamycin kinase	Homo sapiens	154-158
22166573-1	2012	Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	125-154
22166573-1	2012	Sirolimus is an approved anti-rejection agent following liver or kidney transplantation that works through inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	156-160
22186229-3	2012	We found that rapamycin exerts a conserved cardioprotective effect in two adult zebrafish models of cardiomyopathy of different etiology, and provided the first genetic evidence to support a long-term cardioprotective effect of TOR signaling inhibition.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Danio rerio	228-231
21906027-8	2012	Cardiomyocyte-specific deletion of PDK1 (phosphoinositide-dependent kinase 1) and Akt1/3 abolished cardioprotection after MI in the presence of rapamycin administration.	Sirolimus	144-153	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	35-39
22062220-7	2012	Rapamycin, an autophagy activator, reversed the effects of TLR4 antagonism.	Sirolimus	0-9	toll-like receptor 4	Mus musculus	59-63
21906027-8	2012	Cardiomyocyte-specific deletion of PDK1 (phosphoinositide-dependent kinase 1) and Akt1/3 abolished cardioprotection after MI in the presence of rapamycin administration.	Sirolimus	144-153	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	41-76
21906027-8	2012	Cardiomyocyte-specific deletion of PDK1 (phosphoinositide-dependent kinase 1) and Akt1/3 abolished cardioprotection after MI in the presence of rapamycin administration.	Sirolimus	144-153	thymoma viral proto-oncogene 1	Mus musculus	82-86
24116273-0	2012	Destabilization of TNF-alpha mRNA by Rapamycin.	Sirolimus	37-46	tumor necrosis factor	Rattus norvegicus	19-28
24116273-7	2012	TNF-alpha mRNA stability analysis using reporter construct containing TNF-alpha adenylate/uridylate-rich elements (AREs) shows that rapamycin destabilizes TNF-alpha mRNA via regulating the AU-rich element of TNF-alpha mRNA.	Sirolimus	132-141	tumor necrosis factor	Rattus norvegicus	0-9
24116273-3	2012	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR), reduces the expression of TNF-alpha in rat basophilic leukemia (RBL-2H3) cells.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	56-85
24116273-7	2012	TNF-alpha mRNA stability analysis using reporter construct containing TNF-alpha adenylate/uridylate-rich elements (AREs) shows that rapamycin destabilizes TNF-alpha mRNA via regulating the AU-rich element of TNF-alpha mRNA.	Sirolimus	132-141	tumor necrosis factor	Rattus norvegicus	70-79
24116273-7	2012	TNF-alpha mRNA stability analysis using reporter construct containing TNF-alpha adenylate/uridylate-rich elements (AREs) shows that rapamycin destabilizes TNF-alpha mRNA via regulating the AU-rich element of TNF-alpha mRNA.	Sirolimus	132-141	tumor necrosis factor	Rattus norvegicus	70-79
24116273-3	2012	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR), reduces the expression of TNF-alpha in rat basophilic leukemia (RBL-2H3) cells.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	87-91
24116273-7	2012	TNF-alpha mRNA stability analysis using reporter construct containing TNF-alpha adenylate/uridylate-rich elements (AREs) shows that rapamycin destabilizes TNF-alpha mRNA via regulating the AU-rich element of TNF-alpha mRNA.	Sirolimus	132-141	tumor necrosis factor	Rattus norvegicus	70-79
24116273-3	2012	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR), reduces the expression of TNF-alpha in rat basophilic leukemia (RBL-2H3) cells.	Sirolimus	21-30	tumor necrosis factor	Homo sapiens	120-129
24116273-8	2012	The antigen-induced activation of S6K1 is inhibited by specific kinase inhibitors including mTOR, PI3K, PKC and Ca(2+)chelator inhibitor, while TNF-alpha mRNA level is reduced only by rapamycin treatment.	Sirolimus	184-193	tumor necrosis factor	Rattus norvegicus	144-153
24116273-5	2012	Rapamycin specifically inhibits antigen-induced TNF-alpha mRNA level, while other kinase inhibitors have no effect on TNF-alpha mRNA level.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	48-57
21394501-6	2012	The two mTOR inhibitors, rapamycin and CCI-779, inhibited the invasion of brain metastatic cells only at a moderate concentration level, which was lost at higher concentrations secondary to activation of the MAPK signaling pathway.	Sirolimus	25-34	mitogen-activated protein kinase 1	Mus musculus	208-212
22508061-7	2012	LPS stimulated NHE activity, enhanced forward scatter, increased ROS formation, and triggered TNF-alpha release, effects all blunted in the presence of rapamycin.	Sirolimus	152-161	tumor necrosis factor	Mus musculus	94-103
21644050-10	2012	Perifosine blocked phosphorylation of AKT induced by rapamycin and inhibited HIF-2alpha expression in 786-O and CAKI-1.	Sirolimus	53-62	AKT serine/threonine kinase 1	Homo sapiens	38-41
23304619-6	2012	CsA was replaced by sirolimus, an mTOR inhibitor, in order to reduce or control the increase in the cyst and liver volume.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	34-38
22508056-8	2012	Inhibition of the gastric mTOR signaling by rapamycin attenuated the expression of gastric nesfatin-1/NUCB2 mRNA and protein in both lean and obese mice.	Sirolimus	44-53	nucleobindin 2	Mus musculus	91-101
23082251-1	2012	Effects of the mTOR inhibitor rapamycin were characterized on in vitro cultured primary human acute myeloid leukemia (AML) cells and five AML cell lines.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
23082251-8	2012	To conclude, (i) pharmacological characterization of PI3K-Akt-mTOR inhibitors requires carefully standardized experimental models, (ii) rapamycin effects differ between patients, and (iii) combined targeting of different steps in this pathway should be further investigated whereas combination of rapamycin with valproic acid, ATRA, or NF-kappaB inhibitors seems less promising.	Sirolimus	136-145	AKT serine/threonine kinase 1	Homo sapiens	58-61
23082251-8	2012	To conclude, (i) pharmacological characterization of PI3K-Akt-mTOR inhibitors requires carefully standardized experimental models, (ii) rapamycin effects differ between patients, and (iii) combined targeting of different steps in this pathway should be further investigated whereas combination of rapamycin with valproic acid, ATRA, or NF-kappaB inhibitors seems less promising.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	62-66
22508056-8	2012	Inhibition of the gastric mTOR signaling by rapamycin attenuated the expression of gastric nesfatin-1/NUCB2 mRNA and protein in both lean and obese mice.	Sirolimus	44-53	nucleobindin 2	Mus musculus	102-107
22508061-8	2012	NADPH oxidase inhibitor Vas-2870 (10 muM) mimicked the effect of rapamycin on LPS induced stimulation of NHE activity and TNF-alpha release.	Sirolimus	65-74	tumor necrosis factor	Mus musculus	122-131
23006739-6	2012	In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation.	Sirolimus	108-117	AKT serine/threonine kinase 1	Homo sapiens	51-54
22132896-12	2012	Surprisingly, only rapamycin preconditioning treatment increased anti-apoptotic Bcl2 levels (P < 0 001).	Sirolimus	19-28	BCL2 apoptosis regulator	Homo sapiens	80-84
22132896-13	2012	Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-alpha and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus.	Sirolimus	180-189	tumor necrosis factor	Homo sapiens	41-75
22132896-13	2012	Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-alpha and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus.	Sirolimus	180-189	interleukin 6	Homo sapiens	80-98
22059905-6	2012	Rapamycin, the first defined inhibitor of mTOR, showed effectiveness as an anticancer agent in various preclinical models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	42-46
23006739-6	2012	In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation.	Sirolimus	108-117	AKT serine/threonine kinase 1	Homo sapiens	92-95
22614575-7	2012	We review the cutaneous and mucosal toxicities induced by temsirolimus and everolimus, two mTOR inhibitors used as anticancer agents and by their parent molecule sirolimus.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	91-95
22619555-2	2012	Sirolimus, an inhibitor of mammalian target of rapamycin has gained attention for targeted anticancer therapy, but its clinical application has been limited by its poor solubility.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
22062948-0	2012	RhoA and Rho kinase mediate cyclosporine A and sirolimus-induced barrier tightening in renal proximal tubular cells.	Sirolimus	47-56	ras homolog family member A	Homo sapiens	0-4
23094196-0	2012	Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	37-40
23094196-12	2012	Rapamycin exhibited a concentration-dependent TNF induction-suppression response: induction at doses of 0.1 and 1 ng/mL and suppression at 10 and 100 ng/mL.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	46-49
21898543-5	2012	We found that mTOR inhibition by rapamycin blocks Epo-dependent and -independent osteoblastic phenotypes in human bone marrow stromal cells (hBMSCs) and ST2 cells, respectively.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	14-18
21898543-5	2012	We found that mTOR inhibition by rapamycin blocks Epo-dependent and -independent osteoblastic phenotypes in human bone marrow stromal cells (hBMSCs) and ST2 cells, respectively.	Sirolimus	33-42	erythropoietin	Homo sapiens	50-53
22030071-8	2012	Rapamycin is a macrolide that, besides its antiepileptic effect, restores the Akt function and inhibits the mTOR pathway which may have an antidepressant effect.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	78-81
22785354-6	2012	The Bmp15 and cyclin B mRNA levels were significantly reduced in embryos treated with rapamycin compared with the control.	Sirolimus	86-95	bone morphogenetic protein 15	Sus scrofa	4-9
21567203-0	2012	Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1alpha induction.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	104-114
21567203-5	2012	In addition, siRNA and ChIP assay were further applied to demonstrate the role of hypoxia-inducible factor 1 (HIF-1)alpha in regulating survivin expression regulation under hypoxia during rapamycin induced NSCLC cell apoptosis.	Sirolimus	188-197	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-121
21567203-9	2012	The results above collectively showed that rapamycin inhibits HIF-1alpha-induced survivin expression under hypoxia to induce NSCLC apoptosis.	Sirolimus	43-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	62-72
21874011-4	2012	It has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2), with eventual deregulation of the RHEB/MTOR/RPS6KB2 pathway, and it has been observed that some PEComas regressed during sirolimus therapy, an MTOR inhibitor.	Sirolimus	313-322	TSC complex subunit 1	Homo sapiens	131-151
21874011-4	2012	It has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2), with eventual deregulation of the RHEB/MTOR/RPS6KB2 pathway, and it has been observed that some PEComas regressed during sirolimus therapy, an MTOR inhibitor.	Sirolimus	313-322	TSC complex subunit 1	Homo sapiens	153-157
22030071-8	2012	Rapamycin is a macrolide that, besides its antiepileptic effect, restores the Akt function and inhibits the mTOR pathway which may have an antidepressant effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	108-112
21617191-0	2012	Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	78-112
22125057-0	2012	Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	46-50
22125063-6	2012	Moreover, the mTORC2 complex components rictor and sin1 are dephosphorylated and dynamically distributed between the cytoplasm and the nucleus upon long-term treatment with the mTOR-inhibitor rapamycin.	Sirolimus	192-201	MAPK associated protein 1	Homo sapiens	51-55
22125063-6	2012	Moreover, the mTORC2 complex components rictor and sin1 are dephosphorylated and dynamically distributed between the cytoplasm and the nucleus upon long-term treatment with the mTOR-inhibitor rapamycin.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Homo sapiens	14-18
22125064-2	2012	Constitutive mTOR signaling characterizes multiple human malignancies, and pharmacological inhibitors of mTOR such as the immunosuppressant rapamycin and some of its nonimmunosuppressive derivatives not only have been ascribed with promising anticancer properties in vitro and in vivo but are also being extensively evaluated in clinical trials.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	13-17
22125064-2	2012	Constitutive mTOR signaling characterizes multiple human malignancies, and pharmacological inhibitors of mTOR such as the immunosuppressant rapamycin and some of its nonimmunosuppressive derivatives not only have been ascribed with promising anticancer properties in vitro and in vivo but are also being extensively evaluated in clinical trials.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	105-109
21907282-12	2012	The dramatic effect of rapamycin suggests that even with extensive multi-lineage abnormalities, a postnatal therapeutic window may exist for patients with TSC.	Sirolimus	23-32	TSC complex subunit 1	Homo sapiens	155-158
21922152-12	2012	Importantly, knockdown of LRRK2 associated with high proliferative rate in normal             cells and treatment with rapamycin and/or proteosome inhibition suppressed 4E-BP1             protein degradation.	Sirolimus	119-128	leucine rich repeat kinase 2	Homo sapiens	26-31
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	14-18
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	32-41	mitogen-activated protein kinase 1	Homo sapiens	69-113
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	32-41	mitogen-activated protein kinase 3	Homo sapiens	115-121
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	127-130
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	14-18
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	186-195	mitogen-activated protein kinase 1	Homo sapiens	69-113
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	186-195	mitogen-activated protein kinase 3	Homo sapiens	115-121
22057915-1	2012	Inhibition of mTOR signaling by rapamycin has been shown to activate extracellular signal-regulated kinase 1 or 2 (ERK1/2) and Akt in various types of cancer cells, which contributes to rapamycin resistance.	Sirolimus	186-195	AKT serine/threonine kinase 1	Homo sapiens	127-130
22057915-3	2012	We discovered that treatment of human lung cancer cells with rapamycin results in enhanced phosphorylation of Bad at serine (S) 112 and S136 but not S155 in association with activation of ERK1/2 and Akt.	Sirolimus	61-70	mitogen-activated protein kinase 3	Homo sapiens	188-194
22479189-10	2012	Combination treatment using roscovitine (CDK inhibitor) plus either rapamycin (mTOR inhibitor) or sorafenib (a pan kinase inhibitor targeting b-Raf) effectively prevented aberrant acinar formation in LMW-E-expressing cells by inducing G1/S cell cycle arrest.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	79-83
22057915-3	2012	We discovered that treatment of human lung cancer cells with rapamycin results in enhanced phosphorylation of Bad at serine (S) 112 and S136 but not S155 in association with activation of ERK1/2 and Akt.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	199-202
22057915-9	2012	Simultaneous blockage of S112 and S136 phosphorylation of Bad by PD98059 and silencing of Akt significantly enhances rapamycin-induced growth inhibition in vitro and synergistically increases the antitumor efficacy of rapamycin in lung cancer xenografts.	Sirolimus	117-126	AKT serine/threonine kinase 1	Homo sapiens	90-93
22057915-9	2012	Simultaneous blockage of S112 and S136 phosphorylation of Bad by PD98059 and silencing of Akt significantly enhances rapamycin-induced growth inhibition in vitro and synergistically increases the antitumor efficacy of rapamycin in lung cancer xenografts.	Sirolimus	218-227	AKT serine/threonine kinase 1	Homo sapiens	90-93
22916036-4	2012	Treatment with rapamycin, an inhibitor of mTORC1 activity, decreased tumor burden in adult Lkb1 mutant mice.	Sirolimus	15-24	serine/threonine kinase 11	Mus musculus	91-95
22479189-12	2012	The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib.	Sirolimus	157-166	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	4-9
22479189-12	2012	The b-Raf-ERK1/2-mTOR signaling pathway is aberrantly activated in breast cancer and can be suppressed by combination treatment with roscovitine plus either rapamycin or sorafenib.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	17-21
23209838-5	2012	Pretreatment with PI3K inhibitor (Ly294002), Akt inhibitor, or mTORC1 inhibitor (rapamycin) blocked the HGF-induced VEGF-A production.	Sirolimus	81-90	vascular endothelial growth factor A	Homo sapiens	116-122
23272222-6	2012	Rapamycin, a mTORC1 inhibitor, restores the insulin signaling after downregulation of REDD1 expression.	Sirolimus	0-9	insulin	Homo sapiens	44-51
23185517-2	2012	mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activity.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	103-106
23071528-9	2012	Low dose oral sirolimus increases the risk of menstrual cycle disturbances and ovarian cysts and monitoring of sirolimus-associated ovarian toxicity is warranted and might guide clinical practice with mammalian target of rapamycin inhibitors.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	201-230
23118926-1	2012	Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use of this drug combination.	Sirolimus	55-64	calcineurin binding protein 1	Rattus norvegicus	15-36
23118926-1	2012	Enhancement of calcineurin inhibitor nephrotoxicity by sirolimus (SRL) is limiting the clinical use of this drug combination.	Sirolimus	66-69	calcineurin binding protein 1	Rattus norvegicus	15-36
23272151-6	2012	Likewise, stimulation of autophagy by nutrient starvation or rapamycin treatment reduced intracellular AIEC survival and IL-8 production.	Sirolimus	61-70	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
23071528-9	2012	Low dose oral sirolimus increases the risk of menstrual cycle disturbances and ovarian cysts and monitoring of sirolimus-associated ovarian toxicity is warranted and might guide clinical practice with mammalian target of rapamycin inhibitors.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	201-230
22880048-4	2012	Expression of BRAFV600E in NIH3T3 cells significantly suppresses MEK inhibitor (RG7167) or mTORC1 inhibitor (rapamycin) induced AKT phosphorylation (pAKT) and downstream signal activation.	Sirolimus	109-118	thymoma viral proto-oncogene 1	Mus musculus	128-131
22937032-7	2012	Furthermore, small-interfering RNA-mediated knockdown of KLF2 strongly magnified the ability of rapamycin to induce TF and reduce eNOS accumulation in HUVECs.	Sirolimus	96-105	Kruppel like factor 2	Homo sapiens	57-61
22900063-0	2012	Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	77-82
22900063-0	2012	Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	107-111
22900063-3	2012	Here we show that elevated VEGF levels produced by hemangioma endothelial cells are reduced by the mTOR inhibitor rapamycin.	Sirolimus	114-123	vascular endothelial growth factor A	Homo sapiens	27-31
22900063-3	2012	Here we show that elevated VEGF levels produced by hemangioma endothelial cells are reduced by the mTOR inhibitor rapamycin.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	99-103
22848663-5	2012	HBx upregulated cell proliferation and vascular endothelial growth factor (VEGF) production, and these HBx-upregulated phenotypes were abolished by treatment with IKKbeta inhibitor Bay 11-7082 or mTOR inhibitor rapamycin.	Sirolimus	211-220	mechanistic target of rapamycin kinase	Homo sapiens	196-200
22428038-0	2012	Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.	Sirolimus	99-108	AKT serine/threonine kinase 1	Rattus norvegicus	19-22
22859939-6	2012	PTH was lower in sirolimus treated rats.	Sirolimus	17-26	parathyroid hormone	Rattus norvegicus	0-3
22428038-8	2012	CONCLUSIONS: Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.	Sirolimus	136-145	AKT serine/threonine kinase 1	Rattus norvegicus	32-35
22428038-8	2012	CONCLUSIONS: Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.	Sirolimus	264-273	AKT serine/threonine kinase 1	Rattus norvegicus	32-35
20207175-0	2012	Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.	Sirolimus	74-83	AKT serine/threonine kinase 1	Homo sapiens	17-20
22493717-2	2012	As growth hormone (GH) can be used to treat growth retardation in transplanted children, we aimed this study to find out the effect of GH therapy in a model of young rat with growth retardation induced by rapamycin administration.	Sirolimus	205-214	growth hormone 1	Homo sapiens	3-17
22493717-2	2012	As growth hormone (GH) can be used to treat growth retardation in transplanted children, we aimed this study to find out the effect of GH therapy in a model of young rat with growth retardation induced by rapamycin administration.	Sirolimus	205-214	growth hormone 1	Homo sapiens	135-137
22570764-0	2012	Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle.	Sirolimus	10-19	dystrophin, muscular dystrophy	Mus musculus	59-69
20207175-2	2012	Rapamycin, the inhibitor of mTOR Complex 1, provides alternative immunosuppressive therapy after kidney transplantation with less neoplastic potential.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
20207175-9	2012	In vitro, rapamycin also inhibited the cell proliferation, migration, and invasion, as well as the protein expression of vascular endothelial growth factor-A of T24 urothelial carcinoma cells, whereas rapamycin did not induce significant apoptosis in T24 cells.	Sirolimus	10-19	vascular endothelial growth factor A	Homo sapiens	121-157
21994950-4	2011	The ORF45/RSK-mediated eIF4B phosphorylation was distinguishable from that caused by the canonical AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resistant to both rapamycin (an mammalian target of rapamycin inhibitor) and U1026 (an MEK inhibitor).	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	99-102
22039046-0	2011	Nitrogen-responsive regulation of GATA protein family activators Gln3 and Gat1 occurs by two distinct pathways, one inhibited by rapamycin and the other by methionine sulfoximine.	Sirolimus	129-138	solute carrier family 6 member 1	Homo sapiens	74-78
22094953-0	2011	Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.	Sirolimus	83-92	ATP binding cassette subfamily B member 1	Homo sapiens	16-21
22094953-1	2011	BACKGROUNDS: Sirolimus (SRL) absorption and metabolism are affected by p-glycoprotein-mediated transport and CYP3A enzyme activity, which are further under the influences of cytokine concentrations.	Sirolimus	13-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-114
21994950-4	2011	The ORF45/RSK-mediated eIF4B phosphorylation was distinguishable from that caused by the canonical AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resistant to both rapamycin (an mammalian target of rapamycin inhibitor) and U1026 (an MEK inhibitor).	Sirolimus	123-132	ribosomal protein S6 kinase A2	Homo sapiens	133-152
21994950-4	2011	The ORF45/RSK-mediated eIF4B phosphorylation was distinguishable from that caused by the canonical AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resistant to both rapamycin (an mammalian target of rapamycin inhibitor) and U1026 (an MEK inhibitor).	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	225-254
21994950-4	2011	The ORF45/RSK-mediated eIF4B phosphorylation was distinguishable from that caused by the canonical AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resistant to both rapamycin (an mammalian target of rapamycin inhibitor) and U1026 (an MEK inhibitor).	Sirolimus	123-132	mitogen-activated protein kinase kinase 7	Homo sapiens	280-283
21880834-0	2011	TGF-beta1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.	Sirolimus	19-28	transforming growth factor beta 1	Homo sapiens	0-9
22015781-9	2011	Inhibition of mTOR with rapamycin reversed the down-regulation of cellular lipid efflux mediator ABCA1, which resulted from the activation of TLR4 by ligands.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
21880834-6	2011	Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER.	Sirolimus	129-132	transforming growth factor beta 1	Homo sapiens	9-19
21880834-6	2011	Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER.	Sirolimus	129-132	transforming growth factor beta 1	Homo sapiens	54-64
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Sirolimus	40-43	transforming growth factor beta 1	Homo sapiens	65-75
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Sirolimus	40-43	transforming growth factor beta 1	Homo sapiens	168-178
21880834-9	2011	It is most likely that the CsA- and CsA/SRL-induced increases in TGF-beta(1) expression may not be sufficient to trigger the Smad pathway but however may trigger other TGF-beta(1) receptor-mediated signaling including the ERK1/2 signaling pathway.	Sirolimus	40-43	mitogen-activated protein kinase 3	Homo sapiens	222-228
21438065-1	2011	BACKGROUND: Rapamycin is an mTOR inhibitor with preclinical efficacy in squamous cell carcinoma of the head and neck (SCCHN).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	28-32
21889928-8	2011	Importantly, co-treatment with MEK/ERK inhibitor (U0126) and PI3K/Akt (LY294002) or mTOR (rapamycin) inhibitors, instead of ATO, also potentiates lonidamine-provoked apoptosis.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	84-88
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	Sirolimus	49-58	AKT serine/threonine kinase 1	Homo sapiens	75-78
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	Sirolimus	49-58	hypoxia inducible factor 1 subunit alpha	Homo sapiens	141-151
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	Sirolimus	49-58	vascular endothelial growth factor A	Homo sapiens	178-182
20828737-9	2011	Pretreatment with rapamycin, a specific inhibitor of mTOR, resulted in a significant decrease of IL-10 and IL-6 translation and expression but did not affect the LPS-induced TNFalpha production.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	53-57
21964553-4	2011	Rapamycin (final concentration, 0.1 mg/mL) was solubilized in rHDL containing either wild-type (WT) or V156K-apoA-I (1 mg/mL of protein) prepared using the sodium cholate dialysis method.	Sirolimus	0-9	apolipoprotein A1	Homo sapiens	109-115
22021618-9	2011	Increases in IL-13 and leukotrienes were also blocked by rapamycin, although increases in IL-4 were unaffected.	Sirolimus	57-66	interleukin 13	Mus musculus	13-18
22021618-10	2011	These data demonstrated that rapamycin can inhibit cardinal features of allergic asthma, including increases in AHR, IgE, and goblet cells, most likely as a result of its ability to reduce the production of two key mediators of asthma: IL-13 and leukotrienes.	Sirolimus	29-38	interleukin 13	Mus musculus	236-241
21911485-6	2011	Here, we show that both genetic and pharmacologic inhibition of SAPK2/p38 in glioblastoma multiforme cells significantly reduces rapamycin-induced IRES-mediated translation initiation of cyclin D1 and c-MYC, resulting in increased G(1) arrest in vitro and inhibition of tumor growth in xenografts.	Sirolimus	129-138	mitogen-activated protein kinase 11	Mus musculus	64-69
21445948-5	2011	PROCEDURE: Here we retrospectively evaluate a series of six patients with complicated, life-threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	149-153
21972103-5	2011	Rapamycin inhibition of the TOR pathway and deletion of RAS2 gene significantly reduced biofilm formation and FLO11 expression.	Sirolimus	0-9	Flo11p	Saccharomyces cerevisiae S288C	110-115
22071574-0	2011	High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	76-80
22071574-5	2011	We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1).	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	125-129
22071574-9	2011	We show that survival correlated with a hyper-phosphorylation of Akt at S473 at high rapamycin doses, the suppression of which conferred rapamycin sensitivity.	Sirolimus	85-94	AKT serine/threonine kinase 1	Homo sapiens	65-68
22025691-8	2011	Postnatal rapamycin treatment completely reversed these phenotypes and rescued the mutants from epilepsy and premature death, despite prenatal onset of Tsc1 loss and mTOR complex 1 activation in the developing brain.	Sirolimus	10-19	TSC complex subunit 1	Homo sapiens	152-156
21602892-6	2011	Blocking mTOR kinase activity via rapamycin and its activation in TSC2(-/-) cells and via TSC2 small interfering RNAs revealed that it regulates the localization of p70, but not of p85 and p31.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	9-13
21973019-8	2011	KEY FINDINGS: NS-Pten knockouts treated with a single course of rapamycin had recurrence of epilepsy 4-7 weeks after treatment ended.	Sirolimus	64-73	phosphatase and tensin homolog	Mus musculus	17-21
22737268-3	2011	Demonstrated herein, we have shown that both the development and growth of metastatic lesions are markedly reduced by the mTOR inhibitor sirolimus.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	122-126
21302298-6	2011	The effects of TGFbeta and bleomycin on ECM synthesis were blunted by pre-treatment with an mTOR inhibitor rapamycin.	Sirolimus	107-116	transforming growth factor beta 1	Homo sapiens	15-22
21302298-6	2011	The effects of TGFbeta and bleomycin on ECM synthesis were blunted by pre-treatment with an mTOR inhibitor rapamycin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	92-96
21945951-8	2011	Furthermore, p53 activation by AICAR was blocked by rapamycin, a specific inhibitor of the mTOR kinase, which is a crucial regulator of cell growth.	Sirolimus	52-61	tumor protein p53	Homo sapiens	13-16
21945951-8	2011	Furthermore, p53 activation by AICAR was blocked by rapamycin, a specific inhibitor of the mTOR kinase, which is a crucial regulator of cell growth.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	91-95
22099798-5	2011	OBJECTIVE: The aim was to evaluate the cost-effectiveness of early conversion from tacrolimus to mammalian target of rapamycin inhibitors sirolimus or everolimus versus continuous treatment with tacrolimus among renal transplantat patients in Colombia.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	97-126
21968016-8	2011	Rapamycin, the pharmacologic inhibitor of mammalian target of rapamycin (mTOR), diminished NGF-induced S6 phosphorylation, cell migration and protective effects against oxidative stress.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	42-71
21968016-8	2011	Rapamycin, the pharmacologic inhibitor of mammalian target of rapamycin (mTOR), diminished NGF-induced S6 phosphorylation, cell migration and protective effects against oxidative stress.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-77
21968016-8	2011	Rapamycin, the pharmacologic inhibitor of mammalian target of rapamycin (mTOR), diminished NGF-induced S6 phosphorylation, cell migration and protective effects against oxidative stress.	Sirolimus	0-9	nerve growth factor	Homo sapiens	91-94
22037041-2	2011	Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
21692771-0	2011	A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.	Sirolimus	25-34	TSC complex subunit 1	Homo sapiens	119-122
21692771-3	2011	Although rapamycin improves many TSC lesions, significant side-effects appear after systemic administration.	Sirolimus	9-18	TSC complex subunit 1	Homo sapiens	33-36
21692771-5	2011	OBJECTIVES: The efficacy of rapamycin-tacrolimus ointment was examined for TSC-related angiofibroma.	Sirolimus	28-37	TSC complex subunit 1	Homo sapiens	75-78
21692771-11	2011	CONCLUSIONS: Topical application of rapamycin-tacrolimus ointment is a safe and useful treatment for TSC-related angiofibroma.	Sirolimus	36-45	TSC complex subunit 1	Homo sapiens	101-104
21825008-1	2011	Ridaforolimus is a nonprodrug rapamycin analogue that potently inhibits mTOR and has shown significant activity in patients with metastatic sarcoma and endometrial cancer, two diseases where high unmet need remains.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	72-76
22027770-6	2011	Treatment with 20 ng/ml VEGF obviously promoted MSC proliferation, and this effect was inhibited partially by p38 mitogen-activated protein kinase (MAPK) inhibitor rapamycin, PD98059, SB203580, Go6976, and straurosporine.	Sirolimus	164-173	vascular endothelial growth factor A	Homo sapiens	24-28
21742779-10	2011	Upon exposure to H(2)O(2), Akt was intensely phosphorylated in the first 30 min, concurrently with mammalian target of rapamycin inactivation and autophagy, and it was dephosphorylated at 2 h, when > 50% of the cells were dead.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	27-30
21128236-3	2011	We found that, despite showing no effect on HSV replication in tumor cells fully permissive to the virus growth, the mTOR inhibitor rapamycin markedly increased the yield and dissemination of oncolytic HSVs in semipermissive tumor cells.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	117-121
21336564-0	2011	Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	32-36
21336564-5	2011	These results demonstrate that, although the combination of PI3K inhibitor and rapamycin is more effective in inhibiting proliferation of AML, the concomitant inhibition of PI3K and mTOR by LY 294002 and rapamycin has more inhibitory effects on ATRA-mediated differentiation than the presence of PI3K-inhibitor alone, and diminishes positive effects of rapamycin on leukemia cell differentiation.	Sirolimus	204-213	mechanistic target of rapamycin kinase	Homo sapiens	182-186
21911134-2	2011	Newer immunosuppressants such as mycophenolic acid and, particularly, mammalian target of rapamycin (mTOR) inhibitors (eg, sirolimus) may cause significant lung toxicity.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	70-99
21911134-2	2011	Newer immunosuppressants such as mycophenolic acid and, particularly, mammalian target of rapamycin (mTOR) inhibitors (eg, sirolimus) may cause significant lung toxicity.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	101-105
21984149-9	2011	The combination of IDA with rapamycin enhanced the expressions of Caspase 3, PARP, Caspase 8 and Caspase 9.	Sirolimus	28-37	caspase 3	Homo sapiens	66-75
21984149-10	2011	Rapamycin significantly inhibited mTOR signaling upstream Akt and downstream S6K activation triggered by IDA, and the combination of the two agents led to synergistic inhibition of ERK phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	34-38
21690574-7	2011	PM02734 caused inhibition of Akt/mTOR signaling pathways and cotreatment with the Akt inhibitor wortmannin or with the mTOR inhibitor rapamycin led to a significant increase in PM02734-induced cell death.	Sirolimus	134-143	AKT serine/threonine kinase 1	Homo sapiens	29-32
21690574-7	2011	PM02734 caused inhibition of Akt/mTOR signaling pathways and cotreatment with the Akt inhibitor wortmannin or with the mTOR inhibitor rapamycin led to a significant increase in PM02734-induced cell death.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	33-37
21690574-7	2011	PM02734 caused inhibition of Akt/mTOR signaling pathways and cotreatment with the Akt inhibitor wortmannin or with the mTOR inhibitor rapamycin led to a significant increase in PM02734-induced cell death.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	119-123
21252047-6	2011	In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	41-45
21252047-6	2011	In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	105-109
21252047-6	2011	In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected.	Sirolimus	19-28	vascular endothelial growth factor A	Homo sapiens	129-133
21252047-6	2011	In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected.	Sirolimus	19-28	hypoxia inducible factor 1 subunit alpha	Homo sapiens	155-165
21305305-7	2011	Biologically targeted pharmacotherapy with mTOR inhibitors such as sirolimus and everolimus provides a safe and efficacious treatment option for patients with SGCT and has the potential to change the clinical management of these tumors.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	43-47
21538345-5	2011	Following activation, CXCR3-expressing CD4(+) Tregs were maintained in vitro in cell culture in the presence of the mammalian target of rapamycin (mTOR) inhibitor rapamycin, and we detected higher numbers of circulating CXCR3(+) FOXP3(+) T cells in adult and pediatric recipients of renal transplants who were treated with mTOR-inhibitor immunosuppressive therapy.	Sirolimus	136-145	CD4 molecule	Homo sapiens	39-42
21823021-0	2011	Effects of rapamycin on expression of Bcl-2 and Bax in human lens epithelial cells and cell cycle in rats.	Sirolimus	11-20	BCL2 apoptosis regulator	Homo sapiens	38-43
21823021-0	2011	Effects of rapamycin on expression of Bcl-2 and Bax in human lens epithelial cells and cell cycle in rats.	Sirolimus	11-20	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
21823021-1	2011	The effects of rapamycin on the expression of Bcl-2 and Bax protein in in vitro cultured human lens epithelial cells (LECs) and cell cycle were investigated in order to provide the theoretical basis for the development of new inhibitory drugs for clinical prevention and treatment of after-cataract.	Sirolimus	15-24	BCL2 apoptosis regulator	Homo sapiens	46-51
21823021-1	2011	The effects of rapamycin on the expression of Bcl-2 and Bax protein in in vitro cultured human lens epithelial cells (LECs) and cell cycle were investigated in order to provide the theoretical basis for the development of new inhibitory drugs for clinical prevention and treatment of after-cataract.	Sirolimus	15-24	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
21823021-12	2011	Western blot demonstrated that rapamycin could suppress the expression of Bcl-2 protein, but promote the expression of Bax protein.	Sirolimus	31-40	BCL2 apoptosis regulator	Homo sapiens	74-79
21823021-12	2011	Western blot demonstrated that rapamycin could suppress the expression of Bcl-2 protein, but promote the expression of Bax protein.	Sirolimus	31-40	BCL2 associated X, apoptosis regulator	Homo sapiens	119-122
21613408-7	2011	Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	87-91
21600903-1	2011	AIMS: Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian targeting of rapamycin (mTOR) signaling, and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	119-123
21600903-1	2011	AIMS: Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian targeting of rapamycin (mTOR) signaling, and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	119-123
21508335-4	2011	Here, we demonstrate that the inhibition of mTORC1 by rapamycin (mTORC1 inhibitor), torin1 (both mTORC1 and mTORC2 inhibitor) or short hairpin RNA-mediated knockdown of mTOR, regulatory associated protein of mTOR (RAPTOR), and p70 S6 kinase (p70S6K) increased basal NT release via upregulating NT gene expression in BON cells.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	44-48
20686837-6	2011	Further analysis demonstrated that the combination of the mTOR inhibitor rapamycin and cisplatin generated significant drug synergism in basal-like MDA-MB-468, MDA-MB-231, and HCC1937 cells but not in luminal-like T47D or MCF-7 cells.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	58-62
21415215-8	2011	Inhibition of the mTOR catalytic site with OSI-027 results in suppression of both mTORC2 and RI-mTORC1 complexes and elicits much more potent antileukemic responses than selective mTORC1 targeting with rapamycin.	Sirolimus	202-211	mechanistic target of rapamycin kinase	Homo sapiens	18-22
21561413-2	2011	mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this durg.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	0-4
21633171-2	2011	Mammalian TOR (mTOR) is thought to work through 2 independent complexes to regulate cell size and cell replication, and these 2 complexes show differential sensitivity to rapamycin.	Sirolimus	171-180	mechanistic target of rapamycin kinase	Homo sapiens	15-19
21730367-5	2011	Cells which expressed  Akt-1(CA) were hypersensitive to the mTOR inhibitor rapamycin.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	23-28
21730367-5	2011	Cells which expressed  Akt-1(CA) were hypersensitive to the mTOR inhibitor rapamycin.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	29-31
21730367-5	2011	Cells which expressed  Akt-1(CA) were hypersensitive to the mTOR inhibitor rapamycin.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	60-64
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	106-111
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	112-114
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	106-109
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	232-236
21418335-5	2011	The impact of immunosuppression and especially immunosuppression with mammalian target of rapamycin (mTOR) inhibitors on the development of surgical wound complications has been widely discussed following reports of increased occurrence with sirolimus.	Sirolimus	242-251	mechanistic target of rapamycin kinase	Homo sapiens	70-99
21418335-5	2011	The impact of immunosuppression and especially immunosuppression with mammalian target of rapamycin (mTOR) inhibitors on the development of surgical wound complications has been widely discussed following reports of increased occurrence with sirolimus.	Sirolimus	242-251	mechanistic target of rapamycin kinase	Homo sapiens	101-105
21722526-8	2011	ELISA detection manifested that compared with the untreated group different concentrations of RPM could significantly inhibit the IL-2 and IFN-gamma secretion and significantly inhibited T lymphocyte proliferation (P<0.01).	Sirolimus	94-97	interleukin 2	Homo sapiens	130-134
21722526-8	2011	ELISA detection manifested that compared with the untreated group different concentrations of RPM could significantly inhibit the IL-2 and IFN-gamma secretion and significantly inhibited T lymphocyte proliferation (P<0.01).	Sirolimus	94-97	interferon gamma	Homo sapiens	139-148
21690594-3	2011	Sirolimus is a mammalian target of rapamycin inhibitor that has been reported to decrease the size of neoplastic growths in animal models of tuberous sclerosis complex and to reduce the size of angiomyolipomas and stabilize lung function in humans.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-44
21914363-19	2011	With similar results, the RPM treatment had insignificant effects on the expression of IL-6.	Sirolimus	26-29	interleukin 6	Rattus norvegicus	87-91
21454807-3	2011	METHODS AND RESULTS: Using human coronary artery VSMC, we found that recombinant adiponectin in the high-molecular-weight or trimeric forms but not the globular form induced VSMC differentiation through a mechanism similar to the classic feedback signaling used by rapamycin, a drug known to effectively inhibit restenosis on drug-eluting stents.	Sirolimus	265-274	adiponectin, C1Q and collagen domain containing	Homo sapiens	81-92
20715103-5	2011	Simultaneous inhibition of VEGFR downstream effector mTOR using rapamycin 20 mg/kg q2dx5 did not statistically enhance tumor growth delay compared to single agent activities.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	53-57
21385891-7	2011	Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3beta hyperphosphorylation in each sarcoma model.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	45-48
21557327-4	2011	mTOR exists in two distinct complexes-mTORC1 and mTORC2 that differ in their components and sensitivity to rapamycin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	0-4
21380626-1	2011	Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF).	Sirolimus	36-45	vascular endothelial growth factor A	Homo sapiens	186-220
21380626-1	2011	Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF).	Sirolimus	36-45	vascular endothelial growth factor A	Homo sapiens	222-226
21541789-3	2011	Sirolimus and its derivatives (rapalogs) interact with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR and thus disrupting its activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	158-162
21478152-5	2011	Activation of AMPK with 5-aminoimidazole-4-carbozamide-1-beta-D-ribifuranoside or inhibition of mTOR with rapamycin or mTOR siRNA attenuated these resistin-induced changes.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	96-100
21576264-5	2011	CPT1C expression correlates inversely with mammalian target of rapamycin (mTOR) pathway activation, contributes to rapamycin resistance in murine primary tumors, and is frequently up-regulated in human lung tumors.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	74-78
21572994-5	2011	The expression of IFN-gammainduced by IL-12 and IL-18 is sensitive to rapamycin and SB203580, indicating the possible involvement of mTOR and p38 MAP kinase, respectively, in this synergistic pathway.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	133-137
21572994-5	2011	The expression of IFN-gammainduced by IL-12 and IL-18 is sensitive to rapamycin and SB203580, indicating the possible involvement of mTOR and p38 MAP kinase, respectively, in this synergistic pathway.	Sirolimus	70-79	mitogen-activated protein kinase 14	Homo sapiens	142-156
21357504-0	2011	Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	61-64
21357504-8	2011	Rapamycin pretreatment also significantly increased PO-induced Akt phosphorylation at S473, a finding confirmed in cardiomyocytes in vitro to be downstream of mTORC2.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	63-66
21266843-6	2011	The allosteric mTORC1 inhibitor rapamycin fails to induce apoptosis in conjunction with blockade of autophagy, due to feedback-activation of Akt.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	141-144
21266843-7	2011	Apoptosis in the setting of rapamycin therapy requires concurrent inhibition of both autophagy and of PtdIns3K-Akt.	Sirolimus	28-37	AKT serine/threonine kinase 1	Homo sapiens	111-114
20680277-9	2011	In addition, ROS generation was included in downstream signaling events associated with the phosphorylation of mTOR, because pretreatment of cells with rapamycin inhibited ROS generation.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	111-115
21052690-0	2011	The 5352 A allele of the pro-inflammatory caspase-1 gene predicts late-acquired stent malapposition in STEMI patients treated with sirolimus stents.	Sirolimus	131-140	caspase 1	Homo sapiens	42-51
21369693-8	2011	Administration of RPM or AG490 decreased the activity of NF-kappaB and inhibited the release of TNF-alpha, IL-1beta, and IL-6.	Sirolimus	18-21	tumor necrosis factor	Rattus norvegicus	96-105
21369693-8	2011	Administration of RPM or AG490 decreased the activity of NF-kappaB and inhibited the release of TNF-alpha, IL-1beta, and IL-6.	Sirolimus	18-21	interleukin 1 beta	Rattus norvegicus	107-115
21369693-8	2011	Administration of RPM or AG490 decreased the activity of NF-kappaB and inhibited the release of TNF-alpha, IL-1beta, and IL-6.	Sirolimus	18-21	interleukin 6	Rattus norvegicus	121-125
20936651-5	2011	IRS-1 (Ser302) phosphorylation was abolished by wortmannin and rapamycin, suggesting a feedback from the PI3K pathway on insulin signalling.	Sirolimus	63-72	insulin	Homo sapiens	121-128
21520111-1	2011	OBJECTIVES/HYPOTHESIS: To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	69-98
21520111-1	2011	OBJECTIVES/HYPOTHESIS: To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	100-104
21520111-12	2011	CONCLUSIONS: In this study, we demonstrate that the generic mTOR inhibitor sirolimus shows potent antitumor activity in HNSCC and produces comparable effects to the patent drug temsirolimus.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	60-64
21511183-5	2011	The ability of rapamycin to augment HP-induced memory was cell-intrinsic given that silencing mTOR in CD8+ T cells generated identical outcomes.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	94-98
21296326-1	2011	The purpose of the present study was to evaluate the 3-year clinical outcomes after percutaneous coronary intervention with sirolimus-eluting stents in patients with insulin-treated diabetes mellitus (DM-insulin) and those with non-insulin-treated DM (DM-non-insulin) compared to patients without DM.	Sirolimus	124-133	insulin	Homo sapiens	166-173
21304100-8	2011	Blocking of mTOR with rapamycin suppressed the maturation of neonatal MKs without affecting ploidy, in contrast to the synchronous inhibition of polyploidization and cytoplasmic maturation in adult MKs.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	12-16
21138727-3	2011	To demonstrate, we characterized the binding of polyketide ligands based on the mTOR inhibitor rapamycin to the cellular immunophilin FKBP12.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
21446969-4	2011	Here, we review recent findings concerning the contradictory outcomes of rapamycin induced mTOR inhibition on CD4(+) and CD8(+) T cell responses in transplantation and protective immunity.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	91-95
21295008-8	2011	Moreover, forced expression of Oct-2 by transfection with the pCG-Oct-2 plasmid overcame the inhibitory effect of rapamycin on the LTA-induced increase in G-CSF mRNA levels and promoter activity.	Sirolimus	114-123	POU domain, class 2, transcription factor 2	Mus musculus	31-36
21295008-8	2011	Moreover, forced expression of Oct-2 by transfection with the pCG-Oct-2 plasmid overcame the inhibitory effect of rapamycin on the LTA-induced increase in G-CSF mRNA levels and promoter activity.	Sirolimus	114-123	psoriasis susceptibility 1 candidate 2 (human)	Mus musculus	62-65
21295008-8	2011	Moreover, forced expression of Oct-2 by transfection with the pCG-Oct-2 plasmid overcame the inhibitory effect of rapamycin on the LTA-induced increase in G-CSF mRNA levels and promoter activity.	Sirolimus	114-123	POU domain, class 2, transcription factor 2	Mus musculus	66-71
21447721-1	2011	PURPOSE: Sirolimus is the prototypical mTOR inhibitor.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	39-43
21335533-4	2011	The sch9 hyperfilamentous phenotype was independent of Rim15 kinase and was recreated by inhibition of Tor1 kinase by rapamycin or caffeine in a wild-type strain, suggesting that Sch9 suppression requires Tor1.	Sirolimus	118-127	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	4-8
21451536-2	2011	The Spare the Nephron Trial describes the popular approach of early conversion from a CNI to the mTOR agent sirolimus for patients maintained on mycophenolate mofetil and steroids.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	97-101
21228274-4	2011	After treatment of macrophages with Toll-like receptor ligands, pro-IL-1beta was specifically sequestered into autophagosomes, whereas further activation of autophagy with rapamycin induced the degradation of pro-IL-1beta and blocked secretion of the mature cytokine.	Sirolimus	172-181	interleukin 1 beta	Mus musculus	213-221
21228274-7	2011	Induction of autophagy in mice in vivo with rapamycin reduced serum levels of IL-1beta in response to challenge with LPS.	Sirolimus	44-53	interleukin 1 beta	Mus musculus	78-86
21600178-12	2011	And the level of IFN-gamma was significantly higher in LPS group than that in PBS, RAPA and LPS + RAPA groups by co-culture (P < 0.05).	Sirolimus	83-87	interferon gamma	Mus musculus	17-26
21177249-6	2011	Enhanced Akt phosphorylation was not due to activation of phosphatidylinositol 3-kinase but due to activation of mammalian target of rapamycin complex 2 (mTORC2) by PINK1.	Sirolimus	133-142	AKT serine/threonine kinase 1	Homo sapiens	9-12
21097529-5	2011	We further present evidence that L1-CAM was involved in the resistance against therapeutic reagents like rapamycin, sunitinib and cisplatin.	Sirolimus	105-114	L1 cell adhesion molecule	Homo sapiens	33-39
21363918-6	2011	In contrast, rapamycin exerted less effect on tumoral production of VEGF.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	68-72
21308356-7	2011	For chronic GvHD mTOR inhibitors (sirolimus, everolimus) may replace calcineurin-inhibitors with the advantage of not inducing malignant skin tumors.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	17-21
20714941-2	2011	DISCUSSION: Sirolimus is a mTOR inhibitor which has been used as an immunosuppressive medication in patients who are at high risk of tumor reoccurrence after liver transplantation.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	27-31
21350938-6	2011	We also tested whether inhibition of mTOR with low concentrations of rapamycin and ectopic Beclin-1 expression would further sensitize multidrug resistance (MDR)-positive cancer cells by upregulating autophagy.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	37-41
21168265-0	2011	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	52-56
21168265-0	2011	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	154-157
21168265-0	2011	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	52-56
21168265-0	2011	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.	Sirolimus	136-145	AKT serine/threonine kinase 1	Homo sapiens	154-157
21168265-1	2011	The anti-tumor activity of rapamycin is compromised by the feedback-loop-relevant hyperactive PI3K and ERK-MAPK pathway signaling.	Sirolimus	27-36	mitogen-activated protein kinase 1	Homo sapiens	103-106
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	82-85
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	105-108
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	105-108
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	82-85
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	105-108
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	105-108
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	82-85
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	105-108
21168265-2	2011	In breast cancer cells treated with rapamycin, we observed a moderate increase of AKT phosphorylation (P-AKT) in a rapamycin resistant cell line, MDA-MB-231, as well as a slight increase of P-AKT in a rapamycin sensitive cell line, MCF-7.	Sirolimus	115-124	AKT serine/threonine kinase 1	Homo sapiens	105-108
21092744-7	2011	Rapamycin downregulated the expression of S-phase kinase associated protein-2 (Skp2) and increased the FOXO3a protein stability but induced the upregulation of feedback Akt activation-mediated FOXO3a phosphorylation.	Sirolimus	0-9	forkhead box O3	Homo sapiens	103-109
21092744-7	2011	Rapamycin downregulated the expression of S-phase kinase associated protein-2 (Skp2) and increased the FOXO3a protein stability but induced the upregulation of feedback Akt activation-mediated FOXO3a phosphorylation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	169-172
21092744-7	2011	Rapamycin downregulated the expression of S-phase kinase associated protein-2 (Skp2) and increased the FOXO3a protein stability but induced the upregulation of feedback Akt activation-mediated FOXO3a phosphorylation.	Sirolimus	0-9	forkhead box O3	Homo sapiens	193-199
21092744-9	2011	Rapamycin combined with cisplatin as its feedback Akt activation inhibitor revealed the most dramatic FOXO3a nuclear localization and reactivation with the prevention of its feedback loop and exposed significant synergistic effects of decreased cell proliferation and increased apoptosis in vitro and decreased tumor size in vivo.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	50-53
21092744-9	2011	Rapamycin combined with cisplatin as its feedback Akt activation inhibitor revealed the most dramatic FOXO3a nuclear localization and reactivation with the prevention of its feedback loop and exposed significant synergistic effects of decreased cell proliferation and increased apoptosis in vitro and decreased tumor size in vivo.	Sirolimus	0-9	forkhead box O3	Homo sapiens	102-108
21092744-11	2011	In conclusion, rapamycin/cisplatin combination therapy boosts synergistic antitumor effects through the significant FOXO3a reactivation in OSCC cells.	Sirolimus	15-24	forkhead box O3	Homo sapiens	116-122
21307248-10	2011	Intrathecal injection of Substance P activated this cascade (increased phosphorylation) and resulted in hyperalgesia, both of which effects were blocked by intrathecal wortmannin and rapamycin.	Sirolimus	183-192	tachykinin precursor 1	Homo sapiens	25-36
21059646-8	2011	The foci formed after optineurin transfection were increased upon treatment of an autophagic inhibitor but were decreased by treatment of an inducer, rapamycin.	Sirolimus	150-159	optineurin	Mus musculus	22-32
21289178-8	2011	Rapamycin, which displaces FKBP1b from RyRs in myocytes, similarly enhanced VGCC current and the sAHP and also increased CICR.	Sirolimus	0-9	FKBP prolyl isomerase 1B	Rattus norvegicus	27-33
20940044-5	2011	We found that Li(+) activated the mammalian target of rapamycin (mTOR) pathway via GSK-3beta in these cells, and the effect of Li(+) to induce c-Ret was amenable to the inhibitory effect of the mTOR inhibitor, rapamycin.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	65-69
20940044-5	2011	We found that Li(+) activated the mammalian target of rapamycin (mTOR) pathway via GSK-3beta in these cells, and the effect of Li(+) to induce c-Ret was amenable to the inhibitory effect of the mTOR inhibitor, rapamycin.	Sirolimus	54-63	ret proto-oncogene	Mus musculus	143-148
21046356-9	2011	Rapamycin monotherapy was also associated with a decrease in insulin antibody titre (median decrease 110 to 35.9 U/ml; p < 0.001) and fasting serum proinsulin (median decrease 0.51 to 0.28 pmol/l; p = 0.001).	Sirolimus	0-9	insulin	Homo sapiens	151-161
21062901-7	2011	The differences between Tsc1(GFAP1)CKO and Tsc2(GFAP1)CKO mice were correlated with higher levels of mammalian target of rapamycin (mTOR) activation in Tsc2(GFAP1)CKO mice and were reversed by the mTOR inhibitor, rapamycin.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	132-136
21162600-5	2011	De novo use of a mammalian target of rapamycin (mTOR) inhibitor (sirolimus or everolimus) or conversion from a calcineurin inhibitor to an mTOR inhibitor may constitute another therapeutic option to avoid or reduce calcineurin inhibitor-induced nephrotoxicity.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	17-46
21162600-5	2011	De novo use of a mammalian target of rapamycin (mTOR) inhibitor (sirolimus or everolimus) or conversion from a calcineurin inhibitor to an mTOR inhibitor may constitute another therapeutic option to avoid or reduce calcineurin inhibitor-induced nephrotoxicity.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	48-52
21212363-6	2011	Long-term rapamycin treatment of preleukemic Pten-null mice prevents Tcralpha/delta-c-myc translocation and leukemia stem cell (LSC) formation, and it halts T-ALL development.	Sirolimus	10-19	phosphatase and tensin homolog	Mus musculus	45-49
21073880-9	2011	This loop provides much of the surface buried at the protein-protein interface of the ternary complex, leading us to assert that preorganization upon rapamycin binding facilitates binding of the second molecule, mTOR.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	212-216
21208419-0	2011	The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	4-8
21208419-0	2011	The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes.	Sirolimus	26-35	nitric oxide synthase 2	Homo sapiens	46-50
21208419-15	2011	This stimulatory effect was transient, since no differences in either iNOS mRNA or protein levels were detected after 24 h. Interestingly, reduced levels of iNOS mRNA were detected after 48 hours, suggesting that rapamycin can modify iNOS mRNA stability.	Sirolimus	213-222	nitric oxide synthase 2	Homo sapiens	157-161
21208419-15	2011	This stimulatory effect was transient, since no differences in either iNOS mRNA or protein levels were detected after 24 h. Interestingly, reduced levels of iNOS mRNA were detected after 48 hours, suggesting that rapamycin can modify iNOS mRNA stability.	Sirolimus	213-222	nitric oxide synthase 2	Homo sapiens	157-161
21208419-17	2011	Similarly, rapamycin induced a significant up-regulation of tristetraprolin (TTP), a protein involved in the regulation of iNOS mRNA stability.	Sirolimus	11-20	nitric oxide synthase 2	Homo sapiens	123-127
21430336-7	2011	Notable examples include rapamycin (sirolimus) in suppressing the mTOR pathway associated hamartomas in dominantly inherited cancer family syndromes and angiotensin converting enzyme receptor blockers (ACE-RB) in preventing aortic dilatation in Marfan syndrome and related familial arteriopathies.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	66-70
21430336-7	2011	Notable examples include rapamycin (sirolimus) in suppressing the mTOR pathway associated hamartomas in dominantly inherited cancer family syndromes and angiotensin converting enzyme receptor blockers (ACE-RB) in preventing aortic dilatation in Marfan syndrome and related familial arteriopathies.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	66-70
20854798-4	2011	Treatment of rat mesangial cells (MC) with rapamycin dose-dependently reduced the interleukin 1beta (IL-1beta)-triggered increase in gelatinolytic levels as demonstrated by zymography.	Sirolimus	43-52	interleukin 1 beta	Rattus norvegicus	82-99
20854798-4	2011	Treatment of rat mesangial cells (MC) with rapamycin dose-dependently reduced the interleukin 1beta (IL-1beta)-triggered increase in gelatinolytic levels as demonstrated by zymography.	Sirolimus	43-52	interleukin 1 beta	Rattus norvegicus	101-109
20854798-7	2011	Surprisingly, the attenuation of MMP-9 mRNA levels by rapamycin is accompanied by a potentiation of IL-1beta-induced MMP-9 promoter activity in which the stimulatory effects by rapamycin are mainly attributed to a proximal AP-1 binding site.	Sirolimus	54-63	interleukin 1 beta	Rattus norvegicus	100-108
20854798-7	2011	Surprisingly, the attenuation of MMP-9 mRNA levels by rapamycin is accompanied by a potentiation of IL-1beta-induced MMP-9 promoter activity in which the stimulatory effects by rapamycin are mainly attributed to a proximal AP-1 binding site.	Sirolimus	177-186	interleukin 1 beta	Rattus norvegicus	100-108
21439133-1	2011	It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting.	Sirolimus	26-35	CD4 molecule	Homo sapiens	92-95
21439133-1	2011	It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting.	Sirolimus	26-35	CD4 molecule	Homo sapiens	120-123
21439133-1	2011	It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting.	Sirolimus	37-40	CD4 molecule	Homo sapiens	92-95
21439133-1	2011	It has been reported that rapamycin (RPM) can induce de novo conversion of the conventional CD4(+)Foxp3(-) T cells into CD4(+)Foxp3(+) regulatory T cells (iTregs) in transplantation setting.	Sirolimus	37-40	CD4 molecule	Homo sapiens	120-123
21126261-12	2011	Rapamycin (50 nmol/L) enhanced the phosphorylation of Akt kinase but did not affect the phosphorylation of ERK1/2 or eNOS at the end of reperfusion.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
21114628-6	2011	Chromatin immunoprecipitation assays showed that LPS enhanced the binding of Oct-2 to the iNOS and G-CSF promoters and that this effect was inhibited by pretreatment with rapamycin.	Sirolimus	171-180	nitric oxide synthase 2	Homo sapiens	90-94
21745772-4	2011	Rapamycin is an immunosupressor used in transplanted patients that inhibits the mTOR transduction signal pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	80-84
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	itchy E3 ubiquitin protein ligase	Homo sapiens	68-72
21135252-10	2011	Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin.	Sirolimus	162-171	AKT serine/threonine kinase 1	Homo sapiens	36-39
21135252-10	2011	Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin.	Sirolimus	162-171	itchy E3 ubiquitin protein ligase	Homo sapiens	64-68
21135252-10	2011	Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin.	Sirolimus	162-171	itchy E3 ubiquitin protein ligase	Homo sapiens	69-73
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	0-9	cadherin 5	Homo sapiens	207-218
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	0-9	twist family bHLH transcription factor 1	Homo sapiens	243-248
21294052-7	2011	This was observed without a decrease in S6K phosphorylation, suggesting a mechanism different from the feedback loop activation of Akt observed with rapamycin treatment.	Sirolimus	149-158	AKT serine/threonine kinase 1	Homo sapiens	131-134
21406469-6	2011	The common activation of the PI3K pathway in breast cancer has led to the development of compounds targeting the effector mechanisms of the pathway including selective and pan-PI3K/pan-AKT inhibitors, rapamycin analogs for mTOR inhibition, and TOR-catalytic subunit inhibitors.	Sirolimus	201-210	mechanistic target of rapamycin kinase	Homo sapiens	223-227
21406469-6	2011	The common activation of the PI3K pathway in breast cancer has led to the development of compounds targeting the effector mechanisms of the pathway including selective and pan-PI3K/pan-AKT inhibitors, rapamycin analogs for mTOR inhibition, and TOR-catalytic subunit inhibitors.	Sirolimus	201-210	RAR related orphan receptor C	Homo sapiens	224-227
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Sirolimus	67-76	coagulation factor II, thrombin	Homo sapiens	104-112
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Sirolimus	67-76	peroxisome proliferator activated receptor gamma	Homo sapiens	178-188
22132130-9	2011	Interestingly, CED of rapamycin into the brain at a very low dose (50 ng) induced GDNF levels comparable to a 6-week intraperitoneal rapamycin cycle.	Sirolimus	22-31	glial cell derived neurotrophic factor	Homo sapiens	82-86
21915260-2	2011	METHODS: We completed a phase 2 multicenter trial to evaluate the efficacy and tolerability of the mTOR inhibitor, sirolimus, for the treatment of kidney angiomyolipomas.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	99-103
20642495-2	2011	Use of the m-TOR inhibitors everolimus or sirolimus to minimize CNI exposure is usually undertaken to preserve renal function following kidney transplantation, but may also improve cardiovascular risk status.	Sirolimus	42-51	RAR related orphan receptor C	Homo sapiens	13-16
20868675-10	2010	Rapamycin (pharmacological inhibitor of mTOR) resulted in decrease in prolidase activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
20730884-1	2010	Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	24-53
20730884-1	2010	Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	55-59
20730888-3	2010	In vitro rapamycin induces apoptotic death of JN-DSRCT-1 cells, a possible model for desmoplastic small round cell tumors in which the EWS gene is fused to the WT1 gene.	Sirolimus	9-18	WT1 transcription factor	Homo sapiens	160-163
20937815-3	2010	Recently we found that rapamycin inhibits type I insulin-like growth factor (IGF-1)-stimulated lamellipodia formation and cell motility, indicating involvement of mTOR in regulating cell motility.	Sirolimus	23-32	insulin like growth factor 1	Homo sapiens	77-82
20937815-3	2010	Recently we found that rapamycin inhibits type I insulin-like growth factor (IGF-1)-stimulated lamellipodia formation and cell motility, indicating involvement of mTOR in regulating cell motility.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	163-167
20937815-5	2010	Here we show that rapamycin inhibited protein synthesis and activities of small GTPases (RhoA, Cdc42, and Rac1), crucial regulatory proteins for cell migration.	Sirolimus	18-27	ras homolog family member A	Homo sapiens	89-93
20937815-9	2010	Expression of constitutively active RhoA, but not Cdc42 and Rac1, conferred resistance to rapamycin inhibition of IGF-1-stimulated lamellipodia formation and cell migration.	Sirolimus	90-99	ras homolog family member A	Homo sapiens	36-40
20937815-9	2010	Expression of constitutively active RhoA, but not Cdc42 and Rac1, conferred resistance to rapamycin inhibition of IGF-1-stimulated lamellipodia formation and cell migration.	Sirolimus	90-99	insulin like growth factor 1	Homo sapiens	114-119
20937815-10	2010	The results suggest that rapamycin inhibits cell motility at least in part by down-regulation of RhoA protein expression and activity through mTORC1-mediated S6K1 and 4E-BP1-signaling pathways.	Sirolimus	25-34	ras homolog family member A	Homo sapiens	97-101
20937815-10	2010	The results suggest that rapamycin inhibits cell motility at least in part by down-regulation of RhoA protein expression and activity through mTORC1-mediated S6K1 and 4E-BP1-signaling pathways.	Sirolimus	25-34	BP1	Homo sapiens	170-173
20841502-9	2010	Furthermore, mTOR inhibition by rapamycin partially (42%) reduced the arginine-induced protein synthesis response and phosphorylation of mTOR and 4E-BP1.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Sus scrofa	13-17
21189444-8	2010	Additionally, VEGF was significantly suppressed in all individuals after treatment with rapamycin except those who had AA -1154/CA -2578 and AA -1154/AA -2578 VEGF genotype combinations.	Sirolimus	88-97	vascular endothelial growth factor A	Homo sapiens	14-18
21189444-10	2010	Additionally result of another study showed that CYP3A5 genotype markedly influences the pharmacokinetics of rapamycin in kidney transplant recipients.	Sirolimus	109-118	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	49-55
21189444-11	2010	Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype.	Sirolimus	92-101	vascular endothelial growth factor A	Homo sapiens	105-109
21189444-11	2010	Therefore with regard to our results, different suppressive effect of mycophenolic acid and rapamycin on VEGF production might also be dependent on VEGF genotype.	Sirolimus	92-101	vascular endothelial growth factor A	Homo sapiens	148-152
20703217-1	2010	Sirolimus (SRL) is an antiproliferative agent inhibiting the mammalian target of rapamycin (mTOR) proposed as a non-nephrotoxic alternative to calcineurin inhibitors for the prevention of acute rejection in renal transplantation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	61-90
20703217-1	2010	Sirolimus (SRL) is an antiproliferative agent inhibiting the mammalian target of rapamycin (mTOR) proposed as a non-nephrotoxic alternative to calcineurin inhibitors for the prevention of acute rejection in renal transplantation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-96
20861085-4	2010	Here, we show that the inactivation of mammalian target of rapamycin (mTor) by the mTor inhibitor rapamycin or knockdown of mTor reduced sphere formation and the expression of neural stem cell (NSC)/progenitor markers in CSLCs of the A172 glioblastoma cell line.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	70-74
20861085-4	2010	Here, we show that the inactivation of mammalian target of rapamycin (mTor) by the mTor inhibitor rapamycin or knockdown of mTor reduced sphere formation and the expression of neural stem cell (NSC)/progenitor markers in CSLCs of the A172 glioblastoma cell line.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	83-87
20861085-4	2010	Here, we show that the inactivation of mammalian target of rapamycin (mTor) by the mTor inhibitor rapamycin or knockdown of mTor reduced sphere formation and the expression of neural stem cell (NSC)/progenitor markers in CSLCs of the A172 glioblastoma cell line.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	83-87
21223797-4	2010	Treating HepG2 cells with rapamycin, a specific mTOR inhibitor, significantly reduced the survivin protein level but not affected the survivin transcription, indicating that tamoxifen and rapamycin were synergistic in regards to down-regulation of survivin expression in hepatocellular carcinoma cells.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	48-52
21223797-4	2010	Treating HepG2 cells with rapamycin, a specific mTOR inhibitor, significantly reduced the survivin protein level but not affected the survivin transcription, indicating that tamoxifen and rapamycin were synergistic in regards to down-regulation of survivin expression in hepatocellular carcinoma cells.	Sirolimus	188-197	mechanistic target of rapamycin kinase	Homo sapiens	48-52
21045832-1	2010	BACKGROUND: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	114-143
21075311-5	2010	On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance.	Sirolimus	37-46	AKT serine/threonine kinase 1	Homo sapiens	123-126
21040901-1	2010	Pten deficiency depletes hematopoietic stem cells (HSCs) but expands leukemia-initiating cells, and the mTOR inhibitor, rapamycin, blocks these effects.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	104-108
20930550-3	2010	Here, we found for the first time that JAK2/STAT3 was activated in HeLa cells when they were starved or treated with rapamycin.	Sirolimus	117-126	signal transducer and activator of transcription 3	Homo sapiens	44-49
21041974-9	2010	These results might suggest that special attention to patients with hemodialysis and insulin-treated DM is warranted in the setting of sirolimus-eluting stent deployment for DM patients.	Sirolimus	135-144	insulin	Homo sapiens	85-92
20663789-3	2010	Recent reports suggest a possible beneficial role of the mTOR inhibitor rapamycin for TSC.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	57-61
21095445-4	2010	The trend has therefore been to use a low-dose CNI in combination with the mTOR-inhibitor sirolimus in order to reduce the risk of nephrotoxicity.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	75-79
21095447-4	2010	The first family of drugs that have these properties are mammalian target of rapamycin inhibitors: these include sirolimus and everolimus.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	57-86
21095452-2	2010	In animal models of experimental polycystic kidney disease, the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus effectively reduce cyst growth and loss of renal function.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	64-93
21095452-2	2010	In animal models of experimental polycystic kidney disease, the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus effectively reduce cyst growth and loss of renal function.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	95-99
20855840-1	2010	PURPOSE: Synergistic/additive cytotoxicity in tumor models and widespread applicability of fluoropyrimidines in solid tumors prompted the study of the combination of the mammalian target of rapamycin (mTOR) inhibitor, non-prodrug rapamycin analog ridaforolimus, with capecitabine.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Homo sapiens	201-205
21036716-2	2010	The aim of this study was to investigate the effects of the COX2 inhibitor celecoxib and the mTOR antagonist rapamycin on angiosarcoma cell lines.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	93-97
20600853-6	2010	The mTor inhibitor, rapamycin, activates autophagy, prevents PDE4A4 from forming intracellular aggregates and triggers the loss of bound p62 from PDE4A4.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
20935470-8	2010	Rapamycin, a specific inhibitor of mTORC1 kinase, decreased cellular hypertrophy, canceled coffilin phosphorylation and partially restored cell migration in p21(Waf1+/+) cells.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	157-160
20935470-8	2010	Rapamycin, a specific inhibitor of mTORC1 kinase, decreased cellular hypertrophy, canceled coffilin phosphorylation and partially restored cell migration in p21(Waf1+/+) cells.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	161-165
20668023-13	2010	Finally, we observed that IGF-I enhanced the aromatase activity by 50% as early as 1 h after treatment; furthermore, rapamycin, an enhancer of autophagy, completely negated the effect of IGF-I on the enzyme.	Sirolimus	117-126	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	45-54
20668023-13	2010	Finally, we observed that IGF-I enhanced the aromatase activity by 50% as early as 1 h after treatment; furthermore, rapamycin, an enhancer of autophagy, completely negated the effect of IGF-I on the enzyme.	Sirolimus	117-126	insulin like growth factor 1	Homo sapiens	187-192
20811722-0	2010	Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	24-28
20811722-0	2010	Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.	Sirolimus	10-19	tumor protein p53	Homo sapiens	103-106
22091684-1	2011	Sirolimus (SRL) is a mammalian target of rapamycin inhibitor, which provides an immunosuppressive effect by inhibiting cell cycle progression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	21-50
21980128-5	2011	Targeting mTOR and EGFR pathways by treatment with rapamycin and cetuximab (an anti-EGFR mAb), respectively, prevented cixutumumab-induced expression of EGFR, Akt, and survivin and induced synergistic antitumor effects in vitro and in vivo.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	10-14
21980128-5	2011	Targeting mTOR and EGFR pathways by treatment with rapamycin and cetuximab (an anti-EGFR mAb), respectively, prevented cixutumumab-induced expression of EGFR, Akt, and survivin and induced synergistic antitumor effects in vitro and in vivo.	Sirolimus	51-60	epidermal growth factor receptor	Homo sapiens	19-23
21980128-5	2011	Targeting mTOR and EGFR pathways by treatment with rapamycin and cetuximab (an anti-EGFR mAb), respectively, prevented cixutumumab-induced expression of EGFR, Akt, and survivin and induced synergistic antitumor effects in vitro and in vivo.	Sirolimus	51-60	epidermal growth factor receptor	Homo sapiens	84-88
21980128-5	2011	Targeting mTOR and EGFR pathways by treatment with rapamycin and cetuximab (an anti-EGFR mAb), respectively, prevented cixutumumab-induced expression of EGFR, Akt, and survivin and induced synergistic antitumor effects in vitro and in vivo.	Sirolimus	51-60	epidermal growth factor receptor	Homo sapiens	84-88
21980128-5	2011	Targeting mTOR and EGFR pathways by treatment with rapamycin and cetuximab (an anti-EGFR mAb), respectively, prevented cixutumumab-induced expression of EGFR, Akt, and survivin and induced synergistic antitumor effects in vitro and in vivo.	Sirolimus	51-60	AKT serine/threonine kinase 1	Homo sapiens	159-162
21946849-2	2011	Since rapamycin is considered to be a highly specific inhibitor of the mammalian target of rapamycin (mTOR), many have concluded that mTOR plays a key role in CML-induced growth regulatory events.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	71-100
21946849-2	2011	Since rapamycin is considered to be a highly specific inhibitor of the mammalian target of rapamycin (mTOR), many have concluded that mTOR plays a key role in CML-induced growth regulatory events.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	102-106
21946849-2	2011	Since rapamycin is considered to be a highly specific inhibitor of the mammalian target of rapamycin (mTOR), many have concluded that mTOR plays a key role in CML-induced growth regulatory events.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	134-138
22074495-11	2011	Finally, the mTOR inhibitor Rapamycin enhanced the effect of GSI on RhoA expression, resulting in down regulation of phospho-Akt and increased in vitro tumor cytotoxity.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
22074495-11	2011	Finally, the mTOR inhibitor Rapamycin enhanced the effect of GSI on RhoA expression, resulting in down regulation of phospho-Akt and increased in vitro tumor cytotoxity.	Sirolimus	28-37	ras homolog family member A	Homo sapiens	68-72
22074495-11	2011	Finally, the mTOR inhibitor Rapamycin enhanced the effect of GSI on RhoA expression, resulting in down regulation of phospho-Akt and increased in vitro tumor cytotoxity.	Sirolimus	28-37	AKT serine/threonine kinase 1	Homo sapiens	125-128
22074495-16	2011	Enhanced phospho-Akt suppression when GSI is combined with rapamycin suggests that targeting both pathways will lead to a greater efficacy in the treatment of patients with pancreas cancer.	Sirolimus	59-68	AKT serine/threonine kinase 1	Homo sapiens	17-20
21890461-7	2011	Altered regulation of mTOR pathway proteins in BPA-treated HRBECs led to marked resistance to rapamycin, the defining mTOR inhibitor.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	22-26
21890461-7	2011	Altered regulation of mTOR pathway proteins in BPA-treated HRBECs led to marked resistance to rapamycin, the defining mTOR inhibitor.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	118-122
21883182-0	2011	Rapamycin suppresses axon sprouting by somatostatin interneurons in a mouse model of temporal lobe epilepsy.	Sirolimus	0-9	somatostatin	Mus musculus	39-51
21883182-15	2011	SIGNIFICANCE: These findings suggest that rapamycin suppressed axon sprouting by surviving somatostatin/GFP-positive interneurons after pilocarpine-induced status epilepticus in GIN mice.	Sirolimus	42-51	somatostatin	Mus musculus	91-103
21883182-17	2011	The mammalian target of rapamycin (mTOR) signaling pathway might be a useful drug target for influencing GABAergic synaptic reorganization after epileptogenic treatments, but additional side effects of rapamycin treatment must be considered carefully.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	Sirolimus	131-140	insulin	Homo sapiens	4-11
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	158-187
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	189-193
21854819-5	2011	The insulin-induced increase of tau protein level was abolished by LY294002 [an inhibitor of phosphoinositide 3-kinase (PI3K)] and rapamycin [an inhibitor of mammalian target of rapamycin (mTOR)], but not by PD98059 and U0126 [two inhibitors of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)].	Sirolimus	131-140	mitogen-activated protein kinase kinase 7	Homo sapiens	317-320
22336451-0	2011	[Stents coated with sirolimus and anti-CD34 antibody can optimize the performance of sirolimus-eluting stents].	Sirolimus	85-94	CD34 molecule	Homo sapiens	39-43
22336451-13	2011	CONCLUSION: The stents coated with anti-CD34 antibody and sirolimus can attenuate the inhibitory effect of sirolimus on the re-endothelialization at two weeks after stenting and the anti-hyperplasia effect of sirolimus at three months after stenting.	Sirolimus	107-116	CD34 molecule	Homo sapiens	40-44
22336451-13	2011	CONCLUSION: The stents coated with anti-CD34 antibody and sirolimus can attenuate the inhibitory effect of sirolimus on the re-endothelialization at two weeks after stenting and the anti-hyperplasia effect of sirolimus at three months after stenting.	Sirolimus	107-116	CD34 molecule	Homo sapiens	40-44
22016125-8	2011	Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	54-58
22016125-8	2011	Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein.	Sirolimus	71-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-200
22016125-8	2011	Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein.	Sirolimus	71-80	ATP binding cassette subfamily B member 1	Homo sapiens	205-219
22040565-6	2011	Rapa reduced the levels of TNF-alpha (LPS vs. LPS + Rapa, (1672.74 +- 193.73) vs. (539.17 +- 140.48) pg/ml, respectively; P < 0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88 +- 1170.54) vs. (1968.57 +- 474.62) pg/ml, respectively; P < 0.01) in the BAL fluid.	Sirolimus	0-4	tumor necrosis factor	Mus musculus	27-36
22040565-6	2011	Rapa reduced the levels of TNF-alpha (LPS vs. LPS + Rapa, (1672.74 +- 193.73) vs. (539.17 +- 140.48) pg/ml, respectively; P < 0.01) and IL-6 (LPS vs. LPS + Rapa: (7790.88 +- 1170.54) vs. (1968.57 +- 474.62) pg/ml, respectively; P < 0.01) in the BAL fluid.	Sirolimus	0-4	interleukin 6	Mus musculus	139-143
21742783-3	2011	In vitro cigarette smoke extract (CSE) and one of its components, acrolein, inhibit the mammalian target of rapamycin (mTOR)/p70S6K pathway in human endothelial cells, and chemical inhibition of this pathway by rapamycin resulted in elevated MMP-1.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	119-123
21862955-1	2011	BACKGROUND: The mammalian target of rapamycin inhibitor sirolimus has been associated with an increased incidence of wound-healing complications after de novo heart transplantation.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	16-45
21757652-1	2011	RATIONALE: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Danio rerio	72-75
21440356-6	2011	mTOR inhibitor sirolimus reduces angymiolipoma volumes.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
21862872-6	2011	Trastuzumab-resistant sublines were resistant to rapamycin induced changes in mTOR activity and cell growth.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	78-82
21530413-3	2011	Recently, understanding the neurobiology of hamartin and tuberin in the development of epilepsy and cognitive impairment associated with tuberous sclerosis complex allowed the development of sirolimus and everolimus to be used in human clinical trials.	Sirolimus	191-200	TSC complex subunit 1	Homo sapiens	44-52
21702716-3	2011	So far, specific mTOR inhibitors, such as rapamycin analogs, have been developed and studied as anti-cancer agents.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	17-21
21702716-5	2011	EXPERT OPINION: In the near future, mTOR-targeted drugs might represent a new approach for the therapy of thyroid cancer patients; rapamycin analogs have already been developed and are currently being clinically tested.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	36-40
21565906-7	2011	RESULTS: We found that CD4(+)CCR6(+)CD161(+) T cells (i.e., precursor/committed Th17 cells) contaminate the T-regulatory cells cultured ex vivo in the absence of rapamycin.	Sirolimus	162-171	CD4 molecule	Homo sapiens	23-26
21524191-1	2011	The goal of this study was to assess the interaction of the mTOR inhibitors (ImTORs) sirolimus and everolimus with the human organic anion-transporting polypeptides (OATPs) expressed in hepatocytes and enterocytes by conducting uptake experiments using (i) transfected HEK293T cells, (ii) the hepatocyte-like HepaRG cell line and (iii) the enterocyte-like Caco-2 cell line.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	60-64
21524191-2	2011	Sirolimus and everolimus inhibited in a dose-dependent manner the uptake of [3H]-estrone sulphate by OATP1A2 and OATP1B1 and that of mycophenolic acid 7-O-glucuronide (MPAG) by OATP1B3.	Sirolimus	0-9	solute carrier organic anion transporter family member 1B3	Homo sapiens	177-184
21524191-3	2011	ImTOR apparent 50% inhibitory concentrations (IC50) for OATPs were 11.9 microM (OATP1A2), 9.8 microM (OATP1B1) and 1.3 microM (OATP1B3) for sirolimus and 4.2 microM (OATP1A2), 4.1 microM (OATP1B1) and 4.3 microM (OATP1B3) for everolimus.	Sirolimus	140-149	solute carrier organic anion transporter family member 1B3	Homo sapiens	127-134
21984149-10	2011	Rapamycin significantly inhibited mTOR signaling upstream Akt and downstream S6K activation triggered by IDA, and the combination of the two agents led to synergistic inhibition of ERK phosphorylation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	58-61
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	insulin	Homo sapiens	45-52
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	166-173
21672148-1	2011	Rapamycin, an immunosuppressive drug used to prevent rejection after kidney transplantation, influences phosphate homeostasis, induces insulin resistance and has been shown to prolong lifespan in animal models.	Sirolimus	0-9	insulin	Homo sapiens	135-142
21672148-5	2011	In addition, rapamycin increased insulin resistance as shown by HOMA index.	Sirolimus	13-22	insulin	Homo sapiens	33-40
21672148-6	2011	Rapamycin treatment of an immortalized proximal tubular cell line induced the expression of Klotho, the phosphorylation of AKT in Ser473, downstream target of mTORC2 and the expression of RICTOR, mTORC2 main component.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	123-126
21672148-8	2011	In vivo rapamycin treatment induced higher degree of RICTOR and AKT Ser(473) expression directly correlating with long-term rapamycin exposure, FE(PO4) and HOMA index.	Sirolimus	8-17	AKT serine/threonine kinase 1	Homo sapiens	64-67
21480865-8	2011	ACEA, JWH133 and HU210 induced a time-dependent phosphorylation of Akt and mTOR, whereas the inhibitors of PI3K/Akt (LY294002) or of mTOR (rapamycin) reversed the effects of HU-210 on oligodendrocyte differentiation and kinase activation.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	133-137
21827982-4	2011	Thereby, mTOR inhibition with rapamycin (sirolimus) or its derivates (rapalogs) represents promising treatments, either alone or in combination with strategies to target other pathways that may overcome resistance.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	9-13
21827982-4	2011	Thereby, mTOR inhibition with rapamycin (sirolimus) or its derivates (rapalogs) represents promising treatments, either alone or in combination with strategies to target other pathways that may overcome resistance.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	9-13
21168455-0	2011	Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	32-36
21168455-7	2011	CONCLUSIONS: mTOR inhibition by sirolimus and everolimus in experimental liver fibrosis associates with significantly less fibrosis progression and portal hypertension than treatment with calcineurin inhibitors tacrolimus and cyclosporine A.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	13-17
21690228-6	2011	The combination of EGFR inhibition by using lapatinib and mTOR inhibition with rapamycin resulted in significantly greater cytotoxicity than the single agents alone and these effects were synergistic in vitro.	Sirolimus	79-88	epidermal growth factor receptor	Homo sapiens	19-23
21690228-6	2011	The combination of EGFR inhibition by using lapatinib and mTOR inhibition with rapamycin resulted in significantly greater cytotoxicity than the single agents alone and these effects were synergistic in vitro.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	58-62
21772323-3	2011	By inhibiting the activity of mammalian target of rapamycin (mTOR), rapamycin influences a variety of essential cellular processes, such as cell growth and proliferation, protein synthesis and autophagy.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	61-65
21602434-4	2011	At the molecular level, combined inhibition of mTOR prevented the rebound activation of Akt that is seen after treatment with rapamycin and its analogues and caused more sustained inhibition of Akt phosphorylation.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	47-51
21602434-4	2011	At the molecular level, combined inhibition of mTOR prevented the rebound activation of Akt that is seen after treatment with rapamycin and its analogues and caused more sustained inhibition of Akt phosphorylation.	Sirolimus	126-135	AKT serine/threonine kinase 1	Homo sapiens	88-91
21501360-3	2011	Treatment of human epithelial HeLa cells with mTOR inhibitor rapamycin reduced lysosomal exocytosis and MT invasion.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
21530600-0	2011	CD4(+)CD25(high)CD127(low) regulatory T cells in patients with stable angina and their dynamics after intracoronary sirolimus-eluting stent implantation.	Sirolimus	116-125	CD4 molecule	Homo sapiens	0-3
21576371-0	2011	Relieving autophagy and 4EBP1 from rapamycin resistance.	Sirolimus	35-44	nuclear factor kappa B subunit 1	Homo sapiens	25-29
21576371-5	2011	Rapamycin exposure destabilizes mTORC1, but in cell lines where autophagy is drug insensitive, higher levels of mTOR-bound raptor are detected than in cells where rapamycin stimulates autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	32-36
21338617-6	2011	Inhibition of phosphatidylinositol 3-kinase or Akt with LY 294002 or Akti-1/2 stimulates HSP27 phosphorylation while rapamycin, which inhibits mTORC1, does not.	Sirolimus	117-126	AKT serine/threonine kinase 1	Homo sapiens	47-50
21488160-3	2011	Sirolimus (rapamysin) inhibits the serine-threonine kinase mammalian target of rapamysin (mTOR), and blocks CsA-resistant and calcium-independent pathways late in the progression of the T-cell cycle.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	90-94
21715609-5	2011	Interestingly, rapamycin (a Food and Drug Administration-approved drug) restores normal levels of phosphorylated Akt-mTOR proteins and normal rates of local translation in Ts1Cje neurons, opening new therapeutic perspectives for DS.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	113-116
21715609-5	2011	Interestingly, rapamycin (a Food and Drug Administration-approved drug) restores normal levels of phosphorylated Akt-mTOR proteins and normal rates of local translation in Ts1Cje neurons, opening new therapeutic perspectives for DS.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	117-121
21665152-1	2011	Angioproliferative tumors induced by the Kaposi"s sarcoma-associated herpesvirus (KSHV) have been successfully treated with rapamycin, which provided direct evidence of the clinical activity of mTOR inhibitors in human malignancies.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	194-198
21107839-3	2011	We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-beta with rapamycin.	Sirolimus	126-135	CD4 molecule	Homo sapiens	55-58
21107839-3	2011	We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-beta with rapamycin.	Sirolimus	126-135	CD4 molecule	Homo sapiens	83-86
21107839-3	2011	We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-beta with rapamycin.	Sirolimus	126-135	transforming growth factor beta 1	Homo sapiens	112-120
21073857-14	2011	These results suggest that TRPM6 expression is up-regulated by a PI3K/Akt/mTOR pathway and rapamycin reduces TRPM6 mRNA stability, resulting in a decrease in the reabsorption of Mg2+.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	70-73
21639830-0	2011	The isomerase Rrd1 mediates rapid loss of the Sgs1 helicase in response to rapamycin.	Sirolimus	75-84	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	46-50
21639830-6	2011	The analysis revealed that deletion of the SGS1 gene in the rrd1Delta mutant partially suppresses the rapamycin-resistant phenotype of the single rrd1Delta mutant.	Sirolimus	102-111	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	43-47
21639830-8	2011	We further show, and for the first time, that Sgs1 is rapidly lost in the parent cells in response to rapamycin, but not by other agents.	Sirolimus	102-111	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	46-50
21639830-12	2011	Thus, the observed Rrd1-dependent reduction in Sgs1 level may promote expression of specific classes of genes in response to rapamycin.	Sirolimus	125-134	ATP-dependent DNA helicase SGS1	Saccharomyces cerevisiae S288C	47-51
21316758-3	2011	Potentiated ATP depletion and pro-apoptotic effects were seen for 3-BrOP combinations with the cytochrome-c-reductase inhibitor antimycin A and the mTOR inhibitor rapamycin.	Sirolimus	163-172	mechanistic target of rapamycin kinase	Homo sapiens	148-152
21318349-8	2011	The specific mTOR inhibitor rapamycin (10 nM) attenuated leptin-induced RhoA and Rac1 activation.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
20351753-6	2011	Both tacrolimus and rapamycin caused similar suppression of GSIS in cells expressing ZnT-8 R325.	Sirolimus	20-29	solute carrier family 30 member 8	Homo sapiens	85-90
21089180-5	2011	Chrysophanic acid (80 and 120 microm) significantly blocked cell proliferation when combined with the mTOR inhibitor, rapamycin.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	102-106
21471201-10	2011	The subsequent treatment of stabilized SCCs with rapamycin decreased tumor size and induced caspase-3 activation.	Sirolimus	49-58	caspase 3	Homo sapiens	92-101
21478152-8	2011	Resistin also stimulated the activation of p70(S6K), a downstream kinase target of mTOR, and increased phosphorylation of the IRS1 serine 636/639 residues, whereas treatment with rapamycin reduced the phosphorylation of these residues.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	83-87
24212820-2	2011	Knowledge in this field has been gained from discoveries in basic research as well as from observations made in patients treated with allosteric mTOR inhibitors such as rapamycin.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	145-149
21521942-11	2011	The failure to limit mTOR-dependent induction of HIF-1 may contribute to age-related macular degeneration and diabetic retinopathy, suggesting rapamycin for prevention of these age-related diseases.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	21-25
21521942-11	2011	The failure to limit mTOR-dependent induction of HIF-1 may contribute to age-related macular degeneration and diabetic retinopathy, suggesting rapamycin for prevention of these age-related diseases.	Sirolimus	143-152	hypoxia inducible factor 1 subunit alpha	Homo sapiens	49-54
21324487-2	2011	As the c-Jun N-terminal kinase (JNK) signaling pathway has been found to be a functional target of PI3K, we investigate the role of JNK in the anticancer efficacy of rapamycin.	Sirolimus	166-175	mitogen-activated protein kinase 8	Homo sapiens	7-30
21324487-2	2011	As the c-Jun N-terminal kinase (JNK) signaling pathway has been found to be a functional target of PI3K, we investigate the role of JNK in the anticancer efficacy of rapamycin.	Sirolimus	166-175	mitogen-activated protein kinase 8	Homo sapiens	32-35
21324487-2	2011	As the c-Jun N-terminal kinase (JNK) signaling pathway has been found to be a functional target of PI3K, we investigate the role of JNK in the anticancer efficacy of rapamycin.	Sirolimus	166-175	mitogen-activated protein kinase 8	Homo sapiens	132-135
21324487-5	2011	RESULTS: Treatment of LS174T cells with rapamycin resulted in the phosphorylation of JNK as observed by Western Blot.	Sirolimus	40-49	mitogen-activated protein kinase 8	Homo sapiens	85-88
21324487-6	2011	The expression of a negative mutant of JNK in LS174T cells or treatment of LS174T cells with SP600125 enhanced the antiproliferative effects of rapamycin.	Sirolimus	144-153	mitogen-activated protein kinase 8	Homo sapiens	39-42
21324487-8	2011	CONCLUSIONS: Taken together, these results show that rapamycin-induced JNK phosphorylation and activation reduces the antitumor efficacy of rapamycin in LS174T cells.	Sirolimus	53-62	mitogen-activated protein kinase 8	Homo sapiens	71-74
21454539-3	2011	This pathway functions by stimulating IRES-dependent translation in cells with relatively quiescent AKT, resulting in resistance to rapamycin.	Sirolimus	132-141	AKT serine/threonine kinase 1	Homo sapiens	100-103
21454539-7	2011	Utilizing cells in which AKT is conditionally active, we demonstrate that overexpression of this mutant renders quiescent AKT-containing cells sensitive to rapamycin in vitro and in xenografts.	Sirolimus	156-165	AKT serine/threonine kinase 1	Homo sapiens	25-28
21454539-7	2011	Utilizing cells in which AKT is conditionally active, we demonstrate that overexpression of this mutant renders quiescent AKT-containing cells sensitive to rapamycin in vitro and in xenografts.	Sirolimus	156-165	AKT serine/threonine kinase 1	Homo sapiens	122-125
21454539-9	2011	These data demonstrate that the phosphorylation status of hnRNP A1 serine 199 regulates the AKT-dependent sensitivity of cells to rapamycin and functionally links IRES-transacting factor annealing activity to cellular responses to mTOR complex 1 inhibition.	Sirolimus	130-139	AKT serine/threonine kinase 1	Homo sapiens	92-95
21228102-4	2011	Both GSK3 inhibitors reduced the phosphorylation of the mTOR downstream target, p70(S6K), indicating that GSK3 inhibition in podocytes is able to cause similar effects as treatment with rapamycin.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	56-60
21228102-4	2011	Both GSK3 inhibitors reduced the phosphorylation of the mTOR downstream target, p70(S6K), indicating that GSK3 inhibition in podocytes is able to cause similar effects as treatment with rapamycin.	Sirolimus	186-195	ubiquitin associated and SH3 domain containing B	Homo sapiens	80-83
21243421-1	2011	The tuberous sclerosis complex 1/2-mammalian target of rapamycin (TSC1/2-mTOR) proteins act as integrators of a range of intracellular signalling pathways.	Sirolimus	55-64	TSC complex subunit 1	Homo sapiens	66-72
21243421-1	2011	The tuberous sclerosis complex 1/2-mammalian target of rapamycin (TSC1/2-mTOR) proteins act as integrators of a range of intracellular signalling pathways.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	73-77
21329734-6	2011	Inhibition of the mTOR pathway by rapamycin eliminated the angiogenic and proliferative effects of visfatin.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	18-22
21830446-10	2011	RESULTS: Our data showed that rapamycin could inhibit the proliferation and the invasive ability of SGC-7901 and MKN-45 cells.	Sirolimus	30-39	sarcoglycan beta	Homo sapiens	100-103
21094689-5	2011	The results showed that low-dose sirolimus selectively expanded Tregs, increased the expression of CD25(bright) and Foxp3 markers, and suppressed TCR- or allo-antigens induced CD4(+) T cell proliferation in vitro.	Sirolimus	33-42	CD4 molecule	Homo sapiens	176-179
21203833-8	2011	Addition of rapamycin, an inhibitor of mTOR, caused stimulation of the MG-132-induced cell death.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	39-43
21127480-4	2011	The kinases AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) are each linked to food intake regulation, but only mTOR had increased activity in KSR2(-/-) mouse brain, and the ability of rapamycin to inhibit food intake in KSR2(-/-) mice further implicated mTOR in this process.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	83-87
21410393-2	2011	Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	43-47
21410393-2	2011	Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	43-47
21439267-2	2011	Indeed, the inhibition of mTOR with an allosteric inhibitor such as rapamycin reduces the growth of endothelial cell in vitro and inhibits angiogenesis in vivo.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	26-30
21439267-5	2011	Here we found that blocking mTOR with ATP-competitive inhibitors of mTOR or with rapamycin induced the activation of the mitogen-activated protein kinase (MAPK) in endothelial cells.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	28-32
21367753-5	2011	Rapamycin effectively modulated the protein kinase B (Akt)/mTOR pathway by inhibiting the phosphorylation of Akt and mTOR proteins, and this inhibition was further enhanced by radiation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	54-57
21367753-5	2011	Rapamycin effectively modulated the protein kinase B (Akt)/mTOR pathway by inhibiting the phosphorylation of Akt and mTOR proteins, and this inhibition was further enhanced by radiation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	59-63
21367753-5	2011	Rapamycin effectively modulated the protein kinase B (Akt)/mTOR pathway by inhibiting the phosphorylation of Akt and mTOR proteins, and this inhibition was further enhanced by radiation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	109-112
21367753-5	2011	Rapamycin effectively modulated the protein kinase B (Akt)/mTOR pathway by inhibiting the phosphorylation of Akt and mTOR proteins, and this inhibition was further enhanced by radiation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	117-121
21716195-13	2011	CONCLUSIONS: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.	Sirolimus	42-51	WT1 transcription factor	Homo sapiens	197-200
21716195-13	2011	CONCLUSIONS: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.	Sirolimus	42-51	RAR related orphan receptor C	Homo sapiens	229-232
21193837-0	2011	Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.	Sirolimus	0-9	superoxide dismutase 1, soluble	Mus musculus	58-62
21428917-2	2011	Rapamycin inhibits some of the functions of mTORC1, whereas newly developed mTOR kinase inhibitors interfere with the actions of both types of complex.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
21428919-2	2011	The present review highlights molecular and phenotypic differences between AZD8055 and allosteric inhibitors of mTOR such as rapamycin.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	112-116
21277936-7	2011	Functional studies using rapamycin or CCI-779 showed a dominant inhibitory effect of mTOR blockade on interleukin-7-induced proliferation, survival, and cell-cycle progression of T-ALL cells.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	85-89
21277936-7	2011	Functional studies using rapamycin or CCI-779 showed a dominant inhibitory effect of mTOR blockade on interleukin-7-induced proliferation, survival, and cell-cycle progression of T-ALL cells.	Sirolimus	25-34	interleukin 7	Homo sapiens	102-115
21389905-1	2011	BACKGROUND: CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing.	Sirolimus	70-79	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	12-18
21406405-4	2011	Inhibition of MNK1 activity in GBM cells by the small molecule CGP57380 suppressed eIF4E phosphorylation, proliferation, and colony formation whereas concomitant treatment with CGP57380 and the mTOR inhibitor rapamycin accentuated growth inhibition and cell-cycle arrest.	Sirolimus	209-218	mechanistic target of rapamycin kinase	Homo sapiens	194-198
21415462-1	2011	Rapamycin inhibits the mTOR (target of rapamycin) pathway and extends lifespan in multiple species.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	23-27
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	168-173
25961241-8	2011	Long-term oestrogen/insulin-deprived MCF-7 cells had higher levels of phosphorylated p70S6K and developed increased sensitivity to growth inhibition by rapamycin.	Sirolimus	152-161	insulin	Homo sapiens	20-27
21168265-1	2011	The anti-tumor activity of rapamycin is compromised by the feedback-loop-relevant hyperactive PI3K and ERK-MAPK pathway signaling.	Sirolimus	27-36	mitogen-activated protein kinase 1	Homo sapiens	107-111
21092744-0	2011	FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.	Sirolimus	66-75	forkhead box O3	Homo sapiens	0-6
21320304-1	2011	BACKGROUND: Inhibitors of the kinase mTOR, such as rapamycin and everolimus, have been used as cancer therapeutics with limited success since some tumours are resistant.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	37-41
20625781-6	2011	Experiments with the mTOR inhibitor rapamycin revealed that neither blocking the phosphorylation of S6 at S235/236 and S240/244 nor arresting the cell cycle affects the cytoplasmic/nuclear localization of S6 protein.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	21-25
20594757-11	2011	Inhibition of mTOR by rapamycin inhibited the phosphorylation of mTOR, reduced serine307 phosphorylation, elevated tyrosine phosphorylation and partly prevented the decrease of GIR after burn.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20594757-11	2011	Inhibition of mTOR by rapamycin inhibited the phosphorylation of mTOR, reduced serine307 phosphorylation, elevated tyrosine phosphorylation and partly prevented the decrease of GIR after burn.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	65-69
21048785-5	2011	Combined treatment with PI-103 and the prototypic mTORC1 inhibitor rapamycin led to the synergistic suppression of AKT and ribosomal S6 protein phosphorylation and to the induction of apoptosis.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	115-118
21216928-1	2011	The identification of mammalian target of rapamycin (mTOR) as a major mediator of neurofibromatosis-1 (NF1) tumor growth has led to the initiation of clinical trials using rapamycin analogs.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	53-57
20709738-0	2011	The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.	Sirolimus	86-95	thymoma viral proto-oncogene 1	Mus musculus	9-12
20709738-8	2011	Rapamycin prolonged survival, maintained normal renal function, normalized proteinuria, restored nephrin and podocin levels, reduced anti-dsDNA titres, ameliorated histological lesions, and reduced Akt and mTOR glomerular expression activation.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	198-201
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	144-153	thymoma viral proto-oncogene 1	Mus musculus	54-57
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	144-153	thymoma viral proto-oncogene 1	Mus musculus	230-233
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	160-169	thymoma viral proto-oncogene 1	Mus musculus	54-57
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	160-169	thymoma viral proto-oncogene 1	Mus musculus	54-57
21268715-4	2011	Here we show that treating MCF7 breast cancer cells with rapamycin (an mTOR inhibitor) results in significant suppression of homologous recombination (HR) and nonhomologous end joining (NHEJ), two major mechanisms required for repairing ionizing radiation-induced DNA DSBs.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	71-75
21079150-9	2011	Moreover, increased AKT(Ser473) phosphorylation was observed in activated B cells, reminiscent of cancers treated with rapamycin, and was reduced by a DNA-pk inhibitor.	Sirolimus	119-128	thymoma viral proto-oncogene 1	Mus musculus	20-23
21283589-7	2011	Insulin up-regulated alpha-cell proliferation through the IR/IRS2/AKT/mTOR signaling pathway, and increased insulin-mediated proliferation was prevented by pretreatment with rapamycin, a specific mTOR inhibitor.	Sirolimus	174-183	thymoma viral proto-oncogene 1	Mus musculus	66-69
21358177-9	2011	Sirolimus reduced ED-1+ cell infiltrate, interstitial fibrosis and intimal thickening of small vessels observed in I/R kidneys of controls and calcineurin inhibitor-treated rats.	Sirolimus	0-9	calcineurin binding protein 1	Rattus norvegicus	143-164
20943770-8	2011	On immunoblot of kidney, phosphorylated (Ser473) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin.	Sirolimus	138-147	AKT serine/threonine kinase 1	Rattus norvegicus	49-52
20943770-8	2011	On immunoblot of kidney, phosphorylated (Ser473) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin.	Sirolimus	138-147	AKT serine/threonine kinase 1	Rattus norvegicus	54-59
20943770-12	2011	In summary, in female Cy/+ rats, rapamycin had no effect on PKD and proproliferative p-Akt (Ser473) activity was increased by rapamycin.	Sirolimus	126-135	AKT serine/threonine kinase 1	Rattus norvegicus	85-90
21532145-4	2011	Rapamycin treatment is known to induce Akt (ser473) phosphorylation which attenuates the antiproliferative effects of rapamycin.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	39-42
21532145-4	2011	Rapamycin treatment is known to induce Akt (ser473) phosphorylation which attenuates the antiproliferative effects of rapamycin.	Sirolimus	118-127	AKT serine/threonine kinase 1	Homo sapiens	39-42
20727967-7	2011	Rapamycin also decreased carbachol-induced Ca(2+) release in HEK 293A cells in which IP(3)R-1 and IP(3)R-3 had been knocked down.	Sirolimus	0-9	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	85-93
21126261-13	2011	The cardioprotective effect of rapamycin was blocked by the phosphatidylinositol 3-kinase (Akt) inhibitor LY294002 (15 nmol/L).	Sirolimus	31-40	AKT serine/threonine kinase 1	Rattus norvegicus	91-94
21651476-4	2011	Rapamycin, the selective and allosteric inhibitor of mTOR, inhibits the enzyme in mTORC1, but not in mTORC2.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	53-57
21114628-0	2011	Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2.	Sirolimus	0-9	nitric oxide synthase 2	Homo sapiens	93-124
21135252-4	2011	Under conditions of relatively quiescent AKT activity, treatment of cells with rapamycin resulted in upregulation of cyclin D1 and c-MYC nascent transcription, whereas in cells containing active AKT, exposure repressed transcription.	Sirolimus	79-88	AKT serine/threonine kinase 1	Homo sapiens	41-44
21135252-7	2011	Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure.	Sirolimus	163-172	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	25-29
21135252-7	2011	Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure.	Sirolimus	163-172	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	56-60
21135252-7	2011	Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure.	Sirolimus	163-172	AKT serine/threonine kinase 1	Homo sapiens	132-135
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	itchy E3 ubiquitin protein ligase	Homo sapiens	20-24
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	itchy E3 ubiquitin protein ligase	Homo sapiens	25-29
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	mitogen-activated protein kinase 8	Homo sapiens	55-58
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	171-180	cadherin 5	Homo sapiens	207-218
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	171-180	twist family bHLH transcription factor 1	Homo sapiens	243-248
21629335-2	2011	Constant and inadequate proliferation occurring in TS may be blocked by mTOR inhibitors (mammalian target of rapamycin), such as rapamycin.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	72-76
21949767-12	2011	MNK kinase mediated the eIF4E phosphorylation and inhibition or depletion of MNK markedly suppressed proliferation of the CTCL cells when combined with the rapamycin-mediated inhibition of mTORC1.	Sirolimus	156-165	TSPY like 2	Homo sapiens	122-126
21695255-7	2011	Ectopic allotransplants of the mouse ovarian tumor cells with a gain-of-function mutation in beta-catenin and PTEN deletion developed into tumors with OEA histology, the growth of which were significantly inhibited by oral rapamycin treatment.	Sirolimus	223-232	phosphatase and tensin homolog	Mus musculus	110-114
21079551-7	2010	The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	123-152
21200439-7	2010	We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5.	Sirolimus	40-49	interleukin 1 beta	Mus musculus	171-179
21200439-7	2010	We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5.	Sirolimus	40-49	interferon gamma	Mus musculus	181-190
20935504-0	2010	Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin.	Sirolimus	88-97	AKT serine/threonine kinase 1	Homo sapiens	18-21
20935504-4	2010	These compounds enhanced the cytotoxic potential of rapamycin, a chemotherapeutic that inhibits survival signaling downstream of Akt.	Sirolimus	52-61	AKT serine/threonine kinase 1	Homo sapiens	129-132
21098662-8	2010	The remaining LTD was reduced by anisomycin, an inhibitor of protein synthesis, by U0126, an inhibitor of MEK1/2 kinases, and by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suggesting mediation by the same mechanisms as in WT.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	156-185
21098662-8	2010	The remaining LTD was reduced by anisomycin, an inhibitor of protein synthesis, by U0126, an inhibitor of MEK1/2 kinases, and by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suggesting mediation by the same mechanisms as in WT.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	187-191
20926775-1	2010	Rapamycin, an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR), is a widely used immunosuppressive drug.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	55-84
20926775-1	2010	Rapamycin, an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR), is a widely used immunosuppressive drug.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	86-90
20697716-5	2010	Synchronized cell experiments revealed rapamycin-induced defects in pre-anaphase spindle assembly and S phase progression that were more severe in clb5Delta than in wild-type cells but no apparent activation of Rad53-dependent checkpoint pathways.	Sirolimus	39-48	B-type cyclin CLB5	Saccharomyces cerevisiae S288C	147-156
20854816-0	2010	mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20854816-2	2010	To evaluate the involvement of mTOR complexes during ischemia we analyzed the time course of i-LTP by intracellular recordings of MSNs from corticostriatal slices incubated with 1muM mTOR inhibitor rapamycin.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Homo sapiens	183-187
20863555-5	2010	The effect of rapamycin on phosphorylated-S6 and 4E-BP-1 was also assessed by Western blotting.	Sirolimus	14-23	BP1	Homo sapiens	52-56
20863555-10	2010	Sensitivity to rapamycin was independent of PTEN and Akt status.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	53-56
20861822-7	2010	A feature of increasing importance is that the mTOR pathway is central for vital aspects of tumor development, including angiogenesis and cell growth; rapamycin, therefore, has anticancer activities, which may prove critical in the fight against high cancer rates in transplant recipients.	Sirolimus	151-160	mechanistic target of rapamycin kinase	Homo sapiens	47-51
21042741-4	2010	The well known mTOR inhibitor rapamycin has a disadvantage of feedback stimulation of Akt.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
21042741-4	2010	The well known mTOR inhibitor rapamycin has a disadvantage of feedback stimulation of Akt.	Sirolimus	30-39	AKT serine/threonine kinase 1	Homo sapiens	86-89
21042741-8	2010	Our results indicated that anthocyanins significantly decreased phospho-mTOR comparable to rapamycin, a synthetic mTOR inhibitor, and this inhibitory effect of anthocyanins on mTOR was completely abrogated by inactivating AMPKalpha1.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	114-118
21042741-8	2010	Our results indicated that anthocyanins significantly decreased phospho-mTOR comparable to rapamycin, a synthetic mTOR inhibitor, and this inhibitory effect of anthocyanins on mTOR was completely abrogated by inactivating AMPKalpha1.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	114-118
21086573-3	2010	After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP.	Sirolimus	69-78	alpha fetoprotein	Homo sapiens	188-191
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	80-84
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	96-100
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	4-33
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	35-39
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	80-84
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	96-100
21083937-10	2010	Rapamycin prevented Dex-induced expression of cyclin A.	Sirolimus	0-9	cyclin A2	Homo sapiens	46-54
21083937-12	2010	Rapamycin enhanced GC-induced apoptosis and this was not achieved by modulation of glucocorticoid receptor (GR) expression, but synergistically up-regulation of pro-apoptotic proteins like caspase-3, Bax, and Bim, and down-regulation of anti-apoptotic protein of Mcl-1.	Sirolimus	0-9	caspase 3	Homo sapiens	189-198
21083937-12	2010	Rapamycin enhanced GC-induced apoptosis and this was not achieved by modulation of glucocorticoid receptor (GR) expression, but synergistically up-regulation of pro-apoptotic proteins like caspase-3, Bax, and Bim, and down-regulation of anti-apoptotic protein of Mcl-1.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	200-203
21182472-4	2010	Of note, rapamycin and FK506 bind to FKBP12, and the resulting complexes interfere with distinct intracellular signaling pathways driven, respectively, by the mammalian target of rapamycin and calcineurin phosphatase.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	159-188
20620173-10	2010	Interestingly, rapamycin, an mTOR inhibitor, upregulates MT1-MMP expression in PTEN(+/+) cells via PI3K activity.	Sirolimus	15-24	phosphatase and tensin homolog	Mus musculus	79-83
20832409-5	2010	BCAA-treated neurons showed hyperexcitability and rapamycin was able to suppress it and significantly reduce the level of mTOR, Akt and p70S6 phosphorylation.	Sirolimus	50-59	AT rich interactive domain 4B (RBP1-like)	Mus musculus	0-4
20832409-5	2010	BCAA-treated neurons showed hyperexcitability and rapamycin was able to suppress it and significantly reduce the level of mTOR, Akt and p70S6 phosphorylation.	Sirolimus	50-59	thymoma viral proto-oncogene 1	Mus musculus	128-131
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	mitogen-activated protein kinase 8	Homo sapiens	230-253
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	mitogen-activated protein kinase 8	Homo sapiens	255-258
20500493-1	2010	Immediate or early use of proliferation signal inhibitor (PSI)/mammalian target of rapamycin (mTOR) inhibitor therapy can avoid high exposure to calcineurin inhibitors but concerns exist relating to the risk of delayed graft function (DGF) and impaired wound healing with the mTOR sirolimus.	Sirolimus	281-290	mechanistic target of rapamycin kinase	Homo sapiens	63-92
20500493-1	2010	Immediate or early use of proliferation signal inhibitor (PSI)/mammalian target of rapamycin (mTOR) inhibitor therapy can avoid high exposure to calcineurin inhibitors but concerns exist relating to the risk of delayed graft function (DGF) and impaired wound healing with the mTOR sirolimus.	Sirolimus	281-290	mechanistic target of rapamycin kinase	Homo sapiens	94-98
20844194-3	2010	In this study, we report the development of a long-lasting autoactive human mutant TGF-beta1/Fc fusion protein that acts in conjunction with rapamycin to inhibit T cell proliferation and induce the de novo generation of Foxp3(+) Treg in the periphery, while at the same time inhibiting IL-6-mediated Th17 cell differentiation.	Sirolimus	141-150	transforming growth factor beta 1	Homo sapiens	83-92
20844194-3	2010	In this study, we report the development of a long-lasting autoactive human mutant TGF-beta1/Fc fusion protein that acts in conjunction with rapamycin to inhibit T cell proliferation and induce the de novo generation of Foxp3(+) Treg in the periphery, while at the same time inhibiting IL-6-mediated Th17 cell differentiation.	Sirolimus	141-150	interleukin 6	Homo sapiens	286-290
20813961-5	2010	In this study, we show that tuberin regulates the localization of E-cadherin via an Akt/mTORC1/CLIP170-dependent, rapamycin-sensitive pathway.	Sirolimus	114-123	cadherin 1	Homo sapiens	66-76
20813961-5	2010	In this study, we show that tuberin regulates the localization of E-cadherin via an Akt/mTORC1/CLIP170-dependent, rapamycin-sensitive pathway.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	84-87
20417028-0	2010	Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	21-24
20842569-14	2010	Inhibitors of the mammalian target of rapamycin (i.e., sirolimus and everolimus) have not yet assumed a major place as adjunctive agents, as their safety and efficacy have not been well established in children.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	18-47
20429048-3	2010	The inhibitory effects of palmitate on the insulin signaling were diminished in PKCTheta- and mTOR (mammalian target of rapamycin)-deficient C2C12 myotubes, and C2C12 myotubes pre-treated with rapamycin.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	94-98
21495229-4	2010	Novel therapies, such as drugs that target cellular pathways, for example, mTOR inhibitor deforolimus, an analog of rapamycin, have been developed and used in clinical trials to treat women with progressive endometrial cancer.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	75-79
20686448-2	2010	Sirolimus, an inhibitor of the protein kinase mammalian target of rapamycin (mTOR) and a potent anti-proliferative agent, decreases cyst growth in several genetically distinct rodent models of polycystic kidney disease (PKD).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-75
20686448-2	2010	Sirolimus, an inhibitor of the protein kinase mammalian target of rapamycin (mTOR) and a potent anti-proliferative agent, decreases cyst growth in several genetically distinct rodent models of polycystic kidney disease (PKD).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	77-81
20664001-7	2010	It is noteworthy that the mammalian target of rapamycin (mTOR) inhibitor rapamycin also induced phosphorylation of eIF4E in a Mnk-dependent manner, whereas inhibition strongly enhanced its antileukemic effects.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	57-61
20566381-1	2010	Inhibition of mTOR by rapamycin has been shown to suppress seizures in TSC/PTEN genetic models.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20566381-1	2010	Inhibition of mTOR by rapamycin has been shown to suppress seizures in TSC/PTEN genetic models.	Sirolimus	22-31	TSC complex subunit 1	Homo sapiens	71-74
20599569-5	2010	Furthermore, the inhibition of mTOR by chronic infusion of rapamycin, a specific inhibitor of mTOR, into the ventricle retards the establishment of spatial learning.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	31-35
20599569-5	2010	Furthermore, the inhibition of mTOR by chronic infusion of rapamycin, a specific inhibitor of mTOR, into the ventricle retards the establishment of spatial learning.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	94-98
21210335-6	2010	The use of mTOR inhibitors such as rapamycin and everolimus is discussed and recent clinical trials of these drugs in TSC are reviewed.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	11-15
21105579-0	2010	Rapamycin protects heart from ischemia/reperfusion injury independent of autophagy by activating PI3 kinase-Akt pathway and mitochondria K(ATP) channel.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	108-111
20970608-1	2010	BACKGROUND: The mammalian target of rapamycin inhibitors (mTORi) sirolimus (Si) and everolimus (Ev) induce pneumonitis, an unusual but potentially fatal adverse effect.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	16-45
20970608-1	2010	BACKGROUND: The mammalian target of rapamycin inhibitors (mTORi) sirolimus (Si) and everolimus (Ev) induce pneumonitis, an unusual but potentially fatal adverse effect.	Sirolimus	76-78	mechanistic target of rapamycin kinase	Homo sapiens	16-45
20668162-4	2010	Furthermore, the presumed role of mTOR in hypertrophy is derived from studies that used rapamycin to inhibit mTOR; yet, there is very little direct evidence that mTOR is the rapamycin-sensitive element that confers the hypertrophic response.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	109-113
20668162-4	2010	Furthermore, the presumed role of mTOR in hypertrophy is derived from studies that used rapamycin to inhibit mTOR; yet, there is very little direct evidence that mTOR is the rapamycin-sensitive element that confers the hypertrophic response.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	109-113
20668162-5	2010	In this study, we determined that, in skeletal muscle, overexpression of Rheb stimulates a PI3K/PKB-independent activation of mTOR signaling, and this is sufficient for the induction of a rapamycin-sensitive hypertrophic response.	Sirolimus	188-197	mechanistic target of rapamycin kinase	Homo sapiens	126-130
20828737-9	2011	Pretreatment with rapamycin, a specific inhibitor of mTOR, resulted in a significant decrease of IL-10 and IL-6 translation and expression but did not affect the LPS-induced TNFalpha production.	Sirolimus	18-27	interleukin 6	Homo sapiens	107-111
20660299-9	2010	In addition, hCG or FSK-mediated up-regulation of the cell cycle regulatory proteins cyclin-dependent kinase 4, cyclin D3, and proliferating cell nuclear antigen was blocked by rapamycin.	Sirolimus	177-186	cyclin D3	Homo sapiens	112-121
20922700-15	2010	Since m-TOR, the target of sirolimus, is altered in many tumors, sirolimus may be an effective tool.	Sirolimus	27-36	RAR related orphan receptor C	Homo sapiens	8-11
20922700-15	2010	Since m-TOR, the target of sirolimus, is altered in many tumors, sirolimus may be an effective tool.	Sirolimus	65-74	RAR related orphan receptor C	Homo sapiens	8-11
20922700-16	2010	Sirolimus inhibits not only cell proliferation but also tumor neovascularization by reducing VEGF production and inhibiting VEGF receptor signaling in endothelial cells.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	93-97
20922700-16	2010	Sirolimus inhibits not only cell proliferation but also tumor neovascularization by reducing VEGF production and inhibiting VEGF receptor signaling in endothelial cells.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	124-128
20555322-5	2010	Vascular invasion was disturbed in the rapamycin group, there was a significant reduction in osteoclast cells near the chondro-osseus junction, and there was lower VEGF protein and mRNA expression in the terminal chondrocytes of the growth cartilage.	Sirolimus	39-48	vascular endothelial growth factor A	Homo sapiens	164-168
20167228-6	2010	The DHEA-action was sensitive to the PI3K inhibitor LY294002 and the mammalian target of rapamycin (mTOR) inhibitor rapamycin.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	100-104
20716637-9	2010	Compared with single antibodies, the BIIB4 and BIIB5 combination also significantly further enhanced the antitumor activity of the epidermal growth factor receptor inhibitor erlotinib and the mTOR inhibitor rapamycin.	Sirolimus	207-216	mechanistic target of rapamycin kinase	Homo sapiens	192-196
20811357-2	2010	Longevity-promoting regimens, including caloric restriction and inhibition of TOR with rapamycin, resveratrol or the natural polyamine spermidine, have been associated with autophagy (a cytoprotective self-digestive process) and in some cases were reported to require autophagy for their effects.	Sirolimus	87-96	RAR related orphan receptor C	Homo sapiens	78-81
20678995-8	2010	We observed the effectiveness of the activated Akt/mTOR/p70S6K signaling pathway in improving locomotor recovery, significantly increasing the expression of nestin, neuronal nuclei (NeuN), neuron specific enolase (NSE), and neurofilament 200 (NF200), and relatively inhibiting excessive reactive astrogliosis after SCI in a rapamycin-sensitive manner.	Sirolimus	324-333	AKT serine/threonine kinase 1	Rattus norvegicus	47-50
20457271-5	2010	Similarly, both rapamycin and cicaprost have been reported to regulate levels of the cdk inhibitor, p27(kip1).	Sirolimus	16-25	zinc ribbon domain containing 2	Homo sapiens	100-103
21092676-0	2010	[Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma].	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	58-87
21092676-9	2010	RT-PCR showed that rapamycin significantly inhibited mRNA expression of mTOR in CNE-2 cells (t = 10.625, P < 0.01).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	72-76
21092676-10	2010	CONCLUSIONS: Rapamycin inhibits the growth of CNE-1 and CNE-2 cells by inhibiting the progression of cell cycle, which could be achieved through decreasing the expression of mTOR.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	174-178
20600616-10	2010	Treatment with sirolimus resulted in antihyperalgesic and antiallodynic effects and prevented the increased spinal cord TNF-alpha level.	Sirolimus	15-24	tumor necrosis factor	Rattus norvegicus	120-129
20581391-2	2010	The drug sirolimus suppresses mTOR signaling.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	30-34
20505189-8	2010	Primary AML blasts without functional NF1, unlike blasts with functional NF1, displayed sensitivity to rapamycin-induced apoptosis, thus identifying a dependence on mammalian target of rapamycin (mTOR) signaling for survival.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	165-194
20505189-8	2010	Primary AML blasts without functional NF1, unlike blasts with functional NF1, displayed sensitivity to rapamycin-induced apoptosis, thus identifying a dependence on mammalian target of rapamycin (mTOR) signaling for survival.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	196-200
20505189-9	2010	Finally, colony formation in methylcellulose ex vivo of NF1 null CD34+/CD38- cells sorted from AML bone marrow samples was inhibited by low-dose rapamycin.	Sirolimus	145-154	neurofibromin 1	Homo sapiens	56-59
20554536-7	2010	In addition, combination treatment with HBC and various HIF-1 inhibitors, including suberoylanilide hydroxamic acid, rapamycin, and terpestacin, had greater anti-angiogenic activity than treatment with each single agent.	Sirolimus	117-126	hypoxia inducible factor 1 subunit alpha	Homo sapiens	56-61
20368307-5	2010	Co-expression of mTOR significantly enhanced I(pi) in NaPi-IIa-expressing Xenopus oocytes, an effect abrogated by treatment with rapamycin (50 nM for the last 24 h of incubation).	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	17-21
20421347-3	2010	We report a previously unsuspected role for the nonprotein-coding RNA GAS5 in the inhibition of T-cell proliferation produced by mTOR antagonists such as rapamycin.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	129-133
20177775-0	2010	Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	64-68
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-53
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	116-119
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	165-169
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	205-214	AKT serine/threonine kinase 1	Homo sapiens	116-119
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	165-169
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	133-137
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Sirolimus	69-78	AKT serine/threonine kinase 1	Homo sapiens	164-167
20177775-7	2010	Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone.	Sirolimus	47-56	AKT serine/threonine kinase 1	Homo sapiens	142-145
20643380-3	2010	Molecularly-targeted treatments using mTOR inhibitors (such as rapamycin) are showing great promise for the physical and neurological phenotype of TSC.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	38-42
20643380-3	2010	Molecularly-targeted treatments using mTOR inhibitors (such as rapamycin) are showing great promise for the physical and neurological phenotype of TSC.	Sirolimus	63-72	TSC complex subunit 1	Homo sapiens	147-150
20108343-4	2010	In an attempt to avoid bilateral nephrectomies, the patient was treated with the mTOR inhibitor sirolimus.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	81-85
20630348-5	2010	The involvement of mTOR in LAM pathogenesis is the basis for initiation of therapeutic trials of mTOR inhibitors (e.g., sirolimus).	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	19-23
20630348-5	2010	The involvement of mTOR in LAM pathogenesis is the basis for initiation of therapeutic trials of mTOR inhibitors (e.g., sirolimus).	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	97-101
20470887-0	2010	Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway.	Sirolimus	0-9	angiotensinogen	Homo sapiens	84-98
21188109-1	2010	Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are warranted.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	143-172
21188109-1	2010	Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are warranted.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	174-178
20603607-3	2010	In particular, kainate-induced status epilepticus causes abnormal activation of the mTOR pathway, and the mTOR inhibitor, rapamycin, can decrease the development of neuronal death and chronic seizures in the kainate model.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	106-110
20603607-4	2010	Here, we discuss the significance of these findings and extend them further by identifying upstream signaling pathways through which kainate status epilepticus activates the mTOR pathway and by demonstrating limited situations where rapamycin may paradoxically increase mTOR activation and worsen neuronal death in the kainate model.	Sirolimus	233-242	mechanistic target of rapamycin kinase	Homo sapiens	270-274
20360610-10	2010	Mammalian target of rapamycin (mTOR) phosphorylation was increased in G391R cells with increased survival (55%) compared with WT (30%) and had increased sensitivity to rapamycin.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
21364653-6	2010	Wild-type CADM1 was partly localized to the ER of C2C5 cells, whereas mutated CADM1 mainly accumulated in the ER despite different sensitivities toward 4-phenyl butyric acid with chemical chaperone activity and rapamycin with promotion activity for degradation of the aggregated protein.	Sirolimus	211-220	cell adhesion molecule 1	Mus musculus	78-83
20606252-7	2010	In these senescence-prone cells, the mTOR inhibitor rapamycin converted nutlin-3a-induced senescence into quiescence.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
20299603-8	2010	We have demonstrated that exposure of HIMEC to low levels of irradiation induced Akt and mTOR phosphorylation, which was attenuated by curcumin, rapamycin, LY294002, and mTOR small interference RNA (siRNA).	Sirolimus	145-154	AKT serine/threonine kinase 1	Homo sapiens	81-84
20299603-8	2010	We have demonstrated that exposure of HIMEC to low levels of irradiation induced Akt and mTOR phosphorylation, which was attenuated by curcumin, rapamycin, LY294002, and mTOR small interference RNA (siRNA).	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	89-93
20348217-4	2010	Using radioactive assay, we demonstrated that sirolimus inhibited the increase of interleukin-1beta (IL-1beta)-induced cholesterol synthesis in VSMCs.	Sirolimus	46-55	interleukin 1 beta	Homo sapiens	82-99
20348217-4	2010	Using radioactive assay, we demonstrated that sirolimus inhibited the increase of interleukin-1beta (IL-1beta)-induced cholesterol synthesis in VSMCs.	Sirolimus	46-55	interleukin 1 beta	Homo sapiens	101-109
20348217-5	2010	Further studies showed that sirolimus inhibited both the HMGR gene and protein expression in VSMCs treated with or without IL-1beta.	Sirolimus	28-37	interleukin 1 beta	Homo sapiens	123-131
20395440-5	2010	In addition, mTOR inhibition via rapamycin administration reduced cell proliferation in UCC cell lines RT4, T24, J82, and UMUC3 in a dose-dependent manner to 6% of control levels and was significant at 1 nmol/L in J82, T24, and RT4 cells (P < 0.01, P < 0.01, P = 0.03, respectively) and at 10 nmol/L in UMUC3 cells (P = 0.03).	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	13-17
20833335-5	2010	The pathogenesis of these familial syndromes is linked by the shared regulation of a common pathway, the protein kinase mammalian target of rapamycin (mTOR).	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	151-155
20497911-8	2010	Inhibitors of mTOR (sirolimus, temsirolimus) demonstrated an antitumoral activity in the PEComas.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20138985-9	2010	Inhibition of mTORC1 by rapamycin or amino acid deprivation partially abrogated insulin-mediated PRAS40-Ser183 phosphorylation in cultured cell lines.	Sirolimus	24-33	insulin	Homo sapiens	80-87
20138985-9	2010	Inhibition of mTORC1 by rapamycin or amino acid deprivation partially abrogated insulin-mediated PRAS40-Ser183 phosphorylation in cultured cell lines.	Sirolimus	24-33	AKT1 substrate 1	Homo sapiens	97-103
20368736-6	2010	We also found that p53 knockdown or inhibition of mTOR activity by rapamycin cotreatment impairs 6-TG- and 5-FU-induced upregulation of BNIP3 protein levels and autophagy.	Sirolimus	67-76	tumor protein p53	Homo sapiens	19-22
20368736-6	2010	We also found that p53 knockdown or inhibition of mTOR activity by rapamycin cotreatment impairs 6-TG- and 5-FU-induced upregulation of BNIP3 protein levels and autophagy.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	50-54
20368736-6	2010	We also found that p53 knockdown or inhibition of mTOR activity by rapamycin cotreatment impairs 6-TG- and 5-FU-induced upregulation of BNIP3 protein levels and autophagy.	Sirolimus	67-76	BCL2 interacting protein 3	Homo sapiens	136-141
20501622-7	2010	Pharmacodynamic studies showed tumor S6 phosphorylation inhibition in 50% of 10 evaluable rapamycin-treated men with sufficient paired tissue [median 58% inhibition (P = 0.049) versus 2% inhibition in controls (P = 0.75)] with no significant effect on AKT activity.	Sirolimus	90-99	AKT serine/threonine kinase 1	Homo sapiens	252-255
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	solute carrier organic anion transporter family member 1B3	Homo sapiens	106-113
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	134-139
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	solute carrier organic anion transporter family member 1B3	Homo sapiens	154-161
20220747-3	2010	However, competition between sirolimus and ezetimibe for ABCB1 and OATP1B1 is not of major clinical relevance, as confirmed in our randomized, controlled, single-dose study in healthy subjects.	Sirolimus	29-38	ATP binding cassette subfamily B member 1	Homo sapiens	57-62
20496258-2	2010	The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	103-106
20496258-2	2010	The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	74-78
20496258-2	2010	The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	74-78
20299475-2	2010	Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive.	Sirolimus	91-100	insulin	Homo sapiens	27-34
20299475-2	2010	Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	57-61
20299475-2	2010	Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive.	Sirolimus	91-100	insulin	Homo sapiens	127-134
20299475-2	2010	Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive.	Sirolimus	91-100	insulin	Homo sapiens	127-134
20299475-7	2010	These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop.	Sirolimus	121-130	insulin	Homo sapiens	61-68
20299475-7	2010	These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop.	Sirolimus	121-130	AKT serine/threonine kinase 1	Rattus norvegicus	100-103
20351317-13	2010	Furthermore, LH-directed changes in AMPK and GSK3B phosphorylation appear to exert a greater impact on progesterone synthesis in the corpus luteum than rapamycin-sensitive MTOR-mediated events.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	172-176
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	22-26
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	AKT serine/threonine kinase 1	Homo sapiens	130-133
19856312-0	2010	Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	93-96
19856312-2	2010	In this study, to elucidate whether the rapamycin, the inhibitor of the mTOR (mammalian target of rapamaycin), can enhance the potentiation of TXT and 5-fluorouracil (5-Fu) in gastric carcinoma cells.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	72-76
19856312-2	2010	In this study, to elucidate whether the rapamycin, the inhibitor of the mTOR (mammalian target of rapamaycin), can enhance the potentiation of TXT and 5-fluorouracil (5-Fu) in gastric carcinoma cells.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	78-108
19856312-7	2010	Moreover, rapamycin decreased the phosphorylation of 4E-BP1, the phosphorylation of ERK1/2 and enhanced the phosphorylation of c-Jun NH2-terminal kinase, and the activation of caspase of apoptotic pathways in combination with TXT.	Sirolimus	10-19	mitogen-activated protein kinase 3	Homo sapiens	84-90
20375166-11	2010	The mTOR inhibitor rapamycin reversed the inhibitory effects of SOCS3.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
20512842-0	2010	Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	20-23
20512842-0	2010	Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	28-31
20512842-2	2010	In this report, we focused on studying the role of mTORC1 and mTORC2 in rapamycin-mediated Akt and ERK phosphorylation, and the antitumor effect of rapamycin in cancer cells in combination with Akt and ERK inhibitors.	Sirolimus	72-81	AKT serine/threonine kinase 1	Homo sapiens	91-94
20512842-2	2010	In this report, we focused on studying the role of mTORC1 and mTORC2 in rapamycin-mediated Akt and ERK phosphorylation, and the antitumor effect of rapamycin in cancer cells in combination with Akt and ERK inhibitors.	Sirolimus	72-81	mitogen-activated protein kinase 1	Homo sapiens	99-102
20512842-2	2010	In this report, we focused on studying the role of mTORC1 and mTORC2 in rapamycin-mediated Akt and ERK phosphorylation, and the antitumor effect of rapamycin in cancer cells in combination with Akt and ERK inhibitors.	Sirolimus	72-81	mitogen-activated protein kinase 1	Homo sapiens	202-205
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	53-56
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	mitogen-activated protein kinase 1	Homo sapiens	61-64
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	171-174
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	mitogen-activated protein kinase 1	Homo sapiens	179-182
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	171-174
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	mitogen-activated protein kinase 1	Homo sapiens	179-182
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	171-174
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	mitogen-activated protein kinase 1	Homo sapiens	179-182
20512842-6	2010	Therefore, we combined PI3K and ERK inhibitors prevent rapamycin-induced Akt activation and enhanced antitumor effects of rapamycin.	Sirolimus	55-64	mitogen-activated protein kinase 1	Homo sapiens	32-35
20512842-6	2010	Therefore, we combined PI3K and ERK inhibitors prevent rapamycin-induced Akt activation and enhanced antitumor effects of rapamycin.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	73-76
20512842-6	2010	Therefore, we combined PI3K and ERK inhibitors prevent rapamycin-induced Akt activation and enhanced antitumor effects of rapamycin.	Sirolimus	122-131	mitogen-activated protein kinase 1	Homo sapiens	32-35
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	AKT serine/threonine kinase 1	Homo sapiens	124-127
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	mitogen-activated protein kinase 1	Homo sapiens	132-135
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	AKT serine/threonine kinase 1	Homo sapiens	153-156
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	mitogen-activated protein kinase 1	Homo sapiens	161-164
20335389-4	2010	This up-regulation of HIF-1 alpha occurs under normoxic conditions and could be inhibited with wortmannin, Akt inhibitor, and rapamycin, consistent with the activation of a phosphoinositide-3 kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathway, respectively.	Sirolimus	126-135	hypoxia inducible factor 1 subunit alpha	Homo sapiens	22-33
20144629-2	2010	IGF-I-induced IGF-I receptor decrease was abolished by LY294002 (phosphoinositide 3-kinase inhibitor) and partially attenuated by rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	130-139	insulin like growth factor 1	Homo sapiens	0-5
20144629-2	2010	IGF-I-induced IGF-I receptor decrease was abolished by LY294002 (phosphoinositide 3-kinase inhibitor) and partially attenuated by rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	157-186
20144629-2	2010	IGF-I-induced IGF-I receptor decrease was abolished by LY294002 (phosphoinositide 3-kinase inhibitor) and partially attenuated by rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	188-192
20472200-3	2010	The patient received the mammalian target of rapamycin inhibitor, sirolimus, for recurrent subependymal giant cell brain tumors.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	25-54
20530756-2	2010	The target of rapamycin (TOR) pathway is a major regulator of cell growth in eukaryotes, and inhibition of this pathway by rapamycin reduces cell growth.	Sirolimus	14-23	target of rapamycin	Arabidopsis thaliana	25-28
20530756-7	2010	Inhibition of TOR signaling by rapamycin led to suppression of the lrx1 mutant phenotype and caused specific changes to galactan/rhamnogalacturonan-I and arabinogalactan protein components of cell walls that were similar to those observed in the rol5 mutant.	Sirolimus	31-40	target of rapamycin	Arabidopsis thaliana	14-17
20530756-7	2010	Inhibition of TOR signaling by rapamycin led to suppression of the lrx1 mutant phenotype and caused specific changes to galactan/rhamnogalacturonan-I and arabinogalactan protein components of cell walls that were similar to those observed in the rol5 mutant.	Sirolimus	31-40	leucine-rich repeat/extensin 1	Arabidopsis thaliana	67-71
20127734-12	2010	Attenuation of Rheb expression or treatment with the mTOR inhibitor rapamycin decreased proliferation of PC3 and DU145 cells, with a decrease in the activated form of p70S6 kinase, one of the main targets of mTOR.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	53-57
20127734-12	2010	Attenuation of Rheb expression or treatment with the mTOR inhibitor rapamycin decreased proliferation of PC3 and DU145 cells, with a decrease in the activated form of p70S6 kinase, one of the main targets of mTOR.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	208-212
20102553-2	2010	The mammalian target of rapamycin inhibitors (mTORi), sirolimus and everolimus, have been demonstrated to attenuate the progression of CAV and are cytotoxic to EPC.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	4-33
20620549-8	2010	Nitrite accumulation in the supernatants revealed that rapamycin decreased nitrite release induced by interleukin-1beta but did not affect basal or A23187-stimulated nitrite levels.	Sirolimus	55-64	interleukin 1 beta	Rattus norvegicus	102-119
20620549-9	2010	Western blot analysis demonstrated that rapamycin decreased inducible NO synthase protein expression in coronary endothelial cells.	Sirolimus	40-49	nitric oxide synthase 2	Rattus norvegicus	60-81
20457898-8	2010	Like rapamycin, which is known to suppress senescence, p53 inhibited the mTOR pathway.	Sirolimus	5-14	tumor protein p53	Homo sapiens	55-58
20457898-8	2010	Like rapamycin, which is known to suppress senescence, p53 inhibited the mTOR pathway.	Sirolimus	5-14	mechanistic target of rapamycin kinase	Homo sapiens	73-77
20371605-4	2010	Glycolysis in FoxO3a-deficient cells was associated with increased S6K1 phosphorylation and was sensitive to rapamycin, an inhibitor of the mTORC1 pathway that has been linked to glycolysis regulation.	Sirolimus	109-118	forkhead box O3	Homo sapiens	14-20
20495773-8	2010	The mTOR signaling cascade has been implicated in membrane traffic and is activated in nearly all human cancers, but clinical response to the mTOR-specific inhibitor rapamycin has been disappointing.	Sirolimus	166-175	mechanistic target of rapamycin kinase	Homo sapiens	4-8
20495773-8	2010	The mTOR signaling cascade has been implicated in membrane traffic and is activated in nearly all human cancers, but clinical response to the mTOR-specific inhibitor rapamycin has been disappointing.	Sirolimus	166-175	mechanistic target of rapamycin kinase	Homo sapiens	142-146
20498714-5	2010	By the use of genetically defined approaches, including the epithelial-specific ablation of Pten and Tsc1, we show that mTOR activation can dramatically increase epithelial cell proliferation, migration, and cutaneous wound healing, while pharmacological inhibition of mTOR with rapamycin delays wound closure.	Sirolimus	279-288	phosphatase and tensin homolog	Mus musculus	92-96
20421479-3	2010	In this study, we show that Ag-specific memory Th cells were redifferentiated into Foxp3(+) T cells by TGF-beta when stimulated in the presence of all-trans retinoic acid and rapamycin.	Sirolimus	175-184	transforming growth factor beta 1	Homo sapiens	103-111
20459775-4	2010	Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	61-65
20485667-0	2010	Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	19-24
20485667-4	2010	Here we show that rapamycin inhibited the basal or insulin-like growth factor 1 (IGF-1)-induced motility of human Ewing sarcoma (Rh1) and rhabdomyosarcoma (Rh30) cells.	Sirolimus	18-27	insulin like growth factor 1	Homo sapiens	51-79
20485667-4	2010	Here we show that rapamycin inhibited the basal or insulin-like growth factor 1 (IGF-1)-induced motility of human Ewing sarcoma (Rh1) and rhabdomyosarcoma (Rh30) cells.	Sirolimus	18-27	insulin like growth factor 1	Homo sapiens	81-86
20485667-5	2010	Treatment of the cells with rapamycin activated PP2A activity, and concurrently inhibited IGF-1 stimulated phosphorylation of Erk1/2.	Sirolimus	28-37	insulin like growth factor 1	Homo sapiens	90-95
20485667-5	2010	Treatment of the cells with rapamycin activated PP2A activity, and concurrently inhibited IGF-1 stimulated phosphorylation of Erk1/2.	Sirolimus	28-37	mitogen-activated protein kinase 3	Homo sapiens	126-132
20485667-7	2010	Furthermore, inhibition of PP2A with okadaic acid significantly attenuated the inhibitory effect of rapamycin on IGF-1-stimulated phosphorylation of Erk1/2 as well as cell motility.	Sirolimus	100-109	insulin like growth factor 1	Homo sapiens	113-118
20485667-7	2010	Furthermore, inhibition of PP2A with okadaic acid significantly attenuated the inhibitory effect of rapamycin on IGF-1-stimulated phosphorylation of Erk1/2 as well as cell motility.	Sirolimus	100-109	mitogen-activated protein kinase 3	Homo sapiens	149-155
20485667-9	2010	Expression of constitutively active MKK1 also attenuated rapamycin inhibition of IGF-1-stimulated phosphorylation of Erk1/2 and cell motility.	Sirolimus	57-66	insulin like growth factor 1	Homo sapiens	81-86
20485667-9	2010	Expression of constitutively active MKK1 also attenuated rapamycin inhibition of IGF-1-stimulated phosphorylation of Erk1/2 and cell motility.	Sirolimus	57-66	mitogen-activated protein kinase 3	Homo sapiens	117-123
20485667-10	2010	The results suggest that rapamycin inhibits cell motility, in part by targeting PP2A-Erk1/2 pathway.	Sirolimus	25-34	mitogen-activated protein kinase 3	Homo sapiens	85-91
20459645-9	2010	The study suggests that inhibition of mTOR by rapamycin augments whereas overexpression of mTOR/p70S6 kinase inhibits OPN-induced ICAM-1 expression.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	38-42
20459645-14	2010	Inhibition of mTOR by rapamycin attenuates Ser-371 phosphorylation but does not have any effect on Thr-389 and Thr-421/Ser-424 phosphorylation of p70S6 kinase.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20445056-4	2010	To this end, we show that the in vivo infusion of the mTOR inhibitor rapamycin led to a significant attenuation of the phase-delaying effect of early-night light.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	54-58
20139176-5	2010	The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway.	Sirolimus	123-132	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
20139176-5	2010	The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway.	Sirolimus	123-132	tumor necrosis factor	Homo sapiens	32-40
20139176-5	2010	The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway.	Sirolimus	123-132	interleukin 4	Homo sapiens	41-45
20139176-5	2010	The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	151-180
20139176-5	2010	The activation of HIF-1alpha by TNFalpha/IL-4 was countered by the phosphoinositol 3-kinase (PI3K) inhibitor LY-294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the MAPK pathway.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	182-186
20420793-6	2010	Everolimus is derived from the mTOR inhibitor sirolimus and is in Phase III study.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	31-35
20412061-6	2010	IGF-1-stimulated TSC1/TSC2 phosphorylation and redistribution were completely prevented by the phosphoinositide 3-kinase inhibitor wortmannin, but were not with the downstream mTOR inhibitor, rapamycin.	Sirolimus	192-201	insulin like growth factor 1	Homo sapiens	0-5
19951971-7	2010	Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	63-66
19951971-7	2010	Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.	Sirolimus	34-43	insulin like growth factor 1	Homo sapiens	123-128
20412926-12	2010	Milk protein response to RPM was not related to predicted AA deficiency, calculated Met deficiency, or Met as a percentage of MP.	Sirolimus	25-28	Weaning weight-maternal milk	Bos taurus	0-4
19853261-3	2010	Sirolimus is a well-established inhibitor of the mammalian target of rapamycin.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-78
19853261-12	2010	CONCLUSIONS: Sirolimus appears to enhance the cytotoxicity of cisplatin in malignant pleural mesothelioma cell lines through the mammalian target of rapamycin pathway.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	129-158
20406686-6	2010	Reconstitution of the CD4(+) T-lymphocyte subset was significantly lower with sirolimus versus cyclosporine over year 1, but CD8(+) reconstitution did not differ significantly between groups.	Sirolimus	78-87	CD4 molecule	Homo sapiens	22-25
20406686-7	2010	The proportion of naive CD4(+) T-lymphocytes showed an initial decrease with sirolimus versus cyclosporine.	Sirolimus	77-86	CD4 molecule	Homo sapiens	24-27
20406686-9	2010	Memory CD4(+) T-lymphocytes occurred more frequently in sirolimus- versus cyclosporine-treated patients during year 1.	Sirolimus	56-65	CD4 molecule	Homo sapiens	7-10
20178983-6	2010	Using an animal model of AD, we show that pharmacologically restoring mTOR signaling with rapamycin rescues cognitive deficits and ameliorates Abeta and Tau pathology by increasing autophagy.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	70-74
20178983-6	2010	Using an animal model of AD, we show that pharmacologically restoring mTOR signaling with rapamycin rescues cognitive deficits and ameliorates Abeta and Tau pathology by increasing autophagy.	Sirolimus	90-99	amyloid beta precursor protein	Homo sapiens	143-148
20178983-7	2010	Indeed, we further show that autophagy induction is necessary for the rapamycin-mediated reduction in Abeta levels.	Sirolimus	70-79	amyloid beta precursor protein	Homo sapiens	102-107
20178983-8	2010	The results presented here provide a molecular basis for the Abeta-induced cognitive deficits and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces Abeta and Tau pathology.	Sirolimus	119-128	amyloid beta precursor protein	Homo sapiens	61-66
20178983-8	2010	The results presented here provide a molecular basis for the Abeta-induced cognitive deficits and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces Abeta and Tau pathology.	Sirolimus	119-128	amyloid beta precursor protein	Homo sapiens	193-198
20097763-6	2010	Treatment of HCAECs for this period with rapamycin produced an increase in the cyclin-dependent kinase inhibitor p27(Kip), through a decrease in the targeting of the protein for degradation by phosphorylation at Thr(187).	Sirolimus	41-50	zinc ribbon domain containing 2	Homo sapiens	113-116
20133820-7	2010	ANXA1, GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1 genes were likely to be mTOR effector genes in SEGA, as their expression was modulated by an mTOR inhibitor, rapamycin, in SEGA-derived cells.	Sirolimus	160-169	neuronal pentraxin 1	Homo sapiens	45-50
20133820-7	2010	ANXA1, GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1 genes were likely to be mTOR effector genes in SEGA, as their expression was modulated by an mTOR inhibitor, rapamycin, in SEGA-derived cells.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	75-79
20133820-7	2010	ANXA1, GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1 genes were likely to be mTOR effector genes in SEGA, as their expression was modulated by an mTOR inhibitor, rapamycin, in SEGA-derived cells.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	144-148
20168088-0	2010	Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia.	Sirolimus	104-113	AKT serine/threonine kinase 1	Homo sapiens	28-31
20168088-3	2010	The present study was undertaken to assess the potential role of activation of autophagic and phosphatidylinositol 3-kinase (PI3K)/Akt kinase pathways in the neuroprotective effect of rapamycin.	Sirolimus	184-193	AKT serine/threonine kinase 1	Homo sapiens	131-134
19931998-10	2010	Treating HepG2 cells with rapamycin, a specific mTOR inhibitor, significantly reduce survivin protein level but did not affect survivin transcription, which indicated that tamoxifen and rapamycin were synergistic in regards to down-regulation of survivin expression in hepatocellular carcinoma cells.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	48-52
19931998-10	2010	Treating HepG2 cells with rapamycin, a specific mTOR inhibitor, significantly reduce survivin protein level but did not affect survivin transcription, which indicated that tamoxifen and rapamycin were synergistic in regards to down-regulation of survivin expression in hepatocellular carcinoma cells.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	48-52
20116405-1	2010	Inhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosphorylation in cancer cells via mTORC2 activation.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	14-18
20116405-1	2010	Inhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosphorylation in cancer cells via mTORC2 activation.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	83-86
20372065-3	2010	It was reported recently that rapamycin is able to extend the lifespan of a mammal--implicating the mammalian TOR (mTOR).	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	115-119
20704577-5	2010	PBTDs possessed inhibitory activity against mTOR and also impeded hyper-phosphorylation of Akt as a feedback of inhibition of mTOR by rapamycin.	Sirolimus	134-143	AKT serine/threonine kinase 1	Homo sapiens	91-94
20704577-5	2010	PBTDs possessed inhibitory activity against mTOR and also impeded hyper-phosphorylation of Akt as a feedback of inhibition of mTOR by rapamycin.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	126-130
20087180-4	2010	RECENT FINDINGS: In this review, I discuss the basic science findings that position the TSC1 and TSC2 genes as critical regulators of the mammalian target of rapamycin kinase within mammalian target of rapamycin complex 1.	Sirolimus	158-167	TSC complex subunit 1	Homo sapiens	88-92
20087180-4	2010	RECENT FINDINGS: In this review, I discuss the basic science findings that position the TSC1 and TSC2 genes as critical regulators of the mammalian target of rapamycin kinase within mammalian target of rapamycin complex 1.	Sirolimus	202-211	TSC complex subunit 1	Homo sapiens	88-92
20156674-9	2010	The data indicate that in a relatively hypoxic environment HIF-1alpha may play a role in mediating the anti-cancer effect of rapamycin and cyclophosphamide may prevent the feedback activation of Akt by rapamycin.	Sirolimus	125-134	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
20156674-9	2010	The data indicate that in a relatively hypoxic environment HIF-1alpha may play a role in mediating the anti-cancer effect of rapamycin and cyclophosphamide may prevent the feedback activation of Akt by rapamycin.	Sirolimus	202-211	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
20102778-6	2010	mTOR-specific siRNA effectively suppressed HeLa cell growth through mechanisms including inhibition of the cell cycle and increased apoptosis, which were similar to the mechanisms of rapamycin action.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20099302-10	2010	Rapamycin, an inhibitor of mTOR, is known to induce autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
20099302-11	2010	Serotonin could override rapamycin by an mTOR-independent pathway and activate common downstream signals such as p70S6K and 4E-BP1.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	41-45
20130026-2	2010	Calcineurin inhibitors and sirolimus (mTOR inhibitor), commonly used in transplant patients as immunosuppressives, have antifungal activity.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	38-42
20492406-8	2010	Based on the evidence that downregulation of the mTOR pathway due to treatment with rapamycin (everolimus) would suppress tumor cell growth, an experimental study using the GCT cell line was designed to clarify whether HIF-1alpha and VEGF expressions decline.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	49-53
19482307-9	2010	Additionally, rapamycin inhibited activation of Akt phosphorylation and tumor cell migration after prolonged treatment.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	48-51
19482307-10	2010	CONCLUSIONS: Rapamycin suppresses tumor progression due to inhibition of phosphorylated Akt, cell proliferation, and migration.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	88-91
20203102-3	2010	Acute inhibition of mTORC1/S6K1 by rapamycin increases insulin signaling and glucose uptake in myocytes and adipocytes, but whether these effects can be maintained under chronic inhibition of mTORC1 or S6K1 remains unclear.	Sirolimus	35-44	insulin	Homo sapiens	55-62
20371718-1	2010	The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	37-40
20371718-1	2010	The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	72-76
20371718-1	2010	The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	208-212
20371718-3	2010	We confirmed that suppression of mTOR signaling in MM cells by rapamycin was associated with upregulation of Akt phosphorylation.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	33-37
20371718-3	2010	We confirmed that suppression of mTOR signaling in MM cells by rapamycin was associated with upregulation of Akt phosphorylation.	Sirolimus	63-72	AKT serine/threonine kinase 1	Homo sapiens	109-112
20371718-4	2010	We hypothesized that inhibiting this positive feedback by a potent Akt inhibitor perifosine would augment rapamycin-induced cytotoxicity in MM cells.	Sirolimus	106-115	AKT serine/threonine kinase 1	Homo sapiens	67-70
20371718-5	2010	Perifosine inhibited rapamycin-induced phosphorylated Akt, resulting in enhanced cytotoxicity in MM.1S cells even in the presence of interleukin-6, insulin-like growth factor-I, or bone marrow stromal cells.	Sirolimus	21-30	AKT serine/threonine kinase 1	Homo sapiens	54-57
20371718-5	2010	Perifosine inhibited rapamycin-induced phosphorylated Akt, resulting in enhanced cytotoxicity in MM.1S cells even in the presence of interleukin-6, insulin-like growth factor-I, or bone marrow stromal cells.	Sirolimus	21-30	interleukin 6	Homo sapiens	133-146
20371718-5	2010	Perifosine inhibited rapamycin-induced phosphorylated Akt, resulting in enhanced cytotoxicity in MM.1S cells even in the presence of interleukin-6, insulin-like growth factor-I, or bone marrow stromal cells.	Sirolimus	21-30	insulin like growth factor 1	Homo sapiens	148-176
20371718-10	2010	Our data suggest that mutual suppression of the PI3K/Akt/mTOR pathway by rapamycin and perifosine combination induces synergistic MM cell cytotoxicity, providing the rationale for clinical trials in patients with relapsed/refractory MM.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	53-56
20371718-10	2010	Our data suggest that mutual suppression of the PI3K/Akt/mTOR pathway by rapamycin and perifosine combination induces synergistic MM cell cytotoxicity, providing the rationale for clinical trials in patients with relapsed/refractory MM.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	57-61
20106729-4	2010	VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin.	Sirolimus	133-142	vascular endothelial growth factor A	Homo sapiens	0-4
20106729-4	2010	VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	68-72
20106729-4	2010	VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	118-122
20234352-4	2010	First-generation mTOR inhibitors are sirolimus derivatives (rapalogs), which have been evaluated extensively in cancer patients.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	17-21
19642865-0	2010	Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
19642865-4	2010	Under feeder-free culture conditions, rapamycin (an mTOR inhibitor) potently inhibited the activities of mTOR and p70S6K in undifferentiated hESCs; however, LY294002 (a PI3K inhibitor) and an AKT inhibitor had no effects.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	52-56
19642865-4	2010	Under feeder-free culture conditions, rapamycin (an mTOR inhibitor) potently inhibited the activities of mTOR and p70S6K in undifferentiated hESCs; however, LY294002 (a PI3K inhibitor) and an AKT inhibitor had no effects.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	105-109
19642865-4	2010	Under feeder-free culture conditions, rapamycin (an mTOR inhibitor) potently inhibited the activities of mTOR and p70S6K in undifferentiated hESCs; however, LY294002 (a PI3K inhibitor) and an AKT inhibitor had no effects.	Sirolimus	38-47	AKT serine/threonine kinase 1	Homo sapiens	192-195
20149931-6	2010	Rapamycin induced suppression of IFN-gamma, and IL-17 release from antigen-specific T cells in peripheral lymphoid organs.	Sirolimus	0-9	interferon gamma	Mus musculus	33-42
19966866-4	2010	Tsc1-Kras(G12D) tumors showed consistent activation of mTOR (mammalian target of rapamycin)C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in Kras(G12D) alone mice.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	55-59
19966866-8	2010	Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	78-82
20197466-4	2010	JunB inhibits autophagy induced by starvation, overexpression of a short form of ARF (smARF), a potent inducer of autophagy, or even after rapamycin treatment.	Sirolimus	139-148	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-4
20022946-1	2010	The mammalian target of rapamycin (mTOR) Ser/Thr kinase signals in at least two multiprotein complexes distinguished by their different partners and sensitivities to rapamycin.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20022946-4	2010	Before the identification of distinct mTOR complexes, mTOR was reported to autophosphorylate on Ser-2481 in vivo in a rapamycin- and amino acid-insensitive manner.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	54-58
20022946-10	2010	These data suggest that mTORC1- and likely mTORC2-associated mTOR Ser-2481 autophosphorylation directly monitors intrinsic mTORC-specific catalytic activity and reveal that rapamycin inhibits mTORC1 signaling in vivo by reducing mTORC1 catalytic activity.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	24-28
19955189-0	2010	Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression.	Sirolimus	0-9	mitogen-activated protein kinase 1	Canis lupus familiaris	107-113
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	tumor necrosis factor	Mus musculus	98-125
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	tumor necrosis factor	Mus musculus	127-136
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interleukin 1 beta	Mus musculus	139-156
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interleukin 1 beta	Mus musculus	158-166
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interleukin 6	Mus musculus	169-173
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interferon gamma	Mus musculus	181-208
20086156-5	2010	The serum levels of MCP-1 and IL-6, after intranasal exposure to SEB, were significantly reduced in mice given rapamycin versus controls.	Sirolimus	111-120	interleukin 6	Mus musculus	30-34
20392999-0	2010	Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.	Sirolimus	73-82	forkhead box O1	Homo sapiens	19-24
20392999-2	2010	In this report, we have investigated the role of FOXO1, a downstream substrate of the PI3K/Akt pathway in the anticancer efficacy of rapamycin.	Sirolimus	133-142	forkhead box O1	Homo sapiens	49-54
20392999-2	2010	In this report, we have investigated the role of FOXO1, a downstream substrate of the PI3K/Akt pathway in the anticancer efficacy of rapamycin.	Sirolimus	133-142	AKT serine/threonine kinase 1	Homo sapiens	91-94
20392999-4	2010	Colon cancer cells transfected with a constitutively active mutant of FOXO1 or a control plasmid were treated with rapamycin and the antiproliferative efficacy of rapamycin was monitored.	Sirolimus	115-124	forkhead box O1	Homo sapiens	70-75
20392999-4	2010	Colon cancer cells transfected with a constitutively active mutant of FOXO1 or a control plasmid were treated with rapamycin and the antiproliferative efficacy of rapamycin was monitored.	Sirolimus	163-172	forkhead box O1	Homo sapiens	70-75
20392999-5	2010	RESULTS: Rapamycin induced the phosphorylation of FOXO1 as well as its translocation from the nucleus to the cytoplasm, leading to FOXO1 inactivation.	Sirolimus	9-18	forkhead box O1	Homo sapiens	50-55
20392999-5	2010	RESULTS: Rapamycin induced the phosphorylation of FOXO1 as well as its translocation from the nucleus to the cytoplasm, leading to FOXO1 inactivation.	Sirolimus	9-18	forkhead box O1	Homo sapiens	131-136
20392999-7	2010	CONCLUSION: Taken together these results show that rapamycin-induced FOXO1 inactivation reduces the antitumor efficacy of rapamycin.	Sirolimus	51-60	forkhead box O1	Homo sapiens	69-74
20179209-0	2010	Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling.	Sirolimus	16-25	insulin like growth factor 1	Homo sapiens	47-75
20179209-1	2010	Rapamycin-induced apoptosis in sarcoma cells is inhibited by insulin-like growth factor-I (IGF-I) through a signaling pathway independent of Ras-extracellular signal-regulated kinase 1/2 and Akt.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	61-89
20179209-1	2010	Rapamycin-induced apoptosis in sarcoma cells is inhibited by insulin-like growth factor-I (IGF-I) through a signaling pathway independent of Ras-extracellular signal-regulated kinase 1/2 and Akt.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	91-96
20179209-1	2010	Rapamycin-induced apoptosis in sarcoma cells is inhibited by insulin-like growth factor-I (IGF-I) through a signaling pathway independent of Ras-extracellular signal-regulated kinase 1/2 and Akt.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	191-194
20179209-10	2010	Collectively, these data suggest that IGF-I-induced phosphorylation of Bad at multiple sites via a pathway involving PI3K and PKCs is important for protecting sarcoma cells from rapamycin-induced apoptosis.	Sirolimus	178-187	insulin like growth factor 1	Homo sapiens	38-43
20179227-1	2010	Everolimus, an orally administered rapamycin analog, has recently been approved by the U.S. Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling.	Sirolimus	35-44	vascular endothelial growth factor A	Homo sapiens	193-227
20142330-7	2010	Lastly, the finding that endometrial cancer cell lines were especially sensitive to the mTOR (mammalian target of rapamycin) inhibitor rapamycin prompted us to test its efficacy against Lkb1-driven endometrial cancers.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	88-92
20350481-7	2010	Thus mTOR offers a window into diverse facets of lupus pathogenesis as well as a unifying narrative in our understanding of the therapeutic efficacy of rapamycin in SLE.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	5-9
19688827-7	2010	Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	135-139
20075061-2	2010	mTOR inhibitors, such as rapamycin, are highly effective in several rodent models of PKD, but these models result from mutations in genes other than Pkd1 and Pkd2, which are the primary genes responsible for human autosomal dominant PKD.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20155724-2	2010	Its blockade, by mTOR inhibitors (mTOR-Is), such as sirolimus or everolimus, leads to antiproliferative effects.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	17-21
20155724-2	2010	Its blockade, by mTOR inhibitors (mTOR-Is), such as sirolimus or everolimus, leads to antiproliferative effects.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	34-38
20235887-4	2010	However, these Tsc rodent models have been useful in confirming the two-hit model of tumor development in TSC, and in providing systems in which therapeutic trials (e.g., rapamycin) can be performed.	Sirolimus	171-180	TSC complex subunit 1	Homo sapiens	15-18
19903662-0	2010	Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.	Sirolimus	0-9	CD4 molecule	Homo sapiens	85-88
19903662-3	2010	The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro.	Sirolimus	72-81	CD4 molecule	Homo sapiens	134-137
19903662-4	2010	METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA).	Sirolimus	104-113	CD4 molecule	Homo sapiens	9-12
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Sirolimus	23-32	CD4 molecule	Homo sapiens	80-83
19935717-7	2010	Sorafenib induces reciprocal upregulation of Akt phosphorylation; and simultaneous inhibition of downstream mTOR with rapamycin leads to synergistic effects.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	108-112
20048174-0	2010	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	21-25
20629977-2	2010	Rapamycin (=sirolimus), a specific mTOR inhibitor, leads to G(1) arrest of many malignant cell lines and currently, analogues of rapamycin are being investigated as a cancer chemotherapeutic adjuvant.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20629977-2	2010	Rapamycin (=sirolimus), a specific mTOR inhibitor, leads to G(1) arrest of many malignant cell lines and currently, analogues of rapamycin are being investigated as a cancer chemotherapeutic adjuvant.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20629977-2	2010	Rapamycin (=sirolimus), a specific mTOR inhibitor, leads to G(1) arrest of many malignant cell lines and currently, analogues of rapamycin are being investigated as a cancer chemotherapeutic adjuvant.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20581056-7	2010	Tgs receiving rapamycin not only showed inhibition of the mTOR-associated downstream signaling but also displayed attenuated renal lesions.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	58-62
20626386-3	2010	We found that donor BALB/c bone marrow-derived DCs (BMDCs) pharmacologically modified by the mTOR inhibitor rapamycin had significantly enhanced ability to induce CD4(+)CD25(+)Foxp3(+) iTregs of recipient origin (C57BL/6 (B6)) in vitro under Treg driving conditions compared to unmodified BMDCs.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	93-97
20626386-3	2010	We found that donor BALB/c bone marrow-derived DCs (BMDCs) pharmacologically modified by the mTOR inhibitor rapamycin had significantly enhanced ability to induce CD4(+)CD25(+)Foxp3(+) iTregs of recipient origin (C57BL/6 (B6)) in vitro under Treg driving conditions compared to unmodified BMDCs.	Sirolimus	108-117	CD4 molecule	Homo sapiens	163-166
20506288-8	2010	RESULTS: Inhibition of mTOR by sirolimus or everolimus reduced synovial osteoclast formation and protected against local bone erosions and cartilage loss.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	23-27
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	interleukin 6	Mus musculus	70-74
20184961-9	2010	We conclude that vWF, thrombomodulin, and sICAM-1 elevations before and early after transplantation may be useful in predicting VOD in patients receiving sirolimus.	Sirolimus	154-163	von Willebrand factor	Homo sapiens	17-20
20135346-0	2010	Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	53-56
20135346-3	2010	As mTOR inhibition by rapamycin is associated with attenuation of negative feedback to IRS-1, rapamycin is known to increase activation of AKT, which may reduce its anti-neoplastic activity.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	3-7
20522007-8	2010	As a result of these studies, several signalling pathways including phosphatidylinositol 3-kinase (PI3K)/Akt and target of rapamycin (TOR), c-Jun N-terminal kinase (JNK) and bone morphogenetic protein (BMP) signalling, have been shown to be deregulated in models of proteinopathies, suggesting that two or more initiating events may trigger disease formation in an age-related manner.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	105-108
20508517-0	2010	Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation.	Sirolimus	113-122	von Willebrand factor	Homo sapiens	16-19
19856103-6	2010	Ischemia-reperfusion-induced elevation of aspartate aminotransferase serum levels was significantly decreased by sirolimus.	Sirolimus	113-122	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	42-68
20569080-2	2010	AREAS COVERED IN THIS REVIEW: The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resistance mechanisms of rapamycin and rapalogues led to the development of several inhibitory molecules.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	77-80
20569080-2	2010	AREAS COVERED IN THIS REVIEW: The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resistance mechanisms of rapamycin and rapalogues led to the development of several inhibitory molecules.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	81-85
20483386-2	2010	The aim of this cohort study was to evaluate the effect of sirolimus as an mTOR inhibitor on hepatitis C recurrence in liver transplant recipients.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	75-79
19906497-11	2010	When ENZ was combined with the mTOR inhibitor, rapamycin, in H460 lung cancer cells, radiosensitization was observed.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	31-35
20585037-10	2010	The mTOR inhibitor rapamycin, but not AMD3100, inhibited growth of AML tumor xenografts.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
20669343-10	2010	CONCLUSIONS: hs-CRP and apelin levels increased after PCI and sirolimus-eluting stent implantation.	Sirolimus	62-71	apelin	Homo sapiens	24-30
20071026-2	2010	We found that a combination of a farnesyltransferase inhibitor, tipifarnib, and an mTOR inhibitor, rapamycin, synergistically inhibited the growth of myeloid leukemia cell lines and primary leukemia cells by inducing apoptosis and cell-cycle blockage.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	83-87
20070623-2	2010	Recent reports suggest a possible beneficial role of the mTOR-inhibitor (mTOR-I) sirolimus for TSC; however, safety and efficiency of sirolimus in TSC patients after renal transplantation, both as primary immunosuppressant as well as anti-proliferative agent, are still undefined.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	73-77
20070623-7	2010	We show that the inflammatory immune response was significantly altered in TSC patients as compared with controls and sirolimus potently affected both inflammatory cytokine production and vascular endothelial growth factor levels in these patients.	Sirolimus	118-127	vascular endothelial growth factor A	Homo sapiens	188-222
20542014-5	2010	We report that rapamycin (2.5muM), significantly increases Abeta generation in murine neuron-like cells (N2a) transfected with the human "Swedish" mutant amyloid precursor protein (APP).	Sirolimus	15-24	amyloid beta precursor protein	Homo sapiens	154-179
20542014-6	2010	In concert with these observations, we found rapamycin significantly decreases the neuroprotective amino-terminal APP (amyloid precursor protein) cleavage product, soluble APP-alpha (sAPP-alpha) while increasing production of the beta-carboxyl-terminal fragment of APP (beta-CTF).	Sirolimus	45-54	amyloid beta precursor protein	Homo sapiens	119-144
20670831-3	2010	Plasma membrane PIP(2) depletion by rapamycin-induced translocation of an inositol lipid 5-phosphatase or by a voltage-sensitive 5-phosphatase (VSP) suppresses Ca(V)1.2 and Ca(V)1.3 channel currents by approximately 35% and Ca(V)2.1 and Ca(V)2.2 currents by 29% and 55%, respectively.	Sirolimus	36-45	prolactin induced protein	Homo sapiens	16-19
20562737-0	2010	Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene.	Sirolimus	10-19	calcineurin binding protein 1	Mus musculus	23-44
20562737-1	2010	BACKGROUND: The aim of this study was to observe the effect of sirolimus (SRL) on calcineurin inhibitor (CNI)-induced nephrotoxicity in the aging process by using renal expression of KLOTHO, an antiaging gene.	Sirolimus	63-72	calcineurin binding protein 1	Mus musculus	82-103
20486173-8	2010	An increase in AKT phosphorylation was observed in all the osteosarcoma tumors treated with rapamycin.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	15-18
20486173-9	2010	However, phosphorylation of AKT was inhibited when rapamycin was used in combination with R1507.	Sirolimus	51-60	AKT serine/threonine kinase 1	Homo sapiens	28-31
20630061-3	2010	The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	78-81
20439463-4	2010	mTOR inhibitor rapamycin or NS5A knockdown blocked S6K1 and 4EBP1 phosphorylation increase in NS5A-Huh7 and HCV replicon cells, suggesting that NS5A specifically regulated mTOR activation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20439463-4	2010	mTOR inhibitor rapamycin or NS5A knockdown blocked S6K1 and 4EBP1 phosphorylation increase in NS5A-Huh7 and HCV replicon cells, suggesting that NS5A specifically regulated mTOR activation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	172-176
20439463-7	2010	Moreover, NS5A suppressed caspase 3 and poly(ADP-ribose) polymerase activation, which was abolished by NS5A knockdown or rapamycin, indicating NS5A inhibited apoptosis specifically through the mTOR pathway.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	193-197
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	interferon alpha 1	Homo sapiens	96-99
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	interferon alpha 1	Homo sapiens	152-155
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	198-202
20642692-1	2010	Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	114-143
20642692-1	2010	Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	145-149
20642692-8	2010	While sirolimus treatment reduced the activation of mTOR in peripheral blood mononuclear cells, it failed to prevent mTOR activation in kidney tubular cells, this could account for the inefficiency of treatment on cyst growth.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	52-56
20642692-9	2010	Together, our results suggest that the dose of sirolimus required to inhibit mTOR varies according to the tissue.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	77-81
20430366-2	2010	The present study was conducted to assess the association between IL-6 (-174 G/C) gene polymorphism and GO in renal transplant recipients under cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir)-based regimens.	Sirolimus	185-194	interleukin 6	Homo sapiens	66-70
21504089-0	2010	Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice.	Sirolimus	0-9	phosphatase and tensin homolog	Mus musculus	69-73
20597028-4	2010	The efficacy of derivatives of the natural product rapamycin (sirolimus), which functions as an allosteric inhibitor of mTORC1, has validated mTOR inhibition as an anticancer treatment.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	120-124
20392814-8	2010	Rapamycin avoids the activation of both p70 S6 and AKT kinases by TSH, suggesting the involvement of MTORC1 and MTORC2 in TSH effect.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	51-54
20484410-10	2010	However, rapamycin inhibited the activity of these complexes by decreasing the TSH and insulin-mediated stimulation of activating T172 phosphorylation of CDK4.	Sirolimus	9-18	insulin	Homo sapiens	87-94
20048174-3	2010	On this mechanistic basis, we treated three consecutive patients with metastatic PEComa with an oral mTOR inhibitor, sirolimus.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	101-105
20133804-6	2010	FKBP52 is a member of the FKBP (FK506-binding protein) family that comprises intracellular protein effectors of immunosuppressive drugs (such as FK506 and rapamycin).	Sirolimus	155-164	FKBP prolyl isomerase 4	Homo sapiens	0-6
19994912-1	2010	The basic mechanisms underlying calcineurin inhibitor (CI) nephrotoxicity and its enhancement by sirolimus are still largely unknown.	Sirolimus	97-106	calcineurin binding protein 1	Rattus norvegicus	32-53
19815051-0	2010	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.	Sirolimus	4-13	AKT serine/threonine kinase 1	Homo sapiens	92-95
19815051-0	2010	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Homo sapiens	96-100
19879324-4	2010	Rapamycin, an inhibitor of p70 S6 kinase, which attenuated the phosphorylation of p70 S6 kinase induced by TNF-alpha, significantly amplified the TNF-alpha-stimulated IL-6 synthesis.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	107-116
19879324-4	2010	Rapamycin, an inhibitor of p70 S6 kinase, which attenuated the phosphorylation of p70 S6 kinase induced by TNF-alpha, significantly amplified the TNF-alpha-stimulated IL-6 synthesis.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	146-155
19879324-4	2010	Rapamycin, an inhibitor of p70 S6 kinase, which attenuated the phosphorylation of p70 S6 kinase induced by TNF-alpha, significantly amplified the TNF-alpha-stimulated IL-6 synthesis.	Sirolimus	0-9	interleukin 6	Mus musculus	167-171
19879324-5	2010	TNF-alpha-induced phosphorylations of both p44/p42 MAP kinase and Akt were markedly enhanced by rapamycin.	Sirolimus	96-105	tumor necrosis factor	Mus musculus	0-9
19879324-5	2010	TNF-alpha-induced phosphorylations of both p44/p42 MAP kinase and Akt were markedly enhanced by rapamycin.	Sirolimus	96-105	thymoma viral proto-oncogene 1	Mus musculus	66-69
19879324-7	2010	Rapamycin enhanced the IL-6 synthesis and the phosphorylation of Akt induced by TNF-alpha also in human osteoblasts.	Sirolimus	0-9	interleukin 6	Homo sapiens	23-27
19879324-7	2010	Rapamycin enhanced the IL-6 synthesis and the phosphorylation of Akt induced by TNF-alpha also in human osteoblasts.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	65-68
19879324-7	2010	Rapamycin enhanced the IL-6 synthesis and the phosphorylation of Akt induced by TNF-alpha also in human osteoblasts.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	80-89
20014960-4	2010	The mammalian target of rapamycin, which is a sensor of the mitochondrial transmembrane potential, has been successfully targeted for treatment of SLE with rapamycin or sirolimus in both patients and animal models.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	4-33
19903862-6	2010	Inhibition of glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme for hexosamine flux, with 6-diazo-5-oxonorleucine (10 muM) and of mTOR with rapamycin both attenuated glucose-mediated MC proliferation.	Sirolimus	171-180	glutamine--fructose-6-phosphate transaminase 1	Homo sapiens	14-61
19903862-6	2010	Inhibition of glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-limiting enzyme for hexosamine flux, with 6-diazo-5-oxonorleucine (10 muM) and of mTOR with rapamycin both attenuated glucose-mediated MC proliferation.	Sirolimus	171-180	glutamine--fructose-6-phosphate transaminase 1	Homo sapiens	63-67
19940100-8	2010	Furthermore, the effects of leucine on insulin-stimulated 3-MG transport and IRS phosphorylation were abolished by rapamycin.	Sirolimus	115-124	insulin	Homo sapiens	39-46
20193134-4	2010	Moreover, inhibition of mTOR activity by rapamycin resulted in a reduction of SREBP-1c protein expression and adipogenesis in cells.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	24-28
19914305-11	2010	These results, taken together, indicate that Bim protein is the key mediator of apoptosis induced by Dex and also responsible for the potentiating effect of rapamycin, providing molecular criteria for the use of glucocorticoids combined with mTOR inhibitors in myeloma therapy.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	242-246
20072130-2	2010	The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	4-8
19906641-11	2010	In addition, RvE1 enhanced phagocytosis of zymosan A by human macrophages, which are inhibited by PD98059 and rapamycin (mTOR inhibitor).	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	121-125
19945507-6	2010	Only TS but not an equally antiprion active PKC inhibitor could be partially antagonized by substochiometric 1 nM rapamycin suggesting that there are pathways via mammalian target of rapamycin (mTOR) that interfere with tocopherol"s biological effects.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	163-192
20089925-1	2010	We report that rapamycin, an allosteric inhibitor of certain but not all actions of the key cellular kinase mammalian target of rapamycin (mTOR), protects neurons from death in both cellular and animal toxin models of Parkinson"s disease (PD).	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	108-137
20089925-1	2010	We report that rapamycin, an allosteric inhibitor of certain but not all actions of the key cellular kinase mammalian target of rapamycin (mTOR), protects neurons from death in both cellular and animal toxin models of Parkinson"s disease (PD).	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	139-143
19945507-6	2010	Only TS but not an equally antiprion active PKC inhibitor could be partially antagonized by substochiometric 1 nM rapamycin suggesting that there are pathways via mammalian target of rapamycin (mTOR) that interfere with tocopherol"s biological effects.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	194-198
20089925-3	2010	In support of this mechanism, in PD models, rapamycin spares phosphorylation of Akt at a site critical for maintenance of its survival-promoting activity.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	80-83
20089925-4	2010	The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	145-149
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	48-51
20089925-4	2010	The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	221-225
20089925-4	2010	The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.	Sirolimus	16-25	AKT serine/threonine kinase 1	Homo sapiens	267-270
20068177-2	2010	Rapamycin and its analogues (rapalogs) partially inhibit mTOR through allosteric binding to mTOR complex 1 (mTORC1) but not mTOR complex 2 (mTORC2), an emerging player in cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-61
19634141-6	2010	We demonstrate that rapamycin significantly inhibited human NF1-MPNST mTOR pathway activation and explant growth in vivo at doses as low as 1.0 mg/kg/day, without systemic toxicities.	Sirolimus	20-29	neurofibromin 1	Homo sapiens	60-63
19634141-6	2010	We demonstrate that rapamycin significantly inhibited human NF1-MPNST mTOR pathway activation and explant growth in vivo at doses as low as 1.0 mg/kg/day, without systemic toxicities.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	70-74
19634141-7	2010	While rapamycin was effective at reducing NF1-MPNST proliferation and angiogenesis, with decreased CyclinD1 and VEGF respectively, there was no increase in tumor apoptosis.	Sirolimus	6-15	neurofibromin 1	Homo sapiens	42-45
19634141-7	2010	While rapamycin was effective at reducing NF1-MPNST proliferation and angiogenesis, with decreased CyclinD1 and VEGF respectively, there was no increase in tumor apoptosis.	Sirolimus	6-15	vascular endothelial growth factor A	Homo sapiens	112-116
19634141-8	2010	Rapamycin effectively decreased activation of S6 downstream of mTOR, but there was accompanied increased Akt activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	63-67
19634141-8	2010	Rapamycin effectively decreased activation of S6 downstream of mTOR, but there was accompanied increased Akt activation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	105-108
19634141-9	2010	This study demonstrates the therapeutic potential and limitations of rapamycin in NF1-associated, and likely sporadic, MPNSTs.	Sirolimus	69-78	neurofibromin 1	Homo sapiens	82-85
20068177-2	2010	Rapamycin and its analogues (rapalogs) partially inhibit mTOR through allosteric binding to mTOR complex 1 (mTORC1) but not mTOR complex 2 (mTORC2), an emerging player in cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-96
20068177-2	2010	Rapamycin and its analogues (rapalogs) partially inhibit mTOR through allosteric binding to mTOR complex 1 (mTORC1) but not mTOR complex 2 (mTORC2), an emerging player in cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-96
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	225-228
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	105-114	AKT serine/threonine kinase 1	Homo sapiens	48-51
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	105-114	AKT serine/threonine kinase 1	Homo sapiens	225-228
20068168-3	2010	Thus, sensitivity to rapamycin might be increased by imposing an upstream blockade to the PI3K/Akt pathway.	Sirolimus	21-30	AKT serine/threonine kinase 1	Homo sapiens	95-98
19917848-5	2010	TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines.	Sirolimus	68-77	AKT serine/threonine kinase 1	Homo sapiens	44-47
19917848-5	2010	TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	79-83
20146692-6	2010	Antagonism of the mTOR pathway with rapamycin and related compounds may provide new therapeutic options for TSC patients.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	18-22
19879295-5	2010	Low dose rapamycin-treatment of TLR4(-/-) recipients induced permanent engraftment of 45% islet graft (p=0.005) compared to WT recipients.	Sirolimus	9-18	toll-like receptor 4	Mus musculus	32-36
20146692-6	2010	Antagonism of the mTOR pathway with rapamycin and related compounds may provide new therapeutic options for TSC patients.	Sirolimus	36-45	TSC complex subunit 1	Homo sapiens	108-111
20637453-4	2010	In addition, the combination of low dose RPM and high dose IL-2 enhanced mRNA expression of Foxp3, TGF-beta1 and Pim-2 in Tregs but not in CD4(+)CD25(-) T effector cells (Teffs).	Sirolimus	41-44	transforming growth factor, beta 1	Rattus norvegicus	99-108
20019183-6	2010	Rapamycin inhibited S6K at mTOR-sensitive phosphorylation sites in response to strain and hypoxia.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
21220932-7	2010	Exposure to RPM induced an increased synthesis of ECMP and also resulted in elevated apoptosis in adherent CF as measured by terminal deoxynucleotidyl transferase-mediated dUTP digoxigenin nick end labeling (TUNEL) analysis, 4",6-diamidino-2-phenylindole (DAPI) staining, and caspase-3 detection.	Sirolimus	12-15	caspase 3	Homo sapiens	276-285
19890249-4	2010	The pharmacokinetics of both MPA and MPAG were significantly influenced by the OATP1B3 polymorphism 334T>G/699G>A in 70 renal transplant patients receiving combination treatment of MMF with either tacrolimus or sirolimus, but not in 115 patients receiving MMF and cyclosporine.	Sirolimus	217-226	solute carrier organic anion transporter family member 1B3	Homo sapiens	79-86
19919613-1	2010	Sirolimus is one treatment option in transplant recipients with Kaposi"s sarcoma (KS), which involves dysregulation of Akt-mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	119-152
19919613-1	2010	Sirolimus is one treatment option in transplant recipients with Kaposi"s sarcoma (KS), which involves dysregulation of Akt-mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	154-158
19919613-8	2010	VEGF was suppressed thoroughly in two-month use of sirolimus.	Sirolimus	51-60	vascular endothelial growth factor A	Homo sapiens	0-4
19919613-12	2010	Suppressed expression of VEGF, p-Akt, and p-mTOR was the major event of signaling modification through the long-term use of sirolimus.	Sirolimus	124-133	vascular endothelial growth factor A	Homo sapiens	25-29
19919613-12	2010	Suppressed expression of VEGF, p-Akt, and p-mTOR was the major event of signaling modification through the long-term use of sirolimus.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	44-48
20047144-5	2010	More recently, rapamycin (sirolimus) analogs that antagonize the mTOR signaling pathway have been approved for the treatment of several cancers.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	65-69
20047144-5	2010	More recently, rapamycin (sirolimus) analogs that antagonize the mTOR signaling pathway have been approved for the treatment of several cancers.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	65-69
20203370-6	2010	In the androgen responsive prostate cancer cell line LNCaP, androgen and the mTOR inhibitor rapamycin synergistically activated androgen target genes.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	77-81
21063108-8	2010	Blocking mTOR signaling by either rapamycin or overexpression of its negative regulator tuberous sclerosis complex 1 (TSC1) or TSC2 attenuates the inhibitory effect of insulin on the transcription and translation of GOAT.	Sirolimus	34-43	insulin	Capra hircus	168-175
19567381-6	2010	In vitro, rapamycin, everolimus, and zotarolimus (each 10(-7) mol/l) enhanced TNF-alpha-induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity.	Sirolimus	10-19	tumor necrosis factor	Homo sapiens	78-87
19567381-7	2010	Similar to rapamycin, everolimus and zotarolimus abrogated TNF-alpha-induced p70S6K phosphorylation under these conditions.	Sirolimus	11-20	tumor necrosis factor	Homo sapiens	59-68
19768770-4	2010	Hypertrophy was largely suppressed by wortmannin or rapamycin, inhibitors of PI3K or mTOR, respectively.	Sirolimus	52-61	mechanistic target of rapamycin	Gallus gallus	85-89
20549474-8	2010	These inhibitors bind to the ATP binding site of the kinase domain of mTOR and as a result inhibit both mTOR complexes, TORC1 (rapamycin sensitive) and TORC2 (rapamycin resistant).	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	70-74
20549474-8	2010	These inhibitors bind to the ATP binding site of the kinase domain of mTOR and as a result inhibit both mTOR complexes, TORC1 (rapamycin sensitive) and TORC2 (rapamycin resistant).	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	104-108
20924998-11	2010	Oral rapamycin therapy may induce regression of astrocytomas associated with TSC.	Sirolimus	5-14	TSC complex subunit 1	Homo sapiens	77-80
19864431-5	2010	We report that insulin promotes mTORC1-associated phosphorylation of raptor Ser(863) via the canonical PI3K/TSC/Rheb pathway in a rapamycin-sensitive manner.	Sirolimus	130-139	insulin	Homo sapiens	15-22
20129572-0	2010	Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization.	Sirolimus	51-60	CD34 molecule	Sus scrofa	5-9
20129572-1	2010	OBJECTIVES: In this study, we hypothesized that an antihuman-CD34 antibody immobilized on the surface of commercially available sirolimus-eluting stents (SES) could enhance re-endothelialization compared with SES alone.	Sirolimus	128-137	CD34 molecule	Sus scrofa	61-65
19887566-7	2010	Insulin phosphorylation of S6K1 correlated with IRS-1 ser1101 phosphorylation and the mTOR-S6K1 pathway inhibitor rapamycin prevented IRS-1 serine phosphorylation.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	86-90
19661225-7	2010	In contrast, rapamycin-induced inhibition of mTOR did not significantly affect cell proliferation because it simultaneously stimulated PI3K/Akt activation and cyclin D1 expression.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	45-49
19661225-7	2010	In contrast, rapamycin-induced inhibition of mTOR did not significantly affect cell proliferation because it simultaneously stimulated PI3K/Akt activation and cyclin D1 expression.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	140-143
19562254-1	2010	We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) in a phase 2, open-label, single-arm trial.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	176-205
20053781-9	2010	Furthermore, KU-55933 completely abrogates rapamycin-induced feedback activation of Akt.	Sirolimus	43-52	AKT serine/threonine kinase 1	Homo sapiens	84-87
20043723-10	2010	Finally, increased knowledge of molecular and cellular mechanisms involved with NF1 tumorigenesis has led to multiple preclinical and clinical studies of targeted therapy, including the mTOR inhibitor rapamycin, which is demonstrating promising preclinical results for treatment of MPNSTs and gliomas.	Sirolimus	201-210	neurofibromin 1	Homo sapiens	80-83
19845851-0	2010	Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	34-63
19845851-10	2010	Upon rapamycin and CCI-779 treatment, the phosphorylation level of mTOR and p70S6K in HCC cell lines was significantly reduced, indicating that both drugs can suppress mTOR activity in HCC cells.	Sirolimus	5-14	mechanistic target of rapamycin kinase	Homo sapiens	67-71
19845851-10	2010	Upon rapamycin and CCI-779 treatment, the phosphorylation level of mTOR and p70S6K in HCC cell lines was significantly reduced, indicating that both drugs can suppress mTOR activity in HCC cells.	Sirolimus	5-14	mechanistic target of rapamycin kinase	Homo sapiens	168-172
20043723-10	2010	Finally, increased knowledge of molecular and cellular mechanisms involved with NF1 tumorigenesis has led to multiple preclinical and clinical studies of targeted therapy, including the mTOR inhibitor rapamycin, which is demonstrating promising preclinical results for treatment of MPNSTs and gliomas.	Sirolimus	201-210	mechanistic target of rapamycin kinase	Homo sapiens	186-190
20072839-1	2010	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	81-110
19818818-6	2010	Analyses of the explants with in situ hybridization demonstrated that the DEX or rapamycin alone significantly increased Npy gene expression in the arcuate nucleus, but that there were no additive effects of DEX and rapamycin on the expression.	Sirolimus	81-90	neuropeptide Y	Rattus norvegicus	121-124
19800362-4	2010	Previously, the inhibitors, rapamycin for mTOR, wortmannin for phosphoinositide 3 kinase (PI3K) and PD98059 for ERK, each blocked the upregulation of the System A transporter in IAA depleted APC neurons.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	42-46
19944562-7	2010	Hopes are high for mTor inhibitors (sirolimus and everolimus) and treatment trials are currently underway.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	19-23
20072839-1	2010	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	81-110
19666112-10	2009	In conclusion, activation of the profibrotic TGFbeta/Smad signaling cascade accompanies the immunosuppressive and antiproliferative actions of rapamycin.	Sirolimus	143-152	transforming growth factor, beta 1	Rattus norvegicus	45-52
20172351-10	2010	Bcl-2 protein was upregulated in the rapamycin group compared with the control group (P < .01).	Sirolimus	37-46	BCL2, apoptosis regulator	Rattus norvegicus	0-5
20080789-6	2009	Inhibition of mTOR not only enhances aerobic glycolysis, but also induces a state of increased dependence on aerobic glycolysis in leukemic cells, as shown by the synergy between the glycolytic inhibitor 2-deoxyglucose and rapamycin in decreasing cell viability.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19828446-9	2009	In cultured cardiac myocytes, LKB1 silencing induced hypertrophy, which was ameliorated by the expression of a constitutively active form AMPK or by treatment with the inhibitor of mTOR, rapamycin.	Sirolimus	187-196	serine/threonine kinase 11	Mus musculus	30-34
19850943-7	2009	Accordingly, pretreatment of Hsp20(S16A) hearts with rapamycin, an activator of autophagy, resulted in improvement of functional recovery, compared with saline-treated Hsp20(S16A) hearts.	Sirolimus	53-62	heat shock protein family B (small) member 6	Homo sapiens	29-34
19920197-7	2009	These results thus suggest that perifosine inhibits the mTOR axis through a different mechanism from inhibition of mTOR signaling by classic mTOR inhibitors such as rapamycin.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	115-119
19920197-7	2009	These results thus suggest that perifosine inhibits the mTOR axis through a different mechanism from inhibition of mTOR signaling by classic mTOR inhibitors such as rapamycin.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	115-119
19923913-5	2009	Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells.	Sirolimus	112-121	AKT serine/threonine kinase 1	Homo sapiens	33-36
19923913-5	2009	Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	37-41
20013687-5	2009	This overview provides an insight into the disease and the specific mTOR inhibitor sirolimus, which is currently tested in clinical trials.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	68-72
19666112-0	2009	Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.	Sirolimus	0-9	transforming growth factor, beta 1	Rattus norvegicus	22-30
19666112-2	2009	We found that rapamycin induces the TGFbeta/Smad signaling cascade in rat mesangial cells (MC) as depicted by the nuclear translocation of phospho-Smads 2, -3 and Smad-4, respectively.	Sirolimus	14-23	transforming growth factor, beta 1	Rattus norvegicus	36-43
19901542-3	2009	Until recently, we have relied largely on the use of rapamycin to study mTOR function and its anticancer potential.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	72-76
19666112-3	2009	Concomitantly, rapamycin increases the nuclear DNA binding of receptor (R)- and co-Smad proteins to a cognate Smad-binding element (SBE) which in turn causes an increase in profibrotic gene expression as exemplified by the connective tissue growth factor (CTGF) and plasminogen activator inhibitor 1 (PAI-1).	Sirolimus	15-24	serpin family E member 1	Rattus norvegicus	266-299
19666112-3	2009	Concomitantly, rapamycin increases the nuclear DNA binding of receptor (R)- and co-Smad proteins to a cognate Smad-binding element (SBE) which in turn causes an increase in profibrotic gene expression as exemplified by the connective tissue growth factor (CTGF) and plasminogen activator inhibitor 1 (PAI-1).	Sirolimus	15-24	serpin family E member 1	Rattus norvegicus	301-306
19901542-4	2009	Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	70-74
19901542-4	2009	Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	108-112
19901542-4	2009	Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	108-112
20031768-0	2009	Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.	Sirolimus	89-98	C-reactive protein	Homo sapiens	21-39
19901542-8	2009	The discovery of specific, active-site mTOR inhibitors has opened a new chapter in the 40-plus year old odyssey that began with the discovery of rapamycin from a soil sample collected on Easter Island (see Vezina C, et al.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	39-43
20031768-10	2009	There was a progressive increase in neointimal growth after sirolimus-eluting stent implantation during follow-up because preprocedural CRP levels were higher, despite similar angiographic data just after PCI.	Sirolimus	60-69	C-reactive protein	Homo sapiens	136-139
20031768-12	2009	CONCLUSIONS: Increased preprocedural serum CRP levels would predict higher major adverse cardiac events and restenosis rates after sirolimus-eluting stents implantation in patients on hemodialysis.	Sirolimus	131-140	C-reactive protein	Homo sapiens	43-46
19892916-3	2009	We hypothesized that rapamycin, a specific inhibitor of mTOR, will maintain primary human oral keratinocytes as a small-sized, undifferentiated cell population capable of retaining their proliferative capacity.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	56-60
19875810-4	2009	Inhibition of mTOR with rapamycin delays recovery of renal function after acute kidney injury.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19875810-9	2009	Inhibition of mTOR by rapamycin or one of its analogues represents a potentially novel treatment for autosomal dominant polycystic kidney disease.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19892307-2	2009	METHODS: We treated 5 patients with chemotherapy-refractory AML with the mTOR-inhibitor rapamycin at 2mg per os daily for 14 days, with dose adjustment allowed to reach a target serum rapamycin concentration of 10-20 ng/mL.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	73-77
19892307-2	2009	METHODS: We treated 5 patients with chemotherapy-refractory AML with the mTOR-inhibitor rapamycin at 2mg per os daily for 14 days, with dose adjustment allowed to reach a target serum rapamycin concentration of 10-20 ng/mL.	Sirolimus	184-193	mechanistic target of rapamycin kinase	Homo sapiens	73-77
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	interleukin 6	Mus musculus	192-196
19682553-6	2009	The observed results showed that rapamycin alleviated rotenone-induced apoptosis, whose effects were partially blocked when autophagy related gene 5 (Atg5) was suppressed by Atg5 small interference RNA (siRNA) transfection.	Sirolimus	33-42	autophagy related 5	Homo sapiens	150-154
19682553-6	2009	The observed results showed that rapamycin alleviated rotenone-induced apoptosis, whose effects were partially blocked when autophagy related gene 5 (Atg5) was suppressed by Atg5 small interference RNA (siRNA) transfection.	Sirolimus	33-42	autophagy related 5	Homo sapiens	174-178
19682553-7	2009	Additionally, the results showed that rapamycin pretreatment diminished rotenone-induced accumulation of high molecular weight ubiquitinated bands, and reduced rotenone-induced increase of cytochrome c in cytosolic fraction and decreased mitochondrial marker cytochrome oxidase subunit IV (COX IV) in mitochondrial fraction.	Sirolimus	38-47	cytochrome c, somatic	Homo sapiens	189-201
20195232-7	2009	Sirolimus (SRL) and everolimus constitute a new class of compounds designated as the mammalian target of rapamycin (mTOR) inhibitors, which exhibit immunosuppressive and antiproliferative effects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	85-114
20195232-7	2009	Sirolimus (SRL) and everolimus constitute a new class of compounds designated as the mammalian target of rapamycin (mTOR) inhibitors, which exhibit immunosuppressive and antiproliferative effects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	116-120
19940197-3	2009	Here, we show that persistent pain states, but not acute pain behavior, are substantially alleviated by centrally administered rapamycin, an inhibitor of the mTOR pathway.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	158-162
19940197-6	2009	Intrathecal injections of rapamycin inhibited the activation of downstream targets of mTOR in dorsal horn and dorsal roots and reduced the thermal sensitivity of A-fibers.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	86-90
20847591-3	2009	We have now shown that the insulin-induced increase in the abundance of SREBP1c mRNA in cultured AML12 mouse hepatocytes was largely abolished by LY294002, an inhibitor of phosphoinositide 3-kinase, but was reduced only slightly by rapamycin, an inhibitor of mTOR.	Sirolimus	232-241	insulin	Homo sapiens	27-34
19682553-6	2009	The observed results showed that rapamycin alleviated rotenone-induced apoptosis, whose effects were partially blocked when autophagy related gene 5 (Atg5) was suppressed by Atg5 small interference RNA (siRNA) transfection.	Sirolimus	33-42	autophagy related 5	Homo sapiens	124-148
19963096-4	2009	Temsirolimus is an ester analog of rapamycin that retains its potent intrinsic mTOR inhibitory activity while exhibiting better solubility for IV formulation.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	79-83
19963098-2	2009	mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	0-4
20847591-4	2009	Forced expression of a constitutively active form of Akt containing a myristoylation signal sequence (MyrAkt) in these cells with the use of an adenoviral vector resulted in the phosphorylation of p70 S6 kinase, a downstream target of mTOR signaling, and this effect was inhibited by rapamycin.	Sirolimus	284-293	AKT serine/threonine kinase 1	Homo sapiens	53-56
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	tumor necrosis factor	Mus musculus	198-231
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	chemokine (C-C motif) ligand 5	Mus musculus	299-305
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	interleukin 10	Mus musculus	417-422
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Sirolimus	19-28	tumor protein p53	Homo sapiens	157-160
20137731-7	2009	The percentage of CD4(+)Foxp3(+)Treg cells in total CD4(+) cells was significantly higher in rapamycin group and end-stage renal disease group than calcineurin inhibitors group (P < 0.01).	Sirolimus	93-102	CD4 molecule	Homo sapiens	18-21
20137731-7	2009	The percentage of CD4(+)Foxp3(+)Treg cells in total CD4(+) cells was significantly higher in rapamycin group and end-stage renal disease group than calcineurin inhibitors group (P < 0.01).	Sirolimus	93-102	CD4 molecule	Homo sapiens	52-55
19797172-11	2009	Chromatin immunoprecipitation assay demonstrated sirolimus interferes with binding of PPARgamma to its response elements in heme oxygenase-1 promoter.	Sirolimus	49-58	peroxisome proliferator activated receptor gamma	Homo sapiens	86-95
19570961-2	2009	The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	43-72
19570961-2	2009	The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	74-78
19570961-2	2009	The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	125-129
19783659-8	2009	Interestingly, rapamycin blocked CHOP induction by asparaginase in both wild-type and GCN2 null livers.	Sirolimus	15-24	eukaryotic translation initiation factor 2 alpha kinase 4	Mus musculus	86-90
19797172-8	2009	Quantitative polymerase chain reaction in human aortic endothelial cells (HAECs) revealed that sirolimus (but not paclitaxel) inhibited RSG-induced vascular endothelial growth factor transcription.	Sirolimus	95-104	vascular endothelial growth factor A	Homo sapiens	148-182
19797172-9	2009	Western blotting demonstrated that inhibition of molecular signaling in SES+RSG-treated arteries was similar to findings in HAECs treated with RSG and small interfering RNA to PPARgamma, suggesting that sirolimus inhibits PPARgamma.	Sirolimus	203-212	peroxisome proliferator activated receptor gamma	Homo sapiens	222-231
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Sirolimus	19-28	BCL2 apoptosis regulator	Homo sapiens	166-171
19631377-3	2009	The objective of this study was to prepare and characterize rapamycin loaded polymeric poly(lactide-co-glycolide) (PLGA) nanoparticles (NP) that were surface conjugated with antibodies to epidermal growth factor receptor (EGFR), highly expressed on breast cancer cells, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) mediated cross linking agents.	Sirolimus	60-69	epidermal growth factor receptor	Homo sapiens	188-220
19215663-8	2009	The rapamycin treatment increased Abeta production and secretion, but the other two conditions had opposite effects.	Sirolimus	4-13	amyloid beta precursor protein	Homo sapiens	34-39
19215663-9	2009	When the level of phosphorylation of the mammalian target of rapamycin (mTOR) was measured, down-regulation of phosphorylated mTOR levels was observed only in rapamycin-treated cells.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	72-76
19215663-9	2009	When the level of phosphorylation of the mammalian target of rapamycin (mTOR) was measured, down-regulation of phosphorylated mTOR levels was observed only in rapamycin-treated cells.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	126-130
19648118-5	2009	The mTOR inhibitor rapamycin suppresses the translation of some neuronal polarity proteins, including CRMP2 and Tau, thereby inhibiting axon formation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
19648118-5	2009	The mTOR inhibitor rapamycin suppresses the translation of some neuronal polarity proteins, including CRMP2 and Tau, thereby inhibiting axon formation.	Sirolimus	19-28	dihydropyrimidinase like 2	Homo sapiens	102-107
19631377-5	2009	IC(50) doses as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) assay showed the superior antiproliferative activity of EGFR-Rapa-NPs over unconjugated nanoparticles and native rapamycin due to higher cellular uptake on malignant breast cancer cells.	Sirolimus	203-212	epidermal growth factor receptor	Homo sapiens	146-150
19632318-8	2009	Pretreatment with the phosphatidylinositol 3-kinase inhibitor Ly294002 and mTOR inhibitor rapamycin restored the ability of PDBu to downregulate PKC delta in HeLa/CP cells.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	75-79
19843663-0	2009	A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	23-52
19843663-2	2009	We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	91-95
19843663-2	2009	We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	91-95
19843663-3	2009	EXPERIMENTAL DESIGN: We performed a phase I dose escalation study of sirolimus with the chemotherapy regimen MEC (mitoxantrone, etoposide, and cytarabine) in patients with relapsed, refractory, or untreated secondary AML.	Sirolimus	69-78	C-C motif chemokine ligand 28	Homo sapiens	109-112
19843663-6	2009	The maximum tolerated dose (MTD) of sirolimus was determined to be a 12 mg loading dose on day 1 followed by 4 mg/d on days 2 to 7, concurrent with MEC chemotherapy.	Sirolimus	36-45	C-C motif chemokine ligand 28	Homo sapiens	148-151
19718660-7	2009	Cancer cells have a constitutively active mTOR pathway; surprisingly, inhibition of mTOR complex 1 (mTORC1) by rapamycin barely affects the global rate of translation and of initiation of translation, but deeply inhibits mesothelioma spreading on ECM.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	42-46
19718660-7	2009	Cancer cells have a constitutively active mTOR pathway; surprisingly, inhibition of mTOR complex 1 (mTORC1) by rapamycin barely affects the global rate of translation and of initiation of translation, but deeply inhibits mesothelioma spreading on ECM.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	84-88
19917366-1	2009	Herein we have reported the use of rapamycin in immunosuppressive treatment after renal transplantation as a therapy of choice in a patient with diagnosis of tuberous sclerosis complex (TSC).	Sirolimus	35-44	TSC complex subunit 1	Homo sapiens	186-189
19917366-13	2009	Experimental and clinical studies have confirmed that rapamycin exerts beneficial effects in TSC, providing a new therapeutic option.	Sirolimus	54-63	TSC complex subunit 1	Homo sapiens	93-96
19917366-14	2009	Therefore an immunosuppressive regimen with rapamycin should be considered as the treatment of choice after kidney transplantation among patients with TSC seeking to avoid development or progression of disease complications.	Sirolimus	44-53	TSC complex subunit 1	Homo sapiens	151-154
19816606-1	2009	BACKGROUND: The mTOR inhibitor rapamycin has anti-tumor activity across a variety of human cancers, including hepatocellular carcinoma.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	16-20
19641186-0	2009	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	121-124
19631377-3	2009	The objective of this study was to prepare and characterize rapamycin loaded polymeric poly(lactide-co-glycolide) (PLGA) nanoparticles (NP) that were surface conjugated with antibodies to epidermal growth factor receptor (EGFR), highly expressed on breast cancer cells, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) mediated cross linking agents.	Sirolimus	60-69	epidermal growth factor receptor	Homo sapiens	222-226
19641186-4	2009	Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance.	Sirolimus	40-49	AKT serine/threonine kinase 1	Homo sapiens	93-96
19641186-5	2009	Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor, inhibited rapamycin-induced Akt phosphorylation in lymphoma cells.	Sirolimus	102-111	AKT serine/threonine kinase 1	Homo sapiens	120-123
19641186-6	2009	Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	107-111
19816606-7	2009	Rapamycin induced inhibition of cyclin E-dependent kinase activity in some cell lines, but the ability to do so did not correlate with sensitivity.	Sirolimus	0-9	cyclin E1	Rattus norvegicus	32-40
19789339-4	2009	In Ewing sarcoma (EWS) cell lines, CP751,871 inhibited growth poorly (<50%), but prevented rapamycin-induced hyperphosphorylation of AKT(Ser473) and induced greater than additive apoptosis.	Sirolimus	94-103	AKT serine/threonine kinase 1	Homo sapiens	136-139
19785652-9	2009	The mTOR inhibitor LY294002, like rapamycin, decreased IP(3)-evoked Ca(2+) release.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	4-8
19789339-5	2009	Rapamycin treatment also increased secretion of IGF-1 resulting in phosphorylation of IGF-1R (Tyr1131) that was blocked by CP751,871.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	48-53
19789339-11	2009	Rapamycin treatment did not markedly suppress VEGF in tumors and synergized only in tumor lines where VEGF was dramatically inhibited by CP751,871.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	102-106
19789339-12	2009	These data suggest a model in which blockade of IGF-1R suppresses tumor-derived VEGF to a level where rapamycin can effectively suppress the response in vascular endothelial cells.	Sirolimus	102-111	vascular endothelial growth factor A	Homo sapiens	80-84
19761448-6	2009	Most importantly, however, if select focal cortical malformations result from enhanced mTOR signaling, new therapeutic antiepileptic compounds, such as rapamycin, can be designed and tested that specifically target mTOR signaling.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	87-91
19589861-8	2009	Rapamycin blocked activation of P-mTOR, P-S6K1, and P-4EBP1 proteins and significantly reduced the number of proliferating cells in the myometrium of OVX rats.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	54-59
19761448-6	2009	Most importantly, however, if select focal cortical malformations result from enhanced mTOR signaling, new therapeutic antiepileptic compounds, such as rapamycin, can be designed and tested that specifically target mTOR signaling.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	215-219
19694899-5	2009	CONCLUSIONS: Results suggest that reversing the underlying molecular deficits of TSC with rapamycin or other mTOR inhibitors could result in clinically significant improvements of cognitive function and neurological symptoms, even if treatments are started in adulthood.	Sirolimus	90-99	TSC complex subunit 1	Homo sapiens	81-84
19494204-7	2009	Sirolimus treatment of 6-month-old Rdh8(-/-)Abca4(-/-) mice for 4 months prevented choroidal neovascularization without changing retinal VEGF levels.	Sirolimus	0-9	ATP-binding cassette, sub-family A (ABC1), member 4	Mus musculus	44-49
19665249-10	2009	Blockade of Ras and mTOR pathways with sorafenib and rapamycin reduced cell proliferation and induced apoptosis in cell lines.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	20-24
19724909-8	2009	PDGF-induced nuclear localization of mTOR was blocked by pre-treatment with RAPA.	Sirolimus	76-80	mechanistic target of rapamycin kinase	Homo sapiens	37-41
19702335-6	2009	The upregulation of Seryl-aminoacyl-tRNA-synthetase and Eef2 was sensitive to the mTOR inhibitor rapamycin, as determined by Western blot.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	82-86
19554030-7	2009	Expression of IL-10, the principal autocrine growth factor for PEL, was initially reduced in PEL from Rapa-treated mice but rapidly increased despite treatment.	Sirolimus	102-106	interleukin 10	Mus musculus	14-19
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	16-20
19565301-9	2009	TIMP-1 serum levels correlated well (CC = 0.75; P < 0.01) with rapamycin treatment.	Sirolimus	66-75	tissue inhibitor of metalloproteinase 1	Mus musculus	0-6
19789218-8	2009	CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor).	Sirolimus	57-66	hypoxia inducible factor 1 subunit alpha	Homo sapiens	32-42
19596836-5	2009	Treatment of TSC2-null tumors with mTOR inhibitor rapamycin attenuated STAT3 expression and phosphorylation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
19596836-5	2009	Treatment of TSC2-null tumors with mTOR inhibitor rapamycin attenuated STAT3 expression and phosphorylation.	Sirolimus	50-59	signal transducer and activator of transcription 3	Homo sapiens	71-76
19596836-8	2009	Re-expression of TSC2 or treatment with rapamycin inhibited IFN-gamma-induced STAT3 phosphorylation and synergized with IFN-gamma in inhibiting TSC2-null and LAMD cell proliferation.	Sirolimus	40-49	interferon gamma	Homo sapiens	60-69
19596836-8	2009	Re-expression of TSC2 or treatment with rapamycin inhibited IFN-gamma-induced STAT3 phosphorylation and synergized with IFN-gamma in inhibiting TSC2-null and LAMD cell proliferation.	Sirolimus	40-49	signal transducer and activator of transcription 3	Homo sapiens	78-83
19596836-8	2009	Re-expression of TSC2 or treatment with rapamycin inhibited IFN-gamma-induced STAT3 phosphorylation and synergized with IFN-gamma in inhibiting TSC2-null and LAMD cell proliferation.	Sirolimus	40-49	interferon gamma	Homo sapiens	120-129
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-40
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	cyclin dependent kinase inhibitor 1A	Homo sapiens	41-45
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-50
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	cyclin dependent kinase inhibitor 1A	Homo sapiens	51-55
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P < 0.05).	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	163-167
19264150-7	2009	PA interacts with mTOR in a manner that is competitive with rapamycin, and as a consequence, elevated PLD activity confers rapamycin resistance - a point that has been largely overlooked in clinical trials involving rapamycin-based strategies.	Sirolimus	123-132	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	102-105
19584709-0	2009	Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-19
19584709-8	2009	At concentrations higher than 10 nmol/l, RAPA exerted a significant proapoptotic effect, with the collapse of mitochondrial potential and caspase-3 activation.	Sirolimus	41-45	caspase 3	Homo sapiens	138-147
19954658-7	2009	(3) On exposure to RAPA, the levels of p-mTOR, p-S6 and IFN-gamma in T cells in refractory/relapsed AA patients were significantly lower than those before the exposure (all P < 0.05).	Sirolimus	19-23	mechanistic target of rapamycin kinase	Homo sapiens	41-45
19954658-7	2009	(3) On exposure to RAPA, the levels of p-mTOR, p-S6 and IFN-gamma in T cells in refractory/relapsed AA patients were significantly lower than those before the exposure (all P < 0.05).	Sirolimus	19-23	interferon gamma	Homo sapiens	56-65
19607806-4	2009	Treatment with the mTOR inhibitor, rapamycin, inhibited this CCL5-inducible proliferation.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	19-23
19264150-7	2009	PA interacts with mTOR in a manner that is competitive with rapamycin, and as a consequence, elevated PLD activity confers rapamycin resistance - a point that has been largely overlooked in clinical trials involving rapamycin-based strategies.	Sirolimus	123-132	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	102-105
19706799-8	2009	The combination of AVE1642 with rapamycin also induced a synergistic reduction of viability and of AKT phosphorylation.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	99-102
19996130-4	2009	We found that RAPA induced a time-dependent activation of MAPK (pERK1/2) and MEK1/2.	Sirolimus	14-18	mitogen-activated protein kinase 3	Homo sapiens	58-62
19996130-5	2009	Inhibition of upstream kinase MEK1/2 by U0126 partially suppressed RAPA-induced ERK1/2 activation.	Sirolimus	67-71	mitogen-activated protein kinase 3	Homo sapiens	80-86
19564418-5	2009	In support of this, expression of a phosphomimetic mutant AKT(S473D) in rictor-deficient cells rescued myoblast fusion even in the presence of rapamycin.	Sirolimus	143-152	AKT serine/threonine kinase 1	Homo sapiens	58-61
19564418-7	2009	Rapamycin treatment prevented ROCK1 inactivation during differentiation, while suppression of ROCK1 activity during differentiation and myoblast fusion was restored through expression of AKT(S473D), even in the presence of rapamycin.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	187-190
19651486-7	2009	The mTOR inhibitors (sirolimus and everolimus) have different side effects (hyperlipidemia, thrombocytopenia, and pulmonary, cutaneous, and articular events) than ACNs.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	4-8
19453998-0	2009	Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.	Sirolimus	12-21	CD4 molecule	Homo sapiens	44-47
19527683-7	2009	Moreover, the activation of autophagy by rapamycin induced enhanced cell death in TNF-alpha-treated Caco-2 cells, which were autophagy and cell death-resistant.	Sirolimus	41-50	tumor necrosis factor	Homo sapiens	82-91
19535330-4	2009	OGD-induced apoptosis was increased by the combined deletion of S6K1 and S6K2 genes, as well as by treatment with rapamycin that inhibits S6K1 activity by acting on the upstream regulator mTOR (mammalian target of rapamycin).	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	188-192
19535330-4	2009	OGD-induced apoptosis was increased by the combined deletion of S6K1 and S6K2 genes, as well as by treatment with rapamycin that inhibits S6K1 activity by acting on the upstream regulator mTOR (mammalian target of rapamycin).	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	194-223
19131641-3	2009	To examine these issues, we determined the effects of rapamycin-induced inhibition of mTORC1 on TLR2- and TLR4-induced neutrophil activation.	Sirolimus	54-63	toll-like receptor 4	Mus musculus	106-110
19131641-8	2009	Administration of rapamycin also decreased the severity of lung injury after intratracheal LPS or PAM administration, as determined by diminished neutrophil accumulation in the lungs, reduced interstitial pulmonary edema, and diminished levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid.	Sirolimus	18-27	tumor necrosis factor	Homo sapiens	247-256
19131641-8	2009	Administration of rapamycin also decreased the severity of lung injury after intratracheal LPS or PAM administration, as determined by diminished neutrophil accumulation in the lungs, reduced interstitial pulmonary edema, and diminished levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid.	Sirolimus	18-27	interleukin 6	Homo sapiens	261-265
19622581-3	2009	EXPERIMENTAL DESIGN: EL1-luc/TAg transgenic mice of 11 weeks of age were treated with rapamycin (5 mg/kg, i.p.)	Sirolimus	86-95	epilepsy 1	Mus musculus	21-24
19549188-5	2009	However, the mode of action of E1 is different from that of the mTOR inhibitor rapamycin.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	64-68
19375241-13	2009	In addition, rapamycin is a selective and effective mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	52-81
19375241-13	2009	In addition, rapamycin is a selective and effective mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	83-87
19586661-2	2009	mTOR signals via two complexes: TORC1, which contains the Regulatory Associated Protein of TOR (raptor), and TORC2, which contains the Rapamycin-insensitive Companion of TOR (rictor).	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19586661-3	2009	The immunosuppressive/anti-cancer agent rapamycin inhibits TORC1 function by disrupting the mTOR-raptor interaction.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	92-96
19646263-15	2009	Specifically, the cytotoxicity of Docetaxel, Staurosporine and Rapamycin increased significantly (>40% at IC50 dose) in IL-8 depleted cells as compared to that in C-siRNA transfected cells.	Sirolimus	63-72	C-X-C motif chemokine ligand 8	Homo sapiens	123-127
19541609-4	2009	Consistent with a central role for mTORC1 in these tumors, rapamycin as a single agent results in a dramatic suppression of preexisting GI polyps in LKB1+/- mice.	Sirolimus	59-68	serine/threonine kinase 11	Mus musculus	149-153
19541609-6	2009	We demonstrate here that these polyps, and LKB1- and AMPK-deficient mouse embryonic fibroblasts, show dramatic up-regulation of the HIF-1alpha transcription factor and its downstream transcriptional targets in an rapamycin-suppressible manner.	Sirolimus	213-222	serine/threonine kinase 11	Mus musculus	43-47
19337030-7	2009	Further autophagy induction with rapamycin protects DA neurons from lactacystin-mediated cell death by downregulating p53 and its related apoptotic pathways and by inducing autophagy to degrade aggregated proteins.	Sirolimus	33-42	tumor protein p53	Homo sapiens	118-121
19015855-3	2009	In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.	Sirolimus	67-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	130-136
19015855-3	2009	In vitro studies with pooled human liver microsomes showed that temsirolimus and its principal metabolite, sirolimus, inhibit the CYP2D6 isozyme (K(i) = 1.5 and 5 microM, respectively), indicating potential for pharmacokinetic interaction with agents that are substrates of CYP2D6.	Sirolimus	67-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	274-280
19522662-1	2009	Sirolimus is an antiproliferative immunosuppressive agent that inhibits the mammalian target of rapamycin.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	76-105
19483651-3	2009	In particular, rapamycin, is a well-known immunosuppressant that can decrease the activity of the PI3K/mTOR pathway in tumor cells, but also has a profound inhibitory effect on T cells.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	103-107
19421190-1	2009	Because the size of renal cysts in the native kidneys of patients with ADPKD who have been transplanted was found to be reduced when rapamycin was the immunosuppressant, we tested the involvement of the mTOR pathway in cyst enlargement.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	203-207
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	30-59
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	61-65
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	152-156
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	152-156
19386082-1	2009	m-TOR inhibitors (e.g. sirolimus) are well-tolerated immunosuppressants used in renal transplantation for prophylaxis of organ rejection, and are associated with long-term graft survival.	Sirolimus	23-32	RAR related orphan receptor C	Homo sapiens	2-5
19715944-9	2009	The immunosuppressive treatment was switched to the m-TOR inhibitor Rapamycin at therapeutic trough blood levels of 5-8 ng/dL.	Sirolimus	68-77	RAR related orphan receptor C	Homo sapiens	54-57
19553465-6	2009	The present study targeted the mammalian target of rapamycin (mTOR) signaling pathway, which regulates cell growth and is blocked by rapamycin.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	62-66
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Sirolimus	36-45	nitric oxide synthase 3	Homo sapiens	160-193
19339632-9	2009	Inhibition of the PI3K pathways by the selective PI3K inhibitor LY 294002, an Akt inhibitor, or the mTOR inhibitor rapamycin reduced cell proliferation by 51%.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	100-104
18841360-0	2009	Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.	Sirolimus	53-62	CD4 molecule	Homo sapiens	13-16
18841360-0	2009	Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.	Sirolimus	53-62	interleukin 2	Homo sapiens	122-126
19166929-1	2009	The mammalian target of rapamycin (mTOR) signalling pathway is implicated in the pathogenesis of a number of cancers and inherited hamartoma syndromes which have led to mTOR inhibitors, such as rapamycin, being tested in clinical trials.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
19166929-1	2009	The mammalian target of rapamycin (mTOR) signalling pathway is implicated in the pathogenesis of a number of cancers and inherited hamartoma syndromes which have led to mTOR inhibitors, such as rapamycin, being tested in clinical trials.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	169-173
19526041-8	2009	Furthermore, the increased expression of collagen and TGF-beta3 mRNAs in the NILV were attenuated in rapamycin-treated post-MI rats, whereas scar healing was unaffected.	Sirolimus	101-110	transforming growth factor, beta 3	Rattus norvegicus	54-63
19229543-2	2009	This study addresses the effect of AZA and RPM combination therapy on CRC and its influence on the mammalian target of rapamycin (mTOR) and its signal transduction pathway.	Sirolimus	43-46	mechanistic target of rapamycin kinase	Homo sapiens	99-128
19229543-2	2009	This study addresses the effect of AZA and RPM combination therapy on CRC and its influence on the mammalian target of rapamycin (mTOR) and its signal transduction pathway.	Sirolimus	43-46	mechanistic target of rapamycin kinase	Homo sapiens	130-134
19347904-1	2009	mTOR pathway inhibitors, specifically rapamycin and its derivatives, are promising therapeutics that targets downstream pathways including protein translation.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19347904-6	2009	In contrast, treatment with rapamycin for 24 h reduced overall translation by approximately 45% and affected the translation of mRNAs with complex 5" UTRs, specifically VEGF and HIF1alpha.	Sirolimus	28-37	vascular endothelial growth factor A	Homo sapiens	169-173
19347904-6	2009	In contrast, treatment with rapamycin for 24 h reduced overall translation by approximately 45% and affected the translation of mRNAs with complex 5" UTRs, specifically VEGF and HIF1alpha.	Sirolimus	28-37	hypoxia inducible factor 1 subunit alpha	Homo sapiens	178-187
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	TSC complex subunit 1	Homo sapiens	38-41
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	mitogen-activated protein kinase 1	Mus musculus	155-158
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	TSC complex subunit 1	Homo sapiens	38-41
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	mitogen-activated protein kinase 1	Mus musculus	155-158
19539245-7	2009	When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	192-196
19539245-7	2009	When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.	Sirolimus	61-70	mitogen-activated protein kinase 1	Homo sapiens	201-204
19539245-7	2009	When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	261-265
19539245-7	2009	When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.	Sirolimus	61-70	TSC complex subunit 1	Homo sapiens	297-300
19281830-7	2009	In a sprouting assay we found that IL-20 caused cell migration within 24 h at a rate comparable to VEGF-C, and this migration could be inhibited by wortmannin and rapamycin.	Sirolimus	163-172	interleukin 20	Homo sapiens	35-40
19281830-7	2009	In a sprouting assay we found that IL-20 caused cell migration within 24 h at a rate comparable to VEGF-C, and this migration could be inhibited by wortmannin and rapamycin.	Sirolimus	163-172	vascular endothelial growth factor C	Homo sapiens	99-105
19509244-0	2009	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.	Sirolimus	82-91	epidermal growth factor receptor	Homo sapiens	29-61
19509244-0	2009	Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.	Sirolimus	82-91	epidermal growth factor receptor	Homo sapiens	103-135
19435890-2	2009	Thus, mTOR inhibition by rapamycin or TSC1/2 results in increased PI3K-Akt activation.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	6-10
19435890-2	2009	Thus, mTOR inhibition by rapamycin or TSC1/2 results in increased PI3K-Akt activation.	Sirolimus	25-34	AKT serine/threonine kinase 1	Homo sapiens	71-74
19377293-6	2009	Knockout of either Sestrin2 or Dram reduced autophagy elicited by nutrient depletion, rapamycin, lithium or thapsigargin.	Sirolimus	86-95	DNA damage regulated autophagy modulator 1	Homo sapiens	31-35
19245654-4	2009	Recent work has revealed that across eukaryotes mTOR orthologues are found in two biochemically distinct complexes and only one of those complexes (mTORC1 in mammals) is acutely sensitive to rapamycin and regulated by nutrients and AMPK.	Sirolimus	191-200	mechanistic target of rapamycin kinase	Homo sapiens	48-52
19479206-7	2009	In addition, the TGF-beta inhibitor ALK5, retinoid acid, and rapamycin influence the expansion of nTreg cells and the conversion of iTreg cells in vitro and in vivo.	Sirolimus	61-70	transforming growth factor beta 1	Homo sapiens	17-25
19711862-3	2009	Microgravity effects simulated with the use of RPM raised the IL-8 production 1.5 - 6 times and 1.6-2.1 times on the average after 10 days and 20 days of containment, respectively.	Sirolimus	47-50	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
19120326-0	2009	Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	15-19
19120326-0	2009	Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.	Sirolimus	105-114	AKT serine/threonine kinase 1	Homo sapiens	40-43
19120326-6	2009	RESULTS: Rapamycin showed limited effects on cell viability but resulted in strong and lasting AKT phosphorylation in melanoma cells.	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	95-98
19120326-12	2009	Combination of rapamycin and LY294002 suppresses AKT phosphorylation but without significant effect on treatment efficacy.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	49-52
19389529-0	2009	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
19389529-5	2009	We report two cases of patients with metastatic melanoma who showed significant remission after combination of carboplatin and paclitaxel with the mTOR inhibitor sirolimus.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Homo sapiens	147-151
19412427-11	2009	Low-dose sunitinib (20 mg/kg) demonstrates synergistic cytotoxicity with an mTOR inhibitor, rapamycin, which is more effective than the traditional chemotherapeutic drug, cyclophosphamide.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	76-80
19297407-3	2009	The gene products of TSC1 and TSC2, also known as hamartin and tuberin, respectively, form a physical and functional complex and inhibit the mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	21-25
19297407-3	2009	The gene products of TSC1 and TSC2, also known as hamartin and tuberin, respectively, form a physical and functional complex and inhibit the mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	50-58
19414357-1	2009	Rapamycin, an inhibitor of mTOR, is in clinical trials for treatment of cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
19414357-4	2009	Rapamycin inhibition of cell proliferation, the cell cycle and mTOR signaling, including p70S6 and S6RP phosphorylation, was most effective in benign (MCF10A) and premalignant (MCF10AT; MCF10ATG3B) human breast epithelial cells, relative to MCF10CA1a tumor cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	63-67
19154728-1	2009	The calcineurin inhibitors cyclosporin A and tacrolimus and the inhibitors of the mTOR, sirolimus and everolimus bind immunophilins that are required for their immunosuppressive action.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	82-86
19013721-6	2009	Inhibition of mTOR by rapamycin (a natural product) or its analogs aims to prevent the deleterious effects of the abnormal signaling, regardless at which point of the signal pathway has the abnormality launched.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19270529-2	2009	A recent study revealing mechanistically how rapamycin suppresses mTOR provides two explanations for the differential sensitivities to rapamycin.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	66-70
19211763-3	2009	However, although the mTOR inhibitor rapamycin suppressed VV-induced inactivation of 4E-BP1, it failed to inhibit eIF4F assembly.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	22-26
19373661-5	2009	Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax.	Sirolimus	13-22	BCL2 apoptosis regulator	Homo sapiens	100-105
19373661-5	2009	Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax.	Sirolimus	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	154-157
19225151-6	2009	Inhibition of mTOR by rapamycin or leucine deprivation, the conditions that induce autophagy, leads to dephosphorylation of ULK1, ULK2, and Atg13 and activates ULK to phosphorylate FIP200.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19331694-9	2009	In contrast, rapamycin, an inhibitor of mTOR, blocked phosphorylation only of Ser65 and Thr70.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	40-44
19293429-6	2009	Rapamycin treatment of diet-induced obese mice or of transgenic mice with long-term activation of endothelial Akt inhibits activation of mammalian target of rapamycin (mTOR)-rictor complex 2 and Akt, prevents vascular senescence without altering body weight, and reduces the severity of limb necrosis and ischemic stroke.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	110-113
19293429-6	2009	Rapamycin treatment of diet-induced obese mice or of transgenic mice with long-term activation of endothelial Akt inhibits activation of mammalian target of rapamycin (mTOR)-rictor complex 2 and Akt, prevents vascular senescence without altering body weight, and reduces the severity of limb necrosis and ischemic stroke.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	137-166
19293429-6	2009	Rapamycin treatment of diet-induced obese mice or of transgenic mice with long-term activation of endothelial Akt inhibits activation of mammalian target of rapamycin (mTOR)-rictor complex 2 and Akt, prevents vascular senescence without altering body weight, and reduces the severity of limb necrosis and ischemic stroke.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	168-172
19293429-6	2009	Rapamycin treatment of diet-induced obese mice or of transgenic mice with long-term activation of endothelial Akt inhibits activation of mammalian target of rapamycin (mTOR)-rictor complex 2 and Akt, prevents vascular senescence without altering body weight, and reduces the severity of limb necrosis and ischemic stroke.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	195-198
19276265-6	2009	We also tested the efficacy of the mTOR inhibitor rapamycin on signaling and growth of chordoma cell lines.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
19276368-9	2009	Together, using rapamycin phosphoproteomics, we not only advance the global mechanistic understanding of the action of rapamycin but also show that CDC25B may serve as a drug target for improving mTOR-targeted cancer therapies.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	196-200
19112174-1	2009	The 40 S ribosomal S6 kinase 1 (S6K1) acts downstream of mTOR (mammalian target of rapamycin) and is sensitive to inhibition by rapamycin.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	57-61
19260835-0	2009	ID2-VEGF-related pathways in the pathogenesis of Kaposi"s sarcoma: a link disrupted by rapamycin.	Sirolimus	87-96	vascular endothelial growth factor A	Homo sapiens	4-8
19244117-8	2009	Thus, phospho-S2481 on mTOR serves as a biomarker for intact mTORC2 and its sensitivity to rapamycin.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	23-27
19196220-2	2009	Posaconazole, an extended-spectrum triazole, is an inhibitor of the cytochrome P450 (CYP) isoenzyme CYP3A4, and sirolimus, an immunosuppressant, is a substrate of the enzyme.	Sirolimus	112-121	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
18783828-0	2009	Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	99-103
18783828-5	2009	Here, we report that the serine/threonine kinase mTOR (the mammalian target of rapamycin) inhibitor, rapamycin, inhibits the growth of not only the Bcr-Abl-positive lymphoid leukemic cell line, SU-Ph2, established from Ph(+)ALL patients, but also the imatinib-resistant cell line, SU/SR, that has acquired T315I.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	49-53
17990907-4	2009	Recently, some trials treating TSC with the mTOR inhibitor rapamycin have been published; however, the impact of such treatment on heart tumors is not known.	Sirolimus	59-68	TSC complex subunit 1	Homo sapiens	31-34
17990907-4	2009	Recently, some trials treating TSC with the mTOR inhibitor rapamycin have been published; however, the impact of such treatment on heart tumors is not known.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	44-48
19081609-10	2009	Rapamycin decreased hypoxia-induced synthesis of vascular endothelial growth factor.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	49-83
19250527-5	2009	In the tissue culture system, we detected significantly elevated Foxp3 expression and IL-10 production, as well as an increased percentage of Foxp3+ Tregs in nasal polyps after blocking the mTOR signaling pathway with rapamycin.	Sirolimus	218-227	mechanistic target of rapamycin kinase	Homo sapiens	190-194
19019920-10	2009	Our data provide new molecular insights explaining which pathways and molecules are affected in podocytes by an imbalanced mTOR function because of rapamycin treatment.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	123-127
19019941-8	2009	CONCLUSIONS: This study indicates that both RAPA and DEX inhibit the production of IL-17 and IFN-gamma by PBMCs.	Sirolimus	44-48	interferon gamma	Homo sapiens	93-102
19028034-5	2009	Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
19028034-5	2009	Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	38-42
19028034-5	2009	Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical trials have demonstrated its efficacy in various TSC manifestations, suggesting the possibility that rapamycin may have benefit in the treatment of TSC brain disease.	Sirolimus	173-182	TSC complex subunit 1	Homo sapiens	121-124
18759859-15	2009	Rapamycin treatment downregulated the expression of p-ERK1/2, p38 MAPK and Bax in stimulated cardiomyocytes, with or without FKBP12.6 overexpression, and enhanced protein synthesis, but had no effect on DNA synthesis in cardiomyocytes.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	54-60
18759859-15	2009	Rapamycin treatment downregulated the expression of p-ERK1/2, p38 MAPK and Bax in stimulated cardiomyocytes, with or without FKBP12.6 overexpression, and enhanced protein synthesis, but had no effect on DNA synthesis in cardiomyocytes.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
18759859-15	2009	Rapamycin treatment downregulated the expression of p-ERK1/2, p38 MAPK and Bax in stimulated cardiomyocytes, with or without FKBP12.6 overexpression, and enhanced protein synthesis, but had no effect on DNA synthesis in cardiomyocytes.	Sirolimus	0-9	FKBP prolyl isomerase 1B	Homo sapiens	125-133
18845636-2	2009	We report that the role of the phosphatidylinositol (PI)-3-kinase/AKT pathway in increasing HIF-1alpha protein in FSH-stimulated GCs extends beyond an increase in mammalian target of rapamycin-stimulated translation.	Sirolimus	183-192	AKT serine/threonine kinase 1	Homo sapiens	66-69
18845636-2	2009	We report that the role of the phosphatidylinositol (PI)-3-kinase/AKT pathway in increasing HIF-1alpha protein in FSH-stimulated GCs extends beyond an increase in mammalian target of rapamycin-stimulated translation.	Sirolimus	183-192	hypoxia inducible factor 1 subunit alpha	Homo sapiens	92-102
19148492-11	2009	Rapamycin also down-regulated the activity of p70S6, pAkt and p-mTOR, but had no effect on pGSK-3beta, p44Erk, pCdc2, TSC1/2 or Hsp70 or Hsp90.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	64-68
19056683-4	2009	TP53INP2 translocates from the nucleus to the autophagosome structures after activation of autophagy by rapamycin or starvation.	Sirolimus	104-113	tumor protein p53 inducible nuclear protein 2	Homo sapiens	0-8
19165201-5	2009	We show that this subset of NSCLC is also sensitised to the mTOR inhibitor rapamycin.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	60-64
19147764-3	2009	This study tested the hypothesis that rapamycin radiosensitizes soft tissue sarcoma and endothelial cells in vitro and in vivo through the inhibition of mTOR.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	153-157
19147764-11	2009	CONCLUSIONS: Minimally cytotoxic concentrations of rapamycin inhibited the mTOR cascade in culture and in vivo while radiosensitizing soft tissue sarcoma, and produced synergistic effects with radiation on HDMEC microvessel formation.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	75-79
19211363-3	2009	Rapamycin is an inhibitor of mTOR that has first been developed for its immunosuppressive characteristics, as a preventive treatment of graft rejection.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18758183-2	2009	P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel.	Sirolimus	157-166	tumor protein p53	Homo sapiens	8-11
19090006-12	2009	Overall, the current results demonstrated the potential for the application of rapamycin, an mTOR inhibitor, as an additional novel component of chemotherapy for a defined subset of patients with lung carcinoma.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	93-97
18636076-3	2009	Autophagy is negatively regulated by the mammalian target of rapamycin (mTOR) and can be induced in all mammalian cell types by the mTOR inhibitor rapamycin.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	72-76
18636076-3	2009	Autophagy is negatively regulated by the mammalian target of rapamycin (mTOR) and can be induced in all mammalian cell types by the mTOR inhibitor rapamycin.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	132-136
19118035-10	2009	Treatment with the PI3K inhibitors LY294002 or wortmannin resulted in nuclear relocalization of p27, whereas mTOR inhibition by rapamycin did not.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	109-113
19430174-1	2009	We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	25-54
19430174-1	2009	We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	56-60
19430174-1	2009	We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	25-54
19430174-1	2009	We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	56-60
18781596-9	2009	Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes.	Sirolimus	223-232	hypoxia inducible factor 1 subunit alpha	Homo sapiens	20-30
18781596-9	2009	Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes.	Sirolimus	223-232	hypoxia inducible factor 1 subunit alpha	Homo sapiens	133-143
18781596-9	2009	Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	207-211
18781596-9	2009	Thus, activation of HIF-1alpha in exponentially growing cells via hypoxic stimulation is independent of the Akt/mTOR pathway whereas HIF-1alpha activation obtained in high confluency is totally dependent on mTOR pathway as rapamycin totally impaired (i) HIF-1alpha stabilization and (ii) mRNA levels of CA9 and BNIP3, two HIF-target genes.	Sirolimus	223-232	hypoxia inducible factor 1 subunit alpha	Homo sapiens	133-143
19129735-1	2009	Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	86-90
19129735-1	2009	Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	232-236
19129735-1	2009	Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	55-84
19129735-1	2009	Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	86-90
19129735-1	2009	Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	232-236
19827268-6	2009	Resveratrol reduced phosphorylation of ribosomal protein S6 and the mTOR inhibitor rapamycin further enhanced resveratrol-induced cell death.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	68-72
19200882-3	2009	mTORC1 activity is inhibited by rapamycin, a specific inhibitor of mTOR, whereas mTORC2 activity is resistant to short-term treatments with rapamycin.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19139116-5	2009	Similar AKT-dependent regulation of rapamycin responsiveness was shown in a second myeloma model: the PTEN-null OPM-2 cell line transfected with wild-type PTEN.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	8-11
19139116-6	2009	Because extracellular signal-regulated kinase (ERK)/p38 activity facilitates IRES-mediated translation of some transcripts, we investigated ERK/p38 as regulators of AKT-dependent effects on rapamycin sensitivity.	Sirolimus	190-199	mitogen-activated protein kinase 1	Homo sapiens	47-50
19139116-6	2009	Because extracellular signal-regulated kinase (ERK)/p38 activity facilitates IRES-mediated translation of some transcripts, we investigated ERK/p38 as regulators of AKT-dependent effects on rapamycin sensitivity.	Sirolimus	190-199	mitogen-activated protein kinase 14	Homo sapiens	52-55
19139116-6	2009	Because extracellular signal-regulated kinase (ERK)/p38 activity facilitates IRES-mediated translation of some transcripts, we investigated ERK/p38 as regulators of AKT-dependent effects on rapamycin sensitivity.	Sirolimus	190-199	mitogen-activated protein kinase 1	Homo sapiens	140-143
19139116-6	2009	Because extracellular signal-regulated kinase (ERK)/p38 activity facilitates IRES-mediated translation of some transcripts, we investigated ERK/p38 as regulators of AKT-dependent effects on rapamycin sensitivity.	Sirolimus	190-199	mitogen-activated protein kinase 14	Homo sapiens	144-147
19139116-6	2009	Because extracellular signal-regulated kinase (ERK)/p38 activity facilitates IRES-mediated translation of some transcripts, we investigated ERK/p38 as regulators of AKT-dependent effects on rapamycin sensitivity.	Sirolimus	190-199	AKT serine/threonine kinase 1	Homo sapiens	165-168
19139116-9	2009	Furthermore, the ERK inhibitor successfully sensitized myeloma cells to rapamycin in terms of down-regulated D-cyclin protein expression and G1 arrest.	Sirolimus	72-81	mitogen-activated protein kinase 1	Homo sapiens	17-20
20066897-1	2009	The cytotoxic effects and mechanism of action of cisplatin and the mTOR inhibitor rapamycin on Hep-2 laryngeal cancer cells were investigated.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	67-71
20066897-6	2009	p-mTOR and S6K expressions were significantly downregulated by rapamycin.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	2-6
20066897-8	2009	Combined cisplatin and rapamycin treatment resulted in significant downregulated p-mTOR and S6K expression, but no change in ERCC1 expression.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	83-87
20066897-10	2009	Rapamycin may facilitate increased Hep-2 cell apoptosis with cisplatin via inhibiting downstream expression of proteins in the AKT-mTOR signaling pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	127-130
20066897-10	2009	Rapamycin may facilitate increased Hep-2 cell apoptosis with cisplatin via inhibiting downstream expression of proteins in the AKT-mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	131-135
19293927-9	2009	S9 also completely impeded hyper-phosphorylation of Akt as a feedback of inhibition of mTOR by rapamycin.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	52-55
19293927-9	2009	S9 also completely impeded hyper-phosphorylation of Akt as a feedback of inhibition of mTOR by rapamycin.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	87-91
18834941-1	2009	AIMS: To determine how sirolimus (SRL), in comparison to calcineurin inhibitors (CNI), influences gene expression of cytokines: interleukin 1beta, tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and interleukin 10 (IL-10) in peripheral blood mononuclear cells (PBMC) of transplant recipients.	Sirolimus	23-32	interleukin 1 beta	Homo sapiens	128-145
18834941-1	2009	AIMS: To determine how sirolimus (SRL), in comparison to calcineurin inhibitors (CNI), influences gene expression of cytokines: interleukin 1beta, tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and interleukin 10 (IL-10) in peripheral blood mononuclear cells (PBMC) of transplant recipients.	Sirolimus	23-32	tumor necrosis factor	Homo sapiens	147-174
18834941-1	2009	AIMS: To determine how sirolimus (SRL), in comparison to calcineurin inhibitors (CNI), influences gene expression of cytokines: interleukin 1beta, tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and interleukin 10 (IL-10) in peripheral blood mononuclear cells (PBMC) of transplant recipients.	Sirolimus	23-32	tumor necrosis factor	Homo sapiens	176-185
18789402-0	2008	Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	85-88
18789402-0	2008	Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	98-104
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	11-20	AKT serine/threonine kinase 1	Homo sapiens	90-93
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	11-20	nuclear factor kappa B subunit 1	Homo sapiens	94-103
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	11-20	BCL2 like 1	Homo sapiens	117-123
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	197-206	nuclear factor kappa B subunit 1	Homo sapiens	94-103
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	197-206	BCL2 like 1	Homo sapiens	117-123
19074906-8	2008	Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells.	Sirolimus	13-22	C-X-C motif chemokine ligand 16	Homo sapiens	54-60
19074906-8	2008	Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells.	Sirolimus	13-22	C-X-C motif chemokine ligand 8	Homo sapiens	123-127
19074906-8	2008	Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	131-135
19077306-12	2008	Pin1 inhibition greatly increased the sensitivity of Her2-positive breast cancer cells to the mTOR inhibitor Rapamycin, while it did not increase their sensitivity to Trastuzumab, suggesting that Pin1 might act on Her2 signaling.	Sirolimus	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	53-57
19077306-12	2008	Pin1 inhibition greatly increased the sensitivity of Her2-positive breast cancer cells to the mTOR inhibitor Rapamycin, while it did not increase their sensitivity to Trastuzumab, suggesting that Pin1 might act on Her2 signaling.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	94-98
19077306-12	2008	Pin1 inhibition greatly increased the sensitivity of Her2-positive breast cancer cells to the mTOR inhibitor Rapamycin, while it did not increase their sensitivity to Trastuzumab, suggesting that Pin1 might act on Her2 signaling.	Sirolimus	109-118	erb-b2 receptor tyrosine kinase 2	Homo sapiens	214-218
19020099-6	2008	Leptin significantly increases the dose of the mTOR inhibitor sirolimus that is required for effective inhibition of neointimal formation.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	47-51
18809972-4	2008	In contrast, eIF4E phosphorylation is low in PC3 and LNCaP cells with mutated PTEN and constitutively active AKT/mTOR pathway, but it can be strongly induced through inhibition of mTOR activity by rapamycin or serum depletion.	Sirolimus	197-206	mechanistic target of rapamycin kinase	Homo sapiens	180-184
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	174-178
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	AKT serine/threonine kinase 1	Homo sapiens	84-87
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	mitogen-activated protein kinase 1	Homo sapiens	89-92
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	149-153
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	AKT serine/threonine kinase 1	Homo sapiens	242-245
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	mitogen-activated protein kinase 1	Homo sapiens	247-250
19180880-0	2008	Effects of rapamycin on intracellular cholesterol homeostasis of glomerular mesangial cell in the presence of interleukin-1 beta.	Sirolimus	11-20	interleukin 1 beta	Homo sapiens	110-128
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	interleukin 1 beta	Homo sapiens	28-46
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	interleukin 1 beta	Homo sapiens	48-57
19180880-4	2008	Transient expressions of 3 types of mammalian target of rapamycin (mTOR), including mTOR-WT (wild type), mTOR-RR (rapamycin resistant, with kinase activity), and mTOR-RR-KD (rapamycin resistant, without kinase activity), were obtained by plasmid transfection.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	67-71
19180880-5	2008	RESULTS: Rapamycin had no significant influence on intracellular cholesterol concentration under normal condition, but it significantly decreased the intracellular cholesterol concentration in the presence of IL-1 beta.	Sirolimus	9-18	interleukin 1 beta	Homo sapiens	209-218
19180880-6	2008	Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	82-91
19180880-6	2008	Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	154-163
19020771-11	2008	RPMs also lack phagocytosis-induced inhibition of TNF-alpha release after LPS stimulation.	Sirolimus	0-4	tumor necrosis factor	Homo sapiens	50-59
19020771-14	2008	Differential MAPK activation may play a role in the enhanced LPS responsiveness of RPM and the lack of MFG-E8 impedes post-phagocytic suppression of LPS-response through the inhibition of those signaling pathways.	Sirolimus	83-86	mitogen-activated protein kinase 3	Homo sapiens	13-17
19018001-4	2008	We found that rapamycin, which blocks mTORC1 and mTORC2 signaling, inhibited sCD40L-mediated transactivation of VEGF.	Sirolimus	14-23	vascular endothelial growth factor A	Homo sapiens	112-116
19020722-10	2008	Rapamycin treatment revealed a reduction of p-mTOR and p-4E-BP1 but increased p-AKT levels.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
19100909-7	2008	Mammalian TORC1 (mTORC1) is rapamycin sensitive and contains mTOR, raptor, and mLST8.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	17-21
18776922-3	2008	Here, we show that rapamycin treatment stimulated androgen receptor (AR) transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgen-independent prostate cancer cells, to growth inhibition by rapamycin.	Sirolimus	19-28	androgen receptor	Homo sapiens	50-67
18776922-3	2008	Here, we show that rapamycin treatment stimulated androgen receptor (AR) transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgen-independent prostate cancer cells, to growth inhibition by rapamycin.	Sirolimus	19-28	androgen receptor	Homo sapiens	69-71
18776922-7	2008	The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide.	Sirolimus	14-23	androgen receptor	Homo sapiens	27-29
18776922-7	2008	The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	122-125
18776922-7	2008	The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide.	Sirolimus	178-187	androgen receptor	Homo sapiens	27-29
18812319-2	2008	mTOR forms two functionally distinct complexes, termed the mTOR complex 1 (mTORC1) and 2 (mTORC2); only the former of which is inhibited by rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	0-4
18812319-2	2008	mTOR forms two functionally distinct complexes, termed the mTOR complex 1 (mTORC1) and 2 (mTORC2); only the former of which is inhibited by rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	59-63
18651095-2	2008	TOR complex 1 (TORC1) is comprised of TOR, Raptor, and Lst8 and its activity is sensitive to inhibition by the macrolide antibiotic rapamycin.	Sirolimus	132-141	MTOR associated protein, LST8 homolog	Homo sapiens	55-59
18713735-4	2008	We further demonstrate that DeltaPsi(m) reflects the degree of overall mammalian target of rapamycin (mTOR) activation and that the mTOR inhibitor rapamycin reduces metabolic rate, augments differentiation, and inhibits tumor formation of the mouse embryonic stem cells with a high metabolic rate.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	102-106
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	AKT serine/threonine kinase 1	Homo sapiens	52-55
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19016759-5	2008	Cell proliferation tests in control cells demonstrated that the mTOR inhibitor rapamycin enhanced cell sensitivity to endocrine therapy when combined to OH-Tam or to fulvestrant.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	64-68
19016759-7	2008	Reversion of resistance by rapamycin was associated with increased ERalpha protein expression levels and modification of the balance of phospho-ser167 ERalpha/total ERalpha ratio.	Sirolimus	27-36	estrogen receptor 1	Homo sapiens	67-74
19016759-7	2008	Reversion of resistance by rapamycin was associated with increased ERalpha protein expression levels and modification of the balance of phospho-ser167 ERalpha/total ERalpha ratio.	Sirolimus	27-36	estrogen receptor 1	Homo sapiens	151-158
19016759-7	2008	Reversion of resistance by rapamycin was associated with increased ERalpha protein expression levels and modification of the balance of phospho-ser167 ERalpha/total ERalpha ratio.	Sirolimus	27-36	estrogen receptor 1	Homo sapiens	151-158
18818522-2	2008	Moreover, autophagy-inducing stimuli such as nutrient depletion, rapamycin or lithium cause the depletion of cytoplasmic p53, which in turn is required for the induction of autophagy.	Sirolimus	65-74	tumor protein p53	Homo sapiens	121-124
18806968-5	2008	Various studies provided evidence that the macrolide rapamycin decreases growth of brain and kidney tumors by specific inhibition of mTOR kinase.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	133-137
18952591-4	2008	Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left).	Sirolimus	71-80	POU class 3 homeobox 2	Homo sapiens	34-45
25983921-3	2008	Also, vascular endothelial growth factor (VEGF) staining in the biopsy samples resolved following rapamycin therapy.	Sirolimus	98-107	vascular endothelial growth factor A	Homo sapiens	6-40
25983921-3	2008	Also, vascular endothelial growth factor (VEGF) staining in the biopsy samples resolved following rapamycin therapy.	Sirolimus	98-107	vascular endothelial growth factor A	Homo sapiens	42-46
18775633-4	2008	New immunosuppressants that inhibit the m-TOR protein (sirolimus and everolimus) appear to offer promising perspectives, and patients treated with these drugs from the time of their transplantation have fewer skin cancers than patients with the standard protocols.	Sirolimus	55-64	RAR related orphan receptor C	Homo sapiens	42-45
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Sirolimus	0-9	TEK receptor tyrosine kinase	Rattus norvegicus	87-91
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Sirolimus	84-93	TEK receptor tyrosine kinase	Rattus norvegicus	174-178
18929866-12	2008	In a comparison of the control and CsA groups, mRNA expression of Ang1 was increased (P < .05), and mRNA expression of Ang2 and Tie2 was decreased (P < .05) in the rapamycin group at 8 and 12 weeks.	Sirolimus	170-179	TEK receptor tyrosine kinase	Rattus norvegicus	131-135
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	54-63	TEK receptor tyrosine kinase	Rattus norvegicus	108-112
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	167-176	TEK receptor tyrosine kinase	Rattus norvegicus	108-112
18660503-7	2008	Rapamycin decreased NGF-induced inhibition of basolateral NHE1 by 45%.	Sirolimus	0-9	nerve growth factor	Homo sapiens	20-23
18660503-7	2008	Rapamycin decreased NGF-induced inhibition of basolateral NHE1 by 45%.	Sirolimus	0-9	solute carrier family 9 member A1	Homo sapiens	58-62
18768852-6	2008	The observed impairment of skin gammadelta T cell function is directly related to the inhibitory action of rapamycin on mammalian target of rapamycin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	120-149
18722121-9	2008	CONCLUSIONS: We propose a unique mode of mTOR regulation in which RSK-mediated phosphorylation of Raptor regulates mTORC1 activity and thus suggest a means by which the Ras/MAPK pathway might promote rapamycin-sensitive signaling independently of the PI3K/Akt pathway.	Sirolimus	200-209	mechanistic target of rapamycin kinase	Homo sapiens	41-45
18722121-9	2008	CONCLUSIONS: We propose a unique mode of mTOR regulation in which RSK-mediated phosphorylation of Raptor regulates mTORC1 activity and thus suggest a means by which the Ras/MAPK pathway might promote rapamycin-sensitive signaling independently of the PI3K/Akt pathway.	Sirolimus	200-209	ribosomal protein S6 kinase A2	Homo sapiens	66-69
18722121-9	2008	CONCLUSIONS: We propose a unique mode of mTOR regulation in which RSK-mediated phosphorylation of Raptor regulates mTORC1 activity and thus suggest a means by which the Ras/MAPK pathway might promote rapamycin-sensitive signaling independently of the PI3K/Akt pathway.	Sirolimus	200-209	AKT serine/threonine kinase 1	Homo sapiens	256-259
19524688-4	2009	Rapamycin exerts its biological activity by inhibiting the serine-threonine kinase mTOR, which regulates important cellular processes such as control of cell cycle, cell size, translation initiation and transcription.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-87
19524688-5	2009	The ability of rapamycin to cause G1-cell cycle arrest, reduced cell growth and a reduced rate of proliferation has led to efforts to develop rapamycin and related mTOR inhibitors as anti-cystogenesis agents.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	164-168
19576622-7	2009	The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin.	Sirolimus	176-185	poly(ADP-ribose) polymerase 1	Homo sapiens	83-109
19576622-7	2009	The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin.	Sirolimus	176-185	poly(ADP-ribose) polymerase 1	Homo sapiens	111-115
19567519-12	2009	CONCLUSIONS: Rapamycin may provide a useful means of abrogating tumor growth and controlling hypoglycemia in malignant insulinomas by reducing the malignant beta-cell growth and proliferation as well as inhibiting insulin production.	Sirolimus	13-22	insulin	Homo sapiens	119-126
19434632-3	2009	Here we examine the therapeutic effect of rapamycin, a macrolide with anti-tumourigenic and anti-angiogenic properties, in reducing tumour incidence in a large cohort of Lkb1(+/-) mice.	Sirolimus	42-51	serine/threonine kinase 11	Mus musculus	170-174
19434632-10	2009	Overall, we demonstrated that prolonged oral administration of rapamycin from an early age is effective in lowering tumour burden in the Lkb1(+/-) mice without evident side effects.	Sirolimus	63-72	serine/threonine kinase 11	Mus musculus	137-141
19715817-0	2009	Rapamycin--rather than FK506--might promote allograft tolerance induced by CD4+CD25+ regulatory T cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	75-78
19645448-2	2009	Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	54-58
19645448-2	2009	Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	87-91
19523443-1	2009	Rapamycin is an immunosuppressive drug, which inhibits the mammalian target of rapamycin (mTOR) kinase activity inducing changes in cell proliferation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	59-88
19523443-1	2009	Rapamycin is an immunosuppressive drug, which inhibits the mammalian target of rapamycin (mTOR) kinase activity inducing changes in cell proliferation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	90-94
19523443-5	2009	PARP-1 activity was then assayed in vitro, revealing that down-regulation of cellular PAR production by rapamycin was apparently not due to competitive PARP-1 inhibition.	Sirolimus	104-113	poly(ADP-ribose) polymerase 1	Homo sapiens	0-6
19523443-7	2009	Collectively, our data suggest that inhibition of cellular PAR synthesis by rapamycin is mediated by formation of a detergent-sensitive complex in living cells, and that rapamycin may have a potential as therapeutic PARP inhibitor.	Sirolimus	76-85	poly(ADP-ribose) polymerase 1	Homo sapiens	216-220
19625624-2	2009	Rapamycin promotes feedback activation of Akt in some patients, potentially underlying clinical resistance and raising the need for alternative approaches to block mTOR signaling.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	42-45
19625624-2	2009	Rapamycin promotes feedback activation of Akt in some patients, potentially underlying clinical resistance and raising the need for alternative approaches to block mTOR signaling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	164-168
19443844-0	2009	Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	28-31
19443844-3	2009	Rapamycin (0.5 mg/kg/d) effectively inhibited mTOR and downstream S6K1 signaling and partially inhibited Akt signaling, likely through effects on TORC2.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	105-108
19443844-8	2009	Rapamycin decreased phosphorylation of both Akt and S6, suggesting that both the TORC1 and TORC2 pathways are impacted.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	44-47
19808140-2	2009	Sirolimus, the principal metabolite of temsirolimus in humans, also exhibits mTOR inhibitory activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	77-81
19351700-4	2009	The imaging utility of BRET3 at the single-cell level is demonstrated using an intramolecular sensor incorporating two mammalian target of rapamycin pathway proteins (FKBP12 and FRB) that dimerize only in the presence of rapamycin.	Sirolimus	139-148	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	167-173
19220580-9	2009	Treatment of 10-0505 tumours with sorafenib plus rapamycin resulted in growth inhibition, inhibition of vascular endothelial growth factor receptor-2 phosphorylation, increased apoptosis and completely blocked sorafenib-induced phosphorylation of mTOR targets and cyclin B1 expression.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	247-251
19321761-9	2009	Mammalian target of rapamycin (mTOR) activation in the heart, as evidenced by a marked increase in the phospho-S6 protein that was inhibited by rapamycin, was demonstrated in 12-month-old Cy/+ rats.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
19406104-5	2009	Inhibition of mTOR by rapamycin notably increased the level of phosphorylated eEF2 in infected cells.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19108833-5	2009	RESULTS: mTOR and its downstream target p70S6 kinase are phosphorylated and activated by mitogenic concentrations of oxLDL (50 microg/ml), and are involved in SMC proliferation, as assessed by the inhibitory effect of the mTOR inhibitor rapamycin.	Sirolimus	237-246	mechanistic target of rapamycin kinase	Homo sapiens	9-13
19285553-0	2009	Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression.	Sirolimus	160-169	toll-like receptor 4	Mus musculus	82-85
19285553-0	2009	Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression.	Sirolimus	160-169	toll-like receptor 4	Mus musculus	173-176
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	toll-like receptor 4	Mus musculus	28-31
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-49
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	peroxisome proliferator activated receptor alpha	Mus musculus	163-167
19535348-5	2009	Moreover, analysis of distinct hematopoietic progenitor populations revealed that rapamycin treatment inhibited the expansion potential of committed CD34(+) lineage-positive progenitors, but did not affect early hematopoietic progenitors.	Sirolimus	82-91	CD34 molecule	Homo sapiens	149-153
19286253-6	2009	Consequently, e.g. clinical trials for the treatment with rapamycin, a negative regulator of mTOR, of hamartomas in TSC have already been initiated.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	93-97
19286253-6	2009	Consequently, e.g. clinical trials for the treatment with rapamycin, a negative regulator of mTOR, of hamartomas in TSC have already been initiated.	Sirolimus	58-67	TSC complex subunit 1	Homo sapiens	116-119
19557637-4	2009	We investigated the effect of rapamycin on both P-gp function and the MDR phenotype in four cell lines.	Sirolimus	30-39	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
19410601-11	2009	However, this mechanism is not sufficient to explain the high LC3-II activation caused by dopamine: the LC3-II increase was not reversed by IGF-1, which prevented this effect when caused by the mTOR inhibitor rapamycin.	Sirolimus	209-218	mechanistic target of rapamycin kinase	Homo sapiens	194-198
19386082-0	2009	Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.	Sirolimus	65-74	RAR related orphan receptor C	Homo sapiens	49-52
19651290-7	2009	It is anticipated that the inhibition of mTOR with sirolimus can slow disease progression and delay the need for chronic renal replacement therapy.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	41-45
19651294-6	2009	In this review, we summarize the role of mTOR and its inhibitor sirolimus (SRL) on chronic hyperglycemia and insulin resistance in beta cells, adipose tissue, liver, and muscle.	Sirolimus	64-73	insulin	Homo sapiens	109-116
19553991-6	2009	Thus, genomic and genetic, biological, functional and biochemical data in yeast and humans establishes GOLPH3 as a new oncogene that is commonly targeted for amplification in human cancer, and is capable of modulating the response to rapamycin, a cancer drug in clinical use.	Sirolimus	234-243	golgi phosphoprotein 3	Homo sapiens	103-109
19478560-1	2009	Inhibition of mTOR by rapamycin prevents cellular senescence.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19494127-5	2009	Using a genome-wide protein localization study, we found that Stp1 disappeared from the nucleus upon inactivation of TOR complex 1 (TORC1) by rapamycin, suggesting the involvement of Stp1 in the TOR signaling pathway.	Sirolimus	142-151	Stp1p	Saccharomyces cerevisiae S288C	62-66
19494127-5	2009	Using a genome-wide protein localization study, we found that Stp1 disappeared from the nucleus upon inactivation of TOR complex 1 (TORC1) by rapamycin, suggesting the involvement of Stp1 in the TOR signaling pathway.	Sirolimus	142-151	Stp1p	Saccharomyces cerevisiae S288C	183-187
19494127-6	2009	Supporting this notion, a knockout mutant for the STP1 gene was found to be hypersensitive to rapamycin, and overexpression of STP1 conferred resistance to rapamycin.	Sirolimus	94-103	Stp1p	Saccharomyces cerevisiae S288C	50-54
19494127-6	2009	Supporting this notion, a knockout mutant for the STP1 gene was found to be hypersensitive to rapamycin, and overexpression of STP1 conferred resistance to rapamycin.	Sirolimus	156-165	Stp1p	Saccharomyces cerevisiae S288C	50-54
19494127-6	2009	Supporting this notion, a knockout mutant for the STP1 gene was found to be hypersensitive to rapamycin, and overexpression of STP1 conferred resistance to rapamycin.	Sirolimus	156-165	Stp1p	Saccharomyces cerevisiae S288C	127-131
19331815-5	2009	Rapamycin inhibited mTOR kinase activity as demonstrated with a lower phosphorylation level of the mTOR substrate p70 S6 kinase (S6K).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	20-24
19331815-5	2009	Rapamycin inhibited mTOR kinase activity as demonstrated with a lower phosphorylation level of the mTOR substrate p70 S6 kinase (S6K).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	99-103
19483303-1	2009	We investigated the effect of rapamycin, a specific inhibitor of the mammalian serine/threonine kinase, mammalian target of rapamycin (mTOR), on the expression of inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	104-133
19483303-1	2009	We investigated the effect of rapamycin, a specific inhibitor of the mammalian serine/threonine kinase, mammalian target of rapamycin (mTOR), on the expression of inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	135-139
19483303-1	2009	We investigated the effect of rapamycin, a specific inhibitor of the mammalian serine/threonine kinase, mammalian target of rapamycin (mTOR), on the expression of inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.	Sirolimus	30-39	nitric oxide synthase 2	Homo sapiens	163-194
19483303-1	2009	We investigated the effect of rapamycin, a specific inhibitor of the mammalian serine/threonine kinase, mammalian target of rapamycin (mTOR), on the expression of inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.	Sirolimus	30-39	nitric oxide synthase 2	Homo sapiens	196-200
19483303-4	2009	Intriguingly, LPS-induced nitrite production and iNOS protein expression were partially blocked at nanomolar concentrations of rapamycin, whereas phosphorylation of both p70 S6 kinase and 4E-BP1 was completely abolished.	Sirolimus	127-136	nitric oxide synthase 2	Homo sapiens	49-53
19483303-5	2009	The suppression of LPS-induced iNOS expression by rapamycin was reversed by the protease inhibitor lactacystin.	Sirolimus	50-59	nitric oxide synthase 2	Homo sapiens	31-35
19302070-1	2009	Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is increasingly used as an agent for post-transplant immunosuppression and the treatment of solid organ and haematological malignancies and hamartomas.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-60
19302070-1	2009	Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is increasingly used as an agent for post-transplant immunosuppression and the treatment of solid organ and haematological malignancies and hamartomas.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	62-66
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	53-62	interleukin 2	Homo sapiens	12-16
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	53-62	CD4 molecule	Homo sapiens	143-146
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	104-113	interleukin 2	Homo sapiens	12-16
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	104-113	CD4 molecule	Homo sapiens	143-146
18841360-6	2009	These results predict that Sirolimus or Sorafenib would reduce CD4(+)CD25(high) cells if administered prior to antigenic stimulation in an immunotherapy protocol.	Sirolimus	27-36	CD4 molecule	Homo sapiens	63-66
18841360-7	2009	However, administration of IL-2 protects CD4(+)CD25(high) T cells from cytotoxic effects of Sirolimus, a response that may be considered in design of therapeutic protocols.	Sirolimus	92-101	interleukin 2	Homo sapiens	27-31
18841360-7	2009	However, administration of IL-2 protects CD4(+)CD25(high) T cells from cytotoxic effects of Sirolimus, a response that may be considered in design of therapeutic protocols.	Sirolimus	92-101	CD4 molecule	Homo sapiens	41-44
19302577-3	2009	Toxoplasma invasion of multiple cell types rapidly induced sustained mTOR activation that was restricted to infected cells, as determined by rapamycin-sensitive phosphorylation of ribosomal protein S6; however, phosphorylation of the growth-associated mTOR substrates 4E-BP1 and S6K1 was not detected.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	69-73
19302577-7	2009	In spite of a failure to phosphorylate 4E-BP1 and S6K1, intracellular T. gondii triggered host cell cycle progression in an mTOR-dependent manner and progression of infected cells displayed increased sensitivity to rapamycin.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	124-128
19458076-4	2009	Here, we examined the effect of targeting mTOR by rapamycin and/or MEK by PD184352 in human glioblastoma cell lines.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	42-46
19272638-17	2009	These findings warrant further investigation and suggest a potential role for therapeutic agents targeting the PI3K-AKT-mTOR pathway, such as rapamycin, as well as possible targets of EGFR in the treatment of uterine serous carcinoma.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Homo sapiens	120-124
19424604-9	2009	In addition, the mTOR inhibitor rapamycin was found to affect the phosphorylation status of p70S6K in amniotic fluid stem cells.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	17-21
19524730-0	2009	Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma.	Sirolimus	55-64	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
19524730-3	2009	We hypothesized that the antiangiogenic effect of rapamycin may be mediated by suppression of COX-2.	Sirolimus	50-59	prostaglandin-endoperoxide synthase 2	Homo sapiens	94-99
19524730-14	2009	Cyclooxygenase 2 levels are inhibited by low-dose treatment of ES with rapamycin.	Sirolimus	71-80	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
19329430-9	2009	Furthermore, inhibition of the PI3K/Akt/mTOR pathway by rapamycin completely blocks ouabain-induced expression of Na/K-ATPase and converts ouabain-induced growth stimulation to growth inhibition in LLC-PK1 cells.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Sus scrofa	40-44
19474323-7	2009	The mTOR inhibitor rapamycin, administered before kainate, blocked both the acute and chronic phases of seizure-induced mTOR activation and decreased kainate-induced neuronal cell death, neurogenesis, mossy fiber sprouting, and the development of spontaneous epilepsy.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
19474323-7	2009	The mTOR inhibitor rapamycin, administered before kainate, blocked both the acute and chronic phases of seizure-induced mTOR activation and decreased kainate-induced neuronal cell death, neurogenesis, mossy fiber sprouting, and the development of spontaneous epilepsy.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	120-124
19147279-5	2009	We found that rapamycin treatment of Lkb1(+/-) mice initiated before the onset of polyposis in Lkb1(+/-) mice led to a dramatic reduction in both polyp burden and polyp size and this reduction was associated with decreased phosphorylation levels of S6 and 4EBP1.	Sirolimus	14-23	serine/threonine kinase 11	Mus musculus	37-41
19147279-5	2009	We found that rapamycin treatment of Lkb1(+/-) mice initiated before the onset of polyposis in Lkb1(+/-) mice led to a dramatic reduction in both polyp burden and polyp size and this reduction was associated with decreased phosphorylation levels of S6 and 4EBP1.	Sirolimus	14-23	serine/threonine kinase 11	Mus musculus	95-99
19402072-8	2009	Possible mechanisms include the loss of feedback inhibition of insulin receptor substate/PI3K signaling resulting from the inhibition of mTOR complex 1 by rapamycin analogs and the activating phosphorylation of Akt by mTOR complex 2.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	137-141
19424019-8	2009	In conclusion, lymphopenia-induced IL-7 production after induction with ATG and sirolimus might lead to emergence of IFN-gamma-secreting CD8+ T-cells responsible for acute rejection after immunosuppression withdrawal.	Sirolimus	80-89	interleukin 7	Homo sapiens	35-39
19424019-8	2009	In conclusion, lymphopenia-induced IL-7 production after induction with ATG and sirolimus might lead to emergence of IFN-gamma-secreting CD8+ T-cells responsible for acute rejection after immunosuppression withdrawal.	Sirolimus	80-89	interferon gamma	Homo sapiens	117-126
19299514-6	2009	Deletion of Sch9 reduces RNA pol III transcription in a Maf1-dependent manner, yet the cells remain susceptible to further repression by rapamycin and other treatments.	Sirolimus	137-146	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	12-16
19420259-2	2009	The TSC1/TSC2 protein complex plays a major role in controlling the Ser/Thr kinase mammalian target of rapamycin (mTOR), which is a master regulator of protein synthesis and cell growth.	Sirolimus	103-112	TSC complex subunit 1	Homo sapiens	4-8
19420259-2	2009	The TSC1/TSC2 protein complex plays a major role in controlling the Ser/Thr kinase mammalian target of rapamycin (mTOR), which is a master regulator of protein synthesis and cell growth.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	114-118
19420259-5	2009	In Tsc2-deficient neurons, the expression of stress markers such as CHOP and HO-1 is increased, and this increase is completely reversed by the mTOR inhibitor rapamycin both in vitro and in vivo.	Sirolimus	159-168	DNA damage inducible transcript 3	Homo sapiens	68-72
19395652-9	2009	Furthermore, prostate lesion growth in Pten(+/-) mice was dependent on mTOR, as evidenced by a reduction in both phospho-S6 levels and proliferative index after rapamycin treatment.	Sirolimus	161-170	phosphatase and tensin homolog	Mus musculus	39-43
19221467-7	2009	We observed a high level of autophagy activity in zebrafish embryos, which can be further upregulated by the TOR inhibitor rapamycin or the calpain inhibitor calpeptin.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Danio rerio	109-112
19285959-5	2009	We found that FGFR1 activated Akt/mTOR pathway and that the mTOR inhibitor rapamycin partially reversed FGFR1-mediated downregulation of SM marker gene expression.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	60-64
19285959-5	2009	We found that FGFR1 activated Akt/mTOR pathway and that the mTOR inhibitor rapamycin partially reversed FGFR1-mediated downregulation of SM marker gene expression.	Sirolimus	75-84	fibroblast growth factor receptor 1	Homo sapiens	104-109
19336014-2	2009	Dissection of the molecular pathways that regulate proliferation, apoptosis, and angiogenesis has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues including everolimus and temsirolimus.	Sirolimus	297-306	vascular endothelial growth factor A	Homo sapiens	225-259
19002496-9	2009	Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells.	Sirolimus	32-41	vascular endothelial growth factor A	Homo sapiens	80-84
19002496-9	2009	Quantitative RT-PCR showed that sirolimus down-regulated the mRNA expression of VEGF and HIF-1a, but not of bFGF, and TGF-b in MHCC97H cells.	Sirolimus	32-41	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-95
19002496-10	2009	Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia.	Sirolimus	50-59	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-95
19002496-10	2009	Furthermore, western blot analysis confirmed that sirolimus also decreased expression of HIF-1a at protein level, in parallel with the down-regulation of the levels of VEGF protein excretion in a time-dependent manner as compared to untreated control cells following anoxia.	Sirolimus	50-59	vascular endothelial growth factor A	Homo sapiens	168-172
19002496-11	2009	CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression.	Sirolimus	45-54	vascular endothelial growth factor A	Homo sapiens	125-129
19002496-11	2009	CONCLUSIONS: The immunosuppressive macrolide sirolimus prevents the growth and metastatic progression of HCC, and suppresses VEGF synthesis and secretion by downregulating HIF-1a expression.	Sirolimus	45-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	172-178
19384185-2	2009	Sirolimus (SRL) is a non-nephrotoxic immunosuppressive drug blocking T-cell proliferation through mTOR inhibition.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
19368729-3	2009	Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus).	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	137-141
19368729-3	2009	Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus).	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	106-135
19368729-3	2009	Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus).	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	137-141
19190264-4	2009	This effect of insulin on lipolysis was only observed when the mammalian target of rapamycin (mTOR) pathway was inhibited by rapamycin in the adipocytes.	Sirolimus	83-92	insulin	Homo sapiens	15-22
19190264-4	2009	This effect of insulin on lipolysis was only observed when the mammalian target of rapamycin (mTOR) pathway was inhibited by rapamycin in the adipocytes.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	94-98
19208097-1	2009	We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	35-39
19168580-6	2009	Furthermore, Pin1 enhanced the insulin-induced extracellular signal-regulated protein kinase (ERK)1/2 phosphorylation through its interaction with p70S6K, whereas the inhibition of p70S6K activity by rapamycin suppressed insulin-induced ERK1/2 phosphorylation in SK-HEP-1 cells.	Sirolimus	200-209	insulin	Homo sapiens	31-38
19168580-6	2009	Furthermore, Pin1 enhanced the insulin-induced extracellular signal-regulated protein kinase (ERK)1/2 phosphorylation through its interaction with p70S6K, whereas the inhibition of p70S6K activity by rapamycin suppressed insulin-induced ERK1/2 phosphorylation in SK-HEP-1 cells.	Sirolimus	200-209	insulin	Homo sapiens	221-228
19356713-5	2009	Insulin resistance induced by HF/BCAA feeding was accompanied by chronic phosphorylation of mTOR, JNK, and IRS1Ser307 and by accumulation of multiple acylcarnitines in muscle, and it was reversed by the mTOR inhibitor, rapamycin.	Sirolimus	219-228	insulin	Homo sapiens	0-7
19356713-5	2009	Insulin resistance induced by HF/BCAA feeding was accompanied by chronic phosphorylation of mTOR, JNK, and IRS1Ser307 and by accumulation of multiple acylcarnitines in muscle, and it was reversed by the mTOR inhibitor, rapamycin.	Sirolimus	219-228	AT-rich interaction domain 4B	Homo sapiens	30-37
19356713-5	2009	Insulin resistance induced by HF/BCAA feeding was accompanied by chronic phosphorylation of mTOR, JNK, and IRS1Ser307 and by accumulation of multiple acylcarnitines in muscle, and it was reversed by the mTOR inhibitor, rapamycin.	Sirolimus	219-228	mechanistic target of rapamycin kinase	Homo sapiens	203-207
19188252-8	2009	Surprisingly, rapamycin treatment prior to resistance exercise completely blocked the contraction-induced increase in the phosphorylation of ERK1/2 (Thr202/Tyr204) and blunted the increase in MNK1 (Thr197/202) phosphorylation.	Sirolimus	14-23	mitogen-activated protein kinase 3	Homo sapiens	141-147
19379572-6	2009	PCR results showed the down-regulation of mTOR, cyclin D1 and mTOR mRNA expressions after treating RPMI8226 cells with different concentrations of rapamycin for 24 hours.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	42-46
19379572-6	2009	PCR results showed the down-regulation of mTOR, cyclin D1 and mTOR mRNA expressions after treating RPMI8226 cells with different concentrations of rapamycin for 24 hours.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	62-66
19150980-3	2009	Here we find that Torin1, a highly potent and selective ATP-competitive mTOR inhibitor that directly inhibits both complexes, impairs cell growth and proliferation to a far greater degree than rapamycin.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Homo sapiens	72-76
19261747-4	2009	Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies.	Sirolimus	114-123	tumor protein p53	Homo sapiens	40-43
19261747-4	2009	Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	125-129
19276368-5	2009	A siRNA-dependent screen of these proteins showed that AKT induction by rapamycin was attenuated by depleting cellular CDC25B phosphatase.	Sirolimus	72-81	AKT serine/threonine kinase 1	Homo sapiens	55-58
19276368-5	2009	A siRNA-dependent screen of these proteins showed that AKT induction by rapamycin was attenuated by depleting cellular CDC25B phosphatase.	Sirolimus	72-81	cell division cycle 25B	Homo sapiens	119-125
19276368-6	2009	Rapamycin induces the phosphorylation of CDC25B at Serine375, and mutating this site to Alanine substantially reduced CDC25B phosphatase activity.	Sirolimus	0-9	cell division cycle 25B	Homo sapiens	41-47
19276368-6	2009	Rapamycin induces the phosphorylation of CDC25B at Serine375, and mutating this site to Alanine substantially reduced CDC25B phosphatase activity.	Sirolimus	0-9	cell division cycle 25B	Homo sapiens	118-124
19276368-7	2009	Additionally, expression of CDC25B (S375A) inhibited the AKT activation by rapamycin, indicating that phosphorylation of CDC25B is critical for CDC25B activity and its ability to transduce rapamycin-induced oncogenic AKT activity.	Sirolimus	75-84	cell division cycle 25B	Homo sapiens	28-34
19276368-7	2009	Additionally, expression of CDC25B (S375A) inhibited the AKT activation by rapamycin, indicating that phosphorylation of CDC25B is critical for CDC25B activity and its ability to transduce rapamycin-induced oncogenic AKT activity.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	57-60
19276368-7	2009	Additionally, expression of CDC25B (S375A) inhibited the AKT activation by rapamycin, indicating that phosphorylation of CDC25B is critical for CDC25B activity and its ability to transduce rapamycin-induced oncogenic AKT activity.	Sirolimus	75-84	cell division cycle 25B	Homo sapiens	121-127
19276368-7	2009	Additionally, expression of CDC25B (S375A) inhibited the AKT activation by rapamycin, indicating that phosphorylation of CDC25B is critical for CDC25B activity and its ability to transduce rapamycin-induced oncogenic AKT activity.	Sirolimus	75-84	cell division cycle 25B	Homo sapiens	121-127
19276368-7	2009	Additionally, expression of CDC25B (S375A) inhibited the AKT activation by rapamycin, indicating that phosphorylation of CDC25B is critical for CDC25B activity and its ability to transduce rapamycin-induced oncogenic AKT activity.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	217-220
19276368-9	2009	Together, using rapamycin phosphoproteomics, we not only advance the global mechanistic understanding of the action of rapamycin but also show that CDC25B may serve as a drug target for improving mTOR-targeted cancer therapies.	Sirolimus	16-25	cell division cycle 25B	Homo sapiens	148-154
19151764-0	2009	Rapamycin induces transactivation of the EGFR and increases cell survival.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	41-45
19151764-3	2009	Although mTOR inhibitor, rapamycin, has been widely used to inhibit the aberrant signaling due to mTOR activation that plays a major role in hyperproliferative diseases, in some cases rapamycin does not attenuate the cell proliferation and survival.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	9-13
19151764-3	2009	Although mTOR inhibitor, rapamycin, has been widely used to inhibit the aberrant signaling due to mTOR activation that plays a major role in hyperproliferative diseases, in some cases rapamycin does not attenuate the cell proliferation and survival.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	98-102
19151764-5	2009	Our data show that in a variety of cell types the mTOR inhibitor rapamycin activates extracellularly regulated kinases (Erk1/2) signaling.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	50-54
19151764-5	2009	Our data show that in a variety of cell types the mTOR inhibitor rapamycin activates extracellularly regulated kinases (Erk1/2) signaling.	Sirolimus	65-74	mitogen-activated protein kinase 3	Homo sapiens	120-126
19151764-6	2009	Rapamycin-mediated activation of the Erk1/2 signaling requires (a) the epidermal growth factor receptor (EGFR), (b) its tyrosine kinase activity and (c) intact autophosphorylation sites on the receptor.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	37-43
19151764-6	2009	Rapamycin-mediated activation of the Erk1/2 signaling requires (a) the epidermal growth factor receptor (EGFR), (b) its tyrosine kinase activity and (c) intact autophosphorylation sites on the receptor.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	71-103
19151764-6	2009	Rapamycin-mediated activation of the Erk1/2 signaling requires (a) the epidermal growth factor receptor (EGFR), (b) its tyrosine kinase activity and (c) intact autophosphorylation sites on the receptor.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	105-109
19151764-8	2009	We also show that rapamycin treatment triggers activation of cell survival signaling pathway by activating the prosurvival kinases Erk1/2 and p90RSK.	Sirolimus	18-27	mitogen-activated protein kinase 3	Homo sapiens	131-137
19220291-7	2009	Compared with placebo, plasma levels of interleukin-6, monocyte chemoattractant protein-1, interferon gamma, tumour necrosis factor alpha and CD40, and their mRNA levels in aortic tissue were significantly reduced in sirolimus-treated mice.	Sirolimus	217-226	interleukin 6	Mus musculus	40-53
19114562-9	2009	Data provided here demonstrate a PA requirement for the stabilization of both mTORC1 and mTORC2 complexes and reveal a mechanism for the inhibitory effect of rapamycin on mTOR.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	78-82
19114562-10	2009	This study also suggests that by suppressing PLD activity, mTORC2 could be targeted therapeutically with rapamycin.	Sirolimus	105-114	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	45-48
19190131-11	2009	CONCLUSION: These results identify HIF-1alpha as a promising target and provide a rationale for clinical trials of low-dose irinotecan and rapamycin combination toward metastatic colon cancer.	Sirolimus	139-148	hypoxia inducible factor 1 subunit alpha	Homo sapiens	35-45
19231960-7	2009	Expression of total AKT, mTOR, and p70S6K persisted after rapamycin treatment.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	20-23
19074484-5	2009	mTOR inhibition with rapamycin at below pharmacological concentrations blocked p70S6K phosphorylation and induced a differentiated contractile phenotype with smooth muscle (sm)-calponin, sm-alpha-actin, and SM protein 22-alpha (SM22alpha) expression.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	0-4
19177002-4	2009	PI-103 and the mTOR inhibitor rapamycin both inhibited ribosomal protein S6 phosphorylation but there were clear differences in the response of upstream components of the PI3 kinase pathway, such as phosphorylation of Thr(308)-AKT, that were inhibited by PI-103 but not rapamycin.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
19177002-4	2009	PI-103 and the mTOR inhibitor rapamycin both inhibited ribosomal protein S6 phosphorylation but there were clear differences in the response of upstream components of the PI3 kinase pathway, such as phosphorylation of Thr(308)-AKT, that were inhibited by PI-103 but not rapamycin.	Sirolimus	30-39	AKT serine/threonine kinase 1	Homo sapiens	227-230
19177002-4	2009	PI-103 and the mTOR inhibitor rapamycin both inhibited ribosomal protein S6 phosphorylation but there were clear differences in the response of upstream components of the PI3 kinase pathway, such as phosphorylation of Thr(308)-AKT, that were inhibited by PI-103 but not rapamycin.	Sirolimus	270-279	mechanistic target of rapamycin kinase	Homo sapiens	15-19
19125415-6	2009	Exposure of 2T3 cells to the RPM decreased bone formation responses as determined by alkaline phosphatase (ALP) activity and mineralization even in the presence of a submaximal dose of BMP4 (20 ng/ml).	Sirolimus	29-32	alkaline phosphatase, placental	Homo sapiens	85-105
19125415-6	2009	Exposure of 2T3 cells to the RPM decreased bone formation responses as determined by alkaline phosphatase (ALP) activity and mineralization even in the presence of a submaximal dose of BMP4 (20 ng/ml).	Sirolimus	29-32	alkaline phosphatase, placental	Homo sapiens	107-110
19125415-7	2009	However, LMHF mechanical loading prevented the RPM-induced decrease in ALP activity and mineralization.	Sirolimus	47-50	alkaline phosphatase, placental	Homo sapiens	71-74
19190120-8	2009	Similarly, combining a monoclonal anti-HGF antibody (L2G7) with the mTOR inhibitor rapamycin had additive inhibitory effects on glioblastoma cell proliferation.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	68-72
18927120-1	2009	BACKGROUND: The specific mTor inhibitor sirolimus has been implicated in the pathogenesis of renal glomerular lesions and nephrotic syndrome appearance after transplantation.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	25-29
18927120-5	2009	We also evidenced that vascular endothelial growth factor (VEGF) synthesis and Akt phosphorylation were decreased by sirolimus addition.	Sirolimus	117-126	vascular endothelial growth factor A	Homo sapiens	23-57
18927120-5	2009	We also evidenced that vascular endothelial growth factor (VEGF) synthesis and Akt phosphorylation were decreased by sirolimus addition.	Sirolimus	117-126	vascular endothelial growth factor A	Homo sapiens	59-63
18927120-7	2009	WT1 gene and protein expression in podocytes were decreased in a dose-dependent manner after incubation with sirolimus.	Sirolimus	109-118	WT1 transcription factor	Homo sapiens	0-3
18713146-2	2009	Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	55-59
18713146-2	2009	Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	55-59
18987252-4	2009	Inhibition of mTOR by rapamycin significantly reduced the activity of system A (-17%), system L (-28%), and taurine (-40%) amino acid transporters.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19489650-5	2009	The immunosuppressant sirolimus (rapamycin) directly inhibits mTOR activity and suppresses the growth of cancer cells in vitro and in vivo.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	62-66
19489650-5	2009	The immunosuppressant sirolimus (rapamycin) directly inhibits mTOR activity and suppresses the growth of cancer cells in vitro and in vivo.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	62-66
19117990-6	2009	Rapamycin, the pharmacologic inhibitor of mTOR, prevents TGF-beta-mediated anchorage-independent growth without affecting TGF-beta transcriptional responses or extracellular matrix protein induction.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	42-46
19117990-6	2009	Rapamycin, the pharmacologic inhibitor of mTOR, prevents TGF-beta-mediated anchorage-independent growth without affecting TGF-beta transcriptional responses or extracellular matrix protein induction.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	57-65
19139015-7	2009	Furthermore, we show that the inhibition of mTOR by the chronic administration of rapamycin halts the malignant conversion of precancerous lesions and promotes the regression of advanced carcinogen-induced SCCs.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	44-48
19705921-2	2009	In part II, we review the pharmacokinetics and therapeutic drug monitoring of mycophenolate and mammalian target of rapamycin inhibitors--sirolimus and everolimus--in thoracic transplantation, and we provide an overall discussion and suggest various areas for future study.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	96-125
19728747-14	2009	Proliferation signal inhibitors (PSIs) such as sirolimus and everolimus are substrates of CYP3A4 and P-glycoprotein and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with PSIs are comparable to those with calcineurin inhibitors.	Sirolimus	47-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
19728747-14	2009	Proliferation signal inhibitors (PSIs) such as sirolimus and everolimus are substrates of CYP3A4 and P-glycoprotein and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with PSIs are comparable to those with calcineurin inhibitors.	Sirolimus	47-56	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
19834275-6	2009	Sirolimus, an mTOR protein inhibitor, was used to treat epithelioid AML.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19436942-5	2009	Pretreatment of rapa had an inhibitory effect on the IFN-alpha-induced expression of PKR and p48 in a dose dependent manner.	Sirolimus	16-20	interferon alpha 1	Homo sapiens	53-62
19436942-5	2009	Pretreatment of rapa had an inhibitory effect on the IFN-alpha-induced expression of PKR and p48 in a dose dependent manner.	Sirolimus	16-20	interferon regulatory factor 9	Homo sapiens	93-96
19125612-6	2009	Treatment with the mTOR inhibitor rapamycin reduced the p-mTOR level by 25% after 4-24 h of incubation.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
19125612-6	2009	Treatment with the mTOR inhibitor rapamycin reduced the p-mTOR level by 25% after 4-24 h of incubation.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	58-62
19139116-3	2009	The AKT-transfected cells were more sensitive to cytostasis induced in vitro by rapamycin or in vivo by its analogue, CCI-779, whereas cells with quiescent AKT were resistant.	Sirolimus	80-89	AKT serine/threonine kinase 1	Homo sapiens	4-7
20419051-3	2009	Recent work implicates the mammalian target of rapamycin (mTOR) pathway as mediating epileptogenesis in a genetic epilepsy, Tuberous Sclerosis Complex (TSC), and suggests that mTOR inhibitors, such as rapamycin, may have antiepileptogenic properties for epilepsy in TSC.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	58-62
20419051-3	2009	Recent work implicates the mammalian target of rapamycin (mTOR) pathway as mediating epileptogenesis in a genetic epilepsy, Tuberous Sclerosis Complex (TSC), and suggests that mTOR inhibitors, such as rapamycin, may have antiepileptogenic properties for epilepsy in TSC.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	176-180
20419051-5	2009	Here, we describe evidence from a recently-published study that mTOR mediates epileptogenesis in a popular animal model of acquired limbic epilepsy due to brain injury following kainate-induced status epilepticus, and that rapamycin has antiepileptogenic effects in this model.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	64-68
19225562-11	2009	This exploratory approach generated lists of therapeutics that may have specific antagonistic activity against tumors of African-American patients, e.g., sirolimus, resveratrol, and chlorpromazine in estrogen receptor-negative tumors.	Sirolimus	154-163	estrogen receptor 1	Homo sapiens	200-217
19149738-3	2009	Currently, the mTOR inhibitor rapamycin and its analogs have been vigorously evaluated and developed as anticancer drugs.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
19249569-9	2009	CD4(+)CD25(+)FoxP3(+) Treg cells were increased up to 2 times in the presence of rapamycin versus without rapamycin in vitro.	Sirolimus	81-90	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Papio anubis	0-3
19249569-9	2009	CD4(+)CD25(+)FoxP3(+) Treg cells were increased up to 2 times in the presence of rapamycin versus without rapamycin in vitro.	Sirolimus	106-115	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Papio anubis	0-3
20641681-8	2004	For example, PAI-2 (triciribine) and perifosine are potent and selective inhibitors of Akt, rapamycin is an inhibitor for downstream mTOR, and LY294002 is an inhibitor for upstream PI3K.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	133-137
18945681-5	2008	mTOR exists in two complexes, mTORC1 and mTORC2, which are differentially sensitive to rapamycin.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	0-4
18945681-6	2008	We report here that although there are clear differences in the sensitivity of HIF1 alpha and HIF2 alpha to rapamycin, both HIF1 alpha and HIF2 alpha expression is dependent on mTOR.	Sirolimus	108-117	hypoxia inducible factor 1 subunit alpha	Homo sapiens	79-89
19001324-2	2008	Sirolimus, an mTOR inhibitor, also has activity in the treatment and prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
19061837-5	2008	Given that rapamycin alone is mainly cytostatic, this constitutes a strategy for cancer therapy that selectively eradicates cancer cells via Akt activation.	Sirolimus	11-20	AKT serine/threonine kinase 1	Homo sapiens	141-144
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	Sirolimus	19-28	mitogen-activated protein kinase kinase 7	Homo sapiens	140-143
18981735-7	2008	The combination of rapamycin with the MEK inhibitor U0126 significantly enhanced growth inhibitory effects of cancer cells, suggesting that MEK/ERK activation may counteract mTOR inhibitors" anticancer efficacy.	Sirolimus	19-28	mitogen-activated protein kinase 1	Homo sapiens	144-147
18930332-9	2008	Rapamycin inhibits phosphorylation of p70 S6 kinase and 4E-BP-1, downstream targets of mTOR, and decreases VEGF.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	87-91
18930332-9	2008	Rapamycin inhibits phosphorylation of p70 S6 kinase and 4E-BP-1, downstream targets of mTOR, and decreases VEGF.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	107-111
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	cyclin D1	Rattus norvegicus	179-188
18784743-2	2008	Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27(kip1) and downregulation of c-Myc.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	39-43
18776922-7	2008	The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide.	Sirolimus	178-187	AKT serine/threonine kinase 1	Homo sapiens	122-125
18511708-5	2008	In a majority of tumors (67%; 10 of 15), apoptotic resistance could be reduced by more than 50% by rapamycin, an mTOR inhibitor, but not by LY294002, a PI3K inhibitor.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	113-117
18511708-6	2008	Responsiveness to rapamycin correlated with staining for the mTOR target, p-S6K, in the original tumor, but not for p-Akt.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	61-65
18790727-2	2008	We tested whether sirolimus, an immunosuppressive agent that inhibits mTOR, a protein that regulates cell division and differentiation, might modify cardiac hypertrophy after cardiac transplantation.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	70-74
18790727-8	2008	The number of cells in myocardial biopsies positive for p27Kip1, a protein induced by mTOR inhibition, increased in sirolimus-treated subjects (P = 0.0005) and did not change in controls (P = 0.54) suggesting sirolimus acted directly on myocardium.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	86-90
18652845-7	2008	Functionally, RAPA-treated DC used as stimulators in a DC-T cell mixed lymphocyte reaction (MLR) showed 40% inhibition of T cell proliferation relative to untreated DC (P=0.001) whereas CsA-treated DC showed no difference, and IFN-alpha-treated DC stimulated T cell proliferation.	Sirolimus	14-18	interferon alpha 1	Homo sapiens	227-236
18848473-3	2008	Inhibition of mTOR by rapamycin promoted production of proinflammatory cytokines via the transcription factor NF-kappaB but blocked the release of interleukin-10 via the transcription factor STAT3.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
18848473-3	2008	Inhibition of mTOR by rapamycin promoted production of proinflammatory cytokines via the transcription factor NF-kappaB but blocked the release of interleukin-10 via the transcription factor STAT3.	Sirolimus	22-31	nuclear factor kappa B subunit 1	Homo sapiens	110-119
18922908-1	2008	Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal transplant rejection, has recently emerged as an effective treatment for Kaposi"s sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	60-89
18922908-1	2008	Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal transplant rejection, has recently emerged as an effective treatment for Kaposi"s sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	91-95
18922908-1	2008	Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal transplant rejection, has recently emerged as an effective treatment for Kaposi"s sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	60-89
18922908-1	2008	Rapamycin (or sirolimus), the prototypical inhibitor of the mammalian target of rapamycin (mTOR) and an immunosuppressant used for the prevention of renal transplant rejection, has recently emerged as an effective treatment for Kaposi"s sarcoma (KS), an enigmatic vascular tumor and a model for pathologic angiogenesis.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	91-95
18832563-4	2008	Infusion of PI3K inhibitors (wortmannin and LY294002) and an mTOR inhibitor (rapamycin) into the mPFC in vivo suppressed HFS-induced LTP as well as the phosphorylation of PI3K/Akt-mTOR signaling pathway.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	61-65
18832563-4	2008	Infusion of PI3K inhibitors (wortmannin and LY294002) and an mTOR inhibitor (rapamycin) into the mPFC in vivo suppressed HFS-induced LTP as well as the phosphorylation of PI3K/Akt-mTOR signaling pathway.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	176-179
18832563-4	2008	Infusion of PI3K inhibitors (wortmannin and LY294002) and an mTOR inhibitor (rapamycin) into the mPFC in vivo suppressed HFS-induced LTP as well as the phosphorylation of PI3K/Akt-mTOR signaling pathway.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	180-184
18682538-2	2008	To elucidate the molecular mechanism by which leucine stimulates protein synthesis in neonatal muscle, overnight-fasted 7-day-old piglets were treated with rapamycin [an inhibitor of mammalian target of rapamycin (mTOR) complex (mTORC)1] for 1 h and then infused with leucine for 1 h. Fractional rates of protein synthesis and activation of signaling components that lead to mRNA translation were determined in skeletal muscle.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	183-212
18682538-5	2008	Rapamycin blocked the leucine-induced phosphorylation of mTOR, S6 kinase 1 (S6K1), and eukaryotic initiation factor (eIF)4E-binding protein-1 (4E-BP1) and formation of the eIF4E.eIF4G complex and increased eIF4E.4E-BP1 complex abundance.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Sus scrofa	57-61
18838865-4	2008	Chemical inducers of autophagy (including rapamycin, lithium, tunicamycin and ABT737) induced rapid depletion of the p53 protein.	Sirolimus	42-51	tumor protein p53	Homo sapiens	117-120
18614546-0	2008	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Sirolimus	81-90	MAPK associated protein 1	Homo sapiens	173-177
18614546-6	2008	We describe that in primary cells short-term treatment with rapamycin triggers dephosphorylation of rictor and sin1 exclusively in the cytoplasm, but does not affect mTORC2 assembly.	Sirolimus	60-69	MAPK associated protein 1	Homo sapiens	111-115
18614546-10	2008	Our data allow new insights into the molecular consequences of mTOR dysregulation under pathophysiological conditions and should help to optimize rapamycin treatment of human diseases.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	63-67
18565131-9	2008	The phosphatidylinositol 3"-kinase (PI3K) inhibitor, LY294002, and the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exerted an inhibitory effect on the thrombin-induced OPG synthesis.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	102-106
18678646-6	2008	Treatment of both primary cells and cancer cell lines with rapamycin, metformin, and pyrvinium resulted in an increase in p73 levels, as did RNA interference-mediated knockdown of mTOR.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	180-184
18658177-2	2008	However, a series of adverse events has been reported with the first-generation mTOR inhibitor sirolimus that includes hypersensitivity-like interstitial pneumonitis.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
18640276-7	2008	In addition, as a chemical compound, rapamycin caused an increase of bcl2 protein level and blocked the release of cytochrome c from mitochondria to cytosal.	Sirolimus	37-46	BCL2, apoptosis regulator	Rattus norvegicus	69-73
19176057-2	2008	METHODS: The expression of the downstream effector proteins of mTOR were analyzed by Western blot before and after Karpas299, BaF3/NPM-ALK and BaF3 cell lines treated with rapamycin.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	63-67
18660503-9	2008	p70 S6 kinase activation was blocked by wortmannin and rapamycin, consistent with PI3K, mTOR, and p70 S6 kinase in a linear pathway.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	88-92
18922461-2	2008	(2008) demonstrate that fatty acid biosynthesis, under the transcriptional control of SREBP1, is regulated by the rapamycin-sensitive mTOR signaling network, thus expanding the scope of biosynthetic processes integrated by mTOR.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	134-138
18922461-2	2008	(2008) demonstrate that fatty acid biosynthesis, under the transcriptional control of SREBP1, is regulated by the rapamycin-sensitive mTOR signaling network, thus expanding the scope of biosynthetic processes integrated by mTOR.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	223-227
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	169-173
18787170-4	2008	Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Sirolimus	89-98	F-box and WD repeat domain containing 7	Homo sapiens	53-58
18787170-4	2008	Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Sirolimus	89-98	F-box and WD repeat domain containing 7	Homo sapiens	138-143
18787170-4	2008	Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	229-233
18588872-7	2008	Combination of honokiol with the mTOR inhibitor rapamycin presented synergistic effects on induction of apoptosis of breast cancer cells.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	33-37
18602894-5	2008	Rapamycin can cause hyperlipidaemia clinically, and we hypothesised that this may be mediated via an effect of mTOR on SREBP-2.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	111-115
18602894-5	2008	Rapamycin can cause hyperlipidaemia clinically, and we hypothesised that this may be mediated via an effect of mTOR on SREBP-2.	Sirolimus	0-9	sterol regulatory element binding transcription factor 2	Homo sapiens	119-126
18703055-5	2008	Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	56-60
18650261-8	2008	These increases in glucose uptake and GLUT1 levels were prevented by inhibition of mTOR with rapamycin.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	83-87
18757421-0	2008	Chemoprevention and treatment of experimental Cowden"s disease by mTOR inhibition with rapamycin.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	66-70
18762023-4	2008	Furthermore, nuclear accumulation of the mature form of the sterol responsive element binding protein (SREBP1) and expression of SREBP target genes was blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	184-193	Sterol regulatory element binding protein	Drosophila melanogaster	103-108
18559659-0	2008	Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	64-67
18559659-2	2008	Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance.	Sirolimus	0-9	CD4 molecule	Homo sapiens	72-75
18559659-7	2008	However, nTregs isolated from type 1 diabetic patients under rapamycin treatment had an increased capability to suppress proliferation of CD4(+)CD25(-) effector T-cells compared with that before treatment.	Sirolimus	61-70	CD4 molecule	Homo sapiens	138-141
18445640-9	2008	Rapamycin treatment also significantly reduced the amount of immune complex deposition in the glomeruli, suppressed the interstitial infiltration by T-cells, B-cells and macrophages as well as down-regulated the intra-renal expression of RANTES.	Sirolimus	0-9	chemokine (C-C motif) ligand 5	Mus musculus	238-244
18704194-7	2008	Treatment with rapamycin caused feedback activation of AKT in WT cell lines but not PI3K-deficient lines.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	55-58
18725989-3	2008	We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model.	Sirolimus	46-55	mitogen-activated protein kinase 1	Mus musculus	162-165
18598780-1	2008	The signalling components upstream and downstream of the protein kinase mammalian target of rapamycin (mTOR) are frequently altered in a wide variety of human diseases.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	103-107
18445640-10	2008	CONCLUSIONS: We conclude that rapamycin is effective in attenuating the severity of established nephritis in NZB/W F(1) mice.	Sirolimus	30-39	TP53 regulated inhibitor of apoptosis 1	Mus musculus	113-119
18504440-4	2008	We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells.	Sirolimus	14-23	insulin like growth factor 1	Homo sapiens	69-74
18562319-7	2008	Importantly, knockdown of hnRNP A1 also renders quiescent Akt-containing cells sensitive to rapamycin-induced G(1) arrest.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	58-61
18724224-0	2008	Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium.	Sirolimus	61-70	erythropoietin	Homo sapiens	13-27
18394010-8	2008	Rapamycin, while effective in decreasing HIF1alpha protein levels, did not affect HIF2alpha levels in either of the RCC cell lines.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	41-50
18586400-2	2008	By using calcium imaging and patch-clamping techniques to study the role of this signaling pathway in the activity of cultured hippocampal neurons, we found that rapamycin significantly reduces the spontaneous activities of network neurons as well as the efficacy of synaptic transmission through insulin-mTOR signaling pathway.	Sirolimus	162-171	insulin	Homo sapiens	297-304
18586400-2	2008	By using calcium imaging and patch-clamping techniques to study the role of this signaling pathway in the activity of cultured hippocampal neurons, we found that rapamycin significantly reduces the spontaneous activities of network neurons as well as the efficacy of synaptic transmission through insulin-mTOR signaling pathway.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Homo sapiens	305-309
18710627-4	2008	Defects in TGF-beta signaling are common in human cancer, and ironically, cancer cells with defective TGF-beta signaling that do not arrest in G1, instead undergo apoptosis when treated with rapamycin.	Sirolimus	191-200	transforming growth factor beta 1	Homo sapiens	11-19
18710627-4	2008	Defects in TGF-beta signaling are common in human cancer, and ironically, cancer cells with defective TGF-beta signaling that do not arrest in G1, instead undergo apoptosis when treated with rapamycin.	Sirolimus	191-200	transforming growth factor beta 1	Homo sapiens	102-110
18926092-3	2008	Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	23-27
18926092-3	2008	Commercially available mTOR inhibitors include rapamycin (i.e., sirolimus) and temsirolimus.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	23-27
18594209-0	2008	Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	78-81
18594209-0	2008	Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	109-113
18594209-1	2008	Increased Akt phosphorylation was reported in cancer cell lines and tumor tissues of patients exposed to rapamycin, a response likely contributing to the attenuated antitumor activity of rapamycin.	Sirolimus	105-114	AKT serine/threonine kinase 1	Homo sapiens	10-13
18594209-1	2008	Increased Akt phosphorylation was reported in cancer cell lines and tumor tissues of patients exposed to rapamycin, a response likely contributing to the attenuated antitumor activity of rapamycin.	Sirolimus	187-196	AKT serine/threonine kinase 1	Homo sapiens	10-13
18594209-3	2008	We now report that Akt activation in response to rapamycin is abrogated by 17-allylamino-17-demethoxygeldanamycin (17-AAG), a heat shock protein 90 (HSP90) inhibitor.	Sirolimus	49-58	AKT serine/threonine kinase 1	Homo sapiens	19-22
18604159-6	2008	Several distinct autophagy inducers (e.g., starvation, rapamycin, lithium, tunicamycin and thapsigargin) stimulate the rapid degradation of p53.	Sirolimus	55-64	tumor protein p53	Homo sapiens	140-143
18754885-1	2008	Cotylenin A, a plant growth regulator, and rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), are potent inducers of differentiation of myeloid leukemia cells.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	70-99
18547304-0	2008	The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
18547304-7	2008	Immunosuppressive treatment with rapamycin, a specific mTOR inhibitor, initiated because of renal transplantation, reduced facial angiofibroma dramatically.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	55-59
18754885-1	2008	Cotylenin A, a plant growth regulator, and rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), are potent inducers of differentiation of myeloid leukemia cells.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	101-105
18666033-3	2008	The calcineurin inhibitors cyclosporin A and FK-506, the Tor inhibitor rapamycin, and the Hsp90 inhibitor geldanamycin, all act via targets conserved from yeast to humans.	Sirolimus	71-80	RAR related orphan receptor C	Homo sapiens	57-60
18264722-4	2008	Herein, we show that IRS-1 antisense oligonucleotide and rapamycin synergistically antagonize the activation of mTOR in vivo and induced tumor suppression, through inhibition of proliferation and induction of apoptosis, in prostate cancer cell xenografts.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	112-116
18480312-4	2008	When rapamycin was started on the day of immunization (group 1), mice were protected from glomerulonephritis, suggested by a dramatic decrease in albuminuria, influx of inflammatory cells, and Th1-cytokine expression in the kidneys.	Sirolimus	5-14	negative elongation factor complex member C/D, Th1l	Mus musculus	193-196
18480312-7	2008	A significant decrease in vascular endothelial growth factor-A and an increase in IL-6 were detected in kidneys of these rapamycin-treated mice.	Sirolimus	121-130	interleukin 6	Mus musculus	82-86
18492954-3	2008	Rapamycin, an inhibitor of mTOR, enhanced IL-12 production in LPS-stimulated DCs, whereas the activation of mTOR by lentivirus-mediated transduction of a constitutively active form of Rheb suppressed the production of IL-12.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
18559329-0	2008	Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus-eluting and bare-metal stents.	Sirolimus	144-153	vascular endothelial growth factor A	Homo sapiens	0-34
18348264-6	2008	Carbachol-evoked S6 phosphorylation was blocked by the mTOR inhibitor rapamycin, but was independent of phosphoinositide 3-kinase activation.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	55-59
18323781-5	2008	Similar results were obtained with combinations of the MEK inhibitors U0126 (30 microM) or PD98059 (50 microM) with rapamycin (10 nM).	Sirolimus	116-125	mitogen-activated protein kinase kinase 7	Homo sapiens	55-58
18323781-2	2008	Herein, we examined whether targeting the RAS-RAF-MEK-ERK pathway with the RAF inhibitor sorafenib and/or the PI3K-AKT-mTOR pathway with the mTOR inhibitor rapamycin has therapeutic effects against melanoma.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	141-145
18652687-5	2008	These profiles were further correlated with gene expression alterations caused by inhibition of PI3K/mTOR pathway with PI3K inhibitor Ly294002 or mTOR inhibitor rapamycin.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Homo sapiens	101-105
18474542-3	2008	An in vitro study has revealed that mTOR is activated in oesophageal squamous cell carcinoma (OSCC) cell lines and that mTOR expression is inhibited by rapamycin.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	120-124
18652687-5	2008	These profiles were further correlated with gene expression alterations caused by inhibition of PI3K/mTOR pathway with PI3K inhibitor Ly294002 or mTOR inhibitor rapamycin.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Homo sapiens	146-150
18596167-4	2008	Even after macroautophagy is strongly induced by suppressing mTOR (mammalian target of rapamycin) kinase activity with rapamycin or nutrient deprivation, active cathepsin-positive autolysosomes rather than LC3-II-positive autophagosomes predominate, implying efficient autophagosome clearance in healthy neurons.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	61-65
18587048-10	2008	The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells.	Sirolimus	108-117	regulatory associated protein of MTOR, complex 1	Mus musculus	80-86
18622277-9	2008	Tumor necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1beta production from the impure sirolimus group significantly decreased (P<0.05).	Sirolimus	149-158	tumor necrosis factor	Homo sapiens	0-27
18622277-9	2008	Tumor necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1beta production from the impure sirolimus group significantly decreased (P<0.05).	Sirolimus	149-158	interleukin 1 beta	Homo sapiens	29-46
18622277-10	2008	Furthermore, tumor necrosis factor-alpha and macrophage inflammatory protein-1beta production from sorted ductal cells significantly decreased in the sirolimus group (P<0.05).	Sirolimus	150-159	tumor necrosis factor	Homo sapiens	13-40
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Sirolimus	191-200	ATP binding cassette subfamily B member 1	Homo sapiens	105-119
18715846-1	2008	Preclinical studies using human gastric adenocarcinoma (GAC) cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, can inhibit tumor growth and that the extracellular signal-regulated kinase (ERK) of the Ras/Raf kinase/ERK pathway is related to chemoresistance and apoptosis.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	123-127
18715846-1	2008	Preclinical studies using human gastric adenocarcinoma (GAC) cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, can inhibit tumor growth and that the extracellular signal-regulated kinase (ERK) of the Ras/Raf kinase/ERK pathway is related to chemoresistance and apoptosis.	Sirolimus	112-121	mitogen-activated protein kinase 1	Homo sapiens	189-226
18398293-6	2008	Knocking down Beclin 1 markedly decreased the mitochondrial translocation of EGFR that was induced by rapamycin.	Sirolimus	102-111	epidermal growth factor receptor	Homo sapiens	77-81
18454167-3	2008	Angiogenesis and VEGF are thought to play a crucial role in fracture healing and as osteoporotic and traumatic fractures are common complications in immunosuppressed, organ transplantation patients, we conducted this study to analyze the effect of rapamycin treatment on bone repair.	Sirolimus	248-257	vascular endothelial growth factor A	Homo sapiens	17-21
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Sirolimus	191-200	ATP binding cassette subfamily B member 1	Homo sapiens	126-131
17912526-13	2008	CONCLUSION: Our results show that rapamycin displays antiproliferative effects and induces apoptosis in HNSCC cell lines, cellular effects being more potent in cells that do not express BCL2 and MDR1.	Sirolimus	34-43	ATP binding cassette subfamily B member 1	Homo sapiens	195-199
18587045-4	2008	Mammalian target of rapamycin inhibition with sirolimus or everolimus results in attenuation of cyst formation in rat and mouse models of polycystic kidney disease.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	0-29
18418733-0	2008	Rapamycin conditionally inhibits Hsp90 but not Hsp70 mRNA translation in Drosophila: implications for the mechanisms of Hsp mRNA translation.	Sirolimus	0-9	Heat shock protein 83	Drosophila melanogaster	33-38
18418733-4	2008	Intriguingly, during heat shock Hsp90 mRNA becomes significantly less sensitive to rapamycin-mediated inhibition, suggesting the pathway for Hsp90 mRNA translation is altered during heat shock.	Sirolimus	83-92	Heat shock protein 83	Drosophila melanogaster	32-37
18418733-4	2008	Intriguingly, during heat shock Hsp90 mRNA becomes significantly less sensitive to rapamycin-mediated inhibition, suggesting the pathway for Hsp90 mRNA translation is altered during heat shock.	Sirolimus	83-92	Heat shock protein 83	Drosophila melanogaster	141-146
18418733-5	2008	Reporter mRNAs containing the Hsp90 or Hsp70 mRNAs" 5" untranslated region recapitulate these rapamycin-dependent translational characteristics, indicating this region regulates rapamycin-dependent translational sensitivity as well as heat shock preferential translation.	Sirolimus	94-103	Heat shock protein 83	Drosophila melanogaster	30-35
18644990-4	2008	However, rapamycin also inhibits S6K phosphorylation, leading to feedback loop activation of Akt.	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	93-96
18490075-7	2008	Reductions in tumor growth by bevacizumab plus rapamycin were associated with inhibition of downstream targets of the mammalian target-of-rapamycin pathway, reductions in vascular endothelial growth factor expression, and tumor microvessel density.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	118-147
18490075-7	2008	Reductions in tumor growth by bevacizumab plus rapamycin were associated with inhibition of downstream targets of the mammalian target-of-rapamycin pathway, reductions in vascular endothelial growth factor expression, and tumor microvessel density.	Sirolimus	47-56	vascular endothelial growth factor A	Homo sapiens	171-205
18490075-8	2008	Potentially additive effects of bevacizumab plus rapamycin included reductions in vascular endothelial growth factor expression, cyclin D1, and cyclin B1.	Sirolimus	49-58	vascular endothelial growth factor A	Homo sapiens	82-116
18566370-3	2008	We report that in vitro and in vivo conditioning of murine myeloid DC with RAPA elicits the de novo production of IL-1beta by otherwise phenotypically immature DC.	Sirolimus	75-79	interleukin 1 beta	Mus musculus	114-122
18513215-5	2008	Treatment of yeast cells with the specific TORC1 inhibitor rapamycin or caffeine releases Rim15 from TORC1-Sch9-mediated inhibition and consequently increases lifespan.	Sirolimus	59-68	protein kinase RIM15	Saccharomyces cerevisiae S288C	90-95
18513215-5	2008	Treatment of yeast cells with the specific TORC1 inhibitor rapamycin or caffeine releases Rim15 from TORC1-Sch9-mediated inhibition and consequently increases lifespan.	Sirolimus	59-68	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	107-111
18278068-6	2008	MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor.	Sirolimus	155-164	vascular endothelial growth factor A	Homo sapiens	33-37
18675098-1	2008	Sirolimus (SRL) is an mTOR inhibitor that has been shown, in contrast to calcineurin inhibitors (CNI), to inhibit cancers in experimental models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	22-26
18612547-7	2008	Inhibition of this pathway with the specific mTOR inhibitor, rapamycin, markedly decreased cell migration induced by formation of TF-FVIIa-FXa complex.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	45-49
18278068-6	2008	MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	169-173
18559511-4	2008	An increase in PP2A activity or treatment with rapamycin leads to cytosolic retention of GLI3 and, consequently, reduced transcription of the GLI3 target gene and cell cycle regulator, cyclin D1.	Sirolimus	47-56	GLI family zinc finger 3	Homo sapiens	89-93
18448283-10	2008	CONCLUSIONS: The increase in CETP activity and suppression in LPL activity following CsA and RAPA treatment observed in the present study may be associated with elevated LDL cholesterol levels and hypertriglyceridemia seen in patients administered these drugs.	Sirolimus	93-97	cholesteryl ester transfer protein	Homo sapiens	29-33
18570671-0	2008	Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.	Sirolimus	0-9	Wnt family member 1	Homo sapiens	27-32
18570671-5	2008	RESULTS: Rapamycin induced severe immunosuppression and significantly delayed the growth of Wnt-1 tumors.	Sirolimus	9-18	Wnt family member 1	Homo sapiens	92-97
18448283-0	2008	Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma.	Sirolimus	19-28	cholesteryl ester transfer protein	Homo sapiens	45-79
18448283-7	2008	RESULTS: We found an increase in CETP activity in human normolipidemic plasma and rCETP treated with CsA and RAPA.	Sirolimus	109-113	cholesteryl ester transfer protein	Homo sapiens	33-37
18570873-3	2008	Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	9-13
18570873-3	2008	Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA.	Sirolimus	172-181	zinc ribbon domain containing 2	Homo sapiens	105-108
18559511-4	2008	An increase in PP2A activity or treatment with rapamycin leads to cytosolic retention of GLI3 and, consequently, reduced transcription of the GLI3 target gene and cell cycle regulator, cyclin D1.	Sirolimus	47-56	GLI family zinc finger 3	Homo sapiens	142-146
18458675-3	2008	Because temsirolimus and its primary metabolite, sirolimus, are metabolised by the cytochrome P450 3A4 pathway (CYP3A4), the potential exists for pharmacokinetic (PK) drug interactions with the numerous agents that modulate CYP3A4 isozyme activity.	Sirolimus	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-102
18458675-3	2008	Because temsirolimus and its primary metabolite, sirolimus, are metabolised by the cytochrome P450 3A4 pathway (CYP3A4), the potential exists for pharmacokinetic (PK) drug interactions with the numerous agents that modulate CYP3A4 isozyme activity.	Sirolimus	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
18458675-3	2008	Because temsirolimus and its primary metabolite, sirolimus, are metabolised by the cytochrome P450 3A4 pathway (CYP3A4), the potential exists for pharmacokinetic (PK) drug interactions with the numerous agents that modulate CYP3A4 isozyme activity.	Sirolimus	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	224-230
18283037-9	2008	The mTOR inhibitor rapamycin was found to supraadditively increase lapatinib efficacy in MCF-7/HER2 cells [ approximately 10-fold enhancement; combination index (CI(50)) = 0.243 < 1.0 = additivity, P < 0.001] but not in p70S6K1 gene-amplified MCF-7 parental cells ( approximately 1.3-fold enhancement; CI(50) = 0.920 congruent with 1.0 = additivity).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
18283037-11	2008	Rapamycin cotreatment suppressed p70S6K1 hyperactivation and synergistically resensitized MCF-7/HER2-Lap10 cells to lapatinib (>20-fold increase in lapatinib-induced cytotoxicity; CI(50) = 0.175 < 1.0 = additivity).	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100
18283037-9	2008	The mTOR inhibitor rapamycin was found to supraadditively increase lapatinib efficacy in MCF-7/HER2 cells [ approximately 10-fold enhancement; combination index (CI(50)) = 0.243 < 1.0 = additivity, P < 0.001] but not in p70S6K1 gene-amplified MCF-7 parental cells ( approximately 1.3-fold enhancement; CI(50) = 0.920 congruent with 1.0 = additivity).	Sirolimus	19-28	erb-b2 receptor tyrosine kinase 2	Homo sapiens	95-99
18283037-14	2008	Rapamycin analogues such as CCI-779 (Temsirolimus) and RAD001 (Everolimus) may warrant further clinical evaluation to effectively delay or prevent the development of acquired resistance to lapatinib in HER2-positive breast cancer patients.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	202-206
18519793-7	2008	Treatment with rapamycin resulted in inhibition of the downstream signals of the mTOR pathway and increased phosphorylation of Akt in C2 cells, whereas the constitutively activated Akt in PC3 cells was not modulated.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	81-85
17950843-7	2008	Under these conditions FK506, which displaces FKBP12 (to inhibit calcineurin) and rapamycin, which displaces FKBP12 (to inhibit mTOR), each increased the [Ca(2+)](c) rise evoked by caffeine.	Sirolimus	82-91	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	109-115
17950843-7	2008	Under these conditions FK506, which displaces FKBP12 (to inhibit calcineurin) and rapamycin, which displaces FKBP12 (to inhibit mTOR), each increased the [Ca(2+)](c) rise evoked by caffeine.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	128-132
18250144-4	2008	After a 24 h-incubation, rapamycin (100 nM) caused a significant cell loss associated with the increase of both apoptosis and necrosis, as quantified by propidium iodide staining, caspase 3 activity, and lactate dehydrogenase release.	Sirolimus	25-34	caspase 3	Homo sapiens	180-189
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	55-84
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	96-100
18519793-7	2008	Treatment with rapamycin resulted in inhibition of the downstream signals of the mTOR pathway and increased phosphorylation of Akt in C2 cells, whereas the constitutively activated Akt in PC3 cells was not modulated.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	127-130
18519793-8	2008	LBH589 decreased both constitutively expressed and rapamycin-induced phosphorylated Akt levels in PC3 and C2 cell lines.	Sirolimus	51-60	AKT serine/threonine kinase 1	Homo sapiens	84-87
18519641-7	2008	The results provide insight into the effects of Akt/mTOR-dependent signaling on gene expression and into the therapeutic action of rapamycin.	Sirolimus	131-140	AKT serine/threonine kinase 1	Homo sapiens	48-51
18443272-14	2008	The latter was sensitive to the mTOR inhibitor, rapamycin.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	32-36
18313267-6	2008	Addition of rapamycin to cultures containing IL-2 further increased the frequency and absolute number of functional CD4(+)CD25(+)FOXP3(+) Treg.	Sirolimus	12-21	interleukin 2	Homo sapiens	45-49
18313267-6	2008	Addition of rapamycin to cultures containing IL-2 further increased the frequency and absolute number of functional CD4(+)CD25(+)FOXP3(+) Treg.	Sirolimus	12-21	CD4 molecule	Homo sapiens	116-119
18519641-7	2008	The results provide insight into the effects of Akt/mTOR-dependent signaling on gene expression and into the therapeutic action of rapamycin.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	52-56
18431361-6	2008	When the cells were implanted into athymic mice that had been rendered diabetic with streptozotocin (STZ), insulin was detected in the plasma within 1 hour after addition of rapamycin.	Sirolimus	174-183	insulin	Homo sapiens	107-114
18058806-2	2008	We investigated the expression of activated Akt (p-Akt) and mTOR (p-mTOR) in patients with adenocarcinoma of the cervix and the involvement of the p-Akt/p-mTOR pathway in response to combination of inhibitor agents, rapamycin and LY294002, with conventional therapy, cisplatin, in vitro.	Sirolimus	216-225	AKT serine/threonine kinase 1	Homo sapiens	44-47
18431361-3	2008	Lentiviral vectors have been engineered to produce a fusion protein between the furin-cleavable proinsulin and the self-dimerization mutant of FK506-binding protein to yield bioactive insulin in keratinocytes; this insulin is released as a response to exogenous administration of a small organic molecule, rapamycin.	Sirolimus	306-315	insulin	Homo sapiens	184-191
18282244-0	2008	Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
18312854-5	2008	We corroborated these results demonstrating that long-term exposure to rapamycin also inhibited ERK pathway activation in response to MHC class I signaling.	Sirolimus	71-80	mitogen-activated protein kinase 1	Homo sapiens	96-99
18495876-9	2008	Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d. In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.	Sirolimus	30-39	thymoma viral proto-oncogene 1	Mus musculus	319-322
18495876-9	2008	Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d. In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.	Sirolimus	177-186	thymoma viral proto-oncogene 1	Mus musculus	319-322
18339627-4	2008	Inhibitors of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, particularly rapamycin, blocked much of the acquired resistance of the spheroids, suggesting a key role for mTOR.	Sirolimus	72-81	AKT serine/threonine kinase 1	Homo sapiens	48-51
18339627-4	2008	Inhibitors of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, particularly rapamycin, blocked much of the acquired resistance of the spheroids, suggesting a key role for mTOR.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	83-87
18375114-7	2008	Furthermore, mTOR inhibitor rapamycin not only drastically inhibited migration and MMP production, but also induced type II programmed cell death, autophagic cell death.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
18630505-5	2008	Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin).	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	117-121
18630505-5	2008	Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin).	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	123-152
18451215-9	2008	In contrast, although rapamycin inhibited mTOR signaling, it did not relieve phosphorylation of TSC2 at S939.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	42-46
18451215-12	2008	However, whereas rapamycin and its analogues may be efficacious at inhibiting mTOR activity, these drugs do not reverse the functional inactivation of TSC2 that occurs in these tumors.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	78-82
18483275-7	2008	Treatment with the mTOR inhibitor rapamycin effectively sensitizes established cancers to adoptive immunotherapy in vivo.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
18303120-6	2008	Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.	Sirolimus	15-24	insulin	Homo sapiens	163-170
18303120-6	2008	Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	204-207
18303120-6	2008	Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.	Sirolimus	15-24	insulin	Homo sapiens	222-229
18418060-5	2008	We found that rapamycin inhibits the aggregation of a fragment of huntingtin (exon 1) containing 97 polyQs similarly in macroautophagy-proficient (Atg5(+/+)) and macroautophagy-deficient (Atg5(-/-)) cells.	Sirolimus	14-23	autophagy related 5	Homo sapiens	147-151
18418060-5	2008	We found that rapamycin inhibits the aggregation of a fragment of huntingtin (exon 1) containing 97 polyQs similarly in macroautophagy-proficient (Atg5(+/+)) and macroautophagy-deficient (Atg5(-/-)) cells.	Sirolimus	14-23	autophagy related 5	Homo sapiens	188-192
18471048-9	2008	Moreover, a series of new drugs, such as geldanamycin and rapamycin, directly modify the expression of AKT in tumoral cells.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	103-106
18425342-9	2008	Both rapamycin and Ly294002 enhanced cisplatin-induced acti-vation of ERK1/2.	Sirolimus	5-14	mitogen-activated protein kinase 3	Homo sapiens	70-76
18424697-1	2008	Addition of rapamycin to cultures of expanding natural CD4+CD25+Foxp3+ T regulatory cells (Tregs) helps maintain their suppressive activity, but the underlying mechanism is unclear.	Sirolimus	12-21	CD4 molecule	Homo sapiens	55-58
18398477-6	2008	We then showed with electromyographic studies that the mTOR inhibitor rapamycin reduced the sensitivity of a population of myelinated nociceptors known to be important for the increased mechanical sensitivity that follows injury.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	55-59
18033679-11	2008	Inhibition of mTOR by rapamycin abolished the protein synthesis and cell proliferation stimulated by both IGF-1 and leucine.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
18033679-11	2008	Inhibition of mTOR by rapamycin abolished the protein synthesis and cell proliferation stimulated by both IGF-1 and leucine.	Sirolimus	22-31	insulin like growth factor 1	Homo sapiens	106-111
18343502-0	2008	Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation.	Sirolimus	0-9	interleukin 6	Homo sapiens	36-40
18343502-7	2008	Furthermore, disruption of NF-kappaB pathway contributes to the inhibition of TLR4-induced IL-6, PGE(2) production and invasion by rapamycin in colon cancer cells.	Sirolimus	131-140	interleukin 6	Homo sapiens	91-95
18391949-2	2008	Autophagy induction with the mTOR inhibitor rapamycin accelerates clearance of these toxic substrates.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18026138-2	2008	In this study we investigated the phosphorylation status of key proteins in the PI3K/AKT/mTOR pathway and the effects of the mTOR inhibitors rapamycin and CCI-779 on neuroblastoma tumorigenesis.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	125-129
18389497-11	2008	Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1(GFAP)CKO mice.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	68-97
18350576-1	2008	OBJECTIVE: Genetic loss of TSC1/TSC2 function in tuberous sclerosis complex (TSC) results in overactivation of the mammalian target of rapamycin complex 1 pathway, leading to cellular dysplasia.	Sirolimus	135-144	TSC complex subunit 1	Homo sapiens	27-31
18350576-1	2008	OBJECTIVE: Genetic loss of TSC1/TSC2 function in tuberous sclerosis complex (TSC) results in overactivation of the mammalian target of rapamycin complex 1 pathway, leading to cellular dysplasia.	Sirolimus	135-144	TSC complex subunit 1	Homo sapiens	27-30
18389497-11	2008	Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1(GFAP)CKO mice.	Sirolimus	17-26	TSC complex subunit 1	Homo sapiens	179-183
18079107-0	2008	Rapamycin modulates the eNOS vs. shear stress relationship.	Sirolimus	0-9	nitric oxide synthase 3	Homo sapiens	24-28
18079107-2	2008	We evaluated in this study whether rapamycin affects endothelial nitric oxide synthase (eNOS) responsiveness to shear stress under normo- and hypercholesteraemic conditions to explain these findings.	Sirolimus	35-44	nitric oxide synthase 3	Homo sapiens	53-86
18079107-2	2008	We evaluated in this study whether rapamycin affects endothelial nitric oxide synthase (eNOS) responsiveness to shear stress under normo- and hypercholesteraemic conditions to explain these findings.	Sirolimus	35-44	nitric oxide synthase 3	Homo sapiens	88-92
18079107-8	2008	In control carotid arteries, eNOS expression increased by 1.8 +/- 0.3-fold in response to rapamycin.	Sirolimus	90-99	nitric oxide synthase 3	Homo sapiens	29-33
18336469-12	2008	In addition, hypoxia-induced increase of cell-cycle regulatory protein expression and [(3)H]-thymidine incorporation were attenuated by LY294002 (PI3K inhibitor, 10(-6) M), Akt inhibitor (10(-6) M), rapamycin (mTOR inhibitor, 10(-9) M), PD98059 (p44/42 inhibitor, 10(-5) M), and SB203580 (p38 MAPK inhibitor, 10(-6) M).	Sirolimus	199-208	thymoma viral proto-oncogene 1	Mus musculus	173-176
18174523-11	2008	Rapamycin increased the stress-responsive c-Jun NH(2)-terminal kinase pathway in muscle and islets, which could account for its effect on insulin resistance and beta-cell apoptosis.	Sirolimus	0-9	insulin	Homo sapiens	138-145
18381446-4	2008	To determine whether mTOR is involved in 6-TG-induced autophagy, we used rapamycin, a potential anticancer agent, to inhibit mTOR activity.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	125-129
18381446-7	2008	Furthermore, we show that inhibition of mTOR by rapamycin induces the activation of Akt as shown by increased Akt phosphorylation at Ser(473) and the inhibition of 6-TG-induced apoptosis and cell death.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	40-44
18381446-7	2008	Furthermore, we show that inhibition of mTOR by rapamycin induces the activation of Akt as shown by increased Akt phosphorylation at Ser(473) and the inhibition of 6-TG-induced apoptosis and cell death.	Sirolimus	48-57	AKT serine/threonine kinase 1	Homo sapiens	84-87
18381446-7	2008	Furthermore, we show that inhibition of mTOR by rapamycin induces the activation of Akt as shown by increased Akt phosphorylation at Ser(473) and the inhibition of 6-TG-induced apoptosis and cell death.	Sirolimus	48-57	AKT serine/threonine kinase 1	Homo sapiens	110-113
18174523-0	2008	mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
18174523-3	2008	We tested this hypothesis in the Psammomys obesus (P. obesus) model of nutrition-dependent type 2 diabetes, using the mTOR inhibitor rapamycin.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	118-122
18174523-12	2008	Moreover, glucose-stimulated insulin secretion and biosynthesis were impaired in islets treated with rapamycin.	Sirolimus	101-110	insulin	Homo sapiens	29-36
18174523-13	2008	CONCLUSIONS: Rapamycin induces fulminant diabetes by increasing insulin resistance and reducing beta-cell function and mass.	Sirolimus	13-22	insulin	Homo sapiens	64-71
18372239-2	2008	Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the FGF-2-stimulated IL-6 synthesis in a dose-dependent manner.	Sirolimus	0-9	interleukin 6	Mus musculus	86-90
18261725-0	2008	Long-term effects of rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity.	Sirolimus	21-30	AKT serine/threonine kinase 1	Homo sapiens	80-87
18261725-2	2008	Rapamycin is an inhibitor of mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	128-131
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	132-135
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	247-251
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	252-261
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	247-250
18261725-3	2008	The objective of this study was to investigate the effects of rapamycin pretreatment on the insulin mediated phosphorylation of Akt/PKB phosphorylation and GS activity in parental HepG2 and HepG2 cells with overexpression of constitutively active Akt1/PKB-alpha (HepG2-CA-Akt/PKB).	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	252-255
18261725-4	2008	Rapamycin pretreatment resulted in a decrease (20-30%) in the insulin mediated phosphorylation of Akt1 (Ser 473) in parental HepG2 cells but showed an upregulation of phosphorylation in HepG2-CA-Akt/PKB cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	98-102
18261725-4	2008	Rapamycin pretreatment resulted in a decrease (20-30%) in the insulin mediated phosphorylation of Akt1 (Ser 473) in parental HepG2 cells but showed an upregulation of phosphorylation in HepG2-CA-Akt/PKB cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	98-101
18261725-4	2008	Rapamycin pretreatment resulted in a decrease (20-30%) in the insulin mediated phosphorylation of Akt1 (Ser 473) in parental HepG2 cells but showed an upregulation of phosphorylation in HepG2-CA-Akt/PKB cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	199-202
18261725-6	2008	Furthermore, rictor knockdown decreased the phosphorylation of Akt (Ser 473) by 40-60% upon rapamycin pretreatment.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	63-66
18261725-7	2008	GS activity followed similar trends as that of phosphorylated Akt and so with rictor levels in these cells pretreated with rapamycin; parental HepG2 cells showed a decrease in GS activity, whereas as HepG2-CA-Akt/PKB cells showed an increase in GS activity.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	62-65
18261725-7	2008	GS activity followed similar trends as that of phosphorylated Akt and so with rictor levels in these cells pretreated with rapamycin; parental HepG2 cells showed a decrease in GS activity, whereas as HepG2-CA-Akt/PKB cells showed an increase in GS activity.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	209-212
18261725-7	2008	GS activity followed similar trends as that of phosphorylated Akt and so with rictor levels in these cells pretreated with rapamycin; parental HepG2 cells showed a decrease in GS activity, whereas as HepG2-CA-Akt/PKB cells showed an increase in GS activity.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	213-216
17998426-5	2008	Interactions of mTOR with regulatory-associated protein of TOR or rapamycin-insensitive companion of mTOR result in 2 mTOR complexes, with the former (mTOR complex-1) being the primary controller of cell growth and the latter (mTOR complex-2) mediating effects that are insensitive to rapamycin, such as cytoskeletal organization.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	16-20
17645504-13	2008	In the following study, we indicated that hypoxia-inducible factor (HIF)-1alpha inhibitor, rapamycin, could possibly prevent VM and phenotype transformation of SKOV3ip, reflected by down-regulating expression of CD31 and Factor VIII.	Sirolimus	91-100	hypoxia inducible factor 1 subunit alpha	Homo sapiens	42-79
18490844-8	2008	In refed rats, PTB level in the cytoplasmic fraction returned to a level comparable to that in fed rats, but was inhibited by treatment with rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	154-183
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	99-102
18354181-6	2008	In parallel, although rapamycin had no effect on FcepsilonRI-mediated degranulation or Kit-mediated cell adhesion, it inhibited cytokine production, and kit-mediated chemotaxis and cell survival.	Sirolimus	22-31	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	153-156
18182482-7	2008	Sirolimus (rapamycin) had no effect on NCX2 and NCX3 protein expression, yet it reduced NCX2 and NCX3 transport activity.	Sirolimus	0-9	solute carrier family 8 member A3	Homo sapiens	97-101
18182482-7	2008	Sirolimus (rapamycin) had no effect on NCX2 and NCX3 protein expression, yet it reduced NCX2 and NCX3 transport activity.	Sirolimus	11-20	solute carrier family 8 member A3	Homo sapiens	97-101
18021293-8	2008	Treatment with rapamycin, an mTOR inhibitor, blocked Cd-induced phosphorylation of S6K1 and eukaryotic initiation factor 4E binding protein 1, and markedly inhibited Cd-induced apoptosis.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18490844-8	2008	In refed rats, PTB level in the cytoplasmic fraction returned to a level comparable to that in fed rats, but was inhibited by treatment with rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	185-189
17635004-0	2008	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	33-37
18413412-2	2008	The aim of this study was to determine the effect of rapamycin treatment on the development of nephritis in lupus-prone New Zealand Black/White F1 (NZB/W F1) mice.	Sirolimus	53-62	TP53 regulated inhibitor of apoptosis 1	Mus musculus	124-156
18631865-1	2008	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	100-129
18631865-1	2008	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	131-135
18339874-5	2008	Rapamycin repressed mTOR activity and concomitantly resulted in the activation of Akt, which could attenuate the therapeutic effects of mTOR inhibitors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	20-24
17647224-7	2008	Unlike free rapamycin that has shown little if any effect on the expression of maturation markers in immature DCs, PLGA encapsulated rapamycin decreased the expression of all maturation markers under the study, that is, MHC class II, CD86, and CD40, significantly.	Sirolimus	133-142	CD86 antigen	Mus musculus	234-238
18339874-5	2008	Rapamycin repressed mTOR activity and concomitantly resulted in the activation of Akt, which could attenuate the therapeutic effects of mTOR inhibitors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	136-140
18339874-5	2008	Rapamycin repressed mTOR activity and concomitantly resulted in the activation of Akt, which could attenuate the therapeutic effects of mTOR inhibitors.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	82-85
18310292-5	2008	In carcinoid cell lines BON-1 and NCI-H727, cell proliferation was significantly inhibited by rapamycin in vitro, although rapamycin treatment did lead to Akt phosphorylation.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	155-158
18191814-4	2008	By contrast, gefitinib inhibited in a fast and completely way p-EGFR and partially p-Akt while a 3 days-rapamycin exposure resulted in the inhibition of the expression of both mTor and p70S6K.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	176-180
18344684-0	2008	A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	29-33
18305085-0	2008	Vascular endothelial growth factor protein levels and gene expression in peripheral monocytes after stenting: a randomized comparative study of sirolimus: eluting and bare metal stents.	Sirolimus	144-153	vascular endothelial growth factor A	Homo sapiens	0-34
18305085-2	2008	We assessed VEGF serum protein levels and gene expression in peripheral monocytes in relation to in-stent restenosis after implantation of sirolimus-eluting (SES) and bare metal stents (BMS) in a non-blinded, randomized study.	Sirolimus	139-148	vascular endothelial growth factor A	Homo sapiens	12-16
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	74-78
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	cyclin dependent kinase inhibitor 2A	Homo sapiens	251-254
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	cyclin dependent kinase inhibitor 2A	Homo sapiens	255-260
18075305-4	2008	Rapamycin (a specific Mtor inhibitor) could lead to G(1) arrest of many malignant cell lines, and currently analogs of rapamycin are being investigated as a cancer chemotherapeutic adjuvant.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	22-26
18075305-4	2008	Rapamycin (a specific Mtor inhibitor) could lead to G(1) arrest of many malignant cell lines, and currently analogs of rapamycin are being investigated as a cancer chemotherapeutic adjuvant.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	22-26
18075305-7	2008	Further study showed rapamycin plus 5-Fu-induced senescence-like growth arrest was accompanied by down-regulation of AP-1 and NF kappa B transcription activity.	Sirolimus	21-30	nuclear factor kappa B subunit 1	Homo sapiens	126-136
18075305-8	2008	These results suggest that inhibitors of mTOR may have anticancer potential when used together with some other chemotherapeutic agents, and that down-regulation of AP-1 and NF kappa B transcription activity might take part in a senescence-like growth arrest program induced by rapamycin plus 5-Fu.	Sirolimus	277-286	mechanistic target of rapamycin kinase	Homo sapiens	41-45
18075305-8	2008	These results suggest that inhibitors of mTOR may have anticancer potential when used together with some other chemotherapeutic agents, and that down-regulation of AP-1 and NF kappa B transcription activity might take part in a senescence-like growth arrest program induced by rapamycin plus 5-Fu.	Sirolimus	277-286	nuclear factor kappa B subunit 1	Homo sapiens	173-183
18310292-10	2008	In conclusion, rapamycin causes significant growth inhibition in carcinoid tumor cell lines in vitro and in vivo, thus mTOR is a promising therapeutic target for neuroendocrine tumors.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	119-123
18320068-0	2008	FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway.	Sirolimus	69-78	nuclear factor kappa B subunit 1	Homo sapiens	103-112
18199797-1	2008	The immunosuppressive agent sirolimus exerts an antiproliferative effect by inhibiting mammalian target of rapamycin (mTOR).	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	87-116
18199797-1	2008	The immunosuppressive agent sirolimus exerts an antiproliferative effect by inhibiting mammalian target of rapamycin (mTOR).	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	118-122
18199797-8	2008	In summary, treatment with sirolimus was associated with decreased polycystic liver volume, perhaps by preventing aberrant activation of mTOR in epithelial cells lining the cysts.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	137-141
18060476-5	2008	Furthermore, rapamycin, a specific inhibitor of mTOR, blocked the activation of mTOR/p70S6K but not PI3K/Akt.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	48-52
18060476-5	2008	Furthermore, rapamycin, a specific inhibitor of mTOR, blocked the activation of mTOR/p70S6K but not PI3K/Akt.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	80-84
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	ubiquitin-protein ligase RMD5	Saccharomyces cerevisiae S288C	60-64
18320068-9	2008	In addition, FKBP5 overexpression in rapamycin-sensitive U87 cells blocked the cells" response to rapamycin treatment, whereas rapamycin-resistant glioma cells, both PTEN-positive and -negative, were synergistically sensitive to rapamycin after FKBP5 was knocked down, suggesting that the FKBP5 regulates glioma cell response to rapamycin treatment.	Sirolimus	37-46	FKBP prolyl isomerase 5	Homo sapiens	13-18
18320068-9	2008	In addition, FKBP5 overexpression in rapamycin-sensitive U87 cells blocked the cells" response to rapamycin treatment, whereas rapamycin-resistant glioma cells, both PTEN-positive and -negative, were synergistically sensitive to rapamycin after FKBP5 was knocked down, suggesting that the FKBP5 regulates glioma cell response to rapamycin treatment.	Sirolimus	98-107	FKBP prolyl isomerase 5	Homo sapiens	13-18
18320068-9	2008	In addition, FKBP5 overexpression in rapamycin-sensitive U87 cells blocked the cells" response to rapamycin treatment, whereas rapamycin-resistant glioma cells, both PTEN-positive and -negative, were synergistically sensitive to rapamycin after FKBP5 was knocked down, suggesting that the FKBP5 regulates glioma cell response to rapamycin treatment.	Sirolimus	98-107	FKBP prolyl isomerase 5	Homo sapiens	13-18
18025151-6	2008	Rapamycin inhibited mTORC1 signaling and suppressed CTCL cell proliferation but showed little effect on their apoptotic rate when used as a single agent.	Sirolimus	0-9	TSPY like 2	Homo sapiens	52-56
18374093-6	2008	Rapamycin treatment of islets resulted in reduced phosphorylation of p70s6k, a downstream effector molecule of mTOR and increased ERK1/2 phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	111-115
18374093-6	2008	Rapamycin treatment of islets resulted in reduced phosphorylation of p70s6k, a downstream effector molecule of mTOR and increased ERK1/2 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	130-136
17971516-11	2008	Rapamycin inhibited TNF-alpha-induced phosphorylation of the mTOR C1 target p70(S6K) without altering TNF-alpha-induced PS and 4E-BP1 phosphorylation.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	20-29
18250445-6	2008	Long-term pretreatment with the mTOR inhibitor rapamycin significantly blocked both mTOR-raptor and mTOR-rictor complex formation.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	32-36
18250445-6	2008	Long-term pretreatment with the mTOR inhibitor rapamycin significantly blocked both mTOR-raptor and mTOR-rictor complex formation.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	84-88
18250445-6	2008	Long-term pretreatment with the mTOR inhibitor rapamycin significantly blocked both mTOR-raptor and mTOR-rictor complex formation.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	84-88
18250445-7	2008	Interestingly, rapamycin also blocked class I-induced Akt phosphorylation at Ser(473) and Bcl-2 expression.	Sirolimus	15-24	BCL2 apoptosis regulator	Homo sapiens	90-95
17700525-9	2008	Importantly, this study provides evidence indicating that tumors with defective TGF-beta signaling--common in colon and pancreatic cancers--will be selectively sensitive to rapamycin or other strategies that target mTOR.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	215-219
17719815-8	2008	The IGFBP-3-promoted apoptosis in the presence of IFN-gamma could also be abrogated by blockade of the mTOR pathway with its pharmacological inhibitors, LY294002 or rapamycin.	Sirolimus	165-174	interferon gamma	Homo sapiens	50-59
18094032-7	2008	The course of chronic anti-thy1-induced glomerulosclerosis was significantly attenuated by low-dose rapamycin treatment.	Sirolimus	100-109	Thy-1 cell surface antigen	Rattus norvegicus	27-31
18094032-10	2008	In conclusion, low-dose mTOR inhibition by rapamycin limits the progressive course of anti-thy1-induced renal disease toward chronic glomerulosclerosis, tubulointerstitial fibrosis, and renal insufficiency.	Sirolimus	43-52	Thy-1 cell surface antigen	Rattus norvegicus	91-95
18068336-6	2008	mTOR inhibitor rapamycin and a dominant negative mutant of mTOR suppressed TGFbeta-induced phosphorylation of S6 kinase and 4EBP-1.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
18068336-6	2008	mTOR inhibitor rapamycin and a dominant negative mutant of mTOR suppressed TGFbeta-induced phosphorylation of S6 kinase and 4EBP-1.	Sirolimus	15-24	transforming growth factor beta 1	Homo sapiens	75-82
17719815-8	2008	The IGFBP-3-promoted apoptosis in the presence of IFN-gamma could also be abrogated by blockade of the mTOR pathway with its pharmacological inhibitors, LY294002 or rapamycin.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	103-107
18056704-6	2008	Rapamycin did not block maximal phosphorylation of Tyr(204) but retarded the rate of dephosphorylation of Tyr(204) following IGF-I stimulation.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	125-130
18307022-0	2008	Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
18056704-9	2008	Rapamycin-induced inhibition of p44/42 (Thr(202)) phosphorylation by IGF-I was reversed by low concentrations of okadaic acid, suggesting involvement of protein phosphatase 2A (PP2A).	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	69-74
18056704-11	2008	Whereas low concentrations of rapamycin (1 ng/ml) inhibited dissociation of PP2Ac after IGF-I stimulation, it required higher concentrations (> or =100 ng/ml) to block EGF-induced dissociation, consistent with the ability for rapamycin to attenuate growth factor-induced activation of p44/42.	Sirolimus	30-39	insulin like growth factor 1	Homo sapiens	88-93
18240926-8	2008	Cell lines with serial mutations, including activation of Ras and Akt pathways, also demonstrated increased levels of ARF4L protein, which decreased after treatment with rapamycin.	Sirolimus	170-179	AKT serine/threonine kinase 1	Homo sapiens	66-69
18245339-5	2008	We identified critically important cellular functions: (i) amino acid biosynthesis, (ii) microautophagy and sorting of amino acid permease established by the exit from rapamycin-induced growth arrest/Gap1 sorting in the endosome (EGO/GSE) complex, (iii) mitochondrial functions, (iv) membrane trafficking, (v) actin organization mediated by Drs2-Cdc50, and (vi) transcription regulated by the Ccr4-Not complex.	Sirolimus	168-177	amino acid permease GAP1	Saccharomyces cerevisiae S288C	200-204
18245339-5	2008	We identified critically important cellular functions: (i) amino acid biosynthesis, (ii) microautophagy and sorting of amino acid permease established by the exit from rapamycin-induced growth arrest/Gap1 sorting in the endosome (EGO/GSE) complex, (iii) mitochondrial functions, (iv) membrane trafficking, (v) actin organization mediated by Drs2-Cdc50, and (vi) transcription regulated by the Ccr4-Not complex.	Sirolimus	168-177	aminophospholipid translocase regulatory protein CDC50	Saccharomyces cerevisiae S288C	346-351
19099956-0	2008	[Effects of mTOR inhibitor rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3].	Sirolimus	27-36	SMAD family member 3	Rattus norvegicus	40-46
17989712-9	2008	Rapamycin reportedly inhibits degradation of the CDK inhibitor p27 with concomitant downregulation of cyclin D3, implying a proliferative advantage for CDK6 overexpression.	Sirolimus	0-9	dynactin subunit 6	Homo sapiens	63-66
17989712-9	2008	Rapamycin reportedly inhibits degradation of the CDK inhibitor p27 with concomitant downregulation of cyclin D3, implying a proliferative advantage for CDK6 overexpression.	Sirolimus	0-9	cyclin D3	Homo sapiens	102-111
17989712-9	2008	Rapamycin reportedly inhibits degradation of the CDK inhibitor p27 with concomitant downregulation of cyclin D3, implying a proliferative advantage for CDK6 overexpression.	Sirolimus	0-9	cyclin dependent kinase 6	Homo sapiens	152-156
18305058-2	2008	Currently, the mTOR inhibitor rapamycin and its analogues (CCI-779, RAD001, AP23573), which induce cell-cycle arrest in the G(1) phase, are being evaluated in cancer clinical trials.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
18039669-9	2008	In addition, rapamycin inhibited leptin-induced adipose differentiation-related protein accumulation in macrophages and lipid body-dependent leukotriene synthesis, demonstrating a key role for mTOR in lipid body biogenesis and function.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	193-197
17921520-2	2008	Aggregate-prone proteins are cleared by macroautophagy, and upregulating this process by rapamycin, which inhibits the mammalian target of rapamycin (mTOR), attenuates their toxicity in various HD models.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	119-148
17942753-6	2008	Pim 2-deficient B cells are readily protected from death by BLyS stimulation, but this protection is completely abrogated by treatment with the mTOR inhibitor rapamycin.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Homo sapiens	144-148
17921520-2	2008	Aggregate-prone proteins are cleared by macroautophagy, and upregulating this process by rapamycin, which inhibits the mammalian target of rapamycin (mTOR), attenuates their toxicity in various HD models.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	150-154
17921520-6	2008	In order to counteract the autophagy inhibitory effects of mTOR activation resulting from lithium treatment, we have used the mTOR inhibitor rapamycin in combination with lithium.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	59-63
17921520-6	2008	In order to counteract the autophagy inhibitory effects of mTOR activation resulting from lithium treatment, we have used the mTOR inhibitor rapamycin in combination with lithium.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	126-130
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	59-68	interleukin 6	Homo sapiens	13-17
17993646-4	2008	Here we show that rapamycin, the inhibitor of mTOR signaling, rescues insulin signaling and glycogen synthesis from IL-6 inhibition in HepG2 hepatocarcinoma cells as well as in mouse primary hepatocytes.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	46-50
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	124-133	interleukin 6	Homo sapiens	13-17
17993646-4	2008	Here we show that rapamycin, the inhibitor of mTOR signaling, rescues insulin signaling and glycogen synthesis from IL-6 inhibition in HepG2 hepatocarcinoma cells as well as in mouse primary hepatocytes.	Sirolimus	18-27	insulin	Homo sapiens	70-77
17993646-4	2008	Here we show that rapamycin, the inhibitor of mTOR signaling, rescues insulin signaling and glycogen synthesis from IL-6 inhibition in HepG2 hepatocarcinoma cells as well as in mouse primary hepatocytes.	Sirolimus	18-27	interleukin 6	Homo sapiens	116-120
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	124-133	insulin	Homo sapiens	145-152
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	124-133	interleukin 6	Homo sapiens	184-188
17955327-5	2008	Pre-treatment of cardiocytes with the mTOR inhibitor rapamycin blocked the agonist-induced rpL32 mRNA mobilization to polysomes.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	38-42
18184959-2	2008	The drug sirolimus suppresses mTOR signaling.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	30-34
18980674-1	2008	INTRODUCTION: Treatment with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be efficacious in the MRL/lpr and NZB x NZW F1 mouse models of lupus nephritis, indicating a critical role for the mTOR pathway in both models.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	42-71
18980674-1	2008	INTRODUCTION: Treatment with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be efficacious in the MRL/lpr and NZB x NZW F1 mouse models of lupus nephritis, indicating a critical role for the mTOR pathway in both models.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	73-77
17955327-5	2008	Pre-treatment of cardiocytes with the mTOR inhibitor rapamycin blocked the agonist-induced rpL32 mRNA mobilization to polysomes.	Sirolimus	53-62	ribosomal protein L32	Homo sapiens	91-96
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	insulin	Homo sapiens	98-105
17941052-0	2008	Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.	Sirolimus	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	21-26
17941052-0	2008	Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.	Sirolimus	62-71	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37
17941052-1	2008	The objective of this study was to investigate the possible association of the ABCB1 gene C3435 T polymorphism and the CYP3A5 gene A6986G polymorphism with sirolimus (SRL) trough concentration and dose requirements in Chinese stable renal transplant recipients.	Sirolimus	156-165	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	119-125
17941052-5	2008	The SRL concentration/dose ratio (C/D) in patients with CYP3A5 (*)3/(*)3 were significantly higher than that of those with (*)1 allele (p<0.05).	Sirolimus	4-7	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	56-62
18370442-1	2008	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents the over expression of angiogenic growth factors.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	81-110
18370442-1	2008	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents the over expression of angiogenic growth factors.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	81-110
18209481-6	2008	Rapamycin and dibutyryl-cAMP, which inhibited basal signaling via mammalian target of rapamycin (mTOR), restored insulin-induced PKB- but not IRbeta phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	66-95
18209481-6	2008	Rapamycin and dibutyryl-cAMP, which inhibited basal signaling via mammalian target of rapamycin (mTOR), restored insulin-induced PKB- but not IRbeta phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	97-101
18721002-3	2008	Cinacalcet, as well as some immunosuppressants such as ciclosporin, tacrolimus and sirolimus, is partially metabolized by the cytochrome P450 3A enzymes (CYP3A).	Sirolimus	83-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-159
18173550-8	2008	Moreover, rapamycin inhibited the growth of Ba/F3 cells exhibiting various imatinib-resistant mutants of BCR/ABL, including the T315I variant that exhibits resistance against most currently available BCR/ABL kinase inhibitors.	Sirolimus	10-19	BCR activator of RhoGEF and GTPase	Mus musculus	105-112
18173550-8	2008	Moreover, rapamycin inhibited the growth of Ba/F3 cells exhibiting various imatinib-resistant mutants of BCR/ABL, including the T315I variant that exhibits resistance against most currently available BCR/ABL kinase inhibitors.	Sirolimus	10-19	BCR activator of RhoGEF and GTPase	Mus musculus	105-108
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	insulin like growth factor 1	Homo sapiens	110-115
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	insulin	Homo sapiens	209-216
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	insulin like growth factor 1	Homo sapiens	269-274
18094094-7	2008	The observation that the TSC1/TSC2 functions as a negative regulator of the mammalian target of rapamycin (mTOR)/p70 S6 kinase (S6K1) signaling pathway yielded the first rapamycin clinical trial for LAM.	Sirolimus	96-105	TSC complex subunit 1	Homo sapiens	25-29
18556237-5	2008	Stimulation of eIF2Bepsilon translation was reversed by pre-treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	96-105	eukaryotic translation initiation factor 2B subunit epsilon	Homo sapiens	15-27
18564143-12	2008	Phospo-Akt and p70S6 kinase protein levels were increased in the mesenteric tissue of PPVL(placebo) mice compared to Sham(placebo) mice, which were also prevented by treatment with rapamycin.	Sirolimus	181-190	thymoma viral proto-oncogene 1	Mus musculus	7-10
18776537-20	2008	The latter is a downstream kinase of rapamycin and its phosphorylation is inhibited by rapamycin, an mTOR inhibitor.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	101-105
18958173-11	2008	Although rapamycin efficiently inhibited S6 phosphorylation, it was less efficient than anti-EGFR antibody in reverting HMB45 reactivity and blocking ERK phosphorylation.	Sirolimus	9-18	mitogen-activated protein kinase 1	Homo sapiens	150-153
18094094-7	2008	The observation that the TSC1/TSC2 functions as a negative regulator of the mammalian target of rapamycin (mTOR)/p70 S6 kinase (S6K1) signaling pathway yielded the first rapamycin clinical trial for LAM.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	107-111
17713840-3	2007	Rapamycin and its analogs temsirolimus and everolimus are specific inhibitors of mTOR that exert suppressive effects on proliferation, invasion, and metastasis and induce apoptosis of tumor cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	81-85
18509482-1	2008	A 66-year old female with HIV-negative classic Kaposi"s sarcoma responded to mTOR targeting by rapamycin.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	77-81
18094423-13	2007	CONCLUSIONS: Drugs that induce cytochrome P450 3A4, such as EIAEDs, significantly affect the pharmacokinetics of temsirolimus and its active metabolite, sirolimus.	Sirolimus	116-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-50
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Sirolimus	45-54	CD4 molecule	Homo sapiens	20-23
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Sirolimus	45-54	interleukin 6	Homo sapiens	115-119
17908691-3	2007	We have previously reported that rapamycin promotes VSMC differentiation by inhibiting the mammalian target of rapamycin (mTOR) target S6K1.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	91-120
17908691-3	2007	We have previously reported that rapamycin promotes VSMC differentiation by inhibiting the mammalian target of rapamycin (mTOR) target S6K1.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	122-126
17908691-4	2007	Here, we show that rapamycin activates Akt and induces contractile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by relieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).	Sirolimus	19-28	AKT serine/threonine kinase 1	Homo sapiens	39-42
17908691-8	2007	A rapamycin-resistant S6K1 mutant prevents rapamycin-induced Akt activation and VSMC differentiation.	Sirolimus	2-11	AKT serine/threonine kinase 1	Homo sapiens	61-64
17991718-6	2007	Rapamycin, an inhibitor of mTOR, abolished diabetes-induced changes in phosphorylation of eEF2, eEF2 kinase, and p70S6 kinase and ameliorated renal hypertrophy and laminin-beta1 protein content, without affecting hyperglycemia.	Sirolimus	0-9	eukaryotic elongation factor-2 kinase	Mus musculus	96-107
17347776-0	2007	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.	Sirolimus	218-227	erb-b2 receptor tyrosine kinase 2	Homo sapiens	59-64
17347776-0	2007	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.	Sirolimus	218-227	mechanistic target of rapamycin kinase	Homo sapiens	150-154
17347776-8	2007	In vitro studies using MCF-7(HER-2) and BT474 breast cancer cells exposed to gefitinib and rapamycin in combination show that this combination produced significantly greater growth inhibitory effects than either of the drugs alone.	Sirolimus	91-100	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-34
17983731-1	2007	PURPOSE: We assayed the effects of rapamycin, an immunomodulatory agent known to inhibit the activity of the mammalian target of rapamycin (mTOR) cascade, on candidate gene expression and single unit firing properties in cultured rat hippocampal neurons as a strategy to define the effects of rapamycin on neuronal gene transcription and excitability.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	109-138
18056456-3	2007	The MEK inhibitors, CI-1040 or PD0325901, in combination with the mTOR inhibitor, rapamycin, or its analogue AP23573, exhibited dose-dependent synergism in human lung cancer cell lines that was associated with suppression of proliferation rather than enhancement of cell death.	Sirolimus	82-91	mitogen-activated protein kinase kinase 7	Homo sapiens	4-7
17983731-1	2007	PURPOSE: We assayed the effects of rapamycin, an immunomodulatory agent known to inhibit the activity of the mammalian target of rapamycin (mTOR) cascade, on candidate gene expression and single unit firing properties in cultured rat hippocampal neurons as a strategy to define the effects of rapamycin on neuronal gene transcription and excitability.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	140-144
17583372-2	2007	Studies have demonstrated that sirolimus acts as a vascular endothelial growth factor inhibitor, providing prospective therapeutic benefits and possible prevention of tuberous sclerosis and Kaposi"s sarcoma.	Sirolimus	31-40	vascular endothelial growth factor A	Homo sapiens	51-85
18046414-5	2007	In skeletal muscle tissues and cells, the mTOR inhibitor rapamycin decreased the gene expression of the mitochondrial transcriptional regulators PGC-1alpha, oestrogen-related receptor alpha and nuclear respiratory factors, resulting in a decrease in mitochondrial gene expression and oxygen consumption.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	42-46
17968710-0	2007	Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	107-111
18046414-5	2007	In skeletal muscle tissues and cells, the mTOR inhibitor rapamycin decreased the gene expression of the mitochondrial transcriptional regulators PGC-1alpha, oestrogen-related receptor alpha and nuclear respiratory factors, resulting in a decrease in mitochondrial gene expression and oxygen consumption.	Sirolimus	57-66	PPARG coactivator 1 alpha	Homo sapiens	145-189
18046414-7	2007	Knockdown of YY1 caused a significant decrease in mitochondrial gene expression and in respiration, and YY1 was required for rapamycin-dependent repression of those genes.	Sirolimus	125-134	YY1 transcription factor	Homo sapiens	13-16
18046414-7	2007	Knockdown of YY1 caused a significant decrease in mitochondrial gene expression and in respiration, and YY1 was required for rapamycin-dependent repression of those genes.	Sirolimus	125-134	YY1 transcription factor	Homo sapiens	104-107
18082048-1	2007	OBJECTIVE: This study examined the effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), on eukaryotic initiation factor (eIF- 4E) expression in rat myocardial fibroblasts infected by Coxsackievirus B3 (CVB3) in order to identify the drug target for treatment of viral myocarditis.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	72-101
18082048-1	2007	OBJECTIVE: This study examined the effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), on eukaryotic initiation factor (eIF- 4E) expression in rat myocardial fibroblasts infected by Coxsackievirus B3 (CVB3) in order to identify the drug target for treatment of viral myocarditis.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	103-107
17986349-3	2007	Rapamycin (also known as sirolimus), an mTOR inhibitor, has been shown to reduce disease severity in rodent models of TSC and is currently being evaluated in clinical trials in human populations.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
17986349-3	2007	Rapamycin (also known as sirolimus), an mTOR inhibitor, has been shown to reduce disease severity in rodent models of TSC and is currently being evaluated in clinical trials in human populations.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	118-121
17986349-3	2007	Rapamycin (also known as sirolimus), an mTOR inhibitor, has been shown to reduce disease severity in rodent models of TSC and is currently being evaluated in clinical trials in human populations.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	40-44
17986349-3	2007	Rapamycin (also known as sirolimus), an mTOR inhibitor, has been shown to reduce disease severity in rodent models of TSC and is currently being evaluated in clinical trials in human populations.	Sirolimus	25-34	TSC complex subunit 1	Homo sapiens	118-121
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	194-198
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	199-209
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	210-244
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	246-250
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	194-198
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	96-105	hypoxia inducible factor 1 subunit alpha	Homo sapiens	199-209
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	96-105	vascular endothelial growth factor A	Homo sapiens	210-244
17968710-0	2007	Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	112-123
17968710-0	2007	Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	124-128
17968710-1	2007	Sirolimus(SRL, Rapamune(a), rapamycin) is a highly specific inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-102
17968710-5	2007	Sirolimus is effective in vivo against pancreatic carcinoma and demonstrates that the effect of sirolimus on the inhibition of tumor cell proliferation is associated with the suppression of the mTOR/HIF-1alpha/vascular endothelial growth factor (VEGF) pathway.	Sirolimus	96-105	vascular endothelial growth factor A	Homo sapiens	246-250
17968710-1	2007	Sirolimus(SRL, Rapamune(a), rapamycin) is a highly specific inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	104-108
17968710-2	2007	Sirolimus exerts its biological activity by inhibiting the serine-threonine kinase mammalian target of rapamycin (mTOR), which regulates important cellular processes such as control of cell cycle, cell size, translation initiation and transcription.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-112
17968710-2	2007	Sirolimus exerts its biological activity by inhibiting the serine-threonine kinase mammalian target of rapamycin (mTOR), which regulates important cellular processes such as control of cell cycle, cell size, translation initiation and transcription.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	114-118
17968710-3	2007	The ability of sirolimus to inhibit cancer cell proliferation has led to efforts to develop rapamycin and related mTOR inhibitors as anticancer agents.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	114-118
17913896-2	2007	Because temsirolimus and its metabolite, sirolimus, are cytochrome P450 (CYP) 3A4/5 substrates, the potential exists for interaction with drugs that induce CYP3A activity, including enzyme inducers and rifampin.	Sirolimus	11-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-161
17925380-7	2007	Moreover, treatment with rapamycin, which uncouples FKBPs from RyR, led to an increase of RyR-dependent Ca(2+) signaling in wild-type urinary bladder myocytes but not in Ryr1(-/-) myocytes.	Sirolimus	25-34	ryanodine receptor 1, skeletal muscle	Mus musculus	63-66
17925380-7	2007	Moreover, treatment with rapamycin, which uncouples FKBPs from RyR, led to an increase of RyR-dependent Ca(2+) signaling in wild-type urinary bladder myocytes but not in Ryr1(-/-) myocytes.	Sirolimus	25-34	ryanodine receptor 1, skeletal muscle	Mus musculus	90-93
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	116-125	CD4 molecule	Homo sapiens	155-158
17950100-3	2007	To determine if signaling via mTOR might be directly involved in regulation of fatty acid metabolism in hepatocytes, we performed studies with rapamycin, a specific inhibitor of mTOR.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	30-34
17950100-3	2007	To determine if signaling via mTOR might be directly involved in regulation of fatty acid metabolism in hepatocytes, we performed studies with rapamycin, a specific inhibitor of mTOR.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	178-182
18025271-10	2007	Anti-HER2 antibody in combination with LY294002, rapamycin, or SP600125 induced greater cyclin G2 expression than either agent alone.	Sirolimus	49-58	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
17940662-3	2007	Previous studies indicate that Arabidopsis thaliana TOR (AtTOR) activity is resistant to rapamycin whereas maize TOR (ZmTOR) is not, suggesting that plants might have different regulation mechanisms for this signal transduction pathway.	Sirolimus	89-98	target of rapamycin	Arabidopsis thaliana	52-55
17989609-5	2007	RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells.	Sirolimus	9-18	interleukin 1 beta	Homo sapiens	126-143
17989609-7	2007	Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription.	Sirolimus	48-57	sterol regulatory element binding transcription factor 2	Homo sapiens	88-94
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	116-125	CD4 molecule	Homo sapiens	170-173
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	116-125	CD4 molecule	Homo sapiens	170-173
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	127-136	CD4 molecule	Homo sapiens	155-158
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	127-136	CD4 molecule	Homo sapiens	170-173
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	127-136	CD4 molecule	Homo sapiens	170-173
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	51-60	CD4 molecule	Homo sapiens	18-21
17920355-1	2007	The effect of insulin therapy on adverse cardiovascular outcomes in diabetic patients has been debated and a reduced benefit in clinical restenosis outcomes after sirolimus stenting has been reported among diabetic patients requiring insulin therapy.	Sirolimus	163-172	insulin	Homo sapiens	234-241
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	62-71	CD4 molecule	Homo sapiens	18-21
17880416-6	2007	Interestingly, sirolimus was shown to inhibit intracellular IL-6 production in adults (63.1 +/- 12.7% vs. 52.0 +/- 16.0%, p = 0.005), but in neonatal monocytes intracellular IL-6 expression was stimulated (53.5 +/- 22.0% vs. 64.7 +/- 19.1%, p = 0.041).	Sirolimus	15-24	interleukin 6	Homo sapiens	60-64
17880416-6	2007	Interestingly, sirolimus was shown to inhibit intracellular IL-6 production in adults (63.1 +/- 12.7% vs. 52.0 +/- 16.0%, p = 0.005), but in neonatal monocytes intracellular IL-6 expression was stimulated (53.5 +/- 22.0% vs. 64.7 +/- 19.1%, p = 0.041).	Sirolimus	15-24	interleukin 6	Homo sapiens	174-178
17880416-8	2007	Sirolimus was demonstrated to have a distinct effect on neonatal immune cells as shown by increased expression of IL-2 in lymphocytes and IL-6 in monocytes, while only lymphocytic TNF-alpha expression was inhibited.	Sirolimus	0-9	interleukin 2	Homo sapiens	114-118
17880416-8	2007	Sirolimus was demonstrated to have a distinct effect on neonatal immune cells as shown by increased expression of IL-2 in lymphocytes and IL-6 in monocytes, while only lymphocytic TNF-alpha expression was inhibited.	Sirolimus	0-9	interleukin 6	Homo sapiens	138-142
17845575-1	2007	The mammalian-target-of-rapamycin/mTOR-inhibitor sirolimus as a component of the immunosuppressive strategy after solid organ transplantation is effective at preventing allograft rejection.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	4-33
17825298-2	2007	Rapamycin is considered to be a highly specific inhibitor of the protein kinase mTOR; however, mTOR is also considered to be a PI3K-dependent signaling molecule.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	80-84
17664276-6	2007	The insulin resistance of the of the PTP-1B-/- adipocytes could also be rescued by treatment with rapamycin, suggesting that in adipose the loss of PTP-1B results in basal activation of mTOR (mammalian target of rapamycin) complex 1 leading to a tissue-specific insulin resistance.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	186-190
17664276-6	2007	The insulin resistance of the of the PTP-1B-/- adipocytes could also be rescued by treatment with rapamycin, suggesting that in adipose the loss of PTP-1B results in basal activation of mTOR (mammalian target of rapamycin) complex 1 leading to a tissue-specific insulin resistance.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	192-221
17845575-1	2007	The mammalian-target-of-rapamycin/mTOR-inhibitor sirolimus as a component of the immunosuppressive strategy after solid organ transplantation is effective at preventing allograft rejection.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	34-38
17728765-2	2007	Although sirolimus (rapamycin), the oldest inhibitor of mTOR, was discovered more than 30 years ago, renewed interest in this pathway is evident by the numerous rapalogs recently developed.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	56-60
17728765-2	2007	Although sirolimus (rapamycin), the oldest inhibitor of mTOR, was discovered more than 30 years ago, renewed interest in this pathway is evident by the numerous rapalogs recently developed.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	56-60
18251175-1	2007	BACKGROUND/AIMS: Rapamycin is a potent inhibitor of PI3K/Akt pathway activation and its chemotherapeutic effect against pancreatic cancer has been demonstrated.	Sirolimus	17-26	AKT serine/threonine kinase 1	Homo sapiens	57-60
17724683-7	2007	Similarly, functional responses to LPS are partially wortmannin resistant yet sensitive to mTOR inhibition by rapamycin.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	91-95
18251175-9	2007	CONCLUSIONS: As a screening method for assessing the combined effects of rapamycin and gemcitabine, the decrease in expression of Akt/Ser473 and Akt/Thr 308 with rapamycin treatment was promising.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	130-133
17476689-4	2007	It was noted that PIM-2 protected chondrocytes from rapamycin sensitized (TOR inhibited) cell death.	Sirolimus	52-61	RAR related orphan receptor C	Homo sapiens	74-77
18251175-9	2007	CONCLUSIONS: As a screening method for assessing the combined effects of rapamycin and gemcitabine, the decrease in expression of Akt/Ser473 and Akt/Thr 308 with rapamycin treatment was promising.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	145-148
18251175-9	2007	CONCLUSIONS: As a screening method for assessing the combined effects of rapamycin and gemcitabine, the decrease in expression of Akt/Ser473 and Akt/Thr 308 with rapamycin treatment was promising.	Sirolimus	162-171	AKT serine/threonine kinase 1	Homo sapiens	130-133
18251175-9	2007	CONCLUSIONS: As a screening method for assessing the combined effects of rapamycin and gemcitabine, the decrease in expression of Akt/Ser473 and Akt/Thr 308 with rapamycin treatment was promising.	Sirolimus	162-171	AKT serine/threonine kinase 1	Homo sapiens	145-148
18251175-11	2007	Detecting a decrease in Akt/ Ser473 and Akt/Thr308 after rapamycin treatment, by western blotting, may be an effective way for assessing the combined effect of rapamycin and gemcitabine.	Sirolimus	57-66	AKT serine/threonine kinase 1	Homo sapiens	24-27
18251175-11	2007	Detecting a decrease in Akt/ Ser473 and Akt/Thr308 after rapamycin treatment, by western blotting, may be an effective way for assessing the combined effect of rapamycin and gemcitabine.	Sirolimus	57-66	AKT serine/threonine kinase 1	Homo sapiens	40-43
18251175-11	2007	Detecting a decrease in Akt/ Ser473 and Akt/Thr308 after rapamycin treatment, by western blotting, may be an effective way for assessing the combined effect of rapamycin and gemcitabine.	Sirolimus	160-169	AKT serine/threonine kinase 1	Homo sapiens	24-27
18251175-11	2007	Detecting a decrease in Akt/ Ser473 and Akt/Thr308 after rapamycin treatment, by western blotting, may be an effective way for assessing the combined effect of rapamycin and gemcitabine.	Sirolimus	160-169	AKT serine/threonine kinase 1	Homo sapiens	40-43
17804674-2	2007	Our aim was to evaluate the effect of sirolimus, an mTOR inhibitor, on renal function and histology in a proteinuric model of reduced renal mass.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	52-56
17804674-4	2007	Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2.	Sirolimus	33-42	vascular endothelial growth factor A	Homo sapiens	88-122
17804674-4	2007	Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2.	Sirolimus	33-42	vascular endothelial growth factor A	Homo sapiens	124-128
17698581-5	2007	Rapamycin inhibition of TORC1 signaling suppressed the Rad53 checkpoint-mediated induction of ribonucleotide reductase subunits Rnr1 and Rnr3, thereby abrogating MMS-induced mutagenesis and enhancing cell lethality.	Sirolimus	0-9	ribonucleotide-diphosphate reductase subunit RNR3	Saccharomyces cerevisiae S288C	137-141
17670836-9	2007	On the other hand, rapamycin, an mTOR inhibitor, significantly suppressed VSV replication in GADD34-KO MEFs.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	33-37
17698027-6	2007	Experiments using chimeric apoB UTR-luciferase constructs transfected into HepG2 cells followed by treatment with wortmannin, a PI-3K inhibitor, and rapamycin, an mTOR inhibitor, showed that signaling via PI-3K and mTOR pathways is necessary for insulin-mediated inhibition of chimeric 5" UTR-luciferase expression.	Sirolimus	149-158	apolipoprotein B	Homo sapiens	27-31
17868472-2	2007	Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	114-118
17868472-2	2007	Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	229-233
17868472-2	2007	Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration.	Sirolimus	250-259	mechanistic target of rapamycin kinase	Homo sapiens	83-112
17868472-2	2007	Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration.	Sirolimus	250-259	mechanistic target of rapamycin kinase	Homo sapiens	114-118
17868472-2	2007	Evidence has recently been obtained from animal experiments that activation of the mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cyst growth and renal volume expansion, and that the inhibition of mTOR with rapamycin (sirolimus) markedly slows cyst development and renal functional deterioration.	Sirolimus	250-259	mechanistic target of rapamycin kinase	Homo sapiens	229-233
17868472-4	2007	METHOD/DESIGN: This single center, randomised controlled, open label trial assesses the therapeutic effect, safety and tolerability of the mTOR inhibitor sirolimus (Rapamune) in patients with autosomal dominant polycystic kidney disease and preserved renal function.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	139-143
17875723-7	2007	Rapamycin increased the levels of constitutively activated Akt in Daoy and D341 cells, which may explain its ability to enhance myxoma virus oncolysis.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	59-62
17698027-6	2007	Experiments using chimeric apoB UTR-luciferase constructs transfected into HepG2 cells followed by treatment with wortmannin, a PI-3K inhibitor, and rapamycin, an mTOR inhibitor, showed that signaling via PI-3K and mTOR pathways is necessary for insulin-mediated inhibition of chimeric 5" UTR-luciferase expression.	Sirolimus	149-158	mechanistic target of rapamycin kinase	Homo sapiens	163-167
17698027-6	2007	Experiments using chimeric apoB UTR-luciferase constructs transfected into HepG2 cells followed by treatment with wortmannin, a PI-3K inhibitor, and rapamycin, an mTOR inhibitor, showed that signaling via PI-3K and mTOR pathways is necessary for insulin-mediated inhibition of chimeric 5" UTR-luciferase expression.	Sirolimus	149-158	mechanistic target of rapamycin kinase	Homo sapiens	215-219
17698027-6	2007	Experiments using chimeric apoB UTR-luciferase constructs transfected into HepG2 cells followed by treatment with wortmannin, a PI-3K inhibitor, and rapamycin, an mTOR inhibitor, showed that signaling via PI-3K and mTOR pathways is necessary for insulin-mediated inhibition of chimeric 5" UTR-luciferase expression.	Sirolimus	149-158	insulin	Homo sapiens	246-253
17575014-8	2007	Inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin not only inhibited the phosphorylation of p70(S6K) and the expression of cell cycle regulatory proteins but also reduced accumulation of > or =4N cells and BrdU incorporation of >4N cells.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	49-53
17603996-3	2007	We previously reported that rapamycin induces binding activity to the TOP element of ribosomal protein (r-protein) L32 mRNA.	Sirolimus	28-37	ribosomal protein L32	Homo sapiens	85-118
17603996-9	2007	Furthermore, decreases of p45 AUF1 and p42 and/or p40 AUF1 were observed in the polysomal fractions of BJAB cells in which translation of TOP mRNAs was selectively suppressed by rapamycin treatment.	Sirolimus	178-187	nuclear factor, erythroid 2	Homo sapiens	26-29
17624310-5	2007	In addition, D-glucosamine enhanced the growth inhibitory effects of rapamycin, a specific inhibitor of mTOR.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	104-108
17609269-5	2007	This suppression of HBV gene transcription was apparently mediated by the activation of mTOR, as it was abolished by the mTOR inhibitor rapamycin.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	88-92
17390104-0	2007	Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	9-13
17390104-2	2007	Rapamycin is a highly specific inhibitor of mTOR and induces a cytostatic effect in various glioma cell lines.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
17603109-4	2007	Loss of TOR1 restored the ability of the pmr1 strain to grow on media containing 2 mm MnCl2 and conferred wild type as well as the wild-type sensitivity to rapamycin.	Sirolimus	156-165	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	41-45
17603109-7	2007	A strain containing the D53A mutant (Mn2+ transporting) of Pmr1 is rapamycin sensitive, but the Q783A mutant (Ca2+ transporting) strain is rapamycin resistant.	Sirolimus	67-76	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	59-63
17609269-5	2007	This suppression of HBV gene transcription was apparently mediated by the activation of mTOR, as it was abolished by the mTOR inhibitor rapamycin.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	121-125
17889116-5	2007	An mTOR inhibitor was introduced to replace cyclosporine (everolimus, 65%; sirolimus, 35%).	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	3-7
17889117-11	2007	CONCLUSIONS: Patients undergoing conversion from CNI to sirolimus treatment for CAD presented a significant decrease in TGF-beta urine levels, representing a decreased mediator of the CAD fibrogenic process.	Sirolimus	56-65	transforming growth factor beta 1	Homo sapiens	120-128
17889118-3	2007	The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes.	Sirolimus	136-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-188
17889118-3	2007	The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes.	Sirolimus	136-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	190-195
17889118-3	2007	The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes.	Sirolimus	136-145	ATP binding cassette subfamily B member 1	Homo sapiens	228-242
17889118-3	2007	The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes.	Sirolimus	136-145	ATP binding cassette subfamily B member 1	Homo sapiens	263-285
17889118-3	2007	The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes.	Sirolimus	136-145	ATP binding cassette subfamily B member 1	Homo sapiens	287-291
17889118-5	2007	The CYP3A5 polymorphisms have also been associated with sirolimus pharmacokinetics.	Sirolimus	56-65	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	4-10
17604271-5	2007	Consistent with this, starvation of cells of amino acids or treatment with rapamycin alters the phosphorylation of PRAS40.	Sirolimus	75-84	AKT1 substrate 1	Homo sapiens	115-121
17970580-0	2007	[3/3 Inhibitors of mTOR (sirolimus and everolimus)].	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	19-23
17890266-7	2007	This overview provides a summary of the current literature on inhibitors of the mammalian target of rapamycin, with a special focus on sirolimus.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	80-109
17353907-8	2007	Finally, the mTOR inhibitor rapamycin markedly decreased proliferation and increased the apoptotic rate of ALK+TCL cells.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	138-145
17494629-6	2007	S6K deletion in muscle mimics the effect of the mTOR inhibitor rapamycin on rpS6 and eIF4B phosphorylation without affecting eEF2 phosphorylation.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	48-52
17510244-2	2007	Inhibiting mTOR activation using rapamycin significantly reduced the FSH-mediated increase in cyclin D2 mRNA expression, suggesting that mTOR plays a role in the FSH-mediated increase in granulosa cell proliferation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	11-15
17376651-6	2007	TGF-beta-stimulated phosphorylation of p70S6 Kinase and TIMP-3 protein induction was inhibited by rapamycin.	Sirolimus	98-107	transforming growth factor beta 1	Homo sapiens	0-8
17553806-3	2007	In these studies we treated endothelial cells with the mTOR inhibitor rapamycin, and we found that it decreases Akt phosphorylation and activity, as determined by phosphorylation of its substrate glycogen synthase kinase-3.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	55-59
17553806-3	2007	In these studies we treated endothelial cells with the mTOR inhibitor rapamycin, and we found that it decreases Akt phosphorylation and activity, as determined by phosphorylation of its substrate glycogen synthase kinase-3.	Sirolimus	70-79	AKT serine/threonine kinase 1	Homo sapiens	112-115
17553806-4	2007	This effect of rapamycin on Akt phosphorylation could not be demonstrated in endothelial cells transfected with a rapamycin-resistant mTOR construct.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	28-31
17553806-5	2007	Also, in the presence of rapamycin, vascular endothelial growth factor, tumor necrosis factor, and insulin failed to phosphorylate Akt, further indicating that mTOR regulates Akt activation in endothelial cells.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	160-164
17553806-8	2007	We find that rapamycin totally blocks vascular endothelial growth factor and Akt-inducible phosophorylation of these transcription factors in endothelial cells.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	38-72
17553806-8	2007	We find that rapamycin totally blocks vascular endothelial growth factor and Akt-inducible phosophorylation of these transcription factors in endothelial cells.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	77-80
17637444-9	2007	Special attention is paid in this work to TSC treatment options, including therapeutic trials with rapamycin, also known as sirolimus.	Sirolimus	124-133	TSC complex subunit 1	Homo sapiens	42-45
17510244-2	2007	Inhibiting mTOR activation using rapamycin significantly reduced the FSH-mediated increase in cyclin D2 mRNA expression, suggesting that mTOR plays a role in the FSH-mediated increase in granulosa cell proliferation.	Sirolimus	33-42	cyclin D2	Homo sapiens	94-103
17510244-2	2007	Inhibiting mTOR activation using rapamycin significantly reduced the FSH-mediated increase in cyclin D2 mRNA expression, suggesting that mTOR plays a role in the FSH-mediated increase in granulosa cell proliferation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	137-141
17664110-13	2007	CONCLUSION: These results confirm the efficiency of sirolimus released form SES to inhibit RhoA expression and to increase p27kip level in the arterial wall and show the benefit of direct stenting to limit the edge effect with SES.	Sirolimus	52-61	ras homolog family member A	Homo sapiens	91-95
17634255-3	2007	Hearts from male Sprague-Dawley rats fed a meal consisting of rat nonpurified diet were sampled prior to and 3 h following the meal in the presence or absence of treatment with rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) complex 1.	Sirolimus	177-186	mechanistic target of rapamycin kinase	Homo sapiens	208-237
17634255-7	2007	Pretreatment with rapamycin completely prevented the feeding-induced phosphorylation of eIF4G(Ser(1108)), whereas the inhibitor only partially attenuated meal feeding-induced 70-kDa ribosomal protein S6 kinase1(Thr(389)) phosphorylation and extent of 4E-BP1 in the gamma-form.	Sirolimus	18-27	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	251-257
17286201-5	2007	Pretreatment with rapamycin, an inhibitor of mTOR kinase, decreased the expression of p21WAF1/Cip1 protein in PMA-stimulated NB4 cells.	Sirolimus	18-27	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-98
17641780-4	2007	Therapeutic targeting of the AKT/mTOR axis using a rapamycin (sirolimus) derivative ameliorated the serological, cellular, and pathological phenotypes associated with lupus.	Sirolimus	62-71	thymoma viral proto-oncogene 1	Mus musculus	29-32
17766661-3	2007	Currently, the mTOR inhibitor rapamycin and its derivatives CCI-779, RAD001, and AP23573 are being evaluated in cancer clinical trials.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
17004104-7	2007	Anticancer agents tested were cytotoxics used in the treatment of breast cancer, trastuzumab, and rapamycin as an inhibitor of the AKT pathway.	Sirolimus	98-107	AKT serine/threonine kinase 1	Homo sapiens	131-134
17517888-6	2007	Treatment of Akt-transfected mice with rapamycin only partially inhibited liver growth and did not prevent the induction of cyclin E protein, indicating that target of rapamycin activity is not necessary for this response.	Sirolimus	39-48	thymoma viral proto-oncogene 1	Mus musculus	13-16
17502379-4	2007	Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin.	Sirolimus	237-246	mechanistic target of rapamycin kinase	Homo sapiens	34-38
17502379-4	2007	Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin.	Sirolimus	237-246	hypoxia inducible factor 1 subunit alpha	Homo sapiens	130-139
17502379-4	2007	Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin.	Sirolimus	237-246	vascular endothelial growth factor A	Homo sapiens	144-178
17502379-4	2007	Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin.	Sirolimus	237-246	vascular endothelial growth factor A	Homo sapiens	180-184
17502379-10	2007	Our work explains why human cancers with aberrant mTOR signaling are prone to angiogenesis and suggests that inhibition of mTOR with rapamycin might be a suitable therapeutic strategy.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	50-54
17502379-10	2007	Our work explains why human cancers with aberrant mTOR signaling are prone to angiogenesis and suggests that inhibition of mTOR with rapamycin might be a suitable therapeutic strategy.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	123-127
17623090-11	2007	Combined treatment with AICAR and the mTOR inhibitor rapamycin resulted in additive anti-proliferative activity ALL cells.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	38-42
17389711-3	2007	Gastrocnemius from male Sprague-Dawley rats trained to consume a meal consisting of rat chow was sampled prior to and following 3 h of having the meal provided in the presence or absence of treatment with rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) complex 1 (TORC1).	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	236-265
17389711-4	2007	Pretreatment with rapamycin prevented the feeding-induced phosphorylation of mTOR, eIF4G, and S6K1 but only partially attenuated the shift in 4E-BP1 into the gamma-form.	Sirolimus	18-27	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	142-148
17389711-6	2007	Rapamycin also prevented the augmented association of eIF4G with eIF4E and the decreased association of eIF4E with 4E-BP1.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	115-121
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	174-188
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	190-193
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	195-200
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	203-233
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily B member 1	Homo sapiens	235-240
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily C member 1	Homo sapiens	242-247
17646396-5	2007	Rapamycin, a specific inhibitor of mTOR complex 1, inhibits the TGF-beta-induced translation pathway and increase in cell size without affecting the EMT phenotype.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
17646396-5	2007	Rapamycin, a specific inhibitor of mTOR complex 1, inhibits the TGF-beta-induced translation pathway and increase in cell size without affecting the EMT phenotype.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	64-72
17646396-8	2007	Activation of mTOR by TGF-beta, which leads to increased cell size and invasion, adds to the role of TGF-beta-induced EMT in cancer progression and may represent a therapeutic opportunity for rapamycin analogues in cancer.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Homo sapiens	14-18
17646396-8	2007	Activation of mTOR by TGF-beta, which leads to increased cell size and invasion, adds to the role of TGF-beta-induced EMT in cancer progression and may represent a therapeutic opportunity for rapamycin analogues in cancer.	Sirolimus	192-201	transforming growth factor beta 1	Homo sapiens	22-30
17646396-8	2007	Activation of mTOR by TGF-beta, which leads to increased cell size and invasion, adds to the role of TGF-beta-induced EMT in cancer progression and may represent a therapeutic opportunity for rapamycin analogues in cancer.	Sirolimus	192-201	transforming growth factor beta 1	Homo sapiens	101-109
17517883-6	2007	PRAS40 (Ser(183)) was phosphorylated in intact cells; this phosphorylation was inhibited by rapamycin, by 2-deoxyglucose, and by overexpression of the tuberous sclerosis complex heterodimer.	Sirolimus	92-101	AKT1 substrate 1	Homo sapiens	0-6
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Sirolimus	80-89	AKT1 substrate 1	Homo sapiens	14-20
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	253-285
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	287-291
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	293-298
17004104-11	2007	Rapamycin, an inhibitor of MTOR, was synergistic with fluvastatin in two of the four cell lines and antagonistic in two other cell lines.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
17618850-2	2007	A recent report in Molecular Cell (Urban et al., 2007) now extends this conservation to include Sch9, an AGC protein kinase family member from S. cerevisiae, which appears to be the long sought after yeast ortholog of mammalian S6 kinase 1 (S6K1) and a direct target for the rapamycin-sensitive TOR complex I.	Sirolimus	275-284	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	96-100
17031644-7	2007	Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	64-67
17031644-7	2007	Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	69-74
17031644-7	2007	Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM.	Sirolimus	0-9	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-83
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Sirolimus	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	70-73
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Sirolimus	33-42	ATP binding cassette subfamily B member 1	Homo sapiens	75-80
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Sirolimus	33-42	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	85-89
17478757-7	2007	In hypertensive FKBP12.6-/- mice, systolic blood pressures were further elevated after treatment with either rapamycin or FK506.	Sirolimus	109-118	FK506 binding protein 1b	Mus musculus	16-24
17304506-7	2007	The PI3 kinase pathway inhibitors LY294002 and rapamycin inhibited the colony forming ability of all of the lines with the ErbB2 overexpressing lines having a higher sensitivity.	Sirolimus	47-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	123-128
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	40-44
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	46-75
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	insulin	Homo sapiens	124-131
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	kininogen 1	Homo sapiens	247-257
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	insulin	Homo sapiens	287-294
17379645-6	2007	Short-term treatment with rapamycin, an mTOR (mammalian target of rapamycin) inhibitor, completely abrogated the ability of insulin to increase the rate and magnitude of Ca2+ signaling and production of inositol 1,4,5-trisphosphate in response to bradykinin stimulation, indicating that insulin potentiates Gq protein-coupled receptor signaling through an mTOR-dependent pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	356-360
17645716-1	2007	The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	4-8
17645716-1	2007	The mTOR (mammalian target of rapamycin) inhibitors sirolimus (SRL) and everolimus (EVL) are potent immunosuppressive agents, which allow reducing the dose of the nephrotoxic calcineurin inhibitors cyclosporin and tacrolimus (TAC) in solid organ transplant recipients.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	10-39
17304506-9	2007	Rapamycin alone and additively together with herceptin inhibited the breast cancer cell growth especially in ErbB2 overexpressing cells.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	109-114
17304506-10	2007	Rapamycin and herceptin synergistically inhibited tumor growth and endpoint tumor load in a xenograft model using a MCF-7 subline and in a MMTV-ErbB2 transgenic model.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-149
17620442-0	2007	Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.	Sirolimus	126-135	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-16
17394554-7	2007	In parallel, it was found that the NA-induced increase in MCT2 protein was almost completely blocked by LY294002 (phosphoinositide 3-kinase inhibitor) as well as by rapamycin (mTOR inhibitor), while mitogen-activated protein kinase kinase and p38 MAPK inhibitors had much smaller effects.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	176-180
17463046-7	2007	We further demonstrate that placental mTOR regulates activity of the l-amino acid transporter, but not system A or taurine transporters, by determining the mediated uptake of isotope-labelled leucine, methylaminoisobutyric acid and taurine in primary villous fragments after inhibition of mTOR using rapamycin.	Sirolimus	300-309	mechanistic target of rapamycin kinase	Homo sapiens	38-42
17549403-4	2007	IGF-I induction of myogenin protein was blocked by anti-IGF-IR monoclonal antibody alphaIR-3 and the mTOR-specific inhibitor rapamycin.	Sirolimus	125-134	insulin like growth factor 1	Homo sapiens	0-5
17549403-4	2007	IGF-I induction of myogenin protein was blocked by anti-IGF-IR monoclonal antibody alphaIR-3 and the mTOR-specific inhibitor rapamycin.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	101-105
17549426-3	2007	In this study, we have analyzed the molecular impact on a human leiomyosarcoma cell line (SK-LMS-1) of a combination consisting of the mTOR inhibitor rapamycin and either the anti-metabolite drug gemcitabine (Gemzar) or the protein tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571).	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	135-139
17549426-5	2007	Gemcitabine or rapamycin, when added alone, inhibit protein tyrosine phosphorylation as well as phosphorylation of the MAP kinases ERK1/2.	Sirolimus	15-24	mitogen-activated protein kinase 3	Homo sapiens	131-137
17763670-7	2007	m-TOR inhibitors such as sirolimus or everolimus are being used with increasing frequency following heart transplantation due to their potent immunosuppressive and antiproliferative effects.	Sirolimus	25-34	RAR related orphan receptor C	Homo sapiens	2-5
17620442-0	2007	Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.	Sirolimus	126-135	cyclin dependent kinase inhibitor 1A	Homo sapiens	95-98
17620442-0	2007	Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.	Sirolimus	126-135	cyclin dependent kinase inhibitor 1A	Homo sapiens	99-108
17322416-2	2007	The present study was undertaken to investigate the effect of sirolimus on intracellular cholesterol homeostasis in human vascular smooth muscle cells (VSMCs) in the presence of inflammatory cytokine IL-1 beta.	Sirolimus	62-71	interleukin 1 beta	Homo sapiens	200-209
17466941-5	2007	Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suppressed leucine-induced activation of p70 S6 kinase and 4E-BP1 and negated the stimulatory effect of leucine on HGF production.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
17466941-5	2007	Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suppressed leucine-induced activation of p70 S6 kinase and 4E-BP1 and negated the stimulatory effect of leucine on HGF production.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	58-62
17466941-5	2007	Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suppressed leucine-induced activation of p70 S6 kinase and 4E-BP1 and negated the stimulatory effect of leucine on HGF production.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	124-130
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Sirolimus	185-194	interleukin 2	Homo sapiens	28-32
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Sirolimus	185-194	interleukin 2	Homo sapiens	58-62
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Sirolimus	185-194	interleukin 2	Homo sapiens	58-62
17397797-5	2007	Rapamycin increases the V(max) of high affinity arginine transport and causes the appearance of a low affinity component that is particularly evident if the treatment is carried out in the presence of TNFalpha.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	201-209
18240909-4	2007	It has been recently shown that the CYP3A5*3 polymorphism is associated with pharmacokinetics of tacrolimus and sirolimus.	Sirolimus	112-121	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	36-42
17692667-4	2007	Everolimus is an mTOR inhibitor sirolimus analogue, that has proved, to be highly efficacious to prevent acute myocardial rejection and reduce the severity of cardiac allograft vasculopathy in de novo HTx patients.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	17-21
17052793-10	2007	In porcine aortic smooth muscle cells (PASMC), G-CSF increased the growth rate, migration, STAT-3 phosphorylation, and VEGF, which were suppressed by rapamycin and AG490, a STAT-3 inhibitor.	Sirolimus	150-159	colony stimulating factor 3	Sus scrofa	47-52
17397797-2	2007	Here we show that also rapamycin, an inhibitor of mTOR kinase, stimulates system y(+)-mediated arginine uptake in human endothelial cells derived from either saphenous (HSVECs) or umbilical veins (HUVECs).	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	50-54
17543119-0	2007	Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to rapamycin susceptibility.	Sirolimus	101-110	target of rapamycin	Arabidopsis thaliana	59-62
17543119-2	2007	The TOR protein kinase can be inactivated by the antibiotic rapamycin following the formation of a ternary complex between TOR, rapamycin and FKBP12 proteins.	Sirolimus	60-69	target of rapamycin	Arabidopsis thaliana	4-7
17543119-2	2007	The TOR protein kinase can be inactivated by the antibiotic rapamycin following the formation of a ternary complex between TOR, rapamycin and FKBP12 proteins.	Sirolimus	60-69	target of rapamycin	Arabidopsis thaliana	123-126
17543119-3	2007	The TOR protein is also found in higher plants despite the fact that they are rapamycin insensitive.	Sirolimus	78-87	target of rapamycin	Arabidopsis thaliana	4-7
17543119-4	2007	Previous findings using the yeast two hybrid system suggest that the FKBP12 plant homolog is unable to form a complex with rapamycin and TOR, while the FRB domain of plant TOR is still able to bind to heterologous FKBP12 in the presence of rapamycin.	Sirolimus	240-249	target of rapamycin	Arabidopsis thaliana	172-175
17543119-5	2007	The resistance to rapamycin is therefore limiting the molecular dissection of the TOR pathway in higher plants.	Sirolimus	18-27	target of rapamycin	Arabidopsis thaliana	82-85
17543119-7	2007	An antibody has been raised against the AtTOR protein and binding of recombinant yeast ScFKBP12 to native Arabidopsis TOR in the presence of rapamycin was demonstrated in pull-down experiments.	Sirolimus	141-150	target of rapamycin	Arabidopsis thaliana	40-45
17543119-7	2007	An antibody has been raised against the AtTOR protein and binding of recombinant yeast ScFKBP12 to native Arabidopsis TOR in the presence of rapamycin was demonstrated in pull-down experiments.	Sirolimus	141-150	target of rapamycin	Arabidopsis thaliana	42-45
17322416-3	2007	We explored the effect of sirolimus on the lipid accumulation of VSMCs in the presence of IL-1 beta, using Oil Red O staining and quantitative measurement of intracellular cholesterol.	Sirolimus	26-35	interleukin 1 beta	Homo sapiens	90-99
17322416-4	2007	The effect of sirolimus on the gene and protein expression of lipoprotein receptors and ATP binding cassettes (ABCA1 and ABCG1) was examined by real-time PCR and Western blotting, respectively.	Sirolimus	14-23	ATP binding cassette subfamily G member 1	Homo sapiens	121-126
17322416-7	2007	Sirolimus reduced intracellular lipid accumulation in VSMCs mediated by IL-1 beta possibly due to the reduction of expression of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) receptors.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	72-81
17322416-8	2007	Sirolimus increased cholesterol efflux from VSMCs and overrode the suppression of cholesterol efflux induced by IL-1 beta.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	112-121
17322416-9	2007	Sirolimus also increased ABCA1 and ABCG1 genes expression, even in the presence of IL-1 beta.	Sirolimus	0-9	ATP binding cassette subfamily G member 1	Homo sapiens	35-40
17322416-9	2007	Sirolimus also increased ABCA1 and ABCG1 genes expression, even in the presence of IL-1 beta.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	83-92
17322416-10	2007	We further confirmed that sirolimus inhibited mRNA and protein expression of inflammatory cytokines IL-6, tumor necrosis factor-alpha, IL-8, and monocyte chemoattractant protein-1.	Sirolimus	26-35	interleukin 6	Homo sapiens	100-133
17322416-10	2007	We further confirmed that sirolimus inhibited mRNA and protein expression of inflammatory cytokines IL-6, tumor necrosis factor-alpha, IL-8, and monocyte chemoattractant protein-1.	Sirolimus	26-35	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
17496901-5	2007	The rapamycin derivative everolimus substantially decelerated tumor growth on Tagln-cre/Pten(loxP/loxP) mice and prolonged their lifespan.	Sirolimus	4-13	phosphatase and tensin homolog	Mus musculus	88-92
17543777-4	2007	Everolimus and sirolimus, the proliferation signal inhibitors (PSIs) or mammalian target-of-rapamycin (mTOR) inhibitors, now provide new strategies for immunosuppression because of their proven efficacy that translates to a reduction in doses of calcineurin inhibitors needed to prevent acute rejection.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	72-101
17543777-4	2007	Everolimus and sirolimus, the proliferation signal inhibitors (PSIs) or mammalian target-of-rapamycin (mTOR) inhibitors, now provide new strategies for immunosuppression because of their proven efficacy that translates to a reduction in doses of calcineurin inhibitors needed to prevent acute rejection.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	103-107
17545582-0	2007	Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression.	Sirolimus	47-56	thymoma viral proto-oncogene 1	Mus musculus	12-15
17545582-1	2007	Chronic activation of Akt signaling in the endothelium recapitulates the salient features of a tumor vasculature and can be inhibited by rapamycin, an inhibitor of mammalian target of rapamycin.	Sirolimus	137-146	AKT serine/threonine kinase 1	Homo sapiens	22-25
17545582-2	2007	This led to the hypothesis that the antitumor efficacy of rapamycin may be partially dependent on its ability to inhibit endothelial Akt signaling, making rapamycin an antiangiogenic agent and endothelial Akt pathway inhibitor.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	133-136
17545582-2	2007	This led to the hypothesis that the antitumor efficacy of rapamycin may be partially dependent on its ability to inhibit endothelial Akt signaling, making rapamycin an antiangiogenic agent and endothelial Akt pathway inhibitor.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	205-208
17545582-2	2007	This led to the hypothesis that the antitumor efficacy of rapamycin may be partially dependent on its ability to inhibit endothelial Akt signaling, making rapamycin an antiangiogenic agent and endothelial Akt pathway inhibitor.	Sirolimus	155-164	AKT serine/threonine kinase 1	Homo sapiens	133-136
17545582-3	2007	Dose-response studies with rapamycin showed that primary human endothelial cells and fibroblasts had a bimodal Akt response with effective reductions in phosphorylated Akt (pAkt) achieved at 10 ng/mL.	Sirolimus	27-36	AKT serine/threonine kinase 1	Homo sapiens	168-171
17545582-8	2007	Just as we observed in MCF7 cells in vitro, rapamycin doses that were antiangiogenic resulted in increased pAkt levels in total mouse mammary tumor virus-polyoma virus middle T antigen tumor lysates, suggesting that tumor cells had an opposite Akt response following mammalian target of rapamycin inhibition compared with tumor endothelial cells.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	108-111
17329620-11	2007	Rapamycin partially inhibited this increase in mTOR-mediated S6K phosphorylation and IRS-1 Ser312 and Ser636 phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	47-51
17329620-12	2007	In conclusion, rapamycin stimulates insulin-mediated glucose uptake in man under conditions known to activate the mTOR/S6K pathway.	Sirolimus	15-24	insulin	Homo sapiens	36-43
17371807-8	2007	The mTOR inhibitor, rapamycin, also inhibited entry into S phase.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
17483347-6	2007	An inhibitor of mTOR, rapamycin, was able to revert this phenotype.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	16-20
17350953-1	2007	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	185-214
17350953-1	2007	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	216-220
17483341-9	2007	Moreover, incubation of high-risk MDS patient CD34(+) cells with rapamycin decreased the in vitro clonogenic capability of these cells.	Sirolimus	65-74	CD34 molecule	Homo sapiens	46-50
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	0-4
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	30-34
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	30-34
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	237-240
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	256-259
17510408-7	2007	We found that NPM expression in Nf1(-/-) astrocytes was blocked by rapamycin in vitro and in vivo and that expression of a dominant-negative NPM mutant protein in Nf1(-/-) astrocytes rescued actin stress fiber formation and restored cell motility and proliferation to wild-type levels.	Sirolimus	67-76	neurofibromin 1	Homo sapiens	32-35
17498286-0	2007	Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratios.	Sirolimus	0-9	MPL proto-oncogene, thrombopoietin receptor	Homo sapiens	117-120
17483438-5	2007	Rapamycin, a selective inhibitor of mTOR, reduced VEGF production in rhabdomyosarcoma cells under normoxic conditions and partially suppressed hypoxia-driven increases in VEGF.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	36-40
17437482-7	2007	Application of rapamycin to monoculture NF and KF, dose- and time-dependently downregulates the expression of cytoplasmic PCNA, cyclin D1, fibronectin, collagen and alpha-SMA, demonstrating the anti-proliferative effect and therapeutic potential of rapamycin in the treatment of keloid scars.	Sirolimus	15-24	fibronectin 1	Homo sapiens	139-150
17007924-0	2007	Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	32-35
17007924-0	2007	Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	36-40
17007924-2	2007	Rapamycin (1-100 nM, 48h), the inhibitor of mTOR and its analog RAD001 (1-100 nM, 48 h)-induced growth inhibition and G0/G1 cell cycle arrest of these cells in association with de-phosphorylation of p70S6K and 4E-BP-1, although IC50 was not achieved.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
17007924-3	2007	Paradoxically, rapamycin-stimulated phosphorylation of Akt at Ser473.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	55-58
17007924-5	2007	Of note, when rapamycin was combined with LY294002, rapamycin-induced phosphorylation of Akt was blocked, and the ability of rapamycin to induce growth arrest of HTLV-1-infected T-cells and suppress the p-p70S6K and p-4E-BP-1 proteins was potentiated.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	89-92
17007924-5	2007	Of note, when rapamycin was combined with LY294002, rapamycin-induced phosphorylation of Akt was blocked, and the ability of rapamycin to induce growth arrest of HTLV-1-infected T-cells and suppress the p-p70S6K and p-4E-BP-1 proteins was potentiated.	Sirolimus	52-61	AKT serine/threonine kinase 1	Homo sapiens	89-92
17007924-5	2007	Of note, when rapamycin was combined with LY294002, rapamycin-induced phosphorylation of Akt was blocked, and the ability of rapamycin to induce growth arrest of HTLV-1-infected T-cells and suppress the p-p70S6K and p-4E-BP-1 proteins was potentiated.	Sirolimus	52-61	AKT serine/threonine kinase 1	Homo sapiens	89-92
20477665-0	2007	The different effects of cyclosporin A and rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction.	Sirolimus	43-52	CD4 molecule	Homo sapiens	67-70
20477684-1	2007	The mammalian target of rapamycin (mTOR) inhibitor drugs rapamycin (sirolimus) and everolimus have undergone extensive clinical trials for a variety of organ grafts and have been licensed for use in human transplantation.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
20477684-1	2007	The mammalian target of rapamycin (mTOR) inhibitor drugs rapamycin (sirolimus) and everolimus have undergone extensive clinical trials for a variety of organ grafts and have been licensed for use in human transplantation.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	4-33
20477684-1	2007	The mammalian target of rapamycin (mTOR) inhibitor drugs rapamycin (sirolimus) and everolimus have undergone extensive clinical trials for a variety of organ grafts and have been licensed for use in human transplantation.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	35-39
17483438-5	2007	Rapamycin, a selective inhibitor of mTOR, reduced VEGF production in rhabdomyosarcoma cells under normoxic conditions and partially suppressed hypoxia-driven increases in VEGF.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	50-54
17483438-5	2007	Rapamycin, a selective inhibitor of mTOR, reduced VEGF production in rhabdomyosarcoma cells under normoxic conditions and partially suppressed hypoxia-driven increases in VEGF.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	171-175
17483438-7	2007	Rapamycin failed to modulate levels of hypoxia-inducible factor 1alpha (HIF-1alpha) under normoxic conditions and modestly reduced hypoxia-driven increases in HIF-1alpha only in rhabdomyosarcoma cells.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	159-169
17016437-6	2007	Assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines suggesting that an adverse effect on VEGF cap-dependent translation would be comparable.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	80-84
17179228-0	2007	Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	58-61
17179228-2	2007	We investigated the molecular effects of mTOR inhibition by the rapamycin derivatives (RDs) temsirolimus (CCI-779) and everolimus (RAD001) in acute myeloid leukemia (AML) cells.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	41-45
17158029-0	2007	Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin.	Sirolimus	109-118	interferon alpha 1	Homo sapiens	34-43
17482291-4	2007	Wortmannin, SH-5, and rapamycin significantly blocked PDGF-stimulated induction of SphK1 mRNA and protein expression, indicating a regulatory role of the PI3K/AKT/mTOR pathway in SphK1 expression.	Sirolimus	22-31	AKT serine/threonine kinase 1	Homo sapiens	159-162
17482291-4	2007	Wortmannin, SH-5, and rapamycin significantly blocked PDGF-stimulated induction of SphK1 mRNA and protein expression, indicating a regulatory role of the PI3K/AKT/mTOR pathway in SphK1 expression.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	163-167
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	ubiquitin associated and SH3 domain containing B	Homo sapiens	165-168
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	AKT serine/threonine kinase 1	Homo sapiens	196-199
17158029-5	2007	The mTOR inhibitor rapamycin mitigated apoptosis in U266 but potentiated it in H929 cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
17591071-8	2007	Treatment with rapamycin resulted in enhanced phosphorylation of AKT, and phosphorylation of AKT was induced by pAxCAHGF plus U0126.	Sirolimus	15-24	AKT serine/threonine kinase 1	Rattus norvegicus	65-68
17063482-8	2007	Finally, inhibition of differentiation of myeloid cells by a dominant negative mutant of Stat3 stabilizes the UBF1 protein, while rapamycin-induced differentiation of myeloid cells downregulates UBF1 levels.	Sirolimus	130-139	upstream binding transcription factor, RNA polymerase I	Mus musculus	195-199
17591071-8	2007	Treatment with rapamycin resulted in enhanced phosphorylation of AKT, and phosphorylation of AKT was induced by pAxCAHGF plus U0126.	Sirolimus	15-24	AKT serine/threonine kinase 1	Rattus norvegicus	93-96
17445551-3	2007	Nevertheless, increasing data have demonstrated that sirolimus (SRL), the first mTOR introduced in the treatment of solid organ transplant recipients, induces proteinuria, an adverse event that could produce deterioration of long-term renal function.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	80-84
17379004-5	2007	Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the PDGF-BB-stimulated IL-6 synthesis.	Sirolimus	0-9	interleukin 6	Mus musculus	88-92
17301289-6	2007	Although Akt did not require mTOR/RAPTOR to maintain surface Glut1 levels, inhibition of mTOR/RAPTOR by rapamycin greatly diminished glucose uptake, suggesting Akt-stimulated mTOR/RAPTOR may promote Glut1 transporter activity.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	89-93
17301289-6	2007	Although Akt did not require mTOR/RAPTOR to maintain surface Glut1 levels, inhibition of mTOR/RAPTOR by rapamycin greatly diminished glucose uptake, suggesting Akt-stimulated mTOR/RAPTOR may promote Glut1 transporter activity.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	89-93
17299523-2	2007	Therefore, we investigated whether the mTOR inhibitor rapamycin, besides its known antihemangiogenic effect, also impedes regenerative lymphangiogenesis.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	39-43
17327134-4	2007	Rapamycin treated cells failed to proliferate, expressed anergic T cell specific transcription factor genes egr-2 and egr-3 and showed diminished IFN-gamma production in response to Con A stimulation in vitro.	Sirolimus	0-9	interferon gamma	Mus musculus	146-155
17331842-7	2007	Rapamycin exhibits induction apoptosis by activation of caspase-3 and disruption of the mitochondrial membrane potential on hepatocellular carcinoma cells in vitro.	Sirolimus	0-9	caspase 3	Homo sapiens	56-65
17331842-9	2007	CONCLUSION: Rapamycin has significant anti-proliferation effect by induction of apoptosis via activation of caspase-3 and disruption of mitochondrial membrane potential, as well as by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bcl-xl on hepatocellular carcinoma cells.	Sirolimus	12-21	caspase 3	Homo sapiens	108-117
17331842-9	2007	CONCLUSION: Rapamycin has significant anti-proliferation effect by induction of apoptosis via activation of caspase-3 and disruption of mitochondrial membrane potential, as well as by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bcl-xl on hepatocellular carcinoma cells.	Sirolimus	12-21	BCL2 apoptosis regulator	Homo sapiens	226-231
17331842-9	2007	CONCLUSION: Rapamycin has significant anti-proliferation effect by induction of apoptosis via activation of caspase-3 and disruption of mitochondrial membrane potential, as well as by down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bcl-xl on hepatocellular carcinoma cells.	Sirolimus	12-21	BCL2 like 1	Homo sapiens	275-281
17244624-4	2007	Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.	Sirolimus	0-9	insulin	Homo sapiens	41-48
17244624-4	2007	Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.	Sirolimus	0-9	insulin	Homo sapiens	171-178
17244624-4	2007	Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.	Sirolimus	0-9	adiponectin, C1Q and collagen domain containing	Homo sapiens	201-212
17371596-6	2007	Incubation of rapamycin (inhibitor of mTOR) inhibited amino acid or insulin-dependent p70 S6 kinase phosphorylation, blocked (P < 0.05) the inhibitory effects of 1.0 x PC AA on protein degradation, but did not alter the inhibitory effects of insulin or leucine CONCLUSION: In a C2C12 myotube model of myofibrillar protein turnover, amino acid limitation increases proteolysis in a ubiquitin-proteasome-dependent manner.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	38-42
17386117-2	2007	Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi"s sarcoma associated with renal graft.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	132-136
17386117-2	2007	Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi"s sarcoma associated with renal graft.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	138-172
17353769-0	2007	In vivo and in vitro effect of sirolimus on insulin secretion.	Sirolimus	31-40	insulin	Homo sapiens	44-51
17353769-1	2007	BACKGROUND: The effects of sirolimus on insulin secretion are still debated.	Sirolimus	27-36	insulin	Homo sapiens	40-47
17353769-6	2007	RESULTS: (1) Basal and stimulated insulin levels and GDR increased during sirolimus administration and returned to baseline after a wash-out period; (2) regardless of culture duration, sirolimus dose-dependently decreased apoptosis and increased insulin content.	Sirolimus	185-194	insulin	Homo sapiens	34-41
17353769-6	2007	RESULTS: (1) Basal and stimulated insulin levels and GDR increased during sirolimus administration and returned to baseline after a wash-out period; (2) regardless of culture duration, sirolimus dose-dependently decreased apoptosis and increased insulin content.	Sirolimus	185-194	insulin	Homo sapiens	246-253
17331981-9	2007	Rapamycin, which induces eIF2alpha phosphorylation-mediated LC3 conversion, inhibited mutant dysferlin aggregation in the ER.	Sirolimus	0-9	dysferlin	Homo sapiens	93-102
17353769-8	2007	CONCLUSIONS: This study suggests that sirolimus, at plasma-drug concentrations usually targeted in clinical practice, (1) increases basal and stimulated insulin levels in vivo and insulin content in vitro regardless of culture duration; (2) is able to reduce apoptosis.	Sirolimus	38-47	insulin	Homo sapiens	153-160
17353769-8	2007	CONCLUSIONS: This study suggests that sirolimus, at plasma-drug concentrations usually targeted in clinical practice, (1) increases basal and stimulated insulin levels in vivo and insulin content in vitro regardless of culture duration; (2) is able to reduce apoptosis.	Sirolimus	38-47	insulin	Homo sapiens	180-187
17371596-6	2007	Incubation of rapamycin (inhibitor of mTOR) inhibited amino acid or insulin-dependent p70 S6 kinase phosphorylation, blocked (P < 0.05) the inhibitory effects of 1.0 x PC AA on protein degradation, but did not alter the inhibitory effects of insulin or leucine CONCLUSION: In a C2C12 myotube model of myofibrillar protein turnover, amino acid limitation increases proteolysis in a ubiquitin-proteasome-dependent manner.	Sirolimus	14-23	insulin	Homo sapiens	68-75
17371596-6	2007	Incubation of rapamycin (inhibitor of mTOR) inhibited amino acid or insulin-dependent p70 S6 kinase phosphorylation, blocked (P < 0.05) the inhibitory effects of 1.0 x PC AA on protein degradation, but did not alter the inhibitory effects of insulin or leucine CONCLUSION: In a C2C12 myotube model of myofibrillar protein turnover, amino acid limitation increases proteolysis in a ubiquitin-proteasome-dependent manner.	Sirolimus	14-23	ubiquitin associated and SH3 domain containing B	Homo sapiens	86-89
17371596-6	2007	Incubation of rapamycin (inhibitor of mTOR) inhibited amino acid or insulin-dependent p70 S6 kinase phosphorylation, blocked (P < 0.05) the inhibitory effects of 1.0 x PC AA on protein degradation, but did not alter the inhibitory effects of insulin or leucine CONCLUSION: In a C2C12 myotube model of myofibrillar protein turnover, amino acid limitation increases proteolysis in a ubiquitin-proteasome-dependent manner.	Sirolimus	14-23	insulin	Homo sapiens	245-252
17082322-1	2007	The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	29-33
17336708-2	2007	The present study is designed to explore mTOR signaling in peripheral-blood mononuclear cells (PBMCs) from renal transplant recipients with Kaposi sarcoma and ascertain whether it would reflect deregulation of the AKT-mTOR pathway in skin cancer tissue and might help identify which patients would benefit from rapamycin treatment, as well as to monitor their clinical response.	Sirolimus	311-320	mechanistic target of rapamycin kinase	Homo sapiens	41-45
17336708-5	2007	Long-term treatment with rapamycin was associated with marked inhibition of basal and stimulated phosphorylation of both AKT and P70(S6K), in parallel with regression of the dermal neoplasm.	Sirolimus	25-34	AKT serine/threonine kinase 1	Homo sapiens	121-124
17336708-7	2007	Thus, monitoring P70(S6K) phosphorylation can help predict and monitor the biological effectiveness of rapamycin in renal transplant recipients with Kaposi sarcoma and possibly adjust the biologically active doses of the mTOR inhibitor.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	221-225
17110454-6	2007	Inhibition of mTOR by rapamycin blocks clot retraction by human platelets.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
17110454-7	2007	Platelets from wild-type mice synthesize Bcl-3 in response to activation, as do human platelets, and platelets from mice with targeted deletion of Bcl-3 have defective retraction of fibrin in platelet-fibrin clots mimicking treatment of human platelets with rapamycin.	Sirolimus	258-267	B cell leukemia/lymphoma 3	Mus musculus	147-152
17082322-1	2007	The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	29-33
17179073-12	2007	We discuss the complex genetic interactions between tor1(+), tor2(+), and tsc1/2(+) and the implications for rapamycin sensitivity in tsc1 or tsc2 mutants.	Sirolimus	109-118	TSC complex subunit 1	Homo sapiens	134-138
17151193-8	2007	A deeper inhibitory effect of cyclosporine on the CL(int) of sirolimus depletion was found for rCYP 3A4 than for rCYP 3A5 (i.e., -44% versus -8% at 0.62 microM, 750 microg/l cyclosporine), and sirolimus metabolism was slightly less inhibited for HLMs expressing CYP 3A5 than not (-38% versus -56%).	Sirolimus	61-70	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	114-121
17179073-11	2007	Mutants lacking Tsc1 or Tsc2 are highly sensitive to rapamycin under poor nitrogen conditions, suggesting that the function of Tor1 under such conditions is sensitive to rapamycin.	Sirolimus	53-62	TSC complex subunit 1	Homo sapiens	16-20
17287424-6	2007	CD4(+)CD25(high) cells that expressed FOXP3 underwent homeostatic peripheral expansion during immune reconstitution, more intense in patients who received sirolimus than in those who were given CsA.	Sirolimus	155-164	CD4 molecule	Homo sapiens	0-3
17179073-11	2007	Mutants lacking Tsc1 or Tsc2 are highly sensitive to rapamycin under poor nitrogen conditions, suggesting that the function of Tor1 under such conditions is sensitive to rapamycin.	Sirolimus	170-179	TSC complex subunit 1	Homo sapiens	16-20
17234746-6	2007	Furthermore, depletion of PATJ from Caco2 cells induces an increase in mammalian Target Of Rapamycin Complex 1 (mTORC1) activity, which is totally inhibited by rapamycin.	Sirolimus	160-169	PATJ crumbs cell polarity complex component	Homo sapiens	26-30
17362758-10	2007	However, rapamycin surprisingly induced an upregulation of TGF-beta at day 4 (3.05 +/- 0.46 vs 1.85 +/- 0.41, P = .006) and at day 7 (6.33 +/- 0.55 vs 4.97 +/- 0.38, P = .024) with a reduced expression by day 14 (4.03 +/- 1.07 vs 7.89 +/- 0.83, P < .001).	Sirolimus	9-18	transforming growth factor beta 1	Homo sapiens	59-67
17000002-1	2007	Inhibition of the interleukin-2 (IL-2) pathway has potent immunosuppressive activity in humans as is evident from the broad therapeutic utility of cyclosporine, rapamycin, tacrolimus, and monoclonal antibodies blocking the high-affinity subunit of the IL-2 receptor (CD25).	Sirolimus	161-170	interleukin 2	Homo sapiens	18-31
17000002-1	2007	Inhibition of the interleukin-2 (IL-2) pathway has potent immunosuppressive activity in humans as is evident from the broad therapeutic utility of cyclosporine, rapamycin, tacrolimus, and monoclonal antibodies blocking the high-affinity subunit of the IL-2 receptor (CD25).	Sirolimus	161-170	interleukin 2	Homo sapiens	33-37
17382186-6	2007	By affecting downstream signaling, the MEK1/2 inhibitors U0126 and PD184352 blocked growth more effectively than did the EGFR inhibitors in selected renal cell carcinoma lines; this effect was enhanced by the addition of rapamycin.	Sirolimus	221-230	epidermal growth factor receptor	Homo sapiens	121-125
17290308-4	2007	This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells.	Sirolimus	51-60	thymoma viral proto-oncogene 1	Mus musculus	106-109
17109887-4	2007	The sensitivity of these cells to rapamycin has been attributed to activation of the PI3K/Akt/mTOR pathway by nongenomic ER signaling.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	90-93
17109887-4	2007	The sensitivity of these cells to rapamycin has been attributed to activation of the PI3K/Akt/mTOR pathway by nongenomic ER signaling.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	94-98
17109887-10	2007	In our system, this sensitivity is probably not due to nongenomic ER activation of the PI3K/Akt/mTOR pathway; rapid stimulation of mTOR occurred nonspecifically after medium replacement, and addition of E2 stimulated mTOR only after 1 h. Combining rapamycin and tamoxifen under E2-dependent conditions yielded additive/synergistic effects at effective concentrations.	Sirolimus	248-257	mechanistic target of rapamycin kinase	Homo sapiens	131-135
17109887-10	2007	In our system, this sensitivity is probably not due to nongenomic ER activation of the PI3K/Akt/mTOR pathway; rapid stimulation of mTOR occurred nonspecifically after medium replacement, and addition of E2 stimulated mTOR only after 1 h. Combining rapamycin and tamoxifen under E2-dependent conditions yielded additive/synergistic effects at effective concentrations.	Sirolimus	248-257	mechanistic target of rapamycin kinase	Homo sapiens	131-135
17302822-7	2007	Either SIC1 deletion or CLN3 overexpression results in non-cell-cycle-specific arrest upon rapamycin treatment and makes cells sensitive to a sublethal dose of rapamycin and to nutrient starvation.	Sirolimus	91-100	cyclin CLN3	Saccharomyces cerevisiae S288C	24-28
17302822-7	2007	Either SIC1 deletion or CLN3 overexpression results in non-cell-cycle-specific arrest upon rapamycin treatment and makes cells sensitive to a sublethal dose of rapamycin and to nutrient starvation.	Sirolimus	160-169	cyclin CLN3	Saccharomyces cerevisiae S288C	24-28
17360675-10	2007	In mammalian systems, we find that mammalian target of rapamycin (mTOR) carrying analogous mutations (L1460P or E2419K), although sensitive to rapamycin, exhibits constitutive activation even when the cells are starved for nutrients.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	66-70
17318075-9	2007	Prospective clinical trials are needed to test whether the activation status of the mTOR pathway in HCCs predicts the antitumor effect of rapamycin derivative in the posttransplantation course.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	84-88
17329974-6	2007	Indeed, pharmacological inhibition of mTOR with rapamycin has shown promising results in preventing vGPCR tumorigenesis in an animal model for KS.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	38-42
17182613-5	2007	Furthermore, trehalose and mTOR inhibition by rapamycin together exerted an additive effect on the clearance of these aggregate-prone proteins because of increased autophagic activity.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	27-31
17218776-5	2007	Treatment with either PD16839, an EGFr antagonist, or imatinib mesylate (Gleevec), a PDGFr, c-kit and bcr/abl antagonist, enhanced the anti-proliferative effects of rapamycin.	Sirolimus	165-174	platelet derived growth factor receptor beta	Homo sapiens	85-90
17316544-7	2007	The effects of sirolimus (most often studied mTOR inhibitor) appear to depend on serum levels, cell type (ss cell or cell line), species (human or animal) and also environmental nutrients.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	45-49
17218776-6	2007	We therefore assessed the effects of treatment with the RTK antagonist alone and in combination with rapamycin on mTOR targeted proteins.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	114-118
17261663-6	2007	In contrast, CD34-positive cells decreased after sirolimus-eluting stenting (72+/-21% on day 7).	Sirolimus	49-58	CD34 molecule	Homo sapiens	13-17
17218776-5	2007	Treatment with either PD16839, an EGFr antagonist, or imatinib mesylate (Gleevec), a PDGFr, c-kit and bcr/abl antagonist, enhanced the anti-proliferative effects of rapamycin.	Sirolimus	165-174	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	92-97
17108021-4	2007	mTOR is a regulator of cell growth and metabolism downstream of Akt and is specifically inhibited by rapamycin.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	0-4
17192769-0	2007	CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.	Sirolimus	75-84	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
17338432-12	2007	The concomitant use of sirolimus, which inhibits vascular endothelial growth factor, plus gemcitabine may have resulted in TMA.	Sirolimus	23-32	vascular endothelial growth factor A	Homo sapiens	49-83
17283241-9	2007	We further found that rapamycin reduced the TGFbeta1-enhancing effect of FSH-stimulated steroidogenesis, yet it exhibited no effect on FSH action.	Sirolimus	22-31	transforming growth factor, beta 1	Rattus norvegicus	44-52
17108021-4	2007	mTOR is a regulator of cell growth and metabolism downstream of Akt and is specifically inhibited by rapamycin.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	64-67
17200203-5	2007	Accordingly, the enhanced synthesis of fibrillin-1 was blocked by rapamycin, an inhibitor of mTOR.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	93-97
16832347-0	2007	Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta.	Sirolimus	63-72	protein kinase C eta	Homo sapiens	108-128
16832347-3	2007	In U-251MG cells, rapamycin (10 nM) treatment was less effective as an antiproliferative agent when cells were concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent activator of PKC isozymes.	Sirolimus	18-27	protein kinase C eta	Homo sapiens	223-226
16832347-4	2007	Rapamycin-insensitive growth was owing to PKC-eta, as U-1242MG and U-251MG cells infected with a kinase-dead form of PKC-eta (U-251kr) were susceptible to rapamycin-induced inhibition of cell proliferation.	Sirolimus	155-164	protein kinase C eta	Homo sapiens	117-124
16832347-5	2007	Furthermore, U-251MG cells transfected with PKC-eta antisense oligonucleotides were sensitive to rapamycin.	Sirolimus	97-106	protein kinase C eta	Homo sapiens	44-51
17110594-4	2007	Hypoxia (1% O(2)) rapidly (>30 minutes) and in a concentration-dependent manner promoted rapamycin-sensitive and sustained phosphorylation of mTOR-Ser2448 followed by nuclear translocation in RAECs.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	145-149
17110594-6	2007	Phosphorylation of Akt was inhibited by mTOR knockdown and partially with rapamycin.	Sirolimus	74-83	AKT serine/threonine kinase 1	Homo sapiens	19-22
17671379-8	2007	In addition, treatment with rapamycin also down-regulated the enhanced levels of renal p-Akt, phospho-p70S6 kinase, and phospho-ribosomal S6 protein in diabetic rats.	Sirolimus	28-37	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
16952420-0	2007	Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70(S6K) in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	66-70
16920414-5	2007	Sirolimus also significantly reduced the deposition of elastin, collagen III and fibronectin within the vascular wall.	Sirolimus	0-9	fibronectin 1	Homo sapiens	81-92
16920414-8	2007	Local delivery of sirolimus during angioplasty attenuated the expression of structural proteins that included lamin A, vimentin, alpha-1-antitrypsin, and alpha-actin.	Sirolimus	18-27	serpin family A member 1	Homo sapiens	129-148
16952420-3	2007	Therefore, the effects of insulin and rapamycin (an inhibitor of mTOR) on the phosphorylation of mTOR (Ser 2448) and p70(S6K) (Thr 389) as well as on cell proliferation in parental HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB (HepG2-CA-Akt/PKB) were studied.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	97-101
16952420-5	2007	Rapamycin treatment partially decreased the phosphorylation of mTOR but completely abolished the phosphorylation of p70(S6K) in the absence as well as presence of insulin in both cell lines.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	63-67
17393579-5	2007	Importantly, mutations in upstream negative regulators of mTOR cause hamartomas, haemangiomas, and cancers that are sensitive to rapamycin treatment.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	58-62
16952420-5	2007	Rapamycin treatment partially decreased the phosphorylation of mTOR but completely abolished the phosphorylation of p70(S6K) in the absence as well as presence of insulin in both cell lines.	Sirolimus	0-9	insulin	Homo sapiens	163-170
16952420-9	2007	Parental HepG2 cells showed decline in the cell proliferation after 48 h and the presence of insulin prolonged cell survival until 120 h and this effect were also inhibited by rapamycin under serum deprived conditions.	Sirolimus	176-185	insulin	Homo sapiens	93-100
17453966-0	2007	Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.	Sirolimus	0-9	CD4 molecule	Homo sapiens	23-26
18034588-8	2007	Because of activation of the mammalian target of rapamycin (mTOR) pathway, the use of sirolimus (rapamycin) an mTOR inhibitor, markedly reduced cyst formation and decreased polycystic kidney size in several animal models.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	29-58
18034588-8	2007	Because of activation of the mammalian target of rapamycin (mTOR) pathway, the use of sirolimus (rapamycin) an mTOR inhibitor, markedly reduced cyst formation and decreased polycystic kidney size in several animal models.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	60-64
18034588-8	2007	Because of activation of the mammalian target of rapamycin (mTOR) pathway, the use of sirolimus (rapamycin) an mTOR inhibitor, markedly reduced cyst formation and decreased polycystic kidney size in several animal models.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	111-115
17210710-7	2007	Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	106-110
17210710-7	2007	Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	275-279
17453966-10	2007	The addition of rapamycin inhibited expansion of non-regulatory T cells at doses > or =1 ng/mL while increasing suppressor activity and the percentage of CD4(+) CD25(+) CD27(+) Foxp3(+) cells.	Sirolimus	16-25	CD4 molecule	Homo sapiens	157-160
17136757-10	2007	Addition of the inhibitors WP631, mitoxantrone, and Rapamycin to keloid keratinocyte and fibroblast co-cultures, downregulated secreted VEGF expression in a dose-dependent manner, suggesting therapeutic potential for these compounds in the treatment of keloid scars.	Sirolimus	52-61	vascular endothelial growth factor A	Homo sapiens	136-140
17335296-1	2007	Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits cell cycle progression and has proven to be a potent immunosuppressive agent for use in solid organ transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-44
17335296-1	2007	Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits cell cycle progression and has proven to be a potent immunosuppressive agent for use in solid organ transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
17182569-0	2007	Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.	Sirolimus	97-106	CD4 molecule	Homo sapiens	48-51
17182569-3	2007	Human purified CD4(+)CD25(high) T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4(+)CD25(low) or CD4(+)CD25(-) T cells did not.	Sirolimus	146-155	CD4 molecule	Homo sapiens	15-18
17182569-3	2007	Human purified CD4(+)CD25(high) T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4(+)CD25(low) or CD4(+)CD25(-) T cells did not.	Sirolimus	146-155	interleukin 2	Homo sapiens	81-85
17182569-4	2007	The expanding pure populations of CD4(+)CD25(high) T cells were resistant to rapamycin-accelerated apoptosis.	Sirolimus	77-86	CD4 molecule	Homo sapiens	34-37
17182569-5	2007	In contrast, proliferation of CD4(+)CD25(-) T cells was blocked by rapamycin, which induced their apoptosis.	Sirolimus	67-76	CD4 molecule	Homo sapiens	30-33
17260122-13	2007	Dexamethasone increased alkaline phosphatase activity, calcium content, and osteocalcin content, but these effects were decreased by rapamycin.	Sirolimus	133-142	bone gamma-carboxyglutamate protein	Homo sapiens	76-87
18370913-7	2007	CONCLUSION: Endothelial expression of Akt is responsible for tumor responsiveness to rapamycin.	Sirolimus	85-94	AKT serine/threonine kinase 1	Homo sapiens	38-41
16962100-9	2007	Rapamycin, which inhibits mTOR leading to inactivation of p70(S6K), did not affect acetaldehyde-induced inhibition on phosphorylation of Akt and mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	26-30
17895299-2	2007	The immunosuppressive effect of sirolimus is due to inhibition of the mammalian target of rapamycin, necessary for the proliferation and clonal expansion of activated T-cells.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	70-99
17259349-8	2007	Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was found to regulate PDCD4 expression because inhibition of PI3K by LY294002 and wortmannin or of mTOR by rapamycin induced PDCD4 protein and mRNA expression.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	37-40
17259349-8	2007	Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was found to regulate PDCD4 expression because inhibition of PI3K by LY294002 and wortmannin or of mTOR by rapamycin induced PDCD4 protein and mRNA expression.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	72-76
17142730-6	2006	Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported.	Sirolimus	15-24	CD4 molecule	Homo sapiens	58-61
16908189-4	2007	All three natively purified proteins have, within experimental error, the same peptidyl-prolyl isomerase (PPIase) activity (k(cat)/K(m) approximately 1 x 10(6)M(-1)s(-1)), and bind a natural inhibitor, rapamycin, with the same high affinity (K(d) approximately 6 nM).	Sirolimus	202-211	FKBP prolyl isomerase 1B	Homo sapiens	106-112
16908189-5	2007	However, refolding of the protein containing the longer tag in vitro results in reduced PPIase activity (the k(cat)/K(m) was reduced from 1 x 10(6)M(-1)s(-1) to 0.81 x 10(6)M(-1)s(-1)) and a 6-fold affinity loss for rapamycin.	Sirolimus	216-225	FKBP prolyl isomerase 1B	Homo sapiens	88-94
17580729-1	2007	The sirolimus-eluting coronary stent received CE Mark approval in Europe in April 2002.	Sirolimus	4-13	microtubule affinity regulating kinase 1	Homo sapiens	49-53
17077083-0	2006	Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway.	Sirolimus	103-112	forkhead box O1	Homo sapiens	15-20
17077083-0	2006	Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway.	Sirolimus	103-112	insulin	Homo sapiens	38-45
17142730-0	2006	Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.	Sirolimus	0-9	CD4 molecule	Homo sapiens	43-46
17142730-6	2006	Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported.	Sirolimus	15-24	CD4 molecule	Homo sapiens	151-154
17142730-7	2006	The capacity of rapamycin to allow growth of functional CD4+CD25+FOXP3+ Tregs, but also to deplete T effector cells, can be exploited for the design of novel and safe in vitro protocols for cellular immunotherapy in T cell-mediated diseases.	Sirolimus	16-25	CD4 molecule	Homo sapiens	56-59
17166376-0	2006	[The role of caspase-3 in rapamycin-induced apoptosis of hepatocellular carcinoma BEL-7402 cells].	Sirolimus	26-35	caspase 3	Homo sapiens	13-22
17167087-4	2006	When the activation of mTOR was prevented by posttraining injection of rapamycin into the amygdala, formation of the memory and the increase in p70s6 kinase phosphorylation was attenuated.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	23-27
16912221-3	2006	This study shows that in follicular lymphoma (FL) cells, mTOR is active because the cells displayed rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	57-61
17166376-7	2006	Marked morphologic changes of cell apoptosis, such as chromatin condensation and nuclear fragmentation, were observed clearly at 48 h after exposion to rapamycin; Caspase-3 was activated by the loss of Caspase-3 proenzyme (32-ku) and its 20-ku subunit appeared at 24 h after incubation.	Sirolimus	152-161	caspase 3	Homo sapiens	163-172
17166376-8	2006	Caspase-3 inhibitor z-DEVD-FMK could block the apoptosis induced by rapamycin.	Sirolimus	68-77	caspase 3	Homo sapiens	0-9
16929481-6	2006	Inhibition of the kinase mTOR, a key player in the integration of nutrition and growth signals into protein synthesis, with rapamycin reduced serine phosphorylation of eIF3i and resulted in a loss of anchorage-independent growth.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	25-29
17142137-4	2006	Rapamycin, a uniquely specific mTOR inhibitor with clinical applications, increased fatty acid oxidation by 60% accompanied by increased activities of carnitine palmitoyltransferases I and II, the former believed to be the primary intracellular regulatory enzyme of the fatty acid oxidation pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-35
17142137-7	2006	Rapamycin treatment also decreased baseline phosphorylation of mTOR residues S2448 and S2481 by 30% and almost completely abolished p70 S6 kinase phosphorylation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	63-67
17142137-8	2006	These results show that rapamycin causes a metabolic shift from glucose utilization to fatty acid oxidation in model muscle cells in the presence of nutrient abundance and underline the importance of mTOR as a key regulator in glucose and lipid metabolism.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	200-204
17050735-4	2006	In the presence of rapamycin, which induces a tight association between FKBP (FK506-binding protein) and FRAP (FKBP-rapamycin-associated protein), an FKBP-tagged Golgi enzyme can be trapped when it visits the ER by an ER-retained protein fused to FRAP.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	105-109
17095607-3	2006	Deleting PMR1 in two genetic backgrounds confers rapamycin resistance.	Sirolimus	49-58	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	9-13
17050735-4	2006	In the presence of rapamycin, which induces a tight association between FKBP (FK506-binding protein) and FRAP (FKBP-rapamycin-associated protein), an FKBP-tagged Golgi enzyme can be trapped when it visits the ER by an ER-retained protein fused to FRAP.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	111-144
17050735-4	2006	In the presence of rapamycin, which induces a tight association between FKBP (FK506-binding protein) and FRAP (FKBP-rapamycin-associated protein), an FKBP-tagged Golgi enzyme can be trapped when it visits the ER by an ER-retained protein fused to FRAP.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	247-251
17124526-4	2006	A new class of drugs (inhibitors of mammalian target of rapamycin) that includes sirolimus is being increasingly used in stable kidney transplant recipients.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	36-65
17175265-12	2006	Our discovery of IRI-induced up-regulation of genes associated with calcineurin and mTOR pathways are consistent with clinical observations that FK506 and Rapamycin can alter the course of DGF.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	84-88
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	poly(ADP-ribose) polymerase 1	Homo sapiens	181-208
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	298-301
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	302-306
16715128-3	2006	Here, we show that rapamycin inhibited type I insulin-like growth factor (IGF-I)-stimulated motility of a panel of cell lines.	Sirolimus	19-28	insulin like growth factor 1	Homo sapiens	74-79
16715128-7	2006	However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1.	Sirolimus	62-71	nuclear factor kappa B subunit 1	Homo sapiens	127-132
16715128-13	2006	Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	19-24
17121928-8	2006	Consistent with this, the mTOR inhibitor rapamycin strongly potentiated As(2)O(3)-mediated suppression of primitive leukemic progenitors from the bone marrow of chronic myelogenous leukemia patients.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	26-30
16840725-0	2006	Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.	Sirolimus	161-170	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	17-22
16981910-3	2006	Rapamycin, a central immunosuppressant in islet transplantation, is an mTOR inhibitor that has been shown to inhibit cancer angiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	71-75
16981910-7	2006	The expression of angiogenesis-related factors VEGF, alphaVbeta3 integrin and thrombospondin-1 on islet endothelium was altered in the presence of rapamycin.	Sirolimus	147-156	vascular endothelial growth factor A	Homo sapiens	47-51
16981910-7	2006	The expression of angiogenesis-related factors VEGF, alphaVbeta3 integrin and thrombospondin-1 on islet endothelium was altered in the presence of rapamycin.	Sirolimus	147-156	thrombospondin 1	Homo sapiens	78-94
16883576-5	2006	Rapamycin inhibited p70S6K1, but not AKT activation, indicating that rapamycin affects HDM2 phosphorylation via an AKT-independent mechanism.	Sirolimus	69-78	AKT serine/threonine kinase 1	Homo sapiens	115-118
17003813-11	2006	However, prior induction of HO-1 by cobalt protoporphyrin improved the renal dysfunction imposed by rapamycin, mostly at later time points.	Sirolimus	100-109	heme oxygenase 1	Mus musculus	28-32
17121914-0	2006	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	30-62
17121914-10	2006	Rapamycin could fully inhibit S6 in all cell lines, but this was accompanied by activation of Akt phosphorylation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	94-97
17121914-12	2006	Therefore, in select cell lines, inhibition of both S6 and Akt was achieved only with the combination of erlotinib and rapamycin.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	59-62
17121899-1	2006	PURPOSE: To show the efficacy of targeting EWS/FLI-1 expression with a combination of specific antisense oligonucleotides and rapamycin for the control of Ewing"s sarcoma (EWS) cell proliferation in vitro and the treatment of mouse tumor xenografts in vivo.	Sirolimus	126-135	Ewing sarcoma breakpoint region 1	Mus musculus	172-175
17121899-2	2006	EXPERIMENTAL DESIGN: EWS cells were simultaneously exposed to EWS/FLI-1-specific antisense oligonucleotides and rapamycin for various time periods.	Sirolimus	112-121	Ewing sarcoma breakpoint region 1	Mus musculus	21-24
16914544-6	2006	We determined that rapamycin efficiently activates AP-1-driven transcription by rapidly inducing c-jun/AP-1 phosphorylation with activation of the c-Jun N-terminal kinase (JNK) cascade, resulting in enhanced binding of AP-1.DNA complex formation and AP-1-dependent gene transactivation.	Sirolimus	19-28	mitogen-activated protein kinase 8	Homo sapiens	147-170
16914544-6	2006	We determined that rapamycin efficiently activates AP-1-driven transcription by rapidly inducing c-jun/AP-1 phosphorylation with activation of the c-Jun N-terminal kinase (JNK) cascade, resulting in enhanced binding of AP-1.DNA complex formation and AP-1-dependent gene transactivation.	Sirolimus	19-28	mitogen-activated protein kinase 8	Homo sapiens	172-175
16914544-7	2006	Conversely, the JNK inhibitor SP600125 inhibited rapamycin-induced MMP-1 gene transactivation and AP-1/DNA interactions.	Sirolimus	49-58	mitogen-activated protein kinase 8	Homo sapiens	16-19
16955484-7	2006	This phenomenon is associated with caspase-3 activation, and inhibition of mTOR by the inhibitor rapamycin enhances Abeta-induced cell death.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	75-79
16955484-7	2006	This phenomenon is associated with caspase-3 activation, and inhibition of mTOR by the inhibitor rapamycin enhances Abeta-induced cell death.	Sirolimus	97-106	amyloid beta precursor protein	Homo sapiens	116-121
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	Sirolimus	137-146	mitogen-activated protein kinase 1	Homo sapiens	61-64
17041628-2	2006	Rapamycin, the naturally occurring inhibitor of mTOR, along with a number of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compounds containing minor chemical modifications to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	48-52
17047067-3	2006	The mTOR inhibitor rapamycin and its derivatives are cytotoxic to a number of cell lines.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	69-73
17023663-2	2006	We found that the mTOR inhibitor, rapamycin, increased the Kv1.1 voltage-gated potassium channel protein in hippocampal neurons and promoted Kv1.1 surface expression on dendrites without altering its axonal expression.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	18-22
16919239-5	2006	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment of dermal fibroblasts with rapamycin, a potent inhibitor of mTOR abolished procollagen I production.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	47-51
16919239-5	2006	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment of dermal fibroblasts with rapamycin, a potent inhibitor of mTOR abolished procollagen I production.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	172-176
16874098-4	2006	In rapamycin-treated HEK293 cells, there was little accumulation of endogenous GABARAP-PL, even in the presence of lysosomal protease-inhibitors, whereas there was significant accumulation of endogenous LC3-II, together with inactivation of the mTor kinase-signaling pathway.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	245-249
16702957-0	2006	Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.	Sirolimus	76-85	AKT serine/threonine kinase 1	Homo sapiens	92-95
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	0-4
17018601-4	2006	The phosphoinositide-3-kinase inhibitor, wortmannin, and the mTOR inhibitor, rapamycin, blocked E(2)-induced activation of p70 ribosomal protein S6 kinase.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	61-65
16924472-7	2006	TSP-1 production by TEC was enhanced by the treatment with LY294002 and wortmannin and with rapamycin, suggesting a negative regulation of TSP-1 expression by the PI3K/Akt/mTOR pathway.	Sirolimus	92-101	thrombospondin 1	Homo sapiens	0-5
17041093-3	2006	In tissue culture, all three cell lines showed decreased phosphorylated S6 ribosomal protein and decreased phosphorylated extracellular signal-regulated kinase (ERK) following treatment with rapamycin and erlotinib, respectively.	Sirolimus	191-200	mitogen-activated protein kinase 1	Homo sapiens	122-159
17041093-3	2006	In tissue culture, all three cell lines showed decreased phosphorylated S6 ribosomal protein and decreased phosphorylated extracellular signal-regulated kinase (ERK) following treatment with rapamycin and erlotinib, respectively.	Sirolimus	191-200	mitogen-activated protein kinase 1	Homo sapiens	161-164
16896936-0	2006	The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	18-22
16896936-13	2006	CONCLUSIONS/INTERPRETATION: Our results indicate that sirolimus decreases ductal cell numbers in culture and alters glucose-stimulated insulin secretion in vivo.	Sirolimus	54-63	insulin	Homo sapiens	135-142
16896936-14	2006	The administration of sirolimus to islet transplant recipients is likely to impair graft function as a result of decreasing ductal neogenesis and induction of insulin resistance.	Sirolimus	22-31	insulin	Homo sapiens	159-166
16989597-4	2006	Rapamycin and its analogues CCI-779, RAD-001 and AP-23573 are known specific inhibitors of the mTOR kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	95-99
16721582-0	2006	Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus.	Sirolimus	145-154	NPHS2 stomatin family member, podocin	Homo sapiens	54-59
16721582-4	2006	We report on a pediatric kidney transplant recipient with NPHS2-associated nephrotic syndrome and FSGS, who developed biopsy-proven recurrence of FSGS 10 years post-transplant in temporal association with conversion from cyclosporin A (CsA)- to sirolimus (SRL)-based immunosuppression, due to histological evidence of severe CsA-induced nephrotoxicity.	Sirolimus	245-254	NPHS2 stomatin family member, podocin	Homo sapiens	58-63
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	nuclear factor kappa B subunit 1	Homo sapiens	188-193
16682955-7	2006	This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	92-96
16682955-7	2006	This may reflect both inhibition of PI-3 kinase pathways and mammalian target of rapamycin (mTOR)-dependent signaling, as the phosphorylation of Thr389 site was sensitive to treatment with the PI3-K and mTOR inhibitors, LY294002 and rapamycin, respectively.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	203-207
16816403-5	2006	The stimulation of S6K1 in response to PGF2alpha treatment was abolished by the mTOR inhibitor rapamycin.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
17125709-13	2006	CONCLUSIONS: Sirolimus-eluting stent implantation in diabetics with very small vessels is safe and effective, even in insulin-dependent patients.	Sirolimus	13-22	insulin	Homo sapiens	118-125
16920556-0	2006	Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.	Sirolimus	8-17	negative elongation factor complex member C/D, Th1l	Mus musculus	28-31
16847060-5	2006	Disruption of this complex following treatment with the mTOR pharmacological inhibitor rapamycin lowered mitochondrial membrane potential, oxygen consumption, and ATP synthetic capacity.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	56-60
16959574-5	2006	Inhibition of mTOR by rapamycin blocks Wnt-induced cell growth and tumor development, suggesting a potential therapeutic value of rapamycin for cancers with activated Wnt signaling.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
16923447-0	2006	Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent.	Sirolimus	142-151	C-reactive protein	Homo sapiens	12-30
16923447-2	2006	We hypothesized that PCI with sirolimus-eluting stents (SESs) would result in a smaller increase in CRP compared with BMSs and that a high CRP level before PCI would be associated with a higher incidence of death or myocardial infarction at 12 months, regardless of the type of stent implanted.	Sirolimus	30-39	C-reactive protein	Homo sapiens	100-103
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	65-68
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	0-9	selectin, lymphocyte	Mus musculus	181-191
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	0-9	selectin, lymphocyte	Mus musculus	193-198
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	109-118	negative elongation factor complex member C/D, Th1l	Mus musculus	65-68
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	109-118	selectin, lymphocyte	Mus musculus	181-191
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	65-68
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	95-98
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	negative elongation factor complex member C/D, Th1l	Mus musculus	65-68
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	negative elongation factor complex member C/D, Th1l	Mus musculus	95-98
16969122-3	2006	Inhibitors of mTOR currently under evaluation in cancer clinical trials are rapamycin (also known as sirolimus, Wyeth) and derivatives temsirolimus (CCI-779, Wyeth), everolimus, (RAD001, Novartis Pharma AG), and AP23573 (Ariad Pharmaceuticals).	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	14-18
16404634-0	2006	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.	Sirolimus	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	75-107
16404634-0	2006	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.	Sirolimus	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-114
16404634-3	2006	Therefore, the aim of this study was to determine whether the immunosuppressants cyclosporin A, tacrolimus and sirolimus are inhibitors and/or substrates of BCRP.	Sirolimus	111-120	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	157-161
16404634-5	2006	RESULTS: Cyclosporin A, tacrolimus and sirolimus significantly inhibited BCRP-mediated efflux of pheophorbide A, mitoxantrone and BODIPY-prazosin.	Sirolimus	39-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	73-77
16916320-7	2006	Interestingly, when phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling was blocked simultaneously by either LY294002 or rapamycin, growth inhibition mediated by SU11248 was potentiated.	Sirolimus	74-83	AKT serine/threonine kinase 1	Homo sapiens	50-53
16404634-6	2006	The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.	Sirolimus	51-60	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	79-83
16404634-7	2006	Cyclosporin A, tacrolimus and sirolimus also effectively reversed resistance of HEK cells to topotecan and mitoxantrone conferred by BCRP.	Sirolimus	30-39	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	133-137
16959613-4	2006	Furthermore, in TSC2(-/-) MEFs, the rapamycin-mediated inhibition of deregulated mTOR activity restored NF-kappaB activation and survival.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	81-85
16959613-4	2006	Furthermore, in TSC2(-/-) MEFs, the rapamycin-mediated inhibition of deregulated mTOR activity restored NF-kappaB activation and survival.	Sirolimus	36-45	nuclear factor kappa B subunit 1	Homo sapiens	104-113
16959613-5	2006	This rapamycin-mediated effect was reversed by inhibition of NF-kappaB transcriptional activation or by inhibition of ERK1/2 MAP kinase or PI-3K pathways, which lie on signaling cascades that lead to NF-kappaB activation.	Sirolimus	5-14	nuclear factor kappa B subunit 1	Homo sapiens	61-70
16911499-15	2006	Sirolimus is also a substrate of p-glycoprotein and thus may be significantly affected by amiodarone.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	33-47
16959613-5	2006	This rapamycin-mediated effect was reversed by inhibition of NF-kappaB transcriptional activation or by inhibition of ERK1/2 MAP kinase or PI-3K pathways, which lie on signaling cascades that lead to NF-kappaB activation.	Sirolimus	5-14	nuclear factor kappa B subunit 1	Homo sapiens	200-209
16803888-4	2006	Importantly, the impact of Rheb on B-Raf/C-Raf heterodimerization and kinase activity are rapamycin-insensitive, indicating that they are independent of Rheb activation of the mammalian target of rapamycin-Raptor complex.	Sirolimus	90-99	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	35-40
16837925-0	2006	Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.	Sirolimus	72-81	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
16837925-2	2006	Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.	Sirolimus	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	31-45
16837925-2	2006	Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.	Sirolimus	17-26	ATP binding cassette subfamily B member 1	Homo sapiens	47-50
16985050-5	2006	Rapamycin causes down-regulation of cyclin D3 protein, retinoblastoma hypophosphorylation, loss of cyclin-dependent kinase (cdk) 4, cdk6, and cdk2 activity.	Sirolimus	0-9	cyclin D3	Homo sapiens	36-45
16985050-5	2006	Rapamycin causes down-regulation of cyclin D3 protein, retinoblastoma hypophosphorylation, loss of cyclin-dependent kinase (cdk) 4, cdk6, and cdk2 activity.	Sirolimus	0-9	cyclin dependent kinase 6	Homo sapiens	132-136
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	14-23	cyclin D3	Homo sapiens	70-79
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	70-79
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	70-79
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	70-79
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
16985050-7	2006	Additionally, rapamycin caused accumulation of ubiquitinated forms of cyclin D3 protein, proteasome inhibitors blocked the effect of rapamycin on cyclin D3, and rapamycin stimulated the activity of the proteasome, showing that the effect of rapamycin on cyclin D3 is proteasome proteolysis dependent.	Sirolimus	133-142	cyclin D3	Homo sapiens	146-155
17026798-5	2006	Rapamycin and its analogues, including temsirolimus, everolimus, and AP23573, block the mTOR signaling pathway and induce a cellular state akin to starvation, with significant antitumor activity in a variety of malignancies, including renal cell carcinoma (RCC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
17026798-6	2006	Current data from ongoing clinical trials suggest that mTOR-targeted therapy with rapamycin derivatives is well tolerated with significant clinical activity in patients with advanced-stage RCC.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	55-59
16939811-5	2006	Rapamycin and LY294002 suppressed pS6 in 10 of 11 cases that showed increased basal levels, consistent with phosphatidylinositol 3 (PI3)-kinase/Akt/mTOR signaling being the predominant upstream signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	148-152
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Sirolimus	219-228	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-3	2006	We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.	Sirolimus	307-316	ATP binding cassette subfamily B member 1	Homo sapiens	25-28
16837925-8	2006	Pgp expression and function were confirmed in HRECs and cyclosporine and sirolimus were shown to be Pgp inhibitors in this model.	Sirolimus	73-82	ATP binding cassette subfamily B member 1	Homo sapiens	100-103
16837925-13	2006	The inhibitory effect of sirolimus on Pgp-mediated efflux and the cellular concentration of cyclosporine could explain the exacerbation of cyclosporine nephrotoxicity observed clinically.	Sirolimus	25-34	ATP binding cassette subfamily B member 1	Homo sapiens	38-41
16966063-1	2006	Sirolimus (SRL, rapamycin) is a potent immunosuppressive drug that binds to and inhibits mammalian Target Of Rapamycine (mTOR) kinase activity, a central controller of cell growth.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	89-119
16966063-1	2006	Sirolimus (SRL, rapamycin) is a potent immunosuppressive drug that binds to and inhibits mammalian Target Of Rapamycine (mTOR) kinase activity, a central controller of cell growth.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	121-125
16966063-1	2006	Sirolimus (SRL, rapamycin) is a potent immunosuppressive drug that binds to and inhibits mammalian Target Of Rapamycine (mTOR) kinase activity, a central controller of cell growth.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	89-119
16966063-1	2006	Sirolimus (SRL, rapamycin) is a potent immunosuppressive drug that binds to and inhibits mammalian Target Of Rapamycine (mTOR) kinase activity, a central controller of cell growth.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	121-125
16915281-6	2006	Notably, Pml-/- cells and tumours display higher sensitivity both in vitro and in vivo to growth inhibition by rapamycin, and lack of PML inversely correlates with phosphorylation of ribosomal protein S6 and tumour angiogenesis in mouse and human tumours.	Sirolimus	111-120	promyelocytic leukemia	Mus musculus	9-12
16922504-7	2006	Hence, we have identified compounds that can directly mimic rapamycin or can dissociate the FRB binding from the inhibition of the catalytic activity of mTOR.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	153-157
16597595-3	2006	Surprisingly, the mTOR inhibitor rapamycin induces only apoptosis in HMC-1 cells bearing the D816V but not the V560G mutation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	18-22
16885364-2	2006	We have previously shown that enforced expression of Akt, which is a downstream effector of PI(3)K, could promote tumorigenesis and drug resistance in the Emu-myc mouse lymphoma model, and that these tumors were particularly sensitive to inhibition of mammalian target of rapamycin (mTOR) with rapamycin when combined with conventional chemotherapy.	Sirolimus	272-281	thymoma viral proto-oncogene 1	Mus musculus	53-56
16825603-4	2006	Furthermore, cotreatment with rapamycin, a specific mTOR inhibitor, and troglitazone additively inhibited both p70S6K activity and protein synthesis, suggesting that the inhibitory effects of troglitazone are not mediated by mTOR.	Sirolimus	30-39	ribosomal protein S6 kinase B1	Bos taurus	111-117
16904613-5	2006	Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor.	Sirolimus	60-69	AKT serine/threonine kinase 1	Homo sapiens	0-3
16904613-5	2006	Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor.	Sirolimus	60-69	AKT serine/threonine kinase 1	Homo sapiens	153-156
16904613-5	2006	Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	0-3
16904613-5	2006	Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	153-156
16885382-5	2006	DHT treatment increased mTOR activity as assessed by phosphorylation of the downstream targets p70 S6 kinase and 4E-BP1, and mTOR inhibition with rapamycin blocked the DHT-stimulated increase in cyclin D proteins.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	24-28
16885382-5	2006	DHT treatment increased mTOR activity as assessed by phosphorylation of the downstream targets p70 S6 kinase and 4E-BP1, and mTOR inhibition with rapamycin blocked the DHT-stimulated increase in cyclin D proteins.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	125-129
16871590-4	2006	Immunosuppressive drugs used were tacrolimus (a calcineurin inhibitor) and its synergistic partners, rapamycin (a regulator of the mammalian target of rapamycin [mTOR]) and mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibitor).	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	131-160
16807405-5	2006	Therefore, contrary to the expectations, long-term exposure to rapamycin caused the impairment of IRS signaling and AKT activation, and this would help to explain the antiproliferative effect and the possible deterioration of glucose metabolism that are observed in rapamycin-treated patients.	Sirolimus	63-72	AKT serine/threonine kinase 1	Homo sapiens	116-119
16807405-2	2006	On the basis of in vitro studies, the mTOR inhibitor rapamycin has been reported to lead to enhanced activation of AKT by relieving this feedback inhibition on IRS function.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	38-42
16807405-2	2006	On the basis of in vitro studies, the mTOR inhibitor rapamycin has been reported to lead to enhanced activation of AKT by relieving this feedback inhibition on IRS function.	Sirolimus	53-62	AKT serine/threonine kinase 1	Homo sapiens	115-118
16899564-6	2006	PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway.	Sirolimus	40-49	prolactin	Homo sapiens	0-3
16899564-6	2006	PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	18-22
16899564-6	2006	PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	51-55
16899564-8	2006	PRL-induced phosphorylation of p70S6K and 4E-BP1 was inhibited by rapamycin, but not by okadaic acid (inhibitor of protein phosphatase, PP2A).	Sirolimus	66-75	prolactin	Homo sapiens	0-3
16877971-4	2006	METHODS: Male FVB/N mice underwent transverse aortic constriction (TAC) for 5 weeks to allow for establishment of LVH, followed by treatment with the mTOR inhibitor, Rapamune (2 mg/kg per day, gavage), for 4 weeks.	Sirolimus	166-174	mechanistic target of rapamycin kinase	Homo sapiens	150-154
16877971-11	2006	CONCLUSION: Despite sustained pressure overload, inhibition of mTOR by a 4-week period of Rapamune treatment attenuates chronically established LVH and cardiac fibrosis with preserved contractile function.	Sirolimus	90-98	mechanistic target of rapamycin kinase	Homo sapiens	63-67
16769083-1	2006	Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian target of rapamycin (mTOR) signaling and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	79-108
16769083-1	2006	Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian target of rapamycin (mTOR) signaling and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	110-114
16705060-6	2006	TNF-alpha treatment decreased ATGL transcript in a time-dependent manner that paralleled TNF-alpha downregulation of PPARgamma with a maximal decrease noted by 6 h. TNF-alpha effects on ATGL were attenuated by pretreatment with PD-98059, LY-294002, or rapamycin, suggesting involvement of the p44/42 MAP kinase, PI 3-kinase, and p70 ribosomal protein S6 kinase signals.	Sirolimus	252-261	tumor necrosis factor	Mus musculus	0-9
16769083-1	2006	Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian target of rapamycin (mTOR) signaling and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	79-108
16769083-1	2006	Rapamycin (sirolimus) is an antibiotic that inhibits protein synthesis through mammalian target of rapamycin (mTOR) signaling and is used as an immunosuppressant in the treatment of organ rejection in transplant recipients.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	110-114
16717100-7	2006	Phosphorylation of p70(S6K), a known target of mTOR, occurred rapidly following T3 treatment and was inhibited by rapamycin and wortmannin.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	47-51
16730658-8	2006	Preincubation of the oocytes for 24 h with rapamycin (50 nM) did not significantly affect Ip in the absence of mTOR but virtually abolished the increase of Ip following coexpression of mTOR.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	185-189
16951268-11	2006	Rapamycin in a dose-dependent fashion inhibited growth more in SCC-15, which correlated with a greater reduction in constitutively activated p-mTOR (Ser 2448) as shown by Western blotting.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	143-147
16951268-3	2006	Because the mammalian target of the rapamycin (mTOR) pathway contributes to the activation of NF-kappaB through immunophilin/mTOR signaling, we investigated: (a) the immunohistochemical expression and state of activation and potential clinical significance of components of the mTOR signal transduction pathway in SCCT patients (morphoproteomics); and (b) the inhibitory effects of rapamycin on the growth and state of activation of mTOR in 2 HNSCC cell lines (pharmacoproteomics).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	47-51
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	200-209	AKT serine/threonine kinase 1	Homo sapiens	75-78
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	200-209	mechanistic target of rapamycin kinase	Homo sapiens	79-83
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	215-224	AKT serine/threonine kinase 1	Homo sapiens	75-78
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	79-83
16818631-8	2006	We also show that inhibition of mTOR with rapamycin, as well as silencing mTOR gene product expression using mTOR-specific small interfering RNA, decreased phosphorylation of mTOR signaling proteins and induced cell cycle arrest and apoptosis in ALK+ ALCL cells.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	32-36
16645158-6	2006	However, rapamycin potently activates AKT-dependent signaling, an effect that overrides the downregulation of this pathway by insulin resistance and that causes phosphorylation of the AKT-dependent transcription factor FOXO1.	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	38-41
16645158-6	2006	However, rapamycin potently activates AKT-dependent signaling, an effect that overrides the downregulation of this pathway by insulin resistance and that causes phosphorylation of the AKT-dependent transcription factor FOXO1.	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	184-187
16645158-6	2006	However, rapamycin potently activates AKT-dependent signaling, an effect that overrides the downregulation of this pathway by insulin resistance and that causes phosphorylation of the AKT-dependent transcription factor FOXO1.	Sirolimus	9-18	forkhead box O1	Homo sapiens	219-224
16645158-7	2006	This effect is associated with attenuation of the anti-migratory effects of rapamycin under high glucose conditions that are not observed with paclitaxel, as well as with increased protection against ceramide-induced cytotoxicity, both of which are dependent on FOXO1 phosphorylation.	Sirolimus	76-85	forkhead box O1	Homo sapiens	262-267
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	48-52
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	48-52
16855395-4	2006	Since rapamycin is a highly specific inhibitor of a protein kinase called the mammalian target of rapamycin (mTOR), many investigators have concluded that mTOR signaling is necessary for the mechanically induced growth of skeletal muscle.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	78-107
16855395-4	2006	Since rapamycin is a highly specific inhibitor of a protein kinase called the mammalian target of rapamycin (mTOR), many investigators have concluded that mTOR signaling is necessary for the mechanically induced growth of skeletal muscle.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	109-113
16855395-4	2006	Since rapamycin is a highly specific inhibitor of a protein kinase called the mammalian target of rapamycin (mTOR), many investigators have concluded that mTOR signaling is necessary for the mechanically induced growth of skeletal muscle.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	155-159
16772439-11	2006	Finally, rapamycin (0.75 mg/kg) administered to rats 2 h before leucine gavage inhibited the phosphorylation of S6 and 4E-BP1 induced by leucine.	Sirolimus	9-18	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	119-125
16815317-0	2006	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.	Sirolimus	20-29	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
16815317-1	2006	BACKGROUND: The low and highly variable oral bioavailability of the immunosuppressant sirolimus is thought to result partly from genetic polymorphism of the CYP3A5 gene.	Sirolimus	86-95	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	157-163
16815317-2	2006	METHODS: This study aimed to evaluate the contribution of the CYP3A5 single-nucleotide polymorphism A6986G to the interindividual variability of sirolimus pharmacokinetics in 47 renal transplant patients at steady state, 21 of whom were also followed up for the first 3 months after transplantation.	Sirolimus	145-154	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	62-68
16815317-9	2006	Patients with the CYP3A5*1/*1 and *1/*3 genotypes required a significantly higher sirolimus daily dose to achieve the same blood concentration at steady state as *3/*3 patients.	Sirolimus	82-91	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	18-24
16815317-11	2006	CONCLUSION: These results confirm that sirolimus metabolic activity and oral clearance are significantly decreased in patients who are homozygous for the CYP3A5*3 single-nucleotide polymorphism and suggest that the determination of this polymorphism could be useful for a priori dose adjustment of sirolimus, given the long half-life of this drug.	Sirolimus	39-48	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	154-160
16815317-11	2006	CONCLUSION: These results confirm that sirolimus metabolic activity and oral clearance are significantly decreased in patients who are homozygous for the CYP3A5*3 single-nucleotide polymorphism and suggest that the determination of this polymorphism could be useful for a priori dose adjustment of sirolimus, given the long half-life of this drug.	Sirolimus	298-307	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	154-160
16916489-5	2006	Rapamycin (sirolimus), the prototypic mTOR inhibitor, exhibits activity in acute myeloid leukemia.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
16916489-5	2006	Rapamycin (sirolimus), the prototypic mTOR inhibitor, exhibits activity in acute myeloid leukemia.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	38-42
16815851-4	2006	The proliferation signal inhibitors (PSIs)/mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus have shown considerable promise in reducing acute rejection in renal transplant recipients.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	43-72
16849522-8	2006	Therefore, our results indicate that Akt can augment HIF-1alpha expression by increasing its translation under both normoxic and hypoxic conditions; however, the pathway we are investigating seems to be rapamycin insensitive and mTOR independent.	Sirolimus	203-212	hypoxia inducible factor 1 subunit alpha	Homo sapiens	53-63
16849522-10	2006	We did find that rapamycin could decrease HIF-1alpha expression when cells were cultured in low serum, but this seems to represent a different pathway.	Sirolimus	17-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	42-52
17309148-4	2006	Previous reports demonstrated that rapamycin, which inhibits mTOR activity, sensitizes certain resistant cancer cells to chemotherapeutic agents.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	61-65
16815851-4	2006	The proliferation signal inhibitors (PSIs)/mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus have shown considerable promise in reducing acute rejection in renal transplant recipients.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	74-78
16815856-2	2006	Conversion from CNI-based regimens to proliferation signal inhibitors or mammalian target of rapamycin inhibitors, such as everolimus and sirolimus, has been associated with an improvement in cardiovascular risk.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	73-102
16815857-2	2006	The proliferation signal inhibitors/mammalian target of rapamycin inhibitors everolimus and sirolimus may play an important role in achieving CNI withdrawal.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	36-65
16854316-14	2006	The VEGF protein level in the supernatant of the culture fluid of MHCC97H cells of the RPM group was (890.3 +/- 25.1) pg/ml, significantly lower than that of the control group, (1583.7 +/- 17.3) pg/ml (P = 0.000).	Sirolimus	87-90	vascular endothelial growth factor A	Homo sapiens	4-8
16641152-6	2006	Ang II-induced mammalian target of rapamycin activation, [3H]leucine incorporation, and cellular hypertrophy were inhibited by pretreatment with either batimastat or CRM197 or by pretreatment with rapamycin or the EGFR tyrosine kinase inhibitor AG1478.	Sirolimus	35-44	angiotensinogen	Homo sapiens	0-6
16763566-2	2006	In response to insulin, eIF4B is phosphorylated on Ser422 by S6K in a rapamycin-sensitive manner.	Sirolimus	70-79	insulin	Homo sapiens	15-22
16428340-0	2006	Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	22-31
16428340-0	2006	Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	67-76
16428340-3	2006	We investigated the effect of rapamycin on NF-kappaB activation and apoptosis in vascular smooth muscle cells (VSMCs) stimulated with TNF-alpha.	Sirolimus	30-39	nuclear factor kappa B subunit 1	Homo sapiens	43-52
16185698-10	2006	CONCLUSIONS: This study shows that rapamycin influences the inflammatory phenotypes of SMC in opposite directions: it reduces the high basal NF-kappaB activity in niSMC and enhances NF-kappaB activity and TNF-alpha expression in mSMC.	Sirolimus	35-44	tumor necrosis factor	Rattus norvegicus	205-214
16778294-0	2006	Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.	Sirolimus	0-9	CD4 molecule	Homo sapiens	63-66
16428340-6	2006	Activation of NF-kappaB was accompanied by an increase of Bcl-xL and Bfl-1/A1 proteins, detected by Western blot assay, whereas rapamycin prevented the TNF-alpha-induced enhancement of these antiapoptotic proteins.	Sirolimus	128-137	tumor necrosis factor	Homo sapiens	152-161
16428340-7	2006	The extent of apoptosis of VSMCs exposed to TNF-alpha was significantly enhanced by rapamycin.	Sirolimus	84-93	tumor necrosis factor	Homo sapiens	44-53
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	Sirolimus	130-139	insulin	Homo sapiens	4-11
16627974-7	2006	HIF-1alpha activity was found to be required in Akt-induced melanocyte transformation and tumor growth and it was suppressed greatly by mTOR inhibition with rapamycin.	Sirolimus	157-166	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
16627974-7	2006	HIF-1alpha activity was found to be required in Akt-induced melanocyte transformation and tumor growth and it was suppressed greatly by mTOR inhibition with rapamycin.	Sirolimus	157-166	AKT serine/threonine kinase 1	Homo sapiens	48-51
16627974-7	2006	HIF-1alpha activity was found to be required in Akt-induced melanocyte transformation and tumor growth and it was suppressed greatly by mTOR inhibition with rapamycin.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	136-140
16575396-12	2006	This high incidence of mTOR signaling pathway activation suggests that treatment with mTOR inhibitors, such as Rapamycin, may benefit patients with angiomyolipomas independent of the detection of TSC1/TSC2 loss of heterozygosity.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	23-27
16575396-12	2006	This high incidence of mTOR signaling pathway activation suggests that treatment with mTOR inhibitors, such as Rapamycin, may benefit patients with angiomyolipomas independent of the detection of TSC1/TSC2 loss of heterozygosity.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	86-90
16651733-6	2006	Wortmannin and rapamycin were demonstrated to deactivate suppression of AQP3 expression by insulin and troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal pathway for regulating transcription of AQP3.	Sirolimus	15-24	insulin	Homo sapiens	91-98
16651733-6	2006	Wortmannin and rapamycin were demonstrated to deactivate suppression of AQP3 expression by insulin and troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal pathway for regulating transcription of AQP3.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	198-227
16651733-6	2006	Wortmannin and rapamycin were demonstrated to deactivate suppression of AQP3 expression by insulin and troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal pathway for regulating transcription of AQP3.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	229-233
16651424-5	2006	In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance.	Sirolimus	96-105	tumor protein p53	Homo sapiens	41-44
16651424-5	2006	In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	107-111
16651424-5	2006	In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	198-202
16651424-5	2006	In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance.	Sirolimus	96-105	tumor protein p53	Homo sapiens	264-267
16540312-0	2006	Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	49-53
16427044-9	2006	Simultaneously, treatment with LY294002, PD98059, or rapamycin abolished IFN-gamma-induced apoptosis in M12 cells.	Sirolimus	53-62	interferon gamma	Homo sapiens	73-82
16455781-5	2006	In these same cells, inhibition of the insulin effect by rapamycin occurred in the presence of insulin-induced Foxo1/Foxo3 phosphorylation.	Sirolimus	57-66	insulin	Homo sapiens	39-46
16455781-5	2006	In these same cells, inhibition of the insulin effect by rapamycin occurred in the presence of insulin-induced Foxo1/Foxo3 phosphorylation.	Sirolimus	57-66	insulin	Homo sapiens	95-102
16455781-5	2006	In these same cells, inhibition of the insulin effect by rapamycin occurred in the presence of insulin-induced Foxo1/Foxo3 phosphorylation.	Sirolimus	57-66	forkhead box O1	Homo sapiens	111-116
16455781-5	2006	In these same cells, inhibition of the insulin effect by rapamycin occurred in the presence of insulin-induced Foxo1/Foxo3 phosphorylation.	Sirolimus	57-66	forkhead box O3	Homo sapiens	117-122
16427044-7	2006	The IFN-gamma-induced dephosphorylation of pY-STAT3, however, was inhibited when the mTOR pathway was specifically blocked by rapamycin.	Sirolimus	126-135	interferon gamma	Homo sapiens	4-13
16427044-7	2006	The IFN-gamma-induced dephosphorylation of pY-STAT3, however, was inhibited when the mTOR pathway was specifically blocked by rapamycin.	Sirolimus	126-135	signal transducer and activator of transcription 3	Homo sapiens	46-51
16427044-7	2006	The IFN-gamma-induced dephosphorylation of pY-STAT3, however, was inhibited when the mTOR pathway was specifically blocked by rapamycin.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	85-89
16540312-12	2006	Pre-treatment with rapamycin inhibited activation of mTOR signalling and significantly enhanced the sensitivity of CaSki cells to paclitaxel by increasing apoptotic cell death.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	53-57
16603397-0	2006	Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.	Sirolimus	10-19	AKT serine/threonine kinase 1	Homo sapiens	59-66
16775502-8	2006	The inhibitory effects of amino acids are reverted by the mTor inhibitor rapamycin.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	58-62
16638874-5	2006	EXPERIMENTAL DESIGN: Met-1 tumors were used to study the effect of rapamycin treatment on invasive disease.	Sirolimus	67-76	DNA methyltransferase (cytosine-5) 1	Mus musculus	21-26
16638874-9	2006	RESULTS: Rapamycin inhibited in vitro tumor cell proliferation and in vivo Met-1 tumor growth.	Sirolimus	9-18	DNA methyltransferase (cytosine-5) 1	Mus musculus	75-80
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	18-27	AKT serine/threonine kinase 1	Homo sapiens	184-187
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	100-109	AKT serine/threonine kinase 1	Homo sapiens	184-187
16603397-6	2006	The proapoptotic and antitumor effects of rapamycin are suppressed in cells expressing an Akt/PKB mutant that is rapamycin resistant.	Sirolimus	42-51	AKT serine/threonine kinase 1	Homo sapiens	90-97
16603397-6	2006	The proapoptotic and antitumor effects of rapamycin are suppressed in cells expressing an Akt/PKB mutant that is rapamycin resistant.	Sirolimus	113-122	AKT serine/threonine kinase 1	Homo sapiens	90-97
16545079-9	2006	Inhibition of mTOR by rapamycin markedly impairs insulin-activated protein synthesis.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
16545079-9	2006	Inhibition of mTOR by rapamycin markedly impairs insulin-activated protein synthesis.	Sirolimus	22-31	insulin	Homo sapiens	49-56
16396989-10	2006	Rapamycin completely blocked insulin-activated mTOR/p70S(6)K signaling and mitogenesis.	Sirolimus	0-9	insulin	Homo sapiens	29-36
16680182-1	2006	The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen is a significant breakthrough that allows the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year; however, the rate is reduced to 50% at 3 years, attributed to prolonged tacrolimus exposure.	Sirolimus	43-52	insulin	Homo sapiens	151-158
16410300-7	2006	Rapamycin, a specific inhibitor of the FRAP/mammalian target of rapamycin/p70(s6k) pathway, prevented GD-IgG-provoked IL-16 synthesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-73
16410300-7	2006	Rapamycin, a specific inhibitor of the FRAP/mammalian target of rapamycin/p70(s6k) pathway, prevented GD-IgG-provoked IL-16 synthesis.	Sirolimus	0-9	ubiquitin associated and SH3 domain containing B	Homo sapiens	74-77
16647452-1	2006	The mTOR inhibitor sirolimus improves renal transplant function compared with the nephrotoxic calcineurin inhibitors.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
16672275-6	2006	The upregulation of stress genes as a consequence of treatment with rapamycin was largely Msn2p/Msn4p-dependent.	Sirolimus	68-77	stress-responsive transcriptional activator MSN4	Saccharomyces cerevisiae S288C	96-101
16497721-2	2006	Rapamycin, a lipophilic, macrolide antibiotic, induces autophagy by inactivating the protein mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	93-122
16497721-2	2006	Rapamycin, a lipophilic, macrolide antibiotic, induces autophagy by inactivating the protein mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	124-128
16493028-8	2006	Interestingly, rapamycin delayed cell cycle entry of IL-2-sufficient T cells, but did not prevent their expansion.	Sirolimus	15-24	interleukin 2	Homo sapiens	53-57
16466692-6	2006	Preincubation of the oocytes for 32 h with rapamycin (50 nM) decreased the creatine-induced current and abrogated its stimulation by mTOR.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	133-137
16282343-3	2006	We show that phosphorylation of mTOR, p70S6K1, and 4E-BP1 was diminished in thrombopoietin-cultured human MKs after rapamycin treatment.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	32-36
16282343-4	2006	Rapamycin induced an inhibition in the G1/S transition and a decrease in the mean MK ploidy via a diminution of p21 and cyclin D3 occurring at a transcriptional level.	Sirolimus	0-9	cyclin D3	Homo sapiens	120-129
16626322-3	2006	Among these drugs are for example thalidomide,COX-2 inhibitors, PPARgamma agonists (thiazolidindiones) and mTOR antagonists (rapamycin).	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	107-111
16537399-9	2006	Furthermore, we showed that mTOR signaling was partially resistant to rapamycin in muscles subjected to mechanical stimulation.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	28-32
16405911-2	2006	Removal of FKBP12 using FK506 or rapamycin causes an increased open probability and an increase in the frequency of sub-conductance states in RyR1.	Sirolimus	33-42	ryanodine receptor 1	Homo sapiens	142-146
16489035-3	2006	We assessed both effects to understand the mechanism by which mTOR inhibitors like rapamycin sensitize multiple myeloma cells to dexamethasone-induced apoptosis.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	62-66
16507425-12	2006	CONCLUSIONS: Sirolimus enhances immature DC tolerogenicity by induction of T-cell apoptosis, and promotes immature DC-induced inhibition of Stat1, ERK and ATF-2 activation.	Sirolimus	13-22	mitogen-activated protein kinase 1	Mus musculus	147-150
16507425-12	2006	CONCLUSIONS: Sirolimus enhances immature DC tolerogenicity by induction of T-cell apoptosis, and promotes immature DC-induced inhibition of Stat1, ERK and ATF-2 activation.	Sirolimus	13-22	activating transcription factor 2	Mus musculus	155-160
16546986-3	2006	To assess the spectrum of activity in other cell types and to compare PIAs with other inhibitors of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, we compared growth inhibition by PIAs against the PI3K inhibitors LY294002 and wortmannin and the mTOR inhibitor rapamycin in the NCI60 cell line panel.	Sirolimus	165-174	AKT serine/threonine kinase 1	Homo sapiens	141-144
16546986-3	2006	To assess the spectrum of activity in other cell types and to compare PIAs with other inhibitors of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, we compared growth inhibition by PIAs against the PI3K inhibitors LY294002 and wortmannin and the mTOR inhibitor rapamycin in the NCI60 cell line panel.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	176-180
16461044-5	2006	The percentages of CD8+ and CD4+ effector memory T cells, as defined by the CD3+CD45RO+CD27- phenotype, were significantly reduced in patients who received a sirolimus-eluting stent compared with the basal values.	Sirolimus	158-167	CD4 molecule	Homo sapiens	28-31
16477233-9	2006	Next to lowering precursor frequencies, rapamycin also inhibited T cell expansion by inducing apoptosis in divided alloreactive CD4+ and CD8+ T cells.	Sirolimus	40-49	CD4 molecule	Homo sapiens	128-131
16210336-0	2006	Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	89-92
16210336-7	2006	Accordingly, CD4+ CD25+ T(REG)s cultured in the presence of rapamycin displayed much stronger suppressive capacity than CD4+ CD25+ T(REG)s cultured in the presence of CsA.	Sirolimus	60-69	CD4 molecule	Homo sapiens	13-16
16210336-8	2006	In addition, CD4+ CD25+ T(REG) cells cultured in the presence of rapamycin, but not CsA, were able to suppress ongoing alloimmune responses.	Sirolimus	65-74	CD4 molecule	Homo sapiens	13-16
16174862-7	2006	Blockade of the phosphoinositide 3-kinase pathway with LY-294002 or the p70s6-kinase pathway with rapamycin in the presence of TSA and IL-1beta inhibited 389Thr phosphorylation of p70s6 kinase, promoted binding of acetylated histone H4 to the iNOS promoter, and further suppressed iNOS protein expression and iNOS promoter activity.	Sirolimus	98-107	interleukin 1 beta	Mus musculus	135-143
16174862-7	2006	Blockade of the phosphoinositide 3-kinase pathway with LY-294002 or the p70s6-kinase pathway with rapamycin in the presence of TSA and IL-1beta inhibited 389Thr phosphorylation of p70s6 kinase, promoted binding of acetylated histone H4 to the iNOS promoter, and further suppressed iNOS protein expression and iNOS promoter activity.	Sirolimus	98-107	nitric oxide synthase 2, inducible	Mus musculus	243-247
16174862-7	2006	Blockade of the phosphoinositide 3-kinase pathway with LY-294002 or the p70s6-kinase pathway with rapamycin in the presence of TSA and IL-1beta inhibited 389Thr phosphorylation of p70s6 kinase, promoted binding of acetylated histone H4 to the iNOS promoter, and further suppressed iNOS protein expression and iNOS promoter activity.	Sirolimus	98-107	nitric oxide synthase 2, inducible	Mus musculus	281-285
16174862-7	2006	Blockade of the phosphoinositide 3-kinase pathway with LY-294002 or the p70s6-kinase pathway with rapamycin in the presence of TSA and IL-1beta inhibited 389Thr phosphorylation of p70s6 kinase, promoted binding of acetylated histone H4 to the iNOS promoter, and further suppressed iNOS protein expression and iNOS promoter activity.	Sirolimus	98-107	nitric oxide synthase 2, inducible	Mus musculus	281-285
16635351-10	2006	(3) It was also showed that TNF-alpha mRNA expression was significantly inhibited by treatment of either Fludarabine (100 micromol/L) or Rapamycin (25 ng/ml), while TNF-alpha release was not markedly suppressed.	Sirolimus	137-146	tumor necrosis factor	Rattus norvegicus	28-37
16434506-1	2006	Sirolimus (SRL) is a mammalian target of rapamycin inhibitor that, in contrast to cyclosporine (CsA), has been shown to inhibit rather than promote cancers in experimental models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	21-50
16404421-5	2006	Importantly, mutations in upstream negative regulators of mTOR cause hamartomas, haemangiomas, and cancers that are sensitive to rapamycin treatment.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	58-62
16452206-2	2006	In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.	Sirolimus	175-184	AKT serine/threonine kinase 1	Homo sapiens	87-90
16452206-2	2006	In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.	Sirolimus	175-184	mechanistic target of rapamycin kinase	Homo sapiens	148-152
16452206-4	2006	We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Homo sapiens	17-21
16452206-4	2006	We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001.	Sirolimus	224-233	AKT serine/threonine kinase 1	Homo sapiens	144-147
16452206-6	2006	In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.	Sirolimus	61-70	insulin like growth factor 1	Homo sapiens	13-18
16322523-1	2006	We show that mutants lacking either the phosphatase activator Rrd1 or the phosphatase Pph3 are resistant to rapamycin and that double mutants exhibit a synergistic response.	Sirolimus	108-117	phosphoprotein phosphatase PP4 catalytic subunit PPH3	Saccharomyces cerevisiae S288C	86-90
16412252-12	2006	TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2.	Sirolimus	41-50	TSC complex subunit 1	Homo sapiens	0-4
16412252-12	2006	TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2.	Sirolimus	41-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	107-117
16412252-12	2006	TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2.	Sirolimus	41-50	TSC complex subunit 1	Homo sapiens	165-169
16635351-10	2006	(3) It was also showed that TNF-alpha mRNA expression was significantly inhibited by treatment of either Fludarabine (100 micromol/L) or Rapamycin (25 ng/ml), while TNF-alpha release was not markedly suppressed.	Sirolimus	137-146	tumor necrosis factor	Rattus norvegicus	165-174
16424025-6	2006	This approach allowed us to verify the involvement of the Tcl1/Akt/mTOR biochemical pathway in the disease by testing the ability of a specific pharmacologic agent, rapamycin, to slow CLL.	Sirolimus	165-174	T cell lymphoma breakpoint 1	Mus musculus	58-62
16339216-10	2006	Both phenotypes are rescued after pre-treatment with the mTOR inhibitor rapamycin.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	57-61
16424043-2	2006	A biochemical analysis of human mammary tumor cell lines indicated that rapamycin-induced antiproliferative effects correlated with down-regulation of cellular p21 levels and the levels of p21 in cyclin-dependent kinase (Cdk) 2 and 4 complexes.	Sirolimus	72-81	cyclin dependent kinase inhibitor 1A	Homo sapiens	160-163
16424025-6	2006	This approach allowed us to verify the involvement of the Tcl1/Akt/mTOR biochemical pathway in the disease by testing the ability of a specific pharmacologic agent, rapamycin, to slow CLL.	Sirolimus	165-174	thymoma viral proto-oncogene 1	Mus musculus	63-66
16424043-2	2006	A biochemical analysis of human mammary tumor cell lines indicated that rapamycin-induced antiproliferative effects correlated with down-regulation of cellular p21 levels and the levels of p21 in cyclin-dependent kinase (Cdk) 2 and 4 complexes.	Sirolimus	72-81	cyclin dependent kinase inhibitor 1A	Homo sapiens	189-192
16364744-3	2006	The most frequently occurring mutants of p110alpha are oncogenic in vitro and in vivo, show gain of enzymatic function, activate Akt, and their oncogenic activity is sensitive to rapamycin.	Sirolimus	179-188	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	41-50
16424043-4	2006	Experiments using a novel cyclin D1-Cdk2 fusion protein or a kinase-dead mutant of the fusion protein indicated that reversal of rapamycin action required not only the formation of complexes with p21 and PCNA but also complex-associated kinase activity.	Sirolimus	129-138	cyclin dependent kinase inhibitor 1A	Homo sapiens	196-199
16148030-3	2006	Blockade of PI3K-Akt-mTOR-S6K1 signaling by LY-294002, and rapamycin suppressed both thrombin-induced VSMC DNA synthesis and migration.	Sirolimus	59-68	coagulation factor II, thrombin	Homo sapiens	85-93
16298448-6	2006	The addition of alpha-tocopherol also slowed the release of rapamycin from PEG-PCL micelles in the presence of serum albumin, t50% 39 h.	Sirolimus	60-69	albumin	Homo sapiens	117-124
16859513-0	2006	The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
16859513-4	2006	Rapamycin was found to stabilize p27 levels in breast cancer, but whether this effect is mediated through changes in Skp2 expression is unknown.	Sirolimus	0-9	zinc ribbon domain containing 2	Homo sapiens	33-36
16177817-7	2006	However, rapamycin induced elevation of serum hEPO levels, as well as concomitant hematocrit changes, that were dose-dependent, completely reversible, and relatively stable over the course of this study (6 months), with no appreciable change in rapamycin responsiveness.	Sirolimus	9-18	erythropoietin	Homo sapiens	46-50
17048977-12	2006	CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor.	Sirolimus	146-155	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	118-124
17048977-12	2006	CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor.	Sirolimus	228-237	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	118-124
17100699-7	2006	Sirolimus (SRL), as the first member of mTOR inhibitors, has been utilized in many clinical trials with respect to its benefit-risk assessment.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
16380474-4	2006	Acceptance of intrahepatic islet allografts was achieved in CD1d(-/-) mice by a subtherapeutic dose of rapamycin, which was abrogated in conjunction with the transfer of hepatic mononuclear cells from wild-type, but not from CD1d(-/-), mice at islet transplantation.	Sirolimus	103-112	CD1d1 antigen	Mus musculus	60-64
16380474-4	2006	Acceptance of intrahepatic islet allografts was achieved in CD1d(-/-) mice by a subtherapeutic dose of rapamycin, which was abrogated in conjunction with the transfer of hepatic mononuclear cells from wild-type, but not from CD1d(-/-), mice at islet transplantation.	Sirolimus	103-112	CD1d1 antigen	Mus musculus	225-229
17190738-3	2006	Immunosuppressive agents should be used for preventing graft rejection, but of these, rapamycin and cyclosporine A have been reported to inhibit HIF-1.	Sirolimus	86-95	hypoxia inducible factor 1 subunit alpha	Homo sapiens	145-150
16778423-8	2006	The thrombosis and withdrawal of sirolimus may have acted as cofactors in the development of KS, favouring the activation of the VEGF/KDR autocrine loop.	Sirolimus	33-42	vascular endothelial growth factor A	Homo sapiens	129-133
17717968-5	2006	Sirolimus is a member of the mammalian target of rapamycin (mTOR) family.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-58
16647875-3	2006	TOR complex 1 is inhibited by rapamycin and is thought to couple growth cues to cellular metabolism; TOR complex 2 is not inhibited by rapamycin and appears to regulate spatial aspects of growth such as cell polarity.	Sirolimus	30-39	RAR related orphan receptor C	Homo sapiens	0-3
16515634-8	2006	The expression of HIF-1alpha was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group.	Sirolimus	91-100	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
16515634-8	2006	The expression of HIF-1alpha was inhibited, and apoptotic index of tumor cell increased in rapamycin and rapamycin plus paclitaxel group.	Sirolimus	105-114	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
17717968-5	2006	Sirolimus is a member of the mammalian target of rapamycin (mTOR) family.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	60-64
16378065-0	2005	Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment.	Sirolimus	134-143	apolipoprotein E	Homo sapiens	0-16
17937632-0	2006	Sirolimus, the first mTOR inhibitor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	21-25
16005497-5	2006	RESULTS: We found that IL-1beta and IL-6 levels were significantly increased in the coronary sinus of patients receiving either bare, paclitaxel- or sirolimus-eluting stents 20 min after stent implantation as compared with basal concentrations.	Sirolimus	149-158	interleukin 1 beta	Homo sapiens	23-31
16005497-5	2006	RESULTS: We found that IL-1beta and IL-6 levels were significantly increased in the coronary sinus of patients receiving either bare, paclitaxel- or sirolimus-eluting stents 20 min after stent implantation as compared with basal concentrations.	Sirolimus	149-158	interleukin 6	Homo sapiens	36-40
16431291-3	2006	METHODS: We examined the apoptotic effects of the calcineurin inhibitor cyclosporine A and mTOR inhibitor rapamycin on the apoptotic alterations that occur in allospecifically activated human lymphocytes in a one-way mixed lymphocyte culture (MLC).	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	91-95
16150937-6	2005	Furthermore, etoposide consistently decreased the engraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and this effect was enhanced by coincubation with rapamycin, demonstrating that mTOR regulates survival of AML stem cells after etoposide treatment.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Homo sapiens	228-232
17471359-11	2006	CONCLUSIONS: These data suggest that rapamycin induces the loss of P23H opsin and DeltaF508 CFTR from the cell under the experimental conditions described.	Sirolimus	37-46	CF transmembrane conductance regulator	Homo sapiens	92-96
16298682-4	2005	Rapamycin (2 mg/kg/daily), an inhibitor of the mammalian target of rapamycin, and the antioxidant pyrrolidine dithiocarbamate (PDTC; 120 mg/kg/daily), which can inhibit NFkappaB activation, were administered to caAkt mice at 8 weeks of age for 2 weeks.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	169-177
16378065-4	2005	We studied the association between Apo E gene polymorphisms and lipids after kidney transplantation in patients undergoing sirolimus treatment.	Sirolimus	123-132	apolipoprotein E	Homo sapiens	35-40
16204634-6	2005	Expression of a rapamycin-resistant form of S6K2, T388E, in Ba/F3 cells provides a proliferation advantage in the absence or presence of rapamycin, indicating that S6K2 can potentiate IL-3-mediated mitogenic signals.	Sirolimus	16-25	interleukin 3	Mus musculus	184-188
16339025-6	2005	A rapamycin-resistant mutant of mTOR "rescued" the morphogenetic effects of PI3K in the presence of rapamycin.	Sirolimus	2-11	mechanistic target of rapamycin kinase	Homo sapiens	32-36
16123394-9	2005	Apoptotic resistance of mesothelioma cells was significantly reduced by inhibiting either the PI3K/Akt pathway with LY294002 (47 +/- 6% apoptosis) or the mTOR pathway with rapamycin (50 +/- 17% apoptosis).	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	154-158
16354246-1	2005	Sirolimus (Rapamycin, Wyeth Pharmaceuticals Australia Pty Ltd, Baulkham Hills, NSW, Australia) (SRL) has received increasing attention as an immunosuppressant in renal and other solid organ transplantation.	Sirolimus	0-9	sarcalumenin	Homo sapiens	96-99
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	transforming growth factor beta 1	Homo sapiens	13-22
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	ADAM metallopeptidase domain 12	Homo sapiens	31-37
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	71-75
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	76-80
16380505-10	2005	The mTOR antagonist, rapamycin, prevented foci formation of the A549/BMP-2 cells.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	4-8
15895362-7	2005	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment malanoma cells with rapamycin, a potent inhibitor of mTOR effectively induced melanogenesis.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	47-51
15895362-7	2005	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment malanoma cells with rapamycin, a potent inhibitor of mTOR effectively induced melanogenesis.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	165-169
16193082-4	2005	Mechanistic studies showed that inhibition of the mTOR pathway by rapamycin alone sufficiently suppressed the phosphorylation of the downstream molecules p70S6K and 4E-BP-1, but only caused a moderate cytostatic effect.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	50-54
16354246-1	2005	Sirolimus (Rapamycin, Wyeth Pharmaceuticals Australia Pty Ltd, Baulkham Hills, NSW, Australia) (SRL) has received increasing attention as an immunosuppressant in renal and other solid organ transplantation.	Sirolimus	11-20	sarcalumenin	Homo sapiens	96-99
16314788-5	2005	Fibrinogen and CRP levels increased in these patients after sirolimus introduction.	Sirolimus	60-69	fibrinogen beta chain	Homo sapiens	0-10
16314788-5	2005	Fibrinogen and CRP levels increased in these patients after sirolimus introduction.	Sirolimus	60-69	C-reactive protein	Homo sapiens	15-18
16267007-3	2005	Recent studies from our laboratory have shown that neurofibromin also regulates the mammalian target of rapamycin activity in a Ras-dependent fashion, and that the rapamycin-mediated mammalian target of rapamycin inhibition ameliorates the Nf1-/- astrocyte growth advantage.	Sirolimus	104-113	neurofibromin 1	Homo sapiens	51-64
15967420-5	2005	In a separate experiment, rapamycin (2 mg/kg, daily) was administered to TLR4-deficient mice and WT mice immediately following aortic banding.	Sirolimus	26-35	toll-like receptor 4	Mus musculus	73-77
16205124-2	2005	mTOR inhibitors (rapamycin, or analogues such as CCI-779, RAD001, AP23573), which have been shown to have a potent anti-neoplastic effect in many solid tumor models, are now being used in clinical trials.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	0-4
16267020-6	2005	Of interest, this enhanced level of the phosphorylated active form of S6 was rapidly reduced in HNSCC cell lines and HNSCC xenograft models at clinically relevant doses of rapamycin, which specifically inhibits mTOR.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	211-215
16267020-8	2005	These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.	Sirolimus	157-166	AKT serine/threonine kinase 1	Homo sapiens	28-31
16267020-8	2005	These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	32-36
16109729-5	2005	Incubation of the slices with the mRNA translation inhibitor cycloheximide or the mammalian target of rapamycin (mTOR) inhibitor rapamycin blocked late-LTP in both "intact" and "isolated" slice preparations.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	113-117
16237064-3	2005	Using anti-CD3 and anti-CD28 costimulation, CD4+ Th2 cell expansion was preserved partially in high-dose rapamycin (10 microM; Th2.rapa cells).	Sirolimus	105-114	CD4 molecule	Homo sapiens	44-47
16221205-8	2005	The 17 kD active IL-1beta remained unchanged, but 35 kD IL-1beta precursor was decreased by rapamycin in comparison with I/R group (P < 0.05).	Sirolimus	92-101	interleukin 1 beta	Rattus norvegicus	56-64
16249748-0	2005	Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	113-119
16243031-4	2005	Knockout of PKBalpha in PTEN-deficient cells reduces aggressive growth and promotes apoptosis, whereas treatment of PTEN(+/-) mice with rapamycin, an inhibitor of the activation of S6K, reduces neoplasia.	Sirolimus	136-145	phosphatase and tensin homolog	Mus musculus	116-120
16317089-3	2005	Although inhibitors of Akt are not yet clinically available, rapamycin, a mTOR-specific inhibitor, has long been used as an immunosuppressant, and several rapamycin analogues are now in clinical trials in oncology.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	74-78
16317089-5	2005	We show that dominant-negative mTOR diminishes phosphorylation of endogenous Akt and exogenous myristoylated Akt (mAkt), that prolonged exposure to rapamycin also inhibits Akt activation, and that this inhibition is dependent on new protein synthesis.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	31-35
16317089-5	2005	We show that dominant-negative mTOR diminishes phosphorylation of endogenous Akt and exogenous myristoylated Akt (mAkt), that prolonged exposure to rapamycin also inhibits Akt activation, and that this inhibition is dependent on new protein synthesis.	Sirolimus	148-157	AKT serine/threonine kinase 1	Homo sapiens	77-80
16317089-5	2005	We show that dominant-negative mTOR diminishes phosphorylation of endogenous Akt and exogenous myristoylated Akt (mAkt), that prolonged exposure to rapamycin also inhibits Akt activation, and that this inhibition is dependent on new protein synthesis.	Sirolimus	148-157	AKT serine/threonine kinase 1	Homo sapiens	109-112
16317089-5	2005	We show that dominant-negative mTOR diminishes phosphorylation of endogenous Akt and exogenous myristoylated Akt (mAkt), that prolonged exposure to rapamycin also inhibits Akt activation, and that this inhibition is dependent on new protein synthesis.	Sirolimus	148-157	AKT serine/threonine kinase 1	Homo sapiens	109-112
16255777-0	2005	Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	116-120
16255777-10	2005	Melanoma cells containing the B-Raf mutation V599E were more sensitive than cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin.	Sirolimus	141-150	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	30-35
16255777-10	2005	Melanoma cells containing the B-Raf mutation V599E were more sensitive than cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin.	Sirolimus	141-150	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	97-102
16255777-12	2005	As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	56-60
16255777-12	2005	As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity.	Sirolimus	13-22	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	162-167
16244323-7	2005	As a specific inhibitor of mTOR, rapamycin has therapeutic potential for the treatment of TSC hamartomas.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	27-31
16244323-7	2005	As a specific inhibitor of mTOR, rapamycin has therapeutic potential for the treatment of TSC hamartomas.	Sirolimus	33-42	TSC complex subunit 1	Homo sapiens	90-93
16249748-0	2005	Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	124-128
16249748-7	2005	CYP3A5 (intron 3) and MDR1 (exons 12, 21, 26) genotypes were correlated to the adjusted trough concentrations and dose requirements for both sirolimus and tacrolimus.	Sirolimus	141-150	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
16249748-7	2005	CYP3A5 (intron 3) and MDR1 (exons 12, 21, 26) genotypes were correlated to the adjusted trough concentrations and dose requirements for both sirolimus and tacrolimus.	Sirolimus	141-150	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
15790787-7	2005	Moreover, the mTOR inhibitor rapamycin enhanced the suppressive effects of imatinib mesylate on primary leukemic granulocyte macrophage-colony-forming unit (CFU-GM) progenitors from patients with chronic myelogenous leukemia (CML).	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	14-18
16129690-4	2005	Inhibition of serine 307 phosphorylation by rapamycin mimicked type 2 diabetes and reduced the sensitivity of IRS1 tyrosine phosphorylation in response to insulin, while stimulation of the phosphorylation by okadaic acid, in cells from patients with type 2 diabetes, rescued cells from insulin resistance.	Sirolimus	44-53	insulin	Homo sapiens	155-162
16129690-4	2005	Inhibition of serine 307 phosphorylation by rapamycin mimicked type 2 diabetes and reduced the sensitivity of IRS1 tyrosine phosphorylation in response to insulin, while stimulation of the phosphorylation by okadaic acid, in cells from patients with type 2 diabetes, rescued cells from insulin resistance.	Sirolimus	44-53	insulin	Homo sapiens	286-293
16219581-2	2005	The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
16162193-0	2005	Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	88-122
16162193-1	2005	The aim of this study was to examine the clinical characteristics, the histological features and the renal expression of vascular endothelial growth factor (VEGF) of five patients with sirolimus-associated thrombotic microangiopathy (TMA).	Sirolimus	185-194	vascular endothelial growth factor A	Homo sapiens	121-155
16162193-1	2005	The aim of this study was to examine the clinical characteristics, the histological features and the renal expression of vascular endothelial growth factor (VEGF) of five patients with sirolimus-associated thrombotic microangiopathy (TMA).	Sirolimus	185-194	vascular endothelial growth factor A	Homo sapiens	157-161
16162193-3	2005	We found that renal VEGF expression during sirolimus-induced TMA was significantly lower than VEGF expression in normal transplanted kidneys (p < 0.01).	Sirolimus	43-52	vascular endothelial growth factor A	Homo sapiens	20-24
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	58-67	vascular endothelial growth factor A	Homo sapiens	24-28
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	58-67	vascular endothelial growth factor A	Homo sapiens	201-205
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	58-67	vascular endothelial growth factor A	Homo sapiens	201-205
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	58-67	vascular endothelial growth factor A	Homo sapiens	201-205
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	143-152	vascular endothelial growth factor A	Homo sapiens	24-28
16162193-4	2005	Decreased expression of VEGF seems to be a consequence of sirolimus treatment since (i) analysis of two biopsies performed after the switch of sirolimus to calcineurin inhibitor showed reappearance of VEGF expression, (ii) no decreased expression of VEGF was found in five kidneys with classical TMA and, (iii) an increased expression of VEGF was observed in seven kidneys with acute cellular rejection on a sirolimus-free immunosuppressive regimen (p < 0.01).	Sirolimus	143-152	vascular endothelial growth factor A	Homo sapiens	24-28
16162193-5	2005	The potential role of sirolimus-induced downregulation of VEGF as a predisposing factor to the development of TMA is discussed.	Sirolimus	22-31	vascular endothelial growth factor A	Homo sapiens	58-62
15905878-2	2005	When promoted by rapamycin as prototype inhibitor, the mTOR deactivation-dependent cell size reduction was associated with slowed, but not suppressed, proliferation.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	55-59
16219581-2	2005	The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged.	Sirolimus	20-29	cyclin D3	Homo sapiens	114-123
16107580-2	2005	This study was performed to investigate the effect of the withdrawal of calcineurin inhibitors and the switch to sirolimus on peripheral insulin resistance and pancreatic beta cell response.	Sirolimus	113-122	insulin	Homo sapiens	137-144
16107580-6	2005	The increase of insulin resistance and the decrease of disposition index significantly correlated with the change of serum triglyceride concentration after the conversion to sirolimus-based therapy (R(2) = 0.30, P = 0.0002; and R(2) = 0.19, P = 0.004, respectively).	Sirolimus	174-183	insulin	Homo sapiens	16-23
16160601-0	2005	Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis.	Sirolimus	0-9	apolipoprotein E	Mus musculus	59-75
16160601-3	2005	Apolipoprotein E (apoE) knockout mice were fed either a diet supplemented with cholesterol or with cholesterol and rapamycin.	Sirolimus	115-124	apolipoprotein E	Mus musculus	0-16
16298655-12	2005	However, recipients on sirolimus treatment had significantly lower insulinemia during the test and consequently more favorable indices of insulin action as assessed by HOMA-IR.	Sirolimus	23-32	insulin	Homo sapiens	67-74
16227402-1	2005	Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have shown preclinical potential as therapy for multiple myeloma.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
16227402-6	2005	Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	25-28
16227402-6	2005	Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	39-42
16227402-6	2005	Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	39-42
16227402-6	2005	Rapamycin enhanced basal AKT activity, AKT phosphorylation, and PI3K activity in multiple myeloma cells and prolonged activation of AKT induced by exogenous IGF-I.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	157-162
16227402-9	2005	Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 association with IGF-I receptors, and prevented IRS-1 degradation.	Sirolimus	13-22	insulin like growth factor 1	Homo sapiens	98-103
16277894-7	2005	The levels of HIF-1alpha mRNA expression of SKOV3 and ES2 were 0.801 +/- 0.034 and 0.736 +/- 0.059 under hypoxia, which were significantly higher than under hypoxia added with sirolimus (0.025 +/- 0.007, 0.231 +/- 0.035; P < 0.01, P < 0.05), and those under no-hypoxia (0.010 +/- 0.004, 0.011 +/- 0.002; both P < 0.01).	Sirolimus	176-185	hypoxia inducible factor 1 subunit alpha	Homo sapiens	14-24
16277894-7	2005	The levels of HIF-1alpha mRNA expression of SKOV3 and ES2 were 0.801 +/- 0.034 and 0.736 +/- 0.059 under hypoxia, which were significantly higher than under hypoxia added with sirolimus (0.025 +/- 0.007, 0.231 +/- 0.035; P < 0.01, P < 0.05), and those under no-hypoxia (0.010 +/- 0.004, 0.011 +/- 0.002; both P < 0.01).	Sirolimus	176-185	ess-2 splicing factor homolog	Homo sapiens	54-57
16277894-9	2005	Sirolimus can inhibit vasculogenic mimicry effectively by blocking HIF-1alpha at transcription level.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	67-77
15927518-8	2005	The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin reversed the anabolic effect of IGF-I in dexamethasone-treated myotubes.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	36-40
15927518-8	2005	The PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin reversed the anabolic effect of IGF-I in dexamethasone-treated myotubes.	Sirolimus	51-60	insulin like growth factor 1	Homo sapiens	93-98
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	Sirolimus	170-179	insulin	Homo sapiens	22-29
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	Sirolimus	170-179	mechanistic target of rapamycin kinase	Homo sapiens	154-158
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	Sirolimus	170-179	mitogen-activated protein kinase 8	Homo sapiens	188-191
15963500-6	2005	Importantly, a concerted increase of average myonuclei per myotube was observed in IGF-I-stimulated myotubes, which was also inhibited by rapamycin added at a time when it no longer affected normal differentiation.	Sirolimus	138-147	insulin like growth factor 1	Homo sapiens	83-88
16172265-10	2005	FK-506 antagonized the effect of rapamycin on thrombin-induced TF expression.	Sirolimus	33-42	coagulation factor II, thrombin	Homo sapiens	46-54
16007198-10	2005	Finally, rapamycin, an inhibitor of the mTOR kinase, downregulated endogenous HMGA-2 expression and inhibited myogenesis.	Sirolimus	9-18	high mobility group AT-hook 2	Mus musculus	78-84
15886325-0	2005	A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.	Sirolimus	2-11	nuclear factor kappa B subunit 1	Homo sapiens	138-149
16096426-3	2005	Inhibition of mTOR in patients with cancer became more feasible after the development of rapamycin analogs with improved pharmacologic properties.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	14-18
16140948-7	2005	Furthermore, rapamycin, a potent and specific mTOR inhibitor, suppressed profoundly proliferation of cells from all three types of transformed B cells.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	46-50
15923340-6	2005	In human lung epithelial adenocarcinoma (A549) cells, LY303511, like rapamycin, inhibited mTOR-dependent phosphorylation of S6K, but not PI3K-dependent phosphorylation of Akt.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	90-94
16135669-6	2005	Interestingly, the IGF-1-elicited protective effect against HG was nullified by either LY294002 or rapamycin, but not by cyclosporine A or FK506.	Sirolimus	99-108	insulin like growth factor 1	Homo sapiens	19-24
16103051-7	2005	Treatment of human lung cancer cells with rapamycin suppressed the phosphorylation of p70S6 kinase and 4E-BP1, indicating an inhibition of mTOR signaling.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	139-143
15878982-7	2005	Rapamycin inhibited doxorubicin-induced NF-kappaB in ALL samples.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	40-49
15878982-8	2005	Using a short interfering (si) RNA approach, we demonstrate that FKBP51, a large immunophilin inhibited by rapamycin, is essential for drug-induced NF-kappaB activation in human leukemia.	Sirolimus	107-116	nuclear factor kappa B subunit 1	Homo sapiens	148-157
16103051-8	2005	Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	81-84
16103051-9	2005	The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process.	Sirolimus	4-13	AKT serine/threonine kinase 1	Homo sapiens	41-44
15996247-8	2005	Pre-transplant donor-directed IFN-gamma ELISPOT assessment of anti-donor cellular immunity may function as a "cellular crossmatch" and independently correlates with renal allograft function in African Americans receiving tacrolimus- and sirolimus-based immunosuppression.	Sirolimus	237-246	interferon gamma	Homo sapiens	30-39
15955739-1	2005	mTOR kinase plays a central role in the activation of many cell types, and blocking mTOR function with rapamycin results in arrest of the cell cycle at the G1 phase.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	0-4
15955739-1	2005	mTOR kinase plays a central role in the activation of many cell types, and blocking mTOR function with rapamycin results in arrest of the cell cycle at the G1 phase.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	84-88
15969952-7	2005	The expression of iNOS protein, however, was partially suppressed by rapamycin, an upstream inhibitor of p70 S6 kinase.	Sirolimus	69-78	nitric oxide synthase 2, inducible	Mus musculus	18-22
16014032-10	2005	We also found that LY294002 and rapamycin blocked Gas6-induced activation of the Akt/mTOR pathway and mesangial hypertrophy.	Sirolimus	32-41	thymoma viral proto-oncogene 1	Mus musculus	81-84
15769938-4	2005	Sirolimus was found to have an antiatherosclerotic effect in the apolipoprotein E-knockout mice model of hyperlipidemia through its antiproliferative effects.	Sirolimus	0-9	apolipoprotein E	Mus musculus	65-81
15769938-10	2005	Sirolimus overrode the suppression of cholesterol efflux and ABCA1 gene expression induced by the inflammatory cytokine IL-1beta.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	120-128
15769938-11	2005	Furthermore, sirolimus significantly inhibited inflammatory cytokines IL-6 and TNF-alpha production in macrophages.	Sirolimus	13-22	interleukin 6	Homo sapiens	70-74
15769938-11	2005	Furthermore, sirolimus significantly inhibited inflammatory cytokines IL-6 and TNF-alpha production in macrophages.	Sirolimus	13-22	tumor necrosis factor	Homo sapiens	79-88
16018822-8	2005	The effect of sirolimus on activation of mammalian target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389, and activation of RhoA was measured by pull-down assay.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	41-70
16018822-8	2005	The effect of sirolimus on activation of mammalian target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389, and activation of RhoA was measured by pull-down assay.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	72-76
16018822-10	2005	The stimulation of TF expression by sirolimus was associated with inhibition of basal activity of mTOR.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	98-102
16018822-14	2005	CONCLUSION: Although sirolimus stimulates TF protein expression in human SMC associated with inhibition of mTOR, it does not enhance TF activity released from the cells, suggesting a relatively safe profile of CYPHER stents.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	107-111
15899889-6	2005	Here we show that p70S6 kinase phosphorylates mTOR at Ser-2448 in vitro and that ectopic expression of rapamycin-resistant p70S6 kinase restores Ser-2448 phosphorylation in rapamycin-treated cells.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	46-50
15955561-1	2005	FK506 and rapamycin are immunosuppressant drugs that disrupt the interaction of FK506-binding proteins (FKBPs) with ryanodine receptors (RyR1), which form homotetrameric Ca2+ release channels in the sarcoplasmic reticulum (SR) of skeletal muscle.	Sirolimus	10-19	ryanodine receptor 1	Homo sapiens	137-141
15988698-7	2005	Rapamycin, an inhibitor or mTOR, could partially improve insulin-stimulated glucose uptake through maintaining IRS-1 protein levels.	Sirolimus	0-9	insulin	Homo sapiens	57-64
16342424-5	2005	Pretreatment of cells with PD-98059 and rapamycin, inhibitors of mitogen-activated protein kinase (ERK1/2) and mammalian target for rapamycin (mTOR), respectively, partially blocked Ang IV-mediated phosphorylation of 4EBP1.	Sirolimus	40-49	mitogen-activated protein kinase 3	Homo sapiens	99-105
16342424-5	2005	Pretreatment of cells with PD-98059 and rapamycin, inhibitors of mitogen-activated protein kinase (ERK1/2) and mammalian target for rapamycin (mTOR), respectively, partially blocked Ang IV-mediated phosphorylation of 4EBP1.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	111-141
16342424-5	2005	Pretreatment of cells with PD-98059 and rapamycin, inhibitors of mitogen-activated protein kinase (ERK1/2) and mammalian target for rapamycin (mTOR), respectively, partially blocked Ang IV-mediated phosphorylation of 4EBP1.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	143-147
15989961-4	2005	Here, we describe the identification of a conserved member of the RagA subfamily of Ras-related GTPases, Gtr2, which acts in a vacuolar membrane-associated protein complex together with Ego1 and Ego3 to ensure proper exit from rapamycin-induced growth arrest.	Sirolimus	227-236	Meh1p	Saccharomyces cerevisiae S288C	186-190
15944259-5	2005	In the present study, we showed that TCR engagement does not influence hypoxia-dependent stabilization but stimulates protein synthesis of HIF-1alpha, most possibly via PI3K/mammalian target of rapamycin system, and that expression of HIF-1alpha and its target genes is blocked by treatment with rapamycin.	Sirolimus	194-203	hypoxia inducible factor 1 subunit alpha	Homo sapiens	139-149
15956968-6	2005	Iressa blocked ERK1/2 phosphorylation specifically in wt-VHL cells, whereas rapamycin inhibited phospho-RPS6 and 4E-BP1 irrespective of VHL.	Sirolimus	76-85	BP1	Homo sapiens	116-119
16182816-1	2005	The concomitant use of calcineurin inhibitors (CNIs) with mTOR inhibitors, that is, either sirolimus (SRL) or everolimus (ERL), in de novo renal transplant patients is still debated.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	58-62
15958750-4	2005	This effect is blocked by rapamycin, indicating that the increase in EF1A expression is mediated by the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	104-133
15958580-6	2005	These studies underscore the therapeutic potential of mammalian target of rapamycin inhibitors in ErbB2-positive breast cancers and indicate that, relative to monolayer cultures, three-dimensional cell cultures are more predictive in vitro models for studies of the antitumor mechanisms of rapamycin and related compounds.	Sirolimus	74-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-103
15958750-4	2005	This effect is blocked by rapamycin, indicating that the increase in EF1A expression is mediated by the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	135-139
15937108-8	2005	Importantly, tumor cell lines derived from NF1 patients, and a genetically engineered cell system that requires Nf1-deficiency for transformation, are highly sensitive to the mTOR inhibitor rapamycin.	Sirolimus	190-199	neurofibromin 1	Homo sapiens	43-46
15937108-8	2005	Importantly, tumor cell lines derived from NF1 patients, and a genetically engineered cell system that requires Nf1-deficiency for transformation, are highly sensitive to the mTOR inhibitor rapamycin.	Sirolimus	190-199	neurofibromin 1	Homo sapiens	112-115
15937108-8	2005	Importantly, tumor cell lines derived from NF1 patients, and a genetically engineered cell system that requires Nf1-deficiency for transformation, are highly sensitive to the mTOR inhibitor rapamycin.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Homo sapiens	175-179
15937108-12	2005	Finally, these data suggest that rapamycin, or its derivatives, may represent a viable therapy for NF1.	Sirolimus	33-42	neurofibromin 1	Homo sapiens	99-102
15708965-5	2005	Moreover, FN-induced activation of both proteins was inhibited by preincubation with rapamycin for only 30 min.	Sirolimus	85-94	fibronectin 1	Homo sapiens	10-12
15850772-3	2005	Inhibition of the PI3K/Akt downstream target mTOR by rapamycin also significantly enhanced fludarabine-induced apoptosis.	Sirolimus	53-62	AKT serine/threonine kinase 1	Homo sapiens	23-26
15850772-3	2005	Inhibition of the PI3K/Akt downstream target mTOR by rapamycin also significantly enhanced fludarabine-induced apoptosis.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	45-49
15591158-10	2005	GS activity was augmented only in leucine-treated rats and was completely inhibited by rapamycin, an inhibitor of mammalian target of rapamycin.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	114-143
15705789-2	2005	In Akt-transformed leukemic cells, tumor growth can be inhibited by the mTOR inhibitor rapamycin, and clinical trials of rapamycin analogs for the treatment of leukemia are under way.	Sirolimus	87-96	thymoma viral proto-oncogene 1	Mus musculus	3-6
15671443-0	2005	Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	81-85
15671443-6	2005	In human umbilical vein endothelial cells vascular endothelial growth factor (VEGF)-induced tissue factor expression was strongly enhanced by rapamycin.	Sirolimus	142-151	vascular endothelial growth factor A	Homo sapiens	42-76
15705789-2	2005	In Akt-transformed leukemic cells, tumor growth can be inhibited by the mTOR inhibitor rapamycin, and clinical trials of rapamycin analogs for the treatment of leukemia are under way.	Sirolimus	121-130	thymoma viral proto-oncogene 1	Mus musculus	3-6
15671443-6	2005	In human umbilical vein endothelial cells vascular endothelial growth factor (VEGF)-induced tissue factor expression was strongly enhanced by rapamycin.	Sirolimus	142-151	vascular endothelial growth factor A	Homo sapiens	78-82
15671443-9	2005	The circumstance that VEGF is up-regulated in most tumors may explain the remarkable selectivity of tumor vessel thrombosis under rapamycin therapy.	Sirolimus	130-139	vascular endothelial growth factor A	Homo sapiens	22-26
15705789-9	2005	However, though the effects of ectopic Akt-1 were reversed by rapamycin or a nonphosphorylatable form of 4EBP-1, those of Pim-2 were not.	Sirolimus	62-71	thymoma viral proto-oncogene 1	Mus musculus	39-44
15922966-6	2005	Maturation of leukemic cells into APCs was mediated at least partially via a PI3K/mTOR pathway, as the inhibitors LY294002, wortmannin, and rapamycin inhibited the maturation effect induced by the AdTNF.F(pK7) adenovirus.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	82-86
15914125-10	2005	Significantly, rapamycin completely inhibited the phosphorylation of p70(S6K), an mTOR-regulated kinase implicated in the control of proliferation, but had no effect on collagen or total protein synthesis.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	82-86
15784722-0	2005	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	18-22
15784722-0	2005	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.	Sirolimus	147-156	vascular endothelial growth factor A	Homo sapiens	119-123
15784722-1	2005	The mammalian target of rapamycin (mTOR) has recently been described to be constitutively activated in Bcr-Abl-transformed cells and to mediate rapamycin-induced inhibition of growth in respective cell lines.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
15784722-2	2005	We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells.	Sirolimus	28-37	vascular endothelial growth factor A	Homo sapiens	67-101
15784722-2	2005	We have recently shown that rapamycin down-regulates expression of vascular endothelial growth factor (VEGF), a mediator of leukemia-associated angiogenesis, in primary CML cells.	Sirolimus	28-37	vascular endothelial growth factor A	Homo sapiens	103-107
15784722-3	2005	In the present study, we analyzed growth-inhibitory in vitro and in vivo effects of rapamycin on primary CML cells and asked whether rapamycin-induced suppression of VEGF in leukemic cells is related to growth inhibition.	Sirolimus	133-142	vascular endothelial growth factor A	Homo sapiens	166-170
15956255-4	2005	In vivo, the Akt inhibitors slow the progression of tumors when used as monotherapy or in combination with paclitaxel or rapamycin.	Sirolimus	121-130	AKT serine/threonine kinase 1	Homo sapiens	13-16
15846119-8	2005	Like the mTOR inhibitor rapamycin, the patellazoles inhibit translation through the 4EBP1 and S6 kinase pathways.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	9-13
15882288-10	2005	The p70(S6) kinase pathway leading to cell cycle progression was found to be active, and low concentrations of rapamycin dramatically reduced p70(S6) kinase phosphorylation.	Sirolimus	111-120	ubiquitin associated and SH3 domain containing B	Homo sapiens	4-7
15882288-11	2005	Rapamycin completely inhibited the increase in cyclin D3 protein expression and mRNA accumulation induced by fetal calf serum, but did not affect cyclin E or cdk-inhibitor expression levels.	Sirolimus	0-9	cyclin D3	Homo sapiens	47-56
15882288-14	2005	CONCLUSION: Rapamycin inhibits the proliferative response of HRECs to mitogenic stimuli, and causes cell cycle arrest in the early G(1) phase, not only by a nonspecific process due to inhibition of the p70(S6k) pathway, but also by a direct effect on cyclin D3 mRNA stability.	Sirolimus	12-21	cyclin D3	Homo sapiens	251-260
15845392-1	2005	We present immunohistochemical evidence that the mTOR/p70s6k pathway is activated in pancreatic tumors and show that the mTOR inhibitor and rapamycin analog CCI-779 potently suppresses the proliferation of pancreatic cancer cells.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	49-53
15878000-0	2005	Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents.	Sirolimus	118-127	C-reactive protein	Homo sapiens	14-32
15626738-7	2005	The combination of rapamycin, a selective mTOR inhibitor, and FLT3 PTK inhibitors restored the drug sensitivity in FLT3 dual mutant-expressing cells.	Sirolimus	19-28	fms related receptor tyrosine kinase 3	Homo sapiens	115-119
15782132-0	2005	Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	66-69
15782132-0	2005	Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	72-78
15782132-1	2005	Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	127-156
15782132-1	2005	Rapamycin, a complex macrolide and potent fungicide, immunosuppressant and anticancer agent, is a highly specific inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	158-162
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	52-58
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 like 1	Homo sapiens	119-125
15782132-4	2005	Rapamycin induced apoptosis by increasing the Bax : Bcl-xL ratio as a consequence of the concomitant downregulation of Bcl-xL and upregulation of Bax, both at the post-transcriptional level.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	146-149
15782132-5	2005	Rapamycin also downregulated the levels of EWS/WT1, the fusion protein characteristic of DSRCT.	Sirolimus	0-9	WT1 transcription factor	Homo sapiens	43-50
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	82-86
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	53-62	BCL2 like 1	Homo sapiens	132-138
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	157-161
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	157-161
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	82-86
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	BCL2 like 1	Homo sapiens	132-138
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	157-161
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	BCL2 associated X, apoptosis regulator	Homo sapiens	256-259
15782132-6	2005	Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap-dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	157-161
15860581-4	2005	We demonstrated that rapamycin effectively inhibits the growth of tumors that rely on Akt signaling for proliferation, whereas tumors in which Akt signaling is not the driving force in proliferation are resistant to rapamycin.	Sirolimus	21-30	thymoma viral proto-oncogene 1	Mus musculus	86-89
15860581-4	2005	We demonstrated that rapamycin effectively inhibits the growth of tumors that rely on Akt signaling for proliferation, whereas tumors in which Akt signaling is not the driving force in proliferation are resistant to rapamycin.	Sirolimus	216-225	thymoma viral proto-oncogene 1	Mus musculus	143-146
15816883-3	2005	In rodents, donor antigen (e.g., a donor blood transfusion), or mTOR inhibition (e.g., sirolimus), enhances anti-CD154"s efficacy.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	64-68
15816883-3	2005	In rodents, donor antigen (e.g., a donor blood transfusion), or mTOR inhibition (e.g., sirolimus), enhances anti-CD154"s efficacy.	Sirolimus	87-96	CD40 ligand	Homo sapiens	113-118
15591312-1	2005	The contribution of mammalian target of rapamycin (mTOR) signaling to the resistance exercise-induced stimulation of skeletal muscle protein synthesis was assessed by administering rapamycin to Sprague-Dawley rats 2 h prior to a bout of resistance exercise.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	51-55
15591103-4	2005	Rapamycin but not PD-98059 prevented strain-induced S6K activation, and PD-98059 but not rapamycin prevented strain-induced activation of extracellular signal-regulated kinases 1 and 2.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Bos taurus	52-55
15767444-10	2005	In this study, we found that Akt/mTOR is involved in JSRV transformation of mouse NIH 3T3 fibroblasts, because treatment with the mTOR inhibitor rapamycin reduced transformation.	Sirolimus	145-154	AKT serine/threonine kinase 1	Homo sapiens	29-32
15550488-3	2005	In this study, we show that mTOR inhibition by rapamycin strongly inhibits the growth of the most immature acute myeloid leukemia (AML) cell lines through blockade in G0/G1 phase of the cell cycle.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	28-32
15788682-0	2005	A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.	Sirolimus	71-80	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	27-32
15788477-6	2005	The highly specific mTOR inhibitor rapamycin blocked UNX-increased phosphorylation of both rpS6 and 4E-BP1.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	20-24
15827164-3	2005	We show that mTOR is activated by expression of LMP2A in carcinoma cells, leading to wortmannin- and rapamycin-sensitive inhibition of the negative regulator of translation, eukaryotic initiation factor 4E-binding protein 1, and increased c-Myc protein translation.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	13-17
15919492-1	2005	Because of its antiproliferative properties and its known effects on plasma lipids, we evaluated the mechanisms underlying the effect of rapamycin (RPM) on endothelial nitric oxide synthase (eNOS) and matrix metalloproteinases in Apo-E knockout mice.	Sirolimus	137-146	apolipoprotein E	Mus musculus	230-235
15919492-12	2005	Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM.	Sirolimus	198-201	tissue inhibitor of metalloproteinase 1	Mus musculus	62-66
15919492-12	2005	Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM.	Sirolimus	198-201	apolipoprotein E	Mus musculus	173-178
15833867-3	2005	However, the mechanisms underlying the cytotoxic effects of a selective mTOR inhibitor, rapamycin, on malignant glioma cells are poorly understood.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	72-76
15833867-5	2005	We showed that rapamycin induced autophagy but not apoptosis in rapamycin-sensitive malignant glioma U87-MG and T98G cells by inhibiting the function of mTOR.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	153-157
15833867-7	2005	Interestingly, a PI3K inhibitor, LY294002, and an Akt inhibitor, UCN-01 (7-hydroxystaurosporine), both synergistically sensitized U87-MG and T98G cells as well as U373-MG cells to rapamycin by stimulating the induction of autophagy.	Sirolimus	180-189	AKT serine/threonine kinase 1	Homo sapiens	50-53
15833867-8	2005	Enforced expression of active Akt in tumor cells suppressed the combined effects of LY294002 or UCN-01, whereas dominant-negative Akt expression was sufficient to increase the sensitivity of tumor cells to rapamycin.	Sirolimus	206-215	AKT serine/threonine kinase 1	Homo sapiens	130-133
15833867-9	2005	These results indicate that rapamycin exerts its antitumor effect on malignant glioma cells by inducing autophagy and suggest that in malignant glioma cells a disruption of the PI3K/Akt signaling pathway could greatly enhance the effectiveness of mTOR inhibitors.	Sirolimus	28-37	AKT serine/threonine kinase 1	Homo sapiens	182-185
15833867-9	2005	These results indicate that rapamycin exerts its antitumor effect on malignant glioma cells by inducing autophagy and suggest that in malignant glioma cells a disruption of the PI3K/Akt signaling pathway could greatly enhance the effectiveness of mTOR inhibitors.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	247-251
15728109-8	2005	Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours.	Sirolimus	27-36	BCL2 apoptosis regulator	Homo sapiens	115-120
15728109-8	2005	Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours.	Sirolimus	185-194	BCL2 apoptosis regulator	Homo sapiens	51-56
15728109-8	2005	Since apoptosis induced by rapamycin is blocked by BCL-2, strategies aimed at detecting human tumours that express BCL-2 and other anti-apoptotic proteins might allow identification of rapamycin-resistant tumours.	Sirolimus	185-194	BCL2 apoptosis regulator	Homo sapiens	115-120
15634685-0	2005	Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.	Sirolimus	123-132	mitogen-activated protein kinase 1	Homo sapiens	143-160
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	mitogen-activated protein kinase kinase 7	Homo sapiens	139-142
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	mitogen-activated protein kinase 1	Homo sapiens	143-146
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	AKT serine/threonine kinase 1	Homo sapiens	281-284
15591312-7	2005	The proportion of eIF2Bepsilon mRNA in polysomes was increased following exercise, an effect that was prevented by rapamycin treatment, suggesting that the increase in eIF2Bepsilon protein expression was mediated by an mTOR-dependent increase in translation of the mRNA encoding the protein.	Sirolimus	115-124	eukaryotic translation initiation factor 2B subunit epsilon	Homo sapiens	18-30
15591312-7	2005	The proportion of eIF2Bepsilon mRNA in polysomes was increased following exercise, an effect that was prevented by rapamycin treatment, suggesting that the increase in eIF2Bepsilon protein expression was mediated by an mTOR-dependent increase in translation of the mRNA encoding the protein.	Sirolimus	115-124	eukaryotic translation initiation factor 2B subunit epsilon	Homo sapiens	168-180
15591312-7	2005	The proportion of eIF2Bepsilon mRNA in polysomes was increased following exercise, an effect that was prevented by rapamycin treatment, suggesting that the increase in eIF2Bepsilon protein expression was mediated by an mTOR-dependent increase in translation of the mRNA encoding the protein.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	219-223
15868910-2	2005	Sirolimus is an inhibitor of the cytosolic mTOR-kinase, associated with the phosphoinositide-3-kinase/Akt pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	102-105
15707399-4	2005	We studied the effects of the rapamycin derivative everolimus and the anti-CD25 monoclonal antibody basiliximab on the regulatory capacity of human CD4(+)CD25(+) cells in vitro.	Sirolimus	30-39	CD4 molecule	Homo sapiens	148-151
15707415-1	2005	Sirolimus (SRL) is a substrate for cytochromes P-450 3A and P-glycoprotein, the product of the MDR1 gene.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
15707415-3	2005	We then evaluated in 149 renal transplant recipients the effect of polymorphisms CYP3A4*1/*1B, CYP3A5*1/*3 and MDR1 SNPs in exon 12, 21 and 26 on SRL concentration/dose (C/D) ratio 3 months after sirolimus introduction.	Sirolimus	146-149	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	95-101
15707415-3	2005	We then evaluated in 149 renal transplant recipients the effect of polymorphisms CYP3A4*1/*1B, CYP3A5*1/*3 and MDR1 SNPs in exon 12, 21 and 26 on SRL concentration/dose (C/D) ratio 3 months after sirolimus introduction.	Sirolimus	146-149	ATP binding cassette subfamily B member 1	Homo sapiens	111-115
15576463-4	2005	Inhibition of mTOR/S6K1 by rapamycin increased insulin-stimulated glucose transport by as much as 45% in 3T3-L1 adipocytes.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	14-18
15788644-12	2005	Rapamycin, an mTOR inhibitor, had a growth-inhibitory effect in C4-2 cells, but not in LNCaP cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
15833062-3	2005	Currently, the mTOR inhibitor rapamycin (sirolimus, Wyeth) and its derivatives temsirolimus (CCI-779, Wyeth), everolimus (RAD-001, Novartis Pharma AG) and AP-23573 (Ariad Pharmaceuticals) are being evaluated in cancer clinical trials.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
15833062-3	2005	Currently, the mTOR inhibitor rapamycin (sirolimus, Wyeth) and its derivatives temsirolimus (CCI-779, Wyeth), everolimus (RAD-001, Novartis Pharma AG) and AP-23573 (Ariad Pharmaceuticals) are being evaluated in cancer clinical trials.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	15-19
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	insulin	Homo sapiens	45-52
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	insulin receptor substrate 1	Rattus norvegicus	94-99
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	insulin receptor substrate 1	Rattus norvegicus	169-174
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	229-232
15604215-11	2005	In vitro studies with rapamycin suggest that mTOR/S6K1 overactivation contributes to elevated serine phosphorylation of IRS-1, leading to impaired insulin signaling to Akt in liver and muscle of this dietary model of obesity.	Sirolimus	22-31	insulin receptor substrate 1	Rattus norvegicus	120-125
15578690-7	2005	We found that treatment with either an mTOR kinase inhibitor (CCI-779, a rapamycin analog) or with IFN-gamma reduced the severity of TSC-related disease without significant toxicity.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	39-43
15578690-7	2005	We found that treatment with either an mTOR kinase inhibitor (CCI-779, a rapamycin analog) or with IFN-gamma reduced the severity of TSC-related disease without significant toxicity.	Sirolimus	73-82	TSC complex subunit 1	Homo sapiens	133-136
15576463-4	2005	Inhibition of mTOR/S6K1 by rapamycin increased insulin-stimulated glucose transport by as much as 45% in 3T3-L1 adipocytes.	Sirolimus	27-36	insulin	Homo sapiens	47-54
15576463-6	2005	However, insulin-induced activation of Akt was increased by rapamycin.	Sirolimus	60-69	insulin	Homo sapiens	9-16
15576463-6	2005	However, insulin-induced activation of Akt was increased by rapamycin.	Sirolimus	60-69	AKT serine/threonine kinase 1	Homo sapiens	39-42
15576463-8	2005	As in murine cells, rapamycin treatment of human adipocytes inhibited S6K1, blunted Ser636/639 phosphorylation of IRS-1, leading to increased Akt activation and glucose uptake by insulin.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	142-145
15576463-8	2005	As in murine cells, rapamycin treatment of human adipocytes inhibited S6K1, blunted Ser636/639 phosphorylation of IRS-1, leading to increased Akt activation and glucose uptake by insulin.	Sirolimus	20-29	insulin	Homo sapiens	179-186
15576463-9	2005	Further studies in 3T3-L1 adipocytes revealed that rapamycin prevented the relocalization of IRS-1 from the low-density membranes to the cytosol in response to insulin.	Sirolimus	51-60	insulin	Homo sapiens	160-167
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	185-194	mitogen-activated protein kinase 3	Homo sapiens	215-219
15714459-4	2005	The mTOR inhibitor, rapamycin, inhibited phosphorylation of these proteins.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
15723049-3	2005	Deletion of S6K1 does not affect myoblast cell proliferation but reduces myoblast size to the same extent as that observed with mTOR inhibition by rapamycin.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	128-132
15514971-3	2005	SB 203580 and rapamycin reversed the RNA stabilization effect of IL-1beta in a dose-dependent manner, suggesting involvement of the p38/MAP kinase and mTOR pathways.	Sirolimus	14-23	interleukin 1 beta	Homo sapiens	65-73
15514971-3	2005	SB 203580 and rapamycin reversed the RNA stabilization effect of IL-1beta in a dose-dependent manner, suggesting involvement of the p38/MAP kinase and mTOR pathways.	Sirolimus	14-23	mitogen-activated protein kinase 14	Homo sapiens	132-135
15514971-3	2005	SB 203580 and rapamycin reversed the RNA stabilization effect of IL-1beta in a dose-dependent manner, suggesting involvement of the p38/MAP kinase and mTOR pathways.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	151-155
15848592-3	2005	Sirolimus may reduce t-r-VEGF synthesis and inhibit PI3K-p70S6 kinase of endothelial cells.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	25-29
15501927-8	2005	The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	107-111
15767555-0	2005	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.	Sirolimus	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	127-130
15767555-0	2005	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	131-134
15767555-0	2005	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	136-139
15767555-0	2005	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.	Sirolimus	0-9	mitogen-activated protein kinase 8	Homo sapiens	145-148
15767555-2	2005	Treatment of U937 monocytic leukemia cells with rapamycin (10 nmol/L) in conjunction with a minimally toxic concentration of UCN-01 (100 nmol/L) for 36 hours resulted in marked potentiation of mitochondrial injury (i.e., loss of mitochondrial membrane potential and cytosolic release of cytochrome c, AIF, and Smac/DIABLO), caspase activation, and apoptosis.	Sirolimus	48-57	cytochrome c, somatic	Homo sapiens	287-299
15591045-7	2005	However, expression of a large RyR2 C-terminal construct in mammalian cells encompassing the pore-forming transmembrane domains exhibits rapamycin-sensitive binding specifically to FKBP12.6 but not to FKBP12.	Sirolimus	137-146	ryanodine receptor 2	Homo sapiens	31-35
15591045-7	2005	However, expression of a large RyR2 C-terminal construct in mammalian cells encompassing the pore-forming transmembrane domains exhibits rapamycin-sensitive binding specifically to FKBP12.6 but not to FKBP12.	Sirolimus	137-146	FKBP prolyl isomerase 1B	Homo sapiens	181-189
15643982-7	2005	T cells primed by Rapa-treated, alloAg-pulsed DC showed decreased capacity to produce IL-2 and IFNgamma, and were hyporesponsive to subsequent challenge via both the direct and indirect pathways, in an Ag-specific manner.	Sirolimus	18-22	interleukin 2	Homo sapiens	86-103
15677500-3	2005	In this study, we report that tacrolimus, sirolimus, and mycophenolic acid, when added to cultures of freshly isolated human islets, induce a downregulation of the synthesis and secretion of insulin.	Sirolimus	42-51	insulin	Homo sapiens	191-198
15770593-5	2005	Rapamycin is a potent immunosuppressor with antifibrotic action in renal allografts and has a demonstrated anti-VEGF effect.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	112-116
15770593-16	2005	In conclusion, rapamycin shows a mild protective effect on EMT, as it increases E-cadherin and decreases alfa -SMA expression.	Sirolimus	15-24	cadherin 1	Homo sapiens	80-90
15501927-8	2005	The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	121-124
15684402-7	2005	The inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway abolished insulin"s effect on APOA5 gene expression, while the inhibition of the P70 S6 kinase pathway with rapamycin reversed its effect and increased APOA5 gene expression.	Sirolimus	175-184	apolipoprotein A5	Homo sapiens	219-224
15522880-3	2005	In this report, we demonstrate that the IL-12-induced CsA-resistant pathway of IFN-gamma production is sensitive to rapamycin.	Sirolimus	116-125	interferon gamma	Homo sapiens	79-88
15537654-6	2005	In adenoviral-infected beta-cells expressing mTORDelta, the decrease in IRS-2 protein levels was also prevented by rapamycin or lactacystin, further indicating a proteasomal mediated degradation of IRS-2 mediated via mTOR-induced Ser/Thr phosphorylation of IRS-2.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	45-49
15642745-6	2005	Although rapamycin has a minimal effect on wild-type T cell expansion in vitro and in vivo, it completely suppresses the response of Pim-1(-/-)Pim-2(-/-) cells.	Sirolimus	9-18	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	133-138
15642745-7	2005	Thus, endogenous levels of the Pim kinases are required for T cells to mount an immune response in the presence of rapamycin.	Sirolimus	115-124	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	31-34
15522880-5	2005	IL-12-induced phosphorylation of Stat3 on Ser-727 was affected by rapamycin, which may be due to the effect of rapamycin on the IL-12-induced interaction between mammalian target of rapamycin (mTOR) and Stat3.	Sirolimus	66-75	signal transducer and activator of transcription 3	Homo sapiens	33-38
15522880-5	2005	IL-12-induced phosphorylation of Stat3 on Ser-727 was affected by rapamycin, which may be due to the effect of rapamycin on the IL-12-induced interaction between mammalian target of rapamycin (mTOR) and Stat3.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	162-191
15522880-5	2005	IL-12-induced phosphorylation of Stat3 on Ser-727 was affected by rapamycin, which may be due to the effect of rapamycin on the IL-12-induced interaction between mammalian target of rapamycin (mTOR) and Stat3.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	193-197
15522880-5	2005	IL-12-induced phosphorylation of Stat3 on Ser-727 was affected by rapamycin, which may be due to the effect of rapamycin on the IL-12-induced interaction between mammalian target of rapamycin (mTOR) and Stat3.	Sirolimus	66-75	signal transducer and activator of transcription 3	Homo sapiens	203-208
15657358-5	2005	RAD001 (everolimus) is an orally available mTOR inhibitor structurally related to rapamycin.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	43-47
15586002-1	2005	PURPOSE OF REVIEW: The aim of this article is to summarize recent advances in the understanding of the regulation of the target of rapamycin (TOR), a protein kinase that is regulated independently by insulin, amino acids and energy sufficiency and which participates in the control of the component of protein synthesis responsible for cell growth.	Sirolimus	131-140	insulin	Homo sapiens	200-207
15691225-1	2005	Sirolimus (rapamycin) is a macrocyclic lactone isolated from a strain of Streptomyces hygroscopicus that inhibits the mammalian target of rapamycin (mTOR)-mediated signal-transduction pathways, resulting in the arrest of cell cycle of various cell types, including T- and B-lymphocytes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	118-147
15691225-1	2005	Sirolimus (rapamycin) is a macrocyclic lactone isolated from a strain of Streptomyces hygroscopicus that inhibits the mammalian target of rapamycin (mTOR)-mediated signal-transduction pathways, resulting in the arrest of cell cycle of various cell types, including T- and B-lymphocytes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	149-153
15691225-1	2005	Sirolimus (rapamycin) is a macrocyclic lactone isolated from a strain of Streptomyces hygroscopicus that inhibits the mammalian target of rapamycin (mTOR)-mediated signal-transduction pathways, resulting in the arrest of cell cycle of various cell types, including T- and B-lymphocytes.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	118-147
15691225-1	2005	Sirolimus (rapamycin) is a macrocyclic lactone isolated from a strain of Streptomyces hygroscopicus that inhibits the mammalian target of rapamycin (mTOR)-mediated signal-transduction pathways, resulting in the arrest of cell cycle of various cell types, including T- and B-lymphocytes.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	149-153
15643061-2	2005	The inhibition of Tor signaling by rapamycin results in repression of the RP genes and induction of the STRE genes.	Sirolimus	35-44	RAR related orphan receptor C	Homo sapiens	18-21
16372478-9	2005	Wortmannin and rapamycin, an inhibitor of mTOR, suppressed Ang1-induced p70 S6 kinase phosphorylation and partially inhibited the Ang1-induced anti-apoptotic effect.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	42-46
16372478-9	2005	Wortmannin and rapamycin, an inhibitor of mTOR, suppressed Ang1-induced p70 S6 kinase phosphorylation and partially inhibited the Ang1-induced anti-apoptotic effect.	Sirolimus	15-24	ubiquitin associated and SH3 domain containing B	Homo sapiens	72-75
15696050-10	2005	Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	119-125
15696050-10	2005	Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	195-198
15578919-5	2004	Hyperactivation of mTOR signaling has been implicated in tumorigenesis, and promising pre-clinical studies in several tumor types suggest that the anti-proliferative and anti-angiogenic properties of rapamycin may be useful in cancer therapy.	Sirolimus	200-209	mechanistic target of rapamycin kinase	Homo sapiens	19-23
15623621-2	2004	The role of mTOR and S6K in hepatocellular carcinoma has not been investigated, but this pathway is of particular interest because an effective inhibitor, rapamycin, is available.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	12-16
15589136-1	2004	Recent studies show that hyperactivated mTOR, the "target of rapamycin" that senses nutrient availability in eukaryotic cells, inhibits signaling by insulin receptor substrates.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	40-44
15627783-6	2005	The inhibitory effect of rapamycin on neointimal thickening is prevented by the dominant active form of RhoA.	Sirolimus	25-34	ras homolog family member A	Homo sapiens	104-108
15627783-7	2005	Our study shows that stent implantation induces maintained RhoA activation and demonstrates that the inhibitory action of rapamycin on RhoA expression plays a key role in its antirestenotic effect.	Sirolimus	122-131	ras homolog family member A	Homo sapiens	135-139
15319277-0	2004	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
15489897-4	2004	Treatment of cells with the PI-3 kinase inhibitor LY294002 (10 muM) or the mTOR inhibitor rapamycin (10 nM) also reduced PMA-induced proliferation and cell-cycle progression.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	75-79
15501691-5	2004	Rapamycin is a potent immunosuppressant and investigational anticancer drug, which inhibits mTOR, blocking protein synthesis and arresting the cell cycle in G1 phase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	92-96
15571967-0	2004	Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	39-48
15571967-3	2004	Doxorubicin is a striking NF-kappaB/Rel-inducer, we therefore investigated if rapamycin interfered with the pathway of NF-kappaB/Rel activation, i.e. IkappaBalpha-phosphorylation, -degradation and NF-kappaB/Rel nuclear translocation, and found that the macrolide agent caused a block of IKK kinase activity that was responsible for a reduced nuclear translocation of transcription factors.	Sirolimus	78-87	nuclear factor kappa B subunit 1	Homo sapiens	119-128
15571967-3	2004	Doxorubicin is a striking NF-kappaB/Rel-inducer, we therefore investigated if rapamycin interfered with the pathway of NF-kappaB/Rel activation, i.e. IkappaBalpha-phosphorylation, -degradation and NF-kappaB/Rel nuclear translocation, and found that the macrolide agent caused a block of IKK kinase activity that was responsible for a reduced nuclear translocation of transcription factors.	Sirolimus	78-87	NFKB inhibitor alpha	Homo sapiens	150-162
15571967-3	2004	Doxorubicin is a striking NF-kappaB/Rel-inducer, we therefore investigated if rapamycin interfered with the pathway of NF-kappaB/Rel activation, i.e. IkappaBalpha-phosphorylation, -degradation and NF-kappaB/Rel nuclear translocation, and found that the macrolide agent caused a block of IKK kinase activity that was responsible for a reduced nuclear translocation of transcription factors.	Sirolimus	78-87	nuclear factor kappa B subunit 1	Homo sapiens	119-128
15571967-4	2004	Western blots for Bcl-2 and c-IAP1 showed increased levels of these anti-apoptotic proteins in cells incubated with doxorubicin, in accordance with NF-kappaB/Rel activation, while rapamycin clearly downmodulated these proteins, in line with its pro-apoptotic ability.	Sirolimus	180-189	BCL2 apoptosis regulator	Homo sapiens	18-23
15520200-9	2004	Indeed, VEGF-induced proliferation of HUVECs was sensitive to rapamycin, an inhibitor of p70 S6K activation.	Sirolimus	62-71	vascular endothelial growth factor A	Homo sapiens	8-12
15548965-0	2004	Targeted T-cell depletion or CD154 blockade generates mixed hemopoietic chimerism and donor-specific tolerance in mice treated with sirolimus and donor bone marrow.	Sirolimus	132-141	CD40 ligand	Homo sapiens	29-34
15271664-4	2004	The role of FKBP12.6 on Ca2+ release has not been analyzed directly, but rather it was inferred from the effects of immunophilins, such us FK506 and rapamycin, which, among other effects, dissociates FKBP12.6 from the RyR2.	Sirolimus	149-158	FKBP prolyl isomerase 1B	Rattus norvegicus	200-208
15505422-6	2004	Bcl-2/bclxL-specific antisense oligonucleotides restored the sensitivity of SK-OV-3 cells to apoptosis induction by rapamycin and RAD001.	Sirolimus	116-125	BCL2 apoptosis regulator	Homo sapiens	0-5
15505422-6	2004	Bcl-2/bclxL-specific antisense oligonucleotides restored the sensitivity of SK-OV-3 cells to apoptosis induction by rapamycin and RAD001.	Sirolimus	116-125	BCL2 like 1	Homo sapiens	6-11
15505422-7	2004	These results indicate that baseline Bcl-2 expression and therapy-induced downexpression of CCND1 and CDK4 may be regarded as molecular markers enabling the prediction and follow-up of the cellular effects on cell cycle and apoptosis induction of rapamycin in ovarian cancer.	Sirolimus	247-256	BCL2 apoptosis regulator	Homo sapiens	37-42
15686733-1	2004	Sirolimus, a new immunosuppressant drug; is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate of the P-glycoprotein drug efflux pump.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-78
15686733-1	2004	Sirolimus, a new immunosuppressant drug; is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate of the P-glycoprotein drug efflux pump.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
15686733-1	2004	Sirolimus, a new immunosuppressant drug; is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate of the P-glycoprotein drug efflux pump.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
15492868-4	2004	The combination of the anti-metabolite gemcitabine and the mTOR blocker, rapamycin, has achieved an impressive response in a patient with metastatic leiomyosarcoma.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	59-63
15593048-2	2004	Sirolimus and everolimus may interfere with mTOR activity after their binding with FK binding protein.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
15760093-8	2004	Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-52
15383315-8	2004	Expression of endothelial antigens CD144 and von Willebrand factor on differentiating endothelial precursors was reduced by rapamycin.	Sirolimus	124-133	cadherin 5	Homo sapiens	35-40
15558447-1	2004	Sirolimus is an m-TOR inhibitor without renal side effects and potentially protects against the development of malignancy.	Sirolimus	0-9	RAR related orphan receptor C	Homo sapiens	18-21
15501954-8	2004	In vitro, we further confirmed the causal relationship between ErbB2 overexpression and mTOR activation, which was associated with enhanced invasive ability and sensitivity to a mTOR inhibitor, rapamycin.	Sirolimus	194-203	erb-b2 receptor tyrosine kinase 2	Homo sapiens	63-68
15501954-8	2004	In vitro, we further confirmed the causal relationship between ErbB2 overexpression and mTOR activation, which was associated with enhanced invasive ability and sensitivity to a mTOR inhibitor, rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Homo sapiens	88-92
15501954-8	2004	In vitro, we further confirmed the causal relationship between ErbB2 overexpression and mTOR activation, which was associated with enhanced invasive ability and sensitivity to a mTOR inhibitor, rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Homo sapiens	178-182
15760093-8	2004	Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
15760093-8	2004	Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
15760093-8	2004	Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
15367412-6	2004	The PTEN-negative cell line displayed greater sensitivity to the growth inhibitory effects of the PI3K inhibitor, LY294002 and rapamycin, an inhibitor of the PI3K/Akt downstream mediator mTOR, compared with the PTEN-positive cell lines.	Sirolimus	127-136	AKT serine/threonine kinase 1	Homo sapiens	163-166
15501983-10	2004	Furthermore, rapamycin enhanced chemosensitivity to paclitaxel and carboplatin in HER2/neu-overexpressing cells, suggesting a potential approach to these poorly behaving tumors.	Sirolimus	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	82-86
15501983-13	2004	CONCLUSIONS: Rapamycin potentiates the cytotoxicity of selected chemotherapeutic agents in cell lines sensitive to the effects of rapamycin due to aberrations in the phosphatidylinositol 3"-kinase/Akt pathway, suggesting that combination therapy may be effective in patients selected for aberrations in this pathway.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	197-200
15501983-13	2004	CONCLUSIONS: Rapamycin potentiates the cytotoxicity of selected chemotherapeutic agents in cell lines sensitive to the effects of rapamycin due to aberrations in the phosphatidylinositol 3"-kinase/Akt pathway, suggesting that combination therapy may be effective in patients selected for aberrations in this pathway.	Sirolimus	130-139	AKT serine/threonine kinase 1	Homo sapiens	197-200
15367412-6	2004	The PTEN-negative cell line displayed greater sensitivity to the growth inhibitory effects of the PI3K inhibitor, LY294002 and rapamycin, an inhibitor of the PI3K/Akt downstream mediator mTOR, compared with the PTEN-positive cell lines.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	187-191
15367412-9	2004	These findings indicate that inhibitors of mTOR, some of which are already in clinical development (CCI-779, an ester of rapamycin), have the potential to be effective in the treatment of breast cancer patients with PTEN-negative tumors and should be evaluated in this setting.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	43-47
15385826-2	2004	Likewise, sirolimus is a substrate for the major drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp), both of which are expressed in close proximity in epithelial cells lining the small intestine.	Sirolimus	10-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-93
15466272-3	2004	Rapamycin, an immunosuppressive drug inhibiting the Akt axis, is associated with a prolonged DGF.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	52-55
15466272-11	2004	In conclusion, the data suggest that (1) coagulation may play a pathogenic role in I-R injury; (2) the Akt axis is activated after I-R, and its inhibition may explain the prolonged DGF observed in rapamycin-treated patients; and (3) NIK activation in I-R and DGF represents a proinflammatory, rapamycin-insensitive signal, potentially leading to progressive graft injury.	Sirolimus	197-206	AKT serine/threonine kinase 1	Homo sapiens	103-106
15452223-2	2004	However, translation is inhibited by cellular stress responses or rapamycin treatment, which inhibit mTOR kinase activity.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	101-105
15452223-3	2004	We show that during human cytomegalovirus (HCMV) infection, viral protein synthesis and virus production proceed relatively normally when mTOR kinase activity is inhibited due to hypoxic stress or rapamycin treatment.	Sirolimus	197-206	mechanistic target of rapamycin kinase	Homo sapiens	138-142
15385826-2	2004	Likewise, sirolimus is a substrate for the major drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp), both of which are expressed in close proximity in epithelial cells lining the small intestine.	Sirolimus	10-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
15385826-4	2004	Modified Caco-2 cells metabolized [14C]sirolimus to the same CYP3A4-mediated metabolites as human small intestinal and liver microsomes.	Sirolimus	39-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
15385826-10	2004	Along with CYP3A4-mediated metabolism and P-gp-mediated efflux, a novel elimination pathway was identified that may also contribute to the first-pass extraction, and hence low oral bioavailability, of sirolimus.	Sirolimus	201-210	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
15317677-7	2004	Furthermore, ANG II triggered dissociation of the translation initiation factor, eukaryotic initiation factor-4E, from its regulatory binding protein 4E-BP1, which was also inhibited by rapamycin and wortmannin.	Sirolimus	186-195	angiotensinogen	Homo sapiens	13-19
15456827-8	2004	In contrast, rapamycin, an inhibitor of mTOR (mammalian target of rapamycin), altered effects of elevated Akt-1 selectively: it eliminated the increase in stem cells and reduced the proliferative response, but had no effect on survival.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	40-44
15456827-8	2004	In contrast, rapamycin, an inhibitor of mTOR (mammalian target of rapamycin), altered effects of elevated Akt-1 selectively: it eliminated the increase in stem cells and reduced the proliferative response, but had no effect on survival.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	46-75
15456827-8	2004	In contrast, rapamycin, an inhibitor of mTOR (mammalian target of rapamycin), altered effects of elevated Akt-1 selectively: it eliminated the increase in stem cells and reduced the proliferative response, but had no effect on survival.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	106-111
15358118-5	2004	In differentiated 3T3-L1 adipocytes, chronic treatment of rapamycin blunted the phosphorylation of AKT and GSK, which is stimulated by insulin, and reduced insulin-dependent glucose uptake activity.	Sirolimus	58-67	thymoma viral proto-oncogene 1	Mus musculus	99-102
15307840-0	2004	CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.	Sirolimus	113-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15307840-0	2004	CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus.	Sirolimus	113-122	ATP binding cassette subfamily B member 1	Homo sapiens	11-25
15317677-5	2004	ANG II caused a rapid and sustained activation of p70(S6k) activity that paralleled its phosphorylation, and both processes were blocked by rapamycin.	Sirolimus	140-149	angiotensinogen	Homo sapiens	0-6
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Sirolimus	131-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-222
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	196-225
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Sirolimus	131-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	224-230
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Sirolimus	131-140	ATP binding cassette subfamily B member 1	Homo sapiens	236-250
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Sirolimus	131-140	ATP binding cassette subfamily B member 1	Homo sapiens	252-255
15517874-6	2004	Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	123-126
15517874-6	2004	Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	212-216
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Sirolimus	157-166	AKT serine/threonine kinase 1	Homo sapiens	249-252
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	227-231
15218033-1	2004	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	56-85
15218033-1	2004	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53.	Sirolimus	29-38	tumor protein p53	Homo sapiens	298-301
15322222-9	2004	RA-IgG-provoked IL-16 expression is inhibited by rapamycin, a specific macrolide inhibitor of the Akt/FRAP/mammalian target of rapamycin/p70(s6k) pathway, and by dexamethasone.	Sirolimus	49-58	AKT serine/threonine kinase 1	Homo sapiens	98-101
15322222-9	2004	RA-IgG-provoked IL-16 expression is inhibited by rapamycin, a specific macrolide inhibitor of the Akt/FRAP/mammalian target of rapamycin/p70(s6k) pathway, and by dexamethasone.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	102-106
15322222-9	2004	RA-IgG-provoked IL-16 expression is inhibited by rapamycin, a specific macrolide inhibitor of the Akt/FRAP/mammalian target of rapamycin/p70(s6k) pathway, and by dexamethasone.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	107-136
15322222-9	2004	RA-IgG-provoked IL-16 expression is inhibited by rapamycin, a specific macrolide inhibitor of the Akt/FRAP/mammalian target of rapamycin/p70(s6k) pathway, and by dexamethasone.	Sirolimus	49-58	ubiquitin associated and SH3 domain containing B	Homo sapiens	137-140
15218033-1	2004	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	87-91
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	140-144
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	145-149
15251441-7	2004	Furthermore, rapamycin blocked aldosterone-induced Src activation.	Sirolimus	13-22	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	51-54
15028555-11	2004	The mTOR inhibitor rapamycin had similar inhibitory effects on G(1) cell cycle progression and on the expression of cyclin D1, CDK4, CDC25A, and retinoblastoma phosphorylation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
15279778-1	2004	The mammalian target of rapamycin (mTOR) is a large multidomain protein whose function is inhibited by the immunosuppressant drug rapamycin.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
15208671-2	2004	Damaged microtubules induce phosphorylation of the Bcl-2 protein and lower the threshold of programmed cell death, both of which are inhibited by rapamycin.	Sirolimus	146-155	BCL2 apoptosis regulator	Homo sapiens	51-56
15208671-4	2004	In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6KThr421/Ser424 phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin.	Sirolimus	257-266	AKT serine/threonine kinase 1	Homo sapiens	38-41
15150271-8	2004	Consistent with this, inhibition of B-Raf and p42/44 MAPK by Rheb was resistant to rapamycin in contrast to Rheb activation of S6 kinase, which is rapamycin-sensitive.	Sirolimus	83-92	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	36-41
15123681-10	2004	Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity.	Sirolimus	40-49	insulin	Homo sapiens	66-73
15131122-8	2004	Importantly, stable overexpression of cyclin D3 (2-2.5 fold) in Jurkat T cell transfectants renders them resistant to lower doses (1-10 ng/ml) of rapamycin.	Sirolimus	146-155	cyclin D3	Homo sapiens	38-47
15131122-9	2004	These results point to a critical role of cyclin D3 in rapamycin-mediated immunosuppressive effects in T cells and cell cycle regulation in lymphocytes in general.	Sirolimus	55-64	cyclin D3	Homo sapiens	42-51
15123681-10	2004	Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity.	Sirolimus	40-49	interleukin 4	Homo sapiens	152-156
15196065-9	2004	The duration of sirolimus treatment correlated positively with SHBG (p < 0.01), LH (p < 0.05) and FSH (p < 0.05) and negative with the FAI (p < 0.05).	Sirolimus	16-25	sex hormone binding globulin	Homo sapiens	63-67
15487700-5	2004	Combinatorial therapy with pamidronate and Gleevec, an inhibitor of several tyrosine kinases; Velcade, a proteasome inhibitor; or rapamycin, an inhibitor of the mammalian target of rapamycin (m-TOR) all showed additive effects in causing proliferative inhibition in MDA-175 cells.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	161-190
15254091-9	2004	Finally, we observed that both PI3K inhibitors and rapamycin, an mTOR inhibitor, prevented mGluR-LTD induced by DHPG.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	65-69
15158453-4	2004	The mTOR inhibitor rapamycin reversed the dephosphorylation of eEF2 induced by CCK, as did treatment with the p38 MAPK inhibitor SB202190, the MEK inhibitor PD98059, and the phosphatase inhibitor calyculin A.	Sirolimus	19-28	eukaryotic translation elongation factor 2	Rattus norvegicus	63-67
15190216-3	2004	Interestingly, lymphomas expressing Akt, but not those expressing Bcl-2 are sensitized to chemotherapy-induced apoptosis by the mTOR inhibitor rapamycin, an effect that is countered by eIF4E.	Sirolimus	143-152	AKT serine/threonine kinase 1	Homo sapiens	36-39
15190216-3	2004	Interestingly, lymphomas expressing Akt, but not those expressing Bcl-2 are sensitized to chemotherapy-induced apoptosis by the mTOR inhibitor rapamycin, an effect that is countered by eIF4E.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	128-132
15347472-1	2004	OBJECTIVE: To investigate the inhibitory effect of the mammalian target of rapamycin (mTOR) inhibitor, sirolimus on expression of hypoxia-inducible factor (HIF)1alpha protein and growth of ovarian carcinoma in an athymic mouse xenogeneic transplant model of ovarian cancer.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	86-90
15347472-1	2004	OBJECTIVE: To investigate the inhibitory effect of the mammalian target of rapamycin (mTOR) inhibitor, sirolimus on expression of hypoxia-inducible factor (HIF)1alpha protein and growth of ovarian carcinoma in an athymic mouse xenogeneic transplant model of ovarian cancer.	Sirolimus	103-112	hypoxia inducible factor 1 subunit alpha	Homo sapiens	130-166
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	vascular endothelial growth factor A	Homo sapiens	18-22
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
15056668-4	2004	Inhibition of mTOR by rapamycin or by overexpression of a kinase dead mutant of mTOR, efficiently blocked IFNalpha-induced apoptosis.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
15056668-4	2004	Inhibition of mTOR by rapamycin or by overexpression of a kinase dead mutant of mTOR, efficiently blocked IFNalpha-induced apoptosis.	Sirolimus	22-31	interferon alpha 1	Homo sapiens	106-114
15056668-5	2004	A PI3K and mTOR-dependent phosphorylation of p70S6 kinase and 4E-BP1 repressor was induced by IFNalpha treatment of cells and was strongly inhibited by Ly294002 or rapamycin.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	11-15
15056668-5	2004	A PI3K and mTOR-dependent phosphorylation of p70S6 kinase and 4E-BP1 repressor was induced by IFNalpha treatment of cells and was strongly inhibited by Ly294002 or rapamycin.	Sirolimus	164-173	interferon alpha 1	Homo sapiens	94-102
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	40-43
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	67-71
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	vascular endothelial growth factor A	Homo sapiens	113-117
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	36-39
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	146-149
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	142-145
15064712-7	2004	Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	146-149
15123524-9	2004	However, among patients receiving sirolimus-eluting stents, there remains a trend toward a higher frequency of repeat intervention in diabetic patients compared with nondiabetic patients, particularly in the insulin-requiring patients.	Sirolimus	34-43	insulin	Homo sapiens	208-215
15146184-5	2004	This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	62-66
15150095-0	2004	Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.	Sirolimus	144-153	interferon gamma	Mus musculus	154-163
15150095-2	2004	We demonstrate a dramatic decrease of IFN-gamma expression in tumors and mouse embryo fibroblast cell lines that lack either Tsc1 or Tsc2, which is reversed by rapamycin (mammalian target of rapamycin inhibitor) therapy.	Sirolimus	160-169	interferon gamma	Mus musculus	38-47
15150095-2	2004	We demonstrate a dramatic decrease of IFN-gamma expression in tumors and mouse embryo fibroblast cell lines that lack either Tsc1 or Tsc2, which is reversed by rapamycin (mammalian target of rapamycin inhibitor) therapy.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	171-200
15150095-5	2004	A combination of IFN-gamma and rapamycin is markedly synergistic in induction of apoptosis in Tsc1 or Tsc2 null cells because pSTAT3 Tyr705 phosphorylation is abolished completely and the other effects of IFN-gamma are maintained or enhanced.	Sirolimus	31-40	TSC complex subunit 1	Homo sapiens	94-98
15150095-5	2004	A combination of IFN-gamma and rapamycin is markedly synergistic in induction of apoptosis in Tsc1 or Tsc2 null cells because pSTAT3 Tyr705 phosphorylation is abolished completely and the other effects of IFN-gamma are maintained or enhanced.	Sirolimus	31-40	interferon gamma	Homo sapiens	205-214
15150095-6	2004	Rapamycin-IFN-gamma has unique potential therapeutic benefit for management of TSC tumors.	Sirolimus	0-9	interferon gamma	Homo sapiens	10-19
15150095-6	2004	Rapamycin-IFN-gamma has unique potential therapeutic benefit for management of TSC tumors.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	79-82
15070696-2	2004	The use of the macrolide rapamycin, selectively inhibiting the phosphoprotein mammalian target of rapamycin (mTOR) downstream of, for example, insulin-like growth factor-I receptor (IGF-IR), possibly represents such a molecular mode of therapy.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	78-107
15039430-5	2004	Reporter proteins were localized to the proteasome by the addition of rapamycin, a drug that heterodimerizes Fpr1 and Tor1.	Sirolimus	70-79	formyl peptide receptor 1	Homo sapiens	109-113
14982927-6	2004	FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the mTOR inhibitor rapamycin.	Sirolimus	169-178	hypoxia inducible factor 1 subunit alpha	Homo sapiens	15-20
14982927-6	2004	FSH-stimulated HIF-1 activity is inhibited by the PI 3-kinase inhibitor LY294002, the Rheb inhibitor FTI-277 (farnesyltransferase inhibitor-277), and the mTOR inhibitor rapamycin.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	154-158
15064772-0	2004	The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1.	Sirolimus	4-13	Ras-related associated with diabetes	Mus musculus	25-28
14970238-10	2004	These data indicate the actin cytoskeleton is required for nuclear localization of Gln3 in response to limiting nitrogen but not rapamycin-treatment.	Sirolimus	129-138	actin	Saccharomyces cerevisiae S288C	24-29
15070696-3	2004	By using a panel of MM cell lines we showed that rapamycin induced G0/G1 arrest, an effect being associated with an increase of the cyclin-dependent kinase inhibitor p27 and a decrease of cyclins D2 and D3.	Sirolimus	49-58	cyclin D2	Homo sapiens	188-205
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Sirolimus	45-54	insulin like growth factor 1	Homo sapiens	131-136
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Sirolimus	45-54	interleukin 6	Homo sapiens	141-154
15070696-2	2004	The use of the macrolide rapamycin, selectively inhibiting the phosphoprotein mammalian target of rapamycin (mTOR) downstream of, for example, insulin-like growth factor-I receptor (IGF-IR), possibly represents such a molecular mode of therapy.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	109-113
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Sirolimus	45-54	interleukin 6	Homo sapiens	156-160
15070696-3	2004	By using a panel of MM cell lines we showed that rapamycin induced G0/G1 arrest, an effect being associated with an increase of the cyclin-dependent kinase inhibitor p27 and a decrease of cyclins D2 and D3.	Sirolimus	49-58	dynactin subunit 6	Homo sapiens	166-169
15071500-3	2004	Ser422 phosphorylation appears to be regulated by the S6Ks: (a) Ser422 phosphorylation is sensitive to pharmacological inhibitors of phosphoinositide-3 kinase and the mammalian target of rapamycin; (b) S6K1/S6K2 specifically phosphorylate Ser422 in vitro; and (c) rapamycin-resistant S6Ks confer rapamycin resistance upon Ser422 phosphorylation in vivo.	Sirolimus	264-273	mechanistic target of rapamycin kinase	Homo sapiens	167-196
15067056-8	2004	When we examined the phosphorylation of 4EBP-1, a downstream substrate of the mammalian target of rapamycin, we found that rapamycin, but not SFA, inhibited the mammalian target of rapamycin activity.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	161-190
14726531-14	2004	Interestingly, rapamycin treatment suggests a novel connection between the mTOR pathway and eukaryotic initiation factor-2alpha phosphorylation in mammalian cells, which may not, however, be involved in TOP mRNA translational regulation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	75-79
15020250-3	2004	We further investigated the role of mTOR in regulating serine 307 phosphorylation, demonstrating that serine 307 phosphorylation in response to insulin, anisomycin, or tumor necrosis factor was quantitatively and temporally associated with activation of mTOR and could be inhibited by rapamycin.	Sirolimus	285-294	insulin	Homo sapiens	144-151
15020250-2	2004	Rapamycin, an inhibitor of the kinase mTOR, can prevent serine 307 phosphorylation and the development of insulin resistance.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
15048882-4	2004	Pretreatment of the cells with wortmannin, a specific inhibitor of PI3K, or rapamycin, a specific inhibitor of mTOR kinase, prevented H2O2-increased mitosis.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	111-115
15020250-3	2004	We further investigated the role of mTOR in regulating serine 307 phosphorylation, demonstrating that serine 307 phosphorylation in response to insulin, anisomycin, or tumor necrosis factor was quantitatively and temporally associated with activation of mTOR and could be inhibited by rapamycin.	Sirolimus	285-294	tumor necrosis factor	Homo sapiens	168-189
15020250-2	2004	Rapamycin, an inhibitor of the kinase mTOR, can prevent serine 307 phosphorylation and the development of insulin resistance.	Sirolimus	0-9	insulin	Homo sapiens	106-113
15020250-3	2004	We further investigated the role of mTOR in regulating serine 307 phosphorylation, demonstrating that serine 307 phosphorylation in response to insulin, anisomycin, or tumor necrosis factor was quantitatively and temporally associated with activation of mTOR and could be inhibited by rapamycin.	Sirolimus	285-294	mechanistic target of rapamycin kinase	Homo sapiens	254-258
15010863-4	2004	The phosphorylation and activity of PKB/Akt in IL2-stimulated CTLL2 cells were rapamycin-insensitive and reduced upon wortmannin treatment of the cells, confirming a requirement for PI-3K for Akt activity.	Sirolimus	79-88	thymoma viral proto-oncogene 1	Mus musculus	36-39
15066126-6	2004	Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	86-90
15066126-6	2004	Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	140-144
15066126-6	2004	Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	140-144
15010827-4	2004	Recent studies have demonstrated that mTOR inhibition by rapamycin or its analogues have remarkable activity against a wide range of human cancers in vitro and in human tumor xenograft models.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	38-42
15010863-4	2004	The phosphorylation and activity of PKB/Akt in IL2-stimulated CTLL2 cells were rapamycin-insensitive and reduced upon wortmannin treatment of the cells, confirming a requirement for PI-3K for Akt activity.	Sirolimus	79-88	thymoma viral proto-oncogene 1	Mus musculus	40-43
15060135-11	2004	In these cells, as well as in rapamycin-treated wild-type, S6K1(-/-), and S6K2(-/-) cells, this step was catalyzed by a mitogen-activated protein kinase (MAPK)-dependent kinase, most likely p90rsk.	Sirolimus	30-39	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	190-196
15086465-0	2004	Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.	Sirolimus	0-9	transforming growth factor, beta 1	Rattus norvegicus	20-52
15050414-12	2004	Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	36-40
15016873-7	2004	Significantly, rapamycin, an inhibitor commonly used to investigate the mTOR/p70S6K pathway, reduced the in vivo phosphorylation of specific NS5A phosphopeptides, strongly suggesting that p70S6 kinase and potentially related members of this group phosphorylate NS5A inside the cell.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	72-76
15050414-12	2004	Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	41-45
15050414-12	2004	Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression.	Sirolimus	57-66	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-103
15050414-12	2004	Our results also indicated that the mTOR/FRAP inhibitor, rapamycin, inhibited 4-OHE2-induced HIF-1alpha and VEGF-A expression.	Sirolimus	57-66	vascular endothelial growth factor A	Homo sapiens	108-114
15029198-5	2004	Using a murine lymphoma model, we show that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects.	Sirolimus	179-188	thymoma viral proto-oncogene 1	Mus musculus	139-142
15021829-0	2004	Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.	Sirolimus	25-34	transforming growth factor, beta 1	Rattus norvegicus	91-123
15029198-5	2004	Using a murine lymphoma model, we show that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects.	Sirolimus	179-188	thymoma viral proto-oncogene 1	Mus musculus	139-142
14592809-6	2004	Rapamycin induced expression of the VSMC differentiation marker contractile proteins smooth muscle (SM) alpha-actin, calponin, and SM myosin heavy chain (SM-MHC), as observed by immunoblotting and immunohistochemistry.	Sirolimus	0-9	myosin heavy chain 11	Homo sapiens	131-152
15041358-6	2004	Other agents have now become available that provide more effective prophylaxis against acute rejection than azathioprine; these include, mycophenolate and the TOR inhibitors sirolimus and everolimus.	Sirolimus	174-183	RAR related orphan receptor C	Homo sapiens	159-162
15041369-2	2004	The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen was a significant breakthrough that allowed the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year.	Sirolimus	43-52	insulin	Homo sapiens	153-160
14970836-9	2004	Insulin-stimulated 4E-BP1 phosphorylation in 3T3-L1 preadipocytes was only partially affected by rapamycin, consistent with the differentiation data.	Sirolimus	97-106	insulin	Homo sapiens	0-7
14576155-1	2004	Prior work demonstrates that AKT activity regulates sensitivity of cells to G(1) arrest induced by mammalian target of rapamycin (mTOR) inhibitors such as rapamycin and CCI-779.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	29-32
14976243-7	2004	Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL, and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants.	Sirolimus	0-9	fms related receptor tyrosine kinase 3	Homo sapiens	196-200
15123258-0	2004	Rpd3p relocation mediates a transcriptional response to rapamycin in yeast.	Sirolimus	56-65	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	0-5
15123258-2	2004	Consistent with prior studies, we find that RPD3, which encodes a histone deacetylase (HDAC), is required for repression upon rapamycin treatment.	Sirolimus	126-135	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	44-48
15123258-3	2004	To elucidate the mechanism underlying RPD3-mediated repression, we screened all promoters in yeast for occupancy by Rpd3p before and after treatment with rapamycin.	Sirolimus	154-163	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	38-42
15123258-5	2004	These data conflict with a previously proposed model suggesting that Rpd3p is constitutively bound to rapamycin-repressible genes and becomes active only after a stimulus such as treatment with rapamycin.	Sirolimus	102-111	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	69-74
15004009-3	2004	Inhibition of mTOR signaling by rapamycin inactivates TIF-IA and impairs transcription-initiation complex formation.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	14-18
15004009-3	2004	Inhibition of mTOR signaling by rapamycin inactivates TIF-IA and impairs transcription-initiation complex formation.	Sirolimus	32-41	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	54-60
14871980-9	2004	In contrast, overexpression of S6K1, and phosphorylated Akt independent of phosphatase and tensin homologue deleted from chromosome 10 status, were associated with rapamycin sensitivity.	Sirolimus	164-173	AKT serine/threonine kinase 1	Homo sapiens	56-59
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	177-181
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	177-181
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	233-242	mechanistic target of rapamycin kinase	Homo sapiens	177-181
14871980-13	2004	CONCLUSIONS: Overexpression of S6K1 and expression of phosphorylated Akt should be evaluated as predictors of rapamycin sensitivity in breast cancer patients.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	69-72
14970836-5	2004	RESULTS: Rapamycin partially reduced differentiation, measured by Oil Red O staining, triacylglycerol accumulation (by up to 46%), and peroxisome proliferator-activated receptor gamma protein expression (by 50%).	Sirolimus	9-18	peroxisome proliferator activated receptor gamma	Homo sapiens	135-183
14970836-6	2004	In contrast, rapamycin completely inhibited insulin-stimulated p70 S6K activation, assessed by phosphorylation of p70 S6K and its substrate, S6.	Sirolimus	13-22	insulin	Homo sapiens	44-51
14734710-8	2004	Rapamycin did not affect DC IL-12R expression, but markedly suppressed IL-18Ralpha and beta expression, which may in turn down-regulate DC IL-12 autocrine activation.	Sirolimus	0-9	interleukin 18 receptor 1	Homo sapiens	71-82
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase 4	Mus musculus	128-132
14718170-4	2004	Since treatment with rapamycin induces a tight association between FKBP and FRAP, one would expect rapamycin to trap the FKBP-fused Golgi protein in the ER if it ever visits the ER during mitosis.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	76-80
14709354-0	2004	Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway.	Sirolimus	0-9	apolipoprotein E	Mus musculus	71-85
14709354-3	2004	In this study, we show that rapamycin elicits a marked reduction of aortic atherosclerosis in apolipoprotein E (apoE)-null mice fed a high-fat diet despite sustained hypercholesterolemia.	Sirolimus	28-37	apolipoprotein E	Mus musculus	94-110
14709354-3	2004	In this study, we show that rapamycin elicits a marked reduction of aortic atherosclerosis in apolipoprotein E (apoE)-null mice fed a high-fat diet despite sustained hypercholesterolemia.	Sirolimus	28-37	apolipoprotein E	Mus musculus	112-116
14709354-7	2004	However, our studies with fat-fed mice doubly deficient for p27(Kip1) and apoE disclosed an antiatherogenic effect of rapamycin comparable with that found in apoE-null mice with an intact p27(Kip1) gene.	Sirolimus	118-127	apolipoprotein E	Mus musculus	74-78
14979923-2	2004	Our previous studies demonstrated that rapamycin potentiates TGF-beta-induced cell cycle arrest in nontransformed epithelial cells and partially restores TGF-beta-induced growth arrest of some human cancer cell lines.	Sirolimus	39-48	transforming growth factor beta 1	Homo sapiens	61-69
14979923-2	2004	Our previous studies demonstrated that rapamycin potentiates TGF-beta-induced cell cycle arrest in nontransformed epithelial cells and partially restores TGF-beta-induced growth arrest of some human cancer cell lines.	Sirolimus	39-48	transforming growth factor beta 1	Homo sapiens	154-162
15318929-5	2004	Rapamycin is a specific mTOR antagonist that targets this pathway and blocks the downstream signaling elements, resulting in cell cycle arrest in the G1 phase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	24-28
14729612-6	2004	Furthermore, an overexpression of the dominant-negative Akt mutant (Akt-T308A/S473A) blocked nickel-induced Akt phosphorylation and HIF-1 transactivation, whereas inhibition of p70(S6k) activation by pretreatment of cells with rapamycin did not show significant inhibitory effects on HIF-1 transactivation induced by nickel compounds.	Sirolimus	227-236	thymoma viral proto-oncogene 1	Mus musculus	56-59
14729612-6	2004	Furthermore, an overexpression of the dominant-negative Akt mutant (Akt-T308A/S473A) blocked nickel-induced Akt phosphorylation and HIF-1 transactivation, whereas inhibition of p70(S6k) activation by pretreatment of cells with rapamycin did not show significant inhibitory effects on HIF-1 transactivation induced by nickel compounds.	Sirolimus	227-236	thymoma viral proto-oncogene 1	Mus musculus	68-71
14729612-6	2004	Furthermore, an overexpression of the dominant-negative Akt mutant (Akt-T308A/S473A) blocked nickel-induced Akt phosphorylation and HIF-1 transactivation, whereas inhibition of p70(S6k) activation by pretreatment of cells with rapamycin did not show significant inhibitory effects on HIF-1 transactivation induced by nickel compounds.	Sirolimus	227-236	thymoma viral proto-oncogene 1	Mus musculus	68-71
14729612-7	2004	Consistent with HIF-1 transactivation, inhibition of the PI-3K/Akt pathway by either overexpression of Deltap85 or Akt-T308A/S473A caused dramatic inhibition of Cap43 protein expression induced by nickel compounds, whereas pretreatment of cells with rapamycin did not exhibit inhibition of Cap43 induction.	Sirolimus	250-259	thymoma viral proto-oncogene 1	Mus musculus	115-118
15565817-14	2004	Rapamycin, a specific mTOR inhibitor, has potent antitumoral activities in preclinical models of TSC and is currently undergoing phase I/II clinical studies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	22-26
15565817-14	2004	Rapamycin, a specific mTOR inhibitor, has potent antitumoral activities in preclinical models of TSC and is currently undergoing phase I/II clinical studies.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	97-100
14576155-1	2004	Prior work demonstrates that AKT activity regulates sensitivity of cells to G(1) arrest induced by mammalian target of rapamycin (mTOR) inhibitors such as rapamycin and CCI-779.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	130-134
14592809-6	2004	Rapamycin induced expression of the VSMC differentiation marker contractile proteins smooth muscle (SM) alpha-actin, calponin, and SM myosin heavy chain (SM-MHC), as observed by immunoblotting and immunohistochemistry.	Sirolimus	0-9	myosin heavy chain 11	Homo sapiens	154-160
14592809-7	2004	Notably, we detected a striking rapamycin induction of calponin and SM-MHC mRNA, suggesting a role for mTOR in transcriptional control of VSMC gene expression.	Sirolimus	32-41	myosin heavy chain 11	Homo sapiens	68-74
14592809-7	2004	Notably, we detected a striking rapamycin induction of calponin and SM-MHC mRNA, suggesting a role for mTOR in transcriptional control of VSMC gene expression.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	103-107
14569063-0	2004	CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam.	Sirolimus	106-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
14766378-12	2004	Rapamycin also inhibits IL-2 expression, though by interaction with the mammalian Target of Rapamycin (mTOR) protein.	Sirolimus	0-9	interleukin 2	Homo sapiens	24-28
14766378-12	2004	Rapamycin also inhibits IL-2 expression, though by interaction with the mammalian Target of Rapamycin (mTOR) protein.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	72-101
14766378-12	2004	Rapamycin also inhibits IL-2 expression, though by interaction with the mammalian Target of Rapamycin (mTOR) protein.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	103-107
14569063-8	2004	Using CYP3A4-transfected Caco-2 cells we determined that, in contrast to P-gp, CYP3A4 is the major factor limiting sirolimus absorption.	Sirolimus	115-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
14569063-8	2004	Using CYP3A4-transfected Caco-2 cells we determined that, in contrast to P-gp, CYP3A4 is the major factor limiting sirolimus absorption.	Sirolimus	115-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
15163844-9	2004	In the absence of a clear target, common downstream signal transduction proteins that are known to intersect with the ER pathway can be inhibited to address resistance, including G proteins with farnesyltransferase inhibitors and molecular target of rapamycin (mTOR) with rapamycin analogues.	Sirolimus	250-259	mechanistic target of rapamycin kinase	Homo sapiens	261-265
14662900-8	2003	Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy.	Sirolimus	87-96	programmed cell death 1	Mus musculus	190-208
14600284-1	2004	The mechanisms by which non-coplanar 2,2",3,5",6-pentachlorobiphenyl (PCB 95) and rapamycin interact with ryanodine receptor (RyR) complexes to alter Ca2+ signaling, were explored in intact cerebellar granule neurons.	Sirolimus	82-91	ryanodine receptor 1	Homo sapiens	126-129
15047987-1	2004	The aim of present study was to evaluate the effects of immunophilin ligands (cyclosporin A, FK506 and rapamycin) on the simulated ischemia-induced release of pro-inflammatory cytokines (IL-1beta, TNF-alpha and IL-2) in rat primary astrocyte cell cultures.	Sirolimus	103-112	interleukin 1 beta	Rattus norvegicus	187-195
15047987-4	2004	CsA (at concentrations of 10-50 microM), FK506 (at all used concentrations) and rapamycin (in dose-dependent manner) significantly attenuated IL-1beta release after 24 h exposure to ischemic conditions.	Sirolimus	80-89	interleukin 1 beta	Rattus norvegicus	142-150
14662900-8	2003	Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy.	Sirolimus	87-96	CD274 antigen	Mus musculus	315-320
14662900-8	2003	Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy.	Sirolimus	87-96	programmed cell death 1	Mus musculus	210-214
14662900-8	2003	Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy.	Sirolimus	87-96	CD274 antigen	Mus musculus	233-238
14662900-8	2003	Prolonged islet allograft survival achieved by blockade of the MCP-1/CCR2 pathway plus rapamycin therapy was accompanied by a mononuclear cell infiltrate expressing the inhibitory receptor, programmed death-1 (PD-1), and its ligand (PD-L1, B7-H1), and prolongation of islet allograft survival was abrogated by anti-PD-L1 mAb therapy.	Sirolimus	87-96	CD274 antigen	Mus musculus	240-245
14612424-7	2003	Rapamycin treatment led to a rapid dephosphorylation of the carboxy-terminal activation domain of the rDNA transcription factor, UBF, which significantly reduced its ability to associate with the basal rDNA transcription factor SL-1.	Sirolimus	0-9	upstream binding transcription factor, RNA polymerase I	Mus musculus	129-132
14657335-0	2003	Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.	Sirolimus	0-9	interleukin 7	Homo sapiens	102-106
14679009-10	2003	These results indicate that rapamycin exerts variable inhibitory actions on mTOR signaling functions and suggest that direct inhibitors of the mTOR kinase domain will display substantially broader anticancer activities than rapamycin.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	76-80
14679009-10	2003	These results indicate that rapamycin exerts variable inhibitory actions on mTOR signaling functions and suggest that direct inhibitors of the mTOR kinase domain will display substantially broader anticancer activities than rapamycin.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	143-147
14681687-6	2003	We demonstrate that rapamycin, an mTOR inhibitor, efficiently blocked the proliferation of all cell lines by promoting cell cycle arrest at the G1 phase.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	34-38
14617207-6	2003	The introduction of a steroid-free, sirolimus-based, anti-rejection protocol and islets prepared from two (or rarely three) donors led to high rates of insulin independence.	Sirolimus	36-45	insulin	Homo sapiens	152-159
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	0-9	upstream binding transcription factor, RNA polymerase I	Mus musculus	103-106
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	0-9	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	0-9	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	0-9	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	225-234	upstream binding transcription factor, RNA polymerase I	Mus musculus	103-106
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	225-234	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	225-234	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14612424-8	2003	Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF.	Sirolimus	225-234	upstream binding transcription factor, RNA polymerase I	Mus musculus	122-125
14559232-8	2003	The mTOR inhibitor rapamycin has similar inhibitory effects on G(1) cell cycle progression and expression of cyclin D1, CDK4, and Rb phosphorylation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
14623952-2	2003	The mTOR inhibitor rapamycin can prevent forms of protein synthesis-dependent synaptic plasticity such as long-term facilitation in Aplysia and late-phase long-term potentiation (L-LTP) in the hippocampal CA1 region of rodents.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
14697997-3	2003	The aim of this study was to evaluate the effect of sirolimus treatment on the development of atherosclerosis in the aortic arch of apo E-/- mice fed a high-fat (Western) diet.	Sirolimus	52-61	apolipoprotein E	Mus musculus	132-137
14605212-5	2003	In contrast to FKBP12-/- cells, splenic FKBP12.6-/- T cells exhibited a decreased proliferative response to IL-2 in the presence of rapamycin without affecting p70S6K or ERK activation.	Sirolimus	132-141	FKBP prolyl isomerase 1B	Homo sapiens	40-48
14605212-5	2003	In contrast to FKBP12-/- cells, splenic FKBP12.6-/- T cells exhibited a decreased proliferative response to IL-2 in the presence of rapamycin without affecting p70S6K or ERK activation.	Sirolimus	132-141	interleukin 2	Homo sapiens	108-112
12876075-3	2003	Rapamycin, a specific inhibitor of mTOR function, was found to inhibit the Akt-induced increase in cell size by 70%, presumably via inhibition of the Akt-induced increase in protein synthesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
12876075-3	2003	Rapamycin, a specific inhibitor of mTOR function, was found to inhibit the Akt-induced increase in cell size by 70%, presumably via inhibition of the Akt-induced increase in protein synthesis.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	75-78
12876075-3	2003	Rapamycin, a specific inhibitor of mTOR function, was found to inhibit the Akt-induced increase in cell size by 70%, presumably via inhibition of the Akt-induced increase in protein synthesis.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	150-153
14607085-3	2003	Together, these genetic, biochemical and cell-biological studies have demonstrated that the tuberin-hamartin complex inhibits target of rapamycin (TOR) signaling by acting as a GTPase-activating protein for the Ras-related small G protein Rheb.	Sirolimus	136-145	TSC complex subunit 1	Homo sapiens	100-108
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
14557767-0	2003	Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.	Sirolimus	56-65	insulin	Homo sapiens	0-7
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	201-207
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	127-131
14555183-6	2003	With regard to the involvement of mammalian target of rapamycin (mTOR) and p70 S6 kinase, angiotensin II-induced phosphorylation was abolished by pretreatment with rapamycin, but not by tosylphenylalanine chloromethyl ketone or tosyllysine chloromethyl ketone.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	65-69
14555183-6	2003	With regard to the involvement of mammalian target of rapamycin (mTOR) and p70 S6 kinase, angiotensin II-induced phosphorylation was abolished by pretreatment with rapamycin, but not by tosylphenylalanine chloromethyl ketone or tosyllysine chloromethyl ketone.	Sirolimus	54-63	angiotensinogen	Homo sapiens	90-104
12807916-9	2003	Thus, LPS and IFN-gamma activate the PI3K and mTOR pathways, which converge to regulate STAT1-dependent transcription of pro-apoptotic and pro-inflammatory genes in a rapamycin-insensitive manner.	Sirolimus	167-176	interferon gamma	Homo sapiens	14-23
12807916-9	2003	Thus, LPS and IFN-gamma activate the PI3K and mTOR pathways, which converge to regulate STAT1-dependent transcription of pro-apoptotic and pro-inflammatory genes in a rapamycin-insensitive manner.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	46-50
14500340-5	2003	Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
14500340-5	2003	Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	55-59
14500340-5	2003	Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	63-67
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	206-209
12957289-6	2003	Rapamycin normalizes HIF levels in TSC2(-/-) cells, indicating that TSC2 regulates HIF by inhibiting mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	101-105
12914928-4	2003	However, we recently found that the regulation of the IGFBP1 but not the PEPCK or G6Pase genes by insulin was sensitive to rapamycin, an inhibitor of mTOR.	Sirolimus	123-132	insulin	Homo sapiens	98-105
12914928-4	2003	However, we recently found that the regulation of the IGFBP1 but not the PEPCK or G6Pase genes by insulin was sensitive to rapamycin, an inhibitor of mTOR.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	150-154
12906785-6	2003	This dissociation is completely sensitive to rapamycin (an mTOR inhibitor) but not wortmannin (a phosphoinositide 3-kinase [PI3K] inhibitor).	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	59-63
12906785-7	2003	Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	158-162
12875979-14	2003	Pretreatment of cells with rapamycin (an inhibitor of FRAP/mTOR which is the immediate upstream kinase of the p70 S6 kinase) attenuated the effects induced by zinc.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	54-58
12875979-14	2003	Pretreatment of cells with rapamycin (an inhibitor of FRAP/mTOR which is the immediate upstream kinase of the p70 S6 kinase) attenuated the effects induced by zinc.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	59-63
12957289-7	2003	In contrast, Rapamycin only partially downregulates VEGF in this setting, implying an mTOR-independent link between TSC2 loss and VEGF.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	52-56
12939469-1	2003	Rapamycin exerts its biological activity by inhibiting the kinase mammalian target of rapamycin (mTOR), which regulates important cellular processes such as control of cell cycle and cell size, translation initiation, and transcription.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	66-95
12912932-5	2003	Exposure of Raji lymphoblastoid cells to increasing concentrations of rapamycin resulted in a linear concentration-dependent inhibition of p70(s6) kinase activity, suggesting that p70(s6) kinase activity could be an appropriate marker for mTOR-interacting agents.	Sirolimus	70-79	ubiquitin associated and SH3 domain containing B	Homo sapiens	139-142
12912932-5	2003	Exposure of Raji lymphoblastoid cells to increasing concentrations of rapamycin resulted in a linear concentration-dependent inhibition of p70(s6) kinase activity, suggesting that p70(s6) kinase activity could be an appropriate marker for mTOR-interacting agents.	Sirolimus	70-79	ubiquitin associated and SH3 domain containing B	Homo sapiens	180-183
12912932-5	2003	Exposure of Raji lymphoblastoid cells to increasing concentrations of rapamycin resulted in a linear concentration-dependent inhibition of p70(s6) kinase activity, suggesting that p70(s6) kinase activity could be an appropriate marker for mTOR-interacting agents.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	239-243
12939469-1	2003	Rapamycin exerts its biological activity by inhibiting the kinase mammalian target of rapamycin (mTOR), which regulates important cellular processes such as control of cell cycle and cell size, translation initiation, and transcription.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	97-101
12939469-3	2003	Some investigators have hypothesized that loss of the PTEN tumor suppressor may sensitize tumor cells to the antiproliferative activity of rapamycin because PTEN loss leads to activation of the mTOR pathway.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	194-198
12939469-9	2003	We demonstrate that rapamycin inhibits phosphorylation of downstream targets of mTOR such as p70(S6K) kinase and 4E-BP1 translation repressor.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	80-84
12916871-0	2003	Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: possible clinical application of rapamycin.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	64-68
12740386-4	2003	The immunosuppressant FK506 failed to inhibit p70S6K activation, but was able to rescue the rapamycin-induced downshift, pointing to a role for the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	148-177
12740386-4	2003	The immunosuppressant FK506 failed to inhibit p70S6K activation, but was able to rescue the rapamycin-induced downshift, pointing to a role for the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	179-183
12740386-7	2003	This component was totally inhibited by pre-incubating the cells with the mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor PD-98059 prior to treatment with rapamycin.	Sirolimus	170-179	mitogen-activated protein kinase kinase 7	Homo sapiens	122-125
12713446-7	2003	This activity was resistant to the effects of rapamycin or wortmannin, indicating that mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) regulate S6K2 activity via Thr-388.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	87-116
12713446-7	2003	This activity was resistant to the effects of rapamycin or wortmannin, indicating that mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) regulate S6K2 activity via Thr-388.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	118-122
12713446-7	2003	This activity was resistant to the effects of rapamycin or wortmannin, indicating that mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) regulate S6K2 activity via Thr-388.	Sirolimus	46-55	ribosomal protein S6 kinase B2	Homo sapiens	170-174
12835079-14	2003	Rapamycin, which is similar to Tacrolimus, inhibits graft rejection by blocking IL-2 activation and phosphorylation of 70 S6 kinase thus inhibiting the progression of T-cell from G to S phase.	Sirolimus	0-9	interleukin 2	Homo sapiens	80-84
12916871-8	2003	These results suggest that rapamycin could be included in the therapeutic modality for the patients with MDS who have the mTOR sequences in GSTT-1 gene.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	122-126
12813467-2	2003	Rapamycin is a highly specific inhibitor of mTOR in clinical trials for the treatment of breast and other cancers.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
12813467-8	2003	Elevating PLD activity in MCF-7 cells led to rapamycin resistance; and inhibition of PLD activity in MDA-MB-231 cells increased rapamycin sensitivity.	Sirolimus	128-137	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	85-88
12829920-7	2003	CONCLUSIONS: Sirolimus can be successfully combined with humanized mAb against CD80 and CD86.	Sirolimus	13-22	T-lymphocyte activation antigen CD86	Macaca fascicularis	88-92
12813467-7	2003	MCF-7 cells, with relatively low levels of PLD activity, were highly sensitive to the growth-arresting effects of rapamycin, whereas MDA-MB-231 cells, with a 10-fold higher PLD activity than MCF-7 cells, were highly resistant to rapamycin.	Sirolimus	114-123	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	43-46
12813467-9	2003	Elevated PLD activity in MCF-7 cells also caused rapamycin resistance for S6 kinase phosphorylation and serum-induced Myc expression.	Sirolimus	49-58	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	9-12
12813467-10	2003	These data implicate mTOR as a critical target for survival signals generated by PLD and suggest that PLD levels in breast cancer could be a valuable indicator of the likely efficacy of rapamycin treatment.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	21-25
12813467-10	2003	These data implicate mTOR as a critical target for survival signals generated by PLD and suggest that PLD levels in breast cancer could be a valuable indicator of the likely efficacy of rapamycin treatment.	Sirolimus	186-195	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	81-84
12813467-10	2003	These data implicate mTOR as a critical target for survival signals generated by PLD and suggest that PLD levels in breast cancer could be a valuable indicator of the likely efficacy of rapamycin treatment.	Sirolimus	186-195	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	102-105
12813467-8	2003	Elevating PLD activity in MCF-7 cells led to rapamycin resistance; and inhibition of PLD activity in MDA-MB-231 cells increased rapamycin sensitivity.	Sirolimus	45-54	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	10-13
12820963-1	2003	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces apoptosis of cells lacking functional p53.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	56-85
12773161-3	2003	Hamartin and tuberin form a complex and antagonise phosphoinositide 3-kinase/protein kinase B/target of rapamycin signal transduction by inhibiting p70 S6 kinase, an activator of translation, and activating 4E-binding protein 1, an inhibitor of translation initiation.	Sirolimus	104-113	TSC complex subunit 1	Homo sapiens	0-8
12796300-5	2003	Treatment with rapamycin resulted in the hyperphosphorylation of Put3p, which was independent of Gln3p, Nil1p, and Ure2p.	Sirolimus	15-24	glutathione peroxidase	Saccharomyces cerevisiae S288C	115-120
12820963-1	2003	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces apoptosis of cells lacking functional p53.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	87-91
12820963-1	2003	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces apoptosis of cells lacking functional p53.	Sirolimus	29-38	tumor protein p53	Homo sapiens	140-143
12820963-5	2003	Rapamycin induces p21(Cip1) binding to ASK1, suppressing kinase activity and attenuating cellular stress.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-21
12820963-5	2003	Rapamycin induces p21(Cip1) binding to ASK1, suppressing kinase activity and attenuating cellular stress.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	22-26
12604610-5	2003	Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Homo sapiens	30-34
12800089-0	2003	Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake.	Sirolimus	13-22	insulin	Homo sapiens	47-54
12800089-4	2003	Pretreatment of L6 cells with sodium orthovanadate (Na(3)VO(4)) plus the mTOR inhibitor rapamycin caused a 5-fold increase in insulin-responsive glucose uptake at 2 hours when compared to insulin alone.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	73-77
12800089-4	2003	Pretreatment of L6 cells with sodium orthovanadate (Na(3)VO(4)) plus the mTOR inhibitor rapamycin caused a 5-fold increase in insulin-responsive glucose uptake at 2 hours when compared to insulin alone.	Sirolimus	88-97	insulin	Homo sapiens	126-133
12800089-4	2003	Pretreatment of L6 cells with sodium orthovanadate (Na(3)VO(4)) plus the mTOR inhibitor rapamycin caused a 5-fold increase in insulin-responsive glucose uptake at 2 hours when compared to insulin alone.	Sirolimus	88-97	insulin	Homo sapiens	188-195
12800089-7	2003	When L6 cells were pretreated with Na(3)VO(4) plus the proteasome inhibitor MG-132 or the mTOR inhibitor rapamycin prior to insulin addition, IRS-1 mass loss as well as IRS-1/PI-3 kinase complex decay was blocked at 2 hours and PI 3-kinase activity was increased 2.5-fold and 4-fold, respectively, over insulin alone.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	90-94
12800089-8	2003	Finally, treatment of L6 cells with subtherapeutic amounts of vanadyl sulfate and rapamycin induced a synergistic 3-fold increase in insulin-induced glucose uptake at 2 hours.	Sirolimus	82-91	insulin	Homo sapiens	133-140
12604610-5	2003	Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Homo sapiens	94-98
12604610-5	2003	Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Homo sapiens	94-98
12750770-7	2003	The PI 3-kinase inhibitor LY294002 and the mTOR inhibitor rapamycin, but not the MEK1 inhibitor PD98059, could prevent IRS1 changes in oxidized cells.	Sirolimus	58-67	insulin receptor substrate 1	Rattus norvegicus	119-123
12752312-3	2003	ApoE KO mice were fed a high fat diet and sirolimus was administered.	Sirolimus	42-51	apolipoprotein E	Mus musculus	0-4
12752312-9	2003	Sirolimus treatment resulted in decreased expression of IL-12p40, IFN-gamma and IL-10 mRNA.	Sirolimus	0-9	interferon gamma	Mus musculus	66-75
12752312-9	2003	Sirolimus treatment resulted in decreased expression of IL-12p40, IFN-gamma and IL-10 mRNA.	Sirolimus	0-9	interleukin 10	Mus musculus	80-85
12752312-11	2003	Sirolimus significantly reduced atherosclerosis in apo E-KO mice; this effect is independent of, and obviates, elevated plasma TC and LDLc.	Sirolimus	0-9	apolipoprotein E	Mus musculus	51-56
12554767-4	2003	Akt activation was blocked by wortmannin and LY 294,002, two inhibitors of PI 3-K; by genistein, a protein tyrosine kinase inhibitor and an ER agonist; by AG825, a selective ErbB2 inhibitor; and by the antiestrogens ICI 182,780 and 4-hydroxy-tamoxifen; but not by rapamycin, an inhibitor of the ribosomal protein kinase p70S6K; nor by AG30, a selective epidermal growth factor receptor inhibitor.	Sirolimus	264-273	AKT serine/threonine kinase 1	Homo sapiens	0-3
12742477-1	2003	Sirolimus is the first of a group of mammalian target of rapamycin inhibitors to be introduced for clinical use in the United States.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	37-66
12719473-7	2003	Further, we show that a sublethal concentration of rapamycin mimics the Gap1p sorting defect of an lst8 mutant.	Sirolimus	51-60	amino acid permease GAP1	Saccharomyces cerevisiae S288C	72-77
12515720-6	2003	The mTOR inhibitors rapamycin and CCI-779, the PI3-kinase inhibitor LY294002, and the MEK inhibitor PD98059 all significantly curtailed growth of mutant ras-containing cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
12742500-4	2003	Sirolimus targets a unique serine-threonine kinase, mammalian target of rapamycin (mTor), which plays a key role in mitogenic and nutritional cells signals.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	52-81
12742500-4	2003	Sirolimus targets a unique serine-threonine kinase, mammalian target of rapamycin (mTor), which plays a key role in mitogenic and nutritional cells signals.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-87
12681504-5	2003	Amino acid-induced S6K1 activation was inhibited by LY294002 (PI3-kinase inhibitor) and rapamycin (inhibitor of the mammalian target of rapamycin, mTOR), suggesting the involvement of an avian homolog of mTOR.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	116-145
12647306-8	2003	Treatment of cells with rapamycin, an inhibitor of the mammalian target of mTOR, resulted in a 47% and a 53% decrease in the AP activity induced by OP-1 alone and by OP-1 plus IGF-I, respectively.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	75-79
12647306-8	2003	Treatment of cells with rapamycin, an inhibitor of the mammalian target of mTOR, resulted in a 47% and a 53% decrease in the AP activity induced by OP-1 alone and by OP-1 plus IGF-I, respectively.	Sirolimus	24-33	insulin like growth factor 1	Homo sapiens	176-181
12681504-5	2003	Amino acid-induced S6K1 activation was inhibited by LY294002 (PI3-kinase inhibitor) and rapamycin (inhibitor of the mammalian target of rapamycin, mTOR), suggesting the involvement of an avian homolog of mTOR.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	147-151
12569580-7	2003	Progression of the cell cycle from G1 to S phase was inhibited up to 90% by wortmannin or rapamycin, an inhibitor of mTOR, which acts downstream of PI3K.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	117-121
12569580-9	2003	On the other hand, rapamycin inhibited both IGF-I-induced cell cycle progression and cell proliferation in complete medium, although it had no effect on IGF-I-mediated MycN induction.	Sirolimus	19-28	insulin like growth factor 1	Homo sapiens	44-49
12443530-10	2003	The effects of FKBP12.6 on hRyR2-mediated intracellular Ca(2+) handling could be antagonized using rapamycin (5 microM).	Sirolimus	99-108	FKBP prolyl isomerase 1B	Homo sapiens	15-23
12443530-10	2003	The effects of FKBP12.6 on hRyR2-mediated intracellular Ca(2+) handling could be antagonized using rapamycin (5 microM).	Sirolimus	99-108	ryanodine receptor 2	Homo sapiens	27-32
12504590-5	2002	Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR.	Sirolimus	128-137	signal transducer and activator of transcription 3	Homo sapiens	72-77
12393642-6	2003	In our present study, we demonstrated that rapamycin induced cell cycle arrest in proliferating B-CLL cells and inhibited phosphorylation of p70s6 kinase (p70(s6k)).	Sirolimus	43-52	ubiquitin associated and SH3 domain containing B	Homo sapiens	141-144
12417722-0	2002	Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	22-53
12417722-5	2002	Rapamycin also augmented the ability of TGF-beta to inhibit the proliferation of E2F1-, c-Myc-, and (V12)H-Ras-transformed cells, even though these cells were insensitive to TGF-beta-mediated growth arrest in the absence of rapamycin.	Sirolimus	224-233	transforming growth factor beta 1	Homo sapiens	40-48
12543789-0	2003	Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3"-kinase-Akt signaling pathways.	Sirolimus	54-63	insulin like growth factor 1	Homo sapiens	0-28
12543789-1	2003	The mTOR inhibitor rapamycin induces G1 cell cycle accumulation and p53-independent apoptosis of the human rhabdomyosarcoma cell line Rh1.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
12543789-1	2003	The mTOR inhibitor rapamycin induces G1 cell cycle accumulation and p53-independent apoptosis of the human rhabdomyosarcoma cell line Rh1.	Sirolimus	19-28	tumor protein p53	Homo sapiens	68-71
12543789-3	2003	Because the Ras-Erk1-Erk2 and phosphatidylinositol 3"-kinase (PI3K)-Akt pathways are implicated in the survival of various cancer cells, we determined whether protection from rapamycin-induced apoptosis by IGF-I requires one or both of these pathways.	Sirolimus	175-184	mitogen-activated protein kinase 3	Homo sapiens	16-20
12543789-3	2003	Because the Ras-Erk1-Erk2 and phosphatidylinositol 3"-kinase (PI3K)-Akt pathways are implicated in the survival of various cancer cells, we determined whether protection from rapamycin-induced apoptosis by IGF-I requires one or both of these pathways.	Sirolimus	175-184	insulin like growth factor 1	Homo sapiens	206-211
12543789-4	2003	Despite the blocking of Ras-Erk signaling by the addition of PD 98059 (a MEK1 inhibitor) or by the overexpression of dominant-negative RasN17, IGF-I completely prevented rapamycin-induced death.	Sirolimus	170-179	mitogen-activated protein kinase 1	Homo sapiens	28-31
12543789-4	2003	Despite the blocking of Ras-Erk signaling by the addition of PD 98059 (a MEK1 inhibitor) or by the overexpression of dominant-negative RasN17, IGF-I completely prevented rapamycin-induced death.	Sirolimus	170-179	insulin like growth factor 1	Homo sapiens	143-148
12543789-8	2003	The prevention of rapamycin-induced apoptosis by IGF-I was not inhibited by expression of dominant-negative Akt either alone or under conditions in which LY 294002 inhibited PI3K signaling.	Sirolimus	18-27	insulin like growth factor 1	Homo sapiens	49-54
12543789-9	2003	Furthermore, IGF-I prevented rapamycin-induced apoptosis when the Ras-Erk1-Erk2 and PI3K-Akt pathways were blocked simultaneously.	Sirolimus	29-38	insulin like growth factor 1	Homo sapiens	13-18
12543789-9	2003	Furthermore, IGF-I prevented rapamycin-induced apoptosis when the Ras-Erk1-Erk2 and PI3K-Akt pathways were blocked simultaneously.	Sirolimus	29-38	mitogen-activated protein kinase 3	Homo sapiens	70-74
12543789-9	2003	Furthermore, IGF-I prevented rapamycin-induced apoptosis when the Ras-Erk1-Erk2 and PI3K-Akt pathways were blocked simultaneously.	Sirolimus	29-38	mitogen-activated protein kinase 1	Homo sapiens	75-79
12543789-9	2003	Furthermore, IGF-I prevented rapamycin-induced apoptosis when the Ras-Erk1-Erk2 and PI3K-Akt pathways were blocked simultaneously.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	89-92
12509460-4	2003	Genetic and biochemical evidence identifies Rpd3 as the major histone deacetylase responsible for reversing histone H4 acetylation at RP gene promoters in response to Tor inhibition by rapamycin or nutrient limitation.	Sirolimus	185-194	histone deacetylase 1	Homo sapiens	44-48
12509460-4	2003	Genetic and biochemical evidence identifies Rpd3 as the major histone deacetylase responsible for reversing histone H4 acetylation at RP gene promoters in response to Tor inhibition by rapamycin or nutrient limitation.	Sirolimus	185-194	RAR related orphan receptor C	Homo sapiens	167-170
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	Sirolimus	94-103	kininogen 1	Homo sapiens	162-172
12504590-5	2002	Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	155-159
12469693-9	2002	Sirolimus is metabolised by the cytochrome P450 isoenzyme CYP3A4, so may induce drug interactions.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
12384443-7	2002	In contrast, only sirolimus resulted in a decrease in host splenic T-cell numbers in anti-CD40L mAb-treated recipients.	Sirolimus	18-27	CD40 ligand	Homo sapiens	90-95
12393646-7	2002	BCR/ABL-induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen-activated protein kinase pathway.	Sirolimus	123-132	vascular endothelial growth factor A	Homo sapiens	16-20
12393646-7	2002	BCR/ABL-induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen-activated protein kinase pathway.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	151-180
12393646-7	2002	BCR/ABL-induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen-activated protein kinase pathway.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	182-186
12414639-3	2002	This study aimed to determine the effects of PTEN status and treatment with rapamycin, an inhibitor of mTOR, in the response of prostate cancer cell lines to doxorubicin.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	103-107
12414639-7	2002	Furthermore, treatment of mice bearing the PTEN-negative PC-3 prostate cancer xenografts with CCI-779, an ester of rapamycin in clinical development combined with doxorubicin, inhibited the growth of the doxorubicin-resistant PC-3 tumors confirming the observations in vitro.	Sirolimus	115-124	phosphatase and tensin homolog	Mus musculus	43-47
12393186-3	2002	Rapamycin, which binds to FRAP/mTOR and completely suppressed the activation of p70S6 kinase by insulin, almost completely blocked the induction of the hexokinase II gene, and caused an approximately 50% inhibition of the induction of the Fra-1 gene.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	26-30
12431638-0	2002	Effect of rapamycin and prednisolone in differentiated THP-1 and U937 cells.	Sirolimus	10-19	GLI family zinc finger 2	Homo sapiens	55-60
12384518-7	2002	Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting.	Sirolimus	127-136	TSC complex subunit 1	Homo sapiens	83-86
12414688-6	2002	This effect was similar to those of FK506 and rapamycin, two drugs known to cause dissociation of FKBP12 from RyR.	Sirolimus	46-55	ryanodine receptor 1, skeletal muscle	Mus musculus	110-113
12193593-6	2002	LY294002 and rapamycin, potent inhibitors of PI3-kinase and mTOR, respectively, also blocked the DNA synthesis induced by 5(S)-HETE.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	60-64
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	AKT serine/threonine kinase 1	Homo sapiens	211-220
12225947-5	2002	Although an inhibitor of mitogen-activated protein kinase kinase, PD-98059, but not rapamycin, blocked ANG IV-induced phosphorylation of ERK1/2, both PD-98059 and rapamycin independently caused partial reduction in ANG IV-mediated cell proliferation.	Sirolimus	163-172	mitogen-activated protein kinase 3	Homo sapiens	137-143
12393186-3	2002	Rapamycin, which binds to FRAP/mTOR and completely suppressed the activation of p70S6 kinase by insulin, almost completely blocked the induction of the hexokinase II gene, and caused an approximately 50% inhibition of the induction of the Fra-1 gene.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-35
12393186-3	2002	Rapamycin, which binds to FRAP/mTOR and completely suppressed the activation of p70S6 kinase by insulin, almost completely blocked the induction of the hexokinase II gene, and caused an approximately 50% inhibition of the induction of the Fra-1 gene.	Sirolimus	0-9	insulin	Homo sapiens	96-103
12234610-6	2002	A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	50-54
12167617-7	2002	Treatment of HuH-7 with rapamycin to disrupt the heterocomplex reduced surface ASGPR binding activity by 65 +/- 5.7%.	Sirolimus	24-33	asialoglycoprotein receptor 1	Homo sapiens	79-84
12234610-6	2002	A molecular mechanism for rapamycin inhibition of mTOR signaling is proposed, in which a putative interaction between PA and mTOR is abolished by rapamycin binding.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	125-129
12351422-3	2002	Rapamycin, an inhibitor of mTOR, is a potent immunosuppressant due, in part, to its ability to interfere with T-cell activation at the level of translation, and it has gained a prominent role in preventing the development and progression of rejection in pancreatic islet transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
12242281-5	2002	Pretreatment of PC-3 cells with the mTOR inhibitor, rapamycin, inhibited both the accumulation of HIF-1alpha and HIF-1-dependent transcription induced by hypoxia or CoCl(2).	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	36-40
12235265-8	2002	The interaction of sirolimus with P-glycoprotein was also evaluated in vitro using HCT-8 and Caco-2 cell monolayers.	Sirolimus	19-28	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
12242281-5	2002	Pretreatment of PC-3 cells with the mTOR inhibitor, rapamycin, inhibited both the accumulation of HIF-1alpha and HIF-1-dependent transcription induced by hypoxia or CoCl(2).	Sirolimus	52-61	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
12242281-5	2002	Pretreatment of PC-3 cells with the mTOR inhibitor, rapamycin, inhibited both the accumulation of HIF-1alpha and HIF-1-dependent transcription induced by hypoxia or CoCl(2).	Sirolimus	52-61	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-103
12242281-6	2002	Transfection of these cells with wild-type mTOR enhanced HIF-1 activation by hypoxia or CoCl(2), while expression of a rapamycin-resistant mTOR mutant rendered both HIF-1alpha stabilization and HIF-1 transactivating function refractory to inhibition by rapamycin.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	139-143
12242281-6	2002	Transfection of these cells with wild-type mTOR enhanced HIF-1 activation by hypoxia or CoCl(2), while expression of a rapamycin-resistant mTOR mutant rendered both HIF-1alpha stabilization and HIF-1 transactivating function refractory to inhibition by rapamycin.	Sirolimus	119-128	hypoxia inducible factor 1 subunit alpha	Homo sapiens	165-175
12242281-6	2002	Transfection of these cells with wild-type mTOR enhanced HIF-1 activation by hypoxia or CoCl(2), while expression of a rapamycin-resistant mTOR mutant rendered both HIF-1alpha stabilization and HIF-1 transactivating function refractory to inhibition by rapamycin.	Sirolimus	119-128	hypoxia inducible factor 1 subunit alpha	Homo sapiens	165-170
12242281-8	2002	These studies position mTOR as an upstream activator of HIF-1 function in cancer cells and suggest that the antitumor activity of rapamycin is mediated, in part, through the inhibition of cellular responses to hypoxic stress.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	23-27
12148116-0	2002	Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation.	Sirolimus	0-9	myeloperoxidase	Homo sapiens	17-32
12231370-7	2002	Exposure to tacrolimus and rapamycin caused severe impairment of relaxations to serotonin and a lesser one to bradykinin.	Sirolimus	27-36	kininogen 1	Homo sapiens	110-120
12022919-6	2002	Ivermectin, cyclosporin A and rapamycin all inhibited the skeletal muscle sarcoplasmic reticulum Ca(2+)-ATPase (SERCA1).	Sirolimus	30-39	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	Homo sapiens	112-118
12148116-1	2002	We report the case of a child with microscopic polyangiitis (myeloperoxidase-antineutrophil cytoplasmic antibody [p-ANCA]-positive vasculitis) whose disease progressed to end-stage renal failure, in whom sirolimus contributed to normalization of myeloperoxidase and ANCA titers.	Sirolimus	204-213	myeloperoxidase	Homo sapiens	61-76
12165425-4	2002	"Induction" of NCR-sensitive gene expression and dephosphorylation of Gln3 (and Ure2 in some laboratories) when cells are treated with rapamycin implicates the Tor1/2 signal transduction pathway in this regulation.	Sirolimus	135-144	glutathione peroxidase	Saccharomyces cerevisiae S288C	80-84
12134068-9	2002	The mTOR inhibitor rapamycin diminished Akt-mediated increases in cell size, mitochondrial membrane potential, and cell survival.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
12176409-0	2002	Rapamycin blocks the generation of regulatory T cells facilitated by posttransplant infusion of donor T cells through increasing the apoptosis of thymic CD4(+)CD25(+) cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	153-156
12176411-0	2002	Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function.	Sirolimus	57-66	interferon gamma	Homo sapiens	36-45
12089560-4	2002	Introduction of this activator into human cells allowed expression of the chromosomal VEGF gene to be induced by a small-molecule dimerizer compound consisting of a nonimmunosuppressive rapamycin analog.	Sirolimus	186-195	vascular endothelial growth factor A	Homo sapiens	86-90
12134068-9	2002	The mTOR inhibitor rapamycin diminished Akt-mediated increases in cell size, mitochondrial membrane potential, and cell survival.	Sirolimus	19-28	AKT serine/threonine kinase 1	Homo sapiens	40-43
12032842-6	2002	C2Ras myoblasts failed to restore differentiation when rapamycin or PD169316 were added in the presence of insulin+PD98059, indicating that the activation of both P70S6K and p38-MAPK was necessary to reach a fully differentiated phenotype.	Sirolimus	55-64	insulin	Homo sapiens	107-114
12036883-6	2002	Treatment with rapamycin blocked IL-2 production after activation of human peripheral blood T cells with phorbol ester (PMA) and anti-CD28 (CsA-resistant pathway), whereas this drug did not have any effect on PMA plus ionomycin stimulation (CsA-sensitive pathway).	Sirolimus	15-24	interleukin 2	Homo sapiens	33-37
12065239-10	2002	The immunosuppressant drug rapamycin inhibited proliferation of Nb2 cells in response to PRL or interleukin-2, but had no effect on Nb2-Sp cells.	Sirolimus	27-36	prolactin	Rattus norvegicus	89-92
12032842-8	2002	A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis.	Sirolimus	59-68	mitogen-activated protein kinase 14	Homo sapiens	31-39
12032842-8	2002	A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis.	Sirolimus	59-68	insulin	Homo sapiens	87-94
12039858-8	2002	However, mTOR inhibition by rapamycin specifically abrogated hypoxia-mediated amplification of proliferation and angiogenesis, but was without effect on proliferation under normoxia.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	9-13
12032842-8	2002	A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis.	Sirolimus	59-68	AKT serine/threonine kinase 1	Homo sapiens	105-108
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	50-54
12051762-0	2002	Rapamycin partially prevents insulin resistance induced by chronic insulin treatment.	Sirolimus	0-9	insulin	Homo sapiens	29-36
12051762-0	2002	Rapamycin partially prevents insulin resistance induced by chronic insulin treatment.	Sirolimus	0-9	insulin	Homo sapiens	67-74
12051762-2	2002	In this study, to investigate whether rapamycin (an mTOR inhibitor) could prevent insulin resistance induced by hyperinsulinemia, 3T3-L1 adipocytes were incubated chronically in the presence of insulin with or without the addition of rapamycin.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	52-56
12051762-2	2002	In this study, to investigate whether rapamycin (an mTOR inhibitor) could prevent insulin resistance induced by hyperinsulinemia, 3T3-L1 adipocytes were incubated chronically in the presence of insulin with or without the addition of rapamycin.	Sirolimus	38-47	insulin	Homo sapiens	82-89
12051762-2	2002	In this study, to investigate whether rapamycin (an mTOR inhibitor) could prevent insulin resistance induced by hyperinsulinemia, 3T3-L1 adipocytes were incubated chronically in the presence of insulin with or without the addition of rapamycin.	Sirolimus	38-47	insulin	Homo sapiens	117-124
12051762-5	2002	Rapamycin prevented the reduction of IRS-1 protein levels and insulin-induced PKB Ser-473 phosphorylation with a partial normalization of insulin-induced glucose transport.	Sirolimus	0-9	insulin	Homo sapiens	62-69
11872747-7	2002	In contrast, IL-6-induced phosphorylation of 4E-BP1 was inhibited by rapamycin, wortmannin, and dominant negative AKT but ERK inhibitors had no effect, indicating ERK function was dispensable.	Sirolimus	69-78	interleukin 6	Homo sapiens	13-17
11872747-9	2002	Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth.	Sirolimus	96-105	interleukin 6	Homo sapiens	14-18
11872747-9	2002	Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth.	Sirolimus	96-105	BP1	Homo sapiens	49-52
11872747-9	2002	Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth.	Sirolimus	96-105	interleukin 6	Homo sapiens	165-169
11983923-2	2002	Here we show that Arabidopsis thaliana possesses a single TOR gene encoding a protein able to complex with yeast 12-kDa FK506-binding protein and rapamycin despite the insensitivity of Arabidopsis vegetative growth to rapamycin.	Sirolimus	146-155	target of rapamycin	Arabidopsis thaliana	58-61
12042641-8	2002	RESULTS: Rapamycin conditioning of renal cancer cells upregulated E-cadherin expression and induced phenotypic transition from invasive spindle, or dome-shaped cells, with exploratory pseudopodia to noninvasive cuboidal cells that formed cell-to-cell adhesions.	Sirolimus	9-18	cadherin 1	Mus musculus	66-76
11875068-5	2002	Our results show that Delta10mTORrr signals 4E-BP1 and permits rapamycin-treated myoblasts to differentiate, confirming the mTOR dependence of the inhibition of myogenesis by rapamycin.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	29-33
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	264-273	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
11907172-2	2002	Modified Caco-2 cells metabolized [(14)C]sirolimus to the predicted amounts of CYP3A4-mediated products based on CYP3A4 content, which was approximately 20% of that measured in human small intestinal mucosal homogenate.	Sirolimus	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
11907172-2	2002	Modified Caco-2 cells metabolized [(14)C]sirolimus to the predicted amounts of CYP3A4-mediated products based on CYP3A4 content, which was approximately 20% of that measured in human small intestinal mucosal homogenate.	Sirolimus	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	214-223	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
11847216-1	2002	To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosarcoma cells were selected for rapamycin resistance.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	169-173
11847216-1	2002	To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosarcoma cells were selected for rapamycin resistance.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Homo sapiens	169-173
11909972-8	2002	Rapamycin attenuated caAkt-induced overgrowth of the heart, suggesting that the mammalian target of rapamycin (mTOR) or effectors of mTOR mediated caAkt-induced heart growth.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	80-109
11909972-8	2002	Rapamycin attenuated caAkt-induced overgrowth of the heart, suggesting that the mammalian target of rapamycin (mTOR) or effectors of mTOR mediated caAkt-induced heart growth.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	111-115
11909972-8	2002	Rapamycin attenuated caAkt-induced overgrowth of the heart, suggesting that the mammalian target of rapamycin (mTOR) or effectors of mTOR mediated caAkt-induced heart growth.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	133-137
11855825-6	2002	The phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin and the mammalian target of rapamycin (mTOR) inhibitor rapamycin, but not the mitogen-activated protein kinase (MAPK)-activating kinase (MEK) inhibitor PD98059, reversed the IGF-1-induced effects observed on eIF-4E/4G assembly and phosphorylation status of 4E-BP1, eIF-4E, and eIF-4G.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	102-106
11799119-5	2002	The TPA-stimulated phosphorylation of all these sites is sensitive to inhibitors of MEK and to the inhibitor of mTOR, rapamycin, indicating that inputs from both mTOR and MEK are required for the regulation of 4E-BP1 phosphorylation by TPA.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	112-116
11799119-5	2002	The TPA-stimulated phosphorylation of all these sites is sensitive to inhibitors of MEK and to the inhibitor of mTOR, rapamycin, indicating that inputs from both mTOR and MEK are required for the regulation of 4E-BP1 phosphorylation by TPA.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	162-166
11784721-5	2002	Importantly, we demonstrate that insulin regulation of the thymine-rich insulin response element of the IGFBP-1 promoter was also inhibited by rapamycin.	Sirolimus	143-152	insulin	Homo sapiens	33-40
11784721-5	2002	Importantly, we demonstrate that insulin regulation of the thymine-rich insulin response element of the IGFBP-1 promoter was also inhibited by rapamycin.	Sirolimus	143-152	insulin	Homo sapiens	72-79
11872661-7	2002	We conclude that 1) combination therapy with sirolimus and IL-2 is synergistic in protecting islet beta-cells from autoimmune destruction; 2) diabetes prevention continues after withdrawal of therapy; and 3) the mechanism of protection involves a shift from Th1- to Th2- and Th3-type cytokine-producing cells, possibly due to deletion of autoreactive Th1 cells.	Sirolimus	45-54	negative elongation factor complex member C/D, Th1l	Mus musculus	258-261
11872661-7	2002	We conclude that 1) combination therapy with sirolimus and IL-2 is synergistic in protecting islet beta-cells from autoimmune destruction; 2) diabetes prevention continues after withdrawal of therapy; and 3) the mechanism of protection involves a shift from Th1- to Th2- and Th3-type cytokine-producing cells, possibly due to deletion of autoreactive Th1 cells.	Sirolimus	45-54	negative elongation factor complex member C/D, Th1l	Mus musculus	351-354
12489846-8	2002	However, HBC4 cells were sensitized to anoikis when PD98059 was combined with the mTOR inhibitor rapamycin.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	82-86
11935154-9	2002	Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA.	Sirolimus	18-27	negative elongation factor complex member C/D, Th1l	Mus musculus	108-111
11935154-9	2002	Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA.	Sirolimus	18-27	interferon gamma	Mus musculus	128-138
11935154-10	2002	CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets.	Sirolimus	80-89	negative elongation factor complex member C/D, Th1l	Mus musculus	231-234
11935154-10	2002	CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets.	Sirolimus	80-89	interferon gamma	Mus musculus	246-256
11805719-1	2002	The intracellular class of proteins that bind the interleukin-2 suppressing drugs (cyclosporin, tacrolimus, and sirolimus) are called immunophilins.	Sirolimus	112-121	interleukin 2	Homo sapiens	50-63
11805722-7	2002	SRL disrupts costimulatory and cytokine-stimulated T cell activation by inhibiting a multifunctional kinase, mammalian target of sirolimus (mTOR).	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	140-144
11792863-9	2002	The inhibition by rapamycin was blocked by FK506, which competitively inhibits those effects of rapamycin that are mediated by inhibition of mTOR.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	141-145
11756682-9	2002	Disruption of mTOR signaling by rapamycin results in a reduction of late-phase LTP expression induced by high-frequency stimulation; the early phase of LTP is unaffected.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	14-18
11792863-9	2002	The inhibition by rapamycin was blocked by FK506, which competitively inhibits those effects of rapamycin that are mediated by inhibition of mTOR.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	141-145
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	129-133
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	134-138
12030785-6	2001	In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity.	Sirolimus	82-91	tumor protein p53	Homo sapiens	32-35
11762554-1	2001	Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp).	Sirolimus	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
11762554-1	2001	Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp).	Sirolimus	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	169-173
11948686-2	2002	Inhibition of mTOR with rapamycin resulted in approximately 50% inhibition of the insulin-induced degradation of IRS-1.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
11948686-2	2002	Inhibition of mTOR with rapamycin resulted in approximately 50% inhibition of the insulin-induced degradation of IRS-1.	Sirolimus	24-33	insulin	Homo sapiens	82-89
12030785-6	2001	In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity.	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	42-56
11707420-5	2001	However, similarly to yeast and Drosophila, loss of Cdh1 induced unscheduled accumulation of mitotic cyclins in G1, resulting in abrogation of G1 arrest caused by treatment with rapamycin, an inducer of p27(Kip1).	Sirolimus	178-187	fizzy-related	Drosophila melanogaster	52-56
11739559-5	2001	IL-8 expression was attenuated more by the Src kinase inhibitor PP1 than by the p70s6k inhibitor rapamycin.	Sirolimus	97-106	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
11739804-9	2001	Activation of the MAP kinase or cAMP pathways, or mutation of the Sok2 repressor, restored filamentation in rapamycin treated cells, supporting models in which the Tor pathway acts in parallel with these known pathways.	Sirolimus	108-117	Sok2p	Saccharomyces cerevisiae S288C	66-70
11713299-7	2001	Inhibition of mTOR by rapamycin led to fast and complete repression of S6K1, as judged by rpS6 phosphorylation, but to only partial and delayed repression of translational activation of TOP mRNAs.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
11695998-10	2001	In cultured human myotubes, up-regulation of p85alpha, p55alpha and p50alpha mRNAs by insulin was abolished by LY294002 (10 microM) and by rapamycin (50 nM), suggesting that the PI 3-kinase/protein kinase B/p70 S6 kinase pathway could be involved in the stimulation of grb-1 gene expression by insulin in human muscle cells.	Sirolimus	139-148	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	45-53
11695998-10	2001	In cultured human myotubes, up-regulation of p85alpha, p55alpha and p50alpha mRNAs by insulin was abolished by LY294002 (10 microM) and by rapamycin (50 nM), suggesting that the PI 3-kinase/protein kinase B/p70 S6 kinase pathway could be involved in the stimulation of grb-1 gene expression by insulin in human muscle cells.	Sirolimus	139-148	insulin	Homo sapiens	86-93
11695998-10	2001	In cultured human myotubes, up-regulation of p85alpha, p55alpha and p50alpha mRNAs by insulin was abolished by LY294002 (10 microM) and by rapamycin (50 nM), suggesting that the PI 3-kinase/protein kinase B/p70 S6 kinase pathway could be involved in the stimulation of grb-1 gene expression by insulin in human muscle cells.	Sirolimus	139-148	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	269-274
11695998-10	2001	In cultured human myotubes, up-regulation of p85alpha, p55alpha and p50alpha mRNAs by insulin was abolished by LY294002 (10 microM) and by rapamycin (50 nM), suggesting that the PI 3-kinase/protein kinase B/p70 S6 kinase pathway could be involved in the stimulation of grb-1 gene expression by insulin in human muscle cells.	Sirolimus	139-148	insulin	Homo sapiens	294-301
11698435-2	2001	Anti-CTLA-4 mAb treatment during primary Ag exposure increases cell cycle progression and enhances recall Ag responsiveness; however, simultaneous treatment with rapamycin, an inhibitor of the mammalian target of rapamycin and potent antiproliferative agent, prevents both effects.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Homo sapiens	193-222
11825325-6	2001	Since the inhibitory effect of sirolimus disables virtually all responses to cytokine mediators due to the widespread involvement of mTOR in multiple signalling pathways, the agent is likely also to retard proliferation of endothelial and vascular smooth muscle cells, an important component of the immuno-obliterative processes associated with chronic rejection.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	133-137
11733037-7	2001	The kinase activity of p70beta1 was less sensitive to the inhibition induced by rapamycin, wortmannin and amino acid withdrawal than that of p70alpha.	Sirolimus	80-89	ribosomal protein S6 kinase B2	Homo sapiens	23-31
11753643-11	2001	However, even at 100 ng/ml, rapamycin only partially inhibited S6K2.	Sirolimus	28-37	ribosomal protein S6 kinase B2	Homo sapiens	63-67
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Sirolimus	26-35	AKT serine/threonine kinase 1	Homo sapiens	129-132
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Sirolimus	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	230-235
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Sirolimus	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	279-284
11709727-6	2001	Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002- and rapamycin-mediated inhibition of colony formation.	Sirolimus	163-172	erb-b2 receptor tyrosine kinase 2	Homo sapiens	21-26
11597394-0	2001	Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	54-59
11733037-8	2001	The portion of p70beta activity inhibited by rapamycin was rescued by the rapamycin-resistant mutant of the mammalian target of rapamycin (mTOR).	Sirolimus	45-54	ribosomal protein S6 kinase B2	Homo sapiens	15-22
11733037-8	2001	The portion of p70beta activity inhibited by rapamycin was rescued by the rapamycin-resistant mutant of the mammalian target of rapamycin (mTOR).	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	108-137
11733037-8	2001	The portion of p70beta activity inhibited by rapamycin was rescued by the rapamycin-resistant mutant of the mammalian target of rapamycin (mTOR).	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	139-143
11733037-13	2001	Activated p70beta may be less sensitive to dephosphorylation mediated by putative phosphatases activated by rapamycin, amino acid withdrawal, and probably wortmannin.	Sirolimus	108-117	ribosomal protein S6 kinase B2	Homo sapiens	10-17
11715023-4	2001	Furthermore, rapamycin, a selective blocker of mTOR, blocked hypertrophy in all models tested, without causing atrophy in control muscles.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	47-51
11690632-3	2001	A human growth hormone (hGH) expression construct containing the promoter region and 5" untranslated region (UTR) of EF1A linked to the hGH coding region (EF1A/hGH) was translationally repressed following rapamycin treatment in similar fashion to endogenous EF1A in human B lymphocytes.	Sirolimus	205-214	growth hormone 1	Homo sapiens	8-22
11574405-11	2001	Glucose- and insulin-stimulated translocation of PDX-1 to the nucleoplasm was inhibited by wortmannin and SB 203580, indicating that a pathway involving PI 3-kinase and SAPK2/p38 was involved; translocation was unaffected by PD 098959 and rapamycin, suggesting that neither mitogen-activated protein kinase nor p70(s6k) were involved.	Sirolimus	239-248	insulin	Homo sapiens	13-20
11498541-5	2001	The effect of amino acids was fully prevented by the specific mTOR inhibitor rapamycin.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	62-66
11602850-0	2001	Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.	Sirolimus	10-19	apolipoprotein B	Homo sapiens	41-48
11574405-11	2001	Glucose- and insulin-stimulated translocation of PDX-1 to the nucleoplasm was inhibited by wortmannin and SB 203580, indicating that a pathway involving PI 3-kinase and SAPK2/p38 was involved; translocation was unaffected by PD 098959 and rapamycin, suggesting that neither mitogen-activated protein kinase nor p70(s6k) were involved.	Sirolimus	239-248	mitogen-activated protein kinase 14	Homo sapiens	175-178
11431469-7	2001	Rapamycin completely blocked S6K2 activation by either PE or insulin.	Sirolimus	0-9	ribosomal protein S6 kinase B2	Homo sapiens	29-33
11573200-7	2001	We conclude that a component of the adipogenic program, operating after the completion of clonal expansion, is inhibited by rapamycin, suggesting an ongoing need for mTOR function in this process.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	166-170
11593425-1	2001	Rapamycin, a specific inhibitor of the serine/threonine mTOR kinase, markedly inhibited both cell growth and apoptosis in human B-cell lines.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	56-60
11593425-4	2001	Rapamycin did not affect bcl-2 mRNA although it increased cellular BCL-2 concentration by inhibiting phosphorylation, a mechanism initiating the decay process.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	67-72
11593425-6	2001	It was found that the mTOR kinase was activated in cells treated with taxol or with nocodazole although it was inhibited in cells pre-treated with rapamycin.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	22-26
11567647-5	2001	Exposure of chondrifying mesenchymal cells to rapamycin blocked activation of the protein kinase C alpha and p38 MAP kinase, but had no discernible effect on ERK-1 signaling.	Sirolimus	46-55	protein kinase C alpha	Homo sapiens	82-104
11567647-5	2001	Exposure of chondrifying mesenchymal cells to rapamycin blocked activation of the protein kinase C alpha and p38 MAP kinase, but had no discernible effect on ERK-1 signaling.	Sirolimus	46-55	mitogen-activated protein kinase 14	Homo sapiens	109-123
11567647-7	2001	Taken together, our data indicate that the immunosuppressant rapamycin inhibits the chondrogenesis of mesenchymal cells at the post-precartilage condensation stage by modulating signaling pathways including those of PKCalpha and p38 MAP kinase.	Sirolimus	61-70	protein kinase C alpha	Homo sapiens	216-224
11567647-7	2001	Taken together, our data indicate that the immunosuppressant rapamycin inhibits the chondrogenesis of mesenchymal cells at the post-precartilage condensation stage by modulating signaling pathways including those of PKCalpha and p38 MAP kinase.	Sirolimus	61-70	mitogen-activated protein kinase 14	Homo sapiens	229-243
11384247-0	2001	Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations.	Sirolimus	14-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-76
11500364-2	2001	Insulin induces dephosphorylation of eEF2 and inactivation of eEF2 kinase, and these effects are blocked by rapamycin, which inhibits the mammalian target of rapamycin, mTOR.	Sirolimus	108-117	insulin	Homo sapiens	0-7
11500364-2	2001	Insulin induces dephosphorylation of eEF2 and inactivation of eEF2 kinase, and these effects are blocked by rapamycin, which inhibits the mammalian target of rapamycin, mTOR.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	138-167
11500364-2	2001	Insulin induces dephosphorylation of eEF2 and inactivation of eEF2 kinase, and these effects are blocked by rapamycin, which inhibits the mammalian target of rapamycin, mTOR.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	169-173
11500364-7	2001	In response to insulin-like growth factor 1, which activates p70 S6 kinase but not Erk, regulation of eEF2 is blocked by rapamycin.	Sirolimus	121-130	insulin like growth factor 1	Homo sapiens	15-43
11418477-0	2001	Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages.	Sirolimus	0-9	CD34 molecule	Homo sapiens	45-49
11402043-4	2001	Similarly, TNF significantly up-regulated PAI-1 synthesis when p70(S6K) phosphorylation was inhibited by rapamycin.	Sirolimus	105-114	tumor necrosis factor	Homo sapiens	11-14
11493700-4	2001	Rapamycin inhibited mitochondrial-based p70S6K, which prevented phosphorylation of Ser-136 on BAD and blocked cell survival induced by insulin-like growth factor 1 (IGF-1).	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	135-163
11493700-4	2001	Rapamycin inhibited mitochondrial-based p70S6K, which prevented phosphorylation of Ser-136 on BAD and blocked cell survival induced by insulin-like growth factor 1 (IGF-1).	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	165-170
11356843-5	2001	gln3 Delta and ure2 Delta mutants are partially resistant and hypersensitive to growth inhibition by rapamycin, respectively.	Sirolimus	101-110	glutathione peroxidase	Saccharomyces cerevisiae S288C	15-19
11406149-5	2001	The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD.	Sirolimus	157-166	CD8a molecule	Rattus norvegicus	18-26
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	59-88
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	90-94
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	insulin	Homo sapiens	123-130
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	AKT serine/threonine kinase 1	Homo sapiens	153-156
11438661-3	2001	After prolonged insulin stimulation, inhibition of the redistribution of IRS-1 by rapamycin resulted in increased levels of IRS-1 and the associated phosphatidylinositol (PI) 3-kinase in both the LDM and cytosol, whereas the proteasome inhibitor lactacystin increased the levels only in the cytosol.	Sirolimus	82-91	insulin	Homo sapiens	16-23
11438661-4	2001	Since rapamycin but not lactacystin enhances insulin-stimulated 2-deoxyglucose (2-DOG) uptake, IRS-1-associated PI 3-kinase localized at the LDM was suggested to be important in the regulation of glucose transport.	Sirolimus	6-15	insulin	Homo sapiens	45-52
11390463-9	2001	However, it blocks IL-2-dependent proliferation and cytokine production of T cells, in this respect resembling rapamycin.	Sirolimus	111-120	interleukin 2	Homo sapiens	19-23
11384247-1	2001	A combination of quantum chemical calculations and molecular simulations (DOCKing and molecular dynamics) is used to investigate the metabolism of sirolimus (rapamycin) and its derivative everolimus (SDZ-RAD) by cytochrome P450 3A4.	Sirolimus	147-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	212-231
11384247-1	2001	A combination of quantum chemical calculations and molecular simulations (DOCKing and molecular dynamics) is used to investigate the metabolism of sirolimus (rapamycin) and its derivative everolimus (SDZ-RAD) by cytochrome P450 3A4.	Sirolimus	158-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	212-231
11459127-13	2001	These results suggest that NO and peptide neurotransmitter(s) including VIP mediate the NANC relaxation in porcine RPM.	Sirolimus	115-118	vasoactive intestinal peptide	Homo sapiens	72-75
11352836-8	2001	Treatment with rapamycin, an inhibitor of the p70S6 kinase activator mTOR, also resulted in growth inhibition, further suggesting the importance of the PI3K signaling pathway in AVP-induced proliferation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	69-73
11309295-0	2001	p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.	Sirolimus	37-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	4-7
11341787-4	2001	METHODS: Quiescent BxPC3 and Panc-1 human pancreatic cancer cells treated with or without 20 ng/mL rapamycin (FRAP inhibitor) were repleted with 10% FCS to induce cell cycle entry.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	110-114
11343241-9	2001	Acetaldehyde-elicited fibronectin and alpha2(I) collagen upregulation was inhibited by calphostin C. However, while PD98059, wortmannin and rapamycin (a pp70(S6K) inhibitor) completely abrogated alpha2(I) collagen upregulation, they had no effect on fibronectin expression.	Sirolimus	140-149	collagen type I alpha 2 chain	Homo sapiens	38-56
11309295-0	2001	p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.	Sirolimus	37-46	tumor protein p53	Homo sapiens	0-3
11319875-6	2001	Rapamycin or PD98059 was used to inhibit pp70(S6k) or ERK1/2 activation, respectively.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	54-60
11309295-0	2001	p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.	Sirolimus	37-46	cyclin dependent kinase inhibitor 1A	Homo sapiens	8-12
11309295-6	2001	Infection of Rh30 cells with either Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p21(CIP1), and complete protection of cells from rapamycin-induced apoptosis.	Sirolimus	184-193	tumor protein p53	Homo sapiens	39-42
11309295-6	2001	Infection of Rh30 cells with either Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p21(CIP1), and complete protection of cells from rapamycin-induced apoptosis.	Sirolimus	184-193	cyclin dependent kinase inhibitor 1A	Homo sapiens	49-52
11309295-13	2001	In contrast, rapamycin significantly induced apoptosis in cells deficient in p53 ( approximately 2.4-fold) or p21(CIP1) ( approximately 5.5-fold).	Sirolimus	13-22	tumor protein p53	Homo sapiens	77-80
11309295-13	2001	In contrast, rapamycin significantly induced apoptosis in cells deficient in p53 ( approximately 2.4-fold) or p21(CIP1) ( approximately 5.5-fold).	Sirolimus	13-22	cyclin dependent kinase inhibitor 1A	Homo sapiens	110-113
11309295-13	2001	In contrast, rapamycin significantly induced apoptosis in cells deficient in p53 ( approximately 2.4-fold) or p21(CIP1) ( approximately 5.5-fold).	Sirolimus	13-22	cyclin dependent kinase inhibitor 1A	Homo sapiens	114-118
11309295-20	2001	Taken together, the data suggest that p53 cooperates in enforcing G(1) cell cycle arrest, leading to a cytostatic response to rapamycin.	Sirolimus	126-135	tumor protein p53	Homo sapiens	38-41
11241670-7	2001	Rapamycin, an inhibitor of p70 S6 protein kinase and a downstream target of ERK1/2 and PI 3-K, did not affect the activation of ERK1 and ERK2 by the growth factors.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	76-82
11287630-8	2001	mTOR induced the serine phosphorylation of IRS-1 (Ser-636/639), and such phosphorylation was inhibited by rapamycin.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	0-4
11241670-7	2001	Rapamycin, an inhibitor of p70 S6 protein kinase and a downstream target of ERK1/2 and PI 3-K, did not affect the activation of ERK1 and ERK2 by the growth factors.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	76-80
11222720-4	2001	Experiments undertaken to determine the function of RPMS revealed that RPMS interacts with both CBF1 and components of the CBF1-associated corepressor complex.	Sirolimus	52-56	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	96-100
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	10-19	interleukin 2	Homo sapiens	92-96
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	215-224	interleukin 2	Homo sapiens	92-96
11222720-4	2001	Experiments undertaken to determine the function of RPMS revealed that RPMS interacts with both CBF1 and components of the CBF1-associated corepressor complex.	Sirolimus	52-56	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	123-127
11231341-7	2001	Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt.	Sirolimus	0-9	insulin	Homo sapiens	58-65
11231341-7	2001	Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	93-122
11222720-4	2001	Experiments undertaken to determine the function of RPMS revealed that RPMS interacts with both CBF1 and components of the CBF1-associated corepressor complex.	Sirolimus	71-75	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	96-100
11231341-7	2001	Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	124-128
11231341-7	2001	Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	154-157
11222720-4	2001	Experiments undertaken to determine the function of RPMS revealed that RPMS interacts with both CBF1 and components of the CBF1-associated corepressor complex.	Sirolimus	71-75	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	123-127
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	0-4	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	22-26
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	0-4	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	175-179
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	118-122	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	22-26
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	118-122	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	175-179
11222720-9	2001	RPMS has been shown to interfere with NotchIC and EBNA2 activation of CBF1-containing promoters in reporter assays.	Sirolimus	0-4	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	70-74
11222720-13	2001	The results revealed that RPMS blocked relief of CBF1-mediated repression and interfered with SKIP-CIR interactions.	Sirolimus	26-30	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	49-53
11222720-14	2001	We conclude that RPMS acts as a negative regulator of EBNA2 and Notch activity through its interactions with the CBF1-associated corepressor complex.	Sirolimus	17-21	recombination signal binding protein for immunoglobulin kappa J region	Homo sapiens	113-117
11245436-6	2001	Phosphatidylinositol 3-kinase, mitogen-activated protein kinase kinase, and p70 kinase were inhibited with LY294002, PD98059, and rapamycin, respectively.	Sirolimus	130-139	ubiquitin associated and SH3 domain containing B	Homo sapiens	76-79
11013237-3	2001	Insulin further stimulates glycogen synthesis in the presence of lithium ions, an effect abolished by wortmannin and rapamycin.	Sirolimus	117-126	insulin	Homo sapiens	0-7
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	insulin	Homo sapiens	178-185
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	insulin	Homo sapiens	229-236
11147790-4	2001	Wortmannin and rapamycin blocked this mobility shift of IRS-1, maintained the insulin-induced tyrosine phosphorylation of IRS-1, and blocked its degradation.	Sirolimus	15-24	insulin	Homo sapiens	78-85
11400101-3	2001	Rapamycin, an mTOR signaling inhibitor, immunosuppressant, and G1-phase arresting agent, was identified and tested for efficacy in restraining cell cycle progression in CRL 1606 hybridoma cultures.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
11180036-1	2001	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects.	Sirolimus	60-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
11121811-5	2001	Platelet-induced secretion of MCP-1 and monocyte-endothelium adhesion was reduced by the MAP kinase p38-specific inhibitor SB203580, but not by other kinase inhibitors including PD98059, wortmannin, or rapamycin.	Sirolimus	202-211	mitogen-activated protein kinase 14	Homo sapiens	100-103
11255225-4	2001	Rapamycin, an inhibitor of p70 S6 kinase, suppressed the BMP-4-stimulated VEGF synthesis as well as the phosphorylation of p70 S6 kinase.	Sirolimus	0-9	bone morphogenetic protein 4	Mus musculus	57-62
10981855-4	2000	Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR), which is an upstream signaling of p70S6K, completely inhibited FCS-induced cell size increases and protein synthesis, but had no effect on SKA mRNA expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	39-68
11103940-11	2000	Similarly, rapamycin, known to inhibit p70S6 kinase, a downstream component of the PI3K-Akt pathway, also inhibited gag-IR/IGFR-induced, but not v-Src-induced, focus and colony formation.	Sirolimus	11-20	AKT serine/threonine kinase 1	Rattus norvegicus	88-91
11054111-9	2000	Consistent with this observation, pretreatment of resting cells with rapamycin suppresses the activation of TOP mRNA translation induced by act D. These results indicate that the effect of act D on translation is mediated by the S6Ks through FRAP/mTOR.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	242-246
11054111-9	2000	Consistent with this observation, pretreatment of resting cells with rapamycin suppresses the activation of TOP mRNA translation induced by act D. These results indicate that the effect of act D on translation is mediated by the S6Ks through FRAP/mTOR.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	247-251
10971657-5	2000	These deletions also abolished the ability of a rapamycin-resistant mTOR mutant to rescue the activity of p70 alpha from inhibition induced by rapamycin in vivo.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	68-72
11062058-8	2000	Preincubation of cardiomyocytes with 20 microM rapamycin which dissociates FKBP12.6 from the RyR, evoked Ca(2+) oscillations, probably due to the leakiness of the RyR.	Sirolimus	47-56	FKBP prolyl isomerase 1B	Rattus norvegicus	75-83
11052963-7	2000	The results reveal that treating 18-h fasted pigs with rapamycin, a specific inhibitor of mTOR, before feeding prevented the activation of S6K1 and the changes in eIF4F complex formation observed in skeletal muscle and liver after feeding.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Sus scrofa	90-94
11027279-7	2000	Although rapamycin treatment elicited the rapid dephosphorylation of Npr1 and induction of Gap1 expression, hydrostatic pressure did not affect the phosphorylation state of Npr1 and it decreased the level of Gap1 protein, suggesting that the pressure-sensing pathway may be independent of Npr1 function.	Sirolimus	9-18	amino acid permease GAP1	Saccharomyces cerevisiae S288C	91-95
11023817-5	2000	Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-57
11042022-3	2000	Insulin rescued serum-deprived immortalized brown adipocytes from apoptosis through phosphatidylinositol (PI) 3-kinase and Akt pathways, but independently of p70S6-kinase, as demonstrated by the use of inhibitors such as LY294002 or Rapamycin, and transfection experiments with dominant-negative constructs of Akt or p85 subunit of PI 3-kinase.	Sirolimus	233-242	insulin	Homo sapiens	0-7
10981855-4	2000	Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR), which is an upstream signaling of p70S6K, completely inhibited FCS-induced cell size increases and protein synthesis, but had no effect on SKA mRNA expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	70-74
10775131-5	2000	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked flow-induced pp70(S6k) activation; FK-506, a rapamycin analog with minimal mTOR inhibitory activity, and PD-98059, an inhibitor of the flow-sensitive mitogen-activated protein kinase pathway, had no effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-60
10849422-6	2000	SCF induced cyclin D3 expression and phosphorylation of the retinoblastoma protein through a pathway that is sensitive to both wortmannin and rapamycin.	Sirolimus	142-151	cyclin D3	Homo sapiens	12-21
10849422-9	2000	Constitutively active v-AKT highly phosphorylated p70S6K, which was totally inhibited by rapamycin.	Sirolimus	89-98	AKT serine/threonine kinase 1	Homo sapiens	24-27
10910062-8	2000	Furthermore, the activation status of the PI3K-AKT pathway in cancer cells may be an important determinant of cellular sensitivity to the cytostatic effect of rapamycin.	Sirolimus	159-168	AKT serine/threonine kinase 1	Homo sapiens	47-50
10781282-3	2000	The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine.	Sirolimus	51-60	ryanodine receptor 1	Homo sapiens	120-140
10781282-3	2000	The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine.	Sirolimus	51-60	ryanodine receptor 1	Homo sapiens	187-207
10985305-10	2000	IL-2 production remained sensitive to inhibition with the PI3K competitive inhibitor Ly294002, and to the fungal macrolide, rapamycin.	Sirolimus	124-133	interleukin 2	Homo sapiens	0-4
10775131-5	2000	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked flow-induced pp70(S6k) activation; FK-506, a rapamycin analog with minimal mTOR inhibitory activity, and PD-98059, an inhibitor of the flow-sensitive mitogen-activated protein kinase pathway, had no effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	62-66
10775131-5	2000	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), and wortmannin, a phosphatidylinositol 3-kinase inhibitor, blocked flow-induced pp70(S6k) activation; FK-506, a rapamycin analog with minimal mTOR inhibitory activity, and PD-98059, an inhibitor of the flow-sensitive mitogen-activated protein kinase pathway, had no effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	211-215
10775131-6	2000	Synthesis of Bcl-3, a protein whose translation is controlled by an mTOR-dependent pathway, was induced by flow and inhibited by rapamycin and wortmannin.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	68-72
10753934-2	2000	All these effects were blocked by rapamycin, a specific inhibitor of mTOR.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	69-73
10771484-3	2000	Here we show that late tumor necrosis factor alpha gene expression is sensitive to rapamycin, implicating FKBP12-rapamycin-associated protein, a member of the DNA protein kinase family, as a signal transducer of ultraviolet-induced DNA damage.	Sirolimus	83-92	tumor necrosis factor	Mus musculus	23-50
10749688-13	2000	PDE4A4 was also selectively activated by challenge of U937 cells with either bacterial lipopolysaccharide (LPS) or IFN-gamma through a process which was attenuated by both wortmannin and rapamycin.	Sirolimus	187-196	interferon gamma	Homo sapiens	115-124
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	tumor protein p53	Homo sapiens	76-79
10749698-6	2000	Insulin caused phosphorylation of 4E-BP1 and induced its dissociation from eIF4E, and these effects were also blocked by rapamycin.	Sirolimus	121-130	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	34-40
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	100-103
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	tumor protein p53	Homo sapiens	212-215
10749698-10	2000	The phosphorylation of eEF2 itself was also decreased by insulin, and this effect and the inactivation of eEF2 kinase were attenuated by rapamycin.	Sirolimus	137-146	eukaryotic translation elongation factor 2	Rattus norvegicus	23-27
10749698-10	2000	The phosphorylation of eEF2 itself was also decreased by insulin, and this effect and the inactivation of eEF2 kinase were attenuated by rapamycin.	Sirolimus	137-146	eukaryotic translation elongation factor 2	Rattus norvegicus	106-110
10713512-0	2000	Structure of FKBP12.6 in complex with rapamycin.	Sirolimus	38-47	FKBP prolyl isomerase 1B	Homo sapiens	13-21
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	84-118
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	143-148
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	189-192
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	193-197
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	207-212
10711524-3	2000	It appears to block cell-cycle progression in the mid-to-late G1 phase; it also inhibits interleukin-2-dependent and independent proliferation of B-lymphocytes and production of immunoglobulins A, M, and G. Sirolimus is extensively metabolized by the liver and undergoes O-demethylation and hydroxylation.	Sirolimus	207-216	interleukin 2	Homo sapiens	89-102
10660603-5	2000	The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	4-8
10732978-7	2000	The approach described here has yielded modified rapamycin analogues (RP2 and RP3) as targets for biosynthesis by modified polyketide synthases.	Sirolimus	49-58	RP2 activator of ARL3 GTPase	Homo sapiens	70-73
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Sirolimus	52-61	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Sirolimus	52-61	tumor necrosis factor	Homo sapiens	118-126
10660603-5	2000	The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts.	Sirolimus	26-35	ubiquitin associated and SH3 domain containing B	Homo sapiens	131-134
10660603-5	2000	The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts.	Sirolimus	26-35	matrix metallopeptidase 3	Homo sapiens	188-193
10716639-4	2000	Rapamycin kills normal cells more readily in normal than in A-T cells, and inhibits the FRAP target p70 S6 kinase (p70S6K) more readily in normal than in A-T cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
10706056-2	2000	METHODS: Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow cytometry, after isolation from 14 renal transplant recipients receiving CSA+prednisone, and double-blind rapamycin (rapamycin:placebo=4:1).	Sirolimus	239-248	interleukin 2	Homo sapiens	23-42
10706056-2	2000	METHODS: Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow cytometry, after isolation from 14 renal transplant recipients receiving CSA+prednisone, and double-blind rapamycin (rapamycin:placebo=4:1).	Sirolimus	250-259	interleukin 2	Homo sapiens	23-42
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	insulin like growth factor 1	Homo sapiens	42-47
10660304-5	2000	We found that CNTF-induced phosphorylation of Ser727 was inhibited by the mTOR inhibitor rapamycin, but not by inhibitors of MAPK and protein kinase C (PKC) activation.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	74-78
10778917-8	2000	RESULTS: Cyclosporin (1-5 microg/ml) and rapamycin (1.0-10 nM) but not FK-506 (5-10 nM) inhibited both iNOS and COX-2 expression at mRNA level which led to significant inhibition of NO and PGE2 production.	Sirolimus	41-50	nitric oxide synthase 2, inducible	Mus musculus	103-107
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	insulin like growth factor 1	Homo sapiens	101-106
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	insulin like growth factor binding protein 5	Homo sapiens	117-124
10583395-9	1999	Gastrin-stimulated p70 S6 kinase activity and protein synthesis were blocked by rapamycin and wortmannin.	Sirolimus	80-89	gastrin	Mus musculus	0-7
10574945-7	1999	Phosphorylation at the Ser-662 site is independently controlled by a pathway involving mammalian TOR (mTOR) because the rapamycin-induced block of its phosphorylation is overcome by co-expression of a rapamycin-resistant mutant of mTOR.	Sirolimus	120-129	RAR related orphan receptor C	Homo sapiens	97-100
10611304-6	1999	Inhibiting Tor proteins with rapamycin increases the electrophoretic mobility of Ure2p.	Sirolimus	29-38	glutathione peroxidase	Saccharomyces cerevisiae S288C	81-86
10617575-4	1999	TOR inhibition by rapamycin induces expression of nitrogen source utilization genes controlled by the Ure2 repressor and the transcriptional regulator Gln3, and globally represses ribosomal protein expression.	Sirolimus	18-27	glutathione peroxidase	Saccharomyces cerevisiae S288C	102-106
10617575-6	1999	We find that Ure2 is a phosphoprotein in vivo that is rapidly dephosphorylated in response to rapamycin or nitrogen limitation.	Sirolimus	94-103	glutathione peroxidase	Saccharomyces cerevisiae S288C	13-17
10574945-7	1999	Phosphorylation at the Ser-662 site is independently controlled by a pathway involving mammalian TOR (mTOR) because the rapamycin-induced block of its phosphorylation is overcome by co-expression of a rapamycin-resistant mutant of mTOR.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	102-106
10574945-7	1999	Phosphorylation at the Ser-662 site is independently controlled by a pathway involving mammalian TOR (mTOR) because the rapamycin-induced block of its phosphorylation is overcome by co-expression of a rapamycin-resistant mutant of mTOR.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	231-235
10567366-8	1999	On the other hand, the insulin effect was totally abolished by LY294002 (10 microM) and rapamycin (50 nM).	Sirolimus	88-97	insulin	Homo sapiens	23-30
10564160-8	1999	NRG-1 also activated 70-kDa ribosomal S6 kinase, which was inhibited by either rapamycin or wortmannin.	Sirolimus	79-88	neuregulin 1	Rattus norvegicus	0-5
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	164-168
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	206-215	mechanistic target of rapamycin kinase	Homo sapiens	164-168
10551878-9	1999	Rapamycin abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA.	Sirolimus	0-9	insulin	Homo sapiens	24-31
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	217-221
10516933-4	1999	The objective of this review is to discuss the effects of P-gp modulation on the pharmacokinetics and the pharmacodynamics of immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids.	Sirolimus	185-194	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
10499523-10	1999	Furthermore, rapamycin, a selective inhibitor of mammalian target of rapamycin, completely blocked ET-1-stimulated [3H]leucine and [3H]thymidine uptake.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	49-78
10499523-10	1999	Furthermore, rapamycin, a selective inhibitor of mammalian target of rapamycin, completely blocked ET-1-stimulated [3H]leucine and [3H]thymidine uptake.	Sirolimus	13-22	endothelin 1	Homo sapiens	99-103
10516161-7	1999	Rapamycin inhibited 4E-BP phosphorylation in response to insulin but had no effect on eIF-4F complex formation.	Sirolimus	0-9	insulin	Homo sapiens	57-64
10509564-7	1999	However, the activation of JNK was maximal at concentrations of 100 nM of GST-Tat2E and was blocked by the S6-kinase inhibitor rapamycin, whereas the activation of ERK/MAPK was already maximal at 1 nM of GST-Tat2E and was enhanced by rapamycin.	Sirolimus	127-136	mitogen-activated protein kinase 8	Homo sapiens	27-30
10509564-7	1999	However, the activation of JNK was maximal at concentrations of 100 nM of GST-Tat2E and was blocked by the S6-kinase inhibitor rapamycin, whereas the activation of ERK/MAPK was already maximal at 1 nM of GST-Tat2E and was enhanced by rapamycin.	Sirolimus	234-243	mitogen-activated protein kinase 8	Homo sapiens	27-30
10464317-4	1999	Insulin-augmented (125)I-alpha(2)M* binding to macrophages was severely reduced by wortmannin, LY294002, PD98059, SB203580, or rapamycin.	Sirolimus	127-136	insulin	Homo sapiens	0-7
10490847-1	1999	Rapamycin is an immunosuppressant which antagonizes cellular proliferation by inhibiting the function of mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	105-109
10490847-5	1999	Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin.	Sirolimus	102-111	ribosomal protein S6 kinase B2	Homo sapiens	17-21
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B2	Homo sapiens	30-33
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B2	Homo sapiens	77-80
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B2	Homo sapiens	77-80
10454535-7	1999	Microinjection of highly specific inhibitors of PI3K or Rac1, or treatment with the p70s6k inhibitor rapamycin, impaired cAMP-stimulated DNA synthesis, demonstrating that PKA-dependent and -independent pathways contribute to cAMP-mediated mitogenesis.	Sirolimus	101-110	cathelicidin antimicrobial peptide	Homo sapiens	121-125
10454535-7	1999	Microinjection of highly specific inhibitors of PI3K or Rac1, or treatment with the p70s6k inhibitor rapamycin, impaired cAMP-stimulated DNA synthesis, demonstrating that PKA-dependent and -independent pathways contribute to cAMP-mediated mitogenesis.	Sirolimus	101-110	cathelicidin antimicrobial peptide	Homo sapiens	225-229
10362146-7	1999	Synthesis of Src protein was also inhibited in cells treated with rapamycin.	Sirolimus	66-75	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	13-16
10446394-7	1999	This was further supported by the observation that troglitazone was able to reduce PEPCK mRNA levels in the presence of the insulin signaling pathway inhibitors wortmannin, rapamycin, and PD98059.	Sirolimus	173-182	insulin	Homo sapiens	124-131
10446965-2	1999	Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	47-51
10358075-5	1999	The IGF-1-induced phosphorylation was abolished by the PtdIns 3-kinase inhibitor wortmannin but not by PD 98059 (an inhibitor of the mitogen-activated protein kinase cascade) or by rapamycin.	Sirolimus	181-190	insulin like growth factor 1	Homo sapiens	4-9
10373522-6	1999	Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses.	Sirolimus	16-25	ubiquitin associated and SH3 domain containing B	Homo sapiens	46-49
10424436-4	1999	Rapamycin suppressed the anti-CD40-induced proliferation of splenic B cells, suppressed differentiation to surface IgMhigh/IgDlow B cells, and inhibited an anti-CD40-mediated prevention of apoptosis induced by BCR cross-linkage of WEHI-231 cells.	Sirolimus	0-9	BCR activator of RhoGEF and GTPase	Mus musculus	210-213
10330171-4	1999	Phosphorylation of the 4E-BPs is effected by the phosphatidylinositol (PI) 3-kinase signal transduction pathway and is inhibited by rapamycin through its binding to FRAP/mTOR (FK506 binding protein-rapamycin-associated protein or mammalian target of rapamycin).	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	170-174
10361256-2	1999	The mechanism of this inhibition is investigated using FK506, which competes with rapamycin for binding to their common target FK506-binding protein (FKBP)12.	Sirolimus	82-91	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	150-157
10359590-6	1999	Similarly, inhibition of the PI3K-mTOR pathway by addition of the PI3K inhibitor 2-[4-morpholinyl]-8-phenyl-4H-1-benzopyran-4-one (LY294002) or the mTOR inhibitor rapamycin, although reducing several parameters of transformation, also failed to block transformation.	Sirolimus	163-172	mechanistic target of rapamycin kinase	Homo sapiens	34-38
10212283-5	1999	Rapamycin, a potent inhibitor of p70(S6k), also failed to prevent PGF2alpha-induced global protein synthesis and bFGF-2 expression, although it partially decreased ERK2 activity.	Sirolimus	0-9	ubiquitin associated and SH3 domain containing B	Homo sapiens	33-36
10339425-0	1999	Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex.	Sirolimus	0-9	protein kinase C alpha	Homo sapiens	39-42
10339425-0	1999	Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex.	Sirolimus	0-9	protein kinase C alpha	Homo sapiens	85-88
10318894-2	1999	We describe a dominant clonal-selection assay of stably transfected cells expressing partner proteins FKBP (FK506 binding protein) and FRAP (FKBP-rapamycin binding protein) fused to DHFR fragments and show a rapamycin dose-dependent survival of clones that requires approximately 25 molecules of reconstituted DHFR per cell.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	135-139
10227994-6	1999	Inhibition of IL-2 production by cyclosporin A, or inhibition of IL-2 signaling by rapamycin or anti-IL-2 neutralizing Abs prevents the decrease in FLIP levels and confers resistance to Fas-mediated apoptosis following T cell activation.	Sirolimus	83-92	interleukin 2	Homo sapiens	65-69
10227994-6	1999	Inhibition of IL-2 production by cyclosporin A, or inhibition of IL-2 signaling by rapamycin or anti-IL-2 neutralizing Abs prevents the decrease in FLIP levels and confers resistance to Fas-mediated apoptosis following T cell activation.	Sirolimus	83-92	interleukin 2	Homo sapiens	65-69
10206976-9	1999	Rapamycin, an inhibitor of the protein kinase mTOR, prevented all of the leucine-induced effects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
10200280-2	1999	Depriving cells of amino acids or treating them with the small molecule rapamycin inhibits FRAP and results in rapid dephosphorylation and inactivation of the translational regulators 4E-BP1(eukaryotic initiation factor 4E-binding protein 1) and p70(s6k) (the 70-kDa S6 kinase).	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	91-95
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	0-4
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	111-115
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	111-115
10092613-7	1999	Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	53-56
10217658-14	1999	CONCLUSIONS: Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27(kip1) and inhibition of the pRb phosphorylation within the vessel wall.	Sirolimus	13-22	zinc ribbon domain containing 2	Homo sapiens	154-157
10092613-7	1999	Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	106-135
10092613-7	1999	Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	137-141
10092613-7	1999	Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt.	Sirolimus	75-84	AKT serine/threonine kinase 1	Homo sapiens	177-180
9891068-9	1999	Unlike mitogen stimulation, the p110 induction of cyclin D1 was sensitive to rapamycin.	Sirolimus	77-86	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Mus musculus	32-36
10100627-1	1999	The signalling pathways by which insulin triggers protein synthesis were studied using an antisense strategy to deplete ERK1/ERK2 and rapamycin to inhibit the p70S6K pathway.	Sirolimus	134-143	insulin	Homo sapiens	33-40
10029080-0	1999	Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-53
10029080-0	1999	Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.	Sirolimus	0-9	tumor protein p53	Homo sapiens	66-69
10029080-3	1999	Here, we report that rapamycin, a specific inhibitor of mTOR kinase, induces G1 cell cycle arrest and apoptosis in two rhabdomyosarcoma cell lines (Rh1 and Rh30) under conditions of autocrine cell growth.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	56-60
10029080-9	1999	Rh1 and Rh30 mTOR-rr clones were highly resistant (>3000-fold) to both growth inhibition and apoptosis induced by rapamycin.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	13-17
10029080-12	1999	However, in rapamycin-treated cultures, the response to IGF-I differed between the cell lines: Rh1 cells proliferated normally, whereas Rh30 cells remained arrested in G1 phase but viable.	Sirolimus	12-21	insulin like growth factor 1	Homo sapiens	56-61
10029080-14	1999	To examine the rate at which the mTOR pathway recovered, the ability of IGF-I to stimulate p70S6K activity was followed in cells treated for 1 h with rapamycin and then allowed to recover in medium containing > or =100-fold excess of FK506 (to prevent rapamycin from rebinding to its cytosolic receptor FKBP-12).	Sirolimus	150-159	insulin like growth factor 1	Homo sapiens	72-77
10082514-10	1999	Translation assays in vivo using both DNA and RNA reporter constructs with the 5"-TOP from elongation factor 2 showed decreased translational activity with rapamycin, whereas constructs without a 5"-TOP or with an internal ribosome entry site were translated more efficiently upon rapamycin treatment.	Sirolimus	156-165	eukaryotic translation elongation factor 2, gene 1 S homeolog	Xenopus laevis	91-110
10072524-4	1999	Similar to conventional anergy (induction by signal 1 alone), the rapamycin-induced anergic cells show a decrease in mitogen-activated protein kinase activation, and these cells can be rescued by culture in IL-2.	Sirolimus	66-75	interleukin 2	Homo sapiens	207-211
9933636-2	1999	Consistent with these findings, SB 203580 (a specific inhibitor of SAPK2/p38) or rapamycin (which blocks the activation of p70 S6 kinase) prevented the formation of multinucleated myotubes, as well as the expression of muscle-specific proteins that included SAPK3 (another MAPK family member).	Sirolimus	81-90	mitogen-activated protein kinase 12	Mus musculus	258-263
9933636-2	1999	Consistent with these findings, SB 203580 (a specific inhibitor of SAPK2/p38) or rapamycin (which blocks the activation of p70 S6 kinase) prevented the formation of multinucleated myotubes, as well as the expression of muscle-specific proteins that included SAPK3 (another MAPK family member).	Sirolimus	81-90	mitogen-activated protein kinase 1	Mus musculus	273-277
9873015-5	1999	A partial decrease in the fold activation of GS was, however, observed when p70(S6k) activation was blocked with rapamycin, suggesting a contribution of this pathway to the control of GS by either hormone.	Sirolimus	113-122	ubiquitin associated and SH3 domain containing B	Homo sapiens	76-79
10048588-5	1999	Selective inhibition of ERK, PI 3-kinase, and p70 S6 kinase with the inhibitors PD098059, LY294002, and rapamycin, respectively, inhibited VEGF-stimulated HUVEC proliferation.	Sirolimus	104-113	mitogen-activated protein kinase 1	Homo sapiens	24-27
10048588-5	1999	Selective inhibition of ERK, PI 3-kinase, and p70 S6 kinase with the inhibitors PD098059, LY294002, and rapamycin, respectively, inhibited VEGF-stimulated HUVEC proliferation.	Sirolimus	104-113	vascular endothelial growth factor A	Homo sapiens	139-143
9878560-4	1998	Similar to p70(S6K), p70(S6Kbeta) was activated by serum stimulation, and the serum-induced activation was inhibited by wortmannin and rapamycin.	Sirolimus	135-144	ribosomal protein S6 kinase B2	Homo sapiens	21-32
9852118-1	1998	Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	263-292
9852118-1	1998	Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	294-298
9852118-1	1998	Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	122-131	insulin	Homo sapiens	161-168
9865315-0	1998	In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin.	Sirolimus	127-136	tumor protein p53	Homo sapiens	72-75
9837907-12	1998	Rapamycin also blocked the effect of IL-4-induced regulation, thus suggesting the role of p70 S6 kinase.	Sirolimus	0-9	interleukin 4	Homo sapiens	37-41
9822578-4	1998	RESULTS: We isolated two Saccharomyces cerevisiae genes, BMH1 and BMH2, as multicopy suppressors of the growth-inhibitory phenotype caused by rapamycin in budding yeast.	Sirolimus	142-151	14-3-3 family protein BMH1	Saccharomyces cerevisiae S288C	57-61
9806882-1	1998	The effects of insulin and rapamycin on the phosphorylation of the translation regulator, initiation factor 4E-binding protein 1 (4E-BP1) have been studied in rat fat cells by following changes in the incorporation of 32P from [32P]Pi under steady-state conditions.	Sirolimus	27-36	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	108-128
9806882-1	1998	The effects of insulin and rapamycin on the phosphorylation of the translation regulator, initiation factor 4E-binding protein 1 (4E-BP1) have been studied in rat fat cells by following changes in the incorporation of 32P from [32P]Pi under steady-state conditions.	Sirolimus	27-36	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	130-136
9806882-7	1998	However, the present study also provides evidence that insulin increases the phosphorylation of 4E-BP1 bound to eIF4E on a further site (Ser-111) and that this is by a rapamycin-insensitive mechanism.	Sirolimus	168-177	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	96-102
9864662-9	1998	Sirolimus, the latest pharmaceutical agent to complete phase III trials, acts to inhibit IL-2 driven lymphocyte proliferation and reduces the risk of acute rejection to below 20%.	Sirolimus	0-9	interleukin 2	Homo sapiens	89-93
9792703-7	1998	PI 3-kinase inhibitors such as wortmannin and LY294002, and rapamycin, an inhibitor of FRAP/TOR, cause a decline in the level of D-cyclins, whereas inhibitors of mitogen-activated protein kinase kinase and farnesyltransferase do not.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	87-91
9792703-7	1998	PI 3-kinase inhibitors such as wortmannin and LY294002, and rapamycin, an inhibitor of FRAP/TOR, cause a decline in the level of D-cyclins, whereas inhibitors of mitogen-activated protein kinase kinase and farnesyltransferase do not.	Sirolimus	60-69	RAR related orphan receptor C	Homo sapiens	92-95
9804755-7	1998	The p70beta kinase was found to be significantly less sensitive to wortmannin and rapamycin than p70alpha.	Sirolimus	82-91	ribosomal protein S6 kinase B2	Homo sapiens	4-11
9755080-10	1998	We have previously shown that GLUT-1 protein synthesis in these cells is stimulated by insulin via the mTOR-p70 S6 kinase pathway, based on its sensitivity to rapamycin.	Sirolimus	159-168	insulin	Homo sapiens	87-94
9774438-9	1998	In exploring the signaling pathway responsible for these effects, we find that rapamycin (25 nM) inhibits the ability of branched-chain amino acids to stimulate the phosphorylation of PHAS-I and p70(s6) kinase, suggesting that the mammalian target of rapamycin signaling pathway is involved.	Sirolimus	79-88	ubiquitin associated and SH3 domain containing B	Homo sapiens	195-209
9755080-10	1998	We have previously shown that GLUT-1 protein synthesis in these cells is stimulated by insulin via the mTOR-p70 S6 kinase pathway, based on its sensitivity to rapamycin.	Sirolimus	159-168	ubiquitin associated and SH3 domain containing B	Homo sapiens	108-111
9621041-1	1998	Inhibitors of the phosphatidylinositol 3-kinase (PI3 kinase)-FKBP-rapamycin-associated protein (FRAP) pathway, such as rapamycin and wortmannin, induce dephosphorylation and activation of the suppressor of cap-dependent translation, 4E-BP1.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	96-100
9705862-4	1998	Rapamycin caused a significant increase in alkaline phosphatase (ALP) activity and in the expression of osteopontin and osteocalcin mRNAs.	Sirolimus	0-9	bone gamma-carboxyglutamate protein	Rattus norvegicus	120-131
9879060-2	1998	To study postreceptor signaling events leading to insulin-stimulated glycogen synthesis in these cells, we have employed pathway-specific chemical inhibitors such as LY294002, rapamycin and PD98059 to inhibit phosphatidylinositol-3-kinase (PI3K), p70 ribosomal S6 kinase and mitogen-activated protein kinase (MAPK) kinase/MAPK, respectively.	Sirolimus	176-185	insulin	Homo sapiens	50-57
9722592-9	1998	Phosphorylation of p70 S6 kinase and 4E-BP1 is also repressed by PI3K inhibitors as well as by rapamycin, the selective inhibitor of FRAP/mTOR.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	133-137
9722592-9	1998	Phosphorylation of p70 S6 kinase and 4E-BP1 is also repressed by PI3K inhibitors as well as by rapamycin, the selective inhibitor of FRAP/mTOR.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	138-142
9742506-1	1998	BACKGROUND: The 12 kD FK506 binding protein FKBP12 is a cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	117-126	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	44-50
9603962-7	1998	The selective inhibition of p70 and eIF-4E BP1 phosphorylation by amino acid withdrawal resembles the response to rapamycin, which prevents p70 reactivation by amino acids, indicating that mTOR is required for the response to amino acids.	Sirolimus	114-123	eukaryotic translation initiation factor 4E-binding protein 1	Cricetulus griseus	36-46
9632736-7	1998	Upon addition of rapamycin or wortmannin to insulin-treated cells, the decrease in activity of p70 was closely correlated with the disappearance of anti-Thr-412(P) immunoreactivity and the most slowly migrating p70 polypeptides, whereas considerable phosphorylation at Ser-434 and Thr-252 persisted after the disappearance of 40 S kinase activity.	Sirolimus	17-26	insulin	Homo sapiens	44-51
9632736-7	1998	Upon addition of rapamycin or wortmannin to insulin-treated cells, the decrease in activity of p70 was closely correlated with the disappearance of anti-Thr-412(P) immunoreactivity and the most slowly migrating p70 polypeptides, whereas considerable phosphorylation at Ser-434 and Thr-252 persisted after the disappearance of 40 S kinase activity.	Sirolimus	17-26	ubiquitin associated and SH3 domain containing B	Homo sapiens	95-98
9632736-7	1998	Upon addition of rapamycin or wortmannin to insulin-treated cells, the decrease in activity of p70 was closely correlated with the disappearance of anti-Thr-412(P) immunoreactivity and the most slowly migrating p70 polypeptides, whereas considerable phosphorylation at Ser-434 and Thr-252 persisted after the disappearance of 40 S kinase activity.	Sirolimus	17-26	ubiquitin associated and SH3 domain containing B	Homo sapiens	211-214
9636226-4	1998	Insulin also increased by severalfold the 32P content of mTOR that was determined after purifying the protein from 32P-labeled adipocytes with rapamycin.FKBP12 agarose beads.	Sirolimus	143-152	insulin	Homo sapiens	0-7
9636226-4	1998	Insulin also increased by severalfold the 32P content of mTOR that was determined after purifying the protein from 32P-labeled adipocytes with rapamycin.FKBP12 agarose beads.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	57-61
9591746-4	1998	Preincubation of isolated rat adipose cells with wortmannin completely abrogated the stimulation of LPL activity by insulin, while preincubation with rapamycin caused approximately a 60% inhibition of insulin-stimulated LPL activity.	Sirolimus	150-159	lipoprotein lipase	Rattus norvegicus	220-223
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Sirolimus	138-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	5-10
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Sirolimus	138-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Sirolimus	138-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Sirolimus	217-226	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	5-10
9618413-5	1998	Of 32 drugs tested, only known CYP3A substrates inhibited sirolimus intestinal metabolism with inhibitor constants (Ki) equal to those in human liver microsomes.	Sirolimus	58-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-36
9618413-8	1998	Intestinal drug metabolism and countertransport into the gut lumen, drug interactions with CYP3A substrates and inhibitors in the small intestine and an 8-fold interindividual variability of the intestinal metabolite formation rate significantly contribute to the low and highly variable bioavailability of sirolimus.	Sirolimus	307-316	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
9465841-1	1998	INTRODUCTION: Sirolimus and cyclosporine (INN, ciclosporin) share the same cytochrome P4503A metabolic pathways, and both drugs are substrates for p-glycoprotein countertransport.	Sirolimus	14-23	ATP binding cassette subfamily B member 1	Homo sapiens	147-161
9472019-4	1998	PI 3-kinase elicits the phosphorylation of 4E-BP1 in a wortmannin- and rapamycin-sensitive manner, whereas activated Akt-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive.	Sirolimus	184-193	AKT serine/threonine kinase 1	Homo sapiens	117-120
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Sirolimus	5-14	insulin	Homo sapiens	53-60
9531494-4	1998	CPPD crystals induced a robust, transient activation (peak activity at 2 min) of p70(S6K) that was fully inhibited by pretreatment with rapamycin.	Sirolimus	136-145	ubiquitin associated and SH3 domain containing B	Homo sapiens	81-84
9528925-8	1998	Rapamycin which indirectly prevents activation of the p70 ribosomal protein-S6 kinase (p70S6k), suppressed IGFBP-5 induction.	Sirolimus	0-9	insulin-like growth factor binding protein 5	Mus musculus	107-114
9685211-1	1998	Although the immunosuppressive drugs FK506, rapamycin and cyclosporin A have been reported to potentiate transcriptional activation mediated by a non-saturating concentration of the glucocorticoid receptor agonist dexamethasone, the precise mechanism(s) underlying these responses remains unclear.	Sirolimus	44-53	nuclear receptor subfamily 3 group C member 1	Homo sapiens	182-205
9497382-4	1998	Insulin lowers IGFBP-1 mRNA levels, inhibits IGFBP-1 promoter activity, and activates PKB/Akt in HepG2 hepatoma cells through a PI3K-dependent, rapamycin-insensitive mechanism.	Sirolimus	144-153	insulin	Homo sapiens	0-7
9497382-4	1998	Insulin lowers IGFBP-1 mRNA levels, inhibits IGFBP-1 promoter activity, and activates PKB/Akt in HepG2 hepatoma cells through a PI3K-dependent, rapamycin-insensitive mechanism.	Sirolimus	144-153	AKT serine/threonine kinase 1	Homo sapiens	86-93
9480896-7	1998	Rapamycin, an inhibitor of p70 S6 kinase action, strongly inhibited the potentiating effects of ethanol on insulin- and PCho-induced mitogenesis.	Sirolimus	0-9	insulin	Homo sapiens	107-114
9434772-4	1997	Protein kinase activity directed towards mTOR was tightly associated with mTOR immunoprecipitates and this kinase activity was inhibited by FKBP12-rapamycin indicating it was due to an autokinase activity present in mTOR.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	41-45
9498625-6	1998	The stimulation by insulin of ERK-2 was blocked by a mitogen-activated protein (MEK) inhibitor (PD 98059) and of p70rsk by rapamycin.	Sirolimus	123-132	insulin	Homo sapiens	19-26
9448082-4	1997	Sirolimus quantitation involves a simple sample clean-up procedure followed by isocratic chromatography on a heated C18 analytical column with an 70% methanol-water mobile phase and ultraviolet detection at 278 nm.	Sirolimus	0-9	Bardet-Biedl syndrome 9	Homo sapiens	116-119
9434772-4	1997	Protein kinase activity directed towards mTOR was tightly associated with mTOR immunoprecipitates and this kinase activity was inhibited by FKBP12-rapamycin indicating it was due to an autokinase activity present in mTOR.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	74-78
9434772-4	1997	Protein kinase activity directed towards mTOR was tightly associated with mTOR immunoprecipitates and this kinase activity was inhibited by FKBP12-rapamycin indicating it was due to an autokinase activity present in mTOR.	Sirolimus	147-156	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	140-146
9434772-4	1997	Protein kinase activity directed towards mTOR was tightly associated with mTOR immunoprecipitates and this kinase activity was inhibited by FKBP12-rapamycin indicating it was due to an autokinase activity present in mTOR.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	74-78
9389753-4	1997	These investigations demonstrate precise in vivo control of protein expression from cells that are engineered to secrete human growth hormone (hGH) in response to stimulation by rapamycin.	Sirolimus	178-187	growth hormone 1	Homo sapiens	127-141
9371685-8	1997	Translation of another class of mRNAs, those with 5"-UTRs containing polypyrimidine tracts is also activated by insulin and this, like phosphorylation of the 4E-BPs, appears to involve the rapamycin-sensitive signalling pathway which leads to activation of the 70 kDa ribosomal protein S6 kinase (p70 S6 kinase) and the phosphorylation of the ribosomal protein S6.	Sirolimus	189-198	insulin	Homo sapiens	112-119
9373220-0	1997	Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells.	Sirolimus	0-9	interleukin 6	Homo sapiens	22-35
9368076-4	1997	Rapamycin blocks the PDBu-induced accumulation of p21cip1 (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-57
9368076-4	1997	Rapamycin blocks the PDBu-induced accumulation of p21cip1 (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-53
9368076-4	1997	Rapamycin blocks the PDBu-induced accumulation of p21cip1 (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	53-57
9395070-3	1997	Here we show that the phorbol ester-stimulated release of choline- and ethanolamine-metabolites from C6 glioma cells due to phospholipid hydrolysis by phospholipase D (PLD) is not inhibited by rapamycin or PD98059, specific inhibitors respectively of p70 S6 kinase and MAPKK (MEK) and thus of MAPKAP kinase-1beta but is still completely blocked by Ro31-8220.	Sirolimus	193-202	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	168-171
9373220-4	1997	In spite of this intrinsic antiproliferative effect, rapamycin was found to abrogate IL-6 induced growth arrest.	Sirolimus	53-62	interleukin 6	Homo sapiens	85-89
9373220-6	1997	Excess levels of the FK-506 analogue ascomycin reversed the antagonistic effect of rapamycin on IL-6 mediated growth suppression, suggesting that this biological action of rapamycin is mediated by a rapamycin/immunophilin complex.	Sirolimus	83-92	interleukin 6	Homo sapiens	96-100
9373220-6	1997	Excess levels of the FK-506 analogue ascomycin reversed the antagonistic effect of rapamycin on IL-6 mediated growth suppression, suggesting that this biological action of rapamycin is mediated by a rapamycin/immunophilin complex.	Sirolimus	172-181	interleukin 6	Homo sapiens	96-100
9381729-2	1997	Rapamycin is metabolically transformed in rat liver microsomes to 3,4- and 5,6-dihydrodiol metabolites under the influence of the cytochrome P-450 mixed function oxygenase system.	Sirolimus	0-9	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	130-146
21528311-0	1997	Rapamycin-induced apoptosis is p53-independent in human prostate carcinoma PC-3 cells.	Sirolimus	0-9	tumor protein p53	Homo sapiens	31-34
21528311-2	1997	Rapamycin induced apoptosis as well as the expression of p21(waf1) mRNA and protein, independent of p53.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	57-60
21528311-2	1997	Rapamycin induced apoptosis as well as the expression of p21(waf1) mRNA and protein, independent of p53.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1A	Homo sapiens	61-65
21528311-5	1997	Since this induction occurred soon after rapamycin treatment, possibly, the early induction of p21(waf1) and G(1)-arrest are important components of the mechanism by which rapamycin induces apoptosis in PC-3 cells.	Sirolimus	172-181	cyclin dependent kinase inhibitor 1A	Homo sapiens	95-98
21528311-5	1997	Since this induction occurred soon after rapamycin treatment, possibly, the early induction of p21(waf1) and G(1)-arrest are important components of the mechanism by which rapamycin induces apoptosis in PC-3 cells.	Sirolimus	172-181	cyclin dependent kinase inhibitor 1A	Homo sapiens	99-103
9334222-1	1997	The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin.	Sirolimus	140-149	insulin	Homo sapiens	58-65
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	56-60
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	61-67
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	68-72
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	195-199
9334222-3	1997	We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	25-29
9334222-3	1997	We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	204-208
21528277-0	1997	Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells.	Sirolimus	0-9	tachykinin precursor 1	Homo sapiens	19-30
9249059-1	1997	The role of phosphatidylinositol 3-kinase and FK506-binding protein rapamycin-associated protein (FRAP) in translational control has been examined by treating RD-rhabdomyosarcoma cells with wortmannin and rapamycin and studying the effects on cell-growth, translation initiation, and protein synthesis.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	98-102
9190906-3	1997	However, a third immunosuppressive drug, rapamycin, normally associated with inhibiting the effects, but not the production, of cytokines, inhibited IL-10, but not IFN-gamma, production.	Sirolimus	41-50	interferon gamma	Homo sapiens	164-173
9237106-0	1997	Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and rapamycin.	Sirolimus	100-109	interleukin 2	Homo sapiens	32-36
9182578-0	1997	Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase.	Sirolimus	108-117	interleukin 2	Homo sapiens	24-37
9182578-0	1997	Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase.	Sirolimus	108-117	interleukin 2	Homo sapiens	39-42
9182578-0	1997	Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase.	Sirolimus	108-117	interleukin 2	Homo sapiens	80-83
9248697-7	1997	Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K.	Sirolimus	34-43	insulin	Homo sapiens	69-76
9144421-7	1997	Pretreatment of cells with rapamycin, to inhibit p70s6k activation, inhibits thrombin-induced stress fibre formation and the associated presence of p70s6k on the fibres, supporting a role for p70s6k in thrombin-stimulated stress fibre formation.	Sirolimus	27-36	coagulation factor II	Mus musculus	77-85
9145907-3	1997	Disruption of the association between immunophilin FKBP12 and Ry1R with FK 506 or rapamycin completely eliminates PCB 95-enhanced binding of [3H]ryanodine (IC50 approximately 35 microM) to Ry1R and PCB 95-induced release of Ca2+ from actively loaded SR vesicles (IC50 approximately 11 microM), demonstrating a FKBP12-dependent mechanism.	Sirolimus	82-91	pyruvate carboxylase	Homo sapiens	114-117
9147322-8	1997	Inhibition of FKBP by the immunosuppressants FK506 or rapamycin increased the duration of spontaneous or depolarization-evoked Ca2+ sparks 6- to 7-fold.	Sirolimus	54-63	carbonic anhydrase 2	Rattus norvegicus	127-130
9109420-0	1997	Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue.	Sirolimus	107-116	insulin	Homo sapiens	0-7
9109420-3	1997	Thus rapamycin-insensitive pathways mediate the acute effect of insulin on glycogen synthase in the major insulin-responsive tissues.	Sirolimus	5-14	insulin	Homo sapiens	64-71
9109420-3	1997	Thus rapamycin-insensitive pathways mediate the acute effect of insulin on glycogen synthase in the major insulin-responsive tissues.	Sirolimus	5-14	insulin	Homo sapiens	106-113
9182578-11	1997	Finally, we established that the IL2-activated Stat5a/b serine kinase is insensitive to several selective inhibitors of known IL2-stimulated kinases including MEK1/MEK2 (PD98059), mTOR (rapamycin), and phosphatidylinositol 3-kinase (wortmannin) as determined by phosphoamino acid and DNA binding analysis, thus suggesting that a yet-to-be-identified serine kinase mediates Stat5a/b activation.	Sirolimus	186-195	interleukin 2	Homo sapiens	33-36
9158086-2	1997	Rapamycin treatment down-regulated bcl-2 expression on rheumatoid synovial cells in a dose-dependent manner.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	35-40
9158086-5	1997	Our results suggest that rapamycin augments the sensitivity of rheumatoid synovial fibroblasts to apoptosis by down-regulating bcl-2 expression.	Sirolimus	25-34	BCL2 apoptosis regulator	Homo sapiens	127-132
9092573-0	1997	Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes.	Sirolimus	115-124	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	72-78
9144421-7	1997	Pretreatment of cells with rapamycin, to inhibit p70s6k activation, inhibits thrombin-induced stress fibre formation and the associated presence of p70s6k on the fibres, supporting a role for p70s6k in thrombin-stimulated stress fibre formation.	Sirolimus	27-36	coagulation factor II	Mus musculus	202-210
9144421-8	1997	Thrombin is also shown to stimulate p70s6k activity and that this is inhibited by rapamycin.	Sirolimus	82-91	coagulation factor II	Mus musculus	0-8
9045696-6	1997	In sharp contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase, and rapamycin, an inhibitor of the activation of p70 S6 kinase (p70(S6k)), completely abolished IGF stimulation of L6A1 differentiation.	Sirolimus	80-89	ubiquitin associated and SH3 domain containing B	Homo sapiens	125-128
9127694-0	1997	Identification of a 37 kDa tacrolimus, sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the Jurkat T cell line.	Sirolimus	39-48	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	98-138
8955182-0	1996	IL-2 induces beta2-integrin adhesion via a wortmannin/LY294002-sensitive, rapamycin-resistant pathway.	Sirolimus	74-83	interleukin 2	Homo sapiens	0-4
9045922-4	1997	Blocking the IL-2 pathway by cyclosporin A, FK506, rapamycin, anti-IL-2 or CD25 antibodies, prevented the development of sensitivity to apoptosis.	Sirolimus	51-60	interleukin 2	Homo sapiens	13-17
9006957-8	1997	Expression of a dominant negative mutant of the p85 subunit of PI 3"-kinase or treatments with the PI 3"-kinase inhibitor wortmannin only partially (approximately 40-50%) reduced the combined effects of ChoP, ATP, and insulin on DNA synthesis; in contrast, the pp70 S6 kinase inhibitor rapamycin almost completely inhibited these effects.	Sirolimus	286-295	insulin	Homo sapiens	218-225
9067639-2	1997	Thrombin stimulated p70s6k activity in a time and concentration-dependent manner which was abolished by the macrolide rapamycin.	Sirolimus	118-127	ribosomal protein S6 kinase B1	Bos taurus	20-26
8955134-10	1996	The formation of the complexes between FKBP59 or FKBP12 and FAP48 is prevented by FK506 and rapamycin in a dose-dependent manner.	Sirolimus	92-101	FKBP prolyl isomerase 4	Homo sapiens	39-45
9039923-2	1997	The objective of our study was to evaluate the efficacy of sirolimus versus cyclosporine in augmenting the unresponsiveness induced by an antilymphocyte serum (ALS)/donor-specific bone marrow (BM)-based regimen across three levels of histoincompatibility: class I and II disparate (DBA/2 to B6AF1), complete mismatch (AKR to C57BL/6), and xenograft (ACI rat to B6AF1).	Sirolimus	59-68	DBA2	Homo sapiens	282-287
8955182-6	1996	In contrast, rapamycin strongly inhibits IL-2-induced proliferation without inhibiting IL-2-induced adhesion.	Sirolimus	13-22	interleukin 2	Homo sapiens	41-45
8943845-5	1996	The IL-2-mediated induction of BAG-1 expression required the activation of tyrosine kinase(s) and was sensitive to rapamycin as the induction of bcl-2 expression was.	Sirolimus	115-124	B cell leukemia/lymphoma 2	Mus musculus	145-150
8939643-4	1996	Another immunosuppressant, rapamycin, binds to the same immunophilin as FK506 but inactivates a protein kinase p70(s6k).	Sirolimus	27-36	ubiquitin associated and SH3 domain containing B	Homo sapiens	111-114
8878544-4	1996	IL-3 induces the phosphorylation of S17 in the IL3-responsive cell line, BaF3, and this phosphorylation is inhibited by rapamycin.	Sirolimus	120-129	interleukin 3	Mus musculus	0-4
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Sirolimus	42-51	insulin	Homo sapiens	15-22
8906804-4	1996	Interference with the IL-2 pathway was achieved by 1) inhibition of cytokine synthesis using cyclosporin A or FK506, 2) neutralization of IL-2 by anti-IL-2 Ab, 3) inhibition of binding to IL-2R by CD25 mAb, and 4) blocking of IL-2R signaling by rapamycin.	Sirolimus	245-254	interleukin 2	Homo sapiens	22-26
8878544-4	1996	IL-3 induces the phosphorylation of S17 in the IL3-responsive cell line, BaF3, and this phosphorylation is inhibited by rapamycin.	Sirolimus	120-129	interleukin 3	Mus musculus	47-50
8836145-3	1996	PDGF stimulated an increase in PtdIns 3-kinase activity and a sustained 15-fold increase in p70s6k activity that was abolished by both wortmannin and rapamycin.	Sirolimus	150-159	ribosomal protein S6 kinase B1	Bos taurus	92-98
8805627-6	1996	Furthermore, basal transcription of the endogenous IRF-1 gene was decreased as a result of anti-Ig treatment, and this effect of anti-Ig was blocked by co-incubation with rapamycin.	Sirolimus	171-180	interferon regulatory factor 1	Homo sapiens	51-56
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	insulin	Homo sapiens	144-151
8702500-12	1996	Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin.	Sirolimus	251-260	ATP binding cassette subfamily B member 1	Homo sapiens	169-172
8662507-1	1996	Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	108-141
8662507-1	1996	Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	143-147
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	insulin	Homo sapiens	252-259
8663315-7	1996	In addition, rapamycin blocked the insulin-induced expression of an HKII promoter-chloramphenicol acetyltransferase fusion gene transiently transfected into L6 myotubes, whereas PD98059 had no such effect.	Sirolimus	13-22	insulin	Homo sapiens	35-42
8842531-9	1996	Rapamycin, an inhibitor of p70 ribosomal S6 kinase, was without effect on any of these parameters, but both rapamycin and wortmannin inhibit growth factor-stimulated p70 ribosomal S6 kinase activity.	Sirolimus	0-9	ubiquitin associated and SH3 domain containing B	Homo sapiens	27-30
8635249-6	1996	In the present study, we measured the activity of cardiac RyRs incorporated into planar lipid bilayers to show that rapamycin, a drug that inhibits the prolyl isomerase activity of FKBP and dissociates FKBP from the RyR, increases the open probability and reduces the current amplitude of cardiac muscle Ca(2+)-release channels.	Sirolimus	116-125	ryanodine receptor 1	Homo sapiens	58-61
8663063-7	1996	Both rapamycin and wortmannin inhibited the IL-10-induced proliferation of D36 cells but in contrast had no effect on the antiinflammatory effects of the cytokine on lipopolysaccharide-stimulated monocytes.	Sirolimus	5-14	interleukin 10	Mus musculus	44-49
8660826-4	1996	Rapamycin, an inhibitor of IL-2-induced S phase entry, prevented this apoptotic death.	Sirolimus	0-9	interleukin 2	Homo sapiens	27-31
8842531-9	1996	Rapamycin, an inhibitor of p70 ribosomal S6 kinase, was without effect on any of these parameters, but both rapamycin and wortmannin inhibit growth factor-stimulated p70 ribosomal S6 kinase activity.	Sirolimus	108-117	ubiquitin associated and SH3 domain containing B	Homo sapiens	166-169
8668925-2	1996	Rapamycin was compared to cyclosporine A for its ability to inhibit P-glycoprotein on normal human peripheral blood mononuclear cells (PBMC).	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	68-82
8687386-7	1996	Rapamycin, a specific inhibitor of the activation of this latter kinase, inhibits dissociation of 4E-BP1 from eIF-4E in cells incubated with insulin but reveals a phosphorylated from of 4E-BP1 which remains bound to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	98-104
8687386-7	1996	Rapamycin, a specific inhibitor of the activation of this latter kinase, inhibits dissociation of 4E-BP1 from eIF-4E in cells incubated with insulin but reveals a phosphorylated from of 4E-BP1 which remains bound to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	186-192
8633019-6	1996	The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin.	Sirolimus	125-134	insulin	Homo sapiens	4-11
8812665-0	1996	Immunophilin Modulation of Calcium Channel Gating The FK506 binding protein (FKBP12) is the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	153-162	FKBP prolyl isomerase 1A L homeolog	Xenopus laevis	54-75
8812665-0	1996	Immunophilin Modulation of Calcium Channel Gating The FK506 binding protein (FKBP12) is the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	153-162	FKBP prolyl isomerase 1A L homeolog	Xenopus laevis	77-83
8812665-4	1996	These effects were reversed by adding FK506 or rapamycin, both of which inhibit FKBP12 isomerase activity and dissociate the FKBP-RyR complex.	Sirolimus	47-56	FKBP prolyl isomerase 1A L homeolog	Xenopus laevis	80-86
8668925-7	1996	P-glycoprotein inhibition of ex vivo lymphocytes with three multi-drug resistant T-cell lines showed susceptibility of P-glycoprotein to rapamycin dependent on the cell type.	Sirolimus	137-146	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
8668925-7	1996	P-glycoprotein inhibition of ex vivo lymphocytes with three multi-drug resistant T-cell lines showed susceptibility of P-glycoprotein to rapamycin dependent on the cell type.	Sirolimus	137-146	ATP binding cassette subfamily B member 1	Homo sapiens	119-133
8668925-8	1996	Compared to cyclosporine A, the reduced ability of rapamycin to inhibit P-glycoprotein reflects a reduced avidity in its binding to P-glycoprotein and perhaps increased access to the cell interior.	Sirolimus	51-60	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
8668925-8	1996	Compared to cyclosporine A, the reduced ability of rapamycin to inhibit P-glycoprotein reflects a reduced avidity in its binding to P-glycoprotein and perhaps increased access to the cell interior.	Sirolimus	51-60	ATP binding cassette subfamily B member 1	Homo sapiens	132-146
8668925-10	1996	The authors speculate that interactions with P-glycoprotein may partially modulate the immunosuppressive effects of rapamycin.	Sirolimus	116-125	ATP binding cassette subfamily B member 1	Homo sapiens	45-59
8603701-5	1996	An immunosuppressant agent, rapamycin, inhibited Ang II-induced p70S6K activation but not the activation of MAP kinases or the induction of c-fos gene expression.	Sirolimus	28-37	angiotensinogen	Rattus norvegicus	49-55
7586215-0	1995	Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro.	Sirolimus	0-9	angiotensinogen	Rattus norvegicus	31-45
8595879-6	1996	Moreover, TOR2-RAFT1 and TOR1-RAFT1 hybrid proteins mutated at the position corresponding to rapamycin-resistant TOR mutants (S20351) conferred rapamycin resistance.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	30-35
8595879-6	1996	Moreover, TOR2-RAFT1 and TOR1-RAFT1 hybrid proteins mutated at the position corresponding to rapamycin-resistant TOR mutants (S20351) conferred rapamycin resistance.	Sirolimus	93-102	RAR related orphan receptor C	Homo sapiens	10-13
8594303-6	1996	A second, later effect of rapamycin in IL-2-stimulated T cells is an inhibition of the enzymatic activity of the cyclin-dependent kinase cdk2-cyclin E complex, which functions as a crucial regulator of G1/S transition.	Sirolimus	26-35	interleukin 2	Homo sapiens	39-43
8805102-6	1996	Rapamycin depressed the production of IL-6 and TNF-alpha, and FK506 depressed the production of TNF-alpha.	Sirolimus	0-9	interleukin 6	Homo sapiens	38-42
8805102-6	1996	Rapamycin depressed the production of IL-6 and TNF-alpha, and FK506 depressed the production of TNF-alpha.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	47-56
7586215-9	1995	Rapamycin inhibited Ang II-induced activation of p70S6K in a dose-dependent manner, with an IC50 of 0.14 ng/mL (0.15 nmol/L).	Sirolimus	0-9	angiotensinogen	Rattus norvegicus	20-26
7586215-11	1995	In contrast, a dose-dependent inhibition of p70S6K by rapamycin is very closely correlated with its inhibition of the Ang II-induced increase in protein synthesis.	Sirolimus	54-63	angiotensinogen	Rattus norvegicus	118-124
7592869-10	1995	Our results suggest that FKBP12.6 has both a unique physiological role in excitation-contraction coupling in cardiac muscle and the potential to contribute to the immunosuppressive and toxic effects of FK506 and rapamycin.	Sirolimus	212-221	FKBP prolyl isomerase 1B	Homo sapiens	25-33
8521476-6	1995	We now report that calcineurin is physiologically associated with the IP3R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin.	Sirolimus	171-180	ryanodine receptor 2	Homo sapiens	86-89
8557519-3	1995	Rapamycin, which does not affect IL-2 transcription, surprisingly inhibited IL-2R upregulation after anti-CD3- or ionomycin-induced stimulation, but not by phorbol ester or IL-2.	Sirolimus	0-9	interleukin 2	Homo sapiens	76-80
7673106-6	1995	Thus, it is likely that, in vivo, rapamycin does not directly inhibit the PI 4-kinase activity and affects the RAFT1/FRAP protein through another mechanism.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	111-116
7673106-6	1995	Thus, it is likely that, in vivo, rapamycin does not directly inhibit the PI 4-kinase activity and affects the RAFT1/FRAP protein through another mechanism.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	117-121
7559428-0	1995	Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin.	Sirolimus	68-77	interleukin 4	Homo sapiens	0-13
7556070-5	1995	The insulin-stimulated increase in RAC-PK alpha activity was inhibited by wortmannin (an inhibitor of phosphatidylinositol 3-kinase) in a dose-dependent manner with a half-maximal inhibition of 10 nM, but not by 20 ng/ml of rapamycin.	Sirolimus	224-233	AKT serine/threonine kinase 1	Rattus norvegicus	35-47
7629182-7	1995	Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity.	Sirolimus	10-19	insulin	Homo sapiens	76-83
7629182-8	1995	Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70S6K.	Sirolimus	0-9	insulin	Homo sapiens	35-42
7638171-0	1995	cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.	Sirolimus	10-19	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	127-133
7638171-6	1995	The effects of PDGF and IGF-I on increasing PHAS-I phosphorylation, on dissociating the PHAS-I-eIF-4E complex, and on increasing p70S6K were abolished by rapamycin.	Sirolimus	154-163	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	44-50
7638171-6	1995	The effects of PDGF and IGF-I on increasing PHAS-I phosphorylation, on dissociating the PHAS-I-eIF-4E complex, and on increasing p70S6K were abolished by rapamycin.	Sirolimus	154-163	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	88-94
7638171-7	1995	The results indicate that IGF-I and PDGF increase PHAS-I phosphorylation in smooth muscle cells by the same rapamycin-sensitive pathway that leads to activation of p70S6K.	Sirolimus	108-117	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	50-56
7797543-9	1995	The immunosuppressant rapamycin, a potent inhibitor of insulin or phorbol ester stimulation of p70/p85 ribosomal S6 protein kinase, has no significant effect on the regulation of PEPCK gene expression by insulin or phorbol esters.	Sirolimus	22-31	insulin	Homo sapiens	55-62
7797543-9	1995	The immunosuppressant rapamycin, a potent inhibitor of insulin or phorbol ester stimulation of p70/p85 ribosomal S6 protein kinase, has no significant effect on the regulation of PEPCK gene expression by insulin or phorbol esters.	Sirolimus	22-31	ubiquitin associated and SH3 domain containing B	Homo sapiens	95-98
7613145-5	1995	In contrast, the immunosuppressant rapamycin inhibited the formation of LTB4 after subsequent stimulation with fMLP.	Sirolimus	35-44	formyl peptide receptor 1	Homo sapiens	111-115
7531689-4	1995	In skeletal muscle TC, FK-590 or rapamycin binds to and dissociates FKBP from the RyR in a time- and temperature-dependent manner which increases the open probability of the channel.	Sirolimus	33-42	ryanodine receptor 1	Homo sapiens	82-85
7739516-4	1995	Serum activation of p70 delta CT104, as with the parent, full-length p70, is accompanied by an increase in 32P content (about twofold) in situ and a slowing in electrophoretic mobility; both modifications are inhibited by pretreatment with wortmannin or rapamycin.	Sirolimus	254-263	ubiquitin associated and SH3 domain containing B	Homo sapiens	69-72
7739516-9	1995	Deletion of residues 29 to 46 also abolishes completely the sensitivity of p70 to inhibition by rapamycin but does not alter the susceptibility to activation by serum of inhibition by wortmannin.	Sirolimus	96-105	ubiquitin associated and SH3 domain containing B	Homo sapiens	75-78
7739516-12	1995	Disinhibition from the carboxy-terminal tail requires, in addition to its multisite phosphorylation, an activating input dependent on the presence of amino acids 29 to 46; this p70-activating input may be the same as that inhibited by rapamycin but is distinct from that arising from the wortmannin-inhibitable phosphatidylinositol 3-kinase.	Sirolimus	235-244	ubiquitin associated and SH3 domain containing B	Homo sapiens	177-180
7534292-5	1995	The immunosuppressant drug rapamycin was found to selectively inhibit the activation of p70S6K by AII, but not the activation of mitogen-activated protein kinase or the induction of c-fos mRNA expression.	Sirolimus	27-36	angiotensinogen	Homo sapiens	98-101
9383417-2	1995	In the case of FK506, ascomycin and cyclosporin, the target of the immunophilin-immunosuppressant complex is calcineurin; in the case of rapamycin, the target is FRAP (TOR/RAFT1).	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	162-166
7628296-9	1995	Therefore, compounds interacting with CYP3A proteins are expected to cause drug-drug interactions (i.e. the antimycotics ketoconazole and clotrimazole, the steroids ethinylestradiol and testosterone, the ergots, the calcium channel blocker nifedipine, and the immunosuppressants FK-506 and rapamycin).	Sirolimus	290-299	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
7551978-1	1995	This study evaluates the ability of the immunosuppressive drugs dexamethasone, cyclosporine, FK506 and rapamycin, alone and in combination to suppress interleukin-1 beta (IL-1 beta) secretion in vitro by THP-1 cells when stimulated by lipopolysaccharide.	Sirolimus	103-112	interleukin 1 beta	Homo sapiens	151-169
7551978-1	1995	This study evaluates the ability of the immunosuppressive drugs dexamethasone, cyclosporine, FK506 and rapamycin, alone and in combination to suppress interleukin-1 beta (IL-1 beta) secretion in vitro by THP-1 cells when stimulated by lipopolysaccharide.	Sirolimus	103-112	interleukin 1 beta	Homo sapiens	171-180
7551978-4	1995	Cyclosporine, FK506 and rapamycin only partially suppress secretion of IL-1 beta at concentrations within their therapeutic ranges and increasing concentrations of the drugs do not result in further suppression of secretion.	Sirolimus	24-33	interleukin 1 beta	Homo sapiens	71-80
7551978-7	1995	These data suggest that cyclosporine, FK506 and rapamycin all share a common effect on the production of IL-1 beta, different from that of dexamethasone.	Sirolimus	48-57	interleukin 1 beta	Homo sapiens	105-114
7739516-3	1995	Carboxy-terminal deletion reduces the extent of maximal inhibition produced by rapamycin, from > 95% in the full-length p70 to 60 to 80% in p70 delta CT104, without altering the sensitivity to rapamycin inhibition (50% inhibitory concentration of 2 nM).	Sirolimus	79-88	ubiquitin associated and SH3 domain containing B	Homo sapiens	123-126
7739516-3	1995	Carboxy-terminal deletion reduces the extent of maximal inhibition produced by rapamycin, from > 95% in the full-length p70 to 60 to 80% in p70 delta CT104, without altering the sensitivity to rapamycin inhibition (50% inhibitory concentration of 2 nM).	Sirolimus	79-88	ubiquitin associated and SH3 domain containing B	Homo sapiens	143-146
7739516-4	1995	Serum activation of p70 delta CT104, as with the parent, full-length p70, is accompanied by an increase in 32P content (about twofold) in situ and a slowing in electrophoretic mobility; both modifications are inhibited by pretreatment with wortmannin or rapamycin.	Sirolimus	254-263	ubiquitin associated and SH3 domain containing B	Homo sapiens	20-23
7721872-10	1995	Using DNA binding gel mobility shift assay we demonstrated that rapamycin potently inhibited the binding of CREB/ATF transcription factors to CRE elements in the murine proximal PCNA promoter.	Sirolimus	64-73	cAMP responsive element binding protein 1	Mus musculus	108-112
7532989-2	1995	Based on functional and sequence homology studies, it was recently discovered that hsp56 also belongs to the FKBP class of immunophilin proteins, which are thought to mediate the actions of the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	228-237	FKBP prolyl isomerase 4	Homo sapiens	83-88
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	35-44	ADP-ribosyltransferase 1	Mus musculus	101-106
7530217-0	1995	Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression.	Sirolimus	0-9	prolactin	Homo sapiens	49-58
7530217-1	1995	In this work we demonstrate that transcription of the human prolactin gene is inhibited by the immunosuppressants FK506 (IC50 = 25 nM), cyclosporin A (IC50 = 190 nM) and rapamycin (IC50 = 25 nM).	Sirolimus	170-179	prolactin	Homo sapiens	60-69
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	160-169	ADP-ribosyltransferase 1	Mus musculus	101-106
7995960-6	1995	Rapamycin, a potent immunosuppressant, which arrests IL-2-stimulated T lymphocytes at G1/S, inhibited the IL-2-induced CRE binding activities concomitantly with inhibition of DNA synthesis.	Sirolimus	0-9	interleukin 2	Homo sapiens	53-57
7879050-0	1995	Effect of rapamycin on the in vitro release of soluble interleukin-2 receptor by phytohemagglutinin, phorbol myristate acetate, and ionomycin-activated peripheral blood mononuclear cells.	Sirolimus	10-19	interleukin 2	Homo sapiens	55-68
7826337-6	1995	Rapamycin inhibited insulin-stimulated glucose incorporation into glycogen to a similar extent and with similar dose-dependency, while having no effect on insulin-stimulated glucose transport.	Sirolimus	0-9	insulin	Homo sapiens	20-27
7528328-5	1995	The T-cell immunosuppressant rapamycin potently antagonizes IL-2-(PI3K)- and phorbol ester (cPKC)-mediated activation of pp70S6k.	Sirolimus	29-38	interleukin 2	Homo sapiens	60-64
7528328-6	1995	Thus, wortmannin and rapamycin antagonize IL-2-mediated activation of pp70S6k at distinct points along the PI3K-regulated signalling pathway, or rapamycin antagonizes another pathway required for pp70S6k activity.	Sirolimus	21-30	interleukin 2	Homo sapiens	42-46
7995960-6	1995	Rapamycin, a potent immunosuppressant, which arrests IL-2-stimulated T lymphocytes at G1/S, inhibited the IL-2-induced CRE binding activities concomitantly with inhibition of DNA synthesis.	Sirolimus	0-9	interleukin 2	Homo sapiens	106-110
7809080-3	1994	Using a two-hybrid system we isolated mammalian clones that interact with the human FK506/rapamycin-binding protein (FKBP12) in the presence of rapamycin.	Sirolimus	90-99	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	117-123
7974715-3	1994	The IL-2-mediated proliferation of long-term T cell lines generated in this fashion is typically insensitive to the immunosuppressive agent, cyclosporine but sensitive to rapamycin.	Sirolimus	171-180	interleukin 2	Homo sapiens	4-8
7530727-6	1994	These results demonstrate that hsp56 binds FK506 and rapamycin with similar affinities, and suggest that hsp56 may play a role in mediating the cellular function of both of these drugs.	Sirolimus	53-62	FKBP prolyl isomerase 4	Homo sapiens	31-36
7935449-6	1994	Rapamycin, which blocks anisomycin-stimulated p70/85S6k activation without affecting nuclear responses, has no effect on p45 or p55 kinase.	Sirolimus	0-9	ubiquitin associated and SH3 domain containing B	Homo sapiens	46-55
7523510-4	1994	Although rapamycin also inhibits IL-2 secretion, there is no effect of EC on the sensitivity of T cells to this drug.	Sirolimus	9-18	interleukin 2	Homo sapiens	33-37
7923750-4	1994	Cyclosporine and related agents such as FK-506 and rapamycin selectively inhibit adaptive immune responses by blocking T cell-dependent biosynthesis of lymphokines, particularly interleukin 2 at the level of messenger ribonucleic acid (mRNA) transcription.	Sirolimus	51-60	interleukin 2	Homo sapiens	178-191
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 3	Mus musculus	127-140
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 3	Mus musculus	142-146
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 6	Mus musculus	149-162
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	interleukin 6	Mus musculus	164-168
7520778-4	1994	In vitro, rapamycin inhibited the proliferation of primary bone marrow cells induced by IL-3, GM-CSF, KL, or a complex mixture of factors present in cell-conditioned media.	Sirolimus	10-19	interleukin 3	Mus musculus	88-92
7520778-5	1994	Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.	Sirolimus	0-9	interleukin 3	Mus musculus	102-106
7518356-5	1994	Sequences (330 amino acids total) of tryptic peptides derived from the 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast.	Sirolimus	202-211	mechanistic target of rapamycin kinase	Homo sapiens	79-84
7518356-5	1994	Sequences (330 amino acids total) of tryptic peptides derived from the 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast.	Sirolimus	202-211	RAR related orphan receptor C	Homo sapiens	125-128
7518620-4	1994	Using this method, we studied the time course and effects of CsA and rapamycin on IL-2, IFN-gamma, IL-4, and IL-10 gene expression following Con A stimulation.	Sirolimus	69-78	interleukin 10	Mus musculus	109-114
8004821-2	1994	Results show that rapamycin strongly inhibited production of both IgM and IgG measured at the end of the secondary culture supported by IL-2/IL-6, whereas CsA up-regulated the immunoglobulin production.	Sirolimus	18-27	interleukin 2	Homo sapiens	136-140
8004821-2	1994	Results show that rapamycin strongly inhibited production of both IgM and IgG measured at the end of the secondary culture supported by IL-2/IL-6, whereas CsA up-regulated the immunoglobulin production.	Sirolimus	18-27	interleukin 6	Homo sapiens	141-145
8289787-0	1994	Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction.	Sirolimus	15-24	ubiquitin associated and SH3 domain containing B	Homo sapiens	52-61
8154043-9	1994	In addition, RPM treatment prevented intragraft production of the proinflammatory cytokines IL-1 beta, IL-6, and IL-8.	Sirolimus	13-16	interleukin 1 beta	Rattus norvegicus	92-101
8154043-9	1994	In addition, RPM treatment prevented intragraft production of the proinflammatory cytokines IL-1 beta, IL-6, and IL-8.	Sirolimus	13-16	interleukin 6	Rattus norvegicus	103-107
8286755-7	1994	In these studies, we showed that RAPA administration can inhibit MHC class I-restricted CD8+ or class II-restricted CD4+ T-cell-mediated graft rejection without compromising recipient survival.	Sirolimus	33-37	CD4 molecule	Homo sapiens	116-119
8289787-7	1994	These results suggest the possible use of anisomycin and rapamycin to define upstream and downstream boundaries of an area of signalling above p70/85S6k which contains a bifurcation that produces histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction in the nucleus.	Sirolimus	57-66	ubiquitin associated and SH3 domain containing B	Homo sapiens	143-152
8287594-8	1994	Moreover, pretreatment of RPM from non-diseased MRL/Mp-+/+ mice with the culture supernatant of spleen cells from diseased MRL/lpr mice reduced their IC degradation activity.	Sirolimus	26-29	Fas (TNF receptor superfamily member 6)	Mus musculus	127-130
8222329-0	1993	Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin.	Sirolimus	80-89	interleukin 4	Homo sapiens	24-28
7507316-4	1993	In contrast, rapamycin, a structural analogue of FK 506, interferes with the immune response at a different level, by blocking the response induced by cytokines such as IL-2.	Sirolimus	13-22	interleukin 2	Homo sapiens	169-173
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Sirolimus	127-136	interleukin 4	Homo sapiens	214-218
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Sirolimus	127-136	interleukin 6	Homo sapiens	222-226
8254211-10	1994	Furthermore, TTK expression was prevented by incubation of the cells with rapamycin, which blocks IL-2 signaling.	Sirolimus	74-83	interleukin 2	Homo sapiens	98-102
7504992-0	1993	Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells.	Sirolimus	149-158	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	27-34
7504992-0	1993	Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells.	Sirolimus	149-158	Fc receptor, IgE, high affinity I, gamma polypeptide	Mus musculus	134-147
8376945-6	1993	Also, cells exposed to IL-2 in the presence of rapamycin showed full Erk2 activation but not DNA synthesis.	Sirolimus	47-56	mitogen-activated protein kinase 1	Mus musculus	69-73
8268127-6	1993	Induction of cyclins D2 and D3 was independent of the cyclosporin A-sensitive calcineurin pathway and of rapamycin-sensitive pathways, despite the ability of rapamycin to severely inhibit entry into S phase.	Sirolimus	105-114	cyclin D2	Homo sapiens	13-30
7689858-2	1993	Recently, we showed that p59 purified from human lymphocytes is an immunophilin (FKBP59) which binds both FK506 and rapamycin.	Sirolimus	116-125	FKBP prolyl isomerase 4	Homo sapiens	81-87
8413204-2	1993	In Saccharomyces cerevisiae, rapamycin sensitivity is mediated by a specific cytoplasmic receptor which is a homolog of human FKBP12 (hFKBP12).	Sirolimus	29-38	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	126-132
8413204-2	1993	In Saccharomyces cerevisiae, rapamycin sensitivity is mediated by a specific cytoplasmic receptor which is a homolog of human FKBP12 (hFKBP12).	Sirolimus	29-38	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	134-141
8413204-3	1993	Deletion of the gene for yeast FKBP12 (RBP1) results in recessive drug resistance, and expression of hFKBP12 restores rapamycin sensitivity.	Sirolimus	118-127	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	101-108
8377379-10	1993	The effect of rapamycin on the IL-1 alpha enhanced TNF alpha production differed from the effect of CsA.	Sirolimus	14-23	tumor necrosis factor	Homo sapiens	51-60
8377379-0	1993	CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC.	Sirolimus	32-41	tumor necrosis factor	Homo sapiens	50-59
8335897-3	1993	In this study we tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-alpha cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties.	Sirolimus	44-47	C-X-C motif chemokine ligand 8	Homo sapiens	358-362
8377379-6	1993	FK506, corticosteroids and rapamycin also inhibited TNF alpha production in a dose dependent fashion, although not as effectively as CsA.	Sirolimus	27-36	tumor necrosis factor	Homo sapiens	52-61
7689258-4	1993	Unexpectedly, rapamycin actually synergized with IL-4 in both the upregulation of CD23 expression and the down-regulation of the type II (p75) TNF receptor, while in the same B cell line, rapamycin simultaneously inhibited the IL-4-dependent production of TNF alpha and beta.	Sirolimus	14-23	interleukin 4	Homo sapiens	227-231
7689258-4	1993	Unexpectedly, rapamycin actually synergized with IL-4 in both the upregulation of CD23 expression and the down-regulation of the type II (p75) TNF receptor, while in the same B cell line, rapamycin simultaneously inhibited the IL-4-dependent production of TNF alpha and beta.	Sirolimus	14-23	tumor necrosis factor	Homo sapiens	256-265
7689258-4	1993	Unexpectedly, rapamycin actually synergized with IL-4 in both the upregulation of CD23 expression and the down-regulation of the type II (p75) TNF receptor, while in the same B cell line, rapamycin simultaneously inhibited the IL-4-dependent production of TNF alpha and beta.	Sirolimus	188-197	interleukin 4	Homo sapiens	49-53
7689258-5	1993	These results raise the possibility that multiple IL-4 signaling pathways may be responsible for the pleiotropic effects of IL-4, and have important implications for both the experimental and possible clinical in vivo use of rapamycin as a selective immunosuppressant.	Sirolimus	225-234	interleukin 4	Homo sapiens	50-54
7689258-5	1993	These results raise the possibility that multiple IL-4 signaling pathways may be responsible for the pleiotropic effects of IL-4, and have important implications for both the experimental and possible clinical in vivo use of rapamycin as a selective immunosuppressant.	Sirolimus	225-234	interleukin 4	Homo sapiens	124-128
8335897-11	1993	In contrast, the allografts from RPM-treated hosts showed essentially no neutrophil infiltration and minor, focal staining for IL-8 and IFN-gamma.	Sirolimus	33-36	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
8335897-13	1993	It also documents a novel effect of RPM in vivo, which results in the suppression of intragraft IL-8-like and CTL-dependent mRNA/protein production and diminished neutrophil infiltration; these may contribute to the striking efficacy of RPM therapy in sensitized graft recipients.	Sirolimus	36-39	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
8335897-13	1993	It also documents a novel effect of RPM in vivo, which results in the suppression of intragraft IL-8-like and CTL-dependent mRNA/protein production and diminished neutrophil infiltration; these may contribute to the striking efficacy of RPM therapy in sensitized graft recipients.	Sirolimus	237-240	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
7679106-2	1993	Rapamycin completely blocked activation of pp70-S6 kinase by insulin in 3T3-L1 adipocytes, but did not inhibit insulin-stimulated glucose transport, translocation of GLUT4 to the cell surface, or activation of pp90rsk or pp44mapk by insulin.	Sirolimus	0-9	insulin	Homo sapiens	61-68
8363215-0	1993	Rapamycin inhibits lymphocyte proliferation in a popliteal lymph node model via an IL-2-independent mechanism.	Sirolimus	0-9	interleukin 2	Homo sapiens	83-87
7679106-5	1993	These data demonstrate that rapamycin blocks insulin activation of pp70-S6 kinase in 3T3-L1 adipocytes and that pp70-S6 kinase is not required in the signaling pathway leading to insulin-stimulated glucose transport.	Sirolimus	28-37	insulin	Homo sapiens	45-52
1279700-4	1992	Recombinant hFKBP52 has peptidyl-prolyl cis-trans isomerase activity that is inhibited by FK506 and rapamycin and an FKBP12-like consensus sequence that probably defines the immunosuppressant-binding site.	Sirolimus	100-109	FKBP prolyl isomerase 4	Homo sapiens	12-19
1380801-0	1992	Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells.	Sirolimus	0-9	interleukin 2	Homo sapiens	59-63
1281674-0	1992	FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA.	Sirolimus	10-19	interleukin 2	Homo sapiens	55-59
1281674-2	1992	Using Northern analyses and promoter-reporter constructs we analyzed the transcriptional and posttranscriptional effects of FK506 and rapamycin on IL-2, GM-CSF, and IL-2R alpha gene expression.	Sirolimus	134-143	interleukin 2	Homo sapiens	147-151
1281674-4	1992	In contrast, rapamycin only partially inhibited IL-2 and GM-CSF promoter activity.	Sirolimus	13-22	interleukin 2	Homo sapiens	48-52
1381629-8	1992	This is supported by the ability of FK506 and rapamycin to directly compete the binding of the photoaffinity analogue 125I-iodoaryl azidoprazosin to the P-glycoprotein.	Sirolimus	46-55	ATP binding cassette subfamily B member 1	Homo sapiens	153-167
1385058-0	1992	Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.	Sirolimus	79-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-16
1385058-1	1992	The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro studies.	Sirolimus	105-114	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	12-28
1385058-7	1992	It is concluded that in human and rat liver FK506 and rapamycin are metabolized primarily by cytochrome P-450 3A4.	Sirolimus	54-63	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
1375932-6	1992	The PPIase activity of FKBP25 was far more sensitive to inhibition by rapamycin (IC50 = 50 nM) than FK506 (IC50 = 400 nM).	Sirolimus	70-79	FKBP prolyl isomerase 5	Homo sapiens	4-10
1614535-0	1992	Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.	Sirolimus	0-9	interleukin 2	Homo sapiens	31-44
1614535-2	1992	In mammals, rapamycin inhibits interleukin-2 receptor-induced S phase entry and subsequent T-cell proliferation, resulting in immunosuppression.	Sirolimus	12-21	interleukin 2	Homo sapiens	31-44
1614535-4	1992	Rapamycin completely and rapidly inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase at concentrations comparable to those blocking S phase entry of T cells (0.05-0.2 nM).	Sirolimus	0-9	interleukin 2	Homo sapiens	42-55
1375932-7	1992	PPIase activity of 100 nM FKBP25 was almost completely inhibited by 150 nM rapamycin while only 90% inhibition was achieved by 4 microM FK506.	Sirolimus	75-84	FKBP prolyl isomerase 5	Homo sapiens	0-6
1715317-0	1991	Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production.	Sirolimus	55-64	interleukin 2	Homo sapiens	68-72
1374452-9	1992	Moreover, the spontaneous clonal proliferation was insensitive to cyclosporin A and FK 506 while being highly sensitive to rapamycin, which is known to inhibit IL-2-mediated signaling.	Sirolimus	123-132	interleukin 2	Homo sapiens	160-164
1374452-10	1992	Together these results demonstrate that IL-2 is not required for the HTLV-I-induced spontaneous clonal proliferation and further suggest that HTLV-I may induce signaling pathways replacing an IL-2 receptor signal proximal to the site of action of rapamycin.	Sirolimus	247-256	interleukin 2	Homo sapiens	192-196
1515410-7	1992	In contrast, rapamycin blocks T-cell responses to IL-2.	Sirolimus	13-22	interleukin 2	Homo sapiens	50-54
1371698-4	1992	FKBP25 displays the rotamase activity characteristic of FKBPs; the activity is inhibited by the immunosuppressants rapamycin (Ki = 0.9 nM) and FK506 (Ki = 160 nM), but not cyclosporin A.	Sirolimus	115-124	FKBP prolyl isomerase 3	Bos taurus	0-6
1376003-3	1992	A 59-kilodalton member of the FK506- and rapamycin-binding class was found to associate in the absence of these drugs with two heat shock proteins (hsp90 and hsp70) and the glucocorticoid receptor (GR).	Sirolimus	41-50	nuclear receptor subfamily 3 group C member 1	Homo sapiens	173-196
1376003-3	1992	A 59-kilodalton member of the FK506- and rapamycin-binding class was found to associate in the absence of these drugs with two heat shock proteins (hsp90 and hsp70) and the glucocorticoid receptor (GR).	Sirolimus	41-50	nuclear receptor subfamily 3 group C member 1	Homo sapiens	198-200
1721312-0	1991	FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.	Sirolimus	8-17	interleukin 4	Homo sapiens	48-52
1715317-4	1991	In contrast, rapamycin was a poor inhibitor of IL-2 production, although it inhibited cellular responses to IL-2.	Sirolimus	13-22	interleukin 2	Homo sapiens	47-51
1715317-4	1991	In contrast, rapamycin was a poor inhibitor of IL-2 production, although it inhibited cellular responses to IL-2.	Sirolimus	13-22	interleukin 2	Homo sapiens	108-112
2123553-2	1990	On the other hand, interleukin 2 (IL-2)-induced signals are blocked by rapamycin but not by FK506.	Sirolimus	71-80	interleukin 2	Homo sapiens	19-32
2123553-5	1990	However, an excess of rapamycin is needed to revert FK506-mediated inhibition of IL-2 production, apoptosis, and transcriptional activation of NF-AT, a T-cell-specific transcription factor necessary for IL-2 gene activation.	Sirolimus	22-31	interleukin 2	Homo sapiens	81-85
2123553-5	1990	However, an excess of rapamycin is needed to revert FK506-mediated inhibition of IL-2 production, apoptosis, and transcriptional activation of NF-AT, a T-cell-specific transcription factor necessary for IL-2 gene activation.	Sirolimus	22-31	interleukin 2	Homo sapiens	203-207
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Sirolimus	62-71	interleukin 6	Mus musculus	112-116
2123553-6	1990	Similarly, an excess of FK506 is needed to revert rapamycin-mediated inhibition of IL-2-induced proliferation.	Sirolimus	50-59	interleukin 2	Homo sapiens	83-87
2123553-10	1990	Rather, these findings suggest that immunophilin bound to FK506 interferes with antigen receptor-induced signals, while rapamycin bound to the immunophilin interferes with IL-2-induced signals.	Sirolimus	120-129	interleukin 2	Homo sapiens	172-176
2123553-2	1990	On the other hand, interleukin 2 (IL-2)-induced signals are blocked by rapamycin but not by FK506.	Sirolimus	71-80	interleukin 2	Homo sapiens	34-38
33797919-3	2021	In this study, we used stable isotope labeling of amino acids in cell culture with a two-step strategy for phosphopeptide enrichment and high-throughput quantitative mass spectrometry to perform a global phosphoproteome analysis of mTOR inhibition by rapamycin.	Sirolimus	251-260	mechanistic target of rapamycin kinase	Homo sapiens	232-236
33971279-1	2021	Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin attenuates heart failure (HF) and age-associated changes in left ventricular (LV) function.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	49-53
33971279-2	2021	Rapamycin has also been suggested as a therapy for pulmonary hypertension (PH) and concomitant right heart failure (PH-RHF) based on reports of elevated mTOR signaling in young models with PH.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	153-157
33797919-4	2021	By monitoring the phosphoproteome alterations upon rapamycin treatment, downregulation of mTOR signaling pathway was detected and enriched.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	90-94
33797919-9	2021	In conclusion, we presented a high-confidence phosphoproteome map inside the cells upon mTOR inhibition by rapamycin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	88-92
33126251-2	2021	The formation and maintenance of intestinal tight junctions is supported by glucagon-like peptide-2 (GLP-2), which via insulin-like growth factor I activity boosts phosphoinositide 3-kinase/Akt/mammalian target of rapamycin complex 1 (PI3K/Akt/mTORC1) signaling in enterocytes.	Sirolimus	214-223	glucagon	Homo sapiens	76-99
33126251-2	2021	The formation and maintenance of intestinal tight junctions is supported by glucagon-like peptide-2 (GLP-2), which via insulin-like growth factor I activity boosts phosphoinositide 3-kinase/Akt/mammalian target of rapamycin complex 1 (PI3K/Akt/mTORC1) signaling in enterocytes.	Sirolimus	214-223	glucagon	Homo sapiens	101-106
33126251-2	2021	The formation and maintenance of intestinal tight junctions is supported by glucagon-like peptide-2 (GLP-2), which via insulin-like growth factor I activity boosts phosphoinositide 3-kinase/Akt/mammalian target of rapamycin complex 1 (PI3K/Akt/mTORC1) signaling in enterocytes.	Sirolimus	214-223	insulin like growth factor 1	Homo sapiens	119-147
33816275-7	2021	Mechanistically, NRBP2 regulated the activation of the 5"-adenosine monophosphate (AMP)-activated protein kinase/ mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	150-154
33773987-3	2021	Rapamycin (sirolimus) shrinks TSC tumors but clinical benefits of sirolimus are not sustained after its withdrawal.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	30-33
33773987-3	2021	Rapamycin (sirolimus) shrinks TSC tumors but clinical benefits of sirolimus are not sustained after its withdrawal.	Sirolimus	11-20	TSC complex subunit 1	Homo sapiens	30-33
33773987-7	2021	Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	180-184
33773987-7	2021	Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	304-307
33773987-9	2021	These results suggest that sirolimus may decrease the size of TSC tumors by reducing TSC2-/- cell volume, altering cell cycle and reprogramming TSC2-null cells.	Sirolimus	27-36	TSC complex subunit 1	Homo sapiens	62-65
33819917-5	2021	Overexpressing genetic or pharmacological interventions were performed to explore the potential mechanisms of Sirtuins 3/AMP-activated protein kinase/mammalian target of rapamycin/hypoxia-inducible factor-1alpha (SIRT3/AMPK/mTOR/HIF-1alpha).	Sirolimus	170-179	sirtuin 3	Homo sapiens	213-218
33772986-8	2021	In conclusion, we identified an effective combination therapy involving class I histone deacetylase and mammalian target of rapamycin complex 1/2 inhibition that effectively blocked the EMT of tumor cells by upregulating FoxO1 expression to inhibit Twist1 transcription.	Sirolimus	124-133	forkhead box O1	Homo sapiens	221-226
33772986-8	2021	In conclusion, we identified an effective combination therapy involving class I histone deacetylase and mammalian target of rapamycin complex 1/2 inhibition that effectively blocked the EMT of tumor cells by upregulating FoxO1 expression to inhibit Twist1 transcription.	Sirolimus	124-133	twist family bHLH transcription factor 1	Homo sapiens	249-255
32795223-0	2021	Serum Vascular Endothelial Growth Factor-C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis.	Sirolimus	82-91	vascular endothelial growth factor C	Homo sapiens	6-42
33804169-6	2021	We find that within GBM cells, radiation exposure induces DYRK3 expression and DYRK3 regulates mammalian target of rapamycin complex 1 (mTORC1) activity through phosphorylation of proline-rich AKT1 substrate 1 (PRAS40).	Sirolimus	115-124	AKT1 substrate 1	Homo sapiens	180-209
33800526-10	2021	Additionally, co-treatment with OxyR with rapamycin intended to inhibit the mammalian target of rapamycin (mTOR) caused significantly lower levels of phospho-S6 ribosomal protein (pS6) and higher LC3-II expression, implying that OxyR-mediated autophagy was dependent on the mTOR pathway.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	76-105
33800526-10	2021	Additionally, co-treatment with OxyR with rapamycin intended to inhibit the mammalian target of rapamycin (mTOR) caused significantly lower levels of phospho-S6 ribosomal protein (pS6) and higher LC3-II expression, implying that OxyR-mediated autophagy was dependent on the mTOR pathway.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	107-111
33800526-10	2021	Additionally, co-treatment with OxyR with rapamycin intended to inhibit the mammalian target of rapamycin (mTOR) caused significantly lower levels of phospho-S6 ribosomal protein (pS6) and higher LC3-II expression, implying that OxyR-mediated autophagy was dependent on the mTOR pathway.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	274-278
32796405-7	2020	Furthermore, UBE2T appears to exert its effects via the mammalian target of rapamycin (mTOR) pathway as the cellular effects caused by UBE2T overexpression are inhibited by the mTOR inhibitor rapamycin.	Sirolimus	76-85	ubiquitin conjugating enzyme E2 T	Homo sapiens	13-18
33034924-5	2021	This effect was dependent on protein kinase B/mechanistic target of rapamycin (mTOR)/ p70 S6 Kinase signaling.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	79-83
32796405-7	2020	Furthermore, UBE2T appears to exert its effects via the mammalian target of rapamycin (mTOR) pathway as the cellular effects caused by UBE2T overexpression are inhibited by the mTOR inhibitor rapamycin.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	87-91
32796405-7	2020	Furthermore, UBE2T appears to exert its effects via the mammalian target of rapamycin (mTOR) pathway as the cellular effects caused by UBE2T overexpression are inhibited by the mTOR inhibitor rapamycin.	Sirolimus	76-85	ubiquitin conjugating enzyme E2 T	Homo sapiens	135-140
32796405-7	2020	Furthermore, UBE2T appears to exert its effects via the mammalian target of rapamycin (mTOR) pathway as the cellular effects caused by UBE2T overexpression are inhibited by the mTOR inhibitor rapamycin.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	177-181
33817096-12	2018	Conclusion: Arterial infusion of rapamycin combined with TACE can improve treatment efficacy by decreasing HIF-1a, VEGF, iNOS and CD34 expression.	Sirolimus	33-42	hematopoietic progenitor cell antigen CD34	Oryctolagus cuniculus	130-134
32796887-2	2020	Mammalian target of rapamycin complex 1 (mTORC1), a protein complex that contains the serine-threonine kinase mTOR, mediates signaling that underlies the control of cellular functions such as proliferation and autophagy by various external stimuli.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	41-45
33817078-7	2018	After IL-12 treatment, the expression of mTOR and its downstream signaling molecule S6 kinase, number of CD8+ Tem cells and interferon-gamma expression were significantly increased, while they were significantly decreased after treatment with rapamycin.	Sirolimus	243-252	interferon gamma	Mus musculus	124-140
32889867-3	2020	Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	77-106
32889867-3	2020	Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	108-112
32889867-10	2020	CONCLUSIONS: mTOR-inhibitor treatment with sirolimus for >=3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	13-17
32889867-10	2020	CONCLUSIONS: mTOR-inhibitor treatment with sirolimus for >=3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients.	Sirolimus	43-52	alpha fetoprotein	Homo sapiens	129-132
25752454-8	2015	Rapamycin treatment suppressed epileptiform activity, improved baseline EEG activity, and increased survival in severely epileptic NS-Pten KO mice.	Sirolimus	0-9	phosphatase and tensin homolog	Mus musculus	134-138
17360108-0	2007	An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	13-17
23997112-7	2013	Stimulation of mammalian target of rapamycin (mTOR)-dependent signaling protected against cell death induced by paraquat, whereas MPP+-induced toxicity was enhanced by wortmannin, a phosphoinositide 3-kinase class III inhibitor, rapamycin, and trehalose, an mTOR-independent autophagy activator.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	46-50
23888043-1	2013	The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	37-41
17360108-0	2007	An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	153-157
15894895-10	2005	Treatment with 6 nmol/l rapamycin partly antagonized the effect of DMSO, indicating the involvement of mTOR in regulation of the smooth muscle phenotype of MSCs.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	103-107
11826398-6	2002	The phosphatidylinositol 3-kinase (PI3-kinase) inhibitors wortmannin or LY294002 and rapamycin, an inhibitor of p70 S6 kinase phosphorylation, ameliorated the insulin-mediated decrease in CYP2E1 mRNA levels.	Sirolimus	85-94	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	188-194
34922249-7	2022	Finally, in order to prove that AKT/mTOR signaling potentially mediated DHA-induced macrophage differentiation, we used rapamycin to specifically block the activity of mTOR and stimulated macrophages under M1 stimuli.	Sirolimus	120-129	thymoma viral proto-oncogene 1	Mus musculus	32-35
19709321-8	2009	Increased tacrolimus half-life and increased dose interval of sirolimus and tacrolimus were due to CYP3A4/5 and/or P-glycoprotein inhibition by protease inhibitors.	Sirolimus	62-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
19709321-8	2009	Increased tacrolimus half-life and increased dose interval of sirolimus and tacrolimus were due to CYP3A4/5 and/or P-glycoprotein inhibition by protease inhibitors.	Sirolimus	62-71	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
34847519-2	2022	Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that is a kinase protein playing a pivotal role in cell growth and proliferation by activation of several metabolic processes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-80
34847519-2	2022	Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that is a kinase protein playing a pivotal role in cell growth and proliferation by activation of several metabolic processes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	82-86
34191518-5	2022	Our studies showed that WRX606 formed a ternary complex with FK506-binding protein-12 (FKBP12) and FKBP-rapamycin-binding (FRB) domain of mTOR, resulting in the allosteric inhibition of mTORC1.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	138-142
34902496-6	2022	In both in vivo ISCI model in rats and in vitro OGD model in BV-2 cells, the PI3K/AKT/mTOR pathway showed to be inhibited, whereas the PI3K/AKT/mTOR pathway was further inhibited by mild hypothermia in ISCI rats or rapamycin treatment in OGD-stimulated BV-2 cells.	Sirolimus	215-224	thymoma viral proto-oncogene 1	Mus musculus	140-143
34902358-5	2022	We determined that the knockdown of Maf1 promoted the survival of RGCs and their axon regeneration through altering the activity of the PTEN/mTOR pathway, which could be blocked by rapamycin.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	141-145
34748756-6	2022	The observed effects of Gpc4 on MFS were significantly antagonized when mice were treated with L-leucine or rapamycin, an agonist or antagonist of the mammalian target of rapamycin (mTOR) signal, respectively, demonstrating that mTOR pathway is an essential requirement for Gpc4-regulated MFS.	Sirolimus	108-117	glypican 4	Mus musculus	24-28
34959190-8	2022	In addition, treatment with rapamycin, an inhibitor of mTOR, reversed the SKBR3-TR-induced promotion of tube formation.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	55-59
34715309-9	2022	But rapamycin could reverse the increasing expression of p-JNK/JNK, p-ERK/ERK and the release of IL-6 induced by GFP-SNCA Exo.	Sirolimus	4-13	mitogen-activated protein kinase 8	Homo sapiens	59-62
34715309-9	2022	But rapamycin could reverse the increasing expression of p-JNK/JNK, p-ERK/ERK and the release of IL-6 induced by GFP-SNCA Exo.	Sirolimus	4-13	mitogen-activated protein kinase 8	Homo sapiens	63-66
34715309-9	2022	But rapamycin could reverse the increasing expression of p-JNK/JNK, p-ERK/ERK and the release of IL-6 induced by GFP-SNCA Exo.	Sirolimus	4-13	mitogen-activated protein kinase 1	Homo sapiens	70-73
34715309-9	2022	But rapamycin could reverse the increasing expression of p-JNK/JNK, p-ERK/ERK and the release of IL-6 induced by GFP-SNCA Exo.	Sirolimus	4-13	mitogen-activated protein kinase 1	Homo sapiens	74-77
34715309-9	2022	But rapamycin could reverse the increasing expression of p-JNK/JNK, p-ERK/ERK and the release of IL-6 induced by GFP-SNCA Exo.	Sirolimus	4-13	interleukin 6	Homo sapiens	97-101
34304300-3	2022	We report our experience of using sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of CHI in seven newborns who are poorly responding to standard medical therapy.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	47-76
34304300-3	2022	We report our experience of using sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of CHI in seven newborns who are poorly responding to standard medical therapy.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	78-82
34304300-9	2022	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, was recently reported to be useful for refractory CHI cases with variable efficacy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
34304300-9	2022	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, was recently reported to be useful for refractory CHI cases with variable efficacy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
34370147-0	2022	Synergistic effects of Rapamycin and Fluorouracil to treat a gastric tumor in a PTEN conditional deletion mouse model.	Sirolimus	23-32	phosphatase and tensin homolog	Mus musculus	80-84
34370147-3	2022	The purpose of the study was to investigate the combined treatment of gastric tumorigenesis using Rapamycin and Fluorouracil (5-Fu) through interfering with the Akt/mTOR pathway in a mouse model with PTEN conditional deletion.	Sirolimus	98-107	thymoma viral proto-oncogene 1	Mus musculus	161-164
34370147-3	2022	The purpose of the study was to investigate the combined treatment of gastric tumorigenesis using Rapamycin and Fluorouracil (5-Fu) through interfering with the Akt/mTOR pathway in a mouse model with PTEN conditional deletion.	Sirolimus	98-107	phosphatase and tensin homolog	Mus musculus	200-204
34370147-8	2022	Our study indicates that Rapamycin has a synergistic interaction with chemotherapeutic 5-Fu, and demonstrates a potential therapeutic combination treatment on glandular stomach tumor with PTEN functional absence or aberrantly activated Akt/mTOR pathway.	Sirolimus	25-34	thymoma viral proto-oncogene 1	Mus musculus	236-239
34797524-12	2022	Accordingly, the in vivo and in vitro experiments revealed that the mTOR inhibitor rapamycin further increased cell mortality and exhibited enhanced antitumor effect on GBM cells when co-treated with the ERK inhibitor.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	68-72
34797524-12	2022	Accordingly, the in vivo and in vitro experiments revealed that the mTOR inhibitor rapamycin further increased cell mortality and exhibited enhanced antitumor effect on GBM cells when co-treated with the ERK inhibitor.	Sirolimus	83-92	mitogen-activated protein kinase 1	Homo sapiens	204-207
34619135-7	2022	Inhibiting mTOR activity with rapamycin induces raptor and restores AKT activity, allowing beta-cells to gain proliferation capacity that are lost after HFD exposure.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	11-15
34619135-7	2022	Inhibiting mTOR activity with rapamycin induces raptor and restores AKT activity, allowing beta-cells to gain proliferation capacity that are lost after HFD exposure.	Sirolimus	30-39	AKT serine/threonine kinase 1	Homo sapiens	68-71
34673129-5	2022	Mechanistic studies demonstrated that KDM1A inhibition attenuated the activation of mTOR signaling cascade and abolished rapamycin induced feedback activation of Akt.	Sirolimus	121-130	AKT serine/threonine kinase 1	Homo sapiens	162-165
34673129-6	2022	RNA-seq analysis identified that KDM1A inhibition downregulated the expression of genes involved in rapamycin induced activation of Akt, including the mTORC2 complex.	Sirolimus	100-109	AKT serine/threonine kinase 1	Homo sapiens	132-135
34748756-6	2022	The observed effects of Gpc4 on MFS were significantly antagonized when mice were treated with L-leucine or rapamycin, an agonist or antagonist of the mammalian target of rapamycin (mTOR) signal, respectively, demonstrating that mTOR pathway is an essential requirement for Gpc4-regulated MFS.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	151-180
34748756-6	2022	The observed effects of Gpc4 on MFS were significantly antagonized when mice were treated with L-leucine or rapamycin, an agonist or antagonist of the mammalian target of rapamycin (mTOR) signal, respectively, demonstrating that mTOR pathway is an essential requirement for Gpc4-regulated MFS.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	182-186
34748756-6	2022	The observed effects of Gpc4 on MFS were significantly antagonized when mice were treated with L-leucine or rapamycin, an agonist or antagonist of the mammalian target of rapamycin (mTOR) signal, respectively, demonstrating that mTOR pathway is an essential requirement for Gpc4-regulated MFS.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	229-233
34922208-10	2022	Moreover, the effects of NIS on cells were enhanced by autophagy activator Rapamycin whereas reversed by autophagy inhibitor 3-Methyladenine (3-MA).	Sirolimus	75-84	solute carrier family 5 member 5	Homo sapiens	25-28
34839054-1	2022	A phase II study was conducted to ascertain whether sequential exposure to decitabine followed by rapamycin, an mTOR (mechanistic target of rapamycin) inhibitor would result in better responses than decitabine alone.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	112-116
34839054-1	2022	A phase II study was conducted to ascertain whether sequential exposure to decitabine followed by rapamycin, an mTOR (mechanistic target of rapamycin) inhibitor would result in better responses than decitabine alone.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	118-149
34662660-9	2022	These effects of LicA were restored or suppressed by mTOR inhibitor rapamycin or PI3K inhibitor LY294002.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	53-57
34739690-0	2022	Hormetic effect of low doses of rapamycin triggers anti-aging cascades in WRL-68 cells by modulating an mTOR-mitochondria cross-talk.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	104-108
34739690-5	2022	Although previous studies have suggested that hormetic (low) doses of rapamycin can cause partial/incomplete inhibition of mTOR, the actual modus operandi of how such partial mTOR inhibition might modulate the mTOR-mitochondria cross-talk remained to be deciphered in the context of cellular aging.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	123-127
34739690-5	2022	Although previous studies have suggested that hormetic (low) doses of rapamycin can cause partial/incomplete inhibition of mTOR, the actual modus operandi of how such partial mTOR inhibition might modulate the mTOR-mitochondria cross-talk remained to be deciphered in the context of cellular aging.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	175-179
34739690-5	2022	Although previous studies have suggested that hormetic (low) doses of rapamycin can cause partial/incomplete inhibition of mTOR, the actual modus operandi of how such partial mTOR inhibition might modulate the mTOR-mitochondria cross-talk remained to be deciphered in the context of cellular aging.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	210-214
34739690-11	2022	CONCLUSIONS: We established that low doses of rapamycin can hormetically amend the mTOR-mitochondria cross-talk, and can consequently promote anti-aging outcome in cells.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	83-87
34957601-4	2022	As infants have a very low CYP3-enzyme expression at birth, which rises during ageing, we hypothesize, that a reduced metabolization of sirolimus might lead to high sirolimus serum levels and low dose may be sufficient without the side effects.	Sirolimus	136-145	peptidylprolyl isomerase F	Homo sapiens	27-31
34961940-6	2022	Direct suppression of mTOR activity by rapamycin selectively impaired IL-10 production by B cells whereas secretion was restored upon GSK3 inhibition.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	22-26
34965300-2	2022	The mTOR inhibitor Rapamycin (RAPA) is used as an immunosuppressive agent in patients with organ transplants and other immunological disorders; and it also has anti-tumorigenic potential.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34965300-2	2022	The mTOR inhibitor Rapamycin (RAPA) is used as an immunosuppressive agent in patients with organ transplants and other immunological disorders; and it also has anti-tumorigenic potential.	Sirolimus	30-34	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34965300-3	2022	However, long-term use of RAPA causes reactivation of Akt, and ultimately leads to enhanced tumor growth.	Sirolimus	26-30	AKT serine/threonine kinase 1	Homo sapiens	54-57
34958137-0	2022	Suppression of transient receptor potential melastatin 7 regulates pluripotency, proliferation, and differentiation of mouse embryonic stem cells via mechanistic target of rapamycin-extracellular signal-regulated kinase activation.	Sirolimus	172-181	transient receptor potential cation channel, subfamily M, member 7	Mus musculus	15-56
34936813-8	2022	mTOR inhibitor rapamycin significantly suppressed the elevation of IL-6, IL-8, and VEGF stimulated by 7-KC.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
34983907-3	2022	Increasing evidence shows that mTOR also regulates VSMC proliferation in vascular proliferative diseases and that mTOR inhibitors, such as rapamycin, effectively restrain VSMC proliferation.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	31-35
34949833-3	2022	Here, using a mouse model of acute infection with lymphocytic choriomeningitis virus (LCMV), we found that the serine/threonine kinase complex mammalian target of rapamycin complex 2 (mTORC2) is critical for the long-term persistence of virus-specific memory CD4+ T cells.	Sirolimus	163-172	CD4 molecule	Homo sapiens	259-262
34936813-0	2022	Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	0-29
34936813-0	2022	Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells.	Sirolimus	40-49	vascular endothelial growth factor A	Homo sapiens	114-148
34983907-3	2022	Increasing evidence shows that mTOR also regulates VSMC proliferation in vascular proliferative diseases and that mTOR inhibitors, such as rapamycin, effectively restrain VSMC proliferation.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	114-118
34970878-1	2021	OBJECTIVE: To observe the effect of acupuncture of "Yinlingquan"(SP9) and "Sanyinjiao"(SP6) on expression of phosphatidylinositol-3 kinase/protein kinase B/mammalian target protein of rapamycin (PI3K/Akt/mTOR) signaling in adjuvant arthritis (AA) rats, so as to explore its mechanism underlying improvement of AA.	Sirolimus	184-193	Sp9 transcription factor	Homo sapiens	65-68
34970878-1	2021	OBJECTIVE: To observe the effect of acupuncture of "Yinlingquan"(SP9) and "Sanyinjiao"(SP6) on expression of phosphatidylinositol-3 kinase/protein kinase B/mammalian target protein of rapamycin (PI3K/Akt/mTOR) signaling in adjuvant arthritis (AA) rats, so as to explore its mechanism underlying improvement of AA.	Sirolimus	184-193	AKT serine/threonine kinase 1	Homo sapiens	200-203
34970878-1	2021	OBJECTIVE: To observe the effect of acupuncture of "Yinlingquan"(SP9) and "Sanyinjiao"(SP6) on expression of phosphatidylinositol-3 kinase/protein kinase B/mammalian target protein of rapamycin (PI3K/Akt/mTOR) signaling in adjuvant arthritis (AA) rats, so as to explore its mechanism underlying improvement of AA.	Sirolimus	184-193	mechanistic target of rapamycin kinase	Homo sapiens	204-208
34987517-8	2021	Blockade of the pathway with mTOR inhibitor sirolimus not only inhibits tumor growth but also suppresses the T cell infiltration in colitic lesions.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	29-33
34987517-9	2021	More importantly, combination with sirolimus and anti-PD-1 synergistically inhibits tumor growth via inducing the immunogenic cell death of tumor cells in vivo.	Sirolimus	35-44	programmed cell death 1	Mus musculus	54-58
34936813-8	2022	mTOR inhibitor rapamycin significantly suppressed the elevation of IL-6, IL-8, and VEGF stimulated by 7-KC.	Sirolimus	15-24	interleukin 6	Homo sapiens	67-71
34936813-8	2022	mTOR inhibitor rapamycin significantly suppressed the elevation of IL-6, IL-8, and VEGF stimulated by 7-KC.	Sirolimus	15-24	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
34936813-8	2022	mTOR inhibitor rapamycin significantly suppressed the elevation of IL-6, IL-8, and VEGF stimulated by 7-KC.	Sirolimus	15-24	vascular endothelial growth factor A	Homo sapiens	83-87
34936813-9	2022	Rapamycin not only decreased the level of phosphorylated mTOR, P70S6K, 4EBP1 but also inhibited the activation of MAPK pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-61
34254124-8	2021	The clinically established mTOR-inhibitor sirolimus (rapamycin) efficiently abrogates the development of venous malformations in this zebrafish model.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Danio rerio	27-31
34924000-8	2021	RESULTS: The ALP activity and the expression of RunX2 in fractured osteoblasts were significantly elevated, the apoptotic rate was suppressed by rapamycin, 60, and 80 muM beta-ecdysterone.	Sirolimus	145-154	RUNX family transcription factor 2	Homo sapiens	48-53
34924000-11	2021	Lastly, the PI3K/AKT/mTOR pathway both in fractured osteoblasts and femurs was inhibited by rapamycin and beta-ecdysterone.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	17-20
34924000-11	2021	Lastly, the PI3K/AKT/mTOR pathway both in fractured osteoblasts and femurs was inhibited by rapamycin and beta-ecdysterone.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	21-25
34254124-8	2021	The clinically established mTOR-inhibitor sirolimus (rapamycin) efficiently abrogates the development of venous malformations in this zebrafish model.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Danio rerio	27-31
34547769-6	2021	In vivo mTOR inhibition by rapamycin reduced both STIM1 and ORAI1 expression and calcium flows, resulting in a normalization of platelet susceptibility to activation.	Sirolimus	27-36	stromal interaction molecule 1	Mus musculus	50-55
34944044-4	2021	Importantly, calcium signaling produced by TRPML1 (transient receptor potential cation channel, mucolipin subfamily) has been shown to regulate autophagic progression through biogenesis of autophagic-lysosomal organelles, activation of mTORC1 (mechanistic target of rapamycin complex 1) and degradation of autophagic cargo.	Sirolimus	266-275	mucolipin TRP cation channel 1	Homo sapiens	43-49
34919773-1	2022	BACKGROUND: The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	27-56
34919773-1	2022	BACKGROUND: The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	58-62
34931134-6	2021	Further inhibition of PI3K signaling, using LY294002, or of mTOR, by rapamycin, blocked the migration and invasion of UM cells similarly to artemisinin.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	60-64
34944711-11	2021	Finally, the treatment with mTOR inhibitor rapamycin predominantly reduced the formation of autophagy and ultimately mitigated the cellular migration ability of ccRCC cells with LTF knockdown.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	28-32
34944711-11	2021	Finally, the treatment with mTOR inhibitor rapamycin predominantly reduced the formation of autophagy and ultimately mitigated the cellular migration ability of ccRCC cells with LTF knockdown.	Sirolimus	43-52	lactotransferrin	Homo sapiens	178-181
34948065-4	2021	We performed RAPIDS (rapamycin- and APEX-dependent identification of proteins by SILAC) to identify proteins that interact with or are in close proximity to P56S-VAPB.	Sirolimus	21-30	VAMP associated protein B and C	Homo sapiens	162-166
34956168-8	2021	This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-gamma production and cytotoxicity in NK cells promoted by Daphnetin.	Sirolimus	129-138	AKT serine/threonine kinase 1	Homo sapiens	71-74
34956168-8	2021	This was further confirmed by the finding that both inhibitors of PI3K-Akt and its main downstream signaling mTOR, LY294002, and rapamycin, respectively, can reverse the increase of IFN-gamma production and cytotoxicity in NK cells promoted by Daphnetin.	Sirolimus	129-138	interferon gamma	Homo sapiens	182-191
34948101-7	2021	Moreover, a higher level of p53 protein in the presence of rapamycin or doxorubicin and the combination of both antibiotics was noticed in PCBP2-overexpressed cells compared to control cells.	Sirolimus	59-68	tumor protein p53	Homo sapiens	28-31
34948101-7	2021	Moreover, a higher level of p53 protein in the presence of rapamycin or doxorubicin and the combination of both antibiotics was noticed in PCBP2-overexpressed cells compared to control cells.	Sirolimus	59-68	poly(rC) binding protein 2	Homo sapiens	139-144
34899911-10	2021	Furthermore, PC4 mediated lung adenocarcinoma cell sensitivity to the HIF-PH inhibitor DMOG and the mTOR inhibitor rapamycin, and PC4 mediated the synergistic effect of DMOG and cisplatin.	Sirolimus	115-124	SUB1 regulator of transcription	Homo sapiens	13-16
34876569-12	2021	In addition, the enhanced sensitivity was partially diminished by rapamycin-mediated inhibition of mTOR in TTK knockdown cells.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	99-103
34943047-0	2021	mTOR Inhibition via Rapamycin Treatment Partially Reverts the Deficit in Energy Metabolism Caused by FH Loss in RPE Cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	0-4
34943047-8	2021	We found that silencing of CFH results in hyperactivation of mTOR signaling along with decreased mitochondrial respiration and that mTOR inhibition via rapamycin can partially rescue these metabolic defects.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	132-136
34899911-10	2021	Furthermore, PC4 mediated lung adenocarcinoma cell sensitivity to the HIF-PH inhibitor DMOG and the mTOR inhibitor rapamycin, and PC4 mediated the synergistic effect of DMOG and cisplatin.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	100-104
34585990-9	2021	Mechanistically, IL-23 induced EMT was mTOR/S6 signaling dependent and reversible by rapamycin.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	39-43
34718162-6	2021	Clinical trials in SLE patients have provided preliminary evidence that mTOR blockade by sirolimus (rapamycin) can reverse pro-inflammatory lineage skewing, including the expansion of Th17 and double-negative T cells and plasma cells and the contraction of regulatory T cells.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	72-76
34718162-6	2021	Clinical trials in SLE patients have provided preliminary evidence that mTOR blockade by sirolimus (rapamycin) can reverse pro-inflammatory lineage skewing, including the expansion of Th17 and double-negative T cells and plasma cells and the contraction of regulatory T cells.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	72-76
34718162-7	2021	Moreover, sirolimus has shown promising efficacy in the treatment of refractory idiopathic multicentric Castleman disease, newly characterized by systemic autoimmunity due to mTOR overactivation.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	175-179
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	97-106	AKT serine/threonine kinase 1	Rattus norvegicus	262-265
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	219-228	AKT serine/threonine kinase 1	Rattus norvegicus	262-265
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	339-348	AKT serine/threonine kinase 1	Rattus norvegicus	262-265
34700229-0	2021	Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	79-82
34700229-0	2021	Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-87
34563639-0	2021	Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.	Sirolimus	84-93	cyclin dependent kinase inhibitor 2A	Homo sapiens	35-41
34563639-4	2021	Of interest, the rapamycin-resistant DU145 and NCI-H2228 cells have mutations in the RB and CDKN2A tumor suppressor genes.	Sirolimus	17-26	cyclin dependent kinase inhibitor 2A	Homo sapiens	92-98
34563639-5	2021	The gene products of RB and CDKN2A (pRb and p14ARF) suppress E2F family transcription factors that promote cell cycle progression from G1 into S. Restoration of wild type RB or inhibition of E2F activity in DU145 and NCI-H2228 cells led to rapamycin sensitivity.	Sirolimus	240-249	cyclin dependent kinase inhibitor 2A	Homo sapiens	28-34
34563639-5	2021	The gene products of RB and CDKN2A (pRb and p14ARF) suppress E2F family transcription factors that promote cell cycle progression from G1 into S. Restoration of wild type RB or inhibition of E2F activity in DU145 and NCI-H2228 cells led to rapamycin sensitivity.	Sirolimus	240-249	cyclin dependent kinase inhibitor 2A	Homo sapiens	44-50
34563639-6	2021	These data provide evidence that the combination of mutant RB and mutant CDKN2A in cancer cells leads to rapamycin resistance, which has implications for precision medicine approaches to anti-cancer therapies.	Sirolimus	105-114	cyclin dependent kinase inhibitor 2A	Homo sapiens	73-79
34888748-11	2021	Furthermore, the rescue assay exhibited that the mTOR inhibitor rapamycin significantly reversed the promoting effect of NUP37 in cell proliferation, migration, and invasion.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	49-53
34607803-7	2021	Prior work shows that mammalian target of rapamycin (mTOR) inhibitor, rapamycin, induces the proliferation and effector function of gammadelta T cells.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	22-51
34607803-7	2021	Prior work shows that mammalian target of rapamycin (mTOR) inhibitor, rapamycin, induces the proliferation and effector function of gammadelta T cells.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	53-57
34672766-3	2021	Regulated in DNA damage and development 1 (REDD1) is a stress-response protein that is transcriptionally upregulated in muscle during wasting conditions and inhibits mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	188-197	DNA-damage-inducible transcript 4	Mus musculus	43-48
34859624-1	2021	OBJECTIVES: To study the effects of 17beta-estradiol (E2) on the regulation of the proliferation of condylar chondrocytes and provide a preliminary discussion on the role of phosphorylate-mammalian target of rapamycin (p-mTOR) in this regulatory process.	Sirolimus	208-217	mechanistic target of rapamycin kinase	Homo sapiens	221-225
34580903-7	2021	The patient responded well to targeted therapy with sirolimus, an mTOR inhibitor.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	66-70
34536195-6	2021	The data suggest that Omp31 as well as rapamycin, the autophagy inducer, can decrease TNF-alpha levels through the inhibition of the NF-kappaB p65 signaling pathway.	Sirolimus	39-48	tumor necrosis factor	Homo sapiens	86-95
33907035-7	2021	The Sirtuin 1 activator SRT2104 and the inhibitor Sirtinol were injected into the lateral ventricle, which revealed that the activation of Sirtuin 1 increased the expression levels of target of rapamycin complex 1, phosphorylated cAMP-response element-binding protein, and brain-derived neurotrophic factor.	Sirolimus	194-203	sirtuin 1	Rattus norvegicus	4-13
33907035-7	2021	The Sirtuin 1 activator SRT2104 and the inhibitor Sirtinol were injected into the lateral ventricle, which revealed that the activation of Sirtuin 1 increased the expression levels of target of rapamycin complex 1, phosphorylated cAMP-response element-binding protein, and brain-derived neurotrophic factor.	Sirolimus	194-203	sirtuin 1	Rattus norvegicus	139-148
34624607-3	2021	The mechanistic target of rapamycin inhibitors everolimus and sirolimus have shown to be effective treatments for multiple conditions.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	4-35
34847842-11	2021	The officially accepted mTOR inhibitors that have undergone clinical testing are sirolimus, everolimus, temsirolimus, and tacrolimus.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	24-28
34274968-10	2021	The inhibition of MAPK signaling by the ERK1/ERK2 inhibitor and mTOR signaling by rapamycin abrogated the miR-592-mediated upregulation of neuronal differentiation-related genes.	Sirolimus	82-91	mitogen-activated protein kinase 3	Homo sapiens	18-22
34274968-10	2021	The inhibition of MAPK signaling by the ERK1/ERK2 inhibitor and mTOR signaling by rapamycin abrogated the miR-592-mediated upregulation of neuronal differentiation-related genes.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	64-68
34916960-5	2021	Surprisingly, aging lends unique atrophy resistance to tibialis anteria muscle, accompanied by an increase in the cascade of mammalian target of rapamycin complex 1 (mTORC1)-independent anabolic events involving Akt signaling, rRNA biogenesis, and protein synthesis during denervation.	Sirolimus	145-154	AKT serine/threonine kinase 1	Homo sapiens	212-215
34668283-7	2021	Sirolimus appeared to be associated with a pro-inflammatory cytokine release, including TNF-alpha (p = 0.0027) and IL-1beta (p = 0.0016), in response to SARS-CoV-2 peptides.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	88-97
34819120-15	2021	Autophagy induced by starvation and rapamycin significantly enhanced the autophagic flux and apoptosis induced by aloin, which verified the role of the PI3K/AKT axis in the pharmacological action of aloin.	Sirolimus	36-45	thymoma viral proto-oncogene 1	Mus musculus	157-160
34850372-3	2022	Metformin activates AMP-activated kinase (AMPK), which inhibits mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	86-95	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	20-40
34850372-3	2022	Metformin activates AMP-activated kinase (AMPK), which inhibits mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	86-95	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	42-46
34806651-1	2021	Mutations underlying disease in tuberous sclerosis complex (TSC) give rise to tumors with biallelic mutations in TSC1 or TSC2 and hyperactive mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	162-171	TSC complex subunit 1	Homo sapiens	60-63
34965576-6	2022	Nprl2-cKO and Nprl3-cKO mice recapitulated the major abnormal features of patients-spontaneous seizures, and dysmorphic enlarged neuronal cells with increased mechanistic target of rapamycin complex 1 signaling-similar to Depdc5-cKO mice.	Sirolimus	181-190	NPR2 like, GATOR1 complex subunit	Mus musculus	0-5
34965576-8	2022	However, the benefit of rapamycin after withdrawal was less durable in Nprl2- and Nprl3-cKO mice compared with Depdc5-cKO mice.	Sirolimus	24-33	NPR2 like, GATOR1 complex subunit	Mus musculus	71-76
34609839-1	2021	Rapamycin-induced dimerization of FKBP and FRB is the most commonly utilized chemically induced protein dimerization system.	Sirolimus	0-9	FKBP prolyl isomerase 7	Danio rerio	34-38
34637337-2	2021	To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570).	Sirolimus	210-219	mechanistic target of rapamycin kinase	Homo sapiens	166-195
34609839-4	2021	Importantly, the caged rapamycin analog shows minimal background activity with regard to protein dimerization and can be directly interfaced with a wide range of established (and often commercially available) FKBP/FRB systems.	Sirolimus	23-32	FKBP prolyl isomerase 7	Danio rerio	209-213
34520980-5	2021	Gain and loss of function assays confirmed that UBE2S exerts oncogenic activities in UBC by mediating the activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	144-153	ubiquitin conjugating enzyme E2 S	Homo sapiens	48-53
34780278-10	2022	SP-A-induced activation of mechanistic target of rapamycin complex 1 (mTORC1) kinase requires beta-arrestin2 and is critically involved in degradation of LPS-induced TLR4.	Sirolimus	49-58	toll-like receptor 4	Mus musculus	166-170
34858182-5	2021	In contrast, longer rapamycin exposure (>24 h), resulted in differential AKT (T308) and AKT (S473) phosphorylation with increases in phosphorylation of AKT at T308 and decreased phosphorylation at S473.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	73-76
34858182-5	2021	In contrast, longer rapamycin exposure (>24 h), resulted in differential AKT (T308) and AKT (S473) phosphorylation with increases in phosphorylation of AKT at T308 and decreased phosphorylation at S473.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	88-91
34858182-5	2021	In contrast, longer rapamycin exposure (>24 h), resulted in differential AKT (T308) and AKT (S473) phosphorylation with increases in phosphorylation of AKT at T308 and decreased phosphorylation at S473.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	152-155
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	95-104	platelet derived growth factor receptor alpha	Homo sapiens	24-34
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	95-104	platelet derived growth factor receptor beta	Homo sapiens	39-48
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	241-245
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	182-191	platelet derived growth factor receptor alpha	Homo sapiens	24-34
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	182-191	platelet derived growth factor receptor beta	Homo sapiens	39-48
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	182-191	mechanistic target of rapamycin kinase	Homo sapiens	241-245
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	305-314	platelet derived growth factor receptor alpha	Homo sapiens	24-34
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	305-314	platelet derived growth factor receptor beta	Homo sapiens	39-48
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	305-314	mechanistic target of rapamycin kinase	Homo sapiens	241-245
34858182-7	2021	Combined exposure of rapamycin with the PDGFR inhibitor, imatinib significantly reduced the proliferation and migration of hPASMCs compared to either agent alone.	Sirolimus	21-30	platelet derived growth factor receptor beta	Homo sapiens	40-45
34765012-8	2021	We also found that QYLGT had the ability to activate phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	86-89
34858182-10	2021	Conclusion: Prolonged rapamycin treatment activates PDGFR signaling, in part, via mTORC2 inhibition.	Sirolimus	22-31	platelet derived growth factor receptor beta	Homo sapiens	52-57
34858401-8	2021	Notably, TBK1 inhibition prevented LPS-induced NLRP3 inflammasome activation by targeting the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	114-123	NLR family pyrin domain containing 3	Homo sapiens	47-52
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	thymoma viral proto-oncogene 1	Mus musculus	121-124
34732225-11	2021	The log-rank test showed that the RFS of the sirolimus group (sirolimus use after SPC) was significantly better than that of the non-sirolimus group (p = 0.001), and no significant difference was observed for other factors.	Sirolimus	45-54	surfactant protein C	Homo sapiens	82-85
34732225-12	2021	CONCLUSION: We first reported sirolimus might effectively suppress the recurrence of pneumothoraces in LAM patients who received SPC.	Sirolimus	30-39	surfactant protein C	Homo sapiens	129-132
34765012-8	2021	We also found that QYLGT had the ability to activate phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	125-129
34765012-9	2021	Treatment with PI3K inhibitors, LY294002 and wortmannin, or mTOR inhibitors, rapamycin and Torin 1, could not only recover QYLGT-inhibited cell viability of NPC cells but also inhibit Atg3 expression.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	60-64
34711683-8	2021	Calcineurin was also found to be required for the phosphorylation of ER-alpha at Ser118 by mechanistic target of rapamycin complex 1 and the consequent activation of ER-alpha in response to beta-estradiol treatment.	Sirolimus	113-122	estrogen receptor 1	Homo sapiens	69-77
34711683-8	2021	Calcineurin was also found to be required for the phosphorylation of ER-alpha at Ser118 by mechanistic target of rapamycin complex 1 and the consequent activation of ER-alpha in response to beta-estradiol treatment.	Sirolimus	113-122	estrogen receptor 1	Homo sapiens	166-174
34099592-3	2021	Pharmacological inhibitors of mTOR, such as rapamycin and Torin2, markedly suppressed the mRNA level as well as the protein level of HMMR in LNCaP and PC-3 cells.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	30-34
34099592-8	2021	Furthermore, the upregulation of HMMR by DHT was abolished by stimulation with rapamycin, prior to DHT treatment, suggesting that mTOR activity is required for the induction of HMMR expression by androgen.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	130-134
34233960-0	2021	Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells.	Sirolimus	0-9	nuclear receptor subfamily 1, group I, member 3	Mus musculus	80-83
34233960-7	2021	Subsequent investigations revealed that aberrantly activated mTORC1 signaling in CAR-T cells results in decreased bone marrow infiltration and decreased the levels of the rapamycin target CXCR4.	Sirolimus	171-180	nuclear receptor subfamily 1, group I, member 3	Mus musculus	81-84
34233960-8	2021	Attenuating mTORC1 activity with the rapamycin pretreatment increased the capacity of CAR-T cells to infiltrate bone marrow and enhanced the extent of bone marrow AML cell elimination in leukemia xenograft mouse models.	Sirolimus	37-46	nuclear receptor subfamily 1, group I, member 3	Mus musculus	86-89
34560177-11	2021	We detected the changes in autophagy marker protein LC3-II and lipid accumulation using an AKT inhibitor ARQ-092 or a mTOR inhibitor rapamycin in HepG2 cells.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	118-122
34560177-12	2021	Compared with 1,3-DCP group, lipid accumulation was decreased, LC3-II and FOXO1 nuclear localization were increased, p-FOXO1 levels were decreased in HepG2 cells pretreated with ARQ-092 or rapamycin.	Sirolimus	189-198	forkhead box O1	Homo sapiens	74-79
34560177-12	2021	Compared with 1,3-DCP group, lipid accumulation was decreased, LC3-II and FOXO1 nuclear localization were increased, p-FOXO1 levels were decreased in HepG2 cells pretreated with ARQ-092 or rapamycin.	Sirolimus	189-198	forkhead box O1	Homo sapiens	119-124
34364639-9	2021	Also, IGF-1-induced XBP1s and ER biogenesis-associated gene expression was inhibited by rapamycin, an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), indicating that IRE1-XBP1 activation by IGF-1 is mediated by mTORC1.	Sirolimus	88-97	insulin like growth factor 1	Homo sapiens	6-11
34603530-13	2021	The knockdown effects of NF1-siRNA on the autophagy and osteogenic differentiation of BMSCs were reversed by the autophagy activator RAPA, while the overexpression effects of NF1-pcDNA3.0 on the autophagy and osteogenic differentiation of BMSCs were reversed by the autophagy inhibitor 3-MA.	Sirolimus	133-137	neurofibromin 1	Homo sapiens	25-28
34551966-8	2021	Our results show that TLR-4-induced IFN-gamma production is regulated by the ribosomal protein S6 kinase (p70S6K) through the activation of PI3K, the mammalian target of rapamycin complex 1/2 (mTORC1/2), and the JNK MAPK pathways.	Sirolimus	170-179	interferon gamma	Homo sapiens	36-45
34561230-5	2021	IFN-gamma stimulation conferred on M0 macrophages the sensitivity to SM-induced cell death through the Jak/STAT, IFN regulatory factor-1, and mammalian target of rapamycin complex-1 (mTORC-1)/ribosomal protein S6 kinase pathways.	Sirolimus	162-171	interferon gamma	Homo sapiens	0-9
34364639-9	2021	Also, IGF-1-induced XBP1s and ER biogenesis-associated gene expression was inhibited by rapamycin, an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), indicating that IRE1-XBP1 activation by IGF-1 is mediated by mTORC1.	Sirolimus	88-97	insulin like growth factor 1	Homo sapiens	205-210
34478760-8	2021	Knocking down Raptor in Caco-2 cells or treating Caco-2 cells with rapamycin enhanced Caco-2 TNFalpha gene expression revealing the anti-inflammatory role of a functional mTORC1 in intestinal epithelial cells exposed to macrophage-derived pro-inflammatory stimuli.	Sirolimus	67-76	tumor necrosis factor	Homo sapiens	93-101
34638024-10	2021	In terms of LBR, PBMCs (2.96, 1.67-5.27) and sirolimus (3.55, 1.18-10.64) were effective.	Sirolimus	45-54	lamin B receptor	Homo sapiens	12-15
34498712-8	2021	The results showed that the expression levels of collagen-I (COL-I) and alpha-smooth muscle actin (alpha-SMA) were increased in miR221-overexpressing LX2 cells, while the autophagy inducer rapamycin reversed the inhibition of autophagic flux induced by miR221.	Sirolimus	189-198	actin alpha 1, skeletal muscle	Homo sapiens	99-108
34534609-5	2021	The enhancement of H2S donors on autophagic flux was mediated by adenosine 5"-monophosphate-activated protein kinase (AMPK)-dependent mammalian target of rapamycin (mTOR) inhibition, as H2S donors activated AMPK but reduced the mTOR activity and H2S donors-induced LC3-II increase was diminished by mTOR activator.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	165-169
34224916-6	2021	Furthermore, MTORC1 inhibition reduced both intracellular and secreted glucagon in rapamycin-treated mice, in response to hypoglycaemia.	Sirolimus	83-92	origin recognition complex, subunit 1	Mus musculus	13-19
34224916-6	2021	Furthermore, MTORC1 inhibition reduced both intracellular and secreted glucagon in rapamycin-treated mice, in response to hypoglycaemia.	Sirolimus	83-92	glucagon	Homo sapiens	71-79
34757123-6	2022	The mTOR inhibitor, rapamycin, completely abolished activation of mTORC1 and mTORC2 after long term treatment with receptor antibodies.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34778262-2	2021	In response to nutrient shortage and stresses, the TSC complex inhibits the mechanistic target of rapamycin complex 1 (mTORC1) at the lysosomes.	Sirolimus	98-107	TSC complex subunit 1	Homo sapiens	51-54
34853810-1	2021	Loss of function of tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) leads to the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	116-125	TSC complex subunit 1	Homo sapiens	55-59
34986526-7	2021	Compared with the model group, the differentiation level of Treg cells in the rapamycin group was significantly increased, the proliferation level of CD4CD25 T cells was decreased, and the phosphorylations of the mTORC1/2 substrates, S6 protein and Akt were decreased (all <0.05).	Sirolimus	78-87	thymoma viral proto-oncogene 1	Mus musculus	249-252
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	59-68	thymoma viral proto-oncogene 1	Mus musculus	76-79
34689411-7	2022	Rapamycin co-treatment also augmented the expression of HSP70 and activation of AKT, which could recover proteostasis and promote cell survival, respectively.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	80-83
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	59-68	thymoma viral proto-oncogene 1	Mus musculus	80-83
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	128-137	thymoma viral proto-oncogene 1	Mus musculus	76-79
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	128-137	thymoma viral proto-oncogene 1	Mus musculus	80-83
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	215-224	thymoma viral proto-oncogene 1	Mus musculus	76-79
34689241-8	2021	RESULTS: After pretreatment with LY294002, Triciribine and Rapamycin, the p-Akt/Akt ratio of pathway protein in Triciribine and Rapamycin groups decreased (P < 0.05), while the autophagy protein LC3-II/LC3-I in the Rapamycin group was upregulated obviously (P < 0.001).	Sirolimus	215-224	thymoma viral proto-oncogene 1	Mus musculus	80-83
34689241-10	2021	CONCLUSION: Pretreatment with Triciribine or Rapamycin has a greater effect on pathway protein Akt, cell cycle arrest, autophagy protein, and cell proliferation but with inconsistent magnitude, which may be inferred that the Akt/mTOR pathway, as well as its feedback loop, were more likely involved in these processes.	Sirolimus	45-54	thymoma viral proto-oncogene 1	Mus musculus	95-98
34689241-10	2021	CONCLUSION: Pretreatment with Triciribine or Rapamycin has a greater effect on pathway protein Akt, cell cycle arrest, autophagy protein, and cell proliferation but with inconsistent magnitude, which may be inferred that the Akt/mTOR pathway, as well as its feedback loop, were more likely involved in these processes.	Sirolimus	45-54	thymoma viral proto-oncogene 1	Mus musculus	225-228
34735882-1	2021	Abnormal activation of the mechanistic target of rapamycin (mTOR) signaling is commonly observed in many cancers and attracts extensive attention as an oncology drug discovery target, which is encouraged by the success of rapamycin and its analogs (rapalogs) in treatment of mTORC1-hyperactive cancers in both pre-clinic models and clinical trials.	Sirolimus	222-231	mechanistic target of rapamycin kinase	Homo sapiens	27-58
34706270-0	2022	Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	18-23
34706270-4	2022	In this study, we use a chemical proteomics strategy that has identified STAT3, a transcription factor considered to be undruggable, as a direct functional protein target of rapamycin.	Sirolimus	174-183	signal transducer and activator of transcription 3	Mus musculus	73-78
34706270-6	2022	Furthermore, we show that rapamycin suppresses tumor growth along with a decreased expression of STAT3 and c-Myc in an in vivo xenograft mouse model for hepatocellular carcinoma.	Sirolimus	26-35	signal transducer and activator of transcription 3	Mus musculus	97-102
34706270-7	2022	Our data suggest that rapamycin acts directly on STAT3 to decrease its transcription activity, providing important information for the pharmacological and pharmaceutical development of STAT3 inhibitors for cancer therapy.	Sirolimus	22-31	signal transducer and activator of transcription 3	Mus musculus	49-54
34706270-7	2022	Our data suggest that rapamycin acts directly on STAT3 to decrease its transcription activity, providing important information for the pharmacological and pharmaceutical development of STAT3 inhibitors for cancer therapy.	Sirolimus	22-31	signal transducer and activator of transcription 3	Mus musculus	185-190
34735882-1	2021	Abnormal activation of the mechanistic target of rapamycin (mTOR) signaling is commonly observed in many cancers and attracts extensive attention as an oncology drug discovery target, which is encouraged by the success of rapamycin and its analogs (rapalogs) in treatment of mTORC1-hyperactive cancers in both pre-clinic models and clinical trials.	Sirolimus	222-231	mechanistic target of rapamycin kinase	Homo sapiens	60-64
34669157-3	2021	In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and the combination of cabozantinib and mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exhibited a synergistic inhibitory effect on the in vitro cell proliferation and in vivo tumor growth of these cells.	Sirolimus	182-191	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	29-33
34675258-7	2021	Akt phosphorylation and activation was indispensable for rapamycin-induced TCTP degradation and PLK1 activation, and depended on S6K inhibition, but not mTORC2 activation.	Sirolimus	57-66	AKT serine/threonine kinase 1	Homo sapiens	0-3
34669157-3	2021	In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and the combination of cabozantinib and mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exhibited a synergistic inhibitory effect on the in vitro cell proliferation and in vivo tumor growth of these cells.	Sirolimus	182-191	mechanistic target of rapamycin kinase	Homo sapiens	134-163
34669157-3	2021	In this study, we found that cMet-low HCC cells showed primary resistance to cMet inhibitors, and the combination of cabozantinib and mammalian target of rapamycin (mTOR) inhibitor, rapamycin, exhibited a synergistic inhibitory effect on the in vitro cell proliferation and in vivo tumor growth of these cells.	Sirolimus	182-191	mechanistic target of rapamycin kinase	Homo sapiens	165-169
34669157-4	2021	Mechanically, the combination of rapamycin with cabozantinib resulted in the remarkable inhibition of AKT, extracellular signal-regulated protein kinases, mTOR, and common downstream signal molecules of receptor tyrosine kinases; decreased cyclin D1 expression; and induced cell cycle arrest.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	102-105
34669157-4	2021	Mechanically, the combination of rapamycin with cabozantinib resulted in the remarkable inhibition of AKT, extracellular signal-regulated protein kinases, mTOR, and common downstream signal molecules of receptor tyrosine kinases; decreased cyclin D1 expression; and induced cell cycle arrest.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	155-159
34669157-5	2021	Meanwhile, rapamycin enhanced the inhibitory effects of cabozantinib on the migration and tubule formation of human umbilical vascular endothelial cells and human growth factor-induced invasion of cMet inhibitor-resistant HCC cells under hypoxia condition.	Sirolimus	11-20	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	197-201
34321280-1	2021	PURPOSE: To evaluate the safety and tolerability in phase 1 first-in-human combination therapy with pexidartinib, an inhibitor of colony-stimulating factor-1 receptor, and sirolimus, an mTOR inhibitor, to target tumor associated macrophage (TAM) polarization in soft tissue sarcomas (STSs).	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	186-190
34644574-3	2021	Using conditional mutagenesis and chemogenetics, we show that blockade of the energy sensor mechanistic target of rapamycin complex 1 (mTORC1) in POMC neurons causes hyperphagia by mimicking a cellular negative energy state.	Sirolimus	114-123	proopiomelanocortin	Homo sapiens	146-150
34679726-10	2021	The mTOR inhibitor rapamycin produced a similar reduction in SGK1 mRNA and protein levels as well as phosphorylation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34635641-6	2021	Mechanistic studies have shown that MYH9 regulates stem cell-like features of LCCs by regulating the mTOR signaling pathway, which was supported by sphere formation experiments after LCCs were treated with inhibitors Rapamycin and CHIR-99021.	Sirolimus	217-226	myosin heavy chain 9	Homo sapiens	36-40
34635641-6	2021	Mechanistic studies have shown that MYH9 regulates stem cell-like features of LCCs by regulating the mTOR signaling pathway, which was supported by sphere formation experiments after LCCs were treated with inhibitors Rapamycin and CHIR-99021.	Sirolimus	217-226	mechanistic target of rapamycin kinase	Homo sapiens	101-105
34790050-13	2021	Rapamycin, an inhibitor of mTOR, remarkably abolished UBE2O-induced mTOR phosphorylation and HCC cell proliferation and mobility.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
34790050-13	2021	Rapamycin, an inhibitor of mTOR, remarkably abolished UBE2O-induced mTOR phosphorylation and HCC cell proliferation and mobility.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	68-72
34126195-13	2021	Rapamycin decreased phosphorylated S6K, Gli2 and PD-L1 expression in PDO/immune cell co-cultures.	Sirolimus	0-9	GLI family zinc finger 2	Homo sapiens	40-44
34610303-2	2021	The serum- and glucocorticoid-regulated family of protein kinases (SGK) is activated downstream of mechanistic target of rapamycin complex 2 (mTORC2) in response to insulin in parallel to AKT.	Sirolimus	121-130	thymoma viral proto-oncogene 1	Mus musculus	188-191
34685691-5	2021	Moreover, analysis of SZT2 ablated cells revealed increased mTORC1 signaling activation that could be reversed by Rapamycin or Torin treatments.	Sirolimus	114-123	SZT2 subunit of KICSTOR complex	Homo sapiens	22-26
34082015-17	2021	Furthermore, the effects of SZL on myelin proteins, p-Akt, and p-mTOR were clearly inhibited by LY294002 and/or rapamycin, antagonists of PI3K and m-TOR, respectively.	Sirolimus	112-121	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
34543777-12	2021	Treatment of rapamycin and let-7i-5p inhibitor reversed the effects of downregulated DICER in cell viability, ratio of LC3-II/LC3-I, autophagosomes, cell apoptosis rate and the phosphorylation levels of PI3K/AKT/mTOR in A549/DDP cells.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	208-211
34543777-12	2021	Treatment of rapamycin and let-7i-5p inhibitor reversed the effects of downregulated DICER in cell viability, ratio of LC3-II/LC3-I, autophagosomes, cell apoptosis rate and the phosphorylation levels of PI3K/AKT/mTOR in A549/DDP cells.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	212-216
34384247-7	2021	Finally, we demonstrated that the time-dependent therapeutic effects are conserved in a mouse AIC model and that spironolactone and rapamycin activated autophagy in an Atg7-dependent fashion.	Sirolimus	132-141	autophagy related 7	Mus musculus	168-172
34351835-4	2021	Drugs targeting mTOR and AMPK, such as sirolimus, rapamycin, and metformin, have shown some efficacy and tolerability in clinical trials on patients with SLE, but have not led to breakthroughs.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	16-20
34119651-0	2021	Review: Schistosoma mansoni phosphatidylinositol 3 kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	65-68
34119651-0	2021	Review: Schistosoma mansoni phosphatidylinositol 3 kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	102-106
34351835-4	2021	Drugs targeting mTOR and AMPK, such as sirolimus, rapamycin, and metformin, have shown some efficacy and tolerability in clinical trials on patients with SLE, but have not led to breakthroughs.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	16-20
34547141-3	2021	We firstly investigated the role of autophagy in SWH-induced wound closure rate, inflammatory response, and histopathology, utilizing an inhibitor of autophagy 3-methyladenine (3-MA) and its agonist rapamycin (RAP).	Sirolimus	199-208	regulatory associated protein of MTOR, complex 1	Mus musculus	210-213
34475980-0	2021	Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	30-33
34475980-0	2021	Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	34-38
34475980-10	2021	In addition, SIRT1 transfection rescued the decreased level of phosphorylated (p)-PI3K, p-AKT and p-mTOR induced by rapamycin treatment.	Sirolimus	116-125	AKT serine/threonine kinase 1	Homo sapiens	90-93
34475980-10	2021	In addition, SIRT1 transfection rescued the decreased level of phosphorylated (p)-PI3K, p-AKT and p-mTOR induced by rapamycin treatment.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	100-104
34475980-11	2021	Taken together, the present results suggested that rapamycin suppressed the cell viability, migration, invasion and PI3K/AKT/mTOR signaling pathway in EC by negatively regulating SIRT1.	Sirolimus	51-60	AKT serine/threonine kinase 1	Homo sapiens	121-124
34475980-11	2021	Taken together, the present results suggested that rapamycin suppressed the cell viability, migration, invasion and PI3K/AKT/mTOR signaling pathway in EC by negatively regulating SIRT1.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	125-129
34298397-8	2021	Neutrophil number was decreased in the peripheral blood of IF1-KO mice, which was associated with a reduction in LC3A/B proteins in the KO neutrophils in Rapamycin-induced autophagy response.	Sirolimus	154-163	NDV-induced circulating interferon	Mus musculus	59-62
34155681-3	2021	Here, we demonstrated that Rictor, a key component of mechanistic target of rapamycin complex 2 (mTORC2), was crucial for TRAF6/TRAF3 expression in osteoclasts.	Sirolimus	76-85	TNF receptor-associated factor 6	Mus musculus	122-127
34168367-3	2021	These "bi-steric inhibitors" comprise a rapamycin-like core moiety covalently linked to an mTOR active-site inhibitor.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	91-95
34795945-10	2021	Notably, ezrin deletion in autophagic TAMs induced by rapamycin reduced TGF-beta1 expression and suppressed EMT in lung adenocarcinoma cells.	Sirolimus	54-63	transforming growth factor beta 1	Homo sapiens	72-81
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	AKT serine/threonine kinase 1	Homo sapiens	141-144
34818236-0	2022	GPR43 Suppresses Intestinal Tumor Growth by Modification of the Mammalian Target of Rapamycin Complex 1 Activity in ApcMin/+ Mice.	Sirolimus	84-93	free fatty acid receptor 2	Homo sapiens	0-5
34818236-9	2022	CONCLUSION: Collectively, GPR43 affords protection against tumor growth at least partly through inhibition of the mammalian target of rapamycin complex 1 pathway.	Sirolimus	134-143	free fatty acid receptor 2	Homo sapiens	26-31
34365138-4	2021	Regarding the cytological smear samples, RPM supplementation tended to increase mRNA expression of methionine adenosyltransferase 1 alpha (MAT1A) and increased the mRNA expression of fibroblast growth factor 7 (FGF7), with an effect of time for the latter.	Sirolimus	41-44	methionine adenosyltransferase 1A	Bos taurus	99-137
34365138-4	2021	Regarding the cytological smear samples, RPM supplementation tended to increase mRNA expression of methionine adenosyltransferase 1 alpha (MAT1A) and increased the mRNA expression of fibroblast growth factor 7 (FGF7), with an effect of time for the latter.	Sirolimus	41-44	methionine adenosyltransferase 1A	Bos taurus	139-144
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	177-206
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	208-212
34585416-2	2022	Here, we show that mechanistic target of rapamycin complex 2 (mTORC2)-dependent Akt activation is instrumental for metabolic reprogramming at the early stages of macrophage-mediated immunity.	Sirolimus	41-50	AKT serine/threonine kinase 1	Homo sapiens	80-83
34627459-2	2021	Sirolimus, as an immunosuppressant against of mTOR, induces immune tolerance by adjusting Treg cells, which has application prospect in the treatment of refractory autoimmune cytopenia.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
34712915-0	2021	Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-61
34544857-1	2021	Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are caused by aberrant mechanistic Target of Rapamycin Complex 1 (mTORC1) activation due to loss of either TSC1 or TSC2 Cytokine profiling of TSC2-deficient LAM patient-derived cells revealed striking up-regulation of Interleukin-6 (IL-6).	Sirolimus	113-122	TSC complex subunit 1	Homo sapiens	28-31
34712915-3	2021	The FKBP12-mTOR association can be strengthened by the immunosuppressant rapamycin, but the underlying mechanism remains elusive.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	11-15
34712915-10	2021	In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	44-48
34712915-10	2021	In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	68-72
34554926-7	2021	In addition, the mechanism of action of miR-19b-3p was clarified using the PTEN inhibitor (VO-Ohpic triphosphate) or the mTOR inhibitor (Rapamycin) on the basis of IL-1beta intervention and miR-19b-3p mimics transfection.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	121-125
34632383-2	2021	The main cellular activity of the mechanistic target of rapamycin cascade funnels through mechanistic target of rapamycin complex 1, which is inhibited by rapamycin, a macrolide compound produced by the bacterium Streptomyces hygroscopicus.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	34-65
34632383-2	2021	The main cellular activity of the mechanistic target of rapamycin cascade funnels through mechanistic target of rapamycin complex 1, which is inhibited by rapamycin, a macrolide compound produced by the bacterium Streptomyces hygroscopicus.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	34-65
34518220-8	2021	mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability.	Sirolimus	23-32	tripartite motif containing 28	Homo sapiens	65-71
34390347-7	2021	The MLH complex containing FRB and FKBP domains in the Mlh1 IDR displayed a rapamycin-dependent defect in Mlh1-Pms1 endonuclease activity.	Sirolimus	76-85	ATP-binding mismatch repair protein	Saccharomyces cerevisiae S288C	111-115
34572126-6	2021	Rapamycin preconditioning resulted in activated autophagy and improved survival of ADSCs achieved by increased autophagosomes, upregulated autophagy-specific LC3-II gene, decreased protein degradation/ubiquitination by downregulated p62 gene, downregulated mTOR gene, and finally, upregulated antiapoptotic BCL-2 gene.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	257-261
34537895-3	2021	In continuation to the earlier work, the present study was devised to explore the role of rapamycin (mTOR inhibitor and clinically used immunosuppressive agent) in a zebrafish kindling model and associated cardiac damage.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Danio rerio	101-105
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	signal transducer and activator of transcription 3 (acute-phase response factor)	Danio rerio	59-64
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	thioredoxin reductase 3	Danio rerio	118-123
34537895-11	2021	Furthermore, rapamycin treatment also decreased p-mTOR expression and protein carbonyls level in the fish cardiac tissue.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Danio rerio	50-54
34537895-12	2021	The present study concluded that rapamycin reduces seizures and associated cardiac damage by inhibiting mTOR activation in the zebrafish kindling model.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Danio rerio	104-108
34572126-6	2021	Rapamycin preconditioning resulted in activated autophagy and improved survival of ADSCs achieved by increased autophagosomes, upregulated autophagy-specific LC3-II gene, decreased protein degradation/ubiquitination by downregulated p62 gene, downregulated mTOR gene, and finally, upregulated antiapoptotic BCL-2 gene.	Sirolimus	0-9	BCL2 apoptosis regulator	Homo sapiens	307-312
34531361-2	2021	For this reason, the mammalian target of rapamycin inhibitors (mTORi) such as sirolimus (SRL) and everolimus (EVE) has been preferred more frequently, as they are associated with fewer complications and longer graft function.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	21-50
34543857-9	2021	Consistently, SKO cells were more responsive to mTOR inhibition by rapamycin and presented impairment of the feedback activation loop in Akt.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	48-52
34603030-8	2021	On HT-22 cells induced by autophagy inducer rapamycin, NGR1 markedly attenuated excessive autophagy and apoptosis, and the alleviative effect was abolished by the MTNR1A inhibitor.	Sirolimus	44-53	reticulon 4 receptor	Mus musculus	55-59
34518579-4	2021	Embryonic stem cells from this mouse model were used to study the onset, progression, and therapeutic remediation of TDP-43 aggregates using a novel microfluidic rapamycin concentration gradient generator.	Sirolimus	162-171	TAR DNA binding protein	Mus musculus	117-123
34114360-2	2021	First-generation mTOR inhibitors include rapamycin and its analogues (rapalogs) which act as allosteric inhibitors of TORC1.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	17-21
34493557-3	2021	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is frequently used as a second-line maintenance immunosuppressive agent in solid organ transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
34243067-8	2021	Intriguingly, rapamycin treatment did not reverse insulin resistance but alleviated adipose tissue inflammation caused by Depdc5 deletion.	Sirolimus	14-23	DEP domain containing 5	Mus musculus	122-128
34493557-3	2021	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is frequently used as a second-line maintenance immunosuppressive agent in solid organ transplant recipients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
34494222-11	2021	Akt/mTOR/ p70S6K signaling cascade was proved to be present in NPCs, IGF-I overexpression significantly activated Akt/mTOR/p70S6K signaling cascade, while rapamycin addition inhibited its expression.	Sirolimus	155-164	AKT serine/threonine kinase 1	Rattus norvegicus	0-3
34089901-5	2021	The activation of mammalian target of rapamycin (mTOR) signaling is one of the core and detrimental mechanisms related to aging; rapamycin can reduce the rate of aging, improve age-related diseases by inhibiting the mTOR pathway, and prolong lifespan and healthspan effectively.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	18-47
34089901-5	2021	The activation of mammalian target of rapamycin (mTOR) signaling is one of the core and detrimental mechanisms related to aging; rapamycin can reduce the rate of aging, improve age-related diseases by inhibiting the mTOR pathway, and prolong lifespan and healthspan effectively.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	49-53
34089901-5	2021	The activation of mammalian target of rapamycin (mTOR) signaling is one of the core and detrimental mechanisms related to aging; rapamycin can reduce the rate of aging, improve age-related diseases by inhibiting the mTOR pathway, and prolong lifespan and healthspan effectively.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	216-220
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	112-121	activating transcription factor 4	Mus musculus	80-84
34533799-1	2021	OBJECTIVE: To investigate the pharmacodynamic mechanism of curcumin against myocardial ischaemia-reperfusion injury by regulating the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/rapamycin target protein (mTOR) signalling pathway.	Sirolimus	194-203	AKT serine/threonine kinase 1	Rattus norvegicus	189-192
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	activating transcription factor 4	Mus musculus	80-84
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	activating transcription factor 4	Mus musculus	227-231
34242625-7	2021	Furthermore, we inhibited HIF1-alpha with PX-478 and inactivated mTOR with Rapamycin before the silence of PTEN in H/R model.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	65-69
34405459-2	2021	The aim of this study was to compare the protracted effects of adolescent versus late-adolescent chronic exposure to THC on short-term memory and plasticity, and to examine whether rapamycin, a blocker of the mammalian target of rapamycin (mTOR) pathway, can restore THC-induced deficits in memory and plasticity.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	209-238
34405459-2	2021	The aim of this study was to compare the protracted effects of adolescent versus late-adolescent chronic exposure to THC on short-term memory and plasticity, and to examine whether rapamycin, a blocker of the mammalian target of rapamycin (mTOR) pathway, can restore THC-induced deficits in memory and plasticity.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	240-244
34304249-6	2021	The mTOR inhibitors, rapamycin and NVP-BEZ235, induced cell cycle arrest and apoptosis in CR cell lines.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34331013-4	2021	The mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested, potently induced tumor-suppressive autophagy, but not apoptosis.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	4-8
34523354-0	2021	Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation.	Sirolimus	78-87	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	21-27
34247114-10	2021	Mechanism investigations further approved that either CXCL1 overexpression or autophagic activator rapamycin can significantly abrogated the anti-metastatic effects of ADQ formula, suggesting that CXCL1-mediated autophagy may be the crucial pathway of ADQ formula in suppressing breast cancer metastasis.	Sirolimus	99-108	chemokine (C-X-C motif) ligand 1	Mus musculus	197-202
34703880-6	2021	Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT.	Sirolimus	185-194	superoxide dismutase 1	Homo sapiens	41-63
34214676-10	2021	Moreover, PA interacts with the rapamycin binding domain of mTOR, demonstrated by the molecular dynamic (MD) simulation and binding free energy calculations.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	60-64
34577576-0	2021	Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling.	Sirolimus	42-51	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	133-136
34522186-11	2021	Furthermore, inhibition of the AKT/mTOR signaling by MK2206 or rapamycin significantly attenuated PRMT4-mediated malignant phenotypes.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	35-39
34512728-12	2021	We observed that the target proteins of the FDA-approved drug rapamycin (a known inhibitor of mTOR) were conserved across all four species.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	94-98
34540765-5	2021	Targeted therapies with PI3Kdelta-Akt-mTOR pathway pharmacologic inhibitors (i.e., Rapamycin, Theophylline, PI3K inhibitors) represent a good therapeutic strategy.	Sirolimus	83-92	AKT serine/threonine kinase 1	Homo sapiens	34-37
34522186-11	2021	Furthermore, inhibition of the AKT/mTOR signaling by MK2206 or rapamycin significantly attenuated PRMT4-mediated malignant phenotypes.	Sirolimus	63-72	AKT serine/threonine kinase 1	Homo sapiens	31-34
34540765-5	2021	Targeted therapies with PI3Kdelta-Akt-mTOR pathway pharmacologic inhibitors (i.e., Rapamycin, Theophylline, PI3K inhibitors) represent a good therapeutic strategy.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	38-42
34175438-1	2021	Proline rich Akt substrate (PRAS40) is a component of mammalian target of rapamycin complex 1 (mTORC1) and activated mTORC1 plays important roles for cellular survival in response to oxidative stress.	Sirolimus	74-83	AKT1 substrate 1	Homo sapiens	28-34
34385317-2	2021	Toll-like receptor (TLR)7/9- and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-mediated inflammatory responses require SLC15A4 function for regulating the mechanistic target of rapamycin complex 1 (mTORC1) or transporting L-Ala-gamma-D-Glu-meso-diaminopimelic acid, IL-12: interleukin-12 (Tri-DAP), respectively.	Sirolimus	201-210	solute carrier family 15, member 4	Mus musculus	143-150
34416638-10	2021	Moreover, Akt and mTOR inhibition by using LY294002 and rapamycin, respectively, blocked inflammatory cytokine overexpression induced by TCS.	Sirolimus	56-65	thymoma viral proto-oncogene 1	Mus musculus	10-13
34381142-6	2021	VEGF-A, VEGF receptor 2, and the co-receptor Neuropilin-1 were upregulated by Rapamycin within 7 days.	Sirolimus	78-87	neuropilin 1	Rattus norvegicus	45-57
34445471-1	2021	The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is activated by the small G-protein, Ras homolog enriched in brain (RHEB-GTPase).	Sirolimus	36-45	Rac family small GTPase 2	Homo sapiens	85-100
34527488-5	2021	Use of sirolimus in a patient with renal transplant recipient helped in preventing intensification of the severity in COVID-19 attributing to its inhibiting effect on mammalian target of rapamycin (mTOR) which he was using post his renal transplant, therefore, proving to be a blessing in disguise.	Sirolimus	7-16	mechanistic target of rapamycin kinase	Homo sapiens	167-196
34527488-5	2021	Use of sirolimus in a patient with renal transplant recipient helped in preventing intensification of the severity in COVID-19 attributing to its inhibiting effect on mammalian target of rapamycin (mTOR) which he was using post his renal transplant, therefore, proving to be a blessing in disguise.	Sirolimus	7-16	mechanistic target of rapamycin kinase	Homo sapiens	198-202
34445344-6	2021	Rapamycin, as an mTOR inhibitor, blocked T3-induced autophagic suppression and UCP1 upregulation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	17-21
34445268-2	2021	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has a proven efficacy in patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
34368895-2	2022	Our previous study showed that inhibition of MTOR with rapamycin treatment suppressed human endothelial cell tube formation, concomitant with the down-regulation of miR-107.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	45-49
34445268-2	2021	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has a proven efficacy in patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
34445268-7	2021	Sirolimus showed efficacy in patients with LAM, who exhibited a reduced expression of mTOR and p-cofilin as well as reduced interstitial septal thickness.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	86-90
34445268-8	2021	In addition, sirolimus suppresses mTOR and p-cofilin, thus suppressing the migration and proliferation of LAM cells isolated from the patient"s lung tissue.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	34-38
34452154-1	2021	The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	66-69
34452418-7	2021	Besides that, rapamycin could disturb the expression of p62 and LC3B-II, and the transcription level of SCRV nucleoprotein mRNA.	Sirolimus	14-23	nucleoprotein	Siniperca chuatsi rhabdovirus	109-122
34452154-1	2021	The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	106-110
34590575-5	2021	Fatty acids and glucose metabolites are involved in regulation of immune response mainly via free fatty acid receptors and AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	188-192
34341336-5	2021	PLA enhanced FGFBP1 expression through activation of the mechanistic target of rapamycin complex 1-signal transducer and activator of transcription 3 (mTORC1-STAT3) signaling pathway.	Sirolimus	79-88	signal transducer and activator of transcription 3	Mus musculus	99-149
34341336-5	2021	PLA enhanced FGFBP1 expression through activation of the mechanistic target of rapamycin complex 1-signal transducer and activator of transcription 3 (mTORC1-STAT3) signaling pathway.	Sirolimus	79-88	signal transducer and activator of transcription 3	Mus musculus	158-163
34361836-1	2021	Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	107-111
34102263-3	2021	Additionally, the therapeutic effects of rapamycin, an allosteric inhibitor of mammalian target of rapamycin (mTOR), which negatively regulates autophagy, on the sensory disturbance are not fully investigated.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	79-108
34102263-3	2021	Additionally, the therapeutic effects of rapamycin, an allosteric inhibitor of mammalian target of rapamycin (mTOR), which negatively regulates autophagy, on the sensory disturbance are not fully investigated.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	110-114
34394184-8	2021	Then, the combined application of overexpressed PDK1 and rapamycin verified that PDK1 could regulate the expression of PD-L1 in NSCLC cells through the mTOR signaling pathway.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	152-156
34331820-1	2022	The mammalian target of rapamycin inhibitor (mTOR-I) Rapamycin, a drug widely used in kidney transplantation, exerts important anti-cancer effects, particularly in Kaposi"s Sarcoma (KS), through several biological interactions.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	4-33
34331820-7	2022	In conclusion, our in vitro data demonstrated, for the first time, that in Kaposi"s sarcoma, autophagy triggered by Rapamycin through p75NTR represented a major mechanism by which mTOR inhibitors may induce tumor regression.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	180-184
34594200-3	2021	Variable therapeutic modalities were used in the management of BRBNS; sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, is found to be a promising therapy for vascular anomalies.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	89-118
34594200-3	2021	Variable therapeutic modalities were used in the management of BRBNS; sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, is found to be a promising therapy for vascular anomalies.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	120-124
34594200-3	2021	Variable therapeutic modalities were used in the management of BRBNS; sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, is found to be a promising therapy for vascular anomalies.	Sirolimus	81-84	mechanistic target of rapamycin kinase	Homo sapiens	89-118
34594200-3	2021	Variable therapeutic modalities were used in the management of BRBNS; sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, is found to be a promising therapy for vascular anomalies.	Sirolimus	81-84	mechanistic target of rapamycin kinase	Homo sapiens	120-124
34360785-9	2021	The rapamycin + doxycycline combination did not cause apoptosis or necrosis/necroptosis, but the alterations in autophagy- and mitochondria-related protein levels (LC3-B-II/I, p62, MitoTracker, TOM20 and certain co-stainings) were correlated to autophagy induction and mitophagy, without mitochondria repopulation.	Sirolimus	4-13	translocase of outer mitochondrial membrane 20	Homo sapiens	194-199
34301883-1	2021	Tuberous sclerosis complex 1 (Tsc1) is a tumor suppressor that functions together with Tsc2 to negatively regulate the mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	141-150	TSC complex subunit 1	Homo sapiens	0-28
34301883-1	2021	Tuberous sclerosis complex 1 (Tsc1) is a tumor suppressor that functions together with Tsc2 to negatively regulate the mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	141-150	TSC complex subunit 1	Homo sapiens	30-34
34421360-5	2021	Here, we found that activation of ERK pathway was responsible for rapamycin drug resistance in non-small-cell lung cancer (NSCLC) cells.	Sirolimus	66-75	mitogen-activated protein kinase 1	Homo sapiens	34-37
34421360-6	2021	Accordingly, rapamycin-resistant NSCLC cells were more sensitive to ERK inhibitor (ERKi), trametinib, and in turn, trametinib-resistant NSCLC cells were also susceptible to rapamycin.	Sirolimus	13-22	mitogen-activated protein kinase 1	Homo sapiens	68-71
34421360-9	2021	Mechanistically, rapamycin in combination with trametinib resulted in a greater decrease of phosphorylation of AKT, ERK, mTOR and 4EBP1.	Sirolimus	17-26	AKT serine/threonine kinase 1	Homo sapiens	111-114
34421360-9	2021	Mechanistically, rapamycin in combination with trametinib resulted in a greater decrease of phosphorylation of AKT, ERK, mTOR and 4EBP1.	Sirolimus	17-26	mitogen-activated protein kinase 1	Homo sapiens	116-119
34421360-9	2021	Mechanistically, rapamycin in combination with trametinib resulted in a greater decrease of phosphorylation of AKT, ERK, mTOR and 4EBP1.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	121-125
34135202-5	2021	Based on these results we decided to test a novel treatment using sirolimus, an mTOR inhibitor, for epileptic seizures in patients with FCD type II.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	80-84
34354602-11	2021	Rapalink-1 significantly decreased phosphorylated S6 and Akt to half the level of the control rats in the IR-C, which suggests that both of the mechanistic target of rapamycin complex 1 and 2 (mTORC1 and mTORC2) were inhibited.	Sirolimus	166-175	AKT serine/threonine kinase 1	Rattus norvegicus	57-60
34440627-7	2021	The mutation in Eif2b5 prompts reactive oxygen species (ROS)-mediated inferior ability to stimulate the AMP-activated protein kinase (AMPK) axis, due to a requirement to increase the mammalian target of rapamycin complex-1 (mTORC1) signalling in order to enable oxidative glycolysis and generation of specific subclass of ROS-regulating proteins, similar to cancer cells.	Sirolimus	203-212	eukaryotic translation initiation factor 2B subunit epsilon	Homo sapiens	16-22
34349839-1	2021	Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, which encode proteins that antagonise the mammalian isoform of the target of rapamycin complex 1 (mTORC1) - a key mediator of cell growth and metabolism.	Sirolimus	184-193	TSC complex subunit 1	Homo sapiens	28-31
34281475-1	2021	BACKGROUND: Sirolimus constitutes a safe and effective treatment for cardiac manifestations of tuberous sclerosis complex (TSC) in children but only four cases describing prenatal treatment of rhabdomyomas with mTOR inhibitors have been published.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	211-215
34275490-7	2021	In vitro organotypic culture-induced activation of the PI3K/PTEN/Akt pathway is counteracted by cryopreservation with rapamycin and in vitro culture in the presence of LY294002.	Sirolimus	118-127	phosphatase and tensin homolog	Mus musculus	60-64
34275490-7	2021	In vitro organotypic culture-induced activation of the PI3K/PTEN/Akt pathway is counteracted by cryopreservation with rapamycin and in vitro culture in the presence of LY294002.	Sirolimus	118-127	thymoma viral proto-oncogene 1	Mus musculus	65-68
34349839-1	2021	Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, which encode proteins that antagonise the mammalian isoform of the target of rapamycin complex 1 (mTORC1) - a key mediator of cell growth and metabolism.	Sirolimus	184-193	TSC complex subunit 1	Homo sapiens	87-91
34401617-2	2021	Sirolimus is a mechanistic target of rapamycin inhibitor used as an immunosuppressive drug.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-46
34401617-4	2021	We have described the case of a patient with KTS receiving a therapeutic anticoagulation dose, for whom sirolimus was initiated, and who had presented with an extensive venous thromboembolism.	Sirolimus	104-113	KTWS	Homo sapiens	45-48
34282122-6	2021	Moreover, both AMP-activated protein kinase (AMPK) agonist metformin and two mammalian targets of rapamycin (mTOR) inhibitors (INK128 and rapamycin) inhibited the percentage of M-MDSCs in lupus mice as well as in the TLR7- and IFN-alpha-induced bone marrow (BM) differentiation into MDSCs in vitro.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	109-113
34235896-8	2021	Intravitreal administration of rapamycin, a negative regulator of mTOR, inhibits the mTOR pathway in rd1 photoreceptors.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	66-70
34235896-8	2021	Intravitreal administration of rapamycin, a negative regulator of mTOR, inhibits the mTOR pathway in rd1 photoreceptors.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	85-89
34282122-6	2021	Moreover, both AMP-activated protein kinase (AMPK) agonist metformin and two mammalian targets of rapamycin (mTOR) inhibitors (INK128 and rapamycin) inhibited the percentage of M-MDSCs in lupus mice as well as in the TLR7- and IFN-alpha-induced bone marrow (BM) differentiation into MDSCs in vitro.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	109-113
34356626-5	2021	Interestingly, circadian pathways hold an intricate relationship with autophagy, the mechanistic target of rapamycin (mTOR), the silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), mammalian forkhead transcription factors (FoxOs), and the trophic factor erythropoietin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	118-122
34326770-1	2021	Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	12-41
34326770-1	2021	Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	43-47
34244482-4	2021	Here we report that mechanistic target of rapamycin complex 1 (mTORC1) signal inhibits GLDC acetylation at lysine (K) 514 by inducing transcription of the deacetylase sirtuin 3 (SIRT3).	Sirolimus	42-51	sirtuin 3	Homo sapiens	167-176
34244482-4	2021	Here we report that mechanistic target of rapamycin complex 1 (mTORC1) signal inhibits GLDC acetylation at lysine (K) 514 by inducing transcription of the deacetylase sirtuin 3 (SIRT3).	Sirolimus	42-51	sirtuin 3	Homo sapiens	178-183
34236783-11	2022	As for cytokines, rapamycin or paclitaxel concentrations >=1 ug/mL could significantly increase the level of inflammatory cytokines IL-6 (P<0.05 or P<0.01), which was enhanced with the increase of drug concentration.	Sirolimus	18-27	interleukin 6	Homo sapiens	132-136
34238334-11	2021	Currently, there are no systemic agents that have regulatory approval for these disorders, but the mTOR inhibitor sirolimus has been used for several years in clinical trials and off label to address symptoms.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	99-103
34236783-12	2022	However, rapamycin or paclitaxel concentrations >=1 mug/mL could significantly reduce the levels of anti-inflammatory cytokines IL-35 and transforming growth factor beta (TGF-beta) (P<0.05 or P<0.01), which decreased with the increase of drug concentration.	Sirolimus	9-18	tumor necrosis factor	Homo sapiens	138-169
34221806-5	2021	Rapamycin treatment alleviated I/R-induced lung histopathologically injury and increased the concentration of MDA while decreased activity of SOD and expression of NLRP3, Caspase-1, interleukin-1beta (IL-1beta), and IL-18 in rat.	Sirolimus	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	164-169
34221806-5	2021	Rapamycin treatment alleviated I/R-induced lung histopathologically injury and increased the concentration of MDA while decreased activity of SOD and expression of NLRP3, Caspase-1, interleukin-1beta (IL-1beta), and IL-18 in rat.	Sirolimus	0-9	interleukin 1 beta	Rattus norvegicus	182-199
34221806-5	2021	Rapamycin treatment alleviated I/R-induced lung histopathologically injury and increased the concentration of MDA while decreased activity of SOD and expression of NLRP3, Caspase-1, interleukin-1beta (IL-1beta), and IL-18 in rat.	Sirolimus	0-9	interleukin 1 alpha	Rattus norvegicus	201-209
34221806-8	2021	In vitro experiments showed that LPS induction caused a significant increase in LOC102553434, MMP9, IL-1beta, and IL-18 in L2 cells, but rapamycin treatment significantly reversed the effects.	Sirolimus	137-146	interleukin 1 alpha	Rattus norvegicus	100-108
34221806-9	2021	After interfering with the expression of LOC102553434 in the LPS-injured cells pretreated with rapamycin, cell proliferation significantly increased, and the expression of MMP, NLRP3 and caspase-1 were significantly decreased.	Sirolimus	95-104	NLR family, pyrin domain containing 3	Rattus norvegicus	177-182
34087234-8	2021	Phosphorylation of p62 at Ser349 by mammalian target of rapamycin complex 1 (mTORC1), a critical step in p62-Keap1 interaction, was induced by I/R, but diminished by R1alpha loss.	Sirolimus	56-65	kelch like ECH associated protein 1	Homo sapiens	109-114
34215308-7	2021	Beyond rapamycin; an mTOR inhibitor, there are rapalogs having greater tolerability and micro delivery modes, that hold promise in arresting these age dependent conditions.	Sirolimus	7-16	mechanistic target of rapamycin kinase	Homo sapiens	21-25
34209274-4	2021	The mammalian target of the Rapamycin (mTOR) signaling pathway that acts via two distinct multiprotein complexes, mTORC1 and mTORC2, can affect oxidative stress.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	39-43
34276381-9	2021	Rapamycin, an inhibitor of mTOR, prevented oligodendrocyte growth differentiation and myelination.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
34276381-12	2021	The finding that these effects are reduced when OPCs are exposed to rapamycin suggests an involvement of mTOR signaling in PEALut effects.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	105-109
34180556-9	2022	Moreover, rapamycin, a mTOR inhibitor, could enhance the cytotoxicity effect in xanthatin treated HT-29 cells.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	23-27
34226528-6	2021	Inhibition of mammalian target of rapamycin (mTOR) by rapamycin preserved tight junction proteins and attenuated BBB leakage and neuronal apoptosis after HI in the endothelial-specific IRS-1 transgenic pups.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	14-43
34226528-6	2021	Inhibition of mammalian target of rapamycin (mTOR) by rapamycin preserved tight junction proteins and attenuated BBB leakage and neuronal apoptosis after HI in the endothelial-specific IRS-1 transgenic pups.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	45-49
34209599-5	2021	Metabolic dysfunction, upregulation of the mammalian target of the rapamycin (mTOR) pathway, the gut microbiome, 3-hydroxyisobutyrate, inflammation, and the collusion of G-protein coupled receptors (GPCRs) are among the indicators and causes of metabolic disorders generating from amino acids that contribute to IR and the onset of type 2 diabetes mellitus (T2DM).	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	78-82
34204449-1	2021	We recently found that, in human osteoblasts, Homer1 complexes to Calcium-sensing receptor (CaSR) and mediates AKT initiation via mechanistic target of rapamycin complex (mTOR) complex 2 (mTORC2) leading to beneficial effects in osteoblasts including beta-catenin stabilization and mTOR complex 1 (mTORC1) activation.	Sirolimus	152-161	homer scaffold protein 1	Homo sapiens	46-52
34178631-4	2021	We also aimed to investigate the effect of the FDA approved drug rapamycin and the vitamin A metabolite retinoic acid (RA) in cell lines with TSC mutation.	Sirolimus	65-74	TSC complex subunit 1	Homo sapiens	142-145
34142125-9	2021	Incubation of human pluripotent stem cell-derived cardiomyocytes with elevated concentration of BCAAs induced similar calcium dysregulation and pro-arrhythmic events which were prevented by rapamycin, demonstrating the crucial involvement of mTOR pathway activation.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Homo sapiens	242-246
34249417-1	2021	The phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling pathways are critical for normal human physiology, and any alteration in their regulation leads to several human cancers.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	89-93
34178631-11	2021	Combination of the two FDA approved drugs -RA for acute myeloid leukaemia and rapamycin for TSC mutation- normalised ALDH and ADH expression and activity, restored RARbeta expression and reduced cellular proliferation and migration.	Sirolimus	78-87	TSC complex subunit 1	Homo sapiens	92-95
34178631-14	2021	Based on our data, translational studies could confirm whether combination of RA with reduced dosage of rapamycin would have more beneficial effects to higher dosage of rapamycin monotherapy meanwhile reducing adverse effects of rapamycin for patients with TSC mutation.	Sirolimus	229-238	TSC complex subunit 1	Homo sapiens	257-260
34082911-2	2021	Sirolimus, a mammalian target of rapamycin inhibitor, has demonstrated promise as a primary medical therapy for PVS, but the impact on patient survival is unknown.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
34103076-3	2021	Sirolimus, which is an inhibitor of mammalian target of rapamycin, has been shown to have promising potential in the treatment of complicated vascular anomalies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	36-65
34082911-3	2021	OBJECTIVES: The authors sought to investigate whether mTOR inhibition with sirolimus as a primary medical therapy would improve outcomes in high-risk infants and children with PVS.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	54-58
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	interleukin 6	Homo sapiens	116-120
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	tumor necrosis factor	Homo sapiens	126-135
34104708-6	2021	IF inhibits the mTOR pathway which is similar to the effects of Rapamycin in some animal models.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	16-20
34103528-6	2021	Mechanistically, AKT1-R391 methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading to AKT1 membrane translocation and subsequent activation by phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of rapamycin complex 2 (mTORC2).	Sirolimus	301-310	AKT serine/threonine kinase 1	Homo sapiens	17-21
34103528-6	2021	Mechanistically, AKT1-R391 methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading to AKT1 membrane translocation and subsequent activation by phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of rapamycin complex 2 (mTORC2).	Sirolimus	301-310	AKT serine/threonine kinase 1	Homo sapiens	171-175
34258421-4	2021	The concentrations of most serum AA and the AA transporters related gene expressions were highest in 7-d-old piglets (P < 0.05), whereas the phosphorylation status of the mammalian target of the rapamycin (mTOR) signaling pathway in the small intestine increased in piglets from 1 to 21 d old (P < 0.05).	Sirolimus	195-204	mechanistic target of rapamycin kinase	Homo sapiens	206-210
34295558-2	2021	Methods: We retrospectively analyzed the clinical data of 46 patients who underwent liver transplantation for HCC and performed next generation sequencing to analyze the relationship between the efficacy of sirolimus after liver transplantation for HCC and mutations in mTOR pathway-related genes, especially tuberous sclerosis complex (TSC) mutations.	Sirolimus	207-216	mechanistic target of rapamycin kinase	Homo sapiens	270-274
34295558-2	2021	Methods: We retrospectively analyzed the clinical data of 46 patients who underwent liver transplantation for HCC and performed next generation sequencing to analyze the relationship between the efficacy of sirolimus after liver transplantation for HCC and mutations in mTOR pathway-related genes, especially tuberous sclerosis complex (TSC) mutations.	Sirolimus	207-216	TSC complex subunit 1	Homo sapiens	337-340
34295558-7	2021	Of the 35 patients using sirolimus, those with mTOR-related mutations had significantly better survival rates than patients without mTOR-related mutations (P=0.016).	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	47-51
34295558-7	2021	Of the 35 patients using sirolimus, those with mTOR-related mutations had significantly better survival rates than patients without mTOR-related mutations (P=0.016).	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	132-136
34295558-9	2021	Patients with mTOR-related gene mutations, especially TSC mutations, can gain significant benefits from the use of mTOR inhibitors such as sirolimus.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	14-18
34295558-9	2021	Patients with mTOR-related gene mutations, especially TSC mutations, can gain significant benefits from the use of mTOR inhibitors such as sirolimus.	Sirolimus	139-148	TSC complex subunit 1	Homo sapiens	54-57
34295558-9	2021	Patients with mTOR-related gene mutations, especially TSC mutations, can gain significant benefits from the use of mTOR inhibitors such as sirolimus.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	115-119
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	49-53	collagen type I alpha 1 chain	Rattus norvegicus	0-6
33269749-11	2021	Both LY294002 (20 muM) and rapamycin (500 nM), which are inhibitors of the PI3K/Akt/mTOR pathway, significantly attenuated the inhibition of autophagy and apoptosis caused by apelin-13.	Sirolimus	27-36	AKT serine/threonine kinase 1	Homo sapiens	80-83
33269749-11	2021	Both LY294002 (20 muM) and rapamycin (500 nM), which are inhibitors of the PI3K/Akt/mTOR pathway, significantly attenuated the inhibition of autophagy and apoptosis caused by apelin-13.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	84-88
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	49-53	RUNX family transcription factor 2	Rattus norvegicus	8-13
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	199-203	collagen type I alpha 1 chain	Rattus norvegicus	0-6
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	199-203	RUNX family transcription factor 2	Rattus norvegicus	8-13
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	199-203	integrin-binding sialoprotein	Rattus norvegicus	113-117
34065350-5	2021	Administration of the mTOR inhibitor rapamycin rescues mitochondrial alterations.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	22-26
34122092-16	2021	However, rapamycin could cooperate with KD to enhance autophagic activation to increase insulin sensitivity in LO2 cells.	Sirolimus	9-18	insulin	Homo sapiens	88-95
34079249-8	2021	Furthermore, exosomal anti-let-7i-5p promoted the activation the tuberous sclerosis complex subunit 1/mammalian target of rapamycin (TSC1/mTOR) signaling pathway in vivo and in vitro.	Sirolimus	122-131	TSC complex subunit 1	Homo sapiens	133-137
34079249-8	2021	Furthermore, exosomal anti-let-7i-5p promoted the activation the tuberous sclerosis complex subunit 1/mammalian target of rapamycin (TSC1/mTOR) signaling pathway in vivo and in vitro.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	138-142
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	137-166
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	168-172
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	79-83	mechanistic target of rapamycin kinase	Homo sapiens	137-166
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	79-83	mechanistic target of rapamycin kinase	Homo sapiens	168-172
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	heme oxygenase 1	Mus musculus	263-266
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	interleukin 10	Mus musculus	24-28
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	tumor necrosis factor	Mus musculus	183-187
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	interleukin 1 beta	Mus musculus	189-193
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	interleukin 6	Mus musculus	199-202
34074073-10	2021	Compared with 10 mgF(-)/kg and 20 mgF(-)/kg groups, there were no obvious dental fluorosis symptoms in 2 mg/kg RAPA+10 mgF(-)/kg group and 2 mg/kg RAPA+20 mgF(-)/kg group, and serum ALP, BGP and OPG levels were significantly increased (P<0.05) .	Sirolimus	111-115	bone gamma-carboxyglutamate protein	Rattus norvegicus	187-190
34079820-13	2021	On the other hand, RAPA, mimic lncRNA-ATB and miR-200b inhibitor reduced fibrogenic effect of MMC on HEFs.	Sirolimus	19-23	microRNA 200b	Homo sapiens	46-54
34065746-2	2021	AKT activation mechanisms have been extensively studied; however, the mechanism underlying target of rapamycin complex 2 (mTORC2) phosphorylation of AKT at Ser473 in the cellular endomembrane system remains to be elucidated.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	0-3
34064854-9	2021	Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	35-38
34065746-2	2021	AKT activation mechanisms have been extensively studied; however, the mechanism underlying target of rapamycin complex 2 (mTORC2) phosphorylation of AKT at Ser473 in the cellular endomembrane system remains to be elucidated.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	149-152
34150053-5	2021	RESULTS: Autophagy triggered by rapamycin could protect neurons from IL-6-induced injury and astrocytes from OGD/R-induced injury in vitro and in rat brain tissue from MCAO in vivo.	Sirolimus	32-41	interleukin 6	Rattus norvegicus	69-73
34123648-2	2021	Recent reports have suggested that mTOR inhibitor sirolimus and related drugs show some benefit in non-tuberous sclerosis complex PEComas.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
34064854-11	2021	Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions.	Sirolimus	0-9	BCL2, apoptosis regulator	Rattus norvegicus	130-135
34084203-4	2021	Determining effective environmental factors such as stress conditions on the expression of PD1 and PD-L1 genes can provide an immunotherapeutic strategy to control PD1 signaling in the patients Mammalian target of rapamycin signaling is a stress-responsive pathway in the cells that can be blocked by rapamycin.	Sirolimus	301-310	mechanistic target of rapamycin kinase	Homo sapiens	194-223
34084203-6	2021	Experimental approach: Daily administration of rapamycin (1.5 mg/kg per day) was used in the mouse model of restraint stress and the relative expression of PD1, PD-L1, and Foxp3 genes in the brain and spleen were evaluated using quantitative real-time polymerase chain reaction method.	Sirolimus	47-56	CD274 antigen	Mus musculus	161-166
34084203-9	2021	In another observation, daily administration of rapamycin decreased the expression of PD-L1 in the brain cells of mice.	Sirolimus	48-57	CD274 antigen	Mus musculus	86-91
34084203-11	2021	Conclusion and implications: Downregulation of the PD-L1 gene in the brain induced by rapamycin can be followed in future experiences for preventing immunosuppressive effects of PD/PD-L1 signal in the brain.	Sirolimus	86-95	CD274 antigen	Mus musculus	51-56
34084203-11	2021	Conclusion and implications: Downregulation of the PD-L1 gene in the brain induced by rapamycin can be followed in future experiences for preventing immunosuppressive effects of PD/PD-L1 signal in the brain.	Sirolimus	86-95	CD274 antigen	Mus musculus	181-186
34351887-3	2021	El objetivo de este reporte es mostrar la experiencia del tratamiento con sirolimus por via oral en un paciente pediatrico con HEK asociado a fenomeno de Kasabach-Merritt refractario al tratamiento de primera linea, quien mostro excelente respuesta al tratamiento.	Sirolimus	74-83	cytochrome p450 oxidoreductase	Homo sapiens	84-87
34703427-1	2021	We present a rare case of KRAS keratinocytic epidermal nevus syndrome with lymphatic malformation, responsive to treatment with sirolimus, an mTOR inhibitor.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	142-146
34915755-7	2021	Moreover, Cisplatin-induced activation of mammalian target of rapamycin mTOR and inactivation of AMPK/PI3K/Akt signal pathway, and was coupled with induction of p53 activity and the executioner caspase3 to induce apoptotic renal cell death.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	72-76
34187243-5	2021	After repeated recurrence, the patient was treated with mTOR inhibitor sirolimus, which had a safety mechanism and specifically rebalance the DNT/Treg axis.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	56-60
34247157-11	2021	Functionally, rapamycin, but not Gleevec, significantly enhanced the expression of endothelial differentiation marker proteins, while attenuating the expression of mammalian target of rapamycin signaling-related proteins.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	164-193
34522717-9	2021	The phosphorylation of AKT at Ser473 and phosphorylation of S6 at Ser235/236 were inhibited in other patients with APDS1 who underwent rapamycin therapy.	Sirolimus	135-144	AKT serine/threonine kinase 1	Homo sapiens	23-26
34497233-7	2021	Sirolimus and roxadustat may be effective for relapsed/refractory PRCA with renal insufficiency and anti-erythropoietin antibody-mediated PRCA, respectively.	Sirolimus	0-9	erythropoietin	Homo sapiens	105-119
34476091-2	2021	The mammalian target of rapamycin inhibitor sirolimus (SRL) has immunosuppressive and antitumour activities but knowledge about its use in recipients with cancer is limited.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	4-33
34476091-2	2021	The mammalian target of rapamycin inhibitor sirolimus (SRL) has immunosuppressive and antitumour activities but knowledge about its use in recipients with cancer is limited.	Sirolimus	55-58	mechanistic target of rapamycin kinase	Homo sapiens	4-33
34522717-10	2021	Here, we showed the coexistence of immunodeficiency and SLE phenotype in APDS1, and the inhibition of rapamycin in activated Akt-mTOR signaling pathway.	Sirolimus	102-111	AKT serine/threonine kinase 1	Homo sapiens	125-128
34522717-10	2021	Here, we showed the coexistence of immunodeficiency and SLE phenotype in APDS1, and the inhibition of rapamycin in activated Akt-mTOR signaling pathway.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	129-133
35487271-8	2022	Application of rapamycin, the mTOR inhibitor, significantly reduced the upregulation of the proliferation, migration, and invasion abilities of lung adenocarcinoma cells transfected with Rab22a.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	30-34
35487271-8	2022	Application of rapamycin, the mTOR inhibitor, significantly reduced the upregulation of the proliferation, migration, and invasion abilities of lung adenocarcinoma cells transfected with Rab22a.	Sirolimus	15-24	RAB22A, member RAS oncogene family	Homo sapiens	187-193
35605444-3	2022	The patients were treated with mTOR inhibitors (rapamycin).	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	31-35
35192892-6	2022	However, these effects were markedly reversed by MARKs inhibitor 39621, or MARK2/4 deletion, mTOR inhibitor rapamycin, or AMPK activator AICAR.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	93-97
35428493-10	2022	WB results showed that LC3-II/I expression was significantly elevated in KHE primary cells treated with rapamycin, while the level of p-mTOR, p-S6K1, and p-4E-BP1 expression was reduced.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	136-140
35428493-12	2022	CONCLUSIONS: Rapamycin inhibited KHE primary cell proliferation, induced apoptosis and autophagy, and blocked the mTOR signaling pathway.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	114-118
35523039-10	2022	Unexpectedly, the elevated PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr ratio had the greatest ability to discriminate between pSS and HC, and sirolimus therapy restored the PD-1+ICOS+Tfh cells:CD45RA-Foxp3high activated Tfr ratio, and controlled disease activity.	Sirolimus	143-152	transferrin receptor	Sus scrofa	221-224
35521831-4	2022	One such drug, rapamycin, is currently under study for this purpose, given its immunosuppressant effects that are mediated by its inhibition of the mechanistic target of rapamycin (mTOR), a master regulator of cell growth.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	148-179
35489420-10	2022	MiR-199a-3p directly targeted and repressed mTOR, and its suppression effect on ICAM-1 and VCAM-1 was abolished by mTOR inhibitor rapamycin, and rescued by mTOR activator MHY1485.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	44-48
35489420-10	2022	MiR-199a-3p directly targeted and repressed mTOR, and its suppression effect on ICAM-1 and VCAM-1 was abolished by mTOR inhibitor rapamycin, and rescued by mTOR activator MHY1485.	Sirolimus	130-139	vascular cell adhesion molecule 1	Homo sapiens	91-97
35489420-10	2022	MiR-199a-3p directly targeted and repressed mTOR, and its suppression effect on ICAM-1 and VCAM-1 was abolished by mTOR inhibitor rapamycin, and rescued by mTOR activator MHY1485.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	115-119
35439535-7	2022	Our results also confirmed that mTOR inhibitor sensitized senolytic cell death is apoptotic and pan-mTOR inhibitors PP242 and AZD8055 works more effectively than mTORC1 inhibitor Rapamycin.	Sirolimus	179-188	Megator	Drosophila melanogaster	32-36
35439535-7	2022	Our results also confirmed that mTOR inhibitor sensitized senolytic cell death is apoptotic and pan-mTOR inhibitors PP242 and AZD8055 works more effectively than mTORC1 inhibitor Rapamycin.	Sirolimus	179-188	Megator	Drosophila melanogaster	100-104
35521831-4	2022	One such drug, rapamycin, is currently under study for this purpose, given its immunosuppressant effects that are mediated by its inhibition of the mechanistic target of rapamycin (mTOR), a master regulator of cell growth.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	181-185
35521831-5	2022	Consistent with this premise, acute rapamycin administration in young healthy humans blocks or attenuates mTOR and its downstream effectors, leading to the inhibition of muscle protein synthesis (MPS).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	106-110
35384254-1	2022	OBJECTIVES: To compare the efficacy and safety of the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent (DTS) and the sirolimus-eluting Orsiro stent (SES) in patients with and without diabetes mellitus (DM) included in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X study.	Sirolimus	89-98	CD34 molecule	Homo sapiens	67-71
35363301-1	2022	PURPOSE: To report efficacy and safety of samotolisib (LY3023414; phosphoinositide 3- kinase/mechanistic target of rapamycin (PI3K/mTOR) dual kinase and DNA-dependent protein kinase (DNA-PK) inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following cancer progression on abiraterone.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	131-135
35176419-8	2022	Currently, the only clinically available p70S6K inhibitors are rapamycin analogs (rapalogs) which target mTOR.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	105-109
35107743-12	2022	Studies on other respiratory viruses suggest that the therapeutic inhibitors of the mTOR pathway, especially rapamycin, can be a potential approach to anti-SARS-CoV-2 therapy.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	84-88
35596872-10	2022	Treatment with anti-seizure medication (ASM) or in combination with rapamycin results in clinical remission in most patients with TSC-associated seizures (14/15).	Sirolimus	68-77	TSC complex subunit 1	Homo sapiens	130-133
35488725-4	2022	The mTOR inhibitor sirolimus, which preferentially inhibits mTORC1, has led to sustained remission in a small cohort of anti-IL-6-refractory iMCD patients with thrombocytopenia, anasarca, fever, renal dysfunction and organomegaly (iMCD-TAFRO).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
35488725-4	2022	The mTOR inhibitor sirolimus, which preferentially inhibits mTORC1, has led to sustained remission in a small cohort of anti-IL-6-refractory iMCD patients with thrombocytopenia, anasarca, fever, renal dysfunction and organomegaly (iMCD-TAFRO).	Sirolimus	19-28	interleukin 6	Homo sapiens	125-129
35426265-10	2022	As rapamycin acts against angiogenesis and reduces phosphorylated-AKT levels, targeted molecular therapy should be discussed as first-line therapy in patients with proven molecular diagnosis and diffuse VM inaccessible to conventional treatment.	Sirolimus	3-12	AKT serine/threonine kinase 1	Homo sapiens	66-69
35286973-8	2022	The levels of phosphorylated mTOR and ribosomal protein S6 kinase 1 (p70S6K) were increased after GLUT1 inhibition and decreased by an mTOR inhibitor (rapamycin, Rapa) during the odontogenic induction of hDPSCs.	Sirolimus	151-160	mechanistic target of rapamycin kinase	Homo sapiens	29-33
35286973-8	2022	The levels of phosphorylated mTOR and ribosomal protein S6 kinase 1 (p70S6K) were increased after GLUT1 inhibition and decreased by an mTOR inhibitor (rapamycin, Rapa) during the odontogenic induction of hDPSCs.	Sirolimus	151-160	mechanistic target of rapamycin kinase	Homo sapiens	135-139
35599422-28	2022	Compared with that in wild-type control group, the percentage of wound area of mice in rapamycin control group increased significantly on PID 1-6 (P<0.01), the percentage of wound area of mice in Vgamma4 T cell+IL-22 inhibitor group increased significantly on PID 1 and PID 3-6 (P<0.05 or P<0.01).	Sirolimus	87-96	prion incubation determinant 3	Mus musculus	270-277
35367291-5	2022	Rapamycin rescued the inhibition of TFEB nuclear translocation induced by miR-34a/ATG9A activation, restored autophagic flux and consequently prevented HEI-OC1 cell death.	Sirolimus	0-9	microRNA 34a	Mus musculus	74-81
35599422-31	2022	On PID 3, compared with those in wild-type group, the expression levels of IL-22 protein and mRNA (with t values of -7.82 and -5.04, respectively, P<0.01) and CCL20 protein and mRNA (with t values of -7.12 and -5.73, respectively, P<0.01) were decreased significantly in the peri-wound epidermis tissue of mice in rapamycin group.	Sirolimus	314-323	prion incubation determinant 3	Mus musculus	3-8
35629245-8	2022	ABCB1 homozygous polymorphisms were observed with significantly lower time spent in the therapeutic range with cyclosporine and everolimus/sirolimus.	Sirolimus	139-148	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	tumor protein p53	Homo sapiens	0-3
35628508-9	2022	RAPA eliminates excessive ROS, inhibits NF-kappaB nuclear translocation and down-regulates the TXNIP/NLRP3 axis, consequently suppressing ROS-mediated NLRP3 inflammasome activation, which may be the underlying mechanism of the protective effect of autophagy on realgar-induced liver injury.	Sirolimus	0-4	thioredoxin interacting protein	Mus musculus	95-100
35316218-0	2022	Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy.	Sirolimus	0-9	CD4 molecule	Homo sapiens	17-20
35585420-9	2022	Notably, their expressions were decreased when the mTOR pathway was inhibited by rapamycin.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	51-55
35589065-12	2022	Rapamycin restored the protein expression levels of beclin1, LC3-II/LC3-I and OCN, OPN, OSX under the high lactate conditions.	Sirolimus	0-9	bone gamma-carboxyglutamate protein	Homo sapiens	78-81
35580815-6	2022	Here, we use a rapamycin-dependent oligomerization system to direct LRRK2 to various endomembranes including the Golgi apparatus, lysosomes, the plasma membrane, recycling, early, and late endosomes.	Sirolimus	15-24	leucine rich repeat kinase 2	Homo sapiens	68-73
35585885-8	2022	Of note, the effect of OG on Nrf2/Keap1 signaling was neutralized by the mTOR inhibitor rapamycin.	Sirolimus	88-97	nuclear factor, erythroid derived 2, like 2	Mus musculus	29-33
35596965-1	2022	TRPML1 is an endolysosomally-expressed cation channel, activated physiologically by PI(3,5)P2 and by several synthetic agonists including rapamycin.	Sirolimus	138-147	mucolipin TRP cation channel 1	Homo sapiens	0-6
35596965-2	2022	New high resolution cryo-EM- structures of TRPML1 bound to both PI(3,5)P2 and temsirolimus - a rapamycin analog provides molecular insight into how the channel integrates two agonists that bind to distal sites but act cooperatively.	Sirolimus	95-104	mucolipin TRP cation channel 1	Homo sapiens	43-49
35573101-7	2022	Sirolimus could effectively block the upstream and downstream factors of mammalian target of rapamycin signaling pathways to achieve the antiangiogenic effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-102
35276460-11	2022	Then, RAPA was used to inhibit the mTOR pathway, and the inflammatory factors IL-17A and IFN-gamma were downregulated in EAM mouse muscle and serum.	Sirolimus	6-10	interferon gamma	Mus musculus	89-98
35526176-4	2022	METHODS: A systematic search of the literature regarding studies on sirolimus treatment of children with lymphatic malformations of the head and neck was performed in PubMed, Embase, and Google Scholar up to July 2021 with the search terms "lymphatic malformation", "lymphangioma", "cystic hygroma", "low-flow malformation", "sirolimus", "rapamycin", "mTOR inhibitor" and "children".	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	352-356
35563840-7	2022	The loss of Lcn2 dismisses the effect of mTORC1 inhibition by rapamycin on COX2, thermogenesis genes, lipogenesis, and lipolysis, but has no impact on p70 S6Kinase-ULK1 activation in Lcn2-deficient adipocytes.	Sirolimus	62-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	75-79
35588700-8	2022	Among the mTOR inhibitors, everolimus and sirolimus showed the best results.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	10-14
35092164-6	2022	Mechanistically, we revealed that the enhanced autophagic turnover by RAPA inhibited NLRP3 inflammasome activity through NLRP3 degradation.	Sirolimus	70-74	NLR family pyrin domain containing 3	Homo sapiens	85-90
35092164-6	2022	Mechanistically, we revealed that the enhanced autophagic turnover by RAPA inhibited NLRP3 inflammasome activity through NLRP3 degradation.	Sirolimus	70-74	NLR family pyrin domain containing 3	Homo sapiens	121-126
35092164-7	2022	While blocking the fusion of autophagosomes with lysosomes by bafilomycin A1(BafA1), the reduced NLRP3 inflammasome activity induced by RAPA was significantly restored, with increased protein levels of NLRP3 and cleaved Casp-1(p10), as well as IL-1beta secretion.	Sirolimus	136-140	NLR family pyrin domain containing 3	Homo sapiens	97-102
35092164-7	2022	While blocking the fusion of autophagosomes with lysosomes by bafilomycin A1(BafA1), the reduced NLRP3 inflammasome activity induced by RAPA was significantly restored, with increased protein levels of NLRP3 and cleaved Casp-1(p10), as well as IL-1beta secretion.	Sirolimus	136-140	NLR family pyrin domain containing 3	Homo sapiens	202-207
35092164-7	2022	While blocking the fusion of autophagosomes with lysosomes by bafilomycin A1(BafA1), the reduced NLRP3 inflammasome activity induced by RAPA was significantly restored, with increased protein levels of NLRP3 and cleaved Casp-1(p10), as well as IL-1beta secretion.	Sirolimus	136-140	caspase 1	Homo sapiens	220-226
35092164-7	2022	While blocking the fusion of autophagosomes with lysosomes by bafilomycin A1(BafA1), the reduced NLRP3 inflammasome activity induced by RAPA was significantly restored, with increased protein levels of NLRP3 and cleaved Casp-1(p10), as well as IL-1beta secretion.	Sirolimus	136-140	S100 calcium binding protein A10	Homo sapiens	227-230
35344224-15	2022	Lastly, treatment of cGAS KO mice with rapamycin decreased the severity of colitis.	Sirolimus	39-48	cyclic GMP-AMP synthase	Mus musculus	21-25
35586047-5	2022	We found that SIK2 overexpression could alleviate the neuronal damage, reduce the area of cerebral infarction, and increase the adenosine triphosphate (ATP) content, which could promote the expression of phosphorylated-mammalian target of rapamycin-1 (p-mTORC1), hypoxia-inducible factor-1alpha (HIF-1alpha), phosphatase and tensin homologue-induced putative kinase 1 (PINK1) and E3 ubiquitinligating enzyme (Parkin).	Sirolimus	239-248	salt inducible kinase 2	Homo sapiens	14-18
35506423-3	2022	Everolimus is a mechanistic/mammalian target of rapamycin (mTOR) inhibitor used to prevent tumor growth by inhibiting the PI3K signaling pathway.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	59-63
35167417-4	2022	Here, we found that loss of CDK6 in cervical adenocarcinoma HeLa cell line inhibited cell proliferation but induced apoptosis as well as autophagy, accompanied by attenuated expression of mammalian target of rapamycin complex 1 (mTORC1) and hexokinase 2 (HK2), reduced glycolysis, and production of protein, nucleotide, and lipid.	Sirolimus	208-217	cyclin dependent kinase 6	Homo sapiens	28-32
35235160-8	2022	Furthermore, we found that the downregulation of AKT was mediated by downregulation of mTORC2 (the complex 2 of the mechanistic target of rapamycin) instead of its common upstream kinases, phosphatidylinositol 3-kinase and phosphoinositide-dependent kinase-1.	Sirolimus	138-147	thymoma viral proto-oncogene 1	Mus musculus	49-52
35438806-8	2022	Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning.	Sirolimus	135-144	AKT serine/threonine kinase 1	Rattus norvegicus	46-49
35438806-8	2022	Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning.	Sirolimus	135-144	AKT serine/threonine kinase 1	Rattus norvegicus	270-273
35380294-14	2022	Despite Diaph3 expression not correlating with survival and tumor size in GBM, there is an accumulating body of evidence that Diaph3 correlates with mTOR activity and can thus be used as a predictor for response to rapamycin and taxanes, clinical studies of which have shown promising, if mixed results in GBM.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	149-153
35142986-10	2022	These results generate compelling evidence that Alzheimer"s disease pathology exacerbated by oligomeric amyloid beta may be restored by FGF21 supplementation combined with Rapamycin and thus present an appropriate treatment paradigm for people affected with Alzheimer"s disease.	Sirolimus	172-181	amyloid beta precursor protein	Homo sapiens	104-116
35218870-7	2022	The use of rapamycin to prolong life in different animal models may be attributable to the multiple roles played by mTOR signaling in various processes involved in ageing, protein translation, autophagy, stem cell pool turnover, inflammation, and cellular senescence.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	116-120
35449295-8	2022	Consequently, abrogating the Akt-mTOR-autophagy signaling pathway abolishes CYLD-induced spine loss, whereas enhancing autophagy in vivo by the mTOR inhibitor rapamycin rescues the synaptic pruning and LTD deficits in mutant mice.	Sirolimus	159-168	thymoma viral proto-oncogene 1	Mus musculus	29-32
35299066-2	2022	Besides providing nitrogen substrates and carbon framework for energy homeostasis and transamination, BCAA also function as signaling molecules in the regulation of glucose, lipid, and protein synthesis via protein kinase B and as a mechanistic target of the rapamycin (AKT-mTOR) signaling pathway that is important for muscle accretion.	Sirolimus	259-268	AT-rich interaction domain 4B	Homo sapiens	102-106
35299066-2	2022	Besides providing nitrogen substrates and carbon framework for energy homeostasis and transamination, BCAA also function as signaling molecules in the regulation of glucose, lipid, and protein synthesis via protein kinase B and as a mechanistic target of the rapamycin (AKT-mTOR) signaling pathway that is important for muscle accretion.	Sirolimus	259-268	AKT serine/threonine kinase 1	Homo sapiens	270-273
35299066-2	2022	Besides providing nitrogen substrates and carbon framework for energy homeostasis and transamination, BCAA also function as signaling molecules in the regulation of glucose, lipid, and protein synthesis via protein kinase B and as a mechanistic target of the rapamycin (AKT-mTOR) signaling pathway that is important for muscle accretion.	Sirolimus	259-268	mechanistic target of rapamycin kinase	Homo sapiens	274-278
35472723-6	2022	These alterations, which mirror diabetes-associated human beta-cell dysfunction, are partially reversed by acute mTOR inhibition with rapamycin.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	113-117
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Sirolimus	27-36	transforming growth factor beta 1	Homo sapiens	94-103
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Sirolimus	27-36	interleukin 6	Homo sapiens	107-111
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	130-134
35571122-9	2022	Both mycophenolic acid and rapamycin inhibited inflammatory and fibrotic processes induced by TGF-beta1 or IL-6 by downregulating mTOR and ERK phosphorylation.	Sirolimus	27-36	mitogen-activated protein kinase 1	Homo sapiens	139-142
35571122-10	2022	Conclusions: Our findings indicate that combined mycophenolate and rapamycin, at reduced dose, improves kidney fibrosis in murine lupus nephritis through their distinct effect on mTOR and ERK signaling in mesangial cells.	Sirolimus	67-76	mitogen-activated protein kinase 1	Mus musculus	188-191
35434896-7	2022	In a more stringent model of haplo-mismatched hearts from BALB/cxB6.HLA-A2 F1 donors, A2-CAR Tregs slightly increased median graft survival from 11 days to 14 days, which was further extended to >100 days when combined with a 9-day course of rapamycin treatment.	Sirolimus	242-251	nuclear receptor subfamily 1, group I, member 3	Mus musculus	89-92
35483522-6	2022	Genetic deletion of the Tuberous sclerosis 1 gene in kidney glomerular podocytes activated mammalian target of rapamycin complex 1 signaling to rpS6 phosphorylation, resulting in podocyte hypertrophy and pathologic features similar to those of patients with FSGS including podocyte loss, leading to segmental glomerulosclerosis.	Sirolimus	111-120	TSC complex subunit 1	Homo sapiens	24-44
35563682-5	2022	Following preconditioning, both Rapa and 3-MA-treated hASCs demonstrated preservation of stemness, as well as upregulated transcription of cyclooxygenase-2 (COX2) and interleukin-6 (IL-6).	Sirolimus	32-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	139-155
35563682-5	2022	Following preconditioning, both Rapa and 3-MA-treated hASCs demonstrated preservation of stemness, as well as upregulated transcription of cyclooxygenase-2 (COX2) and interleukin-6 (IL-6).	Sirolimus	32-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	157-161
35563682-5	2022	Following preconditioning, both Rapa and 3-MA-treated hASCs demonstrated preservation of stemness, as well as upregulated transcription of cyclooxygenase-2 (COX2) and interleukin-6 (IL-6).	Sirolimus	32-36	interleukin 6	Homo sapiens	167-180
35563682-5	2022	Following preconditioning, both Rapa and 3-MA-treated hASCs demonstrated preservation of stemness, as well as upregulated transcription of cyclooxygenase-2 (COX2) and interleukin-6 (IL-6).	Sirolimus	32-36	interleukin 6	Homo sapiens	182-186
35563682-8	2022	Rapa-pretreated cells, but not 3-MA-pretreated cells, further amplified COX2 and IL-6 transcripts following IFNgamma exposure, and both groups upregulated secretion of prostaglandin-E2 (PGE2), the enzymatic product of COX2.	Sirolimus	0-4	prostaglandin-endoperoxide synthase 2	Homo sapiens	72-76
35563682-8	2022	Rapa-pretreated cells, but not 3-MA-pretreated cells, further amplified COX2 and IL-6 transcripts following IFNgamma exposure, and both groups upregulated secretion of prostaglandin-E2 (PGE2), the enzymatic product of COX2.	Sirolimus	0-4	interleukin 6	Homo sapiens	81-85
35563682-8	2022	Rapa-pretreated cells, but not 3-MA-pretreated cells, further amplified COX2 and IL-6 transcripts following IFNgamma exposure, and both groups upregulated secretion of prostaglandin-E2 (PGE2), the enzymatic product of COX2.	Sirolimus	0-4	interferon gamma	Homo sapiens	108-116
35563682-8	2022	Rapa-pretreated cells, but not 3-MA-pretreated cells, further amplified COX2 and IL-6 transcripts following IFNgamma exposure, and both groups upregulated secretion of prostaglandin-E2 (PGE2), the enzymatic product of COX2.	Sirolimus	0-4	prostaglandin-endoperoxide synthase 2	Homo sapiens	218-222
35629278-6	2022	In contrast, in osteogenic conditions, cells exposed to RPM showed a reduction in the presence of calcification-like structures, mineral deposits and PTX3 expression, suggesting that the effects of RPM exposure on mineralizing matrix deposition depend on the presence of osteogenic factors in the culture medium.	Sirolimus	56-59	pentraxin 3	Homo sapiens	150-154
35629278-6	2022	In contrast, in osteogenic conditions, cells exposed to RPM showed a reduction in the presence of calcification-like structures, mineral deposits and PTX3 expression, suggesting that the effects of RPM exposure on mineralizing matrix deposition depend on the presence of osteogenic factors in the culture medium.	Sirolimus	198-201	pentraxin 3	Homo sapiens	150-154
35436937-1	2022	BACKGROUND: Increasing evidence has shown that the mammalian target of rapamycin (mTOR) pathway plays a critical role in oocyte meiosis and embryonic development, however, previous studies reporting the effects of rapamycin on oocyte IVM showed different or even opposite results, and the specific mechanisms were not clear.	Sirolimus	214-223	mechanistic target of rapamycin kinase	Homo sapiens	51-80
35436937-1	2022	BACKGROUND: Increasing evidence has shown that the mammalian target of rapamycin (mTOR) pathway plays a critical role in oocyte meiosis and embryonic development, however, previous studies reporting the effects of rapamycin on oocyte IVM showed different or even opposite results, and the specific mechanisms were not clear.	Sirolimus	214-223	mechanistic target of rapamycin kinase	Homo sapiens	82-86
35436937-7	2022	Additionally, oocytes cultured with 10 nM rapamycin presented decreased ROS levels, reduced chromosome aberration, and attenuated levels of gamma-H2AX.	Sirolimus	42-51	H2A.X variant histone	Mus musculus	140-150
35436937-9	2022	Correspondingly, the expressions of Nrf2, Atm, Atr, and Prkdc in IVM oocytes were markedly increased, following the inhibition of mTORC1 pathway by 10 nM rapamycin.	Sirolimus	154-163	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
35436937-9	2022	Correspondingly, the expressions of Nrf2, Atm, Atr, and Prkdc in IVM oocytes were markedly increased, following the inhibition of mTORC1 pathway by 10 nM rapamycin.	Sirolimus	154-163	ataxia telangiectasia and Rad3 related	Mus musculus	47-50
35495903-8	2022	High levels of dietary valine stimulated lipid deposition by suppressing the GCN2-eIF2alpha-ATF4-fibroblast growth factor-19 (FGF19)-target of rapamycin complex 1 (TORC1) signaling pathway to promote fatty acid synthesis, repress fatty acid utilization, and eventually accelerate the development of NAFLD.	Sirolimus	143-152	activating transcription factor 4	Gallus gallus	92-96
35456509-8	2022	The drugs with a mostly anti-correlated signature were: efavirenz, an anti-retroviral drug; tacrolimus, a calcineurin inhibitor; and sirolimus, an mTOR inhibitor.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	147-151
35444442-3	2022	Current research shows that rapamycin, an mTOR inhibitor, is probably a promising adjunctive therapy for PWS, which suggests that the mTOR signaling pathway may play an important role in its pathological process.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	42-46
35444442-3	2022	Current research shows that rapamycin, an mTOR inhibitor, is probably a promising adjunctive therapy for PWS, which suggests that the mTOR signaling pathway may play an important role in its pathological process.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	134-138
35405122-7	2022	RN-1747 and rapamycin molecules were successfully loaded in sHA-oleylamide, previously prepared at 12 mg/mL in PBS; both formulations were stable, sterile and confirmed in vitro to have mTOR inhibition by rapamycin and TRPV4 activation activity by RN-1747.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	186-190
35405287-0	2022	Activation of mitophagy by rapamycin eliminated the accumulation of TDP-43 on mitochondrial and promoted the resolution of carbon tetrachloride-induced liver fibrosis in mice.	Sirolimus	27-36	TAR DNA binding protein	Mus musculus	68-74
35405287-10	2022	Mechanistically, RAPA could eliminate the accumulation of TDP-43 on mitochondrial through enhancing mitophagy, thereby improving mitochondrial function.	Sirolimus	17-21	TAR DNA binding protein	Mus musculus	58-64
35444553-2	2022	With its analogs (everolimus, ridaforolimus, and rapamycin), it forms a group of anticancer agents that block the activity of one of the two mammalian targets of rapamycin (mTOR) complexes, mTORC1.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	173-177
35391614-8	2022	Treatment with MAP kinase inhibitor U0126 prevented the change to a spindle-shaped morphology in NRASQ61R endothelial cells, whereas mTOR inhibitor rapamycin did not.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	133-137
35444553-2	2022	With its analogs (everolimus, ridaforolimus, and rapamycin), it forms a group of anticancer agents that block the activity of one of the two mammalian targets of rapamycin (mTOR) complexes, mTORC1.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Homo sapiens	173-177
35406578-6	2022	Here, we aim to clarify the role of the hypoxia-responding mammalian target of the rapamycin (mTOR) pathway in esophageal CSCs.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	94-98
35143831-10	2022	Use of Sirolimus (mTOR inhibitor) was significantly associated with higher BCAA plasma levels, independent of age, sex, time after OLTx, MetS and other immunosuppressive medication (adjusted P=0.002).	Sirolimus	7-16	mechanistic target of rapamycin kinase	Homo sapiens	18-22
35253967-1	2022	BACKGROUND AND PURPOSE: To provide further evidence for sirolimus, a mammalian target of rapamycin inhibitor, as a treatment strategy for patients with inclusion body myositis (IBM).	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	69-98
35384725-4	2022	Rapamycin reduced IL-17 production, TBX21, and RORc expression by splenic and CNS cell cultures.	Sirolimus	0-9	RAR-related orphan receptor gamma	Mus musculus	47-51
35183509-3	2022	We hypothesized that systemic induction of autophagy, via phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibition, would be effective in preventing anal cancer development in human papillomavirus (HPV) mice (K14E6/E7) with established low-grade anal dysplasia.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	120-124
35088890-1	2022	The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathway is a therapeutic target for various types of human tumors, and dual PI3K/mTOR inhibitors demonstrate antitumor activities in both preclinical and clinical studies.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	70-74
35040506-0	2022	mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	0-4
35040506-2	2022	Sirolimus (rapamycin) is an mTOR inhibitor that promotes alpha-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
35040506-2	2022	Sirolimus (rapamycin) is an mTOR inhibitor that promotes alpha-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	28-32
34999137-7	2022	The yeast OSBP homologue (Osh) proteins execute multifaceted functions in sterol and glycerophospholipid homeostasis, post-Golgi vesicle transport, phosphatidylinositol-4-phosphate, sphingolipid and target of rapamycin (TOR) signalling, and cell cycle control.	Sirolimus	209-218	oxysterol binding protein	Homo sapiens	10-14
35153184-1	2022	OBJECTIVE: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of the rapamycin (PI3K-AKT-mTOR) signaling pathway is an important regulator of cell proliferation, survival, and motility.	Sirolimus	86-95	AKT serine/threonine kinase 1	Homo sapiens	102-105
35153184-1	2022	OBJECTIVE: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of the rapamycin (PI3K-AKT-mTOR) signaling pathway is an important regulator of cell proliferation, survival, and motility.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	106-110
35358003-5	2022	Rapamycin, a reversible inhibitor of growth, slows down mTOR-driven geroconversion.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	56-60
35433677-8	2022	Our results showed patients in C2 NSCLC had the highest sensitivity to MK.2206 (AKT.inhibitor) and Rapamycin (mTOR inhibitor).	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	110-114
35316619-1	2022	The protein kinase mechanistic target of rapamycin (mTOR) functions as a central regulator of metabolism, integrating diverse nutritional and hormonal cues to control anabolic processes, organismal physiology, and even aging.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	52-56
35337287-0	2022	Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	129-133
35348612-2	2022	Multiple studies, sought to reveal the precise mechanism employed, commonly used autophagy inducers, such as rapamycin, which is a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	131-160
35348612-2	2022	Multiple studies, sought to reveal the precise mechanism employed, commonly used autophagy inducers, such as rapamycin, which is a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	162-166
35337287-4	2022	METHODS: The mTOR inhibitor rapamycin was used to treat human retinal pericytes (HRP) at doses ranging from 0.005 to 15 g/ml.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
35337287-12	2022	CONCLUSIONS: Rapamycin allows for an efficient modulation of aspects of angiogenesis in pericytes via mTOR-modulation in vitro.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	102-106
35372343-1	2022	Rapamycin, also known as sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), is a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	52-81
35372343-1	2022	Rapamycin, also known as sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), is a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-87
35372343-1	2022	Rapamycin, also known as sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), is a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	52-81
35372343-1	2022	Rapamycin, also known as sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), is a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	83-87
35359607-8	2022	The previous inhibition of mTOR by rapamycin had a synergistic effect with SFs, reducing cell viability even more significantly than the untreated control.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	27-31
35359647-1	2022	Objective: Tuberous sclerosis complex (TSC) is a genetic disease that arises from TSC1 or TSC2 abnormalities and induces the overactivation of the mammalian/mechanistic target of rapamycin pathways.	Sirolimus	179-188	TSC complex subunit 1	Homo sapiens	39-42
35328525-10	2022	SNPs combined with rapamycin (RAP), an autophagy activator, enhanced testosterone production and increased StAR expression, whereas SNPs combined with 3-methyladenine (3-MA) and chloroquine (CQ), autophagy inhibitors, had an opposite effect.	Sirolimus	19-28	regulatory associated protein of MTOR, complex 1	Mus musculus	30-33
35330555-1	2022	Background: Rapamycin was shown to reduce transforming growth factor beta1 (TGF-beta1) expression, inhibit the Mammalian target of rapamycin function, and prevent TGF-beta1-induced pulmonary fibrosis.	Sirolimus	12-21	transforming growth factor beta 1	Homo sapiens	42-74
35330555-1	2022	Background: Rapamycin was shown to reduce transforming growth factor beta1 (TGF-beta1) expression, inhibit the Mammalian target of rapamycin function, and prevent TGF-beta1-induced pulmonary fibrosis.	Sirolimus	12-21	transforming growth factor beta 1	Homo sapiens	76-85
35330555-1	2022	Background: Rapamycin was shown to reduce transforming growth factor beta1 (TGF-beta1) expression, inhibit the Mammalian target of rapamycin function, and prevent TGF-beta1-induced pulmonary fibrosis.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	111-140
35330555-1	2022	Background: Rapamycin was shown to reduce transforming growth factor beta1 (TGF-beta1) expression, inhibit the Mammalian target of rapamycin function, and prevent TGF-beta1-induced pulmonary fibrosis.	Sirolimus	12-21	transforming growth factor beta 1	Homo sapiens	163-172
35330555-20	2022	The mechanism may be related to the effect of rapamycin on inhibiting TGF-beta1 and Smad3 expression and promoting MMP1 expression in urethral tissues.	Sirolimus	46-55	transforming growth factor beta 1	Homo sapiens	70-79
35432890-5	2022	Further, small molecule (+)-JQ1- and rapamycin-derived iPr acyl silanes were shown to selectively label recombinant BRD4-BD1 and FKBP12, respectively, with minimal background.	Sirolimus	37-46	bromodomain containing 4	Homo sapiens	116-120
35432890-5	2022	Further, small molecule (+)-JQ1- and rapamycin-derived iPr acyl silanes were shown to selectively label recombinant BRD4-BD1 and FKBP12, respectively, with minimal background.	Sirolimus	37-46	defensin beta 1	Homo sapiens	121-124
35356282-14	2022	Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs.	Sirolimus	19-28	tumor protein p53	Homo sapiens	106-109
35255005-5	2022	Mechanistic dissection demonstrated that FOXH1-induced cell growth and cell migration/invasion relied on mTOR signaling because inhibition of mTOR signaling by rapamycin could attenuate FOXH1-mediated phenotypic alterations of HCC cells.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	105-109
35238644-5	2022	Herein, based on pharmacological and genetic interventions, we found that a high dose of sirolimus resulted in severe hearing loss by reducing the mTORC2/AKT signaling pathway in the cochlea.	Sirolimus	89-98	thymoma viral proto-oncogene 1	Mus musculus	154-157
35255005-5	2022	Mechanistic dissection demonstrated that FOXH1-induced cell growth and cell migration/invasion relied on mTOR signaling because inhibition of mTOR signaling by rapamycin could attenuate FOXH1-mediated phenotypic alterations of HCC cells.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	142-146
35048556-5	2022	In the presence of rapamycin, the split sec-TEVp-based RAPID components dimerize, regain their proteolytic activity, and remove the KDEL retention signal from insulin.	Sirolimus	19-28	insulin	Homo sapiens	159-166
35246210-5	2022	Although mTOR inhibitors (rapamycin/everolimus) demonstrate great potential in TSC management, two major concerns hamper their generalized application.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	9-13
35246210-5	2022	Although mTOR inhibitors (rapamycin/everolimus) demonstrate great potential in TSC management, two major concerns hamper their generalized application.	Sirolimus	26-35	TSC complex subunit 1	Homo sapiens	79-82
35402590-3	2022	Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has been reported to reduce viral replication and improve clinical outcomes in severe H1N1 infections when combined with oseltamivir.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-60
35184679-0	2022	Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	102-131
35402590-3	2022	Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has been reported to reduce viral replication and improve clinical outcomes in severe H1N1 infections when combined with oseltamivir.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	62-66
35184679-0	2022	Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	133-137
35184679-0	2022	Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	139-166
35184679-0	2022	Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	168-173
35184679-1	2022	Rapamycin inhibits the activation of NOD-like receptor protein 3 (NLRP3) by regulating the mammalian target of rapamycin (mTOR) to treat obstructive sleep apnea-related renal injury.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	37-64
35184679-1	2022	Rapamycin inhibits the activation of NOD-like receptor protein 3 (NLRP3) by regulating the mammalian target of rapamycin (mTOR) to treat obstructive sleep apnea-related renal injury.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	66-71
35184679-1	2022	Rapamycin inhibits the activation of NOD-like receptor protein 3 (NLRP3) by regulating the mammalian target of rapamycin (mTOR) to treat obstructive sleep apnea-related renal injury.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	91-120
35184679-1	2022	Rapamycin inhibits the activation of NOD-like receptor protein 3 (NLRP3) by regulating the mammalian target of rapamycin (mTOR) to treat obstructive sleep apnea-related renal injury.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	122-126
35014047-4	2022	The stimulatory effects of insulin upon cell proliferation and 3 H-DG uptake were hampered by rapamycin, LY294001 and BAY-876, in both cell lines.	Sirolimus	94-103	insulin	Homo sapiens	27-34
35235808-6	2022	Treatment with the mTOR inhibitor rapamycin decreases the growth of syngeneic KPC tumors with Galpha13 loss by promoting cell death.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
35235777-6	2022	Rather, loss of Slc6a8 or Ckb disrupts naive T cell homeostasis and weakens TCR-mediated activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling required for CD8+ T cell expansion.	Sirolimus	125-134	creatine kinase B	Homo sapiens	26-29
35149934-0	2022	Rapamycin attenuated podocyte apoptosis via upregulation of nestin in Ang II-induced podocyte injury.	Sirolimus	0-9	nestin	Homo sapiens	60-66
35300418-11	2022	In agreement with these results, reduced expression of vascular endothelial growth factor (VEGF) mRNA was observed in MGCs with Rapamycin, whereas pigment epithelium-derived factor (PEDF) mRNA levels significantly increased in MGCs incubated with Resveratrol.	Sirolimus	128-137	vascular endothelial growth factor A	Homo sapiens	55-89
35300418-11	2022	In agreement with these results, reduced expression of vascular endothelial growth factor (VEGF) mRNA was observed in MGCs with Rapamycin, whereas pigment epithelium-derived factor (PEDF) mRNA levels significantly increased in MGCs incubated with Resveratrol.	Sirolimus	128-137	vascular endothelial growth factor A	Homo sapiens	91-95
35059731-6	2022	For instance, short-term treatment with mammalian target of rapamycin inhibitors (such as everolimus and sirolimus) has been found to improve responses to influenza vaccination in adults, with benefits possibly persisting for a year following treatment.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	40-69
35149934-0	2022	Rapamycin attenuated podocyte apoptosis via upregulation of nestin in Ang II-induced podocyte injury.	Sirolimus	0-9	angiotensinogen	Homo sapiens	70-76
35149934-2	2022	Convincing evidence indicates that the mTOR inhibitor rapamycin could play a fundamental role in protection against podocyte injury.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	39-43
35149934-4	2022	The purpose of this study was to investigate the effect of rapamycin on podocyte injury induced by Ang II and to clarify the role and mechanism of nestin in the protective effect of rapamycin of podocyte injury.	Sirolimus	59-68	angiotensinogen	Homo sapiens	99-105
35149934-4	2022	The purpose of this study was to investigate the effect of rapamycin on podocyte injury induced by Ang II and to clarify the role and mechanism of nestin in the protective effect of rapamycin of podocyte injury.	Sirolimus	182-191	nestin	Homo sapiens	147-153
35149934-7	2022	We observed that Ang II induced podocyte injury both in vivo and in vitro, whereas rapamycin treatment relieved Ang II-induced podocyte injury.	Sirolimus	83-92	angiotensinogen	Homo sapiens	112-118
35149934-8	2022	We further found that nestin co-localized with p-mTOR in glomeruli, and the protective effect of rapamycin was reduced by nestin-siRNA in podocytes.	Sirolimus	97-106	nestin	Homo sapiens	22-28
35149934-8	2022	We further found that nestin co-localized with p-mTOR in glomeruli, and the protective effect of rapamycin was reduced by nestin-siRNA in podocytes.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	49-53
35149934-8	2022	We further found that nestin co-localized with p-mTOR in glomeruli, and the protective effect of rapamycin was reduced by nestin-siRNA in podocytes.	Sirolimus	97-106	nestin	Homo sapiens	122-128
35149934-10	2022	CONCLUSION: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.	Sirolimus	33-42	nestin	Homo sapiens	93-99
35149934-10	2022	CONCLUSION: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	123-127
35149934-10	2022	CONCLUSION: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.	Sirolimus	33-42	angiotensinogen	Homo sapiens	159-165
35220880-8	2022	In therapeutic studies, supplementation with LPA or the autophagy inducer rapamycin significantly promotes dMphi autophagy and cell residence, and improves embryo resorption in Enpp2+- and spontaneous abortion mouse models, which should be dependent on the activation of DDIT4-autophagy-CLDN7-adhesion molecules axis.	Sirolimus	74-83	DNA-damage-inducible transcript 4	Mus musculus	271-276
35251323-1	2022	It has been reported that the mammalian target of rapamycin (mTOR) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE), and increasing evidence has shown the effect of mTOR-targeted therapies with sirolimus in SLE.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	30-59
35251323-1	2022	It has been reported that the mammalian target of rapamycin (mTOR) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE), and increasing evidence has shown the effect of mTOR-targeted therapies with sirolimus in SLE.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	61-65
35251323-1	2022	It has been reported that the mammalian target of rapamycin (mTOR) pathway is involved in the pathogenesis of systemic lupus erythematosus (SLE), and increasing evidence has shown the effect of mTOR-targeted therapies with sirolimus in SLE.	Sirolimus	223-232	mechanistic target of rapamycin kinase	Homo sapiens	194-198
35251323-5	2022	Treatment with the mTOR inhibitor sirolimus was initiated in this patient.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
35202484-2	2022	Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam.	Sirolimus	154-163	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	29-35
35251315-3	2022	Genetic alterations in the mammalian target for rapamycin (mTOR) pathway have been identified in NEN, providing a rationale for treatment with the mTOR-inhibitor everolimus.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	59-63
35007565-7	2022	Western blot was used to determine the down-regulation of rapamycin (mTOR) signaling and autophagy enhancement induced by ORFV.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	69-73
35282339-6	2022	Our group has also demonstrated that conversion from calcineurin inhibitor to the mammalian target of rapamycin (mTOR) inhibitor, sirolimus, as a primary immunosuppression was associated with a decreased risk of PTLD following HT.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	82-111
35282339-6	2022	Our group has also demonstrated that conversion from calcineurin inhibitor to the mammalian target of rapamycin (mTOR) inhibitor, sirolimus, as a primary immunosuppression was associated with a decreased risk of PTLD following HT.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	113-117
35051778-8	2022	Further analysis revealed that MEOX2 negatively modulated the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2) pathways.	Sirolimus	128-137	mesenchyme homeobox 2	Homo sapiens	31-36
35051778-8	2022	Further analysis revealed that MEOX2 negatively modulated the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2) pathways.	Sirolimus	128-137	AKT serine/threonine kinase 1	Homo sapiens	100-103
35051778-8	2022	Further analysis revealed that MEOX2 negatively modulated the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2) pathways.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	139-143
35182368-1	2022	It has recently emerged that drugs such as the mTOR inhibitor rapamycin (Rapa) may play a key role in the treatment of airway inflammation associated with lung diseases, such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	47-51
35182368-1	2022	It has recently emerged that drugs such as the mTOR inhibitor rapamycin (Rapa) may play a key role in the treatment of airway inflammation associated with lung diseases, such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis.	Sirolimus	73-77	mechanistic target of rapamycin kinase	Homo sapiens	47-51
35131932-3	2022	Recently, rapamycin has also been shown to directly bind and activate TRPML1.	Sirolimus	10-19	mucolipin TRP cation channel 1	Homo sapiens	70-76
35114332-3	2022	Naturally aged C57BL/6J mice were used to identify the role of autophagy in ARHL, and rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, was administered for 34 weeks to explore the potential therapeutic effect of rapamycin in ARHL.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	130-134
35601254-3	2022	This study was completed to investigate the role of mammalian target of the rapamycin (mTOR) signaling in regulating the expression and function of PepT2 in BMEC.	Sirolimus	76-85	solute carrier family 15 member 2	Homo sapiens	148-153
35197970-0	2022	Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways.	Sirolimus	0-9	NFE2 like bZIP transcription factor 2	Rattus norvegicus	120-124
35197970-13	2022	In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity.	Sirolimus	39-48	NFE2 like bZIP transcription factor 2	Rattus norvegicus	230-234
35125022-0	2022	Efficacy of mTOR inhibitors (sirolimus) in isolated limb overgrowth: a systematic review.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	12-16
35185612-7	2022	Our results showed that prolonged RPM exposure not only caused satellite cell death, but also induced changes in myostatin expression levels with group-dependent variations.	Sirolimus	34-37	myostatin	Homo sapiens	113-122
35186935-13	2022	Cell viability and colony formed ability were recovered when OE-CSP cells were exposed to rapamycin.	Sirolimus	90-99	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	64-67
35185612-9	2022	Noteworthy, we found that the negative effect of RPM exposure was counteracted by treatment with anti-MSTN antibodies, which allowed the formation of numerous myotubes.	Sirolimus	49-52	myostatin	Homo sapiens	102-106
35185612-10	2022	Our results highlight the role of myostatin as a major effector of the cellular degeneration observed with RPM exposure, suggesting it as a potential therapeutic target to slow the muscle mass loss that occurs in the absence of loading.	Sirolimus	107-110	myostatin	Homo sapiens	34-43
35040598-1	2022	OBJECTIVE: To determine whether sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, reduces epileptic seizures associated with focal cortical dysplasia (FCD) type II.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	45-76
35044284-0	2022	RAS protein activator like 2 promotes the proliferation and migration of pulmonary artery smooth muscle cell through AKT/mammalian target of Rapamycin complex 1 pathway in pulmonary hypertension.	Sirolimus	141-150	AKT serine/threonine kinase 1	Homo sapiens	117-120
35044284-6	2022	Mechanistically, we found elevated phosphorylation of AKT and two downstream effectors of mammalian target of Rapamycin complex 1 (mTORC1), S6 and 4E-Binding Protein 1 (4EBP1) after Rasal2 overexpression in hypoxia-challenged PASMC.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	54-57
35085453-4	2022	Rapamycin, a mechanistic target of rapamycin (mTOR) inhibitor, was added during rabbit embryonic fibroblasts induction to improve the autophagy level.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-44
35040598-1	2022	OBJECTIVE: To determine whether sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, reduces epileptic seizures associated with focal cortical dysplasia (FCD) type II.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	78-82
35085453-4	2022	Rapamycin, a mechanistic target of rapamycin (mTOR) inhibitor, was added during rabbit embryonic fibroblasts induction to improve the autophagy level.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
35133561-8	2022	Furthermore, Ang II-induced loss of autophagy and promotion of apoptosis in CFs were prevented by the treatment with Pyr1-apelin-13 or AMPK agonist AICAR or mTOR inhibitor rapamycin, respectively.	Sirolimus	172-181	angiotensinogen	Rattus norvegicus	13-19
35143341-7	2022	Furthermore, hyperactivation of mTOR signaling was relieved by rapamycin.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	32-36
34998548-14	2022	Compared with the control, the 5 nM rapamycin treatment upregulated the abundance of ATGL, the ratio of p-HSL to HSL and LC3-II to LC3-I, and the glycerol content, whereas it downregulated the abundance of PLIN1 and p62 in calf adipocytes.	Sirolimus	36-45	lipase E, hormone sensitive type	Bos taurus	106-109
34998548-14	2022	Compared with the control, the 5 nM rapamycin treatment upregulated the abundance of ATGL, the ratio of p-HSL to HSL and LC3-II to LC3-I, and the glycerol content, whereas it downregulated the abundance of PLIN1 and p62 in calf adipocytes.	Sirolimus	36-45	lipase E, hormone sensitive type	Bos taurus	113-116
34998548-14	2022	Compared with the control, the 5 nM rapamycin treatment upregulated the abundance of ATGL, the ratio of p-HSL to HSL and LC3-II to LC3-I, and the glycerol content, whereas it downregulated the abundance of PLIN1 and p62 in calf adipocytes.	Sirolimus	36-45	perilipin 1	Bos taurus	206-211
35133561-8	2022	Furthermore, Ang II-induced loss of autophagy and promotion of apoptosis in CFs were prevented by the treatment with Pyr1-apelin-13 or AMPK agonist AICAR or mTOR inhibitor rapamycin, respectively.	Sirolimus	172-181	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	135-139
34977975-4	2022	The protein kinase target of rapamycin (TOR) complex negatively regulates autophagy when nutrients are present in adequate amounts.	Sirolimus	29-38	target of rapamycin	Arabidopsis thaliana	40-43
35587661-1	2022	PURPOSE: To investigate the mechanism of microRNA-100-5p (miR-100-5p) on mammalian target (mTOR) of rapamycin in temporomandibular arthritis.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	91-95
35173685-8	2022	Furthermore, ESCs of the Rapamycin-treated group showed significant decidual-like changes with significantly increased decidual prolactin level at 72 h after in vitro decidualization.	Sirolimus	25-34	prolactin	Homo sapiens	128-137
35174167-4	2021	ARHGEF3 also binds the mammalian target of rapamycin complex 2 (mTORC2) and subsequently inhibits mTORC2 and Akt.	Sirolimus	43-52	AKT serine/threonine kinase 1	Homo sapiens	109-112
34874016-9	2022	On the other hand, rapamycin abolished the effects of T-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/ S6K1/4EBP1 signaling pathway in a concentration-dependent manner.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	177-181
35153674-9	2021	In addition, data also described that the protein expression level of p-S6, mTOR and Raptor are lower than PGPS group after RPM treatment.	Sirolimus	124-127	regulatory associated protein of MTOR, complex 1	Mus musculus	85-91
35153674-10	2021	The accumulation of LC3-II, Beclin-1, and ATG7 are decreased, and the expression of Rab7 and Syntaxin 17 are increased significantly after RPM treatment.	Sirolimus	139-142	autophagy related 7	Mus musculus	42-46
35153674-10	2021	The accumulation of LC3-II, Beclin-1, and ATG7 are decreased, and the expression of Rab7 and Syntaxin 17 are increased significantly after RPM treatment.	Sirolimus	139-142	RAB7, member RAS oncogene family	Mus musculus	84-88
35153674-10	2021	The accumulation of LC3-II, Beclin-1, and ATG7 are decreased, and the expression of Rab7 and Syntaxin 17 are increased significantly after RPM treatment.	Sirolimus	139-142	syntaxin 17	Mus musculus	93-104
33626860-7	2022	Masson staining and Western blot were used to observe the succinate dehydrogenase subunit A (SDHA) and malate dehydrogenase (MDH2), citrate synthase (CS), ketoglutarate dehydrogenase (OGDH), and target of rapamycin 1 (mTORC1) pathway involved in mitochondrial tricarboxylic acid cycle in liver tissues.	Sirolimus	205-214	succinate dehydrogenase complex, subunit A, flavoprotein (Fp)	Mus musculus	93-97
35159256-2	2022	Rapamycin, a specific inhibitor of MTOR, has been widely used as an immunosuppressant in organ transplant patients, and its clinical application has been recently expanded to cancer therapy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
35163076-6	2022	Therapeutic strategies associated with rapamycin have worked well in a number of different diseases, and there is every reason to believe that targeting components of the mTOR pathway may pay off in atherosclerosis as well.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	171-175
35159680-10	2022	Repeated dosing of rapamycin PFC nanoparticles did not affect overall spleen T cell proliferation and responses to stimulation, although it significantly decreased the number of Foxp3+CD4+ T cells and NK1.1+ cells were observed.	Sirolimus	19-28	CD4 molecule	Homo sapiens	184-187
35040438-6	2022	Interestingly, treatment with the mTOR inhibitor rapamycin improves skin symptoms in Skiv2l-deficient mice, suggesting a possible therapeutic avenue for patients with THES2.	Sirolimus	49-58	Ski2 like RNA helicase	Homo sapiens	167-172
34904422-7	2022	Finally, we found that CP blocked the interaction of L. japonicus protein kinase B (AKT) with LjHSP90ab1 by competitively binding the NM domain of LjHSP90ab1 to inhibit the AKT-mechanistic target of the rapamycin (MTOR) pathway.	Sirolimus	203-212	AKT serine/threonine kinase 1	Homo sapiens	84-87
34904422-7	2022	Finally, we found that CP blocked the interaction of L. japonicus protein kinase B (AKT) with LjHSP90ab1 by competitively binding the NM domain of LjHSP90ab1 to inhibit the AKT-mechanistic target of the rapamycin (MTOR) pathway.	Sirolimus	203-212	AKT serine/threonine kinase 1	Homo sapiens	173-176
35038351-5	2022	METHODS: Peripheral blood CD14+ monocytes from asthmatic patients (n=83) and healthy controls (n=46) were stimulated with LPS/ATP to induce NLRP3 activation with or without the autophagy inducer, rapamycin.	Sirolimus	196-205	NLR family pyrin domain containing 3	Homo sapiens	140-145
34904422-7	2022	Finally, we found that CP blocked the interaction of L. japonicus protein kinase B (AKT) with LjHSP90ab1 by competitively binding the NM domain of LjHSP90ab1 to inhibit the AKT-mechanistic target of the rapamycin (MTOR) pathway.	Sirolimus	203-212	mechanistic target of rapamycin kinase	Homo sapiens	214-218
35012940-10	2022	However, mTOR-selective inhibitors (everolimus, rapamycin) alone did not exert cytotoxic effects.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	9-13
35499412-12	2022	In November 2021, the FDA approved nab-sirolimus (mTOR inhibitor) for PEComas.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	50-54
34985382-6	2022	Consequently, treatment of TAFAZZIN knockdown mice with rapamycin, a potent inhibitor of MTORC1, not only restored mitophagy, but also mitigated mitochondrial dysfunction and dilated cardiomyopathy.	Sirolimus	56-65	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	27-35
34985382-6	2022	Consequently, treatment of TAFAZZIN knockdown mice with rapamycin, a potent inhibitor of MTORC1, not only restored mitophagy, but also mitigated mitochondrial dysfunction and dilated cardiomyopathy.	Sirolimus	56-65	origin recognition complex, subunit 1	Mus musculus	89-95
35087713-0	2022	Brain targeted delivery of rapamycin using transferrin decorated nanostructured lipid carriers.	Sirolimus	27-36	transferrin	Homo sapiens	43-54
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	interleukin 6	Mus musculus	132-136
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	tumor necrosis factor	Mus musculus	138-147
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	chemokine (C-X-C motif) ligand 1	Mus musculus	149-155
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	chemokine (C-X-C motif) ligand 2	Mus musculus	157-163
35087713-1	2022	Introduction: Recent studies showed that rapamycin, as a mammalian target of rapamycin (mTOR) inhibitor, could have beneficial therapeutic effects for the central nervous system (CNS) related diseases.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	57-86
35087713-1	2022	Introduction: Recent studies showed that rapamycin, as a mammalian target of rapamycin (mTOR) inhibitor, could have beneficial therapeutic effects for the central nervous system (CNS) related diseases.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	88-92
35087713-3	2022	To overcome these drawbacks, a transferrin (Tf) decorated nanostructured lipid carrier (NLC) containing rapamycin was designed and developed.	Sirolimus	104-113	transferrin	Homo sapiens	31-42
34987640-9	2022	Further, to reactivate functionally indolent TILs, we reprogrammed ex vivo TILs with Ibrutinib plus Rapamycin to block interleukin-2-inducible kinase (ITK) and mTOR pathways, respectively.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	160-164
33838212-7	2021	In addition, phosphorylation levels of phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt) and mammalian rapamycin target protein (mTOR) decreased after HS treatment in early and medium stages of PD rats.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	140-144
33872697-1	2021	Activation of the protein kinase mechanistic target of rapamycin (mTOR) in both complexes 1 and 2 (mTORC1/2) in the liver is repressed during fasting and rapidly stimulated in response to a meal.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	66-70
34813306-8	2021	The combination treatment of BDMC and rapamycin enhanced the inhibition of TNBC proliferation and metastasis through increasing the blockage of mTOR activation.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	144-148
33955513-0	2021	Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	81-110
33955513-6	2021	Mechanistically, rapamycin inhibited the renal expression of phosphorylated (p-)mammalian target of rapamycin (mTOR) and p-ribosomal S6 protein kinase 1, which in turn activated renal autophagy and decreased apoptosis, probably by removing AA-elicited damaged mitochondria and misfolded proteins.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	111-115
33955513-6	2021	Mechanistically, rapamycin inhibited the renal expression of phosphorylated (p-)mammalian target of rapamycin (mTOR) and p-ribosomal S6 protein kinase 1, which in turn activated renal autophagy and decreased apoptosis, probably by removing AA-elicited damaged mitochondria and misfolded proteins.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	111-115
33955513-7	2021	The findings of the present study demonstrated that rapamycin protects against AA-induced nephropathy by activating the mTOR-autophagy axis and suggested that rapamycin may be a promising pharmacological target for the treatment of AAN.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	120-124
33955513-7	2021	The findings of the present study demonstrated that rapamycin protects against AA-induced nephropathy by activating the mTOR-autophagy axis and suggested that rapamycin may be a promising pharmacological target for the treatment of AAN.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Homo sapiens	120-124
33741330-5	2021	Modulation of autophagy by rapamycin, 3-methyladenine or ATG-5 knockdown regulated the expression of CAFs markers, suggesting a role of autophagy in the tumor promotion mechanism of TGF-beta1-induced CAFs activation.	Sirolimus	27-36	transforming growth factor beta 1	Homo sapiens	182-191
33949020-11	2021	Mechanistically, the deletion of Setd2 resulted in the activation of AKT/mTOR signalling pathway, while the pharmacological inhibition of AKT and mTOR with MK2206 and rapamycin, respectively, delayed wound closure.	Sirolimus	167-176	SET domain containing 2	Mus musculus	33-38
33554444-8	2021	Inhibition of mTOR with rapamycin blocked the effects of GPR39 overexpression on protein synthesis and repressed cardiac hypertrophy.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
34059001-17	2021	Repression of mTOR with rapamycin blocked the effects of KLK11 on S6K1 and 4EBP1 as well as protein synthesis.	Sirolimus	24-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-80
33846781-5	2021	MET and the mTOR inhibitor rapamycin (RAPA) decreased the viability in control and resistant cells, and decreased the cell size increase induced by CIS.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	12-16
33846781-5	2021	MET and the mTOR inhibitor rapamycin (RAPA) decreased the viability in control and resistant cells, and decreased the cell size increase induced by CIS.	Sirolimus	38-42	mechanistic target of rapamycin kinase	Homo sapiens	12-16
33620645-7	2021	Integrative functional genomic analysis of the YY1 gene sets revealed an association among the pathways Wnt/beta-catenin, Rapamycin, Cyclin-D1, Myc, E2F, PDGF, and AKT.	Sirolimus	122-131	YY1 transcription factor	Homo sapiens	47-50
33949020-11	2021	Mechanistically, the deletion of Setd2 resulted in the activation of AKT/mTOR signalling pathway, while the pharmacological inhibition of AKT and mTOR with MK2206 and rapamycin, respectively, delayed wound closure.	Sirolimus	167-176	thymoma viral proto-oncogene 1	Mus musculus	138-141
34050114-4	2021	Previous studies have suggested that all-trans retinoic acid (atRA) and rapamycin (RAPA), an mTOR inhibitor, protect lipopolysaccharide (LPS)-induced neuronal inflammation through inhibiting nuclear import of NFkappaB.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	93-97
34050114-4	2021	Previous studies have suggested that all-trans retinoic acid (atRA) and rapamycin (RAPA), an mTOR inhibitor, protect lipopolysaccharide (LPS)-induced neuronal inflammation through inhibiting nuclear import of NFkappaB.	Sirolimus	72-81	nuclear factor kappa B subunit 1	Homo sapiens	209-217
34050114-4	2021	Previous studies have suggested that all-trans retinoic acid (atRA) and rapamycin (RAPA), an mTOR inhibitor, protect lipopolysaccharide (LPS)-induced neuronal inflammation through inhibiting nuclear import of NFkappaB.	Sirolimus	83-87	mechanistic target of rapamycin kinase	Homo sapiens	93-97
34050114-4	2021	Previous studies have suggested that all-trans retinoic acid (atRA) and rapamycin (RAPA), an mTOR inhibitor, protect lipopolysaccharide (LPS)-induced neuronal inflammation through inhibiting nuclear import of NFkappaB.	Sirolimus	83-87	nuclear factor kappa B subunit 1	Homo sapiens	209-217
34048926-2	2021	The disease involves the mTOR pathway and the cutaneous manifestation responds to topical treatment with sirolimus (SIR).	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	25-29
34058434-8	2021	Rapamycin reversed the TNF-alpha-induced decrease in osteogenesis of BMSCs, assessed by alkaline phosphatase (ALP) activity and Alizarin staining.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	23-32
34058434-8	2021	Rapamycin reversed the TNF-alpha-induced decrease in osteogenesis of BMSCs, assessed by alkaline phosphatase (ALP) activity and Alizarin staining.	Sirolimus	0-9	alkaline phosphatase, placental	Homo sapiens	88-108
34058434-8	2021	Rapamycin reversed the TNF-alpha-induced decrease in osteogenesis of BMSCs, assessed by alkaline phosphatase (ALP) activity and Alizarin staining.	Sirolimus	0-9	alkaline phosphatase, placental	Homo sapiens	110-113
34031457-6	2021	Pre-treatment with IGF-1 signal pathway specific inhibitors such as picropodophyllin, LY294002, and rapamycin attenuated EE induced myotube hypertrophy and MyHC isoform overexpression.	Sirolimus	100-109	myosin heavy chain, cardiac muscle complex	Mus musculus	156-160
34048926-2	2021	The disease involves the mTOR pathway and the cutaneous manifestation responds to topical treatment with sirolimus (SIR).	Sirolimus	116-119	mechanistic target of rapamycin kinase	Homo sapiens	25-29
33908567-0	2021	Facile synthesis of rapamycin-peptide conjugates as mTOR and Akt inhibitors.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	52-56
34021461-10	2021	Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells.	Sirolimus	105-114	angiotensinogen	Rattus norvegicus	198-204
33908567-0	2021	Facile synthesis of rapamycin-peptide conjugates as mTOR and Akt inhibitors.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	61-64
33908567-4	2021	Rapamycin is also conjugated to the peptides known for inhibiting the kinase activity of Akt protein.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	89-92
33609687-8	2021	Phosphorylation of p70S6K was inhibited by siRNA knockdown and rapamycin to restore TNFalpha-inhibited autophagy, which prevented the synergistic effect on TVX-induced cytotoxicity.	Sirolimus	63-72	tumor necrosis factor	Homo sapiens	84-92
34003452-2	2021	Previous studies have shown that the mTOR inhibitor sirolimus can reduce complaints and improve QoL in some patients.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
34004440-8	2021	Inhibition of mTOR with rapamycin or knockdown of mTOR enhanced metformin"s suppression of hsBAFF-induced phosphorylation of S6K1, PTEN, Akt, and Erk1/2, as well as B-cell proliferation/viability.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
33888602-4	2021	We have previously shown that mechanistic/mammalian target of rapamycin (mTOR) drives cerebrovascular dysfunction in models of AD by reducing the activity of endothelial nitric oxide synthase (eNOS), and that attenuation of mTOR activity with rapamycin is sufficient to restore eNOS-dependent cerebrovascular function.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	73-77
33991364-4	2021	Previous reports indicate increased systemic exposures of cyclosporine and sirolimus in patients receiving high-dose marine omega-3 FA supplements (3, 4) which could be related to reduced drug metabolism supported by the in vitro experimental observation of an inhibitory effect of omega-3 FAs on cytochrome P450 (CYP) 3A enzymes (5) expressed in the intestine and liver.	Sirolimus	75-84	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	297-321
33978540-5	2021	Remarkably, downregulation of subunits of V-ATPase, of Pdk1, or of the Tor (Target of rapamycin) complex 1 (TORC1) component raptor prevents overgrowth and normalize ref(2)P levels.	Sirolimus	86-95	raptor	Drosophila melanogaster	125-131
33888602-4	2021	We have previously shown that mechanistic/mammalian target of rapamycin (mTOR) drives cerebrovascular dysfunction in models of AD by reducing the activity of endothelial nitric oxide synthase (eNOS), and that attenuation of mTOR activity with rapamycin is sufficient to restore eNOS-dependent cerebrovascular function.	Sirolimus	62-71	nitric oxide synthase 3	Homo sapiens	158-191
33888602-4	2021	We have previously shown that mechanistic/mammalian target of rapamycin (mTOR) drives cerebrovascular dysfunction in models of AD by reducing the activity of endothelial nitric oxide synthase (eNOS), and that attenuation of mTOR activity with rapamycin is sufficient to restore eNOS-dependent cerebrovascular function.	Sirolimus	62-71	nitric oxide synthase 3	Homo sapiens	193-197
33888602-4	2021	We have previously shown that mechanistic/mammalian target of rapamycin (mTOR) drives cerebrovascular dysfunction in models of AD by reducing the activity of endothelial nitric oxide synthase (eNOS), and that attenuation of mTOR activity with rapamycin is sufficient to restore eNOS-dependent cerebrovascular function.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	224-228
33888602-4	2021	We have previously shown that mechanistic/mammalian target of rapamycin (mTOR) drives cerebrovascular dysfunction in models of AD by reducing the activity of endothelial nitric oxide synthase (eNOS), and that attenuation of mTOR activity with rapamycin is sufficient to restore eNOS-dependent cerebrovascular function.	Sirolimus	62-71	nitric oxide synthase 3	Homo sapiens	278-282
33888602-5	2021	Here we show mTOR drives NVC impairments in an AD model through the inhibition of neuronal NOS and non-NOS dependent components of NVC, and that mTOR attenuation with rapamycin is sufficient to restore NVC and even enhance it above WT responses.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	145-149
33957967-11	2021	The autophagy promoter (3-MA) and inhibitor (rapamycin) significantly decreased or increased the expression of TNF-alpha, IL-6, and IL-1beta by DCs.	Sirolimus	45-54	tumor necrosis factor	Homo sapiens	111-120
33990769-11	2021	We found that SZ subjects are globally more sensitive to rapamycin treatment and AMP-activated protein kinase (AMPK) contributes to this differential kinase activity.	Sirolimus	57-66	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	81-109
33990769-11	2021	We found that SZ subjects are globally more sensitive to rapamycin treatment and AMP-activated protein kinase (AMPK) contributes to this differential kinase activity.	Sirolimus	57-66	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	111-115
33957967-11	2021	The autophagy promoter (3-MA) and inhibitor (rapamycin) significantly decreased or increased the expression of TNF-alpha, IL-6, and IL-1beta by DCs.	Sirolimus	45-54	interleukin 6	Homo sapiens	122-126
33742521-1	2021	We hypothesized that rapamycin (Rapa), acarbose (ACA), which both increase mouse lifespan, and 17alpha-estradiol, which increases lifespan in males (17aE2) all share common intracellular signaling pathways with long-lived Snell dwarf, PAPPA-KO, and Ghr-/- mice.	Sirolimus	21-30	growth hormone receptor	Mus musculus	249-252
33949684-6	2021	We show that both Tregs and RA+ Tregs could be expanded in large numbers and the presence of rapamycin is essential to inhibit the growth of IFN-gamma producing cells.	Sirolimus	93-102	interferon gamma	Homo sapiens	141-150
33128812-6	2021	Concomitant treatment with belatacept plus a mammalian target of rapamycin inhibitor (mTORi; sirolimus or everolimus) has yielded AR rates ranging from 0 to 4%.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	45-74
33947426-7	2021	Rapamycin did not protect against DHEA-induced acyclicity and PCO morphology, but impeded follicle development and elevated serum testosterone levels in DHEA-induced mice, which was related with suppressed Hsd3b1, Cyp17a1, and Cyp19a1 expression.	Sirolimus	0-9	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Mus musculus	206-212
33231291-2	2021	The mTOR inhibitor sirolimus is emerging as targeted therapy in KHE.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33952452-2	2021	The phosphatidylinositol-3-kinase/AKT serine/threonine kinase/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway is frequently activated in colorectal cancer (CRC).	Sirolimus	82-91	AKT serine/threonine kinase 1	Homo sapiens	34-37
33952452-2	2021	The phosphatidylinositol-3-kinase/AKT serine/threonine kinase/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway is frequently activated in colorectal cancer (CRC).	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	102-106
33706141-6	2021	Rapamycin pre-treatment completely blocked the phosphorylation of mTOR and p70S6K1 proteins, and the cell cycle progression induced by 1 muM Cd, and accelerated 15 muM Cd-induced cell apoptosis and cell cycle arrest.	Sirolimus	0-9	mechanistic target of rapamycin	Gallus gallus	66-70
33649784-11	2021	The pharmacological induction of autophagy with rapamycin or metformin attenuated the pro-migratory effects of IL-8.	Sirolimus	48-57	C-X-C motif chemokine ligand 8	Homo sapiens	111-115
33531656-6	2021	Thus, we designed a novel therapeutic approach that implements dual targeting of mTOR: direct inhibition of the mTOR protein (with rapamycin), in combination with IKAROS-mediated transcriptional repression of the MTOR gene (using the CK2 inhibitor, CX-4945).	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	112-116
33354770-9	2021	Rapamycin and bafilomycin A1 treatment showed that FUS KO cells were not able to initiate autophagy as efficiently as wild-type cells, suggesting that the autophagosome formation is affected in the absence of FUS.	Sirolimus	0-9	FUS RNA binding protein	Homo sapiens	51-54
33930202-0	2021	Rapamycin attenuates depression and anxiety like behaviours through modulation of the NLRP3 pathway in pentylenetetrazole-kindled male Wistar rats.	Sirolimus	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	86-91
33913609-8	2021	Both mTOR inhibitor rapamycin and MEK inhibitor trametinib inhibited growth of the two cell lines.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	5-9
33542495-4	2021	The mTOR inhibitor rapamycin impeded glycolysis and limited flagellin-induced secretion of immune mediators.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33116044-10	2021	In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta.	Sirolimus	44-53	interleukin 6	Mus musculus	220-224
33116044-10	2021	In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta.	Sirolimus	44-53	mast cell protease 1	Mus musculus	226-231
33930202-15	2021	In addition, rapamycin increased the catalase and superoxide dismutase levels in the serum and significantly decreased the gene expression of I11b and Nlrp3 compared to the PTZ group.	Sirolimus	13-22	catalase	Rattus norvegicus	37-45
33930202-15	2021	In addition, rapamycin increased the catalase and superoxide dismutase levels in the serum and significantly decreased the gene expression of I11b and Nlrp3 compared to the PTZ group.	Sirolimus	13-22	NLR family, pyrin domain containing 3	Rattus norvegicus	151-156
33930202-16	2021	Our results showed that the inhibitory effect of mTOR inhibitor (rapamycin) on reactive oxygen species production during NLRP3 inflammasome activation could bring about behavioral alterations in anxiety and depression.	Sirolimus	65-74	NLR family, pyrin domain containing 3	Rattus norvegicus	121-126
34056375-0	2021	Improved Skin Permeability after Topical Treatment with Serine Protease: Probing the Penetration of Rapamycin by Scanning Transmission X-ray Microscopy.	Sirolimus	100-109	coagulation factor II, thrombin	Homo sapiens	56-71
33891611-2	2021	Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drugs show highly variable treatment benefit in patients with such cancers.	Sirolimus	99-108	TSC complex subunit 1	Homo sapiens	33-37
34056375-6	2021	However, rapamycin is observed to penetrate more efficiently the stratum corneum when modifications of the skin barrier are induced by the topical pretreatment with the serine protease trypsin for variable time periods ranging from 2 to 16 h. After the longest exposure time to serine protease, the drug is even found in the viable epidermis.	Sirolimus	9-18	coagulation factor II, thrombin	Homo sapiens	169-184
34056375-6	2021	However, rapamycin is observed to penetrate more efficiently the stratum corneum when modifications of the skin barrier are induced by the topical pretreatment with the serine protease trypsin for variable time periods ranging from 2 to 16 h. After the longest exposure time to serine protease, the drug is even found in the viable epidermis.	Sirolimus	9-18	coagulation factor II, thrombin	Homo sapiens	278-293
33910008-1	2021	Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits.	Sirolimus	82-91	TSC complex subunit 1	Homo sapiens	175-179
33894212-5	2021	This was associated with a greater BCAA-induced activation of mTOR signaling in the heart at the end of the active period; pharmacological inhibition of mTOR (through rapamycin) blocked BCAA-induced augmentation of cardiac mass and cardiomyocyte size.	Sirolimus	167-176	AT rich interactive domain 4B (RBP1-like)	Mus musculus	35-39
33930827-8	2021	Rapamycin, an inhibitor of mTOR, was used to study the role of mTOR signaling pathway on exosomes mediated migration of SW480 cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
33894212-5	2021	This was associated with a greater BCAA-induced activation of mTOR signaling in the heart at the end of the active period; pharmacological inhibition of mTOR (through rapamycin) blocked BCAA-induced augmentation of cardiac mass and cardiomyocyte size.	Sirolimus	167-176	AT rich interactive domain 4B (RBP1-like)	Mus musculus	186-190
33924197-6	2021	Autophagy inhibition by chloroquine reduced decorin mRNA levels, while autophagy activation using the mTOR inhibitor rapamycin enhanced decorin transcription.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	102-106
33959512-4	2021	Rapamycin and 3BDO were used to regulate the mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	45-49
33959512-7	2021	Rapamycin reduced the secretion of IL-4 in tumor cells as well as YM1 in macrophages.	Sirolimus	0-9	interleukin 4	Homo sapiens	35-39
33922284-1	2021	BACKGROUND: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence.	Sirolimus	197-206	mechanistic target of rapamycin kinase	Homo sapiens	213-217
33902956-0	2021	Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	102-108
33902956-2	2021	Sirolimus is a typical mammalian target of rapamycin (mTOR) inhibitor, and tuberous sclerosis 1-tuberous sclerosis 2 complex (TSC1/TSC2) is an important negative effector in the mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	23-52
33902956-2	2021	Sirolimus is a typical mammalian target of rapamycin (mTOR) inhibitor, and tuberous sclerosis 1-tuberous sclerosis 2 complex (TSC1/TSC2) is an important negative effector in the mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	54-58
33902956-2	2021	Sirolimus is a typical mammalian target of rapamycin (mTOR) inhibitor, and tuberous sclerosis 1-tuberous sclerosis 2 complex (TSC1/TSC2) is an important negative effector in the mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	178-182
33902956-11	2021	Subgroup (TSC1-based or TSC2-based) analyses revealed that patients with low TSC1 or TSC2 expression benefited from sirolimus (DFS: P = 0.046, OS: P = 0.006 for TSC1; DFS: P = 0.05, OS: P = 0.003 for TSC2) compared with patients with high expression.	Sirolimus	116-125	TSC complex subunit 1	Homo sapiens	77-81
33902956-11	2021	Subgroup (TSC1-based or TSC2-based) analyses revealed that patients with low TSC1 or TSC2 expression benefited from sirolimus (DFS: P = 0.046, OS: P = 0.006 for TSC1; DFS: P = 0.05, OS: P = 0.003 for TSC2) compared with patients with high expression.	Sirolimus	116-125	TSC complex subunit 1	Homo sapiens	77-81
33902956-12	2021	TSC1 knockdown in Huh-7 and Bel-7402 HCC cell lines activated the mTORC1 pathway and enhanced cell proliferation, migration and sensitivity to SRL in vitro and in vivo.	Sirolimus	143-146	TSC complex subunit 1	Homo sapiens	0-4
33902956-13	2021	CONCLUSION: TSC1/2 expression could be used to predict the prognosis of patients with HCC beyond the Milan criteria who underwent SRL-based immunosuppression following LT. TSC1 knockdown promoted HCC malignancy and enhanced sensitivity to SRL.	Sirolimus	130-133	TSC complex subunit 1	Homo sapiens	12-18
33902956-13	2021	CONCLUSION: TSC1/2 expression could be used to predict the prognosis of patients with HCC beyond the Milan criteria who underwent SRL-based immunosuppression following LT. TSC1 knockdown promoted HCC malignancy and enhanced sensitivity to SRL.	Sirolimus	130-133	TSC complex subunit 1	Homo sapiens	12-16
33902956-13	2021	CONCLUSION: TSC1/2 expression could be used to predict the prognosis of patients with HCC beyond the Milan criteria who underwent SRL-based immunosuppression following LT. TSC1 knockdown promoted HCC malignancy and enhanced sensitivity to SRL.	Sirolimus	239-242	TSC complex subunit 1	Homo sapiens	12-18
33902956-13	2021	CONCLUSION: TSC1/2 expression could be used to predict the prognosis of patients with HCC beyond the Milan criteria who underwent SRL-based immunosuppression following LT. TSC1 knockdown promoted HCC malignancy and enhanced sensitivity to SRL.	Sirolimus	239-242	TSC complex subunit 1	Homo sapiens	12-16
33860865-5	2021	The study also reveals that treatment of TSC mutant cells with the drug candidate Proxison combined with reduced concentration of rapamycin can increase production of reactive oxygen species (ROS), can modify miRNA expression pattern associated with p53 regulation and can reduce cell viability.	Sirolimus	130-139	TSC complex subunit 1	Homo sapiens	41-44
33860865-5	2021	The study also reveals that treatment of TSC mutant cells with the drug candidate Proxison combined with reduced concentration of rapamycin can increase production of reactive oxygen species (ROS), can modify miRNA expression pattern associated with p53 regulation and can reduce cell viability.	Sirolimus	130-139	tumor protein p53	Homo sapiens	250-253
33935683-5	2021	This study aimed to explore whether rapamycin can ameliorate anesthesia/surgery-induced cognitive deficits by inhibiting mTOR, activating autophagy and rising synaptic plasticity-related proteins in the hippocampus.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	121-125
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	mitogen-activated protein kinase 3	Homo sapiens	30-73
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	mitogen-activated protein kinase 3	Homo sapiens	75-81
33880473-4	2022	While rapamycin and rapamycin analogs (rapalogs) are FDA-approved for use as mTOR inhibitors in multiple clinical settings, including cancer, we previously found that rapamycin can increase the susceptibility of cells to infection by Influenza A virus.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	77-81
33880473-4	2022	While rapamycin and rapamycin analogs (rapalogs) are FDA-approved for use as mTOR inhibitors in multiple clinical settings, including cancer, we previously found that rapamycin can increase the susceptibility of cells to infection by Influenza A virus.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	77-81
33880473-4	2022	While rapamycin and rapamycin analogs (rapalogs) are FDA-approved for use as mTOR inhibitors in multiple clinical settings, including cancer, we previously found that rapamycin can increase the susceptibility of cells to infection by Influenza A virus.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	77-81
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	TSC complex subunit 1	Homo sapiens	28-31
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	TSC complex subunit 1	Homo sapiens	91-95
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	TSC complex subunit 1	Homo sapiens	97-105
33923449-8	2021	Rapamycin efficiently decreased mTORC1 activity of these TSC1-deficient cells in vitro.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	57-61
33923449-9	2021	In vivo, TSC1-deficient cells could form SEGA-like tumors and Rapamycin treatment decreased tumor growth.	Sirolimus	62-71	TSC complex subunit 1	Homo sapiens	9-13
33921372-7	2021	Rapamycin reduced the aggravated skin inflammation induced by TCDD and restored TCDD-induced autophagy suppression and the increase of AHR expression, oxidative stress, and inflammatory response in the skin lesions of a psoriatic mouse model.	Sirolimus	0-9	aryl-hydrocarbon receptor	Mus musculus	135-138
33206174-5	2021	CHIR-124, a selective CHK1 inhibitor, impairs cell viability and induces remarkable synergistic lethality with mTOR inhibitor rapamycin in MYC-overexpressing cells.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	111-115
33927621-8	2021	However, these protective effects against HIBD could be suppressed when rapamycin, a specific inhibitor of mTOR, was included.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	107-111
33921372-8	2021	In conclusion, we demonstrated that rapamycin alleviates TCDD-induced aggravated dermatitis in mice with imiquimod-induced psoriasis-like dermatitis through AHR and autophagy modulation.	Sirolimus	36-45	aryl-hydrocarbon receptor	Mus musculus	157-160
33897695-11	2021	We found rapamycin, a mTOR inhibitor, partly inhibited cell proliferation, invasion, and migration in shTOX HCT116 cells.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	22-26
33897381-1	2021	Hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) due to mutations in genes along the PI3K-mTOR pathway and the GATOR1 complex causes a spectrum of neurodevelopmental disorders (termed mTORopathies) associated with malformation of cortical development and intractable epilepsy.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	66-70
33912444-0	2021	Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRalpha-Positive Breast Cancer.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	69-72
33912444-0	2021	Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRalpha-Positive Breast Cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	73-77
33839363-11	2021	Accordingly, LUAD-0061AS3 cells were more sensitive to MTOR inhibitors than MDA-MB-175-VII cells and targeting the MTOR pathway with rapamycin blocked growth of LUAD-0061AS3 PDX tumors in vivo.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	55-59
33839363-11	2021	Accordingly, LUAD-0061AS3 cells were more sensitive to MTOR inhibitors than MDA-MB-175-VII cells and targeting the MTOR pathway with rapamycin blocked growth of LUAD-0061AS3 PDX tumors in vivo.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	115-119
33280021-9	2021	GRK4 overexpression in cardiomyocytes aggravated apoptosis, repressed autophagy, and decreased beclin-1 expression, which were partially rescued by the autophagy agonist rapamycin.	Sirolimus	170-179	G protein-coupled receptor kinase 4	Mus musculus	0-4
33962348-2	2021	A mammalian target of rapamycin (mTOR) inhibitor (mTORi), either everolimus or sirolimus, is now routinely prescribed for multiple clinical manifestations of TSC, including subependymal giant cell astrocytoma and epilepsy.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	2-31
33916918-8	2021	In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug.	Sirolimus	57-61	mechanistic target of rapamycin kinase	Homo sapiens	157-186
33916918-8	2021	In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug.	Sirolimus	57-61	mechanistic target of rapamycin kinase	Homo sapiens	188-192
33962348-2	2021	A mammalian target of rapamycin (mTOR) inhibitor (mTORi), either everolimus or sirolimus, is now routinely prescribed for multiple clinical manifestations of TSC, including subependymal giant cell astrocytoma and epilepsy.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	33-37
33826265-12	2021	Two patients were treated with mTOR inhibitors (rapamycin), with a progressive decrease in extracutaneous involvement and platelet recovery, but with a poor response in dermal lesions.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	31-35
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	98-101
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	nitric oxide synthase 3	Homo sapiens	102-106
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	161-164
33540491-5	2021	We also found that LPAR5 specific antagonists TC LPA5 4, PI3K inhibitor Wortmannin or mTOR inhibitor Rapamycin pretreatment abrogated phosphorylation of Akt and p70S6K1 stimulated by LPA in CGTH-W3 and TPC-1 cells.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	86-90
33540491-5	2021	We also found that LPAR5 specific antagonists TC LPA5 4, PI3K inhibitor Wortmannin or mTOR inhibitor Rapamycin pretreatment abrogated phosphorylation of Akt and p70S6K1 stimulated by LPA in CGTH-W3 and TPC-1 cells.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	153-156
33540491-5	2021	We also found that LPAR5 specific antagonists TC LPA5 4, PI3K inhibitor Wortmannin or mTOR inhibitor Rapamycin pretreatment abrogated phosphorylation of Akt and p70S6K1 stimulated by LPA in CGTH-W3 and TPC-1 cells.	Sirolimus	101-110	two pore segment channel 1	Homo sapiens	202-207
33300153-3	2021	Rapamycin, the mTOR inhibitor, showed inhibitory effects on T-ALL cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-19
33300153-7	2021	Rapamycin and MYCN inhibition suppressed both Wnt/beta-catenin and mTOR signaling pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	67-71
33300153-0	2021	Growth inhibition and suppression of the mTOR and Wnt/beta-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	41-45
33717266-7	2021	Additionally, SOX2 activated AKT through the PTEN/PI3K/phosphoinositide-dependent protein kinase 1 and mammalian target of rapamycin complex 2 signaling pathways.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	29-32
33692862-8	2021	Furthermore, METTL1 promoted proliferation and colony formation of A549 cells, and inhibited autophagy via the AKT/mechanistic target of rapamycin complex 1 signaling pathway.	Sirolimus	137-146	AKT serine/threonine kinase 1	Homo sapiens	111-114
33070461-4	2021	Furthermore, the evidence of an efficient T-cell alloimmunity abrogation accompanied by a sustained anti-viral response after sirolimus addition, promotes the potential benefit of converting patients to an mTOR-based immunosuppression in case of PVAN.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	206-210
33534053-1	2021	The mechanistic (or mammalian) target of rapamycin (mTOR) is considered as a critical regulatory enzyme involved in essential signaling pathways affecting cell growth, cell proliferation, protein translation, regulation of cellular metabolism, and cytoskeletal structure.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	52-56
33892851-5	2021	In recent decades, the identification of the responsible genes and gene products forming the mechanistic target of rapamycin complex, previously termed the mammalian target of rapamycin, not only has expanded our understanding of tuberous sclerosis pathophysiology, but has also inspired the search for targeted interventions.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	156-185
33156513-6	2021	In addition, autophagy inhibitor 3-methyladenine (3-MA) had a protective effect similar to that of AMI, but autophagy activator rapamycin eliminated the protective effect of AMI by suppressing mTOR activation.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	193-197
33352257-6	2021	Further analysis indicated that a certain dosage of 3-MA and rapamycin decreased apoptosis and the caspase-3 expression, which suggested that As-induced autophagy regulated AML-12 cells apoptosis through the expressions of PI3K, mTOR, P62 and Bcl-2.	Sirolimus	61-70	B cell leukemia/lymphoma 2	Mus musculus	243-248
33307051-10	2021	Furthermore, the treatment efficacy of IGF were blocked with AMPA receptor inhibitor NBQX or mTOR inhibitor Rapamycin.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	93-97
33775188-4	2021	3-Methyladenine (inhibitors of autophagy) and rapamycin (activator of autophagy) respectively inhibits or activates Ang II-induced autophagy levels.	Sirolimus	46-55	angiotensinogen	Homo sapiens	116-122
33775188-7	2021	Rapamycin further decreases NO production combined with Ang II.	Sirolimus	0-9	angiotensinogen	Homo sapiens	56-62
33383488-0	2021	Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	108-111
33383488-13	2021	Overexpression of PI3K, AKT and mTOR were suppressed by RAPA treatment.	Sirolimus	56-60	AKT serine/threonine kinase 1	Rattus norvegicus	24-27
33383488-16	2021	We proposed a potential mechanism that RAPA may play improving role by inhibiting neuronal apoptosis and enhancing mitophagy through PI3K/AKT/mTOR pathway.	Sirolimus	39-43	AKT serine/threonine kinase 1	Rattus norvegicus	138-141
33977204-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) complex is the major nutrient sensor in mammalian cells that responds to amino acids, energy levels, growth factors, and hormones, such as insulin, to control anabolic and catabolic processes.	Sirolimus	24-33	insulin	Homo sapiens	192-199
33395696-8	2021	These abnormalities were ameliorated by pharmacological activation of UNC-51/ATG1, a FEZ1-activating kinase, with rapamycin and metformin.	Sirolimus	114-123	fasciculation and elongation protein zeta 1	Homo sapiens	85-89
33865602-11	2021	The expression of p-mTOR, p-4EBP1, and p-P70S6K decreased and the ratio of LC-3 II/LC-3 I elevated after treatment of sirolimus.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	20-24
33865602-13	2021	Sirolimus may block mTOR-mediated pathways and induced autophagy in KHE.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	20-24
33661803-7	2021	Rapamycin, an inhibitor of mTOR, was used to further study the role of H19 in autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
33340561-8	2021	Silencing FAM135B shows synergy with PI3K/Akt/mTOR pathway inhibitor (rapamycin) in increasing radiosensitivity, regulating the expression of cell cycle protein and inducing apoptosis of ESCC cells.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	46-50
33790644-0	2021	Rapamycin Inhibits Glioma Cells Growth and Promotes Autophagy by miR-26a-5p/DAPK1 Axis.	Sirolimus	0-9	death associated protein kinase 1	Homo sapiens	76-81
33790644-9	2021	Rapamycin substantially inhibited cell proliferation and cell percentage in the S phase and promoted cell apoptosis; miR-26a-5p inhibitor increased cell proliferation and cell cycle and decreased cell apoptosis; DAPK1 overexpression further induced cell proliferation, increased the cell number in the S phase, and inhibited apoptosis in glioma cells.	Sirolimus	0-9	death associated protein kinase 1	Homo sapiens	212-217
33790644-11	2021	Conclusion: Rapamycin exerts anti-tumor effects by promoting autophagy in glioma cells, which was dependent on the miR-26a-5p/DAPK1 pathway activation by rapamycin.	Sirolimus	12-21	death associated protein kinase 1	Homo sapiens	126-131
33790644-11	2021	Conclusion: Rapamycin exerts anti-tumor effects by promoting autophagy in glioma cells, which was dependent on the miR-26a-5p/DAPK1 pathway activation by rapamycin.	Sirolimus	154-163	death associated protein kinase 1	Homo sapiens	126-131
33723228-8	2021	We found that rapamycin effectively reduced the aggregation of TDP-43 in OPTN (E50K) mice and decreased the protein levels of p62/SQSTM1 and the autophagic marker LC3-II.	Sirolimus	14-23	TAR DNA binding protein	Mus musculus	63-69
33723228-8	2021	We found that rapamycin effectively reduced the aggregation of TDP-43 in OPTN (E50K) mice and decreased the protein levels of p62/SQSTM1 and the autophagic marker LC3-II.	Sirolimus	14-23	optineurin	Mus musculus	73-77
33710804-12	2021	SNORA23 and rapamycin blocked the PI3K/AKT/mTOR signaling pathway and impaired HCC growth in vivo.	Sirolimus	12-21	AKT serine/threonine kinase 1	Homo sapiens	39-42
33710804-12	2021	SNORA23 and rapamycin blocked the PI3K/AKT/mTOR signaling pathway and impaired HCC growth in vivo.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	43-47
33753729-6	2021	The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed that FGF21 was related to autophagy and the phosphatidylinositol 3-kinase-Akt kinase-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway.	Sirolimus	185-194	fibroblast growth factor 21	Homo sapiens	85-90
33753729-6	2021	The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed that FGF21 was related to autophagy and the phosphatidylinositol 3-kinase-Akt kinase-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway.	Sirolimus	185-194	AKT serine/threonine kinase 1	Homo sapiens	154-157
33737259-3	2021	Sirolimus, a downstream inhibitor of the PI3K/AKT pathway and best known for its immunosuppressive effect, has been used off-label for lesions for which approved therapies were associated with unsatisfactory results or recurrence.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	46-49
33683500-0	2021	Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro.	Sirolimus	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	46-49
33683500-6	2021	The suppressed activation of mTOR and MEK by combined rapamycin and binimetinib treatment was confirmed using Western blot assay.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	29-33
33683500-6	2021	The suppressed activation of mTOR and MEK by combined rapamycin and binimetinib treatment was confirmed using Western blot assay.	Sirolimus	54-63	mitogen-activated protein kinase kinase 7	Homo sapiens	38-41
33691148-4	2021	Against this background, the present study aimed interfering with extinction of conditioned anti-proliferative and immunosuppressive immune responses in a taste-associative learning paradigm with the mTOR inhibitor rapamycin.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	200-204
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	325-329
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	325-329
33675613-3	2021	Previous studies have reported that sertraline and fluoxetine can suppress the growth of gastric carcinoma, melanoma and nonsmall cell lung cancers by inhibiting the mammalian target rapamycin (mTOR) activity.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	194-198
33416457-2	2021	The mechanistic target of the rapamycin (mTOR) pathway is vital for fetal lung development and implicated in hypoxia-associated PH, yet its involvement in the developmental programming of PH remains unclear.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	41-45
33598769-7	2021	However, Akt and mTOR inhibitors (MK-2206 and Rapamycin) blocked the effect of taurine on improving axonal damage.	Sirolimus	46-55	AKT serine/threonine kinase 1	Rattus norvegicus	9-12
33658088-2	2021	Mutations in the TSC1 or TSC2 genes have been reported to cause disruption in the TSC1-TSC2 intracellular protein complex, causing over-activation of the mammalian target of rapamycin protein complex.	Sirolimus	174-183	TSC complex subunit 1	Homo sapiens	17-21
33658088-2	2021	Mutations in the TSC1 or TSC2 genes have been reported to cause disruption in the TSC1-TSC2 intracellular protein complex, causing over-activation of the mammalian target of rapamycin protein complex.	Sirolimus	174-183	TSC complex subunit 1	Homo sapiens	82-86
33657380-5	2021	Further interrogation of the rapamycin-insensitive phosphorylation events identifies the S473 residue on Tripartite Motif-Containing 28 (TRIM28) as one of the most robust MIC-regulated phosphorylation sites, and extensive follow-up studies suggest that TRIM28 significantly contributes to the homeostatic regulation of muscle size and function as well as the hypertrophy that occurs in response to increased mechanical loading.	Sirolimus	29-38	tripartite motif containing 28	Homo sapiens	137-143
33646885-8	2021	Rapamycin, an inhibitor of mTOR, reduced the BMP-4-stimulated p70 S6 kinase phosphorylation, and compound C, an inhibitor of BMP type I receptor, suppressed the SMAD1/5/8 phosphorylation stimulated by BMP-4.	Sirolimus	0-9	bone morphogenetic protein 4	Mus musculus	45-50
33646885-8	2021	Rapamycin, an inhibitor of mTOR, reduced the BMP-4-stimulated p70 S6 kinase phosphorylation, and compound C, an inhibitor of BMP type I receptor, suppressed the SMAD1/5/8 phosphorylation stimulated by BMP-4.	Sirolimus	0-9	bone morphogenetic protein 4	Mus musculus	201-206
33050984-6	2021	The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRalpha, CYP7A1, ABCG1, PPARgamma, ApoA1) in the liver.	Sirolimus	25-29	nuclear receptor subfamily 1, group H, member 3	Mus musculus	159-167
33050984-6	2021	The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRalpha, CYP7A1, ABCG1, PPARgamma, ApoA1) in the liver.	Sirolimus	25-29	cytochrome P450, family 7, subfamily a, polypeptide 1	Mus musculus	169-175
33050984-8	2021	ATV and RAPA+ATV decreased the levels of Tnf-alpha and Il-1beta in the spleen, but not in the aorta.	Sirolimus	8-12	tumor necrosis factor	Mus musculus	41-50
33050984-9	2021	Together, these results indicate that, in CKD-induced ApoE-/- mice, RAPA significantly reduces the development of atherosclerosis by regulating the expression of inflammatory cytokines and the co-application of ATV improves lipid metabolism.	Sirolimus	68-72	apolipoprotein E	Mus musculus	54-58
33369022-1	2021	INTRODUCTION: Sirolimus has become a pillar in the treatment of vascular anomalies due to its inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	112-141
33481427-8	2021	SUMMARY: The mTOR inhibitor sirolimus is the most used targeted therapy so far but new molecules are tested currently.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
33527306-4	2021	Recently, some researchers have suggested the therapeutic potential of mTOR inhibitors such as rapamycin against COVID-19.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	71-75
32037974-1	2021	Rapamycin and their derivatives known as rapalogs, were the first-generation mTOR inhibitors which interacted with mTORC1 but not with the mTORC2 protein.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	77-81
33723462-8	2021	Moreover, we find that fasting-induced or genetic overexpression of FOXO4 and FKBP5 is sufficient to downregulate mammalian target of rapamycin complex 1 signalling and suppress signal transducer and activator of transcription 1/3 activation.	Sirolimus	134-143	FKBP prolyl isomerase 5	Homo sapiens	78-83
33423298-2	2021	Previous studies suggest a connection between the FA protein FANCD2 and the non-FA protein mechanistic target of rapamycin (mTOR).	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	124-128
33748286-6	2021	Furthermore, rapamycin reduced urinary protein-induced NGAL and KIM-1 secretion and cell growth inhibition, while chloroquine played the opposite effect, indicating that autophagy activation by ERK pathway was an adaptive response in the exposure to urinary proteins.	Sirolimus	13-22	mitogen-activated protein kinase 1	Homo sapiens	194-197
33653802-13	2021	BCG-induced cytokines showed a progressive increase in IL-8 (p=0.02) and TNF-alpha (p=0.04) over time for patients on rapamycin 2.0 mg, whereas patients receiving placebo had no significant change in urinary cytokines.	Sirolimus	118-127	C-X-C motif chemokine ligand 8	Homo sapiens	55-59
33653802-13	2021	BCG-induced cytokines showed a progressive increase in IL-8 (p=0.02) and TNF-alpha (p=0.04) over time for patients on rapamycin 2.0 mg, whereas patients receiving placebo had no significant change in urinary cytokines.	Sirolimus	118-127	tumor necrosis factor	Homo sapiens	73-82
33660929-2	2021	In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	15-19
33369022-1	2021	INTRODUCTION: Sirolimus has become a pillar in the treatment of vascular anomalies due to its inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	143-147
33640883-2	2021	mTOR inhibition by rapamycin can sensitize cancer cells to radiotherapy.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33641344-3	2021	Our goal was to assess the effects of mTOR inhibition by rapamycin on inflammation, microglial activation, oxidative stress, and apoptosis associated with the changes in the inhibitor-kappaB (IkappaB)-alpha/nuclear factor-kappaB (NF-kappaB)/hypoxia-inducible factor-1alpha (HIF-1alpha) pathway activity following a systemic challenge with lipopolysaccharide (LPS).	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	38-42
33641344-5	2021	Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues.	Sirolimus	22-31	synaptotagmin 1	Rattus norvegicus	95-98
33641344-6	2021	Rapamycin attenuated the increment in the expression of tumor necrosis factor-alpha and interleukin-1beta, the inducible nitric oxide synthase, gp91phox, and p47phox in addition to nitrite levels elicited by LPS in tissues or sera.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	56-83
33641344-6	2021	Rapamycin attenuated the increment in the expression of tumor necrosis factor-alpha and interleukin-1beta, the inducible nitric oxide synthase, gp91phox, and p47phox in addition to nitrite levels elicited by LPS in tissues or sera.	Sirolimus	0-9	interleukin 1 beta	Rattus norvegicus	88-105
33641344-6	2021	Rapamycin attenuated the increment in the expression of tumor necrosis factor-alpha and interleukin-1beta, the inducible nitric oxide synthase, gp91phox, and p47phox in addition to nitrite levels elicited by LPS in tissues or sera.	Sirolimus	0-9	nitric oxide synthase 2	Rattus norvegicus	111-142
32482020-3	2021	Sirolimus, a mammalian target of rapamycin(mTOR) inhibitor recently has been reported to be effective in the treatment of insulinoma and CHI patients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
32482020-3	2021	Sirolimus, a mammalian target of rapamycin(mTOR) inhibitor recently has been reported to be effective in the treatment of insulinoma and CHI patients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	43-47
33718332-2	2020	As such, rapamycin that inhibits the mechanistic target of rapamycin (mTOR), the downstream effector of this signaling pathway, is of great interest.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	37-68
33718332-2	2020	As such, rapamycin that inhibits the mechanistic target of rapamycin (mTOR), the downstream effector of this signaling pathway, is of great interest.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	70-74
33718332-10	2020	Interestingly, cells cultivated in normoxia (21% O2) seem to be more sensitive to mTOR inhibition by rapamycin than those cultivated in hypoxia (0.4% O2).	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	82-86
33367372-0	2021	PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.	Sirolimus	37-46	CD274 antigen	Mus musculus	0-5
33367372-4	2021	In this study, we bioengineered cell membrane-derived PD-L1 nanovesicles (PD-L1 NVs) to carry low doses of RAPA.	Sirolimus	107-111	CD274 antigen	Mus musculus	54-59
33367372-6	2021	Importantly, PD-L1 NVs encapsulated with rapamycin exerted stronger effects on inhibiting T-cell proliferation than PD-L1 NVs or rapamycin alone.	Sirolimus	41-50	CD274 antigen	Mus musculus	13-18
33679734-2	2021	Recent findings indicate that the mammalian target of the rapamycin (mTOR)-signaling pathway is implicated in the regulation of BTB assembly and restructuring.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	69-73
33665668-0	2021	[The new target of Rapamycin: lysosomal calcium channel TRPML1].	Sirolimus	19-28	mucolipin TRP cation channel 1	Homo sapiens	56-62
33681258-13	2021	Further assessments revealed that activation of mTOR and GSK3beta was almost completely inhibited by rapamycin and SB216763, respectively, which significantly increased the caspase-3 levels.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	48-52
33681258-13	2021	Further assessments revealed that activation of mTOR and GSK3beta was almost completely inhibited by rapamycin and SB216763, respectively, which significantly increased the caspase-3 levels.	Sirolimus	101-110	caspase 3	Homo sapiens	173-182
33482580-0	2021	Methionine controls insulin/mammalian target of rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability.	Sirolimus	48-57	insulin	Homo sapiens	20-27
33621205-6	2021	The relevant mechanisms were related to activation of mTOR, and selective inhibition of mTOR by rapamycin could weaken the sensitization of nicardipine to temozolomide, which suggest that nicardipine can be applied as an adjuvant to inhibit autophagy in GSCs, and enhance apoptosis-promoting effect of temozolomide in GSCs as well.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	88-92
33599151-6	2021	mTOR forms two protein complexes, mTORC1, which is sensitive to rapamycin and mTORC2, which is not directly inhibited by this drug.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33669763-2	2021	We employed a structure-based workflow to identify new inhibitors targeting mTOR kinase at rapamycin binding site.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	76-80
33669763-8	2021	Furthermore, the stability of the resulting complexes was studied by means of MD simulation which revealed that the selected compounds were able to form a stable ternary complex with FKBP12 and FRB domain, thus underlining their potential ability to inhibit mTOR with a rapamycin-like mechanism.	Sirolimus	270-279	mechanistic target of rapamycin kinase	Homo sapiens	258-262
33382998-5	2021	While insulin-activated IRS/PI3K/PKB pathway cascades are primarily known to reduce glucose production, it was recently discovered to increase the Hh signaling pathway"s stability, thereby activating the PI3K/PKB/mammalian target of rapamycin complex 2 (mTORC2) signaling pathway.	Sirolimus	233-242	insulin	Homo sapiens	6-13
33643212-4	2021	In cell models of epilepsy and TSC, rapamycin, an mTOR inhibitor, has been shown to decrease seizure frequency and duration, and positively affect cell growth and morphology.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	50-54
33412209-6	2021	However, U0126, a potent extracellular signal-regulated kinase 1/2 (Erk1/2) inhibitor, decreased PDGF-BB-induced LC3 expression, while rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), increased it.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	166-195
33574160-4	2021	A hypomorphic mtor strain or rapamycin was used to inhibit mTOR activity.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Danio rerio	59-63
33578031-11	2021	Mechanistically, BAG3 overexpression in NRVCs promoted physiological hypertrophy by activating the protein kinase B (AKT)/mammalian (or mechanistic) target of rapamycin (mTOR) pathway.	Sirolimus	159-168	BAG cochaperone 3	Homo sapiens	17-21
33672955-6	2021	In addition, Octpep-1 combined with rapamycin (mTORC1 inhibitor) or LY3214996 (ERK1/2 inhibitor) augmented the cytotoxicity against BRAF(V600E) melanoma cells in comparison with the inhibitors or Octpep-1 alone.	Sirolimus	36-45	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	132-136
33634164-3	2020	The presence of these populations in VAs is supported, in part, by the observed clinical effect of the mTOR inhibitor, sirolimus, that regulates differentiation of embryonic stem cells (ESCs).	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	103-107
33578031-11	2021	Mechanistically, BAG3 overexpression in NRVCs promoted physiological hypertrophy by activating the protein kinase B (AKT)/mammalian (or mechanistic) target of rapamycin (mTOR) pathway.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Homo sapiens	170-174
33548116-13	2021	Treatment of cells with autophagy inducer rapamycin reduced LC3-positive aggregates, CHOP and cell death induced by 2bpIns-OPTN.	Sirolimus	42-51	optineurin	Mus musculus	123-127
33197504-12	2021	Rapamycin abolished the protective effects of sh BACE1-AS against Abeta1-42 induced cell injury.	Sirolimus	0-9	beta-secretase 1	Homo sapiens	49-54
33547375-1	2021	Rictor is a key component of the mammalian target of rapamycin complex 2 (mTORC2) and is required for Akt phosphorylation (Ser473).	Sirolimus	53-62	AKT serine/threonine kinase 1	Homo sapiens	102-105
33450548-2	2021	Herein, a series of flavonol-based derivatives of fisetin, a plant-based flavonoid identified as an anti-tumorigenic agent targeting the mammalian targets of rapamycin (mTOR)-regulated pathways, were synthesized and fully characterized.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	169-173
33614662-0	2021	Rapamycin Protects Skin Fibroblasts From UVA-Induced Photoaging by Inhibition of p53 and Phosphorylated HSP27.	Sirolimus	0-9	tumor protein p53	Homo sapiens	81-84
33614662-5	2021	In addition, treatment with rapamycin significantly increased cell autophagy levels, decreased the expression of p53 and phosphorylated HSP27, and reduced genotoxic and oxidative cellular stress levels in UVA-induced HDFs.	Sirolimus	28-37	tumor protein p53	Homo sapiens	113-116
33497611-3	2021	They act in a non-redundant manner to anchor the tuberous sclerosis complex (TSC) protein complex to lysosomes and suppress activation of the metabolic master regulator mechanistic target of rapamycin complex 1 (mTORC1) by amino acids and insulin.	Sirolimus	191-200	insulin	Homo sapiens	239-246
33574709-2	2021	Inhibition of mTORC1 (mechanistic target of rapamycin complex 1) activity upon aspirin treatment has been reported in breast cancer cells harboring PI3KCA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation and is considered to account for anticancer action.	Sirolimus	44-53	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	156-226
33614622-10	2020	Meanwhile, the BMP9-induced Wnt10b is also reduced by a PI3K-specific inhibitor (Ly294002) or rapamycin, respectively.	Sirolimus	94-103	growth differentiation factor 2	Homo sapiens	15-19
33614622-10	2020	Meanwhile, the BMP9-induced Wnt10b is also reduced by a PI3K-specific inhibitor (Ly294002) or rapamycin, respectively.	Sirolimus	94-103	Wnt family member 10B	Homo sapiens	28-34
33435684-5	2021	Thus, rapamycin differentially influences protein and lipid synthesis in mTOR signaling.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	73-77
33359326-5	2021	In this study, we examined the effects of mammalian target of rapamycin (mTOR) inhibitors (rapamycin or Torin1) on the fibrotic response induced by transforming growth factor-beta 1 (TGF-beta1) in cultured human conjunctival fibroblast (HCF) cells.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	73-77
33277337-6	2021	mRNA expression analysis and differential proteomics on betaFurKO islets revealed activation of Activating Transcription Factor 4 (ATF4), which was mediated by mammalian target of rapamycin C1 (mTORC1).	Sirolimus	180-189	activating transcription factor 4	Mus musculus	96-129
33277337-6	2021	mRNA expression analysis and differential proteomics on betaFurKO islets revealed activation of Activating Transcription Factor 4 (ATF4), which was mediated by mammalian target of rapamycin C1 (mTORC1).	Sirolimus	180-189	activating transcription factor 4	Mus musculus	131-135
32457486-4	2021	Both the classical autophagy inducer rapamycin and the classical ferroptosis activator RSL3 can block MTOR activation and cause GPX4 protein degradation in human pancreatic cancer cells.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	102-106
33352197-5	2021	The results showed that, after an intraperitoneal injection of rapamycin (2 mg/kg/day) for seven days, the alkali-induced opacity and NV were remarkably decreased mainly by suppressing the infiltration of immune cells into injured corneas, angiogenesis, VEGF expression and myofibroblasts differentiation; as well as by promoting corneal cell proliferation and PI3K/AKT/mTOR signaling.	Sirolimus	63-72	thymoma viral proto-oncogene 1	Mus musculus	366-369
33352197-6	2021	More significantly, these findings showed that epigenetic regulatory mechanisms by DNA methylation played a key role in corneal NV, including in corneal alkali burn-induced methylation modification and rapamycin-induced DNA demethylation which involved the regulation of the PI3K/AKT/mTOR signaling pathway at the protein level.	Sirolimus	202-211	thymoma viral proto-oncogene 1	Mus musculus	280-283
33359326-5	2021	In this study, we examined the effects of mammalian target of rapamycin (mTOR) inhibitors (rapamycin or Torin1) on the fibrotic response induced by transforming growth factor-beta 1 (TGF-beta1) in cultured human conjunctival fibroblast (HCF) cells.	Sirolimus	62-71	transforming growth factor beta 1	Homo sapiens	148-181
33359326-5	2021	In this study, we examined the effects of mammalian target of rapamycin (mTOR) inhibitors (rapamycin or Torin1) on the fibrotic response induced by transforming growth factor-beta 1 (TGF-beta1) in cultured human conjunctival fibroblast (HCF) cells.	Sirolimus	62-71	transforming growth factor beta 1	Homo sapiens	183-192
33359326-8	2021	And those TGF-beta1-induced changes were significantly attenuated with mTOR inhibitors, rapamycin or Torin1.	Sirolimus	88-97	transforming growth factor beta 1	Homo sapiens	10-19
32835451-6	2021	Treatment with the mTOR inhibitor rapamycin decreased astroglial VEGFR-3 expression and GLT-1 expression after SE.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
32835451-6	2021	Treatment with the mTOR inhibitor rapamycin decreased astroglial VEGFR-3 expression and GLT-1 expression after SE.	Sirolimus	34-43	solute carrier family 1 member 2	Homo sapiens	88-93
33387853-3	2021	In this paper, we examined the CDPs produced by the bacteria Pseudomonas aeruginosa PAO1, which are known as opportunistic pathogens of humans and plants on TARGET OF RAPAMYCIN (TOR) signaling pathways, and regulation of root system architecture.	Sirolimus	167-176	target of rapamycin	Arabidopsis thaliana	178-181
33337347-11	2021	ICV BMP9-induced increase in hepatic insulin sensitivity and related metabolic effects were blocked by ICV injection of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling.	Sirolimus	120-129	growth differentiation factor 2	Homo sapiens	4-8
33337347-11	2021	ICV BMP9-induced increase in hepatic insulin sensitivity and related metabolic effects were blocked by ICV injection of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	147-176
33337347-11	2021	ICV BMP9-induced increase in hepatic insulin sensitivity and related metabolic effects were blocked by ICV injection of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	178-182
33183431-3	2021	Therefore, research at home and abroad is actively focusing on the mTOR signaling pathway to further clarify the pathogenesis of the disease, and from a clinical point of view, to summarize the clinical data of more patients treated with mTOR inhibitors, to conduct a long-term follow-up and exploration of rapamycin treatment, and to summarize mature treatment experience.	Sirolimus	307-316	mechanistic target of rapamycin kinase	Homo sapiens	67-71
33183431-3	2021	Therefore, research at home and abroad is actively focusing on the mTOR signaling pathway to further clarify the pathogenesis of the disease, and from a clinical point of view, to summarize the clinical data of more patients treated with mTOR inhibitors, to conduct a long-term follow-up and exploration of rapamycin treatment, and to summarize mature treatment experience.	Sirolimus	307-316	mechanistic target of rapamycin kinase	Homo sapiens	238-242
33140268-5	2021	Rapamycin, an inhibitor of mTOR, rescued the STZ-induced increases in mTOR/p70S6K activities, tau phosphorylation and Abeta levels, as well as mitochondria abnormality and cognitive impairment in mice.	Sirolimus	0-9	histocompatibility 2, class II antigen A, beta 1	Mus musculus	118-123
33540133-9	2021	Sirolimus, a strong inhibitor of mTOR, has shown tremendous promise in the treatment of LM, both as an oral and a topical agent.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	33-37
33522203-0	2021	Effect of Shenzhu Tiaopi granule on hepatic insulin resistance in diabetic Goto-Kakizakirats via liver kinase B1/adenosine 5"-monophosphate/mammalian target of rapamycin signaling pathway.	Sirolimus	160-169	insulin	Homo sapiens	44-51
33565716-8	2021	Rapamycin or miR-138-5p mimics similarly suppressed the activation of AKT and mTOR, whereas UCA1 overexpression exert opposite roles.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	70-73
33316689-3	2021	Sirolimus is an mammalian target of rapamycin inhibitor studied in other vascular anomalies and a potentially promising therapy in Sturge-Weber syndrome.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	16-45
33565716-8	2021	Rapamycin or miR-138-5p mimics similarly suppressed the activation of AKT and mTOR, whereas UCA1 overexpression exert opposite roles.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	78-82
33565716-9	2021	Interestingly, administration of rapamycin or miR-138-5p mimics apparently antagonized the effects of UCA1 on AKT and mTOR activation.	Sirolimus	33-42	AKT serine/threonine kinase 1	Homo sapiens	110-113
33565716-9	2021	Interestingly, administration of rapamycin or miR-138-5p mimics apparently antagonized the effects of UCA1 on AKT and mTOR activation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	118-122
33270949-5	2021	Post-radiation regeneration of HSPCs in mice treated with sirolimus was accompanied by decreased gamma-H2AX levels detected by flow cytometry and increased expression of DNA repair genes by quantitative PCR.	Sirolimus	58-67	H2A.X variant histone	Mus musculus	97-107
33219627-4	2021	This may be related to Rapamycin inhibiting the phosphorylation of mTOR and affecting the expression of cell cycle-related genes (CDK2, CDK4, P27, CycleD1, and CycleD3).	Sirolimus	23-32	serine/threonine-protein kinase mTOR	Bubalus bubalis	67-71
33219627-4	2021	This may be related to Rapamycin inhibiting the phosphorylation of mTOR and affecting the expression of cell cycle-related genes (CDK2, CDK4, P27, CycleD1, and CycleD3).	Sirolimus	23-32	cyclin-dependent kinase 4	Bubalus bubalis	136-140
33270949-9	2021	In human to mouse xeno-transplantation, sirolimus enhanced engraftment of irradiated human CD34+ cells.	Sirolimus	40-49	CD34 molecule	Homo sapiens	91-95
33516270-9	2021	Consistently, the autophagy initiator rapamycin could decrease EGFR levels and increase the sensitivity of icotinib-resistant LUAD cells to icotinib.	Sirolimus	38-47	epidermal growth factor receptor	Homo sapiens	63-67
33512760-4	2021	We demonstrate that RAPA mitigates GVHD by decreasing T-cell engraftment and differentiation, inhibiting CD8+ T-cell activation and increasing the long-term IL-2 secretion, thereby supporting regulatory T-cell (Treg) proliferation.	Sirolimus	20-24	interleukin 2	Homo sapiens	157-161
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	27-31	interleukin 2	Homo sapiens	91-95
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	27-31	interleukin 2	Homo sapiens	152-156
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	27-31	interleukin 2	Homo sapiens	152-156
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	250-254	interleukin 2	Homo sapiens	152-156
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	250-254	interleukin 2	Homo sapiens	152-156
33307091-1	2021	The Tuberous Sclerosis Complex (TSC) protein complex (TSCC), comprising TSC1, TSC2, and TBC1D7, is widely recognised as a key integration hub for cell growth and intracellular stress signals upstream of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	227-236	TSC complex subunit 1	Homo sapiens	72-76
33496749-4	2021	Activation of the mammalian target of rapamycin (mTOR) was diminished in hypoxic leukemic cells, and treatment of T-ALL with the mTOR inhibitor rapamycin in normoxia mimicked the hypoxia effects, namely decreased cell growth and increased quiescence and drug resistance.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	49-53
33496749-4	2021	Activation of the mammalian target of rapamycin (mTOR) was diminished in hypoxic leukemic cells, and treatment of T-ALL with the mTOR inhibitor rapamycin in normoxia mimicked the hypoxia effects, namely decreased cell growth and increased quiescence and drug resistance.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	129-133
33307091-1	2021	The Tuberous Sclerosis Complex (TSC) protein complex (TSCC), comprising TSC1, TSC2, and TBC1D7, is widely recognised as a key integration hub for cell growth and intracellular stress signals upstream of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	227-236	TBC1 domain family member 7	Homo sapiens	88-94
33442914-5	2022	Akt acts by activating mechanistic target of rapamycin complex 1 (mTORC1) and by arresting autophagic gene expression.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	0-3
33124663-9	2021	Rapamycin treatment was associated with a decrease in insulin antibody titer and changes in hormonal/immunological profile.	Sirolimus	0-9	insulin	Homo sapiens	54-61
33124663-10	2021	CONCLUSIONS: Rapamycin reduced insulin requirement, but did not restore beta-cell function in patients with long-standing type 1 diabetes.	Sirolimus	13-22	insulin	Homo sapiens	31-38
33479328-6	2021	Treatment with rapamycin inhibited the diabetes-induced VEGF and GFAP increases.	Sirolimus	15-24	vascular endothelial growth factor A	Homo sapiens	56-60
33479203-9	2021	Notably, therapeutic inhibition of mTOR with rapamycin or temsirolimus induced preferential apoptosis of CSC, when compared to bulk tumor cells.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	35-39
33469286-12	2021	In addition, rapamycin liposomes and 5-FU can synergistically improve the efficacy of colorectal cancer via the Akt/mTOR and P53 pathways.	Sirolimus	13-22	thymoma viral proto-oncogene 1	Mus musculus	112-115
33323505-8	2021	Since endothelial autophagy is a pre-requisite for angiogenesis, knockdown of PTP-PEST also attenuated endothelial cell migration and capillary tube formation with autophagy inducer rapamycin (200 nM) rescuing angiogenesis.	Sirolimus	182-191	protein tyrosine phosphatase non-receptor type 12	Homo sapiens	78-86
33428109-9	2021	The mTOR inhibitor rapamycin mitigated TGF-beta-induced expression of p21, p16, and DNA damage foci and improved replicative potential of preadipocytes, supporting the cell-specific response to this cytokine.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33431351-3	2021	The discovery of this underlying mechanism paved the way for the use of a class of drugs called mTOR inhibitors including rapamycin and everolimus and specifically targeting this pathway.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	96-100
33431351-4	2021	Rapamycin has been widely used in different animal models of TSC-related epilepsy and proved to be able not only to suppress seizures but also to prevent the development of epilepsy, thus demonstrating an antiepileptogenic potential.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	61-64
33489922-3	2020	mTOR inhibitors, such as Rapamycin and Rapamycin analogs (Rapalogs), have become a promising class of agents to treat malignant blood diseases-either alone or in combination with other treatment regimens.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33489922-3	2020	mTOR inhibitors, such as Rapamycin and Rapamycin analogs (Rapalogs), have become a promising class of agents to treat malignant blood diseases-either alone or in combination with other treatment regimens.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33450223-8	2021	Of note, the autophagy activator rapamycin (RAP) ablated the positive effects of 1,25D in diabetic environment, leading to a marked increase in autolysosomes and autophagosomes, examined by mRFP-GFP-LC3 fluorescence double labeling.	Sirolimus	33-42	regulatory associated protein of MTOR, complex 1	Mus musculus	44-47
33411714-9	2021	We confirmed internalization of mf-derived EVs by human DCs and monocytes using confocal microscopy and flow cytometry, and further demonstrated through flow cytometry, that mf-derived EVs downregulate the phosphorylation of mTOR in human monocytes (THP-1 cells) to the same degree that rapamycin (a known mTOR inhibitor) does.	Sirolimus	287-296	mechanistic target of rapamycin kinase	Homo sapiens	225-229
33405944-2	2021	The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33405944-2	2021	The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	10-39
33419207-8	2021	Whereas RICTOR (rapamycin independent companion of mammalian target of rapamycin) was predicted to be inhibited in both WB and FE datasets, the predictions were based on different downstream molecules.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	51-80
33428109-9	2021	The mTOR inhibitor rapamycin mitigated TGF-beta-induced expression of p21, p16, and DNA damage foci and improved replicative potential of preadipocytes, supporting the cell-specific response to this cytokine.	Sirolimus	19-28	cyclin dependent kinase inhibitor 2A	Homo sapiens	75-78
33858600-2	2021	Among many important molecular machines that lie at the intersection of this triad, the mechanistic (formerly mammalian) target of rapamycin (mTOR) is a central regulator of cell metabolism, proliferation, and survival.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	142-146
33402188-17	2021	RAPA and BBG inhibited the activation of microglia, limited the inflammatory response, and reduced the expression of CGRP and c-fos.	Sirolimus	0-4	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	117-121
33398801-1	2021	Tuberous sclerosis complex (TSC) is a dominant autosomal genetic disorder caused by loss-of-function mutations in TSC1 and TSC2, which lead to constitutive activation of the mammalian target of rapamycin C1 (mTORC1) with its decoupling from regulatory inputs.	Sirolimus	194-203	TSC complex subunit 1	Homo sapiens	28-31
33398801-1	2021	Tuberous sclerosis complex (TSC) is a dominant autosomal genetic disorder caused by loss-of-function mutations in TSC1 and TSC2, which lead to constitutive activation of the mammalian target of rapamycin C1 (mTORC1) with its decoupling from regulatory inputs.	Sirolimus	194-203	TSC complex subunit 1	Homo sapiens	114-118
32755490-5	2021	However, it has been hypothesised that mammalian target of rapamycin complex 1 (mTORC1) hyperactivation in the presence of amino acid overload contributes to reduced insulin-stimulated glucose uptake due to insulin receptor substrate (IRS) degradation and reduced Akt-AS160 activity.	Sirolimus	59-68	insulin	Homo sapiens	166-173
32755490-5	2021	However, it has been hypothesised that mammalian target of rapamycin complex 1 (mTORC1) hyperactivation in the presence of amino acid overload contributes to reduced insulin-stimulated glucose uptake due to insulin receptor substrate (IRS) degradation and reduced Akt-AS160 activity.	Sirolimus	59-68	AKT serine/threonine kinase 1	Homo sapiens	264-267
33858600-4	2021	Accordingly, the pharmacological implications of mTOR inhibition using rapamycin or others rapalogs span the treatment of various human diseases from immune disorders to cancer.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	49-53
33384406-6	2021	Importantly, inhibition of mTOR signaling by rapamycin serves as an effective osteoanabolic therapeutic strategy to protect against TNFalpha deficiency and mechanical unloading.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	27-31
33162031-3	2021	Different from previous reports about additives treatment on recipient after ovarian transplantation, we here report a new vitrification protocol with pretreatment of rapamycin, an inhibitor of the mTOR signaling pathway.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	198-202
33275526-6	2021	It was found that GLDs considerably inhibited the phosphorylation of Akt at Thr308/Ser473, whereas the silencing of Gal-3 could reverse the inhibition of Akt activity through phosphoinositide 3-kinase-AktThr308 (PI3K-AktThr308) and AMP-activated protein kinase-mammalian target of rapamycin complex 2-AktSer473 (AMPK-mTOR2-AktSer473) pathways.	Sirolimus	281-290	AKT serine/threonine kinase 1	Homo sapiens	69-72
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	Sirolimus	82-91	interleukin 6	Mus musculus	127-131
33272162-12	2021	Furthermore, tumor necrosis factor alpha level increased significantly in the sirolimus group, whereas the everolimus and control groups showed constant values.	Sirolimus	78-87	tumor necrosis factor	Homo sapiens	13-40
32988344-5	2021	The mechanism of these effects involves multiple cell kinases and signaling pathways, including activation of AMPK and forkhead box transcription factor O3a (FOXO3a), accumulation of reactive oxygen species (ROS), and inhibition of the activity of PI3K/AKT, rapamycin (mTOR) and nuclear factor-kappaB (NF-kappaB).	Sirolimus	258-267	AKT serine/threonine kinase 1	Homo sapiens	253-256
33184932-5	2021	Here, using pharmacological inhibitor and genetic approaches, we found that like rapamycin, inhibition of DAPK1 activity led to enhanced expression of the homing receptors CD62L and CCR7.	Sirolimus	81-90	death associated protein kinase 1	Mus musculus	106-111
33184932-5	2021	Here, using pharmacological inhibitor and genetic approaches, we found that like rapamycin, inhibition of DAPK1 activity led to enhanced expression of the homing receptors CD62L and CCR7.	Sirolimus	81-90	selectin, lymphocyte	Mus musculus	172-177
33184932-5	2021	Here, using pharmacological inhibitor and genetic approaches, we found that like rapamycin, inhibition of DAPK1 activity led to enhanced expression of the homing receptors CD62L and CCR7.	Sirolimus	81-90	chemokine (C-C motif) receptor 7	Mus musculus	182-186
32507936-9	2021	A single case report of rapamycin, an mTOR inhibitor, used as chemoprevention in FAP patients exists, but no formal clinical studies have been conducted.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	38-42
34034560-3	2021	The present study was designed to observe the role of rapamycin in MC proliferation and to explore the mechanism by which rapamycin acts on Akt and MAPK/ERK1/2 pathways in mesangial cells.	Sirolimus	122-131	AKT serine/threonine kinase 1	Rattus norvegicus	140-143
34034560-9	2021	Moreover, our results revealed that 1000 nmol/L rapamycin led to Raf1-MEK1/2-ERK pathway activation through a p70S6K-PI3K-mediated feedback loop in MCs.	Sirolimus	48-57	Eph receptor B1	Rattus norvegicus	77-80
32583421-7	2021	Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARalpha, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells.	Sirolimus	149-158	carnitine palmitoyltransferase 1A	Homo sapiens	115-120
33278711-5	2021	mTOR inhibitor such as rapamycin are thought to induce tolerance and are used as anticancer drugs in several cancers.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	0-4
32803763-8	2021	Finally, with mTOR inhibitor rapamycin, we confirmed that NEAT1 promoted glioma activity through mTOR signaling both in vitro and in vivo.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32803763-8	2021	Finally, with mTOR inhibitor rapamycin, we confirmed that NEAT1 promoted glioma activity through mTOR signaling both in vitro and in vivo.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	97-101
32394479-3	2021	The mTOR protein is incorporated into two distinct complexes: mammalian target of Rapamycin complex 1 (mTORC1) and mammalian target of Rapamycin complex 2 (mTORC2).	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	4-8
32394479-3	2021	The mTOR protein is incorporated into two distinct complexes: mammalian target of Rapamycin complex 1 (mTORC1) and mammalian target of Rapamycin complex 2 (mTORC2).	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	4-8
32583421-4	2021	In this study, we showed that lack of ChREBP significantly improved renal injury, inhibited oxidative stress, lipid deposition, fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC) and thioredoxin-interacting protein (TXNIP) expression, as well as the activity of mammalian target of rapamycin complex 1 (mTORC1) in diabetic kidneys.	Sirolimus	288-297	MLX interacting protein like	Homo sapiens	38-44
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	fatty acid binding protein 3	Homo sapiens	132-137
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	peroxisome proliferator activated receptor gamma	Homo sapiens	183-188
33189285-2	2021	The mammalian target of rapamycin/eukaryotic initiation factor 4E (mTOR/eIF4E) signaling pathway is involved in fat synthesis.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	67-71
33141044-5	2021	Although the mTOR signaling might be inhibited by rapamycin treatment, signals transmitted from the upstream pathway supports cell survival and proliferation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	13-17
33141044-12	2021	In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases.	Sirolimus	22-31	forkhead box O3	Homo sapiens	78-83
31736460-3	2021	Here we investigated whether putatively interfering with synaptic plasticity using the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, could weaken retrieved chocolate reward memories through blockade of reconsolidation.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	118-122
33888207-4	2021	A recent proof-of-concept study examined model biosensors that incorporated the affinity partners FKBP12 and the rapamycin-binding domain of m-Tor (FRB) as well as p53 (1-92) and HDM2 (1-128).	Sirolimus	113-122	RAR related orphan receptor C	Homo sapiens	143-146
33040459-7	2021	In Ba/F3 cells transformed by NPM-ALK and Ki-JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC-0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1.	Sirolimus	171-180	tumor protein p53	Homo sapiens	55-58
33040459-7	2021	In Ba/F3 cells transformed by NPM-ALK and Ki-JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC-0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1.	Sirolimus	171-180	EBNA1 binding protein 2	Homo sapiens	94-98
33085775-10	2021	Moreover, after using the autophagy activator rapamycin, the expression of the inflammatory cytokines interleukin-1beta was decreased and the pain symptoms were alleviated.	Sirolimus	46-55	interleukin 1 beta	Mus musculus	102-119
33508825-5	2021	In this patient, the modification of an immunosuppressive regimen with introduction of rapamycin (mTOR) inhibitors and withdrawal of calcineurin inhibitors (CNIs) led to the resolution of this severe condition.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	98-102
33130049-2	2020	This study, hence, examined whether treatment with Art alone or in combination with rapamycin (Rapa), an mTOR inhibitor, can ameliorate hepatic I/R injury via targeting the NLRP3 inflammasome signaling pathway.	Sirolimus	95-99	NLR family, pyrin domain containing 3	Rattus norvegicus	173-178
33214245-6	2021	Functional studies using CRISPR-Cas9 gene-edited cells demonstrated a key role for the TSC2/RHEB axis in regulating TGF-beta1-induced mechanistic target of rapamycin complex 1 activation and collagen I deposition in mesenchymal cells reflecting IPF and other disease settings, including cancer-associated fibroblasts.	Sirolimus	156-165	transforming growth factor beta 1	Homo sapiens	116-125
33333712-6	2020	Rapamycin, which modulated mRNA turnover by inhibiting the mTOR pathway, improved nucleotide pool imbalance in exosc2-/- zebrafish, resulting in prolonged survival and partial rescue of neuronal defects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Danio rerio	59-63
33176606-9	2021	Pretreatment with mTOR inhibitor, rapamycin, could attenuate the activation of mTOR and the secretion of RANKL in OBs.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	18-22
33176606-9	2021	Pretreatment with mTOR inhibitor, rapamycin, could attenuate the activation of mTOR and the secretion of RANKL in OBs.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	79-83
33372169-8	2020	Interestingly, the protective effects of MCH were blocked by the mTOR inhibitor, rapamycin.	Sirolimus	81-90	pro-melanin concentrating hormone	Homo sapiens	41-44
33372169-8	2020	Interestingly, the protective effects of MCH were blocked by the mTOR inhibitor, rapamycin.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	65-69
33170612-4	2020	Rapamycin was used to activate the process of autophagy, which was impaired in the moderate TBI model, and this treatment reversed the expression of pyroptosis associated proteins, interleukin-13 (IL-13) and the pJAK-1 pathway, which were upregulated significantly after TBI.	Sirolimus	0-9	interleukin 13	Mus musculus	181-195
33170612-4	2020	Rapamycin was used to activate the process of autophagy, which was impaired in the moderate TBI model, and this treatment reversed the expression of pyroptosis associated proteins, interleukin-13 (IL-13) and the pJAK-1 pathway, which were upregulated significantly after TBI.	Sirolimus	0-9	interleukin 13	Mus musculus	197-202
33317397-4	2020	The present study investigates the potential of therapeutic plant peptides against cellular senescence by targeting three key proteins in the ageing network - target of rapamycin (mTOR), adenosine monophosphate-activated protein kinase (AMPK) and sirtuin 1 (SIRT1).	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	180-184
33318468-6	2020	Data from SCC-25 cells demonstrated that rapamycin and Earle"s balanced salt solution (EBSS) promoted autophagy, leading to increased FN1 degradation, while 3-methyladenine (3-MA), bafilomycin A1 (Baf A1) and chloroquine (CQ) inhibited autophagy, leading to decreased FN1 degradation.	Sirolimus	41-50	fibronectin 1	Homo sapiens	134-137
33327544-9	2020	These IL-2 conditioning-mediated impacts were counteracted with TWS119 or rapamycin but not with Torin1.	Sirolimus	74-83	interleukin 2	Homo sapiens	6-10
33318468-6	2020	Data from SCC-25 cells demonstrated that rapamycin and Earle"s balanced salt solution (EBSS) promoted autophagy, leading to increased FN1 degradation, while 3-methyladenine (3-MA), bafilomycin A1 (Baf A1) and chloroquine (CQ) inhibited autophagy, leading to decreased FN1 degradation.	Sirolimus	41-50	fibronectin 1	Homo sapiens	268-271
33311440-5	2020	In addition, Comp34 alone is effective in cells with secondary resistance to rapamycin, the best-known inhibitor of mTOR, and displays a greater in vivo antitumor efficacy and lower toxicity than rapamycin in TNBC xenografted models.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	116-120
32978258-4	2020	In this study, using various biochemical and cellular assays, we demonstrate that IGPR-1 is activated by autophagy-inducing stimuli, such as amino acid starvation, nutrient deprivation, rapamycin and lipopolysaccharide (LPS).	Sirolimus	186-195	transmembrane and immunoglobulin domain containing 2	Homo sapiens	82-88
33327255-2	2020	Although sirolimus, a mammalian target of rapamycin inhibitor, has been suggested to be effective in patients with iMCD, the long-term safety and efficacy of sirolimus on individuals with IL-6 inhibitor-resistant iMCD have not been evaluated.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	22-51
33229575-8	2020	Although physical activity enhances TORC1 activity, and the TORC1 inhibitor rapamycin inhibits clock-driven daytime growth, no effect on muscle growth at night was detected.	Sirolimus	76-85	clock circadian regulator a	Danio rerio	95-100
33307758-8	2021	These findings were associated with an increase in ERK, Akt, and mTOR phosphorylation, whereas autophagy induction through mTOR/p70S6K inhibition by rapamycin significantly suppressed NO-induced cell apoptosis.	Sirolimus	149-158	mechanistic target of rapamycin kinase	Homo sapiens	123-127
33389971-3	2020	For example, mechanistic target of rapamycin (mTOR) inhibitors such as rapamycin, phenols, and flavonoids show antioxidant characteristics, while spermidine induces autophagy.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	46-50
33267766-8	2021	RESULTS: It was probed that after the suppression of autophagy-associated miRNAs by adriamycin and rapamycin, while most of the miRNAs were down-regulated in osteosarcoma cell lines, some miRNAs" expressions, such as miR-3141, miR-4296, miR-133b, and miR-720, were strikingly increased.	Sirolimus	99-108	microRNA 3141	Homo sapiens	217-225
33267766-8	2021	RESULTS: It was probed that after the suppression of autophagy-associated miRNAs by adriamycin and rapamycin, while most of the miRNAs were down-regulated in osteosarcoma cell lines, some miRNAs" expressions, such as miR-3141, miR-4296, miR-133b, and miR-720, were strikingly increased.	Sirolimus	99-108	microRNA 133b	Homo sapiens	237-245
33275600-9	2020	Furthermore, signaling downstream of EphA7 shifts during development, such that in vivo inhibition of mTOR by rapamycin in EphA7-mutant neurons ameliorates dendritic branching, but not dendritic spine phenotypes.	Sirolimus	110-119	Eph receptor A7	Mus musculus	37-42
33275600-9	2020	Furthermore, signaling downstream of EphA7 shifts during development, such that in vivo inhibition of mTOR by rapamycin in EphA7-mutant neurons ameliorates dendritic branching, but not dendritic spine phenotypes.	Sirolimus	110-119	Eph receptor A7	Mus musculus	123-128
33490152-8	2020	Finally, it was shown that the application of SKP-SC-EVs could activate the Akt/mTOR/p70S6K signaling pathway that can be abolished by rapamycin.	Sirolimus	135-144	AKT serine/threonine kinase 1	Homo sapiens	76-79
33205940-4	2020	The hydrophobic chemotherapeutic, rapamycin (RAP), is self-assembled into the pure drug nanocore, and the metal-organic framework (MOF) shell based on coordination between Mn2+ and tannic acid (TA) is coated on the surface to coload an autophagy-inhibiting DNAzyme.	Sirolimus	34-43	regulatory associated protein of MTOR, complex 1	Mus musculus	45-48
31852323-5	2020	The NPs were conjugated with profilin-1 antibody (PFN1) to specifically target vascular smooth muscle cells (VSMCs) in the atherosclerotic plaque and integrated with the anti-inflammatory drug, rapamycin.	Sirolimus	194-203	profilin 1	Homo sapiens	50-54
33194193-0	2020	Sirolimus and MMF are insufficient immunosuppressants for regulation of the proliferation of CD133+EpCAM+ cell populations in HCC cell lines.	Sirolimus	0-9	epithelial cell adhesion molecule	Homo sapiens	99-104
33194193-4	2020	Sirolimus and MMF reduced the proliferation of Huh7 and HEP3B cells; however, the proportion of CD133+EpCAM+ was notably increased in treated Huh7 cells.	Sirolimus	0-9	epithelial cell adhesion molecule	Homo sapiens	102-107
33194193-5	2020	Sirolimus treatment alone resulted in G0-G1 cell cycle arrest at all doses in all Huh7 and CD133-EpCAM- populations; however, CD133+EpCAM+ populations showed only slight G1 arrest at higher doses only.	Sirolimus	0-9	epithelial cell adhesion molecule	Homo sapiens	97-102
32985258-2	2020	Herein, we sought to explore the anti-cancer mechanisms of ISL loaded nanoliposomes (ISL-NLs) on AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathways mediated glycolysis.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	162-166
33490152-8	2020	Finally, it was shown that the application of SKP-SC-EVs could activate the Akt/mTOR/p70S6K signaling pathway that can be abolished by rapamycin.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	80-84
32507695-2	2020	The COMBO sirolimus-eluting biodegradable-polymer stent has a proprietary anti-CD34 antibody layer to enhance homogeneous endothelialization, which may be advantageous in treating small vessels.	Sirolimus	10-19	CD34 molecule	Homo sapiens	79-83
33171062-6	2020	Mechanistically, curcumin inactivates the mechanistic target of rapamycin complex 1 (mTORC1), the upstream regulator of rDNA transcription and autophagy induction, by inhibiting mTOR lysosomal localization.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	85-89
32681646-1	2020	The immunosuppressant rapamycin (RAPA) inhibits mTOR (mammalian target of rapamycin) functions and is applied after allogeneic bone marrow transplantation (BMT) to attenuate the development of graft-versus-host disease (GVHD) although the cellular targets of RAPA treatment are not well defined.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	48-52
32681646-1	2020	The immunosuppressant rapamycin (RAPA) inhibits mTOR (mammalian target of rapamycin) functions and is applied after allogeneic bone marrow transplantation (BMT) to attenuate the development of graft-versus-host disease (GVHD) although the cellular targets of RAPA treatment are not well defined.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	54-83
32681646-1	2020	The immunosuppressant rapamycin (RAPA) inhibits mTOR (mammalian target of rapamycin) functions and is applied after allogeneic bone marrow transplantation (BMT) to attenuate the development of graft-versus-host disease (GVHD) although the cellular targets of RAPA treatment are not well defined.	Sirolimus	33-37	mechanistic target of rapamycin kinase	Homo sapiens	48-52
32681646-1	2020	The immunosuppressant rapamycin (RAPA) inhibits mTOR (mammalian target of rapamycin) functions and is applied after allogeneic bone marrow transplantation (BMT) to attenuate the development of graft-versus-host disease (GVHD) although the cellular targets of RAPA treatment are not well defined.	Sirolimus	33-37	mechanistic target of rapamycin kinase	Homo sapiens	54-83
33254688-9	2020	Rapamycin alleviated PFOA-induced lipid accumulation and NLRP3 inflammasome activation by activating autophagic flux.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	57-62
33349211-1	2020	Lung toxicity is a rare but serious side effect of sirolimus, a mammalian target of rapamycin inhibitor used as an immunosuppressive agent in solid-organ transplant recipients.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	64-93
33174028-13	2020	Furthermore, depleting expression of RAGE or mTORC2 protein components (rapamycin-insensitive companion of mTOR) by small interfering RNA was found to reduce the cell viability, migration and angiogenesis of S100A8/9-treated HUVECs.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	45-49
33103304-9	2020	Further investigation showed that Ang1/Tie2 pathway might be involved in rapamycin"s vascular protection in phase 1 OIR retinas.	Sirolimus	73-82	angiopoietin 1	Mus musculus	34-38
33103304-9	2020	Further investigation showed that Ang1/Tie2 pathway might be involved in rapamycin"s vascular protection in phase 1 OIR retinas.	Sirolimus	73-82	TEK receptor tyrosine kinase	Mus musculus	39-43
32610114-13	2020	Rapamycin, the mTOR inhibitor, can inhibit the pro-tumorigenic effect of VEPH1-knockdown.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-19
32865663-4	2020	Mechanistic (formerly mammalian) target of rapamycin (mTOR), sirtuin (SIRT) and insulin/insulin growth factor 1 (IGF1) signalling pathways are among the most important pathways in ageing-associated conditions, such as neurodegeneration.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	54-58
32865663-4	2020	Mechanistic (formerly mammalian) target of rapamycin (mTOR), sirtuin (SIRT) and insulin/insulin growth factor 1 (IGF1) signalling pathways are among the most important pathways in ageing-associated conditions, such as neurodegeneration.	Sirolimus	43-52	insulin	Homo sapiens	80-87
32865663-4	2020	Mechanistic (formerly mammalian) target of rapamycin (mTOR), sirtuin (SIRT) and insulin/insulin growth factor 1 (IGF1) signalling pathways are among the most important pathways in ageing-associated conditions, such as neurodegeneration.	Sirolimus	43-52	insulin like growth factor 1	Homo sapiens	113-117
33324011-2	2020	Mechanistic target of rapamycin (mTOR) inhibition with rapamycin attenuates disease progression in a mouse model of Leigh syndrome (Ndufs4 knock-out (KO) mouse); however, the mechanism of rescue is unknown.	Sirolimus	22-31	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	132-138
32666288-1	2020	Deregulated activity of protein kinase B/mammalian target of rapamycin complex-1 (Akt/mTORC1) incites crucial pathological characteristics of diabetic nephropathy.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	82-85
33324011-3	2020	Here we identify protein kinase C (PKC) downregulation as a key event mediating the beneficial effects of rapamycin treatment of Ndufs4 KO mice.	Sirolimus	106-115	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	129-135
33324011-4	2020	Assessing the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice, we find that rapamycin restores mitochondrial protein levels, inhibits signalling through both mTOR complexes and reduces the abundance and activity of multiple PKC isoforms.	Sirolimus	24-33	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	79-85
33324011-4	2020	Assessing the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice, we find that rapamycin restores mitochondrial protein levels, inhibits signalling through both mTOR complexes and reduces the abundance and activity of multiple PKC isoforms.	Sirolimus	108-117	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	79-85
32279604-9	2020	mTOR activity in the brain following the IF and rapamycin treatment was differentially regulated by age.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	0-4
32279604-10	2020	Interestingly, rapamycin inhibited mTOR more potently in young animals than IF.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	35-39
33010263-9	2020	Finally, rapamycin-mediated promotion of autophagy attenuated LPS-induced anxiety-like behavior and decreased interleukin-1beta and Iba-1 expression in the hippocampus.	Sirolimus	9-18	interleukin 1 beta	Mus musculus	110-127
33329581-6	2020	In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells.	Sirolimus	45-54	CD4 molecule	Homo sapiens	10-13
33262410-3	2020	PARP1-mediated autophagy was evaluated in vitro by CCK-8 assay, clonogenic assay, immunofluorescence, and western blot in the HCC-827, H1975, and H1299 cells treated with icotinib (Ico), rapamycin, and AZD2281 (olaparib) alone or in combination.	Sirolimus	187-196	poly(ADP-ribose) polymerase 1	Homo sapiens	0-5
33329581-7	2020	Rapamycin induced IFN-gamma-producing T-bet+Foxp3lo cells accompanied with enhanced lipid metabolism, whereas 2DG induced IFN-gamma-non-producing T-bet+Foxp3hi cells.	Sirolimus	0-9	interferon gamma	Homo sapiens	18-27
33243998-4	2020	Mechanistically, ISO inhibits AKT as well as, downstream of AKT, the mechanistic target of rapamycin complex 1 (mTORC1), coupled to the activation of the pro-autophagic transcription factors EB (TFEB) and E3 (TFE3).	Sirolimus	91-100	thymoma viral proto-oncogene 1	Mus musculus	60-63
33329339-0	2020	Rapamycin Alleviates the Symptoms of Multiple Sclerosis in Experimental Autoimmune Encephalomyelitis (EAE) Through Mediating the TAM-TLRs-SOCS Pathway.	Sirolimus	0-9	cytokine inducible SH2-containing protein	Mus musculus	138-142
33329339-11	2020	Rapamycin injection relieved the nerve function of and the loss of myelin sheath in the EAE mice, mainly through mediating the TAM-TLRs-SOCS signaling pathway to regulate natural immunity.	Sirolimus	0-9	cytokine inducible SH2-containing protein	Mus musculus	136-140
33255287-5	2020	Tear cytokine/chemokine profile showed a pronounced increase in vascular endothelial cell growth factor-A (VEGF-A) and a trend towards decreased concentration of Interferon gamma (IFN)-gamma in rapamycin-treated groups.	Sirolimus	194-203	interferon gamma	Mus musculus	162-190
33200217-3	2021	The present study investigated the efficacy and safety of sirolimus in refractory CTD-TP patients.	Sirolimus	58-67	CTD	Homo sapiens	82-85
33190588-8	2021	Inhibition of MTORC1 by rapamycin induced autophagy and increased the expression levels of FAO-related genes and concomitantly attenuated lipid accumulation in PA-treated txnip-knockout (KO) hepatocytes, which was further abolished by silencing of Atg7.	Sirolimus	24-33	origin recognition complex, subunit 1	Mus musculus	14-20
33200217-12	2021	CONCLUSION: Sirolimus is an effective and safe treatment option for refractory CTD-TP patients.	Sirolimus	12-21	CTD	Homo sapiens	79-82
33190588-8	2021	Inhibition of MTORC1 by rapamycin induced autophagy and increased the expression levels of FAO-related genes and concomitantly attenuated lipid accumulation in PA-treated txnip-knockout (KO) hepatocytes, which was further abolished by silencing of Atg7.	Sirolimus	24-33	thioredoxin interacting protein	Mus musculus	171-176
32901500-8	2020	In addition, rapamycin, an mTOR inhibitor, promoted the development of autophagy, further inhibited the protective effect on Cx43 expression and increased cell hypertrophy.	Sirolimus	13-22	gap junction protein, alpha 1	Mus musculus	125-129
33190588-8	2021	Inhibition of MTORC1 by rapamycin induced autophagy and increased the expression levels of FAO-related genes and concomitantly attenuated lipid accumulation in PA-treated txnip-knockout (KO) hepatocytes, which was further abolished by silencing of Atg7.	Sirolimus	24-33	autophagy related 7	Mus musculus	248-252
33190588-9	2021	Rapamycin treatment also attenuated MCD diet-induced steatosis, inflammation, and fibrosis with increased TFEB nuclear translocation and restored FAO in txnip-KO mice.	Sirolimus	0-9	thioredoxin interacting protein	Mus musculus	153-158
32599680-1	2020	Therapeutics targeting the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway initially produce potent antitumor effects, but resistance frequently occurs.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	93-97
33312358-12	2020	PI3K, p-AKT1, p-mTOR, p-p70S6K and caspase-3 were down-regulated by rapamycin and beta-ecdysterone, and up-regulated by 3-methyladenine in both the chondrocytes and the cartilage tissues.	Sirolimus	68-77	AKT serine/threonine kinase 1	Rattus norvegicus	8-12
32878988-12	2020	Pretreating cells with mTORC1 inhibitor rapamycin restored BCKAs effect on insulin-induced AKT phosphorylation.	Sirolimus	40-49	thymoma viral proto-oncogene 1	Mus musculus	91-94
33202661-8	2020	When mTOR was inhibited directly via the macrolide rapamycin, peroxisome degradation was still partially suppressed by Ras2, while inactivation of Ras2 resulted in an enhanced degradation of peroxisomes, suggesting a role of Ras2 in the inhibition of peroxisome degradation in glucose-grown cells.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	5-9
33294353-11	2020	Rapamycin has been used in several cases based on the purported activation of the mammalian target of rapamycin (mTOR) in DIPNECH.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	82-111
33292704-6	2020	Milk protein synthesis is governed at mammary level by a set of transduction pathways, including the mechanistic target of rapamycin complex 1 (mTORC1), the integrated stress response (ISR), and the unfolded protein response (UPR).	Sirolimus	123-132	casein beta	Bos taurus	0-12
33294353-11	2020	Rapamycin has been used in several cases based on the purported activation of the mammalian target of rapamycin (mTOR) in DIPNECH.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	113-117
33158864-1	2020	The protein kinase mammalian target of rapamycin (mTOR) is the central regulator of cell growth.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	50-54
33158864-5	2020	It reveals entangled folds of the defining Rictor and the substrate-binding SIN1 subunits, identifies the carboxyl-terminal domain of Rictor as the source of the rapamycin insensitivity of mTORC2, and resolves mechanisms for mTORC2 regulation by complex destabilization.	Sirolimus	162-171	MAPK associated protein 1	Homo sapiens	76-80
33237667-5	2021	Cells from patients with TED and controls were treated with rapamycin [mechanistic target of rapamycin an (mTOR) inhibitor] and MHY1485 (an mTOR stimulator) as well as inhibitors upstream in the same signaling cascade (saracatinib and befatinib).	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	71-105
33138632-1	2020	The drug rapamycin is a potent inhibitor of the mTOR complex, acting directly in the signaling cascade of this protein complex; interrupting cell proliferation, in addition to being an extremely efficient immunosuppressant.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	48-52
33237667-5	2021	Cells from patients with TED and controls were treated with rapamycin [mechanistic target of rapamycin an (mTOR) inhibitor] and MHY1485 (an mTOR stimulator) as well as inhibitors upstream in the same signaling cascade (saracatinib and befatinib).	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31931659-12	2020	Collectively, our results identify ROS as central inducers of MTORC2 activation during chronic autophagy, which in turn fuels senescence activation and myofibroblast differentiation in distinct cellular subpopulations.Abbreviations: 3-MA: 3-methyladenine; ACTA2: actin, alpha 2, smooth muscle, aorta; AKT1: AKT serine/threonine kinase 1; p-AKT1: AKT1 Ser473 phosphorylation; t-AKT1: total AKT serine/threonine kinase 1; ATG4A: autophagy related 4A cysteine peptidase; ATG7: autophagy gene 7; C12FDG: 5-dodecanoylaminofluorescein Di-beta-D-Galactopyranoside; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; Ctl: control; DAPI: 4",6-diamidino-2-phenylindole, dilactate; ECM: extracellular matrix; GSH: L-glutathione reduced; H2O2: hydrogen peroxide; HLF: adult human lung fibroblasts; Ho: Hoechst 33342 (2"-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2.5"-bi-1H-benzimidazole); HSC: hepatic stellate cells; LY: LY294002; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MTORC1/2: mechanistic target of rapamycin kinase complex 1/2; N: normal growth medium; NAC: N-acetyl-L-cysteine; PBS: phosphate-buffered saline; PDGFA: platelet derived growth factor subunit A; PRKCA/PKCalpha: protein kinase C alpha; PtdIns3K: class III phosphatidylinositol 3-kinase; PTEN: phosphatase and tensin homolog; R: rapamycin; RICTOR: RPTOR independent companion of MTOR complex 2; ROS: reactive oxygen species; RPTOR: regulatory associated protein of MTOR complex 1; SA-GLB1/beta-gal: senescence-associated galactosidase beta 1; SGK1: serum/glucocorticoid regulated kinase 1; shRNA: short hairpin RNA; siCtl: control siRNA; siRNA: small interfering RNA; SQSTM1: sequestosome 1; SS: serum-free (serum starvation) medium; TP53: tumor protein p53; TUBA: tubulin alpha; V: vehicle.	Sirolimus	1063-1072	mechanistic target of rapamycin kinase	Homo sapiens	62-66
33139753-6	2020	Treatment with rapamycin (which induce autophagic clearance of progerin and reverse progerin-induced cellular phenotypes) down-regulated progerin-induced NM deformation, whereas treatment with bafilomycin A1 (an inhibitor of autophagy and lysosome-based degradation) or CHMP4B depletion antagonized the effects of rapamycin.	Sirolimus	15-24	charged multivesicular body protein 4B	Homo sapiens	270-276
33313247-10	2020	Moreover, BNIP3 knockdown further aggravated hypoxia-induced impairments in D407 cells, which can be reversed by rapamycin.	Sirolimus	113-122	BCL2 interacting protein 3	Homo sapiens	10-15
31865844-8	2020	: intra peritoneal; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NPHS1: nephrosis 1, nephrin; NPHS2: nephrosis 2, podocin; PLA: proximity-ligation assay; PRKAA: 5"-AMP-activated protein kinase catalytic subunit alpha; RPTOR/RAPTOR: regulatory associated protein of MTOR, complex 1; RFP: red fluorescent protein; TSC1: tuberous sclerosis 1; ULK1: unc-51 like kinase 1.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	81-85
31931659-12	2020	Collectively, our results identify ROS as central inducers of MTORC2 activation during chronic autophagy, which in turn fuels senescence activation and myofibroblast differentiation in distinct cellular subpopulations.Abbreviations: 3-MA: 3-methyladenine; ACTA2: actin, alpha 2, smooth muscle, aorta; AKT1: AKT serine/threonine kinase 1; p-AKT1: AKT1 Ser473 phosphorylation; t-AKT1: total AKT serine/threonine kinase 1; ATG4A: autophagy related 4A cysteine peptidase; ATG7: autophagy gene 7; C12FDG: 5-dodecanoylaminofluorescein Di-beta-D-Galactopyranoside; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; Ctl: control; DAPI: 4",6-diamidino-2-phenylindole, dilactate; ECM: extracellular matrix; GSH: L-glutathione reduced; H2O2: hydrogen peroxide; HLF: adult human lung fibroblasts; Ho: Hoechst 33342 (2"-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2.5"-bi-1H-benzimidazole); HSC: hepatic stellate cells; LY: LY294002; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MTORC1/2: mechanistic target of rapamycin kinase complex 1/2; N: normal growth medium; NAC: N-acetyl-L-cysteine; PBS: phosphate-buffered saline; PDGFA: platelet derived growth factor subunit A; PRKCA/PKCalpha: protein kinase C alpha; PtdIns3K: class III phosphatidylinositol 3-kinase; PTEN: phosphatase and tensin homolog; R: rapamycin; RICTOR: RPTOR independent companion of MTOR complex 2; ROS: reactive oxygen species; RPTOR: regulatory associated protein of MTOR complex 1; SA-GLB1/beta-gal: senescence-associated galactosidase beta 1; SGK1: serum/glucocorticoid regulated kinase 1; shRNA: short hairpin RNA; siCtl: control siRNA; siRNA: small interfering RNA; SQSTM1: sequestosome 1; SS: serum-free (serum starvation) medium; TP53: tumor protein p53; TUBA: tubulin alpha; V: vehicle.	Sirolimus	1357-1366	mechanistic target of rapamycin kinase	Homo sapiens	62-66
32805499-6	2020	Further, as a drug-delivery vehicle, a rapamycin (RM)-coated eStent was designed to amplify the inhibitory effect of eStent on intimal hyperplasia through the synergistic effects of the Hippo and mammalian target of rapamycin (mTOR) signaling pathways.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	196-225
33030400-8	2021	In therapeutic studies, low doses of rapamycin, a known autophagy inducer that significantly promotes endometrium autophagy and NK cell residence, and improves embryo absorption in spontaneous abortion mice models, which should be dependent on the activation of MITF-TNFRSF14/HVEM-MMP9-adhension molecules axis.	Sirolimus	37-46	melanogenesis associated transcription factor	Mus musculus	262-266
32805499-6	2020	Further, as a drug-delivery vehicle, a rapamycin (RM)-coated eStent was designed to amplify the inhibitory effect of eStent on intimal hyperplasia through the synergistic effects of the Hippo and mammalian target of rapamycin (mTOR) signaling pathways.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	227-231
32519137-9	2020	Of note, we observed that HTR2A promoted the activation (phosphorylation) of AKT-mTOR (mammalian target of rapamycin) signaling in cardiomyocytes, and repression of AKT-mTOR with perifosine or rapamycin blocked the effects of HTR2A on cardiomyocyte hypertrophy.	Sirolimus	107-116	5-hydroxytryptamine receptor 2A	Homo sapiens	26-31
32896607-8	2020	In addition, the levels of p62 and Snail were increased in high glucose-treated HLE-B3 cells, and their interactions were demonstrated by co-immunoprecipitation and immunoflurence staining, but all these changes were attenuated by application of rapamycin.	Sirolimus	246-255	snail family transcriptional repressor 1	Homo sapiens	35-40
33031791-5	2020	Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	51-55
31738412-0	2020	STAT3-miR-17/20 Signaling Axis Plays a Critical Role in Attenuating Myocardial Infarction following Rapamycin Treatment in Diabetic mice.	Sirolimus	100-109	signal transducer and activator of transcription 3	Mus musculus	0-5
31738412-9	2020	RAPA increased STAT3 phosphorylation and miRNA-17/20a expression in diabetic hearts.	Sirolimus	0-4	signal transducer and activator of transcription 3	Mus musculus	15-20
31738412-10	2020	In addition, RAPA restored AKT phosphorylation (target of mTORC2), but suppressed S6 phosphorylation (target of mTORC1) following I/R injury.	Sirolimus	13-17	thymoma viral proto-oncogene 1	Mus musculus	27-30
31738412-11	2020	RAPA-induced cardioprotection against I/R injury as well as the induction of miR-17/20a and AKT phosphorylation were abolished in cardiac-specific STAT3-deficient diabetic mice, without alteration of S6 phosphorylation.	Sirolimus	0-4	thymoma viral proto-oncogene 1	Mus musculus	92-95
31738412-13	2020	The post-I/R restoration of phosphorylation of STAT3 and AKT with RAPA were also abolished in miRNA-17-92-deficient diabetic mice.	Sirolimus	66-70	signal transducer and activator of transcription 3	Mus musculus	47-52
31738412-13	2020	The post-I/R restoration of phosphorylation of STAT3 and AKT with RAPA were also abolished in miRNA-17-92-deficient diabetic mice.	Sirolimus	66-70	thymoma viral proto-oncogene 1	Mus musculus	57-60
33031791-5	2020	Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	57-86
33031791-6	2020	Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10.	Sirolimus	0-9	interleukin 2	Homo sapiens	162-166
33031791-6	2020	Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10.	Sirolimus	0-9	interleukin 6	Homo sapiens	168-172
32475067-1	2020	The rapamycin analogue everolimus (EVR) is a potent inhibitor of the mammalian target of rapamycin (mTOR) and clinically used to prevent allograft rejections as well as tumor growth.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Homo sapiens	69-98
31738412-15	2020	CONCLUSION: Induction of STAT3-miRNA-17-92 signaling axis plays a critical role in attenuating myocardial infarction in RAPA-treated diabetic mice.	Sirolimus	120-124	signal transducer and activator of transcription 3	Mus musculus	25-30
31738412-19	2020	Specifically, the results show an essential role of a highly innovative STAT3-miR-17-92-mTOR signaling axis in cardioprotection in diabetes, which may have potential clinical relevance in preventing I/R injury in diabetics because RAPA has relatively mild side effects at low dose.	Sirolimus	231-235	signal transducer and activator of transcription 3	Mus musculus	72-77
33055173-2	2020	PATIENTS AND METHODS: During the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	139-143
32475067-1	2020	The rapamycin analogue everolimus (EVR) is a potent inhibitor of the mammalian target of rapamycin (mTOR) and clinically used to prevent allograft rejections as well as tumor growth.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Homo sapiens	100-104
32567791-1	2020	BACKGROUND: Recently, insulin-like growth factor-1 (IGF-1), forkhead box transcription factor (Fox) O1, and mechanistic target of rapamycin complex 1 (mTORC1) signalling have been introduced as key elements in acne pathogenesis.	Sirolimus	130-139	insulin like growth factor 1	Homo sapiens	22-50
32898934-1	2020	Ginsenoside Rg3, a ginsenoside isolated from Panax ginseng, can regulate autophagy via AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	152-156
32324261-8	2020	Furthermore, we demonstrated that HDAC1 serves as an important modulator of the migration and phenotypic switch of SMCs by suppressing the PKD1- mammalian target of the rapamycin signaling pathway.	Sirolimus	169-178	histone deacetylase 1	Homo sapiens	34-39
31960417-5	2020	Moreover, molecular studies showed that E35 remarkably downregulated drug-resistant gene and dramatically inhibited the Akt/mammalian target of rapamycin signaling pathway.	Sirolimus	144-153	AKT serine/threonine kinase 1	Homo sapiens	120-123
32771373-5	2020	Treatment with rapamycin (an mTOR inhibitor) inhibited some effects of PA on inflammation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
33043596-8	2020	In vitro, studies revealed that calindol and rapamycin exacerbated MI-induced autophagy and NLRP3 inflammasome activation in peritoneal macrophages.	Sirolimus	45-54	NLR family, pyrin domain containing 3	Rattus norvegicus	92-97
32703671-7	2020	Reversal of heart failure occurred after tacrolimus discontinuation and the switch to a mammalian target of rapamycin (mTOR) inhibitor: sirolimus.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	88-117
33142533-10	2020	Rapamycin significantly inhibited the mTOR pathway-related genes mRNA levels (P < 0.05).	Sirolimus	0-9	mechanistic target of rapamycin	Gallus gallus	38-42
32871057-5	2020	In the present study, we investigated the effect of mTOR inhibition with rapamycin from different time points on human umbilical cord blood-derived CD34+ cell erythropoiesis in vitro and the underlying mechanisms.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	52-56
32871057-5	2020	In the present study, we investigated the effect of mTOR inhibition with rapamycin from different time points on human umbilical cord blood-derived CD34+ cell erythropoiesis in vitro and the underlying mechanisms.	Sirolimus	73-82	CD34 molecule	Homo sapiens	148-152
32703671-7	2020	Reversal of heart failure occurred after tacrolimus discontinuation and the switch to a mammalian target of rapamycin (mTOR) inhibitor: sirolimus.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	119-123
33149623-3	2020	Rapamycin is a new type macrocyclic lactone, which can inhibit the serine/threonine protein kinase mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	99-103
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	interleukin 6	Mus musculus	275-279
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	tumor necrosis factor	Mus musculus	281-290
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	interleukin 6	Mus musculus	259-263
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	tumor necrosis factor	Mus musculus	265-274
33149623-14	2020	Conclusion: The results suggested that 3-BrPA combined with rapamycin could induce cell apoptosis in NB cells by inhibiting mTOR activity.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	124-128
33149623-13	2020	Rapamycin individually discourages the mTOR signaling pathway, while combined with 3-BrPA can enhance this phenomenon and influence cell metabolism of the NB cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	39-43
33126764-13	2020	Autophagy induction by rapamycin treatment in keloid fibroblasts effectively suppressed expression levels of Notch1 and NLRP3 inflammasome proteins.	Sirolimus	23-32	notch receptor 1	Homo sapiens	109-115
33126764-13	2020	Autophagy induction by rapamycin treatment in keloid fibroblasts effectively suppressed expression levels of Notch1 and NLRP3 inflammasome proteins.	Sirolimus	23-32	NLR family pyrin domain containing 3	Homo sapiens	120-125
33114161-5	2020	Treatment with a combination Gem and Rapa was much more effective than that of either single agent with respect to reducing cell viability, cell invasion, cell migration, and vascular endothelial growth factor production in vitro.	Sirolimus	37-41	vascular endothelial growth factor A	Homo sapiens	175-209
32819718-2	2020	Recently, the mTOR inhibitor rapamycin and its analogs have attracted growing interests and evaluated as therapeutic agents against TNBC, in which the PI3K/AKT/mTOR pathway is often activated.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	14-18
33097830-6	2020	Mechanistically, we find that L-arginine stimulates Wnt2b secretion by CD90+ stromal cells through the mammalian target of rapamycin complex 1 (mTORC1) and that blocking Wnt2b production prevents L-arginine-induced ISC expansion.	Sirolimus	123-132	Wnt family member 2B	Homo sapiens	52-57
32819718-4	2020	In this study, we found that the sensitivity of TNBC cells to rapamycin was highly dependent on the expression level of rapamycin-insensitive companion of mTOR (Rictor), a key component of the mTOR complex 2.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	155-159
32819718-2	2020	Recently, the mTOR inhibitor rapamycin and its analogs have attracted growing interests and evaluated as therapeutic agents against TNBC, in which the PI3K/AKT/mTOR pathway is often activated.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	156-159
32819718-6	2020	Furthermore, we showed that the suppression of Rictor expression was also effective in rapamycin-insensitive cells that had acquired resistance to mTOR kinase inhibitors.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	147-151
32819718-2	2020	Recently, the mTOR inhibitor rapamycin and its analogs have attracted growing interests and evaluated as therapeutic agents against TNBC, in which the PI3K/AKT/mTOR pathway is often activated.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	160-164
33145347-10	2020	Furthermore, rapamycin reduced the expression of mTOR, whereas the promotion of LC3-II/LC3-I was blocked by the GSK3beta inhibitor TWS119.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	49-53
33079330-7	2021	Furthermore, we showed that pretreatment with rapamycin exacerbated H2O2-mediated cytotoxicity and caspase-3 activation but that 3-MA or siRNAs specific for Beclin 1 and Atg7 genes ameliorated H2O2-mediated GC apoptosis.	Sirolimus	46-55	caspase 3	Homo sapiens	99-108
33105631-9	2020	For instance, rapamycin is currently being investigated for the treatment of various vascular malformations associated with hyperactivation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	173-176
33105631-9	2020	For instance, rapamycin is currently being investigated for the treatment of various vascular malformations associated with hyperactivation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	177-206
33105631-9	2020	For instance, rapamycin is currently being investigated for the treatment of various vascular malformations associated with hyperactivation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	213-216
33105631-9	2020	For instance, rapamycin is currently being investigated for the treatment of various vascular malformations associated with hyperactivation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	217-221
33173419-3	2020	Present study is aimed to assess the activity of the two mTOR inhibitors (rapamycin - RAP and sapanisertib - MLN) as a single agent and combined with gemcitabine (GEM, one of substances commonly used in systemic anticancer treatment) in uterine sarcoma and carcinosarcoma in vitro models.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	57-61
33092063-2	2020	The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectively.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	18-49
33092063-2	2020	The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectively.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	51-55
33092063-2	2020	The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectively.	Sirolimus	117-126	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-89
33123600-11	2020	Furthermore, the secretion of IL-10 of Tregs in AA mice increased significantly after the therapy of Rapa combined with Elt, but there was no significant difference in the number of Treg cells.	Sirolimus	101-105	interleukin 10	Mus musculus	30-35
33076974-9	2020	The mTOR inhibitor rapamycin suppresses neuronal hyperactivity, but does not increase synchronised network activity, whereas activation of AMPK restores some aspects of network activity.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	30-39	RAR related orphan receptor C	Homo sapiens	155-158
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	114-123	RAR related orphan receptor C	Homo sapiens	155-158
33195437-8	2020	The current review highlights FK506/rapamycin-FKBP12 interactions with calcineurin/TOR kinase in human and fungi, and development of non-immunosuppressive analogs of FK506, rapamycin, and novel small molecules in inhibition of fungal calcineurin and TOR kinase.	Sirolimus	36-45	RAR related orphan receptor C	Homo sapiens	83-86
33195437-8	2020	The current review highlights FK506/rapamycin-FKBP12 interactions with calcineurin/TOR kinase in human and fungi, and development of non-immunosuppressive analogs of FK506, rapamycin, and novel small molecules in inhibition of fungal calcineurin and TOR kinase.	Sirolimus	36-45	RAR related orphan receptor C	Homo sapiens	250-253
33162811-2	2020	While a well-known mTOR inhibitor, rapamycin, has been shown to reduce glioblastoma survival, the role of mitochondria in achieving this therapeutic effect is less well known.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	19-23
33123600-14	2020	Compared with the AA group, the level of plasma IFN-gamma, IL-2, and TNF-alpha decreased significantly (P < 0.05), but IL-10, IL-4, IL-5, and IL-1beta increased significantly in the Rapa group (P < 0.05).	Sirolimus	182-186	interleukin 10	Mus musculus	119-124
33123600-15	2020	As for IL-10, IL-12p70, IL-2, IL-6, KC/GRO, and TNF-alpha, the therapy of Rapa combined with Elt showed a more significant effect than Rapa alone in AA mice.	Sirolimus	74-78	chemokine (C-X-C motif) ligand 1	Mus musculus	39-42
33123600-15	2020	As for IL-10, IL-12p70, IL-2, IL-6, KC/GRO, and TNF-alpha, the therapy of Rapa combined with Elt showed a more significant effect than Rapa alone in AA mice.	Sirolimus	74-78	tumor necrosis factor	Mus musculus	48-57
32828826-8	2020	Knockdown of RhoC and ROCK2 with corresponding siRNA significantly inhibited the secretion of exosomes originating from intraluminal vesicles (ILVs) in NPCs, even when NPCs were subsequently treated with Rap.	Sirolimus	204-207	ras homolog family member C	Rattus norvegicus	13-17
32798557-9	2020	KEY FINDINGS: Rapamycin was demonstrated to improve renal injury induced by Iodixanol diabetic rats, decrease the levels of SCr, BUN, KIM-1, NAG, improve renal functions, reduce inflammatory response and oxidative stress injury, down-regulate Bax, while up-regulate BCl-2 and inhibit apoptosis.	Sirolimus	14-23	BCL2, apoptosis regulator	Rattus norvegicus	266-271
33050143-9	2020	The AKT-mammalian target of the rapamycin (mTOR) signal pathway, which is important for muscle protein synthesis, was increased in LL-administered groups.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	4-7
33076263-1	2020	Research has suggested that nutrient, exercise, and metabolism-related proteins interact to regulate mammalian target of rapamycin complex one (mTOR) post-exercise and their interactions needs clarification.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	144-148
33060680-9	2020	Treatment with rapamycin, which inhibits protein synthesis via the mTOR pathway, also rescued photoreceptor apoptosis in beta-snap1 mutants.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Danio rerio	67-71
33053849-9	2020	The type of immunosuppressant remained a nonsignificant factor for recurrence in multivariate analysis; however, SRL significantly prolonged OS (TAC hazard ratio: 15 [1.3-172.85], p = 0.03) after adjusting for alpha-fetoprotein and positron emission tomography standardised uptake value ratio (tumour/background liver).	Sirolimus	113-116	alpha fetoprotein	Homo sapiens	210-227
33038032-8	2021	The levels of miR-27a were upregulated in both rapamycin-treated NPCs and their exosomes, compared to the control.	Sirolimus	47-56	microRNA 27a	Homo sapiens	14-21
33050143-9	2020	The AKT-mammalian target of the rapamycin (mTOR) signal pathway, which is important for muscle protein synthesis, was increased in LL-administered groups.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	43-47
32905798-5	2020	HFSC fate reversibility and glutamine metabolism are regulated by the mammalian target of rapamycin complex 2 (mTORC2)-Akt signaling axis within the niche.	Sirolimus	90-99	AKT serine/threonine kinase 1	Homo sapiens	119-122
33019479-5	2020	METHODS: The literatures about the management of vascular malformations with sirolimus would be searched from databases of MEDLINE, EMBASE, PubMed, Web of Science, Clinicaltrials.org., Cochrane Library, China Biology Medicine Database (CBM), Wan Fang Database, China National Knowledge Infrastructure Database (CNKI), and VIP Science Technology Periodical Database.	Sirolimus	77-86	vasoactive intestinal peptide	Homo sapiens	322-325
33009372-6	2020	To confirm the observations of the genetic approach, we used a pharmacological method and determined that the mTORC1 inhibitor rapamycin has a profound influence upon post-synaptic D2R-dependent functions.	Sirolimus	127-136	dopamine receptor D2	Mus musculus	181-184
32557381-6	2020	The mTOR inhibitor sirolimus is the most studied compound for the treatment of venous, lymphatic, and complex malformations.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	Sirolimus	1331-1340	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	38-43
32480429-10	2020	Conversely, the AMPK activator metformin or the mTORC1 inhibitor rapamycin reversed the effects of FL on the alterations of autophagy, hypertrophy and apoptosis in cardiomyocytes induced by Ang II.	Sirolimus	65-74	angiotensinogen	Rattus norvegicus	190-196
33024904-9	2021	Significant differences between sirolimus and paclitaxel NPs in anti-proliferation effect under normoxia and hypoxia may due to the different inhibitory effects on HIF-1alpha expression and glycolysis.	Sirolimus	32-41	hypoxia inducible factor 1 subunit alpha	Homo sapiens	164-174
32590192-7	2020	A dual-targeting delivery liposomal system was designed with dual-modification of PD-L1 nanobody and mannose ligands for co-delivering an mTOR inhibitor (rapamycin) and an anti-angiogenic drug (regorafenib).	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	138-142
32761379-4	2020	The identification of TSC1 and TSC2, as tumor suppressor genes causative of the disorder, led to the elucidation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and its pivotal role in the pathogenesis of hamartoma formation.	Sirolimus	140-149	TSC complex subunit 1	Homo sapiens	22-26
32861747-0	2020	Upregulation of Akt/Raptor signaling is associated with rapamycin resistance of breast cancer cells.	Sirolimus	56-65	AKT serine/threonine kinase 1	Homo sapiens	16-19
32861747-2	2020	Here to study the mechanism of the acquired resistance of MCF-7 breast cancer cells to mTOR inhibitors two different models of the cell resistance were used: rapamycin-resistant MCF-7/Rap subline developed under long-term rapamycin treatment, and metformin-resistant MCF-7/M subline obtained by long-term metformin treatment.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Homo sapiens	87-91
32861747-5	2020	Transfection of mir-181c, one of the positive regulators of Akt and mTOR, lead to an increase in the cell resistance to both mTOR inhibitors, rapamycin, and metformin, which correlated with Raptor overexpression and activation of Akt/AP-1 signaling.	Sirolimus	142-151	AKT serine/threonine kinase 1	Homo sapiens	60-63
32861747-5	2020	Transfection of mir-181c, one of the positive regulators of Akt and mTOR, lead to an increase in the cell resistance to both mTOR inhibitors, rapamycin, and metformin, which correlated with Raptor overexpression and activation of Akt/AP-1 signaling.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Homo sapiens	68-72
33016658-1	2020	OBJECTIVE: Sirolimus mTOR inhibitor represents a major advance in the treatment of patients with complicated vascular abnormalities.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	21-25
32808351-8	2020	Inhibition of mTOR/FOXO1 by rapamycin/AS1842856 decreased the ratio of Bcl-2/Bax and exacerbated TJ protein loss.	Sirolimus	28-37	B cell leukemia/lymphoma 2	Mus musculus	71-76
32457396-8	2020	Topical Rapamycin treatment improved extramammary PD-associated symptoms in humans, suggesting mTOR inhibition as a novel therapeutic treatment in PD.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	95-99
30945580-0	2020	Rapamycin Inhibits Nf-KappaB Activation by Autophagy to Reduce Catabolism in Human Chondrocytes.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	19-28
33448097-8	2020	OS cell lines exhibited differential sensitivity to mTOR inhibitor Rapamycin.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	52-56
33448097-9	2020	Evaluation of phosphorylated STAT3 showed that in Rapamycin-sensitive 143B cells, the inhibitor decreased phosphorylation of STAT3 at Y705, but not at S727 whereas, in Rapamycin-resistant U2OS cells, the inhibitor decreased S727 phosphorylation but not Y705.	Sirolimus	50-59	signal transducer and activator of transcription 3	Homo sapiens	29-34
33448097-9	2020	Evaluation of phosphorylated STAT3 showed that in Rapamycin-sensitive 143B cells, the inhibitor decreased phosphorylation of STAT3 at Y705, but not at S727 whereas, in Rapamycin-resistant U2OS cells, the inhibitor decreased S727 phosphorylation but not Y705.	Sirolimus	50-59	signal transducer and activator of transcription 3	Homo sapiens	125-130
33448097-9	2020	Evaluation of phosphorylated STAT3 showed that in Rapamycin-sensitive 143B cells, the inhibitor decreased phosphorylation of STAT3 at Y705, but not at S727 whereas, in Rapamycin-resistant U2OS cells, the inhibitor decreased S727 phosphorylation but not Y705.	Sirolimus	168-177	signal transducer and activator of transcription 3	Homo sapiens	29-34
33448097-9	2020	Evaluation of phosphorylated STAT3 showed that in Rapamycin-sensitive 143B cells, the inhibitor decreased phosphorylation of STAT3 at Y705, but not at S727 whereas, in Rapamycin-resistant U2OS cells, the inhibitor decreased S727 phosphorylation but not Y705.	Sirolimus	168-177	signal transducer and activator of transcription 3	Homo sapiens	125-130
33448097-10	2020	However, knockdown of STAT3 in U2OS cells made them sensitive to Rapamycin.	Sirolimus	65-74	signal transducer and activator of transcription 3	Homo sapiens	22-27
33448097-11	2020	Immunofluorescence (IF) analysis showed that mTOR is constitutively activated in the 143B cells but is suppressed in the U2OS cells, indicating that this might be their reason for being resistant to Rapamycin.	Sirolimus	199-208	mechanistic target of rapamycin kinase	Homo sapiens	45-49
30945580-12	2020	CONCLUSIONS: Rapamycin can inhibit the overexpression of inflammatory catabolic genes by activating autophagy, and can suppress the NF-kappaB signaling pathway in chondrocytes to break the positive feedback loop with inflammatory factors and reduce the rate and level of inflammation progression.	Sirolimus	13-22	nuclear factor kappa B subunit 1	Homo sapiens	132-141
32747423-9	2020	Combined mTOR (rapamycin) and CDK4/6 (palbociclib) inhibition decreased tumor size and proliferation in tumor flank transplants, increased survival in an intravenous transplant model of disseminated leukemia compared to single agent treatment and cooperatively decreased cell viability in human T-ALL/LBL cell lines.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	9-13
31869431-1	2020	AIMS: Oxidative stress is evident in resected epileptogenic brain tissue of patients with developmental brain malformations related to mammalian target of rapamycin activation: tuberous sclerosis complex (TSC) and focal cortical dysplasia type IIb (FCD IIb).	Sirolimus	155-164	TSC complex subunit 1	Homo sapiens	205-208
33038070-2	2020	The mechanistic target of rapamycin complex 1 (mTORC1) and its upstream protein kinase Akt1 have been implicated as a central signaling pathway that regulates protein synthesis in the skeletal muscle; however, the precise molecular regulation of mTORC1 activity is largely unknown.	Sirolimus	26-35	thymoma viral proto-oncogene 1	Mus musculus	87-91
32810332-1	2020	AKT-mTORC1 (mammalian target of rapamycin complex 1) signaling pathway plays a critical role in tumorigenesis and can be targeted by rapamycin.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	0-3
32810332-10	2020	Our results demonstrated the lncRNA EPIC1 expression activated the AKT-mTORC1 signaling pathway through Myc and led to rapamycin resistance in breast and ovarian cancer.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	67-70
32160289-12	2020	Inhibition of the mechanistic target of the rapamycin (mTOR) pathway suppressed IFNalpha production from monocytes and downregulated enhanced STING expression and its downstream molecules.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	55-59
32949703-12	2020	The effects by THP on lung injury, PI3K/AKT/mTOR signaling and autophagy were also observed after treatment with 3-MA, an autophagy inhibitor, whereas were blocked by combinational treatment with RAPA, an autophagy inducer.	Sirolimus	196-200	AKT serine/threonine kinase 1	Rattus norvegicus	40-43
32160289-12	2020	Inhibition of the mechanistic target of the rapamycin (mTOR) pathway suppressed IFNalpha production from monocytes and downregulated enhanced STING expression and its downstream molecules.	Sirolimus	44-53	interferon alpha 1	Homo sapiens	80-88
33069284-6	2020	Advances in medical therapy through inhibition of the mTOR/PI3K/AKT pathway with Sirolimus and more proximal targeted drugs along with advances in sclerotherapy techniques are promising for the long-term improvement and amelioration of symptoms in patients with venous malformations.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	54-58
33004923-6	2020	In further experiments, in vitro exposure to rapamycin inhibited placental glutamine and glutamate uptake (24 h, uncomplicated pregnancies) indicating a role of mTOR in regulating placental transport of these amino acids.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	161-165
33069284-6	2020	Advances in medical therapy through inhibition of the mTOR/PI3K/AKT pathway with Sirolimus and more proximal targeted drugs along with advances in sclerotherapy techniques are promising for the long-term improvement and amelioration of symptoms in patients with venous malformations.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	64-67
33062677-5	2020	In the present study, we investigated if Wubeizi ointment suppressed keloid formation through the modulation of key molecules of the rapamycin (mTOR) pathway including phosphatase and tensin homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt).	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	144-148
33193709-3	2020	It is also known that hamartin is involved as a target in the rapamycin (mTOR) signaling pathway, which functions to integrate a variety of environmental triggers in order to exert control over cellular metabolism and homeostasis.	Sirolimus	62-71	TSC complex subunit 1	Homo sapiens	22-30
33193709-3	2020	It is also known that hamartin is involved as a target in the rapamycin (mTOR) signaling pathway, which functions to integrate a variety of environmental triggers in order to exert control over cellular metabolism and homeostasis.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	73-77
32879008-1	2020	Low-glucose and -insulin conditions, associated with ketogenic diets, can reduce the activity of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, potentially leading to a range of positive medical and health-related effects.	Sirolimus	123-132	insulin	Homo sapiens	17-24
32603426-0	2020	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors.	Sirolimus	0-9	DnaJ heat shock protein family (Hsp40) member C5	Homo sapiens	15-18
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	83-87
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	161-165
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	glucagon	Homo sapiens	110-115
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	161-165
32389853-20	2020	And the results of enrichment analysis shown the pathways mainly contained phosphoinositide-3-kinase/Akt (PI3K/Akt) signal pathway, neurotrophic factors (NTFs) signal pathway, Hypoxia-inducible factor 1 (HIF-1) signal pathway, mechanistic Target of Rapamycin (mTOR) signal pathway, Tumor necrosis factor (TNF) signal pathway, insulin resistance (IR).	Sirolimus	249-258	AKT serine/threonine kinase 1	Homo sapiens	101-104
32389853-20	2020	And the results of enrichment analysis shown the pathways mainly contained phosphoinositide-3-kinase/Akt (PI3K/Akt) signal pathway, neurotrophic factors (NTFs) signal pathway, Hypoxia-inducible factor 1 (HIF-1) signal pathway, mechanistic Target of Rapamycin (mTOR) signal pathway, Tumor necrosis factor (TNF) signal pathway, insulin resistance (IR).	Sirolimus	249-258	AKT serine/threonine kinase 1	Homo sapiens	111-114
32693673-10	2020	Mechanistically, LAPTM4B regulated the activity of mammalian target of rapamycin complex 1 (mTORC1) via interacting with mTOR through its EC3 domain.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	92-96
32707053-9	2020	Moreover, the expression of Rab31-induced p-p70S6K was almost inhibited by rapamycin, a well-established inhibitor of mTOR.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	118-122
33013932-3	2020	Our results show that RLR stimulation increased the phosphorylation of the mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt, respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes.	Sirolimus	219-228	mechanistic target of rapamycin kinase	Homo sapiens	75-79
33013932-3	2020	Our results show that RLR stimulation increased the phosphorylation of the mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt, respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes.	Sirolimus	219-228	AKT serine/threonine kinase 1	Homo sapiens	145-148
33013932-7	2020	In addition, rapamycin abrogated the ability of both DC subtypes to promote the proliferation and differentiation of IFN-y and Granzyme B producing CD8 + T cells.	Sirolimus	13-22	interferon gamma	Homo sapiens	117-122
32912327-7	2020	TLR5-mediated microglial function involves the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1) pathway, as specific inhibitors of this signaling pathway abolish microglial activation.	Sirolimus	76-85	AKT serine/threonine kinase 1	Homo sapiens	52-55
32450402-6	2020	Specific inhibitors of PI3K (LY294002) and mTOR (Rapamycin) and siRNA of Nrf2 were employed to verify that upregulation of Nrf2 correlated with activating the PI3K/Akt pathway.	Sirolimus	49-58	NFE2 like bZIP transcription factor 2	Homo sapiens	123-127
32927859-1	2020	TSC1 is a tumor suppressor that inhibits cell growth via negative regulation of the mammalian target of rapamycin complex (mTORC1).	Sirolimus	104-113	TSC complex subunit 1	Homo sapiens	0-4
32911743-8	2020	In both HT29 and DLD-1 cells, the CSC population was significantly decreased following treatment with metformin, AMPK activator (AICAR), HMG-CoA reductase inhibitor (simvastatin), or mTOR inhibitor (rapamycin), and was increased by mevalonate.	Sirolimus	199-208	mechanistic target of rapamycin kinase	Homo sapiens	183-187
32599128-7	2020	Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	65-68
32900356-9	2021	LY294002 and rapamycin inhibited PI3K/Akt/mTOR and AQP1 expression (P<0.01), prevented the change of AQP1 location in SRA01/04 plasma membrane (P<0.01).	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	38-41
32900356-9	2021	LY294002 and rapamycin inhibited PI3K/Akt/mTOR and AQP1 expression (P<0.01), prevented the change of AQP1 location in SRA01/04 plasma membrane (P<0.01).	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	42-46
32900356-9	2021	LY294002 and rapamycin inhibited PI3K/Akt/mTOR and AQP1 expression (P<0.01), prevented the change of AQP1 location in SRA01/04 plasma membrane (P<0.01).	Sirolimus	13-22	aquaporin 1 (Colton blood group)	Homo sapiens	51-55
32900356-9	2021	LY294002 and rapamycin inhibited PI3K/Akt/mTOR and AQP1 expression (P<0.01), prevented the change of AQP1 location in SRA01/04 plasma membrane (P<0.01).	Sirolimus	13-22	aquaporin 1 (Colton blood group)	Homo sapiens	101-105
33083762-3	2020	The PPIs examined included those between FKBP12 and the rapamycin-binding domain of m-Tor (FRB) and between p53 (1-92) and HDM2 (1-128).	Sirolimus	56-65	RAR related orphan receptor C	Homo sapiens	86-89
32619236-6	2020	Mechanistically, Rim15 kinase phosphorylates Rph1 upon rapamycin treatment.	Sirolimus	55-64	protein kinase RIM15	Saccharomyces cerevisiae S288C	17-22
32599128-8	2020	Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs.	Sirolimus	45-54	thymoma viral proto-oncogene 1	Mus musculus	148-151
32726607-3	2020	Here, we report that in damaged proximal tubules of high-fat diet-fed ApoE-knockout mice, a model of non-proteinuric DKD, ATP production shifted from lipolysis to ketolysis dependent due to hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	235-244	apolipoprotein E	Mus musculus	70-74
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	CD4 molecule	Homo sapiens	6-9
32776229-3	2020	Several reports indicate that the inhibitor of mTOR rapamycin can reverse GC resistance, but the molecular mechanism involved in this synergistic effect has not been fully defined.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	47-51
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	CD4 molecule	Homo sapiens	59-62
32779245-2	2020	Several data support the involvement of the mammalian target of rapamycin complex 1 (mTORC1) signaling in the interplay between androgens, insulin, insulin-like growth factor (IGF1), and high glycemic index diet in acne.	Sirolimus	64-73	insulin	Homo sapiens	139-174
32779245-2	2020	Several data support the involvement of the mammalian target of rapamycin complex 1 (mTORC1) signaling in the interplay between androgens, insulin, insulin-like growth factor (IGF1), and high glycemic index diet in acne.	Sirolimus	64-73	insulin like growth factor 1	Homo sapiens	176-180
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	Sirolimus	97-106	cAMP responsive element binding protein 1	Mus musculus	160-164
32495040-2	2020	Several reports have demonstrated that mitogen-activated protein kinases 3 and 1 (MAPK3/1)-mammalian target of rapamycin complex 1 (mTORC1) signaling in pre-granulosa cells promotes primordial follicle activation by increasing KIT ligand (KITL) expression and then stimulating phosphatidylinositol 3 kinase signaling in oocytes.	Sirolimus	111-120	mitogen-activated protein kinase 3	Homo sapiens	39-80
32495040-2	2020	Several reports have demonstrated that mitogen-activated protein kinases 3 and 1 (MAPK3/1)-mammalian target of rapamycin complex 1 (mTORC1) signaling in pre-granulosa cells promotes primordial follicle activation by increasing KIT ligand (KITL) expression and then stimulating phosphatidylinositol 3 kinase signaling in oocytes.	Sirolimus	111-120	mitogen-activated protein kinase 3	Homo sapiens	82-87
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	Sirolimus	97-106	cAMP responsive element binding protein 1	Mus musculus	223-227
32739207-2	2020	As an important negative regulatory factor of the mammalian target of rapamycin complex 1 (mTORC1) signal, tuberous sclerosis complex 1 (Tsc1) is also a key regulatory point of glycolysis.	Sirolimus	70-79	TSC complex subunit 1	Homo sapiens	107-135
32064785-8	2020	However, administration of rapamycin, an inhibitor of the autophagy, to activate autophagy resulted in the inhibition of NLRP3 inflammasome, and finally alleviated myocardial I/RI.	Sirolimus	27-36	NLR family, pyrin domain containing 3	Rattus norvegicus	121-126
32739207-2	2020	As an important negative regulatory factor of the mammalian target of rapamycin complex 1 (mTORC1) signal, tuberous sclerosis complex 1 (Tsc1) is also a key regulatory point of glycolysis.	Sirolimus	70-79	TSC complex subunit 1	Homo sapiens	137-141
32335998-0	2020	Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.	Sirolimus	84-93	methyl-CpG binding protein 2	Homo sapiens	123-128
32720689-12	2020	Accordingly, the adenosine 5"-monophosphate-activated protein kinase/protein kinase B-mechanistic target of rapamycin (AMPK/AKT-mTOR) signaling was significantly activated in the 2 fish models with inhibited mitochondrial FAO (P < 0.05).	Sirolimus	108-117	mechanistic target of rapamycin kinase	Danio rerio	128-132
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	98-102
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	98-102
32737433-9	2020	Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model.	Sirolimus	181-190	AKT serine/threonine kinase 1	Homo sapiens	102-105
32717360-5	2020	RESULTS: We show that high-grade chondrosarcoma cells contain a population of radioresistant cancer stem cells that can be targeted by a combination of carbon-ion therapy, miR-34 mimic administration and/or rapamycin treatment that triggers FOXO3 and miR-34 over-expression.	Sirolimus	207-216	forkhead box O3	Homo sapiens	241-246
32737433-9	2020	Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model.	Sirolimus	181-190	SMAD specific E3 ubiquitin protein ligase 1	Homo sapiens	18-24
32428390-2	2020	Previous reports showed resolution of immune cytopenias in solid organ transplant recipients following replacement of the calcineurin inhibitor tacrolimus with the mTOR inhibitor sirolimus.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	164-168
32717360-6	2020	mTOR inhibition by rapamycin triggered FOXO3 and miR-34, leading to KLF4 repression.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
32717360-6	2020	mTOR inhibition by rapamycin triggered FOXO3 and miR-34, leading to KLF4 repression.	Sirolimus	19-28	forkhead box O3	Homo sapiens	39-44
32878322-3	2020	Targeting 786-O cells by SH-859 inhibited cell growth and affected the protein kinase B/mechanistic target of rapamycin 1 pathway, which in turn downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, as well as other signaling proteins.	Sirolimus	110-119	lactate dehydrogenase A	Homo sapiens	207-230
32772681-1	2020	BACKGROUND AND PURPOSE: Rapamycin is a clinically approved mammalian target of rapamycin inhibitor that has been shown to be neuroprotective in animal models of stroke.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	59-88
32759469-1	2020	While the growth factors like insulin initiate a signaling cascade to induce conformational changes in the mechanistic target of rapamycin complex 1 (mTORC1), amino acids cause the complex to localize to the site of activation, the lysosome.	Sirolimus	129-138	insulin	Homo sapiens	30-37
32867785-9	2020	Mechanically, RAPA ameliorated the physiological function of mutant ECs by inhibiting AKT-mTOR pathway, but also facilitated the nuclear location of FOXO1 and the expression of PDGFB in mutant ECs, and then improved paracrine interactions between ECs and SMCs.	Sirolimus	14-18	AKT serine/threonine kinase 1	Homo sapiens	86-89
32867785-9	2020	Mechanically, RAPA ameliorated the physiological function of mutant ECs by inhibiting AKT-mTOR pathway, but also facilitated the nuclear location of FOXO1 and the expression of PDGFB in mutant ECs, and then improved paracrine interactions between ECs and SMCs.	Sirolimus	14-18	mechanistic target of rapamycin kinase	Homo sapiens	90-94
32867785-9	2020	Mechanically, RAPA ameliorated the physiological function of mutant ECs by inhibiting AKT-mTOR pathway, but also facilitated the nuclear location of FOXO1 and the expression of PDGFB in mutant ECs, and then improved paracrine interactions between ECs and SMCs.	Sirolimus	14-18	forkhead box O1	Homo sapiens	149-154
32736702-3	2020	In the present study, using cultured ARPE-19 cells, we determined that TGF-beta initiates a signaling pathway through extracellular signal-regulated kinase (ERK)-mammalian target of rapamycin complex 1 (mTORC1) that stimulates trans-differentiation and fibrosis of retinal pigment epithelium.	Sirolimus	182-191	mitogen-activated protein kinase 1	Homo sapiens	118-155
32553629-2	2020	The target of rapamycin complex 1 (TORC1) kinase promotes G1/S transition via upregulation of the G1 cyclin Cln3 that activates MBF and SBF in favorable nutrient conditions.	Sirolimus	14-23	cyclin CLN3	Saccharomyces cerevisiae S288C	108-112
32736702-3	2020	In the present study, using cultured ARPE-19 cells, we determined that TGF-beta initiates a signaling pathway through extracellular signal-regulated kinase (ERK)-mammalian target of rapamycin complex 1 (mTORC1) that stimulates trans-differentiation and fibrosis of retinal pigment epithelium.	Sirolimus	182-191	mitogen-activated protein kinase 1	Homo sapiens	157-160
32847614-6	2020	Moreover, both MA-TAM master regulators and their target genes are significantly correlated with poor clinical outcomes and are often associated with genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.	Sirolimus	246-255	neurofibromin 1	Homo sapiens	173-188
32843029-11	2020	We prescribed sirolimus, which is an oral mTOR inhibitor, for two consecutive years.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	42-46
32847614-6	2020	Moreover, both MA-TAM master regulators and their target genes are significantly correlated with poor clinical outcomes and are often associated with genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.	Sirolimus	246-255	neurofibromin 1	Homo sapiens	190-193
32847614-6	2020	Moreover, both MA-TAM master regulators and their target genes are significantly correlated with poor clinical outcomes and are often associated with genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.	Sirolimus	246-255	AKT serine/threonine kinase 1	Homo sapiens	256-259
32847614-6	2020	Moreover, both MA-TAM master regulators and their target genes are significantly correlated with poor clinical outcomes and are often associated with genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.	Sirolimus	246-255	mechanistic target of rapamycin kinase	Homo sapiens	274-278
32847614-6	2020	Moreover, both MA-TAM master regulators and their target genes are significantly correlated with poor clinical outcomes and are often associated with genomic aberrations in neurofibromin 1 (NF1) and phosphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.	Sirolimus	246-255	AKT serine/threonine kinase 1	Homo sapiens	279-282
32825760-6	2020	We have demonstrated metformin"s ability to enhance the cytostatic activity of the tamoxifen and rapamycin on both parent MCF-7 cells and MCF-7-resistant derivates mediated via the suppression of mTOR signaling and growth-related transcriptional factors.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	196-200
32824248-1	2020	The constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) leads to the overproduction of apoB-containing triacylglycerol-rich lipoproteins in HepG2 cells.	Sirolimus	57-66	apolipoprotein B	Homo sapiens	117-121
32885169-5	2020	Based on this, we demonstrate that our rapamycin-VEGF hierarchical coating impressively promoted the competitive growth of endothelial cells over smooth muscle cells (ratio of EC/SMC~25) while relieving the adverse impact of rapamycin to ECs.	Sirolimus	39-48	vascular endothelial growth factor A	Homo sapiens	49-53
32885169-5	2020	Based on this, we demonstrate that our rapamycin-VEGF hierarchical coating impressively promoted the competitive growth of endothelial cells over smooth muscle cells (ratio of EC/SMC~25) while relieving the adverse impact of rapamycin to ECs.	Sirolimus	225-234	vascular endothelial growth factor A	Homo sapiens	49-53
32885169-6	2020	We further conducted the real-time loading of VEGF on stents and demonstrate that the hierarchical combination of rapamycin and VEGF showed remarkable endothelium regeneration while maintaining a very low level of in-stent restenosis.	Sirolimus	114-123	vascular endothelial growth factor A	Homo sapiens	46-50
32526201-6	2020	Western blot results showed that NEP down-regulates the production of phospho-mammalian target of rapamycin (p-mTOR), whereas increases the expression of key autophagy-related molecules such as Beclin-1, Atg5-Atg12, and LC3-II.	Sirolimus	98-107	membrane metalloendopeptidase	Homo sapiens	33-36
32526201-6	2020	Western blot results showed that NEP down-regulates the production of phospho-mammalian target of rapamycin (p-mTOR), whereas increases the expression of key autophagy-related molecules such as Beclin-1, Atg5-Atg12, and LC3-II.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	111-115
32531316-0	2020	Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.	Sirolimus	50-59	AKT serine/threonine kinase 1	Homo sapiens	94-97
32531316-0	2020	Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	98-102
32531316-2	2020	While rapamycin has been shown to exhibit anti-tumor effects, it may also activate AKT, resulting in increased cell survival and drug resistance, thereby limiting its anti-tumor effects.	Sirolimus	6-15	AKT serine/threonine kinase 1	Homo sapiens	83-86
32531316-11	2020	Co-administration significantly enhanced the anti-tumor effects than use of any one drug, and significantly reduced the phosphorylation of AKT and p70S6K compared to treatment with rapamycin alone.	Sirolimus	181-190	AKT serine/threonine kinase 1	Homo sapiens	139-142
32518161-9	2020	Moreover, rapamycin treatment partially restored normal hepatic gene expression as well as the nuclear location of the transcription factor Hnf4a.	Sirolimus	10-19	hepatocyte nuclear factor 4, alpha	Danio rerio	140-145
32631952-9	2020	Besides the modestly increased insulin sensitivity, male IRS-2 KO rats displayed the enhanced insulin-induced activation of the mammalian target of rapamycin complex 1 pathway in the liver compared to WT rats.	Sirolimus	148-157	insulin receptor substrate 2	Rattus norvegicus	57-62
32479955-5	2020	PIM kinases usually appear to be important downstream effectors of oncoproteins which overexpresses and helps in mediating drug resistance to available agents, such as rapamycin.	Sirolimus	168-177	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-3
33505579-6	2020	The inhibitory effects of fucoidan on NLRP3 inflammasome were enhanced by autophagy activator rapamycin (Rapa) and alleviated by autophagy inhibitor 3-methyladenine (3-MA).	Sirolimus	94-103	NLR family pyrin domain containing 3	Homo sapiens	38-43
32823598-8	2020	In the present study, we mitigated the effects of IR-induced inflammatory EVs (i.e., TNF-alpha), through the use of mTOR inhibitors (mTORi; Rapamycin and INK128).	Sirolimus	140-149	tumor necrosis factor	Homo sapiens	85-94
32823598-8	2020	In the present study, we mitigated the effects of IR-induced inflammatory EVs (i.e., TNF-alpha), through the use of mTOR inhibitors (mTORi; Rapamycin and INK128).	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	116-120
32848709-5	2020	In addition, within striatum, ERK1/2 is also able to modulate in a D1 receptor-dependent manner the activity of the mammalian target of rapamycin complex 1 (mTORC1) pathway under DA depletion and L-DOPA therapy.	Sirolimus	136-145	mitogen-activated protein kinase 3	Homo sapiens	30-36
32850379-8	2020	Deoxyshikonin inactivated the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	48-51
32850379-8	2020	Deoxyshikonin inactivated the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	88-92
33505579-6	2020	The inhibitory effects of fucoidan on NLRP3 inflammasome were enhanced by autophagy activator rapamycin (Rapa) and alleviated by autophagy inhibitor 3-methyladenine (3-MA).	Sirolimus	105-109	NLR family pyrin domain containing 3	Homo sapiens	38-43
32748349-7	2021	Mechanistically, we identified TBC1D7 as a binding partner of KIF2C, and this interaction disrupts the formation of the TSC complex, resulting in the enhancement of mammalian target of rapamycin complex1 (mTORC1) signal transduction.	Sirolimus	185-194	TBC1 domain family member 7	Homo sapiens	31-37
32502382-1	2020	The TSC complex is the cognate GTPase-activating protein (GAP) for the small GTPase Rheb and a crucial regulator of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	142-151	TSC complex subunit 1	Homo sapiens	4-7
32335491-0	2020	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.	Sirolimus	23-32	nuclear receptor subfamily 4 group A member 1	Homo sapiens	91-107
31810732-6	2020	Treatment with sirolimus was shown on a repeat kidney biopsy to successfully inhibit the AKT/mTORC pathway and was associated with significant improvement in kidney function and lesions of vasculopathy.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	89-92
32335491-1	2020	BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	91-95
32335491-1	2020	BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	110-126
32335491-1	2020	BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	128-130
32335491-2	2020	METHODS: All patients with HR-positive metastatic breast cancer treated with sirolimus plus endocrine therapy between December 2017 and July 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences were consecutively and retrospectively reviewed.	Sirolimus	77-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	27-29
32335491-10	2020	For patients who received less than 3 lines of chemotherapy, those with PI3K/Akt/mTOR pathway alterations had a better response to sirolimus than those without alterations, with a median PFS of 7.0 months vs 4.3 months (hazard ratio = 0.01, 95% CI 0.00-0.34, P = 0.010).	Sirolimus	131-140	AKT serine/threonine kinase 1	Homo sapiens	77-80
32335491-10	2020	For patients who received less than 3 lines of chemotherapy, those with PI3K/Akt/mTOR pathway alterations had a better response to sirolimus than those without alterations, with a median PFS of 7.0 months vs 4.3 months (hazard ratio = 0.01, 95% CI 0.00-0.34, P = 0.010).	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	81-85
32335491-11	2020	CONCLUSIONS: Sirolimus is a potentially effective treatment option for patients with HR-positive advanced breast cancer.	Sirolimus	13-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	85-87
32057805-3	2020	A major pathway leading to senescence is via the activation of PI3 kinase-mammalian target of rapamycin (mTOR) signaling.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	105-109
31900833-8	2020	The suppression of the autophagic flux inhibited the apoptosis of compound C-treated U937 and U937/HQ cells, whereas co-treatment with rapamycin, a mTOR inhibitor, sensitized the two cell lines to compound C cytotoxicity.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	148-152
32293025-10	2020	Graft-infiltrating macrophages of G-CSF/rapamycin-treated mice had an M2 phenotype, characterized by higher CD206 expression and interleukin (IL)-10 production, whereas splenic macrophages only had an increased CD206 expression.	Sirolimus	40-49	interleukin 10	Mus musculus	129-148
32381646-0	2020	Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice.	Sirolimus	28-37	CD4 molecule	Homo sapiens	61-64
32381646-9	2020	The combination of IL-2 and rapamycin has the potential to inhibit human islet-allograft rejection by expanding CD4+FOXP3+ Tregs in vivo and supressing effector cell function, and could be the basis of effective tolerance-based regimens.	Sirolimus	28-37	CD4 molecule	Homo sapiens	112-115
32416459-3	2020	Of note, first-generation mTOR inhibitors are mainly reported to be rapamycin and its derivatives and second-generation mTOR inhibitors that consist of several ATP-competitive kinase inhibitors.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	26-30
32416459-4	2020	Interestingly, the third-generation mTOR inhibitor, RapaLink-1, mediates rapamycin and mTOR kinase inhibitors via the same molecule and shows much higher efficiency.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	36-40
31782176-10	2020	Furthermore, hepatocyte-derived exosomal miR-192-5p inhibited the protein expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), which further inhibited the phosphorylation levels of Akt and forkhead box transcription factor O1 (FoxO1) and resulted in the activation of FoxO1 and subsequent induction of the inflammatory response.	Sirolimus	92-101	microRNA 192	Homo sapiens	41-48
32742319-13	2020	Of note, calcineurin, cyclosporin A, mTOR inhibitor rapamycin and NFATC2-specific small interfering RNA restored the function of SOCE in p.R304W-mutant BMDMs.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
32592217-8	2020	Notably, rapamycin, a familiar autophagy agonist, reduces ERalpha levels and the proliferation ability of ULM cells.	Sirolimus	9-18	estrogen receptor 1	Homo sapiens	58-65
32467992-10	2020	However, treatment with the autophagy inducers rapamycin or LiCl eliminated the hyperoxia-induced reduction in STX17, partially restored the autophagy flux and increased the survival of AT-II cells exposed to hyperoxia.	Sirolimus	47-56	syntaxin 17	Rattus norvegicus	111-116
31782176-10	2020	Furthermore, hepatocyte-derived exosomal miR-192-5p inhibited the protein expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), which further inhibited the phosphorylation levels of Akt and forkhead box transcription factor O1 (FoxO1) and resulted in the activation of FoxO1 and subsequent induction of the inflammatory response.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	221-224
31782176-10	2020	Furthermore, hepatocyte-derived exosomal miR-192-5p inhibited the protein expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), which further inhibited the phosphorylation levels of Akt and forkhead box transcription factor O1 (FoxO1) and resulted in the activation of FoxO1 and subsequent induction of the inflammatory response.	Sirolimus	92-101	forkhead box O1	Homo sapiens	229-265
31782176-10	2020	Furthermore, hepatocyte-derived exosomal miR-192-5p inhibited the protein expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), which further inhibited the phosphorylation levels of Akt and forkhead box transcription factor O1 (FoxO1) and resulted in the activation of FoxO1 and subsequent induction of the inflammatory response.	Sirolimus	92-101	forkhead box O1	Homo sapiens	267-272
31782176-10	2020	Furthermore, hepatocyte-derived exosomal miR-192-5p inhibited the protein expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor), which further inhibited the phosphorylation levels of Akt and forkhead box transcription factor O1 (FoxO1) and resulted in the activation of FoxO1 and subsequent induction of the inflammatory response.	Sirolimus	92-101	forkhead box O1	Homo sapiens	308-313
32535143-9	2020	While the proportion of activated splenic CD4 + Foxp3- T cells expressing IFN-gamma were similar in control and RPM-treated groups, RPM decreased the proportions ICOS+ and CD8+ IFN-gamma + splenic T cells.	Sirolimus	132-135	interferon gamma	Mus musculus	177-186
32815764-7	2020	RESULTS: The final covariates that affect sirolimus clearance include weight and the CYP3A5 genotype.	Sirolimus	42-51	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	85-91
32815764-8	2020	The initial dosage of sirolimus for individuals with CYP3A5*3/*3 was 0.20 mg/kg split into two doses for 5 to 60 kg body weight.	Sirolimus	22-31	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	53-59
32485435-6	2020	We confirm that rapamycin and LPS induce autophagy in M. tuberculosis infected THP-1-derived macrophages or PMA primed THP-1 macrophages [THP-1(A)].	Sirolimus	16-25	GLI family zinc finger 2	Homo sapiens	79-84
32485435-6	2020	We confirm that rapamycin and LPS induce autophagy in M. tuberculosis infected THP-1-derived macrophages or PMA primed THP-1 macrophages [THP-1(A)].	Sirolimus	16-25	GLI family zinc finger 2	Homo sapiens	119-124
32696949-8	2020	Western blot results showed that activated caspase-3 was inhibited by RES effect, and was up-regulated again after the addition of RAPA and SB216763.	Sirolimus	131-135	caspase 3	Homo sapiens	43-52
32849956-8	2020	Conclusions: Since many tumors are characterized by deregulated PI3K/AKT/mTOR pathway, rapamycin is thought to inhibit the pathway and tumor growth.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	69-72
32849956-8	2020	Conclusions: Since many tumors are characterized by deregulated PI3K/AKT/mTOR pathway, rapamycin is thought to inhibit the pathway and tumor growth.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	73-77
32696949-9	2020	In addition, p-mTOR and p-GSK-3beta were up-regulated by RES and down-regulated by RAPA and SB216763.	Sirolimus	83-87	mechanistic target of rapamycin kinase	Homo sapiens	15-19
32922169-0	2020	Rapamycin blocks the IL-13-induced deficiency of Epidermal Barrier Related Proteins via upregulation of miR-143 in HaCaT Keratinocytes.	Sirolimus	0-9	interleukin 13	Homo sapiens	21-26
32850534-0	2020	Early Adjuvant Medication With the mTOR Inhibitor Sirolimus in a Preterm Neonate With Compressive Cystic Lymphatic Malformation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	35-39
32850534-3	2020	An mTOR inhibitor, sirolimus, was started from the first day of life, and was combined with iterative sclerotherapy procedures.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	3-7
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	AKT serine/threonine kinase 1	Homo sapiens	93-96
32711543-4	2020	Although sirolimus known as a mTOR inhibitor has good response to FAVA, expression pattern of the mTOR pathway was still unclear.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	30-34
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	interleukin 13	Homo sapiens	125-130
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	loricrin cornified envelope precursor protein	Homo sapiens	253-261
32692750-0	2020	Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF.	Sirolimus	12-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-94
32774365-2	2020	Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-44
32766308-12	2020	In addition, rapamycin, the mTOR inhibitor, has cooperative effect with minocycline on suppression of TNF-alpha release and induction of autophagy by repressing mTOR.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	28-32
32766308-12	2020	In addition, rapamycin, the mTOR inhibitor, has cooperative effect with minocycline on suppression of TNF-alpha release and induction of autophagy by repressing mTOR.	Sirolimus	13-22	tumor necrosis factor	Homo sapiens	102-111
32766308-12	2020	In addition, rapamycin, the mTOR inhibitor, has cooperative effect with minocycline on suppression of TNF-alpha release and induction of autophagy by repressing mTOR.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	161-165
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	Sirolimus	136-145	activating transcription factor 4	Mus musculus	48-52
32683410-13	2020	Finally, treatment with rapamycin (an mTOR inhibitor) was shown to abolish the increased proliferation capability of DM1 SSCs due to MBNL1 overexpression.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	38-42
32692750-0	2020	Retraction: Rapamycin Inhibits Proliferation of Hemangioma Endothelial Cells by Reducing HIF-1-Dependent Expression of VEGF.	Sirolimus	12-21	vascular endothelial growth factor A	Homo sapiens	119-123
32668776-1	2020	Background and objectives: Everolimus (EVE) is a mammalian target of the rapamycin (mTOR) inhibitor that is widely used in cancer patients.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	84-88
32765227-4	2020	Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	TSC complex subunit 1	Homo sapiens	26-29
32765227-4	2020	Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	TSC complex subunit 1	Homo sapiens	37-41
32647003-5	2020	HEM1 loss also blocked mechanistic target of rapamycin complex 2 (mTORC2)-dependent AKT phosphorylation, T cell proliferation, and selected effector functions, leading to immunodeficiency.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	84-87
32676162-4	2020	We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32676162-4	2020	We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	144-148
32676162-5	2020	Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	11-15
32635337-2	2020	However, prolonged Rapamycin treatment re-activates Akt and can promote cancer growth.	Sirolimus	19-28	thymoma viral proto-oncogene 1	Mus musculus	52-55
32753891-13	2020	Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation.	Sirolimus	97-106	AKT serine/threonine kinase 1	Homo sapiens	73-76
32753891-13	2020	Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation.	Sirolimus	97-106	AKT serine/threonine kinase 1	Homo sapiens	170-173
32753891-13	2020	Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	174-178
32635337-6	2020	We observed that compared with Rapamycin alone, Rapamycin + Honokiol combination can effectively down-regulate c-Met-induced Akt phosphorylation in renal cancer cells; and it markedly inhibited Ras activation and cell proliferation and promoted G1 phase cell cycle arrest.	Sirolimus	48-57	thymoma viral proto-oncogene 1	Mus musculus	125-128
32635337-9	2020	In mouse renal cancer cells and Balb/c splenocytes co-culture assay, Rapamycin + Honokiol markedly potentiated immune-cell-mediated killing of cancer cells, possibly through the down-regulation of PD-L1.	Sirolimus	69-78	CD274 antigen	Mus musculus	197-202
31931658-5	2020	By acting as a nutrient status sensor, TP53INP2 switches its role between transcription and autophagy by changing its subcellular localization and helps the cell to cope with environmental changes.Abbreviations: Atg: autophagy related; DOR: diabetes and obesity related gene; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTORC1: mechanistic target of rapamycin complex 1; rDNA: ribosomal DNA; TP53INP2: tumor protein p53 inducible nuclear protein 2; UIM: ubiquitin-interacting motif.	Sirolimus	396-405	tumor protein p53 inducible nuclear protein 2	Homo sapiens	39-47
32630768-3	2020	The discovery of mTOR signaling started from isolation of rapamycin in 1975 and cloning of TOR genes in 1993.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	17-21
32630768-3	2020	The discovery of mTOR signaling started from isolation of rapamycin in 1975 and cloning of TOR genes in 1993.	Sirolimus	58-67	RAR related orphan receptor C	Homo sapiens	18-21
32348869-8	2020	Finally, we observed that rapamycin, an mTOR inhibitor, blocked both the MK-801-induced increases in phosphorylated mTOR and the MK-801 facilitating effect on memory consolidation.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	40-44
32421368-12	2020	We found that mTORC1 inhibition with low doses of rapamycin (2, 20 nM) lowered macrophage priming of IL-1b mRNA and secretion of IL-1b caused by multiple statins.	Sirolimus	50-59	interleukin 1 beta	Mus musculus	101-106
32421368-12	2020	We found that mTORC1 inhibition with low doses of rapamycin (2, 20 nM) lowered macrophage priming of IL-1b mRNA and secretion of IL-1b caused by multiple statins.	Sirolimus	50-59	interleukin 1 beta	Mus musculus	129-134
32421368-13	2020	Rapamycin (20 nM) or the rapalog, Everolimus (20 nM) prevented atorvastatin-induced lowering of insulin-mediated phosphorylation of Akt in mouse adipose tissue.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	132-135
32348869-8	2020	Finally, we observed that rapamycin, an mTOR inhibitor, blocked both the MK-801-induced increases in phosphorylated mTOR and the MK-801 facilitating effect on memory consolidation.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	116-120
32344255-6	2020	To test this, rapamycin, an mTOR inhibitor, was used.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	28-32
32167156-11	2020	As expected, DMSO-induced wound healing and cell proliferation were impaired by rapamycin, an inhibitor of AKT/mTOR signalling.	Sirolimus	80-89	thymoma viral proto-oncogene 1	Mus musculus	107-110
32298692-6	2020	KEY RESULTS: Rapamycin affects platelet procoagulant responses by reducing externalisation of the procoagulant phospholipid phosphatidylserine, formation of balloon-like structures and local generation of thrombin.	Sirolimus	13-22	coagulation factor II, thrombin	Homo sapiens	205-213
32524929-3	2020	More recently, those invasive or challenging tumours have been successfully treated with mammalian target of rapamycin inhibitors, typically everolimus and sirolimus.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	89-118
32652785-3	2020	However, it is unknown if RPM reduction with centrifugal flow LVADs may minimize VWF degradation.	Sirolimus	26-29	von Willebrand factor	Homo sapiens	81-84
32541317-2	2020	Indeed, they harbour loss of function of TSC1/TSC2, which lead to the activation of the mammalian target of rapamycin (mTOR) pathway, which is targetable therapeutically with mTOR inhibitors like sirolimus.	Sirolimus	196-205	TSC complex subunit 1	Homo sapiens	41-45
32541317-2	2020	Indeed, they harbour loss of function of TSC1/TSC2, which lead to the activation of the mammalian target of rapamycin (mTOR) pathway, which is targetable therapeutically with mTOR inhibitors like sirolimus.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	88-117
32541317-2	2020	Indeed, they harbour loss of function of TSC1/TSC2, which lead to the activation of the mammalian target of rapamycin (mTOR) pathway, which is targetable therapeutically with mTOR inhibitors like sirolimus.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	119-123
32541317-2	2020	Indeed, they harbour loss of function of TSC1/TSC2, which lead to the activation of the mammalian target of rapamycin (mTOR) pathway, which is targetable therapeutically with mTOR inhibitors like sirolimus.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Homo sapiens	175-179
32706077-8	2020	Also, rapamycin treatment increased the expressions of bcl-2, bcl-xL, HSP70, and HSP90.	Sirolimus	6-15	B cell leukemia/lymphoma 2	Mus musculus	55-60
32706077-8	2020	Also, rapamycin treatment increased the expressions of bcl-2, bcl-xL, HSP70, and HSP90.	Sirolimus	6-15	heat shock protein 1B	Mus musculus	70-75
32706077-8	2020	Also, rapamycin treatment increased the expressions of bcl-2, bcl-xL, HSP70, and HSP90.	Sirolimus	6-15	heat shock protein 86, pseudogene 2	Mus musculus	81-86
32706077-9	2020	In addition, rapamycin treatment promoted the nuclear accumulation of Nrf2 protein.	Sirolimus	13-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	70-74
32706077-10	2020	However, Nrf2 downregulation significantly impaired the effects of rapamycin on the reductions of infarct size, cell apoptosis, troponin I and ROS levels.	Sirolimus	67-76	nuclear factor, erythroid derived 2, like 2	Mus musculus	9-13
32469097-7	2020	Supplementing miR-196b-5p activity in progenitor cells reduced the protein level of TSC1 and activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	123-132	TSC complex subunit 1	Homo sapiens	84-88
32319590-8	2020	Furthermore, it was found that the energy metabolism of cervical cancer cells was inhibited following treatment with the mTOR inhibitor rapamycin.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	121-125
32652785-4	2020	We tested the hypothesis that RPM reduction preserves VWF multimers in the centrifugal-flow EVAHEART left ventricular assist system (LVAS), which is designed to minimize shear stress and blood trauma.	Sirolimus	30-33	von Willebrand factor	Homo sapiens	54-57
32652785-9	2020	RPM reduction protected VWF from pathologic degradation.	Sirolimus	0-3	von Willebrand factor	Homo sapiens	24-27
32652785-12	2020	CONCLUSIONS: RPM reduction significantly reduced VWF degradation with the centrifugal-flow EVAHEART LVAS, an LVAD specifically designed with low shear stress.	Sirolimus	13-16	von Willebrand factor	Homo sapiens	49-52
32409220-2	2020	Drugs that inhibit the mTOR pathway, such as sirolimus, can reduce the size of both SGCTs and AMLs.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	23-27
32404282-8	2020	HRG blocked the inhibitory effect of mTOR inhibitors, such as rapamycin and everolimus, on cell growth but not that of a PI3K inhibitor.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	37-41
32352655-7	2020	Higher reactivity to the mTOR complex 1 activation marker, phospho-ribosomal protein S6, was associated with a better lung function response to rapamycin (p = 0.0001).	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	25-29
32352655-10	2020	Markers of mTOR activation predict the response to rapamycin, suggesting that more advanced LAM may be less mTOR responsive and treatments specifically targeted towards LAM associated fibroblasts may have roles as adjuncts to mTOR inhibition.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	11-15
32386481-9	2020	More important, preconditioning with PI3K/AKT inhibitor LY294002 or mTOR inhibitor rapamycin both aggravated KLK10 knockdown-suppressed cancer cell growth and glucose metabolism.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	68-72
32372406-2	2020	alpha2 -AMPK activity-deficient mice have lower contraction-stimulated protein synthesis Increasing glycogen activates mTORC1-S6K1 independently of AMPK alpha2 Normalizing muscle glycogen content rescues reduced protein synthesis in AMPK-deficient mice ABSTRACT: Objective The mammalian Target of Rapamycin Complex 1 (mTORC1)-S6K1 signalling pathway regulates muscle growth-related protein synthesis and is antagonized by AMP-activated protein kinase (AMPK) in multiple cell types.	Sirolimus	297-306	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Mus musculus	0-6
32447719-3	2020	Following the addition of rapamycin, we detected that autophagy activation could reduce the increased expression level of alphaSMA and the accumulation of extracellular matrix component proteins namely fibronectin and type I collagen induced by TGF-beta1 via the inhibition of SMAD2 phosphorylation.	Sirolimus	26-35	actin alpha 1, skeletal muscle	Homo sapiens	122-130
32447719-3	2020	Following the addition of rapamycin, we detected that autophagy activation could reduce the increased expression level of alphaSMA and the accumulation of extracellular matrix component proteins namely fibronectin and type I collagen induced by TGF-beta1 via the inhibition of SMAD2 phosphorylation.	Sirolimus	26-35	fibronectin 1	Homo sapiens	202-213
32447719-3	2020	Following the addition of rapamycin, we detected that autophagy activation could reduce the increased expression level of alphaSMA and the accumulation of extracellular matrix component proteins namely fibronectin and type I collagen induced by TGF-beta1 via the inhibition of SMAD2 phosphorylation.	Sirolimus	26-35	transforming growth factor beta 1	Homo sapiens	245-254
32027426-4	2020	Cell lines derived from NF1-related tumours have shown to be sensitive to the mTOR inhibitor rapamycin.	Sirolimus	93-102	neurofibromin 1	Homo sapiens	24-27
32323340-3	2020	Sirolimus, an mTOR inhibitor, is a promising drug for the treatment of vascular malformations and vascular tumors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32027426-4	2020	Cell lines derived from NF1-related tumours have shown to be sensitive to the mTOR inhibitor rapamycin.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	78-82
32391547-0	2020	Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	36-40
32665850-5	2020	Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway.	Sirolimus	287-296	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	189-192
32670280-16	2020	Inhibition of mTOR in purified NK cells from healthy donors by rapamycin decreased the synthesis of IFN-gamma.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32670280-16	2020	Inhibition of mTOR in purified NK cells from healthy donors by rapamycin decreased the synthesis of IFN-gamma.	Sirolimus	63-72	interferon gamma	Homo sapiens	100-109
32579942-1	2020	Tuberous sclerosis complex (TSC) is a neurogenetic disorder that leads to elevated mechanistic targeting of rapamycin complex 1 (mTORC1) activity.	Sirolimus	108-117	TSC complex subunit 1	Homo sapiens	28-31
32655497-6	2020	The insulin-resistant state, commonly reported in AD brain, results in neuronal glucose deprivation, due to a dampening down of the PI3K/Akt pathway, including overactivity of the mammalian target of rapamycin 1 (mTORC1) complex, hyperphosphorylation of p53 and neuronal death.	Sirolimus	200-209	insulin	Homo sapiens	4-11
32665850-5	2020	Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway.	Sirolimus	287-296	AKT serine/threonine kinase 1	Homo sapiens	259-262
32513927-6	2020	Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions.	Sirolimus	72-81	vascular endothelial growth factor C	Homo sapiens	23-29
32580379-5	2020	The mammalian target of rapamycin/ribosomal S6 kinase (mTOR/S6K) pathway is blocked in these conditions, and we provide evidence that this is mediated by modulation of both the 5" AMP-activated protein kinase (AMPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	55-59
32580379-5	2020	The mammalian target of rapamycin/ribosomal S6 kinase (mTOR/S6K) pathway is blocked in these conditions, and we provide evidence that this is mediated by modulation of both the 5" AMP-activated protein kinase (AMPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	273-276
32642630-3	2020	CDK4/6 inhibitor monotherapy is ineffective due to RAS-mediated activation of alternative pathways, including phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR).	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	176-180
32037130-11	2020	Similar findings, by indirect evidence, were confirmed for bio-absorbable-polymer-CoCr-sirolimus eluting stent (LMV/MVD trials excluded OR = 0.46; 95%CI = 0.29-0.74, all-comer/post-MI trials excluded: OR = 0.41;95%CI:0.22-0.79).	Sirolimus	82-96	mevalonate diphosphate decarboxylase	Homo sapiens	116-119
32240681-11	2020	Moreover, PLD1 inhibitors not only exhibited similar effects with rapamycin in TGFbeta1-induced fibrogenesis, but also blunted MHY1485 enhanced cell proliferation of HSC-T6.	Sirolimus	66-75	phospholipase D1	Rattus norvegicus	10-14
32240681-11	2020	Moreover, PLD1 inhibitors not only exhibited similar effects with rapamycin in TGFbeta1-induced fibrogenesis, but also blunted MHY1485 enhanced cell proliferation of HSC-T6.	Sirolimus	66-75	transforming growth factor, beta 1	Rattus norvegicus	79-87
32545664-2	2020	Sirolimus (SRL) is a clinically important drug with antiproliferative and immunosuppressive activities that is widely used for coating stents.	Sirolimus	0-9	sarcalumenin	Homo sapiens	11-14
32531927-4	2020	We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells.	Sirolimus	192-201	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	51-55
32513927-6	2020	Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	61-65
32512849-1	2020	Progressive bladder cancer growth is associated with abnormal activation of the mammalian target of the rapamycin (mTOR) pathway, but treatment with an mTOR inhibitor has not been as effective as expected.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	115-119
32512849-1	2020	Progressive bladder cancer growth is associated with abnormal activation of the mammalian target of the rapamycin (mTOR) pathway, but treatment with an mTOR inhibitor has not been as effective as expected.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	152-156
32488108-10	2020	The mTOR inhibitor rapamycin inhibited AP-induced DC-SIGN expression, CD4+ Th1/Th17 cell differentiation and the pro-inflammatory response via Myc.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
32488108-5	2020	The mTOR inhibitor rapamycin was administered before AP induction.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
32488108-10	2020	The mTOR inhibitor rapamycin inhibited AP-induced DC-SIGN expression, CD4+ Th1/Th17 cell differentiation and the pro-inflammatory response via Myc.	Sirolimus	19-28	CD209 molecule	Homo sapiens	50-57
32488108-10	2020	The mTOR inhibitor rapamycin inhibited AP-induced DC-SIGN expression, CD4+ Th1/Th17 cell differentiation and the pro-inflammatory response via Myc.	Sirolimus	19-28	CD4 molecule	Homo sapiens	70-73
31996011-7	2020	For rats in the EA+Rapa group, rapamycin, a mammalian target of rapamycin (mTor) pathway inhibitor, was injected intramuscularly (1 mg/kg/day) near the site of crush injury in the sciatic nerve and an equivalent amount of dimethyl sulfoxide was injected in the other three groups every other day.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	44-73
31996011-7	2020	For rats in the EA+Rapa group, rapamycin, a mammalian target of rapamycin (mTor) pathway inhibitor, was injected intramuscularly (1 mg/kg/day) near the site of crush injury in the sciatic nerve and an equivalent amount of dimethyl sulfoxide was injected in the other three groups every other day.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	75-79
32184097-8	2020	The treatment with AKT1/2 inhibitor and the mTOR inhibitor rapamycin abolished CBD protective effects.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	44-48
32299030-8	2020	Moreover, increased Bcl-2 and Bax levels were observed after treatment with an agonist (rapamycin) and antagonist (3MA) of autophagy in high-glucose-cultured cells.	Sirolimus	88-97	BCL2, apoptosis regulator	Rattus norvegicus	20-25
32173556-0	2020	APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer"s disease.	Sirolimus	53-62	apolipoprotein E	Mus musculus	0-4
32173556-5	2020	Another goal of the study was to identify the potential pharmacogenetic differences in response to rapamycin between the E4FAD and E3FAD mice, the mice with human APOE epsilon3 allele.	Sirolimus	99-108	apolipoprotein E	Homo sapiens	163-167
32067331-1	2020	The mammalian target of rapamycin (mTOR) inhibitor sirolimus is an effective treatment for difficult-to-treat lymphatic anomalies.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	4-33
32236601-6	2020	Furthermore, inhibition of the mTOR signaling pathway by rapamycin or knockdown of mTOR suppressed neural differentiation.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	31-35
32505499-5	2020	The anemia was successfully treated with an intense course of corticosteroids ands witch of immunosuppressive therapy from a calcineurin inhibitor to sirolimus, a mammalian target of rapamycin inhibitor.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	163-192
32067331-1	2020	The mammalian target of rapamycin (mTOR) inhibitor sirolimus is an effective treatment for difficult-to-treat lymphatic anomalies.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	35-39
32509933-8	2020	Furthermore Runx2+/- mice exhibited delayed and suppressed expression of mammalian target of rapamycin (mTOR) and rapamycin-insensitive companion of mTOR (Rictor), essential factors of mTORC2, which is regulated by Runx2 to phosphorylate Akt to regulate cell proliferation and differentiation, in osteoblasts on the tension side of tooth movement in vivo and in vitro.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	104-108
32469178-3	2020	Therein, we investigated clinical manifestations of APDS1 and collected data on the efficacy and safety profile of sirolimus, a mammalian target of rapamycin inhibitor and pathway-specific targeted medicine.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	128-157
32347294-3	2020	As the mTOR name implies it is the target of natural product called rapamycin, a clinically approved drug used to treat human disease.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	7-11
32548479-5	2020	An autophagy activator (rapamycin) inhibited the oxidative stress (reactive oxygen species, reactive nitrogen species, malondialdehyde, and hydrogen peroxide) and inflammatory response (interleukin-1beta, -6, -8, and tumor necrosis factor-alpha) in the colon samples.	Sirolimus	24-33	tumor necrosis factor	Mus musculus	186-244
32548479-6	2020	Antioxidant indices (superoxide dismutase, glutathione peroxidase, catalase, and total antioxidant capacity) in serum and colonic mucosa were significantly increased in the rapamycin group.	Sirolimus	173-182	catalase	Mus musculus	67-75
32460884-3	2020	The aim of this study was to determine if the addition of ACr to BCAAs can enhance MPS and activate expression of the mammalian target of the rapamycin (mTOR) pathway compared to BCAAs and exercise alone in exercise-trained rats.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Homo sapiens	153-157
32548479-10	2020	Moreover, rapamycin significantly elevated the gene abundance of zonula occludens-1, occludin, claudin-1, and claudin-4.	Sirolimus	10-19	occludin	Mus musculus	85-93
32548479-10	2020	Moreover, rapamycin significantly elevated the gene abundance of zonula occludens-1, occludin, claudin-1, and claudin-4.	Sirolimus	10-19	claudin 4	Mus musculus	110-119
32444668-4	2020	We observed reduced mTOR signalling and proliferation in human parietal epithelial cells after rapamycin treatment.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	20-24
32523648-1	2020	PURPOSE: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA).	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
32444674-10	2020	AMPK inhibits mTOR, and the mTOR inhibitor rapamycin also decreases NaCT expression.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	28-32
31509054-3	2020	In this study we found that during integrin alphaIIbbeta3 outside-in signaling PI3Kbeta-dependent phosphorylation of Akt on Serine473 is mediated by the mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	173-182	AKT serine/threonine kinase 1	Homo sapiens	117-120
32434116-0	2020	Corrigendum to "Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation" [Mol.	Sirolimus	16-25	interleukin 6	Homo sapiens	52-56
32434116-0	2020	Corrigendum to "Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation" [Mol.	Sirolimus	16-25	nuclear factor kappa B subunit 1	Homo sapiens	133-142
32424120-1	2020	Rapamycin inhibits protein translation in cells, including neural stem cells (NSCs), by suppressing the mechanistic target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	104-135
32424120-1	2020	Rapamycin inhibits protein translation in cells, including neural stem cells (NSCs), by suppressing the mechanistic target of rapamycin (mTOR).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	137-141
32206779-4	2020	We previously reported three anti-IL-6 non-responders with increased mTOR activation who responded to mTOR inhibition with sirolimus.	Sirolimus	123-132	interleukin 6	Homo sapiens	34-38
32253240-5	2020	Transplantation of SA-PDL1-engineered islet grafts with a short course of rapamycin regimen resulted in sustained graft survival and function in >90% of allogeneic recipients over a 100-d observation period.	Sirolimus	74-83	CD274 antigen	Mus musculus	22-26
32422996-9	2020	In particular, the data suggest an action mechanism for molecules including Chitosan and macrolides such as the mTOR (mammalian target of Rapamycin) pathway inhibitor Rapamycin.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	112-116
32397282-4	2020	Rapamycin treatment was started either at day 1 or at day 7 of BAPN+AngII challenge, and continued throughout the observational period.	Sirolimus	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	68-73
32397282-8	2020	Rapamycin augmented the activation of Akt1, Akt2, and Stat3, and maintained the contractile phenotype of aortic smooth muscle cells.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	38-42
32397282-8	2020	Rapamycin augmented the activation of Akt1, Akt2, and Stat3, and maintained the contractile phenotype of aortic smooth muscle cells.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	54-59
32206779-4	2020	We previously reported three anti-IL-6 non-responders with increased mTOR activation who responded to mTOR inhibition with sirolimus.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	69-73
32206779-4	2020	We previously reported three anti-IL-6 non-responders with increased mTOR activation who responded to mTOR inhibition with sirolimus.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	102-106
32206779-8	2020	Further, the degree of mTOR activation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease driven by mTOR hyperactivation that responds to sirolimus treatment.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	23-27
32206779-8	2020	Further, the degree of mTOR activation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease driven by mTOR hyperactivation that responds to sirolimus treatment.	Sirolimus	164-173	mechanistic target of rapamycin kinase	Homo sapiens	126-130
32206779-12	2020	These findings support mTOR activation as a novel therapeutic target for iMCD, which is being investigated through a trial of sirolimus (NCT03933904).	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	23-27
32566604-7	2020	In vitro, except IgG levels, the increased glycolysis levels, expression of key glycolytic enzymes, BAFF-R and frequency of CD80 and CD86 of B cells, could be inhibited by rapamycin and PX-478.	Sirolimus	172-181	TNF receptor superfamily member 13C	Homo sapiens	100-106
32376799-4	2020	Our data suggest that GCN2 senses amino acid deficiency in beta cells and limits signaling by mechanistic target of rapamycin complex 1 to prevent beta cell failure during the consumption of a high-fat diet.	Sirolimus	116-125	eukaryotic translation initiation factor 2 alpha kinase 4	Mus musculus	22-26
32369692-3	2020	We have previously shown that Tacrolimus (FK506) exerts a more potent pro-apoptotic and anti-proliferative effects than the mammalian target of rapamycin (mTOR) inhibitors (Sirolimus and Everolimus) in liver cancer cells.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	124-153
32369692-3	2020	We have previously shown that Tacrolimus (FK506) exerts a more potent pro-apoptotic and anti-proliferative effects than the mammalian target of rapamycin (mTOR) inhibitors (Sirolimus and Everolimus) in liver cancer cells.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	155-159
32369692-9	2020	The inhibition of the mTOR pathway by Sirolimus and Everolimus was related to an induction of autophagy; and at a high dose, these drugs impaired translation likely at a very early step of the elongation phase.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	22-26
32045600-5	2020	Moreover, Nar increases the phosphorylation levels of phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt) and mammalian rapamycin target protein (mTOR).	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	155-159
32440147-7	2020	RT-PCR was used to detect the expression of miR-145 and phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin/p70 ribosomal protein S6 kinase/HIF-1alpha (PI3K/Akt/mTOR/p70S6K/HIF-1alpha) mRNA.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	86-89
32375443-1	2020	Objective: To exploer the effect of mammalian target ofrapamycin(mTOR)on cognitive dysfunction of mice with Alzheimer"s disease (AD) induced by amyloid beta(1-42) (Abeta(1-42)) via observing the regulation effect of rapamycin on Homer3 in hippocampus.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	65-69
32528831-4	2020	Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27.	Sirolimus	107-116	signal transducer and activator of transcription 3	Mus musculus	26-76
32528831-4	2020	Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27.	Sirolimus	107-116	signal transducer and activator of transcription 3	Mus musculus	78-83
32031317-5	2020	Here, we present a case of rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, in treating recurrent IVL.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	40-69
31943518-2	2020	This study aimed to investigate the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway in sepsis-induced leucine resistance and its upstream signals, and to seek a way to correct leucine resistance in sepsis.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	101-105
32062191-0	2020	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	136-139
32062191-0	2020	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	140-146
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	cyclin dependent kinase 6	Homo sapiens	198-202
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	cyclin A2	Homo sapiens	204-212
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	BCL2 apoptosis regulator	Homo sapiens	353-358
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	BCL2 like 1	Homo sapiens	360-366
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	BCL2 associated X, apoptosis regulator	Homo sapiens	454-457
32062191-5	2020	In addition, rapamycin blocked hsBAFF-stimulated B-cell proliferation and survival by preventing hsBAFF from inactivating PTEN and activating the Akt-Erk1/2 pathway.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	146-149
32062191-5	2020	In addition, rapamycin blocked hsBAFF-stimulated B-cell proliferation and survival by preventing hsBAFF from inactivating PTEN and activating the Akt-Erk1/2 pathway.	Sirolimus	13-22	mitogen-activated protein kinase 3	Homo sapiens	150-156
32062191-6	2020	Overexpression of wild type PTEN or ectopic expression of dominant negative Akt potentiated rapamycin"s suppression of hsBAFF-induced Erk1/2 activation and proliferation/viability in Raji cells.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	76-79
32062191-6	2020	Overexpression of wild type PTEN or ectopic expression of dominant negative Akt potentiated rapamycin"s suppression of hsBAFF-induced Erk1/2 activation and proliferation/viability in Raji cells.	Sirolimus	92-101	mitogen-activated protein kinase 3	Homo sapiens	134-140
32062191-7	2020	Interestingly, PP242 (mTORC1/2 inhibitor) or Akt inhibitor X, like rapamycin (mTORC1 inhibitor), reduced the basal or hsBAFF-induced [Ca2+]i elevations.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	45-48
32062191-9	2020	The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway.	Sirolimus	26-35	AKT serine/threonine kinase 1	Homo sapiens	187-190
32062191-9	2020	The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway.	Sirolimus	26-35	mitogen-activated protein kinase 3	Homo sapiens	191-197
32031317-5	2020	Here, we present a case of rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, in treating recurrent IVL.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	71-75
32231246-10	2020	Instead, we find that steatohepatitis in OTULIN-deficient livers is associated with aberrant mTOR activation, and inhibition of mTOR by rapamycin administration significantly reduces the liver pathology.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	128-132
32072192-9	2020	Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality.	Sirolimus	178-187	advanced glycosylation end product-specific receptor	Mus musculus	68-72
32072192-9	2020	Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality.	Sirolimus	178-187	toll-like receptor 4	Mus musculus	98-103
31663119-8	2020	miR-574-5p repressed the phosphorylation of members of protein kinase B (AKT)-mammalian target of rapamycin pathway via downregulating MAP3K9 and AKT3, resulting in reducing the secretion of beta-casein and triglycerides in GMECs.	Sirolimus	98-107	AKT serine/threonine kinase 1	Homo sapiens	73-76
31958214-2	2020	The main etiology of TSC is the loss-of-function mutation of TSC1 or TSC2 gene, which leads to aberrant activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	TSC complex subunit 1	Homo sapiens	21-24
31958214-2	2020	The main etiology of TSC is the loss-of-function mutation of TSC1 or TSC2 gene, which leads to aberrant activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	TSC complex subunit 1	Homo sapiens	61-65
31958214-8	2020	In addition, combination of rapamycin with PFK15, a PFKFB3 inhibitor, exerts a stronger inhibitory effect on cell proliferation of Tsc1- or Tsc2-null MEFs than treatment with single drug.	Sirolimus	28-37	TSC complex subunit 1	Homo sapiens	131-135
31958214-9	2020	We conclude that loss of TSC1 or TSC2 led to upregulated expression of PFKFB3 through activation of mTORC1/HIF-1alpha signaling pathway and co-administration of rapamycin and PFK15 may be a promising strategy for the treatment of TSC tumors as well as other hyperactivated mTORC1-related tumors.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	25-29
31958214-9	2020	We conclude that loss of TSC1 or TSC2 led to upregulated expression of PFKFB3 through activation of mTORC1/HIF-1alpha signaling pathway and co-administration of rapamycin and PFK15 may be a promising strategy for the treatment of TSC tumors as well as other hyperactivated mTORC1-related tumors.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	25-28
32689766-0	2020	Rapamycin repairs damaged nerve cells and neurological function in rats with spinal cord injury through ERK signaling pathway.	Sirolimus	0-9	Eph receptor B1	Rattus norvegicus	104-107
32689766-1	2020	The object of this study was to explore the effect of rapamycin regulating the proliferation of Schwann cells through activating the extracellular signal-regulated kinase (ERK) signaling pathway on rats with spinal cord injury (SCI).	Sirolimus	54-63	Eph receptor B1	Rattus norvegicus	133-170
32689766-1	2020	The object of this study was to explore the effect of rapamycin regulating the proliferation of Schwann cells through activating the extracellular signal-regulated kinase (ERK) signaling pathway on rats with spinal cord injury (SCI).	Sirolimus	54-63	Eph receptor B1	Rattus norvegicus	172-175
32689766-9	2020	It was verified that lowdose rapamycin (1.5 nM) could significantly promote the proliferation of Schwann cells cultured in vitro (P<0.001), most significantly at 48 h. Rapamycin could activate the ERK signaling pathway.	Sirolimus	29-38	Eph receptor B1	Rattus norvegicus	197-200
32689766-9	2020	It was verified that lowdose rapamycin (1.5 nM) could significantly promote the proliferation of Schwann cells cultured in vitro (P<0.001), most significantly at 48 h. Rapamycin could activate the ERK signaling pathway.	Sirolimus	168-177	Eph receptor B1	Rattus norvegicus	197-200
32689766-13	2020	Rapamycin regulates the proliferation of Schwann cells through the ERK signaling pathway.	Sirolimus	0-9	Eph receptor B1	Rattus norvegicus	67-70
31990892-3	2020	Sirolimus, which inhibits mammalian target of rapamycin, a regulator of cell growth and vascular endothelial growth factor expression, has successfully treated systemic vascular malformations.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	26-55
31990892-3	2020	Sirolimus, which inhibits mammalian target of rapamycin, a regulator of cell growth and vascular endothelial growth factor expression, has successfully treated systemic vascular malformations.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	88-122
32313883-2	2020	Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	50-54
32384426-2	2020	We identified pathophysiology of a neurodegenerative disorder in PDS patient derived cochlear cells that were induced via induced pluripotent stem cells and found sirolimus, an mTOR inhibitor, as an inhibitor of cell death with the minimum effective concentration less than 1/10 of the approved dose for other diseases.	Sirolimus	163-172	mechanistic target of rapamycin kinase	Homo sapiens	177-181
31577671-7	2020	The per protocol analysis identified LT recipients in group B with concomitant early CNI minimization and Sirolimus treatment >= year 1 with significantly superior eGFR and lowest rate of chronic kidney disease (>= stage 3) from year 1 onwards until study end.	Sirolimus	106-115	epidermal growth factor receptor	Homo sapiens	164-168
32313883-2	2020	Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	68-71
32313883-2	2020	Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	72-76
32353830-9	2020	Combined treatment with MVC-RAPA showed a synergistic increase in p-AKT, p-mTOR and SIRT1 levels.	Sirolimus	28-32	thymoma viral proto-oncogene 1	Mus musculus	68-71
32004591-8	2020	Moreover, our study also revealed an increase in the transcript abundance of genes associated with synaptic protein synthesis (brain-derived neurotrophic factor, synaptophysin, and the mechanistic target of rapamycin).	Sirolimus	207-216	brain-derived neurotrophic factor	Danio rerio	127-160
32311015-4	2020	Here, we found that adding interleukin-2 (IL-2) to rapamycin in vivo supported a logarithmic increase in the half-life of adoptively transferred carboxyfluorescein diacetate succinimidyl ester-labeled, autologous NHP Tregs, effectively doubling the number of cells in the peripheral blood Treg compartment compared with Treg infusion when rapamycin was given alone.	Sirolimus	51-60	interleukin 2	Homo sapiens	27-40
32311015-4	2020	Here, we found that adding interleukin-2 (IL-2) to rapamycin in vivo supported a logarithmic increase in the half-life of adoptively transferred carboxyfluorescein diacetate succinimidyl ester-labeled, autologous NHP Tregs, effectively doubling the number of cells in the peripheral blood Treg compartment compared with Treg infusion when rapamycin was given alone.	Sirolimus	51-60	interleukin 2	Homo sapiens	42-46
32311015-4	2020	Here, we found that adding interleukin-2 (IL-2) to rapamycin in vivo supported a logarithmic increase in the half-life of adoptively transferred carboxyfluorescein diacetate succinimidyl ester-labeled, autologous NHP Tregs, effectively doubling the number of cells in the peripheral blood Treg compartment compared with Treg infusion when rapamycin was given alone.	Sirolimus	339-348	interleukin 2	Homo sapiens	27-40
32311015-4	2020	Here, we found that adding interleukin-2 (IL-2) to rapamycin in vivo supported a logarithmic increase in the half-life of adoptively transferred carboxyfluorescein diacetate succinimidyl ester-labeled, autologous NHP Tregs, effectively doubling the number of cells in the peripheral blood Treg compartment compared with Treg infusion when rapamycin was given alone.	Sirolimus	339-348	interleukin 2	Homo sapiens	42-46
32295051-7	2020	Besides, DMF stimulated the phosphatidylinositol 3-kinase-Akt pathway, consequently activating the mammalian target of rapamycin-eukaryotic initiation factor 4E-binding protein 1-70-kDa ribosomal protein S6 kinase pathway for protein synthesis.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	58-61
32326642-5	2020	Here, we established two autophagy models through serum starvation and rapamycin treatment and detected that the overexpression of Mark4 increased the expression of autophagy-related factors Beclin1, ATG7, and significantly decreased the autophagy substrate P62.	Sirolimus	71-80	autophagy related 7	Mus musculus	200-204
31876121-3	2020	They demonstrated that CD4+ T cells isolated from Takayasu"s arteritis (TAK) are biased to differentiate into Th1 and Th17 cells because of mechanistic target of rapamycin complex 1 (mTORC1) hyperactivity.	Sirolimus	162-171	CD4 molecule	Homo sapiens	23-26
32029275-7	2020	Intriguingly, mTOR inhibitor Rapamycin was incapable to reverse this damped autophagy and EPC damage.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31899361-6	2020	RESULTS: Rapamycin compromised AAT production under inflammatory conditions.	Sirolimus	9-18	serpin family A member 1	Homo sapiens	31-34
31479623-6	2020	Chromosome conformation capture (3C) analysis demonstrated the strengthening or loss of specific long-range chromatin interactions in response to rapamycin and quiescence induction, including a cluster of genes containing Interleukin-8 and several chemokine genes on chromosome 4.	Sirolimus	146-155	C-X-C motif chemokine ligand 8	Homo sapiens	222-235
32256773-13	2020	The findings suggest that rapamycin can ameliorate kidney injury induced by AAI via blockade of mTOR, and thus could be a therapeutic strategy for patients with CAAN.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	96-100
31950225-8	2020	Importantly, NK cell treatment with the PI3K or mTOR inhibitors, idelalisib and rapamycin, respectively, prevents the enhanced cytokine responsiveness, thus, highlighting the relevance of the PI3K/mTOR axis in CD16-dependent priming.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	48-52
31950225-8	2020	Importantly, NK cell treatment with the PI3K or mTOR inhibitors, idelalisib and rapamycin, respectively, prevents the enhanced cytokine responsiveness, thus, highlighting the relevance of the PI3K/mTOR axis in CD16-dependent priming.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	197-201
32145384-10	2020	Furthermore, mTOR inhibition by rapamycin or serum starvation reduced ectopic expression of CCND1.tv.-derived CCND1 protein, but not 5"-UTR less CCND1-derived CCND1 protein in HEK293 cells, suggesting that the protein expression of CCND1.tv.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	13-17
32090494-6	2020	Inhibition of mTOR with rapamycin reversed LA-induced inactivation of autophagy and abolished LA-induced suppression of A549 cell viability.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32273566-5	2020	In the present study, we evaluated the effect of mTOR inhibition by rapamycin on the cellular function of human cardiac progenitor cells and discovered that treatment with rapamycin markedly attenuated replicative cell senescence in human cardiac progenitor cells (hCPCs) and promoted their cellular functions.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	49-53
32273566-5	2020	In the present study, we evaluated the effect of mTOR inhibition by rapamycin on the cellular function of human cardiac progenitor cells and discovered that treatment with rapamycin markedly attenuated replicative cell senescence in human cardiac progenitor cells (hCPCs) and promoted their cellular functions.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	49-53
32273566-6	2020	Furthermore, rapamycin not only inhibited mTOR signaling but also influenced signaling pathways, including STAT3 and PIM1, in hCPCs.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	42-46
32273566-6	2020	Furthermore, rapamycin not only inhibited mTOR signaling but also influenced signaling pathways, including STAT3 and PIM1, in hCPCs.	Sirolimus	13-22	signal transducer and activator of transcription 3	Homo sapiens	107-112
32273566-6	2020	Furthermore, rapamycin not only inhibited mTOR signaling but also influenced signaling pathways, including STAT3 and PIM1, in hCPCs.	Sirolimus	13-22	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	117-121
31264496-10	2020	Further, treatment of patient-derived macrophages with rapamycin, an autophagy inducer agent, successfully regulated the production of LDL, IL-6, TNF-alpha, and ApoB expression via activation of autophagosome formation.	Sirolimus	55-64	interleukin 6	Homo sapiens	140-144
31677991-0	2020	Autophagy induction by rapamycin ameliorates experimental colitis and improves intestinal epithelial barrier function in IL-10 knockout mice.	Sirolimus	23-32	interleukin 10	Mus musculus	121-126
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	tumor necrosis factor	Mus musculus	132-141
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	interferon gamma	Mus musculus	143-152
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	chemokine (C-X-C motif) ligand 1	Mus musculus	189-195
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	chemokine (C-X-C motif) ligand 2	Mus musculus	200-206
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	interleukin 10	Mus musculus	315-320
31677991-7	2020	CONCLUSION: Autophagy induction by rapamycin significantly improved intestinal barrier function and protected IL-10 KO mice from the experimental chronic colitis.	Sirolimus	35-44	interleukin 10	Mus musculus	110-115
31985020-5	2020	Flow cytometry was used to detect the expression of adiponectin receptor 1 (AdipoR1) and the phosphorylation of the mechanistic target of rapamycin kinase (mTOR) pathway-associated proteins mTOR and eukaryotic translation initiation factor 4E-binding protein (4EBP1).	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	156-160
31264496-10	2020	Further, treatment of patient-derived macrophages with rapamycin, an autophagy inducer agent, successfully regulated the production of LDL, IL-6, TNF-alpha, and ApoB expression via activation of autophagosome formation.	Sirolimus	55-64	tumor necrosis factor	Homo sapiens	146-155
31985020-5	2020	Flow cytometry was used to detect the expression of adiponectin receptor 1 (AdipoR1) and the phosphorylation of the mechanistic target of rapamycin kinase (mTOR) pathway-associated proteins mTOR and eukaryotic translation initiation factor 4E-binding protein (4EBP1).	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	190-194
31264496-10	2020	Further, treatment of patient-derived macrophages with rapamycin, an autophagy inducer agent, successfully regulated the production of LDL, IL-6, TNF-alpha, and ApoB expression via activation of autophagosome formation.	Sirolimus	55-64	apolipoprotein B	Homo sapiens	161-165
32124948-9	2020	Pretreatment with the mTOR phosphorylation inhibitor rapamycin affected the autophagy of MPPa-PDT-induced osteosarcoma MG-63 cells and enhanced apoptosis through targeting mTOR.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	22-26
32124943-13	2020	GSEA indicated that certain pathways, including mammalian target of rapamycin complex 1 and protein secretion were upregulated, while pathways, such as hypoxia and KRas were downregulated in the Rab22a high level group.	Sirolimus	68-77	RAB22A, member RAS oncogene family	Homo sapiens	195-201
32124948-9	2020	Pretreatment with the mTOR phosphorylation inhibitor rapamycin affected the autophagy of MPPa-PDT-induced osteosarcoma MG-63 cells and enhanced apoptosis through targeting mTOR.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	172-176
32032574-5	2020	Treatment of mice at P7 with rapamycin or 3-methyladenine (activator and inhibitor of autophagy, respectively) for 7 days led to the significant elevations of hearing threshold across frequencies from P15 to P30.	Sirolimus	29-38	cyclin dependent kinase inhibitor 2B	Mus musculus	201-204
31874182-10	2020	Furthermore inhibition of GITR and Ebi3 partially reverted in vitro suppression by in vivo rapamycin-conditioned Tregs.	Sirolimus	91-100	TNF receptor superfamily member 18	Homo sapiens	26-30
31874182-10	2020	Furthermore inhibition of GITR and Ebi3 partially reverted in vitro suppression by in vivo rapamycin-conditioned Tregs.	Sirolimus	91-100	Epstein-Barr virus induced 3	Homo sapiens	35-39
32218850-0	2020	Rapamycin inhibits proliferation and apoptosis of retinoblastoma cells through PI3K/AKT signaling pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	84-87
32218850-11	2020	Rapamycin inhibits proliferation and promotes apoptosis of retinoblastoma cells through inhibiting the PI3K/AKT signaling pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	108-111
31925925-3	2020	Here, we describe three patients who received therapy with the mTOR inhibitor sirolimus with improvement in clinical symptoms, imaging, and overall well-being.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	63-67
32420174-0	2020	The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a meta-analysis.	Sirolimus	36-45	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
32279296-8	2020	Sirolimus, an mTOR inhibitor, has been approved for LAM treatment in the United States and many other countries.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32296709-4	2020	Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor that has been demonstrated to inhibit lymphocyte activity, indicating potential for SRL in treatment of ITP.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	21-50
32296709-4	2020	Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor that has been demonstrated to inhibit lymphocyte activity, indicating potential for SRL in treatment of ITP.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	52-56
32296709-4	2020	Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor that has been demonstrated to inhibit lymphocyte activity, indicating potential for SRL in treatment of ITP.	Sirolimus	11-14	mechanistic target of rapamycin kinase	Homo sapiens	21-50
32296709-4	2020	Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor that has been demonstrated to inhibit lymphocyte activity, indicating potential for SRL in treatment of ITP.	Sirolimus	11-14	mechanistic target of rapamycin kinase	Homo sapiens	52-56
32296709-4	2020	Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor that has been demonstrated to inhibit lymphocyte activity, indicating potential for SRL in treatment of ITP.	Sirolimus	152-155	mechanistic target of rapamycin kinase	Homo sapiens	52-56
32296709-5	2020	Activation of the mTOR pathway in autoimmune diseases suggests that SRL might be a useful agent for treating ITP.	Sirolimus	68-71	mechanistic target of rapamycin kinase	Homo sapiens	18-22
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	111-116
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	78-92
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
32420174-1	2020	Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1.	Sirolimus	23-26	ATP binding cassette subfamily B member 1	Homo sapiens	111-116
32420174-2	2020	The relationship between ABCB1 polymorphism and the pharmacokinetics of SRL in different studies were conflicting in renal transplant recipients.	Sirolimus	72-75	ATP binding cassette subfamily B member 1	Homo sapiens	25-30
32420174-3	2020	Thus, this meta-analysis aims to investigate the influence of ABCB1 C3435T, C1236T, and G2677T/A polymorphisms on the dose-adjusted trough level (C/D) of SRL in renal transplant recipients.	Sirolimus	154-157	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
32420174-15	2020	To achieve target therapeutic concentrations, ABCB1 C1236T homozygous mutant TT genotype will require a higher dose of sirolimus than wild type GG, especially in Caucasian renal transplant recipients.	Sirolimus	119-128	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
32256210-9	2020	The signaling pathway was analyzed with western blot and mTOR was inhibited with rapamycin.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	57-61
32256210-15	2020	Finally, we showed that inhibition of mTOR with rapamycin blocked the effects of JMJD2A on protein synthesis, cell proliferation and colony formation of glioma cells.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	38-42
32235551-6	2020	The pharmaceutical inhibition of mTORC1 activity by rapamycin reinforced autophagy initiation but suppressed the cellular migration and lung metastatic abilities of IMPA2-silenced ccRCC cells.	Sirolimus	52-61	inositol monophosphatase 2	Homo sapiens	165-170
32257249-4	2020	Patient underwent surgical resection of the primary lesion in the abdomen and sigmoid colon followed by adjuvant therapy with the mTOR inhibitor, sirolimus.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	130-134
32420174-16	2020	ABCB1 G2677T/A TT genotype will also need a higher dose of sirolimus genotype.	Sirolimus	59-68	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
32420174-17	2020	Genotyping of ABCB1 might help to improve the individualization of SRL for renal transplant recipients.	Sirolimus	67-70	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
31887337-3	2020	Earlier studies demonstrated the important role of the mammalian targets of the rapamycin (MTOR) signaling pathway in the activation of primordial follicles and suggested that treatment with the MTOR inhibitor rapamycin could maintain the follicle pool in rodents.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	91-95
32309446-6	2020	Western blotting was used to examine autophagy and mammalian target of rapamycin/P70S6 kinase (mTOR/p70S6K) pathway-related proteins.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	95-99
31887337-3	2020	Earlier studies demonstrated the important role of the mammalian targets of the rapamycin (MTOR) signaling pathway in the activation of primordial follicles and suggested that treatment with the MTOR inhibitor rapamycin could maintain the follicle pool in rodents.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	195-199
31887337-3	2020	Earlier studies demonstrated the important role of the mammalian targets of the rapamycin (MTOR) signaling pathway in the activation of primordial follicles and suggested that treatment with the MTOR inhibitor rapamycin could maintain the follicle pool in rodents.	Sirolimus	210-219	mechanistic target of rapamycin kinase	Homo sapiens	91-95
31887337-3	2020	Earlier studies demonstrated the important role of the mammalian targets of the rapamycin (MTOR) signaling pathway in the activation of primordial follicles and suggested that treatment with the MTOR inhibitor rapamycin could maintain the follicle pool in rodents.	Sirolimus	210-219	mechanistic target of rapamycin kinase	Homo sapiens	195-199
32001270-12	2020	In myocytes undergoing simulated I/R, BCAA treatment significantly preserved cell viability (71.7 +- 2.7% vs. 34.5 +- 1.6%, respectively, p < 0.0001), whereas rapamycin prevented this BCAA-induced cardioprotective effect (43.5 +- 3.4% vs. BCAA, p < 0.0001).	Sirolimus	159-168	AT rich interactive domain 4B (RBP1-like)	Mus musculus	184-188
32001270-8	2020	KEY FINDINGS: Mice treated with BCAAs had a significant reduction in infarct size as a percentage of the area at risk compared to controls (34.1 +- 3.9% vs. 44.7 +- 2.6%, P = 0.001), whereas mice treated with the mTOR inhibitor rapamycin were not protected by BCAA administration (42.2 +- 6.5%, vs. control, P = 0.015).	Sirolimus	228-237	AT rich interactive domain 4B (RBP1-like)	Mus musculus	32-36
32001270-12	2020	In myocytes undergoing simulated I/R, BCAA treatment significantly preserved cell viability (71.7 +- 2.7% vs. 34.5 +- 1.6%, respectively, p < 0.0001), whereas rapamycin prevented this BCAA-induced cardioprotective effect (43.5 +- 3.4% vs. BCAA, p < 0.0001).	Sirolimus	159-168	AT rich interactive domain 4B (RBP1-like)	Mus musculus	184-188
31705533-13	2020	CONCLUSION AND IMPLICATIONS: The hypertensive effects of the immunosuppressant drugs FK506 and rapamycin, while mediated by endothelial cells, do not appear to be exerted at documented cellular targets of the drugs on Ca2+ release and altered FKBP binding to IP3 and RyR.	Sirolimus	95-104	ryanodine receptor 2	Homo sapiens	267-270
31882118-5	2020	In neurons and cells with high c-FLIP expression, rapamycin-induced Fas activation triggered the activation of the non-apoptotic pathway components instead of cell death.	Sirolimus	50-59	CASP8 and FADD like apoptosis regulator	Homo sapiens	31-37
32051250-3	2020	From a forward genetic screen for altered PD transport, we discovered that the conserved eukaryotic glucose-TOR (TARGET OF RAPAMYCIN) metabolic signaling network restricts PD transport in leaves.	Sirolimus	123-132	RAR related orphan receptor C	Homo sapiens	108-111
31913698-7	2020	Inhibition of the kinase mTOR (rapamycin, palomid, siRNA), which is normally associated with cell growth, reduces VSOAC activity synergistically to TSA.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	25-29
32108266-4	2020	Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation.	Sirolimus	5-14	AKT serine/threonine kinase 1	Homo sapiens	202-205
31786107-11	2020	Inhibition of mTORC1 by rapamycin or siRNA can lead to dissociation of alphaB-crystallin from the ATP6V1A and mTORC1complex, shortening the half-life of ATP6V1A and increasing the lysosomal pH.	Sirolimus	24-33	ATPase, H+ transporting, lysosomal V1 subunit A	Mus musculus	98-105
31786107-11	2020	Inhibition of mTORC1 by rapamycin or siRNA can lead to dissociation of alphaB-crystallin from the ATP6V1A and mTORC1complex, shortening the half-life of ATP6V1A and increasing the lysosomal pH.	Sirolimus	24-33	ATPase, H+ transporting, lysosomal V1 subunit A	Mus musculus	153-160
32114433-3	2020	We have previously shown that rapamycin inhibits p-mTOR to repress PS1 transcription and Notch 1-signaling.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	49-55
31678537-7	2020	Significant risk factors identified in multivariable analysis for the development of VOD/SOS were sirolimus use (hazard ratio (HR) 5.1, 95% CI 1.8-14.2, p=0.002) and RIC regimen with Flu/Bu2+-ATG (HR 34, 95% CI 4.5 - 252, p&lt;0.001) or other (HR 32, 95% CI 3.9 - 257, p=0.001) compared to Flu/Bu1+-ATG.	Sirolimus	98-107	xylosyltransferase 2	Homo sapiens	89-92
31675454-8	2020	p-JNK and p-38 expression were also clearly decreased in the Rapa group.	Sirolimus	61-65	mitogen-activated protein kinase 8	Homo sapiens	2-5
31675454-8	2020	p-JNK and p-38 expression were also clearly decreased in the Rapa group.	Sirolimus	61-65	mitogen-activated protein kinase 14	Homo sapiens	10-14
32231197-2	2020	Rapamycin, an mTOR kinase inhibitor, and also a potent autophagy inducer, could not only effectively reverse glucocorticoid resistance, but also promote autophagy in the ALL cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
32231197-7	2020	RESULTS: Inhibition of mTOR by rapamycin could reverse glucocorticoid resistance in CEM-C1 cells, and also induce autophagy in these cells by up-regulation of LC3-II and Beclin-1 expressions.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	23-27
32114433-3	2020	We have previously shown that rapamycin inhibits p-mTOR to repress PS1 transcription and Notch 1-signaling.	Sirolimus	30-39	notch receptor 1	Homo sapiens	89-96
32114433-6	2020	We now report that rapamycin inhibits the phosphorylation of both mTOR (p-mTOR) and JNK (p-JNK).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	66-70
32114433-6	2020	We now report that rapamycin inhibits the phosphorylation of both mTOR (p-mTOR) and JNK (p-JNK).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	74-78
32114433-6	2020	We now report that rapamycin inhibits the phosphorylation of both mTOR (p-mTOR) and JNK (p-JNK).	Sirolimus	19-28	mitogen-activated protein kinase 8	Homo sapiens	84-87
32114433-6	2020	We now report that rapamycin inhibits the phosphorylation of both mTOR (p-mTOR) and JNK (p-JNK).	Sirolimus	19-28	mitogen-activated protein kinase 8	Homo sapiens	89-94
31931362-10	2020	In vitro, our results showed that DHA could downregulate the mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/S6K1) signaling pathway, promote cell autophagy, and ameliorate cell proliferation in aIgA1-induced HMCs.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	127-131
32087218-4	2020	METHODS AND RESULTS: Western blotting, quantitative PCR, and a dual-luciferase reporter assay indicated that mTOR inhibitors rapamycin and torin 1 upregulated IRF-1 expression and increased its transcriptional activity.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	109-113
31884111-10	2020	Inhibition of AKT/mTOR signaling by MK2206 or rapamycin attenuates the PRMT6-mediated EMC progression.	Sirolimus	46-55	AKT serine/threonine kinase 1	Homo sapiens	14-17
31884111-10	2020	Inhibition of AKT/mTOR signaling by MK2206 or rapamycin attenuates the PRMT6-mediated EMC progression.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	18-22
31884111-10	2020	Inhibition of AKT/mTOR signaling by MK2206 or rapamycin attenuates the PRMT6-mediated EMC progression.	Sirolimus	46-55	protein arginine methyltransferase 6	Homo sapiens	71-76
32006551-5	2020	Transcription assays of calcineurin (CaN)- and mTOR (mammalian target of rapamycin)-downstream target genes confirm that BbFKBP12 is the target of both FK506 and rapamycin, associated with CaN- and mTOR-signal pathways in B. bassiana.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	47-51
32087218-4	2020	METHODS AND RESULTS: Western blotting, quantitative PCR, and a dual-luciferase reporter assay indicated that mTOR inhibitors rapamycin and torin 1 upregulated IRF-1 expression and increased its transcriptional activity.	Sirolimus	125-134	interferon regulatory factor 1	Homo sapiens	159-164
31837522-4	2020	Sirolimus, a mTOR inhibitor, acts by inhibiting the T-cell proliferation and the release of inflammatory cytokines, have been widely investigated for its potential role in the treatment of PSED.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
31891737-4	2020	DGKbeta induced neurite outgrowth by activation of mammalian target of rapamycin complex 1 (mTORC1) through a kinase-dependent pathway.	Sirolimus	71-80	diacylglycerol kinase beta	Homo sapiens	0-7
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	25-29
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	153-157
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	153-157
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	25-29
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	153-157
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	153-157
32020232-9	2020	HK2 and LDHA expression decreased after AML tumor cells were treated with Akt inhibitor or rapamycin.	Sirolimus	91-100	lactate dehydrogenase A	Homo sapiens	8-12
33406024-8	2020	Results: Treatment with RAPA markedly attenuated OVA-induced neutrophilic airway inflammation in DO11.10 mice.	Sirolimus	24-28	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	49-52
31836451-5	2020	We provide a comprehensive overview of PIM kinase"s role as an escape mechanism to targeted therapies including PI3K/mTOR inhibitors, MET inhibitors, anti-HER2/EGFR treatments and the immunosuppressant rapamycin, providing a rationale for co-targeting treatment strategies for a more durable patient response.	Sirolimus	202-211	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	39-42
31769520-5	2020	In contrast, mTOR inhibitors rapamycin and AZD2014 did not induce apoptosis in SVEC cells.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	13-17
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	interleukin 6	Homo sapiens	44-48
32125970-1	2020	INRODUCTION: The mechanistic target of rapamycin inhibitors (mTORi) sirolimus and everolimus stabilize lung function in patients with pulmonary lymphangioleiomyomatosis (LAM) but do not induce remission.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	17-48
32194539-0	2019	mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	0-4
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	interleukin 13	Homo sapiens	53-58
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	interleukin 6	Homo sapiens	134-138
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	interleukin 13	Homo sapiens	143-148
32094377-7	2020	Suppression of IFN-alpha expression in the Met-DM group was associated with a reduction in the mechanistic target of rapamycin complex-1 pathway and impaired IgG avidity index.	Sirolimus	117-126	interferon alpha 1	Homo sapiens	15-24
32194539-4	2019	Therefore, the inhibition of mTOR (with rapamycin) could be a promising therapeutic avenue in SpA.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	29-33
31959630-1	2020	Cell growth is positively controlled by the phosphoinositide 3-kinase (PI3K)-target of rapamycin (TOR) signaling pathway under conditions of abundant growth factors and nutrients.	Sirolimus	87-96	Phosphatidylinositol 3-kinase 92E	Drosophila melanogaster	44-69
32194539-10	2019	Results: In vitro TNFalpha and IL-17A protein production by SpA PBMCs was inhibited in the presence of rapamycin.	Sirolimus	103-112	tumor necrosis factor	Homo sapiens	18-26
31846626-9	2020	Sirolimus" function of amplifying Bregs was weakened, and its function of amplifying Tregs even disappeared after IL-10 and TGF-beta1 were neutralized.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	124-133
32075941-1	2020	Epilepsy treatments for patients with mechanistic target of rapamycin (mTOR) disorders, such as tuberous sclerosis complex (TSC) or focal cortical dysplasia type II (FCDII), are urgently needed.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	71-75
32070029-5	2020	The inhibition of the mTOR pathway by currently available pharmacological compounds (i.e., sirolimus or everolimus) is able to hamper tumor progression both in vitro and in animal models.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	22-26
32054043-4	2020	The immunosuppressant drug rapamycin and its analogs that inhibit mTOR are currently being evaluated for their potential as anti-cancer agents, albeit with limited efficacy.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	66-70
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	autophagy related 5	Homo sapiens	38-42
32104716-0	2020	Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides.	Sirolimus	16-25	mitogen-activated protein kinase 1	Homo sapiens	73-76
32104716-13	2020	IL-37 levels were induced by rapamycin and chloroquine through the LC3, Erk1/2, and NF-kappaB/AP-1 pathways.	Sirolimus	29-38	mitogen-activated protein kinase 3	Homo sapiens	72-78
32046043-6	2020	Silencing of PARP2 inhibited the activity of AMP-activated kinase (AMPK) and the mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	101-110	poly(ADP-ribose) polymerase 2	Homo sapiens	13-18
31863766-5	2020	In this study, we found that rapamycin (an mTOR inhibitor) and p70S6K siRNA diminished thrombin-induced IL-8/CXCL8 release.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	43-47
32023458-6	2020	MGO induces AKT activation through phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin 2 (mTORC2) and Hsp27 regulation.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	12-15
31863766-5	2020	In this study, we found that rapamycin (an mTOR inhibitor) and p70S6K siRNA diminished thrombin-induced IL-8/CXCL8 release.	Sirolimus	29-38	coagulation factor II, thrombin	Homo sapiens	87-95
31863766-5	2020	In this study, we found that rapamycin (an mTOR inhibitor) and p70S6K siRNA diminished thrombin-induced IL-8/CXCL8 release.	Sirolimus	29-38	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
31863766-5	2020	In this study, we found that rapamycin (an mTOR inhibitor) and p70S6K siRNA diminished thrombin-induced IL-8/CXCL8 release.	Sirolimus	29-38	C-X-C motif chemokine ligand 8	Homo sapiens	109-114
31863766-7	2020	Moreover, rapamycin attenuated thrombin-stimulated p70S6K phosphorylation.	Sirolimus	10-19	coagulation factor II, thrombin	Homo sapiens	31-39
31863766-9	2020	Moreover, thrombin-stimulated p300 phosphorylation was attenuated by Akt DN, rapamycin, and p70S6K siRNA.	Sirolimus	77-86	coagulation factor II, thrombin	Homo sapiens	10-18
31689244-6	2020	Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs-including in HHT patient blood outgrowth ECs-and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs.	Sirolimus	27-36	growth differentiation factor 2	Homo sapiens	193-197
31794259-2	2020	Grb10 is also a substrate for the mechanistic target of rapamycin complex 1 (mTORC1) that mediates its feedback inhibition on phosphatidylinositide 3-kinase (PI3K)/Akt signaling.	Sirolimus	56-65	AKT serine/threonine kinase 1	Homo sapiens	164-167
32014025-9	2020	Recent studies have demonstrated a satisfactory efficacy of sirolimus, an inhibitor of mammalian target of rapamycin, in the treatment of KHE.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	87-116
31794259-7	2020	However, acute inhibition of mTORC1 with rapamycin blocked Grb10 Ser476 phosphorylation and repressed a negative-feedback loop on PI3K/Akt signaling that increased myotube responsiveness to insulin.	Sirolimus	41-50	AKT serine/threonine kinase 1	Homo sapiens	135-138
31794259-7	2020	However, acute inhibition of mTORC1 with rapamycin blocked Grb10 Ser476 phosphorylation and repressed a negative-feedback loop on PI3K/Akt signaling that increased myotube responsiveness to insulin.	Sirolimus	41-50	insulin	Homo sapiens	190-197
31886628-10	2020	Furthermore, URB1 and CCNA2 expression were also impeded by rapamycin, which is a specific inhibitor of mTORC1.	Sirolimus	60-69	URB1 ribosome biogenesis homolog	Homo sapiens	13-17
31666191-10	2020	Extracellular TG2 promoted the phosphorylation of Akt, mechanistic target of rapamycin (mTOR), and ribosomal p70 S6 kinase (p70S6K), and inhibitors of mTOR, phosphatidylinositol 3-kinase, and Src (rapamycin, LY294002, and Src I1, respectively) inhibited TG2-increased phosphorylation of mTOR and p70S6K.	Sirolimus	77-86	thymoma viral proto-oncogene 1	Mus musculus	50-53
31147259-0	2020	Clinical outcomes of the Dual-Therapy CD34 antibody-covered sirolimus-eluting stent versus standard drug-eluting coronary stents: A meta-analysis.	Sirolimus	60-69	CD34 molecule	Homo sapiens	38-42
31147259-2	2020	The Dual-Therapy CD34 antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization.	Sirolimus	39-48	CD34 molecule	Homo sapiens	17-21
31147259-2	2020	The Dual-Therapy CD34 antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization.	Sirolimus	39-48	CD34 molecule	Homo sapiens	124-128
31147259-2	2020	The Dual-Therapy CD34 antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization.	Sirolimus	95-104	CD34 molecule	Homo sapiens	17-21
31886628-10	2020	Furthermore, URB1 and CCNA2 expression were also impeded by rapamycin, which is a specific inhibitor of mTORC1.	Sirolimus	60-69	cyclin A2	Homo sapiens	22-27
32127188-0	2020	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	76-80
31423743-8	2020	Mechanistically, our results demonstrated that autophagy activation by AMPK activator metformin or mTOR inhibitor rapamycin obviously promotes cell survival and autophagy flux, improved mitochondrial ultrastructure, and reduced expression of Cyt-C and caspase-3 in CORT-induced PC12 cells.	Sirolimus	114-123	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	71-75
31301076-0	2020	Rapamycin attenuates the paraquat-induced pulmonary fibrosis through activating Nrf2 pathway.	Sirolimus	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	80-84
31301076-5	2020	In this study, we tried to confirm that rapamycin attenuates PQ-induced pulmonary fibrosis by regulating Nrf2 pathway.	Sirolimus	40-49	NFE2 like bZIP transcription factor 2	Homo sapiens	105-109
31301076-6	2020	In vivo, we proved that rapamycin could inhibit the degree of PQ-induced oxidant stress as well as enhanced the expression of Nrf2.	Sirolimus	24-33	NFE2 like bZIP transcription factor 2	Homo sapiens	126-130
31301076-9	2020	Furthermore, we also found that Nrf2 knockdown reduced the inhibitory effect of rapamycin on PQ-induced pulmonary fibrosis, as well as decreased Nrf2 transfer from the cytoplasm into the nucleus.	Sirolimus	80-89	NFE2 like bZIP transcription factor 2	Homo sapiens	32-36
31301076-10	2020	Our findings demonstrated that the protective effect of rapamycin is associated with the activation of the Nrf2 pathway in pulmonary fibrosis induced by PQ poisoning.	Sirolimus	56-65	NFE2 like bZIP transcription factor 2	Homo sapiens	107-111
31895414-2	2020	Objective: To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	52-81
31958467-7	2020	The activation of mammalian target of rapamycin complex-1 (mTORC1) during increased workload in presence of glucose as the only substrate was prevented by C/EBPbeta knockdown, thereby abating contractile dysfunction in cardiomyocytes.	Sirolimus	38-47	CCAAT enhancer binding protein alpha	Homo sapiens	155-164
31895414-2	2020	Objective: To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	83-87
31966066-10	2020	The implication of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) in Ca-125 modulation was investigated using specific inhibitors.	Sirolimus	105-114	AKT serine/threonine kinase 1	Homo sapiens	121-124
31966066-10	2020	The implication of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) in Ca-125 modulation was investigated using specific inhibitors.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	125-129
31793097-11	2020	Additionally, rapamycin (a mTOR antagonist) notably attenuated the effects of Rheb on the autophagy, proliferation, apoptosis, and MITF expression in LCA-treated melanoma cells.	Sirolimus	14-23	melanogenesis associated transcription factor	Mus musculus	131-135
31667906-11	2020	The rates of p/t-p70S6K, p/t-mammalian target of rapamycin (mTOR) and p/t-adenosine monophosphate-activated protein kinase (AMPK) were raised by BB and suppressed by silencing miR-153 under TNF-alpha induced condition.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	60-64
31862477-18	2020	In contrast, everolimus, temsirolimus, and sirolimus are larger molecules (MW   1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	174-203
31862477-18	2020	In contrast, everolimus, temsirolimus, and sirolimus are larger molecules (MW   1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	205-209
33346412-7	2020	The expressions of LC3 and Bcl-2 in the testis tissue were significantly higher in the VC + rapamycin (P<0.01) but lower in the VC + chloroquine group (P<0.01), while those of p62 and Bax remarkably lower in the VC + rapamycin (P<0.01) but higher in the VC + chloroquine group than in the VC model controls (P<0.01).	Sirolimus	92-101	BCL2, apoptosis regulator	Rattus norvegicus	27-32
31735334-4	2020	We now show that G6Pase-alpha deficiency-mediated hepatic autophagy impairment leads to sustained accumulation of an autophagy-specific substrate p62 which can activate tumor-promoting pathways including nuclear factor erythroid 2-related factor 2 (Nrf2) and mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	279-288	NFE2 like bZIP transcription factor 2	Homo sapiens	249-253
31825077-3	2020	Placental mechanistic target of rapamycin Complex 2 (mTORC2) signaling is inhibited in IUGR and regulates the trafficking of key amino acid transporter (AAT) isoforms to the ST plasma membrane, however the molecular mechanisms are unknown.	Sirolimus	32-41	solute carrier family 38 member 7	Homo sapiens	153-156
32047439-5	2019	In angiotensin II (Ang II)-treated EPCs, enhancing autophagy through rapamycin mitigated Ang II-induced cell senescence, on the contrary, 3-methyladenine aggravated the senescence by weakening autophagy.	Sirolimus	69-78	angiotensinogen	Homo sapiens	19-25
32047439-5	2019	In angiotensin II (Ang II)-treated EPCs, enhancing autophagy through rapamycin mitigated Ang II-induced cell senescence, on the contrary, 3-methyladenine aggravated the senescence by weakening autophagy.	Sirolimus	69-78	angiotensinogen	Homo sapiens	89-95
31963866-9	2020	Activation of autophagy with autophagy inducer rapamycin also inhibited ROS-induced cell death and decreased proapoptotic proteins but increased antiapoptotic protein Bcl-XL, NF-kappaB, and Nrf2.	Sirolimus	47-56	BCL2 like 1	Homo sapiens	167-173
31963866-9	2020	Activation of autophagy with autophagy inducer rapamycin also inhibited ROS-induced cell death and decreased proapoptotic proteins but increased antiapoptotic protein Bcl-XL, NF-kappaB, and Nrf2.	Sirolimus	47-56	nuclear factor kappa B subunit 1	Homo sapiens	175-184
31963866-9	2020	Activation of autophagy with autophagy inducer rapamycin also inhibited ROS-induced cell death and decreased proapoptotic proteins but increased antiapoptotic protein Bcl-XL, NF-kappaB, and Nrf2.	Sirolimus	47-56	NFE2 like bZIP transcription factor 2	Homo sapiens	190-194
31825077-3	2020	Placental mechanistic target of rapamycin Complex 2 (mTORC2) signaling is inhibited in IUGR and regulates the trafficking of key amino acid transporter (AAT) isoforms to the ST plasma membrane, however the molecular mechanisms are unknown.	Sirolimus	32-41	solute carrier family 38 member 7	Homo sapiens	129-151
31838137-7	2020	Importantly, we found that HBO reduced excessive autophagy in the prefrontal cortex, which was evidenced by activating of the mammalian target of the rapamycin (mTOR) and 4E-BP1, as well as suppression of LC3II and ATG5.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	161-165
31941840-2	2020	To elucidate the effects of 2 commonly used agents, the calcineurin inhibitor tacrolimus (TAC) and the mTOR inhibitor sirolimus (SIR), on islet function and test whether these effects could be reversed or prevented, we investigated human islets transplanted into immunodeficient mice treated with TAC or SIR at clinically relevant levels.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	103-107
31941840-2	2020	To elucidate the effects of 2 commonly used agents, the calcineurin inhibitor tacrolimus (TAC) and the mTOR inhibitor sirolimus (SIR), on islet function and test whether these effects could be reversed or prevented, we investigated human islets transplanted into immunodeficient mice treated with TAC or SIR at clinically relevant levels.	Sirolimus	129-132	mechanistic target of rapamycin kinase	Homo sapiens	103-107
31941840-3	2020	Both TAC and SIR impaired insulin secretion in fasted and/or stimulated conditions.	Sirolimus	13-16	insulin	Homo sapiens	26-33
31941840-4	2020	Treatment with TAC or SIR increased amyloid deposition and islet macrophages, disrupted insulin granule formation, and induced broad transcriptional dysregulation related to peptide processing, ion/calcium flux, and the extracellular matrix; however, it did not affect regulation of beta cell mass.	Sirolimus	22-25	insulin	Homo sapiens	88-95
31947591-1	2020	Studies of the mechanistic (mammalian) target of rapamycin inhibitors (mTOR) represent a step towards the targeted treatment of gynecological cancers.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	71-75
31633763-8	2020	Moreover, flow cytometry and immunoblotting analyses demonstrated that A151 is able to reverse mTOR phosphorylation comparably to the well-known mTOR inhibitor rapamycin.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	145-149
32047421-9	2020	The brown fat-like phenotype in 3T3-L1 adipocytes induced by Res was possibly mediated by activation of mammalian target of rapamycin (mTOR), as brown adipocyte-specific markers were decreased by rapamycin, an inhibitor of mTOR and the MHY1485 treatment, an activator of mTOR, showed the similar effect of Res on browning markers.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	135-139
31936065-2	2020	These insights in the biological pathways have resulted in the development of multiple agents targeting vascular endothelial growth factor (VEGF), as well as inhibitors of the mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	200-209	mechanistic target of rapamycin kinase	Homo sapiens	211-215
31921404-0	2020	TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.	Sirolimus	108-117	TSC complex subunit 1	Homo sapiens	0-3
31921404-2	2020	The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin.	Sirolimus	84-93	TSC complex subunit 1	Homo sapiens	37-40
31921404-9	2020	In TSC1-Het and Null NPCs, we also observed basal activation of ERK1/2, which was further activated upon rapamycin treatment.	Sirolimus	105-114	TSC complex subunit 1	Homo sapiens	3-7
31921404-9	2020	In TSC1-Het and Null NPCs, we also observed basal activation of ERK1/2, which was further activated upon rapamycin treatment.	Sirolimus	105-114	mitogen-activated protein kinase 3	Homo sapiens	64-70
31921404-10	2020	Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	51-55
31921404-12	2020	Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects.	Sirolimus	61-70	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
31921404-12	2020	Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects.	Sirolimus	61-70	TSC complex subunit 1	Homo sapiens	166-169
31693798-3	2020	We have previously shown that the mechanistic/mammalian target of rapamycin (mTOR) drives disease progression in mouse models of AD and in models of cognitive impairment associated with atherosclerosis, closely recapitulating vascular cognitive impairment.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	77-81
32329644-5	2020	Rapamycin pre-treatment with Naringin showed significant decrease in mTOR phosphorylation and increase in LC3B activation in AGS cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	69-73
31611063-6	2020	Interestingly, this autophagy promotion concurred with enhanced anabolic activation via AKT-mammalian target of rapamycin (mTOR)-p70S6K signaling cascade and enhanced antioxidant capacity such as copper zinc superoxide dismutase (CuZnSOD), glutathione peroxidase (GPX), and peroxiredoxin 3 (PRX3), known to be as antagonists of autophagy.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	123-127
31782272-1	2020	BACKGROUND: Rapamycin inhibits the mammalian target of rapamycin (mTOR) activity and has been proven effective for the treatment of lung injury.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	35-64
31782272-1	2020	BACKGROUND: Rapamycin inhibits the mammalian target of rapamycin (mTOR) activity and has been proven effective for the treatment of lung injury.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	66-70
31782272-12	2020	Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	130-135
31663933-2	2020	Although mTOR inhibitors are usually well tolerated, their adverse effects have been reported: sirolimus treatment in transplant patients has been rarely reported to be associated with lymphedema of the skin and subcutaneous tissues, whereas the use of everolimus seemed to be less burdened by this type of adverse effect.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	9-13
31834371-1	2020	Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder caused by inactivating mutations in TSC1 or TSC2, key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	188-197	TSC complex subunit 1	Homo sapiens	28-31
33268702-8	2020	Accordingly, YZFDF increased the expression of the phosphorylated mammalian targets of rapamycin (mTOR), leading to inhibition of autophagy (downregulated LC3 and upregulated P62).	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	98-102
31834371-1	2020	Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder caused by inactivating mutations in TSC1 or TSC2, key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	188-197	TSC complex subunit 1	Homo sapiens	130-134
32356448-0	2020	Investigation of the effects of rapamycin on the mTOR pathway and apoptosis in metastatic and non-metastatic human breast cancer cell lines.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	49-53
32356448-1	2020	AIM: The aim of this study was to analyze the effects of rapamycin treatment on apoptosis via mTOR pathway in metastatic and non-metastatic human breast cancer cell lines by immunohistochemical and TUNEL analysis.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	94-98
32356448-8	2020	In addition, the demonstration and confirmation of increased apoptosis in Rapamycin treated groups suggested that Rapamycin, an inhibitor of mTOR, is promising in the treatment of breast cancer (Tab.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	141-145
32502530-13	2020	Lineage tracing from Bmi1-marked cells showed that rapamycin blocked FSC activation post-irradiation.	Sirolimus	51-60	Bmi1 polycomb ring finger oncogene	Mus musculus	21-25
33028104-8	2020	Moreover, inhibition of the mammalian target of rapamycin (mTOR) activity by rapamycin influenced the effects of GASAL1 on cell proliferation, invasion, and apoptosis.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	59-63
32686984-0	2020	Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-alpha in MG-63 Cells.	Sirolimus	11-20	tumor necrosis factor	Homo sapiens	70-79
32686984-3	2020	This study is to explore the effects of RAPA combined with CDDP on the expression of TNF-alpha in osteosarcoma MG-63 cells.	Sirolimus	40-44	tumor necrosis factor	Homo sapiens	85-94
32686984-7	2020	The results of PCR showed that both the separate drug use and drug combination could significantly lower the relative expression quantity of TNF-alpha gene (*P < 0.5), but the combination was more effective (*P < 0.5); the expression quantity of TNF-alpha gene in the RAPA + CDDP group at 48 h was much lower than that at 24 h (***P < 0.001).	Sirolimus	268-272	tumor necrosis factor	Homo sapiens	141-150
32686984-7	2020	The results of PCR showed that both the separate drug use and drug combination could significantly lower the relative expression quantity of TNF-alpha gene (*P < 0.5), but the combination was more effective (*P < 0.5); the expression quantity of TNF-alpha gene in the RAPA + CDDP group at 48 h was much lower than that at 24 h (***P < 0.001).	Sirolimus	268-272	tumor necrosis factor	Homo sapiens	246-255
32686984-10	2020	RAPA combined with CDDP can significantly reduce the expression of TNF-alpha in MG-63 cells, which is time dependent.	Sirolimus	0-4	tumor necrosis factor	Homo sapiens	67-76
33115392-0	2020	The genetic polymorphism of CYP3A4 rs2242480 is associated with sirolimus trough concentrations among adult renal transplant recipients.	Sirolimus	64-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
31074719-3	2020	The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission.	Sirolimus	60-69	CD4 molecule	Homo sapiens	108-111
31074719-3	2020	The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission.	Sirolimus	94-103	CD4 molecule	Homo sapiens	108-111
32640952-6	2020	The mTOR-inhibitors (sirolimus, everolimus) are use rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	4-8
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	53-57
32016998-5	2020	RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells.	Sirolimus	63-72	BCL2 associated X, apoptosis regulator	Homo sapiens	244-247
32016998-5	2020	RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells.	Sirolimus	63-72	BCL2 apoptosis regulator	Homo sapiens	272-277
31914609-6	2020	FAIM2 overexpression increased autophagy flux, while autophagy flux was impaired in shRNA-mediated knockdown (shFAIM2) cells, and the impairment was more evident in the presence of rapamycin.	Sirolimus	181-190	Fas apoptotic inhibitory molecule 2	Homo sapiens	0-5
31621069-6	2020	This study yielded 35 small cell-permeable compounds with a reproducible inhibitory effect on B-cell activation and plasmablast formation, among which was the clinically applied mTOR inhibitor rapamycin.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Homo sapiens	178-182
31444939-6	2020	Interestingly, transient mTOR inhibition by rapamycin only reversibly suppresses MGPC proliferation, while its longer suppression by knocking down Raptor significantly inhibits the regeneration of retinal neurons.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Danio rerio	25-29
31625572-3	2020	Phosphoinositide 3-kinase (PI3K)/AKT signaling activates mammalian target of rapamycin complex 1 (mTORC1) and hyperactivation of mTORC1 is a common event in PKD; however, mTORC1 inhibitors have yielded disappointing results in clinical trials.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	33-36
32475472-4	2020	Interestingly, PC2-related pathologies are usually treated with rapamycin, an autophagy stimulator.	Sirolimus	64-73	polycystin 2, transient receptor potential cation channel	Homo sapiens	15-18
31746373-15	2020	Furthermore, rapamycin prevented angiotensin II-induced H9c2 cell apoptosis and promoted autophagy by inhibiting the mTORC1 and ER stress pathways.	Sirolimus	13-22	angiotensinogen	Rattus norvegicus	33-47
31660692-4	2020	Application of ApoE-/- mice with rapamycin (an autophagy inducer) inhibited necrotic core formation in vulnerable plaques by decreasing macrophage apoptosis.	Sirolimus	33-42	apolipoprotein E	Mus musculus	15-19
33202415-6	2020	The results show that 3-MA has a significant inhibitory effect on ATG12 in THP-1 cells; on the contrary, the expression of ATG12 was upreg-ulated in THP-1 cells that were treated with rapamycin.	Sirolimus	184-193	autophagy related 12	Homo sapiens	123-128
31567652-1	2020	BACKGROUND: Rapamycin is a type of immunosuppressive agent that acts through inhibition of mammalian target of rapamycin (mTOR).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	91-120
31199578-0	2020	Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus.	Sirolimus	127-136	glucagon	Homo sapiens	22-45
31199578-13	2020	The cardiac protection of GLP-1 might be dependent on inhibition of mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase, through an adenosine monophosphate-activated protein kinase-mediated pathway.	Sirolimus	88-97	glucagon	Homo sapiens	26-31
31567652-1	2020	BACKGROUND: Rapamycin is a type of immunosuppressive agent that acts through inhibition of mammalian target of rapamycin (mTOR).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	122-126
30794726-2	2020	However, the side effects associated with long-term rapamycin treatment, many of which are due to inhibition of a second mTOR complex, mTORC2, have seemed to preclude the routine use of rapamycin as a therapy for age-related diseases.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	121-125
30794726-2	2020	However, the side effects associated with long-term rapamycin treatment, many of which are due to inhibition of a second mTOR complex, mTORC2, have seemed to preclude the routine use of rapamycin as a therapy for age-related diseases.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	121-125
31605630-7	2020	Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	61-65
31801817-10	2020	To confirm the role of mTOR activation, we found that rapamycin diminished the effect of pembrolizumab-mediated downregulation of FOXP3.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	23-27
31605630-7	2020	Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin.	Sirolimus	47-56	AKT serine/threonine kinase 1	Homo sapiens	121-124
31605630-7	2020	Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	127-131
31678323-6	2020	Indeed, AMPK-deficient mouse embryonic fibroblasts failed to respond to phenformin (AMPK activator) and compound C (AMPK inhibitor), while rapamycin induced a marked increase in TXNIP levels, confirming the known AMPK/mTOR control over TXNIP.	Sirolimus	139-148	thioredoxin interacting protein	Mus musculus	178-183
32579497-5	2020	Mammalian target to rapamycin complex 1 (mTORC1), another form of mTOR complex regulates translation of synaptic proteins involved in alcohol-induced plasticity.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	41-45
32921582-1	2020	The giant 532 kDa HERC1 protein is a ubiquitin ligase that interacts with tuberous sclerosis complex subunit 2 (TSC2), a negative upstream regulator of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	176-185	HECT and RLD domain containing E3 ubiquitin protein ligase family member 1	Homo sapiens	18-23
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	AKT serine/threonine kinase 1	Homo sapiens	14-17
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	BCL2 like 1	Homo sapiens	186-192
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	282-287
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	prostaglandin-endoperoxide synthase 2	Homo sapiens	288-304
31678323-6	2020	Indeed, AMPK-deficient mouse embryonic fibroblasts failed to respond to phenformin (AMPK activator) and compound C (AMPK inhibitor), while rapamycin induced a marked increase in TXNIP levels, confirming the known AMPK/mTOR control over TXNIP.	Sirolimus	139-148	thioredoxin interacting protein	Mus musculus	236-241
31889120-9	2019	Rapamycin, but not GW9662, inhibit IL-10 secretion.	Sirolimus	0-9	interleukin 10	Mus musculus	35-40
31763809-4	2019	In such system, catalase acted as oxygen-self-supplier to catalyze the decomposition of tumor abundant H2O2 into O2, and the sustained release of RAP down-regulated HIF-1alpha, which collectively potentiated the PDT efficacy against tumor.	Sirolimus	146-149	hypoxia inducible factor 1 subunit alpha	Homo sapiens	165-175
31493485-6	2019	To understand the mechanism by which rapamycin differentially inhibits the mTOR complexes in the cancer cells, we present a mathematical model of rapamycin mode of action based on the first explanation, i.e., Le Chatelier"s principle.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	75-79
31493485-6	2019	To understand the mechanism by which rapamycin differentially inhibits the mTOR complexes in the cancer cells, we present a mathematical model of rapamycin mode of action based on the first explanation, i.e., Le Chatelier"s principle.	Sirolimus	146-155	mechanistic target of rapamycin kinase	Homo sapiens	75-79
31493485-8	2019	This model shows that rapamycin has stronger effects on mTORC1 compared with mTORC2, simply due to its direct interaction with free mTOR and mTORC1, but not mTORC2, without the need to consider other components that might further stabilize mTORC2.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	56-60
31847908-4	2019	Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) involved in angio-lymphangiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-58
31847908-4	2019	Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) involved in angio-lymphangiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	60-64
31848319-2	2019	Compounds that block mTOR signaling and eIF4F complex formation, such as rapamycin and its analogs, have been used in combination therapies to enhance cell killing, although their success has been limited.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	21-25
31820607-17	2019	Compared with the model group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were reduced in the moxibustion group, the rapamycin group and the combination group (all P<0.01).	Sirolimus	119-128	thymoma viral proto-oncogene 1	Mus musculus	50-53
31792194-3	2019	We reveal that the target of rapamycin (TOR) kinase, a conserved central growth regulator, is essential for glucose- and nicotinamide-mediated control of the circadian period in Arabidopsis Nicotinamide affects the cytosolic adenosine triphosphate concentration, and blocks the effect of glucose-TOR energy signaling on period length adjustment, meristem activation, and root growth.	Sirolimus	29-38	target of rapamycin	Arabidopsis thaliana	40-43
31820607-17	2019	Compared with the model group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were reduced in the moxibustion group, the rapamycin group and the combination group (all P<0.01).	Sirolimus	119-128	thymoma viral proto-oncogene 1	Mus musculus	56-59
31820607-18	2019	Compared with the moxibustion group, the levels of PI3K Akt and p-mTOR were increased in the rapamycin group and the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (all P<0.01).	Sirolimus	93-102	thymoma viral proto-oncogene 1	Mus musculus	56-59
31820607-19	2019	Compared with the rapamycin group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (P<0.01).	Sirolimus	18-27	thymoma viral proto-oncogene 1	Mus musculus	54-57
31820607-19	2019	Compared with the rapamycin group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (P<0.01).	Sirolimus	18-27	thymoma viral proto-oncogene 1	Mus musculus	60-63
31835352-5	2019	mechanistic target of rapamycin (mTOR)is the core hub regulating autophagy, which is subject to different upstream signaling pathways to regulate autophagy.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	33-37
31817676-10	2019	Since rapamycin does not fully inhibit mTOR activity, new compounds have been engineered to inhibit the catalytic activity of mTOR to more potently block its functions.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	126-130
31791403-1	2019	BACKGROUND: The mammalian target of rapamycin complex 2 (mTORC2), containing the essential protein rictor, regulates cellular metabolism and cytoskeletal organization by phosphorylating protein kinases, such as PKB/Akt, PKC, and SGK.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	211-214
31817676-4	2019	The elucidation of the regulation and functions of mTOR can be traced to the discovery of the natural compound, rapamycin.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	51-55
31817676-5	2019	Studies using rapamycin have unraveled the role of mTOR in the control of cell growth and metabolism.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	51-55
31791403-1	2019	BACKGROUND: The mammalian target of rapamycin complex 2 (mTORC2), containing the essential protein rictor, regulates cellular metabolism and cytoskeletal organization by phosphorylating protein kinases, such as PKB/Akt, PKC, and SGK.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	215-218
31499159-11	2019	Knockdown of TFEB expression attenuated rapamycin-induced protection from necroptosis in TNF/zVAD-treated cells.	Sirolimus	40-49	transcription factor EB	Rattus norvegicus	13-17
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	10-19	AKT serine/threonine kinase 1	Rattus norvegicus	185-188
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	21-25	AKT serine/threonine kinase 1	Rattus norvegicus	185-188
32042772-8	2019	Catalpol can also reversed proteins reduced by Rapa related with PI3K/AKT/mTOR pathway.	Sirolimus	47-51	AKT serine/threonine kinase 1	Rattus norvegicus	70-73
31499159-9	2019	Protective effects of rapamycin on TNF/zVAD-induced RIP1-RIP3 binding and necroptosis were undetected in cells transfected with RIP1-S320A.	Sirolimus	22-31	tumor necrosis factor	Rattus norvegicus	35-38
31499159-11	2019	Knockdown of TFEB expression attenuated rapamycin-induced protection from necroptosis in TNF/zVAD-treated cells.	Sirolimus	40-49	tumor necrosis factor	Rattus norvegicus	89-92
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	90-94
31870254-7	2019	Although rapamycin inhibited mTOR (mammalian target of rapamycin) signaling, it failed to enhance the autophagy and to ameliorate the severity of AKI caused by ischemia or cisplatin-induced nephrotoxicity.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	29-33
31870254-7	2019	Although rapamycin inhibited mTOR (mammalian target of rapamycin) signaling, it failed to enhance the autophagy and to ameliorate the severity of AKI caused by ischemia or cisplatin-induced nephrotoxicity.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	35-64
31553107-10	2019	Inhibition of p70S6K /p85S6K by rapamycin also reduced the expressions of STAT3 and cyclin D1.	Sirolimus	32-41	signal transducer and activator of transcription 3	Homo sapiens	74-79
31512504-2	2019	To gain therapeutic levels of Tregs there is a need to expand obtained cells ex vivo, usually in the presence of the mTOR inhibitor Rapamycin due to its ability to suppress proliferation of non-Treg T cells, thus promoting a purer Treg yield.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	117-121
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	170-174
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Homo sapiens	170-174
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	226-235	mechanistic target of rapamycin kinase	Homo sapiens	90-94
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	226-235	mechanistic target of rapamycin kinase	Homo sapiens	170-174
31732331-3	2019	A growing body of preclinical evidence in in vitro and rodent model systems suggests that mTOR signaling may be altered in status epilepticus (SE) and that modulation of mTOR activation with mTOR inhibitors such as rapamycin (sirolimus) could provide new therapeutic avenues for treatment of both refractory epilepsy and SE.	Sirolimus	226-235	mechanistic target of rapamycin kinase	Homo sapiens	170-174
31761958-3	2019	To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	67-98
31089971-15	2019	CONCLUSION: Based on the pharmacokinetic profiles observed, the nano-amorphous formulation could be a better alternative to Rapamune  for the treatment of mammalian target of rapamycin-responsive malignancies.	Sirolimus	124-132	mechanistic target of rapamycin kinase	Homo sapiens	155-184
31761958-8	2019	Topical rapamycin reduced the expression of the p16INK4A protein consistent with a reduction in cellular senescence.	Sirolimus	8-17	cyclin dependent kinase inhibitor 2A	Homo sapiens	48-56
31761958-3	2019	To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	100-104
31381473-2	2019	Clinical researches have shown that rapamycin, a specific inhibitor of mTOR, is effective in treating LMs.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	71-75
31636463-4	2019	The hypoxic tumor microenvironment drove the sustained activation of mechanistic target of rapamycin-GTPase dynamin-related protein 1 (mTOR-Drp1) in NK cells, resulting in excessive mitochondrial fission into fragments.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	135-139
31606937-2	2019	While sirolimus, another mammalian target of rapamycin [mTOR] inhibitor had been used off-label for many years prior to the approval of EVR, the latter"s shorter terminal half-life and quicker time to steady-state trough level resulted in the requirement for no loading dose and easier dosing.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	25-54
31606937-2	2019	While sirolimus, another mammalian target of rapamycin [mTOR] inhibitor had been used off-label for many years prior to the approval of EVR, the latter"s shorter terminal half-life and quicker time to steady-state trough level resulted in the requirement for no loading dose and easier dosing.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	56-60
31350329-1	2019	LESSONS LEARNED: This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene.Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without significant toxicity.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Homo sapiens	174-178
31350329-1	2019	LESSONS LEARNED: This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene.Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without significant toxicity.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Homo sapiens	201-205
31350329-14	2019	CONCLUSION: A 56-day course of sirolimus was well tolerated in subjects with Cowden syndrome and was associated with some evidence of improvement in symptoms, skin and GI lesions, cerebellar function, and decreased mTOR signaling.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	215-219
31564190-9	2019	Furthermore, DMEC (5, 10, and 20 muM) reduced the expression of phosphatidylinositol-3-kinase (PI3K), phosphorylated (p)-protein kinase B (Akt), and p-mammalian target of rapamycin (p-mTOR), which were further evidenced by pretreatment with IGF-1, a PI3K activator.	Sirolimus	171-180	latexin	Homo sapiens	33-36
30782087-7	2019	The importance of Tregs at the time of embryo implantation has been well established and immunotherapy treatments, such as rapamycin (mammalian target of rapamycin inhibitor), may prove to be an effective treatment for patients with RPL, RIF, or unexplained infertility with low Treg.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	134-163
31504946-6	2019	In chick embryos at embryonic age 18 D, significant upregulation of poultry target of rapamycin (pTOR) occurred in the liver and breast muscle, as well as threonine dehydrogenase (TDH) in the thigh, and aminopeptidase (ANPEP) (P < 0.05) in the duodenum and ileum due to dietary Thr supplementation, but there were no effects on MUC2 expression in the duodenum and ileum (P > 0.05).	Sirolimus	86-95	mucin 2, oligomeric mucus/gel-forming	Gallus gallus	328-332
31552622-8	2019	Previous work has also demonstrated that inhibition of the mTOR pathway, via rapamycin, altered total levels of BZLF1 transcripts.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	59-63
31733794-2	2019	We examined whether the calcineurin inhibitor tacrolimus (TAC) and the mammalian target of rapamycin (mtor) inhibitor sirolimus (SRL) inhibit Tfh cell differentiation, and affect subsequent B-cell functions.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	71-100
31739256-2	2019	Rapamycin is a potent inhibitor of mammalian target of rapamycin (mTOR) with various applications.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-64
31852644-8	2019	Compared with the menthol-treated cells, the cells treated with both menthol and rapamycin showed significantly decreased TNF- alpha, IL-1beta, and p-mTOR expression and obviously lowered intracellular Ca2+ concentration (P < 0.05).	Sirolimus	81-90	tumor necrosis factor	Homo sapiens	122-132
31852644-8	2019	Compared with the menthol-treated cells, the cells treated with both menthol and rapamycin showed significantly decreased TNF- alpha, IL-1beta, and p-mTOR expression and obviously lowered intracellular Ca2+ concentration (P < 0.05).	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	150-154
31739256-2	2019	Rapamycin is a potent inhibitor of mammalian target of rapamycin (mTOR) with various applications.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	66-70
31772273-5	2019	Depletion of KPNA1 by RNAi prevented the nuclear import of PKCdelta in cells exposed to the mTORC1 inhibitor rapamycin or amino acid restriction.	Sirolimus	109-118	karyopherin subunit alpha 1	Homo sapiens	13-18
31885770-11	2019	Nonetheless, treatment of AAA-ASCs with rapamycin (an autophagy activator) dramatically reduced secretion of IL-6 and TNF-alpha and enhanced secretion of IL-10.	Sirolimus	40-49	interleukin 6	Homo sapiens	109-113
31885770-11	2019	Nonetheless, treatment of AAA-ASCs with rapamycin (an autophagy activator) dramatically reduced secretion of IL-6 and TNF-alpha and enhanced secretion of IL-10.	Sirolimus	40-49	tumor necrosis factor	Homo sapiens	118-127
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	MAPK associated protein 1	Homo sapiens	46-50
31775035-4	2019	In particular, we identify the ribosomal S6 Kinase/RSKS-1, previously characterized as an mTOR (mechanistic target of rapamycin) effector, as a regulator of DAF-2 endosomal recycling transport, which traces a functional correlation between endocytic recycling and aging processes.	Sirolimus	118-127	Insulin-like receptor subunit beta;Protein kinase domain-containing protein;Receptor protein-tyrosine kinase	Caenorhabditis elegans	157-162
31704693-4	2019	This paper fills this void by examining the effect of mTOR inhibition by rapamycin on several different qualities of larval Drosophila Various dosages of the compound were fed to second instar larvae.	Sirolimus	73-82	Megator	Drosophila melanogaster	54-58
31704693-9	2019	These results allow for several conclusions as to how mTOR inhibition by rapamycin affects a developing organism.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	54-58
31747377-8	2019	It inhibited Akt-mammalian target of rapamycin (mTOR) signaling pathway and also downregulated the expression of essential proteins that are involved in tumorigenesis such as cyclin D1, cyclooxygenase 2 (COX2), survivin, matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor-A (VEGF-A).	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	48-52
31591157-8	2019	Finally, we found that treatment of iPSC-derived neurons with rapamycin reduced neuronal activity and partially reversed gene expression abnormalities, demonstrating that mTOR dysregulation contributes to both phenotypes.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	171-175
31748639-8	2019	Inhibition of mTOR signalling with rapamycin reduced the expression of endogenous VIP and of VIP-induced S6 phosphorylation.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Sirolimus	14-23	tumor necrosis factor	Mus musculus	181-190
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Sirolimus	14-23	interleukin 1 beta	Mus musculus	192-200
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Sirolimus	14-23	interleukin 6	Mus musculus	202-206
31748639-8	2019	Inhibition of mTOR signalling with rapamycin reduced the expression of endogenous VIP and of VIP-induced S6 phosphorylation.	Sirolimus	35-44	vasoactive intestinal peptide	Homo sapiens	82-85
31748639-8	2019	Inhibition of mTOR signalling with rapamycin reduced the expression of endogenous VIP and of VIP-induced S6 phosphorylation.	Sirolimus	35-44	vasoactive intestinal peptide	Homo sapiens	93-96
31554636-7	2019	Additionally, the HRI-eIF2alphaP-ATF4 pathway represses mechanistic target of rapamycin complex 1 (mTORC1) signaling, specifically in the erythroid lineage as a feedback mechanism of erythropoietin-stimulated erythropoiesis during iron/heme deficiency.	Sirolimus	78-87	erythropoietin	Homo sapiens	183-197
31798451-3	2019	Some studies indicate the overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway in this disease, being, thus, a potential target for pharmacological treatment.	Sirolimus	130-139	thymoma viral proto-oncogene 1	Mus musculus	103-106
31814871-2	2019	One of these properties is the inhibition of several enzymes and factors, such as beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1), cyclooxygenases (COXs), lipoxygenases (LOXs), mammalian (or mechanistic) target for rapamycin (mTOR), and transcription factor NF-kappaB.	Sirolimus	235-244	beta-secretase 1	Homo sapiens	143-148
31717694-5	2019	Targeting PKM2 affected the protein kinase B (AKT)/mechanistic target of the rapamycin 1 (mTOR) pathway, and downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, and other downstream signaling key proteins.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	46-49
31540687-7	2019	The mTOR inhibitor rapamycin and mTOR siRNA blocked the TNF-alpha-induced up-regulation of DC-SIGN expression.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
31540687-7	2019	The mTOR inhibitor rapamycin and mTOR siRNA blocked the TNF-alpha-induced up-regulation of DC-SIGN expression.	Sirolimus	19-28	tumor necrosis factor	Homo sapiens	56-65
31540687-7	2019	The mTOR inhibitor rapamycin and mTOR siRNA blocked the TNF-alpha-induced up-regulation of DC-SIGN expression.	Sirolimus	19-28	CD209 molecule	Homo sapiens	91-98
31540687-10	2019	Finally, we found that HK-2 cells exposed to rapamycin or mTOR siRNA reduced the TNF-alpha-induced up-regulation of RUNX1.	Sirolimus	45-54	tumor necrosis factor	Homo sapiens	81-90
31717694-5	2019	Targeting PKM2 affected the protein kinase B (AKT)/mechanistic target of the rapamycin 1 (mTOR) pathway, and downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, and other downstream signaling key proteins.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	90-94
31750334-10	2019	Radical surgical resection constitutes the treatment of choice for localized disease, while mammalian target of the rapamycin (mTOR) inhibitors constitute the most promising therapy for disseminated disease.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Homo sapiens	127-131
31695068-3	2019	It has been shown that manipulating the mTOR (mammalian target of rapamycin) pathway using rapamycin or its analogue CCI-779 can improve the cellular and behavioural phenotypes of HD models.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	40-44
31695068-4	2019	Ribosomal protein S6 kinase 1 (S6K1) is a major downstream signalling molecule of mTOR, and its activity is reduced by rapamycin suggesting that deregulation of S6K1 activity may be beneficial in HD.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	82-86
31685878-10	2019	Alterations in SHFYNG patient fibroblast lines and iPSC-derived neurons are rescued by treatment with the mTOR inhibitor rapamycin.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	106-110
31388935-4	2019	A systematic drug combination screen was subsequently performed to identify that AEE788, an inhibitor targeting multiple receptor tyrosine kinases (RTKs) EGFR/HER2 and VEGFR, synergizes with selective mTOR inhibitor rapamycin as well as its analogs (rapalogs) temsirolimus and everolimus to inhibit TNBC cell proliferation.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Homo sapiens	201-205
31592908-4	2019	The normal human chondrocyte pre-treated with rapamycin or 3-methyladenine, treated with interleukin-1beta (IL-1beta).	Sirolimus	46-55	interleukin 1 beta	Homo sapiens	89-106
31592908-4	2019	The normal human chondrocyte pre-treated with rapamycin or 3-methyladenine, treated with interleukin-1beta (IL-1beta).	Sirolimus	46-55	interleukin 1 beta	Homo sapiens	108-116
31781682-2	2019	Sirolimus, a mTOR inhibitor, is reported to allow growth of functional Tregs; here, we investigated the efficacy of low-dose sirolimus combined with conventional immunosuppressants (sirolimus immunoregulation therapy) for RA treatment with lower side effects and better tolerance.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
31665839-1	2019	Objective: To investigate the efficacy and safety of rapamycin in children with tuberous sclerosis complex (TSC) associated renal disease.	Sirolimus	53-62	TSC complex subunit 1	Homo sapiens	108-111
31665839-15	2019	Conclusions: Rapamycin could decrease the diameter of TSC-related RAML, but could not inhibit the growth of cysts.	Sirolimus	13-22	TSC complex subunit 1	Homo sapiens	54-57
31271885-2	2019	Sirolimus is a mammalian target of rapamycin inhibitor that has proven effective in GVHD prophylaxis in combination with a calcineurin inhibitor, such as tacrolimus.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-44
31485623-12	2019	Promotion of KLK12 overexpression-induced cell viability was reversed by 5-aminoimidazole-4-carboxamide ribonucleotide, an activator of the AMPK signaling pathway, and rapamycin, a specific inhibitor of the mTOR signaling pathway.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Homo sapiens	207-211
31062368-3	2019	Mammalian target of rapamycin complex 2 (mTORC2) has been implicated in cancer by regulating multiple AGC kinases, especially AKT proteins.	Sirolimus	20-29	AKT serine/threonine kinase 1	Homo sapiens	126-129
32128100-10	2019	In addition, eupafolin promoted expression of PI3K/AKT/mTOR signaling pathway and mTOR inhibitor rapamycin reversed the inhibitory effects on LPS-induced cardiomyocyte autophagy.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	82-86
31277013-10	2019	Pretreatment with rapamycin significantly aggravated intestinal injury evidenced by increased Chiu"s score, intestinal mucosal wet-to-dry ratio and lactic acid level, increased autophagy level evidenced by increased autophagosomes and LC3-II/LC3-I and decreased expression of p62, and downregulated expression of p-mTOR/mTOR.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	315-319
31297862-11	2019	Therefore, our findings provide a rationale for rapamycin treatment of NBR1-knockdown human urothelial cancer through the regulation of autophagy and mitochondrial dysfunction by regulating the AMPK/mTOR signaling pathway, indicating that NBR1 can be a potential therapeutic target of human urothelial cancer.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	199-203
31277013-10	2019	Pretreatment with rapamycin significantly aggravated intestinal injury evidenced by increased Chiu"s score, intestinal mucosal wet-to-dry ratio and lactic acid level, increased autophagy level evidenced by increased autophagosomes and LC3-II/LC3-I and decreased expression of p62, and downregulated expression of p-mTOR/mTOR.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	320-324
31057050-6	2019	The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment.	Sirolimus	113-122	AKT serine/threonine kinase 1	Rattus norvegicus	25-28
31351920-9	2019	Pharmacological activators of PPARalpha and AMPK had minor effects, while the mTOR inhibitor rapamycin potentiated the effect of TTA.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Homo sapiens	78-82
31057050-11	2019	In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway.	Sirolimus	61-70	AKT serine/threonine kinase 1	Rattus norvegicus	131-134
31736762-0	2019	Rapamycin Attenuates High Glucose-Induced Inflammation Through Modulation of mTOR/NF-kappaB Pathways in Macrophages.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	77-81
31550444-8	2019	Therefore, blocking this signaling pathway via rapamycin addition resulted in the inhibition of Cxcl9 and improvement of osteogenic differentiation and angiogenic capacity of co-culture in OIM.	Sirolimus	47-56	C-X-C motif chemokine ligand 9	Homo sapiens	96-101
31736762-7	2019	Rapamycin reduced NLRP3 inflammasome activation by inhibiting mTOR phosphorylation and NF-kappaB activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	62-66
31736762-0	2019	Rapamycin Attenuates High Glucose-Induced Inflammation Through Modulation of mTOR/NF-kappaB Pathways in Macrophages.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	82-91
31736762-7	2019	Rapamycin reduced NLRP3 inflammasome activation by inhibiting mTOR phosphorylation and NF-kappaB activation.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	87-96
31736762-6	2019	Results: We found that rapamycin reduced NLRP3 inflammasome activation in macrophages.	Sirolimus	23-32	NLR family pyrin domain containing 3	Homo sapiens	41-46
31736762-9	2019	Conclusion: Rapamycin can ameliorate high glucose-induced NLRP3 inflammasome activation by attenuating the mTOR/NF-kappaB signaling pathway in macrophages.	Sirolimus	12-21	NLR family pyrin domain containing 3	Homo sapiens	58-63
31736762-9	2019	Conclusion: Rapamycin can ameliorate high glucose-induced NLRP3 inflammasome activation by attenuating the mTOR/NF-kappaB signaling pathway in macrophages.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31736762-7	2019	Rapamycin reduced NLRP3 inflammasome activation by inhibiting mTOR phosphorylation and NF-kappaB activation.	Sirolimus	0-9	NLR family pyrin domain containing 3	Homo sapiens	18-23
31736762-9	2019	Conclusion: Rapamycin can ameliorate high glucose-induced NLRP3 inflammasome activation by attenuating the mTOR/NF-kappaB signaling pathway in macrophages.	Sirolimus	12-21	nuclear factor kappa B subunit 1	Homo sapiens	112-121
31671832-7	2019	In addition, our in vivo results show that administration of chronic ethanol, binge ethanol and LPS (EBL) in wild-type C57BL/6 mice activated all three Akt isoforms with concomitant increases in activated forms of phosphoinositide dependent kinase-1 (PDK1), mammalian target-of-rapamycin complex 2 (mTORC2), and PI3K, resulting in upregulation in expression of inflammatory, proliferative, and fibrogenic genes.	Sirolimus	278-287	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	214-249
31627299-3	2019	We previously established that irinotecan has antiangiogenic properties and it is known that new mammalian target of rapamycin (mTOR) catalytic AZD inhibitors, unlike rapamycin, target both mTORC1 and mTORC2.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	128-132
31655847-0	2019	Three-Dimensional Printed Titanium Scaffolds Enhance Osteogenic Differentiation and New Bone Formation by Cultured Adipose Tissue-Derived Stem Cells Through the IGF-1R/AKT/Mammalian Target of Rapamycin Complex 1 (mTORC1) Pathway.	Sirolimus	192-201	AKT serine/threonine kinase 1	Homo sapiens	168-171
31640284-5	2019	RESULTS: Rapamycin and cetuximab inhibited the mTOR/HIF-1alpha axis, and sensitized the SQ20B cell line to EGFR-inhibition.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	47-51
31640284-5	2019	RESULTS: Rapamycin and cetuximab inhibited the mTOR/HIF-1alpha axis, and sensitized the SQ20B cell line to EGFR-inhibition.	Sirolimus	9-18	hypoxia inducible factor 1 subunit alpha	Homo sapiens	52-62
31640284-5	2019	RESULTS: Rapamycin and cetuximab inhibited the mTOR/HIF-1alpha axis, and sensitized the SQ20B cell line to EGFR-inhibition.	Sirolimus	9-18	epidermal growth factor receptor	Homo sapiens	107-111
31627436-10	2019	Rapamycin treatment alone led to increased AKT phosphorylation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	43-46
31434610-4	2019	In addition, whether rapamycin, a specific blocker of the mTOR signaling pathway, plays a therapeutic role by inhibiting lymphocyte metabolism remains unclear.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	58-62
31624262-2	2019	In a melanoma patient in whom programmed-death 1 (PD-1) blockade resulted in organ rejection and colitis, the addition of the mTOR inhibitor sirolimus resulted in ongoing anti-tumor efficacy while promoting allograft tolerance.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	126-130
31624262-5	2019	Interestingly, numbers of IFN-gamma+ CD4+ T cells and serum IFN-gamma levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy.	Sirolimus	108-117	interferon gamma	Homo sapiens	26-35
31624262-5	2019	Interestingly, numbers of IFN-gamma+ CD4+ T cells and serum IFN-gamma levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy.	Sirolimus	108-117	CD4 molecule	Homo sapiens	37-40
31624262-5	2019	Interestingly, numbers of IFN-gamma+ CD4+ T cells and serum IFN-gamma levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy.	Sirolimus	108-117	interferon gamma	Homo sapiens	60-69
30805585-13	2019	To screen the potential drug candidates, the gene expression profile of the GCPR module was mapped connectivity map (Cmap), and the mTOR inhibitor (Sirolimus) was found to be the most promising candidate.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	132-136
31518555-8	2019	Rapamycin treatment during unloading abolished p70S6K and E3 ligases upregulation and increased HDAC5 nuclear accumulation.	Sirolimus	0-9	histone deacetylase 5	Rattus norvegicus	96-101
31434610-9	2019	By inhibiting the mTOR signaling pathway, rapamycin could ameliorate the phenotype of the immune-mediated AA model and inhibit the proliferation of T cells by preventing cell cycle transition from G0 to G1 phase.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	18-22
31434610-11	2019	We confirmed that mitochondrial oxidative phosphorylation is involved in the metabolic reprogramming of T cells in AA and further extended the mechanism of rapamycin in treating AA by inhibiting the mTOR signaling pathway.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Homo sapiens	199-203
32181277-4	2020	It is important to differentiate APDS from the usual polygenic CVID in view of the availability of targeted therapy like mTOR inhibitors such as Rapamycin and selective PI3Kdelta inhibitors.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	121-125
31601789-2	2019	One or several among these alterations are also found after starvation, ketogenic diet, and pharmacological treatment with rapamycin or antibody-mediated neutralization of the obesogenic factor ACBP/DBI.	Sirolimus	123-132	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	194-198
31762815-12	2019	Rapamycin, an mTOR antagonist, compromised DHA-induced autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31601789-2	2019	One or several among these alterations are also found after starvation, ketogenic diet, and pharmacological treatment with rapamycin or antibody-mediated neutralization of the obesogenic factor ACBP/DBI.	Sirolimus	123-132	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	199-202
31582588-3	2019	We found that inhibition of the mTORC1-Sch9 pathway by SCH9 deletion, rapamycin or myriocin treatment resulted in a dramatic decrease in H2S production.	Sirolimus	70-79	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	39-43
31582588-6	2019	Overexpression of CYS3 or CYS4 in Deltasch9 cells or WT cells treated with rapamycin rescued the deficiency of H2S production.	Sirolimus	75-84	cystathionine beta-synthase CYS4	Saccharomyces cerevisiae S288C	26-30
31582588-7	2019	Finally, we also observed a reduction in H2S production and lowering of both mRNA and protein levels of CGL and CBS in cultured human cells treated with rapamycin to reduce mTORC1 pathway activity.	Sirolimus	153-162	cystathionine beta-synthase	Homo sapiens	112-115
31575848-11	2019	Tivantinib (1 mumol/L) in combination with PI3K inhibitor LY294002 (0.5 mumol/L) and mTOR inhibitor rapamycin (0.1 nmol/L) largely inhibited the proliferation of glioblastoma cells.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	85-89
33911648-8	2019	Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	42-71
31582727-6	2019	We revealed that circCDR1as enhanced autophagy in OSCC cells via inhibition of rapamycin (mTOR) activity and upregulation of AKT and ERK1/2 pathways.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	90-94
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	interleukin 6	Mus musculus	107-111
31345937-2	2019	We generated Ngn3RapKO mice (ablation of Raptor, an essential component of mechanistic target of rapamycin [mTORC1] in Ngn3+ endocrine progenitor cells) and found that mTORC1 was dispensable for endocrine cell lineage formation but specifically regulated both proliferation and identity maintenance of neonatal beta-cells.	Sirolimus	97-106	regulatory associated protein of MTOR, complex 1	Mus musculus	41-47
31345937-2	2019	We generated Ngn3RapKO mice (ablation of Raptor, an essential component of mechanistic target of rapamycin [mTORC1] in Ngn3+ endocrine progenitor cells) and found that mTORC1 was dispensable for endocrine cell lineage formation but specifically regulated both proliferation and identity maintenance of neonatal beta-cells.	Sirolimus	97-106	neurogenin 3	Mus musculus	13-17
31231866-7	2019	Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia.	Sirolimus	37-46	interleukin 6	Mus musculus	74-87
31231866-7	2019	Rescuing autophagy by treatment with rapamycin was sufficient to decrease interleukin 6 (IL-6) but not tumor necrosis factor (TNF) secretion in cultured microglia.	Sirolimus	37-46	interleukin 6	Mus musculus	89-93
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	interleukin 6	Mus musculus	31-35
30864227-12	2019	The combination of HMGB1 short interference (si) RNA and the autophagy activator rapamycin protected against podocyte apoptosis and EMT progression by inhibiting the AKT/mTOR and TGF-beta/smad signaling pathway, respectively.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	166-169
31594908-1	2019	The Target of Rapamycin (TOR or mTOR) is a serine/threonine kinase that regulates growth, development, and behaviors by modulating protein synthesis, autophagy, and multiple other cellular processes in response to changes in nutrients and other cues.	Sirolimus	14-23	RAR related orphan receptor C	Homo sapiens	25-28
31236744-8	2019	Meanwhile, rapamycin, a specific inhibitor of mTORC1, was co-applied with gentamicin to verify the role of mTOR signaling.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	46-50
31524635-5	2019	Treatment with sirolimus, an mTOR inhibitor, induced remission in all three patients.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
30864227-12	2019	The combination of HMGB1 short interference (si) RNA and the autophagy activator rapamycin protected against podocyte apoptosis and EMT progression by inhibiting the AKT/mTOR and TGF-beta/smad signaling pathway, respectively.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	170-174
30864227-13	2019	CONCLUSIONS: Although HMGB1 siRNA and rapamycin treatment had opposite effects on autophagy and AKT/mTOR signaling, there was no contradiction about the role of HMGB1 siRNA and rapamycin on AKT/mTOR pathway because autophagy and AKT/mTOR signaling play dual roles in intracellular biological processes.	Sirolimus	38-47	AKT serine/threonine kinase 1	Homo sapiens	96-99
30864227-13	2019	CONCLUSIONS: Although HMGB1 siRNA and rapamycin treatment had opposite effects on autophagy and AKT/mTOR signaling, there was no contradiction about the role of HMGB1 siRNA and rapamycin on AKT/mTOR pathway because autophagy and AKT/mTOR signaling play dual roles in intracellular biological processes.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	100-104
31166253-8	2019	In addition, BNIP3 knockdown upregulated p-mTOR and p-p70s6k as well as decreased apoptosis, whereas rapamycin (which is an inhibitor of mTOR) reversed apoptosis.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	137-141
31331823-5	2019	The treatment of denervated animals with rapamycin blocked the stimulatory effects of CGRP on mTORC1 and its inhibitory actions on autophagic flux and NMJ degeneration.	Sirolimus	41-50	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	86-90
31047942-0	2019	Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	146-150
31047942-0	2019	Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B3	Homo sapiens	208-215
31047942-3	2019	Preincubation with everolimus and sirolimus significantly decreased OATP1B1/1B3-mediated transport even after washing and decreased inhibition constant values up to 8.3- and 2.9-fold for OATP1B1 and both 2.7-fold for OATP1B3, respectively.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B3	Homo sapiens	217-224
31432123-0	2019	Rapamycin improves sevoflurane-induced cognitive dysfunction in aged rats by mediating autophagy through the TLR4/MyD88/NF-kappaB signaling pathway.	Sirolimus	0-9	toll-like receptor 4	Rattus norvegicus	109-113
31393061-2	2019	Phosphorylation of Akt Thr308 by PI3K-PDK1 and Akt Ser473 by mammalian target of rapamycin complex 2 (mTORC2) activates Akt.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	19-22
31393061-2	2019	Phosphorylation of Akt Thr308 by PI3K-PDK1 and Akt Ser473 by mammalian target of rapamycin complex 2 (mTORC2) activates Akt.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	47-50
31393061-2	2019	Phosphorylation of Akt Thr308 by PI3K-PDK1 and Akt Ser473 by mammalian target of rapamycin complex 2 (mTORC2) activates Akt.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	47-50
31432123-1	2019	The present study was aimed to observe the protective effect of rapamycin on cognitive dysfunction induced by sevoflurane in aged rats and its effect on autophagy-related proteins, and to investigate the regulatory mechanism of the Toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor-kappaB (TLR4/MyD88/NF-kappaB) signaling pathway.	Sirolimus	64-73	toll-like receptor 4	Rattus norvegicus	232-252
31432123-1	2019	The present study was aimed to observe the protective effect of rapamycin on cognitive dysfunction induced by sevoflurane in aged rats and its effect on autophagy-related proteins, and to investigate the regulatory mechanism of the Toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor-kappaB (TLR4/MyD88/NF-kappaB) signaling pathway.	Sirolimus	64-73	toll-like receptor 4	Rattus norvegicus	320-324
31432123-10	2019	This function of rapamycin was demonstrated to depend on the TLR4/MyD88/NF-kappaB signaling pathway.	Sirolimus	17-26	toll-like receptor 4	Rattus norvegicus	61-65
31607290-0	2019	[Rapamycin Induces Apoptosis of K562 Cells through EZH2/Hedgehog Signaling Pathway].	Sirolimus	1-10	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	51-55
32274481-1	2019	PURPOSE: To investigate the expression of rapamycin target protein (mTOR) mRNA and transferrin receptor 1(Tfr1) mRNA in mucoepidermoid carcinoma of parotid gland and its relationship with prognosis.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	68-72
31607290-11	2019	CONCLUSION: Rapamycin can inhibit the protein expression of EZH2 in leukemic cells, thus interfere with the activation of Hedgehog signaling pathway, promote the expression of apoptotic protein, reduce the level of anti apoptotic protein, and eventually induce apoptosis of leukemia cells.	Sirolimus	12-21	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	60-64
31546722-10	2019	On the other hand, inhibition of mTOR activation by rapamycin (an allosteric mTOR inhibitor) significantly attenuated neuronal death induced by HFD, showing reduction of HFD-induced increases of oxidative stress indicators and proinflammatory cytokines, and microglia activation.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	33-37
31568401-10	2019	Disruption of PNO1 expression significantly reduced protein kinase B (AKT)/rapamycin (mTOR) signaling, indicating that this pathway may be involved in PNO1-mediated tumorigenic activity.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	86-90
31723531-4	2019	This somatic mutation is, in turn, associated with the activation of the protein kinase B-mammalian target of the rapamycin (AKT-mTOR) pathway that drives various signaling cascades.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	125-128
31723531-4	2019	This somatic mutation is, in turn, associated with the activation of the protein kinase B-mammalian target of the rapamycin (AKT-mTOR) pathway that drives various signaling cascades.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	129-133
31608069-7	2019	Use of allosteric panAkt inhibitor MK2206 and mTOR inhibitor rapamycin confirmed the role of Akt/mTOR signaling in autophagy inhibition by P. gingivalis in DCs.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
31579114-4	2019	The GC cells were subsequently transfected with siRNA against LINC01419 or Rapamycin (the inhibitor of the mTOR pathway), or both, in order to measure cell migration and invasion in vitro as well as tumor growth and metastasis in vivo.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31546722-10	2019	On the other hand, inhibition of mTOR activation by rapamycin (an allosteric mTOR inhibitor) significantly attenuated neuronal death induced by HFD, showing reduction of HFD-induced increases of oxidative stress indicators and proinflammatory cytokines, and microglia activation.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	77-81
31242443-8	2019	Consequent effects of rapamycin administration included enhanced ductlet generation in bovine implants and higher milk-protein gene expression in cultured mouse mammary cells.	Sirolimus	22-31	casein beta	Bos taurus	114-126
31534118-8	2019	Following that, we use Rapamycin and MK-2206 to inhibit the Akt/mTOR signaling pathway, meanwhile, Rattus 4EBP1, p70S6K, Akt1 and Akt2 were transfected to H9C2 cells to establish the stably transfected cell lines.	Sirolimus	23-32	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
30672370-6	2019	Pre-treatment of spinal neurons with a PI3K inhibitor, LY294002 or mammalian target of rapamycin (mTOR) inhibitor, rapamycin blocked bpV activation of Akt and ribosomal protein S6 activity, respectively.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	98-102
31632585-13	2019	CONCLUSION: The data indicated that rapamycin, an inhibitor of mTOR, blocked iNOS and NO production during asthma onset.	Sirolimus	36-45	nitric oxide synthase 2, inducible	Mus musculus	77-81
30672370-6	2019	Pre-treatment of spinal neurons with a PI3K inhibitor, LY294002 or mammalian target of rapamycin (mTOR) inhibitor, rapamycin blocked bpV activation of Akt and ribosomal protein S6 activity, respectively.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	151-154
30672370-7	2019	Treatment with bpV increased extracellular signal-related kinase (Erk) activity after scratch injury in vitro, and rapamycin reduced influence by bpV on Erk phosphorylation.	Sirolimus	115-124	mitogen-activated protein kinase 1	Homo sapiens	153-156
31483776-0	2019	Overexpression of Biglycan is Associated with Resistance to Rapamycin in Human WERI-Rb-1 Retinoblastoma Cells by Inducing the Activation of the Phosphatidylinositol 3-Kinases (PI3K)/Akt/Nuclear Factor kappa B (NF-kappaB) Signaling Pathway.	Sirolimus	60-69	biglycan	Homo sapiens	18-26
31323368-8	2019	Upon also considering the results of Caco-2 cell assay, it could be speculated that the transport of rapamycin in vivo involved active transport as well as P-glycoprotein (P-gp) based efflux.	Sirolimus	101-110	ATP binding cassette subfamily B member 1	Homo sapiens	156-170
31323368-8	2019	Upon also considering the results of Caco-2 cell assay, it could be speculated that the transport of rapamycin in vivo involved active transport as well as P-glycoprotein (P-gp) based efflux.	Sirolimus	101-110	ATP binding cassette subfamily B member 1	Homo sapiens	172-176
31645839-11	2019	All together these data suggest that the inhibition of mTORC1 in human microglia by rapamycin results in complex immunomodulatory effects, including a significant increase in the expression and release of the pro-inflammatory IL-6.	Sirolimus	84-93	interleukin 6	Homo sapiens	226-230
31484501-12	2019	Low dose of IL-2 combined with rapamycin was able to restore the number of Tregs and the balance of Th17/Treg cells.	Sirolimus	31-40	interleukin 2	Homo sapiens	12-16
31483776-2	2019	The mammalian target of rapamycin (mTOR) inhibitor, rapamycin, is a treatment for advanced retinoblastoma.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
31483776-3	2019	This study aimed to investigate the effects of expression of BGN on the response of human WERI-Rb-1 retinoblastoma cells to rapamycin and to investigate the associated signaling pathways.	Sirolimus	124-133	biglycan	Homo sapiens	61-64
31483776-4	2019	MATERIAL AND METHODS BGN gene expression was induced in human WERI-Rb-1 retinoblastoma cells, which were incubated with rapamycin at doses of 0, 5, 10, 20, 30, and 50 mug/ml.	Sirolimus	120-129	biglycan	Homo sapiens	21-24
31483776-9	2019	RESULTS Rapamycin impaired cell growth, induced cell apoptosis, and suppressed the expression levels of p-PI3K, p-Akt, nuclear NF-kappaB, and p65.	Sirolimus	8-17	AKT serine/threonine kinase 1	Homo sapiens	114-117
31649854-1	2019	Recently, considerable attention in the field of cancer therapy has been focused on the mammalian rapamycin target (mTOR), inhibition of which could result in autophagic cell death (ACD).	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	116-120
31483776-9	2019	RESULTS Rapamycin impaired cell growth, induced cell apoptosis, and suppressed the expression levels of p-PI3K, p-Akt, nuclear NF-kappaB, and p65.	Sirolimus	8-17	nuclear factor kappa B subunit 1	Homo sapiens	127-136
31483776-11	2019	In cells that overexpressed BGN, inhibition of the PI3K/Akt pathway by LY294002 increased the sensitivity of human WERI-Rb-1 retinoblastoma cells to rapamycin.	Sirolimus	149-158	biglycan	Homo sapiens	28-31
31483776-11	2019	In cells that overexpressed BGN, inhibition of the PI3K/Akt pathway by LY294002 increased the sensitivity of human WERI-Rb-1 retinoblastoma cells to rapamycin.	Sirolimus	149-158	AKT serine/threonine kinase 1	Homo sapiens	56-59
31483776-12	2019	CONCLUSIONS Overexpression of BGN induced rapamycin resistance in WERI-Rb-1 retinoblastoma cells by activating PI3K/Akt/NF-kappaB signaling.	Sirolimus	42-51	biglycan	Homo sapiens	30-33
31315433-10	2019	On the contrary, lentivirus-mediated overexpression of Rheb in macrophages increased oxidized LDL-induced lipid uptake and inflammation, and the stimulatory effect of Rheb was suppressed by the mTOR (mammalian target of rapamycin) inhibitor rapamycin or the PKA (protein kinase A) activator forskolin.	Sirolimus	220-229	mechanistic target of rapamycin kinase	Homo sapiens	194-198
31296735-7	2019	Unexpectedly, rapamycin, a well-established inhibitor of mTOR, also strongly protected NK-A20-/- cells from death, and further studies revealed that A20 restricts mTOR activation in NK cells.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	57-61
31296735-7	2019	Unexpectedly, rapamycin, a well-established inhibitor of mTOR, also strongly protected NK-A20-/- cells from death, and further studies revealed that A20 restricts mTOR activation in NK cells.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	163-167
31199921-0	2019	Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells.	Sirolimus	95-104	caveolin 1	Homo sapiens	22-32
31398711-3	2019	Several mTOR inhibitors, including sirolimus, temsirolimus and everolimus have been clinically developed.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	8-12
30546074-12	2019	Moreover, rapamycin prevented the inhibitory effect of TNFalpha and ceramides on erythropoiesis while inhibiting induction of myelopoiesis.	Sirolimus	10-19	tumor necrosis factor	Homo sapiens	55-63
30565371-13	2019	CONDENSED ABSTRACT: The COMBO stent is a sirolimus-eluting stent with a luminal anti-CD34-antibody layer, that binds endothelial progenitor cells.	Sirolimus	41-50	CD34 molecule	Homo sapiens	85-89
31167878-7	2019	Like BCAAs, BCKAs also suppressed insulin signaling via activation of mammalian target of rapamycin complex 1.	Sirolimus	90-99	insulin	Homo sapiens	34-41
31120172-4	2019	We showed that branching buds in the salivary glands were substantially decreased and phosphorylation of mTORC1 signalling pathway related proteins (mTOR, p70 ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1) was inhibited by rapamycin (an mTOR inhibitor).	Sirolimus	261-270	mechanistic target of rapamycin kinase	Homo sapiens	105-109
31174205-8	2019	Rapamycin decreased the enlarged brain size of Depdc5cc+ mice with corresponding decrease in neuronal soma size.	Sirolimus	0-9	DEP domain containing 5	Mus musculus	47-53
30604513-11	2019	The side effects associated with sirolimus therapy included bronchitis; lymphopenia; elevated AST, ALT and platelets; hyperlipidaemia; opportunistic infection; mild reversible leukopenia; mucositis; fever; pain and skin rash/vomiting and diarrhoea.	Sirolimus	33-42	solute carrier family 17 member 5	Homo sapiens	94-97
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	52-61	amyloid beta precursor protein	Homo sapiens	92-97
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	52-61	NLR family pyrin domain containing 3	Homo sapiens	169-174
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	52-61	caspase 1	Homo sapiens	175-184
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	63-67	amyloid beta precursor protein	Homo sapiens	92-97
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	63-67	NLR family pyrin domain containing 3	Homo sapiens	169-174
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	63-67	caspase 1	Homo sapiens	175-184
31299610-5	2019	Sirolimus as the most common mTOR (mammalian target of Rapamycin) inhibitor is able to effectively prevent allograft rejection.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	29-33
31299610-5	2019	Sirolimus as the most common mTOR (mammalian target of Rapamycin) inhibitor is able to effectively prevent allograft rejection.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-64
31021470-12	2019	Preconditioning with mTOR inhibitor rapamycin engendered not only a reduction in mTOR activation, but also a reactivation of autophagy in REDD1 knockdown-neurons upon OGD/R.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	21-25
31021470-12	2019	Preconditioning with mTOR inhibitor rapamycin engendered not only a reduction in mTOR activation, but also a reactivation of autophagy in REDD1 knockdown-neurons upon OGD/R.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	81-85
31226272-8	2019	Gain-of-function and loss-of-function approaches have demonstrated that IRF1 suppresses the mechanistic target of rapamycin (mTOR)/p70 S6 kinase (p70 S6K) cascade to exert its anti-Mtb effect.	Sirolimus	114-123	interferon regulatory factor 1	Homo sapiens	72-76
31404320-0	2019	Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	113-117
31404320-9	2019	Rapamycin and doxorubicin also reduced the phosphorylation levels of mTOR and p70S6K.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	69-73
31404320-5	2019	The aim of the present study was to investigate the effects of rapamycin and doxorubicin on K562 cell proliferation following the combination treatment, and further focus on confirming whether rapamycin enhanced the antitumor effects of doxorubicin by downregulating the mTOR/ribosomal protein S6 kinase (p70S6K) pathway.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Homo sapiens	271-275
31404320-12	2019	These results suggested that rapamycin could enhance the antitumor effects of doxorubicin on K562 cells by downregulating mTOR/p70S6K signaling.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	122-126
31173788-7	2019	Mechanistically, mTOR signaling, responsible for autophagy induction, was activated in vivo and in vitro, and targeting inhibition of mTOR with rapamycin protected SH-SY5Y cells from defective autophagy and excessive apoptosis, thereby enhancing neuronal survival.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	17-21
31102490-0	2019	Inhibition of mTOR by Rapamycin Aggravates Corneal Epithelial Stem Cell Deficiency by Upregulating Inflammatory Response.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	170-179	signal transducer and activator of transcription 3	Homo sapiens	24-74
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	170-179	toll like receptor 2	Homo sapiens	124-144
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	239-248	signal transducer and activator of transcription 3	Homo sapiens	24-74
31102490-6	2019	Hence, our data reveal that the mTOR signaling is implicated in the control of the pro-inflammatory and anti-inflammatory balance in the cornea and that mTOR inhibition with rapamycin is detrimental to CESCs by accelerating inflammation-induced collateral damage to the cells.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Homo sapiens	153-157
31173788-7	2019	Mechanistically, mTOR signaling, responsible for autophagy induction, was activated in vivo and in vitro, and targeting inhibition of mTOR with rapamycin protected SH-SY5Y cells from defective autophagy and excessive apoptosis, thereby enhancing neuronal survival.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	134-138
31406198-8	2019	Furthermore, when combined with the inhibitors MK2206 and rapamycin to inhibit Akt and mTOR kinase activity, Pae-induced autophagy was increased.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	79-82
31524870-7	2019	From the proteolytic curve we saw that the proteolysis of mTOR by pronase was inhibited by the presence of rapamycin.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	58-62
31594080-24	2019	The expression of alpha-SMA in Rapa group and Rapa+Sal B group was similar to M group, while Rapa + CQ group and Rapa + FZ group were significantly lower than Rapa group and M group (P < 0.01).	Sirolimus	31-35	actin alpha 2, smooth muscle, aorta	Mus musculus	18-27
31150648-8	2019	However, rapamycin significantly inhibited mTOR, which can impact the anti-ischemic effect of crocin in vitro.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	43-47
31406105-2	2019	Puzzlingly, rapamycin can induce insulin sensitivity, but may also induce insulin resistance or glucose intolerance without insulin resistance.	Sirolimus	12-21	insulin	Homo sapiens	33-40
31406105-2	2019	Puzzlingly, rapamycin can induce insulin sensitivity, but may also induce insulin resistance or glucose intolerance without insulin resistance.	Sirolimus	12-21	insulin	Homo sapiens	74-81
31406105-2	2019	Puzzlingly, rapamycin can induce insulin sensitivity, but may also induce insulin resistance or glucose intolerance without insulin resistance.	Sirolimus	12-21	insulin	Homo sapiens	74-81
31406198-8	2019	Furthermore, when combined with the inhibitors MK2206 and rapamycin to inhibit Akt and mTOR kinase activity, Pae-induced autophagy was increased.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	87-91
31408438-7	2019	Proteomic, immunophenotypic, and clinical response assessments were performed to quantify the effects of administration of the mTOR inhibitor, sirolimus.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	127-131
31408438-9	2019	Administration of sirolimus significantly attenuated CD8+ T cell activation and decreased VEGF-A levels.	Sirolimus	18-27	vascular endothelial growth factor A	Homo sapiens	90-96
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	protein kinase C alpha	Homo sapiens	36-44
31358596-4	2019	Rapamycin inhibits mTOR and is effective in preventing kidney transplant rejection, with the additional merits of reduced incidence of malignancies and viral infections.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	19-23
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Sirolimus	18-27	mitogen-activated protein kinase 1	Homo sapiens	57-94
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Sirolimus	18-27	mitogen-activated protein kinase 1	Homo sapiens	96-99
30728467-9	2019	In HepG2 cells, rapamycin (a mTOR inhibitor) significantly reduced the OLZ-stimulated hepatocellular lipid contents and weakened the ability of Sim to lower lipids via a mechanism associated with the upregulation of SREBP1c-mediated de novo lipogenesis.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	29-33
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	80-84
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	hypoxia inducible factor 1 subunit alpha	Homo sapiens	132-141
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	hypoxia inducible factor 1 subunit alpha	Homo sapiens	132-136
31066320-2	2019	This has resulted in calls for the use of the MTOR inhibitor rapamycin for the treatment of dementia in humans.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
31102854-2	2019	To combat in-stent restenosis, drug-eluting stents (DES) delivering mTOR inhibitors such as sirolimus or everolimus have become standard for coronary stenting.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	68-72
30528864-1	2019	BACKGROUND: During the past decade, mTOR inhibitors (mTORi), everolimus and sirolimus, have been increasingly used after adult liver transplantation (LT).	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	36-40
31173192-8	2019	Furthermore, co-treatment with MK-2206 (an Akt specific inhibitor) or rapamycin (an inhibitor of mTOR) enhanced T7 peptide-induced autophagy, whereas co-treatment with insulin (an activator of the Akt/mTOR signaling pathway) alleviated T7 peptide-induced autophagy, which suggested that the T7 peptide may induce autophagy activation via inhibition of the Akt/mTOR signaling pathway.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	97-101
31147742-16	2019	Furthermore, we found that the nuclear translocation of NF-kappaB increased after LPS administration, and NF-kappaB"s nuclear translocation was significantly increased in comparison with the LPS group after RAPA pretreatment.	Sirolimus	207-211	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	106-115
30549029-1	2019	Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has significant potential for application in the treatment of urothelial carcinoma (URCa) of the bladder.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
30549029-1	2019	Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, has significant potential for application in the treatment of urothelial carcinoma (URCa) of the bladder.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
30549029-6	2019	Rapamycin enhanced growth inhibition and apoptosis in stable LKB1-knockdown URCa cells and in a xenograft mouse model.	Sirolimus	0-9	serine/threonine kinase 11	Mus musculus	61-65
30549029-8	2019	Our findings suggest that the absence of LKB1 can be targeted to induce dysregulated mitochondrial biogenesis by rapamycin treatment in the design of novel therapeutic strategies for bladder cancer.	Sirolimus	113-122	serine/threonine kinase 11	Mus musculus	41-45
30701530-9	2019	Knockdown of miR-30b reduced MMP and autophagy, elevated VC, and suppressed the presence of rapamycin (an inhibitor of the mTOR signaling pathway).	Sirolimus	92-101	microRNA 30b	Homo sapiens	13-20
31021425-9	2019	OPTN is inhibited by autophagy inhibitors, such as Acteoside and 3-MA and is promoted by the autophagy activator, Rapamycin.	Sirolimus	114-123	optineurin	Homo sapiens	0-4
31021425-10	2019	Meanwhile, PI3K and AKT are elevated by Acteoside and 3-MA and inhibited by Rapamycin.	Sirolimus	76-85	AKT serine/threonine kinase 1	Homo sapiens	20-23
30701530-9	2019	Knockdown of miR-30b reduced MMP and autophagy, elevated VC, and suppressed the presence of rapamycin (an inhibitor of the mTOR signaling pathway).	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	123-127
30710341-4	2019	Researchers report that rapamycin, a selective mTOR inhibitor, and immunosuppressive agent, has surprising immunostimulatory effects on inducing both quantitative and qualitative aspects of virus-specific memory CD8+ T-cells differentiation and homeostasis in a T-cell-intrinsic manner.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	47-51
31329230-8	2019	Further study showed the functional roles of the mTOR signaling pathway in the hyperstimulation-induced ovarian extracellular matrix remodeling as the expression of alpha2M, a broad proteolytic inhibitor in both ovary and serum, was dramatically decreased after rapamycin treatment.	Sirolimus	262-271	alpha-2-macroglobulin	Mus musculus	165-172
30905858-1	2019	Rapamycin is an immunosuppressant that inhibits the mammalian or mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in organisms including mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	65-96
31366686-9	2019	Treatment with sirolimus, an mTOR inhibitor, was initiated with the aim of inhibiting polyp growth.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	97-106	B cell leukemia/lymphoma 2	Mus musculus	50-55
30905858-6	2019	p-ERK expression increased with rapamycin treatment for 24 and 36 h compared to that without rapamycin, but decreased for 48 h. p-Akt expression decreased with rapamycin treatment for 36 and 48 h compared to that without rapamycin.	Sirolimus	32-41	mitogen-activated protein kinase 1	Mus musculus	2-5
30905858-1	2019	Rapamycin is an immunosuppressant that inhibits the mammalian or mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in organisms including mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	0-9	mitogen-activated protein kinase 1	Mus musculus	218-221
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	225-228
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	0-9	catalase	Mus musculus	234-242
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	0-9	superoxide dismutase 2, mitochondrial	Mus musculus	270-276
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	167-176	mitogen-activated protein kinase 1	Mus musculus	218-221
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	167-176	thymoma viral proto-oncogene 1	Mus musculus	225-228
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	167-176	catalase	Mus musculus	234-242
30905858-4	2019	Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner.	Sirolimus	167-176	superoxide dismutase 2, mitochondrial	Mus musculus	270-276
31316104-7	2019	Rapamycin treatment rescued mitophagy, blocked the increase in MTOR and phosphorylated-MTOR, and increased the mitophagy-related gene expression in Gas6-depleted MII oocytes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	63-67
31363142-6	2019	AVF in mice treated with rapamycin had reduced Akt1 and mTORC1 but not mTORC2 phosphorylation.	Sirolimus	25-34	thymoma viral proto-oncogene 1	Mus musculus	47-51
31330912-7	2019	Additionally, the Akt (protein kinase B) inhibitor BML257 and the mTOR (mammalian target of rapamycin) inhibitor rapamycin contributed to the survival of astrocytes.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	66-70
31167789-9	2019	Mechanistically, we found that mOC-ABs induce osteoblast differentiation by activatingPI3K/AKT/mechanistic target of rapamycin (mTOR)/ribosomal protein S6 kinase signaling.	Sirolimus	117-126	thymoma viral proto-oncogene 1	Mus musculus	91-94
31316104-7	2019	Rapamycin treatment rescued mitophagy, blocked the increase in MTOR and phosphorylated-MTOR, and increased the mitophagy-related gene expression in Gas6-depleted MII oocytes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	87-91
31315300-10	2019	The Western blot results showed that the expression levels of Beclin1, LC3-I/II, and ERK were significantly elevated in HEMA-treated cells and in cells co-treated with rapamycin, an autophagic promoter.	Sirolimus	168-177	mitogen-activated protein kinase 1	Homo sapiens	85-88
30959047-2	2019	We compared the effect of two synthetic mammalian mTOR blockers MC2141 and MC2183 with that of natural/plant-derived mTOR blocker rapamycin and mTOR activator resveratrol on cultured human ovarian granulosa cells.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	117-121
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	RAR-related orphan receptor gamma	Mus musculus	100-104
31360296-8	2019	The protein kinase B/mammalian target of the rapamycin (Akt/mTOR) pathway which is involved in cardiac remodeling process was activated in response to norepinephrine and was mitigated by bucindolol.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	56-59
31360296-8	2019	The protein kinase B/mammalian target of the rapamycin (Akt/mTOR) pathway which is involved in cardiac remodeling process was activated in response to norepinephrine and was mitigated by bucindolol.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	60-64
30445633-10	2019	Taken together, our study demonstrated that metformin suppressed the carcinogenesis of ESCC through inhibiting AMPK/mammalian target of the rapamycin (mTOR) signaling pathway, resulting in its chemopreventive effects on the carcinogenesis of ESCC.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	151-155
30959047-2	2019	We compared the effect of two synthetic mammalian mTOR blockers MC2141 and MC2183 with that of natural/plant-derived mTOR blocker rapamycin and mTOR activator resveratrol on cultured human ovarian granulosa cells.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	117-121
31042058-9	2019	Both sirolimus and torin2 decreased phosphorylated S6 protein, phosphorylated eukaryotic translation initiation factor 4E-binding protein 1, phosphorylated Akt, and proliferation in Pkd1RC/RC kidneys.	Sirolimus	5-14	thymoma viral proto-oncogene 1	Mus musculus	156-159
30499005-9	2019	mTOR inhibition with rapamycin effectively blocks the migration and proliferation of the RPE cells.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	0-4
30995105-6	2019	Interestingly, inhibition of mTOR with rapamycin did not alter HIF-1alpha or PDHK1 protein levels in LSFC fibroblasts.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	29-33
30958627-5	2019	The expression of ERK1/2 and phosphatidylinositol 3 kinase/protein kinase B/mammalian targets of the rapamycin (PI3K/AKt/mTOR) signals and transferrin receptor (TfR/CD71) was detected with the methods of immunoblotting.	Sirolimus	101-110	mitogen-activated protein kinase 3	Homo sapiens	18-24
30958627-5	2019	The expression of ERK1/2 and phosphatidylinositol 3 kinase/protein kinase B/mammalian targets of the rapamycin (PI3K/AKt/mTOR) signals and transferrin receptor (TfR/CD71) was detected with the methods of immunoblotting.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	117-120
30958627-5	2019	The expression of ERK1/2 and phosphatidylinositol 3 kinase/protein kinase B/mammalian targets of the rapamycin (PI3K/AKt/mTOR) signals and transferrin receptor (TfR/CD71) was detected with the methods of immunoblotting.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	121-125
31044492-1	2019	Insulin, insulin-like growth factor-1 (IGF-1) and essential amino acids activate the mechanistic target of rapamycin complex 1 (mTORC1), the main nutrient-sensitive kinase.	Sirolimus	107-116	insulin	Homo sapiens	0-7
31044492-1	2019	Insulin, insulin-like growth factor-1 (IGF-1) and essential amino acids activate the mechanistic target of rapamycin complex 1 (mTORC1), the main nutrient-sensitive kinase.	Sirolimus	107-116	insulin like growth factor 1	Homo sapiens	9-37
31044492-1	2019	Insulin, insulin-like growth factor-1 (IGF-1) and essential amino acids activate the mechanistic target of rapamycin complex 1 (mTORC1), the main nutrient-sensitive kinase.	Sirolimus	107-116	insulin like growth factor 1	Homo sapiens	39-44
31115485-7	2019	Rapamycin also increased Abeta clearance by promoting autophagy and reduced Tau hyperphosphorylation by upregulating the levels of insulin-degrading enzyme.	Sirolimus	0-9	insulin	Homo sapiens	131-138
31028762-4	2019	Rapamycin was used to verify the mTORC1/p70S6K/YY1 signaling pathway in HK-2 cells.	Sirolimus	0-9	YY1 transcription factor	Mus musculus	47-50
31025371-6	2019	Importantly, treatment of the mTOR inhibitor rapamycin blocked the neuroprotective effects of AO-2 on reducing LC3-II and cleaved Caspase-3 expression and cancelled AO-2-mediated neuronal survival.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	30-34
31025371-6	2019	Importantly, treatment of the mTOR inhibitor rapamycin blocked the neuroprotective effects of AO-2 on reducing LC3-II and cleaved Caspase-3 expression and cancelled AO-2-mediated neuronal survival.	Sirolimus	45-54	caspase 3	Homo sapiens	130-139
31338346-3	2019	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used as an immunosuppressant after organ transplantation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
31338346-3	2019	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used as an immunosuppressant after organ transplantation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
31018220-10	2019	It was completely abolished by pretreatment of platelet-rich plasma with the mechanistic target of rapamycin (mTOR) inhibitors rapamycin or everolimus.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	110-114
30965356-10	2019	Rapamycin, an mTOR inhibitor, blocks IL-6Ralpha protein expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30965356-10	2019	Rapamycin, an mTOR inhibitor, blocks IL-6Ralpha protein expression.	Sirolimus	0-9	interleukin 6 receptor	Homo sapiens	37-47
31147387-2	2019	Canonically, Akt is activated by phosphoinositide-dependent kinase 1 and mechanistic target of rapamycin complex 2, which phosphorylate it on two regulatory residues in its kinase domain upon targeting of Akt to the plasma membrane by PI(3,4,5)P3 Recent evidence, however, has shown that, in addition to phosphorylation, Akt activity is allosterically coupled to the engagement of PI(3,4,5)P3 or PI(3,4)P2 in cellular membranes.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	13-16
31147387-2	2019	Canonically, Akt is activated by phosphoinositide-dependent kinase 1 and mechanistic target of rapamycin complex 2, which phosphorylate it on two regulatory residues in its kinase domain upon targeting of Akt to the plasma membrane by PI(3,4,5)P3 Recent evidence, however, has shown that, in addition to phosphorylation, Akt activity is allosterically coupled to the engagement of PI(3,4,5)P3 or PI(3,4)P2 in cellular membranes.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	205-208
31147387-2	2019	Canonically, Akt is activated by phosphoinositide-dependent kinase 1 and mechanistic target of rapamycin complex 2, which phosphorylate it on two regulatory residues in its kinase domain upon targeting of Akt to the plasma membrane by PI(3,4,5)P3 Recent evidence, however, has shown that, in addition to phosphorylation, Akt activity is allosterically coupled to the engagement of PI(3,4,5)P3 or PI(3,4)P2 in cellular membranes.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	205-208
31196153-8	2019	Rapamycin (a mTOR inhibitor, an autophagy activator) further down-regulated h/R-induced decrease of the phosphorylated PI3K, Akt and mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
31247000-6	2019	Rapamycin and Ly-294,002 increased PDK4 mRNA expression in both cell lines but significance was only reached in U87.	Sirolimus	0-9	pyruvate dehydrogenase kinase 4	Homo sapiens	35-39
31247000-10	2019	Rapamycin reduced phosphorylation of mTOR, and Ly-294,002 that of Akt.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	37-41
31247000-10	2019	Rapamycin reduced phosphorylation of mTOR, and Ly-294,002 that of Akt.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	66-69
31221957-6	2019	In this review, we focus on the molecular mechanisms regulating HIF-1alpha and aging-associated signaling proteins, such as sirtuins, AMP-activated protein kinase, mechanistic target of rapamycin complex 1, UNC-51-like kinase 1, and nuclear factor kappaB, and their roles in aging and aging-related diseases.	Sirolimus	186-195	hypoxia inducible factor 1 subunit alpha	Homo sapiens	64-74
31023527-8	2019	Our data therefore suggest that Oleate activated the ATF-2 via p38 kinase which inhibited the ULK1 via binding to ULK1 promoter, and eventually the rapamycin-induced autophagy was suppressed.	Sirolimus	148-157	activating transcription factor 2	Mus musculus	53-58
31312368-7	2019	This migration promotion was alleviated by the specific mTOR inhibitor rapamycin, indicating that the GSK3/mTOR signaling pathway was involved in this process.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	56-60
31312368-7	2019	This migration promotion was alleviated by the specific mTOR inhibitor rapamycin, indicating that the GSK3/mTOR signaling pathway was involved in this process.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31196153-8	2019	Rapamycin (a mTOR inhibitor, an autophagy activator) further down-regulated h/R-induced decrease of the phosphorylated PI3K, Akt and mTOR.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	125-128
31196153-8	2019	Rapamycin (a mTOR inhibitor, an autophagy activator) further down-regulated h/R-induced decrease of the phosphorylated PI3K, Akt and mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	133-137
31247083-1	2019	Purpose: To analyze the activity of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinases/mechanistic target of rapamycin (PI3K/mTOR) pathways in benign and malignant conjunctival melanocytic proliferations and explore whether specific inhibitors can suppress growth of conjunctival melanoma (CJM) cells.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	145-149
31354297-0	2019	Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	86-92
31354297-0	2019	Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.	Sirolimus	0-9	vascular endothelial growth factor C	Homo sapiens	105-111
31354297-3	2019	Rapamycin, an mTOR inhibitor, was reported to have anti-angiogenic and anti-lymphangiogenic properties.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31354297-9	2019	Results: The results showed that CD34(+) blood vessels and LYVE-1(+) lymphatic vessels decreased in the peritumor and intratumor region in rapamycin-treated tumors.	Sirolimus	139-148	CD34 molecule	Homo sapiens	33-37
31354297-12	2019	Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	111-115
31354297-12	2019	Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.	Sirolimus	27-36	vascular endothelial growth factor A	Homo sapiens	181-187
31354297-12	2019	Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.	Sirolimus	27-36	vascular endothelial growth factor C	Homo sapiens	200-206
31244838-12	2019	The mTOR inhibitor rapamycin restored pro-IL-1beta protein levels as well as LPS/ATP-induced IL-1beta release from serum starved cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
31244838-12	2019	The mTOR inhibitor rapamycin restored pro-IL-1beta protein levels as well as LPS/ATP-induced IL-1beta release from serum starved cells.	Sirolimus	19-28	interleukin 1 beta	Homo sapiens	38-50
31244838-12	2019	The mTOR inhibitor rapamycin restored pro-IL-1beta protein levels as well as LPS/ATP-induced IL-1beta release from serum starved cells.	Sirolimus	19-28	interleukin 1 beta	Homo sapiens	42-50
31171801-7	2019	Overall, we suggest that rapamycin induces transcriptional activation of BDSCs towards osteogenic differentiation, through increased GATA4 and Sox17 that modulate downstream transcription factors (like Runx2), critical for bone formation.	Sirolimus	25-34	RUNX family transcription factor 2	Homo sapiens	202-207
31236308-7	2019	Furthermore, studies demonstrated the efficacy of the mammalian target of rapamycin (mTOR) inhibitor sirolimus for these lymphatic diseases.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	54-83
31236308-7	2019	Furthermore, studies demonstrated the efficacy of the mammalian target of rapamycin (mTOR) inhibitor sirolimus for these lymphatic diseases.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	85-89
31174699-4	2019	Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis.	Sirolimus	44-53	interleukin 1 beta	Mus musculus	180-197
31041622-13	2019	Rapamycin and NAC, which impact on the MTOR pathway, both reduced both pools of progerin without increasing prelamin A in HGPS cell nuclei.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	39-43
31174699-4	2019	Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis.	Sirolimus	44-53	interleukin 1 beta	Mus musculus	199-207
31174699-4	2019	Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis.	Sirolimus	44-53	tumor necrosis factor	Mus musculus	210-237
31174699-4	2019	Here, results showed that pretreatment with rapamycin reduced the pyroptosis of peritoneal macrophages stimulated by cecal contents and the release of inflammatory factors such as interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha); In septic mice, rapamycin treatment decreased the activation of inflammasome in lung, and alleviated the pathological injuries in lung, liver and spleen tissues during acute stage of sepsis.	Sirolimus	44-53	tumor necrosis factor	Mus musculus	239-248
31120393-4	2019	Notably, targeting metabolism such as the mTOR by rapamycin, hexokinase by 2-deoxy-D-glucose, AMP-activated protein kinase by metformin, may be used to ameliorate autoimmune inflammation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	42-46
30838516-2	2019	This study aims to describe the IGF pathway in ACC and to explore the response to the combined treatment with the IGF1R/IR inhibitor linsitinib, and mTOR inhibitors (sirolimus and everolimus) in in vitro models of ACC.	Sirolimus	166-175	mechanistic target of rapamycin kinase	Homo sapiens	149-153
31125447-3	2019	Here, we further examined whether hypervascularization occurs in animal models of global and focal MCD with and without seizures, and whether it is sensitive to the mTOR blocker, rapamycin, that is approved for epilepsy treatment in tuberous sclerosis complex.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	165-169
31049797-5	2019	Rapamycin, an inhibitor of mTOR activity, can reverse the effect of DPSCs stimulated by IGF-1.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
30954259-2	2019	We tested the hypothesis that RPM could increase abundance of genes and proteins related to glutathione (GSH) metabolism and the antioxidant transcription factor nuclear factor erythroid 2-like 2 (NFE2L2) in subcutaneous adipose tissue.	Sirolimus	30-33	NFE2 like bZIP transcription factor 2	Bos taurus	162-195
30954259-2	2019	We tested the hypothesis that RPM could increase abundance of genes and proteins related to glutathione (GSH) metabolism and the antioxidant transcription factor nuclear factor erythroid 2-like 2 (NFE2L2) in subcutaneous adipose tissue.	Sirolimus	30-33	NFE2 like bZIP transcription factor 2	Bos taurus	197-203
31049797-5	2019	Rapamycin, an inhibitor of mTOR activity, can reverse the effect of DPSCs stimulated by IGF-1.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	88-93
30825612-9	2019	A higher compensatory increase in Akt phosphorylation after rapamycin treatment of LKB1-deficient cells than after rapamycin treatment of LKB1 wild-type cells is responsible for the synergistic effect of mTOR and PI3K inhibition.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	204-208
31026345-1	2019	KEY POINTS: In muscular cells, eukaryotic initiation factor subunit f (eIF3f) activates protein synthesis by allowing physical interaction between mechanistic target of rapamycin complex 1 (MTORC1) and ribosomal protein S6 kinase 1 (S6K1), although its physiological role in animals is unknown.	Sirolimus	169-178	origin recognition complex, subunit 1	Mus musculus	190-196
30825612-9	2019	A higher compensatory increase in Akt phosphorylation after rapamycin treatment of LKB1-deficient cells than after rapamycin treatment of LKB1 wild-type cells is responsible for the synergistic effect of mTOR and PI3K inhibition.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	204-208
30877063-9	2019	In contrast, sirolimus, temsirolimus, and everolimus are larger molecules (MW   1000) that bind to FKBP-12 to generate a complex that inhibits mTOR (mammalian target of rapamycin).	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	143-147
30793789-0	2019	The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	18-22
31124053-1	2019	BACKGROUND: It has been 15 years since sirolimus, an mTOR inhibitor, received Food and Drug Administration approval to prevent acute rejection in kidney transplantation, and 8 years since its analog everolimus acquired the same status.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	53-57
31124053-4	2019	AIMS: The aims of this study were to describe our center"s experience with sirolimus and everolimus in managing rare pediatric conditions for which mTOR inhibitors have been reported as a therapeutic option, although without conclusive approval from regulatory agencies, and to evaluate safety and tolerability of the treatment at the prescribed doses.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	148-152
31130397-6	2019	Given the absence of worrisome feature, we ruled out surgery and decided to initiate treatment with Sirolimus, an mTOR inhibitor.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	114-118
30877063-9	2019	In contrast, sirolimus, temsirolimus, and everolimus are larger molecules (MW   1000) that bind to FKBP-12 to generate a complex that inhibits mTOR (mammalian target of rapamycin).	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	149-178
31113850-5	2019	We further delineated the signaling pathways involved and showed that TGF-beta1-induced ATF4 production depended on cooperation between canonical TGF-beta1 signaling through Smad3 and activation of mechanistic target of rapamycin complex 1 (mTORC1) and its downstream target eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1).	Sirolimus	220-229	transforming growth factor beta 1	Homo sapiens	70-79
31012209-1	2019	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a potent immunosuppressant that is increasingly used in prevention and treatment of graft-vs-host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) patients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
31012209-1	2019	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, is a potent immunosuppressant that is increasingly used in prevention and treatment of graft-vs-host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) patients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
30840341-0	2019	Rapamycin Induced Autophagy Inhibits Inflammation-Mediated Endplate Degeneration by Enhancing Nrf2/Keap1 Signaling of Cartilage Endplate Stem Cells.	Sirolimus	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
30840341-4	2019	We found that the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) increased the level of intracellular reactive oxygen species (ROS) and caused cell senescence and osteogenic differentiation of cartilage endplate stem cells (CESCs), whereas rapamycin-induced autophagy protected CESCs from TNF-alpha-induced oxidative stress and cell senescence.	Sirolimus	255-264	tumor necrosis factor	Mus musculus	40-67
30840341-4	2019	We found that the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) increased the level of intracellular reactive oxygen species (ROS) and caused cell senescence and osteogenic differentiation of cartilage endplate stem cells (CESCs), whereas rapamycin-induced autophagy protected CESCs from TNF-alpha-induced oxidative stress and cell senescence.	Sirolimus	255-264	tumor necrosis factor	Mus musculus	69-78
30840341-6	2019	Further study revealed that autophagy activated by rapamycin or inhibited by chloroquine influenced the expression and nuclear translocation of Nrf2, thereby controlling the expression of antioxidant proteins and the scavenging of ROS.	Sirolimus	51-60	nuclear factor, erythroid derived 2, like 2	Mus musculus	144-148
30840341-7	2019	Taken together, the results indicate that rapamycin-induced autophagy enhances Nrf2/Keap1 signaling and promotes the expression of antioxidant proteins, thereby eliminating ROS, alleviating cell senescence, reducing the osteogenic differentiation of CESCs, and ultimately protecting CEPs from chronic inflammation-induced degeneration.	Sirolimus	42-51	nuclear factor, erythroid derived 2, like 2	Mus musculus	79-83
31367538-2	2019	Preclinical studies showed promising synergistic effects when the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	66-95
31367538-2	2019	Preclinical studies showed promising synergistic effects when the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	97-101
31312666-8	2019	Interestingly, we observed that mTORC1 inhibition with rapamycin improved myogenic and chondrogenic differentiation and reduced levels of apoptosis and senescence in Zmpste24 -/- MDSPCs.	Sirolimus	55-64	zinc metallopeptidase, STE24	Mus musculus	166-174
31191530-7	2019	Our recent data suggest that Rapamycin treatment during TCP manufacture, conferring partial inhibition of mTOR, might improve its composition.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	106-110
31191530-9	2019	Using cytomegalovirus (CMV) as model, our next-generation Rapamycin-treated (Rapa-)TCP showed consistently increased proportions of CD4+ T-cells as well as CD4+ and CD8+ central-memory T-cells (TCM).	Sirolimus	58-67	CD4 molecule	Homo sapiens	132-135
31191530-9	2019	Using cytomegalovirus (CMV) as model, our next-generation Rapamycin-treated (Rapa-)TCP showed consistently increased proportions of CD4+ T-cells as well as CD4+ and CD8+ central-memory T-cells (TCM).	Sirolimus	58-67	CD4 molecule	Homo sapiens	156-159
31136303-4	2019	It is instead retarded by rapamycin, the potent inhibitor of the mTOR complex which governs many pathways relating to cellular metabolism.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	65-69
31091245-8	2019	Further studies indicated that pretreatment with the Akt inhibitor GSK690693 or the mTOR inhibitor rapamycin promoted Rk3-induced apoptosis and autophagy, demonstrating that the PI3K/Akt/mTOR pathway is related to Rk3-induced apoptosis and autophagy.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	84-88
30703503-0	2019	Functional Effects of Cuprizone-Induced Demyelination in the Presence of the mTOR-Inhibitor Rapamycin.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	77-81
30703503-5	2019	Thus, in an effort to inhibit spontaneous remyelination, the mTOR inhibitor rapamycin has been administered during cuprizone diet.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	61-65
31092879-5	2019	Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2).	Sirolimus	173-182	AKT serine/threonine kinase 1	Homo sapiens	57-60
31092879-6	2019	Impaired activation of Akt increased mRNA expression of the muscle atrophy F-Box (MAFbx), decreased activation of the mammalian Target of Rapamycin Complex 1 (mTORC1) and stimulated apoptosis by impairing the Ser9 phosphorylation of glycogen synthase kinase 3beta.	Sirolimus	138-147	AKT serine/threonine kinase 1	Homo sapiens	23-26
31091245-8	2019	Further studies indicated that pretreatment with the Akt inhibitor GSK690693 or the mTOR inhibitor rapamycin promoted Rk3-induced apoptosis and autophagy, demonstrating that the PI3K/Akt/mTOR pathway is related to Rk3-induced apoptosis and autophagy.	Sirolimus	99-108	AKT serine/threonine kinase 1	Homo sapiens	183-186
31091245-8	2019	Further studies indicated that pretreatment with the Akt inhibitor GSK690693 or the mTOR inhibitor rapamycin promoted Rk3-induced apoptosis and autophagy, demonstrating that the PI3K/Akt/mTOR pathway is related to Rk3-induced apoptosis and autophagy.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	187-191
30904162-0	2019	Rapamycin attenuates a murine model of thoracic aortic aneurysm by downregulating the miR-126-3p mediated activation of MAPK/ERK signalling pathway.	Sirolimus	0-9	mitogen-activated protein kinase 1	Mus musculus	120-124
31133985-0	2019	Polycystin-2 Is Required for Starvation- and Rapamycin-Induced Atrophy in Myotubes.	Sirolimus	45-54	polycystin 2, transient receptor potential cation channel	Homo sapiens	0-12
31133985-5	2019	Here, we show that PC2 is required for the induction of atrophy in C2C12 myotubes caused by nutrient deprivation or rapamycin exposure.	Sirolimus	116-125	polycystin 2, transient receptor potential cation channel	Homo sapiens	19-22
30904162-0	2019	Rapamycin attenuates a murine model of thoracic aortic aneurysm by downregulating the miR-126-3p mediated activation of MAPK/ERK signalling pathway.	Sirolimus	0-9	mitogen-activated protein kinase 1	Mus musculus	125-128
30989721-2	2019	Conversely, mechanistic target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) have been suggested to reduce recurrence rates and improve survival in this patient group.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	12-43
31010692-11	2019	However, a search of more effective way to target mTOR has generated a third generation inhibitor of mTOR, "Rapalink", that bivalently combines rapamycin with an ATP-binding inhibitor, which effectively abolishes the mTORC1 activity.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	50-54
31010692-11	2019	However, a search of more effective way to target mTOR has generated a third generation inhibitor of mTOR, "Rapalink", that bivalently combines rapamycin with an ATP-binding inhibitor, which effectively abolishes the mTORC1 activity.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	101-105
30989721-2	2019	Conversely, mechanistic target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) have been suggested to reduce recurrence rates and improve survival in this patient group.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	45-49
30879817-16	2019	Enhanced RPM supply upregulated overall protein abundance of solute carrier family 1 member 3, p-mTOR, and ribosomal protein S6.	Sirolimus	9-12	solute carrier family 1 member 3	Bos taurus	61-93
30814053-10	2019	By inhibiting mTOR signalling with metformin or rapamycin, a reduction of cell death and release of inflammatory mediators was observed.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30724000-3	2019	Sirolimus is a mTOR pathway inhibitor, and has been tried successfully in the treatment of various vascular anomalies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-19
30794430-7	2019	Moreover, inhibiting the mammalian target of rapamycin (mTOR) complex 1, an important downstream effector of PI3K-Akt, by short-term application of rapamycin attenuated the effects of M1 receptors on GluA1.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	56-60
30794430-7	2019	Moreover, inhibiting the mammalian target of rapamycin (mTOR) complex 1, an important downstream effector of PI3K-Akt, by short-term application of rapamycin attenuated the effects of M1 receptors on GluA1.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	114-117
30270358-0	2019	Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.	Sirolimus	32-41	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	49-55
30270358-3	2019	As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	3-7
30270358-3	2019	As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
30911930-0	2019	mTOR inhibitor sirolimus negatively impacts in vitro fertilization outcomes.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
30670777-6	2019	Rapamycin, a lactate transport blocker and metformin were used as modulators of the Akt-mTOR pathway and cell metabolism.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	84-87
31151763-7	2019	Treatment with the mTOR signaling pathway inhibitor, rapamycin, inhibited the phosphorylation of mTOR and AKT, decreased Snail and Vimentin protein levels, and increased VE-cad protein levels.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	19-23
31151763-7	2019	Treatment with the mTOR signaling pathway inhibitor, rapamycin, inhibited the phosphorylation of mTOR and AKT, decreased Snail and Vimentin protein levels, and increased VE-cad protein levels.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	97-101
31151763-7	2019	Treatment with the mTOR signaling pathway inhibitor, rapamycin, inhibited the phosphorylation of mTOR and AKT, decreased Snail and Vimentin protein levels, and increased VE-cad protein levels.	Sirolimus	53-62	AKT serine/threonine kinase 1	Homo sapiens	106-109
31151763-7	2019	Treatment with the mTOR signaling pathway inhibitor, rapamycin, inhibited the phosphorylation of mTOR and AKT, decreased Snail and Vimentin protein levels, and increased VE-cad protein levels.	Sirolimus	53-62	snail family transcriptional repressor 1	Homo sapiens	121-126
30647455-6	2019	Activation of autophagy by rapamycin noticeably reduced the AGR2 protein in cells and in the mouse tissue samples administrated with bortezomib.	Sirolimus	27-36	anterior gradient 2	Mus musculus	60-64
30670777-6	2019	Rapamycin, a lactate transport blocker and metformin were used as modulators of the Akt-mTOR pathway and cell metabolism.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
30614215-3	2019	EBV utilizes the mammalian target of rapamycin (mTOR) pathway for tumor growth, and sirolimus, a mTOR inhibitor, has shown to result in a short-term response.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	17-46
30614215-3	2019	EBV utilizes the mammalian target of rapamycin (mTOR) pathway for tumor growth, and sirolimus, a mTOR inhibitor, has shown to result in a short-term response.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	97-101
31005720-11	2019	And pharmacological inhibitor of mTOR, rapamycin could antagonize the effects of allicin on Ang II-induced cardiac hypertrophy and autophagy.	Sirolimus	39-48	angiotensinogen	Rattus norvegicus	92-98
30838711-6	2019	LY294002 and rapamycin were added to inhibit the PI3K/AKT pathway and mTOR pathway, respectively.	Sirolimus	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	54-57
31183237-2	2019	Sirolimus, an inhibitor of the mammalian target of rapamycin, is effective against vascular anomalies with few severe adverse drug reactions.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-60
30828862-3	2019	This case demonstrates the efficacy of topical sirolimus in the management of neurofibromas in NF1.	Sirolimus	47-56	neurofibromin 1	Homo sapiens	95-98
30873702-9	2019	Meanwhile, repression of mTOR by rapamycin promoted autophagy and AIM2/caspase-1 activation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	25-29
30873702-9	2019	Meanwhile, repression of mTOR by rapamycin promoted autophagy and AIM2/caspase-1 activation.	Sirolimus	33-42	absent in melanoma 2	Homo sapiens	66-70
30873702-9	2019	Meanwhile, repression of mTOR by rapamycin promoted autophagy and AIM2/caspase-1 activation.	Sirolimus	33-42	caspase 1	Homo sapiens	71-80
31113922-8	2019	Rapamycin, histone deacetylase inhibitor MS-275, and rabdosia are effective in drug-resistant NSCLC patients with FBXW7 mutation.	Sirolimus	0-9	F-box and WD repeat domain containing 7	Homo sapiens	114-119
30860477-10	2019	In one approach, drugs can be targeted at known patient dysfunctional processes such as in the case of patients carrying autophagy-related genetic polymorphisms being treated with rapamycin, a drug that inhibits mTOR inhibitor and enhances autophagy.	Sirolimus	180-189	mechanistic target of rapamycin kinase	Homo sapiens	212-216
30923227-11	2019	Furthermore, CB2R dysfunction significantly attenuated the cardiac protective effects of rapamycin both in vivo and in vitro Finally, we found that CB2R-mediated autophagy was induced by AMPK-mTOR-p70S6K signaling pathway.	Sirolimus	89-98	cannabinoid receptor 2 (macrophage)	Mus musculus	13-17
30923227-11	2019	Furthermore, CB2R dysfunction significantly attenuated the cardiac protective effects of rapamycin both in vivo and in vitro Finally, we found that CB2R-mediated autophagy was induced by AMPK-mTOR-p70S6K signaling pathway.	Sirolimus	89-98	cannabinoid receptor 2 (macrophage)	Mus musculus	148-152
30923227-11	2019	Furthermore, CB2R dysfunction significantly attenuated the cardiac protective effects of rapamycin both in vivo and in vitro Finally, we found that CB2R-mediated autophagy was induced by AMPK-mTOR-p70S6K signaling pathway.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	192-196
30846465-9	2019	Baseline serum vascular endothelial growth factor (VEGF)-D &gt;600 pg mL-1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus.	Sirolimus	181-190	vascular endothelial growth factor A	Homo sapiens	15-49
30867239-5	2019	Using supraphysiological stimulation of 4-1BB in the boost phase of a prime-boost immunization, we show that the effect of 4-1BB on Trm generation requires local delivery of both Ag and costimulation, is inhibited by rapamycin treatment during secondary CD8 effector T cell expansion, and is dependent on the signaling adaptor TRAF1.	Sirolimus	217-226	TNF receptor associated factor 1	Homo sapiens	327-332
30976008-6	2019	MTOR inhibition by rapamycin equalizes cytokine production in CBMPhi and PBMPhi.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
30846465-9	2019	Baseline serum vascular endothelial growth factor (VEGF)-D &gt;600 pg mL-1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus.	Sirolimus	181-190	vascular endothelial growth factor A	Homo sapiens	51-55
30747999-8	2019	Western blot for phosphorylated-S6 (pS6) and phosphorylated S6K confirmed that rapamycin inhibited the mTOR pathway, whereas curcumin only lowered pS6 expression at one phosphorylation site.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	103-107
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	TSC complex subunit 1	Homo sapiens	7-15
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	TSC complex subunit 1	Homo sapiens	137-145
30747999-9	2019	Real-time quantitative polymerase chain reaction results indicated a trend toward lower expression of inflammatory markers IL-1beta and IL-6 and transforming growth factor beta after 3 weeks of treatment with rapamycin and curcumin compared to vehicle.	Sirolimus	209-218	interleukin 1 beta	Homo sapiens	123-131
30747999-9	2019	Real-time quantitative polymerase chain reaction results indicated a trend toward lower expression of inflammatory markers IL-1beta and IL-6 and transforming growth factor beta after 3 weeks of treatment with rapamycin and curcumin compared to vehicle.	Sirolimus	209-218	interleukin 6	Homo sapiens	136-140
30552782-6	2019	Blockage of mTOR by rapamycin or inhibition of glutaminolysis abolished the discrepancy in tumorigenic capacity between SIRT4-depleted hepatoma cells and control cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	12-16
30746902-5	2019	Gly-HDL-induced apoptosis, PERK phosphorylation and CHOP up-regulation were suppressed by rapamycin (an autophagy inducer), whereas aggravated by 3-methyladenine (an autophagy inhibitor) and beclin-1 siRNA.	Sirolimus	90-99	DNA damage inducible transcript 3	Homo sapiens	52-56
30506571-3	2019	Exposure of primary mouse hepatocytes and HepG2 cells to the CB1 R agonist arachidonyl-2"-chloroethylamide inhibited the expression of Sirtuin-1 (Sirt1) and Rictor, a component of mechanistic target of rapamycin complex 2 (mTORC2) and suppressed insulin-induced Akt phosphorylation at serine 473.	Sirolimus	202-211	cannabinoid receptor 1	Homo sapiens	61-66
30170123-1	2019	BACKGROUND: Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor kappaB, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1.	Sirolimus	250-259	caspase recruitment domain family member 11	Homo sapiens	12-56
30170123-1	2019	BACKGROUND: Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor kappaB, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1.	Sirolimus	250-259	caspase recruitment domain family member 11	Homo sapiens	58-64
30317677-10	2019	Preconditioning with mTOR antagonist rapamycin engendered not only mTOR inhibition but also abrogated GAS5-mediated depression in cisplatin-evoked autophagy.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	21-25
30317677-10	2019	Preconditioning with mTOR antagonist rapamycin engendered not only mTOR inhibition but also abrogated GAS5-mediated depression in cisplatin-evoked autophagy.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	67-71
30320900-8	2019	This study provides theoretical support to the therapeutic evaluation of RAPA and MCC950 to make the mammalian targets of RAPA and NLRP3 the therapeutic targets of MS.	Sirolimus	73-77	NLR family pyrin domain containing 3	Homo sapiens	131-136
30746902-6	2019	Administration of diabetic apoE-/- mice with rapamycin attenuated MOMA-2 and CHOP up-regulation and apoptosis in atherosclerotic lesions.	Sirolimus	45-54	apolipoprotein E	Mus musculus	27-31
30144378-10	2019	Consistently, the inhibition of mTOR by rapamycin also sensitized cells to cisplatin, and the effects of cisplatin plus rapamycin were identical to those obtained with cisplatin plus ADP.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	32-36
30918504-4	2019	Heterologous expressing VdFKBP12 in Arabidopsis conferred rapamycin sensitivity, indicating that VdFKBP12 can bridge the interaction between rapamycin and TOR across species.	Sirolimus	58-67	target of rapamycin	Arabidopsis thaliana	155-158
30632514-0	2019	Neuroprotective effects of rapamycin on spinal cord injury in rats by increasing autophagy and Akt signaling.	Sirolimus	27-36	AKT serine/threonine kinase 1	Rattus norvegicus	95-98
30632514-1	2019	Rapamycin treatment has been shown to increase autophagy activity and activate Akt phosphorylation, suppressing apoptosis in several models of ischemia reperfusion injury.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	79-82
30632514-3	2019	We hypothesized that both effects of rapamycin, the increased autophagy activity and Akt signaling, would contribute to its neuroprotective properties.	Sirolimus	37-46	AKT serine/threonine kinase 1	Rattus norvegicus	85-88
30632514-8	2019	Rapamycin prevented the decrease of bcl-2 expression in injured spinal cord tissue, reduced Bax, cytochrome c and caspase-3 expression levels and reduced the number of apoptotic neurons in injured spinal cord tissue 24 hours after spinal cord injury.	Sirolimus	0-9	BCL2, apoptosis regulator	Rattus norvegicus	36-41
30632514-9	2019	3-Methyladenine and Akt inhibitor IV intervention suppressed the expression of Beclin-1 and phosphorylated-Akt in injured spinal cord tissue and reduced the protective effect of rapamycin on apoptotic neurons.	Sirolimus	178-187	AKT serine/threonine kinase 1	Rattus norvegicus	20-23
31019827-3	2019	Sirolimus, an inhibitor of the mammalian target of rapamycin, is a relatively new medical therapy for the treatment of vascular malformations.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-60
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	sclerostin	Homo sapiens	95-105
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	sclerostin	Homo sapiens	107-111
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	bone gamma-carboxyglutamate protein	Homo sapiens	114-125
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	bone gamma-carboxyglutamate protein	Homo sapiens	127-129
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	interleukin 1 beta	Homo sapiens	174-192
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	interleukin 1 beta	Homo sapiens	194-202
30972187-8	2019	Furthermore, combined inhibition of FGFR and mTOR pathways by BGJ398 and Rapamycin induced remarkable cell cycle arrest and apoptosis in OC cells.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	45-49
31182914-0	2019	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.	Sirolimus	51-60	serum/glucocorticoid regulated kinase 3	Mus musculus	23-27
31182914-0	2019	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.	Sirolimus	51-60	thymoma viral proto-oncogene 1	Mus musculus	32-35
31182914-7	2019	Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo.	Sirolimus	123-132	serum/glucocorticoid regulated kinase 3	Mus musculus	10-14
31182914-7	2019	Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo.	Sirolimus	123-132	thymoma viral proto-oncogene 1	Mus musculus	44-47
31182914-7	2019	Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo.	Sirolimus	157-166	serum/glucocorticoid regulated kinase 3	Mus musculus	10-14
31182914-7	2019	Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo.	Sirolimus	157-166	thymoma viral proto-oncogene 1	Mus musculus	44-47
31182914-8	2019	Mechanistically, the feedback activation of SGK3 by rapamycin was dependent on hVps34 and mTORC2, and reactivated mTORC1/4EBP1 axis by phosphorylating TSC2.	Sirolimus	52-61	serum/glucocorticoid regulated kinase 3	Mus musculus	44-48
30843885-7	2019	Treatment with angiotensin-converting enzyme inhibitors was reported by approximately 15% of patients and was significantly associated with a slower rate of decline in percentage predicted forced expiratory volume (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) in patients not treated with sirolimus.	Sirolimus	313-322	angiotensin I converting enzyme	Homo sapiens	15-44
31182914-9	2019	Collectively, our study reveals a critical role of SGK3 in mediating rapamycin resistance, and provides a rationale for targeting SGK3 to improve mTOR-targeted therapies.	Sirolimus	69-78	serum/glucocorticoid regulated kinase 3	Mus musculus	51-55
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	176-185	nuclear factor kappa B subunit 1	Homo sapiens	96-105
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	187-191	nuclear factor kappa B subunit 1	Homo sapiens	96-105
30321448-4	2019	Echocardiography, hematoxylin-eosin staining, plasma brain natriuretic peptide, myocardial cells apoptosis, and Akt activation in rapamycin-treated rats were detected.	Sirolimus	130-139	AKT serine/threonine kinase 1	Rattus norvegicus	112-115
30242894-7	2019	Our study demonstrated that rapamycin decreased the protective effects of HGF on the endothelium by decreasing tight junction protein occludin expression and cell proliferation, and raising lipopolysaccharide (LPS)-induced endothelial permeability, endothelial cell injury factors ET-1 and vWF.	Sirolimus	28-37	von Willebrand factor	Homo sapiens	290-293
30242894-10	2019	Reversely, rapamycin or S3I-201 inhibited mTOR/STAT-3 activation.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	42-46
30242894-10	2019	Reversely, rapamycin or S3I-201 inhibited mTOR/STAT-3 activation.	Sirolimus	11-20	signal transducer and activator of transcription 3	Homo sapiens	47-53
31128031-0	2019	A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.	Sirolimus	28-37	AKT serine/threonine kinase 1	Homo sapiens	117-120
31128031-0	2019	A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	121-125
31128031-1	2019	PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro.	Sirolimus	35-44	AKT serine/threonine kinase 1	Homo sapiens	181-184
31128031-1	2019	PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	186-215
31128031-1	2019	PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	217-221
31128031-7	2019	3: Rapamycin combined with cisplatin could inhibit the expressions of PI3K, AKT and phosphorylated mTOR (p-mTOR) in pancreatic cancer cells (p<0.05).	Sirolimus	3-12	AKT serine/threonine kinase 1	Homo sapiens	76-79
31128031-7	2019	3: Rapamycin combined with cisplatin could inhibit the expressions of PI3K, AKT and phosphorylated mTOR (p-mTOR) in pancreatic cancer cells (p<0.05).	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	99-103
31128031-7	2019	3: Rapamycin combined with cisplatin could inhibit the expressions of PI3K, AKT and phosphorylated mTOR (p-mTOR) in pancreatic cancer cells (p<0.05).	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	107-111
31128031-8	2019	CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin.	Sirolimus	12-21	AKT serine/threonine kinase 1	Homo sapiens	65-68
31128031-8	2019	CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	69-73
31128031-8	2019	CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin.	Sirolimus	173-182	AKT serine/threonine kinase 1	Homo sapiens	65-68
31128031-8	2019	CONCLUSION: Rapamycin combined with cisplatin can alter the PI3K/AKT/mTOR signal transduction pathway which leads to markedly increased cell apoptosis rate, indicating that rapamycin can mediate the sensitivity of pancreatic cancer cells to cisplatin.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	69-73
30321448-8	2019	Myocardial cells apoptotic percentage, Akt expression, and pathological changes of the myocardium in HF rats were inhibited by rapamycin administration.	Sirolimus	127-136	AKT serine/threonine kinase 1	Rattus norvegicus	39-42
30455224-1	2019	Tuberous sclerosis complex (TSC) is a rare disease that causes multisystem benign neoplasm, induced by dysregulation of the mammalian target of the rapamycin pathway (mTOR).	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	167-171
30664164-6	2019	In addition, suppression of the PI3K/AKT pathway using LY294002 or rapamycin counteracted the protective effects of ABCG2 against chemotherapeutic drug treatment.	Sirolimus	67-76	AKT serine/threonine kinase 1	Homo sapiens	37-40
30690083-6	2019	KEY FINDINGS: Rapamycin promoted autophagy and the X protein synthesis concomitantly with elevation in Akt phosphorylation and Beclin1 expression.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	103-106
30747221-11	2019	ER-positive breast cancer cells exhibiting low BAG-1 expression appeared to be more sensitive to treatment with the mTOR inhibitor rapamycin.	Sirolimus	131-140	BAG cochaperone 1	Homo sapiens	47-52
30664164-6	2019	In addition, suppression of the PI3K/AKT pathway using LY294002 or rapamycin counteracted the protective effects of ABCG2 against chemotherapeutic drug treatment.	Sirolimus	67-76	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	116-121
30747221-11	2019	ER-positive breast cancer cells exhibiting low BAG-1 expression appeared to be more sensitive to treatment with the mTOR inhibitor rapamycin.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	116-120
30863363-10	2019	Both palmitate and brefeldin induced PERK, CHOP and BiP gene expression, which was partially, but significantly prevented by rapamycin.	Sirolimus	125-134	DNA damage inducible transcript 3	Homo sapiens	43-47
29752013-1	2019	BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor used after organ transplantation and to treat vascular malformations.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	27-56
29752013-1	2019	BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor used after organ transplantation and to treat vascular malformations.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	58-62
30816216-2	2019	Dysregulation of mTOR signaling has been implicated in the pathogenesis of certain types of ASD, and inhibition of mTOR by rapamycin has been demonstrated to be an effective therapeutics for impaired social interaction in Tsc1+/-, Tsc2+/-, Pten-/- mice and valproic acid-induced ASD animal models.	Sirolimus	123-132	phosphatase and tensin homolog	Mus musculus	240-244
30863363-10	2019	Both palmitate and brefeldin induced PERK, CHOP and BiP gene expression, which was partially, but significantly prevented by rapamycin.	Sirolimus	125-134	growth differentiation factor 10	Homo sapiens	52-55
30863363-12	2019	Compared to untreated T2D cells, rapamycin-exposed diabetic islets showed improved insulin secretion, reduced proportion of beta cells showing signs of apoptosis and better preserved insulin granules, mitochondria and ER ultrastructure; this was associated with significant reduction of PERK, CHOP and BiP gene expression.	Sirolimus	33-42	insulin	Homo sapiens	83-90
30863363-12	2019	Compared to untreated T2D cells, rapamycin-exposed diabetic islets showed improved insulin secretion, reduced proportion of beta cells showing signs of apoptosis and better preserved insulin granules, mitochondria and ER ultrastructure; this was associated with significant reduction of PERK, CHOP and BiP gene expression.	Sirolimus	33-42	DNA damage inducible transcript 3	Homo sapiens	293-297
30863363-12	2019	Compared to untreated T2D cells, rapamycin-exposed diabetic islets showed improved insulin secretion, reduced proportion of beta cells showing signs of apoptosis and better preserved insulin granules, mitochondria and ER ultrastructure; this was associated with significant reduction of PERK, CHOP and BiP gene expression.	Sirolimus	33-42	growth differentiation factor 10	Homo sapiens	302-305
30842775-10	2019	Rapamycin reduced Gal-9-mediated secretion of IL-2 (4.4-fold, P = 0.001) and TNF (4-fold, P = 0.02) without impacting viral reactivation (16.8% compared to 16.1%; P = 0.2).	Sirolimus	0-9	galectin 9	Homo sapiens	18-23
30842775-10	2019	Rapamycin reduced Gal-9-mediated secretion of IL-2 (4.4-fold, P = 0.001) and TNF (4-fold, P = 0.02) without impacting viral reactivation (16.8% compared to 16.1%; P = 0.2).	Sirolimus	0-9	interleukin 2	Homo sapiens	46-50
30842775-10	2019	Rapamycin reduced Gal-9-mediated secretion of IL-2 (4.4-fold, P = 0.001) and TNF (4-fold, P = 0.02) without impacting viral reactivation (16.8% compared to 16.1%; P = 0.2).	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	77-80
30842775-13	2019	In addition, uncoupling Gal-9-mediated viral reactivation from undesirable pro-inflammatory effects, using rapamycin, may increase the potential utility of recombinant Gal-9 within the reversal of HIV latency eradication framework.	Sirolimus	107-116	galectin 9	Homo sapiens	24-29
30842775-13	2019	In addition, uncoupling Gal-9-mediated viral reactivation from undesirable pro-inflammatory effects, using rapamycin, may increase the potential utility of recombinant Gal-9 within the reversal of HIV latency eradication framework.	Sirolimus	107-116	galectin 9	Homo sapiens	168-173
30728291-2	2019	TSC is caused by inactivating mutations in the genes encoding TSC1/2, negative regulators of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	117-126	TSC complex subunit 1	Homo sapiens	0-3
30795552-4	2019	Mammalian (or mechanistic) target of rapamycin (mTOR) is a conserved serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase family (PIKK) and resides in two distinct signalling complexes named mTORC1, involved in mRNA translation and protein synthesis and mTORC2 that controls cell survival and migration.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	48-52
30782662-7	2019	MLN0128 inhibited phosphorylation of mTOR complex 1 and 2 targets, while rapamycin only partially inhibited mTOR complex 1 targets.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	108-112
30728291-2	2019	TSC is caused by inactivating mutations in the genes encoding TSC1/2, negative regulators of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	117-126	TSC complex subunit 1	Homo sapiens	62-68
30791416-6	2019	Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers" clearance.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	128-132
30420444-0	2019	Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30420444-1	2019	PURPOSE: We studied the impact of mTOR signaling inhibition with rapamycin in head and neck squamous cell carcinoma (HNSCC) in the neoadjuvant setting.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	34-38
30420444-13	2019	CONCLUSIONS: Rapamycin treatment was well tolerated, reduced mTOR signaling and tumor growth, and resulted in significant clinical responses despite the brief treatment duration, thus supporting the potential role of mTOR inhibitors in treatment regimens for HNSCC.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	61-65
30420444-13	2019	CONCLUSIONS: Rapamycin treatment was well tolerated, reduced mTOR signaling and tumor growth, and resulted in significant clinical responses despite the brief treatment duration, thus supporting the potential role of mTOR inhibitors in treatment regimens for HNSCC.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	217-221
30760308-0	2019	Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	23-27
30765891-7	2019	Cultured tissue slices were metabolically active and responsive to rapamycin, an mTOR inhibitor.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	81-85
30787878-2	2019	Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal models as well as in patients with both antiphospholipid syndrome and SLE.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	18-47
30739121-2	2019	More recently, tapering of calcineurin inhibitor-based immunotherapies with concurrent administration of the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been employed within pharmacological regimens designed to achieve better safety and efficacy for preservation of allograft kidney function.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	109-138
30739121-2	2019	More recently, tapering of calcineurin inhibitor-based immunotherapies with concurrent administration of the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been employed within pharmacological regimens designed to achieve better safety and efficacy for preservation of allograft kidney function.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Homo sapiens	140-144
30787878-2	2019	Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal models as well as in patients with both antiphospholipid syndrome and SLE.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	49-53
30462552-5	2019	Inhibition of mTOR through siRNA-mediated depletion or treatment with chemical inhibitors rapamycin or torin 1 suppressed VCAM1 transcription, which translated to inhibition of VCAM-1 surface expression by HAECs and concomitant decreased adhesion of monocytes.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30468013-2	2019	Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF-kappaB signalling.	Sirolimus	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	153-162
30468013-3	2019	However, it is unknown if rapamycin has beneficial effects in the context of compromised NF-kappaB signalling, such as that which occurs in several age-related chronic diseases.	Sirolimus	26-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
30462552-5	2019	Inhibition of mTOR through siRNA-mediated depletion or treatment with chemical inhibitors rapamycin or torin 1 suppressed VCAM1 transcription, which translated to inhibition of VCAM-1 surface expression by HAECs and concomitant decreased adhesion of monocytes.	Sirolimus	90-99	vascular cell adhesion molecule 1	Homo sapiens	122-127
30462552-5	2019	Inhibition of mTOR through siRNA-mediated depletion or treatment with chemical inhibitors rapamycin or torin 1 suppressed VCAM1 transcription, which translated to inhibition of VCAM-1 surface expression by HAECs and concomitant decreased adhesion of monocytes.	Sirolimus	90-99	vascular cell adhesion molecule 1	Homo sapiens	177-183
29486589-6	2019	Treatment with rapamycin promoted autophagy but inhibited oxidation, NLRP3 inflammasome, and lung fibrosis after bleomycin (BLM) infusion.	Sirolimus	15-24	NLR family pyrin domain containing 3	Homo sapiens	69-74
30711941-2	2019	In this study, we investigated the combined effect of the autophagy inhibitor chloroquine and the mTOR inhibitor rapamycin on MG63 osteosarcoma cells.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	98-102
30711941-4	2019	Effects of chloroquine and/or rapamycin on the mTOR pathway components, autophagy, and apoptosis were investigated by western blot, flow cytometry, and fluorescence microscopy using immunocytochemical staining of LC3 and Annexin V-FITC/propidium iodide.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	47-51
30711941-6	2019	Rapamycin promoted autophagy by blocking the mTOR pathway, and chloroquine enhanced apoptosis by blocking autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	45-49
30548896-3	2019	Sirolimus, an inhibitor of mammalian target of rapamycin, is used for immunosuppression in kidney transplantation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
30447474-12	2019	Importantly, blocking oxidative stress with VE or blocking Akt/mTOR with rapamycin mitigated the exacerbation of AITD and the suppression of normal autophagy.	Sirolimus	73-82	AKT serine/threonine kinase 1	Rattus norvegicus	59-62
31056947-4	2019	On the other hand, mTOR inhibitors, as rapamycin and/or its derivatives, restore corticosteroid sensitivity in peripheral blood mononuclear cells from chronic obstructive pulmonary disease (COPD) patients, and overexpression of mTOR suppresses cigarette smoke-induced inflammation and emphysema, suggesting that induction of mTOR expression/activity might be useful to treat COPD.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	19-23
31056947-4	2019	On the other hand, mTOR inhibitors, as rapamycin and/or its derivatives, restore corticosteroid sensitivity in peripheral blood mononuclear cells from chronic obstructive pulmonary disease (COPD) patients, and overexpression of mTOR suppresses cigarette smoke-induced inflammation and emphysema, suggesting that induction of mTOR expression/activity might be useful to treat COPD.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	228-232
31056947-4	2019	On the other hand, mTOR inhibitors, as rapamycin and/or its derivatives, restore corticosteroid sensitivity in peripheral blood mononuclear cells from chronic obstructive pulmonary disease (COPD) patients, and overexpression of mTOR suppresses cigarette smoke-induced inflammation and emphysema, suggesting that induction of mTOR expression/activity might be useful to treat COPD.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	228-232
29962282-0	2019	Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer"s disease lesion in hippocampus of rats with type 2 diabetes mellitus.	Sirolimus	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	33-37
30557824-0	2019	Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1beta and IL-18 production.	Sirolimus	0-9	interleukin 1 beta	Mus musculus	81-89
30557824-2	2019	However, it is not clear whether the mTOR specific inhibitor rapamycin can attenuate lipopolysaccharide (LPS)-induced ALI by modulating IL-1beta and IL-18 production.	Sirolimus	61-70	interleukin 1 beta	Mus musculus	136-144
30557824-3	2019	In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1beta and IL-18 secretion.	Sirolimus	29-38	interferon activated gene 208	Mus musculus	106-131
30557824-3	2019	In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1beta and IL-18 secretion.	Sirolimus	29-38	interleukin 1 beta	Mus musculus	162-170
29962282-3	2019	This study aims to investigate effects of rapamycin on AD in hippocampus of T2DM rat by AMPK/mTOR signaling pathway.	Sirolimus	42-51	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	88-92
29962282-8	2019	RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR.	Sirolimus	28-37	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	271-275
29962282-8	2019	RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR.	Sirolimus	28-37	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	298-302
29962282-9	2019	CONCLUSION: The study demonstrated that rapamycin reduces the risk of AD in T2DM rats and inhibits activation of AMPK-mTOR signaling pathway, thereby improving AD lesion in hippocampus of T2DM rats.	Sirolimus	40-49	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	113-117
30615938-0	2019	Rapamycin - mTOR + BRAF = ?	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	12-16
30489210-3	2019	Animal studies investigating the effect of rapamycin on mTOR inhibition following cerebral ischemia have shown conflicting results.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	56-60
30615938-0	2019	Rapamycin - mTOR + BRAF = ?	Sirolimus	0-9	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	19-23
30569107-8	2019	The antioxidant N-acetylcysteine, the phosphoinositide 3-kinase (PI3K)/AKT inhibitor LY294002 and the mTOR inhibitor rapamycin ameliorated the effects of high glucose.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	102-106
30623816-5	2019	mDC were pre-treated with rapamycin (mTOR-inhibitor), U0126, SP600125, SB202190 (MAPK kinase inhibitors), as well as dexamethasone (MAPK- and NFkappaB-inhibitor) and analyzed for MPLA-induced cytokine secretion and cell metabolic state.	Sirolimus	26-35	chemokine (C-C motif) ligand 22	Mus musculus	0-3
29405800-2	2019	Recently, pharmacologic inhibition of the mTOR pathway by sirolimus was reported as a safe and efficacious treatment option for lymphatic malformations (also known as lymphangiomas).	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	42-46
30336218-0	2019	Protective effect of rapamycin on endothelial-to-mesenchymal transition in HUVECs through the Notch signaling pathway.	Sirolimus	21-30	notch receptor 1	Homo sapiens	94-99
30336218-9	2019	Finally, consistently with the results from Notch inhibitor DAPT treatment, rapamycin suppressed the migration of HUVECs in vitro.	Sirolimus	76-85	notch receptor 1	Homo sapiens	44-49
30295407-1	2019	INTRODUCTION: Isavuconazole, a triazole antifungal, is an inhibitor of cytochrome P450 3A4, which also metabolizes tacrolimus and sirolimus.	Sirolimus	130-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-90
30336218-10	2019	Together, these findings indicate that rapamycin may function as an effective inhibitor of the EndMT in HUVECs by suppressing targeting the Notch signaling pathway.	Sirolimus	39-48	notch receptor 1	Homo sapiens	140-145
30692064-8	2019	High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta.	Sirolimus	10-19	interferon gamma	Mus musculus	65-74
30703123-8	2019	Despite all rapamycin-treated cells secreted significantly reduced levels of IL6, a major SASP cytokine, and expressed significantly higher levels of the pluripotency marker NANOG, the expression patterns of these markers were not correlated with the rapamycin-mediated increase in lifespan.	Sirolimus	12-21	interleukin 6	Homo sapiens	77-80
30692064-8	2019	High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta.	Sirolimus	10-19	interleukin 10	Mus musculus	136-141
30847392-5	2019	Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits the pathway downstream of PIK3CA.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-44
30682771-6	2019	Rapalogs, such as sirolimus and everolimus, partially inhibit mTOR complex 1 (mTORC1) and exhibit anti-cancer activity in vitro and in vivo in BTC.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	62-66
30723481-5	2018	Similar gene downregulation was observed when CD34+ cells were co-cultured with alloreactive T cells CD34+ cells for 48-72 h, and this effect was partially prevented by rapamycin and an anti-TNFalpha antibody.	Sirolimus	169-178	tumor necrosis factor	Mus musculus	191-199
30847392-5	2019	Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits the pathway downstream of PIK3CA.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	46-50
30847392-5	2019	Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor that inhibits the pathway downstream of PIK3CA.	Sirolimus	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	102-108
30581017-6	2019	Pharmacological intervention with the mTOR regulator rapamycin suppressed these defects.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	38-42
30602778-3	2019	Here we demonstrate that rapamycin-insensitive mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-beta1 stimulated collagen synthesis in human lung fibroblasts, whereas canonical PI3K/Akt signaling is not required.	Sirolimus	25-34	transforming growth factor beta 1	Homo sapiens	101-110
30621732-17	2019	Rapamycin may be an effective treatment for non-syndromic ASD in adolescent and adult patients who present impairments in the mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	126-130
30647914-3	2019	MTORC1 is activated in an interdependent manner by insulin/growth factors and nutrients, especially amino acids, and is inhibited by stressors such as hypoxia and by the drug rapamycin.	Sirolimus	175-184	insulin	Homo sapiens	51-58
30053339-8	2019	Four-train HFS (HFS x 4) induced rapamycin-sensitive long-LTP in Akt1-KO mice, but not Akt3-KO mice.	Sirolimus	33-42	thymoma viral proto-oncogene 1	Mus musculus	65-69
30904097-4	2019	Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	29-33
30904097-4	2019	Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered.	Sirolimus	161-170	TSC complex subunit 1	Homo sapiens	29-32
30904097-5	2019	Rapamycin, an mTORC1 inhibitor, is now the only pharmacological therapy approved for the treatment of TSC.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	102-105
30481554-3	2019	This in vivo study aimed to determine the potential role of the transcription factor STAT3 in the rapamycin-mediated neuroprotection in a mouse model of SAH.	Sirolimus	98-107	signal transducer and activator of transcription 3	Mus musculus	85-90
30414939-13	2019	In addition, ACSL4 inhibition and chemotherapeutic treatment combined with rapamycin-induced mTOR inhibition synergically inhibited proliferation and reduced ABCG2 expression in cells overexpressing ACSL4.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	93-97
30414939-13	2019	In addition, ACSL4 inhibition and chemotherapeutic treatment combined with rapamycin-induced mTOR inhibition synergically inhibited proliferation and reduced ABCG2 expression in cells overexpressing ACSL4.	Sirolimus	75-84	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	158-163
30414939-13	2019	In addition, ACSL4 inhibition and chemotherapeutic treatment combined with rapamycin-induced mTOR inhibition synergically inhibited proliferation and reduced ABCG2 expression in cells overexpressing ACSL4.	Sirolimus	75-84	acyl-CoA synthetase long chain family member 4	Homo sapiens	199-204
30481554-11	2019	We propose that rapamycin is a novel pharmacological strategy to target STAT3 activation, with a possible crosstalk through the ERK pathway, for the treatment of post-SAH early brain injury.	Sirolimus	16-25	mitogen-activated protein kinase 1	Mus musculus	128-131
30481554-10	2019	These data suggest that ERK and JAK/STAT3 pathways play an important role in the neurocardiac protection by rapamycin after SAH.	Sirolimus	108-117	mitogen-activated protein kinase 1	Mus musculus	24-27
30481554-10	2019	These data suggest that ERK and JAK/STAT3 pathways play an important role in the neurocardiac protection by rapamycin after SAH.	Sirolimus	108-117	signal transducer and activator of transcription 3	Mus musculus	36-41
30481554-11	2019	We propose that rapamycin is a novel pharmacological strategy to target STAT3 activation, with a possible crosstalk through the ERK pathway, for the treatment of post-SAH early brain injury.	Sirolimus	16-25	signal transducer and activator of transcription 3	Mus musculus	72-77
30651769-0	2019	The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	121-124
30858935-2	2019	Sirolimus inhibits mammalian target of rapamycin (mTOR) and its administration in past studies was hopeful in treatment of patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	19-48
30858935-2	2019	Sirolimus inhibits mammalian target of rapamycin (mTOR) and its administration in past studies was hopeful in treatment of patients with LAM.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	50-54
30651769-0	2019	The combination of NVP-BEZ235 and rapamycin regulates nasopharyngeal carcinoma cell viability and apoptosis via the PI3K/AKT/mTOR pathway.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	125-129
30387804-8	2019	Treatment of MDAH-2774 cells with the mTOR inhibitors resulted in the significant upregulation of DEPTOR mRNA, whereas treatment with rapamycin and BEZ-235 (100 nM) resulted in downregulation of the mTOR protein expression after 48 h of treatment.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	199-203
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	thymus cell antigen 1, theta	Mus musculus	145-149
30334673-7	2019	One such therapy already in use in transplant medicine is the mTOR inhibitor rapamycin.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	62-66
30373500-6	2019	However, ketamine-induced apoptosis in hippocampal neurons was reversed significantly by the administration of rapamycin, as evident by the decrease in expressions of pro-apoptotic proteins (Bax and cleaved Caspase-3) and the increase in anti-apoptotic protein (Bcl-2).	Sirolimus	111-120	BCL2, apoptosis regulator	Rattus norvegicus	262-267
29790114-9	2019	Ivabradine and rapamycin also decreased the expression of PI3K/Akt and mTOR induced by TAC.	Sirolimus	15-24	thymoma viral proto-oncogene 1	Mus musculus	63-66
30888659-6	2019	Resveratrol, rapamycin, metformin and aspirin, showing effectiveness in model organism life- and healthspan extension mainly target the master regulators of aging such as mTOR, FOXO and PGC1alpha, affecting autophagy, inflammation and oxidative stress.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	171-175
30483781-0	2019	Rapamycin-induced autophagy attenuates hormone-imbalance-induced chronic non-bacterial prostatitis in rats via the inhibition of NLRP3 inflammasome-mediated inflammation.	Sirolimus	0-9	NLR family, pyrin domain containing 3	Rattus norvegicus	129-134
30483781-9	2019	In addition, reductions in the number of autophagosomes and the expression levels of autophagy-associated, including microtubule-associated protein 1 light chain 3beta (LC3B) and Beclin 1, were also detected in the CNBP group; however, treatment with rapamycin reversed these effects.	Sirolimus	251-260	microtubule-associated protein 1 light chain 3 beta	Rattus norvegicus	117-167
30483781-10	2019	Collectively, the findings of the present study indicated that the NLRP3 inflammasome-mediated inflammatory response was activated by a hormonal imbalance in the prostate glands of rats; however, these effects may be suppressed via rapamycin-induced autophagy.	Sirolimus	232-241	NLR family, pyrin domain containing 3	Rattus norvegicus	67-72
30542717-5	2019	We demonstrated that rapamycin, an FDA-approved mammalian target of rapamycin (mTOR) inhibitor, enhanced the effects of endocrine therapy with tamoxifen, and the concentration of tamoxifen required for ER+ breast cancer cell growth inhibition was substantially reduced.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	48-77
30542717-5	2019	We demonstrated that rapamycin, an FDA-approved mammalian target of rapamycin (mTOR) inhibitor, enhanced the effects of endocrine therapy with tamoxifen, and the concentration of tamoxifen required for ER+ breast cancer cell growth inhibition was substantially reduced.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	79-83
30542717-9	2019	Taken together, the findings of this study indicate that combination therapy with rapamycin and tamoxifen underlying p73-mediated ERalpha expression may provide new insight into the drug combination for the treatment of ER+ breast cancer.	Sirolimus	82-91	estrogen receptor 1	Homo sapiens	130-137
31256869-11	2019	However, conversion to sirolimus did produce a significant decrease in the level of transforming growth factor beta cytokine, this level being closely associated with fibroadenomas.	Sirolimus	23-32	transforming growth factor beta 1	Homo sapiens	84-115
30888659-6	2019	Resveratrol, rapamycin, metformin and aspirin, showing effectiveness in model organism life- and healthspan extension mainly target the master regulators of aging such as mTOR, FOXO and PGC1alpha, affecting autophagy, inflammation and oxidative stress.	Sirolimus	13-22	PPARG coactivator 1 alpha	Homo sapiens	186-195
30297200-12	2018	Other agents such as tyrosine kinase inhibitors (imatinib and nilotinib) and mTOR inhibitors (sirolimus) may also cause eyelid edema.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	77-81
30594149-9	2018	Pro-apoptotic protein, Bcl-2 associated x (Bax), exhibited a slight, but significant decrease with rapamycin treatment, while its anti-apoptotic counterpart, B cell lymphoma-2 (Bcl-2), was to a similar degree upregulated.	Sirolimus	99-108	B cell leukemia/lymphoma 2	Mus musculus	23-28
30619313-0	2018	Selective Effects of mTOR Inhibitor Sirolimus on Naive and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	21-25
30619313-2	2018	However, recent clinical observations indicate that mammalian target of rapamycin (mTOR) inhibition with sirolimus may improve the outcome of CMV complications.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	52-81
30619313-2	2018	However, recent clinical observations indicate that mammalian target of rapamycin (mTOR) inhibition with sirolimus may improve the outcome of CMV complications.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	83-87
30584274-9	2018	Curcumin and rapamycin treatment inhibited the increased levels of proinflammatory cytokines including IL-1beta, TNF-alpha, MMP-1, and MMP-3 in CIA rats.	Sirolimus	13-22	interleukin 1 beta	Rattus norvegicus	103-111
30584274-9	2018	Curcumin and rapamycin treatment inhibited the increased levels of proinflammatory cytokines including IL-1beta, TNF-alpha, MMP-1, and MMP-3 in CIA rats.	Sirolimus	13-22	tumor necrosis factor	Rattus norvegicus	113-122
30095976-9	2018	Together, these data demonstrate that PD-1/PD-L1-mediated immunosuppression may occur in LAM, and suggest new opportunities for therapeutic targeting that may provide benefits beyond those of rapamycin.	Sirolimus	192-201	programmed cell death 1	Mus musculus	38-42
30095976-9	2018	Together, these data demonstrate that PD-1/PD-L1-mediated immunosuppression may occur in LAM, and suggest new opportunities for therapeutic targeting that may provide benefits beyond those of rapamycin.	Sirolimus	192-201	CD274 antigen	Mus musculus	43-48
29871517-16	2018	Treatment with rapamycin decreased p53 accumulation, and 3-MA inhibited the decrease in p53 induced by HPC.	Sirolimus	15-24	tumor protein p53	Homo sapiens	35-38
30138677-8	2018	Treatment with rapamycin ameliorated the lymphoproliferative immunodeficiency caused by hyperactivation of mTOR.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	107-111
30198771-7	2018	Blocking mTOR pathway with rapamycin eliminated such neuroprotective effects of BCAAs.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	9-13
30311510-4	2018	We report a novel STRADA gene deletion of exons 7-9 in 2 sisters from nonconsanguineous parents, as well as an improvement in seizure control in 1 sibling following treatment with sirolimus, an m-Tor inhibitor of potential benefit to patients with this genetic mutation.	Sirolimus	180-189	RAR related orphan receptor C	Homo sapiens	196-199
30229539-10	2018	NT157 downregulation of IRS protein expression also sensitized ERalpha+ breast cancer cells to rapamycin.	Sirolimus	95-104	isoleucyl-tRNA synthetase 1	Homo sapiens	24-27
30229539-10	2018	NT157 downregulation of IRS protein expression also sensitized ERalpha+ breast cancer cells to rapamycin.	Sirolimus	95-104	estrogen receptor 1	Homo sapiens	63-70
30145837-5	2018	Besides, the regulatory relationships between Sox2ot and miR-211, miR-211 and MCL-1, as well as between MCL-1 and the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR)/p70 ribosomal S6 protein kinase (p70S6K) signaling pathway were explored.	Sirolimus	165-174	AKT serine/threonine kinase 1	Homo sapiens	136-139
30145837-5	2018	Besides, the regulatory relationships between Sox2ot and miR-211, miR-211 and MCL-1, as well as between MCL-1 and the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR)/p70 ribosomal S6 protein kinase (p70S6K) signaling pathway were explored.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	176-180
30442335-3	2018	Rapamycin, a macrolide antibiotic and mTOR inhibitor, has recently also been implicated in telomerase inhibition and telomere attrition, although the mechanisms remain poorly understood.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
30365078-0	2018	Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway.	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	126-130
30442335-4	2018	Using breast cancer cells (MCF-7 and MDA-MB-231) wherein telomerase activity and mTOR pathway are concurrently overexpressed, this study sought to unravel novel mechanisms by which rapamycin may affect these pathways.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	81-85
30442335-7	2018	While long term treatment with a clinically relevant dose of rapamycin resulted in compromised population doubling capacity and mTOR pathway inhibition, there was no effect on telomere functionality and telomerase activity as evidenced by our assessments of hTERT protein levels, in vitro telomerase activity, telomere length and telomere FISH analyses.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	128-132
30060978-2	2018	Recently, an intravitreal formulation of sirolimus, an immunosuppressant that inhibits the mammalian target of rapamycin, a key regulator of cell growth in the immune system, was developed.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	91-120
29663284-10	2018	Use of the mTOR inhibitor rapamycin blunts the effects of FLX on body weight and on functional and structural plasticity of POMC neurons.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	11-15
29663284-10	2018	Use of the mTOR inhibitor rapamycin blunts the effects of FLX on body weight and on functional and structural plasticity of POMC neurons.	Sirolimus	26-35	proopiomelanocortin	Homo sapiens	124-128
29964224-8	2018	RESULTS: mTOR pathway inhibitor rapamycin decreased the level of P-p70 S6K reduced by ALA-PDT.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	9-13
29964224-8	2018	RESULTS: mTOR pathway inhibitor rapamycin decreased the level of P-p70 S6K reduced by ALA-PDT.	Sirolimus	32-41	ubiquitin associated and SH3 domain containing B	Homo sapiens	67-70
30393233-8	2018	The WB results showed that the expression levels of Beclin-1 and LC3-II/LC3-I were significantly elevated in NB cells treated with Rapamycin, while the expression levels of P62, mTOR, and p-mTOR proteins were significantly reduced compared with the control cells (P&lt;0.05).	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	178-182
30393233-8	2018	The WB results showed that the expression levels of Beclin-1 and LC3-II/LC3-I were significantly elevated in NB cells treated with Rapamycin, while the expression levels of P62, mTOR, and p-mTOR proteins were significantly reduced compared with the control cells (P&lt;0.05).	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	190-194
30515090-6	2018	Upregulation of autophagy via serum deprivation or pharmacologic activators (rapamycin and resveratrol) promoted microglia polarization toward M2 phenotype, as evidenced by suppressed M1 and elevated M2 gene expression, while inhibition of autophagy with 3-MA or Atg5 siRNA consistently aggravated the M1 polarization induced by TNF-alpha.	Sirolimus	77-86	tumor necrosis factor	Mus musculus	329-338
30514691-8	2018	Rapamycin treatment dose-dependently increased the expressions of caspase-3 and caspase- 9 at both the mRNA (P &amp;lt; 0.001) and protein (P &amp;lt; 0.001) levels without causing significant changes in the expressions of caspase-8.	Sirolimus	0-9	LOW QUALITY PROTEIN: caspase-9	Oryctolagus cuniculus	80-90
30514691-8	2018	Rapamycin treatment dose-dependently increased the expressions of caspase-3 and caspase- 9 at both the mRNA (P &amp;lt; 0.001) and protein (P &amp;lt; 0.001) levels without causing significant changes in the expressions of caspase-8.	Sirolimus	0-9	LOW QUALITY PROTEIN: caspase-8	Oryctolagus cuniculus	223-232
30346689-4	2018	Through enzymological and biochemical studies, we demonstrate that a rapamycin-upregulated enolase isozyme (ENO1) favors gluconeogenesis and a rapamycin-upregulated alcohol dehydrogenase isozyme (ALD4) promotes the reduction of NAD+ to NADH (instead of NADP+ to NADPH).	Sirolimus	69-78	phosphopyruvate hydratase ENO1	Saccharomyces cerevisiae S288C	108-112
30205205-0	2018	Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	113-116
30205205-0	2018	Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.	Sirolimus	0-9	mitogen-activated protein kinase 1	Mus musculus	131-134
30205205-1	2018	Rapamycin prevents experimental autoimmune encephalomyelitis (EAE) and activates the MAPK/ERK pathway in EAE.	Sirolimus	0-9	mitogen-activated protein kinase 1	Mus musculus	90-93
30179613-6	2018	Pre-treatment of rats with rapamycin for 24 h by intraperitoneal injection inhibited the expression of mRNA encoding the sinusoidal influx transporters Ntcp, Oatp1 and 2 and the canalicular efflux transporter Bsep, and increased expression of canalicular Mrp2.	Sirolimus	27-36	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	158-169
30442153-9	2018	Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro.	Sirolimus	84-93	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	42-48
30442153-9	2018	Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro.	Sirolimus	84-93	thymoma viral proto-oncogene 1	Mus musculus	58-61
30422993-0	2018	Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration.	Sirolimus	25-34	NLR family pyrin domain containing 3	Homo sapiens	120-125
30422993-2	2018	Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), was effective in improving clinical outcomes in patients with severe H1N1 infection; however, the mechanisms by which it attenuates acute lung injury have not been elucidated.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
30422993-2	2018	Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), was effective in improving clinical outcomes in patients with severe H1N1 infection; however, the mechanisms by which it attenuates acute lung injury have not been elucidated.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	58-62
30422993-10	2018	These results demonstrated that combined treatment with sirolimus and oseltamivir attenuates pH1N1-induced severe lung injury, which is correlated with suppressed mTOR-NLRP3-IL-1beta axis and reduced viral titer.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	163-167
30422993-10	2018	These results demonstrated that combined treatment with sirolimus and oseltamivir attenuates pH1N1-induced severe lung injury, which is correlated with suppressed mTOR-NLRP3-IL-1beta axis and reduced viral titer.	Sirolimus	56-65	NLR family pyrin domain containing 3	Homo sapiens	168-173
30422993-10	2018	These results demonstrated that combined treatment with sirolimus and oseltamivir attenuates pH1N1-induced severe lung injury, which is correlated with suppressed mTOR-NLRP3-IL-1beta axis and reduced viral titer.	Sirolimus	56-65	interleukin 1 beta	Homo sapiens	174-182
30179613-6	2018	Pre-treatment of rats with rapamycin for 24 h by intraperitoneal injection inhibited the expression of mRNA encoding the sinusoidal influx transporters Ntcp, Oatp1 and 2 and the canalicular efflux transporter Bsep, and increased expression of canalicular Mrp2.	Sirolimus	27-36	ATP binding cassette subfamily B member 11	Rattus norvegicus	209-213
29786783-12	2018	This VM xenograft model could be instrumental to test the therapeutic efficacy of Sirolimus in the presence of the different TIE2 or PIK3CA mutations or to test for efficacy of additional compounds in targeting the specific mutated protein(s), thus enabling development of personalized treatment options for VM patients.	Sirolimus	82-91	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	133-139
30357890-1	2018	Rapamycin is an mTOR allosteric inhibitor with multiple functions such as immunosuppressive, anticancer, and lifespan prolonging activities.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	16-20
29380900-3	2018	In this study, we report a novel dendrimer conjugate modified to deliver the mammalian target of rapamycin (mTOR) inhibitor, rapamycin.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	108-112
30005812-1	2018	OBJECTIVE: To evaluate the safety of mTOR inhibitors (sirolimus or everolimus) in infants and very young children with tuberous sclerosis complex (TSC) under two years of age.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	37-41
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	CD4 molecule	Homo sapiens	82-85
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	interferon gamma	Homo sapiens	86-94
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	CD4 molecule	Homo sapiens	97-100
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	CD4 molecule	Homo sapiens	97-100
30220530-0	2018	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
30499059-6	2018	The changes of phosphorylation of Akt and mammalian target of rapamycin (mTOR) signaling pathway after rapamycin treatment were detected by flow cytometry and real-time PCR.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	73-77
30499059-13	2018	Rapamycin inhibited the activated Akt-mTOR signaling pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	34-37
30499059-13	2018	Rapamycin inhibited the activated Akt-mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	38-42
30499059-15	2018	Treatment with the mTOR inhibitor rapamycin improved patient outcomes.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
30220530-2	2018	Randomized studies of kidney-transplanted patients indicate a significant lower susceptibility for cSCC among patients receiving the mTOR-inhibitor Sirolimus, compared to patients without mTOR-regimen.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	133-137
29449635-7	2018	The mTOR inhibitor rapamycin rescued the deficits in differentiation, synaptic dysfunction, and hypoexcitability of TSC2 mutant hiPSC-PCs in vitro.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
30156471-3	2018	Npr1 exerts its regulatory effects on Mep1 and Mep3 via Par32 (phosphorylated after rapamycin).	Sirolimus	84-93	natriuretic peptide receptor 1	Homo sapiens	0-4
30156471-6	2018	Loss of Par32 renders cells unable to recover from exposure to rapamycin and reverses the resistance to rapamycin of Delta npr1 cells.	Sirolimus	104-113	natriuretic peptide receptor 1	Homo sapiens	123-127
29772587-5	2018	In accordance with rapamycin, the activation of the mammalian target of rapamycin and its downstream target, ribosomal protein S6 kinase 1, was inhibited by cardamonin, while pyrrolidine dithiocarbamate substantially blocked nuclear factor-kappaB activation and mildly inhibited the phosphorylation of the mammalian target of rapamycin and ribosomal protein S6 kinase 1.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	52-81
29395359-3	2018	Moreover, rapamycin further enhanced the Abeta production and cell apoptosis, whereas these processes were effectively inhibited by 3-MA.	Sirolimus	10-19	amyloid beta precursor protein	Homo sapiens	41-46
29772587-7	2018	In cells pretreated with rapamycin, the inhibitory effects of cardamonin were completely suppressed with regards to the phosphorylation of the mammalian target of rapamycin, ribosomal protein S6 kinase 1, TNF-alpha, and interleukin-6, and nuclear factor-kappaB p65 protein expression was decreased.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	143-172
29772587-7	2018	In cells pretreated with rapamycin, the inhibitory effects of cardamonin were completely suppressed with regards to the phosphorylation of the mammalian target of rapamycin, ribosomal protein S6 kinase 1, TNF-alpha, and interleukin-6, and nuclear factor-kappaB p65 protein expression was decreased.	Sirolimus	25-34	tumor necrosis factor	Homo sapiens	205-214
29772587-7	2018	In cells pretreated with rapamycin, the inhibitory effects of cardamonin were completely suppressed with regards to the phosphorylation of the mammalian target of rapamycin, ribosomal protein S6 kinase 1, TNF-alpha, and interleukin-6, and nuclear factor-kappaB p65 protein expression was decreased.	Sirolimus	25-34	interleukin 6	Homo sapiens	220-233
30373605-3	2018	Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	237-240
30713663-12	2019	The addition of rapamycin, the mTOR inhibitor, activated the autophagic pathway that accelerated the removal of damaged proteins.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	31-35
30713663-15	2019	Both rapamycin treatment and mTOR knockdown enhanced ERK activity further, but reduced JNK activity and the p62 level in arsenite-treated cells.	Sirolimus	5-14	mitogen-activated protein kinase 8	Homo sapiens	87-90
30510618-3	2018	Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	114-118
30510618-3	2018	Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	292-296
30510618-3	2018	Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	114-118
30564080-1	2018	Everolimus (EVR), as a rapamycin analog, is a selective inhibitor of the mammalian target of rapamycin (mTOR) kinase and its associated signaling pathway.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	73-102
30564080-1	2018	Everolimus (EVR), as a rapamycin analog, is a selective inhibitor of the mammalian target of rapamycin (mTOR) kinase and its associated signaling pathway.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	104-108
30373605-3	2018	Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	241-270
30373605-3	2018	Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	272-276
30326670-2	2018	mTOR functions in two distinct complexes-mTORC1 is sensitive to rapamycin, while, mTORC2 is insensitive to this drug.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	0-4
30301809-6	2018	We found that the effect of rapamycin treatment on lentiviral transduction is diminished upon IFITM silencing or knockout in primary and transformed cells, and the extent of transduction enhancement depends on basal expression of IFITM proteins, with a major contribution from IFITM3.	Sirolimus	28-37	interferon induced transmembrane protein 3	Homo sapiens	277-283
30337735-10	2018	Moreover, the knock down of either Ulk1 or LC3 decreased the ST-caused apoptosis.Interestingly, we observed that rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin) and an inducer of autophagy, also showed to inhibit cell viability and increased the cleavage of PARP-1 in the ST-treated cells, suggesting that autophagy was likely to play a dual role in the regulation of the ST-induced apoptosis.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	148-152
30337735-10	2018	Moreover, the knock down of either Ulk1 or LC3 decreased the ST-caused apoptosis.Interestingly, we observed that rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin) and an inducer of autophagy, also showed to inhibit cell viability and increased the cleavage of PARP-1 in the ST-treated cells, suggesting that autophagy was likely to play a dual role in the regulation of the ST-induced apoptosis.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	154-183
30337735-10	2018	Moreover, the knock down of either Ulk1 or LC3 decreased the ST-caused apoptosis.Interestingly, we observed that rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin) and an inducer of autophagy, also showed to inhibit cell viability and increased the cleavage of PARP-1 in the ST-treated cells, suggesting that autophagy was likely to play a dual role in the regulation of the ST-induced apoptosis.	Sirolimus	113-122	poly(ADP-ribose) polymerase 1	Homo sapiens	282-288
30416863-12	2018	Levels of p-mTOR (Ser2448) and p-p70S6K (Thr389) increased in URI-overexpressing cells treated with the mTOR inhibitor rapamycin but decreased in URI-silenced cells.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	12-16
30324134-7	2018	Furthermore, the muscle contractions were recovered by single treatments and cotreatment with rapamycin (a mechanistic target of rapamycin inhibitor) and bosutinib (an Src/c-Abl inhibitor).	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	107-138
30324134-9	2018	Moreover, administering the drugs via an endothelial cell barrier decreased the expression of P-glycoprotein (an efflux pump that transports bosutinib) in the endothelial cells, indicating that rapamycin and bosutinib cotreatment has considerable potential for ALS treatment.	Sirolimus	194-203	ATP binding cassette subfamily B member 1	Homo sapiens	94-108
30416863-12	2018	Levels of p-mTOR (Ser2448) and p-p70S6K (Thr389) increased in URI-overexpressing cells treated with the mTOR inhibitor rapamycin but decreased in URI-silenced cells.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	104-108
29758325-9	2018	However, these effects were reversed by AICAR (an agonist of adenosine monophosphate [AMP]-activated protein kinase [AMPK]) and rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	155-184
29758325-9	2018	However, these effects were reversed by AICAR (an agonist of adenosine monophosphate [AMP]-activated protein kinase [AMPK]) and rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	186-190
30285764-13	2018	Interestingly, silencing menin in BON1 cells elevated S473 phosphorylation of Akt in both acute and chronic treatments with rapamycin.	Sirolimus	124-133	menin 1	Homo sapiens	25-30
30285764-13	2018	Interestingly, silencing menin in BON1 cells elevated S473 phosphorylation of Akt in both acute and chronic treatments with rapamycin.	Sirolimus	124-133	AKT serine/threonine kinase 1	Homo sapiens	78-81
30285764-15	2018	CONCLUSIONS: Menin is involved in regulatory mechanism between the two mTOR complexes, and its reduced expression is accompanied with increased mTORC2-Akt signaling, which consequently impairs anti-migratory effect of rapamycin.	Sirolimus	218-227	menin 1	Homo sapiens	13-18
30285764-15	2018	CONCLUSIONS: Menin is involved in regulatory mechanism between the two mTOR complexes, and its reduced expression is accompanied with increased mTORC2-Akt signaling, which consequently impairs anti-migratory effect of rapamycin.	Sirolimus	218-227	mechanistic target of rapamycin kinase	Homo sapiens	71-75
30285764-15	2018	CONCLUSIONS: Menin is involved in regulatory mechanism between the two mTOR complexes, and its reduced expression is accompanied with increased mTORC2-Akt signaling, which consequently impairs anti-migratory effect of rapamycin.	Sirolimus	218-227	AKT serine/threonine kinase 1	Homo sapiens	151-154
29744857-8	2018	Similarly, inhibition of mTOR with Rapamycin totally abolished the 10 microM NaHS-induced stimulation of PMECs proliferation and alteration of proliferative genes expression, with no influence on PI3 K/Akt signaling pathway.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	25-29
29691838-9	2018	Rapamycin enhanced MCs-HUVECs adhesion that was reversed by NAC, catalase, and DPI.	Sirolimus	0-9	catalase	Homo sapiens	65-73
30144504-2	2018	The TSC1 and TSC2 genes encode proteins forming a complex (TSC), which is a major regulator and suppressor of mammalian target of rapamycin complex 1 (mTORC1), a signaling complex that promotes cell growth and proliferation.	Sirolimus	130-139	TSC complex subunit 1	Homo sapiens	4-8
30144504-2	2018	The TSC1 and TSC2 genes encode proteins forming a complex (TSC), which is a major regulator and suppressor of mammalian target of rapamycin complex 1 (mTORC1), a signaling complex that promotes cell growth and proliferation.	Sirolimus	130-139	TSC complex subunit 1	Homo sapiens	4-7
30223538-2	2018	Constitutive activation of the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, and this pathway integrates signaling from several upstream receptors/mediators.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	61-64
30127391-1	2018	Tuberous sclerosis complex (TSC) is a multisystem developmental disorder caused by mutations in the TSC1 or TSC2 genes, whose protein products are negative regulators of mechanistic target of rapamycin complex 1 signaling.	Sirolimus	192-201	TSC complex subunit 1	Homo sapiens	28-31
30127391-1	2018	Tuberous sclerosis complex (TSC) is a multisystem developmental disorder caused by mutations in the TSC1 or TSC2 genes, whose protein products are negative regulators of mechanistic target of rapamycin complex 1 signaling.	Sirolimus	192-201	TSC complex subunit 1	Homo sapiens	100-104
29627129-7	2018	Rapamycin, a PIK3/AKT/mTOR pathway inhibitor, demonstrated its efficiency for some forms of PROS.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	18-21
29627129-7	2018	Rapamycin, a PIK3/AKT/mTOR pathway inhibitor, demonstrated its efficiency for some forms of PROS.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	22-26
30319625-0	2018	Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome.	Sirolimus	0-9	NLR family CARD domain containing 4	Homo sapiens	39-44
30223538-2	2018	Constitutive activation of the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, and this pathway integrates signaling from several upstream receptors/mediators.	Sirolimus	87-96	AKT serine/threonine kinase 1	Homo sapiens	103-106
30223538-2	2018	Constitutive activation of the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, and this pathway integrates signaling from several upstream receptors/mediators.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	107-111
30258985-0	2018	ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.	Sirolimus	36-45	ETS variant transcription factor 7	Homo sapiens	0-4
30258985-2	2018	Although rapamycin inhibits the two canonical mTOR complexes, mTORC1 and mTORC2, it often shows minimal benefit as an anticancer drug.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	46-50
30258985-3	2018	This is caused by rapamycin resistance of many different tumors, and we show that a third mTOR complex, mTORC3, contributes to this resistance.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	90-94
30258985-3	2018	This is caused by rapamycin resistance of many different tumors, and we show that a third mTOR complex, mTORC3, contributes to this resistance.	Sirolimus	18-27	CREB regulated transcription coactivator 3	Mus musculus	104-110
30258985-6	2018	Many human cancers activate mTORC3 at considerable frequency, and tumor cell lines that lose mTORC3 expression become rapamycin-sensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 3	Mus musculus	93-99
29203371-9	2018	The expression of Sema3A, and mTOR signaling were up-regulated in HaCaT cells incubated with HG or rSema3A, and this could be attenuated by rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	30-34
30208576-6	2018	Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	19-22
30208576-6	2018	Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	23-27
30208576-6	2018	Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR.	Sirolimus	110-119	AKT serine/threonine kinase 1	Homo sapiens	184-187
30208576-6	2018	Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	192-196
30256440-7	2018	In addition, chloroquine (as the autophagy/lysosome inhibitor, CQ) or rapamycin (as the autophagy/lysosome inhibitor, Rap) attenuated osteoclast differentiation and bone resorption activity by OPG treatment via AMPK/mTOR/p70S6K signaling pathway.	Sirolimus	70-79	regulatory associated protein of MTOR, complex 1	Mus musculus	118-121
30181250-4	2018	The Akt/mammalian target of sirolimus (mTOR) pathway is inhibited by both bacterial species in vitro, indicating that several regulatory pathways are involved in the distinct intracellular lipid outcomes associated with each bacterial species.	Sirolimus	28-37	AKT serine/threonine kinase 1	Homo sapiens	4-7
30181250-4	2018	The Akt/mammalian target of sirolimus (mTOR) pathway is inhibited by both bacterial species in vitro, indicating that several regulatory pathways are involved in the distinct intracellular lipid outcomes associated with each bacterial species.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	39-43
30066399-5	2018	Furthermore, preincubation of ex-vivo-expanded DN Tregs with a mechanistic target of rapamycin (mTOR) inhibitor rapamycin enhanced their immune regulatory function further.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	96-100
30109759-3	2018	Rapamycin, also known as sirolimus, selectively inhibits mammalian target of rapamycin, a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-86
30109759-3	2018	Rapamycin, also known as sirolimus, selectively inhibits mammalian target of rapamycin, a regulatory kinase responsible for multiple signal transduction pathways.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	57-86
30170968-5	2018	In vivo modulation of mTOR and autophagy was achieved by using AZD8055, rapamycin and 3-methyladenine.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	22-26
29979258-6	2018	Sirolimus, an mTor inhibitor, has benefited patients with primary autoimmune cytopenias, possibly by stimulating T regulatory cells, and may also have efficacy for SLE-associated cytopenias.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30186415-10	2018	In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	55-89
29964122-2	2018	Herein, inhalable multi-compartmental nanocomposites with the capability for both localized and modulated release of the hydrophobic mTOR inhibitor, rapamycin (RAP) and the hydrophilic herbal drug, berberine (BER) have been developed for lung cancer therapy.	Sirolimus	149-158	mechanistic target of rapamycin kinase	Homo sapiens	133-137
30186415-10	2018	In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	91-95
31949841-2	2018	As a natural mTOR inhibitor, rapamycin has been demonstrated to regulate various cellular biological behaviors of cancer cells, including growth inhibition and induction of apoptosis in multiple types of malignant tumors.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	13-17
31949841-6	2018	The expressions of glycolysis enzymes, Hexokinase 2, PKM2 and LDHA are upregulated in rapamycin resistant cells.	Sirolimus	86-95	lactate dehydrogenase A	Homo sapiens	62-66
31949841-7	2018	We observed promotion of cellular glycolysis by overexpressing LDHA renders colon cancer cells resistant to rapamycin and inhibition of glycolysis by knockdown LDHA sensitizes colon cancer cells to rapamycin.	Sirolimus	108-117	lactate dehydrogenase A	Homo sapiens	63-67
29699851-8	2018	RESULTS: We found that the combination of cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA4Ig) and rapamycin with LFA-1 blockade enhanced bone marrow engraftment and led to more efficient T-cell engraftment and subsequent tolerization.	Sirolimus	104-113	integrin beta 2	Mus musculus	119-124
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	Sirolimus	73-82	interferon gamma	Homo sapiens	138-147
31949841-7	2018	We observed promotion of cellular glycolysis by overexpressing LDHA renders colon cancer cells resistant to rapamycin and inhibition of glycolysis by knockdown LDHA sensitizes colon cancer cells to rapamycin.	Sirolimus	198-207	lactate dehydrogenase A	Homo sapiens	160-164
29748632-8	2018	In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT2AR signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	41-44
29748632-8	2018	In addition, we found that inhibition of Akt/mTOR pathway by rapamycin blocks the changes in 5-HT2AR signaling pattern and the supersensitivity to schizophrenia-like effects induced by chronic THC.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	45-49
29999213-9	2018	All patients with thrombocytopenia or hypofibrinogenemia reached a normal platelet count and a normal fibrinogen level within 3 to 4 weeks after sirolimus treatment.	Sirolimus	145-154	fibrinogen beta chain	Homo sapiens	42-52
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	AKT serine/threonine kinase 1	Rattus norvegicus	63-66
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	regulatory associated protein of MTOR, complex 1	Rattus norvegicus	118-124
30015406-1	2018	The mTOR inhibitor rapamycin is used systemically for the treatment of vascular lesions.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
30347925-11	2018	Furthermore, the inhibition of PI3K/Akt by LY294002 or that of mTOR by rapamycin augmented LCA-induced autophagy.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	63-67
30154572-7	2018	We inhibited mTOR by treating MCF7 cells with rapamycin and observed that the expression of NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	13-17
30154572-7	2018	We inhibited mTOR by treating MCF7 cells with rapamycin and observed that the expression of NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation.	Sirolimus	46-55	N-myristoyltransferase 1	Homo sapiens	92-96
30154572-7	2018	We inhibited mTOR by treating MCF7 cells with rapamycin and observed that the expression of NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	13-17
30154572-7	2018	We inhibited mTOR by treating MCF7 cells with rapamycin and observed that the expression of NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation.	Sirolimus	112-121	N-myristoyltransferase 1	Homo sapiens	92-96
30177877-14	2018	Our findings indicated that the P45 component changes depending on the RPM frequency, suggesting that somatosensory inputs induced by RPM influences S1 excitability.	Sirolimus	71-74	nuclear factor, erythroid 2	Homo sapiens	32-35
30087333-5	2018	Knockout of either TSC1 or DEPDC5 led to enhanced HIV-1 reactivation in both a T-cell line (C11) and a monocyte cell line (U1), and this enhancement could be antagonized by the mTORC1 inhibitor rapamycin.	Sirolimus	194-203	TSC complex subunit 1	Homo sapiens	19-23
30120246-4	2018	Rapamycin treatment prevents CD8 T-cell dysfunction in menin-deficient CD8 T cells.	Sirolimus	0-9	menin 1	Homo sapiens	55-60
30058583-9	2018	Results: The beneficial effects of rapamycin on neuropathic pain were attributed to a reduction in mammalian target of rapamycin sensitive complex 1 (mTORC1)-positive cells (70.80 +- 2.41 vs. 112.30 +- 5.66, F = 34.36, P &lt; 0.01) and mTORC1 activity in the mouse spinal cord.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	99-128
30135653-0	2018	Rapamycin Upregulates Connective Tissue Growth Factor Expression in Hepatic Progenitor Cells Through TGF-beta-Smad2 Dependent Signaling.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	101-109
30135653-1	2018	Rapamycin (sirolimus) is a mTOR kinase inhibitor and is widely used as an immunosuppressive drug to prevent graft rejection in organ transplantation currently.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
30135653-1	2018	Rapamycin (sirolimus) is a mTOR kinase inhibitor and is widely used as an immunosuppressive drug to prevent graft rejection in organ transplantation currently.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	27-31
30135653-4	2018	Using lentivirus-mediated small hairpin RNA (shRNA) we demonstrated that knockdown of mTOR, Raptor, or Rictor mimicked the effect of rapamycin treatment.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	86-90
30135653-5	2018	Mechanistically, inhibition of mTOR activity with rapamycin resulted in a hyperactive PI3K-Akt pathway, whereas this activation inhibited the expression of CTGF in HPCs.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	31-35
30135653-6	2018	Besides, rapamycin activated the TGF-beta-Smad signaling, and TGF-beta receptor type I (TGFbetaRI) serine/threonine kinase inhibitors completely blocked the effects of rapamycin on HPCs.	Sirolimus	9-18	transforming growth factor beta 1	Homo sapiens	33-41
30135653-6	2018	Besides, rapamycin activated the TGF-beta-Smad signaling, and TGF-beta receptor type I (TGFbetaRI) serine/threonine kinase inhibitors completely blocked the effects of rapamycin on HPCs.	Sirolimus	168-177	transforming growth factor beta 1	Homo sapiens	33-41
30135653-8	2018	Rapamycin also induced ROS generation and latent TGF-beta activation which contributed to TGF-beta-Smad signaling.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	49-57
30135653-8	2018	Rapamycin also induced ROS generation and latent TGF-beta activation which contributed to TGF-beta-Smad signaling.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	90-98
30015070-4	2018	Enzyme inhibition assay was performed for compound 19 against mTOR (IC50 = 0.64 muM) and VEGFR-2 (IC50 = 1.97 muM) to show high potency in comparison to rapamycin (IC50 = 0.43 muM) and sorafenib (IC50 = 0.3 muM) as references, respectively.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	62-66
29717938-7	2018	To overcome this problem, we previously demonstrated that folate-conjugated rapamycin (FC-rapa) targets polycystic kidneys due to the high expression of the folate receptor (FRalpha) and that treatment of a nonortholgous PKD mouse model leads to inhibition of renal cyst growth.	Sirolimus	76-85	rabaptin, RAB GTPase binding effector protein 2	Mus musculus	174-181
29948021-1	2018	BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	27-56
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	hypoxia inducible factor 1 subunit alpha	Homo sapiens	178-188
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	241-245
29948021-1	2018	BACKGROUND: Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	58-62
29948021-2	2018	Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	25-29
29675586-0	2018	Rapamycin Alleviates Hormone Imbalance-Induced Chronic Nonbacterial Inflammation in Rat Prostate Through Activating Autophagy via the mTOR/ULK1/ATG13 Signaling Pathway.	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	139-143
29676052-1	2018	We evaluated the neuroprotective role of rapamycin, a mammalian target of rapamycin (mTOR) kinase inhibitor, in cerebral ischaemia and locomotor function in a mouse model of subarachnoid haemorrhage (SAH).	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	54-83
29676052-1	2018	We evaluated the neuroprotective role of rapamycin, a mammalian target of rapamycin (mTOR) kinase inhibitor, in cerebral ischaemia and locomotor function in a mouse model of subarachnoid haemorrhage (SAH).	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	85-89
29675586-9	2018	In addition to some histological changes in the prostate tissues, we found the levels of NF-kappaB and IL-1beta were significantly increased in the model group, along with significantly suppressed autophagy, whereas rapamycin could reverse these effects which involved in the mTOR/ULK1/ATG13 signaling pathway.	Sirolimus	216-225	unc-51 like autophagy activating kinase 1	Rattus norvegicus	281-285
29857052-4	2018	Pre-senescent HUVECs were prolonged treated with low dose rapamycin (1 nM), an MTOR inhibitor.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	79-83
29458247-4	2018	In April 2016 a new sirolimus-coated balloon (Magic Touch , Envision Scientific PVT, Bhatpore, India) obtained the CE Mark.	Sirolimus	20-29	microtubule affinity regulating kinase 1	Homo sapiens	118-122
29857052-5	2018	Rapamycin treatment down-regulated the phosphorylated MTOR, RPS6 and 4EBP1 expressions, which confirmed MTORC1 suppression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	54-58
29857052-6	2018	Prolonged low dose rapamycin treatment has significantly reduced the percentage of senescence-associated beta galactosidase (SA-beta gal) positively stained senescent cells and P16INK4A expression in these cells.	Sirolimus	19-28	cyclin dependent kinase inhibitor 2A	Homo sapiens	177-185
29959473-7	2018	Notably, combined treatment with BI 2536 and rapamycin produced more potent inhibitory effects on the activation of S6 and AKT than either alone.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	123-126
29924669-0	2018	Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
30051818-4	2018	We additionally performed context-specific fitness screens for resistance to or synergy with trametinib, a Ras/ERK/ETS inhibitor, or rapamycin, an mTOR inhibitor, and identified key regulators of each pathway.	Sirolimus	133-142	Megator	Drosophila melanogaster	147-151
30013633-5	2018	The results showed that DRAM1 knockdown by specific siRNA abrogated cell autophagy, as well as inhibited the migration and invasion of HepG2 cells in Transwell assays, which may be reversed by rapamycin treatment.	Sirolimus	193-202	DNA damage regulated autophagy modulator 1	Homo sapiens	24-29
30013633-6	2018	In addition, DRAM1 knockdown increased the expression of E-Cadherin while decreased the expression of vimentin in HepG2 cells, which was also be reversed by rapamycin treatment.	Sirolimus	157-166	DNA damage regulated autophagy modulator 1	Homo sapiens	13-18
30013633-6	2018	In addition, DRAM1 knockdown increased the expression of E-Cadherin while decreased the expression of vimentin in HepG2 cells, which was also be reversed by rapamycin treatment.	Sirolimus	157-166	cadherin 1	Homo sapiens	57-67
29929111-1	2018	PURPOSE: Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway.	Sirolimus	188-197	TSC complex subunit 1	Homo sapiens	104-108
29929111-1	2018	PURPOSE: Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway.	Sirolimus	188-197	mechanistic target of rapamycin kinase	Homo sapiens	199-203
29929111-2	2018	Rapamycin, an mTOR inhibitor, is clinically used to treat hamartomatous lesionsas in TSC and its effect on controlling epilepsy is also reported in many studies.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
30111405-7	2018	After treatmant with 2micromol/L rapamycin for different time (12 24 h), the number of autophagosomes in the control group was less , while in the treatment groups was more, the mRNA level of LC3-II was raised as compared with the control group, while the mRNA and protein level of UCH-L3 declined (P&lt;0.05).	Sirolimus	33-42	ubiquitin C-terminal hydrolase L3	Homo sapiens	282-288
30037344-1	2018	BACKGROUND: Previous studies in various rodent epilepsy models have suggested that mammalian target of rapamycin (mTOR) inhibition with rapamycin has anti-epileptogenic potential.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	114-118
30037344-8	2018	RESULTS: Rapamycin, but not curcumin, suppressed mTOR activation in cultured astrocytes.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	49-53
29668485-2	2018	Conventional chemotherapy has little activity in this disease, but case reports are available on the activity of mammalian target of rapamycin inhibitors (e.g. sirolimus and temsirolimus).	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	113-142
30050079-7	2018	Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells.	Sirolimus	51-60	estrogen receptor 1	Homo sapiens	121-125
30050079-8	2018	In combination with tamoxifen (inhibiting ESR1), both S6RP phosphorylation and rapamycin-induced 4E-BP1 upregulation in TNBC bulk cells was inhibited.	Sirolimus	79-88	estrogen receptor 1	Homo sapiens	42-46
30050079-12	2018	Furthermore, co-administration of rapamycin, valproic acid, and tamoxifen retarded tumor growth and reduced CD44high/+/CD24low/- CSCs in a human TNBC xenograft model and hampered tumorigenesis after secondary transplantation.	Sirolimus	34-43	CD24 molecule	Homo sapiens	119-123
29668485-3	2018	Pharmacokinetic assays of sirolimus are available as this drug has a precise therapeutic window and blood levels might be influenced by CYP3A4 polymorphisms and drug interactions.	Sirolimus	26-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	136-142
29668485-11	2018	This case confirms the activity of mammalian target of rapamycin inhibitors in PEComa and strengthens the importance of pharmacokinetic drug blood levels monitoring in patients treated with sirolimus.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Homo sapiens	35-64
29889583-1	2018	OBJECTIVES: Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	77-80
29889583-1	2018	OBJECTIVES: Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	101-110	AKT serine/threonine kinase 1	Homo sapiens	117-120
29889583-1	2018	OBJECTIVES: Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mammalian target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	121-125
29633296-9	2018	In addition, treatment with rapamycin showed a non-significant trend toward PSMA upregulation.	Sirolimus	28-37	folate hydrolase 1	Homo sapiens	76-80
29633296-11	2018	Total PSMA protein expression was significantly enhanced after treatment with enzalutamide and rapamycin (both P &lt; 0.05), whereas dutasteride led to a non-significant upregulation.	Sirolimus	95-104	folate hydrolase 1	Homo sapiens	6-10
29785723-8	2018	This suggests that the balance of proteins that up- or downregulate E-cadherin mediates the tendency of MCF7 cells to form MCS during RPM exposure.	Sirolimus	134-137	cadherin 1	Homo sapiens	68-78
29633296-12	2018	Uptake of 177 Lu-PSMA-617 was significantly increased after treatment of LNCaP with enzalutamide, dutasteride, and rapamycin (P &lt; 0.05).	Sirolimus	115-124	folate hydrolase 1	Homo sapiens	17-21
30057537-3	2018	Case Report: We treated 3 consecutive infants aged less than 12 months with sirolimus, an oral mTOR inhibitor.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	95-99
29945674-5	2018	Sirolimus directly inhibits the mTOR pathway, thereby inhibiting cell proliferation and angio/lymphangiogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	32-36
29727731-2	2018	Although it has been shown that rapamycin (a specific inhibitor of mammalian target of rapamycin) can reduce astrocyte reactivation in the early stage of TBI, its effect on glial scar formation has not been characterized in TBI and other acute brain injury models.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	67-96
29727731-7	2018	At 14 d post-injury, 0.5 mg/kg rapamycin significantly reduced the area and thickness of glial scar and chondroitin sulfate proteoglycan expression, accompanied by decreased expression of p-S6 and enhanced expression of growth associated protein 43 (an axon regeneration marker) in the region of glial scar.	Sirolimus	31-40	growth associated protein 43	Mus musculus	220-248
30317760-9	2018	Rapamycin alleviated lipid deposition caused by oleic acid and palmitic acid and inhibited their induction of increased expression of mTOR, S6K1, and SREBP-1c.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	134-138
29730285-7	2018	In support of this, a surface plasmon resonance analysis showed a direct interaction of rapamycin with NTCP.	Sirolimus	88-97	solute carrier family 10 member 1	Homo sapiens	103-107
29885659-5	2018	Current immunomodulators include various immunosuppressants and biologics but mammalian target of rapamycin (mTOR) inhibitors (such as sirolimus and everolimus) may also be contenders for this role.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	78-107
29885659-5	2018	Current immunomodulators include various immunosuppressants and biologics but mammalian target of rapamycin (mTOR) inhibitors (such as sirolimus and everolimus) may also be contenders for this role.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	109-113
29342502-10	2018	Indeed, anti-beta2 GPI aPL inhibited basal trophoblast autophagy, and reversing this with rapamycin inhibited aPL-induced inflammasome function and IL-1beta secretion.	Sirolimus	90-99	interleukin 1 beta	Homo sapiens	148-156
29226570-2	2018	Elective conversion to inhibitors of the mammalian target of rapamycin (mTOR, eg, sirolimus) pathway might avoid long-term CNI renal damage and improve outcomes.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	41-70
29226570-2	2018	Elective conversion to inhibitors of the mammalian target of rapamycin (mTOR, eg, sirolimus) pathway might avoid long-term CNI renal damage and improve outcomes.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	72-76
29175009-1	2018	BACKGROUND: The mammalian targets of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVR]) are used after transplantation for their immunosuppressive activity.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	48-52
29447340-10	2018	In addition, silencing DDIT4 caused up-regulated p-mTOR and p-p70s6k and reduced apoptosis, whereas rapamycin, an inhibitor of mTOR, reversed the result of apoptosis.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	127-131
29559472-0	2018	Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.	Sirolimus	63-72	TSC complex subunit 1	Homo sapiens	33-37
29559472-6	2018	Tumors derived from cancer cells expressing the TSC1-S467E/S578E mutant exhibited greater sensitivity to rapamycin than those expressing WT TSC1.	Sirolimus	105-114	TSC complex subunit 1	Homo sapiens	48-52
29559472-7	2018	Collectively, our data support a model in which Plk1, instead of AKT, regulates the TSC/mTORC1 pathway during mitosis, eventually regulating the efficacy of rapamycin.Significance: This seminal report shows that activation of mTORC1 can be independent of AKT during mitosis.	Sirolimus	157-166	TSC complex subunit 1	Homo sapiens	84-87
29559472-7	2018	Collectively, our data support a model in which Plk1, instead of AKT, regulates the TSC/mTORC1 pathway during mitosis, eventually regulating the efficacy of rapamycin.Significance: This seminal report shows that activation of mTORC1 can be independent of AKT during mitosis.	Sirolimus	157-166	AKT serine/threonine kinase 1	Homo sapiens	255-258
29757021-7	2018	Other studies report that Advagraf -treated patients receiving a mTOR-inhibitor agent (sirolimus or everolimus) instead of MMF: this was associated with good allograft outcome, and might also prevent late-onset cytomegalovirus infection.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	65-69
29462337-11	2018	Conclusions: Our findings indicate that anxiety-related behavior following rapamycin treatment was not directly attributed to mTOR-dependent mechanisms or stress but rather due to hyperexcitability of the amygdala together with glucocorticoid receptor-regulated mechanism(s) in this brain region.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	126-130
29462337-11	2018	Conclusions: Our findings indicate that anxiety-related behavior following rapamycin treatment was not directly attributed to mTOR-dependent mechanisms or stress but rather due to hyperexcitability of the amygdala together with glucocorticoid receptor-regulated mechanism(s) in this brain region.	Sirolimus	75-84	nuclear receptor subfamily 3 group C member 1	Homo sapiens	228-251
29483712-8	2018	Importantly, mTOR inhibition with rapamycin inhibited anti-huCD69-induced mobilization of hematopoietic stem and progenitor cells (HSPCs).	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	13-17
29607508-12	2018	PDLSCs treated with rapamycin or transfected with cDNA-Beclin-1 showed higher expression levels of bFGF and Ang that promoted tube formation by the co-cultured ECs.	Sirolimus	20-29	fibroblast growth factor 2	Homo sapiens	99-103
29633504-10	2018	Combination of gefitinib with rapamycin treatment suppresses tumor formation of gefitinib-resistant (GR) FBXW7-knockdown cells.	Sirolimus	30-39	F-box and WD repeat domain containing 7	Homo sapiens	105-110
29481864-7	2018	mTORC1-dependent effects of DEPDC5/NPRL3 KD were determined using the mTOR inhibitor rapamycin.	Sirolimus	85-94	DEP domain containing 5	Mus musculus	28-34
29901635-2	2018	Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Danio rerio	19-50
29901635-2	2018	Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Danio rerio	52-56
29901635-2	2018	Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions.	Sirolimus	0-9	sequestosome 1	Danio rerio	202-208
29901635-2	2018	Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions.	Sirolimus	0-9	TAR DNA binding protein	Mus musculus	320-325
29481864-12	2018	DEPDC5/NPRL3 KD effects on morphology and functional mTOR activation were reversed by rapamycin.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	53-57
29532571-10	2018	As far as we know, these are the first 2 GLILD patients treated successfully with sirolimus, suggesting the advisability of further study of mTOR inhibitors as a more targeted treatment for GLILD, if impairment in Tregs is demonstrated.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	141-145
29872523-3	2018	Sirolimus, a mammalian target of rapamycin inhibitor, produced rapid and dramatic improvement of the Kasabach-Merritt phenomenon and kaposiform hemangioendothelioma shrinkage.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
29736615-5	2018	The effects of BDNF were completely inhibited by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	76-105
29736615-5	2018	The effects of BDNF were completely inhibited by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	107-111
29506143-8	2018	Purified IgG from TA patients induced a significant EC proliferation compared with to GCA and HC IgG, and this effect was decreased after EC exposure with sirolimus, a specific mTOR inhibitor and PI3K inhibitor.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	177-181
29880342-3	2018	The aim of this study was to determine the effect of sirolimus, an mTOR inhibitor, on cyst volume regression in patients with ADPKD who have undergone renal transplantation.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	67-71
29716894-8	2018	When administered in the early postnatal period, prior to hamartoma formation, rapamycin reduces hamartoma size, but also induces new morphological abnormalities in the Pten cKO retinal periphery.	Sirolimus	79-88	phosphatase and tensin homolog	Mus musculus	169-173
29136244-4	2018	Results: An unbiased phosphoproteomic screen quantified phosphorylation changes associated with chronic exposure to the mTOR inhibitor rapamycin, and our analysis implicated a role for glycogen synthase kinase (GSK)3B attenuation in mediating resistance that was confirmed by functional studies.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Homo sapiens	120-124
29804411-13	2018	It showed a dose-dependent down-regulation of p-mTOR, Cbfalpha1 and OPN in high phosphorus + Rapamycin (1, 10, 100 ng/ml) groups (all P&lt;0.05).	Sirolimus	93-102	RUNX family transcription factor 2	Rattus norvegicus	54-63
29862167-6	2018	RESULTS: In C57BL/6 mice, rapamycin treatment decreased the clinical scores and production of the pro-inflammatory cytokine, IL-1beta.	Sirolimus	26-35	interleukin 1 beta	Mus musculus	125-133
29862167-7	2018	The expression of TLR4, stimulated by A. fumigatus, was reduced as well when the mTOR signaling pathway was suppressed by rapamycin.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	81-85
29804411-11	2018	After treated with Wortmannin or Rapamycin for 24 h, compared with high phosphorus group, the mRNA expressions of Cbfalpha1 and OPN decreased significantly in high phosphorus + Wortmannin (30, 50 and 100 nmol/L) groups (all P&lt;0.05) and high phosphorus + Rapamycin (1, 10 and 100 ng/ml) groups (all P&lt;0.05).	Sirolimus	33-42	RUNX family transcription factor 2	Rattus norvegicus	114-123
29861744-7	2018	Rapamycin-induced inhibition of mTOR decreased liver lipid accumulation at 24 h after PHx, leading to impaired LR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	32-36
29804411-11	2018	After treated with Wortmannin or Rapamycin for 24 h, compared with high phosphorus group, the mRNA expressions of Cbfalpha1 and OPN decreased significantly in high phosphorus + Wortmannin (30, 50 and 100 nmol/L) groups (all P&lt;0.05) and high phosphorus + Rapamycin (1, 10 and 100 ng/ml) groups (all P&lt;0.05).	Sirolimus	257-266	RUNX family transcription factor 2	Rattus norvegicus	114-123
29804411-12	2018	After treated with Wortmannin or Rapamycin for 48 h, compared with high phosphorus group, the protein expressions of p-Akt, Cbfalpha1 and OPN down-regulated significantly in high phosphorus + Wortmannin (30, 50 and 100 nmol/L) groups (all P&lt;0.05).	Sirolimus	33-42	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
29804411-12	2018	After treated with Wortmannin or Rapamycin for 48 h, compared with high phosphorus group, the protein expressions of p-Akt, Cbfalpha1 and OPN down-regulated significantly in high phosphorus + Wortmannin (30, 50 and 100 nmol/L) groups (all P&lt;0.05).	Sirolimus	33-42	RUNX family transcription factor 2	Rattus norvegicus	124-141
29720621-2	2018	Mammalian target of rapamycin (mTOR) is a vital modulator in cell growth control and related diseases, and we have recently demonstrated that rapamycin can suppress eosinophil differentiation in allergic airway inflammation.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26911848-7	2018	Rosiglitazone also inhibited the phosphorylation of Akt and antagonized the activation of Akt induced by rapamycin.	Sirolimus	105-114	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
29466710-11	2018	Notably, although low SS had no influence on eNOS Ser1177 phosphorylation, whereas boosted eNOS Ser1177 phosphorylation by rapamycin were in favor of the eNOS recoupling through restoration of autophagic flux.	Sirolimus	123-132	nitric oxide synthase 3	Homo sapiens	91-95
29276026-1	2018	The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).	Sirolimus	79-88	AKT serine/threonine kinase 1	Homo sapiens	52-55
29276026-1	2018	The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).	Sirolimus	79-88	AKT serine/threonine kinase 1	Homo sapiens	95-98
29276026-1	2018	The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	99-103
29466710-11	2018	Notably, although low SS had no influence on eNOS Ser1177 phosphorylation, whereas boosted eNOS Ser1177 phosphorylation by rapamycin were in favor of the eNOS recoupling through restoration of autophagic flux.	Sirolimus	123-132	nitric oxide synthase 3	Homo sapiens	91-95
29725433-8	2018	After treatment with rapamycin, the expression levels of Bcl-2, Bax, cleaved caspase-3, autophagy-related genes and proteins, p62, LC3-II/I and Atg7 were similar to those in the control group.	Sirolimus	21-30	BCL2 apoptosis regulator	Homo sapiens	57-62
29760379-9	2018	Finally, overexpressed Cav-1 rescued rapamycin-induced autophagic degradation of Cav-1 to maintain LSECs fenestrae; whereas knockdown of Cav-1 facilitated defenestration due to the activation of the AMPK-dependent autophagy.	Sirolimus	37-46	caveolin 1	Homo sapiens	23-28
29760379-9	2018	Finally, overexpressed Cav-1 rescued rapamycin-induced autophagic degradation of Cav-1 to maintain LSECs fenestrae; whereas knockdown of Cav-1 facilitated defenestration due to the activation of the AMPK-dependent autophagy.	Sirolimus	37-46	caveolin 1	Homo sapiens	81-86
29760379-9	2018	Finally, overexpressed Cav-1 rescued rapamycin-induced autophagic degradation of Cav-1 to maintain LSECs fenestrae; whereas knockdown of Cav-1 facilitated defenestration due to the activation of the AMPK-dependent autophagy.	Sirolimus	37-46	caveolin 1	Homo sapiens	81-86
29432811-3	2018	Rapamycin administration intraperitoneally markedly reduced clinical signs, total and OVA-specific IgE and IgG1/G2a ratio in serum, and conjunctival eosinophilic infiltration.	Sirolimus	0-9	G protein-coupled receptor 132	Mus musculus	112-115
29432811-4	2018	Infiltrations of CD11c+ dendritic cells and CD4+ T cells, and the expressions of chemokines and adhesion molecules in the conjunctiva were attenuated in rapamycin-treated mice, as well as decreased Th1 and Th2 cytokines in the cervical lymph nodes compared to non-treated mice.	Sirolimus	153-162	negative elongation factor complex member C/D, Th1l	Mus musculus	198-201
29673286-7	2018	Consistently, serum inflammatory mediators TNF-alpha and IL-6 were decreased by the treatment of LPS combined with 3-MA as compared with LPS alone, while administration of LPS combined with rapamycin increased the serum TNF-alpha and IL-6 levels.	Sirolimus	190-199	tumor necrosis factor	Mus musculus	220-229
29673286-7	2018	Consistently, serum inflammatory mediators TNF-alpha and IL-6 were decreased by the treatment of LPS combined with 3-MA as compared with LPS alone, while administration of LPS combined with rapamycin increased the serum TNF-alpha and IL-6 levels.	Sirolimus	190-199	interleukin 6	Mus musculus	234-238
29483210-8	2018	Finally, proliferation of NSGCT cells in vitro and in vivo is significantly inhibited by combined treatment with the clinically available agents erlotinib and rapamycin, which target EGFR and mTORC1 signaling, respectively.	Sirolimus	159-168	epidermal growth factor receptor	Homo sapiens	183-187
29725433-8	2018	After treatment with rapamycin, the expression levels of Bcl-2, Bax, cleaved caspase-3, autophagy-related genes and proteins, p62, LC3-II/I and Atg7 were similar to those in the control group.	Sirolimus	21-30	BCL2 associated X, apoptosis regulator	Homo sapiens	64-67
29731844-6	2018	These results suggested that downregulation of the mTOR signaling cascades is likely to be a crucial mediator in the impairment of viability and the induction of apoptosis resulting from combined therapy with resveratrol and rapamycin in MM1.S cells.	Sirolimus	225-234	mechanistic target of rapamycin kinase	Homo sapiens	51-55
29241092-2	2018	Trehalose, a naturally occurring nontoxic disaccharide found in plants, insects, microorganisms and invertebrates, but not in mammals, was reported to function as a mechanistic target of the rapamycin (mTOR)-independent inducer of autophagy.	Sirolimus	191-200	mechanistic target of rapamycin kinase	Homo sapiens	202-206
29549527-8	2018	Using ARQ 092 to target AKT, a critical node connecting PI3K and mTOR pathways, we observed the following: (1) strong anti-proliferative activity [ARQ 092 at 0.5, 1, and 2.5 muM blunted phosphorylation of AKT and its downstream targets (in the presence or absence of serum) and inhibited proliferation after 72 h; rapamycin at 100 nM did not decrease AKT phosphorylation] and (2) less cytotoxicity as compared to rapamycin and wortmannin.	Sirolimus	314-323	AKT serine/threonine kinase 1	Homo sapiens	24-27
29549527-8	2018	Using ARQ 092 to target AKT, a critical node connecting PI3K and mTOR pathways, we observed the following: (1) strong anti-proliferative activity [ARQ 092 at 0.5, 1, and 2.5 muM blunted phosphorylation of AKT and its downstream targets (in the presence or absence of serum) and inhibited proliferation after 72 h; rapamycin at 100 nM did not decrease AKT phosphorylation] and (2) less cytotoxicity as compared to rapamycin and wortmannin.	Sirolimus	413-422	AKT serine/threonine kinase 1	Homo sapiens	24-27
29703175-6	2018	RESULTS: Gene and protein expression of tenascin-c and fibronectin of fibrotic fibroblasts were reduced by pirfenidone or rapamycin treatment.	Sirolimus	122-131	fibronectin 1	Homo sapiens	55-66
29257864-0	2018	Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	162-165
29257864-0	2018	Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways.	Sirolimus	0-9	cAMP responsive element binding protein 1	Mus musculus	166-170
29257864-6	2018	Moreover, rapamycin showed a marked neuroprotective effect in the N2a cells by decreasing intracellular reactive oxygen species (ROS) production and by up-regulating the activities of the anti-ROS enzymes superoxide dismutase and catalase and recovering glutathione (GSH) levels to normal.	Sirolimus	10-19	catalase	Mus musculus	230-238
29257864-7	2018	Moreover, rapamycin pretreatment protected against colistin-induced mitochondrial dysfunction, caspase activation, and subsequent apoptosis by up-regulating autophagy and activating the Akt/CREB, NGF, and Nrf2 pathways, while inhibiting p53 signaling.	Sirolimus	10-19	thymoma viral proto-oncogene 1	Mus musculus	186-189
29257864-7	2018	Moreover, rapamycin pretreatment protected against colistin-induced mitochondrial dysfunction, caspase activation, and subsequent apoptosis by up-regulating autophagy and activating the Akt/CREB, NGF, and Nrf2 pathways, while inhibiting p53 signaling.	Sirolimus	10-19	cAMP responsive element binding protein 1	Mus musculus	190-194
29257864-7	2018	Moreover, rapamycin pretreatment protected against colistin-induced mitochondrial dysfunction, caspase activation, and subsequent apoptosis by up-regulating autophagy and activating the Akt/CREB, NGF, and Nrf2 pathways, while inhibiting p53 signaling.	Sirolimus	10-19	nuclear factor, erythroid derived 2, like 2	Mus musculus	205-209
29636391-3	2018	We show that TPC2 is required for intracellular Ca2+ signaling in response to NAADP or to mTOR inhibition by rapamycin.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	90-94
29581305-3	2018	Previous work has shown that treatment of HGPS cells with the mTOR inhibitor rapamycin or with the rapamycin analog everolimus corrects several of the phenotypes seen at the cellular level-at least in part by increasing autophagy and reducing the amount of progerin, the toxic form of lamin A that is overproduced in HGPS patients.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	62-66
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	129-132
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	signal transducer and activator of transcription 3	Homo sapiens	134-139
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	198-201
29636391-7	2018	In HEK293 cells stably overexpressing human TPC2, shRNA-mediated knockdown of mTOR blocked rapamycin- and NAADP-evoked Ca2+ signals.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	78-82
29721158-1	2018	The mechanistic target of the rapamycin (mTOR) inhibitor, temsirolimus, has significantly improved the outcome of patients with renal cell carcinoma (RCC).	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	41-45
29692710-7	2018	We provide further insights that explain the reasons for the failure of numerous clinical trials conducted to date targeting PI3K or mTOR complex 1 (mTORC1) with rapamycin and its analogs.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Homo sapiens	133-137
29444470-10	2018	Sirolimus reduced portal pressure and plasma levels of alanine aminotransferase, aspartate aminotransferase and ammonia, and attenuated hepatic inflammation and fibrosis in cirrhotic rats.	Sirolimus	0-9	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	81-107
29524402-5	2018	PI3K inhibitor (LY 294002), ERK inhibitor (PD98059) and mTOR inhibitor (Rapamycin) inhibited ghrelin-induced A549 cell proliferation.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	56-60
29444470-11	2018	In addition, the hepatic phosphorylated mammalian target of rapamycin (mTOR) and P70S6K protein expressions were significantly downregulated and endothelial nitric oxide synthase (eNOS) expression upregulated by sirolimus.	Sirolimus	212-221	mechanistic target of rapamycin kinase	Homo sapiens	71-75
29444470-11	2018	In addition, the hepatic phosphorylated mammalian target of rapamycin (mTOR) and P70S6K protein expressions were significantly downregulated and endothelial nitric oxide synthase (eNOS) expression upregulated by sirolimus.	Sirolimus	212-221	nitric oxide synthase 3	Homo sapiens	145-178
29336620-3	2018	THP-1 activated cells were incubated with or without PI3K inhibitor-wortmannin or with mTOR inhibitor-rapamycin.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	87-91
29351469-4	2018	We and others recently established that inhibition of the mammalian/mechanistic target of rapamycin (mTOR) pathway with rapamycin yields significant neuroprotective effects, improving cerebrovascular and cognitive function in mouse models of AD.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	101-105
29440231-9	2018	SI-NET was more sensitive to the mTOR inhibitor sirolimus than the other solid tumor types tested.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	33-37
29336620-11	2018	Rapamycin inhibited mTOR activation as the number of p-S6 positive cells decreased in the tested cases.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	20-24
29475988-8	2018	Importantly, suppression of mTORC2 for 24 h with rapamycin or everolimus or treatment with mTOR active-site inhibitors enhanced HLA-II Ab-stimulated phosphorylation of ERK.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	28-32
29091294-9	2018	Treatment with rapamycin restored bile acid excretion, attenuated hepatocyte damage, and extended the life span of abcb11b mutant zebrafish, correlating with the recovery of canalicular multidrug resistance protein 1 localization.	Sirolimus	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 11b	Danio rerio	115-122
29091294-9	2018	Treatment with rapamycin restored bile acid excretion, attenuated hepatocyte damage, and extended the life span of abcb11b mutant zebrafish, correlating with the recovery of canalicular multidrug resistance protein 1 localization.	Sirolimus	15-24	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	186-216
29475988-8	2018	Importantly, suppression of mTORC2 for 24 h with rapamycin or everolimus or treatment with mTOR active-site inhibitors enhanced HLA-II Ab-stimulated phosphorylation of ERK.	Sirolimus	49-58	mitogen-activated protein kinase 1	Homo sapiens	168-171
29247557-0	2018	Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	88-91
28355970-2	2018	Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-47
28355970-2	2018	Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	74-88
28355970-2	2018	Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	90-94
29247557-0	2018	Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	92-96
29247557-2	2018	However, the effectiveness of treatment with the mTOR inhibitor rapamycin is often limited by chemoresistance.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	49-53
29247557-8	2018	Relationships between inhibition of the mTOR pathway, reactive oxygen species (ROS), and apoptosis and mitophagy reportedly increased the cytotoxic effects of rapamycin in HNSCC.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Homo sapiens	40-44
29247557-9	2018	Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	154-158
29247557-9	2018	Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity.	Sirolimus	54-63	AKT serine/threonine kinase 1	Homo sapiens	178-181
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	CD4 molecule	Homo sapiens	19-22
28786074-2	2018	We previously reported that pretreatment with perifosine, an inhibitor of Akt (also called protein kinase B), abolishes the rapamycin-induced paradoxical increase of S6 phosphorylation in a rat model induced by kainic acid (KA).	Sirolimus	124-133	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
29545903-0	2018	Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK.	Sirolimus	0-9	death associated protein kinase 1	Homo sapiens	134-138
29665934-9	2018	mTOR inhibitor rapamycin did not only inhibit the adipogenic differentiation of BM-MSCs from AA pateints at the early-middle stage, but also partly reversed the adipogenic differention of BM-MSCs from AA pateints at the late stage by PPARgamma regulation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
29665934-9	2018	mTOR inhibitor rapamycin did not only inhibit the adipogenic differentiation of BM-MSCs from AA pateints at the early-middle stage, but also partly reversed the adipogenic differention of BM-MSCs from AA pateints at the late stage by PPARgamma regulation.	Sirolimus	15-24	peroxisome proliferator activated receptor gamma	Homo sapiens	234-243
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	interleukin 4	Homo sapiens	103-116
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	CD4 molecule	Homo sapiens	150-153
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	CD4 molecule	Homo sapiens	150-153
29619032-4	2018	Addition of the mTOR inhibitor rapamycin to Treg cultures enhances FOXP3 expression and Treg stability, but does impair proliferative capacity.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	16-20
29619032-9	2018	Addition of rapamycin to CD28 superagonist-stimulated Treg led to a high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound TNFalpha.	Sirolimus	12-21	tumor necrosis factor	Homo sapiens	236-244
29562463-12	2018	On the contrary, RAPA-treated group exhibited CD4+ CD25+ Tregs with a reduction in apoptosis rate [(22.39+-3.71)%], Akt phosphorylation and Stat3 phosphorylation compared with the SAA group (P&lt;0.05, respectively).	Sirolimus	17-21	thymoma viral proto-oncogene 1	Mus musculus	116-119
29562463-12	2018	On the contrary, RAPA-treated group exhibited CD4+ CD25+ Tregs with a reduction in apoptosis rate [(22.39+-3.71)%], Akt phosphorylation and Stat3 phosphorylation compared with the SAA group (P&lt;0.05, respectively).	Sirolimus	17-21	signal transducer and activator of transcription 3	Mus musculus	140-145
29506489-9	2018	This technique further showed that the inhibition of AKT1 signaling is phenocopied by blocking the mTORC1 pathway with rapamycin.	Sirolimus	119-128	AKT serine/threonine kinase 1	Homo sapiens	53-57
29509701-1	2018	The mechanistic target of rapamycin (mTOR) is part of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AkT)/mTOR pathway and owes its name to the inhibitory effect of rapamycin.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	37-41
29509701-1	2018	The mechanistic target of rapamycin (mTOR) is part of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AkT)/mTOR pathway and owes its name to the inhibitory effect of rapamycin.	Sirolimus	26-35	AKT serine/threonine kinase 1	Homo sapiens	109-112
29509701-1	2018	The mechanistic target of rapamycin (mTOR) is part of the phosphoinositide-3-kinase (PI3K)/protein kinase B (AkT)/mTOR pathway and owes its name to the inhibitory effect of rapamycin.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	114-118
29670840-2	2018	Metformin and rapamycin may decrease the expression of VEGF protein and subsequently angiogenesis.	Sirolimus	14-23	vascular endothelial growth factor A	Homo sapiens	55-59
29670840-10	2018	Rapamycin but not metformin decreases VEGF gene expression in HepG2 cells.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	38-42
29072256-4	2018	Knockdown of mTOR or rictor, rather than raptor, mimicked the effects of rapamycin.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	13-17
29161463-14	2018	In turn, blockade of mTORC1 by 3-day rapamycin treatment enhanced transforming growth factor beta production, while dual blockade of mTORC1 and mTORC2 by 4-week rapamycin treatment induced autophagy, restored the expression of GATA-3 and CTLA-4, and corrected Treg cell function.	Sirolimus	37-46	transforming growth factor beta 1	Homo sapiens	66-97
29072256-5	2018	Ox-LDL (100 mug/mL) time-dependently increased PKC phosphorylation in HUVECs, which was abolished by rapamycin or rictor siRNA.	Sirolimus	101-110	proline rich transmembrane protein 2	Homo sapiens	47-50
29233209-4	2018	Here we report rapid regression of several massive cardiac rhadomyomas in two neonates with the use of the mammalian target of rapamycin inhibitor sirolimus.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	107-136
29334671-11	2018	Investigation of the underlying mechanism showed that glucosamine inhibited the phosphorylation of m-TOR in a concentration-dependent manner within 48 h, and rapamycin significantly inhibited the phosphorylation of m-TOR.	Sirolimus	158-167	RAR related orphan receptor C	Homo sapiens	217-220
29456672-11	2018	Rapamycin was able to inhibit the effect of testosterone and promoted prostate tissue hyperplasia by inhibiting the PI3K/Akt pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	121-124
28969943-7	2018	The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	39-43
28969943-7	2018	The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13.	Sirolimus	54-63	interleukin 13	Homo sapiens	150-155
28969943-8	2018	Moreover, 4E-BP1, a target of mTOR, appeared to mediate the protective effects of rapamycin.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	30-34
29314656-2	2018	Rapamycin is an inhibitor of serine/threonine kinase mammalian target of rapamycin (mTOR) involved in the regulation of autophagy as well as oxidative/nitrative stress.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	53-82
29599839-4	2018	It was revealed that rapamycin significantly downregulated the mesenchymal cell marker, alpha-smooth muscle actin, and significantly upregulated the epithelial cell marker, E-cadherin, at mRNA and protein expression levels compared with the PQ group.	Sirolimus	21-30	cadherin 1	Homo sapiens	173-183
29190547-7	2018	Treatment of H23 cells with mTOR siRNA or the mTOR inhibitor rapamycin abrogated LF-activated Akt-mTOR-Hif1-Foxo signaling and stemness-associated sonic hedgehog pathway, reversed Warburg metabolic switch and diminished invasion of H23 cells.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
29190547-7	2018	Treatment of H23 cells with mTOR siRNA or the mTOR inhibitor rapamycin abrogated LF-activated Akt-mTOR-Hif1-Foxo signaling and stemness-associated sonic hedgehog pathway, reversed Warburg metabolic switch and diminished invasion of H23 cells.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	94-97
29190547-7	2018	Treatment of H23 cells with mTOR siRNA or the mTOR inhibitor rapamycin abrogated LF-activated Akt-mTOR-Hif1-Foxo signaling and stemness-associated sonic hedgehog pathway, reversed Warburg metabolic switch and diminished invasion of H23 cells.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	46-50
29190547-7	2018	Treatment of H23 cells with mTOR siRNA or the mTOR inhibitor rapamycin abrogated LF-activated Akt-mTOR-Hif1-Foxo signaling and stemness-associated sonic hedgehog pathway, reversed Warburg metabolic switch and diminished invasion of H23 cells.	Sirolimus	61-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	103-107
29314656-2	2018	Rapamycin is an inhibitor of serine/threonine kinase mammalian target of rapamycin (mTOR) involved in the regulation of autophagy as well as oxidative/nitrative stress.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	84-88
29314656-8	2018	Moreover, rapamycin significantly mitigated MI/R-induced endoplasmic reticulum stress and mitochondrial impairment demonstrated by reduced Caspase-12 activity, inhibited CHOP activation, decreased cytoplasmic Cyto-C release and preserved intact mitochondria.	Sirolimus	10-19	DNA damage inducible transcript 3	Homo sapiens	170-174
29328421-11	2018	It is worth noting that the inhibition of mTOR by rapamycin or of PI3K/Akt by LY294002 augmented curcumin-induced apoptosis and autophagy, leading to significant inhibition of cell proliferation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	42-46
29087803-4	2018	Both approved mTOR inhibitors everolimus and sirolimus are widely used as immunosuppressive agents after organ transplantation.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	14-18
29343616-1	2018	Rapamycin, the macrolide immunosuppressant and active pharmaceutic in drug-eluting stents (DES), has a well-recognized antiproliferative action that involves inhibition of the mTOR pathway after binding to the cytosolic protein FKBP12.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	176-180
29515583-9	2018	Small-molecule enhancer of rapamycin 3, an ubiquitin ligase inhibitor reversed the K63-linked polyubiquitination on TRAF6 in R848-primed BMDMs and subsequently decreased TAK1 and MAPK phosphorylation, and cytokine production as well as reversed the decreased bacterial clearance capacity of BMDMs.	Sirolimus	27-36	TNF receptor-associated factor 6	Mus musculus	116-121
29343616-9	2018	In addition, rapamycin induction of endothelial-to-mesenchymal transition (EndMT) was potentiated by IL-1beta and efficiently blocked by TGFRIi.	Sirolimus	13-22	interleukin 1 beta	Homo sapiens	101-109
29378959-3	2018	We found that rapamycin extended life span in control normal (N) mice, whereas it had the opposite effect in GHR-KO mice.	Sirolimus	14-23	growth hormone receptor	Mus musculus	109-112
29378959-5	2018	Glucose and lipid homeostasis were impaired, and old GHR-KO mice treated with rapamycin lost functional immune cells and had increased inflammation.	Sirolimus	78-87	growth hormone receptor	Mus musculus	53-56
29424687-4	2018	We report the architecture of human mTORC2 at intermediate resolution, revealing a conserved binding site for accessory proteins on mTOR and explaining the structural basis for the rapamycin insensitivity of the complex.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	36-40
29445291-7	2018	Results: Rapamycin, AZD8055, and cardamonin inhibited the activity of mammalian target of rapamycin (mTOR).	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	70-99
29445291-7	2018	Results: Rapamycin, AZD8055, and cardamonin inhibited the activity of mammalian target of rapamycin (mTOR).	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	101-105
29416002-5	2018	Moreover, when compared with counterparts, chloroquine alone, or chloroquine with rapamycin treatment led to more LC3II accumulation in EZH2 inhibited or knockdown VSMCs, which indicated that EZH2 negatively regulated autophagosome formation.	Sirolimus	82-91	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	136-140
29439710-10	2018	Rapamycin, an inhibitor of AKT/mTOR, could reverse the effects of SeMet on OTA-induced autophagy and the PCV2 replication promotion.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-35
29416002-5	2018	Moreover, when compared with counterparts, chloroquine alone, or chloroquine with rapamycin treatment led to more LC3II accumulation in EZH2 inhibited or knockdown VSMCs, which indicated that EZH2 negatively regulated autophagosome formation.	Sirolimus	82-91	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	192-196
28488736-1	2018	Rapamycin (mTOR inhibitor) has been reported to have negative effect on human male gonadal function.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	11-15
29132870-8	2018	We found that RAPA-treated PMN-MDSCs can restrain the differentiation of Th1/Th2 cells and promote induction of regulatory T cells in in vitro studies.	Sirolimus	14-18	negative elongation factor complex member C/D, Th1l	Mus musculus	73-76
29270715-5	2018	Furthermore, p70S6K knockdown and the specific mTOR inhibitor rapamycin decreased the expression levels of p-p70S6K and alpha-SMA in cultured fibroblasts from grade T3 pterygium.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	47-51
29100748-6	2018	Notably, inhibition of autophagy in NaF-treated SH-SY5Y cells with Wortmannin or Chloroquine decreased, while induction of autophagy by Rapamycin increased the cell viability.	Sirolimus	136-145	C-X-C motif chemokine ligand 8	Homo sapiens	36-39
29160909-4	2018	Sirolimus/everolimus (mammalian target of rapamycin [mTOR] inhibitors) was added to baseline immunosuppression as rescue therapy in patients with CR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	22-51
29160909-4	2018	Sirolimus/everolimus (mammalian target of rapamycin [mTOR] inhibitors) was added to baseline immunosuppression as rescue therapy in patients with CR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	53-57
30074157-0	2018	Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity.	Sirolimus	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	31-45
30074157-7	2018	The results revealed that rapamycin treatment significantly attenuated the incidence of Ang II induced-AAA in ApoE-/- mice.	Sirolimus	26-35	apolipoprotein E	Mus musculus	110-114
30074157-11	2018	Moreover, rapamycin reversed Ang II -induced VSMCs phenotypic change both in vivo and in vitro.	Sirolimus	10-19	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	29-35
29310109-15	2018	Moreover, long-term administration of sirolimus would up-regulate sCEACAM-1 level, while exert similar regulatory effects on Tim-3 and Gal-9 compared to tacrolimus.	Sirolimus	38-47	galectin 9	Homo sapiens	135-140
29146131-3	2018	Although we have already confirmed that topical rapamycin treatment (an mTOR inhibitor) protects patients with TSC against macular hypopigmentation, the pathogenesis of such lesions remains poorly understood.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	72-76
29434854-5	2018	Additionally, the combined treatment with COE and rapamycin (an mTOR inhibitor) acted synergistically in ECA-109 cells compared with the treatment with COE or rapamycin alone.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	64-68
29224866-8	2018	Inhibition of mTORC1 by rapamycin attenuated the phosphorylation of molecules related to mTORC1 signaling and caused a marked decrease in LAT1 expression in the cultured cells; expression of beta-casein also decreased significantly.	Sirolimus	24-33	casein beta	Bos taurus	191-202
29434877-6	2018	Additionally, metformin (20 mmol/l) + rapamycin (200 ng/ml) significantly suppressed the expression of phosphorylated mTOR compared with metformin or rapamycin alone.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	118-122
28843050-6	2018	This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	72-76
29434877-6	2018	Additionally, metformin (20 mmol/l) + rapamycin (200 ng/ml) significantly suppressed the expression of phosphorylated mTOR compared with metformin or rapamycin alone.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	118-122
29074462-7	2018	Researchers show that mTOR inhibitor rapamycin reduces telomerase activity without changing hTERT mRNA activity.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	22-26
28263222-3	2018	mTOR inhibitors, when used as immunosuppressive agents (sirolimus, everolimus), can induce diabetes with an incidence which is low when used without calcineurin inhibitors but high when used in combination with calcineurin inhibitors (from 11.0% to 38.1%).	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	0-4
29339522-1	2018	Lymphangioleiomyomatosis (LAM), a rare disease of women, is associated with cystic lung destruction resulting from the proliferation of abnormal smooth muscle-like LAM cells with mutations in the tuberous sclerosis complex (TSC) genes TSC1 and/or TSC2 The mutant genes and encoded proteins are responsible for activation of the mechanistic target of rapamycin (mTOR), which is inhibited by sirolimus (rapamycin), a drug used to treat LAM.	Sirolimus	390-399	TSC complex subunit 1	Homo sapiens	224-227
29369972-3	2018	Agents that inhibit mTOR, such as sirolimus and everolimus, are incorporated in immunosuppressive regimens to prevent renal allograft rejection and are often used to facilitate calcineurin inhibitor minimization or to reduce the incidence of tumor recurrence.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	20-24
29339522-1	2018	Lymphangioleiomyomatosis (LAM), a rare disease of women, is associated with cystic lung destruction resulting from the proliferation of abnormal smooth muscle-like LAM cells with mutations in the tuberous sclerosis complex (TSC) genes TSC1 and/or TSC2 The mutant genes and encoded proteins are responsible for activation of the mechanistic target of rapamycin (mTOR), which is inhibited by sirolimus (rapamycin), a drug used to treat LAM.	Sirolimus	350-359	TSC complex subunit 1	Homo sapiens	224-227
29382066-1	2018	Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	65-68
29382066-1	2018	Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	107-110
29382066-1	2018	Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	111-115
29492193-8	2018	Our data indicate that there is a significant involvement of the mTOR network in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful therapeutic approach in this clinical setting.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	65-69
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	matrix metallopeptidase 3	Homo sapiens	53-58
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	matrix metallopeptidase 13	Homo sapiens	60-66
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	68-76
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	interleukin 6	Homo sapiens	78-82
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	84-93
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	cyclin dependent kinase inhibitor 2A	Homo sapiens	117-120
29348392-10	2018	Our findings demonstrated that mammalian target of rapamycin (mTOR) signaling affects cellular senescence, catabolic and inflammatory responses, and multi-differentiation potential, suggesting that potential treatment value of rapamycin for disc degenerative diseases, especially lower back pain.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	62-66
29186990-1	2018	Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressive, antiproliferative, antiangiogenic, antifungal, anti-restenosis and anti-inflammatory properties.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
29186990-1	2018	Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressive, antiproliferative, antiangiogenic, antifungal, anti-restenosis and anti-inflammatory properties.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	58-62
29186990-1	2018	Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressive, antiproliferative, antiangiogenic, antifungal, anti-restenosis and anti-inflammatory properties.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	27-56
29186990-1	2018	Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with immunosuppressive, antiproliferative, antiangiogenic, antifungal, anti-restenosis and anti-inflammatory properties.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	58-62
29749806-2	2018	Interestingly, it has been demonstrated that in the human proximal tubular renal cell line, HK-2, the MTOR inhibitor rapamycin enhanced autophagy and mitigated the apoptosis damage induced by urinary protein overload.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	102-106
29099279-4	2018	Pharmacological inhibition of MTOR activity by rapamycin (RPM) causes severe thymic atrophy and reduction of TECs.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	30-34
29099279-4	2018	Pharmacological inhibition of MTOR activity by rapamycin (RPM) causes severe thymic atrophy and reduction of TECs.	Sirolimus	58-61	mechanistic target of rapamycin kinase	Homo sapiens	30-34
28881154-4	2018	The possible role of mTOR was evaluated by the injection of rapamycin (5 mg/kg body weight, by intraperitoneal injection) before I/R was induced.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	21-25
30044707-7	2018	Consistently, interference of MTORC1 activation with rapamycin or with a constitutively activated RRAGA mutant at the peak or nadir of MTORC1 oscillation enhanced or reduced the lysosome function, respectively.	Sirolimus	53-62	origin recognition complex, subunit 1	Mus musculus	30-36
30044707-7	2018	Consistently, interference of MTORC1 activation with rapamycin or with a constitutively activated RRAGA mutant at the peak or nadir of MTORC1 oscillation enhanced or reduced the lysosome function, respectively.	Sirolimus	53-62	origin recognition complex, subunit 1	Mus musculus	135-141
29975938-9	2018	However, the AMPK activator AICAR and the mTOR inhibitor rapamycin reduced the protective effects of melatonin on IRI.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	42-46
30138914-6	2018	To activate NLRP3 inflammasome and autophagy, Caco-2 cells were treated with LPS+ATP and rapamycin respectively without or with SCFAs.	Sirolimus	89-98	NLR family pyrin domain containing 3	Homo sapiens	12-17
29554648-12	2018	Increased phospho-AMPKalpha, CHOP and Grp78 as well as cellular apoptosis were prevented by mTOR inhibitor rapamycin in HG-treated podocytes.	Sirolimus	107-116	DNA damage inducible transcript 3	Homo sapiens	29-33
29466794-6	2018	Either treatment with FOXO1 siRNA or resveratrol, a sirt1 agonist, inhibited autophagic flux, resulting in oxidative stress, mitochondrial dysfunction (MtD) and apoptosis in QBC939 cells, which were attenuated by enhancing autophagy with rapamycin.	Sirolimus	238-247	forkhead box O1	Homo sapiens	22-27
29554648-12	2018	Increased phospho-AMPKalpha, CHOP and Grp78 as well as cellular apoptosis were prevented by mTOR inhibitor rapamycin in HG-treated podocytes.	Sirolimus	107-116	heat shock protein family A (Hsp70) member 5	Homo sapiens	38-43
29554648-12	2018	Increased phospho-AMPKalpha, CHOP and Grp78 as well as cellular apoptosis were prevented by mTOR inhibitor rapamycin in HG-treated podocytes.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	92-96
28696243-5	2018	Clinical trials using allosteric mTOR inhibitors (rapamycin and rapalogs) to treat patients with glioblastoma have also been unsuccessful or uncertain, in part, because rapamycin inefficiently blocks the mTORC1 target 4EBP1 and feeds back to activate PI3K-AKT signaling.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	33-37
29113979-9	2018	Substitution of the basic amino acid repeats in the Ure2 relief sequence or phosphomimetic aspartate substitutions for the serine residues between them abolishes nuclear Gln3-Myc13 localization in response to both limiting nitrogen and rapamycin treatment.	Sirolimus	236-245	glutathione peroxidase	Saccharomyces cerevisiae S288C	52-56
29758934-3	2018	The mTOR pathway which is found to be regulated in lipomatous tissue as well as associated with brown adipose tissue can be inhibited by a compound called rapamycin.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28888335-2	2018	mTOR inhibitors (Sirolimus and Everolimus) are currently approved only for the treatment of growing subependymal giant cell astrocytomas, renal angiomyolipomas and lymphangioleiomyomatosis in TSC.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	0-4
29478616-5	2018	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce renal and brain lesion size, and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
29478616-5	2018	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce renal and brain lesion size, and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	20-29	TSC complex subunit 1	Homo sapiens	146-149
29190625-3	2018	Inhibition of the mTOR complex 1 (mTORC1) with rapamycin is currently the only known pharmacological treatment that increases lifespan in all model organisms studied.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	18-22
28475412-8	2018	Importantly, a clinically used mTOR inhibitor, rapamycin, potently inhibited both experimental and patient-derived rotavirus strains.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	31-35
29478616-5	2018	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce renal and brain lesion size, and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	4-8
29478616-5	2018	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce renal and brain lesion size, and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	31-40	TSC complex subunit 1	Homo sapiens	146-149
28300280-2	2018	Recently, we have reported that rapamycin, a macrocyclic lactone, attenuates human soluble BAFF (hsBAFF)-stimulated B-cell proliferation/survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	161-165
28300280-3	2018	Here, we show that the inhibitory effect of rapamycin on hsBAFF-promoted B cell proliferation/survival is also related to blocking hsBAFF-stimulated phosphorylation of Akt, S6K1, and 4E-BP1, as well as expression of survivin in normal and B-lymphoid (Raji and Daudi) cells.	Sirolimus	44-53	AKT serine/threonine kinase 1	Homo sapiens	168-171
29195127-5	2018	Exposure with rapamycin enhanced the cytotoxicity of NK cells by upregulating the expression of IL-27 in UECC and IL-27 receptors (IL-27Rs: WSX-1 and gp130) on NK cells and further restricted the growth of UEC in Ishikawa-xenografted nude mice.	Sirolimus	14-23	interleukin 27 receptor, alpha	Mus musculus	140-145
29195127-5	2018	Exposure with rapamycin enhanced the cytotoxicity of NK cells by upregulating the expression of IL-27 in UECC and IL-27 receptors (IL-27Rs: WSX-1 and gp130) on NK cells and further restricted the growth of UEC in Ishikawa-xenografted nude mice.	Sirolimus	14-23	interleukin 6 signal transducer	Mus musculus	150-155
30779006-3	2018	Caloric restriction, the most widely studied longevity promoting intervention, works through multiple nutrient signaling pathways, while inhibition of mTOR through treatment with rapamycin reproducibly delays ageing and disease through specific inhibition of the mTOR complexes.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	151-155
30779006-3	2018	Caloric restriction, the most widely studied longevity promoting intervention, works through multiple nutrient signaling pathways, while inhibition of mTOR through treatment with rapamycin reproducibly delays ageing and disease through specific inhibition of the mTOR complexes.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	263-267
30056926-0	2018	Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	23-52
28777210-9	2018	In contrast, the systemic production of IL-10 was markedly elevated in old recipients treated with rapamycin.	Sirolimus	99-108	interleukin 10	Mus musculus	40-45
28777210-10	2018	In parallel to this shift in cytokine balance, IFN-gamma/IL-10 double-positive regulatory type 1 cells emerged during T helper type 1 differentiation of old T helper cells in presence of rapamycin.	Sirolimus	187-196	interferon gamma	Mus musculus	47-56
28777210-10	2018	In parallel to this shift in cytokine balance, IFN-gamma/IL-10 double-positive regulatory type 1 cells emerged during T helper type 1 differentiation of old T helper cells in presence of rapamycin.	Sirolimus	187-196	interleukin 10	Mus musculus	57-62
29287601-8	2017	RESULTS: Inhibition of mTOR signaling using rapamycin enhanced the immunosuppressive functions of MSCs, while prolonged exposure to rapamycin did not.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	23-27
29282029-10	2017	However, addition of rapamycin, an inhibitor of the mTOR signaling pathways, 1 h before addition of estradiol or insulin increased the pAkt/Akt ratio and FASN expression, and this effect was inhibited by addition of DHA 48 h before rapamycin.	Sirolimus	21-30	insulin	Homo sapiens	113-120
29056443-8	2017	Further, we report on successful co-loading of 17-AAG (Hsp90) and rapamycin (mTOR) (g-EAR).	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	77-81
29282029-10	2017	However, addition of rapamycin, an inhibitor of the mTOR signaling pathways, 1 h before addition of estradiol or insulin increased the pAkt/Akt ratio and FASN expression, and this effect was inhibited by addition of DHA 48 h before rapamycin.	Sirolimus	21-30	AKT serine/threonine kinase 1	Homo sapiens	136-139
29269724-1	2017	BACKGROUND Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor, which is used in immunosuppressive treatment regimens in organ transplant recipients.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	26-55
29468175-11	2018	Rapamycin markedly decreased the number of FJB-positive cells and the expression of cleaved caspase-3 and cleaved caspase-9 proteins as well as increased the activation of autophagy reflected by ULK1, Beclin-1 and LC3.	Sirolimus	0-9	caspase 9	Rattus norvegicus	114-123
29468175-11	2018	Rapamycin markedly decreased the number of FJB-positive cells and the expression of cleaved caspase-3 and cleaved caspase-9 proteins as well as increased the activation of autophagy reflected by ULK1, Beclin-1 and LC3.	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	195-199
29269724-1	2017	BACKGROUND Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor, which is used in immunosuppressive treatment regimens in organ transplant recipients.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	57-61
29246172-1	2017	We first introduced the concept of the mTOR pathway"s involvement in congenital hyperinsulinism of infancy (CHI), based largely on morphoproteomic observations and clinical outcomes using sirolimus (rapamycin) as a therapeutic agent in infants refractory to octreotide and diazoxide treatment.	Sirolimus	188-197	mechanistic target of rapamycin kinase	Homo sapiens	39-43
29021448-1	2017	Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM).	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	37-66
29246172-1	2017	We first introduced the concept of the mTOR pathway"s involvement in congenital hyperinsulinism of infancy (CHI), based largely on morphoproteomic observations and clinical outcomes using sirolimus (rapamycin) as a therapeutic agent in infants refractory to octreotide and diazoxide treatment.	Sirolimus	199-208	mechanistic target of rapamycin kinase	Homo sapiens	39-43
29040365-8	2017	Meanwhile, rapamycin, an mTOR inhibitor, reversed the increased cell proliferation induced by the HPV11 L1-L2 plasmid.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	25-29
29240812-9	2017	In addition, vaspin increased the phosphorylation levels of mTOR and p70S6K, which was inhibited by rapamycin.	Sirolimus	100-109	serpin family A member 12	Rattus norvegicus	13-19
29238469-7	2017	Immunohistochemistry results indicated that sirolimus increased the expressions of podocin and ZO-1 at the early DN (P&lt;0.05), but reduced the expressions of ZO-1 and podocin (P&lt;0.05) at the advanced DN.	Sirolimus	44-53	NPHS2 stomatin family member, podocin	Rattus norvegicus	83-90
27860549-4	2017	Our findings suggest five novel potential mTOR inhibitors, with similar or better properties than the classic inhibitor complex, rapamycin.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	42-46
28888969-5	2017	In addition, we pharmacologically validated the TSC model by demonstrating the dramatic rescue effect of pericardially injected rapamycin, a well-known mTOR inhibitor, on selected behavioral read-outs and at the molecular level.	Sirolimus	128-137	TSC complex subunit 2	Danio rerio	48-51
28888969-5	2017	In addition, we pharmacologically validated the TSC model by demonstrating the dramatic rescue effect of pericardially injected rapamycin, a well-known mTOR inhibitor, on selected behavioral read-outs and at the molecular level.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Danio rerio	152-156
28885497-7	2017	By 21 days (10 days after drug withdrawal), however, T follicular helper and B cells and donor-specific IgG1 and IgG2c antibody titers were significantly lower in RAPA-treated compared with AZD2014-treated mice.	Sirolimus	163-167	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	104-108
29162840-0	2017	Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3beta/mTOR Signaling.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	130-134
29162840-6	2017	Furthermore, combining WPC with rapamycin depleted GSH levels and reduced Nrf2 nuclear accumulation.	Sirolimus	32-41	NFE2 like bZIP transcription factor 2	Homo sapiens	74-78
29127369-6	2017	Only rapamycin proved effective against acute Th17-dependent airway inflammation, accompanied by increased plasmacytoid dendritic cells (pDCs) and reduced neutrophils as well as reduced CXCL-1 levels in BAL.	Sirolimus	5-14	chemokine (C-X-C motif) ligand 1	Mus musculus	186-192
29158477-3	2017	Here we show that sirolimus impairs glucose-stimulated insulin secretion both in human and murine pancreatic islets and in clonal beta cells in a dose- and time-dependent manner.	Sirolimus	18-27	insulin	Homo sapiens	55-62
29158477-6	2017	Taken together, our findings indicate that sirolimus causes depletion of intracellular Ca2+ stores and alters mitochondrial fitness, eventually leading to decreased insulin release.	Sirolimus	43-52	insulin	Homo sapiens	165-172
29165314-2	2017	Metformin and rapamycin are two FDA-approved mTOR inhibitors proposed for this purpose, exhibiting significant anti-cancer and anti-aging properties beyond their current clinical applications.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	45-49
29078414-1	2017	In my PNAS Inaugural Article, I describe the development of the mTOR field, starting with efforts to understand the mechanism of action of the drug rapamycin, which ~25 y ago led to the discovery of the mTOR protein kinase.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	203-207
29078414-1	2017	In my PNAS Inaugural Article, I describe the development of the mTOR field, starting with efforts to understand the mechanism of action of the drug rapamycin, which ~25 y ago led to the discovery of the mTOR protein kinase.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	64-68
29061787-10	2017	Interestingly, the expression of P-gp was synergistically inhibited by combined treatment of U0126 with LY294002 and also inhibited by an mTORC1 inhibitor, rapamycin.	Sirolimus	156-165	ATP binding cassette subfamily B member 1	Homo sapiens	33-37
28903183-4	2017	Rapamycin is a well-know potent antiangiogenic agent, whereas the daily oral administration of rapamycin exerts undesired metabolic effects due to its inhibition of mechanistic target of rapamycin (mTOR) which is critical in cell metabolism.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	198-202
28903183-4	2017	Rapamycin is a well-know potent antiangiogenic agent, whereas the daily oral administration of rapamycin exerts undesired metabolic effects due to its inhibition of mechanistic target of rapamycin (mTOR) which is critical in cell metabolism.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	165-196
28903183-4	2017	Rapamycin is a well-know potent antiangiogenic agent, whereas the daily oral administration of rapamycin exerts undesired metabolic effects due to its inhibition of mechanistic target of rapamycin (mTOR) which is critical in cell metabolism.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	198-202
28916337-13	2017	Rapamycin can enhance the level of autophagy by inhibiting mTOR, and 3-methyladenine (3-MA) can inhibit autophagosome formation through blocking class III phosphatidylinositol 3-kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	59-63
28836710-2	2017	We present a 9-year-old girl, remote from transplant, who presented with airway plaque after a change in immunosuppression to include the mTOR inhibitor sirolimus.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	138-142
28954814-7	2017	Induction of autophagy by adiponectin or rapamycin attenuated HIHG-induced ER stress and improved insulin sensitivity.	Sirolimus	41-50	insulin	Homo sapiens	98-105
28220552-9	2017	Furthermore, when the mTOR inhibitor rapamycin was administered with ketamine to the HBdMECs, the expression of FSP-1 decreased significantly.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	22-26
28882485-9	2017	Both the phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002 and the mammalian target of rapamycin (mTOR) inhibitor rapamycin abolished ZnCl2-induced transport stimulation.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	105-109
29085896-1	2017	Following traumatic brain injury (TBI), treatment with rapamycin suppresses mammalian (mechanistic) target of rapamycin (mTOR) activity and specific components of hippocampal synaptic reorganization associated with altered cortical excitability and seizure susceptibility.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	121-125
29062000-6	2017	Further analysis of the Gap1 permease showed that FTY720 elicits its ubiquitylation via the same factors that promote this modification when TORC1 is inhibited by rapamycin.	Sirolimus	163-172	amino acid permease GAP1	Saccharomyces cerevisiae S288C	24-28
28807764-6	2017	However, SEC2/ST-4-induced changes in cell cycle and PI3K/mTOR signaling were significantly relieved by either LY294002 or rapamycin, and the induction of NF-kB/p65 induced was significantly downregulated by Bay11-7085.	Sirolimus	123-132	fucosyltransferase 2	Homo sapiens	9-13
28807764-6	2017	However, SEC2/ST-4-induced changes in cell cycle and PI3K/mTOR signaling were significantly relieved by either LY294002 or rapamycin, and the induction of NF-kB/p65 induced was significantly downregulated by Bay11-7085.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	58-62
28729300-5	2017	Rapamycin effectively reduced Th1 inflammatory cytokines interferon-gamma and tumor necrosis factor-alpha, increased the Th2 cytokine interleukin-10, stimulated expansion of functional regulatory T cells, eliminated effector CD8+ T cells (notably T cells specific to target cells bearing minor histocompatibility antigen H60), and preserved hematopoietic stem and progenitor cells.	Sirolimus	0-9	negative elongation factor complex member C/D, Th1l	Mus musculus	30-33
28608572-9	2017	Among the missense mutations, one in the rapamycin-insensitive companion of mammalian target of rapamycin (RICTOR)-coding gene (rs140964083: G > A, found in one proband) was predicted to be hazardous.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	76-105
29021349-6	2017	We found that Akt-mTORC1 (mammalian target of rapamycin complex 1) signaling was increased, and treatment with 2.24 mg/kg d rapamycin or 40% caloric restriction for 9 weeks partially rescued cardiomyopathy or heart failure and restored autophagic flux in knockin mice.	Sirolimus	46-55	AKT serine/threonine kinase 1	Homo sapiens	14-17
28729300-5	2017	Rapamycin effectively reduced Th1 inflammatory cytokines interferon-gamma and tumor necrosis factor-alpha, increased the Th2 cytokine interleukin-10, stimulated expansion of functional regulatory T cells, eliminated effector CD8+ T cells (notably T cells specific to target cells bearing minor histocompatibility antigen H60), and preserved hematopoietic stem and progenitor cells.	Sirolimus	0-9	interferon gamma	Mus musculus	57-105
28729300-5	2017	Rapamycin effectively reduced Th1 inflammatory cytokines interferon-gamma and tumor necrosis factor-alpha, increased the Th2 cytokine interleukin-10, stimulated expansion of functional regulatory T cells, eliminated effector CD8+ T cells (notably T cells specific to target cells bearing minor histocompatibility antigen H60), and preserved hematopoietic stem and progenitor cells.	Sirolimus	0-9	interleukin 10	Mus musculus	134-148
31966350-2	2017	Rapamycin (RAPA), a highly specific inhibitor of mTOR, is widely used in cancer studies for its antiangiogenic activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-53
31966350-2	2017	Rapamycin (RAPA), a highly specific inhibitor of mTOR, is widely used in cancer studies for its antiangiogenic activity.	Sirolimus	11-15	mechanistic target of rapamycin kinase	Homo sapiens	49-53
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	signal transducer and activator of transcription 3	Mus musculus	129-134
28432555-3	2017	Rotundarpene, Akt inhibitor, Bay 11-7085, rapamycin, and N-acetylcysteine inhibited the TNF-alpha-stimulated production of cytokines and chemokines, increase in the levels of p-Akt and mTOR, activation of NF-kappaB, and production of reactive oxygen species in keratinocytes.	Sirolimus	42-51	tumor necrosis factor	Homo sapiens	88-97
28710231-4	2017	Previously, we identified rapamycin-insensitive upregulation of cyclooxygenase 2 (PTGS2/COX2) and prostaglandin E2 (PGE2) production in TSC2-deficient cells and postulated that the action of excess PGE2 and its cognate receptors (EP) contributes to cell survival.	Sirolimus	26-35	prostaglandin-endoperoxide synthase 2	Homo sapiens	64-80
28710231-4	2017	Previously, we identified rapamycin-insensitive upregulation of cyclooxygenase 2 (PTGS2/COX2) and prostaglandin E2 (PGE2) production in TSC2-deficient cells and postulated that the action of excess PGE2 and its cognate receptors (EP) contributes to cell survival.	Sirolimus	26-35	prostaglandin-endoperoxide synthase 2	Homo sapiens	82-87
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	sequestosome 1	Rattus norvegicus	231-245
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	251-271
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Rattus norvegicus	273-277
27660271-6	2017	In addition, rapamycin induced the activation of autophagy that further activated p-PI3K, p-Akt1 (Ser473), and p-CREB (Ser183) expression in Abeta1-42-treated rats.	Sirolimus	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	92-96
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	signal transducer and activator of transcription 3	Mus musculus	136-141
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	signal transducer and activator of transcription 3	Mus musculus	136-141
28722255-3	2017	All of these agents are inhibitors of cytochrome P450 3A4, which plays a key role in metabolizing immunosuppressant drugs such as cyclosporine, tacrolimus, and sirolimus.	Sirolimus	160-169	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-57
29070114-0	2017	[Effects of mTOR Inhibitor Rapamycin on Burkitt"s Lymphoma Cells].	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	12-16
28514891-3	2017	Herein, we have investigated the beneficial effect of cotreatment with CRM-candidate drugs, rapamycin (an immunosuppressant drug and inhibitor of mammalian target of rapamycin) and metformin (an antidiabetic biguanide and activator of adenosine monophosphate kinase), against aging-induced oxidative stress in erythrocytes and plasma of aging rats.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	146-175
29070114-1	2017	OBJECTIVE: To explore the effects of mTOR inhibitor rapamycin on proliferation, cell cycle and apoptosis of Burkitt"s lymphoma cell line Raji and CA46 cells and its mechanism, so as to provide the experimental evidence for a therapeutic target of Burkitt"s lymphoma.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
29070114-5	2017	The expressions of RPS6, p-RPS6, survivin and caspase-3 proteins were detected by Western blot after treating with rapamycin.	Sirolimus	115-124	caspase 3	Homo sapiens	46-55
29070114-10	2017	After treatment with rapamycin, the expression of p-RPS6 and survivin of Raji and CA46 cells was obviously down-regulated, the expression of caspase-3 was obviously up-regulated in a time- and dose-dependent manners.	Sirolimus	21-30	caspase 3	Homo sapiens	141-150
28993730-8	2017	However, targeting the altered biological pathways (mTOR, PDGFRB, FGF2, HDAC) guided identification of possibly beneficial treatment with a combination of sirolimus, thalidomide, sunitinib, and vorinostat.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	52-56
28926611-2	2017	Here, we report that the mTOR inhibitors rapamycin (sirolimus) and structurally related temsirolimus are capable of inducing UPR in sarcoma cells.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	25-29
28931653-3	2017	Conversely, mechanistic target of rapamycin (mTOR) inhibition with sirolimus is more Treg-compatible but is inadequate to fully control Teff activation.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	12-43
28931653-3	2017	Conversely, mechanistic target of rapamycin (mTOR) inhibition with sirolimus is more Treg-compatible but is inadequate to fully control Teff activation.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Homo sapiens	45-49
28926611-2	2017	Here, we report that the mTOR inhibitors rapamycin (sirolimus) and structurally related temsirolimus are capable of inducing UPR in sarcoma cells.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	25-29
28637240-1	2017	Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in either of two genes, TSC1 or TSC2, resulting in the constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	201-210	TSC complex subunit 1	Homo sapiens	28-31
28979705-7	2017	Furthermore, Rictor knockdown attenuated cell cycle progression and enhanced apoptosis, synergistic with treatment of mTORC1 inhibitor rapamycin owing to abrogating the feedback activation of Akt.	Sirolimus	135-144	AKT serine/threonine kinase 1	Homo sapiens	192-195
28894133-8	2017	Rapamycin abrogated 5-MTP-mediated suppression of p16, p21, SA-beta-Gal and IL-6 and rise of BrdU incorporation.	Sirolimus	0-9	cyclin dependent kinase inhibitor 2A	Homo sapiens	50-53
28894133-8	2017	Rapamycin abrogated 5-MTP-mediated suppression of p16, p21, SA-beta-Gal and IL-6 and rise of BrdU incorporation.	Sirolimus	0-9	interleukin 6	Homo sapiens	76-80
28676933-2	2017	The metabolism of temsirolimus and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 (CYP3A4/A5) and the ABCB1 transporter.	Sirolimus	21-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-106
28676933-2	2017	The metabolism of temsirolimus and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 (CYP3A4/A5) and the ABCB1 transporter.	Sirolimus	21-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
28676933-2	2017	The metabolism of temsirolimus and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 (CYP3A4/A5) and the ABCB1 transporter.	Sirolimus	21-30	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
28676933-11	2017	These NR1I2 SNPs were also predictive of temsirolimus half-life and global exposure to temsirolimus and sirolimus.	Sirolimus	44-53	nuclear receptor subfamily 1 group I member 2	Homo sapiens	6-11
28676933-12	2017	Finally, the effect of the ABCB1-rs1128503, ABCB1-rs2032582 and CYP3A5*3 SNPs on sirolimus pharmacokinetics was confirmed.	Sirolimus	81-90	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
28676933-12	2017	Finally, the effect of the ABCB1-rs1128503, ABCB1-rs2032582 and CYP3A5*3 SNPs on sirolimus pharmacokinetics was confirmed.	Sirolimus	81-90	ATP binding cassette subfamily B member 1	Homo sapiens	44-49
28676933-12	2017	Finally, the effect of the ABCB1-rs1128503, ABCB1-rs2032582 and CYP3A5*3 SNPs on sirolimus pharmacokinetics was confirmed.	Sirolimus	81-90	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	64-70
28637240-1	2017	Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in either of two genes, TSC1 or TSC2, resulting in the constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	201-210	TSC complex subunit 1	Homo sapiens	119-123
28667702-4	2017	Hamartin-Tuberin complex is involved in the phosphoinositide 3-kinase-protein kinase B-mammalian target of rapamycin signal transduction pathway, and suppresses mammalian target of rapamycin complex 1 activity, which is a center for various functions.	Sirolimus	107-116	TSC complex subunit 1	Homo sapiens	0-8
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28711252-9	2017	Although ethyl-cellulose RPM supplementation increased milk protein content by 0.16 percentage units compared with the control during the fresh period, no differences were observed for milk fat, lactose, and milk urea nitrogen concentration.	Sirolimus	25-28	Weaning weight-maternal milk	Bos taurus	55-59
28724580-10	2017	mTOR activation was central to this process, because rapamycin systematically inhibited the beneficial effect of recombinant human IL-7.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	0-4
28724580-10	2017	mTOR activation was central to this process, because rapamycin systematically inhibited the beneficial effect of recombinant human IL-7.	Sirolimus	53-62	interleukin 7	Homo sapiens	131-135
28737825-0	2017	Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy/p62/Nrf2 pathway.	Sirolimus	15-24	nuclear factor, erythroid derived 2, like 2	Mus musculus	177-181
28737825-6	2017	The rapamycin and SAMC combination activated antioxidant transcription expressions of Nrf2 and downstream gene NQO1.	Sirolimus	4-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	86-90
28771801-14	2017	Topical sirolimus appears to be both effective and well-tolerated as a treatment of facial angiofibromas in children with TSC.	Sirolimus	8-17	TSC complex subunit 1	Homo sapiens	122-125
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	72-76
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	C-C motif chemokine receptor 7	Homo sapiens	141-145
28765952-10	2017	Conversely, rapamycin deceased TNF-alpha and NF-kappaB activity, the latter of which was further confirmed by immunofluorescence analysis demonstrating increased levels of NF-kappaB present in the cytoplasm compared with the nucleus.	Sirolimus	12-21	tumor necrosis factor	Homo sapiens	31-40
28765952-10	2017	Conversely, rapamycin deceased TNF-alpha and NF-kappaB activity, the latter of which was further confirmed by immunofluorescence analysis demonstrating increased levels of NF-kappaB present in the cytoplasm compared with the nucleus.	Sirolimus	12-21	nuclear factor kappa B subunit 1	Homo sapiens	45-54
28765952-10	2017	Conversely, rapamycin deceased TNF-alpha and NF-kappaB activity, the latter of which was further confirmed by immunofluorescence analysis demonstrating increased levels of NF-kappaB present in the cytoplasm compared with the nucleus.	Sirolimus	12-21	nuclear factor kappa B subunit 1	Homo sapiens	172-181
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Homo sapiens	45-55
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	mitogen-activated protein kinase 3	Homo sapiens	75-81
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	75-78
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	vascular endothelial growth factor A	Homo sapiens	210-216
28734155-6	2017	The mTOR inhibitor rapamycin (100nM) could attenuate the elevated expression of TF and IL-8.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28734155-6	2017	The mTOR inhibitor rapamycin (100nM) could attenuate the elevated expression of TF and IL-8.	Sirolimus	19-28	C-X-C motif chemokine ligand 8	Homo sapiens	87-91
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	mitogen-activated protein kinase 1	Homo sapiens	66-69
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	mitogen-activated protein kinase 3	Homo sapiens	71-77
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	mitogen-activated protein kinase 8	Homo sapiens	186-189
28814333-0	2017	Rapamycin Prevents cyclophosphamide-induced Over-activation of Primordial Follicle pool through PI3K/Akt/mTOR Signaling Pathway in vivo.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	101-104
28860495-8	2017	Furthermore, Rapamycin negated miR-96 mediated brain injury attenuation through inducing autophagosome formation.	Sirolimus	13-22	microRNA 96	Rattus norvegicus	31-37
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	fibroblast growth factor 2	Homo sapiens	39-44
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	fibroblast growth factor 2	Homo sapiens	73-78
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	NFE2 like bZIP transcription factor 2	Homo sapiens	90-95
28624451-0	2017	Rapamycin protects against paraquat-induced pulmonary fibrosis: Activation of Nrf2 signaling pathway.	Sirolimus	0-9	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
28624451-6	2017	And the EMT associated transcription factor Snail was decreased by rapamycin treatment compared with PQ group.	Sirolimus	67-76	snail family transcriptional repressor 1	Homo sapiens	44-49
28624451-9	2017	And knockdowon of Nrf2 could abolish the inhibitory effects of rapamycin of PQ-induced EMT.	Sirolimus	63-72	NFE2 like bZIP transcription factor 2	Homo sapiens	18-22
28624451-10	2017	In conclusion, rapamycin protects against paraquat-induced pulmonary fibrosis by activation of Nrf2 signaling pathway.	Sirolimus	15-24	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	thymoma viral proto-oncogene 1	Mus musculus	14-17
28814333-10	2017	CONCLUSIONS: Rapamycin can prevent the primordial follicle activation induced by cyclophosphamide through PI3K/Akt/mTOR signaling pathway and thus plays a role in preserving the follicle pool.	Sirolimus	13-22	thymoma viral proto-oncogene 1	Mus musculus	111-114
29340326-4	2018	Mammalian target of rapamycin complex 1 (mTORC1) inhibitors (e.g., sirolimus) have been found to be effective in treating TSC- or lymphangioleiomyomatosis-associated AML, but to date it is unknown whether this strategy is effective for sporadic AML.	Sirolimus	67-76	TSC complex subunit 1	Homo sapiens	122-126
28814666-0	2017	Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.	Sirolimus	0-9	vascular endothelial growth factor C	Mus musculus	22-28
29340326-7	2018	Consequently, we showed that in vitro treatment with sirolimus results in significant growth inhibition of the human sporadic AML cell line SV7Tert, similar to the effect seen when the same treatment is applied to the human TSC-associated AML cell line UMBSV-tel.	Sirolimus	53-62	TSC complex subunit 1	Homo sapiens	224-227
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	46-49
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	76-80
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	AKT serine/threonine kinase 1	Homo sapiens	175-178
28768489-12	2017	The newly predicted drug responses of GDSC dataset suggest that mTOR inhibitor rapamycin was sensitive to non-small cell lung cancer (NSCLC), and expression of AK1RC3 and HINT1 may be adjunct markers of cell line sensitivity to rapamycin.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	64-68
28720705-8	2017	The phase of diapause termination is associated with enhanced transcript levels in several positive elements stimulating direct development (the 20-hydroxyecdysone pathway: Ecr, Shd, Broad; the Wnt pathway: basket, c-jun) that are countered by up-regulation in some negative elements (the insulin-signaling pathway: Ilp8, PI3k, Akt; the target of rapamycin pathway: Tsc2 and 4EBP; the Wnt pathway: shaggy).	Sirolimus	347-356	Jun-related antigen	Drosophila melanogaster	215-220
28768489-12	2017	The newly predicted drug responses of GDSC dataset suggest that mTOR inhibitor rapamycin was sensitive to non-small cell lung cancer (NSCLC), and expression of AK1RC3 and HINT1 may be adjunct markers of cell line sensitivity to rapamycin.	Sirolimus	228-237	histidine triad nucleotide binding protein 1	Homo sapiens	171-176
28528119-7	2017	Specifically, the mTOR-dependent autophagy inducer rapamycin enhanced the knockdown efficiency of both lipoplex and polyplex, whereas mTOR-dependent autophagy inhibitor 3-methyladenine (3-MA) suppressed their silencing efficiency.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	18-22
28550180-10	2017	Our study suggests the K475E mutation induces alteration in basal AMPK activity and results in a hypertrophy phenotype involving the mechanistic target of rapamycin signaling pathway, which can be reversed with rapamycin.NEW &amp; NOTEWORTHY We identified a novel, de novo PRKAG2 mutation (K475E) in the cystathionine beta-synthase 3 repeat, a region critical for AMP binding but with no previous reported mutation.	Sirolimus	155-164	cystathionine beta-synthase	Homo sapiens	304-331
28542038-10	2017	Western Blotting indicated that both doxorubicin and rapamycin inhibit hypoxia-induced accumulation of HIF-1alpha.	Sirolimus	53-62	hypoxia inducible factor 1 subunit alpha	Homo sapiens	103-113
28643873-9	2017	In vitro studies using cultured human astrocytes showed that interleukin (IL)-1beta-induced (immuno)proteasome gene expression could be attenuated by rapamycin.	Sirolimus	150-159	interleukin 1 beta	Homo sapiens	61-83
28167236-4	2017	Rapamycin, an inhibitor of mTOR that increases longevity in several species, inhibits cell senescence in vitro, while silencing the Nrf2 gene induces premature senescence.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
28167236-5	2017	We have found that rapamycin activates the Nrf2 pathway to regulate cell cycle arrest, but not the production of SASP, which is regulated by a different pathway, probably involving the inhibition of MAPKAPK2.	Sirolimus	19-28	NFE2 like bZIP transcription factor 2	Homo sapiens	43-47
28556421-11	2017	There was a significant increase in the frequency of contractions after ciclosporin, tacrolimus, azathioprine and sirolimus treatment compared with control animals (4.6 +- 0.3 cycles min-1 ).	Sirolimus	114-123	CD59 molecule (CD59 blood group)	Homo sapiens	183-188
28566443-5	2017	Signalling in dermal fibroblasts from one patient and efficacy of the mTOR inhibitor Sirolimus on pathway activation were examined.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	70-74
28475806-0	2017	Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	86-89
28475806-9	2017	CONCLUSIONS: Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the CA-JV shunt-induced PAH model in rats.	Sirolimus	13-22	AKT serine/threonine kinase 1	Rattus norvegicus	99-102
28634253-9	2017	The autophagy inducer rapamycin ameliorated TNF-alpha-induced apoptosis.	Sirolimus	22-31	tumor necrosis factor	Mus musculus	44-53
29085582-9	2017	The rats treated with rapamycin had significant decreases in the MDA and caspase-3 levels and significant increases in the SOD, CAT and GPx activities in ipsilateral testis compared with the T/D group (P&lt;0.001); germ cell apoptosis was decreased, and MSTD was improved.	Sirolimus	22-31	catalase	Rattus norvegicus	128-131
28571990-10	2017	A similar negative effect on the expression of RPS6KB1 and EIF4EBP1 was detected when the cells were cultured with either rapamycin or mTOR small interference RNA.	Sirolimus	122-131	ribosomal protein S6 kinase B1	Bos taurus	47-54
28665070-3	2017	We validated mTOR downstream genes with immunohistochemistry using a tissue microarray (TMA) of 125 non-muscle invasive HG-UC patients and knockout study to evaluate the synergistic effect with rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Homo sapiens	13-17
28634253-14	2017	TNF-alpha-mediated induction of cleaved caspase-3 was downregulated by rapamycin, but upregulated by 3-MA, respectively.	Sirolimus	71-80	tumor necrosis factor	Mus musculus	0-9
28700521-0	2017	Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.	Sirolimus	77-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	10-16
28507054-8	2017	In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	142-146
28507054-8	2017	In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.	Sirolimus	13-22	androgen receptor	Homo sapiens	189-191
29152062-0	2017	Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.	Sirolimus	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	62-66
28700521-0	2017	Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.	Sirolimus	77-86	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	21-27
28700521-3	2017	Sirolimus is primarily metabolized by cytochrome CYP3A4 and CYP3A5.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
28700521-3	2017	Sirolimus is primarily metabolized by cytochrome CYP3A4 and CYP3A5.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	60-66
28700521-4	2017	This study aimed to clarify the effect of CYP3A genetic polymorphisms, including the CYP3A4*1G and CYP3A5*3 polymorphisms, on the pharmacokinetics of sirolimus.	Sirolimus	150-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-47
28700521-4	2017	This study aimed to clarify the effect of CYP3A genetic polymorphisms, including the CYP3A4*1G and CYP3A5*3 polymorphisms, on the pharmacokinetics of sirolimus.	Sirolimus	150-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
28700521-4	2017	This study aimed to clarify the effect of CYP3A genetic polymorphisms, including the CYP3A4*1G and CYP3A5*3 polymorphisms, on the pharmacokinetics of sirolimus.	Sirolimus	150-159	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	99-105
28700521-12	2017	CONCLUSIONS: CYP3A4 and CYP3A5 genetic polymorphisms are important factors affecting pharmacokinetic parameters of sirolimus.	Sirolimus	115-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
28700521-12	2017	CONCLUSIONS: CYP3A4 and CYP3A5 genetic polymorphisms are important factors affecting pharmacokinetic parameters of sirolimus.	Sirolimus	115-124	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	24-30
28700521-13	2017	Our data support the monitoring of blood sirolimus concentrations, especially in CYP3A5*1 and CYP3A4*1 G carriers, to ensure accurate dosing in the clinical setting.	Sirolimus	41-50	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	81-87
28700521-13	2017	Our data support the monitoring of blood sirolimus concentrations, especially in CYP3A5*1 and CYP3A4*1 G carriers, to ensure accurate dosing in the clinical setting.	Sirolimus	41-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-100
28698309-5	2017	The concept that mTOR has a crucial role in ageing is supported by numerous reports on the lifespan-prolonging effects of the mTOR inhibitor rapamycin in invertebrate and vertebrate model organisms.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	17-21
28724379-11	2017	The c-MYC inhibitor, the PI3K inhibitor LY294002, the mTOR inhibitor Rapamycin and 2-DG all diminished the number of viable cells.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	54-58
28724388-6	2017	Inhibition of MTOR by rapamycin decreased basal levels of protein O-GlcNAcylation, decreased AKT activation and partially reversed the effect of thiamet G on alpha-synuclein monomer accumulation.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28724388-6	2017	Inhibition of MTOR by rapamycin decreased basal levels of protein O-GlcNAcylation, decreased AKT activation and partially reversed the effect of thiamet G on alpha-synuclein monomer accumulation.	Sirolimus	22-31	AKT serine/threonine kinase 1	Homo sapiens	93-96
28528212-7	2017	We found that these LRPmAb were effective in delivering rapamycin and showed higher therapeutic efficacy in breast cancer cells overexpressing HER2/neu receptors compared with cells that did not overexpress these receptors.	Sirolimus	56-65	erb-b2 receptor tyrosine kinase 2	Homo sapiens	143-147
28819418-8	2017	Results: CENPH inhibited CRC malignant phenotypes, conferred reduced sensitivity to rapamycin, and attenuated both mTORC1 and mTORC2 in mTOR signaling pathway through the interaction with golgi phosphoprotein 3 (GOLPH3), which has been identified as a potential oncogene and modulates the response to rapamycin.	Sirolimus	301-310	golgi phosphoprotein 3	Homo sapiens	188-210
28819418-12	2017	Conclusions: Our results suggest that CENPH inhibits rapamycin sensitivity by regulating GOLPH3 dependent mTOR pathway.	Sirolimus	53-62	golgi phosphoprotein 3	Homo sapiens	89-95
28819418-12	2017	Conclusions: Our results suggest that CENPH inhibits rapamycin sensitivity by regulating GOLPH3 dependent mTOR pathway.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	106-110
28698309-5	2017	The concept that mTOR has a crucial role in ageing is supported by numerous reports on the lifespan-prolonging effects of the mTOR inhibitor rapamycin in invertebrate and vertebrate model organisms.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	126-130
28525374-0	2017	The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).	Sirolimus	14-23	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	98-104
28696356-12	2017	Rapamycin was able to protect chondrocytes from cell death in an OA-model shown by reduced Caspase 3/7 activity and diminished LDH release.	Sirolimus	0-9	caspase 3	Homo sapiens	91-100
28525374-6	2017	We assessed the therapeutic effects of four compounds (rapamycin, NVP-BEZ235, aspirin, and metformin) on PI3K/AKT/mTOR signaling pathway and cell growth.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	110-113
28525374-6	2017	We assessed the therapeutic effects of four compounds (rapamycin, NVP-BEZ235, aspirin, and metformin) on PI3K/AKT/mTOR signaling pathway and cell growth.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	114-118
28504198-0	2017	Rapamycin suppresses Abeta25-35- or LPS-induced neuronal inflammation via modulation of NF-kappaB signaling.	Sirolimus	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	88-97
28903387-6	2017	Most importantly, rapamycin in combination with AG1295, a PDGFR inhibitor, significantly inhibited growth of TSC1/TSC2 complex-deficient cells in vitro and in vivo.	Sirolimus	18-27	platelet derived growth factor receptor beta	Homo sapiens	58-63
28903387-6	2017	Most importantly, rapamycin in combination with AG1295, a PDGFR inhibitor, significantly inhibited growth of TSC1/TSC2 complex-deficient cells in vitro and in vivo.	Sirolimus	18-27	TSC complex subunit 1	Homo sapiens	109-113
28903387-7	2017	Therefore, downregulated FOXO3a/PDGFRalpha/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment.	Sirolimus	194-203	forkhead box O3	Homo sapiens	25-31
28903387-7	2017	Therefore, downregulated FOXO3a/PDGFRalpha/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment.	Sirolimus	194-203	platelet derived growth factor receptor alpha	Homo sapiens	32-42
28903387-7	2017	Therefore, downregulated FOXO3a/PDGFRalpha/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment.	Sirolimus	194-203	AKT serine/threonine kinase 1	Homo sapiens	43-46
28484962-3	2017	Recent studies demonstrate treatment with rapamycin-a key inhibitor of the mTOR pathway-can skew T cell development, moving T cell responses away from inflammatory phenotypes and toward regulatory T cells (TREGS).	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	75-79
28217909-3	2017	Reversion of the atrial ectopic tachycardia was achieved with mammalian target of rapamycin pathway (mTOR) inhibitor sirolimus.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	62-91
28450279-7	2017	Cultured mouse podocytes were treated with the autophagy activators, rapamycin or Earle"s balanced salt solution (EBSS), for 48 h. Both rapamycin and EBSS significantly decreased p62 protein levels, increased ERK1/2 activation by phosphorylating pTpY185/187, and increased mRNA and protein expressions of PRR.	Sirolimus	136-145	ATPase, H+ transporting, lysosomal accessory protein 2	Mus musculus	305-308
28450279-8	2017	Utilizing confocal microscopy demonstrated that rapamycin and EBSS significantly decreased p62/SQSTM1 and increased PRR protein expressions.	Sirolimus	48-57	ATPase, H+ transporting, lysosomal accessory protein 2	Mus musculus	116-119
28450279-11	2017	ERK1/2 inhibitor U0126 significantly attenuated mRNA and protein expressions of PRR in podocytes treated with rapamycin.	Sirolimus	110-119	ATPase, H+ transporting, lysosomal accessory protein 2	Mus musculus	80-83
28217909-3	2017	Reversion of the atrial ectopic tachycardia was achieved with mammalian target of rapamycin pathway (mTOR) inhibitor sirolimus.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	101-105
27714857-5	2017	However, rapamycin, a representative non-selective autophagy inducer, triggered autophagy in alpha-MSH-stimulated cells, which was characterized by a considerable decrease in p62, but it was unable to inhibit melanogenesis.	Sirolimus	9-18	proopiomelanocortin	Homo sapiens	93-102
28595829-5	2017	We report on six cases of complicated VAs, refractory to current treatments, treated with rapamycin, an mTor inhibitor recently used in VAs.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	104-108
28116487-10	2017	Sirolimus directly increased IL-1beta mRNA expression (P &lt; 0.01) and enhanced IL-1beta release into the culture media (P &lt; 0.01) in CASMCs, but not in HUVECs.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	29-37
28672994-0	2017	Rapamycin enhances the antiproliferative effect of transforming growth factor-beta on MCF-7 human breast cancer cells.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	51-82
28672994-6	2017	The present study also demonstrated that rapamycin enhances the antiproliferative effect of TGF-beta.	Sirolimus	41-50	transforming growth factor beta 1	Homo sapiens	92-100
28433555-5	2017	In contrast, sirolimus reduced the adhesion of leukocytes (CD45+) and bone marrow-derived progenitor cells (CD34+) to activated EC by down-regulating the adhesion molecules ICAM-1 and VCAM-1.	Sirolimus	13-22	vascular cell adhesion molecule 1	Homo sapiens	184-190
28433555-6	2017	In addition, sirolimus treatment also significantly reduced the upregulation of ICAM-1 and VCAM-1 and the recruitment of monocytic cells (MOMA-2+) in neointimal lesions in vivo.	Sirolimus	13-22	vascular cell adhesion molecule 1	Homo sapiens	91-97
28116487-10	2017	Sirolimus directly increased IL-1beta mRNA expression (P &lt; 0.01) and enhanced IL-1beta release into the culture media (P &lt; 0.01) in CASMCs, but not in HUVECs.	Sirolimus	0-9	interleukin 1 beta	Homo sapiens	81-89
28560385-8	2017	Inhibition of mTOR with rapamycin promoted autophagy and viral mRNA replication but did not impact VP1 expression.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
31966605-8	2017	Autophagy promotion by rapamycin enhanced apoptosis in bladder cancer cells, especially in AR-positive UM-UC-3 cells when AR signaling was inhibited by bicalutamide.	Sirolimus	23-32	androgen receptor	Homo sapiens	91-93
31966605-8	2017	Autophagy promotion by rapamycin enhanced apoptosis in bladder cancer cells, especially in AR-positive UM-UC-3 cells when AR signaling was inhibited by bicalutamide.	Sirolimus	23-32	androgen receptor	Homo sapiens	122-124
28134984-2	2017	The mTOR inhibitor sirolimus was used in selected liver graft recipients despite safety concerns and lack of approval.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28407242-6	2017	Meanwhile, induction of autophagy with rapamycin treatment could significantly suppress microglial inflammatory responses, mitochondrial ROS production, activation of MAPKs and NF-kappaB.	Sirolimus	39-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	177-186
28647341-9	2017	Rapamycin inhibited RIP1-p62 and RIP1-RIP3 interactions induced by TNF/zVAD and partly restored autophagic flux and suppressed LDH release in TNF/zVAD-treated cells.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	67-70
28647341-9	2017	Rapamycin inhibited RIP1-p62 and RIP1-RIP3 interactions induced by TNF/zVAD and partly restored autophagic flux and suppressed LDH release in TNF/zVAD-treated cells.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	142-145
28685070-0	2017	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.	Sirolimus	15-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	42-48
28685070-3	2017	The current pilot study assessed the efficacy and safety of sirolimus in patients with refractory cancer with PIK3CA mutation/amplification.	Sirolimus	60-69	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	110-116
28685070-15	2017	Sirolimus had modest efficacy and a tolerable toxicity-profile in patients with refractory cancer with PIK3CA mutation/amplification.	Sirolimus	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	103-109
28693280-7	2017	In conclusion, rapamycin improves the anti-tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3beta/cyclin D1 signaling pathways.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	102-105
28693280-7	2017	In conclusion, rapamycin improves the anti-tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3beta/cyclin D1 signaling pathways.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	145-148
28904691-12	2017	RESULTS: Our results show that rapamycin arrests the differentiation of, and expands AFP specific Tscm cells.	Sirolimus	31-40	alpha fetoprotein	Homo sapiens	85-88
28489580-6	2017	Therefore, our results suggest that rapamycin negatively regulates macrophage activation by restricting a feedback loop of NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62/SQSTM1-dependent manners.	Sirolimus	36-45	NLR family pyrin domain containing 3	Homo sapiens	123-128
28507282-10	2017	In addition, TP53 mutant cancer cells had elevation of RRM1 and RRM2, which was reduced by rapamycin.	Sirolimus	91-100	ribonucleotide reductase M1	Mus musculus	55-59
28489580-6	2017	Therefore, our results suggest that rapamycin negatively regulates macrophage activation by restricting a feedback loop of NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62/SQSTM1-dependent manners.	Sirolimus	36-45	mitogen-activated protein kinase 14	Homo sapiens	142-145
28489580-6	2017	Therefore, our results suggest that rapamycin negatively regulates macrophage activation by restricting a feedback loop of NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62/SQSTM1-dependent manners.	Sirolimus	36-45	nuclear factor kappa B subunit 1	Homo sapiens	151-159
28663780-4	2017	Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	19-23
28706974-1	2017	BACKGROUND: Kidney transplant recipients (KTRs) receiving the mammalian target of rapamycin inhibitor sirolimus may display a reduced risk of skin cancer development compared to KTRs receiving calcineurin inhibitors.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	62-91
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	GATA binding protein 4	Mus musculus	137-142
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	myocyte enhancer factor 2C	Mus musculus	162-167
28396518-7	2017	Mechanistic studies showed that rapamycin inhibits Wnt/beta-catenin and Notch signaling but promotes the expression of fibroblast growth factor (Fgf8), Fgf10, and Nodal at early stage, and bone morphogenetic protein 2 (Bmp 2) at later stages.	Sirolimus	32-41	bone morphogenetic protein 2	Mus musculus	219-224
28579603-9	2017	Immunohistochemistry of the cysts demonstrated a high level of phosphorylation of p70S6 kinase, a downstream mTOR target, and since a target therapy that blocks PI3K/Akt/mTOR pathway has been shown to have a scientific and logical rationale to treat this rare intra-abdominal neoplasia, we started the patient on low dose rapamycin therapy, an mTOR inhibitor.	Sirolimus	322-331	AKT serine/threonine kinase 1	Homo sapiens	166-169
28579603-9	2017	Immunohistochemistry of the cysts demonstrated a high level of phosphorylation of p70S6 kinase, a downstream mTOR target, and since a target therapy that blocks PI3K/Akt/mTOR pathway has been shown to have a scientific and logical rationale to treat this rare intra-abdominal neoplasia, we started the patient on low dose rapamycin therapy, an mTOR inhibitor.	Sirolimus	322-331	mechanistic target of rapamycin kinase	Homo sapiens	170-174
28579603-9	2017	Immunohistochemistry of the cysts demonstrated a high level of phosphorylation of p70S6 kinase, a downstream mTOR target, and since a target therapy that blocks PI3K/Akt/mTOR pathway has been shown to have a scientific and logical rationale to treat this rare intra-abdominal neoplasia, we started the patient on low dose rapamycin therapy, an mTOR inhibitor.	Sirolimus	322-331	mechanistic target of rapamycin kinase	Homo sapiens	170-174
28579603-11	2017	CONCLUSIONS The current case is the first report of BMPM successfully treated with rapamycin, which resulted in a long-lasting response to mTOR inhibition.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	139-143
28575052-8	2017	Treatment of hiPSC precursors with autophagy stimulators Rapamycin, Perifosine, or AT101 showed reduction in VCP pathology markers TDP-43, LC3-I/II and p62/SQSTM1.	Sirolimus	57-66	TAR DNA binding protein	Homo sapiens	131-137
28450107-5	2017	Activation of autophagy by Rapamycin or Trehalose could reduce the expression of Snail, demonstrating a role of autophagy in regulating Snail production both by transcriptional and post-transcriptional mechanism.	Sirolimus	27-36	snail family transcriptional repressor 1	Homo sapiens	81-86
28450107-5	2017	Activation of autophagy by Rapamycin or Trehalose could reduce the expression of Snail, demonstrating a role of autophagy in regulating Snail production both by transcriptional and post-transcriptional mechanism.	Sirolimus	27-36	snail family transcriptional repressor 1	Homo sapiens	136-141
28254579-1	2017	Previous work revealed that intracellular Ca2+ signals and the inositol 1,4,5-trisphosphate (IP3) receptors (IP3R) are essential to increase autophagic flux in response to mTOR inhibition, induced by either nutrient starvation or rapamycin treatment.	Sirolimus	230-239	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	109-113
28371119-0	2017	Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.	Sirolimus	0-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	67-71
28371119-4	2017	Therefore, we explored whether Nrf2 is involved in the mechanism by which rapamycin delays cell senescence.	Sirolimus	74-83	nuclear factor, erythroid derived 2, like 2	Mus musculus	31-35
28371119-5	2017	In wild-type (WT) mouse fibroblasts, rapamycin increased the levels of Nrf2, and this correlates with the activation of autophagy and a reduction in the induction of cell senescence, as measured by SA-beta-galactosidase (beta-gal) staining, senescence-associated secretory phenotype (SASP), and p16 and p21 molecular markers.	Sirolimus	37-46	nuclear factor, erythroid derived 2, like 2	Mus musculus	71-75
28371119-5	2017	In wild-type (WT) mouse fibroblasts, rapamycin increased the levels of Nrf2, and this correlates with the activation of autophagy and a reduction in the induction of cell senescence, as measured by SA-beta-galactosidase (beta-gal) staining, senescence-associated secretory phenotype (SASP), and p16 and p21 molecular markers.	Sirolimus	37-46	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	295-298
28254579-1	2017	Previous work revealed that intracellular Ca2+ signals and the inositol 1,4,5-trisphosphate (IP3) receptors (IP3R) are essential to increase autophagic flux in response to mTOR inhibition, induced by either nutrient starvation or rapamycin treatment.	Sirolimus	230-239	mechanistic target of rapamycin kinase	Homo sapiens	172-176
27915965-7	2017	The mammalian target of rapamycin inhibitors everolimus and sirolimus are preferred due to their complementary mechanisms of action and favorable nephrotoxicity profile, which have opened the way for calcineurin inhibitor reduction/withdrawal in the early posttransplant period.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	4-33
28257810-0	2017	Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.	Sirolimus	60-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
28434143-5	2017	While short-term treatment with rapamycin, an mTOR inhibitor, is a promising strategy for cardiac diseases such as acute myocardial infarction and cardiac hypertrophy in T2DM, there are many concerns about chronic usage of rapamycin.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	46-50
26945892-6	2017	Interestingly, RPM promoted the retention of Cx43 in the Golgi apparatus detected by co-immunofluorescence with antibodies against Cx43 and 58 K Golgi marker protein.	Sirolimus	15-18	gap junction protein, alpha 1	Mus musculus	45-49
28238805-7	2017	Interestingly, the LSD1 inhibitor, RN-1, and the mitophagy-inducing agent mammalian target of rapamycin (mTOR) inhibitor, sirolimus, increased RBC lifespan and reduced ROS accumulation in parallel with reducing mitochondria-retaining RBCs in the SCD mouse model.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	74-103
28238805-7	2017	Interestingly, the LSD1 inhibitor, RN-1, and the mitophagy-inducing agent mammalian target of rapamycin (mTOR) inhibitor, sirolimus, increased RBC lifespan and reduced ROS accumulation in parallel with reducing mitochondria-retaining RBCs in the SCD mouse model.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Homo sapiens	105-109
26945892-6	2017	Interestingly, RPM promoted the retention of Cx43 in the Golgi apparatus detected by co-immunofluorescence with antibodies against Cx43 and 58 K Golgi marker protein.	Sirolimus	15-18	gap junction protein, alpha 1	Mus musculus	131-135
26945892-8	2017	Together, this study demonstrates increased activity of Cx43 hemichannels to RPM, and active Cx43 hemichannels with prostaglandin E2 release are likely to module biological function under simulated weightless conditions.	Sirolimus	77-80	gap junction protein, alpha 1	Mus musculus	56-60
28625629-0	2017	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.	Sirolimus	61-70	epidermal growth factor receptor	Homo sapiens	88-120
28548953-4	2017	Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor.	Sirolimus	28-37	phosphodiesterase 5A	Homo sapiens	197-201
28548953-1	2017	Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28542147-10	2017	In addition, the NGF inhibitor K252a and the mTOR inhibitor rapamycin constitute good candidates for protecting follicular reserve against over exhaustion after ovarian surgery.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	45-49
28548953-1	2017	Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28086065-11	2017	In addition, rapamycin suppressed cell apoptosis, and decreased Bax/Bcl-2 ratio and cleaved caspase-3 expression.	Sirolimus	13-22	B cell leukemia/lymphoma 2	Mus musculus	68-73
28573133-5	2017	Inhibition of mTOR with rapamycin (10 nM) significantly interfered with all aspects of osteoclastogenesis.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28559962-10	2017	Treatment with wortmannin or rapamycin attenuated the expression of p-Akt, p-S6K1, and osteogenesis proteins/genes.	Sirolimus	29-38	AKT serine/threonine kinase 1	Homo sapiens	70-73
28514674-4	2017	We also discuss the impact of metabolic constraints in tissues on immune homeostasis and disease, and how manipulating mTOR activity with drugs such as rapamycin can modulate immunity in these contexts.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	119-123
28469076-4	2017	Treatment of primary human keratinocytes (PHKs) with hydrocortisone or rapamycin, but not the p38 MAPK inhibitor SB202190, significantly increases DSG3 mRNA and protein expression and correspondingly reduces phospho-S727 Stat3.	Sirolimus	71-80	signal transducer and activator of transcription 3	Homo sapiens	221-226
28330873-9	2017	Finally, rapamycin treatment, which abolished delayed monocyte differentiation in ApoE-/-/AMPKalpha1-/- mice, lost its atherosclerosis-lowering effects in these mice.	Sirolimus	9-18	apolipoprotein E	Mus musculus	82-86
28330873-9	2017	Finally, rapamycin treatment, which abolished delayed monocyte differentiation in ApoE-/-/AMPKalpha1-/- mice, lost its atherosclerosis-lowering effects in these mice.	Sirolimus	9-18	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	90-100
28330873-11	2017	Rapamycin treatment increased FoxO3 activity as well as LC3 and ULK1 expressions in macrophages from AMPKalpha1-/- mice.	Sirolimus	0-9	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	101-111
28553309-4	2017	The core components of TOR complex including TOR, RAPTOR, and LST8 are highly conserved in potato, but the seedlings of potato are insensitive to rapamycin, implying FK506 Binding Protein 12 KD (FKBP12) lost the function to bridge the interaction of rapamycin and TOR in potato.	Sirolimus	250-259	target of rapamycin	Arabidopsis thaliana	23-26
28469076-7	2017	Topical hydrocortisone, rapamycin, or Stat3 inhibitor XVIII prevents autoantibody-induced blistering in the PV passive transfer mouse model, correlating with increased epidermal DSG3 expression and decreased phospho-S727 Stat3.	Sirolimus	24-33	signal transducer and activator of transcription 3	Mus musculus	221-226
28469076-6	2017	Hydrocortisone- or rapamycin-treated PHKs demonstrate increased number and length of desmosomes by electron microscopy and are resistant to PV IgG-induced loss of cell adhesion, whereas constitutive activation of Stat3 in PHKs abrogates DSG3 upregulation and inhibits hydrocortisone and rapamycin"s therapeutic effects.	Sirolimus	19-28	signal transducer and activator of transcription 3	Homo sapiens	213-218
27447863-8	2017	In addition, inhibition of AKT signaling by AKT inhibitor IV and Rapamycin reversed CTMP-mediated trastuzumab resistance.	Sirolimus	65-74	AKT serine/threonine kinase 1	Homo sapiens	27-30
28161373-2	2017	Recent evidence shows that rapamycin administered both intraperitoneally or in the diet delays disease onset and enhances survival in the Ndufs4 null mouse model of mitochondrial encephalopathy.	Sirolimus	27-36	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	138-144
28418837-3	2017	Therefore, in the present study we administered different doses of the mTOR inhibitor rapamycin to explore whether the transcription of specific genes are modified.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Homo sapiens	71-75
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	60-64
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	76-80
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	76-80
28186963-7	2017	In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp.	Sirolimus	47-56	AKT serine/threonine kinase 1	Homo sapiens	123-126
28258008-7	2017	The assay identified 12 potent inhibitors including two known MRP1 inhibitors, cyclosporine A and rapamycin.	Sirolimus	98-107	ATP binding cassette subfamily C member 1	Homo sapiens	62-66
28502292-9	2017	Meanwhile, 3-MA or rapamycin pretreatment further regulated the protein expressions of IkappaBalpha and p-NF-kBp65 induced by LPS in macrophages.	Sirolimus	19-28	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	87-99
28186963-7	2017	In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	127-131
28186963-7	2017	In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp.	Sirolimus	47-56	ATP binding cassette subfamily B member 1	Homo sapiens	213-217
28186963-7	2017	In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp.	Sirolimus	47-56	ATP binding cassette subfamily B member 1	Homo sapiens	317-321
28400511-4	2017	SHPRH enrichment at the rDNA promoter was inhibited by cell starvation, by treatment with actinomycin D or rapamycin, or by depletion of CHD4.	Sirolimus	107-116	SNF2 histone linker PHD RING helicase	Homo sapiens	0-5
28450865-3	2017	Inhibition of mTOR complex 1 by rapamycin revealed the immunosuppressive activity of Dex was independent from the effect of enhancing NK cell proliferation.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	14-18
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	interleukin 1 beta	Rattus norvegicus	92-100
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	interleukin 6	Rattus norvegicus	102-106
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	tumor necrosis factor	Rattus norvegicus	111-120
28507917-6	2017	The mTOR inhibitors such as everolimus and sirolimus, due to their complementary mechanism of action and favourable nephrotoxicity profile; better glomerular filtration, lower serum creatinine with equivalent survival.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28379293-4	2017	We recently found that RA stimulation of the Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian target of rapamycin (mTOR) kinase signaling pathway is required for differentiation, and that short-term inhibition of mTOR complex 1 (mTORC1) by rapamycin blocked spermatogonial differentiation in vivo and prevented RA-induced translational activation.	Sirolimus	106-115	AKT serine/threonine kinase 1	Homo sapiens	82-85
28317380-8	2017	The Ingenuity Systems software identified 16 pathways, and this analysis indicated sirolimus, an mTOR pathway inhibitor, as a potential inhibitor of CypA.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	97-101
28379293-4	2017	We recently found that RA stimulation of the Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian target of rapamycin (mTOR) kinase signaling pathway is required for differentiation, and that short-term inhibition of mTOR complex 1 (mTORC1) by rapamycin blocked spermatogonial differentiation in vivo and prevented RA-induced translational activation.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	117-121
28209733-7	2017	Rapamycin had the converse effect, linking MTOR signaling to induction of fiber cell differentiation by TGFbeta.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	43-47
28104700-2	2017	The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	25-29
28119225-8	2017	Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	39-43
28209733-7	2017	Rapamycin had the converse effect, linking MTOR signaling to induction of fiber cell differentiation by TGFbeta.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	104-111
28336152-5	2017	The gene products of TSC1/2 form a complex which at energy limiting states, down-regulates the activity of the regulator of protein synthesis, the mammalian target of rapamycin complex1 (mTORC1).	Sirolimus	167-176	TSC complex subunit 1	Homo sapiens	21-27
31988901-4	2017	Herein, we report a premature neonate at the gestational age of 30 + 4 weeks with severe left ventricular outflow tract obstructive cardiac rhabdomyoma who was successfully treated with the mTOR inhibitor sirolimus.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Homo sapiens	190-194
28386356-13	2017	Similar to FA, downregulation of mTOR signaling by rapamycin inhibited VSMC dedifferentiation.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	33-37
28333137-5	2017	MDSCs, especially CD11b+Ly6G+Ly6Clow G-MDSCs were recruited to the injured kidney following the interaction of CXCL1, CXCL2 and their receptor CXCR2 after inhibiting mTOR signal with rapamycin treatment.	Sirolimus	183-192	integrin alpha M	Mus musculus	18-23
28333137-7	2017	In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs.	Sirolimus	205-214	interleukin 1 beta	Mus musculus	58-66
28333137-7	2017	In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs.	Sirolimus	205-214	interferon gamma	Mus musculus	71-80
28333137-8	2017	Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group.	Sirolimus	21-30	interleukin 1 beta	Mus musculus	84-92
28333137-8	2017	Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group.	Sirolimus	21-30	interleukin 6	Mus musculus	94-98
28333137-8	2017	Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group.	Sirolimus	21-30	interferon gamma	Mus musculus	103-112
28333142-7	2017	Like rapamycin, NaHS also significantly inhibited expression of p-PI3K, p-Akt and mTOR proteins in HCC cells.	Sirolimus	5-14	mechanistic target of rapamycin kinase	Homo sapiens	82-86
28292440-2	2017	Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	11-15
28292440-2	2017	Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi).	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	66-70
28279316-0	2017	The REMEDEE-OCT Study: An Evaluation of the Bioengineered COMBO Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary Syndromes: Insights From Optical Coherence Tomography Imaging Analysis.	Sirolimus	99-108	CD34 molecule	Homo sapiens	77-81
28400999-1	2017	The mTOR pathway was discovered in the late 1970s after the compound and natural inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces hygroscopicus.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28292440-6	2017	RapaLink-1 showed better efficacy than rapamycin or TORKi, potently blocking cancer-derived, activating mutants of mTOR.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	115-119
28257428-11	2017	mTOR phosphorylation can be decreased by the mTOR antagonist, rapamycin.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	0-4
28257428-11	2017	mTOR phosphorylation can be decreased by the mTOR antagonist, rapamycin.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	45-49
28400999-1	2017	The mTOR pathway was discovered in the late 1970s after the compound and natural inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces hygroscopicus.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	94-98
28400999-7	2017	Rapamycin and its analogues (rapalogues) bind to the intercellular receptor FKBP12, and then predominantly inhibit mTORC1 signaling via an allosteric mechanism.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	76-82
28245187-0	2017	Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.	Sirolimus	58-67	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
28303141-8	2017	Rapamycin interfered with the interaction between FKBP13 and IgA and enhanced the amount of secreted IgA.	Sirolimus	0-9	FK506 binding protein 2	Mus musculus	50-56
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	Sirolimus	174-183	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	214-219
28181194-2	2017	Here we report the case of a 12-year-old girl with widespread disfiguring facial angiofibromas that were successfully treated with topical rapamycin, a mTOR inhibitor.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	152-156
28245187-0	2017	Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.	Sirolimus	58-67	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
28243129-13	2017	Furthermore, inhibition of the mTOR/p70s6k signaling pathway by rapamycin significantly induced autophagy and apoptosis and inhibited cell viability (P&lt;0.05).	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	31-35
27651429-8	2017	The antiproliferative effect of sirolimus (SRL) and cyclosporine A (CsA), which target the IL-2 signaling pathway, was diminished by DSCs in vitro.	Sirolimus	32-41	interleukin 2	Homo sapiens	91-95
27651429-8	2017	The antiproliferative effect of sirolimus (SRL) and cyclosporine A (CsA), which target the IL-2 signaling pathway, was diminished by DSCs in vitro.	Sirolimus	43-46	interleukin 2	Homo sapiens	91-95
28027414-7	2017	Upstream of p62, we found that BDNF triggered phosphorylation of mammalian target of rapamycin (mTOR) and its downstream mediator p70S6K; importantly, the mTOR inhibitor rapamycin reduced both BDNF-dependent p62 induction as well as 3-NP resistance.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	96-100
28027414-7	2017	Upstream of p62, we found that BDNF triggered phosphorylation of mammalian target of rapamycin (mTOR) and its downstream mediator p70S6K; importantly, the mTOR inhibitor rapamycin reduced both BDNF-dependent p62 induction as well as 3-NP resistance.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Homo sapiens	155-159
28138700-11	2017	Furthermore, the autophagy inhibitor 3-methyladenine and miR-410 expression were able to improve the therapeutic response of the cells to chemotherapy drugs (rapamycin, doxorubicin and cisplatin), thus indicating that miR-410 enhanced chemosensitivity through autophagy inhibition in osteosarcoma cells.	Sirolimus	158-167	microRNA 410	Homo sapiens	57-64
28138700-11	2017	Furthermore, the autophagy inhibitor 3-methyladenine and miR-410 expression were able to improve the therapeutic response of the cells to chemotherapy drugs (rapamycin, doxorubicin and cisplatin), thus indicating that miR-410 enhanced chemosensitivity through autophagy inhibition in osteosarcoma cells.	Sirolimus	158-167	microRNA 410	Homo sapiens	218-225
28469644-5	2017	In addition, we demonstrated alterations in mechanistic target of rapamycin complex 1 (mTORC1) signaling and functional rescue of the lifespan, locomotor defects and hypersensitivity to oxidative stress on treatment of GCase-deficient flies with the mTOR inhibitor rapamycin.	Sirolimus	66-75	Megator	Drosophila melanogaster	87-91
28469656-8	2017	By contrast, rapamycin further elevated hippocampal GluR1 levels and exacerbated decreased GluR2 expression levels in neonates with HIBD.	Sirolimus	13-22	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	52-57
28469656-8	2017	By contrast, rapamycin further elevated hippocampal GluR1 levels and exacerbated decreased GluR2 expression levels in neonates with HIBD.	Sirolimus	13-22	glutamate ionotropic receptor AMPA type subunit 2	Rattus norvegicus	91-96
28439198-11	2017	mTOR inhibitors such as everolimus and sirolimus have been increasingly used in the treatment of these tumors.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	0-4
28367235-3	2017	Thus, rapamycin, as an mTOR specific inhibitor, has been assumed as a potential drug for the treatment of TSC.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	23-27
27524416-4	2017	Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment.	Sirolimus	144-153	phosphatase and tensin homolog	Mus musculus	79-83
28367235-3	2017	Thus, rapamycin, as an mTOR specific inhibitor, has been assumed as a potential drug for the treatment of TSC.	Sirolimus	6-15	TSC complex subunit 1	Homo sapiens	106-109
28367235-7	2017	Furthermore, MK-2206 increased the cytotoxicity of rapamycin in Tsc1-/- or Tsc2-/- MEFs.	Sirolimus	51-60	TSC complex subunit 1	Homo sapiens	64-68
28367235-9	2017	We conclude that the combination of rapamycin and MK-2206 may be utilized as a new therapeutic regimen for TSC.	Sirolimus	36-45	TSC complex subunit 1	Homo sapiens	107-110
27399332-3	2017	Here we show that Rheb-Y35N causes not only constitutive mTORC1 activation, but sustained activation of the MEK-ERK pathway in a TSC1/TSC2/TBC1D7 protein complex and mTORC1-independent manner, contributing to intrinsic resistance to rapamycin.	Sirolimus	233-242	mitogen-activated protein kinase kinase 7	Homo sapiens	108-111
27399332-3	2017	Here we show that Rheb-Y35N causes not only constitutive mTORC1 activation, but sustained activation of the MEK-ERK pathway in a TSC1/TSC2/TBC1D7 protein complex and mTORC1-independent manner, contributing to intrinsic resistance to rapamycin.	Sirolimus	233-242	mitogen-activated protein kinase 1	Homo sapiens	112-115
27399332-4	2017	Rheb-Y35N transforms NIH3T3 cells, resulting in aggressive tumor formation in xenograft nude mice, which could be suppressed by combined treatment with rapamycin and an extracellular signal-regulated kinase (ERK) inhibitor.	Sirolimus	152-161	mitogen-activated protein kinase 1	Mus musculus	208-211
28182002-0	2017	Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson"s disease.	Sirolimus	0-9	interleukin 6	Mus musculus	48-52
28182765-8	2017	Furthermore, osteogenesis of MC3T3-E1 showed significant association with the mammalian target of rapamycin (mTOR) phosphorylation by RA, which required further study about the mechanism.	Sirolimus	134-136	mechanistic target of rapamycin kinase	Homo sapiens	78-107
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	20-33
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	35-39
28182002-5	2017	Rapamycin increased interleukin-6 (IL-6) expression, which was associated with reduced expression of inflammatory cytokines, indicating anti-inflammatory properties of IL-6 in the MPTP model.	Sirolimus	0-9	interleukin 6	Mus musculus	168-172
28182002-6	2017	NF-kappaB was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes.	Sirolimus	45-54	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-9
28182002-6	2017	NF-kappaB was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes.	Sirolimus	186-195	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-9
28182002-6	2017	NF-kappaB was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes.	Sirolimus	186-195	signal transducer and activator of transcription 3	Mus musculus	80-130
28182002-6	2017	NF-kappaB was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes.	Sirolimus	186-195	thymoma viral proto-oncogene 1	Mus musculus	163-166
28182765-8	2017	Furthermore, osteogenesis of MC3T3-E1 showed significant association with the mammalian target of rapamycin (mTOR) phosphorylation by RA, which required further study about the mechanism.	Sirolimus	134-136	mechanistic target of rapamycin kinase	Homo sapiens	109-113
28165011-3	2017	We show that Akt phosphorylates TFEB at Ser467 and represses TFEB nuclear translocation independently of mechanistic target of rapamycin complex 1 (mTORC1), a known TFEB inhibitor.	Sirolimus	127-136	thymoma viral proto-oncogene 1	Mus musculus	13-16
28057888-8	2017	Re-inactivation of mTORC1 activity via rapamycin may resist hypoxia-induced cell death in TSC1 knockdown lymphocytes.	Sirolimus	39-48	TSC complex subunit 1	Homo sapiens	90-94
27888296-9	2017	Finally, promoting autophagy with rapamycin or pharmacological inhibition of the TLR2 signaling pathway prevented the TLR2-mediated increase in alpha-synuclein in neuronal cell cultures.	Sirolimus	34-43	toll like receptor 2	Homo sapiens	118-122
28132811-7	2017	Interestingly, we discovered that tightening of ER-mitochondria contacts by overexpression of VAPB or PTPIP51 impairs rapamycin- and torin 1-induced, but not starvation-induced, autophagy.	Sirolimus	118-127	VAMP associated protein B and C	Homo sapiens	94-98
28132811-7	2017	Interestingly, we discovered that tightening of ER-mitochondria contacts by overexpression of VAPB or PTPIP51 impairs rapamycin- and torin 1-induced, but not starvation-induced, autophagy.	Sirolimus	118-127	regulator of microtubule dynamics 3	Homo sapiens	102-109
27660040-11	2017	Aortic adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and expression of the cell cycle-related proteins PTEN and p27kip were increased with rapamycin treatment in old mice (all P &lt; 0.05).	Sirolimus	165-174	phosphatase and tensin homolog	Mus musculus	129-133
27990590-4	2017	Blood was collected at baseline and then 6 and 12 months after treatment with the mTOR inhibitor sirolimus.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	82-86
27683229-0	2017	Rapamycin suppresses hypoxia/reoxygenation-induced islet injury by up-regulation of miR-21 via PI3K/Akt signalling pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	100-103
27683229-6	2017	When the PI3k/Akt signalling pathways was blocked by wortmannin, the up-regulative effects of rapamycin on miR-21 expression were inhibited in vitro.	Sirolimus	94-103	AKT serine/threonine kinase 1	Homo sapiens	14-17
27862340-2	2017	Recently, mTOR inhibitors such as sirolimus and everolimus (EVR) have been used with or without CNIs in LT recipients for their renal-sparing effect.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	10-14
26725440-0	2017	Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.	Sirolimus	103-112	AKT serine/threonine kinase 1	Homo sapiens	151-154
27692982-4	2017	Although rapamycin did not affect the increase in body weight and adiposity, it exacerbated the glucose intolerance and adipose tissue inflammation induced by HFD feeding, as evidenced by the increased adipose tissue percentage of M1 macrophages, naive and activated cytotoxic T lymphocytes, and mRNA levels of proinflammatory molecules, such as TNF-alpha, IL-6 and MCP-1.	Sirolimus	9-18	tumor necrosis factor	Mus musculus	346-355
27941362-4	2017	Microsatellite instability hypermutated tumors commonly have alterations in the phosphatidylinositide 3-kinases/AKT/mechanistic target of rapamycin pathway and limiting targeted therapy to this group may lead to greater response rates.	Sirolimus	138-147	AKT serine/threonine kinase 1	Homo sapiens	112-115
28260460-1	2017	The mammalian target of rapamycin inhibitor sirolimus was introduced into clinical transplant practice in 1999.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	4-33
27692982-4	2017	Although rapamycin did not affect the increase in body weight and adiposity, it exacerbated the glucose intolerance and adipose tissue inflammation induced by HFD feeding, as evidenced by the increased adipose tissue percentage of M1 macrophages, naive and activated cytotoxic T lymphocytes, and mRNA levels of proinflammatory molecules, such as TNF-alpha, IL-6 and MCP-1.	Sirolimus	9-18	interleukin 6	Mus musculus	357-361
27692982-4	2017	Although rapamycin did not affect the increase in body weight and adiposity, it exacerbated the glucose intolerance and adipose tissue inflammation induced by HFD feeding, as evidenced by the increased adipose tissue percentage of M1 macrophages, naive and activated cytotoxic T lymphocytes, and mRNA levels of proinflammatory molecules, such as TNF-alpha, IL-6 and MCP-1.	Sirolimus	9-18	mast cell protease 1	Mus musculus	366-371
28028691-4	2017	To investigate the mechanism for the variability in the change in PCSK9 levels, lymphoblastoid cell lines were incubated with both sirolimus and everolimus, resulting in a 2-3 fold increase in PCSK9 expression and protein levels in mTOR inhibitor sensitive but not in mTOR inhibitor resistant cell lines.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	232-236
27225870-4	2017	In this study, we asked whether combination treatment with rapamycin and resveratrol could be effective in concurrently inhibiting mTOR and PI3K signaling and inducing cell death in bladder cancer cells.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	131-135
27225870-5	2017	In combination with rapamycin, resveratrol was able to block rapamycin-induced Akt activation, while maintaining mTOR pathway inhibition.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	79-82
27225870-6	2017	In addition, combination treatment with rapamycin and resveratrol induced cell death specifically in TSC1-/- MEF cells, and not in wild-type MEFs.	Sirolimus	40-49	TSC complex subunit 1	Homo sapiens	101-105
28028691-4	2017	To investigate the mechanism for the variability in the change in PCSK9 levels, lymphoblastoid cell lines were incubated with both sirolimus and everolimus, resulting in a 2-3 fold increase in PCSK9 expression and protein levels in mTOR inhibitor sensitive but not in mTOR inhibitor resistant cell lines.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	268-272
27574736-11	2017	Neutralizing CCL22 hindered CD4+FoxP3+ Treg migration to cardiac allografts and reversed long-term allograft survival induced by tanshinol plus rapamycin.	Sirolimus	144-153	chemokine (C-C motif) ligand 22	Mus musculus	13-18
27585353-5	2017	MTOR inhibitors such as Everolimus or Sirolimus are implemented in the treatment of TSC/LAM and found to control disease burden.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	0-4
28094770-3	2017	Here, we have explored a strategy that involves a combination of immune activation and the immunosuppressive mTOR inhibitor rapamycin.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	109-113
28356986-7	2017	The results revealed that cell viability and invasion increased under hypoxic conditions, but decreased following rapamycin treatment in SGC-7901 and BGC-823 cells.	Sirolimus	114-123	sarcoglycan beta	Homo sapiens	137-140
28356986-9	2017	However, this hypoxia-induced increase in HIF-1alpha and CD44 protein and mRNA expression levels was inhibited by rapamycin.	Sirolimus	114-123	hypoxia inducible factor 1 subunit alpha	Homo sapiens	42-52
27913296-5	2017	In separate studies, REDD1 KO mice were injected with 5 mg/kg BW of the mTOR inhibitor, rapamycin, 3 h prior to acute insulin treatment.	Sirolimus	88-97	DNA-damage-inducible transcript 4	Mus musculus	21-26
27974559-8	2017	Together, these findings demonstrate that mTOR signals play an essential role in antigen-specific humoral immune responses by differentially regulating B cell and CD4 T cell responses during acute viral infection and that rapamycin treatment alters the interplay of immune cell subsets involved in antiviral humoral immunity.	Sirolimus	222-231	mechanistic target of rapamycin kinase	Homo sapiens	42-46
27974559-12	2017	Here we found that rapamycin treatment predominantly inhibited GC B cell responses during viral infection and that this led to biased helper CD4 T cell differentiation as well as impaired antibody responses.	Sirolimus	19-28	CD4 molecule	Homo sapiens	141-144
28345001-7	2017	The rapamycin plus prednisolone treatment also significantly reduced frequencies of IgD-IgG+ class-switched/FAS+CL7+ germinal center B cells, and of activated CD4+ T cells expressing PD1 and GL7, in spleen.	Sirolimus	4-13	programmed cell death 1	Mus musculus	183-186
28117338-6	2017	Clenbuterol activated the phosphatidylinositol-3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway and decreased the accumulation of polyglutamine-expanded AR.	Sirolimus	89-98	thymoma viral proto-oncogene 1	Mus musculus	63-66
28109197-7	2017	RESULTS: Everolimus was significantly more effective than rapamycin in inhibiting iNOS and mTOR signaling pathways in both models of neuroinflammation (LPS) and seizure (KA).	Sirolimus	58-67	nitric oxide synthase 2, inducible	Mus musculus	82-86
28100577-2	2017	Its physiopathology is unclear but there might be an association with mammalian target of rapamycin (m-TOR) inhibitors, especially in patients with chronic hepatitis C. We report a case of late spontaneous decapsulation 12 years after kidney transplant in a patient infected with hepatitis C under treatment with sirolimus.	Sirolimus	313-322	mechanistic target of rapamycin kinase	Homo sapiens	70-99
28100577-2	2017	Its physiopathology is unclear but there might be an association with mammalian target of rapamycin (m-TOR) inhibitors, especially in patients with chronic hepatitis C. We report a case of late spontaneous decapsulation 12 years after kidney transplant in a patient infected with hepatitis C under treatment with sirolimus.	Sirolimus	313-322	RAR related orphan receptor C	Homo sapiens	103-106
28109197-8	2017	Everolimus significantly attenuated the mRNA expression of iNOS by LPS and nitrite production by KA and LPS than that by rapamycin.	Sirolimus	121-130	nitric oxide synthase 2, inducible	Mus musculus	59-63
27895122-6	2017	Specifically, growth under limiting potassium alters the activities of Npr1 and another TORC1 effector kinase, Sch9; hal4 hal5 and trk1 trk2 mutants display hypersensitivity to rapamycin, and reciprocally, TORC1 inhibition reduces potassium accumulation.	Sirolimus	177-186	serine/threonine protein kinase SCH9	Saccharomyces cerevisiae S288C	111-115
28031240-2	2017	MATERIALS AND METHODS: The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ-resistant U87 cell line.	Sirolimus	98-107	signal transducer and activator of transcription 3	Homo sapiens	66-71
28054657-10	2017	Rapamycin treated cells demonstrated less senescence by X-beta-Gal SA staining and by lower expression of p16.	Sirolimus	0-9	cyclin dependent kinase inhibitor 2A	Homo sapiens	106-109
28017472-4	2017	Inhibition of mTOR activity by rapamycin or partially restoring autophagy delays neurodegeneration in dNrd1 mutant flies.	Sirolimus	31-40	Megator	Drosophila melanogaster	14-18
28031240-4	2017	Western blotting analysis demonstrated that the inhibitory effect of STX-0119 on S6 and 4E-BP1 activation through regulation of YKL-40 expression occurred in addition to the inhibitory effect of rapamycin against the mTOR pathway.	Sirolimus	195-204	mechanistic target of rapamycin kinase	Homo sapiens	217-221
28237991-9	2017	Rapamycin treatment increased autophagy and decreased the expression of cyclin D1.	Sirolimus	0-9	cyclin D1	Rattus norvegicus	72-81
27914823-12	2017	Moreover, rapamycin (10nM) inhibited mTOR-FABP4 signaling and HemEC proliferation.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Homo sapiens	37-41
27764525-9	2017	Inhibition of mTOR with rapamycin or knockdown of mTOR potentiated prevention by celastrol, of Cd-induced phosphorylation of p70 S6 kinase 1/eukaryotic initiation factor 4E binding protein 1 and apoptosis.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 1	Homo sapiens	66-74
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 1	Homo sapiens	27-30
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 1	Homo sapiens	109-113
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 1	Homo sapiens	114-118
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 1	Homo sapiens	99-102
28214861-11	2017	Both the Akt inhibitor MK2206 and mTOR inhibitor rapamycin further increased TNF-alpha-induced VAF autophagy.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	34-38
28214861-11	2017	Both the Akt inhibitor MK2206 and mTOR inhibitor rapamycin further increased TNF-alpha-induced VAF autophagy.	Sirolimus	49-58	tumor necrosis factor	Homo sapiens	77-86
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	thymoma viral proto-oncogene 1	Mus musculus	27-30
27225450-12	2017	Cytotoxicity studies showed that the HER2-positive SK-BR-3 cell line was sensitive to trastuzumab, either as free drug or in the context of immunoliposomes, and is more sensitive to rapamycin than the triple negative MDA-MB-231 cells.	Sirolimus	182-191	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
28848090-13	2017	All effects were offset by pretreating with rapamycin (an mTOR antagonist).	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	58-62
28721811-7	2017	Interestingly, the circadian clock system relies upon the regulation of the critical pathways of autophagy, the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1) as well as proliferative mechanisms that involve the wingless pathway of Wnt/beta-catenin pathway to foster cell survival during injury and block tumor cell growth.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	145-149
29216630-9	2017	In addition, autophagy inhibition increased the apoptosis rate and activated caspase-3 expression level in response to OGD, and these were markedly inhibited by rapamycin preconditioning.	Sirolimus	161-170	caspase 3	Homo sapiens	77-86
29216630-11	2017	However, autophagy promotion by rapamycin increased oil droplet accumulation and LPL and PPARgamma expression.	Sirolimus	32-41	peroxisome proliferator activated receptor gamma	Homo sapiens	89-98
28487599-8	2017	Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	52-56
28487599-8	2017	Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells.	Sirolimus	13-22	BCL2 apoptosis regulator	Homo sapiens	117-122
28487599-8	2017	Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells.	Sirolimus	13-22	BCL2 associated X, apoptosis regulator	Homo sapiens	123-126
27615559-7	2017	However, percent area stenosis was significantly decreased in the SRL-containing group (27.5% +- 2.52 in DSS and 27.9% +- 3.30 in PSS) compared to BMS (35.9% +- 3.51, p &lt; 0.05).	Sirolimus	66-69	PSS	Homo sapiens	130-133
28078989-2	2017	There is a need for efficacious steroid-sparing immunomodulatory therapy for these patients, and the mTOR inhibitors (sirolimus and everolimus) may be contenders for this role.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	101-105
27690737-3	2017	Areas covered: In this review, we report all the current findings on the use of mTOR inhibitors (rapamycin, rapalogues) in the treatment of AD.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	80-84
26721390-3	2017	The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer"s disease-like symptoms in pre-symptomatic Apolipoprotein E e4 transgenic mice.	Sirolimus	73-82	apolipoprotein E	Mus musculus	238-254
26721390-4	2017	Using in vivo, multimodal neuroimaging, we found that apolipoprotein E e4 mice treated with rapamycin had restored cerebral blood flow, blood-brain barrier integrity and glucose metabolism, compared to age- and gender-matched wild-type controls.	Sirolimus	92-101	apolipoprotein E	Mus musculus	54-70
26721390-6	2017	We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E e4 transgenics.	Sirolimus	19-28	apolipoprotein E	Mus musculus	178-194
27903739-6	2017	Further investigation revealed that the Akt-mechanistic target of rapamycin signaling pathway was involved in this process, as the mechanistic target of rapamycin inhibitor rapamycin inhibited Hcy-induced changes in PKM2 enzyme activity and B cell activation.	Sirolimus	66-75	thymoma viral proto-oncogene 1	Mus musculus	40-43
28035937-2	2017	Even less studied or understood in AD is mammalian target of rapamycin complex 2 (mTORC2) that influences cellular metabolism, in part through the regulations of Akt/PKB and SGK.	Sirolimus	61-70	AKT serine/threonine kinase 1	Homo sapiens	162-169
28035937-10	2017	Rapamycin decreased phospho-mTOR and to lesser degree p-Rictor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
27479935-3	2017	Using engineered rapamycin-sensitive Binding Protein 12-2 (BP12-2) plants, the present study showed that combined treatment with rapamycin and active-site TOR inhibitors (asTORis) results in synergistic inhibition of TOR activity and plant growth in Arabidopsis.	Sirolimus	17-26	target of rapamycin	Arabidopsis thaliana	155-158
27807044-1	2017	Golgi-specific sialyltransferase (ST) expressed as a chimera with the rapamycin-binding domain of mTOR, FRB, relocates to the endoplasmic reticulum (ER) in cells exposed to rapamycin that also express invariant chain (Ii)-FKBP in the ER.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	98-102
27479935-3	2017	Using engineered rapamycin-sensitive Binding Protein 12-2 (BP12-2) plants, the present study showed that combined treatment with rapamycin and active-site TOR inhibitors (asTORis) results in synergistic inhibition of TOR activity and plant growth in Arabidopsis.	Sirolimus	17-26	target of rapamycin	Arabidopsis thaliana	173-176
28123588-5	2017	Targeted knockdown of YB-1 reduced IL-7-mediated protection against rapamycin, and an inhibitor of MEK1/2 potentiated rapamycin-mediated killing in the presence of IL-7.	Sirolimus	68-77	interleukin 7	Homo sapiens	35-39
28123588-5	2017	Targeted knockdown of YB-1 reduced IL-7-mediated protection against rapamycin, and an inhibitor of MEK1/2 potentiated rapamycin-mediated killing in the presence of IL-7.	Sirolimus	118-127	interleukin 7	Homo sapiens	164-168
28123588-5	2017	Targeted knockdown of YB-1 reduced IL-7-mediated protection against rapamycin, and an inhibitor of MEK1/2 potentiated rapamycin-mediated killing in the presence of IL-7.	Sirolimus	68-77	Y-box binding protein 1	Homo sapiens	22-26
28191279-8	2017	These effects were inhibited by the PI3K inhibitor LY294002, the AKT inhibitor triciribine, the mTOR inhibitor rapamycin, mTOR siRNA, and N-acetyl cysteine.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	96-100
28373901-0	2017	Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK.	Sirolimus	25-34	thymoma viral proto-oncogene 1	Mus musculus	90-93
28373901-0	2017	Reperfusion Therapy with Rapamycin Attenuates Myocardial Infarction through Activation of AKT and ERK.	Sirolimus	25-34	mitogen-activated protein kinase 1	Mus musculus	98-101
28373901-8	2017	Rapamycin induced phosphorylation of AKT S473 (target of mTORC2) but abolished ribosomal protein S6 phosphorylation (target of mTORC1) after I/R.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	37-40
28373901-11	2017	Rapamycin also attenuated Bax and increased Bcl-2/Bax ratio.	Sirolimus	0-9	B cell leukemia/lymphoma 2	Mus musculus	44-49
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	119-128	TSC complex subunit 1	Homo sapiens	42-45
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	50-54
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	97-101
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	119-128	TSC complex subunit 1	Homo sapiens	244-247
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	144-153	TSC complex subunit 1	Homo sapiens	42-45
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	50-54
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	97-101
28386314-3	2017	The establishment of a connection between TSC and mTOR led to the clinical use of drugs known as mTOR inhibitors (like rapamycin, also known as sirolimus and everolimus), which are becoming an increasingly interesting tool in the management of TSC-associated features, such as subependymal giant cell astrocytomas, renal angiomyolipomas, and also epilepsy.	Sirolimus	144-153	TSC complex subunit 1	Homo sapiens	244-247
28400912-9	2017	Finally, MTOR inhibition by Rapamycin, everolimus, or pp242 did not affect the series of biological events in keratinocytes exposed to UVB, including the downregulation of BiP and PERK, activation of Histone H2A and JNK, and cleavage of caspase-3 and PARP.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	9-13
28713484-6	2017	Rapamycin was able to increase collagen content and a-SMA distribution relatively, as well as decrease necrotic core area.	Sirolimus	0-9	actin alpha 2, smooth muscle, aorta	Mus musculus	52-57
27769712-0	2016	CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	194-197
28804534-6	2017	In addition, when infected by prominent periodontal pathogens, Porphyromonas gingivalis (ATCC 33277), rapamycin-pretreated groups decreased the expression of inflammatory cytokines (IL-6 and IL-8) compared with the control group.	Sirolimus	102-111	interleukin 6	Homo sapiens	182-186
28804534-6	2017	In addition, when infected by prominent periodontal pathogens, Porphyromonas gingivalis (ATCC 33277), rapamycin-pretreated groups decreased the expression of inflammatory cytokines (IL-6 and IL-8) compared with the control group.	Sirolimus	102-111	C-X-C motif chemokine ligand 8	Homo sapiens	191-195
29556614-8	2017	The lowest immunoexpression of CD34, podoplanin, PDGFA, EGFR has been noticed in the Rapamycin-treated group without important differences correlated to dosage and time.	Sirolimus	85-94	podoplanin	Gallus gallus	37-47
27547865-5	2017	The mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, are increasingly used after organ transplantation with potential advantages in virus-associated posttransplant malignancies as well as anti-cancer properties.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	4-33
27547865-5	2017	The mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, are increasingly used after organ transplantation with potential advantages in virus-associated posttransplant malignancies as well as anti-cancer properties.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	35-39
27989873-11	2016	PGB treatment increased the phosphorylation of AMP-activated protein kinase (AMPK) and subsequently suppressed the AKT/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	143-152	AKT serine/threonine kinase 1	Homo sapiens	115-118
27989873-11	2016	PGB treatment increased the phosphorylation of AMP-activated protein kinase (AMPK) and subsequently suppressed the AKT/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Homo sapiens	154-158
27769712-0	2016	CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	198-202
27769712-10	2016	Interestingly, rapamycin inhibited Akt-mediated therapeutic resistance, indicating that these effects were dependent on mTOR.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	35-38
27769712-10	2016	Interestingly, rapamycin inhibited Akt-mediated therapeutic resistance, indicating that these effects were dependent on mTOR.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	120-124
28053551-6	2017	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce the size of renal and brain lesions and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28053551-6	2017	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce the size of renal and brain lesions and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	20-29	TSC complex subunit 1	Homo sapiens	153-156
28053551-6	2017	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce the size of renal and brain lesions and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	4-8
28053551-6	2017	The mTOR inhibitors rapamycin (sirolimus) and everolimus have been shown to reduce the size of renal and brain lesions and improve pulmonary function in TSC, and these compounds may also decrease seizure frequency.	Sirolimus	31-40	TSC complex subunit 1	Homo sapiens	153-156
27713162-6	2016	The association between tumor drug resistance and the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K-AKT-mTOR) pathway was measured by western blot, assessing the changes in protein kinase B (AKT), phosphor-AKT (p-AKT), P70, and p-P70 protein levels.	Sirolimus	123-132	AKT serine/threonine kinase 1	Homo sapiens	139-142
27713162-6	2016	The association between tumor drug resistance and the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K-AKT-mTOR) pathway was measured by western blot, assessing the changes in protein kinase B (AKT), phosphor-AKT (p-AKT), P70, and p-P70 protein levels.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	143-147
27863431-9	2016	Inhibition of Akt by salubrinal potentiates the efficacy of rapamycin both in vitro and in vivo.	Sirolimus	60-69	AKT serine/threonine kinase 1	Homo sapiens	14-17
27992581-7	2016	Inhibition of autophagy by 3-methyladenine shortens the transient phase, while inhibition of mTOR by rapamycin or resveratrol prolongs it.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	93-97
27992581-9	2016	The negative effect of GADD34 inhibition is diminished when guanabenz or siGADD34 treatment is combined with rapamycin or resveratrol addition.	Sirolimus	109-118	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	23-29
27342399-8	2016	CONCLUSIONS: Metastatic competence of osteosarcoma cells is dependent on efficient mRNA translation during stressful periods of metastatic progression, and the mTOR inhibitor, rapamycin, can mitigate this translation and inhibit metastasis in vivo Our data suggest that mTOR pathway inhibitors should be reconsidered in the clinic using rationally designed dosing schedules and clinical metrics related to metastatic progression.	Sirolimus	176-185	mechanistic target of rapamycin kinase	Homo sapiens	160-164
27342399-8	2016	CONCLUSIONS: Metastatic competence of osteosarcoma cells is dependent on efficient mRNA translation during stressful periods of metastatic progression, and the mTOR inhibitor, rapamycin, can mitigate this translation and inhibit metastasis in vivo Our data suggest that mTOR pathway inhibitors should be reconsidered in the clinic using rationally designed dosing schedules and clinical metrics related to metastatic progression.	Sirolimus	176-185	mechanistic target of rapamycin kinase	Homo sapiens	270-274
27566137-7	2016	Treatment with rapamycin and PP242, that target the PI3K/AKT/mTOR signaling pathway, modified starvation-induced autophagy and apoptosis in IPF fibroblasts.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	57-60
28123835-6	2016	Blocking mTOR by using rapamycin selectively enhanced activities of IL-6 and TNF-alpha signaling pathways, which was accompanied with an increase of Caspase-3, indicating cellular apoptosis and worsened learning performance.	Sirolimus	23-32	interleukin 6	Rattus norvegicus	68-72
28123835-6	2016	Blocking mTOR by using rapamycin selectively enhanced activities of IL-6 and TNF-alpha signaling pathways, which was accompanied with an increase of Caspase-3, indicating cellular apoptosis and worsened learning performance.	Sirolimus	23-32	tumor necrosis factor	Rattus norvegicus	77-86
27686967-0	2016	Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes.	Sirolimus	0-9	insulin	Homo sapiens	29-36
27686967-4	2016	We have analyzed the impact of rapamycin on insulin signaling, thermogenic gene-expression and mitochondrial respiration in BAT.	Sirolimus	31-40	insulin	Homo sapiens	44-51
27686967-5	2016	Treatment of brown adipocytes with rapamycin for 16h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation.	Sirolimus	35-44	insulin	Homo sapiens	77-84
27686967-5	2016	Treatment of brown adipocytes with rapamycin for 16h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation.	Sirolimus	35-44	AKT serine/threonine kinase 1	Homo sapiens	171-174
27686967-8	2016	These effects of rapamycin on insulin signaling in brown adipocytes were partly prevented by a JNK inhibitor.	Sirolimus	17-26	insulin	Homo sapiens	30-37
27686967-8	2016	These effects of rapamycin on insulin signaling in brown adipocytes were partly prevented by a JNK inhibitor.	Sirolimus	17-26	mitogen-activated protein kinase 8	Homo sapiens	95-98
27686967-9	2016	In vivo treatment of rats with rapamycin for three weeks abolished insulin-mediated Akt phosphorylation in BAT.	Sirolimus	31-40	insulin	Homo sapiens	67-74
27686967-9	2016	In vivo treatment of rats with rapamycin for three weeks abolished insulin-mediated Akt phosphorylation in BAT.	Sirolimus	31-40	AKT serine/threonine kinase 1	Rattus norvegicus	84-87
27686967-10	2016	Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) and uncoupling protein (UCP)-1 in brown adipocytes.	Sirolimus	0-9	PPARG coactivator 1 alpha	Homo sapiens	82-149
27686967-10	2016	Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) and uncoupling protein (UCP)-1 in brown adipocytes.	Sirolimus	0-9	PPARG coactivator 1 alpha	Homo sapiens	151-161
27566137-7	2016	Treatment with rapamycin and PP242, that target the PI3K/AKT/mTOR signaling pathway, modified starvation-induced autophagy and apoptosis in IPF fibroblasts.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	61-65
27815691-2	2016	The mTOR pathway has become an exciting treatment target for these various disorders, with mTOR inhibitors such as rapamycin being studied for their potential therapeutic applications.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	91-95
27789294-7	2016	By induction of autophagy via inhibition of mTOR using rapamycin an increase of ferritin H turnover was obtained in senescent cells, demonstrating a mTOR dependent reduction of autophagy in senescent human fibroblasts.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	44-48
27671674-8	2016	PD-L1 attenuation also reduced mTORC1 activity and augmented the antiproliferative effects of the mTORC1 inhibitor rapamycin.	Sirolimus	115-124	CD274 antigen	Mus musculus	0-5
27789294-7	2016	By induction of autophagy via inhibition of mTOR using rapamycin an increase of ferritin H turnover was obtained in senescent cells, demonstrating a mTOR dependent reduction of autophagy in senescent human fibroblasts.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	149-153
26276683-5	2016	RESULTS: The mTOR inhibitor rapamycin was found to be a potent inhibitor for HCV RNA replication in Huh-7.5 cells as well as primary human hepatocytes.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
28529994-4	2016	Rapamycin, a potent inhibitor of mTOR (mammalian target of rapamycin), has been demonstrated to be a potential pharmacological agent against the aberrant mTOR signaling seen in ciliopathies such as polycystic kidney disease (PKD) and tuberous sclerosis complex (TSC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	33-37
27371338-1	2016	We previously demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), protects against N-methyl-d-aspartic acid (NMDA)-induced retinal damage in rats.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	63-92
27371338-1	2016	We previously demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), protects against N-methyl-d-aspartic acid (NMDA)-induced retinal damage in rats.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	94-98
28529994-4	2016	Rapamycin, a potent inhibitor of mTOR (mammalian target of rapamycin), has been demonstrated to be a potential pharmacological agent against the aberrant mTOR signaling seen in ciliopathies such as polycystic kidney disease (PKD) and tuberous sclerosis complex (TSC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	39-68
28529994-4	2016	Rapamycin, a potent inhibitor of mTOR (mammalian target of rapamycin), has been demonstrated to be a potential pharmacological agent against the aberrant mTOR signaling seen in ciliopathies such as polycystic kidney disease (PKD) and tuberous sclerosis complex (TSC).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	154-158
27797139-4	2016	TSC is caused by the lack of functional Tsc1-Tsc2 complex, which serves as a major cellular inhibitor of mammalian Target of Rapamycin Complex 1 (mTORC1).	Sirolimus	125-134	TSC complex subunit 1	Homo sapiens	0-3
27797139-4	2016	TSC is caused by the lack of functional Tsc1-Tsc2 complex, which serves as a major cellular inhibitor of mammalian Target of Rapamycin Complex 1 (mTORC1).	Sirolimus	125-134	TSC complex subunit 1	Homo sapiens	40-44
27797139-6	2016	Consequently, mTORC1 inhibitors, such as rapamycin, serve as experimental or already approved drugs for several TSC symptoms.	Sirolimus	41-50	TSC complex subunit 1	Homo sapiens	112-115
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	AKT serine/threonine kinase 1	Homo sapiens	174-177
27922820-5	2016	In fact, rapamycin increased insulin sensitivity and reduced weight gain in 3 models, and decreased hyperinsulinemia in 2 models.	Sirolimus	9-18	insulin	Homo sapiens	29-36
27691052-3	2016	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been reported to obviate the need for pancreatectomy, but experience is limited.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-42
27691052-3	2016	Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been reported to obviate the need for pancreatectomy, but experience is limited.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	44-48
27871466-6	2016	Furthermore, when cells were pretreated with rapamycin, autophagy was activated and expression of inflammatory factors (tumor necrosis factor-alpha and interleukin-6) induced by oxLDL was downregulated.	Sirolimus	45-54	tumor necrosis factor	Homo sapiens	120-147
27871466-6	2016	Furthermore, when cells were pretreated with rapamycin, autophagy was activated and expression of inflammatory factors (tumor necrosis factor-alpha and interleukin-6) induced by oxLDL was downregulated.	Sirolimus	45-54	interleukin 6	Homo sapiens	152-165
27495747-1	2016	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are increasingly used in cardiothoracic transplantation.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	4-33
27495747-1	2016	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are increasingly used in cardiothoracic transplantation.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	35-39
27916907-8	2016	In addition, the anti-EMT effects of metformin could be partially in accord with rapamycin, a specific mTOR inhibitor.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	103-107
27917191-5	2016	Here we find that tomato plants showed obvious growth inhibition when treated with rapamycin and the inhibitory phenotype is similar to suppression of TOR causing by active-site TOR inhibitors (asTORis) such as KU63794, AZD8055, and Torin1.	Sirolimus	83-92	target of rapamycin	Arabidopsis thaliana	151-154
27917191-5	2016	Here we find that tomato plants showed obvious growth inhibition when treated with rapamycin and the inhibitory phenotype is similar to suppression of TOR causing by active-site TOR inhibitors (asTORis) such as KU63794, AZD8055, and Torin1.	Sirolimus	83-92	target of rapamycin	Arabidopsis thaliana	178-181
27663762-10	2016	Rapamycin treatment attenuated interleukin 1beta and transforming growth factor beta induction in irradiated lungs compared with the control diet.	Sirolimus	0-9	interleukin 1 beta	Mus musculus	31-84
27904683-9	2016	Rapamycin significantly suppressed secretion of IL-6 by tumor cells (P&lt;0.05).	Sirolimus	0-9	interleukin 6	Homo sapiens	48-52
27904683-11	2016	Rapamycin effectively reverted the stimulatory effect of IL-6 secreted by tumor cells on endothelial cell invasiveness.	Sirolimus	0-9	interleukin 6	Homo sapiens	57-61
27463007-8	2016	Notably, rapamycin rescued oxidative stress-induced embryonic defects via modulating gene expression of sirtuin and mammalian target of rapamycin.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	116-145
27778276-4	2016	Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and Smad3 in response to various signals such as TGFbeta, retinoic acid, and rapamycin.	Sirolimus	248-257	nuclear factor kappa B subunit 1	Homo sapiens	91-113
28124643-9	2016	RESULTS: Whereas rapamycin (range, 0-400 nM) had no significant cytotoxic effects on TGF beta 1 induced NPDFs, it significantly reduced the expression levels of alpha-SMA in TGF beta 1 induced NPDFs in a dose-dependent manner.	Sirolimus	17-26	transforming growth factor beta 1	Homo sapiens	174-184
28124643-10	2016	TGF beta 1 induced collagen production and collagen contraction were significantly inhibited by rapamycin treatment.	Sirolimus	96-105	transforming growth factor beta 1	Homo sapiens	0-10
27599716-10	2016	Inhibition of autophagic clearance of Abeta led to increased ROS levels and aggravating mitochondrial defects, which were blocked by Rapamycin (an mTOR inhibitor).	Sirolimus	133-142	amyloid beta precursor protein	Homo sapiens	38-43
28124643-11	2016	Rapamycin also attenuated the TGF beta 1 induced activation of PI3K and mTOR, and its inhibitory effects were similar to those of mTOR silencing and a specific PI3K inhibitor.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	30-40
28124643-11	2016	Rapamycin also attenuated the TGF beta 1 induced activation of PI3K and mTOR, and its inhibitory effects were similar to those of mTOR silencing and a specific PI3K inhibitor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	72-76
27599716-10	2016	Inhibition of autophagic clearance of Abeta led to increased ROS levels and aggravating mitochondrial defects, which were blocked by Rapamycin (an mTOR inhibitor).	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	147-151
27245261-2	2016	More recently mTOR inhibitors such as sirolimus and everolimus have been introduced to the field of allogeneic haematopoietic stem cell transplantation where their unique combination of immunosuppressive purposes offering reduced nephrotoxicity and potential antimalignant effects reflect a unique drug profile that has led to their widespread use in both prophylaxis and therapy of graft-versus-host disease (GVHD).	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26952863-2	2016	Recently, this signalling pathway has come to the attention of the scientific community owing to the unexpected finding that inhibition of mTOR by rapamycin, an antibiotic with immunosuppressant and chemotherapeutic properties, extends lifespan in diverse animal models.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	139-143
27760048-4	2016	Acute treatment with rapamycin recapitulated the effects of RAPTOR deficiency, and both strategies led to the ablation of newly formed plasma cells in the spleen and bone marrow while also obliterating preexisting germinal centers.	Sirolimus	21-30	regulatory associated protein of MTOR, complex 1	Mus musculus	60-66
27256566-3	2016	Here, we showed that suppressing mTOR signaling in in vitro-expanded Vgamma4 gammadelta T cells via the mechanistic inhibitor rapamycin enhanced their cytotoxicity against multiple tumor cell lines, and these cells performed better tumor-suppressing effects upon adoptive therapy.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	33-37
27770822-5	2016	ApCPEB4 which we have named after its mammalian CPEB4-like homolog lacks a prion-like domain, is responsive to 5-hydroxytryptamine, and is translated (but not transcribed) in an emetine-sensitive, rapamycin-insensitive, and PKA-dependent manner.	Sirolimus	197-206	cytoplasmic polyadenylation element binding protein 4	Homo sapiens	2-7
27400793-6	2016	Our results demonstrated that rapamycin strengthened the capacity of MSCs to inhibit CD4+ T-cell proliferation, whereas 3-MA weakened the inhibitory ability of MSCs.	Sirolimus	30-39	CD4 molecule	Homo sapiens	85-88
27400793-7	2016	Mechanistically, 3-MA-pretreated MSCs secreted less, whereas rapamycin-pretreated MSCs secreted more transforming growth factor-beta1 (TGF-beta1) compared with the control cells.	Sirolimus	61-70	transforming growth factor beta 1	Homo sapiens	101-133
27400793-7	2016	Mechanistically, 3-MA-pretreated MSCs secreted less, whereas rapamycin-pretreated MSCs secreted more transforming growth factor-beta1 (TGF-beta1) compared with the control cells.	Sirolimus	61-70	transforming growth factor beta 1	Homo sapiens	135-144
27400793-8	2016	Furthermore, exogenous TGF-beta1 addition recovered the immunosuppressive capacity of 3-MA-pretreated MSCs, whereas exogenous anti-TGF-beta1 antibody addition reduced the immunosuppressive capacity of rapamycin-pretreated MSCs.	Sirolimus	201-210	transforming growth factor beta 1	Homo sapiens	131-140
27569211-5	2016	IFNgamma signals were required in both hematopoietic and nonhematopoietic cells for rapamycin to optimally promote epidermal infiltration of gammadelta TCRmid T cells, as mediated by CXCR3-CXCL10 interactions, along with the antitumor effects of these cells.	Sirolimus	84-93	interferon gamma	Mus musculus	0-8
27826244-6	2016	This review summarizes the evidence supporting the notion of intermittent, low dose rapamycin for treating insulin resistance.	Sirolimus	84-93	insulin	Homo sapiens	107-114
27589687-0	2016	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	37-41
27735842-8	2016	Additionally, DOXO significantly induced mTOR expression in hCPCs, and inhibition of mTOR signaling by rapamycin, a specific inhibitor, rescued DOXO-mediated autophagosome depletion in hCPCs with significant reduction of DOXO-mediated cytosolic Ca2+ accumulation in hCPCs, and restored SMP30 and mTOR expression.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	85-89
27616194-1	2016	Rapamycin, a specific inhibitor of mTOR used extensively as an immunosuppressant, has been expanded recently to cancer therapy, because the mTOR signal is known to be up-regulated in various cancer cells including hepatocellular carcinoma (HCC) cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
27616194-1	2016	Rapamycin, a specific inhibitor of mTOR used extensively as an immunosuppressant, has been expanded recently to cancer therapy, because the mTOR signal is known to be up-regulated in various cancer cells including hepatocellular carcinoma (HCC) cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	140-144
27616194-10	2016	Finally, we found that the extracellular signal-regulated kinase 1/2 (ERK1/2) signal was regulated by p53 whose expression was induced by rapamycin.	Sirolimus	138-147	mitogen-activated protein kinase 1	Homo sapiens	27-68
27616194-10	2016	Finally, we found that the extracellular signal-regulated kinase 1/2 (ERK1/2) signal was regulated by p53 whose expression was induced by rapamycin.	Sirolimus	138-147	mitogen-activated protein kinase 3	Homo sapiens	70-76
27616194-10	2016	Finally, we found that the extracellular signal-regulated kinase 1/2 (ERK1/2) signal was regulated by p53 whose expression was induced by rapamycin.	Sirolimus	138-147	tumor protein p53	Homo sapiens	102-105
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	38-47	tumor protein p53	Homo sapiens	125-128
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	38-47	mitogen-activated protein kinase 3	Homo sapiens	153-159
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	38-47	tumor protein p53	Homo sapiens	184-187
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	266-270
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	279-288	tumor protein p53	Homo sapiens	184-187
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	279-288	mechanistic target of rapamycin kinase	Homo sapiens	266-270
27735842-8	2016	Additionally, DOXO significantly induced mTOR expression in hCPCs, and inhibition of mTOR signaling by rapamycin, a specific inhibitor, rescued DOXO-mediated autophagosome depletion in hCPCs with significant reduction of DOXO-mediated cytosolic Ca2+ accumulation in hCPCs, and restored SMP30 and mTOR expression.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	85-89
27459239-8	2016	Knockdown of DUSP1 sensitized CAOV3 cells to rapamycin-induced antigrowth activity.	Sirolimus	45-54	dual specificity phosphatase 1	Homo sapiens	13-18
27705797-3	2016	Here, we show that simultaneous inhibition of mTOR signaling to both S6K1 and 4E-BP1 is sufficient to reduce AKT-induced muscle growth and render it insensitive to the mTORC1-inhibitor rapamycin.	Sirolimus	185-194	mechanistic target of rapamycin kinase	Homo sapiens	46-50
27459239-10	2016	Knockdown of DUSP1 in CAOV3-CR cells restored sensitivity to rapamycin.	Sirolimus	61-70	dual specificity phosphatase 1	Homo sapiens	13-18
27459239-11	2016	Collectively, this work identifies a previously unrecognized role for DUSP1 in regulating autophagy and suggests that suppression of DUSP1 may enhance the therapeutic activity of rapamycin.	Sirolimus	179-188	dual specificity phosphatase 1	Homo sapiens	70-75
27459239-11	2016	Collectively, this work identifies a previously unrecognized role for DUSP1 in regulating autophagy and suggests that suppression of DUSP1 may enhance the therapeutic activity of rapamycin.	Sirolimus	179-188	dual specificity phosphatase 1	Homo sapiens	133-138
27822418-6	2016	Pharmacological inhibition of mTORC1 signaling with rapamycin decreased LDHA level and glycolytic capacity of six HCC cell lines.	Sirolimus	52-61	lactate dehydrogenase A	Homo sapiens	72-76
27581648-4	2016	First, inhibition of translation with cycloheximide had a more potent effect on protein synthesis than rapamycin indicating that mTOR function during hypertrophy is not on general, but rather on specific protein synthesis.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	129-133
27581648-8	2016	Inhibition of mTOR signaling by rapamycin disrupted mTOR-rDNA promoter interaction and resulted in altered histone marks indicative of repressed transcription and formation of higher-order chromatin structure.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27581648-8	2016	Inhibition of mTOR signaling by rapamycin disrupted mTOR-rDNA promoter interaction and resulted in altered histone marks indicative of repressed transcription and formation of higher-order chromatin structure.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	52-56
27209607-0	2016	Rapamycin Decreases the Osteogenic Response in Aortic Valve Interstitial Cells Through the Stat3 Pathway.	Sirolimus	0-9	signal transducer and activator of transcription 3	Homo sapiens	91-96
27209607-3	2016	Rapamycin, a drug used clinically, induces feedback activation of Akt.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	66-69
27484210-2	2016	We further hypothesized that co-treatment of CDK inhibitors with rapamycin, an mTOR inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer regard to androgen receptor (AR) status due to inhibition of proliferative pathway, PI3K/AKT/mTOR, and induction of cell death mechanisms.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	79-83
27217298-3	2016	TGFbeta1/Fc induced Smad2/3 protein phosphorylation in rhesus and human peripheral blood mononuclear cells and augmented the suppressive effect of rapamycin on rhesus Tmem proliferation after either alloactivation or anti-CD3/CD28 stimulation.	Sirolimus	147-156	transforming growth factor beta 1	Homo sapiens	0-8
27484210-2	2016	We further hypothesized that co-treatment of CDK inhibitors with rapamycin, an mTOR inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer regard to androgen receptor (AR) status due to inhibition of proliferative pathway, PI3K/AKT/mTOR, and induction of cell death mechanisms.	Sirolimus	65-74	androgen receptor	Homo sapiens	186-203
27484210-2	2016	We further hypothesized that co-treatment of CDK inhibitors with rapamycin, an mTOR inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer regard to androgen receptor (AR) status due to inhibition of proliferative pathway, PI3K/AKT/mTOR, and induction of cell death mechanisms.	Sirolimus	65-74	androgen receptor	Homo sapiens	205-207
27484210-2	2016	We further hypothesized that co-treatment of CDK inhibitors with rapamycin, an mTOR inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer regard to androgen receptor (AR) status due to inhibition of proliferative pathway, PI3K/AKT/mTOR, and induction of cell death mechanisms.	Sirolimus	65-74	AKT serine/threonine kinase 1	Homo sapiens	265-268
27484210-2	2016	We further hypothesized that co-treatment of CDK inhibitors with rapamycin, an mTOR inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer regard to androgen receptor (AR) status due to inhibition of proliferative pathway, PI3K/AKT/mTOR, and induction of cell death mechanisms.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	269-273
27484210-4	2016	Co-treatment of rapamycin modulated CDK inhibitors-induced cytotoxicity and apoptosis that CDK inhibitors were more potent to induce cell death in AR (+) LNCaP cells than AR (-) DU145 cells.	Sirolimus	16-25	androgen receptor	Homo sapiens	147-149
27484210-4	2016	Co-treatment of rapamycin modulated CDK inhibitors-induced cytotoxicity and apoptosis that CDK inhibitors were more potent to induce cell death in AR (+) LNCaP cells than AR (-) DU145 cells.	Sirolimus	16-25	androgen receptor	Homo sapiens	171-173
27411383-7	2016	Reduction of GLUT4 protein in sedentary animals upon treatment with rapamycin revealed mTORC1-dependent GLUT4 regulation.	Sirolimus	68-77	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	104-109
27371614-3	2016	Rapamycin is a well-characterized inhibitor of mTOR complex 1 signalling and a potent inducer of Treg cells in the periphery.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	47-51
27411383-7	2016	Reduction of GLUT4 protein in sedentary animals upon treatment with rapamycin revealed mTORC1-dependent GLUT4 regulation.	Sirolimus	68-77	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	13-18
27530708-1	2016	Being a substrate of the cytochrome P450 3A4 (CYP3A4) isoenzyme, sirolimus metabolism is decreased when posaconazole is administered concomitantly.	Sirolimus	65-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-44
27530708-1	2016	Being a substrate of the cytochrome P450 3A4 (CYP3A4) isoenzyme, sirolimus metabolism is decreased when posaconazole is administered concomitantly.	Sirolimus	65-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
26604019-6	2016	mTOR inhibitors such as sirolimus or everolimus have shown a beneficial effect on the decline in pulmonary function and a reduction of angiomyolipoma size, but are necessary in only some patients.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	0-4
27423526-1	2016	BACKGROUND: The purpose of the study was to evaluate lipid homeostasis before and after treatment of everolimus, the mammalian target of the rapamycin (mTOR) inhibitor, among patients with tuberous sclerosis complex (TSC).	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	152-156
27545763-9	2016	Rapamycin also inhibited LH-induced increase in EREG mRNA abundance in granulosa cells in vitro.	Sirolimus	0-9	epiregulin	Bos taurus	48-52
27310200-1	2016	BACKGROUND: Sirolimus is a mammalian target of rapamycin inhibitor that is being used to prevent organ rejection in kidney transplant patients often in combination with calcineurin inhibitors (CNIs; cyclosporine and tacrolimus).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	27-56
27310200-4	2016	METHODS: In vitro inhibition assay with sirolimus were conducted using recombinant CYP3As and human microsomes in the presence and absence of CNIs.	Sirolimus	40-49	peptidylprolyl isomerase F	Homo sapiens	83-87
27694325-2	2016	Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR) implicated in the progression of many different forms of renal disease.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-86
27694325-2	2016	Rapamycin is an inhibitor of the serine/threonine kinase mammalian target of rapamycin (mTOR) implicated in the progression of many different forms of renal disease.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
27694325-3	2016	Given that Na/K-ATPase signaling is known to stimulate the mTOR system, we speculated that the ameliorative effects of rapamycin might influence this pathway.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	59-63
27694325-10	2016	Our results suggest that rapamycin may have a dual effect on cardiac fibrosis through (1) mTOR inhibition and (2) inhibiting MBG-mediated profibrotic signaling and provide support for beneficial effect of a novel therapy for uremic cardiomyopathy.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	90-94
27755955-8	2016	ELISA and real-time quantitative PCR demonstrated that rapamycin inhibited ICH-induced excessive expression of TNF-alpha and IL-1beta in ipsilateral hemisphere.	Sirolimus	55-64	tumor necrosis factor	Rattus norvegicus	111-120
27473087-0	2016	Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.	Sirolimus	28-37	notch receptor 1	Homo sapiens	99-105
27641460-3	2016	Interestingly, this turn motif displays strong similarities with the FKBP52 FK1 domain-binding moiety of macrolide immunomodulators such as rapamycin and GPI-1046, an immunophilin ligand with neuroprotective characteristics.	Sirolimus	140-149	FKBP prolyl isomerase 4	Homo sapiens	69-75
27755955-8	2016	ELISA and real-time quantitative PCR demonstrated that rapamycin inhibited ICH-induced excessive expression of TNF-alpha and IL-1beta in ipsilateral hemisphere.	Sirolimus	55-64	interleukin 1 beta	Rattus norvegicus	125-133
27557496-7	2016	Rapamycin enhanced the AR protein level without altering phosphoAR-Ser81 and CYP17A1.	Sirolimus	0-9	androgen receptor	Homo sapiens	23-25
27493206-2	2016	The gene products hamartin and tuberin form the TSC complex that acts as GTPase-activating protein for Rheb and negatively regulates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	TSC complex subunit 1	Homo sapiens	18-26
27658964-10	2016	Importantly, rapamycin, a well-known mTOR inhibitor, is able to reduce STAT3 phosphorylation to basal levels in our experimental model.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	37-41
27658964-10	2016	Importantly, rapamycin, a well-known mTOR inhibitor, is able to reduce STAT3 phosphorylation to basal levels in our experimental model.	Sirolimus	13-22	signal transducer and activator of transcription 3	Homo sapiens	71-76
27493206-2	2016	The gene products hamartin and tuberin form the TSC complex that acts as GTPase-activating protein for Rheb and negatively regulates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	TSC complex subunit 1	Homo sapiens	48-51
27392709-10	2016	Both PI3K inhibitor LY294002 and mTOR inhibitor rapamycin decreased the augmented caspase-3 expression and TC content induced by ox-LDL, respectively.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	33-37
27392709-10	2016	Both PI3K inhibitor LY294002 and mTOR inhibitor rapamycin decreased the augmented caspase-3 expression and TC content induced by ox-LDL, respectively.	Sirolimus	48-57	caspase 3	Homo sapiens	82-91
27188418-7	2016	Rapamycin (50 nM; an inhibitor of mTOR) attenuated (P &lt; 0.05) the stimulatory effect of AKG on mTOR signaling and syntheses of milk protein and lactose, while relieving (P &lt; 0.05) an inhibitory effect of AKG on expression of proteins related to ERS.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	34-38
27188418-7	2016	Rapamycin (50 nM; an inhibitor of mTOR) attenuated (P &lt; 0.05) the stimulatory effect of AKG on mTOR signaling and syntheses of milk protein and lactose, while relieving (P &lt; 0.05) an inhibitory effect of AKG on expression of proteins related to ERS.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
27217295-9	2016	Transfection of the let-7 antimiR significantly reduced the infarct size of diabetic rats (p &lt; 0.0001), and such an antiinfarct effect was abolished completely by pretreatment of Akt inhibitor LY294002 or mTOR inhibitor rapamycin.	Sirolimus	223-232	AKT serine/threonine kinase 1	Rattus norvegicus	182-185
27742384-3	2016	Mammalian target of rapamycin inhibitors, both sirolimus and everolimus, have been studied in several trials to facilitate preservation of kidney function with variable effects on kidney allograft function and immunogenicity.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	0-29
27163752-4	2016	Using a formalin-induced conditioned place avoidance (F-CPA) test, the current study investigated the effects of the mTOR specific inhibitor rapamycin on noxious stimulation induced aversion in the rostral anterior cingulate cortex (rACC).	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	117-121
26036652-2	2016	Rapamycin (RPM) is in the clinical trials for breast cancer treatment, but its P-gp substrate property leads to poor oral bioavailability and efficacy.	Sirolimus	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
27593484-4	2016	Such decreased pro-IL-1beta expression in TSC1 KO macrophages was rescued by reducing mTORC1 activity with rapamycin or deletion of mTOR.	Sirolimus	107-116	interleukin 1 beta	Homo sapiens	19-27
27593484-4	2016	Such decreased pro-IL-1beta expression in TSC1 KO macrophages was rescued by reducing mTORC1 activity with rapamycin or deletion of mTOR.	Sirolimus	107-116	TSC complex subunit 1	Homo sapiens	42-46
27593484-4	2016	Such decreased pro-IL-1beta expression in TSC1 KO macrophages was rescued by reducing mTORC1 activity with rapamycin or deletion of mTOR.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	86-90
26036652-2	2016	Rapamycin (RPM) is in the clinical trials for breast cancer treatment, but its P-gp substrate property leads to poor oral bioavailability and efficacy.	Sirolimus	11-14	ATP binding cassette subfamily B member 1	Homo sapiens	79-83
26036652-8	2016	This reveals that the uptake of the RPM (P-gp substrate) has been increased in the presence of chemosensitizer.	Sirolimus	36-39	ATP binding cassette subfamily B member 1	Homo sapiens	41-45
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD24 molecule	Homo sapiens	53-57
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD24 molecule	Homo sapiens	89-93
27482884-0	2016	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	43-47
27258186-4	2016	Sirolimus significantly enhances the cytokine production of transforming growth factor-beta1 (TGF-beta1) and interleukin-10 (IL-10) in PBMCs with B cells, and the enhancement significantly decreased in PBMCs without B cells.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	60-92
27258186-4	2016	Sirolimus significantly enhances the cytokine production of transforming growth factor-beta1 (TGF-beta1) and interleukin-10 (IL-10) in PBMCs with B cells, and the enhancement significantly decreased in PBMCs without B cells.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	94-103
27258186-7	2016	The amplification of Tregs by Sirolimus was partially inhibited when either TGF-beta1 or IL-10 was neutralized, and it even disappeared when these two cytokines were both neutralized.	Sirolimus	30-39	transforming growth factor beta 1	Homo sapiens	76-85
27044634-9	2016	The expression of HIF-1alpha protein and SNAIL mRNA could be inhibited gradually by rapamycin.	Sirolimus	84-93	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
27044634-9	2016	The expression of HIF-1alpha protein and SNAIL mRNA could be inhibited gradually by rapamycin.	Sirolimus	84-93	snail family transcriptional repressor 1	Homo sapiens	41-46
27482884-8	2016	Moreover, VHL-deficient cells that expressed activating mTOR mutants grew tumors that were sensitive to rapamycin treatment.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	56-60
27198515-5	2016	Brefeldin A, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), and rapamycin (mTOR inhibitor) inhibited the TNF-alpha-stimulated productions of inflammatory mediators, and activations of Akt, mTOR, and NF-kappaB in keratinocytes.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	95-99
27506738-7	2016	More interestingly, the glucose uptake and the phosphorylation of the insulin receptor were decreased by 3-MA stimulation and increased by rapamycin, illustrating that the responsiveness of insulin was regulated by autophagy.	Sirolimus	139-148	insulin	Homo sapiens	70-77
27198515-5	2016	Brefeldin A, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), and rapamycin (mTOR inhibitor) inhibited the TNF-alpha-stimulated productions of inflammatory mediators, and activations of Akt, mTOR, and NF-kappaB in keratinocytes.	Sirolimus	84-93	tumor necrosis factor	Homo sapiens	125-134
27635236-4	2016	However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	41-45
27635236-4	2016	However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	167-171
27635236-4	2016	However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	167-171
27635236-4	2016	However, progress in using inhibitors of mTOR signaling as therapeutic agents in oncology has been limited by a number of factors, including the fact that the classic mTOR inhibitor, rapamycin, inhibits only some of the effects of mTOR; the existence of several feedback loops; and the crucial importance of mTOR in normal physiology.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	167-171
27246695-11	2016	In vitro study revealed that AMPK activation using AICAR or mTOR inhibition using rapamycin effectively negated the beneficial cardiomyocyte mechanical effects of TLR4 inhibition (CLI-095) against paraquat toxicity, supporting a permissive role for AMPK-mTOR in TLR4 inhibition-offered cardioprotection against paraquat.	Sirolimus	82-91	toll-like receptor 4	Mus musculus	163-167
27566410-9	2016	Expression of both constitutive and immunoproteasome subunits in FCD II-derived astroglial cultures was negatively regulated by treatment with the immunomodulatory drug rapamycin (inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is activated in both TSC and FCD II).	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	197-226
27566410-9	2016	Expression of both constitutive and immunoproteasome subunits in FCD II-derived astroglial cultures was negatively regulated by treatment with the immunomodulatory drug rapamycin (inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is activated in both TSC and FCD II).	Sirolimus	169-178	mechanistic target of rapamycin kinase	Homo sapiens	228-232
27174915-9	2016	Testing their cooperation in vitro, a significant involvement of IDO1 in mTOR immunogenic pathway was found, able to counteract the aim of rapamycin treatment.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	73-77
27610411-1	2016	Mammalian target of rapamycin (mTOR) signaling is a core pathway in cellular metabolism, and control of the mTOR pathway by rapamycin shows potential for the treatment of metabolic diseases.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
27610411-1	2016	Mammalian target of rapamycin (mTOR) signaling is a core pathway in cellular metabolism, and control of the mTOR pathway by rapamycin shows potential for the treatment of metabolic diseases.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	108-112
27418134-12	2016	MiR-184 based supplementary therapeutics and mTOR blocker, like rapamycin, are prospective options for AMD treatment.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	45-49
27297394-4	2016	Utilizing Western blot analysis, we demonstrate that similar to rapamycin (a known mTOR inhibitor), mf downregulate the phosphorylation of mTOR and its regulatory proteins, p70S6K1 and 4E-BP1, a process essential for DC protein synthesis.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	83-87
27297394-4	2016	Utilizing Western blot analysis, we demonstrate that similar to rapamycin (a known mTOR inhibitor), mf downregulate the phosphorylation of mTOR and its regulatory proteins, p70S6K1 and 4E-BP1, a process essential for DC protein synthesis.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	139-143
28903328-8	2017	Rapamycin, an mTOR inhibitor, hinders cell proliferation along with sphere formation in vitro and impedes tumor growth in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27525306-6	2016	These effects mimicked that of c-Met inhibitor SU11274 or PI3 kinase inhibitor LY294002 or mTOR inhibitor rapamycin treatment.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	91-95
27221774-5	2016	Myricetin, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), rapamycin (mTOR inhibitor) and N-acetylcysteine attenuated TNF-alpha-induced activation of Akt, mTOR and NF-kappaB.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	89-93
27221774-5	2016	Myricetin, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), rapamycin (mTOR inhibitor) and N-acetylcysteine attenuated TNF-alpha-induced activation of Akt, mTOR and NF-kappaB.	Sirolimus	78-87	tumor necrosis factor	Homo sapiens	137-146
27221774-5	2016	Myricetin, Akt inhibitor, Bay 11-7085 (an inhibitor of NF-kappaB activation), rapamycin (mTOR inhibitor) and N-acetylcysteine attenuated TNF-alpha-induced activation of Akt, mTOR and NF-kappaB.	Sirolimus	78-87	AKT serine/threonine kinase 1	Homo sapiens	169-172
27601112-1	2016	Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	33-62
27601112-1	2016	Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant for solid-organ transplant recipients and patients with autoimmune disorders.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	64-68
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	70-73
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	11-20	AKT serine/threonine kinase 1	Homo sapiens	70-73
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	28-32
27648364-7	2016	We determined the expression of cyclin D1 and phosphorylated-mTOR proteins in association with the response to rapamycin in two androgen sensitive (22RV1 and LNCaP) and two androgen independent (DU145 and PC3) prostate cancer cell lines and found that the base-line and changes of cyclin D1 level, but not the expression level of p-mTOR, correlated with rapamycin sensitivity.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	61-65
27394642-8	2016	Inhibition of mTOR pathway using rapamycin rescued the aberrant differentiation.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	14-18
27501453-6	2016	CYP3A-dependent sirolimus metabolite formation changed in a similar fashion.	Sirolimus	16-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
27254006-6	2016	To test the functional role of brain mTORC1 in mediating the action of Ang II, we examined the consequence of mTORC1 inhibition with rapamycin on Ang II-induced increase in water intake and arterial pressure.	Sirolimus	133-142	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	146-152
27254006-7	2016	ICV pretreatment with rapamycin blocked ICV Ang II-mediated increases in the frequency, duration, and amount of water intake but did not interfere with the pressor response evoked by Ang II.	Sirolimus	22-31	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	44-50
27630374-0	2016	The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	70-99
26758248-2	2016	In our study, allogeneic polyclonal CD4 (+) CD25 (+) Tregs and CD4 (+) CD25 (+) CD127(lo)Tregs expanded in vitro in the presence of rapamycin and low dose IL-2 suppressed proliferation of 11 out of 12 established lymphoma B-cell lines.	Sirolimus	132-141	CD4 molecule	Homo sapiens	63-66
26758248-6	2016	CD4 (+) CD25 (+) Tregs or CD4 (+) CD25 (+) CD127(lo)Tregs expanded ex vivo with rapamycin could be used to suppress regrowth of residual lymphoma after autologous hematopoietic cell transplantation (HCT), and to counteract both graft-versus-host disease and lymphoma re-growth after allogeneic HCT in select patients with lymphoma susceptible to the regulation by Tregs.	Sirolimus	80-89	CD4 molecule	Homo sapiens	26-29
27531779-4	2016	The expression levels of caspase 3 and ATK in U266 cells treated with rapamycin, 17-AAG and their combination were higher and lower than those in control group respectively, and the efficacy of 2 drug combination was superior to signle drug.	Sirolimus	70-79	caspase 3	Homo sapiens	25-34
27630374-0	2016	The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	101-105
27630374-1	2016	PURPOSE: To determine if two different doses of intravitreal sirolimus, an mTOR inhibitor, can decrease inflammation and is safe in eyes with non-infectious posterior, intermediate, or panuveitis in the Sirolimus as a Therapeutic Approach UVEitis: Protocol-2 (SAVE-2) Study.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	75-79
27226562-8	2016	Interestingly, inhibition of mTORC1 with rapamycin reduces the abundance of FOXO1 to the levels in T2D.	Sirolimus	41-50	forkhead box O1	Homo sapiens	76-81
27473161-4	2016	Autophagy in THP-1 macrophage FCs and in apoE-/- mice was regulated by Rapamycin (80 ug/mL) or 3-MA (10 mM).	Sirolimus	71-80	apolipoprotein E	Mus musculus	41-45
27329724-8	2016	Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	219-223
27329724-8	2016	Further, three other cell lines established independently from the tumors of three patients with HCC were also approximately 2,000-fold times more sensitive to rapamycin, which correlated closely with the inhibition of mTOR Ser2481 phosphorylation by rapamycin.	Sirolimus	251-260	mechanistic target of rapamycin kinase	Homo sapiens	219-223
27493626-6	2016	This was reversed dose-dependently by administering the mTOR inhibitor rapamycin.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	56-60
26991755-9	2016	The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin inhibited APR-246-induced nuclear translocation of NFE2L2 and counteracted the protective cellular responses to APR-246, resulting in synergistic cell killing together with APR-246.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	38-42
27345368-5	2016	Notably, the mTOR inhibitor rapamycin, previously reported to mimic effects of CR, abolishes this expansion of ISCs.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
27076449-5	2016	Rapamycin enhanced expansion of peripheral antigen-specific CD8 T cells and IFNgamma production following ex vivo antigen stimulation.	Sirolimus	0-9	interferon gamma	Homo sapiens	76-84
27076449-6	2016	More CD8 T cells infiltrated and were activated after PD-L1 mAb treatment in mice with immunogenic MOC1 tumors, which were stable or increased by the addition of rapamycin, but suppressed when PD901 was added.	Sirolimus	162-171	CD274 antigen	Mus musculus	54-59
27076449-7	2016	Rapamycin increased IFNgamma production capacity in peripheral and tumor-infiltrating CD8 T cells.	Sirolimus	0-9	interferon gamma	Homo sapiens	20-28
27076449-9	2016	Rapamycin also enhanced IFNgamma or PD-L1 mAb treatment-associated induction of MHC class I expression on MOC1 tumor cells, an effect abrogated by depleting infiltrating CD8 T cells from the tumor microenvironment.	Sirolimus	0-9	interferon gamma	Homo sapiens	24-32
26991755-9	2016	The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin inhibited APR-246-induced nuclear translocation of NFE2L2 and counteracted the protective cellular responses to APR-246, resulting in synergistic cell killing together with APR-246.	Sirolimus	53-62	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	73-76
26991755-9	2016	The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin inhibited APR-246-induced nuclear translocation of NFE2L2 and counteracted the protective cellular responses to APR-246, resulting in synergistic cell killing together with APR-246.	Sirolimus	53-62	NFE2 like bZIP transcription factor 2	Homo sapiens	114-120
26991755-9	2016	The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin inhibited APR-246-induced nuclear translocation of NFE2L2 and counteracted the protective cellular responses to APR-246, resulting in synergistic cell killing together with APR-246.	Sirolimus	53-62	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	175-178
26991755-9	2016	The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin inhibited APR-246-induced nuclear translocation of NFE2L2 and counteracted the protective cellular responses to APR-246, resulting in synergistic cell killing together with APR-246.	Sirolimus	53-62	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	175-178
26538632-7	2016	Kim-1 expression led to activation of the mammalian target of rapamycin (mTOR) pathway, and inhibition of this pathway with rapamycin increased survival.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	73-77
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	0-4
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	0-4
27019134-1	2016	Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	90-119
27019134-1	2016	Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	121-125
27352049-8	2016	Among the 3D cultures on the three matrices, increased expression of beta-III tubulin in DU145 cells was correlated with increased resistance to Docetaxel, and decreased expression of EGFR in DU145 cells was correlated with increased sensitivity to Rapamycin.	Sirolimus	249-258	epidermal growth factor receptor	Homo sapiens	184-188
26526985-3	2016	It is associated with the mutation of two genes: TSC1 (hamartin) and TSC2 (tuberin), with the change in the functionality of the complex target of rapamycin (mTOR).	Sirolimus	147-156	TSC complex subunit 1	Homo sapiens	49-53
26526985-3	2016	It is associated with the mutation of two genes: TSC1 (hamartin) and TSC2 (tuberin), with the change in the functionality of the complex target of rapamycin (mTOR).	Sirolimus	147-156	TSC complex subunit 1	Homo sapiens	55-63
26526985-3	2016	It is associated with the mutation of two genes: TSC1 (hamartin) and TSC2 (tuberin), with the change in the functionality of the complex target of rapamycin (mTOR).	Sirolimus	147-156	mechanistic target of rapamycin kinase	Homo sapiens	158-162
27569951-5	2016	CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups.	Sirolimus	165-174	CD4 molecule	Homo sapiens	0-3
27569951-5	2016	CD4(+) T-cell iATP level in the FK506 group and FK506 + prednisone (Pred) groups was higher than in the FK506 + mycophenolate mofetil (MMF), FK506 + MMF + Pred, and rapamycin (Rapa) groups.	Sirolimus	176-180	CD4 molecule	Homo sapiens	0-3
28123821-8	2016	Also, we showed that blocking spinal mTOR by intrathecal injection of rapamycin significantly inhibited pain responses induced by mechanical and thermal stimulation.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	37-41
27045863-0	2016	Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	86-90
30634218-1	2016	OBJECTIVE: To explore the mechanism of electropuncture (EA) for reducing diet-induced obesity (DIO) rat weight through tuberous sclerosis complex 1 (TSC1 )-mammalian target of rapa- mycin (mTOR) signal pathway in hypothalamus.	Sirolimus	176-187	TSC complex subunit 1	Rattus norvegicus	119-147
30634218-1	2016	OBJECTIVE: To explore the mechanism of electropuncture (EA) for reducing diet-induced obesity (DIO) rat weight through tuberous sclerosis complex 1 (TSC1 )-mammalian target of rapa- mycin (mTOR) signal pathway in hypothalamus.	Sirolimus	176-187	TSC complex subunit 1	Rattus norvegicus	149-153
30634218-1	2016	OBJECTIVE: To explore the mechanism of electropuncture (EA) for reducing diet-induced obesity (DIO) rat weight through tuberous sclerosis complex 1 (TSC1 )-mammalian target of rapa- mycin (mTOR) signal pathway in hypothalamus.	Sirolimus	176-187	mechanistic target of rapamycin kinase	Homo sapiens	189-193
27045863-9	2016	Moreover, activation of mTOR signaling induced by Huaier contributes to the increased sensitivity of cells to rapamycin or cisplatin in response to Huaier treatment.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	24-28
26840085-8	2016	A higher cytotoxic effect was observed with AZD8055 compared to rapamycin in the NF1-null MPNST-derived cell lines with IC50 ranging from 70 to 140 nM and antiproliferative effect was confirmed in PNF-derived Schwann cells.	Sirolimus	64-73	neurofibromin 1	Homo sapiens	81-84
27338360-1	2016	The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui).	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	38-67
27338360-1	2016	The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui).	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	69-73
27338360-1	2016	The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui).	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	69-73
27167192-6	2016	Treatment with mTOR pathway inhibitor rapamycin further verified its contribution to HCC progression in AIM2 absent HCC cells.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	15-19
27167192-6	2016	Treatment with mTOR pathway inhibitor rapamycin further verified its contribution to HCC progression in AIM2 absent HCC cells.	Sirolimus	38-47	absent in melanoma 2	Homo sapiens	104-108
27256228-1	2016	OBJECTIVE: To assess the efficacy and safety of mammalian target of rapamycin (mTOR) inhibitor rapamycin in treatment of children with cardiac rhabdomyoma, associated with tuberous sclerosis complex (TSC).	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	79-83
27296621-10	2016	The efficacy of PKC inhibitor (GF 109203X) or mTOR complex 1 inhibitor (rapamycin) for attenuating mechanical hyperalgesia and mechanical allodynia by intraplantar injection was dose-dependent.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	46-50
27030639-0	2016	Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	68-72
27103123-1	2016	PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	28-32
27478785-0	2016	Interactions Between Sirolimus and Anti-Inflammatory Drugs: Competitive Binding for Human Serum Albumin.	Sirolimus	21-30	albumin	Homo sapiens	90-103
27478785-2	2016	The binding site of Sirolimus on human serum albumin (HSA) was also determined.	Sirolimus	20-29	albumin	Homo sapiens	39-52
27150260-1	2016	Rapamycin, a potent antifungal antibiotic, was approved as immunosuppressant, and lately its derivatives have been developed into mTOR targeting anticancer drugs.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	130-134
26975583-10	2016	In support of p27 lying downstream of AMPK on the activation of autophagy in Tsc2-null cells, a p27 mutant that preferentially localizes in the cytosol recovered the effect of rapamycin on autophagy in both p27- and LKB1-depleted cells, but a nuclear p27 mutant was inactive.	Sirolimus	176-185	zinc ribbon domain containing 2	Homo sapiens	96-99
26975583-10	2016	In support of p27 lying downstream of AMPK on the activation of autophagy in Tsc2-null cells, a p27 mutant that preferentially localizes in the cytosol recovered the effect of rapamycin on autophagy in both p27- and LKB1-depleted cells, but a nuclear p27 mutant was inactive.	Sirolimus	176-185	zinc ribbon domain containing 2	Homo sapiens	96-99
26975583-10	2016	In support of p27 lying downstream of AMPK on the activation of autophagy in Tsc2-null cells, a p27 mutant that preferentially localizes in the cytosol recovered the effect of rapamycin on autophagy in both p27- and LKB1-depleted cells, but a nuclear p27 mutant was inactive.	Sirolimus	176-185	zinc ribbon domain containing 2	Homo sapiens	96-99
26975583-11	2016	Finally, we show that p27-dependent activation of autophagy is involved in Tsc2-null cell survival under rapamycin treatment.	Sirolimus	105-114	zinc ribbon domain containing 2	Homo sapiens	22-25
26975583-12	2016	These results indicate that an AMPK/p27 axis is promoting a survival mechanism that could explain in part the relapse of TSC tumors treated with rapamycin, exposing new avenues for designing more efficient treatments for TSC patients.	Sirolimus	145-154	zinc ribbon domain containing 2	Homo sapiens	36-39
26975583-12	2016	These results indicate that an AMPK/p27 axis is promoting a survival mechanism that could explain in part the relapse of TSC tumors treated with rapamycin, exposing new avenues for designing more efficient treatments for TSC patients.	Sirolimus	145-154	TSC complex subunit 1	Homo sapiens	121-124
26975583-12	2016	These results indicate that an AMPK/p27 axis is promoting a survival mechanism that could explain in part the relapse of TSC tumors treated with rapamycin, exposing new avenues for designing more efficient treatments for TSC patients.	Sirolimus	145-154	TSC complex subunit 1	Homo sapiens	221-224
27253629-4	2016	The proportion of cells in G0/G1 phase was significantly higher among cells treated with 1 muM rapamycin for 3 days (D3-1R) than among control and serum-starved cells (p &lt; 0.05).	Sirolimus	95-104	latexin	Homo sapiens	91-94
27103123-1	2016	PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation.	Sirolimus	9-18	vascular endothelial growth factor A	Homo sapiens	259-263
27103123-17	2016	4 mg weekly sirolimus did not reduce the sunitinib-induced circulating VEGF production but stimulated more VEGF production through some unknown compensatory mechanism.	Sirolimus	12-21	vascular endothelial growth factor A	Homo sapiens	107-111
27245610-2	2016	In this issue of Science Signaling, So et al found that the isoform of 4E-BP (4E-BP2) in lymphocytes that regulates messenger RNA translation is more sensitive to the effects of rapamycin than is the 4E-BP isoform found in nonlymphoid cells.	Sirolimus	178-187	eukaryotic translation initiation factor 4E binding protein 2	Homo sapiens	71-76
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 2	Homo sapiens	127-131
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 4	Homo sapiens	133-137
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 6	Homo sapiens	145-149
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 13	Homo sapiens	165-170
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interferon gamma	Homo sapiens	179-188
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	tumor necrosis factor	Homo sapiens	193-202
27350635-11	2016	CONCLUSION: Based on the findings of this study, rapamycin has some immunosuppressive effects, such as decreasing IFN -gamma, which can improve the quality of life of the patients with multiple sclerosis.	Sirolimus	49-58	interferon gamma	Homo sapiens	114-124
26505782-8	2016	IGF-1 dose-dependently enhanced AKT and p70S6K phosphorylation at 2 and 6 h. PFF enhanced phosphorylation of AKT and p70S6K already within 1 h. Both IGF-1 and PFF enhanced total protein per cell by ~30%, but not in the presence of rapamycin.	Sirolimus	231-240	insulin like growth factor 1	Homo sapiens	0-5
26505782-8	2016	IGF-1 dose-dependently enhanced AKT and p70S6K phosphorylation at 2 and 6 h. PFF enhanced phosphorylation of AKT and p70S6K already within 1 h. Both IGF-1 and PFF enhanced total protein per cell by ~30%, but not in the presence of rapamycin.	Sirolimus	231-240	AKT serine/threonine kinase 1	Homo sapiens	109-112
26505782-8	2016	IGF-1 dose-dependently enhanced AKT and p70S6K phosphorylation at 2 and 6 h. PFF enhanced phosphorylation of AKT and p70S6K already within 1 h. Both IGF-1 and PFF enhanced total protein per cell by ~30%, but not in the presence of rapamycin.	Sirolimus	231-240	insulin like growth factor 1	Homo sapiens	149-154
27245610-2	2016	In this issue of Science Signaling, So et al found that the isoform of 4E-BP (4E-BP2) in lymphocytes that regulates messenger RNA translation is more sensitive to the effects of rapamycin than is the 4E-BP isoform found in nonlymphoid cells.	Sirolimus	178-187	eukaryotic translation initiation factor 4E binding protein 2	Homo sapiens	78-84
27245610-2	2016	In this issue of Science Signaling, So et al found that the isoform of 4E-BP (4E-BP2) in lymphocytes that regulates messenger RNA translation is more sensitive to the effects of rapamycin than is the 4E-BP isoform found in nonlymphoid cells.	Sirolimus	178-187	eukaryotic translation initiation factor 4E binding protein 2	Homo sapiens	78-83
27245614-5	2016	Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 2	Homo sapiens	120-126
27245614-5	2016	Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 2	Homo sapiens	200-206
27109477-5	2016	Overexpression of FXR prevented the growth of cells and induced cell cycle arrest, which was enhanced by the mTOR/S6K inhibitor rapamycin.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	109-113
26799240-10	2016	Among the mammalian target of rapamycin (mTOR) inhibitors, sirolimus was approved in 2002, and its use increased to 8.7% in 2009.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	10-39
26799240-10	2016	Among the mammalian target of rapamycin (mTOR) inhibitors, sirolimus was approved in 2002, and its use increased to 8.7% in 2009.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	41-45
27105919-10	2016	Treatment with rapamycin, an inhibitor of mTOR signaling, together with Slc7a7 knockdown synergistically perturbed spaw expression, indicating an interaction between Slc7a7 and mTOR signaling affecting gene expression required for LR specification.	Sirolimus	15-24	spaw	Oryzias latipes	115-119
27216612-3	2016	Recent studies have suggested that mTOR inhibitors such as rapamycin can reverse TSC-associated deficits in rodent models of TSC.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	35-39
27216612-3	2016	Recent studies have suggested that mTOR inhibitors such as rapamycin can reverse TSC-associated deficits in rodent models of TSC.	Sirolimus	59-68	TSC complex subunit 1	Homo sapiens	81-84
27216612-3	2016	Recent studies have suggested that mTOR inhibitors such as rapamycin can reverse TSC-associated deficits in rodent models of TSC.	Sirolimus	59-68	TSC complex subunit 1	Homo sapiens	125-128
27217700-13	2016	Rapamycin treatment significantly increased contractile force and myocardial localization of phosphorylated-mTOR and decreased cardiac TNF-alpha concentration compared to cirrhotic rats with no treatment.	Sirolimus	0-9	tumor necrosis factor	Rattus norvegicus	135-144
27196739-11	2016	The combination of ICG-001 and mTOR inhibitor, rapamycin, yielded an additive effect on the inhibition of viability in TamR cells.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	31-35
27050906-5	2016	We show that Npm1 gene expression is dependent on mTOR as demonstrated by treatment of wild-type and Pten inactivated MEFs cultured with rapamycin or by transient transfections of small interfering RNA directed against mTOR.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Homo sapiens	50-54
27050906-8	2016	Using a prostate-specific Pten-deleted mouse model of cancer, Npm1 mRNA levels were found up-regulated and sensitive to rapamycin.	Sirolimus	120-129	phosphatase and tensin homolog	Mus musculus	26-30
27037216-3	2016	This study was performed to investigate how pre-inhibition of the mTOR pathway with rapamycin would affect BBB disruption and the size of the infarcted cortical area in the early stage of focal cerebral ischemia-reperfusion using quantitative analysis of BBB disruption.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	66-70
27078846-2	2016	Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) is the primary alteration underlying TSC tumors.	Sirolimus	39-48	TSC complex subunit 1	Rattus norvegicus	105-108
27078846-9	2016	We conclude that downregulation of COX2 exerts a protective effect against hyperactivated mTORC1-mediated tumorigenesis caused by the loss of TSC2, and the combination of rapamycin and celecoxib may be an effective new approach to treating TSC.	Sirolimus	171-180	TSC complex subunit 1	Rattus norvegicus	142-145
27037216-10	2016	Our data suggest that activation of mTOR pathway is necessary for neuronal survival in the early stage of cerebral ischemia-perfusion and that the reason for the enlarged cortical infarct by rapamycin pretreatment may be related to its non-BBB effects on the mTOR pathway.	Sirolimus	191-200	mechanistic target of rapamycin kinase	Homo sapiens	36-40
27037216-10	2016	Our data suggest that activation of mTOR pathway is necessary for neuronal survival in the early stage of cerebral ischemia-perfusion and that the reason for the enlarged cortical infarct by rapamycin pretreatment may be related to its non-BBB effects on the mTOR pathway.	Sirolimus	191-200	mechanistic target of rapamycin kinase	Homo sapiens	259-263
27009856-7	2016	Immunoprecipitation assay further revealed that KPNA2 physically associated with the phospho-mTOR/mTOR and this association was abolished by rapamycin treatment.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	93-97
27132889-5	2016	Mechanistically, small interfering RNA knockdown of RAPTOR, a component of mTOR complex 1, phenocopied the mesendoderm-enhancing effects of rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	75-79
27009856-7	2016	Immunoprecipitation assay further revealed that KPNA2 physically associated with the phospho-mTOR/mTOR and this association was abolished by rapamycin treatment.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	98-102
26607948-6	2016	Sirolimus was the most frequent mTOR inhibitor used (98.8%, n = 83).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	32-36
27048648-0	2016	Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	185-189
27137757-5	2016	Molecular targeting of Akt by Akt inhibitor MK2206 or knockdown of Akt1 led to a rapamycin-induced radiosensitization of non-responder cells.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	23-26
27137757-5	2016	Molecular targeting of Akt by Akt inhibitor MK2206 or knockdown of Akt1 led to a rapamycin-induced radiosensitization of non-responder cells.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	30-33
27137757-5	2016	Molecular targeting of Akt by Akt inhibitor MK2206 or knockdown of Akt1 led to a rapamycin-induced radiosensitization of non-responder cells.	Sirolimus	81-90	AKT serine/threonine kinase 1	Homo sapiens	67-71
27137757-7	2016	Together, lack of radiosensitization induced by rapamycin was associated with rapamycin-mediated Akt1 activation.	Sirolimus	78-87	AKT serine/threonine kinase 1	Homo sapiens	97-101
26348114-7	2016	RESULTS: In vitro western blot analysis showed that there were lower levels of expression of phosphorylated mammalian target of rapamycin, p70S6K and p4EBP1, transforming growth factor-beta and pSmad3 expression in the cells treated with sirolimus, MMF and sirolimus plus MMF.	Sirolimus	238-247	mechanistic target of rapamycin kinase	Homo sapiens	108-137
26348114-7	2016	RESULTS: In vitro western blot analysis showed that there were lower levels of expression of phosphorylated mammalian target of rapamycin, p70S6K and p4EBP1, transforming growth factor-beta and pSmad3 expression in the cells treated with sirolimus, MMF and sirolimus plus MMF.	Sirolimus	257-266	mechanistic target of rapamycin kinase	Homo sapiens	108-137
26946108-0	2016	Intrathecal administration of rapamycin inhibits the phosphorylation of DRG Nav1.8 and attenuates STZ-induced painful diabetic neuropathy in rats.	Sirolimus	30-39	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	76-82
27032457-11	2016	Under conditions of this study, RPM plus RPL improved milk yield and protein contents of dairy cows and was better than supplying RPM alone.	Sirolimus	32-35	Weaning weight-maternal milk	Bos taurus	54-58
30044067-8	2016	Conclusions: Rapamycin could inhibit the proliferation of keloid fibroblasts, and could not affect the apoptosis of cells.However, rapamycin induced the autophagy of keloid fibroblasts through regulating the expression of autophagy-related non-coding RNAs and genes in the mTOR signaling pathway.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Homo sapiens	273-277
27029073-4	2016	To overcome this problem, CH12 was combined with the mTOR inhibitor rapamycin, leading to a synergistic inhibitory effect on EGFRvIII+PTEN- GBM in vivo.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	53-57
27029073-5	2016	Mechanistically, the synergistic antitumor effect was achieved via attenuating EGFR and PI3K/AKT/mTOR pathway more effectively and reversing the STAT5 activation caused by rapamycin treatment.	Sirolimus	172-181	epidermal growth factor receptor	Homo sapiens	79-83
27029073-5	2016	Mechanistically, the synergistic antitumor effect was achieved via attenuating EGFR and PI3K/AKT/mTOR pathway more effectively and reversing the STAT5 activation caused by rapamycin treatment.	Sirolimus	172-181	AKT serine/threonine kinase 1	Homo sapiens	93-96
27029073-5	2016	Mechanistically, the synergistic antitumor effect was achieved via attenuating EGFR and PI3K/AKT/mTOR pathway more effectively and reversing the STAT5 activation caused by rapamycin treatment.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Homo sapiens	97-101
26946108-8	2016	Furthermore, the intrathecal administration of rapamycin, inhibiting the activity of mTOR, suppressed the phosphorylation of DRG Nav1.8, reduced the TTX-R current density, heightened the voltage threshold for activation and lowered the voltage threshold for inactivation and relieved mechanical hypersensitivity in diabetic rats.	Sirolimus	47-56	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	129-135
26946108-10	2016	of rapamycin inhibited the phosphorylation and enhanced the functional availability of DRG Nav1.8 attenuated STZ-induced hyperalgesia.	Sirolimus	3-12	sodium voltage-gated channel alpha subunit 10	Rattus norvegicus	91-97
27098694-8	2016	These effects were corrected by rapamycin treatmentin vivo Importantly, Akt activity in the transgenic mice did not induce myelination of nonmyelinating Schwann cells in the sympathetic trunk or Remak fibers of the dorsal roots, although, in those structures, they wrapped membranes redundantly around axons.	Sirolimus	32-41	thymoma viral proto-oncogene 1	Mus musculus	72-75
27090655-9	2016	Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26566757-5	2016	Additionally, rapamycin enhanced attenuations of protein kinase Ce (PKCe)/protein kinase A (PKA) induced by morphine and further extended analgesia of morphine via micro-opioid receptor (MOR).	Sirolimus	14-23	protein kinase C, epsilon	Rattus norvegicus	49-66
26566757-5	2016	Additionally, rapamycin enhanced attenuations of protein kinase Ce (PKCe)/protein kinase A (PKA) induced by morphine and further extended analgesia of morphine via micro-opioid receptor (MOR).	Sirolimus	14-23	protein kinase C, epsilon	Rattus norvegicus	68-72
26846849-9	2016	Following acute Tsc1 deletion from hepatocytes, Akt phosphorylation, but not IRS1/PI3K association, was rapidly restored by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	160-169	thymoma viral proto-oncogene 1	Mus musculus	48-51
27070592-5	2016	In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	28-32
27070592-5	2016	In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells.	Sirolimus	45-54	tumor protein p53	Homo sapiens	122-125
27070592-5	2016	In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells.	Sirolimus	45-54	caspase 3	Homo sapiens	130-139
26879868-5	2016	We also found that a dominant negative mutant of Ras (Ras DN), a PI3K inhibitor (LY 294002), an Akt DN, and an mTOR inhibitor (rapamycin) attenuated ghrelin-caused colon cancer cell proliferation.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	111-115
26924291-15	2016	CONCLUSION: Sirolimus increases the sensitivity of human OS cells to anticancer drugs in vitro by up-regulating miR-34b interacting with PAK1 and ABCB1.	Sirolimus	12-21	ATP binding cassette subfamily B member 1	Homo sapiens	146-151
26851524-7	2016	The identification of the mutation provides a novel therapeutic modality for the affected patients: those who carry somatic mutations in the PIK3CA gene are potential recipients of a novel "repurposing" approach of rapamycin treatment.	Sirolimus	215-224	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	141-147
26729448-2	2016	The mTOR inhibitor sirolimus has been used in the prevention and treatment of graft-versus-host disease (GVHD) after allogeneic haematopoietic stem cell transplantation (HSCT).	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26927950-4	2016	However, pharmacological therapy with mTOR inhibitors such as everolimus and sirolimus is now emerging as an alternate approach.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	38-42
26886375-3	2016	We report an 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and an intractable pleural effusion that responded dramatically to the combination of the mammalian target of rapamycin (mTOR) inhibitor sirolimus and the aminobisphosphonate zoledronic acid after failing interferon therapy.	Sirolimus	225-234	mechanistic target of rapamycin kinase	Homo sapiens	178-207
26886375-3	2016	We report an 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and an intractable pleural effusion that responded dramatically to the combination of the mammalian target of rapamycin (mTOR) inhibitor sirolimus and the aminobisphosphonate zoledronic acid after failing interferon therapy.	Sirolimus	225-234	mechanistic target of rapamycin kinase	Homo sapiens	209-213
26749462-7	2016	6-Gingerol, wortmannin, and rapamycin treatment showed almost two-fold higher expression of caspase 3 in all cell lines.	Sirolimus	28-37	caspase 3	Homo sapiens	92-101
27020819-8	2016	The expression of P-p70S6K1 declined after rapamycin treatment, showing that the signaling pathway of mTOR is inhibited by rapamycin.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	102-106
27020819-8	2016	The expression of P-p70S6K1 declined after rapamycin treatment, showing that the signaling pathway of mTOR is inhibited by rapamycin.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Homo sapiens	102-106
26916825-0	2016	Expression of zTOR-associated microRNAs in zebrafish embryo treated with rapamycin.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Danio rerio	14-18
26916825-8	2016	KEY FINDINGS: Rapamycin (400 nM) suppressed zTOR pathway by down-regulating the phosphorylation of zTOR-associated proteins such as P70S6K and S6K at both 4h post-fertilisation (hpf) and 8hpf while 4E-BP1 was only down-regulated at 8hpf when compared to their respective vehicle controls.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Danio rerio	44-48
26916825-8	2016	KEY FINDINGS: Rapamycin (400 nM) suppressed zTOR pathway by down-regulating the phosphorylation of zTOR-associated proteins such as P70S6K and S6K at both 4h post-fertilisation (hpf) and 8hpf while 4E-BP1 was only down-regulated at 8hpf when compared to their respective vehicle controls.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Danio rerio	99-103
26626406-4	2016	Based on the evidence of mammalian target of rapamycin mTORC, mTOR Complex; RAS, Rat sarcoma; RAF, rapidly accelerated fibrosarcoma (mTOR) pathway activation in the tumor, targeted therapy was applied resulting in complete remission of disease.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	55-59
27000748-8	2016	However, the presenescent SMSCs can be rejuvenated by agents that stimulate autophagy, such as the mTOR inhibitor rapamycin.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	99-103
26977999-9	2016	Regarding monitoring of mTOR inhibitors (mTORis), the results of the first study that provided data on measurement of mTOR pathway molecules [p70 ribosomal protein S6 kinase (p70S6 kinase) and phosphorylated ribosomal protein S6] suggest that they are suitable targets for individualized PD monitoring of sirolimus and everolimus after organ transplantation.	Sirolimus	305-314	mechanistic target of rapamycin kinase	Homo sapiens	41-45
27095138-5	2016	BM cells showed increased phosphorylation of Akt and mTorc1, and extramedullary hematopoiesis was significantly reduced by treating mice with rapamycin in vivo, suggesting that the mTorc1 pathway was activated by loss of Flcn expression in hematopoietic cells in vivo.	Sirolimus	142-151	thymoma viral proto-oncogene 1	Mus musculus	45-48
27011924-5	2016	But recently therapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus has shown promising results in the stabilization of lung function and reduction of chylous effusions in LAM.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	26-55
27011924-5	2016	But recently therapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus has shown promising results in the stabilization of lung function and reduction of chylous effusions in LAM.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	57-61
27047390-0	2016	Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.	Sirolimus	0-9	Eph receptor B1	Rattus norvegicus	74-77
27008180-3	2016	mTOR inhibition by rapamycin significantly preserves neuronal ATP levels, particularly when oxidative phosphorylation is impaired, such as in neurons treated with mitochondrial inhibitors, or in neurons derived from maternally inherited Leigh syndrome (MILS) patient iPS cells with ATP synthase deficiency.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
27047390-4	2016	Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and p62.	Sirolimus	55-64	Eph receptor B1	Rattus norvegicus	18-21
27047390-6	2016	In vivo experiments showed that rapamycin decreased AB-induced cardiac hypertrophy in a MEK/ERK dependent manner.	Sirolimus	32-41	Eph receptor B1	Rattus norvegicus	92-95
26748241-2	2016	Temsirolimus (TEM) and its primary active metabolite rapamycin allosterically block mTOR complex 1 substrate recruitment.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	84-88
26873994-5	2016	Despite the fact that both these cytokine combinations robustly upregulated mammalian Target of Rapamycin Complex 1 in human NK cells, only the IL-2-induced metabolic changes were sensitive to mammalian Target of Rapamycin Complex 1 inhibition by rapamycin.	Sirolimus	247-256	interleukin 2	Homo sapiens	144-148
27014314-2	2016	Rapamycin inhibits TOR kinase activity viaFK506 binding protein 12 kDa (FKBP12) in all examined heterotrophic eukaryotic organisms.	Sirolimus	0-9	target of rapamycin	Arabidopsis thaliana	19-22
26936590-11	2016	The use of tacrolimus was associated with increased concentrations of MCP-1 in plasma and rapamycin was associated with decreased concentrations of MCP-1 in plasma.	Sirolimus	90-99	mast cell protease 1-like 1	Rattus norvegicus	148-153
26962683-8	2016	Blocking IL10R, p-AKT, p-mTOR, and p-STAT3 using specific inhibitors (IL10RB, LY294002, rapamycin, and cryptotanshinone, respectively) showed that IL10 inhibited autophagy via IL10Ralpha-mediated activation of STAT3 (the IL10R-STAT3 pathway) and by directly activating the AKT-mTOR pathway.	Sirolimus	88-97	signal transducer and activator of transcription 3	Homo sapiens	37-42
26882569-6	2016	Combination of rapamycin with trametinib, a MEK1/2 inhibitor, demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including HNSCC cells expressing the HRAS and PIK3CA oncogenes.	Sirolimus	15-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	183-189
26740621-5	2016	In contrast, rapamycin preferentially inhibits the phosphorylation of p70(S6k) and blocks 35% of translation.	Sirolimus	13-22	ubiquitin associated and SH3 domain containing B	Homo sapiens	70-73
26801880-0	2016	Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.	Sirolimus	66-75	thymoma viral proto-oncogene 1	Mus musculus	14-17
26931735-2	2016	mTOR signalling is upregulated in PKD and rapamycin slows cyst expansion, whereas renal inactivation of the Tsc genes causes cysts.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26639422-4	2016	Sirolimus impaired BKPyV replication with a 90% inhibitory concentration of 4 ng/mL by interfering with mTOR-SP6-kinase activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	104-108
26801880-9	2016	We validated that rapamycin causes increased Akt (S473) phosphorylation in the epidermis after SSL, and show for the first time that this dysregulation can be inhibited in vivo by a selective PDK1/Akt inhibitor, PHT-427.	Sirolimus	18-27	thymoma viral proto-oncogene 1	Mus musculus	45-48
26801880-9	2016	We validated that rapamycin causes increased Akt (S473) phosphorylation in the epidermis after SSL, and show for the first time that this dysregulation can be inhibited in vivo by a selective PDK1/Akt inhibitor, PHT-427.	Sirolimus	18-27	thymoma viral proto-oncogene 1	Mus musculus	197-200
26801880-9	2016	We validated that rapamycin causes increased Akt (S473) phosphorylation in the epidermis after SSL, and show for the first time that this dysregulation can be inhibited in vivo by a selective PDK1/Akt inhibitor, PHT-427.	Sirolimus	18-27	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	192-196
26733005-6	2016	RESULTS: Chronic rapamycin treatment induced insulin resistance and impaired glucose metabolism in hepatic and muscle cells.	Sirolimus	17-26	insulin	Homo sapiens	45-52
26698679-6	2016	Primary hSCs cultures were established from each biopsy and divided into a control group and one treated with rapamycin, the inhibitor of mTOR, for 24 hours.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	138-142
26733005-8	2016	Whereas rapamycin treatment inhibited Akt phosphorylation, PF-4708671 increased Akt phosphorylation in both cell lines.	Sirolimus	8-17	thymoma viral proto-oncogene 1	Mus musculus	38-41
26910393-3	2016	Here we show that the transcription of miR-495 negatively correlates with the translation of ATG3 under nutrient-deprived or rapamycin-treated conditions.	Sirolimus	125-134	microRNA 495	Homo sapiens	39-46
27007909-5	2016	Additionally, in duck myoblasts treated with LY294002 and rapamycin, the specific inhibitors ofPI3K and mTOR, respectively, the overexpression of Six1 could significantly ameliorate inhibitive effects of these inhibitors on protein synthesis.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	104-108
26861999-5	2016	We applied the blockers of Kv1.3 (Anuroctoxin), KCa3.1 (TRAM-34) and CRAC (2-Apb) channels of T cells either alone or in combination with rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR).	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	170-199
26901106-6	2016	The mTORC1 inhibitor rapamycin diminishes FBP enrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids.	Sirolimus	21-30	AKT serine/threonine kinase 1	Homo sapiens	109-112
26861999-5	2016	We applied the blockers of Kv1.3 (Anuroctoxin), KCa3.1 (TRAM-34) and CRAC (2-Apb) channels of T cells either alone or in combination with rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR).	Sirolimus	138-147	mechanistic target of rapamycin kinase	Homo sapiens	201-205
26719046-7	2016	Furthermore, insulin induced activation of these kinases was abrogated by pretreatment with PP242 as compared with rapamycin.	Sirolimus	115-124	insulin	Homo sapiens	13-20
26335579-10	2016	Surprisingly, rapamycin (an mTOR inhibitor), cAMP, and its natural inducer isoproterenol, elicit identical dephosphorylation kinetics on both S6K1 ribosomal kinase (a downstream mTOR target) and H3.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	28-32
26800397-6	2016	Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin.	Sirolimus	58-67	AKT serine/threonine kinase 1	Homo sapiens	27-30
26800397-6	2016	Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Homo sapiens	48-52
26335579-10	2016	Surprisingly, rapamycin (an mTOR inhibitor), cAMP, and its natural inducer isoproterenol, elicit identical dephosphorylation kinetics on both S6K1 ribosomal kinase (a downstream mTOR target) and H3.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	178-182
26916116-5	2016	First, different doses of rapamycin are needed to suppress mTOR in different cell lines; second, different doses of rapamycin are needed to suppress the phosphorylation of different mTOR substrates; and third, there is a differential sensitivity of the two mTOR complexes mTORC1 and mTORC2 to rapamycin.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	59-63
26916116-6	2016	Intriguingly, the enigmatic properties of rapamycin dosage can be explained in large part by the competition between rapamycin and phosphatidic acid (PA) for mTOR.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	158-162
26698023-9	2016	Rapamycin (which primarily inhibits mTORC1), ATP-competitive, dual mTORC1/mTORC2 inhibitors and upstream regulators of the mTOR pathway are being developed to treat autoimmune, hyperproliferative and degenerative diseases.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	36-40
26854565-6	2016	Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2(-/-) mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein.	Sirolimus	100-109	insulin-like growth factor binding protein 5	Mus musculus	187-193
26756219-9	2016	Moreover, the co-treatment prevented the Sirolimus-induced AKT activation as escape mechanism.	Sirolimus	41-50	AKT serine/threonine kinase 1	Homo sapiens	59-62
27239444-0	2016	mTOR inhibition by rapamycin increases ceramide synthesis by promoting transforming growth factor-beta1/Smad signaling in the skin.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
27239444-0	2016	mTOR inhibition by rapamycin increases ceramide synthesis by promoting transforming growth factor-beta1/Smad signaling in the skin.	Sirolimus	19-28	transforming growth factor beta 1	Homo sapiens	71-103
26937175-7	2016	Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis.	Sirolimus	249-258	tumor protein p53	Homo sapiens	13-16
26888095-0	2016	Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice.	Sirolimus	0-9	toll-like receptor 4	Mus musculus	50-53
26888095-9	2016	Rapamycin attenuated lung injury by inhibiting the differentiation of Th17 cells through RORgammat and STAT3 dysfunction.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	103-108
26886923-0	2016	Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate.	Sirolimus	130-139	CD4 molecule	Homo sapiens	50-53
26879559-6	2016	Inhibition of mTOR signaling with rapamycin, an mTOR signaling inhibitor, disturbed PGRN- or IL-6-mediated proliferation, migration and invasion of HCC cells in vitro.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26879559-6	2016	Inhibition of mTOR signaling with rapamycin, an mTOR signaling inhibitor, disturbed PGRN- or IL-6-mediated proliferation, migration and invasion of HCC cells in vitro.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	48-52
26879559-6	2016	Inhibition of mTOR signaling with rapamycin, an mTOR signaling inhibitor, disturbed PGRN- or IL-6-mediated proliferation, migration and invasion of HCC cells in vitro.	Sirolimus	34-43	granulin precursor	Homo sapiens	84-88
26879559-6	2016	Inhibition of mTOR signaling with rapamycin, an mTOR signaling inhibitor, disturbed PGRN- or IL-6-mediated proliferation, migration and invasion of HCC cells in vitro.	Sirolimus	34-43	interleukin 6	Homo sapiens	93-97
26937175-7	2016	Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis.	Sirolimus	249-258	tumor protein p53	Homo sapiens	200-203
26937175-7	2016	Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis.	Sirolimus	249-258	hypoxia inducible factor 1 subunit alpha	Homo sapiens	208-217
26937175-7	2016	Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis.	Sirolimus	249-258	tumor protein p53	Homo sapiens	200-203
26937175-7	2016	Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis.	Sirolimus	249-258	hypoxia inducible factor 1 subunit alpha	Homo sapiens	208-217
26314990-4	2016	Computational modeling confirmed that diffusion and binding constants of Corolimus and Sirolimus are identical and explained that the sustained retention of Corolimus was facilitated by binding to high affinity intracellular receptors (FKBP12).	Sirolimus	87-96	FKBP prolyl isomerase 1A pseudogene 3	Homo sapiens	236-242
26496029-8	2016	Remarkably, the latter feature coincided with a gain of sensitivity to the mTOR inhibitor rapamycin.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	75-79
26325438-6	2016	For sirolimus, rs2032582 (ABCB1) T-carriers versus non-T-carriers were associated with higher blood levels (P = .01), with similar results for C/D ratio.	Sirolimus	4-13	ATP binding cassette subfamily B member 1	Homo sapiens	26-31
26776341-6	2016	Rapamycin and PP242 inhibit phosphorylation of Akt, ribosomal S6 kinase, 4EBP1 and mTOR.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	47-50
26776341-6	2016	Rapamycin and PP242 inhibit phosphorylation of Akt, ribosomal S6 kinase, 4EBP1 and mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	83-87
26707081-2	2016	Mammalian target of rapamycin (mTOR) activation is one of the most frequent events in human malignancies, and is critical for sustaining the self-renewing ability of cancer stem cells (CSCs); inhibition by rapamycin is an effective and promising strategy in anticancer treatments.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26707081-3	2016	In the present study, we found that mTOR activity was closely related to the self-renewal ability of BrCSCs, and in triple negative MDA-MB-453 and MDA-MB-468 cells, rapamycin repression of mTOR phosphorylation decreased the number of mammospheres and helped to sensitize the resistant CSCs to low-dose radiation therapy.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	36-40
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	128-132
26707081-3	2016	In the present study, we found that mTOR activity was closely related to the self-renewal ability of BrCSCs, and in triple negative MDA-MB-453 and MDA-MB-468 cells, rapamycin repression of mTOR phosphorylation decreased the number of mammospheres and helped to sensitize the resistant CSCs to low-dose radiation therapy.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Homo sapiens	189-193
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	AKT serine/threonine kinase 1	Homo sapiens	209-212
26713679-8	2016	Whilst the mTOR inhibitor rapamycin has shown some benefit in patients with LAM, with stabilisation of lung function and improved quality of life, cessation of treatment results in recurrence of the disease progression.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	11-15
26481278-13	2016	Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-beta1(+)) cells when compared with dimethyl sulfoxide controls.	Sirolimus	0-9	interleukin 10	Mus musculus	82-87
26481278-14	2016	Rapamycin treatment inhibited interleukin-1beta, 6, 13, and 17 on days 7 and 14.	Sirolimus	0-9	interleukin 1 beta	Mus musculus	30-47
26659860-3	2016	In syncytiotrophoblasts, starvation, rapamycin, or punicalagin all decreased the expression of phosphorylated ribosomal protein S6, a downstream target of the mTOR kinase, and of the autophagy markers, LC3-II and p62.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	159-163
26833095-2	2016	Immunosuppressive drug rapamycin (RPM), targeting on the key cellular metabolism molecule mTOR, is currently used in clinics to treat patients with allo-grafts, autoimmune diseases and tumors.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	90-94
26833095-2	2016	Immunosuppressive drug rapamycin (RPM), targeting on the key cellular metabolism molecule mTOR, is currently used in clinics to treat patients with allo-grafts, autoimmune diseases and tumors.	Sirolimus	34-37	mechanistic target of rapamycin kinase	Homo sapiens	90-94
26833095-4	2016	RPM significantly decreases the cell number and the immunosuppressive ability on T cells of CD11b(+) Ly6C(high) monocytic MDSCs (M-MDSCs) in both allo-grafts-transplanted and tumor-bearing mice respectively.	Sirolimus	0-3	integrin alpha M	Mus musculus	92-97
26913393-1	2016	OBJECTIVE: To investigate the effect of rapamycin on the expression of survivin and caspase-3 at mRNA level in K562 cells and the influence of rapamycin on K562 cell ultrastructure.	Sirolimus	40-49	caspase 3	Homo sapiens	84-93
26913393-5	2016	The expression of caspase-3 at mRNA level increased with increase of rapamycin concentration.	Sirolimus	69-78	caspase 3	Homo sapiens	18-27
26426522-7	2016	MEASUREMENTS AND MAIN RESULTS: mTOR activity was increased in peripheral blood mononuclear cells from patients with COPD, and treatment with rapamycin inhibited this as well as restoring corticosteroid sensitivity.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26639426-4	2016	Here, we found that acute (within 2min) bath-application of rapamycin (0.5mugml(-1)) was able to depolarize the current-clamp baseline potentials significantly at postnatal day (P) 4, P10 in rats and P90 in mice (P&lt;0.05), and altered the membrane current/voltage (I/V) curves in an age-dependent manner.	Sirolimus	60-69	S100 calcium binding protein A10	Homo sapiens	184-187
26639426-5	2016	Rapamycin not only increased the standard deviation or the peak amplitude of baseline membrane potential, but also increased the frequencies of spontaneous action potentials in more mature neurons (P10 and P90).	Sirolimus	0-9	S100 calcium binding protein A10	Homo sapiens	198-201
26639426-7	2016	These findings suggest that acute inhibition of mTOR signaling by rapamycin induces an immediate impact on L5 pyramidal neurons" electrophysiological properties, indicating that its effects might involve mechanisms of ion channel"s regulation.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	48-52
26426522-9	2016	CONCLUSIONS: mTOR inhibition by rapamycin restores corticosteroid sensitivity via inhibition of c-Jun expression, and thus mTOR is a potential novel therapeutic target for COPD.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	13-17
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	35-41
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	103-109
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	103-109
26946694-2	2016	The aims of this review are to describe the clinical approach and diagnosis of non-hereditary bradykinin-mediated angioedema induced by drugs such as: angiotensin-converting inhibitor, sartan, gliptins, rapamycin or some thrombolytic reagents and renin inhibitors.	Sirolimus	203-212	kininogen 1	Homo sapiens	94-104
26607598-2	2016	There are several FDA-approved mTOR inhibitors (sirolimus, everolimus, and temsirolimus) with indications for cancer treatment and for prevention of solid organ rejection.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26752047-0	2016	Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-kappaB/LOX-1 Pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	105-109
26752047-0	2016	Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-kappaB/LOX-1 Pathway.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	110-119
26752047-6	2016	Western blotting showed that rapamycin inhibited mechanistic target of rapamycin (mTOR), p70s6k and IkappaBalpha phosphorylation triggered by ox-LDL.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	49-80
26752047-6	2016	Western blotting showed that rapamycin inhibited mechanistic target of rapamycin (mTOR), p70s6k and IkappaBalpha phosphorylation triggered by ox-LDL.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	82-86
26752047-6	2016	Western blotting showed that rapamycin inhibited mechanistic target of rapamycin (mTOR), p70s6k and IkappaBalpha phosphorylation triggered by ox-LDL.	Sirolimus	29-38	NFKB inhibitor alpha	Homo sapiens	100-112
26752047-8	2016	Moreover, immunofluorescent staining showed that rapamycin reduced the accumulation of p65 in the nucleus after ox-LDL treatment for 30 h. mTOR knockdown decreased LOX-1 protein production and IkappaBalpha phosphorylation induced by ox-LDL.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Homo sapiens	139-143
26752047-8	2016	Moreover, immunofluorescent staining showed that rapamycin reduced the accumulation of p65 in the nucleus after ox-LDL treatment for 30 h. mTOR knockdown decreased LOX-1 protein production and IkappaBalpha phosphorylation induced by ox-LDL.	Sirolimus	49-58	NFKB inhibitor alpha	Homo sapiens	193-205
26752047-10	2016	CONCLUSIONS: These findings demonstrate that rapamycin reduce mTOR phosphorylation and subsequently inhibit NF-kappaB activation and suppresses LOX-1, resulting in a reduction in ox-LDL uptake in HUVECs.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	62-66
26752047-10	2016	CONCLUSIONS: These findings demonstrate that rapamycin reduce mTOR phosphorylation and subsequently inhibit NF-kappaB activation and suppresses LOX-1, resulting in a reduction in ox-LDL uptake in HUVECs.	Sirolimus	45-54	nuclear factor kappa B subunit 1	Homo sapiens	108-117
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	89-93
26771918-3	2016	The mice were subsequently treated with rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	53-82
26771918-3	2016	The mice were subsequently treated with rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	84-88
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	Sirolimus	78-87	hypoxia inducible factor 1 subunit alpha	Homo sapiens	149-159
26427479-3	2016	Rapamycin, an allosteric mTOR inhibitor, has been shown to block only one of the primary downstream mTOR effectors, p70 S6 kinase 1, in many cell types.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	25-29
26520031-7	2016	In addition IL-1beta increased p-P70S6K, p-P90S6K, p-S6, and p-P38 proteins in a time-dependent manner, but IL-1beta-induced activation of P70S6K and S6 proteins was significantly decreased in the presence of pharmacological inhibitors for ERK1/2 (U0126), MTOR (rapamycin), and P38 (SB203580).	Sirolimus	262-271	interleukin-1 beta	Sus scrofa	12-20
26520031-7	2016	In addition IL-1beta increased p-P70S6K, p-P90S6K, p-S6, and p-P38 proteins in a time-dependent manner, but IL-1beta-induced activation of P70S6K and S6 proteins was significantly decreased in the presence of pharmacological inhibitors for ERK1/2 (U0126), MTOR (rapamycin), and P38 (SB203580).	Sirolimus	262-271	interleukin-1 beta	Sus scrofa	108-116
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	61-70	zinc ribbon domain containing 2	Homo sapiens	290-293
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	72-75	zinc ribbon domain containing 2	Homo sapiens	290-293
27776426-8	2016	Moreover, TSG significantly activated Akt-mTOR signaling in HUVECs and reduced the autophagic levels in vitro, which were almost completely blocked by rapamycin.	Sirolimus	151-160	AKT serine/threonine kinase 1	Rattus norvegicus	38-41
26427479-3	2016	Rapamycin, an allosteric mTOR inhibitor, has been shown to block only one of the primary downstream mTOR effectors, p70 S6 kinase 1, in many cell types.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	100-104
27274989-12	2016	Combination of rapamycin and beta-elemene exerted significant synergistic antiproliferative effects in FTC-133 cell lines in vitro, based on inhibiting the AKT feedback activation induced by rapamycin.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	156-159
27274989-12	2016	Combination of rapamycin and beta-elemene exerted significant synergistic antiproliferative effects in FTC-133 cell lines in vitro, based on inhibiting the AKT feedback activation induced by rapamycin.	Sirolimus	191-200	AKT serine/threonine kinase 1	Homo sapiens	156-159
27825169-9	2016	Importantly, the rapamycin resistant cells demonstrated attenuated accumulation of p53 in the nucleus in response to rapamycin treatment.	Sirolimus	17-26	tumor protein p53	Homo sapiens	83-86
27050460-5	2016	Importantly, we found that modulation of MTOR activity by treatment with rapamycin and phosphatidic acid had strong effects on the neurodegenerative phenotypes of TBPH (Drosophila TARDBP)-depleted flies.	Sirolimus	73-82	Megator	Drosophila melanogaster	41-45
27825169-10	2016	Moreover, the inhibition of MDM2 by siMDM2 sensitizes A498 cells to rapamycin through the activation of p53.	Sirolimus	68-77	tumor protein p53	Homo sapiens	104-107
26563881-2	2016	mTORC1, consisting of mTOR, raptor, and mLST8 (GbetaL), is sensitive to rapamycin and thought to control autonomous cell growth in response to nutrient availability and growth factors.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26563881-2	2016	mTORC1, consisting of mTOR, raptor, and mLST8 (GbetaL), is sensitive to rapamycin and thought to control autonomous cell growth in response to nutrient availability and growth factors.	Sirolimus	72-81	MTOR associated protein, LST8 homolog (S. cerevisiae)	Mus musculus	40-45
26563881-2	2016	mTORC1, consisting of mTOR, raptor, and mLST8 (GbetaL), is sensitive to rapamycin and thought to control autonomous cell growth in response to nutrient availability and growth factors.	Sirolimus	72-81	MTOR associated protein, LST8 homolog	Homo sapiens	47-53
26691741-2	2016	In the accompanying contrast-enhanced magnetic resonance imaging (CE-MRI) study we showed that the mammalian target of rapamycin (mTOR) inhibitor rapamycin reduced BBB leakage and seizure activity during the chronic epileptic phase.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	130-134
26687832-5	2016	The interactions of calcineurin inhibitors and mammalian target of rapamycin inhibitor sirolimus also promote hypertension.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	47-76
26667069-1	2016	INTRODUCTION: Mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) are a class of immunosuppressive drugs approved for solid organ transplantation (SOT).	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	14-43
27855235-3	2016	Sirolimus, an mTOR inhibitor, has reportedly been successful in treating children with severe diffuse HH, thus obviating the need for pancreatectomy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26667069-1	2016	INTRODUCTION: Mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) are a class of immunosuppressive drugs approved for solid organ transplantation (SOT).	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	45-49
27833825-8	2016	mTOR inhibitors, (e.g., sirolimus) are effective in stabilizing lung function, and reducing the size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26863215-7	2016	To avoid a subtotal pancreatectomy, an mTOR inhibitor - sirolimus - was introduced.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	39-43
26530936-3	2016	The aim of this study was to examine the effects of rapamycin, an mTOR inhibitor, on MG63 osteosarcoma cells.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	66-70
26427711-4	2016	The mTOR inhibitor rapamycin dose-dependently reduced the cell viability of the breast cancer cell line, MCF-7, but did not reduce the cell viability of the colon cancer cell line, HT-29.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26427711-5	2016	Rapamycin reduced the VEGF expression in the culture medium of MCF-7, while rapamycin did not contribute VEGF expression in the culture medium of HT-29.	Sirolimus	0-9	vascular endothelial growth factor A	Homo sapiens	22-26
26427711-6	2016	VEGF stimulated cell viability and VEGF inhibition reduced cell viability of MCF-7, and rapamycin dose-dependently restored the cell viability of MCF-7 reduced by rapamycin.	Sirolimus	163-172	vascular endothelial growth factor A	Homo sapiens	0-4
26530936-7	2016	We found that rapamycin inhibited cell proliferation and decreased the phosphorylation of mTOR pathway components in MG63 cells.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	90-94
27883166-1	2016	Rapamycin, an mTOR inhibitor affects senescence through suppression of senescence-associated secretory phenotype (SASP).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25715851-8	2016	These analyses revealed that both TBTO and the mTOR inhibitor rapamycin inactivate RPS6, but via different mechanisms.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	47-51
26462881-8	2016	An increase in the level of HDAC10 was also obtained when mTOR was inhibited by Rapamycin.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Homo sapiens	58-62
27595116-1	2016	It has been demonstrated that mTOR/p70S6K pathway was abnormally activated in many cancers and rapamycin and its analogs can restrain tumor growth through inhibiting this pathway, but some tumors including esophageal squamous cell carcinoma (ESCC) appear to be insensitive to rapamycin in recent studies.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	30-34
26949542-12	2016	Immunohistochemical analysis showed positive stain of RPMs for both MMP-9 and TIMP-1.	Sirolimus	54-58	metalloproteinase inhibitor 1	Oryctolagus cuniculus	78-84
26849067-0	2016	The Inhibitory Effect of Rapamycin on Toll Like Receptor 4 and Interleukin 17 in the Early Stage of Rat Diabetic Nephropathy.	Sirolimus	25-34	toll-like receptor 4	Rattus norvegicus	38-58
26849067-11	2016	RESULTS: Our results demonstrated that the expression of both TLR4 and IL-17 were upregulated in early stage DN and reduced by rapamycin.	Sirolimus	127-136	toll-like receptor 4	Rattus norvegicus	62-66
26471831-5	2016	RESULTS: mTOR inhibitors AZD8055, RAD-001, rapamycin and BEZ235 induced synergistic cytotoxicity with the Chk1 inhibitor V158411 in p53 mutant colon cancer cells.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Homo sapiens	9-13
26849067-17	2016	Although the underlying mechanisms need to be explored, the observed increase of TLR4 and IL-17 during the early stages of DN and their suppression with rapamycin treatment suggest the importance of TLR4 and IL-17 in DN pathophysiology.	Sirolimus	153-162	toll-like receptor 4	Rattus norvegicus	81-85
26849067-17	2016	Although the underlying mechanisms need to be explored, the observed increase of TLR4 and IL-17 during the early stages of DN and their suppression with rapamycin treatment suggest the importance of TLR4 and IL-17 in DN pathophysiology.	Sirolimus	153-162	toll-like receptor 4	Rattus norvegicus	199-203
26471831-5	2016	RESULTS: mTOR inhibitors AZD8055, RAD-001, rapamycin and BEZ235 induced synergistic cytotoxicity with the Chk1 inhibitor V158411 in p53 mutant colon cancer cells.	Sirolimus	43-52	checkpoint kinase 1	Homo sapiens	106-110
26471831-5	2016	RESULTS: mTOR inhibitors AZD8055, RAD-001, rapamycin and BEZ235 induced synergistic cytotoxicity with the Chk1 inhibitor V158411 in p53 mutant colon cancer cells.	Sirolimus	43-52	tumor protein p53	Homo sapiens	132-135
27565326-1	2016	The presented study aimed to investigate the antitumor efficacy of combination of oxaliplatin with rapamycin, an mTOR inhibitor, in hepatocellular carcinoma (HCC).	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	113-117
27504842-3	2016	This review discusses data regarding patient outcomes that were used to develop current guidelines for embolization of renal angiomyolipomas and presents recent data on 2 available mTOR inhibitors - sirolimus and everolimus - in the treatment of angiomyolipoma.	Sirolimus	199-208	mechanistic target of rapamycin kinase	Homo sapiens	181-185
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Sirolimus	65-74	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Sirolimus	65-74	BCL2 apoptosis regulator	Homo sapiens	18-23
27565326-10	2016	The ratios of Bax/Bcl-2 in cells exposed to both oxaliplatin and rapamycin were significantly increased compared to those in cells subjected to oxaliplatin or rapamycin alone treatment.	Sirolimus	159-168	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
27421126-6	2016	Partial response of TSC-associated tumors and decrease the rate of lung function decline in females with LAM due to inhibition of mTOR pathway with sirolimus have been demonstrated.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Homo sapiens	130-134
26636543-2	2015	Here we studied the role of mTOR-dependent autophagy in implementating the antiprolifrative effect of mTORC1-specific inhibitor rapamycin and ATP-competitive mTOR kinase inhibitor pp242.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	28-32
26636543-2	2015	Here we studied the role of mTOR-dependent autophagy in implementating the antiprolifrative effect of mTORC1-specific inhibitor rapamycin and ATP-competitive mTOR kinase inhibitor pp242.	Sirolimus	128-137	mechanistic target of rapamycin kinase	Homo sapiens	102-106
26566676-7	2015	Akt-mediated downregulation of Mfn2 was via the mTORC1 pathway because this downregulation was blocked by rapamycin, and overexpression of wild-type, but not kinase-dead mTOR, caused Mfn2 downregulation.	Sirolimus	106-115	AKT serine/threonine kinase 1	Homo sapiens	0-3
32262937-6	2015	Moreover, we use rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR), to induce autophagy and inhibit cell growth.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	49-78
32262937-6	2015	Moreover, we use rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR), to induce autophagy and inhibit cell growth.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	80-84
26566676-7	2015	Akt-mediated downregulation of Mfn2 was via the mTORC1 pathway because this downregulation was blocked by rapamycin, and overexpression of wild-type, but not kinase-dead mTOR, caused Mfn2 downregulation.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Homo sapiens	48-52
26256674-0	2015	The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.	Sirolimus	39-48	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	14-20
26652716-8	2015	By treatment of MKN45 gastric cancer cells with rapamycin, a reduction of p-mTOR in the Western blot was achieved; however, expression of MMPs remained unaffected.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	76-80
26256674-1	2015	AIMS: Sirolimus is an mTOR inhibitor metabolized by CYP3A4 and CYP3A5.	Sirolimus	6-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
26256674-1	2015	AIMS: Sirolimus is an mTOR inhibitor metabolized by CYP3A4 and CYP3A5.	Sirolimus	6-15	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	63-69
26256674-1	2015	AIMS: Sirolimus is an mTOR inhibitor metabolized by CYP3A4 and CYP3A5.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	22-26
26256674-2	2015	Reported effects of CYP3A5 polymorphisms on sirolimus pharmacokinetics (PK) have shown unexplained discrepancies across studies.	Sirolimus	44-53	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	20-26
26256674-3	2015	We quantitatively assessed the effect of CYP3A5*3 status on sirolimus PK by in vitro assessment and simulation using a physiologically-based PK (PBPK) model.	Sirolimus	60-69	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	41-47
26118661-0	2015	Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	82-86
26256674-9	2015	The PBPK model developed based on CL(int) of recombinant CYP3A4, CYP3A5 and CYP2C8 predicted a small CYP3A5*3 effect on simulated sirolimus PK profiles.	Sirolimus	130-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
26256674-9	2015	The PBPK model developed based on CL(int) of recombinant CYP3A4, CYP3A5 and CYP2C8 predicted a small CYP3A5*3 effect on simulated sirolimus PK profiles.	Sirolimus	130-139	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	65-71
26256674-9	2015	The PBPK model developed based on CL(int) of recombinant CYP3A4, CYP3A5 and CYP2C8 predicted a small CYP3A5*3 effect on simulated sirolimus PK profiles.	Sirolimus	130-139	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	101-107
26256674-11	2015	CONCLUSIONS: This study suggests that CYP3A5 contribution to sirolimus metabolism is much smaller than that of CYP3A4.	Sirolimus	61-70	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	38-44
26256674-13	2015	PBPK model simulations allowed mechanism-based evaluation of the effects of CYP3A5 genotype on sirolimus PK and provided preliminary data for the design of a future prospective study.	Sirolimus	95-104	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	76-82
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mitogen-activated protein kinase 3	Homo sapiens	199-205
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	73-77
26118661-7	2015	The findings indicate that rapamycin inhibits BAFF-stimulated cell proliferation/survival by targeting mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	103-107
26118661-4	2015	Here, we show that rapamycin inhibited human soluble BAFF (hsBAFF)-induced cell proliferation and survival in normal and B-lymphoid (Raji and Daudi) cells by activation of PP2A and inactivation of Erk1/2.	Sirolimus	19-28	mitogen-activated protein kinase 3	Homo sapiens	197-203
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	67-71
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	73-77
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	73-77
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	73-77
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	AKT serine/threonine kinase 1	Rattus norvegicus	19-22
26449264-2	2015	This multi-organ disorder results from inactivating point mutations in either the TSC1 or the TSC2 genes and consequent activation of the canonical mammalian target of rapamycin complex 1 signalling (mTORC1) pathway.	Sirolimus	168-177	TSC complex subunit 1	Homo sapiens	82-86
26549380-2	2015	Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), may inhibit growth of lymphatic malformations.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
26481769-8	2015	Such responses comprise the decrease in the inflammation area, increase in the number of proliferating satellite cells and size of regenerating myofibers, combined with the modulation of components of the phosphoinositide 3-kinase/Akt-protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway and ubiquitin-proteasome system.	Sirolimus	272-281	AKT serine/threonine kinase 1	Homo sapiens	231-234
26549380-2	2015	Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), may inhibit growth of lymphatic malformations.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	58-62
26496900-9	2015	These effects were enhanced following treatment with selected inhibitors of PI3K (LY294002), Akt (SH-6) and mTOR (rapamycin).	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	108-112
26490657-6	2015	These effects were observed with as little as 0.5 nM rapamycin, demonstrating the profound affinity the compound has for FK-binding protein 12 (FKBP12), which subsequently forms the FKBP12/rapamycin complex to inhibit mTOR.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Homo sapiens	218-222
26289591-0	2015	Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	20-24
26289591-5	2015	The molecular connection between TSC and mTOR led to the clinical use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.	Sirolimus	101-110	TSC complex subunit 1	Homo sapiens	33-36
26289591-5	2015	The molecular connection between TSC and mTOR led to the clinical use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	41-45
26289591-5	2015	The molecular connection between TSC and mTOR led to the clinical use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	84-88
26289591-5	2015	The molecular connection between TSC and mTOR led to the clinical use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.	Sirolimus	101-110	TSC complex subunit 1	Homo sapiens	148-151
26289591-8	2015	Everolimus and sirolimus selectively inhibit mTOR signaling with similar molecular mechanisms, but with distinct clinical profiles.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	45-49
26770910-8	2015	In addition, rapamycin blocked the effects of Orn completely (p70S6K and S6) or partially (4EBP1).	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	91-96
26371515-5	2015	We further showed that Prp8 could regulate NES(AR) function using short hairpin RNA knockdown of Prp8 coupled with a rapamycin export assay in mammalian cells and knockdown of Prp8 could induce nuclear accumulation of GFP-tagged AR in PC3 cells.	Sirolimus	117-126	androgen receptor	Homo sapiens	47-49
26284586-4	2015	We used an in vitro model to examine combination treatment with vemurafenib and mammalian target of rapamycin (mTOR) inhibitors, metformin and rapamycin.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	111-115
26120766-8	2015	Knockdown of ATG5 with siRNA increased OSS-mediated mtO2( -), whereas starvation or rapamycin-induced autophagy reduced OSS-mediated mtO2( -), mitochondrial respiration, and complex II activity.	Sirolimus	84-93	tRNA mitochondrial 2-thiouridylase	Homo sapiens	133-137
26597054-4	2015	PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasiveness via activation of mTOR, attributes which were sensitive to rapamycin treatment.	Sirolimus	142-151	protein tyrosine phosphatase 4a3	Mus musculus	0-5
26588841-7	2015	Co-treatment with the antiprogestin mifepristone reduced graft growth (four independent donors, p&lt;0.0001 two-sided t-test), as did treatment with the mTOR inhibitor rapamycin (three independent donors, p&lt;0.0001 two-sided t-test).	Sirolimus	168-177	mechanistic target of rapamycin kinase	Homo sapiens	153-157
27606328-3	2015	Systemic pharmacological inhibition of mTOR signaling with rapamycin has been shown to rescue DISC1 deficiency-induced neurodevelopmental defects, as well as cognitive and affective deficits.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	39-43
26569621-10	2015	Mice bearing advanced stage chemically-induced bladder tumours mimicking the histological and molecular nature of human tumours were then administrated with mTOR-pathway inhibitor sirolimus (rapamycin).	Sirolimus	180-189	mechanistic target of rapamycin kinase	Homo sapiens	157-161
26546739-5	2015	To evaluate a potential therapeutic option for the patient, we treated her primary skin fibroblasts and BM HSCs with the mTOR inhibitor rapamycin.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	121-125
26561782-11	2015	Whereas rapamycin augmented the A2E-mediated autophagy, attenuated protein expression of inflammation-associated and angiogenic factors, and blocked the Akt/mTOR pathway.	Sirolimus	8-17	AKT serine/threonine kinase 1	Homo sapiens	153-156
26561782-11	2015	Whereas rapamycin augmented the A2E-mediated autophagy, attenuated protein expression of inflammation-associated and angiogenic factors, and blocked the Akt/mTOR pathway.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Homo sapiens	157-161
26561782-12	2015	Taken together, A2E induces autophagy in RPE cells at the early stage of incubation, and this autophagic response can be inhibited by 3-MA or augmented by rapamycin via the mTOR pathway.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Homo sapiens	173-177
26540269-5	2015	Chronic systemic rapamycin treatment partially inhibited phosphorylation of a mechanistic target of rapamycin substrate in brain and stimulated LC3 cleavage, a marker of autophagic flux.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Homo sapiens	78-109
26431326-2	2015	Rapamycin, a specific inhibitor of mTOR, exerts prolongevity effects in evolutionarily diverse species.	Sirolimus	0-9	Megator	Drosophila melanogaster	35-39
26297217-9	2015	The Atg5 silence counteracted the protective effect of rapamycin.	Sirolimus	55-64	autophagy related 5	Homo sapiens	4-8
26586952-1	2015	Mammalian target of rapamycin (mTOR) has been shown to be overactive in human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to show clinical efficacy against colorectal cancer.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26010766-6	2015	Rapamycin, an inhibitor of mTOR, can suppress the glucose-induced phosphorylation of HSF1/S326 and the expression of alpha B-crystallin.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
26226122-4	2015	Introduction of sirolimus, an mTOR (mammalian target of rapamycin) inhibitor, obviated the requirement for glucose infusion.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	30-34
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	cyclin dependent kinase inhibitor 2B	Homo sapiens	24-27
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1C	Homo sapiens	32-35
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	64-68
26226122-4	2015	Introduction of sirolimus, an mTOR (mammalian target of rapamycin) inhibitor, obviated the requirement for glucose infusion.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	36-65
26358751-3	2015	Current clinical mTOR inhibitors only inhibit the mTORC1 complex and are derivatives of the macrolide rapamycin (rapalogs).	Sirolimus	102-111	mechanistic target of rapamycin kinase	Homo sapiens	17-21
26381051-0	2015	Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol.	Sirolimus	58-67	microRNA 208a	Rattus norvegicus	22-30
26471225-3	2015	These findings open the possibility of disabling the pathological effects of senescence with mTOR inhibitors and may explain the anti-aging properties of rapamycin.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	93-97
26363453-5	2015	Moreover, Atg5 knocking down could significantly increase the expression of MMP2, MMP9 and uPA in EPCs while rapamycin could decrease the expression of uPA and MMP9.	Sirolimus	109-118	plasminogen activator, urokinase	Homo sapiens	152-155
26543771-0	2015	CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.	Sirolimus	51-60	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
26543771-0	2015	CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.	Sirolimus	51-60	ATP binding cassette subfamily B member 1	Homo sapiens	11-16
26693177-2	2015	The TSC1 and TSC2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	76-85	TSC complex subunit 1	Homo sapiens	4-8
26181590-7	2015	Further, the apoptotic effect of 1 was suppressed by treatment of cell with rapamycin, a well-known inhibitor of the mTOR signaling pathway, illustrating the selectivity of the compound.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Homo sapiens	117-121
26232156-9	2015	In the first case, the cause was revealed to be a drug that was added to the patient"s treatment regimen (posaconazole) that inhibits CYP3A4 which is responsible for sirolimus metabolism.	Sirolimus	166-175	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
26449763-0	2015	Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo.	Sirolimus	22-31	insulin	Homo sapiens	63-70
26543746-7	2015	In total, 25 correlated and four anti-correlated drug sensitivities were revealed of which only one drug, Sirolimus, showed significantly lower IC50 values in the luminal/ERBB2 breast cancer subtype.	Sirolimus	106-115	erb-b2 receptor tyrosine kinase 2	Homo sapiens	171-176
26208432-8	2015	Using the mTOR inhibitors rapamycin, everolimus and PF-04691502 (a dual PI3K/mTOR inhibitor) and in combination with tamoxifen, significant reduction in mammosphere formation was observed.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	10-14
26208432-8	2015	Using the mTOR inhibitors rapamycin, everolimus and PF-04691502 (a dual PI3K/mTOR inhibitor) and in combination with tamoxifen, significant reduction in mammosphere formation was observed.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	77-81
26449763-5	2015	In vitro, rapamycin treatment reversed inflammatory cytokine-stimulated IRS-1 serine phosphorylation, increased insulin signaling to AKT and enhanced glucose utilization.	Sirolimus	10-19	insulin	Homo sapiens	112-119
26449763-5	2015	In vitro, rapamycin treatment reversed inflammatory cytokine-stimulated IRS-1 serine phosphorylation, increased insulin signaling to AKT and enhanced glucose utilization.	Sirolimus	10-19	thymoma viral proto-oncogene 1	Mus musculus	133-136
26449763-7	2015	Our results indicate a paradoxical effect of rapamycin on insulin resistance between the in vitro and in vivo environments under inflammatory stress and provide additional insight into the clinical application of rapamycin.	Sirolimus	45-54	insulin	Homo sapiens	58-65
26311737-9	2015	Furthermore, the inhibition of PI3K/Akt by LY294002/si-Akt or of mTOR by rapamycin augmented LicA-induced apoptosis and autophagy.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	65-69
26123689-7	2015	Sirolimus, which is directed against the PI3/AKT/mTOR downstream signalling pathway involved in lymphangiogenesis, has also shown promising results, although further study is needed.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	45-48
26382207-0	2015	Retraction: "Rapamycin Attenuates Liver Graft Injury in Cirrhotic Recipient-The Significance of Down-Regulation of Rho-ROCK-VEGF Pathway" by K. Man, M. Su, K.T.	Sirolimus	13-22	vascular endothelial growth factor A	Homo sapiens	124-128
26123689-7	2015	Sirolimus, which is directed against the PI3/AKT/mTOR downstream signalling pathway involved in lymphangiogenesis, has also shown promising results, although further study is needed.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	49-53
26050578-1	2015	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus have shown their efficacy in kidney transplantation, but their wider introduction has been limited by relative high discontinuation rates.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	4-33
26644772-5	2015	Sirolimus causes immunosuppressive effects by inhibiting mammalian target of rapamycin (mTOR), and has well known side effects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	57-86
26644772-5	2015	Sirolimus causes immunosuppressive effects by inhibiting mammalian target of rapamycin (mTOR), and has well known side effects.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	88-92
26050578-1	2015	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus have shown their efficacy in kidney transplantation, but their wider introduction has been limited by relative high discontinuation rates.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	35-39
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	31-34
26722609-0	2015	The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration [Retraction].	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	38-42
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	lactate dehydrogenase A	Homo sapiens	246-250
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	AKT serine/threonine kinase 1	Homo sapiens	287-290
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	291-295
26004903-4	2015	RPM harvested from HCR vs. LCR demonstrated reduced cellular oxidation (21%), increased paraoxonase 2 activity (28%) and decreased triglycerides mass (44%).	Sirolimus	0-3	paraoxonase 2	Rattus norvegicus	88-101
26623104-9	2015	In contrast, treatment with RAPA only significantly inhibited the protein expression of p-mTOR (P&lt;0.05).	Sirolimus	28-32	mechanistic target of rapamycin kinase	Homo sapiens	90-94
26061549-6	2015	Interestingly, the expression of Klotho, an antiaging gene that suppresses VC, was reduced in calcified vasculature, whereas rapamycin reversed membrane and secreted Klotho decline through mTOR inhibition.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	189-193
26002629-5	2015	Coincidently, rapamycin markedly blocked Cd-induced phosphorylation of Akt, S6K1 and 4E-BP1 in the cells.	Sirolimus	14-23	AKT serine/threonine kinase 1	Homo sapiens	71-74
26337526-0	2015	Down-regulation of mitogen-activated protein kinases and nuclear factor-kappaB signaling is involved in rapamycin suppression of TLR2-induced inflammatory response in monocytic THP-1 cells.	Sirolimus	104-113	toll like receptor 2	Homo sapiens	129-133
26337526-3	2015	Here, the mechanism by which rapamycin suppresses TLR2-induced inflammatory responses was investigated.	Sirolimus	29-38	toll like receptor 2	Homo sapiens	50-54
26337526-8	2015	Additionally, western blot showed that pre-treatment of THP-1 cells with rapamycin down-regulates MAPKs and NF-kappaB signaling induced by Pam3CSK4 stimulation, suggesting that rapamycin suppresses Pam3CSK4-induced pro-inflammatory cytokines via inhibition of TLR2 signaling.	Sirolimus	73-82	toll like receptor 2	Homo sapiens	260-264
26337526-8	2015	Additionally, western blot showed that pre-treatment of THP-1 cells with rapamycin down-regulates MAPKs and NF-kappaB signaling induced by Pam3CSK4 stimulation, suggesting that rapamycin suppresses Pam3CSK4-induced pro-inflammatory cytokines via inhibition of TLR2 signaling.	Sirolimus	177-186	toll like receptor 2	Homo sapiens	260-264
26337526-9	2015	It was concluded that rapamycin suppresses TLR2-induced inflammatory responses by down-regulation of Erk and NF-kappaB signaling.	Sirolimus	22-31	toll like receptor 2	Homo sapiens	43-47
26337526-9	2015	It was concluded that rapamycin suppresses TLR2-induced inflammatory responses by down-regulation of Erk and NF-kappaB signaling.	Sirolimus	22-31	mitogen-activated protein kinase 1	Homo sapiens	101-104
26002629-6	2015	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of Cd-induced cell death, implying that the preventive effect of rapamycin on Cd-induced neurotoxicity is mTOR kinase activity-dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	54-58
26002629-6	2015	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of Cd-induced cell death, implying that the preventive effect of rapamycin on Cd-induced neurotoxicity is mTOR kinase activity-dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
26002629-6	2015	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of Cd-induced cell death, implying that the preventive effect of rapamycin on Cd-induced neurotoxicity is mTOR kinase activity-dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
26002629-6	2015	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of Cd-induced cell death, implying that the preventive effect of rapamycin on Cd-induced neurotoxicity is mTOR kinase activity-dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
26002629-6	2015	Expression of a rapamycin-resistant and kinase-active mTOR (S2035T, mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR (S2035T/D2357E, mTOR-TE), conferred resistance to rapamycin inhibition of Cd-induced cell death, implying that the preventive effect of rapamycin on Cd-induced neurotoxicity is mTOR kinase activity-dependent.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	68-72
26002629-8	2015	Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect.	Sirolimus	182-191	AKT serine/threonine kinase 1	Homo sapiens	121-124
26002629-8	2015	Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect.	Sirolimus	182-191	AKT serine/threonine kinase 1	Homo sapiens	147-150
26356487-6	2015	With LPS + rapamycin monocytes from patients with TSC showed gene expression patterns different from healthy subjects.	Sirolimus	11-20	TSC complex subunit 1	Homo sapiens	50-53
26356487-8	2015	CONCLUSION: The effects of LPS, even more of LPS with rapamycin on monocytes from patients with TSC suggested that inflammatory processes are distinct from those in healthy subjects.	Sirolimus	54-63	TSC complex subunit 1	Homo sapiens	96-99
26053964-7	2015	In addition, rapamycin reduced the production of IL-6 and IL-13 by eosinophils.	Sirolimus	13-22	interleukin 6	Mus musculus	49-53
26053964-7	2015	In addition, rapamycin reduced the production of IL-6 and IL-13 by eosinophils.	Sirolimus	13-22	interleukin 13	Mus musculus	58-63
26407295-7	2015	Hence, we next explored the possibilities of using VCAM-1 as a cell-surface receptor to deliver the potent immunosuppressant rapamycin to TNFalpha-activated podocytes using the lipid-based nanocarrier system Saint-O-Somes.	Sirolimus	125-134	vascular cell adhesion molecule 1	Homo sapiens	51-57
26046470-8	2015	Reduced intracellular sirolimus concentration was followed by increased p70S6k phosphorylation suggesting preservation of the mTOR-signaling pathway.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	126-130
26407295-7	2015	Hence, we next explored the possibilities of using VCAM-1 as a cell-surface receptor to deliver the potent immunosuppressant rapamycin to TNFalpha-activated podocytes using the lipid-based nanocarrier system Saint-O-Somes.	Sirolimus	125-134	tumor necrosis factor	Homo sapiens	138-146
26407295-8	2015	Anti-VCAM-1-rapamycin-SAINT-O-Somes more effectively inhibited the cell migration of AB8/13 cells than free rapamycin and non-targeted rapamycin-SAINT-O-Somes indicating the potential of VCAM-1 targeted drug delivery to podocytes.	Sirolimus	12-21	vascular cell adhesion molecule 1	Homo sapiens	5-11
26407295-8	2015	Anti-VCAM-1-rapamycin-SAINT-O-Somes more effectively inhibited the cell migration of AB8/13 cells than free rapamycin and non-targeted rapamycin-SAINT-O-Somes indicating the potential of VCAM-1 targeted drug delivery to podocytes.	Sirolimus	12-21	vascular cell adhesion molecule 1	Homo sapiens	187-193
26353013-12	2015	Co-treatment of EBR with rapamycin, an upstream mTOR pathway inhibitor, prevented EBR-induced cell viability loss and PARP cleavage in LNCaP prostate cancer cells, suggesting that EBR could induce ER stress in these cells.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	48-52
26416965-5	2015	Blocking mTOR signaling with rapamycin or PP242 or mitochondrial ATP production (e.g., with CCCP) reduced mitochondrial Ca(2+) uptake and membrane potential, and impaired cellular ATP release and neutrophil chemotaxis.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	9-13
26377470-0	2015	Mitochondrial Quality Control via the PGC1alpha-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin.	Sirolimus	141-150	PPARG coactivator 1 alpha	Homo sapiens	38-47
26377470-5	2015	Treatment with rapamycin was found to independently restore PGC1alpha-TFEB signaling in a manner not requiring parkin activity and to abrogate impairment of mitochondrial quality control and neurodegenerative features associated with this in vivo model.	Sirolimus	15-24	PPARG coactivator 1 alpha	Homo sapiens	60-69
26377470-6	2015	Losses in PGC1alpha-TFEB signaling in cultured rat DAergic cells expressing the Q311X mutation associated with reduced mitochondrial function and cell viability were found to be PARIS-dependent and to be independently restored by rapamycin in a manner requiring TFEB.	Sirolimus	230-239	PPARG coactivator 1 alpha	Rattus norvegicus	10-19
26377470-6	2015	Losses in PGC1alpha-TFEB signaling in cultured rat DAergic cells expressing the Q311X mutation associated with reduced mitochondrial function and cell viability were found to be PARIS-dependent and to be independently restored by rapamycin in a manner requiring TFEB.	Sirolimus	230-239	transcription factor EB	Rattus norvegicus	20-24
26377470-6	2015	Losses in PGC1alpha-TFEB signaling in cultured rat DAergic cells expressing the Q311X mutation associated with reduced mitochondrial function and cell viability were found to be PARIS-dependent and to be independently restored by rapamycin in a manner requiring TFEB.	Sirolimus	230-239	transcription factor EB	Rattus norvegicus	262-266
26377470-12	2015	Treatment with rapamycin independently restores PGC1alpha-TFEB signaling in a manner not requiring parkin activity and abrogates subsequent mitochondrial impairment and neuronal cell loss.	Sirolimus	15-24	PPARG coactivator 1 alpha	Homo sapiens	48-57
26227152-12	2015	Peroxisome proliferator activated receptor-gamma coactivator-1alpha, pyruvate dehydrogenase kinase 4 and mitochondrial transcription factor A mRNA increased post-exercise (P &lt; 0.05) and this response was augmented by rapamycin (P &lt; 0.05).	Sirolimus	220-229	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	69-100
26041743-3	2015	We tested in this study, the efficacy and safety of the mTOR-inhibitor sirolimus (SRL) plus prednisone (PDN) in patients with ECD.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	56-60
26027660-9	2015	Treatment with rapamycin or RAD001 significantly increased the phosphorylation of AKT in both LKB1 wild-type and LKB1 mutant NSCLC cells, which was attenuated by the PI3K inhibitor LY294002.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	82-85
26442001-6	2015	Most of the DEGs and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways involved in cell wall elongation, ribosome biogenesis, and cell autophagy were common to both AZD- and rapamycin-treated samples, but AZD displayed much broader and more efficient inhibition of TOR compared with rapamycin.	Sirolimus	180-189	target of rapamycin	Arabidopsis thaliana	271-274
25943403-5	2015	Due to lack of treatment options and the involvement of the mTOR pathway in TSC, a trial of an mTOR inhibitor, rapamycin, was initiated.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	95-99
26208739-13	2015	All the observation was confirmed by silencing TS and inactivating the mTOR/p70S6K1 signaling pathway by rapamycin, both of which increased the chemo-sensitizing efficacy of 5-FU.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	71-75
25943210-4	2015	Here, the results from a murine cardiac transplantation model revealed that rapamycin treatment (3 mg/kg, intraperitoneally on postoperative days 0, 2, 4, and 6) led to the recruitment of MDSCs and increased their expression of inducible nitric oxide synthase (iNOS).	Sirolimus	76-85	nitric oxide synthase 2, inducible	Mus musculus	228-259
25943210-4	2015	Here, the results from a murine cardiac transplantation model revealed that rapamycin treatment (3 mg/kg, intraperitoneally on postoperative days 0, 2, 4, and 6) led to the recruitment of MDSCs and increased their expression of inducible nitric oxide synthase (iNOS).	Sirolimus	76-85	nitric oxide synthase 2, inducible	Mus musculus	261-265
26562280-3	2015	The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients.	Sirolimus	94-103	neurofibromin 1	Homo sapiens	40-43
26562280-3	2015	The advent of new treatment options for NF1 such as topical vitamin D3 analogues, lovastatin, rapamycin (or sirolimus), and imatinib mesylate has added new dimensions that require further investigation to provide the greatest benefit to patients.	Sirolimus	108-117	neurofibromin 1	Homo sapiens	40-43
25980751-14	2015	In phosphatase and tensin homolog-null mouse embryonic fibroblasts with constitutively activated mTOR, GP73 was up-regulated compared with control mouse embryonic fibroblasts; this increase was reversed after incubation with rapamycin.	Sirolimus	225-234	golgi membrane protein 1	Mus musculus	103-107
25980751-15	2015	Expression of GP73 also was reduced in HCC and other cancer cell lines incubated with rapamycin.	Sirolimus	86-95	golgi membrane protein 1	Mus musculus	14-18
26186486-1	2015	BACKGROUND: Sirolimus (SRL), a mammalian target of rapamycin inhibitor, has been used as a de novo base therapy with steroids and mycophenolate mofetil to avoid the use of calcineurin inhibitors.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	31-60
26253719-2	2015	Mip exhibits peptidyl prolyl cis-trans isomerase (PPIase) activity, which can be inhibited by rapamycin and FK506.	Sirolimus	94-103	major intrinsic protein of lens fiber	Homo sapiens	0-3
26202311-0	2015	Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26202311-6	2015	Interestingly, we found that rapamycin inhibited mTOR signaling in addition to simultaneously downregulating the expression of CD44, SOX2 and MMP-2 and that it affected cell growth and tumor size and weight both in vitro and in vivo.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	49-53
26238486-5	2015	Importantly, however, FOXP3(+) iNKT cells only acquired suppressive abilities when cultured in the presence of the mTOR inhibitor rapamycin.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	115-119
26169455-7	2015	RESULTS: In the DAY1 group, treatment with sirolimus resulted in decreased intracellular levels of cyclins D2 and A (P &lt; .05).	Sirolimus	43-52	cyclin D2	Homo sapiens	99-115
26169455-8	2015	Increased D cyclins and reduced levels of cyclins E and A (P &lt; .05) in the DAY5 group indicated a permanent G1/S block by sirolimus.	Sirolimus	125-134	cyclin A2	Homo sapiens	42-57
26280535-3	2015	In a drug screen to find new SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	63-67
26239133-2	2015	Inhibition of mTOR by rapamycin has been shown to attenuate pathological cardiac hypertrophy and improve the function of aging heart, accompanied by an inhibition of the cardiac proteasome activity.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26239133-6	2015	In addition, rapamycin attenuated the induction of the immunoproteasome in H9c2 cells by inflammatory cytokines, including INFgamma and TNFalpha, by suppressing NF-kappaB signaling.	Sirolimus	13-22	tumor necrosis factor	Rattus norvegicus	136-144
26138072-5	2015	Cmpd1 also blocked epidermal growth factor-stimulated pStat1 induction, whereas upregulating pSrc, pAkt, p-p38, pHeat shock protein 27, and pmammalian target of rapamycin levels.	Sirolimus	161-170	CMD1B	Homo sapiens	0-5
26048361-12	2015	Our findings suggest that rapamycin targeting of Akt to restore normal cerebral metabolism could have therapeutic potential in tuberous sclerosis and autism.	Sirolimus	26-35	AKT serine/threonine kinase 1	Rattus norvegicus	49-52
26048361-2	2015	Inhibition of mTOR by rapamycin can mitigate some of the phenotypic abnormalities associated with TSC and autism, but whether this is due to the mTOR-related function in energy metabolism remains to be elucidated.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26073719-2	2015	Classic mTOR inhibitors such as rapamycin or everolimus are commonly used in transplant as well as cancer patients to prevent transplant rejection or cancer progression, respectively.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	8-12
23745794-5	2015	Growth inhibition and cell cycle effects were assessed for pathway inhibitors AZD6244 (MAPK) and rapamycin (PI3K/AKT) in human and canine melanoma cells.	Sirolimus	97-106	AKT serine/threonine kinase 1	Homo sapiens	113-116
26020804-4	2015	Treatment of FaDu and SCC-1 cell lines with rapamycin, an inhibitor of mTOR pathway, also reduced cell viability of HNSCC cells.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	71-75
26046303-2	2015	Recently we have shown that rapamycin prevents Cd-induced neuronal cell death by inhibiting mTOR signaling pathway.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	92-96
26046303-3	2015	Here we found that rapamycin exerted its prevention against Cd-induced neuronal cell death also partially via blocking Erk1/2 pathway.	Sirolimus	19-28	mitogen-activated protein kinase 3	Homo sapiens	119-125
29388579-6	2015	Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to use of pharmacotherapies such as the mTOR inhibitors everolimus and sirolimus in the treatment of TSC disease.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Homo sapiens	79-83
29388579-6	2015	Improved understanding of the genetic basis of TSC and of the central issue of mTOR overactivation has led to use of pharmacotherapies such as the mTOR inhibitors everolimus and sirolimus in the treatment of TSC disease.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Homo sapiens	147-151
26302180-3	2015	This function might be crucial for the growth and survival of cancer cells, especially for those resistant to the allosteric mTOR inhibitor rapamycin.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Homo sapiens	125-129
26011939-0	2015	PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.	Sirolimus	32-41	tumor protein D52	Homo sapiens	0-4
26287365-9	2015	Additionally, the mTOR inhibitor rapamycin further reduced the cell viability of TSA- and SAHA-treated SGC-996 cells and the phosphorylation of mTOR, whereas the mTOR activator 1,2-dioctanoyl-sn-glycero-3-phosphate (C8-PA) exerted the opposite influence.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	18-22
26287365-9	2015	Additionally, the mTOR inhibitor rapamycin further reduced the cell viability of TSA- and SAHA-treated SGC-996 cells and the phosphorylation of mTOR, whereas the mTOR activator 1,2-dioctanoyl-sn-glycero-3-phosphate (C8-PA) exerted the opposite influence.	Sirolimus	33-42	sarcoglycan beta	Homo sapiens	103-106
26287365-9	2015	Additionally, the mTOR inhibitor rapamycin further reduced the cell viability of TSA- and SAHA-treated SGC-996 cells and the phosphorylation of mTOR, whereas the mTOR activator 1,2-dioctanoyl-sn-glycero-3-phosphate (C8-PA) exerted the opposite influence.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	144-148
26287365-9	2015	Additionally, the mTOR inhibitor rapamycin further reduced the cell viability of TSA- and SAHA-treated SGC-996 cells and the phosphorylation of mTOR, whereas the mTOR activator 1,2-dioctanoyl-sn-glycero-3-phosphate (C8-PA) exerted the opposite influence.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	144-148
26011939-0	2015	PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.	Sirolimus	32-41	tumor protein D52	Homo sapiens	5-9
26011939-5	2015	Here, we report that PC-1 overexpression confers PCa cells resistance to rapamycin treatment by antagonizing rapamycin-induced cytostasis and autophagy (rapamycin-sensitivity was observed in PC-1-deficient (shPC-1) C4-2 cells).	Sirolimus	73-82	tumor protein D52	Homo sapiens	21-25
26011939-5	2015	Here, we report that PC-1 overexpression confers PCa cells resistance to rapamycin treatment by antagonizing rapamycin-induced cytostasis and autophagy (rapamycin-sensitivity was observed in PC-1-deficient (shPC-1) C4-2 cells).	Sirolimus	109-118	tumor protein D52	Homo sapiens	21-25
26011939-5	2015	Here, we report that PC-1 overexpression confers PCa cells resistance to rapamycin treatment by antagonizing rapamycin-induced cytostasis and autophagy (rapamycin-sensitivity was observed in PC-1-deficient (shPC-1) C4-2 cells).	Sirolimus	109-118	tumor protein D52	Homo sapiens	21-25
26550253-7	2015	Low-dose rapamycin and valsartan could enhance the expressions of nephrin and podocin, reduce kidney damages, thus achieving the protective effects towards the kidneys, and the effects of the combined therapy were superior to those of monotherapy.	Sirolimus	9-18	NPHS2 stomatin family member, podocin	Rattus norvegicus	78-85
26309858-8	2015	Rapamycin also significantly increased TGF-beta1 production but had no effect on IL-6 productionof T lymphocytes from EAU rats in vitro.	Sirolimus	0-9	transforming growth factor, beta 1	Rattus norvegicus	39-48
25944619-4	2015	We found that the epithelial marker E-cadherin protein is higher in rapamycin sensitive (RS) cells and mesenchymal breast cancer cell lines selected by transcriptional EMT signatures are less sensitive to rapamycin.	Sirolimus	68-77	cadherin 1	Homo sapiens	36-46
26163589-4	2015	Persistent Ag exposure results in prolonged activation of the AKT-mTORC1 pathway in Ag-specific CD8 T cells, favoring their development into effector memory T cells at the expense of central memory T cells, and inhibition of mTORC1 by rapamycin largely corrects the impairment by promoting central memory T cell development.	Sirolimus	235-244	thymoma viral proto-oncogene 1	Mus musculus	62-65
25944619-5	2015	MCF7 cells, transfected with constitutively active mutant Snail, had increased rapamycin resistance (RR) compared to cells transfected with wild-type Snail.	Sirolimus	79-88	snail family transcriptional repressor 1	Homo sapiens	58-63
25847297-11	2015	Rapamycin, an autophagy inducer, reversed Nef-induced senescence and oxidative stress.	Sirolimus	0-9	S100 calcium binding protein B	Homo sapiens	42-45
26248290-13	2015	Furthermore, the content of IL-1beta, IL-2, IFN-gamma, TNF-alpha in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats.	Sirolimus	144-153	interleukin 1 beta	Rattus norvegicus	28-36
26248290-13	2015	Furthermore, the content of IL-1beta, IL-2, IFN-gamma, TNF-alpha in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats.	Sirolimus	144-153	tumor necrosis factor	Rattus norvegicus	55-64
26200935-3	2015	The concern with the monotherapy use of mTORC1 inhibitors, such as rapamycin, is that they cause upregulation of autophagy, a cell survival mechanism, and suppress the negative feedback loop to the oncogene Akt.	Sirolimus	67-76	thymoma viral proto-oncogene 1	Mus musculus	207-210
26349966-8	2015	Activation of PI3K by 740Y-P treatment leaded to upregulation of p-Akt, mTOR and MMP-9; inactivation of mTOR by Rapamycin treatment inhibited expression MMP-9 while activation of mTOR by l-Leucine treatment enhanced MMP-9 expression in Schisandrin B incubated cells.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	104-108
26071551-11	2015	Pretreatment of HO-1(+/+) PECs with rapamycin induced autophagy and resulted in reduced cell death upon cadmium treatment.	Sirolimus	36-45	heme oxygenase 1	Mus musculus	16-20
26349966-8	2015	Activation of PI3K by 740Y-P treatment leaded to upregulation of p-Akt, mTOR and MMP-9; inactivation of mTOR by Rapamycin treatment inhibited expression MMP-9 while activation of mTOR by l-Leucine treatment enhanced MMP-9 expression in Schisandrin B incubated cells.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	104-108
26045471-8	2015	Inhibition of mTOR activity by rapamycin or blocking S6 expression by siRNA inhibited GDH and GLS activity, leading to a decrease in glutamine-induced cell proliferation.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25884889-6	2015	Despite these beneficial effects, rapamycin-treated lean mice showed greater glucose intolerance, reduced insulin sensitivity, lower muscle GLUT4 expression and changes in chromium levels in tissues even with high insulin levels.	Sirolimus	34-43	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	140-145
25481271-3	2015	Rapamycin has been shown to prevent (and possibly restore in some cases) the deficit in memory observed in the mouse model of Alzheimer"s disease (AD-Tg) as well as reduce Abeta and tau aggregation, restore cerebral blood flow and vascularization, and reduce microglia activation.	Sirolimus	0-9	histocompatibility 2, class II antigen A, beta 1	Mus musculus	172-177
26367731-6	2015	Western-blot and real time-PCR were used to test whether mTOR-signaling pathway was inhibited with rapamycin treatment.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	57-61
26367731-9	2015	p-mTOR, p-p70S6K and p-4E-BP1 were expressed in the cytoplasm of SW1990 cells and those proteins were significantly reduced with rapamycin (p &lt; 0.05).	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	2-6
26049685-10	2015	In vivo studies confirmed that the activation of AKT/mTOR by acemannan played a key role in wound healing, which could be reversed by rapamycin.	Sirolimus	134-143	thymoma viral proto-oncogene 1	Mus musculus	49-52
26033306-10	2015	However, a combination of rapamycin (an mTOR inhibitor) and pimasertib did not induce a synergistic effect in endometrial cancer cells, except for HEC-1B cells.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	40-44
26051878-8	2015	Inhibitors of mTORC1, such as rapamycin, effectively suppress the symptoms of TSC.	Sirolimus	30-39	TSC complex subunit 1	Homo sapiens	78-81
26006020-9	2015	Fibrin-cultured cells treated with rapamycin, the mTOR pathway inhibitor, had significantly decreased phospho-p70(s6k) and PDX-1 expression.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	50-54
27088062-1	2015	BACKGROUND: We hypothesize that the combination of an mTOR inhibitor, sirolimus, with a well-known cytotoxic agent, cyclophosphamide, provides a well-tolerated and promising alternative treatment for advanced, differentiated thyroid cancers (DTC).	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	54-58
26192087-9	2015	We demonstrated that rapamycin amplified basal or TGF-beta1-induced CCN2 mRNA and protein expression in normal or fibrotic fibroblasts by Smad-independent but PI3K-dependent pathway.	Sirolimus	21-30	transforming growth factor beta 1	Homo sapiens	50-59
25182869-7	2015	Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and rapamycin were able to restore the response of PD cells to serum stimulation.	Sirolimus	75-84	cyclin D3	Homo sapiens	14-23
25182869-7	2015	Inhibitors of cyclin D3/CDK6 activity like sodium butyrate, PD-332991, and rapamycin were able to restore the response of PD cells to serum stimulation.	Sirolimus	75-84	cyclin dependent kinase 6	Homo sapiens	24-28
26147250-8	2015	Reduced IL1A diminished NF-kappaB transcriptional activity, which controls much of the SASP; exogenous IL1A restored IL6 secretion to rapamycin-treated cells.	Sirolimus	134-143	interleukin 6	Mus musculus	117-120
26026051-7	2015	In contrast, rapamycin or knockdown of mTORC1 increased phosphorylation of AKT (Ser473), yet had little antiproliferative effect.	Sirolimus	13-22	thymoma viral proto-oncogene 1	Mus musculus	75-78
26148957-3	2015	Sirolimus inhibits the mammalian target of rapamycin, which acts as a master switch of numerous cellular processes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	23-52
25867817-0	2015	iPSC-MSCs Combined with Low-Dose Rapamycin Induced Islet Allograft Tolerance Through Suppressing Th1 and Enhancing Regulatory T-Cell Differentiation.	Sirolimus	33-42	negative elongation factor complex member C/D, Th1l	Mus musculus	97-100
26253949-1	2015	PURPOSE: This phase I/II study sought to determine the safety and maximum tolerated dose (MTD) of the combination of rapamycin, an mTOR inhibitor, with short-course radiotherapy in rectal cancer patients.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	131-135
26257526-4	2015	The tumor had shown significant avidity on PET/CT as well as an evident response to sirolimus (rapamycin, Rapamune ) that supports the utility of mTOR inhibitors as an effective treatment for malignant PEComa.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	146-150
26229595-8	2015	In cases of facial overgrowth, which involve PTEN/Akt/TOR dysregulation, sirolimus could be used for limiting cell overgrowth.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	50-53
26224859-6	2015	Importantly, transcripts for the activating transcription factor-3 (Atf3) and mitochondrial uncoupling protein-2 (Ucp2) are highly induced in Tsc2-deficient neurons, as well as in a neuron-specific Tsc1 conditional knock-out mouse model, and show differential responses to the mTOR inhibitor rapamycin.	Sirolimus	292-301	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	78-112
26255626-7	2015	Mutations in the FAT domain of MTOR and in RHEB remained sensitive to rapamycin, though several of these mutations demonstrated residual mTOR kinase activity after treatment with rapamycin at clinically relevant doses.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26224859-6	2015	Importantly, transcripts for the activating transcription factor-3 (Atf3) and mitochondrial uncoupling protein-2 (Ucp2) are highly induced in Tsc2-deficient neurons, as well as in a neuron-specific Tsc1 conditional knock-out mouse model, and show differential responses to the mTOR inhibitor rapamycin.	Sirolimus	292-301	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	114-118
26170311-3	2015	Rapamycin is an allosteric inhibitor of mTOR that selectively inhibits mTORC1.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	40-44
26199284-8	2015	Finally, we show that that rapamycin, an mTOR inhibitor previously shown to alter the fitness of the ipt1 mutant, can effectively prevent the formation of mitoxantrone resistance.	Sirolimus	27-36	inositolphosphotransferase	Saccharomyces cerevisiae S288C	101-105
26255626-7	2015	Mutations in the FAT domain of MTOR and in RHEB remained sensitive to rapamycin, though several of these mutations demonstrated residual mTOR kinase activity after treatment with rapamycin at clinically relevant doses.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	31-35
26255626-7	2015	Mutations in the FAT domain of MTOR and in RHEB remained sensitive to rapamycin, though several of these mutations demonstrated residual mTOR kinase activity after treatment with rapamycin at clinically relevant doses.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Homo sapiens	137-141
26379864-0	2015	Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26379864-7	2015	Further Western blot assays showed that rapamycin induced activation of caspase-9 and caspase-8 and the cleavage of caspase-3.	Sirolimus	40-49	caspase 3	Homo sapiens	116-125
26379864-8	2015	Rapamycin induced cleavages of caspase-3 and apoptosis was inhibited by both Z-LETD-FMK and Z-IETD-FMK treatment.	Sirolimus	0-9	caspase 3	Homo sapiens	31-40
26158631-6	2015	The rapamycin-mediated protection against oxidative stress is due in part to an increase in the transcription of antioxidant genes mediated by cap-n-collar (Drosophila ortholog of Nrf2).	Sirolimus	4-13	cap-n-collar	Drosophila melanogaster	143-155
25968579-8	2015	Incubation with rapamycin and AZD8055 indicated that mammalian target of rapamycin complex (mTORC)2, but not mTORC1, also is required for LIF-stimulated glucose uptake.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Homo sapiens	53-82
26158631-6	2015	The rapamycin-mediated protection against oxidative stress is due in part to an increase in the transcription of antioxidant genes mediated by cap-n-collar (Drosophila ortholog of Nrf2).	Sirolimus	4-13	cap-n-collar	Drosophila melanogaster	180-184
25978917-1	2015	BACKGROUND AND OBJECTIVE: Sirolimus (SR) is a lipophilic macrocytic lactone with immunosuppressive properties (mTOR inhibitor) commonly used in solid organ transplantation and recently introduced in the prophylaxis and treatment of graft-versus-host disease.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	111-115
25978917-1	2015	BACKGROUND AND OBJECTIVE: Sirolimus (SR) is a lipophilic macrocytic lactone with immunosuppressive properties (mTOR inhibitor) commonly used in solid organ transplantation and recently introduced in the prophylaxis and treatment of graft-versus-host disease.	Sirolimus	37-39	mechanistic target of rapamycin kinase	Homo sapiens	111-115
26094583-1	2015	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	4-33
26094583-1	2015	The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	35-39
25349217-14	2015	However, rapamycin upregulated p27(Kip1) at least in part via AKT (also known as protein kinase B)/mTOR.	Sirolimus	9-18	AKT serine/threonine kinase 1	Rattus norvegicus	62-65
25836987-8	2015	In rats and mice, continuous administration of low doses of rapamycin reduced levels of NHE3 in intestinal tissues; this effect was not observed in mice with intestinal deletion of ATG7, indicating that autophagy is required for the reduction.	Sirolimus	60-69	solute carrier family 9 (sodium/hydrogen exchanger), member 3	Mus musculus	88-92
25912929-1	2015	INTRODUCTION: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppressants after organ transplantation in combination with calcineurin inhibitors (CNIs) but also as proliferation signal inhibitors coated on drug-eluting stents and in cancer therapy.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	36-65
25912929-1	2015	INTRODUCTION: The inhibitors of the mammalian target of rapamycin (mTOR) sirolimus and everolimus are used not only as immunosuppressants after organ transplantation in combination with calcineurin inhibitors (CNIs) but also as proliferation signal inhibitors coated on drug-eluting stents and in cancer therapy.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	67-71
25836987-8	2015	In rats and mice, continuous administration of low doses of rapamycin reduced levels of NHE3 in intestinal tissues; this effect was not observed in mice with intestinal deletion of ATG7, indicating that autophagy is required for the reduction.	Sirolimus	60-69	autophagy related 7	Mus musculus	181-185
25836987-9	2015	Administration of single high doses of rapamycin to mice, to model the spikes in rapamycin levels that occur in patients with severe diarrheal episodes, resulted in reduced phosphorylation of S6 and AKT in ileal tissues, indicating inhibition of the mTOR complex (mTORC1 and mTORC2).	Sirolimus	39-48	AKT serine/threonine kinase 1	Homo sapiens	199-202
25836987-9	2015	Administration of single high doses of rapamycin to mice, to model the spikes in rapamycin levels that occur in patients with severe diarrheal episodes, resulted in reduced phosphorylation of S6 and AKT in ileal tissues, indicating inhibition of the mTOR complex (mTORC1 and mTORC2).	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	250-254
25836987-14	2015	Loss of mTOR regulation of NHE3 could mediate the development of diarrhea in patients undergoing rapamycin therapy.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	8-12
25758096-6	2015	In U937 cells, rapamycin alone increased the activity of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and the addition of ATO decreased the level of phosphorylated ERK, Ser473 phosphorylated Akt and anti-apoptotic Mcl-1 protein.	Sirolimus	15-24	mitogen-activated protein kinase 1	Homo sapiens	129-133
25758096-6	2015	In U937 cells, rapamycin alone increased the activity of mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and the addition of ATO decreased the level of phosphorylated ERK, Ser473 phosphorylated Akt and anti-apoptotic Mcl-1 protein.	Sirolimus	15-24	mitogen-activated protein kinase 1	Homo sapiens	134-137
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26151793-3	2015	Immunosuppressants that inhibit mTOR, such as sirolimus, may be used in combination with a systemic retinoid for chemoprophylaxis of cutaneous malignancies.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	32-36
26151793-7	2015	It is postulated that this interaction was mediated by acitretin inhibition of CYP3A4, the primary enzyme responsible for sirolimus metabolism.	Sirolimus	122-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
25701378-5	2015	We further show that combined treatment with celecoxib and rapamycin results in an additive inhibitory effect on the growth of gastric cancer cells through suppression of rapamycin-induced Akt activation.	Sirolimus	171-180	AKT serine/threonine kinase 1	Homo sapiens	189-192
26540919-7	2015	The expression levels of P-mTOR, P-70S6, P-4EBP1 in spherical cells were gradually decreased with increasing of the concentrations of rapamycin, but the difference of the expression levels of mTOR, P70S6, 4EBP1 were not significant.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Homo sapiens	27-31
26540919-8	2015	CONCLUSION: The proteins of mTOR signaling pathway of CSCs in nasopharyngeal carcinoma are overexpressed, and rapamycin can effectively inhibit cell proliferation of CSCs in nasopharyngeal carcinoma by blocking mTOR signaling pathway.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	28-32
26540919-8	2015	CONCLUSION: The proteins of mTOR signaling pathway of CSCs in nasopharyngeal carcinoma are overexpressed, and rapamycin can effectively inhibit cell proliferation of CSCs in nasopharyngeal carcinoma by blocking mTOR signaling pathway.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Homo sapiens	211-215
25701378-0	2015	Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.	Sirolimus	39-48	AKT serine/threonine kinase 1	Homo sapiens	92-95
25701378-8	2015	Our results suggest that celecoxib-mediated upregulation of Cbl-b is responsible, at least in part, for the additive antitumor effect of celecoxib and rapamycin via inhibition of rapamycin-induced Akt activation.	Sirolimus	151-160	AKT serine/threonine kinase 1	Homo sapiens	197-200
25701378-5	2015	We further show that combined treatment with celecoxib and rapamycin results in an additive inhibitory effect on the growth of gastric cancer cells through suppression of rapamycin-induced Akt activation.	Sirolimus	59-68	AKT serine/threonine kinase 1	Homo sapiens	189-192
25701378-8	2015	Our results suggest that celecoxib-mediated upregulation of Cbl-b is responsible, at least in part, for the additive antitumor effect of celecoxib and rapamycin via inhibition of rapamycin-induced Akt activation.	Sirolimus	179-188	AKT serine/threonine kinase 1	Homo sapiens	197-200
26104664-6	2015	RESULTS: Comparison of the acetylcholine-induced relaxation revealed a significant concentration-dependent decrease to 66 +- 7 % and 36 +- 7 % (mean +- SEM) after 20-h incubation with 1 and 10 muM rapamycin.	Sirolimus	197-206	latexin	Homo sapiens	193-196
26071984-3	2015	A number of studies have indicated that the mTOR inhibitors everolimus and sirolimus suppress cell proliferation and tumor growth in animal models of HCC.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Homo sapiens	44-48
26104664-8	2015	Western blots after 20-h incubation with rapamycin (10 nM-1 muM) revealed a significant and concentration-dependent reduction of p (Ser 1177)-eNOS (down to 38 +- 8 %) in human mammary epithelial cells (Hmec)-1.	Sirolimus	41-50	latexin	Homo sapiens	60-63
26104664-10	2015	CONCLUSIONS: The present data suggests that 20-h exposure of ITA rings to rapamycin reduces endothelium-mediated relaxation through down-regulation of Akt-phosphorylation via the mTOR signalling axis within the ITA tissue without injuring the endothelial cell layer.	Sirolimus	74-83	AKT serine/threonine kinase 1	Homo sapiens	151-154
26104664-10	2015	CONCLUSIONS: The present data suggests that 20-h exposure of ITA rings to rapamycin reduces endothelium-mediated relaxation through down-regulation of Akt-phosphorylation via the mTOR signalling axis within the ITA tissue without injuring the endothelial cell layer.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	179-183
26061184-0	2015	Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.	Sirolimus	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	70-73
26087255-1	2015	The direct effect of immunosuppressive drugs calcineurin inhibitor (Tacrolimus, TAC) and mTOR inhibitor (Sirolimus, SRL) on B cell activation, differentiation and proliferation is not well documented.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	89-93
25961827-0	2015	AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.	Sirolimus	25-34	AKT serine/threonine kinase 1	Homo sapiens	0-3
25961827-0	2015	AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.	Sirolimus	25-34	AKT1 substrate 1	Homo sapiens	86-92
25961827-2	2015	Here, we found that activated AKT signaling is associated with rapamycin resistance in breast and colon cancers by sustained phosphorylation of the translational repressor 4E-BP1.	Sirolimus	63-72	AKT serine/threonine kinase 1	Homo sapiens	30-33
26053020-9	2015	TUSC2 inhibits mTOR activation and the latter cell lines were responsive to the mTOR inhibitor rapamycin combined with erlotinib.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
26061184-0	2015	Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	79-83
26061184-5	2015	Mechanistic investigations demonstrated that FoxO1/FoxO3a and p70S6K/4E-BP1, the molecules at downstream of Src-PI3K-Akt and mTOR signaling, were significantly suppressed by the combined use of Dasatinib and Rapamycin.	Sirolimus	208-217	forkhead box O1	Homo sapiens	45-50
26061184-5	2015	Mechanistic investigations demonstrated that FoxO1/FoxO3a and p70S6K/4E-BP1, the molecules at downstream of Src-PI3K-Akt and mTOR signaling, were significantly suppressed by the combined use of Dasatinib and Rapamycin.	Sirolimus	208-217	forkhead box O3	Homo sapiens	51-57
26061184-5	2015	Mechanistic investigations demonstrated that FoxO1/FoxO3a and p70S6K/4E-BP1, the molecules at downstream of Src-PI3K-Akt and mTOR signaling, were significantly suppressed by the combined use of Dasatinib and Rapamycin.	Sirolimus	208-217	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	108-111
26061184-5	2015	Mechanistic investigations demonstrated that FoxO1/FoxO3a and p70S6K/4E-BP1, the molecules at downstream of Src-PI3K-Akt and mTOR signaling, were significantly suppressed by the combined use of Dasatinib and Rapamycin.	Sirolimus	208-217	mechanistic target of rapamycin kinase	Homo sapiens	125-129
25649370-0	2015	Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Homo sapiens	22-51
26037126-7	2015	Treatment with rapamycin increased survival, blocked breakdown of the blood-brain barrier and brain hemorrhaging, decreased the influx of both CD4(+) and CD8(+) T cells into the brain and the accumulation of parasitized red blood cells in the brain.	Sirolimus	15-24	CD4 molecule	Homo sapiens	143-146
25907074-3	2015	Although rapamycin was originally developed as an inhibitor of T cell proliferation for preventing organ transplant rejection, its molecular target, mTOR, has been subsequently identified as a central regulator of metabolic cues that drive lineage specification in the immune system.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	149-153
26026094-7	2015	In order to evaluate the effect of rapamycin, a natural inhibitor of mTOR kinase, on S-LAM1 cells, a sulforhodamine B cell viability assay was performed with different concentrations of rapamycin.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	69-73
26902021-0	2015	Rapamycin-Mediated mTOR Inhibition Reverses Drug Resistance to Adriamycin in Colon Cancer Cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	19-23
25682989-12	2015	CNI, as well as rapamycin and methylprednisolone, inhibited the in-vitro differentiation of Tfh from naive CD4(+) T cells.	Sirolimus	16-25	CD4 molecule	Homo sapiens	107-110
25851741-6	2015	CONCLUSIONS: Sirolimus-based immunosuppression had a lower incidence of CMV infection compared with conventional prophylaxis therapy and did not increase rejection risks and mortality after liver transplantation, indicating that with the use of an mammalian target-of-rapamycin (mTOR)-inhibitor, CMV prophylaxis may be dispensable.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	248-277
25794661-0	2015	Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	58-91
25794661-5	2015	Rapamycin, an inhibitor of mTORC1 (mTOR complex 1) did not elicit apoptosis in lymphoma cells; however, the combination of rapamycin with exogenous TGF-beta1 induced apoptosis and restored TGF-beta1 dependent apoptotic machinery in several lymphoma cell lines with reduced TGF-beta sensitivity in vitro.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
25794661-5	2015	Rapamycin, an inhibitor of mTORC1 (mTOR complex 1) did not elicit apoptosis in lymphoma cells; however, the combination of rapamycin with exogenous TGF-beta1 induced apoptosis and restored TGF-beta1 dependent apoptotic machinery in several lymphoma cell lines with reduced TGF-beta sensitivity in vitro.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	148-157
25794661-5	2015	Rapamycin, an inhibitor of mTORC1 (mTOR complex 1) did not elicit apoptosis in lymphoma cells; however, the combination of rapamycin with exogenous TGF-beta1 induced apoptosis and restored TGF-beta1 dependent apoptotic machinery in several lymphoma cell lines with reduced TGF-beta sensitivity in vitro.	Sirolimus	123-132	transforming growth factor beta 1	Homo sapiens	189-198
25818165-11	2015	PI3K/Akt/mTOR inhibitor, PF-04691502 and mTOR inhibitor rapamycin enhanced the apoptosis-inducing effect of celastrol.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	41-45
25794646-11	2015	The present results demonstrated that topical 4% RPM and/or 1% MPA improved TNCB-induced AD-like lesions of NC/Nga mice by suppressing expression of Th2-related cytokines (IL-4) and Th1-related cytokines (IFN-gamma).	Sirolimus	49-52	negative elongation factor complex member C/D, Th1l	Mus musculus	182-185
25794646-11	2015	The present results demonstrated that topical 4% RPM and/or 1% MPA improved TNCB-induced AD-like lesions of NC/Nga mice by suppressing expression of Th2-related cytokines (IL-4) and Th1-related cytokines (IFN-gamma).	Sirolimus	49-52	interferon gamma	Mus musculus	205-214
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	19-29
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	vascular endothelial growth factor A	Homo sapiens	34-38
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	93-97
25989965-0	2015	Long-Term Effects of Novel Combination Coating Anti-CD34 Antibody Applied on Sirolimus-Eluting Stents.	Sirolimus	77-86	CD34 molecule	Homo sapiens	52-56
25985273-4	2015	Administration of rapamycin to Pten(ptKO) mice diminished hypertrophy.	Sirolimus	18-27	phosphatase and tensin homolog	Mus musculus	31-41
25151963-9	2015	Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	27-31
25689470-5	2015	For this purpose, we investigated the effects of two histone deacetylase (HDAC) inhibitors, suberoylanilide hydroxamic (SAHA) acid and sodium butyrate (NaB), and the m-TOR inhibitor rapamycin on cell viability and cyclin D3/CDK6 activity.	Sirolimus	182-191	RAR related orphan receptor C	Homo sapiens	168-171
26060906-8	2015	Mutations in the TSC1 and TSC2 genes that cause tuberous sclerosis lead to hyperactivation of signaling via the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	132-141	TSC complex subunit 1	Homo sapiens	17-21
25875045-5	2015	The inhibitory effect of CRFR2 signaling required cAMP production and is involved the mammalian target of rapamycine pathway, as rapamycin reversed the inhibitory effect of CRFR2 stimulation on insulin-induced glucose uptake.	Sirolimus	106-115	insulin	Homo sapiens	194-201
25875045-8	2015	Consistent with this notion, Ucn 2 reduced insulin-induced tyrosine phosphorylation of IRS-1, and treatment with rapamycin reversed the inhibitory effect of Ucn 2 on IRS-1 and Akt phosphorylation.	Sirolimus	113-122	AKT serine/threonine kinase 1	Homo sapiens	176-179
25945786-7	2015	The results obtained from a chromatin immunoprecipitation assay demonstrated that the ability of C/EBPalpha to bind to the GLUT4 gene promoter was reduced by the treatment with fisetin, which agreed well with those obtained when 3T3-L1 cells were allowed to differentiate into adipocytes in medium in the presence of rapamycin, an inhibitor for mTOR.	Sirolimus	317-326	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	123-128
25162215-0	2015	Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.	Sirolimus	25-34	neurofibromin 1	Homo sapiens	73-97
25162215-1	2015	BACKGROUND: Sirolimus is an inhibitor of mammalian target of rapamycin, which exhibits large interindividual pharmacokinetic variability.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	41-70
25162215-2	2015	We report sirolimus pharmacokinetic data collected as part of a concentration-controlled multicenter phase II clinical trial in pediatric patients with neurofibromatosis type 1.	Sirolimus	10-19	neurofibromin 1	Homo sapiens	152-176
25162215-10	2015	CONCLUSIONS: This study suggests that the age-dependent changes in sirolimus clearance can be explained by size-related increases in CYP3A metabolic capacity, most likely due to liver and intestinal growth.	Sirolimus	67-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-138
25833958-5	2015	Whereas in conventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced by Flt3L, increased mTOR1 activity renders pDCs more resistant to inhibition by rapamycin.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	58-87
25903737-7	2015	Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons.	Sirolimus	59-68	AKT serine/threonine kinase 1	Homo sapiens	100-103
25903737-7	2015	Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons.	Sirolimus	59-68	interleukin 1 beta	Homo sapiens	167-175
25833958-5	2015	Whereas in conventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced by Flt3L, increased mTOR1 activity renders pDCs more resistant to inhibition by rapamycin.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	89-93
25833958-5	2015	Whereas in conventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced by Flt3L, increased mTOR1 activity renders pDCs more resistant to inhibition by rapamycin.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	89-93
25944097-18	2015	In addition, we showed that rapamycin decreased the level of mTOR in Klf4 (-/-) MEFs, but did not restore autophagy.	Sirolimus	28-37	Kruppel-like factor 4 (gut)	Mus musculus	69-73
25942007-6	2015	Inhibition of PI3K with LY294002 and wortmannin, and of mTORC1 with rapamycin decreased flagellin-induced TNF-alpha and IL-6 expression and cell proliferation.	Sirolimus	68-77	tumor necrosis factor	Homo sapiens	106-115
25942007-6	2015	Inhibition of PI3K with LY294002 and wortmannin, and of mTORC1 with rapamycin decreased flagellin-induced TNF-alpha and IL-6 expression and cell proliferation.	Sirolimus	68-77	interleukin 6	Homo sapiens	120-124
25911189-3	2015	Considering the potent cardioprotective effect of mTOR inhibitor, rapamycin, we hypothesized that reperfusion therapy with rapamycin would reduce infarct size in the diabetic hearts through STAT3 signaling.	Sirolimus	66-75	signal transducer and activator of transcription 3	Mus musculus	190-195
25657110-7	2015	Furthermore, rapamycin, a specific inhibitor of mTOR, almost completely blocked FN-induced phosphorylation of 4E-BP1 and also partially abrogated the stimulatory effects of FN on GBC cell proliferation and invasion.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	48-52
25657110-7	2015	Furthermore, rapamycin, a specific inhibitor of mTOR, almost completely blocked FN-induced phosphorylation of 4E-BP1 and also partially abrogated the stimulatory effects of FN on GBC cell proliferation and invasion.	Sirolimus	13-22	fibronectin 1	Homo sapiens	80-82
25657110-7	2015	Furthermore, rapamycin, a specific inhibitor of mTOR, almost completely blocked FN-induced phosphorylation of 4E-BP1 and also partially abrogated the stimulatory effects of FN on GBC cell proliferation and invasion.	Sirolimus	13-22	fibronectin 1	Homo sapiens	173-175
25659819-0	2015	Rapamycin-induced G1 cell cycle arrest employs both TGF-beta and Rb pathways.	Sirolimus	0-9	transforming growth factor beta 1	Homo sapiens	52-60
25659819-6	2015	Data are provided demonstrating that G1 cell cycle arrest induced by rapamycin is due to up-regulation of TGF-beta signaling and down-regulation of Rb phosphorylation via phosphorylation of the mTORC1 substrates S6K and 4E-BP1 respectively.	Sirolimus	69-78	transforming growth factor beta 1	Homo sapiens	106-114
25659819-6	2015	Data are provided demonstrating that G1 cell cycle arrest induced by rapamycin is due to up-regulation of TGF-beta signaling and down-regulation of Rb phosphorylation via phosphorylation of the mTORC1 substrates S6K and 4E-BP1 respectively.	Sirolimus	69-78	nuclear factor kappa B subunit 1	Homo sapiens	221-226
25911189-3	2015	Considering the potent cardioprotective effect of mTOR inhibitor, rapamycin, we hypothesized that reperfusion therapy with rapamycin would reduce infarct size in the diabetic hearts through STAT3 signaling.	Sirolimus	123-132	signal transducer and activator of transcription 3	Mus musculus	190-195
25911189-7	2015	Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in the diabetic heart.	Sirolimus	0-9	signal transducer and activator of transcription 3	Mus musculus	48-53
25911189-7	2015	Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in the diabetic heart.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	67-70
25911189-12	2015	STAT3 signaling plays critical role in reducing IS and attenuates cardiomyocyte death following reperfusion therapy with rapamycin in diabetic heart.	Sirolimus	121-130	signal transducer and activator of transcription 3	Mus musculus	0-5
25576058-2	2015	We used a Panc02 pancreatic tumor cell transplant model in diet-induced obese (DIO) C57BL/6 mice to compare the effects of metformin and the direct mammalian target of rapamycin (mTOR) inhibitor rapamycin on PC growth, glucose regulation, mTOR pathway signaling, and candidate microRNA (miR) expression.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Homo sapiens	179-183
26191215-0	2015	Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
26191153-12	2015	Trend of GSH-Px and SOD activity was control group&gt;RAPA treatment group&gt;PQ group (P&lt;0.05).	Sirolimus	54-58	glutathione peroxidase 1	Rattus norvegicus	9-15
25738543-3	2015	The protein complex TSC1/2 has been reported to have an inhibitory function on mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	99-108	TSC complex subunit 1	Homo sapiens	20-26
26191215-5	2015	Western blot assay demonstrated that the mTOR pathway in Y79 cells was blocked by rapamycin.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	41-45
26191215-8	2015	Together, all these results illustrated that rapamycin induced growth inhibition of human retinoblastoma cells, and inactive of mTOR pathway and downregulation of Bmi-1 was involved in its action mechanism.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	128-132
25788584-15	2015	Blocking the mTOR pathway with rapamycin reversed these effects.	Sirolimus	31-40	mechanistic target of rapamycin	Gallus gallus	13-17
25216324-6	2015	Rapamycin treatment completely blocked the increase in p70S6K and synergistically potentiated the decrease in H3 phosphorylation upon FoxK2 knockdown.	Sirolimus	0-9	forkhead box K2	Mus musculus	134-139
25518065-8	2015	Sirolimus, a mTOR inhibitor, was commenced at 9 weeks of age following which he showed a marked improvement in his glycaemic control.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
26176526-2	2015	Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patients, especially those with extrapulmonary manifestations.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	0-29
26176526-2	2015	Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patients, especially those with extrapulmonary manifestations.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	31-35
25773262-5	2015	Treatment with rapamycin, an mTOR inhibitor, attenuated the proliferation of THP-1 cells.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
25773262-5	2015	Treatment with rapamycin, an mTOR inhibitor, attenuated the proliferation of THP-1 cells.	Sirolimus	15-24	GLI family zinc finger 2	Homo sapiens	77-82
25899445-4	2015	The mammalian target of rapamycin (mTOR) inhibitor sirolimus (SIR) is an immunosuppressant with strong antiproliferative effects, and is potentially able to stop or reduce cyst growth and preserve renal function in ADPKD.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	4-33
26390657-4	2015	With the intervention of mammalian target of rapamycin mTOR inhibitor rapamycin (100 nmol x L(-1)) , the effect of blocking mTOR signaling pathway on autophagic inhibition of emodin was observed.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	124-128
25899445-4	2015	The mammalian target of rapamycin (mTOR) inhibitor sirolimus (SIR) is an immunosuppressant with strong antiproliferative effects, and is potentially able to stop or reduce cyst growth and preserve renal function in ADPKD.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	35-39
25866192-3	2015	Here we show that gene expression for several myogenic transcription factors including Myf5, Myog and Mef2c but not MyoD and myosin heavy chain isoforms decrease when C2C12 cells are treated with rapamycin, supporting a role for mTORC1 pathway during muscle development.	Sirolimus	196-205	myocyte enhancer factor 2C	Mus musculus	102-107
25884947-6	2015	Herein, we report results of administration of rapamycin, a specific inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway, and chloroquine, a lysosomal inhibitor which reverses autophagy by accumulating in lysosomes, responsible for blocking autophagy in 20-month old VCPR155H/+ mice.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	86-117
25884947-6	2015	Herein, we report results of administration of rapamycin, a specific inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway, and chloroquine, a lysosomal inhibitor which reverses autophagy by accumulating in lysosomes, responsible for blocking autophagy in 20-month old VCPR155H/+ mice.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	119-123
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	TAR DNA binding protein	Homo sapiens	146-152
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	optineurin	Homo sapiens	264-274
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	294-300
25906314-7	2015	Further investigation showed that MTOR activation was enhanced in cilia-suppressed cells and the MTOR inhibitor rapamycin could largely reverse autophagy suppression.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	34-38
25897262-8	2015	Sirolimus and everolimus, two mTOR inhibitors, are effective in stabilizing lung function and reducing the size of chylous effusions, lymphangioleiomyo-mas, and angiomyolipomas.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	30-34
25780003-2	2015	METHODS: NMSC and peritumoral epidermis protein expression of Bcl-xL and Mcl-1 were assessed by immunohistochemistry in renal transplant recipients receiving tacrolimus or sirolimus and the general population not receiving immunosuppression.	Sirolimus	172-181	BCL2 like 1	Homo sapiens	62-68
25424831-13	2015	Treatment with the mTOR inhibitor rapamycin also diminished cellular proliferation, sprouting and AKT phosphorylation, but only in LM-LEC.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
25424831-13	2015	Treatment with the mTOR inhibitor rapamycin also diminished cellular proliferation, sprouting and AKT phosphorylation, but only in LM-LEC.	Sirolimus	34-43	AKT serine/threonine kinase 1	Homo sapiens	98-101
25906314-7	2015	Further investigation showed that MTOR activation was enhanced in cilia-suppressed cells and the MTOR inhibitor rapamycin could largely reverse autophagy suppression.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	97-101
25644152-2	2015	Rapamycin is an inhibitor of the serine/threonine protein kinase mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	65-69
25644152-9	2015	Rapamycin alone blocked the mTOR signaling pathway, whereas 3-BrPA did not potentiate this effect.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	28-32
24755936-5	2015	To begin clarifying the mechanism(s) involved in insulin resistance induced by rapamycin, we compared several aspects of liver metabolism in mice treated with DR or rapamycin for 6 months.	Sirolimus	79-88	insulin	Homo sapiens	49-56
25402866-1	2015	Rapamycin-related mTOR inhibitors (rapalogs) possess immunosuppressive and antiproliferative properties.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	18-22
25402866-5	2015	This review presents the clinical experience of rapamycin-related mTOR inhibitors in patients with TSC and summarizes their toxicity profiles in renal transplant and TSC populations.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	66-70
24902807-9	2015	Importantly, pretreatment with 3-methyladenine (autophagy inhibitor) enhanced while rapamycin (autophagy inducer) decreased the expression of LOX-1, TLR4, and P-P38 MAPK.	Sirolimus	84-93	toll-like receptor 4	Mus musculus	149-153
25354238-6	2015	Sirolimus conversion led to an increase in CD4(+)25(+++)Foxp3(+) regulatory T cells.	Sirolimus	0-9	CD4 molecule	Homo sapiens	43-46
25770080-4	2015	Rapamycin, an inhibitor of mTOR signaling, can exert neuroprotective effects in several CNS diseases.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
25770080-9	2015	Moreover, rapamycin attenuated astrocytic migration and mitigated production of inflammatory factors such as TNF-alpha and iNOS induced by astrocytes exposed to OGD/R.	Sirolimus	10-19	tumor necrosis factor	Homo sapiens	109-118
25770080-9	2015	Moreover, rapamycin attenuated astrocytic migration and mitigated production of inflammatory factors such as TNF-alpha and iNOS induced by astrocytes exposed to OGD/R.	Sirolimus	10-19	nitric oxide synthase 2	Homo sapiens	123-127
25770080-10	2015	Taken together, our findings indicated that mTOR blockade by rapamycin attenuates astrocyte migration, proliferation and production of inflammation mediators.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	44-48
25698234-5	2015	Co-treatment with inhibitors of the PI3K/Akt/p70s6k pathway (wortmannin, SH-6 and rapamycin) completely abolished the infarct-limiting effect of BNP postconditioning (BNPPost+Wi 36+-5%, BNPPost+SH-6 41+-4%, BNPPost+Rap 37+-6% vs. BNPPost 17+-2%, p&lt;0.001).	Sirolimus	82-91	natriuretic peptide B	Rattus norvegicus	145-148
25537496-4	2015	While compounds used to study mTOR signaling, such as rapamycin and related analogs, primarily inhibit mTORC1, prolonged exposure can also disrupt mTORC2 function, confounding interpretation of inhibitor studies.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	30-34
25314964-4	2015	Converging evidence has demonstrated that the NF1 tumor suppressor protein, neurofibromin, negatively regulates activity in the mammalian Target of Rapamycin pathway.	Sirolimus	148-157	neurofibromin 1	Homo sapiens	46-49
25314964-4	2015	Converging evidence has demonstrated that the NF1 tumor suppressor protein, neurofibromin, negatively regulates activity in the mammalian Target of Rapamycin pathway.	Sirolimus	148-157	neurofibromin 1	Homo sapiens	76-89
25314964-9	2015	CONCLUSIONS: This study demonstrated that sirolimus prolongs TTP by almost 4 months in patients with NF1-associated progressive PN.	Sirolimus	42-51	neurofibromin 1	Homo sapiens	101-104
25880415-16	2015	Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	94-97
25578324-11	2015	Human cerebrovascular smooth muscle cells exposed to purified NOTCH3 ectodomain upregulated BGN, DCN, and COL4A1 through mechanisms that are sensitive to rapamycin, a potent mTOR inhibitor.	Sirolimus	154-163	biglycan	Homo sapiens	92-95
25578324-11	2015	Human cerebrovascular smooth muscle cells exposed to purified NOTCH3 ectodomain upregulated BGN, DCN, and COL4A1 through mechanisms that are sensitive to rapamycin, a potent mTOR inhibitor.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	174-178
25880415-16	2015	Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	98-102
26069529-0	2015	The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
25807077-6	2015	Inhibition of mTOR by rapamycin blocked radiation-induced mTOR mitochondrial relocation and the shift of glycolysis to mitochondrial respiration, and reduced the clonogenic survival.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25807077-6	2015	Inhibition of mTOR by rapamycin blocked radiation-induced mTOR mitochondrial relocation and the shift of glycolysis to mitochondrial respiration, and reduced the clonogenic survival.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	58-62
26069529-4	2015	Consistently, inhibitors of mTOR (e.g., rapamycin, also known as sirolimus or Rapamune ) have been shown to impair mitochondrial function.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	28-32
26069529-6	2015	Sirolimus (10 muM) inhibited renal (22%, p = 0.002), hepatic (39%, p &lt; 0.001), and cardiac (42%, p = 0.005) cellular respiration.	Sirolimus	0-9	latexin	Homo sapiens	14-17
25767889-6	2015	Phosphorylation-deficient mutations in regulatory motifs of Ypk3 abrogate Rps6 phosphorylation, and complementation of ypk3Delta cells with human S6 kinase restores Rps6 phosphorylation in a rapamycin-sensitive manner.	Sirolimus	191-200	putative protein kinase YPK3	Saccharomyces cerevisiae S288C	60-64
25749036-8	2015	Mechanistically, treatment with rapamycin, a mTOR inhibitor, inhibited EMT, stem-like capacity and metastasis induced by FBXW7 silencing both in vitro and in vivo.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	45-49
25749036-8	2015	Mechanistically, treatment with rapamycin, a mTOR inhibitor, inhibited EMT, stem-like capacity and metastasis induced by FBXW7 silencing both in vitro and in vivo.	Sirolimus	32-41	F-box and WD repeat domain containing 7	Homo sapiens	121-126
25749036-9	2015	Furthermore, the expression of EMT regulating transcription factors, snail, slug and ZEB1, were also decreased markedly with rapamycin treatment.	Sirolimus	125-134	snail family transcriptional repressor 1	Homo sapiens	69-74
25410659-0	2015	Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD.	Sirolimus	62-71	sequestosome 1	Danio rerio	0-6
25410659-8	2015	Furthermore, treatment of zebrafish embryos with rapamycin, a known inhibitor of the mTOR pathway, yielded an amelioration of the locomotor phenotype in the sqstm1 knock-down model.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Danio rerio	85-89
25410659-8	2015	Furthermore, treatment of zebrafish embryos with rapamycin, a known inhibitor of the mTOR pathway, yielded an amelioration of the locomotor phenotype in the sqstm1 knock-down model.	Sirolimus	49-58	sequestosome 1	Danio rerio	157-163
25767889-6	2015	Phosphorylation-deficient mutations in regulatory motifs of Ypk3 abrogate Rps6 phosphorylation, and complementation of ypk3Delta cells with human S6 kinase restores Rps6 phosphorylation in a rapamycin-sensitive manner.	Sirolimus	191-200	putative protein kinase YPK3	Saccharomyces cerevisiae S288C	119-128
25884175-8	2015	Different dosages of p-Akt inhibitor LY294002 (12.5 muM, 25 muM, 50 muM) and p-mTOR inhibitor Rapamycin (25 nM, 50 nM, 100 nM) were given to gastric cancer cell line SGC-7901 in vitro.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	79-83
25482865-0	2015	Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	0-29
25482865-1	2015	The mammalian target of rapamycin (mTOR) inhibitor sirolimus is effective in reducing incidence of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	4-33
25482865-1	2015	The mammalian target of rapamycin (mTOR) inhibitor sirolimus is effective in reducing incidence of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	35-39
25466898-7	2015	Inhibition of mTOR complex 1 (mTORC1) by rapamycin [drug concentration causing 50% inhibition (IC50) = 5 nM] and mTORC1/mTORC2 by Torin2 (IC50 = 6 nM), or by knocking down key mTORC1/2 components, Raptor and Rictor, respectively, decreased directional cell migration toward CXCL12.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25599164-2	2015	Although sirolimus is being used increasingly for the prevention of GVHD, it is a substrate of CYP3A4, which is inhibited by voriconazole, and concurrent administration can lead to significantly increased exposure to sirolimus.	Sirolimus	9-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
25599164-2	2015	Although sirolimus is being used increasingly for the prevention of GVHD, it is a substrate of CYP3A4, which is inhibited by voriconazole, and concurrent administration can lead to significantly increased exposure to sirolimus.	Sirolimus	217-226	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
25586480-5	2015	In vitro and in vivo experiments with the mTOR inhibitor sirolimus plus gemcitabine showed dramatic results in preclinical models of sarcoma.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	42-46
25643582-5	2015	Inhibition of the insulin/IGF-1 signaling system through genetic deletion of the insulin receptor alone or in combination with the IGF-1 receptor or treatment with rapamycin prevented hyperphosphorylation of S6RP without affecting the mitochondrial structural defect, alleviated renal disease, and delayed the onset of kidney failure in PHB2-deficient animals.	Sirolimus	164-173	insulin	Homo sapiens	18-25
25643582-5	2015	Inhibition of the insulin/IGF-1 signaling system through genetic deletion of the insulin receptor alone or in combination with the IGF-1 receptor or treatment with rapamycin prevented hyperphosphorylation of S6RP without affecting the mitochondrial structural defect, alleviated renal disease, and delayed the onset of kidney failure in PHB2-deficient animals.	Sirolimus	164-173	insulin like growth factor 1	Homo sapiens	26-31
26011354-3	2015	Rapamycin, as an inhibitor of mTOR, has been developed as potentially valuable therapeutic agent.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	30-34
25814705-7	2015	Sirolimus belongs to a novel class of anticancer drugs known as mTOR (mammalian target of Rapamycin) inhibitors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	64-68
25814705-7	2015	Sirolimus belongs to a novel class of anticancer drugs known as mTOR (mammalian target of Rapamycin) inhibitors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	70-99
25814705-8	2015	Sirolimus has been used as a targeted therapy for the renal and neurological manifestations of TSC.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	95-98
26045804-0	2015	The mTOR inhibitor sirolimus suppresses renal, hepatic, and cardiac tissue cellular respiration.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26045804-4	2015	Consistently, inhibitors of mTOR (e.g., rapamycin, also known as sirolimus or Rapamune ) have been shown to impair mitochondrial function.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	28-32
26045804-6	2015	Sirolimus (10 muM) inhibited renal (22%, P=0.002), hepatic (39%, P&lt;0.001), and cardiac (42%, P=0.005) cellular respiration.	Sirolimus	0-9	latexin	Homo sapiens	14-17
25457208-8	2015	Moreover, ethanol (100 mM) and acetaldehyde (100 and 500 muM) increased levels of IL-6 and IFN-gamma, and suppressed autophagy in VA-13 cells, effects which were markedly alleviated by rapamycin.	Sirolimus	185-194	interferon gamma	Homo sapiens	91-100
25404086-0	2015	Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-beta signalling pathway in kidney transplant.	Sirolimus	49-58	transforming growth factor beta 1	Homo sapiens	111-142
25404086-3	2015	This study attempted to examine the histological aspect of interstitial fibrosis and the modulation of the transforming growth factor-beta (TGF-beta) canonical signalling pathway following early withdrawal of CNI from sirolimus-based immunosuppressive therapy.	Sirolimus	218-227	transforming growth factor beta 1	Homo sapiens	107-138
25404086-3	2015	This study attempted to examine the histological aspect of interstitial fibrosis and the modulation of the transforming growth factor-beta (TGF-beta) canonical signalling pathway following early withdrawal of CNI from sirolimus-based immunosuppressive therapy.	Sirolimus	218-227	transforming growth factor beta 1	Homo sapiens	140-148
25404086-13	2015	On the other hand, the removal of CNI with increase in the dose of sirolimus limited the enhancement of the chronicity index at 12 m (SRL, 2.18 vs TAC, 3.12, P = 0.0007), diminished the deposition of fibrosis and promoted the stabilization of TGF-beta, TGF-beta-R2, p-Smad2/3 and myofibroblasts as well as the reduction of TGF-beta-R1 (P = 0.01).	Sirolimus	67-76	transforming growth factor beta 1	Homo sapiens	243-251
25404086-13	2015	On the other hand, the removal of CNI with increase in the dose of sirolimus limited the enhancement of the chronicity index at 12 m (SRL, 2.18 vs TAC, 3.12, P = 0.0007), diminished the deposition of fibrosis and promoted the stabilization of TGF-beta, TGF-beta-R2, p-Smad2/3 and myofibroblasts as well as the reduction of TGF-beta-R1 (P = 0.01).	Sirolimus	67-76	transforming growth factor beta 1	Homo sapiens	253-261
25404086-13	2015	On the other hand, the removal of CNI with increase in the dose of sirolimus limited the enhancement of the chronicity index at 12 m (SRL, 2.18 vs TAC, 3.12, P = 0.0007), diminished the deposition of fibrosis and promoted the stabilization of TGF-beta, TGF-beta-R2, p-Smad2/3 and myofibroblasts as well as the reduction of TGF-beta-R1 (P = 0.01).	Sirolimus	67-76	transforming growth factor beta 1	Homo sapiens	253-261
25527453-7	2015	In KYO-1 cells where Akt is not constitutively active, Mnk inhibitors increase the sensitivity of cells to rapamycin, resulting in a more pronounced anti-proliferative activity.	Sirolimus	107-116	AKT serine/threonine kinase 1	Homo sapiens	21-24
25663935-8	2015	Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA-MB-231 cells, which were resistant to rapamycin-induced inhibition.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	67-96
25327687-9	2015	Rapamycin also synergized with PSMA ADC in certain settings.	Sirolimus	0-9	folate hydrolase 1	Homo sapiens	31-35
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	44-48
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25738366-9	2015	However, silencing mTOR or mLST8 mimicked the effect of rapamycin, inhibiting mSin1 phosphorylation.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	19-23
25738366-9	2015	However, silencing mTOR or mLST8 mimicked the effect of rapamycin, inhibiting mSin1 phosphorylation.	Sirolimus	56-65	MTOR associated protein, LST8 homolog (S. cerevisiae)	Mus musculus	27-32
25738366-10	2015	Our findings suggest that rapamycin inhibits mSin1 phosphorylation, which is independent of mTORC1 and mTORC2, but is possibly dependent on a new mTOR complex, which at least contains mTOR and mLST8.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	103-107
25738366-10	2015	Our findings suggest that rapamycin inhibits mSin1 phosphorylation, which is independent of mTORC1 and mTORC2, but is possibly dependent on a new mTOR complex, which at least contains mTOR and mLST8.	Sirolimus	26-35	MTOR associated protein, LST8 homolog (S. cerevisiae)	Mus musculus	193-198
25663111-2	2015	Mip exhibits peptidyl prolyl cistrans isomerase (PPIase) activity, which can be inhibited by Rapamycin and FK506.	Sirolimus	93-102	major intrinsic protein of lens fiber	Homo sapiens	0-3
24632604-9	2015	Long-term treatment with rapamycin reduced both Akt and mTORC1 activity in normal kidney tissues and blocked the development of all types of renal lesions.	Sirolimus	25-34	thymoma viral proto-oncogene 1	Mus musculus	48-51
24632604-10	2015	In conclusion, in contrast to previous studies, we found that Akt signalling is not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR pathway, rapamycin is highly effective in preventing Tsc-associated tumours.	Sirolimus	181-190	thymoma viral proto-oncogene 1	Mus musculus	163-166
25646773-9	2015	However, liver TG levels were significantly reduced in the Tsc1-/-;Pten-/- mice compared to the Pten-/- mice, which was restored with rapamycin.	Sirolimus	134-143	phosphatase and tensin homolog	Mus musculus	67-71
25428129-7	2015	Inhibition of mTOR with rapamycin partially suppressed the phosphorylation of PERK and eIF2a and the induction of CHOP and GRP78 induction during tunicamycin treatment.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25673929-0	2015	Synergistic Inhibition of Tumor Necrosis Factor-Alpha-Stimulated Pro-Inflammatory Cytokine Expression in HaCaT Cells by a Combination of Rapamycin and Mycophenolic Acid.	Sirolimus	137-146	tumor necrosis factor	Homo sapiens	26-53
25428129-7	2015	Inhibition of mTOR with rapamycin partially suppressed the phosphorylation of PERK and eIF2a and the induction of CHOP and GRP78 induction during tunicamycin treatment.	Sirolimus	24-33	DNA damage inducible transcript 3	Homo sapiens	114-118
25428129-7	2015	Inhibition of mTOR with rapamycin partially suppressed the phosphorylation of PERK and eIF2a and the induction of CHOP and GRP78 induction during tunicamycin treatment.	Sirolimus	24-33	heat shock protein family A (Hsp70) member 5	Homo sapiens	123-128
25456069-1	2015	The involvement of mammalian target of rapamycin (mTOR) in lifespan control in invertebrates, calorie-restricted rodents, and extension of mouse lifespan by rapamycin have prompted speculation that diminished mTOR function may contribute to mammalian longevity in several settings.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25687356-0	2015	Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	50-54
25687356-2	2015	This phase II trial was designed to evaluate the safety and clinical activity of daily oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in combination with trastuzumab in HER2-positive metastatic breast cancer following disease progression on prior trastuzumab therapy.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	105-134
25687356-2	2015	This phase II trial was designed to evaluate the safety and clinical activity of daily oral sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in combination with trastuzumab in HER2-positive metastatic breast cancer following disease progression on prior trastuzumab therapy.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	136-140
25687356-12	2015	Sirolimus 6 mg administered daily with trastuzumab appears to be well tolerated in patients with metastatic HER2-positive breast cancer following disease progression on prior trastuzumab therapy, with evidence of disease activity.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-112
26225230-5	2015	Simulated clearance estimates with a sirolimus physiologically based pharmacokinetic model that included CYP3A4/5/7 and CYP2C8 maturation profiles were in close agreement with observed in vivo clearance values.	Sirolimus	37-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111
25673186-0	2015	Rapamycin protects cardiomyocytes against anoxia/reoxygenation injury by inducing autophagy through the PI3k/Akt pathway.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	109-112
25673186-7	2015	It is concluded that Rapamycin has a cardioprotection effect by inducing autophagy in a concentration-dependent manner against apopotosis through PI3K/Akt signaling pathway during A/R in NRVM.	Sirolimus	21-30	AKT serine/threonine kinase 1	Rattus norvegicus	151-154
25304685-5	2015	Depletion of DAPK3 enhanced growth factor-dependent mTOR activation and, furthermore, enlarged DAPK3 acini structures were uniquely sensitive to low doses of rapamycin.	Sirolimus	158-167	death-associated protein kinase 3	Mus musculus	13-18
25503302-3	2015	Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the phosphoinositide 3-Kinase signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	19-48
25503302-3	2015	Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the phosphoinositide 3-Kinase signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25304685-5	2015	Depletion of DAPK3 enhanced growth factor-dependent mTOR activation and, furthermore, enlarged DAPK3 acini structures were uniquely sensitive to low doses of rapamycin.	Sirolimus	158-167	death-associated protein kinase 3	Mus musculus	95-100
25581066-7	2015	Rapamycin-induced suppression of mTOR activity during the early postnatal period enhanced not only autophagy but also developmental reduction of myelinating Schwann cells cytoplasm in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	33-37
25590801-7	2015	Inhibition of mTORC1 by rapamycin restores Akt activity in eIF2alphaP-deficient cells but renders them highly susceptible to Akt-mediated death by oxidative stress.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	43-46
25571970-8	2015	Furthermore, the mTOR inhibitor rapamycin increased iso-GNA-induced cell death by enhancing autophagy.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	17-21
25442674-7	2015	Rapamycin (sirolimus) and its analogs known as rapalogues, such as RAD001 (everolimus) and CCI-779 (temsirolimus), suppress mTOR activity through an allosteric mechanism that acts at a distance from the ATP-catalytic binding site, and are considered incomplete inhibitors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	124-128
25442674-7	2015	Rapamycin (sirolimus) and its analogs known as rapalogues, such as RAD001 (everolimus) and CCI-779 (temsirolimus), suppress mTOR activity through an allosteric mechanism that acts at a distance from the ATP-catalytic binding site, and are considered incomplete inhibitors.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Homo sapiens	124-128
26517816-10	2015	In ex-vivo study, LPS induced prominent production of IL-1beta and MCP-1 in cultured RAW264.7 cells, which was significantly suppressed by rapamycin.	Sirolimus	139-148	interleukin 1 beta	Mus musculus	54-62
26517816-10	2015	In ex-vivo study, LPS induced prominent production of IL-1beta and MCP-1 in cultured RAW264.7 cells, which was significantly suppressed by rapamycin.	Sirolimus	139-148	mast cell protease 1	Mus musculus	67-72
25714412-4	2015	Here, we report on the induction of autophagy initiated by the pathogen receptor HSP90AA1 (heat shock protein 90 kDa alpha [cytosolic], class A member 1) via the AKT-MTOR (mechanistic target of rapamycin)-dependent pathway.	Sirolimus	194-203	AKT serine/threonine kinase 1	Homo sapiens	162-165
25714412-4	2015	Here, we report on the induction of autophagy initiated by the pathogen receptor HSP90AA1 (heat shock protein 90 kDa alpha [cytosolic], class A member 1) via the AKT-MTOR (mechanistic target of rapamycin)-dependent pathway.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Homo sapiens	166-170
25759780-11	2015	RESULTS: TGF-beta and TNF-alpha values in the sirolimus group were found to be statistically significantly lower than in the control and colchicine groups, but the differences between the control and colchicine groups were not statistically significant.	Sirolimus	46-55	transforming growth factor, beta 1	Rattus norvegicus	9-17
25759780-11	2015	RESULTS: TGF-beta and TNF-alpha values in the sirolimus group were found to be statistically significantly lower than in the control and colchicine groups, but the differences between the control and colchicine groups were not statistically significant.	Sirolimus	46-55	tumor necrosis factor	Rattus norvegicus	22-31
25918725-0	2015	Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite Formation In Vitro.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
26521828-1	2015	We previously demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), protects against N-methyl-D-aspartic acid (NMDA)-induced retinal neurotoxicity, but the mechanism underlying this protection is not fully understood.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	63-92
26521828-1	2015	We previously demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), protects against N-methyl-D-aspartic acid (NMDA)-induced retinal neurotoxicity, but the mechanism underlying this protection is not fully understood.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	94-98
25791172-6	2015	This sequence of events could be prevented by pretreatment with rapamycin (mTOR inhibition) or metformin (enzyme 5"-AMP-activated protein kinase activation).	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	75-79
26583091-3	2015	In many cases, autophagy is regulated by the phosphatidylinositol 3-phosphate kinase/AKT/mammalian target of rapamycin/p70 ribosomal protein S6 kinase (PI3K/AKT/mTOR/p70S6K) signaling pathway.	Sirolimus	109-118	AKT serine/threonine kinase 1	Homo sapiens	85-88
26583091-3	2015	In many cases, autophagy is regulated by the phosphatidylinositol 3-phosphate kinase/AKT/mammalian target of rapamycin/p70 ribosomal protein S6 kinase (PI3K/AKT/mTOR/p70S6K) signaling pathway.	Sirolimus	109-118	AKT serine/threonine kinase 1	Homo sapiens	157-160
26583091-3	2015	In many cases, autophagy is regulated by the phosphatidylinositol 3-phosphate kinase/AKT/mammalian target of rapamycin/p70 ribosomal protein S6 kinase (PI3K/AKT/mTOR/p70S6K) signaling pathway.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	161-165
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	24-53
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	55-59
24882386-9	2015	Sirolimus and everolimus decreased the tumor necrosis factor (TNF)-alpha-induced adhesion of neutrophils to human endothelial cells and human extracellular matrix.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	39-72
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	C-X-C motif chemokine ligand 8	Homo sapiens	161-165
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	vascular endothelial growth factor A	Homo sapiens	186-220
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	vascular endothelial growth factor A	Homo sapiens	222-226
25945415-3	2015	Suppression of mTOR predominantly causes G1 cell cycle arrest, which likely contributes to the ineffectiveness of rapamycin-based therapeutic strategies.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	15-19
26017929-11	2015	Pre-treatment with rapamycin significantly inhibited leptin effects in LD formation, COX-2 and TGF-beta production in IEC-6 cells.	Sirolimus	19-28	transforming growth factor, beta 1	Rattus norvegicus	95-103
24835482-3	2015	Here we isolated mesenchymal stem cells from human hair follicles (HF-MSCs) and engineered them to overexpress the human insulin gene and release human insulin in a time- and dose-dependent manner in response to rapamycin.	Sirolimus	212-221	insulin	Homo sapiens	121-128
26115221-3	2015	Cells pretreated with rapamycin before exposure to HG showed significant decrease phosphorylation of CREB, increase in AMPK activity and decrease protein/mRNA and promoter activity of fibronectin.	Sirolimus	22-31	cAMP responsive element binding protein 1	Mus musculus	101-105
26115221-7	2015	Furthermore, db/db mice treated with rapamycin showed significant increase in AMPK activity, decrease in expression of p-CREB and protein/mRNA of fibronectin.	Sirolimus	37-46	cAMP responsive element binding protein 1	Mus musculus	121-125
26323019-6	2015	However, AICAR also suppresses production of phosphatidic acid (PA), which interacts with mTOR in a manner that is competitive with rapamycin.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	90-94
26323019-7	2015	The reduced level of PA sensitizes mTORC2 to rapamycin at tolerable nano-molar doses leading reduced Akt phosphorylation and apoptosis.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	101-104
24835482-3	2015	Here we isolated mesenchymal stem cells from human hair follicles (HF-MSCs) and engineered them to overexpress the human insulin gene and release human insulin in a time- and dose-dependent manner in response to rapamycin.	Sirolimus	212-221	insulin	Homo sapiens	152-159
25714699-5	2015	This is the reason to consider the mTOR inhibitors such as rapamycin analogs as an encouraging therapy for malignant glioma, but current investigations suggest that single inhibition of mTOR may be insufficient.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	35-39
25591762-7	2015	In cultured renal fibroblasts, overexpression of AMPKalpha1D157A upregulated mTOR signaling and matrix synthesis, which were ameliorated by co-treatment with the inhibitor of mTOR, rapamycin.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	77-81
25314592-5	2015	Rapamycin, the prototypical inhibitor of the mTOR signaling pathway, has recently emerged as an effective treatment for KS when administered orally.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	45-49
25145583-5	2015	Combined treatment with rapamycin and 4EBP1A4 completely inhibited AKT/Ras hepatocarcinogenesis.	Sirolimus	24-33	thymoma viral proto-oncogene 1	Mus musculus	67-70
26351512-6	2015	Interestingly, auraptene induces an increase in the phosphorylation of Akt, which is reminiscent of the effect of rapamycin, the mTOR inhibitor that triggers a negative feedback loop on Akt/mTOR pathway.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	71-74
26351512-6	2015	Interestingly, auraptene induces an increase in the phosphorylation of Akt, which is reminiscent of the effect of rapamycin, the mTOR inhibitor that triggers a negative feedback loop on Akt/mTOR pathway.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	129-133
26351512-6	2015	Interestingly, auraptene induces an increase in the phosphorylation of Akt, which is reminiscent of the effect of rapamycin, the mTOR inhibitor that triggers a negative feedback loop on Akt/mTOR pathway.	Sirolimus	114-123	AKT serine/threonine kinase 1	Homo sapiens	186-189
26351512-6	2015	Interestingly, auraptene induces an increase in the phosphorylation of Akt, which is reminiscent of the effect of rapamycin, the mTOR inhibitor that triggers a negative feedback loop on Akt/mTOR pathway.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Homo sapiens	190-194
25171343-4	2015	The experimental results showed that after spinal cord injury, rapamycin reduced the numbers of activated microglia and neutrophils in the damage zone, lowered the expression levels of TNF-alpha and IL-1beta, reduced the apoptotic cells, and increased the survival of neurons.	Sirolimus	63-72	tumor necrosis factor	Homo sapiens	185-194
25171343-4	2015	The experimental results showed that after spinal cord injury, rapamycin reduced the numbers of activated microglia and neutrophils in the damage zone, lowered the expression levels of TNF-alpha and IL-1beta, reduced the apoptotic cells, and increased the survival of neurons.	Sirolimus	63-72	interleukin 1 beta	Homo sapiens	199-207
25976336-1	2015	OBJECTIVE: This study aimed to investigate the efficacy of combination of rapamycin, an mammalian target of rapamycin (mTOR) inhibitor for treating rejection after organ transplantation, and oxaliplatin, a third-generation of platinum drug usually used to treat chemoresistant or progressive ovarian cancer, in cisplatin-resistant ovarian carcinoma cells A2780cis.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	88-117
24950765-7	2015	Rapamycin treatment reduced the left ventricular ejection fraction to 23.5% (P &lt; .05), and the collagen volume fraction of the ISO and ISO plus rapamycin groups was 5.9% and 25.9%, respectively, in TLR4 KO mice.	Sirolimus	0-9	toll-like receptor 4	Mus musculus	201-205
24950765-8	2015	Compared with the WT mice, Beclin 1 and autophagy were downregulated in TLR4 KO mice (P &lt; .05); however, the ISO plus rapamycin group had higher autophagy activity than did the ISO group in TLR4 KO mice (P &lt; .05).	Sirolimus	121-130	toll-like receptor 4	Mus musculus	193-197
25976336-8	2015	Rapamycin slightly induced cell apoptosis but significantly enhanced the effect of oxaliplatin in soliciting apoptosis of A2780cis cells, which might be ascribed to its ability in further increasing the levels of cleaved caspase-8 and -3 and PARP induced by oxaliplatin.	Sirolimus	0-9	poly(ADP-ribose) polymerase 1	Homo sapiens	242-246
25976336-1	2015	OBJECTIVE: This study aimed to investigate the efficacy of combination of rapamycin, an mammalian target of rapamycin (mTOR) inhibitor for treating rejection after organ transplantation, and oxaliplatin, a third-generation of platinum drug usually used to treat chemoresistant or progressive ovarian cancer, in cisplatin-resistant ovarian carcinoma cells A2780cis.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	119-123
25069858-10	2015	Furthermore, rapamycin augmented MG-132-induced activation of extracellular signal-regulated kinases 1 and 2, which are involved in the regulation of cell death and survival.	Sirolimus	13-22	mitogen-activated protein kinase 3	Homo sapiens	62-108
25797293-6	2015	Gene expression analysis revealed that transcript abundance of Beclin 1 and microtubule-associated protein 1 light chain 3 mRNAs was significantly increased in MPCOCs by rapamycin relative to the control.	Sirolimus	170-179	beclin 1	Sus scrofa	63-71
25277143-7	2015	Rapamycin, a specific mTOR inhibitor, significantly reversed the inhibitory effect of IFN-gamma on nonopsonized phagocytosis of macrophages and restored c/EBPbeta and MARCO expression.	Sirolimus	0-9	interferon gamma	Mus musculus	86-95
25559956-17	2015	CONCLUSIONS: This study demonstrates that RAPA treatment effectively suppresses PQ-induced alveolar collapse and collagen deposition in lung tissues through reducing the expression of TGF-beta1 and alpha-SMA.	Sirolimus	42-46	actin alpha 2, smooth muscle, aorta	Mus musculus	198-207
26237681-2	2015	Still, rapamycin derivatives may activate a pro-survival feedback loop through PI3K-Akt.	Sirolimus	7-16	AKT serine/threonine kinase 1	Homo sapiens	84-87
25653476-0	2015	Rapamycin improves palmitate-induced ER stress/NF kappa B pathways associated with stimulating autophagy in adipocytes.	Sirolimus	0-9	nuclear factor kappa B subunit 1	Homo sapiens	47-57
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	DNA damage inducible transcript 3	Homo sapiens	145-149
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 8	Homo sapiens	155-158
25653476-9	2015	Furthermore, rapamycin decreased PA-induced nuclear translocation of NFkappaB P65 subunit, thereby NFkappaB-dependent inflammatory cytokines MCP-1 and IL-6 expression and secretion.	Sirolimus	13-22	nuclear factor kappa B subunit 1	Homo sapiens	69-77
25653476-9	2015	Furthermore, rapamycin decreased PA-induced nuclear translocation of NFkappaB P65 subunit, thereby NFkappaB-dependent inflammatory cytokines MCP-1 and IL-6 expression and secretion.	Sirolimus	13-22	interleukin 6	Homo sapiens	151-155
25653476-10	2015	In conclusion, rapamycin attenuated PA-induced ER stress/NFkappaB pathways to counterbalance adipocytes stress and inflammation.	Sirolimus	15-24	nuclear factor kappa B subunit 1	Homo sapiens	57-65
25240598-5	2015	APRPG-TEPA-PCL/si-mTOR treatment did not induce Akt phosphorylation (Ser473) in either B16F10 or 2H-11 cells although there was strong phosphorylation of Akt in response to rapamycin treatment.	Sirolimus	173-182	thymoma viral proto-oncogene 1	Mus musculus	154-157
26278147-7	2015	Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8, -3, and PARP compared to those treated with topotecan alone.	Sirolimus	40-49	poly(ADP-ribose) polymerase 1	Homo sapiens	126-130
25034463-7	2015	We measured the activity of mammalian target of rapamycin (mTOR) in the pilocarpine rat model pretreated with the mTOR-specific inhibitor, rapamycin, and SB-399885 using western blotting.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	59-63
26652669-5	2015	Rapamycin treatment induced the upregulation of cytokine genes, including those from the Interleukin (IL)-6 signaling network, such as IL-8 and the Leukemia Inhibitory Factor (LIF), while quiescent fibroblasts demonstrated up-regulation of genes involved in the complement and coagulation cascade.	Sirolimus	0-9	interleukin 6	Homo sapiens	89-107
26770837-2	2015	Previous studies have suggested that rapamycin (an mTOR inhibitor) can attenuate nociceptive behaviors in many pain models, most likely at the spinal cord level.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	51-55
26652669-5	2015	Rapamycin treatment induced the upregulation of cytokine genes, including those from the Interleukin (IL)-6 signaling network, such as IL-8 and the Leukemia Inhibitory Factor (LIF), while quiescent fibroblasts demonstrated up-regulation of genes involved in the complement and coagulation cascade.	Sirolimus	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	135-139
25340604-0	2015	Rapamycin protection of livers from ischemia and reperfusion injury is dependent on both autophagy induction and mammalian target of rapamycin complex 2-Akt activation.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	153-156
25478892-1	2015	Rapamycin, an inhibitor of mTOR activity, is a potent inducer of erythroid differentiation and fetal hemoglobin production in beta-thalassemic patients.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-31
25340604-6	2015	The treatment with RPM, but not Torin 1, resulted in the enhanced activation of the mTORC2-Akt signaling pathway activation in livers after reperfusion.	Sirolimus	19-22	AKT serine/threonine kinase 1	Homo sapiens	91-94
25340604-9	2015	Rapamycin, but not Trin 1, protected hepatocytes from stress and tumor necrosis factor-alpha induced cell death; and inhibition of autophagy by chloroquine or Akt by Triciribine abolished RPM-mediated cytoprotection.	Sirolimus	188-191	AKT serine/threonine kinase 1	Homo sapiens	159-162
25340604-10	2015	CONCLUSION: Rapamycin protected livers from IRI by both autophagy and mTORC2-Akt activation mechanisms.	Sirolimus	12-21	AKT serine/threonine kinase 1	Homo sapiens	77-80
25801056-6	2015	Perifosine or rapamycin almost abolished the decrease of the Ces1d and Ces1e expression and the hydrolytic activity induced by the insulin in the primary mouse hepatocytes.	Sirolimus	14-23	insulin	Homo sapiens	131-138
25587030-9	2014	Either MEK or mTOR was sufficient to phosphorylate these PMA-induced rapamycin-resistant sites because co-treatment with U0126 and rapamycin was required to abrogate them.	Sirolimus	69-78	mitogen-activated protein kinase kinase 7	Homo sapiens	7-10
25587030-9	2014	Either MEK or mTOR was sufficient to phosphorylate these PMA-induced rapamycin-resistant sites because co-treatment with U0126 and rapamycin was required to abrogate them.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25453101-10	2014	On the other hand, rapamycin treatment leads to transient appearance of monomeric mTORC1 before complete disruption of the mTOR-raptor interaction, whereas mTORC2 stoichiometry is unaffected.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	82-86
25546383-3	2014	In the current study, we find that cytosolic FoxO1 indeed stimulates cellular autophagy in multiple cancer cell lines, and that it regulates not only basal autophagy but also that induced by rapamycin and that in response to nutrient deprivation.	Sirolimus	191-200	forkhead box O1	Homo sapiens	45-50
25552900-8	2015	Additionally, mTOR inhibitors (everolimus/sirolimus) were applied since 2003.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25628925-4	2015	In the present study, we describe that AZD2014, a small molecular ATP-competitive inhibitor of mTOR, was a highly potent inhibitor of mTORC1 and mTORC2 in human HCC cells, which led to a more thorough inhibition of mTORC1 than rapamycin, and the inhibition of mTORC2 prevented the feedback activation of AKT signaling.	Sirolimus	227-236	mechanistic target of rapamycin kinase	Homo sapiens	95-99
25514416-8	2014	Incubation of cells with rapamycin, a known inhibitor of mTOR kinase activity, increased the total Edc4 protein expression but at the same time decreased the Edc4 interaction with mTORC1.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	57-61
25445040-3	2014	Specific inhibitors of growth-related signal transducers, such as AG1478, LY294002, PD98059, and rapamycin, completely abolished IL-1beta-stimulated hepatocyte DNA synthesis and proliferation.	Sirolimus	97-106	interleukin 1 beta	Homo sapiens	129-137
25388971-7	2014	Rapamycin, an mTOR inhibitor, blocked osteogenic differentiation induced by IGF-1.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25156122-2	2014	New data now show elevated ATF4 levels, and elevation of ATF4-dependent proteins and mRNAs, in liver of mice treated with acarbose or rapamycin, calorically restricted mice, methionine-restricted mice, and mice subjected to litter crowding.	Sirolimus	134-143	activating transcription factor 4	Mus musculus	57-61
24879590-6	2014	The cell invasiveness induced by LKB1 loss was nearly suppressed by mammalian target of rapamycin (mTOR) inhibitor (rapamycin and everolimus) and mTOR/AKT dual inhibitor Palomid 529 (P529).	Sirolimus	88-97	mechanistic target of rapamycin kinase	Homo sapiens	99-103
25388971-7	2014	Rapamycin, an mTOR inhibitor, blocked osteogenic differentiation induced by IGF-1.	Sirolimus	0-9	insulin like growth factor 1	Homo sapiens	76-81
25489805-1	2014	OBJECTIVES: The mammalian target of rapamycin inhibitors sirolimus and everolimus are immunosuppressive drugs for kidney transplant patients, but adverse events may include proteinuria.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	16-45
25580270-4	2014	The major development in the treatment of LAM is the discovery of two mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, as effective drugs.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	70-99
25199529-2	2014	Rapamycin, an inhibitor of the mTOR pathway, has been shown in a landmark clinical trial to halt the decline in lung function, as long as it is used continuously.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	31-35
25580270-4	2014	The major development in the treatment of LAM is the discovery of two mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, as effective drugs.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Homo sapiens	101-105
25580270-7	2014	Another consequence of mTOR inhibition by sirolimus is an increase in Rho activity, resulting in reduced programmed cell death.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Homo sapiens	23-27
25580270-8	2014	From these data, the concept evolved that a combination of sirolimus with disruption of Rho activity with statins (e.g. simvastatin) may increase TSC-null cell death and reduce LAM cell survival.	Sirolimus	59-68	TSC complex subunit 1	Homo sapiens	146-149
25060812-7	2014	Furthermore, such crosstalk was also noted in an in vivo context, after mTOR inhibition by rapamycin treatment of perinatal pups.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Homo sapiens	72-76
24375594-0	2014	The immunosuppressant tributyltin oxide blocks the mTOR pathway, like rapamycin, albeit by a different mechanism.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	51-55
25347473-5	2014	Indeed, treatment with the clinically available mTOR inhibitor rapamycin suppressed the growth of cancer cells in which PRL was overexpressed.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	48-52
25480578-0	2014	Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1beta in the rat spinal cord.	Sirolimus	0-9	interleukin 1 beta	Rattus norvegicus	78-95
25480578-6	2014	Our results showed that rapamycin could ameliorate neuropathic pain by activating autophagy and inhibiting IL-1beta in the spinal cord.	Sirolimus	24-33	interleukin 1 beta	Rattus norvegicus	107-115
25531195-0	2014	Lung injury associated with mTOR inhibitors (sirolimus and everolimus).	Sirolimus	45-54	mechanistic target of rapamycin kinase	Homo sapiens	28-32
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	NFE2 like bZIP transcription factor 2	Homo sapiens	171-214
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	NFE2 like bZIP transcription factor 2	Homo sapiens	216-220
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	233-252
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	nuclear receptor subfamily 1 group I member 2	Homo sapiens	254-258
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	UDP glucuronosyltransferase family 1 member A10	Homo sapiens	288-295
25289568-7	2014	The FRB also binds the mTOR inhibitor rapamycin that has been referred to as an allosteric inhibitor, implying that this inhibitor is actually a competitive inhibitor of the protein substrate.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Homo sapiens	23-27
25310356-7	2014	Moreover, the cells treated with the combination of the two agents exhibited significantly decreased protein levels of phosphorylated (p)-p70S6 kinase 1 (Thr389), the downstream effector of mTOR, compared with the cells treated with rapamycin or berberine alone.	Sirolimus	233-242	mechanistic target of rapamycin kinase	Homo sapiens	190-194
25310356-8	2014	Furthermore, overexpression of cluster of differentiation (CD) 147, a transmembrance glycoprotein associated with the anticancer effects of berberine, was found to upregulate p-mTOR expression and inhibit cell death in SMMC7721 cells co-treated with rapamycin and berberine.	Sirolimus	250-259	mechanistic target of rapamycin kinase	Homo sapiens	177-181
25375091-2	2014	Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	31-35
25375091-2	2014	Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells.	Sirolimus	18-27	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	100-103
25375091-3	2014	The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin.	Sirolimus	32-41	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	50-53
25375091-3	2014	The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin.	Sirolimus	32-41	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	113-116
25375091-3	2014	The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin.	Sirolimus	32-41	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	113-116
25375091-3	2014	The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin.	Sirolimus	32-41	autophagy related 5	Homo sapiens	216-220
25375091-5	2014	The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model.	Sirolimus	44-53	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	89-92
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	75-81
25193464-3	2014	We have used loss-of-function RNAi screens of the mTOR inhibitor rapamycin to identify sensitizers of mTOR inhibition.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25193464-3	2014	We have used loss-of-function RNAi screens of the mTOR inhibitor rapamycin to identify sensitizers of mTOR inhibition.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	102-106
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	125-131
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	phosphoinositide-3-kinase regulatory subunit 1	Homo sapiens	125-131
25416705-10	2014	Both the high- and low-risk alleles respond to allosteric mTOR inhibition by rapamycin until, at high drug levels, allelic differences are eliminated.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	58-62
25411474-7	2014	However, we found that rapamycin, in addition to inhibiting the mammalian target of rapamycin (mTOR) pathway, facilitated autophagy and prevented p62 accumulation-induced NF-kappaB activation and tumor cell proliferation.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	64-93
25464856-3	2014	Blockade of inhibitory receptor programmed cell death protein 1 (PD-1) in vivo increased mTOR activity in virus-specific CTLs, and its therapeutic effects were abrogated by the mTOR inhibitor rapamycin.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Homo sapiens	89-93
25464856-3	2014	Blockade of inhibitory receptor programmed cell death protein 1 (PD-1) in vivo increased mTOR activity in virus-specific CTLs, and its therapeutic effects were abrogated by the mTOR inhibitor rapamycin.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Homo sapiens	177-181
25411474-7	2014	However, we found that rapamycin, in addition to inhibiting the mammalian target of rapamycin (mTOR) pathway, facilitated autophagy and prevented p62 accumulation-induced NF-kappaB activation and tumor cell proliferation.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	95-99
25411474-7	2014	However, we found that rapamycin, in addition to inhibiting the mammalian target of rapamycin (mTOR) pathway, facilitated autophagy and prevented p62 accumulation-induced NF-kappaB activation and tumor cell proliferation.	Sirolimus	23-32	nuclear factor kappa B subunit 1	Homo sapiens	171-180
25553802-5	2014	We demonstrate that NF-kappaB up-regulation is cell-intrinsic and mediated in part by phosphatidylinositol 3-kinase (PI3K) activity induced in response to metabolic activity, which can be moderated by rapamycin treatment.	Sirolimus	201-210	nuclear factor kappa B subunit 1	Homo sapiens	20-29
25520866-11	2014	Inhibition of mTOR by rapamycin could effectively reduced tumor growth.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	14-18
24827931-1	2014	Ridaforolimus, a unique non-prodrug analog of rapamycin, is a potent inhibitor of mTOR under development for cancer treatment.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	82-86
24890505-4	2014	Using 3-methyladenine (3-MA) and rapamycin to regulate the activity of mTOR, it was found that the efficiency of neuronal differentiation was affected.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	71-75
25258031-3	2014	METHODS: Pharmaceutical specific inhibitors BEZ235 and rapamycin were used to vertical inhibit PI3K/Akt/mTOR signaling and mTOR signaling alone in cultured fibroblasts and in mice.	Sirolimus	55-64	thymoma viral proto-oncogene 1	Mus musculus	100-103
25270513-8	2014	CONCLUSION: Topical application of 1% RPM can significantly and systematically suppress the PDL-induced early stage of angiogenesis via inhibition of the AKT/mTOR/P70S6K pathway in a rodent model.	Sirolimus	38-41	AKT serine/threonine kinase 1	Homo sapiens	154-157
25270513-8	2014	CONCLUSION: Topical application of 1% RPM can significantly and systematically suppress the PDL-induced early stage of angiogenesis via inhibition of the AKT/mTOR/P70S6K pathway in a rodent model.	Sirolimus	38-41	mechanistic target of rapamycin kinase	Homo sapiens	158-162
24114993-5	2014	Targeting mTORC1 with rapamycin effectively inhibited TPA-induced epidermal hyperplasia and hyperproliferation as well as tumor promotion in a dose-dependent manner in both wild-type and BK5.Akt(WT) mice.	Sirolimus	22-31	thymoma viral proto-oncogene 1	Mus musculus	191-194
24810750-0	2014	Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	49-53
24810750-4	2014	Successfully treatment of the prior fatal course of the KHE with KMP was initiated not till adding the mTOR inhibitor sirolimus to therapy.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	103-107
25193511-10	2014	Combination of MEDI-573 with either rapamycin or AZD2014, another mTOR inhibitor (mTORi), significantly enhanced the antitumor activity of MEDI-573, and this response correlated with modulation of AKT and mTOR signaling.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	66-70
24548545-1	2014	OBJECTIVES: Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with antiproliferative activity.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	39-68
24548545-1	2014	OBJECTIVES: Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with antiproliferative activity.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Homo sapiens	70-74
24548545-1	2014	OBJECTIVES: Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with antiproliferative activity.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	39-68
24548545-1	2014	OBJECTIVES: Sirolimus (rapamycin) is a mammalian target of rapamycin (mTOR) inhibitor with antiproliferative activity.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	70-74
25175735-5	2014	In vitro, U87 malignant glioblastoma cells formed tube structures similar to HUVECs on Matrigel in 3D culture, and mTOR-specific inhibitor rapamycin inhibited VM formation in the U87 malignant glioblastoma cells under both normoxia and hypoxia.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	115-119
25193511-10	2014	Combination of MEDI-573 with either rapamycin or AZD2014, another mTOR inhibitor (mTORi), significantly enhanced the antitumor activity of MEDI-573, and this response correlated with modulation of AKT and mTOR signaling.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	197-200
25193511-10	2014	Combination of MEDI-573 with either rapamycin or AZD2014, another mTOR inhibitor (mTORi), significantly enhanced the antitumor activity of MEDI-573, and this response correlated with modulation of AKT and mTOR signaling.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	82-86
25582464-1	2014	OBJECTIVE: To evaluate the therapeutic effect and safety of rapamycin in treatment of children with tuberous sclerosis complex (TSC) complicated with epilepsy.	Sirolimus	60-69	TSC complex subunit 1	Homo sapiens	128-131
25347447-0	2014	Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.	Sirolimus	0-9	phospholipase A2 group IB	Homo sapiens	49-65
25164809-10	2014	The abundance of PDK4 dictated the responsiveness of cells to the mTOR inhibitor, rapamycin.	Sirolimus	82-91	pyruvate dehydrogenase kinase 4	Homo sapiens	17-21
25164809-10	2014	The abundance of PDK4 dictated the responsiveness of cells to the mTOR inhibitor, rapamycin.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	66-70
25336989-6	2014	Although the clinical trial with temsirolimus, an mTOR inhibitor, did not show any benefit when compared with endocrine therapy alone, a Phase II clinical trial with sirolimus has been promising.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25288394-1	2014	Genetic studies have shown that the tuberous sclerosis complex (TSC) 1-TSC2-mammalian target of Rapamycin (mTOR) and the Hippo-Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	107-111
25200144-7	2014	Additionally, the overexpression of duck FST also relieved the inhibition of myoblast proliferation caused by the addition of rapamycin (an mTOR inhibitor) through PI3K/Akt/mTOR signalling.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	140-144
25200144-7	2014	Additionally, the overexpression of duck FST also relieved the inhibition of myoblast proliferation caused by the addition of rapamycin (an mTOR inhibitor) through PI3K/Akt/mTOR signalling.	Sirolimus	126-135	AKT serine/threonine kinase 1	Homo sapiens	169-172
25200144-7	2014	Additionally, the overexpression of duck FST also relieved the inhibition of myoblast proliferation caused by the addition of rapamycin (an mTOR inhibitor) through PI3K/Akt/mTOR signalling.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	173-177
25043732-9	2014	Together, these results demonstrate that acute blockade of mTOR signaling by acute rapamycin administration not only causes changes in neuronal activity, but also leads to elevated protein expression in protein kinase pathways others than mTOR, contributing to the development of anxiety-like behavior.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	59-63
25043732-9	2014	Together, these results demonstrate that acute blockade of mTOR signaling by acute rapamycin administration not only causes changes in neuronal activity, but also leads to elevated protein expression in protein kinase pathways others than mTOR, contributing to the development of anxiety-like behavior.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	239-243
25330241-5	2014	However, the effects of mTOR inhibitor, rapamycin and Go-6976 were not additive and only rapamycin restored impaired insulin-stimulated AKT activation.	Sirolimus	89-98	insulin	Homo sapiens	117-124
25330241-5	2014	However, the effects of mTOR inhibitor, rapamycin and Go-6976 were not additive and only rapamycin restored impaired insulin-stimulated AKT activation.	Sirolimus	89-98	AKT serine/threonine kinase 1	Homo sapiens	136-139
25150927-6	2014	Rapamycin exerted substantial axonal protection after TNF injection.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	54-57
25150927-8	2014	Treatment with rapamycin also significantly inhibited increased p62 protein levels induced by TNF.	Sirolimus	15-24	tumor necrosis factor	Homo sapiens	94-97
24980657-8	2014	Furthermore, we show that pre- and co-treatment with rapamycin ameliorates H2O2-induced caspase-3 and caspase-6 activation and cell toxicity but that 3-methyladenine exacerbates H2O2-induced cell apoptotic cell death.	Sirolimus	53-62	caspase 3	Homo sapiens	88-97
25091623-5	2014	However, 3-DSC-mediated HO-1 induction was completely blocked by treatment with cycloheximide, a translational inhibitor, or rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR).	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	156-185
25123131-6	2014	The low cytotoxic combination of EPA-FFA 150 microM, EGCG 175 microM and GS extract 15 microM completely inhibited the mTOR signaling in HCT116 and SW480 cells, reaching an effect stronger than or comparable to that of the mTOR inhibitor Rapamycin in HCT116 or SW480 cells, respectively.	Sirolimus	238-247	mechanistic target of rapamycin kinase	Homo sapiens	119-123
26779398-8	2014	EXPERT OPINION: Targeting mTOR activation with rapamycin analogs sirolimus and everolimus are awaiting approval by the FDA for treatment of LAM.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	26-30
26779398-8	2014	EXPERT OPINION: Targeting mTOR activation with rapamycin analogs sirolimus and everolimus are awaiting approval by the FDA for treatment of LAM.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	26-30
25091623-5	2014	However, 3-DSC-mediated HO-1 induction was completely blocked by treatment with cycloheximide, a translational inhibitor, or rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR).	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	187-191
24986086-2	2014	Interestingly, epidemiological studies have shown that patients administered the mammalian target of rapamycin (mTOR) inhibitor, sirolimus (rapamycin), exhibit more favourable outcomes, suggestive of activity against HCMV in vivo.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	81-110
24998203-12	2014	HNRNPA2B1 is required for KRAS activation of c-akt murine thymoma oncogene homolog 1-mammalian target of rapamycin signaling, interaction with phosphatidylinositide 3-kinase, and PDAC cell survival and tumor formation in mice.	Sirolimus	105-114	heterogeneous nuclear ribonucleoprotein A2/B1	Mus musculus	0-9
24986086-2	2014	Interestingly, epidemiological studies have shown that patients administered the mammalian target of rapamycin (mTOR) inhibitor, sirolimus (rapamycin), exhibit more favourable outcomes, suggestive of activity against HCMV in vivo.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	112-116
24986086-2	2014	Interestingly, epidemiological studies have shown that patients administered the mammalian target of rapamycin (mTOR) inhibitor, sirolimus (rapamycin), exhibit more favourable outcomes, suggestive of activity against HCMV in vivo.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Homo sapiens	112-116
24859454-0	2014	Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	115-119
25001862-3	2014	In this study, we demonstrate that the PI3K/mTOR pathway is indispensable for eliciting intact type I and III IFN responses in moDCs stimulated with polyI:C. The inhibition of mTOR functionality by rapamycin impairs the pIRF3 and also a few members of the MAPK family, suggesting that mTOR contributes to the activation of multiple signaling pathways in the presence of viral antigens.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Homo sapiens	44-48
24842780-5	2014	We found that downregulation of TOR by feeding the drug rapamycin or by overexpressing the negative TOR regulators TSC1/TSC2, resulted in a specific induction of the AMPs Diptericin (Dpt) and Metchnikowin (Mtk).	Sirolimus	56-65	Metchnikowin	Drosophila melanogaster	192-204
24842780-5	2014	We found that downregulation of TOR by feeding the drug rapamycin or by overexpressing the negative TOR regulators TSC1/TSC2, resulted in a specific induction of the AMPs Diptericin (Dpt) and Metchnikowin (Mtk).	Sirolimus	56-65	Metchnikowin	Drosophila melanogaster	206-209
24804854-1	2014	Mammalian target of rapamycin inhibitors (mTOR-I), everolimus and sirolimus, are immunosuppressive drugs extensively used in renal transplantation.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Homo sapiens	42-46
25001862-3	2014	In this study, we demonstrate that the PI3K/mTOR pathway is indispensable for eliciting intact type I and III IFN responses in moDCs stimulated with polyI:C. The inhibition of mTOR functionality by rapamycin impairs the pIRF3 and also a few members of the MAPK family, suggesting that mTOR contributes to the activation of multiple signaling pathways in the presence of viral antigens.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Homo sapiens	176-180
25001862-3	2014	In this study, we demonstrate that the PI3K/mTOR pathway is indispensable for eliciting intact type I and III IFN responses in moDCs stimulated with polyI:C. The inhibition of mTOR functionality by rapamycin impairs the pIRF3 and also a few members of the MAPK family, suggesting that mTOR contributes to the activation of multiple signaling pathways in the presence of viral antigens.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Homo sapiens	176-180
25060689-3	2014	The events were secondary to the activation of the mammalian-target of rapamycin (mTOR)-pathway induced by leptin, as testified by its reversion induced by mTOR inhibition with rapamycin.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	82-86
25060689-3	2014	The events were secondary to the activation of the mammalian-target of rapamycin (mTOR)-pathway induced by leptin, as testified by its reversion induced by mTOR inhibition with rapamycin.	Sirolimus	71-80	mechanistic target of rapamycin kinase	Homo sapiens	156-160
25109305-6	2014	In order to investigate whether mammalian target of rapamycin (mTOR) is involved in mediating the protective effect of ulinastatin, cells were treated with the mTOR inhibitor, rapamycin 30 min prior to ulinastatin treatment.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Homo sapiens	63-67
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
26993551-2	2014	We successfully managed the patient"s severely restricted arm mobility and consumptive coagulopathy with surgical debulking followed by medical therapy with the mammalian target of rapamycin inhibitor sirolimus.	Sirolimus	201-210	mechanistic target of rapamycin kinase	Homo sapiens	161-190
24943720-2	2014	The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	4-33
25380949-3	2014	mTOR inhibitors (mTOR-I, rapamycin/everolimus) may correct underlying defects in TSC.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	0-4
25380949-3	2014	mTOR inhibitors (mTOR-I, rapamycin/everolimus) may correct underlying defects in TSC.	Sirolimus	25-34	TSC complex subunit 1	Homo sapiens	81-84
25380949-4	2014	Previous data prove benefits and safety of mTOR-I on a wide spectrum of disease manifestations and effectiveness of rapamycin in TSC patients after kidney transplantation (KT).	Sirolimus	116-125	TSC complex subunit 1	Homo sapiens	129-132
25257976-0	2014	Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	15-19
25257976-1	2014	BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and its derivative, everolimus, are potent immunosuppressive and antiproliferative drugs.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	12-41
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	mitogen-activated protein kinase 14	Homo sapiens	178-181
25257976-1	2014	BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and its derivative, everolimus, are potent immunosuppressive and antiproliferative drugs.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	43-47
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
25258166-4	2014	She was first treated with a low dose of the mammalian target of rapamycin (mTOR) inhibitor sirolimus (up to 3 mg/day over a 12-month period) and following significant AML size reduction, percutaneous cryoablation was performed.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	45-74
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	GLI family zinc finger 2	Homo sapiens	128-133
25257976-10	2014	In addition, sirolimus suppressed the LPS-induced phosphorylation of p38 and p65 in the THP-1 and human primary monocytes.	Sirolimus	13-22	mitogen-activated protein kinase 14	Homo sapiens	69-72
25257976-10	2014	In addition, sirolimus suppressed the LPS-induced phosphorylation of p38 and p65 in the THP-1 and human primary monocytes.	Sirolimus	13-22	GLI family zinc finger 2	Homo sapiens	88-93
25258166-4	2014	She was first treated with a low dose of the mammalian target of rapamycin (mTOR) inhibitor sirolimus (up to 3 mg/day over a 12-month period) and following significant AML size reduction, percutaneous cryoablation was performed.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	76-80
25243405-11	2014	Finally, we found that the effects of ICK or MOK knockdown on cilium length and IFT are suppressed by rapamycin treatment, suggesting that these effects require the mTORC1 pathway.	Sirolimus	102-111	MOK protein kinase	Mus musculus	45-48
25092287-6	2014	mTOR inhibition by rapamycin also down-regulated TCTP protein expression, whereas knockdown or overexpression of TCTP suppressed or activated mTOR signaling, respectively, and affected cell viability.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	0-4
25115395-8	2014	Inhibition of mTOR activity by rapamycin sensitized Aur-A-overexpressed breast cancer cells to metabolic stress-induced cell death.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25128827-7	2014	Moreover, PGE2 increased colon cancer cell proliferation as well as the growth of colon cancer cell colonies grown in matrigel and blocking mTORC1 by rapamycin or ATP-competitive inhibitors of mTOR abrogated these effects.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	140-144
24291098-8	2014	Recently, we found that selectively disrupting hippocampal FKBP1b function in young rats, either by microinjecting adeno-associated viral vectors expressing siRNA, or by treatment with rapamycin, increases the sAHP and recapitulates much of the hippocampal Ca(2+) dysregulation phenotype.	Sirolimus	185-194	FKBP prolyl isomerase 1B	Rattus norvegicus	59-65
25214801-5	2014	Everolimus, a 40-O-(2-hydroxyethyl) derivative of mTOR inhibitor sirolimus, has a distinct pharmacokinetic profile.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	50-54
25058027-7	2014	We also observed that rapamycin reduces Cox2 expression, whereas celecoxib reduces mTORC1 activity.	Sirolimus	22-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	40-44
25180793-1	2014	Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	47-51
25180793-4	2014	Catalytic mTOR inhibition with BEZ235 decreased proliferation and increased apoptosis better than allosteric mTOR inhibition with rapamycin.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Homo sapiens	109-113
24988326-7	2014	Compared with wild-type (WT) mice, prkaa1(-/-) mice exhibited a shortened erythrocyte life span, hemolytic destruction of erythrocytes, splenomegaly, and anemia, all of which were alleviated by the administration of either rapamycin to activate autophagy or Mito-tempol, a mitochondria-targeted antioxidant, to scavenge mitochondrial ROS.	Sirolimus	223-232	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	35-41
25016184-8	2014	We reversed the anti-inflammatory phenotype of Rtp801(-/-) mice with the mTORC1 inhibitor, rapamycin, reassuring against mTORC1-independent effects of Rtp801.	Sirolimus	91-100	DNA-damage-inducible transcript 4	Mus musculus	47-53
25016184-8	2014	We reversed the anti-inflammatory phenotype of Rtp801(-/-) mice with the mTORC1 inhibitor, rapamycin, reassuring against mTORC1-independent effects of Rtp801.	Sirolimus	91-100	DNA-damage-inducible transcript 4	Mus musculus	151-157
25711103-4	2014	It exists in two mTOR protein complexes mTORC1 and mTORC2 with various sensitivity to the inhibitory effect of rapamycin.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Homo sapiens	17-21
24794719-0	2014	Rapamycin protects against Abeta-induced synaptotoxicity by increasing presynaptic activity in hippocampal neurons.	Sirolimus	0-9	amyloid beta precursor protein	Homo sapiens	27-32
24590896-3	2014	Expression of the reactive oxygen species-controlling kinase Mirk/dyrk1B was increased severalfold by the mammalian target of rapamycin (mTOR) inhibitors RAD001, WYE354 and rapamycin, with less effect by the Akt inhibitors AZD5363 and MK-2206.	Sirolimus	126-135	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	61-65
24590896-3	2014	Expression of the reactive oxygen species-controlling kinase Mirk/dyrk1B was increased severalfold by the mammalian target of rapamycin (mTOR) inhibitors RAD001, WYE354 and rapamycin, with less effect by the Akt inhibitors AZD5363 and MK-2206.	Sirolimus	126-135	dual specificity tyrosine phosphorylation regulated kinase 1B	Homo sapiens	66-72
24590896-3	2014	Expression of the reactive oxygen species-controlling kinase Mirk/dyrk1B was increased severalfold by the mammalian target of rapamycin (mTOR) inhibitors RAD001, WYE354 and rapamycin, with less effect by the Akt inhibitors AZD5363 and MK-2206.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Homo sapiens	137-141
25023728-12	2014	In a model of human EGFR-2-positive (HER2(+)) disease, dasatinib alone is ineffective, but potentiates the efficacy of rapamycin.	Sirolimus	119-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	37-41
24898389-2	2014	Interleukin (IL)-12 is critical for the generation of memory CTLs, and inhibition of mammalian target of rapamycin (mTOR) by rapamycin can effectively enhance the memory CTL response.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Homo sapiens	116-120
25242764-10	2014	Chronic rapamycin treatment reduces adipose tissue size and beta-cell mass/function, causes hyperlipidemia, severe insulin resistance, and glucose intolerance, and promotes hepatic gluconeogenesis.	Sirolimus	8-17	insulin	Homo sapiens	115-122
24984264-9	2014	The mTOR inhibitor rapamycin can neutralize the protective effects of LL-37 on mitochondria.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
24984264-9	2014	The mTOR inhibitor rapamycin can neutralize the protective effects of LL-37 on mitochondria.	Sirolimus	19-28	cathelicidin antimicrobial peptide	Homo sapiens	70-75
25162929-1	2014	OBJECTIVE: To analyze upper-limb lymphedema characteristics of renal transplant recipients taking sirolimus, an mTOR inhibitor.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	112-116
25166211-3	2014	HIF-1alpha protein accumulation in normoxia was inhibited by rapamycin.	Sirolimus	61-70	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
25149531-6	2014	In addition, cells treated with rapamycin showed a significant increase in p-Akt and a decrease in p-p70S6K that was associated with a decrease expression of vimentin and a slight increase expression in N-cadherin.	Sirolimus	32-41	AKT serine/threonine kinase 1	Homo sapiens	77-80
25187723-14	2014	An effective treatment for LAM is now available, namely using a mechanistic target of rapamycin (mTOR) inhibitor such as sirolimus.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	97-101
25003665-0	2014	Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	57-61
25003665-9	2014	In vitro and in vivo studies suggested mTOR pathway hyperactivation by gemcitabine that was reversed by sirolimus.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Homo sapiens	39-43
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	71-74
24682598-6	2014	Membrane-associated LRRK2 co-localized to autophagosome membranes following either TLR4 stimulation or mTOR inhibition with rapamycin.	Sirolimus	124-133	leucine rich repeat kinase 2	Homo sapiens	20-25
24682598-6	2014	Membrane-associated LRRK2 co-localized to autophagosome membranes following either TLR4 stimulation or mTOR inhibition with rapamycin.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	103-107
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	203-232
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	234-238
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Homo sapiens	249-253
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	75-79
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	81-84
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	signal transducer and activator of transcription 3	Homo sapiens	94-99
24914132-3	2014	We show here that rapamycin, an allosteric inhibitor of the mammalian target of rapamycin complexes, facilitates highly efficient lentiviral transduction of mouse and human HSCs and dramatically enhances marking frequency in long-term engrafting cells in mice.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Homo sapiens	60-89
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	AKT serine/threonine kinase 1	Homo sapiens	177-180
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Homo sapiens	181-185
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	mitogen-activated protein kinase 1	Homo sapiens	187-190
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	signal transducer and activator of transcription 3	Homo sapiens	200-205
25116684-7	2014	Moreover, the forced expression of AKT, ERK and STAT3 could induce a significant suppression of apoptosis in these cells after treatment of rapamycin.	Sirolimus	140-149	AKT serine/threonine kinase 1	Homo sapiens	35-38
25116684-7	2014	Moreover, the forced expression of AKT, ERK and STAT3 could induce a significant suppression of apoptosis in these cells after treatment of rapamycin.	Sirolimus	140-149	mitogen-activated protein kinase 1	Homo sapiens	40-43
25116684-7	2014	Moreover, the forced expression of AKT, ERK and STAT3 could induce a significant suppression of apoptosis in these cells after treatment of rapamycin.	Sirolimus	140-149	signal transducer and activator of transcription 3	Homo sapiens	48-53
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	AKT serine/threonine kinase 1	Homo sapiens	123-126
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	127-131
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	mitogen-activated protein kinase 1	Homo sapiens	133-136
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	signal transducer and activator of transcription 3	Homo sapiens	146-151
24842496-5	2014	This review highlights the important and well-described aspects of the critical phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway and discusses the mechanisms of action of rapamycin, its clinical efficacy in lymphoid malignancies, and the mechanisms of resistance.	Sirolimus	193-202	AKT serine/threonine kinase 1	Homo sapiens	134-137
24800850-0	2014	Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	56-60
24800850-9	2014	In addition, the induction of EMT in HuH7 and HepG2 cells significantly decreased cetuximab cytotoxicity; however, rapamycin treatment significantly restored cetuximab sensitivity and decreased mTOR signaling in these cells.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	194-198
24842496-5	2014	This review highlights the important and well-described aspects of the critical phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway and discusses the mechanisms of action of rapamycin, its clinical efficacy in lymphoid malignancies, and the mechanisms of resistance.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Homo sapiens	138-142
24991977-6	2014	SUMMARY: Initial studies focused on the ability of the mTOR inhibitor rapamycin to suppress immune responses by inhibiting T cell proliferation.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	55-59
24891456-2	2014	The aim of the current study is to describe the expression of the mTOR pathway in normal adrenals (NAs) and pathological adrenals and to explore whether there are correlation between the expression of these proteins and the in vitro response to sirolimus.	Sirolimus	245-254	mechanistic target of rapamycin kinase	Homo sapiens	66-70
24936056-5	2014	Notably, depletion/inhibition of PRCP/PREP destabilized IRS-1 in the cells treated with rapamycin, blocking the feedback activation PI3K/AKT.	Sirolimus	88-97	AKT serine/threonine kinase 1	Homo sapiens	137-140
24366287-8	2014	Rapamycin, an mTOR inhibitor, was used for analysis of the suppressive effect on the Th17 response in vitro.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
24962700-3	2014	Although mTOR was originally discovered as a target protein of rapamycin, a natural macrolide immunosuppressant, rapamycin mainly inhibits the kinase activity of mTORC1, whereas mTORC2 is affected to a much lesser extent.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	9-13
23902659-7	2014	In the blastocyst embryos, anti-apoptotic Bcl-xL transcript levels were elevated in the 1nM rapamycin-treated group, whereas pro-apoptotic Bax transcript levels were decreased.	Sirolimus	92-101	BCL2 like 1	Homo sapiens	42-48
23902659-5	2014	In the analyses of cytoplasmic maturation, we found that the level of p34(cdc2), a cytoplasmic maturation marker, and the monospermic fertilisation rate were higher in the 1nM rapamycin treatment group than in the other groups.	Sirolimus	176-185	general transcription factor IIH subunit 3	Homo sapiens	70-73
23902659-7	2014	In the blastocyst embryos, anti-apoptotic Bcl-xL transcript levels were elevated in the 1nM rapamycin-treated group, whereas pro-apoptotic Bax transcript levels were decreased.	Sirolimus	92-101	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
24946052-4	2014	Computational analyses suggested components of several signal transduction mechanisms including the AKT (also PKB, protein kinase B)/mTOR (mechanistic target of rapamycin) pathway are overrepresented in EV from PC9R cells.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Homo sapiens	133-137
25009644-1	2014	The aim of the present study was to investigate whether radiation induces the mammalian target of rapamycin (Rap) (mTOR) signaling pathway in esophageal carcinoma Eca109 cells, and whether mTOR inhibition by rapamycin increases Eca109 cell radiosensitivity.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	115-119
25161878-7	2014	The effect of perturbed mTOR activity in ER stressed cells was studied on autophagy and cell viability by using agents causing mTOR pathway inhibition (such as rapamycin or metyrapone).	Sirolimus	160-169	mechanistic target of rapamycin kinase	Homo sapiens	24-28
24325131-5	2014	Cetuximab in combination with rapamycin had synergistic effects on inhibiting the phosphrylation of proteins in PI3K/AKT/mTOR and Ras/MAPK signaling pathway.	Sirolimus	30-39	AKT serine/threonine kinase 1	Homo sapiens	117-120
24325131-5	2014	Cetuximab in combination with rapamycin had synergistic effects on inhibiting the phosphrylation of proteins in PI3K/AKT/mTOR and Ras/MAPK signaling pathway.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	121-125
24917666-7	2014	shRNA against the autophagic machinery Atg7 or Atg5 prolonged the survival of neurons co-treated with BDNF and rapamycin, suggesting that suppression of mTOR in BDNF-treated cells resulted in excessive autophagy.	Sirolimus	111-120	autophagy related 5	Homo sapiens	47-51
25024188-6	2014	This seems to be mediated at least in part through the mammalian target of rapamycin complex 1 (MTORC1) pathway, because levels of Ser757-phosphorylated Unc-51-like kinase 1 (ULK1), an MTORC1 target, were greatly reduced in the G85R SOD1YFP motor neurons, correspondent to an activated state of ULK1 that initiates autophagy.	Sirolimus	75-84	superoxide dismutase 1	Homo sapiens	233-237
25048611-9	2014	Rapamycin, an mTOR-specific inhibitor, reduced the phosphorylation of mTOR signalling pathway and decreased the CD36 translational efficiency and protein level even under inflammatory stress resulting in the alleviation of inflammatory stress-induced hepatic lipid accumulation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
25048611-9	2014	Rapamycin, an mTOR-specific inhibitor, reduced the phosphorylation of mTOR signalling pathway and decreased the CD36 translational efficiency and protein level even under inflammatory stress resulting in the alleviation of inflammatory stress-induced hepatic lipid accumulation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	70-74
24769511-2	2014	In the current study, we found that 7-O-succinyl macrolactin A (SMA), a macrolide, potently inhibited TNF-alpha-induced adhesion of monocytes to colonic epithelial cells in a concentration-dependent manner, similar to rapamycin, a mTOR inhibitor.	Sirolimus	218-227	tumor necrosis factor	Rattus norvegicus	102-111
24599401-2	2014	TSC1/2 protein complex negatively regulates the mammalian target of rapamycin complex 1 (mTORC1) a master regulator of protein synthesis, cell growth and autophagy.	Sirolimus	68-77	TSC complex subunit 1	Homo sapiens	0-6
24982337-1	2014	BACKGROUND: The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	104-133
23995790-10	2014	Rapamycin, the mTOR inhibitor, significantly reduced Smurf1 protein levels, and Smurf1 was degraded in mitosis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	15-19
23995790-10	2014	Rapamycin, the mTOR inhibitor, significantly reduced Smurf1 protein levels, and Smurf1 was degraded in mitosis.	Sirolimus	0-9	SMAD specific E3 ubiquitin protein ligase 1	Homo sapiens	53-59
24982337-1	2014	BACKGROUND: The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Homo sapiens	135-139
24982384-13	2014	CONCLUSION: Our study confirms that mTOR inhibition with sirolimus/temsirolimus is well-tolerated with good radiological responses, albeit short-lived, and supports its use in PEComas.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Homo sapiens	36-40
24910242-5	2014	Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin-6 (IL-6) production, activation of signal transducer and activator of transcription 3 (STAT3), and enhanced HCC development, despite a transient reduction in hepatosteatosis.	Sirolimus	9-18	interleukin 6	Homo sapiens	120-133
24713582-1	2014	The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	35-39
24713582-1	2014	The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	4-33
24713582-1	2014	The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Homo sapiens	35-39
24713582-4	2014	By using the mTOR inhibitor rapamycin, we show that SR-BI is down-regulated in human umbilical vein endothelial cells (HUVECs).	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	13-17
24713582-8	2014	We demonstrate that inhibition of mTOR leads to endothelial cell dysfunction and decreased SR-BI expression, which may contribute to atherogenesis during rapamycin treatment.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	34-38
24910242-5	2014	Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin-6 (IL-6) production, activation of signal transducer and activator of transcription 3 (STAT3), and enhanced HCC development, despite a transient reduction in hepatosteatosis.	Sirolimus	9-18	interleukin 6	Homo sapiens	135-139
24910242-5	2014	Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin-6 (IL-6) production, activation of signal transducer and activator of transcription 3 (STAT3), and enhanced HCC development, despite a transient reduction in hepatosteatosis.	Sirolimus	9-18	signal transducer and activator of transcription 3	Homo sapiens	167-217
24910242-5	2014	Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin-6 (IL-6) production, activation of signal transducer and activator of transcription 3 (STAT3), and enhanced HCC development, despite a transient reduction in hepatosteatosis.	Sirolimus	9-18	signal transducer and activator of transcription 3	Homo sapiens	219-224
25098457-1	2014	The mammalian target of rapamycin inhibitors (mTOR-I) sirolimus and everolimus represents a class of immunosuppressive drugs largely used in renal transplantation.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	4-33
24650522-4	2014	Utilizing both rapamycin to inhibit mTORC1 activity and shRNA to knock down Rheb, we demonstrated that the decrease in Akt Ser473 phosphorylation stimulated by insulin after C2-ceramide incubation can be prevented.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	119-122
24650522-4	2014	Utilizing both rapamycin to inhibit mTORC1 activity and shRNA to knock down Rheb, we demonstrated that the decrease in Akt Ser473 phosphorylation stimulated by insulin after C2-ceramide incubation can be prevented.	Sirolimus	15-24	insulin	Homo sapiens	160-167
25098457-1	2014	The mammalian target of rapamycin inhibitors (mTOR-I) sirolimus and everolimus represents a class of immunosuppressive drugs largely used in renal transplantation.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Homo sapiens	46-50
24915467-0	2014	Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D.	Sirolimus	0-9	tumor protein p53	Homo sapiens	45-48
24944633-0	2014	Interferon-alpha enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Homo sapiens	97-101
24944633-4	2014	The observations indicated that IFN-alpha significantly increased the susceptibility of RCC cells to RPM and the synergistic effect of IFN-alpha and RPM against RCC cells was confirmed in all three RCC cell lines.	Sirolimus	101-104	interferon alpha 1	Homo sapiens	32-41
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	14-17	mechanistic target of rapamycin kinase	Homo sapiens	57-61
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	14-17	interferon alpha 1	Homo sapiens	111-120
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	14-17	mechanistic target of rapamycin kinase	Homo sapiens	179-183
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	148-151	interferon alpha 1	Homo sapiens	0-9
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	148-151	mechanistic target of rapamycin kinase	Homo sapiens	57-61
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	148-151	interferon alpha 1	Homo sapiens	111-120
24944633-6	2014	IFN-alpha and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN-alpha significantly enhanced the RPM-induced suppression of the mTOR pathway.	Sirolimus	148-151	mechanistic target of rapamycin kinase	Homo sapiens	179-183
24944633-7	2014	However, in RCC cells with low mTOR activity, the synergy of IFN-alpha and RPM was eliminated.	Sirolimus	75-78	mechanistic target of rapamycin kinase	Homo sapiens	31-35
25313747-8	2014	In ECs in culture LY294002, an inhibitor of phosphatidylinositol-3-kinase (PI3K)/Akt pathway and rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) reversed the effect of sarcosine.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	124-153
24915467-1	2014	The activation of the p53 pathway by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a molecule that mimics metabolic stress, is attenuated by rapamycin, an inhibitor of mTOR kinase, immunosuppressant, and cancer drug.	Sirolimus	150-159	tumor protein p53	Homo sapiens	22-25
24915467-1	2014	The activation of the p53 pathway by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a molecule that mimics metabolic stress, is attenuated by rapamycin, an inhibitor of mTOR kinase, immunosuppressant, and cancer drug.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Homo sapiens	177-181
24915467-5	2014	Rapamycin inhibited the accumulation of phospho-Ser46 p53, attenuated upregulation of some p53 target genes, and altered cell-cycle progression.	Sirolimus	0-9	tumor protein p53	Homo sapiens	54-57
24915467-5	2014	Rapamycin inhibited the accumulation of phospho-Ser46 p53, attenuated upregulation of some p53 target genes, and altered cell-cycle progression.	Sirolimus	0-9	tumor protein p53	Homo sapiens	91-94
24915467-0	2014	Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D.	Sirolimus	0-9	tumor protein p53	Homo sapiens	95-98
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mitogen-activated protein kinase 1	Mus musculus	298-302
24012802-4	2014	Systemic blockade of mTOR with rapamycin immediately or 12h after training or reactivation impairs both consolidation and reconsolidation of an auditory fear memory.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	21-25
24012802-8	2014	These findings also provide evidence for a cogent treatment model for reducing the emotional strength of established, traumatic memories analogous to those observed in acquired anxiety disorders such as posttraumatic stress disorder (PTSD) and specific phobias, through pharmacologic blockade of mTOR using systemic rapamycin following reactivation.	Sirolimus	316-325	mechanistic target of rapamycin kinase	Homo sapiens	296-300
24810875-4	2014	Thus, the systemic treatment with mammalian target of rapamycin inhibitors such as sirolimus and everolimus has recently been established to treat specific tuberous sclerosis complex-associated lesions.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Homo sapiens	34-63
24569835-0	2014	Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	102-105
24569835-0	2014	Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	106-110
24569835-1	2014	Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	49-52
24569835-1	2014	Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Homo sapiens	84-88
23740036-1	2014	The mammalian target of the rapamycin (mTOR) inhibitors sirolimus and everolimus are increasingly being used in pediatric kidney transplantation in different combinations and doses.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	39-43
24682932-0	2014	Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	140-144
24682932-2	2014	We recently found that rapamycin could induce G0/G1 phase arrest and apoptosis and inhibit proliferation of K562 cells through inhibiting mammalian target of rapamycin (mTOR) pathway.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	138-167
24685370-1	2014	Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg, advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus).	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	0-29
24685370-1	2014	Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients (everolimus and sirolimus) and as antineoplastic therapies for various cancers (eg, advanced renal cell carcinoma; everolimus, temsirolimus, ridaforolimus).	Sirolimus	145-154	mechanistic target of rapamycin kinase	Homo sapiens	31-35
24682932-2	2014	We recently found that rapamycin could induce G0/G1 phase arrest and apoptosis and inhibit proliferation of K562 cells through inhibiting mammalian target of rapamycin (mTOR) pathway.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Homo sapiens	169-173
24682932-8	2014	Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P &lt; 0.05).	Sirolimus	170-179	mechanistic target of rapamycin kinase	Homo sapiens	92-96
24682932-9	2014	In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	126-130
24931608-0	2014	Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	61-93
24910976-5	2014	Topical use of the mTOR inhibitor rapamycin is an effective treatment for the skin tumours (angiofibromas) in tuberous sclerosis complex, which is also characterised by mTOR deregulation.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	19-23
24964744-5	2014	Combination of EGFR inhibitors with either the PI3K inhibitor ZSTK474 or the MTOR inhibitor sirolimus showed increased activity.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Homo sapiens	77-81
24814708-5	2014	Biliverdin administration inhibited lipopolysaccharide (LPS)-induced C5aR expression (without altering basal expression), an effect partially blocked by rapamycin, an inhibitor of mTOR signaling.	Sirolimus	153-162	complement C5a receptor 1	Homo sapiens	69-73
24814708-5	2014	Biliverdin administration inhibited lipopolysaccharide (LPS)-induced C5aR expression (without altering basal expression), an effect partially blocked by rapamycin, an inhibitor of mTOR signaling.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Homo sapiens	180-184
24927123-5	2014	The absence of TGFbeta signaling results in resistance to rapamycin.	Sirolimus	58-67	transforming growth factor beta 1	Homo sapiens	15-22
24910976-5	2014	Topical use of the mTOR inhibitor rapamycin is an effective treatment for the skin tumours (angiofibromas) in tuberous sclerosis complex, which is also characterised by mTOR deregulation.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Homo sapiens	169-173
24889507-2	2014	Tsc1 and Tsc2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signalling through Rheb-GTPase.	Sirolimus	72-81	TSC complex subunit 1	Homo sapiens	0-4
24936148-7	2014	These effects of S100A4 were abolished by treatment with either the specific PI3K/Akt inhibitor LY294002, or the specific mTOR/p70S6K inhibitor rapamycin.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	122-126
24936148-8	2014	Furthermore, overexpression of S100A4 resulted in upregulation of VEGF and downregulation of E-cadherin, which were strongly reversed by either LY294002 or rapamycin.	Sirolimus	156-165	cadherin 1	Homo sapiens	93-103
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	BCL2 like 1	Homo sapiens	141-147
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	cytochrome c, somatic	Homo sapiens	226-238
24623173-7	2014	To elucidate the effect of autophagy on apoptosis, the mechanically-injured neurons were treated with the mTOR inhibitor rapamycin and 3-methyl adenine (3-MA), which are known to regulate autophagy positively and negatively, respectively.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Homo sapiens	106-110
24676456-3	2014	In the present study, we demonstrate that an mTOR inhibitor, rapamycin, induces autophagy in the Nara-H malignant fibrous histiocytoma (MFH) cell line through the activation of ERK1/2.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	45-49
24676456-3	2014	In the present study, we demonstrate that an mTOR inhibitor, rapamycin, induces autophagy in the Nara-H malignant fibrous histiocytoma (MFH) cell line through the activation of ERK1/2.	Sirolimus	61-70	mitogen-activated protein kinase 3	Homo sapiens	177-183
24676456-4	2014	Rapamycin-induced apoptosis was enhanced following the inhibition of the MEK/ERK pathway.	Sirolimus	0-9	mitogen-activated protein kinase kinase 7	Homo sapiens	73-76
24676456-4	2014	Rapamycin-induced apoptosis was enhanced following the inhibition of the MEK/ERK pathway.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	77-80
24676456-9	2014	Simultaneously, phospho-ERK1/2 was activated by rapamycin.	Sirolimus	48-57	mitogen-activated protein kinase 3	Homo sapiens	24-30
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	Sirolimus	36-45	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	Sirolimus	36-45	mitogen-activated protein kinase 1	Homo sapiens	102-105
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	Sirolimus	36-45	mitogen-activated protein kinase kinase 7	Homo sapiens	184-187
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	Sirolimus	133-142	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
24676456-10	2014	The present study demonstrates that rapamycin induces autophagy in Nara-H cells by activating the MEK/ERK signaling pathway, and the rapamycin-induced apoptosis can be enhanced by the MEK inhibitor, U0126.	Sirolimus	133-142	mitogen-activated protein kinase kinase 7	Homo sapiens	184-187
24630239-0	2014	Effects of the immunosuppressant rapamycin on the expression of human alpha2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.	Sirolimus	33-42	collagen type I alpha 2 chain	Homo sapiens	70-88
24630239-9	2014	In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells.	Sirolimus	13-22	mitogen-activated protein kinase 8	Homo sapiens	100-103
24569105-10	2014	Rapamycin treatment or mTOR inhibition promotes CD11b+Gr1+Ly6C(high) MDSC recruitment and is critically required for protection against hepatic injury.	Sirolimus	0-9	integrin alpha M	Mus musculus	48-53
24813579-3	2014	Switch of the immunosuppressive regimen to mTOR-inhibitors such as everolimus or sirolimus can have an antitumor effect.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Homo sapiens	43-47
24510654-9	2014	Both NMDA and rapamycin increased the level of phosphorylated ERK (pERK) in Muller cells, and coinjection of both agents further increased pERK levels.	Sirolimus	14-23	Eph receptor B1	Rattus norvegicus	62-65
24510654-0	2014	Rapamycin prevents N-methyl-D-aspartate-induced retinal damage through an ERK-dependent mechanism in rats.	Sirolimus	0-9	Eph receptor B1	Rattus norvegicus	74-77
24510654-10	2014	These results suggest that rapamycin has a neuroprotective effect against NMDA-induced retinal neurotoxicity and that this effect could be patially mediated by activation of the ERK pathway in retinal Muller cells.	Sirolimus	27-36	Eph receptor B1	Rattus norvegicus	178-181
24688046-9	2014	mTOR-targeting drugs (rapamycin and AZD8055) significantly reduced proliferation of PELP1-overexpressed breast cancer cells in both in vitro and in vivo xenograft tumor models.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	0-4
25010764-15	2014	We also showed that rapamycin was able to augment the effect of chemotherapeutic agents and TGF-beta.	Sirolimus	20-29	transforming growth factor beta 1	Homo sapiens	92-100
24532005-12	2014	The suppressive effect of Lys on the proteolysis by the autophagic-lysosomal system was maintained partially when mTOR activity was inhibited by 100 nM rapamycin, suggesting that some regulator other than mTOR signaling, for example, Akt, might also suppress the autophagic-lysosomal system.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Homo sapiens	114-118
24688046-9	2014	mTOR-targeting drugs (rapamycin and AZD8055) significantly reduced proliferation of PELP1-overexpressed breast cancer cells in both in vitro and in vivo xenograft tumor models.	Sirolimus	22-31	proline, glutamate and leucine rich protein 1	Homo sapiens	84-89
24737099-9	2014	The decrease in the expression and phosphorylation of mTOR and its downstream kinases may be one of the molecular mechanisms underlying rapamycin resistance.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	54-58
24705351-7	2014	However, rapamycin did not show a synergistic effect with sorafenib to inhibit cell proliferation, while it also activated Akt via a feedback mechanism in sorafenib-resistant HCC cells.	Sirolimus	9-18	AKT serine/threonine kinase 1	Homo sapiens	123-126
24411482-6	2014	Specifically, we show that rapamycin, an mTOR inhibitor, prevents the detrimental effects of sucrose in the brain without altering changes in peripheral insulin resistance.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	41-45
24777450-6	2014	Constitutive expression of these mutants in zebrafish embryos resulted in a heart failure phenotype with AKT hyperactivation that was rescued by treatment with rapamycin.	Sirolimus	160-169	AKT serine/threonine kinase 1	Homo sapiens	105-108
24932295-5	2014	Furthermore, the selected inhibitors of PI3K (LY294002), Akt (SH-6) and mTOR (rapamycin) enhanced the effects of resveratrol in K562 cells.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	72-76
24737049-3	2014	In the present study, the HNSCC cell lines CAL27 and SCC4 were pre-treated with rapamycin then stimulated with a TLR4 ligand lipopolysaccharide (LPS).	Sirolimus	80-89	MAU2 sister chromatid cohesion factor	Homo sapiens	53-57
24641525-5	2014	Sirolimus antagonizes the mTOR pathway, which regulates cell proliferation, differentiation, and migration, and is being studied as an anti-neoplastic agent for solid tumors.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	26-30
24469593-7	2014	Rapamycin reduced drug seeking in signaled non-drug-available periods, PR responding, and cue-induced reinstatement, with these effects linked to reduced mTORC1 activity, total CAMKIIalpha, and GluA1 AMPAR levels in the NACsh.	Sirolimus	0-9	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	194-199
24851266-0	2014	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.	Sirolimus	0-9	neurofibromin 1	Homo sapiens	30-33
24851266-5	2014	Sirolimus is a macrolide antibiotic that inhibits mTOR activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	50-54
24851266-7	2014	In stratum 2, we sought to determine whether the mTOR inhibitor sirolimus in subjects with NF1 results in objective radiographic responses in inoperable PNs in the absence of documented radiographic progression at trial entry.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	49-53
24851266-7	2014	In stratum 2, we sought to determine whether the mTOR inhibitor sirolimus in subjects with NF1 results in objective radiographic responses in inoperable PNs in the absence of documented radiographic progression at trial entry.	Sirolimus	64-73	neurofibromin 1	Homo sapiens	91-94
24864177-0	2014	Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.	Sirolimus	0-9	neurofibromin 1	Homo sapiens	27-30
24864177-4	2014	We present 3 cases of patients with NF1, aged 8, 16, and 17 years, followed for inoperable and symptomatic PNs; patients received sirolimus for life-threatening and painful neurofibromas after multidisciplinary consultation.	Sirolimus	130-139	neurofibromin 1	Homo sapiens	36-39
24864177-7	2014	Sirolimus for inoperable symptomatic PNs in patients with NF1 permitted stabilization of mass and produced unpredictable and important alleviation of pain in all cases with good tolerance.	Sirolimus	0-9	neurofibromin 1	Homo sapiens	58-61
24989291-5	2014	It is concluded that rapamycin plays an critical role in inhibiting cell proliferation, cell cycles, and adipogenesis, these effects may be related with the autophagy activation and mTOR inhibition resulting from rapamycin.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	182-186
24861463-10	2014	Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD.	Sirolimus	144-153	androgen receptor	Homo sapiens	181-183
24861504-4	2014	Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).	Sirolimus	78-87	mechanistic target of rapamycin kinase	Homo sapiens	40-44
24935295-1	2014	BACKGROUND: Based on evidence available in the literature, rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, but not calcineurin inhibitors (CNIs), has been shown to decrease spleen size.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	72-101
24935295-1	2014	BACKGROUND: Based on evidence available in the literature, rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, but not calcineurin inhibitors (CNIs), has been shown to decrease spleen size.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Homo sapiens	103-107
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	AKT serine/threonine kinase 1	Homo sapiens	38-41
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	42-46
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	erb-b2 receptor tyrosine kinase 2	Homo sapiens	98-102
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	168-172
24866893-6	2014	Cerulenin, a FASN inhibitor, synergized with rapamycin to induce apoptosis and inhibit cell migration and tumorigenesis in ER/HER2-positive breast cancer cells.	Sirolimus	45-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130
24861463-10	2014	Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	244-273
24861463-10	2014	Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Homo sapiens	275-279
24904824-4	2014	The initial mTOR inhibitor, sirolimus (also known as rapamycin), was first discovered in 1975 in the soil of Easter Island.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	12-16
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Homo sapiens	23-27
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	catalase	Homo sapiens	176-184
24614082-4	2014	Combining the mTOR inhibitor rapamycin with ABT-737 rescued this resistance mechanism, was highly synergistic in vitro, and provided durable tumor regressions in vivo without notable hematologic suppression.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	14-18
24614082-6	2014	Rapamycin exposure was consistently associated with an increase in the proapoptotic protein BAX, whereas ABT-737 caused dose-dependent decreases in BAX.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Homo sapiens	92-95
24904824-6	2014	Shortly thereafter, recognition of sirolimus"s ability to inhibit cellular proliferation and cell cycle progression brought sirolimus to the forefront as a possible inhibitor of mTOR.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	178-182
24904824-6	2014	Shortly thereafter, recognition of sirolimus"s ability to inhibit cellular proliferation and cell cycle progression brought sirolimus to the forefront as a possible inhibitor of mTOR.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	178-182
24810045-7	2014	Evidence supporting a key role of mTOR/PP2A signaling included the finding that, similar to metformin, the canonical mTOR inhibitor rapamycin was capable of lowering the ratio of phospho-Ser129 alpha-synuclein to total alpha-synuclein.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	34-38
24607296-3	2014	Here, we demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), markedly protected 661W photoreceptor cells from visible light exposure-induced damage at the nanomolar level.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	58-87
24607296-3	2014	Here, we demonstrated that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), markedly protected 661W photoreceptor cells from visible light exposure-induced damage at the nanomolar level.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Homo sapiens	89-93
24810045-7	2014	Evidence supporting a key role of mTOR/PP2A signaling included the finding that, similar to metformin, the canonical mTOR inhibitor rapamycin was capable of lowering the ratio of phospho-Ser129 alpha-synuclein to total alpha-synuclein.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Homo sapiens	117-121
24810050-8	2014	Insulin-induced Akt phosphorylation was decreased and restored by rapamycin and an inhibitor of S6K.	Sirolimus	66-75	insulin	Homo sapiens	0-7
24810050-8	2014	Insulin-induced Akt phosphorylation was decreased and restored by rapamycin and an inhibitor of S6K.	Sirolimus	66-75	thymoma viral proto-oncogene 1	Mus musculus	16-19
24619883-7	2014	Rosiglitazone also restored insulin"s ability to stimulate glucose uptake and its incorporation into glycogen in skeletal muscle of rapamycin-treated rats, which was associated with normalization of Akt Ser(473) phosphorylation.	Sirolimus	132-141	AKT serine/threonine kinase 1	Rattus norvegicus	199-202
25049998-4	2014	Rapamycin treatment of aged oocytes for 24 h (68 h in vitro maturation [IVM]; 44 h+10 muM rapamycin/24 h, 47.52+-5.68) or control oocytes (44 h IVM; 42.14+-4.40) significantly increased the development rate and total cell number compared with untreated aged oocytes (68 h IVM, 22.04+-5.68) (p&lt;0.05).	Sirolimus	0-9	latexin	Homo sapiens	86-89
25049998-5	2014	Rapamycin treatment of aged IVM oocytes for 24 h also rescued aberrant spindle organization and chromosomal misalignment, blocked the decrease in the level of phosphorylated-p44/42 mitogen-activated protein kinase (MAPK), and increased the mRNA expression of cytoplasmic maturation factor genes (MOS, BMP15, GDF9, and CCNB1) compared with untreated, 24 h-aged IVM oocytes (p&lt;0.05).	Sirolimus	0-9	bone morphogenetic protein 15	Homo sapiens	301-306
24518659-9	2014	Downregulation of mTOR by siRNA or rapamycin significantly inhibited osteoblastic differentiation of VSMCs and decreased the expression and phosphorylation of mTOR and P70 ribosomal S6 kinase in a time- and concentration-dependent manner.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	18-22
24375611-4	2014	This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin.	Sirolimus	137-146	AKT serine/threonine kinase 1	Rattus norvegicus	50-53
24375611-8	2014	The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins.	Sirolimus	43-52	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
24518659-9	2014	Downregulation of mTOR by siRNA or rapamycin significantly inhibited osteoblastic differentiation of VSMCs and decreased the expression and phosphorylation of mTOR and P70 ribosomal S6 kinase in a time- and concentration-dependent manner.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	159-163
24043497-5	2014	However, clinical trials with rapamycin, an effective inhibitor of mTOR, have not been up to the created expectations and a plausible explanation is missing.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Homo sapiens	67-71
23708663-0	2014	Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Homo sapiens	44-48
24217803-9	2014	In particular, data regarding the role of mammalian target of rapamycin inhibitors (mTORi), such as sirolimus and everolimus, in the PRO development are still controversial.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Homo sapiens	42-71
24683191-7	2014	DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +- 1.48%, rapamycin: 5.03 +- 0.66%; p &lt; 0.001).	Sirolimus	141-150	interleukin 4	Homo sapiens	23-27
24683191-7	2014	DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +- 1.48%, rapamycin: 5.03 +- 0.66%; p &lt; 0.001).	Sirolimus	141-150	CD4 molecule	Homo sapiens	44-47
24683191-9	2014	IFN-gamma expression was reduced in all lupus T cell subsets (p = 1.0 x 10(-5)) and also resisted rapamycin.	Sirolimus	98-107	interferon gamma	Homo sapiens	0-9
24683191-10	2014	IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +- 0.66%, HC: 2.29 +- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +- 0.79%, rapamycin: 2.22 +- 0.60%; p &lt; 0.001).	Sirolimus	131-140	CD4 molecule	Homo sapiens	34-37
24815166-11	2014	Rapamycin treatment also causes the activation of FAK and ILK in a dose-dependent manner.	Sirolimus	0-9	integrin linked kinase	Homo sapiens	58-61
24732420-8	2014	Further signaling dissection revealed that PDGF-BB posttranscriptional upregulated p21WAF1/Cip1 protein expression, which was inhibited by rapamycin, an activator of autophagy via suppressing mammalian target of rapamycin (mTOR), rather than MG132, a proteasome inhibitor.	Sirolimus	139-148	cyclin dependent kinase inhibitor 1A	Homo sapiens	91-95
24685479-1	2014	Rapamycin, a mammalian target of rapamycin (mTOR)-specific inhibitor, has the effect of anti-lipid deposition on non-alcoholic fatty liver disease (NAFLD), but the mechanisms with which rapamycin alleviates hepatic steatosis are not fully disclosed.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Homo sapiens	44-48
24685479-9	2014	We further confirmed that rapamycin inhibited the phosphorylation of mTOR and its downstream translational regulators including p70 ribosomal protein S6 kinase (p70S6K), eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), and eukaryotic initiation factor 4E (eIF4E).	Sirolimus	26-35	mechanistic target of rapamycin kinase	Homo sapiens	69-73
24685479-10	2014	This study demonstrates that rapamycin inhibits hepatic CD36 translational efficiency through the mTOR pathway, resulting in reduction of CD36 protein expression and alleviation of hepatic steatosis.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Homo sapiens	98-102
24752605-10	2014	Treatment of cells with rapamycin, an inducer of autophagy, reduced E50K-OPTN-induced cell death.	Sirolimus	24-33	optineurin	Homo sapiens	73-77
24732420-8	2014	Further signaling dissection revealed that PDGF-BB posttranscriptional upregulated p21WAF1/Cip1 protein expression, which was inhibited by rapamycin, an activator of autophagy via suppressing mammalian target of rapamycin (mTOR), rather than MG132, a proteasome inhibitor.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	192-221
24732420-8	2014	Further signaling dissection revealed that PDGF-BB posttranscriptional upregulated p21WAF1/Cip1 protein expression, which was inhibited by rapamycin, an activator of autophagy via suppressing mammalian target of rapamycin (mTOR), rather than MG132, a proteasome inhibitor.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Homo sapiens	223-227
24714658-1	2014	The TSC1-TSC2-TBC1D7 complex is an important negative regulator of the mechanistic target of rapamycin complex 1 that controls cell growth in response to environmental cues.	Sirolimus	93-102	TSC complex subunit 1	Homo sapiens	4-8
24441414-4	2014	Our previous study shows that rapamycin, an MTOR-dependent autophagic activator, accelerates disease progression in the SOD1(G93A) mouse model of ALS.	Sirolimus	30-39	superoxide dismutase 1, soluble	Mus musculus	120-124
24714658-1	2014	The TSC1-TSC2-TBC1D7 complex is an important negative regulator of the mechanistic target of rapamycin complex 1 that controls cell growth in response to environmental cues.	Sirolimus	93-102	TBC1 domain family member 7	Homo sapiens	14-20
24569994-7	2014	Moreover, treatment of fibroblasts over-expressing tTG with PP2, or with inhibitors that inactivate components of the PI3-kinase pathway, including PI3-kinase (LY294002) and mTORC1 (rapamycin), ablated the tTG-promoted survival of the cells.	Sirolimus	182-191	transglutaminase 2	Homo sapiens	51-54
24667713-1	2014	BACKGROUND: Everolimus, an orally administered rapamycin analogue, inhibits the mammalian target of rapamycin (mTOR), a highly conserved intracellular serine-threonine kinase that is a central node in a network of signaling pathways controlling cellular metabolism, growth, survival, proliferation, angiogenesis, and immune function.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	80-109
24667713-1	2014	BACKGROUND: Everolimus, an orally administered rapamycin analogue, inhibits the mammalian target of rapamycin (mTOR), a highly conserved intracellular serine-threonine kinase that is a central node in a network of signaling pathways controlling cellular metabolism, growth, survival, proliferation, angiogenesis, and immune function.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	111-115
24458007-4	2014	The same as in nucleated mammalian cells, autophagy was stimulated by cell starvation or the MTOR inhibitor rapamycin in a phosphatidylinositol 3-kinase (PtdIns3K)-dependent manner.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	93-97
24285256-0	2014	ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.	Sirolimus	31-40	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
24534455-3	2014	A large body of evidence indicates that mammalian target of rapamycin (mTOR) inhibitors such as rapamycin or everolimus have pleiotropic anti-atherosclerotic effects so that these drugs can be used as add-on therapy to prevent or delay the pathogenesis of atherosclerosis.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Homo sapiens	71-75
27919033-4	2014	We determined the transcription profiles of bmh1 and bmh2 yeast after treatment with rapamycin.	Sirolimus	85-94	14-3-3 family protein BMH1	Saccharomyces cerevisiae S288C	44-48
24549759-6	2014	Recently, biologically targeted pharmacotherapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus has provided a safe and efficacious treatment option for patients with SEGAs.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	53-82
24549759-6	2014	Recently, biologically targeted pharmacotherapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus has provided a safe and efficacious treatment option for patients with SEGAs.	Sirolimus	109-118	mechanistic target of rapamycin kinase	Homo sapiens	84-88
24285256-2	2014	The aim of this study was to analyse the dose-normalized trough blood concentrations (C0 /D ratio) of sirolimus in patients with different genotypes and attempt to investigate the possible associations between ABCB1/CYP3A5 genotypes and sirolimus dose requirements in Chinese renal transplant recipients.	Sirolimus	237-246	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	216-222
24285256-5	2014	A significant allele-dependent effect was observed between the CYP3A5*3 polymorphism and the C0 /D ratio of sirolimus.	Sirolimus	108-117	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	63-69
24285256-6	2014	The patients bearing at least one CYP3A5*1 allele had a lower sirolimus C0/D ratio compared with those with a homozygous CYP3A5*3 genotype (p &lt; 0.05).	Sirolimus	62-71	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	34-40
24285256-9	2014	These results demonstrated that the haplotype of ABCB1 might be a better index for the prediction of sirolimus blood concentration than single SNPs.	Sirolimus	101-110	ATP binding cassette subfamily B member 1	Homo sapiens	49-54
24285256-10	2014	Genotyping of ABCB1 and CYP3A5 might help to optimize individualized sirolimus treatments for Chinese renal transplant recipients.	Sirolimus	69-78	ATP binding cassette subfamily B member 1	Homo sapiens	14-19
24285256-10	2014	Genotyping of ABCB1 and CYP3A5 might help to optimize individualized sirolimus treatments for Chinese renal transplant recipients.	Sirolimus	69-78	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	24-30
24671870-6	2014	Other promising strategies are inhibition of interleukin 1beta signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the alpha2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity.	Sirolimus	213-222	erythropoietin	Homo sapiens	263-277
25852858-1	2014	Mammalian target of rapamycin inhibitor (mTOR-I)/proliferation signal inhibitors (PSI) including sirolimus and everolimus represent a new class of drugs increasingly used in solid-organ transplantation as alternatives to calcineurin inhibitors for patients with renal dysfunction, transplant coronary arterial vasculopathy or malignancy.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Homo sapiens	0-29
24504412-8	2014	Additionally, rapamycin prevented the denervation-induced upregulation of the mTORC2 substrates Akt and SGK.	Sirolimus	14-23	thymoma viral proto-oncogene 1	Mus musculus	96-99
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	CD4 molecule	Homo sapiens	26-29
24319109-9	2014	Although rapamycin treatment induced autophagy and led to apoptosis promotion, the pro-apoptotic effect of rapamycin was reversed by the addition of 3-MA, suggesting that mTOR inhibition promotes endometriotic cell apoptosis via autophagy induction.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	171-175
24671870-6	2014	Other promising strategies are inhibition of interleukin 1beta signaling by drugs such as VX-765; modulation of sphingosine 1-phosphate signaling by drugs such as fingolimod; activation of the mammalian target of rapamycin by drugs such as rapamycin; the hormone erythropoietin; and, paradoxically, drugs such as the alpha2 adrenergic receptor antagonist atipamezole and the CB1 cannabinoid antagonist SR141716A (rimonabant) with proexcitatory activity.	Sirolimus	213-222	cannabinoid receptor 1	Homo sapiens	375-378
24486221-9	2014	Rapamycin, an mTOR inhibitor, has been used successfully in Tsc-deficient mice to prevent and treat seizures and behavioral abnormalities.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	60-63
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	interleukin 6	Mus musculus	69-73
24366516-4	2014	We describe a therapeutic attempt with the mammalian target of rapamycin (mTOR) inhibitor sirolimus for a PHTS patient suffering from thymus hyperplasia and lipomatosis.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	43-72
24366516-4	2014	We describe a therapeutic attempt with the mammalian target of rapamycin (mTOR) inhibitor sirolimus for a PHTS patient suffering from thymus hyperplasia and lipomatosis.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	74-78
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	interleukin 10	Mus musculus	140-145
24691473-6	2014	Treatment of those same cells used in the imatinib studies with rapamycin, an inhibitor of mTOR, resulted in elevated GPx-1 and GPx-4 protein levels independent of Bcr-Abl expression.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Homo sapiens	91-95
24742865-10	2014	IL-6 levels in the circulation were increased after rapamycin and combination therapies.	Sirolimus	52-61	interleukin 6	Mus musculus	0-4
24675464-5	2014	However, 3 days following ligation with rapamycin treatment, a selective mTOR inhibitor, gland weights were maintained, 4E-BP1 and S6rp phosphorylation was inhibited, and there were morphological signs of recovery from atrophy.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Homo sapiens	73-77
24675464-6	2014	However, following 5 and 7 days of ligation and rapamycin treatment, glands expressed active mTOR and showed signs of considerable atrophy.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Homo sapiens	93-97
24675464-7	2014	This evidence suggests that inhibition of mTOR by rapamycin delays ligation-induced atrophy of salivary glands.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Homo sapiens	42-46
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	Sirolimus	136-145	vascular endothelial growth factor A	Homo sapiens	13-17
24645945-3	2014	We examined the effectiveness of the mammalian target of rapamycin (mTOR) inhibitor sirolimus in four infants with severe hyperinsulinemic hypoglycemia that had been unresponsive to maximal doses of diazoxide (20 mg per kilogram of body weight per day) and octreotide (35 mug per kilogram per day).	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	37-66
24645945-3	2014	We examined the effectiveness of the mammalian target of rapamycin (mTOR) inhibitor sirolimus in four infants with severe hyperinsulinemic hypoglycemia that had been unresponsive to maximal doses of diazoxide (20 mg per kilogram of body weight per day) and octreotide (35 mug per kilogram per day).	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	68-72
24508654-11	2014	Both rapamycin and cardamonin decreased the phosphorylation of mTOR and p70S6K in two kinds of transfected cells.	Sirolimus	5-14	mechanistic target of rapamycin kinase	Homo sapiens	63-67
24462935-9	2014	Our findings demonstrated that toxicity of simulated ischemia conditions were enhanced in HUVEC when autophagy was blocked, and that rapamycin effectively prevented OGD-evoked damage by induction of protective autophagy via inhibition of the mTOR pathway.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	242-246
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	Sirolimus	136-145	mitogen-activated protein kinase 3	Homo sapiens	185-191
24451985-9	2014	Furthermore, VEGF significantly stimulated proliferation and migration of pTr cells, but these effects were blocked by SB203580, U0126, rapamycin, and LY294002, which inhibit p38 MAPK, ERK1/2, mTOR, and PI3K, respectively.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Homo sapiens	193-197
24602288-11	2014	Rapamycin treatment significantly improved the neurobehavioral deficit after ICH, increased the number of Tregs, increased levels of interleukin-10 and transforming growth factor-beta and reduced interferon-gamma both in peripheral blood and brain.	Sirolimus	0-9	interferon gamma	Homo sapiens	196-212
24603487-6	2014	PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin.	Sirolimus	108-117	AKT serine/threonine kinase 1	Homo sapiens	11-14
24516119-0	2014	Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.	Sirolimus	0-9	tumor necrosis factor	Homo sapiens	22-25
24516119-0	2014	Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.	Sirolimus	0-9	vascular cell adhesion molecule 1	Homo sapiens	39-45
24516119-6	2014	Preventing activation of ERK1/2 reduced the ability of rapamycin to inhibit TNF-induced VCAM-1 expression.	Sirolimus	55-64	mitogen-activated protein kinase 3	Homo sapiens	25-31
24603487-6	2014	PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	93-97
24508508-3	2014	Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	35-39
24516119-6	2014	Preventing activation of ERK1/2 reduced the ability of rapamycin to inhibit TNF-induced VCAM-1 expression.	Sirolimus	55-64	tumor necrosis factor	Homo sapiens	76-79
24516119-6	2014	Preventing activation of ERK1/2 reduced the ability of rapamycin to inhibit TNF-induced VCAM-1 expression.	Sirolimus	55-64	vascular cell adhesion molecule 1	Homo sapiens	88-94
24516119-7	2014	In vivo, rapamycin inhibited mTORC2 activity and potentiated activation of ERK1/2.	Sirolimus	9-18	mitogen-activated protein kinase 3	Homo sapiens	75-81
24366076-5	2014	Rapamycin administration mitigated the exacerbated hypertrophic responses in MIF(-/-) mice.	Sirolimus	0-9	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	77-80
24516119-9	2014	Functionally, rapamycin reduced infiltration of leukocytes into renal glomeruli, an effect which was partially reversed by inhibition of ERK1/2.	Sirolimus	14-23	mitogen-activated protein kinase 3	Homo sapiens	137-143
24598733-2	2014	With only a single previously reported X-ray structure of FKBP12.6, bound to the immunosuppressant rapamycin, structural inferences for this protein have been drawn from the more extensive studies of the homologous FKBP12.	Sirolimus	99-108	FKBP prolyl isomerase 1B	Homo sapiens	58-66
24266948-4	2014	Because the mTOR pathway plays major roles in normal cell growth, metabolism, and survival, we hypothesized that inhibiting it with rapamycin before an acute myocardial ischemia-reperfusion injury (IRI) would confer cardioprotection by virtue of slowing down cardiac function and metabolism.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Sus scrofa	12-16
24334270-7	2014	As the mTOR inhibitor rapamycin up-regulated PDCD4 mRNA levels, the PI3K-Akt-mTOR signaling pathway may control the transcription of the PDCD4 gene as well as the degradation of the protein.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	7-11
24334270-7	2014	As the mTOR inhibitor rapamycin up-regulated PDCD4 mRNA levels, the PI3K-Akt-mTOR signaling pathway may control the transcription of the PDCD4 gene as well as the degradation of the protein.	Sirolimus	22-31	AKT serine/threonine kinase 1	Homo sapiens	73-76
24334270-7	2014	As the mTOR inhibitor rapamycin up-regulated PDCD4 mRNA levels, the PI3K-Akt-mTOR signaling pathway may control the transcription of the PDCD4 gene as well as the degradation of the protein.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Homo sapiens	77-81
23564336-10	2014	CONCLUSIONS: The calcineurin inhibitor cyclosporine A and the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, improve the course of AIP in MRL/Mp mice via different mechanisms.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Homo sapiens	93-97
24429254-3	2014	Here we evaluate the synergy of pharmacologically affecting both of these critical pathways using the mTOR inhibitor sirolimus and the histone deacetylase inhibitor entinostat.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Homo sapiens	102-106
24464150-4	2014	This paper wants to share experience of mTOR inhibitors sirolimus in the treatment of refractory KHE.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	40-44
23741975-0	2014	Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.	Sirolimus	0-9	AKT serine/threonine kinase 1	Homo sapiens	174-177
23741975-0	2014	Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	178-207
23741975-0	2014	Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.	Sirolimus	0-9	mitogen-activated protein kinase 1	Homo sapiens	212-247
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	BCL2 apoptosis regulator	Homo sapiens	57-62
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	139-143
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	mitogen-activated protein kinase 1	Homo sapiens	148-183
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	mitogen-activated protein kinase 1	Homo sapiens	185-188
24396066-4	2014	The Paip1-eIF3 interaction is impaired by the mTORC1 inhibitors, rapamycin and PP242.	Sirolimus	65-74	poly(A) binding protein interacting protein 1	Homo sapiens	4-9
24658085-7	2014	In vivo, the combination of rapamycin and pemetrexed inhibited growth of NSCLC xenografts, which correlated with decreased mTOR activity and suppression of pemetrexed-induced TS expression.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	123-127
24575738-4	2014	Since the mTOR pathway is often altered in PEComas and responses have been reported with mTOR-inhibitors such as sirolimus or temsirolimus, we decided to start a neoadjuvant treatment with sirolimus.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Homo sapiens	89-93
24575738-4	2014	Since the mTOR pathway is often altered in PEComas and responses have been reported with mTOR-inhibitors such as sirolimus or temsirolimus, we decided to start a neoadjuvant treatment with sirolimus.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Homo sapiens	10-14
24575738-9	2014	For patients with a large and histologically aggressive PEComa, we think that neoadjuvant treatment with mTOR-inhibitor sirolimus may be considered to facilitate surgery and allow early control of a potentially metastatic disease.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Homo sapiens	105-109
24570486-6	2014	Rapamycin treatment of mice restored Akt activity, suggesting that the denervation-induced increase in mTORC1 activity was producing feedback inhibition of Akt.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	37-40
24570486-6	2014	Rapamycin treatment of mice restored Akt activity, suggesting that the denervation-induced increase in mTORC1 activity was producing feedback inhibition of Akt.	Sirolimus	0-9	thymoma viral proto-oncogene 1	Mus musculus	156-159
24586420-2	2014	Analogs of the allosteric mTOR inhibitor rapamycin are approved for mantle cell lymphoma but have limited efficacy in other blood cancers.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	26-30
24577082-9	2014	Pretreatment with Akt inhibitor viii and rapamycin inhibited Akt and S6 phosphorylation events, mitochondrial reactive oxygen species production, and necroptosis by over 50% without affecting RIPK1-RIPK3 complex assembly.	Sirolimus	41-50	thymoma viral proto-oncogene 1	Mus musculus	61-64
24586420-3	2014	ATP-competitive "active-site" mTOR inhibitors produce more complete mTOR inhibition and are more effective than rapamycin in preclinical models of leukemia, lymphoma and multiple myeloma.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Homo sapiens	30-34
24528777-7	2014	Since mycobacterial killing could be observed only at fairly high concentrations of the mTOR inhibitors, exceeding doses necessary to inhibit mTOR, we hypothesized that high doses of Rapamycin, the most commonly utilized mTOR inhibitor for inducing autophagic killing, may exert a direct bactericidal effect on the mycobacteria.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Homo sapiens	88-92
24558502-6	2014	Rapamycin, a mTOR inhibitor, is effective in treating TSC-associated angiofibromas.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	13-17
24558502-6	2014	Rapamycin, a mTOR inhibitor, is effective in treating TSC-associated angiofibromas.	Sirolimus	0-9	TSC complex subunit 1	Homo sapiens	54-57
24226526-2	2014	Many of these advances originated from studies of the genetic disease tuberous sclerosis complex (TSC), leading to one of the clearest therapeutic opportunities to target mTOR with rapamycin and its analogs ("rapalogs"), which effectively inhibit mTOR complex 1 (mTORC1) by an allosteric mechanism.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Homo sapiens	171-175
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Homo sapiens	95-99
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	182-185
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	AKT serine/threonine kinase 1	Homo sapiens	288-291
24057571-8	2014	Treatment with rapamycin, an mTOR inhibitor, MK2206, an Akt inhibitor, and BI-D1870, a RSK inhibitor, partially suppressed CdCl2-induced ATF4 expression.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	29-33
24100276-7	2014	Finally, combination of the FGFR inhibitor BGJ398 with rapamycin significantly inhibits AKT phosphorylation and enhances their antiproliferative effects in FGFR-addicted cells, suggesting an effective combination strategy for clinical development of FGFR inhibitors.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	88-91
24269559-5	2014	Rapamycin (1muM) inhibited ecdysteroid secretion in Carcinus maenas and Gecarcinus lateralis YOs in vitro, indicating that ecdysteroidogenesis requires mTOR-dependent protein synthesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	152-156
24300666-4	2014	The MTOR inhibitor rapamycin was used as a reference treatment to emphasize the differences between an MTOR-dependent and -independent autophagy-induction.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	4-8
24377908-1	2014	Sirolimus and its derivate everolimus are two immunosuppressive drugs with similar chemical structure that inhibit the proliferation of T cells by interfering with a serine-threonine kinase, called mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	198-202
23954967-2	2014	3-Methyladenine (3-MA) is a selective inhibitor of autophagy, whereas rapamycin, an antifungal agent, is a specific inducer of autophagy, inhibiting the protein mammalian target of rapamycin.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Homo sapiens	161-190
24101601-8	2014	These data demonstrate the potential for pharmacological inhibition of mTOR kinase activity to activate mitophagy as a strategy to drive selection against a heteroplasmic mtDNA G11778A mutation and raise the exciting possibility that rapamycin may have therapeutic potential for the treatment of mitochondrial disorders associated with heteroplasmic mtDNA mutations, although further studies are needed to determine if a similar strategy will be effective for other mutations and other cell types.	Sirolimus	234-243	mechanistic target of rapamycin kinase	Homo sapiens	71-75
24067927-9	2014	The STS- and C.C-induced dopaminergic neurite outgrowth was suppressed by rapamycin, an mTOR inhibitor.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Homo sapiens	88-92
23853042-5	2014	The mTOR inhibitors such as rapamycin have been proven to ameliorate the AD-like pathology and cognitive deficits effectively in a broad range of animal models.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	4-8
24497939-2	2014	MMF alone or in combination with sirolimus, can be the basis of calcineurin inhibitor (CNI)-free, kidney sparing drug protocols.	Sirolimus	33-42	calcineurin binding protein 1	Rattus norvegicus	64-85
24395886-5	2014	Estradiol increased the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in prostaglandin biosynthesis, which was also increased at baseline in TSC-deficient cells and was not affected by rapamycin treatment.	Sirolimus	202-211	prostaglandin-endoperoxide synthase 2	Homo sapiens	56-61
24438107-10	2014	The anti-proliferation effect and mTOR inhibition ability of rapamycin-loaded PHBHHxPEG NPs was stronger than that of drug-loaded PHBHHx NPs and free rapamycin.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Homo sapiens	34-38
24395633-3	2014	Against this background, we report a dramatic response in a young patient with advanced HL refractory to the standard treatment who responded to the combination of a pan-histone deacetylase inhibitor (vorinostat, suberoylanilide hydroxamic acid, SAHA) and mammalian target of rapamycin (mTOR) inhibitor therapy (sirolimus,rapamume).	Sirolimus	312-321	mechanistic target of rapamycin kinase	Homo sapiens	256-285
24395633-3	2014	Against this background, we report a dramatic response in a young patient with advanced HL refractory to the standard treatment who responded to the combination of a pan-histone deacetylase inhibitor (vorinostat, suberoylanilide hydroxamic acid, SAHA) and mammalian target of rapamycin (mTOR) inhibitor therapy (sirolimus,rapamume).	Sirolimus	312-321	mechanistic target of rapamycin kinase	Homo sapiens	287-291
24395633-12	2014	The morphoproteomic/morphometric findings in this "unusual responder" patient"s relapsed HL that correlate best, as a response signature with the subsequent clinical remission following rapamycin (sirolimus) and vorinostat (SAHA) therapies, center on an immune dysregulation involving an imbalance between effector and functional T regulatory cells in addition to targeting the mTOR pathway.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Homo sapiens	378-382
24505621-7	2014	Additionally, while the autophagy inhibitor chloroquine had no effect, significant neuroprotection was seen instead with two drugs that enhance autophagy induction by different mechanisms, rapamycin (mTOR-dependent) and trehalose (mTOR-independent).	Sirolimus	189-198	mechanistic target of rapamycin kinase	Homo sapiens	200-204
24316214-9	2014	Further, mTOR inhibition by rapamycin, or by mTOR siRNA knockdown, diminished alpha-MSH"s pro-survival effect in RPE cells.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Homo sapiens	9-13
24316214-9	2014	Further, mTOR inhibition by rapamycin, or by mTOR siRNA knockdown, diminished alpha-MSH"s pro-survival effect in RPE cells.	Sirolimus	28-37	proopiomelanocortin	Homo sapiens	78-87
24404143-10	2014	Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats.	Sirolimus	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	169-172
24404161-4	2014	HRES-1/Rab4 exhibited minimal baseline colocalization with LC3, which was enhanced 22-fold upon starvation or 6-fold upon rapamycin treatment.	Sirolimus	122-131	RAB4A, member RAS oncogene family	Homo sapiens	0-11
24404161-5	2014	Colocalization of HRES-1/Rab4 with mitochondria was increased &gt;2-fold by starvation or rapamycin.	Sirolimus	90-99	RAB4A, member RAS oncogene family	Homo sapiens	18-29
24404161-6	2014	HRES-1/Rab4 overexpression promoted the colocalization of mitochondria with LC3 upon starvation or rapamycin treatment.	Sirolimus	99-108	RAB4A, member RAS oncogene family	Homo sapiens	0-11
24404161-8	2014	A constitutively active mutant, HRES-1/Rab4(Q72L) showed diminished colocalization with LC3 but promoted the partitioning of mitochondria with LC3 upon starvation or rapamycin treatment.	Sirolimus	166-175	RAB4A, member RAS oncogene family	Homo sapiens	32-43
24404161-10	2014	A newly discovered C-terminally truncated native isoform, HRES-1/Rab4(1-121), showed enhanced localization to LC3 and mitochondria without starvation or rapamycin treatment.	Sirolimus	153-162	RAB4A, member RAS oncogene family	Homo sapiens	58-69
25495560-9	2014	Inhibiting MTORC2 activation with long-term exposure to rapamycin or by silencing RICTOR, a central component of the MTORC2 complex abolished AKT rephosphorylation.	Sirolimus	56-65	AKT serine/threonine kinase 1	Homo sapiens	142-145
24603476-3	2014	The present study was designed to explore the renoprotective potential of low-dose mammalian target of rapamycin (mTOR) inhibitor rapamycin in an IgAN rat model and the possible mechanism of action.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Homo sapiens	114-118
24835866-4	2014	To examine its mechanism of action, we performed genomewide microarray on human fibroblasts (from normal skin, HTS, and keloid scars) treated with the mTOR inhibitor, rapamycin.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Homo sapiens	151-155
25482947-6	2014	We found that inhibitors of the mTOR pathway including rapamycin, wortmannin, and caffeine blunted the p53 response to nucleolar stress induced by actinomycin D.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	32-36
24327332-3	2014	Rapamycin is an immunomodulatory drug that targets the mammalian target of rapamycin pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	55-84
25482947-6	2014	We found that inhibitors of the mTOR pathway including rapamycin, wortmannin, and caffeine blunted the p53 response to nucleolar stress induced by actinomycin D.	Sirolimus	55-64	tumor protein p53	Homo sapiens	103-106
25482947-10	2014	We found that rapamycin mimicked the effect of RPL11 depletion in terms of blunting the p53 response to nucleolar stress.	Sirolimus	14-23	tumor protein p53	Homo sapiens	88-91
25104960-8	2014	We report the outcome of one patient with pretreated, progressing low grade metastatic ESS treated with medroxyprogesterone acetate in combination with the mTOR inhibitor sirolimus.	Sirolimus	171-180	mechanistic target of rapamycin kinase	Homo sapiens	156-160
24575309-9	2014	Since ranolazine is a documented P-GP and CYP3A inhibitor, and sirolimus a known substrate for both pathways, it is proposed that ranolazine inhibition of P-GP and CYP3A4 contributed to the significant elevation in sirolimus exposure.	Sirolimus	215-224	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170
24407515-7	2014	In contrast, MCF-7/GSK-3beta(KD) cells displayed an elevated sensitivity to the mTORC1 blocker rapamycin compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells, while no differences between the 3 cell types were observed upon treatment with a MEK inhibitor by itself.	Sirolimus	95-104	mitogen-activated protein kinase kinase 7	Homo sapiens	251-254
24018642-6	2014	Combination of rapamycin with sunitinib resulted in enhanced cell cycle arrest in G1 phase, which was accompanied with enhanced suppression of mTOR signaling and disruption of the negative feedback loop that activate AKT upon mTORC1 inhibition.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	143-147
24018642-6	2014	Combination of rapamycin with sunitinib resulted in enhanced cell cycle arrest in G1 phase, which was accompanied with enhanced suppression of mTOR signaling and disruption of the negative feedback loop that activate AKT upon mTORC1 inhibition.	Sirolimus	15-24	AKT serine/threonine kinase 1	Homo sapiens	217-220
24018642-7	2014	Furthermore, sunitinib and rapamycin displayed synergistic activity against tube formation by human microvessel endothelial cells as well as outgrowth of endothelial tubes and microvessels both in vitro and in vivo, which is associated with down-regulation of VEGF secretion and HIF1alpha expression.	Sirolimus	27-36	vascular endothelial growth factor A	Homo sapiens	260-264
24018642-7	2014	Furthermore, sunitinib and rapamycin displayed synergistic activity against tube formation by human microvessel endothelial cells as well as outgrowth of endothelial tubes and microvessels both in vitro and in vivo, which is associated with down-regulation of VEGF secretion and HIF1alpha expression.	Sirolimus	27-36	hypoxia inducible factor 1 subunit alpha	Homo sapiens	279-288
24304514-2	2014	The concern with the use of mTORC1 inhibitors, such as rapamycin or its analogs (rapalogs), is that they cause upregulation of autophagy and suppress the negative feedback loop to Akt, which promotes cell survival, causing the therapy to be only partially effective, and relapse occurs upon cessation of treatment.	Sirolimus	55-64	AKT serine/threonine kinase 1	Homo sapiens	180-183
24304514-7	2014	Thus, the addition of resveratrol to rapamycin treatment may be a promising option for selective and targeted therapy for diseases with TSC loss and mTORC1 hyperactivation.	Sirolimus	37-46	TSC complex subunit 1	Homo sapiens	136-139
24735369-16	2014	A newly synthesised dual inhibitor of PI3K and mTOR BEZ235 has been shown to be more effective than mTOR inhibitor rapamycin.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	47-51
24496328-4	2014	We found that rapamycin decreased HIF-1 and lactate levels in proliferating and senescent cells in vitro.	Sirolimus	14-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	34-39
27128230-1	2014	Sirolimus, metabolized primarily by intestinal and hepatic CYP3A4, is a substrate for P-glycoprotein.	Sirolimus	0-9	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
27128230-2	2014	CYP3A4 inducers would be expected to decrease sirolimus exposure.	Sirolimus	46-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
27128230-3	2014	This open-label, nonrandomized study investigated effects of CYP3A4 induction, by rifampin, on sirolimus pharmacokinetics.	Sirolimus	95-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
25597356-10	2014	Cells treated with rapamycin, an inhibitor of mTOR, displayed less expression of pRKIP after H. pylori infection.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	46-50
24735369-16	2014	A newly synthesised dual inhibitor of PI3K and mTOR BEZ235 has been shown to be more effective than mTOR inhibitor rapamycin.	Sirolimus	115-124	mechanistic target of rapamycin kinase	Homo sapiens	100-104
24735369-17	2014	BEZ235 can inhibit feedback activation of PI3K/Akt pathway by rapamycin.	Sirolimus	62-71	AKT serine/threonine kinase 1	Homo sapiens	47-50
24389203-4	2014	Treatment with rapamycin significantly reduced the expression of DC-SIGN in a dose-dependent manner associated with suppression of PU.1 gene expression and the ability of DC to migrate and stimulate T cell proliferation.	Sirolimus	15-24	CD209 molecule	Homo sapiens	65-72
23530502-3	2014	Using rapamycin derivative (RAD001) as a prototype inhibitor, we aimed to systematically analyze the molecular mechanisms underlying the pleiotropic effects of mTOR signaling.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Homo sapiens	160-164
24076964-11	2014	In summary, blockade of the proximal PI3K catalytic subunit increases MMP-1 and MMP-9, whereas rapamycin decreased both MMP-1 and MMP-3.	Sirolimus	95-104	matrix metallopeptidase 3	Homo sapiens	130-135
24434865-3	2014	OBJECTIVE: Here, we investigate how different types of immunosuppressive therapy, namely the calcineurin inhibitors cyclosporin A and tacrolimus, as well as the mTOR inhibitor rapamycin, affect the function of immune cells in young and elderly persons.	Sirolimus	176-185	mechanistic target of rapamycin kinase	Homo sapiens	161-165
24434865-6	2014	All three immunosuppressive drugs inhibited the production of IL-2 equally well, whereas the production of IFN-gamma was less well inhibited by rapamycin.	Sirolimus	144-153	interferon gamma	Homo sapiens	107-116
24434958-8	2014	Further investigations are necessary to determine whether new drugs such as the mTOR inhibitor rapamycin may be effective for treatment of diffuse LM.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
26464852-0	2014	p21(WAF1/CIP1) Expression is Differentially Regulated by Metformin and Rapamycin.	Sirolimus	71-80	cyclin dependent kinase inhibitor 1A	Homo sapiens	0-3
26464852-0	2014	p21(WAF1/CIP1) Expression is Differentially Regulated by Metformin and Rapamycin.	Sirolimus	71-80	cyclin dependent kinase inhibitor 1A	Homo sapiens	4-8
26464852-0	2014	p21(WAF1/CIP1) Expression is Differentially Regulated by Metformin and Rapamycin.	Sirolimus	71-80	cyclin dependent kinase inhibitor 1A	Homo sapiens	9-13
26464852-8	2014	However, the inhibition of the mTOR pathway by rapamycin did not have a negative effect on p21 expression, suggesting that metformin regulates p21 upstream of mTOR.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Homo sapiens	31-35
24924131-6	2014	Moreover, here we demonstrate that SIRT3 expression is responsive to rapamycin, a small inhibitor of mammalian target of rapamycin that has been extensively employed as a caloric restriction mimetic.	Sirolimus	69-78	sirtuin 3	Homo sapiens	35-40
24563652-4	2014	Lithium stimulates autophagy by decreasing the intracellular myo-inositol-1,4,5-triphosphate levels, while rapamycin acts through the inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	152-181
24563652-4	2014	Lithium stimulates autophagy by decreasing the intracellular myo-inositol-1,4,5-triphosphate levels, while rapamycin acts through the inhibition of the mammalian target of rapamycin (mTOR).	Sirolimus	107-116	mechanistic target of rapamycin kinase	Homo sapiens	183-187
24924131-6	2014	Moreover, here we demonstrate that SIRT3 expression is responsive to rapamycin, a small inhibitor of mammalian target of rapamycin that has been extensively employed as a caloric restriction mimetic.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Homo sapiens	101-130
24072614-0	2014	LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.	Sirolimus	13-22	AKT serine/threonine kinase 1	Homo sapiens	109-112
24587596-0	2014	Rapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	75-79
24587596-3	2014	Since mTOR (mammalian target of rapamycin) pathway is involved in the antioxidative sestrins expression, we hypothesized that rapamycin attenuated low SS (LSS) induced endothelial dysfunction through mTOR and sestrin1 associated redox regulation.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Homo sapiens	6-10
24164895-5	2014	The mTOR inhibitor rapamycin was identified as a possible modulator, and it inhibited the mTOR-dependent phosphorylation of Mint3 that is required for FIH-1 inhibition.	Sirolimus	19-28	amyloid beta (A4) precursor protein-binding, family A, member 3	Mus musculus	124-129
24072614-0	2014	LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	113-117
24348843-0	2014	Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report.	Sirolimus	23-32	epidermal growth factor receptor	Homo sapiens	70-102
24231806-4	2013	Administration of rapamycin to these mice, which are deficient in the mitochondrial respiratory chain subunit Ndufs4 [NADH dehydrogenase (ubiquinone) Fe-S protein 4], delays onset of neurological symptoms, reduces neuroinflammation, and prevents brain lesions.	Sirolimus	18-27	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	110-116
23956145-1	2014	BACKGROUND: The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	47-76
23956145-1	2014	BACKGROUND: The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Homo sapiens	78-82
24756806-1	2014	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	81-110
24756806-1	2014	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	3-12	mechanistic target of rapamycin kinase	Homo sapiens	112-116
24756806-1	2014	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	81-110
24756806-1	2014	Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin (mTOR) and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Homo sapiens	112-116
24507028-3	2014	The drug sirolimus suppresses mTOR signaling but plays an uncertain role in the treatment of ADPKD.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Homo sapiens	30-34
24392034-4	2013	Therefore, we propose that combining ATO and rapamycin may circumvent the AKT feedback loop and increase the anti-tumor effects.	Sirolimus	45-54	AKT serine/threonine kinase 1	Homo sapiens	74-77
24231806-4	2013	Administration of rapamycin to these mice, which are deficient in the mitochondrial respiratory chain subunit Ndufs4 [NADH dehydrogenase (ubiquinone) Fe-S protein 4], delays onset of neurological symptoms, reduces neuroinflammation, and prevents brain lesions.	Sirolimus	18-27	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	118-164
24297901-5	2013	Treatment with AZD8055, an inhibitor of both Akt and mammalian target of rapamycin phosphorylation, but not with rapamycin, disrupts Akt-mediated TIF-IA stability, translocation, and activity.	Sirolimus	73-82	AKT serine/threonine kinase 1	Homo sapiens	133-136
24334905-14	2013	Rapamycin pretreatment rescued doxorubicin-induced cardiomyopathy in WT and MIF(-/-) mice.	Sirolimus	0-9	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	76-79
24056904-3	2013	Measurements of cell proliferation in human coronary artery smooth muscle cells (hCASM) demonstrated a higher antiproliferative activity of sirolimus compared with pimecrolimus.	Sirolimus	140-149	LSM1 homolog, mRNA degradation associated	Homo sapiens	81-86
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	mitogen-activated protein kinase 3	Homo sapiens	149-155
24184927-3	2013	Using the MTOR inhibitor rapamycin we augmented colchicine"s myotoxic effect by increasing the autophagic flux; this resulted in an acute myopathy with muscle necrosis.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Homo sapiens	10-14
24189100-1	2013	Hyperactivation of mechanistic target of rapamycin (MTOR) is a common feature of human cancers, and MTOR inhibitors, such as rapamycin, are thus becoming therapeutics in targeting certain cancers.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	52-56
24189100-1	2013	Hyperactivation of mechanistic target of rapamycin (MTOR) is a common feature of human cancers, and MTOR inhibitors, such as rapamycin, are thus becoming therapeutics in targeting certain cancers.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	100-104
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	AKT serine/threonine kinase 1	Homo sapiens	157-160
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	165-169
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	mitogen-activated protein kinase 3	Homo sapiens	213-219
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	AKT serine/threonine kinase 1	Homo sapiens	221-224
24012499-9	2013	This effect was attenuated by treatment with the pharmacological inhibitors U0126, LY294002 and rapamycin, which selectively block the activation of ERK1/2, Akt and mTOR, respectively, and siRNAs directed against ERK1/2, Akt and mTOR.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Homo sapiens	229-233
24018049-7	2013	The recovery of mTORC1 signaling and the failure of Akt phosphorylation to do so in the REDD1 knockout cells were accompanied by a dramatic increase in caspase-3 cleavage and cell death, both of which were blocked by rapamycin.	Sirolimus	217-226	caspase 3	Homo sapiens	152-161
23968562-7	2013	In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation.	Sirolimus	12-21	toll like receptor 7	Homo sapiens	125-130
23933173-5	2013	Rapamycin, an mTOR inhibitor, significantly suppressed ESC-positive NPC cell growth in vitro and tumor formation in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	14-18
23968562-3	2013	A clinically relevant concentration of rapamycin inhibited Toll-like receptor (TLR)-7-induced IFN-alpha secretion potently (-64%) but TLR-9-induced IFN-alpha secretion only slightly (-20%), while the same concentration suppressed proinflammatory cytokine production by TLR-7-activated and TLR-9-activated PDC with similar efficacy.	Sirolimus	39-48	interferon alpha 1	Homo sapiens	94-103
23968562-7	2013	In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation.	Sirolimus	12-21	CD4 molecule	Homo sapiens	159-162
23968562-3	2013	A clinically relevant concentration of rapamycin inhibited Toll-like receptor (TLR)-7-induced IFN-alpha secretion potently (-64%) but TLR-9-induced IFN-alpha secretion only slightly (-20%), while the same concentration suppressed proinflammatory cytokine production by TLR-7-activated and TLR-9-activated PDC with similar efficacy.	Sirolimus	39-48	toll like receptor 7	Homo sapiens	269-274
23968562-7	2013	In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation.	Sirolimus	12-21	CD4 molecule	Homo sapiens	198-201
23968562-4	2013	Rapamycin inhibited the ability of both TLR-7-activated and TLR-9-activated PDC to stimulate production of IFN-gamma and interleukin (IL)-10 by allogeneic T cells.	Sirolimus	0-9	toll like receptor 7	Homo sapiens	40-45
23974086-8	2013	RESULTS: In vitro, the CYP3A4*22 allele resulted in approximately 20% lower metabolic rates of SRL (P = 0.0411).	Sirolimus	95-98	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
23968562-4	2013	Rapamycin inhibited the ability of both TLR-7-activated and TLR-9-activated PDC to stimulate production of IFN-gamma and interleukin (IL)-10 by allogeneic T cells.	Sirolimus	0-9	interferon gamma	Homo sapiens	107-116
23968562-5	2013	Surprisingly, mTOR-inhibition enhanced the capacity of TLR-7-activated PDC to stimulate naive and memory T helper cell proliferation, which was caused by rapamycin-induced up-regulation of CD80 expression on PDC.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Homo sapiens	14-18
23968562-5	2013	Surprisingly, mTOR-inhibition enhanced the capacity of TLR-7-activated PDC to stimulate naive and memory T helper cell proliferation, which was caused by rapamycin-induced up-regulation of CD80 expression on PDC.	Sirolimus	154-163	toll like receptor 7	Homo sapiens	55-60
23968562-6	2013	Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+)  Treg .	Sirolimus	9-18	toll like receptor 7	Homo sapiens	32-37
23968562-6	2013	Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+)  Treg .	Sirolimus	9-18	CD4 molecule	Homo sapiens	86-89
23689994-2	2013	Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2.	Sirolimus	124-133	AKT serine/threonine kinase 1	Homo sapiens	64-67
24108520-5	2013	We found that brief rapamycin treatment significantly increased GLT-1 expression in cultured astrocytes.	Sirolimus	20-29	solute carrier family 1 member 2	Homo sapiens	64-69
24108520-6	2013	Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	129-133
24108520-6	2013	Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	145-149
24108520-6	2013	Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression.	Sirolimus	0-9	solute carrier family 1 member 2	Homo sapiens	197-202
23689994-2	2013	Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Homo sapiens	68-72
24067973-8	2013	We found that S6K was hyperphosphorylated in ANDV-infected, hypoxia-treated MECs and LECs and that rapamycin treatment for 1 h inhibited mTOR signaling responses and blocked permeability and giant cell formation in ANDV-infected monolayers.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Homo sapiens	137-141
23952610-2	2013	A large part of the immune response depends on the proliferation and clonal expansion of antigen-specific T cells, which depends on mTOR activation, and the pharmacological inhibition of this pathway by rapamycin is therefore potently immunosuppressive.	Sirolimus	203-212	mechanistic target of rapamycin kinase	Homo sapiens	132-136
24314180-2	2013	We examined the involvement of the mammalian target of rapamycin (mTOR) signaling pathway in granulation formation and examined the effects of rapamycin.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Homo sapiens	66-70
23911398-7	2013	Interestingly, the impaired memory CTL programming by wnt was partially rescued by mTOR inhibitor rapamycin.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Homo sapiens	83-87
24138944-1	2013	A phase I study utilizing decitabine (DAC) followed by the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, in patients with relapsed/refractory adult AML was undertaken to assess safety and feasibility.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Homo sapiens	90-94
23911398-8	2013	In conclusion, we found that crosstalk between wnt and the IL-12 signaling inhibits T-bet and mTOR pathways and impairs memory programming which can be recovered in part by rapamycin.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Homo sapiens	94-98
24344117-8	2013	Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion.	Sirolimus	247-256	family with sequence similarity 83 member D	Homo sapiens	50-56
24344117-8	2013	Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion.	Sirolimus	247-256	F-box and WD repeat domain containing 7	Homo sapiens	71-76
24344117-8	2013	Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion.	Sirolimus	247-256	F-box and WD repeat domain containing 7	Homo sapiens	206-211
24344117-8	2013	Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion.	Sirolimus	247-256	mechanistic target of rapamycin kinase	Homo sapiens	221-225
24344117-8	2013	Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion.	Sirolimus	247-256	family with sequence similarity 83 member D	Homo sapiens	270-276
24303008-7	2013	In support of this supposition, animals in which the mTOR/S6K1 intracellular pathway was blocked by chronic rapamycin treatment, rimonabant had no effect on ghrelin secretion.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Homo sapiens	53-57
24312355-5	2013	In studies with the mTOR inhibitor rapamycin, we have elucidated the stimulatory role of a mTOR-HIF-1alpha-VEGF axis in allergic response.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	20-24
24312355-5	2013	In studies with the mTOR inhibitor rapamycin, we have elucidated the stimulatory role of a mTOR-HIF-1alpha-VEGF axis in allergic response.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Homo sapiens	91-95
24126911-4	2013	Low dose rapamycin led to a rapid activation of both AKT and ERK pathways with a subsequent increase in MKP-1 expression.	Sirolimus	9-18	thymoma viral proto-oncogene 1	Mus musculus	53-56
24126911-4	2013	Low dose rapamycin led to a rapid activation of both AKT and ERK pathways with a subsequent increase in MKP-1 expression.	Sirolimus	9-18	mitogen-activated protein kinase 1	Mus musculus	61-64
24126911-5	2013	Rapamycin treatment led to phosphorylation of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cyclic AMP-responsive elements on the Mkp-1 promoter.	Sirolimus	0-9	cAMP responsive element binding protein 1	Mus musculus	46-50
24126911-5	2013	Rapamycin treatment led to phosphorylation of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cyclic AMP-responsive elements on the Mkp-1 promoter.	Sirolimus	0-9	activating transcription factor 2	Mus musculus	87-91
24126911-8	2013	Using bone marrow-derived macrophages (BMDMs) derived from wild-type (WT) mice or mice deficient in AKT1 and AKT2 isoforms or BMDM from targeted deficiency in MEK1 and MEK2, we show that rapamycin treatment led to an increased MKP1 expression in BMDM from WT but failed to do so in BMDMs lacking the AKT1 isoform or MEK1 and MEK2.	Sirolimus	187-196	thymoma viral proto-oncogene 1	Mus musculus	300-304
26824026-10	2013	We found that both rapamycin, a specific mTORC1 blocker, and PP242 a mTOR antagonist induce the arrest of myeloma cells irrespective of bortezomib sensitivity.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Homo sapiens	41-45
24049142-8	2013	Reactive oxygen species (ROS) increased by 32% after TGF-beta1 exposure for 48 h. TGF-beta activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-beta1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation.	Sirolimus	125-134	transforming growth factor beta 1	Homo sapiens	53-61
24123683-7	2013	However, the concurrent administration of rapamycin, with or without IL-2/anti-IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer.	Sirolimus	42-51	CD4 molecule	Homo sapiens	169-172
24123683-10	2013	These data demonstrate that CD4 iTregs can be produced rapidly in large, clinically relevant numbers and, when transferred in the presence of systemic rapamycin and IL-2, induce tolerance in transplant recipients.	Sirolimus	151-160	CD4 molecule	Homo sapiens	28-31
24231729-4	2013	The mTOR inhibitor, rapamycin, reduced the viability of CD133(+) pancreatic cancer cells and sphere formation which is an index of self-renewal of stem-like cells, indicating that the mTOR pathway functions to maintain cancer stem-like cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	4-8
24231729-4	2013	The mTOR inhibitor, rapamycin, reduced the viability of CD133(+) pancreatic cancer cells and sphere formation which is an index of self-renewal of stem-like cells, indicating that the mTOR pathway functions to maintain cancer stem-like cells.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Homo sapiens	184-188
24049142-8	2013	Reactive oxygen species (ROS) increased by 32% after TGF-beta1 exposure for 48 h. TGF-beta activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-beta1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation.	Sirolimus	125-134	mechanistic target of rapamycin kinase	Homo sapiens	136-140
24049142-8	2013	Reactive oxygen species (ROS) increased by 32% after TGF-beta1 exposure for 48 h. TGF-beta activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-beta1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation.	Sirolimus	125-134	transforming growth factor beta 1	Homo sapiens	177-186
24260371-1	2013	Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	99-128
24106124-2	2013	The purpose of this study was to examine the effects of rapamycin (an inhibitor of the mammalian target of rapamycin [mTOR] pathway) on myofibroblast formation in vitro and in-vivo.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	87-116
24106124-2	2013	The purpose of this study was to examine the effects of rapamycin (an inhibitor of the mammalian target of rapamycin [mTOR] pathway) on myofibroblast formation in vitro and in-vivo.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Homo sapiens	118-122
24157830-8	2013	CONCLUSION: The mTOR inhibitor rapamycin significantly contributes to tumour growth inhibition and normalisation of the tumour vasculature through potent antiangiogenic effects.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Homo sapiens	16-20
24260371-1	2013	Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Homo sapiens	130-134
24265670-8	2013	Among T cells, the frequency of Treg was increased in rapamycin treated mice in draining lymph nodes (16.9 +- 2.2% vs. 9.3 +- 1.4%, p&lt;0.001), which were mostly activated regulatory T cells (CD62L(low)CD44(high): 58.1 +- 5.78% vs. 33.1 +- 7%, treated vs. untreated, p&lt;0.001).	Sirolimus	54-63	selectin, lymphocyte	Mus musculus	193-198
24244418-3	2013	As little as 30 min of RPM exposure resulted in increased expression of several genes responsible for cell motility, structure and integrity (beta-actin); control of cell growth, cell proliferation, cell differentiation and apoptosis (TGF-beta1, osteopontin); and cytoskeletal components such as microtubules (beta-tubulin) and intermediate filaments (vimentin).	Sirolimus	23-26	transforming growth factor beta 1	Homo sapiens	235-244
23932230-5	2013	Treatment of ARH-77 cells with the NF-kappaB inhibitor dimethyl fumarate or the mTOR inhibitor rapamycin suppressed NF-kappaB p65 nuclear translocation and enhanced the cytotoxic effect of melphalan.	Sirolimus	95-104	low density lipoprotein receptor adaptor protein 1	Homo sapiens	13-16
23932230-5	2013	Treatment of ARH-77 cells with the NF-kappaB inhibitor dimethyl fumarate or the mTOR inhibitor rapamycin suppressed NF-kappaB p65 nuclear translocation and enhanced the cytotoxic effect of melphalan.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Homo sapiens	80-84
23316753-6	2013	As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	23-52
24085506-2	2013	However, current immunosuppression regimens containing tacrolimus and sirolimus have been shown to induce insulin resistance in rodents.	Sirolimus	70-79	insulin	Homo sapiens	106-113
23963679-2	2013	The analysis of function of TOR in plant growth and development has been limited by the fact that plants are very poorly sensitive to rapamycin.	Sirolimus	134-143	target of rapamycin	Arabidopsis thaliana	28-31
23316753-6	2013	As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	54-58
23316753-6	2013	As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Homo sapiens	139-143
24204783-1	2013	In an effort to circumvent resistance to rapamycin--an mTOR inhibitor--we searched for novel rapamycin-downstream-targets that may be key players in the response of cancer cells to therapy.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Homo sapiens	55-59
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	56-60
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	151-155
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Homo sapiens	151-155
24205274-2	2013	Studies of signal transduction pathways leading to accelerated senescence have revealed that inhibition of mammalian target of rapamycin (mTOR) by rapamycin rescues cells from senescence.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Homo sapiens	138-142
24205274-6	2013	Ly294002 (a phosphatidylinositol-3-kinase [PI3K] inhibitor) or rapamycin (an mTOR inhibitor) blocked the induction of cellular senescence markers suggesting roles for PI3K and mTOR.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	77-81
24205274-6	2013	Ly294002 (a phosphatidylinositol-3-kinase [PI3K] inhibitor) or rapamycin (an mTOR inhibitor) blocked the induction of cellular senescence markers suggesting roles for PI3K and mTOR.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Homo sapiens	176-180
24095276-5	2013	STX13 was present on LC3-positive phagophores induced by rapamycin and was highly enriched on multilamellar structures induced by dysfunctional ESCRT-III.	Sirolimus	57-66	syntaxin 12	Homo sapiens	0-5
24008047-11	2013	Interestingly, pretreatment with rapamycin, an autophagy inducer, significantly enhanced the viability of FPN-exposed cells; the enhancement of cell viability was partially due to alleviation of FPN-induced apoptosis via a decrease in levels of cleaved caspase-3.	Sirolimus	33-42	caspase 3	Homo sapiens	253-262
24159260-9	2013	CONCLUSION: To evaluate the financial consequence of adding mTOR inhibitors to the insurers" formulary, in the present study, a budget impact analysis was conducted on sirolimus.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Homo sapiens	60-64
24012930-6	2013	Rapamycin, an inhibitor of mammalian target of rapamycin, evokes autophagy, as do capsaicin or thapsigargin, a sarco(endo)plasmic reticulum Ca(2+) ATPase inhibitor that causes Ca(2+) store depletion.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	27-56
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Homo sapiens	328-332
23580240-4	2013	Temsirolimus, an analog of the mTOR inhibitor rapamycin, is approved for the treatment of relapsed MCL.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Homo sapiens	31-35
24030701-1	2013	PURPOSE: mTOR pathway hyperactivation occurs in approximately 90% of glioblastomas, but the allosteric mTOR inhibitor rapamycin has failed in the clinic.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Homo sapiens	103-107
24099268-9	2013	injection of rapamycin - a specific inhibitor of mTOR - was observed to result in the reduction of spontaneous pain responses and the attenuation of unilateral thermal and bilateral mechanical hypersensitivity elicited by BmK I.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Homo sapiens	49-53
24130883-0	2013	Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.	Sirolimus	15-24	snail family zinc finger 2	Mus musculus	98-102
24116217-5	2013	The reduced mitochondrial respiration of icp55 deletion strains in glucose media requires the mitochondrial peptide transporter, Mdl1p, and was corrected by Tor1p inhibition with rapamycin.	Sirolimus	179-188	aminopeptidase	Saccharomyces cerevisiae S288C	41-46
24124460-5	2013	Chemopreventive experiments using mTOR inhibitor-rapamycin treatment significantly delayed the onset of the ASCC tumors and reduced the tumor burden in 2cKO mice by decreasing the phosphorylation of Akt and S6.	Sirolimus	49-58	thymoma viral proto-oncogene 1	Mus musculus	199-202
23636313-8	2013	Rituximab combined with rapamycin synergically downregulated the PI3K/AKT/mTOR signaling pathway.	Sirolimus	24-33	AKT serine/threonine kinase 1	Homo sapiens	70-73
23887639-0	2013	Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-alpha activation and disruption of the p120-vascular endothelial cadherin interaction.	Sirolimus	0-9	FK506 binding protein 1b	Mus musculus	10-18
23928863-0	2013	Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into smooth muscle cells via epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signaling pathway.	Sirolimus	0-9	epidermal growth factor receptor	Homo sapiens	110-142
23928863-8	2013	Mechanistically, we showed that sirolimus-induced progenitor-SMC differentiation was mediated via epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 activation that lead to beta-catenin nuclear translocation.	Sirolimus	32-41	epidermal growth factor receptor	Homo sapiens	98-130
23928863-8	2013	Mechanistically, we showed that sirolimus-induced progenitor-SMC differentiation was mediated via epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 activation that lead to beta-catenin nuclear translocation.	Sirolimus	32-41	mitogen-activated protein kinase 3	Homo sapiens	135-174
23928863-9	2013	The ablation of epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, or beta-catenin attenuated sirolimus-induced SM-22alpha promoter activation and SMC differentiation.	Sirolimus	120-129	epidermal growth factor receptor	Homo sapiens	16-48
23928863-9	2013	The ablation of epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, or beta-catenin attenuated sirolimus-induced SM-22alpha promoter activation and SMC differentiation.	Sirolimus	120-129	mitogen-activated protein kinase 3	Homo sapiens	50-91
23928863-10	2013	CONCLUSIONS: These findings provide direct evidence of sirolimus-induced progenitor cell migration and differentiation into SMC via CXCR4 and epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signal pathways, thus implicating a novel mechanism of restenosis formation after sirolimus-eluting stent treatment.	Sirolimus	55-64	epidermal growth factor receptor	Homo sapiens	142-174
23928863-10	2013	CONCLUSIONS: These findings provide direct evidence of sirolimus-induced progenitor cell migration and differentiation into SMC via CXCR4 and epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signal pathways, thus implicating a novel mechanism of restenosis formation after sirolimus-eluting stent treatment.	Sirolimus	308-317	epidermal growth factor receptor	Homo sapiens	142-174
23636313-8	2013	Rituximab combined with rapamycin synergically downregulated the PI3K/AKT/mTOR signaling pathway.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Homo sapiens	74-78
24108003-7	2013	Interestingly, rapamycin, an inhibitor of MTOR, enhanced the expression of the autophagosomal marker LC3-II and GRP was localized within LC3-II-marked autophagosomes in vitro as well as in vivo, indicating autophagy-mediated degradation of GRP.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	42-46
23742760-5	2013	We show that inhibition of mTORC1 with rapamycin causes a reduction of PrP(Sc) accumulation at similar low levels as seen when the interaction between the translation initiation factors eIF4E and eIF4G downstream mTORC1 is inhibited using 4EGI-1.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	27-33
23924694-7	2013	Map4k4 silencing in cultured adipocytes elevates both the total protein expression and cleavage of sterol-regulated element binding protein-1 (Srebp-1) in a rapamycin-sensitive manner, consistent with Map4k4 signaling via mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	CREB regulated transcription coactivator 1	Mus musculus	265-271
23938603-8	2013	Rapamycin fully inhibited mTORC1 and partially inhibited mTORC2 activities, including the phosphorylation of Akt (serine 473) and PKCalpha, in vascular tumor cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	26-32
23938603-8	2013	Rapamycin fully inhibited mTORC1 and partially inhibited mTORC2 activities, including the phosphorylation of Akt (serine 473) and PKCalpha, in vascular tumor cells.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	57-63
23742760-5	2013	We show that inhibition of mTORC1 with rapamycin causes a reduction of PrP(Sc) accumulation at similar low levels as seen when the interaction between the translation initiation factors eIF4E and eIF4G downstream mTORC1 is inhibited using 4EGI-1.	Sirolimus	39-48	prion protein	Mus musculus	71-74
23742760-5	2013	We show that inhibition of mTORC1 with rapamycin causes a reduction of PrP(Sc) accumulation at similar low levels as seen when the interaction between the translation initiation factors eIF4E and eIF4G downstream mTORC1 is inhibited using 4EGI-1.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	213-219
23948070-9	2013	The increased expression of PSD95 and the interaction ratio of GluA2-PSD95 or NR2B-PSD95 could also be inhibited by intrathecal injection of rapamycin.	Sirolimus	141-150	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	63-68
24277558-10	2013	Following extensive research on the pathologic activation of the mTORC1 pathway, an initial way of halting progression has been found in using mTORC1 inhibitors (Sirolimus, Everolimus).	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	65-71
23673367-3	2013	Both complexes are sensitive to a pharmacological inhibitor, torin1, although only mTORC1 is inhibited by rapamycin.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	83-89
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	121-125
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	158-162
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	CD19 molecule	Homo sapiens	166-170
23991179-1	2013	Mammalian target of rapamycin complex 1 and 2 (mTORC1/2) are overactive in colorectal carcinomas; however, the first generation of mTOR inhibitors such as rapamycin have failed to show clinical benefits in treating colorectal carcinoma in part due to their effects only on mTORC1.	Sirolimus	20-29	CREB regulated transcription coactivator 2	Mus musculus	47-55
23991179-1	2013	Mammalian target of rapamycin complex 1 and 2 (mTORC1/2) are overactive in colorectal carcinomas; however, the first generation of mTOR inhibitors such as rapamycin have failed to show clinical benefits in treating colorectal carcinoma in part due to their effects only on mTORC1.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	47-53
23601176-4	2013	By combining a low dose of rapamycin, to reduce activity of the target of rapamycin complex 1 (TORC1) protein kinase, and myriocin, to reduce sphingolipid synthesis, we show enhancement of autophagy, genomic stability, mitochondrial function, and AMP kinase pathway activity.	Sirolimus	27-36	CREB regulated transcription coactivator 1	Homo sapiens	64-93
23601176-4	2013	By combining a low dose of rapamycin, to reduce activity of the target of rapamycin complex 1 (TORC1) protein kinase, and myriocin, to reduce sphingolipid synthesis, we show enhancement of autophagy, genomic stability, mitochondrial function, and AMP kinase pathway activity.	Sirolimus	27-36	CREB regulated transcription coactivator 1	Homo sapiens	95-100
23963659-10	2013	Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	15-21
23963659-10	2013	Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	158-164
23747720-0	2013	eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase.	Sirolimus	50-59	eukaryotic translation initiation factor 4E	Cricetulus griseus	0-5
23716625-10	2013	Corneal TGF-beta1 levels were lower in the rapamycin-treated group than in the control group at 4 weeks after chemical burn injury (P &lt; 0.05).	Sirolimus	43-52	transforming growth factor, beta 1	Mus musculus	8-17
23716625-13	2013	Rapamycin protected the cornea from chemical damage via reduction of IL-6 and TGF-beta1 expression.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	78-87
23633667-5	2013	Therefore, rapamycin induction of T cell autophagy can be used for gene therapy applications, including the CD19-DTYMKDelta cell-fate control axis to improve the safety of T cell immuno-gene therapy.	Sirolimus	11-20	CD19 molecule	Homo sapiens	108-112
23759595-5	2013	To further define the role of mTORC1 cascade in AKT/Ras induced HCC development, the mTORC1 inhibitor Rapamycin was administered to AKT/Ras mice at the time when small tumors started to emerge in the liver.	Sirolimus	102-111	CREB regulated transcription coactivator 1	Mus musculus	85-91
24277558-10	2013	Following extensive research on the pathologic activation of the mTORC1 pathway, an initial way of halting progression has been found in using mTORC1 inhibitors (Sirolimus, Everolimus).	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	143-149
23108404-5	2013	The endoplasmic reticulum Ca(2+) sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	144-150
23935103-1	2013	Five different physiological conditions have been used interchangeably to establish the sequence of molecular events needed to achieve nitrogen-responsive down-regulation of TorC1 and its subsequent regulation of downstream reporters: nitrogen starvation, methionine sulfoximine (Msx) addition, nitrogen limitation, rapamycin addition, and leucine starvation.	Sirolimus	316-325	CREB regulated transcription coactivator 1	Homo sapiens	174-179
23585690-8	2013	Rapamycin-induced inhibition of mammalian/mechanistic target of rapamycin complex 1 (mTORC1), a mediator of the feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased cytoplasmic FAS enzyme activity, and increased PPARalpha target gene expression.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	85-91
23826229-0	2013	Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.	Sirolimus	12-21	CD3 antigen, epsilon polypeptide	Mus musculus	30-33
23826229-6	2013	Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05).	Sirolimus	32-41	CD3 antigen, epsilon polypeptide	Mus musculus	309-312
23826229-6	2013	Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05).	Sirolimus	32-41	CD3 antigen, epsilon polypeptide	Mus musculus	309-312
23826229-6	2013	Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P&lt;0.05).	Sirolimus	318-327	CD3 antigen, epsilon polypeptide	Mus musculus	23-26
23661807-7	2013	These Rheb transgenic mice exhibited increased activation of mTORC1 signaling in both kidney tubular and interstitial cells as well as progressive interstitial renal fibrosis; rapamycin inhibited these effects.	Sirolimus	176-185	Ras homolog enriched in brain	Mus musculus	6-10
23661807-7	2013	These Rheb transgenic mice exhibited increased activation of mTORC1 signaling in both kidney tubular and interstitial cells as well as progressive interstitial renal fibrosis; rapamycin inhibited these effects.	Sirolimus	176-185	CREB regulated transcription coactivator 1	Mus musculus	61-67
23661807-8	2013	Similarly, mice with fibroblast-specific deletion of Tsc1, a negative regulator of Rheb, exhibited activated mTORC1 signaling in kidney interstitial fibroblasts and increased renal fibrosis, both of which rapamycin abolished.	Sirolimus	205-214	TSC complex subunit 1	Mus musculus	53-57
23576438-6	2013	Knockdown of HSF-1 increased the LC3 lipidation associated with formation of autophagosomal organelles, whereas depletion of HSF-1 potentiated both starvation- and rapamycin-induced autophagy.	Sirolimus	164-173	heat shock transcription factor 1	Homo sapiens	125-130
24034707-0	2013	Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells.	Sirolimus	0-9	interleukin 27	Homo sapiens	41-46
23643747-4	2013	This effect was abolished by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	Sirolimus	29-38	CREB regulated transcription coactivator 1	Mus musculus	101-107
23536185-5	2013	Inhibition of mammalian target of rapamycin complex 1 (mTORC1), for example with rapamycin, increases Akt phosphorylation while inhibiting mTORC1 signaling.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
23536185-5	2013	Inhibition of mammalian target of rapamycin complex 1 (mTORC1), for example with rapamycin, increases Akt phosphorylation while inhibiting mTORC1 signaling.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	139-145
23479136-6	2013	Protracted sunitinib exposure in 786-Suni cells yielded an increase in p27 expression and a decreased sensitivity to rapamycin analogs, although mTORC1 function could be inhibited with rapamycin analogs.	Sirolimus	185-194	CREB regulated transcription coactivator 1	Mus musculus	145-151
23831578-0	2013	Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
23479136-9	2013	CONCLUSIONS: Rapamycin analogs inhibited mTORC1 downstream targets and yielded anti-proliferative effects in HCC and RCC cells.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	41-47
23831578-3	2013	Rapamycin increases eIF4E phosphorylation in cancer cells, potentially limiting their anti-cancer effects.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	20-25
23147251-5	2013	MATERIALS AND METHODS: We used PP242, a dual inhibitor of mTORC1/mTORC2 and the mTORC1 specific inhibitor rapamycin.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	80-86
23831578-4	2013	Here we show that the rapamycin-induced increase in eIF4E phosphorylation reflects increased activity of Mnk2 but not Mnk1.	Sirolimus	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
23922392-7	2013	In direct support of SAD-A as a unique mediator of mTORC1 signaling in islet beta-cells, we demonstrate that glucose dramatically stimulated SAD-A protein translation in isolated mouse islets, which was potently inhibited by rapamycin, an inhibitor of mTORC1.	Sirolimus	225-234	BR serine/threonine kinase 2	Mus musculus	21-26
23386687-3	2013	Rapamycin and related drugs have been shown to have clinical benefit for these tumors in patients with TSC and those with sporadic forms of TSC-related neoplasms.	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	103-106
23386687-3	2013	Rapamycin and related drugs have been shown to have clinical benefit for these tumors in patients with TSC and those with sporadic forms of TSC-related neoplasms.	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	140-143
23922392-7	2013	In direct support of SAD-A as a unique mediator of mTORC1 signaling in islet beta-cells, we demonstrate that glucose dramatically stimulated SAD-A protein translation in isolated mouse islets, which was potently inhibited by rapamycin, an inhibitor of mTORC1.	Sirolimus	225-234	CREB regulated transcription coactivator 1	Mus musculus	51-57
23922392-7	2013	In direct support of SAD-A as a unique mediator of mTORC1 signaling in islet beta-cells, we demonstrate that glucose dramatically stimulated SAD-A protein translation in isolated mouse islets, which was potently inhibited by rapamycin, an inhibitor of mTORC1.	Sirolimus	225-234	BR serine/threonine kinase 2	Mus musculus	141-146
23922392-7	2013	In direct support of SAD-A as a unique mediator of mTORC1 signaling in islet beta-cells, we demonstrate that glucose dramatically stimulated SAD-A protein translation in isolated mouse islets, which was potently inhibited by rapamycin, an inhibitor of mTORC1.	Sirolimus	225-234	CREB regulated transcription coactivator 1	Mus musculus	252-258
23297825-2	2013	The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is in sensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
23863152-3	2013	On the other hand, the rapamycin-insensitive mTORC2 responds to the presence of growth factors such as insulin by phosphorylating Akt to promote its maturation and allosteric activation.	Sirolimus	23-32	CREB regulated transcription coactivator 2	Mus musculus	45-51
23297825-2	2013	The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is in sensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation.	Sirolimus	24-33	CREB regulated transcription coactivator 2	Mus musculus	273-279
23252795-2	2013	The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR signaling, including rapalogs (sirolimus, temsirolimus, everolimus and deforolimus), which complex with FK506-binding protein 12 (FK-BP12) to inhibit mTOR complex 1 (MTORC1) activity in an allosteric manner, or the more recent ATP-competitive mTOR inhibitors (mTORi), which target the catalytic site of the enzyme.	Sirolimus	135-144	FKBP prolyl isomerase 1A	Homo sapiens	208-232
23252795-2	2013	The importance of mTOR in health and diseases has fueled the development of molecules that inhibit mTOR signaling, including rapalogs (sirolimus, temsirolimus, everolimus and deforolimus), which complex with FK506-binding protein 12 (FK-BP12) to inhibit mTOR complex 1 (MTORC1) activity in an allosteric manner, or the more recent ATP-competitive mTOR inhibitors (mTORi), which target the catalytic site of the enzyme.	Sirolimus	135-144	FKBP prolyl isomerase 1A	Homo sapiens	234-241
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	interleukin 1 complex	Mus musculus	0-4
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	insulin-like growth factor 1	Mus musculus	150-155
22875246-0	2013	Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	93-99
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	Sirolimus	250-259	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
23722550-7	2013	In tumor xenografts, we showed that administering rapamycin delayed tumor regrowth after irradiation and increased senescence-associated beta-galactosidase staining in the tumor.	Sirolimus	50-59	galactosidase beta 1	Homo sapiens	137-155
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	41-47
24096474-6	2013	ChIMP is potentially extendable to small-molecule drug discovery, as engineering FK506-binding protein into intracellular sites within CaV1.2-alpha1C permits heterodimerization-initiated channel inhibition with rapamycin.	Sirolimus	211-220	ring finger and CHY zinc finger domain containing 1	Homo sapiens	0-5
23117422-7	2013	Immunohistochemistry using antibodies against TH indicated that the number of dopaminergic neurons in the substantia nigra following MPTP treatment was significantly higher in rapamycin-treated mice compared with saline-treated controls (p &lt; 0.01).	Sirolimus	176-185	tyrosine hydroxylase	Mus musculus	46-48
23117422-13	2013	These results demonstrate that treatment with rapamycin is able to prevent the loss of TH-positive neurons and to ameliorate the loss of DOPAC following MPTP treatment, likely via activation of autophagy/lysosome pathways.	Sirolimus	46-55	tyrosine hydroxylase	Mus musculus	87-89
23089982-5	2012	Interestingly, despite apparent inactivation of the PI3K/AKT signaling pathway, resistant cells exhibited constitutive activation of mammalian target of rapamycin complex 1 (mTORC1) and were highly sensitive to mTOR inhibition with rapamycin and the dual PI3K/mTOR inhibitor NVP-BEZ235.	Sirolimus	153-162	CREB regulated transcription coactivator 1	Mus musculus	174-180
23007575-0	2012	The expression of URGCP gene in prostate cancer cell lines: correlation with rapamycin.	Sirolimus	77-86	upregulator of cell proliferation	Homo sapiens	18-23
23007575-8	2012	The mean relative ratios of URGCP gene expression in DU145, LNCAP and PC3 cells were found as -1.48, 6.59 and -13.00, respectively, when compared to rapamycin-free cells.	Sirolimus	149-158	upregulator of cell proliferation	Homo sapiens	28-33
22859719-11	2012	In 2cKO HNSCC tongue tumors, rapamycin treatment induced apoptosis, inhibited cell proliferation and phosphorylation of Akt and S6, and decreased survivin expression.	Sirolimus	29-38	baculoviral IAP repeat-containing 5	Mus musculus	146-154
22859719-12	2012	CONCLUSIONS: These findings indicate that tumorigenesis in 2cKO HNSCC is associated with activation of the Akt/mTOR/survivin pathway, and inhibition of this pathway by rapamycin treatment successfully ameliorates the onset and progression of tumorigenesis.	Sirolimus	168-177	baculoviral IAP repeat-containing 5	Mus musculus	116-124
22973301-0	2012	Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	105-111
22973301-0	2012	Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	116-122
22973301-1	2012	Rapamycin, an inhibitor of mTOR complex 1 (mTORC1), improves insulin sensitivity in acute studies in vitro and in vivo by disrupting a negative feedback loop mediated by S6 kinase.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	43-49
22973301-2	2012	We find that rapamycin has a clear biphasic effect on insulin sensitivity in C2C12 myotubes, with enhanced responsiveness during the first hour that declines to almost complete insulin resistance by 24-48 h. We and others have recently observed that chronic rapamycin treatment induces insulin resistance in rodents, at least in part due to disruption of mTORC2, an mTOR-containing complex that is not acutely sensitive to the drug.	Sirolimus	13-22	CREB regulated transcription coactivator 2	Mus musculus	355-361
22973301-7	2012	Selective inhibition of mTORC1 or mTORC2 by shRNA-mediated knockdown of specific components (Raptor and Rictor, respectively) confirmed that mitochondrial effects of rapamycin are mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of mTORC2.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	24-30
22973301-7	2012	Selective inhibition of mTORC1 or mTORC2 by shRNA-mediated knockdown of specific components (Raptor and Rictor, respectively) confirmed that mitochondrial effects of rapamycin are mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of mTORC2.	Sirolimus	166-175	CREB regulated transcription coactivator 2	Mus musculus	34-40
22973301-7	2012	Selective inhibition of mTORC1 or mTORC2 by shRNA-mediated knockdown of specific components (Raptor and Rictor, respectively) confirmed that mitochondrial effects of rapamycin are mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of mTORC2.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	180-186
22973301-7	2012	Selective inhibition of mTORC1 or mTORC2 by shRNA-mediated knockdown of specific components (Raptor and Rictor, respectively) confirmed that mitochondrial effects of rapamycin are mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of mTORC2.	Sirolimus	166-175	CREB regulated transcription coactivator 2	Mus musculus	264-270
22973301-8	2012	Thus, mTORC2 disruption, rather than inhibition of mitochondria, causes insulin resistance in rapamycin-treated myotubes, and this system may serve as a useful model to understand the effects of rapamycin on mTOR signaling in vivo.	Sirolimus	94-103	CREB regulated transcription coactivator 2	Mus musculus	6-12
22767218-8	2012	Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin.	Sirolimus	137-146	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
22696593-4	2012	In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	42-48
22696593-4	2012	In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance.	Sirolimus	185-194	CREB regulated transcription coactivator 1	Mus musculus	42-48
22496407-4	2012	The activity of mTOR complex 1 (mTORC1) is necessary for renal regeneration and repair after AKI, and inhibition of mTORC1 by rapamycin has been shown to delay recovery from ischemic AKI in animal studies, and to prolong delayed graft function in humans who have received a kidney transplant.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	116-122
22544908-0	2012	Functional analysis of the single Est1/Ebs1 homologue in Kluyveromyces lactis reveals roles in both telomere maintenance and rapamycin resistance.	Sirolimus	125-134	Est1p	Saccharomyces cerevisiae S288C	34-38
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	CD28 molecule	Homo sapiens	193-197
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	CD28 molecule	Homo sapiens	221-225
22421346-6	2012	Treatment of osteoblast precursor cells with rapamycin or FK-506, either alone, or synergistically with BMP-2, increased levels of phospho-Smad 1/5/8 protein and transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblast differentiation.	Sirolimus	45-54	bone morphogenetic protein 2	Homo sapiens	104-109
22421346-6	2012	Treatment of osteoblast precursor cells with rapamycin or FK-506, either alone, or synergistically with BMP-2, increased levels of phospho-Smad 1/5/8 protein and transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblast differentiation.	Sirolimus	45-54	Sp7 transcription factor	Homo sapiens	187-190
22466652-5	2012	Mouse models of obesity also exhibit increased hepatic activity of mammalian target of rapamycin complex 1 (mTORC1) and ER stress, and we found that administration of the mTOR inhibitor rapamycin to ob/ob mice reduced ER stress and increased hepatic sortilin-1 levels.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	108-114
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	CREB regulated transcription coactivator 2	Mus musculus	60-66
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	CREB regulated transcription coactivator 2	Mus musculus	61-66
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	ras homolog family member A	Mus musculus	171-175
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	cell division cycle 42	Mus musculus	177-182
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	Rac family small GTPase 1	Mus musculus	188-192
22311674-4	2012	In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin.	Sirolimus	45-54	S-phase kinase associated protein 2	Homo sapiens	71-75
22311674-4	2012	In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin.	Sirolimus	168-177	S-phase kinase associated protein 2	Homo sapiens	71-75
22433289-5	2012	With the use of rapamycin-mediated FKBP-FRB heterodimerization, we have developed a method for rapidly inducible activation or inactivation of small GTPases including Rac(4), Cdc42(4), RhoA(4) and Ras(5), in which rapamycin induces translocation of FKBP-fused GTPases, or their activators, to the plasma membrane where FRB is anchored.	Sirolimus	16-25	cell division cycle 42	Homo sapiens	175-180
22080835-5	2012	We found that mitophagy could be induced following treatment with the mTORC1 inhibitor rapamycin in cybrids carrying either large-scale partial deletions of mtDNA or complete depletion of mtDNA.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	70-76
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	202-207
23376634-9	2013	These data indicate that the cytostatic effect of rapamycin is suppression of both S6 kinase and eIF4E, while the cytotoxic effects are due suppression of eIF4E in the absence of S6 kinase-dependent activation of TGF-beta signals.	Sirolimus	50-59	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
23651256-5	2013	We show that Aro80 is absolutely required for Gat1 binding to the ARO9, ARO10 and ARO80 promoters upon rapamycin treatment.	Sirolimus	103-112	Aro80p	Saccharomyces cerevisiae S288C	13-18
23651256-5	2013	We show that Aro80 is absolutely required for Gat1 binding to the ARO9, ARO10 and ARO80 promoters upon rapamycin treatment.	Sirolimus	103-112	Gat1p	Saccharomyces cerevisiae S288C	46-50
23651256-5	2013	We show that Aro80 is absolutely required for Gat1 binding to the ARO9, ARO10 and ARO80 promoters upon rapamycin treatment.	Sirolimus	103-112	phenylpyruvate decarboxylase ARO10	Saccharomyces cerevisiae S288C	72-77
23651256-5	2013	We show that Aro80 is absolutely required for Gat1 binding to the ARO9, ARO10 and ARO80 promoters upon rapamycin treatment.	Sirolimus	103-112	Aro80p	Saccharomyces cerevisiae S288C	82-87
23730416-3	2013	On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	96-102
23696882-12	2013	In vivo, administration with rapamycin suppressed activation of mTORC1 and JNK, but not eIF2alpha, in the kidney of Cd-treated mice.	Sirolimus	29-38	CREB regulated transcription coactivator 1	Mus musculus	64-70
23691153-3	2013	Recently, the mammalian target of rapamycin complex 1 (mTORC1) pathway has been implicated in mechanisms of epileptogenesis and the mTORC1 inhibitor, rapamycin, has been proposed to have antiepileptogenic effects in preventing some types of epilepsy.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
22347189-9	2012	The importance of understanding the role of this signaling pathway in the development of addiction vulnerability is underscored by the fact that the mTORC1 inhibitor rapamycin reduces drug-seeking in pre-clinical models and preliminary evidence indicating that rapamycin suppresses drug craving in humans.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	149-155
21779001-2	2012	We found that rapamycin, an inhibitor of mTOR complex 1 (mTORC1), attenuated endoplasmic reticulum (ER) stress-induced apoptosis.	Sirolimus	14-23	CREB regulated transcription coactivator 1	Mus musculus	57-63
21993902-9	2012	The data presented an increase of G0/G1 phase cells and decrease of S phase cells             after rapamycin treatment, and the decreased expression of cyclinD1, higher expression             of p21 at mRNA level was also detected in K562 with rapamycin.	Sirolimus	245-254	cyclin D1	Homo sapiens	153-161
23691153-6	2013	Controlled cortical impact injury caused immediate hyperactivation of the mTORC1 pathway lasting at least one week, which was reversed by rapamycin treatment.	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	74-80
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	53-59
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 2	Mus musculus	64-70
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	peroxisome proliferator activated receptor gamma	Mus musculus	101-111
23443316-5	2013	Because genetic dysregulation of TGF-beta signaling is commonly observed in pancreatic cancers-with defects in the Smad4 gene being most prevalent, we hypothesized that pancreatic cancers would display a synthetic lethality to rapamycin in the presence of serum/TGF-beta.	Sirolimus	227-236	SMAD family member 4	Homo sapiens	115-120
23443316-8	2013	Suppression of rapamycin-induced Akt phosphorylation restored rapamycin sensitivity in Smad4-null, but not Smad4 wild-type pancreatic cancer cells.	Sirolimus	15-24	SMAD family member 4	Homo sapiens	87-92
23443316-8	2013	Suppression of rapamycin-induced Akt phosphorylation restored rapamycin sensitivity in Smad4-null, but not Smad4 wild-type pancreatic cancer cells.	Sirolimus	62-71	SMAD family member 4	Homo sapiens	87-92
23208421-3	2013	Antisense Uchl1 specifically promotes the translation of UCHL1 under rapamycin treatment.	Sirolimus	69-78	ubiquitin carboxy-terminal hydrolase L1	Mus musculus	10-15
23208421-3	2013	Antisense Uchl1 specifically promotes the translation of UCHL1 under rapamycin treatment.	Sirolimus	69-78	ubiquitin carboxy-terminal hydrolase L1	Mus musculus	57-62
23250913-9	2013	Further mTORC1 inhibition with rapamycin hastened weakness, atrophy and vacuolation in VCP-IBM mice.	Sirolimus	31-40	CREB regulated transcription coactivator 1	Mus musculus	8-14
22227194-6	2012	These defects are phenocopied by inhibiting mTORC1 activity with rapamycin.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	44-50
22102284-9	2012	Moreover, adult hippocampal NP proliferation induced by HU-308 and excitotoxicity was blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	118-127	CREB regulated transcription coactivator 1	Mus musculus	101-107
22113203-8	2012	At the early stage of OGD, autophagy inducer rapamycin protected against neuronal injury induced by Nampt knockdown, whereas autophagy inhibitor 3-methyladenine abolished the neuroprotective effect of Nampt partly.	Sirolimus	45-54	nicotinamide phosphoribosyltransferase	Homo sapiens	100-105
22785354-11	2012	Finally, blastocysts derived following treatment with 3-MA or rapamycin exhibited significantly decreased expression of selected transcription factors, including Pou5f1, Sox2 and Nanog.	Sirolimus	62-71	transcription factor SOX-2	Sus scrofa	170-174
23449430-5	2013	RESULTS: Western blotting of HAECs treated with Mf and the mTOR inhibitor sirolimus and 14-day rabbit iliacs treated with the combination of zotarolimus-eluting stents (ZES) and oral Mf demonstrated greater inhibition of S6 kinase (S6K), a downstream effector of mTOR complex 1, than either treatment alone.	Sirolimus	74-83	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	59-63
23143994-5	2013	Maternal administration of rapamycin, a classical mTOR inhibitor, significantly increased the survival time of Fabp4-Tsc1cKO mice for up to 23 days.	Sirolimus	27-36	TSC complex subunit 1	Mus musculus	117-121
21944908-13	2012	Inhibition of autophagy with 3MA or chloroquine abrogated tube formation, whereas its induction with rapamycin enhanced tubing and promoted HMGB1 translocation.	Sirolimus	101-110	high mobility group box 1	Homo sapiens	140-145
21874011-4	2012	It has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2), with eventual deregulation of the RHEB/MTOR/RPS6KB2 pathway, and it has been observed that some PEComas regressed during sirolimus therapy, an MTOR inhibitor.	Sirolimus	313-322	Ras homolog, mTORC1 binding	Homo sapiens	226-230
23272222-6	2012	Rapamycin, a mTORC1 inhibitor, restores the insulin signaling after downregulation of REDD1 expression.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	13-19
23227176-3	2012	By contrast, Hxt3 is endocytosed and degraded in the vacuole when cells are starved of glucose and Hxt7 in response to rapamycin treatment or when nitrogen is limiting.	Sirolimus	119-128	hexose transporter HXT7	Saccharomyces cerevisiae S288C	99-103
22859939-7	2012	FGF 23 levels were unchanged at day 2 but lower in sirolimus treated rats after 7 days.	Sirolimus	51-60	fibroblast growth factor 23	Rattus norvegicus	0-6
23080369-7	2013	Rapamycin also inhibited the RB of healthy PMNs, which was associated with impaired phosphorylation of the NOX2 component, p47phox (phox: phagocyte oxidase), on its mitogen-activated protein kinase (MAPK) site (S345) as well as a preferential inhibition of p38-MAPK relative to p44/42-MAPK.	Sirolimus	0-9	interferon induced protein 44	Homo sapiens	278-281
23339165-8	2013	Because rapamycin downregulated ERbeta in female mice, we next studied ERbeta(-/-) normotensive DOCA-salt females.	Sirolimus	8-17	estrogen receptor 2 (beta)	Mus musculus	32-38
22105664-5	2011	Downregulation of BdS6K activity by rapamycin treatment in larval stage resulted in the developmental defects of larvae, pupae, and adults, with a reduced yolk protein (YP) expression in the fat body throughout the first reproductive cycle with a substantial reduction in ovary size, and also repressed the egg development in female fruit fly.	Sirolimus	36-45	Yolk protein 1	Drosophila melanogaster	155-167
23339165-10	2013	In contrast to males, both mTORCs were decreased by rapamycin, in particular mTORC2 by 60%.	Sirolimus	52-61	CREB regulated transcription coactivator 2	Mus musculus	77-83
23391520-9	2013	Finally, knocking down Rheb by siRNA and treatment with rapamycin or lovastatin showed that not only astrocytic proliferation decreased but also neuronal protection.	Sirolimus	56-65	Ras homolog, mTORC1 binding	Homo sapiens	23-27
23402365-13	2013	In addition, the expressions of MAP1LC3A and ATG5 were higher in normal pigs than in miniature pigs both in the presence and absence of rapamycin.	Sirolimus	136-145	microtubule associated protein 1 light chain 3 alpha	Sus scrofa	32-40
24093774-3	2013	However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	73-79
24093774-3	2013	However, the dual nature of mTOR, existing in two multiprotein complexes mTORC1 and mTORC2 driven by different feedback loops, decreases the therapeutic effects of rapamycin, the specific mTOR inhibitor.	Sirolimus	164-173	CREB regulated transcription coactivator 2	Mus musculus	84-90
23555865-4	2013	The mTOR inhibitor, Rapamycin, stabilizes lung function in LAM and decreases the volume of renal angiomyolipomas, but lung function declines and angiomyolipomas regrow when treatment is discontinued, suggesting that factors induced by mTORC1 inhibition may promote the survival of TSC2-deficient cells.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	235-241
23326514-6	2013	To study the functional and pathological roles of elevated mTORC1 signaling in the oocytes, we treated the Pten-mutant mice with the specific mTORC1 inhibitor rapamycin.	Sirolimus	159-168	CREB regulated transcription coactivator 1	Mus musculus	59-65
23326514-6	2013	To study the functional and pathological roles of elevated mTORC1 signaling in the oocytes, we treated the Pten-mutant mice with the specific mTORC1 inhibitor rapamycin.	Sirolimus	159-168	CREB regulated transcription coactivator 1	Mus musculus	142-148
23476113-0	2013	Rapamycin Inhibits ALDH Activity, Resistance to Oxidative Stress, and Metastatic Potential in Murine Osteosarcoma Cells.	Sirolimus	0-9	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	19-23
23476113-6	2013	Rapamycin treatment reduces the expression and enzymatic activity of ALDH in K7M2 cells.	Sirolimus	0-9	aldehyde dehydrogenase family 3, subfamily A1	Mus musculus	69-73
23375289-6	2013	However, the increasing of both pro- and anti-inflammatory subsets of FoxP3(+) T cells also indicates the potential compromising of the effects of sirolimus on immune regulation.	Sirolimus	147-156	forkhead box P3	Homo sapiens	70-75
22627923-1	2012	Rapamycin, a specific mTOR inhibitor, has been used as a chemical activator in autophagy research both in vitro and in vivo.	Sirolimus	0-9	serine/threonine-protein kinase mTOR	Cricetulus griseus	22-26
22025690-2	2011	Using mutant mice, mimicking aspects of human preterm birth, we show here that uterine decidual senescence early in pregnancy via heightened mammalian target of rapamycin complex 1 (mTORC1) signaling is a significant contributor of preterm birth and fetal death, and that these adverse phenotypes are rescued by a low dose of rapamycin, an inhibitor of mTORC1 signaling.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	182-188
23035046-7	2012	The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9.	Sirolimus	19-28	matrix metallopeptidase 9	Mus musculus	141-146
21854390-8	2011	In our neuronal cell model, allosteric inhibition of mTORC1 by everolimus, a rapamycin analogue, did not induce autophagy or affect aggregate degradation.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	53-59
22827930-5	2012	LH/hCG-mediated stimulation of the steroidogenic enzyme mRNA was blocked by the mTORC1 inhibitor, rapamycin.	Sirolimus	98-107	glycoprotein hormones, alpha polypeptide	Homo sapiens	3-6
21930466-0	2011	Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model.	Sirolimus	55-64	PDZ and LIM domain 5	Homo sapiens	45-48
21524191-2	2011	Sirolimus and everolimus inhibited in a dose-dependent manner the uptake of [3H]-estrone sulphate by OATP1A2 and OATP1B1 and that of mycophenolic acid 7-O-glucuronide (MPAG) by OATP1B3.	Sirolimus	0-9	solute carrier organic anion transporter family member 1A2	Homo sapiens	101-108
22827930-5	2012	LH/hCG-mediated stimulation of the steroidogenic enzyme mRNA was blocked by the mTORC1 inhibitor, rapamycin.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	80-86
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	10-14
22827930-7	2012	Furthermore, pharmacological targeting of mTORC1 with rapamycin also blocked LH/hCG- or forskolin-induced expression of cAMP response element-binding protein (CREB) and steroidogenic enzymes (P450 side-chain cleavage enzyme, 3beta-hydroxysteroid dehydrogenase type 1, and 17alpha-hydroxylase/17,20 lyase) but produced no effect on steroidogenic acute regulatory protein levels.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	42-48
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	TBC1 domain family member 4	Homo sapiens	178-183
22827930-7	2012	Furthermore, pharmacological targeting of mTORC1 with rapamycin also blocked LH/hCG- or forskolin-induced expression of cAMP response element-binding protein (CREB) and steroidogenic enzymes (P450 side-chain cleavage enzyme, 3beta-hydroxysteroid dehydrogenase type 1, and 17alpha-hydroxylase/17,20 lyase) but produced no effect on steroidogenic acute regulatory protein levels.	Sirolimus	54-63	glycoprotein hormones, alpha polypeptide	Homo sapiens	80-83
21672148-0	2011	Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	78-84
22827930-9	2012	LH/hCG-stimulated androgen production was also blocked by rapamycin.	Sirolimus	58-67	glycoprotein hormones, alpha polypeptide	Homo sapiens	3-6
21672148-6	2011	Rapamycin treatment of an immortalized proximal tubular cell line induced the expression of Klotho, the phosphorylation of AKT in Ser473, downstream target of mTORC2 and the expression of RICTOR, mTORC2 main component.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	159-165
22827930-11	2012	Chromatin immunoprecipitation assays revealed the association of CREB with the proximal promoter of the Cyp17a1 gene in response to hCG, and this association was reduced by rapamycin treatment.	Sirolimus	173-182	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	104-111
21672148-6	2011	Rapamycin treatment of an immortalized proximal tubular cell line induced the expression of Klotho, the phosphorylation of AKT in Ser473, downstream target of mTORC2 and the expression of RICTOR, mTORC2 main component.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	196-202
22827930-11	2012	Chromatin immunoprecipitation assays revealed the association of CREB with the proximal promoter of the Cyp17a1 gene in response to hCG, and this association was reduced by rapamycin treatment.	Sirolimus	173-182	glycoprotein hormones, alpha polypeptide	Homo sapiens	132-135
22708827-7	2012	Rapamycin-induced dimerization of FRB and FKBP at the TGN traps the shuttling protein outside of the nucleus, making nuclear export permanent.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	42-46
21585650-7	2011	Tolerized mice instead had a CD4(+)CD25(+)FoxP3(+) T cell response to FVIII that suppressed antibody formation upon adoptive transfer, indicating a shift from Th2 to Treg if FVIII antigen was introduced to T cells during inhibition with rapamycin.	Sirolimus	237-246	coagulation factor VIII	Mus musculus	70-75
21585650-9	2011	The presence of FVIII antigen during the time of rapamycin administration was required for specific tolerance induction.	Sirolimus	49-58	coagulation factor VIII	Mus musculus	16-21
21585650-10	2011	CONCLUSIONS: The study shows that a prophylactic immune tolerance protocol for FVIII can be developed using rapamycin, a drug that is already widely in clinical application.	Sirolimus	108-117	coagulation factor VIII	Mus musculus	79-84
21851176-4	2011	The Food and Drug Administration (FDA)-approved immunosuppressive macrolide rapamycin binds immunophilin FKBP12 (FK506-binding protein) to inhibit mTORC1.	Sirolimus	76-85	FKBP prolyl isomerase 1A	Homo sapiens	92-111
22956830-0	2012	Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Straussler-Scheinker disease.	Sirolimus	0-9	prion protein	Mus musculus	44-47
22956830-6	2012	We observed a dose-related delay in disease onset, a reduction in symptom severity, and an extension of survival in rapamycin-treated Tg(PrP-A116V) mice.	Sirolimus	116-125	prion protein	Mus musculus	137-140
22700793-5	2012	Thus we employed a cell culture model of murine skeletal muscle and subjected the myotubes to CCA for 3 h per day for 4 consecutive days in the presence or absence of the mTORC1 inhibitor rapamycin.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	171-177
21851176-4	2011	The Food and Drug Administration (FDA)-approved immunosuppressive macrolide rapamycin binds immunophilin FKBP12 (FK506-binding protein) to inhibit mTORC1.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	147-153
21851176-5	2011	Unlike most other interventions tested to date, inhibition of mTORC1 by rapamycin extends life span in old mice, likely by a combination of increased autophagy and decreased mRNA translation.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	62-68
22700793-7	2012	Rapamycin-mediated inhibition of mTORC1 did not suppress these CCA-induced increases in mitochondrial proteins and organelle content.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	33-39
21592956-4	2011	Both PP242 and Torin1 blocked thrombin and insulin-like growth factor 1-mediated Akt Ser(473) phosphorylation with an IC(50) between 1 and 5 nm, whereas the mTORC1 inhibitor rapamycin had no effect.	Sirolimus	174-183	CREB regulated transcription coactivator 1	Mus musculus	157-163
22023701-4	2012	Given that neurotoxicity is a well-established side effect of CNI, the patient was converted to rapamycin and subsequently experienced significant neurologic recovery.	Sirolimus	96-105	5'-nucleotidase, cytosolic IA	Homo sapiens	62-65
22023701-5	2012	The temporal resolution of the patient"s symptoms suggests that prompt recognition of central pontine and EPM and conversion from tacrolimus to rapamycin during the early post-operative course may have therapeutic benefits for patients undergoing pediatric transplant with CNI-related neurotoxicity.	Sirolimus	144-153	5'-nucleotidase, cytosolic IA	Homo sapiens	273-276
22820188-6	2012	To introduce a constitutively active Akt (CA-Akt) in cultured RPE cells increased MMP-9 expression, and to block mTORC1 activation by rapamycin inhibited its effect.	Sirolimus	134-143	CREB regulated transcription coactivator 1	Mus musculus	113-119
20957397-7	2011	Moreover, in both low and high AA concentrations in the presence of insulin, AICAR decreased the mTOR phosphorylation, and in the presence of both AICAR and rapamycin, AICAR reversed the effects of rapamycin.	Sirolimus	198-207	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	147-152
20957397-7	2011	Moreover, in both low and high AA concentrations in the presence of insulin, AICAR decreased the mTOR phosphorylation, and in the presence of both AICAR and rapamycin, AICAR reversed the effects of rapamycin.	Sirolimus	198-207	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	147-152
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	19-25
21076853-0	2011	mTORC1 activation in childhood ependymoma and response to sirolimus.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	0-6
21576371-3	2011	Rapamycin, an allosteric mTORC1 inhibitor, does not antagonize equally these outputs, but the reason for this is unknown.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	25-31
21576371-5	2011	Rapamycin exposure destabilizes mTORC1, but in cell lines where autophagy is drug insensitive, higher levels of mTOR-bound raptor are detected than in cells where rapamycin stimulates autophagy.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	32-38
21576371-6	2011	Using small interfering RNA (siRNA), we find that knockdown of raptor relieves autophagy and the eIF4E effector pathway from rapamycin resistance.	Sirolimus	125-134	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
21576371-7	2011	Importantly, nonefficacious concentrations of an ATP-competitive mTOR inhibitor can be combined with rapamycin to synergistically inhibit mTORC1 and activate autophagy but leave mTORC2 signaling intact.	Sirolimus	101-110	CREB regulated transcription coactivator 1	Mus musculus	138-144
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	69-78	CREB regulated transcription coactivator 2	Mus musculus	205-211
21338617-6	2011	Inhibition of phosphatidylinositol 3-kinase or Akt with LY 294002 or Akti-1/2 stimulates HSP27 phosphorylation while rapamycin, which inhibits mTORC1, does not.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	143-149
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	101-110	CREB regulated transcription coactivator 1	Mus musculus	19-25
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	101-110	CREB regulated transcription coactivator 2	Mus musculus	205-211
21639830-0	2011	The isomerase Rrd1 mediates rapid loss of the Sgs1 helicase in response to rapamycin.	Sirolimus	75-84	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	14-18
21639830-2	2011	Deletion of the RRD1 gene encoding a peptidyl prolyl isomerase resulted in mutants that are resistant to rapamycin.	Sirolimus	105-114	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	16-20
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	Sirolimus	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
21639830-4	2011	It is believed that the isomerase function of Rrd1 plays a role in changing the transcriptional profile upon rapamycin exposure.	Sirolimus	109-118	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	46-50
21639830-10	2011	Genes such as PUT4 and HSP42, known to be upregulated in the parent in response to rapamycin, were not induced in the rrd1Delta mutant if the SGS1 gene was deleted.	Sirolimus	83-92	proline permease PUT4	Saccharomyces cerevisiae S288C	14-18
21639830-12	2011	Thus, the observed Rrd1-dependent reduction in Sgs1 level may promote expression of specific classes of genes in response to rapamycin.	Sirolimus	125-134	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	19-23
21454539-9	2011	These data demonstrate that the phosphorylation status of hnRNP A1 serine 199 regulates the AKT-dependent sensitivity of cells to rapamycin and functionally links IRES-transacting factor annealing activity to cellular responses to mTOR complex 1 inhibition.	Sirolimus	130-139	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	58-66
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	81-111
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	113-121
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	175-183
22452883-0	2012	Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.	Sirolimus	131-140	CREB regulated transcription coactivator 1	Mus musculus	14-20
22452883-0	2012	Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.	Sirolimus	131-140	SMAD family member 1	Homo sapiens	38-51
22452883-2	2012	Here, we show that rapamycin activates Smads 1 and 5 in human prostate cancer cells and tissues through blocking mTORC1 kinase.	Sirolimus	19-28	SMAD family member 1	Homo sapiens	39-52
22452883-2	2012	Here, we show that rapamycin activates Smads 1 and 5 in human prostate cancer cells and tissues through blocking mTORC1 kinase.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	113-119
21329734-6	2011	Inhibition of the mTOR pathway by rapamycin eliminated the angiogenic and proliferative effects of visfatin.	Sirolimus	34-43	nicotinamide phosphoribosyltransferase	Homo sapiens	99-107
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Sirolimus	5-14	nicotinamide phosphoribosyltransferase	Homo sapiens	59-67
22452883-7	2012	Immunohistochemical analysis showed increased levels of phospho-Smad1/5 concomitant with suppression of phospho-S6 and survivin levels in PC3 human prostate cancer xenografts in athymic mice administered rapamycin (intraperitoneally, 5 mg/kg/d, 2-6 days).	Sirolimus	204-213	SMAD family member 1	Homo sapiens	64-69
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Sirolimus	5-14	glycogen synthase kinase 3 beta	Homo sapiens	76-84
22496482-7	2012	Rapamycin decreased the proliferation of ovarian cancer cells, and this was accompanied by inhibition of the phosphorylation of S6, a protein used as readout of mTORC1 function.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	161-167
21321189-7	2011	These effects were abolished by mTORC1 inhibition by rapamycin in human HepG2 cells.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	32-38
21094689-5	2011	The results showed that low-dose sirolimus selectively expanded Tregs, increased the expression of CD25(bright) and Foxp3 markers, and suppressed TCR- or allo-antigens induced CD4(+) T cell proliferation in vitro.	Sirolimus	33-42	interleukin 2 receptor subunit alpha	Homo sapiens	99-103
21094689-5	2011	The results showed that low-dose sirolimus selectively expanded Tregs, increased the expression of CD25(bright) and Foxp3 markers, and suppressed TCR- or allo-antigens induced CD4(+) T cell proliferation in vitro.	Sirolimus	33-42	forkhead box P3	Homo sapiens	116-121
21716195-1	2011	BACKGROUND: In this case report, we describe a predisposed renal transplant patient who developed FSGS with cellular and collapsing features after sirolimus exposure and discuss the potential molecular mechanisms.	Sirolimus	147-156	actinin alpha 4	Homo sapiens	98-102
21716195-10	2011	The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS.	Sirolimus	74-83	actinin alpha 4	Homo sapiens	40-44
21716195-10	2011	The etiology of cellular and collapsing FSGS was thought to be related to sirolimus based on timing of exposure and negative work up for secondary causes of collapsing FSGS.	Sirolimus	74-83	actinin alpha 4	Homo sapiens	168-172
21716195-13	2011	CONCLUSIONS: We report a case of possible sirolimus-induced collapsing FSGS in a renal transplant recipient who may have been predisposed to develop a podocytopathy possibly due to TMA and altered WT1 expression resulting from m-TOR exposure.	Sirolimus	42-51	actinin alpha 4	Homo sapiens	71-75
21428917-2	2011	Rapamycin inhibits some of the functions of mTORC1, whereas newly developed mTOR kinase inhibitors interfere with the actions of both types of complex.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	44-50
21282357-6	2011	We found that rapamycin reversed splenomegaly in Tg6/lambda-MYC mice prior to tumor formation by targeting B cells.	Sirolimus	14-23	myelocytomatosis oncogene	Mus musculus	60-63
21102526-8	2011	Low-dose rapamycin treatments have been shown to affect the translation of 5" terminal oligopyrimidine (5" TOP) tract mRNA, which encodes the translational machinery, implicating RPS6 in 5" TOP translation.	Sirolimus	9-18	ribosomal protein S6	Homo sapiens	179-183
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	CD69 molecule	Homo sapiens	117-121
22496482-8	2012	However, rapamycin had only a marginal effect on the phosphorylation status of 4E-BP1, another mTORC1 substrate.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	95-101
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	CD69 molecule	Homo sapiens	132-136
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	160-164
22496482-9	2012	Therefore, mTORC1 probably controls p4E-BP1 along two distinct pathways, one of them sensitive to rapamycin and another insensitive.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	11-17
22355179-4	2012	PI3K inhibition by LY294002 increased NIS-mediated radioiodide uptake (RAIU) mainly through upregulation of NIS expression, however, mTORC1 inhibition by Rapamycin did not increase NIS-mediated RAIU despite increased NIS protein levels.	Sirolimus	154-163	CREB regulated transcription coactivator 1	Mus musculus	133-139
21048785-3	2011	Here, we studied the effect of targeting the PI3K/mTORC1/mTORC2 pathway by PI-103 and rapamycin in melanoma cells and in a melanoma mouse model.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	50-56
21048785-3	2011	Here, we studied the effect of targeting the PI3K/mTORC1/mTORC2 pathway by PI-103 and rapamycin in melanoma cells and in a melanoma mouse model.	Sirolimus	86-95	CREB regulated transcription coactivator 2	Mus musculus	57-63
21048785-5	2011	Combined treatment with PI-103 and the prototypic mTORC1 inhibitor rapamycin led to the synergistic suppression of AKT and ribosomal S6 protein phosphorylation and to the induction of apoptosis.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	50-56
22450807-8	2012	In addition, LPS and IFN-beta-induced apoptosis was absent in cultured cells lacking STAT1, and, unlike in wild-type cells, a permissive effect of rapamycin was not observed.	Sirolimus	147-156	interferon beta 1	Homo sapiens	21-29
22461615-0	2012	Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	52-58
24843461-11	2011	The viability of hIAPP-expressing cells was increased after treatment with rapamycin, an inducer of autophagy, and decreased after treatment with 3-methyladenine, an inhibitor of autophagy.	Sirolimus	75-84	islet amyloid polypeptide	Homo sapiens	17-22
22461615-2	2012	Calorie restriction, which increases life span and insulin sensitivity, is proposed to function by inhibition of mTORC1, yet paradoxically, chronic administration of rapamycin substantially impairs glucose tolerance and insulin action.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	113-119
22461615-3	2012	We demonstrate that rapamycin disrupted a second mTOR complex, mTORC2, in vivo and that mTORC2 was required for the insulin-mediated suppression of hepatic gluconeogenesis.	Sirolimus	20-29	CREB regulated transcription coactivator 2	Mus musculus	63-69
22461615-5	2012	Thus, mTORC2 disruption is an important mediator of the effects of rapamycin in vivo.	Sirolimus	67-76	CREB regulated transcription coactivator 2	Mus musculus	6-12
22209856-2	2012	We have previously shown that in neonatal rats subjected to hypoxia-ischemia (HI) the neuroprotective effect of rapamycin was associated with increased autophagy and decreased caspase-3 activation.	Sirolimus	112-121	caspase 3	Rattus norvegicus	176-185
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	69-78	caspase 3	Rattus norvegicus	42-51
22080480-2	2012	Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	56-62
22408430-2	2012	mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
23209838-5	2012	Pretreatment with PI3K inhibitor (Ly294002), Akt inhibitor, or mTORC1 inhibitor (rapamycin) blocked the HGF-induced VEGF-A production.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	63-69
23209838-5	2012	Pretreatment with PI3K inhibitor (Ly294002), Akt inhibitor, or mTORC1 inhibitor (rapamycin) blocked the HGF-induced VEGF-A production.	Sirolimus	81-90	hepatocyte growth factor	Homo sapiens	104-107
23185517-2	2012	mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activity.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	0-6
23185517-2	2012	mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activity.	Sirolimus	114-123	CREB regulated transcription coactivator 2	Mus musculus	132-138
22880048-4	2012	Expression of BRAFV600E in NIH3T3 cells significantly suppresses MEK inhibitor (RG7167) or mTORC1 inhibitor (rapamycin) induced AKT phosphorylation (pAKT) and downstream signal activation.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	91-97
22768106-9	2012	Indeed mTORC1 inhibitor rapamycin prevented HSF1-S326 phosphorylation, suggesting that this complex is involved in HSF1 regulation in stress.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	7-13
21253593-6	2011	Examination of CD45RA+ and CD45RA- Treg subsets revealed that ATRA failed to maintain suppressive activity in either population, but interestingly, Tregs expanded in the presence of both rapamycin and ATRA displayed more suppressive activity and had a more favorable epigenetic status of the FOXP3 gene than Tregs expanded in the presence of rapamycin only.	Sirolimus	187-196	forkhead box P3	Homo sapiens	292-297
20943770-8	2011	On immunoblot of kidney, phosphorylated (Ser473) Akt (p-Akt), a marker of mTORC2 activity, was increased in female Cy/+ rats treated with rapamycin.	Sirolimus	138-147	CREB regulated transcription coactivator 2	Mus musculus	74-80
20727967-7	2011	Rapamycin also decreased carbachol-induced Ca(2+) release in HEK 293A cells in which IP(3)R-1 and IP(3)R-3 had been knocked down.	Sirolimus	0-9	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	98-106
21651476-4	2011	Rapamycin, the selective and allosteric inhibitor of mTOR, inhibits the enzyme in mTORC1, but not in mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	82-88
21627613-12	2011	During cultivation of CD4+ lymphocytes in the presence of rapamycin we noted antiproliferative effect relative to FOXP3-cells and accumulation of regulatory +-lymphocytes.	Sirolimus	58-67	forkhead box P3	Homo sapiens	114-119
21135252-4	2011	Under conditions of relatively quiescent AKT activity, treatment of cells with rapamycin resulted in upregulation of cyclin D1 and c-MYC nascent transcription, whereas in cells containing active AKT, exposure repressed transcription.	Sirolimus	79-88	cyclin D1	Homo sapiens	117-126
21135252-7	2011	Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure.	Sirolimus	163-172	cyclin D1	Homo sapiens	81-90
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	171-180	matrix metallopeptidase 2	Homo sapiens	330-335
22219636-13	2011	CONCLUSIONS: Rapamycin inhibited cell migration and extracellular matrix degradation by inhibiting endothelial-to-mesenchymal transition and the endothelial cell secretion of MMP-2 and MMP-9; these may be possible mechanisms for the inhibition of angiogenesis by rapamycin.	Sirolimus	263-272	matrix metallopeptidase 2	Homo sapiens	175-180
21931802-8	2011	CONCLUSIONS: Our data demonstrate a new role for mTOR in CXCL12-induced T cell migration, and enrich the current knowledge regarding the clinical use of rapamycin.	Sirolimus	153-162	C-X-C motif chemokine ligand 12	Homo sapiens	57-63
22768106-9	2012	Indeed mTORC1 inhibitor rapamycin prevented HSF1-S326 phosphorylation, suggesting that this complex is involved in HSF1 regulation in stress.	Sirolimus	24-33	heat shock transcription factor 1	Homo sapiens	44-48
21949767-11	2011	RESULTS: Whereas the treatment with rapamycin persistently inhibited mTORC1 signaling, it suppressed only partially the cell growth.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	69-75
21949767-12	2011	MNK kinase mediated the eIF4E phosphorylation and inhibition or depletion of MNK markedly suppressed proliferation of the CTCL cells when combined with the rapamycin-mediated inhibition of mTORC1.	Sirolimus	156-165	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
21949767-12	2011	MNK kinase mediated the eIF4E phosphorylation and inhibition or depletion of MNK markedly suppressed proliferation of the CTCL cells when combined with the rapamycin-mediated inhibition of mTORC1.	Sirolimus	156-165	CREB regulated transcription coactivator 1	Mus musculus	189-195
22768106-9	2012	Indeed mTORC1 inhibitor rapamycin prevented HSF1-S326 phosphorylation, suggesting that this complex is involved in HSF1 regulation in stress.	Sirolimus	24-33	heat shock transcription factor 1	Homo sapiens	115-119
19533419-9	2010	Results indicate that bi-specifics targeting clusterin are statistically effective, and are similarly enhanced by Rapamycin, or Taxol.	Sirolimus	114-123	clusterin	Homo sapiens	45-54
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	27-33
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Sirolimus	39-48	chorionic gonadotropin subunit beta 5	Homo sapiens	64-67
21887235-2	2011	In yeast, rapamycin mediates a profound transcriptional response for which the RRD1 gene is required.	Sirolimus	10-19	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	79-83
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Sirolimus	39-48	ribosomal protein S6	Homo sapiens	108-112
21887235-3	2011	To further investigate this connection, we performed genome-wide location analysis of RNA polymerase II (RNAPII) and Rrd1 in response to rapamycin and found that Rrd1 colocalizes with RNAPII on actively transcribed genes and that both are recruited to rapamycin responsive genes.	Sirolimus	137-146	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	117-121
20660299-9	2010	In addition, hCG or FSK-mediated up-regulation of the cell cycle regulatory proteins cyclin-dependent kinase 4, cyclin D3, and proliferating cell nuclear antigen was blocked by rapamycin.	Sirolimus	177-186	chorionic gonadotropin subunit beta 5	Homo sapiens	13-16
21887235-3	2011	To further investigate this connection, we performed genome-wide location analysis of RNA polymerase II (RNAPII) and Rrd1 in response to rapamycin and found that Rrd1 colocalizes with RNAPII on actively transcribed genes and that both are recruited to rapamycin responsive genes.	Sirolimus	137-146	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	162-166
21887235-3	2011	To further investigate this connection, we performed genome-wide location analysis of RNA polymerase II (RNAPII) and Rrd1 in response to rapamycin and found that Rrd1 colocalizes with RNAPII on actively transcribed genes and that both are recruited to rapamycin responsive genes.	Sirolimus	252-261	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	162-166
20660299-9	2010	In addition, hCG or FSK-mediated up-regulation of the cell cycle regulatory proteins cyclin-dependent kinase 4, cyclin D3, and proliferating cell nuclear antigen was blocked by rapamycin.	Sirolimus	177-186	cyclin dependent kinase 4	Homo sapiens	85-110
21887235-4	2011	Strikingly, when Rrd1 is lacking, RNAPII remains inappropriately associated to ribosomal genes and fails to be recruited to rapamycin responsive genes.	Sirolimus	124-133	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	17-21
19805415-1	2010	Target of rapamycin (TOR) signaling stimulates cell growth by regulating protein synthesis in response to a variety of stimuli in a wide range of species and is inhibited by rapamycin, a naturally occurring antifungal compound produced by bacteria and discovered on Easter Island or in the local vernacular, Rapa Nui (rapamycin"s namesake).	Sirolimus	10-19	transcriptional regulating factor 1	Homo sapiens	308-312
21887235-6	2011	Further, we demonstrate that Rrd1 is also involved in various other transcriptional stress responses besides rapamycin.	Sirolimus	109-118	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	29-33
19956083-7	2010	Further, in Smad3-deficient mice rapamycin reduced the expression of alpha-smooth muscle actin, which is an epithelial-to-mesenchymal transition-associated gene.	Sirolimus	33-42	SMAD family member 3	Mus musculus	12-17
21203451-8	2010	We then assessed selected compounds that stimulate autophagy and found that the antihelmintic chemical niclosamide prevents large aggregate formation induced by proteasome inhibition, while the prototypical mTORC1 inhibitor rapamycin had no apparent effect.	Sirolimus	224-233	CREB regulated transcription coactivator 1	Mus musculus	207-213
21200439-3	2010	METHODOLOGY/PRINCIPAL FINDINGS: Mice were treated with the mTORC1 inhibitor rapamycin or vehicle prior to lethal endotoxin challenge.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	59-65
21200439-7	2010	We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	14-20
19956083-8	2010	Hence, we conclude that TGF-beta1 causes peritoneal injury through Smad-dependent and Smad-independent pathways; the latter involves redundant mechanisms inhibited by rapamycin, suggesting that suppression of both pathways may be necessary to abrogate mesothelial transition.	Sirolimus	167-176	transforming growth factor, beta 1	Mus musculus	24-33
20072130-2	2010	The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Homo sapiens	44-49
21326806-4	2010	mTORC1 is sensitive to the selective inhibitor rapamycin.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	0-6
21129186-0	2010	Rrd1 isomerizes RNA polymerase II in response to rapamycin.	Sirolimus	49-58	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	0-4
21129186-4	2010	Circular dichroism revealed that Rrd1 mediates structural changes onto the C-terminal domain (CTD) of the large subunit of RNA polymerase II (Rpb1) in response to rapamycin, although this appears to be independent of the overall phosphorylation status of the CTD.	Sirolimus	163-172	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	33-37
21129186-4	2010	Circular dichroism revealed that Rrd1 mediates structural changes onto the C-terminal domain (CTD) of the large subunit of RNA polymerase II (Rpb1) in response to rapamycin, although this appears to be independent of the overall phosphorylation status of the CTD.	Sirolimus	163-172	DNA-directed RNA polymerase II core subunit RPO21	Saccharomyces cerevisiae S288C	142-146
21042876-0	2010	mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	0-6
21042876-2	2010	Numerous clinical trials employing the mTORC1 inhibitor rapamycin (aka sirolimus) to immuno-suppress patients following organ transplantation have documented the development of hypertriglyceridemia and elevated serum free fatty acids (FFA).	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	39-45
21042876-2	2010	Numerous clinical trials employing the mTORC1 inhibitor rapamycin (aka sirolimus) to immuno-suppress patients following organ transplantation have documented the development of hypertriglyceridemia and elevated serum free fatty acids (FFA).	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	39-45
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	96-102
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	24-33	CREB regulated transcription coactivator 2	Mus musculus	193-199
21228924-1	2010	The mammalian target of rapamycin (MTOR) assembles into two distinct complexes: mTOR complex 1 (mTORC1) is predominantly cytoplasmic and highly responsive to rapamycin, whereas mTOR complex 2 (mTORC2) is both cytoplasmic and nuclear, and relatively resistant to rapamycin.	Sirolimus	158-167	CREB regulated transcription coactivator 1	Mus musculus	96-102
20637453-4	2010	In addition, the combination of low dose RPM and high dose IL-2 enhanced mRNA expression of Foxp3, TGF-beta1 and Pim-2 in Tregs but not in CD4(+)CD25(-) T effector cells (Teffs).	Sirolimus	41-44	forkhead box P3	Rattus norvegicus	92-97
20637453-4	2010	In addition, the combination of low dose RPM and high dose IL-2 enhanced mRNA expression of Foxp3, TGF-beta1 and Pim-2 in Tregs but not in CD4(+)CD25(-) T effector cells (Teffs).	Sirolimus	41-44	serine/threonine-protein kinase pim-2	Rattus norvegicus	113-118
19901542-4	2009	Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	124-130
19755425-5	2009	Surprisingly, inhibition of the mTOR protein complex 1 (mTORC1) with rapamycin did not impair LTP maintenance or Arc synthesis nor did it inhibit eIF4F formation or phosphorylation of eIF4E.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	56-62
19815708-6	2009	Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization.	Sirolimus	19-28	microtubule associated protein 1 light chain 3 beta	Homo sapiens	151-155
19632318-8	2009	Pretreatment with the phosphatidylinositol 3-kinase inhibitor Ly294002 and mTOR inhibitor rapamycin restored the ability of PDBu to downregulate PKC delta in HeLa/CP cells.	Sirolimus	90-99	protein kinase C delta	Homo sapiens	145-154
19749176-6	2009	Thus, Sit4/Sap190 and Sit4/Sap155 holophosphatases apparently play opposing roles following rapamycin treatment, although rapamycin inhibition is operational in the absence of all Sap family members or Sit4.	Sirolimus	92-101	Sap190p	Saccharomyces cerevisiae S288C	11-17
19729590-9	2009	Taken together, these findings indicate that in vivo insulin resistance can occur without an increase in mTORC1 activity in skeletal muscle and that inhibition of mTORC1 with rapamycin does not improve insulin action.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	163-169
19699613-0	2009	Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.	Sirolimus	0-9	keratin 6A	Homo sapiens	67-70
20884880-7	2010	SGK-1 activation in response to stretch is blocked by insulin-like growth factor (IGF)-1 receptor inhibitor and mammalian target of rapamycin complex (mTORC)2 inhibitor (Ku-0063794) but not mTORC1 inhibitor (rapamycin).	Sirolimus	132-141	CREB regulated transcription coactivator 2	Mus musculus	151-158
20464435-5	2010	In time course experiments with the mTORC1 inhibitor rapamycin we here demonstrate rapamycin-resistant phosphorylation of the ribosomal protein S6 at S240/244.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	36-42
20464435-5	2010	In time course experiments with the mTORC1 inhibitor rapamycin we here demonstrate rapamycin-resistant phosphorylation of the ribosomal protein S6 at S240/244.	Sirolimus	53-62	ribosomal protein S6	Homo sapiens	126-146
19699613-3	2009	Published sequence data suggest the 5" untranslated regions of K6a and K6b mRNAs contain 5" TOP motifs and therefore may be sensitive to rapamycin treatment.	Sirolimus	137-146	keratin 6A	Homo sapiens	63-66
19699613-3	2009	Published sequence data suggest the 5" untranslated regions of K6a and K6b mRNAs contain 5" TOP motifs and therefore may be sensitive to rapamycin treatment.	Sirolimus	137-146	keratin 6B	Homo sapiens	71-74
19656203-9	2009	CSA shows circadian pk regardless of sirolimus dose or blood concentration.	Sirolimus	37-46	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	0-3
19698731-5	2009	The levels of p-mTOR, cyclin D1, and p21(WAF1/CIP1/SDI1) as well as the aging-related phenotypes were all reduced in cells treated with rapamycin (an inhibitor of mTOR) than in control cells (P &lt; 0.05).	Sirolimus	136-145	cyclin D1	Homo sapiens	22-31
18504440-4	2008	We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells.	Sirolimus	14-23	protein tyrosine kinase 2	Homo sapiens	304-325
18504440-4	2008	We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells.	Sirolimus	14-23	protein tyrosine kinase 2	Homo sapiens	327-330
18664580-5	2008	Tumors from Tsc2(+/-)E mu-Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin.	Sirolimus	88-97	myelocytomatosis oncogene	Mus musculus	26-29
18664580-5	2008	Tumors from Tsc2(+/-)E mu-Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	78-84
18650380-6	2008	Down-regulation of ATF6alpha or Rheb reverted dormant tumor cell resistance to rapamycin and induced pronounced killing only of dormant cancer cells in vivo.	Sirolimus	79-88	activating transcription factor 6	Mus musculus	19-28
20798356-8	2010	Changes in pancreatic weight and RNA content were completely inhibited, and changes in protein content were partially abated, when the mTORC1 inhibitor rapamycin was administered during high-protein chow feeding.	Sirolimus	152-161	CREB regulated transcription coactivator 1	Mus musculus	135-141
20728939-2	2010	Here we show that TLR3 signaling can induce robust cytokine secretion including interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), IL-12p70 and interferon beta (IFN-beta), and our data reveal for the first time that inhibiting mTOR with rapamycin, suppresses these TLR3 induced responses but actually enhances bioactive IL-12p70 production in human oral keratinocytes.	Sirolimus	257-266	toll like receptor 3	Homo sapiens	18-22
20728939-2	2010	Here we show that TLR3 signaling can induce robust cytokine secretion including interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), IL-12p70 and interferon beta (IFN-beta), and our data reveal for the first time that inhibiting mTOR with rapamycin, suppresses these TLR3 induced responses but actually enhances bioactive IL-12p70 production in human oral keratinocytes.	Sirolimus	257-266	interferon beta 1	Homo sapiens	181-189
18650380-6	2008	Down-regulation of ATF6alpha or Rheb reverted dormant tumor cell resistance to rapamycin and induced pronounced killing only of dormant cancer cells in vivo.	Sirolimus	79-88	Ras homolog enriched in brain	Mus musculus	32-36
18644990-3	2008	Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
18644990-8	2008	eIF4E knockdown inhibited the growth of cells with varying total and phosphorylated 4E-BP1 levels and inhibited rapamycin-insensitive as well as rapamycin-sensitive cell lines.	Sirolimus	112-121	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
20976781-2	2010	Rats were treated or not with rapamycin, an mTORC1 inhibitor.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	44-50
18644990-8	2008	eIF4E knockdown inhibited the growth of cells with varying total and phosphorylated 4E-BP1 levels and inhibited rapamycin-insensitive as well as rapamycin-sensitive cell lines.	Sirolimus	145-154	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
18559511-4	2008	An increase in PP2A activity or treatment with rapamycin leads to cytosolic retention of GLI3 and, consequently, reduced transcription of the GLI3 target gene and cell cycle regulator, cyclin D1.	Sirolimus	47-56	cyclin D1	Homo sapiens	185-194
20844194-3	2010	In this study, we report the development of a long-lasting autoactive human mutant TGF-beta1/Fc fusion protein that acts in conjunction with rapamycin to inhibit T cell proliferation and induce the de novo generation of Foxp3(+) Treg in the periphery, while at the same time inhibiting IL-6-mediated Th17 cell differentiation.	Sirolimus	141-150	forkhead box P3	Homo sapiens	220-225
18519793-8	2008	LBH589 decreased both constitutively expressed and rapamycin-induced phosphorylated Akt levels in PC3 and C2 cell lines.	Sirolimus	51-60	keratin 6A	Homo sapiens	98-101
20813961-5	2010	In this study, we show that tuberin regulates the localization of E-cadherin via an Akt/mTORC1/CLIP170-dependent, rapamycin-sensitive pathway.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	88-94
18424697-1	2008	Addition of rapamycin to cultures of expanding natural CD4+CD25+Foxp3+ T regulatory cells (Tregs) helps maintain their suppressive activity, but the underlying mechanism is unclear.	Sirolimus	12-21	forkhead box P3	Homo sapiens	64-69
20670375-10	2010	On the other hand, Rapamycin, an allosteric inhibitor of mTORC1, down-regulates leptin expression, increases tau phosphorylation, and does not affect Akt and GSK-3beta.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	57-63
20686448-9	2010	Hence, our study found that inhibition of mTORC1 by sirolimus correlated with decreased renal cyst growth in this model of human ADPKD but had no effect on the decline in renal function.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	42-48
18424697-4	2008	Introduction of Foxp3, but not Foxp3Delta2, into effector T cells induced pim 2 expression and conferred preferential expansion in the presence of rapamycin, indicating that Foxp3 can regulate pim 2 expression.	Sirolimus	147-156	forkhead box P3	Homo sapiens	16-21
18389497-5	2008	METHODS: Tsc1(GFAP)CKO mice and littermate control animals were treated with rapamycin or vehicle starting at postnatal day 14 (early treatment) or 6 weeks of age (late treatment), corresponding to times before and after onset of neurological abnormalities in Tsc1(GFAP)CKO mice.	Sirolimus	77-86	TSC complex subunit 1	Mus musculus	9-13
18389497-9	2008	RESULTS: Early treatment with rapamycin prevented the development of epilepsy and premature death observed in vehicle-treated Tsc1(GFAP)CKO mice.	Sirolimus	30-39	TSC complex subunit 1	Mus musculus	126-130
20664001-7	2010	It is noteworthy that the mammalian target of rapamycin (mTOR) inhibitor rapamycin also induced phosphorylation of eIF4E in a Mnk-dependent manner, whereas inhibition strongly enhanced its antileukemic effects.	Sirolimus	46-55	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
18389497-10	2008	Late treatment with rapamycin suppressed seizures and prolonged survival in Tsc1(GFAP)CKO mice that had already developed epilepsy.	Sirolimus	20-29	TSC complex subunit 1	Mus musculus	76-80
18389497-12	2008	INTERPRETATION: Rapamycin has strong efficacy for preventing seizures and prolonging survival in Tsc1(GFAP)CKO mice.	Sirolimus	16-25	TSC complex subunit 1	Mus musculus	97-101
18372239-2	2008	Rapamycin, an inhibitor of p70 S6 kinase, significantly enhanced the FGF-2-stimulated IL-6 synthesis in a dose-dependent manner.	Sirolimus	0-9	fibroblast growth factor 2	Mus musculus	69-74
20861369-6	2010	Finally, stimulation of NAc core p70s6k and rps6 phosphorylation by NMDA enhanced cue-induced reinstatement, an effect reversed by rapamycin pretreatment.	Sirolimus	131-140	ribosomal protein S6	Homo sapiens	44-48
20668162-5	2010	In this study, we determined that, in skeletal muscle, overexpression of Rheb stimulates a PI3K/PKB-independent activation of mTOR signaling, and this is sufficient for the induction of a rapamycin-sensitive hypertrophic response.	Sirolimus	188-197	Ras homolog, mTORC1 binding	Homo sapiens	73-77
18308998-5	2008	Newer immunosuppressive agents such as mycophenolate mofetil and sirolimus (Rapa) have raised the possibility of withdrawing or avoiding CNIs or steroids altogether.	Sirolimus	65-74	transcriptional regulating factor 1	Homo sapiens	76-80
20460585-6	2010	Treatment with rapamycin prevented p70S6K phosphorylation and rescued cell size control in AMPK-deficient cells.	Sirolimus	15-24	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	91-95
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	67-76	interferon beta 1	Homo sapiens	128-135
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	78-87	interferon beta 1	Homo sapiens	128-135
18042615-8	2008	Sirolimus treatment leads to decreased protein expression of MMP-2 and MMP-14 in Cy/+, whereas MMP-2 and MMP-14 mRNA levels and TIMP-2 protein levels were not affected by sirolimus.	Sirolimus	0-9	matrix metallopeptidase 2	Rattus norvegicus	61-66
18042615-8	2008	Sirolimus treatment leads to decreased protein expression of MMP-2 and MMP-14 in Cy/+, whereas MMP-2 and MMP-14 mRNA levels and TIMP-2 protein levels were not affected by sirolimus.	Sirolimus	0-9	matrix metallopeptidase 14	Rattus norvegicus	71-77
18042615-10	2008	Sirolimus treatment was associated with a marked improvement of MMP-2 and MMP-14 overexpression, and this correlated also with less matrix and TBM alterations and milder cystic disease.	Sirolimus	0-9	matrix metallopeptidase 2	Rattus norvegicus	64-69
18042615-10	2008	Sirolimus treatment was associated with a marked improvement of MMP-2 and MMP-14 overexpression, and this correlated also with less matrix and TBM alterations and milder cystic disease.	Sirolimus	0-9	matrix metallopeptidase 14	Rattus norvegicus	74-80
18025151-6	2008	Rapamycin inhibited mTORC1 signaling and suppressed CTCL cell proliferation but showed little effect on their apoptotic rate when used as a single agent.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	20-26
17971516-11	2008	Rapamycin inhibited TNF-alpha-induced phosphorylation of the mTOR C1 target p70(S6K) without altering TNF-alpha-induced PS and 4E-BP1 phosphorylation.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	61-68
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	59-68	suppressor of cytokine signaling 3	Homo sapiens	26-31
17993646-7	2008	Furthermore, IL-6-induced SOCS3 expression is inhibited by rapamycin, and ectopic expression of SOCS3 blocks the ability of rapamycin to enhance insulin sensitivity in the presence of IL-6.	Sirolimus	124-133	suppressor of cytokine signaling 3	Homo sapiens	96-101
18188819-11	2008	Due to its antiproliferative effects, the immunosuppressive drug sirolimus may play a role for secondary prevention of HCC following transplantation.	Sirolimus	65-74	HCC	Homo sapiens	119-122
18165767-9	2007	Rapamycin treatment of islets in vitro resulted in reduced p70s6k phosphorylation, which was paralleled by increased ERK1/2 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	117-123
20631133-9	2010	The increase in cap-dependent translation likely results from HPV16 E6-induced AKT/mTORC1 activation, as the assembly of the translation initiation complex and cap-dependent translation are rapamycin sensitive.	Sirolimus	190-199	CREB regulated transcription coactivator 1	Mus musculus	83-89
20439490-9	2010	In addition, mitotic raptor promotes translation by internal ribosome entry sites (IRES) on mRNA during mitosis and is demonstrated to be associated with rapamycin resistance.	Sirolimus	154-163	regulatory associated protein of MTOR complex 1	Homo sapiens	21-27
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	124-129
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	205-214	eukaryotic translation initiation factor 4E	Homo sapiens	124-129
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Sirolimus	69-78	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
20177775-7	2010	Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Sirolimus	45-54	myristoylated alanine rich protein kinase C substrate	Homo sapiens	6-10
17927956-6	2007	Rapamycin inhibited ODC synthesis by 40-50% at both the G1/S boundary and the G2/M phase.	Sirolimus	0-9	ornithine decarboxylase 1	Homo sapiens	20-23
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	116-125	interleukin 2 receptor subunit alpha	Homo sapiens	161-165
18021968-2	2007	In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients.	Sirolimus	127-136	interleukin 2 receptor subunit alpha	Homo sapiens	161-165
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	51-60	interleukin 2 receptor subunit alpha	Homo sapiens	24-28
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	51-60	forkhead box P3	Homo sapiens	31-36
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	62-71	interleukin 2 receptor subunit alpha	Homo sapiens	24-28
18021968-8	2007	The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients.	Sirolimus	62-71	forkhead box P3	Homo sapiens	31-36
17609423-4	2007	Administration of a 3-drug regimen consisting of mycophenolate mofetil (MMF), sirolimus, and the anti-IL-2 receptor antibody daclizumab consistently resulted in formation of inhibitory antibodies to human F.IX following hepatic artery administration of an AAV-hF.IX vector, whereas a 2-drug regimen consisting only of MMF and sirolimus did not.	Sirolimus	326-335	interleukin 2 receptor subunit beta	Homo sapiens	102-115
17698581-5	2007	Rapamycin inhibition of TORC1 signaling suppressed the Rad53 checkpoint-mediated induction of ribonucleotide reductase subunits Rnr1 and Rnr3, thereby abrogating MMS-induced mutagenesis and enhancing cell lethality.	Sirolimus	0-9	serine/threonine/tyrosine protein kinase RAD53	Saccharomyces cerevisiae S288C	55-60
17494629-6	2007	S6K deletion in muscle mimics the effect of the mTOR inhibitor rapamycin on rpS6 and eIF4B phosphorylation without affecting eEF2 phosphorylation.	Sirolimus	63-72	ribosomal protein S6	Homo sapiens	76-80
17630656-2	2007	The FKBPs are distinguished by their peptidyl-prolyl cis-trans isomerase (PPIase) activity and ability to bind the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	149-158	peptidyl-prolyl cis-trans isomerase	Bombyx mori	74-80
17671185-6	2007	The imaging utility of the new BRET vector is shown by constructing a sensor using two mammalian target of rapamycin pathway proteins (FKBP12 and FRB) that dimerize only in the presence of rapamycin.	Sirolimus	107-116	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	135-141
20457610-2	2010	mTORC1, which is directly inhibited by rapamycin, promotes cell growth by stimulating protein synthesis and inhibiting autophagy.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	0-6
20348217-8	2010	We demonstrated that sirolimus increased Insig-1 expression which may bind to the SCAP, preventing the exit of SCAP-SREBP complexes from the ER.	Sirolimus	21-30	SREBF chaperone	Homo sapiens	82-86
20348217-8	2010	We demonstrated that sirolimus increased Insig-1 expression which may bind to the SCAP, preventing the exit of SCAP-SREBP complexes from the ER.	Sirolimus	21-30	SREBF chaperone	Homo sapiens	111-115
20138985-9	2010	Inhibition of mTORC1 by rapamycin or amino acid deprivation partially abrogated insulin-mediated PRAS40-Ser183 phosphorylation in cultured cell lines.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
20496258-2	2010	The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2.	Sirolimus	36-45	CREB regulated transcription coactivator 2	Mus musculus	74-80
20496258-2	2010	The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2.	Sirolimus	198-207	CREB regulated transcription coactivator 1	Mus musculus	181-187
20299475-2	2010	Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	73-79
20299475-7	2010	These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop.	Sirolimus	121-130	CREB regulated transcription coactivator 1	Mus musculus	182-188
20375166-5	2010	We further analyzed the role of mTOR in the effects of SOCS3 by treating selected cells with rapamycin.	Sirolimus	93-102	suppressor of cytokine signaling 3	Homo sapiens	55-60
20375166-11	2010	The mTOR inhibitor rapamycin reversed the inhibitory effects of SOCS3.	Sirolimus	19-28	suppressor of cytokine signaling 3	Homo sapiens	64-69
20512842-0	2010	Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	56-62
20512842-0	2010	Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	67-73
20512842-2	2010	In this report, we focused on studying the role of mTORC1 and mTORC2 in rapamycin-mediated Akt and ERK phosphorylation, and the antitumor effect of rapamycin in cancer cells in combination with Akt and ERK inhibitors.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	51-57
20512842-2	2010	In this report, we focused on studying the role of mTORC1 and mTORC2 in rapamycin-mediated Akt and ERK phosphorylation, and the antitumor effect of rapamycin in cancer cells in combination with Akt and ERK inhibitors.	Sirolimus	72-81	CREB regulated transcription coactivator 2	Mus musculus	62-68
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	91-97
20512842-4	2010	We found that low concentrations rapamycin increased Akt and ERK phosphorylation through a mTORC1-dependent mechanism because knockdowned raptor induced the activation of Akt and ERK, but higher doses of rapamycin inhibited Akt and ERK phosphorylation mainly via the mTORC2 signaling pathway because that the silencing of rictor led to the inhibition of Akt and ERK phosphorylation.	Sirolimus	33-42	CREB regulated transcription coactivator 2	Mus musculus	267-273
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	CREB regulated transcription coactivator 2	Mus musculus	31-37
20512842-7	2010	Collectively, we conclude that mTORC2 plays a much more important role than mTORC1 in rapamycin-mediated phosphorylation of Akt and ERK, and cotargeting AKT and ERK signaling may be a new strategy for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	76-82
20530756-7	2010	Inhibition of TOR signaling by rapamycin led to suppression of the lrx1 mutant phenotype and caused specific changes to galactan/rhamnogalacturonan-I and arabinogalactan protein components of cell walls that were similar to those observed in the rol5 mutant.	Sirolimus	31-40	repressor of lrx1	Arabidopsis thaliana	246-250
20620516-0	2010	Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation.	Sirolimus	0-9	forkhead box P3	Rattus norvegicus	43-48
20620516-3	2010	In this study, we characterized CD4(+)Foxp3(+) Tregs in liver grafts and peripheral blood following rapamycin treatment using a syngeneic liver transplant model.	Sirolimus	100-109	forkhead box P3	Rattus norvegicus	38-43
20620516-5	2010	In the first 2 weeks the percentage of CD4(+)Foxp3(+) Tregs was increased in the liver grafts and blood only among the rapamycin group compared with control group.	Sirolimus	119-128	forkhead box P3	Rattus norvegicus	45-50
20620516-8	2010	Thus, rapamycin can significantly enhance the percentages of CD4(+)Foxp3(+) Tregs in the thymus and periphery, indicating that rapamycin favors Tregs expansion and may suppress other CD4(+) T cells.	Sirolimus	6-15	forkhead box P3	Rattus norvegicus	67-72
17568186-8	2007	The addition of rapamycin, an inhibitor of mTORC1, diminished the remaining activity of mTORC1 and significantly intensified the cytotoxic action of cisplatin in AFPGC cells.	Sirolimus	16-25	CREB regulated transcription coactivator 1	Mus musculus	43-49
20308064-8	2010	In addition, we define a new role of hnRNP F in driving cell proliferation, which could be partially attenuated by rapamycin treatment.	Sirolimus	115-124	heterogeneous nuclear ribonucleoprotein F	Homo sapiens	37-44
17568186-8	2007	The addition of rapamycin, an inhibitor of mTORC1, diminished the remaining activity of mTORC1 and significantly intensified the cytotoxic action of cisplatin in AFPGC cells.	Sirolimus	16-25	CREB regulated transcription coactivator 1	Mus musculus	88-94
20371605-4	2010	Glycolysis in FoxO3a-deficient cells was associated with increased S6K1 phosphorylation and was sensitive to rapamycin, an inhibitor of the mTORC1 pathway that has been linked to glycolysis regulation.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	140-146
17570654-6	2007	Rapamycin abrogated the phosphorylation of p70S6kinase and consistently inhibited the formation of tubes induced by FGF-2.	Sirolimus	0-9	fibroblast growth factor 2	Rattus norvegicus	116-121
20421479-3	2010	In this study, we show that Ag-specific memory Th cells were redifferentiated into Foxp3(+) T cells by TGF-beta when stimulated in the presence of all-trans retinoic acid and rapamycin.	Sirolimus	175-184	forkhead box P3	Homo sapiens	83-88
17429052-6	2007	Consequently, SNAT2 inhibition strongly impaired signaling through mammalian target of rapamycin to ribosomal protein S6 kinase, ribosomal protein S6, and 4E-BP1, leading to impairment of protein synthesis comparable with that induced by rapamycin.	Sirolimus	87-96	ribosomal protein S6	Homo sapiens	129-161
20404504-5	2010	In addition, cells overexpressing the active form of Plk1 were characterized by abnormal growth that could be reversed by rapamycin, a specific inhibitor of the TORC1 complex.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Homo sapiens	161-166
19951971-7	2010	Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	10-16
20131403-11	2010	IGF1-stimulated LCEC proliferation was inhibited by rapamycin and SU5416 (a vascular endothelial growth factor receptor 2 inhibitor).	Sirolimus	52-61	insulin-like growth factor 1	Mus musculus	0-4
20213584-0	2010	Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation.	Sirolimus	70-79	mitogen-activated protein kinase 14	Mus musculus	102-105
20213584-5	2010	Rapamycin was found to increase phosphorylation of c-Jun amino-terminal kinase (JNK) and p38 in 30 minutes in MIN6 cells and Wistar rat islets while exendin-4 decreased their phosphorylation.	Sirolimus	0-9	jun proto-oncogene	Mus musculus	51-56
20213584-5	2010	Rapamycin was found to increase phosphorylation of c-Jun amino-terminal kinase (JNK) and p38 in 30 minutes in MIN6 cells and Wistar rat islets while exendin-4 decreased their phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 14	Mus musculus	89-92
20181700-2	2010	However, the phosphorylation of mTORC1 targets is differentially sensitive to the mTORC1 inhibitor rapamycin, and the drug inhibits HCMV replication to a modest extent.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	32-38
20181700-2	2010	However, the phosphorylation of mTORC1 targets is differentially sensitive to the mTORC1 inhibitor rapamycin, and the drug inhibits HCMV replication to a modest extent.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	82-88
20116405-1	2010	Inhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosphorylation in cancer cells via mTORC2 activation.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	14-20
20116405-1	2010	Inhibition of mTORC1 with the mTOR inhibitor rapamycin may lead to an induction of Akt phosphorylation in cancer cells via mTORC2 activation.	Sirolimus	45-54	CREB regulated transcription coactivator 2	Mus musculus	123-129
19443154-1	2010	PURPOSE: New evidence is emerging that the availability of nutrients plays a key role in regulating the mammalian target of rapamycin complex-1 (mTORC1) signaling pathway in human cancers.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Mus musculus	145-151
20085809-14	2010	The promotion of gliogenesis by FGF-2 was not only inhibited by U0126 but also by LY294002 and rapamycin, inhibitors of the Akt pathway, and by Akt-1 siRNA.	Sirolimus	95-104	fibroblast growth factor 2	Mus musculus	32-37
20203102-3	2010	Acute inhibition of mTORC1/S6K1 by rapamycin increases insulin signaling and glucose uptake in myocytes and adipocytes, but whether these effects can be maintained under chronic inhibition of mTORC1 or S6K1 remains unclear.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	20-26
19642865-0	2010	Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.	Sirolimus	0-9	SMAD family member 1	Homo sapiens	135-139
20149931-2	2010	We investigated the effect of rapamycin administration to SJL/j mice affected by PLP(139-151)-induced relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE).	Sirolimus	30-39	proteolipid protein (myelin) 1	Mus musculus	81-84
20357108-11	2010	In agreement, neuronal differentiation significantly decreased after exposure to an anti-Tie-2 neutralizing antibody and to rapamycin.	Sirolimus	124-133	TEK receptor tyrosine kinase	Homo sapiens	89-94
20022946-8	2010	Although insulin stimulates both mTORC1- and mTORC2-associated mTOR Ser(P)-2481 in a phosphatidylinositol 3-kinase-dependent manner, rapamycin acutely inhibits insulin-stimulated mTOR Ser(P)-2481 in mTORC1 but not mTORC2.	Sirolimus	133-142	CREB regulated transcription coactivator 2	Mus musculus	45-51
20022946-8	2010	Although insulin stimulates both mTORC1- and mTORC2-associated mTOR Ser(P)-2481 in a phosphatidylinositol 3-kinase-dependent manner, rapamycin acutely inhibits insulin-stimulated mTOR Ser(P)-2481 in mTORC1 but not mTORC2.	Sirolimus	133-142	CREB regulated transcription coactivator 1	Mus musculus	199-205
20022946-8	2010	Although insulin stimulates both mTORC1- and mTORC2-associated mTOR Ser(P)-2481 in a phosphatidylinositol 3-kinase-dependent manner, rapamycin acutely inhibits insulin-stimulated mTOR Ser(P)-2481 in mTORC1 but not mTORC2.	Sirolimus	133-142	CREB regulated transcription coactivator 2	Mus musculus	214-220
20022946-10	2010	These data suggest that mTORC1- and likely mTORC2-associated mTOR Ser-2481 autophosphorylation directly monitors intrinsic mTORC-specific catalytic activity and reveal that rapamycin inhibits mTORC1 signaling in vivo by reducing mTORC1 catalytic activity.	Sirolimus	173-182	CREB regulated transcription coactivator 1	Mus musculus	24-30
20022946-10	2010	These data suggest that mTORC1- and likely mTORC2-associated mTOR Ser-2481 autophosphorylation directly monitors intrinsic mTORC-specific catalytic activity and reveal that rapamycin inhibits mTORC1 signaling in vivo by reducing mTORC1 catalytic activity.	Sirolimus	173-182	CREB regulated transcription coactivator 2	Mus musculus	43-49
20022946-10	2010	These data suggest that mTORC1- and likely mTORC2-associated mTOR Ser-2481 autophosphorylation directly monitors intrinsic mTORC-specific catalytic activity and reveal that rapamycin inhibits mTORC1 signaling in vivo by reducing mTORC1 catalytic activity.	Sirolimus	173-182	CREB regulated transcription coactivator 1	Mus musculus	192-198
20022946-10	2010	These data suggest that mTORC1- and likely mTORC2-associated mTOR Ser-2481 autophosphorylation directly monitors intrinsic mTORC-specific catalytic activity and reveal that rapamycin inhibits mTORC1 signaling in vivo by reducing mTORC1 catalytic activity.	Sirolimus	173-182	CREB regulated transcription coactivator 1	Mus musculus	192-198
20160076-6	2010	Importantly, elevated ROS and dysregulation of mTORC1 in ATM-deficient cells is inhibited by rapamycin, which also rescues lymphomagenesis in Atm-deficient mice.	Sirolimus	93-102	CREB regulated transcription coactivator 1	Mus musculus	47-53
20160076-6	2010	Importantly, elevated ROS and dysregulation of mTORC1 in ATM-deficient cells is inhibited by rapamycin, which also rescues lymphomagenesis in Atm-deficient mice.	Sirolimus	93-102	ataxia telangiectasia mutated	Mus musculus	57-60
20160076-6	2010	Importantly, elevated ROS and dysregulation of mTORC1 in ATM-deficient cells is inhibited by rapamycin, which also rescues lymphomagenesis in Atm-deficient mice.	Sirolimus	93-102	ataxia telangiectasia mutated	Mus musculus	142-145
20005306-3	2010	Rapamycin and its analogs (rapalogs) function as allosteric inhibitors of mTORC1 and are currently used in the treatment of advanced renal cell carcinoma.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	74-80
17287424-6	2007	CD4(+)CD25(high) cells that expressed FOXP3 underwent homeostatic peripheral expansion during immune reconstitution, more intense in patients who received sirolimus than in those who were given CsA.	Sirolimus	155-164	forkhead box P3	Homo sapiens	38-43
20013896-7	2010	We previously reported that aberrant mTORC1 activation leads to supernumerary centrosomes, a phenotype rescued by the mTORC1 inhibitor rapamycin.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	37-43
20013896-7	2010	We previously reported that aberrant mTORC1 activation leads to supernumerary centrosomes, a phenotype rescued by the mTORC1 inhibitor rapamycin.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	118-124
19688827-7	2010	Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1, two critical downstream targets of the mTOR pathway.	Sirolimus	15-24	ribosomal protein S6	Homo sapiens	81-94
17181399-11	2007	The FGF-2-induced phosphorylation of p70 S6 kinase was suppressed by rapamycin.	Sirolimus	69-78	fibroblast growth factor 2	Mus musculus	4-9
20209637-8	2010	Immunohistochemistry demonstrated more Foxp3+ staining of intestinal cells in the RAPA group than in the FK506 group or the control group.	Sirolimus	82-86	forkhead box P3	Rattus norvegicus	39-44
20209637-9	2010	In conclusion, the reduced mortality induced by RAPA in a rat model of aGVHD after LTx was associated with higher percentages of CD4+CD25+Foxp3+ Treg cells in PBMCs in blood and tissues than those occurring after the administration of FK506.	Sirolimus	48-52	forkhead box P3	Rattus norvegicus	138-143
17181399-12	2007	Rapamycin markedly enhanced the FGF-2-induced phosphorylation of SAPK/JNK without affecting the phosphorylation of p44/p42 MAP kinase or p38 MAP kinase.	Sirolimus	0-9	fibroblast growth factor 2	Mus musculus	32-37
17453966-0	2007	Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	30-34
17453966-0	2007	Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.	Sirolimus	0-9	forkhead box P3	Homo sapiens	46-51
20019084-0	2010	Cytocidal amino acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2{Delta}) mutants is influenced by the carbon source and rapamycin.	Sirolimus	164-173	acetolactate synthase catalytic subunit	Saccharomyces cerevisiae S288C	104-108
17453966-0	2007	Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	94-98
19903662-0	2010	Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	89-93
19903662-3	2010	The goal of this study was to compare the effects of cyclosporine A and rapamycin on the induction and suppressive functions of human CD4(+)CD25(+) Tregs in vitro.	Sirolimus	72-81	interleukin 2 receptor subunit alpha	Homo sapiens	140-144
17453966-10	2007	The addition of rapamycin inhibited expansion of non-regulatory T cells at doses &gt; or =1 ng/mL while increasing suppressor activity and the percentage of CD4(+) CD25(+) CD27(+) Foxp3(+) cells.	Sirolimus	16-25	interleukin 2 receptor subunit alpha	Homo sapiens	164-168
19903662-4	2010	METHODS: CD4(+)CD25(+) Tregs were induced in two-way mixed lymphocyte reaction (MLR) in the presence of rapamycin (Treg-Rapa) or cyclosporine A (Treg-CsA).	Sirolimus	104-113	interleukin 2 receptor subunit alpha	Homo sapiens	15-19
19903662-8	2010	RESULTS: Although both rapamycin and cyclosporine A suppressed the induction of CD4(+)CD25(+) Tregs during MLRs, this effect was significantly more pronounced in cells cultured with cyclosporine.	Sirolimus	23-32	interleukin 2 receptor subunit alpha	Homo sapiens	86-90
17453966-10	2007	The addition of rapamycin inhibited expansion of non-regulatory T cells at doses &gt; or =1 ng/mL while increasing suppressor activity and the percentage of CD4(+) CD25(+) CD27(+) Foxp3(+) cells.	Sirolimus	16-25	forkhead box P3	Homo sapiens	180-185
17453966-12	2007	Treg were also readily expanded in cultures of CD25-enriched cells obtained from patients with multiple sclerosis in the presence of rapamycin.	Sirolimus	133-142	interleukin 2 receptor subunit alpha	Homo sapiens	47-51
17259349-8	2007	Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was found to regulate PDCD4 expression because inhibition of PI3K by LY294002 and wortmannin or of mTOR by rapamycin induced PDCD4 protein and mRNA expression.	Sirolimus	61-70	programmed cell death 4	Homo sapiens	118-123
20133650-6	2010	In contrast, subnanomolar concentrations of rapamycin, an inhibitor of the mTORC1 kinase, blocked insulin induction of SREBP-1c, but had no effect on insulin suppression of PEPCK.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	75-81
17142730-6	2006	Interestingly, rapamycin promotes expansion of functional CD4+CD25+FOXP3+ Tregs also in type 1 diabetic patients, in whom a defect in freshly isolated CD4+CD25+ Tregs has been reported.	Sirolimus	15-24	forkhead box P3	Homo sapiens	67-72
20133650-6	2010	In contrast, subnanomolar concentrations of rapamycin, an inhibitor of the mTORC1 kinase, blocked insulin induction of SREBP-1c, but had no effect on insulin suppression of PEPCK.	Sirolimus	44-53	sterol regulatory element binding transcription factor 1	Rattus norvegicus	119-127
17142730-7	2006	The capacity of rapamycin to allow growth of functional CD4+CD25+FOXP3+ Tregs, but also to deplete T effector cells, can be exploited for the design of novel and safe in vitro protocols for cellular immunotherapy in T cell-mediated diseases.	Sirolimus	16-25	forkhead box P3	Homo sapiens	65-70
20048174-0	2010	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	142-148
17142137-4	2006	Rapamycin, a uniquely specific mTOR inhibitor with clinical applications, increased fatty acid oxidation by 60% accompanied by increased activities of carnitine palmitoyltransferases I and II, the former believed to be the primary intracellular regulatory enzyme of the fatty acid oxidation pathway.	Sirolimus	0-9	carnitine palmitoyltransferase 2	Homo sapiens	151-191
19879324-5	2010	TNF-alpha-induced phosphorylations of both p44/p42 MAP kinase and Akt were markedly enhanced by rapamycin.	Sirolimus	96-105	mitogen-activated protein kinase 3	Mus musculus	43-46
19879324-5	2010	TNF-alpha-induced phosphorylations of both p44/p42 MAP kinase and Akt were markedly enhanced by rapamycin.	Sirolimus	96-105	cyclin-dependent kinase 20	Mus musculus	47-50
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	caspase 8	Homo sapiens	213-222
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	cyclin D1	Homo sapiens	311-320
16715128-13	2006	Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
17088424-2	2006	Rapa-induced PM recruitment of a truncated type IV 5-ptase containing only the 5-ptase domain fused to FKBP12 rapidly decreased PM PtdIns(4,5)P(2) as monitored by the PLCdelta1PH-GFP fusion construct.	Sirolimus	0-4	inositol polyphosphate-5-phosphatase B	Homo sapiens	51-58
17088424-2	2006	Rapa-induced PM recruitment of a truncated type IV 5-ptase containing only the 5-ptase domain fused to FKBP12 rapidly decreased PM PtdIns(4,5)P(2) as monitored by the PLCdelta1PH-GFP fusion construct.	Sirolimus	0-4	inositol polyphosphate-5-phosphatase B	Homo sapiens	79-86
17097997-15	2006	CONCLUSION: Sirolimus improved late CNI-related chronic renal dysfunction.	Sirolimus	12-21	5'-nucleotidase, cytosolic IA	Homo sapiens	36-39
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	CREB regulated transcription coactivator 1	Mus musculus	0-6
16870609-4	2006	mTORC2 is rapamycin-insensitive and likely regulates actin organization and activates Akt/protein kinase B.	Sirolimus	10-19	CREB regulated transcription coactivator 2	Mus musculus	0-6
16638821-5	2006	Plasma leptin rose more slowly, peaking at 3 h, and was inhibited by rapamycin (0.75 mg/kg) pretreatment.	Sirolimus	69-78	leptin	Rattus norvegicus	7-13
20193259-15	2010	Both RPM and DOC significantly increased the caspase activity in a dosage-dependent manner.	Sirolimus	5-8	caspase 9	Mus musculus	45-52
20193259-22	2010	RPM enhanced the DOC-induced upregulation of caspase activity, resulting in an increasing number of cells in sub-G1 phases.	Sirolimus	0-3	caspase 9	Mus musculus	45-52
19661225-7	2010	In contrast, rapamycin-induced inhibition of mTOR did not significantly affect cell proliferation because it simultaneously stimulated PI3K/Akt activation and cyclin D1 expression.	Sirolimus	13-22	cyclin D1	Homo sapiens	159-168
19812126-8	2010	Analysis of enzymes in the Krebs cycle revealed that activity of alpha-ketoglutarate dehydrogenase (KGDH), which catalyzes one of the slowest reactions in the Krebs cycle, was reduced by rapamycin (10.08+/-0.82, rapamycin versus 13.82+/-0.84 nmol/mg mitochondrial protein per min, control, n=5, P&lt;0.01).	Sirolimus	187-196	oxoglutarate dehydrogenase	Rattus norvegicus	65-98
19812126-8	2010	Analysis of enzymes in the Krebs cycle revealed that activity of alpha-ketoglutarate dehydrogenase (KGDH), which catalyzes one of the slowest reactions in the Krebs cycle, was reduced by rapamycin (10.08+/-0.82, rapamycin versus 13.82+/-0.84 nmol/mg mitochondrial protein per min, control, n=5, P&lt;0.01).	Sirolimus	187-196	oxoglutarate dehydrogenase	Rattus norvegicus	100-104
19805410-11	2010	In yeast, FPR1 encodes the rapamycin-binding protein Fpr1 that inhibits the TORC1 kinase in the presence of rapamycin.	Sirolimus	27-36	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	10-14
19805410-11	2010	In yeast, FPR1 encodes the rapamycin-binding protein Fpr1 that inhibits the TORC1 kinase in the presence of rapamycin.	Sirolimus	27-36	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	53-57
19682553-7	2009	Additionally, the results showed that rapamycin pretreatment diminished rotenone-induced accumulation of high molecular weight ubiquitinated bands, and reduced rotenone-induced increase of cytochrome c in cytosolic fraction and decreased mitochondrial marker cytochrome oxidase subunit IV (COX IV) in mitochondrial fraction.	Sirolimus	38-47	cytochrome c oxidase subunit 4I1	Homo sapiens	290-296
19783659-10	2009	Rapamycin modifies the hepatic AADR to asparaginase by preventing CHOP induction while maximizing inhibition of mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	112-118
16705060-6	2006	TNF-alpha treatment decreased ATGL transcript in a time-dependent manner that paralleled TNF-alpha downregulation of PPARgamma with a maximal decrease noted by 6 h. TNF-alpha effects on ATGL were attenuated by pretreatment with PD-98059, LY-294002, or rapamycin, suggesting involvement of the p44/42 MAP kinase, PI 3-kinase, and p70 ribosomal protein S6 kinase signals.	Sirolimus	252-261	peroxisome proliferator activated receptor gamma	Mus musculus	117-126
19692352-6	2009	Furthermore, cyst development requires mTORC1 activation, as low dosage of rapamycin administration effectively blocks cyst formation.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	39-45
16627617-3	2006	TORC1, which is sensitive to rapamycin, regulates translation and cell growth, whereas TORC2, which is insensitive to rapamycin, regulates cell morphology and cell growth.	Sirolimus	29-38	CREB regulated transcription coactivator 1	Homo sapiens	0-5
19641186-0	2009	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.	Sirolimus	44-53	CREB regulated transcription coactivator 2	Mus musculus	143-149
19641186-4	2009	Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance.	Sirolimus	40-49	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
19641186-4	2009	Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance.	Sirolimus	40-49	CREB regulated transcription coactivator 2	Mus musculus	79-85
19641186-5	2009	Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor, inhibited rapamycin-induced Akt phosphorylation in lymphoma cells.	Sirolimus	102-111	CREB regulated transcription coactivator 2	Mus musculus	30-36
19641186-6	2009	Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation.	Sirolimus	74-83	LBH regulator of WNT signaling pathway	Homo sapiens	52-58
19641186-6	2009	Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation.	Sirolimus	74-83	LBH regulator of WNT signaling pathway	Homo sapiens	52-55
16648664-2	2006	cADPR induced Ca2+ release in digitonin-permeabilized chromaffin cells and this was blocked by FK506 and rapamycin, ligands for FKBPs; 8Br-cADPR, a competitive antagonist for cADPR; and antibody for FKBP12/12.6, while it was enhanced by cyclosporin A.	Sirolimus	105-114	peptidyl-prolyl cis-trans isomerase FKBP1A	Bos taurus	199-205
19641186-8	2009	This is the first demonstration that a HDI such as LBH can overcome rapamycin resistance through a phosphatase that antagonizes mTORC2 activation.	Sirolimus	68-77	LBH regulator of WNT signaling pathway	Homo sapiens	51-54
19641186-8	2009	This is the first demonstration that a HDI such as LBH can overcome rapamycin resistance through a phosphatase that antagonizes mTORC2 activation.	Sirolimus	68-77	CREB regulated transcription coactivator 2	Mus musculus	128-134
16603397-0	2006	Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.	Sirolimus	10-19	CREB regulated transcription coactivator 2	Mus musculus	39-45
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	18-27	CREB regulated transcription coactivator 2	Mus musculus	53-59
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	18-27	CREB regulated transcription coactivator 2	Mus musculus	142-148
19474189-9	2009	The highly selective mTOR inhibitor, rapamycin, inhibited increased phosphorylation of rpS6 and blocked 60-70% of the hypertrophy seen in wild-type mice but failed to prevent the approximately 10% hypertrophy seen in S6K1(-/-) mice in response to uninephrectomy (UNX) although it did inhibit the basal rpS6 phosphorylation.	Sirolimus	37-46	ribosomal protein S6	Mus musculus	87-91
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	100-109	CREB regulated transcription coactivator 2	Mus musculus	53-59
19474189-9	2009	The highly selective mTOR inhibitor, rapamycin, inhibited increased phosphorylation of rpS6 and blocked 60-70% of the hypertrophy seen in wild-type mice but failed to prevent the approximately 10% hypertrophy seen in S6K1(-/-) mice in response to uninephrectomy (UNX) although it did inhibit the basal rpS6 phosphorylation.	Sirolimus	37-46	ribosomal protein S6	Mus musculus	302-306
16603397-5	2006	Here we show that rapamycin inhibits the assembly of mTORC2 and that, in many cell types, prolonged rapamycin treatment reduces the levels of mTORC2 below those needed to maintain Akt/PKB signaling.	Sirolimus	100-109	CREB regulated transcription coactivator 2	Mus musculus	142-148
16410300-7	2006	Rapamycin, a specific inhibitor of the FRAP/mammalian target of rapamycin/p70(s6k) pathway, prevented GD-IgG-provoked IL-16 synthesis.	Sirolimus	0-9	interleukin 16	Homo sapiens	118-123
16517728-11	2006	Furthermore, the study identifies essential, positive regulators of the FOXP3 gene and highlights cyclosporin A as an inhibitor of FOXP3 expression contrasting other immunosuppressants such as steroids or rapamycin.	Sirolimus	205-214	forkhead box P3	Homo sapiens	72-77
19625166-0	2009	Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.	Sirolimus	15-24	forkhead box P3	Rattus norvegicus	198-203
16487345-0	2006	Differing responses of Gat1 and Gln3 phosphorylation and localization to rapamycin and methionine sulfoximine treatment in Saccharomyces cerevisiae.	Sirolimus	73-82	Gat1p	Saccharomyces cerevisiae S288C	23-27
19303679-0	2009	Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases.	Sirolimus	0-9	actinin alpha 4	Homo sapiens	14-48
19303679-4	2009	We describe results for 3 patients treated with a combination of low-dose steroids and rapamycin for FSGS, focusing on the importance of maintaining low drug (rapamycin) levels by using a twice-daily regimen.	Sirolimus	87-96	actinin alpha 4	Homo sapiens	101-105
19303679-4	2009	We describe results for 3 patients treated with a combination of low-dose steroids and rapamycin for FSGS, focusing on the importance of maintaining low drug (rapamycin) levels by using a twice-daily regimen.	Sirolimus	159-168	actinin alpha 4	Homo sapiens	101-105
16210336-0	2006	Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	93-97
16859513-0	2006	The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.	Sirolimus	19-28	S-phase kinase associated protein 2	Homo sapiens	91-95
16859513-6	2006	The effect of rapamycin on the degradation rate of Skp2 expression was examined in cycloheximide-treated cells and in relationship to the anaphase promoting complex/Cdh1 (APC\C) inhibitor Emi1.	Sirolimus	14-23	S-phase kinase associated protein 2	Homo sapiens	51-55
19522878-9	2009	Of note, addition of sirolimus (SRL) augmented BAFF-enhanced B-cell activation whereas CNIs blocked it.	Sirolimus	21-30	TNF superfamily member 13b	Homo sapiens	47-51
19443844-3	2009	Rapamycin (0.5 mg/kg/d) effectively inhibited mTOR and downstream S6K1 signaling and partially inhibited Akt signaling, likely through effects on TORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	146-151
19443844-8	2009	Rapamycin decreased phosphorylation of both Akt and S6, suggesting that both the TORC1 and TORC2 pathways are impacted.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	81-86
16859513-9	2006	In addition, rapamycin enhanced the degradation rate of Skp2 and down-regulated the expression of the APC\C inhibitor Emi1.	Sirolimus	13-22	S-phase kinase associated protein 2	Homo sapiens	56-60
16859513-10	2006	CONCLUSION: These results suggest that Skp2, an important oncogene in the development and progression of breast cancer, may be a novel target for rapamycin treatment.	Sirolimus	146-155	S-phase kinase associated protein 2	Homo sapiens	39-43
17717968-4	2006	In order to maintain adequate immunosuppression levels, sirolimus may be used in association with CsA withdrawal.	Sirolimus	56-65	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	98-101
17717968-7	2006	Early withdrawal of CsA with sirolimus is associated with a significant improvement of renal function.	Sirolimus	29-38	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	20-23
16322256-5	2005	Experiments with the potentiometric dye, JC-1, revealed an oligomycin-dependent increase in mitochondrial membrane potential following radiation or rapamycin treatment, suggesting that both lead to reversal of F0F1ATPase activity.	Sirolimus	148-157	ATP synthase F1 subunit epsilon	Homo sapiens	210-220
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Sirolimus	133-142	caspase 3	Rattus norvegicus	10-19
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Sirolimus	133-142	caspase 3	Rattus norvegicus	50-59
16221205-10	2005	The 24 kD caspase-3, which proved to be an active caspase-3 subunit, was increased in I/R and CsA groups and deceased by tacrolimus, rapamycin, or MMF (P &lt; 0.05), but not 32 kD precursor or 17 kD active caspase-3.	Sirolimus	133-142	caspase 3	Rattus norvegicus	50-59
16219581-2	2005	The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged.	Sirolimus	20-29	cyclin D1	Homo sapiens	141-150
16160601-9	2005	Rapamycin, in a dose-dependent manner, inhibited monocyte chemotaxis elicited by stromal cell-derived factor-1.	Sirolimus	0-9	chemokine (C-X-C motif) ligand 12	Mus musculus	81-110
16298655-2	2005	The aim of our study was to compare effects of tacrolimus-based immunosuppression in conjunction with sirolimus (RAPA) versus mycophenolate mofetil (MMF) on glucose metabolism in type 1 diabetic recipients following a simultaneous pancreas and kidney transplantation (SPK).	Sirolimus	102-111	transcriptional regulating factor 1	Homo sapiens	113-117
16055440-8	2005	Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	Sirolimus	89-98	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	13-17
15886325-0	2005	A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.	Sirolimus	2-11	CCAAT enhancer binding protein beta	Homo sapiens	96-133
16103051-8	2005	Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E.	Sirolimus	15-24	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
16103051-9	2005	The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process.	Sirolimus	4-13	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
16126062-0	2005	Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).	Sirolimus	44-53	forkhead box P3	Homo sapiens	57-61
16126062-2	2005	We report the successful use of sirolimus in 3 patients with IPEX.	Sirolimus	32-41	forkhead box P3	Homo sapiens	61-65
15958750-4	2005	This effect is blocked by rapamycin, indicating that the increase in EF1A expression is mediated by the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	26-35	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	69-73
15705789-4	2005	Here, we show that Pim-2 is required to confer rapamycin resistance.	Sirolimus	47-56	proviral integration site 2	Mus musculus	19-24
15773967-8	2005	This observation points to the effectiveness of cyclosporine for the recurrence of FSGS and indicates that sirolimus should be given with caution in such cases.	Sirolimus	107-116	actinin alpha 4	Homo sapiens	83-87
19451225-8	2009	In conclusion, the deregulation of mTORC1 activation underlies the aberrant growth and proliferation of NF2-associated tumors and may restrain the growth of these lesions through negative feedback mechanisms, suggesting that rapamycin in combination with phosphoinositide 3-kinase inhibitors may be therapeutic for NF2.	Sirolimus	225-234	CREB regulated transcription coactivator 1	Mus musculus	35-41
19374918-1	2009	Sirolimus is a member of a novel class of immunosuppressant drug that potently suppresses T cell proliferation and expansion by inhibition of the Target of Rapamycin Complex 1 (TORC1) protein kinase.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	146-175
19374918-1	2009	Sirolimus is a member of a novel class of immunosuppressant drug that potently suppresses T cell proliferation and expansion by inhibition of the Target of Rapamycin Complex 1 (TORC1) protein kinase.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	177-182
19374918-5	2009	In polycystic kidney disease, TORC1 activation mediates renal tubular epithelial cell (TEC) proliferation and cyst growth in animals, and Phase III clinical trials are underway to determine the effect of sirolimus in attenuating disease progression in humans.	Sirolimus	204-213	CREB regulated transcription coactivator 1	Homo sapiens	30-35
15781656-0	2005	Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.	Sirolimus	0-9	ezrin	Mus musculus	19-24
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	46-55	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	185-194	glycogen synthase kinase 3 beta	Homo sapiens	159-168
19435852-5	2009	Moreover, the effect of intra-VTA leptin administration to reduce 4- and 20-h food intake and 20-h body weight was blocked by an inhibitor of Jak-2, at a dose that had no effect on food intake or body weight by itself, but not by local inhibition of either PI 3-kinase (LY-294002) or mTOR (rapamycin) in this timeframe.	Sirolimus	290-299	Janus kinase 2	Homo sapiens	142-147
15459004-5	2005	A short course of rapamycin plus agonistic CD28 treatment showed synergism at suboptimal doses, was highly effective in preventing lethal GVHD, and was superior to rapamycin plus CD28 blockade in a major histocompatibility complex class I- and II-mismatched HCT model.	Sirolimus	18-27	CD28 molecule	Homo sapiens	179-183
19285553-0	2009	Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression.	Sirolimus	160-169	matrix metallopeptidase 9	Mus musculus	185-189
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	mitogen-activated protein kinase 14	Mus musculus	124-127
19285553-5	2009	Rapamycin also enhanced the LPS-induced NF-kappaB transactivation as determined by a reporter assay, phosphorylation of the p38 and Erk1/2 MAPKs, and counteracted PPAR activity.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	132-138
15654601-6	2005	Coincubation with the mTOR inhibitor, rapamycin, effectively inhibited the proteosomal degradation of IRS-1 caused by the chronic insulin treatment.	Sirolimus	38-47	insulin receptor substrate 1	Canis lupus familiaris	102-107
19364503-4	2009	Here, we show that inhibition of mTOR signaling with its specific inhibitor, rapamycin, suppresses normal thymocyte DNA synthesis by downregulating 4EBP1, but not S6K, and that 4EBP1 phosphorylation and cyclin D1 expression are coordinately increased in Atm-/- thymocytes.	Sirolimus	77-86	ataxia telangiectasia mutated	Mus musculus	254-257
19364503-5	2009	Administration of rapamycin to Atm-/- mice attenuates elevated phospho-4EBP1, c-Myc and cyclin D1 in their thymocytes, and delays thymic lymphoma development.	Sirolimus	18-27	ataxia telangiectasia mutated	Mus musculus	31-34
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	53-62	interleukin 2 receptor subunit alpha	Homo sapiens	149-153
15654601-7	2005	Although the coincubation with rapamycin and advanced overexpression of IRS-1 effectively ameliorated subsequent insulin-induced phosphorylation of Akt, insulin stimulation of PKClambda activity and 2-DOG uptake was partly restored by these treatments.	Sirolimus	31-40	insulin receptor substrate 1	Canis lupus familiaris	72-77
18841360-5	2009	Addition of IL-2 prevented the apoptotic response to Sirolimus, potentially accounting for reports that Sirolimus can enhance proliferation of CD4(+)CD25(high) cells.	Sirolimus	104-113	interleukin 2 receptor subunit alpha	Homo sapiens	149-153
18841360-6	2009	These results predict that Sirolimus or Sorafenib would reduce CD4(+)CD25(high) cells if administered prior to antigenic stimulation in an immunotherapy protocol.	Sirolimus	27-36	interleukin 2 receptor subunit alpha	Homo sapiens	69-73
15701277-7	2005	In U-87 cells, MMP-2 was downregulated, and in D-54 cells, both MMP-2 and MMP-9 were downregulated after treatment with rapamycin.	Sirolimus	120-129	matrix metallopeptidase 9	Mus musculus	74-79
18841360-7	2009	However, administration of IL-2 protects CD4(+)CD25(high) T cells from cytotoxic effects of Sirolimus, a response that may be considered in design of therapeutic protocols.	Sirolimus	92-101	interleukin 2 receptor subunit alpha	Homo sapiens	47-51
15760093-1	2004	Sirolimus (rapamycin, RAPAMUNE, RAPA) is an immunosuppressive agent used for the prophylaxis of renal allograft rejection and exhibits an immunosuppressive mechanism that is distinct from that for cyclosporine and tacrolimus.	Sirolimus	0-9	transcriptional regulating factor 1	Homo sapiens	22-26
19402072-8	2009	Possible mechanisms include the loss of feedback inhibition of insulin receptor substate/PI3K signaling resulting from the inhibition of mTOR complex 1 by rapamycin analogs and the activating phosphorylation of Akt by mTOR complex 2.	Sirolimus	155-164	insulin receptor	Homo sapiens	63-79
19368729-3	2009	Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus).	Sirolimus	126-135	TSC complex subunit 1	Mus musculus	32-35
15355912-10	2004	Rapamycin analogs can potentially be used as adjuvant therapy for patients with eIF4E-positive margins.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
19368729-3	2009	Early clinical trials show that TSC-related kidney tumors (angiomyolipomas) regress when treated with the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (also known as sirolimus).	Sirolimus	179-188	TSC complex subunit 1	Mus musculus	32-35
19368729-6	2009	RESULTS: Here, we examine the efficacy of a prolonged maintenance dose of rapamycin in Tsc2+/- mice with TSC-related kidney tumors.	Sirolimus	74-83	TSC complex subunit 1	Mus musculus	105-108
19190264-7	2009	Furthermore, we found that triacylglycerol hydrolase (TGH) activity was required for the stimulation of lipolysis by combined exposure to insulin and rapamycin.	Sirolimus	150-159	carboxylesterase 1	Homo sapiens	27-52
19190264-7	2009	Furthermore, we found that triacylglycerol hydrolase (TGH) activity was required for the stimulation of lipolysis by combined exposure to insulin and rapamycin.	Sirolimus	150-159	carboxylesterase 1	Homo sapiens	54-57
15352124-11	2004	The mTOR inhibitor rapamycin lowered HMG-CoA reductase synthesis by 50 and 60% in rb4E and CHO cells, respectively; no equivalent effect was observed for HMG-CoA reductase mRNA levels with rapamycin treatment.	Sirolimus	19-28	serine/threonine-protein kinase mTOR	Cricetulus griseus	4-8
19270529-5	2009	Second, the efficacy of rapamycin is dependent on the level of phosphatidic acid (PA), which is required for the assembly of both mTORC1 and mTORC2 complexes.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	130-136
15352124-11	2004	The mTOR inhibitor rapamycin lowered HMG-CoA reductase synthesis by 50 and 60% in rb4E and CHO cells, respectively; no equivalent effect was observed for HMG-CoA reductase mRNA levels with rapamycin treatment.	Sirolimus	189-198	serine/threonine-protein kinase mTOR	Cricetulus griseus	4-8
19270529-5	2009	Second, the efficacy of rapamycin is dependent on the level of phosphatidic acid (PA), which is required for the assembly of both mTORC1 and mTORC2 complexes.	Sirolimus	24-33	CREB regulated transcription coactivator 2	Mus musculus	141-147
19270529-8	2009	A practical outcome of the recent study is that if PA levels are suppressed, mTORC2 becomes sensitive to concentrations of rapamycin that can be achieved clinically.	Sirolimus	123-132	CREB regulated transcription coactivator 2	Mus musculus	77-83
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	Sirolimus	13-22	myogenin	Homo sapiens	87-95
19356717-6	2009	Treatment with the mTOR inhibitor, rapamycin, ameliorated the hyperphagia, obesity, and the altered Pomc neuronal morphology in developing or adult Pomc-Tsc1cKO mice, and cessation of treatment reinstated these phenotypes.	Sirolimus	35-44	pro-opiomelanocortin-alpha	Mus musculus	100-104
19356717-6	2009	Treatment with the mTOR inhibitor, rapamycin, ameliorated the hyperphagia, obesity, and the altered Pomc neuronal morphology in developing or adult Pomc-Tsc1cKO mice, and cessation of treatment reinstated these phenotypes.	Sirolimus	35-44	pro-opiomelanocortin-alpha	Mus musculus	148-152
15150095-2	2004	We demonstrate a dramatic decrease of IFN-gamma expression in tumors and mouse embryo fibroblast cell lines that lack either Tsc1 or Tsc2, which is reversed by rapamycin (mammalian target of rapamycin inhibitor) therapy.	Sirolimus	160-169	TSC complex subunit 1	Mus musculus	125-129
14662900-6	2003	CCR2(-/-) mice treated with rapamycin also maintained islet allografts long-term.	Sirolimus	28-37	chemokine (C-C motif) receptor 2	Mus musculus	0-4
14559232-8	2003	The mTOR inhibitor rapamycin has similar inhibitory effects on G(1) cell cycle progression and expression of cyclin D1, CDK4, and Rb phosphorylation.	Sirolimus	19-28	cyclin D1	Homo sapiens	109-118
14559232-8	2003	The mTOR inhibitor rapamycin has similar inhibitory effects on G(1) cell cycle progression and expression of cyclin D1, CDK4, and Rb phosphorylation.	Sirolimus	19-28	cyclin dependent kinase 4	Homo sapiens	120-124
14517308-5	2003	The inactivation of TOR with rapamycin promotes the nuclear accumulation and stabilization of Ime1, with consequent induction of early meiotic genes.	Sirolimus	29-38	transcription factor IME1	Saccharomyces cerevisiae S288C	94-98
12820961-4	2003	In contrast, Tap42 inactivation, as does inactivation of the protein phosphatases Sit4 and Pph21/22, blocks rapamycin induction of nitrogen discrimination pathway genes.	Sirolimus	108-117	phosphoprotein phosphatase 2A catalytic subunit PPH21	Saccharomyces cerevisiae S288C	91-96
12604610-5	2003	Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Sirolimus	224-233	regulatory associated protein of MTOR complex 1	Homo sapiens	0-6
12742487-1	2003	BACKGROUND: Sirolimus (Rapammune, rapamycin, RAPA) is a strong immunosuppressive agent that reduces kidney transplant rejection.	Sirolimus	12-21	transcriptional regulating factor 1	Homo sapiens	45-49
12742499-16	2003	Oral SRL proved to be synergistic in both CsA-resistant mouse (CI = 0.4-1.5) and CsA-sensitive rat (CI = 0.3-0.6) models.	Sirolimus	5-8	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	42-45
12742499-16	2003	Oral SRL proved to be synergistic in both CsA-resistant mouse (CI = 0.4-1.5) and CsA-sensitive rat (CI = 0.3-0.6) models.	Sirolimus	5-8	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	81-84
12773967-6	2003	The IL-2R mAbs have been used with a variety of maintenance immunosuppression regimens double therapy with cyclosporine and prednisone, triple therapy with cyclosporine, azathioprine and prednisone and with newer regimens such as cyclosporine or tacrolimus, mycophenolate mofetil (MMF) and prednisone, and most recently with sirolimus, MMF and prednisone.	Sirolimus	325-334	interleukin 2 receptor subunit alpha	Homo sapiens	4-9
12599018-0	2003	Rapamycin induces Smad activity in prostate cancer cell lines.	Sirolimus	0-9	SMAD family member 4	Homo sapiens	18-22
12599018-6	2003	Rapamycin induced BMP4 and reduced follistatin expression in PC3 cells.	Sirolimus	0-9	bone morphogenetic protein 4	Homo sapiens	18-22
12202955-3	2002	Furthermore, since the rapamycin receptor protein binds transforming growth factor beta (TGF-beta) receptors, and TGF-beta enhances osteoclastogenesis induced by RANKL, we also examined potential synergistic effects of rapamycin and TGF-beta1.	Sirolimus	23-32	transforming growth factor, beta 1	Mus musculus	89-97
12202955-8	2002	The combination of rapamycin (10 ng/ml) and TGF-beta1 (1 ng/ml) increased TRAP+MNC 3.1- and 6.9-fold as compared with rapamycin or TGF-beta1 alone, respectively, and enhanced CTR mRNA expression induced by TGF-beta1 by 1.9-fold.	Sirolimus	19-28	calcitonin receptor	Mus musculus	175-178
12202955-9	2002	Rapamycin also increased osteoclastic resorption activity by 6.5-fold compared with control, and this was enhanced further by the addition of TGF-beta by 3-fold, compared with rapamycin alone.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	142-150
12202955-9	2002	Rapamycin also increased osteoclastic resorption activity by 6.5-fold compared with control, and this was enhanced further by the addition of TGF-beta by 3-fold, compared with rapamycin alone.	Sirolimus	176-185	transforming growth factor, beta 1	Mus musculus	142-150
11937029-8	2002	Finally, we find that rapamycin treatment or nitrogen starvation induces resistance to the cell wall-digesting enzyme zymolyase by a Pkc1-dependent mechanism.	Sirolimus	22-31	protein kinase C	Saccharomyces cerevisiae S288C	133-137
11935154-9	2002	Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA.	Sirolimus	18-27	transforming growth factor, beta 1	Mus musculus	174-177
11935154-10	2002	CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets.	Sirolimus	80-89	transforming growth factor, beta 1	Mus musculus	207-217
11574405-11	2001	Glucose- and insulin-stimulated translocation of PDX-1 to the nucleoplasm was inhibited by wortmannin and SB 203580, indicating that a pathway involving PI 3-kinase and SAPK2/p38 was involved; translocation was unaffected by PD 098959 and rapamycin, suggesting that neither mitogen-activated protein kinase nor p70(s6k) were involved.	Sirolimus	239-248	pancreatic and duodenal homeobox 1	Homo sapiens	49-54
11574405-11	2001	Glucose- and insulin-stimulated translocation of PDX-1 to the nucleoplasm was inhibited by wortmannin and SB 203580, indicating that a pathway involving PI 3-kinase and SAPK2/p38 was involved; translocation was unaffected by PD 098959 and rapamycin, suggesting that neither mitogen-activated protein kinase nor p70(s6k) were involved.	Sirolimus	239-248	mitogen-activated protein kinase 11	Homo sapiens	169-174
11510015-1	2001	Although sirolimus (SRL) binds the immunophilin FK506-binding protein-12 (FKBP-12) with greater avidity than tacrolimus (TAC), animal studies have shown that SRL and TAC act synergistically to prevent rejection.	Sirolimus	9-18	FKBP prolyl isomerase 1A	Homo sapiens	74-81
11162519-4	2001	Cyclosporine A, rapamycin, and FK-506 decreased OPG mRNA and protein levels in undifferentiated marrow stromal cells (by 63, 44, and 68%, respectively, P &lt; 0.001).	Sirolimus	16-25	TNF receptor superfamily member 11b	Homo sapiens	48-51
19188252-2	2009	In an effort to determine whether mTORC1 signalling is essential for regulating muscle protein synthesis in humans, we treated subjects with a potent mTORC1 inhibitor (rapamycin) prior to performing a series of high-intensity muscle contractions.	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	150-156
19188252-4	2009	In addition, several downstream components of the mTORC1 signalling pathway were also blunted or blocked by rapamycin.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	50-56
19188252-7	2009	Rapamycin administration prior to exercise also reduced the ability of raptor to associate with mTORC1 during post-exercise recovery.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	96-102
19162189-9	2009	In situ MMP-2/MMP-9 activity was significantly reduced in grafts treated with tacrolimus and rapamycin compared to controls (p&lt;0.05).	Sirolimus	93-102	matrix metallopeptidase 2	Homo sapiens	8-13
19376376-11	2009	Substitution of sirolimus (40/177) was shown in univariate, multivariate and Cox regression analyses to be a renal protector (P &lt; .002).	Sirolimus	16-25	cytochrome c oxidase subunit 8A	Homo sapiens	77-80
19379572-6	2009	PCR results showed the down-regulation of mTOR, cyclin D1 and mTOR mRNA expressions after treating RPMI8226 cells with different concentrations of rapamycin for 24 hours.	Sirolimus	147-156	cyclin D1	Homo sapiens	48-57
11045651-1	2000	BACKGROUND: Under certain conditions rapamycin and transforming growth factor- (TGF) beta have similar immunoregulatory effects, suggesting a potential functional link between rapamycin and TGF-beta.	Sirolimus	37-46	transforming growth factor, beta 1	Mus musculus	190-198
10884572-3	2000	In contrast, rapamycin markedly increased neurite outgrowth in PC12 cells in the presence of a low concentration of nerve growth factor (EC(50)=10 nM).	Sirolimus	13-22	nerve growth factor	Rattus norvegicus	116-135
19150980-2	2009	Rapamycin is a potent allosteric mTORC1 inhibitor with clinical applications as an immunosuppressant and anti-cancer agent.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	33-39
19150980-6	2009	Our findings challenge the assumption that rapamycin completely inhibits mTORC1 and indicate that direct inhibitors of mTORC1 kinase activity may be more successful than rapamycin at inhibiting tumors that depend on mTORC1.	Sirolimus	43-52	CREB regulated transcription coactivator 1	Mus musculus	73-79
19220291-7	2009	Compared with placebo, plasma levels of interleukin-6, monocyte chemoattractant protein-1, interferon gamma, tumour necrosis factor alpha and CD40, and their mRNA levels in aortic tissue were significantly reduced in sirolimus-treated mice.	Sirolimus	217-226	CD40 antigen	Mus musculus	142-146
19114562-0	2009	Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	14-20
19114562-0	2009	Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.	Sirolimus	88-97	CREB regulated transcription coactivator 2	Mus musculus	25-31
19114562-8	2009	Suppressing PA production substantially increased the sensitivity of mTORC2 to rapamycin.	Sirolimus	79-88	CREB regulated transcription coactivator 2	Mus musculus	69-75
19114562-9	2009	Data provided here demonstrate a PA requirement for the stabilization of both mTORC1 and mTORC2 complexes and reveal a mechanism for the inhibitory effect of rapamycin on mTOR.	Sirolimus	158-167	CREB regulated transcription coactivator 1	Mus musculus	78-84
19114562-9	2009	Data provided here demonstrate a PA requirement for the stabilization of both mTORC1 and mTORC2 complexes and reveal a mechanism for the inhibitory effect of rapamycin on mTOR.	Sirolimus	158-167	CREB regulated transcription coactivator 2	Mus musculus	89-95
19114562-10	2009	This study also suggests that by suppressing PLD activity, mTORC2 could be targeted therapeutically with rapamycin.	Sirolimus	105-114	CREB regulated transcription coactivator 2	Mus musculus	59-65
19074484-5	2009	mTOR inhibition with rapamycin at below pharmacological concentrations blocked p70S6K phosphorylation and induced a differentiated contractile phenotype with smooth muscle (sm)-calponin, sm-alpha-actin, and SM protein 22-alpha (SM22alpha) expression.	Sirolimus	21-30	transgelin	Homo sapiens	228-237
19143643-5	2009	Phase I/II clinical trials of the mTORC1 inhibitor rapamycin have demonstrated reduction in size of tuberous-sclerosis- and LAM-associated renal tumours (angiomyolipomas) and some evidence for reversible improvement in lung function in patients with LAM.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	34-40
19013662-10	2009	We also show that IGF-I and EGF are involved in the activation of mTOR in bovine MEC, whereas inhibition of mTOR by rapamycin abrogated the suppressive effects of IGF-I and EGF on autophagy.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Bos taurus	108-112
19125415-6	2009	Exposure of 2T3 cells to the RPM decreased bone formation responses as determined by alkaline phosphatase (ALP) activity and mineralization even in the presence of a submaximal dose of BMP4 (20 ng/ml).	Sirolimus	29-32	bone morphogenetic protein 4	Homo sapiens	185-189
10749698-6	2000	Insulin caused phosphorylation of 4E-BP1 and induced its dissociation from eIF4E, and these effects were also blocked by rapamycin.	Sirolimus	121-130	eukaryotic translation initiation factor 4E	Rattus norvegicus	75-80
10660069-5	2000	Deletion of RRD1 caused pleiotropic phenotypes under a wide range of conditions, including sensitivity to Ca2+, vanadate, ketoconazole, cycloheximide and Calcofluor white, and resistance to caffeine and rapamycin.	Sirolimus	203-212	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	12-16
19305497-8	2009	Inhibition of mTORC1 by rapamycin did not affect proinsulin and total protein synthesis in beta-cells incubated at high glucose with palmitate.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
18945681-5	2008	mTOR exists in two complexes, mTORC1 and mTORC2, which are differentially sensitive to rapamycin.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	30-36
18945681-5	2008	mTOR exists in two complexes, mTORC1 and mTORC2, which are differentially sensitive to rapamycin.	Sirolimus	87-96	CREB regulated transcription coactivator 2	Mus musculus	41-47
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	229-233
18776922-8	2008	These results indicate the presence of two parallel cell-survival pathways in prostate cancer cells: a strong Akt-independent, but rapamycin-sensitive pathway downstream of mTORC1, and an AR-dependent pathway downstream of mTORC2 and Akt, that is stimulated by mTORC1 inhibition.	Sirolimus	131-140	CREB regulated transcription coactivator 1	Mus musculus	173-179
18955708-3	2008	It is generally accepted that rapamycin, a specific inhibitor of mTORC1, is a potent translational repressor.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	65-71
18614546-0	2008	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	62-68
18614546-0	2008	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Sirolimus	81-90	CREB regulated transcription coactivator 2	Mus musculus	73-79
18614546-0	2008	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Sirolimus	81-90	CREB regulated transcription coactivator 2	Mus musculus	144-150
18678646-6	2008	Treatment of both primary cells and cancer cell lines with rapamycin, metformin, and pyrvinium resulted in an increase in p73 levels, as did RNA interference-mediated knockdown of mTOR.	Sirolimus	59-68	tumor protein p73	Homo sapiens	122-125
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	glycogen synthase kinase 3 beta	Homo sapiens	33-42
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	cyclin D1	Homo sapiens	98-107
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	glycogen synthase kinase 3 beta	Homo sapiens	135-144
18611860-9	2008	Rapamycin, an inducer of autophagy, both down-regulated survivin and decreased PC3 cell viability in serum-deprived conditions.	Sirolimus	0-9	keratin 6A	Homo sapiens	79-82
18762023-4	2008	Furthermore, nuclear accumulation of the mature form of the sterol responsive element binding protein (SREBP1) and expression of SREBP target genes was blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	184-193	CREB regulated transcription coactivator 1	Mus musculus	167-173
18559659-0	2008	Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	68-72
18559659-0	2008	Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.	Sirolimus	0-9	forkhead box P3	Homo sapiens	73-78
18559659-2	2008	Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	78-82
10579326-2	1999	In subconfluent cultures, wortmannin, LY294002, and rapamycin reversed insulin- and EGF-induced [3H]thymidine incorporation into DNA.	Sirolimus	52-61	epidermal growth factor like 1	Rattus norvegicus	84-87
18559659-2	2008	Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal for the induction and maintenance of peripheral tolerance.	Sirolimus	0-9	forkhead box P3	Homo sapiens	85-90
18559659-7	2008	However, nTregs isolated from type 1 diabetic patients under rapamycin treatment had an increased capability to suppress proliferation of CD4(+)CD25(-) effector T-cells compared with that before treatment.	Sirolimus	61-70	interleukin 2 receptor subunit alpha	Homo sapiens	144-148
10454551-6	1999	Moreover, despite rapamycin-induced dephosphorylation of 4BP-1, eIF-4E-eIF-4G complexes (eIF-4F) were still detected.	Sirolimus	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
18587048-10	2008	The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	88-93
18587048-10	2008	The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	142-147
10454551-6	1999	Moreover, despite rapamycin-induced dephosphorylation of 4BP-1, eIF-4E-eIF-4G complexes (eIF-4F) were still detected.	Sirolimus	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	89-95
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	96-102
10447669-5	1999	Increases in CYP2A5 activity were also observed after exposure of the hepatocytes to other protein kinase inhibitors affecting the cell cycle, i.e. roscovitine, K-252a and rapamycin.	Sirolimus	172-181	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	13-19
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	CREB regulated transcription coactivator 2	Mus musculus	107-113
18495876-9	2008	Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d. In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	308-314
18495876-9	2008	Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d. In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.	Sirolimus	177-186	CREB regulated transcription coactivator 1	Mus musculus	308-314
18303120-6	2008	Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	91-97
18418060-3	2008	Recently it was proposed that rapamycin and its derivatives enhance the clearance (and/or reduce the accumulation) of mutant intracellular proteins causing proteinopathies such as tau, alpha-synuclein, ataxin-3, and full-length or fragments of huntingtin containing a polyglutamine (polyQ) expansion, by upregulating macroautophagy.	Sirolimus	30-39	huntingtin	Homo sapiens	244-254
10424436-2	1999	We found that activation of B cells through CD40 is selectively inhibited by an immunosuppressant drug, rapamycin.	Sirolimus	104-113	CD40 antigen	Mus musculus	44-48
18418060-5	2008	We found that rapamycin inhibits the aggregation of a fragment of huntingtin (exon 1) containing 97 polyQs similarly in macroautophagy-proficient (Atg5(+/+)) and macroautophagy-deficient (Atg5(-/-)) cells.	Sirolimus	14-23	huntingtin	Homo sapiens	66-76
10424436-3	1999	This effect of rapamycin on anti-CD40-mediated activation of B cells was observed using three different in vitro assays.	Sirolimus	15-24	CD40 antigen	Mus musculus	33-37
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	inhibitor of DNA binding 1, HLH protein	Homo sapiens	148-151
10424436-4	1999	Rapamycin suppressed the anti-CD40-induced proliferation of splenic B cells, suppressed differentiation to surface IgMhigh/IgDlow B cells, and inhibited an anti-CD40-mediated prevention of apoptosis induced by BCR cross-linkage of WEHI-231 cells.	Sirolimus	0-9	CD40 antigen	Mus musculus	30-34
10424436-4	1999	Rapamycin suppressed the anti-CD40-induced proliferation of splenic B cells, suppressed differentiation to surface IgMhigh/IgDlow B cells, and inhibited an anti-CD40-mediated prevention of apoptosis induced by BCR cross-linkage of WEHI-231 cells.	Sirolimus	0-9	CD40 antigen	Mus musculus	161-165
10424436-7	1999	Therefore, rapamycin affects a novel element of the CD40 signal transduction pathway which influences the proliferation, differentiation, and prevention of apoptosis of B cells.	Sirolimus	11-20	CD40 antigen	Mus musculus	52-56
10329624-4	1999	We show that inactivation of either Cdc55 or Tpd3, which regulate Pph21/22 activity, results in rapamycin resistance and that this resistance correlates with an increased association of Tap42 with Pph21/22.	Sirolimus	96-105	phosphoprotein phosphatase 2A catalytic subunit PPH21	Saccharomyces cerevisiae S288C	66-71
17986252-0	2008	Components of the Vid30c are needed for the rapamycin-induced degradation of the high-affinity hexose transporter Hxt7p in Saccharomyces cerevisiae.	Sirolimus	44-53	hexose transporter HXT7	Saccharomyces cerevisiae S288C	114-119
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	glucose-induced degradation complex subunit VID30	Saccharomyces cerevisiae S288C	48-53
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	glucose-induced degradation complex subunit VID30	Saccharomyces cerevisiae S288C	54-58
10212283-7	1999	PGF2alpha-induced phosphorylation of eIF4E and 4E-BP1 was also found to be sensitive to inhibition by both wortmannin and rapamycin.	Sirolimus	122-131	eukaryotic translation initiation factor 4E	Homo sapiens	37-53
17700525-4	2008	We report here that transforming growth factor-beta (TGF-beta) suppresses rapamycin-induced apoptosis in serum-deprived MDA-MB-231 cells in a protein kinase Cdelta (PKCdelta)-dependent manner.	Sirolimus	74-83	protein kinase C delta	Homo sapiens	165-173
17724476-3	2008	In MCF7 breast adenocarcinoma cells, rapamycin decreases levels of cyclin D1, without affecting cytoplasmic levels of its mRNA.	Sirolimus	37-46	cyclin D1	Homo sapiens	67-76
9614103-6	1998	Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that S6 kinase is also necessary for the insulin induction of G6PDH expression.	Sirolimus	0-9	glucose-6-phosphate dehydrogenase	Rattus norvegicus	128-133
18245339-5	2008	We identified critically important cellular functions: (i) amino acid biosynthesis, (ii) microautophagy and sorting of amino acid permease established by the exit from rapamycin-induced growth arrest/Gap1 sorting in the endosome (EGO/GSE) complex, (iii) mitochondrial functions, (iv) membrane trafficking, (v) actin organization mediated by Drs2-Cdc50, and (vi) transcription regulated by the Ccr4-Not complex.	Sirolimus	168-177	aminophospholipid-translocating P4-type ATPase DRS2	Saccharomyces cerevisiae S288C	341-345
18245339-5	2008	We identified critically important cellular functions: (i) amino acid biosynthesis, (ii) microautophagy and sorting of amino acid permease established by the exit from rapamycin-induced growth arrest/Gap1 sorting in the endosome (EGO/GSE) complex, (iii) mitochondrial functions, (iv) membrane trafficking, (v) actin organization mediated by Drs2-Cdc50, and (vi) transcription regulated by the Ccr4-Not complex.	Sirolimus	168-177	CCR4-NOT core exoribonuclease subunit CCR4	Saccharomyces cerevisiae S288C	393-397
9614103-6	1998	Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that S6 kinase is also necessary for the insulin induction of G6PDH expression.	Sirolimus	0-9	glucose-6-phosphate dehydrogenase	Rattus norvegicus	208-213
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Sirolimus	179-188	5'-nucleotidase, cytosolic IA	Homo sapiens	39-42
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Sirolimus	179-188	5'-nucleotidase, cytosolic IA	Homo sapiens	86-89
9603962-7	1998	The selective inhibition of p70 and eIF-4E BP1 phosphorylation by amino acid withdrawal resembles the response to rapamycin, which prevents p70 reactivation by amino acids, indicating that mTOR is required for the response to amino acids.	Sirolimus	114-123	serine/threonine-protein kinase mTOR	Cricetulus griseus	189-193
18578558-6	2008	Because de novo immunosuppression uses CNI in more than 93% of patients, reduction of CNI-related adverse effects has focused on CNI sparing or withdrawal.A recurring theme where sirolimus and mycophenolate mofetil have been used for this purpose is the importance of their early introduction to limit CNI damage and provide long-term benefit: for example, long-term renal function critically reflects that at 1 year post-transplant.	Sirolimus	179-188	5'-nucleotidase, cytosolic IA	Homo sapiens	86-89
18556237-5	2008	Stimulation of eIF2Bepsilon translation was reversed by pre-treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	79-85
9528776-4	1998	In quiescent mammalian cells, AtS6k2 is activated by serum stimulation, a response which is abolished by the fungal metabolite wortmannin but is resistant to rapamycin.	Sirolimus	158-167	serine/threonine protein kinase 2	Arabidopsis thaliana	30-36
18082048-1	2007	OBJECTIVE: This study examined the effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), on eukaryotic initiation factor (eIF- 4E) expression in rat myocardial fibroblasts infected by Coxsackievirus B3 (CVB3) in order to identify the drug target for treatment of viral myocarditis.	Sirolimus	45-54	eukaryotic translation initiation factor 4E	Homo sapiens	143-150
18025271-10	2007	Anti-HER2 antibody in combination with LY294002, rapamycin, or SP600125 induced greater cyclin G2 expression than either agent alone.	Sirolimus	49-58	cyclin G2	Homo sapiens	88-97
9528776-5	1998	Treatment of mammalian cells with rapamycin abolishes in vivo S6 phosphorylation by p70s6k; however, ectopic expression of AtS6k2 rescues the rapamycin block.	Sirolimus	34-43	serine/threonine protein kinase 2	Arabidopsis thaliana	123-129
9528776-5	1998	Treatment of mammalian cells with rapamycin abolishes in vivo S6 phosphorylation by p70s6k; however, ectopic expression of AtS6k2 rescues the rapamycin block.	Sirolimus	142-151	serine/threonine protein kinase 2	Arabidopsis thaliana	123-129
9404561-0	1997	Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival.	Sirolimus	11-20	interleukin 5	Homo sapiens	58-71
9404561-6	1997	Dexamethasone and rapamycin produced significant, concentration-dependent inhibition of IL-5-enhanced eosinophil survival at pharmacologic concentrations, whereas cyclosporin A did not.	Sirolimus	18-27	interleukin 5	Homo sapiens	88-92
9404561-8	1997	Cyclosporin A and rapamycin significantly inhibited IL-5-enhanced ECP release in a concentration-dependent fashion, whereas dexamethasone did not.	Sirolimus	18-27	interleukin 5	Homo sapiens	52-56
9394786-2	1997	We evaluated the dose-effect relationship of 1,25(OH)2D3 and sirolimus (rapamycin, RAP) in vitro, on the inhibition of PHA-stimulated PBMC proliferation, by using the median effect analysis.	Sirolimus	61-70	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	83-86
9399022-1	1997	OBJECTIVE: Sirolimus (RAPA) is a new immunosuppressive drug currently in Phase III clinical trials in combination with cyclosporine A (CsA).	Sirolimus	11-20	transcriptional regulating factor 1	Homo sapiens	22-26
8980296-6	1997	TGF-alpha stimulation of S6 kinase activity was inhibited in a concentration-dependent manner by rapamycin (IC50 &lt; 0.2 nM) and the specific EGF receptor antagonist PD153035 (IC50 = 20 nM).	Sirolimus	97-106	transforming growth factor alpha	Homo sapiens	0-9
8955182-0	1996	IL-2 induces beta2-integrin adhesion via a wortmannin/LY294002-sensitive, rapamycin-resistant pathway.	Sirolimus	74-83	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-18
8878544-3	1996	The phosphorylation of S17 in T- and B-cell lines is specifically inhibited by rapamycin.	Sirolimus	79-88	sperm associated antigen 5	Mus musculus	23-26
8878544-4	1996	IL-3 induces the phosphorylation of S17 in the IL3-responsive cell line, BaF3, and this phosphorylation is inhibited by rapamycin.	Sirolimus	120-129	sperm associated antigen 5	Mus musculus	36-39
8878544-7	1996	These data suggest that the ribosomal protein S17 is a substrate for p70 S6 kinase both in vitro and in vivo and that S17 may be involved in mediating the inhibitory effects of rapamycin on protein translation in cells of different lineages.	Sirolimus	177-186	ribosomal protein S17	Mus musculus	28-49
8878544-7	1996	These data suggest that the ribosomal protein S17 is a substrate for p70 S6 kinase both in vitro and in vivo and that S17 may be involved in mediating the inhibitory effects of rapamycin on protein translation in cells of different lineages.	Sirolimus	177-186	sperm associated antigen 5	Mus musculus	46-49
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	hexokinase 2	Homo sapiens	239-243
8663315-7	1996	In addition, rapamycin blocked the insulin-induced expression of an HKII promoter-chloramphenicol acetyltransferase fusion gene transiently transfected into L6 myotubes, whereas PD98059 had no such effect.	Sirolimus	13-22	hexokinase 2	Homo sapiens	68-72
8770969-1	1996	A 14-day ascending dose course of sirolimus (rapamycin, RAPA) was administered to quiescent renal transplant patients receiving a double-drug cyclosporine (CsA)/corticosteroid regimen in a double-blinded randomized study.	Sirolimus	34-43	transcriptional regulating factor 1	Homo sapiens	56-60
7559654-5	1995	p70 was purified to homogeneity; analysis of four tryptic peptides revealed that p70 is identical to the recently described FPR3 gene product, a nucleolarly localized proline rotamase of the FK506- and rapamycin-binding family.	Sirolimus	202-211	peptidylprolyl isomerase FPR3	Saccharomyces cerevisiae S288C	124-128
17645419-5	2007	Therefore, newer immunosuppressive agents such as mycophenolate mofetil and sirolimus (Rapa) have raised the possibility of withdrawing or avoiding CNIs altogether.	Sirolimus	76-85	transcriptional regulating factor 1	Homo sapiens	87-91
8557519-1	1995	We investigated the transcription and expression of the interleukin-2 receptor (IL-2R, CD25) in human T-lymphocytes after different modes of T-lymphocyte stimulation in the presence of the immunosuppressants cyclosporin (CsA) and tacrolimus (FK506) as well as the structurally related macrolide rapamycin.	Sirolimus	295-304	interleukin 2 receptor subunit alpha	Homo sapiens	56-78
8557519-3	1995	Rapamycin, which does not affect IL-2 transcription, surprisingly inhibited IL-2R upregulation after anti-CD3- or ionomycin-induced stimulation, but not by phorbol ester or IL-2.	Sirolimus	0-9	interleukin 2 receptor subunit alpha	Homo sapiens	76-81
17656678-5	2007	Our work establishes an immunologic stimulus for mTORC1 signaling in vascular smooth muscle cells, emphasizes that mTORC1 activation is critical in immune-mediated vascular remodeling, and provides further mechanistic insight into the successful clinical application of rapamycin therapy for atherosclerosis and graft arteriosclerosis.	Sirolimus	270-279	CREB regulated transcription coactivator 1	Mus musculus	49-55
7629182-7	1995	Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity.	Sirolimus	10-19	eukaryotic translation initiation factor 4E	Homo sapiens	130-136
17656678-5	2007	Our work establishes an immunologic stimulus for mTORC1 signaling in vascular smooth muscle cells, emphasizes that mTORC1 activation is critical in immune-mediated vascular remodeling, and provides further mechanistic insight into the successful clinical application of rapamycin therapy for atherosclerosis and graft arteriosclerosis.	Sirolimus	270-279	CREB regulated transcription coactivator 1	Mus musculus	115-121
7629182-8	1995	Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70S6K.	Sirolimus	0-9	ribosomal protein S6	Homo sapiens	76-96
7629182-11	1995	Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	77-83
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	regulatory associated protein of MTOR complex 1	Homo sapiens	46-52
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	92-98
7638171-0	1995	cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.	Sirolimus	10-19	eukaryotic translation initiation factor 4E	Rattus norvegicus	63-94
7638171-6	1995	The effects of PDGF and IGF-I on increasing PHAS-I phosphorylation, on dissociating the PHAS-I-eIF-4E complex, and on increasing p70S6K were abolished by rapamycin.	Sirolimus	154-163	eukaryotic translation initiation factor 4E	Rattus norvegicus	95-101
7532879-7	1995	The extent of the antagonism of RPM"s inhibition of bFGF-induced VSMC DNA synthesis by FK506 was inversely proportional to RPM concentration and directly proportional to FK506 concentration.	Sirolimus	32-35	fibroblast growth factor 2	Rattus norvegicus	52-56
17660033-7	2007	RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels.	Sirolimus	24-33	transcriptional regulating factor 1	Homo sapiens	96-100
7532879-7	1995	The extent of the antagonism of RPM"s inhibition of bFGF-induced VSMC DNA synthesis by FK506 was inversely proportional to RPM concentration and directly proportional to FK506 concentration.	Sirolimus	123-126	fibroblast growth factor 2	Rattus norvegicus	52-56
17502379-4	2007	Our work shows that activation of mTOR by Ras homologue enriched in brain (Rheb) overexpression potently enhances the activity of HIF1alpha and vascular endothelial growth factor (VEGF)-A secretion during hypoxia, which is reversed with rapamycin.	Sirolimus	237-246	Ras homolog, mTORC1 binding	Homo sapiens	75-79
7982907-2	1994	CD28 signaling is resistant to the immunosuppressant cyclosporin A (CsA) but sensitive to the immunosuppressant rapamycin.	Sirolimus	112-121	CD28 molecule	Homo sapiens	0-4
17502379-8	2007	Rapamycin treatments do not affect the stability of HIF1alpha and modulate HIF activity via a Von Hippel-Lindau (VHL)-independent mechanism.	Sirolimus	0-9	von Hippel-Lindau tumor suppressor	Homo sapiens	94-111
17389711-0	2007	Rapamycin blunts nutrient stimulation of eIF4G, but not PKCepsilon phosphorylation, in skeletal muscle.	Sirolimus	0-9	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	41-46
17389711-4	2007	Pretreatment with rapamycin prevented the feeding-induced phosphorylation of mTOR, eIF4G, and S6K1 but only partially attenuated the shift in 4E-BP1 into the gamma-form.	Sirolimus	18-27	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	83-88
17389711-6	2007	Rapamycin also prevented the augmented association of eIF4G with eIF4E and the decreased association of eIF4E with 4E-BP1.	Sirolimus	0-9	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	54-59
17389711-6	2007	Rapamycin also prevented the augmented association of eIF4G with eIF4E and the decreased association of eIF4E with 4E-BP1.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Rattus norvegicus	65-70
8089500-8	1994	In contrast, on days 60 and 300 postgrafting heart allografts from RAPA-treated unresponsive recipients showed increased levels of IL-10 and IL-4 but not of IL-2 mRNA, suggesting preferential activation of Th2 cells.	Sirolimus	67-71	interleukin 4	Rattus norvegicus	141-145
17389711-6	2007	Rapamycin also prevented the augmented association of eIF4G with eIF4E and the decreased association of eIF4E with 4E-BP1.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Rattus norvegicus	104-109
17389711-8	2007	Perfusion of gastrocnemius with medium containing rapamycin partially prevented the leucine-induced increase in phosphorylation of eIF4G.	Sirolimus	50-59	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	131-136
17389711-9	2007	Thus, rapamycin attenuated a feeding- or leucine-induced phosphorylation of eIF4G in skeletal muscle both in vivo and in situ.	Sirolimus	6-15	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	76-81
17031644-1	2007	PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).	Sirolimus	107-116	major vault protein	Homo sapiens	354-357
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Sirolimus	33-42	major vault protein	Homo sapiens	139-142
17031644-9	2007	CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.	Sirolimus	102-111	major vault protein	Homo sapiens	139-142
17284572-7	2007	The ability of GH to stimulate the phosphorylation of S6 and 4E-BP1 was blocked by rapamycin.	Sirolimus	83-92	gonadotropin releasing hormone receptor	Rattus norvegicus	15-17
17284572-7	2007	The ability of GH to stimulate the phosphorylation of S6 and 4E-BP1 was blocked by rapamycin.	Sirolimus	83-92	Blood pressure QTL 1	Rattus norvegicus	64-67
17284572-13	2007	Finally, the activation of overall protein synthesis by GH in H4IIE cells was essentially completely inhibited by wortmannin or rapamycin.	Sirolimus	128-137	gonadotropin releasing hormone receptor	Rattus norvegicus	56-58
17397797-0	2007	Rapamycin stimulates arginine influx through CAT2 transporters in human endothelial cells.	Sirolimus	0-9	solute carrier family 7 member 2	Homo sapiens	45-49
17449225-3	2007	In the present study, we observed that the immunosuppressive drug cyclosporin A (CsA) could significantly reduce BTLA but not CD25 and CD69 expression on CD4+ T cells during activation in vitro, while rapamycin (RPM) had little effect on it.	Sirolimus	201-210	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	81-84
17449225-3	2007	In the present study, we observed that the immunosuppressive drug cyclosporin A (CsA) could significantly reduce BTLA but not CD25 and CD69 expression on CD4+ T cells during activation in vitro, while rapamycin (RPM) had little effect on it.	Sirolimus	212-215	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	81-84
17510408-7	2007	We found that NPM expression in Nf1(-/-) astrocytes was blocked by rapamycin in vitro and in vivo and that expression of a dominant-negative NPM mutant protein in Nf1(-/-) astrocytes rescued actin stress fiber formation and restored cell motility and proliferation to wild-type levels.	Sirolimus	67-76	nucleophosmin 1	Homo sapiens	14-17
7510408-2	1994	Changing tyrosine-82 to phenylalanine in FKBP-12 abolishes protein-ligand hydrogen bond interactions in the FKBP-12 complexes with tacrolimus or rapamycin and leads to a large apparent enthalpic stabilization of binding in both H2O and D2O.	Sirolimus	145-154	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	41-48
7510408-2	1994	Changing tyrosine-82 to phenylalanine in FKBP-12 abolishes protein-ligand hydrogen bond interactions in the FKBP-12 complexes with tacrolimus or rapamycin and leads to a large apparent enthalpic stabilization of binding in both H2O and D2O.	Sirolimus	145-154	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	108-115
8109837-4	1993	These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2.	Sirolimus	28-37	cyclin-dependent kinase 1	Mus musculus	222-229
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD3 antigen, epsilon polypeptide	Mus musculus	192-195
8222329-0	1993	Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin.	Sirolimus	80-89	CD28 molecule	Homo sapiens	5-9
17289850-8	2007	Basal, IGF-, or estradiol-stimulated IGFBP-2 was abrogated by LY294002 and rapamycin and an inhibitor of IGFR1 tyrosine kinase activity, AG1024.	Sirolimus	75-84	insulin like growth factor binding protein 2	Homo sapiens	37-44
8335897-0	1993	Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.	Sirolimus	0-9	C-X-C motif chemokine ligand 2	Rattus norvegicus	58-63
8335897-3	1993	In this study we tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-alpha cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties.	Sirolimus	44-47	C-X-C motif chemokine ligand 2	Rattus norvegicus	217-250
8335897-3	1993	In this study we tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-alpha cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties.	Sirolimus	44-47	C-X-C motif chemokine ligand 2	Rattus norvegicus	252-257
7684925-4	1993	Two largely nonpolar, structurally related macrolide ligands, tacrolimus (also known as FK506) and rapamycin, each bind with high affinity to a common site on a small FK506 binding protein (FKBP-12) and inhibit its peptidylprolyl cis-trans-isomerase activity.	Sirolimus	99-108	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	190-197
17524933-1	2007	UNLABELLED: Both tacrolimus (TAC) and sirolimus (SRL) bind to the same immunophilin FKBP12; however, their mechanisms of action are distinct.	Sirolimus	38-47	FKBP prolyl isomerase 1A	Homo sapiens	71-90
17438408-3	2007	Zotarolimus was found to be mechanistically similar to sirolimus in having high-affinity binding to the immunophilin FKBP12 and comparable potency for inhibiting in vitro proliferation of both human and rat T cells.	Sirolimus	55-64	FKBP prolyl isomerase 1A	Homo sapiens	104-123
17301289-6	2007	Although Akt did not require mTOR/RAPTOR to maintain surface Glut1 levels, inhibition of mTOR/RAPTOR by rapamycin greatly diminished glucose uptake, suggesting Akt-stimulated mTOR/RAPTOR may promote Glut1 transporter activity.	Sirolimus	104-113	regulatory associated protein of MTOR complex 1	Homo sapiens	94-100
17301289-6	2007	Although Akt did not require mTOR/RAPTOR to maintain surface Glut1 levels, inhibition of mTOR/RAPTOR by rapamycin greatly diminished glucose uptake, suggesting Akt-stimulated mTOR/RAPTOR may promote Glut1 transporter activity.	Sirolimus	104-113	regulatory associated protein of MTOR complex 1	Homo sapiens	94-100
17234746-6	2007	Furthermore, depletion of PATJ from Caco2 cells induces an increase in mammalian Target Of Rapamycin Complex 1 (mTORC1) activity, which is totally inhibited by rapamycin.	Sirolimus	160-169	CREB regulated transcription coactivator 1	Mus musculus	112-118
17382186-8	2007	Although eIF4E overexpression has been suggested to make cells resistant to rapamycin, we observed marked growth inhibition with rapamycin as a single agent in SKRC39, which has marked overexpression of eIF4E.	Sirolimus	76-85	eukaryotic translation initiation factor 4E	Homo sapiens	9-14
17382186-8	2007	Although eIF4E overexpression has been suggested to make cells resistant to rapamycin, we observed marked growth inhibition with rapamycin as a single agent in SKRC39, which has marked overexpression of eIF4E.	Sirolimus	129-138	eukaryotic translation initiation factor 4E	Homo sapiens	203-208
1465771-3	1992	Primary anti-MHC class I alloantibody responses, detected by indirect hemagglutination and complement-dependent cytotoxicity assays, were abrogated in high-responder WAG (RT1u) recipients of DA (RT1a) blood transfusions, given on days 0 and 7 of a 14-day course of rapamycin (3 mg/kg/day).	Sirolimus	265-274	RT1 class II, locus Da	Rattus norvegicus	171-175
33816275-7	2021	Mechanistically, NRBP2 regulated the activation of the 5"-adenosine monophosphate (AMP)-activated protein kinase/ mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	134-143	nuclear receptor binding protein 2	Homo sapiens	17-22
33816275-7	2021	Mechanistically, NRBP2 regulated the activation of the 5"-adenosine monophosphate (AMP)-activated protein kinase/ mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	134-143	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	145-149
33803410-2	2021	Recent epidemiological studies associate the intake of cow"s milk with an increased risk of diseases, which are associated with overactivated mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	185-191
33778324-3	2021	In addition, we showed that resveratrol reduces mammalian target of rapamycin complex 1 (mTORC1) signaling, suggesting a potential mechanism.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
34936504-11	2022	In addition, rapamycin-induced autophagy and ATG5 expression were partially reversed by SR9009 treatment in mouse GCs.	Sirolimus	13-22	autophagy related 5	Mus musculus	45-49
34191518-5	2022	Our studies showed that WRX606 formed a ternary complex with FK506-binding protein-12 (FKBP12) and FKBP-rapamycin-binding (FRB) domain of mTOR, resulting in the allosteric inhibition of mTORC1.	Sirolimus	104-113	FKBP prolyl isomerase 1A	Homo sapiens	61-85
34191518-5	2022	Our studies showed that WRX606 formed a ternary complex with FK506-binding protein-12 (FKBP12) and FKBP-rapamycin-binding (FRB) domain of mTOR, resulting in the allosteric inhibition of mTORC1.	Sirolimus	104-113	FKBP prolyl isomerase 1A	Homo sapiens	87-93
34191518-5	2022	Our studies showed that WRX606 formed a ternary complex with FK506-binding protein-12 (FKBP12) and FKBP-rapamycin-binding (FRB) domain of mTOR, resulting in the allosteric inhibition of mTORC1.	Sirolimus	104-113	CREB regulated transcription coactivator 1	Mus musculus	186-192
34779571-6	2022	Loss of genes belonging to von Hippel-Lindau (VHL) and mammalian target of rapamycin complex 1 (mTORC1) pathways caused resistance to acute IMT1 treatment and the relevance of these pathways was confirmed by chemical modulation.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	96-102
34905649-6	2022	Moreover, rapamycin successfully restores the impaired autophagic flux and alleviates liver senescence in GDF11 overexpression mice, while the GDF11 knockdown-mediated benefits are abolished by the autophagy inhibitor bafilomycin A1.	Sirolimus	10-19	growth differentiation factor 11	Mus musculus	106-111
34905649-8	2022	Mechanistically, GDF11 significantly activates mammalian target of rapamycin complex 1 (mTORC1) and subsequently represses transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	88-94
34905649-8	2022	Mechanistically, GDF11 significantly activates mammalian target of rapamycin complex 1 (mTORC1) and subsequently represses transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy.	Sirolimus	67-76	transcription factor EB	Homo sapiens	123-146
34866401-1	2022	In mice, exercise is suggested to activate the mechanistic target of rapamycin complex 2 (mTORC2) in skeletal muscle, and mTORC2 is required for normal muscle glucose uptake during exercise.	Sirolimus	69-78	CREB regulated transcription coactivator 2	Mus musculus	90-96
34866401-1	2022	In mice, exercise is suggested to activate the mechanistic target of rapamycin complex 2 (mTORC2) in skeletal muscle, and mTORC2 is required for normal muscle glucose uptake during exercise.	Sirolimus	69-78	CREB regulated transcription coactivator 2	Mus musculus	122-128
34963894-7	2021	Importantly, lysosomal 3-PIs are needed for growth-factor-induced activities of Akt and mechanistic target of rapamycin complex 1 (mTORC1) on the lysosomal surface, as targeted depletion of 3-PIs has detrimental effects.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
17164244-10	2007	Thus, this later action may partially account for the increased phosphorylation of eEF2 in response to EtOH and the observed sensitivity of AMPK to rapamycin and PD98059 treatments.	Sirolimus	148-157	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	140-144
34931755-7	2022	Rapamycin, an autophagy activator, blocked the protective functions of miR-379-5p.	Sirolimus	0-9	microRNA 379	Homo sapiens	71-78
17202813-2	2007	The effect of rapamycin on proliferation and cellular function was studied in hepatocytes stimulated by hepatocyte growth factor (HGF) or transforming growth factor-alpha (TGFalpha).	Sirolimus	14-23	hepatocyte growth factor	Homo sapiens	104-128
17202813-5	2007	The HGF- or TGFalpha-induced increase in DNA synthesis and in albumin or fibrinogen concentrations was suppressed by the addition of rapamycin, as well as wortmannin, a phosphatidylinositol-3 kinase inhibitor.	Sirolimus	133-142	hepatocyte growth factor	Homo sapiens	4-8
17202813-5	2007	The HGF- or TGFalpha-induced increase in DNA synthesis and in albumin or fibrinogen concentrations was suppressed by the addition of rapamycin, as well as wortmannin, a phosphatidylinositol-3 kinase inhibitor.	Sirolimus	133-142	transforming growth factor alpha	Homo sapiens	12-20
17182569-5	2007	In contrast, proliferation of CD4(+)CD25(-) T cells was blocked by rapamycin, which induced their apoptosis.	Sirolimus	67-76	interleukin 2 receptor subunit alpha	Homo sapiens	36-40
17013836-5	2006	While MEK-ERK1/2 inhibition by PD98059 and mTOR inhibition by rapamycin affected the cyclin D1 nuclear shift and cell proliferation to a lesser extent, both these inhibitors reduced cyclin D1 levels.	Sirolimus	62-71	midkine	Mus musculus	6-9
16939628-0	2006	Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients.	Sirolimus	11-20	hemoglobin subunit alpha 2	Homo sapiens	40-70
17052453-4	2006	In these settings, GSK3 phosphorylation is sensitive to mTORC1 inhibition by rapamycin or amino acid withdrawal, and GSK3 becomes a direct target of S6K1.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	56-62
34923568-8	2021	When incubating Sidt2-/- cells with the autophagy activator rapamycin, we found that it could activate autophagy, which manifested as an increase in autophagosomes, but it could not improve autophagolysosome degradation.	Sirolimus	60-69	SID1 transmembrane family, member 2	Mus musculus	16-21
16894343-3	2006	EXPERIMENTAL APPROACH: We tested in vitro the potential of rapamycin to inhibit endothelial cell sprouting using the aortic ring assay and we further studied its effect on the expression of proliferating cell nuclear antigen (PCNA), apoptotic cell death-associated activated caspase-3 and vascular endothelial growth factor (VEGF) in cultured endometrial tissue fragments.	Sirolimus	59-68	proliferating cell nuclear antigen	Mesocricetus auratus	226-230
16894343-3	2006	EXPERIMENTAL APPROACH: We tested in vitro the potential of rapamycin to inhibit endothelial cell sprouting using the aortic ring assay and we further studied its effect on the expression of proliferating cell nuclear antigen (PCNA), apoptotic cell death-associated activated caspase-3 and vascular endothelial growth factor (VEGF) in cultured endometrial tissue fragments.	Sirolimus	59-68	vascular endothelial growth factor A	Mesocricetus auratus	289-323
16894343-3	2006	EXPERIMENTAL APPROACH: We tested in vitro the potential of rapamycin to inhibit endothelial cell sprouting using the aortic ring assay and we further studied its effect on the expression of proliferating cell nuclear antigen (PCNA), apoptotic cell death-associated activated caspase-3 and vascular endothelial growth factor (VEGF) in cultured endometrial tissue fragments.	Sirolimus	59-68	vascular endothelial growth factor A	Mesocricetus auratus	325-329
16803888-4	2006	Importantly, the impact of Rheb on B-Raf/C-Raf heterodimerization and kinase activity are rapamycin-insensitive, indicating that they are independent of Rheb activation of the mammalian target of rapamycin-Raptor complex.	Sirolimus	90-99	Ras homolog, mTORC1 binding	Homo sapiens	27-31
16803888-4	2006	Importantly, the impact of Rheb on B-Raf/C-Raf heterodimerization and kinase activity are rapamycin-insensitive, indicating that they are independent of Rheb activation of the mammalian target of rapamycin-Raptor complex.	Sirolimus	90-99	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	41-46
16985050-5	2006	Rapamycin causes down-regulation of cyclin D3 protein, retinoblastoma hypophosphorylation, loss of cyclin-dependent kinase (cdk) 4, cdk6, and cdk2 activity.	Sirolimus	0-9	cyclin dependent kinase 4	Homo sapiens	99-130
16985050-5	2006	Rapamycin causes down-regulation of cyclin D3 protein, retinoblastoma hypophosphorylation, loss of cyclin-dependent kinase (cdk) 4, cdk6, and cdk2 activity.	Sirolimus	0-9	cyclin dependent kinase 2	Homo sapiens	142-146
16717100-9	2006	40 S ribosomal protein S6, a target of p70(S6K), and 4E-BP1, a target of mTOR, were both phosphorylated within 15-25 min of T3 treatment and could be inhibited by wortmannin and rapamycin.	Sirolimus	178-187	ribosomal protein S6	Homo sapiens	0-25
16604438-9	2006	The direct GSK-3beta inhibitor SB216763 (3 microM) also prolonged the time to fluorescence loss (49.2+/-2.1 min, P&lt;0.001 versus control), and its protection could not be blocked by rapamycin (42.2+/-2.3 min, P&lt;0.001 versus control).	Sirolimus	184-193	glycogen synthase kinase-3 beta	Oryctolagus cuniculus	11-20
16713440-0	2006	Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs.	Sirolimus	0-9	serine/threonine-protein kinase mTOR	Cavia porcellus	14-18
16672275-10	2006	The same effect was observed upon treatment with rapamycin, indicating an unexpected relationship of Arp4 to TOR-mediated cell cycle arrest.	Sirolimus	49-58	Arp4p	Saccharomyces cerevisiae S288C	101-105
16405911-2	2006	Removal of FKBP12 using FK506 or rapamycin causes an increased open probability and an increase in the frequency of sub-conductance states in RyR1.	Sirolimus	33-42	FKBP prolyl isomerase 1A	Homo sapiens	11-17
34941746-6	2021	IS also induced epithelial-mesenchymal transition of tubular epithelial cells (HK-2 cells), differentiation of fibroblasts into myofibroblasts (NRK-49F cells), and inflammatory response of macrophages (THP-1 cells), which are associated with renal fibrosis, and these effects were inhibited in the presence of rapamycin (mTORC1 inhibitor).	Sirolimus	310-319	CREB regulated transcription coactivator 1	Mus musculus	321-327
16391472-11	2006	Rapamycin administration at 0.8 mg/kg/day for 7 days resulted in enhanced atrophy and attenuated the phosphorylation of ERK1, STAT3, and p70S6K without altering gene expression.	Sirolimus	0-9	mitogen activated protein kinase 3	Rattus norvegicus	120-124
16253991-9	2005	Gat1p is translocated to the nucleus only upon TOR inhibition by rapamycin.	Sirolimus	65-74	Gat1p	Saccharomyces cerevisiae S288C	0-5
16083867-9	2005	Rapamycin (10 microM), which removes FKBP binding proteins from RyR2 with no effect on calcineurin, mimicked the effect of FK506 on I(K1).	Sirolimus	0-9	ryanodine receptor 2	Rattus norvegicus	64-68
15767555-0	2005	Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.	Sirolimus	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	121-126
15586002-4	2005	A second advance has been achieved by the identification of the TOR-associated protein raptor, as an indispensable substrate binding sub-unit of the TOR complex, and as the site at which the inhibitory effects on TOR signaling of rapamycin and amino acid deficiency converge.	Sirolimus	230-239	regulatory associated protein of MTOR complex 1	Homo sapiens	87-93
16372478-9	2005	Wortmannin and rapamycin, an inhibitor of mTOR, suppressed Ang1-induced p70 S6 kinase phosphorylation and partially inhibited the Ang1-induced anti-apoptotic effect.	Sirolimus	15-24	angiopoietin 1	Homo sapiens	59-63
16372478-9	2005	Wortmannin and rapamycin, an inhibitor of mTOR, suppressed Ang1-induced p70 S6 kinase phosphorylation and partially inhibited the Ang1-induced anti-apoptotic effect.	Sirolimus	15-24	angiopoietin 1	Homo sapiens	130-134
15589136-1	2004	Recent studies show that hyperactivated mTOR, the "target of rapamycin" that senses nutrient availability in eukaryotic cells, inhibits signaling by insulin receptor substrates.	Sirolimus	61-70	insulin receptor	Homo sapiens	149-165
15561916-8	2004	Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of S6K1 at an intermediate glucose concentration (8 mmol/l) in a rapamycin-sensitive manner.	Sirolimus	159-168	glucagon like peptide 1 receptor	Homo sapiens	17-31
15571967-4	2004	Western blots for Bcl-2 and c-IAP1 showed increased levels of these anti-apoptotic proteins in cells incubated with doxorubicin, in accordance with NF-kappaB/Rel activation, while rapamycin clearly downmodulated these proteins, in line with its pro-apoptotic ability.	Sirolimus	180-189	baculoviral IAP repeat containing 2	Homo sapiens	28-34
15505422-4	2004	In cells exposed to rapamycin, we observed a dose-dependent downregulation of CCND1 (cyclin D1) and CDK4 gene expression and late G1 cell cycle arrest.	Sirolimus	20-29	cyclin D1	Homo sapiens	78-83
15505422-4	2004	In cells exposed to rapamycin, we observed a dose-dependent downregulation of CCND1 (cyclin D1) and CDK4 gene expression and late G1 cell cycle arrest.	Sirolimus	20-29	cyclin D1	Homo sapiens	85-94
15505422-4	2004	In cells exposed to rapamycin, we observed a dose-dependent downregulation of CCND1 (cyclin D1) and CDK4 gene expression and late G1 cell cycle arrest.	Sirolimus	20-29	cyclin dependent kinase 4	Homo sapiens	100-104
15505422-7	2004	These results indicate that baseline Bcl-2 expression and therapy-induced downexpression of CCND1 and CDK4 may be regarded as molecular markers enabling the prediction and follow-up of the cellular effects on cell cycle and apoptosis induction of rapamycin in ovarian cancer.	Sirolimus	247-256	cyclin D1	Homo sapiens	92-97
15505422-7	2004	These results indicate that baseline Bcl-2 expression and therapy-induced downexpression of CCND1 and CDK4 may be regarded as molecular markers enabling the prediction and follow-up of the cellular effects on cell cycle and apoptosis induction of rapamycin in ovarian cancer.	Sirolimus	247-256	cyclin dependent kinase 4	Homo sapiens	102-106
15467718-6	2004	Like yeast TORC2, mTORC2 is rapamycin insensitive and seems to function upstream of Rho GTPases to regulate the actin cytoskeleton.	Sirolimus	28-37	CREB regulated transcription coactivator 2	Mus musculus	18-24
15292274-5	2004	Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates.	Sirolimus	23-32	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
15367655-6	2004	Strains lacking Sap185 and Sap190 are hypersensitive to rapamycin, and this sensitivity is Gcn2 dependent and correlated with a defect in translation, constitutive eukaryotic initiation factor 2alpha hyperphosphorylation, induction of GCN4 translation, and hypersensitivity to amino acid starvation.	Sirolimus	56-65	Sap190p	Saccharomyces cerevisiae S288C	27-33
15307840-1	2004	This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients.	Sirolimus	131-140	transcriptional regulating factor 1	Homo sapiens	142-146
15322222-9	2004	RA-IgG-provoked IL-16 expression is inhibited by rapamycin, a specific macrolide inhibitor of the Akt/FRAP/mammalian target of rapamycin/p70(s6k) pathway, and by dexamethasone.	Sirolimus	49-58	interleukin 16	Homo sapiens	16-21
34941746-8	2021	The administration of AST-120 or rapamycin targeted to IS or mTORC1 ameliorated renal fibrosis in Adenine-induced CKD mice.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	61-67
15284440-3	2004	Fused to the rapamycin-binding domain (FRB) of the kinase mammalian target of rapamycin and FK506-binding protein 12 (FKBP), respectively, the optimized FRB-N-terminal luciferase fragment (NLuc)/C-terminal luciferase fragment (CLuc)-FKBP luciferase complementation imaging (LCI) pair reconstituted luciferase activity in cells upon single-site binding of rapamycin in an FK506-competitive manner.	Sirolimus	13-22	FKBP prolyl isomerase 1A	Homo sapiens	118-122
34944053-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) has been linked to different diseases.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
15028555-11	2004	The mTOR inhibitor rapamycin had similar inhibitory effects on G(1) cell cycle progression and on the expression of cyclin D1, CDK4, CDC25A, and retinoblastoma phosphorylation.	Sirolimus	19-28	cyclin D1	Homo sapiens	116-125
15028555-11	2004	The mTOR inhibitor rapamycin had similar inhibitory effects on G(1) cell cycle progression and on the expression of cyclin D1, CDK4, CDC25A, and retinoblastoma phosphorylation.	Sirolimus	19-28	cyclin dependent kinase 4	Homo sapiens	127-131
34938782-8	2021	Besides, HCP1 activated the activity of mechanistic target of rapamycin complex 1 (mTORC1), co-treatment with AMPK activator acadesine eliminated the effect of HCP1 on mTORC1 activity as well as autophagy.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	83-89
15249188-9	2004	Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P &lt; 0.01).	Sirolimus	79-88	mitogen activated protein kinase 3	Rattus norvegicus	65-71
15249188-9	2004	Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P &lt; 0.01).	Sirolimus	147-151	mitogen activated protein kinase 3	Rattus norvegicus	65-71
15014039-13	2004	With regard to angiogenesis, dRib-induced endothelial cell migration and aortic ring formation were completely abrogated by rapamycin, correlating with blockage of dRib-induced p70/S6 kinase activation in endothelial cells.	Sirolimus	124-133	annexin A6	Mus musculus	177-180
14871980-14	2004	Furthermore, changes in cyclin D1 levels provide a potential pharmacodynamic marker of response to rapamycin.	Sirolimus	99-108	cyclin D1	Homo sapiens	24-33
34944458-4	2021	Interestingly, both wild-type DGKbeta and the kinase-negative (KN) mutant partially induced neurite outgrowth, and these functions shared a common pathway via the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	197-206	CREB regulated transcription coactivator 1	Mus musculus	218-224
34365025-4	2021	Herein, we report that constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling via Tsc1 (Tuberous sclerosis 1) deletion in chondrocytes causes abnormal skull development with decreased size and rounded shape.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
14734710-0	2004	Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway.	Sirolimus	62-71	Janus kinase 2	Homo sapiens	87-91
34365025-4	2021	Herein, we report that constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling via Tsc1 (Tuberous sclerosis 1) deletion in chondrocytes causes abnormal skull development with decreased size and rounded shape.	Sirolimus	76-85	TSC complex subunit 1	Mus musculus	119-123
34365025-4	2021	Herein, we report that constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling via Tsc1 (Tuberous sclerosis 1) deletion in chondrocytes causes abnormal skull development with decreased size and rounded shape.	Sirolimus	76-85	TSC complex subunit 1	Mus musculus	125-145
34365025-9	2021	Lastly, treatment with rapamycin, an inhibitor of mTORC1, rescued the abnormality in synchondroses.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	50-56
14573608-4	2004	Previously, we found that, depending on the strength of the signal delivered to the T cell via both the T cell receptor and the costimulatory molecule CD28, CD8+ T cells are capable of rapamycin-resistant proliferation.	Sirolimus	185-194	CD28 molecule	Homo sapiens	151-155
34563639-1	2021	Inhibition of mammalian target of rapamycin complex 1 (mTORC1) with rapamycin in the absence of transforming growth factor-beta (TGFbeta) signaling induces apoptosis in many cancer cell lines.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
14729612-7	2004	Consistent with HIF-1 transactivation, inhibition of the PI-3K/Akt pathway by either overexpression of Deltap85 or Akt-T308A/S473A caused dramatic inhibition of Cap43 protein expression induced by nickel compounds, whereas pretreatment of cells with rapamycin did not exhibit inhibition of Cap43 induction.	Sirolimus	250-259	N-myc downstream regulated gene 1	Mus musculus	161-166
34563639-1	2021	Inhibition of mammalian target of rapamycin complex 1 (mTORC1) with rapamycin in the absence of transforming growth factor-beta (TGFbeta) signaling induces apoptosis in many cancer cell lines.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	55-61
34563639-2	2021	In the presence of TGFbeta, rapamycin induces G1 cell cycle arrest; however, in the absence of TGFbeta, cells do not arrest in G1 and progress into S-phase where rapamycin is cytotoxic rather than cytostatic.	Sirolimus	28-37	transforming growth factor alpha	Homo sapiens	19-26
34563639-5	2021	The gene products of RB and CDKN2A (pRb and p14ARF) suppress E2F family transcription factors that promote cell cycle progression from G1 into S. Restoration of wild type RB or inhibition of E2F activity in DU145 and NCI-H2228 cells led to rapamycin sensitivity.	Sirolimus	240-249	RB transcriptional corepressor 1	Homo sapiens	36-39
14607085-3	2003	Together, these genetic, biochemical and cell-biological studies have demonstrated that the tuberin-hamartin complex inhibits target of rapamycin (TOR) signaling by acting as a GTPase-activating protein for the Ras-related small G protein Rheb.	Sirolimus	136-145	Ras homolog, mTORC1 binding	Homo sapiens	239-243
34767636-4	2021	Interestingly, the residual hypertrophy after Raptor deletion can be completely prevented by administration of the mTORC1 inhibitor rapamycin.	Sirolimus	132-141	regulatory associated protein of MTOR complex 1	Homo sapiens	46-52
12906785-7	2003	Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.	Sirolimus	63-72	Ras homolog, mTORC1 binding	Homo sapiens	0-4
12906785-7	2003	Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.	Sirolimus	63-72	Ras homolog, mTORC1 binding	Homo sapiens	110-114
34767636-4	2021	Interestingly, the residual hypertrophy after Raptor deletion can be completely prevented by administration of the mTORC1 inhibitor rapamycin.	Sirolimus	132-141	CREB regulated transcription coactivator 1	Mus musculus	115-121
34888748-11	2021	Furthermore, the rescue assay exhibited that the mTOR inhibitor rapamycin significantly reversed the promoting effect of NUP37 in cell proliferation, migration, and invasion.	Sirolimus	64-73	nucleoporin 37	Homo sapiens	121-126
12864941-6	2003	Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle.	Sirolimus	0-9	cyclin D1	Homo sapiens	162-171
12864941-6	2003	Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle.	Sirolimus	0-9	cyclin dependent kinase 4	Homo sapiens	207-211
12864941-6	2003	Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle.	Sirolimus	0-9	cyclin D1	Homo sapiens	212-221
12864941-6	2003	Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle.	Sirolimus	308-317	cyclin dependent kinase 4	Homo sapiens	207-211
34672766-3	2021	Regulated in DNA damage and development 1 (REDD1) is a stress-response protein that is transcriptionally upregulated in muscle during wasting conditions and inhibits mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	209-215
12796300-5	2003	Treatment with rapamycin resulted in the hyperphosphorylation of Put3p, which was independent of Gln3p, Nil1p, and Ure2p.	Sirolimus	15-24	Gat1p	Saccharomyces cerevisiae S288C	104-109
34536195-6	2021	The data suggest that Omp31 as well as rapamycin, the autophagy inducer, can decrease TNF-alpha levels through the inhibition of the NF-kappaB p65 signaling pathway.	Sirolimus	39-48	RELA proto-oncogene, NF-kB subunit	Homo sapiens	133-146
34916960-5	2021	Surprisingly, aging lends unique atrophy resistance to tibialis anteria muscle, accompanied by an increase in the cascade of mammalian target of rapamycin complex 1 (mTORC1)-independent anabolic events involving Akt signaling, rRNA biogenesis, and protein synthesis during denervation.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	166-172
34917890-2	2021	The phosphoinositide 3-kinase (PI3K) promotes degradation of PDCD4 via mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	91-100	programmed cell death 4	Homo sapiens	61-66
34917890-2	2021	The phosphoinositide 3-kinase (PI3K) promotes degradation of PDCD4 via mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
34880790-13	2021	A decreased level of TORC1-the mechanistic target of the rapamycin complex, suggests a possible future approach to therapy in FXTAS.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Homo sapiens	21-26
12654728-4	2003	We show that rapamycin stimulates eIF2alpha phosphorylation by GCN2, with attendant induction of GCN4 translation, while reducing Ser 577 phosphorylation in nonstarved cells.	Sirolimus	13-22	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	97-101
34806651-1	2021	Mutations underlying disease in tuberous sclerosis complex (TSC) give rise to tumors with biallelic mutations in TSC1 or TSC2 and hyperactive mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-189
12654728-7	2003	Rapamycin-induced dephosphorylation of Ser 577, eIF2alpha phosphorylation, and induction of GCN4 all involve TAP42, a regulator of type 2A-related protein phosphatases.	Sirolimus	0-9	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	92-96
34785644-5	2021	In the engineered FAK, all of FAK domain architecture is retained and key intramolecular interactions between the kinase and the FERM domains are externally controlled through a rapamycin-inducible uniRapR module in the kinase domain and a light-inducible LOV2 module in the FERM domain.	Sirolimus	178-187	protein tyrosine kinase 2	Homo sapiens	18-21
12646166-6	2003	The BCAA mixture dose-dependently promoted the production of albumin, with leucine being the major effector half of which was inhibited by the mTOR inhibitor rapamycin.	Sirolimus	158-167	AT-rich interaction domain 4B	Rattus norvegicus	4-8
12446670-5	2003	Transfection with cyclin D1 or E2F2, but not cyclin E or activated Akt, overcame the rapamycin-mediated cell cycle arrest.	Sirolimus	85-94	E2F transcription factor 2	Mus musculus	31-35
12410861-8	2002	Also, in renal transplant patients initially immunosuppressed with rapamycin, cyclosporine and corticosteroids, after the elimination of CSA, a lower blood pressure is achieved.	Sirolimus	67-76	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	137-140
34453429-2	2021	Glutamine is used as an energy substrate and is involved in the activation of mechanistic target of rapamycin complex 1 (mTORC1) during porcine preimplantation development.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	121-127
12177161-1	2002	Sirolimus (Rapammune, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection.	Sirolimus	0-9	transcriptional regulating factor 1	Homo sapiens	33-37
11875047-6	2002	Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin.	Sirolimus	144-153	TSC complex subunit 1	Mus musculus	0-4
11875047-6	2002	Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin.	Sirolimus	144-153	TSC complex subunit 1	Mus musculus	233-237
11875047-6	2002	Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin.	Sirolimus	144-153	TSC complex subunit 1	Mus musculus	247-255
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	interleukin 16	Homo sapiens	106-111
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	interleukin 16	Homo sapiens	176-181
34520980-5	2021	Gain and loss of function assays confirmed that UBE2S exerts oncogenic activities in UBC by mediating the activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	165-171
34562654-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) acts as a central regulator of metabolic pathways that drive cellular growth.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34717796-2	2021	We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2, which comprise the large neutral amino acid transporter, was required for mammalian target of rapamycin complex 1 (mTORC1) nutrient sensor activation in response to toll-like receptor agonists.	Sirolimus	179-188	Janus kinase 2	Homo sapiens	27-41
34717796-2	2021	We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2, which comprise the large neutral amino acid transporter, was required for mammalian target of rapamycin complex 1 (mTORC1) nutrient sensor activation in response to toll-like receptor agonists.	Sirolimus	179-188	CREB regulated transcription coactivator 1	Mus musculus	200-206
34805133-1	2021	Mechanistic Target of Rapamycin Complex 2 (mTORC2) regulates placental amino acid and folate transport.	Sirolimus	22-31	CREB regulated transcription coactivator 2	Mus musculus	43-49
34829625-5	2021	In addition, TET mitigated excessive apoptosis and restored autophagy in the renal cortex, as well as suppressed the development of morphological abnormalities in the mitochondria of proximal tubular cells, which were also accompanied by the restoration of AMP-activated kinase (AMPK) activity and suppression of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	339-348	CREB regulated transcription coactivator 1	Mus musculus	360-366
11751303-6	2002	In contrast, this interaction is strongly potentiated by the immunophilin FKBP12 (EC(50) = 10 nM) and inhibited by both rapamycin (IC(50) = 5 nM) and FK506.	Sirolimus	120-129	FKBP prolyl isomerase 1A	Homo sapiens	61-80
11713299-7	2001	Inhibition of mTOR by rapamycin led to fast and complete repression of S6K1, as judged by rpS6 phosphorylation, but to only partial and delayed repression of translational activation of TOP mRNAs.	Sirolimus	22-31	ribosomal protein S6	Homo sapiens	90-94
11557736-6	2001	Furthermore, blocking p70 S6 kinase phosphorylation with rapamycin inhibited cyclin D1 expression and proliferation, suggesting that activation of p70 S6 kinase is critical in EDG-1/G(i)-mediated cell proliferation.	Sirolimus	57-66	cyclin D1	Homo sapiens	77-86
11589784-7	2001	After sirolimus treatment, Mrp2 mRNA was also reduced together with reduced levels of most CYPs and increased Oatp2, possibly leading to accumulation of toxic metabolites in the hepatocytes.	Sirolimus	6-15	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	110-115
11500364-2	2001	Insulin induces dephosphorylation of eEF2 and inactivation of eEF2 kinase, and these effects are blocked by rapamycin, which inhibits the mammalian target of rapamycin, mTOR.	Sirolimus	108-117	eukaryotic elongation factor 2 kinase	Homo sapiens	62-73
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	10-19	interleukin 2 receptor subunit alpha	Homo sapiens	167-172
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	215-224	interleukin 2 receptor subunit alpha	Homo sapiens	167-172
34099592-3	2021	Pharmacological inhibitors of mTOR, such as rapamycin and Torin2, markedly suppressed the mRNA level as well as the protein level of HMMR in LNCaP and PC-3 cells.	Sirolimus	44-53	hyaluronan mediated motility receptor	Homo sapiens	133-137
34099592-8	2021	Furthermore, the upregulation of HMMR by DHT was abolished by stimulation with rapamycin, prior to DHT treatment, suggesting that mTOR activity is required for the induction of HMMR expression by androgen.	Sirolimus	79-88	hyaluronan mediated motility receptor	Homo sapiens	33-37
34099592-8	2021	Furthermore, the upregulation of HMMR by DHT was abolished by stimulation with rapamycin, prior to DHT treatment, suggesting that mTOR activity is required for the induction of HMMR expression by androgen.	Sirolimus	79-88	hyaluronan mediated motility receptor	Homo sapiens	177-181
34233960-7	2021	Subsequent investigations revealed that aberrantly activated mTORC1 signaling in CAR-T cells results in decreased bone marrow infiltration and decreased the levels of the rapamycin target CXCR4.	Sirolimus	171-180	CREB regulated transcription coactivator 1	Mus musculus	61-67
34233960-8	2021	Attenuating mTORC1 activity with the rapamycin pretreatment increased the capacity of CAR-T cells to infiltrate bone marrow and enhanced the extent of bone marrow AML cell elimination in leukemia xenograft mouse models.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	12-18
34364639-9	2021	Also, IGF-1-induced XBP1s and ER biogenesis-associated gene expression was inhibited by rapamycin, an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), indicating that IRE1-XBP1 activation by IGF-1 is mediated by mTORC1.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	115-121
34364639-9	2021	Also, IGF-1-induced XBP1s and ER biogenesis-associated gene expression was inhibited by rapamycin, an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), indicating that IRE1-XBP1 activation by IGF-1 is mediated by mTORC1.	Sirolimus	88-97	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	181-185
34478760-1	2021	AIMS: The sustained activation of intestinal mechanistic target of rapamycin complex 1 (mTORC1) brought about by repeated mucosal insult or injury has been linked to escalation of gut inflammatory response, which may progress to damage the epithelium if not controlled.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	88-94
34303878-1	2021	OBJECTIVE: The mechanistic target of rapamycin complex 1 (mTORC1) is dynamically regulated by fasting and feeding cycles in the liver to promote protein and lipid synthesis while suppressing autophagy.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
34303878-4	2021	METHODS: ATF4 protein levels and expression of canonical gene targets were analyzed in the liver following fasting and physiological feeding in the presence or absence of the mTORC1 inhibitor rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	175-181
34341503-2	2021	Previous work has shown that the serine/threonine kinase mammalian target of rapamycin complex 1 (mTORC1) is involved in generating protective ILC3 cytokine responses during bacterial infection.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	98-104
34769253-3	2021	AZD8055, an ATP-competitive mechanistic target of rapamycin complex 1/2 (mTORC1/2) inhibitor, was selected as a translational suppressor.	Sirolimus	50-59	CREB regulated transcription coactivator 2	Mus musculus	73-81
11015466-9	2000	Additionally, rapamycin prevented the stimulatory effects of leucine on eIF4E availability for binding eIF4G and inhibited leucine-dependent phosphorylation of S6K1.	Sirolimus	14-23	eukaryotic translation initiation factor 4E	Rattus norvegicus	72-77
11015466-9	2000	Additionally, rapamycin prevented the stimulatory effects of leucine on eIF4E availability for binding eIF4G and inhibited leucine-dependent phosphorylation of S6K1.	Sirolimus	14-23	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	103-108
10698949-5	2000	PKCdelta-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive.	Sirolimus	72-81	protein kinase C delta	Homo sapiens	0-8
10334873-7	1999	Ethanol-plus-S1P-induced DNA synthesis was partially inhibited by both PD 98059 (50 microM) and rapamycin (10 nM), inhibitors of p42/p44 MAP kinase kinase and mTOR/p70 S6 kinases, respectively.	Sirolimus	96-105	cyclin-dependent kinase 20	Mus musculus	129-132
10334873-7	1999	Ethanol-plus-S1P-induced DNA synthesis was partially inhibited by both PD 98059 (50 microM) and rapamycin (10 nM), inhibitors of p42/p44 MAP kinase kinase and mTOR/p70 S6 kinases, respectively.	Sirolimus	96-105	mitogen-activated protein kinase 3	Mus musculus	133-136
10216124-2	1999	It is also suppressed by inhibitors of various protein kinases, including rapamycin, which blocks activation of p70 S6 kinase (p70(S6k)), PD98059, which inhibits the activation of extracellular-regulated kinase (ERK), and SB 203580, an inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK).	Sirolimus	74-83	mitogen activated protein kinase 1	Rattus norvegicus	212-215
10216124-2	1999	It is also suppressed by inhibitors of various protein kinases, including rapamycin, which blocks activation of p70 S6 kinase (p70(S6k)), PD98059, which inhibits the activation of extracellular-regulated kinase (ERK), and SB 203580, an inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK).	Sirolimus	74-83	mitogen activated protein kinase 14	Rattus norvegicus	253-289
10216124-2	1999	It is also suppressed by inhibitors of various protein kinases, including rapamycin, which blocks activation of p70 S6 kinase (p70(S6k)), PD98059, which inhibits the activation of extracellular-regulated kinase (ERK), and SB 203580, an inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK).	Sirolimus	74-83	mitogen activated protein kinase 14	Rattus norvegicus	291-299
10209117-5	1999	RESULTS: We used an activated Cdc42 protein that could be recruited to an engineered membrane receptor by adding rapamycin as a bridge, and added antibody-coupled beads to aggregate these receptors.	Sirolimus	113-122	cell division cycle 42	Homo sapiens	30-35
10082514-5	1999	Rapamycin, an inhibitor of p70(S6K) activation, caused oocytes to undergo germinal vesicle breakdown earlier than control oocytes, and sensitivity to progesterone was increased.	Sirolimus	0-9	ribosomal protein S6 kinase B1 L homeolog	Xenopus laevis	27-34
10082514-6	1999	Injection of a rapamycin-insensitive, constitutively active mutant of p70(S6K) reversed the effects of rapamycin.	Sirolimus	15-24	ribosomal protein S6 kinase B1 L homeolog	Xenopus laevis	70-77
10082514-6	1999	Injection of a rapamycin-insensitive, constitutively active mutant of p70(S6K) reversed the effects of rapamycin.	Sirolimus	103-112	ribosomal protein S6 kinase B1 L homeolog	Xenopus laevis	70-77
9927327-12	1999	Lastly, the antiapoptotic effects of SCF/LIF or IGF-I were almost entirely eliminated by cotreatment of fetal ovaries with either one of two inhibitors of phosphatidylinositol-3"-kinase (PI3K), LY294002 (5 microM) or wortmannin (50 nM), whereas cotreatment with an inhibitor of p70 S6 kinase (rapamycin, 25 ng/ml) was without effect.	Sirolimus	293-302	insulin-like growth factor 1	Mus musculus	48-53
9873047-6	1999	The activity of RLPK stimulated by epidermal growth factor was not inhibited by several known protein kinase C inhibitors nor by rapamycin, a known specific inhibitor for p70(RSK), but could be inhibited by herbimycin A, a tyrosine kinase inhibitor, and partially inhibited by PD98059 or SB203580, inhibitors for the mitogen-activated protein kinase pathways.	Sirolimus	129-138	ribosomal protein S6 kinase A5	Homo sapiens	16-20
34757123-6	2022	The mTOR inhibitor, rapamycin, completely abolished activation of mTORC1 and mTORC2 after long term treatment with receptor antibodies.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	66-72
34757123-6	2022	The mTOR inhibitor, rapamycin, completely abolished activation of mTORC1 and mTORC2 after long term treatment with receptor antibodies.	Sirolimus	20-29	CREB regulated transcription coactivator 2	Mus musculus	77-83
34853810-1	2021	Loss of function of tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) leads to the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	116-125	CREB regulated transcription coactivator 1	Mus musculus	137-143
34733478-3	2021	Recent findings support the impairment of the mammalian target of rapamycin complex 1 (mTORC1) in MDD.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Mus musculus	87-93
34986526-7	2021	Compared with the model group, the differentiation level of Treg cells in the rapamycin group was significantly increased, the proliferation level of CD4CD25 T cells was decreased, and the phosphorylations of the mTORC1/2 substrates, S6 protein and Akt were decreased (all <0.05).	Sirolimus	78-87	CREB regulated transcription coactivator 2	Mus musculus	213-221
34986526-8	2021	Rapamycin can promote the differentiation and function of Treg cells via inhibition of the mTORC1/2 signaling pathway.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	91-99
34459485-4	2021	Cultured mouse-C2C12 skeletal muscle cells were treated with mammalian target of rapamycin complex 1 (mTORC1) or protein kinase b (Akt) inhibitor, and protein synthesis was quantified.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	102-108
34735882-1	2021	Abnormal activation of the mechanistic target of rapamycin (mTOR) signaling is commonly observed in many cancers and attracts extensive attention as an oncology drug discovery target, which is encouraged by the success of rapamycin and its analogs (rapalogs) in treatment of mTORC1-hyperactive cancers in both pre-clinic models and clinical trials.	Sirolimus	222-231	CREB regulated transcription coactivator 1	Mus musculus	275-281
34735882-5	2021	Mechanistically, we found that hayatine disrupts the interaction between mTORC1 complex and its lysosomal adaptor RagA/C by binding to the hydrophobic loop of RagC, leading to mTORC1 inhibition that holds great promise to overcome rapamycin resistance.	Sirolimus	231-240	CREB regulated transcription coactivator 1	Mus musculus	73-79
34669157-4	2021	Mechanically, the combination of rapamycin with cabozantinib resulted in the remarkable inhibition of AKT, extracellular signal-regulated protein kinases, mTOR, and common downstream signal molecules of receptor tyrosine kinases; decreased cyclin D1 expression; and induced cell cycle arrest.	Sirolimus	33-42	cyclin D1	Homo sapiens	240-249
34644574-3	2021	Using conditional mutagenesis and chemogenetics, we show that blockade of the energy sensor mechanistic target of rapamycin complex 1 (mTORC1) in POMC neurons causes hyperphagia by mimicking a cellular negative energy state.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
34610303-2	2021	The serum- and glucocorticoid-regulated family of protein kinases (SGK) is activated downstream of mechanistic target of rapamycin complex 2 (mTORC2) in response to insulin in parallel to AKT.	Sirolimus	121-130	CREB regulated transcription coactivator 2	Mus musculus	142-148
34351835-4	2021	Drugs targeting mTOR and AMPK, such as sirolimus, rapamycin, and metformin, have shown some efficacy and tolerability in clinical trials on patients with SLE, but have not led to breakthroughs.	Sirolimus	39-48	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	25-29
34351835-4	2021	Drugs targeting mTOR and AMPK, such as sirolimus, rapamycin, and metformin, have shown some efficacy and tolerability in clinical trials on patients with SLE, but have not led to breakthroughs.	Sirolimus	50-59	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	25-29
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	249-277
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	279-283
34585416-2	2022	Here, we show that mechanistic target of rapamycin complex 2 (mTORC2)-dependent Akt activation is instrumental for metabolic reprogramming at the early stages of macrophage-mediated immunity.	Sirolimus	41-50	CREB regulated transcription coactivator 2	Mus musculus	62-68
34638732-8	2021	The results confirmed the elevation of AMPK and mitochondrial respiratory activities and reduction in reactive O2 species (ROS) levels in premutation cells and revealed for the first time that target of rapamycin complex I (TORC1) activities are reduced.	Sirolimus	203-212	CREB regulated transcription coactivator 1	Homo sapiens	224-229
34712915-0	2021	Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	29-35
34712915-3	2021	The FKBP12-mTOR association can be strengthened by the immunosuppressant rapamycin, but the underlying mechanism remains elusive.	Sirolimus	73-82	FKBP prolyl isomerase 1A	Homo sapiens	4-10
34712915-7	2021	Rapamycin recruits SIRT2 with a high affinity for FKBP12 association and deacetylation.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	50-56
9836529-8	1998	Addition of rapamycin, a p70 S6 kinase inhibitor that blocks adipocyte differentiation, to the 3T3-L1 differentiation medium prevented the rise in NAIP expression.	Sirolimus	12-21	NLR family, apoptosis inhibitory protein 1	Mus musculus	147-151
34712915-10	2021	In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12.	Sirolimus	13-22	FKBP prolyl isomerase 1A	Homo sapiens	37-43
34712915-10	2021	In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12.	Sirolimus	13-22	FKBP prolyl isomerase 1A	Homo sapiens	127-133
34325132-2	2021	In response to nutrient cue, tuberous sclerosis complex (TSC) works as a tumor suppressor which inhibits cell growth via negative regulation of the mammalian target of rapamycin complex (mTORC1).	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	187-193
9605135-8	1998	In situ mRNA hybridization also showed that TDL T cells from RAPA-treated mice had a lower frequency of granzyme B+ cells, indicating that RAPA inhibited the generation of CTL capable of mediating cytolysis through the release of granzyme B.	Sirolimus	61-65	granzyme B	Mus musculus	104-114
9605135-8	1998	In situ mRNA hybridization also showed that TDL T cells from RAPA-treated mice had a lower frequency of granzyme B+ cells, indicating that RAPA inhibited the generation of CTL capable of mediating cytolysis through the release of granzyme B.	Sirolimus	61-65	granzyme B	Mus musculus	230-240
34518220-8	2021	mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
34390347-4	2021	A strain containing FRB and FKBP domains in the Mlh1 IDR displayed a complete defect in MMR when grown with rapamycin.	Sirolimus	108-117	mismatch repair ATPase MLH1	Saccharomyces cerevisiae S288C	48-52
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Sirolimus	5-14	eukaryotic translation initiation factor 4E	Homo sapiens	133-139
9368076-4	1997	Rapamycin blocks the PDBu-induced accumulation of p21cip1 (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation.	Sirolimus	0-9	protein kinase C delta	Homo sapiens	113-116
34390347-7	2021	The MLH complex containing FRB and FKBP domains in the Mlh1 IDR displayed a rapamycin-dependent defect in Mlh1-Pms1 endonuclease activity.	Sirolimus	76-85	mismatch repair ATPase MLH1	Saccharomyces cerevisiae S288C	106-110
21528311-3	1997	Rapamycin treatment also resulted in: a decrease in cdk2 kinase activity; an increase in hypophosphorylated retinoblastoma protein (pRb); a dephosphorylation of p70 S6 kinase; and, growth-arrest in G(1)-phase of cell cycle.	Sirolimus	0-9	cyclin dependent kinase 2	Homo sapiens	52-56
34603030-8	2021	On HT-22 cells induced by autophagy inducer rapamycin, NGR1 markedly attenuated excessive autophagy and apoptosis, and the alleviative effect was abolished by the MTNR1A inhibitor.	Sirolimus	44-53	melatonin receptor 1A	Mus musculus	163-169
21528311-3	1997	Rapamycin treatment also resulted in: a decrease in cdk2 kinase activity; an increase in hypophosphorylated retinoblastoma protein (pRb); a dephosphorylation of p70 S6 kinase; and, growth-arrest in G(1)-phase of cell cycle.	Sirolimus	0-9	RB transcriptional corepressor 1	Homo sapiens	132-135
34388363-3	2021	Sestrins are a class of stress-inducible proteins that act as antioxidants and inhibit the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling complex.	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	150-156
9160663-6	1997	Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059.	Sirolimus	121-130	eukaryotic translation initiation factor 4E	Homo sapiens	80-86
9145907-3	1997	Disruption of the association between immunophilin FKBP12 and Ry1R with FK 506 or rapamycin completely eliminates PCB 95-enhanced binding of [3H]ryanodine (IC50 approximately 35 microM) to Ry1R and PCB 95-induced release of Ca2+ from actively loaded SR vesicles (IC50 approximately 11 microM), demonstrating a FKBP12-dependent mechanism.	Sirolimus	82-91	FKBP prolyl isomerase 1A	Homo sapiens	38-57
9145907-3	1997	Disruption of the association between immunophilin FKBP12 and Ry1R with FK 506 or rapamycin completely eliminates PCB 95-enhanced binding of [3H]ryanodine (IC50 approximately 35 microM) to Ry1R and PCB 95-induced release of Ca2+ from actively loaded SR vesicles (IC50 approximately 11 microM), demonstrating a FKBP12-dependent mechanism.	Sirolimus	82-91	FKBP prolyl isomerase 1A	Homo sapiens	51-57
9145782-6	1997	The effect of EGF was almost completely suppressed by genistein (5 X 10(-6) M) and rapamycin (10 ng/ml), but it was unaffected by wortmannin (10(-7) M).	Sirolimus	83-92	epidermal growth factor like 1	Rattus norvegicus	14-17
9029760-1	1997	Sirolimus (rapamycin, RAPA) is a natural fermentation product (macrolide antibiotic) that has demonstrated potent immunosuppressive activity.	Sirolimus	0-9	transcriptional regulating factor 1	Homo sapiens	22-26
8976197-6	1996	Treatment of TGF-beta 1 -/- mice with rapamycin abrogated the characteristic inflammatory wasting syndrome and prolonged survival indefinitely, but did not result in population of the epidermis with LC.	Sirolimus	38-47	transforming growth factor, beta 1	Mus musculus	13-23
8895523-7	1996	Despite the phosphorylation of RB/p107/ p130, the expression of cyclin A and its associated kinase activity is delayed in rapamycin-treated N-3T3 cells.	Sirolimus	122-131	RB transcriptional corepressor like 1	Mus musculus	34-38
8895523-7	1996	Despite the phosphorylation of RB/p107/ p130, the expression of cyclin A and its associated kinase activity is delayed in rapamycin-treated N-3T3 cells.	Sirolimus	122-131	cyclin A2	Mus musculus	64-72
8895523-8	1996	Ectopic expression of cyclin A, but not cyclins D and E or E2F-1 and -4, can overcome the effect of rapamycin.	Sirolimus	100-109	cyclin A2	Mus musculus	22-30
8884067-1	1996	OBJECTIVES: To develop a radioreceptor assay (RRA) for sirolimus (rapamycin, RAPA).	Sirolimus	55-64	transcriptional regulating factor 1	Homo sapiens	77-81
8687386-7	1996	Rapamycin, a specific inhibitor of the activation of this latter kinase, inhibits dissociation of 4E-BP1 from eIF-4E in cells incubated with insulin but reveals a phosphorylated from of 4E-BP1 which remains bound to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Rattus norvegicus	110-116
8687386-7	1996	Rapamycin, a specific inhibitor of the activation of this latter kinase, inhibits dissociation of 4E-BP1 from eIF-4E in cells incubated with insulin but reveals a phosphorylated from of 4E-BP1 which remains bound to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Rattus norvegicus	216-222
34246831-1	2021	Amino acids can affect protein synthesis by activating mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	96-102
34646153-5	2021	This prioritization/interference may be due to the interplay between the 5" AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling cascades and/or the high skeletal muscle energy requirements for the synthesis and maintenance of cellular organelles.	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	159-165
34575924-6	2021	Here, we introduce the current knowledge of hypoxia signaling with two-well known cellular energy and nutrient sensing pathways, AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	191-200	CREB regulated transcription coactivator 1	Mus musculus	212-218
8641294-5	1996	Rapamycin, a macrolide immunosuppressant which blocks the signalling pathway leading to the stimulation of the 70/85 kDa ribosomal protein S6 kinases, substantially blocks the activation of elongation, the fall in eEF-2 phosphorylation and the decrease in eEF-2 kinase activity, suggesting that p7O S6 kinase (p70s6k) and eEF-2 kinase may tie on a common signalling pathway.	Sirolimus	0-9	eukaryotic elongation factor 2 kinase	Homo sapiens	256-268
8641294-5	1996	Rapamycin, a macrolide immunosuppressant which blocks the signalling pathway leading to the stimulation of the 70/85 kDa ribosomal protein S6 kinases, substantially blocks the activation of elongation, the fall in eEF-2 phosphorylation and the decrease in eEF-2 kinase activity, suggesting that p7O S6 kinase (p70s6k) and eEF-2 kinase may tie on a common signalling pathway.	Sirolimus	0-9	eukaryotic elongation factor 2 kinase	Homo sapiens	322-334
8631827-7	1996	PDGF-stimulated, PI 3"-kinase-dependent tyrosine phosphorylation of p125FAK was not inhibited by rapamycin, and thus it was dissociated from the activation of p70 S6 kinase, previously identified as a molecular downstream target of PI 3"-kinase.	Sirolimus	97-106	protein tyrosine kinase 2	Homo sapiens	68-75
8565319-0	1996	Effect of rapamycin on the expression of the IL-2 receptor (CD25).	Sirolimus	10-19	interleukin 2 receptor subunit beta	Homo sapiens	45-58
8565319-0	1996	Effect of rapamycin on the expression of the IL-2 receptor (CD25).	Sirolimus	10-19	interleukin 2 receptor subunit alpha	Homo sapiens	60-64
8565319-6	1996	Interestingly, sensitivity to rapamycin correlates with the requirement of de novo protein synthesis, as demonstrated by anisomycin inhibition of both ionomycin- and CD3-induced CD25 transcription.	Sirolimus	30-39	interleukin 2 receptor subunit alpha	Homo sapiens	178-182
8594303-6	1996	A second, later effect of rapamycin in IL-2-stimulated T cells is an inhibition of the enzymatic activity of the cyclin-dependent kinase cdk2-cyclin E complex, which functions as a crucial regulator of G1/S transition.	Sirolimus	26-35	cyclin dependent kinase 2	Homo sapiens	137-141
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	colony stimulating factor 3 (granulocyte)	Mus musculus	171-208
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	colony stimulating factor 3 (granulocyte)	Mus musculus	210-215
7521360-6	1994	Our results show that when CsA is used as the primary ISD, further proliferation can be inhibited by rapamycin, mycophenolic acid, or suramin.	Sirolimus	101-110	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	27-30
7521360-8	1994	If rapamycin is the primary ISD, both CsA and FK-506 show antagonistic interactions.	Sirolimus	3-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	38-41
34572527-1	2021	Amino acids are critical for mammalian target of rapamycin complex 1 (mTORC1) activation on the lysosomal surface.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
34159368-6	2021	Insulin- and amino acid-signaling components relevant to mechanistic target of rapamycin complex (mTORC) 1 activation and protein translation were measured.	Sirolimus	79-88	insulin	Sus scrofa	0-7
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	133-139
34187836-1	2021	Transmembrane 4 L six family member 5 (TM4SF5) functions as a sensor for lysosomal arginine levels and activates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	137-146	CREB regulated transcription coactivator 1	Mus musculus	158-164
8125138-13	1994	The generation of the CD3-SP under the influence of RAPA could be used as a useful model for further study of the function and signal transduction of these CD3-defective SP cells.	Sirolimus	52-56	CD3 antigen, epsilon polypeptide	Mus musculus	22-25
8125138-13	1994	The generation of the CD3-SP under the influence of RAPA could be used as a useful model for further study of the function and signal transduction of these CD3-defective SP cells.	Sirolimus	52-56	CD3 antigen, epsilon polypeptide	Mus musculus	156-159
8254211-10	1994	Furthermore, TTK expression was prevented by incubation of the cells with rapamycin, which blocks IL-2 signaling.	Sirolimus	74-83	TTK protein kinase	Homo sapiens	13-16
7510997-0	1994	Effects of immunosuppressants FK506 and rapamycin on the heterooligomeric form of the progesterone receptor.	Sirolimus	40-49	progesterone receptor	Homo sapiens	86-107
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	72-81	cyclin-dependent kinase 1	Mus musculus	212-219
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	158-167	cyclin-dependent kinase 1	Mus musculus	212-219
7690315-11	1993	The capacity of rapamycin to alter the in vitro IL5-mediated survival of eosinophils was also studied.	Sirolimus	16-25	interleukin 5	Homo sapiens	48-51
7690315-12	1993	The results of this study demonstrated that rapamycin was effective in reducing the ability of IL5 to maintain the survival of eosinophils in culture; by contrast, FK506 had minimal effects on the IL5-mediated survival of eosinophils.	Sirolimus	44-53	interleukin 5	Homo sapiens	95-98
1281674-2	1992	Using Northern analyses and promoter-reporter constructs we analyzed the transcriptional and posttranscriptional effects of FK506 and rapamycin on IL-2, GM-CSF, and IL-2R alpha gene expression.	Sirolimus	134-143	interleukin 2 receptor subunit alpha	Homo sapiens	165-176
34081952-1	2021	RATIONALE: The nutrient sensing mechanistic target of rapamycin complex 1 (mTORC1) and its primary inhibitor, tuberin (TSC2), are cues for the development of cardiac hypertrophy.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	75-81
34278477-10	2021	Notably, the rapamycin-mediated suppression of phosphorylated-mTOR, and elevation of Beclin 1 and LC3II expression in the rat hippocampus could not be alleviated by asiaticoside treatment.	Sirolimus	13-22	beclin 1	Rattus norvegicus	85-93
34240738-8	2021	Recent studies identified the proline rotamase Fpr1, known primarily for its role in rapamycin-mediated inhibition of the TORC1 kinase, as an additional TF at RPG promoters.	Sirolimus	85-94	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	47-51
34703880-6	2021	Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT.	Sirolimus	185-194	CREB regulated transcription coactivator 1	Mus musculus	206-212
34703880-6	2021	Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT.	Sirolimus	185-194	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	278-283
34476273-4	2021	We describe the clinical case of a patient with JPS with a childhood juvenile polyposis phenotype because of a mutation on the SMAD4 gene, who received treatment with sirolimus successfully.	Sirolimus	167-176	SMAD family member 4	Homo sapiens	127-132
33771483-7	2021	In this study, we found that PD-L1 induces the upregulation of CD206 expression, which is inhibited by nivolumab, LY294002, U0126, and rapamycin.	Sirolimus	135-144	mannose receptor C-type 1	Homo sapiens	63-68
34449653-1	2021	Rapamycin is an exogenous compound that has been shown to improve cognition in Alzheimer"s disease mouse models and can regulate pathways downstream of the insulin receptor signaling pathway.	Sirolimus	0-9	insulin receptor	Mus musculus	156-172
34449653-6	2021	Using young male and female CD-1 mice, we measured the effects of rapamycin on the basal levels of serum factors, insulin receptor signaling, vascular binding, and BBB pharmacokinetics.	Sirolimus	66-75	insulin receptor	Mus musculus	114-130
34449653-7	2021	We found chronic rapamycin treatment was able to affect basal levels of circulating serum factors and endothelial cell insulin receptor signaling.	Sirolimus	17-26	insulin receptor	Mus musculus	119-135
34429398-8	2021	Once induced, SESN2 halted protein synthesis by inhibiting the mammalian target of rapamycin complex 1 (mTORC1), thereby attenuating ERS.	Sirolimus	83-92	sestrin 2	Homo sapiens	14-19
33802760-4	2021	We have previously reported that the Ras homolog protein enriched in brain (Rheb)-mammalian target of rapamycin complex 1 (mTORC1) axis plays a vital role in preventing neuronal death in the brain of AD and PD patients.	Sirolimus	102-111	Ras homolog, mTORC1 binding	Homo sapiens	76-80
33802760-4	2021	We have previously reported that the Ras homolog protein enriched in brain (Rheb)-mammalian target of rapamycin complex 1 (mTORC1) axis plays a vital role in preventing neuronal death in the brain of AD and PD patients.	Sirolimus	102-111	CREB regulated transcription coactivator 1	Mus musculus	123-129
34429398-8	2021	Once induced, SESN2 halted protein synthesis by inhibiting the mammalian target of rapamycin complex 1 (mTORC1), thereby attenuating ERS.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
34175438-1	2021	Proline rich Akt substrate (PRAS40) is a component of mammalian target of rapamycin complex 1 (mTORC1) and activated mTORC1 plays important roles for cellular survival in response to oxidative stress.	Sirolimus	74-83	CREB regulated transcription coactivator 1	Mus musculus	95-101
33804169-6	2021	We find that within GBM cells, radiation exposure induces DYRK3 expression and DYRK3 regulates mammalian target of rapamycin complex 1 (mTORC1) activity through phosphorylation of proline-rich AKT1 substrate 1 (PRAS40).	Sirolimus	115-124	dual specificity tyrosine phosphorylation regulated kinase 3	Homo sapiens	79-84
33804169-6	2021	We find that within GBM cells, radiation exposure induces DYRK3 expression and DYRK3 regulates mammalian target of rapamycin complex 1 (mTORC1) activity through phosphorylation of proline-rich AKT1 substrate 1 (PRAS40).	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	136-142
33800501-3	2021	Thus, the critical roles of mammalian/mechanistic target of rapamycin complex 1 (mTORC1) pathway and its regulators are reviewed.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	81-87
34175438-1	2021	Proline rich Akt substrate (PRAS40) is a component of mammalian target of rapamycin complex 1 (mTORC1) and activated mTORC1 plays important roles for cellular survival in response to oxidative stress.	Sirolimus	74-83	CREB regulated transcription coactivator 1	Mus musculus	117-123
34245671-5	2021	Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) directly phosphorylates GRASP55 to maintain its Golgi localization, thus revealing a physiological role for mTORC1 at this organelle.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
34245671-5	2021	Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) directly phosphorylates GRASP55 to maintain its Golgi localization, thus revealing a physiological role for mTORC1 at this organelle.	Sirolimus	45-54	golgi reassembly stacking protein 2	Homo sapiens	98-105
34245671-5	2021	Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) directly phosphorylates GRASP55 to maintain its Golgi localization, thus revealing a physiological role for mTORC1 at this organelle.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	182-188
34385317-2	2021	Toll-like receptor (TLR)7/9- and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-mediated inflammatory responses require SLC15A4 function for regulating the mechanistic target of rapamycin complex 1 (mTORC1) or transporting L-Ala-gamma-D-Glu-meso-diaminopimelic acid, IL-12: interleukin-12 (Tri-DAP), respectively.	Sirolimus	201-210	CREB regulated transcription coactivator 1	Mus musculus	222-228
34445460-4	2021	In addition, chronological lifespan is reduced in a deg1 ssd1-d mutant, and the negative genetic interactions of the U34 modifier genes ELP3 and URM1 with DEG1 are aggravated by ssd1-d. A loss of function mutation in SSD1, ELP3, and DEG1 induces pleiotropic and overlapping phenotypes, including sensitivity against target of rapamycin (TOR) inhibitor drug and cell wall stress by calcofluor white.	Sirolimus	326-335	mRNA-binding translational repressor SSD1	Saccharomyces cerevisiae S288C	178-182
34445460-4	2021	In addition, chronological lifespan is reduced in a deg1 ssd1-d mutant, and the negative genetic interactions of the U34 modifier genes ELP3 and URM1 with DEG1 are aggravated by ssd1-d. A loss of function mutation in SSD1, ELP3, and DEG1 induces pleiotropic and overlapping phenotypes, including sensitivity against target of rapamycin (TOR) inhibitor drug and cell wall stress by calcofluor white.	Sirolimus	326-335	mRNA-binding translational repressor SSD1	Saccharomyces cerevisiae S288C	217-221
34389720-4	2021	LATS2 activates mechanistic target of rapamycin complex 1 (mTORC1), a physiological suppressor of autophagy, in beta-cells and genetic and pharmacological inhibition of mTORC1 counteracts the pro-apoptotic action of activated LATS2.	Sirolimus	38-47	large tumor suppressor 2	Mus musculus	0-5
33234350-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) is a central modulator of inflammation and tumorigenesis in the gastrointestinal tract.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
26220174-5	2015	Rapamycin treatment normalized mitochondrial structure, number, and the maximal respiration rate in Acsl1(T-/-) hearts, but did not improve ADP-stimulated oxygen consumption, which was likely caused by the 33-51% lower ATP synthase activity present in both vehicle- and rapamycin-treated Acsl1(T-/-) hearts.	Sirolimus	0-9	acyl-CoA synthetase long-chain family member 1	Mus musculus	100-105
26220174-5	2015	Rapamycin treatment normalized mitochondrial structure, number, and the maximal respiration rate in Acsl1(T-/-) hearts, but did not improve ADP-stimulated oxygen consumption, which was likely caused by the 33-51% lower ATP synthase activity present in both vehicle- and rapamycin-treated Acsl1(T-/-) hearts.	Sirolimus	0-9	acyl-CoA synthetase long-chain family member 1	Mus musculus	288-293
34389720-4	2021	LATS2 activates mechanistic target of rapamycin complex 1 (mTORC1), a physiological suppressor of autophagy, in beta-cells and genetic and pharmacological inhibition of mTORC1 counteracts the pro-apoptotic action of activated LATS2.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	59-65
34382907-8	2022	Furthermore, the impaired activity of MTORC1 via rapamycin treatment or STING1 deficiency decreased the numbers of LDs in cells.	Sirolimus	49-58	origin recognition complex subunit 1	Homo sapiens	38-44
34977370-9	2022	In summary, our results indicated that glycine alleviates ER stress-induced apoptosis and intestinal barrier dysfunction in IPEC-1 cells in a mammalian target of rapamycin complex 1 (mTORC1)-dependent manner.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-189
34852208-1	2022	Following anabolic stimuli (mechanical loading and/or amino acid provision) the mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of protein synthesis, translocates toward the cell periphery.	Sirolimus	102-111	CREB regulated transcription coactivator 1	Mus musculus	123-129
34972198-6	2021	Deletion of the gene encoding the GTPase RHE2, whose mammalian orthologue activates mTORC1, led to rapamycin hypersensitivity and altered secondary metabolism, but had an only minor effect on vegetative growth and mycoparasitic overgrowth.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	84-90
34970878-1	2021	OBJECTIVE: To observe the effect of acupuncture of "Yinlingquan"(SP9) and "Sanyinjiao"(SP6) on expression of phosphatidylinositol-3 kinase/protein kinase B/mammalian target protein of rapamycin (PI3K/Akt/mTOR) signaling in adjuvant arthritis (AA) rats, so as to explore its mechanism underlying improvement of AA.	Sirolimus	184-193	Sp6 transcription factor	Homo sapiens	87-90
34445268-0	2021	Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.	Sirolimus	0-9	cofilin 1	Homo sapiens	40-47
34445268-7	2021	Sirolimus showed efficacy in patients with LAM, who exhibited a reduced expression of mTOR and p-cofilin as well as reduced interstitial septal thickness.	Sirolimus	0-9	cofilin 1	Homo sapiens	97-104
34445268-8	2021	In addition, sirolimus suppresses mTOR and p-cofilin, thus suppressing the migration and proliferation of LAM cells isolated from the patient"s lung tissue.	Sirolimus	13-22	cofilin 1	Homo sapiens	45-52
34343111-9	2021	And the mTORC1 inhibitor, Rapamycin, has been proved to exert neuroprotective effects in the ultra-early and early cerebral ischemia-reperfusion.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	8-14
34348155-4	2021	Sustained hyper-activation of mechanistic target of rapamycin complex 1 (mTORC1) is the primary mechanism of the PHLPP upregulation linking chronic metabolic stress to ultimate beta-cell death.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	73-79
34987410-1	2021	Background: The mechanistic target of rapamycin complex 1 (mTORC1) signaling has served as a promising target for therapeutic intervention of major depressive disorder (MDD), but the mTORC1 signaling underlying MDD has not been well elucidated.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	59-65
34987410-1	2021	Background: The mechanistic target of rapamycin complex 1 (mTORC1) signaling has served as a promising target for therapeutic intervention of major depressive disorder (MDD), but the mTORC1 signaling underlying MDD has not been well elucidated.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	183-189
34927743-2	2021	5"-Adenosine monophosphate-activated protein kinase (AMPK) is an important energy sensor suppressing mammalian target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	121-130	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-51
34927743-2	2021	5"-Adenosine monophosphate-activated protein kinase (AMPK) is an important energy sensor suppressing mammalian target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	121-130	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	53-57
34927743-2	2021	5"-Adenosine monophosphate-activated protein kinase (AMPK) is an important energy sensor suppressing mammalian target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	121-130	CREB regulated transcription coactivator 1	Mus musculus	142-148
34408668-6	2021	Upregulated CALHM1/2 in proliferative PASMCs were associated with an increased ratio of pAKT/AKT and pmTOR/mTOR and an increased expression of the cell proliferation marker PCNA, whereas serum starvation and rapamycin significantly downregulated CALHM1/2.	Sirolimus	208-217	calcium homeostasis modulator 1	Rattus norvegicus	246-254
34189960-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) signaling complex is emerging as a critical regulator of cardiovascular function with alterations in this pathway implicated in cardiovascular diseases.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34121197-4	2021	Other regulators of ferroptosis have also been discovered recently, among them the mechanistic target of rapamycin complex 1 (mTORC1), a central controller of cell growth and metabolism.	Sirolimus	105-114	CREB regulated transcription coactivator 1	Mus musculus	126-132
34326413-4	2021	Inhibition of the mechanistic target of rapamycin complex 1 (mTORC1), a major intracellular effector of insulin receptor, blocked the beneficial effects of intranasal insulin on anesthesia-induced apoptosis.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	61-67
34089815-9	2021	The antidepressant-like and pro-synaptogenic effects elicited by ketamine plus guanosine were abolished by the pretreatment with rapamycin (0.2 nmol/site, i.c.v., a selective mTORC1 inhibitor).	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	175-181
34326413-4	2021	Inhibition of the mechanistic target of rapamycin complex 1 (mTORC1), a major intracellular effector of insulin receptor, blocked the beneficial effects of intranasal insulin on anesthesia-induced apoptosis.	Sirolimus	40-49	insulin receptor	Mus musculus	104-120
34667552-1	2021	Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1).	Sirolimus	21-30	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	170-208
34976315-3	2022	Lack of nutrients or the presence of stress leads to downregulation of ribosome biogenesis, a process for which mechanistic target of rapamycin complex I (mTORC1) is key.	Sirolimus	134-143	CREB regulated transcription coactivator 1	Mus musculus	155-161
34673573-2	2021	To identify the molecular underpinnings of this phenotype, we analyzed a large cohort of MBs developing in p53-deficient Ptch+/- SHH mice that, unexpectedly, showed LC/A traits that correlated with mechanistic Target Of Rapamycin Complex 1 (mTORC1) hyperactivation.	Sirolimus	220-229	CREB regulated transcription coactivator 1	Mus musculus	241-247
34876569-12	2021	In addition, the enhanced sensitivity was partially diminished by rapamycin-mediated inhibition of mTOR in TTK knockdown cells.	Sirolimus	66-75	TTK protein kinase	Homo sapiens	107-110
34862383-1	2021	Amino acid availability is sensed by various signaling molecules, including general control nonderepressible 2 (GCN2) and mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	165-171
34667552-1	2021	Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1).	Sirolimus	21-30	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	210-215
34354601-2	2021	They also serve as signaling molecules, for example, being able to activate mammalian/mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	129-135
34354602-11	2021	Rapalink-1 significantly decreased phosphorylated S6 and Akt to half the level of the control rats in the IR-C, which suggests that both of the mechanistic target of rapamycin complex 1 and 2 (mTORC1 and mTORC2) were inhibited.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	193-199
34354602-11	2021	Rapalink-1 significantly decreased phosphorylated S6 and Akt to half the level of the control rats in the IR-C, which suggests that both of the mechanistic target of rapamycin complex 1 and 2 (mTORC1 and mTORC2) were inhibited.	Sirolimus	166-175	CREB regulated transcription coactivator 2	Mus musculus	204-210
34336098-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) signaling plays pivotal roles in cell growth and diseases.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34349839-1	2021	Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, which encode proteins that antagonise the mammalian isoform of the target of rapamycin complex 1 (mTORC1) - a key mediator of cell growth and metabolism.	Sirolimus	184-193	CREB regulated transcription coactivator 1	Mus musculus	205-211
34253722-1	2021	Tuberous Sclerosis Complex (TSC) is caused by TSC1 or TSC2 mutations, resulting in hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	149-155
34236783-12	2022	However, rapamycin or paclitaxel concentrations >=1 mug/mL could significantly reduce the levels of anti-inflammatory cytokines IL-35 and transforming growth factor beta (TGF-beta) (P<0.05 or P<0.01), which decreased with the increase of drug concentration.	Sirolimus	9-18	transforming growth factor alpha	Homo sapiens	171-179
34236783-14	2022	However, rapamycin or paclitaxel combined with anti- IL-10 or anti-TGF-beta can significantly enhance foam cell proliferation (P<0.01).	Sirolimus	9-18	transforming growth factor alpha	Homo sapiens	67-75
34335979-6	2021	The bioengineered CXCR4-overexpressing cell membrane-functionalized ROS-responsive nanotherapeutics, loaded with rapamycin (RAPA), were fabricated to enhance the targeted delivery to lesions with pathological overexpression of SDF-1.	Sirolimus	113-122	chemokine (C-X-C motif) ligand 12	Mus musculus	227-232
34335979-7	2021	Results: RAPA@BMHOP exhibited a three-fold higher rate of target delivery efficacy via the CXCR4/SDF-1 axis than its non-targeting counterpart in an in vivo model.	Sirolimus	9-13	chemokine (C-X-C motif) ligand 12	Mus musculus	97-102
34087234-8	2021	Phosphorylation of p62 at Ser349 by mammalian target of rapamycin complex 1 (mTORC1), a critical step in p62-Keap1 interaction, was induced by I/R, but diminished by R1alpha loss.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	77-83
34738031-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1).	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34116056-1	2021	Cellular growth and proliferation are primarily dictated by the mechanistic target of rapamycin complex 1 (mTORC1), which balances nutrient availability against the cell"s anabolic needs.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	107-113
34075648-2	2021	In cancer cells, glutamine has been implicated in the activation of mechanistic target of rapamycin complex 1 (mTORC1) to support rapid proliferation.	Sirolimus	90-99	CREB regulated transcription coactivator 1	Mus musculus	111-117
34392719-0	2021	Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1alpha, Bcl-2, Bax expression and microvessel density.	Sirolimus	25-34	apoptosis regulator BAX	Oryctolagus cuniculus	133-136
34392719-15	2021	Arterial instillation of rapamycin+TACE in treatment of rabbit hepatic xenograft tumors can reduce tumor neovascularization and inhibit iNOS, HIF-1alpha, VEGF, Bcl-2, and Bax protein expression.	Sirolimus	25-34	apoptosis regulator BAX	Oryctolagus cuniculus	171-174
34209274-4	2021	The mammalian target of the Rapamycin (mTOR) signaling pathway that acts via two distinct multiprotein complexes, mTORC1 and mTORC2, can affect oxidative stress.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Mus musculus	114-120
34209274-4	2021	The mammalian target of the Rapamycin (mTOR) signaling pathway that acts via two distinct multiprotein complexes, mTORC1 and mTORC2, can affect oxidative stress.	Sirolimus	28-37	CREB regulated transcription coactivator 2	Mus musculus	125-131
34209274-6	2021	Thus, Rapamycin-a selective inhibitor of mTORC1, Torin-2-a non-selective mTORC1/mTORC2 inhibitor, and FK-506-a drug that impacts oxidative stress in an mTOR-independent manner were used.	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	41-47
34209274-12	2021	Because these effects were completely reversed by Rapamycin, an mTORC1 inhibitor, this outcome suggests its usefulness as a preventive therapy in disorders connected with prenatal ethanol exposure.	Sirolimus	50-59	CREB regulated transcription coactivator 1	Mus musculus	64-70
34234741-3	2021	The YO transitions through four physiological states over the molt cycle, which are mediated by molt-inhibiting hormone (MIH; basal state), mechanistic Target of Rapamycin Complex 1 (mTORC1; activated state), Transforming Growth Factor-beta (TGFbeta)/Activin (committed state), and ecdysteroid (repressed state) signaling pathways.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-189
34135321-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates cellular nutrient signaling and hormonal cues to control metabolism.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34699314-0	2021	LINC00998 functions as a novel tumor suppressor in acute myeloid leukemia via regulating the ZFP36 ring finger protein/mammalian target of rapamycin complex 2 axis.	Sirolimus	139-148	ZFP36 ring finger protein	Homo sapiens	93-98
34699314-6	2021	LINC00998 was mainly located in the cytoplasm, in which interacted with ZFP36 ring finger protein (ZFP36), a mRNA destabilizing factor, resulting in increased decay of mammalian target of rapamycin complex 2 (mTORC2), a well-known proto-oncogene in AML.	Sirolimus	188-197	ZFP36 ring finger protein	Homo sapiens	72-97
34699314-6	2021	LINC00998 was mainly located in the cytoplasm, in which interacted with ZFP36 ring finger protein (ZFP36), a mRNA destabilizing factor, resulting in increased decay of mammalian target of rapamycin complex 2 (mTORC2), a well-known proto-oncogene in AML.	Sirolimus	188-197	ZFP36 ring finger protein	Homo sapiens	99-104
34699314-6	2021	LINC00998 was mainly located in the cytoplasm, in which interacted with ZFP36 ring finger protein (ZFP36), a mRNA destabilizing factor, resulting in increased decay of mammalian target of rapamycin complex 2 (mTORC2), a well-known proto-oncogene in AML.	Sirolimus	188-197	CREB regulated transcription coactivator 2	Mus musculus	209-215
34580903-0	2021	A novel SERPINE1-FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K-AKT-mTOR signaling pathway and responsiveness to sirolimus.	Sirolimus	172-181	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-21
34626605-9	2021	Further, these acetate molecules regulate genes involved in mammalian target of rapamycin complex 2 (mTORC2) such as mammalian stress-activated protein kinase-interacting protein (mSIN1), protein observed with Rictor 2 (Protor 2), and protein kinase C alpha (PKCalpha).	Sirolimus	80-89	CREB regulated transcription coactivator 2	Mus musculus	101-107
34626605-9	2021	Further, these acetate molecules regulate genes involved in mammalian target of rapamycin complex 2 (mTORC2) such as mammalian stress-activated protein kinase-interacting protein (mSIN1), protein observed with Rictor 2 (Protor 2), and protein kinase C alpha (PKCalpha).	Sirolimus	80-89	mitogen-activated protein kinase associated protein 1	Mus musculus	180-185
34795452-2	2021	Selective nutrients interplay with immunological signals to activate mechanistic target of rapamycin complex 1 (mTORC1), a key driver of cell metabolism2-4, but how these environmental signals are integrated for immune regulation remains unclear.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
34309811-6	2021	These phenotypic abnormalities in zebrafish embryos and larvae were rescued by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	98-104
34861413-4	2022	Grb10-deficient beta-cells exhibit enhanced mTORC1 signaling and reduced beta-cell dedifferentiation, which could be blocked by rapamycin.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	44-50
34850372-3	2022	Metformin activates AMP-activated kinase (AMPK), which inhibits mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	107-113
34840266-4	2022	Cardiac and vascular hypertrophy, oxidative stress, and infiltration of macrophages (CD68+), the marker of inflammation, were also reduced in rapamycin-treated DOCA-salt hypertensive rats.	Sirolimus	142-151	Cd68 molecule	Rattus norvegicus	85-89
34135323-1	2021	The Mechanistic Target Of Rapamycin Complex 1 (mTORC1) pathway controls several aspects of neuronal development.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
34130715-6	2021	The majority of the affected pathways are downstream targets of the mammalian target of rapamycin complex 2 (mTORC2), indicating that this stress-responsive complex plays a role in propagating the epigenetic memory of alcohol exposure through gestation.	Sirolimus	88-97	CREB regulated transcription coactivator 2	Mus musculus	109-115
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	high mobility group box 1	Homo sapiens	17-22
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	CD40 molecule	Homo sapiens	54-58
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	CD86 molecule	Homo sapiens	64-68
34164408-7	2021	Rapamycin can inhibit HMGB1-induced activation of mDCs and secretion of pro-inflammatory cytokines.	Sirolimus	0-9	high mobility group box 1	Homo sapiens	22-27
34099704-1	2021	Lysosomes are involved in nutrient sensing via the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	94-100
34840266-6	2022	Moreover, these pathophysiological changes in DOCA-salt hypertensive rats were associated with increased NADPH oxidase (NOX) activity, gp91phox (formerly NOX2) expression, ERK1/2, and p38 MAPK activities in the heart, aorta, and kidney were minimized by rapamycin.	Sirolimus	254-263	mitogen activated protein kinase 3	Rattus norvegicus	172-178
34780278-10	2022	SP-A-induced activation of mechanistic target of rapamycin complex 1 (mTORC1) kinase requires beta-arrestin2 and is critically involved in degradation of LPS-induced TLR4.	Sirolimus	49-58	surfactant associated protein A1	Mus musculus	0-4
34780278-10	2022	SP-A-induced activation of mechanistic target of rapamycin complex 1 (mTORC1) kinase requires beta-arrestin2 and is critically involved in degradation of LPS-induced TLR4.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
34858182-4	2021	Methods and Results: Immunoblotting analyses revealed that short-term exposure to rapamycin (6h) significantly reduced phosphorylation of p70S6K (mTORC1-specific) in hPASMCs but had no effect on the phosphorylation of AKT (p-AKT S473, considered mTORC2-specific).	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	146-152
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	49-53	secreted phosphoprotein 1	Rattus norvegicus	19-23
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	95-104	CREB regulated transcription coactivator 2	Mus musculus	284-290
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	182-191	CREB regulated transcription coactivator 2	Mus musculus	284-290
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	305-314	CREB regulated transcription coactivator 2	Mus musculus	284-290
34141480-11	2021	Col1a1, Runx2, and Spp1 expressed most in 100 nM RAPA group on 7 and 14 d. Osteogenesis-related genes except for Ibsp expression between four groups tended to be consistent on 21 d. 100 nM and 10 nM RAPA-treated groups showed more bone formation in vivo.	Sirolimus	199-203	secreted phosphoprotein 1	Rattus norvegicus	19-23
34858182-10	2021	Conclusion: Prolonged rapamycin treatment activates PDGFR signaling, in part, via mTORC2 inhibition.	Sirolimus	22-31	CREB regulated transcription coactivator 2	Mus musculus	82-88
34195689-1	2021	Mechanistic (or mammalian) target of rapamycin complex 1 (mTORC1) is a major signalling kinase in cells that regulates proliferation and metabolism and is controlled by extrinsic and intrinsic signals.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
34858401-8	2021	Notably, TBK1 inhibition prevented LPS-induced NLRP3 inflammasome activation by targeting the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
34607910-7	2021	The GTPase RagD encoded by RRAGD plays a role in mediating amino acid signaling to the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	130-136
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	NLR family pyrin domain containing 3	Bos taurus	103-108
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	NLR family pyrin domain containing 3	Bos taurus	202-207
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	caspase 1	Bos taurus	212-217
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	caspase 1	Bos taurus	231-236
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	interleukin 1 beta	Bos taurus	260-264
34551966-8	2021	Our results show that TLR-4-induced IFN-gamma production is regulated by the ribosomal protein S6 kinase (p70S6K) through the activation of PI3K, the mammalian target of rapamycin complex 1/2 (mTORC1/2), and the JNK MAPK pathways.	Sirolimus	170-179	CREB regulated transcription coactivator 2	Mus musculus	193-201
34561230-5	2021	IFN-gamma stimulation conferred on M0 macrophages the sensitivity to SM-induced cell death through the Jak/STAT, IFN regulatory factor-1, and mammalian target of rapamycin complex-1 (mTORC-1)/ribosomal protein S6 kinase pathways.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-190
34073521-9	2021	These results suggested that intra-ureteral administration of rapamycin by DE stent provides modification of fibrosis signaling pathway, and inhibiting mTOR may result in fibrotic process change.	Sirolimus	62-71	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	152-156
34398293-4	2021	Initiation of autophagy is regulated by two key components of the nutrient/energy sensor pathways; mammalian target of rapamycin 1 (mTORC1) and AMP-activated kinase (AMPK).	Sirolimus	119-128	CREB regulated transcription coactivator 1	Mus musculus	132-138
34224916-4	2021	Western blot, electron microscopy and immunofluorescence analyses were performed to study crinophagy and glucagon secretion in alphaTC9 cells and C57BL/6 mice, in response to the mammalian target of rapamycin complex 1 (MTORC1) inhibitor rapamycin.	Sirolimus	199-208	origin recognition complex subunit 1	Homo sapiens	220-226
34224916-4	2021	Western blot, electron microscopy and immunofluorescence analyses were performed to study crinophagy and glucagon secretion in alphaTC9 cells and C57BL/6 mice, in response to the mammalian target of rapamycin complex 1 (MTORC1) inhibitor rapamycin.	Sirolimus	238-247	glucagon	Mus musculus	105-113
34224916-4	2021	Western blot, electron microscopy and immunofluorescence analyses were performed to study crinophagy and glucagon secretion in alphaTC9 cells and C57BL/6 mice, in response to the mammalian target of rapamycin complex 1 (MTORC1) inhibitor rapamycin.	Sirolimus	238-247	origin recognition complex subunit 1	Homo sapiens	220-226
34778262-2	2021	In response to nutrient shortage and stresses, the TSC complex inhibits the mechanistic target of rapamycin complex 1 (mTORC1) at the lysosomes.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	119-125
34482023-1	2021	Ras-related GTP binding (Rag) GTPases are required to activate mechanistic target of rapamycin complex 1 (mTORC1), which plays a central role in cell growth and metabolism and is considered as one of the most important oncogenic pathways.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	106-112
34677125-3	2021	Here, we find that the hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) in an RPC subset by deletion of tuberous sclerosis complex 1 (Tsc1) makes the RPCs arrive at the division limit precociously and produce Muller glia (MG) that degenerate from senescence-associated cell death.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	85-91
34677125-3	2021	Here, we find that the hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) in an RPC subset by deletion of tuberous sclerosis complex 1 (Tsc1) makes the RPCs arrive at the division limit precociously and produce Muller glia (MG) that degenerate from senescence-associated cell death.	Sirolimus	64-73	TSC complex subunit 1	Mus musculus	125-153
34677125-3	2021	Here, we find that the hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) in an RPC subset by deletion of tuberous sclerosis complex 1 (Tsc1) makes the RPCs arrive at the division limit precociously and produce Muller glia (MG) that degenerate from senescence-associated cell death.	Sirolimus	64-73	TSC complex subunit 1	Mus musculus	155-159
34698133-12	2021	Unlike rapamycin, fasting enhanced the active expression of ABCB1 efflux protein, providing insights on the potential ameliorative effects of fasting in DN that require further elucidation.	Sirolimus	7-16	ATP binding cassette subfamily B member 1A	Rattus norvegicus	60-65
34123875-0	2021	Rapamycin Improves the Response of Effector and Memory CD8+ T Cells Induced by Immunization With ASP2 of Trypanosoma cruzi.	Sirolimus	0-9	audiogenic seizure prone 2	Mus musculus	97-101
34744761-8	2021	Furthermore, the knockdown of burs or pburs downregulated the expression of the insulin/insulin-like signaling/target of rapamycin (TOR) signaling genes encoding insulin receptor (InR), protein kinase B (Akt), TOR, and ribosomal protein S6 kinase (S6K).	Sirolimus	121-130	insulin-like receptor	Tribolium castaneum	162-178
34744761-8	2021	Furthermore, the knockdown of burs or pburs downregulated the expression of the insulin/insulin-like signaling/target of rapamycin (TOR) signaling genes encoding insulin receptor (InR), protein kinase B (Akt), TOR, and ribosomal protein S6 kinase (S6K).	Sirolimus	121-130	insulin-like receptor	Tribolium castaneum	180-183
34673774-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) senses multiple stimuli to regulate anabolic and catabolic processes.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
34650053-5	2021	Here we show that mammalian target of rapamycin complex 2 (mTORC2) is essential for the survival of experimental animals after ocular HSV-1 infection in vivo.	Sirolimus	38-47	CREB regulated transcription coactivator 2	Mus musculus	59-65
34123875-7	2021	In comparison with vehicle-injection, rapamycin administration during immunization enhanced the frequency of ASP2-specific CD8+ T-cells and the percentage of the polyfunctional population, which degranulated (CD107a+) and secreted both interferon gamma (IFNgamma) and tumor necrosis factor (TNF).	Sirolimus	38-47	audiogenic seizure prone 2	Mus musculus	109-113
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	catenin delta 1	Homo sapiens	25-31
34685712-2	2021	The present study aimed to investigate if mechanistic target of rapamycin complex 1 (mTORC1) plays a role in FFA-induced organelle dysfunction, thereby contributing to the development of ALD.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	85-91
34685712-4	2021	C57BL/6J wild-type mice were subjected to chronic alcohol feeding with or without rapamycin to inhibit mTORC1 activation.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	103-109
34685712-5	2021	We revealed that palmitic acid (PA)-induced ER stress and suppression of LAMP2 and autophagy flux were mTORC1-dependent as rapamycin reversed such deleterious effects.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	103-109
34685712-7	2021	Supplementation with rapamycin to alcohol-fed mice attenuated mTORC1 activation and ER stress, restored LAMP2 protein, and improved autophagy, leading to amelioration of alcohol-induced liver injury.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	62-68
34065350-6	2021	In detail, rapamycin induces the expression of genes promoting mitophagy (PINK1, PARKIN, ULK1, AMBRA1) and mitochondrial fission (FIS1, DRP1).	Sirolimus	11-20	unc-51 like autophagy activating kinase 1	Homo sapiens	89-93
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	246-251
34084203-0	2021	Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain.	Sirolimus	0-9	forkhead box P3	Homo sapiens	83-88
34859817-8	2022	Metformin and rapamycin elicited similar effects, which were blocked by pharmacological inhibition of AMPK.	Sirolimus	14-23	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	102-106
35107743-11	2022	Rapamycin is the most famous inhibitor of mTORC1 among all.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	42-48
35361526-3	2022	Recent findings snapped the pieces of the phosphorylation puzzle into place to unveil a process that involves a newly described motif (TOR interaction motif, TIM), a well-described kinase (mechanistic target of rapamycin complex 2 (mTORC2)), and an often-used mechanism (autophosphorylation) to prime PKC to signal.	Sirolimus	211-220	Rho guanine nucleotide exchange factor 5	Homo sapiens	158-161
35361526-3	2022	Recent findings snapped the pieces of the phosphorylation puzzle into place to unveil a process that involves a newly described motif (TOR interaction motif, TIM), a well-described kinase (mechanistic target of rapamycin complex 2 (mTORC2)), and an often-used mechanism (autophosphorylation) to prime PKC to signal.	Sirolimus	211-220	CREB regulated transcription coactivator 2	Mus musculus	232-238
35623884-3	2022	Targeting the key metabolic regulator mechanistic target of rapamycin complex 1 (mTORC1) and its downstream pathway shows efficacy only in subsets of patients but gene modifiers maximising response remain to be identified.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	81-87
35599422-28	2022	Compared with that in wild-type control group, the percentage of wound area of mice in rapamycin control group increased significantly on PID 1-6 (P<0.01), the percentage of wound area of mice in Vgamma4 T cell+IL-22 inhibitor group increased significantly on PID 1 and PID 3-6 (P<0.05 or P<0.01).	Sirolimus	87-96	phosphotyrosine interaction domain containing 1	Mus musculus	138-145
35599422-28	2022	Compared with that in wild-type control group, the percentage of wound area of mice in rapamycin control group increased significantly on PID 1-6 (P<0.01), the percentage of wound area of mice in Vgamma4 T cell+IL-22 inhibitor group increased significantly on PID 1 and PID 3-6 (P<0.05 or P<0.01).	Sirolimus	87-96	phosphotyrosine interaction domain containing 1	Mus musculus	260-265
35599422-29	2022	Compared with that in rapamycin control group, the percentage of wound area of mice in Vgamma4 T cell only group decreased significantly on PID 1-6 (P<0.05 or P<0.01).	Sirolimus	22-31	phosphotyrosine interaction domain containing 1	Mus musculus	140-147
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
35561222-1	2022	SignificanceThe mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is frequently elevated in human disease, including cancer, type 2 diabetes, metabolic disorders, and neurodegeneration.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
34633285-2	2021	Paneth cells rely heavily on the glycolytic metabolic program, which is in part controlled by the kinase complex Mechanistic target of rapamycin (mTORC1).	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	146-152
34255842-3	2021	First, we use capCLIP to identify the eIF4E cap-omes in human cells with/without the mTORC1 (mechanistic target of rapamycin, complex 1) inhibitor rapamycin, there being an emerging consensus that rapamycin inhibits translation of TOP (terminal oligopyrimidine) mRNAs by displacing eIF4E from their caps.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	282-287
34685691-5	2021	Moreover, analysis of SZT2 ablated cells revealed increased mTORC1 signaling activation that could be reversed by Rapamycin or Torin treatments.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	60-66
34097069-1	2021	OBJECTIVE: This study was designed to explore the efficacy and feasibility of cognitive behavioural therapy(CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of mRNA expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients.	Sirolimus	354-363	CREB regulated transcription coactivator 1	Mus musculus	367-373
35316218-3	2022	Here we determined the effects of chronic mTOR inhibition with rapamycin +/- T cell activation in SIV-infected rhesus macaques (RM) on ART.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Macaca mulatta	42-46
35561748-1	2022	Mechanistic target of rapamycin complex 1 (mTORC1) is a multi-protein complex widely found in eukaryotes.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
35560184-5	2022	Furthermore, IGF1Rhi Tregs exhibited higher phosphorylation of the mammalian target of the rapamycin complex 1 (mTORC1) in vivo.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
35553680-1	2022	The first objective was to investigate the effects of feeding rumen-protected methionine (RPM) during a heat stress (HS) challenge on abundance and phosphorylation of mechanistic target of rapamycin (mTOR)-related signaling proteins in mammary gland.	Sirolimus	90-93	mechanistic target of rapamycin kinase	Bos taurus	167-198
35553680-1	2022	The first objective was to investigate the effects of feeding rumen-protected methionine (RPM) during a heat stress (HS) challenge on abundance and phosphorylation of mechanistic target of rapamycin (mTOR)-related signaling proteins in mammary gland.	Sirolimus	90-93	mechanistic target of rapamycin kinase	Bos taurus	200-204
35553680-14	2022	Abundance of phosphorylated mTOR and ratio of phosphorylated eukaryotic translation elongation factor 2 (p-EEF2) to total EEF2 in non-challenged tissue was greater with RPM supplementation (P = 0.04 for both) and in both cases tended to be greater with HS (P = 0.08 for both).	Sirolimus	169-172	mechanistic target of rapamycin kinase	Bos taurus	28-32
35553680-14	2022	Abundance of phosphorylated mTOR and ratio of phosphorylated eukaryotic translation elongation factor 2 (p-EEF2) to total EEF2 in non-challenged tissue was greater with RPM supplementation (P = 0.04 for both) and in both cases tended to be greater with HS (P = 0.08 for both).	Sirolimus	169-172	eukaryotic translation elongation factor 2	Bos taurus	61-103
35553680-14	2022	Abundance of phosphorylated mTOR and ratio of phosphorylated eukaryotic translation elongation factor 2 (p-EEF2) to total EEF2 in non-challenged tissue was greater with RPM supplementation (P = 0.04 for both) and in both cases tended to be greater with HS (P = 0.08 for both).	Sirolimus	169-172	eukaryotic translation elongation factor 2	Bos taurus	107-111
35553680-14	2022	Abundance of phosphorylated mTOR and ratio of phosphorylated eukaryotic translation elongation factor 2 (p-EEF2) to total EEF2 in non-challenged tissue was greater with RPM supplementation (P = 0.04 for both) and in both cases tended to be greater with HS (P = 0.08 for both).	Sirolimus	169-172	eukaryotic translation elongation factor 2	Bos taurus	122-126
34620223-7	2021	Rap and Rap+Met inhibited articular cartilage mTORC1 but not mTORC2 signaling.	Sirolimus	0-3	CREB regulated transcription coactivator 1	Mus musculus	46-52
34620223-7	2021	Rap and Rap+Met inhibited articular cartilage mTORC1 but not mTORC2 signaling.	Sirolimus	8-12	CREB regulated transcription coactivator 1	Mus musculus	46-52
35553680-19	2022	Overall, RPM supplementation may alter mTOR activation.	Sirolimus	9-12	mechanistic target of rapamycin kinase	Bos taurus	39-43
35577075-1	2022	The mechanistic target of rapamycin complex 1 (mTORC1) is a serine/threonine kinase complex that promotes anabolic processes including protein, lipid, and nucleotide synthesis, while suppressing catabolic processes such as macroautophagy.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
35538662-6	2022	Specific inhibition of mTORC1 using rapamycin also induced changes in the expression of metabolic genes.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	23-29
35527284-6	2022	Furthermore, Sestrin2 can vigorously inhibit oncogenic signaling pathways through downregulation of mammalian target of rapamycin complex 1 (mTORC1) and hypoxia-inducible factor 1-alpha (HIF-1alpha).	Sirolimus	120-129	sestrin 2	Homo sapiens	13-21
34636300-5	2022	The mechanistic target of rapamycin complex1 (mTORC1) is a promising candidate.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	46-52
34636300-8	2022	<P> Methods: The perspective grounds its method on recent literature along with the actual experimental procedure to elicit status epilepticus from the piriform cortex and the method to administer the mTORC1 inhibitor rapamycin to mitigate seizure expression and brain damage.	Sirolimus	218-227	CREB regulated transcription coactivator 1	Mus musculus	201-207
34461118-4	2021	In contrast to simvastatin, the mTORC1 inhibitor rapamycin did not inhibit mTORC2 activity and was not cytotoxic.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	32-38
35527284-6	2022	Furthermore, Sestrin2 can vigorously inhibit oncogenic signaling pathways through downregulation of mammalian target of rapamycin complex 1 (mTORC1) and hypoxia-inducible factor 1-alpha (HIF-1alpha).	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	141-147
35442666-3	2022	The cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1) is a crucial upstream regulator of the mechanistic target of rapamycin complex 1 (mTORC1) signaling, which has close connections with apoptosis.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Mus musculus	34-40
35442666-3	2022	The cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1) is a crucial upstream regulator of the mechanistic target of rapamycin complex 1 (mTORC1) signaling, which has close connections with apoptosis.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Mus musculus	143-149
35563840-7	2022	The loss of Lcn2 dismisses the effect of mTORC1 inhibition by rapamycin on COX2, thermogenesis genes, lipogenesis, and lipolysis, but has no impact on p70 S6Kinase-ULK1 activation in Lcn2-deficient adipocytes.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	41-47
35441596-6	2022	In addition, HRI-elF2alphaP specifically enhances translation of ATF4 mRNA leading to the repression of mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	126-135	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	13-16
34523696-4	2021	Rapamycin and its analogs were less successful in clinical trials for patients with GB due to their incomplete inhibition of mTORC1 and the activation of mitogenic pathways via negative feedback loops.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	125-131
34155681-3	2021	Here, we demonstrated that Rictor, a key component of mechanistic target of rapamycin complex 2 (mTORC2), was crucial for TRAF6/TRAF3 expression in osteoclasts.	Sirolimus	76-85	CREB regulated transcription coactivator 2	Mus musculus	97-103
34155681-3	2021	Here, we demonstrated that Rictor, a key component of mechanistic target of rapamycin complex 2 (mTORC2), was crucial for TRAF6/TRAF3 expression in osteoclasts.	Sirolimus	76-85	RPTOR independent companion of MTOR, complex 2	Mus musculus	27-33
35441596-6	2022	In addition, HRI-elF2alphaP specifically enhances translation of ATF4 mRNA leading to the repression of mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	147-153
34435708-3	2022	Mechanistic target of rapamycin complex 1 (mTORC1) also has been reported to be highly activated in HCC.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
34479772-0	2021	Sirolimus diminishes the expression of GRO-alpha (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells.	Sirolimus	0-9	C-X-C motif chemokine receptor 2	Homo sapiens	59-64
34479772-11	2021	Moreover, sirolimus decreased the expression of the corresponding receptor CXCR2.	Sirolimus	10-19	C-X-C motif chemokine receptor 2	Homo sapiens	75-80
34333229-7	2021	The results of in vitro experiment showed that rapamycin enhanced the cell activity of iPSCs, increased the number of nestin positive cells, up-regulated Beclin-1 and LC3BI/II expressions, and down-regulated p62 expression.	Sirolimus	47-56	beclin 1	Rattus norvegicus	154-162
34333229-7	2021	The results of in vitro experiment showed that rapamycin enhanced the cell activity of iPSCs, increased the number of nestin positive cells, up-regulated Beclin-1 and LC3BI/II expressions, and down-regulated p62 expression.	Sirolimus	47-56	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	208-211
34365138-4	2021	Regarding the cytological smear samples, RPM supplementation tended to increase mRNA expression of methionine adenosyltransferase 1 alpha (MAT1A) and increased the mRNA expression of fibroblast growth factor 7 (FGF7), with an effect of time for the latter.	Sirolimus	41-44	fibroblast growth factor 7	Bos taurus	183-209
34365138-4	2021	Regarding the cytological smear samples, RPM supplementation tended to increase mRNA expression of methionine adenosyltransferase 1 alpha (MAT1A) and increased the mRNA expression of fibroblast growth factor 7 (FGF7), with an effect of time for the latter.	Sirolimus	41-44	fibroblast growth factor 7	Bos taurus	211-215
34544857-1	2021	Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are caused by aberrant mechanistic Target of Rapamycin Complex 1 (mTORC1) activation due to loss of either TSC1 or TSC2 Cytokine profiling of TSC2-deficient LAM patient-derived cells revealed striking up-regulation of Interleukin-6 (IL-6).	Sirolimus	113-122	CREB regulated transcription coactivator 1	Mus musculus	134-140
34632383-6	2021	DEPDC5, NPRL2 and NPRL3 code for subunits of the GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1), the principal amino acid-sensing regulator of mechanistic target of rapamycin complex 1.	Sirolimus	191-200	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	0-6
34632383-10	2021	Rapamycin reduced seizures in rodent models of DEPDC5-related epilepsy and focal cortical dysplasia type II.	Sirolimus	0-9	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	47-53
35573741-1	2022	Objective: The mammalian target of the rapamycin complex 1 (mTORC1) signaling pathway has emerged as a crucial player in the oncogenesis and development of head and neck squamous cell carcinoma (HNSCC), however, to date, no relevant gene signature has been identified.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	60-66
34546793-0	2021	Dissecting the biology of mTORC1 beyond rapamycin.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	26-32
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	natriuretic peptide B	Danio rerio	32-36
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	potassium voltage-gated channel, subfamily H (eag-related), member 6a	Danio rerio	38-43
34519641-5	2021	Moreover, we demonstrate that these pathways are involved in the demyelination process, and that inhibition of mTORC1 using rapamycin partially rescues the demyelinating pathology.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Mus musculus	111-117
35547814-9	2022	Rapamycin significantly blocked mTORC1 signaling pathway in the irradiated testis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	32-38
35547814-10	2022	Inhibition of mTORC1 signaling pathway by rapamycin treatment after radiation could significantly improve cell proliferation in testis and alleviate radiation-induced testicular injury after radiation exposure.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	14-20
35547814-12	2022	These findings imply that rapamycin treatment can accelerate testis recovery under radiation condition through inhibiting mTORC1 signaling pathway.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	122-128
35503070-9	2022	The expression levels of Beclin-1, microtubule- associated protein light chain 3-II (LC3-II), mammalian target of rapamycin complex 1 (mTORC1), and VEGF were measured by immunohistochemistry and Western blot.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
34589488-4	2021	Studies in this model have identified that decanoic acid reduces phosphoinositide turnover, diacylglycerol kinase (DGK) activity, and also inhibits the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	174-183	CREB regulated transcription coactivator 1	Mus musculus	195-201
34589493-2	2021	Previous studies have shown that Rg3 treatment downregulates the activity of rapamycin complex 1 (mTORC1) activity and inhibits the growth of cancer cells.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	98-104
34243067-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) is a crucial regulator of adipogenesis and systemic energy metabolism.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
34552615-4	2021	We also propose that the blockage of some effector functions of ORF8 with Rapamycin, such as the mTORC1 activation through MAPKs 40 pathway, with Rapamycin, can be a promising approach to reduce COVID-19 mortality.	Sirolimus	74-83	ORF8 protein	Severe acute respiratory syndrome coronavirus 2	64-68
34552615-4	2021	We also propose that the blockage of some effector functions of ORF8 with Rapamycin, such as the mTORC1 activation through MAPKs 40 pathway, with Rapamycin, can be a promising approach to reduce COVID-19 mortality.	Sirolimus	146-155	ORF8 protein	Severe acute respiratory syndrome coronavirus 2	64-68
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	CREB regulated transcription coactivator 1	Mus musculus	133-139
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	CREB regulated transcription coactivator 1	Mus musculus	169-175
35547764-6	2022	Methods: We profiled mTORC1-dependent long non-coding RNAs (lncRNAs) by RNA-seq of HCC cells treated with rapamycin.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	21-27
34280391-4	2021	GS catalyzes the transformation of neurotoxic glutamate (Glu) into nontoxic glutamine (Gln) to activate the mammalian target of rapamycin complex 1 (mTORC1), which promotes the activation of RMCs.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	149-155
34294367-3	2021	2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	195-204	CREB regulated transcription coactivator 1	Mus musculus	216-222
34294370-3	2021	Preclinical studies have revealed that the antidepressant actions of ketamine are mediated via the release of brain-derived neurotrophic factor and vascular endothelial growth factor, with the subsequent activation of mechanistic target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex.	Sirolimus	240-249	CREB regulated transcription coactivator 1	Mus musculus	261-267
34503187-2	2021	Intracellular levels of free amino acids, especially leucine, regulate the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	116-122
34512171-10	2021	The autophagy activator rapamycin promotes the antitumor effect of verteporfin, a YAP inhibitor.	Sirolimus	24-33	Yes1 associated transcriptional regulator	Homo sapiens	82-85
34411822-0	2021	Rapamycin antagonizes cadmium-induced breast cancer cell proliferation and metastasis through directly modulating ACSS2.	Sirolimus	0-9	acyl-CoA synthetase short chain family member 2	Homo sapiens	114-119
34411822-4	2021	Here, we hypothesize that rapamycin antagonizes Cd-induced BC cell proliferation and metastasis by directly modulating ACSS2.	Sirolimus	26-35	acyl-CoA synthetase short chain family member 2	Homo sapiens	119-124
34411822-6	2021	Moreover, a surface plasmon resonance (SPR) assay confirmed that rapamycin directly binds to the ACSS2 protein with a calculated equilibrium dissociation constant (KD) of 18.3 muM.	Sirolimus	65-74	acyl-CoA synthetase short chain family member 2	Homo sapiens	97-102
34411822-7	2021	Molecular docking showed that there are three binding sites in the ACSS2 protein and that rapamycin binds at the coenzyme A (COA) binding site with a docking score of - 12.26 and a binding free energy of - 26.34 kcal/mol.	Sirolimus	90-99	acyl-CoA synthetase short chain family member 2	Homo sapiens	67-72
34411822-8	2021	More importantly, rapamycin suppresses Cd-induced BC progression by activating ACSS2.	Sirolimus	18-27	acyl-CoA synthetase short chain family member 2	Homo sapiens	79-84
34411822-9	2021	After cells were cotreated with an ACSS2 inhibitor, the effects of rapamycin were abolished.	Sirolimus	67-76	acyl-CoA synthetase short chain family member 2	Homo sapiens	35-40
34411822-10	2021	In conclusion, our findings suggest that rapamycin suppresses Cd-augmented BC progression by upregulating ACSS2, and ACSS2 may serve as a direct target of rapamycin for inhibiting xenobiotic (e.g., Cd)-mediated BC progression.	Sirolimus	41-50	acyl-CoA synthetase short chain family member 2	Homo sapiens	106-111
35517785-8	2022	Reduced cyclin D1 protein levels were consistent with G0/G1 phase arrest, especially when resulting from the combination of ITZ with rapamycin.	Sirolimus	133-142	cyclin D1	Homo sapiens	8-17
34411822-10	2021	In conclusion, our findings suggest that rapamycin suppresses Cd-augmented BC progression by upregulating ACSS2, and ACSS2 may serve as a direct target of rapamycin for inhibiting xenobiotic (e.g., Cd)-mediated BC progression.	Sirolimus	155-164	acyl-CoA synthetase short chain family member 2	Homo sapiens	117-122
34445471-1	2021	The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is activated by the small G-protein, Ras homolog enriched in brain (RHEB-GTPase).	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
35101523-3	2022	The parent study for the secondary pilot analyses presented here was a double-blind, cross-over trial that found pretreatment with the mechanistic target of rapamycin complex 1 (mTORC1) prolonged the antidepressant effects of ketamine.	Sirolimus	157-166	CREB regulated transcription coactivator 1	Mus musculus	178-184
35457142-4	2022	BCAAs-in particular leucine-activate the rapamycin complex1 mTORC1, which regulates cell growth and metabolism, glucose metabolism and several more essential physiological processes.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	60-66
35495903-8	2022	High levels of dietary valine stimulated lipid deposition by suppressing the GCN2-eIF2alpha-ATF4-fibroblast growth factor-19 (FGF19)-target of rapamycin complex 1 (TORC1) signaling pathway to promote fatty acid synthesis, repress fatty acid utilization, and eventually accelerate the development of NAFLD.	Sirolimus	143-152	eukaryotic translation initiation factor 2A	Gallus gallus	82-91
35388773-7	2022	After autophagy was activated by rapamycin (Rapa), the amount of p-Akt and p-mTOR decreased significantly, whilst the amount of intracellular S. agalactiae increased significantly.	Sirolimus	33-42	AKT serine/threonine kinase 1	Bos taurus	67-70
35388773-7	2022	After autophagy was activated by rapamycin (Rapa), the amount of p-Akt and p-mTOR decreased significantly, whilst the amount of intracellular S. agalactiae increased significantly.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Bos taurus	77-81
35388773-7	2022	After autophagy was activated by rapamycin (Rapa), the amount of p-Akt and p-mTOR decreased significantly, whilst the amount of intracellular S. agalactiae increased significantly.	Sirolimus	44-48	AKT serine/threonine kinase 1	Bos taurus	67-70
35388773-7	2022	After autophagy was activated by rapamycin (Rapa), the amount of p-Akt and p-mTOR decreased significantly, whilst the amount of intracellular S. agalactiae increased significantly.	Sirolimus	44-48	mechanistic target of rapamycin kinase	Bos taurus	77-81
35321785-3	2022	Under nutrient-rich conditions, mTOR complex 1 (mTORC1) phosphorylates the ULK1 complex, preventing its activation and subsequent autophagosome formation, while inhibition of mTORC1 using either rapamycin or nutrient deprivation induces autophagy.	Sirolimus	195-204	unc-51 like autophagy activating kinase 1	Homo sapiens	75-79
35321785-3	2022	Under nutrient-rich conditions, mTOR complex 1 (mTORC1) phosphorylates the ULK1 complex, preventing its activation and subsequent autophagosome formation, while inhibition of mTORC1 using either rapamycin or nutrient deprivation induces autophagy.	Sirolimus	195-204	CREB regulated transcription coactivator 1	Mus musculus	175-181
35390228-19	2022	We found that degradation of cardiac GATA4 by Bmi-1 was mainly dependent on autophagy rather than proteasome, and autophagy agonists metformin and rapamycin could ameliorate the SA-PCH, suggesting that activation of autophagy with metformin or rapamycin could also be a promising method to prevent SA-PCH.	Sirolimus	147-156	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	46-51
35390228-19	2022	We found that degradation of cardiac GATA4 by Bmi-1 was mainly dependent on autophagy rather than proteasome, and autophagy agonists metformin and rapamycin could ameliorate the SA-PCH, suggesting that activation of autophagy with metformin or rapamycin could also be a promising method to prevent SA-PCH.	Sirolimus	244-253	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	46-51
35318320-3	2022	Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates PDK1 at its pleckstrin homology (PH) domain, and impairs PDK1 interaction with and activation of AKT.	Sirolimus	134-143	CREB regulated transcription coactivator 1	Mus musculus	155-161
35359988-6	2022	Mechanistically, we discovered that the mammalian target of rapamycin complex 1 (mTORC1) signaling inhibition leads to decreased glycolysis and OXPHOS in dNK.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	81-87
35255005-5	2022	Mechanistic dissection demonstrated that FOXH1-induced cell growth and cell migration/invasion relied on mTOR signaling because inhibition of mTOR signaling by rapamycin could attenuate FOXH1-mediated phenotypic alterations of HCC cells.	Sirolimus	160-169	forkhead box H1	Homo sapiens	41-46
35165201-7	2022	Targeted deletion of NPRL2 in primary neurons increases the expression of sodium channel Scn1A, whereas treatment with the pharmacological mTORC1 inhibitor called rapamycin prevents Scn1A upregulation.	Sirolimus	163-172	CREB regulated transcription coactivator 1	Mus musculus	139-145
34318888-9	2021	Pharmacologic inhibition of the Wnt/beta-catenin pathway (ICG-001) or rapamycin-mediated activation of autophagy effectively blocked BRG1-induced tubular senescence and fibrotic responses, while bafilomycin A1-mediated inhibition of autophagy abolished the effects of ICG-001.	Sirolimus	70-79	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Mus musculus	133-137
34368895-2	2022	Our previous study showed that inhibition of MTOR with rapamycin treatment suppressed human endothelial cell tube formation, concomitant with the down-regulation of miR-107.	Sirolimus	55-64	microRNA 107	Homo sapiens	165-172
34452418-7	2021	Besides that, rapamycin could disturb the expression of p62 and LC3B-II, and the transcription level of SCRV nucleoprotein mRNA.	Sirolimus	14-23	microtubule associated protein 1 light chain 3 beta	Homo sapiens	64-68
34342774-3	2021	FKBP2 (FKBP13) and FKBP1 (FKBP12), known as immunophilins, are binding proteins for rapamycin and FK506, which are immunosuppressive drugs.	Sirolimus	84-93	FKBP prolyl isomerase 1A	Homo sapiens	19-24
34342774-5	2021	Within the 15 mammalian FKBPs known, FKBP1 is merely the only one proven to form complexes with rapamycin and FK506 in the cytosol and facilitate their T cells immunosuppressive effects, FKBP2 is a luminal protein of the endoplasmic reticulum (ER) and is reported to take part in protein folding in the ER.	Sirolimus	96-105	FKBP prolyl isomerase 1A	Homo sapiens	37-42
34341336-5	2021	PLA enhanced FGFBP1 expression through activation of the mechanistic target of rapamycin complex 1-signal transducer and activator of transcription 3 (mTORC1-STAT3) signaling pathway.	Sirolimus	79-88	CREB regulated transcription coactivator 1	Mus musculus	151-157
35165201-7	2022	Targeted deletion of NPRL2 in primary neurons increases the expression of sodium channel Scn1A, whereas treatment with the pharmacological mTORC1 inhibitor called rapamycin prevents Scn1A upregulation.	Sirolimus	163-172	sodium voltage-gated channel alpha subunit 1	Homo sapiens	182-187
35433951-11	2022	JPTGY affects browning of 3T3-L1 cells through mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	90-96
34131827-13	2021	In conclusion, these findings suggested that the CLOCK-dependent rapamycin signaling pathway is a critical mediator in ox-LDL-induced VSMCs with defective autophagy that exacerbates plaque destabilization.	Sirolimus	65-74	clock circadian regulator	Homo sapiens	49-54
35137127-7	2022	Among the protein targets measured, although abundance of phosphorylated (p) AKT serine/threonine kinase (p-AKT) (P = 0.05) and p-mechanistic target of rapamycin (p-MTOR) (P = 0.04) were lowest in HP explants, this effect was attenuated in HPARG and especially HPARGMET compared with CTR.	Sirolimus	152-161	mechanistic target of rapamycin kinase	Bos taurus	165-169
34512126-6	2021	In the intestinal epithelium, CR suppresses the mechanistic target of rapamycin complex 1 (mTORC1) signalling in Paneth cells to shift the stem cell equilibrium towards self-renewal at the cost of differentiation.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	91-97
34102263-6	2021	Conversely, the increments of both Beclin 1 and microtubule-associated protein-1 light chain 3-II protein levels in the proximal and distal stumps of the transected IAN was induced by rapamycin administration.	Sirolimus	184-193	beclin 1	Rattus norvegicus	35-43
34226146-1	2021	T cell asymmetry upon specific cell-cell interactions during mammalian immunological synapse (IS) contacts requires mammalian target of rapamycin complex (mTORC) activation and chaperones, such as the eukaryotic chaperonin containing TCP1 (CCT) for protein synthesis and folding.	Sirolimus	136-145	t-complex 1	Homo sapiens	234-238
34393724-4	2021	Most importantly, AMPK activation is known to suppress the translational machinery by inhibiting the mechanistic target of rapamycin complex 1 (mTORC1), activating translational regulators, and phosphorylating nuclear transporter factors.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	144-150
34301883-1	2021	Tuberous sclerosis complex 1 (Tsc1) is a tumor suppressor that functions together with Tsc2 to negatively regulate the mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	141-150	CREB regulated transcription coactivator 1	Mus musculus	162-168
34381417-11	2021	Inhibition of miR 223 induced increased autophagy in BV2 cells upon Rapamycin stimulation.	Sirolimus	68-77	microRNA 223	Mus musculus	14-21
34440627-7	2021	The mutation in Eif2b5 prompts reactive oxygen species (ROS)-mediated inferior ability to stimulate the AMP-activated protein kinase (AMPK) axis, due to a requirement to increase the mammalian target of rapamycin complex-1 (mTORC1) signalling in order to enable oxidative glycolysis and generation of specific subclass of ROS-regulating proteins, similar to cancer cells.	Sirolimus	203-212	CREB regulated transcription coactivator 1	Mus musculus	224-230
34267188-2	2021	DEP domain-containing protein 5 (DEPDC5), a component of GAP activities towards Rags 1 (GATOR1) complex, is a repressor of amino acid-sensing branch of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	176-185	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	0-31
34267188-2	2021	DEP domain-containing protein 5 (DEPDC5), a component of GAP activities towards Rags 1 (GATOR1) complex, is a repressor of amino acid-sensing branch of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	176-185	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	33-39
34267188-2	2021	DEP domain-containing protein 5 (DEPDC5), a component of GAP activities towards Rags 1 (GATOR1) complex, is a repressor of amino acid-sensing branch of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	176-185	CREB regulated transcription coactivator 1	Mus musculus	197-203
35183507-1	2022	The mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is activated by intracellular nutritional sufficiency and extracellular growth signals.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
35349401-11	2022	Also, it is demonstrated that Vpg interacts with eIF4E and that rapamycin treatment partially diminishes the viral protein synthesis.	Sirolimus	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
34990741-4	2022	However, combined treatment with LIF relieved the follicular regression caused by rapamycin, mainly resulting in alleviating the decline of GCs viability and cell autophagic apoptosis, and eventually, promoting follicle development.	Sirolimus	82-91	leukemia inhibitory factor	Gallus gallus	33-36
35020443-2	2022	The nuclear localization of TFEB is blocked by the mechanistic target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of TFEB at multiple sites including Ser-211.	Sirolimus	73-82	transcription factor EB	Homo sapiens	28-32
35020443-2	2022	The nuclear localization of TFEB is blocked by the mechanistic target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of TFEB at multiple sites including Ser-211.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	94-100
35020443-2	2022	The nuclear localization of TFEB is blocked by the mechanistic target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of TFEB at multiple sites including Ser-211.	Sirolimus	73-82	transcription factor EB	Homo sapiens	131-135
35181635-1	2022	Lymphangioleiomyomatosis (LAM) is a rare progressive disease, characterized by mutations in the tuberous sclerosis complex genes (TSC1 or TSC2) and hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	189-198	CREB regulated transcription coactivator 1	Mus musculus	210-216
35172150-1	2022	AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) are metabolic kinases that co-ordinate nutrient supply with cell growth.	Sirolimus	62-71	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	0-28
35172150-1	2022	AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) are metabolic kinases that co-ordinate nutrient supply with cell growth.	Sirolimus	62-71	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	30-34
35172150-1	2022	AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) are metabolic kinases that co-ordinate nutrient supply with cell growth.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	83-89
35131932-5	2022	To reveal the structural basis underlying the synergistic activation of TRPML1 by PI(3,5)P2 and rapamycin, we determined the high-resolution cryoelectron microscopy (cryo-EM) structures of the mouse TRPML1 channel in various states, including apo closed, PI(3,5)P2-bound closed, and PI(3,5)P2/temsirolimus (a rapamycin analog)-bound open states.	Sirolimus	309-318	peripheral myelin protein 2	Mus musculus	89-105
35105357-0	2022	Rapamycin, Acarbose and 17alpha-estradiol share common mechanisms regulating the MAPK pathways involved in intracellular signaling and inflammation.	Sirolimus	0-9	mitogen-activated protein kinase 14	Mus musculus	81-85
35153674-3	2021	In this study, we found that hearing loss and OM infections in OM mice were significantly alleviated after treatment with rapamycin (RPM), a widely used mechanistic target of RPM complex 1 (mTORC1) inhibitor and autophagy inducer.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Mus musculus	190-196
35153674-3	2021	In this study, we found that hearing loss and OM infections in OM mice were significantly alleviated after treatment with rapamycin (RPM), a widely used mechanistic target of RPM complex 1 (mTORC1) inhibitor and autophagy inducer.	Sirolimus	133-136	CREB regulated transcription coactivator 1	Mus musculus	190-196
35114453-9	2022	Mechanistically, ISL activates adenosine monophosphate-activated protein kinase (AMPK) and inhibits mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	141-147
34322484-4	2021	Moreover, rapamycin significantly decreased the proliferation and non-tenocyte differentiation of PTSCs as indicated by the reduced expression levels of LPL, PPARgamma, SOX-9, collagen II, Runx-2, and osteocalcin genes.	Sirolimus	10-19	peroxisome proliferator activated receptor gamma	Mus musculus	158-167
34253722-1	2021	Tuberous Sclerosis Complex (TSC) is caused by TSC1 or TSC2 mutations, resulting in hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	128-137	TSC complex subunit 1	Mus musculus	28-31
34253722-1	2021	Tuberous Sclerosis Complex (TSC) is caused by TSC1 or TSC2 mutations, resulting in hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	128-137	TSC complex subunit 1	Mus musculus	46-50
34244482-4	2021	Here we report that mechanistic target of rapamycin complex 1 (mTORC1) signal inhibits GLDC acetylation at lysine (K) 514 by inducing transcription of the deacetylase sirtuin 3 (SIRT3).	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	63-69
34244482-4	2021	Here we report that mechanistic target of rapamycin complex 1 (mTORC1) signal inhibits GLDC acetylation at lysine (K) 514 by inducing transcription of the deacetylase sirtuin 3 (SIRT3).	Sirolimus	42-51	glycine decarboxylase	Homo sapiens	87-91
34996966-5	2022	When rapamycin was combined with saturating concentrations of BafA, no significant further increase of LC3B lipidation could be detected over the levels induced by the late-stage inhibitor.	Sirolimus	5-14	microtubule associated protein 1 light chain 3 beta	Homo sapiens	103-107
35499056-11	2022	The autophagy activator rapamycin reversed the deleterious effects of LRRK2 overexpression.	Sirolimus	24-33	leucine-rich repeat kinase 2	Mus musculus	70-75
34004356-1	2021	The nutrient sensors peroxisome proliferator-activated receptor gamma (PPARgamma) and mechanistic target of rapamycin complex 1 (mTORC1) closely interact in the regulation of adipocyte lipid storage.	Sirolimus	108-117	peroxisome proliferator activated receptor gamma	Mus musculus	21-69
34233775-5	2021	In addition, amino acids and glucose (energy stress) manipulate the ferroptosis pathway through the nutrient-sensitive kinases mechanistic target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK).	Sirolimus	149-158	CREB regulated transcription coactivator 1	Mus musculus	170-176
34143450-4	2021	The mammalian target of rapamycin complex 1 (mTORC1) signaling on late endosomes (LEs)/lysosomes may control cargo selection, membrane biogenesis, and exosome secretion, which may be fine controlled by lysosomal sphingolipids such as CER.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
34004356-1	2021	The nutrient sensors peroxisome proliferator-activated receptor gamma (PPARgamma) and mechanistic target of rapamycin complex 1 (mTORC1) closely interact in the regulation of adipocyte lipid storage.	Sirolimus	108-117	peroxisome proliferator activated receptor gamma	Mus musculus	71-80
34004356-1	2021	The nutrient sensors peroxisome proliferator-activated receptor gamma (PPARgamma) and mechanistic target of rapamycin complex 1 (mTORC1) closely interact in the regulation of adipocyte lipid storage.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	129-135
33054526-5	2021	We further confirmed that the translational efficiency of Tudor-SN mRNA was controlled by the mammalian target of rapamycin complex 1 (mTORC1) pathway, as revealed via inhibition of activated mTORC1 in primary neonatal mouse cardiomyocytes and activation of silenced mTORC1 in adult mouse myocardia; additionally, this result was recapitulated in H9c2 cells.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
34187953-4	2021	We also examined whether the glial cell expression and phosphorylated p38 (p-p38) mitogen-activated protein kinases (MAPKs) in the TNC are affected by rapamycin.	Sirolimus	151-160	mitogen-activated protein kinase 14	Mus musculus	70-73
34187953-4	2021	We also examined whether the glial cell expression and phosphorylated p38 (p-p38) mitogen-activated protein kinases (MAPKs) in the TNC are affected by rapamycin.	Sirolimus	151-160	mitogen-activated protein kinase 14	Mus musculus	77-80
34187953-9	2021	Furthermore, the number of p-p38-ir cells the in ipsilateral TNC was significantly decreased in animals treated with high-dose rapamycin; p-p38 expression was co-localized in microglia, but not neurons and astrocytes.	Sirolimus	127-136	mitogen-activated protein kinase 14	Mus musculus	29-32
34187953-9	2021	Furthermore, the number of p-p38-ir cells the in ipsilateral TNC was significantly decreased in animals treated with high-dose rapamycin; p-p38 expression was co-localized in microglia, but not neurons and astrocytes.	Sirolimus	127-136	mitogen-activated protein kinase 14	Mus musculus	140-143
34059001-17	2021	Repression of mTOR with rapamycin blocked the effects of KLK11 on S6K1 and 4EBP1 as well as protein synthesis.	Sirolimus	24-33	kallikrein related-peptidase 11	Mus musculus	57-62
34277614-10	2021	These findings suggest that vinculin and beta-catenin are key mediators of BCC to form MCS during 24 h of RPM-exposure.	Sirolimus	106-109	vinculin	Homo sapiens	28-36
34059001-18	2021	Besides, rapamycin treatment blocked the roles of KLK11 in the regulation of cardiomyocyte hypertrophy.	Sirolimus	9-18	kallikrein related-peptidase 11	Mus musculus	50-55
33949851-12	2021	Similarly, our work developing biosensors to monitor the subcellular mechanistic target of rapamycin complex 1 (mTORC1) signaling allowed us to not only clarify the presence of mTORC1 activity in the nucleus but also identify a novel mechanism governing the activation of mTORC1 in this location.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
34258253-3	2021	Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	105-111
34187514-6	2021	We show that the harmful effect of AMPK is exerted through inhibition of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	97-106	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	35-39
34187514-6	2021	We show that the harmful effect of AMPK is exerted through inhibition of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	118-124
33949851-12	2021	Similarly, our work developing biosensors to monitor the subcellular mechanistic target of rapamycin complex 1 (mTORC1) signaling allowed us to not only clarify the presence of mTORC1 activity in the nucleus but also identify a novel mechanism governing the activation of mTORC1 in this location.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	177-183
33949851-12	2021	Similarly, our work developing biosensors to monitor the subcellular mechanistic target of rapamycin complex 1 (mTORC1) signaling allowed us to not only clarify the presence of mTORC1 activity in the nucleus but also identify a novel mechanism governing the activation of mTORC1 in this location.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	177-183
34001117-4	2021	RESULTS: In response to con-specific pheromones indicative of stress, AMP-activated protein kinase (AMPK), mechanistic target of rapamycin complex 1 (mTORC1), and insulin signaling regulate stress resistance and sex determination across one generation, and these effects can be mimicked by pathway modulators.	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	150-156
34198993-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) is a master growth regulator by controlling protein synthesis and autophagy in response to environmental cues.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
34103528-6	2021	Mechanistically, AKT1-R391 methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading to AKT1 membrane translocation and subsequent activation by phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of rapamycin complex 2 (mTORC2).	Sirolimus	301-310	CREB regulated transcription coactivator 2	Mus musculus	322-328
34079249-8	2021	Furthermore, exosomal anti-let-7i-5p promoted the activation the tuberous sclerosis complex subunit 1/mammalian target of rapamycin (TSC1/mTOR) signaling pathway in vivo and in vitro.	Sirolimus	122-131	microRNA let-7i	Homo sapiens	27-33
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	112-118
34073791-2	2021	Neuroprotection and recovery after SCI can be partially achieved by rapamycin (RAPA) treatment, an inhibitor of mTORC1, complex 1 of the mammalian target of rapamycin (mTOR) pathway.	Sirolimus	79-83	CREB regulated transcription coactivator 1	Mus musculus	112-118
34065421-8	2021	Pathway analysis showed IL10 signaling as a major contributing pathway to the altered immunophenotype after Rapamycin treatment compared to vehicle with significantly lower cytokines Tnfa, Il1b, and Il6, while regulators of mitochondrial content Pgc1a, Tfam, and Ho1 remained elevated.	Sirolimus	108-117	transcription factor A, mitochondrial	Mus musculus	253-257
34095131-13	2021	Rather, rapamycin treatment in IGF1 transgenic mice, but not in WT mice, increased numbers of cells labeled with BrdU at 3 days after injury that survived to 10 days, and enhanced the proportion of posttrauma-born cells that differentiated into neurons.	Sirolimus	8-17	insulin-like growth factor 1	Mus musculus	31-35
34079457-17	2021	Mechanically, it accelerated the degradation of NLRP3 inflammasome via the autophagy-ubiquitin pathway and reduced the green fluorescent protein/red fluorescent protein MAP1LC3B ratio, which was comparable to the effect when using the autophagy activator rapamycin (Rapa).	Sirolimus	255-264	microtubule-associated protein 1 light chain 3 beta	Mus musculus	169-177
34079457-17	2021	Mechanically, it accelerated the degradation of NLRP3 inflammasome via the autophagy-ubiquitin pathway and reduced the green fluorescent protein/red fluorescent protein MAP1LC3B ratio, which was comparable to the effect when using the autophagy activator rapamycin (Rapa).	Sirolimus	266-270	microtubule-associated protein 1 light chain 3 beta	Mus musculus	169-177
34187243-0	2021	Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: A pedigree case report with homozygous variation PRKCD.	Sirolimus	0-9	protein kinase C delta	Homo sapiens	125-130
35460832-6	2022	Rapamycin-induced blockage of mTOR complex 1 (mTORC1) signaling, which regulates metabolism, differentially inhibited LF- and HF-modulated protein signatures of mitochondrial NADH dehydrogenase ubiquinone flavoprotein 2, mitochondrial glutathione peroxidase 4, kynureninase, and alpha-crystallin B chain as well as programmed cell death 5 in transcript levels; it subsequently diminished apoptosis and oncospheroid formation in LF/HF-exposed cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	46-52
35274444-3	2022	As RAB3GAP2 has been recently shown to be involved in the autophagy process, we analyzed patient-derived fibroblasts by fluorescence microscopy and demonstrated defective autophagic flux under rapamycin and serum starvation conditions when compared with wild-type cells.	Sirolimus	193-202	RAB3 GTPase activating non-catalytic protein subunit 2	Homo sapiens	3-11
35523039-0	2022	Sirolimus therapy restores the PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr cell balance in primary Sjogren"s syndrome.	Sirolimus	0-9	forkhead box P3	Homo sapiens	52-57
35523039-0	2022	Sirolimus therapy restores the PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr cell balance in primary Sjogren"s syndrome.	Sirolimus	0-9	transferrin receptor	Homo sapiens	72-75
35502657-12	2022	TET2 coimmunoprecipitated with p300, and this interaction was enhanced by rapamycin but repressed by platelet-derived growth factor (PDGF) treatment, with p300 promoting TET2 protein stability.	Sirolimus	74-83	tet methylcytosine dioxygenase 2	Homo sapiens	0-4
35439535-7	2022	Our results also confirmed that mTOR inhibitor sensitized senolytic cell death is apoptotic and pan-mTOR inhibitors PP242 and AZD8055 works more effectively than mTORC1 inhibitor Rapamycin.	Sirolimus	179-188	CREB regulated transcription coactivator 1	Mus musculus	162-168
35486977-5	2022	From the additional compounds that could reverse this metabolic reprogramming, the mTORC1 inhibitor sirolimus was selected.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	83-89
35291809-4	2022	Since initial studies found that the acute increase of RPP resulted in activation of mTORC1 (phosphorylation of S6S235/236), the effects of inhibition of mTORC1 with rapamycin pretreatment were then determined.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	154-160
35291809-8	2022	Significant increases in CD68-positive macrophages were found in both the cortex (intraglomerular and periglomerular regions) and in the outer medullary interstitial regions of the kidney and prevented by rapamycin treatment.	Sirolimus	205-214	Cd68 molecule	Rattus norvegicus	25-29
35488725-4	2022	The mTOR inhibitor sirolimus, which preferentially inhibits mTORC1, has led to sustained remission in a small cohort of anti-IL-6-refractory iMCD patients with thrombocytopenia, anasarca, fever, renal dysfunction and organomegaly (iMCD-TAFRO).	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	60-66
35488725-5	2022	However, sirolimus has not shown uniform effect, potentially due to its limited mTORC2 inhibition.	Sirolimus	9-18	CREB regulated transcription coactivator 2	Mus musculus	80-86
34054807-0	2021	Rapamycin Modulates the Proinflammatory Memory-Like Response of Microglia Induced by BAFF.	Sirolimus	0-9	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	85-89
35426265-0	2022	Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.	Sirolimus	95-104	TEK receptor tyrosine kinase	Homo sapiens	8-11
35426265-4	2022	METHODS: We report a case with intraarticular bleeding due to VM with a TEK pathogenic somatic variant treated with rapamycin.	Sirolimus	116-125	TEK receptor tyrosine kinase	Homo sapiens	72-75
35286973-8	2022	The levels of phosphorylated mTOR and ribosomal protein S6 kinase 1 (p70S6K) were increased after GLUT1 inhibition and decreased by an mTOR inhibitor (rapamycin, Rapa) during the odontogenic induction of hDPSCs.	Sirolimus	151-160	transcriptional regulating factor 1	Homo sapiens	162-166
35367291-5	2022	Rapamycin rescued the inhibition of TFEB nuclear translocation induced by miR-34a/ATG9A activation, restored autophagic flux and consequently prevented HEI-OC1 cell death.	Sirolimus	0-9	autophagy related 9A	Homo sapiens	82-87
34054807-9	2021	Pretreating the BV2 cells or mouse primary microglial cells with rapamycin blocked mTOR/HIF-1alpha activation and cellular metabolic reprogramming induced by BAFF training.	Sirolimus	65-74	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	158-162
34054807-10	2021	Consistently, rapamycin efficiently suppressed the trained immunity-like responses of microglia triggered by BAFF.	Sirolimus	14-23	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	109-113
34054807-15	2021	Rapamycin inhibits microglial priming triggered by BAFF through targeting the mTOR/HIF-1alpha signaling pathway.	Sirolimus	0-9	tumor necrosis factor (ligand) superfamily, member 13b	Mus musculus	51-55
33976205-4	2021	While Tanc2-null mice show embryonic lethality, Tanc2-haploinsufficient mice survive but display mTORC1/2 hyperactivity accompanying synaptic and behavioral deficits reversed by mTOR-inhibiting rapamycin.	Sirolimus	194-203	tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2	Mus musculus	48-53
35597502-2	2022	Sestrin2 content is involved in the function of mechanistic target of rapamycin complex 1 (mTORC1) in mouse embryonic fibroblasts and C2C12 cells.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	91-97
35585420-2	2022	The synthesis, uptake, and efflux of cellular cholesterol are significantly linked to the mammalian target of rapamycin complex-1 (mTORC1).	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
35579957-3	2022	Here, we showed that tissue inflammation-induced activation of the mammalian target of rapamycin complex 2 (mTORC2) triggers changes in the architecture of nociceptive terminals and leads to inflammatory pain.	Sirolimus	87-96	CREB regulated transcription coactivator 2	Mus musculus	108-114
35577782-8	2022	Intra-mPFC IGF-1 infusion also produced antidepressant-like effects in the LPS-challenged mice via mechanistic target of rapamycin complex 1 activation.	Sirolimus	121-130	insulin-like growth factor 1	Mus musculus	11-16
35589065-12	2022	Rapamycin restored the protein expression levels of beclin1, LC3-II/LC3-I and OCN, OPN, OSX under the high lactate conditions.	Sirolimus	0-9	TNF receptor superfamily member 11b	Homo sapiens	83-86
35589065-12	2022	Rapamycin restored the protein expression levels of beclin1, LC3-II/LC3-I and OCN, OPN, OSX under the high lactate conditions.	Sirolimus	0-9	Sp7 transcription factor	Homo sapiens	88-91
35573101-4	2022	The report shows some positive findings of TEK gene mutations and the efficacy of sirolimus treatment.	Sirolimus	82-91	TEK receptor tyrosine kinase	Homo sapiens	43-46
33976205-4	2021	While Tanc2-null mice show embryonic lethality, Tanc2-haploinsufficient mice survive but display mTORC1/2 hyperactivity accompanying synaptic and behavioral deficits reversed by mTOR-inhibiting rapamycin.	Sirolimus	194-203	CREB regulated transcription coactivator 2	Mus musculus	97-105
33734592-7	2021	Topical application of rapamycin improved clinical symptoms in rosacea patients, suggesting mTORC1 inhibition can serve as a novel therapeutic avenue for rosacea.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	92-98
33635313-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) integrates mitogenic and stress signals to control growth and metabolism.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
33742521-4	2021	mTORC1 activity showed the reciprocal pattern, with age-related increases blocked by Rapa, ACA, and 17aE2 (in males only).	Sirolimus	85-89	CREB regulated transcription coactivator 1	Mus musculus	0-6
33742521-5	2021	METTL3, required for addition of 6-methyl-adenosine to mRNA and thus a trigger for CIT, also showed an age-dependent increase blunted by Rapa, ACA, and 17aE2 (in males).	Sirolimus	137-141	methyltransferase like 3	Mus musculus	0-6
33930632-9	2021	Interestingly, we also detected that the addition of LY294002 and Rapamycin inhibited the PI3K/Akt pathway and the mTOR pathway, respectively, resulting in changes in both apoptosis and autophagy.	Sirolimus	66-75	AKT serine/threonine kinase 1	Bos taurus	95-98
35437883-8	2022	Further investigation uncovered that H19 also acted as an orchestra conductor that inhibited the function of mechanistic target of rapamycin complex 1 (mTORC1) by disrupting the interaction of mTORC1 with eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1).	Sirolimus	131-140	H19, imprinted maternally expressed transcript	Mus musculus	37-40
35437883-8	2022	Further investigation uncovered that H19 also acted as an orchestra conductor that inhibited the function of mechanistic target of rapamycin complex 1 (mTORC1) by disrupting the interaction of mTORC1 with eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1).	Sirolimus	131-140	CREB regulated transcription coactivator 1	Mus musculus	152-158
35437883-8	2022	Further investigation uncovered that H19 also acted as an orchestra conductor that inhibited the function of mechanistic target of rapamycin complex 1 (mTORC1) by disrupting the interaction of mTORC1 with eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1).	Sirolimus	131-140	CREB regulated transcription coactivator 1	Mus musculus	193-199
35142986-0	2022	Neuroprotective Effect of Lentivirus-Mediated FGF21 Gene Delivery in Experimental Alzheimer"s Disease is Augmented when Concerted with Rapamycin.	Sirolimus	135-144	fibroblast growth factor 21	Rattus norvegicus	46-51
35142986-9	2022	Moreover, FGF21 overexpressed rats treated with Rapamycin revamped the neuronal density as confirmed by histochemical, cresyl violet and immunofluorescence analysis.	Sirolimus	48-57	fibroblast growth factor 21	Rattus norvegicus	10-15
33930632-9	2021	Interestingly, we also detected that the addition of LY294002 and Rapamycin inhibited the PI3K/Akt pathway and the mTOR pathway, respectively, resulting in changes in both apoptosis and autophagy.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Bos taurus	115-119
33910229-7	2021	Consistent with these findings, the mTORC1 inhibitor Rapamycin effectively blocks CCM formation in mouse models.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	36-42
35293604-3	2022	Here, we define the role of intracellular zinc in axon formation and elongation, involving the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	136-142
35449295-8	2022	Consequently, abrogating the Akt-mTOR-autophagy signaling pathway abolishes CYLD-induced spine loss, whereas enhancing autophagy in vivo by the mTOR inhibitor rapamycin rescues the synaptic pruning and LTD deficits in mutant mice.	Sirolimus	159-168	CYLD lysine 63 deubiquitinase	Mus musculus	76-80
35483522-6	2022	Genetic deletion of the Tuberous sclerosis 1 gene in kidney glomerular podocytes activated mammalian target of rapamycin complex 1 signaling to rpS6 phosphorylation, resulting in podocyte hypertrophy and pathologic features similar to those of patients with FSGS including podocyte loss, leading to segmental glomerulosclerosis.	Sirolimus	111-120	ribosomal protein S6	Homo sapiens	144-148
33879610-3	2021	We show that IR preferentially stimulates phosphorylations associated with mammalian target of rapamycin complex 1 (mTORC1) and Akt pathways, whereas IGF1R preferentially stimulates phosphorylations on proteins associated with the Ras homolog family of guanosine triphosphate hydrolases (Rho GTPases), and cell cycle progression.	Sirolimus	95-104	insulin receptor	Homo sapiens	13-15
33879610-3	2021	We show that IR preferentially stimulates phosphorylations associated with mammalian target of rapamycin complex 1 (mTORC1) and Akt pathways, whereas IGF1R preferentially stimulates phosphorylations on proteins associated with the Ras homolog family of guanosine triphosphate hydrolases (Rho GTPases), and cell cycle progression.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	116-122
34027051-2	2021	Our recent study linked cyst(e)ine availability with glutathione peroxidase 4 (GPX4) protein synthesis and ferroptosis mitigation via a Rag-mechanistic target of rapamycin complex 1 (mTORC1) axis, and proposed that co-targeting mTORC1 and ferroptosis is a promising strategy for cancer therapy.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	228-234
33922083-7	2021	The mTORC1 inhibitor Sirolimus is the only FDA-approved drug to treat LAM.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
33922083-10	2021	New methods successfully implicated mTORC1 inhibitors, including Sirolimus, as capable of reverting the LAM transcriptional signatures.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	36-42
33881936-2	2021	The serine/threonine kinase, the mechanistic target of rapamycin complex 1 (mTORC1), also plays a fundamental role in the regulation of protein turnover and cell size, including in skeletal muscle, where mTORC1 is sufficient to increase protein synthesis and muscle fiber size, and is necessary for mechanical overload-induced muscle hypertrophy.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	76-82
33881936-2	2021	The serine/threonine kinase, the mechanistic target of rapamycin complex 1 (mTORC1), also plays a fundamental role in the regulation of protein turnover and cell size, including in skeletal muscle, where mTORC1 is sufficient to increase protein synthesis and muscle fiber size, and is necessary for mechanical overload-induced muscle hypertrophy.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	204-210
33881936-5	2021	Mechanical overload induced an increase in mTORC1 signalling, protein synthesis and muscle mass, and these were associated with rapamycin-sensitive increases in adenosylmethione decarboxylase 1 (Amd1), spermidine synthase (SpdSyn) and c-Myc.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	43-49
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	CREB regulated transcription coactivator 1	Mus musculus	204-210
33923449-8	2021	Rapamycin efficiently decreased mTORC1 activity of these TSC1-deficient cells in vitro.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	32-38
33368291-6	2021	Concordantly, loss of GPT2 results in an impairment of mechanistic target of rapamycin complex 1 (mTORC1) activity as well as the induction of autophagy.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	98-104
33876772-1	2021	The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals to regulate critical cellular processes such as mRNA translation, lipid biogenesis, and autophagy.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
35461323-8	2022	Electron microscopy analysis revealed that the number of lysosomes increased relative to that of MVBs and the level of EVs decreased after treatment with asteltoxin or rapamycin, an mTORC1 inhibitor.	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	182-188
35440545-4	2022	The mTORC1 inhibitor, rapamycin, is considered a potential CR mimetic and is proven to counteract age-related muscle loss.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	4-10
35436937-9	2022	Correspondingly, the expressions of Nrf2, Atm, Atr, and Prkdc in IVM oocytes were markedly increased, following the inhibition of mTORC1 pathway by 10 nM rapamycin.	Sirolimus	154-163	ataxia telangiectasia mutated	Mus musculus	42-45
35436937-9	2022	Correspondingly, the expressions of Nrf2, Atm, Atr, and Prkdc in IVM oocytes were markedly increased, following the inhibition of mTORC1 pathway by 10 nM rapamycin.	Sirolimus	154-163	protein kinase, DNA activated, catalytic polypeptide	Mus musculus	56-61
35436937-9	2022	Correspondingly, the expressions of Nrf2, Atm, Atr, and Prkdc in IVM oocytes were markedly increased, following the inhibition of mTORC1 pathway by 10 nM rapamycin.	Sirolimus	154-163	CREB regulated transcription coactivator 1	Mus musculus	130-136
35436937-11	2022	The inhibition of mTORC1 pathway, which involved in activating DDR-associated genes may act as a potential mechanism for oocyte quality improvement by rapamycin.	Sirolimus	151-160	CREB regulated transcription coactivator 1	Mus musculus	18-24
33852892-1	2021	The activation of cap-dependent translation in eukaryotes requires multisite, hierarchical phosphorylation of 4E-BP by the 1 MDa kinase mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	CREB regulated transcription coactivator 1	Mus musculus	177-183
33795781-6	2021	In the present investigation, a poly(D,L-lactic acid)-coated and rapamycin eluting (PDLLA/RAPA) JDBM BRS was prepared, and its biosafety and efficacy for coronary artery stenosis were evaluated via in vitro and in vivo experiments.	Sirolimus	65-74	transcriptional regulating factor 1	Homo sapiens	90-94
33791857-4	2021	Recent studies in budding yeast have identified novel roles for Ccr4-Not as a key regulator of core nutrient signaling pathways that control cell growth and proliferation, including signaling through the mechanistic target of rapamycin complex 1 (TORC1) pathway.	Sirolimus	226-235	CCR4-NOT core exoribonuclease subunit CCR4	Saccharomyces cerevisiae S288C	64-68
33977204-0	2021	Deletion of Rptor in Preosteoblasts Reveals a Role for the Mammalian Target of Rapamycin Complex 1 (mTORC1) Complex in Dietary-Induced Changes to Bone Mass and Glucose Homeostasis in Female Mice.	Sirolimus	79-88	regulatory associated protein of MTOR complex 1	Homo sapiens	12-17
33977204-0	2021	Deletion of Rptor in Preosteoblasts Reveals a Role for the Mammalian Target of Rapamycin Complex 1 (mTORC1) Complex in Dietary-Induced Changes to Bone Mass and Glucose Homeostasis in Female Mice.	Sirolimus	79-88	CREB regulated transcription coactivator 1	Mus musculus	100-106
33977204-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) complex is the major nutrient sensor in mammalian cells that responds to amino acids, energy levels, growth factors, and hormones, such as insulin, to control anabolic and catabolic processes.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
33744865-4	2021	We previously showed that myriocin, which impairs sphingolipid synthesis, increases lifespan in Saccharomyces cerevisiae by modulating signaling pathways including the target of rapamycin complex 1 (TORC1).	Sirolimus	178-187	CREB regulated transcription coactivator 1	Homo sapiens	199-204
33561653-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) signaling is the prototypical pathway regulating protein synthesis and cell proliferation.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33741392-6	2021	This excessive division could be completely blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	59-65
35427192-4	2022	Rapamycin treatment or starvation conditions induced slower electrophoretic mobility of Atg11 in an Atg1 kinase activity-dependent manner.	Sirolimus	0-9	unc-51 like autophagy activating kinase 1	Homo sapiens	100-104
33515593-4	2021	Inhibition of mTORC1 with rapamycin or knockdown of raptor, regulatory-associated protein of mTORC1, with shRNA dramatically rescued the cells from Bort-caused apoptosis.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	14-20
33656206-2	2021	The pharmacologically interesting mechanistic Target of Rapamycin Complex1 (mTORC1) is a central regulator of cellular growth and metabolism and a causative role has been attributed for a number of inflammatory pathologies such as psoriasis1,2 .	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	76-82
33347604-1	2021	BACKGROUND AND PURPOSE: Cannabidiol (CBD) has been shown to differentially regulate the mechanistic target of rapamycin complex 1 (mTORC1) in preclinical models of disease, where it reduces activity in models of epilepsies and cancer and increases it in models of multiple sclerosis (MS) and psychosis.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
33559185-3	2021	In this study, we examined whether intravitreal injection of TGF-beta1 into the mouse eye elicits senescence-like morphological alterations in the RPE and if this can be prevented by suppressing mammalian target of rapamycin complex 1 (mTORC1) or NADPH oxidase (NOX) signaling.	Sirolimus	215-224	transforming growth factor, beta 1	Mus musculus	61-70
35219732-4	2022	A detailed description of signaling pathways of mTORC1 and mTORC2 that are inhibited by rapamycin and other mTOR inhibitor analogues is accentuated.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	48-54
35219732-4	2022	A detailed description of signaling pathways of mTORC1 and mTORC2 that are inhibited by rapamycin and other mTOR inhibitor analogues is accentuated.	Sirolimus	88-97	CREB regulated transcription coactivator 2	Mus musculus	59-65
35420934-2	2022	The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
35420934-2	2022	The mechanistic target of rapamycin complex 1 (mTORC1) pathway is a potential therapeutic target, but conflicting interpretations have been proposed for how mTORC1 controls lipid homeostasis.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	157-163
35444643-7	2022	The combined effects of IL-4 and SP-A on the mTORC1 and GSK3 branches of PI3K-Akt signaling contribute to increased AM proliferation and alternative activation, as revealed by pharmacological inhibition of Akt (inhibitor VIII) and mTORC1 (rapamycin and torin).	Sirolimus	239-248	CREB regulated transcription coactivator 1	Mus musculus	45-51
35379807-1	2022	Activation of the cannabinoid-1 receptor (CB1R) and the mammalian target of rapamycin complex 1 (mTORC1) in the renal proximal tubular cells (RPTCs) contributes to the development of diabetic kidney disease (DKD).	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
35365781-7	2022	We further analyzed the changes in the expression of angiogenesis-associated genes in rapamycin-primed MSCs and found higher expression of several genes related to angiogenesis, such as VEGFR2 and CTGF/CCN2, in primed cells than in unprimed MSCs.	Sirolimus	86-95	cellular communication network factor 2	Homo sapiens	197-201
35365781-7	2022	We further analyzed the changes in the expression of angiogenesis-associated genes in rapamycin-primed MSCs and found higher expression of several genes related to angiogenesis, such as VEGFR2 and CTGF/CCN2, in primed cells than in unprimed MSCs.	Sirolimus	86-95	cellular communication network factor 2	Homo sapiens	202-206
35321881-6	2022	The MAPK and mammalian target of rapamycin complex 1 (mTORC1) axes, which are involved in TCR-mediated signaling, were also required for LcIL-2-mediated T cell response.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	54-60
33524531-3	2021	It is well established that REDD1 mediates the cellular response to a number of diverse stressors through repression of the central metabolic regulator known as mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	183-192	CREB regulated transcription coactivator 1	Mus musculus	204-210
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	147-153
32956517-7	2021	Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	177-183
33673489-3	2021	Thus, we investigated the influence of pre-treatment with rapamycin, an mTORC1 inhibitor, on the development of recognition memory deficits in adult rats that were neonatally exposed to ethanol.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	72-78
33279634-4	2021	Rapamycin (a selective mTORC1 inhibitor, 0.2 nmol/site, i.c.v.)	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	23-29
33708210-6	2021	Mechanistically, we unravel that IL-10 activates the mammalian target of rapamycin complex 1 (mTORC1) to regulate metabolic reprogramming in human NK cells.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	94-100
35358174-1	2022	Mechanistic target of rapamycin complex I (mTORC1) is central to cellular metabolic regulation.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
33679734-7	2021	More importantly, rapamycin (a specific mTORC1 inhibitor) significantly restored the expression of cell-junction proteins and exerted a protective effect on the BTB during UPEC infection.	Sirolimus	18-27	CREB regulated transcription coactivator 1	Mus musculus	40-46
33547375-1	2021	Rictor is a key component of the mammalian target of rapamycin complex 2 (mTORC2) and is required for Akt phosphorylation (Ser473).	Sirolimus	53-62	CREB regulated transcription coactivator 2	Mus musculus	74-80
33285244-4	2021	We used leucine and rapamycin to modulate mTORC1 activation and evaluate this effect on circadian rhythms.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	42-48
33285244-9	2021	Inhibition of liver mTORC1 by leucine or rapamycin led to low-amplitude circadian rhythms.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	20-26
33284085-10	2021	In H4IIE cells, expression of a 4E-BP1 variant that is unable to be phosphorylated by mTORC1 or suppression of mTORC1 with rapamycin attenuated activity of a luciferase reporter encoding the Rbp4 mRNA 5"-untranslated region (UTR).	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	111-117
32956825-6	2021	In addition, the expressions of IDH2 and SDHB were reduced by rapamycin.	Sirolimus	62-71	isocitrate dehydrogenase 2 (NADP+), mitochondrial	Mus musculus	32-36
35422798-6	2022	The aim of this study was to construct a Rapamycin-loaded MSC-sEVs delivery system (Rapa-sEVs) and investigate its therapeutic effect on EAU by subconjunctival injection.	Sirolimus	41-50	transcriptional regulating factor 1	Homo sapiens	84-88
35401560-6	2022	T-cell receptor (TCR), mechanistic target of rapamycin complex 1 (mTORC1), myelocytomatosis oncogene (MYC) signaling pathways and E2F6 might be "master regulators" of glycolytic activity.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
35368869-4	2022	While both MD and AA+MD increased phosphorylation of AMP-activated protein kinase (AMPK), the well-known autophagy promotor, only the combined treatment affected its downstream targets, mechanistic target of rapamycin complex 1 (mTORC1), Unc 51-like kinase 1 (ULK1), and increased the expression of several autophagy-related genes.	Sirolimus	208-217	CREB regulated transcription coactivator 1	Mus musculus	229-235
35275792-4	2022	This study suggests that chronic activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway in degenerating photoreceptor neurons could stimulate the degradation of ubiquitinated proteins and enhance proteasomal activity through phosphorylation.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	92-98
35330555-20	2022	The mechanism may be related to the effect of rapamycin on inhibiting TGF-beta1 and Smad3 expression and promoting MMP1 expression in urethral tissues.	Sirolimus	46-55	mothers against decapentaplegic homolog 3	Oryctolagus cuniculus	84-89
35330555-20	2022	The mechanism may be related to the effect of rapamycin on inhibiting TGF-beta1 and Smad3 expression and promoting MMP1 expression in urethral tissues.	Sirolimus	46-55	interstitial collagenase	Oryctolagus cuniculus	115-119
35238644-3	2022	We previously demonstrated the efficacy of sirolimus in ARHL in mice by decreasing mTORC1.	Sirolimus	43-52	CREB regulated transcription coactivator 1	Mus musculus	83-89
35238644-5	2022	Herein, based on pharmacological and genetic interventions, we found that a high dose of sirolimus resulted in severe hearing loss by reducing the mTORC2/AKT signaling pathway in the cochlea.	Sirolimus	89-98	CREB regulated transcription coactivator 2	Mus musculus	147-153
32956825-6	2021	In addition, the expressions of IDH2 and SDHB were reduced by rapamycin.	Sirolimus	62-71	succinate dehydrogenase complex, subunit B, iron sulfur (Ip)	Mus musculus	41-45
33665645-2	2021	Inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) has been shown to delay or reverse many age-related phenotypes, including declining immune function.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	61-67
33665645-3	2021	Rapamycin (sirolimus) and rapamycin derivatives are US Food and Drug Administration-approved inhibitors of mTORC1 with broad clinical utility and well established dosing and safety profiles.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	107-113
33665645-3	2021	Rapamycin (sirolimus) and rapamycin derivatives are US Food and Drug Administration-approved inhibitors of mTORC1 with broad clinical utility and well established dosing and safety profiles.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	107-113
33665645-3	2021	Rapamycin (sirolimus) and rapamycin derivatives are US Food and Drug Administration-approved inhibitors of mTORC1 with broad clinical utility and well established dosing and safety profiles.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	107-113
33565716-9	2021	Interestingly, administration of rapamycin or miR-138-5p mimics apparently antagonized the effects of UCA1 on AKT and mTOR activation.	Sirolimus	33-42	urothelial cancer associated 1	Homo sapiens	102-106
33503424-5	2021	Using metabolomic and lipidomic profiling, cellular response to PHGDH inhibition is identified as accumulation of unsaturated lipids, branched chain amino acids, and methionine cycle intermediates, leading to activation of pro-survival mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	256-265	phosphoglycerate dehydrogenase	Homo sapiens	64-69
35309056-9	2022	Moreover, LY294002 and rapamycin promoted expression of autophagy-related proteins LC3-II/I, p62, and beclin-1.	Sirolimus	23-32	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	93-96
35309056-9	2022	Moreover, LY294002 and rapamycin promoted expression of autophagy-related proteins LC3-II/I, p62, and beclin-1.	Sirolimus	23-32	beclin 1	Rattus norvegicus	102-110
35165201-2	2022	NPRL2 is a requisite subunit of the Gap Activity TOward Rags 1 (GATOR1) complex, which functions as a negative regulator of mammalian Target Of Rapamycin Complex 1 (mTORC1) kinase when intracellular amino acids are low.	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	165-171
35165201-7	2022	Targeted deletion of NPRL2 in primary neurons increases the expression of sodium channel Scn1A, whereas treatment with the pharmacological mTORC1 inhibitor called rapamycin prevents Scn1A upregulation.	Sirolimus	163-172	sodium voltage-gated channel alpha subunit 1	Homo sapiens	89-94
35235244-9	2022	Rapamycin treatment resulted in significant increase in Beclin-1 and LC3-II levels and further aggravation of alveolar tissue damage, while 3-MA treatment led to opposite effects.	Sirolimus	0-9	beclin 1	Rattus norvegicus	56-64
35235244-9	2022	Rapamycin treatment resulted in significant increase in Beclin-1 and LC3-II levels and further aggravation of alveolar tissue damage, while 3-MA treatment led to opposite effects.	Sirolimus	0-9	annexin A3	Rattus norvegicus	69-72
35235777-6	2022	Rather, loss of Slc6a8 or Ckb disrupts naive T cell homeostasis and weakens TCR-mediated activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling required for CD8+ T cell expansion.	Sirolimus	125-134	CREB regulated transcription coactivator 1	Mus musculus	146-152
35059731-8	2022	Sirolimus induces the expression of fetal hemoglobin (and this may contribute to the amelioration of the clinical parameters of patients with beta-thalassemia) and induces autophagy (thereby reducing the excessive levels of alpha-globin).	Sirolimus	0-9	hemoglobin subunit alpha 2	Homo sapiens	224-236
33503424-5	2021	Using metabolomic and lipidomic profiling, cellular response to PHGDH inhibition is identified as accumulation of unsaturated lipids, branched chain amino acids, and methionine cycle intermediates, leading to activation of pro-survival mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	256-265	CREB regulated transcription coactivator 1	Mus musculus	277-283
33307091-1	2021	The Tuberous Sclerosis Complex (TSC) protein complex (TSCC), comprising TSC1, TSC2, and TBC1D7, is widely recognised as a key integration hub for cell growth and intracellular stress signals upstream of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	248-254
33527023-1	2021	The present study aimed to investigate the role of mammalian target of rapamycin complex 1 (mTORC1) in the remodeling of the condyle subchondral bone in rats with temporomandibular joint osteoarthritis (TMJ OA) and explore the mechanisms involved.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	92-98
35196486-5	2022	Molecular analyses reveal that loss of Slc38a4 imprinting leads to over-activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway in cloned placentae, which is likely due to the increased amino acids transport by SLC38A4.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	133-139
35169271-7	2022	Preadministration of rapamycin eliminated the repressive effect of ghrelin, while Gsk3 inhibitors failed to mimic ghrelin"s effect.	Sirolimus	21-30	ghrelin and obestatin prepropeptide	Rattus norvegicus	67-74
35215987-6	2022	Moreover, K205R inhibited the serine/threonine kinase 1 and the mechanistic target of the rapamycin kinase signaling pathway, thereby activating unc-51 like autophagy activating kinase 1, and hence autophagy.	Sirolimus	90-99	pK205R	African swine fever virus	10-15
35215987-6	2022	Moreover, K205R inhibited the serine/threonine kinase 1 and the mechanistic target of the rapamycin kinase signaling pathway, thereby activating unc-51 like autophagy activating kinase 1, and hence autophagy.	Sirolimus	90-99	unc-51 like autophagy activating kinase 1	Homo sapiens	145-186
33527023-10	2021	The mTORC1 pathway was inhibited by a local injection of rapamycin, and the number of osteoblasts and mRNA levels of osteogenic markers in the condyle subchondral bone decreased, but the number of osteoclasts was basically unchanged.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Mus musculus	4-10
33189863-4	2021	It activated mammalian target of rapamycin complex 1 (mTORC1) and suppressed autophagy in glomeruli of fructose-fed rats and in fructose-exposed conditionally immortalized human podocytes (HPCs).	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	54-60
33442914-5	2022	Akt acts by activating mechanistic target of rapamycin complex 1 (mTORC1) and by arresting autophagic gene expression.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
33597869-2	2020	Antigen-induced T-cell proliferation via mTORC1 suppressed by Rapamycin has been used to improve SLE primarily.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	41-47
33428109-9	2021	The mTOR inhibitor rapamycin mitigated TGF-beta-induced expression of p21, p16, and DNA damage foci and improved replicative potential of preadipocytes, supporting the cell-specific response to this cytokine.	Sirolimus	19-28	transforming growth factor alpha	Homo sapiens	39-47
34034560-3	2021	The present study was designed to observe the role of rapamycin in MC proliferation and to explore the mechanism by which rapamycin acts on Akt and MAPK/ERK1/2 pathways in mesangial cells.	Sirolimus	122-131	mitogen activated protein kinase 3	Rattus norvegicus	153-159
34034560-9	2021	Moreover, our results revealed that 1000 nmol/L rapamycin led to Raf1-MEK1/2-ERK pathway activation through a p70S6K-PI3K-mediated feedback loop in MCs.	Sirolimus	48-57	Raf-1 proto-oncogene, serine/threonine kinase	Rattus norvegicus	65-69
34034560-9	2021	Moreover, our results revealed that 1000 nmol/L rapamycin led to Raf1-MEK1/2-ERK pathway activation through a p70S6K-PI3K-mediated feedback loop in MCs.	Sirolimus	48-57	mitogen activated protein kinase kinase 1	Rattus norvegicus	70-76
34034560-10	2021	This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation.	Sirolimus	39-48	mitogen activated protein kinase 3	Rattus norvegicus	58-64
34034560-10	2021	This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation.	Sirolimus	168-177	mitogen activated protein kinase 3	Rattus norvegicus	58-64
32583421-7	2021	Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARalpha, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells.	Sirolimus	149-158	CREB regulated transcription coactivator 1	Mus musculus	184-190
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Bos taurus	93-97
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Bos taurus	99-104
33141044-11	2021	The combination of rapamycin and AZD3463 (AZD-RAPA) was determined as an additive according to isobologram analysis.	Sirolimus	19-28	transcriptional regulating factor 1	Homo sapiens	46-50
33141044-12	2021	In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases.	Sirolimus	22-31	protein kinase C beta	Homo sapiens	132-137
35224490-1	2022	The p70 ribosomal S6 kinases (p70 ribosomal S6 kinase 1 and p70 ribosomal S6 kinase 2) are downstream targets of the mechanistic target of rapamycin signalling pathway.	Sirolimus	139-148	interleukin 2 receptor, beta chain	Mus musculus	4-7
33378666-1	2020	The mechanistic target of rapamycin complex 2 (mTORC2) controls cell metabolism and survival in response to environmental inputs.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	47-53
35136019-2	2022	Vertebrate retinal development involves a delicate and coordinated process of retinal progenitor cell (RPC) differentiation, and the mammalian target of rapamycin complex 1 (mTORC1) has been reported to play a significant role in this complex process.	Sirolimus	153-162	CREB regulated transcription coactivator 1	Mus musculus	174-180
33375025-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) integrates signals from growth factors and nutrients to control biosynthetic processes, including protein, lipid, and nucleic acid synthesis.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
35135573-12	2022	Abnormal lipid accumulation, changes of gene expression profile and upregulation of multi-component mechanistic target of rapamycin complex 1 (mTOR)/Peroxisome proliferator-activated receptor-gamma pathway was observed in liver, accompanied with decreased bile acids level, unsaturated fatty acids androgens and prostaglandins in serum.	Sirolimus	122-131	peroxisome proliferator activated receptor gamma	Mus musculus	149-197
33299044-6	2020	Furthermore, the suppression of Fgf23 expression by PTEN knockdown or insulin simulation in UMR106 cells was partially restored by the treatment with the mTORC1 inhibitor, rapamycin.	Sirolimus	172-181	fibroblast growth factor 23	Rattus norvegicus	32-37
35108047-3	2022	To endow HMs with the ability to form self-renewable hydration layers and maintain cellular homeostasis, rapamycin-liposome-incorporating hyaluronic acid-based HMs (RAPA@Lipo@HMs) were created using microfluidic technology and photopolymerization processes.	Sirolimus	105-114	transcriptional regulating factor 1	Homo sapiens	165-169
35187108-8	2021	Combined with intraperitoneal injection of rapamycin, the effect of autophagy on AOPP-induced p53 SUMOylation was also confirmed in vivo.	Sirolimus	43-52	peroxiredoxin 5	Mus musculus	81-85
35134872-10	2022	Further studies showed that L-arginine, a GPRC6A agonist, promoted colonic ILC3 expansion and function via mammalian target of rapamycin complex 1 (mTORC1) signalling in vitro.	Sirolimus	127-136	CREB regulated transcription coactivator 1	Mus musculus	148-154
35044284-0	2022	RAS protein activator like 2 promotes the proliferation and migration of pulmonary artery smooth muscle cell through AKT/mammalian target of Rapamycin complex 1 pathway in pulmonary hypertension.	Sirolimus	141-150	RAS protein activator like 2	Homo sapiens	0-28
35044284-6	2022	Mechanistically, we found elevated phosphorylation of AKT and two downstream effectors of mammalian target of Rapamycin complex 1 (mTORC1), S6 and 4E-Binding Protein 1 (4EBP1) after Rasal2 overexpression in hypoxia-challenged PASMC.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
33299044-6	2020	Furthermore, the suppression of Fgf23 expression by PTEN knockdown or insulin simulation in UMR106 cells was partially restored by the treatment with the mTORC1 inhibitor, rapamycin.	Sirolimus	172-181	CREB regulated transcription coactivator 1	Mus musculus	154-160
33227845-1	2020	Background: Sestrin2 (Sesn2) is involved in the maintenance of metabolic homeostasis and aging via modulation of the 5" AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) pathway.	Sirolimus	169-178	sestrin 2	Homo sapiens	12-20
35163619-1	2022	Classically activated M1 macrophages reprogram their metabolism towards enhanced glycolysis to obtain energy and produce pro-inflammatory cytokines after activation by mammalian target of rapamycin complex 1 (mTORC1) and hypoxia-inducible factor (HIF)-1alpha.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	209-215
34998548-14	2022	Compared with the control, the 5 nM rapamycin treatment upregulated the abundance of ATGL, the ratio of p-HSL to HSL and LC3-II to LC3-I, and the glycerol content, whereas it downregulated the abundance of PLIN1 and p62 in calf adipocytes.	Sirolimus	36-45	patatin like phospholipase domain containing 2	Bos taurus	85-89
32722876-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) functions as regulating different cellular processes, including cell growth, proliferation, motility, survival, metabolism, autophagy, and protein transcription.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
35171658-1	2022	PURPOSE: Sapanisertib is a kinase inhibitor that inhibits both mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
33222863-1	2020	Different models of lactation offer conflicting evidence as to whether insulin signaling is required for AA to stimulate mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	164-170
35174167-4	2021	ARHGEF3 also binds the mammalian target of rapamycin complex 2 (mTORC2) and subsequently inhibits mTORC2 and Akt.	Sirolimus	43-52	CREB regulated transcription coactivator 2	Mus musculus	64-70
35174167-4	2021	ARHGEF3 also binds the mammalian target of rapamycin complex 2 (mTORC2) and subsequently inhibits mTORC2 and Akt.	Sirolimus	43-52	CREB regulated transcription coactivator 2	Mus musculus	98-104
35159256-0	2022	PROX1, a Key Mediator of the Anti-Proliferative Effect of Rapamycin on Hepatocellular Carcinoma Cells.	Sirolimus	58-67	prospero homeobox 1	Homo sapiens	0-5
32393842-5	2020	Among patients receiving tacrolimus/sirolimus, nivolumab-exposed patients had a higher incidence of severe aGVHD and a more effector T-cell profile compared with anti-PD-1-naive patients.	Sirolimus	36-45	programmed cell death 1	Homo sapiens	167-171
35159256-5	2022	Interestingly, rapamycin increased Prospero-related homeobox 1 (PROX1) expression at the protein level, but did not affect its transcript in Huh7 as well as Hep3B cells.	Sirolimus	15-24	prospero homeobox 1	Homo sapiens	35-62
35159256-5	2022	Interestingly, rapamycin increased Prospero-related homeobox 1 (PROX1) expression at the protein level, but did not affect its transcript in Huh7 as well as Hep3B cells.	Sirolimus	15-24	prospero homeobox 1	Homo sapiens	64-69
35159256-6	2022	Moreover, immunoprecipitation assays showed that PROX1 ubiquitination was downregulated by rapamycin.	Sirolimus	91-100	prospero homeobox 1	Homo sapiens	49-54
35159256-8	2022	The effect of PROX1 over-expression on the sensitivity to rapamycin was not synergistic, but the effect of MTOR inhibition on cell proliferation was diminished by PROX1 siRNA.	Sirolimus	58-67	prospero homeobox 1	Homo sapiens	14-19
35159256-8	2022	The effect of PROX1 over-expression on the sensitivity to rapamycin was not synergistic, but the effect of MTOR inhibition on cell proliferation was diminished by PROX1 siRNA.	Sirolimus	58-67	prospero homeobox 1	Homo sapiens	163-168
35159256-10	2022	The xenograft volume was decreased and PROX1 expression was increased by rapamycin.	Sirolimus	73-82	prospero homeobox 1	Mus musculus	39-44
35159256-11	2022	These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.	Sirolimus	87-96	prospero homeobox 1	Mus musculus	28-33
35159256-11	2022	These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.	Sirolimus	87-96	prospero homeobox 1	Mus musculus	128-133
35159256-11	2022	These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.	Sirolimus	236-245	prospero homeobox 1	Mus musculus	28-33
35159256-11	2022	These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.	Sirolimus	236-245	prospero homeobox 1	Mus musculus	128-133
35125916-3	2022	The mechanistic target of rapamycin complex 1 (mTORC1) is a central regulator of protein metabolism in cells.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
35128865-1	2022	OBJECTIVE: To investigate the effects of electroacupuncture (EA) on the expression of related proteins in the brain-derived neurotrophic factor (BDNF)/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and synapse-associated proteins and the density of dendrite spines in the prefrontal cortex (PFC) of depression model rats, and to reveal the underlying mechanism by which EA regulates the synaptic plasticity to improve depressive symptoms.	Sirolimus	171-180	CREB regulated transcription coactivator 1	Mus musculus	192-198
33174028-0	2020	S100A8 and S100A9 promote endothelial cell activation through the RAGE-mediated mammalian target of rapamycin complex 2 pathway.	Sirolimus	100-109	S100 calcium binding protein A8	Homo sapiens	0-6
33174028-13	2020	Furthermore, depleting expression of RAGE or mTORC2 protein components (rapamycin-insensitive companion of mTOR) by small interfering RNA was found to reduce the cell viability, migration and angiogenesis of S100A8/9-treated HUVECs.	Sirolimus	72-81	CREB regulated transcription coactivator 2	Mus musculus	45-51
33174028-13	2020	Furthermore, depleting expression of RAGE or mTORC2 protein components (rapamycin-insensitive companion of mTOR) by small interfering RNA was found to reduce the cell viability, migration and angiogenesis of S100A8/9-treated HUVECs.	Sirolimus	72-81	S100 calcium binding protein A8	Homo sapiens	208-216
33243998-4	2020	Mechanistically, ISO inhibits AKT as well as, downstream of AKT, the mechanistic target of rapamycin complex 1 (mTORC1), coupled to the activation of the pro-autophagic transcription factors EB (TFEB) and E3 (TFE3).	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
33238127-6	2020	However, conventional type 2 dendritic cells (cDC2) and T cell functions of mammalian target of rapamycin complex 1 (mTORC1) increase effector precursor induction while decreasing the proportion of T cells that can become peripheral Foxp3+ regulatory T (pTreg) cells.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	117-123
34989232-8	2022	Furthermore, the PSTPP strategy was successfully applied to analyze the binding targets of rapamycin, identifying the well-known targets, FKBP1A, as well as revealing a few other potential targets.	Sirolimus	91-100	FKBP prolyl isomerase 1A	Homo sapiens	138-144
35159680-10	2022	Repeated dosing of rapamycin PFC nanoparticles did not affect overall spleen T cell proliferation and responses to stimulation, although it significantly decreased the number of Foxp3+CD4+ T cells and NK1.1+ cells were observed.	Sirolimus	19-28	forkhead box P3	Homo sapiens	178-183
35022234-2	2022	Amino acid and growth factor signaling pathways coordinately regulate the mechanistic target of rapamycin complex 1 (mTORC1) kinase in cell growth and organ development.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	117-123
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	chemokine (C-X-C motif) ligand 10	Mus musculus	165-172
33238127-6	2020	However, conventional type 2 dendritic cells (cDC2) and T cell functions of mammalian target of rapamycin complex 1 (mTORC1) increase effector precursor induction while decreasing the proportion of T cells that can become peripheral Foxp3+ regulatory T (pTreg) cells.	Sirolimus	96-105	forkhead box P3	Homo sapiens	233-238
32878988-12	2020	Pretreating cells with mTORC1 inhibitor rapamycin restored BCKAs effect on insulin-induced AKT phosphorylation.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	23-29
33187130-3	2020	The mammalian target of Rapamycin Complex 1 (mTORC1) is a major functional axis regulating various aspects of cellular growth and metabolism.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
34979914-2	2022	Sesns regulate metabolism mainly through activation of the key energy sensor AMP-dependent protein kinase (AMPK) and inhibition of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	151-160	CREB regulated transcription coactivator 1	Mus musculus	172-178
35240344-3	2022	Downstream of insulin signaling, the mechanistic target of rapamycin complex 1 (mTORC1), is a key regulator of lipid metabolism.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	80-86
35038970-0	2022	PSAT1 gene as a biomarker for targeting triple negative breast cancer in presence of Rapamycin.	Sirolimus	85-94	phosphoserine aminotransferase 1	Homo sapiens	0-5
35038970-6	2022	The outcomes showed that the expression of the decreased gene by Rapamycin among other drugs increased in TNBC subtype compared to the other two subtypes including triple-positive and ER+/PR+.	Sirolimus	65-74	epiregulin	Homo sapiens	184-186
35038970-7	2022	The expression of PSAT1 in TNBC group was significant higher than normal and other subtypes (p <= 0.0001), and was introduced as a biomarker in TNBC that its expression was down-regulated by Rapamycin based on in silico studies.	Sirolimus	191-200	phosphoserine aminotransferase 1	Homo sapiens	18-23
35038970-9	2022	Moreover, RT-qPCR revealed PSAT1 expression more decreased under Rapamycin-treatment in TNBC cells compared to ER + PR + cells.	Sirolimus	65-74	phosphoserine aminotransferase 1	Homo sapiens	27-32
35005610-4	2022	Hypoxia also represses all early signaling responses associated with YM155, including activation of AMPK and retinoblastoma protein (Rb), inactivation of the mechanistic target of rapamycin complex 1 (mTORC1), inhibition of phospho-ribosomal protein S6 (rS6), and suppression of the expression of Cyclin Ds, Mcl-1 and Survivin.	Sirolimus	180-189	CREB regulated transcription coactivator 1	Mus musculus	201-207
33872697-1	2021	Activation of the protein kinase mechanistic target of rapamycin (mTOR) in both complexes 1 and 2 (mTORC1/2) in the liver is repressed during fasting and rapidly stimulated in response to a meal.	Sirolimus	55-64	CREB regulated transcription coactivator 2	Mus musculus	99-107
33269476-2	2021	Although the critical effect of mechanistic target of rapamycin complex 1 (mTORC1) in shaping mTEC differentiation has been studied, the regulatory role of mTORC2 in the differentiation and maturation of mTECs is poorly understood.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	75-81
34045438-5	2021	mTORC1 inhibitors Rapamycin and Everolimus block cystine-induced cancer cell proliferation.	Sirolimus	18-27	CREB regulated transcription coactivator 1	Mus musculus	0-6
34021461-10	2021	Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells.	Sirolimus	105-114	indoleamine 2,3-dioxygenase 1	Rattus norvegicus	139-143
33224946-10	2020	Systemic inhibition of VAMP3 and SNAP23 by treatment of mice with rapamycin significantly ameliorated the FeCl3-induced thrombogenesis, whereas intraluminal overexpression of VAMP3 and SNAP23 aggravated it.	Sirolimus	66-75	synaptosomal-associated protein 23	Mus musculus	33-39
34003330-7	2021	Mechanistically, LKB1 directly binds and phosphorylates phosphatase and tensin homolog (PTEN), an upstream regulator of mammalian target of rapamycin complex 1 (mTORC1), which is independent of AMP-activated protein kinase (AMPK).	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	161-167
33157014-1	2020	Amino-acid-induced lysosomal mechanistic target of rapamycin complex 1 (mTORC1) localization through the Rag GTPases is a critical step for its activation by Rheb GTPase.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	72-78
33313107-9	2020	Rapamycin increased LC3-II/LC3-I and beclin-1 expression, and decreased p62 expression, gentamicin had no effect on their expression of autophagy markers.	Sirolimus	0-9	beclin 1	Rattus norvegicus	37-45
33313107-9	2020	Rapamycin increased LC3-II/LC3-I and beclin-1 expression, and decreased p62 expression, gentamicin had no effect on their expression of autophagy markers.	Sirolimus	0-9	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	72-75
31738412-19	2020	Specifically, the results show an essential role of a highly innovative STAT3-miR-17-92-mTOR signaling axis in cardioprotection in diabetes, which may have potential clinical relevance in preventing I/R injury in diabetics because RAPA has relatively mild side effects at low dose.	Sirolimus	231-235	Mir17 host gene (non-protein coding)	Mus musculus	78-87
32977361-12	2020	Meanwhile, the oncogenic effect of BUB1B will be impaired when the mTORC1 signaling pathway was inhibited by rapamycin.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	67-73
33988249-1	2021	The mammalian target of rapamycin complex 1 (mTORC1) integrates nutrients, growth factors, stress, and energy status to regulate cell growth and metabolism.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
33988501-3	2021	Here we show that inhibition of mTORC1 by the lifespan-extending drug rapamycin increases expression of histones H3 and H4 post-transcriptionally, through eIF3-mediated translation.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	32-38
33988501-7	2021	In mice, rapamycin treatment increases expression of histone proteins and Wdfy3 transcription, and alters chromatin organisation in the small intestine, suggesting the mTORC1-histone axis is at least partially conserved in mammals and may offer new targets for anti-ageing interventions.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	168-174
32567791-1	2020	BACKGROUND: Recently, insulin-like growth factor-1 (IGF-1), forkhead box transcription factor (Fox) O1, and mechanistic target of rapamycin complex 1 (mTORC1) signalling have been introduced as key elements in acne pathogenesis.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	151-157
33992580-7	2021	Mechanistically, overexpression of ZNRF2 inhibited the over-induction of autophagy induced by OGD/R which was abolished by mTORC1 inhibitor rapamycin.	Sirolimus	140-149	zinc and ring finger 2	Rattus norvegicus	35-40
33992580-7	2021	Mechanistically, overexpression of ZNRF2 inhibited the over-induction of autophagy induced by OGD/R which was abolished by mTORC1 inhibitor rapamycin.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	123-129
32871684-1	2020	BACKGROUND: Recent studies have suggested the role of mammalian target of rapamycin complex 1 (mTORC1) in the pathophysiology of depression.	Sirolimus	74-83	CREB regulated transcription coactivator 1	Mus musculus	95-101
33740659-1	2021	The degradation of nucleolar proteins - nucleophagy - is elicited by nutrient starvation or the inactivation of target of rapamycin complex 1 (TORC1) protein kinase in budding yeast.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Homo sapiens	143-148
33938445-4	2021	Using functional assays, we show that MIR4435-2HG directly influenced the metabolic state of mDCs, likely through epigenetic mechanisms involving H3K27ac enrichment at an intronic enhancer in the RPTOR gene locus, the main component of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	260-269	regulatory associated protein of MTOR complex 1	Homo sapiens	196-201
33571703-3	2021	It is the intention of this review to delineate potential molecular aging mechanisms related to the intake of non-fermented milk versus yogurt on the basis of mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	181-190	CREB regulated transcription coactivator 1	Mus musculus	202-208
33444645-1	2021	Endocytosis plays an important role in the immune defence systems of invertebrates through the interaction between the mechanical target of rapamycin complex 2 (mTORC2) and the AGC kinase family.	Sirolimus	140-149	CREB regulated transcription coactivator 2	Mus musculus	161-167
32871684-7	2020	RESULT: Our results showed that the decreasing effects of CUMS and CSDS on the mTORC1 signaling cascade in the hippocampus and mPFC were restored by venlafaxine, and the use of rapamycin, LY294002, U0126 and mTORC1-shRNA fully abolished the anti-stress actions of venlafaxine in mice.	Sirolimus	177-186	CREB regulated transcription coactivator 1	Mus musculus	79-85
32901865-3	2020	Proline rich polypeptide 1 (PRP-1), which is a 15-amino acid inhibitor of mammalian target of rapamycin complex-1 (mTORC1), has been indicated to exert cytostatic and immunomodulatory properties in human chondrosarcoma cells in a monolayer.	Sirolimus	94-103	CREB regulated transcription coactivator 1	Mus musculus	115-121
33145347-11	2020	Taken together, these results indicate that rapamycin enhances the chondrogenesis of SMSCs by inducing autophagy, and GSK3beta may be an important regulator in the process of rapamycin-induced autophagy.	Sirolimus	175-184	glycogen synthase kinase 3 alpha	Homo sapiens	118-126
33082544-4	2020	By using both molecular and theoretical biological techniques, here we reveal that a delayed negative feedback loop between active AMPK and ULK1 is essential to manage a proper cellular answer after prolonged starvation or rapamycin addition.	Sirolimus	223-232	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	131-135
33991444-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) plays a central role in muscle protein synthesis and repeated bouts of resistance exercise (RE) blunt mTORC1 activation.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
33991444-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) plays a central role in muscle protein synthesis and repeated bouts of resistance exercise (RE) blunt mTORC1 activation.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	153-159
33910001-1	2021	Leucyl-tRNA synthetase 1 (LARS1) mediates activation of leucine-dependent mechanistic target of rapamycin complex 1 (mTORC1) as well as ligation of leucine to its cognate tRNAs, yet its mechanism of leucine sensing is poorly understood.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	117-123
33910008-1	2021	Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	103-109
33910008-1	2021	Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	148-154
33903099-6	2021	Rapamycin and its analogs only partially inhibit mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	49-55
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	119-123
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	182-186
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	CREB regulated transcription coactivator 1	Mus musculus	348-354
33912444-11	2021	Moreover, rapamycin, an inhibitor of mTOR complex 1 (mTORC1), downregulated BCRP expression and enhanced the effects of particular drugs, including doxorubicin and paclitaxel.	Sirolimus	10-19	CREB regulated transcription coactivator 1	Mus musculus	53-59
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	72-78
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	204-210
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	204-210
33476693-8	2021	Although a disruption of the mechanistic target of rapamycin complex 1 (mTORC1) pathway by niclosamide was previously hypothesized as a mechanism against pH-independent viruses like RSV, using a chemical mTORC1 inhibitor, temsirolimus, and a chemical mTORC1 agonist, MHY1485 (MHY), we show here that the mechanism of RSV inhibition by niclosamide was mTORC1 independent.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	204-210
33471625-1	2021	Disuse-induced muscle atrophy is accompanied by a blunted postprandial response of the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	128-134
33082544-4	2020	By using both molecular and theoretical biological techniques, here we reveal that a delayed negative feedback loop between active AMPK and ULK1 is essential to manage a proper cellular answer after prolonged starvation or rapamycin addition.	Sirolimus	223-232	unc-51 like autophagy activating kinase 1	Homo sapiens	140-144
32798557-10	2020	Moreover, Rapamycin could inhibit the phosphorylation of mTOR/p70S6K pathway-associated proteins, activate autophagy and increase the levels of LC3 and Beclin1.	Sirolimus	10-19	annexin A3	Rattus norvegicus	144-147
32798557-10	2020	Moreover, Rapamycin could inhibit the phosphorylation of mTOR/p70S6K pathway-associated proteins, activate autophagy and increase the levels of LC3 and Beclin1.	Sirolimus	10-19	beclin 1	Rattus norvegicus	152-159
32460327-1	2020	The two primary molecular regulators of lifespan are sirtuin-1 (SIRT1) and mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	116-122
32905798-5	2020	HFSC fate reversibility and glutamine metabolism are regulated by the mammalian target of rapamycin complex 2 (mTORC2)-Akt signaling axis within the niche.	Sirolimus	90-99	CREB regulated transcription coactivator 2	Mus musculus	111-117
31884871-11	2020	Thus, our studies discover the TGFB-INHB/activin-mediated inhibition of TORC2 as a novel mechanism for age-dependent decreases in autophagic activity and cardiac health.Abbreviations: AI: arrhythmia index; BafA1: bafilomycin A1; BMP: bone morphogenetic protein; CQ: chloroquine; CVD: cardiovascular diseases; DI: diastolic interval; ER: endoplasmic reticulum; HP: heart period; HR: heart rate; MTOR: mechanistic target of rapamycin kinase; NGS: normal goat serum; PBST: PBS with 0.1% Triton X-100; PDPK1: 3-phosphoinositide dependent protein kinase 1; RICTOR: RPTOR independent companion of MTOR complex 2; ROI: region of interest; ROUT: robust regression and outlier removal; ROS: reactive oxygen species; R-SMAD: receptor-activated SMAD; SI: systolic interval; SOHA: semi-automatic optical heartbeat analysis; TGFB: transformation growth factor beta; TSC1: TSC complex subunit 1.	Sirolimus	422-431	glass bottom boat	Drosophila melanogaster	31-35
31884871-11	2020	Thus, our studies discover the TGFB-INHB/activin-mediated inhibition of TORC2 as a novel mechanism for age-dependent decreases in autophagic activity and cardiac health.Abbreviations: AI: arrhythmia index; BafA1: bafilomycin A1; BMP: bone morphogenetic protein; CQ: chloroquine; CVD: cardiovascular diseases; DI: diastolic interval; ER: endoplasmic reticulum; HP: heart period; HR: heart rate; MTOR: mechanistic target of rapamycin kinase; NGS: normal goat serum; PBST: PBS with 0.1% Triton X-100; PDPK1: 3-phosphoinositide dependent protein kinase 1; RICTOR: RPTOR independent companion of MTOR complex 2; ROI: region of interest; ROUT: robust regression and outlier removal; ROS: reactive oxygen species; R-SMAD: receptor-activated SMAD; SI: systolic interval; SOHA: semi-automatic optical heartbeat analysis; TGFB: transformation growth factor beta; TSC1: TSC complex subunit 1.	Sirolimus	422-431	Activin-beta	Drosophila melanogaster	41-48
32488849-11	2020	Furthermore, we found that focal adhesion kinase (FAK) activation decreased in response to ascofuranone, rapamycin, compound C and wortmannin treatment.	Sirolimus	105-114	protein tyrosine kinase 2	Homo sapiens	27-48
32488849-11	2020	Furthermore, we found that focal adhesion kinase (FAK) activation decreased in response to ascofuranone, rapamycin, compound C and wortmannin treatment.	Sirolimus	105-114	protein tyrosine kinase 2	Homo sapiens	50-53
32761379-4	2020	The identification of TSC1 and TSC2, as tumor suppressor genes causative of the disorder, led to the elucidation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and its pivotal role in the pathogenesis of hamartoma formation.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	161-167
32761379-5	2020	This knowledge was translated into standard clinical practice with the discovery of rapamycin, and additional analogues, as inhibitors of mTORC1.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	138-144
32861747-0	2020	Upregulation of Akt/Raptor signaling is associated with rapamycin resistance of breast cancer cells.	Sirolimus	56-65	regulatory associated protein of MTOR complex 1	Homo sapiens	20-26
32861747-5	2020	Transfection of mir-181c, one of the positive regulators of Akt and mTOR, lead to an increase in the cell resistance to both mTOR inhibitors, rapamycin, and metformin, which correlated with Raptor overexpression and activation of Akt/AP-1 signaling.	Sirolimus	142-151	microRNA 181c	Homo sapiens	16-24
32861747-5	2020	Transfection of mir-181c, one of the positive regulators of Akt and mTOR, lead to an increase in the cell resistance to both mTOR inhibitors, rapamycin, and metformin, which correlated with Raptor overexpression and activation of Akt/AP-1 signaling.	Sirolimus	142-151	regulatory associated protein of MTOR complex 1	Homo sapiens	190-196
32878509-8	2020	In addition, rapamycin scavenged the cellular reactive oxygen species (ROS) and diminished p-JNK, p-ERK1/2 and p-p38 expression of MAPK pathways in RAW264.7 cells infected with P. aeruginosa.	Sirolimus	13-22	mitogen-activated protein kinase 3	Mus musculus	100-106
32878509-8	2020	In addition, rapamycin scavenged the cellular reactive oxygen species (ROS) and diminished p-JNK, p-ERK1/2 and p-p38 expression of MAPK pathways in RAW264.7 cells infected with P. aeruginosa.	Sirolimus	13-22	mitogen-activated protein kinase 14	Mus musculus	113-116
32480256-1	2020	OBJECTIVES: Resistance training combined with consumption of a high-protein diet (HPD) is typically recommended to increase muscle mass, as both acute resistance exercise (RE) and dietary protein intake stimulate mechanistic target of rapamycin complex 1 (mTORC1) and muscle protein synthesis (MPS).	Sirolimus	235-244	CREB regulated transcription coactivator 1	Mus musculus	256-262
32207633-6	2021	In an ependymoma mouse xenograft model, MTOR inhibition by rapamycin therapeutically suppressed TPR expression and reduced tumor size in vivo.	Sirolimus	59-68	translocated promoter region, nuclear basket protein	Mus musculus	96-99
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	29-35
33834258-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) is an important regulator of cellular metabolism that is commonly hyperactivated in cancer.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33244735-1	2021	Recently, it was reported that mechanistic/mammalian target of rapamycin complex 1 (mTORC1) activity during memory retrieval is required for normal expression of aversive and non-aversive long-term memories.	Sirolimus	63-72	CREB regulated transcription coactivator 1	Mus musculus	84-90
33244735-5	2021	Additionally, we found that GluA1 levels decreased and GluA2 levels increased at the hippocampal postsynaptic density subcellular fraction of rapamycin-infused animals during memory retrieval.	Sirolimus	142-151	glutamate ionotropic receptor AMPA type subunit 2	Homo sapiens	55-60
33692862-8	2021	Furthermore, METTL1 promoted proliferation and colony formation of A549 cells, and inhibited autophagy via the AKT/mechanistic target of rapamycin complex 1 signaling pathway.	Sirolimus	137-146	methyltransferase 1, tRNA methylguanosine	Homo sapiens	13-19
33782423-4	2021	Its production is supported by mechanistic target of rapamycin complex 1 (mTORC1) and signal transducer and activator of transcription 3 (STAT3).	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	74-80
33395696-8	2021	These abnormalities were ameliorated by pharmacological activation of UNC-51/ATG1, a FEZ1-activating kinase, with rapamycin and metformin.	Sirolimus	114-123	unc-51 like autophagy activating kinase 1	Homo sapiens	70-76
33395696-8	2021	These abnormalities were ameliorated by pharmacological activation of UNC-51/ATG1, a FEZ1-activating kinase, with rapamycin and metformin.	Sirolimus	114-123	unc-51 like autophagy activating kinase 1	Homo sapiens	77-81
33694218-3	2021	Rheb is a small GTPase which, when bound to GTP, activates mechanistic target of rapamycin complex 1 (mTORC1), a protein kinase that drives anabolic processes including protein synthesis and ribosome biogenesis.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	102-108
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	169-178	citrate synthase	Homo sapiens	94-96
33674554-2	2021	In the present study, we found that both sham surgery and unilateral nephrectomy (UNX), which is used as a model of renal compensatory hypertrophy, in mice resulted in increased mammalian target of rapamycin complex 1/2 (mTORC1/2) in the remaining kidney.	Sirolimus	198-207	CREB regulated transcription coactivator 2	Mus musculus	221-229
33038070-2	2020	The mechanistic target of rapamycin complex 1 (mTORC1) and its upstream protein kinase Akt1 have been implicated as a central signaling pathway that regulates protein synthesis in the skeletal muscle; however, the precise molecular regulation of mTORC1 activity is largely unknown.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33038070-2	2020	The mechanistic target of rapamycin complex 1 (mTORC1) and its upstream protein kinase Akt1 have been implicated as a central signaling pathway that regulates protein synthesis in the skeletal muscle; however, the precise molecular regulation of mTORC1 activity is largely unknown.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	246-252
32999282-2	2020	Lysosomes also serve as signaling hubs to monitor the intracellular levels of nutrients and energy by acting as platforms for the assembly of multiple signaling pathways, such as mammalian target of rapamycin complex 1 (mTORC1) and adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK).	Sirolimus	199-208	CREB regulated transcription coactivator 1	Mus musculus	220-226
32978410-1	2020	The mammalian Target of Rapamycin complex 1 (mTORC1) nutrient-sensing pathway is a central regulator of cell growth and metabolism and is dysregulated in diabetes.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
33132009-7	2021	Immunoblot assays showed the expected inhibition of complex 1 of mechanistic or mammalian target of rapamycin (mTORC1) and effectors (S6K rpS6 and S6K eEF2K eEF2) in colon by lifelong rapamycin treatments.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	111-117
33132009-7	2021	Immunoblot assays showed the expected inhibition of complex 1 of mechanistic or mammalian target of rapamycin (mTORC1) and effectors (S6K rpS6 and S6K eEF2K eEF2) in colon by lifelong rapamycin treatments.	Sirolimus	100-109	ribosomal protein S6	Homo sapiens	138-142
33132009-8	2021	To address the question of cell types affected by chronic enteric rapamycin treatment, immunohistochemistry analyses demonstrated that crypt cells had a prominent reduction in rpS6 phosphorylation and increase in eEF2 phosphorylation relative controls.	Sirolimus	66-75	ribosomal protein S6	Homo sapiens	176-180
33132009-9	2021	CONCLUSION: These data indicate that enteric rapamycin prevents or delays colon neoplasia in ApcMin/+-DSS mice through inhibition of mTORC1 in the crypt cells.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	133-139
32037974-1	2021	Rapamycin and their derivatives known as rapalogs, were the first-generation mTOR inhibitors which interacted with mTORC1 but not with the mTORC2 protein.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	115-121
33641344-6	2021	Rapamycin attenuated the increment in the expression of tumor necrosis factor-alpha and interleukin-1beta, the inducible nitric oxide synthase, gp91phox, and p47phox in addition to nitrite levels elicited by LPS in tissues or sera.	Sirolimus	0-9	neutrophil cytosolic factor 1	Rattus norvegicus	158-165
33641344-7	2021	Concomitantly, rapamycin treatment reduced microglial activation, brain expression of caspase-3, and Bcl-2-associated X protein while increased expression of B-cell lymphoma 2 induced by LPS.	Sirolimus	15-24	caspase 3	Rattus norvegicus	86-95
33718332-0	2020	Rapamycin-Loaded Lipid Nanocapsules Induce Selective Inhibition of the mTORC1-Signaling Pathway in Glioblastoma Cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	71-77
33718332-9	2020	Nevertheless, it demonstrated the selective inhibition of the phosphorylation of mTORC1 signaling pathway on Ser2448 at a concentration of 1 muM rapamycin in serum-free medium.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	81-87
33681258-13	2021	Further assessments revealed that activation of mTOR and GSK3beta was almost completely inhibited by rapamycin and SB216763, respectively, which significantly increased the caspase-3 levels.	Sirolimus	101-110	glycogen synthase kinase 3 alpha	Homo sapiens	57-65
33672955-6	2021	In addition, Octpep-1 combined with rapamycin (mTORC1 inhibitor) or LY3214996 (ERK1/2 inhibitor) augmented the cytotoxicity against BRAF(V600E) melanoma cells in comparison with the inhibitors or Octpep-1 alone.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	47-53
33614662-7	2021	Rapamycin mitigated these effects by activation of the classical TGF-beta/Smad signaling pathway and increasing the transcriptional activity of MAPK/AP-1.	Sirolimus	0-9	transforming growth factor alpha	Homo sapiens	65-73
33614662-7	2021	Rapamycin mitigated these effects by activation of the classical TGF-beta/Smad signaling pathway and increasing the transcriptional activity of MAPK/AP-1.	Sirolimus	0-9	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	149-153
33497611-3	2021	They act in a non-redundant manner to anchor the tuberous sclerosis complex (TSC) protein complex to lysosomes and suppress activation of the metabolic master regulator mechanistic target of rapamycin complex 1 (mTORC1) by amino acids and insulin.	Sirolimus	191-200	CREB regulated transcription coactivator 1	Mus musculus	212-218
33178015-7	2020	Once activated, AMPK inhibits the mechanistic target of rapamycin complex 1 (mTORC1), which in turn avoids the phosphorylation of p70 ribosomal protein S6 kinase 1 and phosphatidylinositol 3-kinase/protein kinase B signaling pathways and reduces cap-dependent translation initiation.	Sirolimus	56-65	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	16-20
33165974-2	2021	Extensive studies have attributed the lysosomal localization of the mechanistic target of rapamycin complex 1 (mTORC1) during its activation.	Sirolimus	90-99	CREB regulated transcription coactivator 1	Mus musculus	111-117
33352197-0	2021	Rapamycin ameliorates corneal injury after alkali burn through methylation modification in mouse TSC1 and mTOR genes.	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	97-101
33310138-6	2021	This review discusses the effect of Sesn2 on the redox signal, mainly via participation in the signaling pathway of nuclear factor erythroid 2-related factor 2, activation of adenosine monophosphate-activated protein kinase and inhibition of mammalian target of rapamycin complex 1.	Sirolimus	262-271	sestrin 2	Homo sapiens	36-41
33451752-8	2021	Further mechanistic study uncovered that inhibition of mTORC1 with rapamycin blocked BV-induced ER stress, and treatment with Sestrin2 siRNA blocked the inhibition effect of AMPK to mTORC1.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	55-61
33272830-1	2021	Autophagy and cap-dependent mRNA translation are tightly regulated by the mechanistic target of rapamycin complex 1 (mTORC1) signalling complex in response to nutrient availability.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	117-123
33157024-2	2021	At lysosomes and endosomes, the Fab1 lipid kinase complex and the nutrient-regulated target of rapamycin complex 1 (TORC1) control the integrity of the endolysosomal homeostasis and cellular metabolism.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Homo sapiens	116-121
33480149-13	2021	Moreover, RAPA decreased p62/LC3 ratio indicated enhanced autophagy, and significantly reduced caspase-3 and RIPK1 expression.	Sirolimus	10-14	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	25-28
33480149-13	2021	Moreover, RAPA decreased p62/LC3 ratio indicated enhanced autophagy, and significantly reduced caspase-3 and RIPK1 expression.	Sirolimus	10-14	annexin A3	Rattus norvegicus	29-32
33480149-13	2021	Moreover, RAPA decreased p62/LC3 ratio indicated enhanced autophagy, and significantly reduced caspase-3 and RIPK1 expression.	Sirolimus	10-14	caspase 3	Rattus norvegicus	95-104
33483593-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) deficiency or chronic hyperactivation in pancreatic beta-cells leads to diabetes.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
33178015-7	2020	Once activated, AMPK inhibits the mechanistic target of rapamycin complex 1 (mTORC1), which in turn avoids the phosphorylation of p70 ribosomal protein S6 kinase 1 and phosphatidylinositol 3-kinase/protein kinase B signaling pathways and reduces cap-dependent translation initiation.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	77-83
32879008-1	2020	Low-glucose and -insulin conditions, associated with ketogenic diets, can reduce the activity of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, potentially leading to a range of positive medical and health-related effects.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	144-150
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	glucagon like peptide 1 receptor	Homo sapiens	110-124
32693734-10	2020	Furthermore, using autophagy inhibitor NH4Cl and GSK-3beta inhibitor CHIR-99021, we found rapamycin-induced autophagy promoted cardiomyocyte differentiation at middle stage by negatively regulating the Wnt/beta-catenin signaling pathway.	Sirolimus	90-99	glycogen synthase kinase 3 alpha	Homo sapiens	49-58
32934076-3	2020	Selected chemical and genetic perturbations in this screening platform, including rapamycin treatment and genetic ablation of the Ragulator subunit LAMTOR4, revealed the known core mTORC1 regulatory signaling complexes and the intimate interplay of the mTORC1 pathway with lysosomal function, validating the approach.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	181-187
33237838-5	2021	Using pHLARE we show decreased pHlys with inhibiting activity of the mammalian target of rapamycin complex 1 (mTORC1), in breast, pancreatic, colon, and glioblastoma cancer cells compared with untransformed cells, and with the activated oncogenes H-RasV12 and R-RasV12.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	110-116
33452321-7	2021	Morphological and biochemical validation of autophagy markers in the cell model of 3-NPA revealed incomplete autophagy mediated by mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway.	Sirolimus	153-162	CREB regulated transcription coactivator 2	Mus musculus	174-180
33597869-11	2020	INK128 effectively suppressed mTORC1 and mTORC2 activity in T cells, but rapamycin just suppressed mTORC1 activity.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	99-105
32920594-5	2020	Blocking mTORC1 signal with rapamycin alleviated the neuropathic pain and restored morphine efficacy in CCI model.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Mus musculus	9-15
32920594-8	2020	In spinal slice recording, CCI increased the firing frequency of neurons expressing HCN channels; inhibition of mTORC1 with rapamycin could reverse the increased spinal neuronal activity in neuropathic pain.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Mus musculus	112-118
32693673-10	2020	Mechanistically, LAPTM4B regulated the activity of mammalian target of rapamycin complex 1 (mTORC1) via interacting with mTOR through its EC3 domain.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	92-98
33013932-3	2020	Our results show that RLR stimulation increased the phosphorylation of the mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt, respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes.	Sirolimus	219-228	CREB regulated transcription coactivator 2	Mus musculus	102-108
33013932-3	2020	Our results show that RLR stimulation increased the phosphorylation of the mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt, respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes.	Sirolimus	219-228	CREB regulated transcription coactivator 1	Mus musculus	202-208
33013932-3	2020	Our results show that RLR stimulation increased the phosphorylation of the mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt, respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes.	Sirolimus	219-228	CREB regulated transcription coactivator 1	Mus musculus	249-255
32912327-7	2020	TLR5-mediated microglial function involves the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1) pathway, as specific inhibitors of this signaling pathway abolish microglial activation.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
32913260-7	2020	Furthermore, Rac1 cKO reduced the number of autophagosomes and apoptotic RGCs induced by rapamycin injected intravitreally, which suggests that Rac1 negatively regulates mTOR activity.	Sirolimus	89-98	Rac family small GTPase 1	Mus musculus	13-17
33511116-5	2020	In this review, we will systematically summarize the recent progress of amino acid metabolism in malignancy and discuss their interconnection with mammalian target of rapamycin complex 1 (mTORC1) signaling, epigenetic modification, tumor growth and immunity, and ferroptosis.	Sirolimus	167-176	CREB regulated transcription coactivator 1	Mus musculus	188-194
33445779-1	2021	Target of rapamycin complex 1 (TORC1), a serine/threonine-protein kinase complex highly conserved among eukaryotes, coordinates cellular growth and metabolism with environmental cues, including nutrients and growth factors.	Sirolimus	10-19	CREB regulated transcription coactivator 1	Homo sapiens	31-36
33429026-3	2021	In this context, the activity of the mechanistic Target Of Rapamycin Complex 1 (mTORC1) is of major importance.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	80-86
33275526-6	2021	It was found that GLDs considerably inhibited the phosphorylation of Akt at Thr308/Ser473, whereas the silencing of Gal-3 could reverse the inhibition of Akt activity through phosphoinositide 3-kinase-AktThr308 (PI3K-AktThr308) and AMP-activated protein kinase-mammalian target of rapamycin complex 2-AktSer473 (AMPK-mTOR2-AktSer473) pathways.	Sirolimus	281-290	galectin 3	Homo sapiens	116-121
32913260-7	2020	Furthermore, Rac1 cKO reduced the number of autophagosomes and apoptotic RGCs induced by rapamycin injected intravitreally, which suggests that Rac1 negatively regulates mTOR activity.	Sirolimus	89-98	Rac family small GTPase 1	Mus musculus	144-148
32826333-8	2020	Finally, using the mTORC1 inhibitor rapamycin, we demonstrate that LIN28B promotes supporting cell plasticity in an mTORC1-dependent manner.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	19-25
32826333-8	2020	Finally, using the mTORC1 inhibitor rapamycin, we demonstrate that LIN28B promotes supporting cell plasticity in an mTORC1-dependent manner.	Sirolimus	36-45	lin-28 homolog B	Mus musculus	67-73
32906669-8	2020	Therefore, protein administration plus IL effectively prevented skeletal muscle atrophy induced by disuse, potentially via enhanced activation of targets downstream of mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	209-215
32747435-7	2020	Inhibition of mTor signaling by rapamycin partially rescued Erk1/2 depletion-induced intestinal defects and significantly prolonged mutant mice life span.	Sirolimus	32-41	mitogen-activated protein kinase 3	Mus musculus	60-66
33356791-6	2021	Importantly, inhibition of mTORC1 signaling either by the mTORC1 inhibitor rapamycin or by knockdown of Raptor, a unique component of mTORC1, during palbociclib treatment of CAMA1 cells blocks the induction of complete senescence.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	27-33
32394479-3	2021	The mTOR protein is incorporated into two distinct complexes: mammalian target of Rapamycin complex 1 (mTORC1) and mammalian target of Rapamycin complex 2 (mTORC2).	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	103-109
32394479-3	2021	The mTOR protein is incorporated into two distinct complexes: mammalian target of Rapamycin complex 1 (mTORC1) and mammalian target of Rapamycin complex 2 (mTORC2).	Sirolimus	135-144	CREB regulated transcription coactivator 2	Mus musculus	156-162
33189285-2	2021	The mammalian target of rapamycin/eukaryotic initiation factor 4E (mTOR/eIF4E) signaling pathway is involved in fat synthesis.	Sirolimus	24-33	eukaryotic translation initiation factor 4E	Homo sapiens	72-77
32640907-7	2020	mTORC1 inhibition by nicotine or rapamycin promoted lysosomal exocytosis and CTSS secretion.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	0-6
33110172-0	2021	Correction: Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase.	Sirolimus	12-21	cellular communication network factor 2	Homo sapiens	32-36
33040459-7	2021	In Ba/F3 cells transformed by NPM-ALK and Ki-JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC-0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1.	Sirolimus	171-180	CREB regulated transcription coactivator 1	Mus musculus	154-160
33317171-5	2020	Interestingly, the pre-treatment with rapamycin, an mTOR inhibitor, further increased the expression levels of LC3-II induced by OGT inhibition, implicating the involvement of mTOR signaling in O-GlcNAcylation-dependent autophagy.	Sirolimus	38-47	O-linked N-acetylglucosamine (GlcNAc) transferase	Rattus norvegicus	129-132
33273014-2	2021	Previously we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 signaling, leading to clinical trials for NF2 and meningioma.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	88-94
32985258-2	2020	Herein, we sought to explore the anti-cancer mechanisms of ISL loaded nanoliposomes (ISL-NLs) on AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathways mediated glycolysis.	Sirolimus	146-155	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	157-161
33171062-6	2020	Mechanistically, curcumin inactivates the mechanistic target of rapamycin complex 1 (mTORC1), the upstream regulator of rDNA transcription and autophagy induction, by inhibiting mTOR lysosomal localization.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	85-91
32640907-7	2020	mTORC1 inhibition by nicotine or rapamycin promoted lysosomal exocytosis and CTSS secretion.	Sirolimus	33-42	cathepsin S	Homo sapiens	77-81
32599128-6	2020	Inhibition of mTORC1 with rapamycin reversed the deficits of insulin signaling associated kinases activity, decreased levels of AGEs and AD-like tau phosphorylation, and also improved memory deficit in both STZ mice.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	14-20
32599128-7	2020	Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells.	Sirolimus	0-9	glycogen synthase kinase 3 alpha	Homo sapiens	74-83
32599128-8	2020	Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs.	Sirolimus	45-54	glycogen synthase kinase 3 alpha	Mus musculus	157-166
32621956-2	2020	Multiple experimental studies have highlighted the role of increased mammalian target of rapamycin complex 1 (mTORC1) and reduced AMP-activated protein kinase (AMPK) signaling in modulating cyst growth in ADPKD.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	110-116
32715871-2	2020	We previously mapped a late G1 cell cycle checkpoint for lipids upstream from a mammalian target of rapamycin complex 1 (mTORC1)-mediated checkpoint and downstream from a mid-G1 checkpoint known as the Restriction point.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	121-127
32474911-7	2020	Furthermore, our mechanistic studies unveiled that the SLC34a1-CreERT2 recombinase-mediated Pik3c3 downregulation inhibited UNX- or amino acid-stimulated lysosomal localization and signaling activation of mechanistic target of rapamycin complex 1 (mTORC1) in the renal proximal tubules.	Sirolimus	227-236	solute carrier family 34 member 1	Homo sapiens	55-62
32474911-7	2020	Furthermore, our mechanistic studies unveiled that the SLC34a1-CreERT2 recombinase-mediated Pik3c3 downregulation inhibited UNX- or amino acid-stimulated lysosomal localization and signaling activation of mechanistic target of rapamycin complex 1 (mTORC1) in the renal proximal tubules.	Sirolimus	227-236	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	92-98
32474911-7	2020	Furthermore, our mechanistic studies unveiled that the SLC34a1-CreERT2 recombinase-mediated Pik3c3 downregulation inhibited UNX- or amino acid-stimulated lysosomal localization and signaling activation of mechanistic target of rapamycin complex 1 (mTORC1) in the renal proximal tubules.	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	248-254
32666288-1	2020	Deregulated activity of protein kinase B/mammalian target of rapamycin complex-1 (Akt/mTORC1) incites crucial pathological characteristics of diabetic nephropathy.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Mus musculus	86-92
33256738-14	2020	The pyroptosic effect by S. aureus infection was promoted by either rapamycin or Stattic, a specific inhibitor for mTORC1 or STAT3.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	115-121
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	interleukin 2 receptor subunit alpha	Homo sapiens	10-14
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	interleukin 2 receptor subunit alpha	Homo sapiens	63-67
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	forkhead box P3	Homo sapiens	68-73
32535334-5	2020	These CD4+CD25- T cells were induced to differentiate into CD4+CD25+Foxp3+ Tregs through incubating with CD3 and CD28 antibodies, TGF-beta, IL-2 and rapamycin in vitro.	Sirolimus	149-158	CD28 molecule	Homo sapiens	113-117
32779245-2	2020	Several data support the involvement of the mammalian target of rapamycin complex 1 (mTORC1) signaling in the interplay between androgens, insulin, insulin-like growth factor (IGF1), and high glycemic index diet in acne.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	85-91
32721041-3	2020	As the assembly and activation of the mechanistic target of rapamycin complex 1 (mTORC1) occur on the lysosome surface, increased lysosome mass with aging leads to higher mTORC1 activity.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	81-87
33238462-7	2020	Similar to vertebrate PKD, the BicC fly PKD model responds to the antiproliferative drugs rapamycin and mimics of the second mitochondria-derived activator of caspases (Smac).	Sirolimus	90-99	Protein Kinase D	Drosophila melanogaster	40-43
33312358-12	2020	PI3K, p-AKT1, p-mTOR, p-p70S6K and caspase-3 were down-regulated by rapamycin and beta-ecdysterone, and up-regulated by 3-methyladenine in both the chondrocytes and the cartilage tissues.	Sirolimus	68-77	caspase 3	Rattus norvegicus	35-44
33202661-8	2020	When mTOR was inhibited directly via the macrolide rapamycin, peroxisome degradation was still partially suppressed by Ras2, while inactivation of Ras2 resulted in an enhanced degradation of peroxisomes, suggesting a role of Ras2 in the inhibition of peroxisome degradation in glucose-grown cells.	Sirolimus	51-60	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	119-123
33292704-6	2020	Milk protein synthesis is governed at mammary level by a set of transduction pathways, including the mechanistic target of rapamycin complex 1 (mTORC1), the integrated stress response (ISR), and the unfolded protein response (UPR).	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	144-150
33171588-3	2020	Polymerase chain reaction (PCR) Array Technology shows upregulation of mammalian Target Of Rapamycin Complex 1 (mTORC1), inflammation, and mitochondrial dysfunction.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
33159078-1	2020	Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in tuberous sclerosis complex (TSC1/TSC2) genes coding for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	208-217	TSC complex subunit 1	Mus musculus	139-143
32721041-3	2020	As the assembly and activation of the mechanistic target of rapamycin complex 1 (mTORC1) occur on the lysosome surface, increased lysosome mass with aging leads to higher mTORC1 activity.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	171-177
32495040-2	2020	Several reports have demonstrated that mitogen-activated protein kinases 3 and 1 (MAPK3/1)-mammalian target of rapamycin complex 1 (mTORC1) signaling in pre-granulosa cells promotes primordial follicle activation by increasing KIT ligand (KITL) expression and then stimulating phosphatidylinositol 3 kinase signaling in oocytes.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	132-138
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	80-86
32495040-6	2020	Western blotting results demonstrated that both the MAPK3/1 inhibitor U0126 and mTORC1 inhibitor rapamycin significantly decreased the levels of phosphorylated CREB, indicating that MAPK3/1-mTORC1 signaling is required for CREB activation.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	190-196
32030764-4	2020	The BCAA mimic satiety to inhibit autophagy via mechanistic targets of rapamycin complex 1 (mTORC1) activation and, in contrast, their catabolism supplements de novo lipogenesis for the formation of autophagosome membranes.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	92-98
32739207-2	2020	As an important negative regulatory factor of the mammalian target of rapamycin complex 1 (mTORC1) signal, tuberous sclerosis complex 1 (Tsc1) is also a key regulatory point of glycolysis.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	91-97
32739207-6	2020	Prior incubation with rapamycin inhibited mTORC1 activation and abolished the enhanced glycolysis and tubular epithelial cell proliferation.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	42-48
32601986-0	2020	The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
32717360-5	2020	RESULTS: We show that high-grade chondrosarcoma cells contain a population of radioresistant cancer stem cells that can be targeted by a combination of carbon-ion therapy, miR-34 mimic administration and/or rapamycin treatment that triggers FOXO3 and miR-34 over-expression.	Sirolimus	207-216	microRNA 34a	Homo sapiens	251-257
32717360-6	2020	mTOR inhibition by rapamycin triggered FOXO3 and miR-34, leading to KLF4 repression.	Sirolimus	19-28	microRNA 34a	Homo sapiens	49-55
32759469-1	2020	While the growth factors like insulin initiate a signaling cascade to induce conformational changes in the mechanistic target of rapamycin complex 1 (mTORC1), amino acids cause the complex to localize to the site of activation, the lysosome.	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	150-156
32736702-3	2020	In the present study, using cultured ARPE-19 cells, we determined that TGF-beta initiates a signaling pathway through extracellular signal-regulated kinase (ERK)-mammalian target of rapamycin complex 1 (mTORC1) that stimulates trans-differentiation and fibrosis of retinal pigment epithelium.	Sirolimus	182-191	transforming growth factor alpha	Homo sapiens	71-79
32736702-3	2020	In the present study, using cultured ARPE-19 cells, we determined that TGF-beta initiates a signaling pathway through extracellular signal-regulated kinase (ERK)-mammalian target of rapamycin complex 1 (mTORC1) that stimulates trans-differentiation and fibrosis of retinal pigment epithelium.	Sirolimus	182-191	CREB regulated transcription coactivator 1	Mus musculus	203-209
32874166-8	2020	Moreover, the expression of LC-3 and NFkappaB was also significantly reduced after rapamycin pretreatment.	Sirolimus	83-92	annexin A3	Rattus norvegicus	28-32
32668192-8	2020	Rapamycin, which incompletely and allosterically inhibits mTORC1, had no effect on TGF-beta-mediated induction of ATF4; however, Rapalink-1, which specifically targets the kinase domain of mTORC1, completely inhibited ATF4 induction and metabolic reprogramming downstream of TGF-beta.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	189-195
33030400-8	2021	In therapeutic studies, low doses of rapamycin, a known autophagy inducer that significantly promotes endometrium autophagy and NK cell residence, and improves embryo absorption in spontaneous abortion mice models, which should be dependent on the activation of MITF-TNFRSF14/HVEM-MMP9-adhension molecules axis.	Sirolimus	37-46	matrix metallopeptidase 9	Mus musculus	281-285
33280811-13	2020	Enhancement of autophagy with rapamycin markedly alleviated the pathological changes and decreased the levels of apoptosis and caspase-3 while increasing the expression of LC3 and Beclin1 and the ratio of LC3-II to LC3-I.	Sirolimus	30-39	caspase 3	Rattus norvegicus	127-136
33280811-13	2020	Enhancement of autophagy with rapamycin markedly alleviated the pathological changes and decreased the levels of apoptosis and caspase-3 while increasing the expression of LC3 and Beclin1 and the ratio of LC3-II to LC3-I.	Sirolimus	30-39	annexin A3	Rattus norvegicus	172-175
33280811-13	2020	Enhancement of autophagy with rapamycin markedly alleviated the pathological changes and decreased the levels of apoptosis and caspase-3 while increasing the expression of LC3 and Beclin1 and the ratio of LC3-II to LC3-I.	Sirolimus	30-39	beclin 1	Rattus norvegicus	180-187
33280811-13	2020	Enhancement of autophagy with rapamycin markedly alleviated the pathological changes and decreased the levels of apoptosis and caspase-3 while increasing the expression of LC3 and Beclin1 and the ratio of LC3-II to LC3-I.	Sirolimus	30-39	annexin A3	Rattus norvegicus	205-208
33280811-13	2020	Enhancement of autophagy with rapamycin markedly alleviated the pathological changes and decreased the levels of apoptosis and caspase-3 while increasing the expression of LC3 and Beclin1 and the ratio of LC3-II to LC3-I.	Sirolimus	30-39	annexin A3	Rattus norvegicus	205-208
31738412-0	2020	STAT3-miR-17/20 Signaling Axis Plays a Critical Role in Attenuating Myocardial Infarction following Rapamycin Treatment in Diabetic mice.	Sirolimus	100-109	microRNA 17	Mus musculus	6-12
31738412-10	2020	In addition, RAPA restored AKT phosphorylation (target of mTORC2), but suppressed S6 phosphorylation (target of mTORC1) following I/R injury.	Sirolimus	13-17	CREB regulated transcription coactivator 2	Mus musculus	58-64
31738412-10	2020	In addition, RAPA restored AKT phosphorylation (target of mTORC2), but suppressed S6 phosphorylation (target of mTORC1) following I/R injury.	Sirolimus	13-17	CREB regulated transcription coactivator 1	Mus musculus	112-118
31738412-11	2020	RAPA-induced cardioprotection against I/R injury as well as the induction of miR-17/20a and AKT phosphorylation were abolished in cardiac-specific STAT3-deficient diabetic mice, without alteration of S6 phosphorylation.	Sirolimus	0-4	microRNA 17	Mus musculus	77-83
32558194-8	2020	Co-treatment of GABA with an inhibitor specific for PI3K, mTORC1/2, or p70S6K (via wortmannin, rapamycin, or PF-4708671, respectively) abolished GABA-stimulated beta-cell proliferation in mouse and human islets.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	58-64
32862047-2	2020	The mammalian target of rapamycin complex 1 (mTORC1) is a negative regulator of autophagy, but its role in Cd-induced autophagy inhibition and possible regulatory mechanisms remains poorly understood.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
32862047-5	2020	Importantly, Cd exposure triggered the recruitment of mTORC1 onto lysosome membrane assessed by immunofluorescence co-localization analysis, which was obviously inhibited by rapamycin or torin 1.	Sirolimus	174-183	CREB regulated transcription coactivator 1	Mus musculus	54-60
32791085-8	2020	Moreover, intra-vlPAG GLYX-13 microinjection produced a long-lasting antidepressant effect; however, this effect was prevented by the intra-vlPAG microinjection of tropomyosin-related kinase B (TrkB) receptor antagonist ANA-12, a selective mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, and CNQX, an AMPA receptor antagonist.	Sirolimus	260-269	neurotrophic receptor tyrosine kinase 2	Homo sapiens	164-192
32791085-8	2020	Moreover, intra-vlPAG GLYX-13 microinjection produced a long-lasting antidepressant effect; however, this effect was prevented by the intra-vlPAG microinjection of tropomyosin-related kinase B (TrkB) receptor antagonist ANA-12, a selective mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, and CNQX, an AMPA receptor antagonist.	Sirolimus	260-269	neurotrophic receptor tyrosine kinase 2	Homo sapiens	194-198
32791085-8	2020	Moreover, intra-vlPAG GLYX-13 microinjection produced a long-lasting antidepressant effect; however, this effect was prevented by the intra-vlPAG microinjection of tropomyosin-related kinase B (TrkB) receptor antagonist ANA-12, a selective mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, and CNQX, an AMPA receptor antagonist.	Sirolimus	299-308	neurotrophic receptor tyrosine kinase 2	Homo sapiens	164-192
32791085-8	2020	Moreover, intra-vlPAG GLYX-13 microinjection produced a long-lasting antidepressant effect; however, this effect was prevented by the intra-vlPAG microinjection of tropomyosin-related kinase B (TrkB) receptor antagonist ANA-12, a selective mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, and CNQX, an AMPA receptor antagonist.	Sirolimus	299-308	neurotrophic receptor tyrosine kinase 2	Homo sapiens	194-198
32799865-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) is an essential regulator of cell growth and metabolism through the modulation of protein and lipid synthesis, lysosome biogenesis, and autophagy.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
31781847-7	2020	Administration of MEL + RAP produced the strongest effects on bone parameters and strength for distal femurs and regulation of OPG/RANKL signalling pathway-related gene expression.	Sirolimus	24-27	TNF superfamily member 11	Rattus norvegicus	131-136
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	choline acetyltransferase	Mus musculus	69-73
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	tyrosine hydroxylase	Mus musculus	75-77
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	microtubule-associated protein 1 light chain 3 beta	Mus musculus	222-227
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	choline acetyltransferase	Mus musculus	59-63
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	tyrosine hydroxylase	Mus musculus	65-67
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	microtubule-associated protein 1 light chain 3 beta	Mus musculus	313-318
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	microtubule-associated protein 1 light chain 3 beta	Mus musculus	297-302
32824248-1	2020	The constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1) leads to the overproduction of apoB-containing triacylglycerol-rich lipoproteins in HepG2 cells.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Mus musculus	78-84
32850834-3	2020	Among the nutrient-sensing pathways, the mechanistic target of rapamycin complex 1 (mTORC1) acts as the central regulator of cellular functions, which include autophagy.	Sirolimus	63-72	CREB regulated transcription coactivator 1	Mus musculus	84-90
32716476-1	2020	Sirolimus, also known as rapamycin, and its closely-related rapamycin analog (rapalog) Everolimus inhibit "mammalian target of rapamycin complex 1" (mTORC1), whose activity is required for spermatogenesis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	149-155
32716476-1	2020	Sirolimus, also known as rapamycin, and its closely-related rapamycin analog (rapalog) Everolimus inhibit "mammalian target of rapamycin complex 1" (mTORC1), whose activity is required for spermatogenesis.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	149-155
32716476-1	2020	Sirolimus, also known as rapamycin, and its closely-related rapamycin analog (rapalog) Everolimus inhibit "mammalian target of rapamycin complex 1" (mTORC1), whose activity is required for spermatogenesis.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	149-155
32716476-1	2020	Sirolimus, also known as rapamycin, and its closely-related rapamycin analog (rapalog) Everolimus inhibit "mammalian target of rapamycin complex 1" (mTORC1), whose activity is required for spermatogenesis.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	149-155
33097830-6	2020	Mechanistically, we find that L-arginine stimulates Wnt2b secretion by CD90+ stromal cells through the mammalian target of rapamycin complex 1 (mTORC1) and that blocking Wnt2b production prevents L-arginine-induced ISC expansion.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	144-150
33076974-2	2020	It is characterised by hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway and has severe neurodevelopmental and neurological components including autism, intellectual disability and epilepsy.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
32908958-1	2020	Background: The mechanistic target of rapamycin complex 1 (mTORC1) is a nutrient-sensing pathway and a key regulator of amino acid and glucose metabolism.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	59-65
33060361-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) couples nutrient sufficiency to cell growth.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32748349-7	2021	Mechanistically, we identified TBC1D7 as a binding partner of KIF2C, and this interaction disrupts the formation of the TSC complex, resulting in the enhancement of mammalian target of rapamycin complex1 (mTORC1) signal transduction.	Sirolimus	185-194	CREB regulated transcription coactivator 1	Mus musculus	205-211
33163944-4	2020	Here, we show that under pharmacological and genetic c-Abl inhibition, TFEB translocates into the nucleus promoting the expression of its target genes independently of its well-known regulator, mammalian target of rapamycin complex 1.	Sirolimus	214-223	transcription factor EB	Homo sapiens	71-75
32293025-4	2020	We employed a mouse model of transplant tolerance where treatment with granulocyte colony-stimulating factor (G-CSF)/rapamycin induces permanent engraftment of allogeneic pancreatic islets in C57BL/6 mice via Tr1 cells.	Sirolimus	117-126	colony stimulating factor 3 (granulocyte)	Mus musculus	71-108
32293025-4	2020	We employed a mouse model of transplant tolerance where treatment with granulocyte colony-stimulating factor (G-CSF)/rapamycin induces permanent engraftment of allogeneic pancreatic islets in C57BL/6 mice via Tr1 cells.	Sirolimus	117-126	colony stimulating factor 3 (granulocyte)	Mus musculus	110-115
32293025-4	2020	We employed a mouse model of transplant tolerance where treatment with granulocyte colony-stimulating factor (G-CSF)/rapamycin induces permanent engraftment of allogeneic pancreatic islets in C57BL/6 mice via Tr1 cells.	Sirolimus	117-126	taste receptor, type 1, member 1	Mus musculus	209-212
33116622-7	2020	On the contrary, Rapamycin reversed the promoting effect of GAS8-AS1 in OC cells.	Sirolimus	17-26	prostaglandin D2 receptor	Homo sapiens	65-68
32293025-10	2020	Graft-infiltrating macrophages of G-CSF/rapamycin-treated mice had an M2 phenotype, characterized by higher CD206 expression and interleukin (IL)-10 production, whereas splenic macrophages only had an increased CD206 expression.	Sirolimus	40-49	colony stimulating factor 3 (granulocyte)	Mus musculus	34-39
32293025-11	2020	Graft-infiltrating cells from G-CSF/rapamycin-treated mice-induced Tr1-cell expansion in vitro.	Sirolimus	36-45	taste receptor, type 1, member 1	Mus musculus	67-70
32293025-13	2020	Taken together, in this mouse model of Tr1-cell induced tolerance to allogeneic islets, M2 macrophages infiltrating the graft upon G-CSF/rapamycin treatment are key for Tr1-cell induction.	Sirolimus	137-146	taste receptor, type 1, member 1	Mus musculus	39-42
32293025-13	2020	Taken together, in this mouse model of Tr1-cell induced tolerance to allogeneic islets, M2 macrophages infiltrating the graft upon G-CSF/rapamycin treatment are key for Tr1-cell induction.	Sirolimus	137-146	taste receptor, type 1, member 1	Mus musculus	169-172
33046706-4	2020	We show that lack of CTSD impaired mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling and induced reversible cellular quiescence.	Sirolimus	57-66	cathepsin D	Homo sapiens	21-25
32553594-10	2020	In addition, Cyld gene gain- and/or loss-of-function approaches in vitro and in vivo demonstrated that CYLD mediated cardiomyocyte death associated with impaired reactivation of mechanistic target of rapamycin complex 1 (mTORC1) and upregulated Ras genes from rat brain 7 (Rab7), two key components for autolysosomal degradation.	Sirolimus	200-209	CREB regulated transcription coactivator 1	Mus musculus	221-227
33046706-4	2020	We show that lack of CTSD impaired mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling and induced reversible cellular quiescence.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Mus musculus	78-84
33116499-5	2020	In addition, increasing or decreasing the autophagosomes number by rapamycin or 3-methyladenine (3-MA) will result in augmentation or attenuation of Arg1.	Sirolimus	67-76	arginase 1	Homo sapiens	149-153
33009372-6	2020	To confirm the observations of the genetic approach, we used a pharmacological method and determined that the mTORC1 inhibitor rapamycin has a profound influence upon post-synaptic D2R-dependent functions.	Sirolimus	127-136	CREB regulated transcription coactivator 1	Mus musculus	110-116
32480429-10	2020	Conversely, the AMPK activator metformin or the mTORC1 inhibitor rapamycin reversed the effects of FL on the alterations of autophagy, hypertrophy and apoptosis in cardiomyocytes induced by Ang II.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	48-54
32592088-6	2020	This phenomenon was accompanied by upregulated Skp2 and downregulated p27kip1 expression and was abolished by rapamycin, an inhibitor of mTOR.	Sirolimus	110-119	S-phase kinase-associated protein 2	Mus musculus	47-51
33409304-7	2020	In other words, the addition of rapamycin was found to increase the expression of MMP-2 in the inner cell mass and trophoblast, while it inhibited apoptosis.	Sirolimus	32-41	matrix metallopeptidase 2	Homo sapiens	82-87
33409304-8	2020	Conclusion: The addition of rapamycin influences the regulation of apoptosis and MMPs, and based on this, it is presumed to have a positive effect on blastocyst development.	Sirolimus	28-37	matrix metallopeptidase 2	Homo sapiens	81-85
32812483-3	2020	The aim of the present study is to systematically investigate the effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLN) surface charge on efficacy and penetration into the lymphatics.	Sirolimus	84-93	transcriptional regulating factor 1	Homo sapiens	121-125
32820673-3	2020	Aim: The effect of inhaled rapamycin solid lipid nanoparticles (Rapa-SLNs) size on its penetration through the lymphatics.	Sirolimus	27-36	transcriptional regulating factor 1	Homo sapiens	64-68
32820673-6	2020	Conclusion: Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients.	Sirolimus	68-77	transcriptional regulating factor 1	Homo sapiens	12-16
32470351-2	2020	Mammalian target of rapamycin complex 1 (mTORC1) pathway in mouse striatum is highly involved in excessive alcohol intake and seeking, and in the U50,488H-induced conditioned place aversion.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
32587106-2	2020	Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
32810332-1	2020	AKT-mTORC1 (mammalian target of rapamycin complex 1) signaling pathway plays a critical role in tumorigenesis and can be targeted by rapamycin.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	4-10
32810332-10	2020	Our results demonstrated the lncRNA EPIC1 expression activated the AKT-mTORC1 signaling pathway through Myc and led to rapamycin resistance in breast and ovarian cancer.	Sirolimus	119-128	CREB regulated transcription coactivator 1	Mus musculus	71-77
32470351-4	2020	This study focuses on: (1) how chronic excessive alcohol drinking (4-day drinking-in-the-dark paradigm followed by 3-week chronic intermittent access drinking paradigm [two-bottle choice, 24-h access every other day]) affected nuclear transcript levels of the mTORC1 pathway genes in mouse nucleus accumbens shell (NAcs), using transcriptome-wide RNA sequencing analysis; and (2) whether selective mTORC1 inhibitor rapamycin could alter excessive alcohol drinking and prevent U50,488H-promoted alcohol intake.	Sirolimus	415-424	CREB regulated transcription coactivator 1	Mus musculus	260-266
32696949-9	2020	In addition, p-mTOR and p-GSK-3beta were up-regulated by RES and down-regulated by RAPA and SB216763.	Sirolimus	83-87	glycogen synthase kinase 3 alpha	Homo sapiens	26-35
32720643-1	2020	Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongly in females than males, perhaps because inhibition of hepatic mTORC2 (mTOR Complex 2) specifically reduces the lifespan of males.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	185-191
32722591-5	2020	The two most common pathological alterations that contribute to NCDs discussed in this review will be the regulation of eukaryotic initiation factor 2 (eIF2) by the integrated stress response (ISR) and the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	226-235	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	120-150
32722591-5	2020	The two most common pathological alterations that contribute to NCDs discussed in this review will be the regulation of eukaryotic initiation factor 2 (eIF2) by the integrated stress response (ISR) and the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	226-235	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	152-156
32722591-5	2020	The two most common pathological alterations that contribute to NCDs discussed in this review will be the regulation of eukaryotic initiation factor 2 (eIF2) by the integrated stress response (ISR) and the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	226-235	CREB regulated transcription coactivator 1	Mus musculus	247-253
32922169-0	2020	Rapamycin blocks the IL-13-induced deficiency of Epidermal Barrier Related Proteins via upregulation of miR-143 in HaCaT Keratinocytes.	Sirolimus	0-9	microRNA 143	Homo sapiens	104-111
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	microRNA 143	Homo sapiens	158-165
32246916-15	2020	The effects induced by G-CSF were all reversed by rapamycin.	Sirolimus	50-59	colony stimulating factor 3	Rattus norvegicus	23-28
32990653-7	2020	Results: V-ATPase activity in PTs was markedly enhanced by insulin, and its activation was completely inhibited by bafilomycin (a V-ATPase-specific inhibitor), Akt inhibitor VIII, and PP242 (an mTORC1/2 inhibitor), but not by rapamycin (an mTORC1 inhibitor).	Sirolimus	226-235	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	9-17
32647003-5	2020	HEM1 loss also blocked mechanistic target of rapamycin complex 2 (mTORC2)-dependent AKT phosphorylation, T cell proliferation, and selected effector functions, leading to immunodeficiency.	Sirolimus	45-54	CREB regulated transcription coactivator 2	Mus musculus	66-72
32484794-4	2020	Injection of rapamycin to pregnant mice inhibited the mTOR pathway and tubular cell proliferation in kidneys of TSC1 null offspring.	Sirolimus	13-22	TSC complex subunit 1	Mus musculus	112-116
32974014-5	2020	Mechanistically, formate induces mechanistic target of rapamycin complex 1 (mTORC1) activity as quantified by phosphorylation of its targets S6, 4E-BP1, S6K1 and CAD.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	76-82
32974014-6	2020	Treatment with the allosteric mTORC1 inhibitor rapamycin abrogates CAD phosphorylation and pyrimidine synthesis induced by formate.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	30-36
32707053-10	2020	Similarly, rapamycin also significantly decreased the stimulatory effect of Rab31 on the expression of cyclin D1.	Sirolimus	11-20	cyclin D1	Homo sapiens	103-112
32484794-6	2020	Gene expression analysis of proximal tubule cells, identified sets of genes and pathways that were modified secondary to TSC1 deletion and rescued by rapamycin administration during nephrogenesis.	Sirolimus	150-159	TSC complex subunit 1	Mus musculus	121-125
32615541-6	2020	In contrast, the inhibition of mTORC1 activity by rapamycin suppressed autophagosome degradation but mitigated the cell invasion ability and LM potential of Galphah-overexpressing HCC1806 cells.	Sirolimus	50-59	CREB regulated transcription coactivator 1	Mus musculus	31-37
32694311-1	2020	We recently reported that upregulation of the constitutively active ras homolog enriched in brain [Rheb(S16H)], which induces the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, can protect adult neurons, mediated by the induction of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), in animal models of neurodegenerative diseases.	Sirolimus	168-177	Ras homolog, mTORC1 binding	Homo sapiens	99-103
32694311-1	2020	We recently reported that upregulation of the constitutively active ras homolog enriched in brain [Rheb(S16H)], which induces the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, can protect adult neurons, mediated by the induction of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), in animal models of neurodegenerative diseases.	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	189-195
32908143-4	2020	We demonstrate that chronic mTORC1 inhibition with rapamycin is overwhelmingly, but not entirely, positive for aging mouse skeletal muscle, while genetic, muscle fiber-specific activation of mTORC1 is sufficient to induce molecular signatures of sarcopenia.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	28-34
32619236-6	2020	Mechanistically, Rim15 kinase phosphorylates Rph1 upon rapamycin treatment.	Sirolimus	55-64	Rph1p	Saccharomyces cerevisiae S288C	45-49
32619236-7	2020	Phosphorylation-mimetic mutant of Rph1 exhibited more resistance to rapamycin treatment, decreased association with ribosome-related genes, and faster cell growth compared to the wild-type, indicating that Rph1 dissociation from chromatin ensures cell survival upon nutrient stress.	Sirolimus	68-77	Rph1p	Saccharomyces cerevisiae S288C	34-38
31961063-2	2020	Activation of mechanistic target of rapamycin complex 1 (mTORC1) is regulated by amino acid levels.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
31885313-9	2020	Taken together, our study identified that Avibirnavirus VP3 links PIK3C3-PDPK1 complex to AKT-MTOR pathway and inhibits autophagy, a critical step for controlling virus replication.Abbreviations: ATG14/Barkor: autophagy related 14; BECN1: beclin 1; CC: coiled-coil; ER: endoplasmic reticulum; hpi: hours post-infection; IBDV: infectious bursal disease virus; IP: co-immunoprecipitation; mAb: monoclonal antibody; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; MTOR: mechanistic target of rapamycin kinase; PDPK1: 3-phosphoinositid-dependent protein kinase-1; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol-3-phosphate; SQSTM1: sequestosome 1; vBCL2: viral BCL2 apoptosis regulator.	Sirolimus	534-543	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	66-72
32765763-8	2020	In COPD, cell senescence is linked to the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
32335998-8	2020	Linc-ROR promoted the cell proliferation, colony formation, cell migration and invasion of breast cancer and decreased the sensitivity of breast cancer cells to rapamycin.	Sirolimus	161-170	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	0-8
32335998-0	2020	Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.	Sirolimus	84-93	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	0-8
32335998-11	2020	In conclusion, linc-ROR serves as an onco-lncRNA in breast cancer and promotes the survival of breast cancer cells during rapamycin treatment by functioning as a ceRNA sponge for miR-194-3p, which targets MECP2.	Sirolimus	122-131	long intergenic non-protein coding RNA, regulator of reprogramming	Homo sapiens	15-23
32298692-2	2020	Rapamycin complexes with the immunophilin FKBP12, which subsequently binds and inhibits mTORC1.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	29-48
32298692-2	2020	Rapamycin complexes with the immunophilin FKBP12, which subsequently binds and inhibits mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	88-94
32422433-4	2020	Application of drugs that target either calcineurin (cyclosporine A) or FKBP12 (tacrolimus known as FK506 and sirolimus known as rapamycin) caused a decrease in TMEM16A activity.	Sirolimus	110-119	FKBP prolyl isomerase 1A	Homo sapiens	72-78
32719541-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) kinase regulates cell growth by setting the balance between anabolic and catabolic processes.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32612235-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) is a key metabolic hub that controls the cellular response to environmental cues by exerting its kinase activity on multiple substrates1-3.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32863202-1	2020	Sestrin2 (Sesn2) is a stress sensor for the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	64-73	sestrin 2	Homo sapiens	0-8
32863202-1	2020	Sestrin2 (Sesn2) is a stress sensor for the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	64-73	sestrin 2	Homo sapiens	10-15
32863202-1	2020	Sestrin2 (Sesn2) is a stress sensor for the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	85-91
32867785-8	2020	TIE2 mutant ECs revealed enhanced cell viability and motility, and decreased tube formation, whereas these phenotypes could be reversed by rapamycin.	Sirolimus	139-148	TEK receptor tyrosine kinase	Homo sapiens	0-4
32422433-4	2020	Application of drugs that target either calcineurin (cyclosporine A) or FKBP12 (tacrolimus known as FK506 and sirolimus known as rapamycin) caused a decrease in TMEM16A activity.	Sirolimus	129-138	FKBP prolyl isomerase 1A	Homo sapiens	72-78
32475313-7	2020	Significant reductions of renal T lymphocyte and macrophage together with inhibition of cell proliferation were observed in rapamycin treated rats suggesting a role of mTORC1 independent of NOX4 in the proliferation of immune cell.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Mus musculus	168-174
33042258-6	2020	Results: Our screen identified the inhibitors of mammalian target of rapamycin complex 1 (mTORC1), which increased cell uptake of [177Lu]Lu-PP-F11N.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	90-96
32553629-4	2020	Various proteins involved in G1/S transition, including Mbp1 and Swi4, but not Swi6, were largely lost after rapamycin treatment.	Sirolimus	109-118	transcription factor MBP1	Saccharomyces cerevisiae S288C	56-60
32553629-4	2020	Various proteins involved in G1/S transition, including Mbp1 and Swi4, but not Swi6, were largely lost after rapamycin treatment.	Sirolimus	109-118	SBF complex DNA-binding subunit SWI4	Saccharomyces cerevisiae S288C	65-69
32553629-8	2020	Mutant cells with an unstable Mbp1 protein were hypersensitive to rapamycin and more accumulated G1 cells in the absence and presence of rapamycin.	Sirolimus	66-75	transcription factor MBP1	Saccharomyces cerevisiae S288C	30-34
32553629-8	2020	Mutant cells with an unstable Mbp1 protein were hypersensitive to rapamycin and more accumulated G1 cells in the absence and presence of rapamycin.	Sirolimus	137-146	transcription factor MBP1	Saccharomyces cerevisiae S288C	30-34
32820315-5	2020	Moreover, we also analyzed the potential role of LeuRS in activation of mammalian target of rapamycin complex 1 (mTORC1) signaling transduction pathway in response to anabolic stimuli such as exercise and amino acids ingestion.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	113-119
32908624-8	2020	In contrast to the reported impairment of CHK1 activation in Atg7-deficient mouse embryonic fibroblasts, we found that the level of phosphorylated CHK1 was increased by CQ or ATG5 depletion but decreased by rapamycin or Torin1, suggesting that the increased genomic instability by defective autophagy is not caused by insufficient activation of CHK1-homologous recombination cascade.	Sirolimus	207-216	autophagy related 5	Mus musculus	175-179
32101625-6	2020	Moreover, NPY activated mTORC1 pathway in articular chondrocytes, while the administration of rapamycin (an mTORC1 inhibitor) in vitro abrogated NPY-mediated effects.	Sirolimus	94-103	CREB regulated transcription coactivator 1	Mus musculus	108-114
32703435-7	2020	The promoting effects of PCYT1A silencing on cell proliferation and migration could be abolished when mTORC1 signaling was inhibited by rapamycin or RAPTOR depletion.	Sirolimus	136-145	phosphate cytidylyltransferase 1A, choline	Homo sapiens	25-31
32703435-7	2020	The promoting effects of PCYT1A silencing on cell proliferation and migration could be abolished when mTORC1 signaling was inhibited by rapamycin or RAPTOR depletion.	Sirolimus	136-145	CREB regulated transcription coactivator 1	Mus musculus	102-108
32101625-6	2020	Moreover, NPY activated mTORC1 pathway in articular chondrocytes, while the administration of rapamycin (an mTORC1 inhibitor) in vitro abrogated NPY-mediated effects.	Sirolimus	94-103	neuropeptide Y	Mus musculus	145-148
32447719-3	2020	Following the addition of rapamycin, we detected that autophagy activation could reduce the increased expression level of alphaSMA and the accumulation of extracellular matrix component proteins namely fibronectin and type I collagen induced by TGF-beta1 via the inhibition of SMAD2 phosphorylation.	Sirolimus	26-35	SMAD family member 2	Homo sapiens	277-282
32603360-0	2020	Fpr1, a primary target of rapamycin, functions as a transcription factor for ribosomal protein genes cooperatively with Hmo1 in Saccharomyces cerevisiae.	Sirolimus	26-35	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	0-4
32603360-1	2020	Fpr1 (FK506-sensitive proline rotamase 1), a protein of the FKBP12 (FK506-binding protein 12 kDa) family in Saccharomyces cerevisiae, is a primary target for the immunosuppressive agents FK506 and rapamycin.	Sirolimus	197-206	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	0-4
32603360-1	2020	Fpr1 (FK506-sensitive proline rotamase 1), a protein of the FKBP12 (FK506-binding protein 12 kDa) family in Saccharomyces cerevisiae, is a primary target for the immunosuppressive agents FK506 and rapamycin.	Sirolimus	197-206	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	6-40
32603360-2	2020	Fpr1 inhibits calcineurin and TORC1 (target of rapamycin complex 1) when bound to FK506 and rapamycin, respectively.	Sirolimus	47-56	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	0-4
32603360-2	2020	Fpr1 inhibits calcineurin and TORC1 (target of rapamycin complex 1) when bound to FK506 and rapamycin, respectively.	Sirolimus	92-101	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	0-4
32603360-7	2020	Furthermore, mutation analyses of Fpr1 indicated that for transcriptional function on RPG promoters, Fpr1 requires its N-terminal domain and the binding surface for rapamycin, but not peptidyl-prolyl isomerase activity.	Sirolimus	165-174	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	101-105
32603360-8	2020	Notably, Fpr1 orthologues from other species also inhibit TORC1 when bound to rapamycin, but do not regulate transcription in yeast, which suggests that these two functions of Fpr1 are independent of each other.	Sirolimus	78-87	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	9-13
32612825-2	2020	The mechanistic target of rapamycin complex 1 (mTORC1) is a central hub of translation regulation, processing extra- and intra-cellular signals of nutrient availability and physiological state, such as amino acids and energy.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32612825-6	2020	A third group of mice was fed an adequate protein diet and treated with the mTORC1 inhibitor rapamycin (4 mg/kg every other day) intraperitoneally, with the first two groups treated with vehicle as control.	Sirolimus	93-102	CREB regulated transcription coactivator 1	Mus musculus	76-82
32612825-11	2020	Mammary phosphorylation of mTORC1"s downstream targets were decreased by protein restriction and rapamycin treatment (P < 0.05), while very little effect was observed in the liver of rapamycin treated mice, and none by protein restriction.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	27-33
32720716-4	2020	Release of Rab11-positive exosomes from cancer cells is increased relative to late endosomal exosomes by reducing growth regulatory Akt/mechanistic Target of Rapamycin Complex 1 (mTORC1) signalling or depleting the key metabolic substrate glutamine, which diverts membrane flux through recycling endosomes.	Sirolimus	158-167	RAB11A, member RAS oncogene family	Homo sapiens	11-16
32612825-11	2020	Mammary phosphorylation of mTORC1"s downstream targets were decreased by protein restriction and rapamycin treatment (P < 0.05), while very little effect was observed in the liver of rapamycin treated mice, and none by protein restriction.	Sirolimus	183-192	CREB regulated transcription coactivator 1	Mus musculus	27-33
32604881-2	2020	This unique organelle plays a critical role in restricting mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is essential for quiescent cells to maintain their quiescence.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	102-108
32807195-5	2020	Although mTORC1 inhibitor rapamycin and Rapalogs have demonstrated exciting results in the recent clinical trials, however, tumors rebound and upon the discontinuation of the mTORC1 inhibition.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	9-15
32807195-5	2020	Although mTORC1 inhibitor rapamycin and Rapalogs have demonstrated exciting results in the recent clinical trials, however, tumors rebound and upon the discontinuation of the mTORC1 inhibition.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	175-181
32923403-5	2020	Application of mTORC1/2 inhibitors (AZD8055, WYE-125132, MTI-31, and rapamycin) or genetic mTORC-depletion all reduced TF expression, which appeared to be differentially mediated depending on cellular context.	Sirolimus	69-78	CREB regulated transcription coactivator 2	Mus musculus	15-23
32588887-2	2020	TSC results from inactivating variants within the TSC1 or TSC2 genes, leading to constitutive activation of mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling.	Sirolimus	130-139	TSC complex subunit 1	Mus musculus	0-3
32588887-2	2020	TSC results from inactivating variants within the TSC1 or TSC2 genes, leading to constitutive activation of mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling.	Sirolimus	130-139	TSC complex subunit 1	Mus musculus	50-54
32588887-2	2020	TSC results from inactivating variants within the TSC1 or TSC2 genes, leading to constitutive activation of mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	151-157
32848709-0	2020	Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	25-31
32848709-5	2020	In addition, within striatum, ERK1/2 is also able to modulate in a D1 receptor-dependent manner the activity of the mammalian target of rapamycin complex 1 (mTORC1) pathway under DA depletion and L-DOPA therapy.	Sirolimus	136-145	CREB regulated transcription coactivator 1	Mus musculus	157-163
32848709-10	2020	Inhibition of mTORC1 by coadministration of rapamycin to L-DOPA was able to limit the magnitude of LID expression, accounting for a therapeutic effect of this drug.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	14-20
32554565-7	2020	In each case, the insulin-induced phosphorylation was abrogated by mTORC1 inhibitor rapamycin.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	67-73
32764289-2	2020	Amino acid signaling is mediated via two pathways: the mammalian target of rapamycin complex 1 (mTORC1) and the amino acid responsive (AAR) pathways.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	96-102
32764389-1	2020	The mammalian target of rapamycin complex 1 (mTORC1) is a central regulator of metabolism that integrates environmental inputs, including nutrients, growth factors, and stress signals.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
32576769-6	2020	However, the neuroprotective effects of Ang-1 were counteracted by rapamycin, an autophagy activating agent.	Sirolimus	67-76	angiopoietin 1	Homo sapiens	40-45
32502382-1	2020	The TSC complex is the cognate GTPase-activating protein (GAP) for the small GTPase Rheb and a crucial regulator of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	142-151	Ras homolog, mTORC1 binding	Homo sapiens	84-88
32502382-1	2020	The TSC complex is the cognate GTPase-activating protein (GAP) for the small GTPase Rheb and a crucial regulator of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	142-151	CREB regulated transcription coactivator 1	Mus musculus	163-169
32381646-0	2020	Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice.	Sirolimus	28-37	interleukin 2 receptor subunit alpha	Homo sapiens	65-69
32381646-0	2020	Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice.	Sirolimus	28-37	forkhead box P3	Homo sapiens	70-75
32381646-9	2020	The combination of IL-2 and rapamycin has the potential to inhibit human islet-allograft rejection by expanding CD4+FOXP3+ Tregs in vivo and supressing effector cell function, and could be the basis of effective tolerance-based regimens.	Sirolimus	28-37	forkhead box P3	Homo sapiens	116-121
32560625-9	2020	In contrast, rapamycin (an autophagy inducer) dramatically restores the inhibitory effect of NaBr on the mRNA expression levels of clock genes (Bmal1, Cry1 and Roralpha) and glycolytic genes (Hk2 and Pkm2).	Sirolimus	13-22	pyruvate kinase M1/2	Rattus norvegicus	200-204
32436749-3	2020	In the current study, we identified that mammalian target of rapamycin complex 1 (mTORC1) activation plays an important role in regulating the detrimental effects of SFA palmitate in hepatocytes, in specific cell death, and TG overproduction.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Mus musculus	82-88
32636835-2	2020	HMGB1 binds to its specific receptors not only to activate the nuclear factor (NF)-kappaB and mitogen-activated protein kinase (MAPK) pathways but also to regulate the activation of the phosphatidylinositol 3"-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/AKT/mTOR) pathway.	Sirolimus	258-267	high mobility group box 1	Homo sapiens	0-5
32666017-4	2020	One key complex that regulates beta-catenin activity is the mammalian target of rapamycin complex 2 (mTORc2).	Sirolimus	80-89	CREB regulated transcription coactivator 2	Mus musculus	101-107
32642911-11	2020	Rapamycin could prevent the aggravation of HTG-associated AP via inhibiting mTORC1/S6K1 pathway.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	76-82
32470351-7	2020	U50,488H increased alcohol drinking, and pretreatment with rapamycin, at a dose lower than effective doses, blocked the U50,488H-promoted alcohol intake in a dose-dependent manner, indicating a mTORC1-mediated mechanism.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	194-200
32470351-8	2020	Our results provide supportive and direct evidence relevant to the transcriptional profiling of the critical mTORC1 genes in mouse NAc shell: with functional and pharmacological effects of rapamycin, altered nuclear transcripts in the mTORC1 signaling pathway after excessive alcohol drinking may contribute to increased alcohol intake triggered by KOP-r activation.	Sirolimus	189-198	CREB regulated transcription coactivator 1	Mus musculus	109-115
32470351-8	2020	Our results provide supportive and direct evidence relevant to the transcriptional profiling of the critical mTORC1 genes in mouse NAc shell: with functional and pharmacological effects of rapamycin, altered nuclear transcripts in the mTORC1 signaling pathway after excessive alcohol drinking may contribute to increased alcohol intake triggered by KOP-r activation.	Sirolimus	189-198	CREB regulated transcription coactivator 1	Mus musculus	235-241
32655783-11	2020	More importantly, LINC00265 overexpression or miR-485-5p inhibitor reversed the 3-methyladenine (3-MA, an autophagy inhibitor)-mediated proliferation-inhibitory and pro-apoptotic effects, whereas LINC00265 silencing or miR-485-5p mimic overturned the proliferation-promoting and anti-apoptotic effects of autophagy activator rapamycin.	Sirolimus	325-334	long intergenic non-protein coding RNA 265	Homo sapiens	18-27
32366581-9	2020	GPA33high Treg cells universally express the transcription factor Helios that preferentially marks tTreg cells and can robustly and stably be expanded in vitro even without rapamycin.	Sirolimus	173-182	IKAROS family zinc finger 2	Homo sapiens	66-72
32434914-4	2020	Mimicking aspects of this metabolic profile in PRs of wild-type mice by activation of the mammalian target of rapamycin complex 1 (mTORC1) caused early drusen-like pathologies, as well as advanced AMD-like pathologies.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	unc-51 like autophagy activating kinase 1	Homo sapiens	0-41
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	unc-51 like autophagy activating kinase 1	Homo sapiens	43-47
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	CREB regulated transcription coactivator 1	Mus musculus	195-201
31441382-8	2020	Rapamycin rescued the effect of Atg5 siRNA in Ppargc1a+/+, but not in ppargc1a-/- VSMCs, suggesting that other targets of MTOR (mechanistic target of rapamycin kinase), in addition to autophagy, also contribute to senescence.	Sirolimus	0-9	autophagy related 5	Mus musculus	32-36
31441382-8	2020	Rapamycin rescued the effect of Atg5 siRNA in Ppargc1a+/+, but not in ppargc1a-/- VSMCs, suggesting that other targets of MTOR (mechanistic target of rapamycin kinase), in addition to autophagy, also contribute to senescence.	Sirolimus	0-9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	46-54
32336756-1	2020	BACKGOUND: The mechanistic target of rapamycin complex 1 (mTORC1) is important in the development and progression of many cancers.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
32314828-0	2020	HCC recurrence in HCV patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs.	Sirolimus	93-102	HCC	Homo sapiens	0-3
32944531-11	2020	Western blotting revealed that vitexin significantly increased the phosphorylation levels of Adenosine Monophosphate Activated Protein Kinase (AMPK) and c-Jun N-terminal kinase (JNK) in ACHN and OS-RC-2 cells, while decreasing the phosphorylation levels of phosphatidylinositol 3-kinase/activates protein kinase/mammalian target of rapamycin (PI3K/AKT/mTOR).	Sirolimus	332-341	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	143-147
32505344-2	2020	While 5"-adenosine monophosphate-activated protein kinase (AMPK) is a negative regulator of adipocyte differentiation and lipid accumulation, activation of mammalian target of rapamycin complex 1 (mTORC1), which is inhibited by AMPK, is required for adipocyte differentiation and positively regulates lipid accumulation.	Sirolimus	176-185	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	59-63
32505344-2	2020	While 5"-adenosine monophosphate-activated protein kinase (AMPK) is a negative regulator of adipocyte differentiation and lipid accumulation, activation of mammalian target of rapamycin complex 1 (mTORC1), which is inhibited by AMPK, is required for adipocyte differentiation and positively regulates lipid accumulation.	Sirolimus	176-185	CREB regulated transcription coactivator 1	Mus musculus	197-203
32505344-2	2020	While 5"-adenosine monophosphate-activated protein kinase (AMPK) is a negative regulator of adipocyte differentiation and lipid accumulation, activation of mammalian target of rapamycin complex 1 (mTORC1), which is inhibited by AMPK, is required for adipocyte differentiation and positively regulates lipid accumulation.	Sirolimus	176-185	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	228-232
32732901-5	2020	However, the results also provided evidence, for the first time, that omega-6 PUFAs (linoleic acid) induced autophagy and increased antioxidant ability through the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway and the AMPK-target of rapamycin (TOR) signaling pathway in hepatocytes in vitro.	Sirolimus	261-270	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	214-218
32774365-4	2020	This study aimed to evaluate the potential therapeutic effects of sirolimus in CHI patients with mutations in the ABCC8 and KCNJ11 genes.	Sirolimus	66-75	ATP binding cassette subfamily C member 8	Homo sapiens	114-119
32774365-12	2020	The oldest participant with a mutation in the ABCC8 gene responded well to sirolimus therapy after surgery and remained asymptomatic for 18 months.	Sirolimus	75-84	ATP binding cassette subfamily C member 8	Homo sapiens	46-51
32689970-1	2020	BACKGROUND: To investigate the expression and significance of mechanistic target of rapamycin complex 1(mTORC1) in diabetic retinopathy (DR), and to find new targets and new methods for the treatment of DR. METHODS: A DR rat model was prepared by general feeding combined with intraperitoneal injection of 10% streptozotocin (60 mg/kg).	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	104-110
32765037-11	2020	The results indicated an elevated level of autophagy in rapamycin and puerarin groups compared with the DN model, as demonstrated by the upregulated expression of autophagy markers Beclin-1, LC3II, and Atg5, and downregulated p62 expression.	Sirolimus	56-65	autophagy related 5	Mus musculus	202-206
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	Sirolimus	136-145	eukaryotic translation initiation factor 2A	Mus musculus	33-42
32683410-13	2020	Finally, treatment with rapamycin (an mTOR inhibitor) was shown to abolish the increased proliferation capability of DM1 SSCs due to MBNL1 overexpression.	Sirolimus	24-33	muscleblind like splicing regulator 1	Homo sapiens	133-138
32765227-4	2020	Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	Ras homolog, mTORC1 binding	Homo sapiens	97-101
32765227-4	2020	Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	CREB regulated transcription coactivator 1	Mus musculus	177-183
32660632-10	2020	Suppression of mTORC1/p70S6K pathway by either rapamycin or p70S6K knockdown promoted heterochromatin organization and ameliorated Dox- or H2O2-induced DNA damage and senescence.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	15-21
32421368-12	2020	We found that mTORC1 inhibition with low doses of rapamycin (2, 20 nM) lowered macrophage priming of IL-1b mRNA and secretion of IL-1b caused by multiple statins.	Sirolimus	50-59	CREB regulated transcription coactivator 1	Mus musculus	14-20
32706077-8	2020	Also, rapamycin treatment increased the expressions of bcl-2, bcl-xL, HSP70, and HSP90.	Sirolimus	6-15	BCL2-like 1	Mus musculus	62-68
32469097-7	2020	Supplementing miR-196b-5p activity in progenitor cells reduced the protein level of TSC1 and activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	144-150
32372406-2	2020	alpha2 -AMPK activity-deficient mice have lower contraction-stimulated protein synthesis Increasing glycogen activates mTORC1-S6K1 independently of AMPK alpha2 Normalizing muscle glycogen content rescues reduced protein synthesis in AMPK-deficient mice ABSTRACT: Objective The mammalian Target of Rapamycin Complex 1 (mTORC1)-S6K1 signalling pathway regulates muscle growth-related protein synthesis and is antagonized by AMP-activated protein kinase (AMPK) in multiple cell types.	Sirolimus	297-306	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	8-12
32372406-2	2020	alpha2 -AMPK activity-deficient mice have lower contraction-stimulated protein synthesis Increasing glycogen activates mTORC1-S6K1 independently of AMPK alpha2 Normalizing muscle glycogen content rescues reduced protein synthesis in AMPK-deficient mice ABSTRACT: Objective The mammalian Target of Rapamycin Complex 1 (mTORC1)-S6K1 signalling pathway regulates muscle growth-related protein synthesis and is antagonized by AMP-activated protein kinase (AMPK) in multiple cell types.	Sirolimus	297-306	CREB regulated transcription coactivator 1	Mus musculus	119-125
32386481-9	2020	More important, preconditioning with PI3K/AKT inhibitor LY294002 or mTOR inhibitor rapamycin both aggravated KLK10 knockdown-suppressed cancer cell growth and glucose metabolism.	Sirolimus	83-92	kallikrein related peptidase 10	Homo sapiens	109-114
32612145-8	2020	Finally, we show that inhibition of mTORC1 with rapamycin in ACD mucosal explants reduces p-4EBP and production of IL-15, a master cytokine produced by epithelial cells in this disorder.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Mus musculus	36-42
32579942-1	2020	Tuberous sclerosis complex (TSC) is a neurogenetic disorder that leads to elevated mechanistic targeting of rapamycin complex 1 (mTORC1) activity.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	129-135
32655497-6	2020	The insulin-resistant state, commonly reported in AD brain, results in neuronal glucose deprivation, due to a dampening down of the PI3K/Akt pathway, including overactivity of the mammalian target of rapamycin 1 (mTORC1) complex, hyperphosphorylation of p53 and neuronal death.	Sirolimus	200-209	CREB regulated transcription coactivator 1	Mus musculus	213-219
31904150-5	2020	Additionally, mTOR inhibition with rapamycin in differentiating OPCs alters the transcriptional complex present at the Id2 promoter.	Sirolimus	35-44	inhibitor of DNA binding 2	Mus musculus	119-122
32642630-3	2020	CDK4/6 inhibitor monotherapy is ineffective due to RAS-mediated activation of alternative pathways, including phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR).	Sirolimus	160-169	cyclin dependent kinase 4	Homo sapiens	0-6
32560625-9	2020	In contrast, rapamycin (an autophagy inducer) dramatically restores the inhibitory effect of NaBr on the mRNA expression levels of clock genes (Bmal1, Cry1 and Roralpha) and glycolytic genes (Hk2 and Pkm2).	Sirolimus	13-22	cryptochrome circadian regulator 1	Rattus norvegicus	151-155
32470053-12	2020	Rapamycin-sensitive insulin treatment and amino acids increased S297 phosphorylation, suggesting that the response to food intake might be regulated via the insulin-mTORC1 pathway.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	165-171
32561715-2	2020	The mechanistic target of rapamycin complex 1 (mTORC1) is a well-conserved negative regulator of autophagy.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32444657-3	2020	However, RE-induced rapamycin-sensitive mechanistic target of rapamycin complex 1 (mTORC1) activation is higher and has a longer duration than after AE.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	83-89
32549199-7	2020	The mTORC1 inhibitor rapamycin abolished the increase in LC3-I and p62.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
32531927-4	2020	We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	213-219
32444657-3	2020	However, RE-induced rapamycin-sensitive mechanistic target of rapamycin complex 1 (mTORC1) activation is higher and has a longer duration than after AE.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	83-89
32312749-1	2020	The mammalian target of rapamycin complex 1 (mTORC1) senses nutrients to mediate anabolic processes within the cell.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
32444657-6	2020	In this study, we used an electrical stimulation-induced RE model in rats, with rapamycin as an inhibitor of mTORC1 activation.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	109-115
32598580-16	2020	Furthermore, SHP affected fibrosis by inhibiting autophagy activated through treatment with rapamycin in LX2 cells.	Sirolimus	92-101	nuclear receptor subfamily 0 group B member 2	Homo sapiens	13-16
31509054-3	2020	In this study we found that during integrin alphaIIbbeta3 outside-in signaling PI3Kbeta-dependent phosphorylation of Akt on Serine473 is mediated by the mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	173-182	CREB regulated transcription coactivator 2	Mus musculus	194-200
32375048-2	2020	However, UCP1 expression but not DNL activation requires rapamycin-sensitive mTORC1.	Sirolimus	57-66	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	9-13
32152006-8	2020	Moreover, our data reflect that the deletion of Sirt4 rescued the metabolic response to rapamycin among the introgressed strains.	Sirolimus	88-97	Sirtuin 4	Drosophila melanogaster	48-53
32449834-4	2020	Inhibition of TORC1 signaling by either TOR1 deletion or rapamycin treatment decreased PMA1 expression, pHc, and vacuolar pH, whereas activation of TORC1 signaling by expressing constitutively active GTR1 (GTR1Q65L) resulted in the opposite phenotypes.	Sirolimus	57-66	H(+)-exporting P2-type ATPase PMA1	Saccharomyces cerevisiae S288C	87-91
32350925-7	2020	Importantly, these effects were mediated by the mammalian target of rapamycin complex 1 (mTORC1)-RPS6 pathway.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
32350925-7	2020	Importantly, these effects were mediated by the mammalian target of rapamycin complex 1 (mTORC1)-RPS6 pathway.	Sirolimus	68-77	ribosomal protein S6	Homo sapiens	97-101
32566604-7	2020	In vitro, except IgG levels, the increased glycolysis levels, expression of key glycolytic enzymes, BAFF-R and frequency of CD80 and CD86 of B cells, could be inhibited by rapamycin and PX-478.	Sirolimus	172-181	CD80 molecule	Homo sapiens	124-128
32566604-7	2020	In vitro, except IgG levels, the increased glycolysis levels, expression of key glycolytic enzymes, BAFF-R and frequency of CD80 and CD86 of B cells, could be inhibited by rapamycin and PX-478.	Sirolimus	172-181	CD86 molecule	Homo sapiens	133-137
31958214-9	2020	We conclude that loss of TSC1 or TSC2 led to upregulated expression of PFKFB3 through activation of mTORC1/HIF-1alpha signaling pathway and co-administration of rapamycin and PFK15 may be a promising strategy for the treatment of TSC tumors as well as other hyperactivated mTORC1-related tumors.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	273-279
32301281-7	2020	The expression levels of LC3-II, Beclin1 and lncRNA H19 were increased in intestinal tissues and IEC-6 cells after rapamycin treatment but were reversed after 3-MA treatment.	Sirolimus	115-124	beclin 1	Rattus norvegicus	33-40
31875479-1	2020	BACKGROUND: The protein kinase target of rapamycin (mTOR) in complex 1 (mTORC1) is activated by amino acids and in turn upregulates anabolic processes.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	72-78
31965176-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) is a highly evolutionarily conserved serine/threonine kinase that regulates cell growth and metabolism in response to multiple environmental cues, such as nutrients, hormones, energy, and stress.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
32092760-0	2020	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	60-66
32391090-8	2020	The AMP-dependent protein kinase (AMPK)/target of rapamycin complex (mTORC) 1 signaling pathway participates in the regulation of NUCB-2-mediated metastasis and EMT.	Sirolimus	50-59	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	4-32
32391090-8	2020	The AMP-dependent protein kinase (AMPK)/target of rapamycin complex (mTORC) 1 signaling pathway participates in the regulation of NUCB-2-mediated metastasis and EMT.	Sirolimus	50-59	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	34-38
32278045-0	2020	The anticancer effects of curcumin via targeting the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	94-100
32347294-4	2020	Short-term rapamycin treatment inhibits the kinase activity of mTORC1 but not mTORC2.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	63-69
32548088-3	2020	Rapamycin (RAPA) has been recognized as a promising drug for alleviating hepatic steatosis on NAFLD, but the poorly water-soluble properties and side effects of RAPA limit their clinical use.	Sirolimus	0-9	transcriptional regulating factor 1	Homo sapiens	11-15
32280987-8	2020	mTORC1 inhibition with rapamycin significantly improved survival of CKO animals and prevented observed seizures, including for up to forty days following rapamycin withdrawal.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
32280987-8	2020	mTORC1 inhibition with rapamycin significantly improved survival of CKO animals and prevented observed seizures, including for up to forty days following rapamycin withdrawal.	Sirolimus	154-163	CREB regulated transcription coactivator 1	Mus musculus	0-6
32518628-1	2020	A complex molecular machinery converges on the surface of lysosomes to ensure that the growth-promoting signaling mediated by mechanistic target of rapamycin complex 1 (mTORC1) is tightly controlled by the availability of nutrients and growth factors.	Sirolimus	148-157	CREB regulated transcription coactivator 1	Mus musculus	169-175
32092760-2	2020	To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	79-85
32311329-1	2020	Using cryo-electron microscopy and molecular characterization, David Sabatini and colleagues provide crucial new insights that validate and expand their model of how amino acids are sensed and signal at the lysosome to activate mechanistic target of rapamycin complex 1 (mTORC1) and cell growth-regulating processes.	Sirolimus	250-259	CREB regulated transcription coactivator 1	Mus musculus	271-277
32275833-5	2020	Meanwhile, the myogenic regulatory factors (MRFs) and the mammalian target of rapamycin complex 1 (mTORC1) pathway showed the same tendencies of changes as the differentiation of SCs.	Sirolimus	78-87	CREB regulated transcription coactivator 1	Mus musculus	99-105
32275833-6	2020	After Lys was resupplemented with rapamycin, the mTORC1 pathway was inhibited, and the differentiation ability of SCs was suppressed.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	49-55
32348753-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) is a master modulator of cellular growth, and its aberrant regulation is recurrently documented within breast cancer.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
31982508-1	2020	Leucine, nutrient signal and substrate for the branched chain aminotransferase (BCAT) activates the mechanistic target of rapamycin (mTORC1) and regulates autophagic flux, mechanisms implicated in the pathogenesis of neurodegenerative conditions such as Alzheimer"s disease (AD).	Sirolimus	122-131	CREB regulated transcription coactivator 1	Mus musculus	133-139
32433973-4	2020	We demonstrate that Lunapark interacts with mechanistic target of rapamycin complex-1 (mTORC1), a central cellular regulator that coordinates growth and metabolism with environmental conditions.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Mus musculus	87-93
32035621-3	2020	Unlike other autophagy genes, KO of ULK1 or ATG13 attenuated ER stress and promoted mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	104-113	unc-51 like autophagy activating kinase 1	Homo sapiens	36-40
32035621-3	2020	Unlike other autophagy genes, KO of ULK1 or ATG13 attenuated ER stress and promoted mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	104-113	CREB regulated transcription coactivator 1	Mus musculus	125-131
31733178-8	2020	Rapamycin partially inhibited human, baboon, and pig IL-6/IL-6Ralpha/STAT3 pathways, and suppressed inflammatory gene expression.	Sirolimus	0-9	interleukin 6	Sus scrofa	53-57
32421369-6	2020	Furthermore, the glucagon-induced upregulation of FGF21 mRNA translation is associated with suppressed activity of the mechanistic target of rapamycin in complex 1 (mTORC1).	Sirolimus	141-150	fibroblast growth factor 21	Rattus norvegicus	50-55
32421369-6	2020	Furthermore, the glucagon-induced upregulation of FGF21 mRNA translation is associated with suppressed activity of the mechanistic target of rapamycin in complex 1 (mTORC1).	Sirolimus	141-150	CREB regulated transcription coactivator 1	Mus musculus	165-171
32421369-7	2020	Similarly, the results show that rapamycin-induced suppression of mTORC1 leads to upregulation of FGF21 mRNA translation with no change in FGF21 mRNA abundance.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	66-72
32421369-7	2020	Similarly, the results show that rapamycin-induced suppression of mTORC1 leads to upregulation of FGF21 mRNA translation with no change in FGF21 mRNA abundance.	Sirolimus	33-42	fibroblast growth factor 21	Rattus norvegicus	98-103
32424120-7	2020	Furthermore, the SOX2/NeuN ratio in the DG was decreased in mice treated with rapamycin.	Sirolimus	78-87	RNA binding protein, fox-1 homolog (C. elegans) 3	Mus musculus	22-26
31917615-7	2020	DP1 deficiency promoted PASMC hypertrophy and proliferation in response to hypoxia via induction of mammalian target of rapamycin complex (mTORC) 1 activity.	Sirolimus	120-129	prostaglandin D2 receptor	Homo sapiens	0-3
31917615-8	2020	Rapamycin, an inhibitor of mTORC1, alleviated the hypoxia-induced exacerbation of PAH in DP1-/- mice.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	27-33
32375878-2	2020	TSC1 and TSC2 are repressors of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of protein synthesis.	Sirolimus	58-67	TSC complex subunit 1	Mus musculus	0-4
32375878-2	2020	TSC1 and TSC2 are repressors of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of protein synthesis.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	79-85
31733178-8	2020	Rapamycin partially inhibited human, baboon, and pig IL-6/IL-6Ralpha/STAT3 pathways, and suppressed inflammatory gene expression.	Sirolimus	0-9	interleukin 6 receptor	Sus scrofa	58-68
32395516-0	2020	Reduction of FoxP3+ Tregs by an immunosuppressive protocol of rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat model of hepatocellular carcinoma.	Sirolimus	62-71	forkhead box P3	Rattus norvegicus	13-18
32395516-6	2020	Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02).	Sirolimus	29-33	forkhead box P3	Rattus norvegicus	148-153
31876121-3	2020	They demonstrated that CD4+ T cells isolated from Takayasu"s arteritis (TAK) are biased to differentiate into Th1 and Th17 cells because of mechanistic target of rapamycin complex 1 (mTORC1) hyperactivity.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-189
31876121-4	2020	Subsequently, using human artery-NSG chimera model, they showed that mTORC1 inhibition, by either rapamycin or RNAi technology, effectively abrogated the mal-differentiation of TAK CD4+ T cells and vascular inflammation.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	69-75
31923703-12	2020	Rapamycin treatment of mpz-EGFP/osterix-DsRed double transgenic medaka inhibited not only the crosslink connection of mpz+ cells but also osterix+ osteoblast accumulation at the fracture site, accompanied with a fracture healing defect.	Sirolimus	0-9	myelin protein P0	Oryzias latipes	23-26
31923703-12	2020	Rapamycin treatment of mpz-EGFP/osterix-DsRed double transgenic medaka inhibited not only the crosslink connection of mpz+ cells but also osterix+ osteoblast accumulation at the fracture site, accompanied with a fracture healing defect.	Sirolimus	0-9	myelin protein P0	Oryzias latipes	118-121
32068977-7	2020	In terms of mechanism, we found mTORC1 activity was impaired by downregulation of METTL3, additional silencing of METTL3 cannot further decrease the phosphorylation level of mTORC1 and glycolysis activity in Rapamycin-treated HCC cells.	Sirolimus	208-217	CREB regulated transcription coactivator 1	Mus musculus	174-180
31985872-2	2020	Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 mediated transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction.	Sirolimus	146-155	coagulation factor VIII	Homo sapiens	28-39
31985872-2	2020	Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 mediated transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction.	Sirolimus	146-155	coagulation factor VIII	Homo sapiens	41-46
32032574-5	2020	Treatment of mice at P7 with rapamycin or 3-methyladenine (activator and inhibitor of autophagy, respectively) for 7 days led to the significant elevations of hearing threshold across frequencies from P15 to P30.	Sirolimus	29-38	high mobility group box 1	Mus musculus	208-211
31927699-6	2020	In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased.	Sirolimus	98-107	C-X-C motif chemokine ligand 12	Rattus norvegicus	170-175
32188096-1	2020	Ras homolog protein enriched in brain (Rheb) is a key activator of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	87-96	Ras homolog, mTORC1 binding	Homo sapiens	39-43
32188096-1	2020	Ras homolog protein enriched in brain (Rheb) is a key activator of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	108-114
32375878-13	2020	Chronic, but not acute treatment, with the mTORC1 inhibitor rapamycin reversed the impairment in synaptic inhibition.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	43-49
31930970-5	2020	In addition, LPS stimulation potently induced transcriptional upregulation of RagD, an important activation factor of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	159-165
32528831-0	2020	Interleukin-27 decreases ghrelin production through signal transducer and activator of transcription 3-mechanistic target of rapamycin signaling.	Sirolimus	125-134	ghrelin	Mus musculus	25-32
32528831-4	2020	Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27.	Sirolimus	107-116	ghrelin	Mus musculus	162-169
32528831-8	2020	Inhibition of mTOR activity induced by mTOR siRNA or rapamycin blocked the suppression of ghrelin production induced by IL-27 in mHypoE-N42 cells.	Sirolimus	53-62	ghrelin	Mus musculus	90-97
32114433-3	2020	We have previously shown that rapamycin inhibits p-mTOR to repress PS1 transcription and Notch 1-signaling.	Sirolimus	30-39	presenilin 1	Homo sapiens	67-70
31891737-4	2020	DGKbeta induced neurite outgrowth by activation of mammalian target of rapamycin complex 1 (mTORC1) through a kinase-dependent pathway.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	92-98
31932481-7	2020	HuR silencing in cultured IECs also prevented rapamycin-induced autophagy, which was abolished by overexpressing ATG16L1.	Sirolimus	46-55	autophagy related 16 like 1	Homo sapiens	113-120
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	153-159
32118186-10	2020	NBQX (an AMPAR blocker), MK 2206 (an Akt blocker), and rapamycin (an mTOR blocker) used in pretreatment attenuated the antidepressant effects of vanillic acid, but SL327 (an ERK inhibitor) did not.	Sirolimus	55-64	Eph receptor B2	Mus musculus	174-177
32142833-10	2020	However, the protective effects of GSK3beta siRNA were blocked by rapamycin.	Sirolimus	66-75	glycogen synthase kinase 3 alpha	Rattus norvegicus	35-43
32062191-0	2020	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	TNF superfamily member 13b	Homo sapiens	19-43
32062191-0	2020	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	TNF superfamily member 13b	Homo sapiens	45-49
32062191-2	2020	Recent studies have shown that rapamycin can prevent BAFF-induced B-cell proliferation and survival, but the underlying mechanism remains to be elucidated.	Sirolimus	31-40	TNF superfamily member 13b	Homo sapiens	53-57
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	TNF superfamily member 13b	Homo sapiens	53-57
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	cyclin dependent kinase 2	Homo sapiens	186-190
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	cyclin dependent kinase 4	Homo sapiens	192-196
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	cyclin D1	Homo sapiens	214-223
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	239-248	TNF superfamily member 13b	Homo sapiens	53-57
32062191-9	2020	The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway.	Sirolimus	26-35	TNF superfamily member 13b	Homo sapiens	45-49
32062191-9	2020	The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	107-113
32062191-10	2020	Our finding underscores that rapamycin may be exploited for prevention of excessive BAFF-induced aggressive B-cell malignancies and autoimmune diseases.	Sirolimus	29-38	TNF superfamily member 13b	Homo sapiens	84-88
31863766-9	2020	Moreover, thrombin-stimulated p300 phosphorylation was attenuated by Akt DN, rapamycin, and p70S6K siRNA.	Sirolimus	77-86	E1A binding protein p300	Homo sapiens	30-34
31689244-6	2020	Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs-including in HHT patient blood outgrowth ECs-and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs.	Sirolimus	27-36	SMAD family member 1	Homo sapiens	163-170
31823466-3	2020	Previous work from our laboratory indicated that short-term (10-week) treatment with rapamycin, an mTORC1 inhibitor, improved measures of these age-related changes.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	99-105
31903726-4	2020	The ITP found rapamycin, an inhibitor to the pro-growth mTORC1 (mechanistic target of rapamycin complex 1) pathway, improved survival and it suppressed tumors in Apc+/Min mice providing a plausible rationale to ask if acarbose had a similar effect.	Sirolimus	14-23	CREB regulated transcription coactivator 1	Mus musculus	56-62
31794259-2	2020	Grb10 is also a substrate for the mechanistic target of rapamycin complex 1 (mTORC1) that mediates its feedback inhibition on phosphatidylinositide 3-kinase (PI3K)/Akt signaling.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	77-83
31794259-7	2020	However, acute inhibition of mTORC1 with rapamycin blocked Grb10 Ser476 phosphorylation and repressed a negative-feedback loop on PI3K/Akt signaling that increased myotube responsiveness to insulin.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	29-35
31794259-8	2020	Chronic rapamycin treatment reduced Grb10 protein abundance in conjunction with increased insulin receptor protein levels.	Sirolimus	8-17	insulin receptor	Homo sapiens	90-106
31886628-1	2020	Mammalian target of rapamycin complex 1 (mTORC1) is evolutionally conserved and frequently activated in various tumors, including colorectal cancer (CRC).	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
31886628-10	2020	Furthermore, URB1 and CCNA2 expression were also impeded by rapamycin, which is a specific inhibitor of mTORC1.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	104-110
31651100-2	2020	It is well established that Mammalian Target of Rapamycin Complex 1 (mTORC1) signalling is a key modulator in mediating increases in skeletal muscle mass and function.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Mus musculus	69-75
31978396-3	2020	We previously identified the conserved zinc finger/RING protein Unkempt (Unk) as a key temporal regulator of neuronal differentiation in the Drosophila developing eye and showed that Unk acts downstream of the mechanistic target of rapamycin (mTOR) pathway together with its binding partner Headcase (Hdc).	Sirolimus	232-241	headcase	Drosophila melanogaster	291-299
31978396-3	2020	We previously identified the conserved zinc finger/RING protein Unkempt (Unk) as a key temporal regulator of neuronal differentiation in the Drosophila developing eye and showed that Unk acts downstream of the mechanistic target of rapamycin (mTOR) pathway together with its binding partner Headcase (Hdc).	Sirolimus	232-241	headcase	Drosophila melanogaster	301-304
32072192-9	2020	Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality.	Sirolimus	178-187	high mobility group box 1	Mus musculus	34-39
31958214-2	2020	The main etiology of TSC is the loss-of-function mutation of TSC1 or TSC2 gene, which leads to aberrant activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	159-165
32003113-7	2020	Gal-3 also activated protein kinase B/glycogen synthase kinase-3 beta/mammalian target of rapamycin signaling pathways in PVECs.	Sirolimus	90-99	galectin 3	Homo sapiens	0-5
32003113-8	2020	These results suggest that a hypoxia-mediated increase in Gal-3 promotes apoptosis and inhibits autophagy by inhibiting the TRPC1/4 pathway and activating the protein kinase B/glycogen synthase kinase-3 beta/mammalian target of rapamycin signaling pathway in PVECs.	Sirolimus	228-237	galectin 3	Homo sapiens	58-63
31674073-12	2020	PCAT-1 silence caused decrease in Wnt3a, beta-catenin, and phosphorylation of protein kinase B and mechanistic target of rapamycin was abolished by miR-124-3p inhibitor.	Sirolimus	121-130	prostate cancer associated transcript 1	Homo sapiens	0-6
31915367-9	2020	In contrast, the postnatal treatment of jck mice with sirolimus reduced both Cdk2 and Cdk1 activity and reduced renal cyst growth.	Sirolimus	54-63	cyclin-dependent kinase 1	Mus musculus	86-90
32287270-4	2020	The best-known function of SESN2 is the inhibition of the mechanistic target of rapamycin complex 1 kinase (mTORC1) that plays a central role in support of cell growth and suppression of autophagy.	Sirolimus	80-89	sestrin 2	Homo sapiens	27-32
32287270-4	2020	The best-known function of SESN2 is the inhibition of the mechanistic target of rapamycin complex 1 kinase (mTORC1) that plays a central role in support of cell growth and suppression of autophagy.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	108-114
31697050-2	2020	Signalling via the mammalian target of rapamycin complex 1 (mTORC1) regulates proteostasis in skeletal muscle by affecting protein synthesis and autophagosomal protein degradation.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	60-66
31697050-4	2020	However, systemic dampening of mTORC1 signalling by its allosteric inhibitor rapamycin is beneficial at the organismal level and increases lifespan.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	31-37
32002721-8	2020	However, using rapamycin, an autophagy activator, could rescue these adverse effects of BMSCs caused by SIRT6 inhibition.	Sirolimus	15-24	sirtuin 6	Homo sapiens	104-109
31782083-3	2020	We provide evidence that eIF4E phosphorylation is regulated by mTORC1 by virtue of its interaction with Raptor through a novel TPTPNPP motif and consequent phosphorylation invitro and in vivo in a Rapamycin-sensitive manner.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
31782083-3	2020	We provide evidence that eIF4E phosphorylation is regulated by mTORC1 by virtue of its interaction with Raptor through a novel TPTPNPP motif and consequent phosphorylation invitro and in vivo in a Rapamycin-sensitive manner.	Sirolimus	197-206	CREB regulated transcription coactivator 1	Mus musculus	63-69
31782083-3	2020	We provide evidence that eIF4E phosphorylation is regulated by mTORC1 by virtue of its interaction with Raptor through a novel TPTPNPP motif and consequent phosphorylation invitro and in vivo in a Rapamycin-sensitive manner.	Sirolimus	197-206	regulatory associated protein of MTOR complex 1	Homo sapiens	104-110
31782083-4	2020	While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation.	Sirolimus	75-84	eukaryotic translation initiation factor 4E	Homo sapiens	46-51
31782083-4	2020	While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation.	Sirolimus	123-132	eukaryotic translation initiation factor 4E	Homo sapiens	153-158
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
32015438-1	2020	The Hippo and mammalian target of rapamycin complex 1 (mTORC1) pathways are the two predominant growth-control pathways that dictate proper organ development.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
31605778-6	2020	Both the sleep abnormalities and increased orexin expression in Tsc1GFAPCKO mice were reversed by rapamycin treatment, indicating their dependence on mTOR activation.	Sirolimus	98-107	hypocretin	Mus musculus	43-49
31793097-11	2020	Additionally, rapamycin (a mTOR antagonist) notably attenuated the effects of Rheb on the autophagy, proliferation, apoptosis, and MITF expression in LCA-treated melanoma cells.	Sirolimus	14-23	Ras homolog enriched in brain	Mus musculus	78-82
31793097-11	2020	Additionally, rapamycin (a mTOR antagonist) notably attenuated the effects of Rheb on the autophagy, proliferation, apoptosis, and MITF expression in LCA-treated melanoma cells.	Sirolimus	14-23	clathrin, light polypeptide (Lca)	Mus musculus	150-153
31822355-3	2020	This basic leucine-zipper (bZIP) transcription factor is controlled by the lifespan regulator mechanistic/mammalian target of rapamycin complex 1 (mTORC1) and plays an important role in energy homeostasis and adipose tissue differentiation.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	147-153
32047109-6	2020	Intriguingly, we found that metformin- or rapamycin-induced activation of autophagy significantly lessened the size and levels of CCFs and repressed the activation of the cGAS-STING-NF-kappaB-SASP cascade and cellular senescence.	Sirolimus	42-51	stimulator of interferon response cGAMP interactor 1	Mus musculus	176-181
32035060-3	2020	Mammalian target of rapamycin complex 2 (mTORC2) was identified to regulate cell metabolism, proliferation and survival.	Sirolimus	20-29	CREB regulated transcription coactivator 2	Mus musculus	41-47
33346412-7	2020	The expressions of LC3 and Bcl-2 in the testis tissue were significantly higher in the VC + rapamycin (P<0.01) but lower in the VC + chloroquine group (P<0.01), while those of p62 and Bax remarkably lower in the VC + rapamycin (P<0.01) but higher in the VC + chloroquine group than in the VC model controls (P<0.01).	Sirolimus	92-101	annexin A3	Rattus norvegicus	19-22
31985274-9	2020	Moreover, rapamycin (an autophagy activator) effectively attenuated the MALAT1-mediated enhancement of cardiomyocyte apoptosis.	Sirolimus	10-19	metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)	Mus musculus	72-78
31877229-8	2020	Interestingly, the AMPK activator AICAR, the autophagy inducer rapamycin and the demethylation inhibitor difenoconazole negated CD74 ablation-offered benefit against LPS-induced cardiac dysfunction while the SUV39H1 inhibitor chaetocin or methylation inhibitor 5-AzaC ameliorated LPS-induced GFP-LC3B formation and cardiomyocyte contractile dysfunction.	Sirolimus	63-72	CD74 molecule	Homo sapiens	128-132
33346412-7	2020	The expressions of LC3 and Bcl-2 in the testis tissue were significantly higher in the VC + rapamycin (P<0.01) but lower in the VC + chloroquine group (P<0.01), while those of p62 and Bax remarkably lower in the VC + rapamycin (P<0.01) but higher in the VC + chloroquine group than in the VC model controls (P<0.01).	Sirolimus	217-226	annexin A3	Rattus norvegicus	19-22
31735334-4	2020	We now show that G6Pase-alpha deficiency-mediated hepatic autophagy impairment leads to sustained accumulation of an autophagy-specific substrate p62 which can activate tumor-promoting pathways including nuclear factor erythroid 2-related factor 2 (Nrf2) and mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	279-288	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	17-29
31898848-5	2020	NPRL3 is a component of the GAP Activity Towards Rags 1 (GATOR1) protein complex that inhibits mammalian Target of Rapamycin Complex 1 (mTORC1) activity and it is found mutated in familial focal cortical dysplasia and familial focal epilepsy.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	136-142
31969673-1	2020	The group II metabotropic glutamate 2/3 (mGlu2/3) receptor antagonist LY341495 produces antidepressant-like effects by acting on mammalian target of rapamycin complex 1 (mTORC1) signaling and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors in rodent.	Sirolimus	149-158	CREB regulated transcription coactivator 1	Mus musculus	170-176
32317516-7	2020	Result: One-way ANOVA test showed a significant difference in all markers that have been used (P < 0.05) on MNU-breast tumor treated with rapamycin (M= 90.1664, SD= 7.4487), PF4 (M= 93.7946, SD= 7.1303) and rapamycin + PF4 (M= 93.6990, SD= 1.8432).	Sirolimus	138-147	platelet factor 4	Rattus norvegicus	219-222
31874182-0	2020	Treatment with Rapamycin Can Restore Regulatory T Cell Function in IPEX Patients.	Sirolimus	15-24	forkhead box P3	Homo sapiens	67-71
31874182-4	2020	Rapamycin has been shown to suppress peripheral T cells while sparing Tregs expressing wild-type FOXP3, thereby proving beneficial in the clinical setting of immune-dysregulation.	Sirolimus	0-9	forkhead box P3	Homo sapiens	97-102
31874182-6	2020	OBJECTIVE: To determine the cellular and molecular basis of the clinical benefit observed under rapamycin treatment in six IPEX patients with different FOXP3 mutations.	Sirolimus	96-105	forkhead box P3	Homo sapiens	123-127
31874182-6	2020	OBJECTIVE: To determine the cellular and molecular basis of the clinical benefit observed under rapamycin treatment in six IPEX patients with different FOXP3 mutations.	Sirolimus	96-105	forkhead box P3	Homo sapiens	152-157
31874182-7	2020	METHODS: We tested phenotype and function of FOXP3-mutated Tregs from rapamycin-treated IPEX patients by flow cytometry and in vitro suppression assays, and the gene expression profile of rapamycin-conditioned Tregs by droplet-digital-PCR.	Sirolimus	70-79	forkhead box P3	Homo sapiens	45-50
31874182-7	2020	METHODS: We tested phenotype and function of FOXP3-mutated Tregs from rapamycin-treated IPEX patients by flow cytometry and in vitro suppression assays, and the gene expression profile of rapamycin-conditioned Tregs by droplet-digital-PCR.	Sirolimus	70-79	forkhead box P3	Homo sapiens	88-92
31874182-11	2020	CONCLUSION: Rapamycin is able to impact on Treg suppressive function via a FOXP3-independent mechanism, thus sustaining the clinical improvement observed in IPEX patients under rapamycin treatment.	Sirolimus	12-21	forkhead box P3	Homo sapiens	75-80
31874182-11	2020	CONCLUSION: Rapamycin is able to impact on Treg suppressive function via a FOXP3-independent mechanism, thus sustaining the clinical improvement observed in IPEX patients under rapamycin treatment.	Sirolimus	12-21	forkhead box P3	Homo sapiens	157-161
31874182-11	2020	CONCLUSION: Rapamycin is able to impact on Treg suppressive function via a FOXP3-independent mechanism, thus sustaining the clinical improvement observed in IPEX patients under rapamycin treatment.	Sirolimus	177-186	forkhead box P3	Homo sapiens	75-80
31874182-11	2020	CONCLUSION: Rapamycin is able to impact on Treg suppressive function via a FOXP3-independent mechanism, thus sustaining the clinical improvement observed in IPEX patients under rapamycin treatment.	Sirolimus	177-186	forkhead box P3	Homo sapiens	157-161
32279295-3	2020	The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN"s GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.	Sirolimus	127-136	CREB regulated transcription coactivator 1	Mus musculus	148-154
32279295-3	2020	The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN"s GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.	Sirolimus	127-136	transcription factor binding to IGHM enhancer 3	Homo sapiens	297-301
32235551-6	2020	The pharmaceutical inhibition of mTORC1 activity by rapamycin reinforced autophagy initiation but suppressed the cellular migration and lung metastatic abilities of IMPA2-silenced ccRCC cells.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	33-39
31623699-1	2020	The present study was conducted to evaluate the effects of glucose, soya oil or glutamine on jejunal morphology, protein metabolism and protein expression of the mammalian target of rapamycin complex 1 (mTORC1) signalling pathway in jejunal villus or crypt compartment of piglets.	Sirolimus	182-191	CREB regulated transcription coactivator 1	Mus musculus	203-209
32127537-5	2020	Treatment of G2-Terc-/- mice with rapamycin, an inhibitor of mTORC1, decreases survival, in contrast to lifespan extension in wild-type controls.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	61-67
31969673-8	2020	These effects were blocked by pretreatment with the AMPA receptor inhibitor 2,3-dihydroxy-6-nitro-7sulfamoyl-benzo(f)quinoxaline (NBQX) and the mTORC1 inhibitor rapamycin.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	144-150
31963899-6	2020	Leucine, a BCAA, and its metabolite, beta-hydroxy-beta-methylbutyrate (HMB), both activate mammalian target of rapamycin complex 1 (mTORC1) and increase protein synthesis, but the mechanisms of activation appear to be different.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	132-138
31904289-7	2020	Mechanistically, UNX-induced mammalian target of rapamycin complex 1 (mTORC1) signaling to phosphorylation of ribosomal protein S6 (rpS6) in the remaining kidney is markedly inhibited in Pik3c3-hypomorphic mice.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
31904289-7	2020	Mechanistically, UNX-induced mammalian target of rapamycin complex 1 (mTORC1) signaling to phosphorylation of ribosomal protein S6 (rpS6) in the remaining kidney is markedly inhibited in Pik3c3-hypomorphic mice.	Sirolimus	49-58	ribosomal protein S6	Homo sapiens	110-130
31904289-7	2020	Mechanistically, UNX-induced mammalian target of rapamycin complex 1 (mTORC1) signaling to phosphorylation of ribosomal protein S6 (rpS6) in the remaining kidney is markedly inhibited in Pik3c3-hypomorphic mice.	Sirolimus	49-58	ribosomal protein S6	Homo sapiens	132-136
31786107-11	2020	Inhibition of mTORC1 by rapamycin or siRNA can lead to dissociation of alphaB-crystallin from the ATP6V1A and mTORC1complex, shortening the half-life of ATP6V1A and increasing the lysosomal pH.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
31786107-11	2020	Inhibition of mTORC1 by rapamycin or siRNA can lead to dissociation of alphaB-crystallin from the ATP6V1A and mTORC1complex, shortening the half-life of ATP6V1A and increasing the lysosomal pH.	Sirolimus	24-33	crystallin, alpha B	Mus musculus	71-88
31786107-11	2020	Inhibition of mTORC1 by rapamycin or siRNA can lead to dissociation of alphaB-crystallin from the ATP6V1A and mTORC1complex, shortening the half-life of ATP6V1A and increasing the lysosomal pH.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	110-116
31605764-0	2020	Effective and safe treatment of a novel IL2RA deficiency with rapamycin.	Sirolimus	62-71	interleukin 2 receptor subunit alpha	Homo sapiens	40-45
32058469-3	2020	PURPOSE: We investigated the effect of cancer cachexia on the diurnal regulation of feeding, physical activity, and skeletal muscle mechanistic target of rapamycin complex 1 (mTORC1) signaling in tumor-bearing mice.	Sirolimus	154-163	CREB regulated transcription coactivator 1	Mus musculus	175-181
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	67-76	FKBP prolyl isomerase 1A	Homo sapiens	96-124
31894316-3	2020	There are two classes of mTOR inhibitors: i) The rapalogs, such as rapamycin, which bind to the 12-kDa FK506-binding protein/rapamycin-binding domain of mTOR; and ii) the ATP-competitive inhibitors, such as AZD8055, which block the mTOR kinase domain.	Sirolimus	125-134	FKBP prolyl isomerase 1A	Homo sapiens	96-124
32020232-9	2020	HK2 and LDHA expression decreased after AML tumor cells were treated with Akt inhibitor or rapamycin.	Sirolimus	91-100	hexokinase 2	Homo sapiens	0-3
33406024-4	2020	Methods: Ovalbumin (OVA) T cell receptor transgenic DO11.10 mice (DO11.10 mice) were used to establish NEA model, and few mice received specific mTORC1 inhibitor rapamycin (RAPA) before intranasal administration of OVA.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	145-151
31769520-9	2020	Although AZD2014 was more effective for cell growth inhibition and PDT enhancement than rapamycin at the higher concentrations examined in the study, both inhibitors effectively enhanced PDT response, suggesting that inhibition of mTORC1 is crucial for PDT enhancement.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	231-237
32081881-12	2020	In atheroprone vessels of mice receiving rapamycin to induce autophagy, the enhanced expression of SIRT1 was observed together with YAP repression.	Sirolimus	41-50	yes-associated protein 1	Mus musculus	132-135
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	autophagy related 7	Homo sapiens	44-48
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	microtubule associated protein 1 light chain 3 beta	Homo sapiens	60-65
31698038-3	2020	This study aims to develop an inhaled formulation of rapamycin solid lipid nanoparticles (Rapa-SLNs) to avoid first-pass metabolism, increase invivo half-life and facilitate entry into the lymphatic system through the lungs.	Sirolimus	53-62	transcriptional regulating factor 1	Homo sapiens	90-94
32063747-8	2020	Moreover, combined with the rapamycin, ZA effectively suppressed the tumor recurrence after drug withdrawal and ZA inhibited the activity of GTPase RhoA by decreasing protein geranylgeranylation, resulting in changes of Yap nucleus translocation.	Sirolimus	28-37	yes-associated protein 1	Mus musculus	220-223
32104716-0	2020	Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides.	Sirolimus	16-25	interleukin 37	Homo sapiens	34-48
32104716-8	2020	IL-37 was upregulated by rapamycin and chloroquine in both U937 cells and human PBMCs in the presence of LPS.	Sirolimus	25-34	interleukin 37	Homo sapiens	0-5
32104716-13	2020	IL-37 levels were induced by rapamycin and chloroquine through the LC3, Erk1/2, and NF-kappaB/AP-1 pathways.	Sirolimus	29-38	interleukin 37	Homo sapiens	0-5
32046043-6	2020	Silencing of PARP2 inhibited the activity of AMP-activated kinase (AMPK) and the mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	101-110	CREB regulated transcription coactivator 2	Mus musculus	122-128
32023458-6	2020	MGO induces AKT activation through phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin 2 (mTORC2) and Hsp27 regulation.	Sirolimus	92-101	CREB regulated transcription coactivator 2	Mus musculus	105-111
31924219-15	2020	When the autophagy inducer, rapamycin, is used to facilitate the mitophagy flux, this treatment results in attenuated NF-kappaB activation and reduced PIC release in exogenous disulfide HMGB1 (ds-HMGB1)-stimulated microglia.	Sirolimus	28-37	high mobility group box 1	Mus musculus	186-191
31924219-15	2020	When the autophagy inducer, rapamycin, is used to facilitate the mitophagy flux, this treatment results in attenuated NF-kappaB activation and reduced PIC release in exogenous disulfide HMGB1 (ds-HMGB1)-stimulated microglia.	Sirolimus	28-37	high mobility group box 1	Mus musculus	196-201
31921404-0	2020	TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.	Sirolimus	108-117	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
31921404-2	2020	The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	27-33
31921404-2	2020	The aberrant activation of mTORC1 in TSC has led to treatment with mTORC1 inhibitor rapamycin as a lifelong therapy for tumors, but TSC-associated neurocognitive manifestations remain unaffected by rapamycin.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	67-73
31921404-10	2020	Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
33834178-10	2020	Immunohistochemistry assays of rpS6 phosphorylation showed that rapamycin reduction of mTORC1 activity was on the same level, with the most prominent difference being in intestinal crypt Paneth cells in both sexes.	Sirolimus	64-73	ribosomal protein S6	Mus musculus	31-35
33834178-10	2020	Immunohistochemistry assays of rpS6 phosphorylation showed that rapamycin reduction of mTORC1 activity was on the same level, with the most prominent difference being in intestinal crypt Paneth cells in both sexes.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	87-93
33834178-13	2020	Conclusions: In males and females, these findings link rapamycin-mediated intestinal polyposis prevention with mTORC1 inhibition in Paneth cells and concomitant reduced epithelial cell proliferation.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	111-117
32329644-5	2020	Rapamycin pre-treatment with Naringin showed significant decrease in mTOR phosphorylation and increase in LC3B activation in AGS cells.	Sirolimus	0-9	microtubule associated protein 1 light chain 3 beta	Homo sapiens	106-110
31819177-8	2020	siRNA knockdown of Raptor or treatment with rapamycin inhibited PKD1-accelerated lactate production as well as glucose consumption in cells, which confirms the association of mTORC1 with PKD1-induced metabolic alterations.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	175-181
31834371-1	2020	Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder caused by inactivating mutations in TSC1 or TSC2, key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	209-215
32356448-6	2020	Increased apoptotic cells were observed in mTORC1 inhibition by Rapamycin administration.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	43-49
31862317-12	2020	Conversely, ectopic overexpression of H19 in cultured IECs prevented rapamycin-induced autophagy and abolished the rapamycin-induced protection of the epithelial barrier against LPS.	Sirolimus	69-78	H19, imprinted maternally expressed transcript	Mus musculus	38-41
31862317-12	2020	Conversely, ectopic overexpression of H19 in cultured IECs prevented rapamycin-induced autophagy and abolished the rapamycin-induced protection of the epithelial barrier against LPS.	Sirolimus	115-124	H19, imprinted maternally expressed transcript	Mus musculus	38-41
32502530-5	2020	IGF-1 signaling or its downstream effector mTORC1 were inhibited by administering BMS-754807 or rapamycin, respectively.	Sirolimus	96-105	insulin-like growth factor 1	Mus musculus	0-5
32502530-5	2020	IGF-1 signaling or its downstream effector mTORC1 were inhibited by administering BMS-754807 or rapamycin, respectively.	Sirolimus	96-105	CREB regulated transcription coactivator 1	Mus musculus	43-49
32502530-11	2020	Similarly, rapamycin inhibition of mTORC1 during the growth factor surge blunted the regenerative response.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	35-41
33183203-4	2020	An innovative strategy involves the vitamin nicotinamide and the pathways associated with the silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), the mechanistic target of rapamycin (mTOR), mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase (AMPK), and clock genes.	Sirolimus	210-219	CREB regulated transcription coactivator 1	Mus musculus	244-250
33183203-4	2020	An innovative strategy involves the vitamin nicotinamide and the pathways associated with the silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), the mechanistic target of rapamycin (mTOR), mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase (AMPK), and clock genes.	Sirolimus	210-219	CREB regulated transcription coactivator 2	Mus musculus	269-275
32016998-5	2020	RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells.	Sirolimus	63-72	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	337-342
31949495-1	2020	Aberrant activation of the mammalian target of rapamycin complex 1 (mTORC1) plays a critical role in tumorigenesis.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	68-74
30794726-1	2020	Inhibition of mTORC1 (mechanistic Target Of Rapamycin Complex 1) with the pharmaceutical rapamycin prolongs the lifespan and healthspan of model organisms including rodents, with evidence now emerging that rapamycin and its analogs may also have rejuvenative effects in dogs and humans.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	14-20
30794726-1	2020	Inhibition of mTORC1 (mechanistic Target Of Rapamycin Complex 1) with the pharmaceutical rapamycin prolongs the lifespan and healthspan of model organisms including rodents, with evidence now emerging that rapamycin and its analogs may also have rejuvenative effects in dogs and humans.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	14-20
30794726-1	2020	Inhibition of mTORC1 (mechanistic Target Of Rapamycin Complex 1) with the pharmaceutical rapamycin prolongs the lifespan and healthspan of model organisms including rodents, with evidence now emerging that rapamycin and its analogs may also have rejuvenative effects in dogs and humans.	Sirolimus	206-215	CREB regulated transcription coactivator 1	Mus musculus	14-20
30794726-2	2020	However, the side effects associated with long-term rapamycin treatment, many of which are due to inhibition of a second mTOR complex, mTORC2, have seemed to preclude the routine use of rapamycin as a therapy for age-related diseases.	Sirolimus	52-61	CREB regulated transcription coactivator 2	Mus musculus	135-141
30794726-2	2020	However, the side effects associated with long-term rapamycin treatment, many of which are due to inhibition of a second mTOR complex, mTORC2, have seemed to preclude the routine use of rapamycin as a therapy for age-related diseases.	Sirolimus	186-195	CREB regulated transcription coactivator 2	Mus musculus	135-141
30794726-4	2020	Instead, modestly but specifically inhibiting mTORC1 via a variety of emerging techniques, including intermittent or transient treatment with rapamycin derivatives, or specific dietary regimens, may be sufficient to promote health and longevity with reduced side effects.	Sirolimus	142-151	CREB regulated transcription coactivator 1	Mus musculus	46-52
32821719-4	2020	The mammalian target of rapamycin complex 1 (mTORC1) pathway plays a key role in sensing cellular nutrient and energy status and regulating the proliferation and growth of cells by controlling various anabolic and catabolic processes.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
32023468-1	2020	Mechanistic or mammalian target of rapamycin complex 1 (mTORC1) is an important regulator of effector functions, proliferation, and cellular metabolism in macrophages.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	56-62
31689244-5	2020	Mechanistically, in vivo in BMP9/10ib mouse ECs, sirolimus and nintedanib blocked the overactivation of mTOR and VEGFR2, respectively.	Sirolimus	49-58	kinase insert domain protein receptor	Mus musculus	113-119
31689244-6	2020	Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs-including in HHT patient blood outgrowth ECs-and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs.	Sirolimus	27-36	SMAD family member 1	Homo sapiens	61-68
31841452-6	2020	Further experiments showed that alpha-KG down-regulated the expression of M1-polarized marker genes and inhibited the activities of mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal protein S6 kinase (p70S6K) signaling pathway in M1-polarized MH-S cells.	Sirolimus	152-161	CREB regulated transcription coactivator 1	Mus musculus	173-179
31699566-1	2020	The target of rapamycin complex 2 (TORC2) was discovered in 2002 in budding yeast.	Sirolimus	14-23	CREB regulated transcription coactivator 2	Mus musculus	35-40
31978319-8	2020	Compared with the control group, the fluorescence of autophagy-labeled protein LC3B and lysosome-labeled protein lysosome-associated membrane protein 1 (LAMP1) in the cytoplasm of HUVEC induced by rapamycin was observed, and intensity was significantly enhanced under confocal laser scanning microscope, after fluorescence synthesis, the fluorescence of autophagy-labeled protein LC3B and lysosome-labeled protein LAMP1 overlaps were reduced.	Sirolimus	197-206	lysosomal associated membrane protein 1	Homo sapiens	113-151
30972602-3	2020	The mammalian target of rapamycin complex 1 (mTORC1) is upregulated by UVB.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
31493485-8	2019	This model shows that rapamycin has stronger effects on mTORC1 compared with mTORC2, simply due to its direct interaction with free mTOR and mTORC1, but not mTORC2, without the need to consider other components that might further stabilize mTORC2.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	56-62
31493485-8	2019	This model shows that rapamycin has stronger effects on mTORC1 compared with mTORC2, simply due to its direct interaction with free mTOR and mTORC1, but not mTORC2, without the need to consider other components that might further stabilize mTORC2.	Sirolimus	22-31	CREB regulated transcription coactivator 2	Mus musculus	77-83
31493485-8	2019	This model shows that rapamycin has stronger effects on mTORC1 compared with mTORC2, simply due to its direct interaction with free mTOR and mTORC1, but not mTORC2, without the need to consider other components that might further stabilize mTORC2.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	141-147
31493485-9	2019	Based on our results, even when mTORC2 is less stable compared with mTORC1, it can be less inhibited by rapamycin.	Sirolimus	104-113	CREB regulated transcription coactivator 2	Mus musculus	32-38
31493485-9	2019	Based on our results, even when mTORC2 is less stable compared with mTORC1, it can be less inhibited by rapamycin.	Sirolimus	104-113	CREB regulated transcription coactivator 1	Mus musculus	68-74
31921198-7	2019	After infected by Micrococcus luteus or Listonella anguillarum, mRNA expression of Ss-Raptor rapidly increased within 48 h. Once Raptor/mTORC1 signaling was blocked by rapamycin, expression of the pro-inflammatory cytokines IL-1beta and IL-8 was severely impaired, suggesting potential regulatory role of Raptor/mTORC1 signaling in the innate immune response of rockfish.	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	136-142
31842972-6	2019	This is mediated via alterations in the levels and activities of the cellular nutrient sensors 5" adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1), intracellular accumulation of metabolic intermediates such as succinate and citrate, and increases in free fatty acids (FFAs) and hyperglycaemia-induced advanced glycation end-products (AGEs) that bind to receptors on the macrophage surface.	Sirolimus	178-187	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	98-146
31746509-7	2020	mTOR inhibition by rapamycin reversed negative effects of high glucose concentrations on HBV replication, suggesting that low glucose concentration promotes HBV replication by stimulating the AMPK/mTOR-ULK1-autophagy axis.	Sirolimus	19-28	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	192-196
31746509-7	2020	mTOR inhibition by rapamycin reversed negative effects of high glucose concentrations on HBV replication, suggesting that low glucose concentration promotes HBV replication by stimulating the AMPK/mTOR-ULK1-autophagy axis.	Sirolimus	19-28	unc-51 like autophagy activating kinase 1	Homo sapiens	202-206
31423743-8	2020	Mechanistically, our results demonstrated that autophagy activation by AMPK activator metformin or mTOR inhibitor rapamycin obviously promotes cell survival and autophagy flux, improved mitochondrial ultrastructure, and reduced expression of Cyt-C and caspase-3 in CORT-induced PC12 cells.	Sirolimus	114-123	caspase 3	Rattus norvegicus	252-261
31958467-7	2020	The activation of mammalian target of rapamycin complex-1 (mTORC1) during increased workload in presence of glucose as the only substrate was prevented by C/EBPbeta knockdown, thereby abating contractile dysfunction in cardiomyocytes.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	59-65
31664701-8	2020	Rapamycin in the adulthood reversed iron-induced memory deficits, decreased the ratio phospho-mTOR/total mTOR, and recovered LC3 II levels in iron-treated rats.	Sirolimus	0-9	annexin A3	Rattus norvegicus	125-128
31667906-11	2020	The rates of p/t-p70S6K, p/t-mammalian target of rapamycin (mTOR) and p/t-adenosine monophosphate-activated protein kinase (AMPK) were raised by BB and suppressed by silencing miR-153 under TNF-alpha induced condition.	Sirolimus	49-58	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	124-128
31862477-18	2020	In contrast, everolimus, temsirolimus, and sirolimus are larger molecules (MW   1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.	Sirolimus	28-37	FKBP prolyl isomerase 1A	Homo sapiens	99-123
31862477-18	2020	In contrast, everolimus, temsirolimus, and sirolimus are larger molecules (MW   1000) that bind to FK506 binding protein-12 (FKBP-12) to generate a complex that inhibits the mammalian target of rapamycin (mTOR) protein kinase complex.	Sirolimus	28-37	FKBP prolyl isomerase 1A	Homo sapiens	125-132
31546204-4	2019	Rapamycin is an inhibitor of mammalian TORC1 (target of rapamycin complex-1) and used in the treatment of some diseases like cancer, cardiovascular and neurological diseases.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	39-44
31894839-7	2020	Furthermore, EPS1-1-mediated apoptosis is regulated by inactivation of mammalian target of rapamycin complex 1 (mTORC1) and activation of the jun-NH2 kinase (JNK)-p53 signaling axis dependent on AMPK activation.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
31969105-0	2021	In silico-based approach to investigate the ability of PEGylated rapamycin to inhibit Galectin-3.	Sirolimus	65-74	galectin 3	Homo sapiens	86-96
31969105-2	2021	In this study, we have investigated the ability of modified rapamycin (RP) to bind to the carbohydrate recognition domain of Gal-3.	Sirolimus	60-69	galectin 3	Homo sapiens	125-130
31969105-2	2021	In this study, we have investigated the ability of modified rapamycin (RP) to bind to the carbohydrate recognition domain of Gal-3.	Sirolimus	71-73	galectin 3	Homo sapiens	125-130
31546204-4	2019	Rapamycin is an inhibitor of mammalian TORC1 (target of rapamycin complex-1) and used in the treatment of some diseases like cancer, cardiovascular and neurological diseases.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	46-75
31969105-5	2021	According to the results obtained from the molecular modeling algorithm based on shape complementarity principles, RP-MPEG with the molecular weight of 1178.51 g/mol and a logP value of 3.79 has the best affinity for a non-carbohydrate-based Gal-3 inhibitor.	Sirolimus	115-117	galectin 3	Homo sapiens	242-247
31676287-3	2019	Under the control of mammalian target of rapamycin complex 1 (mTORC1), LARP1 regulates translation of these transcripts.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	62-68
31969105-6	2021	Moreover, in vitro hemagglutination assay results revealed that RP analog, everolimus, has possessed potent agglutination inhibition with a minimum inhibitory concentration of 160.77 +- 2.52 mug/mL, which suggested that RP derivatives are potential Gal-3 inhibitors.	Sirolimus	64-66	galectin 3	Homo sapiens	249-254
31969105-6	2021	Moreover, in vitro hemagglutination assay results revealed that RP analog, everolimus, has possessed potent agglutination inhibition with a minimum inhibitory concentration of 160.77 +- 2.52 mug/mL, which suggested that RP derivatives are potential Gal-3 inhibitors.	Sirolimus	220-222	galectin 3	Homo sapiens	249-254
31676287-3	2019	Under the control of mammalian target of rapamycin complex 1 (mTORC1), LARP1 regulates translation of these transcripts.	Sirolimus	41-50	La ribonucleoprotein 1, translational regulator	Homo sapiens	71-76
31791403-1	2019	BACKGROUND: The mammalian target of rapamycin complex 2 (mTORC2), containing the essential protein rictor, regulates cellular metabolism and cytoskeletal organization by phosphorylating protein kinases, such as PKB/Akt, PKC, and SGK.	Sirolimus	36-45	CREB regulated transcription coactivator 2	Mus musculus	57-63
31813279-5	2019	Furthermore, both loss and gain-of-function assays strengthen the evidence that MELK enforces the malignant phenotype of ccRCC cells through over-activating the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	181-190	maternal embryonic leucine zipper kinase	Homo sapiens	80-84
31973180-5	2020	Moreover, the molecular relevance of endothelial nitric oxide synthase (eNOS) and mechanistic/mammalian target of rapamycin complex 1 (mTORC1) was studied in both cardiac tissue and HL-1 cardiomyocytes.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
31813279-5	2019	Furthermore, both loss and gain-of-function assays strengthen the evidence that MELK enforces the malignant phenotype of ccRCC cells through over-activating the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	181-190	CREB regulated transcription coactivator 1	Mus musculus	202-208
32395371-2	2020	Sesn2 regulates cellular metabolism by inhibiting the mammalian target of rapamycin complex 1 through the AMP-activated protein kinase (AMPK) signaling pathway.	Sirolimus	74-83	sestrin 2	Homo sapiens	0-5
31299246-2	2019	Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	43-49
31959796-8	2020	The Pdgfb induction system was distinct from that of inflammatory cytokines mediated by mechanistic target of rapamycin complex 1 (mTORC1) and NFkappaB signaling.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	131-137
31825077-3	2020	Placental mechanistic target of rapamycin Complex 2 (mTORC2) signaling is inhibited in IUGR and regulates the trafficking of key amino acid transporter (AAT) isoforms to the ST plasma membrane, however the molecular mechanisms are unknown.	Sirolimus	32-41	CREB regulated transcription coactivator 2	Mus musculus	53-59
31941840-6	2020	Furthermore, cotreatment with a GLP-1 receptor agonist completely prevented TAC-induced beta cell dysfunction and partially prevented SIR-induced beta cell dysfunction.	Sirolimus	134-137	glucagon like peptide 1 receptor	Homo sapiens	32-46
31669651-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) plays crucial roles in male fertility.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
31669651-4	2020	In the present study, it was found that treatment of rapamycin, an mTORC1 inhibitor, resulted in infertility with decreased milt production and sperm motility in zebrafish.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	67-73
31299246-2	2019	Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	43-49
31924779-4	2020	Mechanistically, macropinocytosis in T cells provides access of extracellular AA to an endolysosomal compartment to sustain activation of the mechanistic target of rapamycin complex 1 (mTORC1) that promotes T cell growth.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	185-191
31299246-3	2019	Based on the hypothesis that simultaneous inhibition of mTORC1 and autophagy would limit the availability of critical nutrients and inhibit LAM cells, we conducted a phase 1 clinical trial of sirolimus and hydroxychloroquine for LAM.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	56-62
31682474-8	2019	In summary, these findings illustrate that Cdc42 is working downstream of the mammalian target of rapamycin complex 1/rpS6/Akt1/2 signaling pathway to support NC1 peptide-mediated effects on Sertoli cell function in the testis using the rat as an animal model.-Su, W., Cheng, C. Y.	Sirolimus	98-107	cell division cycle 42	Homo sapiens	43-48
31682474-8	2019	In summary, these findings illustrate that Cdc42 is working downstream of the mammalian target of rapamycin complex 1/rpS6/Akt1/2 signaling pathway to support NC1 peptide-mediated effects on Sertoli cell function in the testis using the rat as an animal model.-Su, W., Cheng, C. Y.	Sirolimus	98-107	ribosomal protein S6	Homo sapiens	118-122
31719166-3	2020	The administration and withdrawal of the combination of cuprizone and rapamycin (Cup/Rap) in C57BL/6J male mice efficiently demyelinated and remyelinated the hippocampus, respectively.	Sirolimus	70-79	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	85-88
31650481-1	2019	Inhibition of mammalian target of rapamycin complex I (mTORC1) by rapamycin improves cardiac function in both aging and heart failure.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
31650481-1	2019	Inhibition of mammalian target of rapamycin complex I (mTORC1) by rapamycin improves cardiac function in both aging and heart failure.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Mus musculus	55-61
31564412-0	2019	Prevention of post-ischemic seizure by rapamycin is associated with deactivation of mTOR and ERK1/2 pathways in hyperglycemic rats.	Sirolimus	39-48	mitogen activated protein kinase 3	Rattus norvegicus	93-99
31564412-11	2019	We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling.	Sirolimus	160-169	mitogen activated protein kinase 3	Rattus norvegicus	135-141
31564412-11	2019	We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling.	Sirolimus	160-169	mitogen activated protein kinase 3	Rattus norvegicus	257-263
31582215-2	2019	Attenuation of mechanistic target of rapamycin complex 1 (mTORC1) activation by repetitive resistance exercise is involved in this process, but the mechanism leading to inactivation of mTORC1 remains unclear.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
31772273-1	2019	Inactivation of the protein complex "mechanistic target of rapamycin complex 1" (mTORC1) can increase the nuclear content of transcriptional regulators of metabolism and apoptosis.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	81-87
31772273-4	2019	In this study, we demonstrate that PKCdelta, a STAT1 kinase, contains a functional "target of rapamycin signaling" (TOS) motif that directs its interaction with mTORC1.	Sirolimus	94-103	protein kinase C delta	Homo sapiens	35-43
31772273-4	2019	In this study, we demonstrate that PKCdelta, a STAT1 kinase, contains a functional "target of rapamycin signaling" (TOS) motif that directs its interaction with mTORC1.	Sirolimus	94-103	CREB regulated transcription coactivator 1	Mus musculus	161-167
31772273-5	2019	Depletion of KPNA1 by RNAi prevented the nuclear import of PKCdelta in cells exposed to the mTORC1 inhibitor rapamycin or amino acid restriction.	Sirolimus	109-118	protein kinase C delta	Homo sapiens	59-67
31772273-5	2019	Depletion of KPNA1 by RNAi prevented the nuclear import of PKCdelta in cells exposed to the mTORC1 inhibitor rapamycin or amino acid restriction.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	92-98
31772273-7	2019	In cells expressing wild-type PKCdelta, STAT1 activity and apoptosis were increased by rapamycin or interferon-beta.	Sirolimus	87-96	protein kinase C delta	Homo sapiens	30-38
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	CREB regulated transcription coactivator 2	Mus musculus	108-114
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	CREB regulated transcription coactivator 2	Mus musculus	204-210
31672913-1	2019	The tumor suppressor folliculin (FLCN) enables nutrient-dependent activation of the mechanistic target of rapamycin complex 1 (mTORC1) protein kinase via its guanosine triphosphatase (GTPase) Activating Protein (GAP) activity toward the GTPase RagC.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	127-133
31554636-7	2019	Additionally, the HRI-eIF2alphaP-ATF4 pathway represses mechanistic target of rapamycin complex 1 (mTORC1) signaling, specifically in the erythroid lineage as a feedback mechanism of erythropoietin-stimulated erythropoiesis during iron/heme deficiency.	Sirolimus	78-87	eukaryotic translation initiation factor 2 alpha kinase 1	Homo sapiens	18-21
31554636-7	2019	Additionally, the HRI-eIF2alphaP-ATF4 pathway represses mechanistic target of rapamycin complex 1 (mTORC1) signaling, specifically in the erythroid lineage as a feedback mechanism of erythropoietin-stimulated erythropoiesis during iron/heme deficiency.	Sirolimus	78-87	CREB regulated transcription coactivator 1	Mus musculus	99-105
31693882-2	2019	The kinase mechanistic target of rapamycin (mTOR) forms the enzymatic core of the highly conserved mTOR complexes mTORC1 and mTORC2.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	114-120
31693882-2	2019	The kinase mechanistic target of rapamycin (mTOR) forms the enzymatic core of the highly conserved mTOR complexes mTORC1 and mTORC2.	Sirolimus	33-42	CREB regulated transcription coactivator 2	Mus musculus	125-131
30890204-6	2019	Interestingly, Ad-Cyp8b1 increased ceramide synthesis and activated hepatic mechanistic target of rapamycin complex 1 (mTORC1)-p70S6K signaling cascade and inhibited AKT/insulin signaling in mice.	Sirolimus	98-107	cytochrome P450, family 8, subfamily b, polypeptide 1	Mus musculus	18-24
32553647-9	2020	The activation of mammalian target of rapamycin complex 1 (mTORC1), a central regulator of autophagy, was found to be negatively correlated with autophagic synthesis; moreover, pharmacological inhibition of mTORC1 by rapamycin alleviated hepatic steatosis through recovery of autophagic flux in hepatocytes with prolonged PA treatment.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	59-65
32553647-9	2020	The activation of mammalian target of rapamycin complex 1 (mTORC1), a central regulator of autophagy, was found to be negatively correlated with autophagic synthesis; moreover, pharmacological inhibition of mTORC1 by rapamycin alleviated hepatic steatosis through recovery of autophagic flux in hepatocytes with prolonged PA treatment.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	207-213
32553647-9	2020	The activation of mammalian target of rapamycin complex 1 (mTORC1), a central regulator of autophagy, was found to be negatively correlated with autophagic synthesis; moreover, pharmacological inhibition of mTORC1 by rapamycin alleviated hepatic steatosis through recovery of autophagic flux in hepatocytes with prolonged PA treatment.	Sirolimus	217-226	CREB regulated transcription coactivator 1	Mus musculus	59-65
32553647-9	2020	The activation of mammalian target of rapamycin complex 1 (mTORC1), a central regulator of autophagy, was found to be negatively correlated with autophagic synthesis; moreover, pharmacological inhibition of mTORC1 by rapamycin alleviated hepatic steatosis through recovery of autophagic flux in hepatocytes with prolonged PA treatment.	Sirolimus	217-226	CREB regulated transcription coactivator 1	Mus musculus	207-213
31600529-8	2020	Moreover, rapamycin treatment attenuated the SOX9-mediated malignant phenotypes and potentiated cisplatin-mediated inhibition of tumor growth.	Sirolimus	10-19	SRY-box transcription factor 9	Homo sapiens	45-49
32641600-1	2020	Mechanistic target of rapamycin complex 1 (mTORC1) plays a pivotal role in controlling cell growth and metabolism in response to nutrients and growth factors.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
31074719-3	2020	The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission.	Sirolimus	60-69	forkhead box P3	Homo sapiens	117-122
31074719-3	2020	The aim of the present study was to evaluate the effects of rapamycin, under the generic name sirolimus, on CD4+CD25+FoxP3+ Treg cells in rheumatoid arthritis (RA) patients with low disease activity or in DAS28 remission.	Sirolimus	94-103	forkhead box P3	Homo sapiens	117-122
31625572-3	2020	Phosphoinositide 3-kinase (PI3K)/AKT signaling activates mammalian target of rapamycin complex 1 (mTORC1) and hyperactivation of mTORC1 is a common event in PKD; however, mTORC1 inhibitors have yielded disappointing results in clinical trials.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	98-104
30890204-6	2019	Interestingly, Ad-Cyp8b1 increased ceramide synthesis and activated hepatic mechanistic target of rapamycin complex 1 (mTORC1)-p70S6K signaling cascade and inhibited AKT/insulin signaling in mice.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	119-125
31659101-1	2019	BACKGROUND: Hyperactivity of the mechanistic target of rapamycin complex 1 (mTORC1) is implicated in a variety of diseases such as cancer and diabetes.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	76-82
31691510-1	2019	Resistance exercise (RE) activates the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway and increases muscle protein synthesis.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Mus musculus	82-88
31673045-6	2019	The present study demonstrates that despite reduced lipogenesis, liver specific SCD1 deficiency activates the mechanistic target of rapamycin complex 1 (mTORC1) along with induction of PGC-1alpha and ER stress.	Sirolimus	132-141	CREB regulated transcription coactivator 1	Mus musculus	153-159
31667787-10	2020	Moreover, treatment with the autophagy activator rapamycin effectively abrogated the CCND1 silencing-reduced CD133 + cell percentage.	Sirolimus	49-58	cyclin D1	Homo sapiens	85-90
31667787-10	2020	Moreover, treatment with the autophagy activator rapamycin effectively abrogated the CCND1 silencing-reduced CD133 + cell percentage.	Sirolimus	49-58	prominin 1	Homo sapiens	109-114
32395334-7	2020	mTORC1 signaling was inhibited using rapamycin.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	0-6
31746373-15	2020	Furthermore, rapamycin prevented angiotensin II-induced H9c2 cell apoptosis and promoted autophagy by inhibiting the mTORC1 and ER stress pathways.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	117-123
31241126-4	2020	Since rapamycin (RAP)-induced inhibition of target of rapamycin complex 1 (mTORC1) activates autophagy and prevents apoptosis, we hypothesized that RAP may preserve osteoblast viability and reduce PA-induced lipotoxicity.	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	75-81
31241126-4	2020	Since rapamycin (RAP)-induced inhibition of target of rapamycin complex 1 (mTORC1) activates autophagy and prevents apoptosis, we hypothesized that RAP may preserve osteoblast viability and reduce PA-induced lipotoxicity.	Sirolimus	17-20	CREB regulated transcription coactivator 1	Mus musculus	75-81
31241126-4	2020	Since rapamycin (RAP)-induced inhibition of target of rapamycin complex 1 (mTORC1) activates autophagy and prevents apoptosis, we hypothesized that RAP may preserve osteoblast viability and reduce PA-induced lipotoxicity.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	75-81
31241126-4	2020	Since rapamycin (RAP)-induced inhibition of target of rapamycin complex 1 (mTORC1) activates autophagy and prevents apoptosis, we hypothesized that RAP may preserve osteoblast viability and reduce PA-induced lipotoxicity.	Sirolimus	148-151	CREB regulated transcription coactivator 1	Mus musculus	75-81
31641080-3	2019	In follicular B cells, the expression of genes involved in ribosome biogenesis, aerobic respiration, and mammalian target of rapamycin complex 1 (mTORC1) signaling was reduced when compared to that in transitional B cells.	Sirolimus	125-134	CREB regulated transcription coactivator 1	Mus musculus	146-152
31627299-3	2019	We previously established that irinotecan has antiangiogenic properties and it is known that new mammalian target of rapamycin (mTOR) catalytic AZD inhibitors, unlike rapamycin, target both mTORC1 and mTORC2.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	190-196
31627299-3	2019	We previously established that irinotecan has antiangiogenic properties and it is known that new mammalian target of rapamycin (mTOR) catalytic AZD inhibitors, unlike rapamycin, target both mTORC1 and mTORC2.	Sirolimus	117-126	CREB regulated transcription coactivator 2	Mus musculus	201-207
31636571-2	2019	Moreover, the mammalian target of rapamycin complex 1 (mTORC1) is a key signaling complex regulating exercise/nutrient-induced alterations in muscle protein synthesis.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	55-61
31783035-8	2020	Rapamycin, an autophagy activator, alleviated the adverse effect of AMPKalpha2 knockdown.	Sirolimus	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	68-78
31582588-3	2019	We found that inhibition of the mTORC1-Sch9 pathway by SCH9 deletion, rapamycin or myriocin treatment resulted in a dramatic decrease in H2S production.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	32-38
31582588-7	2019	Finally, we also observed a reduction in H2S production and lowering of both mRNA and protein levels of CGL and CBS in cultured human cells treated with rapamycin to reduce mTORC1 pathway activity.	Sirolimus	153-162	CREB regulated transcription coactivator 1	Mus musculus	173-179
31316183-4	2019	We showed that hypoxia promoted wound healing of PASMCs, which was dose-dependently blocked by the mTORC1 inhibitor rapamycin (5-20 nM).	Sirolimus	116-125	CREB regulated transcription coactivator 1	Mus musculus	99-105
32526757-4	2020	METHODS AND RESULTS: Rapamycin induced the activation of autophagy and release of CyPA from primary cultured rat aortic smooth muscle cells (RASMCs).	Sirolimus	21-30	peptidylprolyl isomerase A	Rattus norvegicus	82-86
32526757-7	2020	Finally, we confirmed that rapamycin-induced extracellular CyPA originated from apoptotic RASMCs.	Sirolimus	27-36	peptidylprolyl isomerase A	Rattus norvegicus	59-63
32526757-8	2020	Furthermore, the decreased activation of myosin II by blebbistatin blocked the release of CyPA from apoptotic RASMCs induced by rapamycin.	Sirolimus	128-137	peptidylprolyl isomerase A	Rattus norvegicus	90-94
32526757-9	2020	CONCLUSIONS: Rapamycin induced the release of CyPA from apoptotic RASMCs but did not affect exocytosis through autophagosomes.	Sirolimus	13-22	peptidylprolyl isomerase A	Rattus norvegicus	46-50
32526757-11	2020	Myosin II activation modulated the apoptosis of vascular smooth muscle cells and the release of CyPA from rapamycin-induced apoptotic cell death.	Sirolimus	106-115	peptidylprolyl isomerase A	Rattus norvegicus	96-100
32579497-3	2020	Alcohol via upstream kinases like mammalian target to rapamycin complex 1 (mTORC1) or 2 (mTORC2), may affect the activities of PKCepsilon or vice versa in AUD.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	75-81
32579497-3	2020	Alcohol via upstream kinases like mammalian target to rapamycin complex 1 (mTORC1) or 2 (mTORC2), may affect the activities of PKCepsilon or vice versa in AUD.	Sirolimus	54-63	CREB regulated transcription coactivator 2	Mus musculus	89-95
32579497-5	2020	Mammalian target to rapamycin complex 1 (mTORC1), another form of mTOR complex regulates translation of synaptic proteins involved in alcohol-induced plasticity.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
31373126-2	2019	mTOR is found in two protein complexes, mTORC1 and mTORC2, that have distinct components and substrates and are both inhibited by rapamycin, a macrolide drug that robustly extends lifespan in multiple species including worms and mice.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	40-46
31701625-1	2020	The p90 ribosomal S6 kinase (RSK) family, a downstream target of Ras/extracellular signal-regulated kinase (ERK) signaling, can mediate cross-talk with the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	176-185	ribosomal protein S6 kinase A3	Homo sapiens	29-32
31701625-1	2020	The p90 ribosomal S6 kinase (RSK) family, a downstream target of Ras/extracellular signal-regulated kinase (ERK) signaling, can mediate cross-talk with the mammalian target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	176-185	CREB regulated transcription coactivator 1	Mus musculus	197-203
31833032-8	2020	Our results showed that MMF vs. SRL treated recipient showed an increase in pDC % with increased in the expression of ILT3/ILT4 which is in favor of better allograft survival; However, for confirming the results of this preliminary study, a cohort study with larger sample size is necessary.	Sirolimus	32-35	leukocyte immunoglobulin like receptor B2	Homo sapiens	123-127
32921582-1	2020	The giant 532 kDa HERC1 protein is a ubiquitin ligase that interacts with tuberous sclerosis complex subunit 2 (TSC2), a negative upstream regulator of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	176-185	CREB regulated transcription coactivator 1	Mus musculus	197-203
31648572-7	2020	Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-associated X protein Bcl-2 B-cell lymphoma 2 CDC2 cyclin-dependent kinase 2 Bcl-xL B-cell lymphoma-extra large c-FLIP cellular FLICE-like inhibitory protein CDDP cisplatin COX-2 cyclooxygenase-2 cyt c cytochrome c DNA-PKcs DNA-dependent protein kinase EGFR epidermal growth factor receptor EMT epithelial-mesenchymal transition ERK extracellular signal-regulated kinase ES Ewing`s sarcoma ETS2 erythroblastosis virus transcription factor 2 GBM glioblastoma multiforme HCC hepatocellular carcinoma HNSCC head and neck squamous cell carcinoma IAP inhibitor of apoptosis protein IkappaBalpha inhibitor of kappaB alpha IKK inhibitor of kappaB kinase IR ionizing radiation lncRNA long non-coding RNA luc luciferase Mcl-1 myeloid cell leukemia-1 MDR1 multidrug resistance protein 1 miR microRNA MMP-9 matrix metalloproteinase-9 mTOR mammalian target of rapamycin NB neuroblastoma NF-kappaB nuclear factor-kappaB NPC nasopharyngeal carcinoma NSCLC non-small cell lung cancer OSCC oral squamous cell carcinoma PARP poly-(ADP-ribose)-polymerase pH2AX phosphorylated histone 2AX-immunoreactive PI3K phosphatidylinositol 3-kinase Prp4K Pre-mRNA processing factor 4 kinase RCC renal cell carcinoma ROS reactive oxygen species SCC squamous cell carcinoma SLN solid lipid nanoparticle SOD2 superoxide dismutase 2 TERT telomerase reverse transcriptase TNF-alpha tumor necrosis factor-alpha TxnRd1 thioredoxin reductase-1 VEGF vascular endothelial growth factor XIAP X-linked inhibitor of apoptosis protein DeltaPsim mitochondrial membrane potential.	Sirolimus	957-966	superoxide dismutase 2	Homo sapiens	1381-1385
31444991-8	2020	Importantly, both accelerated wound healing and fibrotic phenotypes were largely reversed by the mTORC1 inhibitor, rapamycin.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	97-103
31373126-2	2019	mTOR is found in two protein complexes, mTORC1 and mTORC2, that have distinct components and substrates and are both inhibited by rapamycin, a macrolide drug that robustly extends lifespan in multiple species including worms and mice.	Sirolimus	130-139	CREB regulated transcription coactivator 2	Mus musculus	51-57
31577953-4	2019	These include rapamycin, which extends mouse lifespan yet induces insulin resistance by disrupting mTORC2 (mechanistic target of rapamycin complex 2).	Sirolimus	14-23	CREB regulated transcription coactivator 2	Mus musculus	99-105
31577953-4	2019	These include rapamycin, which extends mouse lifespan yet induces insulin resistance by disrupting mTORC2 (mechanistic target of rapamycin complex 2).	Sirolimus	129-138	CREB regulated transcription coactivator 2	Mus musculus	99-105
31226256-7	2019	Intracerebroventricular injection of the mTORC1 inhibitor, rapamycin, revealed a role for mTOR in the socially-induced hypertrophy of GnRH1 neurons.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	41-47
31882658-6	2019	Inhibition of mTORC1 with Rapamycin elicited reciprocal activation of mTORC2, enhanced autophagy and recruited anti-apoptotic signals, conferring protection from calcification.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	14-20
31882658-6	2019	Inhibition of mTORC1 with Rapamycin elicited reciprocal activation of mTORC2, enhanced autophagy and recruited anti-apoptotic signals, conferring protection from calcification.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	70-76
31878201-2	2019	Sirolimus (rapamycin), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume during treatment and does not provide benefit for all LAM patients.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	37-43
31878201-2	2019	Sirolimus (rapamycin), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume during treatment and does not provide benefit for all LAM patients.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	37-43
31712311-2	2019	Here we show that in the highly lethal brain tumor glioblastoma (GBM), mechanistic target of rapamycin complex 2 (mTORC2), a critical core component of the growth factor signaling system, couples acetyl-CoA production with nuclear translocation of histone-modifying enzymes including pyruvate dehydrogenase (PDH) and class IIa histone deacetylases (HDACs) to globally alter histone acetylation.	Sirolimus	93-102	CREB regulated transcription coactivator 2	Mus musculus	114-120
31226256-8	2019	Rapamycin treatment also had effects at the pituitary and testes, suggesting involvement of the mTORC1 complex at multiple levels of the reproductive axis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	96-102
30864227-12	2019	The combination of HMGB1 short interference (si) RNA and the autophagy activator rapamycin protected against podocyte apoptosis and EMT progression by inhibiting the AKT/mTOR and TGF-beta/smad signaling pathway, respectively.	Sirolimus	81-90	transforming growth factor alpha	Homo sapiens	179-187
30864227-12	2019	The combination of HMGB1 short interference (si) RNA and the autophagy activator rapamycin protected against podocyte apoptosis and EMT progression by inhibiting the AKT/mTOR and TGF-beta/smad signaling pathway, respectively.	Sirolimus	81-90	SMAD family member 1	Homo sapiens	188-192
31331823-5	2019	The treatment of denervated animals with rapamycin blocked the stimulatory effects of CGRP on mTORC1 and its inhibitory actions on autophagic flux and NMJ degeneration.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	94-100
31492813-0	2019	Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to rapamycin.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	55-61
31921637-4	2019	The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of numerous cellular processes implicated in proliferation, metabolism, and cell growth.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
31231029-3	2019	Rapamycin and its analogs target mTORC1 directly; however, chronic treatment in certain cell types and in vivo results in the inhibition of both mTORC1 and mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	33-39
31231029-3	2019	Rapamycin and its analogs target mTORC1 directly; however, chronic treatment in certain cell types and in vivo results in the inhibition of both mTORC1 and mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	145-151
31231029-3	2019	Rapamycin and its analogs target mTORC1 directly; however, chronic treatment in certain cell types and in vivo results in the inhibition of both mTORC1 and mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	156-162
31408605-5	2019	Here we report on the design, characterization, pharmacokinetics, and biodistribution of a new ICAM-1-targeted ELP Rapa carrier (IBPAF) and its preliminary characterization in a murine model exhibiting elevated ICAM-1.	Sirolimus	115-119	intercellular adhesion molecule 1	Mus musculus	95-101
31820733-1	2019	The mechanistic target of rapamycin complex 1 (mTORC1) plays an important role in dendritic translation and in learning and memory.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
31408605-5	2019	Here we report on the design, characterization, pharmacokinetics, and biodistribution of a new ICAM-1-targeted ELP Rapa carrier (IBPAF) and its preliminary characterization in a murine model exhibiting elevated ICAM-1.	Sirolimus	115-119	intercellular adhesion molecule 1	Mus musculus	211-217
31408605-11	2019	This accumulation was transient with no differences detected at 8 or 24 h. This study describes the first ICAM-1 targeted protein-polymer carrier for Rapa that specifically binds to ICAM-1 in vitro and accumulates in ICAM-1 overexpressing tissue in vivo, which may be useful for molecular targeting in diverse inflammatory diseases where ICAM-1 is elevated.	Sirolimus	150-154	intercellular adhesion molecule 1	Mus musculus	106-112
31408605-11	2019	This accumulation was transient with no differences detected at 8 or 24 h. This study describes the first ICAM-1 targeted protein-polymer carrier for Rapa that specifically binds to ICAM-1 in vitro and accumulates in ICAM-1 overexpressing tissue in vivo, which may be useful for molecular targeting in diverse inflammatory diseases where ICAM-1 is elevated.	Sirolimus	150-154	intercellular adhesion molecule 1	Mus musculus	182-188
31408605-11	2019	This accumulation was transient with no differences detected at 8 or 24 h. This study describes the first ICAM-1 targeted protein-polymer carrier for Rapa that specifically binds to ICAM-1 in vitro and accumulates in ICAM-1 overexpressing tissue in vivo, which may be useful for molecular targeting in diverse inflammatory diseases where ICAM-1 is elevated.	Sirolimus	150-154	intercellular adhesion molecule 1	Mus musculus	182-188
31921849-2	2019	Here we show that both global mRNA translation and mammalian/mechanistic target of rapamycin complex 1 (mTORC1) kinase activity are declined in a senescent model of mouse embryonic fibroblasts (MEFs).	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
31408605-11	2019	This accumulation was transient with no differences detected at 8 or 24 h. This study describes the first ICAM-1 targeted protein-polymer carrier for Rapa that specifically binds to ICAM-1 in vitro and accumulates in ICAM-1 overexpressing tissue in vivo, which may be useful for molecular targeting in diverse inflammatory diseases where ICAM-1 is elevated.	Sirolimus	150-154	intercellular adhesion molecule 1	Mus musculus	182-188
31552299-1	2019	The pathophysiological role of mammalian target of rapamycin complex 1 (mTORC1) in neurodegenerative diseases is established, but possible therapeutic targets responsible for its activation in neurons must be explored.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	72-78
31857853-2	2019	Many of the effects of SESTRINs are mediated by negative and positive regulation of mechanistic target of rapamycin kinase complexes 1 and 2 (mTORC1 and mTORC2), respectively, that are often deregulated in human cancers where they support cell growth, proliferation, and cell viability.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	142-148
31857853-2	2019	Many of the effects of SESTRINs are mediated by negative and positive regulation of mechanistic target of rapamycin kinase complexes 1 and 2 (mTORC1 and mTORC2), respectively, that are often deregulated in human cancers where they support cell growth, proliferation, and cell viability.	Sirolimus	106-115	CREB regulated transcription coactivator 2	Mus musculus	153-159
31487268-8	2019	The mTOR complex (mTORC)1 inhibitor rapamycin suppressed proinflammatory cytokine production by T cells and alleviated autoimmunity in Srsf1-deficient mice.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	18-25
31461340-5	2019	This review summarizes the current knowledge of the mechanisms that underpin MPS, which are broadly divided into mechanistic target of rapamycin complex 1 (mTORC1)-dependent, mTORC1-independent, and ribosomal biogenesis-related, and describes the evidence that shows how they are regulated by anabolic stimuli (exercise and/or nutrition) in healthy human skeletal muscle.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	156-162
31553107-10	2019	Inhibition of p70S6K /p85S6K by rapamycin also reduced the expressions of STAT3 and cyclin D1.	Sirolimus	32-41	cyclin D1	Homo sapiens	84-93
31512504-8	2019	Azithromycin and Rapamycin both promoted a FoxP3-positive Treg phenotype in bulk Tregs, while Rapamycin also increased FoxP3 and FoxP3+Helios positivity in naive and memory Tregs.	Sirolimus	17-26	forkhead box P3	Homo sapiens	43-48
31512504-8	2019	Azithromycin and Rapamycin both promoted a FoxP3-positive Treg phenotype in bulk Tregs, while Rapamycin also increased FoxP3 and FoxP3+Helios positivity in naive and memory Tregs.	Sirolimus	94-103	forkhead box P3	Homo sapiens	119-124
31512504-8	2019	Azithromycin and Rapamycin both promoted a FoxP3-positive Treg phenotype in bulk Tregs, while Rapamycin also increased FoxP3 and FoxP3+Helios positivity in naive and memory Tregs.	Sirolimus	94-103	forkhead box P3	Homo sapiens	119-124
31475823-9	2019	mTOR inhibition by rapamycin totally blocked the stimulation of leucine and methionine on CRTC2 expression.	Sirolimus	19-28	CREB regulated transcription coactivator 2	Mus musculus	90-95
31510109-3	2019	In GBs, mTORC1 inhibitors such as rapamycin have performed poorly in clinical trials, and in vitro protect GB cells from nutrient and oxygen deprivation.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	8-14
31649854-3	2019	In attempt to actively trigger ACD for synergistic chemotherapy, here we incorporated autophagy inducer rapamycin (RAP) into 7pep-modified PEG-DSPE polymer micelles (7pep-M-RAP) to specifically target and efficiently priming ACD of MCF-7 human breast cancer cells with high expression of transferrin receptor (TfR).	Sirolimus	104-113	transferrin receptor	Homo sapiens	288-308
31649854-3	2019	In attempt to actively trigger ACD for synergistic chemotherapy, here we incorporated autophagy inducer rapamycin (RAP) into 7pep-modified PEG-DSPE polymer micelles (7pep-M-RAP) to specifically target and efficiently priming ACD of MCF-7 human breast cancer cells with high expression of transferrin receptor (TfR).	Sirolimus	104-113	transferrin receptor	Homo sapiens	310-313
30022576-6	2019	We further report that the selective mTORC1 inhibitor, rapamycin, abolishes reinstatement of alcohol place preference.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	37-43
30616697-7	2019	In addition, rapamycin inhibited the mTOR signal pathway factors during leucine treatment.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Bos taurus	37-41
31599935-4	2019	These effects were regulated by hyperactivation of mammalian target of rapamycin complex 1(mTORC1) signaling, and thereby inhibition of autophagy and induction of ER stress in growth plate chondrocytes.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	91-97
31599935-5	2019	Intraperitoneal injection of mTORC1 inhibitor, rapamycin, to mice with Sirt1 deletion, partially neutralized such inhibitory effects of Sirt1 ablation on longitudinal bone growth, indicating the causative link between SIRT1 and mTORC1 signaling in the growth plate.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	29-35
31599935-5	2019	Intraperitoneal injection of mTORC1 inhibitor, rapamycin, to mice with Sirt1 deletion, partially neutralized such inhibitory effects of Sirt1 ablation on longitudinal bone growth, indicating the causative link between SIRT1 and mTORC1 signaling in the growth plate.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	228-234
31136010-5	2019	Using a zebrafish liver extreme injury model, we found that mammalian target of rapamycin complex 1 (mTORC1) signaling regulated dedifferentiation of BECs and proliferation of BP-PCs.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	101-107
31678320-2	2019	Mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is a mega protein complex that promotes energy-consuming anabolic processes of protein and nucleic acid synthesis as well lipogenesis in times of energy and nutrient abundance.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	53-59
31315433-10	2019	On the contrary, lentivirus-mediated overexpression of Rheb in macrophages increased oxidized LDL-induced lipid uptake and inflammation, and the stimulatory effect of Rheb was suppressed by the mTOR (mammalian target of rapamycin) inhibitor rapamycin or the PKA (protein kinase A) activator forskolin.	Sirolimus	220-229	Ras homolog, mTORC1 binding	Homo sapiens	55-59
31315433-10	2019	On the contrary, lentivirus-mediated overexpression of Rheb in macrophages increased oxidized LDL-induced lipid uptake and inflammation, and the stimulatory effect of Rheb was suppressed by the mTOR (mammalian target of rapamycin) inhibitor rapamycin or the PKA (protein kinase A) activator forskolin.	Sirolimus	220-229	Ras homolog, mTORC1 binding	Homo sapiens	167-171
31120172-4	2019	We showed that branching buds in the salivary glands were substantially decreased and phosphorylation of mTORC1 signalling pathway related proteins (mTOR, p70 ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1) was inhibited by rapamycin (an mTOR inhibitor).	Sirolimus	261-270	CREB regulated transcription coactivator 1	Mus musculus	105-111
30597187-10	2019	FOXP3 mRNA levels in the patients who received Tac/MMF were increased 4 months after transplantation and the expression was significantly higher than patients who received Tac/SRL.	Sirolimus	176-179	forkhead box P3	Homo sapiens	0-5
31676673-2	2019	In response to low energy, AMPK stimulates catabolic pathways such as autophagy to enhance energy production while inhibiting anabolic pathways regulated by the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	183-192	CREB regulated transcription coactivator 1	Mus musculus	204-210
31740775-3	2019	Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA.	Sirolimus	178-187	CREB regulated transcription coactivator 1	Mus musculus	199-205
31174205-10	2019	Rapamycin failed to rescue GATOR1 protein levels but rather rescued downstream mTORC1 hyperactivity as measured by phosphorylation of S6.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	79-85
31078684-6	2019	Loss of either Tsc1 or Tsc2 from astrocytes resulted in a marked increase in Aqp4 expression which was sensitive to mTORC1 inhibition with rapamycin.	Sirolimus	139-148	TSC complex subunit 1	Mus musculus	15-19
31078684-6	2019	Loss of either Tsc1 or Tsc2 from astrocytes resulted in a marked increase in Aqp4 expression which was sensitive to mTORC1 inhibition with rapamycin.	Sirolimus	139-148	CREB regulated transcription coactivator 1	Mus musculus	116-122
31227218-8	2019	In contrast, the mTORC1 inhibitor rapamycin did not have a significant effect on eEF2 dephosphorylation.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	17-23
31226250-3	2019	On the other hand, eEF-2K is inactivated by the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	68-77	eukaryotic elongation factor 2 kinase	Homo sapiens	19-25
31454827-8	2019	D-methadone increased phospho-p70S6 kinase, a downstream target of mTORC1 in the mPFC, and intra-mPFC infusion of the selective mTORC1 inhibitor rapamycin blocked the antidepressant actions of d-methadone in the FUST and NSFT.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	67-73
31454827-8	2019	D-methadone increased phospho-p70S6 kinase, a downstream target of mTORC1 in the mPFC, and intra-mPFC infusion of the selective mTORC1 inhibitor rapamycin blocked the antidepressant actions of d-methadone in the FUST and NSFT.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	128-134
31226250-3	2019	On the other hand, eEF-2K is inactivated by the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
31116586-1	2019	Everolimus inhibits mammalian target of rapamycin complex 1 (mTORC1) and is known to cause induction of autophagy and G1 cell cycle arrest.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	61-67
31142473-9	2019	In addition, the mammalian target of rapamycin complex 1 (mTORC1) pathway was remarkably activated in lupus AtMs, and blocking mTORC1 signalling by rapamycin abolished the generation of T-bet+ B cells and terminal differentiation of lupus AtMs.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
31622525-4	2019	We examine how metabolic sensors such as AMP-activated protein kinase (AMPK), mechanistic target of rapamycin complex 1 (mTORC1) and hypoxia inducible factor 1 (HIF1) determine sufficiency of various metabolites, and in turn modulate cellular functions that includes control of endocytic membrane traffic.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	121-127
31801253-4	2019	In this study, we investigated whether SCs participate directly in Lys-induced skeletal muscle growth and whether the mammalian target of rapamycin complex 1 (mTORC1) pathway was activated both in vivo and in vitro to mediate SC functions in response to Lys supplementation.	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	159-165
31801253-8	2019	After verifying that rapamycin inhibits the mTORC1 pathway and suppresses SC proliferation, we conclude that Lys is not only a molecular building block for protein synthesis but also a signal that activates SCs to manipulate muscle growth via the mTORC1 pathway.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	44-50
31801253-8	2019	After verifying that rapamycin inhibits the mTORC1 pathway and suppresses SC proliferation, we conclude that Lys is not only a molecular building block for protein synthesis but also a signal that activates SCs to manipulate muscle growth via the mTORC1 pathway.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	247-253
31775035-4	2019	In particular, we identify the ribosomal S6 Kinase/RSKS-1, previously characterized as an mTOR (mechanistic target of rapamycin) effector, as a regulator of DAF-2 endosomal recycling transport, which traces a functional correlation between endocytic recycling and aging processes.	Sirolimus	118-127	Ribosomal protein S6 kinase beta	Caenorhabditis elegans	51-57
31142473-9	2019	In addition, the mammalian target of rapamycin complex 1 (mTORC1) pathway was remarkably activated in lupus AtMs, and blocking mTORC1 signalling by rapamycin abolished the generation of T-bet+ B cells and terminal differentiation of lupus AtMs.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	127-133
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	65-71
31803749-6	2019	The mTORC1 inhibitor rapamycin prevented the glycine-stimulated protection of myotube diameter, and glycine-stimulated S6 phosphorylation, suggesting that mTORC1 signaling may be necessary for glycine"s protective effects in vitro.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
31803749-6	2019	The mTORC1 inhibitor rapamycin prevented the glycine-stimulated protection of myotube diameter, and glycine-stimulated S6 phosphorylation, suggesting that mTORC1 signaling may be necessary for glycine"s protective effects in vitro.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	155-161
31699965-6	2019	Duman"s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	91-97
31651917-9	2019	Furthermore, western blot analysis showed that LR1 activated the mammalian target of the rapamycin complex 1 (mTORC1) signaling pathway by increasing the phosphorylation of S6 and 70S6K1 in the gut-liver axis of weaned pigs.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	110-116
31062368-3	2019	Mammalian target of rapamycin complex 2 (mTORC2) has been implicated in cancer by regulating multiple AGC kinases, especially AKT proteins.	Sirolimus	20-29	CREB regulated transcription coactivator 2	Mus musculus	41-47
31487224-7	2019	The reduction of protein synthesis was associated with a marked inhibition of mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1, a mechanism consistent with reduced translation initiation.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	119-125
31297862-9	2019	Although rapamycin treatment-induced autophagy by adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in NBR1-knockdown cells, it did not process the conjugated form of LC3B-II after activation by unc-51 like autophagy-activating kinase 1 (ULK1).	Sirolimus	9-18	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	50-98
31297862-9	2019	Although rapamycin treatment-induced autophagy by adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in NBR1-knockdown cells, it did not process the conjugated form of LC3B-II after activation by unc-51 like autophagy-activating kinase 1 (ULK1).	Sirolimus	9-18	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	100-104
31297862-9	2019	Although rapamycin treatment-induced autophagy by adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in NBR1-knockdown cells, it did not process the conjugated form of LC3B-II after activation by unc-51 like autophagy-activating kinase 1 (ULK1).	Sirolimus	9-18	unc-51 like autophagy activating kinase 1	Homo sapiens	217-258
31297862-9	2019	Although rapamycin treatment-induced autophagy by adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in NBR1-knockdown cells, it did not process the conjugated form of LC3B-II after activation by unc-51 like autophagy-activating kinase 1 (ULK1).	Sirolimus	9-18	unc-51 like autophagy activating kinase 1	Homo sapiens	260-264
31297862-11	2019	Therefore, our findings provide a rationale for rapamycin treatment of NBR1-knockdown human urothelial cancer through the regulation of autophagy and mitochondrial dysfunction by regulating the AMPK/mTOR signaling pathway, indicating that NBR1 can be a potential therapeutic target of human urothelial cancer.	Sirolimus	48-57	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	194-198
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	162-168
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	151-160	CREB regulated transcription coactivator 1	Mus musculus	65-71
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	151-160	CREB regulated transcription coactivator 1	Mus musculus	162-168
31211512-7	2019	Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide treatment may act in part through TCR-mediated mammalian target of rapamycin complex 1 (mTORC1) signalling activation.	Sirolimus	129-138	beta-carboline-induced seizures 2	Mus musculus	0-5
31211512-7	2019	Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide treatment may act in part through TCR-mediated mammalian target of rapamycin complex 1 (mTORC1) signalling activation.	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	150-156
30549029-7	2019	In spite of the stable downregulation of LKB1 expression, rapamycin induced AMPK activation in URCa cells, causing loss of the mitochondrial membrane potential, ATP depletion, and ROS accumulation, indicating an alteration of mitochondrial biogenesis.	Sirolimus	58-67	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	76-80
31364468-8	2019	Moreover, the mTOR inhibitor rapamycin, NAD+ precursor nicotinamide riboside, and ABC99, a small molecule Notum inhibitor, have all been reported to rejuvenate ISC function in old mice and thus may have promise in humans.	Sirolimus	29-38	notum palmitoleoyl-protein carboxylesterase	Mus musculus	106-111
31581152-3	2019	Here, we show that increasing A20 expression in allogeneic islet grafts resulted in permanent survival for ~45% of recipients, and > 80% survival when combined with subtherapeutic rapamycin.	Sirolimus	180-189	TNF alpha induced protein 3	Homo sapiens	30-33
31371743-8	2019	These results suggest that EV-miR-6127, miR-6746-5p and miR-6787-5p could be a potential epigenetic mechanism induced by RAPA therapy in the regulation of the pre-metastatic niche of post-transplant colorectal cancer.	Sirolimus	121-125	microRNA 6746	Homo sapiens	40-48
31324799-0	2019	A novel rapamycin analog is highly selective for mTORC1 in vivo.	Sirolimus	8-17	CREB regulated transcription coactivator 1	Mus musculus	49-55
31324799-1	2019	Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	70-76
31324799-1	2019	Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
31324799-3	2019	Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	104-110
31319820-9	2019	Using these as initial readouts, we identified rich media conditions that promoted rapid cell growth but, upon mTORC1 inactivation by rapamycin, led to a growth/development switch.	Sirolimus	134-143	CREB regulated transcription coactivator 1	Mus musculus	111-117
31352855-15	2019	However, RAPA increases the numbers of macrophages autophagosome that inhibited by HG, resulting in a recovery of autophagy level with increase expression of LC3 and Beclin-1, whereas a reduction expression of P62, which lead to inhibition of adhesion and migration of macrophages induced by HG (p < .05) Conclusions: High glucose efficiently reduced the level of macrophage autophagy, following macrophages adhesion and migration enhanced when autophagy is suppressed.	Sirolimus	9-13	annexin A3	Rattus norvegicus	158-161
31352855-15	2019	However, RAPA increases the numbers of macrophages autophagosome that inhibited by HG, resulting in a recovery of autophagy level with increase expression of LC3 and Beclin-1, whereas a reduction expression of P62, which lead to inhibition of adhesion and migration of macrophages induced by HG (p < .05) Conclusions: High glucose efficiently reduced the level of macrophage autophagy, following macrophages adhesion and migration enhanced when autophagy is suppressed.	Sirolimus	9-13	beclin 1	Rattus norvegicus	166-174
31352855-15	2019	However, RAPA increases the numbers of macrophages autophagosome that inhibited by HG, resulting in a recovery of autophagy level with increase expression of LC3 and Beclin-1, whereas a reduction expression of P62, which lead to inhibition of adhesion and migration of macrophages induced by HG (p < .05) Conclusions: High glucose efficiently reduced the level of macrophage autophagy, following macrophages adhesion and migration enhanced when autophagy is suppressed.	Sirolimus	9-13	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	210-213
31665642-1	2019	The mechanistic target of rapamycin complex 2 (mTORC2) coordinates cell proliferation, survival, and metabolism with environmental inputs, yet how extracellular stimuli such as growth factors (GFs) activate mTORC2 remains enigmatic.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	47-53
31665642-1	2019	The mechanistic target of rapamycin complex 2 (mTORC2) coordinates cell proliferation, survival, and metabolism with environmental inputs, yet how extracellular stimuli such as growth factors (GFs) activate mTORC2 remains enigmatic.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	207-213
31658248-7	2019	Finally, we provide evidence that Art2 mediated Thi7 endocytosis is regulated by the target of rapamycin complex 1 (TORC1) and requires the Sit4 phosphatase but is not inhibited by the Npr1 kinase.	Sirolimus	95-104	Ecm21p	Saccharomyces cerevisiae S288C	34-38
31658248-7	2019	Finally, we provide evidence that Art2 mediated Thi7 endocytosis is regulated by the target of rapamycin complex 1 (TORC1) and requires the Sit4 phosphatase but is not inhibited by the Npr1 kinase.	Sirolimus	95-104	thiamine transporter THI7	Saccharomyces cerevisiae S288C	48-52
31619583-1	2019	The mechanistic target of rapamycin complex 2 (mTORC2) is a potentially novel and promising anticancer target due to its critical roles in proliferation, apoptosis, and metabolic reprogramming of cancer cells.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	47-53
31624262-2	2019	In a melanoma patient in whom programmed-death 1 (PD-1) blockade resulted in organ rejection and colitis, the addition of the mTOR inhibitor sirolimus resulted in ongoing anti-tumor efficacy while promoting allograft tolerance.	Sirolimus	141-150	programmed cell death 1	Homo sapiens	30-48
31624262-2	2019	In a melanoma patient in whom programmed-death 1 (PD-1) blockade resulted in organ rejection and colitis, the addition of the mTOR inhibitor sirolimus resulted in ongoing anti-tumor efficacy while promoting allograft tolerance.	Sirolimus	141-150	programmed cell death 1	Homo sapiens	50-54
31624262-5	2019	Interestingly, numbers of IFN-gamma+ CD4+ T cells and serum IFN-gamma levels increased with the addition of sirolimus treatment likely promoting ongoing anti-PD-1 efficacy.	Sirolimus	108-117	programmed cell death 1	Homo sapiens	158-162
31042058-2	2019	Proproliferative mechanistic target of rapamycin (mTOR) complexes 1 and 2 (mTORC1 and mTORC2) are activated in the kidneys of mice with PKD.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	75-81
31624262-6	2019	Thus, our results indicate that sirolimus has the potential to uncouple anti-PD-1 therapy toxicity and efficacy.	Sirolimus	32-41	programmed cell death 1	Homo sapiens	77-81
31042058-2	2019	Proproliferative mechanistic target of rapamycin (mTOR) complexes 1 and 2 (mTORC1 and mTORC2) are activated in the kidneys of mice with PKD.	Sirolimus	39-48	CREB regulated transcription coactivator 2	Mus musculus	86-92
31042058-3	2019	Sirolimus indirectly inhibits mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	30-36
31042058-10	2019	In conclusion, torin2 and sirolimus were equally effective in decreasing cyst burden and improving kidney function and mediated comparable effects on mTORC1 and mTORC2 signaling and proliferation in the Pkd1RC/RC kidney.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	150-156
31518555-4	2019	For experiment 2, rats were treated with mTORC1 inhibitor rapamycin during 24-h HS.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	41-47
31042058-10	2019	In conclusion, torin2 and sirolimus were equally effective in decreasing cyst burden and improving kidney function and mediated comparable effects on mTORC1 and mTORC2 signaling and proliferation in the Pkd1RC/RC kidney.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	161-167
31112404-2	2019	For instance, specific inhibition of mTORC1 by treating Sertoli cells with rapamycin promotes the Sertoli cell barrier, making it "tighter."	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	37-43
31548394-2	2019	Their regulation of tumor growth is closely tied to the ability of these enzymes to mainly stimulate protein synthesis by activating mTORC1 (mammalian target of rapamycin complex 1) signaling, although the exact mechanism is not completely understood.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	133-139
31159662-2	2019	Here, we aimed to establish a new in vitro muscle contraction model for analyzing the activation of mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	141-147
31345937-2	2019	We generated Ngn3RapKO mice (ablation of Raptor, an essential component of mechanistic target of rapamycin [mTORC1] in Ngn3+ endocrine progenitor cells) and found that mTORC1 was dispensable for endocrine cell lineage formation but specifically regulated both proliferation and identity maintenance of neonatal beta-cells.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	108-114
31345937-2	2019	We generated Ngn3RapKO mice (ablation of Raptor, an essential component of mechanistic target of rapamycin [mTORC1] in Ngn3+ endocrine progenitor cells) and found that mTORC1 was dispensable for endocrine cell lineage formation but specifically regulated both proliferation and identity maintenance of neonatal beta-cells.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	168-174
31353861-8	2019	Tsc1 gene deletion resulted in a strong activation of the mTORC1 pathway, and both epileptogenesis and lethality could be entirely prevented by RHEB1 gene deletion or rapamycin treatment.	Sirolimus	167-176	TSC complex subunit 1	Mus musculus	0-4
31353861-8	2019	Tsc1 gene deletion resulted in a strong activation of the mTORC1 pathway, and both epileptogenesis and lethality could be entirely prevented by RHEB1 gene deletion or rapamycin treatment.	Sirolimus	167-176	CREB regulated transcription coactivator 1	Mus musculus	58-64
31115485-10	2019	In this study, we provide evidence that rapamycin inhibits GSK3beta activation and elevates beta-catenin expression by improving the Wnt3a expression levels, which facilitates the amelioration of AD pathology.	Sirolimus	40-49	Wnt family member 3A	Homo sapiens	133-138
31115485-11	2019	On the whole, our findings indicate that rapamycin inhibits the activation of mTOR and alters the Wnt/GSK3beta/beta-catenin signalling pathway; thus, it may serve as a therapeutic target in the treatment of AD.	Sirolimus	41-50	Wnt family member 3A	Homo sapiens	98-101
31115485-11	2019	On the whole, our findings indicate that rapamycin inhibits the activation of mTOR and alters the Wnt/GSK3beta/beta-catenin signalling pathway; thus, it may serve as a therapeutic target in the treatment of AD.	Sirolimus	41-50	glycogen synthase kinase 3 alpha	Homo sapiens	102-110
30917412-5	2019	The effect of NR is blocked by the mTORC1 inhibitor rapamycin or the SIRT1 inhibitor EX527.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	35-41
31328833-11	2019	Further, T2DM significantly reduced mechanistic target of rapamycin complex 1 (mTORC1) activity (phosphorylation of p70S6KThr389 and 4E-BP1Thr37/46 ) to insulin stimulation and the number of myonuclei in the untrained basal condition, but RT-mediated adaptations were not affected by T2DM.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	79-85
31236744-8	2019	Meanwhile, rapamycin, a specific inhibitor of mTORC1, was co-applied with gentamicin to verify the role of mTOR signaling.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	46-52
31219657-6	2019	Cellular metabolic state is monitored by sensing lysosomal metabolites by the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	119-125
31426028-11	2019	Interference of mTOR activity by mTOR siRNA or rapamycin abolished the stimulation of GLP-1 production induced by IL-27 in STC-1 cells.	Sirolimus	47-56	glucagon	Mus musculus	86-91
31393061-2	2019	Phosphorylation of Akt Thr308 by PI3K-PDK1 and Akt Ser473 by mammalian target of rapamycin complex 2 (mTORC2) activates Akt.	Sirolimus	81-90	CREB regulated transcription coactivator 2	Mus musculus	102-108
31568401-10	2019	Disruption of PNO1 expression significantly reduced protein kinase B (AKT)/rapamycin (mTOR) signaling, indicating that this pathway may be involved in PNO1-mediated tumorigenic activity.	Sirolimus	75-84	partner of NOB1 homolog	Homo sapiens	14-18
31645839-8	2019	Consistently with its known molecular mechanism of action, rapamycin reduced the extent of activation of the so-called "mechanistic" target of rapamycin complex 1 (mTORC1) kinase and the total amount of intracellular proteins.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	164-170
31645839-8	2019	Consistently with its known molecular mechanism of action, rapamycin reduced the extent of activation of the so-called "mechanistic" target of rapamycin complex 1 (mTORC1) kinase and the total amount of intracellular proteins.	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	164-170
31645839-11	2019	All together these data suggest that the inhibition of mTORC1 in human microglia by rapamycin results in complex immunomodulatory effects, including a significant increase in the expression and release of the pro-inflammatory IL-6.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	55-61
31483776-9	2019	RESULTS Rapamycin impaired cell growth, induced cell apoptosis, and suppressed the expression levels of p-PI3K, p-Akt, nuclear NF-kappaB, and p65.	Sirolimus	8-17	RELA proto-oncogene, NF-kB subunit	Homo sapiens	142-145
30821607-4	2019	Interestingly, protein-protein interaction assays showed that TMED10 directly binds to ATG4B (autophagy related gene 4B cysteine peptidase), and the interaction is diminished under autophagy activation conditions such as rapamycin treatment and serum deprivation.	Sirolimus	221-230	autophagy related 4B cysteine peptidase	Homo sapiens	87-92
30782019-9	2019	A systemic injection of rapamycin activated chondrocyte autophagy, which increased the expression of LC3 and ATG-5, and reduced OARSI scores, the expression of beta-catenin, MMP-13, and VEGF, and chondrocyte apoptosis in rapamycin treated mice when compared with vehicle-treated mice.	Sirolimus	24-33	autophagy related 5	Mus musculus	109-114
30782019-9	2019	A systemic injection of rapamycin activated chondrocyte autophagy, which increased the expression of LC3 and ATG-5, and reduced OARSI scores, the expression of beta-catenin, MMP-13, and VEGF, and chondrocyte apoptosis in rapamycin treated mice when compared with vehicle-treated mice.	Sirolimus	24-33	matrix metallopeptidase 13	Mus musculus	174-180
31302450-9	2019	In addition, western blot analysis revealed increased LC3B II but decreased p62 protein expression levels in the IPC + RAPA group, indicating that autophagic flux was restored by combined ischemic and rapamycin preconditioning.	Sirolimus	201-210	microtubule-associated protein 1 light chain 3 beta	Mus musculus	54-58
31060359-5	2019	Rapamycin, a specific inhibitor of mTORC1, downregulated 4EBP1 phosphorylation and the expression of PPARgamma and the following lipogenic genes: lipin 1, DGAT1, ACC, and FAS.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	35-41
31060359-5	2019	Rapamycin, a specific inhibitor of mTORC1, downregulated 4EBP1 phosphorylation and the expression of PPARgamma and the following lipogenic genes: lipin 1, DGAT1, ACC, and FAS.	Sirolimus	0-9	peroxisome proliferator activated receptor gamma	Bos taurus	101-110
31072927-1	2019	During skeletal muscle regeneration, muscle stem cells (MuSCs) respond to multiple signaling inputs that converge onto mammalian target of rapamycin complex 1 (mTORC1) signaling pathways.	Sirolimus	139-148	CREB regulated transcription coactivator 1	Mus musculus	160-166
31113850-5	2019	We further delineated the signaling pathways involved and showed that TGF-beta1-induced ATF4 production depended on cooperation between canonical TGF-beta1 signaling through Smad3 and activation of mechanistic target of rapamycin complex 1 (mTORC1) and its downstream target eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1).	Sirolimus	220-229	CREB regulated transcription coactivator 1	Mus musculus	241-247
30904162-8	2019	Mechanistic studies showed that rapamycin attenuates TAA progression by inhibiting miR-126-3p through ERK1/2 inactivation.	Sirolimus	32-41	mitogen-activated protein kinase 3	Mus musculus	102-108
30710527-9	2019	Treg cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high levels of integrin alpha4beta7, as well as CD62L and FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.	Sirolimus	48-57	forkhead box P3	Homo sapiens	158-163
30362538-10	2019	More important, RAPA could also abrogate the changes induced by knockdown of UCA1.	Sirolimus	16-20	urothelial cancer associated 1	Homo sapiens	77-81
30879817-16	2019	Enhanced RPM supply upregulated overall protein abundance of solute carrier family 1 member 3, p-mTOR, and ribosomal protein S6.	Sirolimus	9-12	mechanistic target of rapamycin kinase	Bos taurus	97-101
31295472-11	2019	Importantly, upregulating autophagy with Rapamycin could mimic the effects of SIRT2 inhibition on apoptosis by increasing caspase-3 activation, whereas downregulating autophagy with 3-MA could abolish those effects by blocking caspase-3 activation.	Sirolimus	41-50	sirtuin 2	Bos taurus	78-83
31295472-11	2019	Importantly, upregulating autophagy with Rapamycin could mimic the effects of SIRT2 inhibition on apoptosis by increasing caspase-3 activation, whereas downregulating autophagy with 3-MA could abolish those effects by blocking caspase-3 activation.	Sirolimus	41-50	caspase 3	Bos taurus	122-131
30923110-8	2019	Inhibition of mTORC1 with rapamycin decreases protein synthesis and ubiquitin accumulation in UCH-L1-deficient neurons.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	14-20
31201822-5	2019	We demonstrated that HA-19 led to the increase of the protein synthesis by activating mechanistic target of rapamycin complex 1 (mTORC1)/p70 S6K pathways, and also enhanced myoblast proliferation and terminal differentiation via up-regulating of the myogenic transcription factors Pax7, MyoD and Myogenin.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	129-135
31433805-3	2019	Here, we demonstrate a special metabolic-epigenetic coupling mechanism orchestrated by tuberous sclerosis complex subunit 1 (TSC1)-mechanistic target of rapamycin (mTOR) for homeostatic DC function.	Sirolimus	153-162	TSC complex subunit 1	Mus musculus	87-123
31433805-3	2019	Here, we demonstrate a special metabolic-epigenetic coupling mechanism orchestrated by tuberous sclerosis complex subunit 1 (TSC1)-mechanistic target of rapamycin (mTOR) for homeostatic DC function.	Sirolimus	153-162	TSC complex subunit 1	Mus musculus	125-129
31434755-4	2019	Systemic treatment with the mTORC1 inhibitor rapamycin reduces alpha-globin precipitates and lessens pathologies in beta-thalassemic mice via an ULK1-dependent pathway.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	28-34
31434755-4	2019	Systemic treatment with the mTORC1 inhibitor rapamycin reduces alpha-globin precipitates and lessens pathologies in beta-thalassemic mice via an ULK1-dependent pathway.	Sirolimus	45-54	unc-51 like kinase 1	Mus musculus	145-149
31594080-17	2019	Compared with group M, the expression of LC3B II in Rapa group was significantly higher (F = 7.514, P = 0.01).	Sirolimus	52-56	microtubule-associated protein 1 light chain 3 beta	Mus musculus	41-45
31409770-8	2019	Rapamycin inhibited both mTORC1 and mTORC2 activation, whereas p62 siRNA inhibited only mTORC1 activation and maintained mTORC2 and Akt activation.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	25-31
31409770-8	2019	Rapamycin inhibited both mTORC1 and mTORC2 activation, whereas p62 siRNA inhibited only mTORC1 activation and maintained mTORC2 and Akt activation.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	36-42
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Sirolimus	18-27	transforming growth factor, beta 1	Mus musculus	215-224
30663221-4	2019	Ibr-7 was observed to dramatically suppress the mammalian target of Rapamycin complex 1 (mTORC1)/S6 signaling pathway, which is only slightly affected by ibrutinib, thus accounting for the superior anti-cancer activity of Ibr-7 towards NSCLC.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
30676865-4	2019	Current evidence suggests that for acute contraction models of mechanical stimuli, there is an emerging pattern suggesting that there is an early increase in protein synthesis governed by a rapamycin-sensitive mTORC1-dependent mechanism, while at later poststimulation time points, the mechanism may change to a rapamycin-insensitive mTORC1-dependent or even an mTORC1-independent mechanism.	Sirolimus	190-199	CREB regulated transcription coactivator 1	Mus musculus	210-216
30676865-4	2019	Current evidence suggests that for acute contraction models of mechanical stimuli, there is an emerging pattern suggesting that there is an early increase in protein synthesis governed by a rapamycin-sensitive mTORC1-dependent mechanism, while at later poststimulation time points, the mechanism may change to a rapamycin-insensitive mTORC1-dependent or even an mTORC1-independent mechanism.	Sirolimus	190-199	CREB regulated transcription coactivator 1	Mus musculus	334-340
30676865-4	2019	Current evidence suggests that for acute contraction models of mechanical stimuli, there is an emerging pattern suggesting that there is an early increase in protein synthesis governed by a rapamycin-sensitive mTORC1-dependent mechanism, while at later poststimulation time points, the mechanism may change to a rapamycin-insensitive mTORC1-dependent or even an mTORC1-independent mechanism.	Sirolimus	190-199	CREB regulated transcription coactivator 1	Mus musculus	334-340
30676865-4	2019	Current evidence suggests that for acute contraction models of mechanical stimuli, there is an emerging pattern suggesting that there is an early increase in protein synthesis governed by a rapamycin-sensitive mTORC1-dependent mechanism, while at later poststimulation time points, the mechanism may change to a rapamycin-insensitive mTORC1-dependent or even an mTORC1-independent mechanism.	Sirolimus	312-321	CREB regulated transcription coactivator 1	Mus musculus	210-216
30552925-0	2019	Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	0-31
31189691-6	2019	To better characterize the connection between these two pathways, we performed a phosphoproteome analysis of ER-positive MCF7 breast cancer cells treated with estrogen or estrogen and the mTORC1 inhibitor rapamycin.	Sirolimus	205-214	CREB regulated transcription coactivator 1	Mus musculus	188-194
31363142-6	2019	AVF in mice treated with rapamycin had reduced Akt1 and mTORC1 but not mTORC2 phosphorylation.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	56-62
31372056-10	2019	The PI3K/Akt pathway inhibitor, rapamycin, and LY294002 could partially attenuate the effect of Ezrin on cell proliferation, invasion, EMT progression, and YAP phosphorylation and translocation.	Sirolimus	32-41	Yes1 associated transcriptional regulator	Homo sapiens	156-159
31354497-9	2019	In addition, rapamycin was used to inhibit mTORC1 signaling, and it was found that colon length, disease associated index (DAI), and proportion of Treg cells of mice in the rapamycin-DSS group were not different from those of mice in the rapamycin/berberine-DSS group.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	43-49
31157925-3	2019	However, recent work has recognized the inhibitory impact this spatial redistribution has on mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of metabolism.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	136-142
31005665-0	2019	Nicotine inhibits rapamycin-induced pain through activating mTORC1/S6K/IRS-1-related feedback inhibition loop.	Sirolimus	18-27	CREB regulated transcription coactivator 1	Mus musculus	60-66
31005665-1	2019	Mammalian target of rapamycin complex 1 (mTORC1) inhibitors increase the incidence of pain in patients, and this finding has been replicated in animal models.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
30552925-0	2019	Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
30552925-6	2019	The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently.	Sirolimus	110-119	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
30992737-11	2019	The antiapoptotic effects of miR-25 were paralleled by inhibition of the p70S6K pathway, a convergence target for the survival signaling pathways, and protection by pre-miR-25 was abrogated by the p70S6k inhibitor rapamycin.	Sirolimus	214-223	microRNA 25	Mus musculus	29-35
30992737-11	2019	The antiapoptotic effects of miR-25 were paralleled by inhibition of the p70S6K pathway, a convergence target for the survival signaling pathways, and protection by pre-miR-25 was abrogated by the p70S6k inhibitor rapamycin.	Sirolimus	214-223	microRNA 25	Mus musculus	169-175
31182914-0	2019	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	88-94
31182914-1	2019	The mTORC1 inhibitors, such as rapamycin and its analogs, show limited antitumor activity in clinic, reasons for which have not been clearly elucidated.	Sirolimus	31-40	CREB regulated transcription coactivator 1	Mus musculus	4-10
31182914-8	2019	Mechanistically, the feedback activation of SGK3 by rapamycin was dependent on hVps34 and mTORC2, and reactivated mTORC1/4EBP1 axis by phosphorylating TSC2.	Sirolimus	52-61	phosphatidylinositol 3-kinase catalytic subunit type 3	Homo sapiens	79-85
31182914-8	2019	Mechanistically, the feedback activation of SGK3 by rapamycin was dependent on hVps34 and mTORC2, and reactivated mTORC1/4EBP1 axis by phosphorylating TSC2.	Sirolimus	52-61	CREB regulated transcription coactivator 2	Mus musculus	90-96
30563829-4	2019	To address the translational relevance of these findings, the effects of the mTOR complex 1 (mTORC1) inhibitor, rapamycin, on tumor and T cells were monitored in patients undergoing cystectomy for bladder cancer.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	93-99
30563829-8	2019	Rapamycin significantly inhibited tumor mTORC1, shown by decreased rpS6 phosphorylation in treated versus control patients (P = 0.008).	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	40-46
30563829-8	2019	Rapamycin significantly inhibited tumor mTORC1, shown by decreased rpS6 phosphorylation in treated versus control patients (P = 0.008).	Sirolimus	0-9	ribosomal protein S6	Homo sapiens	67-71
30650200-7	2019	The OSI-027 treatment of keloid keratinocytes showed more effectively inhibited cell proliferation and migration compared to the mTORC1 inhibitor, rapamycin.	Sirolimus	147-156	CREB regulated transcription coactivator 1	Mus musculus	129-135
30145794-1	2019	The hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) in chondrocytes has been shown to accelerate the severity of destabilization of the medial meniscus-induced and age-related osteoarthritis (OA) phenotypes with aberrant chondrocyte hypertrophy and angiogenesis.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	176-185	high mobility group box 1	Homo sapiens	85-90
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	187-191	high mobility group box 1	Homo sapiens	85-90
29228766-0	2019	The effects of addition of coenzyme Q10 to metformin on sirolimus-induced diabetes mellitus.	Sirolimus	56-65	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	43-52
29228766-1	2019	BACKGROUND/AIMS: This study was performed to determine whether adding coenzyme Q10 (CoQ10) to metformin (MET) has a beneficial effect as a treatment for sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	153-162	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	94-103
29228766-1	2019	BACKGROUND/AIMS: This study was performed to determine whether adding coenzyme Q10 (CoQ10) to metformin (MET) has a beneficial effect as a treatment for sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	153-162	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	105-108
29228766-1	2019	BACKGROUND/AIMS: This study was performed to determine whether adding coenzyme Q10 (CoQ10) to metformin (MET) has a beneficial effect as a treatment for sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	164-167	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	94-103
30892958-8	2019	The modified Morris water maze test showed that vision-dependent behavior was also significantly improved in the rapamycin + z-vad-fmk group.Western Blotting results demonstrated that rapamycin promoted the activation of autophagy by promoting beclin-1 and LC-3 induction and inhibited z-vad-fmk-induced necroptosis by inhibiting RIP-1 expression.	Sirolimus	113-122	beclin 1	Rattus norvegicus	244-252
29228766-1	2019	BACKGROUND/AIMS: This study was performed to determine whether adding coenzyme Q10 (CoQ10) to metformin (MET) has a beneficial effect as a treatment for sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	164-167	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	105-108
30892958-8	2019	The modified Morris water maze test showed that vision-dependent behavior was also significantly improved in the rapamycin + z-vad-fmk group.Western Blotting results demonstrated that rapamycin promoted the activation of autophagy by promoting beclin-1 and LC-3 induction and inhibited z-vad-fmk-induced necroptosis by inhibiting RIP-1 expression.	Sirolimus	113-122	annexin A3	Rattus norvegicus	257-261
31044492-1	2019	Insulin, insulin-like growth factor-1 (IGF-1) and essential amino acids activate the mechanistic target of rapamycin complex 1 (mTORC1), the main nutrient-sensitive kinase.	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	128-134
29228766-2	2019	METHODS: DM was induced in rats by daily treatment with SRL (0.3 mg/kg, subcutaneous) for 28 days, and animals were treated with CoQ10 (20 mg/kg, oral) and MET (250 mg/kg, oral) alone or in combination for the latter 14 days of SRL treatment.	Sirolimus	56-59	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	0-3
29228766-2	2019	METHODS: DM was induced in rats by daily treatment with SRL (0.3 mg/kg, subcutaneous) for 28 days, and animals were treated with CoQ10 (20 mg/kg, oral) and MET (250 mg/kg, oral) alone or in combination for the latter 14 days of SRL treatment.	Sirolimus	228-231	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	0-3
31115485-0	2019	Alteration of the Wnt/GSK3beta/beta-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer"s disease model.	Sirolimus	66-75	Wnt family member 3A	Homo sapiens	18-21
31115485-0	2019	Alteration of the Wnt/GSK3beta/beta-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer"s disease model.	Sirolimus	66-75	glycogen synthase kinase 3 alpha	Homo sapiens	22-30
32694720-1	2019	The protein kinase complex mechanistic target of rapamycin complex 1 (mTORC1) serves as a key conduit between growth signals and the metabolic processes underlying cell growth.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	70-76
31115485-10	2019	In this study, we provide evidence that rapamycin inhibits GSK3beta activation and elevates beta-catenin expression by improving the Wnt3a expression levels, which facilitates the amelioration of AD pathology.	Sirolimus	40-49	glycogen synthase kinase 3 alpha	Homo sapiens	59-67
30728291-2	2019	TSC is caused by inactivating mutations in the genes encoding TSC1/2, negative regulators of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	138-144
30791416-6	2019	Pharmacological activation of autophagy is typically achieved by blocking the kinase activity of mammalian target of rapamycin (mTOR) enzymatic complex 1 (mTORC1), removing its autophagy suppressor activity observed under physiological conditions; acting in this way, rapamycin provided the first proof of principle that pharmacological autophagy enhancement can induce neuroprotection through the facilitation of oligomers" clearance.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	155-161
31234465-5	2019	In older men, we observed an inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) in the highly viable spermatozoa population.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	90-96
30718659-9	2019	Mechanistic target of rapamycin suppression-induced inhibition of cap-dependent translation, and downregulation of the NMD components UPF1, SMG7, and eIF4A3, were probably involved in stress-induced NMD suppression.	Sirolimus	22-31	SMG7 nonsense mediated mRNA decay factor	Homo sapiens	140-144
31023527-5	2019	Mechanistically, the inhibitory effects of Oleate acid on rapamycin-induced autophagy were completely blocked by treatment with dominant negative p38alpha and p38 inhibitor SB203580.	Sirolimus	58-67	mitogen-activated protein kinase 14	Mus musculus	146-154
31023527-5	2019	Mechanistically, the inhibitory effects of Oleate acid on rapamycin-induced autophagy were completely blocked by treatment with dominant negative p38alpha and p38 inhibitor SB203580.	Sirolimus	58-67	mitogen-activated protein kinase 14	Mus musculus	146-149
30956113-1	2019	The mechanistic target of rapamycin complex (mTORC1) is a signaling hub on the lysosome surface, responding to lysosomal amino acids.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	45-51
30892080-6	2019	Furthermore, we found that pharmacological inhibition of the mTORC1 complex with rapamycin not only restored mitochondrial homeostasis but also reduced cellular senescence to bleomycin in lung epithelial cells.	Sirolimus	81-90	CREB regulated transcription coactivator 1	Mus musculus	61-67
30798505-2	2019	The state of senescence is controlled by extensive rewiring of signalling pathways, at the heart of which lies the mammalian Target of Rapamycin Complex I (mTORC1).	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	156-162
30946956-7	2019	In vitro study revealed that LPS-induced SERCA oxidation, autophagy and cardiac dysfunction were abrogated by ALDH2 activator Alda-1, the ER chaperone TUDCA, the autophagy inhibitor 3-MA, or the AMPK inhibitor Compound C. The beneficial effect of Alda-1 against LPS was nullified by AMPK activator AICAR or rapamycin.	Sirolimus	307-316	aldehyde dehydrogenase 2 family member	Homo sapiens	110-115
30718659-9	2019	Mechanistic target of rapamycin suppression-induced inhibition of cap-dependent translation, and downregulation of the NMD components UPF1, SMG7, and eIF4A3, were probably involved in stress-induced NMD suppression.	Sirolimus	22-31	eukaryotic translation initiation factor 4A3	Homo sapiens	150-156
30967006-3	2019	Consistent with this idea, activation of the metabolic regulator mechanistic target of rapamycin complex-1 (mTORC1) in response to acute stimulation by growth factors and extracellular amino acids requires internalization of amino acids by macropinocytosis.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	108-114
30582934-8	2019	The results revealed the additive effect of the combined treatment with rapamycin and trehalose on dopaminergic deficits (according to the levels of TH expression in the nigrostriatal system) but not on the behavioral performance in the mouse PD model.	Sirolimus	72-81	tyrosine hydroxylase	Mus musculus	149-151
30692064-0	2019	[Rapamycin alleviates inflammation by up-regulating TGF-beta/Smad signaling in a mouse model of autoimmune encephalomyelitis].	Sirolimus	1-10	transforming growth factor, beta 1	Mus musculus	52-60
30692064-8	2019	High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta.	Sirolimus	10-19	interleukin 23, alpha subunit p19	Mus musculus	86-91
30692064-8	2019	High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta.	Sirolimus	10-19	transforming growth factor, beta 1	Mus musculus	146-154
30692064-10	2019	In the in vitro experiment, combined treatments of the lymphocytes isolated from the mice with rapamycin and TGF-beta induced a significant increase in the number of Treg cells (13.66+-1.89) compared with the treatment with rapamycin (6.23+-0.80) or TGF-beta (4.87+-0.85) alone.	Sirolimus	95-104	transforming growth factor, beta 1	Mus musculus	250-258
30670706-3	2019	We hypothesized that mechanistic Target of Rapamycin Complex 1 (mTORC1) is a positive regulator of key genes encoding Electron Transport Chain (ETC) proteins and stimulates oxidative phosphorylation in trophoblast and that ETC protein expression is down-regulated in placentas of infants with intrauterine growth restriction (IUGR).	Sirolimus	43-52	CREB regulated transcription coactivator 1	Mus musculus	64-70
30705972-5	2019	Phosphorylation of p70 S6 kinase (p70S6K), an essential factor for promoting protein synthesis in skeletal muscle, was significantly increased by S42 to almost the same extent as by insulin, but this was significantly prevented by treatment with rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	246-255	CREB regulated transcription coactivator 1	Mus musculus	316-322
30903363-4	2019	The major molecular targets of metformin include complex I of the mitochondrial electron transport chain, adenosine monophosphate (AMP)-activated protein kinase (AMPK), and mechanistic target of rapamycin complex 1 (mTORC1), but AMPK-independent effects of metformin have also been described.	Sirolimus	195-204	CREB regulated transcription coactivator 1	Mus musculus	216-222
31033201-3	2019	The agent also stimulates AMP-activated protein kinase (AMPK) and consequently influences the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	114-123	CREB regulated transcription coactivator 1	Mus musculus	135-141
31312666-8	2019	Interestingly, we observed that mTORC1 inhibition with rapamycin improved myogenic and chondrogenic differentiation and reduced levels of apoptosis and senescence in Zmpste24 -/- MDSPCs.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	32-38
30530594-5	2019	In this study, we used an in vitro murine model in which the mTORC1 inhibitor rapamycin, when added after a B cell has committed to divide, suppresses class switching while preserving proliferation.	Sirolimus	78-87	CREB regulated transcription coactivator 1	Mus musculus	61-67
30952607-5	2019	Sptlc2 deficiency reduced sphingolipid biosynthetic flux and led to prolonged activation of the mechanistic target of rapamycin complex 1 (mTORC1), endoplasmic reticulum (ER) stress, and CD8+ T cell death.	Sirolimus	118-127	CREB regulated transcription coactivator 1	Mus musculus	139-145
31092879-5	2019	Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2).	Sirolimus	173-182	CREB regulated transcription coactivator 2	Mus musculus	194-200
31092879-6	2019	Impaired activation of Akt increased mRNA expression of the muscle atrophy F-Box (MAFbx), decreased activation of the mammalian Target of Rapamycin Complex 1 (mTORC1) and stimulated apoptosis by impairing the Ser9 phosphorylation of glycogen synthase kinase 3beta.	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	159-165
30670976-10	2018	Interestingly, by using pharmacological inhibition of the kinase mammalian target of rapamycin complex 1 (mTORC1) by Rapamycin, we were able to recapitulate similar changes in the proliferation dynamics of intestinal stem cells.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	106-112
31133888-7	2019	Low-dose rapamycin (0.1 nM) normalized respiration with the magnitude of this normalization greater for AD-A LCLs, suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may have a different dynamic range for regulating mitochondrial activity in individuals with ASD with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) regulation.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	176-182
31010692-11	2019	However, a search of more effective way to target mTOR has generated a third generation inhibitor of mTOR, "Rapalink", that bivalently combines rapamycin with an ATP-binding inhibitor, which effectively abolishes the mTORC1 activity.	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	217-223
30640966-7	2019	The allosteric inhibitor rapamycin only partially suppressed mTORC1 activity and exhibited a minimal effect on the induction of profibrotic markers.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	61-67
30835510-1	2019	Previous studies established that leucine stimulates protein synthesis in skeletal muscle to the same extent as a complete mixture of amino acids, and the effect occurs through activation of the mechanistic target of rapamycin in complex 1 (mTORC1).	Sirolimus	217-226	CREB regulated transcription coactivator 1	Mus musculus	241-247
30474386-11	2019	The sirolimus mesh markedly suppressed MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC migration, and reduced phospho-mTOR levels.	Sirolimus	4-13	matrix metallopeptidase 2	Rattus norvegicus	39-44
30507612-7	2019	Lipin 2/3 deficiency caused phosphatidic acid accumulation and mammalian target of rapamycin complex 1 (mTORC1) activation, which were associated with enhanced protein levels of a key phospholipid biosynthetic enzyme (CTP:phosphocholine cytidylyltransferase alpha) and altered membrane phospholipid composition.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
30765845-3	2019	In this report, we found that mTOR inhibitor rapamycin or mTOR deletion in CX3Cr1+ mononuclear phagocytes inhibits expression of interleukin (IL)-23, accompanied by reduced intestinal production of IL-22 and ameliorated fibrosis in the TNBS-induced fibrosis mouse model.	Sirolimus	45-54	interleukin 23, alpha subunit p19	Mus musculus	129-148
31327863-7	2019	In addition, in vitro study showed that ablation of Tsc2 promoted the development of intestinal organoids without epidermal growth factor, while mTORC1 inhibitor, rapamycin, diminished this phenotype.	Sirolimus	163-172	CREB regulated transcription coactivator 1	Mus musculus	145-151
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	106-112
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	196-202
30602778-3	2019	Here we demonstrate that rapamycin-insensitive mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-beta1 stimulated collagen synthesis in human lung fibroblasts, whereas canonical PI3K/Akt signaling is not required.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	47-53
30904097-4	2019	Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	182-188
30904097-5	2019	Rapamycin, an mTORC1 inhibitor, is now the only pharmacological therapy approved for the treatment of TSC.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	14-20
30838925-9	2019	This beneficial compensatory remodeling of cortical GABAergic innervation is mechanistic target of rapamycin complex 1 (mTORC1)-dependent, and its inhibition with rapamycin leads to a striking increase in motor seizures.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	120-126
31840789-5	2019	Many protein associations and regulatory pathways for mTORC1 and mTORC2 in Dictyostelium have context similarity to mammalian cells and specificity to inhibition by the immunosuppressive drug rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	54-60
30362509-3	2019	The expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and mechanistic target of rapamycin complex 2 (mTORC2) were decreased in the livers of iAs-treated mice.	Sirolimus	106-115	CREB regulated transcription coactivator 2	Mus musculus	127-133
31840789-5	2019	Many protein associations and regulatory pathways for mTORC1 and mTORC2 in Dictyostelium have context similarity to mammalian cells and specificity to inhibition by the immunosuppressive drug rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 2	Mus musculus	65-71
31840789-6	2019	In Dictyostelium, mTORC1 function is inactivated upon starvation-induced development, but development is directly induced through rapamycin-mediated inhibition of mTORC1 activity, even in the absence of nutrient withdrawal.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	163-169
30935290-1	2019	The current study, inspired by the immunosuppressive property of rapamycin (Rapa) and the benefit of microspheres both as drug delivery system and cell carriers, was designed to develop an efficient Rapa delivery system with tunable controllability to facilitate its local administration.	Sirolimus	65-74	transcriptional regulating factor 1	Homo sapiens	76-80
30935290-1	2019	The current study, inspired by the immunosuppressive property of rapamycin (Rapa) and the benefit of microspheres both as drug delivery system and cell carriers, was designed to develop an efficient Rapa delivery system with tunable controllability to facilitate its local administration.	Sirolimus	65-74	transcriptional regulating factor 1	Homo sapiens	199-203
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	unc-51 like kinase 1	Mus musculus	194-198
30932134-1	2019	BACKGROUND: The mammalian target of rapamycin complex 1 (mTORC1) is fundamental for many cellular processes, yet it is often dysregulated with aging.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	57-63
30946377-3	2019	The BiOSS LIM C is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 mum) releasing sirolimus (1.4 mug/mm) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids.	Sirolimus	133-142	PDZ and LIM domain 5	Homo sapiens	10-13
30632514-8	2019	Rapamycin prevented the decrease of bcl-2 expression in injured spinal cord tissue, reduced Bax, cytochrome c and caspase-3 expression levels and reduced the number of apoptotic neurons in injured spinal cord tissue 24 hours after spinal cord injury.	Sirolimus	0-9	caspase 3	Rattus norvegicus	114-123
30910807-3	2019	Here, single-cell measurements of signal transduction intermediates in the mechanistic target of rapamycin complex 1 (mTORC1) pathway reveal that ventral NSPCs have higher levels of signaling than dorsal NSPCs.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	118-124
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	TNF receptor superfamily member 11b	Homo sapiens	132-147
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	TNF receptor superfamily member 11b	Homo sapiens	149-152
30469030-7	2019	In differentiating 3T3-L1 cells, the mTOR inhibitor rapamycin and the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) likewise suppressed SELENBP1 induction, adipocyte differentiation and lipid accumulation.	Sirolimus	52-61	selenium binding protein 1	Mus musculus	157-165
30527742-1	2019	Although emerging evidence indicates an important role of the circadian clock in modulating the diurnal oscillation of mammalian target of rapamycin complex 1 (mTORC1) signaling, the underlying molecular mechanism remains elusive.	Sirolimus	139-148	CREB regulated transcription coactivator 1	Mus musculus	160-166
30537044-11	2019	CONCLUSIONS: Preconditioning of UC-MSCs by rapamycin afforded increased protection against liver I/R injury by enhancing immunosuppression and strengthening the homing and migratory capacity of these cells via the CXCR4/CXCL12 axis.	Sirolimus	43-52	chemokine (C-X-C motif) ligand 12	Mus musculus	220-226
30747228-0	2019	Rapamycin-induced miR-30a downregulation inhibits senescence of VSMCs by targeting Beclin1.	Sirolimus	0-9	microRNA 30a	Homo sapiens	18-25
30242894-7	2019	Our study demonstrated that rapamycin decreased the protective effects of HGF on the endothelium by decreasing tight junction protein occludin expression and cell proliferation, and raising lipopolysaccharide (LPS)-induced endothelial permeability, endothelial cell injury factors ET-1 and vWF.	Sirolimus	28-37	hepatocyte growth factor	Homo sapiens	74-77
30242894-7	2019	Our study demonstrated that rapamycin decreased the protective effects of HGF on the endothelium by decreasing tight junction protein occludin expression and cell proliferation, and raising lipopolysaccharide (LPS)-induced endothelial permeability, endothelial cell injury factors ET-1 and vWF.	Sirolimus	28-37	occludin	Homo sapiens	134-142
30550561-7	2018	We also observed that iTreg development by CD71+ erythroid cells is mediated through the inhibition of key signaling molecules phosphorylated protein kinase B (phospho-Akt) and phosphorylated mechanistic target of rapamycin (phospho-mTOR).	Sirolimus	214-223	transferrin receptor	Mus musculus	43-47
30387865-8	2019	Urinary N-acetyl-beta-D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +- 137.6 and -62.0 +- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +- 7763.5 ng/g creatinine; P < .05).	Sirolimus	58-67	O-GlcNAcase	Homo sapiens	8-39
30387865-8	2019	Urinary N-acetyl-beta-D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +- 137.6 and -62.0 +- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +- 7763.5 ng/g creatinine; P < .05).	Sirolimus	262-271	O-GlcNAcase	Homo sapiens	8-39
30665937-2	2019	In this study, myeloid cell-specific Raptor knockout (KO) mice were used to determine the roles of mechanistic target of rapamycin complex 1 (mTORC1) in regulating macrophage function from Lewis lung carcinoma (LLC) s.c. tumors and lung tumor metastasis.	Sirolimus	121-130	CREB regulated transcription coactivator 1	Mus musculus	142-148
29228766-10	2019	CONCLUSION: Addition of CoQ10 to MET has a beneficial effect on SRL-induced DM compared to MET alone.	Sirolimus	64-67	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	33-36
30816216-2	2019	Dysregulation of mTOR signaling has been implicated in the pathogenesis of certain types of ASD, and inhibition of mTOR by rapamycin has been demonstrated to be an effective therapeutics for impaired social interaction in Tsc1+/-, Tsc2+/-, Pten-/- mice and valproic acid-induced ASD animal models.	Sirolimus	123-132	TSC complex subunit 1	Mus musculus	222-226
30808817-5	2019	Glycolytic metabolism promoted the translocation of hexokinase-II to mitochondria and the activation of mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	124-133	CREB regulated transcription coactivator 2	Mus musculus	145-151
30795552-4	2019	Mammalian (or mechanistic) target of rapamycin (mTOR) is a conserved serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase family (PIKK) and resides in two distinct signalling complexes named mTORC1, involved in mRNA translation and protein synthesis and mTORC2 that controls cell survival and migration.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	231-237
30795552-4	2019	Mammalian (or mechanistic) target of rapamycin (mTOR) is a conserved serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase family (PIKK) and resides in two distinct signalling complexes named mTORC1, involved in mRNA translation and protein synthesis and mTORC2 that controls cell survival and migration.	Sirolimus	37-46	CREB regulated transcription coactivator 2	Mus musculus	294-300
30863496-14	2019	Thus, Rapamycin reduces HB in a clinically relevant model driven by beta-catenin and Yap1, supporting use of mTORC1 inhibitors in their therapy.	Sirolimus	6-15	yes-associated protein 1	Mus musculus	85-89
30863496-14	2019	Thus, Rapamycin reduces HB in a clinically relevant model driven by beta-catenin and Yap1, supporting use of mTORC1 inhibitors in their therapy.	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	109-115
30297804-4	2018	We showed that rapamycin and its analog RAD001 (everolimus) exerted only mild inhibition on the viability of Jurkat, CEM and Molt-4 cell lines (for everolimus the maximum inhibition was &lt;40% at 100 nM), but greatly enhanced the phosphorylation of eIF4E, a downstream substrate of MAPK-interacting kinase (MNK) that was involved in promoting cell survival.	Sirolimus	15-24	eukaryotic translation initiation factor 4E	Homo sapiens	250-255
30514904-1	2019	Mechanistic target of rapamycin mTOR complex 1 (mTORC1) plays a key role in the integration of various environmental signals to regulate cell growth and metabolism.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	48-54
30557824-0	2019	Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1beta and IL-18 production.	Sirolimus	0-9	interleukin 18	Mus musculus	94-99
30557824-2	2019	However, it is not clear whether the mTOR specific inhibitor rapamycin can attenuate lipopolysaccharide (LPS)-induced ALI by modulating IL-1beta and IL-18 production.	Sirolimus	61-70	interleukin 18	Mus musculus	149-154
30557824-3	2019	In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1beta and IL-18 secretion.	Sirolimus	29-38	interleukin 18	Mus musculus	175-180
29761287-6	2019	The expression of inflammation markers, bone structure-associated proteins and mammalian target of rapamycin complex1 (mTORC1) pathway-related proteins was assessed by immunohistochemical staining.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	119-125
30698725-5	2019	Blood and muscle biopsies were collected over 360 min during recovery from exercise to assess MyoPS and MitoPS rates and signaling through mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	159-168	CREB regulated transcription coactivator 1	Mus musculus	180-186
30523518-3	2019	mTORC1 repression by rapamycin prior to irradiation, or metabolic activation by minocycline after irradiation, partially rescues neuroepithelium integrity, neurite-growing capacity, ventricle formation and extracellular acidification rate as an integral measure of metabolic output.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	0-6
30144045-11	2018	A higher cathepsin activity, particularly of cathepsin B, was observed, which was reduced by mTORC1 inhibition with rapamycin in vivo.	Sirolimus	116-125	CREB regulated transcription coactivator 1	Mus musculus	93-99
30515090-6	2018	Upregulation of autophagy via serum deprivation or pharmacologic activators (rapamycin and resveratrol) promoted microglia polarization toward M2 phenotype, as evidenced by suppressed M1 and elevated M2 gene expression, while inhibition of autophagy with 3-MA or Atg5 siRNA consistently aggravated the M1 polarization induced by TNF-alpha.	Sirolimus	77-86	autophagy related 5	Mus musculus	263-267
30515090-9	2018	The neurotoxicity was further aggravated when Atg5 knockdown in BV2 cells but alleviated when microglia pretreatment with rapamycin.	Sirolimus	122-131	autophagy related 5	Mus musculus	46-50
30410117-1	2018	Although rapamycin is a well-known conformational inhibitor of mTORC1, it is now widely used for treating arterial restenosis.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	63-69
30179613-6	2018	Pre-treatment of rats with rapamycin for 24 h by intraperitoneal injection inhibited the expression of mRNA encoding the sinusoidal influx transporters Ntcp, Oatp1 and 2 and the canalicular efflux transporter Bsep, and increased expression of canalicular Mrp2.	Sirolimus	27-36	solute carrier family 10 member 1	Rattus norvegicus	152-156
29786783-12	2018	This VM xenograft model could be instrumental to test the therapeutic efficacy of Sirolimus in the presence of the different TIE2 or PIK3CA mutations or to test for efficacy of additional compounds in targeting the specific mutated protein(s), thus enabling development of personalized treatment options for VM patients.	Sirolimus	82-91	TEK receptor tyrosine kinase	Homo sapiens	125-129
30042494-6	2018	Treatment with MitoQ or rapamycin impaired both phosphorylation of ULK1 and expression of Atg proteins.	Sirolimus	24-33	unc-51 like autophagy activating kinase 1	Homo sapiens	67-71
30547365-1	2019	Previous studies showed that repeated intrathecal morphine injection activated the mammalian target of rapamycin complex 1 (mTORC1) in spinal dorsal horn neurons and that blocking this activation by intrathecal infusion of rapamycin, a specific mTORC1 inhibitor, prevented the initiation of morphine-induced tolerance and hyperalgesia.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	124-130
30547365-1	2019	Previous studies showed that repeated intrathecal morphine injection activated the mammalian target of rapamycin complex 1 (mTORC1) in spinal dorsal horn neurons and that blocking this activation by intrathecal infusion of rapamycin, a specific mTORC1 inhibitor, prevented the initiation of morphine-induced tolerance and hyperalgesia.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	245-251
30622053-9	2019	Consistently, rapamycin alone or rapamycin in combination with either 3-BrPA or CB-839 had stronger inhibitory effects on mTORC1 and proliferation of tumor cells than combination of 3-BrPA and CB-839.	Sirolimus	14-23	CREB regulated transcription coactivator 1	Mus musculus	122-128
30622053-9	2019	Consistently, rapamycin alone or rapamycin in combination with either 3-BrPA or CB-839 had stronger inhibitory effects on mTORC1 and proliferation of tumor cells than combination of 3-BrPA and CB-839.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	122-128
30682771-6	2019	Rapalogs, such as sirolimus and everolimus, partially inhibit mTOR complex 1 (mTORC1) and exhibit anti-cancer activity in vitro and in vivo in BTC.	Sirolimus	18-27	CREB regulated transcription coactivator 1	Mus musculus	78-84
30647914-3	2019	MTORC1 is activated in an interdependent manner by insulin/growth factors and nutrients, especially amino acids, and is inhibited by stressors such as hypoxia and by the drug rapamycin.	Sirolimus	175-184	origin recognition complex subunit 1	Homo sapiens	0-6
29928901-3	2018	In this study, we sought to understand the neuroprotective effect of rapamycin, the selective inhibitor of mTORC1, on RGC survival and the cellular mechanics that mediate this effect.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	107-113
30553437-8	2019	Rapamycin treatment in MT-COMP mice reduced mTORC1 signaling and intracellular retention of COMP, and increased proliferation, but did not change inflammatory markers IL-16 and eosinophil peroxidase.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	44-50
30335577-2	2019	A large body of work shows that a mammalian target of rapamycin complex 1 (mTORC1)-mediated increase of muscle protein synthesis is the key, but not sole, mechanism by which resistance exercise causes muscle hypertrophy.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	75-81
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	89-98	unc-51 like kinase 1	Mus musculus	12-16
31379141-1	2019	The mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and metabolism in response to various environmental inputs, especially amino acids.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
30542717-9	2019	Taken together, the findings of this study indicate that combination therapy with rapamycin and tamoxifen underlying p73-mediated ERalpha expression may provide new insight into the drug combination for the treatment of ER+ breast cancer.	Sirolimus	82-91	tumor protein p73	Homo sapiens	117-120
30594149-5	2018	Rapamycin increased viability of HT22 cells exposed to CoCl2 and reduced activation of caspases-9 and -3.	Sirolimus	0-9	caspase 9	Mus musculus	87-104
30546014-2	2018	TFEB activity is inhibited following its phosphorylation by mammalian target of rapamycin complex 1 (mTORC1) on the surface of the lysosome.	Sirolimus	80-89	transcription factor EB	Homo sapiens	0-4
30546014-2	2018	TFEB activity is inhibited following its phosphorylation by mammalian target of rapamycin complex 1 (mTORC1) on the surface of the lysosome.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	101-107
30341150-8	2018	Further analysis showed that platelet microparticles activated the mammalian target of rapamycin complex 1 (mTORC1) pathway in glomerular endothelial cells; inhibition of the mTORC1 pathway by rapamycin or raptor siRNA significantly protected against microparticle-induced glomerular endothelial injury in vivo and in vitro.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	108-114
30514811-3	2018	Here, we report that p62 was proteolytically trimmed by the protease caspase-8 into a stable protein, which we called p62TRM We found that p62TRM, but not full-length p62, was involved in nutrient sensing and homeostasis through the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	255-264	caspase 8	Homo sapiens	69-78
30365078-0	2018	Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	113-119
30365078-0	2018	Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway.	Sirolimus	0-9	autophagy related 13	Rattus norvegicus	120-125
30514691-8	2018	Rapamycin treatment dose-dependently increased the expressions of caspase-3 and caspase- 9 at both the mRNA (P &amp;lt; 0.001) and protein (P &amp;lt; 0.001) levels without causing significant changes in the expressions of caspase-8.	Sirolimus	0-9	caspase-3	Oryctolagus cuniculus	66-75
30341150-8	2018	Further analysis showed that platelet microparticles activated the mammalian target of rapamycin complex 1 (mTORC1) pathway in glomerular endothelial cells; inhibition of the mTORC1 pathway by rapamycin or raptor siRNA significantly protected against microparticle-induced glomerular endothelial injury in vivo and in vitro.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	175-181
30247156-3	2018	Here, we demonstrate that mTORC1 signaling is highly and specifically activated in the cochlear neurosensory epithelium (NSE) in aging mice, and rapamycin injection prevents ARHL.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	26-32
30341250-11	2018	Rapamycin pretreatment induced overexpression of LC3II/I and Beclin-1.	Sirolimus	0-9	beclin 1	Rattus norvegicus	61-69
30341250-12	2018	Moreover, LC3-labeled autophagosomes increasingly overlapped with TOMM20-labeled mitochondria and LAMP2-labeled lysosomes in CI-AKI, which was further enhanced by rapamycin administration.	Sirolimus	163-172	translocase of outer mitochondrial membrane 20	Rattus norvegicus	66-72
30348864-2	2018	Using two-photon fluorescence lifetime microscopy of the coenzymes, NADH and NADPH, and tracking brain oxygen metabolism with multi-parametric photoacoustic microscopy, we show that activation of lysosomal mechanistic target of rapamycin complex 1 (mTORC1) by insulin or amino acids stimulates mitochondrial activity and regulates mitochondrial DNA synthesis in neurons.	Sirolimus	228-237	CREB regulated transcription coactivator 1	Mus musculus	249-255
30309855-5	2018	This stark difference supports the idea that inhibition of mTORC1 by rapamycin has a key role in the improvement of the mitochondrial function in Cox15 sm/sm muscle.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	59-65
30247156-8	2018	Treatment with rapamycin and the antioxidant N-acetylcysteine rescued Tsc1-cKO hair cells from injury in vivo.	Sirolimus	15-24	TSC complex subunit 1	Mus musculus	70-74
29772587-7	2018	In cells pretreated with rapamycin, the inhibitory effects of cardamonin were completely suppressed with regards to the phosphorylation of the mammalian target of rapamycin, ribosomal protein S6 kinase 1, TNF-alpha, and interleukin-6, and nuclear factor-kappaB p65 protein expression was decreased.	Sirolimus	25-34	RELA proto-oncogene, NF-kB subunit	Homo sapiens	261-264
30326670-2	2018	mTOR functions in two distinct complexes-mTORC1 is sensitive to rapamycin, while, mTORC2 is insensitive to this drug.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	41-47
30185506-6	2018	Rapamycin restored LPS-induced up-regulation of EDN1, endothelin converting enzyme-1 (ECE1), and p-JNK in TSC1-knockdown mouse embryonic fibroblasts (MEFs).	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	106-110
30117227-11	2018	We administered continuous rapamycin, a specific mTORC1 inhibitor, orally to C57BL/6J mice concurrently with a high-fat, high-sucrose (HFHS) diet for 20 weeks.	Sirolimus	27-36	CREB regulated transcription coactivator 1	Mus musculus	49-55
30061014-1	2018	BACKGROUND: Mammalian target of rapamycin complex 1 (mTORC 1) drives the proinflammatory expansion of T helper (TH) type 1, TH17 cells and controls fibroblast proliferation, typical features of large vessel vasculitis (LVV) pathogenesis.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	53-60
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	14-20
29992400-5	2018	However, the stimulation of autophagy by rapamycin, an autophagy activator, remarkably suppressed Tox N-induced apoptosis, suggesting that autophagy plays a protective role in Tox N-induced apoptosis.	Sirolimus	41-50	thymocyte selection associated high mobility group box	Homo sapiens	98-101
30232410-4	2018	These two proteins form a complex that negatively regulates mechanistic target of rapamycin complex 1 (mTORC1), a master regulator of cellular growth and metabolism.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	103-109
30456248-0	2018	Redox-proteomes of human NOS1-transduced versus MOCK SH-SY5Y neuroblastoma cells under full nutrition, serum-free starvation, and rapamycin treatment.	Sirolimus	130-139	nitric oxide synthase 1	Homo sapiens	25-29
30456249-0	2018	Deep proteome of human nNOS/NOS1-positive versus MOCK SH-SY5Y neuroblastoma cells under full nutrition, serum free starvation and rapamycin treatment.	Sirolimus	130-139	nitric oxide synthase 1	Homo sapiens	23-27
30456249-0	2018	Deep proteome of human nNOS/NOS1-positive versus MOCK SH-SY5Y neuroblastoma cells under full nutrition, serum free starvation and rapamycin treatment.	Sirolimus	130-139	nitric oxide synthase 1	Homo sapiens	28-32
30456249-3	2018	nNOS+ and MOCK cells were exposed to proteostasis stress by treatment with rapamycin or serum-free starvation.	Sirolimus	75-84	nitric oxide synthase 1, neuronal	Mus musculus	0-4
30337735-10	2018	Moreover, the knock down of either Ulk1 or LC3 decreased the ST-caused apoptosis.Interestingly, we observed that rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin) and an inducer of autophagy, also showed to inhibit cell viability and increased the cleavage of PARP-1 in the ST-treated cells, suggesting that autophagy was likely to play a dual role in the regulation of the ST-induced apoptosis.	Sirolimus	113-122	unc-51 like autophagy activating kinase 1	Homo sapiens	35-39
30266297-11	2018	Rapamycin, an inhibitor of mTOR, reversed the decrease of ghrelin levels and pancreatic fibrosis.	Sirolimus	0-9	ghrelin	Mus musculus	58-65
29992400-5	2018	However, the stimulation of autophagy by rapamycin, an autophagy activator, remarkably suppressed Tox N-induced apoptosis, suggesting that autophagy plays a protective role in Tox N-induced apoptosis.	Sirolimus	41-50	thymocyte selection associated high mobility group box	Homo sapiens	176-179
30285764-15	2018	CONCLUSIONS: Menin is involved in regulatory mechanism between the two mTOR complexes, and its reduced expression is accompanied with increased mTORC2-Akt signaling, which consequently impairs anti-migratory effect of rapamycin.	Sirolimus	218-227	CREB regulated transcription coactivator 2	Mus musculus	144-150
30266904-5	2018	We identify a teQTL hotspot locus interacting with rapamycin treatment, infer putative causal regulators of the teQTL hotspot, and experimentally validate RRD1 as the causal regulator for this teQTL hotspot.	Sirolimus	51-60	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	155-159
29969175-6	2018	Also, our results suggest that mTORC1 pathway overactivation may function as a second hit event contributing to downregulation of the Reelin-DAB1 cascade in patient-derived NPCs, and that inhibition of mTORC1 by rapamycin attenuates Reelin-DAB1 signaling impairment.	Sirolimus	212-221	CREB regulated transcription coactivator 1	Mus musculus	31-37
30206977-4	2018	The inactivation of mTORC1 by rapamycin pretreatment or rotenone-induced mitochondrial complex inhibition showed a similar effect because of the metformin treatment on the proliferation and apoptosis of HaCaT keratinocytes.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	20-26
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	Sirolimus	73-82	interleukin 5	Homo sapiens	155-159
29969175-6	2018	Also, our results suggest that mTORC1 pathway overactivation may function as a second hit event contributing to downregulation of the Reelin-DAB1 cascade in patient-derived NPCs, and that inhibition of mTORC1 by rapamycin attenuates Reelin-DAB1 signaling impairment.	Sirolimus	212-221	CREB regulated transcription coactivator 1	Mus musculus	202-208
30144504-2	2018	The TSC1 and TSC2 genes encode proteins forming a complex (TSC), which is a major regulator and suppressor of mammalian target of rapamycin complex 1 (mTORC1), a signaling complex that promotes cell growth and proliferation.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	151-157
30242175-1	2018	Tuberous Sclerosis Complex (TSC), a rare genetic disorder with mechanistic target of rapamycin complex 1 (mTORC1) hyperactivation, is characterized by multi-organ hamartomatous benign tumors including brain, skin, kidney, and lung (Lymphangioleiomyomatosis).	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	106-112
30166521-11	2018	In PC3 cells, rapamycin retained its ability to activate autophagy without evidences of mitophagy even in presence of docetaxel.	Sirolimus	14-23	keratin 6A	Homo sapiens	3-6
30258985-2	2018	Although rapamycin inhibits the two canonical mTOR complexes, mTORC1 and mTORC2, it often shows minimal benefit as an anticancer drug.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	62-68
30258985-2	2018	Although rapamycin inhibits the two canonical mTOR complexes, mTORC1 and mTORC2, it often shows minimal benefit as an anticancer drug.	Sirolimus	9-18	CREB regulated transcription coactivator 2	Mus musculus	73-79
30237765-0	2018	Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging.	Sirolimus	0-9	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	107-113
30133440-11	2018	Finally, the expression level of CD69, an early activation marker, on splenic and lymph node CD4+ and CD8+ T cells was enhanced in rapamycin-treated mice.	Sirolimus	131-140	CD69 antigen	Mus musculus	33-37
30135653-0	2018	Rapamycin Upregulates Connective Tissue Growth Factor Expression in Hepatic Progenitor Cells Through TGF-beta-Smad2 Dependent Signaling.	Sirolimus	0-9	cellular communication network factor 2	Homo sapiens	22-53
30135653-0	2018	Rapamycin Upregulates Connective Tissue Growth Factor Expression in Hepatic Progenitor Cells Through TGF-beta-Smad2 Dependent Signaling.	Sirolimus	0-9	SMAD family member 2	Homo sapiens	110-115
30135653-3	2018	Here we showed that rapamycin upregulated connective tissue growth factor (CTGF) expression at the transcriptional level in hepatic progenitor cells (HPCs).	Sirolimus	20-29	cellular communication network factor 2	Homo sapiens	42-73
30135653-3	2018	Here we showed that rapamycin upregulated connective tissue growth factor (CTGF) expression at the transcriptional level in hepatic progenitor cells (HPCs).	Sirolimus	20-29	cellular communication network factor 2	Homo sapiens	75-79
30135653-4	2018	Using lentivirus-mediated small hairpin RNA (shRNA) we demonstrated that knockdown of mTOR, Raptor, or Rictor mimicked the effect of rapamycin treatment.	Sirolimus	133-142	regulatory associated protein of MTOR complex 1	Homo sapiens	92-98
29203371-9	2018	The expression of Sema3A, and mTOR signaling were up-regulated in HaCaT cells incubated with HG or rSema3A, and this could be attenuated by rapamycin.	Sirolimus	140-149	semaphorin 3A	Homo sapiens	18-24
30048010-7	2018	This beneficial compensatory remodeling of cortical GABAergic innervation is mTORC1-dependent and its inhibition with rapamycin leads to a striking increase in motor seizures.	Sirolimus	118-127	CREB regulated transcription coactivator 1	Mus musculus	77-83
30135653-6	2018	Besides, rapamycin activated the TGF-beta-Smad signaling, and TGF-beta receptor type I (TGFbetaRI) serine/threonine kinase inhibitors completely blocked the effects of rapamycin on HPCs.	Sirolimus	9-18	SMAD family member 4	Homo sapiens	42-46
30135653-6	2018	Besides, rapamycin activated the TGF-beta-Smad signaling, and TGF-beta receptor type I (TGFbetaRI) serine/threonine kinase inhibitors completely blocked the effects of rapamycin on HPCs.	Sirolimus	168-177	SMAD family member 4	Homo sapiens	42-46
30135653-8	2018	Rapamycin also induced ROS generation and latent TGF-beta activation which contributed to TGF-beta-Smad signaling.	Sirolimus	0-9	SMAD family member 4	Homo sapiens	99-103
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	241-247
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	regulatory associated protein of MTOR complex 1	Homo sapiens	273-279
30079598-5	2018	RESULTS: Tsc1Cx3cr1-Cre CKO mice exhibited a high efficiency of microglia Tsc1 inactivation, mTORC1 activation, increased microglial size and number, and robust epilepsy, which were rapamycin-dependent.	Sirolimus	182-191	TSC complex subunit 1	Mus musculus	9-13
30186415-10	2018	In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs.	Sirolimus	13-22	matrix metallopeptidase 2	Homo sapiens	98-130
29885404-3	2018	Sirolimus, an inhibitor of mTOR complex 1 (mTORC1), slows down disease progression in some, but not all patients.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	43-49
29845333-5	2018	RESULTS: We report that 4 week administration of PV1-PEG combined with rapamycin effectively controlled the progression of autoimmune diabetes in NOD mice at 10 weeks of age by reducing T cell activation and migration into the pancreas.	Sirolimus	71-80	atrophin 1	Homo sapiens	146-149
29857052-5	2018	Rapamycin treatment down-regulated the phosphorylated MTOR, RPS6 and 4EBP1 expressions, which confirmed MTORC1 suppression.	Sirolimus	0-9	ribosomal protein S6	Homo sapiens	60-74
31949841-6	2018	The expressions of glycolysis enzymes, Hexokinase 2, PKM2 and LDHA are upregulated in rapamycin resistant cells.	Sirolimus	86-95	hexokinase 2	Homo sapiens	39-51
30107854-9	2018	Activation of mTORC1, TGF-beta and NF-kappaB signaling pathways was determined in irradiated renal tissues, which were inhibited by rapamycin treatment.	Sirolimus	132-141	CREB regulated transcription coactivator 1	Mus musculus	14-20
29867165-5	2018	A short course of rapamycin treatment boosted the immunomodulatory efficacy of SA-FasL microgels, resulting in acceptance and function of allografts over 200 days.	Sirolimus	18-27	Fas ligand (TNF superfamily, member 6)	Mus musculus	82-86
30050079-7	2018	Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	30-36
29396625-7	2018	The elongated cilium phenotype of Tsc1-/- MEFs is likely due to increased mTORC1-dependent autophagic flux observed in these cells, as both the autophagic flux and the cilia length phenotype was restored by rapamycin.	Sirolimus	207-216	TSC complex subunit 1	Mus musculus	34-38
29635516-1	2018	Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and the quintessential disorder of mechanistic Target of Rapamycin Complex 1 (mTORC1) dysregulation.	Sirolimus	143-152	TSC complex subunit 1	Mus musculus	28-31
29635516-1	2018	Tuberous sclerosis complex (TSC) is an autosomal dominant neurodevelopmental disorder and the quintessential disorder of mechanistic Target of Rapamycin Complex 1 (mTORC1) dysregulation.	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	164-170
30107854-9	2018	Activation of mTORC1, TGF-beta and NF-kappaB signaling pathways was determined in irradiated renal tissues, which were inhibited by rapamycin treatment.	Sirolimus	132-141	transforming growth factor, beta 1	Mus musculus	22-30
29884898-5	2018	Infusion of a selective mTORC1 inhibitor, rapamycin, into the dorsal hippocampus 15 or 40 min but not 3 h before testing at 24 h reversibly disrupted memory expression even in animals that had already expressed IA memory.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	24-30
30107854-13	2018	CONCLUSIONS: These findings indicate that inhibition of mTORC1 signaling by rapamycin ameliorates irradiation-induced renal toxicity mediated by decreasing cellular apoptosis and increasing CD133+ renal stem-like cells.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	56-62
30087333-5	2018	Knockout of either TSC1 or DEPDC5 led to enhanced HIV-1 reactivation in both a T-cell line (C11) and a monocyte cell line (U1), and this enhancement could be antagonized by the mTORC1 inhibitor rapamycin.	Sirolimus	194-203	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	27-33
30087333-5	2018	Knockout of either TSC1 or DEPDC5 led to enhanced HIV-1 reactivation in both a T-cell line (C11) and a monocyte cell line (U1), and this enhancement could be antagonized by the mTORC1 inhibitor rapamycin.	Sirolimus	194-203	CREB regulated transcription coactivator 1	Mus musculus	177-183
30058583-9	2018	Results: The beneficial effects of rapamycin on neuropathic pain were attributed to a reduction in mammalian target of rapamycin sensitive complex 1 (mTORC1)-positive cells (70.80 +- 2.41 vs. 112.30 +- 5.66, F = 34.36, P &lt; 0.01) and mTORC1 activity in the mouse spinal cord.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	150-156
30058583-9	2018	Results: The beneficial effects of rapamycin on neuropathic pain were attributed to a reduction in mammalian target of rapamycin sensitive complex 1 (mTORC1)-positive cells (70.80 +- 2.41 vs. 112.30 +- 5.66, F = 34.36, P &lt; 0.01) and mTORC1 activity in the mouse spinal cord.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	236-242
29675586-0	2018	Rapamycin Alleviates Hormone Imbalance-Induced Chronic Nonbacterial Inflammation in Rat Prostate Through Activating Autophagy via the mTOR/ULK1/ATG13 Signaling Pathway.	Sirolimus	0-9	autophagy related 13	Rattus norvegicus	144-149
29675586-9	2018	In addition to some histological changes in the prostate tissues, we found the levels of NF-kappaB and IL-1beta were significantly increased in the model group, along with significantly suppressed autophagy, whereas rapamycin could reverse these effects which involved in the mTOR/ULK1/ATG13 signaling pathway.	Sirolimus	216-225	autophagy related 13	Rattus norvegicus	286-291
29607465-0	2018	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	93-99
29217498-1	2018	Two newborns with CHI due to homozygous ABCC8 gene mutations were started on sirolimus aged 21 and 17 days, due to lack of response to medical treatment.	Sirolimus	77-86	ATP binding cassette subfamily C member 8	Homo sapiens	40-45
29660335-9	2018	BEX4 abundance dictated the sensitivity of A549 and H1975 cells to rapamycin treatment.	Sirolimus	67-76	brain expressed X-linked 4	Homo sapiens	0-4
29559472-7	2018	Collectively, our data support a model in which Plk1, instead of AKT, regulates the TSC/mTORC1 pathway during mitosis, eventually regulating the efficacy of rapamycin.Significance: This seminal report shows that activation of mTORC1 can be independent of AKT during mitosis.	Sirolimus	157-166	CREB regulated transcription coactivator 1	Mus musculus	226-232
29979572-7	2018	C57BL/6 OVA sensitized mice injected with CD11c-pSiNP loaded with rapamycin + OVA323-339 produced a 5-fold higher number of splenic regulatory T-cells compared to control mice, at 40 days post-pSiNP injection.	Sirolimus	66-75	integrin alpha X	Mus musculus	42-47
29738849-10	2018	Involvement of mechanistic target of rapamycin complex-1 (mTORC1) signaling was also demonstrated, as the sustained antidepressant effects of LY341495 was attenuated by intra-mPFC injection of rapamycin, an mTORC1 inhibitor.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	58-64
30050412-7	2018	Interestingly, injection of Rapamycin, a pharmacological mTORC1 inhibitor, to pregnant mothers increased the lifespan of the mutant offspring, restored myelination as well as the levels of Qk and NfascNF155, and consequently the organization of the paranodal domains.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Mus musculus	57-63
29337352-2	2018	Here, we report in mice that L-LTP failure induced by the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) inhibitor rapamycin is reversed by brain-specific genetic deletion of PKR-like ER kinase, PERK (PERK KO), a kinase for eukaryotic initiation factor 2alpha (eIF2alpha).	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	113-119
29859856-6	2018	Inhibition of ileal mTORC1 signaling by rapamycin significantly attenuated the stimulation of bile acid secretion, TGR5 expression and GLP-1 synthesis induced by RYGB in lean and diet-induced obese mice.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	20-26
29859856-6	2018	Inhibition of ileal mTORC1 signaling by rapamycin significantly attenuated the stimulation of bile acid secretion, TGR5 expression and GLP-1 synthesis induced by RYGB in lean and diet-induced obese mice.	Sirolimus	40-49	glucagon	Mus musculus	135-140
29364507-2	2018	This disorder is characterized by increased activity of mammalian target of rapamycin complex 1 (mTORC1), which is involved in regulating ribosomal biogenesis and translation initiation.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
29732501-6	2018	Mechanistically, Hcy-activated CD4+ T cell increased the protein expression and activity of pyruvate kinase muscle isozyme 2 (PKM2), the final rate-limiting enzyme in glycolysis, via the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling pathway.	Sirolimus	243-252	pyruvate kinase, muscle	Mus musculus	92-124
29732501-6	2018	Mechanistically, Hcy-activated CD4+ T cell increased the protein expression and activity of pyruvate kinase muscle isozyme 2 (PKM2), the final rate-limiting enzyme in glycolysis, via the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling pathway.	Sirolimus	243-252	pyruvate kinase, muscle	Mus musculus	126-130
29607508-12	2018	PDLSCs treated with rapamycin or transfected with cDNA-Beclin-1 showed higher expression levels of bFGF and Ang that promoted tube formation by the co-cultured ECs.	Sirolimus	20-29	angiogenin	Homo sapiens	108-111
29653411-4	2018	In addition, oxalate-induced p38 phosphorylation was significantly attenuated by chloroquine pretreatment but was markedly enhanced by rapamycin pretreatment, whereas the protective effect of chloroquine on rat renal tubular cell oxidative injury was partly reversed by a p38 protein kinase activator anisomycin.	Sirolimus	135-144	mitogen activated protein kinase 14	Rattus norvegicus	29-32
29605662-7	2018	In addition, IPostC promoted the presynaptic growth associated protein 43 (GAP-43) and the postsynaptic protein 95 (PSD-95) levels at 1 week post-stroke, which were reduced by rapamycin.	Sirolimus	176-185	growth associated protein 43	Rattus norvegicus	45-73
29605662-7	2018	In addition, IPostC promoted the presynaptic growth associated protein 43 (GAP-43) and the postsynaptic protein 95 (PSD-95) levels at 1 week post-stroke, which were reduced by rapamycin.	Sirolimus	176-185	growth associated protein 43	Rattus norvegicus	75-81
29605662-7	2018	In addition, IPostC promoted the presynaptic growth associated protein 43 (GAP-43) and the postsynaptic protein 95 (PSD-95) levels at 1 week post-stroke, which were reduced by rapamycin.	Sirolimus	176-185	discs large MAGUK scaffold protein 4	Rattus norvegicus	116-122
29733580-6	2018	Rapamycin, a specific inhibitor of mTOR, was also applied to PA cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Bos taurus	35-39
29357413-7	2018	Short-term treatment of CKD mice with rapamycin, an inhibitor of mTORC1, or tauroursodeoxycholic acid, a bile acid that restores ER homeostasis, normalized mTORC1 activity, molecular markers of UPR, and calcium content of aortas.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	65-71
29357413-7	2018	Short-term treatment of CKD mice with rapamycin, an inhibitor of mTORC1, or tauroursodeoxycholic acid, a bile acid that restores ER homeostasis, normalized mTORC1 activity, molecular markers of UPR, and calcium content of aortas.	Sirolimus	38-47	CREB regulated transcription coactivator 1	Mus musculus	156-162
29786082-3	2018	Moreover, rapamycin blocks mGluR-LTD in mTORC1-deficient mice.	Sirolimus	10-19	CREB regulated transcription coactivator 1	Mus musculus	40-46
29758070-2	2018	mTORC1 is frequently activated in human cancers and, although the mTORC1 inhibitor rapamycin has a cytostatic effect, it is, in general, unable to elicit a robust curative effect or tumor regression.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	0-6
29758070-2	2018	mTORC1 is frequently activated in human cancers and, although the mTORC1 inhibitor rapamycin has a cytostatic effect, it is, in general, unable to elicit a robust curative effect or tumor regression.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	66-72
29743930-10	2018	Furthermore, rapamycin and PF-4708671 enhanced the inhibitory effect of siRNA-LXRalpha.	Sirolimus	13-22	nuclear receptor subfamily 1 group H member 3	Homo sapiens	78-86
29432811-4	2018	Infiltrations of CD11c+ dendritic cells and CD4+ T cells, and the expressions of chemokines and adhesion molecules in the conjunctiva were attenuated in rapamycin-treated mice, as well as decreased Th1 and Th2 cytokines in the cervical lymph nodes compared to non-treated mice.	Sirolimus	153-162	integrin subunit alpha X	Homo sapiens	17-22
29483210-8	2018	Finally, proliferation of NSGCT cells in vitro and in vivo is significantly inhibited by combined treatment with the clinically available agents erlotinib and rapamycin, which target EGFR and mTORC1 signaling, respectively.	Sirolimus	159-168	CREB regulated transcription coactivator 1	Mus musculus	192-198
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	46-52
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	ribosomal protein S6	Homo sapiens	81-85
29692710-7	2018	We provide further insights that explain the reasons for the failure of numerous clinical trials conducted to date targeting PI3K or mTOR complex 1 (mTORC1) with rapamycin and its analogs.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	149-155
29686643-3	2018	We show that rapamycin, which acts as an allosteric inhibitor of mTORC1, counteracts the impairment of novel object recognition.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	65-71
29761115-7	2018	These phenotypic features persisted throughout embryonic development and were significantly reduced upon treatment with the mTORC1 inhibitor, rapamycin, as well as overexpression of human WT DEPDC5 transcript.	Sirolimus	142-151	CREB regulated transcription coactivator 1	Mus musculus	124-130
29241828-2	2018	Several recent studies in genetic mouse models of FOP support involvement of the mechanistic target of rapamycin complex 1 (mTORC1) pathway in the pathophysiology of FOP and propose the repurposed use of rapamycin, an inhibitor of mTORC1 signaling in clinical trials for the management of FOP.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	124-130
29481864-7	2018	mTORC1-dependent effects of DEPDC5/NPRL3 KD were determined using the mTOR inhibitor rapamycin.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	0-6
29481864-12	2018	DEPDC5/NPRL3 KD effects on morphology and functional mTOR activation were reversed by rapamycin.	Sirolimus	86-95	DEP domain containing 5, GATOR1 subcomplex subunit	Homo sapiens	0-6
29844054-4	2018	Upstream stimuli from various metabolic activities converge on mechanistic target of rapamycin complex 1 (mTORC1), and aberrant mTORC1 signaling is implicated in aging and age-related degeneration of the RPE.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	106-112
29545903-0	2018	Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK.	Sirolimus	0-9	autophagy related 7	Homo sapiens	125-129
29545903-3	2018	Changes in cell viability, cell cycle distribution, apoptosis and associated genes were analyzed in MDA-MB-231 cells subjected to DHA following alteration in autophagy levels; the autophagy level was decreased following autophagy-related 7 (Atg7) knockdown or increased using rapamycin.	Sirolimus	276-285	autophagy related 7	Homo sapiens	241-245
29080681-5	2018	By contrast, abrogation of mTORC1 by rapamycin completely reversed the reduced pigmentation, and alleviation of endoplasmic reticulum stress by SMER28 or 4-phenylbutyrate (PBA) or alleviation of mitochondrial oxidative stress by administration of adenosine triphosphate partially reversed the reduced pigmentation in these mice.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	27-33
29136244-4	2018	Results: An unbiased phosphoproteomic screen quantified phosphorylation changes associated with chronic exposure to the mTOR inhibitor rapamycin, and our analysis implicated a role for glycogen synthase kinase (GSK)3B attenuation in mediating resistance that was confirmed by functional studies.	Sirolimus	135-144	glycogen synthase kinase 3 beta	Homo sapiens	211-217
29491408-6	2018	Rapamycin, shRNAs targeting raptor, or inhibition of S6 kinase significantly inhibited the expression of Nox4, resulting in attenuation of production of ROS in tuberin-downregulated proximal tubular epithelial cells.	Sirolimus	0-9	NADPH oxidase 4	Homo sapiens	105-109
29757673-5	2018	Results indicated that both rapamycin and AZD8055 inhibited mTOR complex 1 (mTORC1)/70-kDa ribosomal protein S6 kinase signaling similarly, whereas mTORC1/eukaryotic translation initiation factor 4E-binding protein 1 signaling was greatly inhibited by AZD8055.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Mus musculus	76-82
29515583-9	2018	Small-molecule enhancer of rapamycin 3, an ubiquitin ligase inhibitor reversed the K63-linked polyubiquitination on TRAF6 in R848-primed BMDMs and subsequently decreased TAK1 and MAPK phosphorylation, and cytokine production as well as reversed the decreased bacterial clearance capacity of BMDMs.	Sirolimus	27-36	mitogen-activated protein kinase kinase kinase 7	Mus musculus	170-174
29410391-5	2018	We found that rapamycin treatment promoted autophagy and depressed cell apoptosis increasing the number of NOBOX positive oocytes.	Sirolimus	14-23	NOBOX oogenesis homeobox	Mus musculus	107-112
29744053-5	2018	Further study demonstrated that tunicamycin-induced cell death was enhanced by rapamycin, a specific inhibitor of mTORC1.	Sirolimus	79-88	CREB regulated transcription coactivator 1	Mus musculus	114-120
29731844-4	2018	The results demonstrated that combined treatment with rapamycin and resveratrol effectively inhibited cell viability in the MM1.S cell line through inhibition of the mTORC1 and mTORC2 signaling pathways, compared with resveratrol or rapamycin monotherapy.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	166-172
28334166-6	2018	Inhibition of the overactivated mTORC1-S6K signaling pathway by rapamycin or mGluR5 antagonist ameliorated the deficiency of the excitatory synaptic transmission in the mPFC and the social recognition of Grk5-/- mice.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	32-38
29731844-4	2018	The results demonstrated that combined treatment with rapamycin and resveratrol effectively inhibited cell viability in the MM1.S cell line through inhibition of the mTORC1 and mTORC2 signaling pathways, compared with resveratrol or rapamycin monotherapy.	Sirolimus	54-63	CREB regulated transcription coactivator 2	Mus musculus	177-183
28334166-6	2018	Inhibition of the overactivated mTORC1-S6K signaling pathway by rapamycin or mGluR5 antagonist ameliorated the deficiency of the excitatory synaptic transmission in the mPFC and the social recognition of Grk5-/- mice.	Sirolimus	64-73	G protein-coupled receptor kinase 5	Mus musculus	204-208
29703186-8	2018	We also show that cells expressing HPV-16 E7 or silenced for pRb acquire resistance to the antiproliferative effect of rapamycin.	Sirolimus	119-128	RB transcriptional corepressor 1	Homo sapiens	61-64
30074157-0	2018	Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	145-151
30074157-7	2018	The results revealed that rapamycin treatment significantly attenuated the incidence of Ang II induced-AAA in ApoE-/- mice.	Sirolimus	26-35	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	88-91
29850566-12	2018	Rapamycin elicited concentration-dependent reductions in the mRNA (P &lt; 0.05) and protein (P &lt; 0.01) expressions of Smad2 and eIF-4E.	Sirolimus	0-9	SMAD family member 2	Homo sapiens	121-126
29850566-12	2018	Rapamycin elicited concentration-dependent reductions in the mRNA (P &lt; 0.05) and protein (P &lt; 0.01) expressions of Smad2 and eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	131-137
29344639-4	2018	In addition, western blot analysis indicated that PP242 completely inhibited mTORC1 and mTORC2 downstream signaling activities, whereas rapamycin only partially inhibited mTORC1 activity within LECs.	Sirolimus	136-145	CREB regulated transcription coactivator 1	Mus musculus	171-177
28407241-3	2018	Isolated rat TDSCs were treated with various concentrations of leptin in the presence or absence of mTORC1 signaling specific inhibitor rapamycin in vitro.	Sirolimus	136-145	CREB regulated transcription coactivator 1	Mus musculus	100-106
29224866-8	2018	Inhibition of mTORC1 by rapamycin attenuated the phosphorylation of molecules related to mTORC1 signaling and caused a marked decrease in LAT1 expression in the cultured cells; expression of beta-casein also decreased significantly.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
29224866-8	2018	Inhibition of mTORC1 by rapamycin attenuated the phosphorylation of molecules related to mTORC1 signaling and caused a marked decrease in LAT1 expression in the cultured cells; expression of beta-casein also decreased significantly.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	89-95
29389967-10	2018	Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	81-87
29475988-8	2018	Importantly, suppression of mTORC2 for 24 h with rapamycin or everolimus or treatment with mTOR active-site inhibitors enhanced HLA-II Ab-stimulated phosphorylation of ERK.	Sirolimus	49-58	CREB regulated transcription coactivator 2	Mus musculus	28-34
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	forkhead box P3	Homo sapiens	28-33
29619032-4	2018	Addition of the mTOR inhibitor rapamycin to Treg cultures enhances FOXP3 expression and Treg stability, but does impair proliferative capacity.	Sirolimus	31-40	forkhead box P3	Homo sapiens	67-72
29619032-9	2018	Addition of rapamycin to CD28 superagonist-stimulated Treg led to a high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound TNFalpha.	Sirolimus	12-21	CD28 molecule	Homo sapiens	25-29
29506489-9	2018	This technique further showed that the inhibition of AKT1 signaling is phenocopied by blocking the mTORC1 pathway with rapamycin.	Sirolimus	119-128	CREB regulated transcription coactivator 1	Mus musculus	99-105
29161463-14	2018	In turn, blockade of mTORC1 by 3-day rapamycin treatment enhanced transforming growth factor beta production, while dual blockade of mTORC1 and mTORC2 by 4-week rapamycin treatment induced autophagy, restored the expression of GATA-3 and CTLA-4, and corrected Treg cell function.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	21-27
29314656-4	2018	Our results showed that chronic rapamycin treatment markedly reduced the phosphorylated mTOR and ribosomal protein S6 expression, but not Akt in both normal and aortic-banded mice.	Sirolimus	32-41	ribosomal protein S6	Mus musculus	97-117
29396369-8	2018	Administration of B-type natriuretic peptide (BNP) to mice induced Ucp1 expression in inguinal adipose tissue in vivo, which was completely blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	172-181	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	67-71
29348496-9	2018	These effects were totally abrogated by inhibition of cGMP-dependent protein kinase and mTORC1/2 by rapamycin.	Sirolimus	100-109	CREB regulated transcription coactivator 2	Mus musculus	88-96
29396369-8	2018	Administration of B-type natriuretic peptide (BNP) to mice induced Ucp1 expression in inguinal adipose tissue in vivo, which was completely blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	172-181	CREB regulated transcription coactivator 1	Mus musculus	155-161
29472548-1	2018	Type-II L-arginine:ureahydrolase, arginase-II (Arg-II), is shown to activate mechanistic target of rapamycin complex 1 (mTORC1) pathway and contributes to cell senescence and apoptosis.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	120-126
29507903-9	2018	While exposure to insulin stimulated the cytotoxic activity of healthy NK cells, rapamycin prevented this effect and reduced NK insulin receptor expressions.	Sirolimus	81-90	insulin receptor	Homo sapiens	128-144
29375310-6	2017	We treated Fmr1 KO mice chronically with an mTORC1 inhibitor, rapamycin, to determine if rapamycin treatment could reverse behavioral phenotypes.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	44-50
29424687-4	2018	We report the architecture of human mTORC2 at intermediate resolution, revealing a conserved binding site for accessory proteins on mTOR and explaining the structural basis for the rapamycin insensitivity of the complex.	Sirolimus	181-190	CREB regulated transcription coactivator 2	Mus musculus	36-42
29445291-8	2018	Different from rapamycin and AZD8055, cardamonin suppressed the phosphorylation and protein expression of Raptor.	Sirolimus	15-24	regulatory associated protein of MTOR complex 1	Homo sapiens	106-112
29283439-2	2018	Although the physiological function of TBCK remains unclear, loss-of-function mutations are associated with inhibition of mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	165-171
29190625-3	2018	Inhibition of the mTOR complex 1 (mTORC1) with rapamycin is currently the only known pharmacological treatment that increases lifespan in all model organisms studied.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	34-40
28300280-0	2018	Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	80-86
28300280-5	2018	Also, PP242, an mTORC1/2 kinase inhibitor, repressed survivin expression, and cell proliferation/viability more potently than rapamycin (mTORC1 inhibitor) in B cells in response to hsBAFF.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	137-143
29434788-7	2018	Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells.	Sirolimus	31-40	forkhead box P3	Rattus norvegicus	146-151
29454612-5	2018	Using western blots, we measured the phosphorylation of 4E-BP and S6K proteins, the main targets of TOR, following the in vitro exposure of PGs to brain extract containing PTTH (hereafter referred to as PTTH) and/or the inhibitors of MAPK (U0126), PI3K (LY294002) or TOR (rapamycin).	Sirolimus	272-281	prothoracicotropic hormone	Bombyx mori	172-176
29195127-0	2018	Rapamycin Synergizes with Cisplatin in Antiendometrial Cancer Activation by Improving IL-27-Stimulated Cytotoxicity of NK Cells.	Sirolimus	0-9	interleukin 27	Homo sapiens	86-91
29195127-5	2018	Exposure with rapamycin enhanced the cytotoxicity of NK cells by upregulating the expression of IL-27 in UECC and IL-27 receptors (IL-27Rs: WSX-1 and gp130) on NK cells and further restricted the growth of UEC in Ishikawa-xenografted nude mice.	Sirolimus	14-23	interleukin 27	Homo sapiens	114-119
29195127-6	2018	In addition, treatment with rapamycin resulted in an increased autophagy level of UECC, and IL-27 enhanced this ability of rapamycin.	Sirolimus	123-132	interleukin 27	Homo sapiens	92-97
29195127-8	2018	These results suggest that rapamycin and cisplatin synergistically activate the cytotoxicity of NK cells and inhibit the progression of UEC in both an IL-27-dependent and -independent manner.	Sirolimus	27-36	interleukin 27	Homo sapiens	151-156
29468175-11	2018	Rapamycin markedly decreased the number of FJB-positive cells and the expression of cleaved caspase-3 and cleaved caspase-9 proteins as well as increased the activation of autophagy reflected by ULK1, Beclin-1 and LC3.	Sirolimus	0-9	beclin 1	Rattus norvegicus	201-209
29468175-11	2018	Rapamycin markedly decreased the number of FJB-positive cells and the expression of cleaved caspase-3 and cleaved caspase-9 proteins as well as increased the activation of autophagy reflected by ULK1, Beclin-1 and LC3.	Sirolimus	0-9	annexin A3	Rattus norvegicus	214-217
28972182-7	2017	However, rapamycin further increased uPA expression in TSC2-null tumor cells and immortalized TSC2-null angiomyolipoma cells, but not in cells with intact TSC.	Sirolimus	9-18	TSC complex subunit 1	Mus musculus	55-58
29106387-5	2017	Moreover, inhibition of mTORC1 signaling in alphaRaptorKO mice and in WT animals exposed to chronic rapamycin administration decreased glucagon content and glucagon secretion.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	24-30
29434788-7	2018	Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells.	Sirolimus	31-40	forkhead box P3	Rattus norvegicus	241-246
29233655-10	2018	Treating rats with rapamycin blocked the mTORC1 pathway and masked the abovementioned effects of rhEPO.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	41-47
29138237-2	2018	Through a cross with a honey wine (white tecc) brewing strain from Ethiopia, we map the minimal medium growth defect to SER1, which encodes 3-phosphoserine aminotransferase and is orthologous to the human disease gene, PSAT1 To investigate the impact of this polymorphism under conditions of abundant external nutrients, we examine growth in rich medium alone or with additional stresses, including the drugs caffeine and rapamycin and relatively high concentrations of copper, salt, and ethanol.	Sirolimus	422-431	phosphoserine aminotransferase 1	Homo sapiens	219-224
29019741-7	2017	Inhibition of mTORC1 by rapamycin treatment increased radiation-induced cell apoptosis, reduced cell proliferation and delayed restoration of Wnt signaling in the hair matrix after radiation injury, leading to prolonged dystrophy and hair loss.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	vimentin	Rattus norvegicus	74-82
29191929-0	2018	Correction: Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but Not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin.	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	26-32
29191929-0	2018	Correction: Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but Not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin.	Sirolimus	143-152	SMAD family member 1	Homo sapiens	50-63
29090333-10	2018	Intraperitoneal rapamycin (an mTORC1 inhibitor; 10 mg/kg) blocked the antidepressant effect of intracerebroventricular RvE1.	Sirolimus	16-25	CREB regulated transcription coactivator 1	Mus musculus	30-36
29206176-8	2017	Moreover, inhibiting ERK1/2, AKT, mTOR and STAT5 with U0126, MK2206, Rapamycin and AG490 could block the effects of Kp-10.	Sirolimus	69-78	mitogen-activated protein kinase 3	Bos taurus	21-27
29238469-9	2017	Conclusion: Sirolimus can reduce proteinuria and alleviate the early DN podocyte injury in diabetic rat model by inhibiting the activity of mTORC1; but in the advanced stage of DN, sirolimus can increase podocyte injury and urine protein level.	Sirolimus	12-21	CREB regulated transcription coactivator 1	Mus musculus	140-146
29162840-0	2017	Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3beta/mTOR Signaling.	Sirolimus	63-72	glycogen synthase kinase 3 beta	Homo sapiens	121-129
29061787-10	2017	Interestingly, the expression of P-gp was synergistically inhibited by combined treatment of U0126 with LY294002 and also inhibited by an mTORC1 inhibitor, rapamycin.	Sirolimus	156-165	CREB regulated transcription coactivator 1	Mus musculus	138-144
28901376-6	2017	In addition, rapamycin, a selective mammalian target of rapamycin complex-1 (mTORC1) signaling pathway inhibitor, was employed to determine whether mechanical loading modulates heterotopic ossification in calcific tendinopathy through the mTORC1 signaling pathway.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	77-83
28985184-0	2017	Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation.	Sirolimus	0-9	ATP binding cassette subfamily C member 8	Homo sapiens	129-134
28985184-4	2017	CASE PRESENTATION: A 16-year-old female with CHI due to a dominant ABCC8 gene mutation was switched from diazoxide therapy to sirolimus, due to the hypertrichosis side effect of diazoxide.	Sirolimus	126-135	ATP binding cassette subfamily C member 8	Homo sapiens	67-72
28985184-8	2017	CONCLUSIONS: Patients with dominant ABCC8 gene mutations are prone to DM in adulthood, but Sirolimus therapy might increase the risk of developing diabetes at an early age, as this case illustrates.	Sirolimus	91-100	ATP binding cassette subfamily C member 8	Homo sapiens	36-41
29147488-0	2017	The downregulation of ATG4B mediated by microRNA-34a/34c-5p suppresses rapamycin-induced autophagy.	Sirolimus	71-80	autophagy related 4B cysteine peptidase	Homo sapiens	22-27
29170467-2	2017	However, mTORC1 inhibitors, such as rapamycin, have limited effectiveness as single agent cancer therapies, with feedback mechanisms inherent to the signaling network thought to diminish the anti-tumor effects of mTORC1 inhibition.	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	9-15
29156556-7	2017	Furthermore, the mTORC1 and Wnt/beta-catenin pathway-specific antagonist rapamycin and XAV939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)]-4H -thiopyrano[4,3-d]pyrimidin-4-one) both suppressed the proliferation of IPEC-J2 cells overexpressing CDX2, and that the combination of rapamycin and XAV939 had an additive effect.	Sirolimus	73-82	catenin beta 1	Sus scrofa	32-44
29056426-1	2017	The mechanistic target of rapamycin complex 1 (mTORC1) supports proliferation through parallel induction of key anabolic processes, including protein, lipid, and nucleotide synthesis.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
28916721-5	2017	The hypertrophy-inducing mammalian target of rapamycin complex 1 (mTORC1) pathway was activated in Cpt2M-/- hearts; however, daily rapamycin exposure failed to attenuate hypertrophy in Cpt2M-/- mice.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
28844017-0	2017	Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice.	Sirolimus	43-52	TSC complex subunit 1	Mus musculus	73-77
28986235-6	2017	Benefits may be achieved via nutrient influence on epigenetic signaling pathways governing transcription factors for mitochondrial biogenesis, antioxidant defences and the autophagy-lysosomal pathway, via regulation of the metabolic energy sensor AMP activated protein kinase (AMPK) and the mammalian target of rapamycin mTOR.	Sirolimus	311-320	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	277-281
29062000-6	2017	Further analysis of the Gap1 permease showed that FTY720 elicits its ubiquitylation via the same factors that promote this modification when TORC1 is inhibited by rapamycin.	Sirolimus	163-172	CREB regulated transcription coactivator 1	Homo sapiens	141-146
29021349-6	2017	We found that Akt-mTORC1 (mammalian target of rapamycin complex 1) signaling was increased, and treatment with 2.24 mg/kg d rapamycin or 40% caloric restriction for 9 weeks partially rescued cardiomyopathy or heart failure and restored autophagic flux in knockin mice.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	18-24
29070114-10	2017	After treatment with rapamycin, the expression of p-RPS6 and survivin of Raji and CA46 cells was obviously down-regulated, the expression of caspase-3 was obviously up-regulated in a time- and dose-dependent manners.	Sirolimus	21-30	ribosomal protein S6	Homo sapiens	52-56
28637240-1	2017	Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in either of two genes, TSC1 or TSC2, resulting in the constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	201-210	CREB regulated transcription coactivator 1	Mus musculus	222-228
28520214-5	2017	Conversely, BMMs lacking Tsc1 exhibited a severe defect in osteoclast-like differentiation and absorptive function, both of which were restored following rapamycin treatment.	Sirolimus	154-163	TSC complex subunit 1	Mus musculus	25-29
28701348-5	2017	Persistent induction of DNA double-strand breaks or mTORC1 inhibition by rapamycin results in reduced levels of HMO1 mRNA, but only in the presence of Tor1p.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	52-58
28827472-1	2017	The goal of the present study was to explore the protective effects of mTORC1 (mammalian target of rapamycin complex 1) inhibition by rapamycin on salt-induced hypertension and kidney injury in Dahl salt-sensitive (SS) rats.	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	71-77
28934384-9	2017	Further, mutant PKCepsilon caused impaired mTORC2-dependent pAKT-S473 following rapamycin treatment.	Sirolimus	80-89	CREB regulated transcription coactivator 2	Mus musculus	43-49
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	127-135
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	CREB regulated transcription coactivator 1	Mus musculus	74-80
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	CREB regulated transcription coactivator 1	Mus musculus	243-249
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	82-95
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	ribosomal protein S6	Mus musculus	41-45
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	ribosomal protein S6	Mus musculus	46-50
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	ribosomal protein S6	Mus musculus	211-215
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	148-157	ribosomal protein S6	Mus musculus	41-45
28701517-5	2017	Furthermore, rapamycin treatment of Foxd1ER(+) TSC1 mice suppressed mesangial expansion.	Sirolimus	13-22	TSC complex subunit 1	Mus musculus	47-51
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	148-157	ribosomal protein S6	Mus musculus	46-50
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	148-157	ribosomal protein S6	Mus musculus	211-215
28808237-1	2017	Tuberous Sclerosis Complex (TSC) is a rare genetic disorder that results from a mutation in the TSC1 or TSC2 genes leading to constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	179-188	TSC complex subunit 1	Mus musculus	96-100
28808237-1	2017	Tuberous Sclerosis Complex (TSC) is a rare genetic disorder that results from a mutation in the TSC1 or TSC2 genes leading to constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	179-188	CREB regulated transcription coactivator 1	Mus musculus	200-206
29340326-4	2018	Mammalian target of rapamycin complex 1 (mTORC1) inhibitors (e.g., sirolimus) have been found to be effective in treating TSC- or lymphangioleiomyomatosis-associated AML, but to date it is unknown whether this strategy is effective for sporadic AML.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	41-47
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	118-124
28423237-2	2017	The aim of the study was to assess applicability of the new cobalt-chromium version of the sirolimus-eluting dedicated bifurcation BiOSS  LIM C stent in comparison with regular sirolimus-eluting Orsiro   stent in a porcine coronary model.	Sirolimus	91-100	PDZ and LIM domain 5	Homo sapiens	138-141
28695335-13	2017	The mTORC1 inhibitor rapamycin (0.2 nmol/mouse, i.c.v.)	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	beclin 1	Rattus norvegicus	221-229
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	246-249
28979705-7	2017	Furthermore, Rictor knockdown attenuated cell cycle progression and enhanced apoptosis, synergistic with treatment of mTORC1 inhibitor rapamycin owing to abrogating the feedback activation of Akt.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	118-124
28685977-9	2017	The upregulation of Beclin-1 and PINK1 and the downregulation of caspase-3 and Cyt C extrapolate that rapamycin plays neuroprotective as well as anti-apoptotic role via interposition of both autophagy and mitophagy.	Sirolimus	102-111	beclin 1	Rattus norvegicus	20-28
28685977-9	2017	The upregulation of Beclin-1 and PINK1 and the downregulation of caspase-3 and Cyt C extrapolate that rapamycin plays neuroprotective as well as anti-apoptotic role via interposition of both autophagy and mitophagy.	Sirolimus	102-111	caspase 3	Rattus norvegicus	65-74
28768179-4	2017	mTORC1 inhibition by rapamycin downregulated all components of ISRmt, improved all MM hallmarks, and reversed the progression of even late-stage MM, without inducing mitochondrial biogenesis.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	0-6
28701309-10	2017	The abnormal SMC phenotype observed in the Arhgap18-/- mice can be partially rescued by pharmacological treatment with the mTORC1 inhibitor rapamycin, which reduces the synthetic and proinflammatory phenotype of Arhgap18-deficient SMC.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	123-129
28925470-10	2017	Compared with the AMI group, the expression level of LC3-II in the infarction-peripheral area was significantly increased and that of p62 was significantly decreased after the treatment with RAPA.	Sirolimus	191-195	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	134-137
28244683-0	2017	Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	99-105
28924369-8	2017	Results: After IL-12 treatment, the number of CD8+ Tem and the expression of IFN-gamma increased significantly; while quite the opposite results were observed when the mTOR pathway was blocked by rapamycin.	Sirolimus	196-205	tenomodulin	Mus musculus	51-54
28778941-5	2017	METHODS AND RESULTS: We inhibited mTORC1 in fetal mice by rapamycin treatment of pregnant dams in late gestation.	Sirolimus	58-67	CREB regulated transcription coactivator 1	Mus musculus	34-40
29029388-0	2017	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	78-84
28707282-3	2017	Clinical use of rapamycin is associated with several unwanted side effects, however, and several strategies are being taken to identify mTORC1 inhibitors with fewer side effects.	Sirolimus	16-25	CREB regulated transcription coactivator 1	Mus musculus	136-142
28707282-5	2017	By testing compounds using a wild-type strain and isogenic cells lacking either TOR1 or FPR1, we can resolve not only whether a compound is an inhibitor of mTORC1 but also whether the inhibitor acts through a mechanism similar to rapamycin by binding Fpr1.	Sirolimus	230-239	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	88-92
28707282-5	2017	By testing compounds using a wild-type strain and isogenic cells lacking either TOR1 or FPR1, we can resolve not only whether a compound is an inhibitor of mTORC1 but also whether the inhibitor acts through a mechanism similar to rapamycin by binding Fpr1.	Sirolimus	230-239	CREB regulated transcription coactivator 1	Mus musculus	156-162
29085582-9	2017	The rats treated with rapamycin had significant decreases in the MDA and caspase-3 levels and significant increases in the SOD, CAT and GPx activities in ipsilateral testis compared with the T/D group (P&lt;0.001); germ cell apoptosis was decreased, and MSTD was improved.	Sirolimus	22-31	caspase 3	Rattus norvegicus	73-82
28507054-8	2017	In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	158-164
28244683-0	2017	Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.	Sirolimus	0-9	cyclin-dependent kinase 1	Mus musculus	132-136
28775826-0	2017	A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model.	Sirolimus	35-44	TSC complex subunit 1	Mus musculus	60-64
28775826-3	2017	Heterozygocity induces hyperactivation of mTOR which can be inhibited by mTOR inhibitors, such as rapamycin, which have proven efficacy in the treatment of TSC-associated symptoms.	Sirolimus	98-107	TSC complex subunit 1	Mus musculus	156-159
28775826-4	2017	The aim of the present study was (1) to identify molecular changes associated with social and cognitive deficits in the brain tissue of Tsc1+/- mice and (2) to investigate the molecular effects of rapamycin treatment, which has been shown to ameliorate genotype-related behavioural deficits.	Sirolimus	197-206	TSC complex subunit 1	Mus musculus	136-140
28775826-13	2017	Rapamycin treatment exerted a stronger proteomic effect in Tsc1+/- mice with significant changes (mainly decreased expression) in 231 and 106 proteins, respectively.	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	59-63
28775826-14	2017	The cellular pathways "oxidative stress" and "apoptosis" were found to be affected in Tsc1+/- mice and the cellular compartments "myelin sheet" and "neurofilaments" were affected by rapamycin treatment.	Sirolimus	182-191	TSC complex subunit 1	Mus musculus	86-90
28775826-15	2017	Thirty-three proteins which were altered in Tsc1+/- mice were normalized following rapamycin treatment, amongst them oxidative stress related proteins, myelin-specific and ribosomal proteins.	Sirolimus	83-92	TSC complex subunit 1	Mus musculus	44-48
28486745-3	2017	Rapamycin, a TORC1 inhibitor, inhibits Pma1 dependent on its receptor Fpr1 and on the protein phosphatase Sit4, a TORC1 effector.	Sirolimus	0-9	H(+)-exporting P2-type ATPase PMA1	Saccharomyces cerevisiae S288C	39-43
28648781-6	2017	Ceramides synergize with rapamycin, a TORC1 inhibitor, in counteracting the DDR.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Homo sapiens	38-43
28819418-4	2017	Materials and methods: The effect of CENPH on the cell proliferation, clonogenicity, and cell response to rapamycin in CRC were evaluated by MTT and/or colony formation assays.	Sirolimus	106-115	centromere protein H	Homo sapiens	37-42
28486745-3	2017	Rapamycin, a TORC1 inhibitor, inhibits Pma1 dependent on its receptor Fpr1 and on the protein phosphatase Sit4, a TORC1 effector.	Sirolimus	0-9	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	70-74
28819418-8	2017	Results: CENPH inhibited CRC malignant phenotypes, conferred reduced sensitivity to rapamycin, and attenuated both mTORC1 and mTORC2 in mTOR signaling pathway through the interaction with golgi phosphoprotein 3 (GOLPH3), which has been identified as a potential oncogene and modulates the response to rapamycin.	Sirolimus	84-93	centromere protein H	Homo sapiens	9-14
28819418-8	2017	Results: CENPH inhibited CRC malignant phenotypes, conferred reduced sensitivity to rapamycin, and attenuated both mTORC1 and mTORC2 in mTOR signaling pathway through the interaction with golgi phosphoprotein 3 (GOLPH3), which has been identified as a potential oncogene and modulates the response to rapamycin.	Sirolimus	301-310	centromere protein H	Homo sapiens	9-14
28819418-12	2017	Conclusions: Our results suggest that CENPH inhibits rapamycin sensitivity by regulating GOLPH3 dependent mTOR pathway.	Sirolimus	53-62	centromere protein H	Homo sapiens	38-43
28693280-4	2017	The results indicated that rapamycin alone decreased the phosphorylation of S6 and GSK3beta, as well as the expression of cyclin D1, in NPC cells.	Sirolimus	27-36	glycogen synthase kinase 3 beta	Homo sapiens	83-91
28693280-4	2017	The results indicated that rapamycin alone decreased the phosphorylation of S6 and GSK3beta, as well as the expression of cyclin D1, in NPC cells.	Sirolimus	27-36	cyclin D1	Homo sapiens	122-131
28693280-7	2017	In conclusion, rapamycin improves the anti-tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3beta/cyclin D1 signaling pathways.	Sirolimus	15-24	glycogen synthase kinase 3 beta	Homo sapiens	149-157
28693280-7	2017	In conclusion, rapamycin improves the anti-tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3beta/cyclin D1 signaling pathways.	Sirolimus	15-24	cyclin D1	Homo sapiens	158-167
28575052-8	2017	Treatment of hiPSC precursors with autophagy stimulators Rapamycin, Perifosine, or AT101 showed reduction in VCP pathology markers TDP-43, LC3-I/II and p62/SQSTM1.	Sirolimus	57-66	valosin containing protein	Homo sapiens	109-112
28535645-3	2017	Results: Either of them, rapamycin or chloroquine had an antitumor effect in vitro (RAPA: IC50=1.5 nmol/L; CQ: IC50=400 mumol/L).	Sirolimus	25-34	transcriptional regulating factor 1	Homo sapiens	84-88
28535645-6	2017	The xenograft model also confirmed that rapamycin combined with chloroquine had a better antitumor effect than single usage (relative tumor proliferation rate; T/C%.CQ: 98.4%+-11.6%; RAPA: 65.5%+-7.5%; CQ+ RAPA: 42.0%+-3.4%).	Sirolimus	40-49	transcriptional regulating factor 1	Homo sapiens	183-187
28535645-6	2017	The xenograft model also confirmed that rapamycin combined with chloroquine had a better antitumor effect than single usage (relative tumor proliferation rate; T/C%.CQ: 98.4%+-11.6%; RAPA: 65.5%+-7.5%; CQ+ RAPA: 42.0%+-3.4%).	Sirolimus	40-49	transcriptional regulating factor 1	Homo sapiens	206-210
28469076-4	2017	Treatment of primary human keratinocytes (PHKs) with hydrocortisone or rapamycin, but not the p38 MAPK inhibitor SB202190, significantly increases DSG3 mRNA and protein expression and correspondingly reduces phospho-S727 Stat3.	Sirolimus	71-80	desmoglein 3	Homo sapiens	147-151
27447863-8	2017	In addition, inhibition of AKT signaling by AKT inhibitor IV and Rapamycin reversed CTMP-mediated trastuzumab resistance.	Sirolimus	65-74	thioesterase superfamily member 4	Homo sapiens	84-88
28259097-8	2017	Administration of either L-NAME or 7-NI enhanced the decreased antidepressant activity of EE2 induced by combination with rapamycin.	Sirolimus	122-131	esterase 3	Mus musculus	90-93
28706237-8	2017	Treatment of OLETF with rapamycin, an mTORC1 inhibitor, partially restored autophagic activation in response to I/R and significantly attenuated I/R-induced renal injury.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	38-44
28695825-4	2017	Abnormalities were blocked by the mTORC1 inhibitor sirolimus.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	34-40
28696356-4	2017	The mTORC1 inhibitor rapamycin is a clinical approved immunosuppressant and several studies also verified its chondroprotective effects in OA.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
28696356-6	2017	Therefore, we aimed to investigate if inhibition of mTORC1 by rapamycin can preserve and sustain chondrocytes in an inflammatory environment.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	52-58
28696356-7	2017	Patient-derived chondrocytes were cultured in media supplemented with or without the mTORC1 inhibitor rapamycin.	Sirolimus	102-111	CREB regulated transcription coactivator 1	Mus musculus	85-91
29137374-8	2017	Further analyses showed the significant effect of the mTOR signaling inhibitor rapamycin in inducing Myh7 expression and a hypoxia-triggered reduction in the levels of antisense RNA transcripts associated with the Myh7 gene locus.	Sirolimus	79-88	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	101-105
29137374-8	2017	Further analyses showed the significant effect of the mTOR signaling inhibitor rapamycin in inducing Myh7 expression and a hypoxia-triggered reduction in the levels of antisense RNA transcripts associated with the Myh7 gene locus.	Sirolimus	79-88	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	214-218
28903387-7	2017	Therefore, downregulated FOXO3a/PDGFRalpha/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment.	Sirolimus	194-203	CREB regulated transcription coactivator 1	Mus musculus	105-111
28450279-7	2017	Cultured mouse podocytes were treated with the autophagy activators, rapamycin or Earle"s balanced salt solution (EBSS), for 48 h. Both rapamycin and EBSS significantly decreased p62 protein levels, increased ERK1/2 activation by phosphorylating pTpY185/187, and increased mRNA and protein expressions of PRR.	Sirolimus	136-145	sequestosome 1	Mus musculus	179-182
28450279-7	2017	Cultured mouse podocytes were treated with the autophagy activators, rapamycin or Earle"s balanced salt solution (EBSS), for 48 h. Both rapamycin and EBSS significantly decreased p62 protein levels, increased ERK1/2 activation by phosphorylating pTpY185/187, and increased mRNA and protein expressions of PRR.	Sirolimus	136-145	mitogen-activated protein kinase 3	Mus musculus	209-215
28450279-8	2017	Utilizing confocal microscopy demonstrated that rapamycin and EBSS significantly decreased p62/SQSTM1 and increased PRR protein expressions.	Sirolimus	48-57	sequestosome 1	Mus musculus	91-94
28450279-8	2017	Utilizing confocal microscopy demonstrated that rapamycin and EBSS significantly decreased p62/SQSTM1 and increased PRR protein expressions.	Sirolimus	48-57	sequestosome 1	Mus musculus	95-101
28450279-11	2017	ERK1/2 inhibitor U0126 significantly attenuated mRNA and protein expressions of PRR in podocytes treated with rapamycin.	Sirolimus	110-119	mitogen-activated protein kinase 3	Mus musculus	0-6
28473248-9	2017	Moreover, autophagy inhibitor 3-MA could simulate the effects of TSC2 siRNA while autophagy inducer rapamycin could mimic the effects of raptor siRNA, suggesting that the beneficial effects of mTORC1 deletion were associated with autophagy induction.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	193-199
28647341-9	2017	Rapamycin inhibited RIP1-p62 and RIP1-RIP3 interactions induced by TNF/zVAD and partly restored autophagic flux and suppressed LDH release in TNF/zVAD-treated cells.	Sirolimus	0-9	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	25-28
28566496-3	2017	We found that mutants in PHO84 are hypersensitive to rapamycin and in response to phosphate feeding, generate less phosphorylated ribosomal protein S6 (P-S6) than the WT.	Sirolimus	53-62	phosphate transporter PHO84	Saccharomyces cerevisiae S288C	25-30
28396518-4	2017	Compared with control, mouse ESCs (mESCs) treated with rapamycin (20 nM) and AA yielded a significantly higher percentage of cardiomyocytes, as confirmed by the percentage of beating embryonic bodies (EBs), the immunofluorescence and FACS analysis.	Sirolimus	55-64	acyl-CoA synthetase long-chain family member 1	Mus musculus	234-238
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	NK2 homeobox 5	Mus musculus	144-150
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	T-box 5	Mus musculus	152-156
28450107-6	2017	Co-immunoprecipitation (CoIP) demonstrated that LC3 co-immunoprecipitated with Smad3 and western blot showed that autophagy inducers, Rapamycin and Trehalose, could decrease the phosphorylation level of Smad3.	Sirolimus	134-143	SMAD family member 3	Homo sapiens	79-84
28450107-6	2017	Co-immunoprecipitation (CoIP) demonstrated that LC3 co-immunoprecipitated with Smad3 and western blot showed that autophagy inducers, Rapamycin and Trehalose, could decrease the phosphorylation level of Smad3.	Sirolimus	134-143	SMAD family member 3	Homo sapiens	203-208
28578659-0	2017	Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	11-17
27264687-9	2017	In vivo OVA-Texo-stimulated CTLs upregulated the activities of the mTORC1 pathway-related molecules Akt, S6, eIF4E and T-bet, and treatment of the CTLs with an mTORC1 inhibitor, rapamycin, significantly reduced the OVA-Texo-induced increase in CTLs.	Sirolimus	178-187	CREB regulated transcription coactivator 1	Mus musculus	67-73
28404689-6	2017	Pretreatment of human MCs using the mTORC1 inhibitor rapamycin, the mTORC1/mTORC2 inhibitor Torin1, or the two flavonoids decreases both gene expression and release (P &lt; 0.0001) of all three mediators.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	36-42
28424242-5	2017	By analyzing activated murine wild-type and Rheb-deficient CD4+ T cells, as well as murine CD4+ T cells activated in the presence of rapamycin, a pharmacologic inhibitor of mTORC1, we were able to identify six T-bet phosphorylation sites.	Sirolimus	133-142	CREB regulated transcription coactivator 1	Mus musculus	173-179
28424242-6	2017	Five of these are novel, and four sites are consistently dephosphorylated in both Rheb-deficient CD4+ T cells and T cells treated with rapamycin, suggesting mTORC1 signaling controls their phosphorylation.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	157-163
28330873-11	2017	Rapamycin treatment increased FoxO3 activity as well as LC3 and ULK1 expressions in macrophages from AMPKalpha1-/- mice.	Sirolimus	0-9	unc-51 like kinase 1	Mus musculus	64-68
28469076-6	2017	Hydrocortisone- or rapamycin-treated PHKs demonstrate increased number and length of desmosomes by electron microscopy and are resistant to PV IgG-induced loss of cell adhesion, whereas constitutive activation of Stat3 in PHKs abrogates DSG3 upregulation and inhibits hydrocortisone and rapamycin"s therapeutic effects.	Sirolimus	19-28	desmoglein 3	Homo sapiens	237-241
28465534-7	2017	Besides, our study found that sirolimus reduced the ratio of Tfr cells, while cyclosporine and tacrolimus had no significant effect on Tfr cells.	Sirolimus	30-39	transferrin receptor	Homo sapiens	61-64
28242620-6	2017	Interestingly, treating primary adipocytes with rapamycin only partially alleviated the suppressing effect of Rheb on UCP1 expression, suggesting the presence of a novel mechanism underlying the inhibitory effect of Rheb on thermogenic gene expression.	Sirolimus	48-57	Ras homolog enriched in brain	Mus musculus	110-114
28214587-9	2017	The inhibitory effect of PAQR3 knockdown on autophagy is abrogated by rapamycin treatment, indicating that PAQR3 modulates autophagy via its regulation on mTORC1 signaling.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	155-161
28242620-6	2017	Interestingly, treating primary adipocytes with rapamycin only partially alleviated the suppressing effect of Rheb on UCP1 expression, suggesting the presence of a novel mechanism underlying the inhibitory effect of Rheb on thermogenic gene expression.	Sirolimus	48-57	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	118-122
28242620-6	2017	Interestingly, treating primary adipocytes with rapamycin only partially alleviated the suppressing effect of Rheb on UCP1 expression, suggesting the presence of a novel mechanism underlying the inhibitory effect of Rheb on thermogenic gene expression.	Sirolimus	48-57	Ras homolog enriched in brain	Mus musculus	216-220
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	76-82
27923564-0	2017	Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1-dependent pathway.	Sirolimus	0-9	interleukin 5	Homo sapiens	40-44
27923564-0	2017	Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1-dependent pathway.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	76-82
27634355-3	2017	The results demonstrate that a single dose of GLYX-13 rapidly activates the mTORC1 pathway in the prefrontal cortex (PFC), and that infusion of the selective mTORC1 inhibitor rapamycin into the medial PFC (mPFC) blocks the antidepressant behavioral actions of GLYX-13, indicating a requirement for mTORC1 similar to ketamine.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	158-164
28320515-4	2017	In addition, HMGCS2 enhancement of autophagic marker LC3II was diminished by rapamycin, an inhibitor of mechanistic target of rapamycin.	Sirolimus	77-86	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	13-19
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	caspase 3	Rattus norvegicus	127-136
27634355-3	2017	The results demonstrate that a single dose of GLYX-13 rapidly activates the mTORC1 pathway in the prefrontal cortex (PFC), and that infusion of the selective mTORC1 inhibitor rapamycin into the medial PFC (mPFC) blocks the antidepressant behavioral actions of GLYX-13, indicating a requirement for mTORC1 similar to ketamine.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	158-164
27819676-7	2017	Inhibition of mTORC1 by rapamycin effectively attenuates the compensatory proliferation of hepatocytes in CAMK2gamma-/- livers.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
28496990-6	2017	Inhibition of mTORC1 by rapamycin reduces T-cell expression of KIF13A and cell-surface M6PR, and increases T-cell survival in Listeria monocytogenes-infected mice.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
28469768-6	2017	Of the three specific inhibitors, only rapamycin, an inhibitor of mTORC1, was found to inhibit FAK phosphorylation, suggesting that mTORC1 is the upstream regulator in shock-wave-elicited FAK phosphorylation.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	66-72
28469768-6	2017	Of the three specific inhibitors, only rapamycin, an inhibitor of mTORC1, was found to inhibit FAK phosphorylation, suggesting that mTORC1 is the upstream regulator in shock-wave-elicited FAK phosphorylation.	Sirolimus	39-48	protein tyrosine kinase 2	Homo sapiens	95-98
28469768-6	2017	Of the three specific inhibitors, only rapamycin, an inhibitor of mTORC1, was found to inhibit FAK phosphorylation, suggesting that mTORC1 is the upstream regulator in shock-wave-elicited FAK phosphorylation.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	132-138
28469768-6	2017	Of the three specific inhibitors, only rapamycin, an inhibitor of mTORC1, was found to inhibit FAK phosphorylation, suggesting that mTORC1 is the upstream regulator in shock-wave-elicited FAK phosphorylation.	Sirolimus	39-48	protein tyrosine kinase 2	Homo sapiens	188-191
28469768-9	2017	Besides, rapamycin was found to destruct the granular pattern of mTORC1, while dissociation between F-actin and mTORC1 was noted after cytochalasin D administration.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	65-71
28104514-0	2017	Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.	Sirolimus	156-165	forkhead box P3	Homo sapiens	10-15
28938574-6	2017	GSK2126458 inhibited both PI3K and mTOR while rapamycin exerted stronger inhibitory effect on mTORC1 in renal tumours.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	94-100
28394644-8	2017	BiOSS LIM is the dedicated bifurcation stent with stainless steel platform that releases sirolimus (1.4 microg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids.	Sirolimus	89-98	PDZ and LIM domain 5	Homo sapiens	6-9
28121484-11	2017	In addition, autophagy inhibition attenuated the suppressive effect of SYVN1 on SERPINA1E342K/ATZ cytotoxicity, and the autophagy inducer rapamycin enhanced the suppressive effect of SYVN1 on SERPINA1E342K/ATZ-induced cell apoptosis.	Sirolimus	138-147	synoviolin 1	Homo sapiens	183-188
28323988-8	2017	These laminin alpha2 knockdown-mediated effects on F-actin and MT organization was blocked by exposing Sertoli cells to rapamycin, an inhibitor of mTORC1 signaling, and also SC79, an activator of Akt.	Sirolimus	120-129	laminin subunit alpha 2	Homo sapiens	6-20
28323988-8	2017	These laminin alpha2 knockdown-mediated effects on F-actin and MT organization was blocked by exposing Sertoli cells to rapamycin, an inhibitor of mTORC1 signaling, and also SC79, an activator of Akt.	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	147-153
28336152-5	2017	The gene products of TSC1/2 form a complex which at energy limiting states, down-regulates the activity of the regulator of protein synthesis, the mammalian target of rapamycin complex1 (mTORC1).	Sirolimus	167-176	CREB regulated transcription coactivator 1	Mus musculus	187-193
28043916-7	2017	Additionally, ketamine and extinction exposure increased levels of mTORC1 in the medial prefrontal cortex (mPFC), a region involved in the acquisition and retrieval of extinction, and infusion of the selective mTORC1 inhibitor rapamycin into the mPFC blocked the effects of ketamine on extinction.	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	67-73
28043916-7	2017	Additionally, ketamine and extinction exposure increased levels of mTORC1 in the medial prefrontal cortex (mPFC), a region involved in the acquisition and retrieval of extinction, and infusion of the selective mTORC1 inhibitor rapamycin into the mPFC blocked the effects of ketamine on extinction.	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	210-216
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	34-44
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	216-226
28377693-5	2017	Therefore, this study was conducted to determine the role of mTOR signaling in neuropathic pain and to assess the potential therapeutic effects of rapamycin, an inhibitor of mTORC1, in the IC of rats with neuropathic pain.	Sirolimus	147-156	CREB regulated transcription coactivator 1	Mus musculus	174-180
28377693-8	2017	Rapamycin reduced mechanical allodynia and downregulated the expression of postsynaptic density protein 95 (PSD95), decreased neural excitability in the IC, thereby inhibiting neuropathic pain-induced synaptic plasticity.	Sirolimus	0-9	discs large MAGUK scaffold protein 4	Homo sapiens	75-106
28377693-8	2017	Rapamycin reduced mechanical allodynia and downregulated the expression of postsynaptic density protein 95 (PSD95), decreased neural excitability in the IC, thereby inhibiting neuropathic pain-induced synaptic plasticity.	Sirolimus	0-9	discs large MAGUK scaffold protein 4	Homo sapiens	108-113
28400999-7	2017	Rapamycin and its analogues (rapalogues) bind to the intercellular receptor FKBP12, and then predominantly inhibit mTORC1 signaling via an allosteric mechanism.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	115-121
27935584-8	2017	Moreover, we showed that either knockdown of mTOR or inhibition of mTORC1 with rapamycin increases the expression of HMGCS2 in intestinal cells in vitro and in vivo, suggesting a possible cross-talk between mTOR and HMGCS2/betaHB signaling in intestinal cells.	Sirolimus	79-88	CREB regulated transcription coactivator 1	Mus musculus	67-73
26748416-11	2017	Rapamycin (10nM rapamycin for 24h) had opposite effects to those of Rheb and GTP, and partly abrogated (significant) the effects of Rheb and GTP when added to the culture in combination with these drugs.	Sirolimus	0-9	Ras homolog, mTORC1 binding	Homo sapiens	132-136
28362060-17	2017	In the direct comparison, based on a single trial including 222 participants, tacrolimus plus sirolimus had increased mortality (HR 2.76, 95% CrI 1.30 to 6.69) and graft loss (HR 2.34, 95% CrI 1.28 to 4.61) at maximal follow-up compared with tacrolimus.	Sirolimus	94-103	EP300 interacting inhibitor of differentiation 1	Homo sapiens	142-147
28362060-17	2017	In the direct comparison, based on a single trial including 222 participants, tacrolimus plus sirolimus had increased mortality (HR 2.76, 95% CrI 1.30 to 6.69) and graft loss (HR 2.34, 95% CrI 1.28 to 4.61) at maximal follow-up compared with tacrolimus.	Sirolimus	94-103	EP300 interacting inhibitor of differentiation 1	Homo sapiens	189-194
28580286-8	2017	Rapamycin, an mTORC1 complex inhibitor, reduced the number and proliferation of pancreatic and endocrine progenitors.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	14-20
28333137-5	2017	MDSCs, especially CD11b+Ly6G+Ly6Clow G-MDSCs were recruited to the injured kidney following the interaction of CXCL1, CXCL2 and their receptor CXCR2 after inhibiting mTOR signal with rapamycin treatment.	Sirolimus	183-192	lymphocyte antigen 6 complex, locus G	Mus musculus	24-28
28333137-7	2017	In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs.	Sirolimus	205-214	transforming growth factor, beta 1	Mus musculus	128-137
28333137-8	2017	Adoptive transfer of rapamycin-treated MDSCs also downregulated the serum levels of IL-1beta, IL-6 and IFN-gamma and upregulated the serum levels of TGF-beta1 compared with the IR group and PBS-treated MDSC group.	Sirolimus	21-30	transforming growth factor, beta 1	Mus musculus	149-158
28292440-2	2017	Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi).	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	66-72
27553832-7	2017	Concordantly, Abcb1a/b-/-;Abcg2-/- mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice.	Sirolimus	80-89	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	14-20
27553832-7	2017	Concordantly, Abcb1a/b-/-;Abcg2-/- mice revealed increased brain penetration of rapamycin (13-fold), AZD8055 (7.7-fold), and NVP-BEZ235 (4.5-fold), but not ZSTK474 relative to WT mice.	Sirolimus	80-89	ATP binding cassette subfamily G member 2 (Junior blood group)	Mus musculus	26-31
28469644-5	2017	In addition, we demonstrated alterations in mechanistic target of rapamycin complex 1 (mTORC1) signaling and functional rescue of the lifespan, locomotor defects and hypersensitivity to oxidative stress on treatment of GCase-deficient flies with the mTOR inhibitor rapamycin.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Mus musculus	87-93
28108221-12	2017	Rapamycin decreased the mTORC1 activity, while increasing the pAkt levels.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	24-30
27524416-4	2017	Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment.	Sirolimus	144-153	TSC complex subunit 1	Mus musculus	71-75
27974437-2	2017	To gain information about potential partners of Arl1 and Ypt6 specifically in autophagy, we carried out a high copy number suppressor screen to identify genes that when overexpressed suppress the rapamycin sensitivity phenotype of arl1Delta and ypt6Delta strains at 37 .	Sirolimus	196-205	Arf family GTPase ARL1	Saccharomyces cerevisiae S288C	48-52
27990590-12	2017	After 12 months of sirolimus treatment, Ang-2 levels were lower in KLA and KHE with KMP patients compared to baseline levels and with most patients showing a clinical response.	Sirolimus	19-28	angiopoietin 2	Homo sapiens	40-45
27990590-13	2017	Hence, serum Ang-2 and Ang-1 levels may help in the diagnosis of patients with lymphatic anomalies and are concordant to sirolimus response.	Sirolimus	121-130	angiopoietin 2	Homo sapiens	13-18
27990590-13	2017	Hence, serum Ang-2 and Ang-1 levels may help in the diagnosis of patients with lymphatic anomalies and are concordant to sirolimus response.	Sirolimus	121-130	angiopoietin 1	Homo sapiens	23-28
28496395-8	2017	CONCLUSIONS: Using mouse embryonic fibroblasts, we showed that TSC2-/- KD significantly abrogates lipid biosynthesis and that rapamycin can rescue triglyceride (TG) lipids and we show that SREBP-/- shuts down lipid biosynthesis significantly via mTORC1 signaling pathways.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	246-252
27909227-6	2017	In fasted mice, neither basal nor stimulated rates of protein synthesis were affected by castration despite lower phosphorylation of mechanistic target of rapamycin in complex 1 (mTORC1) substrates [p70S6K1 (Thr389) and 4E-BP1 (Ser65)].	Sirolimus	155-164	CREB regulated transcription coactivator 1	Mus musculus	179-185
28067669-8	2017	Rapamycin, an mTORC1 inhibitor, improved muscle relaxation and increased muscle force in HSALR mice without affecting splicing.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	14-20
27974559-12	2017	Here we found that rapamycin treatment predominantly inhibited GC B cell responses during viral infection and that this led to biased helper CD4 T cell differentiation as well as impaired antibody responses.	Sirolimus	19-28	natriuretic peptide receptor 2	Homo sapiens	63-67
27913296-3	2017	Therefore, we sought to determine: 1) if MEK1/2 inhibition is sufficient to reduce REDD1 protein expression and subsequently insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation via negative feedback of hyperactive mTOR in REDD1 wild-type (WT) mice and 2) if rapamycin-mediated mTOR inhibition is sufficient to improve IRS-1 tyrosine phosphorylation in REDD1 knockout (KO) mice.	Sirolimus	268-277	mitogen-activated protein kinase kinase 1	Mus musculus	41-47
26768596-11	2017	In addition, rapamycin significantly decreased the caspase-3 activity, which was elevated by melamine.	Sirolimus	13-22	caspase 3	Rattus norvegicus	51-60
28097735-7	2017	Studies suggest that the sirolimus promotes the upregulation of the FoxP3 protein that is classically associated with Tregs.	Sirolimus	25-34	forkhead box P3	Homo sapiens	68-73
28278709-5	2017	Rapamycin, an mTORC1 inhibitor, showed similar effects to miR-185-5p.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	14-20
28011637-8	2017	We found that Trib3 indirectly activates unc-51-like autophagy-activating kinase1 (Ulk1) by impeding phosphorylation of, and thus inactivating, a negative regulator of Ulk1, mechanistic target of rapamycin.	Sirolimus	196-205	Autophagy-related 1	Drosophila melanogaster	41-81
28271031-8	2017	GLP-2-stimulated lysine transport was attenuated by co-incubation with wortmannin, rapamycin, or tetrodotoxin ex vivo.	Sirolimus	83-92	glucagon-like peptide 2 receptor	Mus musculus	0-5
28271031-9	2017	Phosphorylation of mTORC1 effector proteins S6 and 4E-BP1 was significantly increased in wild-type mice in response to GLP-2 alone, or when co-administered with protein gavage, and abolished following oral gavage of rapamycin.	Sirolimus	216-225	CREB regulated transcription coactivator 1	Mus musculus	19-25
28011637-8	2017	We found that Trib3 indirectly activates unc-51-like autophagy-activating kinase1 (Ulk1) by impeding phosphorylation of, and thus inactivating, a negative regulator of Ulk1, mechanistic target of rapamycin.	Sirolimus	196-205	Autophagy-related 1	Drosophila melanogaster	83-87
28202715-4	2017	Using similar paradigms with rapamycin (an mTORC1 inhibitor), we show that preweaning rats (PN18-20) do form a long-term memory of the CS-US interval, and detect a 10-sec versus 30-sec temporal prediction error.	Sirolimus	29-38	CREB regulated transcription coactivator 1	Mus musculus	43-49
27399332-3	2017	Here we show that Rheb-Y35N causes not only constitutive mTORC1 activation, but sustained activation of the MEK-ERK pathway in a TSC1/TSC2/TBC1D7 protein complex and mTORC1-independent manner, contributing to intrinsic resistance to rapamycin.	Sirolimus	233-242	Ras homolog, mTORC1 binding	Homo sapiens	18-22
27399332-4	2017	Rheb-Y35N transforms NIH3T3 cells, resulting in aggressive tumor formation in xenograft nude mice, which could be suppressed by combined treatment with rapamycin and an extracellular signal-regulated kinase (ERK) inhibitor.	Sirolimus	152-161	Ras homolog enriched in brain	Mus musculus	0-4
28178522-5	2017	Here, we demonstrate that MNK sustains mTORC1 activity following rapamycin treatment and contributes to mTORC1 signaling following T cell activation and growth stimuli in cancer cells.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	39-45
28057888-8	2017	Re-inactivation of mTORC1 activity via rapamycin may resist hypoxia-induced cell death in TSC1 knockdown lymphocytes.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	19-25
27692982-0	2017	mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
28197073-8	2017	Interestingly, several agents that induce cell death [amyloid beta (Abeta)-peptide, staurosporine and rapamycin], albeit via different mechanisms, all caused dissociation of APP/TrkA complexes and increased production of C-terminal fragment (beta-CTF) APP fragment.	Sirolimus	102-111	neurotrophic receptor tyrosine kinase 1	Homo sapiens	178-182
27993682-10	2017	Consistent with a role for mTORC1/S6K1 signaling promoting trastuzumab resistance, all cell lines were sensitive to S6K1 inactivation with significant growth inhibition following treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	215-224	CREB regulated transcription coactivator 1	Mus musculus	27-33
27993979-7	2017	These phenotypes can all be significantly rescued by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	72-78
27993682-10	2017	Consistent with a role for mTORC1/S6K1 signaling promoting trastuzumab resistance, all cell lines were sensitive to S6K1 inactivation with significant growth inhibition following treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	215-224	CREB regulated transcription coactivator 1	Mus musculus	198-204
27993682-12	2017	Our results further suggest that trastuzumab resistant breast tumor cells are addicted to mTORC1/S6K1 oncogenic signaling and targeting mTORC1 with rapamycin reverses trastuzumab resistance.	Sirolimus	148-157	CREB regulated transcription coactivator 1	Mus musculus	90-96
27993682-12	2017	Our results further suggest that trastuzumab resistant breast tumor cells are addicted to mTORC1/S6K1 oncogenic signaling and targeting mTORC1 with rapamycin reverses trastuzumab resistance.	Sirolimus	148-157	CREB regulated transcription coactivator 1	Mus musculus	136-142
27913296-9	2017	Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 in KO mice.	Sirolimus	12-21	ribosomal protein S6	Mus musculus	41-45
27913296-9	2017	Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 in KO mice.	Sirolimus	12-21	mitogen-activated protein kinase kinase 1	Mus musculus	129-135
27895122-6	2017	Specifically, growth under limiting potassium alters the activities of Npr1 and another TORC1 effector kinase, Sch9; hal4 hal5 and trk1 trk2 mutants display hypersensitivity to rapamycin, and reciprocally, TORC1 inhibition reduces potassium accumulation.	Sirolimus	177-186	Trk1p	Saccharomyces cerevisiae S288C	131-135
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	185-191
28746918-10	2017	Histological analyses showed that low-dose RPM promoted wound healing, and enhanced the expression of IL-15 and IGF-1.	Sirolimus	43-46	insulin-like growth factor 1	Mus musculus	112-117
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	CREB regulated transcription coactivator 2	Mus musculus	31-37
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	insulin-like growth factor 1	Mus musculus	93-98
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	insulin-like growth factor 1	Mus musculus	182-187
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	CREB regulated transcription coactivator 1	Mus musculus	208-214
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	CREB regulated transcription coactivator 2	Mus musculus	219-225
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	140-143	insulin-like growth factor 1	Mus musculus	182-187
28721811-7	2017	Interestingly, the circadian clock system relies upon the regulation of the critical pathways of autophagy, the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1) as well as proliferative mechanisms that involve the wingless pathway of Wnt/beta-catenin pathway to foster cell survival during injury and block tumor cell growth.	Sirolimus	134-143	clock circadian regulator	Homo sapiens	29-34
33834090-5	2017	Among these are mammalian target of rapamycin complexes 1 and 2 (mTORC1/2) and their associated pathways, which function in mitochondrial control and maintenance.	Sirolimus	36-45	CREB regulated transcription coactivator 2	Mus musculus	65-73
27879318-5	2017	Furthermore, pharmacological inhibition of mTORC1 signaling by rapamycin could also inhibit osteoclast differentiation and osteoclast-specific gene expression.	Sirolimus	63-72	CREB regulated transcription coactivator 1	Mus musculus	43-49
28035937-1	2017	Mammalian target of rapamycin complex 1 (mTORC1), a nutrient sensor and central controller of cell growth and proliferation, is altered in various models of Alzheimer"s disease (AD).	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
28035937-2	2017	Even less studied or understood in AD is mammalian target of rapamycin complex 2 (mTORC2) that influences cellular metabolism, in part through the regulations of Akt/PKB and SGK.	Sirolimus	61-70	CREB regulated transcription coactivator 2	Mus musculus	82-88
27279283-10	2017	In addition, the activity of p38 MAPK in the lumbar spinal cord was significantly attenuated by rapamycin treatment.	Sirolimus	96-105	mitogen-activated protein kinase 14	Mus musculus	29-37
27753446-2	2017	Detailed knowledge about the role of the TSC proteins in regulating the activity of the mammalian target of rapamycin complex 1 (mTORC1) underlies this paradigm-shifting progress.	Sirolimus	108-117	CREB regulated transcription coactivator 1	Mus musculus	129-135
28427080-0	2017	Rapamycin Induces Autophagy and Reduces the Apoptosis of Podocytes Under a Stimulated Condition of Immunoglobulin A Nephropathy.	Sirolimus	0-9	IGAN1	Homo sapiens	99-127
28427080-1	2017	Backgroud/Aims: The aim of this study was to investigate the potential renoprotective effect of rapamycin on the autophagy of podocytes treated with the supernatant of mesangial cells cultured with aggregated IgA1 (aIgA1) from immunoglobulin A nephropathy (IgAN) patients.	Sirolimus	96-105	IGAN1	Homo sapiens	227-255
28427080-1	2017	Backgroud/Aims: The aim of this study was to investigate the potential renoprotective effect of rapamycin on the autophagy of podocytes treated with the supernatant of mesangial cells cultured with aggregated IgA1 (aIgA1) from immunoglobulin A nephropathy (IgAN) patients.	Sirolimus	96-105	IGAN1	Homo sapiens	257-261
27807044-5	2017	Moreover, depletion of KDEL receptor prevents trapping of ST-FRB in the ER by rapamycin.	Sirolimus	78-87	KDEL endoplasmic reticulum protein retention receptor 1	Homo sapiens	23-36
27840956-6	2017	HGF-stimulated cell motility of ARMS cell lines was inhibited by U0126 (ERK1/2 inhibitor) but was only partially inhibited by PD98059 (ERK1 inhibitor) or rapamycin (mTOR inhibitor) as observed in wound-healing and migration assays.	Sirolimus	154-163	hepatocyte growth factor	Homo sapiens	0-3
28373901-8	2017	Rapamycin induced phosphorylation of AKT S473 (target of mTORC2) but abolished ribosomal protein S6 phosphorylation (target of mTORC1) after I/R.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	57-63
28373901-8	2017	Rapamycin induced phosphorylation of AKT S473 (target of mTORC2) but abolished ribosomal protein S6 phosphorylation (target of mTORC1) after I/R.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	127-133
28373901-9	2017	Rapamycin induced phosphorylation of ERK1/2 but inhibited p38 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 3	Mus musculus	37-43
28373901-9	2017	Rapamycin induced phosphorylation of ERK1/2 but inhibited p38 phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 14	Mus musculus	58-61
28713484-12	2017	Western blot analysis showed that rapamycin could upregulate ULK1, ATG13 and downregulate mTORC1 and p53 protein expression.	Sirolimus	34-43	unc-51 like kinase 1	Mus musculus	61-65
28713484-12	2017	Western blot analysis showed that rapamycin could upregulate ULK1, ATG13 and downregulate mTORC1 and p53 protein expression.	Sirolimus	34-43	autophagy related 13	Mus musculus	67-72
28713484-12	2017	Western blot analysis showed that rapamycin could upregulate ULK1, ATG13 and downregulate mTORC1 and p53 protein expression.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	90-96
29556614-8	2017	The lowest immunoexpression of CD34, podoplanin, PDGFA, EGFR has been noticed in the Rapamycin-treated group without important differences correlated to dosage and time.	Sirolimus	85-94	CD34 molecule	Gallus gallus	31-35
28090037-6	2017	Treatment with rapamycin (100 nM) for 48 hours significantly increased %number of hemoglobin-producing cells, gamma-globin mRNA levels, erythroid specific 5-aminolevulinate synthase (ALAS2) mRNA levels, and heme content in K562 cells.	Sirolimus	15-24	5'-aminolevulinate synthase 2	Homo sapiens	183-188
28123835-6	2016	Blocking mTOR by using rapamycin selectively enhanced activities of IL-6 and TNF-alpha signaling pathways, which was accompanied with an increase of Caspase-3, indicating cellular apoptosis and worsened learning performance.	Sirolimus	23-32	caspase 3	Rattus norvegicus	149-158
27671892-4	2016	Prior genetic screens for Saccharomyces cerevisiae mutants with increased sensitivity to acetic acid identified loss-of-function mutations in the YPK1 gene, which encodes a protein kinase activated by the target of rapamycin (TOR) complex 2 (TORC2).	Sirolimus	215-224	serine/threonine protein kinase YPK1	Saccharomyces cerevisiae S288C	146-150
27723557-6	2016	The inferior function of statically cultured cardiobundles was rescued by transfer to dynamic conditions, which was accompanied by an increase in mTORC1 activity and decline in AMPK phosphorylation and was blocked by rapamycin.	Sirolimus	217-226	CREB regulated transcription coactivator 1	Mus musculus	146-152
27417217-10	2016	Functional assay revealed that IRGM knockdown inhibited autophagic flux and increased lipid droplet content in HepG2 and PLC/PRF/5 cells, which were reversed by the autophagy inducer rapamycin administration.	Sirolimus	183-192	immunity related GTPase M	Homo sapiens	31-35
27933890-1	2016	Recent studies indicate that LRS may act as a leucine sensor for the mTORC1 pathway, potentially providing an alternative strategy to overcome rapamycin resistance in cancer treatments.	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	69-75
26465375-0	2016	Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM  dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.	Sirolimus	42-51	PDZ and LIM domain 5	Homo sapiens	66-69
26465375-1	2016	AIMS: The aim of this study was to assess prospectively the effectiveness and safety of a new version of the dedicated bifurcation BiOSS stent, the sirolimus-eluting BiOSS LIM, for the treatment of distal left main (LM) stenosis.	Sirolimus	148-157	PDZ and LIM domain 5	Homo sapiens	172-175
27754935-8	2017	Rapamycin reversed the activation of mTORC1, attenuated beta cells hypertrophy and abolished the improvement of glucose tolerance.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	37-43
27903739-6	2017	Further investigation revealed that the Akt-mechanistic target of rapamycin signaling pathway was involved in this process, as the mechanistic target of rapamycin inhibitor rapamycin inhibited Hcy-induced changes in PKM2 enzyme activity and B cell activation.	Sirolimus	66-75	pyruvate kinase, muscle	Mus musculus	216-220
27838442-10	2017	Furthermore, our discovery that administration of rapamycin increased the activation of mTORC2 in microglial cells supports a reappraisal of the beneficial/adverse effects of rapamycin administration.	Sirolimus	50-59	CREB regulated transcription coactivator 2	Mus musculus	88-94
28007739-8	2016	Knockdown of the major H3K9 methyltransferase G9a resulted in a significant decrease in H3K9me2 levels across Mtor, increased Mtor expression, as well as decreased autophagic activity in response to rapamycin and serum starvation.	Sirolimus	199-208	euchromatic histone lysine N-methyltransferase 2	Mus musculus	46-49
27741510-8	2016	Further, we identify a fat storage defect in the ND2 mutant flies that is rescued by rapamycin, supporting a model that rapamycin exerts its effects on mitochondrial disease in these animals by altering metabolism.	Sirolimus	85-94	mitochondrial NADH-ubiquinone oxidoreductase chain 2	Drosophila melanogaster	49-52
27741510-8	2016	Further, we identify a fat storage defect in the ND2 mutant flies that is rescued by rapamycin, supporting a model that rapamycin exerts its effects on mitochondrial disease in these animals by altering metabolism.	Sirolimus	120-129	mitochondrial NADH-ubiquinone oxidoreductase chain 2	Drosophila melanogaster	49-52
27919264-1	2016	BACKGROUND: Blocking the mechanistic target of rapamycin complex-1 (mTORC1) with chemical inhibitors such as rapamycin has shown limited clinical efficacy in cancer.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	68-74
27671674-8	2016	PD-L1 attenuation also reduced mTORC1 activity and augmented the antiproliferative effects of the mTORC1 inhibitor rapamycin.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	98-104
27797139-4	2016	TSC is caused by the lack of functional Tsc1-Tsc2 complex, which serves as a major cellular inhibitor of mammalian Target of Rapamycin Complex 1 (mTORC1).	Sirolimus	125-134	CREB regulated transcription coactivator 1	Mus musculus	146-152
27797139-6	2016	Consequently, mTORC1 inhibitors, such as rapamycin, serve as experimental or already approved drugs for several TSC symptoms.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	14-20
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	75-81
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	178-184
26954224-3	2016	In the present study, we examined the effects of rapamycin, a specific inhibitor of mTORC1, on ELOVL1 expression and docosahexaenoic acid (DHA, C22:6 n-3) synthesis in bovine mammary epithelial cells (BMECs).	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	84-90
27065332-7	2016	Interestingly, while inhibition of PI-3K and AKT lowers 4E-BP1 phosphorylation and expression of Id1 in all cases, inhibition of TORC1 with rapamycin does not consistently have a similar effect, suggesting an alternative mechanism for PI-3K-dependent regulation of Id1 translation.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Homo sapiens	129-134
27808250-4	2016	Here we observed that rapamycin, which inhibits the nutrient-sensing complex mTORC1, increased ER-mitochondria coupling in HeLa cells to a similar extent as did tunicamycin.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	77-83
27173058-5	2016	Both increased mTORC1 and decreased mTORC2 activities were reversed by semi-chronic rapamycin treatment.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	15-21
27173058-5	2016	Both increased mTORC1 and decreased mTORC2 activities were reversed by semi-chronic rapamycin treatment.	Sirolimus	84-93	CREB regulated transcription coactivator 2	Mus musculus	36-42
27173058-6	2016	Acute treatment of hippocampal slices from AS mice with rapamycin or an S6K1 inhibitor, PF4708671, improved LTP, restored actin polymerization, and normalized mTORC1 and mTORC2 activity.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	159-165
27173058-6	2016	Acute treatment of hippocampal slices from AS mice with rapamycin or an S6K1 inhibitor, PF4708671, improved LTP, restored actin polymerization, and normalized mTORC1 and mTORC2 activity.	Sirolimus	56-65	CREB regulated transcription coactivator 2	Mus musculus	170-176
27670946-8	2016	In the presence of rapamycin, LC3B accumulation was further increased; however, this effect was attenuated by 3-MA.	Sirolimus	19-28	microtubule associated protein 1 light chain 3 beta	Homo sapiens	30-34
27545763-8	2016	Rapamycin treatment inhibited mTOR activity and increased AKT activity, but did not alter ERK1/2 phosphorylation and EGR1 protein levels in cultured bovine granulosa cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Bos taurus	30-34
27545763-8	2016	Rapamycin treatment inhibited mTOR activity and increased AKT activity, but did not alter ERK1/2 phosphorylation and EGR1 protein levels in cultured bovine granulosa cells.	Sirolimus	0-9	AKT serine/threonine kinase 1	Bos taurus	58-61
27593484-4	2016	Such decreased pro-IL-1beta expression in TSC1 KO macrophages was rescued by reducing mTORC1 activity with rapamycin or deletion of mTOR.	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	86-92
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD19 molecule	Homo sapiens	84-88
27258186-5	2016	The percentage of CD4+CD25+Foxp3+ Tregs to T cells was also elevated by Sirolimus in PBMCs including B cells.	Sirolimus	72-81	forkhead box P3	Homo sapiens	27-32
27332042-12	2016	Treatment with rapamycin selectively blocked mTORC1 activation, NDUFS3 expression, and aPL production both in transaldolase-deficient mice and in lupus-prone mice.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	45-51
27778276-4	2016	Foxp3 expression is increased by the activation of several transcription factors including nuclear factor-kappa B (NF-kappaB), nuclear factor of activated T cells (NFAT), and Smad3 in response to various signals such as TGFbeta, retinoic acid, and rapamycin.	Sirolimus	248-257	forkhead box P3	Homo sapiens	0-5
27569211-5	2016	IFNgamma signals were required in both hematopoietic and nonhematopoietic cells for rapamycin to optimally promote epidermal infiltration of gammadelta TCRmid T cells, as mediated by CXCR3-CXCL10 interactions, along with the antitumor effects of these cells.	Sirolimus	84-93	C-X-C motif chemokine receptor 3	Homo sapiens	183-188
27723777-5	2016	Sirolimus reduced renal TORC1 activation but not TORC2, NF-kappaB DNA binding activity, CCL2 or TNFalpha expression, and abnormalities in cilia ultrastructure, hypertension and cardiac disease were also not improved.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Rattus norvegicus	24-29
27735842-8	2016	Additionally, DOXO significantly induced mTOR expression in hCPCs, and inhibition of mTOR signaling by rapamycin, a specific inhibitor, rescued DOXO-mediated autophagosome depletion in hCPCs with significant reduction of DOXO-mediated cytosolic Ca2+ accumulation in hCPCs, and restored SMP30 and mTOR expression.	Sirolimus	103-112	regucalcin	Homo sapiens	286-291
27822418-6	2016	Pharmacological inhibition of mTORC1 signaling with rapamycin decreased LDHA level and glycolytic capacity of six HCC cell lines.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	30-36
26921303-7	2016	It was observed that CD8(+)CD28(-) T cells from cultures with CsA or RAPA had similar suppressor properties to cells from control cultures, although the drugs influenced the expression of FOXP3.	Sirolimus	69-73	forkhead box P3	Homo sapiens	188-193
27411383-7	2016	Reduction of GLUT4 protein in sedentary animals upon treatment with rapamycin revealed mTORC1-dependent GLUT4 regulation.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	87-93
27493206-2	2016	The gene products hamartin and tuberin form the TSC complex that acts as GTPase-activating protein for Rheb and negatively regulates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	CREB regulated transcription coactivator 1	Mus musculus	178-184
27466200-7	2016	The underlying mechanism does not involve modulation of mitochondrial biogenesis, but dysregulation of the activity of the metabolic regulators glycogen synthase kinase 3B (GSK3beta), decreased in Atxn1-KO and increased in SCA1 mice, and mechanistic target of rapamycin (serine/threonine kinase) (mTOR), unchanged in the Atxn1-KO and decreased in SCA1 mice cerebellum before the onset of ataxic symptoms.	Sirolimus	260-269	glycogen synthase kinase 3 alpha	Mus musculus	173-181
26991739-6	2016	Treatment with 5 mg/kg rapamycin for 3 weeks to inhibit mTORC1 and mTORC2 fully reversed PH in SM22-TSC1(-/-) mice.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	56-62
26872488-4	2016	Notably, blockade of mTORC1 activity by rapamycin treatment prolonged the life span of hyperphosphatemic alpha-Klotho-deficient (Kl(-/-)) mice.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	21-27
27506738-7	2016	More interestingly, the glucose uptake and the phosphorylation of the insulin receptor were decreased by 3-MA stimulation and increased by rapamycin, illustrating that the responsiveness of insulin was regulated by autophagy.	Sirolimus	139-148	insulin receptor	Homo sapiens	70-86
26991739-6	2016	Treatment with 5 mg/kg rapamycin for 3 weeks to inhibit mTORC1 and mTORC2 fully reversed PH in SM22-TSC1(-/-) mice.	Sirolimus	23-32	CREB regulated transcription coactivator 2	Mus musculus	67-73
26991739-6	2016	Treatment with 5 mg/kg rapamycin for 3 weeks to inhibit mTORC1 and mTORC2 fully reversed PH in SM22-TSC1(-/-) mice.	Sirolimus	23-32	TSC complex subunit 1	Mus musculus	100-104
26991739-7	2016	In chronically hypoxic mice and SM22-5HTT(+) mice exhibiting PH associated with mTORC1 and mTORC2 activation, PH was maximally attenuated by low-dose rapamycin associated with selective mTORC1 inhibition.	Sirolimus	150-159	CREB regulated transcription coactivator 1	Mus musculus	80-86
26991739-7	2016	In chronically hypoxic mice and SM22-5HTT(+) mice exhibiting PH associated with mTORC1 and mTORC2 activation, PH was maximally attenuated by low-dose rapamycin associated with selective mTORC1 inhibition.	Sirolimus	150-159	CREB regulated transcription coactivator 2	Mus musculus	91-97
26991739-7	2016	In chronically hypoxic mice and SM22-5HTT(+) mice exhibiting PH associated with mTORC1 and mTORC2 activation, PH was maximally attenuated by low-dose rapamycin associated with selective mTORC1 inhibition.	Sirolimus	150-159	CREB regulated transcription coactivator 1	Mus musculus	186-192
27232670-1	2016	The authors have previously demonstrated that a low and intermittent peripheral dose of rapamycin (1 mg/kg three times/week) to rats inhibited mTORC1 signalling, but avoided the hyperlipidemia and diabetes-like syndrome associated with higher doses of rapamycin.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	143-149
27571710-0	2016	SOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycin.	Sirolimus	73-82	SRY-box transcription factor 9	Homo sapiens	0-4
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD19 molecule	Homo sapiens	48-52
27448436-5	2016	When 16:0/9al-PC and the TLR2 ligand, zymosan, were added to RPM or AM, an enhancement of 5-LO product formation along with a concomitant decrease in COX product formation was observed.	Sirolimus	61-64	toll-like receptor 2	Mus musculus	25-29
27246732-6	2016	Furthermore, recombinant SEMA3A rescued the attenuation of cell proliferation and glycolytic activity in LLCs after Sema3A knockdown, whereas mTORC1 inhibition by rapamycin completely counteracted this effect.	Sirolimus	163-172	CREB regulated transcription coactivator 1	Mus musculus	142-148
27181066-3	2016	For example, central or intra-accumbal injections of the mTORC1 inhibitor rapamycin attenuates several indices of cocaine-seeking including progressive ratio (PR) responding and reinstatement.	Sirolimus	74-83	CREB regulated transcription coactivator 1	Mus musculus	57-63
27181066-4	2016	These behavioral effects are associated with decreased mTORC1 activity and synaptic protein translation in the nucleus accumbens (NAC) and point to a possible therapeutic role for rapamycin in the treatment of addiction.	Sirolimus	180-189	CREB regulated transcription coactivator 1	Mus musculus	55-61
27181066-11	2016	Thus, systemic administration of rapamycin is as effective at reducing drug seeking behavior and measures of mTORC1 activity compared to direct accumbal application and may therefore represent a possible therapeutic option in the treatment of addiction.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	109-115
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	28-34
27648364-6	2016	Rapamycin (Sirolimus) is an mTORC1 inhibitor, which inhibits the PI3K/Akt/mTOR signaling pathway, which is commonly altered in prostate cancer.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	28-34
27648364-7	2016	We determined the expression of cyclin D1 and phosphorylated-mTOR proteins in association with the response to rapamycin in two androgen sensitive (22RV1 and LNCaP) and two androgen independent (DU145 and PC3) prostate cancer cell lines and found that the base-line and changes of cyclin D1 level, but not the expression level of p-mTOR, correlated with rapamycin sensitivity.	Sirolimus	111-120	cyclin D1	Homo sapiens	32-41
27648364-8	2016	We evaluated the cell killing effect of combined rapamycin and cisplatin treatment and showed that the combination had a more than additive effect in both androgen dependent and independent prostate cancer cells, which may be partially explained by the reduction of cyclin D1 expression by rapamycin.	Sirolimus	49-58	cyclin D1	Homo sapiens	266-275
27648364-8	2016	We evaluated the cell killing effect of combined rapamycin and cisplatin treatment and showed that the combination had a more than additive effect in both androgen dependent and independent prostate cancer cells, which may be partially explained by the reduction of cyclin D1 expression by rapamycin.	Sirolimus	290-299	cyclin D1	Homo sapiens	266-275
27030515-5	2016	Similar effects were observed following oral treatment with the mTORC1 inhibitor, sirolimus.	Sirolimus	82-91	CREB regulated transcription coactivator 1	Mus musculus	64-70
27153139-9	2016	The use of Rapamycin (TORC1 inhibitor) was able on one hand to increase TFEB activation and, on the other hand, to reduce lipofuscin mass, potentiating the lysosomal functionality.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Homo sapiens	22-27
27153139-9	2016	The use of Rapamycin (TORC1 inhibitor) was able on one hand to increase TFEB activation and, on the other hand, to reduce lipofuscin mass, potentiating the lysosomal functionality.	Sirolimus	11-20	transcription factor EB	Homo sapiens	72-76
26758248-6	2016	CD4 (+) CD25 (+) Tregs or CD4 (+) CD25 (+) CD127(lo)Tregs expanded ex vivo with rapamycin could be used to suppress regrowth of residual lymphoma after autologous hematopoietic cell transplantation (HCT), and to counteract both graft-versus-host disease and lymphoma re-growth after allogeneic HCT in select patients with lymphoma susceptible to the regulation by Tregs.	Sirolimus	80-89	interleukin 2 receptor subunit alpha	Homo sapiens	34-38
27345003-3	2016	A primary osteoblast culture showed that rapamycin, an mTORC1 inhibitor, which was recently demonstrated to be an important serine/threonine kinase for bone formation, inhibited the peptide-induced alkaline phosphatase activity.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	55-61
27313209-7	2016	Interestingly, mammalian target of rapamycin complex 1 (mTORC1) signaling was hyperactivated in several tissues from Pip4k2c(-/-) mice and treating Pip4k2c(-/-) mice with rapamycin reduced the inflammatory phenotype, resulting in a decrease in mTORC1 signaling in tissues and a decrease in proinflammatory cytokines in plasma.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	56-62
27313209-7	2016	Interestingly, mammalian target of rapamycin complex 1 (mTORC1) signaling was hyperactivated in several tissues from Pip4k2c(-/-) mice and treating Pip4k2c(-/-) mice with rapamycin reduced the inflammatory phenotype, resulting in a decrease in mTORC1 signaling in tissues and a decrease in proinflammatory cytokines in plasma.	Sirolimus	35-44	phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	Homo sapiens	117-124
27313209-7	2016	Interestingly, mammalian target of rapamycin complex 1 (mTORC1) signaling was hyperactivated in several tissues from Pip4k2c(-/-) mice and treating Pip4k2c(-/-) mice with rapamycin reduced the inflammatory phenotype, resulting in a decrease in mTORC1 signaling in tissues and a decrease in proinflammatory cytokines in plasma.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	244-250
27226562-8	2016	Interestingly, inhibition of mTORC1 with rapamycin reduces the abundance of FOXO1 to the levels in T2D.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	29-35
27489506-0	2016	Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling.	Sirolimus	0-9	mitogen activated protein kinase 3	Rattus norvegicus	104-110
25617379-0	2016	Rapamycin Normalizes Serum Leptin by Alleviating Obesity and Reducing Leptin Synthesis in Aged Rats.	Sirolimus	0-9	leptin	Rattus norvegicus	27-33
25617379-0	2016	Rapamycin Normalizes Serum Leptin by Alleviating Obesity and Reducing Leptin Synthesis in Aged Rats.	Sirolimus	0-9	leptin	Rattus norvegicus	70-76
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	44-50
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	98-107	CREB regulated transcription coactivator 2	Mus musculus	55-61
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	160-169	CREB regulated transcription coactivator 1	Mus musculus	44-50
27208895-3	2016	mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo.	Sirolimus	160-169	CREB regulated transcription coactivator 2	Mus musculus	55-61
27208895-4	2016	Over the past decade, it has become clear that although genetic and pharmacological inhibition of mTORC1 extends lifespan and delays aging, inhibition of mTORC2 has negative effects on mammalian health and longevity and is responsible for many of the negative side effects of rapamycin.	Sirolimus	276-285	CREB regulated transcription coactivator 2	Mus musculus	154-160
27208895-5	2016	In this review, we discuss recent advances in understanding the molecular and physiological effects of rapamycin treatment, and we discuss how the use of alternative rapamycin treatment regimens or rapamycin analogs has the potential to mitigate the deleterious side effects of rapamycin treatment by more specifically targeting mTORC1.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	329-335
27338360-1	2016	The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui).	Sirolimus	76-85	transcriptional regulating factor 1	Homo sapiens	185-189
27338360-1	2016	The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui).	Sirolimus	58-67	transcriptional regulating factor 1	Homo sapiens	185-189
27338360-4	2016	Rapalogues including sirolimus, everolimus, and temsirolimus exert their effect mainly on mTORC1, whereas their inhibitory effect on mTORC2 is mild.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	90-96
27153561-1	2016	The inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) by chemical inhibitors, such as rapamycin, has demonstrated anti-cancer activity in preclinical and clinical trials.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	65-71
26975583-2	2016	Because TSC tumorigenesis correlates with hyperactivation of mTORC1, current therapies focus on mTORC1 inhibition with rapamycin or its analogs.	Sirolimus	119-128	CREB regulated transcription coactivator 1	Mus musculus	96-102
26975583-8	2016	Here, we show that inhibition of AMPK by compound C or by shRNA-mediated depletion of LKB1 reduces activation of autophagy by rapamycin in Tsc2-null cells.	Sirolimus	126-135	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	33-37
26975583-12	2016	These results indicate that an AMPK/p27 axis is promoting a survival mechanism that could explain in part the relapse of TSC tumors treated with rapamycin, exposing new avenues for designing more efficient treatments for TSC patients.	Sirolimus	145-154	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	31-35
27253629-7	2016	To confirm nutrient regulation by rapamycin treatment, we checked the transcript levels of nutrient transporter genes (SLC2A2, SLC2A4, SLC6A14, and SLC7A1).	Sirolimus	34-43	solute carrier family 2 member 4	Homo sapiens	127-133
27093550-12	2016	Thus, rapamycin shows an obvious protective effect on HG-induced EMT, by inhibiting the activation of Rho GTPases (RhoA, Rac1, and Cdc42).	Sirolimus	6-15	Rac family small GTPase 1	Rattus norvegicus	121-125
27093550-12	2016	Thus, rapamycin shows an obvious protective effect on HG-induced EMT, by inhibiting the activation of Rho GTPases (RhoA, Rac1, and Cdc42).	Sirolimus	6-15	cell division cycle 42	Rattus norvegicus	131-136
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 5	Homo sapiens	139-143
27489506-6	2016	Rapamycin ameliorated diabetes-enhanced ischemic brain damage and suppressed phosphorylation of P70S6K and ERK1/2.	Sirolimus	0-9	mitogen activated protein kinase 3	Rattus norvegicus	107-113
27221338-8	2016	Finally, we also found that CRP induced renal fibrosis through a CD32b-Smad3-mTOR pathway because blocking mTOR signaling with rapamycin inhibited CRP-induced CTGF and collagen I expression.	Sirolimus	127-136	SMAD family member 3	Mus musculus	71-76
27221338-8	2016	Finally, we also found that CRP induced renal fibrosis through a CD32b-Smad3-mTOR pathway because blocking mTOR signaling with rapamycin inhibited CRP-induced CTGF and collagen I expression.	Sirolimus	127-136	cellular communication network factor 2	Mus musculus	159-163
27050906-5	2016	We show that Npm1 gene expression is dependent on mTOR as demonstrated by treatment of wild-type and Pten inactivated MEFs cultured with rapamycin or by transient transfections of small interfering RNA directed against mTOR.	Sirolimus	137-146	nucleophosmin 1	Homo sapiens	13-17
27050906-7	2016	Interestingly, rapamycin did not dislodge mTOR from the Npm1 promoter but rather strongly destabilized the Npm1 transcript by increasing its turnover.	Sirolimus	15-24	nucleophosmin 1	Homo sapiens	107-111
27078846-2	2016	Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) is the primary alteration underlying TSC tumors.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	60-66
27078846-8	2016	In addition, rapamycin in combination with celecoxib, a COX2 inhibitor, strongly inhibited Tsc2-deficient cell growth.	Sirolimus	13-22	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	56-60
27078846-9	2016	We conclude that downregulation of COX2 exerts a protective effect against hyperactivated mTORC1-mediated tumorigenesis caused by the loss of TSC2, and the combination of rapamycin and celecoxib may be an effective new approach to treating TSC.	Sirolimus	171-180	CREB regulated transcription coactivator 1	Mus musculus	90-96
27132889-5	2016	Mechanistically, small interfering RNA knockdown of RAPTOR, a component of mTOR complex 1, phenocopied the mesendoderm-enhancing effects of rapamycin.	Sirolimus	140-149	regulatory associated protein of MTOR complex 1	Homo sapiens	52-58
27489506-7	2016	It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings.	Sirolimus	150-159	mitogen activated protein kinase 3	Rattus norvegicus	218-224
27090568-11	2016	Adding rapamycin after Lcn2 could stimulate autophagy and recover insulin sensitivity.	Sirolimus	7-16	lipocalin 2	Rattus norvegicus	23-27
27387347-4	2016	These effects were concomitant with constitutive activation of mTORC1 and can be reversed by addition of amino acids or rapamycin, and by the knockdown of the regulatory-associated protein of mTOR, Raptor.	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	63-69
27044907-8	2016	Graft-versus-host disease prophylaxis with tacrolimus/sirolimus was associated with a low NRM of 11.5% in the alloHCT recipients in CR1.	Sirolimus	54-63	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	132-135
27018708-3	2016	Mice with mTORC1 impairment, either through adipocyte-specific deletion of Raptor or pharmacologic rapamycin treatment, were refractory to the well-known betaAR-dependent increase of uncoupling protein UCP1 expression and expansion of beige/brite adipocytes (so-called browning) in white adipose tissue (WAT).	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	10-16
26837772-0	2016	The effect of rapamycin on TGFbeta1 and MMP1 expression in a rabbit model of urethral stricture.	Sirolimus	14-23	interstitial collagenase	Oryctolagus cuniculus	40-44
27551516-3	2016	Here, we characterized how mTORC1 responds to cell death induced by various anticancer drugs such rapamycin, etoposide, cisplatin, curcumin, staurosporine and Fas ligand.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	27-33
26846849-9	2016	Following acute Tsc1 deletion from hepatocytes, Akt phosphorylation, but not IRS1/PI3K association, was rapidly restored by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	160-169	TSC complex subunit 1	Mus musculus	16-20
26846849-9	2016	Following acute Tsc1 deletion from hepatocytes, Akt phosphorylation, but not IRS1/PI3K association, was rapidly restored by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	160-169	CREB regulated transcription coactivator 1	Mus musculus	143-149
26769362-7	2016	The ability of PACAP to inhibit autophagy was also observed in an in vitro cell assay by the blocking of the p62-sequestration activity produced with the autophagy inducer rapamycin.	Sirolimus	172-181	adenylate cyclase activating polypeptide 1	Homo sapiens	15-20
27019134-1	2016	Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway.	Sirolimus	43-52	CREB regulated transcription coactivator 1	Mus musculus	142-148
26296742-7	2016	Furthermore, pharmacologic treatment of Tsc1 single-mutant mice with rapamycin reduced hyperphosphorylation and accumulation of 4E-BP1 but also inhibited phosphorylation of rpS6.	Sirolimus	69-78	TSC complex subunit 1	Mus musculus	40-44
27019134-1	2016	Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling pathway.	Sirolimus	43-52	CREB regulated transcription coactivator 2	Mus musculus	160-166
26296742-7	2016	Furthermore, pharmacologic treatment of Tsc1 single-mutant mice with rapamycin reduced hyperphosphorylation and accumulation of 4E-BP1 but also inhibited phosphorylation of rpS6.	Sirolimus	69-78	ribosomal protein S6	Mus musculus	173-177
27362797-6	2016	Because cells with TSC loss fail to completely inhibit mTORC1 and properly activate autophagy in the absence of amino acids, we sporadically administered the mTORC1 inhibitor rapamycin, which was sufficient to correct the defects seen in cones, further enhancing the efficiency of cone survival mediated by Tsc1 loss.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	158-164
27362797-6	2016	Because cells with TSC loss fail to completely inhibit mTORC1 and properly activate autophagy in the absence of amino acids, we sporadically administered the mTORC1 inhibitor rapamycin, which was sufficient to correct the defects seen in cones, further enhancing the efficiency of cone survival mediated by Tsc1 loss.	Sirolimus	175-184	TSC complex subunit 1	Mus musculus	307-311
27257474-0	2016	Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.	Sirolimus	10-19	fukutin	Mus musculus	63-70
27241713-7	2016	This was reverted by rapamycin injection, demonstrating that insulin resistance in AdicerKO mice is caused by mTORC1 hyperactivation.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	110-116
27161823-2	2016	Although both complexes are evolutionarily conserved, only TORC1 is acutely inhibited by rapamycin.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Homo sapiens	59-64
27245614-5	2016	Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin.	Sirolimus	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
27109477-5	2016	Overexpression of FXR prevented the growth of cells and induced cell cycle arrest, which was enhanced by the mTOR/S6K inhibitor rapamycin.	Sirolimus	128-137	nuclear receptor subfamily 1 group H member 4	Homo sapiens	18-21
27109477-6	2016	FXR upregulation also intensified the inhibition of cell growth by rapamycin.	Sirolimus	67-76	nuclear receptor subfamily 1 group H member 4	Homo sapiens	0-3
26991235-2	2016	The cause of DA neuronal loss in PD is still unclear; however, accumulating evidence suggests that treatment with certain flavonoids can induce neuroprotective properties, such as activation of mammalian target of rapamycin complex 1 (mTORC1) and anti-inflammatory activities in animal models of PD.	Sirolimus	214-223	CREB regulated transcription coactivator 1	Mus musculus	235-241
27105919-10	2016	Treatment with rapamycin, an inhibitor of mTOR signaling, together with Slc7a7 knockdown synergistically perturbed spaw expression, indicating an interaction between Slc7a7 and mTOR signaling affecting gene expression required for LR specification.	Sirolimus	15-24	serine/threonine-protein kinase mTOR	Oryzias latipes	42-46
27105919-10	2016	Treatment with rapamycin, an inhibitor of mTOR signaling, together with Slc7a7 knockdown synergistically perturbed spaw expression, indicating an interaction between Slc7a7 and mTOR signaling affecting gene expression required for LR specification.	Sirolimus	15-24	serine/threonine-protein kinase mTOR	Oryzias latipes	177-181
27050281-3	2016	Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
26816112-2	2016	Central to TSC pathology is hyper-activation of the mammalian target of rapamycin complex 1 (mTORC1) signalling pathway, which is a key controller of cell growth.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	93-99
26816112-4	2016	The immunosuppressant, rapamycin, is a specific inhibitor of mTORC1 and has shown promise as a therapeutic agent in TSC as well as in malignancy.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	61-67
27050281-3	2016	Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
27009856-6	2016	Specifically, rapamycin treatment induced proteasome-mediated KPNA2 protein decay and attenuated the transcriptional activation of KPNA2 by decreasing Dp1/E2F1 level in vivo.	Sirolimus	14-23	karyopherin subunit alpha 2	Homo sapiens	62-67
27095138-5	2016	BM cells showed increased phosphorylation of Akt and mTorc1, and extramedullary hematopoiesis was significantly reduced by treating mice with rapamycin in vivo, suggesting that the mTorc1 pathway was activated by loss of Flcn expression in hematopoietic cells in vivo.	Sirolimus	142-151	CREB regulated transcription coactivator 1	Mus musculus	181-187
27095138-5	2016	BM cells showed increased phosphorylation of Akt and mTorc1, and extramedullary hematopoiesis was significantly reduced by treating mice with rapamycin in vivo, suggesting that the mTorc1 pathway was activated by loss of Flcn expression in hematopoietic cells in vivo.	Sirolimus	142-151	folliculin	Mus musculus	221-225
27009856-6	2016	Specifically, rapamycin treatment induced proteasome-mediated KPNA2 protein decay and attenuated the transcriptional activation of KPNA2 by decreasing Dp1/E2F1 level in vivo.	Sirolimus	14-23	karyopherin subunit alpha 2	Homo sapiens	131-136
26923592-2	2016	We show that the amino acid sensing of mechanistic target of rapamycin complex 1 (mTORC1) is dysregulated in cells deficient in presenilin, a protein associated with AD.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Mus musculus	82-88
26901106-6	2016	The mTORC1 inhibitor rapamycin diminishes FBP enrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
27009856-6	2016	Specifically, rapamycin treatment induced proteasome-mediated KPNA2 protein decay and attenuated the transcriptional activation of KPNA2 by decreasing Dp1/E2F1 level in vivo.	Sirolimus	14-23	prostaglandin D2 receptor	Homo sapiens	151-159
26854565-6	2016	Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2(-/-) mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	209-215
27009856-7	2016	Immunoprecipitation assay further revealed that KPNA2 physically associated with the phospho-mTOR/mTOR and this association was abolished by rapamycin treatment.	Sirolimus	141-150	karyopherin subunit alpha 2	Homo sapiens	48-53
26873552-5	2016	Consistently, prenatal treatment with mTORC1 inhibitor rapamycin rescued the phenotype of Depdc5(-/-) embryos.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	38-44
27320602-8	2016	RESULTS: Flow cytometric analyses of a cardiac allograft on POD 7 showed that MDSCs derived from rapamycin-treated CTx mice (MDSCs-Rap) transfer led to significant recruitment of Tregs compared with a PBS-injected allograft.	Sirolimus	97-106	low density lipoprotein receptor-related protein associated protein 1	Mus musculus	131-134
27112200-7	2016	The activation of autophagy including TFEB is likely due to fisetin-mediated mammalian target of rapamycin complex 1 (mTORC1) inhibition, since the phosphorylation levels of p70S6 kinase and 4E-BP1 were decreased in the presence of fisetin.	Sirolimus	97-106	transcription factor EB	Homo sapiens	38-42
27112200-7	2016	The activation of autophagy including TFEB is likely due to fisetin-mediated mammalian target of rapamycin complex 1 (mTORC1) inhibition, since the phosphorylation levels of p70S6 kinase and 4E-BP1 were decreased in the presence of fisetin.	Sirolimus	97-106	CREB regulated transcription coactivator 1	Mus musculus	118-124
27111854-8	2016	Rapamycin treatment led to the rapid accumulation of autophagic bodies and autophagy lysosomes, decreased p62 protein levels, and increased the ratio of microtubule-associated protein light chain 3 II (LC3-II) to LC3-I in hippocampal neurons through the mTOR signaling pathway.	Sirolimus	0-9	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	106-109
26903175-7	2016	The ras1, ras2 and tor1 mutants had a high-persister phenotype similar to wild-type biofilm and planktonic cells exposed to the TORC1 pathway inhibitor rapamycin.	Sirolimus	152-161	Ras family GTPase RAS2	Saccharomyces cerevisiae S288C	10-14
26886923-0	2016	Comparative Analysis of Protocols to Induce Human CD4+Foxp3+ Regulatory T Cells by Combinations of IL-2, TGF-beta, Retinoic Acid, Rapamycin and Butyrate.	Sirolimus	130-139	forkhead box P3	Homo sapiens	54-59
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	superoxide dismutase 2	Homo sapiens	37-67
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	superoxide dismutase 2	Homo sapiens	69-74
26707081-4	2016	By inhibiting mTOR and mitochondrial manganese superoxide dismutase (MnSOD), we confirmed that rapamycin functioned through the mTOR/MnSOD/reactive oxygen species (ROS) signaling pathway, and the existence of Akt governed the rapamycin-induced asymmetric division (AD) of stem cells in cases of radiation-treated breast cancer.	Sirolimus	95-104	superoxide dismutase 2	Homo sapiens	133-138
26462884-11	2016	Rapamycin treatment induced autophagy and decreased hepatic triglyceride and glycogen content in G6PC(-/-) mice, as well as reduced liver size and improved circulating markers of liver damage in GSDIa dogs.	Sirolimus	0-9	glucose-6-phosphatase, catalytic	Mus musculus	97-101
26481278-13	2016	Rapamycin treatment markedly induced regulatory B lymphocytes (B220(+)IgM(+)IgG(-)IL-10(+)TGF-beta1(+)) cells when compared with dimethyl sulfoxide controls.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	90-99
26659860-3	2016	In syncytiotrophoblasts, starvation, rapamycin, or punicalagin all decreased the expression of phosphorylated ribosomal protein S6, a downstream target of the mTOR kinase, and of the autophagy markers, LC3-II and p62.	Sirolimus	37-46	ribosomal protein S6	Homo sapiens	110-130
26687947-9	2016	Interestingly, incubation with mTOR inhibitor rapamycin increased in the rate of LTR-positive autolysosomes in hepatocytes from KKAy mice and suppressed p62 accumulation in the liver from KKAy mice which correlated to an increase in the V-ATPase subunits expression.	Sirolimus	46-55	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	237-245
27116987-21	2016	(2)The expression of LC3B of rapamycin + cisplatin group was higher than those of other 3 group cells(1.72+-0.08, 1.43+-0.04, 1.37+-0.11, and 1.11+-0.09; P&lt;0.05).	Sirolimus	29-38	microtubule associated protein 1 light chain 3 beta	Homo sapiens	21-25
27090655-9	2016	Analyzing mechanism of action interference of the mTOR inhibitor sirolimus shows specific impact on the drug resistance signature imposed by cisplatin and paclitaxel, further holding evidence for a synthetic lethal interaction to paclitaxel mechanism of action involving cyclin D1.	Sirolimus	65-74	cyclin D1	Homo sapiens	271-280
26924291-15	2016	CONCLUSION: Sirolimus increases the sensitivity of human OS cells to anticancer drugs in vitro by up-regulating miR-34b interacting with PAK1 and ABCB1.	Sirolimus	12-21	p21 (RAC1) activated kinase 1	Homo sapiens	137-141
26858361-7	2016	Accordingly, rapamycin-treated mice are cold intolerant, failing to maintain body temperature and weight when shifted to 4 C. Adipocyte-specific deletion of the mTORC1 subunit Raptor recapitulated the block in beta-adrenergic signaling.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	161-167
26795955-3	2016	Phosphorylated S6 was up-regulated in Tsc1(-/-) mammary epithelium, which could be reversed by rapamycin, suggesting that mTORC1 was hyperactivated in Tsc1(-/-) mammary epithelium.	Sirolimus	95-104	TSC complex subunit 1	Mus musculus	38-42
26795955-3	2016	Phosphorylated S6 was up-regulated in Tsc1(-/-) mammary epithelium, which could be reversed by rapamycin, suggesting that mTORC1 was hyperactivated in Tsc1(-/-) mammary epithelium.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	122-128
26795955-3	2016	Phosphorylated S6 was up-regulated in Tsc1(-/-) mammary epithelium, which could be reversed by rapamycin, suggesting that mTORC1 was hyperactivated in Tsc1(-/-) mammary epithelium.	Sirolimus	95-104	TSC complex subunit 1	Mus musculus	151-155
26795955-4	2016	The mTORC1 inhibitor rapamycin restored the development of Tsc1(-/-) mammary glands whereas suppressed the development of Tsc1(wt/wt) mammary glands, indicating that a modest activation of mTORC1 is critical for mammary development.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
26795955-4	2016	The mTORC1 inhibitor rapamycin restored the development of Tsc1(-/-) mammary glands whereas suppressed the development of Tsc1(wt/wt) mammary glands, indicating that a modest activation of mTORC1 is critical for mammary development.	Sirolimus	21-30	TSC complex subunit 1	Mus musculus	59-63
26795955-4	2016	The mTORC1 inhibitor rapamycin restored the development of Tsc1(-/-) mammary glands whereas suppressed the development of Tsc1(wt/wt) mammary glands, indicating that a modest activation of mTORC1 is critical for mammary development.	Sirolimus	21-30	TSC complex subunit 1	Mus musculus	122-126
26795955-4	2016	The mTORC1 inhibitor rapamycin restored the development of Tsc1(-/-) mammary glands whereas suppressed the development of Tsc1(wt/wt) mammary glands, indicating that a modest activation of mTORC1 is critical for mammary development.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	189-195
26702100-7	2016	Importantly, inhibition of mTORC1 signaling by rapamycin treatment aggravated the neurodegenerative phenotype in a TDP-43-depleted Drosophila model, whereas activation of mTORC1 signaling by PA treatment ameliorated the neurodegenerative phenotype.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	27-33
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	61-70	matrix metallopeptidase 2	Homo sapiens	205-237
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	72-75	matrix metallopeptidase 2	Homo sapiens	205-237
26949542-12	2016	Immunohistochemical analysis showed positive stain of RPMs for both MMP-9 and TIMP-1.	Sirolimus	54-58	matrix metalloproteinase-9	Oryctolagus cuniculus	68-73
26949542-13	2016	Aqueous humor MMP-9 levels were significantly higher in RPM group postoperatively, while TIMP-1 levels were comparatively lower than that of No-RPM group.	Sirolimus	56-59	matrix metalloproteinase-9	Oryctolagus cuniculus	14-19
26898798-0	2016	The dynamics of histone H2A ubiquitination in HeLa cells exposed to rapamycin, ethanol, hydroxyurea, ER stress, heat shock and DNA damage.	Sirolimus	68-77	H2A clustered histone 18	Homo sapiens	24-27
26898798-5	2016	Furthermore, rapamycin and hydroxyurea treatment, and ER stress increased ubiquitination of hH2A, while methyl methanesulfonate (MMS) treatment induced deubiquitination of hH2A.	Sirolimus	13-22	H2A clustered histone 18	Homo sapiens	92-96
27047390-0	2016	Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.	Sirolimus	0-9	beclin 1	Rattus norvegicus	78-86
27047390-4	2016	Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and p62.	Sirolimus	55-64	beclin 1	Rattus norvegicus	97-105
27047390-4	2016	Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and p62.	Sirolimus	55-64	MCL1 apoptosis regulator, BCL2 family member	Rattus norvegicus	143-148
27047390-4	2016	Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and p62.	Sirolimus	55-64	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	153-156
26844761-10	2016	In this study, we identified many mTORC1-regulated proteins using proteomic analysis by overlapping two different high vs low/no mTORC1 activity comparisons, TSC2(-/-) vs WT MEFs and TSC2(-/-) with/without rapamycin treatment.	Sirolimus	206-215	CREB regulated transcription coactivator 1	Mus musculus	34-40
26687613-6	2016	Interestingly, durable FVIII-specific tolerance was also achieved in animals co-administered with FVIII admixed with nanoparticles encapsulating rapamycin alone.	Sirolimus	145-154	coagulation factor VIII	Mus musculus	23-28
27007909-5	2016	Additionally, in duck myoblasts treated with LY294002 and rapamycin, the specific inhibitors ofPI3K and mTOR, respectively, the overexpression of Six1 could significantly ameliorate inhibitive effects of these inhibitors on protein synthesis.	Sirolimus	58-67	SIX homeobox 1	Homo sapiens	146-150
26698023-9	2016	Rapamycin (which primarily inhibits mTORC1), ATP-competitive, dual mTORC1/mTORC2 inhibitors and upstream regulators of the mTOR pathway are being developed to treat autoimmune, hyperproliferative and degenerative diseases.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	36-42
26922671-6	2016	The effect of rapamycin on the expression of Prox1 was determined by western blotting.	Sirolimus	14-23	prospero homeobox 1	Homo sapiens	45-50
27426069-26	2016	(4) Compared with that in control group (0.46+-0.14), FAK activity of cells in rapamycin group (0.16+-0.08) was significantly down-regulated (t=4.967, P&lt;0.01).	Sirolimus	79-88	protein tyrosine kinase 2	Homo sapiens	54-57
27426069-28	2016	Inhibition effects of rapamycin on migration of HaCaT cells may be mediated by down-regulated activity of FAK.	Sirolimus	22-31	protein tyrosine kinase 2	Homo sapiens	106-109
26636543-2	2015	Here we studied the role of mTOR-dependent autophagy in implementating the antiprolifrative effect of mTORC1-specific inhibitor rapamycin and ATP-competitive mTOR kinase inhibitor pp242.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	102-108
26782505-0	2015	Influence of sirolimus-induced TGF-beta secretion on mouse Treg cell proliferation.	Sirolimus	13-22	transforming growth factor, beta 1	Mus musculus	31-39
26565025-8	2015	Inhibition of mTORC1 by low-dose rapamycin or knockdown of p70S6K protected podocytes through attenuation of Nox4 expression and subsequent oxidative stress-induced apoptosis by TGF-beta1.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	14-20
26652716-8	2015	By treatment of MKN45 gastric cancer cells with rapamycin, a reduction of p-mTOR in the Western blot was achieved; however, expression of MMPs remained unaffected.	Sirolimus	48-57	matrix metallopeptidase 2	Homo sapiens	138-142
26598700-3	2015	When we express an FKBP12-tagged ER trap and FRB-tagged Golgi enzymes, conditions precluding such competition, the Golgi enzymes completely redistribute to the ER upon rapamycin treatment.	Sirolimus	168-177	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	19-25
26256674-9	2015	The PBPK model developed based on CL(int) of recombinant CYP3A4, CYP3A5 and CYP2C8 predicted a small CYP3A5*3 effect on simulated sirolimus PK profiles.	Sirolimus	130-139	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	76-82
26118661-7	2015	The findings indicate that rapamycin inhibits BAFF-stimulated cell proliferation/survival by targeting mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	27-36	TNF superfamily member 13b	Homo sapiens	46-50
26449264-2	2015	This multi-organ disorder results from inactivating point mutations in either the TSC1 or the TSC2 genes and consequent activation of the canonical mammalian target of rapamycin complex 1 signalling (mTORC1) pathway.	Sirolimus	168-177	CREB regulated transcription coactivator 1	Mus musculus	200-206
26490657-6	2015	These effects were observed with as little as 0.5 nM rapamycin, demonstrating the profound affinity the compound has for FK-binding protein 12 (FKBP12), which subsequently forms the FKBP12/rapamycin complex to inhibit mTOR.	Sirolimus	53-62	FKBP prolyl isomerase 1A	Homo sapiens	121-142
26490657-6	2015	These effects were observed with as little as 0.5 nM rapamycin, demonstrating the profound affinity the compound has for FK-binding protein 12 (FKBP12), which subsequently forms the FKBP12/rapamycin complex to inhibit mTOR.	Sirolimus	53-62	FKBP prolyl isomerase 1A	Homo sapiens	144-150
26490657-6	2015	These effects were observed with as little as 0.5 nM rapamycin, demonstrating the profound affinity the compound has for FK-binding protein 12 (FKBP12), which subsequently forms the FKBP12/rapamycin complex to inhibit mTOR.	Sirolimus	53-62	FKBP prolyl isomerase 1A	Homo sapiens	182-188
26681922-4	2015	Inhibition of mTOR by rapamycin markedly reduced ischemia-induced damage; suppressed p-Akt, p-mTOR, p-P70S6K and p-S6 protein levels; decreased LC3-II and Beclin-1; and prevented cytochrome c release in the two structures.	Sirolimus	22-31	beclin 1	Rattus norvegicus	155-163
26010766-6	2015	Rapamycin, an inhibitor of mTOR, can suppress the glucose-induced phosphorylation of HSF1/S326 and the expression of alpha B-crystallin.	Sirolimus	0-9	heat shock transcription factor 1	Homo sapiens	85-89
26504125-4	2015	We report here the case of an 8-year-old boy affected by a severe form of CHI due to a biallelic heterozygous ABCC8 mutation who responded to sirolimus with a dramatic improvement in his glucose blood level regulation and quality of life, with no serious adverse events after 6 months of follow-up.	Sirolimus	142-151	ATP binding cassette subfamily C member 8	Homo sapiens	110-115
26306048-6	2015	Moreover, rapamycin treatment in vivo reduced the skeletal muscle IRE1alpha activation in the Fyn-overexpressing transgenic mice.	Sirolimus	10-19	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	66-75
26071480-1	2015	PURPOSE: We hypothesized that lymphoid-selective host conditioning and subsequent adoptive transfer of sirolimus-resistant allogeneic T cells (T-Rapa), when combined with high-dose sirolimus drug therapy in vivo, would safely achieve antitumor effects while avoiding GVHD.	Sirolimus	103-112	transcriptional regulating factor 1	Homo sapiens	145-149
26071480-7	2015	High-dose sirolimus therapy inhibited multiple T-Rapa DLI, as evidenced by stable mixed donor/host chimerism.	Sirolimus	10-19	transcriptional regulating factor 1	Homo sapiens	49-53
26027949-11	2015	Inhibition of mTORC1 activity by rapamycin improved the behavioral and immunological deficits of CMA mice.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	14-20
26377470-5	2015	Treatment with rapamycin was found to independently restore PGC1alpha-TFEB signaling in a manner not requiring parkin activity and to abrogate impairment of mitochondrial quality control and neurodegenerative features associated with this in vivo model.	Sirolimus	15-24	transcription factor EB	Homo sapiens	70-74
26377470-12	2015	Treatment with rapamycin independently restores PGC1alpha-TFEB signaling in a manner not requiring parkin activity and abrogates subsequent mitochondrial impairment and neuronal cell loss.	Sirolimus	15-24	transcription factor EB	Homo sapiens	58-62
26227152-12	2015	Peroxisome proliferator activated receptor-gamma coactivator-1alpha, pyruvate dehydrogenase kinase 4 and mitochondrial transcription factor A mRNA increased post-exercise (P &lt; 0.05) and this response was augmented by rapamycin (P &lt; 0.05).	Sirolimus	220-229	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	0-67
26922671-10	2016	The loss-of-function of Prox1 was coincident with the increase of triglycerides in HepG2 cells treated with rapamycin.	Sirolimus	108-117	prospero homeobox 1	Homo sapiens	24-29
25943210-8	2015	Finally, co-administration of rapamycin and a mitogen-activated protein kinase kinase (MEK) inhibitor trametinib reversed rapamycin-mediated MDSC recruitment.	Sirolimus	122-131	midkine	Mus musculus	46-85
26892465-7	2016	RESULTS: When combined with FAK down-regulation, rapamycin-induced suppression of cell proliferation, G0/G1 cell cycle arrest, and apoptosis were significantly enhanced.	Sirolimus	49-58	protein tyrosine kinase 2	Homo sapiens	28-31
25943210-8	2015	Finally, co-administration of rapamycin and a mitogen-activated protein kinase kinase (MEK) inhibitor trametinib reversed rapamycin-mediated MDSC recruitment.	Sirolimus	122-131	midkine	Mus musculus	87-90
26041819-5	2015	mTORC1 inhibition with rapamycin partially ameliorated renal disease in B6.Pdss2(kd/kd) mice with complexes I-III/II-III deficiencies, improved viability and mitochondrial physiology in gas-1(fc21) nematodes with complex I deficiency, and rescued viability across a variety of RC-inhibited human cells.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
26892465-8	2016	In addition, REH cell-injected NOD/SCID mice treated with rapamycin and a short-hairpin RNA (shRNA) to down-regulate FAK had significantly longer survival times and slower leukemia progression compared with mice injected with REH-empty vector cells and treated with rapamycin.	Sirolimus	58-67	atrophin 1	Homo sapiens	31-34
26202311-6	2015	Interestingly, we found that rapamycin inhibited mTOR signaling in addition to simultaneously downregulating the expression of CD44, SOX2 and MMP-2 and that it affected cell growth and tumor size and weight both in vitro and in vivo.	Sirolimus	29-38	matrix metallopeptidase 2	Homo sapiens	142-147
26872016-4	2016	Moreover, several recent clinical trials showed that the mTORC1 inhibitors rapamycin and rapalog only reduce the capacity for cell proliferation without promoting cell death, consistent with the concept that rapamycin is cytostatic and reduces disease progression but is not cytotoxic.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	57-63
26872016-6	2016	Here, we report that rapamycin treatment promotes a compensatory increase in transglutaminase 2 (TGM2) levels in mTORC1-driven tumors.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	113-119
26872016-7	2016	TGM2 inhibition potently sensitizes mTORC1-hyperactive cancer cells to rapamycin treatment, and a rapamycin-induced autophagy blockade inhibits the compensatory TGM2 upregulation.	Sirolimus	71-80	CREB regulated transcription coactivator 1	Mus musculus	36-42
26872016-7	2016	TGM2 inhibition potently sensitizes mTORC1-hyperactive cancer cells to rapamycin treatment, and a rapamycin-induced autophagy blockade inhibits the compensatory TGM2 upregulation.	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	36-42
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	100-106
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	32-41	CREB regulated transcription coactivator 2	Mus musculus	252-258
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	CREB regulated transcription coactivator 1	Mus musculus	100-106
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	CREB regulated transcription coactivator 1	Mus musculus	100-106
26463117-4	2016	We hypothesized that different rapamycin dosing schedules or the use of FDA-approved rapamycin analogs with different pharmacokinetics might expand the therapeutic window of rapamycin by more specifically targeting mTORC1.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	215-221
26878791-5	2016	Moreover, similar to the effects in rat brains, this treatment induced the activation of mammalian target of rapamycin complex 1 (mTORC1), which is well known as an important survival factor for DA neurons, and inhibited microglial activation in the substantia nigra (SN) of mouse brains treated with 6-OHDA.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	130-136
26419955-0	2016	Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).	Sirolimus	78-87	CREB regulated transcription coactivator 1	Mus musculus	99-105
26258417-9	2015	In cultured TIE2-L914F-expressing HUVECs, rapamycin effectively reduced mutant TIE2-induced AKT signaling and, though TIE2-TKI did target the WT receptor, it only weakly suppressed mutant-induced AKT signaling.	Sirolimus	42-51	TEK receptor tyrosine kinase	Homo sapiens	12-16
26258417-9	2015	In cultured TIE2-L914F-expressing HUVECs, rapamycin effectively reduced mutant TIE2-induced AKT signaling and, though TIE2-TKI did target the WT receptor, it only weakly suppressed mutant-induced AKT signaling.	Sirolimus	42-51	TEK receptor tyrosine kinase	Homo sapiens	79-83
26258417-9	2015	In cultured TIE2-L914F-expressing HUVECs, rapamycin effectively reduced mutant TIE2-induced AKT signaling and, though TIE2-TKI did target the WT receptor, it only weakly suppressed mutant-induced AKT signaling.	Sirolimus	42-51	TEK receptor tyrosine kinase	Homo sapiens	79-83
25936601-3	2015	In the present study, we examined the effect of rapamycin, an mTORC1 inhibitor and an inducer of autophagy, on recovery from spinal cord injury.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Mus musculus	62-68
26020804-4	2015	Treatment of FaDu and SCC-1 cell lines with rapamycin, an inhibitor of mTOR pathway, also reduced cell viability of HNSCC cells.	Sirolimus	44-53	protein tyrosine phosphatase receptor type J	Homo sapiens	22-27
26419955-8	2016	We provide evidence that a brief repression of mTORC1 activity in vivo by rapamycin has little effect globally, yet leads to a significant remodeling of synaptic proteins, in particular those proteins that reside in the postsynaptic density.	Sirolimus	74-83	CREB regulated transcription coactivator 1	Mus musculus	47-53
26655465-1	2016	Expression of hypoxia-inducible factor 1a (HIF1a) is increased under several pathological conditions such as hyperactive mechanistic target of rapamycin complex 1 (mTORC1) in tuberous sclerosis complex (TSC).	Sirolimus	143-152	CREB regulated transcription coactivator 1	Mus musculus	164-170
26655465-1	2016	Expression of hypoxia-inducible factor 1a (HIF1a) is increased under several pathological conditions such as hyperactive mechanistic target of rapamycin complex 1 (mTORC1) in tuberous sclerosis complex (TSC).	Sirolimus	143-152	TSC complex subunit 1	Mus musculus	203-206
27042678-5	2016	The effect of rapamycin pre- and posttreatment was tested on kainate-induced dendritic injury and cofilin-mediated actin depolymerization.	Sirolimus	14-23	cofilin 1	Homo sapiens	98-105
27042678-6	2016	RESULTS: Kainate-induced seizures caused acute activation of mTORC1 activity, which was prevented by the mTORC1 inhibitor, rapamycin.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	61-67
27042678-6	2016	RESULTS: Kainate-induced seizures caused acute activation of mTORC1 activity, which was prevented by the mTORC1 inhibitor, rapamycin.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	105-111
27042678-7	2016	Rapamycin pretreatment, and to a lesser degree, posttreatment attenuated acute seizure-induced dendritic injury and correspondingly decreased LIM kinase and cofilin-mediated depolymerization of actin.	Sirolimus	0-9	cofilin 1	Homo sapiens	157-164
25867072-3	2016	Rapamycin analogs Everolimus and Temsirolimus are non-ATP-competitive mTORC1 inhibitors, and suppress proliferation and tumor angiogenesis and invasion.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	70-76
26752047-0	2016	Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-kappaB/LOX-1 Pathway.	Sirolimus	0-9	oxidized low density lipoprotein receptor 1	Homo sapiens	120-125
26752047-8	2016	Moreover, immunofluorescent staining showed that rapamycin reduced the accumulation of p65 in the nucleus after ox-LDL treatment for 30 h. mTOR knockdown decreased LOX-1 protein production and IkappaBalpha phosphorylation induced by ox-LDL.	Sirolimus	49-58	RELA proto-oncogene, NF-kB subunit	Homo sapiens	87-90
26752047-8	2016	Moreover, immunofluorescent staining showed that rapamycin reduced the accumulation of p65 in the nucleus after ox-LDL treatment for 30 h. mTOR knockdown decreased LOX-1 protein production and IkappaBalpha phosphorylation induced by ox-LDL.	Sirolimus	49-58	oxidized low density lipoprotein receptor 1	Homo sapiens	164-169
26752047-10	2016	CONCLUSIONS: These findings demonstrate that rapamycin reduce mTOR phosphorylation and subsequently inhibit NF-kappaB activation and suppresses LOX-1, resulting in a reduction in ox-LDL uptake in HUVECs.	Sirolimus	45-54	oxidized low density lipoprotein receptor 1	Homo sapiens	144-149
27047741-2	2016	In the present study, we examined the in vivo effects of treatment with an mTORC1 inhibitor, rapamycin, on cardiac BCKDH complex activity in mice.	Sirolimus	93-102	CREB regulated transcription coactivator 1	Mus musculus	75-81
27047741-5	2016	Rapamycin treatment fully inhibited mTORC1 activity, measured by the phosphorylation state of ribosomal protein S6 kinase 1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	36-42
26563881-2	2016	mTORC1, consisting of mTOR, raptor, and mLST8 (GbetaL), is sensitive to rapamycin and thought to control autonomous cell growth in response to nutrient availability and growth factors.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	0-6
26563881-6	2016	However, the effectiveness of rapamycin as single-agent therapy is suppressed, in part, by the numerous strong mTORC1-dependent negative feedback loops.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	111-117
26563389-7	2016	Specific pharmacological blockade of mTORC1 by 3 nM rapamycin, as well as genetic deletion of p70S6K1, impaired the CB1-antagonist-mediated decrease in GSIS.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	37-43
26563389-7	2016	Specific pharmacological blockade of mTORC1 by 3 nM rapamycin, as well as genetic deletion of p70S6K1, impaired the CB1-antagonist-mediated decrease in GSIS.	Sirolimus	52-61	cannabinoid receptor 1 (brain)	Mus musculus	116-119
25715851-8	2016	These analyses revealed that both TBTO and the mTOR inhibitor rapamycin inactivate RPS6, but via different mechanisms.	Sirolimus	62-71	ribosomal protein S6	Homo sapiens	83-87
27468872-3	2016	Although several evidences suggest that hyper-activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway is crucial for these tumors, modulation of other metabolic pathways might affect tumor growth and progression.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	105-111
26782505-6	2015	Sirolimus-promoted differentiation and proliferation was examined using a TGF-beta neutralizing antibody.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	74-82
26782505-7	2015	Sirolimus-treated CD4+ T cell TGF-beta secretion increased 2.5X over control levels (P &lt; 0.01), but that of the cyclosporine group decreased marginally (P &gt; 0.05).	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	30-38
26782505-11	2015	Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	86-94
26566676-7	2015	Akt-mediated downregulation of Mfn2 was via the mTORC1 pathway because this downregulation was blocked by rapamycin, and overexpression of wild-type, but not kinase-dead mTOR, caused Mfn2 downregulation.	Sirolimus	106-115	CREB regulated transcription coactivator 1	Mus musculus	48-54
26118661-0	2015	Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	TNF superfamily member 13b	Homo sapiens	19-23
26118661-3	2015	However, how rapamycin inhibits BAFF-stimulated B-cell proliferation and survival has not been fully elucidated.	Sirolimus	13-22	TNF superfamily member 13b	Homo sapiens	32-36
26118661-4	2015	Here, we show that rapamycin inhibited human soluble BAFF (hsBAFF)-induced cell proliferation and survival in normal and B-lymphoid (Raji and Daudi) cells by activation of PP2A and inactivation of Erk1/2.	Sirolimus	19-28	TNF superfamily member 13b	Homo sapiens	53-57
25898836-13	2015	In contrast, rapamycin pretreatment ameliorated renal injury, with improved renal function, lower renal tissue injury scores, and inhibited apoptosis based on fewer TUNEL-positive cells and lower caspase-3 expression.	Sirolimus	13-22	caspase 3	Rattus norvegicus	196-205
26306297-9	2015	Rapamycin treatment specifically inhibited LV mTORC1 without altering mTORC2 activity at 8 weeks.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	46-52
26306297-11	2015	CONCLUSION: Rapamycin slows hypertrophy in LV VO by inhibiting early activation of mTORC1 without modulating mTORC2.	Sirolimus	12-21	CREB regulated transcription coactivator 1	Mus musculus	83-89
26297427-10	2015	Our results showed that p70S6K, S6 and Akt phosphorylation were significantly upregulated in IgAN rats, and rapamycin effectively inhibited p70S6K and S6 phosphorylation.	Sirolimus	108-117	IGAN1	Homo sapiens	93-97
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	IGAN1	Homo sapiens	60-64
26309858-0	2015	Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells.	Sirolimus	0-9	forkhead box P3	Rattus norvegicus	120-125
26309858-7	2015	Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.	Sirolimus	0-9	interleukin 4	Rattus norvegicus	91-95
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	IGAN1	Homo sapiens	159-163
26452980-6	2015	Notably, INK128 was more potent than the TORC1 inhibitor rapamycin in down-regulating Mcl-1, diminishing AKT and 4EBP1 phosphorylation, and potentiating ABT-737 activity.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Homo sapiens	41-46
26163589-4	2015	Persistent Ag exposure results in prolonged activation of the AKT-mTORC1 pathway in Ag-specific CD8 T cells, favoring their development into effector memory T cells at the expense of central memory T cells, and inhibition of mTORC1 by rapamycin largely corrects the impairment by promoting central memory T cell development.	Sirolimus	235-244	CREB regulated transcription coactivator 1	Mus musculus	225-231
26032503-6	2015	In particular, inhibition of mTORC1 by rapamycin or by silencing of Raptor significantly blocked the PDGF-dependent phenotypic change of VSMCs whereas silencing of Rictor had no effect.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	29-35
26397133-9	2015	Lung tumors harvested from mice exposed to rapamycin showed a significant decrease in p-mTOR, p-S6K1, PCNA and Bcl-xL as compared with controls in the early and late stage intervention studies.	Sirolimus	43-52	BCL2-like 1	Mus musculus	111-117
26248051-5	2015	Both lithium and rapamycin were shown to induce autophagosomes in esophageal and colorectal cancer cells by western blot analysis of LC3 isoforms, morphology and FACS quantitation of Cyto-ID or mCherry-GFP-LC3.	Sirolimus	17-26	acyl-CoA synthetase long-chain family member 1	Mus musculus	162-166
26241748-6	2015	The mTORC1-specific inhibitor, rapamycin, restored these in vitro and in vivo phenotypic changes.	Sirolimus	31-40	CREB regulated transcription coactivator 1	Mus musculus	4-10
26453749-7	2015	Indeed, rpS6 knockin mice are completely sensitive to the inhibitory effects of rapamycin and an S6 kinase 1 (S6K1)-specific inhibitor on T cell activation and proliferation.	Sirolimus	80-89	ribosomal protein S6	Mus musculus	8-12
26362885-5	2015	Vesicular glutamate transporter 2 (VGLUT2) expression was increased after the plantar incision, which was inhibited by rapamycin.	Sirolimus	119-128	solute carrier family 17 member 6	Homo sapiens	0-33
25997742-4	2015	Lysosomes are dynamic organelles that integrate several degradative pathways and regulate the activity of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	147-153
26051878-8	2015	Inhibitors of mTORC1, such as rapamycin, effectively suppress the symptoms of TSC.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	14-20
26192087-0	2015	Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase.	Sirolimus	0-9	cellular communication network factor 2	Homo sapiens	20-24
26192087-9	2015	We demonstrated that rapamycin amplified basal or TGF-beta1-induced CCN2 mRNA and protein expression in normal or fibrotic fibroblasts by Smad-independent but PI3K-dependent pathway.	Sirolimus	21-30	cellular communication network factor 2	Homo sapiens	68-72
26192087-12	2015	Collectively, this study implies a significant fibrogenic induction activity of rapamycin by activating AKT and inducing CCN2 expression in vitro and provides the possible mechanisms for the in vivo findings which previously showed no antifibrotic effect of rapamycin on lung fibrosis.	Sirolimus	80-89	cellular communication network factor 2	Homo sapiens	121-125
26362885-5	2015	Vesicular glutamate transporter 2 (VGLUT2) expression was increased after the plantar incision, which was inhibited by rapamycin.	Sirolimus	119-128	solute carrier family 17 member 6	Homo sapiens	35-41
27606328-3	2015	Systemic pharmacological inhibition of mTOR signaling with rapamycin has been shown to rescue DISC1 deficiency-induced neurodevelopmental defects, as well as cognitive and affective deficits.	Sirolimus	59-68	DISC1 scaffold protein	Homo sapiens	94-99
25844891-8	2015	Therefore, the combination of rapamycin and resveratrol may be an effective clinical strategy for treatment of LAM and other diseases with mTORC1 hyperactivation.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	139-145
26497134-14	2015	mRNA expression of autophagy markers such as ATG5, LC3A and LC3B was significantly increased in the rapamycin-treated Ad-hMSCs compared with untreated Ad-hMSCs.	Sirolimus	100-109	autophagy related 5	Mus musculus	45-49
26497134-14	2015	mRNA expression of autophagy markers such as ATG5, LC3A and LC3B was significantly increased in the rapamycin-treated Ad-hMSCs compared with untreated Ad-hMSCs.	Sirolimus	100-109	microtubule-associated protein 1 light chain 3 beta	Mus musculus	60-64
26693177-2	2015	The TSC1 and TSC2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	76-85	CREB regulated transcription coactivator 1	Mus musculus	97-103
26375670-2	2015	The purpose of this study was to investigate whether combined treatment with the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients.	Sirolimus	154-163	transcriptional regulating factor 1	Homo sapiens	176-180
26002468-3	2015	We showed that autophagy was induced in an mTORC1-dependent way and played a protective role against PA-induced apoptosis, which was verified by pretreatment with 3-methyladenine (3MA) and rapamycin.	Sirolimus	189-198	CREB regulated transcription coactivator 1	Mus musculus	43-49
26123689-7	2015	Sirolimus, which is directed against the PI3/AKT/mTOR downstream signalling pathway involved in lymphangiogenesis, has also shown promising results, although further study is needed.	Sirolimus	0-9	peptidase inhibitor 3	Homo sapiens	41-44
26224859-6	2015	Importantly, transcripts for the activating transcription factor-3 (Atf3) and mitochondrial uncoupling protein-2 (Ucp2) are highly induced in Tsc2-deficient neurons, as well as in a neuron-specific Tsc1 conditional knock-out mouse model, and show differential responses to the mTOR inhibitor rapamycin.	Sirolimus	292-301	activating transcription factor 3	Mus musculus	33-66
26224859-6	2015	Importantly, transcripts for the activating transcription factor-3 (Atf3) and mitochondrial uncoupling protein-2 (Ucp2) are highly induced in Tsc2-deficient neurons, as well as in a neuron-specific Tsc1 conditional knock-out mouse model, and show differential responses to the mTOR inhibitor rapamycin.	Sirolimus	292-301	activating transcription factor 3	Mus musculus	68-72
26130148-5	2015	On the other hand, the allosteric inhibitor rapamycin induces eIF2alphaS51P through pathways that are independent of mTORC1 inactivation.	Sirolimus	44-53	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	62-66
26224859-6	2015	Importantly, transcripts for the activating transcription factor-3 (Atf3) and mitochondrial uncoupling protein-2 (Ucp2) are highly induced in Tsc2-deficient neurons, as well as in a neuron-specific Tsc1 conditional knock-out mouse model, and show differential responses to the mTOR inhibitor rapamycin.	Sirolimus	292-301	TSC complex subunit 1	Mus musculus	198-202
26170311-3	2015	Rapamycin is an allosteric inhibitor of mTOR that selectively inhibits mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	71-77
25968579-8	2015	Incubation with rapamycin and AZD8055 indicated that mammalian target of rapamycin complex (mTORC)2, but not mTORC1, also is required for LIF-stimulated glucose uptake.	Sirolimus	16-25	CREB regulated transcription coactivator 2	Mus musculus	92-99
25703582-4	2015	Several recent reports showed that rapamycin, an inhibitor of mTORC1, improved sociability and other symptoms in mouse models of Tuberous Sclerosis Complex and autism spectrum disorder, consistent with mTORC1 overactivity playing an important pathogenic role.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	62-68
25703582-4	2015	Several recent reports showed that rapamycin, an inhibitor of mTORC1, improved sociability and other symptoms in mouse models of Tuberous Sclerosis Complex and autism spectrum disorder, consistent with mTORC1 overactivity playing an important pathogenic role.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	202-208
26122303-6	2015	Based on the Western blot studies, different dosing paradigms of rapamycin starting at postnatal day 21 were tested for their ability to prevent epilepsy or pathologic abnormalities in Tsc1(GFAP)CKO mice: 4 days of rapamycin only (4- ), 4 days on-24 days off (4-24), and 4 days on-10 days off (4-10).	Sirolimus	65-74	TSC complex subunit 1	Mus musculus	185-189
26122303-9	2015	SIGNIFICANCE: Intermittent dosing of rapamycin, with drug holidays of more than 3 weeks, maintains significant antiepileptogenic properties in mouse models of TSC.	Sirolimus	37-46	TSC complex subunit 1	Mus musculus	159-162
26146058-8	2015	Rapamycin combined with ASPP2 still promoted OXA or starvation-induced apoptosis, and the apoptosis rate was also lower than that of the ASPP2 group.	Sirolimus	0-9	tumor protein p53 binding protein 2	Homo sapiens	137-142
26146058-9	2015	However, rapamycin counteracted effectively the inhibitory effect of ASPP2 on autophagy.	Sirolimus	9-18	tumor protein p53 binding protein 2	Homo sapiens	69-74
26380452-15	2015	CONCLUSION: PESV combined Rapamycin might inhibit the development of H22 hepatoma transplantation tumor in mice possibly through inhibiting the activity of mTOR, enhancing expressions of ULK1, MAP1LC3A, and Beclin1.	Sirolimus	26-35	unc-51 like kinase 1	Mus musculus	187-191
25940091-7	2015	Importantly, from a drug resistance standpoint, our data also show that reducing LARP1 protein levels by RNA interference attenuates the inhibitory effect of rapamycin, Torin1, and amino acid deprivation on TOP mRNA translation.	Sirolimus	158-167	La ribonucleoprotein 1, translational regulator	Homo sapiens	81-86
26083118-7	2015	The effect of Orz on adipocyte differentiation was dependent on mTORC1 activity because rapamycin blocks cell differentiation in Orz-treated cells.	Sirolimus	88-97	CREB regulated transcription coactivator 1	Mus musculus	64-70
25961827-0	2015	AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	96-102
26130148-5	2015	On the other hand, the allosteric inhibitor rapamycin induces eIF2alphaS51P through pathways that are independent of mTORC1 inactivation.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	117-123
26002629-0	2015	Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	74-80
26002629-0	2015	Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	85-91
25721400-5	2015	Feeding the mice with a diet supplemented with rapamycin prevented the enlargement of the heart and spleen, suggesting that mTORC1 is the mediator of these effects.	Sirolimus	47-56	CREB regulated transcription coactivator 1	Mus musculus	124-130
26002629-9	2015	The findings indicate that rapamycin prevents Cd-induced neuronal cell death via suppressing both mTORC1 and mTORC2 pathways.	Sirolimus	27-36	CREB regulated transcription coactivator 1	Mus musculus	98-104
25721400-9	2015	These observations suggest that the anabolic effect of mTORC1 activation at the organ level by BCAAs and inhibition by rapamycin are complex phenomenon and tissue-specific.	Sirolimus	119-128	CREB regulated transcription coactivator 1	Mus musculus	55-61
26002629-9	2015	The findings indicate that rapamycin prevents Cd-induced neuronal cell death via suppressing both mTORC1 and mTORC2 pathways.	Sirolimus	27-36	CREB regulated transcription coactivator 2	Mus musculus	109-115
25721400-10	2015	In addition, it suggests that rapamycin can be used to counter hypertrophy of the organs when activation of mTORC1 is the underlying cause.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	108-114
26402468-8	2015	Synergy was observed when buparlisib was combined with the IGF1R inhibitor NVP-AEW541 and the mTORC1 inhibitor rapamycin.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	94-100
25794661-5	2015	Rapamycin, an inhibitor of mTORC1 (mTOR complex 1) did not elicit apoptosis in lymphoma cells; however, the combination of rapamycin with exogenous TGF-beta1 induced apoptosis and restored TGF-beta1 dependent apoptotic machinery in several lymphoma cell lines with reduced TGF-beta sensitivity in vitro.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	27-33
25626017-10	2015	Furthermore, the reduced expression of LC3-II and Beclin 1 and the neuroprotective effects were reversed by the autophagy inducer rapamycin.	Sirolimus	130-139	beclin 1	Rattus norvegicus	50-58
26353013-12	2015	Co-treatment of EBR with rapamycin, an upstream mTOR pathway inhibitor, prevented EBR-induced cell viability loss and PARP cleavage in LNCaP prostate cancer cells, suggesting that EBR could induce ER stress in these cells.	Sirolimus	25-34	collagen type XI alpha 2 chain	Homo sapiens	118-122
25855786-3	2015	Although rapamycin analogues, allosteric inhibitors that target only the mTORC1 complex, have shown some clinical activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	73-79
26311343-11	2015	In silico prediction followed by quatitative real-time PCR revealed two of these TFs namely, PU.1 and CCCTC binding factor (CTCF) are down and upregulated, respectively, which may be the reason of the altered expression of miRNAs following rapamycin treatment.	Sirolimus	240-249	spleen focus forming virus (SFFV) proviral integration oncogene	Mus musculus	93-97
25855786-3	2015	Although rapamycin analogues, allosteric inhibitors that target only the mTORC1 complex, have shown some clinical activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	186-192
25855786-3	2015	Although rapamycin analogues, allosteric inhibitors that target only the mTORC1 complex, have shown some clinical activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.	Sirolimus	9-18	CREB regulated transcription coactivator 2	Mus musculus	197-203
25875045-8	2015	Consistent with this notion, Ucn 2 reduced insulin-induced tyrosine phosphorylation of IRS-1, and treatment with rapamycin reversed the inhibitory effect of Ucn 2 on IRS-1 and Akt phosphorylation.	Sirolimus	113-122	urocortin 2	Homo sapiens	157-162
26062414-1	2015	OBJECTIVE: To explore the impact of triple anti-tumor therapy based on thymosin alpha1 (Talpha1) combined with Huaier granule(HG) and sirolimus on the level of serum alpha-fetoprotein (AFP) in rat models of liver cancer.	Sirolimus	134-143	alpha-fetoprotein	Rattus norvegicus	166-183
26236608-9	2015	Following the initiation of treatment with sirolimus, transient elevation of the serum KL-6 level was detected without interstitial pneumonia.	Sirolimus	43-52	mucin 1, cell surface associated	Homo sapiens	87-91
26311343-11	2015	In silico prediction followed by quatitative real-time PCR revealed two of these TFs namely, PU.1 and CCCTC binding factor (CTCF) are down and upregulated, respectively, which may be the reason of the altered expression of miRNAs following rapamycin treatment.	Sirolimus	240-249	CCCTC-binding factor	Mus musculus	102-122
26311343-11	2015	In silico prediction followed by quatitative real-time PCR revealed two of these TFs namely, PU.1 and CCCTC binding factor (CTCF) are down and upregulated, respectively, which may be the reason of the altered expression of miRNAs following rapamycin treatment.	Sirolimus	240-249	CCCTC-binding factor	Mus musculus	124-128
26238486-5	2015	Importantly, however, FOXP3(+) iNKT cells only acquired suppressive abilities when cultured in the presence of the mTOR inhibitor rapamycin.	Sirolimus	130-139	forkhead box P3	Homo sapiens	22-27
26200935-3	2015	The concern with the monotherapy use of mTORC1 inhibitors, such as rapamycin, is that they cause upregulation of autophagy, a cell survival mechanism, and suppress the negative feedback loop to the oncogene Akt.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	40-46
26037201-11	2015	Inhibition of mTOR signalling by rapamycin decreased levels of intestinal and plasma GLP-1 in both normal and diabetic mice.	Sirolimus	33-42	glucagon	Mus musculus	85-90
26006020-9	2015	Fibrin-cultured cells treated with rapamycin, the mTOR pathway inhibitor, had significantly decreased phospho-p70(s6k) and PDX-1 expression.	Sirolimus	35-44	pancreatic and duodenal homeobox 1	Homo sapiens	123-128
26147250-2	2015	Rapamycin suppresses the mammalian TORC1 complex, which regulates translation, and extends lifespan in diverse species, including mice.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	35-40
26255626-7	2015	Mutations in the FAT domain of MTOR and in RHEB remained sensitive to rapamycin, though several of these mutations demonstrated residual mTOR kinase activity after treatment with rapamycin at clinically relevant doses.	Sirolimus	70-79	Ras homolog, mTORC1 binding	Homo sapiens	43-47
26055714-5	2015	Ectopic expression of Tid1 induces autophagy by forming LC3+ autophagosome foci, whereas silencing Tid1 leads to drastic impairment of autophagy as induced by nutrient deprivation or rapamycin.	Sirolimus	183-192	DnaJ heat shock protein family (Hsp40) member A3	Homo sapiens	99-103
25694169-5	2015	Treatment with rapamycin, an autophagy activator, significantly increased LC3B expression, while diminishing 4-HNE and 3-NT levels, reducing noise-induced hair cell loss, and, subsequently, noise-induced hearing loss (NIHL).	Sirolimus	15-24	microtubule-associated protein 1 light chain 3 beta	Mus musculus	74-78
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	236-241
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	236-241
25659819-6	2015	Data are provided demonstrating that G1 cell cycle arrest induced by rapamycin is due to up-regulation of TGF-beta signaling and down-regulation of Rb phosphorylation via phosphorylation of the mTORC1 substrates S6K and 4E-BP1 respectively.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	194-200
25738543-3	2015	The protein complex TSC1/2 has been reported to have an inhibitory function on mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	99-108	CREB regulated transcription coactivator 1	Mus musculus	120-126
25810360-0	2015	4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice.	Sirolimus	34-43	GLIS family zinc finger 3	Mus musculus	52-57
25797247-9	2015	Thus, induction of GSK3-dependent degradation of these oncogenic proteins is likely secondary to mTORC2 inhibition; this effect should be critical for rapamycin to exert its anticancer activity.	Sirolimus	151-160	CREB regulated transcription coactivator 2	Mus musculus	97-103
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	ubiquitin C	Homo sapiens	131-140
26379864-7	2015	Further Western blot assays showed that rapamycin induced activation of caspase-9 and caspase-8 and the cleavage of caspase-3.	Sirolimus	40-49	caspase 8	Homo sapiens	86-95
26176608-5	2015	In this study, by employing automated spectrophotometry, we found the level of glucose uptake was decreased in non-small-cell lung carcinoma (NSCLC) A549, PC-9 and SK-MES-1 cells treated with rapamycin or siRNA against Raptor, indicating that the inhibition of mTORC1 attenuated glycolytic metabolism in NSCLC cells.	Sirolimus	192-201	CREB regulated transcription coactivator 1	Mus musculus	261-267
26219339-4	2015	Our previous work demonstrated aberrant activation of mTORC1 signaling that led to ongoing clinical trials with rapamycin analogs for NF2 and sporadic meningioma patients.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	54-60
25880554-0	2015	17ss-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling.	Sirolimus	47-56	CREB regulated transcription coactivator 2	Mus musculus	25-31
25836987-9	2015	Administration of single high doses of rapamycin to mice, to model the spikes in rapamycin levels that occur in patients with severe diarrheal episodes, resulted in reduced phosphorylation of S6 and AKT in ileal tissues, indicating inhibition of the mTOR complex (mTORC1 and mTORC2).	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	264-270
25880554-7	2015	Under physiological in vivo conditions, rapamycin compromised mTORC2 function only in female, but not in male murine hearts.	Sirolimus	40-49	CREB regulated transcription coactivator 2	Mus musculus	62-68
25880554-9	2015	Use of specific estrogen receptor (ER)alpha- and ERbeta-agonists indicated involvement of both estrogen receptors (ER) in rapamycin effects on mTORC1 and mTORC2.	Sirolimus	122-131	estrogen receptor 2 (beta)	Mus musculus	49-55
25836987-9	2015	Administration of single high doses of rapamycin to mice, to model the spikes in rapamycin levels that occur in patients with severe diarrheal episodes, resulted in reduced phosphorylation of S6 and AKT in ileal tissues, indicating inhibition of the mTOR complex (mTORC1 and mTORC2).	Sirolimus	39-48	CREB regulated transcription coactivator 2	Mus musculus	275-281
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	CREB regulated transcription coactivator 1	Mus musculus	145-151
25652038-2	2015	While rapamycin acutely and directly inhibits mTORC1, only chronic administration of rapamycin can inhibit mTORC2 in some, but not all, cell lines or tissues.	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	46-52
25652038-3	2015	The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	45-51
26086828-7	2015	Similar effects were obtained in cells in which mTORC1 was inhibited by rapamycin.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	48-54
25652038-3	2015	The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	274-280
25652038-3	2015	The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition.	Sirolimus	177-186	CREB regulated transcription coactivator 2	Mus musculus	45-51
25652038-3	2015	The mechanism leading to cell specificity of mTORC2 inhibition by rapamycin is not understood and is especially important because many of the negative metabolic side effects of rapamycin, reported in mouse studies and human clinical trials, have been attributed recently to mTORC2 inhibition.	Sirolimus	177-186	CREB regulated transcription coactivator 2	Mus musculus	274-280
25652038-6	2015	Further reduction of FKBP12 in cell lines with already low FKBP12 levels completely blocks mTORC1 inhibition by rapamycin, indicating that relative FKBP12 levels are critical for both mTORC1 and mTORC2 inhibition, but at different levels.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	91-97
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	200-206
26060906-8	2015	Mutations in the TSC1 and TSC2 genes that cause tuberous sclerosis lead to hyperactivation of signaling via the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	132-141	CREB regulated transcription coactivator 1	Mus musculus	153-159
25645826-11	2015	However, rapamycin treatment significantly increased the expression levels of LC3-II and beclin 1 and decreased the rate of apoptosis of PC-12 cells.	Sirolimus	9-18	beclin 1	Rattus norvegicus	89-97
26024867-3	2015	Rapamycin inhibition of TorC1 elicits nuclear localization of Gln3, a GATA-family transcription activator responsible for the expression of genes encoding proteins required to transport and degrade poor nitrogen sources, e.g., proline.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Homo sapiens	24-29
25739982-7	2015	Rapamycin suppressed 17beta-estradiol-induced Sertoli cell proliferation, appearing to act by reducing the abundance of SKP2, CCND1, and CCNE1 mRNA as well as RB and EMI1 protein.	Sirolimus	0-9	S-phase kinase associated protein 2	Homo sapiens	120-124
25739982-7	2015	Rapamycin suppressed 17beta-estradiol-induced Sertoli cell proliferation, appearing to act by reducing the abundance of SKP2, CCND1, and CCNE1 mRNA as well as RB and EMI1 protein.	Sirolimus	0-9	cyclin D1	Homo sapiens	126-131
25919564-10	2015	At all time points, both Beclin-1 and LC3-II expression levels were significantly higher in HIBD and Ra-treated rats than in sham rats (P&lt;0.05); except LC3-II at 12 hours, Beclin-1 and LC3-II expression levels were significantly higher in Ra-treated rats than in HIBD rats (P&lt;0.05).	Sirolimus	101-103	beclin 1	Rattus norvegicus	25-33
25919564-10	2015	At all time points, both Beclin-1 and LC3-II expression levels were significantly higher in HIBD and Ra-treated rats than in sham rats (P&lt;0.05); except LC3-II at 12 hours, Beclin-1 and LC3-II expression levels were significantly higher in Ra-treated rats than in HIBD rats (P&lt;0.05).	Sirolimus	101-103	annexin A3	Rattus norvegicus	38-41
25919564-10	2015	At all time points, both Beclin-1 and LC3-II expression levels were significantly higher in HIBD and Ra-treated rats than in sham rats (P&lt;0.05); except LC3-II at 12 hours, Beclin-1 and LC3-II expression levels were significantly higher in Ra-treated rats than in HIBD rats (P&lt;0.05).	Sirolimus	101-103	beclin 1	Rattus norvegicus	175-183
25762619-5	2015	Also, PP242, an mTORC1/2 kinase inhibitor, inhibited cell adhesion more potently than rapamycin (mTORC1 inhibitor).	Sirolimus	86-95	CREB regulated transcription coactivator 1	Mus musculus	97-103
25774780-8	2015	Interestingly, the acute orexigenic effect of the mTORC1 inhibitor rapamycin was preserved in HF-fed mice, supporting the assertion that HF-induced increase in baseline cmNTS mTORC1 activity underlies the defect in L-leucine sensing.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	50-56
25774780-8	2015	Interestingly, the acute orexigenic effect of the mTORC1 inhibitor rapamycin was preserved in HF-fed mice, supporting the assertion that HF-induced increase in baseline cmNTS mTORC1 activity underlies the defect in L-leucine sensing.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	175-181
25945786-7	2015	The results obtained from a chromatin immunoprecipitation assay demonstrated that the ability of C/EBPalpha to bind to the GLUT4 gene promoter was reduced by the treatment with fisetin, which agreed well with those obtained when 3T3-L1 cells were allowed to differentiate into adipocytes in medium in the presence of rapamycin, an inhibitor for mTOR.	Sirolimus	317-326	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	97-107
25969542-8	2015	Rapamycin induced phosphorylation of GATA-6 in wild-type mice, but not in Akt2(-/-) mice.	Sirolimus	0-9	GATA binding protein 6	Mus musculus	37-43
25833958-3	2015	Here, we report that the cytokine FMS-like receptor tyrosine kinase ligand (Flt3L) enhances the in vivo effect of rapamycin.	Sirolimus	114-123	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	76-81
25833958-5	2015	Whereas in conventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced by Flt3L, increased mTOR1 activity renders pDCs more resistant to inhibition by rapamycin.	Sirolimus	29-38	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	118-123
25833958-5	2015	Whereas in conventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced by Flt3L, increased mTOR1 activity renders pDCs more resistant to inhibition by rapamycin.	Sirolimus	78-87	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	118-123
25942007-6	2015	Inhibition of PI3K with LY294002 and wortmannin, and of mTORC1 with rapamycin decreased flagellin-induced TNF-alpha and IL-6 expression and cell proliferation.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	56-62
25911189-7	2015	Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in the diabetic heart.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	98-104
25911189-7	2015	Rapamycin treatment restored phosphorylation of STAT3 and enhanced AKT phosphorylation (target of mTORC2), but significantly reduced ribosomal protein S6 phosphorylation (target of mTORC1) in the diabetic heart.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	181-187
25534435-1	2015	We present a case of a bifurcation lesion treated with two dedicated sirolimus eluting bifurcation stents, BiOSS Lim in the setting of non-ST elevation myocardial infarction and poor left ventricular function.	Sirolimus	69-78	PDZ and LIM domain 5	Homo sapiens	113-116
25761126-3	2015	Inputs of the model include intrinsic AMPK kinase activity, which is taken as an adjustable surrogate parameter for cellular energy level or AMP:ATP ratio, and rapamycin dose, which controls MTORC1 activity.	Sirolimus	160-169	CREB regulated transcription coactivator 1	Mus musculus	191-197
26191215-0	2015	Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.	Sirolimus	0-9	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	105-110
26191215-6	2015	Western blot and RT-PCR assay showed that Bmi-1 was downregulated in protein and mRNA level by rapamycin treatment.	Sirolimus	95-104	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	42-47
26191215-8	2015	Together, all these results illustrated that rapamycin induced growth inhibition of human retinoblastoma cells, and inactive of mTOR pathway and downregulation of Bmi-1 was involved in its action mechanism.	Sirolimus	45-54	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	163-168
25518065-0	2015	Sirolimus therapy in a patient with severe hyperinsulinaemic hypoglycaemia due to a compound heterozygous ABCC8 gene mutation.	Sirolimus	0-9	ATP binding cassette subfamily C member 8	Homo sapiens	106-111
25738366-0	2015	Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.	Sirolimus	0-9	mitogen-activated protein kinase associated protein 1	Mus musculus	19-24
25880554-9	2015	Use of specific estrogen receptor (ER)alpha- and ERbeta-agonists indicated involvement of both estrogen receptors (ER) in rapamycin effects on mTORC1 and mTORC2.	Sirolimus	122-131	CREB regulated transcription coactivator 1	Mus musculus	143-149
25738366-3	2015	Studies have shown that rapamycin inhibits phosphorylation of mSin1.	Sirolimus	24-33	mitogen-activated protein kinase associated protein 1	Mus musculus	62-67
25738366-5	2015	Here we found that rapamycin inhibited phosphorylation of mSin1 potently and rapidly.	Sirolimus	19-28	mitogen-activated protein kinase associated protein 1	Mus musculus	58-63
25880554-9	2015	Use of specific estrogen receptor (ER)alpha- and ERbeta-agonists indicated involvement of both estrogen receptors (ER) in rapamycin effects on mTORC1 and mTORC2.	Sirolimus	122-131	CREB regulated transcription coactivator 2	Mus musculus	154-160
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mitogen-activated protein kinase associated protein 1	Mus musculus	165-170
25738366-6	2015	Expression of rapamycin-resistant mutant of mTOR (mTOR-T), but not rapamycin-resistant and kinase dead mutant of mTOR (mTOR-TE), prevented rapamycin from inhibiting mSin1 phosphorylation, suggesting that rapamycin-induced dephosphorylation of mSin1 is mTOR-dependent.	Sirolimus	14-23	mitogen-activated protein kinase associated protein 1	Mus musculus	243-248
25866192-3	2015	Here we show that gene expression for several myogenic transcription factors including Myf5, Myog and Mef2c but not MyoD and myosin heavy chain isoforms decrease when C2C12 cells are treated with rapamycin, supporting a role for mTORC1 pathway during muscle development.	Sirolimus	196-205	CREB regulated transcription coactivator 1	Mus musculus	229-235
25738366-9	2015	However, silencing mTOR or mLST8 mimicked the effect of rapamycin, inhibiting mSin1 phosphorylation.	Sirolimus	56-65	mitogen-activated protein kinase associated protein 1	Mus musculus	78-83
25738366-10	2015	Our findings suggest that rapamycin inhibits mSin1 phosphorylation, which is independent of mTORC1 and mTORC2, but is possibly dependent on a new mTOR complex, which at least contains mTOR and mLST8.	Sirolimus	26-35	mitogen-activated protein kinase associated protein 1	Mus musculus	45-50
24859383-3	2015	Here, we show that transduction of nigral DA neurons with hRheb(S16H) significantly increases the levels of phospho-cyclic adenosine monophosphate (cAMP) response element-binding protein (p-CREB), GDNF, and BDNF in neurons, which are attenuated by rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	248-257	Ras homolog, mTORC1 binding	Homo sapiens	58-63
25738366-10	2015	Our findings suggest that rapamycin inhibits mSin1 phosphorylation, which is independent of mTORC1 and mTORC2, but is possibly dependent on a new mTOR complex, which at least contains mTOR and mLST8.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	92-98
25738366-10	2015	Our findings suggest that rapamycin inhibits mSin1 phosphorylation, which is independent of mTORC1 and mTORC2, but is possibly dependent on a new mTOR complex, which at least contains mTOR and mLST8.	Sirolimus	26-35	CREB regulated transcription coactivator 2	Mus musculus	103-109
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	TSC complex subunit 1	Mus musculus	48-51
24859383-3	2015	Here, we show that transduction of nigral DA neurons with hRheb(S16H) significantly increases the levels of phospho-cyclic adenosine monophosphate (cAMP) response element-binding protein (p-CREB), GDNF, and BDNF in neurons, which are attenuated by rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	303-312	Ras homolog, mTORC1 binding	Homo sapiens	58-63
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	TSC complex subunit 1	Mus musculus	134-138
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	TSC complex subunit 1	Mus musculus	140-148
24902807-9	2015	Importantly, pretreatment with 3-methyladenine (autophagy inhibitor) enhanced while rapamycin (autophagy inducer) decreased the expression of LOX-1, TLR4, and P-P38 MAPK.	Sirolimus	84-93	mitogen-activated protein kinase 14	Mus musculus	161-169
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	CREB regulated transcription coactivator 1	Mus musculus	250-256
25537496-4	2015	While compounds used to study mTOR signaling, such as rapamycin and related analogs, primarily inhibit mTORC1, prolonged exposure can also disrupt mTORC2 function, confounding interpretation of inhibitor studies.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	103-109
25613864-5	2015	mTORC1 is a master regulator of growth processes, and its activity can be reduced by withdrawal of growth factors, decreased energy availability, and by the immunosuppressant rapamycin.	Sirolimus	175-184	CREB regulated transcription coactivator 1	Mus musculus	0-6
24632604-9	2015	Long-term treatment with rapamycin reduced both Akt and mTORC1 activity in normal kidney tissues and blocked the development of all types of renal lesions.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	56-62
25788687-8	2015	Furthermore, inhibitory phosphorylation of rictor, a key regulatory/structural subunit of the mTORC2 complex, was increased in AS mice and decreased after rapamycin treatment.	Sirolimus	155-164	CREB regulated transcription coactivator 2	Mus musculus	94-100
26225230-5	2015	Simulated clearance estimates with a sirolimus physiologically based pharmacokinetic model that included CYP3A4/5/7 and CYP2C8 maturation profiles were in close agreement with observed in vivo clearance values.	Sirolimus	37-46	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	120-126
25767889-6	2015	Phosphorylation-deficient mutations in regulatory motifs of Ypk3 abrogate Rps6 phosphorylation, and complementation of ypk3Delta cells with human S6 kinase restores Rps6 phosphorylation in a rapamycin-sensitive manner.	Sirolimus	191-200	ribosomal protein S6	Homo sapiens	165-169
25466898-7	2015	Inhibition of mTOR complex 1 (mTORC1) by rapamycin [drug concentration causing 50% inhibition (IC50) = 5 nM] and mTORC1/mTORC2 by Torin2 (IC50 = 6 nM), or by knocking down key mTORC1/2 components, Raptor and Rictor, respectively, decreased directional cell migration toward CXCL12.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	30-36
25466898-9	2015	It is surprising that mTORC1 disruption by Raptor knockdown was sufficient to reduce tumor growth by 60% and spontaneous metastasis by 72%, which were nearly abolished by rapamycin.	Sirolimus	171-180	CREB regulated transcription coactivator 1	Mus musculus	22-28
25466898-9	2015	It is surprising that mTORC1 disruption by Raptor knockdown was sufficient to reduce tumor growth by 60% and spontaneous metastasis by 72%, which were nearly abolished by rapamycin.	Sirolimus	171-180	regulatory associated protein of MTOR complex 1	Homo sapiens	43-49
26011354-9	2015	Rapamycin induced autophagy, increased the expression of p27 and decreased the expression of Cyclin D1.	Sirolimus	0-9	cyclin D1	Homo sapiens	93-102
25336146-3	2015	In the present study we investigated the effects of combination therapy of rapamycin (an allosteric mTORC1 inhibitor) together with resveratrol (a phytoestrogen that inhibits autophagy).	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	100-106
25404086-13	2015	On the other hand, the removal of CNI with increase in the dose of sirolimus limited the enhancement of the chronicity index at 12 m (SRL, 2.18 vs TAC, 3.12, P = 0.0007), diminished the deposition of fibrosis and promoted the stabilization of TGF-beta, TGF-beta-R2, p-Smad2/3 and myofibroblasts as well as the reduction of TGF-beta-R1 (P = 0.01).	Sirolimus	67-76	SMAD family member 3	Homo sapiens	268-275
25713290-5	2015	Concurrently, global cardiac transcriptional analysis revealed differential expression of 568 genes in Acsl1(H-/-) hearts, a subset of which we hypothesized were targets of mTOR; subsequently, we measured the transcriptional response of several genes after chronic mTOR inhibition via rapamycin treatment during the period in which cardiac hypertrophy develops.	Sirolimus	285-294	acyl-CoA synthetase long-chain family member 1	Mus musculus	103-108
25677111-11	2015	The Rydell score, histological evaluation, hydroxyproline content, vimentin expression level, and inflammatory activity showed the positive effect of RPM in preventing peridural adhesion, inhibiting fibrotic formation and collagen synthesis, and down-regulating inflammation.	Sirolimus	150-153	vimentin	Rattus norvegicus	67-75
25646773-9	2015	However, liver TG levels were significantly reduced in the Tsc1-/-;Pten-/- mice compared to the Pten-/- mice, which was restored with rapamycin.	Sirolimus	134-143	TSC complex subunit 1	Mus musculus	59-63
25428129-7	2015	Inhibition of mTOR with rapamycin partially suppressed the phosphorylation of PERK and eIF2a and the induction of CHOP and GRP78 induction during tunicamycin treatment.	Sirolimus	24-33	eukaryotic translation initiation factor 2 subunit alpha	Homo sapiens	87-92
25213336-8	2015	Rapamycin reversed the conversion from BAT to WAT in Fabp4-Tsc1(-/-) mice.	Sirolimus	0-9	TSC complex subunit 1	Mus musculus	59-63
25673186-5	2015	In our model, Rapamycin had a preferential action on autophagy, increasing the expression of LC3-II/LC3-I, whereas decreasing the expression of Bim and caspase-3.	Sirolimus	14-23	caspase 3	Rattus norvegicus	152-161
25512609-2	2015	In mammals, LD synthesis is inhibited by rapamycin, a known inhibitor of the mTORC1 pathway.	Sirolimus	41-50	CREB regulated transcription coactivator 1	Mus musculus	77-83
25512609-9	2015	The TORC1-controlled transcriptional activators Gln3p, Gat1p, Rtg1p, and Rtg3p, but not Msn2p and Msn4p, were required for full induction of LDs by rapamycin.	Sirolimus	148-157	CREB regulated transcription coactivator 1	Mus musculus	4-9
25512609-9	2015	The TORC1-controlled transcriptional activators Gln3p, Gat1p, Rtg1p, and Rtg3p, but not Msn2p and Msn4p, were required for full induction of LDs by rapamycin.	Sirolimus	148-157	Gat1p	Saccharomyces cerevisiae S288C	55-60
25342595-5	2015	Here, we show that NH4Cl significantly inhibited rapamycin-induced autophagy in HCC cells through decreasing the levels of Beclin-1, autophagy-related protein 7 (ATG7), p62, and autophagosome marker LC3 and significantly decreased the level of phosphorylated SMAD2 in rapamycin-treated HCC cells.	Sirolimus	49-58	autophagy related 7	Homo sapiens	133-160
25342595-5	2015	Here, we show that NH4Cl significantly inhibited rapamycin-induced autophagy in HCC cells through decreasing the levels of Beclin-1, autophagy-related protein 7 (ATG7), p62, and autophagosome marker LC3 and significantly decreased the level of phosphorylated SMAD2 in rapamycin-treated HCC cells.	Sirolimus	49-58	autophagy related 7	Homo sapiens	162-166
25342595-5	2015	Here, we show that NH4Cl significantly inhibited rapamycin-induced autophagy in HCC cells through decreasing the levels of Beclin-1, autophagy-related protein 7 (ATG7), p62, and autophagosome marker LC3 and significantly decreased the level of phosphorylated SMAD2 in rapamycin-treated HCC cells.	Sirolimus	49-58	SMAD family member 2	Homo sapiens	259-264
25342595-7	2015	We found that induction of SMAD2 in HCC cells completely abolished the inhibitory effect of NH4Cl on rapamycin-induced autophagy in HCC cells, suggesting that NH4Cl inhibits autophagy of HCC cells through inhibiting SMAD2 signaling.	Sirolimus	101-110	SMAD family member 2	Homo sapiens	27-32
25342595-7	2015	We found that induction of SMAD2 in HCC cells completely abolished the inhibitory effect of NH4Cl on rapamycin-induced autophagy in HCC cells, suggesting that NH4Cl inhibits autophagy of HCC cells through inhibiting SMAD2 signaling.	Sirolimus	101-110	SMAD family member 2	Homo sapiens	216-221
25442674-2	2015	mTORC1 function is tightly regulated by PI3-K/Akt and is sensitive to rapamycin.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	0-6
26017929-11	2015	Pre-treatment with rapamycin significantly inhibited leptin effects in LD formation, COX-2 and TGF-beta production in IEC-6 cells.	Sirolimus	19-28	leptin	Rattus norvegicus	53-59
26017929-11	2015	Pre-treatment with rapamycin significantly inhibited leptin effects in LD formation, COX-2 and TGF-beta production in IEC-6 cells.	Sirolimus	19-28	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	85-90
26112996-3	2015	METHODS: We stimulated trout primary hepatocytes with different AA levels and employed acute administration of rapamycin to inhibit mTORC1 activation.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	132-138
25145583-4	2015	Here, we show that inhibition of the RPS6 pathway by rapamycin effectively suppressed, whereas blockade of the 4EBP1/eIF4E cascade by 4EBP1A4, an unphosphorylatable form of 4EBP1, significantly delayed, AKT/Ras-induced hepatocarcinogenesis.	Sirolimus	53-62	ribosomal protein S6	Mus musculus	37-41
25689548-1	2015	OBJECTIVES: The aim was to assess the effectiveness and safety profile of a new dedicated bifurcation stent - sirolimus-eluting BiOSS LIM  (Balton, Poland) in 12-month Registry.	Sirolimus	110-119	PDZ and LIM domain 5	Homo sapiens	134-137
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
25615280-4	2015	Activation of autophagy in vitro or in vivo by rapamycin or starvation downregulated oncogenic fusion protein E2A/Pbx1.	Sirolimus	47-56	transcription factor 3	Homo sapiens	110-113
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E	Homo sapiens	189-194
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	132-141	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	0-3
25439783-8	2015	These data suggest that the 4E-BP1/eIF4E ratio is a determinant for the response of TE1 and TE2 cells to rapamycin treatment.	Sirolimus	105-114	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
25439783-8	2015	These data suggest that the 4E-BP1/eIF4E ratio is a determinant for the response of TE1 and TE2 cells to rapamycin treatment.	Sirolimus	105-114	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	92-95
25439783-9	2015	Egr-1 expression was higher in TE2 cells compared with other esophageal cancer cell lines, and its knockdown increased 4E-BP1 expression in TE2 cells, which became sensitive to rapamycin treatment.	Sirolimus	177-186	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	140-143
25439783-12	2015	Thus, the 4E-BP1/eIF4E ratio may represent a therapeutic index for the prediction of clinical outcome of rapamycin treatment in patients with esophageal squamous cell carcinoma.	Sirolimus	105-114	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
25559956-17	2015	CONCLUSIONS: This study demonstrates that RAPA treatment effectively suppresses PQ-induced alveolar collapse and collagen deposition in lung tissues through reducing the expression of TGF-beta1 and alpha-SMA.	Sirolimus	42-46	transforming growth factor, beta 1	Mus musculus	184-193
25185584-2	2015	The TSC protein complex inhibits the mammalian or mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	93-99
25185584-3	2015	Inhibitors of mTORC1, including rapamycin, induce a cytostatic response in TSC tumors, resulting in temporary disease stabilization and prompt regrowth when treatment is stopped.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	14-20
25185584-5	2015	Using a high-throughput chemical screen in TSC2-deficient, patient-derived cells, we identified a series of molecules antagonized by rapamycin and therefore selective for cells with mTORC1 hyperactivity.	Sirolimus	133-142	CREB regulated transcription coactivator 1	Mus musculus	182-188
25239638-2	2015	Sirolimus and everolimus indirectly bind and inhibit mTORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	53-59
25383520-8	2015	Importantly, treatment of established APC-deficient adenomas with rapamycin (which can target eEF2 through the mTORC1-S6K-eEF2K axis) causes tumour cells to undergo growth arrest and differentiation.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Mus musculus	111-117
25383520-8	2015	Importantly, treatment of established APC-deficient adenomas with rapamycin (which can target eEF2 through the mTORC1-S6K-eEF2K axis) causes tumour cells to undergo growth arrest and differentiation.	Sirolimus	66-75	eukaryotic elongation factor 2 kinase	Homo sapiens	122-127
25590801-7	2015	Inhibition of mTORC1 by rapamycin restores Akt activity in eIF2alphaP-deficient cells but renders them highly susceptible to Akt-mediated death by oxidative stress.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
25534817-6	2015	Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice.	Sirolimus	178-187	transforming growth factor, beta 1	Mus musculus	79-87
25524627-1	2015	The mammalian target of rapamycin complex 1 (mTORC1) integrates multiple signals from growth factors, nutrients, and cellular energy status to control a wide range of metabolic processes, including mRNA biogenesis; protein, nucleotide, and lipid synthesis; and autophagy.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	45-51
25524627-3	2015	Recent studies have shown that the mTORC1 inhibitor rapamycin and its analogs generally suppress proliferation rather than induce apoptosis.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	35-41
26378614-6	2015	C2-ceramide (C2), a PPP2A agonist, activated autophagy in GBA-silenced cells, while GBA knockdown-induced SNCA accumulation was reversed by C2 or rapamycin (an autophagy inducer), suggesting that PPP2A plays an important role in the GBA knockdown-mediated inhibition of autophagy.	Sirolimus	146-155	glucosylceramidase beta	Rattus norvegicus	84-87
26378614-6	2015	C2-ceramide (C2), a PPP2A agonist, activated autophagy in GBA-silenced cells, while GBA knockdown-induced SNCA accumulation was reversed by C2 or rapamycin (an autophagy inducer), suggesting that PPP2A plays an important role in the GBA knockdown-mediated inhibition of autophagy.	Sirolimus	146-155	glucosylceramidase beta	Rattus norvegicus	84-87
26323019-7	2015	The reduced level of PA sensitizes mTORC2 to rapamycin at tolerable nano-molar doses leading reduced Akt phosphorylation and apoptosis.	Sirolimus	45-54	CREB regulated transcription coactivator 2	Mus musculus	35-41
26323019-8	2015	This study reveals how the use of AICAR enhances the efficacy of rapamycin such that rapamycin at low nano-molar doses can suppress mTORC2 and induce apoptosis in human cancer cells at doses that are clinically tolerable.	Sirolimus	65-74	CREB regulated transcription coactivator 2	Mus musculus	132-138
26278147-7	2015	Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8, -3, and PARP compared to those treated with topotecan alone.	Sirolimus	40-49	caspase 8	Homo sapiens	107-116
24990517-0	2015	The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts.	Sirolimus	102-111	fibrinogen-like protein 2	Mus musculus	40-65
25340604-6	2015	The treatment with RPM, but not Torin 1, resulted in the enhanced activation of the mTORC2-Akt signaling pathway activation in livers after reperfusion.	Sirolimus	19-22	CREB regulated transcription coactivator 2	Mus musculus	84-90
25976336-8	2015	Rapamycin slightly induced cell apoptosis but significantly enhanced the effect of oxaliplatin in soliciting apoptosis of A2780cis cells, which might be ascribed to its ability in further increasing the levels of cleaved caspase-8 and -3 and PARP induced by oxaliplatin.	Sirolimus	0-9	caspase 8	Homo sapiens	221-237
25340604-10	2015	CONCLUSION: Rapamycin protected livers from IRI by both autophagy and mTORC2-Akt activation mechanisms.	Sirolimus	12-21	CREB regulated transcription coactivator 2	Mus musculus	70-76
25277143-7	2015	Rapamycin, a specific mTOR inhibitor, significantly reversed the inhibitory effect of IFN-gamma on nonopsonized phagocytosis of macrophages and restored c/EBPbeta and MARCO expression.	Sirolimus	0-9	macrophage receptor with collagenous structure	Mus musculus	167-172
25453101-10	2014	On the other hand, rapamycin treatment leads to transient appearance of monomeric mTORC1 before complete disruption of the mTOR-raptor interaction, whereas mTORC2 stoichiometry is unaffected.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	82-88
25439783-6	2015	RESULTS: The 4E-BP1/eIF4E ratio was adjusted to evaluate the response to rapamycin treatment in TE1 and TE2 esophageal cancer cells.	Sirolimus	73-82	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	104-107
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	0-3
25628925-4	2015	In the present study, we describe that AZD2014, a small molecular ATP-competitive inhibitor of mTOR, was a highly potent inhibitor of mTORC1 and mTORC2 in human HCC cells, which led to a more thorough inhibition of mTORC1 than rapamycin, and the inhibition of mTORC2 prevented the feedback activation of AKT signaling.	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	134-140
25628925-4	2015	In the present study, we describe that AZD2014, a small molecular ATP-competitive inhibitor of mTOR, was a highly potent inhibitor of mTORC1 and mTORC2 in human HCC cells, which led to a more thorough inhibition of mTORC1 than rapamycin, and the inhibition of mTORC2 prevented the feedback activation of AKT signaling.	Sirolimus	227-236	CREB regulated transcription coactivator 1	Mus musculus	215-221
26623657-8	2015	Rapamycin also mediated an obvious increase in Dil-labeled ox-LDL (Dil-ox-LDL)/LC3 and Dil-ox-LDL/LAMP1 co-localization, which was inhibited by 3-methyladenine (3-MA), an autophagic inhibitor.	Sirolimus	0-9	lysosomal associated membrane protein 1	Homo sapiens	98-103
25514416-8	2014	Incubation of cells with rapamycin, a known inhibitor of mTOR kinase activity, increased the total Edc4 protein expression but at the same time decreased the Edc4 interaction with mTORC1.	Sirolimus	25-34	enhancer of mRNA decapping 4	Homo sapiens	99-103
26623657-9	2015	In addition, significant co-localization of LC3 and LAMP1 occurred in cells pretreated with rapamycin.	Sirolimus	92-101	lysosomal associated membrane protein 1	Homo sapiens	52-57
25514416-8	2014	Incubation of cells with rapamycin, a known inhibitor of mTOR kinase activity, increased the total Edc4 protein expression but at the same time decreased the Edc4 interaction with mTORC1.	Sirolimus	25-34	enhancer of mRNA decapping 4	Homo sapiens	158-162
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	41-45
25514416-8	2014	Incubation of cells with rapamycin, a known inhibitor of mTOR kinase activity, increased the total Edc4 protein expression but at the same time decreased the Edc4 interaction with mTORC1.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	180-186
25653476-9	2015	Furthermore, rapamycin decreased PA-induced nuclear translocation of NFkappaB P65 subunit, thereby NFkappaB-dependent inflammatory cytokines MCP-1 and IL-6 expression and secretion.	Sirolimus	13-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	69-81
25476905-5	2014	Rapamycin (sirolimus) is a known specific inhibitor of mTORC1, whereas S-trans,trans-farnesylthiosalicylic acid (FTS; salirasib) has been shown to inhibit Rheb.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	55-61
25476905-5	2014	Rapamycin (sirolimus) is a known specific inhibitor of mTORC1, whereas S-trans,trans-farnesylthiosalicylic acid (FTS; salirasib) has been shown to inhibit Rheb.	Sirolimus	11-20	CREB regulated transcription coactivator 1	Mus musculus	55-61
25096520-8	2014	On the other hand, the mTORC1 inhibitor rapamycin prevented increases in phosphorylated S6, protein synthesis and myotube diameter.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	23-29
24825564-6	2014	Pretreatment with the mTORC1 inhibitor rapamycin not only alleviated pulmonary arterial pressure and pulmonary arteriolar remodeling but also suppressed hypoxia-induced mTORC1 and Notch3 activation.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	22-28
24825564-6	2014	Pretreatment with the mTORC1 inhibitor rapamycin not only alleviated pulmonary arterial pressure and pulmonary arteriolar remodeling but also suppressed hypoxia-induced mTORC1 and Notch3 activation.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	169-175
25385842-8	2014	Insulin-induced TFR1 expression was blocked by IRP2, but not by IRP1 interference, and disappeared when HL-7702 cells were pretreated with LY294002, triciribine hydrate, or rapamycin.	Sirolimus	173-182	transferrin receptor	Rattus norvegicus	16-20
25216585-8	2014	Moreover, autophagy activation with rapamycin reduced the accumulation of FUS-positive SGs in an autophagy-dependent manner.	Sirolimus	36-45	fused in sarcoma	Mus musculus	74-77
25216585-9	2014	Rapamycin further reduced neurite fragmentation and cell death in neurons expressing mutant FUS under oxidative stress.	Sirolimus	0-9	fused in sarcoma	Mus musculus	92-95
25375091-5	2014	The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model.	Sirolimus	44-53	microtubule associated protein 1 light chain 3 beta	Homo sapiens	116-124
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	mitogen-activated protein kinase 12	Homo sapiens	83-89
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	protein kinase D2	Homo sapiens	91-96
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	protein tyrosine kinase 6	Homo sapiens	102-106
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	mitogen-activated protein kinase 12	Homo sapiens	133-139
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	protein kinase D2	Homo sapiens	141-146
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	protein tyrosine kinase 6	Homo sapiens	152-156
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	mitogen-activated protein kinase 12	Homo sapiens	133-139
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	protein kinase D2	Homo sapiens	141-146
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	protein tyrosine kinase 6	Homo sapiens	152-156
25075795-9	2014	Moreover, inhibition of mTORC1 by rapamycin (2 mg/kg, intraperitoneally) enhanced the anticancer activity of oridonin in mice xenograft models.	Sirolimus	34-43	CREB regulated transcription coactivator 1	Mus musculus	24-30
24925055-3	2015	In this study, we sought evidence of mechanistic target of rapamycin complex 1 (mTORC1) activation in fibrolamellar carcinoma, based on anecdotal reports of tumor response to rapamycin analogs.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	80-86
24114993-5	2014	Targeting mTORC1 with rapamycin effectively inhibited TPA-induced epidermal hyperplasia and hyperproliferation as well as tumor promotion in a dose-dependent manner in both wild-type and BK5.Akt(WT) mice.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	10-16
25073740-4	2014	TORC1 inactivation, via nitrogen deprivation or rapamycin treatment, changes cellular levels of SEA complex members.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Homo sapiens	0-5
24865460-6	2014	Inhibition of mTORC1 by rapamycin restored sensitivity of adrenocortical cells to apoptosis in AdKO but not in wild-type mice.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
24916065-0	2014	Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.	Sirolimus	28-37	glycogen synthase kinase 3 alpha	Homo sapiens	76-81
26339682-4	2015	We here observed the effect of intrathecal infusion of rapamycin, a specific mTORC1 inhibitor, on morphine-induced tolerance and hyperalgesia in a neuropathic pain model in rats induced by the fifth lumbar spinal nerve ligation (SNL).	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	77-83
25256739-3	2014	Herein, we tested whether administration of rapamycin could enhance the efficacy of immunotherapy utilizing Fms-like tyrosine kinase 3 ligand (Ad-Flt3L) and thymidine kinase/ganciclovir (Ad-TK/GCV).	Sirolimus	44-53	FMS-like tyrosine kinase 3 ligand	Mus musculus	146-151
25256739-6	2014	Rapamycin administration also prolonged the survival of Ad-Flt3L + Ad-TK/GCV-treated GL26 tumor-bearing mice, associated with an increase in the frequency of tumor-specific and IFNgamma(+) CD8(+) T cells.	Sirolimus	0-9	FMS-like tyrosine kinase 3 ligand	Mus musculus	59-64
25464856-3	2014	Blockade of inhibitory receptor programmed cell death protein 1 (PD-1) in vivo increased mTOR activity in virus-specific CTLs, and its therapeutic effects were abrogated by the mTOR inhibitor rapamycin.	Sirolimus	192-201	programmed cell death 1	Homo sapiens	32-63
25464856-3	2014	Blockade of inhibitory receptor programmed cell death protein 1 (PD-1) in vivo increased mTOR activity in virus-specific CTLs, and its therapeutic effects were abrogated by the mTOR inhibitor rapamycin.	Sirolimus	192-201	programmed cell death 1	Homo sapiens	65-69
25278019-4	2014	This orexin/GPCR-stimulated mTOR activation is sensitive to rapamycin, an inhibitor of mTOR complex 1 (mTORC1) but is independent of two well known mTORC1 activators, Erk and Akt.	Sirolimus	60-69	hypocretin	Mus musculus	5-11
25278019-4	2014	This orexin/GPCR-stimulated mTOR activation is sensitive to rapamycin, an inhibitor of mTOR complex 1 (mTORC1) but is independent of two well known mTORC1 activators, Erk and Akt.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	103-109
25193863-3	2014	We provide evidence that mTORC1 inhibition by rapamycin results in engagement of a negative feedback regulatory loop in malignant medulloblastoma cells, involving phosphorylation of the eukaryotic translation-initiation factor eIF4E.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	25-31
25193863-3	2014	We provide evidence that mTORC1 inhibition by rapamycin results in engagement of a negative feedback regulatory loop in malignant medulloblastoma cells, involving phosphorylation of the eukaryotic translation-initiation factor eIF4E.	Sirolimus	46-55	eukaryotic translation initiation factor 4E	Homo sapiens	227-232
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	RELA proto-oncogene, NF-kB subunit	Homo sapiens	165-168
25243405-11	2014	Finally, we found that the effects of ICK or MOK knockdown on cilium length and IFT are suppressed by rapamycin treatment, suggesting that these effects require the mTORC1 pathway.	Sirolimus	102-111	CREB regulated transcription coactivator 1	Mus musculus	165-171
24847003-2	2014	In human ADPKD studies, sirolimus, a mammalian target of rapamycin complex 1 (mTORC1) inhibitor, had little therapeutic effect.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	78-84
24847003-3	2014	While sirolimus robustly inhibits mTORC1, it has a minimal effect on mTOR complex 2 (mTORC2).	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	34-40
25115395-8	2014	Inhibition of mTOR activity by rapamycin sensitized Aur-A-overexpressed breast cancer cells to metabolic stress-induced cell death.	Sirolimus	31-40	aurora kinase A	Homo sapiens	52-57
25053409-2	2014	In contrast, low doses of rapamycin (10 mug/kg) increase mTORC1 activity and protein synthesis in skeletal muscle.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	57-63
24908670-4	2014	We found that mTORC1 activity was upregulated in Flcn-deficient hearts, and that rapamycin treatment significantly reduced heart mass and ameliorated cardiac dysfunction.	Sirolimus	81-90	folliculin	Mus musculus	49-53
25174408-9	2014	Finally, rapamycin, an mTORC1 inhibitor, was used to treat the CAC model.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	23-29
25157160-6	2014	Inhibition of mTOR signaling by rapamycin markedly attenuated ghrelin-induced up-regulation of lipogenesis in hepatocytes, whereas activation of hepatic mTOR signaling by deletion of TSC1 increased hepatic lipogenesis.	Sirolimus	32-41	ghrelin	Mus musculus	62-69
25288394-1	2014	Genetic studies have shown that the tuberous sclerosis complex (TSC) 1-TSC2-mammalian target of Rapamycin (mTOR) and the Hippo-Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis.	Sirolimus	96-105	TSC complex subunit 1	Mus musculus	64-67
25288394-1	2014	Genetic studies have shown that the tuberous sclerosis complex (TSC) 1-TSC2-mammalian target of Rapamycin (mTOR) and the Hippo-Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis.	Sirolimus	96-105	Yes1 associated transcriptional regulator	Homo sapiens	153-156
25326164-3	2014	We describe the case of a twelve-year old male affected by a very late-onset IPEX with intractable enteropathy, which markedly improved after starting Sirolimus as second-line treatment.	Sirolimus	151-160	forkhead box P3	Homo sapiens	77-81
25014022-3	2014	Pharmacologic modulation of autophagy by rapamycin in neuron-Schwann cell explant cultures from neuropathic mice reduced PMP22 aggregate formation and improved myelination.	Sirolimus	41-50	peripheral myelin protein 22	Mus musculus	121-126
25257976-10	2014	In addition, sirolimus suppressed the LPS-induced phosphorylation of p38 and p65 in the THP-1 and human primary monocytes.	Sirolimus	13-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	77-80
25016184-8	2014	We reversed the anti-inflammatory phenotype of Rtp801(-/-) mice with the mTORC1 inhibitor, rapamycin, reassuring against mTORC1-independent effects of Rtp801.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	73-79
25016184-8	2014	We reversed the anti-inflammatory phenotype of Rtp801(-/-) mice with the mTORC1 inhibitor, rapamycin, reassuring against mTORC1-independent effects of Rtp801.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	121-127
25128827-7	2014	Moreover, PGE2 increased colon cancer cell proliferation as well as the growth of colon cancer cell colonies grown in matrigel and blocking mTORC1 by rapamycin or ATP-competitive inhibitors of mTOR abrogated these effects.	Sirolimus	150-159	CREB regulated transcription coactivator 1	Mus musculus	140-146
24851949-0	2014	Rapamycin attenuates pulmonary allergic vasculitis in murine model by reducing TGF-beta production in the lung.	Sirolimus	0-9	transforming growth factor, beta 1	Mus musculus	79-87
24851949-13	2014	CONCLUSIONS: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis with eosinophil infiltration through reducing eosinophil infiltration and TGF-beta production in the lung and inhibition against biological action of TGF-beta.	Sirolimus	13-22	transforming growth factor, beta 1	Mus musculus	179-187
25134448-11	2014	The chemokines, CXCL9 and CXCL10, as the ligands of CXCR3, were also increased in the rapamycin-treated kidney.	Sirolimus	86-95	chemokine (C-X-C motif) ligand 10	Mus musculus	26-32
24851949-13	2014	CONCLUSIONS: Rapamycin suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis with eosinophil infiltration through reducing eosinophil infiltration and TGF-beta production in the lung and inhibition against biological action of TGF-beta.	Sirolimus	13-22	transforming growth factor, beta 1	Mus musculus	255-263
25058027-5	2014	In this study, we used a Cox2 inhibitor, celecoxib, and an mTORC1 inhibitor, rapamycin, in mouse models of EMC and in human EMC cell lines to explore the interactive roles of Cox2 and mTORC1 signaling.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	59-65
25711103-4	2014	It exists in two mTOR protein complexes mTORC1 and mTORC2 with various sensitivity to the inhibitory effect of rapamycin.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	40-46
24869763-6	2014	Recurrent IgAN was diagnosed in 27 of 124 (22%) patients in clinically indicated kidney allograft biopsies over a median follow-up of 6.86 +- 5.4 yr. On cox proportional hazards model multivariate analysis, the hazard risk (HR) of IgAN recurrence was significantly higher in patients managed with steroid-free (HR 8.59: 3.03, 24.38, p &lt; 0.001) and sirolimus-based (HR = 3.00:1.16, 7.75, p = 0.024) immunosuppression without antilymphocyte globulin induction (HR = 4.5: 1.77, 11.73, p = 0.002).	Sirolimus	351-360	IGAN1	Homo sapiens	10-14
25711103-4	2014	It exists in two mTOR protein complexes mTORC1 and mTORC2 with various sensitivity to the inhibitory effect of rapamycin.	Sirolimus	111-120	CREB regulated transcription coactivator 2	Mus musculus	51-57
24962700-3	2014	Although mTOR was originally discovered as a target protein of rapamycin, a natural macrolide immunosuppressant, rapamycin mainly inhibits the kinase activity of mTORC1, whereas mTORC2 is affected to a much lesser extent.	Sirolimus	63-72	CREB regulated transcription coactivator 1	Mus musculus	162-168
24962700-3	2014	Although mTOR was originally discovered as a target protein of rapamycin, a natural macrolide immunosuppressant, rapamycin mainly inhibits the kinase activity of mTORC1, whereas mTORC2 is affected to a much lesser extent.	Sirolimus	63-72	CREB regulated transcription coactivator 2	Mus musculus	178-184
24898389-7	2014	Rapamycin enhanced IL-12 signaling by upregulating IL-12 receptor beta2 expression and signal transducer and activator of transcription factor 4 phosphorylation in CTLs during early infection.	Sirolimus	0-9	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	66-71
25024188-6	2014	This seems to be mediated at least in part through the mammalian target of rapamycin complex 1 (MTORC1) pathway, because levels of Ser757-phosphorylated Unc-51-like kinase 1 (ULK1), an MTORC1 target, were greatly reduced in the G85R SOD1YFP motor neurons, correspondent to an activated state of ULK1 that initiates autophagy.	Sirolimus	75-84	origin recognition complex subunit 1	Homo sapiens	96-102
25082895-4	2014	L-Tsc1 KO mice displayed reduced locomotor activity, body temperature, and hepatic triglyceride content in a rapamycin-sensitive manner.	Sirolimus	109-118	TSC complex subunit 1	Mus musculus	0-9
25024188-6	2014	This seems to be mediated at least in part through the mammalian target of rapamycin complex 1 (MTORC1) pathway, because levels of Ser757-phosphorylated Unc-51-like kinase 1 (ULK1), an MTORC1 target, were greatly reduced in the G85R SOD1YFP motor neurons, correspondent to an activated state of ULK1 that initiates autophagy.	Sirolimus	75-84	unc-51 like autophagy activating kinase 1	Homo sapiens	153-173
25024188-6	2014	This seems to be mediated at least in part through the mammalian target of rapamycin complex 1 (MTORC1) pathway, because levels of Ser757-phosphorylated Unc-51-like kinase 1 (ULK1), an MTORC1 target, were greatly reduced in the G85R SOD1YFP motor neurons, correspondent to an activated state of ULK1 that initiates autophagy.	Sirolimus	75-84	origin recognition complex subunit 1	Homo sapiens	185-191
25024188-6	2014	This seems to be mediated at least in part through the mammalian target of rapamycin complex 1 (MTORC1) pathway, because levels of Ser757-phosphorylated Unc-51-like kinase 1 (ULK1), an MTORC1 target, were greatly reduced in the G85R SOD1YFP motor neurons, correspondent to an activated state of ULK1 that initiates autophagy.	Sirolimus	75-84	unc-51 like autophagy activating kinase 1	Homo sapiens	295-299
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	hepatocyte growth factor	Homo sapiens	31-34
25116684-0	2014	Rapamycin-Induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways.	Sirolimus	0-9	Janus kinase 2	Homo sapiens	89-93
25116684-4	2014	The purpose of our study was to investigate the potential effects of rapamycin on HGF-induced LECs and the underlying mechanisms by which rapamycin exerted its actions.	Sirolimus	69-78	hepatocyte growth factor	Homo sapiens	82-85
25116684-4	2014	The purpose of our study was to investigate the potential effects of rapamycin on HGF-induced LECs and the underlying mechanisms by which rapamycin exerted its actions.	Sirolimus	138-147	hepatocyte growth factor	Homo sapiens	82-85
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	hepatocyte growth factor	Homo sapiens	146-149
25116684-6	2014	Further investigation of the underlying mechanism using siRNA transfection revealed that rapamycin could promote apoptosis of LECs via inhibiting HGF-induced phosphorylation of AKT/mTOR, ERK and JAK2/STAT3 signaling molecules.	Sirolimus	89-98	Janus kinase 2	Homo sapiens	195-199
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	hepatocyte growth factor	Homo sapiens	71-74
25116684-8	2014	Together, these findings suggested that rapamycin-induced apoptosis in HGF-stimulated LECs is accompanied by inhibition of AKT/mTOR, ERK and JAK2/STAT3 pathways, which supports its use to inhibit PCO in preclinical studies and provides theoretical foundation for future possible practice.	Sirolimus	40-49	Janus kinase 2	Homo sapiens	141-145
24973821-6	2014	The mTORC1 inhibitor rapamycin inhibited NK cell cytotoxicity both in mice and humans; this probably contributes to the immunosuppressive activity of this drug in different clinical settings.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
25084011-8	2014	In addition, we revealed that treatment with rapamycin (an mTORC1 inhibitor) aggravated the deficiency in B cell development in the PB and BM.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	59-65
24917666-7	2014	shRNA against the autophagic machinery Atg7 or Atg5 prolonged the survival of neurons co-treated with BDNF and rapamycin, suggesting that suppression of mTOR in BDNF-treated cells resulted in excessive autophagy.	Sirolimus	111-120	autophagy related 7	Homo sapiens	39-43
24910242-5	2014	Notably, rapamycin treatment or hepatocyte-specific ablation of the specific mTORC1 subunit Raptor resulted in elevated interleukin-6 (IL-6) production, activation of signal transducer and activator of transcription 3 (STAT3), and enhanced HCC development, despite a transient reduction in hepatosteatosis.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	77-83
24311731-7	2014	The mTORC1 inhibitor rapamycin, which has some demonstrated activity in a chordoma cell line, delays the onset of tumor formation in our zebrafish model, and improves survival of tumor-bearing fish.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	4-10
25071375-5	2014	In contrast, sirolimus preserved tubulointerstitial structure and attenuated all markers of injury (interstitial ED-1- and alpha-smooth muscle actin-positive cells and tubular vimentin expression; all P&lt;0.05).	Sirolimus	13-22	vimentin	Rattus norvegicus	176-184
24599401-2	2014	TSC1/2 protein complex negatively regulates the mammalian target of rapamycin complex 1 (mTORC1) a master regulator of protein synthesis, cell growth and autophagy.	Sirolimus	68-77	CREB regulated transcription coactivator 1	Mus musculus	89-95
24970820-2	2014	In such cells, as well as in yeast, the selective TORC1 inhibitor rapamycin blocks this activation in contrast to Hsp90 inhibitors which potently activate Hsf1.	Sirolimus	66-75	CREB regulated transcription coactivator 1	Homo sapiens	50-55
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mitogen-activated protein kinase 3	Mus musculus	80-121
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mitogen-activated protein kinase 3	Mus musculus	123-129
24631968-5	2014	AMN082 administered 60 min before the test increased the levels of pmTOR and pp70S6K, and the mTORC1 antagonist rapamycin reversed AMN082-induced changes in the forced swim test (FST) in rats.	Sirolimus	112-121	CREB regulated transcription coactivator 1	Mus musculus	94-100
24970820-6	2014	Rapamycin inhibition of the yeast Hsf1 was abolished by this Hsp90 mutation, as well as with the loss of Ppt1, the Hsp90-interacting protein phosphatase that is the ortholog of mammalian PP5.	Sirolimus	0-9	protein phosphatase 5 catalytic subunit	Homo sapiens	187-190
24650522-4	2014	Utilizing both rapamycin to inhibit mTORC1 activity and shRNA to knock down Rheb, we demonstrated that the decrease in Akt Ser473 phosphorylation stimulated by insulin after C2-ceramide incubation can be prevented.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	36-42
24797334-4	2014	Our observations demonstrate that naringin could increase the level of GDNF in DA neurons, contributing to neuroprotection in the MPP(+) rat model of PD, with activation of mammalian target of rapamycin complex 1.	Sirolimus	193-202	glial cell derived neurotrophic factor	Rattus norvegicus	71-75
24718867-4	2014	EXPERIMENTAL DESIGN: We tested the efficacy of imatinib or PLX3397 either alone or in combination with TORC1 inhibitor rapamycin in a cell proliferation assay in vitro and by immunoblotting to determine target inhibition.	Sirolimus	119-128	CREB regulated transcription coactivator 1	Homo sapiens	103-108
24796670-9	2014	RESULTS: The rapamycin treatment significantly attenuated cisplatin-induced hearing loss, decreased oxidative stress, and alleviated the hair cell damage that was associated with the upregulation of the LC3-II/GAPDH ratio and increased Beclin-1 expression.	Sirolimus	13-22	beclin 1	Rattus norvegicus	236-244
24889507-2	2014	Tsc1 and Tsc2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signalling through Rheb-GTPase.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	93-99
24615339-4	2014	Interestingly, REDD1 induction was impaired in glucocorticoid-resistant ALL cells and inhibition of mTORC1 using rapamycin restored glucocorticoid sensitivity.	Sirolimus	113-122	CREB regulated transcription coactivator 1	Mus musculus	100-106
24462743-7	2014	In addition to HSCT conditioning type, the use of sirolimus was significantly associated with higher BAFF levels after HSCT, and this also was potentially related to lower B cell numbers.	Sirolimus	50-59	TNF superfamily member 13b	Homo sapiens	101-105
24815166-11	2014	Rapamycin treatment also causes the activation of FAK and ILK in a dose-dependent manner.	Sirolimus	0-9	protein tyrosine kinase 2	Homo sapiens	50-53
24107844-8	2014	ILT3/ILT4 expression was increased in kidney biopsies at the end of the study period along with a significant bias toward a Th2 response within the graft only in the rapamycin-treated patients.	Sirolimus	166-175	leukocyte immunoglobulin like receptor B2	Homo sapiens	5-9
24107844-9	2014	Thus, rapamycin induces the upregulation of ILT3 and ILT4 on the DC surface, and this effect is associated with an increase in the number of Tregs and expansion of the CD8(+)CD28(-) T cell population.	Sirolimus	6-15	leukocyte immunoglobulin like receptor B2	Homo sapiens	53-57
24414536-5	2014	RESULTS: We found that treatment with the mTORC1 inhibitor rapamycin reduced the severity of NF2-related Schwann cell tumorigenesis without significant toxicity.	Sirolimus	59-68	neurofibromin 2	Mus musculus	93-96
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	arginase, liver	Mus musculus	57-67
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	transforming growth factor, beta 1	Mus musculus	79-87
24924566-1	2014	OBJECTIVE: To evaluate the influence of sirolimus on the long-term survival of patients after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC).	Sirolimus	40-49	HCC	Homo sapiens	137-167
24604753-9	2014	Consistent with ROCK2 under-expression, microtubule acetylation was found to be increased with tuberin deficiency; this alteration was abrogated by rapamycin treatment and mimicked by HDAC6 inhibition.	Sirolimus	148-157	Rho associated coiled-coil containing protein kinase 2	Homo sapiens	16-21
24915467-1	2014	The activation of the p53 pathway by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a molecule that mimics metabolic stress, is attenuated by rapamycin, an inhibitor of mTOR kinase, immunosuppressant, and cancer drug.	Sirolimus	150-159	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	84-89
24924566-10	2014	CONCLUSION: The sirolimus-based immunosuppressive protocol reduce long-term postoperative recurrence rate and improve the survival rate of patients after OLT for HCC significantly (especially early-mid HCC).	Sirolimus	16-25	HCC	Homo sapiens	162-165
24924566-10	2014	CONCLUSION: The sirolimus-based immunosuppressive protocol reduce long-term postoperative recurrence rate and improve the survival rate of patients after OLT for HCC significantly (especially early-mid HCC).	Sirolimus	16-25	HCC	Homo sapiens	202-205
24515103-7	2014	Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles.	Sirolimus	211-220	transforming growth factor, beta 1	Mus musculus	55-63
25161886-2	2014	A single injection of the mTOR kinase inhibitor, AZD8055, induced a transient, yet marked increase in fat oxidation and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin had no effect.	Sirolimus	177-186	CREB regulated transcription coactivator 1	Mus musculus	160-166
24515103-7	2014	Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles.	Sirolimus	211-220	CREB regulated transcription coactivator 1	Mus musculus	148-154
24515103-7	2014	Western blot and morphological analyses indicated that TGF-beta signaling manipulated primordial follicle growth through tuberous sclerosis complex/mTORC1 signaling in oocytes, and the mTORC1-specific inhibitor rapamycin could partially reverse the stimulated effect of SD208 on the oocyte growth and decreased the numbers of growing follicles.	Sirolimus	211-220	CREB regulated transcription coactivator 1	Mus musculus	185-191
24480570-5	2014	We showed that 28S rRNA pseudouridylation was increased by rapamycin treatment and/or overexpression of snoRNA U19, but only the latter condition improved ribosome efficiency toward higher global translation, thus implying that the mTOR pathway induces pseudouridylation at different sites along the 28S rRNA possibly with either positive or negative effects on the cellular phenotype.	Sirolimus	59-68	serine/threonine-protein kinase mTOR	Cricetulus griseus	232-236
24308646-3	2014	We observed increased autophagy in WRN knockdown cells; this was further increased by short-term rapamycin treatment.	Sirolimus	97-106	WRN RecQ like helicase	Homo sapiens	35-38
24469593-7	2014	Rapamycin reduced drug seeking in signaled non-drug-available periods, PR responding, and cue-induced reinstatement, with these effects linked to reduced mTORC1 activity, total CAMKIIalpha, and GluA1 AMPAR levels in the NACsh.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	154-160
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	glycogen synthase kinase 3 beta	Homo sapiens	127-135
24591659-3	2014	Pivotal clinical trials have demonstrated that inhibition of mTORC1 with sirolimus can induce a partial response of TSC-associated tumours and decrease the rate of lung function decline in females with LAM.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	61-67
24691032-0	2014	Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by rapamycin.	Sirolimus	127-136	CREB regulated transcription coactivator 1	Mus musculus	14-20
24570486-4	2014	We found that at later stages after denervation of fast-twitch muscle, activation of mTORC1 contributed to atrophy and that denervation-induced atrophy was mitigated by inhibition of mTORC1 with rapamycin.	Sirolimus	195-204	CREB regulated transcription coactivator 1	Mus musculus	183-189
24691032-12	2014	We conclude that activation of mTORC1 signaling and protein synthesis in human muscle following BFR exercise is inhibited in the presence of rapamycin.	Sirolimus	141-150	CREB regulated transcription coactivator 1	Mus musculus	31-37
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	activating transcription factor 6	Mus musculus	262-295
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	activating transcription factor 6	Mus musculus	297-301
24375611-4	2014	This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin.	Sirolimus	137-146	forkhead box O3	Rattus norvegicus	71-77
24375611-8	2014	The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins.	Sirolimus	43-52	forkhead box O3	Rattus norvegicus	156-162
24570486-6	2014	Rapamycin treatment of mice restored Akt activity, suggesting that the denervation-induced increase in mTORC1 activity was producing feedback inhibition of Akt.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	103-109
24683191-5	2014	Rapamycin inhibited mTORC1 and enhanced mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	20-26
24683191-5	2014	Rapamycin inhibited mTORC1 and enhanced mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	40-46
24440703-8	2014	We observed that rapamycin significantly enhanced mitophagy, as evidenced by the increase in LC3-II and Beclin-1 expression in the mitochondria and p62 translocation to the mitochondria.	Sirolimus	17-26	annexin A3	Rattus norvegicus	93-96
24440703-8	2014	We observed that rapamycin significantly enhanced mitophagy, as evidenced by the increase in LC3-II and Beclin-1 expression in the mitochondria and p62 translocation to the mitochondria.	Sirolimus	17-26	beclin 1	Rattus norvegicus	104-112
24440703-8	2014	We observed that rapamycin significantly enhanced mitophagy, as evidenced by the increase in LC3-II and Beclin-1 expression in the mitochondria and p62 translocation to the mitochondria.	Sirolimus	17-26	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	148-151
24226526-2	2014	Many of these advances originated from studies of the genetic disease tuberous sclerosis complex (TSC), leading to one of the clearest therapeutic opportunities to target mTOR with rapamycin and its analogs ("rapalogs"), which effectively inhibit mTOR complex 1 (mTORC1) by an allosteric mechanism.	Sirolimus	181-190	CREB regulated transcription coactivator 1	Mus musculus	263-269
23954967-4	2014	We found that rapamycin could significantly increase the expression of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 at the injury site.	Sirolimus	14-23	beclin 1	Rattus norvegicus	128-135
24273170-9	2014	Inhibition of phosphatidylinositol 3-kinase with wortmannin or mTORC1 with rapamycin effectively inhibits the increased assembly observed upon cluster disruption.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	63-69
24614334-8	2014	Rapamycin, an inducer of autophagy, partially weakened the effect of PDCD5 siRNA.	Sirolimus	0-9	programmed cell death 5	Rattus norvegicus	69-74
24404143-0	2014	Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	130-136
24404143-11	2014	Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin.	Sirolimus	89-98	CREB regulated transcription coactivator 1	Mus musculus	45-51
24404143-11	2014	Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin.	Sirolimus	89-98	CREB regulated transcription coactivator 2	Mus musculus	65-71
25495476-0	2014	RAB3GAP1 and RAB3GAP2 modulate basal and rapamycin-induced autophagy.	Sirolimus	41-50	RAB3 GTPase activating non-catalytic protein subunit 2	Homo sapiens	13-21
25495476-4	2014	Employing C. elegans and human primary fibroblasts, we show that RAB3GAP1 and RAB3GAP2, which are components of the TBC domain-free RAB3GAP complex, influence protein aggregation and affect autophagy at basal and rapamycin-induced conditions.	Sirolimus	213-222	RAB3 GTPase activating non-catalytic protein subunit 2	Homo sapiens	78-86
24196830-9	2014	Combinations of metformin and rapamycin were more effective at blocking epidermal mTORC1 signaling induced by TPA consistent with the greater inhibitory effect on skin tumor promotion.	Sirolimus	30-39	CREB regulated transcription coactivator 1	Mus musculus	82-88
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Sirolimus	65-74	CREB regulated transcription coactivator 1	Mus musculus	55-61
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Sirolimus	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	145-188
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Sirolimus	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
24407515-7	2014	In contrast, MCF-7/GSK-3beta(KD) cells displayed an elevated sensitivity to the mTORC1 blocker rapamycin compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells, while no differences between the 3 cell types were observed upon treatment with a MEK inhibitor by itself.	Sirolimus	95-104	glycogen synthase kinase 3 beta	Homo sapiens	19-28
24407515-7	2014	In contrast, MCF-7/GSK-3beta(KD) cells displayed an elevated sensitivity to the mTORC1 blocker rapamycin compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells, while no differences between the 3 cell types were observed upon treatment with a MEK inhibitor by itself.	Sirolimus	95-104	CREB regulated transcription coactivator 1	Mus musculus	80-86
24407515-11	2014	Taken together, these results demonstrate that introduction of GSK-3beta(KD) into MCF-7 breast cancer cells promotes resistance to doxorubicin and tamoxifen, but sensitizes the cells to mTORC1 blockade by rapamycin.	Sirolimus	205-214	glycogen synthase kinase 3 beta	Homo sapiens	63-72
24407515-11	2014	Taken together, these results demonstrate that introduction of GSK-3beta(KD) into MCF-7 breast cancer cells promotes resistance to doxorubicin and tamoxifen, but sensitizes the cells to mTORC1 blockade by rapamycin.	Sirolimus	205-214	CREB regulated transcription coactivator 1	Mus musculus	186-192
25043067-3	2014	This study sought to evaluate the efficacy and safety of HELIOS completed biodegradable polymer sirolimus-eluting stent (SES) in de novo coronary lesions.	Sirolimus	96-105	IKAROS family zinc finger 2	Homo sapiens	57-63
24557881-12	2014	Although rapamycin blocks Rps6-dependent mTORC2 activation, mTORC2 is still activated by an alternative signaling pathway, demonstrating the redundancy in cardioprotective signaling.	Sirolimus	9-18	ribosomal protein S6	Mus musculus	26-30
24557881-12	2014	Although rapamycin blocks Rps6-dependent mTORC2 activation, mTORC2 is still activated by an alternative signaling pathway, demonstrating the redundancy in cardioprotective signaling.	Sirolimus	9-18	CREB regulated transcription coactivator 2	Mus musculus	41-47
24569994-7	2014	Moreover, treatment of fibroblasts over-expressing tTG with PP2, or with inhibitors that inactivate components of the PI3-kinase pathway, including PI3-kinase (LY294002) and mTORC1 (rapamycin), ablated the tTG-promoted survival of the cells.	Sirolimus	182-191	CREB regulated transcription coactivator 1	Mus musculus	174-180
23968562-7	2013	In general, rapamycin inhibits innate and adaptive immune functions of TLR-stimulated human PDC, but enhances the ability of TLR-7-stimulated PDC to stimulate CD4(+) T cell proliferation and induce CD4(+) FoxP3(+) regulatory T cell generation.	Sirolimus	12-21	forkhead box P3	Homo sapiens	205-210
23955309-7	2013	Pretreatment with rapamycin for 15 min attenuated the orexigenic effect of ghrelin.	Sirolimus	18-27	ghrelin and obestatin prepropeptide	Rattus norvegicus	75-82
24337840-5	2013	Administration of 3-methyladenine (3MA), an inhibitor of class III PI3K, abolished autophagy during reperfusion, while employment of rapamycin, an inhibitor of mTORC1 (normally inducing autophagy), surprisingly weakened the induction of autophagy during reperfusion.	Sirolimus	133-142	CREB regulated transcription coactivator 1	Mus musculus	160-166
26824026-10	2013	We found that both rapamycin, a specific mTORC1 blocker, and PP242 a mTOR antagonist induce the arrest of myeloma cells irrespective of bortezomib sensitivity.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	41-47
24608675-8	2014	Inhibition of autophagy with 3MA sensitized SMMC-7721 cells to PA-induced apoptosis, whereas activation of autophagy by rapamycin attenuated PA-induced PARP cleavage.	Sirolimus	120-129	collagen type XI alpha 2 chain	Homo sapiens	152-156
24049142-8	2013	Reactive oxygen species (ROS) increased by 32% after TGF-beta1 exposure for 48 h. TGF-beta activated the mammalian target of rapamycin (mTOR) pathway, and rapamycin reduced the TGF-beta1-stimulated increases in OCR, ECAR, ATP generation, cellular metabolic activity, and protein generation.	Sirolimus	125-134	transforming growth factor, beta 1	Mus musculus	53-62
23932230-5	2013	Treatment of ARH-77 cells with the NF-kappaB inhibitor dimethyl fumarate or the mTOR inhibitor rapamycin suppressed NF-kappaB p65 nuclear translocation and enhanced the cytotoxic effect of melphalan.	Sirolimus	95-104	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-129
23957229-2	2013	Natural compounds FK506, rapamycin and ascomycin, are FKBP12 ligands used for treating organ transplant rejection and other diseases.	Sirolimus	25-34	FKBP prolyl isomerase 1A	Homo sapiens	54-60
24077167-7	2013	TET2 knockdown prevents rapamycin-induced SMC differentiation, whereas TET2 overexpression is sufficient to induce a contractile phenotype.	Sirolimus	24-33	tet methylcytosine dioxygenase 2	Homo sapiens	0-4
24580843-6	2014	These results suggest that everolimus is more effective than sirolimus at antagonizing both mTORC1 and mTORC2, the latter of which is critical in endothelial cell functional changes leading to TV in solid organ transplantation after HLA I crosslinking.	Sirolimus	61-70	CREB regulated transcription coactivator 1	Mus musculus	92-98
24580843-6	2014	These results suggest that everolimus is more effective than sirolimus at antagonizing both mTORC1 and mTORC2, the latter of which is critical in endothelial cell functional changes leading to TV in solid organ transplantation after HLA I crosslinking.	Sirolimus	61-70	CREB regulated transcription coactivator 2	Mus musculus	103-109
24157310-2	2014	We present first two cases with successful implantation of dedicated coronary bifurcation sirolimus eluting stent BiOSS Lim (Balton, Poland) in complex bifurcation and trifurcation lesions of tibioperoneal trunk.	Sirolimus	90-99	PDZ and LIM domain 5	Homo sapiens	120-123
24194895-5	2013	Furthermore, the activation of p38 MAPK/ATF-2 signaling pathway was blocked by the p38 MAPK inhibitor SB253580, whereas adiponectin had a synergistic effect on the suppression of TOR/p70 S6 Kinase signaling pathway with the TOR inhibitor rapamycin.	Sirolimus	238-247	activating transcription factor 2	Gallus gallus	40-45
24315755-2	2014	The objective of this study was to determine the effects of graded rates of insulin infusion on plasma amino acid concentrations and the activation of factors in the mechanistic target of rapamycin signaling pathway in the skeletal muscle of horses.	Sirolimus	188-197	INS	Equus caballus	76-83
24504412-8	2014	Additionally, rapamycin prevented the denervation-induced upregulation of the mTORC2 substrates Akt and SGK.	Sirolimus	14-23	CREB regulated transcription coactivator 2	Mus musculus	78-84
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	forkhead box P3	Homo sapiens	44-49
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	138-144
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Mus musculus	205-211
24414536-5	2014	RESULTS: We found that treatment with the mTORC1 inhibitor rapamycin reduced the severity of NF2-related Schwann cell tumorigenesis without significant toxicity.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	42-48
23584478-2	2014	Rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1), was known to inhibit protein synthesis.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	68-74
24516119-0	2014	Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	81-87
24516119-2	2014	Here we report that rapamycin pretreatment reduced the ability of TNF-treated ECs to capture T cells under conditions of venular flow.	Sirolimus	20-29	eiger	Drosophila melanogaster	66-69
24516119-7	2014	In vivo, rapamycin inhibited mTORC2 activity and potentiated activation of ERK1/2.	Sirolimus	9-18	CREB regulated transcription coactivator 2	Mus musculus	29-35
24598733-2	2014	With only a single previously reported X-ray structure of FKBP12.6, bound to the immunosuppressant rapamycin, structural inferences for this protein have been drawn from the more extensive studies of the homologous FKBP12.	Sirolimus	99-108	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	58-64
24334270-7	2014	As the mTOR inhibitor rapamycin up-regulated PDCD4 mRNA levels, the PI3K-Akt-mTOR signaling pathway may control the transcription of the PDCD4 gene as well as the degradation of the protein.	Sirolimus	22-31	programmed cell death 4	Homo sapiens	45-50
24334270-7	2014	As the mTOR inhibitor rapamycin up-regulated PDCD4 mRNA levels, the PI3K-Akt-mTOR signaling pathway may control the transcription of the PDCD4 gene as well as the degradation of the protein.	Sirolimus	22-31	programmed cell death 4	Homo sapiens	137-142
24499792-7	2014	Treatment of the overexpressing Rheb cells with rapamycin confirms its involvement in the TOR signalling pathway.	Sirolimus	48-57	Ras homolog, mTORC1 binding	Homo sapiens	32-36
24344203-4	2014	We show here that the sensitivity to rapamycin is mediated via inhibition of TORC1 and suppressed by overexpression of isp7(+), a member of the family of 2-oxoglutarate-Fe(II)-dependent oxygenase genes.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Homo sapiens	77-82
23580240-0	2013	Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	34-40
23580240-0	2013	Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.	Sirolimus	72-81	CREB regulated transcription coactivator 2	Mus musculus	41-47
23580240-6	2013	We demonstrate that inhibition of mTORC1 by rapamycin or blocking of mTORC1 and mTORC2 in conjunction with PI3K by NVP-BEZ235 reduces proliferation of MCL cell lines to a similar extent.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	34-40
23880314-6	2013	Inhibition of TORC1-dependent signal pathways by rapamycin from 8 wk suppressed the decline in mitochondria and exercise endurance observed when mice were fed the high-protein diet in association with preserved AMPK activity.	Sirolimus	49-58	CREB regulated transcription coactivator 1	Mus musculus	14-19
24445976-1	2014	OBJECTIVES: Erlotinib and Rapamycin are both in clinical use and experimental inhibition of their respective molecular targets, EGFR and mTORC1, has improved recovery from spinal cord injury.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	137-143
24445976-10	2014	In vitro studies confirmed that Erlotinib and Rapamycin both inhibit the EGFR-mTORC1 signaling pathway.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	78-84
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	CREB regulated transcription coactivator 2	Mus musculus	95-101
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	lymphocyte antigen 6 complex, locus G	Mus musculus	78-82
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	lymphocyte antigen 6 complex, locus G	Mus musculus	301-305
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	lipase A, lysosomal acid type	Homo sapiens	329-332
23720219-11	2013	Rapamycin treatment after seizure onset reduced TORC1 activity and fully abolished the seizures.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	48-53
23948070-8	2013	The active form of the mTOR signaling pathway (p-mTOR, p-4EBP1 and p-p70S6k) at the spinal level remarkably increased in CCI mice, and rapamycin could inhibit this up-regulation.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Mus musculus	23-27
23847175-5	2014	Rapamycin, low serum (&lt;1%) RPMI, and nutrient starvation induction of autophagy also induced an increase in LysoTracker and LC3B signals.	Sirolimus	0-9	microtubule associated protein 1 light chain 3 beta	Homo sapiens	127-131
24101601-5	2014	Inhibition of mTORC1/S6 kinase signaling by rapamycin induced colocalization of mitochondria with autophagosomes, and resulted in a striking progressive decrease in levels of the G11778A mutation and partial restoration of ATP levels.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	14-20
24401275-3	2014	Targeted depletion of MAPK-interacting Ser/Thr kinase 1 (MNK1) sensitizes glioma cells to the mTORC1 inhibitor rapamycin through an indistinct mechanism.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	94-100
24481314-4	2014	Increased mTOR signaling is associated with accelerated aging; in accordance with that, treatment with the mTORC1 inhibitor rapamycin increased lifespan of Bmal1-/- mice by 50%.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Mus musculus	107-113
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	IGAN1	Homo sapiens	47-51
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	IGAN1	Homo sapiens	149-153
25243120-4	2014	We show that chronic exposure of cells to rapamycin can inhibit mTORC2 pathway, and AKT will be destabilized by administration of the HSP90 inhibitor 17-allylamino-geldanamycin (17-AAG).	Sirolimus	42-51	CREB regulated transcription coactivator 2	Mus musculus	64-70
24018642-6	2014	Combination of rapamycin with sunitinib resulted in enhanced cell cycle arrest in G1 phase, which was accompanied with enhanced suppression of mTOR signaling and disruption of the negative feedback loop that activate AKT upon mTORC1 inhibition.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	226-232
24304514-2	2014	The concern with the use of mTORC1 inhibitors, such as rapamycin or its analogs (rapalogs), is that they cause upregulation of autophagy and suppress the negative feedback loop to Akt, which promotes cell survival, causing the therapy to be only partially effective, and relapse occurs upon cessation of treatment.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	28-34
24304514-7	2014	Thus, the addition of resveratrol to rapamycin treatment may be a promising option for selective and targeted therapy for diseases with TSC loss and mTORC1 hyperactivation.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	149-155
24292708-4	2014	Here, we tested the hypothesis that aptamer-targeted siRNA inhibition of mTOR complex 1 (mTORC1) function in CD8(+) T cells can enhance their differentiation into memory T cells and potentiate antitumor immunity more effectively than the pharmacologic inhibitor rapamycin.	Sirolimus	262-271	CREB regulated transcription coactivator 1	Mus musculus	89-95
25379560-10	2014	Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine.	Sirolimus	113-122	interleukin 2 receptor subunit alpha	Homo sapiens	57-61
25379560-11	2014	At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P &lt; 0.001).	Sirolimus	115-124	interleukin 2 receptor subunit alpha	Homo sapiens	34-38
23994018-4	2013	Rapamycin, an inhibitor of mTORC1, suppressed ghrelin-induced phosphorylation of hypothalamic S6K1 and increased food intake and insulin in rats.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	27-33
23994018-4	2013	Rapamycin, an inhibitor of mTORC1, suppressed ghrelin-induced phosphorylation of hypothalamic S6K1 and increased food intake and insulin in rats.	Sirolimus	0-9	ghrelin and obestatin prepropeptide	Rattus norvegicus	46-53
23968562-3	2013	A clinically relevant concentration of rapamycin inhibited Toll-like receptor (TLR)-7-induced IFN-alpha secretion potently (-64%) but TLR-9-induced IFN-alpha secretion only slightly (-20%), while the same concentration suppressed proinflammatory cytokine production by TLR-7-activated and TLR-9-activated PDC with similar efficacy.	Sirolimus	39-48	toll like receptor 9	Homo sapiens	289-294
23968562-4	2013	Rapamycin inhibited the ability of both TLR-7-activated and TLR-9-activated PDC to stimulate production of IFN-gamma and interleukin (IL)-10 by allogeneic T cells.	Sirolimus	0-9	toll like receptor 9	Homo sapiens	60-65
23968562-5	2013	Surprisingly, mTOR-inhibition enhanced the capacity of TLR-7-activated PDC to stimulate naive and memory T helper cell proliferation, which was caused by rapamycin-induced up-regulation of CD80 expression on PDC.	Sirolimus	154-163	CD80 molecule	Homo sapiens	189-193
23968562-6	2013	Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+)  Treg .	Sirolimus	9-18	forkhead box P3	Homo sapiens	93-115
23968562-6	2013	Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+)  Treg .	Sirolimus	9-18	forkhead box P3	Homo sapiens	117-122
23689994-2	2013	Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2.	Sirolimus	124-133	CREB regulated transcription coactivator 1	Homo sapiens	144-149
24108520-6	2013	Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	145-151
24108520-6	2013	Rapamycin increased phosphorylation of raptor at Ser792 and decreased phosphorylation of rictor at Thr1135, suggesting that both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) are involved in GLT-1 expression.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	173-179
24314180-9	2013	Although the systemic administration of rapamycin significantly decreased the levels of phosphorylated mTOR to 4.0+-2.4 in the five treated rabbits, the clinical outcomes were unsatisfactory.	Sirolimus	40-49	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	103-107
24314180-11	2013	CONCLUSIONS: Although rapamycin effectively reduced the mTOR activity in the granulation tissue, the granulation formation process seemed to be disturbed, most likely owing to the immunosuppressive effects of rapamycin.	Sirolimus	22-31	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	56-60
24123525-6	2013	Pharmacological inhibition of mTORC1 activity in vivo by rapamycin treatment leads to a marked, but partial, suppression of primordial follicle activation.	Sirolimus	57-66	CREB regulated transcription coactivator 1	Mus musculus	30-36
24126911-5	2013	Rapamycin treatment led to phosphorylation of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cyclic AMP-responsive elements on the Mkp-1 promoter.	Sirolimus	0-9	activating transcription factor 1	Mus musculus	76-80
24126911-8	2013	Using bone marrow-derived macrophages (BMDMs) derived from wild-type (WT) mice or mice deficient in AKT1 and AKT2 isoforms or BMDM from targeted deficiency in MEK1 and MEK2, we show that rapamycin treatment led to an increased MKP1 expression in BMDM from WT but failed to do so in BMDMs lacking the AKT1 isoform or MEK1 and MEK2.	Sirolimus	187-196	mitogen-activated protein kinase kinase 1	Mus musculus	316-320
24126911-8	2013	Using bone marrow-derived macrophages (BMDMs) derived from wild-type (WT) mice or mice deficient in AKT1 and AKT2 isoforms or BMDM from targeted deficiency in MEK1 and MEK2, we show that rapamycin treatment led to an increased MKP1 expression in BMDM from WT but failed to do so in BMDMs lacking the AKT1 isoform or MEK1 and MEK2.	Sirolimus	187-196	mitogen-activated protein kinase kinase 2	Mus musculus	325-329
24123683-7	2013	However, the concurrent administration of rapamycin, with or without IL-2/anti-IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer.	Sirolimus	42-51	forkhead box P3	Homo sapiens	150-155
24231729-4	2013	The mTOR inhibitor, rapamycin, reduced the viability of CD133(+) pancreatic cancer cells and sphere formation which is an index of self-renewal of stem-like cells, indicating that the mTOR pathway functions to maintain cancer stem-like cells.	Sirolimus	20-29	prominin 1	Homo sapiens	56-61
24078700-3	2013	In this study, we demonstrate that aging increases TORC2 signaling in murine CD4 T cells, a change blocked by long-term exposure to rapamycin, suggesting that functional defects may be the result of enhanced TORC2 function.	Sirolimus	132-141	CREB regulated transcription coactivator 2	Mus musculus	51-56
24078700-3	2013	In this study, we demonstrate that aging increases TORC2 signaling in murine CD4 T cells, a change blocked by long-term exposure to rapamycin, suggesting that functional defects may be the result of enhanced TORC2 function.	Sirolimus	132-141	CREB regulated transcription coactivator 2	Mus musculus	208-213
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	151-157
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	CREB regulated transcription coactivator 1	Mus musculus	277-283
23792225-3	2013	The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs.	Sirolimus	84-93	CREB regulated transcription coactivator 2	Mus musculus	288-294
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	MYD88 innate immune signal transduction adaptor	Homo sapiens	254-259
24036549-3	2013	Recently we demonstrated that hyper-induction of cyclin D1 during geroconversion was mostly dependent on MEK, whereas rapamycin only partially inhibited cyclin D1 accumulation.	Sirolimus	118-127	cyclin D1	Homo sapiens	153-162
24112984-2	2013	Site-specific analysis of mTORC1 substrates now suggests that the sequence composition of a phosphorylation site determines whether it is sensitive to rapamycin and starvation.	Sirolimus	151-160	CREB regulated transcription coactivator 1	Mus musculus	26-32
23928863-6	2013	We confirmed the sirolimus-mediated increase of migration from the adventitial into the intima side using an ex vivo decellularized vessel scaffold, where they form neointima-like lesions that expressed high levels of smooth muscle cell (SMC) markers (SM-22alpha and calponin).	Sirolimus	17-26	transgelin	Homo sapiens	252-262
23928863-9	2013	The ablation of epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, or beta-catenin attenuated sirolimus-induced SM-22alpha promoter activation and SMC differentiation.	Sirolimus	120-129	transgelin	Homo sapiens	138-148
23898020-3	2013	Our study reports on the development of a sirolimus- (SIR) eluting absorbable polymer stent made from a blend of poly(l-lactide) and poly(4-hydroxybutyrate) (PLLA/P4HB) for peripheral vascular intervention.	Sirolimus	42-51	prolyl 4-hydroxylase subunit beta	Homo sapiens	163-167
23948070-8	2013	The active form of the mTOR signaling pathway (p-mTOR, p-4EBP1 and p-p70S6k) at the spinal level remarkably increased in CCI mice, and rapamycin could inhibit this up-regulation.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Mus musculus	49-53
23948070-9	2013	The increased expression of PSD95 and the interaction ratio of GluA2-PSD95 or NR2B-PSD95 could also be inhibited by intrathecal injection of rapamycin.	Sirolimus	141-150	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	78-82
23948070-10	2013	CONCLUSION: These data suggest that the mTOR pathway is activated in the spinal dorsal horn in CCI-induced neuropathic pain, and the intrathecal injection of rapamycin can reduce mechanical allodynia.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	40-44
23801246-4	2013	Like acetylcholine (ACh), a potent vasodilator, acute rapamycin treatment induced the phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) and NO release in brain endothelium.	Sirolimus	54-63	nitric oxide synthase 3, endothelial cell	Mus musculus	145-149
23643747-4	2013	This effect was abolished by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1).	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	182-186
23889243-5	2013	Furthermore, Culicoides-specific CD4(+) CD25(high) regulatory cells were expanded or induced from CD4(+) CD25(-) cells in vitro in the presence of a combination of rIL-2 and rTGF-beta1 (rIL-2/rTGF-beta1) or of retinoic acid and rapamycin (RetA/Rapa).	Sirolimus	228-237	CD4 molecule	Equus caballus	33-36
23856215-9	2013	Our study supports the hypothesis that early initiation of sirolimus offers greater benefits in the treatment of CAV.	Sirolimus	59-68	caveolin 2	Homo sapiens	113-116
23876886-9	2013	Overexpression of KLF2 strongly reversed rapamycin-induced effects on KLF2, eNOS, TM, TF and PAI-1 expression.	Sirolimus	41-50	thrombomodulin	Homo sapiens	82-84
23876886-9	2013	Overexpression of KLF2 strongly reversed rapamycin-induced effects on KLF2, eNOS, TM, TF and PAI-1 expression.	Sirolimus	41-50	coagulation factor III, tissue factor	Homo sapiens	86-88
23876886-9	2013	Overexpression of KLF2 strongly reversed rapamycin-induced effects on KLF2, eNOS, TM, TF and PAI-1 expression.	Sirolimus	41-50	serpin family E member 1	Homo sapiens	93-98
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	105-111
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	146-152
23425014-7	2013	Complementary to it, we further demonstrate that pharmacologically reducing mTOR signaling with rapamycin ameliorates tau pathology and the associated behavioral deficits in a mouse model overexpressing mutant human tau.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Mus musculus	76-80
24010023-3	2013	Rapamycin, a pharmacological inhibitor of mTOR, causes glucose intolerance and inhibits mitochondrial oxidative function.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	42-46
24010023-9	2013	Rapamycin feeding to db/db mice decreased body weight (58%) and fat mass (33%), elevated markers of fatty acid oxidation and mitochondrial biogenesis in WAT, reduced circulating non-esterified free fatty acids (NEFA), elevated circulating adiponectin and improved insulin sensitivity, compared to control diet fed db/db mice.	Sirolimus	0-9	adiponectin, C1Q and collagen domain containing	Mus musculus	239-250
24010023-10	2013	These data demonstrate that rapamycin exhibits an anti-obesity effect and improves whole body insulin sensitivity in db/db mice and suggest an unexpected effect of simultaneous inhibition mTOR and leptin signaling in mice.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	188-192
23313213-14	2013	Rapamycin decreased the obstruction induced expression of Col1a1, Col3a1, Eln and Mmp7.	Sirolimus	0-9	collagen type III alpha 1 chain	Rattus norvegicus	66-72
23651256-5	2013	We show that Aro80 is absolutely required for Gat1 binding to the ARO9, ARO10 and ARO80 promoters upon rapamycin treatment.	Sirolimus	103-112	aromatic-amino-acid:2-oxoglutarate transaminase	Saccharomyces cerevisiae S288C	66-70
23536185-0	2013	Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.	Sirolimus	82-91	protein phosphatase 2 phosphatase activator	Homo sapiens	8-22
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	ribosomal protein S6 kinase B1	Rattus norvegicus	92-101
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	ribosomal protein S6 kinase B1	Rattus norvegicus	103-106
23515290-11	2013	Rapamycin completely blocked the effects of TGF-beta and PGE2 on phosphorylation of p70S6K and S6 but not on AKT phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	84-90
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	57-61
23389992-8	2013	The pretreatment with rapamycin, a specific inhibitor of mTOR, prevented the TNF-alpha elevation and PPAR-gamma reduction and restored the phosphorylation of IRS-1, PI3-K, and Akt in LRP16-overexpressing cells.	Sirolimus	22-31	insulin receptor substrate 1	Mus musculus	158-163
23638184-5	2013	Inhibition of mTOR by rapamycin or expression of a dominant negative eukaryotic initiation factor 4E binding protein 1 (4EBP1) mutant protein, as well as ablation of eukaryotic initiation factor 4E (eIF4E), efficiently abolishes IGF-1-mediated up-regulation of MDM2.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
23638184-6	2013	In addition, we show that rapamycin effectively inhibits MDM2 expression and sensitizes cancer cells to chemotherapy.	Sirolimus	26-35	transformed mouse 3T3 cell double minute 2	Mus musculus	57-61
23523798-3	2013	In this study, potential longevity drugs, including rapamycin, vitamin C, and vitamin E, blocked CKII downregulation-mediated senescence through reduction of reactive oxygen species (ROS) production in HCT116 cells.	Sirolimus	52-61	casein kinase 2 alpha 1	Homo sapiens	97-101
23595747-8	2013	Axonal application of LY294002, a phosphoinositide3-kinase inhibitor, or rapamycin, an mTOR inhibitor, abolished axonal outgrowth enhanced by overexpression of the miR-17-92 cluster.	Sirolimus	73-82	miR-17-92a-1 cluster host gene	Homo sapiens	164-173
23593290-5	2013	Since these tumors are dependent upon the PI3K pathway, we investigated the potential for tumor response by the targeting of this pathway with rapamycin, an mTOR inhibitor.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Mus musculus	157-161
23159330-3	2013	Rapamycin is a potent inhibitor of mTOR and its efficacy in treating epilepsy and neurological symptoms remains elusive.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	35-39
23532775-9	2013	While ND-huCASMCs exhibited the normal increase in p27(Kip1) in response to rapamycin treatment, the DM-huCASMCs did not.	Sirolimus	76-85	cyclin dependent kinase inhibitor 1B	Homo sapiens	55-59
23473038-2	2013	In the first robust demonstration of pharmacologically-induced life extension in mammals, longevity was extended in mice treated with rapamycin, an inhibitor of mechanistic TOR (mTOR).	Sirolimus	134-143	tortured	Mus musculus	173-176
23473038-2	2013	In the first robust demonstration of pharmacologically-induced life extension in mammals, longevity was extended in mice treated with rapamycin, an inhibitor of mechanistic TOR (mTOR).	Sirolimus	134-143	mechanistic target of rapamycin kinase	Mus musculus	178-182
23482748-7	2013	Rapamycin induced eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) hyperphosphorylation in three cell lines.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	69-75
23223022-4	2013	Further, inhibition of miR-7a activates mTOR signaling and promotes adult beta-cell replication in mouse primary islets, which can be reversed by the treatment with a well-known mTOR inhibitor, rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Mus musculus	40-44
23223022-4	2013	Further, inhibition of miR-7a activates mTOR signaling and promotes adult beta-cell replication in mouse primary islets, which can be reversed by the treatment with a well-known mTOR inhibitor, rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Mus musculus	178-182
23143994-5	2013	Maternal administration of rapamycin, a classical mTOR inhibitor, significantly increased the survival time of Fabp4-Tsc1cKO mice for up to 23 days.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Mus musculus	50-54
23143994-5	2013	Maternal administration of rapamycin, a classical mTOR inhibitor, significantly increased the survival time of Fabp4-Tsc1cKO mice for up to 23 days.	Sirolimus	27-36	fatty acid binding protein 4, adipocyte	Mus musculus	111-116
23143994-7	2013	Levels of surfactant proteins A and B demonstrated a significant decrease in the Fabp4-Tsc1cKO mice, which was rescued by maternal injection of rapamycin.	Sirolimus	144-153	fatty acid binding protein 4, adipocyte	Mus musculus	81-86
22892312-1	2013	Using cultured cortical neurons, we show that the blockade of protein phosphatase 2A (PP2A), either pharmacologically by okadaic acid or by short hairpin RNA (shRNA)-mediated silencing of PP2A catalytic subunit, inhibited basal autophagy and autophagy induced in several experimental settings (including serum deprivation, endoplasmic reticulum stress, rapamycin, and proteasome inhibition) at early stages before autophagosome maturation.	Sirolimus	353-362	protein phosphatase 2 phosphatase activator	Homo sapiens	86-90
23924694-7	2013	Map4k4 silencing in cultured adipocytes elevates both the total protein expression and cleavage of sterol-regulated element binding protein-1 (Srebp-1) in a rapamycin-sensitive manner, consistent with Map4k4 signaling via mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	sterol regulatory element binding transcription factor 1	Homo sapiens	99-141
23924694-7	2013	Map4k4 silencing in cultured adipocytes elevates both the total protein expression and cleavage of sterol-regulated element binding protein-1 (Srebp-1) in a rapamycin-sensitive manner, consistent with Map4k4 signaling via mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	sterol regulatory element binding transcription factor 1	Homo sapiens	143-150
22892312-1	2013	Using cultured cortical neurons, we show that the blockade of protein phosphatase 2A (PP2A), either pharmacologically by okadaic acid or by short hairpin RNA (shRNA)-mediated silencing of PP2A catalytic subunit, inhibited basal autophagy and autophagy induced in several experimental settings (including serum deprivation, endoplasmic reticulum stress, rapamycin, and proteasome inhibition) at early stages before autophagosome maturation.	Sirolimus	353-362	protein phosphatase 2 phosphatase activator	Homo sapiens	188-192
24327986-10	2013	Light chain 3, a microtubule-associated protein, which reflect autophagy, was increased with 5 nM of paclitaxel after pretreatment with 10 nM of rapamycin.	Sirolimus	145-154	regulator of microtubule dynamics 1	Homo sapiens	17-47
23607684-3	2013	GBE1 suppression in embryonic cortical neurons led to polyglucosan accumulation and associated apoptosis, which were reversible by rapamycin or starvation treatments.	Sirolimus	131-140	1,4-alpha-glucan branching enzyme 1	Homo sapiens	0-4
23989949-5	2013	Moreover, PTEN-deficient bladder cancer cells were less sensitive to rapamycin than cells expressing wild-type PTEN, and rapamycin strikingly induced Akt activation in the absence of functional PTEN.	Sirolimus	69-78	phosphatase and tensin homolog	Homo sapiens	10-14
23989949-5	2013	Moreover, PTEN-deficient bladder cancer cells were less sensitive to rapamycin than cells expressing wild-type PTEN, and rapamycin strikingly induced Akt activation in the absence of functional PTEN.	Sirolimus	121-130	phosphatase and tensin homolog	Homo sapiens	10-14
24010830-0	2013	Biological constraints limit the use of rapamycin-inducible FKBP12-Inp54p for depleting PIP2 in dorsal root ganglia neurons.	Sirolimus	40-49	FK506 binding protein 1a	Mus musculus	60-66
24010830-6	2013	We hypothesized that after intercrossing these mice, rapamycin treatment would induce translocation of Venus-FKBP12-Inp54p to the plasma membrane in CGRP+ DRG neurons.	Sirolimus	53-62	FK506 binding protein 1a	Mus musculus	109-115
24010830-7	2013	In control experiments with cell lines, rapamycin induced translocation of Venus-FKBP12-Inp54p to the plasma membrane, and subsequent depletion of PIP2, as measured with a PIP2 biosensor.	Sirolimus	40-49	FK506 binding protein 1a	Mus musculus	81-87
24010830-12	2013	Moreover, our data suggest that high levels of endogenous FKBP12 could compete for binding to FRBPLF, hence limiting the use of rapamycin-inducible systems to cells with low levels of endogenous FKBP12.	Sirolimus	128-137	FK506 binding protein 1a	Mus musculus	58-64
23224428-3	2013	Human FKBP12 and some of its paralogues bind to different macrocyclic antibiotics such as FK506 or rapamycin and their derivatives.	Sirolimus	99-108	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	6-12
23673367-7	2013	Furthermore, phosphorylation of PKCepsilon and Akt at the critical S729 and S473 sites respectively was blocked by torin1 or Rictor knockdown but not by rapamycin, indicating that the phosphorylation at these specific sites occurs downstream of mTORC2.	Sirolimus	153-162	protein kinase C epsilon	Homo sapiens	32-42
23313253-3	2013	Rapamycin treatment increased the expression of miR-21 in HUVECs.	Sirolimus	0-9	microRNA 21	Homo sapiens	48-54
23670972-6	2013	Also, we observed that RAPA counteracted IL-2 effects on Treg cells, failed to control IL-2-boosted NK cells, and broke IL-2-induced tolerance in a reversible way.	Sirolimus	23-27	interleukin 2	Mus musculus	41-45
23313253-4	2013	The downregulation of miR-21 by inhibitors abolished the negative effects of rapamycin on endothelial cell growth and mobility.	Sirolimus	77-86	microRNA 21	Homo sapiens	22-28
23611955-2	2013	Rapamycin, a widely used mTOR inhibitor, has been demonstrated to slow down the progression of HIVAN.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	25-29
23392671-10	2013	OB heterotopia, micronodules, and dendrite hypertrophy were notably prevented by rapamycin treatment, suggesting their mTOR dependence.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Mus musculus	119-123
23716625-6	2013	In vitro-cultured human corneal stromal cells were treated with 0 to 500 nM rapamycin for 3 days and then assessed by immunofluorescence staining of vimentin and alpha-smooth muscle actin (alpha-SMA).	Sirolimus	76-85	vimentin	Homo sapiens	149-157
23585690-8	2013	Rapamycin-induced inhibition of mammalian/mechanistic target of rapamycin complex 1 (mTORC1), a mediator of the feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased cytoplasmic FAS enzyme activity, and increased PPARalpha target gene expression.	Sirolimus	0-9	peroxisome proliferator activated receptor alpha	Homo sapiens	244-253
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	transformation related protein 53, pseudogene	Mus musculus	232-235
23769048-6	2013	To control initial graft-reactive immune responses and facilitate FasL-mediated apoptosis, rapamycin was used as an immunosuppressant at 0.2 mg/kg daily for a total of 15 doses immediately after heart transplantation.	Sirolimus	91-100	Fas ligand	Homo sapiens	66-70
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	138-141
22955948-4	2013	Our results demonstrated that the pro-death function of IKK-beta under oxidative stress was mediated by p85 S6K1 (S6 kinase 1), but not p70 S6K1 through a rapamycin-insensitive and mammalian target of rapamycin complex 1 kinase-independent mechanism.	Sirolimus	155-164	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	56-64
23819061-4	2013	Rapamycin, an inhibitor of mTOR complex 1, reduced the level of HIF-1 alpha and blocked phosphorylation of ribosomal protein S6 kinase 1 (S6K), a transcriptional regulator of mTOR, demonstrating that hypoxia activates mTOR/S6K/HIF-1 alpha signaling in CCA.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	223-226
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	125-134	protein phosphatase 2 phosphatase activator	Homo sapiens	44-48
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	125-134	protein phosphatase 2 phosphatase activator	Homo sapiens	100-104
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	125-134	protein phosphatase 2 phosphatase activator	Homo sapiens	100-104
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	168-177	protein phosphatase 2 phosphatase activator	Homo sapiens	44-48
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	168-177	protein phosphatase 2 phosphatase activator	Homo sapiens	100-104
23536185-8	2013	In several cancer cell lines, inhibition of PP2A with okadaic acid, fostriecin, small T antigen, or PP2A knockdown abrogated rapamycin-induced Akt phosphorylation, and rapamycin increased PP2A activity.	Sirolimus	168-177	protein phosphatase 2 phosphatase activator	Homo sapiens	100-104
23536185-10	2013	Exposure of cancer cells to rapamycin increased DNA-PK activity, and gene silencing-mediated PP2A inhibition attenuated rapamycin-induced DNA-PK activity.	Sirolimus	120-129	protein phosphatase 2 phosphatase activator	Homo sapiens	93-97
22769982-0	2013	Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells.	Sirolimus	16-25	forkhead box P3	Mus musculus	118-123
23536185-11	2013	Collectively these results suggest that rapamycin induces PP2A-dependent and DNA-PK-mediated Akt phosphorylation.	Sirolimus	40-49	protein phosphatase 2 phosphatase activator	Homo sapiens	58-62
22769982-10	2013	CONCLUSIONS: Pretreatment with rapamycin for 14 days before an allogenic corneal transplant enhances the percentage of CD4(+)CD25(+)Foxp3(+)Treg cells in peripheral blood, draining lymph nodes, and grafts, thereby inhibiting graft rejection.	Sirolimus	31-40	forkhead box P3	Mus musculus	132-137
23635649-9	2013	Both wortmannin and rapamycin inhibited isoflurane-induced phospho-4E-BP1 (Ser 65) and phospho-P70(s6k) (Thr 389) and HIF-1alpha expression.	Sirolimus	20-29	ribosomal protein S6 kinase B1	Rattus norvegicus	99-102
23274539-7	2013	Inhibition of mTOR signaling by co-treatment with rapamycin or co-transfection with dominant negative p70S6K blocked completely the effects of alpha-terpineol.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Mus musculus	14-18
23591341-9	2013	Cisplatin treatment inhibited the phosphorylation of mTOR/P70S6K, which was most significant at the concentration of 100 mumol/L for 48 h. Cisplatin also induced cell viability loss, which was 12% and 45% at the concentrations of 50, and 100 mumol/L for 24 h. This effect could be enhanced by rapamycin (F=74.890,P&lt;0.01).	Sirolimus	293-302	ribosomal protein S6 kinase B1	Homo sapiens	58-64
23286486-17	2013	Inhibition of mTOR signaling by rapamycin in Nf1+/- osteoclasts abrogated abnormalities in cellular size and number.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
23334408-5	2013	The CL316,243-induced activation of p70(S6K) was markedly inhibited by wortmannin, a PI3K inhibitor, and rapamycin, a specific inhibitor of mTOR, suggesting a critical involvement of the PI3K-mTOR-p70(S6K) signaling cascade in the anabolic response of L6 cells to beta3-AR agonist.	Sirolimus	105-114	ribosomal protein S6 kinase B1	Rattus norvegicus	36-43
23286486-17	2013	Inhibition of mTOR signaling by rapamycin in Nf1+/- osteoclasts abrogated abnormalities in cellular size and number.	Sirolimus	32-41	neurofibromin 1	Mus musculus	45-48
22684415-0	2013	Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	28-34
22684415-12	2013	The rapamycin group showed significantly decreased CVF (1.87 +- 0.45), accompanied with a significant decrease in mTOR and p70S6K mRNA expression (0.42 +- 0.05 and 0.45 +- 0.04) relative to the Adriamycin group.	Sirolimus	4-13	ribosomal protein S6 kinase B1	Rattus norvegicus	123-129
22480837-11	2013	CTGF messenger ribonucleic acid and protein levels were significantly lower in the RAPA group (P &lt; 0.05), whereas E-cadherin expression was higher in the RAPA group at 4, 8, and 12 wk (P &lt; 0.05).	Sirolimus	83-87	cellular communication network factor 2	Rattus norvegicus	0-4
23555162-7	2013	Additionally, involvement of the phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway was also detected by Western blotting.	Sirolimus	98-107	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	33-62
23453111-2	2013	Granulocyte colony-stimulating factor treatment might attenuate endothelial dysfunction after sirolimus-eluting stent (SES) implantation that may be associated with adverse cardiac events during follow-up.	Sirolimus	94-103	colony stimulating factor 3	Homo sapiens	0-37
22480837-11	2013	CTGF messenger ribonucleic acid and protein levels were significantly lower in the RAPA group (P &lt; 0.05), whereas E-cadherin expression was higher in the RAPA group at 4, 8, and 12 wk (P &lt; 0.05).	Sirolimus	157-161	cadherin 1	Rattus norvegicus	117-127
23555865-0	2013	MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).	Sirolimus	26-35	microRNA 21	Homo sapiens	0-11
23298947-8	2013	Our results showed that the MTOR inhibitor rapamycin induced autophagy, promoted mitochondrial clearance and protected cardiomyocytes from the cytotoxic effects of AMA, as assessed by apoptotic marker activation and viability assays in both mouse atrial HL-1 cardiomyocytes and human ventricular AC16 cells.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Mus musculus	28-32
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	transportin 1	Mus musculus	55-60
23555865-13	2013	The regulation of miR-21 by Rapamycin is cell type independent.	Sirolimus	28-37	microRNA 21	Homo sapiens	18-24
23127854-9	2012	Moreover, the exacerbation of OA-induced events by rapamycin suggests that mTOR and PP2A work in concert to regulate cell survival, activated Akt and the levels of ubiquitinated proteins.	Sirolimus	51-60	protein phosphatase 2 phosphatase activator	Homo sapiens	84-88
23364979-5	2013	Furthermore, we also found that TGF-beta1-induced mTOR and p70S6K phosphorylation were significantly down-regulated by rapamycin.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	59-65
23364979-7	2013	CONCLUSION: These results indicate that rapamycin effectively suppresses TGF-beta1-induced type III collagen and fibronectin levels in primary human lung fibroblasts partly through the mTOR/p70S6K pathway.	Sirolimus	40-49	ribosomal protein S6 kinase B1	Homo sapiens	190-196
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Mus musculus	91-95
22999860-0	2012	Rapamycin protects against myocardial ischemia-reperfusion injury through JAK2-STAT3 signaling pathway.	Sirolimus	0-9	Janus kinase 2	Mus musculus	74-78
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	transformation related protein 53, pseudogene	Mus musculus	199-202
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	transformation related protein 53, pseudogene	Mus musculus	232-235
22999860-13	2012	Rapamycin triggered unique cardioprotective signaling including phosphorylation of ERK, STAT3, eNOS and glycogen synthase kinase-3ss in concert with increased prosurvival Bcl-2 to Bax ratio.	Sirolimus	0-9	nitric oxide synthase 3, endothelial cell	Mus musculus	95-99
23454868-3	2013	Here we report that downregulation of mTOR by radiation is Fbxw7-dependent, and short-term mTOR inhibition by rapamycin after exposure to radiation significantly postpones tumor development in Fbxw7/p53 double heterozygous (Fbxw7+/-p53+/-) mice but not in p53 single heterozygous (p53+/-) mice.	Sirolimus	110-119	transformation related protein 53, pseudogene	Mus musculus	232-235
23026948-0	2012	Transplantation: Sirolimus for secondary SCC prevention in renal transplantation.	Sirolimus	17-26	serpin family B member 3	Homo sapiens	41-44
23153588-6	2013	An mTOR inhibitor, rapamycin also inhibited ABCA1, with IC(50) of 18.8muM.	Sirolimus	19-28	serine/threonine-protein kinase mTOR	Mesocricetus auratus	3-7
23233735-6	2013	Correspondingly, a 1.5- to five-fold reduction (P = 0.07) or a two- to three-fold increase (P &lt; 0.001) was found in cell clusters overexpressing mutant p53 in chronically UV-exposed skin of mice that had been fed rapamycin or cyclosporine, respectively.	Sirolimus	216-225	transformation related protein 53, pseudogene	Mus musculus	155-158
22875246-3	2013	We investigated the activation of the AKT/mTOR pathway in CC cell lines with different degrees of dedifferentiation and found that rapamycin could suppress the motility and the peritoneal dissemination of sarcomatoid SCK cells.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Mus musculus	42-46
23255002-6	2013	We also found that the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) or arsenic trioxide (ATO) in combination with rapamycin markedly inhibited the growth of MCF-7 cells and 17-AAG or ATO suppressed rapamycin-induced phosphorylation of Akt.	Sirolimus	133-142	heat shock protein 90 alpha family class A member 1	Homo sapiens	23-28
23255002-6	2013	We also found that the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) or arsenic trioxide (ATO) in combination with rapamycin markedly inhibited the growth of MCF-7 cells and 17-AAG or ATO suppressed rapamycin-induced phosphorylation of Akt.	Sirolimus	217-226	heat shock protein 90 alpha family class A member 1	Homo sapiens	23-28
23222894-6	2013	Rapamycin, but not tacrolimus, induced a pro-antitumor phenotypic shift from CD62LCD44 effector memory Tc cells to CD62LCD44 central memory Tc cells, which featured up-regulated levels of T-bet and Eomes and preserved levels of interferon-gamma and perforin.	Sirolimus	0-9	eomesodermin	Mus musculus	198-203
24186594-6	2013	Rapamycin in a wide range of concentrations (10(-5) to 10(-8) M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the concentration of 10(-5) M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	185-189
24186594-6	2013	Rapamycin in a wide range of concentrations (10(-5) to 10(-8) M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the concentration of 10(-5) M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.	Sirolimus	0-9	collagen type XVIII alpha 1 chain	Homo sapiens	191-201
23349887-12	2013	IL-4, eotaxin, and inflammatory cell numbers were increased after rapamycin and no effect on AHR was observed.	Sirolimus	66-75	interleukin 4	Mus musculus	0-4
23165214-0	2013	Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.	Sirolimus	0-9	CD160 molecule	Homo sapiens	78-83
23165214-5	2013	The expression of both BTLA and CD160 on T cells increased significantly while the expression of LIGHT on T cells decreased significantly in allo-renal recipients receiving Sirolimus regimen (p&lt;0.05).	Sirolimus	173-182	B and T lymphocyte associated	Homo sapiens	23-27
23165214-7	2013	Though regulating the expression of HVEM/BTLA/CD160/LIGHT costimulatory system, Sirolimus-based regimen promotes inhibitory costimulatory signal in T cells and enhances the function of CD4+ Tregs in allo-renal recipients, which are in benefit of the control of transplant rejection as well as the induction and maintenance of transplant tolerance.	Sirolimus	80-89	B and T lymphocyte associated	Homo sapiens	41-45
23165214-7	2013	Though regulating the expression of HVEM/BTLA/CD160/LIGHT costimulatory system, Sirolimus-based regimen promotes inhibitory costimulatory signal in T cells and enhances the function of CD4+ Tregs in allo-renal recipients, which are in benefit of the control of transplant rejection as well as the induction and maintenance of transplant tolerance.	Sirolimus	80-89	CD160 molecule	Homo sapiens	46-51
23006444-7	2012	PLA were significantly reduced in the sirolimus conversion group at V2 (p &lt; 0.02), whereas no effect was seen in the controls.	Sirolimus	38-47	nibrin	Homo sapiens	65-70
23007575-8	2012	The mean relative ratios of URGCP gene expression in DU145, LNCAP and PC3 cells were found as -1.48, 6.59 and -13.00, respectively, when compared to rapamycin-free cells.	Sirolimus	149-158	chromobox 8	Homo sapiens	70-73
22689083-6	2012	Activation of autophagy with rapamycin resulted in increased wogonin-mediated autophagy via inhibition of mTOR/P70S6K pathway.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	111-117
23117593-2	2012	The inhibition of mTOR by rapamycin, or calorie restriction, has been shown to extend lifespan and delays tumorigenesis in several experimental models suggesting that rapamycin may be used for cancer prevention.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Mus musculus	18-22
23117593-2	2012	The inhibition of mTOR by rapamycin, or calorie restriction, has been shown to extend lifespan and delays tumorigenesis in several experimental models suggesting that rapamycin may be used for cancer prevention.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Mus musculus	18-22
23123616-4	2012	We hypothesize that rapamycin can delay cancer in heterozygous p53+/- mice.	Sirolimus	20-29	transformation related protein 53, pseudogene	Mus musculus	63-66
23123616-5	2012	Here we show that rapamycin (given in a drinking water) extended the mean lifespan of p53+/- mice by 10% and when treatment started early in life (at the age less than 5 months) by 28%.	Sirolimus	18-27	transformation related protein 53, pseudogene	Mus musculus	86-89
23128359-0	2012	Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency.	Sirolimus	0-9	transformation related protein 53, pseudogene	Mus musculus	80-83
22859719-12	2012	CONCLUSIONS: These findings indicate that tumorigenesis in 2cKO HNSCC is associated with activation of the Akt/mTOR/survivin pathway, and inhibition of this pathway by rapamycin treatment successfully ameliorates the onset and progression of tumorigenesis.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Mus musculus	111-115
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	96-108
22285179-4	2012	Moreover, rapamycin inhibited AKT/mTOR signalling by dephosphorylation of the downstream target p70S6 kinase (p70S6K).	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	110-116
22285179-8	2012	In conclusion, we demonstrate that rapamycin effectively inhibits HB growth both in vitro and in vivo by blocking AKT/mTOR signalling at the level of p70S6K and that rapamycin should be considered to treat HB patients especially those to be indicated for liver transplantation to benefit from its anti-tumourigenic and immunosuppressive properties.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	150-156
23066439-1	2012	We demonstrate that rapamycin can induce regression of adenomatous polyposis coli (Apc) mutation-dependent colonic adenomas in genetically engineered mice (CPC;Apc).	Sirolimus	20-29	APC, WNT signaling pathway regulator	Mus musculus	83-86
23066439-1	2012	We demonstrate that rapamycin can induce regression of adenomatous polyposis coli (Apc) mutation-dependent colonic adenomas in genetically engineered mice (CPC;Apc).	Sirolimus	20-29	APC, WNT signaling pathway regulator	Mus musculus	160-163
22161643-0	2012	Rapamycin impairs UV induction of mutant-p53 overexpressing cell clusters without affecting tumor onset.	Sirolimus	0-9	transformation related protein 53, pseudogene	Mus musculus	41-44
22161643-12	2012	Thus, we conclude that rapamycin reduces the formation of mutant-p53-expressing cell clusters without affecting tumor onset, suggesting that tumors grow out of a minor subset of cell clusters, the formation of which is not affected by rapamycin.	Sirolimus	23-32	transformation related protein 53, pseudogene	Mus musculus	65-68
22973301-7	2012	Selective inhibition of mTORC1 or mTORC2 by shRNA-mediated knockdown of specific components (Raptor and Rictor, respectively) confirmed that mitochondrial effects of rapamycin are mTORC1-dependent, whereas insulin resistance was recapitulated only by knockdown of mTORC2.	Sirolimus	166-175	RPTOR independent companion of MTOR complex 2	Homo sapiens	104-110
22958927-2	2012	(2012) show that mTOR inhibition with rapamycin protects against mucositis in mice, suggesting potential treatment strategies against this harmful side effect of anticancer therapies.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Mus musculus	17-21
22562362-5	2012	FABP4 was strongly regulated by mTORC1 and inhibited by Rapamycin.	Sirolimus	56-65	fatty acid binding protein 4	Homo sapiens	0-5
22767218-8	2012	Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin.	Sirolimus	137-146	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	63-69
22895182-3	2012	Recently, we reported that inhibition of mTOR using rapamycin reduces neural tissue damage and locomotor impairment after spinal cord injury (SCI) in mice.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Mus musculus	41-45
22725947-0	2012	Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.	Sirolimus	0-9	polycystin 1, transient receptor potential channel interacting	Mus musculus	64-68
21802234-5	2012	One Tsc2(+/-) mouse was treated with rapamycin for two months after the initial scan.	Sirolimus	37-46	TSC complex subunit 2	Mus musculus	4-8
21802234-10	2012	By MRI, these lesions demonstrated significant growth in the 9 untreated Tsc1(+/-) and Tsc2(+/-) mice but shrinkage in the rapamycin treated Tsc2(+/-) mouse.	Sirolimus	123-132	TSC complex subunit 2	Mus musculus	141-145
22763451-9	2012	Treatment of mutant mice with the mTOR inhibitor, rapamycin, prevented the pathological and behavioural deficits.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Mus musculus	34-38
22982730-6	2012	However, rapamycin, an mTOR inhibitor, was able to thoroughly abolish the protective effects of ALA.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	23-27
22982730-8	2012	However, after pre-treatment with rapamycin, the level of Akt phosphorylation was decreased in primary cultures of CECs but could still be restored by ALA, whereas the levels of mTOR, S6K and 4E-BP1 phosphorylation were significantly decreased and could not be restored.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	178-182
23035046-7	2012	The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9.	Sirolimus	19-28	TSC complex subunit 2	Mus musculus	70-74
23035046-7	2012	The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9.	Sirolimus	19-28	matrix metallopeptidase 3	Mus musculus	130-135
23384908-3	2012	The expressions of mTOR, 4E-BP1 and p70S6K at protein and mRNA level in K562 cells with rapamycin treatment were detected by Western blot and RT-PCR.	Sirolimus	88-97	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	25-31
23384908-3	2012	The expressions of mTOR, 4E-BP1 and p70S6K at protein and mRNA level in K562 cells with rapamycin treatment were detected by Western blot and RT-PCR.	Sirolimus	88-97	ribosomal protein S6 kinase B1	Homo sapiens	36-42
22843690-5	2012	Rapamycin (RAPA) and sorafenib, two commonly used drugs for renal cancer treatment, were found to induce HO-1 expression in renal cancer cells Caki-1 and 786-O; and the apoptotic effect of these drugs was markedly enhanced upon HO-1 knockdown.	Sirolimus	0-9	heme oxygenase 1	Homo sapiens	105-109
22843690-5	2012	Rapamycin (RAPA) and sorafenib, two commonly used drugs for renal cancer treatment, were found to induce HO-1 expression in renal cancer cells Caki-1 and 786-O; and the apoptotic effect of these drugs was markedly enhanced upon HO-1 knockdown.	Sirolimus	0-9	heme oxygenase 1	Homo sapiens	228-232
22843690-5	2012	Rapamycin (RAPA) and sorafenib, two commonly used drugs for renal cancer treatment, were found to induce HO-1 expression in renal cancer cells Caki-1 and 786-O; and the apoptotic effect of these drugs was markedly enhanced upon HO-1 knockdown.	Sirolimus	11-15	heme oxygenase 1	Homo sapiens	105-109
22843690-5	2012	Rapamycin (RAPA) and sorafenib, two commonly used drugs for renal cancer treatment, were found to induce HO-1 expression in renal cancer cells Caki-1 and 786-O; and the apoptotic effect of these drugs was markedly enhanced upon HO-1 knockdown.	Sirolimus	11-15	heme oxygenase 1	Homo sapiens	228-232
22843690-6	2012	Overexpression of HO-1 protected the cells from RAPA- and sorafenib-induced apoptosis and also averted drug-mediated inhibition of cell proliferation.	Sirolimus	48-52	heme oxygenase 1	Homo sapiens	18-22
22863314-7	2012	Conversely, further inhibition of TORC1 activity by rapamycin exacerbated the mutant phenotypes.	Sirolimus	52-61	Target of rapamycin	Drosophila melanogaster	34-39
22828505-8	2012	Furthermore, we found that the activity of the pathway as well as the expression of VEGF, a target of mTOR-induced signaling, were reduced within glomeruli of mice following treatment with rapamycin.	Sirolimus	189-198	mechanistic target of rapamycin kinase	Mus musculus	102-106
22587563-3	2012	We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action.	Sirolimus	46-55	tortured	Mus musculus	341-344
22932872-9	2012	These changes in TDP-43 metabolism are accompanied by rapamycin-induced decreases in mTOR-regulated phospho-p70 S6 kinase (P-p70) and the p62 protein, as well as increases in the autophagic marker LC3.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Mus musculus	85-89
22932872-9	2012	These changes in TDP-43 metabolism are accompanied by rapamycin-induced decreases in mTOR-regulated phospho-p70 S6 kinase (P-p70) and the p62 protein, as well as increases in the autophagic marker LC3.	Sirolimus	54-63	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	197-200
22825337-5	2012	Moreover, we show that perifosine, as an Akt inhibitor, decreases rapamycin-induced phosphorylation of GSK3beta and elevated p-GSK3beta levels in rapamycin-resistant cell lines.	Sirolimus	66-75	glycogen synthase kinase 3 beta	Mus musculus	103-111
22825337-5	2012	Moreover, we show that perifosine, as an Akt inhibitor, decreases rapamycin-induced phosphorylation of GSK3beta and elevated p-GSK3beta levels in rapamycin-resistant cell lines.	Sirolimus	66-75	glycogen synthase kinase 3 beta	Mus musculus	127-135
22826320-5	2012	Therapeutic autologous vaccination with DCs treated with TLR agonists plus the mTOR inhibitor rapamycin results in improved generation of Ag-specific CD8+ T cells in vivo and improved antitumor immunity compared with that observed with DCs treated with TLR agonists alone.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Mus musculus	79-83
22710790-5	2012	The apoptotic effect of             rapamycin was measured by caspase-3 activation and flow cytometric analysis of             Annexin V binding.	Sirolimus	36-45	annexin A5	Homo sapiens	127-136
23105977-7	2012	Intranasal rapamycin attenuated lung MCP-1, IL-2, IL-6, and IFNgamma by 70%, 30%, 64%, and 68% respectively.	Sirolimus	11-20	interleukin 2	Mus musculus	44-48
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	37-43
22843885-6	2012	Phosphorylation of mTORC1 substrate, p70S6K at thr389 was reduced by rapamycin and pretreatment with rapamycin abrogated platelet-derived growth factor (PDGF)-induced activation of S6K, as well as that of mTORC2 substrate pAKT(Ser473).	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	37-43
22843885-9	2012	Cell proliferation was increased by 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of medulloblastoma cells, while it was suppressed following treatment with rapamycin or U0126 (MEK1/2 inhibitor).	Sirolimus	164-173	mitogen-activated protein kinase kinase 1	Homo sapiens	184-190
22538197-15	2012	The levels of IL-2 and IFN-gamma in rapamycin+Lef group were significantly lower than that of rapamycin group or Lef group(P&lt;0.05).	Sirolimus	36-45	interleukin 2	Rattus norvegicus	14-18
22538197-15	2012	The levels of IL-2 and IFN-gamma in rapamycin+Lef group were significantly lower than that of rapamycin group or Lef group(P&lt;0.05).	Sirolimus	36-45	interferon gamma	Rattus norvegicus	23-32
21900343-3	2012	Expression of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) was assessed in HUVECs treated with rapamycin (final concentrations: 1, 10, 100, and 1000 ng/mL) for 24 and 48 hours.	Sirolimus	132-141	serpin family E member 1	Homo sapiens	89-94
21900343-5	2012	However, the expression of PAI-1 was induced by rapamycin (P &lt; .05 to &lt; .01).	Sirolimus	48-57	serpin family E member 1	Homo sapiens	27-32
21900343-7	2012	In conclusion, rapamycin inhibited t-PA and induced PAI-1 expression in HUVECs.	Sirolimus	15-24	serpin family E member 1	Homo sapiens	52-57
22488882-6	2012	This striking myelin pathology, with features of human CMT type 4B1 and HNPP, is dependent on AKT/mTOR signalling, as evidenced by a significant amelioration of the pathology in mice treated with rapamycin.	Sirolimus	196-205	peripheral myelin protein 22	Homo sapiens	72-76
22496482-8	2012	However, rapamycin had only a marginal effect on the phosphorylation status of 4E-BP1, another mTORC1 substrate.	Sirolimus	9-18	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	79-85
22316670-6	2012	RESULTS: In isolated hepatocytes, rapamycin induced a 6-fold increase in HO-1, comparable to that induced by cobalt proporphyrin (CoPP), and a 2-fold increase in peroxiredoxin-1.	Sirolimus	34-43	peroxiredoxin 1	Rattus norvegicus	162-177
22698676-9	2012	Systemic rapamycin treatment of mammary tumors grown in a Cav-1-deficient microenvironment significantly inhibited their tumor growth, decreased their stromal content, and reduced the levels of both vimentin and phospho-S6 in Cav-1-deficient cancer-associated fibroblasts.	Sirolimus	9-18	vimentin	Homo sapiens	199-207
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	Fas cell surface death receptor	Homo sapiens	201-205
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	Fas cell surface death receptor	Homo sapiens	229-233
22559167-7	2012	The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR.	Sirolimus	15-24	H3 histone pseudogene 16	Homo sapiens	86-89
22420007-4	2012	Moreover, the effects of sirolimus on basal and IGF2-stimulated H295 cell colony growth and on basal and IGF1-stimulated phospho-AKT, phospho-S6K1, and phospho-ERK in H295 and SW13 were studied.	Sirolimus	25-34	insulin like growth factor 2	Homo sapiens	48-52
22559167-12	2012	The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib.	Sirolimus	178-187	transformation related protein 53, pseudogene	Mus musculus	63-66
22559167-12	2012	The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib.	Sirolimus	178-187	dynactin 6	Mus musculus	68-71
22559167-13	2012	P53 inhibitor PFT-alpha significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent.	Sirolimus	62-71	transformation related protein 53, pseudogene	Mus musculus	0-3
22559167-13	2012	P53 inhibitor PFT-alpha significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent.	Sirolimus	62-71	transformation related protein 53, pseudogene	Mus musculus	187-190
22420007-12	2012	The blocking of endogenously produced IGF2 increased the antiproliferative effects of sirolimus on H295.	Sirolimus	86-95	insulin like growth factor 2	Homo sapiens	38-42
22559167-13	2012	P53 inhibitor PFT-alpha significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent.	Sirolimus	155-164	transformation related protein 53, pseudogene	Mus musculus	0-3
22559167-13	2012	P53 inhibitor PFT-alpha significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent.	Sirolimus	155-164	transformation related protein 53, pseudogene	Mus musculus	187-190
22683661-5	2012	A recent paper published in Science reported that chronic treatment with rapamycin causes a diabetes-like condition in mice by indirectly inhibiting mTOR complex 2.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Mus musculus	149-153
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Mus musculus	44-48
22407942-2	2012	Prolonged treatment with rapamycin inhibits mTOR complex 2 (mTORC2) activity, and both the mTORC1-mediated S6K1 and 4E-BP1/eIF4E pathways are essential for TORC2-mediated RhoA, Cdc42, and Rac1 expression during cell motility and F-actin reorganization.	Sirolimus	25-34	eukaryotic translation initiation factor 4E	Mus musculus	123-128
22343118-3	2012	Here, we studied the effects of a conventional low dose and a higher dose of sirolimus (blood levels of 3 ng/ml and 30-60 ng/ml, respectively) on mTOR activity and renal cystic disease in two Pkd1-mutant mouse models at different stages of the disease.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	146-150
22383528-7	2012	Exogenous ceramide, as well as inhibitors of Akt (Akt inhibitor VIII), PI 3-kinase (LY294002 and wortmannin), and mTOR (rapamycin) reduced secretion of HA, whereas the NSMase2 inhibitor GW4869 increased HA synthesis and secretion.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Mus musculus	114-118
22034068-12	2012	Rapamycin also protected against cell death induced by sodium nitroprusside and TNFalpha plus actinomycin D and prevented sGAG loss induced by IL-1alpha.	Sirolimus	0-9	interleukin 1 alpha	Homo sapiens	143-152
21701901-11	2012	Sirolimus, a specific inhibitor of mTOR pathway, inhibited MHV68-induced hepatic expression of serine p-IRS-1, increased total IRS-1 levels and improved MHV68-induced hepatic insulin resistance.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	104-109
21701901-11	2012	Sirolimus, a specific inhibitor of mTOR pathway, inhibited MHV68-induced hepatic expression of serine p-IRS-1, increased total IRS-1 levels and improved MHV68-induced hepatic insulin resistance.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	127-132
22426206-10	2012	We therefore suggest that PCSK9 inhibition could be an effective way to reduce the adverse side effect of increased LDL levels that is observed in transplant patients taking rapamycin as immunosuppressive therapy.	Sirolimus	174-183	proprotein convertase subtilisin/kexin type 9	Homo sapiens	26-31
22414694-4	2012	In the present study, rapamycin, a mTOR inhibiter, was injected into the mouse of temporal lobe epilepsy.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	35-39
22441016-1	2012	Sirolimus (rapamycin), an inhibitor of the mechanistic target of rapamycin (MTOR), was originally proposed as an immunosuppressant to prevent rejection of solid organ transplants.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	43-74
22441016-1	2012	Sirolimus (rapamycin), an inhibitor of the mechanistic target of rapamycin (MTOR), was originally proposed as an immunosuppressant to prevent rejection of solid organ transplants.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	76-80
22385271-10	2012	The pharmacological inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt axis reduced the neuroprotective effect of rapamycin without affecting autophagy.	Sirolimus	122-131	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	38-67
22461615-3	2012	We demonstrate that rapamycin disrupted a second mTOR complex, mTORC2, in vivo and that mTORC2 was required for the insulin-mediated suppression of hepatic gluconeogenesis.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	49-53
22574368-0	2012	[Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1].	Sirolimus	1-10	ribosomal protein S6 kinase B1	Homo sapiens	89-94
22574368-4	2012	RESULTS: Rapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P&lt;0.01).	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	116-120
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sirolimus	10-19	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	104-108
21806471-2	2012	Rapamycin, an inhibitor of mTOR signaling, can promote autophagy and exert neuroprotective effects in several diseases of the central nervous system (CNS).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
22351078-11	2012	Rapamycin, an inhibitor of mTOR suppressed TNF-alpha protein levels without any significant effect on its mRNA expression or global protein synthesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
22357207-8	2012	Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway.	Sirolimus	32-41	leptin	Homo sapiens	102-108
21806471-7	2012	These results indicate that rapamycin promoted autophagy by inhibiting the mTOR signaling pathway, and reduced neural tissue damage and locomotor impairment after SCI.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	75-79
22376175-0	2012	Rapamycin inhibition of baculovirus recombinant (BVr) ribosomal protein S6 kinase (S6K1) is mediated by an event other than phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	83-87
22137317-3	2012	Compared with either drug alone, dexamethasone+rapamycin showed significantly greater apoptosis and cell cycle arrest in some cell lines, and was more frequently seen in T-lineage cell lines with PTEN mutation.	Sirolimus	47-56	phosphatase and tensin homolog	Homo sapiens	196-200
22171948-4	2012	Treatment with the mTOR inhibitor rapamycin blocked activation of P70S6K and S6, but it also increased activation of AKT and failed to induce cell death.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	66-72
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	109-113
22281494-3	2012	However, the inhibition of mTOR activity by rapamycin (inhibitor of several intracellular pathways including S6K1 pathways) reversed the ER stress-reduced tyrosine phosphorylation of IRS-1 and glucose uptake.	Sirolimus	44-53	insulin receptor substrate 1	Homo sapiens	183-188
22184107-11	2012	4EBP1 phosphorylation, but not that of S6K1, was uniquely resistant to rapamycin in NS5A-Huh7.5 cells, indicative of an alternate phosphorylation mechanism of 4EBP1.	Sirolimus	71-80	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	0-5
22281494-8	2012	Taken together, these results suggest that rapamycin improved ER stress-induced insulin resistance via inhibition of mTOR/S6K1 hyperphosphorylation in L6 myotubes.	Sirolimus	43-52	ribosomal protein S6 kinase B1	Homo sapiens	122-126
22184110-0	2012	Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.	Sirolimus	33-42	phosphatase and tensin homolog	Homo sapiens	84-114
22281494-0	2012	Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	83-87
22184110-5	2012	To explore the mechanism of PTEN regulation, we used rapamycin and constitutively active mTOR to show that TORC1 increases the expression of PTEN mRNA and protein.	Sirolimus	53-62	phosphatase and tensin homolog	Homo sapiens	141-145
22010857-7	2012	Rapamycin, an inhibitor of mTOR kinase, reduced the growth of Tax-transformed CTLL-2 cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
21993902-7	2012	Moreover, treatment of             CML cell line (K562) with rapamycin resulted in a decrease of phosphorylation             of mTOR, 4E-BP1 and p70S6K.	Sirolimus	61-70	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	134-140
21993902-7	2012	Moreover, treatment of             CML cell line (K562) with rapamycin resulted in a decrease of phosphorylation             of mTOR, 4E-BP1 and p70S6K.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	145-151
21993902-9	2012	The data presented an increase of G0/G1 phase cells and decrease of S phase cells             after rapamycin treatment, and the decreased expression of cyclinD1, higher expression             of p21 at mRNA level was also detected in K562 with rapamycin.	Sirolimus	245-254	H3 histone pseudogene 16	Homo sapiens	196-199
22056317-9	2012	Moreover, inhibition of the mTOR complex by rapamycin extinguished the cardiac hypertrophy of the transgenic FAK mice.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Mus musculus	28-32
22285767-7	2012	As in Fragile X, local dendritic translation seems to be abnormally active in Down"s syndrome mice, while rapamycin, a Food and Drug Administration-approved mTOR inhibitor, restores normal rates of translation.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Mus musculus	157-161
22490538-0	2012	[Effect of granulocyte-macrophage colony-stimulating factor on the mammalian target of sirolimus signaling pathway in the wound of rat].	Sirolimus	87-96	colony stimulating factor 2	Homo sapiens	11-59
22056317-9	2012	Moreover, inhibition of the mTOR complex by rapamycin extinguished the cardiac hypertrophy of the transgenic FAK mice.	Sirolimus	44-53	PTK2 protein tyrosine kinase 2	Mus musculus	109-112
22134914-5	2012	Rapamycin inhibition is relieved in transgenic plants deficient in Arabidopsis FK506-binding protein 12 (FKP12), whereas FKP12 overexpression dramatically enhances rapamycin sensitivity.	Sirolimus	164-173	FK506-binding protein 12	Arabidopsis thaliana	121-126
22134914-6	2012	The role of Arabidopsis FKP12 is highly specific as overexpression of seven closely related FKP proteins fails to increase rapamycin sensitivity.	Sirolimus	123-132	FK506-binding protein 12	Arabidopsis thaliana	24-29
22134914-7	2012	Rapamycin exerts TOR inhibition by inducing direct interaction between the TOR-FRB (FKP-rapamycin binding) domain and FKP12 in plant cells.	Sirolimus	0-9	FK506-binding protein 12	Arabidopsis thaliana	118-123
22134914-8	2012	We suggest that variable endogenous FKP12 protein levels may underlie the molecular explanation for longstanding enigmatic observations on inconsistent rapamycin resistance in plants and in various mammalian cell lines or diverse animal cell types.	Sirolimus	152-161	FK506-binding protein 12	Arabidopsis thaliana	36-41
21394501-6	2012	The two mTOR inhibitors, rapamycin and CCI-779, inhibited the invasion of brain metastatic cells only at a moderate concentration level, which was lost at higher concentrations secondary to activation of the MAPK signaling pathway.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Mus musculus	8-12
23006739-6	2012	In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	63-67
22408430-2	2012	mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	44-58
21922152-12	2012	Importantly, knockdown of LRRK2 associated with high proliferative rate in normal             cells and treatment with rapamycin and/or proteosome inhibition suppressed 4E-BP1             protein degradation.	Sirolimus	119-128	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	169-175
20207175-0	2012	Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin.	Sirolimus	74-83	RPTOR independent companion of MTOR complex 2	Homo sapiens	0-6
22001647-3	2011	In a mouse model of I/R injury, we observed robust mTOR activation, and its inhibition by rapamycin increased injury.	Sirolimus	90-99	mechanistic target of rapamycin kinase	Mus musculus	51-55
21994950-4	2011	The ORF45/RSK-mediated eIF4B phosphorylation was distinguishable from that caused by the canonical AKT/mammalian target of rapamycin/ribosomal S6 kinase and MEK/ERK/RSK pathways because it was resistant to both rapamycin (an mammalian target of rapamycin inhibitor) and U1026 (an MEK inhibitor).	Sirolimus	123-132	eukaryotic translation initiation factor 4B	Homo sapiens	23-28
20660299-8	2010	Pharmacologic targeting of mTORC1 with rapamycin also abrogated hCG or FSK-induced phosphorylation of S6K1, rpS6, and eukaryotic initiation factor 4E binding protein 1.	Sirolimus	39-48	ribosomal protein S6 kinase B1	Homo sapiens	102-106
20678995-8	2010	We observed the effectiveness of the activated Akt/mTOR/p70S6K signaling pathway in improving locomotor recovery, significantly increasing the expression of nestin, neuronal nuclei (NeuN), neuron specific enolase (NSE), and neurofilament 200 (NF200), and relatively inhibiting excessive reactive astrogliosis after SCI in a rapamycin-sensitive manner.	Sirolimus	324-333	ribosomal protein S6 kinase B1	Rattus norvegicus	56-62
20457271-5	2010	Similarly, both rapamycin and cicaprost have been reported to regulate levels of the cdk inhibitor, p27(kip1).	Sirolimus	16-25	cyclin dependent kinase inhibitor 1B	Homo sapiens	104-108
20806034-6	2010	RESULTS: Rapamycin significantly inhibited rLEC proliferation and PCNA protein expression when administered doses and time periods except for 0.1 ng/ml for 24 h. bFGF-induced migration rLECs was inhibited by pretreatment with rapamycin for 48 h. Extracellular matrix Fn formation of rLECs was also reduced by rapamycin.	Sirolimus	9-18	proliferating cell nuclear antigen	Oryctolagus cuniculus	66-70
19597415-8	2010	Further characterization of these cells revealed a higher percentage of regulatory T cells characterized by FoxP3-positive cells in high-dose RAPA-treated mice as compared with controls on day 30.	Sirolimus	142-146	forkhead box P3	Mus musculus	108-113
19995915-6	2010	We identified several phosphorylation sites in Rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner.	Sirolimus	139-148	RPTOR independent companion of MTOR complex 2	Homo sapiens	47-53
22178140-9	2012	Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI.	Sirolimus	31-40	vascular endothelial growth factor A	Rattus norvegicus	108-112
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	85-91
22028412-6	2012	An inhibitor of mTOR, rapamycin, attenuated the ANG II-stimulated phosphorylation of p70S6K and phosphorylation of IRS-1 (Ser(636/639)) and blocked the ability of ANG II to impair insulin-stimulated phosphorylation of eNOS, nitric oxide production, and mesenteric-arteriole vasodilation.	Sirolimus	22-31	insulin receptor substrate 1	Homo sapiens	115-120
19995915-6	2010	We identified several phosphorylation sites in Rictor and found that Thr1135 is directly phosphorylated by S6K1 in vitro and in vivo, in a rapamycin-sensitive manner.	Sirolimus	139-148	ribosomal protein S6 kinase B1	Homo sapiens	107-111
20236585-0	2010	[Effects of rapamycin-loaded poly(lactic-co-glycolic) acid nanoparticles on distribution of cell cycle, expression of p27 protein, and proliferation of human umbilical arterial vascular smooth muscle cell in vitro].	Sirolimus	12-21	interferon alpha inducible protein 27	Homo sapiens	118-121
23132575-4	2012	Moreover, the expression of dilp5, an insulin-like peptide, its receptor InR, and the nutrient sensing molecule TOR, the target of rapamycin, was significantly increased in FDRJ-fed female flies as compared with ones reared on standard and on protein-enriched food.	Sirolimus	131-140	Target of rapamycin	Drosophila melanogaster	112-115
21781945-0	2012	Sirolimus--it doesn"t deserve its bad Rap(a).	Sirolimus	0-9	LDL receptor related protein associated protein 1	Homo sapiens	38-41
22785354-11	2012	Finally, blastocysts derived following treatment with 3-MA or rapamycin exhibited significantly decreased expression of selected transcription factors, including Pou5f1, Sox2 and Nanog.	Sirolimus	62-71	POU domain, class 5, transcription factor 1	Sus scrofa	162-168
22785354-11	2012	Finally, blastocysts derived following treatment with 3-MA or rapamycin exhibited significantly decreased expression of selected transcription factors, including Pou5f1, Sox2 and Nanog.	Sirolimus	62-71	homeobox protein NANOG	Sus scrofa	179-184
23227176-3	2012	By contrast, Hxt3 is endocytosed and degraded in the vacuole when cells are starved of glucose and Hxt7 in response to rapamycin treatment or when nitrogen is limiting.	Sirolimus	119-128	hexose transporter HXT3	Saccharomyces cerevisiae S288C	13-17
23139750-11	2012	To determine the significance of Pten status for treatment with the mTOR inhibitor rapamycin we treated 5 MPNST cell lines with rapamycin.	Sirolimus	83-92	phosphatase and tensin homolog	Homo sapiens	33-37
22952934-3	2012	Based on cross-blocking experiments, hR1 recognizes a region of cysteine-rich domain on the alpha-subunit, different from the epitopes mapped for existing anti-IGF-1R antibodies, yet hR1 is similar to other anti-IGF-1R antibodies in downregulating IGF-1R and inhibiting proliferation, colony formation, or invasion of selected cancer cell lines in vitro, as well as suppressing growth of the RH-30 rhabdomyosarcoma xenograft in nude mice when combined with the mTOR inhibitor, rapamycin.	Sirolimus	477-486	CD1b molecule	Homo sapiens	37-40
22848663-5	2012	HBx upregulated cell proliferation and vascular endothelial growth factor (VEGF) production, and these HBx-upregulated phenotypes were abolished by treatment with IKKbeta inhibitor Bay 11-7082 or mTOR inhibitor rapamycin.	Sirolimus	211-220	X protein	Hepatitis B virus	0-3
22848663-5	2012	HBx upregulated cell proliferation and vascular endothelial growth factor (VEGF) production, and these HBx-upregulated phenotypes were abolished by treatment with IKKbeta inhibitor Bay 11-7082 or mTOR inhibitor rapamycin.	Sirolimus	211-220	X protein	Hepatitis B virus	103-106
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	120-127
20068168-2	2010	However, sensitivity to rapamycin is reduced by Akt activation that results from the ablative effects of rapamycin on a p70 S6K-induced negative feedback loop that blunts phosphoinositide 3-kinase (PI3K)-mediated support for Akt activity.	Sirolimus	105-114	ribosomal protein S6 kinase B1	Homo sapiens	120-127
19917848-5	2010	TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines.	Sirolimus	68-77	phosphatase and tensin homolog	Homo sapiens	9-13
19567381-6	2010	In vitro, rapamycin, everolimus, and zotarolimus (each 10(-7) mol/l) enhanced TNF-alpha-induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity.	Sirolimus	10-19	coagulation factor III, tissue factor	Homo sapiens	96-98
22363816-10	2012	Rapamycin (10 nM), a specific mTOR inhibitor, blocked the effects of resveratrol on LPS-induced microglial activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	30-34
19567381-6	2010	In vitro, rapamycin, everolimus, and zotarolimus (each 10(-7) mol/l) enhanced TNF-alpha-induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity.	Sirolimus	10-19	coagulation factor III, tissue factor	Homo sapiens	192-194
22061624-1	2012	AIMS: In this study, we analyzed the mRNA expression of serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) in the human leukemic T-cell line Jurkat cells treated with rapamycin, to determine whether rapamycin inhibiting cell viability is accompanied with the change of mRNA expression of PP2A.	Sirolimus	173-182	protein phosphatase 2 phosphatase activator	Homo sapiens	107-111
22061624-1	2012	AIMS: In this study, we analyzed the mRNA expression of serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) in the human leukemic T-cell line Jurkat cells treated with rapamycin, to determine whether rapamycin inhibiting cell viability is accompanied with the change of mRNA expression of PP2A.	Sirolimus	173-182	protein phosphatase 2 phosphatase activator	Homo sapiens	294-298
20389030-4	2010	Octreotide and rapamycin induced a significant decrease in VEGF production by all three cell lines; LY294002 significantly inhibited VEGF production by STC-1 and INS-r3 only.	Sirolimus	15-24	vascular endothelial growth factor A	Rattus norvegicus	59-63
22061624-1	2012	AIMS: In this study, we analyzed the mRNA expression of serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) in the human leukemic T-cell line Jurkat cells treated with rapamycin, to determine whether rapamycin inhibiting cell viability is accompanied with the change of mRNA expression of PP2A.	Sirolimus	205-214	protein phosphatase 2 phosphatase activator	Homo sapiens	107-111
22061624-6	2012	IC50 was 343.3 nM at 48 h.We also found rapamycin had a dose and time-dependent effect on the gene expression of PP2A.	Sirolimus	40-49	protein phosphatase 2 phosphatase activator	Homo sapiens	113-117
22039046-0	2011	Nitrogen-responsive regulation of GATA protein family activators Gln3 and Gat1 occurs by two distinct pathways, one inhibited by rapamycin and the other by methionine sulfoximine.	Sirolimus	129-138	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	34-38
22192404-10	2011	Treatment with Rapamycin, a potent mTOR/VEGF inhibitor, dramatically suppressed IH cell growth in vitro.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	35-39
24339841-4	2010	Studies also revealed that nuclear translocation of beta-catenin in response to GSK-3 inhibition regulated these processes and was rapamycin sensitive, indicating a role for mTOR.	Sirolimus	131-140	catenin beta 1	Homo sapiens	52-64
22015781-9	2011	Inhibition of mTOR with rapamycin reversed the down-regulation of cellular lipid efflux mediator ABCA1, which resulted from the activation of TLR4 by ligands.	Sirolimus	24-33	toll like receptor 4	Homo sapiens	142-146
19843528-3	2009	We show here that hTERT is expressed soon after lymphocyte activation and that its expression is inhibited by rapamycin, wortmannin, and FK506, which was the most potent inhibitor.	Sirolimus	110-119	telomerase reverse transcriptase	Homo sapiens	18-23
22340098-7	2011	In serum-containing RPM I1640 culture medium, the proportion of ALDH1(br) cells was decreasing as days passed.	Sirolimus	20-23	aldehyde dehydrogenase 1 family member A1	Homo sapiens	64-69
21946849-3	2011	However, rapamycin can exert mTOR-independent actions and systemic administration of rapamycin will inhibit mTOR signalling in all cells throughout the body.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Mus musculus	108-112
21630275-4	2011	Amino acid transporters such as LAT1 and ASCT2 are upregulated in human cancer cells and are thought to stimulate tumor growth by regulating mammalian target of rapamycin through nutrient pathway.	Sirolimus	161-170	solute carrier family 7 member 5	Homo sapiens	32-36
19794149-7	2009	In the RR/KI-mTOR mice, nascent myofiber formation during the early phase of regeneration proceeds in the presence of rapamycin, but growth of the regenerating myofibers is blocked by rapamycin.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Mus musculus	13-17
19794149-7	2009	In the RR/KI-mTOR mice, nascent myofiber formation during the early phase of regeneration proceeds in the presence of rapamycin, but growth of the regenerating myofibers is blocked by rapamycin.	Sirolimus	184-193	mechanistic target of rapamycin kinase	Mus musculus	13-17
19794149-8	2009	Igf2 mRNA levels increase drastically during early regeneration, which is sensitive to rapamycin in wild-type muscles but partially resistant to rapamycin in both RR- and RR/KI-mTOR muscles, consistent with mTOR regulation of Igf2 expression in a kinase-independent manner.	Sirolimus	87-96	insulin-like growth factor 2	Mus musculus	0-4
19794149-8	2009	Igf2 mRNA levels increase drastically during early regeneration, which is sensitive to rapamycin in wild-type muscles but partially resistant to rapamycin in both RR- and RR/KI-mTOR muscles, consistent with mTOR regulation of Igf2 expression in a kinase-independent manner.	Sirolimus	145-154	insulin-like growth factor 2	Mus musculus	0-4
20003889-6	2009	To our knowledge, this is the first report demonstrating that levels of proteins in DHFR-based bicistronic constructs can be induced and modulated using MTX and rapamycin treatment.	Sirolimus	161-170	dihydrofolate reductase	Homo sapiens	84-88
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	interleukin 1 alpha	Mus musculus	167-190
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	interleukin 4	Mus musculus	324-328
20005342-9	2009	Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney.	Sirolimus	0-9	chemokine (C-C motif) ligand 3	Mus musculus	400-410
19244201-7	2009	Treatment of mice with rapamycin 4 weeks after the induction of TGF-alpha prevented additional weight loss, increases in total collagen, and changes in pulmonary mechanics.	Sirolimus	23-32	transforming growth factor alpha	Mus musculus	64-73
21607286-9	2011	Furthermore, mdx Dia, but not TA, muscle mTOR activation was responsive to RAPA treatment.	Sirolimus	75-79	mechanistic target of rapamycin kinase	Mus musculus	41-45
21524191-2	2011	Sirolimus and everolimus inhibited in a dose-dependent manner the uptake of [3H]-estrone sulphate by OATP1A2 and OATP1B1 and that of mycophenolic acid 7-O-glucuronide (MPAG) by OATP1B3.	Sirolimus	0-9	solute carrier organic anion transporter family member 1B1	Homo sapiens	113-120
21737790-6	2011	Rapamycin enhanced autophagy and, at the same time, abolished the effects of GSK-3beta inhibition on both prolonged ischemic injury and I/R injury.	Sirolimus	0-9	glycogen synthase kinase 3 beta	Mus musculus	77-86
21838918-9	2011	Treatment with the mTOR inhibitor rapamycin eliminated decreases in melanin and LC3 II levels by SPC.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	19-23
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	74-80
21602475-11	2011	Mimicking AMPK activators in the presence of insulin, rapamycin inhibited p70S6K and reduced IRS-1 phosphorylation on serine, resulting in the overphosphorylation of PKB/Akt and AS160.	Sirolimus	54-63	insulin receptor substrate 1	Homo sapiens	93-98
21672148-6	2011	Rapamycin treatment of an immortalized proximal tubular cell line induced the expression of Klotho, the phosphorylation of AKT in Ser473, downstream target of mTORC2 and the expression of RICTOR, mTORC2 main component.	Sirolimus	0-9	RPTOR independent companion of MTOR complex 2	Homo sapiens	188-194
21672148-8	2011	In vivo rapamycin treatment induced higher degree of RICTOR and AKT Ser(473) expression directly correlating with long-term rapamycin exposure, FE(PO4) and HOMA index.	Sirolimus	8-17	RPTOR independent companion of MTOR complex 2	Homo sapiens	53-59
21674478-6	2011	Administration of rapamycin partially corrected the MZ defect, indicating a direct role for mTOR in controlling MZ development.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	92-96
21851176-7	2011	Increased autophagy induced by rapamycin reduces accumulation of progerin, an alternate spliced form of lamin A/C, that forms insoluble toxic aggregates, resulting in reduced HGPS-associated nuclear blebbing, growth inhibition, epigenetic dysregulation, and genomic instability.	Sirolimus	31-40	lamin A/C	Homo sapiens	104-113
21610153-9	2011	Rapamycin dramatically enhanced apoptosis induced by etoposide and the expression of cleaved caspase 9.	Sirolimus	0-9	caspase 9	Homo sapiens	93-102
22848242-10	2011	The combination of L-OHP (1 muM) and RAPA (10 nM) induced 19.76% Annexin V-positive cells, which was found to be higher than L-OHP (11.45%, p&lt;0.01) or RAPA (6.89%, p&lt;0.01) alone.	Sirolimus	37-41	annexin A5	Homo sapiens	65-74
19244201-8	2009	Rapamycin prevented further increases in established pulmonary fibrosis induced by EGFR activation.	Sirolimus	0-9	epidermal growth factor receptor	Mus musculus	83-87
21635950-7	2011	CD3(+)CD56(+)NKT cells were also lower during immunosuppressive therapy with tacrolimus (0.03+-0.01/HPF) than with cyclosporine (0.1+-0.003/HPF), cyclosporine/MMF (0.1+-0.003/HPF) or sirolimus (0.1+-0.01/HPF) treatment.	Sirolimus	183-192	neural cell adhesion molecule 1	Homo sapiens	6-10
19749176-6	2009	Thus, Sit4/Sap190 and Sit4/Sap155 holophosphatases apparently play opposing roles following rapamycin treatment, although rapamycin inhibition is operational in the absence of all Sap family members or Sit4.	Sirolimus	92-101	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	6-10
19749176-6	2009	Thus, Sit4/Sap190 and Sit4/Sap155 holophosphatases apparently play opposing roles following rapamycin treatment, although rapamycin inhibition is operational in the absence of all Sap family members or Sit4.	Sirolimus	92-101	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	22-26
19749176-6	2009	Thus, Sit4/Sap190 and Sit4/Sap155 holophosphatases apparently play opposing roles following rapamycin treatment, although rapamycin inhibition is operational in the absence of all Sap family members or Sit4.	Sirolimus	92-101	Sap155p	Saccharomyces cerevisiae S288C	27-33
19749176-6	2009	Thus, Sit4/Sap190 and Sit4/Sap155 holophosphatases apparently play opposing roles following rapamycin treatment, although rapamycin inhibition is operational in the absence of all Sap family members or Sit4.	Sirolimus	92-101	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	22-26
19656910-10	2009	In sirolimus-treated animals, AQP2 expression was reduced.	Sirolimus	3-12	aquaporin 2	Rattus norvegicus	30-34
19702335-6	2009	The upregulation of Seryl-aminoacyl-tRNA-synthetase and Eef2 was sensitive to the mTOR inhibitor rapamycin, as determined by Western blot.	Sirolimus	97-106	eukaryotic translation elongation factor 2	Homo sapiens	56-60
19720874-2	2009	TOR activity can also enhance cell death, and the TOR inhibitor rapamycin protects cells against proapoptotic stimuli.	Sirolimus	64-73	Target of rapamycin	Drosophila melanogaster	50-53
21264854-10	2011	In conclusion, rapamycin formulated with PEG-b-PBC micelles showed significantly reduced toxicity on INS-1E beta-cells and human islets, but had similar biodistribution profiles as those of nanosuspensions.	Sirolimus	15-24	insulin 1	Rattus norvegicus	101-106
20151325-8	2011	Addition of rapamycin (an inhibitor of mTOR) to culture medium completely suppressed leucine-induced activation of mTOR and inhibited leucine-stimulated leptin receptor production.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	39-43
20151325-8	2011	Addition of rapamycin (an inhibitor of mTOR) to culture medium completely suppressed leucine-induced activation of mTOR and inhibited leucine-stimulated leptin receptor production.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	115-119
20151325-8	2011	Addition of rapamycin (an inhibitor of mTOR) to culture medium completely suppressed leucine-induced activation of mTOR and inhibited leucine-stimulated leptin receptor production.	Sirolimus	12-21	leptin receptor	Mus musculus	153-168
21478152-8	2011	Resistin also stimulated the activation of p70(S6K), a downstream kinase target of mTOR, and increased phosphorylation of the IRS1 serine 636/639 residues, whereas treatment with rapamycin reduced the phosphorylation of these residues.	Sirolimus	179-188	insulin receptor substrate 1	Homo sapiens	126-130
21756803-5	2011	RESULTS: Sirolimus induced the expressions of TF and PAI-1 and inhibited the expressions of eNOS and TM in a concentration-dependent manner.	Sirolimus	9-18	coagulation factor III, tissue factor	Homo sapiens	46-48
21756803-5	2011	RESULTS: Sirolimus induced the expressions of TF and PAI-1 and inhibited the expressions of eNOS and TM in a concentration-dependent manner.	Sirolimus	9-18	serpin family E member 1	Homo sapiens	53-58
21756803-5	2011	RESULTS: Sirolimus induced the expressions of TF and PAI-1 and inhibited the expressions of eNOS and TM in a concentration-dependent manner.	Sirolimus	9-18	thrombomodulin	Homo sapiens	101-103
21756803-7	2011	CONCLUSION: Sirolimus induces endothelial antithrombotic dysfunction and shortens the clotting time through an elevated expression of prothrombotic genes TF and PAI-1 and a lowered expression of antithrombotic genes eNOS and TM.	Sirolimus	12-21	coagulation factor III, tissue factor	Homo sapiens	154-156
21756803-7	2011	CONCLUSION: Sirolimus induces endothelial antithrombotic dysfunction and shortens the clotting time through an elevated expression of prothrombotic genes TF and PAI-1 and a lowered expression of antithrombotic genes eNOS and TM.	Sirolimus	12-21	serpin family E member 1	Homo sapiens	161-166
21756803-7	2011	CONCLUSION: Sirolimus induces endothelial antithrombotic dysfunction and shortens the clotting time through an elevated expression of prothrombotic genes TF and PAI-1 and a lowered expression of antithrombotic genes eNOS and TM.	Sirolimus	12-21	thrombomodulin	Homo sapiens	225-227
21228102-4	2011	Both GSK3 inhibitors reduced the phosphorylation of the mTOR downstream target, p70(S6K), indicating that GSK3 inhibition in podocytes is able to cause similar effects as treatment with rapamycin.	Sirolimus	186-195	ribosomal protein S6 kinase B1	Homo sapiens	84-87
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Sirolimus	5-14	catenin beta 1	Homo sapiens	139-151
21367753-5	2011	Rapamycin effectively modulated the protein kinase B (Akt)/mTOR pathway by inhibiting the phosphorylation of Akt and mTOR proteins, and this inhibition was further enhanced by radiation.	Sirolimus	0-9	protein tyrosine kinase 2 beta	Homo sapiens	36-52
19622787-6	2009	Abrogation of S6K activity by the mTOR blocker rapamycin failed to counteract amino acid-induced inhibition of glucose and palmitate oxidation, which therefore was obviously independent of mTOR/S6K signaling (decrease in glucose oxidation by addition of 44 mmol/l amino acids: without rapamycin, -60 +/- 4%; with rapamycin, -50 +/- 13%; NS).	Sirolimus	47-56	ribosomal protein S6 kinase B1	Rattus norvegicus	14-17
21187718-5	2011	In contrast, rapamycin, the mTOR kinase inhibitor, enhanced autophagy and promoted ATRA-induced PML-RARalpha degradation and myeloid cell differentiation.	Sirolimus	13-22	PML nuclear body scaffold	Homo sapiens	96-99
21187718-5	2011	In contrast, rapamycin, the mTOR kinase inhibitor, enhanced autophagy and promoted ATRA-induced PML-RARalpha degradation and myeloid cell differentiation.	Sirolimus	13-22	retinoic acid receptor alpha	Homo sapiens	100-108
21282357-8	2011	Our data show that rapamycin may be a valuable candidate for the development of a treatment modality for EBV-positive lymphomas, such as Burkitt"s lymphoma, and more importantly, provides a basis to develop inhibitors that specifically target viral gene function in tumor cells that depend on LMP2A signaling for survival and/or growth.	Sirolimus	19-28	LMP2A	Human gammaherpesvirus 4	293-298
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	selectin L	Homo sapiens	109-114
18504440-7	2008	Cells infected with a recombinant adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6 kinase 1 (S6K1) conferred to resistance to rapamycin.	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	129-133
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	selectin L	Homo sapiens	126-131
18664580-5	2008	Tumors from Tsc2(+/-)E mu-Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin.	Sirolimus	88-97	TSC complex subunit 2	Mus musculus	12-16
17805960-2	2008	Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin.	Sirolimus	162-171	phosphatase and tensin homolog	Homo sapiens	122-126
18264722-0	2008	Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.	Sirolimus	25-34	insulin receptor substrate 1	Homo sapiens	67-72
18594053-5	2008	DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus.	Sirolimus	191-200	phosphoglycolate phosphatase	Homo sapiens	121-125
18644990-3	2008	Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	79-85
18644990-3	2008	Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	104-110
18278068-6	2008	MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor.	Sirolimus	155-164	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	0-4
18278068-6	2008	MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor.	Sirolimus	155-164	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	86-90
18559511-6	2008	In summary, our findings reveal the existence of a hitherto unrecognized molecular cross-talk between the oncogenic SHH pathway and the tumor suppressor PP2A and suggest a novel mechanism underlying the anticancerogenic effects of rapamycin.	Sirolimus	231-240	sonic hedgehog signaling molecule	Homo sapiens	116-119
18559511-6	2008	In summary, our findings reveal the existence of a hitherto unrecognized molecular cross-talk between the oncogenic SHH pathway and the tumor suppressor PP2A and suggest a novel mechanism underlying the anticancerogenic effects of rapamycin.	Sirolimus	231-240	protein phosphatase 2 phosphatase activator	Homo sapiens	153-157
18431376-0	2008	Rapamycin treatment for a child with germline PTEN mutation.	Sirolimus	0-9	phosphatase and tensin homolog	Homo sapiens	46-50
18424697-2	2008	Pim 2 is a serine/threonine kinase that can confer rapamycin resistance.	Sirolimus	51-60	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
18490844-8	2008	In refed rats, PTB level in the cytoplasmic fraction returned to a level comparable to that in fed rats, but was inhibited by treatment with rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.	Sirolimus	141-150	polypyrimidine tract-binding protein	Rattus norvegicus	15-18
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	67-76	ribosomal protein S6 kinase B1	Rattus norvegicus	57-61
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	78-87	ribosomal protein S6 kinase B1	Rattus norvegicus	57-61
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	78-87	TSC complex subunit 2	Rattus norvegicus	147-151
18281490-2	2008	Indeed, rapamycin, a clinically relevant mTOR inhibitor, promotes the rapid regression of HNSCC-tumor xenografts in mice.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Mus musculus	41-45
21168265-7	2011	We also present data herein that PTEN is an important contributor to resveratrol"s growth suppressive effects and its potentiation of rapamycin in this therapeutic scenario, as resveratrol"s suppression of rapamycin-mediated induction of P-AKT is both PTEN-dependent and -independent.	Sirolimus	134-143	phosphatase and tensin homolog	Homo sapiens	33-37
21168265-7	2011	We also present data herein that PTEN is an important contributor to resveratrol"s growth suppressive effects and its potentiation of rapamycin in this therapeutic scenario, as resveratrol"s suppression of rapamycin-mediated induction of P-AKT is both PTEN-dependent and -independent.	Sirolimus	206-215	phosphatase and tensin homolog	Homo sapiens	33-37
21216928-2	2011	Previous studies from our laboratory have shown that durable responses to rapamycin treatment in a genetically engineered mouse model of Nf1 optic glioma require 20 mg/kg/day, whereas only transient tumor growth suppression was observed with 5 mg/kg/day rapamycin despite complete silencing of ribosomal S6 activity.	Sirolimus	74-83	neurofibromin 1	Mus musculus	137-140
21216928-6	2011	Third, the incomplete suppression of Nf1-deficient glial cell proliferation in vivo following 5 mg/kg/day rapamycin treatment reflects mTOR-mediated AKT activation, such that combined 5 mg/kg/day rapamycin and PI3-kinase (PI3K) inhibition or dual PI3K/mTOR inhibition recapitulates the growth suppressive effects of 20 mg/kg/day rapamycin.	Sirolimus	106-115	neurofibromin 1	Mus musculus	37-40
21216928-6	2011	Third, the incomplete suppression of Nf1-deficient glial cell proliferation in vivo following 5 mg/kg/day rapamycin treatment reflects mTOR-mediated AKT activation, such that combined 5 mg/kg/day rapamycin and PI3-kinase (PI3K) inhibition or dual PI3K/mTOR inhibition recapitulates the growth suppressive effects of 20 mg/kg/day rapamycin.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Mus musculus	135-139
21216928-6	2011	Third, the incomplete suppression of Nf1-deficient glial cell proliferation in vivo following 5 mg/kg/day rapamycin treatment reflects mTOR-mediated AKT activation, such that combined 5 mg/kg/day rapamycin and PI3-kinase (PI3K) inhibition or dual PI3K/mTOR inhibition recapitulates the growth suppressive effects of 20 mg/kg/day rapamycin.	Sirolimus	106-115	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	210-220
21216928-6	2011	Third, the incomplete suppression of Nf1-deficient glial cell proliferation in vivo following 5 mg/kg/day rapamycin treatment reflects mTOR-mediated AKT activation, such that combined 5 mg/kg/day rapamycin and PI3-kinase (PI3K) inhibition or dual PI3K/mTOR inhibition recapitulates the growth suppressive effects of 20 mg/kg/day rapamycin.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Mus musculus	252-256
20709738-0	2011	The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Mus musculus	13-17
20709738-8	2011	Rapamycin prolonged survival, maintained normal renal function, normalized proteinuria, restored nephrin and podocin levels, reduced anti-dsDNA titres, ameliorated histological lesions, and reduced Akt and mTOR glomerular expression activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	206-210
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	58-62
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	186-190
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	186-190
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Mus musculus	58-62
20709738-9	2011	CONCLUSIONS: These results suggest that: (i) the PI3K/Akt/mTOR pathway is upregulated in murine lupus nephritis, thus justifying treatment with rapamycin; (ii) rapamycin not only blocks mTOR but also negatively regulates the PI3K/Akt/mTOR pathway; and (iii) rapamycin is an effective treatment of murine lupus nephritis.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Mus musculus	58-62
21283589-7	2011	Insulin up-regulated alpha-cell proliferation through the IR/IRS2/AKT/mTOR signaling pathway, and increased insulin-mediated proliferation was prevented by pretreatment with rapamycin, a specific mTOR inhibitor.	Sirolimus	174-183	insulin receptor substrate 2	Mus musculus	61-65
21283589-7	2011	Insulin up-regulated alpha-cell proliferation through the IR/IRS2/AKT/mTOR signaling pathway, and increased insulin-mediated proliferation was prevented by pretreatment with rapamycin, a specific mTOR inhibitor.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Mus musculus	70-74
21283589-7	2011	Insulin up-regulated alpha-cell proliferation through the IR/IRS2/AKT/mTOR signaling pathway, and increased insulin-mediated proliferation was prevented by pretreatment with rapamycin, a specific mTOR inhibitor.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Mus musculus	196-200
20727967-6	2011	We also showed that IGF-1 potentiates carbachol-induced Ca(2+) release in AR4-2J cells, an effect that was prevented by rapamycin.	Sirolimus	120-129	insulin-like growth factor 1	Rattus norvegicus	20-25
21114628-0	2011	Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	51-88
18270585-0	2008	Hsf1 activation inhibits rapamycin resistance and TOR signaling in yeast revealed by combined proteomic and genetic analysis.	Sirolimus	25-34	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	0-4
21701975-7	2011	In the presence of rapamycin, tight association between FK506-binding protein (FKBP) and FKBP rapamycin-binding protein (FRB) is observed.	Sirolimus	19-28	FK506 binding protein 1a	Mus musculus	56-77
21701975-7	2011	In the presence of rapamycin, tight association between FK506-binding protein (FKBP) and FKBP rapamycin-binding protein (FRB) is observed.	Sirolimus	19-28	FK506 binding protein 1a	Mus musculus	79-83
21701975-7	2011	In the presence of rapamycin, tight association between FK506-binding protein (FKBP) and FKBP rapamycin-binding protein (FRB) is observed.	Sirolimus	19-28	FK506 binding protein 1a	Mus musculus	89-93
21701975-8	2011	Based on this principle, a synthetic system consisting of a targeting domain attached to FKBP can recruit a protein of interest fused to FRB upon the addition of rapamycin.	Sirolimus	162-171	FK506 binding protein 1a	Mus musculus	89-93
21135252-4	2011	Under conditions of relatively quiescent AKT activity, treatment of cells with rapamycin resulted in upregulation of cyclin D1 and c-MYC nascent transcription, whereas in cells containing active AKT, exposure repressed transcription.	Sirolimus	79-88	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	131-136
21135252-7	2011	Forced overexpression of JunB or a conditionally active JunB-ER allele repressed cyclin D1 and c-MYC promoter activity in quiescent AKT-containing cells following rapamycin exposure.	Sirolimus	163-172	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-100
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	171-180	vimentin	Homo sapiens	230-238
21966447-5	2011	Furthermore, the regulatory function of rapamycin on CD62L expression in memory CTLs was mainly contributed by the presence of rapamycin in the first 24-hr of stimulation in vitro, whereas the effective window of rapamycin on the size of memory CTLs was determined between 24 to 72 hrs.	Sirolimus	40-49	selectin L	Homo sapiens	53-58
21966447-5	2011	Furthermore, the regulatory function of rapamycin on CD62L expression in memory CTLs was mainly contributed by the presence of rapamycin in the first 24-hr of stimulation in vitro, whereas the effective window of rapamycin on the size of memory CTLs was determined between 24 to 72 hrs.	Sirolimus	127-136	selectin L	Homo sapiens	53-58
21695255-8	2011	These studies demonstrate that rapamycin might be an effective therapeutic for human ovarian endometrioid patients with dysregulated Wnt/beta-catenin and Pten/PI3K signaling.	Sirolimus	31-40	catenin beta 1	Homo sapiens	137-149
21695255-8	2011	These studies demonstrate that rapamycin might be an effective therapeutic for human ovarian endometrioid patients with dysregulated Wnt/beta-catenin and Pten/PI3K signaling.	Sirolimus	31-40	phosphatase and tensin homolog	Homo sapiens	154-158
18270585-7	2008	Among the stress regulators tested, we found that cells (hsf1-R206S, F256S and ssa1-3 ssa2-2) constitutively activated for heat shock transcription factor 1, Hsf1, inhibited rapamycin resistance.	Sirolimus	174-183	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	57-61
18270585-7	2008	Among the stress regulators tested, we found that cells (hsf1-R206S, F256S and ssa1-3 ssa2-2) constitutively activated for heat shock transcription factor 1, Hsf1, inhibited rapamycin resistance.	Sirolimus	174-183	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	158-162
18270585-11	2008	Thus, we propose that activated Hsf1 inhibits rapamycin resistance and TOR signaling via elevated expression of specific target genes in S. cerevisiae.	Sirolimus	46-55	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	32-36
17971516-11	2008	Rapamycin inhibited TNF-alpha-induced phosphorylation of the mTOR C1 target p70(S6K) without altering TNF-alpha-induced PS and 4E-BP1 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	76-79
17962511-6	2008	In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation.	Sirolimus	55-64	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	163-166
21660239-9	2011	Rapamycin treatment was associated with an increased expression of profibrotic Th2 cytokines and reduced expression of INF-gamma.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	79-82
17719815-8	2008	The IGFBP-3-promoted apoptosis in the presence of IFN-gamma could also be abrogated by blockade of the mTOR pathway with its pharmacological inhibitors, LY294002 or rapamycin.	Sirolimus	165-174	insulin like growth factor binding protein 3	Homo sapiens	4-11
18056704-8	2008	Higher concentrations of rapamycin (&gt; or =100 ng/ml) were required to inhibit epidermal growth factor (EGF)-induced phosphorylation of p44/42 (Thr(202)).	Sirolimus	25-34	general transcription factor IIH subunit 2	Homo sapiens	138-141
18056704-9	2008	Rapamycin-induced inhibition of p44/42 (Thr(202)) phosphorylation by IGF-I was reversed by low concentrations of okadaic acid, suggesting involvement of protein phosphatase 2A (PP2A).	Sirolimus	0-9	general transcription factor IIH subunit 2	Homo sapiens	32-35
18056704-9	2008	Rapamycin-induced inhibition of p44/42 (Thr(202)) phosphorylation by IGF-I was reversed by low concentrations of okadaic acid, suggesting involvement of protein phosphatase 2A (PP2A).	Sirolimus	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	177-181
18056704-11	2008	Whereas low concentrations of rapamycin (1 ng/ml) inhibited dissociation of PP2Ac after IGF-I stimulation, it required higher concentrations (&gt; or =100 ng/ml) to block EGF-induced dissociation, consistent with the ability for rapamycin to attenuate growth factor-induced activation of p44/42.	Sirolimus	30-39	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	76-81
18056704-11	2008	Whereas low concentrations of rapamycin (1 ng/ml) inhibited dissociation of PP2Ac after IGF-I stimulation, it required higher concentrations (&gt; or =100 ng/ml) to block EGF-induced dissociation, consistent with the ability for rapamycin to attenuate growth factor-induced activation of p44/42.	Sirolimus	30-39	general transcription factor IIH subunit 2	Homo sapiens	288-291
18039669-9	2008	In addition, rapamycin inhibited leptin-induced adipose differentiation-related protein accumulation in macrophages and lipid body-dependent leukotriene synthesis, demonstrating a key role for mTOR in lipid body biogenesis and function.	Sirolimus	13-22	leptin	Homo sapiens	33-39
18215105-3	2008	METHODS AND FINDINGS: Based on preclinical evidence that phosphatase and tensin homolog deleted on Chromosome 10 (PTEN) loss sensitizes tumors to the inhibition of mammalian target of rapamycin (mTOR), we conducted a proof-of-concept Phase I neoadjuvant trial of rapamycin in patients with recurrent glioblastoma, whose tumors lacked expression of the tumor suppressor PTEN.	Sirolimus	184-193	phosphatase and tensin homolog	Homo sapiens	114-118
21079551-5	2010	To inhibit this pathway, we used sirolimus, which repressed p70S6K phosphorylation and reduced BK virus large T antigen expression in a dose-dependent manner.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	60-66
21079551-7	2010	The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	158-164
21200439-7	2010	We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5.	Sirolimus	40-49	interleukin 5	Mus musculus	195-199
20861467-10	2010	mTOR overexpression suppressed LPS-induced secretion of IL-6 (P &lt; 0.001), and the mTOR inhibitors rapamycin and PP242 abolished this inhibitory effect of mTOR.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Mus musculus	85-89
20861467-10	2010	mTOR overexpression suppressed LPS-induced secretion of IL-6 (P &lt; 0.001), and the mTOR inhibitors rapamycin and PP242 abolished this inhibitory effect of mTOR.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Mus musculus	85-89
20863555-10	2010	Sensitivity to rapamycin was independent of PTEN and Akt status.	Sirolimus	15-24	phosphatase and tensin homolog	Homo sapiens	44-48
21083937-8	2010	Both rapamycin and Dex can induce up-regulation of cyclin-dependent kinase (CDK) inhibitors of p21 and p27 and co-treatment of rapamycin with Dex resulted in a synergistic induction of their expressions.	Sirolimus	5-14	H3 histone pseudogene 16	Homo sapiens	95-98
21083937-8	2010	Both rapamycin and Dex can induce up-regulation of cyclin-dependent kinase (CDK) inhibitors of p21 and p27 and co-treatment of rapamycin with Dex resulted in a synergistic induction of their expressions.	Sirolimus	5-14	interferon alpha inducible protein 27	Homo sapiens	103-106
21083937-8	2010	Both rapamycin and Dex can induce up-regulation of cyclin-dependent kinase (CDK) inhibitors of p21 and p27 and co-treatment of rapamycin with Dex resulted in a synergistic induction of their expressions.	Sirolimus	127-136	interferon alpha inducible protein 27	Homo sapiens	103-106
21083937-12	2010	Rapamycin enhanced GC-induced apoptosis and this was not achieved by modulation of glucocorticoid receptor (GR) expression, but synergistically up-regulation of pro-apoptotic proteins like caspase-3, Bax, and Bim, and down-regulation of anti-apoptotic protein of Mcl-1.	Sirolimus	0-9	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	263-268
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	150-159	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-121
21062985-5	2010	Treatment of tumor-bearing mice using the mTOR inhibitor rapamycin led to complete regression of tumors, indicating that tumor growth was dependent on continued mTOR signaling.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Mus musculus	42-46
21062985-5	2010	Treatment of tumor-bearing mice using the mTOR inhibitor rapamycin led to complete regression of tumors, indicating that tumor growth was dependent on continued mTOR signaling.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Mus musculus	161-165
21182472-4	2010	Of note, rapamycin and FK506 bind to FKBP12, and the resulting complexes interfere with distinct intracellular signaling pathways driven, respectively, by the mammalian target of rapamycin and calcineurin phosphatase.	Sirolimus	9-18	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	37-43
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	solute carrier family 16 member 7	Homo sapiens	119-123
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	solute carrier family 16 member 7	Homo sapiens	225-229
20620173-10	2010	Interestingly, rapamycin, an mTOR inhibitor, upregulates MT1-MMP expression in PTEN(+/+) cells via PI3K activity.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	29-33
18093179-8	2008	In parallel, it was observed that LY294002 and rapamycin almost completely blocked the effects of insulin and IGF-1 on MCT2 protein expression, whereas PD98059 and SB202190 (a p38K inhibitor) had no effect on insulin-induced MCT2 expression and only a slight effect on IGF-1-induced MCT2 expression.	Sirolimus	47-56	solute carrier family 16 member 7	Homo sapiens	225-229
18097008-1	2008	Because ex vivo rapamycin generates murine Th2 cells that prevent Graft-versus-host disease more potently than control Th2 cells, we hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that abrogate fully MHC-disparate hemopoietic stem cell rejection more effectively than control Th2/Tc2 cells.	Sirolimus	16-25	heart and neural crest derivatives expressed 2	Mus musculus	43-46
20832409-5	2010	BCAA-treated neurons showed hyperexcitability and rapamycin was able to suppress it and significantly reduce the level of mTOR, Akt and p70S6 phosphorylation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Mus musculus	122-126
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	83-89
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	99-119
20728939-3	2010	Rapamycin inhibited the phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K) and the 4E binding protein 1 (4EBP-1), and suppressed the mitogen activated protein kinase (MAPK) pathway by decreasing phosphorylation of c-Jun N-terminal kinase (JNK).	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	121-127
18097008-1	2008	Because ex vivo rapamycin generates murine Th2 cells that prevent Graft-versus-host disease more potently than control Th2 cells, we hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that abrogate fully MHC-disparate hemopoietic stem cell rejection more effectively than control Th2/Tc2 cells.	Sirolimus	151-160	heart and neural crest derivatives expressed 2	Mus musculus	43-46
20801951-7	2010	mTOR inhibition by rapamycin markedly suppressed tumor growth in both wild-type and MKR mice.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	0-4
18094094-7	2008	The observation that the TSC1/TSC2 functions as a negative regulator of the mammalian target of rapamycin (mTOR)/p70 S6 kinase (S6K1) signaling pathway yielded the first rapamycin clinical trial for LAM.	Sirolimus	96-105	ribosomal protein S6 kinase B1	Homo sapiens	128-132
17908691-3	2007	We have previously reported that rapamycin promotes VSMC differentiation by inhibiting the mammalian target of rapamycin (mTOR) target S6K1.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	135-139
20656472-1	2010	Inhibition of mTOR by rapamycin is an important approach in cancer therapy.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
17476689-4	2007	It was noted that PIM-2 protected chondrocytes from rapamycin sensitized (TOR inhibited) cell death.	Sirolimus	52-61	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	18-23
20656472-2	2010	In early clinical trials, tuberous sclerosis complex (TSC)-related kidney tumours were found to regress following rapamycin treatment.	Sirolimus	114-123	TSC complex subunit 2	Mus musculus	54-57
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Sirolimus	93-102	TSC complex subunit 2	Mus musculus	30-33
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Sirolimus	93-102	ribosomal protein S6 kinase B1	Homo sapiens	127-133
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Sirolimus	93-102	8-oxoguanine DNA glycosylase	Homo sapiens	207-211
20656472-10	2010	In contrast, transfection of Tsc2(+/-) cells with DN-S6K abolished p70S6K phosphorylation and increased OGG1 expression, a response enhanced by rapamycin.	Sirolimus	144-153	TSC complex subunit 2	Mus musculus	29-33
17575014-8	2007	Inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin not only inhibited the phosphorylation of p70(S6K) and the expression of cell cycle regulatory proteins but also reduced accumulation of &gt; or =4N cells and BrdU incorporation of &gt;4N cells.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	118-121
20656472-11	2010	Treatment of Tsc2(+/-) mice with rapamycin resulted in activation of AMPK, downregulation of phospho-p70S6K and enhanced OGG1 expression.	Sirolimus	33-42	TSC complex subunit 2	Mus musculus	13-17
17494629-6	2007	S6K deletion in muscle mimics the effect of the mTOR inhibitor rapamycin on rpS6 and eIF4B phosphorylation without affecting eEF2 phosphorylation.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	0-3
20876744-10	2010	Instead, rapamycin inhibited SCD1 promoter activity and decreased expression of mature transcription factor sterol regulatory element binding protein 1 (SREBP1).	Sirolimus	9-18	sterol regulatory element binding transcription factor 1	Homo sapiens	108-151
20876744-10	2010	Instead, rapamycin inhibited SCD1 promoter activity and decreased expression of mature transcription factor sterol regulatory element binding protein 1 (SREBP1).	Sirolimus	9-18	sterol regulatory element binding transcription factor 1	Homo sapiens	153-159
20566381-1	2010	Inhibition of mTOR by rapamycin has been shown to suppress seizures in TSC/PTEN genetic models.	Sirolimus	22-31	phosphatase and tensin homolog	Homo sapiens	75-79
17494629-6	2007	S6K deletion in muscle mimics the effect of the mTOR inhibitor rapamycin on rpS6 and eIF4B phosphorylation without affecting eEF2 phosphorylation.	Sirolimus	63-72	eukaryotic translation initiation factor 4B	Homo sapiens	85-90
20861369-6	2010	Finally, stimulation of NAc core p70s6k and rps6 phosphorylation by NMDA enhanced cue-induced reinstatement, an effect reversed by rapamycin pretreatment.	Sirolimus	131-140	ribosomal protein S6 kinase B1	Homo sapiens	33-39
17618624-3	2007	Induction of autophagy by rapamycin, gleevec, thapsigargin and amino acid deprivation led to an accumulation of WIPI-1 at LC3-positive membrane structures (WIPI-1 puncta-formation), suggested to represent autophagosomal isolation membranes.	Sirolimus	26-35	WD repeat domain, phosphoinositide interacting 1	Homo sapiens	112-118
20862213-9	2010	Lastly, rapamycin treatment tempers the starvation sensitivity and lethality associated with reduced AMPK function.	Sirolimus	8-17	AMP-activated protein kinase alpha subunit	Drosophila melanogaster	101-105
20460585-6	2010	Treatment with rapamycin prevented p70S6K phosphorylation and rescued cell size control in AMPK-deficient cells.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	35-41
20517583-10	2010	Rapamycin treatment reduced the phosphorylation of mTOR and its substrates, p70S6K1 and 4EBP1, confirming mTOR inhibition.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	76-93
20448441-7	2010	Furthermore, BFA blocked the glucose-induced mTOR and p70S6K activation, while mTOR inhibition with rapamycin attenuated the glucose induced Beta2 expression and insulin secretion.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Mus musculus	79-83
20348217-3	2010	In this study we hypothesized that sirolimus inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR)-mediated cholesterol synthesis in human vascular smooth muscle cells (VSMCs) under inflammatory stress.	Sirolimus	35-44	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	54-101
20348217-3	2010	In this study we hypothesized that sirolimus inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR)-mediated cholesterol synthesis in human vascular smooth muscle cells (VSMCs) under inflammatory stress.	Sirolimus	35-44	high mobility group AT-hook 1	Homo sapiens	103-107
20348217-5	2010	Further studies showed that sirolimus inhibited both the HMGR gene and protein expression in VSMCs treated with or without IL-1beta.	Sirolimus	28-37	high mobility group AT-hook 1	Homo sapiens	57-61
20348217-8	2010	We demonstrated that sirolimus increased Insig-1 expression which may bind to the SCAP, preventing the exit of SCAP-SREBP complexes from the ER.	Sirolimus	21-30	insulin induced gene 1	Homo sapiens	41-48
20348217-10	2010	In conclusion, sirolimus inhibits cholesterol synthesis induced by inflammatory stress through the downregulation of HMGR expression and the acceleration of HMGR protein degradation.	Sirolimus	15-24	high mobility group AT-hook 1	Homo sapiens	117-121
20348217-10	2010	In conclusion, sirolimus inhibits cholesterol synthesis induced by inflammatory stress through the downregulation of HMGR expression and the acceleration of HMGR protein degradation.	Sirolimus	15-24	high mobility group AT-hook 1	Homo sapiens	157-161
17618850-2	2007	A recent report in Molecular Cell (Urban et al., 2007) now extends this conservation to include Sch9, an AGC protein kinase family member from S. cerevisiae, which appears to be the long sought after yeast ortholog of mammalian S6 kinase 1 (S6K1) and a direct target for the rapamycin-sensitive TOR complex I.	Sirolimus	275-284	ribosomal protein S6 kinase B1	Homo sapiens	228-239
17395699-5	2007	In this study, we used rapamycin to inhibit mTOR function in mice and neonatal cardiomyocyte cultures treated with THs to test whether mTOR/S6 kinase signaling is involved in TH-mediated cardiac hypertrophy.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	44-48
20698768-6	2010	Disruption of p70 S6K-mediated translation by rapamycin or siRNA knockdown in undifferentiated hESCs does not alter cell viability or expression of the pluripotency markers Oct4 and Nanog.	Sirolimus	46-55	ribosomal protein S6 kinase B1	Homo sapiens	14-21
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	solute carrier organic anion transporter family member 1B1	Homo sapiens	141-148
20299475-7	2010	These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Rattus norvegicus	189-193
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	27-33
20230819-5	2010	Inhibition of PI3K or mTOR/p70S6K by wortmannin and rapamycin, respectively, increased apoptosis and inhibited phosphorylation of Akt and p70S6K induced by single-dose oxidative stress.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	138-144
20511674-0	2010	Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model.	Sirolimus	0-9	transmembrane BAX inhibitor motif containing 4	Mus musculus	58-67
19856312-7	2010	Moreover, rapamycin decreased the phosphorylation of 4E-BP1, the phosphorylation of ERK1/2 and enhanced the phosphorylation of c-Jun NH2-terminal kinase, and the activation of caspase of apoptotic pathways in combination with TXT.	Sirolimus	10-19	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	53-59
20127734-12	2010	Attenuation of Rheb expression or treatment with the mTOR inhibitor rapamycin decreased proliferation of PC3 and DU145 cells, with a decrease in the activated form of p70S6 kinase, one of the main targets of mTOR.	Sirolimus	68-77	chromobox 8	Homo sapiens	105-108
20159776-8	2010	In response to artery injury using a carotid artery ligation model, Tsc2(+/-) mice significantly increased neointima formation compared with the control mice, and the neointima formation was inhibited by treatment with rapamycin.	Sirolimus	219-228	TSC complex subunit 2	Mus musculus	68-72
20498714-5	2010	By the use of genetically defined approaches, including the epithelial-specific ablation of Pten and Tsc1, we show that mTOR activation can dramatically increase epithelial cell proliferation, migration, and cutaneous wound healing, while pharmacological inhibition of mTOR with rapamycin delays wound closure.	Sirolimus	279-288	mechanistic target of rapamycin kinase	Mus musculus	120-124
20485667-0	2010	Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway.	Sirolimus	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	58-62
20485667-5	2010	Treatment of the cells with rapamycin activated PP2A activity, and concurrently inhibited IGF-1 stimulated phosphorylation of Erk1/2.	Sirolimus	28-37	protein phosphatase 2 phosphatase activator	Homo sapiens	48-52
20485667-7	2010	Furthermore, inhibition of PP2A with okadaic acid significantly attenuated the inhibitory effect of rapamycin on IGF-1-stimulated phosphorylation of Erk1/2 as well as cell motility.	Sirolimus	100-109	protein phosphatase 2 phosphatase activator	Homo sapiens	27-31
20485667-9	2010	Expression of constitutively active MKK1 also attenuated rapamycin inhibition of IGF-1-stimulated phosphorylation of Erk1/2 and cell motility.	Sirolimus	57-66	mitogen-activated protein kinase kinase 1	Homo sapiens	36-40
20485667-10	2010	The results suggest that rapamycin inhibits cell motility, in part by targeting PP2A-Erk1/2 pathway.	Sirolimus	25-34	protein phosphatase 2 phosphatase activator	Homo sapiens	80-84
20459645-11	2010	However, rapamycin further enhanced these OPN-induced effects.	Sirolimus	9-18	secreted phosphoprotein 1	Homo sapiens	42-45
19951971-7	2010	Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.	Sirolimus	34-43	insulin receptor substrate 2	Homo sapiens	91-95
20131403-9	2010	The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3.	Sirolimus	53-62	polycystin 2, transient receptor potential cation channel	Mus musculus	17-21
20131403-9	2010	The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Mus musculus	38-42
17439949-2	2007	Gln3 is cytoplasmic in cells provided with repressive nitrogen sources such as glutamine and is nuclear in cells growing with a derepressive nitrogen source such as proline or those treated with rapamycin or methionine sulfoximine (Msx).	Sirolimus	195-204	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	0-4
17551589-5	2007	METHODOLOGY/PRINCIPAL FINDINGS: Here, the role of Apis mellifera TOR (amTOR) in caste determination is examined by rapamycin/FK506 pharmacology and RNA interference (RNAi) gene knockdown.	Sirolimus	115-124	serine/threonine-protein kinase mTOR	Apis mellifera	65-68
17551589-5	2007	METHODOLOGY/PRINCIPAL FINDINGS: Here, the role of Apis mellifera TOR (amTOR) in caste determination is examined by rapamycin/FK506 pharmacology and RNA interference (RNAi) gene knockdown.	Sirolimus	115-124	serine/threonine-protein kinase mTOR	Apis mellifera	70-75
17551589-6	2007	We show that in queen-destined larvae, the TOR inhibitor rapamycin induces the development of worker characters that are blocked by the antagonist FK506.	Sirolimus	57-66	serine/threonine-protein kinase mTOR	Apis mellifera	43-46
17322416-10	2007	We further confirmed that sirolimus inhibited mRNA and protein expression of inflammatory cytokines IL-6, tumor necrosis factor-alpha, IL-8, and monocyte chemoattractant protein-1.	Sirolimus	26-35	C-C motif chemokine ligand 2	Homo sapiens	145-179
17496901-5	2007	The rapamycin derivative everolimus substantially decelerated tumor growth on Tagln-cre/Pten(loxP/loxP) mice and prolonged their lifespan.	Sirolimus	4-13	transgelin	Mus musculus	78-83
17384960-12	2007	CONCLUSION: Experimentally, our data show that sirolimus impairs wound healing, and this is reflected by diminished expression of VEGF and nitric oxide in the wound.	Sirolimus	47-56	vascular endothelial growth factor A	Rattus norvegicus	130-134
20237065-0	2010	Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver.	Sirolimus	0-9	X-box binding protein 1	Rattus norvegicus	41-64
19853373-0	2010	mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	0-4
20178983-6	2010	Using an animal model of AD, we show that pharmacologically restoring mTOR signaling with rapamycin rescues cognitive deficits and ameliorates Abeta and Tau pathology by increasing autophagy.	Sirolimus	90-99	microtubule associated protein tau	Homo sapiens	153-156
20178983-8	2010	The results presented here provide a molecular basis for the Abeta-induced cognitive deficits and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces Abeta and Tau pathology.	Sirolimus	119-128	microtubule associated protein tau	Homo sapiens	203-206
20097763-0	2010	Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	107-114
20168088-3	2010	The present study was undertaken to assess the potential role of activation of autophagic and phosphatidylinositol 3-kinase (PI3K)/Akt kinase pathways in the neuroprotective effect of rapamycin.	Sirolimus	184-193	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	94-123
20168088-4	2010	Rapamycin administration caused a significant reduction of 70 kDa S6 kinase (p70S6K) phosphorylation and a significant increase of the autophagic proteins Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3), as of monodansylcadaverine (MDC) labeling in the lesioned side.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	77-83
20203102-3	2010	Acute inhibition of mTORC1/S6K1 by rapamycin increases insulin signaling and glucose uptake in myocytes and adipocytes, but whether these effects can be maintained under chronic inhibition of mTORC1 or S6K1 remains unclear.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	27-31
20371718-1	2010	The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple myeloma (MM) cell proliferation, survival, and development of drug resistance, underscoring the role of mTOR inhibitors, such as rapamycin, with potential anti-MM activity.	Sirolimus	61-70	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	4-29
20376313-0	2010	Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer"s disease.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
20376313-2	2010	It was recently demonstrated that long-term treatment with rapamycin, an inhibitor of the mTOR pathway[5], or ablation of the mTOR target p70S6K[6] extends lifespan in mice, possibly by delaying aging.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	90-94
20376313-5	2010	Here we show that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Abeta(42), a major toxic species in AD[7], in the PDAPP transgenic mouse model.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Mus musculus	42-46
20376313-7	2010	As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Abeta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Abeta.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	35-39
20376313-7	2010	As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Abeta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Abeta.	Sirolimus	79-88	amyloid beta (A4) precursor protein	Mus musculus	181-186
20376313-7	2010	As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Abeta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Abeta.	Sirolimus	79-88	amyloid beta (A4) precursor protein	Mus musculus	310-315
20376313-8	2010	CONCLUSIONS/SIGNIFICANCE: Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Mus musculus	62-66
20017609-5	2010	We have shown that the specific PI3K inhibitors (LY-294002 and wortmannin) and the TOR-kinase inhibitor rapamycin slightly increase the median and maximal lifespan of the fruit fly, Drosophila melanogaster.	Sirolimus	104-113	Target of rapamycin	Drosophila melanogaster	83-86
19642865-0	2010	Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.	Sirolimus	0-9	bone morphogenetic protein 1	Homo sapiens	131-134
19642865-4	2010	Under feeder-free culture conditions, rapamycin (an mTOR inhibitor) potently inhibited the activities of mTOR and p70S6K in undifferentiated hESCs; however, LY294002 (a PI3K inhibitor) and an AKT inhibitor had no effects.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	114-120
19925836-7	2010	Sirolimus analogs and their specific binding target FKBP-12 were less sensitive to alterations of diet in mildly injured arteries, presumably reflecting a faster transient response of FKBP-12 to injury.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	184-191
19966863-0	2010	Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.	Sirolimus	0-9	APC, WNT signaling pathway regulator	Mus musculus	70-73
19966863-0	2010	Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.	Sirolimus	0-9	APC, WNT signaling pathway regulator	Mus musculus	74-77
19966863-6	2010	Moreover, although untreated APC(Min/+) mice lose weight, experience intestinal bleeding and succumb to multiple neoplasia by 22.3+/-1.4 weeks of age, mice treated with rapamycin maintain stable weight and survive long term (39.6+/-3.4 weeks), with more than 30% surviving &gt;1 year.	Sirolimus	169-178	APC, WNT signaling pathway regulator	Mus musculus	29-32
19966863-8	2010	These results show that continuous prophylaxis by rapamycin markedly inhibits the development of APC mutation-related polyposis, and suggest a novel contributing mechanism of action through the blockade of intestinal oncogenic ion channels.	Sirolimus	50-59	APC, WNT signaling pathway regulator	Mus musculus	97-100
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	interleukin 2	Mus musculus	175-179
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	chemokine (C-C motif) ligand 3	Mus musculus	255-293
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	chemokine (C-C motif) ligand 3	Mus musculus	295-305
17452901-0	2007	Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro.	Sirolimus	0-9	integrin subunit alpha E	Homo sapiens	59-64
17452901-7	2007	Addition of rapamycin to allocultures led to an increased percentage of CD103+ CD8+ alloreactive T cells.	Sirolimus	12-21	integrin subunit alpha E	Homo sapiens	72-77
17452901-9	2007	CONCLUSIONS: Alloreactive CD103+ CD8+ T(reg) cells may expand and exert their suppressive function during immunosuppressive treatment with rapamycin.	Sirolimus	139-148	integrin subunit alpha E	Homo sapiens	26-31
17244624-4	2007	Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.	Sirolimus	0-9	serine/threonine kinase 11	Homo sapiens	106-110
17244624-4	2007	Rapamycin, but not adiponectin, enhanced insulin-stimulated Akt phosphorylation in HeLa cells, which lack LKB1, and exogenous expression of LKB1 in HeLa cells rescued the insulin-sensitizing effect of adiponectin.	Sirolimus	0-9	serine/threonine kinase 11	Homo sapiens	140-144
17158352-8	2007	Rapamycin and paclitaxel treated endothelial cells produced dose-dependent increases in PAI-1.	Sirolimus	0-9	serpin family E member 1	Homo sapiens	88-93
17200203-5	2007	Accordingly, the enhanced synthesis of fibrillin-1 was blocked by rapamycin, an inhibitor of mTOR.	Sirolimus	66-75	fibrillin 1	Homo sapiens	39-50
16952420-3	2007	Therefore, the effects of insulin and rapamycin (an inhibitor of mTOR) on the phosphorylation of mTOR (Ser 2448) and p70(S6K) (Thr 389) as well as on cell proliferation in parental HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB (HepG2-CA-Akt/PKB) were studied.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Homo sapiens	121-124
17453966-0	2007	Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis.	Sirolimus	0-9	CD27 molecule	Homo sapiens	38-42
17453966-10	2007	The addition of rapamycin inhibited expansion of non-regulatory T cells at doses &gt; or =1 ng/mL while increasing suppressor activity and the percentage of CD4(+) CD25(+) CD27(+) Foxp3(+) cells.	Sirolimus	16-25	CD27 molecule	Homo sapiens	172-176
17259349-8	2007	Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was found to regulate PDCD4 expression because inhibition of PI3K by LY294002 and wortmannin or of mTOR by rapamycin induced PDCD4 protein and mRNA expression.	Sirolimus	61-70	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	0-29
17205138-5	2006	Maf1 represses pol III transcription in vitro and in vivo and is required for maximal pol III repression after exposure to MMS or rapamycin, treatments that both lead to Maf1 dephosphorylation.	Sirolimus	130-139	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	0-4
19958352-8	2010	Rapamycin, an inhibitor of mTOR involved in CEBPB translation, completely blocked the increase in LIP in FL-stimulated FLT3-WT- but not FLT3-ITD-positive cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
19958352-8	2010	Rapamycin, an inhibitor of mTOR involved in CEBPB translation, completely blocked the increase in LIP in FL-stimulated FLT3-WT- but not FLT3-ITD-positive cells.	Sirolimus	0-9	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	44-49
19958352-8	2010	Rapamycin, an inhibitor of mTOR involved in CEBPB translation, completely blocked the increase in LIP in FL-stimulated FLT3-WT- but not FLT3-ITD-positive cells.	Sirolimus	0-9	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	98-101
20075061-0	2010	Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.	Sirolimus	0-9	polycystin 1, transient receptor potential channel interacting	Homo sapiens	69-73
20075061-3	2010	To address this limitation, we tested the efficacy of rapamycin in a mouse model that results from conditional inactivation of Pkd1.	Sirolimus	54-63	polycystin 1, transient receptor potential channel interacting	Mus musculus	127-131
19804585-0	2010	Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin.	Sirolimus	144-153	selectin L	Homo sapiens	73-78
20174468-9	2010	Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Mus musculus	54-58
20174468-9	2010	Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations.	Sirolimus	27-36	synuclein, alpha	Mus musculus	148-163
20146790-0	2010	Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.	Sirolimus	20-29	TSC complex subunit 2	Mus musculus	54-58
20146790-2	2010	Rapamycin has been shown to reduce the size of kidney angiomyolipomas associated with TSC; however, tumor regression is incomplete and kidney angiomyolipomas regrow after cessation of treatment.	Sirolimus	0-9	TSC complex subunit 2	Mus musculus	86-89
20146790-9	2010	When rapamycin dosing schedules were compared in A/J Tsc2+/- cohorts, we observed a 66% reduction in kidney tumor burden in mice treated daily for 4 weeks, an 82% reduction in mice treated daily for 4 weeks followed by weekly for 8 weeks, and an 81% reduction in mice treated weekly for 12 weeks.	Sirolimus	5-14	TSC complex subunit 2	Mus musculus	53-57
20140209-6	2010	Based on this, we tested the hypothesis that c-Myc is involved in regulation of gene expression by mTOR by comparing genes altered by rapamycin in the hepatic cells and by c-Myc induction in fibroblasts engineered to express c-myc in an inducible manner.	Sirolimus	134-143	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	45-50
20081360-3	2010	We have previously shown that rapamycin attenuates the phenotype in a mouse model of Huntington disease when administered pre-symptomatically and have recently extended this to demonstrate the effectiveness of rapamycin in a transgenic mouse model of spinocerebellar ataxia type 3, a polyglutamine disorder caused by mutations in the ataxin-3 gene.	Sirolimus	30-39	ataxin 3	Mus musculus	334-342
20081360-4	2010	Rapamycin, administered from the initial onset of disease signs, improves motor coordination and results in a decrease in the levels of soluble mutant ataxin-3 and protein aggregates in the brain.	Sirolimus	0-9	ataxin 3	Mus musculus	151-159
20193134-4	2010	Moreover, inhibition of mTOR activity by rapamycin resulted in a reduction of SREBP-1c protein expression and adipogenesis in cells.	Sirolimus	41-50	sterol regulatory element binding transcription factor 1	Homo sapiens	78-86
19634141-5	2010	We developed and characterized a human NF1-MPNST explant grown subcutaneously in NOD-SCID mice, to evaluate the effect of the mTOR inhibitor rapamycin.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Mus musculus	126-130
20019183-6	2010	Rapamycin inhibited S6K at mTOR-sensitive phosphorylation sites in response to strain and hypoxia.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	20-23
19887566-7	2010	Insulin phosphorylation of S6K1 correlated with IRS-1 ser1101 phosphorylation and the mTOR-S6K1 pathway inhibitor rapamycin prevented IRS-1 serine phosphorylation.	Sirolimus	114-123	insulin receptor substrate 1	Homo sapiens	134-139
17205138-5	2006	Maf1 represses pol III transcription in vitro and in vivo and is required for maximal pol III repression after exposure to MMS or rapamycin, treatments that both lead to Maf1 dephosphorylation.	Sirolimus	130-139	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	170-174
17204907-8	2006	Inhibition of VSMC proliferation by both tacrolimus and sirolimus was associated with upregulation of the cell-cycle inhibitor p27.	Sirolimus	56-65	interferon alpha inducible protein 27	Homo sapiens	127-130
19887566-8	2010	The proteasomal inhibitor epoxomicin and the lysosomal pathway inhibitor 3-methyladenine prevented the degradation of IRS-1 and IR by insulin, respectively, and pretreatment with rapamycin, epoxomicin, or 3-methyladenine prevented attenuation of insulin signaling by long-term insulin exposure.	Sirolimus	179-188	insulin receptor substrate 1	Homo sapiens	118-123
16916938-9	2006	Inhibition of Irs2 degradation with rapamycin caused persistent FoxO degradation even during prolonged insulin stimulation.	Sirolimus	36-45	insulin receptor substrate 2	Mus musculus	14-18
17121904-5	2006	RESULTS: In this study, we showed that the combination of rapamycin and 17-AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADP-ribose) polymerase and caspase-8/caspase-9, and dysregulated signaling in the phosphatidylinositol 3-kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways.	Sirolimus	58-67	caspase 9	Homo sapiens	223-232
16715128-0	2006	Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	65-80
16715128-7	2006	However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	103-114
16715128-7	2006	However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	116-120
16715128-8	2006	Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	105-109
16715128-13	2006	Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	79-94
17088424-2	2006	Rapa-induced PM recruitment of a truncated type IV 5-ptase containing only the 5-ptase domain fused to FKBP12 rapidly decreased PM PtdIns(4,5)P(2) as monitored by the PLCdelta1PH-GFP fusion construct.	Sirolimus	0-4	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	103-109
17023663-2	2006	We found that the mTOR inhibitor, rapamycin, increased the Kv1.1 voltage-gated potassium channel protein in hippocampal neurons and promoted Kv1.1 surface expression on dendrites without altering its axonal expression.	Sirolimus	34-43	potassium voltage-gated channel subfamily A member 1	Homo sapiens	59-64
17023663-2	2006	We found that the mTOR inhibitor, rapamycin, increased the Kv1.1 voltage-gated potassium channel protein in hippocampal neurons and promoted Kv1.1 surface expression on dendrites without altering its axonal expression.	Sirolimus	34-43	potassium voltage-gated channel subfamily A member 1	Homo sapiens	141-146
16874098-4	2006	In rapamycin-treated HEK293 cells, there was little accumulation of endogenous GABARAP-PL, even in the presence of lysosomal protease-inhibitors, whereas there was significant accumulation of endogenous LC3-II, together with inactivation of the mTor kinase-signaling pathway.	Sirolimus	3-12	gamma-aminobutyric acid receptor associated protein	Mus musculus	79-86
16874098-4	2006	In rapamycin-treated HEK293 cells, there was little accumulation of endogenous GABARAP-PL, even in the presence of lysosomal protease-inhibitors, whereas there was significant accumulation of endogenous LC3-II, together with inactivation of the mTor kinase-signaling pathway.	Sirolimus	3-12	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	203-206
17010674-4	2006	We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1.	Sirolimus	30-39	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	182-186
16772532-6	2006	Treatment of female mice with rapamycin impaired mammary gland differentiation and milk protein synthesis.	Sirolimus	30-39	casein alpha s2-like A	Mus musculus	83-95
20369473-5	2010	CONCLUSION: Compared to Mycophenolate Mofetil and Cyclosporin A, Everilimus and Sirolimus demonstrate lower toxicity effect on INS-1 cells and rat pancreatic islets in vitro and Everolimus is expected as a new type of immunosuppressive agent used in clinical islet transplantation.	Sirolimus	80-89	insulin 1	Rattus norvegicus	127-132
16772532-10	2006	Rapamycin also prevented the induction of Id2 by lactogenic hormones and milk protein gene expression.	Sirolimus	0-9	casein alpha s2-like A	Mus musculus	73-85
19666112-2	2009	We found that rapamycin induces the TGFbeta/Smad signaling cascade in rat mesangial cells (MC) as depicted by the nuclear translocation of phospho-Smads 2, -3 and Smad-4, respectively.	Sirolimus	14-23	SMAD family member 4	Rattus norvegicus	163-169
17098043-4	2006	Sirolimus affects the immune response by interfering with postreceptor interleukin-2 signaling.	Sirolimus	0-9	interleukin 2	Rattus norvegicus	71-84
19666112-3	2009	Concomitantly, rapamycin increases the nuclear DNA binding of receptor (R)- and co-Smad proteins to a cognate Smad-binding element (SBE) which in turn causes an increase in profibrotic gene expression as exemplified by the connective tissue growth factor (CTGF) and plasminogen activator inhibitor 1 (PAI-1).	Sirolimus	15-24	cellular communication network factor 2	Rattus norvegicus	223-254
19666112-3	2009	Concomitantly, rapamycin increases the nuclear DNA binding of receptor (R)- and co-Smad proteins to a cognate Smad-binding element (SBE) which in turn causes an increase in profibrotic gene expression as exemplified by the connective tissue growth factor (CTGF) and plasminogen activator inhibitor 1 (PAI-1).	Sirolimus	15-24	cellular communication network factor 2	Rattus norvegicus	256-260
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	150-154
19959876-6	2009	Thus, GSK-3 regulated both Wnt and mTOR signaling in mouse HSCs, with these pathways promoting HSC self renewal and lineage commitment, respectively, such that inhibition of Gsk3 in the presence of rapamycin expanded the HSC pool in vivo.	Sirolimus	198-207	glycogen synthase kinase 3 beta	Mus musculus	6-11
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	170-181
16816403-5	2006	The stimulation of S6K1 in response to PGF2alpha treatment was abolished by the mTOR inhibitor rapamycin.	Sirolimus	95-104	ribosomal protein S6 kinase B1	Homo sapiens	19-23
20847591-3	2009	We have now shown that the insulin-induced increase in the abundance of SREBP1c mRNA in cultured AML12 mouse hepatocytes was largely abolished by LY294002, an inhibitor of phosphoinositide 3-kinase, but was reduced only slightly by rapamycin, an inhibitor of mTOR.	Sirolimus	232-241	sterol regulatory element binding transcription factor 1	Mus musculus	72-79
19783659-8	2009	Interestingly, rapamycin blocked CHOP induction by asparaginase in both wild-type and GCN2 null livers.	Sirolimus	15-24	DNA-damage inducible transcript 3	Mus musculus	33-37
16969287-7	2006	These myoglobin-appearing casts were only noted in patients receiving rapamycin.	Sirolimus	70-79	myoglobin	Homo sapiens	6-15
19783659-10	2009	Rapamycin modifies the hepatic AADR to asparaginase by preventing CHOP induction while maximizing inhibition of mTORC1.	Sirolimus	0-9	DNA-damage inducible transcript 3	Mus musculus	66-70
16969287-13	2006	CONCLUSION: We conclude that myoglobinuria with myoglobin cast formation can occur following rapamycin administration, and may be a causative factor in the development of unexpected severe acute renal dysfunction.	Sirolimus	93-102	myoglobin	Homo sapiens	29-38
16920556-0	2006	Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.	Sirolimus	8-17	heart and neural crest derivatives expressed 2	Mus musculus	39-42
16920556-1	2006	Rapamycin prevention of murine graft-versus-host disease (GVHD) is associated with a shift toward Th2- and Tc2-type cytokines.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	98-101
16920556-3	2006	In this study, using a method, without antigen-presenting cells, of T-cell expansion based on CD3,CD28 costimulation, we evaluated whether (1) rapamycin preferentially promotes the generation of Th2/Tc2 cells relative to Th1/Tc1 cells, (2) rapamycin-generated T-cell subsets induce cytokine skewing after allogeneic bone marrow transplantation (BMT), and (3) such in vivo cytokine skewing is sensitive to post-BMT rapamycin therapy.	Sirolimus	143-152	heart and neural crest derivatives expressed 2	Mus musculus	195-198
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	70-73
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	109-118	heart and neural crest derivatives expressed 2	Mus musculus	70-73
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	250-253
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	299-302
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	heart and neural crest derivatives expressed 2	Mus musculus	250-253
16885364-4	2006	Nonetheless, loss of even one PTEN allele resulted in lymphomas that were resistant to conventional chemotherapy yet sensitive to rapamycin/chemotherapy combinations.	Sirolimus	130-139	phosphatase and tensin homolog	Homo sapiens	30-34
16705060-6	2006	TNF-alpha treatment decreased ATGL transcript in a time-dependent manner that paralleled TNF-alpha downregulation of PPARgamma with a maximal decrease noted by 6 h. TNF-alpha effects on ATGL were attenuated by pretreatment with PD-98059, LY-294002, or rapamycin, suggesting involvement of the p44/42 MAP kinase, PI 3-kinase, and p70 ribosomal protein S6 kinase signals.	Sirolimus	252-261	patatin-like phospholipase domain containing 2	Mus musculus	30-34
16705060-6	2006	TNF-alpha treatment decreased ATGL transcript in a time-dependent manner that paralleled TNF-alpha downregulation of PPARgamma with a maximal decrease noted by 6 h. TNF-alpha effects on ATGL were attenuated by pretreatment with PD-98059, LY-294002, or rapamycin, suggesting involvement of the p44/42 MAP kinase, PI 3-kinase, and p70 ribosomal protein S6 kinase signals.	Sirolimus	252-261	patatin-like phospholipase domain containing 2	Mus musculus	186-190
16951269-3	2006	The aim of this study was to evaluate the expression and activation of the Akt-mTOR-p70S6K pathway in renal cell carcinoma (RCC), seeking to strengthen the rationale for targeted therapy of RCC using rapamycin or a rapamycin analogue.	Sirolimus	215-224	ribosomal protein S6 kinase B1	Homo sapiens	84-90
16809313-9	2006	The mTOR kinase inhibitor rapamycin blocked phosphorylation of 4E-BP1 and significantly decreased the level of E7 protein in Caski cells, suggesting that phosphorylation of 4E-BP1 is linked to E7 expression.	Sirolimus	26-35	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	63-69
16809313-9	2006	The mTOR kinase inhibitor rapamycin blocked phosphorylation of 4E-BP1 and significantly decreased the level of E7 protein in Caski cells, suggesting that phosphorylation of 4E-BP1 is linked to E7 expression.	Sirolimus	26-35	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	173-179
20137651-7	2009	(2) The P(70)S6K activities in the placenta from the insulin stimulation group was significantly elevated, the P(70)S6K activities in the placenta from the rapamycin stimulation group was significantly declined, there were statistical significance when each was compared with control group (P &lt; 0.01).	Sirolimus	156-165	ribosomal protein S6 kinase B1	Homo sapiens	111-119
16785324-5	2006	In addition, we find that disruption of endocytosis leads to changes in TOR and phosphatidylinositol-3 kinase activity, affecting cell growth, autophagy, and rapamycin sensitivity.	Sirolimus	158-167	Target of rapamycin	Drosophila melanogaster	72-75
16885839-14	2006	The main pathogenesis hypothesis to explain these nail alterations is inhibition of EGF (epidermal growth factor) pathway by sirolimus.	Sirolimus	125-134	epidermal growth factor	Homo sapiens	84-87
16885839-14	2006	The main pathogenesis hypothesis to explain these nail alterations is inhibition of EGF (epidermal growth factor) pathway by sirolimus.	Sirolimus	125-134	epidermal growth factor	Homo sapiens	89-112
16732193-7	2006	The scores for tubular dilatation, interstitial volume, interstitial collagen deposition, and alpha-smooth muscle actin (alpha-SMA) after UUO were significantly reduced by rapamycin.	Sirolimus	172-181	actin gamma 2, smooth muscle	Rattus norvegicus	94-119
16732193-7	2006	The scores for tubular dilatation, interstitial volume, interstitial collagen deposition, and alpha-smooth muscle actin (alpha-SMA) after UUO were significantly reduced by rapamycin.	Sirolimus	172-181	actin gamma 2, smooth muscle	Rattus norvegicus	121-130
16713952-1	2006	BACKGROUND: The TOR (target of rapamycin) ser/thr protein kinase is the central component of a eukaryotic signaling pathway that regulates growth and is the direct target of the clinically useful drug rapamycin.	Sirolimus	31-40	Target of rapamycin	Drosophila melanogaster	16-19
19773438-8	2009	Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy.	Sirolimus	82-91	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	42-45
19589861-8	2009	Rapamycin blocked activation of P-mTOR, P-S6K1, and P-4EBP1 proteins and significantly reduced the number of proliferating cells in the myometrium of OVX rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	42-46
19494204-7	2009	Sirolimus treatment of 6-month-old Rdh8(-/-)Abca4(-/-) mice for 4 months prevented choroidal neovascularization without changing retinal VEGF levels.	Sirolimus	0-9	retinol dehydrogenase 8	Mus musculus	35-39
19656856-8	2009	The phosphoinositide 3-kinase inhibitors, LY294002 and the mammalian target of rapamycin inhibitor rapamycin, abolished the IL-1Ra induction by 9E,11E-CLA, whereas other kinase inhibitors did not affect this response.	Sirolimus	79-88	interleukin 1 receptor antagonist	Homo sapiens	124-130
19474189-9	2009	The highly selective mTOR inhibitor, rapamycin, inhibited increased phosphorylation of rpS6 and blocked 60-70% of the hypertrophy seen in wild-type mice but failed to prevent the approximately 10% hypertrophy seen in S6K1(-/-) mice in response to uninephrectomy (UNX) although it did inhibit the basal rpS6 phosphorylation.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Mus musculus	21-25
19576622-7	2009	The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin.	Sirolimus	176-185	annexin A5	Homo sapiens	130-139
16424383-7	2006	Rapamycin, a specific S6K1 inhibitor, abolished increased LAM cell growth.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	22-26
16567633-5	2006	Rapamycin, an inhibitor of mTOR, is highly effective in reducing renal cystogenesis in two independent mouse models of PKD.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
19684114-3	2009	Sfp1 is localized to the nucleus in rich nutrients, but upon nutrient limitation or target of rapamycin (TOR) pathway inhibition by rapamycin, Sfp1 rapidly exits the nucleus, leading to repression of the Ribi/RP regulons.	Sirolimus	94-103	zinc-coordinating transcription factor SFP1	Saccharomyces cerevisiae S288C	0-4
19684114-3	2009	Sfp1 is localized to the nucleus in rich nutrients, but upon nutrient limitation or target of rapamycin (TOR) pathway inhibition by rapamycin, Sfp1 rapidly exits the nucleus, leading to repression of the Ribi/RP regulons.	Sirolimus	94-103	zinc-coordinating transcription factor SFP1	Saccharomyces cerevisiae S288C	143-147
19628769-5	2009	Finally, rotenone-induced alpha-syn aggregates were cleared following rapamycin stimulation of autophagy.	Sirolimus	70-79	synuclein, alpha	Mus musculus	26-35
19443844-0	2009	Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	32-36
19443844-3	2009	Rapamycin (0.5 mg/kg/d) effectively inhibited mTOR and downstream S6K1 signaling and partially inhibited Akt signaling, likely through effects on TORC2.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	46-50
19220580-9	2009	Treatment of 10-0505 tumours with sorafenib plus rapamycin resulted in growth inhibition, inhibition of vascular endothelial growth factor receptor-2 phosphorylation, increased apoptosis and completely blocked sorafenib-induced phosphorylation of mTOR targets and cyclin B1 expression.	Sirolimus	49-58	cyclin B1	Homo sapiens	264-273
16396989-10	2006	Rapamycin completely blocked insulin-activated mTOR/p70S(6)K signaling and mitogenesis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	47-51
16487345-0	2006	Differing responses of Gat1 and Gln3 phosphorylation and localization to rapamycin and methionine sulfoximine treatment in Saccharomyces cerevisiae.	Sirolimus	73-82	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	32-36
16489035-7	2006	However, when cap-dependent translation was prevented by transfection with a mutant 4E-BP1 construct, which is resistant to mTOR-induced phosphorylation, cells responded to dexamethasone with enhanced apoptosis, mirroring the effect of coexposure to rapamycin.	Sirolimus	250-259	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	84-90
16210336-0	2006	Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells.	Sirolimus	0-9	CD27 molecule	Homo sapiens	67-71
16326012-7	2006	Immunohistological analysis demonstrated that the concentration of rapamycin used was effective in inhibiting the phosphorylation of p70S6K at Thr389, the main determinant of its pro-translational activity, and that Thr389 phosphorylation recovered after washout.	Sirolimus	67-76	ribosomal protein S6 kinase B1	Rattus norvegicus	133-139
19587680-2	2009	Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	51-55
19541609-9	2009	Furthermore, like HIF-1alpha and its target genes, the FDG-PET signal in the GI tract of these mice is abolished by rapamycin treatment.	Sirolimus	116-125	hypoxia inducible factor 1, alpha subunit	Mus musculus	18-28
19406104-5	2009	Inhibition of mTOR by rapamycin notably increased the level of phosphorylated eEF2 in infected cells.	Sirolimus	22-31	eukaryotic translation elongation factor 2	Homo sapiens	78-82
19435852-5	2009	Moreover, the effect of intra-VTA leptin administration to reduce 4- and 20-h food intake and 20-h body weight was blocked by an inhibitor of Jak-2, at a dose that had no effect on food intake or body weight by itself, but not by local inhibition of either PI 3-kinase (LY-294002) or mTOR (rapamycin) in this timeframe.	Sirolimus	290-299	leptin	Homo sapiens	34-40
19364503-4	2009	Here, we show that inhibition of mTOR signaling with its specific inhibitor, rapamycin, suppresses normal thymocyte DNA synthesis by downregulating 4EBP1, but not S6K, and that 4EBP1 phosphorylation and cyclin D1 expression are coordinately increased in Atm-/- thymocytes.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	33-37
19364503-4	2009	Here, we show that inhibition of mTOR signaling with its specific inhibitor, rapamycin, suppresses normal thymocyte DNA synthesis by downregulating 4EBP1, but not S6K, and that 4EBP1 phosphorylation and cyclin D1 expression are coordinately increased in Atm-/- thymocytes.	Sirolimus	77-86	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	148-153
19364503-4	2009	Here, we show that inhibition of mTOR signaling with its specific inhibitor, rapamycin, suppresses normal thymocyte DNA synthesis by downregulating 4EBP1, but not S6K, and that 4EBP1 phosphorylation and cyclin D1 expression are coordinately increased in Atm-/- thymocytes.	Sirolimus	77-86	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	177-182
19364503-5	2009	Administration of rapamycin to Atm-/- mice attenuates elevated phospho-4EBP1, c-Myc and cyclin D1 in their thymocytes, and delays thymic lymphoma development.	Sirolimus	18-27	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	71-76
19364503-5	2009	Administration of rapamycin to Atm-/- mice attenuates elevated phospho-4EBP1, c-Myc and cyclin D1 in their thymocytes, and delays thymic lymphoma development.	Sirolimus	18-27	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	78-83
19528451-0	2009	Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation.	Sirolimus	59-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-98
19528451-7	2009	CONCLUSION: The combination of rapamycin or temsirolimus with alphaIR3 decreases MYC-N expression, increases MYC-N phosphorylation and induces apoptosis in vitro which may have clinical relevance to children with neuroblastoma.	Sirolimus	31-40	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	81-86
19528451-7	2009	CONCLUSION: The combination of rapamycin or temsirolimus with alphaIR3 decreases MYC-N expression, increases MYC-N phosphorylation and induces apoptosis in vitro which may have clinical relevance to children with neuroblastoma.	Sirolimus	31-40	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	109-114
19424604-9	2009	In addition, the mTOR inhibitor rapamycin was found to affect the phosphorylation status of p70S6K in amniotic fluid stem cells.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	92-98
19329430-9	2009	Furthermore, inhibition of the PI3K/Akt/mTOR pathway by rapamycin completely blocks ouabain-induced expression of Na/K-ATPase and converts ouabain-induced growth stimulation to growth inhibition in LLC-PK1 cells.	Sirolimus	56-65	AKT serine/threonine kinase 1	Sus scrofa	36-39
19474313-6	2009	When mTOR signaling was inhibited chronically in vivo with rapamycin starting at 6 weeks of age, the observed hypermyelination was reduced to approximately the amount of myelin seen in wild-type mice.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	5-9
16424025-6	2006	This approach allowed us to verify the involvement of the Tcl1/Akt/mTOR biochemical pathway in the disease by testing the ability of a specific pharmacologic agent, rapamycin, to slow CLL.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Mus musculus	67-71
16859513-9	2006	In addition, rapamycin enhanced the degradation rate of Skp2 and down-regulated the expression of the APC\C inhibitor Emi1.	Sirolimus	13-22	F-box protein 5	Homo sapiens	118-122
17118264-8	2006	We showed that the autophagy inducer rapamycin reduced the levels of soluble and aggregated huntingtin and attenuated its toxicity in cells, and in transgenic Drosophila and mouse models.	Sirolimus	37-46	huntingtin	Drosophila melanogaster	92-102
16204634-6	2005	Expression of a rapamycin-resistant form of S6K2, T388E, in Ba/F3 cells provides a proliferation advantage in the absence or presence of rapamycin, indicating that S6K2 can potentiate IL-3-mediated mitogenic signals.	Sirolimus	16-25	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	44-48
16204634-6	2005	Expression of a rapamycin-resistant form of S6K2, T388E, in Ba/F3 cells provides a proliferation advantage in the absence or presence of rapamycin, indicating that S6K2 can potentiate IL-3-mediated mitogenic signals.	Sirolimus	16-25	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	164-168
16171514-6	2005	Whereas eEF2 phosphorylation levels altered by BDNF were inhibited by rapamycin, eEF1A phosphorylation was not affected by rapamycin or PD98059, a mitogen-activated protein kinase kinase (MEK) inhibitor.	Sirolimus	70-79	eukaryotic translation elongation factor 2	Homo sapiens	8-12
19457267-3	2009	Most studies of mTOR in immune responses have relied on the use of pharmacological inhibitors, such as rapamycin.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Mus musculus	16-20
19420259-5	2009	In Tsc2-deficient neurons, the expression of stress markers such as CHOP and HO-1 is increased, and this increase is completely reversed by the mTOR inhibitor rapamycin both in vitro and in vivo.	Sirolimus	159-168	TSC complex subunit 2	Mus musculus	3-7
19420259-5	2009	In Tsc2-deficient neurons, the expression of stress markers such as CHOP and HO-1 is increased, and this increase is completely reversed by the mTOR inhibitor rapamycin both in vitro and in vivo.	Sirolimus	159-168	heme oxygenase 1	Homo sapiens	77-81
19420259-5	2009	In Tsc2-deficient neurons, the expression of stress markers such as CHOP and HO-1 is increased, and this increase is completely reversed by the mTOR inhibitor rapamycin both in vitro and in vivo.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Mus musculus	144-148
19395652-9	2009	Furthermore, prostate lesion growth in Pten(+/-) mice was dependent on mTOR, as evidenced by a reduction in both phospho-S6 levels and proliferative index after rapamycin treatment.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Mus musculus	71-75
16160607-0	2005	Involvement of c-Jun NH2 terminal kinase and p38MAPK in rapamycin-mediated inhibition of neointimal formation in rat carotid arteries.	Sirolimus	56-65	mitogen-activated protein kinase 8	Rattus norvegicus	15-40
16160607-5	2005	Ten nmol/L of rapamycin prevented the activation of JNK, p38MAPK, AP-1, and NF-kB (65%, 65%, 67%, and 26% respectively, P&lt;0.01).	Sirolimus	14-23	mitogen-activated protein kinase 8	Rattus norvegicus	52-55
16160607-5	2005	Ten nmol/L of rapamycin prevented the activation of JNK, p38MAPK, AP-1, and NF-kB (65%, 65%, 67%, and 26% respectively, P&lt;0.01).	Sirolimus	14-23	nuclear factor kappa B subunit 1	Rattus norvegicus	76-81
16160607-8	2005	Rapamycin prevented the increase in activation of JNK, p38MAPK, AP-1, and NF-kB in injured artery (42%, 70%, 75%, and 60% respectively, P&lt;0.05).	Sirolimus	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
16160607-8	2005	Rapamycin prevented the increase in activation of JNK, p38MAPK, AP-1, and NF-kB in injured artery (42%, 70%, 75%, and 60% respectively, P&lt;0.05).	Sirolimus	0-9	nuclear factor kappa B subunit 1	Rattus norvegicus	74-79
16160607-9	2005	CONCLUSIONS: Neointimal formation after balloon injury is inhibited by rapamycin, which is partially mediated by inhibition of JNK and p38MAPK, followed by AP-1 and NF-kB.	Sirolimus	71-80	mitogen-activated protein kinase 8	Rattus norvegicus	127-130
16160607-9	2005	CONCLUSIONS: Neointimal formation after balloon injury is inhibited by rapamycin, which is partially mediated by inhibition of JNK and p38MAPK, followed by AP-1 and NF-kB.	Sirolimus	71-80	nuclear factor kappa B subunit 1	Rattus norvegicus	165-170
15940265-12	2005	To the authors" best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone.	Sirolimus	300-309	mechanistic target of rapamycin kinase	Mus musculus	79-83
16103051-9	2005	The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process.	Sirolimus	4-13	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	77-106
15946946-7	2005	The association of eIF3j with the other eIF3 subunits appears to be inhibited by rapamycin, suggesting a mechanism that lies downstream from the mammalian target of rapamycin kinase.	Sirolimus	81-90	eukaryotic translation initiation factor 3 subunit J	Homo sapiens	19-24
19539558-7	2009	Even though the cell numbers of CD4(+) T cells were found to decrease in sirolimus-treated mice, sirolimus selectively enhanced the numbers of CD4(+)CD25(+) cells and increased the expression of Foxp3 in spleens and lymph nodes, respectively, in recipients.	Sirolimus	97-106	forkhead box P3	Mus musculus	195-200
15911613-7	2005	Gln3-Myc13 phosphorylation levels are regulated by at least three mechanisms as follows: (i) depends on Snf1 kinase as observed during carbon starvation, (ii) is Snf1-independent as observed during both carbon starvation and MSX treatment, and (iii) is rapamycin-induced dephosphorylation.	Sirolimus	253-262	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	0-4
15988698-7	2005	Rapamycin, an inhibitor or mTOR, could partially improve insulin-stimulated glucose uptake through maintaining IRS-1 protein levels.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	111-116
15944259-5	2005	In the present study, we showed that TCR engagement does not influence hypoxia-dependent stabilization but stimulates protein synthesis of HIF-1alpha, most possibly via PI3K/mammalian target of rapamycin system, and that expression of HIF-1alpha and its target genes is blocked by treatment with rapamycin.	Sirolimus	194-203	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	37-40
15705789-2	2005	In Akt-transformed leukemic cells, tumor growth can be inhibited by the mTOR inhibitor rapamycin, and clinical trials of rapamycin analogs for the treatment of leukemia are under way.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Mus musculus	72-76
15705789-5	2005	Primary hematopoietic cells from Pim-2- and Pim-1/Pim-2-deficient animals failed to accumulate and underwent apoptosis in the presence of rapamycin.	Sirolimus	138-147	proviral integration site 1	Mus musculus	44-49
15833854-5	2005	mTOR inhibition in K-ras(LA1) mice by treatment with the rapamycin analogue CCI-779 reduced the size and number of early epithelial neoplastic lesions (atypical alveolar hyperplasia and adenomas) and induced apoptosis of intraepithelial macrophages.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Mus musculus	0-4
19377829-6	2009	G-CSF promoted the viability of MSCs, and the promotion was completely inhibited by PKC inhibitor straurosporine and partially inhibited by wortmannin, rapamycin, PD98059, SB203580 or G0697.	Sirolimus	152-161	colony stimulating factor 3	Homo sapiens	0-5
19351759-9	2009	In vitro results showed that MSI-H cell lines due to hypermethylation of MLH1 are preferentially targeted by rapamycin (18.3 versus 4.4 mumol/L; P = 0.0824) and LY-294002 (15.02 versus 10.37 mumol/L; P = 0.0385) when compared with microsatellite-stable cells.	Sirolimus	109-118	RB binding protein 4, chromatin remodeling factor	Homo sapiens	29-32
19351759-9	2009	In vitro results showed that MSI-H cell lines due to hypermethylation of MLH1 are preferentially targeted by rapamycin (18.3 versus 4.4 mumol/L; P = 0.0824) and LY-294002 (15.02 versus 10.37 mumol/L; P = 0.0385) when compared with microsatellite-stable cells.	Sirolimus	109-118	mutL homolog 1	Homo sapiens	73-77
19368729-6	2009	RESULTS: Here, we examine the efficacy of a prolonged maintenance dose of rapamycin in Tsc2+/- mice with TSC-related kidney tumors.	Sirolimus	74-83	TSC complex subunit 2	Mus musculus	87-91
19368729-9	2009	We observed a 94.5% reduction in kidney tumor burden in Tsc2+/- mice treated (part one) daily with rapamycin (8 mg/kg) at 6 months <or= age < 7 months, (part 2) weekly with rapamycin (16 mg/kg) at 7 months <or= age < 12 months, and (part 3) daily with rapamycin (8 mg/kg) at 12 months <or= age < 13 months; but we did not observe any improvement with combination IFN-g plus rapamycin in this study.	Sirolimus	99-108	TSC complex subunit 2	Mus musculus	56-60
15833854-5	2005	mTOR inhibition in K-ras(LA1) mice by treatment with the rapamycin analogue CCI-779 reduced the size and number of early epithelial neoplastic lesions (atypical alveolar hyperplasia and adenomas) and induced apoptosis of intraepithelial macrophages.	Sirolimus	57-66	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	19-24
19332874-6	2009	Pretreating with the IL-2-IL-2 mAb complexes renders the mice resistant to induction of experimental autoimmune encephalomyelitis; combined with rapamycin, the complexes can also be used to treat ongoing disease.	Sirolimus	145-154	interleukin 2	Mus musculus	21-25
19332874-6	2009	Pretreating with the IL-2-IL-2 mAb complexes renders the mice resistant to induction of experimental autoimmune encephalomyelitis; combined with rapamycin, the complexes can also be used to treat ongoing disease.	Sirolimus	145-154	interleukin 2	Mus musculus	26-30
19168580-6	2009	Furthermore, Pin1 enhanced the insulin-induced extracellular signal-regulated protein kinase (ERK)1/2 phosphorylation through its interaction with p70S6K, whereas the inhibition of p70S6K activity by rapamycin suppressed insulin-induced ERK1/2 phosphorylation in SK-HEP-1 cells.	Sirolimus	200-209	ribosomal protein S6 kinase B1	Homo sapiens	181-187
15796538-6	2005	The FKBP12.rapamycin complex, however, binds to FRB 2000-fold more tightly (K(d) = 12 +/- 0.8 nM) than rapamycin alone.	Sirolimus	11-20	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	4-10
19356713-5	2009	Insulin resistance induced by HF/BCAA feeding was accompanied by chronic phosphorylation of mTOR, JNK, and IRS1Ser307 and by accumulation of multiple acylcarnitines in muscle, and it was reversed by the mTOR inhibitor, rapamycin.	Sirolimus	219-228	insulin receptor substrate 1	Homo sapiens	107-111
19356717-6	2009	Treatment with the mTOR inhibitor, rapamycin, ameliorated the hyperphagia, obesity, and the altered Pomc neuronal morphology in developing or adult Pomc-Tsc1cKO mice, and cessation of treatment reinstated these phenotypes.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Mus musculus	19-23
19261747-4	2009	Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies.	Sirolimus	114-123	phosphatase and tensin homolog	Homo sapiens	48-52
19151764-8	2009	We also show that rapamycin treatment triggers activation of cell survival signaling pathway by activating the prosurvival kinases Erk1/2 and p90RSK.	Sirolimus	18-27	ribosomal protein S6 kinase A1	Homo sapiens	142-148
15659381-6	2005	Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	90-94
18649135-11	2009	Furthermore, after being treated with RPM, STAT3 activation was also depressed, which resulted a decreased proliferation of cholangiocytes.	Sirolimus	38-41	signal transducer and activator of transcription 3	Rattus norvegicus	43-48
19073772-8	2009	Nuclear translocation of beta-catenin responsible for cell proliferation was found to be particularly sensitive to rapamycin.	Sirolimus	115-124	catenin beta 1	Homo sapiens	25-37
15659381-6	2005	Deletion or mutations within this RSPRR motif partially rescue the kinase activity of the S6K1 TOS motif mutant (S6K1-F5A), and this rescued activity is rapamycin resistant.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	113-117
19074484-5	2009	mTOR inhibition with rapamycin at below pharmacological concentrations blocked p70S6K phosphorylation and induced a differentiated contractile phenotype with smooth muscle (sm)-calponin, sm-alpha-actin, and SM protein 22-alpha (SM22alpha) expression.	Sirolimus	21-30	ribosomal protein S6 kinase B1	Homo sapiens	79-85
15781656-6	2005	Blockade of the mTOR pathway with rapamycin or its analog, cell cycle inhibitor-779 led to significant inhibition of experimental lung metastasis in vivo.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	16-20
19143643-8	2009	Recent studies in mouse models carrying heterozygous Tsc2 mutations demonstrated improvement in memory and learning deficits following treatment with rapamycin.	Sirolimus	150-159	TSC complex subunit 2	Mus musculus	53-57
15576463-4	2005	Inhibition of mTOR/S6K1 by rapamycin increased insulin-stimulated glucose transport by as much as 45% in 3T3-L1 adipocytes.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	19-23
19013662-10	2009	We also show that IGF-I and EGF are involved in the activation of mTOR in bovine MEC, whereas inhibition of mTOR by rapamycin abrogated the suppressive effects of IGF-I and EGF on autophagy.	Sirolimus	116-125	epidermal growth factor	Bos taurus	173-176
15576463-8	2005	As in murine cells, rapamycin treatment of human adipocytes inhibited S6K1, blunted Ser636/639 phosphorylation of IRS-1, leading to increased Akt activation and glucose uptake by insulin.	Sirolimus	20-29	ribosomal protein S6 kinase B1	Homo sapiens	70-74
15576463-8	2005	As in murine cells, rapamycin treatment of human adipocytes inhibited S6K1, blunted Ser636/639 phosphorylation of IRS-1, leading to increased Akt activation and glucose uptake by insulin.	Sirolimus	20-29	insulin receptor substrate 1	Homo sapiens	114-119
15576463-9	2005	Further studies in 3T3-L1 adipocytes revealed that rapamycin prevented the relocalization of IRS-1 from the low-density membranes to the cytosol in response to insulin.	Sirolimus	51-60	insulin receptor substrate 1	Homo sapiens	93-98
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	46-55	ribosomal protein S6 kinase B1	Homo sapiens	148-154
19436942-5	2009	Pretreatment of rapa had an inhibitory effect on the IFN-alpha-induced expression of PKR and p48 in a dose dependent manner.	Sirolimus	16-20	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	85-88
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	185-194	ribosomal protein S6 kinase B1	Homo sapiens	148-154
15358595-6	2005	Inhibition of phosphatidylinositol (PI)3-kinase with LY-294002 or mTOR/p70S6K1 with rapamycin reduced [3H]thymidine incorporation by 50%, i.e., to levels comparable to those achieved by addition of either AG-1478 or GM-6001.	Sirolimus	84-93	ribosomal protein S6 kinase B1	Rattus norvegicus	71-78
19330036-4	2009	Inhibitors of mTOR such as rapamycin can prevent K-Ras-driven lung tumorigenesis and alter the proportion of cytotoxic and Foxp3+ regulatory T cells, suggesting that lung-associated T cells might be important for tumorigenesis.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Mus musculus	14-18
15501927-8	2005	The activation of p70S6K/S6 pathway was sensitive to inhibition by rapamycin and LY294002, indicating that mTOR and PI3K/Akt are upstream signaling regulators.	Sirolimus	67-76	ribosomal protein S6 kinase B1	Homo sapiens	18-24
19330036-4	2009	Inhibitors of mTOR such as rapamycin can prevent K-Ras-driven lung tumorigenesis and alter the proportion of cytotoxic and Foxp3+ regulatory T cells, suggesting that lung-associated T cells might be important for tumorigenesis.	Sirolimus	27-36	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	49-54
19330036-4	2009	Inhibitors of mTOR such as rapamycin can prevent K-Ras-driven lung tumorigenesis and alter the proportion of cytotoxic and Foxp3+ regulatory T cells, suggesting that lung-associated T cells might be important for tumorigenesis.	Sirolimus	27-36	forkhead box P3	Mus musculus	123-128
15557109-10	2005	Rapamycin also resulted in a significant decrease in the size of the Tsc2-related renal tumors.	Sirolimus	0-9	TSC complex subunit 2	Rattus norvegicus	69-73
19126383-0	2009	[Effect of Rapamycin and Cyclosporin A on the expression of TLR5 and Foxp3 in allorejection].	Sirolimus	11-20	toll-like receptor 5	Mus musculus	60-64
19126383-0	2009	[Effect of Rapamycin and Cyclosporin A on the expression of TLR5 and Foxp3 in allorejection].	Sirolimus	11-20	forkhead box P3	Mus musculus	69-74
19126383-1	2009	AIM: To study the effect of Rapamycin (RAPA) and Cyclosporin A (CsA) on the expression of TLR5 and Foxp3 in allotransplantation model in vivo.	Sirolimus	28-37	toll-like receptor 5	Mus musculus	90-94
19126383-1	2009	AIM: To study the effect of Rapamycin (RAPA) and Cyclosporin A (CsA) on the expression of TLR5 and Foxp3 in allotransplantation model in vivo.	Sirolimus	28-37	forkhead box P3	Mus musculus	99-104
20641681-8	2004	For example, PAI-2 (triciribine) and perifosine are potent and selective inhibitors of Akt, rapamycin is an inhibitor for downstream mTOR, and LY294002 is an inhibitor for upstream PI3K.	Sirolimus	92-101	serpin family B member 2	Homo sapiens	13-18
15808578-11	2005	In conclusion, the mechanism of tacrolimus and sirolimus induced long-term allograft survival in primates relates to up-regulated FasL expression, NKT cells and dendritic cells, with downregulation of MLR sensitivity.	Sirolimus	47-56	Fas ligand	Homo sapiens	130-134
18925875-11	2008	Moreover, rapamycin treatment of HEK (human embryonic kidney)-293, MCF-7 or HeLa cells suppressed phosphorylation of S6K, without affecting SGK1 phosphorylation or activation.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	117-120
18945681-6	2008	We report here that although there are clear differences in the sensitivity of HIF1 alpha and HIF2 alpha to rapamycin, both HIF1 alpha and HIF2 alpha expression is dependent on mTOR.	Sirolimus	108-117	endothelial PAS domain protein 1	Homo sapiens	94-104
15520200-9	2004	Indeed, VEGF-induced proliferation of HUVECs was sensitive to rapamycin, an inhibitor of p70 S6K activation.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	89-96
18853950-0	2008	The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer.	Sirolimus	14-23	kallikrein related peptidase 3	Homo sapiens	27-58
18853950-5	2008	Pretransplant PSA was similar for sirolimus versus tacrolimus recipients (mean, 1.8 versus 1.7 ng/mL, p = 0.89), but posttransplant PSA was significantly lower for recipients on sirolimus (mean, 0.9 versus 1.9 ng/mL, respectively, p &lt; 0.001).	Sirolimus	178-187	kallikrein related peptidase 3	Homo sapiens	132-135
15634505-7	2004	In rapamycin treated group, the expression of HIF-1alpha was inhibited to weak positive or negative (P &lt; 0.05), the VEGF protein and mRNA expression decreased (P &lt; 0.05), MVD was also suppressed to a low level (13 +/- 5).	Sirolimus	3-12	hypoxia inducible factor 1, alpha subunit	Mus musculus	46-56
18853950-6	2008	The mean difference between pretransplant and posttransplant PSA was -0.9 ng/mL (50.0%, p = 0.006) for the sirolimus group versus +0.2 ng/mL (+11.8%, p = 0.24) for the tacrolimus group.	Sirolimus	107-116	kallikrein related peptidase 3	Homo sapiens	61-64
18853950-7	2008	By multivariate analysis, only pretransplant PSA and immunosuppression with sirolimus independently impacted posttransplant PSA.	Sirolimus	76-85	kallikrein related peptidase 3	Homo sapiens	124-127
18853950-8	2008	Our data strongly suggest that sirolimus is associated with a significant PSA decrease in kidney recipients.	Sirolimus	31-40	kallikrein related peptidase 3	Homo sapiens	74-77
18853950-9	2008	Future studies must investigate the clinical implications of our findings for the use of PSA for prostate cancer screening in male kidney recipients on sirolimus.	Sirolimus	152-161	kallikrein related peptidase 3	Homo sapiens	89-92
15367412-6	2004	The PTEN-negative cell line displayed greater sensitivity to the growth inhibitory effects of the PI3K inhibitor, LY294002 and rapamycin, an inhibitor of the PI3K/Akt downstream mediator mTOR, compared with the PTEN-positive cell lines.	Sirolimus	127-136	phosphatase and tensin homolog	Homo sapiens	4-8
18644437-3	2008	Drugs like rapamycin, that induce autophagy, increase the clearance of mutant huntingtin fragments and ameliorate the pathology in cell and animal models of HD and related conditions.	Sirolimus	11-20	huntingtin	Drosophila melanogaster	78-88
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	insulin-like growth factor 1	Rattus norvegicus	170-175
15381120-1	2004	The Saccharomyces cerevisiae allantoate/ureidosuccinate permease gene (DAL5) is often used as a reporter in studies of the Tor1/2 protein kinases which are specifically inhibited by the clinically important immunosuppressant and anti-neoplastic drug, rapamycin.	Sirolimus	251-260	allantoate permease	Saccharomyces cerevisiae S288C	71-75
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	239-247
18784743-2	2008	Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27(kip1) and downregulation of c-Myc.	Sirolimus	47-56	interferon alpha inducible protein 27	Homo sapiens	212-215
15385826-2	2004	Likewise, sirolimus is a substrate for the major drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp), both of which are expressed in close proximity in epithelial cells lining the small intestine.	Sirolimus	10-19	phosphoglycolate phosphatase	Homo sapiens	146-150
18784743-2	2008	Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27(kip1) and downregulation of c-Myc.	Sirolimus	47-56	cyclin dependent kinase inhibitor 1B	Homo sapiens	216-220
18784743-2	2008	Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27(kip1) and downregulation of c-Myc.	Sirolimus	47-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	244-249
15385826-9	2004	Sirolimus, seco-sirolimus (basolaterally dosed), and M2 were all secreted across the apical membrane, and secretion of each was inhibited by the P-gp inhibitor LY335979 (zosuquidar trihydrochloride).	Sirolimus	0-9	phosphoglycolate phosphatase	Homo sapiens	145-149
15385826-10	2004	Along with CYP3A4-mediated metabolism and P-gp-mediated efflux, a novel elimination pathway was identified that may also contribute to the first-pass extraction, and hence low oral bioavailability, of sirolimus.	Sirolimus	201-210	phosphoglycolate phosphatase	Homo sapiens	42-46
15286700-7	2004	Furthermore, rapamycin, an inhibitor of mTOR and consequently of p70S6K, did not alter PRL stimulation of c-Myc and c-Fos mRNA expression and it had a very minor inhibitory effect on PRL stimulation of W53 cell proliferation.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	40-44
18511708-6	2008	Responsiveness to rapamycin correlated with staining for the mTOR target, p-S6K, in the original tumor, but not for p-Akt.	Sirolimus	18-27	ribosomal protein S6 kinase B1	Homo sapiens	74-79
18790727-8	2008	The number of cells in myocardial biopsies positive for p27Kip1, a protein induced by mTOR inhibition, increased in sirolimus-treated subjects (P = 0.0005) and did not change in controls (P = 0.54) suggesting sirolimus acted directly on myocardium.	Sirolimus	116-125	cyclin dependent kinase inhibitor 1B	Homo sapiens	56-63
18790727-8	2008	The number of cells in myocardial biopsies positive for p27Kip1, a protein induced by mTOR inhibition, increased in sirolimus-treated subjects (P = 0.0005) and did not change in controls (P = 0.54) suggesting sirolimus acted directly on myocardium.	Sirolimus	209-218	cyclin dependent kinase inhibitor 1B	Homo sapiens	56-63
18685609-0	2008	Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.	Sirolimus	0-9	nucleophosmin 1	Mus musculus	19-22
18685609-0	2008	Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.	Sirolimus	0-9	anaplastic lymphoma kinase	Mus musculus	23-26
18685609-0	2008	Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	99-103
18685609-5	2008	The mTOR inhibitor rapamycin suppressed activation of p70S6K in BaF3/NPM-ALK cells and reversed GC resistance by synergistically inhibiting mTOR signaling pathway, enhancing cell cycle arrest at G(1) phase and promoting apoptotic cell death.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
18685609-5	2008	The mTOR inhibitor rapamycin suppressed activation of p70S6K in BaF3/NPM-ALK cells and reversed GC resistance by synergistically inhibiting mTOR signaling pathway, enhancing cell cycle arrest at G(1) phase and promoting apoptotic cell death.	Sirolimus	19-28	nucleophosmin 1	Mus musculus	69-72
18685609-5	2008	The mTOR inhibitor rapamycin suppressed activation of p70S6K in BaF3/NPM-ALK cells and reversed GC resistance by synergistically inhibiting mTOR signaling pathway, enhancing cell cycle arrest at G(1) phase and promoting apoptotic cell death.	Sirolimus	19-28	anaplastic lymphoma kinase	Mus musculus	73-76
18685609-5	2008	The mTOR inhibitor rapamycin suppressed activation of p70S6K in BaF3/NPM-ALK cells and reversed GC resistance by synergistically inhibiting mTOR signaling pathway, enhancing cell cycle arrest at G(1) phase and promoting apoptotic cell death.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	140-144
18922904-8	2008	Mechanistically, we find that inhibition of the MAPK pathway circumvents a negative feedback loop imposed on the IGF-IR- insulin receptor substrate 1 (IRS-1) signaling complex, a molecular scenario that parallels the negative feedback loop between mTOR-p70S6K and IRS-1 that mediates rapamycin-directed IGF-IR signaling.	Sirolimus	284-293	insulin receptor substrate 1	Homo sapiens	151-156
18614546-0	2008	Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.	Sirolimus	81-90	RPTOR independent companion of MTOR complex 2	Homo sapiens	162-168
18614546-6	2008	We describe that in primary cells short-term treatment with rapamycin triggers dephosphorylation of rictor and sin1 exclusively in the cytoplasm, but does not affect mTORC2 assembly.	Sirolimus	60-69	RPTOR independent companion of MTOR complex 2	Homo sapiens	100-106
19176057-0	2008	[Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	13-17
19176057-0	2008	[Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].	Sirolimus	39-48	anaplastic lymphoma kinase	Mus musculus	106-109
18922461-2	2008	(2008) demonstrate that fatty acid biosynthesis, under the transcriptional control of SREBP1, is regulated by the rapamycin-sensitive mTOR signaling network, thus expanding the scope of biosynthetic processes integrated by mTOR.	Sirolimus	114-123	sterol regulatory element binding transcription factor 1	Homo sapiens	86-92
18602894-0	2008	Rapamycin down-regulates LDL-receptor expression independently of SREBP-2.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	25-37
18602894-7	2008	However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients.	Sirolimus	55-64	low density lipoprotein receptor	Homo sapiens	9-21
18602894-7	2008	However, LDL-receptor gene expression was decreased by rapamycin, suggesting that this may contribute to the hyperlipidaemia observed in rapamycin-treated patients.	Sirolimus	137-146	low density lipoprotein receptor	Homo sapiens	9-21
18602894-8	2008	Rapamycin did not affect mRNA stability, so the decrease in LDL-receptor gene expression is likely to be occurring at the transcriptional level, although independently of SREBP-2.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	60-72
18762023-4	2008	Furthermore, nuclear accumulation of the mature form of the sterol responsive element binding protein (SREBP1) and expression of SREBP target genes was blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	184-193	sterol regulatory element binding transcription factor 1	Homo sapiens	103-109
18594209-3	2008	We now report that Akt activation in response to rapamycin is abrogated by 17-allylamino-17-demethoxygeldanamycin (17-AAG), a heat shock protein 90 (HSP90) inhibitor.	Sirolimus	49-58	heat shock protein 90 alpha family class A member 1	Homo sapiens	126-147
18594209-3	2008	We now report that Akt activation in response to rapamycin is abrogated by 17-allylamino-17-demethoxygeldanamycin (17-AAG), a heat shock protein 90 (HSP90) inhibitor.	Sirolimus	49-58	heat shock protein 90 alpha family class A member 1	Homo sapiens	149-154
18594209-8	2008	Rapamycin/17-AAG combination alleviates the induction of HSP90 protein, a heat shock response frequently associated with 17-AAG monotherapy.	Sirolimus	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	57-62
15317677-7	2004	Furthermore, ANG II triggered dissociation of the translation initiation factor, eukaryotic initiation factor-4E, from its regulatory binding protein 4E-BP1, which was also inhibited by rapamycin and wortmannin.	Sirolimus	186-195	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	150-156
15349891-7	2004	These effects were antagonized by treatment with rapamycin, indicating that target of rapamycin (TOR) activity is required for eIF4F assembly in the regenerating liver.	Sirolimus	49-58	tortured	Mus musculus	76-95
15349891-7	2004	These effects were antagonized by treatment with rapamycin, indicating that target of rapamycin (TOR) activity is required for eIF4F assembly in the regenerating liver.	Sirolimus	49-58	tortured	Mus musculus	97-100
15235105-8	2004	In addition, there was a concentration-dependent inhibition of cell migration and p70S6K phosphorylation (Thr(389) and Thr(421)/Ser(424)) in the presence of Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR, a downstream of AKT).	Sirolimus	157-166	ribosomal protein S6 kinase B1	Homo sapiens	82-88
15213227-6	2004	Protein synthesis in wild-type livers was decreased concomitant with increased phosphorylation of eIF2 and decreased phosphorylation of 4E-BP1 and S6K1, translation regulators controlled nutritionally by mammalian target of rapamycin.	Sirolimus	224-233	ribosomal protein S6 kinase B1	Homo sapiens	147-151
15218033-1	2004	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53.	Sirolimus	29-38	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	184-220
15218033-1	2004	Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53.	Sirolimus	29-38	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	222-226
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
18568033-7	2008	Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Mus musculus	49-53
15208659-7	2004	Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	91-97
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	Sirolimus	13-22	early growth response 1	Homo sapiens	55-60
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	Sirolimus	13-22	cyclin dependent kinase 5	Homo sapiens	68-72
18534253-4	2008	A well-documented mechanism to induce autophagy is by inhibition of mTOR, a negative modulator of autophagy and rapamycin (sirolimus) is a commonly used inhibitor of mTOR.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Mus musculus	68-72
15208659-8	2004	LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	173-179
18534253-4	2008	A well-documented mechanism to induce autophagy is by inhibition of mTOR, a negative modulator of autophagy and rapamycin (sirolimus) is a commonly used inhibitor of mTOR.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Mus musculus	166-170
18534253-4	2008	A well-documented mechanism to induce autophagy is by inhibition of mTOR, a negative modulator of autophagy and rapamycin (sirolimus) is a commonly used inhibitor of mTOR.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	68-72
18534253-4	2008	A well-documented mechanism to induce autophagy is by inhibition of mTOR, a negative modulator of autophagy and rapamycin (sirolimus) is a commonly used inhibitor of mTOR.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	166-170
15199413-6	2004	Although a 90% reduction in TEL-PDGFbetaR expression was insufficient to induce cell death, stable siRNA expression sensitized transformed cells to the PDGFbetaR inhibitor imatinib or to the mTOR inhibitor rapamycin.	Sirolimus	206-215	mechanistic target of rapamycin kinase	Mus musculus	191-195
18587048-10	2008	The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Mus musculus	75-79
18587048-10	2008	The reduction of beta cell mass in betaTsc2(-/-) mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in beta cells.	Sirolimus	108-117	TSC complex subunit 2	Mus musculus	39-43
18332865-3	2008	A synergistic inhibitory interaction was observed when doxorubicin was combined with rapamycin in the phosphatase-deficient PTEN-transfected cells.	Sirolimus	85-94	phosphatase and tensin homolog	Homo sapiens	124-128
18448283-0	2008	Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma.	Sirolimus	19-28	lipoprotein lipase	Homo sapiens	103-121
18448283-9	2008	LPL activity in post-heparin normal human plasma was suppressed following the co-incubation with CsA, RAPA, FK-506 or MMF whereas HL activity remained unaffected.	Sirolimus	102-106	lipoprotein lipase	Homo sapiens	0-3
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	RPTOR independent companion of MTOR complex 2	Homo sapiens	165-171
18250144-7	2008	Under the conditions adopted, rapamycin inhibited both mammalian target-of-rapamycin complexes (mTORC1 and mTORC2), as indicated by the reduced amount of raptor and rictor bound to mTOR in immunoprecipitates and by the marked hypophosphorylation of protein S6 kinase I (p70S6K) and Akt, determined by western blotting.	Sirolimus	30-39	ribosomal protein S6 kinase B1	Homo sapiens	270-276
18443284-2	2008	Exposure of yeast cells to poor nitrogen sources or treatment with the Tor kinase inhibitor rapamycin elicits activation of Gln3 and transcription of nitrogen catabolite-repressed (NCR) genes whose products function in scavenging and metabolizing nitrogen.	Sirolimus	92-101	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	124-128
18303120-6	2008	Treatment with rapamycin [a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1)] inhibited the increased PTEN expression and partially restored insulin-stimulated glucose transport and Akt activation to insulin-resistant cells.	Sirolimus	15-24	phosphatase and tensin homolog	Homo sapiens	124-128
15150095-2	2004	We demonstrate a dramatic decrease of IFN-gamma expression in tumors and mouse embryo fibroblast cell lines that lack either Tsc1 or Tsc2, which is reversed by rapamycin (mammalian target of rapamycin inhibitor) therapy.	Sirolimus	160-169	TSC complex subunit 2	Mus musculus	133-137
18418060-3	2008	Recently it was proposed that rapamycin and its derivatives enhance the clearance (and/or reduce the accumulation) of mutant intracellular proteins causing proteinopathies such as tau, alpha-synuclein, ataxin-3, and full-length or fragments of huntingtin containing a polyglutamine (polyQ) expansion, by upregulating macroautophagy.	Sirolimus	30-39	synuclein alpha	Homo sapiens	185-200
15135246-8	2004	A selective inhibitor of S(6) kinase, rapamycin, reduced this effect of PDGF-BB, while Akt kinase inhibitor did not.	Sirolimus	38-47	ribosomal protein S6 kinase B1	Rattus norvegicus	25-36
18425342-6	2008	While the ability of cisplatin to induce apoptosis was attenuated in H69/CP cells, inhibition of p70S6K by rapamycin enhanced cisplatin-induced apoptosis in these cells as evident by the increase in cisplatin-induced poly(ADP-ribose) polymerase (PARP) cleavage.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	97-103
15067056-8	2004	When we examined the phosphorylation of 4EBP-1, a downstream substrate of the mammalian target of rapamycin, we found that rapamycin, but not SFA, inhibited the mammalian target of rapamycin activity.	Sirolimus	98-107	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	40-46
18343502-0	2008	Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation.	Sirolimus	0-9	toll like receptor 4	Homo sapiens	21-25
18343502-0	2008	Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation.	Sirolimus	0-9	toll like receptor 4	Homo sapiens	99-103
18343502-7	2008	Furthermore, disruption of NF-kappaB pathway contributes to the inhibition of TLR4-induced IL-6, PGE(2) production and invasion by rapamycin in colon cancer cells.	Sirolimus	131-140	toll like receptor 4	Homo sapiens	78-82
18343502-9	2008	Therefore, we demonstrate that rapamycin may abrogate TLR4-triggered tumor cell immune escape and invasion by downregulating TLR4 expression and inhibiting TLR4-activated NF-kappaB pathway, thus providing new mechanistic explanation for the antitumor effect of rapamycin.	Sirolimus	31-40	toll like receptor 4	Homo sapiens	54-58
18343502-9	2008	Therefore, we demonstrate that rapamycin may abrogate TLR4-triggered tumor cell immune escape and invasion by downregulating TLR4 expression and inhibiting TLR4-activated NF-kappaB pathway, thus providing new mechanistic explanation for the antitumor effect of rapamycin.	Sirolimus	31-40	toll like receptor 4	Homo sapiens	125-129
18343502-9	2008	Therefore, we demonstrate that rapamycin may abrogate TLR4-triggered tumor cell immune escape and invasion by downregulating TLR4 expression and inhibiting TLR4-activated NF-kappaB pathway, thus providing new mechanistic explanation for the antitumor effect of rapamycin.	Sirolimus	31-40	toll like receptor 4	Homo sapiens	125-129
18343502-9	2008	Therefore, we demonstrate that rapamycin may abrogate TLR4-triggered tumor cell immune escape and invasion by downregulating TLR4 expression and inhibiting TLR4-activated NF-kappaB pathway, thus providing new mechanistic explanation for the antitumor effect of rapamycin.	Sirolimus	261-270	toll like receptor 4	Homo sapiens	54-58
15067056-9	2004	Based on these data, we propose that the decision as to whether TCR engagement will lead to productive activation or tolerance is dictated by a rapamycin -inhibitable pathway, independent of the G(1)--&gt;S phase cell cycle progression.	Sirolimus	144-153	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	64-67
15010863-4	2004	The phosphorylation and activity of PKB/Akt in IL2-stimulated CTLL2 cells were rapamycin-insensitive and reduced upon wortmannin treatment of the cells, confirming a requirement for PI-3K for Akt activity.	Sirolimus	79-88	interleukin 2	Mus musculus	47-50
15044617-6	2004	Comparative gene expression analysis of CASMCs treated with rapamycin (100 ng/ml) revealed down-regulation of the transcription factor E2F-1, a key regulator of G(1)/S-phase entry, and of various retinoblastoma protein/E2F-1-regulated genes.	Sirolimus	60-69	E2F transcription factor 1	Homo sapiens	135-140
18358095-7	2008	RESULTS: Rapamycin inhibited the proliferation of Jurkat, induced G1 phase arrest, unregulated the protein level of p21 as well as p27, and downregulated cyclinD3, phospho-p70s6k, and phospho-s6, but had no effect on apoptosis.	Sirolimus	9-18	H3 histone pseudogene 16	Homo sapiens	116-119
18358095-7	2008	RESULTS: Rapamycin inhibited the proliferation of Jurkat, induced G1 phase arrest, unregulated the protein level of p21 as well as p27, and downregulated cyclinD3, phospho-p70s6k, and phospho-s6, but had no effect on apoptosis.	Sirolimus	9-18	interferon alpha inducible protein 27	Homo sapiens	131-134
15044617-6	2004	Comparative gene expression analysis of CASMCs treated with rapamycin (100 ng/ml) revealed down-regulation of the transcription factor E2F-1, a key regulator of G(1)/S-phase entry, and of various retinoblastoma protein/E2F-1-regulated genes.	Sirolimus	60-69	E2F transcription factor 1	Homo sapiens	219-224
15044617-10	2004	Addition of EMAP-II counteracted the antiadhesive effect of rapamycin.	Sirolimus	60-69	aminoacyl tRNA synthetase complex interacting multifunctional protein 1	Homo sapiens	12-19
15060135-11	2004	In these cells, as well as in rapamycin-treated wild-type, S6K1(-/-), and S6K2(-/-) cells, this step was catalyzed by a mitogen-activated protein kinase (MAPK)-dependent kinase, most likely p90rsk.	Sirolimus	30-39	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	74-78
15029198-5	2004	Using a murine lymphoma model, we show that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Mus musculus	164-168
14660591-5	2004	Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin.	Sirolimus	88-97	ribosomal protein S6 kinase B1	Rattus norvegicus	35-41
18216495-4	2008	Using HL-1 cardiac-derived myocytes transfected with GFP-tagged LC3 to track changes in autophagosome formation, autophagy was stimulated by mTOR inhibitor rapamycin.	Sirolimus	156-165	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	64-67
18216495-4	2008	Using HL-1 cardiac-derived myocytes transfected with GFP-tagged LC3 to track changes in autophagosome formation, autophagy was stimulated by mTOR inhibitor rapamycin.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Mus musculus	141-145
18261725-6	2008	Furthermore, rictor knockdown decreased the phosphorylation of Akt (Ser 473) by 40-60% upon rapamycin pretreatment.	Sirolimus	92-101	RPTOR independent companion of MTOR complex 2	Homo sapiens	13-19
18261725-7	2008	GS activity followed similar trends as that of phosphorylated Akt and so with rictor levels in these cells pretreated with rapamycin; parental HepG2 cells showed a decrease in GS activity, whereas as HepG2-CA-Akt/PKB cells showed an increase in GS activity.	Sirolimus	123-132	RPTOR independent companion of MTOR complex 2	Homo sapiens	78-84
18021293-8	2008	Treatment with rapamycin, an mTOR inhibitor, blocked Cd-induced phosphorylation of S6K1 and eukaryotic initiation factor 4E binding protein 1, and markedly inhibited Cd-induced apoptosis.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	83-141
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	121-125
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	200-204
18060476-5	2008	Furthermore, rapamycin, a specific inhibitor of mTOR, blocked the activation of mTOR/p70S6K but not PI3K/Akt.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	85-91
18029408-0	2008	EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury.	Sirolimus	64-73	aminoacyl tRNA synthetase complex interacting multifunctional protein 1	Homo sapiens	0-7
18029408-10	2008	In patients, EMAP-II upregulation was confined to PCI of distal coronary artery segments and profoundly suppressed by oral rapamycin treatment.	Sirolimus	123-132	aminoacyl tRNA synthetase complex interacting multifunctional protein 1	Homo sapiens	13-20
18068336-6	2008	mTOR inhibitor rapamycin and a dominant negative mutant of mTOR suppressed TGFbeta-induced phosphorylation of S6 kinase and 4EBP-1.	Sirolimus	15-24	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	124-130
18192922-11	2008	Glomerular and tubulointerstitial PAI-1 expression was reduced compared to the baseline in the RAPA group, while they were unchanged in the CNI group.	Sirolimus	95-99	serpin family E member 1	Homo sapiens	34-39
18192922-13	2008	CONCLUSIONS: These data suggest that rapamycin may modulate ECM deposition in CAN reducing PAI-1 expression.	Sirolimus	37-46	serpin family E member 1	Homo sapiens	91-96
14592809-8	2004	Rapamycin also induced expression of the cyclin-dependent kinase inhibitors p21(cip) and p27(kip), consistent with cell cycle withdrawal.	Sirolimus	0-9	H3 histone pseudogene 16	Homo sapiens	76-79
14592809-8	2004	Rapamycin also induced expression of the cyclin-dependent kinase inhibitors p21(cip) and p27(kip), consistent with cell cycle withdrawal.	Sirolimus	0-9	interferon alpha inducible protein 27	Homo sapiens	89-92
14560955-1	2004	The p70 S6 kinase (p70 S6K) was the first signaling element in mammalian cells shown to be inhibited by rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	4-17
18819248-3	2008	Streptozotocin-induced diabetic BALB/c mice were transplanted with 500 Wistar-Furth rat islets under the kidney capsule and were either left untreated or treated with short-term administration of rapamycin (0.2 mg/kg) alone, anti-LFA-1 mAb (0.2 mg/ dose) alone, or a combination of rapamycin and anti-LFA-1 mAb using the same doses.	Sirolimus	196-205	integrin subunit alpha L	Rattus norvegicus	230-235
18819248-3	2008	Streptozotocin-induced diabetic BALB/c mice were transplanted with 500 Wistar-Furth rat islets under the kidney capsule and were either left untreated or treated with short-term administration of rapamycin (0.2 mg/kg) alone, anti-LFA-1 mAb (0.2 mg/ dose) alone, or a combination of rapamycin and anti-LFA-1 mAb using the same doses.	Sirolimus	196-205	integrin subunit alpha L	Rattus norvegicus	301-306
17940279-6	2007	VMP1 is induced by starvation and rapamycin treatments.	Sirolimus	34-43	vacuole membrane protein 1	Homo sapiens	0-4
17908691-0	2007	Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	71-99
17908691-0	2007	Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.	Sirolimus	0-9	AKT serine/threonine kinase 2	Homo sapiens	130-134
17908691-4	2007	Here, we show that rapamycin activates Akt and induces contractile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by relieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	166-170
17908691-4	2007	Here, we show that rapamycin activates Akt and induces contractile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by relieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).	Sirolimus	19-28	insulin receptor substrate 1	Homo sapiens	204-232
17908691-4	2007	Here, we show that rapamycin activates Akt and induces contractile protein expression in human VSMC in an insulin-like growth factor I-dependent manner, by relieving S6K1-dependent negative regulation of insulin receptor substrate-1 (IRS-1).	Sirolimus	19-28	insulin receptor substrate 1	Homo sapiens	234-239
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	19-23
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	34-39
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	74-79
17908691-7	2007	Rapamycin inhibits S6K1-dependent IRS-1 serine phosphorylation, increases IRS-1 protein levels, and promotes association of tyrosine-phosphorylated IRS-1 with PI3K.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	74-79
17908691-8	2007	A rapamycin-resistant S6K1 mutant prevents rapamycin-induced Akt activation and VSMC differentiation.	Sirolimus	2-11	ribosomal protein S6 kinase B1	Homo sapiens	22-26
17908691-9	2007	Notably, we find that rapamycin selectively activates only the Akt2 isoform and that Akt2, but not Akt1, is sufficient to induce contractile protein expression.	Sirolimus	22-31	AKT serine/threonine kinase 2	Homo sapiens	63-67
17908691-10	2007	Akt2 is required for rapamycin-induced VSMC differentiation, whereas Akt1 appears to oppose contractile protein expression.	Sirolimus	21-30	AKT serine/threonine kinase 2	Homo sapiens	0-4
17991718-6	2007	Rapamycin, an inhibitor of mTOR, abolished diabetes-induced changes in phosphorylation of eEF2, eEF2 kinase, and p70S6 kinase and ameliorated renal hypertrophy and laminin-beta1 protein content, without affecting hyperglycemia.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
17991718-6	2007	Rapamycin, an inhibitor of mTOR, abolished diabetes-induced changes in phosphorylation of eEF2, eEF2 kinase, and p70S6 kinase and ameliorated renal hypertrophy and laminin-beta1 protein content, without affecting hyperglycemia.	Sirolimus	0-9	eukaryotic translation elongation factor 2	Mus musculus	90-94
17986349-12	2007	Treatment with rapamycin was more effective in reducing tumor growth and improving survival in nude mice bearing Tsc2-/- tumors and also resulted in higher rapamycin levels in blood, brain, and kidney tissue than treatment with an equal milligram dose of CCI-779.	Sirolimus	15-24	TSC complex subunit 2	Mus musculus	113-117
17804674-4	2007	Immunohistochemistry showed that sirolimus attenuated the increased expression of renal vascular endothelial growth factor (VEGF), as well as the expression of VEGF receptors 1 and 2.	Sirolimus	33-42	vascular endothelial growth factor A	Rattus norvegicus	160-164
17804674-5	2007	In conclusion, sirolimus halted the progression of proteinuria and structural damage in a rat model of reduced renal mass, possibly through a reduction in renal VEGF activity.	Sirolimus	15-24	vascular endothelial growth factor A	Rattus norvegicus	161-165
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	234-238
17334390-1	2007	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	257-291
17660033-1	2007	BACKGROUND: Inhibition of P70S6 kinase (P70(S6K)) phosphorylation in activated T cells is 1 of the major mechanisms by which rapamycin exerts its immunosuppressive action.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	26-29
17660033-5	2007	OUTCOMES &amp; MEASUREMENTS: Basal and stimulated phosphorylation of P70(S6K) was measured by using Western blotting in patients" peripheral-blood mononuclear cells before and 6 to 11 months after conversion to rapamycin-based therapy.	Sirolimus	211-220	ribosomal protein S6 kinase B1	Homo sapiens	69-72
17660033-7	2007	RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	48-51
17660033-7	2007	RESULTS: The potency of rapamycin inhibition of P70(S6K) phosphorylation varied among patients (RAPA blood concentration required to achieve 50% inhibition of P70(S6K) activation for mitogen-activated kinase, 3.14 to 12.14 ng/mL) and failed to correlate with drug trough levels.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	159-162
17660033-8	2007	The combination of tacrolimus and rapamycin limited the inhibitory effect of the latter drug on P70(S6K) activation.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	96-99
17660033-11	2007	CONCLUSIONS: Long-term rapamycin treatment inhibits P70(S6K) phosphorylation in peripheral-blood mononuclear cells without significant correlation with rapamycin trough levels.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	52-55
17641780-4	2007	Therapeutic targeting of the AKT/mTOR axis using a rapamycin (sirolimus) derivative ameliorated the serological, cellular, and pathological phenotypes associated with lupus.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Mus musculus	33-37
17699716-8	2007	In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.	Sirolimus	126-135	erb-b2 receptor tyrosine kinase 2	Mus musculus	48-53
17699716-8	2007	In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.	Sirolimus	126-135	erb-b2 receptor tyrosine kinase 2	Mus musculus	54-57
17389711-4	2007	Pretreatment with rapamycin prevented the feeding-induced phosphorylation of mTOR, eIF4G, and S6K1 but only partially attenuated the shift in 4E-BP1 into the gamma-form.	Sirolimus	18-27	ribosomal protein S6 kinase B1	Rattus norvegicus	94-98
14560955-1	2004	The p70 S6 kinase (p70 S6K) was the first signaling element in mammalian cells shown to be inhibited by rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	19-26
17412314-12	2007	Consequently, alpha2M-induced protein synthesis was inhibited upon treatment with the ERK1,2 inhibitor UO126 as well as by LY294002 and wortmannin, which inhibit PI3-kinase, and by rapamycin, which inhibits mammalian target of rapamycin (mTOR) downstream of Akt.	Sirolimus	181-190	alpha-2-macroglobulin	Homo sapiens	14-21
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	205-212
17394554-7	2007	In parallel, it was found that the NA-induced increase in MCT2 protein was almost completely blocked by LY294002 (phosphoinositide 3-kinase inhibitor) as well as by rapamycin (mTOR inhibitor), while mitogen-activated protein kinase kinase and p38 MAPK inhibitors had much smaller effects.	Sirolimus	165-174	solute carrier family 16 member 7	Homo sapiens	58-62
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	340-347
14560955-3	2004	The amino acid-/rapamycin-sensitive input and the PI-3 kinase input are co-dominant but largely independent, in that deletion of the amino-terminal and carboxy-terminal noncatalytic sequences flanking the p70 S6K catalytic domain renders the kinase insensitive to inhibition by both rapamycin and by withdrawal of amino acids, whereas this p70 S6K mutant remains responsive to activation by RTKs and to inhibition by wortmannin.	Sirolimus	283-292	ribosomal protein S6 kinase B1	Homo sapiens	205-212
17052793-10	2007	In porcine aortic smooth muscle cells (PASMC), G-CSF increased the growth rate, migration, STAT-3 phosphorylation, and VEGF, which were suppressed by rapamycin and AG490, a STAT-3 inhibitor.	Sirolimus	150-159	signal transducer and activator of transcription 3	Sus scrofa	91-97
17052793-10	2007	In porcine aortic smooth muscle cells (PASMC), G-CSF increased the growth rate, migration, STAT-3 phosphorylation, and VEGF, which were suppressed by rapamycin and AG490, a STAT-3 inhibitor.	Sirolimus	150-159	vascular endothelial growth factor A	Sus scrofa	119-123
14569063-7	2004	Although both midazolam and sirolimus metabolites were preferentially excreted to the apical compartment, only sirolimus metabolites were transported by P-gp as determined from inhibition studies with GG918.	Sirolimus	111-120	phosphoglycolate phosphatase	Homo sapiens	153-157
17052793-10	2007	In porcine aortic smooth muscle cells (PASMC), G-CSF increased the growth rate, migration, STAT-3 phosphorylation, and VEGF, which were suppressed by rapamycin and AG490, a STAT-3 inhibitor.	Sirolimus	150-159	signal transducer and activator of transcription 3	Sus scrofa	173-179
14634209-6	2003	Rapamycin, a specific inhibitor of FRAP, did not inhibit growth of plasmacytoma cell lines.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	35-39
17516993-0	2007	Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase.	Sirolimus	62-71	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	111-118
17516993-0	2007	Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase.	Sirolimus	62-71	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	123-140
17516993-3	2007	As the sterol 27-hydroxylase (CYP27A1) inhibition by CsA is well known, we evaluated the effect of another immunosuppressive drug, RAPA, on this enzyme in HepG2 mitochondria, which confirmed the dose-dependent inhibition of mitochondrial CYP27A1 by cyclosporine (10-20 microM), while the inhibition by RAPA required a higher dose (50-100 microM).	Sirolimus	131-135	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	7-28
17543119-0	2007	Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to rapamycin susceptibility.	Sirolimus	101-110	FK506-binding protein 12	Arabidopsis thaliana	25-31
17543119-2	2007	The TOR protein kinase can be inactivated by the antibiotic rapamycin following the formation of a ternary complex between TOR, rapamycin and FKBP12 proteins.	Sirolimus	60-69	FK506-binding protein 12	Arabidopsis thaliana	142-148
14612424-7	2003	Rapamycin treatment led to a rapid dephosphorylation of the carboxy-terminal activation domain of the rDNA transcription factor, UBF, which significantly reduced its ability to associate with the basal rDNA transcription factor SL-1.	Sirolimus	0-9	matrix metallopeptidase 3	Mus musculus	228-232
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	phosphoglycolate phosphatase	Homo sapiens	48-52
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	phosphoglycolate phosphatase	Homo sapiens	246-250
12949840-4	2003	We found that the treatment of cells with rapamycin inhibited EGF-induced cell transformation but only slightly inhibited JB6 cell proliferation at 72 h. Although LY294002, a PI3K inhibitor, attenuated EGF-induced activator protein 1 (AP-1) activation, treatment with rapamycin did not affect AP-1 activity.	Sirolimus	42-51	epidermal growth factor	Homo sapiens	62-65
12949840-4	2003	We found that the treatment of cells with rapamycin inhibited EGF-induced cell transformation but only slightly inhibited JB6 cell proliferation at 72 h. Although LY294002, a PI3K inhibitor, attenuated EGF-induced activator protein 1 (AP-1) activation, treatment with rapamycin did not affect AP-1 activity.	Sirolimus	42-51	epidermal growth factor	Homo sapiens	202-205
12949840-4	2003	We found that the treatment of cells with rapamycin inhibited EGF-induced cell transformation but only slightly inhibited JB6 cell proliferation at 72 h. Although LY294002, a PI3K inhibitor, attenuated EGF-induced activator protein 1 (AP-1) activation, treatment with rapamycin did not affect AP-1 activity.	Sirolimus	268-277	epidermal growth factor	Homo sapiens	202-205
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	epidermal growth factor	Homo sapiens	35-38
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	91-112
12949840-5	2003	Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	114-121
12935893-0	2003	Rapamycin inhibits GM-CSF-induced neutrophil migration.	Sirolimus	0-9	colony stimulating factor 2	Homo sapiens	19-25
12935893-3	2003	Both neutrophil chemotaxis and chemokinesis elicited by granulocyte-macrophage colony-stimulating factor (GM-CSF) were strongly inhibited by rapamycin with an IC(50) of 0.3 nM.	Sirolimus	141-150	colony stimulating factor 2	Homo sapiens	56-104
12935893-3	2003	Both neutrophil chemotaxis and chemokinesis elicited by granulocyte-macrophage colony-stimulating factor (GM-CSF) were strongly inhibited by rapamycin with an IC(50) of 0.3 nM.	Sirolimus	141-150	colony stimulating factor 2	Homo sapiens	106-112
12935893-6	2003	Rapamycin also inhibited GM-CSF-induced actin polymerization, a hallmark of leukocyte migration.	Sirolimus	0-9	colony stimulating factor 2	Homo sapiens	25-31
12935893-7	2003	The specificity of the effect of rapamycin was confirmed by the use of the structural analog FK506, which did not have a significant effect on chemotaxis but effectively rescued rapamycin-induced p70S6K inhibition.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	196-202
12935893-7	2003	The specificity of the effect of rapamycin was confirmed by the use of the structural analog FK506, which did not have a significant effect on chemotaxis but effectively rescued rapamycin-induced p70S6K inhibition.	Sirolimus	178-187	ribosomal protein S6 kinase B1	Homo sapiens	196-202
12935893-9	2003	Additionally, GM-CSF-induced chemotaxis was completely (&gt;90%) blocked by a combination of rapamycin and the MAPK kinase (MEK) inhibitor PD-98059.	Sirolimus	93-102	colony stimulating factor 2	Homo sapiens	14-20
12939469-3	2003	Some investigators have hypothesized that loss of the PTEN tumor suppressor may sensitize tumor cells to the antiproliferative activity of rapamycin because PTEN loss leads to activation of the mTOR pathway.	Sirolimus	139-148	phosphatase and tensin homolog	Homo sapiens	54-58
12939469-6	2003	This effect is independent of PTEN status because PTEN-positive ECC-1 cells are as sensitive to rapamycin as PTEN-null Ishikawa and Hec-1B cells, suggesting that rapamycin may be effective against a broad range of endometrial cancers.	Sirolimus	96-105	phosphatase and tensin homolog	Homo sapiens	50-54
12939469-6	2003	This effect is independent of PTEN status because PTEN-positive ECC-1 cells are as sensitive to rapamycin as PTEN-null Ishikawa and Hec-1B cells, suggesting that rapamycin may be effective against a broad range of endometrial cancers.	Sirolimus	96-105	phosphatase and tensin homolog	Homo sapiens	50-54
12964903-3	2003	Rh30 (a rhabdomyosarcoma) made resistant to rapamycin was identical to its parent line and to a subline that had reverted to sensitivity after it was cultured without rapamycin in the medium.	Sirolimus	44-53	Rh blood group D antigen	Homo sapiens	0-4
12820961-4	2003	In contrast, Tap42 inactivation, as does inactivation of the protein phosphatases Sit4 and Pph21/22, blocks rapamycin induction of nitrogen discrimination pathway genes.	Sirolimus	108-117	Tap42p	Saccharomyces cerevisiae S288C	13-18
12820961-4	2003	In contrast, Tap42 inactivation, as does inactivation of the protein phosphatases Sit4 and Pph21/22, blocks rapamycin induction of nitrogen discrimination pathway genes.	Sirolimus	108-117	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	82-86
12820963-5	2003	Rapamycin induces p21(Cip1) binding to ASK1, suppressing kinase activity and attenuating cellular stress.	Sirolimus	0-9	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	39-43
12742462-9	2003	Sirolimus forms an immunosuppressive complex with intracellular protein, FKBP12.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	73-79
12742501-3	2003	Rapamycin upregulates the cyclin-dependent kinase inhibitor p27(kip1), resulting in cell-cycle arrest at the G1 to S transition.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	26-68
12681504-5	2003	Amino acid-induced S6K1 activation was inhibited by LY294002 (PI3-kinase inhibitor) and rapamycin (inhibitor of the mammalian target of rapamycin, mTOR), suggesting the involvement of an avian homolog of mTOR.	Sirolimus	88-97	ribosomal protein S6 kinase B1	Homo sapiens	19-23
12646195-6	2003	MCM6 and MCM7 transcriptional activation is regulated by E2F and activity of a luciferase reporter plasmid driven by four E2F elements was also significantly inhibited by rapamycin.	Sirolimus	171-180	minichromosome maintenance complex component 6	Rattus norvegicus	0-4
12646195-7	2003	The inhibitory effect of rapamycin on MCM6 and MCM7 was reversed by overexpression of E2F, indicating that their downregulation by rapamycin involves an E2F-dependent mechanism.	Sirolimus	25-34	minichromosome maintenance complex component 6	Rattus norvegicus	38-42
12646195-8	2003	These observations suggest that rapamycin inhibits MCM6 and MCM7 expression by blocking their E2F-dependent transactivation which may contribute importantly to the inhibition of VSMC DNA synthesis by rapamycin.	Sirolimus	32-41	minichromosome maintenance complex component 6	Rattus norvegicus	51-55
12591764-0	2003	Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin.	Sirolimus	0-9	heme oxygenase 1	Homo sapiens	18-34
12591764-0	2003	Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin.	Sirolimus	120-129	heme oxygenase 1	Homo sapiens	18-34
12591764-3	2003	In this study, we evaluated whether there is an interaction between rapamycin and HO-1.	Sirolimus	68-77	heme oxygenase 1	Homo sapiens	82-86
17607532-3	2007	Both rapamycin and paclitaxel decrease endothelial cell migration and proliferation; moreover, they induce tissue factor expression through specific interaction with signal transduction mediators.	Sirolimus	5-14	coagulation factor III, tissue factor	Homo sapiens	107-120
17452018-2	2007	mTOR exists in two complexes: mTOR Complex1, which is rapamycin-sensitive and phosphorylates S6K1 and initiation factor 4E binding proteins (4E-BPs), and mTOR Complex2, which is rapamycin-insensitive and phosphorylates protein kinase B (PKB, also known as Akt).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	93-97
12591764-4	2003	METHODS AND RESULTS: In human pulmonary artery endothelial or smooth muscle cells, HO-1 expression was evaluated in response to rapamycin or wortmannin, an inhibitor of the upstream modulator of mammalian target of rapamycin (mTOR) PI-3K.	Sirolimus	128-137	heme oxygenase 1	Homo sapiens	83-87
12591764-6	2003	Rapamycin induced HO-1 expression in both pulmonary endothelial and smooth muscle cells, whereas no to little increase was seen in response to another immunosuppressive agent, cyclosporin A.	Sirolimus	0-9	heme oxygenase 1	Homo sapiens	18-22
17437482-7	2007	Application of rapamycin to monoculture NF and KF, dose- and time-dependently downregulates the expression of cytoplasmic PCNA, cyclin D1, fibronectin, collagen and alpha-SMA, demonstrating the anti-proliferative effect and therapeutic potential of rapamycin in the treatment of keloid scars.	Sirolimus	15-24	proliferating cell nuclear antigen	Homo sapiens	122-126
12591764-9	2003	CONCLUSIONS: The induction of HO-1 expression by rapamycin and, more importantly, the effects of tin protoporphyrin, an inhibitor of HO activity, on the antiproliferative actions of rapamycin suggest that the effects of rapamycin may be, at least in part, modulated by its actions on HO-1.	Sirolimus	49-58	heme oxygenase 1	Homo sapiens	30-34
12591764-9	2003	CONCLUSIONS: The induction of HO-1 expression by rapamycin and, more importantly, the effects of tin protoporphyrin, an inhibitor of HO activity, on the antiproliferative actions of rapamycin suggest that the effects of rapamycin may be, at least in part, modulated by its actions on HO-1.	Sirolimus	182-191	heme oxygenase 1	Homo sapiens	30-34
17437482-7	2007	Application of rapamycin to monoculture NF and KF, dose- and time-dependently downregulates the expression of cytoplasmic PCNA, cyclin D1, fibronectin, collagen and alpha-SMA, demonstrating the anti-proliferative effect and therapeutic potential of rapamycin in the treatment of keloid scars.	Sirolimus	249-258	proliferating cell nuclear antigen	Homo sapiens	122-126
12591764-9	2003	CONCLUSIONS: The induction of HO-1 expression by rapamycin and, more importantly, the effects of tin protoporphyrin, an inhibitor of HO activity, on the antiproliferative actions of rapamycin suggest that the effects of rapamycin may be, at least in part, modulated by its actions on HO-1.	Sirolimus	182-191	heme oxygenase 1	Homo sapiens	284-288
12393532-0	2003	Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression.	Sirolimus	0-9	colony stimulating factor 2	Homo sapiens	39-45
17440093-6	2007	Rapamycin significantly reduced the incidence and severity of gallbladder carcinoma in BK5.erbB2 mice in a dose-dependent manner.	Sirolimus	0-9	erb-b2 receptor tyrosine kinase 2	Mus musculus	91-96
12393532-0	2003	Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression.	Sirolimus	0-9	cyclin dependent kinase inhibitor 1B	Homo sapiens	117-124
15626356-4	2003	We reported how it can inhibit the proliferation and migration of smooth muscle cells after a mechanical aggression, and demonstrated that this effect is mediated by p27 activation by rapamycin.	Sirolimus	184-193	interferon alpha inducible protein 27	Homo sapiens	166-169
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	63-66
16990847-6	2007	In contrast, full-length 4E-BP1 rapidly becomes rephosphorylated and this process is partially inhibited by rapamycin, PD98059 and CGP74514A.	Sirolimus	108-117	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	25-31
17382186-6	2007	By affecting downstream signaling, the MEK1/2 inhibitors U0126 and PD184352 blocked growth more effectively than did the EGFR inhibitors in selected renal cell carcinoma lines; this effect was enhanced by the addition of rapamycin.	Sirolimus	221-230	mitogen-activated protein kinase kinase 1	Homo sapiens	39-45
17164244-10	2007	Thus, this later action may partially account for the increased phosphorylation of eEF2 in response to EtOH and the observed sensitivity of AMPK to rapamycin and PD98059 treatments.	Sirolimus	148-157	eukaryotic translation elongation factor 2	Homo sapiens	83-87
17135708-7	2007	Rapamycin, a selective inhibitor of S6 kinase, reduced this effect of AVP, while Akt kinase inhibitor did not.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	36-45
17671379-7	2007	RESULTS: Rapamycin treatment reduced albuminuria, glomerular enlargement, glomerular basement membrane thickening, renal macrophage recruitment, and levels of renal mRNA expression of proliferating cell nuclear antigen, transforming growth factor-beta1, vascular endothelial growth factor, and monocyte chemoattractant protein-1 without change in blood glucose level and blood pressure in experimental diabetic rats.	Sirolimus	9-18	C-C motif chemokine ligand 2	Rattus norvegicus	294-328
16952420-5	2007	Rapamycin treatment partially decreased the phosphorylation of mTOR but completely abolished the phosphorylation of p70(S6K) in the absence as well as presence of insulin in both cell lines.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	116-119
16962100-10	2007	Interestingly, acetaldehyde enhanced p70(S6K) activation and depressed 4E-BP1 phosphorylation, the effect of which was blunted and exaggerated, respectively, by rapamycin.	Sirolimus	161-170	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	71-77
17013836-5	2006	While MEK-ERK1/2 inhibition by PD98059 and mTOR inhibition by rapamycin affected the cyclin D1 nuclear shift and cell proliferation to a lesser extent, both these inhibitors reduced cyclin D1 levels.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Mus musculus	43-47
16919239-5	2006	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment of dermal fibroblasts with rapamycin, a potent inhibitor of mTOR abolished procollagen I production.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	89-93
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	102-111	heat shock protein 1 (chaperonin)	Mus musculus	35-56
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	102-111	heat shock protein 1 (chaperonin)	Mus musculus	58-63
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	113-116	heat shock protein 1 (chaperonin)	Mus musculus	35-56
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	113-116	heat shock protein 1 (chaperonin)	Mus musculus	58-63
17324390-4	2006	Naive CD4(+) T cells expressed high levels of CD25 and forkhead box P3 (Foxp3) after incubation with rapamycin-treated and HSP60-loaded DC and displayed moderate antigen-specific, IL-10-independent inhibitory function in vitro.	Sirolimus	101-110	forkhead box P3	Mus musculus	55-70
17324390-4	2006	Naive CD4(+) T cells expressed high levels of CD25 and forkhead box P3 (Foxp3) after incubation with rapamycin-treated and HSP60-loaded DC and displayed moderate antigen-specific, IL-10-independent inhibitory function in vitro.	Sirolimus	101-110	forkhead box P3	Mus musculus	72-77
16984645-6	2006	Treatment of cells with Rapamycin, an inhibitor of mTOR, blocked the effects of EGF on beta-casein promotor driven luciferase activity as effectively as PI-3-kinase inhibitors.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	51-55
16984645-6	2006	Treatment of cells with Rapamycin, an inhibitor of mTOR, blocked the effects of EGF on beta-casein promotor driven luciferase activity as effectively as PI-3-kinase inhibitors.	Sirolimus	24-33	epidermal growth factor	Mus musculus	80-83
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	heart and neural crest derivatives expressed 2	Mus musculus	299-302
16894343-3	2006	EXPERIMENTAL APPROACH: We tested in vitro the potential of rapamycin to inhibit endothelial cell sprouting using the aortic ring assay and we further studied its effect on the expression of proliferating cell nuclear antigen (PCNA), apoptotic cell death-associated activated caspase-3 and vascular endothelial growth factor (VEGF) in cultured endometrial tissue fragments.	Sirolimus	59-68	caspase-3	Mesocricetus auratus	275-284
16717100-7	2006	Phosphorylation of p70(S6K), a known target of mTOR, occurred rapidly following T3 treatment and was inhibited by rapamycin and wortmannin.	Sirolimus	114-123	ribosomal protein S6 kinase B1	Homo sapiens	19-26
16717100-9	2006	40 S ribosomal protein S6, a target of p70(S6K), and 4E-BP1, a target of mTOR, were both phosphorylated within 15-25 min of T3 treatment and could be inhibited by wortmannin and rapamycin.	Sirolimus	178-187	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	53-59
16763566-2	2006	In response to insulin, eIF4B is phosphorylated on Ser422 by S6K in a rapamycin-sensitive manner.	Sirolimus	70-79	eukaryotic translation initiation factor 4B	Homo sapiens	24-29
16763566-2	2006	In response to insulin, eIF4B is phosphorylated on Ser422 by S6K in a rapamycin-sensitive manner.	Sirolimus	70-79	ribosomal protein S6 kinase B1	Homo sapiens	61-64
12504590-5	2002	Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR.	Sirolimus	128-137	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	83-90
12414639-6	2002	Treatment of PC-3 PTEN-negative cells with rapamycin inhibited 70-kDa S6 kinase and increased the proliferative response of these cells to doxorubicin, so that it was comparable with the responses of PTEN-positive DU-145 cells and the PC-3-transfected cells.	Sirolimus	43-52	phosphatase and tensin homolog	Homo sapiens	18-22
12183455-2	2002	Phosphorylation of this motif (FLGFT389Y) in p70 S6 kinase (S6K1) is both rapamycin- and wortmannin-sensitive, suggesting a role for both mammalian target of rapamycin- and phosphatidylinositol 3-kinase-dependent pathways.	Sirolimus	74-83	ribosomal protein S6 kinase B1	Homo sapiens	60-64
16702305-6	2006	In contrast, rapamycin decreased the phosphorylation of S6K2 and S6 in myotubes.	Sirolimus	13-22	ribosomal protein S6 kinase, polypeptide 2	Mus musculus	56-60
16651733-6	2006	Wortmannin and rapamycin were demonstrated to deactivate suppression of AQP3 expression by insulin and troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal pathway for regulating transcription of AQP3.	Sirolimus	15-24	aquaporin 3 (Gill blood group)	Homo sapiens	72-76
16651733-6	2006	Wortmannin and rapamycin were demonstrated to deactivate suppression of AQP3 expression by insulin and troglitazone, suggesting that the signal transducers, phosphoinositide 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), are involved in the signal pathway for regulating transcription of AQP3.	Sirolimus	15-24	aquaporin 3 (Gill blood group)	Homo sapiens	303-307
16651424-5	2006	In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance.	Sirolimus	96-105	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	119-148
16652094-1	2006	OBJECTIVE: Everolimus (RAD) is an mTOR inhibitor closely related to rapamycin.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Mus musculus	34-38
16490780-8	2006	This AP20187-mediated apoptosis was rapidly reversed by the addition of an FKBP12-binding competitor molecule (FK506 or rapamycin), indicating that this cell line might be used to screen FK506 derivatives.	Sirolimus	120-129	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	75-81
16672275-6	2006	The upregulation of stress genes as a consequence of treatment with rapamycin was largely Msn2p/Msn4p-dependent.	Sirolimus	68-77	stress-responsive transcriptional activator MSN2	Saccharomyces cerevisiae S288C	90-95
12393186-3	2002	Rapamycin, which binds to FRAP/mTOR and completely suppressed the activation of p70S6 kinase by insulin, almost completely blocked the induction of the hexokinase II gene, and caused an approximately 50% inhibition of the induction of the Fra-1 gene.	Sirolimus	0-9	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	239-244
12176053-4	2002	Wortmannin, a specific inhibitor of PI3K, partially inhibited G-CSF-induced p70 S6K activity and G-CSF-dependent proliferation, whereas rapamycin, an inhibitor of p70 S6K, completely inhibited these activities.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	163-170
12165425-4	2002	"Induction" of NCR-sensitive gene expression and dephosphorylation of Gln3 (and Ure2 in some laboratories) when cells are treated with rapamycin implicates the Tor1/2 signal transduction pathway in this regulation.	Sirolimus	135-144	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	70-74
12161190-6	2002	However, following a systemic administration of rapamycin, Epo was detected in the anterior chamber, peaking on day 3 and returning to baseline 2-3 weeks after withdrawal of the drug.	Sirolimus	48-57	erythropoietin	Rattus norvegicus	59-62
12054624-6	2002	Our data show that functional chemotaxis was inhibited by rapamycin, a specific p70S6K inhibitor, as well as by PD-98059.	Sirolimus	58-67	ribosomal protein S6 kinase B1	Homo sapiens	80-86
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	31-35
11937029-7	2002	We find that Mpk1 is transiently activated by rapamycin treatment via a novel mechanism.	Sirolimus	46-55	mitogen-activated serine/threonine-protein kinase SLT2	Saccharomyces cerevisiae S288C	13-17
11991199-8	2002	Rapamycin, an inhibitor of p70S6K, markedly suppressed DNA synthesis.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	27-33
16249016-11	2006	Treatment with rapamycin reduced hTERT mRNA expression in both rapamycin-sensitive and -resistant cell lines within 24 h. Thus, the effect of rapamycin on hTERT expression was not dependent on its ability to induce G1 cell cycle arrest.	Sirolimus	15-24	telomerase reverse transcriptase	Homo sapiens	33-38
16249016-11	2006	Treatment with rapamycin reduced hTERT mRNA expression in both rapamycin-sensitive and -resistant cell lines within 24 h. Thus, the effect of rapamycin on hTERT expression was not dependent on its ability to induce G1 cell cycle arrest.	Sirolimus	15-24	telomerase reverse transcriptase	Homo sapiens	155-160
16249016-11	2006	Treatment with rapamycin reduced hTERT mRNA expression in both rapamycin-sensitive and -resistant cell lines within 24 h. Thus, the effect of rapamycin on hTERT expression was not dependent on its ability to induce G1 cell cycle arrest.	Sirolimus	63-72	telomerase reverse transcriptase	Homo sapiens	33-38
16249016-11	2006	Treatment with rapamycin reduced hTERT mRNA expression in both rapamycin-sensitive and -resistant cell lines within 24 h. Thus, the effect of rapamycin on hTERT expression was not dependent on its ability to induce G1 cell cycle arrest.	Sirolimus	63-72	telomerase reverse transcriptase	Homo sapiens	155-160
16249016-12	2006	CONCLUSIONS: Our data suggest that rapamycin may potentially exert its anti-tumor effects through two independent pathways by G1 cell cycle arrest as well as suppression of telomerase activity by inhibition of hTERT mRNA transcription.	Sirolimus	35-44	telomerase reverse transcriptase	Homo sapiens	210-215
16368705-2	2006	Previously, we showed that rapamycin, an autophagy inducer, enhances mutant huntingtin fragment clearance and attenuated toxicity.	Sirolimus	27-36	huntingtin	Drosophila melanogaster	76-86
16926534-0	2006	Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.	Sirolimus	27-36	cellular communication network factor 2	Rattus norvegicus	58-89
16926534-3	2006	We tried to determine the effect of two commonly used immunosuppressants, cyclosporine (CsA) and sirolimus (SRL), on CTGF expression in a model of chronic nephrotoxicity.	Sirolimus	97-106	cellular communication network factor 2	Rattus norvegicus	117-121
16391472-11	2006	Rapamycin administration at 0.8 mg/kg/day for 7 days resulted in enhanced atrophy and attenuated the phosphorylation of ERK1, STAT3, and p70S6K without altering gene expression.	Sirolimus	0-9	signal transducer and activator of transcription 3	Rattus norvegicus	126-131
16391472-11	2006	Rapamycin administration at 0.8 mg/kg/day for 7 days resulted in enhanced atrophy and attenuated the phosphorylation of ERK1, STAT3, and p70S6K without altering gene expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	137-143
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	214-223	phosphoglycolate phosphatase	Homo sapiens	42-46
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	214-223	phosphoglycolate phosphatase	Homo sapiens	374-378
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	264-273	phosphoglycolate phosphatase	Homo sapiens	42-46
11907172-10	2002	Along with CYP3A4-mediated metabolism and P-gp-mediated secretion, we conclude that the following novel pathway, which occurs at least in the intestine, may contribute significantly to the first-pass extraction of sirolimus in humans: intracellular degradation of sirolimus to seco-rapamycin, metabolism of seco-rapamycin to M2 by an unidentified non-microsomal enzyme, and P-gp-mediated secretion of M2 and seco-rapamycin.	Sirolimus	264-273	phosphoglycolate phosphatase	Homo sapiens	374-378
11872661-4	2002	Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy.	Sirolimus	11-20	interleukin 2	Mus musculus	222-226
11872661-4	2002	Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy.	Sirolimus	208-217	interleukin 2	Mus musculus	25-29
11872661-7	2002	We conclude that 1) combination therapy with sirolimus and IL-2 is synergistic in protecting islet beta-cells from autoimmune destruction; 2) diabetes prevention continues after withdrawal of therapy; and 3) the mechanism of protection involves a shift from Th1- to Th2- and Th3-type cytokine-producing cells, possibly due to deletion of autoreactive Th1 cells.	Sirolimus	45-54	heart and neural crest derivatives expressed 2	Mus musculus	266-269
11935154-9	2002	Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA.	Sirolimus	18-27	interleukin 2	Mus musculus	143-147
11935154-9	2002	Islet grafts from sirolimus plus tacrolimus-treated mice expressed significantly decreased mRNA contents of Th1-type cytokines (IFN- gamma and IL-2) and the highest ratio of TGF- beta1/IFN- gamma mRNA.	Sirolimus	18-27	hemoglobin, beta adult major chain	Mus musculus	179-195
11935154-10	2002	CONCLUSION/INTERPRETATION: These findings suggest that combination therapy with sirolimus and tacrolimus prevent autoimmune beta-cell destruction by upregulating expression of the immunoregulatory cytokine, TGF- beta1 and reducing Th1 cytokines (IFN- gamma and IL-2) expressed in the islets.	Sirolimus	80-89	interleukin 2	Mus musculus	261-265
12030785-6	2001	In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity.	Sirolimus	82-91	phosphatase and tensin homolog	Homo sapiens	37-41
11707420-5	2001	However, similarly to yeast and Drosophila, loss of Cdh1 induced unscheduled accumulation of mitotic cyclins in G1, resulting in abrogation of G1 arrest caused by treatment with rapamycin, an inducer of p27(Kip1).	Sirolimus	178-187	uncharacterized protein	Drosophila melanogaster	203-206
11741537-6	2001	The binding of TIP41 to TAP42 is stimulated upon rapamycin treatment via SIT4-dependent dephosphorylation of TIP41, suggesting that TIP41 is part of a feedback loop that rapidly amplifies SIT4 phosphatase activity under TOR-inactivating conditions.	Sirolimus	49-58	Tap42p	Saccharomyces cerevisiae S288C	24-29
16595860-2	2006	In addition, the role of rapamycin, an antagonist of the molecular target of rapamycin, in the morphological changes of spine caused by TSC2 silencing was investigated.	Sirolimus	25-34	TSC complex subunit 2	Rattus norvegicus	136-140
16595860-7	2006	However, rapamycin treatment could reverse the effect of TSC2-RNAi on spine length but not on spine density.	Sirolimus	9-18	TSC complex subunit 2	Rattus norvegicus	57-61
16253991-3	2005	To investigate the connections between these two signaling pathways, we have analyzed rapamycin sensitivity of the expression of the RTG target gene CIT2 and of two NCR-sensitive genes, GLN1 and DAL5, in respiratory-competent (rho+) and -incompetent (rho0) yeast cells.	Sirolimus	86-95	citrate (Si)-synthase CIT2	Saccharomyces cerevisiae S288C	149-153
16322235-7	2005	Both baseline and PDGF-induced O2*- levels were significantly higher in TSC2-/- cells and were reduced by treatment with rapamycin and inhibitors of mitochondrial electron transport.	Sirolimus	121-130	TSC complex subunit 2	Rattus norvegicus	72-76
15895362-7	2005	The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment malanoma cells with rapamycin, a potent inhibitor of mTOR effectively induced melanogenesis.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	89-93
16129690-4	2005	Inhibition of serine 307 phosphorylation by rapamycin mimicked type 2 diabetes and reduced the sensitivity of IRS1 tyrosine phosphorylation in response to insulin, while stimulation of the phosphorylation by okadaic acid, in cells from patients with type 2 diabetes, rescued cells from insulin resistance.	Sirolimus	44-53	insulin receptor substrate 1	Homo sapiens	110-114
11741537-6	2001	The binding of TIP41 to TAP42 is stimulated upon rapamycin treatment via SIT4-dependent dephosphorylation of TIP41, suggesting that TIP41 is part of a feedback loop that rapidly amplifies SIT4 phosphatase activity under TOR-inactivating conditions.	Sirolimus	49-58	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	73-77
11741537-6	2001	The binding of TIP41 to TAP42 is stimulated upon rapamycin treatment via SIT4-dependent dephosphorylation of TIP41, suggesting that TIP41 is part of a feedback loop that rapidly amplifies SIT4 phosphatase activity under TOR-inactivating conditions.	Sirolimus	49-58	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	188-192
11690632-3	2001	A human growth hormone (hGH) expression construct containing the promoter region and 5" untranslated region (UTR) of EF1A linked to the hGH coding region (EF1A/hGH) was translationally repressed following rapamycin treatment in similar fashion to endogenous EF1A in human B lymphocytes.	Sirolimus	205-214	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	117-121
11690632-3	2001	A human growth hormone (hGH) expression construct containing the promoter region and 5" untranslated region (UTR) of EF1A linked to the hGH coding region (EF1A/hGH) was translationally repressed following rapamycin treatment in similar fashion to endogenous EF1A in human B lymphocytes.	Sirolimus	205-214	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	155-159
11690632-3	2001	A human growth hormone (hGH) expression construct containing the promoter region and 5" untranslated region (UTR) of EF1A linked to the hGH coding region (EF1A/hGH) was translationally repressed following rapamycin treatment in similar fashion to endogenous EF1A in human B lymphocytes.	Sirolimus	205-214	eukaryotic translation elongation factor 1 alpha 2	Homo sapiens	155-159
11553517-1	2001	The immunosuppressive effect of rapamycin is mediated by inhibition of interleukin-2-stimulated T cell proliferation.	Sirolimus	32-41	interleukin 2	Rattus norvegicus	71-84
16199861-5	2005	In archived material from 12 human GBM tumors, PTEN status was a predictor of activation of the Akt-mTOR-S6K1 pathway and of FLIP(S) levels, while in xenografted human GBM, activation status of the PTEN-Akt-mTOR pathway distinguished the tumors inherently sensitive to TRAIL from those which could be sensitized by the mTOR inhibitor rapamycin.	Sirolimus	334-343	phosphatase and tensin homolog	Homo sapiens	47-51
16227402-9	2005	Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 association with IGF-I receptors, and prevented IRS-1 degradation.	Sirolimus	13-22	insulin receptor substrate 1	Homo sapiens	59-64
16227402-9	2005	Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 association with IGF-I receptors, and prevented IRS-1 degradation.	Sirolimus	13-22	insulin receptor substrate 1	Homo sapiens	75-80
16227402-9	2005	Furthermore, rapamycin prevented serine phosphorylation of IRS-1, enhanced IRS-1 association with IGF-I receptors, and prevented IRS-1 degradation.	Sirolimus	13-22	insulin receptor substrate 1	Homo sapiens	75-80
11553517-16	2001	Furthermore, rapamycin inhibited activation of 70-kDa S6 protein kinase (p70(S6k)) in cultured MPT cells as well as in the renal tissue of rats subjected to RAO.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Rattus norvegicus	77-80
11577586-1	2001	SIROLIMUS: The leading member of the mTOR inhibitor family, sirolimus or rapamycin, has dose-dependent side effects that can generally be well controlled.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	37-41
16172265-0	2005	Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design.	Sirolimus	0-9	coagulation factor III, tissue factor	Homo sapiens	49-62
16172265-5	2005	Rapamycin by itself increased basal TF levels by 40%.	Sirolimus	0-9	coagulation factor III, tissue factor	Homo sapiens	36-38
16103094-9	2005	In this fusion system, rapamycin induced heterodimerization of the FRB and FKBP12 moieties occurred rapidly even at very lower concentrations (0.00001 nmol/L) of rapamycin.	Sirolimus	23-32	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	75-81
16103094-9	2005	In this fusion system, rapamycin induced heterodimerization of the FRB and FKBP12 moieties occurred rapidly even at very lower concentrations (0.00001 nmol/L) of rapamycin.	Sirolimus	162-171	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	75-81
16018822-0	2005	Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells.	Sirolimus	0-9	coagulation factor III, tissue factor	Homo sapiens	20-33
16018822-4	2005	This study investigated the effect of sirolimus on TF expression and activity in cultured human vascular smooth muscle cells (SMCs).	Sirolimus	38-47	coagulation factor III, tissue factor	Homo sapiens	51-53
16018822-8	2005	The effect of sirolimus on activation of mammalian target of rapamycin (mTOR) was measured by phosphorylation of the substrate p70s6k at T389, and activation of RhoA was measured by pull-down assay.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	127-133
16018822-9	2005	RESULTS: Sirolimus increased TF protein level in cultured human SMCs in a concentration and time-dependent manner (about 2-fold, p &lt; 0.01) reaching maximal effect at 5 ng/ml.	Sirolimus	9-18	coagulation factor III, tissue factor	Homo sapiens	29-31
16018822-10	2005	The stimulation of TF expression by sirolimus was associated with inhibition of basal activity of mTOR.	Sirolimus	36-45	coagulation factor III, tissue factor	Homo sapiens	19-21
16018822-12	2005	The stimulation of TF expression by sirolimus (20 ng/ml) was prevented by the HMG-CoA reductase inhibitor fluvastatin (1 micromol/L).	Sirolimus	36-45	coagulation factor III, tissue factor	Homo sapiens	19-21
16018822-14	2005	CONCLUSION: Although sirolimus stimulates TF protein expression in human SMC associated with inhibition of mTOR, it does not enhance TF activity released from the cells, suggesting a relatively safe profile of CYPHER stents.	Sirolimus	21-30	coagulation factor III, tissue factor	Homo sapiens	42-44
15897901-5	2005	Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects.	Sirolimus	131-140	transformation related protein 53, pseudogene	Mus musculus	18-21
15897901-5	2005	Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Mus musculus	116-120
15897901-5	2005	Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects.	Sirolimus	131-140	transformation related protein 53, pseudogene	Mus musculus	156-159
16342424-5	2005	Pretreatment of cells with PD-98059 and rapamycin, inhibitors of mitogen-activated protein kinase (ERK1/2) and mammalian target for rapamycin (mTOR), respectively, partially blocked Ang IV-mediated phosphorylation of 4EBP1.	Sirolimus	40-49	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	217-222
15746082-0	2005	Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.	Sirolimus	0-9	forkhead box P3	Mus musculus	39-44
15846119-8	2005	Like the mTOR inhibitor rapamycin, the patellazoles inhibit translation through the 4EBP1 and S6 kinase pathways.	Sirolimus	24-33	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	84-89
11577586-1	2001	SIROLIMUS: The leading member of the mTOR inhibitor family, sirolimus or rapamycin, has dose-dependent side effects that can generally be well controlled.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	37-41
11577586-1	2001	SIROLIMUS: The leading member of the mTOR inhibitor family, sirolimus or rapamycin, has dose-dependent side effects that can generally be well controlled.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Mus musculus	37-41
11335722-0	2001	Rapamycin blocks sexual development in fission yeast through inhibition of the cellular function of an FKBP12 homolog.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	103-109
15769867-13	2005	Levels of nonphosphorylated p70(s6k) and 4E-BP1 did not vary between groups, but levels of p-p70(s6k) were decreased by rapamycin.	Sirolimus	120-129	ribosomal protein S6 kinase B1	Rattus norvegicus	91-100
15769867-17	2005	Rapamycin influences the cell cycle by up-regulation of p27, down-regulation of p21, and inhibition of p70(s6k) phosphorylation.	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	56-59
15769867-17	2005	Rapamycin influences the cell cycle by up-regulation of p27, down-regulation of p21, and inhibition of p70(s6k) phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	103-111
15882288-10	2005	The p70(S6) kinase pathway leading to cell cycle progression was found to be active, and low concentrations of rapamycin dramatically reduced p70(S6) kinase phosphorylation.	Sirolimus	111-120	ribosomal protein S6 kinase B1	Homo sapiens	4-18
15882288-14	2005	CONCLUSION: Rapamycin inhibits the proliferative response of HRECs to mitogenic stimuli, and causes cell cycle arrest in the early G(1) phase, not only by a nonspecific process due to inhibition of the p70(S6k) pathway, but also by a direct effect on cyclin D3 mRNA stability.	Sirolimus	12-21	ribosomal protein S6 kinase B1	Homo sapiens	202-209
11335722-1	2001	FKBP12 is a ubiquitous and a highly conserved prolyl isomerase that binds the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	112-121	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	0-6
11335722-3	2001	In the budding yeast Saccharomyces cerevisiae and in human T cells, rapamycin forms a complex with FKBP12 that inhibits cell cycle progression by inhibition of the TOR kinases.	Sirolimus	68-77	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	99-105
11335722-5	2001	Here we show that disruption of the S. pombe FKBP12 homolog, fkh1(+), at its chromosomal locus results in a mating-deficient phenotype that is highly similar to that obtained by treatment of wild type cells with rapamycin.	Sirolimus	212-221	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	45-51
11309295-3	2001	Exposure to rapamycin (100 ng/ml) for 24 h significantly increased the proportion of Rh1 and Rh30 cells in G(1) phase, although there were no significant changes in expression of cyclins D1, E, or A in drug-treated cells.	Sirolimus	12-21	Rh blood group D antigen	Homo sapiens	93-97
11309295-6	2001	Infection of Rh30 cells with either Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p21(CIP1), and complete protection of cells from rapamycin-induced apoptosis.	Sirolimus	184-193	Rh blood group D antigen	Homo sapiens	13-17
11309295-11	2001	The response to rapamycin was next examined in wild-type or murine embryo fibroblasts nullizygous for p53or p21(CIP1).	Sirolimus	16-25	transformation related protein 53, pseudogene	Mus musculus	102-105
11309295-15	2001	Under serum-containing conditions, rapamycin inhibited incorporation of BrdUrd significantly more in wild-type murine embryo fibroblasts (MEFs) than in those lacking p53 or p21(CIP1).	Sirolimus	35-44	transformation related protein 53, pseudogene	Mus musculus	166-169
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	0-4	glutathione S-transferase kappa 1	Homo sapiens	49-74
11222720-7	2001	GST affinity assays revealed interaction between RPMS and the corepressor Sin3A and CIR.	Sirolimus	49-53	glutathione S-transferase kappa 1	Homo sapiens	0-3
11222720-7	2001	GST affinity assays revealed interaction between RPMS and the corepressor Sin3A and CIR.	Sirolimus	49-53	SIN3 transcription regulator family member A	Homo sapiens	74-79
11222720-7	2001	GST affinity assays revealed interaction between RPMS and the corepressor Sin3A and CIR.	Sirolimus	49-53	corepressor interacting with RBPJ, CIR1	Homo sapiens	84-87
11222720-13	2001	The results revealed that RPMS blocked relief of CBF1-mediated repression and interfered with SKIP-CIR interactions.	Sirolimus	26-30	corepressor interacting with RBPJ, CIR1	Homo sapiens	99-102
11147790-4	2001	Wortmannin and rapamycin blocked this mobility shift of IRS-1, maintained the insulin-induced tyrosine phosphorylation of IRS-1, and blocked its degradation.	Sirolimus	15-24	insulin receptor substrate 1	Homo sapiens	56-61
11147790-4	2001	Wortmannin and rapamycin blocked this mobility shift of IRS-1, maintained the insulin-induced tyrosine phosphorylation of IRS-1, and blocked its degradation.	Sirolimus	15-24	insulin receptor substrate 1	Homo sapiens	122-127
11216652-3	2000	Treatment with wortmannin or LY294002, a PI-3K inhibitor, or rapamycin, a p70S6k inhibitor, decreased basal levels of 5-bromo-2-deoxyuridine (BrdU)-labeling indices of lactotrophs in a dose-dependent manner.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Rattus norvegicus	74-80
10940301-3	2000	Rapamycin causes dephosphorylation and nuclear translocation of Gln3p, thereby activating nitrogen catabolite repressible-sensitive genes.	Sirolimus	0-9	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	64-69
11101202-10	2000	Imidapril or rapamycin prevented the activation of p70S6K activity in myocardium induced by L-NAME.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Rattus norvegicus	51-57
10981855-4	2000	Rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR), which is an upstream signaling of p70S6K, completely inhibited FCS-induced cell size increases and protein synthesis, but had no effect on SKA mRNA expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	111-117
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Mus musculus	204-208
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	mechanistic target of rapamycin kinase	Mus musculus	209-213
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	223-252
10944451-3	2000	Insulin-induced clonal expansion, Rb phosphorylation and adipocyte differentiation were all inhibited by the PI 3-kinase inhibitors and rapamycin, but not the MEK inhibitor, whereas the MEK inhibitor, but not PI 3-kinase inhibitors or rapamycin, decreased c-fos induction.	Sirolimus	136-145	FBJ osteosarcoma oncogene	Mus musculus	256-261
10949181-0	2000	Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction.	Sirolimus	79-88	CD40 ligand	Mus musculus	92-97
10884573-0	2000	Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca(2+) signaling mechanism in rat hippocampal CA1 neurons.	Sirolimus	0-9	carbonic anhydrase 1	Rattus norvegicus	140-143
16043946-5	2005	Rapamycin (2 mg/kg/day) completely suppressed S6K1 and S6 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	46-50
10775131-6	2000	Synthesis of Bcl-3, a protein whose translation is controlled by an mTOR-dependent pathway, was induced by flow and inhibited by rapamycin and wortmannin.	Sirolimus	129-138	BCL3 transcription coactivator	Homo sapiens	13-18
10749698-3	2000	Insulin rapidly activated the 70-kDa ribosomal S6 kinase (p70 S6k), and this effect was inhibited both by rapamycin and by inhibitors of phosphatidylinositol 3-kinase.	Sirolimus	106-115	ribosomal protein S6 kinase B1	Rattus norvegicus	58-65
15677443-6	2005	Rapamycin blocked phosphorylation of p70S6K but had no affect on PDGF-induced Akt phosphorylation, positioning p70S6K downstream of Akt.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	37-43
10660603-5	2000	The FRAP kinase inhibitor rapamycin and the DNA repair inhibitor aphidicolin significantly suppressed the UVB-mediated increase in p70 ribosomal S6 kinase activity by 50-65% and MMP-1 and MMP-3 protein levels by 34-68% and 42-88% compared with UVB-irradiated fibroblasts.	Sirolimus	26-35	matrix metallopeptidase 1	Homo sapiens	178-183
15767444-10	2005	In this study, we found that Akt/mTOR is involved in JSRV transformation of mouse NIH 3T3 fibroblasts, because treatment with the mTOR inhibitor rapamycin reduced transformation.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Mus musculus	33-37
10716639-4	2000	Rapamycin kills normal cells more readily in normal than in A-T cells, and inhibits the FRAP target p70 S6 kinase (p70S6K) more readily in normal than in A-T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-113
15767444-10	2005	In this study, we found that Akt/mTOR is involved in JSRV transformation of mouse NIH 3T3 fibroblasts, because treatment with the mTOR inhibitor rapamycin reduced transformation.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Mus musculus	130-134
15767663-5	2005	Here we show that amino acids regulate the N-terminal phosphorylation sites in 4E-BP1 through the RAIP motif in a rapamycin-insensitive manner.	Sirolimus	114-123	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	79-85
10716639-4	2000	Rapamycin kills normal cells more readily in normal than in A-T cells, and inhibits the FRAP target p70 S6 kinase (p70S6K) more readily in normal than in A-T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-121
10605009-9	2000	Glycine and rapamycin caused dose-dependent decreases in IL-2-stimulated growth of Ctll-2 cells to about 60% and 40%, respectively, of control.	Sirolimus	12-21	interleukin 2	Mus musculus	57-61
15632115-6	2005	After serum addition, p70S6K phosphorylation was higher and more resistant to rapamycin treatment in cells overexpressing DGKzeta.	Sirolimus	78-87	ribosomal protein S6 kinase B1	Homo sapiens	22-28
15767555-2	2005	Treatment of U937 monocytic leukemia cells with rapamycin (10 nmol/L) in conjunction with a minimally toxic concentration of UCN-01 (100 nmol/L) for 36 hours resulted in marked potentiation of mitochondrial injury (i.e., loss of mitochondrial membrane potential and cytosolic release of cytochrome c, AIF, and Smac/DIABLO), caspase activation, and apoptosis.	Sirolimus	48-57	diablo IAP-binding mitochondrial protein	Homo sapiens	310-314
15767555-2	2005	Treatment of U937 monocytic leukemia cells with rapamycin (10 nmol/L) in conjunction with a minimally toxic concentration of UCN-01 (100 nmol/L) for 36 hours resulted in marked potentiation of mitochondrial injury (i.e., loss of mitochondrial membrane potential and cytosolic release of cytochrome c, AIF, and Smac/DIABLO), caspase activation, and apoptosis.	Sirolimus	48-57	diablo IAP-binding mitochondrial protein	Homo sapiens	315-321
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	ribosomal protein S6 kinase B1	Homo sapiens	56-63
15591045-7	2005	However, expression of a large RyR2 C-terminal construct in mammalian cells encompassing the pore-forming transmembrane domains exhibits rapamycin-sensitive binding specifically to FKBP12.6 but not to FKBP12.	Sirolimus	137-146	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	181-187
10585867-8	1999	One major protein of the first group, p42, had a rapid increase in synthesis that decreased by 8 h. Its synthesis was strongly enhanced by FK506, but reduced by rapamycin after ionomycin+PMA stimulation.	Sirolimus	161-170	cyclin dependent kinase 20	Homo sapiens	38-41
15642745-6	2005	Although rapamycin has a minimal effect on wild-type T cell expansion in vitro and in vivo, it completely suppresses the response of Pim-1(-/-)Pim-2(-/-) cells.	Sirolimus	9-18	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	143-148
10464278-9	1999	Rapamycin, an inhibitor of p70 S6 kinase activity, inhibited G-CSF-dependent proliferation of Trf-R(+) cells and increased fMLP-R expression on these cells.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	61-66
15696050-10	2005	Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38(MAPK) phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-49
15696050-13	2005	CONCLUSIONS: S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	100-106
15557109-6	2005	Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation.	Sirolimus	56-65	TSC complex subunit 2	Rattus norvegicus	159-163
15623621-6	2004	HepG2 and Hep3B cell lines were treated with rapamycin to see the effect on proliferation and S6K phosphorylation.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	94-97
15623621-10	2004	Rapamycin treatment of HepG2 and Hep3B cell lines markedly inhibited cell proliferation and reduced S6K phosphorylation in both cell lines.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-103
15561916-8	2004	Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of S6K1 at an intermediate glucose concentration (8 mmol/l) in a rapamycin-sensitive manner.	Sirolimus	159-168	ribosomal protein S6 kinase B1	Homo sapiens	97-101
15292274-5	2004	Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates.	Sirolimus	23-32	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	100-106
15470255-3	2004	Inactivation of the Tor pathway component Tap42p using tap42(Ts) alleles causes a sustained nuclear localization similar to that after the addition of the Tor kinase inhibitor rapamycin.	Sirolimus	176-185	Tap42p	Saccharomyces cerevisiae S288C	42-48
15470255-5	2004	These results support the notion that rapamycin affects Msn2p by inactivating Tap42p function.	Sirolimus	38-47	stress-responsive transcriptional activator MSN2	Saccharomyces cerevisiae S288C	56-61
15470255-5	2004	These results support the notion that rapamycin affects Msn2p by inactivating Tap42p function.	Sirolimus	38-47	Tap42p	Saccharomyces cerevisiae S288C	78-84
15470255-7	2004	Deletion of either the catalytic or regulatory subunit that forms the PP2A phosphatase complex prevents nuclear accumulation of Msn2p in the tap42(Ts) strain and in wild-type strains treated with rapamycin.	Sirolimus	196-205	stress-responsive transcriptional activator MSN2	Saccharomyces cerevisiae S288C	128-133
10464317-4	1999	Insulin-augmented (125)I-alpha(2)M* binding to macrophages was severely reduced by wortmannin, LY294002, PD98059, SB203580, or rapamycin.	Sirolimus	127-136	alpha-2-macroglobulin	Homo sapiens	25-34
10454535-7	1999	Microinjection of highly specific inhibitors of PI3K or Rac1, or treatment with the p70s6k inhibitor rapamycin, impaired cAMP-stimulated DNA synthesis, demonstrating that PKA-dependent and -independent pathways contribute to cAMP-mediated mitogenesis.	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	84-90
10329624-4	1999	We show that inactivation of either Cdc55 or Tpd3, which regulate Pph21/22 activity, results in rapamycin resistance and that this resistance correlates with an increased association of Tap42 with Pph21/22.	Sirolimus	96-105	protein phosphatase 2A regulatory subunit CDC55	Saccharomyces cerevisiae S288C	36-41
10329624-4	1999	We show that inactivation of either Cdc55 or Tpd3, which regulate Pph21/22 activity, results in rapamycin resistance and that this resistance correlates with an increased association of Tap42 with Pph21/22.	Sirolimus	96-105	protein phosphatase 2A structural subunit TPD3	Saccharomyces cerevisiae S288C	45-49
10329624-5	1999	Furthermore, we show Tor-dependent phosphorylation of Tap42 both in vivo and in vitro and that this phosphorylation is rapamycin sensitive.	Sirolimus	119-128	Tap42p	Saccharomyces cerevisiae S288C	54-59
15452065-11	2004	IGF-1 also induced the phosphorylation of Bad (a pro-apoptotic protein of the Bcl-2 family), which was inhibited by PI-3K inhibitors, but not by the p70 S6K inhibitor rapamycin.	Sirolimus	167-176	insulin-like growth factor I	Oryctolagus cuniculus	0-5
15466272-11	2004	In conclusion, the data suggest that (1) coagulation may play a pathogenic role in I-R injury; (2) the Akt axis is activated after I-R, and its inhibition may explain the prolonged DGF observed in rapamycin-treated patients; and (3) NIK activation in I-R and DGF represents a proinflammatory, rapamycin-insensitive signal, potentially leading to progressive graft injury.	Sirolimus	197-206	mitogen-activated protein kinase kinase kinase 14	Homo sapiens	233-236
15367655-6	2004	Strains lacking Sap185 and Sap190 are hypersensitive to rapamycin, and this sensitivity is Gcn2 dependent and correlated with a defect in translation, constitutive eukaryotic initiation factor 2alpha hyperphosphorylation, induction of GCN4 translation, and hypersensitivity to amino acid starvation.	Sirolimus	56-65	Sap185p	Saccharomyces cerevisiae S288C	16-22
15245566-7	2004	Insulin also increased cell size approximately 2-fold and this was prevented by wortmannin and rapamycin, an inhibitor of Drosphilia target of rapamycin (DTOR).	Sirolimus	95-104	Target of rapamycin	Drosophila melanogaster	122-152
15245566-7	2004	Insulin also increased cell size approximately 2-fold and this was prevented by wortmannin and rapamycin, an inhibitor of Drosphilia target of rapamycin (DTOR).	Sirolimus	95-104	Target of rapamycin	Drosophila melanogaster	154-158
15249188-9	2004	Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P &lt; 0.01).	Sirolimus	79-88	ribosomal protein S6 kinase B1	Rattus norvegicus	11-17
15249188-9	2004	Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P &lt; 0.01).	Sirolimus	147-151	ribosomal protein S6 kinase B1	Rattus norvegicus	11-17
10212283-5	1999	Rapamycin, a potent inhibitor of p70(S6k), also failed to prevent PGF2alpha-induced global protein synthesis and bFGF-2 expression, although it partially decreased ERK2 activity.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	37-40
10200280-2	1999	Depriving cells of amino acids or treating them with the small molecule rapamycin inhibits FRAP and results in rapid dephosphorylation and inactivation of the translational regulators 4E-BP1(eukaryotic initiation factor 4E-binding protein 1) and p70(s6k) (the 70-kDa S6 kinase).	Sirolimus	72-81	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	184-240
10200280-2	1999	Depriving cells of amino acids or treating them with the small molecule rapamycin inhibits FRAP and results in rapid dephosphorylation and inactivation of the translational regulators 4E-BP1(eukaryotic initiation factor 4E-binding protein 1) and p70(s6k) (the 70-kDa S6 kinase).	Sirolimus	72-81	ribosomal protein S6 kinase B1	Homo sapiens	246-253
10200280-5	1999	A calyculin A-sensitive phosphatase is required for the rapamycin- or amino acid deprivation-induced dephosphorylation of p70(s6k), and treatment of Jurkat I cells with rapamycin increases the activity of the protein phosphatase 2A (PP2A) toward 4E-BP1.	Sirolimus	56-65	ribosomal protein S6 kinase B1	Homo sapiens	122-129
10200280-5	1999	A calyculin A-sensitive phosphatase is required for the rapamycin- or amino acid deprivation-induced dephosphorylation of p70(s6k), and treatment of Jurkat I cells with rapamycin increases the activity of the protein phosphatase 2A (PP2A) toward 4E-BP1.	Sirolimus	56-65	protein phosphatase 2 phosphatase activator	Homo sapiens	233-237
10200280-5	1999	A calyculin A-sensitive phosphatase is required for the rapamycin- or amino acid deprivation-induced dephosphorylation of p70(s6k), and treatment of Jurkat I cells with rapamycin increases the activity of the protein phosphatase 2A (PP2A) toward 4E-BP1.	Sirolimus	56-65	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	246-252
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	protein phosphatase 2 phosphatase activator	Homo sapiens	36-40
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	protein phosphatase 2 phosphatase activator	Homo sapiens	103-107
15361291-11	2004	CONCLUSIONS: Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways can act as potent immunoregulatory cells in vitro, and prolong cardiac allograft survival after adoptive transfer in the presence of rapamycin therapy.	Sirolimus	233-242	CD40 ligand	Mus musculus	59-64
15361291-11	2004	CONCLUSIONS: Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways can act as potent immunoregulatory cells in vitro, and prolong cardiac allograft survival after adoptive transfer in the presence of rapamycin therapy.	Sirolimus	233-242	CD28 antigen	Mus musculus	69-73
10199867-7	1999	Rapamycin inhibited BK-stimulated p70(S6K) activity by 93% but had no effect on p90(rsk) activation by BK.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	38-41
15123681-10	2004	Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity.	Sirolimus	40-49	insulin receptor substrate 2	Homo sapiens	99-104
15123681-10	2004	Pretreatment of matured U937 cells with rapamycin blocked chronic insulin + high glucose-dependent IRS-2 Ser/Thr-Pro motif phosphorylation and restored IL-4-dependent IRS-2-associated PI3-kinase activity.	Sirolimus	40-49	insulin receptor substrate 2	Homo sapiens	167-172
10085104-6	1999	Similarly, although p70(s6k) was activated during GH priming, pretreatment of cells with rapamycin, which prevented the activation of p70(s6k), had no effect on GH priming.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	134-141
15347472-0	2004	[Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus].	Sirolimus	108-117	hypoxia inducible factor 1, alpha subunit	Mus musculus	15-46
15347472-5	2004	RESULTS: In sirolimus and sirolimus + paclitaxel groups protein expression of HIF-1alpha was inhibited.	Sirolimus	12-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	78-88
15347472-5	2004	RESULTS: In sirolimus and sirolimus + paclitaxel groups protein expression of HIF-1alpha was inhibited.	Sirolimus	26-35	hypoxia inducible factor 1, alpha subunit	Mus musculus	78-88
15347472-8	2004	CONCLUSION: Sirolimus inhibited protein expression of HIF-1alpha, increased tumor apoptosis and decreased tumor growth.	Sirolimus	12-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	54-64
10214966-3	1999	The effect of leucine on p70S6k was sensitive to rapamycin, but less sensitive to wortmannin.	Sirolimus	49-58	ribosomal protein S6 kinase B1	Rattus norvegicus	25-31
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	phosphoglycolate phosphatase	Homo sapiens	48-52
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	phosphoglycolate phosphatase	Homo sapiens	246-250
10376934-2	1999	Proliferation and selected IL2-driven gene expression are blocked by treatment with rapamycin.	Sirolimus	84-93	interleukin 2	Mus musculus	27-30
15162441-5	2004	While blockade of TCR signaling pathways with inhibitors of the phosphatidylinositol 3-kinase pathway caused a partial pre-integration block, another inhibitor, rapamycin, completely suppressed the infection.	Sirolimus	161-170	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	18-21
14970238-3	2004	When cells are transferred from a good to a poor nitrogen source (glutamine to proline) or treated with rapamycin, an inhibitor of the protein kinases Tor1/2, Gln3 (NCR-sensitive transcription activator) moves from the cytoplasm into the nucleus.	Sirolimus	104-113	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	159-163
14970238-9	2004	In contrast, rapamycin-induced nuclear accumulation of Gln3 is not demonstrably affected by latrunculin treatment.	Sirolimus	13-22	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	55-59
10025577-6	1999	PC12 cells are refractory to the antiproliferative effect of rapamycin, although rapamycin does exert its expected inhibitory effect in PC12 cells on both basal and NGF-stimulated activation of one of its biochemical targets, the 70-kDa S6 protein kinase (p70S6K).	Sirolimus	81-90	ribosomal protein S6 kinase B1	Rattus norvegicus	256-262
14970238-10	2004	These data indicate the actin cytoskeleton is required for nuclear localization of Gln3 in response to limiting nitrogen but not rapamycin-treatment.	Sirolimus	129-138	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	83-87
15070696-7	2004	The phosphorylation of the serine/threonine kinase p70S6K at Thr389 and Thr421/Ser424 was down-regulated by rapamycin and/or dexamethasone.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	51-57
15070696-8	2004	Strikingly, the combinatorial treatment with rapamycin and dexamethasone suppressed the antiapoptotic effects of exogenously added IGF-I and interleukin 6 (IL-6) as well as their stimulation of p70S6K phosphorylation.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	194-200
15016873-7	2004	Significantly, rapamycin, an inhibitor commonly used to investigate the mTOR/p70S6K pathway, reduced the in vivo phosphorylation of specific NS5A phosphopeptides, strongly suggesting that p70S6 kinase and potentially related members of this group phosphorylate NS5A inside the cell.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	77-83
14679193-10	2004	(iii) Gln3-Myc(13) dephosphorylation and nuclear localization correlate with one another at early but not late times after rapamycin treatment.	Sirolimus	123-132	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	6-10
15014039-13	2004	With regard to angiogenesis, dRib-induced endothelial cell migration and aortic ring formation were completely abrogated by rapamycin, correlating with blockage of dRib-induced p70/S6 kinase activation in endothelial cells.	Sirolimus	124-133	ribbon	Drosophila melanogaster	29-33
15014039-13	2004	With regard to angiogenesis, dRib-induced endothelial cell migration and aortic ring formation were completely abrogated by rapamycin, correlating with blockage of dRib-induced p70/S6 kinase activation in endothelial cells.	Sirolimus	124-133	ribbon	Drosophila melanogaster	164-168
14871980-9	2004	In contrast, overexpression of S6K1, and phosphorylated Akt independent of phosphatase and tensin homologue deleted from chromosome 10 status, were associated with rapamycin sensitivity.	Sirolimus	164-173	ribosomal protein S6 kinase B1	Homo sapiens	31-35
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-47
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	75-81
14871980-11	2004	Rapamycin inhibited the phosphorylation of S6K1, ribosomal S6 protein, and 4E-BP1 in rapamycin-resistant as well as -sensitive cells, indicating that its ability to inhibit the mTOR pathway is not sufficient to confer sensitivity to rapamycin.	Sirolimus	85-94	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	75-81
14970836-6	2004	In contrast, rapamycin completely inhibited insulin-stimulated p70 S6K activation, assessed by phosphorylation of p70 S6K and its substrate, S6.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	63-70
14970836-6	2004	In contrast, rapamycin completely inhibited insulin-stimulated p70 S6K activation, assessed by phosphorylation of p70 S6K and its substrate, S6.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	114-121
14717609-9	2004	These events were blocked by rapamycin, an inhibitor of the insulin signal transduction pathway in mammals, at the TOR (target of rapamycin) enzyme level.	Sirolimus	29-38	Serine/threonine-protein kinase TOR	Zea mays	115-118
14717609-9	2004	These events were blocked by rapamycin, an inhibitor of the insulin signal transduction pathway in mammals, at the TOR (target of rapamycin) enzyme level.	Sirolimus	29-38	Serine/threonine-protein kinase TOR	Zea mays	120-139
14573608-6	2004	Under conditions where rapamycin inhibited proliferation, p27kip1 down-regulation was prevented, whereas under conditions resulting in rapamycin-resistant proliferation, p27kip1 was down-regulated.	Sirolimus	23-32	cyclin dependent kinase inhibitor 1B	Homo sapiens	58-65
14573608-6	2004	Under conditions where rapamycin inhibited proliferation, p27kip1 down-regulation was prevented, whereas under conditions resulting in rapamycin-resistant proliferation, p27kip1 was down-regulated.	Sirolimus	135-144	cyclin dependent kinase inhibitor 1B	Homo sapiens	170-177
14612424-4	2003	Using the mTOR inhibitor rapamycin, we show that mTOR is required for the rapid and sustained serum-induced activation of 45S ribosomal gene transcription (rDNA transcription), a major rate-limiting step in ribosome biogenesis and cellular growth.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Mus musculus	10-14
14612424-4	2003	Using the mTOR inhibitor rapamycin, we show that mTOR is required for the rapid and sustained serum-induced activation of 45S ribosomal gene transcription (rDNA transcription), a major rate-limiting step in ribosome biogenesis and cellular growth.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Mus musculus	49-53
12704019-2	2003	Here we report that isoproterenol phosphorylated the protein S6 kinase (p70S6k) in alveolar epithelial cells, which was inhibited by both rapamycin and the MEK1/2 inhibitor U-0126.	Sirolimus	138-147	ribosomal protein S6 kinase B1	Homo sapiens	72-78
9873015-5	1999	A partial decrease in the fold activation of GS was, however, observed when p70(S6k) activation was blocked with rapamycin, suggesting a contribution of this pathway to the control of GS by either hormone.	Sirolimus	113-122	ribosomal protein S6 kinase B1	Homo sapiens	80-83
9886844-7	1999	Interestingly, the negative effect was completely eliminated by a PI3 kinase inhibitor wortmannin (1 microM), whereas a MAP kinase inhibitor PD98059 (20 microM) or S6 kinase inhibitor rapamycin (10 nM) did not influence the effect.	Sirolimus	184-193	ribosomal protein S6 kinase B1	Rattus norvegicus	164-173
12893813-7	2003	Consistent with this interpretation, we find that flies with reduced dRheb activity are hypersensitive to rapamycin, an inhibitor of the growth regulator TOR.	Sirolimus	106-115	Target of rapamycin	Drosophila melanogaster	154-157
12796501-8	2003	Although wortmannin, LY294002, and actinomycin D blocked the increase in SHARP-2 mRNA levels by insulin, rapamycin, staurosporine, PD98059, okadaic acid, and 8-bromocyclic AMP had no effect.	Sirolimus	105-114	basic helix-loop-helix family, member e40	Rattus norvegicus	73-80
12906785-7	2003	Rheb also activates S6K1 during amino acid insufficiency via a rapamycin-sensitive mechanism, suggesting that Rheb participates in nutrient signaling through mTOR.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	20-24
12740386-5	2003	Rapamycin also caused an inhibition (IC50 0.2 nm) of the in vitro enzymatic activity of p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	88-94
12740386-6	2003	However, the inhibition of activity was not complete, but only a 40-50%, indicating that neutrophil p70S6K activity has a rapamycin-resistant component.	Sirolimus	122-131	ribosomal protein S6 kinase B1	Homo sapiens	100-106
12719433-8	2003	Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.	Sirolimus	6-15	synuclein alpha	Homo sapiens	67-82
12773160-7	2003	Recent studies from many laboratories have now confirmed our findings in mice, rats and human patients, and have shown that drugs that antagonize S6K activities, such as rapamycin, diminish tumours in TSC-deficient mice and rats.	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	146-149
12796300-5	2003	Treatment with rapamycin resulted in the hyperphosphorylation of Put3p, which was independent of Gln3p, Nil1p, and Ure2p.	Sirolimus	15-24	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	97-102
12652658-10	2003	The pretreatment with rapamycin abrogated the ISO-mediated mobility shift of p70S6K, and DNA synthesis.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Rattus norvegicus	77-83
12668503-3	2003	METHODS AND RESULTS: To examine the role of mTOR in load-induced cardiac hypertrophy, we administered rapamycin, a specific inhibitor of mTOR, to mice with ascending aortic constriction.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Mus musculus	137-141
12654728-7	2003	Rapamycin-induced dephosphorylation of Ser 577, eIF2alpha phosphorylation, and induction of GCN4 all involve TAP42, a regulator of type 2A-related protein phosphatases.	Sirolimus	0-9	Tap42p	Saccharomyces cerevisiae S288C	109-114
12727112-6	2003	Specifically, expression of Epo was dependent on the presence of a chimeric transcription factor that is activated by the orally available small molecule drug rapamycin.	Sirolimus	159-168	erythropoietin	Mus musculus	28-31
12727112-7	2003	beta-thalassemic mice injected with vectors containing the regulated Epo gene failed to show any effect until they were administered a regimen of rapamycin, which led to the production of Epo and an increase in hematocrit values.	Sirolimus	146-155	erythropoietin	Mus musculus	188-191
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	30-33
12553669-8	2002	We report that p70 S6 kinase (S6K)1 participates in this IF rearrangement since the inhibitor rapamycin or a dominant inhibitory S6K could reduce the Cdc42V12 or bradykinin-induced vimentin collapse.	Sirolimus	94-103	vimentin	Homo sapiens	181-189
9914383-2	1998	In mammalian cells, rapamycin selectively inhibits phosphorylation and activation of p70 S6 kinase (p70(S6K)), a protein involved in the translation of a subset of mRNAs, without affecting other known kinases.	Sirolimus	20-29	ribosomal protein S6 kinase B1	Homo sapiens	107-108
12171921-4	2002	Osmotic stabilization of the plasma membrane prevents both Mpk1 activation by rapamycin and the growth defect that occurs upon the simultaneous absence of Tor1 and Mpk1 function, suggesting that, at least partially, TOR inhibition is sensed by the PKC pathway at the cell envelope.	Sirolimus	78-87	mitogen-activated serine/threonine-protein kinase SLT2	Saccharomyces cerevisiae S288C	59-63
12271141-4	2002	Second, the activity of S6K1 was repressed by coexpression of hamartin and tuberin, but the activity of rapamycin-resistant mutants of S6K1 were not affected, implicating mTOR in the TSC-mediated inhibitory effect on S6K1.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	135-139
12271141-4	2002	Second, the activity of S6K1 was repressed by coexpression of hamartin and tuberin, but the activity of rapamycin-resistant mutants of S6K1 were not affected, implicating mTOR in the TSC-mediated inhibitory effect on S6K1.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	135-139
9914383-6	1998	In quiescent mammalian cells (human lymphocytes and CHEF cells) induced with growth factor to re-enter the cell cycle, rapamycin was effective when cells were exposed at the time of p70(S6K) activation.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	182-185
9832443-10	1998	Moreover, IGF-II-induced human myotube formation was totally blocked by LY294002, a specific PI 3-kinase inhibitor, but remained unaffected in the presence of rapamycin.	Sirolimus	159-168	insulin like growth factor 2	Homo sapiens	10-16
9804616-8	1998	Rapamycin equally inhibited serum-induced phosphorylation of pH acid stable protein I in Rh1 (intrinsically resistant) and sensitive Rh30 cells.	Sirolimus	0-9	annexin A2	Homo sapiens	76-85
9804616-8	1998	Rapamycin equally inhibited serum-induced phosphorylation of pH acid stable protein I in Rh1 (intrinsically resistant) and sensitive Rh30 cells.	Sirolimus	0-9	Rh blood group D antigen	Homo sapiens	133-137
9804616-10	1998	Rapamycin blocked induction in Rh30 cells but not in Rh1 cells.	Sirolimus	0-9	Rh blood group D antigen	Homo sapiens	31-35
9804616-12	1998	These results suggest that the ability of rapamycin to inhibit c-MYC induction correlates with intrinsic sensitivity, whereas failure of rapamycin to inhibit induction or overexpression of c-MYC correlates with intrinsic and acquired resistance, respectively.	Sirolimus	42-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-68
9799659-6	1998	Rapamycin, a specific inhibitor of this kinase, reduces the trophic responses to control levels, suggesting an involvement of the p70(S6)-kinase in the development of cellular hypertrophy.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	130-144
12045200-7	2002	Rapamycin, an immunosuppressant, inhibited hyperphosphorylation of S6, p70S6K activation, and DNA synthesis in LAMD-SM cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	71-77
12358793-9	2002	Rapamycin, which changed the affinity of the transporter, may have acted through an immunophilin on the isomerization of critical prolines that are found in the tCHT1 sequence.	Sirolimus	0-9	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	84-96
12080086-4	2002	Expression of S6K1 mutants that possess partial rapamycin-resistant activity or overexpression of eIF4E individually and additively partially rescues the rapamycin-induced decrease in cell size.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	14-18
11914378-3	2002	S6K1-E389D(3)E has high basal activity and exhibits partial resistance to rapamycin and wortmannin, and its activity can be further augmented by mitogens, effects presumably mediated by Thr(229) phosphorylation.	Sirolimus	74-83	ribosomal protein S6 kinase B1	Homo sapiens	0-4
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	116-120
11967149-7	2002	The TOS motif is essential for S6K1 activation by mTOR, as mutations in this motif mimic the effect of rapamycin on S6K1 phosphorylation, and render S6K1 insensitive to changes in amino acids.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	116-120
11907172-9	2002	Sirolimus, seco-rapamycin (basolaterally dosed), and M2 were all actively secreted across the apical membrane, and secretion of each was inhibited by the P-gp inhibitor LY335979 [(2R)-anti-5-[3-[4-(10,11-difluoromethanodibenzo-suber-5-yl)piperazin-1-yl]-2-hydroxypropoxy]quinoline trihydrochloride].	Sirolimus	0-9	phosphoglycolate phosphatase	Homo sapiens	154-158
11784721-5	2002	Importantly, we demonstrate that insulin regulation of the thymine-rich insulin response element of the IGFBP-1 promoter was also inhibited by rapamycin.	Sirolimus	143-152	insulin like growth factor binding protein 1	Homo sapiens	104-111
11875047-6	2002	Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	197-201
11784055-6	2001	Rapamycin, a specific inhibitor of the kinase mTOR/FRAP/RAFT1, blocks amino acid stimulation of embryo outgrowth, demonstrating that mTOR is required for the initiation of trophectoderm protrusive activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	46-50
11784055-6	2001	Rapamycin, a specific inhibitor of the kinase mTOR/FRAP/RAFT1, blocks amino acid stimulation of embryo outgrowth, demonstrating that mTOR is required for the initiation of trophectoderm protrusive activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	51-55
11784055-6	2001	Rapamycin, a specific inhibitor of the kinase mTOR/FRAP/RAFT1, blocks amino acid stimulation of embryo outgrowth, demonstrating that mTOR is required for the initiation of trophectoderm protrusive activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	56-61
11784055-6	2001	Rapamycin, a specific inhibitor of the kinase mTOR/FRAP/RAFT1, blocks amino acid stimulation of embryo outgrowth, demonstrating that mTOR is required for the initiation of trophectoderm protrusive activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	133-137
11713299-7	2001	Inhibition of mTOR by rapamycin led to fast and complete repression of S6K1, as judged by rpS6 phosphorylation, but to only partial and delayed repression of translational activation of TOP mRNAs.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	71-75
9621041-1	1998	Inhibitors of the phosphatidylinositol 3-kinase (PI3 kinase)-FKBP-rapamycin-associated protein (FRAP) pathway, such as rapamycin and wortmannin, induce dephosphorylation and activation of the suppressor of cap-dependent translation, 4E-BP1.	Sirolimus	66-75	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	233-239
11707573-7	2001	Our studies also determined that rapamycin treatment of the early embryo results in a phenotype indistinguishable from the FRAP mutant, demonstrating that rapamycin has teratogenic activity.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Mus musculus	123-127
11695998-10	2001	In cultured human myotubes, up-regulation of p85alpha, p55alpha and p50alpha mRNAs by insulin was abolished by LY294002 (10 microM) and by rapamycin (50 nM), suggesting that the PI 3-kinase/protein kinase B/p70 S6 kinase pathway could be involved in the stimulation of grb-1 gene expression by insulin in human muscle cells.	Sirolimus	139-148	protein tyrosine kinase 2 beta	Homo sapiens	190-206
9614103-6	1998	Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that S6 kinase is also necessary for the insulin induction of G6PDH expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	85-94
11698435-2	2001	Anti-CTLA-4 mAb treatment during primary Ag exposure increases cell cycle progression and enhances recall Ag responsiveness; however, simultaneous treatment with rapamycin, an inhibitor of the mammalian target of rapamycin and potent antiproliferative agent, prevents both effects.	Sirolimus	162-171	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	5-11
11598004-3	2001	Here we show that, in hemopoietic cells, recruitment of the C-terminal VCA (Verprolin homology, Cofilin homology, Acidic) domain of WASp at the plasma membrane by a ligand technique using rapamycin as an intermediate is not sufficient to elicit efficient Arp2/3 complex-mediated actin polymerization.	Sirolimus	188-197	WASP actin nucleation promoting factor	Homo sapiens	132-136
9614103-6	1998	Rapamycin, an inhibitor of FRAP protein, which is involved in the activation of pp70 S6 kinase, blocks the insulin induction of G6PDH, suggesting that S6 kinase is also necessary for the insulin induction of G6PDH expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	151-160
9566798-7	1998	In contrast, immune lymph node cells from mice that had been treated in vivo with rapamycin gave optimal antigen-specific proliferation and IL-2 production in vitro.	Sirolimus	82-91	interleukin 2	Mus musculus	140-144
11485556-6	2001	Rapamycin, a specific inhibitor of the insulin-stimulated signal transduction pathway, prevented S6 rp phosphorylation in maize axes.	Sirolimus	0-9	insulin	Bos taurus	39-46
11500364-2	2001	Insulin induces dephosphorylation of eEF2 and inactivation of eEF2 kinase, and these effects are blocked by rapamycin, which inhibits the mammalian target of rapamycin, mTOR.	Sirolimus	108-117	eukaryotic translation elongation factor 2	Homo sapiens	37-41
11500364-7	2001	In response to insulin-like growth factor 1, which activates p70 S6 kinase but not Erk, regulation of eEF2 is blocked by rapamycin.	Sirolimus	121-130	eukaryotic translation elongation factor 2	Homo sapiens	102-106
9528776-5	1998	Treatment of mammalian cells with rapamycin abolishes in vivo S6 phosphorylation by p70s6k; however, ectopic expression of AtS6k2 rescues the rapamycin block.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	84-90
9472019-4	1998	PI 3-kinase elicits the phosphorylation of 4E-BP1 in a wortmannin- and rapamycin-sensitive manner, whereas activated Akt-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive.	Sirolimus	71-80	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	43-49
11410517-5	2001	Association was persistent up to 16 h. In mice, administration of rapamycin (5 or 20 mg/kg) caused rapid association of 4E-BP1 with eIF4E within 4 h in both human colon adenocarcinoma GC(3) and rhabdomyosarcoma Rh30 xenografts.	Sirolimus	66-75	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	120-126
11410517-5	2001	Association was persistent up to 16 h. In mice, administration of rapamycin (5 or 20 mg/kg) caused rapid association of 4E-BP1 with eIF4E within 4 h in both human colon adenocarcinoma GC(3) and rhabdomyosarcoma Rh30 xenografts.	Sirolimus	66-75	eukaryotic translation initiation factor 4E	Mus musculus	132-137
11410517-5	2001	Association was persistent up to 16 h. In mice, administration of rapamycin (5 or 20 mg/kg) caused rapid association of 4E-BP1 with eIF4E within 4 h in both human colon adenocarcinoma GC(3) and rhabdomyosarcoma Rh30 xenografts.	Sirolimus	66-75	Rh blood group D antigen	Homo sapiens	211-215
9461216-1	1998	FKBP12, a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin, is ubiquitously expressed and interacts with proteins in several intracellular signal transduction systems.	Sirolimus	81-90	FK506 binding protein 1a	Mus musculus	0-6
11410517-6	2001	Using phospho-specific antibody against Thr(70) of 4E-BP1, rapid and persistent dephosphorylation within 30 min of exposure to rapamycin was detected in Rh18 rhabdomyosarcoma cells.	Sirolimus	127-136	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	51-57
11358856-4	2001	Inhibition of the PI3K downstream target p70S6K by rapamycin, the Raf-MEK-MAPK pathway with PD98059, or the Ras-MEK kinase-p38 pathway with SB203580 had no effect on radiation survival in cells with oncogenic ras.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	41-47
9509307-8	1997	The serum antibody levels to S-Ag and proliferative response of lymphocytes to S-Ag were also significantly suppressed by the combination therapy with low doses of tacrolimus and rapamycin.	Sirolimus	179-188	S-antigen visual arrestin	Rattus norvegicus	29-33
9509307-8	1997	The serum antibody levels to S-Ag and proliferative response of lymphocytes to S-Ag were also significantly suppressed by the combination therapy with low doses of tacrolimus and rapamycin.	Sirolimus	179-188	S-antigen visual arrestin	Rattus norvegicus	79-83
9349496-9	1997	The ATM gene is mutated in the cancer susceptibility syndrome ataxia telangiectasia (AT) but such mutant cells showed a similar sensitivity to rapamycin compared to their normal counterparts.	Sirolimus	143-152	ATM serine/threonine kinase	Homo sapiens	4-7
9299480-3	1997	This activation of p70 S6k is completely blocked by rapamycin but only partially prevented by inhibitors of phosphatidylinositol 3-kinase.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Rattus norvegicus	19-26
9252447-6	1997	Rapamycin potently blocked both the basal and the CCK-stimulated p70s6k activity, and this inhibition was reversed by an excess of FK-506.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	65-71
9224649-12	1997	This increase was prevented by rapamycin, which also completely blocked activation of p70(s6k) by DADLE.	Sirolimus	31-40	ribosomal protein S6 kinase B1	Rattus norvegicus	86-93
9151781-8	1997	Because PCNA is required for cell cycle progression from G1 to S phase, our data indicate that inhibition of PCNA protein synthesis may be an important regulatory element in the ability of rapamycin to exert a G1 block.	Sirolimus	189-198	proliferating cell nuclear antigen	Homo sapiens	8-12
9151781-8	1997	Because PCNA is required for cell cycle progression from G1 to S phase, our data indicate that inhibition of PCNA protein synthesis may be an important regulatory element in the ability of rapamycin to exert a G1 block.	Sirolimus	189-198	proliferating cell nuclear antigen	Homo sapiens	109-113
9139803-6	1997	IGF-I-induced adipogenic- and thermogenic-related gene expression was only partly inhibited by the p70S6k inhibitor rapamycin.	Sirolimus	116-125	insulin-like growth factor 1	Rattus norvegicus	0-5
9139803-6	1997	IGF-I-induced adipogenic- and thermogenic-related gene expression was only partly inhibited by the p70S6k inhibitor rapamycin.	Sirolimus	116-125	ribosomal protein S6 kinase B1	Rattus norvegicus	99-105
9045696-6	1997	In sharp contrast, LY294002, an inhibitor of phosphatidylinositol 3-kinase, and rapamycin, an inhibitor of the activation of p70 S6 kinase (p70(S6k)), completely abolished IGF stimulation of L6A1 differentiation.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	140-147
8940115-8	1996	Wortmannin, a phosphatidylinositol 3-kinase inhibitor, and rapamycin, an inhibitor of 70-kDa S6 kinase activation, prevented insulin-mediated inactivation of PP-2A, suggesting that these pathways may participate in insulin-mediated phosphorylation and inactivation of PP-2A.	Sirolimus	59-68	ribosomal protein S6 kinase B1	Rattus norvegicus	93-102
8943845-5	1996	The IL-2-mediated induction of BAG-1 expression required the activation of tyrosine kinase(s) and was sensitive to rapamycin as the induction of bcl-2 expression was.	Sirolimus	115-124	interleukin 2	Mus musculus	4-8
21232286-5	1996	The immunosuppressant drugs FK506 and rapamycin inhibit the prolyl isomerase activity of FKBP12 and could cause cardiac dysfunction by inducing a Ca(2+) leak from the sarcoplasmic reticulum.	Sirolimus	38-47	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	89-95
8617780-10	1996	The results indicate that the effects of insulin on increasing the synthesis of glycogen and protein in skeletal muscle, two of the most important actions of the hormone, involve a rapamycin-sensitive mechanism that may include elements of the p70S6K signaling pathway.	Sirolimus	181-190	ribosomal protein S6 kinase B1	Rattus norvegicus	244-250
8603701-5	1996	An immunosuppressant agent, rapamycin, inhibited Ang II-induced p70S6K activation but not the activation of MAP kinases or the induction of c-fos gene expression.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Rattus norvegicus	64-70
9005438-1	1996	The 12 kDa FK506-binding protein FKBP12 is a cis-trans peptidyl-prolyl isomerase that binds the macrolides FK506 and rapamycin.	Sirolimus	117-126	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	33-39
9005438-3	1996	For each mutant FKBP12, we measured the affinity for FK506 and rapamycin and the catalytic efficiency in the cis-frans peptidyl-prolyl isomerase reaction.	Sirolimus	63-72	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	16-22
7566123-1	1995	When complexed with the intracellular protein FKBP12, rapamycin is a potent immunosuppressant and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase (p70S6k) and cyclin-dependent kinases (CDKs).	Sirolimus	54-63	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	46-52
7566123-1	1995	When complexed with the intracellular protein FKBP12, rapamycin is a potent immunosuppressant and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase (p70S6k) and cyclin-dependent kinases (CDKs).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	182-195
11355896-0	2001	Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival.	Sirolimus	0-9	interleukin 2	Mus musculus	17-21
7566123-1	1995	When complexed with the intracellular protein FKBP12, rapamycin is a potent immunosuppressant and an inhibitor of a mitogen-stimulated signalling pathway that leads to activation of p70 S6 kinase (p70S6k) and cyclin-dependent kinases (CDKs).	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	197-203
11355896-6	2001	Rapamycin also preserves cell survival by keeping intact the IL-2-induced cell survival programs.	Sirolimus	0-9	interleukin 2	Mus musculus	61-65
7654170-3	1995	Rapamycin, which inhibits the 70 kDa S6 kinase (p70rsk) does not influence the actions of insulin on gene 33 or PEPCK; thus the kinase p70rsk appears to play no direct role in the regulation of expression of these two hepatic genes.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	37-46
11287630-8	2001	mTOR induced the serine phosphorylation of IRS-1 (Ser-636/639), and such phosphorylation was inhibited by rapamycin.	Sirolimus	106-115	insulin receptor substrate 1	Homo sapiens	43-48
7642551-2	1995	The 12- and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus).	Sirolimus	151-160	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	43-49
11231341-7	2001	Rapamycin abrogated 4E-BP1 phosphorylation in response to insulin, suggesting involvement of mammalian target of rapamycin (mTOR), a kinase downstream of Akt.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	20-26
7642551-2	1995	The 12- and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus).	Sirolimus	162-171	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	43-49
11121811-5	2001	Platelet-induced secretion of MCP-1 and monocyte-endothelium adhesion was reduced by the MAP kinase p38-specific inhibitor SB203580, but not by other kinase inhibitors including PD98059, wortmannin, or rapamycin.	Sirolimus	202-211	C-C motif chemokine ligand 2	Homo sapiens	30-35
7629182-7	1995	Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity.	Sirolimus	10-19	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	123-129
11147790-6	2001	Incubation with okadaic acid increased the serine/threonine phosphorylation of IRS-1 and its degradation, mimicking insulin, and its effect was prevented by the proteasome inhibitor lactacystin, as well as by rapamycin.	Sirolimus	209-218	insulin receptor substrate 1	Homo sapiens	79-84
7629182-8	1995	Rapamycin abolished the effects of insulin on increasing phosphorylation of ribosomal protein S6 and on activating p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-121
7629182-11	1995	Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	59-65
7638171-6	1995	The effects of PDGF and IGF-I on increasing PHAS-I phosphorylation, on dissociating the PHAS-I-eIF-4E complex, and on increasing p70S6K were abolished by rapamycin.	Sirolimus	154-163	insulin-like growth factor 1	Rattus norvegicus	24-29
11214180-5	2001	We find that serum-induced phosphorylation of hUpf1p is inhibited by wortmannin at a concentration that selectively inhibits PI 3-kinase related kinases and, to a lesser extent, by rapamycin.	Sirolimus	181-190	UPF1 RNA helicase and ATPase	Homo sapiens	46-52
7638171-6	1995	The effects of PDGF and IGF-I on increasing PHAS-I phosphorylation, on dissociating the PHAS-I-eIF-4E complex, and on increasing p70S6K were abolished by rapamycin.	Sirolimus	154-163	ribosomal protein S6 kinase B1	Rattus norvegicus	129-135
7638171-7	1995	The results indicate that IGF-I and PDGF increase PHAS-I phosphorylation in smooth muscle cells by the same rapamycin-sensitive pathway that leads to activation of p70S6K.	Sirolimus	108-117	insulin-like growth factor 1	Rattus norvegicus	26-31
7638171-7	1995	The results indicate that IGF-I and PDGF increase PHAS-I phosphorylation in smooth muscle cells by the same rapamycin-sensitive pathway that leads to activation of p70S6K.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Rattus norvegicus	164-170
15299838-3	1995	Rapamycin (sirolimus), which is itself an immunosuppressant by a different mechanism, completes with FK506 for binding to FKBP12 and thereby acts as an antagonist of calcineurin inhibition.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	122-128
11076970-6	2000	Remarkably, nuclear accumulation of Rtg1/Rtg3, as well as expression of their target genes, is induced by addition of rapamycin, a specific inhibitor of the target of rapamycin (TOR) kinases.	Sirolimus	118-127	Rtg3p	Saccharomyces cerevisiae S288C	41-45
11076970-7	2000	We demonstrate further that Rtg3 is a phosphoprotein and that its phosphorylation state changes after rapamycin treatment.	Sirolimus	102-111	Rtg3p	Saccharomyces cerevisiae S288C	28-32
15299838-3	1995	Rapamycin (sirolimus), which is itself an immunosuppressant by a different mechanism, completes with FK506 for binding to FKBP12 and thereby acts as an antagonist of calcineurin inhibition.	Sirolimus	11-20	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	122-128
15299838-4	1995	We have solved the X-ray structure of unliganded FKBP12 and of FKBP12 in complex with FK506 and with rapamycin; these structures show localized differences in conformation and mobility in those regions of the protein that are known, by site-directed mutagenesis, to be involved in calcineurin inhibition.	Sirolimus	101-110	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	49-55
15299838-4	1995	We have solved the X-ray structure of unliganded FKBP12 and of FKBP12 in complex with FK506 and with rapamycin; these structures show localized differences in conformation and mobility in those regions of the protein that are known, by site-directed mutagenesis, to be involved in calcineurin inhibition.	Sirolimus	101-110	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	63-69
11075814-6	2000	Stimulation of translation by GnRH is protein kinase C and Ras dependent and sensitive to rapamycin.	Sirolimus	90-99	gonadotropin releasing hormone 1	Mus musculus	30-34
11015466-9	2000	Additionally, rapamycin prevented the stimulatory effects of leucine on eIF4E availability for binding eIF4G and inhibited leucine-dependent phosphorylation of S6K1.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Rattus norvegicus	160-164
7543051-0	1995	Increased LFA-1-mediated homotypic cell adhesion is associated with the G1 growth arrest induced by rapamycin in a T cell lymphoma.	Sirolimus	100-109	integrin alpha L	Mus musculus	10-15
10889198-6	2000	Rapamycin, an inhibitor of p70(S6K), inhibited cell swelling-induced activation of p70(S6K) but failed to inhibit cell swelling-induced stimulation of TC uptake.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	31-34
10889198-6	2000	Rapamycin, an inhibitor of p70(S6K), inhibited cell swelling-induced activation of p70(S6K) but failed to inhibit cell swelling-induced stimulation of TC uptake.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	27-30
7531689-4	1995	In skeletal muscle TC, FK-590 or rapamycin binds to and dissociates FKBP from the RyR in a time- and temperature-dependent manner which increases the open probability of the channel.	Sirolimus	33-42	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	68-72
10971657-5	2000	These deletions also abolished the ability of a rapamycin-resistant mTOR mutant to rescue the activity of p70 alpha from inhibition induced by rapamycin in vivo.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	106-115
7822316-5	1995	In the presence of rapamycin, immobilized GST-FKBP12 specifically precipitates similar high molecular mass proteins from both rat brain and murine T-lymphoma cell extracts.	Sirolimus	19-28	glutathione S-transferase kappa 1	Homo sapiens	42-45
10788447-4	2000	The effect of IGF-1 was blocked by the phosphatidylinositide 3-kinase (PI3K) inhibitors LY294002 (50 micrometer) and wortmannin (0.5 micrometer), but not by the MEK inhibitor PD98059 (50 micrometer) or the p70 S6 kinase pathway inhibitor rapamycin (50 nm), suggesting that the stimulation of Akt by IGF-1 is mediated by the PI3K pathway.	Sirolimus	238-247	insulin-like growth factor 1	Rattus norvegicus	14-19
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	35-44	glutathione S-transferase kappa 1	Homo sapiens	149-152
10786668-4	2000	However, simultaneous inhibition of the MAPK pathway and the p70S6K pathway by PD98059 in conjunction with the p70S6K inhibitor rapamycin essentially restored the normal phenotype.	Sirolimus	128-137	ribosomal protein S6 kinase B1	Rattus norvegicus	111-117
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	35-44	FK506 binding protein 1a	Mus musculus	153-159
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	22-25
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Mus musculus	232-236
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	160-169	glutathione S-transferase kappa 1	Homo sapiens	149-152
10755555-0	2000	Association of glucocorticoids and cyclosporin A or rapamycin prevents E-selectin and IL-8 expression during LPS- and TNFalpha-mediated endothelial cell activation.	Sirolimus	52-61	selectin E	Homo sapiens	71-81
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	160-169	FK506 binding protein 1a	Mus musculus	153-159
10698949-5	2000	PKCdelta-mediated phosphorylation of 4E-BP1 is wortmannin resistant but rapamycin sensitive.	Sirolimus	72-81	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	37-43
7822316-6	1995	Binding experiments performed with rapamycin-sensitive and -resistant mutant clones derived from the YAC-1 T-lymphoma cell line demonstrate that the GST-FKBP12-rapamycin complex recovers significantly lower amounts of the candidate mTOR from rapamycin-resistant cell lines.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Mus musculus	232-236
7822316-10	1995	These results strongly suggest that the FKBP12-rapamycin complex interacts with homologous ligands in yeast and mammalian cells and that the loss of mTOR function is directly related to the inhibitory effect of rapamycin on G1- to S-phase progression in T-lymphocytes and other sensitive cell types.	Sirolimus	47-56	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	40-46
8089500-8	1994	In contrast, on days 60 and 300 postgrafting heart allografts from RAPA-treated unresponsive recipients showed increased levels of IL-10 and IL-4 but not of IL-2 mRNA, suggesting preferential activation of Th2 cells.	Sirolimus	67-71	interleukin 10	Rattus norvegicus	131-136
10617575-4	1999	TOR inhibition by rapamycin induces expression of nitrogen source utilization genes controlled by the Ure2 repressor and the transcriptional regulator Gln3, and globally represses ribosomal protein expression.	Sirolimus	18-27	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	151-155
8089500-8	1994	In contrast, on days 60 and 300 postgrafting heart allografts from RAPA-treated unresponsive recipients showed increased levels of IL-10 and IL-4 but not of IL-2 mRNA, suggesting preferential activation of Th2 cells.	Sirolimus	67-71	interleukin 2	Rattus norvegicus	157-161
8063749-5	1994	Rapamycin blocked activation of p70S6K by insulin, but it did not attenuate the effect (2-fold) of insulin on increasing the glycogen synthase activity ratio (+/-glucose-6-P).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	32-38
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	101-110	ribosomal protein S6 kinase B1	Homo sapiens	44-52
10567431-3	1999	We report here that a mammalian recombinant p70alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412.	Sirolimus	206-215	ribosomal protein S6 kinase B1	Homo sapiens	44-52
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	58-61
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	54-61
8287594-7	1994	The ability of the RPM to degrade IC was remarkably enhanced by the pretreatment with HUT102 cell products and the related human recombinant cytokines, lymphotoxin and IL-1 alpha.	Sirolimus	19-22	interleukin 1 alpha	Homo sapiens	168-178
7522118-2	1993	P59/HBI belongs to the FKBP family since it binds the immunosuppressants FK506 and Rapamycin.	Sirolimus	83-92	peptidyl-prolyl cis-trans isomerase FKBP4	Oryctolagus cuniculus	4-7
8109837-4	1993	These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2.	Sirolimus	28-37	interleukin 2	Mus musculus	188-192
8376945-6	1993	Also, cells exposed to IL-2 in the presence of rapamycin showed full Erk2 activation but not DNA synthesis.	Sirolimus	47-56	interleukin 2	Mus musculus	23-27
8377379-10	1993	The effect of rapamycin on the IL-1 alpha enhanced TNF alpha production differed from the effect of CsA.	Sirolimus	14-23	interleukin 1 alpha	Homo sapiens	31-41
8335897-0	1993	Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.	Sirolimus	0-9	granzyme B	Rattus norvegicus	65-75
8335897-0	1993	Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.	Sirolimus	0-9	interferon gamma	Rattus norvegicus	81-90
8335897-3	1993	In this study we tested the hypothesis that RPM-mediated therapeutic effects on accelerated rejection may be linked to decreased expression of protein encoded by gro/melanoma-growth stimulatory activity gene (KC) and macrophage inflammatory protein-2 (MIP-2) genes, the operational rat homologues of the human intercrine-alpha cytokines with proinflammatory IL-8-like neutrophil activation/chemotactic properties.	Sirolimus	44-47	C-X-C motif chemokine ligand 1	Rattus norvegicus	162-165
8335897-9	1993	Moreover, RPM completely blocked intragraft appearance of granzyme B and IFN-gamma mRNA in long term cardiac allografts.	Sirolimus	10-13	granzyme B	Rattus norvegicus	58-68
8335897-9	1993	Moreover, RPM completely blocked intragraft appearance of granzyme B and IFN-gamma mRNA in long term cardiac allografts.	Sirolimus	10-13	interferon gamma	Rattus norvegicus	73-82
8335897-11	1993	In contrast, the allografts from RPM-treated hosts showed essentially no neutrophil infiltration and minor, focal staining for IL-8 and IFN-gamma.	Sirolimus	33-36	interferon gamma	Rattus norvegicus	136-145
1380801-0	1992	Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	42-55
1375751-3	1992	Two largely nonpolar, immunosuppressive agents, FK506 and rapamycin, each bind with high affinity to a common hydrophobic pocket on a small peptidylproline cis-trans isomerase known as FK506 binding protein (FKBP-12) and inhibit its activity.	Sirolimus	58-67	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	208-215
1375751-4	1992	In an effort to elucidate the structural features of these ligands responsible for the observed energetics, we have undertaken an investigation of the thermodynamics of binding of FK506 and rapamycin to FKBP-12.	Sirolimus	190-199	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	203-210
1723403-6	1991	Cyclosporin A and ascomycin did not inhibit interleukin 2 dependent proliferation, whereas the dunaimycins and rapamycin blocked the uptake of [3H]thymidine in mixed cultures supplemented with exogenous interleukin 2.	Sirolimus	111-120	interleukin 2	Mus musculus	203-216
10502402-9	1999	TRAIL expression was also blocked by rapamycin, which inhibits p70 S6 kinase involved in CD28 and interleukin (IL)-2 receptor signaling.	Sirolimus	37-46	CD28 antigen	Mus musculus	89-93
10580837-8	1999	In contrast, wortmannin, a phosphatidylinositol 3-kinase (PI 3"-kinase) inhibitor and the immunosuppressant rapamycin abrogated PHAS-I phosphorylation and caused a reciprocal shift between the fully phosphorylated PHAS-I gamma form and its non-phosphorylated alpha form.	Sirolimus	108-117	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	128-134
10580837-8	1999	In contrast, wortmannin, a phosphatidylinositol 3-kinase (PI 3"-kinase) inhibitor and the immunosuppressant rapamycin abrogated PHAS-I phosphorylation and caused a reciprocal shift between the fully phosphorylated PHAS-I gamma form and its non-phosphorylated alpha form.	Sirolimus	108-117	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	214-220
10490847-5	1999	Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin.	Sirolimus	102-111	ribosomal protein S6 kinase B1	Homo sapiens	11-15
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B1	Homo sapiens	114-120
1710844-0	1991	Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A.	Sirolimus	24-33	protein phosphatase 2 phosphatase activator	Homo sapiens	165-169
33972683-6	2021	Rapamycin inhibited FTO activity, and directly targeted eIF4G1 transcripts and mediated their expression in an m6A-dependent manner.	Sirolimus	0-9	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	20-23
33549024-8	2021	The levels of key protein p-4EBP1 in the striatum and substantia nigra were both significantly higher in PD group compared with control group (P<0.01), while being pretreated with rapamycin, the expression of p-4EBP1 in the striatum and substantia nigra were both decreased obviously (P<0.01).	Sirolimus	180-189	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-33
33817096-12	2018	Conclusion: Arterial infusion of rapamycin combined with TACE can improve treatment efficacy by decreasing HIF-1a, VEGF, iNOS and CD34 expression.	Sirolimus	33-42	hypoxia-inducible factor 1-alpha	Oryctolagus cuniculus	107-113
25752454-5	2015	A cohort of NS-Pten KO mice was treated with the mTOR inhibitor rapamycin (10 mg/kg i.p., 5 days/week) starting at postnatal week 9 and video-EEG monitored for epileptiform activity.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Mus musculus	49-53
17360108-0	2007	An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	18-24
34922249-7	2022	Finally, in order to prove that AKT/mTOR signaling potentially mediated DHA-induced macrophage differentiation, we used rapamycin to specifically block the activity of mTOR and stimulated macrophages under M1 stimuli.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Mus musculus	36-40
10455142-8	1999	However, calyculin A prevented both rapamycin- and sorbitol-mediated deactivation of S6K.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	85-88
34922249-7	2022	Finally, in order to prove that AKT/mTOR signaling potentially mediated DHA-induced macrophage differentiation, we used rapamycin to specifically block the activity of mTOR and stimulated macrophages under M1 stimuli.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Mus musculus	168-172
34105096-13	2022	The intervention of bafilomycin A1 and rapamycin in HSCs strongly supported the notion that inhibition of autophagy enhanced alpha -SMA protein expression levels (P<0.01).	Sirolimus	39-48	immunoglobulin mu binding protein 2	Mus musculus	132-135
34748756-6	2022	The observed effects of Gpc4 on MFS were significantly antagonized when mice were treated with L-leucine or rapamycin, an agonist or antagonist of the mammalian target of rapamycin (mTOR) signal, respectively, demonstrating that mTOR pathway is an essential requirement for Gpc4-regulated MFS.	Sirolimus	108-117	glypican 4	Homo sapiens	274-278
34920774-2	2021	The discovery of wort-mannin as the first potent PI3K inhibitor (PI3Ki) in the 1990s provided rapid identification of PI3K-dependent processes, which drove the discovery of the PI3K/protein kinase B (PKB/Akt)/target of rapamycin (mTOR) pathway.	Sirolimus	219-228	mechanistic target of rapamycin kinase	Mus musculus	230-234
34547769-6	2021	In vivo mTOR inhibition by rapamycin reduced both STIM1 and ORAI1 expression and calcium flows, resulting in a normalization of platelet susceptibility to activation.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Mus musculus	8-12
34547769-6	2021	In vivo mTOR inhibition by rapamycin reduced both STIM1 and ORAI1 expression and calcium flows, resulting in a normalization of platelet susceptibility to activation.	Sirolimus	27-36	ORAI calcium release-activated calcium modulator 1	Mus musculus	60-65
34938382-10	2021	Inhibition of mTOR by Rapamycin counteracted the combined protection of SeMet and Tau against LPS-induced inflammatory damage, the inhibition of PI3K by LY294002 blocked the activation of mTOR, and the accumulation of ROS by the ROS agonist blocked the activation of PI3K.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
10430629-5	1999	We also show that overexpression of ICSBP in the human U937 monocytic cell line enhances the rate of spontaneous apoptosis and the sensitivity to apoptosis induced by etoposide, lipopolysaccharide plus ATP, or rapamycin.	Sirolimus	210-219	interferon regulatory factor 8	Homo sapiens	36-41
10446965-2	1999	Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	79-85
10446965-2	1999	Treatment of cells with rapamycin, a selective FRAP Inhibitor, inhibited basal p70s6K kinase activity and induced dephosphorylation of p70s6K and 4E-BP1.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	135-152
10334873-7	1999	Ethanol-plus-S1P-induced DNA synthesis was partially inhibited by both PD 98059 (50 microM) and rapamycin (10 nM), inhibitors of p42/p44 MAP kinase kinase and mTOR/p70 S6 kinases, respectively.	Sirolimus	96-105	sphingosine-1-phosphate receptor 1	Mus musculus	13-16
10334873-7	1999	Ethanol-plus-S1P-induced DNA synthesis was partially inhibited by both PD 98059 (50 microM) and rapamycin (10 nM), inhibitors of p42/p44 MAP kinase kinase and mTOR/p70 S6 kinases, respectively.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Mus musculus	159-163
10318894-2	1999	We describe a dominant clonal-selection assay of stably transfected cells expressing partner proteins FKBP (FK506 binding protein) and FRAP (FKBP-rapamycin binding protein) fused to DHFR fragments and show a rapamycin dose-dependent survival of clones that requires approximately 25 molecules of reconstituted DHFR per cell.	Sirolimus	146-155	dihydrofolate reductase	Homo sapiens	182-186
10216124-2	1999	It is also suppressed by inhibitors of various protein kinases, including rapamycin, which blocks activation of p70 S6 kinase (p70(S6k)), PD98059, which inhibits the activation of extracellular-regulated kinase (ERK), and SB 203580, an inhibitor of the p38 mitogen-activated protein kinase (p38 MAPK).	Sirolimus	74-83	ribosomal protein S6 kinase B1	Rattus norvegicus	127-134
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	150-156
10200280-7	1999	FRAP also is shown to phosphorylate PP2A in vitro, consistent with a model in which phosphorylation of PP2A by FRAP prevents the dephosphorylation of 4E-BP1 and p70(s6k), whereas amino acid deprivation or rapamycin treatment inhibits FRAP"s ability to restrain the phosphatase.	Sirolimus	205-214	ribosomal protein S6 kinase B1	Homo sapiens	161-168
10082514-8	1999	mos mRNA, which does not contain a 5"-terminal oligopyrimidine tract (5"-TOP), was translated earlier, and a larger amount of Mos protein was produced in rapamycin-treated oocytes.	Sirolimus	154-163	MOS proto-oncogene, serine/threonine kinase L homeolog	Xenopus laevis	0-3
10082514-8	1999	mos mRNA, which does not contain a 5"-terminal oligopyrimidine tract (5"-TOP), was translated earlier, and a larger amount of Mos protein was produced in rapamycin-treated oocytes.	Sirolimus	154-163	MOS proto-oncogene, serine/threonine kinase L homeolog	Xenopus laevis	126-129
10049913-1	1999	The immunosuppressive drugs FK506 and rapamycin bind to the cellular protein FKBP12, and the resulting FKBP12-drug complexes inhibit signal transduction.	Sirolimus	38-47	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	77-83
10049913-1	1999	The immunosuppressive drugs FK506 and rapamycin bind to the cellular protein FKBP12, and the resulting FKBP12-drug complexes inhibit signal transduction.	Sirolimus	38-47	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	103-109
9927327-12	1999	Lastly, the antiapoptotic effects of SCF/LIF or IGF-I were almost entirely eliminated by cotreatment of fetal ovaries with either one of two inhibitors of phosphatidylinositol-3"-kinase (PI3K), LY294002 (5 microM) or wortmannin (50 nM), whereas cotreatment with an inhibitor of p70 S6 kinase (rapamycin, 25 ng/ml) was without effect.	Sirolimus	293-302	kit ligand	Mus musculus	37-40
9927327-12	1999	Lastly, the antiapoptotic effects of SCF/LIF or IGF-I were almost entirely eliminated by cotreatment of fetal ovaries with either one of two inhibitors of phosphatidylinositol-3"-kinase (PI3K), LY294002 (5 microM) or wortmannin (50 nM), whereas cotreatment with an inhibitor of p70 S6 kinase (rapamycin, 25 ng/ml) was without effect.	Sirolimus	293-302	leukemia inhibitory factor	Mus musculus	41-44
9872748-4	1999	Administration of rapamycin resulted in 200-fold induction of plasma Epo.	Sirolimus	18-27	erythropoietin	Mus musculus	69-72
34944458-4	2021	Interestingly, both wild-type DGKbeta and the kinase-negative (KN) mutant partially induced neurite outgrowth, and these functions shared a common pathway via the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	197-206	diacylglycerol kinase alpha	Homo sapiens	30-37
9852118-1	1998	Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway.	Sirolimus	122-131	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	228-234
34585990-9	2021	Mechanistically, IL-23 induced EMT was mTOR/S6 signaling dependent and reversible by rapamycin.	Sirolimus	85-94	interleukin 23 subunit alpha	Homo sapiens	17-22
9822578-4	1998	RESULTS: We isolated two Saccharomyces cerevisiae genes, BMH1 and BMH2, as multicopy suppressors of the growth-inhibitory phenotype caused by rapamycin in budding yeast.	Sirolimus	142-151	14-3-3 family protein BMH2	Saccharomyces cerevisiae S288C	66-70
9722592-9	1998	Phosphorylation of p70 S6 kinase and 4E-BP1 is also repressed by PI3K inhibitors as well as by rapamycin, the selective inhibitor of FRAP/mTOR.	Sirolimus	95-104	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	37-43
33522374-4	2021	Cell viability, autophagy, and apoptosis were evaluated by cell counting kit 8 assay, transmission electron microscopy, and TUNEL staining after treatment with ligustrazine, PI3K inhibitor Ly294002, and/or mTOR inhibitor rapamycin, respectively.	Sirolimus	221-230	mechanistic target of rapamycin kinase	Mus musculus	206-210
9743407-2	1998	The immunosuppressants FK506 and rapamycin both bind to FKBP12 and in turn dissociate the protein from the ryanodine receptor.	Sirolimus	33-42	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	56-62
34673243-0	2021	Efficacy and safety of sirolimus therapy in familial hypoinsulinemic hypoglycemia caused by AKT2 mutation inherited from the mosaic father.	Sirolimus	23-32	AKT serine/threonine kinase 2	Homo sapiens	92-96
9712868-17	1998	However, both wortmannin, a PI3K inhibitor, and rapamycin, an inhibitor of p70(S6K) activity, inhibit 8,12-iso-iPF2alpha-III -induced myocyte hypertrophy, with IC50 values of 60 +/- 12 and 3 +/- 1.7 nM, respectively, whereas neither compound abrogates the PGF2alpha-mediated response.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Rattus norvegicus	79-82
34673243-2	2021	Herein, we describe a metabolic and hormonal profile before and during treatment with sirolimus in two brothers with AKT2 mutation inherited from the mosaic father, who showed low-level mosaicism in sperm.	Sirolimus	86-95	AKT serine/threonine kinase 2	Homo sapiens	117-121
9715279-7	1998	The signalling inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response.	Sirolimus	26-35	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	82-88
9715279-7	1998	The signalling inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response.	Sirolimus	26-35	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	138-143
34525858-6	2021	Furthermore, administering D4F or Rapa to T2DM mice upregulated LC3-II and attenuated CHOP expression, cell apoptosis, and atherosclerotic lesions.	Sirolimus	34-38	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	64-67
9618150-4	1998	Transient transfection of dominant-negative form of phosphatidylinositol (PI) 3-kinase completely blocked the transactivation of the fusion gene UCP1-CAT induced by either IGF-I or insulin, although inhibition of p70S6kinase with rapamycin does not preclude transactivation of the UCP1 promoter by insulin.	Sirolimus	230-239	uncoupling protein 1	Homo sapiens	145-149
34525858-6	2021	Furthermore, administering D4F or Rapa to T2DM mice upregulated LC3-II and attenuated CHOP expression, cell apoptosis, and atherosclerotic lesions.	Sirolimus	34-38	DNA-damage inducible transcript 3	Mus musculus	86-90
34912349-4	2021	As previously shown by our group, injecting mice with IL-2/anti-IL-2 complexes (IL-2cplx) to augment expansion of CD4 T regulatory cells (Tregs) induces tolerance towards islet allografts, and also to skin allografts when IL-2cplx treatment is supplemented with rapamycin and a short-term treatment of anti-IL-6.	Sirolimus	262-271	interleukin 2	Mus musculus	54-58
34917890-2	2021	The phosphoinositide 3-kinase (PI3K) promotes degradation of PDCD4 via mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	91-100	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	4-29
34887852-14	2021	Partial rapamycin resistance was observed possibly due to the reactivation of the pathway by a functionally different complex of mTOR, i.e., mTORC2.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Mus musculus	129-133
34717796-2	2021	We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2, which comprise the large neutral amino acid transporter, was required for mammalian target of rapamycin complex 1 (mTORC1) nutrient sensor activation in response to toll-like receptor agonists.	Sirolimus	179-188	interleukin 3	Homo sapiens	14-18
34717796-2	2021	We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2, which comprise the large neutral amino acid transporter, was required for mammalian target of rapamycin complex 1 (mTORC1) nutrient sensor activation in response to toll-like receptor agonists.	Sirolimus	179-188	solute carrier family 7 member 5	Homo sapiens	66-72
34717796-2	2021	We found that IL-3-induced Janus kinase 2-dependent expression of SLC7A5 and SLC3A2, which comprise the large neutral amino acid transporter, was required for mammalian target of rapamycin complex 1 (mTORC1) nutrient sensor activation in response to toll-like receptor agonists.	Sirolimus	179-188	solute carrier family 3 member 2	Homo sapiens	77-83
34737104-7	2022	Rapamycin (RAPA) promoted autophagy in murine HSCs and reversed the increased malignant transformation induced by heterozygous SPTBN1 deletion.	Sirolimus	0-9	spectrin beta, non-erythrocytic 1	Mus musculus	127-133
9560223-5	1998	In contrast, rapamycin inhibited phosphorylation of initiation factor 4E-binding protein 1 (4E-BP1), general mRNA translation, and overall protein synthesis in p70(s6k-/-) cells, indicating that these events proceed independently of p70(s6k) activity.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	70-90
9560223-5	1998	In contrast, rapamycin inhibited phosphorylation of initiation factor 4E-binding protein 1 (4E-BP1), general mRNA translation, and overall protein synthesis in p70(s6k-/-) cells, indicating that these events proceed independently of p70(s6k) activity.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	92-98
9545268-6	1998	Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo.	Sirolimus	19-28	FKBP prolyl isomerase 7	Homo sapiens	59-65
9427710-0	1998	The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines.	Sirolimus	31-40	cyclin dependent kinase inhibitor 1B	Homo sapiens	20-27
9427710-5	1998	Furthermore, we showed that Rap-sensitive cells with elevated p27Kip1 expression lost sensitivity to Rap when antisense p27Kip1 was introduced, which indicates that the basal level of p27Kip1 is one of the limiting factors that determine the sensitivity to Rap in already cycling cells.	Sirolimus	28-31	cyclin dependent kinase inhibitor 1B	Homo sapiens	62-69
9427710-5	1998	Furthermore, we showed that Rap-sensitive cells with elevated p27Kip1 expression lost sensitivity to Rap when antisense p27Kip1 was introduced, which indicates that the basal level of p27Kip1 is one of the limiting factors that determine the sensitivity to Rap in already cycling cells.	Sirolimus	28-31	cyclin dependent kinase inhibitor 1B	Homo sapiens	120-127
9427710-5	1998	Furthermore, we showed that Rap-sensitive cells with elevated p27Kip1 expression lost sensitivity to Rap when antisense p27Kip1 was introduced, which indicates that the basal level of p27Kip1 is one of the limiting factors that determine the sensitivity to Rap in already cycling cells.	Sirolimus	28-31	cyclin dependent kinase inhibitor 1B	Homo sapiens	120-127
9458729-6	1998	Furthermore, stimulation of p70S6k phosphorylation by amino acids was prevented by either rapamycin or LY-294002.	Sirolimus	90-99	ribosomal protein S6 kinase B1	Rattus norvegicus	28-34
9458731-3	1998	The stimulation of protein synthesis was accompanied by increased phosphorylation of p70S6k, an effect that was blocked by rapamycin and wortmannin but not PD-98059.	Sirolimus	123-132	ribosomal protein S6 kinase B1	Homo sapiens	85-91
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Sirolimus	5-14	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	80-86
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Sirolimus	5-14	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	122-128
9395487-9	1997	Fibroblasts derived from PHAS-I-deficient mouse embryos exhibited normal rates of growth and overall protein synthesis, responded normally to serum stimulation of ornithine decarboxylase activity and cell growth, and rapamycin inhibition of cell growth.	Sirolimus	217-226	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	25-31
9396011-4	1997	Rapamycin binds to FKBP and the complex binds to Rapamycin And FKBP-12 Target (RAFT).	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	63-70
9396011-4	1997	Rapamycin binds to FKBP and the complex binds to Rapamycin And FKBP-12 Target (RAFT).	Sirolimus	49-58	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	63-70
34737104-7	2022	Rapamycin (RAPA) promoted autophagy in murine HSCs and reversed the increased malignant transformation induced by heterozygous SPTBN1 deletion.	Sirolimus	11-15	spectrin beta, non-erythrocytic 1	Mus musculus	127-133
9234702-5	1997	Moreover, rapamycin treatment blocks Gas6-induced entry into the S phase of serum-starved NIH 3T3 cells.	Sirolimus	10-19	growth arrest specific 6	Mus musculus	37-41
34765012-8	2021	We also found that QYLGT had the ability to activate phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	114-123	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	53-78
34841735-6	2021	Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were both up to two-fold higher in the RAPA group, suggesting the inconsistent reactivation potential of the FK506 and RAPA groups when an anti-tumour or anti-infection immune response is concerned.	Sirolimus	117-121	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-77
9202048-13	1997	Other antiproliferative agents including rapamycin, mimosine, and nitric oxide agonists also synergized with EGF to stimulate differentiation.	Sirolimus	41-50	epidermal growth factor	Rattus norvegicus	109-112
9248697-7	1997	Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K.	Sirolimus	34-43	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	107-113
9248697-7	1997	Incubating 3T3-L1 adipocytes with rapamycin and wortmannin inhibited insulin-stimulated phosphorylation of PHAS-I at concentrations similar to those that inhibited activation of p70S6K.	Sirolimus	34-43	ribosomal protein S6 kinase B1	Homo sapiens	178-184
9248697-9	1997	Incubating adipocytes with the protein phosphatase inhibitors, calyculin A and okadaic acid, increased PHAS-I phosphorylation and opposed the effects of rapamycin on decreasing PHAS-I phosphorylation.	Sirolimus	153-162	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	177-183
9218810-2	1997	In parallel, rapamycin blocks mitogen-induced p70 ribosomal protein S6 kinase (p70s6k) phosphorylation and activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	46-77
9218810-2	1997	In parallel, rapamycin blocks mitogen-induced p70 ribosomal protein S6 kinase (p70s6k) phosphorylation and activation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	79-85
9154824-1	1997	We analyzed the effect of rapamycin on autocrine mast cell tumor lines with abnormally stable interleukin-3 (IL-3) transcripts due to a defect in mRNA degradation.	Sirolimus	26-35	interleukin 3	Homo sapiens	94-107
9160663-6	1997	Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059.	Sirolimus	121-130	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	41-47
9160663-6	1997	Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059.	Sirolimus	121-130	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	68-74
9151781-0	1997	Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.	Sirolimus	0-9	proliferating cell nuclear antigen	Homo sapiens	31-65
9151781-0	1997	Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.	Sirolimus	11-20	proliferating cell nuclear antigen	Homo sapiens	31-65
9151781-6	1997	Cells treated with rapamycin exhibited decreased PCNA expression while cyclin D1 expression, which precedes PCNA expression in the cell cycle, was not affected.	Sirolimus	19-28	proliferating cell nuclear antigen	Homo sapiens	49-53
9109413-0	1997	PHAS-I phosphorylation in response to foetal bovine serum (FBS) is regulated by an ERK1/ERK2-independent and rapamycin-sensitive pathway in 3T3-L1 adipocytes.	Sirolimus	109-118	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	0-6
9109413-6	1997	However, treatment of cells with a specific p70S6k pathway inhibitor, rapamycin, markedly attenuated FBS-stimulated PHAS-I phosphorylation.	Sirolimus	70-79	ribosomal protein S6 kinase B1	Homo sapiens	44-50
9109413-6	1997	However, treatment of cells with a specific p70S6k pathway inhibitor, rapamycin, markedly attenuated FBS-stimulated PHAS-I phosphorylation.	Sirolimus	70-79	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	116-122
9109413-7	1997	These results indicate that PHAS-I phosphorylation in response to FBS occurs through an ERK1/ERK2-independent and rapamycin-sensitive pathway in 3T3-L1 adipocytes.	Sirolimus	114-123	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-34
9051292-3	1997	The immunosuppressant drug, rapamycin, blocked the induction of ODC in response to serum by roughly 50% but was without effect on transport of putrescine into the intracellular space.	Sirolimus	28-37	ornithine decarboxylase 1	Rattus norvegicus	64-67
9051292-10	1997	At a concentration of 10 nM, rapamycin inhibited the induction of ODC by 50%, a level of inhibition which could not be enhanced by exposure cells to 1000 nM rapamycin.	Sirolimus	29-38	ornithine decarboxylase 1	Rattus norvegicus	66-69
8955134-10	1996	The formation of the complexes between FKBP59 or FKBP12 and FAP48 is prevented by FK506 and rapamycin in a dose-dependent manner.	Sirolimus	92-101	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	49-55
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	108-111
8887654-2	1996	Recent reports have focused on the role of the amino terminus of the p85(s6k) isoform in mediating kinase activity, with the observation that amino-terminal truncation mutants are activated in the presence of rapamycin while retaining their sensitivity to wortmannin.	Sirolimus	209-218	ribosomal protein S6 kinase B1	Homo sapiens	69-76
8806686-6	1996	This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70S6k) by both a downward mobility shift on SDS-PAGE and inhibition of activity.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	110-116
8761471-11	1996	The serum-induced degradation of IGF-II mRNAs does not require de novo protein synthesis, and is abolished by rapamycin, an inhibitor of p70 S6 kinase.	Sirolimus	110-119	insulin like growth factor 2	Homo sapiens	33-39
8660826-5	1996	Prevention of cell death correlated with delayed entry into S phase from G1 following TCR religation in the rapamycin-treated cultures.	Sirolimus	108-117	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	86-89
8687386-10	1996	The second event does result in dissociation and is blocked by rapamycin, suggesting that the p70S6K signalling pathway is involved: p70S6K itself is probably not involved directly as this kinase does not phosphorylate 4E-BP1 in vitro.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Rattus norvegicus	94-100
8687386-10	1996	The second event does result in dissociation and is blocked by rapamycin, suggesting that the p70S6K signalling pathway is involved: p70S6K itself is probably not involved directly as this kinase does not phosphorylate 4E-BP1 in vitro.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Rattus norvegicus	133-139
8645341-2	1996	Here, we show that the immunosuppressant rapamycin inhibited basal- as well as erythropoietin-stimulated proliferation of the erythroid cell line J2E.	Sirolimus	41-50	erythropoietin	Mus musculus	79-93
34841735-6	2021	Meanwhile, percentages of regulatory T cells (Tregs) and expression of CTLA-4 were both up to two-fold higher in the RAPA group, suggesting the inconsistent reactivation potential of the FK506 and RAPA groups when an anti-tumour or anti-infection immune response is concerned.	Sirolimus	197-201	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	71-77
8641294-5	1996	Rapamycin, a macrolide immunosuppressant which blocks the signalling pathway leading to the stimulation of the 70/85 kDa ribosomal protein S6 kinases, substantially blocks the activation of elongation, the fall in eEF-2 phosphorylation and the decrease in eEF-2 kinase activity, suggesting that p7O S6 kinase (p70s6k) and eEF-2 kinase may tie on a common signalling pathway.	Sirolimus	0-9	eukaryotic translation elongation factor 2	Homo sapiens	214-219
8641294-5	1996	Rapamycin, a macrolide immunosuppressant which blocks the signalling pathway leading to the stimulation of the 70/85 kDa ribosomal protein S6 kinases, substantially blocks the activation of elongation, the fall in eEF-2 phosphorylation and the decrease in eEF-2 kinase activity, suggesting that p7O S6 kinase (p70s6k) and eEF-2 kinase may tie on a common signalling pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	310-316
34364639-9	2021	Also, IGF-1-induced XBP1s and ER biogenesis-associated gene expression was inhibited by rapamycin, an inhibitor of mTORC1 (mammalian target of rapamycin complex 1), indicating that IRE1-XBP1 activation by IGF-1 is mediated by mTORC1.	Sirolimus	88-97	X-box binding protein 1	Homo sapiens	186-190
34498712-8	2021	The results showed that the expression levels of collagen-I (COL-I) and alpha-smooth muscle actin (alpha-SMA) were increased in miR221-overexpressing LX2 cells, while the autophagy inducer rapamycin reversed the inhibition of autophagic flux induced by miR221.	Sirolimus	189-198	microRNA 221	Homo sapiens	253-259
8633019-2	1996	However, the immunosuppressant rapamycin blocks serum-induced 4E-BP1 phosphorylation and, in parallel, p70s6k activation, with no apparent effect on p42mapk activation.	Sirolimus	31-40	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	62-68
8633019-2	1996	However, the immunosuppressant rapamycin blocks serum-induced 4E-BP1 phosphorylation and, in parallel, p70s6k activation, with no apparent effect on p42mapk activation.	Sirolimus	31-40	ribosomal protein S6 kinase B1	Homo sapiens	103-109
8633019-6	1996	The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin.	Sirolimus	125-134	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	22-28
8633019-6	1996	The insulin effect on 4E-BP1 phosphorylation and p70s6k activation in both cell types is blocked by SQ20006, wortmannin, and rapamycin.	Sirolimus	125-134	ribosomal protein S6 kinase B1	Homo sapiens	49-55
8812665-0	1996	Immunophilin Modulation of Calcium Channel Gating The FK506 binding protein (FKBP12) is the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	153-162	peptidylprolyl isomerase A (cyclophilin A) L homeolog	Xenopus laevis	0-12
34689241-10	2021	CONCLUSION: Pretreatment with Triciribine or Rapamycin has a greater effect on pathway protein Akt, cell cycle arrest, autophagy protein, and cell proliferation but with inconsistent magnitude, which may be inferred that the Akt/mTOR pathway, as well as its feedback loop, were more likely involved in these processes.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Mus musculus	229-233
34735882-5	2021	Mechanistically, we found that hayatine disrupts the interaction between mTORC1 complex and its lysosomal adaptor RagA/C by binding to the hydrophobic loop of RagC, leading to mTORC1 inhibition that holds great promise to overcome rapamycin resistance.	Sirolimus	231-240	Ras related GTP binding A	Homo sapiens	114-118
34735882-5	2021	Mechanistically, we found that hayatine disrupts the interaction between mTORC1 complex and its lysosomal adaptor RagA/C by binding to the hydrophobic loop of RagC, leading to mTORC1 inhibition that holds great promise to overcome rapamycin resistance.	Sirolimus	231-240	Ras related GTP binding C	Homo sapiens	159-163
8785272-1	1996	The FK506-binding protein (FKBP12) is important in the immunosuppressant action of FK506 and rapamycin.	Sirolimus	93-102	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	27-33
34675258-7	2021	Akt phosphorylation and activation was indispensable for rapamycin-induced TCTP degradation and PLK1 activation, and depended on S6K inhibition, but not mTORC2 activation.	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	129-132
8595879-6	1996	Moreover, TOR2-RAFT1 and TOR1-RAFT1 hybrid proteins mutated at the position corresponding to rapamycin-resistant TOR mutants (S20351) conferred rapamycin resistance.	Sirolimus	93-102	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	10-14
34675258-8	2021	Furthermore, the minimal dose of rapamycin required to induce TCTP proteolysis enhanced the efficacy of DNA-damaging drugs, such as cisplatin and doxorubicin, through the induction of apoptotic cell death in vitro and in vivo.	Sirolimus	33-42	tumor protein, translationally-controlled 1	Homo sapiens	62-66
34680338-6	2021	In glioblastoma and melanoma cells, DGKalpha attenuates apoptosis by enhancing the phosphodiesterase (PDE)-4A1-mammalian target of the rapamycin pathway.	Sirolimus	135-144	diacylglycerol kinase alpha	Homo sapiens	36-44
8598490-13	1996	The demonstration of IL-12 in long term allografts after RPM therapy may reflect late activation of macrophages that, coupled with the appearance of IgG2b, may contribute to the chronic rejection of cardiac allografts.	Sirolimus	57-60	interleukin 12B	Rattus norvegicus	21-26
34685712-7	2021	Supplementation with rapamycin to alcohol-fed mice attenuated mTORC1 activation and ER stress, restored LAMP2 protein, and improved autophagy, leading to amelioration of alcohol-induced liver injury.	Sirolimus	21-30	lysosomal-associated membrane protein 2	Mus musculus	104-109
34543777-12	2021	Treatment of rapamycin and let-7i-5p inhibitor reversed the effects of downregulated DICER in cell viability, ratio of LC3-II/LC3-I, autophagosomes, cell apoptosis rate and the phosphorylation levels of PI3K/AKT/mTOR in A549/DDP cells.	Sirolimus	13-22	dicer 1, ribonuclease III	Homo sapiens	85-90
7559428-0	1995	Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin.	Sirolimus	68-77	high mobility group AT-hook 1	Homo sapiens	43-51
7545671-4	1995	The inhibitory effect of rapamycin on serum-induced p70s6k activation and the phosphorylation of Thr229, Thr389, Ser404, and Ser411 is rescued by FK506, providing further evidence that the inhibitory effect is exerted through a complex of rapamycin-FKBP12.	Sirolimus	25-34	FK506 binding protein 1a	Mus musculus	249-255
34685593-6	2021	Inhibition of either mTOR (rapamycin) or SAP/JNK-MAPK signaling (SP600125) resulted in dose-dependent metabolic suppression.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Mus musculus	21-25
7642551-7	1995	Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin.	Sirolimus	237-246	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	108-114
7583777-1	1995	The effects of cyclosporin A (CsA), FK506 and rapamycin (Rapa) on the intracellular localization of a mutated rabbit progesterone receptor (PR) which lacks the main constitutive nuclear localization signal (NLS) (delta 638-642) and is cytoplasmic in the absence of progesterone (Prog), were assayed by indirect immunofluorescence in Lcl3 cells, a mouse L-cell line stably expressing this mutant.	Sirolimus	46-55	progesterone receptor	Oryctolagus cuniculus	117-138
7583777-1	1995	The effects of cyclosporin A (CsA), FK506 and rapamycin (Rapa) on the intracellular localization of a mutated rabbit progesterone receptor (PR) which lacks the main constitutive nuclear localization signal (NLS) (delta 638-642) and is cytoplasmic in the absence of progesterone (Prog), were assayed by indirect immunofluorescence in Lcl3 cells, a mouse L-cell line stably expressing this mutant.	Sirolimus	46-55	progesterone receptor	Oryctolagus cuniculus	140-142
7728769-3	1995	To determine whether this pathway plays a role in the regulation of apoptosis, we assessed the effect of rapamycin on apoptosis induced by interleukin 2 deprivation in murine T-cell lines, by T-cell receptor ligation in a murine T-cell hybridoma, by enforced c-myc expression in murine fibroblasts, and by corticosteroids in murine T-lymphoma cell lines.	Sirolimus	105-114	interleukin 2	Mus musculus	139-152
7534292-5	1995	The immunosuppressant drug rapamycin was found to selectively inhibit the activation of p70S6K by AII, but not the activation of mitogen-activated protein kinase or the induction of c-fos mRNA expression.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	88-94
9383417-3	1995	Rapamycin, ascomycin and FK506 have a common domain responsible for binding to FKBP12, their cellular receptor, and different effector domains that determine the target of the complex.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	79-85
7852343-7	1995	Immunosuppressant rapamycin completely blocked activation of pp70 S6 kinase by insulin or IGF-I, but rapamycin alone or in combination with induction of negative dominant Ras failed to antagonize glycogen synthase activation by these hormones.	Sirolimus	18-27	insulin-like growth factor 1	Rattus norvegicus	90-95
7836465-8	1995	The inhibition by amino acids of both autophagic proteolysis and autophagic sequestration of electro-injected cytosolic [14C]sucrose was partially prevented by rapamycin, a compound known to inhibit activation of p70 S6 kinase.	Sirolimus	160-169	ribosomal protein S6 kinase B1	Rattus norvegicus	217-226
7533090-0	1995	FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.	Sirolimus	64-73	FK506 binding protein 1a	Mus musculus	0-24
7533090-7	1995	Increased expression of FKBP12 resulted in increased sensitivity to FK506 and rapamycin, as measured by inhibition of calcineurin activity and p70 S6 kinase activity, respectively.	Sirolimus	78-87	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	24-30
7533090-9	1995	Two distinct point mutations in FKBP12, one altering a hydrophobic residue within the drug-binding pocket and the other changing a charged surface residue of FKBP12, abrogated its ability to mediate sensitivity to FK506 and rapamycin.	Sirolimus	224-233	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	32-38
7533090-9	1995	Two distinct point mutations in FKBP12, one altering a hydrophobic residue within the drug-binding pocket and the other changing a charged surface residue of FKBP12, abrogated its ability to mediate sensitivity to FK506 and rapamycin.	Sirolimus	224-233	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	158-164
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	60-66
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	134-140
7945242-5	1994	Rapamycin blocked the activation of p70 S6 kinase by IGF-1 in L6 cells, but had no effect on the inhibition of GSK3 or the activation of MAPKAP kinase-1 beta.	Sirolimus	0-9	insulin-like growth factor 1	Rattus norvegicus	53-58
7520778-1	1994	The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4).	Sirolimus	27-36	interleukin 2	Mus musculus	122-135
7520778-1	1994	The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4).	Sirolimus	27-36	interleukin 2	Mus musculus	137-141
7520778-1	1994	The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4).	Sirolimus	27-36	interleukin 4	Mus musculus	147-160
7520778-1	1994	The immunosuppressive drug rapamycin suppresses T-cell activation by impairing the T-cell response to lymphokines such as interleukin-2 (IL-2) and interleukin-4 (IL-4).	Sirolimus	27-36	interleukin 4	Mus musculus	162-166
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	kit ligand	Mus musculus	281-291
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	kit ligand	Mus musculus	293-295
7520778-4	1994	In vitro, rapamycin inhibited the proliferation of primary bone marrow cells induced by IL-3, GM-CSF, KL, or a complex mixture of factors present in cell-conditioned media.	Sirolimus	10-19	kit ligand	Mus musculus	102-104
7520778-5	1994	Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.	Sirolimus	0-9	kit ligand	Mus musculus	164-166
7521160-4	1994	The p210 binds to sirolimus:FKBP12 complex, but only at background levels to FKBP12 alone, to FK506:FKBP12 complex, or sirolimus-biotin alone.	Sirolimus	18-27	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	28-34
7521160-5	1994	Among the sirolimus analogs tested, the binding ability of p210 to drug:FKBP12 complexes correlates with the immunosuppressive activity of the drugs, suggesting that p210 is the sirolimus effector protein.	Sirolimus	10-19	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	72-78
7518620-4	1994	Using this method, we studied the time course and effects of CsA and rapamycin on IL-2, IFN-gamma, IL-4, and IL-10 gene expression following Con A stimulation.	Sirolimus	69-78	interleukin 2	Mus musculus	82-86
7509089-3	1994	Rapamycin inhibited the proliferation of BMMP cultured in the presence of 10% L cell-conditioned medium, used as a source of macrophage CSF.	Sirolimus	0-9	colony stimulating factor 2	Homo sapiens	136-139
7507662-5	1994	In an additional test for cellular function, expression of both wild-type and mutant human FKBP12 in a strain of Saccharomyces cerevisiae rendered resistant to rapamycin by deletion of the gene encoding a cytosolic rapamycin binding protein (RPB1), the yeast homologue of FKBP12, restored wild-type drug sensitivity.	Sirolimus	160-169	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	91-97
34486033-1	2021	In this study we employed C3HeB/FeJ mice as an experimental model to investigate the potential role of rapamycin, an mTOR inhibitor, as an adjunctive therapy candidate during the treatment of Mycobacterium tuberculosis infection with moxifloxacin.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Mus musculus	117-121
8186460-1	1994	The Saccharomyces cerevisiae genes TOR1 and TOR2 were originally identified by mutations that confer resistance to the immunosuppressant rapamycin.	Sirolimus	137-146	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	44-48
8186460-4	1994	TOR1 is not essential, but a TOR1 TOR2 double disruption uniquely confers a cell cycle (G1) arrest as does exposure to rapamycin; disruption of TOR2 alone is lethal but does not cause a cell cycle arrest.	Sirolimus	119-128	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	34-38
8186460-6	1994	The TOR1-1 and TOR2-1 mutations, which confer rapamycin resistance, alter the same potential protein kinase C site in the respective protein"s lipid kinase domain.	Sirolimus	46-55	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	15-19
7522118-2	1993	P59/HBI belongs to the FKBP family since it binds the immunosuppressants FK506 and Rapamycin.	Sirolimus	83-92	peptidyl-prolyl cis-trans isomerase FKBP4	Oryctolagus cuniculus	0-3
7504992-0	1993	Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells.	Sirolimus	149-158	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	100-105
7504992-6	1993	We also show that the immunosuppressant rapamycin, but not FK506, can inhibit both SCF-dependent pp70-S6 kinase activation and SCF-dependent proliferation in mouse mast cells, without suppressing IgE- and antigen-dependent mediator release.	Sirolimus	40-49	kit ligand	Mus musculus	83-86
7504992-6	1993	We also show that the immunosuppressant rapamycin, but not FK506, can inhibit both SCF-dependent pp70-S6 kinase activation and SCF-dependent proliferation in mouse mast cells, without suppressing IgE- and antigen-dependent mediator release.	Sirolimus	40-49	kit ligand	Mus musculus	127-130
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	72-81	interleukin 2	Mus musculus	6-19
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	72-81	interleukin 2	Mus musculus	21-25
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	158-167	interleukin 2	Mus musculus	6-19
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	158-167	interleukin 2	Mus musculus	21-25
8109837-2	1993	In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle.	Sirolimus	158-167	interleukin 2	Mus musculus	182-186
8109837-4	1993	These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2.	Sirolimus	28-37	interleukin 2	Mus musculus	48-52
8268127-8	1993	Rapamycin was found to target a pathway late in G1 that is distal to induction of D-type cyclin gene expression but proximal to DNA replication, perhaps involving the function of the D-type cyclin proteins or their associated kinases.	Sirolimus	0-9	proliferating cell nuclear antigen	Homo sapiens	89-95
34298397-8	2021	Neutrophil number was decreased in the peripheral blood of IF1-KO mice, which was associated with a reduction in LC3A/B proteins in the KO neutrophils in Rapamycin-induced autophagy response.	Sirolimus	154-163	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	113-119
8268127-8	1993	Rapamycin was found to target a pathway late in G1 that is distal to induction of D-type cyclin gene expression but proximal to DNA replication, perhaps involving the function of the D-type cyclin proteins or their associated kinases.	Sirolimus	0-9	proliferating cell nuclear antigen	Homo sapiens	190-196
7690317-3	1993	In mouse systems, rapamycin caused a dose-dependent inhibition of both Ca(2+)-dependent (concanavalin A (Con A), phytohemagglutinin (PHA), and phorbol 12-myristate 13-acetate + ionomycin) and Ca(2+)-independent (lipopolysaccharide and PMA + interleukin-2) activation, whereas in the rat only Ca(2+)-independent responses were inhibited.	Sirolimus	18-27	interleukin 2	Mus musculus	241-254
34399087-3	2021	Treatment of JEG-3 cells with DEX (1microM), GRalpha siRNA, LY294002 (50microM), XO/HX (7.2microM/36nM) or rapamycin (80nM) inhibited cell proliferation, induced apoptosis, significantly decreased MMP and hCG and hPL content and increased ROS levels.	Sirolimus	107-116	galectin 1	Homo sapiens	213-216
34399087-5	2021	Treatment of JEG-3 cells with GRalpha siRNA, LY294002, XO/HX or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (PI3K), Akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mTOR) and induced the phosphorylation of AMP-activated protein kinase (AMPK) and tuberous sclerosis complex 2.	Sirolimus	64-73	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	103-132
34712915-0	2021	Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity.	Sirolimus	0-9	sirtuin 2	Homo sapiens	19-24
34712915-7	2021	Rapamycin recruits SIRT2 with a high affinity for FKBP12 association and deacetylation.	Sirolimus	0-9	sirtuin 2	Homo sapiens	19-24
34712915-10	2021	In contrast, rapamycin strengthening FKBP12-mTOR association blocks mTOR antiviral activity by recruiting SIRT2 to deacetylate FKBP12.	Sirolimus	13-22	sirtuin 2	Homo sapiens	106-111
34554926-7	2021	In addition, the mechanism of action of miR-19b-3p was clarified using the PTEN inhibitor (VO-Ohpic triphosphate) or the mTOR inhibitor (Rapamycin) on the basis of IL-1beta intervention and miR-19b-3p mimics transfection.	Sirolimus	137-146	interleukin 1 alpha	Homo sapiens	164-172
34518220-8	2021	mTORC1 inhibition with rapamycin analog Ridaforolimus suppresses TRIM28 phosphorylation, hTERT expression, and cell viability.	Sirolimus	23-32	telomerase reverse transcriptase	Homo sapiens	89-94
34119480-8	2021	Depletion of GLS1-induced inhibition of DLD1 and SW480 CRC cell proliferation, colony formation and migration was reversed by autophagy inducer rapamycin.	Sirolimus	144-153	glutaminase	Homo sapiens	13-17
34518579-2	2021	Rapamycin, an mTOR inhibitor and a commonly used immunosuppressive drug, has been shown to increase the survivability of Amyotrophic Lateral Sclerosis (ALS) affected motor neurons.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
34494222-11	2021	Akt/mTOR/ p70S6K signaling cascade was proved to be present in NPCs, IGF-I overexpression significantly activated Akt/mTOR/p70S6K signaling cascade, while rapamycin addition inhibited its expression.	Sirolimus	155-164	ribosomal protein S6 kinase B1	Rattus norvegicus	10-16
34494222-13	2021	However, the rapamycin addition inhibited the cell response induced by IGF-I overexpression.	Sirolimus	13-22	insulin-like growth factor 1	Rattus norvegicus	71-76
34571738-6	2021	Rapamycin supplementation (downregulation of TOR activity) produced smaller flies with smaller wing epidermal cells.	Sirolimus	0-9	Target of rapamycin	Drosophila melanogaster	45-48
34533799-1	2021	OBJECTIVE: To investigate the pharmacodynamic mechanism of curcumin against myocardial ischaemia-reperfusion injury by regulating the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/rapamycin target protein (mTOR) signalling pathway.	Sirolimus	194-203	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	134-163
34540654-1	2021	Background: Rapamycin-insensitive companion of mammalian target of rapamycin (Rictor) protein is a core subunit of mammalian target of rapamycin complex 2, and is associated with cancer progression.	Sirolimus	135-144	RPTOR independent companion of MTOR complex 2	Homo sapiens	47-85
34081952-1	2021	RATIONALE: The nutrient sensing mechanistic target of rapamycin complex 1 (mTORC1) and its primary inhibitor, tuberin (TSC2), are cues for the development of cardiac hypertrophy.	Sirolimus	54-63	TSC complex subunit 2	Mus musculus	110-117
34081952-1	2021	RATIONALE: The nutrient sensing mechanistic target of rapamycin complex 1 (mTORC1) and its primary inhibitor, tuberin (TSC2), are cues for the development of cardiac hypertrophy.	Sirolimus	54-63	TSC complex subunit 2	Mus musculus	119-123
34182227-13	2021	CONCLUSION: Rapa modified tolDCs derived from BM-MSCs reversed graft rejection by improve tolerance characteristics of CD8+CD45RC-Treg in acute liver rat transplantation.	Sirolimus	12-16	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	123-129
8387896-3	1993	The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin.	Sirolimus	22-31	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	90-94
8387896-3	1993	The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin.	Sirolimus	22-31	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	155-159
8387896-3	1993	The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin.	Sirolimus	22-31	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	155-159
8449029-10	1993	The anti-S-antigen antibody response was delayed by 3 days under RAPA treatment and the serum levels lowered in a dose dependent manner.	Sirolimus	65-69	S-antigen visual arrestin	Rattus norvegicus	9-18
1281674-0	1992	FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA.	Sirolimus	10-19	colony stimulating factor 2	Homo sapiens	64-70
1281674-2	1992	Using Northern analyses and promoter-reporter constructs we analyzed the transcriptional and posttranscriptional effects of FK506 and rapamycin on IL-2, GM-CSF, and IL-2R alpha gene expression.	Sirolimus	134-143	colony stimulating factor 2	Homo sapiens	153-159
1281674-4	1992	In contrast, rapamycin only partially inhibited IL-2 and GM-CSF promoter activity.	Sirolimus	13-22	colony stimulating factor 2	Homo sapiens	57-63
1380162-7	1992	Rapamycin, a macrolide immunosuppressant that inhibits IL-2-dependent proliferation, inhibited IL-2-stimulated 70-kDa S6 kinase activity subsequent to early increases in tyrosine kinase activity.	Sirolimus	0-9	interleukin 2	Mus musculus	55-59
1380162-7	1992	Rapamycin, a macrolide immunosuppressant that inhibits IL-2-dependent proliferation, inhibited IL-2-stimulated 70-kDa S6 kinase activity subsequent to early increases in tyrosine kinase activity.	Sirolimus	0-9	interleukin 2	Mus musculus	95-99
1376003-3	1992	A 59-kilodalton member of the FK506- and rapamycin-binding class was found to associate in the absence of these drugs with two heat shock proteins (hsp90 and hsp70) and the glucocorticoid receptor (GR).	Sirolimus	41-50	heat shock protein 90 alpha family class A member 1	Homo sapiens	148-153
33771483-7	2021	In this study, we found that PD-L1 induces the upregulation of CD206 expression, which is inhibited by nivolumab, LY294002, U0126, and rapamycin.	Sirolimus	135-144	CD274 molecule	Homo sapiens	29-34
33813773-5	2021	We also verified that L-leucine enhanced p-mTOR/p-S6K activation in neurons by testing with an mTOR inhibitor, rapamycin.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Mus musculus	95-99
33763414-4	2021	Notably, nutrition signals are mediated by the insulin receptor/target of rapamycin (InR/TOR) pathways to regulate cellular metabolism and growth.	Sirolimus	74-83	Target of rapamycin	Drosophila melanogaster	89-92
33769701-1	2021	The mechanistic target of rapamycin (mTOR) is a key mediator of energy metabolism, cell growth, and survival.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Mus musculus	37-41
33767588-9	2021	Moreover, the miR-26b mimic inhibited doxorubicin-induced autophagy and the autophagy inducer, rapamycin, eliminated the differences in the drug sensitivity effect of miR-26b.	Sirolimus	95-104	microRNA 26b	Homo sapiens	167-174
34278477-10	2021	Notably, the rapamycin-mediated suppression of phosphorylated-mTOR, and elevation of Beclin 1 and LC3II expression in the rat hippocampus could not be alleviated by asiaticoside treatment.	Sirolimus	13-22	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	98-103
34453960-10	2021	However, administering Rapamycin or vitamin E, inhibited the oxidative stress and activation of the mTOR pathway induced by Phe exposure, effectively alleviating the above-mentioned autistic-like anxious social behaviors.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	100-104
18089405-0	2007	Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation.	Sirolimus	90-99	interleukin 2	Mus musculus	20-23
18089405-0	2007	Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation.	Sirolimus	90-99	interleukin 2	Mus musculus	33-36
34522005-4	2022	In this study, we showed that mTOR signaling was activated during the expression of behavioral sensitization to cocaine and that intraperitoneal or intra-nucleus accumbens (NAc) treatment with rapamycin, a specific mTOR inhibitor, attenuated cocaine-induced behavioural sensitization.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Mus musculus	30-34
34522005-4	2022	In this study, we showed that mTOR signaling was activated during the expression of behavioral sensitization to cocaine and that intraperitoneal or intra-nucleus accumbens (NAc) treatment with rapamycin, a specific mTOR inhibitor, attenuated cocaine-induced behavioural sensitization.	Sirolimus	193-202	mechanistic target of rapamycin kinase	Mus musculus	215-219
34902357-8	2022	After treating with the mTOR inhibitor rapamycin, autophagy and BDNF levels were elevated.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	24-28
34902357-8	2022	After treating with the mTOR inhibitor rapamycin, autophagy and BDNF levels were elevated.	Sirolimus	39-48	brain derived neurotrophic factor	Mus musculus	64-68
34902358-5	2022	We determined that the knockdown of Maf1 promoted the survival of RGCs and their axon regeneration through altering the activity of the PTEN/mTOR pathway, which could be blocked by rapamycin.	Sirolimus	181-190	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	36-40
34902358-5	2022	We determined that the knockdown of Maf1 promoted the survival of RGCs and their axon regeneration through altering the activity of the PTEN/mTOR pathway, which could be blocked by rapamycin.	Sirolimus	181-190	phosphatase and tensin homolog	Homo sapiens	136-140
34370147-3	2022	The purpose of the study was to investigate the combined treatment of gastric tumorigenesis using Rapamycin and Fluorouracil (5-Fu) through interfering with the Akt/mTOR pathway in a mouse model with PTEN conditional deletion.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Mus musculus	165-169
34370147-7	2022	The combined Rapamycin administration with 5-Fu resulted in better outcomes than their separate administration for the treatment of gastric cancer by inhibiting the mTOR signal pathway.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	165-169
34370147-8	2022	Our study indicates that Rapamycin has a synergistic interaction with chemotherapeutic 5-Fu, and demonstrates a potential therapeutic combination treatment on glandular stomach tumor with PTEN functional absence or aberrantly activated Akt/mTOR pathway.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Mus musculus	240-244
34893663-4	2021	We hypothesized a synergism of the immunotolerogenic effects of rapamycin (mTOR inhibition) and plerixafor (CXCR4 antagonist) for Treg cell induction.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Mus musculus	75-79
34673573-2	2021	To identify the molecular underpinnings of this phenotype, we analyzed a large cohort of MBs developing in p53-deficient Ptch+/- SHH mice that, unexpectedly, showed LC/A traits that correlated with mechanistic Target Of Rapamycin Complex 1 (mTORC1) hyperactivation.	Sirolimus	220-229	sonic hedgehog	Mus musculus	129-132
34877936-5	2021	All phenotypes were rescued after early treatment with rapamycin, an mTOR inhibitor.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	69-73
34738031-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1).	Sirolimus	26-35	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	236-297
34738031-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1).	Sirolimus	26-35	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	299-304
34738031-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) integrates various types of signal inputs, such as energy, growth factors, and amino acids to regulate cell growth and proliferation mainly through the 2 direct downstream targets, eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1).	Sirolimus	26-35	ribosomal protein S6 kinase B1	Homo sapiens	341-345
34699314-0	2021	LINC00998 functions as a novel tumor suppressor in acute myeloid leukemia via regulating the ZFP36 ring finger protein/mammalian target of rapamycin complex 2 axis.	Sirolimus	139-148	small integral membrane protein 30	Homo sapiens	0-9
34699314-6	2021	LINC00998 was mainly located in the cytoplasm, in which interacted with ZFP36 ring finger protein (ZFP36), a mRNA destabilizing factor, resulting in increased decay of mammalian target of rapamycin complex 2 (mTORC2), a well-known proto-oncogene in AML.	Sirolimus	188-197	small integral membrane protein 30	Homo sapiens	0-9
34580903-0	2021	A novel SERPINE1-FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K-AKT-mTOR signaling pathway and responsiveness to sirolimus.	Sirolimus	172-181	serpin family E member 1	Homo sapiens	8-16
34668283-7	2021	Sirolimus appeared to be associated with a pro-inflammatory cytokine release, including TNF-alpha (p = 0.0027) and IL-1beta (p = 0.0016), in response to SARS-CoV-2 peptides.	Sirolimus	0-9	interleukin 1 alpha	Homo sapiens	115-123
34861413-4	2022	Grb10-deficient beta-cells exhibit enhanced mTORC1 signaling and reduced beta-cell dedifferentiation, which could be blocked by rapamycin.	Sirolimus	128-137	growth factor receptor bound protein 10	Mus musculus	0-5
34540765-5	2021	Targeted therapies with PI3Kdelta-Akt-mTOR pathway pharmacologic inhibitors (i.e., Rapamycin, Theophylline, PI3K inhibitors) represent a good therapeutic strategy.	Sirolimus	83-92	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	24-33
34385317-2	2021	Toll-like receptor (TLR)7/9- and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-mediated inflammatory responses require SLC15A4 function for regulating the mechanistic target of rapamycin complex 1 (mTORC1) or transporting L-Ala-gamma-D-Glu-meso-diaminopimelic acid, IL-12: interleukin-12 (Tri-DAP), respectively.	Sirolimus	201-210	nucleotide-binding oligomerization domain containing 1	Mus musculus	33-95
34385317-2	2021	Toll-like receptor (TLR)7/9- and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-mediated inflammatory responses require SLC15A4 function for regulating the mechanistic target of rapamycin complex 1 (mTORC1) or transporting L-Ala-gamma-D-Glu-meso-diaminopimelic acid, IL-12: interleukin-12 (Tri-DAP), respectively.	Sirolimus	201-210	nucleotide-binding oligomerization domain containing 1	Mus musculus	97-101
34381142-6	2021	VEGF-A, VEGF receptor 2, and the co-receptor Neuropilin-1 were upregulated by Rapamycin within 7 days.	Sirolimus	78-87	vascular endothelial growth factor A	Rattus norvegicus	0-6
34348155-4	2021	Sustained hyper-activation of mechanistic target of rapamycin complex 1 (mTORC1) is the primary mechanism of the PHLPP upregulation linking chronic metabolic stress to ultimate beta-cell death.	Sirolimus	52-61	PH domain and leucine rich repeat protein phosphatase 1	Homo sapiens	113-118
34452154-1	2021	The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors.	Sirolimus	95-104	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	4-33
34542745-1	2021	We studied the possibilities of inhibition of neurodegeneration in MPTP-induced model of Parkinson"s disease (PD) in C57Bl/6J mice and transgenic model of early PD stage (5-monthold B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J mice) by autophagy activation through mTOR-dependent and mTOR-independent pathways with rapamycin and trehalose, respectively.	Sirolimus	303-312	mechanistic target of rapamycin kinase	Mus musculus	253-257
34789284-5	2021	In addition, MM@PCM/RAP can effectively improve the solubility of rapamycin and respond to the high concentration level of ROS accumulated in pathological lesion for controlling local cargo release, thereby increasing drug availability and reducing toxic side effects.	Sirolimus	66-75	LDL receptor related protein associated protein 1	Homo sapiens	20-23
34780278-10	2022	SP-A-induced activation of mechanistic target of rapamycin complex 1 (mTORC1) kinase requires beta-arrestin2 and is critically involved in degradation of LPS-induced TLR4.	Sirolimus	49-58	arrestin, beta 2	Mus musculus	94-108
34858182-4	2021	Methods and Results: Immunoblotting analyses revealed that short-term exposure to rapamycin (6h) significantly reduced phosphorylation of p70S6K (mTORC1-specific) in hPASMCs but had no effect on the phosphorylation of AKT (p-AKT S473, considered mTORC2-specific).	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	138-144
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	95-104	RPTOR independent companion of MTOR complex 2	Homo sapiens	249-255
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	182-191	RPTOR independent companion of MTOR complex 2	Homo sapiens	249-255
34858182-6	2021	Phosphorylation of both PDGFRalpha and PDGFRbeta was increased in hPASMCs after treatment with rapamycin for 48 and 72 h. Based on co-immunoprecipitation studies, longer exposure to rapamycin (24-72 h) significantly inhibited the binding of mTOR to Rictor, mechanistically suggesting mTORC2 inhibition by rapamycin.	Sirolimus	305-314	RPTOR independent companion of MTOR complex 2	Homo sapiens	249-255
34858401-8	2021	Notably, TBK1 inhibition prevented LPS-induced NLRP3 inflammasome activation by targeting the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	114-123	TANK binding kinase 1	Homo sapiens	9-13
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	66-95
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Mus musculus	159-163
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	transformed mouse 3T3 cell double minute 2	Mus musculus	197-201
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	transformation related protein 53, pseudogene	Mus musculus	233-236
34454753-11	2021	In contrast, induction of autophagy by rapamycin ameliorated the FFA-activated NF-kappaB signaling and NLRP3 inflammasome as demonstrated by a lower ratio of p-NF-kappaB/NF-kappaB, protein abundance of NLRP3 and CASP1, activity of CASP1, and mRNA abundance of IL1B and IL18.	Sirolimus	39-48	interleukin 18	Bos taurus	269-273
34551966-8	2021	Our results show that TLR-4-induced IFN-gamma production is regulated by the ribosomal protein S6 kinase (p70S6K) through the activation of PI3K, the mammalian target of rapamycin complex 1/2 (mTORC1/2), and the JNK MAPK pathways.	Sirolimus	170-179	toll like receptor 4	Homo sapiens	22-27
34551966-8	2021	Our results show that TLR-4-induced IFN-gamma production is regulated by the ribosomal protein S6 kinase (p70S6K) through the activation of PI3K, the mammalian target of rapamycin complex 1/2 (mTORC1/2), and the JNK MAPK pathways.	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	106-112
34394184-8	2021	Then, the combined application of overexpressed PDK1 and rapamycin verified that PDK1 could regulate the expression of PD-L1 in NSCLC cells through the mTOR signaling pathway.	Sirolimus	57-66	CD274 molecule	Homo sapiens	119-124
34440619-11	2021	An autophagy inducer, rapamycin, partially rescued the neurodegeneration in Nrf2-knockdown Drosophila by enhancing autophagy.	Sirolimus	22-31	Keap1	Drosophila melanogaster	76-80
34221806-5	2021	Rapamycin treatment alleviated I/R-induced lung histopathologically injury and increased the concentration of MDA while decreased activity of SOD and expression of NLRP3, Caspase-1, interleukin-1beta (IL-1beta), and IL-18 in rat.	Sirolimus	0-9	interleukin 18	Rattus norvegicus	216-221
34221806-8	2021	In vitro experiments showed that LPS induction caused a significant increase in LOC102553434, MMP9, IL-1beta, and IL-18 in L2 cells, but rapamycin treatment significantly reversed the effects.	Sirolimus	137-146	interleukin 18	Rattus norvegicus	114-119
34392719-0	2021	Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1alpha, Bcl-2, Bax expression and microvessel density.	Sirolimus	25-34	hypoxia-inducible factor 1-alpha	Oryctolagus cuniculus	114-124
34392719-15	2021	Arterial instillation of rapamycin+TACE in treatment of rabbit hepatic xenograft tumors can reduce tumor neovascularization and inhibit iNOS, HIF-1alpha, VEGF, Bcl-2, and Bax protein expression.	Sirolimus	25-34	hypoxia-inducible factor 1-alpha	Oryctolagus cuniculus	142-152
34135323-8	2021	Finally, we identify a sensitive period during the third postnatal week during which treatment with the mTOR inhibitor Rapamycin rescues deficits in both PV cell innervation and social behavior in adult conditional haploinsufficient mice.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	104-108
34221236-10	2021	Rapamycin attenuated oxLDL/beta2GPI/anti-beta2GPI complex-induced endothelial inflammation, oxidative stress, and apoptosis, whereas 3-MA alone induced the endothelial injury.	Sirolimus	0-9	apolipoprotein H	Homo sapiens	27-35
34221236-10	2021	Rapamycin attenuated oxLDL/beta2GPI/anti-beta2GPI complex-induced endothelial inflammation, oxidative stress, and apoptosis, whereas 3-MA alone induced the endothelial injury.	Sirolimus	0-9	apolipoprotein H	Homo sapiens	41-49
34178631-11	2021	Combination of the two FDA approved drugs -RA for acute myeloid leukaemia and rapamycin for TSC mutation- normalised ALDH and ADH expression and activity, restored RARbeta expression and reduced cellular proliferation and migration.	Sirolimus	78-87	alcohol dehydrogenase 1A (class I), alpha polypeptide	Homo sapiens	126-129
34178631-11	2021	Combination of the two FDA approved drugs -RA for acute myeloid leukaemia and rapamycin for TSC mutation- normalised ALDH and ADH expression and activity, restored RARbeta expression and reduced cellular proliferation and migration.	Sirolimus	78-87	retinoic acid receptor alpha	Homo sapiens	164-171
34164408-6	2021	In contrast, the HMGB1-mediated expression of HLA-DR, CD40, and CD86 on dendritic cells and production of IL-1beta, IL-6, and TNF-alpha were reduced by rapamycin.	Sirolimus	152-161	interleukin 1 alpha	Homo sapiens	106-114
34088267-7	2021	The findings suggest that rapamycin promotes autophagy and autophagosomal uptake of the rhodopsin that has accumulated abnormally in the cytoplasm, thereby alleviating stress and delaying photoreceptor cell death.	Sirolimus	26-35	rhodopsin	Rattus norvegicus	88-97
34723336-12	2022	Since rapamycin significantly attenuated asthma characteristics, the mTOR pathway may be important in this murine model.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Mus musculus	69-73
34077553-6	2021	Subsequently, we observed that the proliferation of progenitor cells was suppressed in Akt3-KO mice and the mTOR inhibitor rapamycin-treated mice, whereas enhanced in running WT mice rather than running Akt3-KO mice.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	108-112
34123875-4	2021	Therefore, our aim was to assess the role of rapamycin, the pharmacological inhibitor of mTOR, in CD8+ T response against T. cruzi induced by heterologous prime-boost vaccine.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Mus musculus	89-93
34123875-11	2021	Trying to shed light on the biological mechanisms involved in these beneficial effects on CD8+ T-cells by mTOR inhibition after immunization, we showed that in vivo proliferation was higher after rapamycin treatment compared with vehicle-injected group.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Mus musculus	106-110
34123875-12	2021	Taken together, our data provide a new approach to vaccine development against intracellular parasites, placing the mTOR inhibitor rapamycin as an adjuvant to improve effective CD8+ T-cell response.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Mus musculus	116-120
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	collagen type XI alpha 1 chain	Homo sapiens	16-23
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	hyaluronan synthase 1	Homo sapiens	70-74
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	matrix metallopeptidase 1	Homo sapiens	97-101
34065350-6	2021	In detail, rapamycin induces the expression of genes promoting mitophagy (PINK1, PARKIN, ULK1, AMBRA1) and mitochondrial fission (FIS1, DRP1).	Sirolimus	11-20	autophagy and beclin 1 regulator 1	Homo sapiens	95-101
34065421-5	2021	In contrast, rapamycin multiple (M) treatment (Rapa-M-DC) were exposed to 3 treatments over 7 days.	Sirolimus	13-22	transcriptional regulating factor 1	Mus musculus	47-51
34074073-10	2021	Compared with 10 mgF(-)/kg and 20 mgF(-)/kg groups, there were no obvious dental fluorosis symptoms in 2 mg/kg RAPA+10 mgF(-)/kg group and 2 mg/kg RAPA+20 mgF(-)/kg group, and serum ALP, BGP and OPG levels were significantly increased (P<0.05) .	Sirolimus	111-115	TNF receptor superfamily member 11B	Rattus norvegicus	195-198
34079820-13	2021	On the other hand, RAPA, mimic lncRNA-ATB and miR-200b inhibitor reduced fibrogenic effect of MMC on HEFs.	Sirolimus	19-23	embryonal Fyn-associated substrate	Homo sapiens	101-105
34064854-9	2021	Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms.	Sirolimus	0-9	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	85-90
34064854-11	2021	Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	137-140
34064854-11	2021	Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	235-267
34064854-11	2021	Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	269-273
34084203-4	2021	Determining effective environmental factors such as stress conditions on the expression of PD1 and PD-L1 genes can provide an immunotherapeutic strategy to control PD1 signaling in the patients Mammalian target of rapamycin signaling is a stress-responsive pathway in the cells that can be blocked by rapamycin.	Sirolimus	301-310	CD274 molecule	Homo sapiens	99-104
34084203-6	2021	Experimental approach: Daily administration of rapamycin (1.5 mg/kg per day) was used in the mouse model of restraint stress and the relative expression of PD1, PD-L1, and Foxp3 genes in the brain and spleen were evaluated using quantitative real-time polymerase chain reaction method.	Sirolimus	47-56	forkhead box P3	Mus musculus	172-177
34084203-7	2021	Findings/Results: With our observation, daily restraint stress ceased rapamycin to decrease the expression of Foxp3 in the brain significantly.	Sirolimus	70-79	forkhead box P3	Mus musculus	110-115
35618000-3	2022	LAT1 also has an important role in the peripheral immune system, by regulating the activation status of several immune cells through modulation of the mechanistic target of rapamycin kinase.	Sirolimus	173-182	solute carrier family 7 member 5	Homo sapiens	0-4
34418347-10	2021	Mechanistically, autophagy agonist rapamycin attenuated the neuroprotective effect of NPAS4 in propofol-treated HT22 cells.	Sirolimus	35-44	neuronal PAS domain protein 4	Mus musculus	86-91
34706270-1	2022	Rapamycin is widely recognized as an inhibitor of mTOR, and has been approved for clinical use as an immunosuppressant.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	50-54
34675258-7	2021	Akt phosphorylation and activation was indispensable for rapamycin-induced TCTP degradation and PLK1 activation, and depended on S6K inhibition, but not mTORC2 activation.	Sirolimus	57-66	tumor protein, translationally-controlled 1	Homo sapiens	75-79
34685712-5	2021	We revealed that palmitic acid (PA)-induced ER stress and suppression of LAMP2 and autophagy flux were mTORC1-dependent as rapamycin reversed such deleterious effects.	Sirolimus	123-132	lysosomal-associated membrane protein 2	Mus musculus	73-78
35609863-2	2022	There are two ways to induce autophagy: through mTOR-dependent and mTOR-independent pathways (here, by means of rapamycin and trehalose, respectively).	Sirolimus	112-121	mechanistic target of rapamycin kinase	Mus musculus	48-52
35609863-2	2022	There are two ways to induce autophagy: through mTOR-dependent and mTOR-independent pathways (here, by means of rapamycin and trehalose, respectively).	Sirolimus	112-121	mechanistic target of rapamycin kinase	Mus musculus	67-71
35599422-28	2022	Compared with that in wild-type control group, the percentage of wound area of mice in rapamycin control group increased significantly on PID 1-6 (P<0.01), the percentage of wound area of mice in Vgamma4 T cell+IL-22 inhibitor group increased significantly on PID 1 and PID 3-6 (P<0.05 or P<0.01).	Sirolimus	87-96	interleukin 22	Mus musculus	211-216
35599422-32	2022	After being cultured for 24 hours, the expression levels of IL-22 protein and mRNA in Vgamma4 T cells in rapamycin group were significantly lower than those in normal control group (with t values of -7.75 and -6.04, respectively, P<0.01).	Sirolimus	105-114	interleukin 22	Mus musculus	60-65
35599422-33	2022	Conclusions: In mice with full-thickness skin defects, rapamycin may impair the CCL20 chemotactic system by inhibiting the expression of CCL20, leading to a decrease in the recruitment of Vgamma4 T cells to the epidermis, and at the same time inhibit the secretion of IL-22 by Vgamma4 T cells, thereby slowing the wound healing rate.	Sirolimus	55-64	chemokine (C-C motif) ligand 20	Mus musculus	80-85
35599422-33	2022	Conclusions: In mice with full-thickness skin defects, rapamycin may impair the CCL20 chemotactic system by inhibiting the expression of CCL20, leading to a decrease in the recruitment of Vgamma4 T cells to the epidermis, and at the same time inhibit the secretion of IL-22 by Vgamma4 T cells, thereby slowing the wound healing rate.	Sirolimus	55-64	chemokine (C-C motif) ligand 20	Mus musculus	137-142
35599422-33	2022	Conclusions: In mice with full-thickness skin defects, rapamycin may impair the CCL20 chemotactic system by inhibiting the expression of CCL20, leading to a decrease in the recruitment of Vgamma4 T cells to the epidermis, and at the same time inhibit the secretion of IL-22 by Vgamma4 T cells, thereby slowing the wound healing rate.	Sirolimus	55-64	interleukin 22	Mus musculus	268-273
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	mitochondrial fission process 1	Homo sapiens	110-141
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	mitochondrial fission process 1	Homo sapiens	143-148
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	dynamin 1 like	Homo sapiens	181-206
35589683-3	2022	p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation.	Sirolimus	37-46	dynamin 1 like	Homo sapiens	208-212
35585885-8	2022	Of note, the effect of OG on Nrf2/Keap1 signaling was neutralized by the mTOR inhibitor rapamycin.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Mus musculus	73-77
34642952-2	2022	Here, we describe amammalian target of rapamycin (mTOR)-dependent and NBCe1-mediated astroglial response to extracellular acidosis.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	50-54
35276460-11	2022	Then, RAPA was used to inhibit the mTOR pathway, and the inflammatory factors IL-17A and IFN-gamma were downregulated in EAM mouse muscle and serum.	Sirolimus	6-10	mechanistic target of rapamycin kinase	Mus musculus	35-39
34642952-5	2022	Acidosis-induced upregulation of NBCe1 activity was prevented following inhibition of mTOR signaling by rapamycin.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Mus musculus	86-90
34104954-7	2021	Using an established porcine trophectoderm (pTr1) cell line, it was determined that 10-7 M ADM stimulated proliferation of pTr1 cells (P < 0.05) at 48 h, and increased phosphorylated mechanistic target of rapamycin (p-MTOR) and 4E binding protein 1 (p-4EBP1) by 6.1- and 4.9-fold (P < 0.0001), respectively.	Sirolimus	205-214	mechanistic target of rapamycin kinase	Mus musculus	218-222
35092164-7	2022	While blocking the fusion of autophagosomes with lysosomes by bafilomycin A1(BafA1), the reduced NLRP3 inflammasome activity induced by RAPA was significantly restored, with increased protein levels of NLRP3 and cleaved Casp-1(p10), as well as IL-1beta secretion.	Sirolimus	136-140	interleukin 1 alpha	Homo sapiens	244-252
35624154-5	2022	Primary mouse choroidal GFP-positive pericytes were treated with TGF-beta2 in combination with siRNAs targeting Smad2/3, the Akt inhibitor MK2206 or the mTOR inhibitor rapamycin to examine cell proliferation, migration, and differentiation into myofibroblasts.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Mus musculus	153-157
34126195-13	2021	Rapamycin decreased phosphorylated S6K, Gli2 and PD-L1 expression in PDO/immune cell co-cultures.	Sirolimus	0-9	CD274 molecule	Homo sapiens	49-54
34126195-14	2021	Transcriptional regulation of PD-L1 by GLI1 and GLI2 was blocked by rapamycin.	Sirolimus	68-77	CD274 molecule	Homo sapiens	30-35
34419763-0	2021	Rapamycin prevents heterotopic ossification by inhibiting the mTOR pathway and oxidative stress.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	62-66
34419763-1	2021	Rapamycin (RAPA), which was first described as an anti-fungal agent, is a potent immunosuppressant that suppresses tumors and inhibits the mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	139-143
35218805-3	2022	Here, we report the crystal structure of the AtFKBP53 FKBD in complex with rapamycin.	Sirolimus	75-84	FK506 BINDING PROTEIN 53	Arabidopsis thaliana	45-53
34419763-1	2021	Rapamycin (RAPA), which was first described as an anti-fungal agent, is a potent immunosuppressant that suppresses tumors and inhibits the mTOR signaling pathway.	Sirolimus	11-15	mechanistic target of rapamycin kinase	Mus musculus	139-143
34419763-4	2021	In this study, we focused on the role of oxidative stress (OS) in the early stage of traumatic HO, and explored the underlying mechanism of traumatic HO by using RAPA to specifically inhibit the mTOR pathway, which is known to play a role in the pathogenesis of HO.	Sirolimus	162-166	mechanistic target of rapamycin kinase	Mus musculus	195-199
34419763-9	2021	Furthermore, RAPA reduces the vascularization triggered by mTOR signaling that leads to HO formation.	Sirolimus	13-17	mechanistic target of rapamycin kinase	Mus musculus	59-63
35543155-5	2022	Furthermore, we report SHH signaling pathway defects that are independent of AMPK and mechanistic target of rapamycin (MTOR) activation.	Sirolimus	108-117	sonic hedgehog	Mus musculus	23-26
34082015-17	2021	Furthermore, the effects of SZL on myelin proteins, p-Akt, and p-mTOR were clearly inhibited by LY294002 and/or rapamycin, antagonists of PI3K and m-TOR, respectively.	Sirolimus	112-121	tortured	Mus musculus	149-152
35413227-5	2022	Furthermore, in both QBC939 and QBC939/DDP cells, the autophagy agonist rapamycin eliminated the increased cisplatin sensitivity of ClC-3 knockdown without affecting ClC-3 expression.	Sirolimus	72-81	chloride voltage-gated channel 3	Homo sapiens	132-137
34977433-4	2022	Herein, we design a ROS-responsive targeted micelle system (TT-NM/Rapa) to enhance the delivery efficiency of rapamycin to neurons in AD lesions guided by the fusion peptide TPL, and facilitate its intracellular release via ROS-mediated disassembly of micelles, thereby maximizing autophagic flux modulating efficacy of rapamycin in neurons.	Sirolimus	110-119	transcriptional regulating factor 1	Mus musculus	66-70
34977433-4	2022	Herein, we design a ROS-responsive targeted micelle system (TT-NM/Rapa) to enhance the delivery efficiency of rapamycin to neurons in AD lesions guided by the fusion peptide TPL, and facilitate its intracellular release via ROS-mediated disassembly of micelles, thereby maximizing autophagic flux modulating efficacy of rapamycin in neurons.	Sirolimus	320-329	transcriptional regulating factor 1	Mus musculus	66-70
34423683-4	2021	AAV-mediated overexpression of c-Myc in mouse skeletal muscles for 2 weeks increased the DNA polymerase subunit POL1 mRNA, 45S-pre-rRNA, total RNA, and muscle protein synthesis without altering mechanistic target of rapamycin complex 1 (mTORC1) signaling under both ad libitum and fasted conditions.	Sirolimus	216-225	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
34311070-6	2021	The current study was designed to determine the IC50 values of OATP1B1 and OATP1B3 inhibitors everolimus (EVR), sirolimus (SIR), and dasatinib against OATP1B substrates in physiologically relevant primary human hepatocytes with or without inhibitor-preincubation and to compare the OATP-mediated DDI prediction using data from primary human hepatocytes and that reported previously in transporter-expressing cell lines.	Sirolimus	112-121	solute carrier organic anion transporter family member 1B1	Homo sapiens	63-70
34475980-9	2021	In vivo, si-SIRT1 or SIRT1 overexpression in mice could enhance or rescue the inhibitory effects of rapamycin on tumor growth.	Sirolimus	100-109	sirtuin 1	Mus musculus	12-17
34475980-9	2021	In vivo, si-SIRT1 or SIRT1 overexpression in mice could enhance or rescue the inhibitory effects of rapamycin on tumor growth.	Sirolimus	100-109	sirtuin 1	Mus musculus	21-26
34475980-10	2021	In addition, SIRT1 transfection rescued the decreased level of phosphorylated (p)-PI3K, p-AKT and p-mTOR induced by rapamycin treatment.	Sirolimus	116-125	sirtuin 1	Mus musculus	13-18
34475980-11	2021	Taken together, the present results suggested that rapamycin suppressed the cell viability, migration, invasion and PI3K/AKT/mTOR signaling pathway in EC by negatively regulating SIRT1.	Sirolimus	51-60	sirtuin 1	Mus musculus	179-184
34795945-10	2021	Notably, ezrin deletion in autophagic TAMs induced by rapamycin reduced TGF-beta1 expression and suppressed EMT in lung adenocarcinoma cells.	Sirolimus	54-63	ezrin	Homo sapiens	9-14
34632383-6	2021	DEPDC5, NPRL2 and NPRL3 code for subunits of the GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1), the principal amino acid-sensing regulator of mechanistic target of rapamycin complex 1.	Sirolimus	191-200	NPR2 like, GATOR1 complex subunit	Homo sapiens	8-13
34632383-6	2021	DEPDC5, NPRL2 and NPRL3 code for subunits of the GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1), the principal amino acid-sensing regulator of mechanistic target of rapamycin complex 1.	Sirolimus	191-200	NPR3 like, GATOR1 complex subunit	Homo sapiens	18-23
34659568-4	2021	The SKOV3 and CAOV3 cell lines were treated with exogenous resistin and rapamycin (resistin inhibitor), and the expression of mTOR in SKOV3 and CAOV3 cells was measured.	Sirolimus	72-81	resistin	Homo sapiens	83-91
34576341-5	2021	Correspondingly, peripheral administration of SB258585, a 5-HT6 receptor inverse agonist, or rapamycin, abolished deficits in long-term social and associative memories in Nf1+/- mice, whereas administration of CPPQ, a neutral antagonist, did not produce cognitive improvement.	Sirolimus	93-102	neurofibromin 1	Mus musculus	171-174
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	mitogen-activated protein kinase 8b	Danio rerio	52-57
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	ribosomal protein S6	Danio rerio	66-70
34537895-10	2021	The cardiac expressions of gpx, nppb, kcnh2, scn5a, mapk8, stat3, rps6 and ddit were decreased, whereas the levels of trxr2 and beclin 1 were increased following rapamycin treatment in kindled fish.	Sirolimus	162-171	beclin 1, autophagy related	Danio rerio	128-136
34572595-0	2021	Mechanistic Target of Rapamycin Complex 1 Signaling Links Hypoxia to Increased IGFBP-1 Phosphorylation in Primary Human Decidualized Endometrial Stromal Cells.	Sirolimus	22-31	insulin like growth factor binding protein 1	Homo sapiens	79-86
34542533-5	2021	Fusing an engineered mutant of the rapamycin-binding protein FKBP12 to Cas9 (DD-Cas9) enables the rapid degradation of Cas9 that in turn can be stabilized by the presence of an FKBP12 synthetic ligand (Shield-1).	Sirolimus	35-44	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	61-67
34542533-5	2021	Fusing an engineered mutant of the rapamycin-binding protein FKBP12 to Cas9 (DD-Cas9) enables the rapid degradation of Cas9 that in turn can be stabilized by the presence of an FKBP12 synthetic ligand (Shield-1).	Sirolimus	35-44	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	177-183
34331013-5	2021	Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845.	Sirolimus	149-158	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	91-95
34819968-0	2021	Thin-strut bioresorbable-polymer sirolimus-eluting stent use for an optimal result of rescue coronary angioplasty in acute myocardial infarction failed thrombolytic therapy: the Bangladesh National Heart Foundation Annual Conference OCT-assisted live case.	Sirolimus	33-42	plexin A2	Homo sapiens	233-236
34577576-0	2021	Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	137-141
34462635-6	2021	In silico analysis showed that taxifolin can bind to the rapamycin binding site of mTOR and the catalytic site of PI3K (p110alpha).	Sirolimus	57-66	mechanistic target of rapamycin kinase	Mus musculus	83-87
34416638-10	2021	Moreover, Akt and mTOR inhibition by using LY294002 and rapamycin, respectively, blocked inflammatory cytokine overexpression induced by TCS.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	18-22
34445344-6	2021	Rapamycin, as an mTOR inhibitor, blocked T3-induced autophagic suppression and UCP1 upregulation.	Sirolimus	0-9	uncoupling protein 1	Homo sapiens	79-83
35384725-0	2022	Effect of Rapamycin on MOG-Reactive Immune Cells and Lipopolysaccharide-Activated Microglia: An In Vitro Approach for Screening New Therapies for Multiple Sclerosis.	Sirolimus	10-19	myelin oligodendrocyte glycoprotein	Mus musculus	23-26
35384725-2	2022	In this study, we evaluated the in vitro effect of rapamycin on immune cells pivotally involved in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), which is an animal model to study MS. Splenocytes and central nervous system (CNS)-mononuclear cells obtained from EAE mice were stimulated with a myelin oligodendrocyte glycoprotein peptide, whereas the microglial BV-2 cell line was activated with LPS.	Sirolimus	51-60	myelin oligodendrocyte glycoprotein	Mus musculus	315-350
35318320-3	2022	Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates PDK1 at its pleckstrin homology (PH) domain, and impairs PDK1 interaction with and activation of AKT.	Sirolimus	134-143	ribosomal protein S6 kinase A1	Homo sapiens	20-54
35318320-3	2022	Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates PDK1 at its pleckstrin homology (PH) domain, and impairs PDK1 interaction with and activation of AKT.	Sirolimus	134-143	ribosomal protein S6 kinase B1	Homo sapiens	56-60
35372343-0	2022	Rapamycin Promotes the Expansion of Myeloid Cells by Increasing G-CSF Expression in Mesenchymal Stem Cells.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	64-69
35372343-4	2022	Rapamycin induced bone marrow mesenchymal stem cells to produce more G-CSF in vitro and in vivo, and promoted the myeloid cells expansion.	Sirolimus	0-9	colony stimulating factor 3	Homo sapiens	69-74
35399709-0	2022	Hinokitiol impedes tumor drug resistance by suppressing protein kinase B/mammalian targets of rapamycin axis.	Sirolimus	94-103	protein tyrosine kinase 2 beta	Homo sapiens	56-72
35328525-10	2022	SNPs combined with rapamycin (RAP), an autophagy activator, enhanced testosterone production and increased StAR expression, whereas SNPs combined with 3-methyladenine (3-MA) and chloroquine (CQ), autophagy inhibitors, had an opposite effect.	Sirolimus	19-28	steroidogenic acute regulatory protein	Mus musculus	107-111
35356282-14	2022	Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs.	Sirolimus	19-28	H3 histone pseudogene 16	Homo sapiens	111-114
35235808-0	2022	Galpha13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin.	Sirolimus	98-107	guanine nucleotide binding protein, alpha 13	Mus musculus	0-8
35235808-0	2022	Galpha13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin.	Sirolimus	98-107	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	17-21
35235808-0	2022	Galpha13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin.	Sirolimus	98-107	transformation related protein 53	Mus musculus	22-26
34980764-7	2022	Because GRB10 suppresses insulin signaling and the subsequent mammalian target of rapamycin complex 1 activity, increased expression of GRB10 may have resulted in a decrease in protein anabolism.	Sirolimus	82-91	growth factor receptor bound protein 10	Homo sapiens	8-13
34980764-7	2022	Because GRB10 suppresses insulin signaling and the subsequent mammalian target of rapamycin complex 1 activity, increased expression of GRB10 may have resulted in a decrease in protein anabolism.	Sirolimus	82-91	growth factor receptor bound protein 10	Homo sapiens	136-141
35149934-10	2022	CONCLUSION: We demonstrated that rapamycin attenuated podocyte apoptosis via upregulation of nestin expression through the mTOR/P70S6K signaling pathway in an Ang II-induced podocyte injury.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	128-134
35295093-8	2022	Therefore, the inhibitor of mTOR, rapamycin was used to suppress the expression of mTOR and interfere with photoreceptor degeneration.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	28-32
35295093-8	2022	Therefore, the inhibitor of mTOR, rapamycin was used to suppress the expression of mTOR and interfere with photoreceptor degeneration.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	83-87
35295093-11	2022	Also, the autophagy in rapamycin group was activated, which revealed that rapamycin may protect the retinal photoreceptor by inhibiting mTOR and then activating autophagy.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	136-140
35295093-11	2022	Also, the autophagy in rapamycin group was activated, which revealed that rapamycin may protect the retinal photoreceptor by inhibiting mTOR and then activating autophagy.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Mus musculus	136-140
35220880-8	2022	In therapeutic studies, supplementation with LPA or the autophagy inducer rapamycin significantly promotes dMphi autophagy and cell residence, and improves embryo resorption in Enpp2+- and spontaneous abortion mouse models, which should be dependent on the activation of DDIT4-autophagy-CLDN7-adhesion molecules axis.	Sirolimus	74-83	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	177-182
35220880-8	2022	In therapeutic studies, supplementation with LPA or the autophagy inducer rapamycin significantly promotes dMphi autophagy and cell residence, and improves embryo resorption in Enpp2+- and spontaneous abortion mouse models, which should be dependent on the activation of DDIT4-autophagy-CLDN7-adhesion molecules axis.	Sirolimus	74-83	claudin 7	Mus musculus	287-292
35131932-5	2022	To reveal the structural basis underlying the synergistic activation of TRPML1 by PI(3,5)P2 and rapamycin, we determined the high-resolution cryoelectron microscopy (cryo-EM) structures of the mouse TRPML1 channel in various states, including apo closed, PI(3,5)P2-bound closed, and PI(3,5)P2/temsirolimus (a rapamycin analog)-bound open states.	Sirolimus	309-318	mucolipin 1	Mus musculus	72-78
35131932-5	2022	To reveal the structural basis underlying the synergistic activation of TRPML1 by PI(3,5)P2 and rapamycin, we determined the high-resolution cryoelectron microscopy (cryo-EM) structures of the mouse TRPML1 channel in various states, including apo closed, PI(3,5)P2-bound closed, and PI(3,5)P2/temsirolimus (a rapamycin analog)-bound open states.	Sirolimus	309-318	mucolipin 1	Mus musculus	199-205
34091997-4	2021	Subsequently, we demonstrated that AQP3 was necessary for the facilitated diffusion of exogenous H2 O2 in LUAD cells and that the AQP3-dependent transport of H2 O2 accelerated cell growth and inhibited rapamycin-induced autophagy.	Sirolimus	202-211	aquaporin 3 (Gill blood group)	Homo sapiens	35-39
35197970-0	2022	Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	34-37
34091997-4	2021	Subsequently, we demonstrated that AQP3 was necessary for the facilitated diffusion of exogenous H2 O2 in LUAD cells and that the AQP3-dependent transport of H2 O2 accelerated cell growth and inhibited rapamycin-induced autophagy.	Sirolimus	202-211	aquaporin 3 (Gill blood group)	Homo sapiens	130-134
34102263-5	2021	The expression levels of the phosphorylated p70S6K, a downstream molecule of mTOR, in the proximal and distal stumps of the transected IAN were significantly reduced by rapamycin administration to the injured site.	Sirolimus	169-178	ribosomal protein S6 kinase B1	Rattus norvegicus	44-50
35197970-0	2022	Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	109-115
34331820-0	2022	Rapamycin promotes autophagy cell death of Kaposi"s sarcoma cells through P75NTR activation.	Sirolimus	0-9	nerve growth factor receptor	Homo sapiens	74-80
34331820-2	2022	In this in vivo and in vitro study we explored whether the activation of the autophagic pathway through the low-affinity receptor for Nerve Growth Factor, p75NTR , may have a pivotal role in the anti-cancer effect exerted by Rapamycin in KS.	Sirolimus	225-234	nerve growth factor receptor	Homo sapiens	155-161
35197970-12	2022	Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	72-78
34331820-4	2022	In vitro experiments on KS cell lines showed that Rapamycin exposure reduced cell viability by increasing the autophagic process, in the absence of apoptosis, through the transcriptional activation of p75NTR via EGR1.	Sirolimus	50-59	nerve growth factor receptor	Homo sapiens	201-207
34331820-4	2022	In vitro experiments on KS cell lines showed that Rapamycin exposure reduced cell viability by increasing the autophagic process, in the absence of apoptosis, through the transcriptional activation of p75NTR via EGR1.	Sirolimus	50-59	early growth response 1	Homo sapiens	212-216
34331820-7	2022	In conclusion, our in vitro data demonstrated, for the first time, that in Kaposi"s sarcoma, autophagy triggered by Rapamycin through p75NTR represented a major mechanism by which mTOR inhibitors may induce tumor regression.	Sirolimus	116-125	nerve growth factor receptor	Homo sapiens	134-140
34331820-8	2022	Additionally, it suggested that p75NTR protein analysis could be proposed as a new potential biomarker to predict response to Rapamycin in kidney transplant recipients affected by Kaposi"s sarcoma.	Sirolimus	126-135	nerve growth factor receptor	Homo sapiens	32-38
34421360-9	2021	Mechanistically, rapamycin in combination with trametinib resulted in a greater decrease of phosphorylation of AKT, ERK, mTOR and 4EBP1.	Sirolimus	17-26	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	130-135
35197970-12	2022	Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	91-94
35197970-13	2022	In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity.	Sirolimus	39-48	microtubule associated protein tau	Homo sapiens	118-121
35197970-13	2022	In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity.	Sirolimus	39-48	ribosomal protein S6 kinase B1	Rattus norvegicus	194-200
35153674-9	2021	In addition, data also described that the protein expression level of p-S6, mTOR and Raptor are lower than PGPS group after RPM treatment.	Sirolimus	124-127	mechanistic target of rapamycin kinase	Mus musculus	76-80
35153674-10	2021	The accumulation of LC3-II, Beclin-1, and ATG7 are decreased, and the expression of Rab7 and Syntaxin 17 are increased significantly after RPM treatment.	Sirolimus	139-142	beclin 1, autophagy related	Mus musculus	28-36
35159195-0	2022	Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP-FRB Interaction and Autophagy.	Sirolimus	51-60	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	10-16
34235896-0	2021	Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
34264340-5	2022	Finally, we demonstrate that administration of the mTOR inhibitor rapamycin following kindled seizures rescued enhanced remote and long-term memory deficits associated with earlier kindling and prevented the seizure-induced increases in Alzheimer"s disease neuropathology.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Mus musculus	51-55
34322484-3	2021	Application of rapamycin, a specific inhibitor of mTOR, attenuated the phosphorylation of S6 and 4E-BP1 and as such, largely inhibited the mechanical activation of mTOR.	Sirolimus	15-24	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	90-103
34322484-4	2021	Moreover, rapamycin significantly decreased the proliferation and non-tenocyte differentiation of PTSCs as indicated by the reduced expression levels of LPL, PPARgamma, SOX-9, collagen II, Runx-2, and osteocalcin genes.	Sirolimus	10-19	runt related transcription factor 2	Mus musculus	189-195
34322484-4	2021	Moreover, rapamycin significantly decreased the proliferation and non-tenocyte differentiation of PTSCs as indicated by the reduced expression levels of LPL, PPARgamma, SOX-9, collagen II, Runx-2, and osteocalcin genes.	Sirolimus	10-19	bone gamma-carboxyglutamate protein 2	Mus musculus	201-212
34322484-7	2021	Collectively, these findings suggest that mechanical loading activates the mTOR signaling in TSCs, and rapamycin may be used to prevent tendinopathy development by blocking non-tenocyte differentiation due to mechanical over-activation of mTOR in TSCs.	Sirolimus	103-112	mechanistic target of rapamycin kinase	Mus musculus	239-243
34253722-1	2021	Tuberous Sclerosis Complex (TSC) is caused by TSC1 or TSC2 mutations, resulting in hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	128-137	TSC complex subunit 2	Mus musculus	54-58
34187953-3	2021	This study determined whether rapamycin, an mTOR inhibitor, reduces nociceptive responses and the number of Fos-immunoreactive (Fos-ir) cells in the trigeminal nucleus caudalis (TNC) in a mouse orofacial formalin model.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Mus musculus	44-48
34187953-3	2021	This study determined whether rapamycin, an mTOR inhibitor, reduces nociceptive responses and the number of Fos-immunoreactive (Fos-ir) cells in the trigeminal nucleus caudalis (TNC) in a mouse orofacial formalin model.	Sirolimus	30-39	FBJ osteosarcoma oncogene	Mus musculus	108-111
34187953-3	2021	This study determined whether rapamycin, an mTOR inhibitor, reduces nociceptive responses and the number of Fos-immunoreactive (Fos-ir) cells in the trigeminal nucleus caudalis (TNC) in a mouse orofacial formalin model.	Sirolimus	30-39	FBJ osteosarcoma oncogene	Mus musculus	128-131
34187953-8	2021	The number of Fos-ir cells in the ipsilateral TNC was also reduced by high-dose rapamycin compared with vehicle-treated animals.	Sirolimus	80-89	FBJ osteosarcoma oncogene	Mus musculus	14-17
35040438-6	2022	Interestingly, treatment with the mTOR inhibitor rapamycin improves skin symptoms in Skiv2l-deficient mice, suggesting a possible therapeutic avenue for patients with THES2.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	34-38
34187953-10	2021	Therefore, the mTOR inhibitor, rapamycin, reduces orofacial nociception and Fos expression in the TNC, and its antinociceptive action on orofacial pain may be associated with the inhibition of p-p38 MAPK in the microglia.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Mus musculus	15-19
34187953-10	2021	Therefore, the mTOR inhibitor, rapamycin, reduces orofacial nociception and Fos expression in the TNC, and its antinociceptive action on orofacial pain may be associated with the inhibition of p-p38 MAPK in the microglia.	Sirolimus	31-40	FBJ osteosarcoma oncogene	Mus musculus	76-79
34277614-9	2021	The target genes BCL9, MYC and JUN of the Wnt/beta-catenin signaling pathway were differentially expressed in RPM-exposed MCF-7 cells.	Sirolimus	110-113	BCL9 transcription coactivator	Homo sapiens	17-21
34277614-9	2021	The target genes BCL9, MYC and JUN of the Wnt/beta-catenin signaling pathway were differentially expressed in RPM-exposed MCF-7 cells.	Sirolimus	110-113	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	23-26
35096638-7	2021	We found that overexpression of Egr-1 inhibited the phagocytic activity of macrophages, and the autophagy activator rapamycin and inhibitor chloroquine could reverse the effects of Egr-1 knockdown and Egr-1 overexpression on phagocytosis of P. aeruginosa, respectively.	Sirolimus	116-125	early growth response 1	Mus musculus	181-186
34277614-9	2021	The target genes BCL9, MYC and JUN of the Wnt/beta-catenin signaling pathway were differentially expressed in RPM-exposed MCF-7 cells.	Sirolimus	110-113	catenin beta 1	Homo sapiens	46-58
34277614-10	2021	These findings suggest that vinculin and beta-catenin are key mediators of BCC to form MCS during 24 h of RPM-exposure.	Sirolimus	106-109	catenin beta 1	Homo sapiens	41-53
34258253-3	2021	Here, we propose a plausible molecular mechanism, wherein cryptotanshinone represses rapamycin-sensitive mTORC1/S6K1 mediated cancer cell growth and cell transformation.	Sirolimus	85-94	ribosomal protein S6 kinase B1	Homo sapiens	112-116
34275928-9	2021	Compared with the UUO group, the expression levels of E-cadherin and LC3II in the UUO+high-dose rapamycin group and the UUO+low-dose rapamycin group were significantly increased (P<0.01 and P<0.05, respectively), and the expression level of alpha-SMA was significantly decreased (P<0.01 and P<0.05, respectively).	Sirolimus	96-105	cadherin 1	Rattus norvegicus	54-64
34275928-9	2021	Compared with the UUO group, the expression levels of E-cadherin and LC3II in the UUO+high-dose rapamycin group and the UUO+low-dose rapamycin group were significantly increased (P<0.01 and P<0.05, respectively), and the expression level of alpha-SMA was significantly decreased (P<0.01 and P<0.05, respectively).	Sirolimus	96-105	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	69-74
34275928-9	2021	Compared with the UUO group, the expression levels of E-cadherin and LC3II in the UUO+high-dose rapamycin group and the UUO+low-dose rapamycin group were significantly increased (P<0.01 and P<0.05, respectively), and the expression level of alpha-SMA was significantly decreased (P<0.01 and P<0.05, respectively).	Sirolimus	133-142	cadherin 1	Rattus norvegicus	54-64
34275928-9	2021	Compared with the UUO group, the expression levels of E-cadherin and LC3II in the UUO+high-dose rapamycin group and the UUO+low-dose rapamycin group were significantly increased (P<0.01 and P<0.05, respectively), and the expression level of alpha-SMA was significantly decreased (P<0.01 and P<0.05, respectively).	Sirolimus	133-142	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	69-74
34275928-12	2021	Compared with the control group, the expression levels of LC3II and E-cadherin were significantly elevated, and the expression levels of alpha-SMA and Snail 1 in the rapamycin group were significantly reduced (all P<0.05); the expression levels of LC3II and E-cadherin were significantly reduced, and the expression levels of alpha-SMA and Snail 1 were significantly increased in the Beclin 1 siRNA group (all P<0.05).	Sirolimus	166-175	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	58-63
34275928-12	2021	Compared with the control group, the expression levels of LC3II and E-cadherin were significantly elevated, and the expression levels of alpha-SMA and Snail 1 in the rapamycin group were significantly reduced (all P<0.05); the expression levels of LC3II and E-cadherin were significantly reduced, and the expression levels of alpha-SMA and Snail 1 were significantly increased in the Beclin 1 siRNA group (all P<0.05).	Sirolimus	166-175	cadherin 1	Rattus norvegicus	68-78
35096638-7	2021	We found that overexpression of Egr-1 inhibited the phagocytic activity of macrophages, and the autophagy activator rapamycin and inhibitor chloroquine could reverse the effects of Egr-1 knockdown and Egr-1 overexpression on phagocytosis of P. aeruginosa, respectively.	Sirolimus	116-125	early growth response 1	Mus musculus	201-206
34275928-12	2021	Compared with the control group, the expression levels of LC3II and E-cadherin were significantly elevated, and the expression levels of alpha-SMA and Snail 1 in the rapamycin group were significantly reduced (all P<0.05); the expression levels of LC3II and E-cadherin were significantly reduced, and the expression levels of alpha-SMA and Snail 1 were significantly increased in the Beclin 1 siRNA group (all P<0.05).	Sirolimus	166-175	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	248-253
34275928-12	2021	Compared with the control group, the expression levels of LC3II and E-cadherin were significantly elevated, and the expression levels of alpha-SMA and Snail 1 in the rapamycin group were significantly reduced (all P<0.05); the expression levels of LC3II and E-cadherin were significantly reduced, and the expression levels of alpha-SMA and Snail 1 were significantly increased in the Beclin 1 siRNA group (all P<0.05).	Sirolimus	166-175	cadherin 1	Rattus norvegicus	258-268
34983878-8	2022	We further confirmed this conclusion with the activator (Rapamycin, RAP) and inhibitor (Wortmannin) of autophagy.	Sirolimus	57-66	LDL receptor related protein associated protein 1	Homo sapiens	68-71
34249417-1	2021	The phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling pathways are critical for normal human physiology, and any alteration in their regulation leads to several human cancers.	Sirolimus	78-87	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	4-33
35046889-4	2021	Ddit4 is a direct target of Mir221 and Mir222, and the upregulation of Ddit4 in Mir221/222AdipoKO was associated with the suppression of TSC2 (tuberous sclerosis complex 2)/mammalian target of rapamycin complex 1 (mTORC1)/S6K (ribosomal protein S6 kinase) pathway.	Sirolimus	193-202	microRNA 221	Homo sapiens	80-86
34077672-9	2021	Moreover, in the HFCD, the expression of p-mechanical targets of the rapamycin (mTOR) was increased, whereas that of p-AMP-activated protein kinase (AMPK) was decreased compared with that in the CON.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Mus musculus	80-84
34093717-12	2021	QYSL serum inhibited p-mTOR in a similar manner to rapamycin while reducing the activating effects of MHY1485 on p-mTOR.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	23-27
34093717-12	2021	QYSL serum inhibited p-mTOR in a similar manner to rapamycin while reducing the activating effects of MHY1485 on p-mTOR.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	115-119
34987640-9	2022	Further, to reactivate functionally indolent TILs, we reprogrammed ex vivo TILs with Ibrutinib plus Rapamycin to block interleukin-2-inducible kinase (ITK) and mTOR pathways, respectively.	Sirolimus	100-109	IL2 inducible T cell kinase	Homo sapiens	119-149
34065203-1	2021	Rapamycin is a powerful inhibitor of the TOR (Target of Rapamycin) pathway, which is an evolutionarily conserved protein kinase, that plays a central role in plants and animals.	Sirolimus	0-9	Target of rapamycin	Drosophila melanogaster	41-44
34065203-1	2021	Rapamycin is a powerful inhibitor of the TOR (Target of Rapamycin) pathway, which is an evolutionarily conserved protein kinase, that plays a central role in plants and animals.	Sirolimus	0-9	Target of rapamycin	Drosophila melanogaster	46-65
34095131-10	2021	To determine whether mTOR activation is necessary for IGF1-mediated stimulation of posttraumatic hippocampal neurogenesis, wildtype and IGF1 transgenic mice received the mTOR inhibitor rapamycin daily beginning at 3 days after TBI, following pulse labeling with bromodeoxyuridine.	Sirolimus	185-194	mechanistic target of rapamycin kinase	Mus musculus	170-174
34987640-9	2022	Further, to reactivate functionally indolent TILs, we reprogrammed ex vivo TILs with Ibrutinib plus Rapamycin to block interleukin-2-inducible kinase (ITK) and mTOR pathways, respectively.	Sirolimus	100-109	IL2 inducible T cell kinase	Homo sapiens	151-154
34079457-17	2021	Mechanically, it accelerated the degradation of NLRP3 inflammasome via the autophagy-ubiquitin pathway and reduced the green fluorescent protein/red fluorescent protein MAP1LC3B ratio, which was comparable to the effect when using the autophagy activator rapamycin (Rapa).	Sirolimus	255-264	NLR family, pyrin domain containing 3	Mus musculus	48-53
34079457-17	2021	Mechanically, it accelerated the degradation of NLRP3 inflammasome via the autophagy-ubiquitin pathway and reduced the green fluorescent protein/red fluorescent protein MAP1LC3B ratio, which was comparable to the effect when using the autophagy activator rapamycin (Rapa).	Sirolimus	266-270	NLR family, pyrin domain containing 3	Mus musculus	48-53
33949020-8	2021	Finally, the results were validated in functional rescue experiments using AKT and mTOR inhibitors (MK2206 and rapamycin).	Sirolimus	111-120	mechanistic target of rapamycin kinase	Mus musculus	83-87
35428493-10	2022	WB results showed that LC3-II/I expression was significantly elevated in KHE primary cells treated with rapamycin, while the level of p-mTOR, p-S6K1, and p-4E-BP1 expression was reduced.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	144-148
35428493-10	2022	WB results showed that LC3-II/I expression was significantly elevated in KHE primary cells treated with rapamycin, while the level of p-mTOR, p-S6K1, and p-4E-BP1 expression was reduced.	Sirolimus	104-113	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	156-162
35523039-10	2022	Unexpectedly, the elevated PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr ratio had the greatest ability to discriminate between pSS and HC, and sirolimus therapy restored the PD-1+ICOS+Tfh cells:CD45RA-Foxp3high activated Tfr ratio, and controlled disease activity.	Sirolimus	143-152	forkhead box P3	Sus scrofa	48-53
35523039-10	2022	Unexpectedly, the elevated PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr ratio had the greatest ability to discriminate between pSS and HC, and sirolimus therapy restored the PD-1+ICOS+Tfh cells:CD45RA-Foxp3high activated Tfr ratio, and controlled disease activity.	Sirolimus	143-152	forkhead box P3	Sus scrofa	201-206
34059001-17	2021	Repression of mTOR with rapamycin blocked the effects of KLK11 on S6K1 and 4EBP1 as well as protein synthesis.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
33609687-8	2021	Phosphorylation of p70S6K was inhibited by siRNA knockdown and rapamycin to restore TNFalpha-inhibited autophagy, which prevented the synergistic effect on TVX-induced cytotoxicity.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	19-25
34054807-9	2021	Pretreating the BV2 cells or mouse primary microglial cells with rapamycin blocked mTOR/HIF-1alpha activation and cellular metabolic reprogramming induced by BAFF training.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Mus musculus	83-87
35477092-1	2022	When asynchronously growing cells suffer from nutrient depletion and inactivation of target of rapamycin complex 1 (TORC1) protein kinase, the rDNA (rRNA gene) region is condensed in budding yeast Saccharomyces cerevisiae, which is executed by condensin and Cdc14 protein phosphatase.	Sirolimus	95-104	phosphoprotein phosphatase CDC14	Saccharomyces cerevisiae S288C	258-263
34054807-9	2021	Pretreating the BV2 cells or mouse primary microglial cells with rapamycin blocked mTOR/HIF-1alpha activation and cellular metabolic reprogramming induced by BAFF training.	Sirolimus	65-74	hypoxia inducible factor 1, alpha subunit	Mus musculus	88-98
33888602-0	2021	mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer"s disease.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	0-4
33981041-6	2021	The treatment of Vav-iCre+/-;Ercc1-/fl mice with rapamycin reduced markers of senescence in immune cells and improved immune function11,12.	Sirolimus	49-58	vav 1 oncogene	Mus musculus	17-20
35513096-10	2022	Then, micelles with N-Acetylneuraminic acid and Chondroitin sulfate were prepared to load rapamycin(RAP).	Sirolimus	90-99	LDL receptor related protein associated protein 1	Homo sapiens	100-103
35176419-8	2022	Currently, the only clinically available p70S6K inhibitors are rapamycin analogs (rapalogs) which target mTOR.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	41-47
33981041-6	2021	The treatment of Vav-iCre+/-;Ercc1-/fl mice with rapamycin reduced markers of senescence in immune cells and improved immune function11,12.	Sirolimus	49-58	excision repair cross-complementing rodent repair deficiency, complementation group 1	Mus musculus	29-34
35286973-8	2022	The levels of phosphorylated mTOR and ribosomal protein S6 kinase 1 (p70S6K) were increased after GLUT1 inhibition and decreased by an mTOR inhibitor (rapamycin, Rapa) during the odontogenic induction of hDPSCs.	Sirolimus	151-160	ribosomal protein S6 kinase B1	Homo sapiens	69-75
33957967-11	2021	The autophagy promoter (3-MA) and inhibitor (rapamycin) significantly decreased or increased the expression of TNF-alpha, IL-6, and IL-1beta by DCs.	Sirolimus	45-54	interleukin 1 alpha	Homo sapiens	132-140
35633088-7	2022	Mechanistic experimentation illustrated that TRPM2 interacted with p47 phox and positively regulated p47 phox, such that p47 phox up-regulation or use of Rapamycin (autophagy activator) weakened the inhibitory role of silencing TRPM2.	Sirolimus	154-163	pleckstrin	Homo sapiens	101-104
33742521-1	2021	We hypothesized that rapamycin (Rapa), acarbose (ACA), which both increase mouse lifespan, and 17alpha-estradiol, which increases lifespan in males (17aE2) all share common intracellular signaling pathways with long-lived Snell dwarf, PAPPA-KO, and Ghr-/- mice.	Sirolimus	21-30	pregnancy-associated plasma protein A	Mus musculus	235-240
33910214-8	2021	Current therapeutic approaches center on rapamycin and its analogs, drugs that are administered systemically to inhibit mTOR activity.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Mus musculus	120-124
35628508-7	2022	RAPA treatment (an inducer of autophagy) significantly improved realgar-induced liver injury and NLRP3 inflammasome activation, while 3-MA (an inhibitor of autophagy) aggravated the realgar-induced liver injury and NLRP3 inflammasome activation.	Sirolimus	0-4	NLR family, pyrin domain containing 3	Mus musculus	97-102
35628508-7	2022	RAPA treatment (an inducer of autophagy) significantly improved realgar-induced liver injury and NLRP3 inflammasome activation, while 3-MA (an inhibitor of autophagy) aggravated the realgar-induced liver injury and NLRP3 inflammasome activation.	Sirolimus	0-4	NLR family, pyrin domain containing 3	Mus musculus	215-220
35628508-9	2022	RAPA eliminates excessive ROS, inhibits NF-kappaB nuclear translocation and down-regulates the TXNIP/NLRP3 axis, consequently suppressing ROS-mediated NLRP3 inflammasome activation, which may be the underlying mechanism of the protective effect of autophagy on realgar-induced liver injury.	Sirolimus	0-4	NLR family, pyrin domain containing 3	Mus musculus	101-106
35628508-9	2022	RAPA eliminates excessive ROS, inhibits NF-kappaB nuclear translocation and down-regulates the TXNIP/NLRP3 axis, consequently suppressing ROS-mediated NLRP3 inflammasome activation, which may be the underlying mechanism of the protective effect of autophagy on realgar-induced liver injury.	Sirolimus	0-4	NLR family, pyrin domain containing 3	Mus musculus	151-156
35559682-2	2022	We report a strategy through which cotransplantation of allogeneic islets and streptavidin (SA)-FasL-presenting microgels to the omentum under transient rapamycin monotherapy resulted in robust glycemic control, sustained C-peptide levels, and graft survival in diabetic nonhuman primates for >6 months.	Sirolimus	153-162	Fas ligand	Homo sapiens	96-100
33910029-6	2021	Inhibition of mTOR with rapamycin significantly reduced the quantity and duration of USVs in both sexes.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
33894212-5	2021	This was associated with a greater BCAA-induced activation of mTOR signaling in the heart at the end of the active period; pharmacological inhibition of mTOR (through rapamycin) blocked BCAA-induced augmentation of cardiac mass and cardiomyocyte size.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Mus musculus	153-157
33935683-12	2021	Pretreating mice with rapamycin inhibited the activation of mTOR and restored autophagy function, also increased the expression of SYN and PSD-95.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	60-64
33935683-12	2021	Pretreating mice with rapamycin inhibited the activation of mTOR and restored autophagy function, also increased the expression of SYN and PSD-95.	Sirolimus	22-31	synaptophysin	Mus musculus	131-134
33935683-15	2021	An mTOR inhibitor, rapamycin, ameliorated anesthesia/surgery-related cognitive impairments by inhibiting the mTOR activity, inducing activation of autophagy, enhancing SYN and PSD-95 expression.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	3-7
33935683-15	2021	An mTOR inhibitor, rapamycin, ameliorated anesthesia/surgery-related cognitive impairments by inhibiting the mTOR activity, inducing activation of autophagy, enhancing SYN and PSD-95 expression.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	109-113
33935683-15	2021	An mTOR inhibitor, rapamycin, ameliorated anesthesia/surgery-related cognitive impairments by inhibiting the mTOR activity, inducing activation of autophagy, enhancing SYN and PSD-95 expression.	Sirolimus	19-28	synaptophysin	Mus musculus	168-171
33912444-11	2021	Moreover, rapamycin, an inhibitor of mTOR complex 1 (mTORC1), downregulated BCRP expression and enhanced the effects of particular drugs, including doxorubicin and paclitaxel.	Sirolimus	10-19	BCR pseudogene 1	Homo sapiens	76-80
33912444-14	2021	Rapamycin might enhance the therapeutic effect of chemotherapy agents in mPRalpha-positive MDA-MB-453/BCRP cells and might be a therapeutic option for mPRalpha-positive invasive BCa with BCRP overexpression.	Sirolimus	0-9	S100 calcium binding protein A6 (calcyclin)	Mus musculus	73-81
33912444-14	2021	Rapamycin might enhance the therapeutic effect of chemotherapy agents in mPRalpha-positive MDA-MB-453/BCRP cells and might be a therapeutic option for mPRalpha-positive invasive BCa with BCRP overexpression.	Sirolimus	0-9	BCR pseudogene 1	Homo sapiens	102-106
33912444-14	2021	Rapamycin might enhance the therapeutic effect of chemotherapy agents in mPRalpha-positive MDA-MB-453/BCRP cells and might be a therapeutic option for mPRalpha-positive invasive BCa with BCRP overexpression.	Sirolimus	0-9	S100 calcium binding protein A6 (calcyclin)	Mus musculus	151-159
33912444-14	2021	Rapamycin might enhance the therapeutic effect of chemotherapy agents in mPRalpha-positive MDA-MB-453/BCRP cells and might be a therapeutic option for mPRalpha-positive invasive BCa with BCRP overexpression.	Sirolimus	0-9	BCR pseudogene 1	Homo sapiens	187-191
33921372-3	2021	However, the effects and detailed molecular mechanisms of the mTOR inhibitor rapamycin and TCDD on psoriasis in vivo remain to be elucidated.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	62-66
33852892-7	2021	Finally, our findings provide a mechanistic explanation for the differential rapamycin sensitivity of the 4E-BP1 phosphorylation sites.	Sirolimus	77-86	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	106-112
33846885-14	2021	RAPA treatment also restored the neuronal and macro-vascular marker, EphB2, back to normal levels.	Sirolimus	0-4	Eph receptor B2	Rattus norvegicus	69-74
33300153-0	2021	Growth inhibition and suppression of the mTOR and Wnt/beta-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	Sirolimus	113-122	catenin beta 1	Homo sapiens	54-66
33300153-4	2021	In this study, we showed that rapamycin significantly reduced MYCN mRNA and protein in a concentration-dependent manner in T-ALL cells.	Sirolimus	30-39	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	62-66
33300153-7	2021	Rapamycin and MYCN inhibition suppressed both Wnt/beta-catenin and mTOR signaling pathways.	Sirolimus	0-9	catenin beta 1	Homo sapiens	50-62
33300153-8	2021	The results suggest the effects of rapamycin on adult T-ALL is likely mediated by downregulation of MYCN.	Sirolimus	35-44	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	100-104
32869336-8	2021	Additionally, the autophagic enhancer, rapamycin, induced the clearance of alpha-Syn aggregates 13 days post-PFF addition, indicating that autophagy is the major pathway for aggregated alpha-Syn clearance.	Sirolimus	39-48	synuclein alpha	Homo sapiens	75-84
35550871-4	2022	Interestingly, the inhibition of mTOR signaling by rapamycin has no effect on miR-182-5p levels in primary subcutaneous white adipocytes, suggesting the presence of an mTOR-independent mechanism regulating Rheb-mediated miR-182-5p expression.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	33-37
32869336-8	2021	Additionally, the autophagic enhancer, rapamycin, induced the clearance of alpha-Syn aggregates 13 days post-PFF addition, indicating that autophagy is the major pathway for aggregated alpha-Syn clearance.	Sirolimus	39-48	synuclein alpha	Homo sapiens	185-194
33640883-0	2021	Maf1 suppression of ATF5-dependent mitochondrial unfolded protein response contributes to rapamycin-induced radio-sensitivity in lung cancer cell line A549.	Sirolimus	90-99	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	0-4
35603144-10	2022	Additionally, co-treatment with TAK-242 (a TLR-4 inhibitor) and rapamycin more effectively alleviated the damaging effects of AR following liver transplantation than either drug alone.	Sirolimus	64-73	toll like receptor 4	Homo sapiens	43-48
33640883-3	2021	Here we show that Maf1 is required for rapamycin to increase radio-sensitivity in A549 lung cancer cells.	Sirolimus	39-48	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	18-22
33640883-5	2021	Rapamycin suppresses IR-induced Maf1 re-phosphorylation and UPRmt activation in A549 cells, resulting in increased sensitivity to IR-mediated cytotoxicity.	Sirolimus	0-9	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	32-36
33640883-6	2021	Consistently, Maf1 knockdown activates ATF5-transcription of mtHSP70 and HSP60, enhances mitochondrial membrane potential, reduces intracellular ROS levels and dampens rapamycin"s effect on increasing IR-mediated cytotoxicity.	Sirolimus	168-177	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	14-18
33640883-9	2021	Together, our study reveals a novel role of Maf1-UPRmt axis in mediating rapamycin"s enhancing effect on IR sensitivity in A549 lung cancer cells.	Sirolimus	73-82	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	44-48
33382998-5	2021	While insulin-activated IRS/PI3K/PKB pathway cascades are primarily known to reduce glucose production, it was recently discovered to increase the Hh signaling pathway"s stability, thereby activating the PI3K/PKB/mammalian target of rapamycin complex 2 (mTORC2) signaling pathway.	Sirolimus	233-242	protein tyrosine kinase 2 beta	Homo sapiens	209-212
33548116-13	2021	Treatment of cells with autophagy inducer rapamycin reduced LC3-positive aggregates, CHOP and cell death induced by 2bpIns-OPTN.	Sirolimus	42-51	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	60-63
33548116-13	2021	Treatment of cells with autophagy inducer rapamycin reduced LC3-positive aggregates, CHOP and cell death induced by 2bpIns-OPTN.	Sirolimus	42-51	DNA-damage inducible transcript 3	Mus musculus	85-89
33547375-1	2021	Rictor is a key component of the mammalian target of rapamycin complex 2 (mTORC2) and is required for Akt phosphorylation (Ser473).	Sirolimus	53-62	RPTOR independent companion of MTOR complex 2	Homo sapiens	0-6
33532886-0	2021	Treatment of Immune Dysregulation Due to a PTEN Variant with Sirolimus.	Sirolimus	61-70	phosphatase and tensin homolog	Homo sapiens	43-47
33284085-11	2021	Purine substitutions to disrupt a terminal oligopyrimidine (TOP)-like sequence in the Rbp4 5"-UTRprevented the suppressive effect of rapamycin on reporter activity.	Sirolimus	133-142	retinol binding protein 4	Rattus norvegicus	86-90
33284085-12	2021	Rapamycin also prevented upregulation of Rbp4 mRNA translation in the liver, and reduced serum levels of RBP4 in response to feeding.	Sirolimus	0-9	retinol binding protein 4	Rattus norvegicus	41-45
33284085-12	2021	Rapamycin also prevented upregulation of Rbp4 mRNA translation in the liver, and reduced serum levels of RBP4 in response to feeding.	Sirolimus	0-9	retinol binding protein 4	Rattus norvegicus	105-109
33140268-5	2021	Rapamycin, an inhibitor of mTOR, rescued the STZ-induced increases in mTOR/p70S6K activities, tau phosphorylation and Abeta levels, as well as mitochondria abnormality and cognitive impairment in mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
33140268-5	2021	Rapamycin, an inhibitor of mTOR, rescued the STZ-induced increases in mTOR/p70S6K activities, tau phosphorylation and Abeta levels, as well as mitochondria abnormality and cognitive impairment in mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	70-74
33140268-6	2021	These findings imply that rapamycin prevents cognitive impairment and protects hippocampus neurons from AD-like pathology and mitochondrial abnormality, and also that rapamycin treatment could normalize these STZ-induced alterations by decreasing hippocampus mTOR/p70S6K hyperactivity.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Mus musculus	259-263
33270949-3	2021	Sorted Lin- CD150+ BM cells from sirolimus-treated TBI mice had increased expression of c-Kit and other hematopoietic genes.	Sirolimus	33-42	signaling lymphocytic activation molecule family member 1	Mus musculus	12-17
33270949-3	2021	Sorted Lin- CD150+ BM cells from sirolimus-treated TBI mice had increased expression of c-Kit and other hematopoietic genes.	Sirolimus	33-42	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	88-93
33270949-8	2021	In contrast, sirolimus showed no effect on HSPCs in normal mice at steady state, but stimulated HSPC expansion in mice carrying the Wv mutation at the c-Kit locus.	Sirolimus	13-22	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	151-156
33478110-7	2021	(2) PP2A-mediated inhibition of target of rapamycin complex (TORC) dependent signaling pathways contributes to autophagy and this has possible connections to the brassinosteroid signaling pathway.	Sirolimus	42-51	protein phosphatase 2 phosphatase activator	Homo sapiens	4-8
33469286-12	2021	In addition, rapamycin liposomes and 5-FU can synergistically improve the efficacy of colorectal cancer via the Akt/mTOR and P53 pathways.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	116-120
33469286-12	2021	In addition, rapamycin liposomes and 5-FU can synergistically improve the efficacy of colorectal cancer via the Akt/mTOR and P53 pathways.	Sirolimus	13-22	transformation related protein 53, pseudogene	Mus musculus	125-128
33428109-9	2021	The mTOR inhibitor rapamycin mitigated TGF-beta-induced expression of p21, p16, and DNA damage foci and improved replicative potential of preadipocytes, supporting the cell-specific response to this cytokine.	Sirolimus	19-28	H3 histone pseudogene 16	Homo sapiens	70-73
34034560-0	2021	The p70S6K/PI3K/MAPK feedback loop releases the inhibition effect of high-dose rapamycin on rat mesangial cell proliferation.	Sirolimus	79-88	ribosomal protein S6 kinase B1	Rattus norvegicus	4-10
34034560-8	2021	The results of western blotting showed that 1000 nmol/L rapamycin more significantly inhibited the phosphorylation of p70S6K than 100 nmol/L, suggesting there should be another signaling pathway that activates the proliferation of MCs.	Sirolimus	56-65	ribosomal protein S6 kinase B1	Rattus norvegicus	118-124
34034560-9	2021	Moreover, our results revealed that 1000 nmol/L rapamycin led to Raf1-MEK1/2-ERK pathway activation through a p70S6K-PI3K-mediated feedback loop in MCs.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Rattus norvegicus	110-116
34034560-10	2021	This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation.	Sirolimus	39-48	ribosomal protein S6 kinase B1	Rattus norvegicus	86-92
34034560-10	2021	This study demonstrated that high-dose rapamycin leads to ERK1/2 activation through a p70S6K/PI3K/MAPK feedback loop in rat MCs, thus reducing the inhibitory effect of rapamycin on MC proliferation.	Sirolimus	168-177	ribosomal protein S6 kinase B1	Rattus norvegicus	86-92
32583421-7	2021	Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARalpha, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells.	Sirolimus	149-158	peroxisome proliferator activated receptor alpha	Homo sapiens	104-113
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	106-110
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	112-117
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	sterol regulatory element binding transcription factor 1	Homo sapiens	171-177
33141044-12	2021	In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases.	Sirolimus	22-31	cyclin dependent kinase inhibitor 1B	Homo sapiens	64-70
33141044-12	2021	In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases.	Sirolimus	22-31	phosphatase and tensin homolog	Homo sapiens	72-76
33141044-12	2021	In the combination of rapamycin with AZD3463, the expression of CDKN1B, PTEN, FOXO3, and APC genes increases, and the expression of PRKCB and PIK3CG genes decreases.	Sirolimus	22-31	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	142-148
34050468-4	2021	The optical cross talk-free feature is exemplified with the multiplex system, which simultaneously illuminated antiestrogenic and rapamycin activities without optical cross talks.	Sirolimus	130-139	bone morphogenetic protein receptor type 2	Homo sapiens	18-22
33339388-13	2020	Intermediate filaments form clusters under RPM conditions as detected by vimentin staining after 7 d and 14 d. Larger meshes appear in the network in 28-day samples.	Sirolimus	43-46	vimentin	Homo sapiens	73-81
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	27-36	signal transducer and activator of transcription 3	Rattus norvegicus	81-131
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	27-36	signal transducer and activator of transcription 3	Rattus norvegicus	133-138
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	38-42	signal transducer and activator of transcription 3	Rattus norvegicus	81-131
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	38-42	signal transducer and activator of transcription 3	Rattus norvegicus	133-138
35437883-8	2022	Further investigation uncovered that H19 also acted as an orchestra conductor that inhibited the function of mechanistic target of rapamycin complex 1 (mTORC1) by disrupting the interaction of mTORC1 with eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1).	Sirolimus	131-140	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	205-266
35380294-14	2022	Despite Diaph3 expression not correlating with survival and tumor size in GBM, there is an accumulating body of evidence that Diaph3 correlates with mTOR activity and can thus be used as a predictor for response to rapamycin and taxanes, clinical studies of which have shown promising, if mixed results in GBM.	Sirolimus	215-224	diaphanous related formin 3	Homo sapiens	126-132
35449295-8	2022	Consequently, abrogating the Akt-mTOR-autophagy signaling pathway abolishes CYLD-induced spine loss, whereas enhancing autophagy in vivo by the mTOR inhibitor rapamycin rescues the synaptic pruning and LTD deficits in mutant mice.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Mus musculus	33-37
35449295-8	2022	Consequently, abrogating the Akt-mTOR-autophagy signaling pathway abolishes CYLD-induced spine loss, whereas enhancing autophagy in vivo by the mTOR inhibitor rapamycin rescues the synaptic pruning and LTD deficits in mutant mice.	Sirolimus	159-168	mechanistic target of rapamycin kinase	Mus musculus	144-148
35571122-10	2022	Conclusions: Our findings indicate that combined mycophenolate and rapamycin, at reduced dose, improves kidney fibrosis in murine lupus nephritis through their distinct effect on mTOR and ERK signaling in mesangial cells.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Mus musculus	179-183
35447117-4	2022	Furthermore, conditioned media derived from calpain-activated ECs facilitated the phosphorylation of ribosomal protein S6 kinase (S6K) and de novo lipogenesis in hepatocytes, which were abolished by the amino acid transporter inhibitor, JPH203, and the mTORC1 inhibitor, rapamycin.	Sirolimus	271-280	ribosomal protein S6 kinase B1	Homo sapiens	130-133
35366690-9	2022	RESULTS: The autophagy agonist rapamycin reduced the lesion size, the microvessel density, and VEGF expression, and promoted the production of autophagosomes and the expression of autophagy-related proteins, while the autophagy inhibitor chloroquine had the opposite effects.	Sirolimus	31-40	vascular endothelial growth factor A	Rattus norvegicus	95-99
35040506-2	2022	Sirolimus (rapamycin) is an mTOR inhibitor that promotes alpha-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.	Sirolimus	0-9	synuclein alpha	Homo sapiens	57-72
35040506-2	2022	Sirolimus (rapamycin) is an mTOR inhibitor that promotes alpha-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.	Sirolimus	11-20	synuclein alpha	Homo sapiens	57-72
35153184-1	2022	OBJECTIVE: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of the rapamycin (PI3K-AKT-mTOR) signaling pathway is an important regulator of cell proliferation, survival, and motility.	Sirolimus	86-95	protein tyrosine kinase 2 beta	Homo sapiens	45-61
35190469-3	2022	In this study, we identify a critical period for the development of ASD-relevant behaviors in a cerebellar male mouse model of Tuberous Sclerosis Complex (TSC), by using the mechanistic target of rapamycin (mTOR) inhibitor, rapamycin, to pharmacologically inhibit dysregulated downstream signaling.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Mus musculus	174-205
35190469-3	2022	In this study, we identify a critical period for the development of ASD-relevant behaviors in a cerebellar male mouse model of Tuberous Sclerosis Complex (TSC), by using the mechanistic target of rapamycin (mTOR) inhibitor, rapamycin, to pharmacologically inhibit dysregulated downstream signaling.	Sirolimus	224-233	mechanistic target of rapamycin kinase	Mus musculus	207-211
33490152-8	2020	Finally, it was shown that the application of SKP-SC-EVs could activate the Akt/mTOR/p70S6K signaling pathway that can be abolished by rapamycin.	Sirolimus	135-144	ribosomal protein S6 kinase B1	Homo sapiens	85-91
32722876-4	2020	Here, we identified that the phosphorylation of mechanistic target of rapamycin (mTOR) and the expression of DEP domain-containing mTOR-interacting protein (DEPTOR) was increased in gastric mucosa of H. pylori-infected patients and mice, as well as in H. pylori-infected gastric epithelial cells, which were largely depended on H. pylori cagA.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Mus musculus	81-85
33222863-0	2020	Insulin potentiates essential amino acids effects on mechanistic target of rapamycin complex 1 signaling in MAC-T cells.	Sirolimus	75-84	insulin	Bos taurus	0-7
33324011-2	2020	Mechanistic target of rapamycin (mTOR) inhibition with rapamycin attenuates disease progression in a mouse model of Leigh syndrome (Ndufs4 knock-out (KO) mouse); however, the mechanism of rescue is unknown.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	33-37
33324011-4	2020	Assessing the impact of rapamycin on the brain proteome and phosphoproteome of Ndufs4 KO mice, we find that rapamycin restores mitochondrial protein levels, inhibits signalling through both mTOR complexes and reduces the abundance and activity of multiple PKC isoforms.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Mus musculus	190-194
32615844-6	2020	Rapamycin (mTOR inbibitor) was used to investigate SXNI-induced hypersensitivity reactions both in mice and HUVECs.Results: SXNI (70 mg/kg) induced vascular leakage in mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	11-15
33243998-4	2020	Mechanistically, ISO inhibits AKT as well as, downstream of AKT, the mechanistic target of rapamycin complex 1 (mTORC1), coupled to the activation of the pro-autophagic transcription factors EB (TFEB) and E3 (TFE3).	Sirolimus	91-100	transcription factor E3	Mus musculus	209-213
33255287-0	2020	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface.	Sirolimus	0-9	forkhead box P3	Mus musculus	33-38
33255287-7	2020	In the lacrimal gland and draining lymph nodes, we also observed a significant increase in the CD45+CD4+Foxp3+ cells in the rapamycin-treated mice.	Sirolimus	124-133	protein tyrosine phosphatase, receptor type, C	Mus musculus	95-99
33255287-7	2020	In the lacrimal gland and draining lymph nodes, we also observed a significant increase in the CD45+CD4+Foxp3+ cells in the rapamycin-treated mice.	Sirolimus	124-133	forkhead box P3	Mus musculus	104-109
33204002-3	2021	Combined treatment of Smurf1 knockdown with rapamycin showed collaborative antitumor effects in mice.	Sirolimus	44-53	SMAD specific E3 ubiquitin protein ligase 1	Mus musculus	22-28
32901500-8	2020	In addition, rapamycin, an mTOR inhibitor, promoted the development of autophagy, further inhibited the protective effect on Cx43 expression and increased cell hypertrophy.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	27-31
34986233-9	2022	When CD45-ADC was combined with pre-transplant TBI (50cGy) and post-transplant Rapamycin, Cytoxan or a JAK inhibitor, 90-100% of recipients achieved stable chimerism (mean: 77%, 59%, 78%, respectively).	Sirolimus	79-88	protein tyrosine phosphatase, receptor type, C	Mus musculus	5-9
33037141-4	2020	Inhibiting mTOR activity with rapamycin rescued the generation of Foxp3+ T cells.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Mus musculus	11-15
35432890-5	2022	Further, small molecule (+)-JQ1- and rapamycin-derived iPr acyl silanes were shown to selectively label recombinant BRD4-BD1 and FKBP12, respectively, with minimal background.	Sirolimus	37-46	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	129-135
33037141-4	2020	Inhibiting mTOR activity with rapamycin rescued the generation of Foxp3+ T cells.	Sirolimus	30-39	forkhead box P3	Mus musculus	66-71
33158864-5	2020	It reveals entangled folds of the defining Rictor and the substrate-binding SIN1 subunits, identifies the carboxyl-terminal domain of Rictor as the source of the rapamycin insensitivity of mTORC2, and resolves mechanisms for mTORC2 regulation by complex destabilization.	Sirolimus	162-171	RPTOR independent companion of MTOR complex 2	Homo sapiens	43-49
33158864-5	2020	It reveals entangled folds of the defining Rictor and the substrate-binding SIN1 subunits, identifies the carboxyl-terminal domain of Rictor as the source of the rapamycin insensitivity of mTORC2, and resolves mechanisms for mTORC2 regulation by complex destabilization.	Sirolimus	162-171	RPTOR independent companion of MTOR complex 2	Homo sapiens	134-140
31738412-19	2020	Specifically, the results show an essential role of a highly innovative STAT3-miR-17-92-mTOR signaling axis in cardioprotection in diabetes, which may have potential clinical relevance in preventing I/R injury in diabetics because RAPA has relatively mild side effects at low dose.	Sirolimus	231-235	mechanistic target of rapamycin kinase	Mus musculus	88-92
32977361-12	2020	Meanwhile, the oncogenic effect of BUB1B will be impaired when the mTORC1 signaling pathway was inhibited by rapamycin.	Sirolimus	109-118	BUB1 mitotic checkpoint serine/threonine kinase B	Homo sapiens	35-40
32871473-10	2020	Compared to baseline values, both drugs caused a significant increase in number of platelets over the course of treatment; sirolimus group: 15,800/mcL vs 96,566/mcL, (P < 0.001), cyclosporine group: 14,400/mcL vs 111,266/mcL, P < 0.001,).	Sirolimus	123-132	C-type lectin domain family 4 member D	Homo sapiens	147-150
32324261-8	2020	Furthermore, we demonstrated that HDAC1 serves as an important modulator of the migration and phenotypic switch of SMCs by suppressing the PKD1- mammalian target of the rapamycin signaling pathway.	Sirolimus	169-178	polycystin 1, transient receptor potential channel interacting	Homo sapiens	139-143
32971423-0	2020	Low nitrogen induces root elongation via auxin-induced acid growth and auxin-regulated target of rapamycin (TOR) pathway in maize.	Sirolimus	97-106	Serine/threonine-protein kinase TOR	Zea mays	108-111
32861641-16	2020	This effect was reversed by rapamycin administration, suggesting the activation of mTOR signaling in the effect of AZD in the NSF test.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	83-87
32819718-0	2020	Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.	Sirolimus	37-46	RPTOR independent companion of MTOR complex 2	Homo sapiens	0-6
32819718-4	2020	In this study, we found that the sensitivity of TNBC cells to rapamycin was highly dependent on the expression level of rapamycin-insensitive companion of mTOR (Rictor), a key component of the mTOR complex 2.	Sirolimus	62-71	RPTOR independent companion of MTOR complex 2	Homo sapiens	120-159
32819718-4	2020	In this study, we found that the sensitivity of TNBC cells to rapamycin was highly dependent on the expression level of rapamycin-insensitive companion of mTOR (Rictor), a key component of the mTOR complex 2.	Sirolimus	62-71	RPTOR independent companion of MTOR complex 2	Homo sapiens	161-167
33145347-0	2020	Rapamycin-Induced Autophagy Promotes the Chondrogenic Differentiation of Synovium-Derived Mesenchymal Stem Cells in the Temporomandibular Joint in Response to IL-1beta.	Sirolimus	0-9	interleukin 1 alpha	Homo sapiens	159-167
33145347-8	2020	Further study revealed that rapamycin pretreatment promoted the migration of SMSCs and the expression of chondrogenesis-related markers in the presence of IL-1beta by inducing autophagy.	Sirolimus	28-37	interleukin 1 alpha	Homo sapiens	155-163
33173419-3	2020	Present study is aimed to assess the activity of the two mTOR inhibitors (rapamycin - RAP and sapanisertib - MLN) as a single agent and combined with gemcitabine (GEM, one of substances commonly used in systemic anticancer treatment) in uterine sarcoma and carcinosarcoma in vitro models.	Sirolimus	74-83	LDL receptor related protein associated protein 1	Homo sapiens	86-89
33123600-14	2020	Compared with the AA group, the level of plasma IFN-gamma, IL-2, and TNF-alpha decreased significantly (P < 0.05), but IL-10, IL-4, IL-5, and IL-1beta increased significantly in the Rapa group (P < 0.05).	Sirolimus	182-186	interleukin 4	Mus musculus	126-130
33123600-14	2020	Compared with the AA group, the level of plasma IFN-gamma, IL-2, and TNF-alpha decreased significantly (P < 0.05), but IL-10, IL-4, IL-5, and IL-1beta increased significantly in the Rapa group (P < 0.05).	Sirolimus	182-186	interleukin 5	Mus musculus	132-136
33123600-14	2020	Compared with the AA group, the level of plasma IFN-gamma, IL-2, and TNF-alpha decreased significantly (P < 0.05), but IL-10, IL-4, IL-5, and IL-1beta increased significantly in the Rapa group (P < 0.05).	Sirolimus	182-186	interleukin 1 alpha	Mus musculus	142-150
32828826-8	2020	Knockdown of RhoC and ROCK2 with corresponding siRNA significantly inhibited the secretion of exosomes originating from intraluminal vesicles (ILVs) in NPCs, even when NPCs were subsequently treated with Rap.	Sirolimus	204-207	Rho-associated coiled-coil containing protein kinase 2	Rattus norvegicus	22-27
32798557-0	2020	Rapamycin improves renal injury induced by Iodixanol in diabetic rats by deactivating the mTOR/p70S6K signaling pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	95-101
32798557-9	2020	KEY FINDINGS: Rapamycin was demonstrated to improve renal injury induced by Iodixanol diabetic rats, decrease the levels of SCr, BUN, KIM-1, NAG, improve renal functions, reduce inflammatory response and oxidative stress injury, down-regulate Bax, while up-regulate BCl-2 and inhibit apoptosis.	Sirolimus	14-23	hepatitis A virus cellular receptor 1	Rattus norvegicus	134-139
32798557-9	2020	KEY FINDINGS: Rapamycin was demonstrated to improve renal injury induced by Iodixanol diabetic rats, decrease the levels of SCr, BUN, KIM-1, NAG, improve renal functions, reduce inflammatory response and oxidative stress injury, down-regulate Bax, while up-regulate BCl-2 and inhibit apoptosis.	Sirolimus	14-23	BCL2 associated X, apoptosis regulator	Rattus norvegicus	243-246
32798557-10	2020	Moreover, Rapamycin could inhibit the phosphorylation of mTOR/p70S6K pathway-associated proteins, activate autophagy and increase the levels of LC3 and Beclin1.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Rattus norvegicus	62-68
32798557-11	2020	After treatment with 3MA, an inhibitor of mTOR/p70S6K signaling pathway, the protective effects of Rapamycin on CIAKI were weakened.	Sirolimus	99-108	ribosomal protein S6 kinase B1	Rattus norvegicus	47-53
32798557-12	2020	SIGNIFICANCE: Rapamycin can alleviate renal injury induced by Iodixanol diabetic rats, and its regulatory mechanisms may be related to the regulation of mTOR/p70S6K signaling pathway and the activating autophagy.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Rattus norvegicus	158-164
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	Sirolimus	1331-1340	protein kinase AMP-activated non-catalytic subunit gamma 1	Homo sapiens	72-78
35326570-9	2022	These phenomena are mitigated by rapamycin administration, which reverts nestin- and alpha-syn-related overexpression and phenotypic shifting within co-cultured astrocytes towards baseline conditions of naive astrocytes.	Sirolimus	33-42	synuclein alpha	Homo sapiens	85-94
35326570-10	2022	The present study indicates that: (i) alpha-syn increases in astrocyte co-cultured with GBM cells; (ii) alpha-syn increases in astrocytes along with the stem cell marker nestin; (iii) alpha-syn increases along with a GBM-like shift of cell morphology; (iv) all these changes are replicated in different GBM cell lines and are reverted by the mTOR inhibitor rapamycin.	Sirolimus	357-366	synuclein alpha	Homo sapiens	104-113
35326570-10	2022	The present study indicates that: (i) alpha-syn increases in astrocyte co-cultured with GBM cells; (ii) alpha-syn increases in astrocytes along with the stem cell marker nestin; (iii) alpha-syn increases along with a GBM-like shift of cell morphology; (iv) all these changes are replicated in different GBM cell lines and are reverted by the mTOR inhibitor rapamycin.	Sirolimus	357-366	synuclein alpha	Homo sapiens	184-193
31983282-7	2020	Taken together, our data suggest that PRKDC-mediated phosphorylation of PRKAG1 primes AMPK complex to the lysosomal activation by STK11 in cancer cells thereby linking DNA damage response to autophagy and cellular metabolism.Abbreviations: AXIN1: axin 1; 3-MA: 3-methyladenine; 5-FU: 5-fluorouracil; AA mutant: double alanine mutant (S192A, T284A) of PRKAG1; ACACA: acetyl-CoA carboxylase alpha; AICAR: 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; ATG: autophagy-related; ATM: ataxia telangiectasia mutated; ATR: ATM serine/threonine kinase; AV: autophagic vacuole; AVd: degradative autophagic vacuole; AVi: initial autophagic vacuole; BECN1: beclin 1; BSA: bovine serum albumin; CBS: cystathionine beta-synthase; CDK7: cyclin dependent kinase 7; CDKN1A: cyclin dependent kinase inhibitor 1A; EGFP: enhanced green fluorescent protein; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GST: glutathione S transferase; H2AX/H2AFX: H2A.X variant histone; HBSS: Hanks balanced salt solution; IP: immunopurification; IR: ionizing radiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K9: mitogen-activated protein kinase kinase kinase 9; mRFP: monomeric red fluorescent protein; mCh: mCherry; MCM7: minichromosome maintenance complex component 7; MTORC1: mechanistic target of rapamycin kinase complex 1; NHEJ: non-homologous end joining; NRBP2: nuclear receptor binding protein 2; NTC: non-targeting control; NUAK1: NUAK family kinase 1; PBS: phosphate-buffered saline; PIK3AP1: phosphoinositide-3-kinase adaptor protein 1; PIK3CA: phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; PIKK: phosphatidylinositol 3-kinase-related kinase; PRKAA: protein kinase AMP-activated catalytic subunit alpha; PRKAB: protein kinase AMP-activated non-catalytic subunit beta; PRKAG: protein kinase AMP-activated non-catalytic subunit gamma; PRKDC: protein kinase, DNA-activated, catalytic subunit; RLuc: Renilla luciferase; RPS6KB1: ribosomal protein S6 kinase B1; SQSTM1: sequestosome 1; STK11/LKB1: serine/threonine kinase 11; TP53: tumor protein p53; TSKS: testis specific serine kinase substrate; ULK1: unc-51 like autophagy activating kinase 1; WIPI2: WD repeat domain, phosphoinositide interacting 2; WT: wild type.	Sirolimus	1331-1340	serine/threonine kinase 11	Homo sapiens	130-135
32861747-2	2020	Here to study the mechanism of the acquired resistance of MCF-7 breast cancer cells to mTOR inhibitors two different models of the cell resistance were used: rapamycin-resistant MCF-7/Rap subline developed under long-term rapamycin treatment, and metformin-resistant MCF-7/M subline obtained by long-term metformin treatment.	Sirolimus	158-167	LDL receptor related protein associated protein 1	Homo sapiens	184-187
32808351-8	2020	Inhibition of mTOR/FOXO1 by rapamycin/AS1842856 decreased the ratio of Bcl-2/Bax and exacerbated TJ protein loss.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	14-18
32808351-8	2020	Inhibition of mTOR/FOXO1 by rapamycin/AS1842856 decreased the ratio of Bcl-2/Bax and exacerbated TJ protein loss.	Sirolimus	28-37	forkhead box O1	Mus musculus	19-24
32747423-6	2020	mTOR KD mice had higher levels of let-7a and miR-21 than mTOR WT mice, and rapamycin induced their expression in mTOR WT cells.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Mus musculus	0-4
33071810-12	2020	Furthermore, rapamycin treatment to PKD-1-knockdown VSMCs inhibited the effects caused by PC-1 downregulation.	Sirolimus	13-22	polycystin 1, transient receptor potential channel interacting	Homo sapiens	36-41
35253614-0	2022	OSBPL2 mutations impair autophagy and lead to hearing loss, potentially remedied by rapamycin.	Sirolimus	84-93	oxysterol binding protein-like 2	Mus musculus	0-6
35253614-7	2022	Rapamycin decreased the accumulation of mutant OSBPL2 and partially rescued hearing loss in mice.	Sirolimus	0-9	oxysterol binding protein-like 2	Mus musculus	47-53
35309056-9	2022	Moreover, LY294002 and rapamycin promoted expression of autophagy-related proteins LC3-II/I, p62, and beclin-1.	Sirolimus	23-32	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	83-91
35165201-2	2022	NPRL2 is a requisite subunit of the Gap Activity TOward Rags 1 (GATOR1) complex, which functions as a negative regulator of mammalian Target Of Rapamycin Complex 1 (mTORC1) kinase when intracellular amino acids are low.	Sirolimus	144-153	NPR2 like, GATOR1 complex subunit	Homo sapiens	0-5
35170378-0	2022	Effects of runt-related transcription factor 2 (RUNX2) on the autophagy of rapamycin-treated osteoblasts.	Sirolimus	75-84	runt related transcription factor 2	Mus musculus	11-46
35170378-0	2022	Effects of runt-related transcription factor 2 (RUNX2) on the autophagy of rapamycin-treated osteoblasts.	Sirolimus	75-84	runt related transcription factor 2	Mus musculus	48-53
35170378-8	2022	Further, RUNX2 overexpression was found to significantly enhance the viability and osteoblast mineralization of rapamycin-treated cells and suppress cell autophagy.	Sirolimus	112-121	runt related transcription factor 2	Mus musculus	9-14
35184679-10	2022	Rapamycin ameliorates renal damage by inhibiting the mTOR/NLRP3 signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	53-57
35184679-10	2022	Rapamycin ameliorates renal damage by inhibiting the mTOR/NLRP3 signaling pathway.	Sirolimus	0-9	NLR family, pyrin domain containing 3	Mus musculus	58-63
35088889-11	2022	However, the effects of 4-OHT and rapamycin were reversed by 3MA and knockdown of ATG4A, respectively.	Sirolimus	34-43	autophagy related 4A cysteine peptidase	Homo sapiens	82-87
33071810-12	2020	Furthermore, rapamycin treatment to PKD-1-knockdown VSMCs inhibited the effects caused by PC-1 downregulation.	Sirolimus	13-22	polycystin 1, transient receptor potential channel interacting	Homo sapiens	90-94
33178015-7	2020	Once activated, AMPK inhibits the mechanistic target of rapamycin complex 1 (mTORC1), which in turn avoids the phosphorylation of p70 ribosomal protein S6 kinase 1 and phosphatidylinositol 3-kinase/protein kinase B signaling pathways and reduces cap-dependent translation initiation.	Sirolimus	56-65	protein tyrosine kinase 2 beta	Homo sapiens	198-214
35078109-5	2022	S6K1 nuclear localization was serum dependent and serum deprivation or rapamycin treatment inhibited S6K1 Thr389 phosphorylation and, thereby, S6K1 was retained in the cytoplasm.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	101-105
35078109-5	2022	S6K1 nuclear localization was serum dependent and serum deprivation or rapamycin treatment inhibited S6K1 Thr389 phosphorylation and, thereby, S6K1 was retained in the cytoplasm.	Sirolimus	71-80	ribosomal protein S6 kinase B1	Homo sapiens	143-147
32966340-10	2020	In EPC2, autophagy induction was coupled with phosphorylation of AMP activated protein kinase (AMPK), a cellular energy sensor responding to low ATP levels, and dephosphorylation of downstream substrates of mechanistic Target of Rapamycin Complex (mTORC)-1 signaling.	Sirolimus	229-238	enhancer of polycomb homolog 2	Homo sapiens	3-7
35051778-8	2022	Further analysis revealed that MEOX2 negatively modulated the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) and extracellular signal-regulated kinase (ERK1/2) pathways.	Sirolimus	128-137	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	62-92
35175796-2	2022	We find that in the fat body of fasting Drosophila, lysosomal export of cystine coordinates remobilization of internal nutrient stores with reactivation of the growth regulator target of rapamycin complex 1 (TORC1).	Sirolimus	187-196	Target of rapamycin	Drosophila melanogaster	208-213
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	166-172
35114332-11	2022	Rapamycin enhances autophagy of SGNs by inhibiting mTOR activation, resulting in amelioration of ARHL.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	51-55
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	ribosomal protein S6 kinase B1	Homo sapiens	321-327
32693734-10	2020	Furthermore, using autophagy inhibitor NH4Cl and GSK-3beta inhibitor CHIR-99021, we found rapamycin-induced autophagy promoted cardiomyocyte differentiation at middle stage by negatively regulating the Wnt/beta-catenin signaling pathway.	Sirolimus	90-99	catenin beta 1	Homo sapiens	206-218
32693734-11	2020	These results suggest that rapamycin regulates EB-based cardiomyocyte differentiation in a stage-dependent manner, and the negative regulation of Wnt/beta-catenin signaling pathway by autophagy was involved in the pro-differentiation effect of rapamycin at middle stage.	Sirolimus	244-253	catenin beta 1	Homo sapiens	150-162
32693673-9	2020	In contrast, rapamycin successfully restored the impaired autophagic flux in LAPTM4B-/- mice and the subsequent myocardial I/R injury.	Sirolimus	13-22	lysosomal-associated protein transmembrane 4B	Mus musculus	77-84
33013932-7	2020	In addition, rapamycin abrogated the ability of both DC subtypes to promote the proliferation and differentiation of IFN-y and Granzyme B producing CD8 + T cells.	Sirolimus	13-22	granzyme B	Homo sapiens	127-137
32912327-7	2020	TLR5-mediated microglial function involves the PI3K/Akt/mammalian target of rapamycin complex 1 (mTORC1) pathway, as specific inhibitors of this signaling pathway abolish microglial activation.	Sirolimus	76-85	toll like receptor 5	Homo sapiens	0-4
32913260-7	2020	Furthermore, Rac1 cKO reduced the number of autophagosomes and apoptotic RGCs induced by rapamycin injected intravitreally, which suggests that Rac1 negatively regulates mTOR activity.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Mus musculus	170-174
32747435-7	2020	Inhibition of mTor signaling by rapamycin partially rescued Erk1/2 depletion-induced intestinal defects and significantly prolonged mutant mice life span.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
32715758-2	2020	miR-451 has a modulatory role in cell cycling via downregulation of mechanistic target of rapamycin.	Sirolimus	90-99	microRNA 451a	Mus musculus	0-7
35167340-5	2022	Mechanistically, we found that Themis promoted the activation of the transcription factor Stat and mechanistic target of rapamycin signaling downstream of cytokine receptors.	Sirolimus	121-130	thymocyte selection associated	Mus musculus	31-37
35224490-1	2022	The p70 ribosomal S6 kinases (p70 ribosomal S6 kinase 1 and p70 ribosomal S6 kinase 2) are downstream targets of the mechanistic target of rapamycin signalling pathway.	Sirolimus	139-148	Inverted repeat-binding protein	Drosophila melanogaster	60-63
31818185-12	2020	Our findings suggest a new regulatory link between mitochondria and autophagy through CASP9 activity, especially for the proper operation of the Atg8-family conjugation system and autophagosome closure and maturation.Abbreviations: AA: amino acid; ACD: autophagic cell death; ACTB: actin beta; ANXA5: annexin A5; APAF1: apoptotic peptidase activating factor 1; Atg: autophagy related; ATG16L1: autophagy related 16 like 1; BafA1: bafilomycin A1; BCL2: BCL2 apoptosis regulator; BECN1: beclin 1; CARD: caspase recruitment domain containing; CASP: caspase; CM-H2DCFDA: chloromethyl-2",7"-dichlorodihydrofluorescein diacetate; Deltapsim: mitochondrial membrane potential; DN: dominant-negative; DNM1L/DRP1: dynamin 1 like; EBSS: Earle"s balanced salt solution; GABARAP: GABA type A receptor-associated protein; GABARAPL1: GABA type A receptor associated protein like 1; GABARAPL2: GABA type A receptor associated protein like 2; HCN: hippocampal neural stem cells; IAM: inner autophagosome membrane; INS: insulin; KO: knockout; LEHD: Z-LEHD-fmk; MAP1LC3: microtubule associated protein 1 light chain 3; MFN1: mitofusin 1; MFN2: mitofusin 2; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP1: poly(ADP-ribose) polymerase 1; PBS: phosphate-buffered saline; PE: phosphatidylethanolamine; ROS: reactive oxygen species; sgRNA: single guide RNA; SR-SIM: super-resolution structured illumination microscopy; SQSTM1: sequestosome 1; STS: staurosporine; STX17: syntaxin 17; TMRE: tetramethylrhodamine ethyl ester; TUBB: tubulin beta class I; ULK1: unc-51 like autophagy activating kinase 1; WT: wild type; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1.	Sirolimus	1168-1177	caspase 9	Homo sapiens	86-91
31818185-12	2020	Our findings suggest a new regulatory link between mitochondria and autophagy through CASP9 activity, especially for the proper operation of the Atg8-family conjugation system and autophagosome closure and maturation.Abbreviations: AA: amino acid; ACD: autophagic cell death; ACTB: actin beta; ANXA5: annexin A5; APAF1: apoptotic peptidase activating factor 1; Atg: autophagy related; ATG16L1: autophagy related 16 like 1; BafA1: bafilomycin A1; BCL2: BCL2 apoptosis regulator; BECN1: beclin 1; CARD: caspase recruitment domain containing; CASP: caspase; CM-H2DCFDA: chloromethyl-2",7"-dichlorodihydrofluorescein diacetate; Deltapsim: mitochondrial membrane potential; DN: dominant-negative; DNM1L/DRP1: dynamin 1 like; EBSS: Earle"s balanced salt solution; GABARAP: GABA type A receptor-associated protein; GABARAPL1: GABA type A receptor associated protein like 1; GABARAPL2: GABA type A receptor associated protein like 2; HCN: hippocampal neural stem cells; IAM: inner autophagosome membrane; INS: insulin; KO: knockout; LEHD: Z-LEHD-fmk; MAP1LC3: microtubule associated protein 1 light chain 3; MFN1: mitofusin 1; MFN2: mitofusin 2; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP1: poly(ADP-ribose) polymerase 1; PBS: phosphate-buffered saline; PE: phosphatidylethanolamine; ROS: reactive oxygen species; sgRNA: single guide RNA; SR-SIM: super-resolution structured illumination microscopy; SQSTM1: sequestosome 1; STS: staurosporine; STX17: syntaxin 17; TMRE: tetramethylrhodamine ethyl ester; TUBB: tubulin beta class I; ULK1: unc-51 like autophagy activating kinase 1; WT: wild type; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1.	Sirolimus	1168-1177	cartilage associated protein	Homo sapiens	86-90
32599128-7	2020	Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	97-103
31590614-10	2020	Abbreviations PknB Protein Kinase B mTOR Mammalian target of Rapamycin OPLS Optimized potential for liquid simulations RMSD root mean square deviation RMSF root mean square fluctuation MMGB/SA Molecular Mechanics generalized Born and surface area XP Extra Precision SP Simple Precision DFT Density Functional Theory SPC Simple point charge HOMO Highest occupied molecular orbital LUMO Lowest unoccupied molecular orbital ESP electrostatic potential ALIE Average local ionization energy B3LYP Becke 3-parameter Lee-Yang-Parr Communicated by Ramaswamy H. Sarma.	Sirolimus	61-70	protein tyrosine kinase 2 beta	Homo sapiens	19-35
32800663-10	2020	PD-L1 expression was suppressed significantly when the HIF-1alpha inhibitor rapamycin was added to the culture medium (P = .024).	Sirolimus	76-85	CD274 molecule	Rattus norvegicus	0-5
35136953-7	2022	Nprl3 knockout in vitro caused mTOR pathway hyperactivation, cell soma enlargement, and the formation of cellular aggregates seen in time-lapse videos that were prevented with the mTOR inhibitors rapamycin or torin1.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Mus musculus	180-184
35136953-9	2022	To model human malformations of cortical development associated with NPRL3 variants, we created a focal Nprl3 KO in fetal mouse cortex by in utero electroporation and found altered cortical lamination and white matter heterotopic neurons, effects which were prevented with rapamycin treatment.	Sirolimus	273-282	NPR3 like, GATOR1 complex subunit	Homo sapiens	104-109
35132962-6	2022	Angiotensin II activates mTOR signaling in vascular wall cells, and inhibition of mTOR signaling by rapamycin prevents aortic rupture but promotes dissection.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Mus musculus	25-29
35132962-6	2022	Angiotensin II activates mTOR signaling in vascular wall cells, and inhibition of mTOR signaling by rapamycin prevents aortic rupture but promotes dissection.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Mus musculus	82-86
35135573-12	2022	Abnormal lipid accumulation, changes of gene expression profile and upregulation of multi-component mechanistic target of rapamycin complex 1 (mTOR)/Peroxisome proliferator-activated receptor-gamma pathway was observed in liver, accompanied with decreased bile acids level, unsaturated fatty acids androgens and prostaglandins in serum.	Sirolimus	122-131	mechanistic target of rapamycin kinase	Mus musculus	143-147
35187108-8	2021	Combined with intraperitoneal injection of rapamycin, the effect of autophagy on AOPP-induced p53 SUMOylation was also confirmed in vivo.	Sirolimus	43-52	transformation related protein 53, pseudogene	Mus musculus	94-97
32601986-4	2020	OBJECTIVE: Here, we tested whether different timepoints of vulnerability to rapamycin, a first generation mTOR complex 1 inhibitor, exist for contextual fear memory consolidation and persistence.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Mus musculus	106-110
32878322-3	2020	Targeting 786-O cells by SH-859 inhibited cell growth and affected the protein kinase B/mechanistic target of rapamycin 1 pathway, which in turn downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, as well as other signaling proteins.	Sirolimus	110-119	protein tyrosine kinase 2 beta	Homo sapiens	71-87
32851082-0	2020	Rapamycin Inhibited Pyroptosis and Reduced the Release of IL-1beta and IL-18 in the Septic Response.	Sirolimus	0-9	interleukin 1 alpha	Homo sapiens	58-66
35228901-5	2022	Rapamycin and tamoxifen induce sequential dimerization of FKBP and FRB, cleavage of CreER from the membrane, and translocation into the nucleus.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	58-62
35044284-6	2022	Mechanistically, we found elevated phosphorylation of AKT and two downstream effectors of mammalian target of Rapamycin complex 1 (mTORC1), S6 and 4E-Binding Protein 1 (4EBP1) after Rasal2 overexpression in hypoxia-challenged PASMC.	Sirolimus	110-119	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	169-174
35174167-4	2021	ARHGEF3 also binds the mammalian target of rapamycin complex 2 (mTORC2) and subsequently inhibits mTORC2 and Akt.	Sirolimus	43-52	Rho guanine nucleotide exchange factor 3	Homo sapiens	0-7
34874016-9	2022	On the other hand, rapamycin abolished the effects of T-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/ S6K1/4EBP1 signaling pathway in a concentration-dependent manner.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	183-187
34874016-9	2022	On the other hand, rapamycin abolished the effects of T-induced cardiac hypertrophy, decreased the systolic and diastolic blood pressure of SHR, and inhibited the activation of mTOR/ S6K1/4EBP1 signaling pathway in a concentration-dependent manner.	Sirolimus	19-28	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	188-193
32851082-8	2020	This study shows that RAPA abrogates LPS-mediated increase in IL-1beta and IL-18 by inhibiting pyroptosis and enhancing autophagy.	Sirolimus	22-26	interleukin 1 alpha	Homo sapiens	62-70
35159256-11	2022	These results indicate that PROX1 plays a key role in the anti-proliferative effect of rapamycin and suggest that the increased PROX1 by MTOR inhibition can be used as a useful marker for predicting whether HCC cells can be affected by rapamycin.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Mus musculus	137-141
32553594-10	2020	In addition, Cyld gene gain- and/or loss-of-function approaches in vitro and in vivo demonstrated that CYLD mediated cardiomyocyte death associated with impaired reactivation of mechanistic target of rapamycin complex 1 (mTORC1) and upregulated Ras genes from rat brain 7 (Rab7), two key components for autolysosomal degradation.	Sirolimus	200-209	CYLD lysine 63 deubiquitinase	Rattus norvegicus	13-17
32553594-10	2020	In addition, Cyld gene gain- and/or loss-of-function approaches in vitro and in vivo demonstrated that CYLD mediated cardiomyocyte death associated with impaired reactivation of mechanistic target of rapamycin complex 1 (mTORC1) and upregulated Ras genes from rat brain 7 (Rab7), two key components for autolysosomal degradation.	Sirolimus	200-209	CYLD lysine 63 deubiquitinase	Rattus norvegicus	103-107
35208186-12	2022	Inhibition of mTOR by rapamycin prevents and corrects the increased parathyroid cell proliferation of SHP.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
35128864-16	2022	No significant differences were found between the rapamycin and EA groups in the abovementioned indexes (P>0.05) except p-mTOR and mTOR which were higher in the EA group (P<0.01).	Sirolimus	50-59	mechanistic target of rapamycin kinase	Mus musculus	122-126
32482409-6	2020	XNJ treatment also activated the AKT/mechanistic target of rapamycin (mTOR) pathway, while inhibition of the mTOR pathway by rapamycin could reverse the protective effects of XNJ treatment.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	70-74
35058778-10	2021	Compared with MgIG treatment, activation of autophagy by RAPA also promoted the expression of liver inflammation markers (IL-1beta, IL-6, TNF-alpha, CXCL-1, CXCL-2, CXCL-10, etc.)	Sirolimus	57-61	interleukin 1 alpha	Mus musculus	122-130
35078569-3	2022	The role of signaling pathways was investigated by TLR4 inhibitor TAK-242 and mTOR inhibitor rapamycin.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Mus musculus	78-82
32592088-6	2020	This phenomenon was accompanied by upregulated Skp2 and downregulated p27kip1 expression and was abolished by rapamycin, an inhibitor of mTOR.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Mus musculus	137-141
33949020-11	2021	Mechanistically, the deletion of Setd2 resulted in the activation of AKT/mTOR signalling pathway, while the pharmacological inhibition of AKT and mTOR with MK2206 and rapamycin, respectively, delayed wound closure.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Mus musculus	146-150
32820673-6	2020	Conclusion: Rapa-SLN approximately 200 nm allows efficient entry of rapamycin into the lymphatic system and is therefore a promising treatment for LAM patients.	Sirolimus	68-77	sarcolipin	Homo sapiens	17-20
34003330-7	2021	Mechanistically, LKB1 directly binds and phosphorylates phosphatase and tensin homolog (PTEN), an upstream regulator of mammalian target of rapamycin complex 1 (mTORC1), which is independent of AMP-activated protein kinase (AMPK).	Sirolimus	140-149	serine/threonine kinase 11	Homo sapiens	17-21
34003330-7	2021	Mechanistically, LKB1 directly binds and phosphorylates phosphatase and tensin homolog (PTEN), an upstream regulator of mammalian target of rapamycin complex 1 (mTORC1), which is independent of AMP-activated protein kinase (AMPK).	Sirolimus	140-149	phosphatase and tensin homolog	Homo sapiens	88-92
32696949-7	2020	RT-qPCR results showed IL-1beta significantly increased the level of caspase-3 expression, but it was significantly decreased by using RES, RAPA and SB216763 respectively attenuate effects of RES.	Sirolimus	140-144	interleukin 1 alpha	Homo sapiens	23-31
33988501-7	2021	In mice, rapamycin treatment increases expression of histone proteins and Wdfy3 transcription, and alters chromatin organisation in the small intestine, suggesting the mTORC1-histone axis is at least partially conserved in mammals and may offer new targets for anti-ageing interventions.	Sirolimus	9-18	WD repeat and FYVE domain containing 3	Mus musculus	74-79
32720643-1	2020	Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongly in females than males, perhaps because inhibition of hepatic mTORC2 (mTOR Complex 2) specifically reduces the lifespan of males.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Mus musculus	14-18
32720643-1	2020	Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongly in females than males, perhaps because inhibition of hepatic mTORC2 (mTOR Complex 2) specifically reduces the lifespan of males.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Mus musculus	20-51
33978540-5	2021	Remarkably, downregulation of subunits of V-ATPase, of Pdk1, or of the Tor (Target of rapamycin) complex 1 (TORC1) component raptor prevents overgrowth and normalize ref(2)P levels.	Sirolimus	86-95	Target of rapamycin	Drosophila melanogaster	71-74
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	81-85
34054807-15	2021	Rapamycin inhibits microglial priming triggered by BAFF through targeting the mTOR/HIF-1alpha signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	78-82
34054807-15	2021	Rapamycin inhibits microglial priming triggered by BAFF through targeting the mTOR/HIF-1alpha signaling pathway.	Sirolimus	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	83-93
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	interleukin 13 receptor subunit alpha 1	Homo sapiens	182-194
32922169-6	2020	The current study showed that IL-13 increased the expression levels of p-mTOR, p-S6K1, and p-Akt, and that rapamycin blocked IL-13-induced down-regulation of miR-143, suppressed the IL-13Ralpha1 expression and up-regulated the expressions of filaggrin, loricrin, and involucrin in HaCaT cells.	Sirolimus	107-116	filaggrin	Homo sapiens	242-251
32562599-5	2020	Upon RPM depletion, red pulp fibroblasts transiently produced the monocyte chemoattractants CCL2 and CCL7, thereby contributing to the replenishment of the RPM network.	Sirolimus	5-8	C-C motif chemokine ligand 2	Homo sapiens	92-96
33947426-7	2021	Rapamycin did not protect against DHEA-induced acyclicity and PCO morphology, but impeded follicle development and elevated serum testosterone levels in DHEA-induced mice, which was related with suppressed Hsd3b1, Cyp17a1, and Cyp19a1 expression.	Sirolimus	0-9	cytochrome P450, family 17, subfamily a, polypeptide 1	Mus musculus	214-221
33938392-3	2021	We also show that this interaction is sufficient to overcome rapamycin sensitivity and mTORC1 dependence of S6K1.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Homo sapiens	108-112
33948869-5	2022	Moreover, enhanced activation of protein kinase B/mammalian target of rapamycin complex 1 signaling observed in the muscle tissue of strain CAS III in comparison to that in strain DT indicated elevated anabolic metabolism in strain CAS III.	Sirolimus	70-79	protein tyrosine kinase 2 beta	Homo sapiens	33-49
33910008-1	2021	Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits.	Sirolimus	82-91	phosphatase and tensin homolog	Homo sapiens	183-213
33910008-1	2021	Recent studies have demonstrated that selective activation of mammalian target of rapamycin complex 1 (mTORC1) in the cerebellum by deletion of the mTORC1 upstream repressors TSC1 or phosphatase and tensin homolog (PTEN) in Purkinje cells (PCs) causes autism-like features and cognitive deficits.	Sirolimus	82-91	phosphatase and tensin homolog	Homo sapiens	215-219
33857304-4	2021	In this work, we show that the C-terminal Gln3-Tor1 interaction site is required for wild type, rapamycin-elicited, Sit4-dependent nuclear Gln3 localization, but not for its dephosphorylation.	Sirolimus	96-105	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	42-46
33857304-4	2021	In this work, we show that the C-terminal Gln3-Tor1 interaction site is required for wild type, rapamycin-elicited, Sit4-dependent nuclear Gln3 localization, but not for its dephosphorylation.	Sirolimus	96-105	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	116-120
33857304-4	2021	In this work, we show that the C-terminal Gln3-Tor1 interaction site is required for wild type, rapamycin-elicited, Sit4-dependent nuclear Gln3 localization, but not for its dephosphorylation.	Sirolimus	96-105	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	139-143
33857304-10	2021	Substituting phosphomimetic aspartate for serine/threonine residues in the Gln3 URS abolishes the N-terminal Gln3-Tor1 interaction, rapamycin-elicited nuclear Gln3 localization, and 1/2 of the derepressed levels of nuclear Gln3 localization.	Sirolimus	132-141	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	75-79
33857304-10	2021	Substituting phosphomimetic aspartate for serine/threonine residues in the Gln3 URS abolishes the N-terminal Gln3-Tor1 interaction, rapamycin-elicited nuclear Gln3 localization, and 1/2 of the derepressed levels of nuclear Gln3 localization.	Sirolimus	132-141	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	109-113
32562599-5	2020	Upon RPM depletion, red pulp fibroblasts transiently produced the monocyte chemoattractants CCL2 and CCL7, thereby contributing to the replenishment of the RPM network.	Sirolimus	156-159	C-C motif chemokine ligand 2	Homo sapiens	92-96
33857304-10	2021	Substituting phosphomimetic aspartate for serine/threonine residues in the Gln3 URS abolishes the N-terminal Gln3-Tor1 interaction, rapamycin-elicited nuclear Gln3 localization, and 1/2 of the derepressed levels of nuclear Gln3 localization.	Sirolimus	132-141	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	109-113
33857304-10	2021	Substituting phosphomimetic aspartate for serine/threonine residues in the Gln3 URS abolishes the N-terminal Gln3-Tor1 interaction, rapamycin-elicited nuclear Gln3 localization, and 1/2 of the derepressed levels of nuclear Gln3 localization.	Sirolimus	132-141	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	109-113
32484794-4	2020	Injection of rapamycin to pregnant mice inhibited the mTOR pathway and tubular cell proliferation in kidneys of TSC1 null offspring.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	54-58
32635337-0	2020	A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.	Sirolimus	48-57	met proto-oncogene	Mus musculus	80-85
32635337-1	2020	The mTOR inhibitor Rapamycin has tumor inhibitory properties; and it is also used as an immunosuppressive agent after organ transplantation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
32635337-6	2020	We observed that compared with Rapamycin alone, Rapamycin + Honokiol combination can effectively down-regulate c-Met-induced Akt phosphorylation in renal cancer cells; and it markedly inhibited Ras activation and cell proliferation and promoted G1 phase cell cycle arrest.	Sirolimus	48-57	met proto-oncogene	Mus musculus	111-116
32614880-2	2020	The aim of this study was to determine the effect of rumen-protected methionine (RPM) supplementation on a proposed gene network for muscle fatigue, creatine synthesis (CKM), and reactive oxygen species (ROS) metabolism after a transportation simulation in a test track.	Sirolimus	81-84	creatine kinase, M-type	Bos taurus	169-172
32167156-11	2020	As expected, DMSO-induced wound healing and cell proliferation were impaired by rapamycin, an inhibitor of AKT/mTOR signalling.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Mus musculus	111-115
32422433-4	2020	Application of drugs that target either calcineurin (cyclosporine A) or FKBP12 (tacrolimus known as FK506 and sirolimus known as rapamycin) caused a decrease in TMEM16A activity.	Sirolimus	110-119	anoctamin 1	Homo sapiens	161-168
32422433-4	2020	Application of drugs that target either calcineurin (cyclosporine A) or FKBP12 (tacrolimus known as FK506 and sirolimus known as rapamycin) caused a decrease in TMEM16A activity.	Sirolimus	129-138	anoctamin 1	Homo sapiens	161-168
32422433-7	2020	Rapamycin decreased TMEM16A activity in cells pre-treated with cyclosporine A or FK506.	Sirolimus	0-9	anoctamin 1	Homo sapiens	20-27
32536994-6	2020	The plasma transforming growth factor-beta (TGF-beta) concentration in the rapamycin-treated group was significantly higher compared with the placebo group.	Sirolimus	75-84	transforming growth factor alpha	Mus musculus	44-52
32536994-9	2020	Rapamycin showed better immune suppressive effects than MP in this model of EAM, and these effects were likely to be mediated by the TGF-beta signaling pathway.	Sirolimus	0-9	transforming growth factor alpha	Mus musculus	133-141
32510855-12	2020	Moreover, suppression of autophagy reduced intestinal damage and inhibition of mTOR by rapamycin aggravated intestinal damage following intestinal I/R.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Mus musculus	79-83
32495180-9	2020	Furthermore, the antidepressant action of crocin was blunted after blockade of mTOR signaling with the antagonist rapamycin.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Mus musculus	79-83
32576681-7	2020	Inhibiting mTOR with rapamycin suppressed the growth of subcutaneous MET-mutant cell grafts in mice, including that of MET inhibitor-resistant cells.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Mus musculus	11-15
32569299-8	2020	We created a genetically modified parasite with a rapamycin-inducible functional deletion of uba1; addition of either MLN7243 or rapamycin to the recombinant parasite line resulted in the same phenotype, with parasite development blocked at the schizont stage.	Sirolimus	50-59	ubiquitin like modifier activating enzyme 1	Homo sapiens	93-97
33860440-8	2021	The diabetic mouse model induced by a high-fat diet combined with streptozotocin injection was administrated with rapamycin (mTOR inhibitor) and PDTC (NF-kappaB inhibitor), respectively.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Mus musculus	125-129
33912444-0	2021	Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRalpha-Positive Breast Cancer.	Sirolimus	0-9	BCR pseudogene 1	Homo sapiens	22-26
32207633-6	2021	In an ependymoma mouse xenograft model, MTOR inhibition by rapamycin therapeutically suppressed TPR expression and reduced tumor size in vivo.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	40-44
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	ribosomal protein S6 kinase B1	Homo sapiens	36-40
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	insulin receptor substrate 1	Homo sapiens	92-97
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	insulin receptor substrate 1	Homo sapiens	155-160
33422633-8	2021	Interestingly, inhibition of mTORC1-S6K1 pathway using rapamycin significantly restored the IRS-1/Akt/eNOS activation, suggesting a feedback regulation of IRS-1/Akt signal through S6K1.	Sirolimus	55-64	ribosomal protein S6 kinase B1	Homo sapiens	180-184
33540491-5	2021	We also found that LPAR5 specific antagonists TC LPA5 4, PI3K inhibitor Wortmannin or mTOR inhibitor Rapamycin pretreatment abrogated phosphorylation of Akt and p70S6K1 stimulated by LPA in CGTH-W3 and TPC-1 cells.	Sirolimus	101-110	lysophosphatidic acid receptor 5	Homo sapiens	19-24
33609723-9	2021	Moreover, the results showed that mitoQ and RAPA, in turn, elevated SIRT1 activity by inhibiting DNA damage.	Sirolimus	44-48	sirtuin 1	Mus musculus	68-73
33244735-5	2021	Additionally, we found that GluA1 levels decreased and GluA2 levels increased at the hippocampal postsynaptic density subcellular fraction of rapamycin-infused animals during memory retrieval.	Sirolimus	142-151	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	28-33
33383488-0	2021	Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	112-116
32636835-2	2020	HMGB1 binds to its specific receptors not only to activate the nuclear factor (NF)-kappaB and mitogen-activated protein kinase (MAPK) pathways but also to regulate the activation of the phosphatidylinositol 3"-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/AKT/mTOR) pathway.	Sirolimus	258-267	protein tyrosine kinase 2 beta	Homo sapiens	217-233
32666017-4	2020	One key complex that regulates beta-catenin activity is the mammalian target of rapamycin complex 2 (mTORc2).	Sirolimus	80-89	catenin beta 1	Homo sapiens	31-43
32366581-9	2020	GPA33high Treg cells universally express the transcription factor Helios that preferentially marks tTreg cells and can robustly and stably be expanded in vitro even without rapamycin.	Sirolimus	173-182	glycoprotein A33	Homo sapiens	0-5
32518311-3	2020	Peritransplant CD154 mAb/rapamycin (RPM) induced long-term orthotopic hindlimb VCA survival (BALB/c->C57BL/6), as did CTLA4Ig/RPM.	Sirolimus	25-34	CD40 ligand	Mus musculus	15-20
32518311-3	2020	Peritransplant CD154 mAb/rapamycin (RPM) induced long-term orthotopic hindlimb VCA survival (BALB/c->C57BL/6), as did CTLA4Ig/RPM.	Sirolimus	36-39	CD40 ligand	Mus musculus	15-20
32488108-10	2020	The mTOR inhibitor rapamycin inhibited AP-induced DC-SIGN expression, CD4+ Th1/Th17 cell differentiation and the pro-inflammatory response via Myc.	Sirolimus	19-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	143-146
31441382-8	2020	Rapamycin rescued the effect of Atg5 siRNA in Ppargc1a+/+, but not in ppargc1a-/- VSMCs, suggesting that other targets of MTOR (mechanistic target of rapamycin kinase), in addition to autophagy, also contribute to senescence.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	122-126
31904150-5	2020	Additionally, mTOR inhibition with rapamycin in differentiating OPCs alters the transcriptional complex present at the Id2 promoter.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Mus musculus	14-18
32154791-7	2020	Deletion of iNKT cells in Cd1d-/- mice or inhibition of mTOR by rapamycin reduced immunosuppression and susceptibility to secondary Candida infection.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Mus musculus	56-60
33758188-8	2021	Treatment with an mTOR inhibitor rapamycin ameliorates aberrant expansion of the HSC compartment as well as dysregulated hematopoiesis in aged ASXL1-MT KI mice.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	18-22
33758188-8	2021	Treatment with an mTOR inhibitor rapamycin ameliorates aberrant expansion of the HSC compartment as well as dysregulated hematopoiesis in aged ASXL1-MT KI mice.	Sirolimus	33-42	ASXL transcriptional regulator 1	Mus musculus	143-148
32299030-8	2020	Moreover, increased Bcl-2 and Bax levels were observed after treatment with an agonist (rapamycin) and antagonist (3MA) of autophagy in high-glucose-cultured cells.	Sirolimus	88-97	BCL2 associated X, apoptosis regulator	Rattus norvegicus	30-33
32331968-5	2020	We then tested the impact of the mTOR inhibitor rapamycin, which dramatically attenuates LS in Ndufs4(KO), on region specific metabolism.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Mus musculus	33-37
32331968-5	2020	We then tested the impact of the mTOR inhibitor rapamycin, which dramatically attenuates LS in Ndufs4(KO), on region specific metabolism.	Sirolimus	48-57	NADH:ubiquinone oxidoreductase subunit S4	Homo sapiens	95-101
32173556-7	2020	We found that in the E4FAD mice, rapamycin normalized bodyweight, restored CBF (especially in female), BBB activity for Abeta transport, neurotransmitter levels, neuronal integrity and free fatty acid level, and reduced Abeta retention, which were not observe in the E3FAD-Rapa mice.	Sirolimus	33-42	amyloid beta (A4) precursor protein	Mus musculus	120-125
32173556-7	2020	We found that in the E4FAD mice, rapamycin normalized bodyweight, restored CBF (especially in female), BBB activity for Abeta transport, neurotransmitter levels, neuronal integrity and free fatty acid level, and reduced Abeta retention, which were not observe in the E3FAD-Rapa mice.	Sirolimus	33-42	amyloid beta (A4) precursor protein	Mus musculus	220-225
32509933-8	2020	Furthermore Runx2+/- mice exhibited delayed and suppressed expression of mammalian target of rapamycin (mTOR) and rapamycin-insensitive companion of mTOR (Rictor), essential factors of mTORC2, which is regulated by Runx2 to phosphorylate Akt to regulate cell proliferation and differentiation, in osteoblasts on the tension side of tooth movement in vivo and in vitro.	Sirolimus	93-102	runt related transcription factor 2	Mus musculus	12-17
32459545-3	2021	Although injection of IL-2 complex alone was not capable of decreasing the clinical score of EAU, injection of IL-2 complex/rapamycin significantly delayed the onset of EAU.	Sirolimus	124-133	interleukin 2	Mus musculus	111-115
32448372-2	2020	Activin-A is a key molecule for initiating the process of HO via the activation of mTOR, while rapamycin, an mTOR inhibitor, effectively inhibits the Activin-A-induced HO.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Mus musculus	109-113
32444668-3	2020	In this study we questioned whether the mTOR inhibitor rapamycin (sirolimus) could attenuate the development and progression of glomerulosclerotic lesions in the anti-Thy1.1 transgenic mice.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	40-44
32444668-3	2020	In this study we questioned whether the mTOR inhibitor rapamycin (sirolimus) could attenuate the development and progression of glomerulosclerotic lesions in the anti-Thy1.1 transgenic mice.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Mus musculus	40-44
32444674-10	2020	AMPK inhibits mTOR, and the mTOR inhibitor rapamycin also decreases NaCT expression.	Sirolimus	43-52	solute carrier family 13 member 5	Homo sapiens	68-72
32434116-0	2020	Corrigendum to "Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation" [Mol.	Sirolimus	16-25	toll like receptor 4	Homo sapiens	37-41
33791391-8	2021	Further study found that MPC2 knockdown in CRC cell lines activated the mTOR signaling pathway, and the addition of rapamycin reversed the promoting effect of MPC2 knockdown on CRC proliferation and glycolysis.	Sirolimus	116-125	mitochondrial pyruvate carrier 2	Homo sapiens	159-163
32434116-0	2020	Corrigendum to "Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation" [Mol.	Sirolimus	16-25	toll like receptor 4	Homo sapiens	113-117
33694218-3	2021	Rheb is a small GTPase which, when bound to GTP, activates mechanistic target of rapamycin complex 1 (mTORC1), a protein kinase that drives anabolic processes including protein synthesis and ribosome biogenesis.	Sirolimus	81-90	GTP-binding protein Rheb	Cricetulus griseus	0-4
32098494-9	2020	Inhibiting mTOR activity by rapamycin blunted the neonatal CM proliferation induced by CHK1 overexpression in vitro.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	11-15
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	345-351
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	169-178	ribosomal protein S6 kinase B1	Homo sapiens	345-351
33050984-8	2021	ATV and RAPA+ATV decreased the levels of Tnf-alpha and Il-1beta in the spleen, but not in the aorta.	Sirolimus	8-12	interleukin 1 alpha	Mus musculus	55-63
33132009-8	2021	To address the question of cell types affected by chronic enteric rapamycin treatment, immunohistochemistry analyses demonstrated that crypt cells had a prominent reduction in rpS6 phosphorylation and increase in eEF2 phosphorylation relative controls.	Sirolimus	66-75	eukaryotic translation elongation factor 2	Mus musculus	213-217
33723462-8	2021	Moreover, we find that fasting-induced or genetic overexpression of FOXO4 and FKBP5 is sufficient to downregulate mammalian target of rapamycin complex 1 signalling and suppress signal transducer and activator of transcription 1/3 activation.	Sirolimus	134-143	forkhead box O4	Homo sapiens	68-73
33641344-5	2021	Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues.	Sirolimus	22-31	NFKB inhibitor alpha	Rattus norvegicus	137-150
33641344-7	2021	Concomitantly, rapamycin treatment reduced microglial activation, brain expression of caspase-3, and Bcl-2-associated X protein while increased expression of B-cell lymphoma 2 induced by LPS.	Sirolimus	15-24	BCL2 associated X, apoptosis regulator	Rattus norvegicus	101-127
33669763-3	2021	By combining molecular dynamics (MD) simulation and pharmacophore modelling, a simplified structure-based pharmacophore hypothesis was built starting from the FKBP12-rapamycin-FRB ternary complex retrieved from RCSB Protein Data Bank (PDB code 1FAP).	Sirolimus	166-175	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	159-165
33669763-8	2021	Furthermore, the stability of the resulting complexes was studied by means of MD simulation which revealed that the selected compounds were able to form a stable ternary complex with FKBP12 and FRB domain, thus underlining their potential ability to inhibit mTOR with a rapamycin-like mechanism.	Sirolimus	270-279	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	183-189
33412209-9	2021	Furthermore, PDGF-BB-stimulated VSMC proliferation, migration and proliferating cell nuclear antigen (PCNA) expression were inhibited by U0126 and rapamycin.	Sirolimus	147-156	proliferating cell nuclear antigen	Homo sapiens	66-100
33614662-0	2021	Rapamycin Protects Skin Fibroblasts From UVA-Induced Photoaging by Inhibition of p53 and Phosphorylated HSP27.	Sirolimus	0-9	heat shock protein family B (small) member 1	Homo sapiens	104-109
33614662-5	2021	In addition, treatment with rapamycin significantly increased cell autophagy levels, decreased the expression of p53 and phosphorylated HSP27, and reduced genotoxic and oxidative cellular stress levels in UVA-induced HDFs.	Sirolimus	28-37	heat shock protein family B (small) member 1	Homo sapiens	136-141
33603645-10	2021	Moreover, EA treatment at 24 h after ischaemic stroke obviously suppressed the expression of CCAS3, LC3II/I, Beclin1 while increasing the level of P62 and LAMP1 and hence mediating autophagy, which was reversed by RAP.	Sirolimus	214-217	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	100-107
33603645-10	2021	Moreover, EA treatment at 24 h after ischaemic stroke obviously suppressed the expression of CCAS3, LC3II/I, Beclin1 while increasing the level of P62 and LAMP1 and hence mediating autophagy, which was reversed by RAP.	Sirolimus	214-217	lysosomal-associated membrane protein 1	Rattus norvegicus	155-160
33338748-0	2021	Tumor Susceptibility Gene 101 facilitates rapamycin-induced autophagic flux in neuron cells.	Sirolimus	42-51	tumor susceptibility 101	Homo sapiens	0-29
33338748-6	2021	Our results showed that TSG101 expression was slightly increased in neuron cells when exposed to rapamycin.	Sirolimus	97-106	tumor susceptibility 101	Homo sapiens	24-30
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	0-9	tumor susceptibility 101	Homo sapiens	80-86
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	0-9	tumor susceptibility 101	Homo sapiens	119-125
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	141-150	tumor susceptibility 101	Homo sapiens	80-86
33338748-8	2021	Rapamycin-elevated MAP1LC3-II turnover and RFP+Wasabi- puncta were repressed in TSG101 silenced cells, indicating that TSG101 is involved in rapamycin-induced autophagic flux in cells.	Sirolimus	141-150	tumor susceptibility 101	Homo sapiens	119-125
33338748-10	2021	Taken together, our results suggested that TSG101 might be required for amphisome formation to promote autophagic flux in neuron cells when exposed to rapamycin.	Sirolimus	151-160	tumor susceptibility 101	Homo sapiens	43-49
32457486-4	2021	Both the classical autophagy inducer rapamycin and the classical ferroptosis activator RSL3 can block MTOR activation and cause GPX4 protein degradation in human pancreatic cancer cells.	Sirolimus	37-46	glutathione peroxidase 4	Homo sapiens	128-132
32457486-5	2021	Moreover, GPX4 plays an essential role in the inhibition of autophagy-dependent ferroptosis induced by rapamycin and RSL3.	Sirolimus	103-112	glutathione peroxidase 4	Homo sapiens	10-14
32457486-6	2021	Consequently, GPX4 depletion by RNAi enhances the anticancer activity of rapamycin and RSL3 in vitro or in vivo.	Sirolimus	73-82	glutathione peroxidase 4	Homo sapiens	14-18
33347856-7	2021	And the apoptosis of rapamycin-induced endothelial cells loaded with MSC-derived exosomes was detected using TUNEL and Annexin-V FITC and PI double-staining assays.	Sirolimus	21-30	annexin A5	Homo sapiens	119-128
33352197-0	2021	Rapamycin ameliorates corneal injury after alkali burn through methylation modification in mouse TSC1 and mTOR genes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	106-110
33352197-5	2021	The results showed that, after an intraperitoneal injection of rapamycin (2 mg/kg/day) for seven days, the alkali-induced opacity and NV were remarkably decreased mainly by suppressing the infiltration of immune cells into injured corneas, angiogenesis, VEGF expression and myofibroblasts differentiation; as well as by promoting corneal cell proliferation and PI3K/AKT/mTOR signaling.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Mus musculus	370-374
33352197-6	2021	More significantly, these findings showed that epigenetic regulatory mechanisms by DNA methylation played a key role in corneal NV, including in corneal alkali burn-induced methylation modification and rapamycin-induced DNA demethylation which involved the regulation of the PI3K/AKT/mTOR signaling pathway at the protein level.	Sirolimus	202-211	mechanistic target of rapamycin kinase	Mus musculus	284-288
33462182-11	2021	Meanwhile, PI3K inhibitor (LY294002) and mTOR inhibitor (rapamycin) cooperated with ATO to induce autophagy.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Mus musculus	41-45
33450223-8	2021	Of note, the autophagy activator rapamycin (RAP) ablated the positive effects of 1,25D in diabetic environment, leading to a marked increase in autolysosomes and autophagosomes, examined by mRFP-GFP-LC3 fluorescence double labeling.	Sirolimus	33-42	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	199-202
33419207-8	2021	Whereas RICTOR (rapamycin independent companion of mammalian target of rapamycin) was predicted to be inhibited in both WB and FE datasets, the predictions were based on different downstream molecules.	Sirolimus	16-25	RPTOR independent companion of MTOR complex 2	Homo sapiens	8-14
33402188-17	2021	RAPA and BBG inhibited the activation of microglia, limited the inflammatory response, and reduced the expression of CGRP and c-fos.	Sirolimus	0-4	FBJ osteosarcoma oncogene	Mus musculus	126-131
32942336-9	2021	Additionally, clusterin overexpression repressed LC3 and Beclin-1 expression, reduced the LC3II/LC3I ratio and promoted p62 expression in GC-1 spg cells in the presence of high glucose, and these effects were all mitigated by rapamycin treatment.	Sirolimus	226-235	clusterin	Mus musculus	14-23
32384544-7	2020	To protect against potential toxicity from engineered NK cells, an orthogonal rapamycin-regulated Caspase-9 (iRC9) was included in a 4-gene, dual-switch platform.	Sirolimus	78-87	caspase 9	Homo sapiens	98-107
32454908-8	2020	Finally, we identified Semustine and Sirolimus as two candidate compounds for the treatment of EC based on CMap analysis.	Sirolimus	37-46	cystatin F	Homo sapiens	107-111
32141263-11	2020	Inhibition of IL-17A via the mTOR pathway using rapamycin also attenuated NP formation and inflammation in the murine NP model.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Mus musculus	29-33
33618532-10	2021	RESULTS: In our study, serum MCP-1 levels were significantly higher in cyclosporine and tacrolimus groups than in sirolimus (p<0.05).	Sirolimus	114-123	C-C motif chemokine ligand 2	Homo sapiens	29-34
33362225-4	2020	In our study we monitor the stability of Atg32 protein in the yeast S. cerevisiae and show that Atg32 is degraded under normal growth conditions, upon starvation or rapamycin treatment.	Sirolimus	165-174	mitophagy protein ATG32	Saccharomyces cerevisiae S288C	41-46
33362225-4	2020	In our study we monitor the stability of Atg32 protein in the yeast S. cerevisiae and show that Atg32 is degraded under normal growth conditions, upon starvation or rapamycin treatment.	Sirolimus	165-174	mitophagy protein ATG32	Saccharomyces cerevisiae S288C	96-101
31663119-8	2020	miR-574-5p repressed the phosphorylation of members of protein kinase B (AKT)-mammalian target of rapamycin pathway via downregulating MAP3K9 and AKT3, resulting in reducing the secretion of beta-casein and triglycerides in GMECs.	Sirolimus	98-107	mitogen-activated protein kinase kinase kinase 9	Homo sapiens	135-141
33307758-8	2021	These findings were associated with an increase in ERK, Akt, and mTOR phosphorylation, whereas autophagy induction through mTOR/p70S6K inhibition by rapamycin significantly suppressed NO-induced cell apoptosis.	Sirolimus	149-158	ribosomal protein S6 kinase B1	Homo sapiens	128-134
31635678-10	2020	Meanwhile, the JAK2 or STAT inhibitors AG490 and rapamycin, but not Ruxolitinib, exhibited a similar but even greater JAK2 and STAT3 regulatory effect, thus leading to a greater benefit.	Sirolimus	49-58	signal transducer and activator of transcription 3	Rattus norvegicus	127-132
33022268-14	2020	The administration of rapamycin (mTOR inhibitor, 0.2 nmol/site, i.c.v.)	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	33-37
33022268-16	2020	Creatine or ketamine-treated mice presented increased hippocampal BDNF level, an effect abolished by rapamycin.	Sirolimus	101-110	brain derived neurotrophic factor	Mus musculus	66-70
32781001-9	2020	AA levels and rapamycin differentially modulate S6 and 4E-BP1 phosphorylation and mTOR lysosomal localization in neurons following Tsc2 KO versus Depdc5 KO.	Sirolimus	14-23	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	55-61
32781001-9	2020	AA levels and rapamycin differentially modulate S6 and 4E-BP1 phosphorylation and mTOR lysosomal localization in neurons following Tsc2 KO versus Depdc5 KO.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	82-86
32781001-9	2020	AA levels and rapamycin differentially modulate S6 and 4E-BP1 phosphorylation and mTOR lysosomal localization in neurons following Tsc2 KO versus Depdc5 KO.	Sirolimus	14-23	TSC complex subunit 2	Mus musculus	131-135
32888957-13	2020	Rapamycin promoted OGD/R-induced decrease in cell viability and counteracted NOD1 silencing-induced increase in cell viability.	Sirolimus	0-9	nucleotide-binding oligomerization domain containing 1	Rattus norvegicus	77-81
33329339-9	2020	The expression of Gas6, Tyro3, Axl, Mer, SOCS1, and SOCS3 were decreased in EAE mice at 21 days post-immunization, while the expression of Gas6, Tyro3, Axl, and Mer in rapamycin group was higher than that in EAE group.	Sirolimus	168-177	growth arrest specific 6	Mus musculus	18-22
33259779-7	2021	Furthermore, AKT inhibitor (MK-2206) or mTOR inhibitor (Rapamycin) inhibited the proliferation of c-Myc overexpressing gastric cancer cell lines.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	40-44
33312358-12	2020	PI3K, p-AKT1, p-mTOR, p-p70S6K and caspase-3 were down-regulated by rapamycin and beta-ecdysterone, and up-regulated by 3-methyladenine in both the chondrocytes and the cartilage tissues.	Sirolimus	68-77	ribosomal protein S6 kinase B1	Rattus norvegicus	24-30
33159078-1	2020	Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in tuberous sclerosis complex (TSC1/TSC2) genes coding for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	208-217	TSC complex subunit 2	Mus musculus	144-148
33159078-6	2020	Mesenchymal-restricted deletion of Tsc2 in the mouse lung produces a mTORC1-driven pulmonary phenotype, with a progressive disruption of alveolar structure, a decline in pulmonary function, increase of rapamycin-sensitive expression of WNT ligands, and profound female-specific changes in mesenchymal and epithelial lung cell gene expression.	Sirolimus	202-211	TSC complex subunit 2	Mus musculus	35-39
33140703-7	2022	The five anti-N drugs studied in this work are 4E1RCat, Silmitasertib, TMCB, Sapanisertib, and Rapamycin.	Sirolimus	95-104	nucleocapsid phosphoprotein	Severe acute respiratory syndrome coronavirus 2	14-15
33030400-0	2021	Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence.	Sirolimus	0-9	deoxyribonucleoside kinase	Drosophila melanogaster	95-97
33030400-8	2021	In therapeutic studies, low doses of rapamycin, a known autophagy inducer that significantly promotes endometrium autophagy and NK cell residence, and improves embryo absorption in spontaneous abortion mice models, which should be dependent on the activation of MITF-TNFRSF14/HVEM-MMP9-adhension molecules axis.	Sirolimus	37-46	deoxyribonucleoside kinase	Drosophila melanogaster	128-130
33030400-8	2021	In therapeutic studies, low doses of rapamycin, a known autophagy inducer that significantly promotes endometrium autophagy and NK cell residence, and improves embryo absorption in spontaneous abortion mice models, which should be dependent on the activation of MITF-TNFRSF14/HVEM-MMP9-adhension molecules axis.	Sirolimus	37-46	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	267-275
33030400-8	2021	In therapeutic studies, low doses of rapamycin, a known autophagy inducer that significantly promotes endometrium autophagy and NK cell residence, and improves embryo absorption in spontaneous abortion mice models, which should be dependent on the activation of MITF-TNFRSF14/HVEM-MMP9-adhension molecules axis.	Sirolimus	37-46	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)	Mus musculus	276-280
32841911-8	2020	Hence, a combined platform rapamycin encapsulated zeolitic imidazolate frameworks (Rapa@ZIF-8) was constructed and demonstrated a more significant chemo-sensitized effect relative to ZIF-8 nanoparticles or rapamycin treatment alone.	Sirolimus	27-36	transcriptional regulating factor 1	Mus musculus	83-93
32841911-8	2020	Hence, a combined platform rapamycin encapsulated zeolitic imidazolate frameworks (Rapa@ZIF-8) was constructed and demonstrated a more significant chemo-sensitized effect relative to ZIF-8 nanoparticles or rapamycin treatment alone.	Sirolimus	206-215	transcriptional regulating factor 1	Mus musculus	83-93
31738412-2	2020	We therefore investigated the infarct-limiting effect of chronic treatment with rapamycin (RAPA, mTOR inhibitor) in diabetic mice following myocardial ischemia/reperfusion (I/R) injury and delineated the potential protective mechanism.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Mus musculus	97-101
31738412-14	2020	Additionally, RAPA suppressed the pro-apoptotic prolyl hydroxylase (Egln3/PHD3), a target of miRNA-17/20a in diabetic hearts, which was abrogated in miRNA-17-92-deficient diabetic mice.	Sirolimus	14-18	egl-9 family hypoxia-inducible factor 3	Mus musculus	68-73
31738412-14	2020	Additionally, RAPA suppressed the pro-apoptotic prolyl hydroxylase (Egln3/PHD3), a target of miRNA-17/20a in diabetic hearts, which was abrogated in miRNA-17-92-deficient diabetic mice.	Sirolimus	14-18	egl-9 family hypoxia-inducible factor 3	Mus musculus	74-78
31738412-18	2020	This study provides a novel mechanism by which mTOR inhibition with chronic low-dose RAPA treatment induces protective effect against acute MI in diabetic mice.	Sirolimus	85-89	mechanistic target of rapamycin kinase	Mus musculus	47-51
32390471-3	2020	Abluminus DES+, a biodegradable polymer sirolimus-eluting stent deployed with a drug-coated balloon, has been specifically designed to provide adequate coverage for DM patients and reduce adverse clinical outcomes.	Sirolimus	40-49	desmin	Homo sapiens	10-13
32622856-2	2020	The original member of this family, FKBP12, is a well-known binding partner for the immunosuppressive drugs tacrolimus (FK506) and sirolimus (rapamycin).	Sirolimus	131-140	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	36-42
32622856-2	2020	The original member of this family, FKBP12, is a well-known binding partner for the immunosuppressive drugs tacrolimus (FK506) and sirolimus (rapamycin).	Sirolimus	142-151	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	36-42
31781847-7	2020	Administration of MEL + RAP produced the strongest effects on bone parameters and strength for distal femurs and regulation of OPG/RANKL signalling pathway-related gene expression.	Sirolimus	24-27	TNF receptor superfamily member 11B	Rattus norvegicus	127-130
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	synuclein, alpha	Mus musculus	201-210
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	beclin 1, autophagy related	Mus musculus	212-220
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	synuclein, alpha	Mus musculus	292-301
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	beclin 1, autophagy related	Mus musculus	303-311
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	synuclein, alpha	Mus musculus	276-285
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	beclin 1, autophagy related	Mus musculus	287-295
33097830-6	2020	Mechanistically, we find that L-arginine stimulates Wnt2b secretion by CD90+ stromal cells through the mammalian target of rapamycin complex 1 (mTORC1) and that blocking Wnt2b production prevents L-arginine-induced ISC expansion.	Sirolimus	123-132	Thy-1 cell surface antigen	Homo sapiens	71-75
32819718-5	2020	Repression of the Rictor expression strongly suppressed the growth of rapamycin-insensitive tumor cells.	Sirolimus	70-79	RPTOR independent companion of MTOR complex 2	Homo sapiens	18-24
32819718-6	2020	Furthermore, we showed that the suppression of Rictor expression was also effective in rapamycin-insensitive cells that had acquired resistance to mTOR kinase inhibitors.	Sirolimus	87-96	RPTOR independent companion of MTOR complex 2	Homo sapiens	47-53
32819718-7	2020	These findings indicate that Rictor can be a predictive marker for the use of rapamycin analogs in TNBC and highlight the need to develop therapeutics targeting Rictor in the treatment of TNBC.	Sirolimus	78-87	RPTOR independent companion of MTOR complex 2	Homo sapiens	29-35
32819718-7	2020	These findings indicate that Rictor can be a predictive marker for the use of rapamycin analogs in TNBC and highlight the need to develop therapeutics targeting Rictor in the treatment of TNBC.	Sirolimus	78-87	RPTOR independent companion of MTOR complex 2	Homo sapiens	161-167
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	30-39	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	48-54
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	30-39	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	103-109
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	30-39	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	103-109
33195437-5	2020	Two small molecules FK506 and rapamycin bind to FKBP12 immunophilin and the resulting complexes (FK506-FKBP12 and rapamycin-FKBP12) target calcineurin and TOR, respectively in both humans and fungi.	Sirolimus	114-123	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	48-54
33195437-8	2020	The current review highlights FK506/rapamycin-FKBP12 interactions with calcineurin/TOR kinase in human and fungi, and development of non-immunosuppressive analogs of FK506, rapamycin, and novel small molecules in inhibition of fungal calcineurin and TOR kinase.	Sirolimus	36-45	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	46-52
33116622-7	2020	On the contrary, Rapamycin reversed the promoting effect of GAS8-AS1 in OC cells.	Sirolimus	17-26	growth arrest specific 8	Homo sapiens	60-64
33038032-5	2021	The effect of rapamycin-treated NPC-derived exosomes on NPCs were assessed by co-culture with IL-1beta-stimulated NPCs.	Sirolimus	14-23	interleukin 1 alpha	Homo sapiens	94-102
31944172-11	2020	This study shows that sustained high autophagic flux by RUBCN deficiency in PTECs leads to metabolic syndrome concomitantly with an accelerated mobilization of phospholipids from cellular membranes to lysosomes.Abbreviations: ABC: ATP binding cassette; ACADM: acyl-CoA dehydrogenase medium chain; ACTB: actin, beta; ATG: autophagy related; AUC: area under the curve; Baf: bafilomycin A1; BAT: brown adipose tissue; BODIPY: boron-dipyrromethene; BSA: bovine serum albumin; BW: body weight; CAT: chloramphenicol acetyltransferase; CM: complete medium; CPT1A: carnitine palmitoyltransferase 1a, liver; CQ: chloroquine; CTRL: control; EGFP: enhanced green fluorescent protein; CTSD: cathepsin D; EAT: epididymal adipose tissue; EGFR: epidermal growth factor receptor; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1; FA: fatty acid; FBS: fetal bovine serum; GTT: glucose tolerance test; HE: hematoxylin and eosin; HFD: high-fat diet; I/R: ischemia-reperfusion; ITT: insulin tolerance test; KAP: kidney androgen regulated protein; KO: knockout; LAMP1: lysosomal associated membrane protein 1; LD: lipid droplet; LRP2: low density lipoprotein receptor related protein 2; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; MAT: mesenteric adipose tissue; MS: mass spectrometry; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; NDRG1: N-myc downstream regulated 1; NDUFB5: NADH:ubiquinone oxidoreductase subunit B5; NEFA: non-esterified fatty acid; OA: oleic acid; OCT: optimal cutting temperature; ORO: Oil Red O; PAS: Periodic-acid Schiff; PFA: paraformaldehyde; PIK3C3: phosphatidylinositol 3-kinase catalytic subunit type 3; PPARA: peroxisome proliferator activated receptor alpha; PPARGC1A: PPARG coactivator 1 alpha; PTEC: proximal tubular epithelial cell; RAB7A: RAB7A, member RAS oncogene family; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase B1; RT: reverse transcription; RUBCN: rubicon autophagy regulator; SAT: subcutaneous adipose tissue; SFC: supercritical fluid chromatography; SQSTM1: sequestosome 1; SREBF1: sterol regulatory element binding transcription factor 1; SV-40: simian virus-40; TFEB: transcription factor EB; TG: triglyceride; TS: tissue specific; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; UN: urea nitrogen; UQCRB: ubiquinol-cytochrome c reductase binding protein; UVRAG: UV radiation resistance associated; VPS: vacuolar protein sorting; WAT: white adipose tissue.	Sirolimus	1335-1344	RUN domain and cysteine-rich domain containing, Beclin 1-interacting protein	Mus musculus	56-61
33112549-5	2020	RESULTS: Treatment with sirolimus alone lowered expressions of ER and PgR of breast cancer and reduced tumor size.	Sirolimus	24-33	progesterone receptor	Rattus norvegicus	70-73
32590192-7	2020	A dual-targeting delivery liposomal system was designed with dual-modification of PD-L1 nanobody and mannose ligands for co-delivering an mTOR inhibitor (rapamycin) and an anti-angiogenic drug (regorafenib).	Sirolimus	154-163	CD274 molecule	Homo sapiens	82-87
32457396-7	2020	Mechanistically, the Msi1-mTOR pathway drives keratinocyte-Paget-like cell conversion, and suppression of mTOR signaling with Rapamycin significantly rescued the Paget-like phenotype in Msi1-overexpressing transgenic mice.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Mus musculus	106-110
32810332-0	2020	MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.	Sirolimus	59-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3
32810332-10	2020	Our results demonstrated the lncRNA EPIC1 expression activated the AKT-mTORC1 signaling pathway through Myc and led to rapamycin resistance in breast and ovarian cancer.	Sirolimus	119-128	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	104-107
32745931-1	2020	The Glucose-Target of Rapamycin (Glc-TOR) pathway has been studied in different biological systems, but scarcely during early seed germination.	Sirolimus	22-31	Serine/threonine-protein kinase TOR	Zea mays	37-40
31875479-1	2020	BACKGROUND: The protein kinase target of rapamycin (mTOR) in complex 1 (mTORC1) is activated by amino acids and in turn upregulates anabolic processes.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Mus musculus	52-56
32353830-9	2020	Combined treatment with MVC-RAPA showed a synergistic increase in p-AKT, p-mTOR and SIRT1 levels.	Sirolimus	28-32	mechanistic target of rapamycin kinase	Mus musculus	75-79
32353830-9	2020	Combined treatment with MVC-RAPA showed a synergistic increase in p-AKT, p-mTOR and SIRT1 levels.	Sirolimus	28-32	sirtuin 1	Mus musculus	84-89
32267832-8	2020	Both protein levels were reduced by ANT-DBS, and there was less phosphorylation of downstream regulators, extracellular signal-regulated kinase and Akt, followed by inactivation of mammalian target of rapamycin complex 1.	Sirolimus	201-210	solute carrier family 25 member 6	Homo sapiens	36-39
33117286-4	2020	Such leptin-triggered eosinophilic inflammatory response was shown to be dependent on activation of the mTOR signaling pathway, since it was (i) inhibited by rapamycin pre-treatment and (ii) reduced in PI3K-deficient mice.	Sirolimus	158-167	leptin	Mus musculus	5-11
33117286-4	2020	Such leptin-triggered eosinophilic inflammatory response was shown to be dependent on activation of the mTOR signaling pathway, since it was (i) inhibited by rapamycin pre-treatment and (ii) reduced in PI3K-deficient mice.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	104-108
32974014-5	2020	Mechanistically, formate induces mechanistic target of rapamycin complex 1 (mTORC1) activity as quantified by phosphorylation of its targets S6, 4E-BP1, S6K1 and CAD.	Sirolimus	55-64	aconitate decarboxylase 1	Homo sapiens	162-165
32974014-6	2020	Treatment with the allosteric mTORC1 inhibitor rapamycin abrogates CAD phosphorylation and pyrimidine synthesis induced by formate.	Sirolimus	47-56	aconitate decarboxylase 1	Homo sapiens	67-70
32944864-5	2021	Intraperitoneal injection of the mTOR inhibitor, rapamycin, abolished the effects of Ast.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	33-37
32707053-9	2020	Moreover, the expression of Rab31-induced p-p70S6K was almost inhibited by rapamycin, a well-established inhibitor of mTOR.	Sirolimus	75-84	ribosomal protein S6 kinase B1	Homo sapiens	44-50
31733178-8	2020	Rapamycin partially inhibited human, baboon, and pig IL-6/IL-6Ralpha/STAT3 pathways, and suppressed inflammatory gene expression.	Sirolimus	0-9	signal transducer and activator of transcription 3	Sus scrofa	69-74
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	84-93	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	13-17
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	84-93	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	221-225
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	153-162	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	13-17
32705169-12	2020	Furthermore, IDH1-overexpressing and alpha-KG-treated U87 cells were incubated with rapamycin, an mTOR-specific inhibitor, and the results revealed that rapamycin treatment reversed the increased cell migration caused by IDH1 overexpression and alpha-KG treatment.	Sirolimus	153-162	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	221-225
32705226-8	2020	All effects induced by EX-527, including increased phosphorylated-mTOR and decreased autophagy, were abrogated by rapamycin treatment.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Mus musculus	66-70
32068977-7	2020	In terms of mechanism, we found mTORC1 activity was impaired by downregulation of METTL3, additional silencing of METTL3 cannot further decrease the phosphorylation level of mTORC1 and glycolysis activity in Rapamycin-treated HCC cells.	Sirolimus	208-217	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	114-120
31954176-4	2020	Here we show that a novel target of rapamycin (TOR)-interacting transcriptional activator Vhr2 is required for full expression of some ERG genes for ergosterol biogenesis and for proper sorting of the tryptophan permease Tat2 in budding yeast.	Sirolimus	36-45	Vhr2p	Saccharomyces cerevisiae S288C	90-94
32873229-12	2020	Furthermore, treatment with the autophagy activator rapamycin and ATG7 overexpression in LX-2 cells abolished the HSC activation-suppressive effect of NK-Exo.	Sirolimus	52-61	fucosyltransferase 1 (H blood group)	Homo sapiens	114-117
32737433-9	2020	Moreover, loss of Smurf1 abolishes the aberrant regulation of PTEN, causing negative feedback on PI3K/Akt/mTOR signaling pathway, and thus leading to rescue of tumor sensitivity to rapamycin in an orthotopic GBM model.	Sirolimus	181-190	phosphatase and tensin homolog	Homo sapiens	62-66
31954176-4	2020	Here we show that a novel target of rapamycin (TOR)-interacting transcriptional activator Vhr2 is required for full expression of some ERG genes for ergosterol biogenesis and for proper sorting of the tryptophan permease Tat2 in budding yeast.	Sirolimus	36-45	aromatic amino acid transmembrane transporter TAT2	Saccharomyces cerevisiae S288C	221-225
32256773-0	2020	Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Mus musculus	16-20
32246575-7	2020	Rapamycin, the selective mTOR inhibitor, was used to estimate the potential mechanism.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	25-29
32531316-11	2020	Co-administration significantly enhanced the anti-tumor effects than use of any one drug, and significantly reduced the phosphorylation of AKT and p70S6K compared to treatment with rapamycin alone.	Sirolimus	181-190	ribosomal protein S6 kinase B1	Homo sapiens	147-153
32256773-3	2020	In the present study, the therapeutic effects of blockade of mTOR activity by rapamycin on aristolochic acid nephropathy were investigated.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Mus musculus	61-65
32588887-2	2020	TSC results from inactivating variants within the TSC1 or TSC2 genes, leading to constitutive activation of mechanistic Target of Rapamycin Complex 1 (mTORC1) signaling.	Sirolimus	130-139	TSC complex subunit 2	Mus musculus	58-62
31877436-5	2020	Phosphorylated JAK2 and phosphorylated STAT3 levels were lower in groups PY, RPM, AG490, and LA than in groups VR, NS, and DMSO.	Sirolimus	77-80	signal transducer and activator of transcription 3	Rattus norvegicus	39-44
32850379-8	2020	Deoxyshikonin inactivated the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR) pathway.	Sirolimus	77-86	protein tyrosine kinase 2 beta	Homo sapiens	30-46
31927699-6	2020	In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased.	Sirolimus	98-107	insulin-like growth factor 1	Rattus norvegicus	158-163
32666649-6	2020	Importantly, maintenance of aging GSCs can be enhanced by suppressing Drp1 expression to prevent mitochondrial fission or treating with rapamycin, which is known to promote autophagy via TOR inhibition.	Sirolimus	136-145	Target of rapamycin	Drosophila melanogaster	187-190
31927699-6	2020	In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased.	Sirolimus	98-107	KIT ligand	Rattus norvegicus	165-168
31927699-6	2020	In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased.	Sirolimus	98-107	vascular endothelial growth factor A	Rattus norvegicus	180-184
31927699-9	2020	Tracing of GFP and Sry gene showed that the survival of rapamycin-pretreated cells was increased.	Sirolimus	56-65	sex determining region Y	Rattus norvegicus	19-22
32306690-11	2020	Compared with PQ group, the expression levels of autophagy-related proteins LC3II/LC3I and Beclin1 were significantly increased whlie alpha-synuclein protein level was decreased after RAPA induction (P<0.05) .	Sirolimus	184-188	synuclein alpha	Homo sapiens	134-149
32339661-11	2020	These results indicate that insulin/IGF-1 signaling (IIS) and Drosophila target of rapamycin (dTOR) pathways can mediate the link between mating status and longevity in Drosophila.	Sirolimus	83-92	Target of rapamycin	Drosophila melanogaster	94-98
32306690-12	2020	Similarly, the IF result showed the fluorescence signal of alpha- synuclein significantly decreased after RAPA induction (P<0.05) .	Sirolimus	106-110	synuclein alpha	Homo sapiens	59-75
32642911-11	2020	Rapamycin could prevent the aggravation of HTG-associated AP via inhibiting mTORC1/S6K1 pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	83-87
32191726-6	2020	Rapamycin attenuated podocyte dysfunction and extends survival in Tsc2Deltapodocyte mice.	Sirolimus	0-9	TSC complex subunit 2	Mus musculus	66-70
32182210-0	2020	Rapamycin protects chondrocytes against IL-18-induced apoptosis and ameliorates rat osteoarthritis.	Sirolimus	0-9	interleukin 18	Rattus norvegicus	40-45
31628467-9	2020	Pharmacological stimulation of autophagy with rapamycin also rescued the lethality caused by rrp4 inactivation.	Sirolimus	46-55	Rrp4	Drosophila melanogaster	93-97
32164764-14	2020	RESULTS: A decrease in SA-beta-Gal activity and the suppression of SASP factors were observed in HCAECs undergoing stress-induced premature senescence (SIPS) after rapamycin treatment.	Sirolimus	164-173	thioredoxin	Homo sapiens	67-71
31807781-2	2020	The condition is caused by a mutation in the phosphatase and tensin homolog (PTEN) gene, which results in dysregulation of the mammalian target of rapamycin pathway.	Sirolimus	147-156	phosphatase and tensin homolog	Homo sapiens	77-81
32751882-0	2020	Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Mus musculus	50-54
32751882-0	2020	Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver.	Sirolimus	16-25	mechanistic target of rapamycin kinase	Mus musculus	129-133
32751882-7	2020	Furthermore, in vitro studies show a synergistic effect of cyclopamine and rapamycin on the inhibition of mTor signalling and oxidative respiration in primary hepatocytes from male and female C57BL/6N mice.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Mus musculus	106-110
32765037-11	2020	The results indicated an elevated level of autophagy in rapamycin and puerarin groups compared with the DN model, as demonstrated by the upregulated expression of autophagy markers Beclin-1, LC3II, and Atg5, and downregulated p62 expression.	Sirolimus	56-65	beclin 1, autophagy related	Mus musculus	181-189
32028014-5	2020	Moreover, our results also supported the hypothesis whereby the Treg/Th17 imbalance, induced by perinatal exposure to BPA, was associated with the activation of PI3K/Akt/mTOR signaling in vitro-cultured peripheral blood mononuclear cells by using rapamycin as an inhibitor of mTOR.	Sirolimus	247-256	mechanistic target of rapamycin kinase	Mus musculus	170-174
32502935-3	2020	Mass spectrometry demonstrated that hypoxia (1% O2) or rapamycin increased IGFBP-1 phosphorylation singly at Ser101/119/169 (confirmed using immunoblotting) and dually at pSer169 + 174.	Sirolimus	55-64	insulin like growth factor binding protein 1	Homo sapiens	75-82
32502935-5	2020	Rapamycin and/or hypoxia promoted colocalization of IGFBP-1 and CK2 (dual-immunofluorescence and proximity ligation assay).	Sirolimus	0-9	insulin like growth factor binding protein 1	Homo sapiens	52-59
32660632-10	2020	Suppression of mTORC1/p70S6K pathway by either rapamycin or p70S6K knockdown promoted heterochromatin organization and ameliorated Dox- or H2O2-induced DNA damage and senescence.	Sirolimus	47-56	ribosomal protein S6 kinase B1	Rattus norvegicus	22-28
32753891-13	2020	Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation.	Sirolimus	97-106	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	179-184
32753891-13	2020	Protein microarray and Western blot verification showed that activity of Akt/mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation.	Sirolimus	97-106	ribonucleotide reductase regulatory subunit M2	Homo sapiens	223-227
32475084-11	2020	Furthermore, the mTOR pathway inhibitor rapamycin attenuated the impact of HP both in vivo and in vitro.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Mus musculus	17-21
31931362-10	2020	In vitro, our results showed that DHA could downregulate the mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/S6K1) signaling pathway, promote cell autophagy, and ameliorate cell proliferation in aIgA1-induced HMCs.	Sirolimus	81-90	ribosomal protein S6 kinase B1	Homo sapiens	132-136
31810748-6	2020	The selective inhibitor of mTOR, rapamycin, was further used.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	27-31
32601294-9	2020	The addition of glycolysis inhibitor and rapamycin suppresses HIF1alpha downregulation and pyroptosis.	Sirolimus	41-50	hypoxia inducible factor 1, alpha subunit	Mus musculus	62-71
31932481-7	2020	HuR silencing in cultured IECs also prevented rapamycin-induced autophagy, which was abolished by overexpressing ATG16L1.	Sirolimus	46-55	ELAV like RNA binding protein 1	Homo sapiens	0-3
32097403-2	2020	Both mammals and insects use target of rapamycin (TOR) and insulin signaling pathways to coordinate growth with nutrition.	Sirolimus	39-48	Target of rapamycin	Drosophila melanogaster	50-53
32591533-4	2020	These compounds are more potent than rapamycin, and robustly downregulate phosphorylated and insoluble tau, consequently reducing tau-mediated neuronal stress vulnerability.	Sirolimus	37-46	microtubule associated protein tau	Homo sapiens	103-106
32591533-4	2020	These compounds are more potent than rapamycin, and robustly downregulate phosphorylated and insoluble tau, consequently reducing tau-mediated neuronal stress vulnerability.	Sirolimus	37-46	microtubule associated protein tau	Homo sapiens	130-133
31959630-1	2020	Cell growth is positively controlled by the phosphoinositide 3-kinase (PI3K)-target of rapamycin (TOR) signaling pathway under conditions of abundant growth factors and nutrients.	Sirolimus	87-96	Target of rapamycin	Drosophila melanogaster	98-101
32580379-5	2020	The mammalian target of rapamycin/ribosomal S6 kinase (mTOR/S6K) pathway is blocked in these conditions, and we provide evidence that this is mediated by modulation of both the 5" AMP-activated protein kinase (AMPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	60-63
32580379-5	2020	The mammalian target of rapamycin/ribosomal S6 kinase (mTOR/S6K) pathway is blocked in these conditions, and we provide evidence that this is mediated by modulation of both the 5" AMP-activated protein kinase (AMPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways.	Sirolimus	24-33	protein tyrosine kinase 2 beta	Homo sapiens	250-266
32560625-9	2020	In contrast, rapamycin (an autophagy inducer) dramatically restores the inhibitory effect of NaBr on the mRNA expression levels of clock genes (Bmal1, Cry1 and Roralpha) and glycolytic genes (Hk2 and Pkm2).	Sirolimus	13-22	RAR-related orphan receptor A	Rattus norvegicus	160-168
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	receptor interacting serine/threonine kinase 1	Homo sapiens	141-146
32116708-9	2020	We found the cell death induced by rapamycin and MK-2206 was MYCN-dependent.	Sirolimus	35-44	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	61-65
32446392-4	2020	Starvation and rapamycin treatment induced autophagy with increasing SIRT1 protein, HBc protein and pregenomic RNA (pgRNA) levels in HBV- producing cells.	Sirolimus	15-24	keratin 88, pseudogene	Homo sapiens	84-87
32116708-11	2020	This study delineates the role of MYCN in the cell death induced by combination treatment of rapamycin and MK-2206 in MYCN-amplified NB cells.	Sirolimus	93-102	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	34-38
32116708-11	2020	This study delineates the role of MYCN in the cell death induced by combination treatment of rapamycin and MK-2206 in MYCN-amplified NB cells.	Sirolimus	93-102	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	118-122
32118186-10	2020	NBQX (an AMPAR blocker), MK 2206 (an Akt blocker), and rapamycin (an mTOR blocker) used in pretreatment attenuated the antidepressant effects of vanillic acid, but SL327 (an ERK inhibitor) did not.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	69-73
31863766-7	2020	Moreover, rapamycin attenuated thrombin-stimulated p70S6K phosphorylation.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	51-57
31903726-4	2020	The ITP found rapamycin, an inhibitor to the pro-growth mTORC1 (mechanistic target of rapamycin complex 1) pathway, improved survival and it suppressed tumors in Apc+/Min mice providing a plausible rationale to ask if acarbose had a similar effect.	Sirolimus	14-23	APC, WNT signaling pathway regulator	Mus musculus	162-165
31794259-2	2020	Grb10 is also a substrate for the mechanistic target of rapamycin complex 1 (mTORC1) that mediates its feedback inhibition on phosphatidylinositide 3-kinase (PI3K)/Akt signaling.	Sirolimus	56-65	growth factor receptor bound protein 10	Homo sapiens	0-5
31794259-2	2020	Grb10 is also a substrate for the mechanistic target of rapamycin complex 1 (mTORC1) that mediates its feedback inhibition on phosphatidylinositide 3-kinase (PI3K)/Akt signaling.	Sirolimus	56-65	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	126-156
31794259-7	2020	However, acute inhibition of mTORC1 with rapamycin blocked Grb10 Ser476 phosphorylation and repressed a negative-feedback loop on PI3K/Akt signaling that increased myotube responsiveness to insulin.	Sirolimus	41-50	growth factor receptor bound protein 10	Homo sapiens	59-64
31794259-8	2020	Chronic rapamycin treatment reduced Grb10 protein abundance in conjunction with increased insulin receptor protein levels.	Sirolimus	8-17	growth factor receptor bound protein 10	Homo sapiens	36-41
31007149-8	2020	Inhibition of MTORC1 by TMJ local injection of rapamycin in rats or inducible ablation of MTORC1 expression selectively in chondrocytes in mice promoted chondrocyte autophagy and suppressed apoptosis, and reduced TMJ cartilage loss induced by UAC.	Sirolimus	47-56	origin recognition complex, subunit 1	Rattus norvegicus	14-20
31651100-10	2020	Both muscle-specific deletion of mTOR or Raptor, or the use of rapamycin, was sufficient to induce 3-8% of NCAM-positive fibres (P &lt; 0.01), muscle fibrillation, and neuromuscular junction (NMJ) fragmentation in 24% of examined fibres (P &lt; 0.001).	Sirolimus	63-72	neural cell adhesion molecule 1	Homo sapiens	107-111
31674073-12	2020	PCAT-1 silence caused decrease in Wnt3a, beta-catenin, and phosphorylation of protein kinase B and mechanistic target of rapamycin was abolished by miR-124-3p inhibitor.	Sirolimus	121-130	microRNA 124-3	Homo sapiens	148-158
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	ribosomal protein S6 kinase B1	Homo sapiens	80-84
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	ribosomal protein S6 kinase B1	Homo sapiens	191-195
31974624-14	2020	Further analyses revealed that the miR-421 inhibitor activated the phosphoinositide 3 kinase/protein kinase B/mammalian target of rapamycin signaling pathway in TM-induced human melanocytes.	Sirolimus	130-139	microRNA 421	Homo sapiens	35-42
31605778-6	2020	Both the sleep abnormalities and increased orexin expression in Tsc1GFAPCKO mice were reversed by rapamycin treatment, indicating their dependence on mTOR activation.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Mus musculus	150-154
31865521-3	2020	The present study investigated whether rapamycin can ameliorate surgery-induced cognitive deficits by inhibiting mTOR and activating autophagy in the hippocampus.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	113-117
32289154-4	2020	Our findings reveal that pharmacological inhibition of mTOR using Rapamycin has deleterious effects on hematopoiesis.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Mus musculus	55-59
32391090-8	2020	The AMP-dependent protein kinase (AMPK)/target of rapamycin complex (mTORC) 1 signaling pathway participates in the regulation of NUCB-2-mediated metastasis and EMT.	Sirolimus	50-59	nucleobindin 2	Homo sapiens	130-136
32433973-4	2020	We demonstrate that Lunapark interacts with mechanistic target of rapamycin complex-1 (mTORC1), a central cellular regulator that coordinates growth and metabolism with environmental conditions.	Sirolimus	66-75	lunapark, ER junction formation factor	Homo sapiens	20-28
32397282-2	2020	Although rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has been reported to be effective in preventing aortopathies in mouse models, its mode of action has yet to be clarified.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	36-67
32397282-2	2020	Although rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has been reported to be effective in preventing aortopathies in mouse models, its mode of action has yet to be clarified.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	69-73
32397282-8	2020	Rapamycin augmented the activation of Akt1, Akt2, and Stat3, and maintained the contractile phenotype of aortic smooth muscle cells.	Sirolimus	0-9	thymoma viral proto-oncogene 2	Mus musculus	44-48
32397282-9	2020	These findings indicate that rapamycin was effective both in preventing the development and in suppressing the progression of AD, indicating the importance of the mTOR pathway in AD pathogenesis.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	163-167
32375878-2	2020	TSC1 and TSC2 are repressors of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of protein synthesis.	Sirolimus	58-67	TSC complex subunit 2	Mus musculus	9-13
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	29-33
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	252-256
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	34-43	homer scaffolding protein 3	Mus musculus	310-316
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	208-217	mechanistic target of rapamycin kinase	Mus musculus	29-33
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	208-217	mechanistic target of rapamycin kinase	Mus musculus	252-256
32375443-6	2020	Conclusion: The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.	Sirolimus	208-217	homer scaffolding protein 3	Mus musculus	310-316
32528831-4	2020	Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27.	Sirolimus	107-116	mechanistic target of rapamycin kinase	Mus musculus	118-122
32528831-8	2020	Inhibition of mTOR activity induced by mTOR siRNA or rapamycin blocked the suppression of ghrelin production induced by IL-27 in mHypoE-N42 cells.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Mus musculus	14-18
32062191-0	2020	Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	phosphatase and tensin homolog	Homo sapiens	131-135
32062191-3	2020	Here we found that rapamycin inhibited human soluble BAFF (hsBAFF)-stimulated cell proliferation by inducing G1-cell cycle arrest, which was through downregulating the protein levels of CDK2, CDK4, CDK6, cyclin A, cyclin D1, and cyclin E. Rapamycin reduced hsBAFF-stimulated cell survival by downregulating the levels of anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-xL and survivin) and meanwhile upregulating the levels of pro-apoptotic proteins (BAK and BAX).	Sirolimus	19-28	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	346-351
32062191-5	2020	In addition, rapamycin blocked hsBAFF-stimulated B-cell proliferation and survival by preventing hsBAFF from inactivating PTEN and activating the Akt-Erk1/2 pathway.	Sirolimus	13-22	phosphatase and tensin homolog	Homo sapiens	122-126
32062191-6	2020	Overexpression of wild type PTEN or ectopic expression of dominant negative Akt potentiated rapamycin"s suppression of hsBAFF-induced Erk1/2 activation and proliferation/viability in Raji cells.	Sirolimus	92-101	phosphatase and tensin homolog	Homo sapiens	28-32
32062191-9	2020	The results indicate that rapamycin inhibits BAFF-stimulated B-cell proliferation and survival by blunting mTORC1/2-mediated [Ca2+]i elevations and suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway.	Sirolimus	26-35	phosphatase and tensin homolog	Homo sapiens	182-186
32072192-9	2020	Mechanistic studies revealed that HMGB1 activates receptor for AGE (RAGE) and toll-like receptor (TLR)4 to enhance phosphatidylinositol 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) signalling, thereby impairing Treg stability and functionality.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Mus musculus	189-193
31958214-0	2020	Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.	Sirolimus	88-97	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	42-48
31958214-8	2020	In addition, combination of rapamycin with PFK15, a PFKFB3 inhibitor, exerts a stronger inhibitory effect on cell proliferation of Tsc1- or Tsc2-null MEFs than treatment with single drug.	Sirolimus	28-37	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	52-58
31958214-9	2020	We conclude that loss of TSC1 or TSC2 led to upregulated expression of PFKFB3 through activation of mTORC1/HIF-1alpha signaling pathway and co-administration of rapamycin and PFK15 may be a promising strategy for the treatment of TSC tumors as well as other hyperactivated mTORC1-related tumors.	Sirolimus	161-170	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	71-77
32326642-5	2020	Here, we established two autophagy models through serum starvation and rapamycin treatment and detected that the overexpression of Mark4 increased the expression of autophagy-related factors Beclin1, ATG7, and significantly decreased the autophagy substrate P62.	Sirolimus	71-80	beclin 1, autophagy related	Mus musculus	191-198
31865521-12	2020	Rapamycin treatment restored autophagy function, attenuated phosphorylation of tau protein, and increased BDNF and synaptophysin expression in the hippocampus of surgical mice.	Sirolimus	0-9	brain derived neurotrophic factor	Mus musculus	106-110
31865521-15	2020	Inhibiting the mTOR signaling pathway with rapamycin successfully ameliorated surgery-related cognitive impairments by sustaining autophagic degradation, inhibiting tau hyperphosphorylation, and increasing synaptophysin and BDNF expression.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Mus musculus	15-19
31865521-15	2020	Inhibiting the mTOR signaling pathway with rapamycin successfully ameliorated surgery-related cognitive impairments by sustaining autophagic degradation, inhibiting tau hyperphosphorylation, and increasing synaptophysin and BDNF expression.	Sirolimus	43-52	brain derived neurotrophic factor	Mus musculus	224-228
31793097-11	2020	Additionally, rapamycin (a mTOR antagonist) notably attenuated the effects of Rheb on the autophagy, proliferation, apoptosis, and MITF expression in LCA-treated melanoma cells.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	27-31
31995752-4	2020	Indeed, our data indicate that EGFR acts to stimulate autophagy to preserve early CC function, whereas target of rapamycin (TOR) negatively regulates autophagy in the differentiating CCs.	Sirolimus	113-122	Target of rapamycin	Drosophila melanogaster	124-127
32047423-0	2020	The mTOR Inhibitor Rapamycin Prevents General Anesthesia-Induced Changes in Synaptic Transmission and Mitochondrial Respiration in Late Postnatal Mice.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
32276645-1	2020	BACKGROUND: Rapamycin, an inhibitor of the serine/threonine protein kinase mTOR, is an immunosuppressant used to treat renal transplant recipients, but it can cause endothelial and mitochondrial dysfunction.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	75-79
31479623-7	2020	We further observed that the LIF gene, which is highly induced upon rapamycin treatment, strengthened interactions with up- and down-stream intergenic regions.	Sirolimus	68-77	LIF interleukin 6 family cytokine	Homo sapiens	29-32
32273566-3	2020	Rapamycin is a specific inhibitor of mTOR and pharmacological inhibition of mTOR with rapamycin promote cardiac cell generation from the differentiation of mouse and human embryonic stem cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	37-41
32273566-3	2020	Rapamycin is a specific inhibitor of mTOR and pharmacological inhibition of mTOR with rapamycin promote cardiac cell generation from the differentiation of mouse and human embryonic stem cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	76-80
32273566-3	2020	Rapamycin is a specific inhibitor of mTOR and pharmacological inhibition of mTOR with rapamycin promote cardiac cell generation from the differentiation of mouse and human embryonic stem cells.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Mus musculus	76-80
31898848-5	2020	NPRL3 is a component of the GAP Activity Towards Rags 1 (GATOR1) protein complex that inhibits mammalian Target of Rapamycin Complex 1 (mTORC1) activity and it is found mutated in familial focal cortical dysplasia and familial focal epilepsy.	Sirolimus	115-124	NPR3 like, GATOR1 complex subunit	Homo sapiens	0-5
32112509-18	2020	Rapamycin attenuated the loss of primordial follicles induced by cisplatin through the inhibitory effect of rapamycin on the mTOR pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	125-129
32112509-18	2020	Rapamycin attenuated the loss of primordial follicles induced by cisplatin through the inhibitory effect of rapamycin on the mTOR pathway.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Mus musculus	125-129
32279295-3	2020	The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN"s GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.	Sirolimus	127-136	folliculin	Homo sapiens	4-8
32279295-3	2020	The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN"s GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.	Sirolimus	127-136	folliculin	Homo sapiens	169-173
32279295-3	2020	The FLCN protein functions in multiple signaling and metabolic pathways including positive regulation of mechanistic target of rapamycin complex 1 (mTORC1) activity via FLCN"s GTPase (GAP) activity for Rag C, positive regulation of Wnt signaling (in mesenchymal cells), and negative regulation of TFE3 nuclear localization.	Sirolimus	127-136	Ras related GTP binding C	Homo sapiens	202-207
32047423-9	2020	Pretreatment with the mTOR inhibitor rapamycin not only prevented anesthesia-induced mTOR phosphorylation, but also the increase in mitochondrial respiration and male-dependent enhancement of excitatory synaptic transmission.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Mus musculus	22-26
32047423-9	2020	Pretreatment with the mTOR inhibitor rapamycin not only prevented anesthesia-induced mTOR phosphorylation, but also the increase in mitochondrial respiration and male-dependent enhancement of excitatory synaptic transmission.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Mus musculus	85-89
31647755-7	2020	In mice treated with Leuko-Rapa, flow cytometry of disaggregated aortic tissue revealed fewer proliferating macrophages in the aorta (15.6+-9.79 %) compared with untreated mice (30.2+-13.34 %) and rapamycin alone (26.8+-9.87 %).	Sirolimus	197-206	transcriptional regulating factor 1	Mus musculus	27-31
33834178-2	2020	We previously showed that chronic treatment of Apc Min/+ females with the anti-aging drug, rapamycin, restored a normal lifespan through reduced polyposis and anemia prevention.	Sirolimus	91-100	APC, WNT signaling pathway regulator	Mus musculus	47-50
33834178-11	2020	Chronic rapamycin also reduced crypt depths in both male and female Apc Min/+ mice (P < 0.0001), consistent with reduced crypt epithelial cell proliferation.	Sirolimus	8-17	APC, WNT signaling pathway regulator	Mus musculus	68-71
31611063-6	2020	Interestingly, this autophagy promotion concurred with enhanced anabolic activation via AKT-mammalian target of rapamycin (mTOR)-p70S6K signaling cascade and enhanced antioxidant capacity such as copper zinc superoxide dismutase (CuZnSOD), glutathione peroxidase (GPX), and peroxiredoxin 3 (PRX3), known to be as antagonists of autophagy.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	129-135
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	phosphatase and tensin homolog	Homo sapiens	31-35
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	ribosomal protein S6 kinase B1	Homo sapiens	65-71
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	83-88
32588907-1	2020	INTRODUCTION: Growing evidence indicates that Rictor (Rapamycin-insensitive companion of mTOR) is overexpressed across several malignancies and associated with poor survival.	Sirolimus	54-63	RPTOR independent companion of MTOR complex 2	Homo sapiens	46-52
30854544-1	2020	Since the initial suggestion that rapamycin, an inhibitor of TOR nutrient signaling, increased lifespan comparable to dietary restriction, investigators have viewed rapamycin as a potential dietary restriction mimetic.	Sirolimus	34-43	tortured	Mus musculus	61-64
31605630-7	2020	Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin.	Sirolimus	47-56	epidermal growth factor	Homo sapiens	94-97
31686316-9	2020	More importantly, treatment with rapamycin (inhibitor of mTOR) increased expression of proteins implicated in autophagy and cholesterol efflux in oxLDL-loaded RAW 264.7 macrophage cells.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	57-61
31678323-6	2020	Indeed, AMPK-deficient mouse embryonic fibroblasts failed to respond to phenformin (AMPK activator) and compound C (AMPK inhibitor), while rapamycin induced a marked increase in TXNIP levels, confirming the known AMPK/mTOR control over TXNIP.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	218-222
31841452-6	2020	Further experiments showed that alpha-KG down-regulated the expression of M1-polarized marker genes and inhibited the activities of mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal protein S6 kinase (p70S6K) signaling pathway in M1-polarized MH-S cells.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	214-220
31889120-7	2019	Treatment with mTOR inhibitor rapamycin or PPARgamma inhibitor GW9662 suppressed lipid droplets and PGE2 secretion.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Mus musculus	15-19
31820607-17	2019	Compared with the model group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were reduced in the moxibustion group, the rapamycin group and the combination group (all P<0.01).	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	60-64
31820607-17	2019	Compared with the model group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were reduced in the moxibustion group, the rapamycin group and the combination group (all P<0.01).	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	71-75
31820607-18	2019	Compared with the moxibustion group, the levels of PI3K Akt and p-mTOR were increased in the rapamycin group and the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (all P<0.01).	Sirolimus	93-102	mechanistic target of rapamycin kinase	Mus musculus	66-70
31820607-19	2019	Compared with the rapamycin group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (P<0.01).	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	64-68
31820607-19	2019	Compared with the rapamycin group, the levels of PI3K Akt p-Akt mTOR and p-mTOR were increased in the combination group (P<0.01).	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	75-79
31791403-1	2019	BACKGROUND: The mammalian target of rapamycin complex 2 (mTORC2), containing the essential protein rictor, regulates cellular metabolism and cytoskeletal organization by phosphorylating protein kinases, such as PKB/Akt, PKC, and SGK.	Sirolimus	36-45	RPTOR independent companion of MTOR complex 2	Homo sapiens	99-105
31505123-7	2019	Collectively, these findings suggest that rapamycin protects against I/R-induced oxidative-nitrosative stress and inflammation leading to organ injuries via suppression of mTOR/IkappaB-alpha/NF-kappaB signaling pathway.	Sirolimus	42-51	NFKB inhibitor alpha	Rattus norvegicus	177-190
31636463-4	2019	The hypoxic tumor microenvironment drove the sustained activation of mechanistic target of rapamycin-GTPase dynamin-related protein 1 (mTOR-Drp1) in NK cells, resulting in excessive mitochondrial fission into fragments.	Sirolimus	91-100	dynamin 1 like	Homo sapiens	140-144
31874168-4	2020	Treatment with the Akt inhibitor LY94002 or the mTOR inhibitor rapamycin attenuated pain-related hypersensitivity to noxious mechanical stimuli, heat, and inflammatory substances.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Mus musculus	48-52
31874168-5	2020	Further, suppression of mTOR signaling by rapamycin decreased DRG neuronal hyperexcitability.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	24-28
31350329-0	2019	A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN.	Sirolimus	17-26	phosphatase and tensin homolog	Homo sapiens	118-122
32145700-5	2020	Additionally, the increased levels of S-adenosylmethionine (SAM) in renal tubular cells, which are associated with the reduced expression of glycine N-methyltransferase (Gnmt) and non-restricted Met intake, contributes to the activation of mechanistic target of rapamycin complex 1 (mTORC1) and impaired autophagy, in diabetic kidney.	Sirolimus	262-271	glycine N-methyltransferase	Rattus norvegicus	141-168
32145700-5	2020	Additionally, the increased levels of S-adenosylmethionine (SAM) in renal tubular cells, which are associated with the reduced expression of glycine N-methyltransferase (Gnmt) and non-restricted Met intake, contributes to the activation of mechanistic target of rapamycin complex 1 (mTORC1) and impaired autophagy, in diabetic kidney.	Sirolimus	262-271	glycine N-methyltransferase	Rattus norvegicus	170-174
32127537-5	2020	Treatment of G2-Terc-/- mice with rapamycin, an inhibitor of mTORC1, decreases survival, in contrast to lifespan extension in wild-type controls.	Sirolimus	34-43	telomerase RNA component	Mus musculus	16-20
31733420-0	2019	Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy.	Sirolimus	56-65	NPR3 like, GATOR1 complex subunit	Homo sapiens	70-75
32108266-4	2020	Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation.	Sirolimus	5-14	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	138-144
31552622-8	2019	Previous work has also demonstrated that inhibition of the mTOR pathway, via rapamycin, altered total levels of BZLF1 transcripts.	Sirolimus	77-86	protein Zta	Human gammaherpesvirus 4	112-117
32108266-4	2020	Both rapamycin and BCH blunted 2-DG uptake, irrespective of insulin administration, and this occurred in parallel with a decline in mTOR, 4E-BP1, and p70S6K phosphorylation status, but little effect on AKT phosphorylation.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	150-156
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	RPTOR independent companion of MTOR complex 2	Homo sapiens	28-34
31895126-6	2020	mTOR inhibition via rapamycin and N-acetylcysteine, and blockade of glucose utilization show clinical efficacy in both mouse models and clinical trials, such as systemic lupus erythematosus.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	0-4
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	proline rich 5	Homo sapiens	36-40
31672913-1	2019	The tumor suppressor folliculin (FLCN) enables nutrient-dependent activation of the mechanistic target of rapamycin complex 1 (mTORC1) protein kinase via its guanosine triphosphatase (GTPase) Activating Protein (GAP) activity toward the GTPase RagC.	Sirolimus	106-115	folliculin	Homo sapiens	33-37
32269848-9	2020	Further, the protective role of si-Bcl-3 on the gastric cancer cells could be reversed by the autophagy inducer, rapamycin.	Sirolimus	113-122	BCL3 transcription coactivator	Homo sapiens	35-40
31798451-3	2019	Some studies indicate the overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway in this disease, being, thus, a potential target for pharmacological treatment.	Sirolimus	130-139	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	48-77
31798451-3	2019	Some studies indicate the overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) pathway in this disease, being, thus, a potential target for pharmacological treatment.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Mus musculus	141-145
31714935-5	2019	Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR) signaling, diminished insulin"s effects and increase taste cell generation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-58
31714935-5	2019	Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR) signaling, diminished insulin"s effects and increase taste cell generation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	60-64
31717694-5	2019	Targeting PKM2 affected the protein kinase B (AKT)/mechanistic target of the rapamycin 1 (mTOR) pathway, and downregulated the expression of glycolytic enzymes, including lactate dehydrogenase A and glucose transporter-1, and other downstream signaling key proteins.	Sirolimus	77-86	pyruvate kinase M1/2	Homo sapiens	10-14
31636192-4	2019	This is in part caused by the phosphorylation and nuclear export of MAF1 homolog negative regulator of Poll III (MAF1), via a synergistic casein kinase 2 (CK2)- and mammalian target of rapamycin-dependent signaling cascade downstream of Toll-like receptors (TLRs).	Sirolimus	185-194	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	68-72
31468083-3	2019	Inhibiting mTOR by rapamycin has been reported to alleviate emphysema, but the mechanism is not fully understood.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	11-15
31468083-17	2019	Rapamycin ameliorated emphysema and attenuated Tc1 and Tc17 cell responses probably caused by inhibiting mTOR in cigarette smoke-exposed mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	105-109
30587068-9	2019	MDR1 overexpression increased the resistance of LLC-PK1 cells to tacrolimus, cyclosporine A, sirolimus and everolimus.	Sirolimus	93-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	0-4
30587068-15	2019	These findings indicate that wild-type MDR1 exports tacrolimus and sirolimus more efficiency than the MDR1T-T-T, MDR1C-T-T, MDR1C-G-T variant protein.	Sirolimus	67-76	ATP-binding cassette, sub-family B (MDR/TAP), member 1	Sus scrofa	39-43
31776022-10	2020	The effects of NT-3 on oligodendrocyte survival could be blocked by an autophagy activator rapamycin.	Sirolimus	91-100	neurotrophin 3	Rattus norvegicus	15-19
32194539-10	2019	Results: In vitro TNFalpha and IL-17A protein production by SpA PBMCs was inhibited in the presence of rapamycin.	Sirolimus	103-112	interleukin 17A	Rattus norvegicus	31-37
32194539-15	2019	IL-17A mRNA expression was decreased in the metacarpophalangeal joints after rapamycin treatment.	Sirolimus	77-86	interleukin 17A	Rattus norvegicus	0-6
32194539-17	2019	In the HLA-B27 transgenic rat model of SpA, rapamycin inhibits arthritis and spondylitis development and severity, reduces articular bone erosions, decreases pathologic new bone formation and suppresses IL-17A expression.	Sirolimus	44-53	interleukin 17A	Rattus norvegicus	203-209
32081881-12	2020	In atheroprone vessels of mice receiving rapamycin to induce autophagy, the enhanced expression of SIRT1 was observed together with YAP repression.	Sirolimus	41-50	sirtuin 1	Mus musculus	99-104
31806377-5	2020	Interestingly, we observed that the addition of four different autophagy inducers, rapamycin (RAP), CCI779, ABT737 and temozolomide (TMZ), induced the differences of DR5 expression and cell apoptosis after irradiation.	Sirolimus	83-92	TNF receptor superfamily member 10b	Homo sapiens	166-169
31806377-5	2020	Interestingly, we observed that the addition of four different autophagy inducers, rapamycin (RAP), CCI779, ABT737 and temozolomide (TMZ), induced the differences of DR5 expression and cell apoptosis after irradiation.	Sirolimus	94-97	TNF receptor superfamily member 10b	Homo sapiens	166-169
32023458-6	2020	MGO induces AKT activation through phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin 2 (mTORC2) and Hsp27 regulation.	Sirolimus	92-101	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	35-64
31689244-5	2020	Mechanistically, in vivo in BMP9/10ib mouse ECs, sirolimus and nintedanib blocked the overactivation of mTOR and VEGFR2, respectively.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	104-108
31666191-10	2020	Extracellular TG2 promoted the phosphorylation of Akt, mechanistic target of rapamycin (mTOR), and ribosomal p70 S6 kinase (p70S6K), and inhibitors of mTOR, phosphatidylinositol 3-kinase, and Src (rapamycin, LY294002, and Src I1, respectively) inhibited TG2-increased phosphorylation of mTOR and p70S6K.	Sirolimus	77-86	transglutaminase 2, C polypeptide	Mus musculus	14-17
31759065-8	2020	Furthermore, incubation with mTOR inhibitor rapamycin restored lysosomal pH and decreased cellular triacylglycerol content.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Mus musculus	29-33
32089640-4	2020	Sirolimus is an oral mTOR inhibitor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	21-25
31991851-6	2020	Doxorubicin (DOX) further induced ABC transporters in DPP-4-deficient 4T1 cells, and the induction of ABC transporters was suppressed by either the CXCR4 inhibitor AMD3100, the mTOR inhibitor rapamycin or a neutralizing TGFbeta (1, 2 and 3) antibody(N-TGFbeta).	Sirolimus	192-201	mechanistic target of rapamycin kinase	Mus musculus	177-181
31936125-0	2020	Mmi1, the Yeast Ortholog of Mammalian Translationally Controlled Tumor Protein (TCTP), Negatively Affects Rapamycin-Induced Autophagy in Post-Diauxic Growth Phase.	Sirolimus	106-115	Tma19p	Saccharomyces cerevisiae S288C	0-4
31936125-0	2020	Mmi1, the Yeast Ortholog of Mammalian Translationally Controlled Tumor Protein (TCTP), Negatively Affects Rapamycin-Induced Autophagy in Post-Diauxic Growth Phase.	Sirolimus	106-115	tumor protein, translationally-controlled 1	Homo sapiens	38-78
31936125-0	2020	Mmi1, the Yeast Ortholog of Mammalian Translationally Controlled Tumor Protein (TCTP), Negatively Affects Rapamycin-Induced Autophagy in Post-Diauxic Growth Phase.	Sirolimus	106-115	tumor protein, translationally-controlled 1	Homo sapiens	80-84
31936125-6	2020	However, an increased rapamycin-induced autophagy is detected in mmi1Delta strain when the cells enter the post-diauxic growth phase, and this phenotype can be rescued by inserted wild-type MMI1 gene.	Sirolimus	22-31	Tma19p	Saccharomyces cerevisiae S288C	190-194
31936125-8	2020	In summary, our study suggests that Mmi1 negatively affects rapamycin-induced autophagy in the post-diauxic growth phase and supports the role of Mmi1/TCTP as a negative autophagy regulator in eukaryotic cells.	Sirolimus	60-69	Tma19p	Saccharomyces cerevisiae S288C	36-40
31582588-6	2019	Overexpression of CYS3 or CYS4 in Deltasch9 cells or WT cells treated with rapamycin rescued the deficiency of H2S production.	Sirolimus	75-84	cystathionine gamma-lyase CYS3	Saccharomyces cerevisiae S288C	18-22
31936125-8	2020	In summary, our study suggests that Mmi1 negatively affects rapamycin-induced autophagy in the post-diauxic growth phase and supports the role of Mmi1/TCTP as a negative autophagy regulator in eukaryotic cells.	Sirolimus	60-69	Tma19p	Saccharomyces cerevisiae S288C	146-150
31936125-8	2020	In summary, our study suggests that Mmi1 negatively affects rapamycin-induced autophagy in the post-diauxic growth phase and supports the role of Mmi1/TCTP as a negative autophagy regulator in eukaryotic cells.	Sirolimus	60-69	tumor protein, translationally-controlled 1	Homo sapiens	151-155
31782272-12	2020	Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	119-125
31373126-2	2019	mTOR is found in two protein complexes, mTORC1 and mTORC2, that have distinct components and substrates and are both inhibited by rapamycin, a macrolide drug that robustly extends lifespan in multiple species including worms and mice.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Mus musculus	0-4
31782272-12	2020	Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats.	Sirolimus	0-9	cellular communication network factor 2	Rattus norvegicus	241-245
31226256-7	2019	Intracerebroventricular injection of the mTORC1 inhibitor, rapamycin, revealed a role for mTOR in the socially-induced hypertrophy of GnRH1 neurons.	Sirolimus	59-68	serine/threonine-protein kinase mTOR	Haplochromis burtoni	41-45
31226256-7	2019	Intracerebroventricular injection of the mTORC1 inhibitor, rapamycin, revealed a role for mTOR in the socially-induced hypertrophy of GnRH1 neurons.	Sirolimus	59-68	progonadoliberin-1	Haplochromis burtoni	134-139
32879215-4	2020	In addition, the effect of E2 on LPL secretion was markedly suppressed by an inhibitor of mammalian target of rapamycin complex (mTORC) 1 and 2, KU0063794, but were not by a mTORC1 inhibitor, rapamycin.	Sirolimus	110-119	lipoprotein lipase	Homo sapiens	33-36
32879215-4	2020	In addition, the effect of E2 on LPL secretion was markedly suppressed by an inhibitor of mammalian target of rapamycin complex (mTORC) 1 and 2, KU0063794, but were not by a mTORC1 inhibitor, rapamycin.	Sirolimus	192-201	lipoprotein lipase	Homo sapiens	33-36
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	68-99
31231866-8	2019	Rapamycin mediated decrease of IL-6 secretion suggests a particular mechanistic target of rapamycin (mTOR)-IL-6 link and appeared to be microglia specific.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	101-105
31432123-0	2019	Rapamycin improves sevoflurane-induced cognitive dysfunction in aged rats by mediating autophagy through the TLR4/MyD88/NF-kappaB signaling pathway.	Sirolimus	0-9	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	114-119
31160716-9	2020	Treatment with the mTOR inhibitor rapamycin delayed the growth of PanNETs in both MPR and MPM mice, as well as the growth of PitNETs, resulting in prolonged survival in MPR mice.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	19-23
31432123-1	2019	The present study was aimed to observe the protective effect of rapamycin on cognitive dysfunction induced by sevoflurane in aged rats and its effect on autophagy-related proteins, and to investigate the regulatory mechanism of the Toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor-kappaB (TLR4/MyD88/NF-kappaB) signaling pathway.	Sirolimus	64-73	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	325-330
31432123-10	2019	This function of rapamycin was demonstrated to depend on the TLR4/MyD88/NF-kappaB signaling pathway.	Sirolimus	17-26	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	66-71
32379593-9	2020	Imiglucerase was the least effective enzyme for the sirolimus level (0.80% (95% CI, 0.71-0.89).	Sirolimus	52-61	glucosylceramidase beta	Homo sapiens	0-12
31548690-5	2019	Proof-of-principle experiments are provided for the rapamycin-mediated association between FKBP12 and FRB, a system relevant in both medicine and chemical biology.	Sirolimus	52-61	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	91-97
31625572-3	2020	Phosphoinositide 3-kinase (PI3K)/AKT signaling activates mammalian target of rapamycin complex 1 (mTORC1) and hyperactivation of mTORC1 is a common event in PKD; however, mTORC1 inhibitors have yielded disappointing results in clinical trials.	Sirolimus	77-86	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	0-25
31801817-10	2020	To confirm the role of mTOR activation, we found that rapamycin diminished the effect of pembrolizumab-mediated downregulation of FOXP3.	Sirolimus	54-63	forkhead box P3	Sus scrofa	130-135
32579497-3	2020	Alcohol via upstream kinases like mammalian target to rapamycin complex 1 (mTORC1) or 2 (mTORC2), may affect the activities of PKCepsilon or vice versa in AUD.	Sirolimus	54-63	protein kinase C epsilon	Homo sapiens	127-137
31408605-2	2019	Our team has recently utilized ELPs fused to FKBP12 to carry Rapamycin (Rapa), a potent immunosuppressant.	Sirolimus	61-70	FK506 binding protein 1a	Mus musculus	45-51
31833032-8	2020	Our results showed that MMF vs. SRL treated recipient showed an increase in pDC % with increased in the expression of ILT3/ILT4 which is in favor of better allograft survival; However, for confirming the results of this preliminary study, a cohort study with larger sample size is necessary.	Sirolimus	32-35	leukocyte immunoglobulin like receptor B4	Homo sapiens	118-122
31408605-2	2019	Our team has recently utilized ELPs fused to FKBP12 to carry Rapamycin (Rapa), a potent immunosuppressant.	Sirolimus	61-65	FK506 binding protein 1a	Mus musculus	45-51
31408605-3	2019	Through high affinity binding to Rapa, FKBP carriers can yield beneficial therapeutic effects and reduce the off-site toxicity of Rapa.	Sirolimus	33-37	FK506 binding protein 1a	Mus musculus	39-43
31622602-3	2020	While rapalogs like rapamycin allosterically inhibit the mTOR complex 1 (TORC1), ATP-competitive mTOR inhibitors suppress activities of TORC1 and TORC2 and have been shown to be more efficient in inducing autophagy and reducing protein levels and aggregates than rapalogs.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	57-61
31408605-3	2019	Through high affinity binding to Rapa, FKBP carriers can yield beneficial therapeutic effects and reduce the off-site toxicity of Rapa.	Sirolimus	130-134	FK506 binding protein 1a	Mus musculus	39-43
31475823-9	2019	mTOR inhibition by rapamycin totally blocked the stimulation of leucine and methionine on CRTC2 expression.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	0-4
30597187-0	2019	Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORgammat and T-bet expression in kidney transplantation.	Sirolimus	0-9	T-box transcription factor 21	Homo sapiens	175-180
31654704-2	2020	Rapamycin and similar compounds inhibit mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	40-44
31882658-9	2019	Studies in mice reproduced the in vitro effects of mTOR modulation with Rapamycin on cell fates in vascular cells in vivo.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Mus musculus	51-55
31074104-10	2019	Experiments in vitro revealed that SOS stimulated the activation of the mTORC1 signaling pathway and upregulated RUNX2, OSX, and OCN, rapamycin can reverse it.	Sirolimus	134-143	mtorc1	None	72-78
31878201-5	2019	In this study we demonstrated that rapamycin, at a clinically tolerable concentration (10 nM), inhibited the phosphorylation of S6, but not the critical eIF4E releasing Thr 37/46 phosphorylation sites of 4E-BP1 in TSC2-deficient LAM-derived cells.	Sirolimus	35-44	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	204-210
31807738-4	2019	A specific ligand, rapamycin, then activates inter- and intramolecular interactions of FRB and FKBP12, which develop molecular strain in the sandwiched ALuc23 to accelerate further folding.	Sirolimus	19-28	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	95-101
31078684-6	2019	Loss of either Tsc1 or Tsc2 from astrocytes resulted in a marked increase in Aqp4 expression which was sensitive to mTORC1 inhibition with rapamycin.	Sirolimus	139-148	TSC complex subunit 2	Mus musculus	23-27
31487268-8	2019	The mTOR complex (mTORC)1 inhibitor rapamycin suppressed proinflammatory cytokine production by T cells and alleviated autoimmunity in Srsf1-deficient mice.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Mus musculus	4-8
31404320-0	2019	Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	118-124
31404320-5	2019	The aim of the present study was to investigate the effects of rapamycin and doxorubicin on K562 cell proliferation following the combination treatment, and further focus on confirming whether rapamycin enhanced the antitumor effects of doxorubicin by downregulating the mTOR/ribosomal protein S6 kinase (p70S6K) pathway.	Sirolimus	193-202	ribosomal protein S6 kinase B1	Homo sapiens	305-311
31383843-7	2019	The intracellular calcium-dependent PKCalpha/mammalian target of the rapamycin (mTOR) signaling pathway triggered by cP1P regulated HIF1alpha translation via S6K1, which is critical for HIF1 activation.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	158-162
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	44-53	serine/threonine kinase 11	Homo sapiens	101-105
31152486-6	2019	TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho-mTOR, phospo-p70S6K, and phospo-S6.	Sirolimus	8-12	ribosomal protein S6 kinase B1	Rattus norvegicus	93-99
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	151-160	serine/threonine kinase 11	Homo sapiens	101-105
31499159-9	2019	Protective effects of rapamycin on TNF/zVAD-induced RIP1-RIP3 binding and necroptosis were undetected in cells transfected with RIP1-S320A.	Sirolimus	22-31	myosin phosphatase Rho interacting protein	Rattus norvegicus	57-61
31091421-5	2019	Additionally, increased mammalian target of rapamycin complex 1 (mTORC1) activity is observed in the Lkb1 conditional knockout (cKO) chondrocytes, and rapamycin (mTORC1 inhibitor) treatment significantly alleviates the expansion of growth-plate cartilage and eliminates the enchondroma-like lesions in Lkb1 cKO mice.	Sirolimus	151-160	serine/threonine kinase 11	Homo sapiens	302-306
31553107-10	2019	Inhibition of p70S6K /p85S6K by rapamycin also reduced the expressions of STAT3 and cyclin D1.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	14-20
31232124-7	2019	When the action concentration of rapamycin was 100 ng mL-1, the inhibitory effect was strongest after 48 h (30.25 +- 2.40)%, and the follow-up study was conducted after 48 h. When the action time of rapamycin was 48 h, the inhibitory effect of 150 ng mL-1 at the action concentration was the strongest, and the inhibitory rate was (42.88 +- 3.84)%.	Sirolimus	33-42	L1 cell adhesion molecule	Mus musculus	54-58
31599935-5	2019	Intraperitoneal injection of mTORC1 inhibitor, rapamycin, to mice with Sirt1 deletion, partially neutralized such inhibitory effects of Sirt1 ablation on longitudinal bone growth, indicating the causative link between SIRT1 and mTORC1 signaling in the growth plate.	Sirolimus	47-56	sirtuin 1	Mus musculus	71-76
31599935-5	2019	Intraperitoneal injection of mTORC1 inhibitor, rapamycin, to mice with Sirt1 deletion, partially neutralized such inhibitory effects of Sirt1 ablation on longitudinal bone growth, indicating the causative link between SIRT1 and mTORC1 signaling in the growth plate.	Sirolimus	47-56	sirtuin 1	Mus musculus	136-141
31599935-5	2019	Intraperitoneal injection of mTORC1 inhibitor, rapamycin, to mice with Sirt1 deletion, partially neutralized such inhibitory effects of Sirt1 ablation on longitudinal bone growth, indicating the causative link between SIRT1 and mTORC1 signaling in the growth plate.	Sirolimus	47-56	sirtuin 1	Mus musculus	218-223
31504946-6	2019	In chick embryos at embryonic age 18 D, significant upregulation of poultry target of rapamycin (pTOR) occurred in the liver and breast muscle, as well as threonine dehydrogenase (TDH) in the thigh, and aminopeptidase (ANPEP) (P < 0.05) in the duodenum and ileum due to dietary Thr supplementation, but there were no effects on MUC2 expression in the duodenum and ileum (P > 0.05).	Sirolimus	86-95	alanyl aminopeptidase, membrane	Gallus gallus	203-217
31504946-6	2019	In chick embryos at embryonic age 18 D, significant upregulation of poultry target of rapamycin (pTOR) occurred in the liver and breast muscle, as well as threonine dehydrogenase (TDH) in the thigh, and aminopeptidase (ANPEP) (P < 0.05) in the duodenum and ileum due to dietary Thr supplementation, but there were no effects on MUC2 expression in the duodenum and ileum (P > 0.05).	Sirolimus	86-95	alanyl aminopeptidase, membrane	Gallus gallus	219-224
31232124-7	2019	When the action concentration of rapamycin was 100 ng mL-1, the inhibitory effect was strongest after 48 h (30.25 +- 2.40)%, and the follow-up study was conducted after 48 h. When the action time of rapamycin was 48 h, the inhibitory effect of 150 ng mL-1 at the action concentration was the strongest, and the inhibitory rate was (42.88 +- 3.84)%.	Sirolimus	33-42	L1 cell adhesion molecule	Mus musculus	251-255
31232124-7	2019	When the action concentration of rapamycin was 100 ng mL-1, the inhibitory effect was strongest after 48 h (30.25 +- 2.40)%, and the follow-up study was conducted after 48 h. When the action time of rapamycin was 48 h, the inhibitory effect of 150 ng mL-1 at the action concentration was the strongest, and the inhibitory rate was (42.88 +- 3.84)%.	Sirolimus	199-208	L1 cell adhesion molecule	Mus musculus	54-58
31733794-7	2019	Therapeutic concentrations of TAC and SRL reduced the percentage of pd1+ and icos+ Tfh cells compared to controls.	Sirolimus	38-41	patr class I histocompatibility antigen, A-126 alpha chain-like	Sus scrofa	68-71
31232124-7	2019	When the action concentration of rapamycin was 100 ng mL-1, the inhibitory effect was strongest after 48 h (30.25 +- 2.40)%, and the follow-up study was conducted after 48 h. When the action time of rapamycin was 48 h, the inhibitory effect of 150 ng mL-1 at the action concentration was the strongest, and the inhibitory rate was (42.88 +- 3.84)%.	Sirolimus	199-208	L1 cell adhesion molecule	Mus musculus	251-255
30549029-0	2019	Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.	Sirolimus	0-9	serine/threonine kinase 11	Homo sapiens	75-79
31852644-8	2019	Compared with the menthol-treated cells, the cells treated with both menthol and rapamycin showed significantly decreased TNF- alpha, IL-1beta, and p-mTOR expression and obviously lowered intracellular Ca2+ concentration (P < 0.05).	Sirolimus	81-90	interleukin 1 alpha	Homo sapiens	134-142
30549029-4	2019	Therefore, we hypothesized that LKB1 deficiency in URCa cells could lead to increased sensitivity to rapamycin by inducing mitochondrial defect-mediated mitophagy.	Sirolimus	101-110	serine/threonine kinase 11	Homo sapiens	32-36
31128500-11	2019	Our results suggest that augmentation response of ketamine by guanosine in the NSF test probably involves the activation of mTOR signaling, since the treatment with rapamycin (0.2 nmol/site, i.c.v., a selective mTOR inhibitor) completely abolished this effect.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Mus musculus	124-128
31128500-11	2019	Our results suggest that augmentation response of ketamine by guanosine in the NSF test probably involves the activation of mTOR signaling, since the treatment with rapamycin (0.2 nmol/site, i.c.v., a selective mTOR inhibitor) completely abolished this effect.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Mus musculus	211-215
31329230-0	2019	Successful reversal of ovarian hyperstimulation syndrome in a mouse model by rapamycin, an mTOR pathway inhibitor.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	91-95
31329230-6	2019	Selectively inhibiting mTOR signals by only two injections of rapamycin (2 mg/kg body weight), before or just after hCG treatment, significantly reduced vascular leakage and the severity of OHSS symptoms.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Mus musculus	23-27
31329230-8	2019	Further study showed the functional roles of the mTOR signaling pathway in the hyperstimulation-induced ovarian extracellular matrix remodeling as the expression of alpha2M, a broad proteolytic inhibitor in both ovary and serum, was dramatically decreased after rapamycin treatment.	Sirolimus	262-271	mechanistic target of rapamycin kinase	Mus musculus	49-53
31364468-8	2019	Moreover, the mTOR inhibitor rapamycin, NAD+ precursor nicotinamide riboside, and ABC99, a small molecule Notum inhibitor, have all been reported to rejuvenate ISC function in old mice and thus may have promise in humans.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	14-18
31371743-6	2019	EV-miRNA profiles showed a significant upregulation of miR-6127, miR-6746-5p, and miR-6787-5p under RAPA treatment compared to CsA and untreated conditions in metastatic cell lines that were not observed in non-metastatic cells.	Sirolimus	100-104	microRNA 6787	Homo sapiens	82-90
31371743-8	2019	These results suggest that EV-miR-6127, miR-6746-5p and miR-6787-5p could be a potential epigenetic mechanism induced by RAPA therapy in the regulation of the pre-metastatic niche of post-transplant colorectal cancer.	Sirolimus	121-125	microRNA 6787	Homo sapiens	56-64
30905858-0	2019	Rapamycin-induced autophagy decreases Myf5 and MyoD proteins in C2C12 myoblast cells.	Sirolimus	0-9	myogenic differentiation 1	Mus musculus	47-51
30905858-3	2019	In this study, we determined whether rapamycin-induced autophagy causes the decrease of Myf5 and MyoD protein in C2C12 myoblast cells.	Sirolimus	37-46	myogenic differentiation 1	Mus musculus	97-101
31324799-2	2019	However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	113-117
31324799-2	2019	However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	138-142
31324799-3	2019	Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin.	Sirolimus	64-73	FK506 binding protein 1a	Mus musculus	47-53
31324799-3	2019	Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin.	Sirolimus	116-125	FK506 binding protein 1a	Mus musculus	47-53
31316104-7	2019	Rapamycin treatment rescued mitophagy, blocked the increase in MTOR and phosphorylated-MTOR, and increased the mitophagy-related gene expression in Gas6-depleted MII oocytes.	Sirolimus	0-9	growth arrest specific 6	Homo sapiens	148-152
30995114-12	2019	Finally, we provide evidence that AMPK activates PI3K by inhibiting mechanistic target of rapamycin complex 1 and preventing mechanistic target of rapamycin complex 1-mediated inhibition of insulin receptor substrate-1-associated activation of PI3K.	Sirolimus	147-156	insulin receptor substrate 1	Mus musculus	190-218
31042058-7	2019	Pkd1RC/RC mice were treated with sirolimus or torin2 from 50 to 120 days of age.	Sirolimus	33-42	polycystin 1, transient receptor potential channel interacting	Mus musculus	0-6
31042058-9	2019	Both sirolimus and torin2 decreased phosphorylated S6 protein, phosphorylated eukaryotic translation initiation factor 4E-binding protein 1, phosphorylated Akt, and proliferation in Pkd1RC/RC kidneys.	Sirolimus	5-14	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	78-139
31042058-9	2019	Both sirolimus and torin2 decreased phosphorylated S6 protein, phosphorylated eukaryotic translation initiation factor 4E-binding protein 1, phosphorylated Akt, and proliferation in Pkd1RC/RC kidneys.	Sirolimus	5-14	polycystin 1, transient receptor potential channel interacting	Mus musculus	182-188
31115485-11	2019	On the whole, our findings indicate that rapamycin inhibits the activation of mTOR and alters the Wnt/GSK3beta/beta-catenin signalling pathway; thus, it may serve as a therapeutic target in the treatment of AD.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Mus musculus	78-82
31115485-11	2019	On the whole, our findings indicate that rapamycin inhibits the activation of mTOR and alters the Wnt/GSK3beta/beta-catenin signalling pathway; thus, it may serve as a therapeutic target in the treatment of AD.	Sirolimus	41-50	catenin beta 1	Homo sapiens	111-123
31200728-11	2019	In experiment B, rapamycin injection during the active period of mTOR signaling demonstrated near-complete inhibition of CNV lesion as well as significant induction of autophagy.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Mus musculus	65-69
30592193-14	2019	Live/dead cell analysis with YO-PRO-1 staining showed that rapamycin induced apoptosis in 24% of the cells when used at 1 microM concentration, whereas the rate increased to 61% and 72% when the cells were treated with 2 microM and 5 microM rapamycin, respectively.	Sirolimus	59-68	lamin A/C	Homo sapiens	32-37
31803045-0	2019	Melatonin and Rapamycin Attenuate Isoflurane-Induced Cognitive Impairment Through Inhibition of Neuroinflammation by Suppressing the mTOR Signaling in the Hippocampus of Aged Mice.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	133-137
31803045-10	2019	Melatonin and rapamycin significantly ameliorated the isoflurane-induced cognitive impairment and also led to a decrease in the melatonin levels as well as the expression levels of TNF-alpha, IL-1beta, IL-6, and p-mTOR in the hippocampus.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	214-218
31803045-11	2019	In conclusion, these results showed that melatonin and rapamycin attenuates mTOR expression while affecting the downstream proinflammatory cytokines.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	76-80
31540687-10	2019	Finally, we found that HK-2 cells exposed to rapamycin or mTOR siRNA reduced the TNF-alpha-induced up-regulation of RUNX1.	Sirolimus	45-54	RUNX family transcription factor 1	Homo sapiens	116-121
31695068-4	2019	Ribosomal protein S6 kinase 1 (S6K1) is a major downstream signalling molecule of mTOR, and its activity is reduced by rapamycin suggesting that deregulation of S6K1 activity may be beneficial in HD.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	31-35
31695068-4	2019	Ribosomal protein S6 kinase 1 (S6K1) is a major downstream signalling molecule of mTOR, and its activity is reduced by rapamycin suggesting that deregulation of S6K1 activity may be beneficial in HD.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	161-165
31542387-11	2019	Notably, RAPA significantly inhibited the activation of NF-kB and NLRP3 inflammasome and the production of IL-1beta in APAP-treated mice.	Sirolimus	9-13	NLR family, pyrin domain containing 3	Mus musculus	66-71
31542387-11	2019	Notably, RAPA significantly inhibited the activation of NF-kB and NLRP3 inflammasome and the production of IL-1beta in APAP-treated mice.	Sirolimus	9-13	interleukin 1 alpha	Mus musculus	107-115
31557409-7	2019	In addition, we found that ectopic expression of MACC1 (silencing and overexpression by transfection) resulted in corresponding changes in c-Met and PDL1 expression levels, and c-Met/AKT/mTOR pathway inhibitors (SU11274, MK2206, and rapamycin) blocked the regulation of PDL1 expression by MACC1.	Sirolimus	233-242	MET transcriptional regulator MACC1	Homo sapiens	49-54
31487224-7	2019	The reduction of protein synthesis was associated with a marked inhibition of mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1, a mechanism consistent with reduced translation initiation.	Sirolimus	98-107	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	156-217
30978385-10	2019	Overexpression of TIGAR increased the levels of phosphorylated mTOR and S6KP70 under OGD/R condition, this enhancement effect was suppressed by rapamycin.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	63-67
30825612-9	2019	A higher compensatory increase in Akt phosphorylation after rapamycin treatment of LKB1-deficient cells than after rapamycin treatment of LKB1 wild-type cells is responsible for the synergistic effect of mTOR and PI3K inhibition.	Sirolimus	60-69	serine/threonine kinase 11	Homo sapiens	83-87
30877063-9	2019	In contrast, sirolimus, temsirolimus, and everolimus are larger molecules (MW   1000) that bind to FKBP-12 to generate a complex that inhibits mTOR (mammalian target of rapamycin).	Sirolimus	13-22	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	99-106
31060359-5	2019	Rapamycin, a specific inhibitor of mTORC1, downregulated 4EBP1 phosphorylation and the expression of PPARgamma and the following lipogenic genes: lipin 1, DGAT1, ACC, and FAS.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Bos taurus	57-62
30710527-9	2019	Treg cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high levels of integrin alpha4beta7, as well as CD62L and FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.	Sirolimus	48-57	selectin L	Homo sapiens	148-153
30710527-9	2019	Treg cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high levels of integrin alpha4beta7, as well as CD62L and FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.	Sirolimus	200-209	retinoic acid receptor alpha	Homo sapiens	76-80
30710527-9	2019	Treg cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high levels of integrin alpha4beta7, as well as CD62L and FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.	Sirolimus	200-209	retinoic acid receptor alpha	Homo sapiens	76-80
30876754-0	2019	Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Mus musculus	24-28
31676823-5	2019	Notably, treatment of adult mice with rapamycin, which inhibits MTOR, reverses the phenotypes.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Mus musculus	64-68
31057050-6	2019	The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment.	Sirolimus	113-122	ribosomal protein S6 kinase B1	Rattus norvegicus	33-39
31057050-11	2019	In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Rattus norvegicus	140-146
31518555-8	2019	Rapamycin treatment during unloading abolished p70S6K and E3 ligases upregulation and increased HDAC5 nuclear accumulation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	47-53
31618823-5	2019	Mice were exposed to isoflurane at postnatal day 7 and select cohorts were treated with rapamycin, an mTOR pathway inhibitor.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Mus musculus	102-106
31426028-11	2019	Interference of mTOR activity by mTOR siRNA or rapamycin abolished the stimulation of GLP-1 production induced by IL-27 in STC-1 cells.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Mus musculus	16-20
31047942-0	2019	Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B1	Homo sapiens	52-109
31047942-0	2019	Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B1	Homo sapiens	195-202
31047942-2	2019	Current studies determined the OATP1B1/1B3-mediated drug-drug interaction (DDI) potential of mammalian target of rapamycin (mTOR) inhibitors, everolimus and sirolimus, using R-value and physiologically based pharmacokinetic models.	Sirolimus	157-166	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-42
31047942-3	2019	Preincubation with everolimus and sirolimus significantly decreased OATP1B1/1B3-mediated transport even after washing and decreased inhibition constant values up to 8.3- and 2.9-fold for OATP1B1 and both 2.7-fold for OATP1B3, respectively.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-79
31047942-3	2019	Preincubation with everolimus and sirolimus significantly decreased OATP1B1/1B3-mediated transport even after washing and decreased inhibition constant values up to 8.3- and 2.9-fold for OATP1B1 and both 2.7-fold for OATP1B3, respectively.	Sirolimus	34-43	solute carrier organic anion transporter family member 1B1	Homo sapiens	68-75
31047942-5	2019	Physiologically based pharmacokinetic models predict that everolimus and sirolimus have low OATP1B1/1B3-mediated DDI potential against pravastatin.	Sirolimus	73-82	solute carrier organic anion transporter family member 1B1	Homo sapiens	92-103
31047942-7	2019	The preincubation effects of everolimus and sirolimus on OATP1B1/1B3-mediated transport were similar in cells before preincubation with vehicle control or INK-128, suggesting that inhibition of mTOR activity is not a prerequisite for the preincubation effects observed for everolimus and sirolimus.	Sirolimus	44-53	solute carrier organic anion transporter family member 1B1	Homo sapiens	57-68
31047942-9	2019	We report the everolimus/sirolimus-preincubation-induced inhibitory effects on OATP1B1/1B3 and relatively low OATP1B1/1B3-mediated DDI potential of everolimus and sirolimus.	Sirolimus	25-34	solute carrier organic anion transporter family member 1B1	Homo sapiens	79-90
31047942-9	2019	We report the everolimus/sirolimus-preincubation-induced inhibitory effects on OATP1B1/1B3 and relatively low OATP1B1/1B3-mediated DDI potential of everolimus and sirolimus.	Sirolimus	25-34	solute carrier organic anion transporter family member 1B1	Homo sapiens	110-121
31047942-9	2019	We report the everolimus/sirolimus-preincubation-induced inhibitory effects on OATP1B1/1B3 and relatively low OATP1B1/1B3-mediated DDI potential of everolimus and sirolimus.	Sirolimus	163-172	solute carrier organic anion transporter family member 1B1	Homo sapiens	110-121
31650090-1	2019	AMP-activated protein kinase (AMPK) is an energy-sensing kinase that has emerged as a novel therapeutic target for pain due to its ability to inhibit mechanistic target of rapamycin (mTOR) and mitogen activated protein kinase (MAPK) signaling, two signaling pathways that are linked to pain promotion after injury as well as the development of hyperalgesic priming.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Mus musculus	183-187
31632585-13	2019	CONCLUSION: The data indicated that rapamycin, an inhibitor of mTOR, blocked iNOS and NO production during asthma onset.	Sirolimus	36-45	mechanistic target of rapamycin kinase	Mus musculus	63-67
30782019-9	2019	A systemic injection of rapamycin activated chondrocyte autophagy, which increased the expression of LC3 and ATG-5, and reduced OARSI scores, the expression of beta-catenin, MMP-13, and VEGF, and chondrocyte apoptosis in rapamycin treated mice when compared with vehicle-treated mice.	Sirolimus	24-33	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	101-104
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	52-61	interleukin 1 alpha	Homo sapiens	134-142
31176046-6	2019	However, pharmacological activation of autophagy by Rapamycin (RAPA) efficiently suppressed Abeta-, lipopolysaccharides (LPS)-induced IL-1beta expression via regulating NLRP3-Caspase-1 inflammasome in astrocytes.	Sirolimus	63-67	interleukin 1 alpha	Homo sapiens	134-142
31404320-9	2019	Rapamycin and doxorubicin also reduced the phosphorylation levels of mTOR and p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	78-84
31404320-12	2019	These results suggested that rapamycin could enhance the antitumor effects of doxorubicin on K562 cells by downregulating mTOR/p70S6K signaling.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	127-133
31433805-3	2019	Here, we demonstrate a special metabolic-epigenetic coupling mechanism orchestrated by tuberous sclerosis complex subunit 1 (TSC1)-mechanistic target of rapamycin (mTOR) for homeostatic DC function.	Sirolimus	153-162	mechanistic target of rapamycin kinase	Mus musculus	164-168
31417118-7	2019	The study indicated that the sequential regulation of AMPK-mammalian target of rapamycin complex 1-eEF2 signaling was altered and protein synthesis ability was reduced in the cerebral cortex of hibernating chipmunks.	Sirolimus	79-88	eukaryotic translation elongation factor 2	Homo sapiens	99-103
31358596-8	2019	Both mycophenolate and rapamycin, especially the latter, decreased glomerular mTOR Ser2448 phosphorylation.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	78-82
31358596-12	2019	Mycophenolate and rapamycin also down-regulated mTOR and extracellular signal-regulated kinase (ERK) phosphorylation and inhibited fibrotic responses in mesangial cells that were induced by anti-dsDNA antibodies or TGF-beta1.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	48-52
30728467-9	2019	In HepG2 cells, rapamycin (a mTOR inhibitor) significantly reduced the OLZ-stimulated hepatocellular lipid contents and weakened the ability of Sim to lower lipids via a mechanism associated with the upregulation of SREBP1c-mediated de novo lipogenesis.	Sirolimus	16-25	sterol regulatory element binding transcription factor 1	Homo sapiens	216-223
30552925-0	2019	Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	63-69
30552925-2	2019	Based on the well-described effects of mTORC1/rapamycin complex on 4E-BP1 phosphorylation/s, it is generally accepted that rapamycin is a global inhibitor of cap-dependent translation.	Sirolimus	46-55	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	67-73
30552925-3	2019	We have previously shown that 4E-BP1 resistance to rapamycin was overcome by the stoichiometric abundance of S6K1.	Sirolimus	51-60	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	30-36
30552925-3	2019	We have previously shown that 4E-BP1 resistance to rapamycin was overcome by the stoichiometric abundance of S6K1.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	109-113
30552925-4	2019	Now we present evidence that the TOS-bearing amino terminal domain of S6K1 is sufficient to relieve the rapamycin resistance of 4E-BP1 as TOS deleted variants of S6K1, active or inactive with regard to S6K1 activity failed to bring about relief of 4E-BP1 resistance to rapamycin.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	70-74
30552925-4	2019	Now we present evidence that the TOS-bearing amino terminal domain of S6K1 is sufficient to relieve the rapamycin resistance of 4E-BP1 as TOS deleted variants of S6K1, active or inactive with regard to S6K1 activity failed to bring about relief of 4E-BP1 resistance to rapamycin.	Sirolimus	104-113	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	128-134
30552925-6	2019	The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently.	Sirolimus	110-119	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	135-141
30552925-6	2019	The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently.	Sirolimus	110-119	ribosomal protein S6 kinase B1	Homo sapiens	227-231
31182914-0	2019	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.	Sirolimus	51-60	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	95-100
31182914-0	2019	Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.	Sirolimus	51-60	TSC complex subunit 2	Mus musculus	110-114
31182914-2	2019	Here, we undertook an effort to uncover the mechanisms underlying the limited efficacy of rapamycin, and found that the transit suppression of 4EBP1 phosphorylation led to cap-dependent translation and cell proliferation in breast cancer cells.	Sirolimus	90-99	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	143-148
31182914-7	2019	Moreover, SGK3 deletion in combination with AKT inhibition almost blocked the 4EBP1 re-phosphorylation that was induced by rapamycin and profoundly enhanced rapamycin-induced growth inhibition in vitro and in an MCF7 breast cancer mouse xenograft model in vivo.	Sirolimus	123-132	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	78-83
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	176-185	toll like receptor 4	Homo sapiens	91-95
30260006-10	2019	Treatment with Pingchuanning decoction activated PI3K/Akt/mTOR pathway and inhibited HMGB1/TLR4/NF-kappaB pathway, which could be overturned by LY294002, a PI3K antagonist, or rapamycin (Rapa), an autophagy inducer.	Sirolimus	187-191	toll like receptor 4	Homo sapiens	91-95
30823477-11	2019	In this process, both the LC3I/LC3II ratio and p62 protein levels increased, which indicated that the blockage of CD73 could inhibit cell autophagy, and cell migration and invasion were restored by rapamycin.	Sirolimus	198-207	5' nucleotidase, ecto	Mus musculus	114-118
30863363-10	2019	Both palmitate and brefeldin induced PERK, CHOP and BiP gene expression, which was partially, but significantly prevented by rapamycin.	Sirolimus	125-134	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	37-41
30863363-12	2019	Compared to untreated T2D cells, rapamycin-exposed diabetic islets showed improved insulin secretion, reduced proportion of beta cells showing signs of apoptosis and better preserved insulin granules, mitochondria and ER ultrastructure; this was associated with significant reduction of PERK, CHOP and BiP gene expression.	Sirolimus	33-42	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	287-291
30705972-5	2019	Phosphorylation of p70 S6 kinase (p70S6K), an essential factor for promoting protein synthesis in skeletal muscle, was significantly increased by S42 to almost the same extent as by insulin, but this was significantly prevented by treatment with rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	246-255	ribosomal protein S6 kinase B1	Rattus norvegicus	19-32
30705972-5	2019	Phosphorylation of p70 S6 kinase (p70S6K), an essential factor for promoting protein synthesis in skeletal muscle, was significantly increased by S42 to almost the same extent as by insulin, but this was significantly prevented by treatment with rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	246-255	ribosomal protein S6 kinase B1	Rattus norvegicus	34-40
30636722-0	2019	Rapamycin-mediated mTOR inhibition impairs silencing of sex chromosomes and the pachytene piRNA pathway in the mouse testis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	19-23
30602778-3	2019	Here we demonstrate that rapamycin-insensitive mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-beta1 stimulated collagen synthesis in human lung fibroblasts, whereas canonical PI3K/Akt signaling is not required.	Sirolimus	25-34	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	68-74
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	182-191	beclin 1, autophagy related	Mus musculus	0-7
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	182-191	mechanistic target of rapamycin kinase	Mus musculus	108-112
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	182-191	notch 1	Mus musculus	114-120
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	notch 1	Mus musculus	126-132
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	179-183
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	beclin 1, autophagy related	Mus musculus	185-192
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	204-207
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	211-214
30368647-6	2019	Administering Drosophila both ferulic acid and the TOR inhibitor rapamycin eliminated the physiological and molecular developmental advances indicating that microbial ferulic acid affects energy utilization in a dTOR-dependent manner outlining a potential mechanism of action of L. fermentum NCIMB 5221 on modulating microbiota dynamics to modulate energy homeostasis.	Sirolimus	65-74	Target of rapamycin	Drosophila melanogaster	51-54
30368647-6	2019	Administering Drosophila both ferulic acid and the TOR inhibitor rapamycin eliminated the physiological and molecular developmental advances indicating that microbial ferulic acid affects energy utilization in a dTOR-dependent manner outlining a potential mechanism of action of L. fermentum NCIMB 5221 on modulating microbiota dynamics to modulate energy homeostasis.	Sirolimus	65-74	Target of rapamycin	Drosophila melanogaster	212-216
31240704-3	2019	Similarly, rapamycin (Rapa) and shRaptor block suppression of PTEN by high glucose.	Sirolimus	11-20	phosphatase and tensin homolog	Homo sapiens	62-66
30373500-6	2019	However, ketamine-induced apoptosis in hippocampal neurons was reversed significantly by the administration of rapamycin, as evident by the decrease in expressions of pro-apoptotic proteins (Bax and cleaved Caspase-3) and the increase in anti-apoptotic protein (Bcl-2).	Sirolimus	111-120	BCL2 associated X, apoptosis regulator	Rattus norvegicus	191-194
31240704-3	2019	Similarly, rapamycin (Rapa) and shRaptor block suppression of PTEN by high glucose.	Sirolimus	22-26	phosphatase and tensin homolog	Homo sapiens	62-66
30469030-7	2019	In differentiating 3T3-L1 cells, the mTOR inhibitor rapamycin and the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) likewise suppressed SELENBP1 induction, adipocyte differentiation and lipid accumulation.	Sirolimus	52-61	mechanistic target of rapamycin kinase	Mus musculus	37-41
30594149-0	2018	Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	63-67
30594149-3	2018	In this study, we tested the efficacy of a well-known mTOR inhibitor, rapamycin, in reducing oxidative damage and increasing cell viability in the mouse hippocampal cell line, HT22, during a CoCl2-simulated hypoxic insult.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Mus musculus	54-58
30290159-3	2018	The aim of this study was to further investigate the actions of rapamycin in inducing expression of the antioxidant enzymes heme oxygenase-1 (HO-1) and peroxiredoxin-1 (Prx-1) in normal liver and in tumorigenic liver cells.	Sirolimus	64-73	peroxiredoxin 1	Rattus norvegicus	152-167
30806956-11	2019	Rapamycin alleviated the cardiac function and systemic inflammatory reaction in MI mice as well as inflammatory reaction in macrophages under inflammatory stress, which was attenuated by knocking out alpha7nAChR.	Sirolimus	0-9	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	200-211
31207499-6	2019	Both AZD2014 and rapamycin potently suppressed EMT of renal tumors and effectively blocked tumor progression in Tsc2+/- mice.	Sirolimus	17-26	TSC complex subunit 2	Mus musculus	112-116
30905858-7	2019	In the same conditions, rapamycin-induced autophagy significantly reduced the Myf5 and MyoD proteins.	Sirolimus	24-33	myogenic differentiation 1	Mus musculus	87-91
30905858-8	2019	Together, these results suggest that rapamycin-induced autophagy results in the decrease of Myf5 and MyoD proteins in C2C12 myoblast cells.	Sirolimus	37-46	myogenic differentiation 1	Mus musculus	101-105
30205205-0	2018	Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	117-121
30405153-9	2018	Unexpectedly, TRR1 deletion causes sensitivity to the inhibitors of the TORC1 pathway, such as rapamycin.	Sirolimus	95-104	thioredoxin-disulfide reductase TRR1	Saccharomyces cerevisiae S288C	14-18
31309829-4	2019	Here, we extend PAL and MS methods to derive a binding site hotspot map for the immunosuppressant rapamycin, a complex macrocyclic natural product that forms a ternary complex with the proteins FKBP12 and FRB.	Sirolimus	98-107	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	194-200
30385753-5	2018	Rapamycin, a pharmacological inhibitor of mTOR, stimulated autophagy and mitophagy, and alleviated the development of cisplatin nephrotoxicity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	42-46
30220530-0	2018	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.	Sirolimus	19-28	activating transcription factor 3	Homo sapiens	91-95
30220530-4	2018	OBJECTIVE: Our aim was to investigate the impact of Sirolimus on the expression level of the oncogene ATF3, which is involved in the development and progression of cSCC.	Sirolimus	52-61	activating transcription factor 3	Homo sapiens	102-106
30220530-6	2018	RESULTS: We show that Sirolimus downregulates the expression of ATF3 induced by cyclosporine or cyclosporine plus UV-radiation in keratinocytes.	Sirolimus	22-31	activating transcription factor 3	Homo sapiens	64-68
30220530-7	2018	In line with this we demonstrate a decrease in ATF3 expression, by incubating 3D skin equivalents with Sirolimus prior to cyclosporine and UV-light.	Sirolimus	103-112	activating transcription factor 3	Homo sapiens	47-51
30220530-9	2018	CONCLUSION: Taken together, our study demonstrates that Sirolimus downregulates the CNI or UV-induced ATF3 expression in human keratinocytes, which could be a potential molecular mechanism how Sirolimus reduces cSCC in OTRs.	Sirolimus	56-65	activating transcription factor 3	Homo sapiens	102-106
30220530-9	2018	CONCLUSION: Taken together, our study demonstrates that Sirolimus downregulates the CNI or UV-induced ATF3 expression in human keratinocytes, which could be a potential molecular mechanism how Sirolimus reduces cSCC in OTRs.	Sirolimus	193-202	activating transcription factor 3	Homo sapiens	102-106
30373605-3	2018	Recent preclinical and clinical data demonstrated that sirolimus could offset the progression of vascular malformations and significantly improve quality of life of patients through inhibition of the Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian Target of Rapamycin (mTOR) pathway.	Sirolimus	55-64	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	200-229
30185506-6	2018	Rapamycin restored LPS-induced up-regulation of EDN1, endothelin converting enzyme-1 (ECE1), and p-JNK in TSC1-knockdown mouse embryonic fibroblasts (MEFs).	Sirolimus	0-9	endothelin 1	Mus musculus	48-52
30416863-12	2018	Levels of p-mTOR (Ser2448) and p-p70S6K (Thr389) increased in URI-overexpressing cells treated with the mTOR inhibitor rapamycin but decreased in URI-silenced cells.	Sirolimus	119-128	ribosomal protein S6 kinase B1	Homo sapiens	33-39
30416863-12	2018	Levels of p-mTOR (Ser2448) and p-p70S6K (Thr389) increased in URI-overexpressing cells treated with the mTOR inhibitor rapamycin but decreased in URI-silenced cells.	Sirolimus	119-128	URI1 prefoldin like chaperone	Homo sapiens	62-65
30114398-12	2018	Furthermore, the blockage of mTOR activity by rapamycin increased ER stress in cultured neuronal cells; whereas the activation or inhibition of ER stress by tunicamycin or 4-PBA respectively had little effects on mTOR signaling.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Mus musculus	29-33
29898430-10	2018	Forced lowexpression of miR-338 directly led to increased the level of autophagy in cervical cancer cells, which was similar to the mTOR signaling inhibitor rapamycin.	Sirolimus	157-166	microRNA 338	Homo sapiens	24-31
30079598-5	2018	RESULTS: Tsc1Cx3cr1-Cre CKO mice exhibited a high efficiency of microglia Tsc1 inactivation, mTORC1 activation, increased microglial size and number, and robust epilepsy, which were rapamycin-dependent.	Sirolimus	182-191	TSC22 domain family, member 1	Mus musculus	9-19
30154635-10	2018	Pain secondary to PTEN hamartoma responded poorly to percutaneous sclerosant injection, but demonstrated improvement with sirolimus.	Sirolimus	122-131	phosphatase and tensin homolog	Homo sapiens	18-22
31358056-13	2019	Rapamycin treatment upregulated miR-100 and downregulated MMPs and ADAMTS5.	Sirolimus	0-9	microRNA 100	Homo sapiens	32-39
31167789-9	2019	Mechanistically, we found that mOC-ABs induce osteoblast differentiation by activatingPI3K/AKT/mechanistic target of rapamycin (mTOR)/ribosomal protein S6 kinase signaling.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Mus musculus	128-132
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	forkhead box P3	Mus musculus	27-32
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	forkhead box P3	Mus musculus	90-95
31372056-10	2019	The PI3K/Akt pathway inhibitor, rapamycin, and LY294002 could partially attenuate the effect of Ezrin on cell proliferation, invasion, EMT progression, and YAP phosphorylation and translocation.	Sirolimus	32-41	ezrin	Homo sapiens	96-101
31392083-9	2019	In contrast, loss of EDD in MCF-7 cells increased cell sensitivity to cisplatin, doxorubicin, rapamycin, and selective estrogen receptor modulator tamoxifen.	Sirolimus	94-103	ubiquitin protein ligase E3 component n-recognin 5	Homo sapiens	21-24
31005665-0	2019	Nicotine inhibits rapamycin-induced pain through activating mTORC1/S6K/IRS-1-related feedback inhibition loop.	Sirolimus	18-27	insulin receptor substrate 1	Homo sapiens	71-76
31005665-10	2019	Our results showed that nicotine significantly reduced hyperalgesia in mice that received acute or repeated rapamycin injections, and reversed the effects of rapamycin on the phosphorylation of S6K, 4E-BP1, insulin receptor substrate-1 (IRS-1) at Ser636/639, AKT at Ser473, and ERK at Thr202/Tyr204.	Sirolimus	158-167	insulin receptor substrate 1	Mus musculus	207-235
30958627-5	2019	The expression of ERK1/2 and phosphatidylinositol 3 kinase/protein kinase B/mammalian targets of the rapamycin (PI3K/AKt/mTOR) signals and transferrin receptor (TfR/CD71) was detected with the methods of immunoblotting.	Sirolimus	101-110	protein tyrosine kinase 2 beta	Homo sapiens	59-75
31115485-0	2019	Alteration of the Wnt/GSK3beta/beta-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer"s disease model.	Sirolimus	66-75	catenin beta 1	Homo sapiens	31-43
31115485-5	2019	In this study, we intraperitoneally injected amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice with rapamycin, a known activator of autophagy that inhibits mTOR.	Sirolimus	117-126	amyloid beta (A4) precursor protein	Mus musculus	45-70
31115485-5	2019	In this study, we intraperitoneally injected amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice with rapamycin, a known activator of autophagy that inhibits mTOR.	Sirolimus	117-126	presenilin 1	Mus musculus	77-89
31115485-5	2019	In this study, we intraperitoneally injected amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice with rapamycin, a known activator of autophagy that inhibits mTOR.	Sirolimus	117-126	presenilin 1	Mus musculus	91-94
31115485-5	2019	In this study, we intraperitoneally injected amyloid precursor protein (APP)/presenilin-1 (PS1) transgenic mice with rapamycin, a known activator of autophagy that inhibits mTOR.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Mus musculus	173-177
31115485-10	2019	In this study, we provide evidence that rapamycin inhibits GSK3beta activation and elevates beta-catenin expression by improving the Wnt3a expression levels, which facilitates the amelioration of AD pathology.	Sirolimus	40-49	catenin beta 1	Homo sapiens	92-104
31949841-6	2018	The expressions of glycolysis enzymes, Hexokinase 2, PKM2 and LDHA are upregulated in rapamycin resistant cells.	Sirolimus	86-95	pyruvate kinase M1/2	Homo sapiens	53-57
29787763-5	2018	Under the same conditions, mitophagy defects were strikingly rescued in the SEACIT mutants (1) treated with rapamycin, a specific TOR kinase inhibitor, (2) lacking Gtr1, a TORC1-stimulating Rag family GTPase downstream of SEACIT, and (3) devoid of Pib2, a phosphatidylinositol 3-phosphate-binding TORC1 activator.	Sirolimus	108-117	Pib2p	Saccharomyces cerevisiae S288C	248-252
31263281-3	2019	Here we identified a recurrent gain-of-function ARAF mutation (c.640T&gt;C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient.	Sirolimus	176-185	A-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	48-52
31354297-9	2019	Results: The results showed that CD34(+) blood vessels and LYVE-1(+) lymphatic vessels decreased in the peritumor and intratumor region in rapamycin-treated tumors.	Sirolimus	139-148	lymphatic vessel endothelial hyaluronan receptor 1	Homo sapiens	59-65
31171801-7	2019	Overall, we suggest that rapamycin induces transcriptional activation of BDSCs towards osteogenic differentiation, through increased GATA4 and Sox17 that modulate downstream transcription factors (like Runx2), critical for bone formation.	Sirolimus	25-34	SRY-box transcription factor 17	Homo sapiens	143-148
30801921-2	2019	mTOR functions in two distinct complexes: rapamycin-sensitive mTOR complex (C) 1 and rapamycin-insensitive mTORC2.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	0-4
30801921-2	2019	mTOR functions in two distinct complexes: rapamycin-sensitive mTOR complex (C) 1 and rapamycin-insensitive mTORC2.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Mus musculus	0-4
31125447-0	2019	Hypervascularization in mTOR-dependent focal and global cortical malformations displays differential rapamycin sensitivity.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Mus musculus	24-28
31026345-1	2019	KEY POINTS: In muscular cells, eukaryotic initiation factor subunit f (eIF3f) activates protein synthesis by allowing physical interaction between mechanistic target of rapamycin complex 1 (MTORC1) and ribosomal protein S6 kinase 1 (S6K1), although its physiological role in animals is unknown.	Sirolimus	169-178	eukaryotic translation initiation factor 3, subunit F	Mus musculus	71-76
31092879-5	2019	Furthermore, simvastatin impaired the phosphorylation of Akt (Protein Kinase B) mainly at Ser473 and less at Thr308, indicating impaired activity of the mammalian Target of Rapamycin Complex 2 (mTORC2).	Sirolimus	173-182	protein tyrosine kinase 2 beta	Homo sapiens	62-78
31133888-7	2019	Low-dose rapamycin (0.1 nM) normalized respiration with the magnitude of this normalization greater for AD-A LCLs, suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may have a different dynamic range for regulating mitochondrial activity in individuals with ASD with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) regulation.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	356-360
31133888-7	2019	Low-dose rapamycin (0.1 nM) normalized respiration with the magnitude of this normalization greater for AD-A LCLs, suggesting that the mammalian target of rapamycin complex 1 (mTORC1) pathway may have a different dynamic range for regulating mitochondrial activity in individuals with ASD with and without mitochondrial dysfunction, potentially related to S6K1 (S6 kinase beta-1) regulation.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	362-378
29337352-2	2018	Here, we report in mice that L-LTP failure induced by the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) inhibitor rapamycin is reversed by brain-specific genetic deletion of PKR-like ER kinase, PERK (PERK KO), a kinase for eukaryotic initiation factor 2alpha (eIF2alpha).	Sirolimus	92-101	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	211-215
30317760-9	2018	Rapamycin alleviated lipid deposition caused by oleic acid and palmitic acid and inhibited their induction of increased expression of mTOR, S6K1, and SREBP-1c.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	140-144
30317760-9	2018	Rapamycin alleviated lipid deposition caused by oleic acid and palmitic acid and inhibited their induction of increased expression of mTOR, S6K1, and SREBP-1c.	Sirolimus	0-9	sterol regulatory element binding transcription factor 1	Homo sapiens	150-158
29353241-15	2018	Treatment with the mTOR inhibitor rapamycin or displacing glucose as cardiac substrate by feeding a ketogenic diet prolonged the survival of endothelial-specific Rbp-jkappa-deficient mice.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	19-23
29353241-15	2018	Treatment with the mTOR inhibitor rapamycin or displacing glucose as cardiac substrate by feeding a ketogenic diet prolonged the survival of endothelial-specific Rbp-jkappa-deficient mice.	Sirolimus	34-43	recombination signal binding protein for immunoglobulin kappa J region	Mus musculus	162-172
29445126-7	2018	Importantly, pharmacological inhibition of mTOR with rapamycin decreases osteoblasts differentiation as well as rescues the low bone mass phenotype of Egfr-/- fetuses.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Mus musculus	43-47
29445126-7	2018	Importantly, pharmacological inhibition of mTOR with rapamycin decreases osteoblasts differentiation as well as rescues the low bone mass phenotype of Egfr-/- fetuses.	Sirolimus	53-62	epidermal growth factor receptor	Mus musculus	151-155
30134066-0	2018	Rapamycin rescues BMP mediated midline craniosynostosis phenotype through reduction of mTOR signaling in a mouse model.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	87-91
29481864-7	2018	mTORC1-dependent effects of DEPDC5/NPRL3 KD were determined using the mTOR inhibitor rapamycin.	Sirolimus	85-94	mechanistic target of rapamycin kinase	Mus musculus	0-4
29481864-12	2018	DEPDC5/NPRL3 KD effects on morphology and functional mTOR activation were reversed by rapamycin.	Sirolimus	86-95	NPR3 like, GATOR1 complex subunit	Homo sapiens	7-12
29694832-3	2018	TORC1 kinase phosphorylates Atg13 to repress autophagy under nutrient-rich conditions, but if TORC1 becomes inactive upon nutrient starvation or rapamycin treatment, Atg13 is rapidly dephosphorylated and autophagy is induced.	Sirolimus	145-154	serine/threonine protein kinase regulatory subunit ATG13	Saccharomyces cerevisiae S288C	28-33
30669957-8	2019	The alterations induced by miR-506-3p mimics were partly reversed by SPHK1 overexpression or treatment of rapamycin.	Sirolimus	106-115	microRNA 506	Homo sapiens	27-34
30794430-7	2019	Moreover, inhibiting the mammalian target of rapamycin (mTOR) complex 1, an important downstream effector of PI3K-Akt, by short-term application of rapamycin attenuated the effects of M1 receptors on GluA1.	Sirolimus	45-54	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	200-205
31151763-7	2019	Treatment with the mTOR signaling pathway inhibitor, rapamycin, inhibited the phosphorylation of mTOR and AKT, decreased Snail and Vimentin protein levels, and increased VE-cad protein levels.	Sirolimus	53-62	vimentin	Homo sapiens	131-139
30765845-3	2019	In this report, we found that mTOR inhibitor rapamycin or mTOR deletion in CX3Cr1+ mononuclear phagocytes inhibits expression of interleukin (IL)-23, accompanied by reduced intestinal production of IL-22 and ameliorated fibrosis in the TNBS-induced fibrosis mouse model.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Mus musculus	30-34
30765845-3	2019	In this report, we found that mTOR inhibitor rapamycin or mTOR deletion in CX3Cr1+ mononuclear phagocytes inhibits expression of interleukin (IL)-23, accompanied by reduced intestinal production of IL-22 and ameliorated fibrosis in the TNBS-induced fibrosis mouse model.	Sirolimus	45-54	interleukin 22	Mus musculus	198-203
30923227-11	2019	Furthermore, CB2R dysfunction significantly attenuated the cardiac protective effects of rapamycin both in vivo and in vitro Finally, we found that CB2R-mediated autophagy was induced by AMPK-mTOR-p70S6K signaling pathway.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	197-203
31011190-3	2019	This study investigated how inhibiting both glutamine metabolism with 6-diazo-5-oxo-L-norleucine (DON) and mTOR with rapamycin affects immune cells and the arthritis in a mouse model.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Mus musculus	107-111
30798110-0	2019	Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse.	Sirolimus	0-9	presenilin 1	Mus musculus	120-123
30798110-3	2019	Morris Water Maze tests were used to evaluate the effectiveness of rapamycin in APP/PS1 treatment and Western blot analysis was used to verify the proteomics data.	Sirolimus	67-76	presenilin 1	Mus musculus	84-87
30798110-4	2019	The results of Morris Water Maze tests indicated that rapamycin improved the spatial learning and memory abilities of APP/PS1 mice.	Sirolimus	54-63	presenilin 1	Mus musculus	122-125
29694832-3	2018	TORC1 kinase phosphorylates Atg13 to repress autophagy under nutrient-rich conditions, but if TORC1 becomes inactive upon nutrient starvation or rapamycin treatment, Atg13 is rapidly dephosphorylated and autophagy is induced.	Sirolimus	145-154	serine/threonine protein kinase regulatory subunit ATG13	Saccharomyces cerevisiae S288C	166-171
29872406-9	2018	Further mechanistic studies revealed that TGC increased silent information regulator 1 (Sirt1) expression to reduce the phosphorylation of the mammalian target of rapamycin and its downstream effectors P70S6K and 4EBP1.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	202-218
30879170-2	2019	Human FKBP12 is a prototype of this family and it is involved in many diseases due to its interaction with the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	145-154	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	6-12
30610968-5	2019	These findings revealed the role of mTOR in osteogenesis and angiogenesis in high-turnover osteoporosis with iron accumulation and showed that rapamycin targeting of mTOR ameliorates osteogenesis and angiogenesis to improve bone mass.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Mus musculus	166-170
30294901-1	2019	Autophagy is an essential cellular process concern with cellular homeostasis down-regulated by mTOR, whose activity can be modulated by rapamycin, a kind of lipophilic macrolide antibiotic, through forming a complex with immunophilin FKBP12 essential for mTOR regulation to induce autophagy.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Mus musculus	95-99
30294901-1	2019	Autophagy is an essential cellular process concern with cellular homeostasis down-regulated by mTOR, whose activity can be modulated by rapamycin, a kind of lipophilic macrolide antibiotic, through forming a complex with immunophilin FKBP12 essential for mTOR regulation to induce autophagy.	Sirolimus	136-145	FK506 binding protein 1a	Mus musculus	221-240
30294901-1	2019	Autophagy is an essential cellular process concern with cellular homeostasis down-regulated by mTOR, whose activity can be modulated by rapamycin, a kind of lipophilic macrolide antibiotic, through forming a complex with immunophilin FKBP12 essential for mTOR regulation to induce autophagy.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Mus musculus	255-259
30294901-4	2019	In this study, we synthesized a series of modified compounds based on the FKBP12 binding moiety to as same as the binding structure of rapamycin and FK506 particularly.	Sirolimus	135-144	FK506 binding protein 1a	Mus musculus	74-80
29716894-7	2018	Finally, we used this newly developed model to test whether rapamycin, an mTOR inhibitor that is currently the only PHTS therapy, can block hamartoma growth.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	74-78
29757673-5	2018	Results indicated that both rapamycin and AZD8055 inhibited mTOR complex 1 (mTORC1)/70-kDa ribosomal protein S6 kinase signaling similarly, whereas mTORC1/eukaryotic translation initiation factor 4E-binding protein 1 signaling was greatly inhibited by AZD8055.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Rattus norvegicus	91-118
29257864-0	2018	Rapamycin Confers Neuroprotection against Colistin-Induced Oxidative Stress, Mitochondria Dysfunction, and Apoptosis through the Activation of Autophagy and mTOR/Akt/CREB Signaling Pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	157-161
29257864-7	2018	Moreover, rapamycin pretreatment protected against colistin-induced mitochondrial dysfunction, caspase activation, and subsequent apoptosis by up-regulating autophagy and activating the Akt/CREB, NGF, and Nrf2 pathways, while inhibiting p53 signaling.	Sirolimus	10-19	transformation related protein 53, pseudogene	Mus musculus	237-240
29652799-4	2018	Furthermore, inhibiting p70 S6K through treatment with the FDA approved drug rapamycin prevents RVFV pathogenesis in a mouse model of infection.	Sirolimus	77-86	ribosomal protein S6 kinase B1	Homo sapiens	24-31
30906437-7	2019	Notably, rapamycin significantly inhibited HG-induced p-p70S6K expression, but did not significantly impact p-Akt expression.	Sirolimus	9-18	ribosomal protein S6 kinase B1	Homo sapiens	56-62
31531061-7	2019	Pretreatment with rapamycin, the inhibitor of mTOR, abolished all the above mentioned effects of CM.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	46-50
30746902-6	2019	Administration of diabetic apoE-/- mice with rapamycin attenuated MOMA-2 and CHOP up-regulation and apoptosis in atherosclerotic lesions.	Sirolimus	45-54	DNA-damage inducible transcript 3	Mus musculus	77-81
30632514-8	2019	Rapamycin prevented the decrease of bcl-2 expression in injured spinal cord tissue, reduced Bax, cytochrome c and caspase-3 expression levels and reduced the number of apoptotic neurons in injured spinal cord tissue 24 hours after spinal cord injury.	Sirolimus	0-9	BCL2 associated X, apoptosis regulator	Rattus norvegicus	92-95
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	secreted phosphoprotein 1	Homo sapiens	155-166
30889841-6	2019	RPM exposure also induced a significantly altered release of the cytokines and bone biomarkers sclerostin (SOST), osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), interleukin 1 beta (IL-1beta) and tumour necrosis factor 1 alpha (TNF-1alpha).	Sirolimus	0-3	secreted phosphoprotein 1	Homo sapiens	168-171
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	34-38
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	0-9	forkhead box P3	Mus musculus	50-65
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	0-9	forkhead box P3	Mus musculus	67-72
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	11-15	mechanistic target of rapamycin kinase	Mus musculus	34-38
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	11-15	forkhead box P3	Mus musculus	50-65
29636391-3	2018	We show that TPC2 is required for intracellular Ca2+ signaling in response to NAADP or to mTOR inhibition by rapamycin.	Sirolimus	109-118	two pore segment channel 2	Homo sapiens	13-17
31620191-3	2019	Rapamycin (RAPA), an inhibitor of mTOR, can drive Forkhead box P3 (FOXP3+) induction as a regulatory factor.	Sirolimus	11-15	forkhead box P3	Mus musculus	67-72
30129283-1	2019	Mechanistic target of rapamycin (mTOR) complex (mTORC)1 and mTORC2 regulate the differentiation and function of immune cells.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	33-37
29636391-7	2018	In HEK293 cells stably overexpressing human TPC2, shRNA-mediated knockdown of mTOR blocked rapamycin- and NAADP-evoked Ca2+ signals.	Sirolimus	91-100	two pore segment channel 2	Homo sapiens	44-48
29444470-11	2018	In addition, the hepatic phosphorylated mammalian target of rapamycin (mTOR) and P70S6K protein expressions were significantly downregulated and endothelial nitric oxide synthase (eNOS) expression upregulated by sirolimus.	Sirolimus	212-221	ribosomal protein S6 kinase B1	Homo sapiens	81-87
29444470-13	2018	In conclusion, sirolimus significantly improved hepatic inflammation and fibrosis accompanied by portal pressure reduction in cirrhotic rats, in which down-regulated mTOR/P70S6K and up-regulated eNOS expressions might play a role.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Rattus norvegicus	171-177
29393372-5	2018	After adding the phosphatidylinositol 3-kinase (PI3K)/AKT signaling inhibitor LY294002 or wortmannin to the LIF differentiation group, LIF-induced changes in the protein expression of TUJ1 and MAP2 were reversed, but this effect could not be prevented by rapamycin, a mechanistic target of rapamycin signaling inhibitor.	Sirolimus	255-264	LIF interleukin 6 family cytokine	Homo sapiens	135-138
30625371-9	2019	The results showed that the expressions of GRP78, CHOP and Beclin-1 increased, P62 decreased in model group; the expressions of GRP78 and CHOP were unchanged in 3-MA group and rapamycin group; but the expression of Beclin-1 decreased and P62 increased in 4-PBA group, while the expression of Beclin-1 increased and P62 decreased in TM group.	Sirolimus	176-185	DNA-damage inducible transcript 3	Rattus norvegicus	138-142
31128031-1	2019	PURPOSE: To study the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling pathway in vitro.	Sirolimus	35-44	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	119-148
30900161-6	2019	It was further found that deletion of gene GLN3, long-range LOH in the left arm of synthetic chromosome X, whole chromosome LOH of synthetic chromosome X, and duplication of chromosome VIII (trisomy) lead to increased rapamycin resistance in synthetic yeast.	Sirolimus	218-227	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	43-47
30816188-6	2019	We developed the first Tsc2-null rapamycin-resistant cell line, ELT3-245, which is highly tumorigenic in mice, and refractory to rapamycin treatment.	Sirolimus	33-42	TSC complex subunit 2	Mus musculus	23-27
30816216-2	2019	Dysregulation of mTOR signaling has been implicated in the pathogenesis of certain types of ASD, and inhibition of mTOR by rapamycin has been demonstrated to be an effective therapeutics for impaired social interaction in Tsc1+/-, Tsc2+/-, Pten-/- mice and valproic acid-induced ASD animal models.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	115-119
30816216-2	2019	Dysregulation of mTOR signaling has been implicated in the pathogenesis of certain types of ASD, and inhibition of mTOR by rapamycin has been demonstrated to be an effective therapeutics for impaired social interaction in Tsc1+/-, Tsc2+/-, Pten-/- mice and valproic acid-induced ASD animal models.	Sirolimus	123-132	TSC complex subunit 2	Mus musculus	231-235
30816216-7	2019	Treatment with Akt inhibitor LY294002 or mTOR inhibitor rapamycin rescued the social deficit, but had no effect on hyperactivity and repetitive behavior/restricted behavior in Cntnap2-/- mice.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	41-45
30805927-5	2019	Furthermore, overexpression of BZW2 promotes drug resistance of HCC cells, as shown by the attenuated suppression of cell viability and invasion following rapamycin (RAPA) treatment.	Sirolimus	155-164	basic leucine zipper and W2 domains 2	Homo sapiens	31-35
30794695-7	2019	Subsequent combinatorial treatment, with the mTOR inhibitor Rapamycin and the Src inhibitor Dasatinib reduced A52 HCC growth 29-fold in vivo.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	45-49
30795552-4	2019	Mammalian (or mechanistic) target of rapamycin (mTOR) is a conserved serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase family (PIKK) and resides in two distinct signalling complexes named mTORC1, involved in mRNA translation and protein synthesis and mTORC2 that controls cell survival and migration.	Sirolimus	37-46	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	110-139
30584072-7	2019	KR-induced EMT in cancer cells was inhibited by treatment with the CXCR4 inhibitor AMD3100 or the mTOR inhibitor rapamycin, and AMD3100 suppressed KR-induced metastasis in vivo.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Mus musculus	98-102
30468013-2	2019	Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF-kappaB signalling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
30458362-4	2019	Allogeneic islets modified with biotin and engineered to transiently display SA-FasL on their surface showed sustained survival following transplantation on microporous scaffolds into the peritoneal fat in combination with a short course (15 days) of rapamycin treatment.	Sirolimus	251-260	Fas ligand	Homo sapiens	80-84
30557824-2	2019	However, it is not clear whether the mTOR specific inhibitor rapamycin can attenuate lipopolysaccharide (LPS)-induced ALI by modulating IL-1beta and IL-18 production.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Mus musculus	37-41
30557824-3	2019	In this study, we found that rapamycin ameliorated LPS-induced ALI by inhibiting NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated IL-1beta and IL-18 secretion.	Sirolimus	29-38	NLR family, pyrin domain containing 3	Mus musculus	133-138
29247557-9	2018	Our results demonstrated that combined treatment with rapamycin and melatonin blocked the negative feedback loop from the specific downstream effector of mTOR activation S6K1 to Akt signalling, which decreased cell viability, proliferation and clonogenic capacity.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	170-174
29039413-2	2018	The mTOR inhibitor rapamycin has been shown to attenuate the behavioral effects of drugs of abuse, including cocaine.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
29501742-7	2018	Mechanism study demonstrated that FTO activated the phosphorylation of Tau in a mTOR-dependent manner because FTO activated mTOR and its downstream signaling and rapamycin blocked FTO-mediated phosphorylation of Tau.	Sirolimus	162-171	fat mass and obesity associated	Mus musculus	34-37
29501742-7	2018	Mechanism study demonstrated that FTO activated the phosphorylation of Tau in a mTOR-dependent manner because FTO activated mTOR and its downstream signaling and rapamycin blocked FTO-mediated phosphorylation of Tau.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Mus musculus	80-84
29619032-9	2018	Addition of rapamycin to CD28 superagonist-stimulated Treg led to a high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound TNFalpha.	Sirolimus	12-21	TNF receptor superfamily member 1A	Homo sapiens	87-91
29314656-4	2018	Our results showed that chronic rapamycin treatment markedly reduced the phosphorylated mTOR and ribosomal protein S6 expression, but not Akt in both normal and aortic-banded mice.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	88-92
29314656-7	2018	Mechanically, rapamycin reduced the MI/R-induced iNOS/gp91phox protein expression and decreased the generation of NO and superoxide, as well as the cytotoxic peroxynitrite.	Sirolimus	14-23	inositol-3-phosphate synthase 1	Homo sapiens	49-53
29396369-8	2018	Administration of B-type natriuretic peptide (BNP) to mice induced Ucp1 expression in inguinal adipose tissue in vivo, which was completely blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	172-181	natriuretic peptide type B	Mus musculus	18-44
29396369-8	2018	Administration of B-type natriuretic peptide (BNP) to mice induced Ucp1 expression in inguinal adipose tissue in vivo, which was completely blocked by the mTORC1 inhibitor rapamycin.	Sirolimus	172-181	natriuretic peptide type B	Mus musculus	46-49
29472597-5	2018	During in vitro aging up to 12 h, upregulating autophagy with rapamycin or lithium chloride decreased activation susceptibility, cytoplasmic calcium, p62 contents, oxidative stress, caspase-3 activation and cytoplasmic fragmentation while increasing developmental competence, LC3-II contents, LC3-II/I ratio, mitochondrial membrane potential, spindle/chromosome integrity and normal cortical granule distribution.	Sirolimus	62-71	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	276-279
29343616-1	2018	Rapamycin, the macrolide immunosuppressant and active pharmaceutic in drug-eluting stents (DES), has a well-recognized antiproliferative action that involves inhibition of the mTOR pathway after binding to the cytosolic protein FKBP12.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	228-234
28488736-5	2018	p-p70S6K and Stra8 protein expressions decreased in post-natal testes after rapamycin treatment.	Sirolimus	76-85	stimulated by retinoic acid gene 8	Mus musculus	13-18
29132870-0	2018	mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	0-4
30766792-8	2019	Of the six compounds that were validated on the metabolic level, mTOR inhibitors rapamycin and sapanisertib showed the most consistent decrease in oxidative and glycolytic parameters.	Sirolimus	81-90	mechanistic target of rapamycin kinase	Mus musculus	65-69
29132870-8	2018	We found that RAPA-treated PMN-MDSCs can restrain the differentiation of Th1/Th2 cells and promote induction of regulatory T cells in in vitro studies.	Sirolimus	14-18	heart and neural crest derivatives expressed 2	Mus musculus	77-80
29138237-2	2018	Through a cross with a honey wine (white tecc) brewing strain from Ethiopia, we map the minimal medium growth defect to SER1, which encodes 3-phosphoserine aminotransferase and is orthologous to the human disease gene, PSAT1 To investigate the impact of this polymorphism under conditions of abundant external nutrients, we examine growth in rich medium alone or with additional stresses, including the drugs caffeine and rapamycin and relatively high concentrations of copper, salt, and ethanol.	Sirolimus	422-431	O-phospho-L-serine:2-oxoglutarate transaminase	Saccharomyces cerevisiae S288C	120-124
29138237-3	2018	Consistent with studies that found widespread effects of different auxotrophies on RNA expression patterns in rich media, we find that the SER1 loss-of-function allele dominates the quantitative trait locus (QTL) landscape under many of these conditions, with a notable exacerbation of the effect in the presence of rapamycin and caffeine.	Sirolimus	316-325	O-phospho-L-serine:2-oxoglutarate transaminase	Saccharomyces cerevisiae S288C	139-143
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	cadherin 2	Rattus norvegicus	62-72
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	vascular endothelial growth factor A	Rattus norvegicus	96-100
29749806-6	2018	Concomitantly, using a series of deletion constructs of the NGFR promoter we found that the EGR1 transcription factor was responsible for the rapamycin-mediated transactivation of the NGFR promoter.	Sirolimus	142-151	nerve growth factor receptor	Homo sapiens	60-64
29749806-6	2018	Concomitantly, using a series of deletion constructs of the NGFR promoter we found that the EGR1 transcription factor was responsible for the rapamycin-mediated transactivation of the NGFR promoter.	Sirolimus	142-151	early growth response 1	Homo sapiens	92-96
29749806-6	2018	Concomitantly, using a series of deletion constructs of the NGFR promoter we found that the EGR1 transcription factor was responsible for the rapamycin-mediated transactivation of the NGFR promoter.	Sirolimus	142-151	nerve growth factor receptor	Homo sapiens	184-188
28696243-8	2018	RapaLink-1, a TORKi linked to rapamycin, represents a drug with improved pharmacology against 4EBP1.	Sirolimus	30-39	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	94-99
30509037-0	2018	The level of microRNA 21 is upregulated by rapamycin in serum of tuberous sclerosis complex patients and subependymal giant cell astrocytoma (SEGA)-derived cell cultures.	Sirolimus	43-52	microRNA 21	Homo sapiens	13-24
30509037-6	2018	Next, we studied the influence of prolonged rapamycin administration on miR-21 level in the blood serum of TSC patients (6-12 months of rapamycin) and in primary cultures of SEGA-derived cells treated with rapamycin <i>in vitro</i>.	Sirolimus	44-53	microRNA 21	Homo sapiens	72-78
29113979-2	2018	In nitrogen-limiting medium, in cells treated with TorC1 inhibitor, rapamycin, or the glutamine synthetase inhibitor, methionine sulfoximine (Msx), Gln3 becomes highly nuclear and NCR-sensitive transcription derepressed.	Sirolimus	68-77	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	148-152
29113979-9	2018	Substitution of the basic amino acid repeats in the Ure2 relief sequence or phosphomimetic aspartate substitutions for the serine residues between them abolishes nuclear Gln3-Myc13 localization in response to both limiting nitrogen and rapamycin treatment.	Sirolimus	236-245	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	170-174
29238469-7	2017	Immunohistochemistry results indicated that sirolimus increased the expressions of podocin and ZO-1 at the early DN (P&lt;0.05), but reduced the expressions of ZO-1 and podocin (P&lt;0.05) at the advanced DN.	Sirolimus	44-53	tight junction protein 1	Rattus norvegicus	95-99
29238469-7	2017	Immunohistochemistry results indicated that sirolimus increased the expressions of podocin and ZO-1 at the early DN (P&lt;0.05), but reduced the expressions of ZO-1 and podocin (P&lt;0.05) at the advanced DN.	Sirolimus	44-53	tight junction protein 1	Rattus norvegicus	160-176
28847987-7	2017	Rapamycin did not have therapeutic efficacy in the mouse model despite inhibiting mTOR signaling and markedly suppressing tumor cell growth in culture.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	82-86
28965784-3	2017	Here, we discover a novel pathway of Jen1p endocytosis mediated by the alpha-arrestin Bul1p in response to the presence of cycloheximide or rapamycin, or prolonged growth in lactate.	Sirolimus	140-149	Jen1p	Saccharomyces cerevisiae S288C	37-42
28864813-4	2017	Sequestration of FKBP12 by rapamycin or tacrolimus activates hepcidin both in vitro and in murine hepatocytes.	Sirolimus	27-36	FK506 binding protein 1a	Mus musculus	17-23
27904994-5	2017	Inhibition of mTOR by rapamycin rescued cognitive deficits caused by sepsis (p &lt; 0.05).	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
28729300-5	2017	Rapamycin effectively reduced Th1 inflammatory cytokines interferon-gamma and tumor necrosis factor-alpha, increased the Th2 cytokine interleukin-10, stimulated expansion of functional regulatory T cells, eliminated effector CD8+ T cells (notably T cells specific to target cells bearing minor histocompatibility antigen H60), and preserved hematopoietic stem and progenitor cells.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	121-124
31966350-0	2017	Anti-angiogenic effect of rapamycin in mouse oxygen-induced retinopathy is mediated through suppression of HIF-1alpha/VEGF pathway.	Sirolimus	26-35	hypoxia inducible factor 1, alpha subunit	Mus musculus	107-117
31966350-9	2017	RAPA inhibited HUVECs proliferation and retinal neovascularization by reducing protein and mRNA expressions of HIF-1alpha and VEGF.	Sirolimus	0-4	hypoxia inducible factor 1, alpha subunit	Mus musculus	111-121
31966350-10	2017	RAPA suppresses hypoxia-induced HUVECs cell proliferation and pathological ocular angiogenesis through a mechanism linked to the targeting of HIF-1alpha/VEGF signaling.	Sirolimus	0-4	hypoxia inducible factor 1, alpha subunit	Mus musculus	142-152
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	44-48
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	52-56
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	52-56
28600752-7	2017	By measuring the downstream markers phospho-mTOR (p-mTOR)/mTOR and phospho-signal transducer and activator of transcription 3 (p-STAT3)/STAT3, we showed that rapamycin suppressed the mTOR-STAT3 pathway in EAE mice.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Mus musculus	52-56
28736261-9	2017	Importantly, pharmacological inhibition of mTOR (rapamycin; 10days) normalized cardiac size in CBK mice.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	43-47
30696882-7	2019	Cyst formation in Prx1-Cre; Tsc1f/f and Osx-Cre; Tsc1f/f mice were associated with increase in both proliferative and apoptotic cells in the affected tissue and were largely suppressed by rapamycin.	Sirolimus	188-197	paired related homeobox 1	Mus musculus	18-22
30621732-3	2019	Treatment with the mTOR inhibitor rapamycin improved social interaction deficits in mouse models of TSC.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	19-23
30621732-14	2019	Mice that were exposed to VPA and treated with vehicle exhibited the aberrant expression of genes in the mTOR signaling pathway, and rapamycin treatment recovered changes in the expression of some genes, including Fyb and A330094K24Rik.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Mus musculus	105-109
30252956-7	2019	Treatment with Rapamycin, a mTOR-inhibitor and autophagy activator, ameliorates Fyn-/- mouse baseline erythropoiesis and erythropoietic response to oxidative-stress.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	28-32
30219732-5	2019	The mTOR inhibitor rapamycin was systemically administered to mice to determine the roles of autophagy activation on cognitive changes.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
28522586-8	2017	Rapamycin, an mTOR inhibitor, reduces the prosurvival signaling of cells in a hypoxic environment potentially exacerbated by a vasculature-targeted therapy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
29800648-1	2019	BACKGROUND: Germline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110delta subunit of phosphoinositide 3-kinase (PI3K), result in hyperactivation of the PI3K-AKT-mechanistic target of rapamycin pathway and underlie a novel inborn error of immunity.	Sirolimus	207-216	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	57-63
29800648-1	2019	BACKGROUND: Germline gain-of function (GOF) mutations in PIK3CD, encoding the catalytic p110delta subunit of phosphoinositide 3-kinase (PI3K), result in hyperactivation of the PI3K-AKT-mechanistic target of rapamycin pathway and underlie a novel inborn error of immunity.	Sirolimus	207-216	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	88-97
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	89-98	beclin 1, autophagy related	Mus musculus	0-7
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	89-98	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	37-40
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	89-98	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	44-47
29761871-8	2019	Compared with the PN group, the PN + Rapa group had lower levels of ROS and reduced expression of ER stress-related protein markers, such as BIP, sXBP1 and CHOP.	Sirolimus	37-41	DNA-damage inducible transcript 3	Rattus norvegicus	156-160
29790114-9	2019	Ivabradine and rapamycin also decreased the expression of PI3K/Akt and mTOR induced by TAC.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	71-75
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	81-87
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	epidermal growth factor	Homo sapiens	30-33
28963126-7	2017	Rapamycin decreased basal and EGF stimulated HIF-1alpha and enhanced MAPK (ERK1/2) activation, while MAPK (ERK/12) inhibition downregulated HIF-1alpha expression and the phosphorylation of p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	189-195
31399190-7	2019	We found that Rapa blocked glycolysis in induced Th17 cells, evidenced by reduced glucose uptake, and inhibited expression of glucose transporter 1 and the rate-limiting enzyme HK2.	Sirolimus	14-18	hexokinase 2	Mus musculus	177-180
31399190-9	2019	Conversely, Rapa promoted fatty acid oxidation (FAO) metabolism in differentiated Treg cells, with the elevation of FAO product beta-hydroxybutyrate, and increased expression of ATGL and CPT1A, the key enzymes of FAO in differentiated Treg cells.	Sirolimus	12-16	carnitine palmitoyltransferase 1A	Rattus norvegicus	187-192
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	epidermal growth factor	Homo sapiens	0-3
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	19-25
28963126-8	2017	EGF stimulation of p70S6K was also independent of p-AKT Inhibition of the mTORC1 pathway with rapamycin abolished phosphorylation of p70S6K but had no effect on VEGF-A secretion, indicating that EGF-stimulated VEGF-A secretion did not require mTORC1 pathway activation.	Sirolimus	94-103	ribosomal protein S6 kinase B1	Homo sapiens	133-139
28734155-6	2017	The mTOR inhibitor rapamycin (100nM) could attenuate the elevated expression of TF and IL-8.	Sirolimus	19-28	coagulation factor III, tissue factor	Homo sapiens	80-82
31532131-10	2019	The effect of Rapamycin was obviously stronger than that of penetrative needling in up-regulating the expression of LC3-II/I and LC3 protein (P<0.05).	Sirolimus	14-23	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	116-124
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	apolipoprotein H	Homo sapiens	115-123
30594149-7	2018	mTOR protein itself, along with its downstream signaling target, phospho-S6 ribosomal protein (pS6), were significantly inhibited with CoCl2 and rapamycin addition did not significantly lower expression further.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Mus musculus	0-4
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	apolipoprotein H	Homo sapiens	124-132
28734155-7	2017	In addition, rapamycin could also decrease the phosphorylation of p38, ERK1/2 and NF-kappaB p65 stimulated by anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex, but it had no effect on JNK.	Sirolimus	13-22	apolipoprotein H	Homo sapiens	124-132
28814333-0	2017	Rapamycin Prevents cyclophosphamide-induced Over-activation of Primordial Follicle pool through PI3K/Akt/mTOR Signaling Pathway in vivo.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	105-109
30584274-9	2018	Curcumin and rapamycin treatment inhibited the increased levels of proinflammatory cytokines including IL-1beta, TNF-alpha, MMP-1, and MMP-3 in CIA rats.	Sirolimus	13-22	matrix metallopeptidase 1	Rattus norvegicus	124-129
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Mus musculus	28-32
30524720-2	2018	The aim of this study is to compare the carotid intima-media thickness (cIMT) between de novo tacrolimus/mycophenolate and tacrolimus/sirolimus at low doses.	Sirolimus	134-143	CIMT	Homo sapiens	72-76
30524720-8	2018	The cIMT decreased over time at 6 and 12 months in the sirolimus group (P = 0.012); this decrease continued to be significant in a model adjusted for age, sex, presence of diabetes, statin use and smoking.	Sirolimus	55-64	CIMT	Homo sapiens	4-8
30524720-9	2018	Conclusions: The use of sirolimus plus tacrolimus de novo in kidney transplantation is associated with a reduction in cIMT after 12 months, a decrease more significant than seen with the combination of mycophenolate plus tacrolimus.	Sirolimus	24-33	CIMT	Homo sapiens	118-122
30290159-3	2018	The aim of this study was to further investigate the actions of rapamycin in inducing expression of the antioxidant enzymes heme oxygenase-1 (HO-1) and peroxiredoxin-1 (Prx-1) in normal liver and in tumorigenic liver cells.	Sirolimus	64-73	peroxiredoxin 1	Rattus norvegicus	169-174
28814333-9	2017	Compared to p-Akt/Akt and p-mtor/mtor, p-rps6/rps6 was significantly decreased in rapamycin + cyclophosphamide group (P &lt; 0.05), indicating that rapamycin attenuated the increased level of phosphorylation of rpS6 after cyclophosphamide treatment.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Mus musculus	33-37
30290159-11	2018	It is concluded that, at concentrations comparable to those used clinically, pre-treatment of the liver with rapamycin induces the expression of HO-1 and Prx-1.	Sirolimus	109-118	peroxiredoxin 1	Rattus norvegicus	154-159
28814333-10	2017	CONCLUSIONS: Rapamycin can prevent the primordial follicle activation induced by cyclophosphamide through PI3K/Akt/mTOR signaling pathway and thus plays a role in preserving the follicle pool.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	115-119
28808237-1	2017	Tuberous Sclerosis Complex (TSC) is a rare genetic disorder that results from a mutation in the TSC1 or TSC2 genes leading to constitutive activation of the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	179-188	TSC complex subunit 2	Mus musculus	104-108
30145837-5	2018	Besides, the regulatory relationships between Sox2ot and miR-211, miR-211 and MCL-1, as well as between MCL-1 and the protein kinase B (Akt)/mammalian target of the rapamycin (mTOR)/p70 ribosomal S6 protein kinase (p70S6K) signaling pathway were explored.	Sirolimus	165-174	protein tyrosine kinase 2 beta	Homo sapiens	118-134
28801605-7	2017	Furthermore, we found that pretreatment with the mTOR inhibitor, rapamycin, significantly reduced the expression of the pro-apoptotic protein Bax.	Sirolimus	65-74	BCL2 associated X, apoptosis regulator	Rattus norvegicus	142-145
30341250-12	2018	Moreover, LC3-labeled autophagosomes increasingly overlapped with TOMM20-labeled mitochondria and LAMP2-labeled lysosomes in CI-AKI, which was further enhanced by rapamycin administration.	Sirolimus	163-172	lysosomal-associated membrane protein 2	Rattus norvegicus	98-103
30346689-4	2018	Through enzymological and biochemical studies, we demonstrate that a rapamycin-upregulated enolase isozyme (ENO1) favors gluconeogenesis and a rapamycin-upregulated alcohol dehydrogenase isozyme (ALD4) promotes the reduction of NAD+ to NADH (instead of NADP+ to NADPH).	Sirolimus	69-78	aldehyde dehydrogenase (NADP(+)) ALD4	Saccharomyces cerevisiae S288C	196-200
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	ribosomal protein S6 kinase B1	Homo sapiens	125-131
28831455-2	2017	One potential and current model that explains Akt activation induced by the mTOR inhibitor rapamycin is the relief of mTORC1/p70S6K-mediated feedback inhibition of IRS-1/PI3K/Akt signaling, although this has not been experimentally proven.	Sirolimus	91-100	insulin receptor substrate 1	Homo sapiens	164-169
30464623-10	2018	By futher rescue experiments using rapamycin, activation of autophagy could reversed the the inhibition of cell proliferation and colony formation, as well as promotion of apoptosis mediated by HOTAIR knockdown, indicating that HOTAIR knockdown promoted radiosensitivity of PC cells by regulating autophagy.	Sirolimus	35-44	HOX transcript antisense RNA	Homo sapiens	228-234
28532580-9	2017	Rapamycin, an mTOR specific inhibitor, substantially inhibited the induced inflammation and fibrosis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
30309855-1	2018	The mTOR inhibitor rapamycin ameliorates the clinical and biochemical phenotype of mouse, worm, and cellular models of mitochondrial disease, via an unclear mechanism.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
30309855-2	2018	Here, we show that prolonged rapamycin treatment improved motor endurance, corrected morphological abnormalities of muscle, and increased cytochrome c oxidase (COX) activity of a muscle-specific Cox15 knockout mouse (Cox15 sm/sm ).	Sirolimus	29-38	cytochrome c oxidase assembly protein 15	Mus musculus	195-200
30309855-2	2018	Here, we show that prolonged rapamycin treatment improved motor endurance, corrected morphological abnormalities of muscle, and increased cytochrome c oxidase (COX) activity of a muscle-specific Cox15 knockout mouse (Cox15 sm/sm ).	Sirolimus	29-38	cytochrome c oxidase assembly protein 15	Mus musculus	217-222
30309855-3	2018	Rapamycin treatment restored autophagic flux, which was impaired in naive Cox15 sm/sm muscle, and reduced the number of damaged mitochondria, which accumulated in untreated Cox15 sm/sm mice.	Sirolimus	0-9	cytochrome c oxidase assembly protein 15	Mus musculus	74-79
28775826-3	2017	Heterozygocity induces hyperactivation of mTOR which can be inhibited by mTOR inhibitors, such as rapamycin, which have proven efficacy in the treatment of TSC-associated symptoms.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Mus musculus	42-46
30309855-3	2018	Rapamycin treatment restored autophagic flux, which was impaired in naive Cox15 sm/sm muscle, and reduced the number of damaged mitochondria, which accumulated in untreated Cox15 sm/sm mice.	Sirolimus	0-9	cytochrome c oxidase assembly protein 15	Mus musculus	173-178
30309855-5	2018	This stark difference supports the idea that inhibition of mTORC1 by rapamycin has a key role in the improvement of the mitochondrial function in Cox15 sm/sm muscle.	Sirolimus	69-78	cytochrome c oxidase assembly protein 15	Mus musculus	146-151
28775826-3	2017	Heterozygocity induces hyperactivation of mTOR which can be inhibited by mTOR inhibitors, such as rapamycin, which have proven efficacy in the treatment of TSC-associated symptoms.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Mus musculus	73-77
28716920-7	2017	Systemic inhibition of VAMP3 and SNAP23 by rapamycin or periadventitial application of the endocytosis inhibitor dynasore ameliorates the disturbed flow-induced neointimal formation, whereas intraluminal overexpression of SNAP23 aggravates it.	Sirolimus	43-52	vesicle associated membrane protein 3	Homo sapiens	23-28
30200803-0	2018	The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway.	Sirolimus	26-35	ribosomal protein S6 kinase B1	Rattus norvegicus	118-122
30200803-10	2018	The expression levels of mTOR and S6K1 increased and LC3II expression decreased in the renal tissues of the DN and RAPA groups compared with the NC group (p &lt; .05).	Sirolimus	115-119	ribosomal protein S6 kinase B1	Rattus norvegicus	34-38
29256230-10	2017	The activation of mTOR signaling pathway induced by rUCCAO was reversed by administration of rapamycin, and the apoptotic cell number was significantly decreased (146.1+-16.3 vs 84.5+-9.6, P&lt;0.05).	Sirolimus	93-102	mechanistic target of rapamycin kinase	Mus musculus	18-22
29978260-2	2018	Previously, we showed a remarkable overlap in toxicity profiles between APAP and tyrosine, and a similarity with drugs like rapamycin and quinine, which induce degradation of the amino acid permease Tat2.	Sirolimus	124-133	aromatic amino acid transmembrane transporter TAT2	Saccharomyces cerevisiae S288C	199-203
30266297-11	2018	Rapamycin, an inhibitor of mTOR, reversed the decrease of ghrelin levels and pancreatic fibrosis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
28486745-3	2017	Rapamycin, a TORC1 inhibitor, inhibits Pma1 dependent on its receptor Fpr1 and on the protein phosphatase Sit4, a TORC1 effector.	Sirolimus	0-9	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	106-110
28738971-0	2017	Rapamycin-ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high-fat diet.	Sirolimus	0-9	adiponectin, C1Q and collagen domain containing	Mus musculus	63-74
28213405-5	2017	Rapamycin, a typical mTOR pathway inhibitor, dramatically limits the expansion of the abdominal aorta following intraluminal elastase perfusion.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	21-25
30233712-19	2018	Rapamycin can also inhibit the HIF-1alpha expression level and protect renal ischemia-reperfusion injury.	Sirolimus	0-9	hypoxia inducible factor 1, alpha subunit	Mus musculus	31-41
29691838-9	2018	Rapamycin enhanced MCs-HUVECs adhesion that was reversed by NAC, catalase, and DPI.	Sirolimus	0-9	synuclein alpha	Homo sapiens	60-63
29627129-7	2018	Rapamycin, a PIK3/AKT/mTOR pathway inhibitor, demonstrated its efficiency for some forms of PROS.	Sirolimus	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	13-17
30086367-6	2018	Furthermore, we found that ANA-12 (a TrkB inhibitor) or rapamycin (a mTOR inhibitor) could block the beneficial effects of SFN on LPS-induced cognitive dysfunction, and that hippocampal levels of synaptic proteins, BDNF-TrkB and mTOR signaling pathways were also notably changed.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	69-73
30174295-6	2018	Mechanistically, loss of Mfge8 elevates mTOR1 signaling in RGLs, inhibition of which by rapamycin returns RGLs to quiescence.	Sirolimus	88-97	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	25-30
30256440-7	2018	In addition, chloroquine (as the autophagy/lysosome inhibitor, CQ) or rapamycin (as the autophagy/lysosome inhibitor, Rap) attenuated osteoclast differentiation and bone resorption activity by OPG treatment via AMPK/mTOR/p70S6K signaling pathway.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Mus musculus	216-220
28461508-6	2017	The mTOR inhibitor rapamycin elicited a significant therapeutic response in Dnmt3aR878H/WT mice.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
28559962-10	2017	Treatment with wortmannin or rapamycin attenuated the expression of p-Akt, p-S6K1, and osteogenesis proteins/genes.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	77-81
28409693-4	2017	TPT1 inhibition induced cellular autophagy via the MTORC1 and AMPK pathways, which are inhibited and activated, respectively, during treatment with the MTOR inhibitor rapamycin.	Sirolimus	167-176	tumor protein, translationally-controlled 1	Mus musculus	0-4
28409693-4	2017	TPT1 inhibition induced cellular autophagy via the MTORC1 and AMPK pathways, which are inhibited and activated, respectively, during treatment with the MTOR inhibitor rapamycin.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Mus musculus	51-55
28409693-5	2017	We also found that the depletion of TPT1 potentiated rapamycin-induced autophagy by synergizing with MTORC1 inhibition.	Sirolimus	53-62	tumor protein, translationally-controlled 1	Mus musculus	36-40
28446743-13	2017	Rapamycin inhibited the phosphorylation of p70s6k.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-49
28186963-7	2017	In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp.	Sirolimus	47-56	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	144-149
28235485-6	2017	Beclin1 and LC3 II/I increased in JSRV-Env transfected NIH3T3 cells treated with mTOR inhibitor (rapamycin), ERK1/2 inhibitor (PD 98059), p38 inhibitor (SB 203580) and JNK inhibitor (SP 600125), suggesting that Akt/mTOR and MAPK pathways were responsible for JSRV-Env decreased autophagy.	Sirolimus	97-106	envelope protein	Jaagsiekte sheep retrovirus	39-42
29968153-8	2018	mTOR inhibition by rapamycin decreased the glycolysis and reduced the suppressive activities of these cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	0-4
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	ribosomal protein S6 kinase B1	Rattus norvegicus	126-132
28235485-6	2017	Beclin1 and LC3 II/I increased in JSRV-Env transfected NIH3T3 cells treated with mTOR inhibitor (rapamycin), ERK1/2 inhibitor (PD 98059), p38 inhibitor (SB 203580) and JNK inhibitor (SP 600125), suggesting that Akt/mTOR and MAPK pathways were responsible for JSRV-Env decreased autophagy.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Mus musculus	81-85
28379293-4	2017	We recently found that RA stimulation of the Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian target of rapamycin (mTOR) kinase signaling pathway is required for differentiation, and that short-term inhibition of mTOR complex 1 (mTORC1) by rapamycin blocked spermatogonial differentiation in vivo and prevented RA-induced translational activation.	Sirolimus	106-115	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	45-74
26043934-3	2017	Thus, the aim of the present study was to demonstrate the improved biocompatibility of rapamycin-containing polyethylene glycol (Rapa-PEG)-coating on alginate microcapsules containing xenogeneic islets.	Sirolimus	87-96	transcriptional regulating factor 1	Mus musculus	129-133
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Mus musculus	29-33
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	fat mass and obesity associated	Mus musculus	79-82
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	fat mass and obesity associated	Mus musculus	148-151
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	fat mass and obesity associated	Mus musculus	148-151
28333151-8	2017	Moreover, the involvement of mTOR-PGC-1alpha pathway in the connection between FTO and muscle differentiation is displayed, since the expression of FTO affected the activity of mTOR and rapamycin blocked FTO-induced PGC-1alpha transcription, along with the parallel alteration pattern of FTO expression and mTOR phosphorylation during myoblasts differentiation.	Sirolimus	186-195	fat mass and obesity associated	Mus musculus	148-151
28322267-8	2017	Treating 8-TCS mice with T4 rescued the placental cell proliferation and recovered the activity and expression of amino acid and glucose transporters, which were sensitive to mTOR inhibition by rapamycin.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Mus musculus	175-179
29574227-5	2018	Systemic treatment with rapamycin, a specific mTOR inhibitor, coincident with a daily METH injection suppressed the induction of METH sensitization and reduced the number of dendritic spines in the shell and core of the nucleus accumbens.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	46-50
29864452-7	2018	Inhibition of mTOR, by rapamycin, restores the levels of excitatory scaffolding synaptic proteins (PSD-95 or SHANK3), p62, and partly reestablishes the LC3-II levels in the prefrontal cortices of ethanol-treated WT mice.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	14-18
30133440-9	2018	Moreover, the IL-4 production capacity of splenocytes harvested from infected mice that were treated with rapamycin was significantly reduced.	Sirolimus	106-115	interleukin 4	Mus musculus	14-18
30135653-6	2018	Besides, rapamycin activated the TGF-beta-Smad signaling, and TGF-beta receptor type I (TGFbetaRI) serine/threonine kinase inhibitors completely blocked the effects of rapamycin on HPCs.	Sirolimus	168-177	transforming growth factor beta receptor 1	Homo sapiens	62-98
30219159-13	2018	Furthermore, in vitro studies revealed that the inhibitory effect of rapamycin on the angiogenic ability of HUVECs and its significant inhibitory effects on the protein level of HIF-1alpha and the phosphorylation of proteins involved in the mTORC1 pathway, including mTOR, raptor and p70S6K (P &lt; 0.05), were enhanced by cotreatment with SRT1720 and rapamycin (P &lt; 0.05).	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	284-290
29676052-2	2018	Pretreatment with rapamycin, an mTOR kinase inhibitor, resulted in better recovery from cerebral hypoxia early after SAH than control (P < .05), while the values of peak flow velocity in the middle cerebral artery did not change significantly (P > .05).	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	32-36
29550418-8	2018	Furthermore, rapamycin, a pharmacologic mTOR inhibitor, suppressed the growth of UV-induced BCCs in Ptch1+/-/SKH-1 mice, a model that closely mimics the accelerated BCC growth pattern of patients with basal cell nevus syndrome.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	40-44
29959473-6	2018	More importantly, the mTOR inhibitor rapamycin synergized with PLK1 inhibitor BI 2536 to inhibit ESCC cell proliferation in culture and in mice.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Mus musculus	22-26
29959473-10	2018	These results provide evidence that the mTOR inhibitor rapamycin synergistically enhances the antitumor effect of PLK1 inhibitor BI 2536 in ESCC cells.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	40-44
29845247-0	2018	Long non-coding RNA SENCR alleviates the inhibitory effects of rapamycin on human umbilical vein endothelial cells.	Sirolimus	63-72	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	20-25
29845247-4	2018	Long non-coding RNAs (lncRNAs) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA (SENCR) are able to enhance the proliferation, migration and angiogenesis of endothelial cells, which suggests that they may have potential as antagonists of the adverse effects of RPM in DES.	Sirolimus	368-371	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	31-85
29845247-4	2018	Long non-coding RNAs (lncRNAs) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA (SENCR) are able to enhance the proliferation, migration and angiogenesis of endothelial cells, which suggests that they may have potential as antagonists of the adverse effects of RPM in DES.	Sirolimus	368-371	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	87-93
29845247-4	2018	Long non-coding RNAs (lncRNAs) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and smooth muscle and endothelial cell-enriched migration/differentiation-associated lncRNA (SENCR) are able to enhance the proliferation, migration and angiogenesis of endothelial cells, which suggests that they may have potential as antagonists of the adverse effects of RPM in DES.	Sirolimus	368-371	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	188-193
29845247-6	2018	The current study investigated the role and potential mechanism of the lncRNA SENCR on the activity of human umbilical vein endothelial cells (HUVECs) after RPM treatment.	Sirolimus	157-160	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	78-83
29845247-7	2018	The proliferation, migration, angiogenic capacity and cell cycle progression of lncRNA SENCR-overexpressing HUVECs following RPM treatment was examined.	Sirolimus	125-128	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	87-92
29845247-10	2018	The lncRNA SENCR could alleviate the inhibitory effects of RPM on HUVECs and may be useful as a new combinative agent to avoid the disadvantages of RPM in DES implantation.	Sirolimus	59-62	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	11-16
29845247-10	2018	The lncRNA SENCR could alleviate the inhibitory effects of RPM on HUVECs and may be useful as a new combinative agent to avoid the disadvantages of RPM in DES implantation.	Sirolimus	148-151	smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA	Homo sapiens	11-16
30013633-6	2018	In addition, DRAM1 knockdown increased the expression of E-Cadherin while decreased the expression of vimentin in HepG2 cells, which was also be reversed by rapamycin treatment.	Sirolimus	157-166	vimentin	Homo sapiens	102-110
30084798-5	2018	Our studies were conducted in murine C2C12 myotubes exposed to 2mM leucine or 2mM isoleucine in control situation and compared to the inhibition of mTOR by rapamycin.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Mus musculus	148-152
30050079-8	2018	In combination with tamoxifen (inhibiting ESR1), both S6RP phosphorylation and rapamycin-induced 4E-BP1 upregulation in TNBC bulk cells was inhibited.	Sirolimus	79-88	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	97-103
29396625-5	2018	Hedgehog signaling was restored in Tsc1-/- cells after exogenous expression of Gli2, whereas rapamycin restored HH signaling in Tsc2-/- cells.	Sirolimus	93-102	TSC complex subunit 2	Mus musculus	128-132
28325885-7	2017	Additionally, we showed that PFI could reveal anti-aging effect of mTOR inhibitor rapatar (bioavailable formulation of rapamycin) prior to registration of its effects on longevity.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	67-71
29753783-9	2018	Moreover, immunofluorescent staining of LC3 in the TM3 Leydig cell line indicated that rapamycin and nicotine exposure up-regulates the autophagy phenotype/process and down-regulates their testosterone synthesis.	Sirolimus	87-96	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	40-43
29938004-9	2018	Moreover, miR-100 directly influenced responsiveness of H727 and UMC11 cells to rapamycin.	Sirolimus	80-89	microRNA 100	Homo sapiens	10-17
29401606-7	2018	Additional investigations demonstrated that treatment with rapamycin significantly attenuated adipocyte formation that was induced by Cyr61 small interfering RNA (siRNA) transfection.	Sirolimus	59-68	cellular communication network factor 1	Homo sapiens	134-139
28321181-6	2017	RNF146 also suppressed the excessive autophagy, which is detrimental to HT22 cells survival, induced by glutamate or rapamycin treatment.	Sirolimus	117-126	ring finger protein 146	Mus musculus	0-6
27935584-8	2017	Moreover, we showed that either knockdown of mTOR or inhibition of mTORC1 with rapamycin increases the expression of HMGCS2 in intestinal cells in vitro and in vivo, suggesting a possible cross-talk between mTOR and HMGCS2/betaHB signaling in intestinal cells.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	67-71
28243129-13	2017	Furthermore, inhibition of the mTOR/p70s6k signaling pathway by rapamycin significantly induced autophagy and apoptosis and inhibited cell viability (P&lt;0.05).	Sirolimus	64-73	ribosomal protein S6 kinase B1	Homo sapiens	36-42
27888296-9	2017	Finally, promoting autophagy with rapamycin or pharmacological inhibition of the TLR2 signaling pathway prevented the TLR2-mediated increase in alpha-synuclein in neuronal cell cultures.	Sirolimus	34-43	synuclein alpha	Homo sapiens	144-159
28028691-0	2017	Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients.	Sirolimus	0-9	proprotein convertase subtilisin/kexin type 9	Homo sapiens	62-67
28028691-4	2017	To investigate the mechanism for the variability in the change in PCSK9 levels, lymphoblastoid cell lines were incubated with both sirolimus and everolimus, resulting in a 2-3 fold increase in PCSK9 expression and protein levels in mTOR inhibitor sensitive but not in mTOR inhibitor resistant cell lines.	Sirolimus	131-140	proprotein convertase subtilisin/kexin type 9	Homo sapiens	66-71
28028691-4	2017	To investigate the mechanism for the variability in the change in PCSK9 levels, lymphoblastoid cell lines were incubated with both sirolimus and everolimus, resulting in a 2-3 fold increase in PCSK9 expression and protein levels in mTOR inhibitor sensitive but not in mTOR inhibitor resistant cell lines.	Sirolimus	131-140	proprotein convertase subtilisin/kexin type 9	Homo sapiens	193-198
28028691-5	2017	This first in human study demonstrates that sirolimus therapy is associated with elevation in PCSK9 levels which is not associated with sirolimus-induced hypercholesterolemia.	Sirolimus	44-53	proprotein convertase subtilisin/kexin type 9	Homo sapiens	94-99
28092822-2	2017	The mTOR inhibitors rapamycin and everolimus (rapalogs) have demonstrated clinical efficacy in treating TSC-associated tumors including renal angiomyolipomas.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	4-8
28143498-3	2017	Here, we investigated the effects of mTOR inhibition with rapamycin against neurodegeneration, and motor impairment, as well as inflammatory profile caused by an excitotoxic stimulus.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Mus musculus	37-41
27980219-8	2017	Pharmacological inhibition of mTOR signaling using rapamycin treatment suppressed endometrial hyperplasia in aged mice.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	30-34
27993682-10	2017	Consistent with a role for mTORC1/S6K1 signaling promoting trastuzumab resistance, all cell lines were sensitive to S6K1 inactivation with significant growth inhibition following treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	215-224	ribosomal protein S6 kinase B1	Homo sapiens	116-120
27913296-5	2017	In separate studies, REDD1 KO mice were injected with 5 mg/kg BW of the mTOR inhibitor, rapamycin, 3 h prior to acute insulin treatment.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Mus musculus	72-76
27913296-9	2017	Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 in KO mice.	Sirolimus	12-21	insulin receptor substrate 1	Mus musculus	119-124
28109197-7	2017	RESULTS: Everolimus was significantly more effective than rapamycin in inhibiting iNOS and mTOR signaling pathways in both models of neuroinflammation (LPS) and seizure (KA).	Sirolimus	58-67	mechanistic target of rapamycin kinase	Mus musculus	91-95
27737881-2	2017	Here, we studied the effects of the mTOR inhibitor rapamycin in mouse EL4 T-cell lymphoma.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	36-40
29571225-12	2018	FA and rapamycin treatment inhibited VSMC dedifferentiation in vitro and in vivo, and FA and rapamycin attenuated the mTOR/p70S6K signalling pathway.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Mus musculus	118-122
29901635-0	2018	Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).	Sirolimus	0-9	LDL receptor related protein associated protein 1	Homo sapiens	154-157
29857512-6	2018	Meanwhile, the MMP-9 related signaling pathways, including Phosph-Protein Kinase B (P-AKT) and Phosph-mammalian Targets Of Rapamycin (P-mTOR) were decreased after a Salmonella treatment.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	136-140
30693687-8	2018	CONCLUSIONS: Rapamycin inhibits the activation of mTOR pathway, which contributes to protect against the loss of dopaminergic neurons and provide behavioral improvements in mice with Parkinson"s disease.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	50-54
29844707-2	2018	PTEN mutation in NSCLC may be sensitizing to analogs of rapamycin such as everolimus or temsirolimus, but more investigation is needed.	Sirolimus	56-65	phosphatase and tensin homolog	Homo sapiens	0-4
29862167-7	2018	The expression of TLR4, stimulated by A. fumigatus, was reduced as well when the mTOR signaling pathway was suppressed by rapamycin.	Sirolimus	122-131	toll like receptor 4	Homo sapiens	18-22
29758070-8	2018	In addition, treatment of three primary IGF2-expressing LAM lung cell lines with rapamycin did not result in IGF2 level changes.	Sirolimus	81-90	insulin like growth factor 2	Homo sapiens	40-44
27832967-9	2017	Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent of ATP concentration and that it is a selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 activity.	Sirolimus	44-53	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	165-170
27832967-9	2017	Modelling of the mTOR1 kinetics showed that Rapamycin has an IC50 independent of ATP concentration and that it is a selective inhibitor of mTOR1 substrates S6K1 and 4EBP1: it retains 40% of mTOR1 activity relative to 4EBP1 phosphorylation and inhibits completely S6K1 activity.	Sirolimus	44-53	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	217-222
28031240-2	2017	MATERIALS AND METHODS: The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ-resistant U87 cell line.	Sirolimus	98-107	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	Homo sapiens	83-86
27827806-10	2017	Both rapamycin and PD-98059 inhibited the CIT effect on S6K1, whereas only LY-294002 inhibited the CIT effect on both S6K1 and 4E-BP1.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Rattus norvegicus	56-60
29661681-5	2018	We developed a rapamycin-induced caspase 9 suicide gene.	Sirolimus	15-24	caspase 9	Homo sapiens	33-42
26911848-6	2018	Concomitant use of rosiglitazone and rapamycin further downregulated the p-p70S6K level.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Rattus norvegicus	75-81
27914823-12	2017	Moreover, rapamycin (10nM) inhibited mTOR-FABP4 signaling and HemEC proliferation.	Sirolimus	10-19	fatty acid binding protein 4	Homo sapiens	42-47
28050601-0	2017	Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide.	Sirolimus	85-94	zinc metallopeptidase STE24	Homo sapiens	33-41
28050601-5	2017	Interestingly, the assembly of the vimentin microfibrils in MADB fibroblasts improved with rapamycin and dimethylsulfoxide.	Sirolimus	91-100	vimentin	Homo sapiens	35-43
28487599-8	2017	Furthermore, rapamycin, a specific inhibitor of the mTOR/p70S6K signaling pathway, decreased the levels of Ki-67 and Bcl-2/Bax ratio, inhibited cell proliferation, and promoted apoptosis in EC cells.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	57-63
28123588-5	2017	Targeted knockdown of YB-1 reduced IL-7-mediated protection against rapamycin, and an inhibitor of MEK1/2 potentiated rapamycin-mediated killing in the presence of IL-7.	Sirolimus	118-127	mitogen-activated protein kinase kinase 1	Homo sapiens	99-105
27965423-8	2016	Treating mice bearing these teratomas with an A2b adenosine receptor agonist, the mTOR inhibitor rapamycin, or the bisphosphonate etidronate reduced calcification.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Mus musculus	82-86
27926859-0	2016	Rapamycin Reverses Metabolic Deficits in Lamin A/C-Deficient Mice.	Sirolimus	0-9	lamin A	Mus musculus	41-50
29342507-10	2018	Activation of autophagy with rapamycin rapidly eliminated ~50% of misfolded HLA-B27, while folded HLA-B27 or HLA-B7 monomeric heavy chains were minimally affected.	Sirolimus	29-38	major histocompatibility complex, class I, B	Homo sapiens	76-83
29276026-1	2018	The phosphatidylinositol 3-kinase/protein kinase B (Akt)/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway is amplified in 60-80% of patients with acute myelogenous leukemia (AML).	Sirolimus	79-88	protein tyrosine kinase 2 beta	Homo sapiens	34-50
29432811-0	2018	Rapamycin attenuates Th2-driven experimental allergic conjunctivitis.	Sirolimus	0-9	heart and neural crest derivatives expressed 2	Mus musculus	21-24
29432811-4	2018	Infiltrations of CD11c+ dendritic cells and CD4+ T cells, and the expressions of chemokines and adhesion molecules in the conjunctiva were attenuated in rapamycin-treated mice, as well as decreased Th1 and Th2 cytokines in the cervical lymph nodes compared to non-treated mice.	Sirolimus	153-162	heart and neural crest derivatives expressed 2	Mus musculus	206-209
29432811-5	2018	The expression of mTOR signaling proteins was increased in EAC and reduced by rapamycin treatment.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Mus musculus	18-22
29432811-6	2018	Topical application of rapamycin was also proved to show reduced clinical signs, eosinophil infiltration, and Th2 type immune responses comparable to those from intraperitoneal injection of rapamycin.	Sirolimus	23-32	heart and neural crest derivatives expressed 2	Mus musculus	110-113
29393976-5	2018	We utilized a murine model of 20% total body surface area burn and the mTOR-specific inhibitor rapamycin.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Mus musculus	71-75
27926859-6	2016	Together, our findings indicate that altered mTOR signaling in Lmna-/- mice leads to a lipodystrophic phenotype that can be rescued with rapamycin, highlighting the effect of loss of adipose tissue in Lmna-/- mice and the consequences of altered mTOR signaling.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Mus musculus	45-49
27926859-6	2016	Together, our findings indicate that altered mTOR signaling in Lmna-/- mice leads to a lipodystrophic phenotype that can be rescued with rapamycin, highlighting the effect of loss of adipose tissue in Lmna-/- mice and the consequences of altered mTOR signaling.	Sirolimus	137-146	lamin A	Mus musculus	63-67
27741510-3	2016	Our lab has recently shown that genetic inhibition of the mechanistic target of rapamycin (TOR) rescues the short lifespan of yeast mutants with defective mitochondrial function, and that pharmacological inhibition of TOR by administration of rapamycin significantly rescues the shortened lifespan, neurological symptoms, and neurodegeneration in a mouse model of LS.	Sirolimus	80-89	Target of rapamycin	Drosophila melanogaster	91-94
27741510-3	2016	Our lab has recently shown that genetic inhibition of the mechanistic target of rapamycin (TOR) rescues the short lifespan of yeast mutants with defective mitochondrial function, and that pharmacological inhibition of TOR by administration of rapamycin significantly rescues the shortened lifespan, neurological symptoms, and neurodegeneration in a mouse model of LS.	Sirolimus	80-89	Target of rapamycin	Drosophila melanogaster	218-221
27613445-5	2016	Furthermore, by calibrating the pharmacodynamics of mTOR inhibitors, we have been able to reproduce the dose-dependent effect of rapamycin on liver degeneration and lifespan expansion in wild-type and HER2-neu mice.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Mus musculus	52-56
29483302-7	2018	In tumor cells engineered to express NLS-IRS-1, the IRS-1/LC3 nuclear structures repress autophagy induced by either amino acid starvation or rapamycin treatment.	Sirolimus	142-151	insulin receptor substrate 1	Homo sapiens	41-46
29483302-7	2018	In tumor cells engineered to express NLS-IRS-1, the IRS-1/LC3 nuclear structures repress autophagy induced by either amino acid starvation or rapamycin treatment.	Sirolimus	142-151	insulin receptor substrate 1	Homo sapiens	52-57
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Homo sapiens	26-30
27167250-7	2016	This carbachol-stimulated S6K1 activation was abrogated by LY294002 or the mTORC1 inhibitor rapamycin, supporting the notion that mAChRs mediate S6K1 activation via the PI3K-Akt-mTORC1 pathway.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Homo sapiens	145-149
27167250-11	2016	In the presence of the MEK1/2 inhibitor U0126, cell proliferation was further reduced by rapamycin treatment.	Sirolimus	89-98	mitogen-activated protein kinase kinase 1	Homo sapiens	23-29
28105169-9	2016	Furthermore, the expression of 5"-adenosine monophosphate-activated protein kinase was increased, and that of mechanistic target of rapamycin was decreased, following beta-catenin silencing.	Sirolimus	132-141	catenin beta 1	Homo sapiens	167-179
27332042-12	2016	Treatment with rapamycin selectively blocked mTORC1 activation, NDUFS3 expression, and aPL production both in transaldolase-deficient mice and in lupus-prone mice.	Sirolimus	15-24	NADH:ubiquinone oxidoreductase core subunit S3	Mus musculus	64-70
29854093-7	2018	Blocking mTOR with rapamycin abolished the stimulatory effect of both L-Arg and SNP on protein synthesis and p70S6K phosphorylation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	9-13
27555230-7	2016	Clenbuterol exacerbated protein excretion (13 +- 2 to 26 +- 4 mg/day; P&lt;.05) and antagonized the effect of rapamycin on KIM-1 expression.	Sirolimus	110-119	hepatitis A virus cellular receptor 1	Rattus norvegicus	123-128
29389670-7	2018	Notably, in spite of concurrent Akt hyperactivation in mouse brain lesions, single mTOR inhibition by rapamycin was sufficient to strongly impair mouse SEGA growth.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Mus musculus	83-87
29351469-8	2018	Together, our data establish mTOR activity as a critical mediator of BBB breakdown in AD and, potentially, vascular cognitive impairment and suggest that rapamycin and/or rapalogs could be used for the restoration of BBB integrity.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Mus musculus	29-33
28969943-8	2018	Moreover, 4E-BP1, a target of mTOR, appeared to mediate the protective effects of rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	10-16
29599839-0	2018	Rapamycin protects against paraquat-induced pulmonary epithelial-mesenchymal transition via the Wnt/beta-catenin signaling pathway.	Sirolimus	0-9	catenin beta 1	Homo sapiens	100-112
27777385-8	2016	Importantly, the beneficial effects of rapamycin on mitochondrial function were absent in brains and fibroblasts from first generation TERT -/- mice, and when TERT shuttling was inhibited by the Src kinase inhibitor bosutinib.	Sirolimus	39-48	telomerase reverse transcriptase	Mus musculus	135-139
29599839-7	2018	In conclusion, rapamycin protects against PQ-induced pulmonary EMT via the Wnt/beta-catenin signaling pathway.	Sirolimus	15-24	catenin beta 1	Homo sapiens	79-91
29378959-2	2018	Here, rapamycin (an inhibitor of mTOR) was used in GHR-KO (growth hormone receptor knockout) mice, which have suppressed mTORC1 and up-regulated mTORC2 signaling, to determine the effect of concurrently decreased mTORC1 and mTORC2 signaling on life span.	Sirolimus	6-15	mechanistic target of rapamycin kinase	Mus musculus	33-37
27777385-8	2016	Importantly, the beneficial effects of rapamycin on mitochondrial function were absent in brains and fibroblasts from first generation TERT -/- mice, and when TERT shuttling was inhibited by the Src kinase inhibitor bosutinib.	Sirolimus	39-48	telomerase reverse transcriptase	Mus musculus	159-163
27777385-9	2016	Taken together, our data suggests that the mTOR signalling pathway impinges on the mitochondrial localisation of TERT protein, which might in turn contribute to the protection of the brain by DR or rapamycin against age-associated mitochondrial ROS increase and cognitive decline.	Sirolimus	198-207	mechanistic target of rapamycin kinase	Mus musculus	43-47
27777385-9	2016	Taken together, our data suggests that the mTOR signalling pathway impinges on the mitochondrial localisation of TERT protein, which might in turn contribute to the protection of the brain by DR or rapamycin against age-associated mitochondrial ROS increase and cognitive decline.	Sirolimus	198-207	telomerase reverse transcriptase	Mus musculus	113-117
29270715-5	2018	Furthermore, p70S6K knockdown and the specific mTOR inhibitor rapamycin decreased the expression levels of p-p70S6K and alpha-SMA in cultured fibroblasts from grade T3 pterygium.	Sirolimus	62-71	ribosomal protein S6 kinase B1	Homo sapiens	107-115
27752996-11	2016	Pre-treatment with any of the inhibitors for PI3K (LY294002), MAPK (PD98059), Akt (perifosine), or mTOR (rapamycin) blocked the BDNF/TrkB-induced increases of cell migration and invasion in TB3 cells, and also blocked the BDNF/TrkB-induced expressions of P-Akt, P-Erk, and P-mTOR.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Mus musculus	99-103
29224866-8	2018	Inhibition of mTORC1 by rapamycin attenuated the phosphorylation of molecules related to mTORC1 signaling and caused a marked decrease in LAT1 expression in the cultured cells; expression of beta-casein also decreased significantly.	Sirolimus	24-33	solute carrier family 7 member 5	Homo sapiens	138-142
27752996-11	2016	Pre-treatment with any of the inhibitors for PI3K (LY294002), MAPK (PD98059), Akt (perifosine), or mTOR (rapamycin) blocked the BDNF/TrkB-induced increases of cell migration and invasion in TB3 cells, and also blocked the BDNF/TrkB-induced expressions of P-Akt, P-Erk, and P-mTOR.	Sirolimus	105-114	brain derived neurotrophic factor	Mus musculus	128-132
28752574-6	2018	As a result, the FlimPIA with S440 L acceptor showed the best signal/background ratio for the detection of rapamycin-induced FKBP12-FRB interactions.	Sirolimus	107-116	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	125-131
27589685-5	2016	Treatment with rapamycin, an mTOR inhibitor, antagonized the effects of PFOA and reversed the effects of PFOA activation in a xenograft mouse model of endometrial cancer.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	29-33
29348392-5	2018	Rapamycin treatment decreased the gene expression of MMP-3, MMP-13, IL-1beta, IL-6, TNF-alpha, and protein levels of P16 and P21 in bleomycin-treated AFSCs.	Sirolimus	0-9	H3 histone pseudogene 16	Homo sapiens	125-128
26456737-3	2016	Rapamycin induced and altered the expression of autophagy signature proteins in wild-type cultures as well as in HT22-Beclin-1-knockdown cells.	Sirolimus	0-9	beclin 1, autophagy related	Mus musculus	118-126
29180513-8	2018	In contrast, rapamycin treatment increased the level of the p27KIP1 (also known as CDKN1B) cyclin-dependent kinase inhibitor, and rapamycin-induced ciliogenesis was abrogated in p27KIP1-depleted cells.	Sirolimus	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	60-67
29180513-8	2018	In contrast, rapamycin treatment increased the level of the p27KIP1 (also known as CDKN1B) cyclin-dependent kinase inhibitor, and rapamycin-induced ciliogenesis was abrogated in p27KIP1-depleted cells.	Sirolimus	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	83-89
26456737-5	2016	The amount of LC3, an important protein for the initiation of autophagosome formation and LAMP-1, a major constituent of the lysosomal membrane, underwent a dramatic and highly significant increase in control cultures challenged with rapamycin.	Sirolimus	234-243	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	14-17
29180513-8	2018	In contrast, rapamycin treatment increased the level of the p27KIP1 (also known as CDKN1B) cyclin-dependent kinase inhibitor, and rapamycin-induced ciliogenesis was abrogated in p27KIP1-depleted cells.	Sirolimus	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	178-185
29180513-8	2018	In contrast, rapamycin treatment increased the level of the p27KIP1 (also known as CDKN1B) cyclin-dependent kinase inhibitor, and rapamycin-induced ciliogenesis was abrogated in p27KIP1-depleted cells.	Sirolimus	130-139	cyclin dependent kinase inhibitor 1B	Homo sapiens	83-89
27599409-7	2016	Pretreatment with rapamycin, an mTOR inhibitor, restored the abnormal mTOR/p70S6K signaling induced by surgery, attenuated the accumulation of Abeta and reduced the phosphorylation of tau protein.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	32-36
29180513-8	2018	In contrast, rapamycin treatment increased the level of the p27KIP1 (also known as CDKN1B) cyclin-dependent kinase inhibitor, and rapamycin-induced ciliogenesis was abrogated in p27KIP1-depleted cells.	Sirolimus	130-139	cyclin dependent kinase inhibitor 1B	Homo sapiens	178-185
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	cadherin 1	Rattus norvegicus	146-156
30509037-7	2018	Here we show that rapamycin treatment leads to the upregulation of miR-21 in both patients" serum and in primary SEGA tumor cells in the culture indicating the regulatory relationship between rapamycin treatment and miR-21 expression.	Sirolimus	18-27	microRNA 21	Homo sapiens	67-73
30509037-7	2018	Here we show that rapamycin treatment leads to the upregulation of miR-21 in both patients" serum and in primary SEGA tumor cells in the culture indicating the regulatory relationship between rapamycin treatment and miR-21 expression.	Sirolimus	18-27	microRNA 21	Homo sapiens	216-222
27599409-7	2016	Pretreatment with rapamycin, an mTOR inhibitor, restored the abnormal mTOR/p70S6K signaling induced by surgery, attenuated the accumulation of Abeta and reduced the phosphorylation of tau protein.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	70-74
30509037-7	2018	Here we show that rapamycin treatment leads to the upregulation of miR-21 in both patients" serum and in primary SEGA tumor cells in the culture indicating the regulatory relationship between rapamycin treatment and miR-21 expression.	Sirolimus	192-201	microRNA 21	Homo sapiens	67-73
30509037-7	2018	Here we show that rapamycin treatment leads to the upregulation of miR-21 in both patients" serum and in primary SEGA tumor cells in the culture indicating the regulatory relationship between rapamycin treatment and miR-21 expression.	Sirolimus	192-201	microRNA 21	Homo sapiens	216-222
28300280-2	2018	Recently, we have reported that rapamycin, a macrocyclic lactone, attenuates human soluble BAFF (hsBAFF)-stimulated B-cell proliferation/survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway.	Sirolimus	32-41	protein phosphatase 2 phosphatase activator	Homo sapiens	175-186
28300280-3	2018	Here, we show that the inhibitory effect of rapamycin on hsBAFF-promoted B cell proliferation/survival is also related to blocking hsBAFF-stimulated phosphorylation of Akt, S6K1, and 4E-BP1, as well as expression of survivin in normal and B-lymphoid (Raji and Daudi) cells.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	173-177
27401903-4	2016	We found that treatment with rapamycin, an mTOR-specific inhibitor, reduced intracellular ROS, maintained the mitochondrial membrane potential and restored mitochondrial dysfunction.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	43-47
28300280-3	2018	Here, we show that the inhibitory effect of rapamycin on hsBAFF-promoted B cell proliferation/survival is also related to blocking hsBAFF-stimulated phosphorylation of Akt, S6K1, and 4E-BP1, as well as expression of survivin in normal and B-lymphoid (Raji and Daudi) cells.	Sirolimus	44-53	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	183-189
28777210-11	2018	Similarly, CD4IFN-gammaIL-10 cells expanded among Foxp3-negative cells after in vivo treatment of old recipients with rapamycin.	Sirolimus	118-127	forkhead box P3	Mus musculus	50-55
28972182-7	2017	However, rapamycin further increased uPA expression in TSC2-null tumor cells and immortalized TSC2-null angiomyolipoma cells, but not in cells with intact TSC.	Sirolimus	9-18	plasminogen activator, urokinase	Mus musculus	37-40
28972182-7	2017	However, rapamycin further increased uPA expression in TSC2-null tumor cells and immortalized TSC2-null angiomyolipoma cells, but not in cells with intact TSC.	Sirolimus	9-18	TSC complex subunit 2	Mus musculus	55-59
28972182-7	2017	However, rapamycin further increased uPA expression in TSC2-null tumor cells and immortalized TSC2-null angiomyolipoma cells, but not in cells with intact TSC.	Sirolimus	9-18	TSC complex subunit 2	Mus musculus	94-98
28972182-10	2017	uPA-knock-out mice developed fewer and smaller TSC2-null lung tumors, and introduction of uPA shRNA in tumor cells or amiloride-induced uPA inhibition reduced tumorigenesis in vivo These findings suggest that interference with the uPA-dependent pathway, when used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disorders.	Sirolimus	275-284	plasminogen activator, urokinase	Mus musculus	0-3
28972182-10	2017	uPA-knock-out mice developed fewer and smaller TSC2-null lung tumors, and introduction of uPA shRNA in tumor cells or amiloride-induced uPA inhibition reduced tumorigenesis in vivo These findings suggest that interference with the uPA-dependent pathway, when used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disorders.	Sirolimus	275-284	plasminogen activator, urokinase	Mus musculus	90-93
28972182-10	2017	uPA-knock-out mice developed fewer and smaller TSC2-null lung tumors, and introduction of uPA shRNA in tumor cells or amiloride-induced uPA inhibition reduced tumorigenesis in vivo These findings suggest that interference with the uPA-dependent pathway, when used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disorders.	Sirolimus	275-284	plasminogen activator, urokinase	Mus musculus	90-93
28972182-10	2017	uPA-knock-out mice developed fewer and smaller TSC2-null lung tumors, and introduction of uPA shRNA in tumor cells or amiloride-induced uPA inhibition reduced tumorigenesis in vivo These findings suggest that interference with the uPA-dependent pathway, when used along with rapamycin, might attenuate LAM progression and potentially other TSC-related disorders.	Sirolimus	275-284	plasminogen activator, urokinase	Mus musculus	90-93
29240812-9	2017	In addition, vaspin increased the phosphorylation levels of mTOR and p70S6K, which was inhibited by rapamycin.	Sirolimus	100-109	ribosomal protein S6 kinase B1	Rattus norvegicus	69-75
29025710-3	2017	We have shown that rapamycin promotes vascular smooth muscle cell differentiation in an AKT2-dependent manner in vitro.	Sirolimus	19-28	thymoma viral proto-oncogene 2	Mus musculus	88-92
29025710-9	2017	Mechanistically, rapamycin induced MYOCD (myocardin) mRNA expression.	Sirolimus	17-26	myocardin	Mus musculus	35-40
29025710-9	2017	Mechanistically, rapamycin induced MYOCD (myocardin) mRNA expression.	Sirolimus	17-26	myocardin	Mus musculus	42-51
27694325-4	2016	METHODS AND RESULTS: Biosynthesis of MBG by cultured human JEG-3 cells is initiated by CYP27A1, which is also a target for rapamycin.	Sirolimus	123-132	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	87-94
26990829-0	2016	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig.	Sirolimus	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	110-115
28967097-2	2017	Rapatar is a novel nanoformulated micellar of rapamycin, a putative inhibitor of mTOR that has been rationally designed to increase water solubility of rapamycin to facilitate p.o.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Mus musculus	81-85
28994148-7	2017	RESULTS: We revealed that lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment.	Sirolimus	178-187	tumor protein p53 pathway corepressor 1	Homo sapiens	26-37
26990829-9	2016	This suggests that rapamycin after T cell depletion could affect Treg cells leading to an increase of Tfh cells and DSA production that can be reversed by CTLA4-Ig.	Sirolimus	19-28	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	155-160
28994148-7	2017	RESULTS: We revealed that lincRNA-p21 silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment.	Sirolimus	178-187	pyruvate kinase M1/2	Homo sapiens	98-102
28891034-4	2017	Clinically, those mTOR-related disorders are treated with the mTOR inhibitor rapamycin and its rapalogs.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	18-22
28891034-4	2017	Clinically, those mTOR-related disorders are treated with the mTOR inhibitor rapamycin and its rapalogs.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	62-66
26991739-6	2016	Treatment with 5 mg/kg rapamycin for 3 weeks to inhibit mTORC1 and mTORC2 fully reversed PH in SM22-TSC1(-/-) mice.	Sirolimus	23-32	transgelin	Mus musculus	95-99
26991739-7	2016	In chronically hypoxic mice and SM22-5HTT(+) mice exhibiting PH associated with mTORC1 and mTORC2 activation, PH was maximally attenuated by low-dose rapamycin associated with selective mTORC1 inhibition.	Sirolimus	150-159	transgelin	Mus musculus	32-36
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD38 molecule	Homo sapiens	58-62
26992888-14	2016	Here we have shown that loss of Pten leads to aberrant migration, which can be prevented but not reversed by treatment with rapamycin, a mTor inhibitor.	Sirolimus	124-133	phosphatase and tensin homolog	Homo sapiens	32-36
27246695-11	2016	In vitro study revealed that AMPK activation using AICAR or mTOR inhibition using rapamycin effectively negated the beneficial cardiomyocyte mechanical effects of TLR4 inhibition (CLI-095) against paraquat toxicity, supporting a permissive role for AMPK-mTOR in TLR4 inhibition-offered cardioprotection against paraquat.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Mus musculus	60-64
27174915-9	2016	Testing their cooperation in vitro, a significant involvement of IDO1 in mTOR immunogenic pathway was found, able to counteract the aim of rapamycin treatment.	Sirolimus	139-148	indoleamine 2,3-dioxygenase 1	Homo sapiens	65-69
26954158-2	2016	Rapamycin is a selective inhibitor of mTOR, and induces autophagy in various systems.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	38-42
29209321-9	2017	Administration of rapamycin during AA diet consumption prevented colitis exacerbation suggesting that mTOR activation was involved in the effects triggered by the AA diet.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	102-106
27564518-9	2016	Rapamycin improves lysosomal proteolytic activity by improving cathepsin L activity restoring autophagic cargo degradation, and preventing increased VEGF release (P &lt; 0.0001).	Sirolimus	0-9	cathepsin L	Rattus norvegicus	63-74
27564518-9	2016	Rapamycin improves lysosomal proteolytic activity by improving cathepsin L activity restoring autophagic cargo degradation, and preventing increased VEGF release (P &lt; 0.0001).	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	149-153
27059001-0	2016	Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.	Sirolimus	75-84	dipeptidyl peptidase 4	Homo sapiens	25-48
29152581-4	2017	A homozygous gtr1/gtr1 mutant exhibited impaired TORC1-mediated phosphorylation of ribosomal protein S6 and increased susceptibility to rapamycin.	Sirolimus	136-145	Rag GTPase GTR1	Saccharomyces cerevisiae S288C	13-17
29152581-4	2017	A homozygous gtr1/gtr1 mutant exhibited impaired TORC1-mediated phosphorylation of ribosomal protein S6 and increased susceptibility to rapamycin.	Sirolimus	136-145	Rag GTPase GTR1	Saccharomyces cerevisiae S288C	18-22
29736257-8	2017	Thus, rapamycin-mediated lifespan extension in Lmna-/- mice is in part due to the improvement of skeletal muscle function and can be phenocopied by reduced S6K1 activity, but not 4E-BP1 activation.	Sirolimus	6-15	lamin A	Mus musculus	47-51
29163161-9	2017	The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k.	Sirolimus	50-59	ribosomal protein S6 kinase B1	Homo sapiens	77-83
28669853-0	2017	Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients.	Sirolimus	10-19	integrin-linked kinase	Rattus norvegicus	105-108
28807764-6	2017	However, SEC2/ST-4-induced changes in cell cycle and PI3K/mTOR signaling were significantly relieved by either LY294002 or rapamycin, and the induction of NF-kB/p65 induced was significantly downregulated by Bay11-7085.	Sirolimus	123-132	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	Homo sapiens	14-18
28608572-9	2017	Among the missense mutations, one in the rapamycin-insensitive companion of mammalian target of rapamycin (RICTOR)-coding gene (rs140964083: G > A, found in one proband) was predicted to be hazardous.	Sirolimus	41-50	RPTOR independent companion of MTOR complex 2	Homo sapiens	107-113
28934384-9	2017	Further, mutant PKCepsilon caused impaired mTORC2-dependent pAKT-S473 following rapamycin treatment.	Sirolimus	80-89	protein kinase C epsilon	Homo sapiens	16-26
27059001-2	2016	We tested the effect of addition of a dipeptidyl peptidase IV (DPP IV) inhibitor to MET on sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	91-100	dipeptidyl peptidase 4	Homo sapiens	38-61
27059001-2	2016	We tested the effect of addition of a dipeptidyl peptidase IV (DPP IV) inhibitor to MET on sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	91-100	dipeptidyl peptidase 4	Homo sapiens	63-69
27059001-2	2016	We tested the effect of addition of a dipeptidyl peptidase IV (DPP IV) inhibitor to MET on sirolimus (SRL)-induced diabetes mellitus (DM).	Sirolimus	102-105	dipeptidyl peptidase 4	Homo sapiens	63-69
27478685-1	2015	BACKGROUND: Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular respiration.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Mus musculus	21-25
27478685-1	2015	BACKGROUND: Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular respiration.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Mus musculus	27-56
27489506-6	2016	Rapamycin ameliorated diabetes-enhanced ischemic brain damage and suppressed phosphorylation of P70S6K and ERK1/2.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	96-102
27387559-5	2016	Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1 muM.	Sirolimus	89-98	La ribonucleoprotein 6, translational regulator	Homo sapiens	20-24
27387559-5	2016	Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1 muM.	Sirolimus	89-98	La ribonucleoprotein 6, translational regulator	Homo sapiens	26-33
27387559-5	2016	Rapamycin-resistant ACHN (ACHN/RR) cells were generated with chronic exposure of ACHN to rapamycin ranging from 1nM finally to 1 muM.	Sirolimus	89-98	La ribonucleoprotein 6, translational regulator	Homo sapiens	26-30
27362797-6	2016	Because cells with TSC loss fail to completely inhibit mTORC1 and properly activate autophagy in the absence of amino acids, we sporadically administered the mTORC1 inhibitor rapamycin, which was sufficient to correct the defects seen in cones, further enhancing the efficiency of cone survival mediated by Tsc1 loss.	Sirolimus	175-184	TSC22 domain family, member 1	Mus musculus	19-22
27182890-0	2016	Dual-Modal Imaging-Guided Theranostic Nanocarriers Based on Indocyanine Green and mTOR Inhibitor Rapamycin.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Mus musculus	82-86
26991545-4	2016	Induction of diCre activity in promastigotes with rapamycin resulted in efficient deletion of floxed CRK3, resulting in G2/M growth arrest.	Sirolimus	50-59	v-crk avian sarcoma virus CT10 oncogene homolog	Mus musculus	101-105
28922851-5	2017	Rapamycin treatment was found to reduce infarct size and behavioral deficits and, in GFAP+/HSF1+ zones, enhance alphaEnsa neuronal nuclear translocation and mitigate cell death, relative to controls.	Sirolimus	0-9	heat shock transcription factor 1	Rattus norvegicus	91-95
27660271-0	2017	Neuroprotection Through Rapamycin-Induced Activation of Autophagy and PI3K/Akt1/mTOR/CREB Signaling Against Amyloid-beta-Induced Oxidative Stress, Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats.	Sirolimus	24-33	cAMP responsive element binding protein 1	Rattus norvegicus	85-89
27660271-6	2017	In addition, rapamycin induced the activation of autophagy that further activated p-PI3K, p-Akt1 (Ser473), and p-CREB (Ser183) expression in Abeta1-42-treated rats.	Sirolimus	13-22	cAMP responsive element binding protein 1	Rattus norvegicus	113-117
28979705-7	2017	Furthermore, Rictor knockdown attenuated cell cycle progression and enhanced apoptosis, synergistic with treatment of mTORC1 inhibitor rapamycin owing to abrogating the feedback activation of Akt.	Sirolimus	135-144	RPTOR independent companion of MTOR complex 2	Homo sapiens	13-19
28894133-8	2017	Rapamycin abrogated 5-MTP-mediated suppression of p16, p21, SA-beta-Gal and IL-6 and rise of BrdU incorporation.	Sirolimus	0-9	metallothionein 1B	Homo sapiens	22-25
28894133-8	2017	Rapamycin abrogated 5-MTP-mediated suppression of p16, p21, SA-beta-Gal and IL-6 and rise of BrdU incorporation.	Sirolimus	0-9	H3 histone pseudogene 16	Homo sapiens	55-58
27830533-6	2017	The data suggest that mTOR-related signalling is decreased in these cells and that inhibiting mTOR by rapamycin increases phagocytosis.	Sirolimus	102-111	mechanistic target of rapamycin kinase	Mus musculus	94-98
28737825-2	2017	The present study was employed to verify the combination use of SAMC and rapamycin that is the mTOR inhibitor with anticancer ability but has limited efficacy due to drug resistance, and to explore the underlying mechanisms.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Mus musculus	95-99
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	heme oxygenase 1	Homo sapiens	97-101
28924369-8	2017	Results: After IL-12 treatment, the number of CD8+ Tem and the expression of IFN-gamma increased significantly; while quite the opposite results were observed when the mTOR pathway was blocked by rapamycin.	Sirolimus	196-205	mechanistic target of rapamycin kinase	Mus musculus	168-172
28739896-8	2017	KGF-induced increases in mortality, AECII proliferation, and enhanced IAV susceptibility were all reversed by pretreatment of the animals with the mTOR inhibitor rapamycin before mitogenic stimulation.	Sirolimus	162-171	fibroblast growth factor 7	Mus musculus	0-3
26991545-5	2016	Co-expression of a CRK3 transgene during rapamycin-induced deletion of CRK3 resulted in complementation of growth, whereas expression of an active site CRK3(T178E) mutant did not, showing that protein kinase activity is crucial for CRK3 function.	Sirolimus	41-50	v-crk avian sarcoma virus CT10 oncogene homolog	Mus musculus	19-23
26991545-5	2016	Co-expression of a CRK3 transgene during rapamycin-induced deletion of CRK3 resulted in complementation of growth, whereas expression of an active site CRK3(T178E) mutant did not, showing that protein kinase activity is crucial for CRK3 function.	Sirolimus	41-50	v-crk avian sarcoma virus CT10 oncogene homolog	Mus musculus	71-75
26991545-5	2016	Co-expression of a CRK3 transgene during rapamycin-induced deletion of CRK3 resulted in complementation of growth, whereas expression of an active site CRK3(T178E) mutant did not, showing that protein kinase activity is crucial for CRK3 function.	Sirolimus	41-50	v-crk avian sarcoma virus CT10 oncogene homolog	Mus musculus	71-75
26991545-5	2016	Co-expression of a CRK3 transgene during rapamycin-induced deletion of CRK3 resulted in complementation of growth, whereas expression of an active site CRK3(T178E) mutant did not, showing that protein kinase activity is crucial for CRK3 function.	Sirolimus	41-50	v-crk avian sarcoma virus CT10 oncogene homolog	Mus musculus	71-75
27178693-5	2016	Notably, patients on sirolimus have lower incidence of SCC compared to patients on calcineurin inhibitors.	Sirolimus	21-30	serpin family B member 3	Homo sapiens	55-58
27178693-6	2016	Revision of immunosuppressive regimen to include sirolimus may be a viable preventative measure against SCC in SOTRs who are high at risk for developing SCCs.	Sirolimus	49-58	serpin family B member 3	Homo sapiens	104-107
29100319-6	2017	The effects of the combined treatment were reduced by rapamycin (a mTOR inhibitor) or HgCL2 (an AQP inhibitor), but not Z-VAD-FMK (a caspase inhibitor).	Sirolimus	54-63	mechanistic target of rapamycin kinase	Mus musculus	67-71
29029388-0	2017	Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells.	Sirolimus	0-9	microRNA 21	Homo sapiens	18-24
29029388-3	2017	We discovered that the oncogenic miRNA, miR-21, is increased in Tsc2-deficient cells and, surprisingly, further increased by rapamycin.	Sirolimus	125-134	microRNA 21	Homo sapiens	40-46
27245614-5	2016	Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	147-153
27070592-5	2016	In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Homo sapiens	90-96
26676933-7	2016	We also treated daf-16 worms with rapamycin, allantoin or trichostatin A, and a lifespan extension was observed, suggesting that these drugs act via DAF-16-independent mechanisms, as would be expected from CR mimetics.	Sirolimus	34-43	Fork-head domain-containing protein;Forkhead box protein O	Caenorhabditis elegans	16-22
26924291-11	2016	Treatment of with sirolimus increased miR-34b levels by a factor of 7.5 in the cells.	Sirolimus	18-27	microRNA 34b	Homo sapiens	38-45
26924291-12	2016	Upregulation of miR-34b also induced apoptosis and increased the sensitivity of the cells to the anticancer drugs, whereas transfection with miR-34b-AMO, an inhibitor of miR-34b, reversed the anti-proliferation effect of sirolimus.	Sirolimus	221-230	microRNA 34b	Homo sapiens	16-23
26924291-12	2016	Upregulation of miR-34b also induced apoptosis and increased the sensitivity of the cells to the anticancer drugs, whereas transfection with miR-34b-AMO, an inhibitor of miR-34b, reversed the anti-proliferation effect of sirolimus.	Sirolimus	221-230	microRNA 34b	Homo sapiens	141-148
26924291-12	2016	Upregulation of miR-34b also induced apoptosis and increased the sensitivity of the cells to the anticancer drugs, whereas transfection with miR-34b-AMO, an inhibitor of miR-34b, reversed the anti-proliferation effect of sirolimus.	Sirolimus	221-230	microRNA 34b	Homo sapiens	141-148
26924291-15	2016	CONCLUSION: Sirolimus increases the sensitivity of human OS cells to anticancer drugs in vitro by up-regulating miR-34b interacting with PAK1 and ABCB1.	Sirolimus	12-21	microRNA 34b	Homo sapiens	112-119
27358149-5	2016	Rapamycin promoted the expression of apoptosis-related genes Caspase3 and Caspase8 in the senile group, while 3-MA inhibited them in both the young and senile groups.	Sirolimus	0-9	caspase 8	Mus musculus	74-82
28810557-5	2017	Consequently, hyper phosphorylated Tau (pS199 or pS396) and upregulated mTOR activity were observed in SAMP8 when compared with SAMR1; however, 0.5 microM rapamycin administration significantly reduced the levels of phosphorylated Tau and p70S6K (pT389) in SAMP8 mice.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Mus musculus	72-76
28571990-10	2017	A similar negative effect on the expression of RPS6KB1 and EIF4EBP1 was detected when the cells were cultured with either rapamycin or mTOR small interference RNA.	Sirolimus	122-131	eukaryotic translation initiation factor 4E binding protein 1	Bos taurus	59-67
28724388-6	2017	Inhibition of MTOR by rapamycin decreased basal levels of protein O-GlcNAcylation, decreased AKT activation and partially reversed the effect of thiamet G on alpha-synuclein monomer accumulation.	Sirolimus	22-31	synuclein alpha	Homo sapiens	158-173
28693498-1	2017	BACKGROUND: Inhibitors of mTOR, such as sirolimus, have been shown to induce thymus involution and inflammatory lung disease in mice.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Mus musculus	26-30
28562352-6	2017	This leads to an upregulation of the nanocluster scaffold galectin-1 (Gal-1), which is responsible for the rapamycin-induced increase in H-ras nanoclustering and signaling output.	Sirolimus	107-116	galectin 1	Homo sapiens	58-68
28562352-6	2017	This leads to an upregulation of the nanocluster scaffold galectin-1 (Gal-1), which is responsible for the rapamycin-induced increase in H-ras nanoclustering and signaling output.	Sirolimus	107-116	galectin 1	Homo sapiens	70-75
26700129-4	2016	In an attempt to understand the role of the FRB domain in TOR function, we identified a single point mutation (Tor2(W2041R) ) in the FRB domain of Tor2 that renders yeast cells rapamycin resistant and temperature sensitive.	Sirolimus	177-186	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	111-115
28356345-6	2017	The effects of mTOR activation on hepatic cleaved caspase 3 were reversed by rapamycin, an inhibitor of mTOR signaling.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	15-19
28356345-6	2017	The effects of mTOR activation on hepatic cleaved caspase 3 were reversed by rapamycin, an inhibitor of mTOR signaling.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Mus musculus	104-108
28158917-7	2017	Further, to better understand the relationship between Notch signalling and autophagy in podocyte differentiation, rapamycin was added to enhance autophagy levels in DAPT-treated cells, and as a result, nephrin was recovered and DAPT-induced injury was ameliorated.	Sirolimus	115-124	notch 1	Mus musculus	55-60
28647341-9	2017	Rapamycin inhibited RIP1-p62 and RIP1-RIP3 interactions induced by TNF/zVAD and partly restored autophagic flux and suppressed LDH release in TNF/zVAD-treated cells.	Sirolimus	0-9	myosin phosphatase Rho interacting protein	Rattus norvegicus	38-42
28647341-10	2017	The effect of rapamycin on LDH release was reduced by knockdown of Atg5 expression.	Sirolimus	14-23	autophagy related 5	Rattus norvegicus	67-71
28507282-10	2017	In addition, TP53 mutant cancer cells had elevation of RRM1 and RRM2, which was reduced by rapamycin.	Sirolimus	91-100	transformation related protein 53	Mus musculus	13-17
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	eomesodermin	Mus musculus	124-129
28588256-6	2017	These effects are prevented by pre- or post-treatment with rapamycin, indicating the mTOR pathway is involved in mediating seizure-induced astrocyte injury.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	85-89
28578659-0	2017	Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.	Sirolimus	0-9	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	105-109
28371119-2	2017	Rapamycin, an inhibitor of mTOR, inhibits cell senescence in vitro and increases longevity in several species.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
28393209-8	2017	Furthermore, Pur inhibited the increased levels of autophagy induced by rapamycin, and the autophagy-inhibiting effects of Pur during myocardial H/R were abolished by the Akt signaling inhibitor API-2.	Sirolimus	72-81	baculoviral IAP repeat containing 3	Homo sapiens	195-200
28641612-11	2017	mTOR inhibitor rapamycin can partially alleviate the injury, suggesting that iron overload can lead to injury of erythropoiesis through HIF-1alpha.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	0-4
28641612-11	2017	mTOR inhibitor rapamycin can partially alleviate the injury, suggesting that iron overload can lead to injury of erythropoiesis through HIF-1alpha.	Sirolimus	15-24	hypoxia inducible factor 1, alpha subunit	Mus musculus	136-146
28330873-11	2017	Rapamycin treatment increased FoxO3 activity as well as LC3 and ULK1 expressions in macrophages from AMPKalpha1-/- mice.	Sirolimus	0-9	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	56-59
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	neurofilament heavy chain	Homo sapiens	172-176
28250148-6	2017	Systemic rapamycin treatment, thought to selectively target mTOR complex 1 (mTORC1), suppressed mTOR/S6 signaling, reduced levels of MBP and overall tubulin, and decreased NF-H phosphorylation in nerves strained for 6 h, revealing a role for mTOR in increasing MBP expression and NF-H phosphorylation, and maintaining tubulin levels.	Sirolimus	9-18	neurofilament heavy chain	Homo sapiens	280-284
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	vascular endothelial growth factor A	Rattus norvegicus	197-231
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	vascular endothelial growth factor A	Rattus norvegicus	233-237
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	kinase insert domain receptor	Rattus norvegicus	264-271
28317380-8	2017	The Ingenuity Systems software identified 16 pathways, and this analysis indicated sirolimus, an mTOR pathway inhibitor, as a potential inhibitor of CypA.	Sirolimus	83-92	peptidylprolyl isomerase A	Homo sapiens	149-153
28102559-3	2017	Furthermore, whether Wnt/beta-catenin signaling pathway was activated by RPM-loaded BHA/PAA was explored.	Sirolimus	73-76	catenin beta 1	Homo sapiens	25-37
28102559-8	2017	Furthermore, we found the expression of Wnt1, LDL receptor related protein 6 (Lrp6) and beta-catenin was significantly increased in H37Rv-infected MG63 cells following treatment with RPM-loaded BHA/PAA, as determined by Western blot analysis.	Sirolimus	183-186	catenin beta 1	Homo sapiens	88-100
26700129-4	2016	In an attempt to understand the role of the FRB domain in TOR function, we identified a single point mutation (Tor2(W2041R) ) in the FRB domain of Tor2 that renders yeast cells rapamycin resistant and temperature sensitive.	Sirolimus	177-186	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	147-151
27113190-6	2016	Rapamycin treatment resulted in significantly decreased S6 and P70S6K protein phosphorylation level in the cells (P&lt;0.05).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	63-69
28068606-4	2017	Previously, exposure to alphaSyn pre-formed fibrils (PFFs) has been shown to induce aggregation of endogenous alphaSyn resulting in cell death that is exacerbated by either starvation or inhibition of mTOR by rapamycin, both of which are able to induce autophagy, an intracellular protein degradation pathway.	Sirolimus	209-218	synuclein, alpha	Mus musculus	24-32
28068606-4	2017	Previously, exposure to alphaSyn pre-formed fibrils (PFFs) has been shown to induce aggregation of endogenous alphaSyn resulting in cell death that is exacerbated by either starvation or inhibition of mTOR by rapamycin, both of which are able to induce autophagy, an intracellular protein degradation pathway.	Sirolimus	209-218	synuclein, alpha	Mus musculus	110-118
28068606-4	2017	Previously, exposure to alphaSyn pre-formed fibrils (PFFs) has been shown to induce aggregation of endogenous alphaSyn resulting in cell death that is exacerbated by either starvation or inhibition of mTOR by rapamycin, both of which are able to induce autophagy, an intracellular protein degradation pathway.	Sirolimus	209-218	mechanistic target of rapamycin kinase	Mus musculus	201-205
28333137-5	2017	MDSCs, especially CD11b+Ly6G+Ly6Clow G-MDSCs were recruited to the injured kidney following the interaction of CXCL1, CXCL2 and their receptor CXCR2 after inhibiting mTOR signal with rapamycin treatment.	Sirolimus	183-192	mechanistic target of rapamycin kinase	Mus musculus	166-170
28333137-7	2017	In addition, the expression of pro-inflammatory cytokines IL-1beta and IFN-gamma mRNA was downregulated while the expression of TGF-beta1 and Foxp3 mRNA was upregulated in kidney tissue after transferring rapamycin-treated MDSCs.	Sirolimus	205-214	forkhead box P3	Mus musculus	142-147
28256519-5	2017	We observed that both trehalose and rapamycin activate autophagy in BV2 microglial cells and down-regulate the production of pro-inflammatory cytokines and nitric oxide (NO), in response to LPS and alpha-synuclein.	Sirolimus	36-45	synuclein, alpha	Mus musculus	198-213
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Mus musculus	21-25
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Mus musculus	158-162
27553832-5	2017	The efficacy of PI3K-mTOR inhibition was established using orthotopic allograft and genetically engineered spontaneous glioblastoma mouse models.Results: The mTOR inhibitors rapamycin and AZD8055 are substrates of ABCB1, whereas the dual PI3K/mTOR inhibitor NVP-BEZ235 and the PI3K inhibitor ZSTK474 are not.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Mus musculus	158-162
28469639-5	2017	We have recently published that TERT protein accumulated in mitochondria from brain tissue of mice that have undergone short-term dietary restriction (DR) and rapamycin treatment.	Sirolimus	159-168	telomerase reverse transcriptase	Mus musculus	32-36
27524416-4	2017	Pituitary knockout of either mTOR signaling pathway negative regulator Tsc1 or Pten caused mouse pituitary prolactinoma, which was abolished by rapamycin treatment.	Sirolimus	144-153	mechanistic target of rapamycin kinase	Mus musculus	29-33
27113190-7	2016	CONCLUSION: The mechanism by which rapamycin inhibits the proliferation of valvular interstitial cells probably involves suppression of mTOR to lower S6 and P70S6K phosphorylation level but not direct regulation of the cell cycle.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Rattus norvegicus	157-163
28182002-4	2017	In the MPTP model, rapamycin caused reduced expression of the E3 ubiquitin ligase Nedd4-2 (neuronal precursor cell expressed developmentally downregulated 4-2) and reduced colocalization of glutamate transporters with ubiquitin.	Sirolimus	19-28	neural precursor cell expressed, developmentally down-regulated gene 4-like	Mus musculus	82-89
28182002-6	2017	NF-kappaB was shown to be a key mediator for rapamycin, whereas Janus kinase 2, signal transducer and activator of transcription 3, phosphoinositide 3-kinase, and Akt partially mediated rapamycin effects in astrocytes.	Sirolimus	186-195	Janus kinase 2	Mus musculus	64-78
27248657-6	2016	Further, the presence of the 5"-UTR enhanced SNCA synthesis when cap-dependent translation was attenuated with rapamycin treatment.	Sirolimus	111-120	synuclein alpha	Homo sapiens	45-49
27660040-5	2017	Aging increased mTOR activation in arteries evidenced by elevated S6K phosphorylation (P &lt; 0.01), and this was reversed after rapamycin treatment in old mice (P &lt; 0.05).	Sirolimus	129-138	mechanistic target of rapamycin kinase	Mus musculus	16-20
27047390-4	2016	Inhibition of MEK/ERK signaling reversed the effect of rapamycin on the up-regulation of LC3-II, Beclin-1 and Noxa, and the down-regulation of Mcl-1 and p62.	Sirolimus	55-64	phorbol-12-myristate-13-acetate-induced protein 1	Rattus norvegicus	110-114
27014314-2	2016	Rapamycin inhibits TOR kinase activity viaFK506 binding protein 12 kDa (FKBP12) in all examined heterotrophic eukaryotic organisms.	Sirolimus	0-9	FK506-binding protein 12	Arabidopsis thaliana	72-78
27014314-8	2016	Upon submergence, yeast and human FKBP12 can significantly block cotyledon greening while Arabidopsis FKBP12 only retards plant growth in the presence of rapamycin, suggesting that hypoxia stress could partially restore the functions of AtFKBP12 to bridge the interaction between rapamycin and TOR.	Sirolimus	154-163	FK506-binding protein 12	Arabidopsis thaliana	102-108
26882569-6	2016	Combination of rapamycin with trametinib, a MEK1/2 inhibitor, demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including HNSCC cells expressing the HRAS and PIK3CA oncogenes.	Sirolimus	15-24	mitogen-activated protein kinase kinase 1	Homo sapiens	44-50
26801880-3	2016	Individuals who are treated with rapamycin (sirolimus, a classical mTOR inhibitor) have significantly decreased rates of developing new cutaneous SCCs compared with those that receive traditional immunosuppression.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	67-71
26801880-3	2016	Individuals who are treated with rapamycin (sirolimus, a classical mTOR inhibitor) have significantly decreased rates of developing new cutaneous SCCs compared with those that receive traditional immunosuppression.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Mus musculus	67-71
27239444-4	2016	Ceramide levels and the mRNA levels of serine palmitoyltransferase (SPT) and transforming growth factor (TGF)-beta1 were suppressed in the skin of rats fed high-fat diets, but this abnormality was reversed by supplementation with rapamycin.	Sirolimus	230-239	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	68-71
26892465-8	2016	In addition, REH cell-injected NOD/SCID mice treated with rapamycin and a short-hairpin RNA (shRNA) to down-regulate FAK had significantly longer survival times and slower leukemia progression compared with mice injected with REH-empty vector cells and treated with rapamycin.	Sirolimus	58-67	PTK2 protein tyrosine kinase 2	Mus musculus	117-120
26892465-8	2016	In addition, REH cell-injected NOD/SCID mice treated with rapamycin and a short-hairpin RNA (shRNA) to down-regulate FAK had significantly longer survival times and slower leukemia progression compared with mice injected with REH-empty vector cells and treated with rapamycin.	Sirolimus	266-275	PTK2 protein tyrosine kinase 2	Mus musculus	117-120
26872016-6	2016	Here, we report that rapamycin treatment promotes a compensatory increase in transglutaminase 2 (TGM2) levels in mTORC1-driven tumors.	Sirolimus	21-30	transglutaminase 2, C polypeptide	Mus musculus	77-95
26872016-6	2016	Here, we report that rapamycin treatment promotes a compensatory increase in transglutaminase 2 (TGM2) levels in mTORC1-driven tumors.	Sirolimus	21-30	transglutaminase 2, C polypeptide	Mus musculus	97-101
26872016-7	2016	TGM2 inhibition potently sensitizes mTORC1-hyperactive cancer cells to rapamycin treatment, and a rapamycin-induced autophagy blockade inhibits the compensatory TGM2 upregulation.	Sirolimus	71-80	transglutaminase 2, C polypeptide	Mus musculus	0-4
26872016-7	2016	TGM2 inhibition potently sensitizes mTORC1-hyperactive cancer cells to rapamycin treatment, and a rapamycin-induced autophagy blockade inhibits the compensatory TGM2 upregulation.	Sirolimus	98-107	transglutaminase 2, C polypeptide	Mus musculus	161-165
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	84-88
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	100-104
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	84-88
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	100-104
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	84-88
26463117-3	2016	While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	100-104
26872208-1	2016	Rapamycin, an inhibitor of mTOR signaling, has been shown to reverse diastolic dysfunction in old mice in 10 weeks, highlighting its therapeutic potential for a poorly treatable condition.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
28203482-10	2017	Autophagy inducer, rapamycin, abolished lncRNA H19 effect.	Sirolimus	19-28	H19 imprinted maternally expressed transcript	Homo sapiens	47-50
28120494-6	2017	Reference Li J, Li X, Wang J, Wang Y, Qiu H. MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer.	Sirolimus	92-101	RPTOR independent companion of MTOR complex 2	Homo sapiens	116-122
27683229-0	2017	Rapamycin suppresses hypoxia/reoxygenation-induced islet injury by up-regulation of miR-21 via PI3K/Akt signalling pathway.	Sirolimus	0-9	microRNA 21	Homo sapiens	84-90
27683229-6	2017	When the PI3k/Akt signalling pathways was blocked by wortmannin, the up-regulative effects of rapamycin on miR-21 expression were inhibited in vitro.	Sirolimus	94-103	microRNA 21	Homo sapiens	107-113
27974559-6	2017	Further experiments in which mTOR signaling was modulated by RNA interference (RNAi) revealed that B cells were the primary target cells of rapamycin for the impaired humoral immunity and that reduced Tfh formation in rapamycin-treated mice was due to lower GC B cell responses that are essential for Tfh generation.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Mus musculus	29-33
27974559-6	2017	Further experiments in which mTOR signaling was modulated by RNA interference (RNAi) revealed that B cells were the primary target cells of rapamycin for the impaired humoral immunity and that reduced Tfh formation in rapamycin-treated mice was due to lower GC B cell responses that are essential for Tfh generation.	Sirolimus	218-227	mechanistic target of rapamycin kinase	Mus musculus	29-33
27974559-6	2017	Further experiments in which mTOR signaling was modulated by RNA interference (RNAi) revealed that B cells were the primary target cells of rapamycin for the impaired humoral immunity and that reduced Tfh formation in rapamycin-treated mice was due to lower GC B cell responses that are essential for Tfh generation.	Sirolimus	218-227	natriuretic peptide receptor 2	Mus musculus	258-262
28122627-7	2017	In experimental models, beneficial effects on multiple pathological processes involved in PD, including alpha-syn aggregation, cell death, oxidative stress and mitochondrial dysfunction, have been demonstrated using the autophagy enhancers rapamycin and lithium.	Sirolimus	240-249	synuclein alpha	Homo sapiens	104-113
28117338-6	2017	Clenbuterol activated the phosphatidylinositol-3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway and decreased the accumulation of polyglutamine-expanded AR.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Mus musculus	100-104
28271031-9	2017	Phosphorylation of mTORC1 effector proteins S6 and 4E-BP1 was significantly increased in wild-type mice in response to GLP-2 alone, or when co-administered with protein gavage, and abolished following oral gavage of rapamycin.	Sirolimus	216-225	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	51-57
28138322-6	2017	After treatment with rapamycin, the iron loading-induced increase in the alpha-synuclein level was significantly reversed and ROS generation was alleviated in both cultured neurons and SH-SY5Y cells.	Sirolimus	21-30	synuclein alpha	Homo sapiens	73-88
27909242-4	2017	We show that inhibiting the Tor kinase, either genetically or by administering rapamycin, at least partially reversed many of these pathologies.	Sirolimus	79-88	Target of rapamycin	Drosophila melanogaster	28-31
29216630-11	2017	However, autophagy promotion by rapamycin increased oil droplet accumulation and LPL and PPARgamma expression.	Sirolimus	32-41	lipoprotein lipase	Homo sapiens	81-84
28035937-10	2017	Rapamycin decreased phospho-mTOR and to lesser degree p-Rictor.	Sirolimus	0-9	RPTOR independent companion of MTOR complex 2	Homo sapiens	56-62
27279283-7	2017	The rapamycin treatment suppressed phosphorylated-p70S6K in the injured spinal cord that indicated inhibition of mTOR.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Mus musculus	113-117
27279283-9	2017	In an immunohistochemical analysis, Iba-1-stained microglia in the lumbar spinal cord was significantly decreased in the rapamycin-treated mice.	Sirolimus	121-130	induction of brown adipocytes 1	Mus musculus	36-41
28373901-3	2017	We hypothesized that Rapamycin, given at the onset of reperfusion, reduces myocardial infarct size through modulation of mTOR complexes.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Mus musculus	121-125
28713484-12	2017	Western blot analysis showed that rapamycin could upregulate ULK1, ATG13 and downregulate mTORC1 and p53 protein expression.	Sirolimus	34-43	transformation related protein 53, pseudogene	Mus musculus	101-104
27534900-4	2017	When autophagy was induced by rapamycin or inhibited by bafilomycin A1 in fetal liver cells, we observed a significant decrease in high ploidy megakaryocytes, a reduction of CD41 and CD61 co-expressing cells, and less proplatelet or platelet formation.	Sirolimus	30-39	integrin alpha 2b	Mus musculus	174-178
29556614-8	2017	The lowest immunoexpression of CD34, podoplanin, PDGFA, EGFR has been noticed in the Rapamycin-treated group without important differences correlated to dosage and time.	Sirolimus	85-94	platelet derived growth factor subunit A	Gallus gallus	49-54
29556614-8	2017	The lowest immunoexpression of CD34, podoplanin, PDGFA, EGFR has been noticed in the Rapamycin-treated group without important differences correlated to dosage and time.	Sirolimus	85-94	epidermal growth factor receptor	Gallus gallus	56-60
27438654-1	2016	The p70 ribosomal S6 kinase (p70S6K) is a downstream substrate that is phosphorylated and activated by the mammalian target of rapamycin complex and regulates multiple cellular processes associated with pulmonary fibrogenesis.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	4-27
27438654-1	2016	The p70 ribosomal S6 kinase (p70S6K) is a downstream substrate that is phosphorylated and activated by the mammalian target of rapamycin complex and regulates multiple cellular processes associated with pulmonary fibrogenesis.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	29-35
27686967-0	2016	Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes.	Sirolimus	0-9	uncoupling protein 1	Homo sapiens	67-87
25568097-7	2016	Introduction in the mouse diet of rapamycin, significantly blocked the mTOR activity and limited the activation of myofibroblasts but did not result in a reduction in lung collagen deposition unless it was associated with prevention of cellular senescence.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	71-75
27686967-5	2016	Treatment of brown adipocytes with rapamycin for 16h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation.	Sirolimus	35-44	insulin receptor substrate 1	Homo sapiens	77-105
27686967-5	2016	Treatment of brown adipocytes with rapamycin for 16h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation.	Sirolimus	35-44	insulin receptor substrate 1	Homo sapiens	107-111
27686967-10	2016	Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) and uncoupling protein (UCP)-1 in brown adipocytes.	Sirolimus	0-9	uncoupling protein 1	Homo sapiens	167-193
27371338-2	2016	Rapamycin inhibits mTOR activity, thereby preventing the phosphorylation of ribosomal protein S6, which is a downstream target of S6 kinase.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	130-139
27417217-10	2016	Functional assay revealed that IRGM knockdown inhibited autophagic flux and increased lipid droplet content in HepG2 and PLC/PRF/5 cells, which were reversed by the autophagy inducer rapamycin administration.	Sirolimus	183-192	heparan sulfate proteoglycan 2	Homo sapiens	121-124
26419955-0	2016	Analysis of Proteins That Rapidly Change Upon Mechanistic/Mammalian Target of Rapamycin Complex 1 (mTORC1) Repression Identifies Parkinson Protein 7 (PARK7) as a Novel Protein Aberrantly Expressed in Tuberous Sclerosis Complex (TSC).	Sirolimus	78-87	Parkinsonism associated deglycase	Homo sapiens	150-155
27798166-6	2016	Rapamycin, an inhibitor of mTOR, was transiently administered to C57BL/6 mice before ischemia/reperfusion surgery.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
26648565-13	2016	Treatment with rapamycin, an inhibitor of the mTOR/STAT3 signaling pathway had a similar effect to that of NogoA knockdown in the MPP+-treated PC12 cells.	Sirolimus	15-24	signal transducer and activator of transcription 3	Rattus norvegicus	51-56
27518770-1	2016	Recent studies have identified a role for supraphysiological gamma-aminobutyric acid (GABA) in the regulation of mechanistic target of rapamycin (mTOR), a protein kinase with pleiotropic roles in cellular development and homeostasis, including integration of growth factors and nutrient sensing and synaptic input in neurons (Lakhani et al.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Mus musculus	146-150
26814135-4	2016	Rapamycin-induced autophagy significantly increased the melanin index, tyrosinase activity and expression of several proteins linked to melanosome biogenesis, including microphthalmia transcription factor (MITF), pre-melanosome protein and tyrosinase, in Melan-a melanocytes.	Sirolimus	0-9	melanocyte inducing transcription factor	Homo sapiens	206-210
27785978-1	2016	AIM: This work spotlights on fabrication of CD44-tropic, layer-by-layer (LbL) coated, liquid crystalline nanoparticles of rapamycin (Rap-LbL-LCNPs) to enhance its water solubility and enable its anticancer use.	Sirolimus	122-131	LDL receptor related protein associated protein 1	Homo sapiens	133-136
27798864-0	2016	Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment.	Sirolimus	64-73	galectin 1	Homo sapiens	14-24
27798864-0	2016	Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment.	Sirolimus	64-73	HRas proto-oncogene, GTPase	Homo sapiens	36-40
26655465-1	2016	Expression of hypoxia-inducible factor 1a (HIF1a) is increased under several pathological conditions such as hyperactive mechanistic target of rapamycin complex 1 (mTORC1) in tuberous sclerosis complex (TSC).	Sirolimus	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	14-41
27798864-1	2016	The goal of this study was to develop combinatorial application of two drugs currently either in active use as anticancer agents (rapamycin) or in clinical trials (OTX008) as a novel strategy to inhibit Harvey RAS (HRAS)-driven tumor progression.	Sirolimus	130-139	HRas proto-oncogene, GTPase	Homo sapiens	203-213
27798864-1	2016	The goal of this study was to develop combinatorial application of two drugs currently either in active use as anticancer agents (rapamycin) or in clinical trials (OTX008) as a novel strategy to inhibit Harvey RAS (HRAS)-driven tumor progression.	Sirolimus	130-139	HRas proto-oncogene, GTPase	Homo sapiens	215-219
26655465-1	2016	Expression of hypoxia-inducible factor 1a (HIF1a) is increased under several pathological conditions such as hyperactive mechanistic target of rapamycin complex 1 (mTORC1) in tuberous sclerosis complex (TSC).	Sirolimus	143-152	hypoxia inducible factor 1, alpha subunit	Mus musculus	43-48
27599409-9	2016	The results of the present study suggested that the surgical stimulus activated mTOR/p70S6K signaling excessively, and that the inhibition of mTOR signaling with rapamycin may prevent postoperative cognitive deficits, partly through attenuating the accumulation of Abeta and hyperphosphorylation of tau protein.	Sirolimus	162-171	mechanistic target of rapamycin kinase	Mus musculus	142-146
26687947-9	2016	Interestingly, incubation with mTOR inhibitor rapamycin increased in the rate of LTR-positive autolysosomes in hepatocytes from KKAy mice and suppressed p62 accumulation in the liver from KKAy mice which correlated to an increase in the V-ATPase subunits expression.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Mus musculus	31-35
26792101-6	2016	Whereas acupuncture and rapamycin, a chemical mTOR inhibitor, show comparable alpha-syn clearance and therapeutic effects in the PD mouse model, the latter adopts a distinctly different, mTOR-dependent, autophagy induction process.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	46-50
27521345-9	2016	Treatment of mice with rapamycin, an allosteric inhibitor of mTOR, recapitulated the early B cell developmental block.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Mus musculus	61-65
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	CD38 molecule	Homo sapiens	94-98
26792101-6	2016	Whereas acupuncture and rapamycin, a chemical mTOR inhibitor, show comparable alpha-syn clearance and therapeutic effects in the PD mouse model, the latter adopts a distinctly different, mTOR-dependent, autophagy induction process.	Sirolimus	24-33	synuclein, alpha	Mus musculus	78-87
26374551-7	2016	However, much lower levels of phospho-mTOR, phospho-p70S6K, and AChE expression occurred in both brain regions of diabetic rats treated with rapamycin when compared with untreated ones.	Sirolimus	141-150	ribosomal protein S6 kinase B1	Rattus norvegicus	52-58
26374551-7	2016	However, much lower levels of phospho-mTOR, phospho-p70S6K, and AChE expression occurred in both brain regions of diabetic rats treated with rapamycin when compared with untreated ones.	Sirolimus	141-150	acetylcholinesterase	Rattus norvegicus	64-68
27297394-4	2016	Utilizing Western blot analysis, we demonstrate that similar to rapamycin (a known mTOR inhibitor), mf downregulate the phosphorylation of mTOR and its regulatory proteins, p70S6K1 and 4E-BP1, a process essential for DC protein synthesis.	Sirolimus	64-73	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	173-191
26578517-9	2016	Exposure of palmitate/BSA-treated cells to rapamycin normalized Miox expression and prevented Srebp1 nuclear translocation.	Sirolimus	43-52	sterol regulatory element binding transcription factor 1	Mus musculus	94-100
27181066-0	2016	Rapamycin reduces motivated responding for cocaine and alters GluA1 expression in the ventral but not dorsal striatum.	Sirolimus	0-9	glutamate ionotropic receptor AMPA type subunit 1	Homo sapiens	62-67
26752047-6	2016	Western blotting showed that rapamycin inhibited mechanistic target of rapamycin (mTOR), p70s6k and IkappaBalpha phosphorylation triggered by ox-LDL.	Sirolimus	29-38	ribosomal protein S6 kinase B1	Homo sapiens	89-95
27278252-7	2016	However, treatment of tuberin-deficient cells with rapamycin showed significant decrease in protein expression of all Nox.	Sirolimus	51-60	TSC complex subunit 2	Rattus norvegicus	22-29
26620226-8	2016	The inhibitors LY294002 (PI3K-AKT inhibitor), U0126 (inhibitor of ERK1/2) and rapamycin (mTOR inhibitor) also blocked the ability of EGF to increase HIF-1alpha protein and to phosphorylate AKT, ERK1/2 and mTOR proteins.	Sirolimus	78-87	epidermal growth factor	Homo sapiens	133-136
27278252-9	2016	In addition, treatment of mice deficient in tuberin with rapamycin resulted in significant decrease in all Nox protein expression.	Sirolimus	57-66	TSC complex subunit 2	Mus musculus	44-51
27883166-1	2016	Rapamycin, an mTOR inhibitor affects senescence through suppression of senescence-associated secretory phenotype (SASP).	Sirolimus	0-9	thioredoxin	Homo sapiens	114-118
26459113-5	2016	mTOR pathway inhibition was achieved with rapamycin (an mTOR inhibitor; 5mg/kg) or PF-4708671 (an inhibitor of the downstream p70S6kinase, S6K, 75 mg/kg) immediately following HIL, and then for 3 subsequent days.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	0-4
27345162-3	2016	Cells from several human populations demonstrated variability in expression of a cell surface receptor, CD244 (SlamF4, 2B4), that correlated with changes in rapamycin-induced autophagy.	Sirolimus	157-166	CD177 molecule	Homo sapiens	81-102
27345162-3	2016	Cells from several human populations demonstrated variability in expression of a cell surface receptor, CD244 (SlamF4, 2B4), that correlated with changes in rapamycin-induced autophagy.	Sirolimus	157-166	CD244 molecule	Homo sapiens	104-109
27345162-3	2016	Cells from several human populations demonstrated variability in expression of a cell surface receptor, CD244 (SlamF4, 2B4), that correlated with changes in rapamycin-induced autophagy.	Sirolimus	157-166	CD244 molecule	Homo sapiens	111-122
27313209-7	2016	Interestingly, mammalian target of rapamycin complex 1 (mTORC1) signaling was hyperactivated in several tissues from Pip4k2c(-/-) mice and treating Pip4k2c(-/-) mice with rapamycin reduced the inflammatory phenotype, resulting in a decrease in mTORC1 signaling in tissues and a decrease in proinflammatory cytokines in plasma.	Sirolimus	35-44	phosphatidylinositol-5-phosphate 4-kinase, type II, gamma	Mus musculus	148-155
27076449-9	2016	Rapamycin also enhanced IFNgamma or PD-L1 mAb treatment-associated induction of MHC class I expression on MOC1 tumor cells, an effect abrogated by depleting infiltrating CD8 T cells from the tumor microenvironment.	Sirolimus	0-9	CD274 molecule	Homo sapiens	36-41
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	134-140
27208895-1	2016	Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	73-104
27208895-1	2016	Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	106-110
27208895-1	2016	Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Mus musculus	73-104
27208895-1	2016	Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Mus musculus	106-110
26943752-6	2016	Rapamycin/resveratrol co-incubation significantly decreased viability further at lower doses of resveratrol and resulted in decreased p70S6K phosphorylation compared to rapamycin incubation alone, suggesting that resveratrol potentiated the growth inhibitory effects of rapamycin by reducing p70S6K activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	292-298
27341957-2	2016	We previously reported results from a pilot experiment wherein common marmosets (Callithrix jacchus) were treated orally with rapamycin to reduce mTOR signaling in vivo in line with previous reports in mice and humans.	Sirolimus	126-135	serine/threonine-protein kinase mTOR	Callithrix jacchus	146-150
27493704-10	2016	Rapamycin, an mTOR inhibitor, increased GRP78/BiP and EDC3 levels in a dose-dependent manner and subsequently resulted in a decrease in intracellular production of insulin.	Sirolimus	0-9	enhancer of mRNA decapping 3	Rattus norvegicus	54-58
26975583-8	2016	Here, we show that inhibition of AMPK by compound C or by shRNA-mediated depletion of LKB1 reduces activation of autophagy by rapamycin in Tsc2-null cells.	Sirolimus	126-135	serine/threonine kinase 11	Homo sapiens	86-90
26782505-9	2015	T cell Foxp3 mRNA expression was significantly higher in the sirolimus-treated than in the cyclosporine (53.7 vs 40.2%, P &lt; 0.05) and control groups (P &lt; 0.01), but was significantly lower in the cyclosporine group than in controls (23.6 vs 40.2%, P &lt; 0.01).	Sirolimus	61-70	forkhead box P3	Mus musculus	7-12
26782505-11	2015	Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo.	Sirolimus	0-9	forkhead box P3	Mus musculus	35-40
26118661-0	2015	Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	0-9	protein phosphatase 2 phosphatase activator	Homo sapiens	96-107
26118661-4	2015	Here, we show that rapamycin inhibited human soluble BAFF (hsBAFF)-induced cell proliferation and survival in normal and B-lymphoid (Raji and Daudi) cells by activation of PP2A and inactivation of Erk1/2.	Sirolimus	19-28	protein phosphatase 2 phosphatase activator	Homo sapiens	172-176
26118661-6	2015	Furthermore, expression of a rapamycin-resistant and kinase-active mTOR (mTOR-T), but not a rapamycin-resistant and kinase-dead mTOR-T (mTOR-TE), conferred resistance to rapamycin"s effects on PP2A, Erk1/2 and B-cell proliferation/viability, implying mTOR-dependent mechanism involved.	Sirolimus	29-38	protein phosphatase 2 phosphatase activator	Homo sapiens	193-197
26432419-7	2015	Transforming mTOR mutants were also found to promote 3T3 cell survival, and their oncogenic activity was sensitive to rapamycin.	Sirolimus	118-127	mechanistic target of rapamycin kinase	Mus musculus	13-17
26297427-10	2015	Our results showed that p70S6K, S6 and Akt phosphorylation were significantly upregulated in IgAN rats, and rapamycin effectively inhibited p70S6K and S6 phosphorylation.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Rattus norvegicus	140-146
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	ribosomal protein S6 kinase B1	Rattus norvegicus	28-34
26452980-6	2015	Notably, INK128 was more potent than the TORC1 inhibitor rapamycin in down-regulating Mcl-1, diminishing AKT and 4EBP1 phosphorylation, and potentiating ABT-737 activity.	Sirolimus	57-66	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	86-91
26454249-8	2015	CONCLUSION: Oral transport of sirolimus was significantly improved by coadministration with honokiol, an inhibitor of the P-gp, in polymeric micelles formulation.	Sirolimus	30-39	phosphoglycolate phosphatase	Homo sapiens	122-126
26992362-3	2016	Basal level of tube formation was maximally reduced in the presence of 50 microM of FABP4 inhibitor compared with those by VEGF signaling pathway inhibitors (rapamycin, L-NAME, and p38 MAP kinase inhibitor).	Sirolimus	158-167	fatty acid binding protein 4	Homo sapiens	84-89
26397133-9	2015	Lung tumors harvested from mice exposed to rapamycin showed a significant decrease in p-mTOR, p-S6K1, PCNA and Bcl-xL as compared with controls in the early and late stage intervention studies.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Mus musculus	88-92
26770910-8	2015	In addition, rapamycin blocked the effects of Orn completely (p70S6K and S6) or partially (4EBP1).	Sirolimus	13-22	ribosomal protein S6 kinase B1	Rattus norvegicus	62-68
26497134-14	2015	mRNA expression of autophagy markers such as ATG5, LC3A and LC3B was significantly increased in the rapamycin-treated Ad-hMSCs compared with untreated Ad-hMSCs.	Sirolimus	100-109	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	51-55
26543771-2	2015	Sirolimus are also metabolized by CYP3A subfamily and are substrates of the P-gp.	Sirolimus	0-9	phosphoglycolate phosphatase	Homo sapiens	76-80
26418749-7	2015	We further demonstrated that the mTOR inhibitor, sirolimus, suppresses the tumor"s growth, suggesting that mTOR inhibitors might be effective in control of FLCN-deficient RCC, especially in BHD renal tumorigenesis.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	33-37
26418749-7	2015	We further demonstrated that the mTOR inhibitor, sirolimus, suppresses the tumor"s growth, suggesting that mTOR inhibitors might be effective in control of FLCN-deficient RCC, especially in BHD renal tumorigenesis.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	107-111
26469953-4	2015	We found that RAC3 overexpression in the nontumoral HEK293 cells inhibits the premature senescence induced by hydrogen peroxide or rapamycin.	Sirolimus	131-140	nuclear receptor coactivator 3	Homo sapiens	14-18
27338042-7	2016	Enforced miR-18a overexpression directly led to increased autophagy in MDA-MB-231 cells, the effect of which was similar to that of rapamycin, a mTOR signaling inhibitor.	Sirolimus	132-141	microRNA 18a	Homo sapiens	9-16
27093550-8	2016	Rapamycin significantly inhibited HG-induced EMT, which manifests as increased expression of alpha-SMA, fibronectin, and collagen I, decreased expression of E-cadherin, and increased mobility.	Sirolimus	0-9	actin gamma 2, smooth muscle	Rattus norvegicus	93-102
27093550-8	2016	Rapamycin significantly inhibited HG-induced EMT, which manifests as increased expression of alpha-SMA, fibronectin, and collagen I, decreased expression of E-cadherin, and increased mobility.	Sirolimus	0-9	fibronectin 1	Rattus norvegicus	104-115
27093550-8	2016	Rapamycin significantly inhibited HG-induced EMT, which manifests as increased expression of alpha-SMA, fibronectin, and collagen I, decreased expression of E-cadherin, and increased mobility.	Sirolimus	0-9	cadherin 1	Rattus norvegicus	157-167
27221338-8	2016	Finally, we also found that CRP induced renal fibrosis through a CD32b-Smad3-mTOR pathway because blocking mTOR signaling with rapamycin inhibited CRP-induced CTGF and collagen I expression.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Mus musculus	77-81
27221338-8	2016	Finally, we also found that CRP induced renal fibrosis through a CD32b-Smad3-mTOR pathway because blocking mTOR signaling with rapamycin inhibited CRP-induced CTGF and collagen I expression.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Mus musculus	107-111
27050906-8	2016	Using a prostate-specific Pten-deleted mouse model of cancer, Npm1 mRNA levels were found up-regulated and sensitive to rapamycin.	Sirolimus	120-129	nucleophosmin 1	Mus musculus	62-66
27078846-8	2016	In addition, rapamycin in combination with celecoxib, a COX2 inhibitor, strongly inhibited Tsc2-deficient cell growth.	Sirolimus	13-22	TSC complex subunit 2	Rattus norvegicus	91-95
27028858-5	2016	Conversely, knockdown of Spred2 in tumor cells inhibited upregulation of autophagosome maturation induced by the autophagy inducer Rapamycin, which could be reversed by the rescue Spred2.	Sirolimus	131-140	sprouty related EVH1 domain containing 2	Homo sapiens	25-31
27048303-2	2016	Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	53-84
27048303-2	2016	Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	86-90
27029073-4	2016	To overcome this problem, CH12 was combined with the mTOR inhibitor rapamycin, leading to a synergistic inhibitory effect on EGFRvIII+PTEN- GBM in vivo.	Sirolimus	68-77	phosphatase and tensin homolog	Homo sapiens	134-138
27029073-5	2016	Mechanistically, the synergistic antitumor effect was achieved via attenuating EGFR and PI3K/AKT/mTOR pathway more effectively and reversing the STAT5 activation caused by rapamycin treatment.	Sirolimus	172-181	signal transducer and activator of transcription 5A	Homo sapiens	145-150
26566757-5	2016	Additionally, rapamycin enhanced attenuations of protein kinase Ce (PKCe)/protein kinase A (PKA) induced by morphine and further extended analgesia of morphine via micro-opioid receptor (MOR).	Sirolimus	14-23	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	74-90
26296742-7	2016	Furthermore, pharmacologic treatment of Tsc1 single-mutant mice with rapamycin reduced hyperphosphorylation and accumulation of 4E-BP1 but also inhibited phosphorylation of rpS6.	Sirolimus	69-78	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	128-134
26984393-3	2016	Strengthening the significance of protein synthesis in dendritic spinogenesis, the translation blocker cyclohexamide and the mTOR inhibitor rapamycin reduce dendritic spine density, while a leucine supplement that increases protein synthesis ameliorates the dendritic spine defects caused by Vcp and Atl1 deficiencies.	Sirolimus	140-149	mechanistic target of rapamycin kinase	Mus musculus	125-129
26740621-5	2016	In contrast, rapamycin preferentially inhibits the phosphorylation of p70(S6k) and blocks 35% of translation.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	74-77
26800397-6	2016	Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin.	Sirolimus	58-67	microRNA 222	Homo sapiens	92-99
26854565-6	2016	Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2(-/-) mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein.	Sirolimus	100-109	TSC complex subunit 2	Mus musculus	133-137
26859571-6	2016	Strikingly, mTOR pathway activation, based on pS6 expression, was robustly activated in mouse gastric adenocarcinomas from the earliest stages of tumor development, and treatment with rapamycin impaired tumor growth.	Sirolimus	184-193	mechanistic target of rapamycin kinase	Mus musculus	12-16
26824989-7	2016	Finally, a short incubation of MART-1-specific T cells with rapamycin acted synergistically with IL-15, leading to significantly improved tumor-free survival in recipients with metastatic melanoma.	Sirolimus	60-69	retrotransposon Gag like 1	Homo sapiens	31-37
26833095-4	2016	RPM significantly decreases the cell number and the immunosuppressive ability on T cells of CD11b(+) Ly6C(high) monocytic MDSCs (M-MDSCs) in both allo-grafts-transplanted and tumor-bearing mice respectively.	Sirolimus	0-3	lymphocyte antigen 6 complex, locus C1	Mus musculus	101-105
26875919-0	2016	[Inhibition of Sirolimus on the growth of pancreatic carcinoma and its effect on the expression of glucose transporter and hexokinase II].	Sirolimus	15-24	hexokinase 2	Mus musculus	123-136
26449763-5	2015	In vitro, rapamycin treatment reversed inflammatory cytokine-stimulated IRS-1 serine phosphorylation, increased insulin signaling to AKT and enhanced glucose utilization.	Sirolimus	10-19	insulin receptor substrate 1	Mus musculus	72-77
25989700-0	2015	Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.	Sirolimus	0-9	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	26-31
25989700-4	2015	However, the addition of rapamycin to the CTLA4-Ig regimen was able to quantitatively and qualitatively restore the antigen-specific CD8(+) T cell response to the virus.	Sirolimus	25-34	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	42-47
25989700-5	2015	This improvement was physiologically relevant, in that CTLA4-Ig treated animals exhibited a greater viral burden following infection that was reduced to levels observed in untreated immunocompetent animals by the addition of rapamycin.	Sirolimus	225-234	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	55-60
25529296-1	2015	BACKGROUND: FK506-binding proteins (FKBPs) contain a domain with peptidyl-prolyl-cis/trans-isomerase (PPIase) activity and bind the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	166-175	FKBP prolyl isomerase like	Homo sapiens	65-100
25529296-1	2015	BACKGROUND: FK506-binding proteins (FKBPs) contain a domain with peptidyl-prolyl-cis/trans-isomerase (PPIase) activity and bind the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	166-175	FKBP prolyl isomerase like	Homo sapiens	102-108
26251974-4	2015	Furthermore, the inhibition of Akt or mTOR with an antagonist (wortmannin or rapamycin) suppressed the stretch-induced increase in glucose consumption, lactate levels, intracellular ATP levels and the expression of mitochondrial ATP synthase and LDHA, indicating the significance of the Akt/mTOR/p70s6k pathway in regulating osteoblastic energy metabolism in response to mechanical stretch.	Sirolimus	77-86	ribosomal protein S6 kinase B1	Homo sapiens	296-302
26004903-4	2015	RPM harvested from HCR vs. LCR demonstrated reduced cellular oxidation (21%), increased paraoxonase 2 activity (28%) and decreased triglycerides mass (44%).	Sirolimus	0-3	coiled-coil alpha-helical rod protein 1	Rattus norvegicus	19-22
26002629-5	2015	Coincidently, rapamycin markedly blocked Cd-induced phosphorylation of Akt, S6K1 and 4E-BP1 in the cells.	Sirolimus	14-23	ribosomal protein S6 kinase B1	Homo sapiens	76-91
26002629-8	2015	Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect.	Sirolimus	182-191	ribosomal protein S6 kinase B1	Homo sapiens	31-35
26002629-8	2015	Furthermore, downregulation of S6K1, ectopic expression of constitutively hypophosphorylated 4E-BP1 or dominant negative Akt, or co-treatment with Akt inhibitor also potentiated the rapamycin"s inhibitory effect.	Sirolimus	182-191	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	93-99
26053964-2	2015	Inhibition of mTOR with rapamycin modulates allergic asthma, while the underlying molecular mechanisms remain elusive.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
26053964-6	2015	In vitro colony forming unit assay and liquid culture demonstrated that rapamycin directly inhibited IL-5-induced eosinophil differentiation.	Sirolimus	72-81	interleukin 5	Mus musculus	101-105
26053964-8	2015	Rapamycin was also capable of reducing the eosinophil levels in IL-5 transgenic NJ.1638 mice, again regardless of the constitutive high levels of IL-5.	Sirolimus	0-9	interleukin 5	Mus musculus	64-68
26027660-9	2015	Treatment with rapamycin or RAD001 significantly increased the phosphorylation of AKT in both LKB1 wild-type and LKB1 mutant NSCLC cells, which was attenuated by the PI3K inhibitor LY294002.	Sirolimus	15-24	serine/threonine kinase 11	Homo sapiens	94-98
26027660-9	2015	Treatment with rapamycin or RAD001 significantly increased the phosphorylation of AKT in both LKB1 wild-type and LKB1 mutant NSCLC cells, which was attenuated by the PI3K inhibitor LY294002.	Sirolimus	15-24	serine/threonine kinase 11	Homo sapiens	113-117
26311343-0	2015	Rapamycin (Sirolimus) alters mechanistic target of rapamycin pathway regulation and microRNA expression in mouse meiotic spermatocytes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	29-60
26875919-1	2016	OBJECTIVE: To investigate whether Sirolimus could affect the glycolytic catabolism pathways of pancreatic carcinoma through the control of hypoxia induced factor (HIF-1alpha) to inhibit the growth of tumor, and explore the potential mechanism of targeting the signaling pathways of mTOR for the treatment of pancreatic carcinoma.	Sirolimus	34-43	hypoxia inducible factor 1, alpha subunit	Mus musculus	163-173
26875919-1	2016	OBJECTIVE: To investigate whether Sirolimus could affect the glycolytic catabolism pathways of pancreatic carcinoma through the control of hypoxia induced factor (HIF-1alpha) to inhibit the growth of tumor, and explore the potential mechanism of targeting the signaling pathways of mTOR for the treatment of pancreatic carcinoma.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	282-286
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	244-248
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hypoxia inducible factor 1, alpha subunit	Mus musculus	250-260
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	262-287
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	289-295
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	301-314
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	316-321
26875919-2	2016	METHODS: Sirolimus was applied to treat the pancreatic carcinoma in nude mice orthotopic transplantation model, its difference with the control group was compared; RT-PCR and Western blot were used to measure the mRNA and protein expression of mTOR, HIF-1alpha, Glucose carrier protein 1 (GLUT-1) and Hexokinase II (HK-II), respectively; the changes of activity of HK-II in the tumor was determined.	Sirolimus	9-18	hexokinase 2	Mus musculus	365-370
26875919-5	2016	The activity of HK-II in the control group was higher than that of the Sirolimus group (P&lt;0.05).	Sirolimus	71-80	hexokinase 2	Mus musculus	16-21
26875919-6	2016	CONCLUSION: Sirolimus could affect the expression of GLUT-1 and HK-II in pancreatic carcinoma through the effects of HIF-1alpha to inhibit tumor growth, indicating that blocking the mTOR pathway could control the glycolytic metabolism pathways of pancreatic carcinoma, which may become the new strategy for the treatment of pancreatic carcinoma.	Sirolimus	12-21	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	53-59
26875919-6	2016	CONCLUSION: Sirolimus could affect the expression of GLUT-1 and HK-II in pancreatic carcinoma through the effects of HIF-1alpha to inhibit tumor growth, indicating that blocking the mTOR pathway could control the glycolytic metabolism pathways of pancreatic carcinoma, which may become the new strategy for the treatment of pancreatic carcinoma.	Sirolimus	12-21	hexokinase 2	Mus musculus	64-69
26875919-6	2016	CONCLUSION: Sirolimus could affect the expression of GLUT-1 and HK-II in pancreatic carcinoma through the effects of HIF-1alpha to inhibit tumor growth, indicating that blocking the mTOR pathway could control the glycolytic metabolism pathways of pancreatic carcinoma, which may become the new strategy for the treatment of pancreatic carcinoma.	Sirolimus	12-21	hypoxia inducible factor 1, alpha subunit	Mus musculus	117-127
26875919-6	2016	CONCLUSION: Sirolimus could affect the expression of GLUT-1 and HK-II in pancreatic carcinoma through the effects of HIF-1alpha to inhibit tumor growth, indicating that blocking the mTOR pathway could control the glycolytic metabolism pathways of pancreatic carcinoma, which may become the new strategy for the treatment of pancreatic carcinoma.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	182-186
26771918-0	2016	The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-kappaB Axis during Retinal Inflammation.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Mus musculus	62-66
26771918-7	2016	RESULTS: The post-transcriptional reduction in the visual pigment of rod photoreceptor cells, rhodopsin, OS shortening, and rod photoreceptor cell dysfunction during inflammation were suppressed by rapamycin.	Sirolimus	198-207	rhodopsin	Mus musculus	94-103
27997905-7	2016	Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways.	Sirolimus	23-32	vascular endothelial growth factor A	Rattus norvegicus	87-91
27595116-0	2016	Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	18-24
27595116-1	2016	It has been demonstrated that mTOR/p70S6K pathway was abnormally activated in many cancers and rapamycin and its analogs can restrain tumor growth through inhibiting this pathway, but some tumors including esophageal squamous cell carcinoma (ESCC) appear to be insensitive to rapamycin in recent studies.	Sirolimus	95-104	ribosomal protein S6 kinase B1	Homo sapiens	35-41
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	64-70
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	77-83
27595116-3	2016	The results showed that, after downregulating the expression of p70S6K and p-p70S6K by p70S6K siRNA, the inhibitory effects of rapamycin on cell proliferation, cell cycle, and tumor growth were significantly enhanced in vitro and in vivo.	Sirolimus	127-136	ribosomal protein S6 kinase B1	Homo sapiens	77-83
26311343-0	2015	Rapamycin (Sirolimus) alters mechanistic target of rapamycin pathway regulation and microRNA expression in mouse meiotic spermatocytes.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Mus musculus	29-60
26311343-6	2015	Western blot and immunocytochemical analysis confirm that rapamycin treatment suppresses mTOR and phopsphorylated P70S6 kinase activities in spermatocytes, but not that of phosphorylated 4E-binding protein 1.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Mus musculus	89-93
26311343-12	2015	In conclusion, for the first time, the present study provides insight into how rapamycin regulates mTOR pathway and spermatocyte-specific miRNA expression which in turn, regulate expression of target genes post-transcriptionally.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	99-103
25980751-14	2015	In phosphatase and tensin homolog-null mouse embryonic fibroblasts with constitutively activated mTOR, GP73 was up-regulated compared with control mouse embryonic fibroblasts; this increase was reversed after incubation with rapamycin.	Sirolimus	225-234	mechanistic target of rapamycin kinase	Mus musculus	97-101
26604904-4	2015	Either oxygen-glucose deprivation or Rapamycin down-regulated the expression of BACE1 while 3-methyladenine up-regulated BACE1 expression.	Sirolimus	37-46	beta-site APP cleaving enzyme 1	Mus musculus	80-85
26550253-7	2015	Low-dose rapamycin and valsartan could enhance the expressions of nephrin and podocin, reduce kidney damages, thus achieving the protective effects towards the kidneys, and the effects of the combined therapy were superior to those of monotherapy.	Sirolimus	9-18	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	66-73
26200935-7	2015	Interestingly, the combination of rapamycin and resveratrol selectively promoted apoptosis of cells with mTOR pathway hyperactivation.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	105-109
26033700-5	2015	We also determined the therapeutic benefits of the Akt inhibitor triciribine and the mTOR inhibitor rapamycin for the treatment of pulmonary fibrosis in mice.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Mus musculus	85-89
26037201-11	2015	Inhibition of mTOR signalling by rapamycin decreased levels of intestinal and plasma GLP-1 in both normal and diabetic mice.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	14-18
26049685-10	2015	In vivo studies confirmed that the activation of AKT/mTOR by acemannan played a key role in wound healing, which could be reversed by rapamycin.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Mus musculus	53-57
26147250-8	2015	Reduced IL1A diminished NF-kappaB transcriptional activity, which controls much of the SASP; exogenous IL1A restored IL6 secretion to rapamycin-treated cells.	Sirolimus	134-143	interleukin 1 alpha	Mus musculus	103-107
26229595-8	2015	In cases of facial overgrowth, which involve PTEN/Akt/TOR dysregulation, sirolimus could be used for limiting cell overgrowth.	Sirolimus	73-82	phosphatase and tensin homolog	Homo sapiens	45-49
26189041-1	2015	BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation.	Sirolimus	47-56	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	173-179
27595116-5	2016	These results indicated that p-p70S6K may participate in the invasion and metastasis in the development of ESCC and downregulation of the expression of p-p70S6K could improve the sensitivity of cells to rapamycin in ESCC.	Sirolimus	203-212	ribosomal protein S6 kinase B1	Homo sapiens	31-37
27595116-5	2016	These results indicated that p-p70S6K may participate in the invasion and metastasis in the development of ESCC and downregulation of the expression of p-p70S6K could improve the sensitivity of cells to rapamycin in ESCC.	Sirolimus	203-212	ribosomal protein S6 kinase B1	Homo sapiens	154-160
26849067-0	2016	The Inhibitory Effect of Rapamycin on Toll Like Receptor 4 and Interleukin 17 in the Early Stage of Rat Diabetic Nephropathy.	Sirolimus	25-34	interleukin 17A	Rattus norvegicus	63-77
26849067-11	2016	RESULTS: Our results demonstrated that the expression of both TLR4 and IL-17 were upregulated in early stage DN and reduced by rapamycin.	Sirolimus	127-136	interleukin 17A	Rattus norvegicus	71-76
26849067-17	2016	Although the underlying mechanisms need to be explored, the observed increase of TLR4 and IL-17 during the early stages of DN and their suppression with rapamycin treatment suggest the importance of TLR4 and IL-17 in DN pathophysiology.	Sirolimus	153-162	interleukin 17A	Rattus norvegicus	90-95
26849067-17	2016	Although the underlying mechanisms need to be explored, the observed increase of TLR4 and IL-17 during the early stages of DN and their suppression with rapamycin treatment suggest the importance of TLR4 and IL-17 in DN pathophysiology.	Sirolimus	153-162	interleukin 17A	Rattus norvegicus	208-213
26680373-10	2016	After transplantation with CB and rapamycin, donor-reactive Eomes(lo)CTLA4(hi) CD8+ T cells were reduced.	Sirolimus	34-43	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	69-74
26189041-2	2015	Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistance in 4E-BP1 null lymphoma cells.	Sirolimus	38-47	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	108-114
26379864-7	2015	Further Western blot assays showed that rapamycin induced activation of caspase-9 and caspase-8 and the cleavage of caspase-3.	Sirolimus	40-49	caspase 9	Homo sapiens	72-81
26176608-5	2015	In this study, by employing automated spectrophotometry, we found the level of glucose uptake was decreased in non-small-cell lung carcinoma (NSCLC) A549, PC-9 and SK-MES-1 cells treated with rapamycin or siRNA against Raptor, indicating that the inhibition of mTORC1 attenuated glycolytic metabolism in NSCLC cells.	Sirolimus	192-201	proprotein convertase subtilisin/kexin type 9	Homo sapiens	155-159
25976674-7	2015	Treatment with rapamycin enhanced the effect of reserpine by further increasing the level of alpha-synuclein and neuronal cell death.	Sirolimus	15-24	synuclein alpha	Homo sapiens	93-108
26158631-0	2015	TORC1 Inhibition by Rapamycin Promotes Antioxidant Defences in a Drosophila Model of Friedreich"s Ataxia.	Sirolimus	20-29	Target of rapamycin	Drosophila melanogaster	0-5
26158631-4	2015	Pharmacologic inhibition of TORC1 signalling by rapamycin also restored this phenotype and increased the lifespan and ATP levels.	Sirolimus	48-57	Target of rapamycin	Drosophila melanogaster	28-33
25908215-5	2015	In primary cultured cervical cancer cells, the expression of microRNA-218 was negatively correlated with the mRNA level of Rictor, which predicted cellular sensitivity to Rapamycin (p = 0.002, R(2)  = 0.6810).	Sirolimus	171-180	RPTOR independent companion of MTOR complex 2	Homo sapiens	123-129
25349217-14	2015	However, rapamycin upregulated p27(Kip1) at least in part via AKT (also known as protein kinase B)/mTOR.	Sirolimus	9-18	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	31-34
25349217-14	2015	However, rapamycin upregulated p27(Kip1) at least in part via AKT (also known as protein kinase B)/mTOR.	Sirolimus	9-18	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	35-39
25921086-8	2015	Furthermore, we found that PHF8 inhibited Akt-mTOR pathway in hypertrophic hearts and neonatal rat ventricle myocytes, and rapamycin treatment rescues the effects of PHF8 loss.	Sirolimus	123-132	PHD finger protein 8	Rattus norvegicus	166-170
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	22-26
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	insulin receptor substrate 1	Homo sapiens	78-83
26720731-6	2015	Both rapamycin and trehalose significantly reduced TAU aggregation levels suggesting that iPSC-derived neurons allow for the generation of a biologically relevant human Tauopathy model, highly suitable to screen for compounds that modulate TAU aggregation.	Sirolimus	5-14	microtubule associated protein tau	Homo sapiens	51-54
26720731-6	2015	Both rapamycin and trehalose significantly reduced TAU aggregation levels suggesting that iPSC-derived neurons allow for the generation of a biologically relevant human Tauopathy model, highly suitable to screen for compounds that modulate TAU aggregation.	Sirolimus	5-14	microtubule associated protein tau	Homo sapiens	240-243
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	synuclein alpha	Homo sapiens	118-127
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	152-156
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	synuclein alpha	Homo sapiens	171-180
25813876-6	2015	The mTOR complex (C)1/S6K1 blocker rapamycin inhibited the phosphorylation of IRS-1 at Ser636 in cells overexpressing alpha-Syn, suggesting that mTORC1/S6K1 activation by alpha-Syn causes feedback inhibition of insulin signaling via suppression of IRS-1 function.	Sirolimus	35-44	insulin receptor substrate 1	Homo sapiens	248-253
25701378-7	2015	Knockdown of Cbl-b significantly attenuated celecoxib-mediated inhibition of Akt phosphorylation and impaired the additive anticancer effect of celecoxib and rapamycin.	Sirolimus	158-167	Cbl proto-oncogene B	Homo sapiens	13-18
25701378-8	2015	Our results suggest that celecoxib-mediated upregulation of Cbl-b is responsible, at least in part, for the additive antitumor effect of celecoxib and rapamycin via inhibition of rapamycin-induced Akt activation.	Sirolimus	151-160	Cbl proto-oncogene B	Homo sapiens	60-65
25701378-8	2015	Our results suggest that celecoxib-mediated upregulation of Cbl-b is responsible, at least in part, for the additive antitumor effect of celecoxib and rapamycin via inhibition of rapamycin-induced Akt activation.	Sirolimus	179-188	Cbl proto-oncogene B	Homo sapiens	60-65
25814258-12	2015	Rapamycin treatment reduced PLA2 levels as compared to vehicle group (P&lt;0.05).	Sirolimus	0-9	phospholipase A2 group IB	Rattus norvegicus	28-32
25814258-13	2015	Our findings indicated that rapamycin reduced the increased PLA2 levels and altered brain metabolites after MCAo.	Sirolimus	28-37	phospholipase A2 group IB	Rattus norvegicus	60-64
25943142-7	2015	CONCLUSION: Distal RTA and urine concentrating defect were highly prevalent after kidney transplantation both in the sirolimus and tacrolimus treated patients.	Sirolimus	117-126	MAS related GPR family member F	Homo sapiens	19-22
25794646-11	2015	The present results demonstrated that topical 4% RPM and/or 1% MPA improved TNCB-induced AD-like lesions of NC/Nga mice by suppressing expression of Th2-related cytokines (IL-4) and Th1-related cytokines (IFN-gamma).	Sirolimus	49-52	interleukin 4	Mus musculus	149-176
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	155-161
25988388-5	2015	The suppression of HIF-1alpha and VEGF by rapamycin was associated with dephosphorylation of mTOR and the downstream effector ribosomal protein S6 kinase (P70S6K) and 4E-binding protein-1 (4E-BP1) of mTORC1.	Sirolimus	42-51	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	167-195
26199613-2	2015	In this study, we initially examined the effect of rapamycin on the Wnt/beta-catenin signaling pathway after spinal cord injury, by intraperitoneally injecting spinal cord injured rats with rapamycin over 2 days.	Sirolimus	51-60	catenin beta 1	Rattus norvegicus	72-84
26199613-2	2015	In this study, we initially examined the effect of rapamycin on the Wnt/beta-catenin signaling pathway after spinal cord injury, by intraperitoneally injecting spinal cord injured rats with rapamycin over 2 days.	Sirolimus	190-199	catenin beta 1	Rattus norvegicus	72-84
26199613-4	2015	Rapamycin increased the levels of beta-catenin and brain-derived neurotrophic factor in the injured spinal cord, improved the pathological morphology at the injury site, reduced the loss of motor neurons, and promoted motor functional recovery in rats after spinal cord injury.	Sirolimus	0-9	catenin beta 1	Rattus norvegicus	34-46
25151963-9	2015	Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2.	Sirolimus	70-79	caspase 2	Homo sapiens	194-203
26024867-3	2015	Rapamycin inhibition of TorC1 elicits nuclear localization of Gln3, a GATA-family transcription activator responsible for the expression of genes encoding proteins required to transport and degrade poor nitrogen sources, e.g., proline.	Sirolimus	0-9	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	70-74
25978367-1	2015	Rapamycin, an mTOR inhibitor, has been shown to extend lifespan in a range of model organisms.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
25834103-10	2015	Most interestingly, lipin-1 depletion or lipins inhibition with propranolol sensitized cancer cells to rapamycin.	Sirolimus	103-112	lipin 1	Homo sapiens	20-27
25944097-18	2015	In addition, we showed that rapamycin decreased the level of mTOR in Klf4 (-/-) MEFs, but did not restore autophagy.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Mus musculus	61-65
25911189-3	2015	Considering the potent cardioprotective effect of mTOR inhibitor, rapamycin, we hypothesized that reperfusion therapy with rapamycin would reduce infarct size in the diabetic hearts through STAT3 signaling.	Sirolimus	123-132	mechanistic target of rapamycin kinase	Mus musculus	50-54
25576058-3	2015	In DIO/prediabetic mice, metformin and rapamycin significantly reduced pancreatic tumor growth and mTOR-related signaling.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	99-103
25866192-3	2015	Here we show that gene expression for several myogenic transcription factors including Myf5, Myog and Mef2c but not MyoD and myosin heavy chain isoforms decrease when C2C12 cells are treated with rapamycin, supporting a role for mTORC1 pathway during muscle development.	Sirolimus	196-205	myogenin	Mus musculus	93-97
24902807-9	2015	Importantly, pretreatment with 3-methyladenine (autophagy inhibitor) enhanced while rapamycin (autophagy inducer) decreased the expression of LOX-1, TLR4, and P-P38 MAPK.	Sirolimus	84-93	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	142-147
25799227-8	2015	Inhibition of mTOR with rapamycin suppressed cytomegalic neurons and epileptic seizures.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
25880415-16	2015	Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	47-53
25822756-5	2015	We constructed rapamycin Q"-bodies by linking the two interacting domains FKBP12 and FRB, whose association is triggered by rapamycin.	Sirolimus	15-24	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	74-80
26714929-0	2015	Adopting the rapamycin trapping assay to track the trafficking of murine MHC class I alleles, H-2K(b).	Sirolimus	13-22	histocompatibility 2, K1, K region	Mus musculus	94-101
26575021-3	2015	Here we used gene transcript profiling to gain a deeper understanding of the role of FBXW7 in tumor development and to determine the influence of mTOR inhibition by rapamycin on tumor transcriptome and biological functions.	Sirolimus	165-174	mechanistic target of rapamycin kinase	Mus musculus	146-150
26510498-5	2015	Genetic experiments suggest that Pib2 stimulates the activity of TORC1, a vacuole-associated protein kinase that is sensitive to rapamycin, in a pathway parallel to the Ragulator/EGO complex containing the GTPases Gtr1 and Gtr2.	Sirolimus	129-138	Pib2p	Saccharomyces cerevisiae S288C	33-37
26561008-1	2015	The tight complexes FKBP12 forms with immunosuppressive drugs, such as FK506 and rapamycin, are frequently used as models for developing approaches to structure-based drug design.	Sirolimus	81-90	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	20-26
26118661-7	2015	The findings indicate that rapamycin inhibits BAFF-stimulated cell proliferation/survival by targeting mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.	Sirolimus	27-36	protein phosphatase 2 phosphatase activator	Homo sapiens	117-128
26454249-1	2015	OBJECTIVES: The aims of the present study were to design polymeric micelles loading sirolimus with honokiol to increase drug solubility and to gain an insight into the effect of honokiol on oral transport of P-glycoprotein substrate (P-gp).	Sirolimus	84-93	phosphoglycolate phosphatase	Homo sapiens	234-238
25787015-7	2015	An shRNA against the autophagic machinery Atg7 increased the survival of H9C2 cells co-treated with bFGF and rapamycin.	Sirolimus	109-118	autophagy related 7	Rattus norvegicus	42-46
25888134-12	2015	Over-expression of GLaz is able to reduce p62 and ubiquitinated proteins levels when rapamycin-dependent and SCA1-dependent inductions of autophagy are combined.	Sirolimus	85-94	Glial Lazarillo	Drosophila melanogaster	19-23
26887615-0	2015	[Sensitivity of esophageal squamous cell carcinoma cells to rapamycin can be improved by siRNA-interfered expression of p70S6K].	Sirolimus	60-69	ribosomal protein S6 kinase B1	Homo sapiens	120-126
26887615-7	2015	The results of tumor formation test in vivo showed that the inhibitory effect of rapamycin on tumor growth was stronger after the cells were transfected with p70S6K-siRNA, and the inhibition rate was 96.5%.	Sirolimus	81-90	ribosomal protein S6 kinase B1	Homo sapiens	158-164
26887615-8	2015	CONCLUSION: ESCC cells with different differentiation have different sensitivity to rapamycin, and p70S6K-siRNA can improve the sensitivity of cells to rapamycin in vitro and in vivo.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	99-105
26640431-3	2015	Inhibition of mTOR with rapamycin has shown promise as a potential modulator of epileptogenesis in several animal models of epilepsy, but cellular mechanisms linking mTOR expression and epileptogenesis are unclear.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
26640431-5	2015	Rapamycin (3 or 10 mg/kg), an inhibitor of mTOR signaling, was administered by intraperitoneal injection beginning on the day of injury and continued daily until tissue collection.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	43-47
26597054-4	2015	PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasiveness via activation of mTOR, attributes which were sensitive to rapamycin treatment.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Mus musculus	101-105
25788687-3	2015	The present study focuses on Ube3A deficiency-induced alterations in signaling through the mechanistic target of rapamycin (mTOR) pathway in the cerebellum of the AS mouse model and on potential therapeutic applications of rapamycin.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Mus musculus	124-128
26540269-0	2015	The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
26540269-6	2015	Compared with vehicle-treated controls, rapamycin protected against the tau-induced neuronal loss, synaptotoxicity, reactive microgliosis and astrogliosis, and activation of innate neuroimmunity.	Sirolimus	40-49	microtubule associated protein tau	Homo sapiens	72-75
26540269-8	2015	Finally, rapamycin inhibited trans-synaptic transfer of human tau expression to the dentate granule neuron targets for the perforant pathway, likely by preventing the synaptic spread of the AAV vector in response to pathway degeneration.	Sirolimus	9-18	microtubule associated protein tau	Homo sapiens	62-65
25794286-5	2015	Insulin signal transduction is mainly mediated via phosphoinositide 3-kinase (PI3K)/Akt, the target of rapamycin (TOR) and the extracellular signal-regulated kinase (ERK) pathways in vertebrates.	Sirolimus	103-112	insulin	Bos taurus	0-7
26540269-9	2015	These results identify systemic rapamycin as a treatment that protects the entorhinal cortex and perforant pathway projection from tau-mediated neurodegeneration, axonal and synapse loss, and neuroinflammatory reactive gliosis.	Sirolimus	32-41	microtubule associated protein tau	Homo sapiens	131-134
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
25733860-9	2015	Inhibition of mTOR by rapamycin in vivo resulted in inhibition of E2-induced protein and DNA synthesis.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
26722507-8	2015	Treatment of HSC-T6 cells in culture with rapamycin or 3MA decreased or increased C/EBP-alpha expression, respectively, as shown by Western blotting.	Sirolimus	42-51	CCAAT/enhancer binding protein alpha	Rattus norvegicus	82-93
25631054-8	2015	We determined that the phosphorylation of Ckb1 does not detectably affect the stability of the CK2 holoenzyme but correlates with the reduced occupancy of Ckb1 on tRNA genes after rapamycin treatment.	Sirolimus	180-189	casein kinase 2 regulatory subunit CKB1	Saccharomyces cerevisiae S288C	42-46
25631054-8	2015	We determined that the phosphorylation of Ckb1 does not detectably affect the stability of the CK2 holoenzyme but correlates with the reduced occupancy of Ckb1 on tRNA genes after rapamycin treatment.	Sirolimus	180-189	casein kinase 2 regulatory subunit CKB1	Saccharomyces cerevisiae S288C	155-159
25767889-6	2015	Phosphorylation-deficient mutations in regulatory motifs of Ypk3 abrogate Rps6 phosphorylation, and complementation of ypk3Delta cells with human S6 kinase restores Rps6 phosphorylation in a rapamycin-sensitive manner.	Sirolimus	191-200	ribosomal protein S6 kinase B1	Homo sapiens	146-155
25698201-0	2015	P70S6 kinase phosphorylation: a new site to assess pharmacodynamy of sirolimus.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	0-12
25698201-1	2015	BACKGROUND: The phosphorylation of p70S6 kinase (p70S6K) represents an important target for sensitive detection on pharmacodynamic effects of sirolimus, but the methods of assessing p70S6K phosphorylation are still unclear.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	35-47
25698201-1	2015	BACKGROUND: The phosphorylation of p70S6 kinase (p70S6K) represents an important target for sensitive detection on pharmacodynamic effects of sirolimus, but the methods of assessing p70S6K phosphorylation are still unclear.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	49-55
25698201-9	2015	The p70S6K phosphorylation in patients receiving a sirolimus (19.5 +- 7.7) was significantly lower than in HC (50.1 +- 11.3, P &lt; 0.001), tacrolimus (37.7 +- 15.7, P &lt; 0.001) or cyclosporine treated patients (41.7 +- 11.7, P &lt; 0.001).	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	4-10
25698201-13	2015	Assessment of p70S6K phosphorylation may play an adjunct role to on pharmacodynamically guide and individualize sirolimus based on immunosuppression.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	14-20
26011354-9	2015	Rapamycin induced autophagy, increased the expression of p27 and decreased the expression of Cyclin D1.	Sirolimus	0-9	interferon alpha inducible protein 27	Homo sapiens	57-60
25713290-5	2015	Concurrently, global cardiac transcriptional analysis revealed differential expression of 568 genes in Acsl1(H-/-) hearts, a subset of which we hypothesized were targets of mTOR; subsequently, we measured the transcriptional response of several genes after chronic mTOR inhibition via rapamycin treatment during the period in which cardiac hypertrophy develops.	Sirolimus	285-294	mechanistic target of rapamycin kinase	Mus musculus	173-177
25428129-7	2015	Inhibition of mTOR with rapamycin partially suppressed the phosphorylation of PERK and eIF2a and the induction of CHOP and GRP78 induction during tunicamycin treatment.	Sirolimus	24-33	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	78-82
25377120-4	2015	Cyclosporine A, FK506, rapamycin and juglone are known PPIase inhibitors.	Sirolimus	23-32	FKBP prolyl isomerase 7	Homo sapiens	55-61
25213336-8	2015	Rapamycin reversed the conversion from BAT to WAT in Fabp4-Tsc1(-/-) mice.	Sirolimus	0-9	fatty acid binding protein 4, adipocyte	Mus musculus	53-58
25456069-1	2015	The involvement of mammalian target of rapamycin (mTOR) in lifespan control in invertebrates, calorie-restricted rodents, and extension of mouse lifespan by rapamycin have prompted speculation that diminished mTOR function may contribute to mammalian longevity in several settings.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Mus musculus	209-213
25673186-5	2015	In our model, Rapamycin had a preferential action on autophagy, increasing the expression of LC3-II/LC3-I, whereas decreasing the expression of Bim and caspase-3.	Sirolimus	14-23	Bcl2-like 11	Rattus norvegicus	144-147
25200808-9	2015	The association of bacillus Calmette-Guerin with rapamycin but not rapamycin monotherapy affected p70S6K1 and 4E-BP1 phosphorylation with no features of in situ carcinoma (pTis).	Sirolimus	49-58	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	98-116
25512609-9	2015	The TORC1-controlled transcriptional activators Gln3p, Gat1p, Rtg1p, and Rtg3p, but not Msn2p and Msn4p, were required for full induction of LDs by rapamycin.	Sirolimus	148-157	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	48-53
25512609-9	2015	The TORC1-controlled transcriptional activators Gln3p, Gat1p, Rtg1p, and Rtg3p, but not Msn2p and Msn4p, were required for full induction of LDs by rapamycin.	Sirolimus	148-157	Rtg3p	Saccharomyces cerevisiae S288C	73-78
25573439-0	2015	In vivo Toll-like receptor 5 (TLR5) imaging with radiolabeled anti-TLR5 monoclonal antibody in rapamycin-treated mouse allogeneic skin transplantation model.	Sirolimus	95-104	toll-like receptor 5	Mus musculus	8-28
25573439-0	2015	In vivo Toll-like receptor 5 (TLR5) imaging with radiolabeled anti-TLR5 monoclonal antibody in rapamycin-treated mouse allogeneic skin transplantation model.	Sirolimus	95-104	toll-like receptor 5	Mus musculus	30-34
25573439-0	2015	In vivo Toll-like receptor 5 (TLR5) imaging with radiolabeled anti-TLR5 monoclonal antibody in rapamycin-treated mouse allogeneic skin transplantation model.	Sirolimus	95-104	toll-like receptor 5	Mus musculus	67-71
25573439-9	2015	Organ biodistribution study reflected the same tendency, and (131) I-anti-TLR5 mAb uptake reached a maximum of 12.05 +- 1.86 %ID/g (percent injected dose per gram) at 1 h, and graft-to-native skin ratio reached 8.10 +- 0.10 %ID/g at 72 h after injection in rapamycin-treated grafts.	Sirolimus	257-266	toll-like receptor 5	Mus musculus	74-78
25573439-11	2015	Radiolabeled anti-TLR5 mAb is a new tracer for non-invasive in vivo imaging of TLR5 in rapamycin-treated allograft.	Sirolimus	87-96	toll-like receptor 5	Mus musculus	18-22
25573439-11	2015	Radiolabeled anti-TLR5 mAb is a new tracer for non-invasive in vivo imaging of TLR5 in rapamycin-treated allograft.	Sirolimus	87-96	toll-like receptor 5	Mus musculus	79-83
25714412-4	2015	Here, we report on the induction of autophagy initiated by the pathogen receptor HSP90AA1 (heat shock protein 90 kDa alpha [cytosolic], class A member 1) via the AKT-MTOR (mechanistic target of rapamycin)-dependent pathway.	Sirolimus	194-203	heat shock protein 90 alpha family class A member 1	Homo sapiens	81-89
25714412-4	2015	Here, we report on the induction of autophagy initiated by the pathogen receptor HSP90AA1 (heat shock protein 90 kDa alpha [cytosolic], class A member 1) via the AKT-MTOR (mechanistic target of rapamycin)-dependent pathway.	Sirolimus	194-203	heat shock protein 90 alpha family class A member 1	Homo sapiens	91-152
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	interleukin 1 receptor antagonist	Homo sapiens	305-338
26438653-5	2015	Thereafter, sirolimus was consecutively coated to onto the HA-Pep (designated Pep/SRL).	Sirolimus	12-21	progestagen associated endometrial protein	Homo sapiens	62-65
26438653-5	2015	Thereafter, sirolimus was consecutively coated to onto the HA-Pep (designated Pep/SRL).	Sirolimus	12-21	progestagen associated endometrial protein	Homo sapiens	78-81
24882386-6	2015	Under basal conditions, mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) had the most potent anti-inflammatory effect, decreasing both IL-8 release ( -80%) and vascular endothelial growth factor (VEGF) release ( -65%) and preserving the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA).	Sirolimus	73-82	interleukin 1 receptor antagonist	Homo sapiens	340-346
26059360-2	2015	The success of rapamycin as an agent to extend lifespan in various organisms, including mice, brings hope that chronic mTOR inhibition could also refrain age-related neurodegeneration.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	119-123
26150050-6	2015	The combined clearance of 6beta-hydroxycortisol and 6beta-hydroxycortisone correlated significantly with cyclosporine pharmacokinetics (p &lt; 0.001) after oral dose of a BCS 1 formulation, whereas no relationships were seen after administration of tacrolimus and sirolimus formulations, both of which belonged to BCS 2.	Sirolimus	264-273	BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone	Homo sapiens	171-176
26059360-3	2015	Here we review the evidence suggesting that mTOR inhibition - mainly with rapamycin - is a valid intervention to delay age-related neurodegeneration.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Mus musculus	44-48
26388397-0	2015	Rapamycin restores BDNF-LTP and the persistence of long-term memory in a model of Down"s syndrome.	Sirolimus	0-9	brain derived neurotrophic factor	Mus musculus	19-23
25349249-7	2015	injection of rapamycin, an mTOR inhibitor, on LPS-treated male mice.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	27-31
26388397-5	2015	Interestingly, these deficits were fully reversible using rapamycin, a Food and Drug Administration-approved specific mTOR inhibitor; therefore, rapamycin may be a novel pharmacotherapy to improve cognition in DS.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Mus musculus	118-122
26388397-5	2015	Interestingly, these deficits were fully reversible using rapamycin, a Food and Drug Administration-approved specific mTOR inhibitor; therefore, rapamycin may be a novel pharmacotherapy to improve cognition in DS.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Mus musculus	118-122
26046470-8	2015	Reduced intracellular sirolimus concentration was followed by increased p70S6k phosphorylation suggesting preservation of the mTOR-signaling pathway.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Homo sapiens	72-78
26356805-3	2015	Following TORC1 downregulation by rapamycin treatment or nutrient limitation, clearance of G1 cyclins and C-terminal phosphorylation of Sic1 by unknown protein kinases are both required for Sic1 to escape ubiquitin-dependent proteolysis prompted by its flagging via the SCF(Cdc4) (Skp1/Cul1/F-box protein) ubiquitin ligase complex.	Sirolimus	34-43	cyclin-dependent protein serine/threonine kinase inhibiting protein SIC1	Saccharomyces cerevisiae S288C	190-194
26138646-0	2015	Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs).	Sirolimus	0-9	serpin family B member 3	Homo sapiens	61-64
26138646-1	2015	BACKGROUND: Little is known about the use of sirolimus for primary prevention of cutaneous squamous cell carcinoma (SCC) among solid organ transplant recipients (SOTRs).	Sirolimus	45-54	serpin family B member 3	Homo sapiens	116-119
26138646-2	2015	OBJECTIVE: We examined the association between sirolimus exposure and incident SCC risk among SOTRs within Kaiser Permanente Northern California.	Sirolimus	47-56	serpin family B member 3	Homo sapiens	79-82
26138646-5	2015	We used extended Cox regression to examine the independent association between receipt of sirolimus and risk of SCC.	Sirolimus	90-99	serpin family B member 3	Homo sapiens	112-115
26048361-10	2015	Thus, a rapamycin-sensitive, mTOR-dependent but S6K1-independent, signal led to enhanced oxidative metabolism in the Eker brain.	Sirolimus	8-17	ribosomal protein S6 kinase B1	Rattus norvegicus	48-52
26312014-6	2015	Rapamycin decreased mouse heart-to-body weight ratio, improved cardiac performance, and decreased phosphorylation of mTOR and downstream targets p70S6K and S6 in 10-day-old Ryr2ADA/ADA mice but did not extend longevity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	117-121
26306821-11	2015	Rapamycin attenuated the loss of synaptophysin protein in the affected brain regions.	Sirolimus	0-9	synaptophysin	Mus musculus	33-46
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	161-167
26309858-7	2015	Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.	Sirolimus	0-9	interferon gamma	Rattus norvegicus	67-76
25439783-8	2015	These data suggest that the 4E-BP1/eIF4E ratio is a determinant for the response of TE1 and TE2 cells to rapamycin treatment.	Sirolimus	105-114	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-34
26309858-7	2015	Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.	Sirolimus	0-9	interleukin 2	Rattus norvegicus	78-82
26309858-7	2015	Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.	Sirolimus	0-9	interleukin 17A	Rattus norvegicus	84-89
25439783-9	2015	Egr-1 expression was higher in TE2 cells compared with other esophageal cancer cell lines, and its knockdown increased 4E-BP1 expression in TE2 cells, which became sensitive to rapamycin treatment.	Sirolimus	177-186	early growth response 1	Homo sapiens	0-5
26309858-7	2015	Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.	Sirolimus	0-9	interleukin 10	Rattus norvegicus	101-106
25439783-9	2015	Egr-1 expression was higher in TE2 cells compared with other esophageal cancer cell lines, and its knockdown increased 4E-BP1 expression in TE2 cells, which became sensitive to rapamycin treatment.	Sirolimus	177-186	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	119-125
26248051-5	2015	Both lithium and rapamycin were shown to induce autophagosomes in esophageal and colorectal cancer cells by western blot analysis of LC3 isoforms, morphology and FACS quantitation of Cyto-ID or mCherry-GFP-LC3.	Sirolimus	17-26	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	133-136
25439783-11	2015	Egr-1 can reduce 4E-BP1 gene expression and render esophageal squamous cell carcinoma cells resistant to rapamycin with a relatively low 4E-BP1/eIF4E ratio.	Sirolimus	105-114	early growth response 1	Homo sapiens	0-5
26248051-5	2015	Both lithium and rapamycin were shown to induce autophagosomes in esophageal and colorectal cancer cells by western blot analysis of LC3 isoforms, morphology and FACS quantitation of Cyto-ID or mCherry-GFP-LC3.	Sirolimus	17-26	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	206-209
26248290-13	2015	Furthermore, the content of IL-1beta, IL-2, IFN-gamma, TNF-alpha in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats.	Sirolimus	144-153	interleukin 2	Rattus norvegicus	38-42
25439783-12	2015	Thus, the 4E-BP1/eIF4E ratio may represent a therapeutic index for the prediction of clinical outcome of rapamycin treatment in patients with esophageal squamous cell carcinoma.	Sirolimus	105-114	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	10-16
26248290-13	2015	Furthermore, the content of IL-1beta, IL-2, IFN-gamma, TNF-alpha in serum and cerebral cortex were significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats.	Sirolimus	144-153	interferon gamma	Rattus norvegicus	44-53
26278147-6	2015	Pretreatment with rapamycin significantly enhanced the effects of topotecan in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells.	Sirolimus	18-27	translocase of inner mitochondrial membrane 8A	Homo sapiens	161-164
26278147-9	2015	The results suggested that rapamycin sensitized A2780cis and COC1/DDP cells to topotecan-induced apoptosis and rapamycin-topotecan combination might have a value in treatment of cisplatin-resistant ovarian cancer.	Sirolimus	27-36	translocase of inner mitochondrial membrane 8A	Homo sapiens	66-69
26652669-0	2015	Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production.	Sirolimus	0-9	signal transducer and activator of transcription 5A	Homo sapiens	82-90
26652669-5	2015	Rapamycin treatment induced the upregulation of cytokine genes, including those from the Interleukin (IL)-6 signaling network, such as IL-8 and the Leukemia Inhibitory Factor (LIF), while quiescent fibroblasts demonstrated up-regulation of genes involved in the complement and coagulation cascade.	Sirolimus	0-9	LIF interleukin 6 family cytokine	Homo sapiens	148-174
26195783-6	2015	Amplification is completely repressed by rapamycin, an inhibitor of the nutrient-responsive TOR pathway; this effect is separable from growth rate and is mediated directly through Sir2, Hst3, and Hst4.	Sirolimus	41-50	NAD-dependent histone deacetylase HST3	Saccharomyces cerevisiae S288C	186-190
26652669-5	2015	Rapamycin treatment induced the upregulation of cytokine genes, including those from the Interleukin (IL)-6 signaling network, such as IL-8 and the Leukemia Inhibitory Factor (LIF), while quiescent fibroblasts demonstrated up-regulation of genes involved in the complement and coagulation cascade.	Sirolimus	0-9	LIF interleukin 6 family cytokine	Homo sapiens	176-179
25801056-6	2015	Perifosine or rapamycin almost abolished the decrease of the Ces1d and Ces1e expression and the hydrolytic activity induced by the insulin in the primary mouse hepatocytes.	Sirolimus	14-23	carboxylesterase 1D	Mus musculus	61-66
26208488-10	2015	The anti-inflammatory and osteolysis-targeting drug rapamycin reduced hypersensitivity to mechanical and cold stimuli, attenuated GFAP over-expression, and lowered osteoclast number.	Sirolimus	52-61	glial fibrillary acidic protein	Mus musculus	130-134
25587030-7	2014	Without affecting Akt phosphorylation, PMA increased phosphorylation of S6K (T389) and S6 (S240/244), and that was completely prevented by rapamycin.	Sirolimus	139-148	ribosomal protein S6 kinase B1	Homo sapiens	72-75
26367731-9	2015	p-mTOR, p-p70S6K and p-4E-BP1 were expressed in the cytoplasm of SW1990 cells and those proteins were significantly reduced with rapamycin (p &lt; 0.05).	Sirolimus	129-138	ribosomal protein S6 kinase B1	Homo sapiens	10-16
25587030-8	2014	Yet, T421/S424 and S235/236 (p-S6K and p-S6, respectively) phosphorylation became rapamycin-insensitive in the presence of PMA.	Sirolimus	82-91	ribosomal protein S6 kinase B1	Homo sapiens	29-34
25641578-3	2015	In cells grown in non-preferred nitrogen medium or treated with rapamycin, Gln3 is dephosphorylated and is transported from the cytoplasm to the nucleus, thereby activating the transcription of NCR-sensitive genes.	Sirolimus	64-73	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	75-79
26192087-0	2015	Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase.	Sirolimus	0-9	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	60-85
25063204-6	2014	Pre-treatment of IPEC-J2 cells with inhibitors of mTOR and Akt (rapamycin and wortmannin) or an inhibitor of ERK (PD098059) for 30 min before leucine treatment attenuated the positive effect of leucine in enhancing the protein abundance of ASCT2.	Sirolimus	64-73	AKT serine/threonine kinase 1	Sus scrofa	59-62
25394722-0	2014	Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice.	Sirolimus	48-57	interleukin 2	Mus musculus	31-35
26003087-4	2015	Real-time quantitative RT-PCR, immunohistochemistry, and Western blotting demonstrated increased expression of specific cytokines and chemokines, particularly IL-1beta and CXCL10, in the neocortex and hippocampus of Tsc1(GFAP)CKO mice, which was reversed by treatment with a mammalian target of rapamycin complex 1 (mTORC1) inhibitor.	Sirolimus	295-304	interleukin 1 alpha	Mus musculus	159-167
25968579-8	2015	Incubation with rapamycin and AZD8055 indicated that mammalian target of rapamycin complex (mTORC)2, but not mTORC1, also is required for LIF-stimulated glucose uptake.	Sirolimus	16-25	LIF interleukin 6 family cytokine	Homo sapiens	138-141
26122303-5	2015	METHODS: Western blot analysis of phosphorylation of S6 protein was used to assess the dose- and time-dependence of mTOR inhibition by rapamycin in control mice and conditional knockout mice with inactivation of the Tsc1 gene in glial fibrillary acidic protein (GFAP)-expressing cells (Tsc1(GFAP)CKO mice).	Sirolimus	135-144	mechanistic target of rapamycin kinase	Mus musculus	116-120
26122303-7	2015	RESULTS: mTOR activity was inhibited by rapamycin in a dose-dependent fashion and recovered to baseline by about 10 days after the last rapamycin dose.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Mus musculus	9-13
26122303-7	2015	RESULTS: mTOR activity was inhibited by rapamycin in a dose-dependent fashion and recovered to baseline by about 10 days after the last rapamycin dose.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Mus musculus	9-13
26540919-7	2015	The expression levels of P-mTOR, P-70S6, P-4EBP1 in spherical cells were gradually decreased with increasing of the concentrations of rapamycin, but the difference of the expression levels of mTOR, P70S6, 4EBP1 were not significant.	Sirolimus	134-143	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	43-48
26540919-7	2015	The expression levels of P-mTOR, P-70S6, P-4EBP1 in spherical cells were gradually decreased with increasing of the concentrations of rapamycin, but the difference of the expression levels of mTOR, P70S6, 4EBP1 were not significant.	Sirolimus	134-143	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	205-210
25701378-0	2015	Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.	Sirolimus	39-48	Cbl proto-oncogene B	Homo sapiens	71-76
26380452-15	2015	CONCLUSION: PESV combined Rapamycin might inhibit the development of H22 hepatoma transplantation tumor in mice possibly through inhibiting the activity of mTOR, enhancing expressions of ULK1, MAP1LC3A, and Beclin1.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Mus musculus	156-160
26380452-15	2015	CONCLUSION: PESV combined Rapamycin might inhibit the development of H22 hepatoma transplantation tumor in mice possibly through inhibiting the activity of mTOR, enhancing expressions of ULK1, MAP1LC3A, and Beclin1.	Sirolimus	26-35	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	193-201
25961827-0	2015	AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.	Sirolimus	25-34	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	103-109
25961827-2	2015	Here, we found that activated AKT signaling is associated with rapamycin resistance in breast and colon cancers by sustained phosphorylation of the translational repressor 4E-BP1.	Sirolimus	63-72	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	172-178
24825564-6	2014	Pretreatment with the mTORC1 inhibitor rapamycin not only alleviated pulmonary arterial pressure and pulmonary arteriolar remodeling but also suppressed hypoxia-induced mTORC1 and Notch3 activation.	Sirolimus	39-48	notch receptor 3	Homo sapiens	180-186
25961827-3	2015	Treatment of tumor cells with rapamycin or the AKT inhibitor MK2206 showed a limited activity in inhibiting 4E-BP1 phosphorylation, cap-dependent translation, cell growth and motility.	Sirolimus	30-39	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	108-114
26053020-9	2015	TUSC2 inhibits mTOR activation and the latter cell lines were responsive to the mTOR inhibitor rapamycin combined with erlotinib.	Sirolimus	95-104	tumor suppressor 2, mitochondrial calcium regulator	Homo sapiens	0-5
24825564-9	2014	Furthermore, overexpression of Notch3 intracellular domain partially abrogated the inhibitory effects of rapamycin on human PASMC proliferation.	Sirolimus	105-114	notch receptor 3	Homo sapiens	31-37
26037126-6	2015	In a mouse model of CM, experimental CM (ECM), we show that the mTOR inhibitor rapamycin protects against ECM when administered within the first 4 days of infection.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	64-68
25283154-12	2014	We conclude that radiolabelled anti-TLR5 mAb is capable of detecting allograft with high target specificity after treatment with the immunosuppressive drug rapamycin.	Sirolimus	156-165	toll-like receptor 5	Mus musculus	36-40
26026094-7	2015	In order to evaluate the effect of rapamycin, a natural inhibitor of mTOR kinase, on S-LAM1 cells, a sulforhodamine B cell viability assay was performed with different concentrations of rapamycin.	Sirolimus	35-44	selectin L	Homo sapiens	87-91
25688987-11	2015	Interestingly, pre-treatment with rapamycin abolished the beneficial effects of lin28a overexpression.	Sirolimus	34-43	lin-28 homolog A	Mus musculus	80-86
25688987-13	2015	Rapamycin pre-treatment abolished the effects of increased p-mTOR and p-p70s6k expression exerted by lin28a overexpression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	61-65
25688987-13	2015	Rapamycin pre-treatment abolished the effects of increased p-mTOR and p-p70s6k expression exerted by lin28a overexpression.	Sirolimus	0-9	lin-28 homolog A	Mus musculus	101-107
25855786-3	2015	Although rapamycin analogues, allosteric inhibitors that target only the mTORC1 complex, have shown some clinical activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	73-77
25875045-5	2015	The inhibitory effect of CRFR2 signaling required cAMP production and is involved the mammalian target of rapamycine pathway, as rapamycin reversed the inhibitory effect of CRFR2 stimulation on insulin-induced glucose uptake.	Sirolimus	106-115	corticotropin releasing hormone receptor 2	Homo sapiens	25-30
25875045-5	2015	The inhibitory effect of CRFR2 signaling required cAMP production and is involved the mammalian target of rapamycine pathway, as rapamycin reversed the inhibitory effect of CRFR2 stimulation on insulin-induced glucose uptake.	Sirolimus	106-115	corticotropin releasing hormone receptor 2	Homo sapiens	173-178
25875045-8	2015	Consistent with this notion, Ucn 2 reduced insulin-induced tyrosine phosphorylation of IRS-1, and treatment with rapamycin reversed the inhibitory effect of Ucn 2 on IRS-1 and Akt phosphorylation.	Sirolimus	113-122	insulin receptor substrate 1	Homo sapiens	166-171
26020699-0	2015	Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit  e. The present study aimed to investigate the effect of Eudragit  E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability.	Sirolimus	48-57	esterase D	Rattus norvegicus	186-190
26020699-0	2015	Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit  e. The present study aimed to investigate the effect of Eudragit  E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability.	Sirolimus	214-223	esterase D	Rattus norvegicus	186-190
26020699-0	2015	Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit  e. The present study aimed to investigate the effect of Eudragit  E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability.	Sirolimus	214-223	esterase D	Rattus norvegicus	186-190
26020699-4	2015	E-SD significantly inhibited the degradation of sirolimus in a dose-dependent manner.	Sirolimus	48-57	esterase D	Rattus norvegicus	0-4
26020699-5	2015	E-SD also significantly inhibited the precipitation of sirolimus compared to hydroxypropylmethyl cellulose (HPMC).	Sirolimus	55-64	esterase D	Rattus norvegicus	0-4
26020699-6	2015	Therefore, the results from the present study suggest that the sirolimus-loaded E-SD/TPGS solid dispersion has great potential in clinical applications.	Sirolimus	63-72	esterase D	Rattus norvegicus	80-84
25903737-7	2015	Pre-treatment with inhibitors of the pathway, LY294002 and rapamycin, decreased the expression of p-Akt and p70S6K and alleviated the morphological changes induced by IL-1beta in hippocampal neurons.	Sirolimus	59-68	ribosomal protein S6 kinase B1	Homo sapiens	108-114
25657110-7	2015	Furthermore, rapamycin, a specific inhibitor of mTOR, almost completely blocked FN-induced phosphorylation of 4E-BP1 and also partially abrogated the stimulatory effects of FN on GBC cell proliferation and invasion.	Sirolimus	13-22	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	110-116
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	42-45
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	188-194
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	135-144	ribosomal protein S6 kinase B1	Homo sapiens	42-45
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	135-144	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	188-194
25659819-5	2015	Micro-molar doses of rapamycin are required for complete G1 cell cycle arrest - indicating that 4E-BP1 is a critical target of mTOR for promoting cell cycle progression.	Sirolimus	21-30	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	96-102
25659819-6	2015	Data are provided demonstrating that G1 cell cycle arrest induced by rapamycin is due to up-regulation of TGF-beta signaling and down-regulation of Rb phosphorylation via phosphorylation of the mTORC1 substrates S6K and 4E-BP1 respectively.	Sirolimus	69-78	ribosomal protein S6 kinase B1	Homo sapiens	212-215
25715111-0	2015	The yeast zeta-crystallin/NADPH:quinone oxidoreductase (Zta1p) is under nutritional control by the target of rapamycin pathway and is involved in the regulation of argininosuccinate lyase mRNA half-life.	Sirolimus	109-118	NADPH:quinone reductase	Saccharomyces cerevisiae S288C	56-61
24931163-3	2015	We show that rapamycin reduces HIF-1alpha protein levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model.	Sirolimus	13-22	hypoxia inducible factor 1, alpha subunit	Mus musculus	31-41
24931163-3	2015	We show that rapamycin reduces HIF-1alpha protein levels, and to a lesser extent VEGF-A levels, in renal cystadenoma cells in a Tsc2+/- mouse model.	Sirolimus	13-22	TSC complex subunit 2	Mus musculus	128-132
25652038-6	2015	Further reduction of FKBP12 in cell lines with already low FKBP12 levels completely blocks mTORC1 inhibition by rapamycin, indicating that relative FKBP12 levels are critical for both mTORC1 and mTORC2 inhibition, but at different levels.	Sirolimus	112-121	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	21-27
25652038-8	2015	Our findings reveal that the expression of FKBP12 and FKBP51 is the rate limiting factor that determines the responsiveness of a cell line or tissue to rapamycin.	Sirolimus	152-161	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	43-49
25780003-4	2015	Mcl-1 expression intensity in NMSC was decreased in tacrolimus-treated patients compared with sirolimus-treated patients and the nonimmunosuppressed population (P = .024).	Sirolimus	94-103	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
25780003-7	2015	Importantly in NMSC, Bcl-xL expression was reduced with immunosuppression exposure, and Mcl-1 expression was reduced in tacrolimus-treated compared with sirolimus-treated patients.	Sirolimus	153-162	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	88-93
25739982-7	2015	Rapamycin suppressed 17beta-estradiol-induced Sertoli cell proliferation, appearing to act by reducing the abundance of SKP2, CCND1, and CCNE1 mRNA as well as RB and EMI1 protein.	Sirolimus	0-9	F-box protein 5	Homo sapiens	166-170
25578324-11	2015	Human cerebrovascular smooth muscle cells exposed to purified NOTCH3 ectodomain upregulated BGN, DCN, and COL4A1 through mechanisms that are sensitive to rapamycin, a potent mTOR inhibitor.	Sirolimus	154-163	notch receptor 3	Homo sapiens	62-68
25578324-11	2015	Human cerebrovascular smooth muscle cells exposed to purified NOTCH3 ectodomain upregulated BGN, DCN, and COL4A1 through mechanisms that are sensitive to rapamycin, a potent mTOR inhibitor.	Sirolimus	154-163	decorin	Homo sapiens	97-100
25578324-11	2015	Human cerebrovascular smooth muscle cells exposed to purified NOTCH3 ectodomain upregulated BGN, DCN, and COL4A1 through mechanisms that are sensitive to rapamycin, a potent mTOR inhibitor.	Sirolimus	154-163	collagen type IV alpha 1 chain	Homo sapiens	106-112
25762619-6	2015	Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion.	Sirolimus	61-70	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	191-197
25762619-6	2015	Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion.	Sirolimus	61-70	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	318-324
25762619-6	2015	Of interest, ectopic expression of constitutively active and rapamycin-resistant mutant of p70 kinase 1 (S6K1) or downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) conferred resistance to rapamycin inhibition of cell adhesion, whereas expression of constitutively hypophosphorylated 4E-BP1 (4EBP1-5A) or downregulation of S6K1 suppressed cell adhesion.	Sirolimus	61-70	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	326-334
25729255-7	2015	These findings suggest that both the mTOR pathway downstream of eIF4E and p70S6K can be successfully inhibited by high dose rapamycin only, and p70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Mus musculus	37-41
25729255-7	2015	These findings suggest that both the mTOR pathway downstream of eIF4E and p70S6K can be successfully inhibited by high dose rapamycin only, and p70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression.	Sirolimus	124-133	eukaryotic translation initiation factor 4E	Mus musculus	64-69
25425965-7	2014	Inhibition of mTOR signaling by rapamycin significantly attenuated the growth of the neoplasm.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
25403236-9	2014	A reduction in mTOR expression and the activation of LC3 (an autophagy marker) in the chondrocytes was observed in the rapamycin treated mice.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	15-19
25403236-9	2014	A reduction in mTOR expression and the activation of LC3 (an autophagy marker) in the chondrocytes was observed in the rapamycin treated mice.	Sirolimus	119-128	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	53-56
25414638-1	2014	Rapamycin, an allosteric inhibitor of the mTOR kinase, increases longevity in mice in a sex-specific manner.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	42-46
25438952-0	2015	Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	144-148
25438952-0	2015	Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis.	Sirolimus	0-9	transformation related protein 53, pseudogene	Mus musculus	149-152
25438952-9	2015	RESULTS: Rapamycin administration after TBI was associated with an increased number of neurons, decreased apoptosis index, and improved neurobehavioral function, which was potentially mediated by inactivation of the mTOR-p53-Bax axis.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	216-220
25438952-9	2015	RESULTS: Rapamycin administration after TBI was associated with an increased number of neurons, decreased apoptosis index, and improved neurobehavioral function, which was potentially mediated by inactivation of the mTOR-p53-Bax axis.	Sirolimus	9-18	transformation related protein 53, pseudogene	Mus musculus	221-224
25663935-8	2015	Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA-MB-231 cells, which were resistant to rapamycin-induced inhibition.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Homo sapiens	97-103
25663935-8	2015	Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA-MB-231 cells, which were resistant to rapamycin-induced inhibition.	Sirolimus	28-37	forkhead box P1	Homo sapiens	135-140
25663935-8	2015	Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA-MB-231 cells, which were resistant to rapamycin-induced inhibition.	Sirolimus	87-96	forkhead box P1	Homo sapiens	135-140
25744729-6	2015	The cells isolated from the breast tumor tissues expressing high levels of p27KIP1 were sensitive to rapamycin, whereas the cells from the tissues expressing low levels of p27KIP1 exhibited resistance to rapamycin.	Sirolimus	101-110	cyclin dependent kinase inhibitor 1B	Homo sapiens	75-82
25744729-6	2015	The cells isolated from the breast tumor tissues expressing high levels of p27KIP1 were sensitive to rapamycin, whereas the cells from the tissues expressing low levels of p27KIP1 exhibited resistance to rapamycin.	Sirolimus	204-213	cyclin dependent kinase inhibitor 1B	Homo sapiens	172-179
25744729-8	2015	Moreover, we also found rapamycin significantly decreased phosphorylated p70S6K1 and phosphorylated 4EBP1 in both samples.	Sirolimus	24-33	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	100-105
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	TSC complex subunit 2	Mus musculus	153-157
25613864-1	2015	The genetic disease tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by loss of function mutations in either TSC1 (hamartin) or TSC2 (tuberin), which serve as negative regulators of mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	229-238	TSC complex subunit 2	Mus musculus	159-166
24632604-0	2015	Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.	Sirolimus	113-122	TSC complex subunit 2	Mus musculus	19-23
24632604-10	2015	In conclusion, in contrast to previous studies, we found that Akt signalling is not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR pathway, rapamycin is highly effective in preventing Tsc-associated tumours.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Mus musculus	167-171
24632604-10	2015	In conclusion, in contrast to previous studies, we found that Akt signalling is not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR pathway, rapamycin is highly effective in preventing Tsc-associated tumours.	Sirolimus	181-190	TSC complex subunit 2	Mus musculus	225-228
25527290-9	2015	We found that nuclear Gln3 localization elicited by short- and long-term nitrogen starvation; growth in a poor, derepressive medium; Msx or rapamycin treatment; or ure2Delta mutation is abolished in a sup70-65 mutant.	Sirolimus	140-149	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	22-26
25615280-4	2015	Activation of autophagy in vitro or in vivo by rapamycin or starvation downregulated oncogenic fusion protein E2A/Pbx1.	Sirolimus	47-56	PBX homeobox 1	Homo sapiens	114-118
25383520-8	2015	Importantly, treatment of established APC-deficient adenomas with rapamycin (which can target eEF2 through the mTORC1-S6K-eEF2K axis) causes tumour cells to undergo growth arrest and differentiation.	Sirolimus	66-75	eukaryotic translation elongation factor 2	Homo sapiens	94-98
25534817-6	2015	Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice.	Sirolimus	178-187	mechanistic target of rapamycin kinase	Mus musculus	98-102
26115221-3	2015	Cells pretreated with rapamycin before exposure to HG showed significant decrease phosphorylation of CREB, increase in AMPK activity and decrease protein/mRNA and promoter activity of fibronectin.	Sirolimus	22-31	fibronectin 1	Mus musculus	184-195
26115221-6	2015	Moreover, gel shift analysis shows increase binding of CREB to fibronectin promoter in cells treated with HG while cells pretreated with rapamycin reversed the effect of HG.	Sirolimus	137-146	fibronectin 1	Mus musculus	63-74
26115221-7	2015	Furthermore, db/db mice treated with rapamycin showed significant increase in AMPK activity, decrease in expression of p-CREB and protein/mRNA of fibronectin.	Sirolimus	37-46	fibronectin 1	Mus musculus	146-157
26115221-8	2015	Strong staining of fibronectin and p-CREB was detected in kidney cortex of db/db mice while treated mice with rapamycin reversed hyperglycemia effect.	Sirolimus	110-119	fibronectin 1	Mus musculus	19-30
25414638-9	2014	Further our findings suggest that rapamycin induces indirect regulation of the PMDS/heat-shock response through its modulation of the mTOR pathway rather than via direct interactions between rapamycin and the proteasome.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	134-138
24916432-9	2014	Increased p-p70s6k and p-4EBP were also observed in the expression of nicotine sensitization, which was demonstrated to be inhibited by systemic rapamycin administration.	Sirolimus	145-154	ribosomal protein S6 kinase B1	Homo sapiens	12-18
25270513-6	2014	The phosphorylation levels of P70S6K increased after PDL exposure but those increases were suppressed by the topical RPM.	Sirolimus	117-120	ribosomal protein S6 kinase B1	Homo sapiens	30-36
25270513-8	2014	CONCLUSION: Topical application of 1% RPM can significantly and systematically suppress the PDL-induced early stage of angiogenesis via inhibition of the AKT/mTOR/P70S6K pathway in a rodent model.	Sirolimus	38-41	ribosomal protein S6 kinase B1	Homo sapiens	163-169
25041840-8	2014	Furthermore, we found that curcumin significantly decreased the expression of Phosphatidylinositol 3-Kinase (PI3K), phosphorylated Akt and rapamycin (mTOR) at protein levels, respectively.	Sirolimus	139-148	mechanistic target of rapamycin kinase	Mus musculus	150-154
24980657-8	2014	Furthermore, we show that pre- and co-treatment with rapamycin ameliorates H2O2-induced caspase-3 and caspase-6 activation and cell toxicity but that 3-methyladenine exacerbates H2O2-induced cell apoptotic cell death.	Sirolimus	53-62	caspase 6	Homo sapiens	102-111
25091623-5	2014	However, 3-DSC-mediated HO-1 induction was completely blocked by treatment with cycloheximide, a translational inhibitor, or rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR).	Sirolimus	125-134	heme oxygenase 1	Homo sapiens	24-28
25109305-13	2014	Furthermore, rapamycin was found to attenuate the myocardial protective effect that is induced by ulinastatin.	Sirolimus	13-22	alpha-1-microglobulin/bikunin precursor	Rattus norvegicus	98-109
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	C-C motif chemokine ligand 3	Homo sapiens	110-120
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	C-C motif chemokine ligand 4	Homo sapiens	126-135
25092287-6	2014	mTOR inhibition by rapamycin also down-regulated TCTP protein expression, whereas knockdown or overexpression of TCTP suppressed or activated mTOR signaling, respectively, and affected cell viability.	Sirolimus	19-28	tumor protein, translationally-controlled 1	Homo sapiens	49-53
24847003-3	2014	While sirolimus robustly inhibits mTORC1, it has a minimal effect on mTOR complex 2 (mTORC2).	Sirolimus	6-15	mechanistic target of rapamycin kinase	Mus musculus	34-38
25157160-6	2014	Inhibition of mTOR signaling by rapamycin markedly attenuated ghrelin-induced up-regulation of lipogenesis in hepatocytes, whereas activation of hepatic mTOR signaling by deletion of TSC1 increased hepatic lipogenesis.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
25155956-5	2014	The mTOR inhibitor rapamycin corrected ASD-like behaviors and spine pruning defects in Tsc2 +- mice, but not in Atg7(CKO) neuronal autophagy-deficient mice or Tsc2 +- :Atg7(CKO) double mutants.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
25155956-5	2014	The mTOR inhibitor rapamycin corrected ASD-like behaviors and spine pruning defects in Tsc2 +- mice, but not in Atg7(CKO) neuronal autophagy-deficient mice or Tsc2 +- :Atg7(CKO) double mutants.	Sirolimus	19-28	TSC complex subunit 2	Mus musculus	87-91
24682776-5	2014	Rapamycin restored abnormal mTOR/p70S6K signaling and attenuated the phosphorylation of tau protein in the hippocampus of diabetic mice.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	28-32
25198311-5	2015	Although none of the immunosuppressants directly led to duct cell death, MMF prevented duct cell proliferation, and sirolimus inhibited neurogenin 3-mediated duct-to-(neuro)endocrine cell reprogramming.	Sirolimus	116-125	neurogenin 3	Homo sapiens	136-148
25986568-2	2015	The prototype of this protein family, FKBP12, is the binding partner for immunosuppressive drugs FK506 and rapamycin.	Sirolimus	107-116	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	38-44
24990517-6	2015	Rapamycin-induced, donor-specific tolerance was associated with an expansion of regulatory T (Treg) cells in both the spleen and allograft and elevated plasma levels of fibrinogen-like protein 2 (FGL2).	Sirolimus	0-9	fibrinogen like 2	Homo sapiens	169-194
24990517-6	2015	Rapamycin-induced, donor-specific tolerance was associated with an expansion of regulatory T (Treg) cells in both the spleen and allograft and elevated plasma levels of fibrinogen-like protein 2 (FGL2).	Sirolimus	0-9	fibrinogen like 2	Homo sapiens	196-200
25408212-2	2015	We have investigated the ability of the rapamycin ester CCI-779/Temsilorimus, a mTOR inhibitor with better stability and pharmacological properties compared to rapamycin, to interfere with the development of a motor phenotype and tau pathology in a mutant tau mouse model developing neurofibrillary tangles, by stimulation of mTOR dependent macroautophagy.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Mus musculus	80-84
25277143-7	2015	Rapamycin, a specific mTOR inhibitor, significantly reversed the inhibitory effect of IFN-gamma on nonopsonized phagocytosis of macrophages and restored c/EBPbeta and MARCO expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	22-26
25277143-7	2015	Rapamycin, a specific mTOR inhibitor, significantly reversed the inhibitory effect of IFN-gamma on nonopsonized phagocytosis of macrophages and restored c/EBPbeta and MARCO expression.	Sirolimus	0-9	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	153-162
25439783-6	2015	RESULTS: The 4E-BP1/eIF4E ratio was adjusted to evaluate the response to rapamycin treatment in TE1 and TE2 esophageal cancer cells.	Sirolimus	73-82	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	13-19
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	72-78
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	32-36
25653476-9	2015	Furthermore, rapamycin decreased PA-induced nuclear translocation of NFkappaB P65 subunit, thereby NFkappaB-dependent inflammatory cytokines MCP-1 and IL-6 expression and secretion.	Sirolimus	13-22	C-C motif chemokine ligand 2	Homo sapiens	141-146
25249228-13	2015	Rapamycin significantly reduced p-mTOR expression and increased the LC3-II/LC3-I ratio.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	34-38
25249228-13	2015	Rapamycin significantly reduced p-mTOR expression and increased the LC3-II/LC3-I ratio.	Sirolimus	0-9	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	68-71
25249228-13	2015	Rapamycin significantly reduced p-mTOR expression and increased the LC3-II/LC3-I ratio.	Sirolimus	0-9	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	75-78
25910652-2	2015	We can observe behavioral abnormalities relevant to autism spectrum disorders (ASDs) and their recovery mediated by the mTOR inhibitor rapamycin in mouse models.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Mus musculus	120-124
25512509-7	2014	The TORC1 inhibitor rapamycin can suppress this extra mitotic division.	Sirolimus	20-29	Target of rapamycin	Drosophila melanogaster	4-9
25340612-1	2014	BACKGROUND: CD200 overexpression in transgenic recipients, or by tissue allografts, increases skin and cardiac graft survival in mice receiving rapamycin, in association with increased Foxp3(+)Treg graft infiltration.	Sirolimus	144-153	CD200 antigen	Mus musculus	12-17
24879590-6	2014	The cell invasiveness induced by LKB1 loss was nearly suppressed by mammalian target of rapamycin (mTOR) inhibitor (rapamycin and everolimus) and mTOR/AKT dual inhibitor Palomid 529 (P529).	Sirolimus	88-97	serine/threonine kinase 11	Homo sapiens	33-37
25044816-6	2014	The mTOR inhibitor rapamycin delays the development of SKF81297-induced kindled seizures, and rescues LTP in the DG and object recognition.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
25674207-7	2014	We found that rapamycin attenuated cardiac dysfunction, increase in ANP and BNP as well as apoptosis induced by LPS both in mice and in H9c2 cells.	Sirolimus	14-23	natriuretic peptide type B	Mus musculus	76-79
24682776-7	2014	These findings indicate that mTOR/p70S6K signaling pathway is hyperactive in the hippocampus of STZ-induced diabetic mice and inhibiting mTOR signaling with rapamycin prevents the DM-related cognitive deficits partly through attenuating the hyperphosphorylation of tau protein.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Mus musculus	29-33
24682776-7	2014	These findings indicate that mTOR/p70S6K signaling pathway is hyperactive in the hippocampus of STZ-induced diabetic mice and inhibiting mTOR signaling with rapamycin prevents the DM-related cognitive deficits partly through attenuating the hyperphosphorylation of tau protein.	Sirolimus	157-166	mechanistic target of rapamycin kinase	Mus musculus	137-141
24850187-2	2014	In this study, male Balb/c mice were divided into three groups: control (n = 12), STZ-induced diabetic (n = 12), and rapamycin-treated diabetic (DM + Rapa) (n = 12), which received intraperitoneal injection of rapamycin (2 mg/kg/48 h) after induction of DM.	Sirolimus	117-126	transcriptional regulating factor 1	Mus musculus	150-154
28357221-5	2014	In line with nuclear import of Gln3 being under control of TOR and dephosphorylation by the Sit4 phosphatase, we identify novel TOR-sensitive sit4 mutations that confer rapamycin resistance and importantly, mislocalise Gln3 when TOR is inhibited.	Sirolimus	169-178	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	31-35
28357221-5	2014	In line with nuclear import of Gln3 being under control of TOR and dephosphorylation by the Sit4 phosphatase, we identify novel TOR-sensitive sit4 mutations that confer rapamycin resistance and importantly, mislocalise Gln3 when TOR is inhibited.	Sirolimus	169-178	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	142-146
25278019-4	2014	This orexin/GPCR-stimulated mTOR activation is sensitive to rapamycin, an inhibitor of mTOR complex 1 (mTORC1) but is independent of two well known mTORC1 activators, Erk and Akt.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	28-32
25278019-4	2014	This orexin/GPCR-stimulated mTOR activation is sensitive to rapamycin, an inhibitor of mTOR complex 1 (mTORC1) but is independent of two well known mTORC1 activators, Erk and Akt.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	87-91
25408787-3	2014	Thus hemangioma accompanied by excessive mTOR activation should be sensitive to rapamycin.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Mus musculus	41-45
25208880-5	2014	We evaluated the antitumor effects of mTOR inhibitors (rapamycin and its analogue, CCI-779) against these cell lines in culture and in a murine xenograft model that was established by subcutaneous injection of SNK6 cells into NOG mice.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	38-42
25241363-12	2014	Expressions of p-p70S6K, p-4EBP1, PCNA, and STRA8 decreased significantly in the rapamycin-treated group, where no difference was observed in VASA expression.	Sirolimus	81-90	stimulated by retinoic acid gene 8	Mus musculus	44-49
25258031-3	2014	METHODS: Pharmaceutical specific inhibitors BEZ235 and rapamycin were used to vertical inhibit PI3K/Akt/mTOR signaling and mTOR signaling alone in cultured fibroblasts and in mice.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	104-108
25258031-3	2014	METHODS: Pharmaceutical specific inhibitors BEZ235 and rapamycin were used to vertical inhibit PI3K/Akt/mTOR signaling and mTOR signaling alone in cultured fibroblasts and in mice.	Sirolimus	55-64	mechanistic target of rapamycin kinase	Mus musculus	123-127
25258031-7	2014	mTOR inhibitor rapamycin failed to inhibit dermal fibrosis in an established SSc mouse model.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	0-4
25039425-6	2014	The increase in GM1 expression induced by leptin was inhibited after pre-treatment with inhibitors of phosphatidylinositol 3-kinase (LY294002), Akt (triciribine) and the mammalian target of rapamycin (i.e. rapamycin), but not by an inhibitor of extracellular signal-regulated kinase (PD98059).	Sirolimus	190-199	leptin	Homo sapiens	42-48
25379021-11	2014	Pharmacological inhibition of p70S6K using the PI3K/mTOR inhibitor NVP-BEZ235, the specific mTOR inhibitor Rapamycin and the specific p70S6K inhibitor PF-4708671 potentiated Selumetinib effects in resistant cells.	Sirolimus	107-116	ribosomal protein S6 kinase B1	Homo sapiens	30-36
24998203-12	2014	HNRNPA2B1 is required for KRAS activation of c-akt murine thymoma oncogene homolog 1-mammalian target of rapamycin signaling, interaction with phosphatidylinositide 3-kinase, and PDAC cell survival and tumor formation in mice.	Sirolimus	105-114	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	26-30
24842780-5	2014	We found that downregulation of TOR by feeding the drug rapamycin or by overexpressing the negative TOR regulators TSC1/TSC2, resulted in a specific induction of the AMPs Diptericin (Dpt) and Metchnikowin (Mtk).	Sirolimus	56-65	Target of rapamycin	Drosophila melanogaster	32-35
25290063-5	2014	When given to young postnatal mice, the mTOR inhibitor, rapamycin, inhibits active myelination.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	40-44
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	C-C motif chemokine ligand 2	Homo sapiens	74-79
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	C-C motif chemokine ligand 3	Homo sapiens	95-105
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	C-C motif chemokine ligand 4	Homo sapiens	111-120
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	C-C motif chemokine ligand 2	Homo sapiens	89-94
25149531-6	2014	In addition, cells treated with rapamycin showed a significant increase in p-Akt and a decrease in p-p70S6K that was associated with a decrease expression of vimentin and a slight increase expression in N-cadherin.	Sirolimus	32-41	ribosomal protein S6 kinase B1	Homo sapiens	101-107
25149531-6	2014	In addition, cells treated with rapamycin showed a significant increase in p-Akt and a decrease in p-p70S6K that was associated with a decrease expression of vimentin and a slight increase expression in N-cadherin.	Sirolimus	32-41	vimentin	Homo sapiens	158-166
25134448-10	2014	In addition, the CXCR3+ NKT cell in the kidney increased remarkably in the rapamycin-treated group.	Sirolimus	75-84	chemokine (C-X-C motif) receptor 3	Mus musculus	17-22
25134448-11	2014	The chemokines, CXCL9 and CXCL10, as the ligands of CXCR3, were also increased in the rapamycin-treated kidney.	Sirolimus	86-95	chemokine (C-X-C motif) ligand 9	Mus musculus	16-21
25134448-11	2014	The chemokines, CXCL9 and CXCL10, as the ligands of CXCR3, were also increased in the rapamycin-treated kidney.	Sirolimus	86-95	chemokine (C-X-C motif) receptor 3	Mus musculus	52-57
24801508-11	2014	Moreover ex vivo treatment with rapamycin and resveratrol improved E-CSC capacity to induce cardiac repair upon injection in the mouse infarcted heart, leading to reduced cardiomyocyte senescence and apoptosis and increased abundance of endogenous c-Kit(+) CSC in the peri-infarct area.	Sirolimus	32-41	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	248-253
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	289-295
25324684-14	2014	Compared to untreated MCMV-infected control cells, rapamycin treatment resulted in a significant decrease in the cleaved caspase 3 levels as well as a significant decrease in the ratio of phosphorylated mammalian target of rapamycin (mTOR) to total mTOR and in the ratio of phosphorylated P70S6K to total P70S6K.	Sirolimus	51-60	ribosomal protein S6 kinase B1	Homo sapiens	305-311
24970820-3	2014	Potentially therefore rapamycin could prevent the Hsf1 activation that frequently compromises the efficiency of Hsp90 inhibitor cancer drugs.	Sirolimus	22-31	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	50-54
24970820-3	2014	Potentially therefore rapamycin could prevent the Hsf1 activation that frequently compromises the efficiency of Hsp90 inhibitor cancer drugs.	Sirolimus	22-31	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	112-117
24970820-5	2014	However certain rapamycin resistance mutations sensitised yeast to Hsp90 inhibitor treatment and an Hsp90 mutation that overactivates Hsf1 sensitised cells to rapamycin.	Sirolimus	16-25	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	67-72
24970820-6	2014	Rapamycin inhibition of the yeast Hsf1 was abolished by this Hsp90 mutation, as well as with the loss of Ppt1, the Hsp90-interacting protein phosphatase that is the ortholog of mammalian PP5.	Sirolimus	0-9	stress-responsive transcription factor HSF1	Saccharomyces cerevisiae S288C	34-38
24970820-6	2014	Rapamycin inhibition of the yeast Hsf1 was abolished by this Hsp90 mutation, as well as with the loss of Ppt1, the Hsp90-interacting protein phosphatase that is the ortholog of mammalian PP5.	Sirolimus	0-9	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	61-66
24970820-6	2014	Rapamycin inhibition of the yeast Hsf1 was abolished by this Hsp90 mutation, as well as with the loss of Ppt1, the Hsp90-interacting protein phosphatase that is the ortholog of mammalian PP5.	Sirolimus	0-9	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	115-120
24713582-2	2014	Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia.	Sirolimus	28-37	low density lipoprotein receptor	Homo sapiens	56-68
24713582-2	2014	Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contributes to hypercholesterolemia.	Sirolimus	28-37	low density lipoprotein receptor	Homo sapiens	70-75
24915467-6	2014	Moreover, in cells exposed to actinomycin D, rapamycin attenuated the accumulation of PML, a protein that in some conditions stimulates Ser46 phosphorylation.	Sirolimus	45-54	PML nuclear body scaffold	Homo sapiens	86-89
24682932-9	2014	In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	144-150
24964744-5	2014	Combination of EGFR inhibitors with either the PI3K inhibitor ZSTK474 or the MTOR inhibitor sirolimus showed increased activity.	Sirolimus	92-101	epidermal growth factor	Homo sapiens	15-19
24936148-7	2014	These effects of S100A4 were abolished by treatment with either the specific PI3K/Akt inhibitor LY294002, or the specific mTOR/p70S6K inhibitor rapamycin.	Sirolimus	144-153	ribosomal protein S6 kinase B1	Homo sapiens	127-133
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	ribosomal protein S6 kinase B1	Homo sapiens	57-86
24746805-5	2014	The effects of Grb10 deficiency on lipolysis and thermogenesis were diminished by rapamycin administration in vivo.	Sirolimus	82-91	growth factor receptor bound protein 10	Homo sapiens	15-20
24341993-1	2014	Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
24842496-5	2014	This review highlights the important and well-described aspects of the critical phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT/mTOR pathway and discusses the mechanisms of action of rapamycin, its clinical efficacy in lymphoid malignancies, and the mechanisms of resistance.	Sirolimus	193-202	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	80-126
24936056-5	2014	Notably, depletion/inhibition of PRCP/PREP destabilized IRS-1 in the cells treated with rapamycin, blocking the feedback activation PI3K/AKT.	Sirolimus	88-97	insulin receptor substrate 1	Homo sapiens	56-61
24961812-13	2014	The convergence of multiple proteome-level changes on the Rsp5 system indicates a key role of this pathway in the response to rapamycin treatment.	Sirolimus	126-135	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	58-62
24193408-0	2014	Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.	Sirolimus	126-135	polycystin 1, transient receptor potential channel interacting	Homo sapiens	0-12
23902659-5	2014	In the analyses of cytoplasmic maturation, we found that the level of p34(cdc2), a cytoplasmic maturation marker, and the monospermic fertilisation rate were higher in the 1nM rapamycin treatment group than in the other groups.	Sirolimus	176-185	cyclin dependent kinase 1	Homo sapiens	74-78
24917666-8	2014	Finally, acting as a physiological analog of rapamycin, IL-1beta impaired BDNF signaling by way of inhibiting mTOR activation as follows: the cytokine induced caspase-independent neuronal death and accelerated autophagic flux in BDNF-treated cells.	Sirolimus	45-54	interleukin 1 alpha	Homo sapiens	56-64
24982337-4	2014	RESULTS: Rapamycin combined with 5-fluorouracil significantly reduced tumor size, suppressed expression of B-cell lymphoma 2, increased tumor apoptosis, and inhibited mTOR signaling activity by de-phosphorylation of S6K.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	167-171
24694942-8	2014	In 0% serum, expression of myocardin, a key regulator of smooth muscle differentiation markers, significantly decreased from Fresh, which was significantly rescued by rapamycin.	Sirolimus	167-176	myocardin	Rattus norvegicus	27-36
24922651-5	2014	SAHA combined with LY or rapamycin, or both, synergistically reduced p-p70S6K and p-4E-BP1 levels.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	71-77
24703900-4	2014	METHODS: We exposed GC-resistant MLL-rearranged SEMK2 cells to potent MCL1-inhibiting agents, including gossypol, AT-101, rapamycin, SU9516 and obatoclax (GX15-070) and determined GC sensitisation using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assays.	Sirolimus	122-131	lysine methyltransferase 2A	Homo sapiens	33-36
24644271-9	2014	As a result, the current model describing participation of Vps system components in events associated with translocation of Gln3 into the nucleus following rapamycin treatment or growth in nitrogen-poor medium requires modification.	Sirolimus	156-165	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	124-128
24753052-5	2014	Gonadotropins induced MTOR kinase activity in the ovary, which was inhibited by rapamycin treatment (10 microg/g body weight, intraperitoneal injection).	Sirolimus	80-89	mechanistic target of rapamycin kinase	Mus musculus	22-26
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Mus musculus	176-180
24753052-8	2014	Overexpression of these ovulatory genes was associated with hyper-activation of extracellular signal-regulated kinase 1/2 (ERK1/2), which occurred in response to inhibition of MTOR with rapamycin and suggested that MTOR may function as a negative regulator of the mitogen-activated protein kinase (MAPK) pathway.	Sirolimus	186-195	mechanistic target of rapamycin kinase	Mus musculus	215-219
24682932-8	2014	Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P &lt; 0.05).	Sirolimus	170-179	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	98-104
24682932-8	2014	Western blot and reverse transcription PCR (RT-PCR) analysis showed that the expressions of mTOR, 4E-BP1, and p70S6K were all significantly decreased in K562 cells after rapamycin + celecoxib treatment (P &lt; 0.05).	Sirolimus	170-179	ribosomal protein S6 kinase B1	Homo sapiens	110-116
24682932-9	2014	In conclusion, rapamycin combined with celecoxib could induce cell cycle arrest and apoptosis and decrease the expressions of mTOR, 4E-BP1, and p70S6K.	Sirolimus	15-24	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	132-138
25004403-9	2014	Inhibition of mTOR phosphorylation by rapamycin enhanced the radiosensitivity of BKM120-treated hepatocellular carcinoma cells.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Mus musculus	14-18
24631848-2	2014	These metabolic changes result in the development of both a spontaneous cardiac hypertrophy and increased phosphorylated S6 kinase (S6K), a substrate of the mechanistic target of rapamycin, mTOR.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Mus musculus	190-194
24725019-6	2014	The patient fully recovered from the neurological deficits related to CPM following the switch from the CNI to sirolimus.	Sirolimus	111-120	carboxypeptidase M	Homo sapiens	70-73
24846380-6	2014	Furthermore, we observed sirolimus (i.e., rapamycin)-inducible interactions between FRB and FKBP12 and a dose-dependent abolishment of such interactions by FK506, the ligand of FKBP12.	Sirolimus	25-34	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	92-98
24846380-6	2014	Furthermore, we observed sirolimus (i.e., rapamycin)-inducible interactions between FRB and FKBP12 and a dose-dependent abolishment of such interactions by FK506, the ligand of FKBP12.	Sirolimus	25-34	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	177-183
24846380-6	2014	Furthermore, we observed sirolimus (i.e., rapamycin)-inducible interactions between FRB and FKBP12 and a dose-dependent abolishment of such interactions by FK506, the ligand of FKBP12.	Sirolimus	42-51	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	92-98
24846380-6	2014	Furthermore, we observed sirolimus (i.e., rapamycin)-inducible interactions between FRB and FKBP12 and a dose-dependent abolishment of such interactions by FK506, the ligand of FKBP12.	Sirolimus	42-51	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	177-183
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	ribosomal protein S6 kinase B1	Homo sapiens	140-146
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	222-249
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	endoplasmic reticulum (ER) to nucleus signalling 2	Mus musculus	251-255
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Mus musculus	101-105
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	133-194
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	196-201
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	206-211
24607296-9	2014	Thus, these data indicate that visible light induces ER stress in 661W cells; whereas the mTOR inhibitor, rapamycin, effectively protects 661W cells from light injury through suppressing the ER stress pathway.	Sirolimus	106-115	mechanistic target of rapamycin kinase	Mus musculus	90-94
24375611-4	2014	This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin.	Sirolimus	137-146	ribosomal protein S6 kinase B1	Rattus norvegicus	59-66
24375611-8	2014	The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins.	Sirolimus	43-52	ribosomal protein S6 kinase B1	Rattus norvegicus	139-146
24556924-0	2014	Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.	Sirolimus	109-118	erb-b2 receptor tyrosine kinase 2	Mus musculus	44-53
24630239-0	2014	Effects of the immunosuppressant rapamycin on the expression of human alpha2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.	Sirolimus	33-42	matrix metallopeptidase 1	Homo sapiens	93-119
24630239-9	2014	In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells.	Sirolimus	13-22	matrix metallopeptidase 1	Homo sapiens	49-53
24569105-10	2014	Rapamycin treatment or mTOR inhibition promotes CD11b+Gr1+Ly6C(high) MDSC recruitment and is critically required for protection against hepatic injury.	Sirolimus	0-9	lymphocyte antigen 6 complex, locus C1	Mus musculus	58-62
24737049-7	2014	siRNA knockdown of TLR4 in HNSCC cells demonstrated that rapamycin attenuated LPS-induced pro-oncogenic effects via TLR4.	Sirolimus	57-66	toll like receptor 4	Homo sapiens	19-23
24737049-7	2014	siRNA knockdown of TLR4 in HNSCC cells demonstrated that rapamycin attenuated LPS-induced pro-oncogenic effects via TLR4.	Sirolimus	57-66	toll like receptor 4	Homo sapiens	116-120
24810045-7	2014	Evidence supporting a key role of mTOR/PP2A signaling included the finding that, similar to metformin, the canonical mTOR inhibitor rapamycin was capable of lowering the ratio of phospho-Ser129 alpha-synuclein to total alpha-synuclein.	Sirolimus	132-141	protein phosphatase 2 phosphatase activator	Homo sapiens	39-43
24810045-7	2014	Evidence supporting a key role of mTOR/PP2A signaling included the finding that, similar to metformin, the canonical mTOR inhibitor rapamycin was capable of lowering the ratio of phospho-Ser129 alpha-synuclein to total alpha-synuclein.	Sirolimus	132-141	synuclein alpha	Homo sapiens	194-209
24810045-7	2014	Evidence supporting a key role of mTOR/PP2A signaling included the finding that, similar to metformin, the canonical mTOR inhibitor rapamycin was capable of lowering the ratio of phospho-Ser129 alpha-synuclein to total alpha-synuclein.	Sirolimus	132-141	synuclein alpha	Homo sapiens	219-234
24810045-11	2014	These data reveal a new mechanism leading to alpha-synuclein dephosphorylation that could be targeted for therapeutic intervention by drugs like metformin and rapamycin.	Sirolimus	159-168	synuclein alpha	Homo sapiens	45-60
24619883-4	2014	Rosiglitazone corrected fasting hyperglycemia, attenuated the glucose and insulin intolerances, and abolished the increase in fasting plasma insulin and C-peptide levels induced by rapamycin.	Sirolimus	181-190	insulin 2	Rattus norvegicus	153-162
24619883-6	2014	Furthermore, rosiglitazone partially attenuated rapamycin-induced gluconeogenesis, as evidenced by the improved pyruvate tolerance and reduced mRNA levels of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase.	Sirolimus	48-57	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	196-217
25049998-5	2014	Rapamycin treatment of aged IVM oocytes for 24 h also rescued aberrant spindle organization and chromosomal misalignment, blocked the decrease in the level of phosphorylated-p44/42 mitogen-activated protein kinase (MAPK), and increased the mRNA expression of cytoplasmic maturation factor genes (MOS, BMP15, GDF9, and CCNB1) compared with untreated, 24 h-aged IVM oocytes (p&lt;0.05).	Sirolimus	0-9	cyclin B1	Homo sapiens	318-323
24629569-10	2014	On histological analysis, medial elastin and smooth muscle cell populations were relatively preserved in the rapamycin group.	Sirolimus	109-118	elastin	Mus musculus	33-40
24748656-2	2014	Following the regulatory approval of the rapamycin analogs everolimus and temsirolimus, recent years have seen an explosion in the number of phosphoinositide 3-kinase (PI3K) pathway inhibitors under clinical investigation.	Sirolimus	41-50	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	141-166
23708663-0	2014	Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.	Sirolimus	65-74	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	33-37
24815166-12	2014	In summary, rapamycin could promote podocyte migration through the up-regulation of uPAR.	Sirolimus	12-21	plasminogen activator, urokinase receptor	Homo sapiens	84-88
24441414-4	2014	Our previous study shows that rapamycin, an MTOR-dependent autophagic activator, accelerates disease progression in the SOD1(G93A) mouse model of ALS.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Mus musculus	44-48
24578415-6	2014	Administration of rapamycin to these mice reduced mTOR activity, reduced the elevated mitochondrial numbers, and normalized aberrant antioxidant levels.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	50-54
24763434-14	2014	Rapamycin has potent inhibitory effects in a mouse colon polyposis model, and mTOR inhibition is linked to decreased proliferation and increased expression of differentiation markers in Apc-mutant colon epithelium and delays development of dysplasia.	Sirolimus	0-9	APC, WNT signaling pathway regulator	Mus musculus	186-189
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	53-58
24107844-8	2014	ILT3/ILT4 expression was increased in kidney biopsies at the end of the study period along with a significant bias toward a Th2 response within the graft only in the rapamycin-treated patients.	Sirolimus	166-175	leukocyte immunoglobulin like receptor B4	Homo sapiens	0-4
24107844-9	2014	Thus, rapamycin induces the upregulation of ILT3 and ILT4 on the DC surface, and this effect is associated with an increase in the number of Tregs and expansion of the CD8(+)CD28(-) T cell population.	Sirolimus	6-15	leukocyte immunoglobulin like receptor B4	Homo sapiens	44-48
24486221-9	2014	Rapamycin, an mTOR inhibitor, has been used successfully in Tsc-deficient mice to prevent and treat seizures and behavioral abnormalities.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	versican	Mus musculus	42-50
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	indoleamine 2,3-dioxygenase 1	Mus musculus	52-55
24742865-9	2014	Sunitinib plus rapamycin markedly induced versican, IDO, arginase 1, IL-6, and TGF-beta expression in the lungs, whereas it reduced IDO and IL-10 expression in the primary tumor tissues.	Sirolimus	15-24	indoleamine 2,3-dioxygenase 1	Mus musculus	132-135
24675464-5	2014	However, 3 days following ligation with rapamycin treatment, a selective mTOR inhibitor, gland weights were maintained, 4E-BP1 and S6rp phosphorylation was inhibited, and there were morphological signs of recovery from atrophy.	Sirolimus	40-49	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	120-126
24658577-8	2014	Furthermore, Rapamycin promoted Treg expansion and inducible Treg generation in allogeneic BMT recipients treated with IL-2.	Sirolimus	13-22	interleukin 2	Mus musculus	119-123
24658577-9	2014	Consistent with these observations, CsA abrogated while Rapamycin promoted the protective effect of IL-2 on allogeneic BMT-induced GVHD.	Sirolimus	56-65	interleukin 2	Mus musculus	100-104
24658577-11	2014	Thus, in allogeneic settings, an mTOR inhibitor such as Rapamycin is a better choice for adjunct therapy with IL-2 in expansion of Tregs and protection against allogeneic BMT-induced GVHD.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Mus musculus	33-37
24567410-3	2014	Although rapamycin, an allosteric mTOR inhibitor, is an effective immunosuppressant, the precise roles of mTOR complexes in early T-cell development remain unclear.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	34-38
24618323-9	2014	Rapamycin did not change PI3KCalpha or Akt signaling molecule expression, downregulated S6K1, but upregulated IGF-1R mRNA levels; IGF-1 and SP proteins also were upregulated.	Sirolimus	0-9	insulin-like growth factor 1	Rattus norvegicus	110-115
24710396-5	2014	To address this, we used a mouse model of high-fat diet (HFD)-fed mice with and without pharmacologic mTOR inhibition by rapamycin.	Sirolimus	121-130	mechanistic target of rapamycin kinase	Mus musculus	102-106
27919033-4	2014	We determined the transcription profiles of bmh1 and bmh2 yeast after treatment with rapamycin.	Sirolimus	85-94	14-3-3 family protein BMH2	Saccharomyces cerevisiae S288C	53-57
24764583-8	2014	Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation.	Sirolimus	97-106	CD274 molecule	Homo sapiens	129-134
24764583-8	2014	Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation.	Sirolimus	97-106	phosphatase and tensin homolog	Homo sapiens	163-167
24764583-8	2014	Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation.	Sirolimus	97-106	CD274 molecule	Homo sapiens	190-195
24504412-7	2014	We then treated the denervated mice with the mTOR inhibitor rapamycin and found that, despite a reduction in mTOR activation, there is no alteration of the atrophy phenotype.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	45-49
24504412-7	2014	We then treated the denervated mice with the mTOR inhibitor rapamycin and found that, despite a reduction in mTOR activation, there is no alteration of the atrophy phenotype.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	109-113
24504412-8	2014	Additionally, rapamycin prevented the denervation-induced upregulation of the mTORC2 substrates Akt and SGK.	Sirolimus	14-23	serum/glucocorticoid regulated kinase 1	Mus musculus	104-107
24603487-6	2014	PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin.	Sirolimus	108-117	phosphatase and tensin homolog	Homo sapiens	0-4
24401568-4	2014	Here, by transfection of HBV genomic DNA and HBx in hepatic and hepatoma cells, we showed that HBV- or HBx-induced autophagosome formation was accompanied by unchanged MTOR (mechanistic target of rapamycin) activity and decreased degradation of LC3 and SQSTM1/p62, the typical autophagic cargo proteins.	Sirolimus	196-205	X protein	Hepatitis B virus	103-106
24194502-6	2014	HB-EGF induced proliferation of insulin-secreting MIN6 cells and isolated rat islets, and this effect was blocked in MIN6 cells by the EGFR inhibitor AG1478 or the mTOR inhibitor rapamycin.	Sirolimus	179-188	heparin-binding EGF-like growth factor	Mus musculus	0-6
24194502-6	2014	HB-EGF induced proliferation of insulin-secreting MIN6 cells and isolated rat islets, and this effect was blocked in MIN6 cells by the EGFR inhibitor AG1478 or the mTOR inhibitor rapamycin.	Sirolimus	179-188	mechanistic target of rapamycin kinase	Mus musculus	164-168
24658085-0	2014	Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.	Sirolimus	0-9	thymidylate synthetase	Homo sapiens	24-44
24658085-6	2014	Although pemetrexed as a single agent induced TS, pretreatment with rapamycin suppressed pemetrexed-induced TS expression.	Sirolimus	68-77	thymidylate synthetase	Homo sapiens	108-110
24658085-7	2014	In vivo, the combination of rapamycin and pemetrexed inhibited growth of NSCLC xenografts, which correlated with decreased mTOR activity and suppression of pemetrexed-induced TS expression.	Sirolimus	28-37	thymidylate synthetase	Homo sapiens	175-177
24658085-8	2014	The ability of rapamycin to enhance the efficacy of pemetrexed and prevent TS expression has implications for the design of Phase I and/or Phase II NSCLC clinical trials with mTOR inhibitors in combination with pemetrexed.	Sirolimus	15-24	thymidylate synthetase	Homo sapiens	75-77
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	autophagy and beclin 1 regulator 1	Homo sapiens	35-41
24514902-9	2014	Expression of the activated EGOC GTPase subunits Gtr1(GTP) and Gtr2(GDP) partially suppressed vps-c mutant rapamycin recovery defects, and this suppression was enhanced by increased amino acid concentrations.	Sirolimus	107-116	Rag GTPase GTR1	Saccharomyces cerevisiae S288C	49-58
24691473-6	2014	Treatment of those same cells used in the imatinib studies with rapamycin, an inhibitor of mTOR, resulted in elevated GPx-1 and GPx-4 protein levels independent of Bcr-Abl expression.	Sirolimus	64-73	glutathione peroxidase 4	Homo sapiens	128-133
24760501-10	2014	High rapamycin prevented an increase in SLC38A2/SNAT2 (P = 0.075) and SLC36A1/PAT1 (P &gt;= 0.06) mRNA abundance whereas both rapamycin doses prevented an increase in SLC7A5/LAT1 (P &gt;= 0.902) mRNA abundance.	Sirolimus	5-14	solute carrier family 36 member 1	Homo sapiens	70-77
24760501-10	2014	High rapamycin prevented an increase in SLC38A2/SNAT2 (P = 0.075) and SLC36A1/PAT1 (P &gt;= 0.06) mRNA abundance whereas both rapamycin doses prevented an increase in SLC7A5/LAT1 (P &gt;= 0.902) mRNA abundance.	Sirolimus	5-14	solute carrier family 36 member 1	Homo sapiens	78-82
24508654-11	2014	Both rapamycin and cardamonin decreased the phosphorylation of mTOR and p70S6K in two kinds of transfected cells.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	72-78
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	67-72
23741975-4	2014	Combined treatment with rapamycin and IDA down-regulated Bcl-2 and Mcl-1, and inhibited the activation of phosphoinositide 3-kinase (PI3K)/mTOR and extracellular signal-related kinase (ERK).	Sirolimus	24-33	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	106-131
24462769-8	2014	In addition, chronic treatment with rapamycin, a condition known to interfere with assembly of mTORC2, reduces the interaction between Gbetagamma and mTOR and the phosphorylation of AKT; whereas overexpression of Galphai interfered with the effect of Gbetagamma as promoter of p70S6K and AKT phosphorylation.	Sirolimus	36-45	ribosomal protein S6 kinase B1	Homo sapiens	277-283
23910624-10	2014	S1P1 alone increased CD4+ T (p &lt; 0.01) and Treg cells (p &lt; 0.01; n = 5) in the cervical and mesenteric lymph nodes compared with the controls and S1P1 + rapamycin (p &lt; 0.05; n = 5).	Sirolimus	159-168	sphingosine-1-phosphate receptor 1	Mus musculus	0-4
23949159-0	2014	Contrasting effects of chronic, systemic treatment with mTOR inhibitors rapamycin and metformin on adult neural progenitors in mice.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Mus musculus	56-60
23949159-2	2014	Rapamycin is a pharmacological inhibitor of mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	44-48
23949159-4	2014	Here we report the effects of chronic and systemic administration of the two mTOR inhibitors, rapamycin and metformin, on adult neural stem cells of the subventricular region and the dendate gyrus of the mouse hippocampus.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Mus musculus	77-81
23081885-4	2014	Then, we show that Tsc2 shRNA knockdown (KD) in mouse neural progenitor cells (mNPCs) in vitro results in enhanced mTORC1 (phospho-S6, phospho-4E-BP1) and mTORC2 (phospho-Akt and phospho-NDRG1) signaling, as well as a doubling of cell size that is rescued by rapamycin, an mTORC1 inhibitor.	Sirolimus	259-268	TSC complex subunit 2	Mus musculus	19-23
23081885-5	2014	Tsc2 KD in vivo in the fetal mouse brain by in utero electroporation causes disorganized cortical lamination and increased cell volume that is prevented with rapamycin.	Sirolimus	158-167	TSC complex subunit 2	Mus musculus	0-4
24101677-7	2014	On the contrary, G4 KO mice as well as WT mice treated with the mTOR inhibitor rapamycin developed worse adriamycin-induced nephropathy than WT mice, consistent with the fact that adriamycin toxicity is augmented by mTOR inhibition.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	64-68
24101677-7	2014	On the contrary, G4 KO mice as well as WT mice treated with the mTOR inhibitor rapamycin developed worse adriamycin-induced nephropathy than WT mice, consistent with the fact that adriamycin toxicity is augmented by mTOR inhibition.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Mus musculus	216-220
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	autophagy and beclin 1 regulator 1	Homo sapiens	72-78
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	autophagy and beclin 1 regulator 1	Homo sapiens	72-78
24586612-4	2014	In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway.	Sirolimus	53-62	ribosomal protein S6 kinase B1	Rattus norvegicus	167-176
24586612-4	2014	In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway.	Sirolimus	53-62	ribosomal protein S6 kinase B1	Rattus norvegicus	178-182
24371138-2	2014	Because mTOR inhibition with rapamycin protects against ischemia/reperfusion injury, we hypothesized that rapamycin would prevent cardiac dysfunction associated with type 2 diabetes (T2D).	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	8-12
23682161-4	2014	Rapamycin feeding significantly reduced mTOR activity in most but not all tissues.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	40-44
24481314-4	2014	Increased mTOR signaling is associated with accelerated aging; in accordance with that, treatment with the mTORC1 inhibitor rapamycin increased lifespan of Bmal1-/- mice by 50%.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Mus musculus	10-14
24481314-4	2014	Increased mTOR signaling is associated with accelerated aging; in accordance with that, treatment with the mTORC1 inhibitor rapamycin increased lifespan of Bmal1-/- mice by 50%.	Sirolimus	124-133	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	156-161
24076964-0	2014	Regulation of matrix metalloproteinase-1, -3, and -9 in Mycobacterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI3K/p70(S6K) cascade.	Sirolimus	121-130	ribosomal protein S6 kinase B1	Homo sapiens	146-153
24076964-11	2014	In summary, blockade of the proximal PI3K catalytic subunit increases MMP-1 and MMP-9, whereas rapamycin decreased both MMP-1 and MMP-3.	Sirolimus	95-104	matrix metallopeptidase 1	Homo sapiens	120-125
24292708-4	2014	Here, we tested the hypothesis that aptamer-targeted siRNA inhibition of mTOR complex 1 (mTORC1) function in CD8(+) T cells can enhance their differentiation into memory T cells and potentiate antitumor immunity more effectively than the pharmacologic inhibitor rapamycin.	Sirolimus	262-271	mechanistic target of rapamycin kinase	Mus musculus	73-77
24587596-0	2014	Rapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation.	Sirolimus	0-9	sestrin 1	Homo sapiens	84-92
24587596-6	2014	Rapamycin attenuated LSS induced reactive oxygen species (ROS) and reactive nitrogen species (RNS) production via prohibition of sestrin1 downregulation.	Sirolimus	0-9	sestrin 1	Homo sapiens	129-137
24164895-5	2014	The mTOR inhibitor rapamycin was identified as a possible modulator, and it inhibited the mTOR-dependent phosphorylation of Mint3 that is required for FIH-1 inhibition.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
24164895-5	2014	The mTOR inhibitor rapamycin was identified as a possible modulator, and it inhibited the mTOR-dependent phosphorylation of Mint3 that is required for FIH-1 inhibition.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	90-94
24164895-5	2014	The mTOR inhibitor rapamycin was identified as a possible modulator, and it inhibited the mTOR-dependent phosphorylation of Mint3 that is required for FIH-1 inhibition.	Sirolimus	19-28	hypoxia-inducible factor 1, alpha subunit inhibitor	Mus musculus	151-156
24420861-5	2014	Moreover, the in vivo administration of the specific mTOR inhibitor, rapamycin inhibited lymphangiogenesis independent of MCs in PLN rather than in the skin.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Mus musculus	53-57
25379560-10	2014	Independently from the ConA concentration, inhibition of CD25 and CD95 expression was highest preoperatively for sirolimus and on POD-3 for cyclosporine.	Sirolimus	113-122	Fas cell surface death receptor	Homo sapiens	66-70
25379560-11	2014	At all time points, inhibition of CD25 and CD95 expression was significantly higher after cyclosporine compared to sirolimus treatment (P &lt; 0.001).	Sirolimus	115-124	Fas cell surface death receptor	Homo sapiens	43-47
23994018-4	2013	Rapamycin, an inhibitor of mTORC1, suppressed ghrelin-induced phosphorylation of hypothalamic S6K1 and increased food intake and insulin in rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	94-98
24312548-3	2013	Pharmacologic mTOR inhibition by rapamycin attenuated adverse cardiac remodeling and dysfunction in experimental heart failure (HF).	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	14-18
24312548-13	2013	Rapamycin treatment decreased mTOR mediated regulators of protein synthesis and increased mTOR mediated regulators of autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	30-34
24312548-13	2013	Rapamycin treatment decreased mTOR mediated regulators of protein synthesis and increased mTOR mediated regulators of autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	90-94
23968562-6	2013	Finally, rapamycin treatment of TLR-7-activated PDC enhanced their capacity to induce CD4(+) forkhead box protein 3 (FoxP3)(+) regulatory T cells, but did not affect the generation of suppressive CD8(+) CD38(+) lymphocyte activation gene (LAG)-3(+)  Treg .	Sirolimus	9-18	stathmin 1	Homo sapiens	239-242
24371138-2	2014	Because mTOR inhibition with rapamycin protects against ischemia/reperfusion injury, we hypothesized that rapamycin would prevent cardiac dysfunction associated with type 2 diabetes (T2D).	Sirolimus	106-115	mechanistic target of rapamycin kinase	Mus musculus	8-12
24520418-10	2014	CSF2 significantly stimulated pTr cell proliferation and, U0126, rapamycin and LY294002 blocked this CSF2-induced proliferation of pTr cells.	Sirolimus	65-74	colony stimulating factor 2	Homo sapiens	101-105
24129405-11	2014	A cohort of mice was treated prenatally with mTOR inhibitor rapamycin.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Mus musculus	45-49
24092377-2	2014	Inhibition of mTOR with rapamycin has the potential to promote long-term hematopoiesis of ex vivo expanded HSCs to facilitate the clinical application of HSC transplantation for various hematologic diseases.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Mus musculus	14-18
24092377-8	2014	CONCLUSIONS: These findings suggest that mTOR plays an important role in the regulation of HSC self-renewal in vitro and inhibition of mTOR hyperactivation with rapamycin may represent a novel approach to promote ex vivo expansion and their long-term hematopoietic reconstitution of HSCs.	Sirolimus	161-170	mechanistic target of rapamycin kinase	Mus musculus	135-139
24404143-10	2014	Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	73-100
24575309-9	2014	Since ranolazine is a documented P-GP and CYP3A inhibitor, and sirolimus a known substrate for both pathways, it is proposed that ranolazine inhibition of P-GP and CYP3A4 contributed to the significant elevation in sirolimus exposure.	Sirolimus	63-72	phosphoglycolate phosphatase	Homo sapiens	155-159
24575309-9	2014	Since ranolazine is a documented P-GP and CYP3A inhibitor, and sirolimus a known substrate for both pathways, it is proposed that ranolazine inhibition of P-GP and CYP3A4 contributed to the significant elevation in sirolimus exposure.	Sirolimus	215-224	phosphoglycolate phosphatase	Homo sapiens	155-159
25116350-10	2014	Finally, we found that combined treatment with SAHA and rapamycin down-regulated p21 and enhanced apoptosis in AML cells.	Sirolimus	56-65	H3 histone pseudogene 16	Homo sapiens	81-84
24164828-1	2013	Sirolimus is used in heart transplant patients with CAV and CNI-induced nephropathy.	Sirolimus	0-9	caveolin 2	Homo sapiens	52-55
24126911-5	2013	Rapamycin treatment led to phosphorylation of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cyclic AMP-responsive elements on the Mkp-1 promoter.	Sirolimus	0-9	HNF1 homeobox A	Mus musculus	52-74
25116350-13	2014	In addition, rapamycin may be an effective agent to override p21-mediated resistance to SAHA in AML patients.	Sirolimus	13-22	H3 histone pseudogene 16	Homo sapiens	61-64
23714121-8	2013	Initially, a screening assay for model drug encapsulation in ELP nanoparticles was developed, which showed that Rose Bengal and Rapa have high non-specific encapsulation in the core of ELP nanoparticles with a sequence where Xaa=Ile or Phe.	Sirolimus	128-132	nuclear receptor subfamily 5 group A member 1	Homo sapiens	61-64
24389203-4	2014	Treatment with rapamycin significantly reduced the expression of DC-SIGN in a dose-dependent manner associated with suppression of PU.1 gene expression and the ability of DC to migrate and stimulate T cell proliferation.	Sirolimus	15-24	Spi-1 proto-oncogene	Homo sapiens	131-135
23714121-8	2013	Initially, a screening assay for model drug encapsulation in ELP nanoparticles was developed, which showed that Rose Bengal and Rapa have high non-specific encapsulation in the core of ELP nanoparticles with a sequence where Xaa=Ile or Phe.	Sirolimus	128-132	nuclear receptor subfamily 5 group A member 1	Homo sapiens	185-188
24741640-7	2014	Rapamycin induced iTreg cells showed a stronger CD39/Runx1 expression with the enhanced suppressive function.	Sirolimus	0-9	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	48-52
23989449-3	2013	In higher plants, FKBP12 protein lost its function to bind rapamycin and FK506.	Sirolimus	59-68	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	18-24
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	toll like receptor 4	Homo sapiens	243-248
24741640-7	2014	Rapamycin induced iTreg cells showed a stronger CD39/Runx1 expression with the enhanced suppressive function.	Sirolimus	0-9	RUNX family transcription factor 1	Homo sapiens	53-58
23580240-9	2013	While Mcl-1 protein levels remained unchanged after coculture with rapamycin, they were down-regulated in NVP-BEZ235 treated cells.	Sirolimus	67-76	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	6-11
24741640-9	2014	We conclude that rapamycin favors CD39/Runx1 expression in human iTreg and provides a novel insight into the mechanisms of iTreg generation enhanced by rapamycin.	Sirolimus	17-26	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	34-38
24741640-9	2014	We conclude that rapamycin favors CD39/Runx1 expression in human iTreg and provides a novel insight into the mechanisms of iTreg generation enhanced by rapamycin.	Sirolimus	17-26	RUNX family transcription factor 1	Homo sapiens	39-44
24124380-11	2013	In vitro treatment with rapamycin, RAD001, and AZD8055 reduced cell growth, cell migration, and phospho-p70S6K expression significantly in G-415 and TGBC-2TKB cancer cells (P &lt; 0.001).	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	104-110
23887639-0	2013	Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-alpha activation and disruption of the p120-vascular endothelial cadherin interaction.	Sirolimus	0-9	catenin (cadherin associated protein), delta 1	Mus musculus	120-124
23928863-0	2013	Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into smooth muscle cells via epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signaling pathway.	Sirolimus	0-9	catenin beta 1	Homo sapiens	181-193
23928863-8	2013	Mechanistically, we showed that sirolimus-induced progenitor-SMC differentiation was mediated via epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 activation that lead to beta-catenin nuclear translocation.	Sirolimus	32-41	catenin beta 1	Homo sapiens	201-213
24239965-7	2014	Administration of rapamycin, but not NAC, during early recovery phase improves WT HSC numbers but decreases PGC-1alpha(-/-) HSC numbers.	Sirolimus	18-27	PPARG coactivator 1 alpha	Sus scrofa	108-118
23928863-9	2013	The ablation of epidermal growth factor receptor, extracellular signal-regulated kinase 1/2, or beta-catenin attenuated sirolimus-induced SM-22alpha promoter activation and SMC differentiation.	Sirolimus	120-129	catenin beta 1	Homo sapiens	96-108
23928863-10	2013	CONCLUSIONS: These findings provide direct evidence of sirolimus-induced progenitor cell migration and differentiation into SMC via CXCR4 and epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signal pathways, thus implicating a novel mechanism of restenosis formation after sirolimus-eluting stent treatment.	Sirolimus	55-64	catenin beta 1	Homo sapiens	213-225
24239466-3	2014	RESULTS: A high concentration of rapamycin (10 muM) blocked both S6K1 and elF4E phosphorylation and inhibited cell proliferation in T24 and 5637 cells.	Sirolimus	33-42	ribosomal protein S6 kinase B1	Homo sapiens	65-69
24239466-5	2014	Cells silenced for S6K1 or elF4E expression exhibited significantly reduced cell migration and invasion compared with those of the control but inhibition of both S6K1 and elF4E phosphorylation by rapamycin reduced cell migration and invasion more than siRNA transfection against S6K1 or elF4E in 5637 and T24 cells.	Sirolimus	196-205	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24239466-5	2014	Cells silenced for S6K1 or elF4E expression exhibited significantly reduced cell migration and invasion compared with those of the control but inhibition of both S6K1 and elF4E phosphorylation by rapamycin reduced cell migration and invasion more than siRNA transfection against S6K1 or elF4E in 5637 and T24 cells.	Sirolimus	196-205	ribosomal protein S6 kinase B1	Homo sapiens	162-166
24231806-3	2013	We found that rapamycin, a specific inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway, robustly enhances survival and attenuates disease progression in a mouse model of Leigh syndrome.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	53-84
24231806-3	2013	We found that rapamycin, a specific inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway, robustly enhances survival and attenuates disease progression in a mouse model of Leigh syndrome.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Mus musculus	86-90
24068000-7	2013	After treatment with rapamycin or mTOR siRNA, the activity of the mTOR pathway was blocked.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Mus musculus	66-70
24778131-3	2013	Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	28-32
23974086-0	2013	Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.	Sirolimus	52-61	peroxisome proliferator activated receptor alpha	Homo sapiens	33-38
24244418-3	2013	As little as 30 min of RPM exposure resulted in increased expression of several genes responsible for cell motility, structure and integrity (beta-actin); control of cell growth, cell proliferation, cell differentiation and apoptosis (TGF-beta1, osteopontin); and cytoskeletal components such as microtubules (beta-tubulin) and intermediate filaments (vimentin).	Sirolimus	23-26	secreted phosphoprotein 1	Homo sapiens	246-257
24244418-3	2013	As little as 30 min of RPM exposure resulted in increased expression of several genes responsible for cell motility, structure and integrity (beta-actin); control of cell growth, cell proliferation, cell differentiation and apoptosis (TGF-beta1, osteopontin); and cytoskeletal components such as microtubules (beta-tubulin) and intermediate filaments (vimentin).	Sirolimus	23-26	vimentin	Homo sapiens	352-360
24244418-4	2013	After 4 hours of RPM exposure disruptions in the vimentin network were detected.	Sirolimus	17-20	vimentin	Homo sapiens	49-57
24076274-5	2013	injection of RAPA, a time sufficient for the drug to diffuse to CA1 pyramidal neurons, as demonstrated by MALDI-TOF-TOF imaging.	Sirolimus	13-17	carbonic anhydrase 1	Rattus norvegicus	64-67
23884148-9	2013	Medullary levels of p-GSK3beta were increased in the renal medullas of lithium-treated mice and remained elevated following rapamycin treatment.	Sirolimus	124-133	glycogen synthase kinase 3 beta	Mus musculus	22-30
23580240-0	2013	Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.	Sirolimus	72-81	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	122-127
24124460-5	2013	Chemopreventive experiments using mTOR inhibitor-rapamycin treatment significantly delayed the onset of the ASCC tumors and reduced the tumor burden in 2cKO mice by decreasing the phosphorylation of Akt and S6.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	34-38
23948070-8	2013	The active form of the mTOR signaling pathway (p-mTOR, p-4EBP1 and p-p70S6k) at the spinal level remarkably increased in CCI mice, and rapamycin could inhibit this up-regulation.	Sirolimus	135-144	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	69-75
23799424-0	2013	Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin.	Sirolimus	174-183	CD8a molecule	Homo sapiens	25-28
23963659-10	2013	Suppression of mTORC1 activity was sufficient for sorafenib to hinder glucose utilization in breast cancer cells, as demonstrated by the observation that the mTORC1 inhibitor rapamycin induced a comparable down-regulation of GLUT-1 expression and glucose uptake.	Sirolimus	175-184	solute carrier family 2 member 1	Homo sapiens	225-231
23839034-6	2013	Translational activity is reduced in S6K1-knockout mice following single injection of rapamycin, demonstrating that rapamycin"s effects on translation can occur independently of S6K1.	Sirolimus	86-95	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	37-41
23813776-0	2013	Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	15-36
23585690-8	2013	Rapamycin-induced inhibition of mammalian/mechanistic target of rapamycin complex 1 (mTORC1), a mediator of the feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased cytoplasmic FAS enzyme activity, and increased PPARalpha target gene expression.	Sirolimus	0-9	fatty acid synthase	Homo sapiens	166-169
23585690-8	2013	Rapamycin-induced inhibition of mammalian/mechanistic target of rapamycin complex 1 (mTORC1), a mediator of the feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased cytoplasmic FAS enzyme activity, and increased PPARalpha target gene expression.	Sirolimus	0-9	fatty acid synthase	Homo sapiens	209-212
23466691-7	2013	Finally, ethanol self-administration was assessed in rats administered with either memantine or ketamine but pretreated with the mTOR inhibitor rapamycin (2.5mg/kg).	Sirolimus	144-153	mechanistic target of rapamycin kinase	Rattus norvegicus	129-133
23466691-10	2013	The mTOR inhibitor rapamycin blocked the effects of ketamine, but not those of memantine.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
23092918-4	2013	Here, we investigated for the first time, the effect of some treatment schedules (i.e. early chronic, sub-chronic and acute) with the specific mTOR inhibitor rapamycin, on the development of absence seizures and seizure parameters as well as depressive-like behavior in WAG/Rij rats, a genetic model of absence epilepsy, epileptogenesis and mild-depression comorbidity.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Rattus norvegicus	143-147
23699517-8	2013	Inhibition of mTOR with rapamycin reduced axon sprouting.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
23403511-4	2013	By employing an OSA cell line MG-63, we investigated how rapamycin regulates the phosphorylation of CREB (pCREB) at Ser133 and the expressions of two putative CREB targets, B-cell lymphoma 2 (Bcl-2) and vascular endothelial growth factor-A (VEGF-A).	Sirolimus	57-66	cAMP responsive element binding protein 1	Homo sapiens	100-104
23403511-4	2013	By employing an OSA cell line MG-63, we investigated how rapamycin regulates the phosphorylation of CREB (pCREB) at Ser133 and the expressions of two putative CREB targets, B-cell lymphoma 2 (Bcl-2) and vascular endothelial growth factor-A (VEGF-A).	Sirolimus	57-66	cAMP responsive element binding protein 1	Homo sapiens	107-111
23334408-5	2013	The CL316,243-induced activation of p70(S6K) was markedly inhibited by wortmannin, a PI3K inhibitor, and rapamycin, a specific inhibitor of mTOR, suggesting a critical involvement of the PI3K-mTOR-p70(S6K) signaling cascade in the anabolic response of L6 cells to beta3-AR agonist.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Rattus norvegicus	140-144
22684415-0	2013	Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	23-27
22684415-12	2013	The rapamycin group showed significantly decreased CVF (1.87 +- 0.45), accompanied with a significant decrease in mTOR and p70S6K mRNA expression (0.42 +- 0.05 and 0.45 +- 0.04) relative to the Adriamycin group.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Rattus norvegicus	114-118
23948070-9	2013	The increased expression of PSD95 and the interaction ratio of GluA2-PSD95 or NR2B-PSD95 could also be inhibited by intrathecal injection of rapamycin.	Sirolimus	141-150	discs large MAGUK scaffold protein 4	Mus musculus	28-33
23948070-9	2013	The increased expression of PSD95 and the interaction ratio of GluA2-PSD95 or NR2B-PSD95 could also be inhibited by intrathecal injection of rapamycin.	Sirolimus	141-150	discs large MAGUK scaffold protein 4	Mus musculus	69-74
23948070-9	2013	The increased expression of PSD95 and the interaction ratio of GluA2-PSD95 or NR2B-PSD95 could also be inhibited by intrathecal injection of rapamycin.	Sirolimus	141-150	discs large MAGUK scaffold protein 4	Mus musculus	69-74
23108404-5	2013	The endoplasmic reticulum Ca(2+) sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin.	Sirolimus	161-170	TSC complex subunit 2	Homo sapiens	100-104
23991087-4	2013	We found that CD4(+) T cells that were co-stimulated and polarized with TGF-beta and IL-4 in the presence or absence of rapamycin each yielded effector cells of Th9 phenotype that secreted increased IL-9 and expressed a transcription factor profile characteristic of both Th9 and Th2 cells (high GATA-3/low T-bet).	Sirolimus	120-129	CD4 antigen	Mus musculus	14-17
23991087-5	2013	Augmentation of T cell replete allografts with manufactured rapamycin resistant Th9 cells markedly reduced both CD4(+) and CD8(+) T cell engraftment and strongly inhibited allo-specific T cell secretion of IFN-gamma.	Sirolimus	60-69	CD4 antigen	Mus musculus	112-115
23831578-4	2013	Here we show that the rapamycin-induced increase in eIF4E phosphorylation reflects increased activity of Mnk2 but not Mnk1.	Sirolimus	22-31	MAPK interacting serine/threonine kinase 2	Homo sapiens	105-109
23524376-13	2013	Interestingly, rapamycin negated high fat diet-induced/APN-deficiency-accentuated obesity, cardiac hypertrophy and contractile dysfunction as well as AMPK dephosphorylation, mTOR phosphorylation and p62 buildup.	Sirolimus	15-24	nucleoporin 62	Mus musculus	199-202
23748432-4	2013	Focus formation by Eno2p was inhibited temperature independently by the addition of cycloheximide or rapamycin or by the single substitution of alanine for the Val22 residue.	Sirolimus	101-110	phosphopyruvate hydratase ENO2	Saccharomyces cerevisiae S288C	19-24
23010541-12	2013	Rapamycin enhanced podocyte NF-kappaB and CREB activities but then it decreased AP-1 binding activity.	Sirolimus	0-9	cAMP responsive element binding protein 1	Homo sapiens	42-46
23222894-6	2013	Rapamycin, but not tacrolimus, induced a pro-antitumor phenotypic shift from CD62LCD44 effector memory Tc cells to CD62LCD44 central memory Tc cells, which featured up-regulated levels of T-bet and Eomes and preserved levels of interferon-gamma and perforin.	Sirolimus	0-9	T-box 21	Mus musculus	188-193
23852509-5	2013	Control and streptozotocin-induced diabetic rats were treated with the mTOR inhibitor rapamycin (0.2 mg/day) by oral gavage for 14 days, after which mitochondria function was investigated using high-resolution respirometry.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Rattus norvegicus	71-75
22983163-7	2013	The assay was validated by performing dose-response testing of rapamycin and cyclosporine A, which had previously been reported to inhibit IL-17, and determining, for the first time, their in vitro potencies (IC(50)s of 80 +- 23 pM and 223 +- 52 nM, respectively).	Sirolimus	63-72	interleukin 17A	Homo sapiens	139-144
23902989-3	2013	Expression of slow-twitch MHC isoforms was significantly increased in BO-rats with/without RAPA treatment, compared with controls, but the magnitude of the increase was much smaller in RAPA-treated BO-rats.	Sirolimus	91-95	major histocompatibility complex, class I, C	Homo sapiens	26-29
23536771-9	2013	Rapamycin decreased the SE-induced mTOR activation and attenuated microgliosis which was mostly localized within the CA1 area.	Sirolimus	0-9	carbonic anhydrase 1	Homo sapiens	117-120
23349887-9	2013	In protocol 1, both rapamycin and dexamethasone suppressed goblet cells and total CD4(+) T cells including activated, effector, and regulatory T cells in the lung tissue, with no effect on AHR or total inflammatory cell numbers in the bronchoalveolar lavage fluid.	Sirolimus	20-29	CD4 antigen	Mus musculus	82-85
23476113-8	2013	Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro.	Sirolimus	13-22	vascular endothelial growth factor A	Mus musculus	117-121
22823145-6	2012	Tissue histopathology demonstrated an overall reduction in lymphocyte interstitium infiltration, vascular obstruction and hemorrhage in mice treated with MyD88 and TRIF siRNA vector plus rapamycin.	Sirolimus	187-196	toll-like receptor adaptor molecule 2	Mus musculus	164-168
22285179-5	2012	Most importantly, treating subcutaneous HUH6 xenograft tumour bearing mice orally with 5mg/kg/day rapamycin for three weeks resulted in a striking reduction of tumour growth, as evidenced by reduced volume and weight, and moderately lowered tumour-specific alpha-fetoprotein (AFP) serum levels.	Sirolimus	98-107	alpha fetoprotein	Mus musculus	257-274
22285179-5	2012	Most importantly, treating subcutaneous HUH6 xenograft tumour bearing mice orally with 5mg/kg/day rapamycin for three weeks resulted in a striking reduction of tumour growth, as evidenced by reduced volume and weight, and moderately lowered tumour-specific alpha-fetoprotein (AFP) serum levels.	Sirolimus	98-107	alpha fetoprotein	Mus musculus	276-279
22842983-7	2012	We then assessed whether inhibiting SGK1 activity added to rapamycin-mediated cell growth inhibition by either using the SGK1 inhibitor GSK650394A or expressing an SGK1 shRNA.	Sirolimus	59-68	serum/glucocorticoid regulated kinase 1	Homo sapiens	36-40
22842983-8	2012	We observed sensitivity to rapamycin-mediated growth inhibition and inactivation of insulin-mediated SGK1-Ser422 phosphorylation in ERalpha+ MCF-7 and T47D cells, but not in ERalpha- MDA-MB-231 or MCF10A-Myc cells.	Sirolimus	27-36	serum/glucocorticoid regulated kinase 1	Homo sapiens	101-105
22842983-9	2012	In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin.	Sirolimus	127-136	serum/glucocorticoid regulated kinase 1	Homo sapiens	30-34
22842983-9	2012	In addition, either depleting SGK1 with shRNA or inhibiting SGK1 with GSK650394A preferentially sensitized MDA-MB-231 cells to rapamycin.	Sirolimus	127-136	serum/glucocorticoid regulated kinase 1	Homo sapiens	60-64
22842983-11	2012	Therefore, targeting SGK1 activity may improve the efficacy of rapamycin and its analogs in the treatment of ERalpha- breast cancer.	Sirolimus	63-72	serum/glucocorticoid regulated kinase 1	Homo sapiens	21-25
22696593-0	2012	Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.	Sirolimus	47-56	KRAS proto-oncogene, GTPase	Homo sapiens	99-103
22696593-7	2012	CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib.	Sirolimus	86-95	KRAS proto-oncogene, GTPase	Homo sapiens	26-30
22696593-7	2012	CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib.	Sirolimus	173-182	KRAS proto-oncogene, GTPase	Homo sapiens	26-30
22696593-9	2012	We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA.	Sirolimus	65-74	KRAS proto-oncogene, GTPase	Homo sapiens	168-172
22696593-10	2012	The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations.	Sirolimus	57-66	KRAS proto-oncogene, GTPase	Homo sapiens	186-190
22785114-5	2012	Rapamycin efficacy was monitored measuring p70 phosphorylation in peripheral blood mononuclear cells.	Sirolimus	0-9	annexin A6	Homo sapiens	43-46
22785114-6	2012	RESULTS: Both rapamycin doses significantly reduced p70 phosphorylation.	Sirolimus	14-23	annexin A6	Homo sapiens	52-55
22891340-6	2012	Expression of the inducible costimulator (ICOS) is increased in TSC1-deficient T cells, which can be inhibited by rapamycin.	Sirolimus	114-123	inducible T cell costimulator	Homo sapiens	18-40
22891340-6	2012	Expression of the inducible costimulator (ICOS) is increased in TSC1-deficient T cells, which can be inhibited by rapamycin.	Sirolimus	114-123	inducible T cell costimulator	Homo sapiens	42-46
22828505-8	2012	Furthermore, we found that the activity of the pathway as well as the expression of VEGF, a target of mTOR-induced signaling, were reduced within glomeruli of mice following treatment with rapamycin.	Sirolimus	189-198	vascular endothelial growth factor A	Mus musculus	84-88
22329629-0	2012	Mao-B elevation decreases parkin"s ability to efficiently clear damaged mitochondria: protective effects of rapamycin.	Sirolimus	108-117	monoamine oxidase B	Homo sapiens	0-5
22316670-0	2012	Rapamycin induces heme oxygenase-1 in liver but inhibits bile flow recovery after ischemia.	Sirolimus	0-9	heme oxygenase 1	Rattus norvegicus	18-34
22316670-2	2012	The aim was to investigate whether rapamycin can induce HO-1 expression in the liver, and to test the effects of rapamycin on liver function in the early phase of ischemia reperfusion (IR) injury.	Sirolimus	35-44	heme oxygenase 1	Rattus norvegicus	56-60
22316670-6	2012	RESULTS: In isolated hepatocytes, rapamycin induced a 6-fold increase in HO-1, comparable to that induced by cobalt proporphyrin (CoPP), and a 2-fold increase in peroxiredoxin-1.	Sirolimus	34-43	heme oxygenase 1	Rattus norvegicus	73-77
22300641-3	2012	Both unpulsed and sirolimus-pulsed Tregs (SPTs) are capable of inhibiting proliferation of multiple T cell subpopulations, including CD4(+)  and CD8(+)  T cells, as well as antigen-experienced CD28(+) CD95(+)  memory and CD28(-) CD95(+)  effector subpopulations.	Sirolimus	18-27	CD8a molecule	Homo sapiens	145-148
23480027-10	2013	Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells.	Sirolimus	16-25	interleukin 17A	Mus musculus	151-157
23775875-1	2013	Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.	Sirolimus	32-41	calcineurin binding protein 1	Homo sapiens	67-88
23775875-1	2013	Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.	Sirolimus	43-46	calcineurin binding protein 1	Homo sapiens	67-88
23313213-1	2013	PURPOSE: Previous molecular studies showed that the mTOR inhibitor rapamycin prevents bladder smooth muscle hypertrophy in vitro.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
23313213-14	2013	Rapamycin decreased the obstruction induced expression of Col1a1, Col3a1, Eln and Mmp7.	Sirolimus	0-9	elastin	Rattus norvegicus	74-77
23313213-14	2013	Rapamycin decreased the obstruction induced expression of Col1a1, Col3a1, Eln and Mmp7.	Sirolimus	0-9	matrix metallopeptidase 7	Rattus norvegicus	82-86
23705901-11	2013	CONCLUSIONS: These data comprise the first report to provide one mechanism whereby rapamycin might inhibit the cell fibrosis in kidney tumor of TSC patients.	Sirolimus	83-92	TSC complex subunit 2	Homo sapiens	144-147
23696882-12	2013	In vivo, administration with rapamycin suppressed activation of mTORC1 and JNK, but not eIF2alpha, in the kidney of Cd-treated mice.	Sirolimus	29-38	mitogen-activated protein kinase 8	Mus musculus	75-78
23667674-0	2013	Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
23667674-7	2013	These in vivo and in vitro experiments demonstrate that podocyte injury is associated with changes in autophagy levels, and that rapamycin can reduce podocyte injury by increasing autophagy levels via inhibition of the mTOR-ULK1 pathway.	Sirolimus	129-138	mechanistic target of rapamycin kinase	Rattus norvegicus	219-223
23470622-2	2013	The mTOR pathway involves two independent complexes, mTORC1 and mTORC2, which phosphorylate S6 kinase (S6K) and serine/threonine kinase (Akt), respectively, and differ in their sensitivity to rapamycin.	Sirolimus	192-201	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
23239524-8	2013	Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Rattus norvegicus	47-51
22467681-2	2012	Herein we evaluated the plasma lipid profile, triacylglycerol (TAG) secretion rates, and adipose tissue LPL-dependent lipid uptake, LPL expression/activity, and expression profile of other lipid metabolism genes in rats treated with the PPARgamma agonist rosiglitazone (15 mg/kg/day) in combination or not with the mTOR inhibitor rapamycin (2 mg/kg/day) for 15 days.	Sirolimus	330-339	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	237-246
22559167-12	2012	The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib.	Sirolimus	178-187	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	73-76
22559167-12	2012	The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib.	Sirolimus	178-187	BCL2-associated X protein	Mus musculus	115-118
22577264-9	2012	CONCLUSION: Rapamycin-induced melanin formation may be mediated through the up-regulation of TYR protein and activity.	Sirolimus	12-21	tyrosinase	Homo sapiens	93-96
22266196-4	2012	PI3 kinase inhibition by LY294002 and mTOR inhibition by rapamycin blocked the reversal of the anti-anabolic effects of TNF+IFN-treated myotubes by DAG.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Rattus norvegicus	38-42
22084394-10	2012	Rapamycin treatment also maintained cartilage cellularity and decreased ADAMTS-5 and interleukin-1beta expression in articular cartilage.	Sirolimus	0-9	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2)	Mus musculus	72-80
23239524-8	2013	Upon treatment with rapamycin, an inhibitor of mTOR, we observed a decrease in mTOR signaling, activity of transcription factors, and reduction in fatty infiltration.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Rattus norvegicus	79-83
23274896-10	2013	In conclusion, rapamycin reduces ER stress induced by accumulation of misfolded proinsulin, thereby improving diabetes and preventing beta-cell apoptosis.	Sirolimus	15-24	insulin II	Mus musculus	80-90
23250913-9	2013	Further mTORC1 inhibition with rapamycin hastened weakness, atrophy and vacuolation in VCP-IBM mice.	Sirolimus	31-40	valosin containing protein	Mus musculus	87-90
23228564-7	2013	FK506 and rapamycin reduced the association between TRPC1 and Orai1 with FK506 binding protein (52) (FKBP52) in human platelets, and between TRPC1 and the type II IP(3)R, which association is known to be crucial for the maintenance of SOCE in human platelets.	Sirolimus	10-19	transient receptor potential cation channel subfamily C member 1	Homo sapiens	52-57
23228564-7	2013	FK506 and rapamycin reduced the association between TRPC1 and Orai1 with FK506 binding protein (52) (FKBP52) in human platelets, and between TRPC1 and the type II IP(3)R, which association is known to be crucial for the maintenance of SOCE in human platelets.	Sirolimus	10-19	ORAI calcium release-activated calcium modulator 1	Homo sapiens	62-67
23228564-7	2013	FK506 and rapamycin reduced the association between TRPC1 and Orai1 with FK506 binding protein (52) (FKBP52) in human platelets, and between TRPC1 and the type II IP(3)R, which association is known to be crucial for the maintenance of SOCE in human platelets.	Sirolimus	10-19	transient receptor potential cation channel subfamily C member 1	Homo sapiens	141-146
23080369-7	2013	Rapamycin also inhibited the RB of healthy PMNs, which was associated with impaired phosphorylation of the NOX2 component, p47phox (phox: phagocyte oxidase), on its mitogen-activated protein kinase (MAPK) site (S345) as well as a preferential inhibition of p38-MAPK relative to p44/42-MAPK.	Sirolimus	0-9	cytochrome b-245 beta chain	Homo sapiens	107-111
23080369-7	2013	Rapamycin also inhibited the RB of healthy PMNs, which was associated with impaired phosphorylation of the NOX2 component, p47phox (phox: phagocyte oxidase), on its mitogen-activated protein kinase (MAPK) site (S345) as well as a preferential inhibition of p38-MAPK relative to p44/42-MAPK.	Sirolimus	0-9	neutrophil cytosolic factor 1	Homo sapiens	123-130
23402365-13	2013	In addition, the expressions of MAP1LC3A and ATG5 were higher in normal pigs than in miniature pigs both in the presence and absence of rapamycin.	Sirolimus	136-145	ATG5 autophagy related 5 homolog	Sus scrofa	45-49
22769982-0	2013	Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells.	Sirolimus	16-25	CD4 antigen	Mus musculus	105-108
22769982-10	2013	CONCLUSIONS: Pretreatment with rapamycin for 14 days before an allogenic corneal transplant enhances the percentage of CD4(+)CD25(+)Foxp3(+)Treg cells in peripheral blood, draining lymph nodes, and grafts, thereby inhibiting graft rejection.	Sirolimus	31-40	CD4 antigen	Mus musculus	119-122
23024062-13	2013	We demonstrate that rapamycin decreases cAMP accumulation and CTLA4 expression in ALI.	Sirolimus	20-29	cathelicidin antimicrobial peptide	Mus musculus	40-44
22432756-0	2012	Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	57-78
23024062-13	2013	We demonstrate that rapamycin decreases cAMP accumulation and CTLA4 expression in ALI.	Sirolimus	20-29	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	62-67
24319682-4	2013	The noncoding RNA growth arrest specific transcript 5 (GAS5) has recently been shown to play a key role in growth arrest induced by several mechanisms, including serum withdrawal and treatment with the mTOR inhibitor rapamycin.	Sirolimus	217-226	growth arrest specific 5	Homo sapiens	18-53
24319682-4	2013	The noncoding RNA growth arrest specific transcript 5 (GAS5) has recently been shown to play a key role in growth arrest induced by several mechanisms, including serum withdrawal and treatment with the mTOR inhibitor rapamycin.	Sirolimus	217-226	growth arrest specific 5	Homo sapiens	55-59
23636065-4	2013	Rapamycin, a kind of mTOR inhibitor upregulating autophagy, was given to rats weeks after the immunization at low (1 mg/kg   day i.p.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	21-25
23635649-9	2013	Both wortmannin and rapamycin inhibited isoflurane-induced phospho-4E-BP1 (Ser 65) and phospho-P70(s6k) (Thr 389) and HIF-1alpha expression.	Sirolimus	20-29	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	118-128
23555865-4	2013	The mTOR inhibitor, Rapamycin, stabilizes lung function in LAM and decreases the volume of renal angiomyolipomas, but lung function declines and angiomyolipomas regrow when treatment is discontinued, suggesting that factors induced by mTORC1 inhibition may promote the survival of TSC2-deficient cells.	Sirolimus	20-29	TSC complex subunit 2	Homo sapiens	281-285
23555865-15	2013	In conclusion, our findings demonstrate that Rapamycin upregulates multiple miRs, including pro-survival miRs, in TSC2-deficient patient-derived cells.	Sirolimus	45-54	TSC complex subunit 2	Homo sapiens	114-118
23437092-1	2013	CONTEXT: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC).	Sirolimus	166-175	vascular endothelial growth factor D	Homo sapiens	45-51
22189601-4	2012	CD4(+) T cells were cultured in the presence of rapamycin for three 7-day rounds of stimulation.	Sirolimus	48-57	CD4 antigen	Mus musculus	0-3
22189601-9	2012	With rapamycin, stimulated CD4(+) T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%.	Sirolimus	5-14	CD4 antigen	Mus musculus	27-30
22189601-12	2012	CONCLUSIONS: We demonstrated, for the first time, that CD4(+) T cells expanded with rapamycin in vitro suppressed colitis.	Sirolimus	84-93	CD4 antigen	Mus musculus	55-58
22379028-4	2012	Strikingly, a short course of high-dose, but not low-dose, rapamycin treatment transiently blocks viral vaccination-induced mammalian target of rapamycin activity in CD8(+) T cells favoring persistence and Ag-recall responses over type 1 effector maturation; however, prolonged high-dose rapamycin administration abrogated memory responses.	Sirolimus	59-68	CD8a molecule	Homo sapiens	166-169
22379028-6	2012	These results demonstrate the impact a regimen of rapamycin treatment has on vaccine-induced CD8(+) T cell responses and indicates that judicious application of rapamycin can augment vaccine efficacy for chronic challenges.	Sirolimus	50-59	CD8a molecule	Homo sapiens	93-96
22385271-9	2012	Rapamycin, besides inducing autophagy, also increased Akt and CREB (cAMP response element-binding protein) phosphorylation in the same cells.	Sirolimus	0-9	cAMP responsive element binding protein 1	Homo sapiens	62-66
22385271-9	2012	Rapamycin, besides inducing autophagy, also increased Akt and CREB (cAMP response element-binding protein) phosphorylation in the same cells.	Sirolimus	0-9	cAMP responsive element binding protein 1	Homo sapiens	68-105
22186790-3	2012	Vaccination in combination with both rapamycin (to modulate differentiation) and an OX40 agonist (to enhance costimulation) increased both the quantity and polyfunctionality of the CD8(+) memory T cell population, with expansion of the T(EM) and memory precursor populations.	Sirolimus	37-46	CD8a molecule	Homo sapiens	181-184
22320241-1	2012	Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based regimen (SMART core-study).	Sirolimus	90-99	calcineurin binding protein 1	Homo sapiens	22-43
22287548-5	2012	Rapamycin caused the monocytes to differentiate into M1 macrophages releasing more interleukin (IL)-12 and less IL-10, whereas TSC2 knockdown caused the monocytes to differentiate into M2 macrophages releasing less IL-12 and more IL-10.	Sirolimus	0-9	interleukin 10	Homo sapiens	112-117
22266730-0	2012	Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes.	Sirolimus	0-9	huntingtin	Rattus norvegicus	30-40
22266730-10	2012	Treatment with the autophagy stimulator rapamycin (0.2 mg/mL) significantly reduced the accumulation of mutant Htt-552, and reversed the changes in GLT-1 expression and [(3)H]glutamate uptake in the astrocytes.	Sirolimus	40-49	huntingtin	Rattus norvegicus	111-114
22178316-4	2012	Here we examined the effects of infusions of the mTOR inhibitor rapamycin into the BLA before or after either training or reactivation on retention of novel object recognition (NOR) memory in rats, and compared the effects with those obtained using intra-DH infusions.	Sirolimus	64-73	mechanistic target of rapamycin kinase	Rattus norvegicus	49-53
22198378-8	2012	Basal levels of the autophagosome marker LC3-II were not significantly changed, however, ATP13A2 knockdown cells exhibited decreased autophagic flux, associated with increased levels of phospho-mTOR, and resistance to autophagy induction by rapamycin.	Sirolimus	241-250	ATPase cation transporting 13A2	Homo sapiens	89-96
22227620-3	2012	Recent data from experimental models pointed to the mTOR pathway, which can be potently inhibited by rapamycin.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
22248718-6	2012	We showed that miR-376b expression attenuated starvation- and rapamycin-induced autophagy in MCF-7 and Huh-7 cells.	Sirolimus	62-71	microRNA 376b	Homo sapiens	15-23
22227188-7	2012	Two mutated residues of Tel2-13 near the N-terminus and close to Tel2-1 are sufficient for shortened telomeres whereas multiple mutations within the C-terminal two thirds of the protein are required for enhanced rapamycin lethality.	Sirolimus	212-221	Tel2p	Saccharomyces cerevisiae S288C	24-28
22178140-9	2012	Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	44-48
22178140-9	2012	Furthermore, pretreatment with rapamycin, a mTOR specific inhibitor, significantly inhibited HIF-1alpha and VEGF protein after HI.	Sirolimus	31-40	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	93-103
21929643-4	2012	Here we show that a novel, nondepleting CD40 monoclonal antibody, 3A8, can combine with combined CTLA4Ig and sirolimus in a well-established primate bone marrow chimerism-induction model.	Sirolimus	109-118	CD40 molecule	Macaca mulatta	40-44
22785354-6	2012	The Bmp15 and cyclin B mRNA levels were significantly reduced in embryos treated with rapamycin compared with the control.	Sirolimus	86-95	cyclin B1	Sus scrofa	14-22
23437092-4	2013	DESIGN AND INTERVENTION(S): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM.	Sirolimus	140-149	vascular endothelial growth factor D	Homo sapiens	34-40
21874011-4	2012	It has been demonstrated that most of these lesions are determined by mutations affecting genes of the tuberous sclerosis complex, tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2), with eventual deregulation of the RHEB/MTOR/RPS6KB2 pathway, and it has been observed that some PEComas regressed during sirolimus therapy, an MTOR inhibitor.	Sirolimus	313-322	TSC complex subunit 2	Homo sapiens	185-189
23437092-11	2013	RESULTS: At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787 +- 426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971 +- 4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p=0.013, Mann-Whitney test).	Sirolimus	109-118	vascular endothelial growth factor D	Homo sapiens	23-29
23437092-13	2013	Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed.	Sirolimus	81-90	vascular endothelial growth factor D	Homo sapiens	18-24
23272222-6	2012	Rapamycin, a mTORC1 inhibitor, restores the insulin signaling after downregulation of REDD1 expression.	Sirolimus	0-9	DNA damage inducible transcript 4	Homo sapiens	86-91
23476113-8	2013	Furthermore, rapamycin treatment reduces bone morphogenetic protein-2 (BMP2) and vascular endothelial growth factor (VEGF) gene expression and inhibits K7M2 proliferation, migration, and invasion in vitro.	Sirolimus	13-22	vascular endothelial growth factor A	Mus musculus	81-115
23127854-6	2012	Notably, rapamycin augmented the OA-induced hyperphosphorylation of Akt by suppressing a negative feedback loop of Akt activation through VEGFR2 and its downstream target phosphatidylinositol 3-kinase (PI3K).	Sirolimus	9-18	kinase insert domain receptor	Homo sapiens	138-144
22995918-11	2012	Rapamycin, an autophagy activator, decreased mut-TGFBI, whereas inhibition of autophagy increased active caspase-3, poly (ADP-ribose) polymerase 1 (PARP1) and reduced the viability of GCD2 corneal fibroblasts compared with WT controls.	Sirolimus	0-9	transforming growth factor beta induced	Homo sapiens	45-54
23159854-10	2012	An exception was observed when doxorubicin was combined with rapamycin, as doxorubicin suppressed the sensitivity of the NGAL-transduced MCF-7 cells to rapamycin when compared with the empty vector controls.	Sirolimus	61-70	lipocalin 2	Homo sapiens	121-125
23159854-10	2012	An exception was observed when doxorubicin was combined with rapamycin, as doxorubicin suppressed the sensitivity of the NGAL-transduced MCF-7 cells to rapamycin when compared with the empty vector controls.	Sirolimus	152-161	lipocalin 2	Homo sapiens	121-125
22999860-13	2012	Rapamycin triggered unique cardioprotective signaling including phosphorylation of ERK, STAT3, eNOS and glycogen synthase kinase-3ss in concert with increased prosurvival Bcl-2 to Bax ratio.	Sirolimus	0-9	BCL2-associated X protein	Mus musculus	180-183
22982730-8	2012	However, after pre-treatment with rapamycin, the level of Akt phosphorylation was decreased in primary cultures of CECs but could still be restored by ALA, whereas the levels of mTOR, S6K and 4E-BP1 phosphorylation were significantly decreased and could not be restored.	Sirolimus	34-43	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	187-198
22995302-10	2012	The mTOR inhibitor, rapamycin, abolishes Sirtinol-induced inflammation and NF-kappaB activation associated with p62/Sqstm1 accumulation.	Sirolimus	20-29	sequestosome 1	Homo sapiens	112-115
22995302-10	2012	The mTOR inhibitor, rapamycin, abolishes Sirtinol-induced inflammation and NF-kappaB activation associated with p62/Sqstm1 accumulation.	Sirolimus	20-29	sequestosome 1	Homo sapiens	116-122
23035046-7	2012	The combination of rapamycin and simvastatin prevented both growth of TSC2-null lesions and lung destruction by inhibiting MMP-2, MMP-3, and MMP-9.	Sirolimus	19-28	matrix metallopeptidase 2	Mus musculus	123-128
23035046-8	2012	Our findings demonstrate a mechanistic link between loss of TSC2 and alveolar destruction and suggest that treatment with rapamycin and simvastatin together could benefit patients with LAM by targeting cells with TSC2 dysfunction and preventing airspace enlargement.	Sirolimus	122-131	TSC complex subunit 2	Homo sapiens	60-64
22913509-9	2012	Spontaneous and IL-9-dependent survival and IgE-induced IL-13 secretion, but not degranulation, of BMMCs were reduced by rapamycin.	Sirolimus	121-130	interleukin 9	Mus musculus	16-20
22913509-11	2012	Inhibition of the IL-9 production-mast cell survival axis is one of the mechanisms of the therapeutic effect of rapamycin.	Sirolimus	112-121	interleukin 9	Mus musculus	18-22
22827930-7	2012	Furthermore, pharmacological targeting of mTORC1 with rapamycin also blocked LH/hCG- or forskolin-induced expression of cAMP response element-binding protein (CREB) and steroidogenic enzymes (P450 side-chain cleavage enzyme, 3beta-hydroxysteroid dehydrogenase type 1, and 17alpha-hydroxylase/17,20 lyase) but produced no effect on steroidogenic acute regulatory protein levels.	Sirolimus	54-63	cAMP responsive element binding protein 1	Homo sapiens	120-157
22827930-7	2012	Furthermore, pharmacological targeting of mTORC1 with rapamycin also blocked LH/hCG- or forskolin-induced expression of cAMP response element-binding protein (CREB) and steroidogenic enzymes (P450 side-chain cleavage enzyme, 3beta-hydroxysteroid dehydrogenase type 1, and 17alpha-hydroxylase/17,20 lyase) but produced no effect on steroidogenic acute regulatory protein levels.	Sirolimus	54-63	cAMP responsive element binding protein 1	Homo sapiens	159-163
22827930-11	2012	Chromatin immunoprecipitation assays revealed the association of CREB with the proximal promoter of the Cyp17a1 gene in response to hCG, and this association was reduced by rapamycin treatment.	Sirolimus	173-182	cAMP responsive element binding protein 1	Homo sapiens	65-69
22932872-9	2012	These changes in TDP-43 metabolism are accompanied by rapamycin-induced decreases in mTOR-regulated phospho-p70 S6 kinase (P-p70) and the p62 protein, as well as increases in the autophagic marker LC3.	Sirolimus	54-63	nucleoporin 62	Mus musculus	138-141
22647982-0	2012	Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells.	Sirolimus	117-126	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	68-71
22647982-0	2012	Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells.	Sirolimus	117-126	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	89-92
22552366-3	2012	In search of effective combination             therapies, we show here that simultaneous targeting of EGFR with its inhibitor,             erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation             and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and             extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the             inhibition of cell cycle progression and the growth of both KRAS wild-type and             mutated colorectal carcinoma cells.	Sirolimus	178-187	KRAS proto-oncogene, GTPase	Homo sapiens	472-476
22672902-6	2012	We determined that rapamycin inhibited pS6 at 100-300 pM and inhibited proliferation with IC(50) around 30 pM.	Sirolimus	19-28	taste 2 receptor member 63 pseudogene	Homo sapiens	39-42
22533814-1	2012	Drug release from and coating morphology on a CYPHER sirolimus-eluting coronary stent (SES) during in vitro elution were studied by correlated confocal Raman and atomic force microscopy (CRM and AFM, respectively).	Sirolimus	53-62	LIM domain binding 3	Homo sapiens	46-52
22848534-5	2012	Inhibition of p70S6K by rapamycin reversed these protective effects.	Sirolimus	24-33	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	14-20
22357174-1	2012	BACKGROUND: The role of sirolimus (SRL) conversion in the preservation of kidney function in liver transplant (LT) recipients with calcineurin inhibitor (CNI) nephrotoxicity is unclear.	Sirolimus	24-33	calcineurin binding protein 1	Homo sapiens	131-152
22192404-10	2011	Treatment with Rapamycin, a potent mTOR/VEGF inhibitor, dramatically suppressed IH cell growth in vitro.	Sirolimus	15-24	vascular endothelial growth factor A	Mus musculus	40-44
22015781-9	2011	Inhibition of mTOR with rapamycin reversed the down-regulation of cellular lipid efflux mediator ABCA1, which resulted from the activation of TLR4 by ligands.	Sirolimus	24-33	ATP binding cassette subfamily A member 1	Homo sapiens	97-102
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	0-9	signal transducer and activator of transcription 1	Homo sapiens	136-141
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	0-9	signal transducer and activator of transcription 1	Homo sapiens	175-180
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	111-120	signal transducer and activator of transcription 1	Homo sapiens	136-141
22450807-6	2012	Rapamycin increased lung injury and cellular apoptosis in C57BL/6J mice exposed to intratracheal LPS for 24 h. Rapamycin also augmented STAT1 activation, and the induction of STAT1-dependent genes that mediate cellular apoptosis (i.e., Fas, caspase-3).	Sirolimus	111-120	signal transducer and activator of transcription 1	Homo sapiens	175-180
22014210-0	2012	Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	8-12
22496622-0	2012	Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.	Sirolimus	0-9	fms related receptor tyrosine kinase 4	Homo sapiens	79-124
22496622-6	2012	Furthermore, we found that rapamycin inhibited protein expression of VEGF receptor 3 (VEGFR-3) by inhibiting protein synthesis and promoting protein degradation of VEGFR-3 in the cells.	Sirolimus	27-36	fms related receptor tyrosine kinase 4	Homo sapiens	69-84
22496622-6	2012	Furthermore, we found that rapamycin inhibited protein expression of VEGF receptor 3 (VEGFR-3) by inhibiting protein synthesis and promoting protein degradation of VEGFR-3 in the cells.	Sirolimus	27-36	fms related receptor tyrosine kinase 4	Homo sapiens	86-93
22496622-6	2012	Furthermore, we found that rapamycin inhibited protein expression of VEGF receptor 3 (VEGFR-3) by inhibiting protein synthesis and promoting protein degradation of VEGFR-3 in the cells.	Sirolimus	27-36	fms related receptor tyrosine kinase 4	Homo sapiens	164-171
22496622-7	2012	Down-regulation of VEGFR-3 mimicked the effect of rapamycin, inhibiting IGF-1- or FBS-stimulated tube formation, whereas over-expression of VEGFR-3 conferred high resistance to rapamycin inhibition of LEC tube formation.	Sirolimus	50-59	fms related receptor tyrosine kinase 4	Homo sapiens	19-26
22496622-7	2012	Down-regulation of VEGFR-3 mimicked the effect of rapamycin, inhibiting IGF-1- or FBS-stimulated tube formation, whereas over-expression of VEGFR-3 conferred high resistance to rapamycin inhibition of LEC tube formation.	Sirolimus	177-186	fms related receptor tyrosine kinase 4	Homo sapiens	140-147
22353714-4	2012	Global transcriptional profiling reveals that IL-17A induces artificial nutrient starvation conditions in Candida albicans, resulting in a downregulation of the target of rapamycin signalling pathway and in an increase in autophagic responses and intracellular cAMP.	Sirolimus	171-180	interleukin 17A	Homo sapiens	46-52
21874357-0	2011	Rapamycin protects against dominant negative-HNF1A-induced apoptosis in INS-1 cells.	Sirolimus	0-9	HNF1 homeobox A	Rattus norvegicus	45-50
21874357-5	2011	Here, we show that pharmacological inhibition of mTOR activity with rapamycin protected INS-1 cells against DN-HNF1A-induced apoptosis.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Rattus norvegicus	49-53
21874357-5	2011	Here, we show that pharmacological inhibition of mTOR activity with rapamycin protected INS-1 cells against DN-HNF1A-induced apoptosis.	Sirolimus	68-77	HNF1 homeobox A	Rattus norvegicus	108-116
21874357-6	2011	Rapamycin also prevented DN-HNF1A-induced activation of AMP-activated protein kinase (AMPK), an intracellular energy sensor which we have previously shown to mediate DN-HNF1A-induced apoptosis.	Sirolimus	0-9	HNF1 homeobox A	Rattus norvegicus	25-33
21874357-6	2011	Rapamycin also prevented DN-HNF1A-induced activation of AMP-activated protein kinase (AMPK), an intracellular energy sensor which we have previously shown to mediate DN-HNF1A-induced apoptosis.	Sirolimus	0-9	HNF1 homeobox A	Rattus norvegicus	166-174
21965746-6	2011	Administration of rapamycin was significantly cytotoxic to the ERas-overexpressing clones compared with the control (p&lt;0.01).	Sirolimus	18-27	ES cell expressed Ras	Homo sapiens	63-67
22177999-11	2012	Rapamycin and AZD8055 significantly reduced the level and expression of mTOR, P70S6K1, 4E-BP1 and PCNA (p&lt;0.05).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Canis lupus familiaris	72-76
22177999-11	2012	Rapamycin and AZD8055 significantly reduced the level and expression of mTOR, P70S6K1, 4E-BP1 and PCNA (p&lt;0.05).	Sirolimus	0-9	proliferating cell nuclear antigen	Canis lupus familiaris	98-102
21906027-3	2012	In mice, administration of rapamycin effectively suppressed S6K activation in the heart and significantly improved cardiac function after MI.	Sirolimus	27-36	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	60-63
22428038-0	2012	Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.	Sirolimus	99-108	platelet derived growth factor receptor beta	Rattus norvegicus	50-59
22428038-8	2012	CONCLUSIONS: Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.	Sirolimus	136-145	platelet derived growth factor receptor beta	Rattus norvegicus	63-72
22428038-8	2012	CONCLUSIONS: Activation of PI3K/AKT and MAPK pathway through a PDGFRbeta-dependent feedback loop compromises the anti-tumor activity of rapamycin in HCC, and blockade of this feedback loop by sorafenib is an attractive approach to improve the anti-tumor effect of rapamycin, particularly in preventing or treating HCC recurrence after liver transplantation.	Sirolimus	264-273	platelet derived growth factor receptor beta	Rattus norvegicus	63-72
21880834-6	2011	Use of a TGF-beta(1)-blocking antibody or blockage of TGF-beta(1) receptor kinase activity with SD208 prevented the CsA- and CsA/SRL-induced increase in TER.	Sirolimus	129-132	chorionic somatomammotropin hormone 1	Homo sapiens	116-128
20828737-9	2011	Pretreatment with rapamycin, a specific inhibitor of mTOR, resulted in a significant decrease of IL-10 and IL-6 translation and expression but did not affect the LPS-induced TNFalpha production.	Sirolimus	18-27	interleukin 10	Homo sapiens	97-102
20560106-12	2010	Phenylephrine increased the expression of TR alpha 1 in nucleus and this response was abrogated in the case of mTOR inhibition by rapamycin.	Sirolimus	130-139	mechanistic target of rapamycin kinase	Rattus norvegicus	111-115
21646862-7	2011	The autophagy contributing to apoptosis was Beclin 1-independent, as shown by the fact that Beclin 1 knockdown failed to reduce it but efficiently reduced rapamycin-induced autophagy.	Sirolimus	155-164	beclin 1	Homo sapiens	92-100
21836511-0	2011	De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.	Sirolimus	58-67	calcineurin binding protein 1	Homo sapiens	8-29
21530413-3	2011	Recently, understanding the neurobiology of hamartin and tuberin in the development of epilepsy and cognitive impairment associated with tuberous sclerosis complex allowed the development of sirolimus and everolimus to be used in human clinical trials.	Sirolimus	191-200	TSC complex subunit 2	Homo sapiens	57-64
21630275-4	2011	Amino acid transporters such as LAT1 and ASCT2 are upregulated in human cancer cells and are thought to stimulate tumor growth by regulating mammalian target of rapamycin through nutrient pathway.	Sirolimus	161-170	solute carrier family 1 member 5	Homo sapiens	41-46
32157856-3	2020	mTOR inhibitor Sirolimus has been used in hyperinsulinemic hypoglycemia that was unresponsive to other medical treatment.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Homo sapiens	0-4
32157856-14	2020	Sirolimus treatment, by mTOR inhibition, appeared to be effectively controlling the peristent hypoglycemia and could be a lifesaving tool for these kind of disorders.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Homo sapiens	24-28
23266287-8	2013	The inhibition of GSK-3beta phosphorylation and mTOR was achieved with LY294002 and rapamycin, respectively.	Sirolimus	84-93	glycogen synthase kinase 3 beta	Homo sapiens	18-27
23856247-6	2013	The malignant properties induced by miR-205 in NSCLC cells were reversed by AKT inhibitors, FOXO3a overexpression, rapamycin treatment, or restoring PHLPP2 or PTEN expression.	Sirolimus	115-124	microRNA 205	Homo sapiens	36-43
23843608-3	2013	Loss of either the Tsc1 or Tsc2 gene in ISCs causes rapid ISC loss through TORC1 hyperactivation, because ISCs can be efficiently rescued by mutation of S6k or by rapamycin treatment.	Sirolimus	163-172	Tsc1	Drosophila melanogaster	19-23
23843608-3	2013	Loss of either the Tsc1 or Tsc2 gene in ISCs causes rapid ISC loss through TORC1 hyperactivation, because ISCs can be efficiently rescued by mutation of S6k or by rapamycin treatment.	Sirolimus	163-172	gigas	Drosophila melanogaster	27-31
23913957-7	2013	Rapamycin treatment in vivo blocked the IL-4 production and necrosis of DN T cells, increased the expression of FOXP3 in CD25(+)/CD4(+) T cells, and expanded CD25(+)/CD19(+) B cells.	Sirolimus	0-9	forkhead box P3	Homo sapiens	112-117
23820898-10	2013	Myometrial proliferation and mTORC1/S6 activity were abrogated by the mTORC1 inhibitor rapamycin or by elimination of sex steroid production through ovariectomy or aromatase inhibition.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	29-35
23820898-10	2013	Myometrial proliferation and mTORC1/S6 activity were abrogated by the mTORC1 inhibitor rapamycin or by elimination of sex steroid production through ovariectomy or aromatase inhibition.	Sirolimus	87-96	CREB regulated transcription coactivator 1	Mus musculus	70-76
23827786-5	2013	Rapamycin, known as mTOR inhibitor, was used to inhibit the activation of mTOR, which prevented effectively high glucose-induced SREBP-1 up-regulation and lipogenesis in HKC cells.	Sirolimus	0-9	sterol regulatory element binding transcription factor 1	Rattus norvegicus	129-136
23832089-6	2013	Conversely, Notch gain of function causes fatty liver through constitutive activation of mTorc1, an effect that is reversible by treatment with rapamycin.	Sirolimus	144-153	CREB regulated transcription coactivator 1	Mus musculus	89-95
24252673-12	2013	CONCLUSIONS: Sirolimus can downregulate IL-2 expression and upregulate FoxP3 and IL-10 expression, thereby stimulating FoxP3+ Treg cells, suppressing immunopathological damage, and promoting epithelial repair in bile ducts.	Sirolimus	13-22	forkhead box P3	Homo sapiens	71-76
24252673-12	2013	CONCLUSIONS: Sirolimus can downregulate IL-2 expression and upregulate FoxP3 and IL-10 expression, thereby stimulating FoxP3+ Treg cells, suppressing immunopathological damage, and promoting epithelial repair in bile ducts.	Sirolimus	13-22	forkhead box P3	Homo sapiens	119-124
23744068-5	2013	Refeeding after starvation with a standard mouse chow rapidly suppressed autophagy in both tissues, and this suppression was inhibited by rapamycin administration almost completely in the liver and partially in muscle, confirming that mTORC1 is indeed a crucial regulator in vivo.	Sirolimus	138-147	CREB regulated transcription coactivator 1	Mus musculus	235-241
23520131-9	2013	The inflammatory responses in SNRK knockdown adipocytes can be partially attributable to defective mTORC1 signaling, since rapamycin treatment activates IKKbeta and induces lipolysis in adipocytes.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	99-105
23826334-5	2013	Wild type levels of tunicamycin sensitivity were restored in iph1 null cells when the TORC1 complex was inhibited by rapamycin or by heat inactivation of the Tor2 kinase.	Sirolimus	117-126	CREB regulated transcription coactivator 1	Homo sapiens	86-91
23855221-3	2013	The MILES trial has successfully demonstrated that sirolimus, a mTORC1 inhibitor, can stabilize pulmonary function in LAM, but its effect disappears once sirolimus is discontinued.	Sirolimus	51-60	CREB regulated transcription coactivator 1	Mus musculus	64-70
23855221-4	2013	Limited ability of sirolimus may be due to concomitant activation of autophagy in LAM cells when mTORC1 activity is suppressed by sirolimus.	Sirolimus	19-28	CREB regulated transcription coactivator 1	Mus musculus	97-103
23855221-4	2013	Limited ability of sirolimus may be due to concomitant activation of autophagy in LAM cells when mTORC1 activity is suppressed by sirolimus.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	97-103
23723238-7	2013	In cancer cells with inactivating mutations in GATOR1, mTORC1 is hyperactive and insensitive to amino acid starvation, and such cells are hypersensitive to rapamycin, an mTORC1 inhibitor.	Sirolimus	156-165	CREB regulated transcription coactivator 1	Mus musculus	170-176
23704987-5	2013	Ptc6 mutants are sensitive to rapamycin, albeit to lesser extent than ptc1 cells.	Sirolimus	30-39	type 2C protein phosphatase PTC6	Saccharomyces cerevisiae S288C	0-4
23696882-2	2013	We found that rapamycin, an inhibitor of mTORC1, attenuated Cd-induced apoptosis in renal tubular cells.	Sirolimus	14-23	CREB regulated transcription coactivator 1	Mus musculus	41-47
23443316-0	2013	Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.	Sirolimus	44-53	SMAD family member 4	Homo sapiens	83-88
23616120-0	2013	Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder.	Sirolimus	0-9	STE20 related adaptor alpha	Homo sapiens	47-53
23616120-3	2013	We show that disrupted pathfinding in migrating mouse neural progenitor cells in vitro caused by STRADA depletion is prevented by mTORC1 inhibition with rapamycin or inhibition of its downstream effector p70 S6 kinase (p70S6K) with the drug PF-4708671 (p70S6Ki).	Sirolimus	153-162	STE20-related kinase adaptor alpha	Mus musculus	97-103
23616120-3	2013	We show that disrupted pathfinding in migrating mouse neural progenitor cells in vitro caused by STRADA depletion is prevented by mTORC1 inhibition with rapamycin or inhibition of its downstream effector p70 S6 kinase (p70S6K) with the drug PF-4708671 (p70S6Ki).	Sirolimus	153-162	CREB regulated transcription coactivator 1	Mus musculus	130-136
23616120-6	2013	On the basis of these preclinical findings, we treated five PMSE patients with sirolimus (rapamycin) without complication and observed a reduction in seizure frequency and an improvement in receptive language.	Sirolimus	79-88	STE20 related adaptor alpha	Homo sapiens	60-64
23616120-6	2013	On the basis of these preclinical findings, we treated five PMSE patients with sirolimus (rapamycin) without complication and observed a reduction in seizure frequency and an improvement in receptive language.	Sirolimus	90-99	STE20 related adaptor alpha	Homo sapiens	60-64
29588746-9	2013	Based on the data collected in animal experiments and preliminary data in humans with BiOSS Lim, releasing sirolimus from the surface of the biodegradable coating, one may presume that this version will provide even better clinical results compared with the paclitaxel one.	Sirolimus	107-116	PDZ and LIM domain 5	Homo sapiens	92-95
23121022-4	2013	Proteins with reported chaperone-like activity were overrepresented among proteins up-regulated in rapamycin-fed PDAPP mice and the master regulator of the heat-shock response, heat-shock factor 1, was activated.	Sirolimus	99-108	heat shock factor 1	Mus musculus	177-196
23121022-7	2013	The effects of rapamycin on the reduction of Abeta, up-regulation of chaperones, and amelioration of AD-like cognitive deficits were recapitulated by transgenic over-expression of heat-shock factor 1 in PDAPP mice.	Sirolimus	15-24	heat shock factor 1	Mus musculus	180-199
23283642-0	2013	Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.	Sirolimus	91-100	regulatory associated protein of MTOR complex 1	Homo sapiens	28-34
23283642-7	2013	Perillyl alcohol or rapamycin caused rapid dissociation of the captured hTERT-mTOR-RAPTOR complex, establishing an additional mechanism by which these agents decrease telomerase activity.	Sirolimus	20-29	regulatory associated protein of MTOR complex 1	Homo sapiens	83-89
23261705-4	2013	Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	Sirolimus	42-51	ribosomal protein S6	Homo sapiens	111-115
23261705-6	2013	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin.	Sirolimus	150-159	cyclin dependent kinase 4	Homo sapiens	108-112
23265586-12	2013	Inactivation of mTOR downstream signaling by rapamycin treatment inhibited S6K phosphorylation and abolished the stimulatory effect of IS on GLUT1 expression.	Sirolimus	45-54	solute carrier family 2 member 1	Rattus norvegicus	141-146
23452608-4	2013	mTORC1 is sensitive to rapamycin (also known as sirolimus), a drug prescribed in case of organ transplantation (kidney) due to its immunosuppressive and anti-proliferative properties.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Mus musculus	0-6
23452608-4	2013	mTORC1 is sensitive to rapamycin (also known as sirolimus), a drug prescribed in case of organ transplantation (kidney) due to its immunosuppressive and anti-proliferative properties.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Mus musculus	0-6
23223314-5	2013	RESULTS: Six-month post conversion to sirolimus FOXP3(+) CD127(low)CD25(high)CD69(-), the number of T cells (putative Treg) increased significantly (P = 0.008).	Sirolimus	38-47	forkhead box P3	Homo sapiens	48-53
23273915-7	2013	Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	55-61
23273915-7	2013	Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	184-190
23184930-7	2013	Alteration of the alphacap significantly diminished the response of Ure2 dephosphorylation to the TorC1 inhibitor, rapamycin.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Homo sapiens	98-103
23184942-3	2013	mTORC1, which is directly inhibited by rapamycin, promotes cell growth by stimulating protein synthesis and inhibiting autophagy.	Sirolimus	39-48	CREB regulated transcription coactivator 1	Mus musculus	0-6
23117620-4	2013	The dephosphorylating activity of ferulic acid was almost comparable to that of rapamycin, an established mTor inhibitor (TORC1).	Sirolimus	80-89	CREB regulated transcription coactivator 1	Homo sapiens	122-127
23278901-6	2013	Finally, in a pharmacological challenge in vivo using the specific mTORC1 inhibitor, rapamycin, hair cycle initiation was delayed, suggesting a functional relevance of mTORC1 in anagen entry.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	67-73
23278901-6	2013	Finally, in a pharmacological challenge in vivo using the specific mTORC1 inhibitor, rapamycin, hair cycle initiation was delayed, suggesting a functional relevance of mTORC1 in anagen entry.	Sirolimus	85-94	CREB regulated transcription coactivator 1	Mus musculus	168-174
22959478-1	2013	UNLABELLED: Administration of the mTORC1 inhibitor, rapamycin, to humans blocks the increase in skeletal muscle protein synthesis in response to resistance exercise or amino acid ingestion.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	34-40
23565163-3	2013	The phosphorylation is inhibited by rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) in complex with raptor (mTORC1).	Sirolimus	36-45	regulatory associated protein of MTOR complex 1	Homo sapiens	124-130
23565163-3	2013	The phosphorylation is inhibited by rapamycin, a specific inhibitor of mammalian target of rapamycin (mTOR) in complex with raptor (mTORC1).	Sirolimus	36-45	CREB regulated transcription coactivator 1	Mus musculus	132-138
23437362-4	2013	Here, we demonstrate that treatment of PANC-1 or MiaPaCa-2 pancreatic cancer cells with either rapamycin or active-site mTOR inhibitors suppressed S6K and S6 phosphorylation induced by insulin and the GPCR agonist neurotensin.	Sirolimus	95-104	G protein-coupled receptor 166 pseudogene	Homo sapiens	201-205
23335988-9	2013	In addition, rapamycin, a specific mTORC1 inhibitor, effectively rescued the phenotype caused by increased mTORC1 activity in the Tsc1(cko) ovaries.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	35-41
23335988-9	2013	In addition, rapamycin, a specific mTORC1 inhibitor, effectively rescued the phenotype caused by increased mTORC1 activity in the Tsc1(cko) ovaries.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	107-113
23335988-9	2013	In addition, rapamycin, a specific mTORC1 inhibitor, effectively rescued the phenotype caused by increased mTORC1 activity in the Tsc1(cko) ovaries.	Sirolimus	13-22	TSC complex subunit 1	Mus musculus	130-134
23344033-6	2012	MDC staining showed that the fluorescent density was higher and the number of MDC-labeled particles in PC-2 cells was greater in the Rapa treatment group than in the control group.	Sirolimus	133-137	C-C motif chemokine ligand 22	Homo sapiens	0-3
23344033-6	2012	MDC staining showed that the fluorescent density was higher and the number of MDC-labeled particles in PC-2 cells was greater in the Rapa treatment group than in the control group.	Sirolimus	133-137	C-C motif chemokine ligand 22	Homo sapiens	78-81
23053656-8	2012	Subsequent studies revealed that NDGA may also direct target mTORC1 complex because NDGA suppressed amino acids- and insulin-stimulated mTORC1 and acted like rapamycin to disrupt mTOR-Raptor interaction.	Sirolimus	158-167	CREB regulated transcription coactivator 1	Mus musculus	61-67
22307455-5	2012	We further hypothesized that combining p-XSC with rapamycin, an mTORC1 inhibitor, would be an effective combinatory strategy for the inhibition of prostate cancer.	Sirolimus	50-59	CREB regulated transcription coactivator 1	Mus musculus	64-70
22672579-12	2012	Surprisingly, rapamycin decreased lifespan in sod1 mutant but not wild-type males fed the standard, HS-LP, and low-calorie diets, whereas antioxidant N-acetylcysteine only increased lifespan in sod1 mutant males fed the HS-LP diet, when compared to diet-matched controls.	Sirolimus	14-23	Superoxide dismutase 1	Drosophila melanogaster	46-50
22863900-0	2012	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.	Sirolimus	15-24	regulatory associated protein of MTOR complex 1	Homo sapiens	63-69
23369601-4	2012	RAPA-DC are generated through inhibition of the integrative kinase mammalian target of rapamycin (mTOR) by the immunosuppressive macrolide rapamycin during propagation of monocyte-derived DC.	Sirolimus	87-96	transcriptional regulating factor 1	Homo sapiens	0-4
22884327-0	2012	Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons.	Sirolimus	0-9	pro-opiomelanocortin-alpha	Mus musculus	101-105
22837538-5	2012	Pharmacologic reversal                     of elevated mTORC1 signaling by rapamycin improves cardiac and skeletal muscle                     function and enhances survival in mice lacking A-type lamins.	Sirolimus	75-84	CREB regulated transcription coactivator 1	Mus musculus	55-61
22837538-7	2012	In addition,                     inhibition of mTORC1 signaling with rapamycin improves defective                     autophagic-mediated degradation in                         Lmna(-/-) mice.	Sirolimus	69-78	CREB regulated transcription coactivator 1	Mus musculus	47-53
24358826-1	2012	The recent development of mammalian target of rapamycin (mTOR) kinase domain inhibitors and genetic dissection of rapamycin-sensitive and -insensitive mTOR protein complexes (mTORC1 and mTORC2) have revealed that phosphorylation of the mTOR substrate 4E-BP1 on amino acids Thr37 and/or Thr46 represents a rapamycin-insensitive activity of mTORC1.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	339-345
22532572-3	2012	Hamartin and tuberin form a heterodimer that inhibits the mammalian target of rapamycin complex 1 (mTORC1) kinase, a major cellular regulator of protein translation, cell growth and proliferation.	Sirolimus	78-87	CREB regulated transcription coactivator 1	Mus musculus	99-105
22532572-4	2012	Hyperactivated mTORC1 signaling, an important feature of TSC, has prompted a number of preclinical and clinical studies with the mTORC1 inhibitor rapamycin.	Sirolimus	146-155	CREB regulated transcription coactivator 1	Mus musculus	15-21
22532572-4	2012	Hyperactivated mTORC1 signaling, an important feature of TSC, has prompted a number of preclinical and clinical studies with the mTORC1 inhibitor rapamycin.	Sirolimus	146-155	CREB regulated transcription coactivator 1	Mus musculus	129-135
22519596-11	2012	Rapamycin, an inhibitor of mTORC1, significantly reversed the suppressive effects of eIF2alpha on NF-kappaB.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	27-33
22391948-9	2012	Rapamycin significantly increased the levels of plasma acylated ghrelin in normal C57BL/6J mice, high-fat-diet-induced obese mice and db/db mice.	Sirolimus	0-9	ghrelin	Mus musculus	64-71
21826653-7	2012	Conversely, the effect of T(3) on SREBP-1 level was enhanced by using rapamycin, mTOR-C1 inhibitor.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	81-88
22758368-1	2012	Treatment with rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) can increase mammalian life span.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	83-89
22758368-4	2012	Adenosine monophosphate kinase (AMPK) agonists such as metformin, which inhibits gluconeogenesis by downregulating expression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, might be expected to block the glucose dysmetabolism mediated by rapamycin.	Sirolimus	255-264	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	129-150
22428559-4	2012	Rapamycin inhibits some mTORC1 functions, whereas mTOR-KIs (mTOR kinase inhibitors) interfere with all of them.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	24-30
22560223-5	2012	Rapamycin triggers a similar protective response in C. elegans and mice, but increases worm life span dependent upon SKN-1 and not DAF-16, apparently by interfering with TORC2 along with TORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	170-175
22560223-5	2012	Rapamycin triggers a similar protective response in C. elegans and mice, but increases worm life span dependent upon SKN-1 and not DAF-16, apparently by interfering with TORC2 along with TORC1.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	187-192
22314813-0	2012	Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2).	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	107-113
22314813-7	2012	Although rapamycin acutely inhibited mTOR complex 1 (mTORC1), the toxic effects of rapamycin were more closely correlated to the dissociation and inactivation of mTORC2 and the inhibition of PKB.	Sirolimus	9-18	CREB regulated transcription coactivator 1	Mus musculus	53-59
22314813-7	2012	Although rapamycin acutely inhibited mTOR complex 1 (mTORC1), the toxic effects of rapamycin were more closely correlated to the dissociation and inactivation of mTORC2 and the inhibition of PKB.	Sirolimus	83-92	CREB regulated transcription coactivator 2	Mus musculus	162-168
22314813-9	2012	Moreover, the selective inactivation of mTORC2 using siRNA directed towards rapamycin-insensitive companion of target of rapamycin (RICTOR), mimicked the toxic effects of chronic rapamycin treatment.	Sirolimus	76-85	CREB regulated transcription coactivator 2	Mus musculus	40-46
22314813-10	2012	CONCLUSIONS/INTERPRETATION: This report provides evidence that rapamycin toxicity is mediated by the inactivation of mTORC2 and the inhibition of PKB and thus reveals the molecular basis of rapamycin toxicity and the essential role of mTORC2 in maintaining beta cell function and survival.	Sirolimus	63-72	CREB regulated transcription coactivator 2	Mus musculus	117-123
22314813-10	2012	CONCLUSIONS/INTERPRETATION: This report provides evidence that rapamycin toxicity is mediated by the inactivation of mTORC2 and the inhibition of PKB and thus reveals the molecular basis of rapamycin toxicity and the essential role of mTORC2 in maintaining beta cell function and survival.	Sirolimus	63-72	CREB regulated transcription coactivator 2	Mus musculus	235-241
22314813-10	2012	CONCLUSIONS/INTERPRETATION: This report provides evidence that rapamycin toxicity is mediated by the inactivation of mTORC2 and the inhibition of PKB and thus reveals the molecular basis of rapamycin toxicity and the essential role of mTORC2 in maintaining beta cell function and survival.	Sirolimus	190-199	CREB regulated transcription coactivator 2	Mus musculus	117-123
22227406-11	2012	Rapamycin, a specific inhibitor of mammalian TOR signaling attenuated PTTH-stimulated phosphorylation of 4E-BP and S6K of the glands, and greatly inhibited PTTH-stimulated ecdysteroidogenesis.	Sirolimus	0-9	prothoracicotropic hormone	Bombyx mori	70-74
22227406-11	2012	Rapamycin, a specific inhibitor of mammalian TOR signaling attenuated PTTH-stimulated phosphorylation of 4E-BP and S6K of the glands, and greatly inhibited PTTH-stimulated ecdysteroidogenesis.	Sirolimus	0-9	prothoracicotropic hormone	Bombyx mori	156-160
22445487-6	2012	Rapamycin and caffeine also induce Rho1 activation.	Sirolimus	0-9	Rho family GTPase RHO1	Saccharomyces cerevisiae S288C	35-39
22457328-2	2012	By assembling with unique and shared partner proteins, mTOR forms the catalytic core of at least two complexes, mTOR complex 1 (mTORC1) and mTORC2, that show differential sensitivity to the allosteric mTOR inhibitor rapamycin and that phosphorylate distinct substrates to modulate cell growth, proliferation, survival, and metabolism in response to diverse environmental cues.	Sirolimus	216-225	CREB regulated transcription coactivator 1	Mus musculus	128-134
22457328-2	2012	By assembling with unique and shared partner proteins, mTOR forms the catalytic core of at least two complexes, mTOR complex 1 (mTORC1) and mTORC2, that show differential sensitivity to the allosteric mTOR inhibitor rapamycin and that phosphorylate distinct substrates to modulate cell growth, proliferation, survival, and metabolism in response to diverse environmental cues.	Sirolimus	216-225	CREB regulated transcription coactivator 2	Mus musculus	140-146
22121221-3	2012	We used a new non-radioactive labeling approach to study the effects of rapamycin, an inhibitor of mTORC1, on rRNA synthesis.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	99-105
22675606-7	2012	The leucine-induced stimulation of protein synthesis and S6K1 and 4E-BP1 phosphorylation were completely blocked by rapamycin, suggesting that leucine action is by an mTORC1-dependent mechanism.	Sirolimus	116-125	CREB regulated transcription coactivator 1	Mus musculus	167-173
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	69-78	caspase 3	Rattus norvegicus	304-313
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	183-192	caspase 3	Rattus norvegicus	42-51
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	183-192	caspase 3	Rattus norvegicus	304-313
22070140-5	2012	Treatment with the specific mTORC1 [mTOR (mammalian target of rapamycin) complex 1] inhibitor rapamycin or siRNA (small interfering RNA) knockdown of mTOR destabilized the ODC mRNA, but rapamycin had only a minor effect on ODC translation initiation.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	28-34
21779001-3	2012	Among three major branches of the unfolded protein response, rapamycin selectively suppressed the IRE1-JNK signaling without affecting PERK and ATF6 pathways.	Sirolimus	61-70	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	98-102
22089244-3	2012	We identified a profound FOXP3(+) regulatory T cell defect that coincided with hyperinflammatory T cell responses which were reversible with rapamycin in vitro.	Sirolimus	141-150	forkhead box P3	Homo sapiens	25-30
22863860-3	2012	The effects of OA on mTORC1 activation, cell proliferation, and cell-cycle progression to S and G2/M phases were completely reversed by rapamycin.	Sirolimus	136-145	CREB regulated transcription coactivator 1	Mus musculus	21-27
22125063-6	2012	Moreover, the mTORC2 complex components rictor and sin1 are dephosphorylated and dynamically distributed between the cytoplasm and the nucleus upon long-term treatment with the mTOR-inhibitor rapamycin.	Sirolimus	192-201	CREB regulated transcription coactivator 2	Mus musculus	14-20
22389629-10	2012	Magnetization-based screening of gene knockouts identified Tco89p, a component of TORC1 (Target of rapamycin complex 1), as important for magnetization; loss of TCO89 and treatment with rapamycin reduced magnetization in a TCO89-dependent manner.	Sirolimus	99-108	Tco89p	Saccharomyces cerevisiae S288C	59-65
22389629-10	2012	Magnetization-based screening of gene knockouts identified Tco89p, a component of TORC1 (Target of rapamycin complex 1), as important for magnetization; loss of TCO89 and treatment with rapamycin reduced magnetization in a TCO89-dependent manner.	Sirolimus	99-108	Tco89p	Saccharomyces cerevisiae S288C	161-166
22916036-4	2012	Treatment with rapamycin, an inhibitor of mTORC1 activity, decreased tumor burden in adult Lkb1 mutant mice.	Sirolimus	15-24	CREB regulated transcription coactivator 1	Mus musculus	42-48
23272152-9	2012	mTORC1 activity was sensitive to LY294002 and rapamycin or transfection of cells with GRP78 dsRNA.	Sirolimus	46-55	CREB regulated transcription coactivator 1	Mus musculus	0-6
22470459-7	2012	In vitro study confirmed that rapamycin significantly inhibited the fibrogenic activation of cultured fibroblasts (NIH3T3 cells), which was induced by the stimulation of TGF-beta(1).	Sirolimus	30-39	transforming growth factor, beta 1	Mus musculus	170-181
22363765-6	2012	Results were compared to vehicle treatment and treatment with the mTORC1 inhibitor rapamycin for 1 month.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	66-72
23461035-4	2012	Induction of senescence closely correlates with the activation of the complex mTORC1, as it was shown by inhibiting mTORC1 with rapamycin.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	78-84
23461035-4	2012	Induction of senescence closely correlates with the activation of the complex mTORC1, as it was shown by inhibiting mTORC1 with rapamycin.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	116-122
21890496-4	2011	These observations have led us to examine the benefit of prenatal rapamycin in a new fetal brain model of TSC.	Sirolimus	66-75	TSC complex subunit 1	Mus musculus	106-109
21890496-10	2011	These observations demonstrate the therapeutic benefit and limitations of prenatal rapamycin in a prenatal-onset brain model of TSC.	Sirolimus	83-92	TSC complex subunit 1	Mus musculus	128-131
21911485-1	2011	A variety of mechanisms confer hypersensitivity of tumor cells to the macrolide rapamycin, the prototypic mTORC1 inhibitor.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	106-112
21911485-6	2011	Here, we show that both genetic and pharmacologic inhibition of SAPK2/p38 in glioblastoma multiforme cells significantly reduces rapamycin-induced IRES-mediated translation initiation of cyclin D1 and c-MYC, resulting in increased G(1) arrest in vitro and inhibition of tumor growth in xenografts.	Sirolimus	129-138	mitogen-activated protein kinase 14	Mus musculus	70-73
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Sirolimus	142-151	protein tyrosine kinase 2	Homo sapiens	89-92
22071574-5	2011	We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1).	Sirolimus	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	151-182
22071574-10	2011	This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E.	Sirolimus	48-57	regulatory associated protein of MTOR complex 1	Homo sapiens	100-106
22071574-10	2011	This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E.	Sirolimus	48-57	CREB regulated transcription coactivator 1	Mus musculus	112-118
22071574-10	2011	This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E.	Sirolimus	48-57	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
21973019-2	2011	Recent studies in such models revealed that inhibiting mTORC1 with rapamycin effectively suppressed seizure activity.	Sirolimus	67-76	CREB regulated transcription coactivator 1	Mus musculus	55-61
21945951-8	2011	Furthermore, p53 activation by AICAR was blocked by rapamycin, a specific inhibitor of the mTOR kinase, which is a crucial regulator of cell growth.	Sirolimus	52-61	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	31-36
21625955-5	2011	Rapamycin-treated mice showed lower birth weight, lower body weight, and liver growth retardation in a pattern similar to that observed in the hypoxic mice at P30.	Sirolimus	0-9	high mobility group box 1	Mus musculus	159-162
22028687-9	2011	Finally, administration of rapamycin, a drug which blocks mTORC1, results in a strong reduction of LID.	Sirolimus	27-36	CREB regulated transcription coactivator 1	Mus musculus	58-64
21806543-3	2011	Rapamycin selectively targets mTORC1 function, and the emergence of specific ATP-competitive kinase inhibitors has enabled assessment of dual mTORC1 and mTORC2 blockade.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	30-36
21949366-6	2011	As exposure to rapamycin disrupts GLP-1 effects on beta cell viability, these results demonstrate how a pathway associated with tumor growth also mediates salutary effects of an incretin hormone on pancreatic islet function.	Sirolimus	15-24	glucagon like peptide 1 receptor	Homo sapiens	34-39
21862237-0	2011	mTORC1 activity as a determinant of cancer risk--rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets.	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	0-6
22338143-10	2011	The mRNA expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were significantly lower than that in control group (P &lt; 0.05).	Sirolimus	41-50	peroxisome proliferator activated receptor gamma	Mus musculus	24-33
22338143-10	2011	The mRNA expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were significantly lower than that in control group (P &lt; 0.05).	Sirolimus	68-77	peroxisome proliferator activated receptor gamma	Mus musculus	24-33
22338143-10	2011	The mRNA expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were significantly lower than that in control group (P &lt; 0.05).	Sirolimus	68-77	peroxisome proliferator activated receptor gamma	Mus musculus	24-33
22338143-11	2011	The protein expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were 80%, 74%, and 61% of that in control group (P &lt; 0.05).	Sirolimus	44-53	peroxisome proliferator activated receptor gamma	Mus musculus	27-36
22338143-11	2011	The protein expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were 80%, 74%, and 61% of that in control group (P &lt; 0.05).	Sirolimus	71-80	peroxisome proliferator activated receptor gamma	Mus musculus	27-36
22338143-11	2011	The protein expressions of PPARgamma in the rapamycin 50 nmol/L group, rapamycin 100 nmol/L group, and rapamycin 200 nmol/L group were 80%, 74%, and 61% of that in control group (P &lt; 0.05).	Sirolimus	71-80	peroxisome proliferator activated receptor gamma	Mus musculus	27-36
22338143-15	2011	CONCLUSIONS: By downregulating the expression of PPARgamma, rapamycin can decrease cholesterol accumulation in 3T3-L1 cells and inhibit its leptin-secreting capability.	Sirolimus	60-69	peroxisome proliferator activated receptor gamma	Mus musculus	49-58
21785113-3	2011	mTORC1 activity is sensitive to the selective inhibitor rapamycin, whereas mTORC2 is resistant.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	0-6
21984149-9	2011	The combination of IDA with rapamycin enhanced the expressions of Caspase 3, PARP, Caspase 8 and Caspase 9.	Sirolimus	28-37	collagen type XI alpha 2 chain	Homo sapiens	77-81
21984149-9	2011	The combination of IDA with rapamycin enhanced the expressions of Caspase 3, PARP, Caspase 8 and Caspase 9.	Sirolimus	28-37	caspase 8	Homo sapiens	83-92
21806970-3	2011	We have now shown that medium rich in branched-chain amino acids stimulates expression of the SREBP1c gene in cultured hepatocytes in a manner sensitive both to rapamycin, a pharmacological inhibitor of mTORC1, and to a short hairpin RNA (shRNA) specific for S6 kinase 1 (S6K1), a downstream effector of mTORC1.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	304-310
21538345-5	2011	Following activation, CXCR3-expressing CD4(+) Tregs were maintained in vitro in cell culture in the presence of the mammalian target of rapamycin (mTOR) inhibitor rapamycin, and we detected higher numbers of circulating CXCR3(+) FOXP3(+) T cells in adult and pediatric recipients of renal transplants who were treated with mTOR-inhibitor immunosuppressive therapy.	Sirolimus	136-145	C-X-C motif chemokine receptor 3	Homo sapiens	22-27
21585650-0	2011	Induction of tolerance to factor VIII by transient co-administration with rapamycin.	Sirolimus	74-83	coagulation factor VIII	Mus musculus	26-37
21508335-4	2011	Here, we demonstrate that the inhibition of mTORC1 by rapamycin (mTORC1 inhibitor), torin1 (both mTORC1 and mTORC2 inhibitor) or short hairpin RNA-mediated knockdown of mTOR, regulatory associated protein of mTOR (RAPTOR), and p70 S6 kinase (p70S6K) increased basal NT release via upregulating NT gene expression in BON cells.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	44-50
20686837-0	2011	Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.	Sirolimus	0-9	tumor protein p73	Homo sapiens	102-105
20686837-7	2011	We further showed that the synergistic effect of rapamycin plus cisplatin on basal-like breast cancer cells was mediated through the induction of p73.	Sirolimus	49-58	tumor protein p73	Homo sapiens	146-149
21733825-3	2011	Rapamycin, an established mTORC1 inhibitor, was used to further explore the role of mTORC1 signaling in epithelial carcinogenesis, specifically during the tumor promotion stage.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	26-32
21733825-9	2011	Overall, the data indicate that rapamycin is a potent inhibitor of skin tumor promotion and suggest that signaling through mTORC1 contributes significantly to the process of skin tumor promotion.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	123-129
21415215-8	2011	Inhibition of the mTOR catalytic site with OSI-027 results in suppression of both mTORC2 and RI-mTORC1 complexes and elicits much more potent antileukemic responses than selective mTORC1 targeting with rapamycin.	Sirolimus	202-211	CREB regulated transcription coactivator 1	Mus musculus	180-186
21561413-2	2011	mTOR complex 1 (mTORC1) is potently inhibited by the immunosupressive macrolide rapamycin; whereas, mTORC2 is insensitive to this durg.	Sirolimus	80-89	CREB regulated transcription coactivator 1	Mus musculus	16-22
21576371-7	2011	Importantly, nonefficacious concentrations of an ATP-competitive mTOR inhibitor can be combined with rapamycin to synergistically inhibit mTORC1 and activate autophagy but leave mTORC2 signaling intact.	Sirolimus	101-110	CREB regulated transcription coactivator 2	Mus musculus	178-184
21419848-3	2011	These proteins form a heterodimer that inhibits the mammalian target of rapamycin complex 1 (mTORC1) pathway, controlling translation and cell growth.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	93-99
21419848-10	2011	The cell death and ER stress phenotypes were rescued by treatment with the mTORC1 inhibitor rapamycin.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	75-81
21525000-4	2011	Short rapamycin treatment specifically inhibiting mTORC1 suppressed p70 but not p85 phosphorylation, suggesting that p85 might be directly activated by phosphatidic acid.	Sirolimus	6-15	CREB regulated transcription coactivator 1	Mus musculus	50-56
21525172-3	2011	This study investigated the efficacy and safety of the mTORC1 inhibitor sirolimus for treatment of renal angiomyolipomas in patients with these disorders.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	55-61
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	leptin	Oryctolagus cuniculus	52-58
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	leptin	Oryctolagus cuniculus	107-113
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	147-153
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	CREB regulated transcription coactivator 1	Mus musculus	171-177
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	leptin	Oryctolagus cuniculus	107-113
21472771-9	2011	Mutant GBA-induced SNCA accumulation could be pharmacologically reversed in D409V-expressing PC12-SNCA cells by rapamycin, an autophagy-inducer (<=40%; 10muM; p < 0.02).	Sirolimus	112-121	glucosylceramidase beta	Rattus norvegicus	7-10
21073857-4	2011	Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells.	Sirolimus	0-9	epidermal growth factor like 1	Rattus norvegicus	114-137
21073857-4	2011	Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells.	Sirolimus	0-9	epidermal growth factor like 1	Rattus norvegicus	139-142
21368105-5	2011	Suppression of mTORC2 signaling with siRNA rictor, or inhibition of mTORC1 signaling with rapamycin and metformin, while having little effect on other complex activities, inhibited VSM-H and chronic hypoxia-induced human and rat PAVSM cell proliferation.	Sirolimus	90-99	CREB regulated transcription coactivator 1	Mus musculus	68-74
21385891-7	2011	Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3beta hyperphosphorylation in each sarcoma model.	Sirolimus	20-29	glycogen synthase kinase 3 beta	Homo sapiens	54-84
21385891-8	2011	However, ganitumab in combination with rapamycin also resulted in a marked increase in INSR expression and activity in the SJSA-1 and A673 models.	Sirolimus	39-48	insulin receptor	Homo sapiens	87-91
21557327-4	2011	mTOR exists in two distinct complexes-mTORC1 and mTORC2 that differ in their components and sensitivity to rapamycin.	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	38-44
21557327-4	2011	mTOR exists in two distinct complexes-mTORC1 and mTORC2 that differ in their components and sensitivity to rapamycin.	Sirolimus	107-116	CREB regulated transcription coactivator 2	Mus musculus	49-55
21541789-3	2011	Sirolimus and its derivatives (rapalogs) interact with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR and thus disrupting its activity.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	82-106
21541789-3	2011	Sirolimus and its derivatives (rapalogs) interact with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR and thus disrupting its activity.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	108-114
21258412-5	2011	A careful examination of preclinical and clinical studies performed with rapamycin or derivatives thereof shows that although results are encouraging, we are only half way in the long and winding road to design rationale treatment targeted at the LKB1/AMPK/TSC/mTORC1 pathway.	Sirolimus	73-82	CREB regulated transcription coactivator 1	Mus musculus	261-267
21576264-5	2011	CPT1C expression correlates inversely with mammalian target of rapamycin (mTOR) pathway activation, contributes to rapamycin resistance in murine primary tumors, and is frequently up-regulated in human lung tumors.	Sirolimus	63-72	carnitine palmitoyltransferase 1C	Homo sapiens	0-5
21357504-8	2011	Rapamycin pretreatment also significantly increased PO-induced Akt phosphorylation at S473, a finding confirmed in cardiomyocytes in vitro to be downstream of mTORC2.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	159-165
21357504-9	2011	Analysis of prosurvival signaling in vivo showed that rapamycin increased PO-induced degradation of phosphorylated inhibitor of kappaB, enhanced expression of cellular inhibitor of apoptosis protein 1, and decreased active caspase-3.	Sirolimus	54-63	caspase 3	Rattus norvegicus	223-232
21357504-10	2011	Long-term rapamycin treatment in 2-wk PO myocardium blunted hypertrophy, improved contractile function, and reduced caspase-3 and calpain activation.	Sirolimus	10-19	caspase 3	Rattus norvegicus	116-125
21357511-8	2011	We conclude that rapamycin inhibits H2O2-induced loss of vascular contractility, likely through an mTORC2-calcineurin pathway.	Sirolimus	17-26	CREB regulated transcription coactivator 2	Mus musculus	99-105
21266843-6	2011	The allosteric mTORC1 inhibitor rapamycin fails to induce apoptosis in conjunction with blockade of autophagy, due to feedback-activation of Akt.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	15-21
21430254-4	2011	The trials were identical except during 1 trial, participants were administered a single oral dose of a potent mTORC1 inhibitor (rapamycin) prior to EAA ingestion.	Sirolimus	129-138	CREB regulated transcription coactivator 1	Mus musculus	111-117
21430254-6	2011	In contrast, prior administration of rapamycin completely blocked the increase in muscle protein synthesis and blocked or attenuated activation of mTORC1-signaling proteins.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	147-153
21331075-3	2011	However, allosteric inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL).	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	34-40
21317285-5	2011	Inhibition of TORC1 by rapamycin treatment resulted in the accumulation of stage IV melanosomes but not autophagosomes, whereas starvation resulted in the formation of autophagosomes but not melanin accumulation.	Sirolimus	23-32	CREB regulated transcription coactivator 1	Homo sapiens	14-19
21138727-3	2011	To demonstrate, we characterized the binding of polyketide ligands based on the mTOR inhibitor rapamycin to the cellular immunophilin FKBP12.	Sirolimus	95-104	FKBP prolyl isomerase 1A	Homo sapiens	121-140
21295008-0	2011	Inhibition by rapamycin of the lipoteichoic acid-induced granulocyte-colony stimulating factor expression in mouse macrophages.	Sirolimus	14-23	colony stimulating factor 3 (granulocyte)	Mus musculus	57-94
21295008-3	2011	This study investigated the effect of rapamycin on the lipoteichoic acid (LTA)-induced expression of G-CSF in macrophages and its underlying mechanism.	Sirolimus	38-47	colony stimulating factor 3 (granulocyte)	Mus musculus	101-106
21295008-4	2011	Our data show that LTA induced G-CSF expression in RAW264.7 and bone marrow-derived macrophages and that this effect was inhibited by rapamycin.	Sirolimus	134-143	colony stimulating factor 3 (granulocyte)	Mus musculus	31-36
21295008-8	2011	Moreover, forced expression of Oct-2 by transfection with the pCG-Oct-2 plasmid overcame the inhibitory effect of rapamycin on the LTA-induced increase in G-CSF mRNA levels and promoter activity.	Sirolimus	114-123	colony stimulating factor 3 (granulocyte)	Mus musculus	155-160
21240477-7	2011	Remarkably, rapamycin resistance was found to affect specifically the mTORC1/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) branch of the mTORC1 pathway in the presence of 50 mumol/l oleate.	Sirolimus	12-21	CREB regulated transcription coactivator 1	Mus musculus	70-76
21240477-7	2011	Remarkably, rapamycin resistance was found to affect specifically the mTORC1/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) branch of the mTORC1 pathway in the presence of 50 mumol/l oleate.	Sirolimus	12-21	CREB regulated transcription coactivator 1	Mus musculus	150-156
21212099-0	2011	Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.	Sirolimus	122-131	TSC complex subunit 1	Mus musculus	46-50
21612705-0	2011	[Effect of rapamycin combined with cisplatin on head and neck squamous cancer cells regulated by CCL19].	Sirolimus	11-20	C-C motif chemokine ligand 19	Homo sapiens	97-102
21612705-1	2011	OBJECTIVE: To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine (C-C motif) ligand 19 (CCL19).	Sirolimus	53-62	C-C motif chemokine ligand 19	Homo sapiens	129-160
21612705-1	2011	OBJECTIVE: To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine (C-C motif) ligand 19 (CCL19).	Sirolimus	53-62	C-C motif chemokine ligand 19	Homo sapiens	162-167
21612705-5	2011	RESULTS: Rapamycin and cisplatin could respectively increase the growth arrest, the proportion of G(1) phase and apoptosis of CCL19 induced cancer cells (P &lt; 0.05).	Sirolimus	9-18	C-C motif chemokine ligand 19	Homo sapiens	126-131
21612705-8	2011	CONCLUSIONS: Rapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells" survival.	Sirolimus	13-22	C-C motif chemokine ligand 19	Homo sapiens	49-54
21177249-6	2011	Enhanced Akt phosphorylation was not due to activation of phosphatidylinositol 3-kinase but due to activation of mammalian target of rapamycin complex 2 (mTORC2) by PINK1.	Sirolimus	133-142	CREB regulated transcription coactivator 2	Mus musculus	154-160
20821325-1	2011	Rapamycin is a potent allosteric mTORC1 inhibitor with clinical applications as an anticancer agent.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	33-39
21143198-6	2011	Furthermore, both Pho87 and Pho90 are also targeted to the vacuole upon carbon-source starvation or upon treatment with rapamycin, which mimics nitrogen starvation, but although these responses are independent of PHO pathway signalling, they again require the N-terminal SPX domain of the transporters.	Sirolimus	120-129	SPX domain-containing inorganic phosphate transporter	Saccharomyces cerevisiae S288C	18-23
21143198-6	2011	Furthermore, both Pho87 and Pho90 are also targeted to the vacuole upon carbon-source starvation or upon treatment with rapamycin, which mimics nitrogen starvation, but although these responses are independent of PHO pathway signalling, they again require the N-terminal SPX domain of the transporters.	Sirolimus	120-129	SPX domain-containing inorganic phosphate transporter	Saccharomyces cerevisiae S288C	28-33
21339643-0	2011	Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.	Sirolimus	0-9	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	95-101
21092744-7	2011	Rapamycin downregulated the expression of S-phase kinase associated protein-2 (Skp2) and increased the FOXO3a protein stability but induced the upregulation of feedback Akt activation-mediated FOXO3a phosphorylation.	Sirolimus	0-9	S-phase kinase associated protein 2	Homo sapiens	42-77
21092744-7	2011	Rapamycin downregulated the expression of S-phase kinase associated protein-2 (Skp2) and increased the FOXO3a protein stability but induced the upregulation of feedback Akt activation-mediated FOXO3a phosphorylation.	Sirolimus	0-9	S-phase kinase associated protein 2	Homo sapiens	79-83
20940044-5	2011	We found that Li(+) activated the mammalian target of rapamycin (mTOR) pathway via GSK-3beta in these cells, and the effect of Li(+) to induce c-Ret was amenable to the inhibitory effect of the mTOR inhibitor, rapamycin.	Sirolimus	54-63	glycogen synthase kinase 3 beta	Homo sapiens	83-92
21062901-7	2011	The differences between Tsc1(GFAP1)CKO and Tsc2(GFAP1)CKO mice were correlated with higher levels of mammalian target of rapamycin (mTOR) activation in Tsc2(GFAP1)CKO mice and were reversed by the mTOR inhibitor, rapamycin.	Sirolimus	121-130	TSC complex subunit 1	Mus musculus	24-28
21245298-6	2011	Rapamycin selectively increased p73 occupancy at a subset of its binding sites.	Sirolimus	0-9	tumor protein p73	Homo sapiens	32-35
21073880-8	2011	Binding of the first molecule, rapamycin, quenches microsecond-millisecond motions of the FKBP12 80"s loop.	Sirolimus	31-40	FKBP prolyl isomerase 1A	Homo sapiens	90-96
21208419-17	2011	Similarly, rapamycin induced a significant up-regulation of tristetraprolin (TTP), a protein involved in the regulation of iNOS mRNA stability.	Sirolimus	11-20	ZFP36 ring finger protein	Homo sapiens	60-75
21208419-17	2011	Similarly, rapamycin induced a significant up-regulation of tristetraprolin (TTP), a protein involved in the regulation of iNOS mRNA stability.	Sirolimus	11-20	ZFP36 ring finger protein	Homo sapiens	77-80
20943770-5	2011	Phosphorylated S6 (p-S6) ribosomal protein, a marker of mTORC1 activity, was increased in Cy/+ rats compared with normal littermate controls (+/+) and decreased by rapamycin.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	56-62
21224070-4	2011	In vitro, rapamycin inhibited the proliferation of cells in the basal state and after stimulation by insulin-like growth factor-1.	Sirolimus	10-19	insulin-like growth factor 1	Mus musculus	101-129
21224070-8	2011	Rapamycin treatment was associated with a significant decrease in mitotic index and in intratumoral vascular density within STC-1 tumors.	Sirolimus	0-9	stanniocalcin 1	Mus musculus	124-129
21597297-9	2011	At day 14, wound tensile strength and hydroxyproline content were significantly lower along with an increase in MMP-2 and MMP-9 activity in rapamycin-treated mice.	Sirolimus	140-149	matrix metallopeptidase 9	Mus musculus	122-127
21238650-2	2011	We hypothesize that combining a selective COX-2 antagonist (celecoxib) with rapamycin would decrease lung metastases.	Sirolimus	76-85	prostaglandin-endoperoxide synthase 2	Mus musculus	42-47
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	101-107
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	CREB regulated transcription coactivator 1	Mus musculus	184-190
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	cyclin D1	Homo sapiens	125-134
21135252-10	2011	Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin.	Sirolimus	162-171	cyclin D1	Homo sapiens	113-122
22219636-0	2011	Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study.	Sirolimus	0-9	matrix metallopeptidase 2	Homo sapiens	106-139
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	0-9	matrix metallopeptidase 2	Homo sapiens	330-335
20730888-3	2010	In vitro rapamycin induces apoptotic death of JN-DSRCT-1 cells, a possible model for desmoplastic small round cell tumors in which the EWS gene is fused to the WT1 gene.	Sirolimus	9-18	EWS RNA binding protein 1	Homo sapiens	135-138
20937815-5	2010	Here we show that rapamycin inhibited protein synthesis and activities of small GTPases (RhoA, Cdc42, and Rac1), crucial regulatory proteins for cell migration.	Sirolimus	18-27	cell division cycle 42	Homo sapiens	95-100
20937815-10	2010	The results suggest that rapamycin inhibits cell motility at least in part by down-regulation of RhoA protein expression and activity through mTORC1-mediated S6K1 and 4E-BP1-signaling pathways.	Sirolimus	25-34	CREB regulated transcription coactivator 1	Mus musculus	142-148
21075311-5	2010	On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	20-26
20930550-3	2010	Here, we found for the first time that JAK2/STAT3 was activated in HeLa cells when they were starved or treated with rapamycin.	Sirolimus	117-126	Janus kinase 2	Homo sapiens	39-43
20622751-8	2010	The expressions of the insulin, pancreatic and duodenal homeobox-1, and NeuroD/Beta2 genes were down-regulated via rapamycin treatment.	Sirolimus	115-124	neurogenic differentiation 1	Mus musculus	72-84
20935470-8	2010	Rapamycin, a specific inhibitor of mTORC1 kinase, decreased cellular hypertrophy, canceled coffilin phosphorylation and partially restored cell migration in p21(Waf1+/+) cells.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	35-41
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Sirolimus	37-46	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	129-133
20626386-3	2010	We found that donor BALB/c bone marrow-derived DCs (BMDCs) pharmacologically modified by the mTOR inhibitor rapamycin had significantly enhanced ability to induce CD4(+)CD25(+)Foxp3(+) iTregs of recipient origin (C57BL/6 (B6)) in vitro under Treg driving conditions compared to unmodified BMDCs.	Sirolimus	108-117	forkhead box P3	Homo sapiens	176-181
20573703-4	2010	The GSC loss can be rescued by treatment with TORC1 inhibitor rapamycin, or by eliminating S6K, a TORC1 downstream effecter, suggesting that precocious differentiation of Tsc1/2 mutant GSC is due to hyperactivation of TORC1.	Sirolimus	62-71	Tsc1	Drosophila melanogaster	171-177
20370577-7	2010	Rapamycin and LY294002 induce a decline in Sp1 nuclear abundance and IGFBP-2 mRNA and protein levels.	Sirolimus	0-9	insulin like growth factor binding protein 2	Homo sapiens	69-76
20554235-5	2010	Co-administration of the mTORC1 inhibitor rapamycin with rhGAA in a GAA knockout mouse reduced muscle glycogen content more than rhGAA or rapamycin alone.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	25-31
20600147-8	2010	Sirolimus inhibited the mTORC1 pathway, while the PPAR-gamma agonist rosiglitazone enhanced PP2Ac and reduced p70S6K.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	24-30
20600147-10	2010	Sirolimus and rosiglitazone in combination down-regulated the mTORC1 pathway and over-activated PP2Ac in diabetic kidney.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	62-68
20670831-3	2010	Plasma membrane PIP(2) depletion by rapamycin-induced translocation of an inositol lipid 5-phosphatase or by a voltage-sensitive 5-phosphatase (VSP) suppresses Ca(V)1.2 and Ca(V)1.3 channel currents by approximately 35% and Ca(V)2.1 and Ca(V)2.2 currents by 29% and 55%, respectively.	Sirolimus	36-45	immunoglobulin lambda variable 2-8	Homo sapiens	160-168
20670831-3	2010	Plasma membrane PIP(2) depletion by rapamycin-induced translocation of an inositol lipid 5-phosphatase or by a voltage-sensitive 5-phosphatase (VSP) suppresses Ca(V)1.2 and Ca(V)1.3 channel currents by approximately 35% and Ca(V)2.1 and Ca(V)2.2 currents by 29% and 55%, respectively.	Sirolimus	36-45	immunoglobulin lambda variable 3-1	Homo sapiens	224-232
20670831-3	2010	Plasma membrane PIP(2) depletion by rapamycin-induced translocation of an inositol lipid 5-phosphatase or by a voltage-sensitive 5-phosphatase (VSP) suppresses Ca(V)1.2 and Ca(V)1.3 channel currents by approximately 35% and Ca(V)2.1 and Ca(V)2.2 currents by 29% and 55%, respectively.	Sirolimus	36-45	calcium voltage-gated channel subunit alpha1 B	Homo sapiens	237-245
20633262-6	2010	RAPA administration significantly increased Foxp3 expression in peripheral lymphoid tissues after a single dose of RAPA on Day 3 post-transplant.	Sirolimus	0-4	forkhead box P3	Rattus norvegicus	44-49
20581466-3	2010	Recent evidence indicates that L-DOPA-induced dyskinesia (LID) is associated with persistent activation of the mammalian target of rapamycin complex 1 (mTORC1) in the medium spiny neurons (MSNs) of the striatum, the main component of the basal ganglia.	Sirolimus	131-140	CREB regulated transcription coactivator 1	Mus musculus	152-158
20581466-6	2010	Using a mouse model of LID, we recently showed that administration of the allosteric mTORC1 inhibitor, rapamycin, reduces dyskinesia.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	85-91
20616057-2	2010	Despite extensive work on the functional relevance of rapamycin-sensitive mTORC1 complexes, much less is known on the roles of rapamycin-insensitive (RI) complexes, including mTORC2 and RI-mTORC1, in BCR-ABL-leukemogenesis.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	74-80
20597028-4	2010	The efficacy of derivatives of the natural product rapamycin (sirolimus), which functions as an allosteric inhibitor of mTORC1, has validated mTOR inhibition as an anticancer treatment.	Sirolimus	62-71	CREB regulated transcription coactivator 1	Mus musculus	120-126
20484410-10	2010	However, rapamycin inhibited the activity of these complexes by decreasing the TSH and insulin-mediated stimulation of activating T172 phosphorylation of CDK4.	Sirolimus	9-18	cyclin dependent kinase 4	Homo sapiens	154-158
19786111-9	2010	We conclude that the combination of tacrolimus/sirolimus+/-MTX for GVHD prophylaxis in the setting of RIC HCT for MF appears to reduce the incidence of severe aGVHD and NRM, and leads to improved OS compared to CSA/MMF+/-MTX.	Sirolimus	47-56	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	211-214
19922502-0	2010	Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling.	Sirolimus	0-9	integrin alpha V	Mus musculus	81-96
21873975-6	2011	An RKIP pathway metastasis signature (designated RPMS) derived from the complete signalling cascade predicts high metastatic risk better than the individual genes.	Sirolimus	49-53	phosphatidylethanolamine binding protein 1	Homo sapiens	3-7
21792049-0	2011	Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.	Sirolimus	66-75	calcineurin binding protein 1	Homo sapiens	83-104
21672148-0	2011	Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and Klotho expression.	Sirolimus	0-9	klotho	Homo sapiens	100-106
21672148-6	2011	Rapamycin treatment of an immortalized proximal tubular cell line induced the expression of Klotho, the phosphorylation of AKT in Ser473, downstream target of mTORC2 and the expression of RICTOR, mTORC2 main component.	Sirolimus	0-9	klotho	Homo sapiens	92-98
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	Sirolimus	31-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	Sirolimus	31-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
21600903-0	2011	Rapamycin (sirolimus) protects against hypoxic damage in primary heart cultures via Na+/Ca2+ exchanger activation.	Sirolimus	0-9	nascent polypeptide associated complex subunit alpha 2	Homo sapiens	84-91
21715609-5	2011	Interestingly, rapamycin (a Food and Drug Administration-approved drug) restores normal levels of phosphorylated Akt-mTOR proteins and normal rates of local translation in Ts1Cje neurons, opening new therapeutic perspectives for DS.	Sirolimus	15-24	reciprocal translocation, Chr 12 and 16, Epstein 1	Mus musculus	172-178
21073857-12	2011	In the presence of actinomycin D, a transcriptional inhibitor, rapamycin accelerated the decrease in TRPM6 mRNA.	Sirolimus	63-72	transient receptor potential cation channel subfamily M member 6	Homo sapiens	101-106
21073857-14	2011	These results suggest that TRPM6 expression is up-regulated by a PI3K/Akt/mTOR pathway and rapamycin reduces TRPM6 mRNA stability, resulting in a decrease in the reabsorption of Mg2+.	Sirolimus	91-100	transient receptor potential cation channel subfamily M member 6	Homo sapiens	109-114
21639830-10	2011	Genes such as PUT4 and HSP42, known to be upregulated in the parent in response to rapamycin, were not induced in the rrd1Delta mutant if the SGS1 gene was deleted.	Sirolimus	83-92	heat shock protein HSP42	Saccharomyces cerevisiae S288C	23-28
21624620-10	2011	Claudin-1 upregulation by IL-1beta or TNF-alpha was suppressed by dexamethasone but not by rapamycin, FK506, or salbutamol.	Sirolimus	91-100	claudin 1	Homo sapiens	0-9
21318349-8	2011	The specific mTOR inhibitor rapamycin (10 nM) attenuated leptin-induced RhoA and Rac1 activation.	Sirolimus	28-37	Rac family small GTPase 1	Homo sapiens	81-85
21318349-10	2011	Leptin produced activation of the transcriptional factor GATA4 which was attenuated by the RhoA inhibitor C3, the p38 MAPK inhibitor SB203580 (10 muM) as well as rapamycin.	Sirolimus	162-171	GATA binding protein 4	Homo sapiens	57-62
21394029-2	2011	METHODS: We conducted a prospective 5-year clinical evaluation following implantation of sirolimus-eluting Cypher stents for in-stent restenosis regardless of the patient"s symptomatic status.	Sirolimus	89-98	LIM domain binding 3	Homo sapiens	107-113
21394029-5	2011	CONCLUSION: These results, of a comparably large series, indicate that the implantation of sirolimus-eluting Cypher stents for the treatment of coronary in-stent restenosis is effective and safe and associated with a stable clinical course in the very long term.	Sirolimus	91-100	LIM domain binding 3	Homo sapiens	109-115
21410393-7	2011	As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance.	Sirolimus	40-49	vascular endothelial growth factor D	Homo sapiens	173-209
21410393-7	2011	As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance.	Sirolimus	40-49	vascular endothelial growth factor D	Homo sapiens	211-217
21410393-11	2011	CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life.	Sirolimus	35-44	vascular endothelial growth factor D	Homo sapiens	85-91
21193837-9	2011	In addition, we have demonstrated that rapamycin treatment in the ALS mice causes more severe mitochondrial impairment, higher Bax levels and greater caspase-3 activation.	Sirolimus	39-48	BCL2-associated X protein	Mus musculus	127-130
21193837-9	2011	In addition, we have demonstrated that rapamycin treatment in the ALS mice causes more severe mitochondrial impairment, higher Bax levels and greater caspase-3 activation.	Sirolimus	39-48	caspase 3	Mus musculus	150-159
21428924-3	2011	GAS5 is also required for the inhibitory effects of rapamycin and its analogues on T-cells.	Sirolimus	52-61	growth arrest specific 5	Homo sapiens	0-4
21409566-6	2011	Oca1, Oca2, Siw14/Oca3, Oca4, and Oca6 were involved in the yeast response to caffeine and rapamycin stresses.	Sirolimus	91-100	putative tyrosine protein phosphatase SIW14	Saccharomyces cerevisiae S288C	12-17
21406405-4	2011	Inhibition of MNK1 activity in GBM cells by the small molecule CGP57380 suppressed eIF4E phosphorylation, proliferation, and colony formation whereas concomitant treatment with CGP57380 and the mTOR inhibitor rapamycin accentuated growth inhibition and cell-cycle arrest.	Sirolimus	209-218	MAPK interacting serine/threonine kinase 1	Homo sapiens	14-18
21406405-5	2011	siRNA-mediated knockdown of MNK1 expression reduced proliferation of cells incubated with rapamycin.	Sirolimus	90-99	MAPK interacting serine/threonine kinase 1	Homo sapiens	28-32
21406405-6	2011	Conversely, overexpression of full-length MNK1 reduced rapamycin-induced growth inhibition.	Sirolimus	55-64	MAPK interacting serine/threonine kinase 1	Homo sapiens	42-46
21177249-6	2011	Enhanced Akt phosphorylation was not due to activation of phosphatidylinositol 3-kinase but due to activation of mammalian target of rapamycin complex 2 (mTORC2) by PINK1.	Sirolimus	133-142	PTEN induced kinase 1	Homo sapiens	165-170
21107834-7	2011	Rapamycin altered the phenotype of antigen-specific Vgamma2Vdelta2 cells by inducing a population shift from CD62L + CD69- to CD62L-CD69+, higher expression of CD25 or Bcl-2, lower levels of CCR5 and increased resistance to Fas-mediated cellular apoptosis.	Sirolimus	0-9	C-C motif chemokine receptor 5	Homo sapiens	191-195
20678995-8	2010	We observed the effectiveness of the activated Akt/mTOR/p70S6K signaling pathway in improving locomotor recovery, significantly increasing the expression of nestin, neuronal nuclei (NeuN), neuron specific enolase (NSE), and neurofilament 200 (NF200), and relatively inhibiting excessive reactive astrogliosis after SCI in a rapamycin-sensitive manner.	Sirolimus	324-333	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
20832541-10	2010	In this case report, we introduce a new morphological appearance after sirolimus therapy of isometric cytoplasmic vacuolization of the renal tubules and severe arterial hyalinosis, similar to that seen in calcineurin inhibitor induced tubular toxicity.	Sirolimus	71-80	calcineurin binding protein 1	Homo sapiens	205-226
19956083-6	2010	Rapamycin blocked nuclear localization of beta-catenin independent of glycogen synthase kinase 3beta activity.	Sirolimus	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	42-54
20072130-2	2010	The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs.	Sirolimus	61-70	CREB regulated transcription coactivator 2	Homo sapiens	86-91
20061930-0	2010	Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen.	Sirolimus	43-52	calcineurin binding protein 1	Homo sapiens	97-118
20163539-0	2010	Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo.	Sirolimus	0-9	vascular endothelial growth factor A	Mesocricetus auratus	19-23
20163539-8	2010	RESULTS: Rapamycin at 0.1 and 0.5 mg/kg significantly reduced VEGF-stimulated mean IOI from 63.0 +/- 4.2 to 9.7 +/- 5.0 (85% reduction, P &lt; 0.001) and 3.6 +/- 2.7 (95% reduction, P &lt; 0.001), respectively.	Sirolimus	9-18	vascular endothelial growth factor A	Mesocricetus auratus	62-66
20163539-9	2010	Rapamycin at 2 mg/kg also lowered VEGF-stimulated hyperpermeability (40% reduction, P &lt; 0.05).	Sirolimus	0-9	vascular endothelial growth factor A	Mesocricetus auratus	34-38
20163539-10	2010	However, 10 mg/kg rapamycin increased VEGF-induced microvascular hyperpermeability.	Sirolimus	18-27	vascular endothelial growth factor A	Mesocricetus auratus	38-42
20163539-11	2010	Rapamycin at 0.5 mg/kg attenuated VEGF-induced vasodilation and PAF-induced hyperpermeability, but did not inhibit PAF-induced vasoconstriction.	Sirolimus	0-9	vascular endothelial growth factor A	Mesocricetus auratus	34-38
19917848-5	2010	TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines.	Sirolimus	68-77	TSC complex subunit 2	Homo sapiens	0-4
19755425-5	2009	Surprisingly, inhibition of the mTOR protein complex 1 (mTORC1) with rapamycin did not impair LTP maintenance or Arc synthesis nor did it inhibit eIF4F formation or phosphorylation of eIF4E.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Rattus norvegicus	32-36
19656910-0	2009	Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.	Sirolimus	23-32	solute carrier family 12 member 1	Rattus norvegicus	92-97
19656910-9	2009	Sirolimus treatment reduced expression of NKCC2, and this was accompanied by greater urinary excretion of sodium, potassium, and magnesium.	Sirolimus	0-9	solute carrier family 12 member 1	Rattus norvegicus	42-47
19656910-11	2009	Expression of TRPM6 was increased, which might represent a direct stimulatory effect of sirolimus or a compensatory response.	Sirolimus	88-97	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	14-19
19789339-5	2009	Rapamycin treatment also increased secretion of IGF-1 resulting in phosphorylation of IGF-1R (Tyr1131) that was blocked by CP751,871.	Sirolimus	0-9	insulin like growth factor 1 receptor	Homo sapiens	86-92
19789339-12	2009	These data suggest a model in which blockade of IGF-1R suppresses tumor-derived VEGF to a level where rapamycin can effectively suppress the response in vascular endothelial cells.	Sirolimus	102-111	insulin like growth factor 1 receptor	Homo sapiens	48-54
19554030-6	2009	Levels of VEGF, which promotes vascular permeability contributing to effusion formation, were significantly reduced in ascites of Rapa-treated mice compared with controls.	Sirolimus	130-134	vascular endothelial growth factor A	Mus musculus	10-14
19463904-11	2009	The GLP-1-induced redox restoration was also attenuated by rapamycin.	Sirolimus	59-68	glucagon	Rattus norvegicus	4-9
21123297-6	2011	Expression of DDIT4 mRNA in these cells was induced (1.6-6 fold) by 1,25(OH)(2)D(3) (10-100 nM), and Western blot and flow cytometry analysis showed that this response involved suppression of phosphorylated S6K1(T389) (a downstream target of mTOR) similar to rapamycin treatment.	Sirolimus	259-268	DNA damage inducible transcript 4	Homo sapiens	14-19
19622787-6	2009	Abrogation of S6K activity by the mTOR blocker rapamycin failed to counteract amino acid-induced inhibition of glucose and palmitate oxidation, which therefore was obviously independent of mTOR/S6K signaling (decrease in glucose oxidation by addition of 44 mmol/l amino acids: without rapamycin, -60 +/- 4%; with rapamycin, -50 +/- 13%; NS).	Sirolimus	47-56	mechanistic target of rapamycin kinase	Rattus norvegicus	34-38
18504440-4	2008	We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells.	Sirolimus	14-23	nucleolar and coiled-body phosphoprotein 1	Homo sapiens	346-350
18604275-5	2008	A survey of non-essential MAF1 synthetic sick/lethal (SSL) genes identified six gene-deletions that are defective in transcriptional repression of ribosomal protein (RP) genes following rapamycin treatment.	Sirolimus	186-195	RNA polymerase III-inhibiting protein MAF1	Saccharomyces cerevisiae S288C	26-30
21427787-10	2011	Inhibition of mTOR also radiosensitized GH3 cells such that 2.5 Gy in combination with 500 pM rapamycin or RAD001 reduced cellular viability more effectively than 2.5 or 10 Gy alone.	Sirolimus	94-103	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
20594757-3	2011	We tested this hypothesis in the rat model of 30% TBSA full thickness burn, using the mTOR inhibitor rapamycin.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Rattus norvegicus	86-90
20709738-8	2011	Rapamycin prolonged survival, maintained normal renal function, normalized proteinuria, restored nephrin and podocin levels, reduced anti-dsDNA titres, ameliorated histological lesions, and reduced Akt and mTOR glomerular expression activation.	Sirolimus	0-9	nephrosis 1, nephrin	Mus musculus	97-104
20709738-8	2011	Rapamycin prolonged survival, maintained normal renal function, normalized proteinuria, restored nephrin and podocin levels, reduced anti-dsDNA titres, ameliorated histological lesions, and reduced Akt and mTOR glomerular expression activation.	Sirolimus	0-9	nephrosis 2, podocin	Mus musculus	109-116
20160148-2	2010	In the year 2000, TSC2 gene mutations were found in LAM cells; in 2001 the tuberous sclerosis complex (TSC) genes were discovered to regulate cell size in Drosophila via the kinase TOR (target of rapamycin); and in 2008 the results were published of a clinical trial of rapamycin, a specific inhibitor of TOR, in patients with TSC and LAM with renal angiomyolipomas.	Sirolimus	196-205	gigas	Drosophila melanogaster	18-21
20160148-2	2010	In the year 2000, TSC2 gene mutations were found in LAM cells; in 2001 the tuberous sclerosis complex (TSC) genes were discovered to regulate cell size in Drosophila via the kinase TOR (target of rapamycin); and in 2008 the results were published of a clinical trial of rapamycin, a specific inhibitor of TOR, in patients with TSC and LAM with renal angiomyolipomas.	Sirolimus	196-205	gigas	Drosophila melanogaster	103-106
20068177-2	2010	Rapamycin and its analogues (rapalogs) partially inhibit mTOR through allosteric binding to mTOR complex 1 (mTORC1) but not mTOR complex 2 (mTORC2), an emerging player in cancer.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	108-114
20549474-8	2010	These inhibitors bind to the ATP binding site of the kinase domain of mTOR and as a result inhibit both mTOR complexes, TORC1 (rapamycin sensitive) and TORC2 (rapamycin resistant).	Sirolimus	127-136	CREB regulated transcription coactivator 1	Homo sapiens	120-125
17707630-8	2008	However, addition of amino acids with rapamycin inhibited the nuclear import of PTB.	Sirolimus	38-47	polypyrimidine tract binding protein 1	Homo sapiens	80-83
19864431-5	2010	We report that insulin promotes mTORC1-associated phosphorylation of raptor Ser(863) via the canonical PI3K/TSC/Rheb pathway in a rapamycin-sensitive manner.	Sirolimus	130-139	CREB regulated transcription coactivator 1	Mus musculus	32-38
19864431-5	2010	We report that insulin promotes mTORC1-associated phosphorylation of raptor Ser(863) via the canonical PI3K/TSC/Rheb pathway in a rapamycin-sensitive manner.	Sirolimus	130-139	Ras homolog, mTORC1 binding	Homo sapiens	112-116
21268715-5	2011	We observed that rapamycin impaired recruitment of BRCA1 and Rad51 to DNA repair foci, both essential for HR.	Sirolimus	17-26	BRCA1 DNA repair associated	Homo sapiens	51-56
21268715-5	2011	We observed that rapamycin impaired recruitment of BRCA1 and Rad51 to DNA repair foci, both essential for HR.	Sirolimus	17-26	RAD51 recombinase	Homo sapiens	61-66
18519701-7	2008	Combination of bevacizumab with rapamycin caused loss of half of the VEGFR-2(+) melanoma cells, but no reduction in the number of VEGFR-2(neg) melanoma cells.	Sirolimus	32-41	kinase insert domain receptor	Homo sapiens	69-76
21255728-3	2011	A variety of inhibitors of the PI activity of FKBP12, including FK506, rapamycin, and cycloheximide, increase steady-state palmitoylation.	Sirolimus	71-80	FKBP prolyl isomerase 1A	Rattus norvegicus	46-52
20727967-4	2011	Pretreatment with the mTOR inhibitor rapamycin, decreased carbachol-induced Ca(2+) release in AR4-2J cells.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Rattus norvegicus	22-26
21114628-0	2011	Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2.	Sirolimus	0-9	POU class 2 homeobox 2	Homo sapiens	177-201
19805410-12	2010	Fap1 competes with rapamycin for Fpr1 binding.	Sirolimus	19-28	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	33-37
19805410-13	2010	Deletion of the FPR1 or FAP1 gene abolishes the inhibitory effect of rapamycin on repair.	Sirolimus	69-78	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	16-20
19963098-2	2009	mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin.	Sirolimus	123-132	CREB regulated transcription coactivator 1	Mus musculus	86-92
17434617-0	2008	Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registry.	Sirolimus	41-50	LIM domain binding 3	Homo sapiens	27-33
20045915-4	2009	MEK inhibitor (PD98059), SAPK/p38 inhibitor (SB202190), and mTOR inhibitor (rapamycin) were used to respectively block MEK, SAPK/p38, and mTOR intracellular pathways or the phosphatase inhibitor (calyculin A) pretreatment before CCK treatment.	Sirolimus	76-85	midkine	Mus musculus	119-122
17434617-1	2008	OBJECTIVE: This post-marketing surveillance registry is aimed at determining the safety and reliability of the CYPHER Select Sirolimus-eluting stent (SES) in routine clinical practice.	Sirolimus	125-134	LIM domain binding 3	Homo sapiens	111-117
21131428-5	2011	Addition of rapamycin to anti-CXCR4 therapy further promoted HSC mobilization and islet allograft survival, inducing a robust and transferable host hyporesponsiveness, while administration of an ACK2 (anti-CD117) mAb halted CXCR4 antagonist-mediated HSC release and restored allograft rejection.	Sirolimus	12-21	chemokine (C-X-C motif) receptor 4	Mus musculus	30-35
17876804-1	2008	Raman spectroscopy was used to differentiate each component found in the CYPHER Sirolimus-eluting Coronary Stent.	Sirolimus	80-89	LIM domain binding 3	Homo sapiens	73-79
21131428-5	2011	Addition of rapamycin to anti-CXCR4 therapy further promoted HSC mobilization and islet allograft survival, inducing a robust and transferable host hyporesponsiveness, while administration of an ACK2 (anti-CD117) mAb halted CXCR4 antagonist-mediated HSC release and restored allograft rejection.	Sirolimus	12-21	chemokine (C-X-C motif) receptor 4	Mus musculus	224-229
21251624-0	2011	Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).	Sirolimus	70-79	LIM domain binding 3	Homo sapiens	63-69
21251624-1	2011	OBJECTIVES: The aim of this study was to assess the long-term safety and efficacy of the CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).	Sirolimus	151-160	LIM domain binding 3	Homo sapiens	89-95
19718660-7	2009	Cancer cells have a constitutively active mTOR pathway; surprisingly, inhibition of mTOR complex 1 (mTORC1) by rapamycin barely affects the global rate of translation and of initiation of translation, but deeply inhibits mesothelioma spreading on ECM.	Sirolimus	111-120	CREB regulated transcription coactivator 1	Mus musculus	100-106
18079735-5	2008	Moreover, R18 sensitized BCR-ABL-transformed cells to inhibition with MEK1 inhibitor U0126, Bcl-2 inhibitor GX15-070, or mTOR inhibitor rapamycin.	Sirolimus	136-145	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	25-32
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	0-9	matrix metallopeptidase 9	Homo sapiens	340-345
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	171-180	matrix metallopeptidase 9	Homo sapiens	340-345
18079735-5	2008	Moreover, R18 sensitized BCR-ABL-transformed cells to inhibition with MEK1 inhibitor U0126, Bcl-2 inhibitor GX15-070, or mTOR inhibitor rapamycin.	Sirolimus	136-145	mechanistic target of rapamycin kinase	Rattus norvegicus	121-125
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
18094073-7	2008	However, the re-expression of TSC2 or inhibition of mTOR/S6K1 with rapamycin (sirolimus) augmented antiproliferative effects of IFNbeta in LAM and TSC2-null ELT3 cells.	Sirolimus	78-87	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
18240926-8	2008	Cell lines with serial mutations, including activation of Ras and Akt pathways, also demonstrated increased levels of ARF4L protein, which decreased after treatment with rapamycin.	Sirolimus	170-179	ADP ribosylation factor like GTPase 4D	Homo sapiens	118-123
17971307-0	2008	Renal cortex neuronal nitric oxide synthase in response to rapamycin in kidney transplantation.	Sirolimus	59-68	nitric oxide synthase 1	Rattus norvegicus	13-43
19099956-5	2008	RESULTS: (1) mTOR/beta-actin ratio was dose-dependently reduced (1 nmol/L, 0.381 +/- 0.022; 10 nmol/L, 0.282 +/- 0.014; 100 nmol/L, 0.263 +/- 0.012 vs. control 1.45 +/- 0.04, all P &lt; 0.05 vs. control) after 48 hours rapamycin treatments and time-dependently reduced after 10 nmol/L rapamycin treatment (24 h, 0.203 +/- 0.021; 48 h, 0.163 +/- 0.022; 72 h, 0.144 +/- 0.013 vs. 0 h, 0.341 +/- 0.022, all P &lt; 0.05 vs.0 h) in CVB 3 infected myocardial fibroblasts.	Sirolimus	219-228	mechanistic target of rapamycin kinase	Rattus norvegicus	13-17
22145042-8	2011	In serial implantation of tumor xenografts in nude BALB/c mice, the residual tumor cells that were exposed to rapamycin in vivo displayed higher CD133 expression and had increased secondary tumorigenicity compared with the control group.	Sirolimus	110-119	prominin 1	Mus musculus	145-150
21949767-12	2011	MNK kinase mediated the eIF4E phosphorylation and inhibition or depletion of MNK markedly suppressed proliferation of the CTCL cells when combined with the rapamycin-mediated inhibition of mTORC1.	Sirolimus	156-165	ATPase copper transporting alpha	Homo sapiens	0-3
21695255-7	2011	Ectopic allotransplants of the mouse ovarian tumor cells with a gain-of-function mutation in beta-catenin and PTEN deletion developed into tumors with OEA histology, the growth of which were significantly inhibited by oral rapamycin treatment.	Sirolimus	223-232	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
18217899-7	2008	RESULTS: Calcineurin inhibitor minimization using mycophenolate mofetil or sirolimus may be associated with a modest increase in creatinine clearance (CrCl) and a decrease in serum creatinine (SCr) in the short term.	Sirolimus	75-84	calcineurin binding protein 1	Homo sapiens	9-30
21660239-6	2011	Rapamycin-treatment increased weight loss and decreased survival of bleomycin-treated Sftpc(+/+) and Sftpc(-/-) mice.	Sirolimus	0-9	surfactant associated protein C	Mus musculus	101-111
21200439-7	2010	We found that mTORC1-S6K suppression by rapamycin delayed mortality of mice challenged with lethal endotoxin, and was associated with dampened circulating levels of VEGF, IL-1beta, IFN-gamma and IL-5.	Sirolimus	40-49	vascular endothelial growth factor A	Mus musculus	165-169
21042876-7	2010	Rapamycin enhanced the isoproterenol-stimulated phosphorylation of hormone sensitive lipase (HSL) on Ser-563 (a PKA site), but had no effect on the phosphorylation of HSL S565 (an AMPK site).	Sirolimus	0-9	lipase E, hormone sensitive type	Homo sapiens	67-91
21042876-7	2010	Rapamycin enhanced the isoproterenol-stimulated phosphorylation of hormone sensitive lipase (HSL) on Ser-563 (a PKA site), but had no effect on the phosphorylation of HSL S565 (an AMPK site).	Sirolimus	0-9	lipase E, hormone sensitive type	Homo sapiens	93-96
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	150-159	pyruvate dehydrogenase kinase 1	Homo sapiens	81-85
20884880-7	2010	SGK-1 activation in response to stretch is blocked by insulin-like growth factor (IGF)-1 receptor inhibitor and mammalian target of rapamycin complex (mTORC)2 inhibitor (Ku-0063794) but not mTORC1 inhibitor (rapamycin).	Sirolimus	132-141	serum/glucocorticoid regulated kinase 1	Homo sapiens	0-5
18097008-1	2008	Because ex vivo rapamycin generates murine Th2 cells that prevent Graft-versus-host disease more potently than control Th2 cells, we hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that abrogate fully MHC-disparate hemopoietic stem cell rejection more effectively than control Th2/Tc2 cells.	Sirolimus	151-160	transcobalamin 2	Mus musculus	180-183
18097008-1	2008	Because ex vivo rapamycin generates murine Th2 cells that prevent Graft-versus-host disease more potently than control Th2 cells, we hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that abrogate fully MHC-disparate hemopoietic stem cell rejection more effectively than control Th2/Tc2 cells.	Sirolimus	151-160	transcobalamin 2	Mus musculus	195-198
18097008-1	2008	Because ex vivo rapamycin generates murine Th2 cells that prevent Graft-versus-host disease more potently than control Th2 cells, we hypothesized that rapamycin would generate Th2/Tc2 cells (Th2/Tc2.R cells) that abrogate fully MHC-disparate hemopoietic stem cell rejection more effectively than control Th2/Tc2 cells.	Sirolimus	151-160	transcobalamin 2	Mus musculus	195-198
18094094-7	2008	The observation that the TSC1/TSC2 functions as a negative regulator of the mammalian target of rapamycin (mTOR)/p70 S6 kinase (S6K1) signaling pathway yielded the first rapamycin clinical trial for LAM.	Sirolimus	96-105	TSC complex subunit 2	Homo sapiens	30-34
18165767-9	2007	Rapamycin treatment of islets in vitro resulted in reduced p70s6k phosphorylation, which was paralleled by increased ERK1/2 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	59-65
17885304-2	2007	The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue.	Sirolimus	22-31	C-C motif chemokine receptor 5	Homo sapiens	103-107
20849552-3	2010	In this study, we used a novel MHC-defined rhesus macaque model to examine the impact of MHC matching on the stability of costimulation blockade-/sirolimus-mediated chimerism, and to probe possible mechanisms of bone marrow rejection after nonmyeloablative transplant.	Sirolimus	146-155	major histocompatibility complex, class I, C	Homo sapiens	89-92
20620173-10	2010	Interestingly, rapamycin, an mTOR inhibitor, upregulates MT1-MMP expression in PTEN(+/+) cells via PI3K activity.	Sirolimus	15-24	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	57-64
20813961-5	2010	In this study, we show that tuberin regulates the localization of E-cadherin via an Akt/mTORC1/CLIP170-dependent, rapamycin-sensitive pathway.	Sirolimus	114-123	TSC complex subunit 2	Homo sapiens	28-35
20813961-5	2010	In this study, we show that tuberin regulates the localization of E-cadherin via an Akt/mTORC1/CLIP170-dependent, rapamycin-sensitive pathway.	Sirolimus	114-123	CAP-Gly domain containing linker protein 1	Homo sapiens	95-102
20935455-6	2010	p27(Kip1) is required for rapamycin or nutrient starvation-induced G(1)-arrest, as p27(-/-) fibroblasts were largely insensitive to rapamycin treatment or glucose starvation.	Sirolimus	26-35	cyclin-dependent kinase inhibitor 1B	Mus musculus	0-3
20935455-6	2010	p27(Kip1) is required for rapamycin or nutrient starvation-induced G(1)-arrest, as p27(-/-) fibroblasts were largely insensitive to rapamycin treatment or glucose starvation.	Sirolimus	26-35	cyclin-dependent kinase inhibitor 1B	Mus musculus	4-8
20935455-6	2010	p27(Kip1) is required for rapamycin or nutrient starvation-induced G(1)-arrest, as p27(-/-) fibroblasts were largely insensitive to rapamycin treatment or glucose starvation.	Sirolimus	132-141	cyclin-dependent kinase inhibitor 1B	Mus musculus	0-3
17698581-5	2007	Rapamycin inhibition of TORC1 signaling suppressed the Rad53 checkpoint-mediated induction of ribonucleotide reductase subunits Rnr1 and Rnr3, thereby abrogating MMS-induced mutagenesis and enhancing cell lethality.	Sirolimus	0-9	ribonucleotide-diphosphate reductase subunit RNR1	Saccharomyces cerevisiae S288C	128-132
17353907-8	2007	Finally, the mTOR inhibitor rapamycin markedly decreased proliferation and increased the apoptotic rate of ALK+TCL cells.	Sirolimus	28-37	ALK receptor tyrosine kinase	Homo sapiens	107-110
20405134-2	2010	The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS( ) stent with sirolimus-eluting CYPHER( ) stent for the prevention of symptom-driven clinical end points in a real world clinical setting.	Sirolimus	93-102	LIM domain binding 3	Homo sapiens	111-117
20656472-3	2010	Since loss of function of the DNA repair OGG1 enzyme has a major role in multistep carcinogenesis of the kidney and other organs, we investigated the effect of rapamycin on OGG1 regulation.	Sirolimus	160-169	8-oxoguanine DNA-glycosylase 1	Mus musculus	173-177
20656472-4	2010	Treatment of HK2 cells, mouse Tsc-deficient cells and human VHL-deficient cells (786-O) with rapamycin resulted in decrease in p70S6K phosphorylation at Thr(389), and increase in the expression of NF-YA and OGG1 proteins.	Sirolimus	93-102	nuclear transcription factor Y subunit alpha	Homo sapiens	197-202
17541736-4	2007	The downstream target of phosphatidylinositol 3-kinase includes the mTOR/p70s6 kinase pathway which was pharmacologically inhibited by rapamycin.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Rattus norvegicus	68-72
20656472-5	2010	In addition, rapamycin increased OGG1 promoter activity in cells transfected with OGG1 promoter construct.	Sirolimus	13-22	8-oxoguanine DNA-glycosylase 1	Mus musculus	33-37
20656472-5	2010	In addition, rapamycin increased OGG1 promoter activity in cells transfected with OGG1 promoter construct.	Sirolimus	13-22	8-oxoguanine DNA-glycosylase 1	Mus musculus	82-86
20656472-11	2010	Treatment of Tsc2(+/-) mice with rapamycin resulted in activation of AMPK, downregulation of phospho-p70S6K and enhanced OGG1 expression.	Sirolimus	33-42	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	101-107
20656472-11	2010	Treatment of Tsc2(+/-) mice with rapamycin resulted in activation of AMPK, downregulation of phospho-p70S6K and enhanced OGG1 expression.	Sirolimus	33-42	8-oxoguanine DNA-glycosylase 1	Mus musculus	121-125
20876744-10	2010	Instead, rapamycin inhibited SCD1 promoter activity and decreased expression of mature transcription factor sterol regulatory element binding protein 1 (SREBP1).	Sirolimus	9-18	stearoyl-CoA desaturase	Homo sapiens	29-33
20664001-7	2010	It is noteworthy that the mammalian target of rapamycin (mTOR) inhibitor rapamycin also induced phosphorylation of eIF4E in a Mnk-dependent manner, whereas inhibition strongly enhanced its antileukemic effects.	Sirolimus	46-55	ATPase copper transporting alpha	Homo sapiens	126-129
20517583-10	2010	Rapamycin treatment reduced the phosphorylation of mTOR and its substrates, p70S6K1 and 4EBP1, confirming mTOR inhibition.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
17631219-13	2007	(RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent; http://clinicaltrials.gov/ct/show/NCT00263263?order=1; NCT00263263).	Sirolimus	75-84	LIM domain binding 3	Homo sapiens	68-74
20517583-10	2010	Rapamycin treatment reduced the phosphorylation of mTOR and its substrates, p70S6K1 and 4EBP1, confirming mTOR inhibition.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	106-110
20421347-3	2010	We report a previously unsuspected role for the nonprotein-coding RNA GAS5 in the inhibition of T-cell proliferation produced by mTOR antagonists such as rapamycin.	Sirolimus	154-163	growth arrest specific 5	Homo sapiens	70-74
20448441-7	2010	Furthermore, BFA blocked the glucose-induced mTOR and p70S6K activation, while mTOR inhibition with rapamycin attenuated the glucose induced Beta2 expression and insulin secretion.	Sirolimus	100-109	hemoglobin, beta adult minor chain	Mus musculus	141-146
17554808-1	2007	FKBP-12 mediates the immunosuppressive actions of FK506 and rapamycin, and modulates the activities of the ryanodine, IP3 and type 1 TGF-ss receptors.	Sirolimus	60-69	peptidyl-prolyl cis-trans isomerase FKBP1A	Oryctolagus cuniculus	0-7
17620442-8	2007	In nude mice with xenografted SKOV3.ip1-induced tumors, luteolin significantly inhibited HER2 expression and tumor growth in a dose-dependent manner, and rapamycin further enhanced the effect of luteolin with a concomitant p21 inhibition.	Sirolimus	154-163	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	223-226
20388713-4	2010	In response to rapamycin, caffeine, glucose starvation and oxidative stress provoked by H(2)O(2), mtl1 presents a significant loss of viability as well as a deficiency in the transcriptional response mediated by Msn2/Msn4.	Sirolimus	15-24	Mtl1p	Saccharomyces cerevisiae S288C	98-102
17589348-6	2007	Sirolimus reduced both viability and VEGF production by murine beta-cells, and blockade of VEGF-164 was associated with a reduction in viability.	Sirolimus	0-9	vascular endothelial growth factor A	Mus musculus	37-41
20399760-13	2010	Behavioral study showed that intrathecal mTOR inhibitor, rapamycin, did not affect acute nocicepetive transmission.	Sirolimus	57-66	mechanistic target of rapamycin kinase	Rattus norvegicus	41-45
20232105-0	2010	Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	16-37
20220747-2	2010	Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2.	Sirolimus	59-68	ATP binding cassette subfamily C member 2	Homo sapiens	173-178
20402792-2	2010	Rck2p also regulates rapamycin sensitivity in both S. cerevisiae and Candida albicans.	Sirolimus	21-30	serine/threonine protein kinase RCK2	Saccharomyces cerevisiae S288C	0-5
17589348-8	2007	These data are consistent with the hypothesis that sirolimus is toxic to islets and beta-cells by blockade of VEGF-mediated survival pathways.	Sirolimus	51-60	vascular endothelial growth factor A	Mus musculus	110-114
17322416-4	2007	The effect of sirolimus on the gene and protein expression of lipoprotein receptors and ATP binding cassettes (ABCA1 and ABCG1) was examined by real-time PCR and Western blotting, respectively.	Sirolimus	14-23	ATP binding cassette subfamily A member 1	Homo sapiens	111-116
17322416-9	2007	Sirolimus also increased ABCA1 and ABCG1 genes expression, even in the presence of IL-1 beta.	Sirolimus	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	25-30
17429052-6	2007	Consequently, SNAT2 inhibition strongly impaired signaling through mammalian target of rapamycin to ribosomal protein S6 kinase, ribosomal protein S6, and 4E-BP1, leading to impairment of protein synthesis comparable with that induced by rapamycin.	Sirolimus	87-96	solute carrier family 38 member 2	Homo sapiens	14-19
17179073-12	2007	We discuss the complex genetic interactions between tor1(+), tor2(+), and tsc1/2(+) and the implications for rapamycin sensitivity in tsc1 or tsc2 mutants.	Sirolimus	109-118	TSC complex subunit 2	Homo sapiens	142-146
17329974-6	2007	Indeed, pharmacological inhibition of mTOR with rapamycin has shown promising results in preventing vGPCR tumorigenesis in an animal model for KS.	Sirolimus	48-57	K14	Human gammaherpesvirus 8	100-105
20054613-6	2010	PI3-kinase and mTOR were blocked using wortmannin (0.6 mg/kg) or rapamycin (0.25 mg/kg), respectively.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
17200203-7	2007	Systemic administration of rapamycin to mice subjected to unilateral ureteral obstruction, a model of renal fibrosis and increased fibrillin-1 synthesis, markedly reduced the number of interstitial fibroblasts and fibrillin-1 deposition.	Sirolimus	27-36	fibrillin 1	Mus musculus	131-142
16952420-3	2007	Therefore, the effects of insulin and rapamycin (an inhibitor of mTOR) on the phosphorylation of mTOR (Ser 2448) and p70(S6K) (Thr 389) as well as on cell proliferation in parental HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB (HepG2-CA-Akt/PKB) were studied.	Sirolimus	38-47	annexin A6	Homo sapiens	117-120
20144629-2	2010	IGF-I-induced IGF-I receptor decrease was abolished by LY294002 (phosphoinositide 3-kinase inhibitor) and partially attenuated by rapamycin (an inhibitor of mammalian target of rapamycin [mTOR]).	Sirolimus	130-139	insulin like growth factor 1 receptor	Homo sapiens	14-28
20144629-5	2010	l-leucine increased phosphorylation of mTOR (but not GSK-3beta), and down-regulated IGF-I receptor, both events being abolished by rapamycin.	Sirolimus	131-140	insulin like growth factor 1 receptor	Homo sapiens	84-98
17379975-0	2007	Angiographic and clinical outcome following sirolimus-eluting stent (Cypher) implantation.	Sirolimus	44-53	LIM domain binding 3	Homo sapiens	69-75
20620516-0	2010	Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation.	Sirolimus	0-9	Cd4 molecule	Rattus norvegicus	36-39
20620516-3	2010	In this study, we characterized CD4(+)Foxp3(+) Tregs in liver grafts and peripheral blood following rapamycin treatment using a syngeneic liver transplant model.	Sirolimus	100-109	Cd4 molecule	Rattus norvegicus	32-35
20620516-5	2010	In the first 2 weeks the percentage of CD4(+)Foxp3(+) Tregs was increased in the liver grafts and blood only among the rapamycin group compared with control group.	Sirolimus	119-128	Cd4 molecule	Rattus norvegicus	39-42
20620516-8	2010	Thus, rapamycin can significantly enhance the percentages of CD4(+)Foxp3(+) Tregs in the thymus and periphery, indicating that rapamycin favors Tregs expansion and may suppress other CD4(+) T cells.	Sirolimus	6-15	Cd4 molecule	Rattus norvegicus	61-64
17016853-1	2007	BACKGROUND: Sirolimus (SIR) alone or in combination with cyclosporine (CsA) or tacrolimus (TAC) are used in solid organ transplantation, but uncertainty remains regarding their respective atherogenic potentials.	Sirolimus	12-21	chorionic somatomammotropin hormone 1	Homo sapiens	71-74
20620516-8	2010	Thus, rapamycin can significantly enhance the percentages of CD4(+)Foxp3(+) Tregs in the thymus and periphery, indicating that rapamycin favors Tregs expansion and may suppress other CD4(+) T cells.	Sirolimus	6-15	Cd4 molecule	Rattus norvegicus	183-186
20404486-0	2010	Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.	Sirolimus	0-9	negative elongation factor complex member C/D	Homo sapiens	41-44
20404486-0	2010	Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.	Sirolimus	0-9	transcriptional and immune response regulator	Homo sapiens	45-48
20404486-1	2010	Murine T cells exposed to rapamycin maintain flexibility towards Th1/Tc1 differentiation, thereby indicating that rapamycin promotion of regulatory T cells (Tregs) is conditional.	Sirolimus	26-35	negative elongation factor complex member C/D	Homo sapiens	65-68
20404486-1	2010	Murine T cells exposed to rapamycin maintain flexibility towards Th1/Tc1 differentiation, thereby indicating that rapamycin promotion of regulatory T cells (Tregs) is conditional.	Sirolimus	26-35	transcriptional and immune response regulator	Homo sapiens	69-72
20404486-8	2010	Rather, rapamycin yields an anti-apoptotic Th1/Tc1 effector phenotype by promoting autophagy.	Sirolimus	8-17	negative elongation factor complex member C/D	Homo sapiens	43-46
20404486-8	2010	Rather, rapamycin yields an anti-apoptotic Th1/Tc1 effector phenotype by promoting autophagy.	Sirolimus	8-17	transcriptional and immune response regulator	Homo sapiens	47-50
20404504-5	2010	In addition, cells overexpressing the active form of Plk1 were characterized by abnormal growth that could be reversed by rapamycin, a specific inhibitor of the TORC1 complex.	Sirolimus	122-131	polo like kinase 1	Homo sapiens	53-57
17107279-1	2006	Cypher (sirolimus-eluting stent) and Taxus (paclitaxel-eluting stent) have been approved for use in percutaneous coronary intervention.	Sirolimus	8-17	LIM domain binding 3	Homo sapiens	0-6
19951971-7	2010	Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling.	Sirolimus	34-43	insulin like growth factor 1 receptor	Homo sapiens	129-135
20131403-9	2010	The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3.	Sirolimus	53-62	proliferating cell nuclear antigen	Mus musculus	169-173
20131403-9	2010	The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3.	Sirolimus	53-62	caspase 3	Mus musculus	216-219
20213584-0	2010	Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation.	Sirolimus	70-79	mitogen-activated protein kinase 8	Mus musculus	94-97
20213584-5	2010	Rapamycin was found to increase phosphorylation of c-Jun amino-terminal kinase (JNK) and p38 in 30 minutes in MIN6 cells and Wistar rat islets while exendin-4 decreased their phosphorylation.	Sirolimus	0-9	mitogen-activated protein kinase 8	Mus musculus	80-83
16929481-6	2006	Inhibition of the kinase mTOR, a key player in the integration of nutrition and growth signals into protein synthesis, with rapamycin reduced serine phosphorylation of eIF3i and resulted in a loss of anchorage-independent growth.	Sirolimus	124-133	eukaryotic translation initiation factor 3 subunit I	Homo sapiens	168-173
20133820-7	2010	ANXA1, GPNMB, LTF, RND3, S100A11, SFRP4, and NPTX1 genes were likely to be mTOR effector genes in SEGA, as their expression was modulated by an mTOR inhibitor, rapamycin, in SEGA-derived cells.	Sirolimus	160-169	annexin A1	Homo sapiens	0-5
17096757-0	2006	Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	78-99
17096757-1	2006	We have previously reported sirolimus (SRL) pharmacokinetics (PK) in pediatric renal transplant recipients on a calcineurin inhibitor (CNI)-free protocol.	Sirolimus	28-37	calcineurin binding protein 1	Homo sapiens	112-133
17175304-1	2006	This study compared early postoperative complications in kidney transplant recipients treated with either a sirolimus-based calcineurin inhibitor (CNI)-free regimen or a tacrolimus-based steroid-free regimen.	Sirolimus	108-117	calcineurin binding protein 1	Homo sapiens	124-145
17249257-1	2006	A case of late stent occlusion of a Sirolimus eluting Cypher stent (Cordis, Johnson and Johnson) presenting as acute ST elevation myocardial infarction 22 months after deployment is reported.	Sirolimus	36-45	LIM domain binding 3	Homo sapiens	54-60
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	Sirolimus	137-146	fms related receptor tyrosine kinase 4	Homo sapiens	36-43
16959214-5	2006	It would seem that this increase in VEGFR-3 occurred via the ERK and mTOR pathways, since their respective inhibitors U0126, LY294002 or rapamycin were responsible for a decrease of VEGFR-3.	Sirolimus	137-146	fms related receptor tyrosine kinase 4	Homo sapiens	182-189
16772532-10	2006	Rapamycin also prevented the induction of Id2 by lactogenic hormones and milk protein gene expression.	Sirolimus	0-9	inhibitor of DNA binding 2	Homo sapiens	42-45
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	annexin A6	Homo sapiens	156-159
16920556-0	2006	Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.	Sirolimus	8-17	transcobalamin 2	Mus musculus	43-46
16920556-1	2006	Rapamycin prevention of murine graft-versus-host disease (GVHD) is associated with a shift toward Th2- and Tc2-type cytokines.	Sirolimus	0-9	transcobalamin 2	Mus musculus	107-110
16920556-3	2006	In this study, using a method, without antigen-presenting cells, of T-cell expansion based on CD3,CD28 costimulation, we evaluated whether (1) rapamycin preferentially promotes the generation of Th2/Tc2 cells relative to Th1/Tc1 cells, (2) rapamycin-generated T-cell subsets induce cytokine skewing after allogeneic bone marrow transplantation (BMT), and (3) such in vivo cytokine skewing is sensitive to post-BMT rapamycin therapy.	Sirolimus	143-152	transcobalamin 2	Mus musculus	199-202
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	0-9	transcobalamin 2	Mus musculus	84-87
16920556-5	2006	Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L).	Sirolimus	109-118	transcobalamin 2	Mus musculus	84-87
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	transcobalamin 2	Mus musculus	254-257
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	0-9	transcobalamin 2	Mus musculus	303-306
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	transcobalamin 2	Mus musculus	254-257
17106136-0	2006	Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent.	Sirolimus	19-28	LIM domain binding 3	Homo sapiens	44-50
17106136-1	2006	We estimated the benefit of a sirolimus-eluting stent (SES, Cypher) for diffuse (&gt; 10 mm) in-stent restenosis (ISR) inside bare metal stents (BMS) because the feasibility of the SES was not confirmed after its recent approval in Japan.	Sirolimus	30-39	LIM domain binding 3	Homo sapiens	60-66
16871248-0	2006	The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?	Sirolimus	13-22	calcineurin binding protein 1	Homo sapiens	64-85
16906035-1	2006	BACKGROUND: Calcineurin inhibitor(CNI)-free protocols using sirolimus (SRL) in kidney transplantation have proven effective, although reports have linked SRL to proteinuria.	Sirolimus	60-69	calcineurin binding protein 1	Homo sapiens	12-33
20053795-7	2010	Consistent with data obtained using single transporter transfected cells, compounds that exhibited preferential inhibition of MATE1 such as rapamycin and mitoxantrone induced significant cellular accumulation of cationic substrates.	Sirolimus	140-149	solute carrier family 47 member 1	Homo sapiens	126-131
16740435-13	2006	CONCLUSIONS: Monitored sirolimus conversion with sharp withdrawal of calcineurin inhibitor is an alternative for patients with deteriorating renal function and chronic allograft nephropathy.	Sirolimus	23-32	calcineurin binding protein 1	Homo sapiens	69-90
17067487-8	2006	Similarly, treatment with RPM significantly decreased HMGB1 mRNA expression in the lungs at 2, 6, 24 and 48 h, in the liver at 6 and 24 h, and in the small intestine at 24 and 48 h (P &lt; 0.05 or P &lt; 0.01).	Sirolimus	26-29	high mobility group box 1	Rattus norvegicus	54-59
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	Sirolimus	130-139	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	32-42
16678029-5	2006	With the introduction of rapamycin, the patients were given a lower dose of calcineurin inhibitors, and the calcineurin inhibitor was discontinued in 5 patients.	Sirolimus	25-34	calcineurin binding protein 1	Homo sapiens	76-97
20701074-4	2010	We validated these targets and focused on Annexin A13, a target where decreased expression caused tumor cell insensitivity to Rapamycin.	Sirolimus	126-135	annexin A13	Homo sapiens	42-53
20701074-5	2010	Ectopic overexpression of Annexin A13 was likewise sufficient to sensitize malignant breast cancer cells to treatment with Rapamycin.	Sirolimus	123-132	annexin A13	Homo sapiens	26-37
20168088-0	2010	Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia.	Sirolimus	104-113	cAMP responsive element binding protein 1	Homo sapiens	32-36
20168088-4	2010	Rapamycin administration caused a significant reduction of 70 kDa S6 kinase (p70S6K) phosphorylation and a significant increase of the autophagic proteins Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3), as of monodansylcadaverine (MDC) labeling in the lesioned side.	Sirolimus	0-9	beclin 1	Homo sapiens	155-214
20168088-4	2010	Rapamycin administration caused a significant reduction of 70 kDa S6 kinase (p70S6K) phosphorylation and a significant increase of the autophagic proteins Beclin 1 and microtubule-associated protein 1 light chain 3 (LC3), as of monodansylcadaverine (MDC) labeling in the lesioned side.	Sirolimus	0-9	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	216-219
20087180-4	2010	RECENT FINDINGS: In this review, I discuss the basic science findings that position the TSC1 and TSC2 genes as critical regulators of the mammalian target of rapamycin kinase within mammalian target of rapamycin complex 1.	Sirolimus	158-167	TSC complex subunit 2	Homo sapiens	97-101
20087180-4	2010	RECENT FINDINGS: In this review, I discuss the basic science findings that position the TSC1 and TSC2 genes as critical regulators of the mammalian target of rapamycin kinase within mammalian target of rapamycin complex 1.	Sirolimus	202-211	TSC complex subunit 2	Homo sapiens	97-101
20542782-2	2010	We evaluated the HRQL following sirolimus-eluting coronary stent (SES) (CYPHER(R); Cordis, Johnson &amp; Johnson, Warren, NJ, USA) implantation in patients with multivessel disease, comparing the outcomes with the historical surgical and bare metal stent (BMS) arms of the ARTS-I study.	Sirolimus	32-41	LIM domain binding 3	Homo sapiens	72-78
20206401-7	2010	Interestingly, mTOR signaling was overactivated in the spleen of portal hypertensive rats, and mTOR blockade by rapamycin profoundly ameliorated splenomegaly, causing a 44% decrease in spleen size.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Rattus norvegicus	95-99
20430208-0	2010	Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital"s experience.	Sirolimus	9-18	calcineurin binding protein 1	Homo sapiens	19-40
20723405-14	2010	(3) IL-12p40, IL-12p70 secretion by DC from sirolimus devoid trauma group [(120 +/- 13), (10 +/- 3) pg/mL] were significantly reduced as compared with those from sirolimus devoid control group [(200 +/- 25), (20 +/- 6) pg/mL, with F value respectively 218.646, 310.253, P values all below 0.05].	Sirolimus	44-53	interleukin 12b	Mus musculus	4-12
20149931-1	2010	Rapamycin is an oral immunosuppressant drug previously reported to efficiently induce naturally occurring CD4(+)CD25(+)FoxP3(+) regulatory T ((n)T(reg)) cells re-establishing long-term immune self-tolerance in autoimmune diseases.	Sirolimus	0-9	CD4 antigen	Mus musculus	106-109
19966866-4	2010	Tsc1-Kras(G12D) tumors showed consistent activation of mTOR (mammalian target of rapamycin)C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in Kras(G12D) alone mice.	Sirolimus	81-90	KRAS proto-oncogene, GTPase	Homo sapiens	5-9
19966866-4	2010	Tsc1-Kras(G12D) tumors showed consistent activation of mTOR (mammalian target of rapamycin)C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in Kras(G12D) alone mice.	Sirolimus	126-135	KRAS proto-oncogene, GTPase	Homo sapiens	5-9
19966866-8	2010	Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	83-87
20148532-1	2010	Coadministration of the calcineurin inhibitor cyclosporine (CsA) and the mTOR inhibitors sirolimus (SRL) or everolimus (RAD) increases the efficacy of immunosuppression after organ transplantation.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Rattus norvegicus	73-77
19955189-0	2010	Sirolimus and cyclosporine A alter barrier function in renal proximal tubular cells through stimulation of ERK1/2 signaling and claudin-1 expression.	Sirolimus	0-9	claudin 1	Canis lupus familiaris	128-137
19955189-10	2010	U0126 also reduced the CsA and CsA/SRL-induced increase in the membrane localization of claudin-1.	Sirolimus	35-38	claudin 1	Canis lupus familiaris	88-97
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	chemokine (C-C motif) ligand 2	Mus musculus	211-245
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	chemokine (C-C motif) ligand 2	Mus musculus	247-252
20086156-3	2010	Stimulation of PMBC by SEB was effectively blocked by rapamycin as evidenced by the inhibition of tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), IL-6, IL-2, gamma interferon (IFN-gamma), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-1beta, and T-cell proliferation.	Sirolimus	54-63	chemokine (C-C motif) ligand 4	Mus musculus	308-317
20086156-5	2010	The serum levels of MCP-1 and IL-6, after intranasal exposure to SEB, were significantly reduced in mice given rapamycin versus controls.	Sirolimus	111-120	chemokine (C-C motif) ligand 2	Mus musculus	20-25
19958352-8	2010	Rapamycin, an inhibitor of mTOR involved in CEBPB translation, completely blocked the increase in LIP in FL-stimulated FLT3-WT- but not FLT3-ITD-positive cells.	Sirolimus	0-9	FMS-like tyrosine kinase 3	Mus musculus	119-123
20155737-7	2010	They developed a base and final model with a genotype covariate for CL/F in patients receiving calcineurin inhibitor (CNI)-free therapy with SRL, mycophenolate mofetil and corticosteroids.	Sirolimus	141-144	calcineurin binding protein 1	Homo sapiens	95-116
20209637-9	2010	In conclusion, the reduced mortality induced by RAPA in a rat model of aGVHD after LTx was associated with higher percentages of CD4+CD25+Foxp3+ Treg cells in PBMCs in blood and tissues than those occurring after the administration of FK506.	Sirolimus	48-52	Cd4 molecule	Rattus norvegicus	129-132
19395678-9	2010	Furthermore, multiple other genes were found to be overexpressed in rapamycin-treated TSC2-deficient cells compared with TSC2(+) cells.	Sirolimus	68-77	TSC complex subunit 2	Homo sapiens	86-90
19395678-9	2010	Furthermore, multiple other genes were found to be overexpressed in rapamycin-treated TSC2-deficient cells compared with TSC2(+) cells.	Sirolimus	68-77	TSC complex subunit 2	Homo sapiens	121-125
19805410-9	2010	However, repair of both strands in genes decreases in the wild-type strain and the tor1tor2(ts) mutant exposed to rapamycin.	Sirolimus	114-123	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	83-91
19666112-0	2009	Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	91-95
19666112-1	2009	The mTOR kinase inhibitor rapamycin (sirolimus) is a drug with potent immunosuppressive and antiproliferative properties.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
19666112-1	2009	The mTOR kinase inhibitor rapamycin (sirolimus) is a drug with potent immunosuppressive and antiproliferative properties.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
19858414-0	2009	Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry.	Sirolimus	26-35	LIM domain binding 3	Homo sapiens	134-140
19858414-2	2009	METHODS AND RESULTS: j-Cypher is a multicenter prospective registry of consecutive patients undergoing sirolimus-eluting stent implantation in Japan.	Sirolimus	103-112	LIM domain binding 3	Homo sapiens	23-29
19923086-1	2009	OBJECTIVE: To investigate the efficacy of conversion from calcineurin-inhibitor (CNI) to rapamycin in liver recipients with CNI-associated renal insufficiency.	Sirolimus	89-98	calcineurin binding protein 1	Homo sapiens	124-127
19923086-6	2009	CONCLUSION: Rapamycin can be used safely as a good alternative in liver transplant recipients with CNI-related renal insufficiency.	Sirolimus	12-21	calcineurin binding protein 1	Homo sapiens	99-102
16678029-13	2006	CONCLUSIONS: The introduction of rapamycin to the immunosuppressive regimen of patients taking calcineurin inhibitors, with a concomitant reduction of the calcineurin inhibitor dose, may improve renal function within 30 days, without a significant increase in rejection.	Sirolimus	33-42	calcineurin binding protein 1	Homo sapiens	95-116
19789339-0	2009	The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.	Sirolimus	124-133	insulin like growth factor 1 receptor	Homo sapiens	4-41
16396989-10	2006	Rapamycin completely blocked insulin-activated mTOR/p70S(6)K signaling and mitogenesis.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	52-60
16473276-5	2006	For F3-RARalpha, these properties were rapamycin sensitive.	Sirolimus	39-48	retinoic acid receptor, alpha	Mus musculus	7-15
19542890-5	2009	More substantial reduction in CNI levels is safe and effective with the introduction of sirolimus or everolimus.	Sirolimus	88-97	calcineurin binding protein 1	Homo sapiens	30-33
19589861-8	2009	Rapamycin blocked activation of P-mTOR, P-S6K1, and P-4EBP1 proteins and significantly reduced the number of proliferating cells in the myometrium of OVX rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	34-38
16421477-9	2006	Maintenance immunosuppression with the combination of a calcineurin inhibitor and sirolimus carried a significantly higher risk of TMA than a calcineurin inhibitor alone.	Sirolimus	82-91	calcineurin binding protein 1	Homo sapiens	142-163
19843381-4	2009	In this study, the expression of the wild and mutant type of the GSTT-1 gene of those stable transformants in cell lines and in bone marrow cells from MDS patients by reverse-transcription polymerase chain reaction (RT-PCR) was observed in the presence or absence of rapamycin.	Sirolimus	267-276	glutathione S-transferase theta 1	Homo sapiens	65-71
19843381-5	2009	Significant growth inhibition by rapamycin was observed among stable transformants for the mutant GSTT-1 gene, but not wild type GSTT-1 gene, and was indicative of typical apoptosis.	Sirolimus	33-42	glutathione S-transferase theta 1	Homo sapiens	98-104
19790156-8	2009	The following markers of epithelial-mesenchymal transition--vimentin protein expression, S100 calcium binding protein A4 and transforming growth factor beta 1 messenger RNA, and the mothers against decapentaplegic homolog signaling pathway--were all reduced after rapamycin treatment.	Sirolimus	264-273	S100 calcium-binding protein A4	Rattus norvegicus	89-158
19596836-8	2009	Re-expression of TSC2 or treatment with rapamycin inhibited IFN-gamma-induced STAT3 phosphorylation and synergized with IFN-gamma in inhibiting TSC2-null and LAMD cell proliferation.	Sirolimus	40-49	TSC complex subunit 2	Homo sapiens	144-148
20092777-9	2009	(2) The expression of VEGF mRNA, VEGF and PCNA protein in tumor tissues and concentration of VEGF in the peripheral blood were remarkably down-regulated in RPM group compared with control group (P &lt; 0.05) and were not remarkably different in CsA group from in control (P &gt; 0.05).	Sirolimus	156-159	vascular endothelial growth factor A	Mus musculus	22-26
20092777-9	2009	(2) The expression of VEGF mRNA, VEGF and PCNA protein in tumor tissues and concentration of VEGF in the peripheral blood were remarkably down-regulated in RPM group compared with control group (P &lt; 0.05) and were not remarkably different in CsA group from in control (P &gt; 0.05).	Sirolimus	156-159	vascular endothelial growth factor A	Mus musculus	33-37
20092777-9	2009	(2) The expression of VEGF mRNA, VEGF and PCNA protein in tumor tissues and concentration of VEGF in the peripheral blood were remarkably down-regulated in RPM group compared with control group (P &lt; 0.05) and were not remarkably different in CsA group from in control (P &gt; 0.05).	Sirolimus	156-159	proliferating cell nuclear antigen	Mus musculus	42-46
20092777-9	2009	(2) The expression of VEGF mRNA, VEGF and PCNA protein in tumor tissues and concentration of VEGF in the peripheral blood were remarkably down-regulated in RPM group compared with control group (P &lt; 0.05) and were not remarkably different in CsA group from in control (P &gt; 0.05).	Sirolimus	156-159	vascular endothelial growth factor A	Mus musculus	33-37
20092777-11	2009	CONCLUSION: RPM can inhibit angiogenesis and tumor progression of HCC by down-regulated the gene and protein expression of VEGF and inhibited the growth of tumor.	Sirolimus	12-15	vascular endothelial growth factor A	Mus musculus	123-127
19474189-9	2009	The highly selective mTOR inhibitor, rapamycin, inhibited increased phosphorylation of rpS6 and blocked 60-70% of the hypertrophy seen in wild-type mice but failed to prevent the approximately 10% hypertrophy seen in S6K1(-/-) mice in response to uninephrectomy (UNX) although it did inhibit the basal rpS6 phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	217-221
16386683-4	2006	METHODS: Reports available from April 2003 through December 2004 for hypersensitivity-like reactions associated with the sirolimus-eluting stent (CYPHER, Cordis Corp., Miami Lakes, Florida) and paclitaxel-eluting stent (TAXUS, Boston Scientific Corp., Natick, Massachusetts) were reviewed.	Sirolimus	121-130	LIM domain binding 3	Homo sapiens	146-152
19625166-0	2009	Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.	Sirolimus	15-24	Cd4 molecule	Rattus norvegicus	189-192
19443844-1	2009	OBJECTIVE: We evaluated the stages of VEGF-A(164) driven angiogenesis that are inhibited by therapeutic doses of rapamycin and the potential role of S6K1 in that response.	Sirolimus	113-122	vascular endothelial growth factor A	Mus musculus	38-44
19443844-3	2009	Rapamycin (0.5 mg/kg/d) effectively inhibited mTOR and downstream S6K1 signaling and partially inhibited Akt signaling, likely through effects on TORC2.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	66-70
19220580-9	2009	Treatment of 10-0505 tumours with sorafenib plus rapamycin resulted in growth inhibition, inhibition of vascular endothelial growth factor receptor-2 phosphorylation, increased apoptosis and completely blocked sorafenib-induced phosphorylation of mTOR targets and cyclin B1 expression.	Sirolimus	49-58	kinase insert domain receptor	Homo sapiens	104-149
19451225-8	2009	In conclusion, the deregulation of mTORC1 activation underlies the aberrant growth and proliferation of NF2-associated tumors and may restrain the growth of these lesions through negative feedback mechanisms, suggesting that rapamycin in combination with phosphoinositide 3-kinase inhibitors may be therapeutic for NF2.	Sirolimus	225-234	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	104-107
19451225-8	2009	In conclusion, the deregulation of mTORC1 activation underlies the aberrant growth and proliferation of NF2-associated tumors and may restrain the growth of these lesions through negative feedback mechanisms, suggesting that rapamycin in combination with phosphoinositide 3-kinase inhibitors may be therapeutic for NF2.	Sirolimus	225-234	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	315-318
19451229-8	2009	Merlin-negative lines are sensitive to the growth-inhibitory effect of rapamycin, and the expression of recombinant merlin renders them partially resistant to rapamycin.	Sirolimus	71-80	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	0-6
19451229-11	2009	Furthermore, they reveal that merlin-negative mesotheliomas display unregulated mTORC1 signaling and are sensitive to rapamycin, thus providing a preclinical rationale for prospective, biomarker-driven clinical studies of mTORC1 inhibitors in these tumors.	Sirolimus	118-127	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	30-36
16474302-0	2006	[In-hospital and remote results of the use of sirolimus coated coronary stent CYPHER].	Sirolimus	46-55	LIM domain binding 3	Homo sapiens	78-84
19321761-11	2009	The novel finding that rapamycin decreases hypertension, heart enlargement and mTOR signalling in the heart in PKD rats is reported.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Rattus norvegicus	79-83
16236799-4	2006	Interestingly, however, fluorescent protein constructs incorporating either full-length K-ras4B or its plasma membrane-targeting sequence alone undergo rapamycin-induced transfer from the plasma membrane to mitochondria on a time scale of minutes, demonstrating the rapidly reversible nature of K-ras4B binding to the plasma membrane.	Sirolimus	152-161	KRAS proto-oncogene, GTPase	Homo sapiens	88-95
19564562-1	2009	BACKGROUND: Although both sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents have demonstrated efficacy and safety in clinical trials, human autopsy data have raised concerns about long-term healing and the potential for local inflammatory reactions.	Sirolimus	26-35	LIM domain binding 3	Homo sapiens	37-43
16236799-4	2006	Interestingly, however, fluorescent protein constructs incorporating either full-length K-ras4B or its plasma membrane-targeting sequence alone undergo rapamycin-induced transfer from the plasma membrane to mitochondria on a time scale of minutes, demonstrating the rapidly reversible nature of K-ras4B binding to the plasma membrane.	Sirolimus	152-161	KRAS proto-oncogene, GTPase	Homo sapiens	295-302
16204354-6	2005	By comparing the emission photon yields in the presence and absence of rapamycin, the specific BRET signal was determined.	Sirolimus	71-80	delta/notch-like EGF repeat containing	Mus musculus	95-99
16171514-6	2005	Whereas eEF2 phosphorylation levels altered by BDNF were inhibited by rapamycin, eEF1A phosphorylation was not affected by rapamycin or PD98059, a mitogen-activated protein kinase kinase (MEK) inhibitor.	Sirolimus	70-79	brain derived neurotrophic factor	Homo sapiens	47-51
16221205-9	2005	The 45 kD or 20 kD caspase-1 was increased by I/R or CsA, respectively, and decreased by rapamycin (P &lt; 0.05).	Sirolimus	89-98	caspase 1	Rattus norvegicus	19-28
16179256-3	2005	Impaired checkpoint function is observed both in cells lacking FPR3 and in cells treated with rapamycin, a small molecule inhibitor that binds to the proline isomerase (PPIase) domain of Fpr3.	Sirolimus	94-103	formyl peptide receptor 3	Homo sapiens	187-191
19620795-5	2009	Rapamycin and its related analogs such as Temsirolimus and Everolimus are less toxic for humans compared with other anti-VEGFR inhibitors and has been used as an immunosuppressive agent.	Sirolimus	0-9	kinase insert domain receptor	Homo sapiens	121-126
19364503-4	2009	Here, we show that inhibition of mTOR signaling with its specific inhibitor, rapamycin, suppresses normal thymocyte DNA synthesis by downregulating 4EBP1, but not S6K, and that 4EBP1 phosphorylation and cyclin D1 expression are coordinately increased in Atm-/- thymocytes.	Sirolimus	77-86	cyclin D1	Mus musculus	203-212
19364503-5	2009	Administration of rapamycin to Atm-/- mice attenuates elevated phospho-4EBP1, c-Myc and cyclin D1 in their thymocytes, and delays thymic lymphoma development.	Sirolimus	18-27	cyclin D1	Mus musculus	88-97
15946946-7	2005	The association of eIF3j with the other eIF3 subunits appears to be inhibited by rapamycin, suggesting a mechanism that lies downstream from the mammalian target of rapamycin kinase.	Sirolimus	81-90	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	19-23
15943635-0	2005	Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials.	Sirolimus	38-47	calcineurin binding protein 1	Homo sapiens	0-21
15943635-2	2005	We conducted a systematic review of randomized trials that involved CNI withdrawal from a sirolimus-based immunosuppressive regimen.	Sirolimus	90-99	calcineurin binding protein 1	Homo sapiens	68-71
15943635-4	2005	CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p &lt; 0.00001) at 1 year compared to continued CNI and sirolimus therapy.	Sirolimus	20-29	calcineurin binding protein 1	Homo sapiens	0-3
15943635-4	2005	CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p &lt; 0.00001) at 1 year compared to continued CNI and sirolimus therapy.	Sirolimus	20-29	calcineurin binding protein 1	Homo sapiens	287-290
15943635-4	2005	CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p &lt; 0.00001) at 1 year compared to continued CNI and sirolimus therapy.	Sirolimus	295-304	calcineurin binding protein 1	Homo sapiens	0-3
15943635-7	2005	CNI withdrawal from sirolimus-based therapy is associated with an increased risk of acute rejection in the short term with a significant improvement in renal function and a reduction in hypertension.	Sirolimus	20-29	calcineurin binding protein 1	Homo sapiens	0-3
15737962-5	2005	The aim of this study was to evaluate the relative efficacy of sirolimus-eluting stents (Cypher) as compared with that of bare stents with thin struts (BeStent 2).	Sirolimus	63-72	LIM domain binding 3	Homo sapiens	89-95
15971149-5	2005	Wortmannin and rapamycin preferentially affected the response to GLP-1 and insulin, respectively.	Sirolimus	15-24	glucagon	Rattus norvegicus	65-70
19545746-0	2009	Effect of cyclosporine and sirolimus on fatty acid desaturase activities in cultured HEPG2 cells.	Sirolimus	27-36	stearoyl-CoA desaturase	Homo sapiens	40-61
19424019-8	2009	In conclusion, lymphopenia-induced IL-7 production after induction with ATG and sirolimus might lead to emergence of IFN-gamma-secreting CD8+ T-cells responsible for acute rejection after immunosuppression withdrawal.	Sirolimus	80-89	CD8a molecule	Homo sapiens	137-140
19420259-2	2009	The TSC1/TSC2 protein complex plays a major role in controlling the Ser/Thr kinase mammalian target of rapamycin (mTOR), which is a master regulator of protein synthesis and cell growth.	Sirolimus	103-112	TSC complex subunit 2	Homo sapiens	9-13
19539558-0	2009	Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.	Sirolimus	67-76	CD4 antigen	Mus musculus	20-23
19539558-7	2009	Even though the cell numbers of CD4(+) T cells were found to decrease in sirolimus-treated mice, sirolimus selectively enhanced the numbers of CD4(+)CD25(+) cells and increased the expression of Foxp3 in spleens and lymph nodes, respectively, in recipients.	Sirolimus	73-82	CD4 antigen	Mus musculus	32-35
19539558-7	2009	Even though the cell numbers of CD4(+) T cells were found to decrease in sirolimus-treated mice, sirolimus selectively enhanced the numbers of CD4(+)CD25(+) cells and increased the expression of Foxp3 in spleens and lymph nodes, respectively, in recipients.	Sirolimus	97-106	CD4 antigen	Mus musculus	143-146
19002496-8	2009	Intratumoral microvessel density and circulating levels of VEGF in tumor-bearing mice were also significantly reduced in sirolimus treatment group.	Sirolimus	121-130	vascular endothelial growth factor A	Mus musculus	59-63
15868910-2	2005	Sirolimus is an inhibitor of the cytosolic mTOR-kinase, associated with the phosphoinositide-3-kinase/Akt pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	43-47
15358595-6	2005	Inhibition of phosphatidylinositol (PI)3-kinase with LY-294002 or mTOR/p70S6K1 with rapamycin reduced [3H]thymidine incorporation by 50%, i.e., to levels comparable to those achieved by addition of either AG-1478 or GM-6001.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Rattus norvegicus	66-70
15654601-6	2005	Coincubation with the mTOR inhibitor, rapamycin, effectively inhibited the proteosomal degradation of IRS-1 caused by the chronic insulin treatment.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Canis lupus familiaris	22-26
15654601-6	2005	Coincubation with the mTOR inhibitor, rapamycin, effectively inhibited the proteosomal degradation of IRS-1 caused by the chronic insulin treatment.	Sirolimus	38-47	insulin	Canis lupus familiaris	130-137
15654601-7	2005	Although the coincubation with rapamycin and advanced overexpression of IRS-1 effectively ameliorated subsequent insulin-induced phosphorylation of Akt, insulin stimulation of PKClambda activity and 2-DOG uptake was partly restored by these treatments.	Sirolimus	31-40	insulin	Canis lupus familiaris	113-120
15654601-7	2005	Although the coincubation with rapamycin and advanced overexpression of IRS-1 effectively ameliorated subsequent insulin-induced phosphorylation of Akt, insulin stimulation of PKClambda activity and 2-DOG uptake was partly restored by these treatments.	Sirolimus	31-40	insulin	Canis lupus familiaris	153-160
15654601-9	2005	Furthermore, the decreased insulin-induced PKClambda activity and 2-DOG uptake following chronic insulin treatment were ameliorated by the expression of DeltaIP-SHIP2 more effectively than by the treatment with rapamycin.	Sirolimus	211-220	insulin	Canis lupus familiaris	27-34
15654601-9	2005	Furthermore, the decreased insulin-induced PKClambda activity and 2-DOG uptake following chronic insulin treatment were ameliorated by the expression of DeltaIP-SHIP2 more effectively than by the treatment with rapamycin.	Sirolimus	211-220	insulin	Canis lupus familiaris	97-104
15701277-5	2005	All glioma cell lines tested had markedly diminished production of vascular endothelial growth factor (VEGF) when cultured with rapamycin, even at doses below the IC50.	Sirolimus	128-137	vascular endothelial growth factor A	Mus musculus	67-101
15701277-5	2005	All glioma cell lines tested had markedly diminished production of vascular endothelial growth factor (VEGF) when cultured with rapamycin, even at doses below the IC50.	Sirolimus	128-137	vascular endothelial growth factor A	Mus musculus	103-107
15701277-6	2005	After 48 h of exposure to rapamycin, the glioma cell lines (but not HOG cells) showed downregulation of the membrane type-1 matrix metalloproteinase (MMP) invasion molecule.	Sirolimus	26-35	matrix metallopeptidase 2	Mus musculus	150-153
15701277-7	2005	In U-87 cells, MMP-2 was downregulated, and in D-54 cells, both MMP-2 and MMP-9 were downregulated after treatment with rapamycin.	Sirolimus	120-129	matrix metallopeptidase 2	Mus musculus	64-69
15701277-9	2005	Immunohistochemical studies of subcutaneous U-87 tumors demonstrated diminished production of VEGF in mice treated with rapamycin.	Sirolimus	120-129	vascular endothelial growth factor A	Mus musculus	94-98
15701277-10	2005	Gelatin zymography showed marked reduction of MMP-2 in the mice with subcutaneous U-87 xenografts that were treated with rapamycin as compared with controls treated with phosphatebuffered saline.	Sirolimus	121-130	matrix metallopeptidase 2	Mus musculus	46-51
15557109-14	2005	We conclude that rapamycin-sensitive mTOR activity was critical to tumor progression in the Eker rat model, but rapamycin is unlikely to eradicate all disease as a result of the development of drug resistance.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Rattus norvegicus	37-41
15634505-7	2004	In rapamycin treated group, the expression of HIF-1alpha was inhibited to weak positive or negative (P &lt; 0.05), the VEGF protein and mRNA expression decreased (P &lt; 0.05), MVD was also suppressed to a low level (13 +/- 5).	Sirolimus	3-12	vascular endothelial growth factor A	Mus musculus	119-123
15381120-1	2004	The Saccharomyces cerevisiae allantoate/ureidosuccinate permease gene (DAL5) is often used as a reporter in studies of the Tor1/2 protein kinases which are specifically inhibited by the clinically important immunosuppressant and anti-neoplastic drug, rapamycin.	Sirolimus	251-260	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	123-129
15286700-7	2004	Furthermore, rapamycin, an inhibitor of mTOR and consequently of p70S6K, did not alter PRL stimulation of c-Myc and c-Fos mRNA expression and it had a very minor inhibitory effect on PRL stimulation of W53 cell proliferation.	Sirolimus	13-22	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	65-71
15349891-8	2004	Rapamycin inhibited the induction of cyclin D1, a known eIF4F-sensitive gene, at the level of protein expression but not messenger RNA (mRNA) expression.	Sirolimus	0-9	cyclin D1	Mus musculus	37-46
19273591-1	2009	Yeast ptc1 mutants are rapamycin and caffeine sensitive, suggesting a functional connection between Ptc1 and the TOR pathway that is not shared by most members of the type 2C phosphatase family.	Sirolimus	23-32	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	6-10
15287957-5	2004	The results suggested that rapamycin, when compared with cytosine arabinoside, mithramycin and cisplatin, is a powerful inducer of erythroid differentiation and gamma-globin mRNA accumulation in human leukaemia K562 cells.	Sirolimus	27-36	hemoglobin subunit gamma 1	Homo sapiens	161-173
19273591-2	2009	Genome-wide profiling revealed that the ptc1 mutation largely attenuates the transcriptional response to rapamycin.	Sirolimus	105-114	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	40-44
19273591-3	2009	The lack of Ptc1 significantly prevents the nuclear translocation of Gln3 and Msn2 transcription factors to the nucleus, as well as the dephosphorylation of the Npr1 kinase, in response to rapamycin.	Sirolimus	189-198	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	12-16
19273591-3	2009	The lack of Ptc1 significantly prevents the nuclear translocation of Gln3 and Msn2 transcription factors to the nucleus, as well as the dephosphorylation of the Npr1 kinase, in response to rapamycin.	Sirolimus	189-198	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	161-165
15287957-6	2004	In addition, when normal human erythroid precursors were cultured in the presence of rapamycin, gamma-globin mRNA accumulation and fetal haemoglobin (HbF) production increased to levels that were higher than those obtained using hydroxyurea.	Sirolimus	85-94	hemoglobin subunit gamma 1	Homo sapiens	96-108
19188252-8	2009	Surprisingly, rapamycin treatment prior to resistance exercise completely blocked the contraction-induced increase in the phosphorylation of ERK1/2 (Thr202/Tyr204) and blunted the increase in MNK1 (Thr197/202) phosphorylation.	Sirolimus	14-23	MAPK interacting serine/threonine kinase 1	Homo sapiens	192-196
15291810-5	2004	AU5-dHAND expressed in 293T cells became phosphorylated, possibly at its Akt phosphorylation motif, in the absence of kinase inhibitors, whereas the phosphatidylinositol 3-kinase inhibitor wortmannin and the Akt inhibitor NL-71-101, but not the p70 S6 kinase inhibitor rapamycin, significantly reduced dHAND phosphorylation.	Sirolimus	269-278	hand	Drosophila melanogaster	4-9
19260063-6	2009	Furthermore, repetitive stretching-induced suppression of muscle atrophy was fully inhibited by rapamycin, a potent inhibitor of mTOR.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Rattus norvegicus	129-133
19162189-9	2009	In situ MMP-2/MMP-9 activity was significantly reduced in grafts treated with tacrolimus and rapamycin compared to controls (p&lt;0.05).	Sirolimus	93-102	matrix metallopeptidase 9	Homo sapiens	14-19
19376410-2	2009	The safety and tolerance of calcineurin inhibitor (CNI)-free sirolimus-based immunosuppressant protocols in liver transplant recipients with malignancies or high risk of tumor recurrence has been scarcely evaluated.	Sirolimus	61-70	calcineurin binding protein 1	Homo sapiens	28-49
19295318-0	2009	Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.	Sirolimus	18-27	calcineurin binding protein 1	Homo sapiens	31-52
19220291-0	2009	Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.	Sirolimus	14-23	low density lipoprotein receptor	Mus musculus	122-134
19220291-7	2009	Compared with placebo, plasma levels of interleukin-6, monocyte chemoattractant protein-1, interferon gamma, tumour necrosis factor alpha and CD40, and their mRNA levels in aortic tissue were significantly reduced in sirolimus-treated mice.	Sirolimus	217-226	chemokine (C-C motif) ligand 2	Mus musculus	55-89
19231960-6	2009	Rapamycin treatment resulted in decreases in phosphorylated mTOR expression and phosphorylated p70S6K expression but no change in phosphorylated AKT expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Canis lupus familiaris	60-64
19231960-7	2009	Expression of total AKT, mTOR, and p70S6K persisted after rapamycin treatment.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Canis lupus familiaris	25-29
19231960-10	2009	Activation of the mTOR pathway can be inhibited by rapamycin; treatment of melanoma cells with rapamycin decreased the surviving tumor cell fraction.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Canis lupus familiaris	18-22
19231960-10	2009	Activation of the mTOR pathway can be inhibited by rapamycin; treatment of melanoma cells with rapamycin decreased the surviving tumor cell fraction.	Sirolimus	95-104	mechanistic target of rapamycin kinase	Canis lupus familiaris	18-22
19013662-10	2009	We also show that IGF-I and EGF are involved in the activation of mTOR in bovine MEC, whereas inhibition of mTOR by rapamycin abrogated the suppressive effects of IGF-I and EGF on autophagy.	Sirolimus	116-125	IGFI	Bos taurus	163-168
15158453-4	2004	The mTOR inhibitor rapamycin reversed the dephosphorylation of eEF2 induced by CCK, as did treatment with the p38 MAPK inhibitor SB202190, the MEK inhibitor PD98059, and the phosphatase inhibitor calyculin A.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
15158453-4	2004	The mTOR inhibitor rapamycin reversed the dephosphorylation of eEF2 induced by CCK, as did treatment with the p38 MAPK inhibitor SB202190, the MEK inhibitor PD98059, and the phosphatase inhibitor calyculin A.	Sirolimus	19-28	cholecystokinin	Rattus norvegicus	79-82
15199413-0	2004	Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.	Sirolimus	99-108	ets variant 6	Mus musculus	54-57
15010461-7	2004	Introduction of residue substitutions that impaired dimerization into the full-length protein prevented the ability of Gcn2p to phosphorylate its substrate eukaryotic initiation factor-2alpha and induce GCN4 translational expression in yeast cells subjected to a variety of stresses including amino acid limitation or exposure to rapamycin or high levels of NaCl.	Sirolimus	330-339	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	119-124
19120448-7	2009	We found that (a) the GCN2 pathway was the major, but not unique, signaling pathway involved in the up- and down-regulation of gene expression in response to amino acid starvation, and (b) that rapamycin regulates the expression of a set of genes that only partially overlaps with the set of genes regulated by leucine starvation.	Sirolimus	194-203	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	22-26
19670915-8	2009	Regarding differential efficacy of first-generation DES, a benefit may exist in favour of the Cypher (sirolimus-eluting) stent over Taxus (paclitaxel-eluting), particularly in high-risk lesion subsets.	Sirolimus	102-111	LIM domain binding 3	Homo sapiens	94-100
19330036-13	2009	These studies support clinical testing of rapamycin or other agents that target Treg in K-Ras driven human lung cancer.	Sirolimus	42-51	KRAS proto-oncogene, GTPase	Homo sapiens	88-93
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	46-56
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	102-106
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	179-189
18930332-4	2008	RESULTS: Rapamycin, but not ABT-869, inhibited in vitro growth of Huh7 and SK-HEP-1 HCC cells in a dose dependant manner.	Sirolimus	9-18	MIR7-3 host gene	Homo sapiens	66-70
18930332-5	2008	However, in subcutaneous Huh7 and SK-HEP-1 xenograft models, either ABT-869 or rapamycin can significantly reduce tumor burden.	Sirolimus	79-88	MIR7-3 host gene	Homo sapiens	25-29
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	betacellulin	Rattus norvegicus	153-165
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	225-228
18980262-4	2008	To identify the rapamycin-sensitive phosphorylation sites in yeast Npr1, glutathione-S-transferase (GST)-tagged Npr1 was isolated from untreated or rapamycin-treated cells, and analyzed by mass spectrometry.	Sirolimus	16-25	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	67-71
18980262-4	2008	To identify the rapamycin-sensitive phosphorylation sites in yeast Npr1, glutathione-S-transferase (GST)-tagged Npr1 was isolated from untreated or rapamycin-treated cells, and analyzed by mass spectrometry.	Sirolimus	16-25	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	112-116
18980262-4	2008	To identify the rapamycin-sensitive phosphorylation sites in yeast Npr1, glutathione-S-transferase (GST)-tagged Npr1 was isolated from untreated or rapamycin-treated cells, and analyzed by mass spectrometry.	Sirolimus	148-157	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	67-71
18980262-4	2008	To identify the rapamycin-sensitive phosphorylation sites in yeast Npr1, glutathione-S-transferase (GST)-tagged Npr1 was isolated from untreated or rapamycin-treated cells, and analyzed by mass spectrometry.	Sirolimus	148-157	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	112-116
19100499-0	2008	Severe sirolimus-related inflammatory state anemia in an HIV+ liver transplant patient with calcineurin inhibitor renal insufficiency: a case report.	Sirolimus	7-16	calcineurin binding protein 1	Homo sapiens	92-113
18685609-5	2008	The mTOR inhibitor rapamycin suppressed activation of p70S6K in BaF3/NPM-ALK cells and reversed GC resistance by synergistically inhibiting mTOR signaling pathway, enhancing cell cycle arrest at G(1) phase and promoting apoptotic cell death.	Sirolimus	19-28	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	54-60
18793727-6	2008	Sirolimus is an effective maintenance immunosuppressive agent that safely allows for a reduction in calcineurin-inhibitor dosing.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	100-121
18922904-8	2008	Mechanistically, we find that inhibition of the MAPK pathway circumvents a negative feedback loop imposed on the IGF-IR- insulin receptor substrate 1 (IRS-1) signaling complex, a molecular scenario that parallels the negative feedback loop between mTOR-p70S6K and IRS-1 that mediates rapamycin-directed IGF-IR signaling.	Sirolimus	284-293	insulin like growth factor 1 receptor	Homo sapiens	113-119
18306306-3	2008	As a model, the CYPHER Sirolimus-eluting Coronary Stent was studied.	Sirolimus	23-32	LIM domain binding 3	Homo sapiens	16-22
18650261-8	2008	These increases in glucose uptake and GLUT1 levels were prevented by inhibition of mTOR with rapamycin.	Sirolimus	93-102	solute carrier family 2 member 1	Homo sapiens	38-43
15150095-5	2004	A combination of IFN-gamma and rapamycin is markedly synergistic in induction of apoptosis in Tsc1 or Tsc2 null cells because pSTAT3 Tyr705 phosphorylation is abolished completely and the other effects of IFN-gamma are maintained or enhanced.	Sirolimus	31-40	TSC complex subunit 2	Homo sapiens	102-106
15114090-0	2004	Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation.	Sirolimus	14-23	calcineurin binding protein 1	Homo sapiens	30-51
18657156-0	2008	Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.	Sirolimus	138-147	calcineurin binding protein 1	Homo sapiens	29-50
18798379-1	2008	BACKGROUND: Although previous studies have documented persistent clinical benefit of sirolimus-eluting stents (SES)in reducing the need for target vessel revascularization without an increase in myocardial infarction (MI) or mortality, the long-term safety and efficacy of CYPHER stent use in routine clinical practice, including off-label stent implantation, remains uncertain.	Sirolimus	85-94	LIM domain binding 3	Homo sapiens	273-279
18492954-6	2008	Rapamycin-treated DCs enhanced Th1 induction in vitro compared with untreated DCs.	Sirolimus	0-9	negative elongation factor complex member C/D	Homo sapiens	31-34
18376137-6	2008	We showed that during induction of autophagy by rapamycin, tunicamycin or starvation to amino acids, fluorescence intensity of GFP-LC3 is reduced in a time-dependent manner.	Sirolimus	48-57	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	131-134
18570873-3	2008	Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA.	Sirolimus	172-181	TSC complex subunit 2	Homo sapiens	74-78
18570873-3	2008	Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA.	Sirolimus	172-181	serum/glucocorticoid regulated kinase 1	Homo sapiens	96-100
18570873-3	2008	Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA.	Sirolimus	172-181	serum/glucocorticoid regulated kinase 1	Homo sapiens	199-203
18612231-9	2008	1% steroid- or 0.01% rapamycin-applied eyes both showed positive staining for keratin-4 and -7.	Sirolimus	21-30	keratin 4	Homo sapiens	78-94
18215134-7	2008	Remarkably, loss of TBC1D1 in 3T3-L1 adipocytes activated the mTOR (mammalian target of rapamycin)-p70 S6 protein kinase pathway, and the increase in GLUT1 expression in the cells treated with TBC1D1 siRNA (small interfering RNA) was blocked by the mTOR inhibitor rapamycin.	Sirolimus	88-97	TBC1 domain family member 1	Homo sapiens	20-26
15070696-2	2004	The use of the macrolide rapamycin, selectively inhibiting the phosphoprotein mammalian target of rapamycin (mTOR) downstream of, for example, insulin-like growth factor-I receptor (IGF-IR), possibly represents such a molecular mode of therapy.	Sirolimus	25-34	insulin like growth factor 1 receptor	Homo sapiens	143-180
18418060-3	2008	Recently it was proposed that rapamycin and its derivatives enhance the clearance (and/or reduce the accumulation) of mutant intracellular proteins causing proteinopathies such as tau, alpha-synuclein, ataxin-3, and full-length or fragments of huntingtin containing a polyglutamine (polyQ) expansion, by upregulating macroautophagy.	Sirolimus	30-39	ataxin 3	Homo sapiens	202-210
15070696-2	2004	The use of the macrolide rapamycin, selectively inhibiting the phosphoprotein mammalian target of rapamycin (mTOR) downstream of, for example, insulin-like growth factor-I receptor (IGF-IR), possibly represents such a molecular mode of therapy.	Sirolimus	25-34	insulin like growth factor 1 receptor	Homo sapiens	182-188
18350576-1	2008	OBJECTIVE: Genetic loss of TSC1/TSC2 function in tuberous sclerosis complex (TSC) results in overactivation of the mammalian target of rapamycin complex 1 pathway, leading to cellular dysplasia.	Sirolimus	135-144	TSC complex subunit 2	Homo sapiens	32-36
15060135-11	2004	In these cells, as well as in rapamycin-treated wild-type, S6K1(-/-), and S6K2(-/-) cells, this step was catalyzed by a mitogen-activated protein kinase (MAPK)-dependent kinase, most likely p90rsk.	Sirolimus	30-39	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	59-63
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	sirtuin 1	Homo sapiens	31-36
14660591-5	2004	Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Rattus norvegicus	46-50
18320031-8	2008	It was noted that treatment of SIRT1-.transfected cells with Rapamycin, a mTOR inhibitor, reduced the phosphorylation of S6K1 and the expression of Id1, implying that SIRT1-induced phosphorylation of S6K1 may be partly for the decreased expression of p16(INK4A) and promoted phosphorylation of Rb in 2BS.	Sirolimus	61-70	sirtuin 1	Homo sapiens	167-172
14660591-5	2004	Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin.	Sirolimus	88-97	mechanistic target of rapamycin kinase	Rattus norvegicus	72-76
15256816-0	2004	Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	50-71
18300741-0	2008	Higher incidence and serum levels of minor cardiac biomarker elevation in sirolimus-eluting stent (Cypher) than bare metal stent implantations.	Sirolimus	74-83	LIM domain binding 3	Homo sapiens	99-105
18300741-2	2008	The sirolimus-eluting stent (Cypher) has been reported to require high postinflation pressure for optimal implantation.	Sirolimus	4-13	LIM domain binding 3	Homo sapiens	29-35
18094032-3	2008	The present study explores the efficacy of low-dose mTOR inhibition by rapamycin in a chronic-progressive model of mesangioproliferative glomerulosclerosis (cGS).	Sirolimus	71-80	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
15029110-2	2004	This article reviews the factors previously implicated in the occurrence of stent thrombosis and analyzes recent reports of thrombosis involving a new sirolimus-eluting stent (Cypher).	Sirolimus	151-160	LIM domain binding 3	Homo sapiens	176-182
18094032-10	2008	In conclusion, low-dose mTOR inhibition by rapamycin limits the progressive course of anti-thy1-induced renal disease toward chronic glomerulosclerosis, tubulointerstitial fibrosis, and renal insufficiency.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	24-28
14612104-0	2003	Low-dose sirolimus in combination with mycophenolate in calcineurin inhibitor elimination: the Kuwaiti experience.	Sirolimus	9-18	calcineurin binding protein 1	Homo sapiens	56-77
18173550-8	2008	Moreover, rapamycin inhibited the growth of Ba/F3 cells exhibiting various imatinib-resistant mutants of BCR/ABL, including the T315I variant that exhibits resistance against most currently available BCR/ABL kinase inhibitors.	Sirolimus	10-19	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	109-112
14529371-4	2003	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4 transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	keratin 77	Homo sapiens	270-273
12957289-6	2003	Rapamycin normalizes HIF levels in TSC2(-/-) cells, indicating that TSC2 regulates HIF by inhibiting mTOR.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	35-39
12957289-6	2003	Rapamycin normalizes HIF levels in TSC2(-/-) cells, indicating that TSC2 regulates HIF by inhibiting mTOR.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	68-72
12962787-10	2003	Sirolimus seems to be a promising alternative for the treatment of renal transplant patients who develop calcineurin inhibitor-induced DnHUS.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	105-126
12916871-0	2003	Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: possible clinical application of rapamycin.	Sirolimus	131-140	glutathione S-transferase theta 1	Homo sapiens	12-45
12916871-7	2003	Interestingly, rapamycin could induce significant growth inhibition of the stable transformants for mutant type GSTT-1, which was indicative of apoptosis, but not that of those for wild type GSTT-1.	Sirolimus	15-24	glutathione S-transferase theta 1	Homo sapiens	112-118
12916871-8	2003	These results suggest that rapamycin could be included in the therapeutic modality for the patients with MDS who have the mTOR sequences in GSTT-1 gene.	Sirolimus	27-36	glutathione S-transferase theta 1	Homo sapiens	140-146
12788653-7	2003	of 1 transducing unit/cell and induced with 20 nM rapamycin resulted in a 25-fold increase in RFP mRNA levels after 24 h as assessed by quantitative RT-PCR.	Sirolimus	50-59	tripartite motif containing 27	Homo sapiens	94-97
18608530-4	2008	These results show that rifampicin inhibits rapamycin-induced autophagy, at least in part, via the suppression of PP2A activity.	Sirolimus	44-53	protein phosphatase 2, regulatory subunit A, alpha	Mus musculus	114-118
17996694-2	2007	Using MACS-purified CD4 cells, we found that rapamycin and cyclosporine A (CsA) potently inhibited the TGFbeta and IL-6-induced generation of IL-17-producing cells.	Sirolimus	45-54	interleukin 17A	Homo sapiens	142-147
17664276-6	2007	The insulin resistance of the of the PTP-1B-/- adipocytes could also be rescued by treatment with rapamycin, suggesting that in adipose the loss of PTP-1B results in basal activation of mTOR (mammalian target of rapamycin) complex 1 leading to a tissue-specific insulin resistance.	Sirolimus	98-107	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	37-43
17664276-6	2007	The insulin resistance of the of the PTP-1B-/- adipocytes could also be rescued by treatment with rapamycin, suggesting that in adipose the loss of PTP-1B results in basal activation of mTOR (mammalian target of rapamycin) complex 1 leading to a tissue-specific insulin resistance.	Sirolimus	98-107	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	148-154
17670836-9	2007	On the other hand, rapamycin, an mTOR inhibitor, significantly suppressed VSV replication in GADD34-KO MEFs.	Sirolimus	19-28	protein phosphatase 1, regulatory subunit 15A	Mus musculus	93-99
17603109-10	2007	Overexpression of Ccc1, a Fe2+ and Mn2+ transporter that has been localized to Golgi and the vacuole, does restore rapamycin sensitivity to pmr1Delta.	Sirolimus	115-124	Ccc1p	Saccharomyces cerevisiae S288C	18-22
12750770-7	2003	The PI 3-kinase inhibitor LY294002 and the mTOR inhibitor rapamycin, but not the MEK1 inhibitor PD98059, could prevent IRS1 changes in oxidized cells.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Rattus norvegicus	43-47
12646195-6	2003	MCM6 and MCM7 transcriptional activation is regulated by E2F and activity of a luciferase reporter plasmid driven by four E2F elements was also significantly inhibited by rapamycin.	Sirolimus	171-180	minichromosome maintenance complex component 7	Rattus norvegicus	9-13
12646195-7	2003	The inhibitory effect of rapamycin on MCM6 and MCM7 was reversed by overexpression of E2F, indicating that their downregulation by rapamycin involves an E2F-dependent mechanism.	Sirolimus	25-34	minichromosome maintenance complex component 7	Rattus norvegicus	47-51
12646195-8	2003	These observations suggest that rapamycin inhibits MCM6 and MCM7 expression by blocking their E2F-dependent transactivation which may contribute importantly to the inhibition of VSMC DNA synthesis by rapamycin.	Sirolimus	32-41	minichromosome maintenance complex component 7	Rattus norvegicus	60-64
12505729-9	2003	The EC(50) contour plot for CD54 suggested a nearly identical CsA concentration of 120 ng/ml in the presence of 10 ng/ml of sirolimus.	Sirolimus	124-133	intercellular adhesion molecule 1	Homo sapiens	28-32
12499272-4	2002	In contrast, rapamycin significantly enhanced the efficacy of fractionated radiation of established U87 xenografts in nude mice.	Sirolimus	13-22	small nucleolar RNA, C/D box 87	Mus musculus	100-103
12504590-5	2002	Tsc2 null NEP cells express high levels of phosphorylated S6kinase, S6, Stat3, and 4E-BP-1, which is reversed by treatment with rapamycin, an inhibitor of mTOR.	Sirolimus	128-137	TSC complex subunit 2	Homo sapiens	0-4
12202955-4	2002	Rapamycin inhibited cell proliferation and stimulated tartrate-resistant acid phosphatase (TRAP) activity of RAW cells in a dose-dependent manner.	Sirolimus	0-9	acid phosphatase 5, tartrate resistant	Mus musculus	54-89
12202955-4	2002	Rapamycin inhibited cell proliferation and stimulated tartrate-resistant acid phosphatase (TRAP) activity of RAW cells in a dose-dependent manner.	Sirolimus	0-9	acid phosphatase 5, tartrate resistant	Mus musculus	91-95
12202955-8	2002	The combination of rapamycin (10 ng/ml) and TGF-beta1 (1 ng/ml) increased TRAP+MNC 3.1- and 6.9-fold as compared with rapamycin or TGF-beta1 alone, respectively, and enhanced CTR mRNA expression induced by TGF-beta1 by 1.9-fold.	Sirolimus	19-28	acid phosphatase 5, tartrate resistant	Mus musculus	74-78
12235265-1	2002	The contributions of cytochrome P450 3A (CYP3A) and P-glycoprotein to sirolimus oral bioavailability in rats were evaluated by coadministration of sirolimus (Rapamune) with the CYP3A inhibitor ketoconazole or the P-glycoprotein inhibitor D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS).	Sirolimus	70-79	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	52-66
12165425-4	2002	"Induction" of NCR-sensitive gene expression and dephosphorylation of Gln3 (and Ure2 in some laboratories) when cells are treated with rapamycin implicates the Tor1/2 signal transduction pathway in this regulation.	Sirolimus	135-144	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	160-164
12117303-10	2002	Rapamycin, which prevented insulin-dependent increase in phosphorylation of p70 S6K, increases proteolysis in brown adipocytes and antagonizes the inhibitory effect of insulin on proteolysis, but not the inhibitory effect of NE.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	76-83
17537394-4	2007	The insulin-induced increase of the ENT2 mRNA level was blocked by rapamycin (an inhibitor of mTOR) and by cycloheximide (an inhibitor of protein synthesis), whereas neither wortmannin (an inhibitor of PI3K) nor PD98059 (an inhibitor of MEK) affected the insulin action on the ENT2 transcript level.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Rattus norvegicus	94-98
17537394-7	2007	Rapamycin abolished the insulin effect on the CNT1 mRNA level, but not on the CNT2 mRNA.	Sirolimus	0-9	solute carrier family 28 member 1	Rattus norvegicus	46-50
17570358-3	2007	Treatment of Drosophila Schneider 2 cells with calyculin A, a selective inhibitor of PP2A-like phosphatases, resulted in a 7-fold increase in the basal level of dS6K phosphorylation at the TOR phosphorylation site (Thr398) and blocked dephosphorylation following inactivation of TOR by amino acid starvation or rapamycin treatment.	Sirolimus	311-320	Ribosomal protein S6 kinase	Drosophila melanogaster	161-165
17679098-7	2007	A model is proposed for the molecular architecture of the TOR-KOG1 complex explaining its sensitivity to rapamycin.	Sirolimus	105-114	ubiquitin-binding TORC1 subunit KOG1	Saccharomyces cerevisiae S288C	62-66
17537841-8	2007	Glucose- and insulin-regulated NO production was restored in the presence of the AMPK activator, 5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside or the mTOR inhibitor rapamycin.	Sirolimus	171-180	mechanistic target of rapamycin kinase	Rattus norvegicus	156-160
17376651-6	2007	TGF-beta-stimulated phosphorylation of p70S6 Kinase and TIMP-3 protein induction was inhibited by rapamycin.	Sirolimus	98-107	TIMP metallopeptidase inhibitor 3	Homo sapiens	56-62
17502379-9	2007	We demonstrate that the high levels of HIF activity in cells devoid of TSC2 can be reversed by treatments with rapamycin or the readdition of TSC2.	Sirolimus	111-120	TSC complex subunit 2	Homo sapiens	71-75
17389711-4	2007	Pretreatment with rapamycin prevented the feeding-induced phosphorylation of mTOR, eIF4G, and S6K1 but only partially attenuated the shift in 4E-BP1 into the gamma-form.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Rattus norvegicus	77-81
11931764-3	2002	The genome-wide localization of Rsc9 indicated a relationship between genes targeted by Rsc9 and genes regulated by stress; treatment with hydrogen peroxide or rapamycin, which inhibits TOR signaling, resulted in genome-wide changes in Rsc9 occupancy.	Sirolimus	160-169	Rsc9p	Saccharomyces cerevisiae S288C	32-36
11931764-3	2002	The genome-wide localization of Rsc9 indicated a relationship between genes targeted by Rsc9 and genes regulated by stress; treatment with hydrogen peroxide or rapamycin, which inhibits TOR signaling, resulted in genome-wide changes in Rsc9 occupancy.	Sirolimus	160-169	Rsc9p	Saccharomyces cerevisiae S288C	88-92
11931764-3	2002	The genome-wide localization of Rsc9 indicated a relationship between genes targeted by Rsc9 and genes regulated by stress; treatment with hydrogen peroxide or rapamycin, which inhibits TOR signaling, resulted in genome-wide changes in Rsc9 occupancy.	Sirolimus	160-169	Rsc9p	Saccharomyces cerevisiae S288C	88-92
11916269-1	2002	Quantification of the new immunosuppressant sirolimus (syn.	Sirolimus	44-53	synemin	Homo sapiens	55-58
17616271-4	2007	The approval of the new immunosuppressive agents: rabbit antithymocyte globulin, basiliximab, daclizumab, tacrolimus, mycophenolate, and sirolimus, also has facilitated the development of steroid- and calcineurin inhibitor-sparing regimens in kidney transplantation.	Sirolimus	137-146	calcineurin binding protein 1	Homo sapiens	201-222
17511677-2	2007	Using a transgenic approach to track the fate of host-reactive T cells in a minor antigen disparity model of GVHD, we found that while treatment with CTLA-4 Ig/anti-CD154 retained efficacy, the costimulation agonist anti-CD28 combined with rapamycin failed to prevent GVHD.	Sirolimus	240-249	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	150-156
17321636-6	2007	Animals were treated with the mTOR inhibitor sirolimus for 4 weeks.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Rattus norvegicus	30-34
17331981-9	2007	Rapamycin, which induces eIF2alpha phosphorylation-mediated LC3 conversion, inhibited mutant dysferlin aggregation in the ER.	Sirolimus	0-9	eukaryotic translation initiation factor 2A	Homo sapiens	25-34
17331981-9	2007	Rapamycin, which induces eIF2alpha phosphorylation-mediated LC3 conversion, inhibited mutant dysferlin aggregation in the ER.	Sirolimus	0-9	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	60-63
17353785-0	2007	Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity.	Sirolimus	0-9	interleukin 10	Homo sapiens	32-37
17353785-8	2007	However, we observed only in the RAPA-treated chimeras that the remaining hyporesponsive DLI-derived CD4+ T cells secrete large amounts of IL-10, a known immunoregulatory cytokine.	Sirolimus	33-37	interleukin 10	Homo sapiens	139-144
16990847-5	2007	Both rapamycin and wortmannin, but not PD98059 or CGP74514A, delay the reappearance of eIF4GI.	Sirolimus	5-14	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	87-93
17284993-4	2007	Novel immunosuppressive regimens including mycophenolate mofetil and/or rapamycin that lack nephrotoxicity promise new therapeutic strategies with the efficacy of calcineurin inhibitor-based combinations.	Sirolimus	72-81	calcineurin binding protein 1	Homo sapiens	163-184
17179073-11	2007	Mutants lacking Tsc1 or Tsc2 are highly sensitive to rapamycin under poor nitrogen conditions, suggesting that the function of Tor1 under such conditions is sensitive to rapamycin.	Sirolimus	53-62	TSC complex subunit 2	Homo sapiens	24-28
19153436-1	2007	BACKGROUND: Polymer-based sirolimus (Cypher) and paclitaxel (Taxus) drug-eluting stents (DES) have become the treatment of choice for patients with symptomatic coronary artery disease.	Sirolimus	26-35	LIM domain binding 3	Homo sapiens	37-43
16936779-8	2007	These experiments establish a novel mechanism of action for Bcr-Abl, and they provide insights into the modes of action of imatinib mesylate and rapamycin in treatment of CML.	Sirolimus	145-154	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	60-67
17195205-1	2007	BACKGROUND: Although the sirolimus-eluting stent (CYPHER, Cordis, USA) has shown a dramatic reduction of restenosis, there are still some concerns about its efficacy and safety.	Sirolimus	25-34	LIM domain binding 3	Homo sapiens	50-56
17200203-7	2007	Systemic administration of rapamycin to mice subjected to unilateral ureteral obstruction, a model of renal fibrosis and increased fibrillin-1 synthesis, markedly reduced the number of interstitial fibroblasts and fibrillin-1 deposition.	Sirolimus	27-36	fibrillin 1	Mus musculus	214-225
17671379-2	2007	The effect of mTOR blockade by rapamycin in diabetic nephropathy was investigated, but in vivo study of rapamycin treatment in the course of early diabetes is still insufficient.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
17161482-0	2007	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis.	Sirolimus	58-67	small nucleolar RNA, C/D box 87	Mus musculus	12-15
16891397-7	2006	Pretreatment of the matrix with either sirolimus (2.5 nM) or paclitaxel (10 nM) abolishes the increases in both TGF-beta2 and second harmonic generation in response to epithelial injury.	Sirolimus	39-48	transforming growth factor beta 2	Homo sapiens	112-121
12372044-0	2002	Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.	Sirolimus	102-111	calcineurin binding protein 1	Homo sapiens	0-21
12372044-1	2002	The purpose of this study was to determine whether calcineurin inhibitor (CNI)-induced chronic nephrotoxicity in liver transplant patients is reversible by replacement of the CNI with rapamycin as the primary immunosuppressive agent.	Sirolimus	184-193	calcineurin binding protein 1	Homo sapiens	51-72
12372044-1	2002	The purpose of this study was to determine whether calcineurin inhibitor (CNI)-induced chronic nephrotoxicity in liver transplant patients is reversible by replacement of the CNI with rapamycin as the primary immunosuppressive agent.	Sirolimus	184-193	calcineurin binding protein 1	Homo sapiens	74-77
12372044-11	2002	One patient with chronic nephrolithiasis as a contributing factor to his renal dysfunction has progressed to dialysis dependence despite conversion to rapamycin following exposure to a CNI for 24 months.	Sirolimus	151-160	calcineurin binding protein 1	Homo sapiens	185-188
12372044-15	2002	Rapamycin is an effective replacement agent as primary immunosuppressive therapy following withdrawal of CNIs in liver transplant patients with CNI-induced chronic nephrotoxicity.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	105-108
11309295-15	2001	Under serum-containing conditions, rapamycin inhibited incorporation of BrdUrd significantly more in wild-type murine embryo fibroblasts (MEFs) than in those lacking p53 or p21(CIP1).	Sirolimus	35-44	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	173-176
11309295-15	2001	Under serum-containing conditions, rapamycin inhibited incorporation of BrdUrd significantly more in wild-type murine embryo fibroblasts (MEFs) than in those lacking p53 or p21(CIP1).	Sirolimus	35-44	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	177-181
11171093-7	2001	For the DNA synthesis response to CSF-1, the degree of inhibition by PD98059, wortmannin and rapamycin was significant at low CSF-1 concentrations but was reduced as the CSF-1 dose increased.	Sirolimus	93-102	colony stimulating factor 1 (macrophage)	Mus musculus	34-39
17050028-2	2006	We tested the therapeutic potential of the mTOR inhibitor rapamycin in advanced cirrhosis.	Sirolimus	58-67	mechanistic target of rapamycin kinase	Rattus norvegicus	43-47
17013836-5	2006	While MEK-ERK1/2 inhibition by PD98059 and mTOR inhibition by rapamycin affected the cyclin D1 nuclear shift and cell proliferation to a lesser extent, both these inhibitors reduced cyclin D1 levels.	Sirolimus	62-71	cyclin D1	Mus musculus	85-94
17718966-0	2006	The influence of copolymer chain microstructure on cyclosporine a (CyA) and Sirolimus prolonged and sustained release from PLA/TMC and PLA/PCL matrices.	Sirolimus	76-85	PHD finger protein 1	Homo sapiens	139-142
16883576-5	2006	Rapamycin inhibited p70S6K1, but not AKT activation, indicating that rapamycin affects HDM2 phosphorylation via an AKT-independent mechanism.	Sirolimus	0-9	MDM2 proto-oncogene	Homo sapiens	87-91
16883576-5	2006	Rapamycin inhibited p70S6K1, but not AKT activation, indicating that rapamycin affects HDM2 phosphorylation via an AKT-independent mechanism.	Sirolimus	69-78	MDM2 proto-oncogene	Homo sapiens	87-91
16954170-1	2006	BACKGROUND: Conversion from calcineurin inhibitor to sirolimus, rapamycin has become an option in patients with chronic allograft dysfunction (CAD).	Sirolimus	64-73	calcineurin binding protein 1	Homo sapiens	28-49
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	102-111	interleukin 2 receptor, alpha chain	Mus musculus	80-84
17324390-2	2006	Here, we describe the induction of heat-shock protein 60 (HSP60)-specific CD4(+)CD25(high) T cells by rapamycin (RPM)-treated immature dendritic cells in vitro and explore their effect on plaques in apolipoprotein E-deficient mice.	Sirolimus	113-116	interleukin 2 receptor, alpha chain	Mus musculus	80-84
17324390-4	2006	Naive CD4(+) T cells expressed high levels of CD25 and forkhead box P3 (Foxp3) after incubation with rapamycin-treated and HSP60-loaded DC and displayed moderate antigen-specific, IL-10-independent inhibitory function in vitro.	Sirolimus	101-110	interleukin 2 receptor, alpha chain	Mus musculus	46-50
17324390-6	2006	These findings suggest that RPM-treated DC can induce antigen-specific CD4(+)CD25(high) Treg cells that have inhibitory activity in vitro and prevent the development of plaques in vivo.	Sirolimus	28-31	interleukin 2 receptor, alpha chain	Mus musculus	77-81
16920556-7	2006	Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing.	Sirolimus	45-54	transcobalamin 2	Mus musculus	303-306
16959613-4	2006	Furthermore, in TSC2(-/-) MEFs, the rapamycin-mediated inhibition of deregulated mTOR activity restored NF-kappaB activation and survival.	Sirolimus	36-45	TSC complex subunit 2	Homo sapiens	16-20
11171093-7	2001	For the DNA synthesis response to CSF-1, the degree of inhibition by PD98059, wortmannin and rapamycin was significant at low CSF-1 concentrations but was reduced as the CSF-1 dose increased.	Sirolimus	93-102	colony stimulating factor 1 (macrophage)	Mus musculus	126-131
11171093-7	2001	For the DNA synthesis response to CSF-1, the degree of inhibition by PD98059, wortmannin and rapamycin was significant at low CSF-1 concentrations but was reduced as the CSF-1 dose increased.	Sirolimus	93-102	colony stimulating factor 1 (macrophage)	Mus musculus	126-131
11169223-0	2001	Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production.	Sirolimus	0-9	interleukin 10	Homo sapiens	107-112
16925551-6	2006	Additionally, the transcriptional programme elicited by caffeine resembled that of rapamycin, a potent inhibitor of the TOR1/2 kinases.	Sirolimus	83-92	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	120-124
16762835-2	2006	Chromatin immunoprecipitation (ChIP) coupled to microarray hybridization experiments showed an increased association of Maf1 to Pol III-transcribed genes under repressing condition (rapamycin treatment) correlated with a dissociation of Brf1 and Pol III.	Sirolimus	182-191	RNA polymerase III-inhibiting protein MAF1	Saccharomyces cerevisiae S288C	120-124
16715886-1	2006	Drug-eluting stents (sirolimus-eluting stent: Cypher stent) have showed a reducing the frequency of in-stent restenosis and a good safety profile.	Sirolimus	21-30	LIM domain binding 3	Homo sapiens	46-52
16753877-4	2006	In this study, the expression of wild and mutant type GSTT-1 gene of those stable transformants and bone marrow cells from MDS patients by RT-PCR was observed in the presence or absence of rapamycin.	Sirolimus	189-198	glutathione S-transferase theta 1	Homo sapiens	54-60
16534470-10	2006	CONCLUSIONS: Conversion to a sirolimus-based immunosuppression regimen associated with MMF allowed striking renal function recovery in heart transplant recipients with calcineurin inhibitor-induced renal impairment at midterm follow-up.	Sirolimus	29-38	calcineurin binding protein 1	Homo sapiens	168-189
16507425-12	2006	CONCLUSIONS: Sirolimus enhances immature DC tolerogenicity by induction of T-cell apoptosis, and promotes immature DC-induced inhibition of Stat1, ERK and ATF-2 activation.	Sirolimus	13-22	signal transducer and activator of transcription 1	Mus musculus	140-145
16598544-3	2006	Today, two types of drug-eluting stents are clinically used: the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus).	Sirolimus	65-74	LIM domain binding 3	Homo sapiens	90-96
16778423-8	2006	The thrombosis and withdrawal of sirolimus may have acted as cofactors in the development of KS, favouring the activation of the VEGF/KDR autocrine loop.	Sirolimus	33-42	kinase insert domain receptor	Homo sapiens	134-137
16357868-0	2006	Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension.	Sirolimus	52-61	heme oxygenase 1	Rattus norvegicus	0-16
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	26-35	heme oxygenase 1	Rattus norvegicus	72-88
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	26-35	heme oxygenase 1	Rattus norvegicus	90-94
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	26-35	heme oxygenase 1	Rattus norvegicus	141-145
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	187-196	heme oxygenase 1	Rattus norvegicus	72-88
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	187-196	heme oxygenase 1	Rattus norvegicus	90-94
16357868-2	2006	We previously showed that rapamycin induces the cytoprotective protein, heme oxygenase-1 (HO-1), and more importantly, chemically inhibiting HO-1 blocked the antiproliferative actions of rapamycin.	Sirolimus	187-196	heme oxygenase 1	Rattus norvegicus	141-145
16303023-0	2005	Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials.	Sirolimus	38-47	calcineurin binding protein 1	Homo sapiens	0-21
16358151-3	2005	After the administration of clopidogrel 300 mg associated with acetylsalicylic acid, the patient underwent the implantation of a sirolimus-eluting stent (CYPHER; Johnson &amp; Johnson--Cordis) 2.5 x 1.8 mm in the lesion located at the left marginal branch.	Sirolimus	129-138	LIM domain binding 3	Homo sapiens	154-160
16237714-8	2005	The use of calcineurin inhibitor (CNI)-based immunosuppression is an important factor in the development of chronic kidney disease, and the use of mycophenolic acid- or sirolimus-based immunosuppression with reduced-dose CNI may be of benefit.	Sirolimus	169-178	calcineurin binding protein 1	Homo sapiens	221-224
16243031-4	2005	Knockout of PKBalpha in PTEN-deficient cells reduces aggressive growth and promotes apoptosis, whereas treatment of PTEN(+/-) mice with rapamycin, an inhibitor of the activation of S6K, reduces neoplasia.	Sirolimus	136-145	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	181-184
16162204-0	2005	Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.	Sirolimus	56-65	calcineurin binding protein 1	Homo sapiens	72-93
16321180-1	2005	OBJECTIVE: To compare the short and long-term clinical outcomes of rapamycin (sirolimus)-eluting stent (DES) (CYPHER stent) and paclitaxel-DES (TAXUS stent) in treatment of coronary heart disease (CHD) patients with complicated lesions.	Sirolimus	67-76	LIM domain binding 3	Homo sapiens	110-116
16018822-1	2005	BACKGROUND: Sirolimus-eluting stents (CYPHER stents) demonstrated remarkable efficacy in reducing restenosis rates in patients with coronary artery disease.	Sirolimus	12-21	LIM domain binding 3	Homo sapiens	38-44
15958580-3	2005	Treatment of NeuYD or NeuYD x VEGF mice with rapamycin dramatically inhibited tumor growth accompanied by a marked decrease in tumor vascularization.	Sirolimus	45-54	vascular endothelial growth factor A	Mus musculus	30-34
15769867-17	2005	Rapamycin influences the cell cycle by up-regulation of p27, down-regulation of p21, and inhibition of p70(s6k) phosphorylation.	Sirolimus	0-9	KRAS proto-oncogene, GTPase	Rattus norvegicus	80-83
15849545-0	2005	The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression.	Sirolimus	117-126	calcineurin binding protein 1	Homo sapiens	133-154
15760408-8	2005	Complete abandonment of calcineurin inhibitor therapy by de novo use of the combination sirolimus/mycophenolate mofetil resulted in low rejection rate and avoidance of renal impairment, but should not be used without further evaluation of potential complications in a lager setting.	Sirolimus	88-97	calcineurin binding protein 1	Homo sapiens	24-45
11169223-5	2001	Plasma cytokine analyses revealed a potent inhibitory effect of sirolimus on interleukin(IL)-10 production induced by all bacterial products tested.	Sirolimus	64-73	interleukin 10	Homo sapiens	77-95
15770715-8	2005	RESULTS: Sirolimus alone or combined with tacrolimus inhibited the growth of both cell lines after 5 d by up to 35% in SK-Hep 1 cells, and by up to 68% in Hep 3B cells at 25 ng/mL.	Sirolimus	9-18	DNL-type zinc finger	Homo sapiens	122-127
15770715-10	2005	We found an increase of apoptotic Hep 3B cells from 6 to 16%, and a G1-arrest in SK-Hep 1 cells with an increase of cells from 61 to 82%, when sirolimus and tacrolimus were combined.	Sirolimus	143-152	DNL-type zinc finger	Homo sapiens	84-89
11169223-7	2001	Using a quantitative mRNA analyses, we also observed that sirolimus significantly decreased the IL-10 mRNA accumulation to sub-basal levels in peripheral blood mononuclear cells (PBMC).	Sirolimus	58-67	interleukin 10	Homo sapiens	96-101
11169223-8	2001	This suggests that the sirolimus inhibits IL-10 production by interfering with the IL-10 gene transcription.	Sirolimus	23-32	interleukin 10	Homo sapiens	42-47
11169223-8	2001	This suggests that the sirolimus inhibits IL-10 production by interfering with the IL-10 gene transcription.	Sirolimus	23-32	interleukin 10	Homo sapiens	83-88
11255225-4	2001	Rapamycin, an inhibitor of p70 S6 kinase, suppressed the BMP-4-stimulated VEGF synthesis as well as the phosphorylation of p70 S6 kinase.	Sirolimus	0-9	vascular endothelial growth factor A	Mus musculus	74-78
15692808-12	2005	In addition, we demonstrated that inhibition of the mTOR pathway with rapamycin can prevent insulin resistance caused by chronic hyperinsulinaemia in liver and muscle.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	59-65
15557109-6	2005	Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Rattus norvegicus	40-44
15557109-6	2005	Previous work has shown that a specific mTOR inhibitor, rapamycin, effectively down-regulated mTOR activity in renal tumors of Eker rats that carry a germline Tsc2 mutation.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Rattus norvegicus	94-98
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	99-105
10851233-8	2000	Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity.	Sirolimus	132-141	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	99-105
10454551-6	1999	Moreover, despite rapamycin-induced dephosphorylation of 4BP-1, eIF-4E-eIF-4G complexes (eIF-4F) were still detected.	Sirolimus	18-27	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	71-77
9988711-7	1999	Rapamycin, an inhibitor of p70(s6k) and PHAS-1 phosphorylation, causes a 30-45% reduction in DNA synthesis in keratinocytes, while FTI induces an 80-90% reduction in DNA synthesis.	Sirolimus	0-9	E74 like ETS transcription factor 1	Mus musculus	27-30
15621119-0	2004	Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	113-134
9891068-9	1999	Unlike mitogen stimulation, the p110 induction of cyclin D1 was sensitive to rapamycin.	Sirolimus	77-86	cyclin D1	Mus musculus	50-59
15284343-4	2004	NKCC-mediated (86)Rb(+) influx was enhanced significantly ( approximately 1.6-fold) by acute cell exposure to insulin, but was inhibited significantly by tyrosine kinase inhibitors, wortmannin and rapamycin, consistent with a role for the insulin receptor tyrosine kinase, phosphoinositide 3 (PI3)-kinase and mTOR, respectively, in cotransporter activation.	Sirolimus	197-206	mechanistic target of rapamycin kinase	Rattus norvegicus	309-313
15028555-11	2004	The mTOR inhibitor rapamycin had similar inhibitory effects on G(1) cell cycle progression and on the expression of cyclin D1, CDK4, CDC25A, and retinoblastoma phosphorylation.	Sirolimus	19-28	cell division cycle 25A	Homo sapiens	133-139
15245566-7	2004	Insulin also increased cell size approximately 2-fold and this was prevented by wortmannin and rapamycin, an inhibitor of Drosphilia target of rapamycin (DTOR).	Sirolimus	95-104	Insulin-like receptor	Drosophila melanogaster	0-7
9878560-4	1998	Similar to p70(S6K), p70(S6Kbeta) was activated by serum stimulation, and the serum-induced activation was inhibited by wortmannin and rapamycin.	Sirolimus	135-144	annexin A6	Homo sapiens	11-14
15158963-2	2004	We have demonstrated that the interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine.	Sirolimus	324-333	keratin 77	Homo sapiens	270-273
15366440-0	2004	Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	39-60
9843498-5	1998	Overexpression of NPR1 inhibits growth and induces the degradation of TAT2, whereas loss of NPR1 confers resistance to rapamycin and to FK506, an inhibitor of amino acid import.	Sirolimus	119-128	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	92-96
15064772-0	2004	The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1.	Sirolimus	4-13	cyclin-dependent kinase inhibitor 1B	Mus musculus	89-96
9790922-4	1998	The response to the p85 binding peptide, but not FGF, was inhibited by wortmannin and rapamycin, indicating that the peptide activates the PI 3-kinase/S6 kinase signalling pathway.	Sirolimus	86-95	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	20-23
9755080-10	1998	We have previously shown that GLUT-1 protein synthesis in these cells is stimulated by insulin via the mTOR-p70 S6 kinase pathway, based on its sensitivity to rapamycin.	Sirolimus	159-168	solute carrier family 2 member 1	Homo sapiens	30-36
9636382-0	1998	Effect of cyclosporine and Sirolimus on interleukin-15-driven proliferation of OKT3-preactivated human lymphocytes.	Sirolimus	27-36	interleukin 15	Homo sapiens	40-54
9647434-10	1998	Survival of BN rat small bowel allografts was increased in Lewis (LEW; RTl1) rat recipients treated with RAPA, CsA, and unfractionated BN hepatocytes from 10.2 +/- 1.9 to 21.2 +/- 1.5 days.	Sirolimus	105-109	retrotransposon-like 1	Rattus norvegicus	71-75
9566798-4	1998	In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte.	Sirolimus	9-18	CD4 antigen	Mus musculus	53-56
9475389-1	1998	FKBP59 is an immunophilin that binds the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	75-84	FKBP prolyl isomerase 4	Rattus norvegicus	0-6
9468291-7	1998	Incubation of cells with 100 nM wortmannin or 30 ng/ml rapamycin prevented the dexamethasone-stimulated elevation of GLUT1 protein.	Sirolimus	55-64	solute carrier family 2 member 1	Homo sapiens	117-122
15228089-7	2004	The glucose-induced PTB-binding was only inhibited by the mTOR inhibitor rapamycin.	Sirolimus	73-82	polypyrimidine tract binding protein 1	Rattus norvegicus	20-23
15228089-7	2004	The glucose-induced PTB-binding was only inhibited by the mTOR inhibitor rapamycin.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Rattus norvegicus	58-62
14970238-3	2004	When cells are transferred from a good to a poor nitrogen source (glutamine to proline) or treated with rapamycin, an inhibitor of the protein kinases Tor1/2, Gln3 (NCR-sensitive transcription activator) moves from the cytoplasm into the nucleus.	Sirolimus	104-113	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	151-157
14992811-7	2004	While rapamycin reduced the basal levels of ir-MAP2, it did not affect the ability of either forskolin or A23187 to enhance ir-MAP2 or ir-alphaCaMKII levels.	Sirolimus	6-15	microtubule associated protein 2	Homo sapiens	47-51
14976243-7	2004	Rapamycin/Imatinib combinations also inhibit Imatinib-resistant mutants of BCR/ABL, and rapamycin plus PKC412 synergistically inhibits cells expressing PKC412-sensitive or -resistant leukemogenic FLT3 mutants.	Sirolimus	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	75-82
14744976-1	2004	BACKGROUND: The US Food and Drug Administration recently issued a warning of subacute thrombosis and hypersensitivity reactions to sirolimus-eluting stents (Cypher).	Sirolimus	131-140	LIM domain binding 3	Homo sapiens	157-163
14734710-3	2004	Administration of rapa-DC significantly prolonged survival of B10 cardiac allografts in C3H recipients.	Sirolimus	18-22	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	62-65
9407130-8	1997	Induction of Glut1 mRNA in response to oxidative stress differed from its activation by chronic insulin exposure as demonstrated by the ability of rapamycin to inhibit the latter without an effect on the former.	Sirolimus	147-156	solute carrier family 2 member 1	Homo sapiens	13-18
14734710-0	2004	Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway.	Sirolimus	62-71	signal transducer and activator of transcription 4	Homo sapiens	92-97
14734710-2	2004	The data in this study demonstrated that immunostimulatory activity of B10 (H2(b)) dendritic cells (DC) exposed to rapamycin (rapa-DC) was markedly suppressed as evidenced by the induction of low proliferative responses and specific CTL activity in allogeneic (C3H, H2(k)) T cells.	Sirolimus	115-124	ectonucleotide pyrophosphatase/phosphodiesterase 3	Homo sapiens	71-74
9404561-8	1997	Cyclosporin A and rapamycin significantly inhibited IL-5-enhanced ECP release in a concentration-dependent fashion, whereas dexamethasone did not.	Sirolimus	18-27	ribonuclease A family member 3	Homo sapiens	66-69
9242381-7	1997	Addition of rapamycin to WT-p70s6k cells, which inactivates endogenous and transfected p70s6k, failed to reverse any of the morphological abnormalities.	Sirolimus	12-21	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	87-93
14762856-5	2004	In the sirolimus group, perioperative steroids were reduced, and calcineurin inhibitor initiation was delayed.	Sirolimus	7-16	calcineurin binding protein 1	Homo sapiens	65-86
14573608-4	2004	Previously, we found that, depending on the strength of the signal delivered to the T cell via both the T cell receptor and the costimulatory molecule CD28, CD8+ T cells are capable of rapamycin-resistant proliferation.	Sirolimus	185-194	CD8a molecule	Homo sapiens	157-160
9252447-6	1997	Rapamycin potently blocked both the basal and the CCK-stimulated p70s6k activity, and this inhibition was reversed by an excess of FK-506.	Sirolimus	0-9	cholecystokinin	Rattus norvegicus	50-53
14639603-2	2004	In sensitive cells, rapamycin inhibits the phosphorylation of p70 S6K and of Rb; however, the precise mechanisms involved have not been elucidated.	Sirolimus	20-29	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	62-69
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	49-52
9249059-4	1997	Since ribosomal protein S6 was rapidly dephosphorylated following wortmannin and rapamycin treatment, and the phosphorylation status of the eukaryotic initiation factor 4E was unchanged, our data imply that the p70 signalling pathway has at least one branch-point upstream of FRAP leading to an additional route of translational control.	Sirolimus	81-90	annexin A6	Homo sapiens	211-214
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	53-57
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	58-62
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	83-86
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	87-91
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	92-96
14639603-7	2004	Remarkably, rapamycin reduced the level of total p21(WAF1/CIP1) as well as that of p21(WAF1/CIP1) associated with the cyclin D1/cdk4 complexes.	Sirolimus	12-21	cyclin D1	Mus musculus	118-127
9190906-3	1997	However, a third immunosuppressive drug, rapamycin, normally associated with inhibiting the effects, but not the production, of cytokines, inhibited IL-10, but not IFN-gamma, production.	Sirolimus	41-50	interleukin 10	Homo sapiens	149-154
14639603-9	2004	We propose that the inhibition of the expression of p21(WAF1/CIP1) is a mechanism by which rapamycin inhibits the triggering of the cdk cascade in the BP-A31 cells.	Sirolimus	91-100	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	52-55
14639603-9	2004	We propose that the inhibition of the expression of p21(WAF1/CIP1) is a mechanism by which rapamycin inhibits the triggering of the cdk cascade in the BP-A31 cells.	Sirolimus	91-100	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	56-60
14639603-9	2004	We propose that the inhibition of the expression of p21(WAF1/CIP1) is a mechanism by which rapamycin inhibits the triggering of the cdk cascade in the BP-A31 cells.	Sirolimus	91-100	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	61-65
14709354-0	2004	Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway.	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Mus musculus	111-119
14709354-5	2004	Moreover, rapamycin prevented the normal upregulation of the proatherogenic monocyte chemoattractant protein-1 (MCP-1, CCL2) seen in the aorta of fat-fed mice.	Sirolimus	10-19	chemokine (C-C motif) ligand 2	Mus musculus	76-110
14709354-5	2004	Moreover, rapamycin prevented the normal upregulation of the proatherogenic monocyte chemoattractant protein-1 (MCP-1, CCL2) seen in the aorta of fat-fed mice.	Sirolimus	10-19	chemokine (C-C motif) ligand 2	Mus musculus	112-117
14709354-5	2004	Moreover, rapamycin prevented the normal upregulation of the proatherogenic monocyte chemoattractant protein-1 (MCP-1, CCL2) seen in the aorta of fat-fed mice.	Sirolimus	10-19	chemokine (C-C motif) ligand 2	Mus musculus	119-123
14709354-6	2004	Previous studies have implicated the growth suppressor p27(Kip1) in the antiproliferative and antimigratory activities of rapamycin in vitro.	Sirolimus	122-131	cyclin-dependent kinase inhibitor 1B	Mus musculus	55-58
14709354-6	2004	Previous studies have implicated the growth suppressor p27(Kip1) in the antiproliferative and antimigratory activities of rapamycin in vitro.	Sirolimus	122-131	cyclin-dependent kinase inhibitor 1B	Mus musculus	59-63
14709354-7	2004	However, our studies with fat-fed mice doubly deficient for p27(Kip1) and apoE disclosed an antiatherogenic effect of rapamycin comparable with that found in apoE-null mice with an intact p27(Kip1) gene.	Sirolimus	118-127	cyclin-dependent kinase inhibitor 1B	Mus musculus	60-63
14709354-7	2004	However, our studies with fat-fed mice doubly deficient for p27(Kip1) and apoE disclosed an antiatherogenic effect of rapamycin comparable with that found in apoE-null mice with an intact p27(Kip1) gene.	Sirolimus	118-127	cyclin-dependent kinase inhibitor 1B	Mus musculus	64-68
9190912-4	1997	Anti-CD3 activation of G0 T cells in the presence of cyclosporin A or rapamycin inhibited the down-regulation of p27Kip1, the cellular levels of the inhibitor remained high, and the cells remained in the G1 phase.	Sirolimus	70-79	cyclin-dependent kinase inhibitor 1B	Mus musculus	113-120
14697970-0	2003	Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	65-86
14697970-2	2003	Our clinical experience has revealed sirolimus to be an effective agent in treating renal insufficiency related to calcineurin inhibitor toxicity.	Sirolimus	37-46	calcineurin binding protein 1	Homo sapiens	115-136
14710364-3	2003	Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p &lt; 0.05 for both).	Sirolimus	28-37	insulin-like growth factor binding protein 6	Mus musculus	188-195
14710364-3	2003	Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p &lt; 0.05 for both).	Sirolimus	175-184	insulin-like growth factor binding protein 6	Mus musculus	87-94
14607085-3	2003	Together, these genetic, biochemical and cell-biological studies have demonstrated that the tuberin-hamartin complex inhibits target of rapamycin (TOR) signaling by acting as a GTPase-activating protein for the Ras-related small G protein Rheb.	Sirolimus	136-145	TSC complex subunit 2	Homo sapiens	92-99
12807916-9	2003	Thus, LPS and IFN-gamma activate the PI3K and mTOR pathways, which converge to regulate STAT1-dependent transcription of pro-apoptotic and pro-inflammatory genes in a rapamycin-insensitive manner.	Sirolimus	167-176	signal transducer and activator of transcription 1	Homo sapiens	88-93
9144421-7	1997	Pretreatment of cells with rapamycin, to inhibit p70s6k activation, inhibits thrombin-induced stress fibre formation and the associated presence of p70s6k on the fibres, supporting a role for p70s6k in thrombin-stimulated stress fibre formation.	Sirolimus	27-36	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	49-55
9144421-7	1997	Pretreatment of cells with rapamycin, to inhibit p70s6k activation, inhibits thrombin-induced stress fibre formation and the associated presence of p70s6k on the fibres, supporting a role for p70s6k in thrombin-stimulated stress fibre formation.	Sirolimus	27-36	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	148-154
9144421-7	1997	Pretreatment of cells with rapamycin, to inhibit p70s6k activation, inhibits thrombin-induced stress fibre formation and the associated presence of p70s6k on the fibres, supporting a role for p70s6k in thrombin-stimulated stress fibre formation.	Sirolimus	27-36	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	148-154
8994600-1	1997	FKBP12 was removed from ryanodine receptors (RyRs) by incubation of rabbit skeletal muscle terminal cisternae membranes with rapamycin.	Sirolimus	125-134	peptidyl-prolyl cis-trans isomerase FKBP1A	Oryctolagus cuniculus	0-6
12915736-0	2003	Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.	Sirolimus	0-9	C-C motif chemokine receptor 5	Homo sapiens	36-40
12915736-9	2003	In total PBMC cultures, RAPA-mediated inhibition of CCR5-using strains of HIV-1 occurred at 0.01 nM, a concentration of drug that is approximately 103 times lower than therapeutic through levels of drug in renal transplant recipients.	Sirolimus	24-28	C-C motif chemokine receptor 5	Homo sapiens	52-56
12893813-7	2003	Consistent with this interpretation, we find that flies with reduced dRheb activity are hypersensitive to rapamycin, an inhibitor of the growth regulator TOR.	Sirolimus	106-115	Ras homolog enriched in brain	Drosophila melanogaster	69-74
12893813-8	2003	In cultured cells, the effect of overexpressing dRheb was blocked by the addition of rapamycin.	Sirolimus	85-94	Ras homolog enriched in brain	Drosophila melanogaster	48-53
12766174-3	2003	In isolated jejunal loops, stimulation of fructose absorption by PMA was inhibited by preperfusion with wortmannin or rapamycin, which blocked GLUT2 activation and insertion into the brush-border membrane.	Sirolimus	118-127	solute carrier family 2 member 2	Homo sapiens	143-148
12766174-7	2003	PMA increased the level of the PKC betaII 49-kDa species, which correlates with the GLUT2 level; wortmannin and rapamycin blocked these effects of PMA.	Sirolimus	112-121	solute carrier family 2 member 2	Homo sapiens	84-89
12768627-0	2003	Modulation of translation-initiation in CHO-K1 cells by rapamycin-induced heterodimerization of engineered eIF4G fusion proteins.	Sirolimus	56-65	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	107-112
12768627-8	2003	Rapamycin-induced heterodimerization of eIF4G(Delta)-FKBP and FRB-(Delta)eIF4G fusion proteins reconstituted a functional chimeric elongation factor 4G in a dose-dependent manner.	Sirolimus	0-9	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	40-45
12768627-8	2003	Rapamycin-induced heterodimerization of eIF4G(Delta)-FKBP and FRB-(Delta)eIF4G fusion proteins reconstituted a functional chimeric elongation factor 4G in a dose-dependent manner.	Sirolimus	0-9	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	73-78
12773161-3	2003	Hamartin and tuberin form a complex and antagonise phosphoinositide 3-kinase/protein kinase B/target of rapamycin signal transduction by inhibiting p70 S6 kinase, an activator of translation, and activating 4E-binding protein 1, an inhibitor of translation initiation.	Sirolimus	104-113	TSC complex subunit 2	Homo sapiens	13-20
12796300-5	2003	Treatment with rapamycin resulted in the hyperphosphorylation of Put3p, which was independent of Gln3p, Nil1p, and Ure2p.	Sirolimus	15-24	Put3p	Saccharomyces cerevisiae S288C	65-70
12654728-4	2003	We show that rapamycin stimulates eIF2alpha phosphorylation by GCN2, with attendant induction of GCN4 translation, while reducing Ser 577 phosphorylation in nonstarved cells.	Sirolimus	13-22	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	63-67
12654728-5	2003	The alanine 577 (Ala 577) mutation in GCN2 (S577A) dampened the effects of rapamycin on eIF2alpha phosphorylation and GCN4 translation, suggesting that GCN2 activation by rapamycin involves Ser 577 dephosphorylation.	Sirolimus	75-84	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	38-42
12654728-5	2003	The alanine 577 (Ala 577) mutation in GCN2 (S577A) dampened the effects of rapamycin on eIF2alpha phosphorylation and GCN4 translation, suggesting that GCN2 activation by rapamycin involves Ser 577 dephosphorylation.	Sirolimus	75-84	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	152-156
12654728-5	2003	The alanine 577 (Ala 577) mutation in GCN2 (S577A) dampened the effects of rapamycin on eIF2alpha phosphorylation and GCN4 translation, suggesting that GCN2 activation by rapamycin involves Ser 577 dephosphorylation.	Sirolimus	171-180	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	38-42
12654728-5	2003	The alanine 577 (Ala 577) mutation in GCN2 (S577A) dampened the effects of rapamycin on eIF2alpha phosphorylation and GCN4 translation, suggesting that GCN2 activation by rapamycin involves Ser 577 dephosphorylation.	Sirolimus	171-180	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	152-156
12646166-6	2003	The BCAA mixture dose-dependently promoted the production of albumin, with leucine being the major effector half of which was inhibited by the mTOR inhibitor rapamycin.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Rattus norvegicus	143-147
12606707-8	2003	Binding of BIG1, BIG2, and ARF to membranes was also increased by L-732,531, an agonist structurally related to FK506, but was not increased by a related antagonist, L-685,818, nor by cyclosporin A or rapamycin.	Sirolimus	201-210	ADP ribosylation factor guanine nucleotide exchange factor 1	Homo sapiens	11-15
12606707-8	2003	Binding of BIG1, BIG2, and ARF to membranes was also increased by L-732,531, an agonist structurally related to FK506, but was not increased by a related antagonist, L-685,818, nor by cyclosporin A or rapamycin.	Sirolimus	201-210	ADP ribosylation factor guanine nucleotide exchange factor 2	Homo sapiens	17-21
12592384-7	2003	MT1-MMP induction and invasion were blocked by the PI 3-kinase inhibitors LY294002 and wortmannin and by rapamycin, but not by the MEK inhibitor PD98059.	Sirolimus	105-114	matrix metallopeptidase 14 (membrane-inserted)	Mus musculus	0-7
12446670-5	2003	Transfection with cyclin D1 or E2F2, but not cyclin E or activated Akt, overcame the rapamycin-mediated cell cycle arrest.	Sirolimus	85-94	cyclin D1	Mus musculus	18-27
14727933-1	2003	UNLABELLED: The sirolimus-eluting stent (CYPHER( trade mark )) is a metal stent coated with 140 micro g/cm(2) of sirolimus blended with synthetic polymers.	Sirolimus	16-25	LIM domain binding 3	Homo sapiens	41-47
14727933-1	2003	UNLABELLED: The sirolimus-eluting stent (CYPHER( trade mark )) is a metal stent coated with 140 micro g/cm(2) of sirolimus blended with synthetic polymers.	Sirolimus	113-122	LIM domain binding 3	Homo sapiens	41-47
12493414-0	2002	Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	30-51
12393646-7	2002	BCR/ABL-induced VEGF gene expression was counteracted by the phosphoinositide 3-kinase (PI3-kinase) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen-activated protein kinase pathway.	Sirolimus	123-132	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	0-7
12384518-5	2002	In the Eker rat, short-term inhibition of mTOR by rapamycin was associated with a significant tumor response, including induction of apoptosis and reduction in cell proliferation.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
12384518-7	2002	Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Rattus norvegicus	43-47
12167617-7	2002	Treatment of HuH-7 with rapamycin to disrupt the heterocomplex reduced surface ASGPR binding activity by 65 +/- 5.7%.	Sirolimus	24-33	MIR7-3 host gene	Homo sapiens	13-18
8943845-5	1996	The IL-2-mediated induction of BAG-1 expression required the activation of tyrosine kinase(s) and was sensitive to rapamycin as the induction of bcl-2 expression was.	Sirolimus	115-124	BCL2-associated athanogene 1	Mus musculus	31-36
12042641-9	2002	Rapamycin increased p27 kip1, reduced cyclinD1, and arrested the growth of renal cancer cells in G1/S phase.	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Mus musculus	20-28
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	annexin A6	Homo sapiens	164-167
12042641-9	2002	Rapamycin increased p27 kip1, reduced cyclinD1, and arrested the growth of renal cancer cells in G1/S phase.	Sirolimus	0-9	cyclin D1	Mus musculus	38-46
11875047-6	2002	Tsc1 null embryo fibroblast lines have persistent phosphorylation of the p70S6K (S6K) and its substrate S6, that is sensitive to treatment with rapamycin, indicating constitutive activation of the mTOR-S6K pathway due to loss of the Tsc1 protein, hamartin.	Sirolimus	144-153	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	73-79
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	168-171
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	annexin A6	Homo sapiens	139-142
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	annexin A6	Homo sapiens	201-204
8610419-4	1996	Rapamycin treatment was associated with increased glucose clearance, increased total and stimulated insulin release in response to glucose, and increased fasting plasma insulin level, as well as reduced insulin clearance.	Sirolimus	0-9	insulin	Canis lupus familiaris	100-107
11756682-10	2002	Rapamycin also blocks the synaptic potentiation induced by brain-derived neurotrophic factor in hippocampal slices.	Sirolimus	0-9	brain derived neurotrophic factor	Homo sapiens	59-92
8610419-4	1996	Rapamycin treatment was associated with increased glucose clearance, increased total and stimulated insulin release in response to glucose, and increased fasting plasma insulin level, as well as reduced insulin clearance.	Sirolimus	0-9	insulin	Canis lupus familiaris	169-176
8610419-4	1996	Rapamycin treatment was associated with increased glucose clearance, increased total and stimulated insulin release in response to glucose, and increased fasting plasma insulin level, as well as reduced insulin clearance.	Sirolimus	0-9	insulin	Canis lupus familiaris	169-176
11574531-10	2001	Furthermore, fetal hepatocyte proliferation was sustained even though rapamycin administration resulted in the dephosphorylation of ribosomal protein S6.	Sirolimus	70-79	ribosomal protein S6	Rattus norvegicus	132-152
7673177-9	1995	Mitogenic combinations of cAMP strongly stimulated the phosphorylation and activation of p70s6k an effect that was inhibited by rapamycin.	Sirolimus	128-137	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	89-95
11750386-0	2001	Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.	Sirolimus	14-23	calcineurin binding protein 1	Homo sapiens	73-94
7642551-2	1995	The 12- and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus).	Sirolimus	151-160	FKBP prolyl isomerase 2	Homo sapiens	54-60
7642551-2	1995	The 12- and 13-kDa FK506 binding proteins (FKBP12 and FKBP13) are cis-trans peptidyl-prolyl isomerases that bind the macrolides FK506 (Tacrolimus) and rapamycin (Sirolimus).	Sirolimus	162-171	FKBP prolyl isomerase 2	Homo sapiens	54-60
7542743-7	1995	As judged from peptidyl prolyl isomerase activity, FKBP51 had a slightly higher affinity for rapamycin than for FK520, an FK506 analog.	Sirolimus	93-102	FK506 binding protein 5	Mus musculus	51-57
11583938-3	2001	A strategy that may result in a more benign immunologic course with a substantially beneficial effect on renal function is to administer sirolimus and a calcineurin inhibitor early after transplantation, thereby promoting immunologic adaptation, and then to withdraw the calcineurin inhibitor at some point after transplantation to prevent nephrotoxicity.	Sirolimus	137-146	calcineurin binding protein 1	Homo sapiens	271-292
11557736-6	2001	Furthermore, blocking p70 S6 kinase phosphorylation with rapamycin inhibited cyclin D1 expression and proliferation, suggesting that activation of p70 S6 kinase is critical in EDG-1/G(i)-mediated cell proliferation.	Sirolimus	57-66	sphingosine-1-phosphate receptor 1	Homo sapiens	176-181
11571455-14	2001	However, IL-15 activity is effectively inhibited by Rapa and Dex but not by CsA.	Sirolimus	52-56	interleukin 15	Homo sapiens	9-14
11589784-7	2001	After sirolimus treatment, Mrp2 mRNA was also reduced together with reduced levels of most CYPs and increased Oatp2, possibly leading to accumulation of toxic metabolites in the hepatocytes.	Sirolimus	6-15	ATP binding cassette subfamily C member 2	Rattus norvegicus	27-31
11207273-5	2001	Surprisingly, a heterogeneous proliferative response in the presence of rapamycin was observed among different Ag-specific CD8(+) T cell clones; this was also observed in CD8(+) peripheral blood T cells activated with TCR cross-linking ex vivo.	Sirolimus	72-81	CD8a molecule	Homo sapiens	123-126
11207273-5	2001	Surprisingly, a heterogeneous proliferative response in the presence of rapamycin was observed among different Ag-specific CD8(+) T cell clones; this was also observed in CD8(+) peripheral blood T cells activated with TCR cross-linking ex vivo.	Sirolimus	72-81	CD8a molecule	Homo sapiens	171-174
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	10-19	CD8a molecule	Homo sapiens	51-54
11207273-8	2001	Moreover, rapamycin-resistant proliferation of the CD8(+) T cell clones was blocked by anti-IL-2 Abs, suggesting that while some of the parallel pathways triggered by IL-2R signaling are sensitive to the effects of rapamycin, others account for the Ag-driven rapamycin resistance.	Sirolimus	215-224	CD8a molecule	Homo sapiens	51-54
7797543-9	1995	The immunosuppressant rapamycin, a potent inhibitor of insulin or phorbol ester stimulation of p70/p85 ribosomal S6 protein kinase, has no significant effect on the regulation of PEPCK gene expression by insulin or phorbol esters.	Sirolimus	22-31	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	99-102
7822316-5	1995	In the presence of rapamycin, immobilized GST-FKBP12 specifically precipitates similar high molecular mass proteins from both rat brain and murine T-lymphoma cell extracts.	Sirolimus	19-28	FKBP prolyl isomerase 1A	Rattus norvegicus	46-52
7798592-2	1994	Both methods were used to measure inhibition of proliferative responses of phytohaemagglutinin (PHA1)-stimulated human peripheral blood lymphocytes by tacrolimus (FK 506(1)), cyclosporine A (CsA1), rapamycin (RA1), dexamethasone (DEX1), prednisolone (PR1), and methylprednisolone (MP1).	Sirolimus	198-207	sodium channel epithelial 1 subunit gamma	Homo sapiens	96-100
8289787-0	1994	Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction.	Sirolimus	15-24	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	138-143
8289787-0	1994	Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction.	Sirolimus	15-24	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	144-149
8289787-7	1994	These results suggest the possible use of anisomycin and rapamycin to define upstream and downstream boundaries of an area of signalling above p70/85S6k which contains a bifurcation that produces histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction in the nucleus.	Sirolimus	57-66	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	244-249
8289787-7	1994	These results suggest the possible use of anisomycin and rapamycin to define upstream and downstream boundaries of an area of signalling above p70/85S6k which contains a bifurcation that produces histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction in the nucleus.	Sirolimus	57-66	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	250-255
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	91-94
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	196-199
11160419-4	2001	To test whether S6 kinase is the target for the ability of rapamycin to block synapse-specific facilitation in Aplysia, we cloned Aplysia S6 kinase, its substrate S6, and the S6 kinase kinase phosphoinositide-dependent kinase 1 (PDK-1).	Sirolimus	59-68	pyruvate dehydrogenase kinase 1	Homo sapiens	229-234
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	196-199
7689858-2	1993	Recently, we showed that p59 purified from human lymphocytes is an immunophilin (FKBP59) which binds both FK506 and rapamycin.	Sirolimus	116-125	HLA complex P5B	Homo sapiens	25-28
11127307-0	2000	A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.	Sirolimus	45-54	calcineurin binding protein 1	Homo sapiens	2-23
11076970-6	2000	Remarkably, nuclear accumulation of Rtg1/Rtg3, as well as expression of their target genes, is induced by addition of rapamycin, a specific inhibitor of the target of rapamycin (TOR) kinases.	Sirolimus	118-127	Rtg1p	Saccharomyces cerevisiae S288C	36-40
11015466-3	2000	In the second set of experiments, food-deprived rats were injected intravenously with rapamycin (0.75 mg/kg), a specific inhibitor of mTOR, before leucine administration.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Rattus norvegicus	134-138
1465771-3	1992	Primary anti-MHC class I alloantibody responses, detected by indirect hemagglutination and complement-dependent cytotoxicity assays, were abrogated in high-responder WAG (RT1u) recipients of DA (RT1a) blood transfusions, given on days 0 and 7 of a 14-day course of rapamycin (3 mg/kg/day).	Sirolimus	265-274	RT1 class I, locus A	Rattus norvegicus	195-199
10837353-8	2000	Of interest, the p70 S6 kinase inhibitor rapamycin (10(-6) M) but not wortmannin decreased histamine-stimulated c-jun mRNA by 58.5 +/- 12% (mean +/- SE, n = 4) while not significantly altering c-fos message.	Sirolimus	41-50	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	112-117
1380976-5	1992	Because rapamycin (RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting T cell responses to lymphokines, such an interaction with FKBP-12 is not sufficient to mediate immunosuppression.	Sirolimus	8-17	FKBP prolyl isomerase 1A	Rattus norvegicus	43-50
10837353-8	2000	Of interest, the p70 S6 kinase inhibitor rapamycin (10(-6) M) but not wortmannin decreased histamine-stimulated c-jun mRNA by 58.5 +/- 12% (mean +/- SE, n = 4) while not significantly altering c-fos message.	Sirolimus	41-50	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	193-198
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	annexin A6	Homo sapiens	18-21
1380976-5	1992	Because rapamycin (RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting T cell responses to lymphokines, such an interaction with FKBP-12 is not sufficient to mediate immunosuppression.	Sirolimus	8-17	FKBP prolyl isomerase 1A	Rattus norvegicus	176-183
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	annexin A6	Homo sapiens	54-57
1375932-6	1992	The PPIase activity of FKBP25 was far more sensitive to inhibition by rapamycin (IC50 = 50 nM) than FK506 (IC50 = 400 nM).	Sirolimus	70-79	FKBP prolyl isomerase 3	Homo sapiens	23-29
1375932-7	1992	PPIase activity of 100 nM FKBP25 was almost completely inhibited by 150 nM rapamycin while only 90% inhibition was achieved by 4 microM FK506.	Sirolimus	75-84	FKBP prolyl isomerase 3	Homo sapiens	26-32
10551878-9	1999	Rapamycin abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA.	Sirolimus	0-9	solute carrier family 2 member 1	Homo sapiens	53-58
10551878-9	1999	Rapamycin abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA.	Sirolimus	0-9	solute carrier family 2 member 1	Homo sapiens	107-112
1375932-8	1992	These data demonstrate that FKBP25 has a higher affinity for rapamycin than for FK506 and suggest that this cellular receptor may be an important target molecule for immunosuppression by rapamycin.	Sirolimus	61-70	FKBP prolyl isomerase 3	Homo sapiens	28-34
10551878-9	1999	Rapamycin abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA.	Sirolimus	0-9	solute carrier family 2 member 1	Homo sapiens	107-112
1375932-8	1992	These data demonstrate that FKBP25 has a higher affinity for rapamycin than for FK506 and suggest that this cellular receptor may be an important target molecule for immunosuppression by rapamycin.	Sirolimus	187-196	FKBP prolyl isomerase 3	Homo sapiens	28-34
1371117-1	1992	FK506-binding protein (FKBP) catalyzes the cis-trans isomerization of the peptidyl-prolyl amide bond (the PPIase reaction) and is the major intracellular receptor for the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	205-214	FKBP prolyl isomerase 10	Homo sapiens	106-112
33972683-6	2021	Rapamycin inhibited FTO activity, and directly targeted eIF4G1 transcripts and mediated their expression in an m6A-dependent manner.	Sirolimus	0-9	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	56-62
33817096-12	2018	Conclusion: Arterial infusion of rapamycin combined with TACE can improve treatment efficacy by decreasing HIF-1a, VEGF, iNOS and CD34 expression.	Sirolimus	33-42	vascular endothelial growth factor A	Oryctolagus cuniculus	115-119
34905649-8	2022	Mechanistically, GDF11 significantly activates mammalian target of rapamycin complex 1 (mTORC1) and subsequently represses transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy.	Sirolimus	67-76	growth differentiation factor 11	Homo sapiens	17-22
34961940-6	2022	Direct suppression of mTOR activity by rapamycin selectively impaired IL-10 production by B cells whereas secretion was restored upon GSK3 inhibition.	Sirolimus	39-48	interleukin 10	Homo sapiens	70-75
34938782-8	2021	Besides, HCP1 activated the activity of mechanistic target of rapamycin complex 1 (mTORC1), co-treatment with AMPK activator acadesine eliminated the effect of HCP1 on mTORC1 activity as well as autophagy.	Sirolimus	62-71	solute carrier family 46, member 1	Mus musculus	9-13
34912459-12	2021	Moreover, the activation of pIGF-1R, pAKT, and pS6 was reduced by the IGF-1 neutralizing antibody and NVP-AEW541, and the activation of pS6 was reduced by rapamycin.	Sirolimus	155-164	taste 2 receptor member 63 pseudogene	Homo sapiens	47-50
34912459-12	2021	Moreover, the activation of pIGF-1R, pAKT, and pS6 was reduced by the IGF-1 neutralizing antibody and NVP-AEW541, and the activation of pS6 was reduced by rapamycin.	Sirolimus	155-164	taste 2 receptor member 63 pseudogene	Homo sapiens	136-139
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	97-106	mechanistic target of rapamycin kinase	Rattus norvegicus	266-270
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	219-228	mechanistic target of rapamycin kinase	Rattus norvegicus	266-270
34167449-7	2021	The apoptotic rate of OA chondrocytes was markedly elevated by 3-methyladenine and suppressed by rapamycin and icariin; autophagy genes were drastically downregulated in the 3-methyladenine group and upregulated in the rapamycin and icariin groups; and the PI3K/AKT/mTOR signaling pathway was activated by 3-methyladenine and inhibited by rapamycin and icariin.	Sirolimus	339-348	mechanistic target of rapamycin kinase	Rattus norvegicus	266-270
34700229-0	2021	Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway.	Sirolimus	0-9	phospholipase A2 receptor 1	Homo sapiens	21-26
34859624-9	2021	RAPA could also enhance the relative protein expression of Beclin-1 and LC3-II (P<0.01), and reduce the expression of p-mTOR (P<0.01).	Sirolimus	0-4	beclin 1	Homo sapiens	59-67
34859624-9	2021	RAPA could also enhance the relative protein expression of Beclin-1 and LC3-II (P<0.01), and reduce the expression of p-mTOR (P<0.01).	Sirolimus	0-4	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	72-75
34859624-9	2021	RAPA could also enhance the relative protein expression of Beclin-1 and LC3-II (P<0.01), and reduce the expression of p-mTOR (P<0.01).	Sirolimus	0-4	mechanistic target of rapamycin kinase	Rattus norvegicus	120-124
34533673-10	2021	In contrast, administration of rapamycin (RAPA) autophagy agonist or intravenous injection of PHSML inhibited the beneficial effects of SGB on CD4 + T cells from hemorrhagic shocked rats.	Sirolimus	31-40	Cd4 molecule	Rattus norvegicus	143-146
34533673-10	2021	In contrast, administration of rapamycin (RAPA) autophagy agonist or intravenous injection of PHSML inhibited the beneficial effects of SGB on CD4 + T cells from hemorrhagic shocked rats.	Sirolimus	42-46	Cd4 molecule	Rattus norvegicus	143-146
34893133-12	2021	CONCLUSION: The overall efficacy of calcitriol combined with sirolimus in the treatment of cITP in adults is satisfactory, which can effectively alleviate patient"s condition, improve the quality of life, further increase the platelet level and decrease the expression of VDR in peripheral blood lymphocyte, the mechanism may be related to increasing the level of serum 1,25(OH)2D3 and up-regulating the expression of Treg cells in peripheral blood.	Sirolimus	61-70	vitamin D receptor	Homo sapiens	272-275
34274968-10	2021	The inhibition of MAPK signaling by the ERK1/ERK2 inhibitor and mTOR signaling by rapamycin abrogated the miR-592-mediated upregulation of neuronal differentiation-related genes.	Sirolimus	82-91	microRNA 592	Homo sapiens	106-113
34912349-4	2021	As previously shown by our group, injecting mice with IL-2/anti-IL-2 complexes (IL-2cplx) to augment expansion of CD4 T regulatory cells (Tregs) induces tolerance towards islet allografts, and also to skin allografts when IL-2cplx treatment is supplemented with rapamycin and a short-term treatment of anti-IL-6.	Sirolimus	262-271	CD4 antigen	Mus musculus	114-117
34944575-6	2021	5-azacytidine restored tuberin expression with a reduction of MMP-2 and MMP-7 levels and inhibits motility, similarly to rapamycin and anti-EGFR antibody.	Sirolimus	121-130	matrix metallopeptidase 2	Mus musculus	62-67
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Sirolimus	107-116	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	7-12
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Sirolimus	107-116	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	14-51
10502402-0	1999	Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.	Sirolimus	107-116	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	243-248
10502402-9	1999	TRAIL expression was also blocked by rapamycin, which inhibits p70 S6 kinase involved in CD28 and interleukin (IL)-2 receptor signaling.	Sirolimus	37-46	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	0-5
10446394-7	1999	This was further supported by the observation that troglitazone was able to reduce PEPCK mRNA levels in the presence of the insulin signaling pathway inhibitors wortmannin, rapamycin, and PD98059.	Sirolimus	173-182	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	83-88
9873056-3	1999	Amino acid-induced p70(s6k) activation was completely inhibited by rapamycin but only partially inhibited by wortmannin.	Sirolimus	67-76	annexin A6	Homo sapiens	19-22
34944575-6	2021	5-azacytidine restored tuberin expression with a reduction of MMP-2 and MMP-7 levels and inhibits motility, similarly to rapamycin and anti-EGFR antibody.	Sirolimus	121-130	matrix metallopeptidase 7	Mus musculus	72-77
34944575-9	2021	MMPs appears sensitive to rapamycin and anti-EGFR antibody only during cellular migration.	Sirolimus	26-35	matrix metallopeptidase 2	Mus musculus	0-4
34965576-6	2022	Nprl2-cKO and Nprl3-cKO mice recapitulated the major abnormal features of patients-spontaneous seizures, and dysmorphic enlarged neuronal cells with increased mechanistic target of rapamycin complex 1 signaling-similar to Depdc5-cKO mice.	Sirolimus	181-190	nitrogen permease regulator-like 3	Mus musculus	14-19
34965576-8	2022	However, the benefit of rapamycin after withdrawal was less durable in Nprl2- and Nprl3-cKO mice compared with Depdc5-cKO mice.	Sirolimus	24-33	nitrogen permease regulator-like 3	Mus musculus	82-87
34555398-13	2021	However, these effects on H9c2 cells were notably abolished by the PI3K inhibitor LY294002 and mTOR inhibitor rapamycin.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Rattus norvegicus	95-99
34765012-9	2021	Treatment with PI3K inhibitors, LY294002 and wortmannin, or mTOR inhibitors, rapamycin and Torin 1, could not only recover QYLGT-inhibited cell viability of NPC cells but also inhibit Atg3 expression.	Sirolimus	77-86	autophagy related 3	Homo sapiens	184-188
34233960-7	2021	Subsequent investigations revealed that aberrantly activated mTORC1 signaling in CAR-T cells results in decreased bone marrow infiltration and decreased the levels of the rapamycin target CXCR4.	Sirolimus	171-180	chemokine (C-X-C motif) receptor 4	Mus musculus	188-193
34560177-11	2021	We detected the changes in autophagy marker protein LC3-II and lipid accumulation using an AKT inhibitor ARQ-092 or a mTOR inhibitor rapamycin in HepG2 cells.	Sirolimus	133-142	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	52-55
9790174-4	1998	Rapamycin (25 ng/ml), an inhibitor of p70S6K, also inhibited the effect of PRL on iodide transport; this drug was earlier shown to inhibit PRL effects on milk product synthesis.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	38-44
34374900-10	2021	And rapamycin, an mTOR inhibitor, completely inhibited the antidepressant-like activity of NBP in vivo.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Rattus norvegicus	18-22
9603979-5	1998	Conversely, glucocorticoid-induced apoptosis and transactivation were enhanced after treating S49.1 cells with the immunosuppressant rapamycin, which down-regulates cellular levels of BAG-1, the mouse homolog of RAP46.	Sirolimus	133-142	BCL2-associated athanogene 1	Mus musculus	184-189
9603979-5	1998	Conversely, glucocorticoid-induced apoptosis and transactivation were enhanced after treating S49.1 cells with the immunosuppressant rapamycin, which down-regulates cellular levels of BAG-1, the mouse homolog of RAP46.	Sirolimus	133-142	BCL2-associated athanogene 1	Mus musculus	212-217
9560223-3	1998	In addition, rapamycin inhibited proliferation of p70(s6k-/-) cells, indicating that other events inhibited by the drug, independent of p70(s6k), also are important for both cell proliferation and the action of rapamycin.	Sirolimus	13-22	E74 like ETS transcription factor 1	Mus musculus	50-53
9560223-3	1998	In addition, rapamycin inhibited proliferation of p70(s6k-/-) cells, indicating that other events inhibited by the drug, independent of p70(s6k), also are important for both cell proliferation and the action of rapamycin.	Sirolimus	13-22	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	54-57
9560223-5	1998	In contrast, rapamycin inhibited phosphorylation of initiation factor 4E-binding protein 1 (4E-BP1), general mRNA translation, and overall protein synthesis in p70(s6k-/-) cells, indicating that these events proceed independently of p70(s6k) activity.	Sirolimus	13-22	E74 like ETS transcription factor 1	Mus musculus	160-163
9560223-5	1998	In contrast, rapamycin inhibited phosphorylation of initiation factor 4E-binding protein 1 (4E-BP1), general mRNA translation, and overall protein synthesis in p70(s6k-/-) cells, indicating that these events proceed independently of p70(s6k) activity.	Sirolimus	13-22	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	160-167
9570919-5	1998	In young cells, prior treatment with rapamycin inhibited the induction of DNA synthesis and activation of CDK2 to levels similar to those seen in aged cells without inhibiting ERK activity and cyclin D1 expression.	Sirolimus	37-46	cyclin dependent kinase 2	Rattus norvegicus	106-110
9608681-0	1998	Effects of wortmannin and rapamycin on CSF-1-mediated responses in macrophages.	Sirolimus	26-35	colony stimulating factor 1 (macrophage)	Mus musculus	39-44
9608681-4	1998	Wortmannin (&gt; or = 30 nM) and rapamycin (&gt; or = 3 nM) both weakly inhibited CSF-1-stimulated DNA synthesis in murine bone marrow-derived macrophages (BMM), suggesting that there are PI3-kinase- and p70s6k-independent pathways required for the onset of S phase; interestingly the combination of the drugs gave dramatic suppression.	Sirolimus	33-42	colony stimulating factor 1 (macrophage)	Mus musculus	82-87
9608681-4	1998	Wortmannin (&gt; or = 30 nM) and rapamycin (&gt; or = 3 nM) both weakly inhibited CSF-1-stimulated DNA synthesis in murine bone marrow-derived macrophages (BMM), suggesting that there are PI3-kinase- and p70s6k-independent pathways required for the onset of S phase; interestingly the combination of the drugs gave dramatic suppression.	Sirolimus	33-42	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	204-210
9332457-1	1997	The in vitro effects of rapamycin on prolactin (PRL)-stimulated S6 kinase activity and milk product synthesis were investigated in cultured mouse mammary tissues.	Sirolimus	24-33	prolactin	Mus musculus	37-46
9332457-1	1997	The in vitro effects of rapamycin on prolactin (PRL)-stimulated S6 kinase activity and milk product synthesis were investigated in cultured mouse mammary tissues.	Sirolimus	24-33	prolactin	Mus musculus	48-51
9332457-6	1997	Rapamycin (25-100 ng/ml) impeded, in a dose-dependent fashion, the PRL stimulation of casein, lipid and lactose synthesis in concert with its inhibition of cytoplasmic S6 kinase activity.	Sirolimus	0-9	prolactin	Mus musculus	67-70
34534609-5	2021	The enhancement of H2S donors on autophagic flux was mediated by adenosine 5"-monophosphate-activated protein kinase (AMPK)-dependent mammalian target of rapamycin (mTOR) inhibition, as H2S donors activated AMPK but reduced the mTOR activity and H2S donors-induced LC3-II increase was diminished by mTOR activator.	Sirolimus	154-163	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	265-268
34853810-1	2021	Loss of function of tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) leads to the activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	116-125	TSC complex subunit 2	Homo sapiens	63-67
34745435-7	2021	And Se incubation inhibited activation of mTOR signaling in heat-stress-induced GMECs, which could be eliminated by the mTOR activator MHY1485, and treatment with mTOR inhibitor AY-22989 had the same effect as Se.	Sirolimus	178-186	serine/threonine-protein kinase mTOR	Capra hircus	42-46
34745435-7	2021	And Se incubation inhibited activation of mTOR signaling in heat-stress-induced GMECs, which could be eliminated by the mTOR activator MHY1485, and treatment with mTOR inhibitor AY-22989 had the same effect as Se.	Sirolimus	178-186	serine/threonine-protein kinase mTOR	Capra hircus	163-167
34417329-4	2021	Intradermal administration of inhibitors of mTOR (Rapamycin) and Protein Kinase B (AKT; AKT inhibitor IV), signaling molecules downstream of PI3Kgamma, also attenuates HMWH-induced anti-hyperalgesia.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Rattus norvegicus	44-48
34614009-8	2021	Additionally, treatment with C3G resulted in a significant reduction in the protein expression of inflammatory markers IL-1beta and NLRP3 (p<0.01) as well as an increase in LC3 autophagic marker (p<0.05) in human islets treated with amylin, Abeta1-42, rapamycin, or H2O2.	Sirolimus	252-261	Rap guanine nucleotide exchange factor 1	Homo sapiens	29-32
9316820-8	1997	The mitogenic effects of HGF were almost completely blocked by simultaneous treatment of hepatocytes with genistein (5 x 10(-6) M), U-73122 (10(-6) M), wortmannin (10(-7) M), sphingosine (3 x 10(-6) M) and rapamycin (10 ng/ml).	Sirolimus	206-215	hepatocyte growth factor	Rattus norvegicus	25-28
9151781-5	1997	Although beta1 integrin(bright) expression was not affected, the number of beta1 integrin(bright) cells entering S/G2/M was significantly lowered by rapamycin.	Sirolimus	149-158	integrin subunit beta 1	Homo sapiens	75-89
8999966-0	1997	Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells.	Sirolimus	0-9	E74 like ETS transcription factor 1	Mus musculus	22-25
8999966-0	1997	Rapamycin dissociates p70(S6K) activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	26-29
8999966-4	1997	In striking contrast, the combination of bombesin and insulin in synergy stimulated maximum DNA synthesis in these cells despite persistent inhibition of p70(S6K) by rapamycin throughout G1.	Sirolimus	166-175	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	154-161
8999966-6	1997	The inhibitory effects of rapamycin on bombesin-stimulated cell cycle progression did not involve accumulation of the cyclin-dependent kinase inhibitor p27(kip1) but a striking inhibition of the expression of cyclin D1.	Sirolimus	26-35	cyclin D1	Mus musculus	209-218
9067639-2	1997	Thrombin stimulated p70s6k activity in a time and concentration-dependent manner which was abolished by the macrolide rapamycin.	Sirolimus	118-127	coagulation factor II, thrombin	Bos taurus	0-8
9067639-6	1997	Thrombin also strongly stimulated (over 100 fold) the incorporation of [3H]thymidine into growth arrested PA fibroblasts which was inhibited by rapamycin (by 33.6 +/- 2.0%).	Sirolimus	144-153	coagulation factor II, thrombin	Bos taurus	0-8
8955134-10	1996	The formation of the complexes between FKBP59 or FKBP12 and FAP48 is prevented by FK506 and rapamycin in a dose-dependent manner.	Sirolimus	92-101	glomulin, FKBP associated protein	Homo sapiens	60-65
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Sirolimus	42-51	annexin A6	Homo sapiens	104-107
8805627-3	1996	Nuclear expression of phosphorylated STAT1 alpha was abrogated by co-incubation of anti-Ig-treated B cells with the protein synthesis inhibitor cycloheximide (CHX), with the protein kinase inhibitor H-7, or with the immunosuppressive drug rapamycin.	Sirolimus	239-248	signal transducer and activator of transcription 1	Homo sapiens	37-42
8645341-5	1996	The proliferative status of J2E cells correlated well with the activity of the ribosomal S6 kinase p70S6k, an enzyme effectively blocked by rapamycin.	Sirolimus	140-149	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	99-105
8645341-6	1996	It was concluded from this study that erythroid maturation proceeded normally despite the rapamycin-induced inhibition of mitosis and of p70S6k activity.	Sirolimus	90-99	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	137-143
8595879-6	1996	Moreover, TOR2-RAFT1 and TOR1-RAFT1 hybrid proteins mutated at the position corresponding to rapamycin-resistant TOR mutants (S20351) conferred rapamycin resistance.	Sirolimus	93-102	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	25-29
7586731-0	1995	Direct inhibition of human CD8+ lymphocyte activation by cyclosporine A and Rapamune-Sirolimus.	Sirolimus	76-84	CD8a molecule	Homo sapiens	27-30
7586731-0	1995	Direct inhibition of human CD8+ lymphocyte activation by cyclosporine A and Rapamune-Sirolimus.	Sirolimus	85-94	CD8a molecule	Homo sapiens	27-30
7586731-1	1995	Cyclosporin A (CsA) and Rapamune-Sirolimus (RAP) have been shown to inhibit the in vitro activation of heterogeneous lymphocytes populations, but little is known about their direct actions on isolated CD8+ lymphocytes.	Sirolimus	24-32	CD8a molecule	Homo sapiens	201-204
7545671-0	1995	Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	65-71
7545671-4	1995	The inhibitory effect of rapamycin on serum-induced p70s6k activation and the phosphorylation of Thr229, Thr389, Ser404, and Ser411 is rescued by FK506, providing further evidence that the inhibitory effect is exerted through a complex of rapamycin-FKBP12.	Sirolimus	25-34	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	52-58
7545671-6	1995	Likewise, methylxanthine phosphodiesterase inhibitors block p70s6k activation and phosphorylation of the same set of sites as wortmannin and rapamycin.	Sirolimus	141-150	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	60-66
7545671-8	1995	Together the results indicate that there are two kinase signaling pathways that must converge to activate p70s6k and that only one of these pathways is sensitive to rapamycin, wortmannin, and methylxanthine inhibition.	Sirolimus	165-174	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	106-112
7642551-7	1995	Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin.	Sirolimus	237-246	FKBP prolyl isomerase 2	Homo sapiens	21-27
7642551-7	1995	Replacement of three FKBP13 surface residues (Gln-50, Ala-95, and Lys-98) with the corresponding homologous FKBP12 residues (Arg-42, His-87, and Ile-90) generates an FKBP13 variant that is equivalent to FKBP12 in its affinity for FK506, rapamycin, and calcineurin.	Sirolimus	237-246	FKBP prolyl isomerase 2	Homo sapiens	166-172
7540861-12	1995	We conclude that in both B and T cells the induction of CD5 requires transcriptional regulation, and that the inhibition of CD5 expression by the immunosuppressive drugs CsA, FK-520 and rapamycin requires drug-immunophilin complex formation.	Sirolimus	186-195	CD5 antigen	Mus musculus	124-127
7923380-6	1994	The macrolide rapamycin, a potent and specific inhibitor of p70S6K in vivo, completely blocks CREM activation induced by serum and by p70S6K.	Sirolimus	14-23	cAMP responsive element modulator	Homo sapiens	94-98
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	218-266
7520778-2	1994	In addition, rapamycin blocks the proliferative response of cell lines to a variety of hematopoietic growth factors, including interleukin-3 (IL-3), interleukin-6 (IL-6), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and kit ligand (KL), suggesting that it should be a strong inhibitor of hematopoiesis.	Sirolimus	13-22	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	268-274
7520778-4	1994	In vitro, rapamycin inhibited the proliferation of primary bone marrow cells induced by IL-3, GM-CSF, KL, or a complex mixture of factors present in cell-conditioned media.	Sirolimus	10-19	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	94-100
7520778-5	1994	Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.	Sirolimus	0-9	interleukin 11	Mus musculus	136-150
7520778-5	1994	Rapamycin also inhibited the multiplication of colony-forming cells in suspension cultures containing IL-3 plus interleukin-1 (IL-1) or interleukin-11 (IL-11) plus KL.	Sirolimus	0-9	interleukin 11	Mus musculus	152-157
8186460-1	1994	The Saccharomyces cerevisiae genes TOR1 and TOR2 were originally identified by mutations that confer resistance to the immunosuppressant rapamycin.	Sirolimus	137-146	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	35-39
8186460-4	1994	TOR1 is not essential, but a TOR1 TOR2 double disruption uniquely confers a cell cycle (G1) arrest as does exposure to rapamycin; disruption of TOR2 alone is lethal but does not cause a cell cycle arrest.	Sirolimus	119-128	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	29-33
8186460-6	1994	The TOR1-1 and TOR2-1 mutations, which confer rapamycin resistance, alter the same potential protein kinase C site in the respective protein"s lipid kinase domain.	Sirolimus	46-55	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	4-10
8242902-0	1993	The effect of rapamycin on c-jun expression in human lymphocytes.	Sirolimus	14-23	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	27-32
8387896-3	1993	The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin.	Sirolimus	22-31	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	150-154
8387896-3	1993	The immunosuppressant rapamycin most likely acts by inhibiting PI kinase activity because TOR2 mutations confer resistance to rapamycin and because a TOR1 TOR2 double disruption (TOR1 is a nonessential TOR2 homolog) confers G1 arrest, as does rapamycin.	Sirolimus	22-31	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	179-183
1400439-2	1992	Cyclosporin A inhibited the activity largely localized to the mitochondrial matrix while rapamycin inhibited the PPIase activity associated with the mitochondrial membranes.	Sirolimus	89-98	peptidylprolyl isomerase like 1	Homo sapiens	113-119
1376003-3	1992	A 59-kilodalton member of the FK506- and rapamycin-binding class was found to associate in the absence of these drugs with two heat shock proteins (hsp90 and hsp70) and the glucocorticoid receptor (GR).	Sirolimus	41-50	heat shock protein family A (Hsp70) member 4	Homo sapiens	158-163
1336536-10	1992	RAPA (10mg/kg) inhibited the AH leukocytes and protein content and MPO activity in the ICB.	Sirolimus	0-4	myeloperoxidase	Oryctolagus cuniculus	67-70
1721312-0	1991	FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.	Sirolimus	8-17	interleukin 10	Homo sapiens	57-62
26341392-6	2015	Indeed, the mTOR inhibitor rapamycin, and actinomycin-D, a transcription inhibitor, blocked the enhanced effects of LY39 on NMDAR-mEPSCs.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	12-16
18089405-0	2007	Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation.	Sirolimus	90-99	interleukin 2 receptor, alpha chain	Mus musculus	5-9
34854520-13	2022	Additionally, the hypertrophic responses caused by miR-339-5p was alleviated in the presence of mTOR inhibitor rapamycin.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Rattus norvegicus	96-100
34638732-8	2021	The results confirmed the elevation of AMPK and mitochondrial respiratory activities and reduction in reactive O2 species (ROS) levels in premutation cells and revealed for the first time that target of rapamycin complex I (TORC1) activities are reduced.	Sirolimus	203-212	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	39-43
34863087-5	2021	The proapoptotic effect of HG was rescued by either the Fyn inhibitor PP1 or the mTOR inhibitor rapamycin.	Sirolimus	96-105	mechanistic target of rapamycin kinase	Rattus norvegicus	81-85
34572126-6	2021	Rapamycin preconditioning resulted in activated autophagy and improved survival of ADSCs achieved by increased autophagosomes, upregulated autophagy-specific LC3-II gene, decreased protein degradation/ubiquitination by downregulated p62 gene, downregulated mTOR gene, and finally, upregulated antiapoptotic BCL-2 gene.	Sirolimus	0-9	nucleoporin 62	Homo sapiens	233-236
34862383-1	2021	Amino acid availability is sensed by various signaling molecules, including general control nonderepressible 2 (GCN2) and mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	144-153	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	76-110
34646153-5	2021	This prioritization/interference may be due to the interplay between the 5" AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling cascades and/or the high skeletal muscle energy requirements for the synthesis and maintenance of cellular organelles.	Sirolimus	138-147	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	76-104
34943047-8	2021	We found that silencing of CFH results in hyperactivation of mTOR signaling along with decreased mitochondrial respiration and that mTOR inhibition via rapamycin can partially rescue these metabolic defects.	Sirolimus	152-161	complement factor H	Homo sapiens	27-30
34840266-3	2022	Treatment with rapamycin, the selective inhibitor of mTOR, initiated at the 4th week of DOCA-salt administration normalized the SBP and attenuated rpS6 activity in the heart, aorta, and kidney.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	53-57
34840266-3	2022	Treatment with rapamycin, the selective inhibitor of mTOR, initiated at the 4th week of DOCA-salt administration normalized the SBP and attenuated rpS6 activity in the heart, aorta, and kidney.	Sirolimus	15-24	ribosomal protein S6	Rattus norvegicus	147-151
34646153-5	2021	This prioritization/interference may be due to the interplay between the 5" AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (mTORC1) signaling cascades and/or the high skeletal muscle energy requirements for the synthesis and maintenance of cellular organelles.	Sirolimus	138-147	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	106-110
34840266-6	2022	Moreover, these pathophysiological changes in DOCA-salt hypertensive rats were associated with increased NADPH oxidase (NOX) activity, gp91phox (formerly NOX2) expression, ERK1/2, and p38 MAPK activities in the heart, aorta, and kidney were minimized by rapamycin.	Sirolimus	254-263	cytochrome b-245 beta chain	Rattus norvegicus	135-143
34494222-11	2021	Akt/mTOR/ p70S6K signaling cascade was proved to be present in NPCs, IGF-I overexpression significantly activated Akt/mTOR/p70S6K signaling cascade, while rapamycin addition inhibited its expression.	Sirolimus	155-164	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
34840266-6	2022	Moreover, these pathophysiological changes in DOCA-salt hypertensive rats were associated with increased NADPH oxidase (NOX) activity, gp91phox (formerly NOX2) expression, ERK1/2, and p38 MAPK activities in the heart, aorta, and kidney were minimized by rapamycin.	Sirolimus	254-263	cytochrome b-245 beta chain	Rattus norvegicus	154-158
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	112-121	nicotinamide N-methyltransferase	Mus musculus	49-53
34187836-1	2021	Transmembrane 4 L six family member 5 (TM4SF5) functions as a sensor for lysosomal arginine levels and activates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	137-146	transmembrane 4 L six family member 5	Homo sapiens	0-37
34187836-1	2021	Transmembrane 4 L six family member 5 (TM4SF5) functions as a sensor for lysosomal arginine levels and activates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	137-146	transmembrane 4 L six family member 5	Homo sapiens	39-45
34454349-6	2021	Similarly, treatment with the autophagy activator rapamycin increased Beclin1 expression during OPG-induced inhibition of osteoclastogenesis.	Sirolimus	50-59	beclin 1	Homo sapiens	70-77
34533799-1	2021	OBJECTIVE: To investigate the pharmacodynamic mechanism of curcumin against myocardial ischaemia-reperfusion injury by regulating the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/rapamycin target protein (mTOR) signalling pathway.	Sirolimus	194-203	mechanistic target of rapamycin kinase	Rattus norvegicus	220-224
34784444-4	2022	The present study investigated whether rapamycin can attenuate PND by inhibiting mTOR and activating autophagy in diabetic rats.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Rattus norvegicus	81-85
34784444-11	2022	Pretreatment of rats with rapamycin inhibited mTOR hyperactivation and restored autophagic function, effectively decreasing tau hyperphosphorylation, Abeta deposition, and apoptosis in the hippocampus.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	46-50
34182227-8	2021	Rapa treated not only reduced the expression of CD80/86 and MHC class II but also down-regulated the expression of CD11c after LPS stimulation which was more obviously in tolDCs by loGM-CSF project (P<0.05).	Sirolimus	0-4	Cd80 molecule	Rattus norvegicus	48-55
34784444-11	2022	Pretreatment of rats with rapamycin inhibited mTOR hyperactivation and restored autophagic function, effectively decreasing tau hyperphosphorylation, Abeta deposition, and apoptosis in the hippocampus.	Sirolimus	26-35	amyloid beta precursor protein	Rattus norvegicus	150-155
34853727-5	2021	Mechanistically, HFD- or PA-initiated lipotoxicity suppressed the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR)/murine double minute 2 homolog (MDM2) signaling cascade to activate p53 and enhance the transcriptional activity of LincRNA-p21.	Sirolimus	148-157	tumor protein p53 pathway corepressor 1	Mus musculus	281-292
34278477-10	2021	Notably, the rapamycin-mediated suppression of phosphorylated-mTOR, and elevation of Beclin 1 and LC3II expression in the rat hippocampus could not be alleviated by asiaticoside treatment.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	62-66
34831215-16	2021	CONCLUSION: The allocation of FLT3-ITD to different cellular compartments and targeting distinct downstream signaling pathways by combined treatment with N-glycosylation and HSP90 inhibitors or VPA and rapamycin might represent new therapeutic strategies to overcome resistance towards tyrosine kinase inhibitors in FLT3-ITD-positive AML.	Sirolimus	202-211	FMS-like tyrosine kinase 3	Mus musculus	30-34
34703880-6	2021	Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT.	Sirolimus	185-194	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	129-157
34703880-6	2021	Mechanistically, OA selectively targeted superoxide dismutase 1 (SOD1) and yielded reactive oxygen species (ROS) to activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex 1 (mTORC1)/macroautophagy pathway, thus eliciting lysosomal degradation of HGPRT and 5"-NT.	Sirolimus	185-194	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	159-163
34522186-11	2021	Furthermore, inhibition of the AKT/mTOR signaling by MK2206 or rapamycin significantly attenuated PRMT4-mediated malignant phenotypes.	Sirolimus	63-72	coactivator associated arginine methyltransferase 1	Homo sapiens	98-103
34385317-2	2021	Toll-like receptor (TLR)7/9- and nucleotide-binding oligomerization domain-containing protein 1 (NOD1)-mediated inflammatory responses require SLC15A4 function for regulating the mechanistic target of rapamycin complex 1 (mTORC1) or transporting L-Ala-gamma-D-Glu-meso-diaminopimelic acid, IL-12: interleukin-12 (Tri-DAP), respectively.	Sirolimus	201-210	toll-like receptor 7	Mus musculus	0-27
34590575-5	2021	Fatty acids and glucose metabolites are involved in regulation of immune response mainly via free fatty acid receptors and AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	172-181	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	183-187
34394184-8	2021	Then, the combined application of overexpressed PDK1 and rapamycin verified that PDK1 could regulate the expression of PD-L1 in NSCLC cells through the mTOR signaling pathway.	Sirolimus	57-66	pyruvate dehydrogenase kinase 1	Homo sapiens	81-85
34360785-9	2021	The rapamycin + doxycycline combination did not cause apoptosis or necrosis/necroptosis, but the alterations in autophagy- and mitochondria-related protein levels (LC3-B-II/I, p62, MitoTracker, TOM20 and certain co-stainings) were correlated to autophagy induction and mitophagy, without mitochondria repopulation.	Sirolimus	4-13	nucleoporin 62	Homo sapiens	176-179
34400894-3	2021	CD44+ colon cancer stem cells (CCSCs) were isolated from mouse colorectal carcinoma CT-26 cell cultures and induced to form defective ribosomal products-containing autophagosome-rich blebs (DRibbles) by treatment with rapamycin, bortezomib, and ammonium chloride.	Sirolimus	218-227	CD44 antigen	Mus musculus	0-4
34354602-3	2021	Rapamycin, a first-generation mTOR inhibitor, produces divergent effects on neuronal survival and alteration in BBB disruption.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	30-34
34349839-1	2021	Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 or TSC2 genes, which encode proteins that antagonise the mammalian isoform of the target of rapamycin complex 1 (mTORC1) - a key mediator of cell growth and metabolism.	Sirolimus	184-193	TSC complex subunit 2	Homo sapiens	95-99
34282122-6	2021	Moreover, both AMP-activated protein kinase (AMPK) agonist metformin and two mammalian targets of rapamycin (mTOR) inhibitors (INK128 and rapamycin) inhibited the percentage of M-MDSCs in lupus mice as well as in the TLR7- and IFN-alpha-induced bone marrow (BM) differentiation into MDSCs in vitro.	Sirolimus	98-107	toll-like receptor 7	Mus musculus	217-221
34282122-6	2021	Moreover, both AMP-activated protein kinase (AMPK) agonist metformin and two mammalian targets of rapamycin (mTOR) inhibitors (INK128 and rapamycin) inhibited the percentage of M-MDSCs in lupus mice as well as in the TLR7- and IFN-alpha-induced bone marrow (BM) differentiation into MDSCs in vitro.	Sirolimus	98-107	interferon alpha	Mus musculus	227-236
34335979-6	2021	The bioengineered CXCR4-overexpressing cell membrane-functionalized ROS-responsive nanotherapeutics, loaded with rapamycin (RAPA), were fabricated to enhance the targeted delivery to lesions with pathological overexpression of SDF-1.	Sirolimus	113-122	chemokine (C-X-C motif) receptor 4	Mus musculus	18-23
34335979-6	2021	The bioengineered CXCR4-overexpressing cell membrane-functionalized ROS-responsive nanotherapeutics, loaded with rapamycin (RAPA), were fabricated to enhance the targeted delivery to lesions with pathological overexpression of SDF-1.	Sirolimus	124-128	chemokine (C-X-C motif) receptor 4	Mus musculus	18-23
34335979-7	2021	Results: RAPA@BMHOP exhibited a three-fold higher rate of target delivery efficacy via the CXCR4/SDF-1 axis than its non-targeting counterpart in an in vivo model.	Sirolimus	9-13	chemokine (C-X-C motif) receptor 4	Mus musculus	91-96
34221806-5	2021	Rapamycin treatment alleviated I/R-induced lung histopathologically injury and increased the concentration of MDA while decreased activity of SOD and expression of NLRP3, Caspase-1, interleukin-1beta (IL-1beta), and IL-18 in rat.	Sirolimus	0-9	caspase 1	Rattus norvegicus	171-180
34221806-8	2021	In vitro experiments showed that LPS induction caused a significant increase in LOC102553434, MMP9, IL-1beta, and IL-18 in L2 cells, but rapamycin treatment significantly reversed the effects.	Sirolimus	137-146	matrix metallopeptidase 9	Rattus norvegicus	94-98
34221806-9	2021	After interfering with the expression of LOC102553434 in the LPS-injured cells pretreated with rapamycin, cell proliferation significantly increased, and the expression of MMP, NLRP3 and caspase-1 were significantly decreased.	Sirolimus	95-104	caspase 1	Rattus norvegicus	187-196
34087234-8	2021	Phosphorylation of p62 at Ser349 by mammalian target of rapamycin complex 1 (mTORC1), a critical step in p62-Keap1 interaction, was induced by I/R, but diminished by R1alpha loss.	Sirolimus	56-65	nucleoporin 62	Homo sapiens	19-22
34087234-8	2021	Phosphorylation of p62 at Ser349 by mammalian target of rapamycin complex 1 (mTORC1), a critical step in p62-Keap1 interaction, was induced by I/R, but diminished by R1alpha loss.	Sirolimus	56-65	nucleoporin 62	Homo sapiens	105-108
34392719-0	2021	Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1alpha, Bcl-2, Bax expression and microvessel density.	Sirolimus	25-34	vascular endothelial growth factor A	Oryctolagus cuniculus	102-106
34392719-0	2021	Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1alpha, Bcl-2, Bax expression and microvessel density.	Sirolimus	25-34	BCL-2	Oryctolagus cuniculus	126-131
34392719-15	2021	Arterial instillation of rapamycin+TACE in treatment of rabbit hepatic xenograft tumors can reduce tumor neovascularization and inhibit iNOS, HIF-1alpha, VEGF, Bcl-2, and Bax protein expression.	Sirolimus	25-34	vascular endothelial growth factor A	Oryctolagus cuniculus	154-158
34392719-15	2021	Arterial instillation of rapamycin+TACE in treatment of rabbit hepatic xenograft tumors can reduce tumor neovascularization and inhibit iNOS, HIF-1alpha, VEGF, Bcl-2, and Bax protein expression.	Sirolimus	25-34	BCL-2	Oryctolagus cuniculus	160-165
34222263-10	2021	To further investigate the role of P2X7 in OA, we injected mTOR antagonist rapamycin or P2X7 antagonist A740003 into the knee joints of ACLT rats.	Sirolimus	75-84	mechanistic target of rapamycin kinase	Rattus norvegicus	59-63
34165769-12	2021	Finally, it was shown that rapamycin resulted in an increase in the expression levels of Gabra1 and Pras40 genes at the brain tissues.	Sirolimus	27-36	gamma-aminobutyric acid type A receptor subunit alpha 1	Rattus norvegicus	89-95
34812711-4	2021	The mechanistic target of rapamycin is a central signaling pathway for coordination and control; the administration of rapamycin, a key modulator of this pathway, could be a new therapeutic approach in neurological disorders.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Rattus norvegicus	4-35
34812711-10	2021	CONCLUSIONS: Pretreatment with Sertoli cell transplant plus rapamycin injection may enhance neural survival during ischemia through increased glial cell-derived neurotrophic factor and vascular endothelial growth factor, inhibiting the mechanistic target of rapamycin pathway and increasing autophagy performance.	Sirolimus	60-69	mechanistic target of rapamycin kinase	Rattus norvegicus	236-267
34605572-10	2021	Furthermore, rapamycin suppressed the increased expressions of MAD2B and SnoN induced by PDGF-BB.	Sirolimus	13-22	MAD2 mitotic arrest deficient-like 2	Mus musculus	63-68
34605572-10	2021	Furthermore, rapamycin suppressed the increased expressions of MAD2B and SnoN induced by PDGF-BB.	Sirolimus	13-22	SKI like proto-oncogene	Homo sapiens	73-77
34605572-12	2021	Moreover, rapamycin exerts an inhibitory effect on intimal hyperplasia, possibly via the MAD2B-SnoN axis.	Sirolimus	10-19	MAD2 mitotic arrest deficient-like 2	Mus musculus	89-94
34605572-12	2021	Moreover, rapamycin exerts an inhibitory effect on intimal hyperplasia, possibly via the MAD2B-SnoN axis.	Sirolimus	10-19	SKI like proto-oncogene	Homo sapiens	95-99
34607910-7	2021	The GTPase RagD encoded by RRAGD plays a role in mediating amino acid signaling to the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	109-118	Ras related GTP binding D	Homo sapiens	11-15
34607910-7	2021	The GTPase RagD encoded by RRAGD plays a role in mediating amino acid signaling to the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	109-118	Ras related GTP binding D	Homo sapiens	27-32
34133835-0	2021	Intranodal Sirolimus Induces Regulatory T cells in Human Hepatic Lymph Nodes via IL10 Signaling.	Sirolimus	11-20	interleukin 10	Homo sapiens	81-85
34689411-7	2022	Rapamycin co-treatment also augmented the expression of HSP70 and activation of AKT, which could recover proteostasis and promote cell survival, respectively.	Sirolimus	0-9	heat shock protein family A (Hsp70) member 4	Homo sapiens	56-61
34698133-2	2021	Rapamycin, an inhibitor of mTOR, was shown to stimulate beta-cell autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	27-31
34675258-7	2021	Akt phosphorylation and activation was indispensable for rapamycin-induced TCTP degradation and PLK1 activation, and depended on S6K inhibition, but not mTORC2 activation.	Sirolimus	57-66	polo like kinase 1	Homo sapiens	96-100
34104954-7	2021	Using an established porcine trophectoderm (pTr1) cell line, it was determined that 10-7 M ADM stimulated proliferation of pTr1 cells (P < 0.05) at 48 h, and increased phosphorylated mechanistic target of rapamycin (p-MTOR) and 4E binding protein 1 (p-4EBP1) by 6.1- and 4.9-fold (P < 0.0001), respectively.	Sirolimus	205-214	adrenomedullin	Mus musculus	91-94
34679726-10	2021	The mTOR inhibitor rapamycin produced a similar reduction in SGK1 mRNA and protein levels as well as phosphorylation.	Sirolimus	19-28	serum/glucocorticoid regulated kinase 1	Homo sapiens	61-65
34790050-13	2021	Rapamycin, an inhibitor of mTOR, remarkably abolished UBE2O-induced mTOR phosphorylation and HCC cell proliferation and mobility.	Sirolimus	0-9	ubiquitin conjugating enzyme E2 O	Homo sapiens	54-59
34428297-2	2021	The ATPase activity of RapA is autoinhibited by its N-terminal domain (NTD) but activated with RNAP bound.	Sirolimus	23-27	ATPase	Escherichia coli	4-10
34428297-3	2021	Here, we report a 3.4-A cryo-EM structure of Escherichia coli RapA-RNAP elongation complex, in which the ATPase active site of RapA is structurally remodeled.	Sirolimus	127-131	ATPase	Escherichia coli	105-111
34428297-6	2021	Functional assay demonstrates that removing the ZBD or FTH of RNAP significantly impairs its ability to activate the ATPase activity of RapA.	Sirolimus	136-140	ATPase	Escherichia coli	117-123
34082015-17	2021	Furthermore, the effects of SZL on myelin proteins, p-Akt, and p-mTOR were clearly inhibited by LY294002 and/or rapamycin, antagonists of PI3K and m-TOR, respectively.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Rattus norvegicus	65-69
34165769-12	2021	Finally, it was shown that rapamycin resulted in an increase in the expression levels of Gabra1 and Pras40 genes at the brain tissues.	Sirolimus	27-36	AKT1 substrate 1	Rattus norvegicus	100-106
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	TIMP metallopeptidase inhibitor 3	Homo sapiens	33-38
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	tenascin C	Homo sapiens	44-47
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	integrin subunit alpha 3	Homo sapiens	76-81
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	integrin subunit beta 1	Homo sapiens	83-88
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	laminin subunit alpha 3	Homo sapiens	90-95
34063955-7	2021	Upregulation of COL11A1, CTNND1, TIMP3, and TNC and downregulation of HAS1, ITGA3, ITGB1, LAMA3, MMP1, and MMP11 were detected in RPM exposed MSCs.	Sirolimus	130-133	matrix metallopeptidase 11	Homo sapiens	107-112
34065350-6	2021	In detail, rapamycin induces the expression of genes promoting mitophagy (PINK1, PARKIN, ULK1, AMBRA1) and mitochondrial fission (FIS1, DRP1).	Sirolimus	11-20	PTEN induced kinase 1	Homo sapiens	74-79
34065350-6	2021	In detail, rapamycin induces the expression of genes promoting mitophagy (PINK1, PARKIN, ULK1, AMBRA1) and mitochondrial fission (FIS1, DRP1).	Sirolimus	11-20	fission, mitochondrial 1	Homo sapiens	130-134
34065350-6	2021	In detail, rapamycin induces the expression of genes promoting mitophagy (PINK1, PARKIN, ULK1, AMBRA1) and mitochondrial fission (FIS1, DRP1).	Sirolimus	11-20	utrophin	Homo sapiens	136-140
34074073-0	2021	(Rapamycin activates autophagy by inhibiting mTOR pathway to alleviate early osteoporosis in rats with skeletal fluorosis).	Sirolimus	1-10	mechanistic target of rapamycin kinase	Rattus norvegicus	45-49
34074073-1	2021	Objective: To investigate the effects of rapamycin target protein (mTOR) pathway and autophagy on bone formation and bone resorption in fluorosis osteoporosis in rats.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
34074073-14	2021	Conclusion: RAPA may activate autophagy by inhibiting mTOR phosphorylation, and inhibit bone resorption while promoting bone formation, thus alleviating early osteoporosis in skeletal fluorosis rats.	Sirolimus	12-16	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
34064854-9	2021	Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	43-47
34064854-9	2021	Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms.	Sirolimus	0-9	BCL2 interacting protein 3	Rattus norvegicus	92-97
34064854-9	2021	Rapamycin administration reduced p-AKT and mTOR expressions and increased Beclin and LC3II, Bnip3, Ambra1, and Parkin expressions, activating both mechanisms.	Sirolimus	0-9	autophagy and beclin 1 regulator 1	Rattus norvegicus	99-105
34064854-11	2021	Rapamycin was administered by activating autophagy and mitophagy, which increased apoptosis (assessed by Western blot analysis of Bcl-2, Bax, and Cleaved-caspase 3) and reduced angiogenesis (assessed by immunohistochemical analysis of vascular endothelial grow factor (VEGF) and CD34) in the lesions.	Sirolimus	0-9	CD34 molecule	Rattus norvegicus	279-283
35339509-12	2022	Treatment with EGF or insulin enhanced 14-3-3zeta expression in the nuclear insoluble fraction; in contrast, the addition of rapamycin downregulated 14-3-3zeta expression.	Sirolimus	125-134	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide	Mus musculus	149-159
34190333-0	2021	KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib.	Sirolimus	102-111	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
34475980-0	2021	Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer.	Sirolimus	0-9	sirtuin 1	Homo sapiens	70-75
34475980-7	2021	In vitro, the inhibitory effect of rapamycin on cell viability in EC was strengthened or weakened after small interfering (si)-SIRT1 or pcDNA3.1/SIRT1 transfection.	Sirolimus	35-44	sirtuin 1	Homo sapiens	127-132
34475980-7	2021	In vitro, the inhibitory effect of rapamycin on cell viability in EC was strengthened or weakened after small interfering (si)-SIRT1 or pcDNA3.1/SIRT1 transfection.	Sirolimus	35-44	sirtuin 1	Homo sapiens	145-150
34475980-8	2021	Furthermore, SIRT1 rescued the inhibitory effect of rapamycin on the migration and invasion of EC cells.	Sirolimus	52-61	sirtuin 1	Homo sapiens	13-18
34697389-2	2021	Here, we examined the functional role of regulated in development and DNA damage responses 1 (REDD1), an inhibitor of mammalian target of rapamycin complex 1 (mTORC1), in LDMC-mediated endothelial cell dysfunction.	Sirolimus	138-147	DNA damage inducible transcript 4	Homo sapiens	94-99
34155681-3	2021	Here, we demonstrated that Rictor, a key component of mechanistic target of rapamycin complex 2 (mTORC2), was crucial for TRAF6/TRAF3 expression in osteoclasts.	Sirolimus	76-85	TNF receptor-associated factor 3	Mus musculus	128-133
34479772-0	2021	Sirolimus diminishes the expression of GRO-alpha (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells.	Sirolimus	0-9	C-X-C motif chemokine ligand 1	Homo sapiens	39-48
34479772-0	2021	Sirolimus diminishes the expression of GRO-alpha (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells.	Sirolimus	0-9	C-X-C motif chemokine ligand 1	Homo sapiens	50-57
34479772-10	2021	Incubation with sirolimus significantly inhibited GRO-alpha expression in keratinocytes as well as tumor cell lines.	Sirolimus	16-25	C-X-C motif chemokine ligand 1	Homo sapiens	50-59
34685533-1	2021	Arginine plays an important role in the regulation of the target of the rapamycin (TOR) signaling pathway, and Solute Carrier Family 38 Member 9 (SLC38A9) was identified to participate in the amino acid-dependent activation of TOR in humans.	Sirolimus	72-81	solute carrier family 38 member 9	Homo sapiens	111-144
34685533-1	2021	Arginine plays an important role in the regulation of the target of the rapamycin (TOR) signaling pathway, and Solute Carrier Family 38 Member 9 (SLC38A9) was identified to participate in the amino acid-dependent activation of TOR in humans.	Sirolimus	72-81	solute carrier family 38 member 9	Homo sapiens	146-153
35594496-4	2022	When CD81, a typical EV marker protein, and POI were fused with FKBP and FRB, respectively, rapamycin induced the binding of these proteins through the FKBP-FRB interaction and recruited the POIs into EVs.	Sirolimus	92-101	CD81 molecule	Homo sapiens	5-9
35316214-5	2022	This pathway impeded uncontrolled cardiomyocytes hypertrophy during pregnancy, and mice with cardiac-specific Zfp36l2 deletion developed rapid cardiac dysfunction after delivery, while prenatal treatment of these mice with rapamycin improved post-partum cardiac function.	Sirolimus	223-232	zinc finger protein 36, C3H type-like 2	Mus musculus	110-117
35316218-4	2022	Rapamycin perturbed the expression of multiple genes and signaling pathways important for cellular proliferation and substantially decreased the frequencies of proliferating CD4+ memory T cells (TM) in blood and tissues.	Sirolimus	0-9	CD4 molecule	Macaca mulatta	174-177
35316218-8	2022	These results indicate that while rapamycin can decrease the proliferation of CD4+ TM, chronic mTOR inhibition alone or in combination with T cell activation, was not sufficient to disrupt the stability of the SIV reservoir.	Sirolimus	34-43	CD4 molecule	Macaca mulatta	78-81
35585885-8	2022	Of note, the effect of OG on Nrf2/Keap1 signaling was neutralized by the mTOR inhibitor rapamycin.	Sirolimus	88-97	kelch-like ECH-associated protein 1	Mus musculus	34-39
35276460-11	2022	Then, RAPA was used to inhibit the mTOR pathway, and the inflammatory factors IL-17A and IFN-gamma were downregulated in EAM mouse muscle and serum.	Sirolimus	6-10	interleukin 17A	Mus musculus	78-84
35510853-3	2022	Here, we developed a leak-free inducible CRISPRi/a system by integrating the DiCre/loxP regulon to allow the expression of dCas9-GCN5/-Sir2a upon transient induction with rapamycin, which allows convenient transcriptional regulation of a gene of interest by introducing a guide RNA targeting its transcription start region.	Sirolimus	171-180	lysine acetyltransferase 2A	Homo sapiens	129-133
35510853-3	2022	Here, we developed a leak-free inducible CRISPRi/a system by integrating the DiCre/loxP regulon to allow the expression of dCas9-GCN5/-Sir2a upon transient induction with rapamycin, which allows convenient transcriptional regulation of a gene of interest by introducing a guide RNA targeting its transcription start region.	Sirolimus	171-180	sirtuin 1	Homo sapiens	135-140
35442666-3	2022	The cytosolic arginine sensor for mTORC1 subunit 1 (CASTOR1) is a crucial upstream regulator of the mechanistic target of rapamycin complex 1 (mTORC1) signaling, which has close connections with apoptosis.	Sirolimus	122-131	cytosolic arginine sensor for mTORC1 subunit 1	Homo sapiens	52-59
35190965-10	2022	Moreover, it prevented DOX-induced cardiomyocyte apoptosis; a similar cardioprotection was observed when normal H9c2 cells (without Pdcd1 overexpression) were treated with rapamycin, an autophagy inducer, before the DOX treatment.	Sirolimus	172-181	programmed cell death 1	Rattus norvegicus	132-137
35441596-6	2022	In addition, HRI-elF2alphaP specifically enhances translation of ATF4 mRNA leading to the repression of mechanistic target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	126-135	activating transcription factor 4	Homo sapiens	65-69
35495903-8	2022	High levels of dietary valine stimulated lipid deposition by suppressing the GCN2-eIF2alpha-ATF4-fibroblast growth factor-19 (FGF19)-target of rapamycin complex 1 (TORC1) signaling pathway to promote fatty acid synthesis, repress fatty acid utilization, and eventually accelerate the development of NAFLD.	Sirolimus	143-152	fibroblast growth factor 19	Gallus gallus	97-124
35495903-8	2022	High levels of dietary valine stimulated lipid deposition by suppressing the GCN2-eIF2alpha-ATF4-fibroblast growth factor-19 (FGF19)-target of rapamycin complex 1 (TORC1) signaling pathway to promote fatty acid synthesis, repress fatty acid utilization, and eventually accelerate the development of NAFLD.	Sirolimus	143-152	fibroblast growth factor 19	Gallus gallus	126-131
35559188-5	2022	We have re-engineered this inhibitory interaction to function intermolecularly by independently fusing the SHP2 catalytic and N-SH2 domains to protein domains that heterodimerize upon the introduction of the CID rapamycin.	Sirolimus	212-221	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	107-111
35559188-6	2022	We show that rapamycin-induced protein dimerization leads to potent inhibition of SHP2"s catalytic activity, which is driven by increased proximity of the SHP2 catalytic and N-SH2 domains.	Sirolimus	13-22	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	82-86
35559188-6	2022	We show that rapamycin-induced protein dimerization leads to potent inhibition of SHP2"s catalytic activity, which is driven by increased proximity of the SHP2 catalytic and N-SH2 domains.	Sirolimus	13-22	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	155-159
35166010-6	2022	In further support that BUR1 functions with TORC1, mutation of bur1 alone results in high sensitivity to rapamycin, a TORC1 inhibitor.	Sirolimus	105-114	cyclin-dependent serine/threonine protein kinase SGV1	Saccharomyces cerevisiae S288C	24-28
35166010-6	2022	In further support that BUR1 functions with TORC1, mutation of bur1 alone results in high sensitivity to rapamycin, a TORC1 inhibitor.	Sirolimus	105-114	cyclin-dependent serine/threonine protein kinase SGV1	Saccharomyces cerevisiae S288C	63-67
35390228-19	2022	We found that degradation of cardiac GATA4 by Bmi-1 was mainly dependent on autophagy rather than proteasome, and autophagy agonists metformin and rapamycin could ameliorate the SA-PCH, suggesting that activation of autophagy with metformin or rapamycin could also be a promising method to prevent SA-PCH.	Sirolimus	147-156	GATA binding protein 4	Homo sapiens	37-42
35390228-19	2022	We found that degradation of cardiac GATA4 by Bmi-1 was mainly dependent on autophagy rather than proteasome, and autophagy agonists metformin and rapamycin could ameliorate the SA-PCH, suggesting that activation of autophagy with metformin or rapamycin could also be a promising method to prevent SA-PCH.	Sirolimus	244-253	GATA binding protein 4	Homo sapiens	37-42
35384725-4	2022	Rapamycin reduced IL-17 production, TBX21, and RORc expression by splenic and CNS cell cultures.	Sirolimus	0-9	interleukin 17A	Mus musculus	18-23
35384725-4	2022	Rapamycin reduced IL-17 production, TBX21, and RORc expression by splenic and CNS cell cultures.	Sirolimus	0-9	T-box 21	Mus musculus	36-41
35318320-3	2022	Here we report that ribosomal protein S6 kinase beta 1 (S6K1), a member of AGC kinases and downstream target of mechanistic target of rapamycin complex 1 (mTORC1), directly phosphorylates PDK1 at its pleckstrin homology (PH) domain, and impairs PDK1 interaction with and activation of AKT.	Sirolimus	134-143	3-phosphoinositide dependent protein kinase 1	Homo sapiens	188-192
35356282-14	2022	Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs.	Sirolimus	19-28	serum amyloid A1 cluster	Homo sapiens	85-92
35356282-14	2022	Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs.	Sirolimus	19-28	nucleoporin 62	Homo sapiens	142-145
35356282-14	2022	Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs.	Sirolimus	19-28	beclin 1	Homo sapiens	259-264
35048556-3	2022	Here, an endoplasmic-reticulum-localized split sec-tobacco etch virus protease (TEVp)-based rapamycin-actuated protein-induction device (RAPID) is engineered, which is composed of the rapamycin-inducible dimerization domains FK506 binding protein (FKBP) and FKBP-rapamycin binding protein fused with modified split sec-TEVp components.	Sirolimus	92-101	FKBP prolyl isomerase 3	Homo sapiens	263-288
35048556-3	2022	Here, an endoplasmic-reticulum-localized split sec-tobacco etch virus protease (TEVp)-based rapamycin-actuated protein-induction device (RAPID) is engineered, which is composed of the rapamycin-inducible dimerization domains FK506 binding protein (FKBP) and FKBP-rapamycin binding protein fused with modified split sec-TEVp components.	Sirolimus	184-193	FKBP prolyl isomerase 3	Homo sapiens	263-288
35235808-6	2022	Treatment with the mTOR inhibitor rapamycin decreases the growth of syngeneic KPC tumors with Galpha13 loss by promoting cell death.	Sirolimus	34-43	G protein subunit alpha 13	Homo sapiens	94-102
35197970-0	2022	Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	104-108
35197970-0	2022	Rapamycin Attenuated Zinc-Induced Tau Phosphorylation and Oxidative Stress in Rats: Involvement of Dual mTOR/p70S6K and Nrf2/HO-1 Pathways.	Sirolimus	0-9	heme oxygenase 1	Rattus norvegicus	125-129
35197970-12	2022	Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	27-31
35197970-12	2022	Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
35197970-12	2022	Rapamycin, an inhibitor of mTOR, rescued zinc-induced increases in mTOR/p70S6K activation, tau phosphorylation, and oxidative stress, and Nrf2/HO-1 inactivation, cognitive impairment, and synaptic impairment reduced the expression of synapse-related proteins in zinc-injected rats.	Sirolimus	0-9	heme oxygenase 1	Rattus norvegicus	143-147
35197970-13	2022	In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Rattus norvegicus	189-193
35197970-13	2022	In conclusion, our findings imply that rapamycin prevents zinc-induced cognitive impairment and protects neurons from tau pathology, oxidative stress, and synaptic impairment by decreasing mTOR/p70S6K hyperactivity and increasing Nrf2/HO-1 activity.	Sirolimus	39-48	heme oxygenase 1	Rattus norvegicus	235-239
35133561-8	2022	Furthermore, Ang II-induced loss of autophagy and promotion of apoptosis in CFs were prevented by the treatment with Pyr1-apelin-13 or AMPK agonist AICAR or mTOR inhibitor rapamycin, respectively.	Sirolimus	172-181	mechanistic target of rapamycin kinase	Rattus norvegicus	157-161
35587661-4	2022	After establishment, group C was injected pcDNA3.1-miR-100-5p recombinant plasmid, group D was injected mTOR inhibitor rapamycin, group E was injected with pcDNA3.1-miR-100-5p recombinant plasmid and rapamycin, and group A was injected same amount of normal saline in the same way.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Rattus norvegicus	104-108
35048147-16	2022	Additionally, p-mTOR expression was significantly reduced in groups that rapamycin was injected.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Rattus norvegicus	16-20
35040435-9	2022	Both systemic and topical rapamycin treatment of Skiv2l-deficient mice ameliorated epidermal hyperplasia and skin inflammation.	Sirolimus	26-35	superkiller viralicidic activity 2-like (S. cerevisiae)	Mus musculus	49-55
35040435-11	2022	We also propose SKIV2L-associated trichohepatoenteric syndrome (THES) as a new mTORopathy for which sirolimus may be a promising therapy.	Sirolimus	100-109	superkiller viralicidic activity 2-like (S. cerevisiae)	Mus musculus	16-22
35040438-6	2022	Interestingly, treatment with the mTOR inhibitor rapamycin improves skin symptoms in Skiv2l-deficient mice, suggesting a possible therapeutic avenue for patients with THES2.	Sirolimus	49-58	superkiller viralicidic activity 2-like (S. cerevisiae)	Mus musculus	85-91
35046889-4	2021	Ddit4 is a direct target of Mir221 and Mir222, and the upregulation of Ddit4 in Mir221/222AdipoKO was associated with the suppression of TSC2 (tuberous sclerosis complex 2)/mammalian target of rapamycin complex 1 (mTORC1)/S6K (ribosomal protein S6 kinase) pathway.	Sirolimus	193-202	DNA damage inducible transcript 4	Homo sapiens	0-5
35046889-4	2021	Ddit4 is a direct target of Mir221 and Mir222, and the upregulation of Ddit4 in Mir221/222AdipoKO was associated with the suppression of TSC2 (tuberous sclerosis complex 2)/mammalian target of rapamycin complex 1 (mTORC1)/S6K (ribosomal protein S6 kinase) pathway.	Sirolimus	193-202	DNA damage inducible transcript 4	Homo sapiens	71-76
35046889-4	2021	Ddit4 is a direct target of Mir221 and Mir222, and the upregulation of Ddit4 in Mir221/222AdipoKO was associated with the suppression of TSC2 (tuberous sclerosis complex 2)/mammalian target of rapamycin complex 1 (mTORC1)/S6K (ribosomal protein S6 kinase) pathway.	Sirolimus	193-202	TSC complex subunit 2	Homo sapiens	137-141
34958157-10	2022	However, the autophagy inhibitor 3-methyladenine abolished the lincRNA-p21 knockdown-promoted mineralization, and the autophagy activator rapamycin rescued the mineralization inhibited by lincRNA-p21 overexpression.	Sirolimus	138-147	tumor protein p53 pathway corepressor 1	Mus musculus	188-199
33278579-5	2021	Rapamycin (RM) was also used to treat animals as an mTOR inhibitor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
33054526-5	2021	We further confirmed that the translational efficiency of Tudor-SN mRNA was controlled by the mammalian target of rapamycin complex 1 (mTORC1) pathway, as revealed via inhibition of activated mTORC1 in primary neonatal mouse cardiomyocytes and activation of silenced mTORC1 in adult mouse myocardia; additionally, this result was recapitulated in H9c2 cells.	Sirolimus	114-123	staphylococcal nuclease and tudor domain containing 1	Homo sapiens	58-66
34362635-10	2021	Although rapamycin (mTOR inhibitor) prevented this cardioprotective effect induced by Leu, wortmannin (PI3K inhibitor) did not interfere with this effect.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Rattus norvegicus	20-24
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	nicotinamide N-methyltransferase	Mus musculus	49-53
34059001-17	2021	Repression of mTOR with rapamycin blocked the effects of KLK11 on S6K1 and 4EBP1 as well as protein synthesis.	Sirolimus	24-33	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	66-70
34378991-5	2021	Here, we demonstrated that palmitate upregulates NNMT expression via activating ATF4 in a mechanistic target of rapamycin complex 1 (mTORC1)-dependent mechanism in that mTORC1 inhibition by both Torin1 and rapamycin attenuated ATF4 activation and NNMT upregulation.	Sirolimus	206-215	nicotinamide N-methyltransferase	Mus musculus	247-251
33988537-12	2021	To further investigate the function of PPARalpha in sepsis, we inhibited mTOR with rapamycin and examined mitochondrial injury and ROS levels.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Rattus norvegicus	73-77
34242720-7	2021	Furthermore, Rapa pretreatment antagonized MeHg-induced apoptosis, whereas 3-MA further aggravated apoptosis, which were supported by findings that Rapa activated mTOR-mediated autophagy while 3-MA inhibited Vps34-related autophagy, further affect neuronal apoptosis through regulation of apoptotic factors mentioned above.	Sirolimus	13-17	mechanistic target of rapamycin kinase	Rattus norvegicus	163-167
34242720-7	2021	Furthermore, Rapa pretreatment antagonized MeHg-induced apoptosis, whereas 3-MA further aggravated apoptosis, which were supported by findings that Rapa activated mTOR-mediated autophagy while 3-MA inhibited Vps34-related autophagy, further affect neuronal apoptosis through regulation of apoptotic factors mentioned above.	Sirolimus	148-152	mechanistic target of rapamycin kinase	Rattus norvegicus	163-167
33988537-13	2021	The levels of mitochondrial damage and ROS were reduced after LBP-/- rats were pretreated with rapamycin in the context of LPS-induced sepsis.	Sirolimus	95-104	lipopolysaccharide binding protein	Rattus norvegicus	62-65
34577576-0	2021	Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/mTOR/VEGF Signaling.	Sirolimus	42-51	vascular endothelial growth factor A	Mus musculus	142-146
33930202-16	2021	Our results showed that the inhibitory effect of mTOR inhibitor (rapamycin) on reactive oxygen species production during NLRP3 inflammasome activation could bring about behavioral alterations in anxiety and depression.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Rattus norvegicus	49-53
33891611-7	2021	Rapamycin was significantly more effective than either INK128 or ganetespib (an HSP90 inhibitor) in reducing the growth of TSC2 null SNU-398 cells in a xenograft model.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	123-127
34452418-7	2021	Besides that, rapamycin could disturb the expression of p62 and LC3B-II, and the transcription level of SCRV nucleoprotein mRNA.	Sirolimus	14-23	nucleoporin 62	Homo sapiens	56-59
34342774-3	2021	FKBP2 (FKBP13) and FKBP1 (FKBP12), known as immunophilins, are binding proteins for rapamycin and FK506, which are immunosuppressive drugs.	Sirolimus	84-93	FKBP prolyl isomerase 2	Homo sapiens	0-5
34341336-5	2021	PLA enhanced FGFBP1 expression through activation of the mechanistic target of rapamycin complex 1-signal transducer and activator of transcription 3 (mTORC1-STAT3) signaling pathway.	Sirolimus	79-88	fibroblast growth factor binding protein 1	Mus musculus	13-19
33881936-5	2021	Mechanical overload induced an increase in mTORC1 signalling, protein synthesis and muscle mass, and these were associated with rapamycin-sensitive increases in adenosylmethione decarboxylase 1 (Amd1), spermidine synthase (SpdSyn) and c-Myc.	Sirolimus	128-137	S-adenosylmethionine decarboxylase 1	Mus musculus	161-193
34102263-5	2021	The expression levels of the phosphorylated p70S6K, a downstream molecule of mTOR, in the proximal and distal stumps of the transected IAN were significantly reduced by rapamycin administration to the injured site.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Rattus norvegicus	77-81
33881936-5	2021	Mechanical overload induced an increase in mTORC1 signalling, protein synthesis and muscle mass, and these were associated with rapamycin-sensitive increases in adenosylmethione decarboxylase 1 (Amd1), spermidine synthase (SpdSyn) and c-Myc.	Sirolimus	128-137	S-adenosylmethionine decarboxylase 1	Mus musculus	195-199
34102263-8	2021	Accumulation of myelin protein zero and myelin basic protein in the proximal and distal stumps of the IAN was significantly reduced by rapamycin administration.	Sirolimus	135-144	myelin basic protein	Rattus norvegicus	40-60
34102263-9	2021	Rapamycin administration facilitated axon regeneration after IANX and increased the number of brain-derived neurotrophic factor positive neurons in the trigeminal ganglion.	Sirolimus	0-9	brain-derived neurotrophic factor	Rattus norvegicus	94-127
33935683-12	2021	Pretreating mice with rapamycin inhibited the activation of mTOR and restored autophagy function, also increased the expression of SYN and PSD-95.	Sirolimus	22-31	discs large MAGUK scaffold protein 4	Mus musculus	139-145
34301883-1	2021	Tuberous sclerosis complex 1 (Tsc1) is a tumor suppressor that functions together with Tsc2 to negatively regulate the mechanistic target of rapamycin complex 1 (mTORC1) activity.	Sirolimus	141-150	TSC complex subunit 2	Homo sapiens	87-91
33935683-15	2021	An mTOR inhibitor, rapamycin, ameliorated anesthesia/surgery-related cognitive impairments by inhibiting the mTOR activity, inducing activation of autophagy, enhancing SYN and PSD-95 expression.	Sirolimus	19-28	discs large MAGUK scaffold protein 4	Mus musculus	176-182
34235896-8	2021	Intravitreal administration of rapamycin, a negative regulator of mTOR, inhibits the mTOR pathway in rd1 photoreceptors.	Sirolimus	31-40	phosphodiesterase 6B	Homo sapiens	101-104
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	TSC complex subunit 2	Homo sapiens	110-114
34322484-3	2021	Application of rapamycin, a specific inhibitor of mTOR, attenuated the phosphorylation of S6 and 4E-BP1 and as such, largely inhibited the mechanical activation of mTOR.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
34322484-3	2021	Application of rapamycin, a specific inhibitor of mTOR, attenuated the phosphorylation of S6 and 4E-BP1 and as such, largely inhibited the mechanical activation of mTOR.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	164-168
33923449-1	2021	Tuberous sclerosis complex (TSC) is a genetic disorder caused by inactivating mutations in TSC1 (hamartin) or TSC2 (tuberin), crucial negative regulators of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway.	Sirolimus	183-192	TSC complex subunit 2	Homo sapiens	116-123
34322484-4	2021	Moreover, rapamycin significantly decreased the proliferation and non-tenocyte differentiation of PTSCs as indicated by the reduced expression levels of LPL, PPARgamma, SOX-9, collagen II, Runx-2, and osteocalcin genes.	Sirolimus	10-19	lipoprotein lipase	Mus musculus	153-156
33863987-2	2021	LARS is also essential to sensitize the intracellular leucine concentration to the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	103-112	leucyl-tRNA synthetase 1	Homo sapiens	0-4
34322484-4	2021	Moreover, rapamycin significantly decreased the proliferation and non-tenocyte differentiation of PTSCs as indicated by the reduced expression levels of LPL, PPARgamma, SOX-9, collagen II, Runx-2, and osteocalcin genes.	Sirolimus	10-19	SRY-box transcription factor 9	Rattus norvegicus	169-174
34177589-8	2021	Moreover, the CGGD-containing serum also decreased LC3B or collagen I expression after rapamycin (mTOR inhibitor) or SP600125 (JNK inhibitor) treatment in PSCs.	Sirolimus	87-96	mechanistic target of rapamycin kinase	Rattus norvegicus	98-102
34103528-6	2021	Mechanistically, AKT1-R391 methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading to AKT1 membrane translocation and subsequent activation by phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of rapamycin complex 2 (mTORC2).	Sirolimus	301-310	pyruvate dehydrogenase kinase 1	Homo sapiens	228-263
34103528-6	2021	Mechanistically, AKT1-R391 methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading to AKT1 membrane translocation and subsequent activation by phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of rapamycin complex 2 (mTORC2).	Sirolimus	301-310	pyruvate dehydrogenase kinase 1	Homo sapiens	265-269
35428493-11	2022	LC3 fluorescent spots were increased in the rapamycin treatment group.	Sirolimus	44-53	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	0-3
35523039-0	2022	Sirolimus therapy restores the PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr cell balance in primary Sjogren"s syndrome.	Sirolimus	0-9	protein tyrosine phosphatase receptor type C	Homo sapiens	45-51
35523039-10	2022	Unexpectedly, the elevated PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr ratio had the greatest ability to discriminate between pSS and HC, and sirolimus therapy restored the PD-1+ICOS+Tfh cells:CD45RA-Foxp3high activated Tfr ratio, and controlled disease activity.	Sirolimus	143-152	protein tyrosine phosphatase receptor type C	Homo sapiens	41-47
35523039-10	2022	Unexpectedly, the elevated PD-1+ICOS+Tfh:CD45RA-Foxp3high activated Tfr ratio had the greatest ability to discriminate between pSS and HC, and sirolimus therapy restored the PD-1+ICOS+Tfh cells:CD45RA-Foxp3high activated Tfr ratio, and controlled disease activity.	Sirolimus	143-152	protein tyrosine phosphatase receptor type C	Homo sapiens	194-200
35489420-10	2022	MiR-199a-3p directly targeted and repressed mTOR, and its suppression effect on ICAM-1 and VCAM-1 was abolished by mTOR inhibitor rapamycin, and rescued by mTOR activator MHY1485.	Sirolimus	130-139	microRNA 199a-1	Homo sapiens	0-11
35489420-10	2022	MiR-199a-3p directly targeted and repressed mTOR, and its suppression effect on ICAM-1 and VCAM-1 was abolished by mTOR inhibitor rapamycin, and rescued by mTOR activator MHY1485.	Sirolimus	130-139	intercellular adhesion molecule 1	Homo sapiens	80-86
35502657-12	2022	TET2 coimmunoprecipitated with p300, and this interaction was enhanced by rapamycin but repressed by platelet-derived growth factor (PDGF) treatment, with p300 promoting TET2 protein stability.	Sirolimus	74-83	E1A binding protein p300	Mus musculus	31-35
33368291-6	2021	Concordantly, loss of GPT2 results in an impairment of mechanistic target of rapamycin complex 1 (mTORC1) activity as well as the induction of autophagy.	Sirolimus	77-86	glutamic--pyruvic transaminase 2	Homo sapiens	22-26
33936211-7	2021	Furthermore, autophagy flux following treatment with an autophagy inducer, rapamycin, has shown that CD47 is a key player in autophagy and senescence to maintain and regulate the growth of MSCs, suggesting that CD47 may be a critical key marker for the selection of effective stem cells in cell therapy.	Sirolimus	75-84	CD47 molecule	Homo sapiens	101-105
35490768-8	2022	Also, Gly promoted endomitotic DNA synthesis in silk gland cells via phosphoinositide 3-kinase (PI3K)/Akt/target of rapamycin (TOR) signaling.	Sirolimus	116-125	RAC serine/threonine-protein kinase	Bombyx mori	102-105
35633088-7	2022	Mechanistic experimentation illustrated that TRPM2 interacted with p47 phox and positively regulated p47 phox, such that p47 phox up-regulation or use of Rapamycin (autophagy activator) weakened the inhibitory role of silencing TRPM2.	Sirolimus	154-163	transient receptor potential cation channel subfamily M member 2	Homo sapiens	45-50
35633088-7	2022	Mechanistic experimentation illustrated that TRPM2 interacted with p47 phox and positively regulated p47 phox, such that p47 phox up-regulation or use of Rapamycin (autophagy activator) weakened the inhibitory role of silencing TRPM2.	Sirolimus	154-163	neutrophil cytosolic factor 1	Homo sapiens	67-75
35633088-7	2022	Mechanistic experimentation illustrated that TRPM2 interacted with p47 phox and positively regulated p47 phox, such that p47 phox up-regulation or use of Rapamycin (autophagy activator) weakened the inhibitory role of silencing TRPM2.	Sirolimus	154-163	transient receptor potential cation channel subfamily M member 2	Homo sapiens	228-233
33936211-7	2021	Furthermore, autophagy flux following treatment with an autophagy inducer, rapamycin, has shown that CD47 is a key player in autophagy and senescence to maintain and regulate the growth of MSCs, suggesting that CD47 may be a critical key marker for the selection of effective stem cells in cell therapy.	Sirolimus	75-84	CD47 molecule	Homo sapiens	211-215
33897438-0	2021	Disrupting Reconsolidation by Systemic Inhibition of mTOR Kinase via Rapamycin Reduces Cocaine-Seeking Behavior.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Rattus norvegicus	53-57
33717266-7	2021	Additionally, SOX2 activated AKT through the PTEN/PI3K/phosphoinositide-dependent protein kinase 1 and mammalian target of rapamycin complex 2 signaling pathways.	Sirolimus	123-132	SRY-box transcription factor 2	Homo sapiens	14-18
35612957-7	2022	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	86-95	estrogen receptor 2	Bos taurus	25-31
35612957-7	2022	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	86-95	estrogen receptor 2	Bos taurus	176-182
35612957-7	2022	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	97-101	estrogen receptor 2	Bos taurus	25-31
33340561-8	2021	Silencing FAM135B shows synergy with PI3K/Akt/mTOR pathway inhibitor (rapamycin) in increasing radiosensitivity, regulating the expression of cell cycle protein and inducing apoptosis of ESCC cells.	Sirolimus	70-79	family with sequence similarity 135 member B	Homo sapiens	10-17
35612957-7	2022	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	97-101	estrogen receptor 2	Bos taurus	176-182
33524531-3	2021	It is well established that REDD1 mediates the cellular response to a number of diverse stressors through repression of the central metabolic regulator known as mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	183-192	DNA damage inducible transcript 4	Homo sapiens	28-33
35623563-6	2022	As an mTOR inhibitor, Rap induced autophagy and inhibited NF-kappaB-mediated pro-inflammatory signaling.	Sirolimus	22-25	mechanistic target of rapamycin kinase	Rattus norvegicus	6-10
33640883-0	2021	Maf1 suppression of ATF5-dependent mitochondrial unfolded protein response contributes to rapamycin-induced radio-sensitivity in lung cancer cell line A549.	Sirolimus	90-99	activating transcription factor 5	Homo sapiens	20-24
33640883-6	2021	Consistently, Maf1 knockdown activates ATF5-transcription of mtHSP70 and HSP60, enhances mitochondrial membrane potential, reduces intracellular ROS levels and dampens rapamycin"s effect on increasing IR-mediated cytotoxicity.	Sirolimus	168-177	activating transcription factor 5	Homo sapiens	39-43
35367291-5	2022	Rapamycin rescued the inhibition of TFEB nuclear translocation induced by miR-34a/ATG9A activation, restored autophagic flux and consequently prevented HEI-OC1 cell death.	Sirolimus	0-9	transcription factor EB	Mus musculus	36-40
33708210-6	2021	Mechanistically, we unravel that IL-10 activates the mammalian target of rapamycin complex 1 (mTORC1) to regulate metabolic reprogramming in human NK cells.	Sirolimus	73-82	interleukin 10	Homo sapiens	33-38
35367291-6	2022	Long-term supplementation with rapamycin attenuated outer hair cells (OHCs) and inner hair cell synaptic ribbons, and delayed AHL in C57BL/6 mice.	Sirolimus	31-40	cadherin 23 (otocadherin)	Mus musculus	126-129
35367291-7	2022	Most importantly, rapamycin partially restored TFEB"s nuclear localization and autophagic flux in OHCs of the ageing cochlea.	Sirolimus	18-27	transcription factor EB	Mus musculus	47-51
33285202-0	2021	Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Rattus norvegicus	98-102
35597502-2	2022	Sestrin2 content is involved in the function of mechanistic target of rapamycin complex 1 (mTORC1) in mouse embryonic fibroblasts and C2C12 cells.	Sirolimus	70-79	sestrin 2	Mus musculus	0-8
33285202-5	2021	We could show that treatment with rapamycin diminished GBM tumor growth, confirming mTOR-signaling as one key driver for tumor growth.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Rattus norvegicus	84-88
35589065-12	2022	Rapamycin restored the protein expression levels of beclin1, LC3-II/LC3-I and OCN, OPN, OSX under the high lactate conditions.	Sirolimus	0-9	beclin 1	Homo sapiens	52-59
32835451-6	2021	Treatment with the mTOR inhibitor rapamycin decreased astroglial VEGFR-3 expression and GLT-1 expression after SE.	Sirolimus	34-43	fms related receptor tyrosine kinase 4	Homo sapiens	65-72
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	144-148
35196893-6	2022	Cryptotanshinone (CPT) and rapamycin (Rapa) were used to block activation of the signal transducer and activator of transcription 3 (STAT3) and mTOR signaling pathways, respectively.	Sirolimus	38-42	mechanistic target of rapamycin kinase	Rattus norvegicus	144-148
33530801-1	2021	OBJECTIVE: To investigate the effects of 1,25(OH)2D3 on renal fibrosis associated with the AMP-activated protein kinase (AMPK)alpha/mechanistic target of rapamycin (mTOR) signalling pathway in a rat model of unilateral ureteral obstruction (UUO).	Sirolimus	154-163	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
35438806-8	2022	Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
35438806-8	2022	Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Rattus norvegicus	170-174
35438806-8	2022	Mechanistically, poly(I:C) activated the PI3K/AKT/mTOR pathway to induce autophagy, which was abolished by LY294002 (PI3K antagonist), rapamycin (autophagy activator and mTOR inhibitor), or 3-methyladenine (autophagy inhibitor), suggesting either inhibition of the PI3K/Akt/mTOR pathway or autophagy activity interrupt the beneficial effect of poly(I:C) preconditioning.	Sirolimus	135-144	mechanistic target of rapamycin kinase	Rattus norvegicus	274-278
33140268-5	2021	Rapamycin, an inhibitor of mTOR, rescued the STZ-induced increases in mTOR/p70S6K activities, tau phosphorylation and Abeta levels, as well as mitochondria abnormality and cognitive impairment in mice.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	75-81
33140268-6	2021	These findings imply that rapamycin prevents cognitive impairment and protects hippocampus neurons from AD-like pathology and mitochondrial abnormality, and also that rapamycin treatment could normalize these STZ-induced alterations by decreasing hippocampus mTOR/p70S6K hyperactivity.	Sirolimus	167-176	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	264-270
33307091-1	2021	The Tuberous Sclerosis Complex (TSC) protein complex (TSCC), comprising TSC1, TSC2, and TBC1D7, is widely recognised as a key integration hub for cell growth and intracellular stress signals upstream of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	227-236	TSC complex subunit 2	Homo sapiens	78-82
33181173-9	2021	Autophagy activation by rapamycin enhanced TGF-beta2-triggered fibrogenic responses and cell migration in LECs, whereas pharmacological inhibition of autophagy alleviated TGF-beta2-induced increases of EMT markers and cell migration of LECs.	Sirolimus	24-33	transforming growth factor beta 2	Homo sapiens	43-52
33436008-11	2021	In addition, CDCA4-inhibited EMT, migration and invasion could be partially aggravated by autophagy activator, rapamycin, and reversed by autophagy inhibitor, 3-MA.	Sirolimus	111-120	cell division cycle associated 4	Homo sapiens	13-18
33436008-12	2021	Correspondingly, the application of rapamycin or 3-MA to CDCA4 knockdown cells showed the opposite effects.	Sirolimus	36-45	cell division cycle associated 4	Homo sapiens	57-62
33477144-5	2021	Dual-luciferase reporter assay and pull-down assay were performed to confirm the interaction between miR-96-5p and DEP domain-containing mammalian target of rapamycin-interacting protein (DEPTOR).	Sirolimus	157-166	DEP domain containing MTOR interacting protein	Homo sapiens	188-194
35446876-0	2022	The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
35446876-2	2022	The mTOR inhibitor Rapamycin protects from senescence in experimental models, but its antiproliferative properties have raised concern early after transplantation particularly at higher doses.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
35446876-5	2022	Low Rapamycin trough levels (2.1-6.8 ng/mL) prevented the accumulation of p16INK4a positive cells in tubules, interstitium, and glomerula.	Sirolimus	4-13	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	74-82
35446876-9	2022	mTOR inhibition with low-dose Rapamycin in the immediate posttransplant period protected from premature cellular senescence without negative effects on structural and functional recovery from preservation/reperfusion damage, glucose homeostasis, and growth in a rat kidney transplantation model.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
35365781-7	2022	We further analyzed the changes in the expression of angiogenesis-associated genes in rapamycin-primed MSCs and found higher expression of several genes related to angiogenesis, such as VEGFR2 and CTGF/CCN2, in primed cells than in unprimed MSCs.	Sirolimus	86-95	kinase insert domain receptor	Homo sapiens	186-192
32583421-7	2021	Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARalpha, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells.	Sirolimus	149-158	fatty acid synthase	Homo sapiens	63-67
32583421-7	2021	Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARalpha, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells.	Sirolimus	149-158	acyl-CoA oxidase 1	Homo sapiens	126-131
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	fatty acid synthase	Homo sapiens	119-123
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	acetyl-CoA carboxylase alpha	Homo sapiens	125-130
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	stearoyl-CoA desaturase	Homo sapiens	139-162
33189285-11	2021	Rapamycin effectively inhibited the positive effect of acetate on the relative expression of mTOR, eIF4E, S6K1, 4EBP1, FASN, ACACA, FABP3, stearoyl-CoA desaturase (SCD1), SREBP1, and PPARG.	Sirolimus	0-9	stearoyl-CoA desaturase	Homo sapiens	164-168
33130049-2	2020	This study, hence, examined whether treatment with Art alone or in combination with rapamycin (Rapa), an mTOR inhibitor, can ameliorate hepatic I/R injury via targeting the NLRP3 inflammasome signaling pathway.	Sirolimus	95-99	mechanistic target of rapamycin kinase	Rattus norvegicus	105-109
33299044-6	2020	Furthermore, the suppression of Fgf23 expression by PTEN knockdown or insulin simulation in UMR106 cells was partially restored by the treatment with the mTORC1 inhibitor, rapamycin.	Sirolimus	172-181	phosphatase and tensin homolog	Rattus norvegicus	52-56
33364235-7	2020	RAB39B deficiency also compromised autophagic flux at basal level, which could be overridden by rapamycin-induced autophagy activation.	Sirolimus	96-105	RAB39B, member RAS oncogene family	Mus musculus	0-6
35365237-10	2022	The expression of LAMP1 was significantly increased with lysosome agglomeration after treatment with rapamycin (RAMP).	Sirolimus	101-110	lysosomal-associated membrane protein 1	Mus musculus	18-23
35368869-4	2022	While both MD and AA+MD increased phosphorylation of AMP-activated protein kinase (AMPK), the well-known autophagy promotor, only the combined treatment affected its downstream targets, mechanistic target of rapamycin complex 1 (mTORC1), Unc 51-like kinase 1 (ULK1), and increased the expression of several autophagy-related genes.	Sirolimus	208-217	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	53-81
35368869-4	2022	While both MD and AA+MD increased phosphorylation of AMP-activated protein kinase (AMPK), the well-known autophagy promotor, only the combined treatment affected its downstream targets, mechanistic target of rapamycin complex 1 (mTORC1), Unc 51-like kinase 1 (ULK1), and increased the expression of several autophagy-related genes.	Sirolimus	208-217	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	83-87
35235777-6	2022	Rather, loss of Slc6a8 or Ckb disrupts naive T cell homeostasis and weakens TCR-mediated activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling required for CD8+ T cell expansion.	Sirolimus	125-134	solute carrier family 6 member 8	Homo sapiens	16-22
35235777-6	2022	Rather, loss of Slc6a8 or Ckb disrupts naive T cell homeostasis and weakens TCR-mediated activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling required for CD8+ T cell expansion.	Sirolimus	125-134	CD8a molecule	Homo sapiens	177-180
35300418-9	2022	In our experimental conditions, Rapamycin but not Resveratrol decreased GFAP protein levels in hypoxia.	Sirolimus	32-41	glial fibrillary acidic protein	Homo sapiens	72-76
35088889-10	2022	Treatment with 4-OHT and rapamycin (an autophagy activator) increased the LC3-II/LC3-I ratio, LC3 puncta number and decreased the level of p62 in MCF7/R cells.	Sirolimus	25-34	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	94-97
35088889-10	2022	Treatment with 4-OHT and rapamycin (an autophagy activator) increased the LC3-II/LC3-I ratio, LC3 puncta number and decreased the level of p62 in MCF7/R cells.	Sirolimus	25-34	nucleoporin 62	Homo sapiens	139-142
35282339-6	2022	Our group has also demonstrated that conversion from calcineurin inhibitor to the mammalian target of rapamycin (mTOR) inhibitor, sirolimus, as a primary immunosuppression was associated with a decreased risk of PTLD following HT.	Sirolimus	130-139	calcineurin binding protein 1	Homo sapiens	53-74
35196486-5	2022	Molecular analyses reveal that loss of Slc38a4 imprinting leads to over-activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway in cloned placentae, which is likely due to the increased amino acids transport by SLC38A4.	Sirolimus	112-121	solute carrier family 38, member 4	Mus musculus	39-46
35196486-5	2022	Molecular analyses reveal that loss of Slc38a4 imprinting leads to over-activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway in cloned placentae, which is likely due to the increased amino acids transport by SLC38A4.	Sirolimus	112-121	solute carrier family 38, member 4	Mus musculus	242-249
35136953-7	2022	Nprl3 knockout in vitro caused mTOR pathway hyperactivation, cell soma enlargement, and the formation of cellular aggregates seen in time-lapse videos that were prevented with the mTOR inhibitors rapamycin or torin1.	Sirolimus	196-205	nitrogen permease regulator-like 3	Mus musculus	0-5
34874016-11	2022	Our findings also support the standpoint that the mTOR inhibitor, rapamycin, can eliminate T-induced cardiomyocyte hypertrophy.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
35128865-1	2022	OBJECTIVE: To investigate the effects of electroacupuncture (EA) on the expression of related proteins in the brain-derived neurotrophic factor (BDNF)/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and synapse-associated proteins and the density of dendrite spines in the prefrontal cortex (PFC) of depression model rats, and to reveal the underlying mechanism by which EA regulates the synaptic plasticity to improve depressive symptoms.	Sirolimus	171-180	brain derived neurotrophic factor	Homo sapiens	110-143
35128865-1	2022	OBJECTIVE: To investigate the effects of electroacupuncture (EA) on the expression of related proteins in the brain-derived neurotrophic factor (BDNF)/mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and synapse-associated proteins and the density of dendrite spines in the prefrontal cortex (PFC) of depression model rats, and to reveal the underlying mechanism by which EA regulates the synaptic plasticity to improve depressive symptoms.	Sirolimus	171-180	brain derived neurotrophic factor	Homo sapiens	145-149
34975216-0	2022	Modulation of mTOR signaling by radiation and rapamycin treatment in canine mast cell cancer cells.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Canis lupus familiaris	14-18
34975216-2	2022	Rapamycin inhibits mTOR signaling, a pathway responsible for several essential cell functions.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Canis lupus familiaris	19-23
34975216-3	2022	The objective of this study was to investigate the effects of rapamycin and radiation on the activation and inhibition of mTOR signaling and the relationship between mTOR signaling and DNA damage response in vitro using canine mast cell tumor (MCT) cancer cell lines.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Canis lupus familiaris	122-126
34975216-5	2022	Ionizing radiation (3, 6, or 10 Gy) was able to activate mTOR signalling, but the combination of radiation and rapamycin maintained mTOR inhibition.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Canis lupus familiaris	132-136
33364235-8	2020	Further, treatment with rapamycin partially rescued impaired memory and synaptic plasticity in Rab39b KO mice, without affecting the PSD distribution of NMDA receptors.	Sirolimus	24-33	RAB39B, member RAS oncogene family	Mus musculus	95-101
33273660-2	2020	TSC2 interacts with tuberous sclerosis complex 1 to form a complex that negatively regulates cell growth and proliferation via the inactivation of mechanistic target of rapamycin complex 1.	Sirolimus	169-178	TSC complex subunit 2	Homo sapiens	0-4
33227845-1	2020	Background: Sestrin2 (Sesn2) is involved in the maintenance of metabolic homeostasis and aging via modulation of the 5" AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) pathway.	Sirolimus	169-178	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	180-184
33364468-0	2020	A selectively suppressing amino acid transporter: Sodium-coupled neutral amino acid transporter 2 inhibits cell growth and mammalian target of rapamycin complex 1 pathway in skeletal muscle cells.	Sirolimus	143-152	solute carrier family 38 member 2	Homo sapiens	50-97
33174028-0	2020	S100A8 and S100A9 promote endothelial cell activation through the RAGE-mediated mammalian target of rapamycin complex 2 pathway.	Sirolimus	100-109	S100 calcium binding protein A9	Homo sapiens	11-17
33174028-0	2020	S100A8 and S100A9 promote endothelial cell activation through the RAGE-mediated mammalian target of rapamycin complex 2 pathway.	Sirolimus	100-109	advanced glycosylation end-product specific receptor	Homo sapiens	66-70
33174028-13	2020	Furthermore, depleting expression of RAGE or mTORC2 protein components (rapamycin-insensitive companion of mTOR) by small interfering RNA was found to reduce the cell viability, migration and angiogenesis of S100A8/9-treated HUVECs.	Sirolimus	72-81	advanced glycosylation end-product specific receptor	Homo sapiens	37-41
33029204-6	2020	Treatment with rapamycin further demonstrated that high levels of autophagy elevated miR-224-5p expression in MCC1 cells in a time-dependent manner.	Sirolimus	15-24	microRNA 224	Homo sapiens	85-92
35288479-6	2021	To observe the effect of autophagy in the relationship with VDR and ER stress in hepatic IR injury, the autophagy agonist rapamycin and its inhibitor chloroquine were used in the study.	Sirolimus	122-131	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	60-63
35288479-12	2021	After treatment with rapamycin or chloroquine, the effect of VDR activation or VDR silencing in ER stress was partially reversed.	Sirolimus	21-30	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	61-64
35288479-12	2021	After treatment with rapamycin or chloroquine, the effect of VDR activation or VDR silencing in ER stress was partially reversed.	Sirolimus	21-30	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	79-82
6222791-5	1983	On pPMs IgG2a-mediated functions were mainly affected by FrA with a concentration dependence like that observed with Fc mu Rs on rPM monolayers.	Sirolimus	129-132	gamma-2a immunoglobulin heavy chain	Rattus norvegicus	8-13
34021461-10	2021	Finally, we provided evidence that inhibition of PI3K with pictilisib, AKT with perifosine, or mTOR with rapamycin, blocked the effects of IDO1 on protein synthesis and cardiomyocyte hypertrophy in Ang II-treated cells.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Rattus norvegicus	95-99
33988501-3	2021	Here we show that inhibition of mTORC1 by the lifespan-extending drug rapamycin increases expression of histones H3 and H4 post-transcriptionally, through eIF3-mediated translation.	Sirolimus	70-79	eukaryotic translation initiation factor 3, subunit A	Mus musculus	155-159
33905040-10	2021	Combination treatment with THZ1 and the DDIT4 inhibitor rapamycin effectively suppressed BC cell growth.	Sirolimus	56-65	DNA damage inducible transcript 4	Homo sapiens	40-45
33910001-1	2021	Leucyl-tRNA synthetase 1 (LARS1) mediates activation of leucine-dependent mechanistic target of rapamycin complex 1 (mTORC1) as well as ligation of leucine to its cognate tRNAs, yet its mechanism of leucine sensing is poorly understood.	Sirolimus	96-105	leucyl-tRNA synthetase 1	Homo sapiens	26-31
33243998-4	2020	Mechanistically, ISO inhibits AKT as well as, downstream of AKT, the mechanistic target of rapamycin complex 1 (mTORC1), coupled to the activation of the pro-autophagic transcription factors EB (TFEB) and E3 (TFE3).	Sirolimus	91-100	transcription factor EB	Mus musculus	195-199
33887578-9	2021	Our data suggest that anti-OX40L combined with Rapa and a low dose of IL-2 can suppress Tm, modulate CD4 and CD8 Tregs, and induce long-term heart allograft survival in sensitized mice.	Sirolimus	47-51	CD4 antigen	Mus musculus	101-104
33902956-11	2021	Subgroup (TSC1-based or TSC2-based) analyses revealed that patients with low TSC1 or TSC2 expression benefited from sirolimus (DFS: P = 0.046, OS: P = 0.006 for TSC1; DFS: P = 0.05, OS: P = 0.003 for TSC2) compared with patients with high expression.	Sirolimus	116-125	TSC complex subunit 2	Homo sapiens	85-89
33902956-11	2021	Subgroup (TSC1-based or TSC2-based) analyses revealed that patients with low TSC1 or TSC2 expression benefited from sirolimus (DFS: P = 0.046, OS: P = 0.006 for TSC1; DFS: P = 0.05, OS: P = 0.003 for TSC2) compared with patients with high expression.	Sirolimus	116-125	TSC complex subunit 2	Homo sapiens	85-89
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	transient receptor potential cation channel subfamily C member 1	Homo sapiens	133-173
33864571-9	2021	In the OOA model, upregulated extracellular regulated protein kinases 1/2 (ERK1/2), which can be regulated by SOCC and IP3R proteins transient receptor potential canonical 1 (TRPC1)/IP3R with elevated cytoplasmic calcium signaling, over-inhibited forkhead/winged helix O (FOXO) signaling and over-activated mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	327-336	transient receptor potential cation channel subfamily C member 1	Homo sapiens	175-180
33255287-0	2020	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface.	Sirolimus	0-9	CD4 antigen	Mus musculus	29-32
33857304-4	2021	In this work, we show that the C-terminal Gln3-Tor1 interaction site is required for wild type, rapamycin-elicited, Sit4-dependent nuclear Gln3 localization, but not for its dephosphorylation.	Sirolimus	96-105	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	47-51
33857304-10	2021	Substituting phosphomimetic aspartate for serine/threonine residues in the Gln3 URS abolishes the N-terminal Gln3-Tor1 interaction, rapamycin-elicited nuclear Gln3 localization, and 1/2 of the derepressed levels of nuclear Gln3 localization.	Sirolimus	132-141	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	114-118
33255287-7	2020	In the lacrimal gland and draining lymph nodes, we also observed a significant increase in the CD45+CD4+Foxp3+ cells in the rapamycin-treated mice.	Sirolimus	124-133	CD4 antigen	Mus musculus	95-98
33846885-8	2021	RAPA restored NF-kappaB and HIF-1alpha to normal levels.	Sirolimus	0-4	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	28-38
33224946-10	2020	Systemic inhibition of VAMP3 and SNAP23 by treatment of mice with rapamycin significantly ameliorated the FeCl3-induced thrombogenesis, whereas intraluminal overexpression of VAMP3 and SNAP23 aggravated it.	Sirolimus	66-75	vesicle-associated membrane protein 3	Mus musculus	23-28
33383488-13	2021	Overexpression of PI3K, AKT and mTOR were suppressed by RAPA treatment.	Sirolimus	56-60	mechanistic target of rapamycin kinase	Rattus norvegicus	32-36
33237667-12	2021	By acting downstream of IGF1-R, sirolimus may offer a cost-effective alternative to teprotumumab therapy.	Sirolimus	32-41	insulin like growth factor 1 receptor	Homo sapiens	24-30
33383488-16	2021	We proposed a potential mechanism that RAPA may play improving role by inhibiting neuronal apoptosis and enhancing mitophagy through PI3K/AKT/mTOR pathway.	Sirolimus	39-43	mechanistic target of rapamycin kinase	Rattus norvegicus	142-146
33753454-2	2021	Inhibition of mTOR signaling is biologically-achievable with sirolimus, and might slow the outgrowth of distant metastases.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Canis lupus familiaris	14-18
33001273-11	2020	The agents with the highest AKI RORs were entrectinib (ROR 6.40, 95% CI 2.23, 18.34), sirolimus (ROR 3.76, 95% CI 3.45, 4.09), and cobimetinib (ROR 3.40, 95% CI 2.69, 4.28).	Sirolimus	86-95	RAR related orphan receptor A	Homo sapiens	97-102
33753454-7	2021	CONCLUSIONS: In a population of pet dogs non-genomically segmented for predicted mTOR inhibition response, sequentially-administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend disease-free interval or survival in dogs with appendicular osteosarcoma.	Sirolimus	142-151	mechanistic target of rapamycin kinase	Canis lupus familiaris	81-85
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	42-51	interleukin 10	Homo sapiens	241-255
33691148-5	2021	By pairing sub-effective doses of the US (rapamycin) as reminder cues simultaneously with the CS (taste stimulus) at retrieval, conditioned pharmacological responses of rapamycin persisted peripherally and centrally, reflected as suppressed interleukin-10 production and T cell activity as well as diminished activity of the mTOR target protein p70s6k in the amygdala.	Sirolimus	169-178	interleukin 10	Homo sapiens	241-255
32896607-8	2020	In addition, the levels of p62 and Snail were increased in high glucose-treated HLE-B3 cells, and their interactions were demonstrated by co-immunoprecipitation and immunoflurence staining, but all these changes were attenuated by application of rapamycin.	Sirolimus	246-255	nucleoporin 62	Homo sapiens	27-30
33598769-7	2021	However, Akt and mTOR inhibitors (MK-2206 and Rapamycin) blocked the effect of taurine on improving axonal damage.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Rattus norvegicus	17-21
33031791-6	2020	Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10.	Sirolimus	0-9	interleukin 10	Homo sapiens	178-183
32898934-1	2020	Ginsenoside Rg3, a ginsenoside isolated from Panax ginseng, can regulate autophagy via AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway.	Sirolimus	136-145	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	147-151
32800766-5	2020	Notch pathway mediators overexpression were reverted in FANCA mutant cells when treated with Rapamycin, an autophagy inducer.	Sirolimus	93-102	FA complementation group A	Homo sapiens	56-61
32800766-6	2020	Additionally, Rapamycin stabilized cell viability after treatment with the DNA damaging agent, MitomycinC (MMC) and enhanced cell proliferation genes expression in FANCA mutant cells.	Sirolimus	14-23	FA complementation group A	Homo sapiens	164-169
32915433-0	2020	Refractory Autoimmune Cytopenia in a Young Boy with a Novel LRBA Mutation Successfully Managed with Sirolimus.	Sirolimus	100-109	LPS responsive beige-like anchor protein	Homo sapiens	60-64
33114161-8	2020	Mechanistically, Gem induced apoptosis and increased the levels of cleaved caspases, while Rapa induced autophagy and microtubule-associated protein light chain 3 (LC3)-I/LC3-II expression both in vitro and in vivo.	Sirolimus	91-95	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	164-167
33278393-6	2021	Additionally, the mechanism by which prolonged CI affected autophagy was investigated through determination of the molecules related to the mTOR pathway after treatment with 3-Methyladenine (3-MA), rapamycin and an adenosine triphosphate (ATP) synthase inhibitor oligomycin (OM).	Sirolimus	198-207	mechanistic target of rapamycin kinase	Rattus norvegicus	140-144
33641344-5	2021	Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
33641344-5	2021	Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues.	Sirolimus	22-31	ribosomal protein S6	Rattus norvegicus	63-83
33641344-5	2021	Inhibition of mTOR by rapamycin blocked phosphorylated form of ribosomal protein S6, NF-kappaB p65 activity by increasing degradation of IkappaB-alpha in parallel with HIF-1alpha expression increased by LPS in the kidney, heart, lung, and brain tissues.	Sirolimus	22-31	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	168-178
33641344-6	2021	Rapamycin attenuated the increment in the expression of tumor necrosis factor-alpha and interleukin-1beta, the inducible nitric oxide synthase, gp91phox, and p47phox in addition to nitrite levels elicited by LPS in tissues or sera.	Sirolimus	0-9	cytochrome b-245 beta chain	Rattus norvegicus	144-152
33114161-8	2020	Mechanistically, Gem induced apoptosis and increased the levels of cleaved caspases, while Rapa induced autophagy and microtubule-associated protein light chain 3 (LC3)-I/LC3-II expression both in vitro and in vivo.	Sirolimus	91-95	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	171-174
32798557-0	2020	Rapamycin improves renal injury induced by Iodixanol in diabetic rats by deactivating the mTOR/p70S6K signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	90-94
33668689-1	2021	Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Canis lupus familiaris	80-84
32798557-10	2020	Moreover, Rapamycin could inhibit the phosphorylation of mTOR/p70S6K pathway-associated proteins, activate autophagy and increase the levels of LC3 and Beclin1.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Rattus norvegicus	57-61
33668689-8	2021	Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior.	Sirolimus	183-192	nucleolin	Canis lupus familiaris	132-141
32798557-11	2020	After treatment with 3MA, an inhibitor of mTOR/p70S6K signaling pathway, the protective effects of Rapamycin on CIAKI were weakened.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
32798557-12	2020	SIGNIFICANCE: Rapamycin can alleviate renal injury induced by Iodixanol diabetic rats, and its regulatory mechanisms may be related to the regulation of mTOR/p70S6K signaling pathway and the activating autophagy.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Rattus norvegicus	153-157
33613450-4	2020	This study aimed to investigate the effect of 17beta-E2 on Sirtuin-1 (SIRT1) expression and the induction of mitophagy upregulation by 17beta-E2 via the SIRT1-mediated AMP-activated protein kinase (AMPK)/mammalian target of the rapamycin (mTOR) signaling pathway to protect chondrocytes.	Sirolimus	228-237	sirtuin 1	Homo sapiens	153-158
32761379-4	2020	The identification of TSC1 and TSC2, as tumor suppressor genes causative of the disorder, led to the elucidation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway and its pivotal role in the pathogenesis of hamartoma formation.	Sirolimus	140-149	TSC complex subunit 2	Homo sapiens	31-35
33613450-4	2020	This study aimed to investigate the effect of 17beta-E2 on Sirtuin-1 (SIRT1) expression and the induction of mitophagy upregulation by 17beta-E2 via the SIRT1-mediated AMP-activated protein kinase (AMPK)/mammalian target of the rapamycin (mTOR) signaling pathway to protect chondrocytes.	Sirolimus	228-237	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	168-196
32808351-8	2020	Inhibition of mTOR/FOXO1 by rapamycin/AS1842856 decreased the ratio of Bcl-2/Bax and exacerbated TJ protein loss.	Sirolimus	28-37	BCL2-associated X protein	Mus musculus	77-80
32878509-8	2020	In addition, rapamycin scavenged the cellular reactive oxygen species (ROS) and diminished p-JNK, p-ERK1/2 and p-p38 expression of MAPK pathways in RAW264.7 cells infected with P. aeruginosa.	Sirolimus	13-22	mitogen-activated protein kinase 8	Mus musculus	93-96
33633792-7	2021	Results of RNA-seq and WGCNA analyses showed that the mammalian target of the rapamycin signaling pathway, which plays a major regulatory role, is dysregulated by the overexpression and inhibition of miR-150.	Sirolimus	78-87	microRNA 150	Homo sapiens	200-207
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	nucleoporin 62	Homo sapiens	191-194
33352197-5	2021	The results showed that, after an intraperitoneal injection of rapamycin (2 mg/kg/day) for seven days, the alkali-induced opacity and NV were remarkably decreased mainly by suppressing the infiltration of immune cells into injured corneas, angiogenesis, VEGF expression and myofibroblasts differentiation; as well as by promoting corneal cell proliferation and PI3K/AKT/mTOR signaling.	Sirolimus	63-72	vascular endothelial growth factor A	Mus musculus	254-258
33512760-4	2021	We demonstrate that RAPA mitigates GVHD by decreasing T-cell engraftment and differentiation, inhibiting CD8+ T-cell activation and increasing the long-term IL-2 secretion, thereby supporting regulatory T-cell (Treg) proliferation.	Sirolimus	20-24	CD8a molecule	Homo sapiens	105-108
32621911-7	2020	Compared with liraglutide group, treatment with rapamycin, a specific inhibitor of mTOR, compatibly augmented GLP-1 receptor level, inhibited phosphorylation of mTOR/p70S6K and expression of p62 as well as increased level of LC3-II/LC3-I ratio and Beclin-1, suggesting that there is an interaction between GLP-1 and mTOR/p70S6K signaling in the regulation of autophagy.	Sirolimus	48-57	beclin 1	Homo sapiens	248-256
33512760-6	2021	Importantly, we found that RAPA impact on Treg and CD8+ T cells was closely dependent upon IL-2 signaling and that therapeutic options interfering with IL-2, such as calcineurin inhibitors, antagonize the IL-2-dependent promotion of Treg mediated by RAPA.	Sirolimus	27-31	CD8a molecule	Homo sapiens	51-54
32693734-6	2020	The autophagy was most significant when applying rapamycin at 1 microM for 48 h, demonstrating by the LC3II/LC3I ratio and p62 expression.	Sirolimus	49-58	nucleoporin 62	Homo sapiens	123-126
33480149-13	2021	Moreover, RAPA decreased p62/LC3 ratio indicated enhanced autophagy, and significantly reduced caspase-3 and RIPK1 expression.	Sirolimus	10-14	receptor interacting serine/threonine kinase 1	Rattus norvegicus	109-114
32693673-10	2020	Mechanistically, LAPTM4B regulated the activity of mammalian target of rapamycin complex 1 (mTORC1) via interacting with mTOR through its EC3 domain.	Sirolimus	71-80	lysosomal protein transmembrane 4 beta	Homo sapiens	17-24
32599128-7	2020	Rapamycin attenuated HG-induced tau hyperphosphorylation via the AKT/AMPK/GSK-3beta pathways and p70S6K in SH-SY5Y cells.	Sirolimus	0-9	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	69-73
33578051-5	2021	We found that rapamycin and spermidine were able to decrease the spontaneous mutation rate at the CAN1 locus, whereas dinitrophenol, metformin, and resveratrol were able to protect yeast against CAN1 mutations induced by ethyl methanesulfonate (EMS).	Sirolimus	14-23	arginine permease CAN1	Saccharomyces cerevisiae S288C	98-102
32599128-8	2020	Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs.	Sirolimus	45-54	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	137-143
32599128-8	2020	Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs.	Sirolimus	45-54	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	152-156
32495040-2	2020	Several reports have demonstrated that mitogen-activated protein kinases 3 and 1 (MAPK3/1)-mammalian target of rapamycin complex 1 (mTORC1) signaling in pre-granulosa cells promotes primordial follicle activation by increasing KIT ligand (KITL) expression and then stimulating phosphatidylinositol 3 kinase signaling in oocytes.	Sirolimus	111-120	KIT ligand	Homo sapiens	227-237
33085775-12	2021	Furthermore, in vivo administration of the autophagy activator rapamycin had similar effects on recovering the frequency and function of Treg cells as well as the expression of GATA-3 and CTLA-4.	Sirolimus	63-72	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	188-194
32495040-2	2020	Several reports have demonstrated that mitogen-activated protein kinases 3 and 1 (MAPK3/1)-mammalian target of rapamycin complex 1 (mTORC1) signaling in pre-granulosa cells promotes primordial follicle activation by increasing KIT ligand (KITL) expression and then stimulating phosphatidylinositol 3 kinase signaling in oocytes.	Sirolimus	111-120	KIT ligand	Homo sapiens	239-243
32800663-10	2020	PD-L1 expression was suppressed significantly when the HIF-1alpha inhibitor rapamycin was added to the culture medium (P = .024).	Sirolimus	76-85	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	55-65
32717360-6	2020	mTOR inhibition by rapamycin triggered FOXO3 and miR-34, leading to KLF4 repression.	Sirolimus	19-28	Kruppel like factor 4	Homo sapiens	68-72
33176606-9	2021	Pretreatment with mTOR inhibitor, rapamycin, could attenuate the activation of mTOR and the secretion of RANKL in OBs.	Sirolimus	34-43	TNF superfamily member 11	Homo sapiens	105-110
32851082-0	2020	Rapamycin Inhibited Pyroptosis and Reduced the Release of IL-1beta and IL-18 in the Septic Response.	Sirolimus	0-9	interleukin 18	Homo sapiens	71-76
32851082-8	2020	This study shows that RAPA abrogates LPS-mediated increase in IL-1beta and IL-18 by inhibiting pyroptosis and enhancing autophagy.	Sirolimus	22-26	interleukin 18	Homo sapiens	75-80
32748349-7	2021	Mechanistically, we identified TBC1D7 as a binding partner of KIF2C, and this interaction disrupts the formation of the TSC complex, resulting in the enhancement of mammalian target of rapamycin complex1 (mTORC1) signal transduction.	Sirolimus	185-194	kinesin family member 2C	Homo sapiens	62-67
32712090-7	2020	Intrathecal injection of rapamycin (an mTOR inhibitor) or SRT1720 (an agonist of Sirt1) induced analgesia in BIP rats.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Rattus norvegicus	39-43
32293025-10	2020	Graft-infiltrating macrophages of G-CSF/rapamycin-treated mice had an M2 phenotype, characterized by higher CD206 expression and interleukin (IL)-10 production, whereas splenic macrophages only had an increased CD206 expression.	Sirolimus	40-49	mannose receptor, C type 1	Mus musculus	108-113
33317171-5	2020	Interestingly, the pre-treatment with rapamycin, an mTOR inhibitor, further increased the expression levels of LC3-II induced by OGT inhibition, implicating the involvement of mTOR signaling in O-GlcNAcylation-dependent autophagy.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
32293025-10	2020	Graft-infiltrating macrophages of G-CSF/rapamycin-treated mice had an M2 phenotype, characterized by higher CD206 expression and interleukin (IL)-10 production, whereas splenic macrophages only had an increased CD206 expression.	Sirolimus	40-49	mannose receptor, C type 1	Mus musculus	211-216
33317171-5	2020	Interestingly, the pre-treatment with rapamycin, an mTOR inhibitor, further increased the expression levels of LC3-II induced by OGT inhibition, implicating the involvement of mTOR signaling in O-GlcNAcylation-dependent autophagy.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Rattus norvegicus	176-180
32592088-6	2020	This phenomenon was accompanied by upregulated Skp2 and downregulated p27kip1 expression and was abolished by rapamycin, an inhibitor of mTOR.	Sirolimus	110-119	cyclin-dependent kinase inhibitor 1B	Mus musculus	70-77
33273014-2	2021	Previously we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 signaling, leading to clinical trials for NF2 and meningioma.	Sirolimus	67-76	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	26-29
33273014-2	2021	Previously we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2 signaling, leading to clinical trials for NF2 and meningioma.	Sirolimus	67-76	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	149-152
32535143-9	2020	While the proportion of activated splenic CD4 + Foxp3- T cells expressing IFN-gamma were similar in control and RPM-treated groups, RPM decreased the proportions ICOS+ and CD8+ IFN-gamma + splenic T cells.	Sirolimus	132-135	inducible T cell co-stimulator	Mus musculus	162-166
33267766-8	2021	RESULTS: It was probed that after the suppression of autophagy-associated miRNAs by adriamycin and rapamycin, while most of the miRNAs were down-regulated in osteosarcoma cell lines, some miRNAs" expressions, such as miR-3141, miR-4296, miR-133b, and miR-720, were strikingly increased.	Sirolimus	99-108	microRNA 4296	Homo sapiens	227-235
32694519-9	2020	The autophagy inducer rapamycin partially rescued the cardiac deterioration caused by p21 downregulation in the LPS-stimulated groups.	Sirolimus	22-31	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	86-89
33034763-10	2020	The presence of LC3 in the tissues of the group treated with rapamycin plus SRBV confirmed induction of autophagy, but it was not present in the tissues treated with 3-MA plus SRBV.	Sirolimus	61-70	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	16-19
33332944-7	2020	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	86-95	estrogen receptor 2	Bos taurus	25-31
33332944-7	2020	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	97-101	estrogen receptor 2	Bos taurus	25-31
33332944-7	2020	Furthermore, the role of ERbeta in BGC autophagy was confirmed through treatment with rapamycin (RAPA) or 3-methyladenine (3-MA) in BGCs by cotransfection with si-ERbeta or oe-ERbeta in BGCs.	Sirolimus	97-101	estrogen receptor 2	Bos taurus	163-169
32610114-13	2020	Rapamycin, the mTOR inhibitor, can inhibit the pro-tumorigenic effect of VEPH1-knockdown.	Sirolimus	0-9	ventricular zone expressed PH domain containing 1	Homo sapiens	73-78
32610114-15	2020	CONCLUSIONS: The loss of VEPH1 unleashes mTORC1 signaling activity in HCC, and that rapamycin (or rapalogs) may serve as an effective therapeutic drug for HCC patients with dampened VEPH1 expression.	Sirolimus	84-93	ventricular zone expressed PH domain containing 1	Homo sapiens	182-187
33238462-7	2020	Similar to vertebrate PKD, the BicC fly PKD model responds to the antiproliferative drugs rapamycin and mimics of the second mitochondria-derived activator of caspases (Smac).	Sirolimus	90-99	Bicaudal C	Drosophila melanogaster	31-35
33190588-9	2021	Rapamycin treatment also attenuated MCD diet-induced steatosis, inflammation, and fibrosis with increased TFEB nuclear translocation and restored FAO in txnip-KO mice.	Sirolimus	0-9	transcription factor EB	Mus musculus	106-110
33312358-12	2020	PI3K, p-AKT1, p-mTOR, p-p70S6K and caspase-3 were down-regulated by rapamycin and beta-ecdysterone, and up-regulated by 3-methyladenine in both the chondrocytes and the cartilage tissues.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Rattus norvegicus	16-20
33137119-1	2020	The Target of rapamycin (TOR) protein kinase forms part of TOR complex 1 (TORC1) and TOR complex 2 (TORC2), two multi-subunit protein complexes that regulate growth, proliferation, survival and developmental processes by phosphorylation and activation of AGC-family kinases.	Sirolimus	14-23	CREB regulated transcription coactivator 2	Homo sapiens	100-105
32558194-8	2020	Co-treatment of GABA with an inhibitor specific for PI3K, mTORC1/2, or p70S6K (via wortmannin, rapamycin, or PF-4708671, respectively) abolished GABA-stimulated beta-cell proliferation in mouse and human islets.	Sirolimus	95-104	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	71-77
33350241-13	2020	However, as compared with the model group, the number of activities, ChAT, TH, and p62 expression levels in the rapamycin group were significantly reduced(P<0.05), and the APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	112-121	nucleoporin 62	Mus musculus	83-86
33350241-14	2020	As compared with the 3 MA group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in the low and medium dose piperine groups and rapamycin group(P<0.05); howe-ver, their first foot licking time was significantly prolonged, APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were increased significantly(P<0.05).	Sirolimus	169-178	nucleoporin 62	Mus musculus	73-76
33350241-15	2020	As compared with the medopar group, the number of activities, ChAT, TH, and p62 expression levels were significantly reduced in low dose piperine group and rapamycin group(P<0.05), but their first foot licking time was significantly extended, and APP, p-tau, IL-6, TNF-alpha, alpha-syn, beclin-1, LC3 B and mmu-miR-99 a-5 p expression levels were significantly increased(P<0.05).	Sirolimus	156-165	nucleoporin 62	Mus musculus	76-79
32562599-5	2020	Upon RPM depletion, red pulp fibroblasts transiently produced the monocyte chemoattractants CCL2 and CCL7, thereby contributing to the replenishment of the RPM network.	Sirolimus	5-8	C-C motif chemokine ligand 7	Homo sapiens	101-105
32562599-5	2020	Upon RPM depletion, red pulp fibroblasts transiently produced the monocyte chemoattractants CCL2 and CCL7, thereby contributing to the replenishment of the RPM network.	Sirolimus	156-159	C-C motif chemokine ligand 7	Homo sapiens	101-105
32760285-9	2020	In addition, PPARdelta activation recovered EtOH-induced loss of protein kinase B (AKT) phosphorylation at serine 473 via rapamycin-insensitive companion of mammalian target of rapamycin (Rictor) activation.	Sirolimus	122-131	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
32475313-7	2020	Significant reductions of renal T lymphocyte and macrophage together with inhibition of cell proliferation were observed in rapamycin treated rats suggesting a role of mTORC1 independent of NOX4 in the proliferation of immune cell.	Sirolimus	124-133	NADPH oxidase 4	Rattus norvegicus	190-194
32475313-8	2020	Given the direct activation of mTORC1 by H2O2 and absence of any further protection from salt-induced hypertension in rapamycin-treated SSNox4-/- rats, we conclude that NOX4-H2O2 is a major upstream activator of mTORC1 that contributes importantly to salt-induced hypertension and renal injury in the SS rat model.	Sirolimus	118-127	NADPH oxidase 4	Rattus norvegicus	169-173
32277979-5	2020	KEY FINDINGS: In septic animals, VEGFR2 antagonism declined the expression of cortical p-VEGFR2 and p-mammalian target of rapamycin complex-1 (p-mTORC1).	Sirolimus	122-131	kinase insert domain receptor	Homo sapiens	33-39
32603360-0	2020	Fpr1, a primary target of rapamycin, functions as a transcription factor for ribosomal protein genes cooperatively with Hmo1 in Saccharomyces cerevisiae.	Sirolimus	26-35	Hmo1p	Saccharomyces cerevisiae S288C	120-124
32560625-9	2020	In contrast, rapamycin (an autophagy inducer) dramatically restores the inhibitory effect of NaBr on the mRNA expression levels of clock genes (Bmal1, Cry1 and Roralpha) and glycolytic genes (Hk2 and Pkm2).	Sirolimus	13-22	hexokinase 2	Rattus norvegicus	192-195
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	autophagy related 13	Homo sapiens	71-76
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	207-235
32516310-1	2020	Unc-51-like autophagy activating kinase 1 (ULK1)-autophagy-related 13 (ATG13) is the most upstream autophagy initiation complex that is phosphorylated by mammalian target-of-rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) to induce autophagy in asynchronous conditions.	Sirolimus	174-183	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	237-241
32712092-6	2020	This may be related to the inhibition of RhoA protein activation by RAPA and regulation of the actin cytoskeleton in trabecular meshwork (TM) cells.	Sirolimus	68-72	ras homolog family member A	Rattus norvegicus	41-45
32448372-0	2020	Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1.	Sirolimus	26-35	activin A receptor type 1	Homo sapiens	147-152
32444657-0	2020	Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by rapamycin-sensitive mTOR complex 1 inhibition.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Rattus norvegicus	120-124
32623916-8	2020	Here we treated HIV-1 infected cell cultures with cART or cART plus CCR5-targeting drugs (Maraviroc and Rapamycin).	Sirolimus	104-113	C-C motif chemokine receptor 5	Homo sapiens	68-72
31509054-3	2020	In this study we found that during integrin alphaIIbbeta3 outside-in signaling PI3Kbeta-dependent phosphorylation of Akt on Serine473 is mediated by the mammalian target of rapamycin complex 2 (mTORC2).	Sirolimus	173-182	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	Homo sapiens	79-87
32457396-7	2020	Mechanistically, the Msi1-mTOR pathway drives keratinocyte-Paget-like cell conversion, and suppression of mTOR signaling with Rapamycin significantly rescued the Paget-like phenotype in Msi1-overexpressing transgenic mice.	Sirolimus	126-135	musashi RNA-binding protein 1	Mus musculus	186-190
33409304-6	2020	Results: The findings indicated that the addition of rapamycin to the 10% pFF group during in vitro maturation led to an increase in the rates of cleavage and blastocyst development and the expression of active matrix metallopeptidase (MMP-9), while nucleic acid denaturation was suppressed.	Sirolimus	53-62	matrix metallopeptidase 9	Homo sapiens	236-241
32378972-1	2021	Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
32512114-2	2020	Here, we show that painful symptoms and associated cognitive deficits induced by spinal nerve ligation in the rat are prevented by the administration of serotonin 5-HT6 receptor inverse agonists or by the mTOR inhibitor rapamycin.	Sirolimus	220-229	mechanistic target of rapamycin kinase	Rattus norvegicus	205-209
32378972-1	2021	Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively.	Sirolimus	181-190	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
32378972-1	2021	Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively.	Sirolimus	181-185	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
32378972-1	2021	Objective: To expound the roles of mTOR and NF-kB signaling pathway in intermittent hypoxia (IH)-induced damage of hippocampal neurons.Methods: For rat experiments, mTOR inhibitor (Rapamycin, Rapa) and NF-kappaB signaling inhibitor (ammonium pyrrolidine dithiocarbamate, PDTC) were applied to inhibit mTOR and NF-kappaB signaling, respectively.	Sirolimus	181-185	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
32949703-12	2020	The effects by THP on lung injury, PI3K/AKT/mTOR signaling and autophagy were also observed after treatment with 3-MA, an autophagy inhibitor, whereas were blocked by combinational treatment with RAPA, an autophagy inducer.	Sirolimus	196-200	mechanistic target of rapamycin kinase	Rattus norvegicus	44-48
32378972-10	2021	No notable difference was manifested in PDTC pre-treatment group, while a prominent increase was shown after Rapa pre-administration.Conclusion: The administration of PDTC and Rapa could prevent IH-induced hippocampal neuron impairment, indicating that inhibition of the mTOR and NF-kappaB pathway may likely act as a therapeutic target for obstructive sleep apnea.	Sirolimus	176-180	mechanistic target of rapamycin kinase	Rattus norvegicus	271-275
32098494-9	2020	Inhibiting mTOR activity by rapamycin blunted the neonatal CM proliferation induced by CHK1 overexpression in vitro.	Sirolimus	28-37	checkpoint kinase 1	Mus musculus	87-91
32528831-0	2020	Interleukin-27 decreases ghrelin production through signal transducer and activator of transcription 3-mechanistic target of rapamycin signaling.	Sirolimus	125-134	interleukin 27	Mus musculus	0-14
32958058-10	2020	Moreover, silencing Beclin1 in NUCKS knockdown cells or adding rapamycin in NUCKS-overexpressed cells also confirmed these results.	Sirolimus	63-72	nuclear casein kinase and cyclin dependent kinase substrate 1	Homo sapiens	76-81
32141263-11	2020	Inhibition of IL-17A via the mTOR pathway using rapamycin also attenuated NP formation and inflammation in the murine NP model.	Sirolimus	48-57	interleukin 17A	Mus musculus	14-20
32707053-9	2020	Moreover, the expression of Rab31-induced p-p70S6K was almost inhibited by rapamycin, a well-established inhibitor of mTOR.	Sirolimus	75-84	RAB31, member RAS oncogene family	Homo sapiens	28-33
32707053-10	2020	Similarly, rapamycin also significantly decreased the stimulatory effect of Rab31 on the expression of cyclin D1.	Sirolimus	11-20	RAB31, member RAS oncogene family	Homo sapiens	76-81
32277013-5	2020	Life span impairment by HPF1 was buffered by rapamycin but not by calorie restriction.	Sirolimus	45-54	mannoprotein	Saccharomyces cerevisiae S288C	24-28
33013932-7	2020	In addition, rapamycin abrogated the ability of both DC subtypes to promote the proliferation and differentiation of IFN-y and Granzyme B producing CD8 + T cells.	Sirolimus	13-22	CD8a molecule	Homo sapiens	148-151
32694311-1	2020	We recently reported that upregulation of the constitutively active ras homolog enriched in brain [Rheb(S16H)], which induces the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, can protect adult neurons, mediated by the induction of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), in animal models of neurodegenerative diseases.	Sirolimus	168-177	brain derived neurotrophic factor	Homo sapiens	302-335
32694311-1	2020	We recently reported that upregulation of the constitutively active ras homolog enriched in brain [Rheb(S16H)], which induces the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, can protect adult neurons, mediated by the induction of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), in animal models of neurodegenerative diseases.	Sirolimus	168-177	brain derived neurotrophic factor	Homo sapiens	337-341
32651677-2	2020	Moreover, we assessed whether inhibition of mTOR signaling pathway by rapamycin would protect primordial follicle reserve after ovarian tissue freezing/thawing and re-transplantation.	Sirolimus	70-79	mechanistic target of rapamycin kinase	Rattus norvegicus	44-48
32546661-10	2020	We found that co-administration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis.	Sirolimus	47-56	TNF superfamily member 11	Homo sapiens	145-150
32546661-10	2020	We found that co-administration of LY294002 or Rapamycin with Dexamethasone protected skin against Dexamethasone-induced atrophy, and normalized RANKL/OPG ratio indicating a reduction of Dexamethasone-induced osteoporosis.	Sirolimus	47-56	basic transcription factor 3 pseudogene 11	Homo sapiens	151-154
32772681-0	2020	Rapamycin Induces an eNOS (Endothelial Nitric Oxide Synthase) Dependent Increase in Brain Collateral Perfusion in Wistar and Spontaneously Hypertensive Rats.	Sirolimus	0-9	nitric oxide synthase 3	Rattus norvegicus	21-25
32772681-0	2020	Rapamycin Induces an eNOS (Endothelial Nitric Oxide Synthase) Dependent Increase in Brain Collateral Perfusion in Wistar and Spontaneously Hypertensive Rats.	Sirolimus	0-9	nitric oxide synthase 3	Rattus norvegicus	27-60
32772681-12	2020	CONCLUSIONS: Rapamycin increased collateral perfusion and reperfusion cerebral blood flow in both Wistar and comorbid spontaneously hypertensive rats that appeared to be mediated by enhancing eNOS activation.	Sirolimus	13-22	nitric oxide synthase 3	Rattus norvegicus	192-196
32867785-9	2020	Mechanically, RAPA ameliorated the physiological function of mutant ECs by inhibiting AKT-mTOR pathway, but also facilitated the nuclear location of FOXO1 and the expression of PDGFB in mutant ECs, and then improved paracrine interactions between ECs and SMCs.	Sirolimus	14-18	platelet derived growth factor subunit B	Homo sapiens	177-182
32820315-5	2020	Moreover, we also analyzed the potential role of LeuRS in activation of mammalian target of rapamycin complex 1 (mTORC1) signaling transduction pathway in response to anabolic stimuli such as exercise and amino acids ingestion.	Sirolimus	92-101	leucyl-tRNA synthetase 1	Homo sapiens	49-54
32908624-8	2020	In contrast to the reported impairment of CHK1 activation in Atg7-deficient mouse embryonic fibroblasts, we found that the level of phosphorylated CHK1 was increased by CQ or ATG5 depletion but decreased by rapamycin or Torin1, suggesting that the increased genomic instability by defective autophagy is not caused by insufficient activation of CHK1-homologous recombination cascade.	Sirolimus	207-216	checkpoint kinase 1	Mus musculus	147-151
32908624-8	2020	In contrast to the reported impairment of CHK1 activation in Atg7-deficient mouse embryonic fibroblasts, we found that the level of phosphorylated CHK1 was increased by CQ or ATG5 depletion but decreased by rapamycin or Torin1, suggesting that the increased genomic instability by defective autophagy is not caused by insufficient activation of CHK1-homologous recombination cascade.	Sirolimus	207-216	checkpoint kinase 1	Mus musculus	147-151
32554565-7	2020	In each case, the insulin-induced phosphorylation was abrogated by mTORC1 inhibitor rapamycin.	Sirolimus	84-93	Insulin-like receptor	Drosophila melanogaster	18-25
32642911-9	2020	Preincubation with the mTOR inhibitor rapamycin restored the autophagic flux and markedly reduced the adverse effects of HTG.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Rattus norvegicus	23-27
32596975-10	2020	While PolgA(D257A/D257A) muscles were hypersensitive to eccentric contractions as well as leucine administration, shown by larger downstream signalling response of the mechanistic target of rapamycin complex 1, myogenic progenitors cultured in vitro showed severe anabolic resistance to leucine and robust impairments in cell proliferation.	Sirolimus	190-199	polymerase (DNA directed), gamma	Mus musculus	6-11
32470351-8	2020	Our results provide supportive and direct evidence relevant to the transcriptional profiling of the critical mTORC1 genes in mouse NAc shell: with functional and pharmacological effects of rapamycin, altered nuclear transcripts in the mTORC1 signaling pathway after excessive alcohol drinking may contribute to increased alcohol intake triggered by KOP-r activation.	Sirolimus	189-198	NLR family, pyrin domain containing 1A	Mus musculus	131-134
31663119-8	2020	miR-574-5p repressed the phosphorylation of members of protein kinase B (AKT)-mammalian target of rapamycin pathway via downregulating MAP3K9 and AKT3, resulting in reducing the secretion of beta-casein and triglycerides in GMECs.	Sirolimus	98-107	AKT serine/threonine kinase 3	Homo sapiens	146-150
31635678-10	2020	Meanwhile, the JAK2 or STAT inhibitors AG490 and rapamycin, but not Ruxolitinib, exhibited a similar but even greater JAK2 and STAT3 regulatory effect, thus leading to a greater benefit.	Sirolimus	49-58	Janus kinase 2	Rattus norvegicus	15-19
31635678-10	2020	Meanwhile, the JAK2 or STAT inhibitors AG490 and rapamycin, but not Ruxolitinib, exhibited a similar but even greater JAK2 and STAT3 regulatory effect, thus leading to a greater benefit.	Sirolimus	49-58	Janus kinase 2	Rattus norvegicus	118-122
32353830-8	2020	The apoptotic effector caspase-3 was significantly lower in MVC and RAPA groups (p<0.05 in both cases).	Sirolimus	68-72	caspase 3	Mus musculus	23-32
32335546-7	2020	The pharmacological induction of autophagy using rapamycin markedly suppressed alpha-synuclein oligomerization, restored neurotransmitter equilibrium, and improved cognitive behavior after prolonged anesthesia or anesthesia combined with surgery.	Sirolimus	49-58	synuclein alpha	Rattus norvegicus	79-94
32035621-3	2020	Unlike other autophagy genes, KO of ULK1 or ATG13 attenuated ER stress and promoted mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	104-113	autophagy related 13	Homo sapiens	44-49
32395516-6	2020	Results: Combined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02).	Sirolimus	29-33	mechanistic target of rapamycin kinase	Rattus norvegicus	234-238
31876121-3	2020	They demonstrated that CD4+ T cells isolated from Takayasu"s arteritis (TAK) are biased to differentiate into Th1 and Th17 cells because of mechanistic target of rapamycin complex 1 (mTORC1) hyperactivity.	Sirolimus	162-171	negative elongation factor complex member C/D	Homo sapiens	110-113
31853970-3	2020	We find that the mitotic cyclin Clb4 is required for optimal regulation of glucose starvation-responsive pathways through the target of rapamycin complex 1 (TORC1).	Sirolimus	136-145	B-type cyclin CLB4	Saccharomyces cerevisiae S288C	32-36
32802135-10	2020	The ROS value was increased significantly after rapamycin inhibited mTOR (66.18 (+4.03 vs. 52.31 (+6.01), n = 3, P < 0.05).	Sirolimus	48-57	mechanistic target of rapamycin kinase	Rattus norvegicus	68-72
32774416-10	2020	Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	41-45
32774416-10	2020	Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	111-115
32774416-10	2020	Furthermore, rapamycin, the inhibitor of mTOR, inhibited the promotion of cell viability and upregulation of p-mTOR and MBP caused by SZL-medicated serum.	Sirolimus	13-22	myelin basic protein	Rattus norvegicus	120-123
32774365-4	2020	This study aimed to evaluate the potential therapeutic effects of sirolimus in CHI patients with mutations in the ABCC8 and KCNJ11 genes.	Sirolimus	66-75	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	124-130
32765037-11	2020	The results indicated an elevated level of autophagy in rapamycin and puerarin groups compared with the DN model, as demonstrated by the upregulated expression of autophagy markers Beclin-1, LC3II, and Atg5, and downregulated p62 expression.	Sirolimus	56-65	nucleoporin 62	Mus musculus	226-229
32765037-12	2020	In addition, the levels of PERK, eIF2alpha, and ATF4 were reduced in the DN model, which was partially, but significantly, prevented by rapamycin and puerarin.	Sirolimus	136-145	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	27-31
32765221-13	2020	Furthermore, BMSC-Exos promoted autophagic flux through the AMP-activated kinase (AMPK)/mammalian target of the rapamycin pathway, whereas chloroquine, AMPK silencing, and compound C blocked the inhibitory effect on pyroptosis.	Sirolimus	112-121	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	60-80
31877436-5	2020	Phosphorylated JAK2 and phosphorylated STAT3 levels were lower in groups PY, RPM, AG490, and LA than in groups VR, NS, and DMSO.	Sirolimus	77-80	Janus kinase 2	Rattus norvegicus	15-19
32765221-13	2020	Furthermore, BMSC-Exos promoted autophagic flux through the AMP-activated kinase (AMPK)/mammalian target of the rapamycin pathway, whereas chloroquine, AMPK silencing, and compound C blocked the inhibitory effect on pyroptosis.	Sirolimus	112-121	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	82-86
32765227-4	2020	Inactivating mutations in TSC genes (TSC1/TSC2) cause sustained Ras homologue enriched in brain (RHEB) activation of the mammalian isoform of the target of rapamycin complex 1 (mTORC1).	Sirolimus	156-165	TSC complex subunit 2	Homo sapiens	42-46
31927699-6	2020	In the condition of short-term or long-term hypoxia and serum deprivation, the apoptotic cells in rapamycin-pretreated cells were less, and secretion of HGF, IGF-1, SCF, SDF-1 and VEGF was increased.	Sirolimus	98-107	hepatocyte growth factor	Rattus norvegicus	153-156
32541317-2	2020	Indeed, they harbour loss of function of TSC1/TSC2, which lead to the activation of the mammalian target of rapamycin (mTOR) pathway, which is targetable therapeutically with mTOR inhibitors like sirolimus.	Sirolimus	196-205	TSC complex subunit 2	Homo sapiens	46-50
32306690-11	2020	Compared with PQ group, the expression levels of autophagy-related proteins LC3II/LC3I and Beclin1 were significantly increased whlie alpha-synuclein protein level was decreased after RAPA induction (P<0.05) .	Sirolimus	184-188	beclin 1	Homo sapiens	91-98
32462682-1	2020	The present study examined the potential of Zingiber officinale-Terminalia chebula extract alone (ZO and TC) and in combination (ZOTC) against type 2 diabetes via downregulation of mechanistic target of rapamycin (mTOR).	Sirolimus	203-212	mechanistic target of rapamycin kinase	Rattus norvegicus	214-218
32612145-8	2020	Finally, we show that inhibition of mTORC1 with rapamycin in ACD mucosal explants reduces p-4EBP and production of IL-15, a master cytokine produced by epithelial cells in this disorder.	Sirolimus	48-57	interleukin 15	Homo sapiens	115-120
32182210-6	2020	We also found that treatment with rapamycin (a selective mTOR inhibitor) also exerts chondro-protective effects that ameliorate OA by promoting autophagy.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Rattus norvegicus	57-61
31930970-5	2020	In addition, LPS stimulation potently induced transcriptional upregulation of RagD, an important activation factor of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	Ras related GTP binding D	Homo sapiens	78-82
32645638-2	2020	Rapamycin inhibits activity of immune cells through the mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	56-60
31971825-7	2020	We further observed a decrease in NUPR1 silencing-induced apoptosis in the presence of rapamycin, while an increase in apoptosis after chloroquine and 3-methyladenine treatment.	Sirolimus	87-96	nuclear protein 1, transcriptional regulator	Homo sapiens	34-39
32645638-5	2020	Overall, our findings suggest that rapamycin may act on immune functions not only directly by inhibiting of mTOR in immune cells but also indirectly via modulation of neuroendocrine system.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Rattus norvegicus	108-112
32560625-9	2020	In contrast, rapamycin (an autophagy inducer) dramatically restores the inhibitory effect of NaBr on the mRNA expression levels of clock genes (Bmal1, Cry1 and Roralpha) and glycolytic genes (Hk2 and Pkm2).	Sirolimus	13-22	aryl hydrocarbon receptor nuclear translocator-like	Rattus norvegicus	144-149
32446392-4	2020	Starvation and rapamycin treatment induced autophagy with increasing SIRT1 protein, HBc protein and pregenomic RNA (pgRNA) levels in HBV- producing cells.	Sirolimus	15-24	sirtuin 1	Homo sapiens	69-74
32570711-8	2020	Inhibition of mTOR by rapamycin prevents and corrects the increased parathyroid cell proliferation of SHP.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
32549199-7	2020	The mTORC1 inhibitor rapamycin abolished the increase in LC3-I and p62.	Sirolimus	21-30	nucleoporin 62	Homo sapiens	67-70
32548479-9	2020	Levels of endotoxin, diamine peroxidase, d-lactic acid, and zonulin in serum and colonic mucosa were significantly reduced in the rapamycin group.	Sirolimus	130-139	haptoglobin	Mus musculus	60-67
32548479-10	2020	Moreover, rapamycin significantly elevated the gene abundance of zonula occludens-1, occludin, claudin-1, and claudin-4.	Sirolimus	10-19	claudin 1	Mus musculus	95-104
32272082-2	2020	Heme induces the expression of SPIC transcription factor in monocyte-derived macrophages and promotes their differentiation into RPM precursors, pre-RPMs.	Sirolimus	129-132	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	31-35
32421369-6	2020	Furthermore, the glucagon-induced upregulation of FGF21 mRNA translation is associated with suppressed activity of the mechanistic target of rapamycin in complex 1 (mTORC1).	Sirolimus	141-150	glucagon	Rattus norvegicus	17-25
32424120-7	2020	Furthermore, the SOX2/NeuN ratio in the DG was decreased in mice treated with rapamycin.	Sirolimus	78-87	SRY (sex determining region Y)-box 2	Mus musculus	17-21
31917615-8	2020	Rapamycin, an inhibitor of mTORC1, alleviated the hypoxia-induced exacerbation of PAH in DP1-/- mice.	Sirolimus	0-9	transcription factor Dp 1	Mus musculus	89-92
32528831-4	2020	Here we investigated that signal transducer and activator of transcription 3 (STAT3)-mechanistic target of rapamycin (mTOR) signaling mediates the suppression of ghrelin induced by IL-27.	Sirolimus	107-116	interleukin 27	Mus musculus	181-186
32528831-8	2020	Inhibition of mTOR activity induced by mTOR siRNA or rapamycin blocked the suppression of ghrelin production induced by IL-27 in mHypoE-N42 cells.	Sirolimus	53-62	interleukin 27	Mus musculus	120-125
32114389-9	2020	Rapamycin, an autophagy activator, quantitatively and functionally improved BM ECs from PGF patients in vitro and enhanced their ability to support HSCs by activating the Beclin-1 pathway.	Sirolimus	0-9	beclin 1	Homo sapiens	171-179
32006902-11	2020	More importantly, we have shown that the protective effect of GRb1 against I/R injury induced cardiomyocyte apoptosis is associated with the activation of mTOR signal pathway as evident by the use of rapamycin.	Sirolimus	200-209	mechanistic target of rapamycin kinase	Rattus norvegicus	155-159
31943518-2	2020	This study aimed to investigate the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway in sepsis-induced leucine resistance and its upstream signals, and to seek a way to correct leucine resistance in sepsis.	Sirolimus	85-94	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	96-100
31978396-3	2020	We previously identified the conserved zinc finger/RING protein Unkempt (Unk) as a key temporal regulator of neuronal differentiation in the Drosophila developing eye and showed that Unk acts downstream of the mechanistic target of rapamycin (mTOR) pathway together with its binding partner Headcase (Hdc).	Sirolimus	232-241	unkempt	Drosophila melanogaster	64-71
31978396-3	2020	We previously identified the conserved zinc finger/RING protein Unkempt (Unk) as a key temporal regulator of neuronal differentiation in the Drosophila developing eye and showed that Unk acts downstream of the mechanistic target of rapamycin (mTOR) pathway together with its binding partner Headcase (Hdc).	Sirolimus	232-241	unkempt	Drosophila melanogaster	64-67
31978396-3	2020	We previously identified the conserved zinc finger/RING protein Unkempt (Unk) as a key temporal regulator of neuronal differentiation in the Drosophila developing eye and showed that Unk acts downstream of the mechanistic target of rapamycin (mTOR) pathway together with its binding partner Headcase (Hdc).	Sirolimus	232-241	unkempt	Drosophila melanogaster	73-76
31958214-2	2020	The main etiology of TSC is the loss-of-function mutation of TSC1 or TSC2 gene, which leads to aberrant activation of mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	138-147	TSC complex subunit 2	Homo sapiens	69-73
31958214-8	2020	In addition, combination of rapamycin with PFK15, a PFKFB3 inhibitor, exerts a stronger inhibitory effect on cell proliferation of Tsc1- or Tsc2-null MEFs than treatment with single drug.	Sirolimus	28-37	TSC complex subunit 2	Homo sapiens	140-144
31915367-9	2020	In contrast, the postnatal treatment of jck mice with sirolimus reduced both Cdk2 and Cdk1 activity and reduced renal cyst growth.	Sirolimus	54-63	cyclin-dependent kinase 2	Mus musculus	77-81
32384426-0	2020	A phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/DFNB4.	Sirolimus	62-71	solute carrier family 26 member 4	Homo sapiens	93-98
31577671-0	2020	Randomized Sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function.	Sirolimus	11-20	calcineurin binding protein 1	Homo sapiens	33-54
32326642-5	2020	Here, we established two autophagy models through serum starvation and rapamycin treatment and detected that the overexpression of Mark4 increased the expression of autophagy-related factors Beclin1, ATG7, and significantly decreased the autophagy substrate P62.	Sirolimus	71-80	MAP/microtubule affinity regulating kinase 4	Mus musculus	131-136
32029270-2	2020	Target of rapamycin complex 1 (TORC1) protein kinase negatively regulates ESCRT-0 (Vps27-Hse1) recruitment onto vacuolar membranes and microautophagy induction.	Sirolimus	10-19	ESCRT-0 subunit protein VPS27	Saccharomyces cerevisiae S288C	83-88
32029270-2	2020	Target of rapamycin complex 1 (TORC1) protein kinase negatively regulates ESCRT-0 (Vps27-Hse1) recruitment onto vacuolar membranes and microautophagy induction.	Sirolimus	10-19	ESCRT-0 subunit protein HSE1	Saccharomyces cerevisiae S288C	89-93
31950225-8	2020	Importantly, NK cell treatment with the PI3K or mTOR inhibitors, idelalisib and rapamycin, respectively, prevents the enhanced cytokine responsiveness, thus, highlighting the relevance of the PI3K/mTOR axis in CD16-dependent priming.	Sirolimus	80-89	Fc gamma receptor IIIa	Homo sapiens	210-214
31677991-6	2020	RESULTS: Autophagy induction by rapamycin treatment ameliorated DAI and histological colitis, decreased pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) and chemotactic factors (CXCL-1 and CXCL-2), decreased intestinal and colonic permeability, improved the distribution and expression of TJ proteins in IL-10 KO mice.	Sirolimus	32-41	interleukin 17A	Mus musculus	157-162
32256210-15	2020	Finally, we showed that inhibition of mTOR with rapamycin blocked the effects of JMJD2A on protein synthesis, cell proliferation and colony formation of glioma cells.	Sirolimus	48-57	lysine demethylase 4A	Homo sapiens	81-87
31608388-4	2020	Rotarod motor learning results in increased abundance of RpS6 in the striatum, and inhibition of S6K1 either indirectly with rapamycin or directly with PF-4708671 diminished the offline improvement in motor performance without affecting the initial acquisition of rotarod motor learning when sleep is normal.	Sirolimus	125-134	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	97-101
32231197-7	2020	RESULTS: Inhibition of mTOR by rapamycin could reverse glucocorticoid resistance in CEM-C1 cells, and also induce autophagy in these cells by up-regulation of LC3-II and Beclin-1 expressions.	Sirolimus	31-40	beclin 1	Homo sapiens	170-178
32104252-7	2020	However, treatment of rats with VD with NBP plus the mTOR inhibitor rapamycin failed to significantly suppress Beclin 1 and LC3II expression.	Sirolimus	68-77	mechanistic target of rapamycin kinase	Rattus norvegicus	53-57
31938854-6	2020	Moreover, rapamycin and metformin induced autophagic flux in ARPE-19 cells and increased the LC3-II level in retinal tissues exposed to vital dyes.	Sirolimus	10-19	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	93-96
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	beclin 1	Homo sapiens	50-58
32104716-0	2020	Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides.	Sirolimus	16-25	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	68-71
32104716-0	2020	Chloroquine and Rapamycin Augment Interleukin-37 Expression via the LC3, ERK, and AP-1 Axis in the Presence of Lipopolysaccharides.	Sirolimus	16-25	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	82-86
32104716-13	2020	IL-37 levels were induced by rapamycin and chloroquine through the LC3, Erk1/2, and NF-kappaB/AP-1 pathways.	Sirolimus	29-38	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	67-70
32104716-13	2020	IL-37 levels were induced by rapamycin and chloroquine through the LC3, Erk1/2, and NF-kappaB/AP-1 pathways.	Sirolimus	29-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	94-98
31689244-4	2020	Sirolimus plus nintedanib prevented vascular pathology in the oral mucosa, lungs, and liver of the BMP9/10ib mice, as well as significantly reduced gastrointestinal bleeding and anemia in inducible ALK1-deficient adult mice.	Sirolimus	0-9	growth differentiation factor 2	Mus musculus	99-103
31689244-5	2020	Mechanistically, in vivo in BMP9/10ib mouse ECs, sirolimus and nintedanib blocked the overactivation of mTOR and VEGFR2, respectively.	Sirolimus	49-58	growth differentiation factor 2	Mus musculus	28-32
31689244-6	2020	Furthermore, we found that sirolimus activated ALK2-mediated Smad1/5/8 signaling in primary ECs-including in HHT patient blood outgrowth ECs-and partially rescued Smad1/5/8 activity in vivo in BMP9/10ib mouse ECs.	Sirolimus	27-36	activin A receptor type 1	Homo sapiens	47-51
31423743-8	2020	Mechanistically, our results demonstrated that autophagy activation by AMPK activator metformin or mTOR inhibitor rapamycin obviously promotes cell survival and autophagy flux, improved mitochondrial ultrastructure, and reduced expression of Cyt-C and caspase-3 in CORT-induced PC12 cells.	Sirolimus	114-123	mechanistic target of rapamycin kinase	Rattus norvegicus	99-103
31664701-8	2020	Rapamycin in the adulthood reversed iron-induced memory deficits, decreased the ratio phospho-mTOR/total mTOR, and recovered LC3 II levels in iron-treated rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	94-98
31664701-8	2020	Rapamycin in the adulthood reversed iron-induced memory deficits, decreased the ratio phospho-mTOR/total mTOR, and recovered LC3 II levels in iron-treated rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	105-109
31759633-4	2020	Whereas Atg14 is regulated by both the proteasome and autophagy, Atg9 turnover is normally mediated by the proteasome but impeded upon starvation or rapamycin treatment.	Sirolimus	149-158	autophagy protein ATG9	Saccharomyces cerevisiae S288C	65-69
32395371-2	2020	Sesn2 regulates cellular metabolism by inhibiting the mammalian target of rapamycin complex 1 through the AMP-activated protein kinase (AMPK) signaling pathway.	Sirolimus	74-83	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	106-134
32395371-2	2020	Sesn2 regulates cellular metabolism by inhibiting the mammalian target of rapamycin complex 1 through the AMP-activated protein kinase (AMPK) signaling pathway.	Sirolimus	74-83	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	136-140
31782272-12	2020	Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
31782272-12	2020	Rapamycin inhibited the activation of the mTOR signaling pathway, down-regulated the expression of downstream proteins p70S6K and 4EBP1, reduced the collagen deposition and the production of fibrosis-inducing factors, including TGF-beta and CTGF in hyperoxia-induced lung injury rats.	Sirolimus	0-9	transforming growth factor alpha	Rattus norvegicus	228-236
31782272-13	2020	CONCLUSIONS: Rapamycin may be useful for the treatment of hyperoxia-induced acute lung injury (ALI) by inhibiting the activation of mTOR signaling pathway.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	132-136
31746373-0	2020	Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	117-121
31746373-2	2020	Rapamycin has been shown to be cardioprotective in pressure-overloaded and ischemic heart diseases by regulating the mechanistic target of rapamycin (mTOR) signaling network.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	117-148
31746373-2	2020	Rapamycin has been shown to be cardioprotective in pressure-overloaded and ischemic heart diseases by regulating the mechanistic target of rapamycin (mTOR) signaling network.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	150-154
31746373-14	2020	Rapamycin treatment for 4 weeks inhibited the mTOR and ER stress pathways.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	46-50
31746373-16	2020	These results demonstrated that rapamycin reduced cardiomyocyte apoptosis and promoted cardiomyocyte autophagy, by regulating the crosstalk between the mTOR and ER stress pathways in chronic HF.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Rattus norvegicus	152-156
31353414-9	2020	Interestingly, rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206-) ATMs in females and males, respectively.	Sirolimus	15-24	mannose receptor, C type 1	Mus musculus	74-79
32921582-1	2020	The giant 532 kDa HERC1 protein is a ubiquitin ligase that interacts with tuberous sclerosis complex subunit 2 (TSC2), a negative upstream regulator of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	176-185	TSC complex subunit 2	Homo sapiens	74-110
32921582-1	2020	The giant 532 kDa HERC1 protein is a ubiquitin ligase that interacts with tuberous sclerosis complex subunit 2 (TSC2), a negative upstream regulator of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	176-185	TSC complex subunit 2	Homo sapiens	112-116
31859114-7	2020	Transwell assay show CXCR4 overexpression promote the invasion of TE-1 cells and was attenuated by autophagy inhibitor 3-Methyladenine.On the contrary, invasion cell numbers decreased in siR-CXCR4 group and was rescued by autophagy inducer Rapamycin.	Sirolimus	240-249	C-X-C motif chemokine receptor 4	Homo sapiens	21-26
31859114-7	2020	Transwell assay show CXCR4 overexpression promote the invasion of TE-1 cells and was attenuated by autophagy inhibitor 3-Methyladenine.On the contrary, invasion cell numbers decreased in siR-CXCR4 group and was rescued by autophagy inducer Rapamycin.	Sirolimus	240-249	C-X-C motif chemokine receptor 4	Homo sapiens	191-196
31878201-5	2019	In this study we demonstrated that rapamycin, at a clinically tolerable concentration (10 nM), inhibited the phosphorylation of S6, but not the critical eIF4E releasing Thr 37/46 phosphorylation sites of 4E-BP1 in TSC2-deficient LAM-derived cells.	Sirolimus	35-44	TSC complex subunit 2	Homo sapiens	214-218
32103032-8	2020	The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation in ILC2s.	Sirolimus	21-30	MAPK activated protein kinase 2	Homo sapiens	119-122
32116708-5	2020	The expressions of autophagy markers (ATG5, ATG7, Beclin-1, LC3 B) and the necroptosis marker RIPK3 increased and another necroptosis marker RIPK1 decreased after the combination treatment of rapamycin and MK-2206, and were accompanied by the morphological characteristics of autophagy and necroptosis.	Sirolimus	192-201	receptor interacting serine/threonine kinase 3	Homo sapiens	94-99
32013948-0	2020	Rapamycin prevents retinal neovascularization by downregulation of cyclin D1 in a mouse model of oxygen-induced retinopathy.	Sirolimus	0-9	cyclin D1	Mus musculus	67-76
31878201-8	2019	In contrast, a PI3K/mTOR inhibitor omipalisib blocked the phosphorylation of Akt and both S6K/S6 and 4E-BP/eIF4E branches, and additively decreased the growth of TSC2-null cells with rapamycin.	Sirolimus	183-192	TSC complex subunit 2	Homo sapiens	162-166
32013948-9	2020	Moreover, RAPA decreased activation of cyclin D1 in retina caused by OIR.	Sirolimus	10-14	cyclin D1	Mus musculus	39-48
32013948-10	2020	CONCLUSION: RAPA can inhibit RNV by downregulating the expression of cyclin D1, which indicates its therapeutic potential in treating RNV-related diseases.	Sirolimus	12-16	cyclin D1	Mus musculus	69-78
31490018-5	2020	Of interest, in the present work, we observed that ciRS-7 could inhibit starvation or rapamycin-induced autophagy of ESCC cells and miR-1299 promotes starvation or rapamycin-induced autophagy of ESCC cells.	Sirolimus	86-95	CDR1 antisense RNA	Homo sapiens	51-57
31553625-10	2019	Treatment with mTOR inhibitor rapamycin effectively blocked nicotine-mediated autophagy deficiency and more importantly, reversed nicotine-induced increase in HI brain infarction.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
31152486-2	2019	Tacrolimus (TAC) and rapamycin (Rapa) both bind to FK506-binding protein 12 (FKBP12).	Sirolimus	21-30	FKBP prolyl isomerase 1A	Rattus norvegicus	51-75
31152486-2	2019	Tacrolimus (TAC) and rapamycin (Rapa) both bind to FK506-binding protein 12 (FKBP12).	Sirolimus	21-30	FKBP prolyl isomerase 1A	Rattus norvegicus	77-83
31152486-2	2019	Tacrolimus (TAC) and rapamycin (Rapa) both bind to FK506-binding protein 12 (FKBP12).	Sirolimus	32-36	FKBP prolyl isomerase 1A	Rattus norvegicus	51-75
31152486-2	2019	Tacrolimus (TAC) and rapamycin (Rapa) both bind to FK506-binding protein 12 (FKBP12).	Sirolimus	32-36	FKBP prolyl isomerase 1A	Rattus norvegicus	77-83
31152486-6	2019	TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho-mTOR, phospo-p70S6K, and phospo-S6.	Sirolimus	8-12	mechanistic target of rapamycin kinase	Rattus norvegicus	27-31
31152486-6	2019	TAC and Rapa inhibited the mTOR pathway as reflected by lower levels of phospho-mTOR, phospo-p70S6K, and phospo-S6.	Sirolimus	8-12	mechanistic target of rapamycin kinase	Rattus norvegicus	80-84
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Rattus norvegicus	189-193
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	21-25	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
32042772-4	2019	Moreover, rapamycin (Rapa) was used to inhibit the mTOR pathway to observe the catalpol mechanism on neuronal cell activity to promote axonal growth, and the proteins related with PI3K/AKT/mTOR pathway were detected by Western blot assay.	Sirolimus	21-25	mechanistic target of rapamycin kinase	Rattus norvegicus	189-193
32042772-8	2019	Catalpol can also reversed proteins reduced by Rapa related with PI3K/AKT/mTOR pathway.	Sirolimus	47-51	mechanistic target of rapamycin kinase	Rattus norvegicus	74-78
31127625-7	2019	By treating cells with rapamycin, an inhibitor of mamalian target of rapamycin known to activate autophagy, we noted that periostin-induced inflammation was inhibited.	Sirolimus	23-32	periostin	Rattus norvegicus	122-131
31127625-7	2019	By treating cells with rapamycin, an inhibitor of mamalian target of rapamycin known to activate autophagy, we noted that periostin-induced inflammation was inhibited.	Sirolimus	69-78	periostin	Rattus norvegicus	122-131
31782083-4	2020	While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation.	Sirolimus	123-132	MAPK interacting serine/threonine kinase 1	Homo sapiens	183-187
31966066-10	2020	The implication of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) in Ca-125 modulation was investigated using specific inhibitors.	Sirolimus	105-114	mucin 16, cell surface associated	Homo sapiens	134-140
31735334-4	2020	We now show that G6Pase-alpha deficiency-mediated hepatic autophagy impairment leads to sustained accumulation of an autophagy-specific substrate p62 which can activate tumor-promoting pathways including nuclear factor erythroid 2-related factor 2 (Nrf2) and mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	279-288	nucleoporin 62	Homo sapiens	146-149
31969673-11	2020	Further analyses indicted that induction of BDNF expression produced by LY341495 was blocked by pretreatment with NBQX and rapamycin.	Sirolimus	123-132	brain-derived neurotrophic factor	Rattus norvegicus	44-48
32399023-7	2020	Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	22-26
32399023-7	2020	Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	65-69
32399023-7	2020	Also, blocking spinal mTOR by injection of rapamycin showed that mTOR existed in the injured spinal cord, and EA could significantly activate mTOR in SCI rats.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	65-69
31921404-0	2020	TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.	Sirolimus	108-117	ATPase copper transporting alpha	Homo sapiens	126-129
31921404-10	2020	Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs.	Sirolimus	0-9	MAPK interacting serine/threonine kinase 1	Homo sapiens	25-29
31921404-12	2020	Our data showing upregulation of these signaling pathways by rapamycin support a strategy to combine a MEK or a MNK inhibitor with rapamycin that may be superior for TSC-associated CNS defects.	Sirolimus	61-70	ATPase copper transporting alpha	Homo sapiens	112-115
31693798-5	2020	Using behavioral tools and MRI-based functional imaging, together with biochemical and immunohistochemical approaches, we demonstrate that chronic mTOR attenuation with rapamycin ameliorates deficits in learning and memory, prevents neurovascular uncoupling, and restores cerebral perfusion in aged rats.	Sirolimus	169-178	mechanistic target of rapamycin kinase	Rattus norvegicus	147-151
31611063-6	2020	Interestingly, this autophagy promotion concurred with enhanced anabolic activation via AKT-mammalian target of rapamycin (mTOR)-p70S6K signaling cascade and enhanced antioxidant capacity such as copper zinc superoxide dismutase (CuZnSOD), glutathione peroxidase (GPX), and peroxiredoxin 3 (PRX3), known to be as antagonists of autophagy.	Sirolimus	112-121	peroxiredoxin 3	Homo sapiens	274-289
31611063-6	2020	Interestingly, this autophagy promotion concurred with enhanced anabolic activation via AKT-mammalian target of rapamycin (mTOR)-p70S6K signaling cascade and enhanced antioxidant capacity such as copper zinc superoxide dismutase (CuZnSOD), glutathione peroxidase (GPX), and peroxiredoxin 3 (PRX3), known to be as antagonists of autophagy.	Sirolimus	112-121	peroxiredoxin 3	Homo sapiens	291-295
31819177-8	2020	siRNA knockdown of Raptor or treatment with rapamycin inhibited PKD1-accelerated lactate production as well as glucose consumption in cells, which confirms the association of mTORC1 with PKD1-induced metabolic alterations.	Sirolimus	44-53	protein kinase D1	Homo sapiens	64-68
31819177-8	2020	siRNA knockdown of Raptor or treatment with rapamycin inhibited PKD1-accelerated lactate production as well as glucose consumption in cells, which confirms the association of mTORC1 with PKD1-induced metabolic alterations.	Sirolimus	44-53	protein kinase D1	Homo sapiens	187-191
31591945-7	2019	However, only the phosphorylated level of mTOR decreased obviously after rapamycin administration.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
31834371-1	2020	Tuberous sclerosis complex (TSC) is an autosomal dominantly inherited neurocutaneous disorder caused by inactivating mutations in TSC1 or TSC2, key regulators of the mechanistic target of rapamycin complex 1 (mTORC1) pathway.	Sirolimus	188-197	TSC complex subunit 2	Homo sapiens	138-142
31896113-12	2020	The KHE pattern of expression [PTEN (-), TSC2 (-), p-mTOR (+), p-P70S6K (+), and p-4EBP1 (+)] suggested that sirolimus may be a good therapeutic choice.	Sirolimus	109-118	TSC complex subunit 2	Homo sapiens	41-45
32016998-5	2020	RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells.	Sirolimus	63-72	beclin 1	Homo sapiens	75-83
32016998-5	2020	RESULTS: Compared with the Control group, Rapamycin group, and Rapamycin + Beclin-1 plasmid transfection group had markedly weakened the viability of MG-63 cells, inhibited cell proliferation, remarkably increased cell apoptosis rate, elevated Bax level, notably declined Bcl-2 level, and significantly raised the levels of Beclin-1 and Vps34 proteins in MG-63 cells.	Sirolimus	63-72	beclin 1	Homo sapiens	324-332
30938569-0	2020	Serial optical coherence tomography and angioscopic assessments of 10-year in-stent restenosis of Cypher sirolimus-eluting stent treated with drug-coated balloon angioplasty.	Sirolimus	105-114	LIM domain binding 3	Homo sapiens	98-104
31605630-7	2020	Pretreatment of LY294002 (a PI3K inhibitor) or rapamycin (an mTOR inhibitor) markedly reduced EGF-induced motility and p-AKT/p-mTOR/c-Jun/Sp1 expression when combined with melatonin.	Sirolimus	47-56	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	132-137
32962569-9	2020	The Beclin-1 protein expression of dexamethasone group was lower than those of rapamycin and dexamethasone- rapamycin groups (p<0.001), and the expression of rapamycin group exceeded that of dexamethasone-rapamycin group (p<0.05).	Sirolimus	108-117	beclin 1	Homo sapiens	4-12
32962569-9	2020	The Beclin-1 protein expression of dexamethasone group was lower than those of rapamycin and dexamethasone- rapamycin groups (p<0.001), and the expression of rapamycin group exceeded that of dexamethasone-rapamycin group (p<0.05).	Sirolimus	108-117	beclin 1	Homo sapiens	4-12
32962569-9	2020	The Beclin-1 protein expression of dexamethasone group was lower than those of rapamycin and dexamethasone- rapamycin groups (p<0.001), and the expression of rapamycin group exceeded that of dexamethasone-rapamycin group (p<0.05).	Sirolimus	108-117	beclin 1	Homo sapiens	4-12
31848319-2	2019	Compounds that block mTOR signaling and eIF4F complex formation, such as rapamycin and its analogs, have been used in combination therapies to enhance cell killing, although their success has been limited.	Sirolimus	73-82	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	40-45
31791403-1	2019	BACKGROUND: The mammalian target of rapamycin complex 2 (mTORC2), containing the essential protein rictor, regulates cellular metabolism and cytoskeletal organization by phosphorylating protein kinases, such as PKB/Akt, PKC, and SGK.	Sirolimus	36-45	serum/glucocorticoid regulated kinase 1	Homo sapiens	229-232
31629951-5	2019	We found that rapamycin-induced autophagy could reduce the chemosensitivity of breast cancer cells to XIAOPI formula, and the autophagy suppression and chemosensitizing activity of this formula was CXCL1-dependent.	Sirolimus	14-23	C-X-C motif chemokine ligand 1	Homo sapiens	198-203
31505123-6	2019	Treatment with rapamycin, a selective inhibitor of mTOR, reversed all the I/R-induced changes as manifested by its anti-inflammatory and antioxidant effects in kidney and gastrocnemius muscle of rats.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
31505123-7	2019	Collectively, these findings suggest that rapamycin protects against I/R-induced oxidative-nitrosative stress and inflammation leading to organ injuries via suppression of mTOR/IkappaB-alpha/NF-kappaB signaling pathway.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Rattus norvegicus	172-176
31299246-2	2019	Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	109-113
31299246-2	2019	Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy, which promotes the survival of TSC2-deficient cells.	Sirolimus	11-20	TSC complex subunit 2	Homo sapiens	109-113
31786580-11	2019	After the analysis of a general linear model and 5 sirolimus-adjusted multiple inheritance models, 1 of the SNPs - rs1131243 on the TGF-ssR3 gene - was observed to be significantly associated with the occurrence of AR.	Sirolimus	51-60	signal sequence receptor subunit 3	Homo sapiens	136-140
31788043-14	2019	By contrast, incubation with the autophagy agonist Rapamycin elevated drug resistance of CLDN1-silenced Hep/5FU cells.	Sirolimus	51-60	claudin 1	Homo sapiens	89-94
31733794-8	2019	In addition, T cells grown in the presence of TAC or SRL expressed less IL-21 and provided less B-cell help.	Sirolimus	53-56	interleukin 21	Homo sapiens	72-77
31638215-8	2019	In contrast, treatment with rapamycin, an mTOR inhibitor, produced the opposite phenotype.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
31638226-9	2019	Furthermore, RAPA blocked the increase of CYP24A1 and vitamin D receptor (VDR) expression induced by 1,25(OH)2D3.	Sirolimus	13-17	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	42-49
31638226-9	2019	Furthermore, RAPA blocked the increase of CYP24A1 and vitamin D receptor (VDR) expression induced by 1,25(OH)2D3.	Sirolimus	13-17	vitamin D receptor	Homo sapiens	54-72
31638226-9	2019	Furthermore, RAPA blocked the increase of CYP24A1 and vitamin D receptor (VDR) expression induced by 1,25(OH)2D3.	Sirolimus	13-17	vitamin D receptor	Homo sapiens	74-77
31638226-16	2019	RAPA increased the cell cycle arrest induced by 1,25(OH)2D3 by blocking the upregulated expression of CYP24A1 and VDR.	Sirolimus	0-4	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	102-109
31638226-16	2019	RAPA increased the cell cycle arrest induced by 1,25(OH)2D3 by blocking the upregulated expression of CYP24A1 and VDR.	Sirolimus	0-4	vitamin D receptor	Homo sapiens	114-117
31591945-3	2019	The possible mechanism of mTOR signaling pathway was evaluated by the, inhibitors for mTOR and PI3K, rapamycin and wortmannin, respectively.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Rattus norvegicus	26-30
31564412-0	2019	Prevention of post-ischemic seizure by rapamycin is associated with deactivation of mTOR and ERK1/2 pathways in hyperglycemic rats.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Rattus norvegicus	84-88
31564412-3	2019	Therefore, we wanted to explore specifically the capacity of an mTOR inhibitor, rapamycin, in preventing post-ischemic seizures in hyperglycemic rats and to explore the underlying molecular mechanisms.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Rattus norvegicus	64-68
31564412-9	2019	Rapamycin treatment completely blocked mTOR activation.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	39-43
31849609-7	2019	Treating neurons with either rapamycin to inhibit the mTOR or LY294002 to inhibit the PI3K/Akt activity rescued the morphological abnormalities resulting from either NL3 knockdown or knockout (KO).	Sirolimus	29-38	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
31564412-11	2019	We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Rattus norvegicus	126-130
31564412-11	2019	We conclude that the development of post-ischemic seizures in the hyperglycemic animals may be associated with activations of mTOR and ERK1/2 pathways and that rapamycin treatment inhibited the post-ischemic seizures effectively by suppressing the mTOR and ERK1/2 signaling.	Sirolimus	160-169	mechanistic target of rapamycin kinase	Rattus norvegicus	248-252
31772273-4	2019	In this study, we demonstrate that PKCdelta, a STAT1 kinase, contains a functional "target of rapamycin signaling" (TOS) motif that directs its interaction with mTORC1.	Sirolimus	94-103	signal transducer and activator of transcription 1	Homo sapiens	47-52
31136458-0	2019	Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5"-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.	Sirolimus	213-222	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	0-35
31136458-5	2019	By using hematoxylin-eosin staining, Ki-67 immunohistochemical staining, cell counting kit-8 assay and Ki-67 immunofluorescence staining, we found Wip1 antagonist GSK2830371 (GSK) or mammalian target of rapamycin complex 1 (mTORC1) inhibitor rapamycin both obviously reversed the neointima formation and VSMC proliferation induced by wire injury and PDGF-BB, respectively.	Sirolimus	203-212	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	147-151
31772273-7	2019	In cells expressing wild-type PKCdelta, STAT1 activity and apoptosis were increased by rapamycin or interferon-beta.	Sirolimus	87-96	signal transducer and activator of transcription 1	Homo sapiens	40-45
31057050-6	2019	The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
31591797-2	2019	Using microarrays of a new macrocycle library known as rapafucins that was inspired by rapamycin, we screened for new inhibitors of GLUT1.	Sirolimus	87-96	solute carrier family 2 member 1	Homo sapiens	132-137
31057050-11	2019	In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Rattus norvegicus	135-139
31426028-11	2019	Interference of mTOR activity by mTOR siRNA or rapamycin abolished the stimulation of GLP-1 production induced by IL-27 in STC-1 cells.	Sirolimus	47-56	interleukin 27	Mus musculus	114-119
31885770-11	2019	Nonetheless, treatment of AAA-ASCs with rapamycin (an autophagy activator) dramatically reduced secretion of IL-6 and TNF-alpha and enhanced secretion of IL-10.	Sirolimus	40-49	interleukin 10	Homo sapiens	154-159
31534118-8	2019	Following that, we use Rapamycin and MK-2206 to inhibit the Akt/mTOR signaling pathway, meanwhile, Rattus 4EBP1, p70S6K, Akt1 and Akt2 were transfected to H9C2 cells to establish the stably transfected cell lines.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Rattus norvegicus	64-68
31771139-3	2019	Our studies have identified RICTOR, PRR5, and SIN1 subunits of the mammalian target of rapamycin complex 2 (mTORC2) as interacting partners with the tBRCT domain of BRCA1 leading to the disruption of the mTORC2 complex.	Sirolimus	87-96	BRCA1 DNA repair associated	Homo sapiens	165-170
31554636-7	2019	Additionally, the HRI-eIF2alphaP-ATF4 pathway represses mechanistic target of rapamycin complex 1 (mTORC1) signaling, specifically in the erythroid lineage as a feedback mechanism of erythropoietin-stimulated erythropoiesis during iron/heme deficiency.	Sirolimus	78-87	activating transcription factor 4	Homo sapiens	33-37
31296735-7	2019	Unexpectedly, rapamycin, a well-established inhibitor of mTOR, also strongly protected NK-A20-/- cells from death, and further studies revealed that A20 restricts mTOR activation in NK cells.	Sirolimus	14-23	immunoglobulin kappa variable 1-27	Homo sapiens	90-93
31296735-7	2019	Unexpectedly, rapamycin, a well-established inhibitor of mTOR, also strongly protected NK-A20-/- cells from death, and further studies revealed that A20 restricts mTOR activation in NK cells.	Sirolimus	14-23	immunoglobulin kappa variable 1-27	Homo sapiens	149-152
30821607-4	2019	Interestingly, protein-protein interaction assays showed that TMED10 directly binds to ATG4B (autophagy related gene 4B cysteine peptidase), and the interaction is diminished under autophagy activation conditions such as rapamycin treatment and serum deprivation.	Sirolimus	221-230	transmembrane p24 trafficking protein 10	Homo sapiens	62-68
30782019-0	2019	Rapamycin attenuates articular cartilage degeneration by inhibiting beta-catenin in a murine model of osteoarthritis.	Sirolimus	0-9	catenin (cadherin associated protein), beta 1	Mus musculus	68-80
30782019-9	2019	A systemic injection of rapamycin activated chondrocyte autophagy, which increased the expression of LC3 and ATG-5, and reduced OARSI scores, the expression of beta-catenin, MMP-13, and VEGF, and chondrocyte apoptosis in rapamycin treated mice when compared with vehicle-treated mice.	Sirolimus	24-33	catenin (cadherin associated protein), beta 1	Mus musculus	160-172
30890204-6	2019	Interestingly, Ad-Cyp8b1 increased ceramide synthesis and activated hepatic mechanistic target of rapamycin complex 1 (mTORC1)-p70S6K signaling cascade and inhibited AKT/insulin signaling in mice.	Sirolimus	98-107	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	127-133
30782019-9	2019	A systemic injection of rapamycin activated chondrocyte autophagy, which increased the expression of LC3 and ATG-5, and reduced OARSI scores, the expression of beta-catenin, MMP-13, and VEGF, and chondrocyte apoptosis in rapamycin treated mice when compared with vehicle-treated mice.	Sirolimus	24-33	vascular endothelial growth factor A	Mus musculus	186-190
30782019-10	2019	Conclusions: Systemic injection of rapamycin attenuated articular cartilage degeneration by inhibiting beta-catenin in a murine model of OA.	Sirolimus	35-44	catenin (cadherin associated protein), beta 1	Mus musculus	103-115
31485623-12	2019	Promotion of KLK12 overexpression-induced cell viability was reversed by 5-aminoimidazole-4-carboxamide ribonucleotide, an activator of the AMPK signaling pathway, and rapamycin, a specific inhibitor of the mTOR signaling pathway.	Sirolimus	168-177	kallikrein related peptidase 12	Homo sapiens	13-18
31517703-3	2019	OBJECTIVE: To investigate whether surgery activates the mTOR signaling pathway in aged rats, leading to PND, and whether the mTOR inhibitor, rapamycin, can be used to alleviate PND.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Rattus norvegicus	125-129
31517703-10	2019	CONCLUSIONS: Our results indicate that an altered mTOR signaling pathway after a splenectomy causes PND in aged rats, which can be alleviated by rapamycin.	Sirolimus	145-154	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
31557386-10	2019	Like rapamycin, Mfn2 also significantly inhibited the expressions of p-PI3K, p-Akt and p-mTOR in ACLF.	Sirolimus	5-14	mitofusin 2	Homo sapiens	16-20
31302450-9	2019	In addition, western blot analysis revealed increased LC3B II but decreased p62 protein expression levels in the IPC + RAPA group, indicating that autophagic flux was restored by combined ischemic and rapamycin preconditioning.	Sirolimus	201-210	nucleoporin 62	Mus musculus	76-79
31277013-10	2019	Pretreatment with rapamycin significantly aggravated intestinal injury evidenced by increased Chiu"s score, intestinal mucosal wet-to-dry ratio and lactic acid level, increased autophagy level evidenced by increased autophagosomes and LC3-II/LC3-I and decreased expression of p62, and downregulated expression of p-mTOR/mTOR.	Sirolimus	18-27	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	235-238
31021470-12	2019	Preconditioning with mTOR inhibitor rapamycin engendered not only a reduction in mTOR activation, but also a reactivation of autophagy in REDD1 knockdown-neurons upon OGD/R.	Sirolimus	36-45	DNA damage inducible transcript 4	Homo sapiens	138-143
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	170-179	interleukin 10	Homo sapiens	4-23
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	239-248	interleukin 10	Homo sapiens	4-23
31277013-10	2019	Pretreatment with rapamycin significantly aggravated intestinal injury evidenced by increased Chiu"s score, intestinal mucosal wet-to-dry ratio and lactic acid level, increased autophagy level evidenced by increased autophagosomes and LC3-II/LC3-I and decreased expression of p62, and downregulated expression of p-mTOR/mTOR.	Sirolimus	18-27	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	242-245
31102490-5	2019	The interleukin (IL)-10/signal transducer and activator of transcription 3 anti-inflammatory pathway was downregulated in a Toll-like receptor 2-independent manner after rapamycin treatment and IL-10 replenishment abrogated the effects of rapamycin on inflammation and CESC apoptosis.	Sirolimus	239-248	interleukin 10	Homo sapiens	194-199
31277013-10	2019	Pretreatment with rapamycin significantly aggravated intestinal injury evidenced by increased Chiu"s score, intestinal mucosal wet-to-dry ratio and lactic acid level, increased autophagy level evidenced by increased autophagosomes and LC3-II/LC3-I and decreased expression of p62, and downregulated expression of p-mTOR/mTOR.	Sirolimus	18-27	nucleoporin 62	Homo sapiens	276-279
31673045-6	2019	The present study demonstrates that despite reduced lipogenesis, liver specific SCD1 deficiency activates the mechanistic target of rapamycin complex 1 (mTORC1) along with induction of PGC-1alpha and ER stress.	Sirolimus	132-141	stearoyl-Coenzyme A desaturase 1	Mus musculus	80-84
31314175-5	2019	This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex.	Sirolimus	218-227	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	22-50
31028292-5	2019	We showed that CUR increased the expression of brain-derived neurotrophic factor (BDNF) and phosphorylation of tropomyosin receptor kinase B (TrkB) in the hippocampus, and activated protein kinase B (Akt)-mammalian target of the rapamycin (mTOR) signaling pathway.	Sirolimus	229-238	brain derived neurotrophic factor	Homo sapiens	47-80
31314175-5	2019	This process required AMP-activated protein kinase (AMPK), a known PIKfyve activator, and was additionally dependent on the late endosomal/lysosomal adaptor, mitogen-activated protein kinases and mechanistic target of rapamycin activator (LAMTOR/Ragulator) complex.	Sirolimus	218-227	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	52-56
31434755-4	2019	Systemic treatment with the mTORC1 inhibitor rapamycin reduces alpha-globin precipitates and lessens pathologies in beta-thalassemic mice via an ULK1-dependent pathway.	Sirolimus	45-54	hemoglobin alpha, adult chain 1	Mus musculus	63-75
31434755-5	2019	Similarly, rapamycin reduces free alpha-globin accumulation in erythroblasts derived from CD34+ cells of beta-thalassemic individuals.	Sirolimus	11-20	hemoglobin alpha, adult chain 1	Mus musculus	34-46
31594080-16	2019	The expression of p62 protein in the liver tissue of mice in each drug group was lower than M group, and the difference between Rapa group and Rapa+Sal B group (F = 3.085, P = 0.039, 0.003) was statistically significant, while that of Rapa + Sal B group was lower.	Sirolimus	128-132	nucleoporin 62	Mus musculus	18-21
31594080-16	2019	The expression of p62 protein in the liver tissue of mice in each drug group was lower than M group, and the difference between Rapa group and Rapa+Sal B group (F = 3.085, P = 0.039, 0.003) was statistically significant, while that of Rapa + Sal B group was lower.	Sirolimus	143-147	nucleoporin 62	Mus musculus	18-21
31594080-16	2019	The expression of p62 protein in the liver tissue of mice in each drug group was lower than M group, and the difference between Rapa group and Rapa+Sal B group (F = 3.085, P = 0.039, 0.003) was statistically significant, while that of Rapa + Sal B group was lower.	Sirolimus	143-147	nucleoporin 62	Mus musculus	18-21
31553425-8	2019	The ERS inhibitor, 4-phenylbutyrate (4-PBA), partially attenuated the beta1-AA-induced reduction of cardiomyocyte autophagy, consistent with the effect of the mammalian target of rapamycin inhibitor rapamycin (Rapa).	Sirolimus	179-188	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	70-75
31417118-7	2019	The study indicated that the sequential regulation of AMPK-mammalian target of rapamycin complex 1-eEF2 signaling was altered and protein synthesis ability was reduced in the cerebral cortex of hibernating chipmunks.	Sirolimus	79-88	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	54-58
30082469-3	2019	Here we review the general principles of neuronal translation, focusing on the particular relevance of several key regulators of nervous system translation, including eukaryotic initiation factor 2alpha (eIF2alpha), the mechanistic (or mammalian) target of rapamycin complex 1 (mTORC1), and the eukaryotic elongation factor 2 (eEF2).	Sirolimus	257-266	eukaryotic translation initiation factor 2A	Homo sapiens	204-213
31147742-14	2019	The levels of IL-33 in serum and BALF of the RAPA group was significantly increased after LPS was injected as compared with the LPS group; additionally, the levels of IL-33 in serum and BALF of the 3-MA group was significantly reduced after LPS was injected as compared with the LPS group, and that lung injury was ameliorated after 3-MA pretreatment.	Sirolimus	45-49	interleukin 33	Mus musculus	14-19
31147742-14	2019	The levels of IL-33 in serum and BALF of the RAPA group was significantly increased after LPS was injected as compared with the LPS group; additionally, the levels of IL-33 in serum and BALF of the 3-MA group was significantly reduced after LPS was injected as compared with the LPS group, and that lung injury was ameliorated after 3-MA pretreatment.	Sirolimus	45-49	interleukin 33	Mus musculus	167-172
31173176-8	2019	A prospective mechanism for the function of CUR NPs is that they may activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex-1/p-p70 ribosomal protein S6 kinase signaling pathway, regulate the expression of downstream proteins and resist the palmitate-induced cardiomyocyte injury.	Sirolimus	138-147	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	82-110
31173176-8	2019	A prospective mechanism for the function of CUR NPs is that they may activate the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin complex-1/p-p70 ribosomal protein S6 kinase signaling pathway, regulate the expression of downstream proteins and resist the palmitate-induced cardiomyocyte injury.	Sirolimus	138-147	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	112-116
31028566-12	2019	In conclusion, these results demonstrated that the KLF4-dependent rapamycin signaling pathway is a novel mechanism underlying HA-VSMC phenotypic switching and is crucial for HHcy-induced HA-VSMCs with defective autophagy to accelerate early atherosclerosis.	Sirolimus	66-75	Kruppel like factor 4	Homo sapiens	51-55
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	97-106	BCL2-associated X protein	Mus musculus	0-3
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	138-147	BCL2-associated X protein	Mus musculus	0-3
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	138-147	BCL2-associated X protein	Mus musculus	0-3
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	138-147	BCL2-associated X protein	Mus musculus	0-3
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	326-335	BCL2-associated X protein	Mus musculus	0-3
30905858-5	2019	Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin.	Sirolimus	138-147	BCL2-associated X protein	Mus musculus	0-3
30905858-7	2019	In the same conditions, rapamycin-induced autophagy significantly reduced the Myf5 and MyoD proteins.	Sirolimus	24-33	myogenic factor 5	Mus musculus	78-82
30905858-8	2019	Together, these results suggest that rapamycin-induced autophagy results in the decrease of Myf5 and MyoD proteins in C2C12 myoblast cells.	Sirolimus	37-46	myogenic factor 5	Mus musculus	92-96
31358056-13	2019	Rapamycin treatment upregulated miR-100 and downregulated MMPs and ADAMTS5.	Sirolimus	0-9	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	67-74
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	CD4 antigen	Mus musculus	18-21
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	interleukin 2 receptor, alpha chain	Mus musculus	22-26
30445633-10	2019	Taken together, our study demonstrated that metformin suppressed the carcinogenesis of ESCC through inhibiting AMPK/mammalian target of the rapamycin (mTOR) signaling pathway, resulting in its chemopreventive effects on the carcinogenesis of ESCC.	Sirolimus	140-149	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	111-115
30953772-0	2019	Behavioral conditioning of anti-proliferative and immunosuppressive properties of the mTOR inhibitor rapamycin.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Rattus norvegicus	86-90
31005665-10	2019	Our results showed that nicotine significantly reduced hyperalgesia in mice that received acute or repeated rapamycin injections, and reversed the effects of rapamycin on the phosphorylation of S6K, 4E-BP1, insulin receptor substrate-1 (IRS-1) at Ser636/639, AKT at Ser473, and ERK at Thr202/Tyr204.	Sirolimus	158-167	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	194-197
30892958-8	2019	The modified Morris water maze test showed that vision-dependent behavior was also significantly improved in the rapamycin + z-vad-fmk group.Western Blotting results demonstrated that rapamycin promoted the activation of autophagy by promoting beclin-1 and LC-3 induction and inhibited z-vad-fmk-induced necroptosis by inhibiting RIP-1 expression.	Sirolimus	113-122	receptor interacting serine/threonine kinase 1	Rattus norvegicus	330-333
31553425-8	2019	The ERS inhibitor, 4-phenylbutyrate (4-PBA), partially attenuated the beta1-AA-induced reduction of cardiomyocyte autophagy, consistent with the effect of the mammalian target of rapamycin inhibitor rapamycin (Rapa).	Sirolimus	210-214	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	70-75
31553425-9	2019	Compared to the pretreatment with 4-PBA or Rapa alone, pretreatment with the combination of 4-PBA and Rapa had a greater effect on attenuating the beta1-AA-induced decrease in autophagy and beta1-AA-induced apoptosis in cardiomyocytes.	Sirolimus	102-106	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	147-152
31553425-9	2019	Compared to the pretreatment with 4-PBA or Rapa alone, pretreatment with the combination of 4-PBA and Rapa had a greater effect on attenuating the beta1-AA-induced decrease in autophagy and beta1-AA-induced apoptosis in cardiomyocytes.	Sirolimus	102-106	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	190-195
31074104-10	2019	Experiments in vitro revealed that SOS stimulated the activation of the mTORC1 signaling pathway and upregulated RUNX2, OSX, and OCN, rapamycin can reverse it.	Sirolimus	134-143	ocn	None	129-132
31078684-6	2019	Loss of either Tsc1 or Tsc2 from astrocytes resulted in a marked increase in Aqp4 expression which was sensitive to mTORC1 inhibition with rapamycin.	Sirolimus	139-148	aquaporin 4	Mus musculus	77-81
31408438-9	2019	Administration of sirolimus significantly attenuated CD8+ T cell activation and decreased VEGF-A levels.	Sirolimus	18-27	CD8a molecule	Homo sapiens	53-56
31359237-6	2019	Both CR and rapamycin females displayed a higher number of primordial follicles (P = 0.02 and 0.04, respectively), fewer primary, secondary, and tertiary follicles (P < 0.05) and displayed increased ovarian Foxo3a gene expression (P < 0.05).	Sirolimus	12-21	forkhead box O3	Mus musculus	207-213
31056262-12	2019	Furthermore, autophagy activator rapamycin or inhibitor 3-MA partially reversed the down-regulation or up-regulation of SNHG12 effect in OGD/R-inducedSH-SY5Y cell injury, respectively.	Sirolimus	33-42	small nucleolar RNA host gene 12	Homo sapiens	120-126
31354297-0	2019	Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.	Sirolimus	0-9	kinase insert domain receptor	Homo sapiens	93-100
31354297-0	2019	Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression.	Sirolimus	0-9	fms related receptor tyrosine kinase 4	Homo sapiens	112-119
31354297-12	2019	Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.	Sirolimus	27-36	kinase insert domain receptor	Homo sapiens	188-195
31354297-12	2019	Conclusion: In conclusion, rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by blocking the mTOR signal pathway and subsequently downregulating the expression of VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3.	Sirolimus	27-36	fms related receptor tyrosine kinase 4	Homo sapiens	207-214
31171801-7	2019	Overall, we suggest that rapamycin induces transcriptional activation of BDSCs towards osteogenic differentiation, through increased GATA4 and Sox17 that modulate downstream transcription factors (like Runx2), critical for bone formation.	Sirolimus	25-34	GATA binding protein 4	Homo sapiens	133-138
30654047-12	2019	CONCLUSION: Early-life undernutrition induced mechanistic target of rapamycin 1-dependent glycolysis upregulation and TH2 cytokine locus hypomethylation in CD4+ T cells, resulting in increased T-cell activation, proliferation, and TH2 skewing and further susceptibility to experimental asthma.	Sirolimus	68-77	CD4 antigen	Mus musculus	156-159
31026345-1	2019	KEY POINTS: In muscular cells, eukaryotic initiation factor subunit f (eIF3f) activates protein synthesis by allowing physical interaction between mechanistic target of rapamycin complex 1 (MTORC1) and ribosomal protein S6 kinase 1 (S6K1), although its physiological role in animals is unknown.	Sirolimus	169-178	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	233-237
31033201-3	2019	The agent also stimulates AMP-activated protein kinase (AMPK) and consequently influences the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	114-123	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	26-54
31033201-3	2019	The agent also stimulates AMP-activated protein kinase (AMPK) and consequently influences the mammalian target of rapamycin complex 1 (mTORC1) pathways.	Sirolimus	114-123	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	56-60
30840341-0	2019	Rapamycin Induced Autophagy Inhibits Inflammation-Mediated Endplate Degeneration by Enhancing Nrf2/Keap1 Signaling of Cartilage Endplate Stem Cells.	Sirolimus	0-9	kelch-like ECH-associated protein 1	Mus musculus	99-104
30840341-7	2019	Taken together, the results indicate that rapamycin-induced autophagy enhances Nrf2/Keap1 signaling and promotes the expression of antioxidant proteins, thereby eliminating ROS, alleviating cell senescence, reducing the osteogenic differentiation of CESCs, and ultimately protecting CEPs from chronic inflammation-induced degeneration.	Sirolimus	42-51	kelch-like ECH-associated protein 1	Mus musculus	84-89
31191530-9	2019	Using cytomegalovirus (CMV) as model, our next-generation Rapamycin-treated (Rapa-)TCP showed consistently increased proportions of CD4+ T-cells as well as CD4+ and CD8+ central-memory T-cells (TCM).	Sirolimus	58-67	CD8a molecule	Homo sapiens	165-168
30952607-5	2019	Sptlc2 deficiency reduced sphingolipid biosynthetic flux and led to prolonged activation of the mechanistic target of rapamycin complex 1 (mTORC1), endoplasmic reticulum (ER) stress, and CD8+ T cell death.	Sirolimus	118-127	serine palmitoyltransferase, long chain base subunit 2	Mus musculus	0-6
30474386-11	2019	The sirolimus mesh markedly suppressed MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC migration, and reduced phospho-mTOR levels.	Sirolimus	4-13	matrix metallopeptidase 9	Rattus norvegicus	49-54
30474386-11	2019	The sirolimus mesh markedly suppressed MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC migration, and reduced phospho-mTOR levels.	Sirolimus	4-13	proliferating cell nuclear antigen	Rattus norvegicus	77-81
30474386-11	2019	The sirolimus mesh markedly suppressed MMP-2 and MMP-9 expression, decreased PCNA-positive cell numbers, inhibited RAAFC migration, and reduced phospho-mTOR levels.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Rattus norvegicus	152-156
30867239-5	2019	Using supraphysiological stimulation of 4-1BB in the boost phase of a prime-boost immunization, we show that the effect of 4-1BB on Trm generation requires local delivery of both Ag and costimulation, is inhibited by rapamycin treatment during secondary CD8 effector T cell expansion, and is dependent on the signaling adaptor TRAF1.	Sirolimus	217-226	TNF receptor superfamily member 9	Homo sapiens	40-45
30867239-5	2019	Using supraphysiological stimulation of 4-1BB in the boost phase of a prime-boost immunization, we show that the effect of 4-1BB on Trm generation requires local delivery of both Ag and costimulation, is inhibited by rapamycin treatment during secondary CD8 effector T cell expansion, and is dependent on the signaling adaptor TRAF1.	Sirolimus	217-226	TNF receptor superfamily member 9	Homo sapiens	123-128
30867239-5	2019	Using supraphysiological stimulation of 4-1BB in the boost phase of a prime-boost immunization, we show that the effect of 4-1BB on Trm generation requires local delivery of both Ag and costimulation, is inhibited by rapamycin treatment during secondary CD8 effector T cell expansion, and is dependent on the signaling adaptor TRAF1.	Sirolimus	217-226	CD8a molecule	Homo sapiens	254-257
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	TSC complex subunit 2	Homo sapiens	16-23
30988224-3	2019	As the hamartin-tuberin-complex downregulates the mechanistic/mammalian target of the rapamycin complex1 (mTORC1), dysfunction in either hamartin or tuberin induces the constitutive activation of mTORC1.	Sirolimus	86-95	TSC complex subunit 2	Homo sapiens	149-156
30506571-3	2019	Exposure of primary mouse hepatocytes and HepG2 cells to the CB1 R agonist arachidonyl-2"-chloroethylamide inhibited the expression of Sirtuin-1 (Sirt1) and Rictor, a component of mechanistic target of rapamycin complex 2 (mTORC2) and suppressed insulin-induced Akt phosphorylation at serine 473.	Sirolimus	202-211	sirtuin 1	Homo sapiens	135-144
30317677-10	2019	Preconditioning with mTOR antagonist rapamycin engendered not only mTOR inhibition but also abrogated GAS5-mediated depression in cisplatin-evoked autophagy.	Sirolimus	37-46	growth arrest specific 5	Homo sapiens	102-106
30684510-10	2019	Suppression of mTOR by rapamycin treatment reduced the increase in peak glucose hypermetabolism in muscle denervation.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
30537044-11	2019	CONCLUSIONS: Preconditioning of UC-MSCs by rapamycin afforded increased protection against liver I/R injury by enhancing immunosuppression and strengthening the homing and migratory capacity of these cells via the CXCR4/CXCL12 axis.	Sirolimus	43-52	chemokine (C-X-C motif) receptor 4	Mus musculus	214-219
31359237-7	2019	Despite the divergent metabolic effects of the CR and rapamycin treatments, females from both groups displayed a similar increase in ovarian reserve, which was associated with higher expression of ovarian Foxo3a.	Sirolimus	54-63	forkhead box O3	Mus musculus	205-211
30710341-4	2019	Researchers report that rapamycin, a selective mTOR inhibitor, and immunosuppressive agent, has surprising immunostimulatory effects on inducing both quantitative and qualitative aspects of virus-specific memory CD8+ T-cells differentiation and homeostasis in a T-cell-intrinsic manner.	Sirolimus	24-33	CD8a molecule	Homo sapiens	212-215
31257459-13	2019	As a specific inhibitor of mTOR, rapamycin effectively attenuated the effects of E2.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Rattus norvegicus	27-31
31371743-6	2019	EV-miRNA profiles showed a significant upregulation of miR-6127, miR-6746-5p, and miR-6787-5p under RAPA treatment compared to CsA and untreated conditions in metastatic cell lines that were not observed in non-metastatic cells.	Sirolimus	100-104	microRNA 6127	Homo sapiens	55-63
31371743-8	2019	These results suggest that EV-miR-6127, miR-6746-5p and miR-6787-5p could be a potential epigenetic mechanism induced by RAPA therapy in the regulation of the pre-metastatic niche of post-transplant colorectal cancer.	Sirolimus	121-125	microRNA 6127	Homo sapiens	30-38
30905858-0	2019	Rapamycin-induced autophagy decreases Myf5 and MyoD proteins in C2C12 myoblast cells.	Sirolimus	0-9	myogenic factor 5	Mus musculus	38-42
30905858-3	2019	In this study, we determined whether rapamycin-induced autophagy causes the decrease of Myf5 and MyoD protein in C2C12 myoblast cells.	Sirolimus	37-46	myogenic factor 5	Mus musculus	88-92
31315300-10	2019	The Western blot results showed that the expression levels of Beclin1, LC3-I/II, and ERK were significantly elevated in HEMA-treated cells and in cells co-treated with rapamycin, an autophagic promoter.	Sirolimus	168-177	beclin 1	Homo sapiens	62-69
31028762-4	2019	Rapamycin was used to verify the mTORC1/p70S6K/YY1 signaling pathway in HK-2 cells.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	40-46
30890202-6	2019	RESULTS: We found that bilateral injection of BDNF into the vmPFC-PL induced an antidepressant-like effect, which was blocked by pretreatment with K252a and rapamycin.	Sirolimus	157-166	brain derived neurotrophic factor	Homo sapiens	46-50
30978385-10	2019	Overexpression of TIGAR increased the levels of phosphorylated mTOR and S6KP70 under OGD/R condition, this enhancement effect was suppressed by rapamycin.	Sirolimus	144-153	Trp53 induced glycolysis regulatory phosphatase	Mus musculus	18-23
31060359-5	2019	Rapamycin, a specific inhibitor of mTORC1, downregulated 4EBP1 phosphorylation and the expression of PPARgamma and the following lipogenic genes: lipin 1, DGAT1, ACC, and FAS.	Sirolimus	0-9	lipin 1	Bos taurus	146-153
31060359-5	2019	Rapamycin, a specific inhibitor of mTORC1, downregulated 4EBP1 phosphorylation and the expression of PPARgamma and the following lipogenic genes: lipin 1, DGAT1, ACC, and FAS.	Sirolimus	0-9	diacylglycerol O-acyltransferase 1	Bos taurus	155-160
31113850-5	2019	We further delineated the signaling pathways involved and showed that TGF-beta1-induced ATF4 production depended on cooperation between canonical TGF-beta1 signaling through Smad3 and activation of mechanistic target of rapamycin complex 1 (mTORC1) and its downstream target eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1).	Sirolimus	220-229	activating transcription factor 4	Homo sapiens	88-92
30904162-7	2019	Constant rapamycin administration significantly ameliorates the incidence and severity of Fbn1C1039G/+ mice characterized by decreased aortic media degradation, macrophage infiltration and MMP2/9 expression in the aortic wall.	Sirolimus	9-18	matrix metallopeptidase 2	Mus musculus	189-195
30838711-6	2019	LY294002 and rapamycin were added to inhibit the PI3K/AKT pathway and mTOR pathway, respectively.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	70-74
31113912-18	2019	The GFAP immunohistochemistry positive area and absorbance value in the dorsal horn of the lumbar spinal cord in the CCI rats were decreased in the CCI+early RAPA group compared with the CCI+early DMSO group (P&lt;0.05 or P&lt;0.01), and which were also decreased in the CCI+later RAPA group compared with the CCI+later DMSO group (P&lt;0.05 or P&lt;0.01).	Sirolimus	158-162	glial fibrillary acidic protein	Rattus norvegicus	4-8
30032425-10	2019	Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
30569531-6	2019	RESULTS: We demonstrate, that elevated levels of intracellular p62/NBR1 correlated with bacterial persistence, while pre-treatment with a pharmacological inducer of autophagy, rapamycin, reduced both intracellular p62, and bacterial survival.	Sirolimus	176-185	nucleoporin 62	Mus musculus	63-66
30569531-6	2019	RESULTS: We demonstrate, that elevated levels of intracellular p62/NBR1 correlated with bacterial persistence, while pre-treatment with a pharmacological inducer of autophagy, rapamycin, reduced both intracellular p62, and bacterial survival.	Sirolimus	176-185	nucleoporin 62	Mus musculus	214-217
30747228-0	2019	Rapamycin-induced miR-30a downregulation inhibits senescence of VSMCs by targeting Beclin1.	Sirolimus	0-9	beclin 1	Homo sapiens	83-90
30387865-8	2019	Urinary N-acetyl-beta-D-glucosaminidase decreased in both sirolimus and everolimus groups at 6 months (-68.7 +- 137.6 and -62.0 +- 92.4 U/g creatinine, both P < .05), and the reduction of urinary neutrophil gelatinase-associated lipocalin was significant in the sirolimus group (-4345.1 +- 7763.5 ng/g creatinine; P < .05).	Sirolimus	58-67	lipocalin 2	Homo sapiens	196-238
30690083-6	2019	KEY FINDINGS: Rapamycin promoted autophagy and the X protein synthesis concomitantly with elevation in Akt phosphorylation and Beclin1 expression.	Sirolimus	14-23	beclin 1	Homo sapiens	127-134
30032425-10	2019	Inhibition of mTOR by rapamycin reduced mechanical allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	77-81
30992737-11	2019	The antiapoptotic effects of miR-25 were paralleled by inhibition of the p70S6K pathway, a convergence target for the survival signaling pathways, and protection by pre-miR-25 was abrogated by the p70S6k inhibitor rapamycin.	Sirolimus	214-223	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	73-79
30992737-11	2019	The antiapoptotic effects of miR-25 were paralleled by inhibition of the p70S6K pathway, a convergence target for the survival signaling pathways, and protection by pre-miR-25 was abrogated by the p70S6k inhibitor rapamycin.	Sirolimus	214-223	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	197-203
30553049-0	2019	Rapamycin administration during normal and diabetic pregnancy effects the mTOR and angiogenesis signaling in the rat placenta.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	74-78
30628698-6	2019	Beclin-1, phosphorylated (p)-protein kinase B (Akt), p-glycogen synthase kinase (GSK)3beta and p-mechanistic target of rapamycin (mTOR) expression was also measured in the following PC12 cell groups: Control group, model group, 3-methyladenine group (5 nM), rapamycin group (100 nM) and galangin group (1 microg/ml).	Sirolimus	119-128	mechanistic target of rapamycin kinase	Rattus norvegicus	130-134
30629952-5	2019	Rapamycin (autophagy agonist) treatment increased autophagy levels and decreased the cytotoxicity caused by T-2 toxin while 3-methyladenine (autophagy inhibitor) treatment reduced autophagy levels and enhanced the cytotoxicity of T-2 toxin, suggesting that autophagy protect primary cardiomyocytes from the cytotoxicity of T-2 toxin.	Sirolimus	0-9	solute carrier family 25 member 5	Homo sapiens	108-111
30629952-5	2019	Rapamycin (autophagy agonist) treatment increased autophagy levels and decreased the cytotoxicity caused by T-2 toxin while 3-methyladenine (autophagy inhibitor) treatment reduced autophagy levels and enhanced the cytotoxicity of T-2 toxin, suggesting that autophagy protect primary cardiomyocytes from the cytotoxicity of T-2 toxin.	Sirolimus	0-9	solute carrier family 25 member 5	Homo sapiens	230-233
30629952-5	2019	Rapamycin (autophagy agonist) treatment increased autophagy levels and decreased the cytotoxicity caused by T-2 toxin while 3-methyladenine (autophagy inhibitor) treatment reduced autophagy levels and enhanced the cytotoxicity of T-2 toxin, suggesting that autophagy protect primary cardiomyocytes from the cytotoxicity of T-2 toxin.	Sirolimus	0-9	solute carrier family 25 member 5	Homo sapiens	230-233
30863496-14	2019	Thus, Rapamycin reduces HB in a clinically relevant model driven by beta-catenin and Yap1, supporting use of mTORC1 inhibitors in their therapy.	Sirolimus	6-15	catenin (cadherin associated protein), beta 1	Mus musculus	68-80
30696882-7	2019	Cyst formation in Prx1-Cre; Tsc1f/f and Osx-Cre; Tsc1f/f mice were associated with increase in both proliferative and apoptotic cells in the affected tissue and were largely suppressed by rapamycin.	Sirolimus	188-197	Sp7 transcription factor 7	Mus musculus	40-43
30621732-14	2019	Mice that were exposed to VPA and treated with vehicle exhibited the aberrant expression of genes in the mTOR signaling pathway, and rapamycin treatment recovered changes in the expression of some genes, including Fyb and A330094K24Rik.	Sirolimus	133-142	FYN binding protein	Mus musculus	214-217
30252956-7	2019	Treatment with Rapamycin, a mTOR-inhibitor and autophagy activator, ameliorates Fyn-/- mouse baseline erythropoiesis and erythropoietic response to oxidative-stress.	Sirolimus	15-24	Fyn proto-oncogene	Mus musculus	80-83
29761871-8	2019	Compared with the PN group, the PN + Rapa group had lower levels of ROS and reduced expression of ER stress-related protein markers, such as BIP, sXBP1 and CHOP.	Sirolimus	37-41	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	141-144
30594149-9	2018	Pro-apoptotic protein, Bcl-2 associated x (Bax), exhibited a slight, but significant decrease with rapamycin treatment, while its anti-apoptotic counterpart, B cell lymphoma-2 (Bcl-2), was to a similar degree upregulated.	Sirolimus	99-108	BCL2-associated X protein	Mus musculus	23-41
30594149-9	2018	Pro-apoptotic protein, Bcl-2 associated x (Bax), exhibited a slight, but significant decrease with rapamycin treatment, while its anti-apoptotic counterpart, B cell lymphoma-2 (Bcl-2), was to a similar degree upregulated.	Sirolimus	99-108	BCL2-associated X protein	Mus musculus	43-46
30619313-3	2018	Underlying mechanisms of this observation, particularly the effect of sirolimus on naive- and CMV-specific cytotoxic CD8+ T-cell (CMV-CTL) functionality is still undiscovered.	Sirolimus	70-79	CD8a molecule	Homo sapiens	117-120
30514811-3	2018	Here, we report that p62 was proteolytically trimmed by the protease caspase-8 into a stable protein, which we called p62TRM We found that p62TRM, but not full-length p62, was involved in nutrient sensing and homeostasis through the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	255-264	sequestosome 1	Homo sapiens	21-24
30514811-3	2018	Here, we report that p62 was proteolytically trimmed by the protease caspase-8 into a stable protein, which we called p62TRM We found that p62TRM, but not full-length p62, was involved in nutrient sensing and homeostasis through the mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	255-264	sequestosome 1	Homo sapiens	118-121
30584274-5	2018	Rats were treated with curcumin (200 mg/kg) and the mTOR inhibitor rapamycin (2.5 mg/kg) daily for 3 weeks.	Sirolimus	67-76	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
30584274-9	2018	Curcumin and rapamycin treatment inhibited the increased levels of proinflammatory cytokines including IL-1beta, TNF-alpha, MMP-1, and MMP-3 in CIA rats.	Sirolimus	13-22	matrix metallopeptidase 3	Rattus norvegicus	135-140
30290159-11	2018	It is concluded that, at concentrations comparable to those used clinically, pre-treatment of the liver with rapamycin induces the expression of HO-1 and Prx-1.	Sirolimus	109-118	heme oxygenase 1	Rattus norvegicus	145-149
30818375-11	2019	Serum VEGF-D levels markedly decreased during treatment with sirolimus, but not with GnRH analogues.	Sirolimus	61-70	vascular endothelial growth factor D	Homo sapiens	6-12
30823477-11	2019	In this process, both the LC3I/LC3II ratio and p62 protein levels increased, which indicated that the blockage of CD73 could inhibit cell autophagy, and cell migration and invasion were restored by rapamycin.	Sirolimus	198-207	nucleoporin 62	Mus musculus	47-50
30447474-12	2019	Importantly, blocking oxidative stress with VE or blocking Akt/mTOR with rapamycin mitigated the exacerbation of AITD and the suppression of normal autophagy.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Rattus norvegicus	63-67
29962282-0	2019	Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer"s disease lesion in hippocampus of rats with type 2 diabetes mellitus.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	38-42
29962282-3	2019	This study aims to investigate effects of rapamycin on AD in hippocampus of T2DM rat by AMPK/mTOR signaling pathway.	Sirolimus	42-51	mechanistic target of rapamycin kinase	Rattus norvegicus	93-97
29962282-8	2019	RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR.	Sirolimus	28-37	amyloid beta precursor protein	Rattus norvegicus	317-322
29962282-8	2019	RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Rattus norvegicus	335-339
29962282-8	2019	RESULTS: After treated with rapamycin, T2DM rats and rats with T2DM and AD showed increased learning-memory ability, and decreased levels of FBG, glycosylated hemoglobin, total cholesterol, triglyceride and serum insulin, decreased expression of APP and p-tau, increased AMPK mRNA expression and p-AMPK and decreased Abeta deposition, mTOR mRNA expression and p-mTOR.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Rattus norvegicus	362-366
29962282-9	2019	CONCLUSION: The study demonstrated that rapamycin reduces the risk of AD in T2DM rats and inhibits activation of AMPK-mTOR signaling pathway, thereby improving AD lesion in hippocampus of T2DM rats.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Rattus norvegicus	118-122
29869197-10	2019	Intracerebroventricular injection of the TrkB antagonist, K252a (0.05 nmol/muL), or the mTOR inhibitor, rapamycin (1 nmol/muL), abolished the behavioral effects of CBD.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Rattus norvegicus	88-92
30195918-6	2018	In addition, rapamycin can induce autophagy in lamprey leukocytes and the deficiency of human Beclin1 protein can be rescued by lancelet and lamprey Beclin1 proteins.	Sirolimus	13-22	beclin 1	Homo sapiens	94-101
30195918-6	2018	In addition, rapamycin can induce autophagy in lamprey leukocytes and the deficiency of human Beclin1 protein can be rescued by lancelet and lamprey Beclin1 proteins.	Sirolimus	13-22	beclin 1	Homo sapiens	149-156
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	interleukin 17A	Homo sapiens	101-105
30061014-9	2018	Inhibition of mTORC1 pathway with rapamycin, increase Tregs and decrease effector CD4+IFNgamma+, CD4+IL17+ and CD4+IL21+ T cells in patients with LVV.	Sirolimus	34-43	interleukin 21	Homo sapiens	115-119
30269036-6	2018	Interestingly, ectopic over-expression of miR-150 acted in a feed-forward loop and further sensitized Jurkat cells to a rapamycin-induced cell cycle arrest by targeting a large network of cell cycle genes.	Sirolimus	120-129	microRNA 150	Homo sapiens	42-49
30200803-0	2018	The protective effects of rapamycin on cell autophagy in the renal tissues of rats with diabetic nephropathy via mTOR-S6K1-LC3II signaling pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	113-117
30200803-10	2018	The expression levels of mTOR and S6K1 increased and LC3II expression decreased in the renal tissues of the DN and RAPA groups compared with the NC group (p &lt; .05).	Sirolimus	115-119	mechanistic target of rapamycin kinase	Rattus norvegicus	25-29
30713663-15	2019	Both rapamycin treatment and mTOR knockdown enhanced ERK activity further, but reduced JNK activity and the p62 level in arsenite-treated cells.	Sirolimus	5-14	nucleoporin 62	Homo sapiens	108-111
30337735-10	2018	Moreover, the knock down of either Ulk1 or LC3 decreased the ST-caused apoptosis.Interestingly, we observed that rapamycin, a specific inhibitor of mTOR (mammalian target of rapamycin) and an inducer of autophagy, also showed to inhibit cell viability and increased the cleavage of PARP-1 in the ST-treated cells, suggesting that autophagy was likely to play a dual role in the regulation of the ST-induced apoptosis.	Sirolimus	113-122	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	43-46
30323591-7	2018	Less HES5-positive labeling was found near the ticagrelor-eluting stented vessels (0.33+-0.12) than close to the sirolimus-eluting stented vessels (0.57+-0.15) (p&lt;0.05).	Sirolimus	113-122	hes family bHLH transcription factor 5	Homo sapiens	5-9
30127391-1	2018	Tuberous sclerosis complex (TSC) is a multisystem developmental disorder caused by mutations in the TSC1 or TSC2 genes, whose protein products are negative regulators of mechanistic target of rapamycin complex 1 signaling.	Sirolimus	192-201	TSC complex subunit 2	Homo sapiens	108-112
30208576-6	2018	Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 muM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR.	Sirolimus	110-119	serpin family F member 2	Homo sapiens	151-154
30256440-7	2018	In addition, chloroquine (as the autophagy/lysosome inhibitor, CQ) or rapamycin (as the autophagy/lysosome inhibitor, Rap) attenuated osteoclast differentiation and bone resorption activity by OPG treatment via AMPK/mTOR/p70S6K signaling pathway.	Sirolimus	70-79	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	193-196
30256440-7	2018	In addition, chloroquine (as the autophagy/lysosome inhibitor, CQ) or rapamycin (as the autophagy/lysosome inhibitor, Rap) attenuated osteoclast differentiation and bone resorption activity by OPG treatment via AMPK/mTOR/p70S6K signaling pathway.	Sirolimus	70-79	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	221-227
30692064-8	2019	High-dose rapamycin obviously inhibited the production of IL-12, IFN-gamma, IL-17 and IL-23 and induced the anti-inflammatory cytokines IL-10 and TGF-beta.	Sirolimus	10-19	interleukin 17A	Mus musculus	76-81
30507612-7	2019	Lipin 2/3 deficiency caused phosphatidic acid accumulation and mammalian target of rapamycin complex 1 (mTORC1) activation, which were associated with enhanced protein levels of a key phospholipid biosynthetic enzyme (CTP:phosphocholine cytidylyltransferase alpha) and altered membrane phospholipid composition.	Sirolimus	83-92	lipin 2	Homo sapiens	0-9
30904097-4	2019	Through the discovery of the TSC1 and TSC2 genes and the signaling pathways responsible for the pathology of TSC, a new drug target called mechanistic target of rapamycin complex 1 (mTORC1) was discovered.	Sirolimus	161-170	TSC complex subunit 2	Homo sapiens	38-42
30161287-7	2019	Furthermore, lentivirus-mediated Med19 inhibition significantly attenuated the LC3-II/LC3-I ratio, autophagy-related gene 3 (Atg3) and autophagy-related gene 5 (Atg5) expression, P62 degradation, and red fluorescent protein-LC3 dot formation after treatment with ADM or rapamycin, an autophagy activator.	Sirolimus	270-279	mediator complex subunit 19	Homo sapiens	33-38
30964118-6	2019	Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays.	Sirolimus	182-191	prominin 1	Mus musculus	122-127
30964118-8	2019	Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.	Sirolimus	42-51	prominin 1	Mus musculus	134-139
30325723-8	2019	Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in paclitaxel rats (P < 0.05 vs. without rapamycin).	Sirolimus	20-29	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
30325723-8	2019	Blocking mTOR using rapamycin attenuated peripheral painful neuropathy observed in paclitaxel rats (P < 0.05 vs. without rapamycin).	Sirolimus	121-130	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
30273598-4	2018	In the presence of rapamycin, the effects of either 7-ketocholesterol treatment or CD38 gene deletion were abolished.	Sirolimus	19-28	CD38 antigen	Mus musculus	83-87
30290159-0	2018	Rapamycin induces the expression of heme oxygenase-1 and peroxyredoxin-1 in normal hepatocytes but not in tumorigenic liver cells.	Sirolimus	0-9	heme oxygenase 1	Rattus norvegicus	36-52
30290159-3	2018	The aim of this study was to further investigate the actions of rapamycin in inducing expression of the antioxidant enzymes heme oxygenase-1 (HO-1) and peroxiredoxin-1 (Prx-1) in normal liver and in tumorigenic liver cells.	Sirolimus	64-73	heme oxygenase 1	Rattus norvegicus	124-140
30290159-3	2018	The aim of this study was to further investigate the actions of rapamycin in inducing expression of the antioxidant enzymes heme oxygenase-1 (HO-1) and peroxiredoxin-1 (Prx-1) in normal liver and in tumorigenic liver cells.	Sirolimus	64-73	heme oxygenase 1	Rattus norvegicus	142-146
30144045-11	2018	A higher cathepsin activity, particularly of cathepsin B, was observed, which was reduced by mTORC1 inhibition with rapamycin in vivo.	Sirolimus	116-125	cathepsin B	Mus musculus	45-56
30393233-8	2018	The WB results showed that the expression levels of Beclin-1 and LC3-II/LC3-I were significantly elevated in NB cells treated with Rapamycin, while the expression levels of P62, mTOR, and p-mTOR proteins were significantly reduced compared with the control cells (P&lt;0.05).	Sirolimus	131-140	beclin 1	Homo sapiens	52-60
30393233-8	2018	The WB results showed that the expression levels of Beclin-1 and LC3-II/LC3-I were significantly elevated in NB cells treated with Rapamycin, while the expression levels of P62, mTOR, and p-mTOR proteins were significantly reduced compared with the control cells (P&lt;0.05).	Sirolimus	131-140	nucleoporin 62	Homo sapiens	173-176
30205205-5	2018	Moreover, rapamycin decreased ps6k and increased pAkt and pERK, while combination therapy downregulated pAkt, ps6 k and pERK in EAE mice.	Sirolimus	10-19	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	58-62
30179613-6	2018	Pre-treatment of rats with rapamycin for 24 h by intraperitoneal injection inhibited the expression of mRNA encoding the sinusoidal influx transporters Ntcp, Oatp1 and 2 and the canalicular efflux transporter Bsep, and increased expression of canalicular Mrp2.	Sirolimus	27-36	ATP binding cassette subfamily C member 2	Rattus norvegicus	255-259
29709078-5	2018	We tested our hypothesis by determining the influence of dietary TiO2 NPs (for 72 h) and, separately, of two Akt/Tor pathway inhibitors (LY294002 and rapamycin) on expression of Akt/Tor signaling pathway genes and proteins in the silk glands.	Sirolimus	150-159	RAC serine/threonine-protein kinase	Bombyx mori	109-112
29928901-0	2018	Rapamycin mediates mTOR signaling in reactive astrocytes and reduces retinal ganglion cell loss.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
29709078-5	2018	We tested our hypothesis by determining the influence of dietary TiO2 NPs (for 72 h) and, separately, of two Akt/Tor pathway inhibitors (LY294002 and rapamycin) on expression of Akt/Tor signaling pathway genes and proteins in the silk glands.	Sirolimus	150-159	RAC serine/threonine-protein kinase	Bombyx mori	178-181
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	Sirolimus	73-82	negative elongation factor complex member C/D	Homo sapiens	133-136
29449635-0	2018	Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin.	Sirolimus	140-149	TSC complex subunit 2	Homo sapiens	28-31
29895377-8	2018	In contrast to cyclosporine A and dexamethasone, only zinc aspartate and rapamycin were capable of suppressing the proliferation and Th1 (IFN-gamma), Th2 (IL-5), and Th17 (IL-17) cytokine production of pre-activated T cells.	Sirolimus	73-82	interleukin 17A	Homo sapiens	172-177
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
30224017-18	2018	Compared with DMED group, rapamycin led to lower AMPK/mTOR and AKT/mTOR pathways expression, a higher degree of mTOR (raptor)/p70S6K pathway inhibition, and no change in the mTORC2-related pathway.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
29959473-10	2018	These results provide evidence that the mTOR inhibitor rapamycin synergistically enhances the antitumor effect of PLK1 inhibitor BI 2536 in ESCC cells.	Sirolimus	55-64	polo like kinase 1	Mus musculus	114-118
29449635-7	2018	The mTOR inhibitor rapamycin rescued the deficits in differentiation, synaptic dysfunction, and hypoexcitability of TSC2 mutant hiPSC-PCs in vitro.	Sirolimus	19-28	TSC complex subunit 2	Homo sapiens	116-120
30405339-6	2018	The increase in BDNF expression was completely blocked by rapamycin and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX).	Sirolimus	58-67	brain-derived neurotrophic factor	Rattus norvegicus	16-20
29929111-1	2018	PURPOSE: Tuberous sclerosis (TSC) is an autosomal dominant inherited disease caused by mutations in the TSC1 or TSC2 gene and results in the over-activation of the mammalian target of the rapamycin (mTOR) signaling pathway.	Sirolimus	188-197	TSC complex subunit 2	Homo sapiens	112-116
30084798-8	2018	However, when the cells were exposed to rapamycin (80nM), leucine inhibited the expression of SMAD and FoxO3a, showing that leucine was able to modulate the degradation pathway when protein synthesis is compromised.	Sirolimus	40-49	forkhead box O3	Mus musculus	103-109
30050079-7	2018	Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells.	Sirolimus	51-60	histone deacetylase 9	Homo sapiens	41-45
30050079-12	2018	Furthermore, co-administration of rapamycin, valproic acid, and tamoxifen retarded tumor growth and reduced CD44high/+/CD24low/- CSCs in a human TNBC xenograft model and hampered tumorigenesis after secondary transplantation.	Sirolimus	34-43	CD44 molecule (Indian blood group)	Homo sapiens	108-112
29559472-0	2018	Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.	Sirolimus	63-72	polo like kinase 1	Homo sapiens	0-4
29559472-7	2018	Collectively, our data support a model in which Plk1, instead of AKT, regulates the TSC/mTORC1 pathway during mitosis, eventually regulating the efficacy of rapamycin.Significance: This seminal report shows that activation of mTORC1 can be independent of AKT during mitosis.	Sirolimus	157-166	polo like kinase 1	Homo sapiens	48-52
29859856-6	2018	Inhibition of ileal mTORC1 signaling by rapamycin significantly attenuated the stimulation of bile acid secretion, TGR5 expression and GLP-1 synthesis induced by RYGB in lean and diet-induced obese mice.	Sirolimus	40-49	G protein-coupled bile acid receptor 1	Mus musculus	115-119
29512710-0	2018	Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody.	Sirolimus	9-18	kinase insert domain receptor	Homo sapiens	92-97
29571225-12	2018	FA and rapamycin treatment inhibited VSMC dedifferentiation in vitro and in vivo, and FA and rapamycin attenuated the mTOR/p70S6K signalling pathway.	Sirolimus	93-102	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	123-129
29732501-6	2018	Mechanistically, Hcy-activated CD4+ T cell increased the protein expression and activity of pyruvate kinase muscle isozyme 2 (PKM2), the final rate-limiting enzyme in glycolysis, via the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling pathway.	Sirolimus	243-252	CD4 antigen	Mus musculus	31-34
29901635-2	2018	Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophagy with demonstrated beneficial effects in neurodegeneration in cell line and animal models, improving phenotype in SQSTM1 zebrafish, in Drosophila model of ALS-TDP, and in the TDP43 mouse model, in which it reduced neuronal loss and TDP43 inclusions.	Sirolimus	0-9	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	263-268
29736615-5	2018	The effects of BDNF were completely inhibited by rapamycin, an inhibitor of mammalian target of rapamycin (mTOR).	Sirolimus	49-58	brain derived neurotrophic factor	Homo sapiens	15-19
30346929-6	2018	We found that rapamycin significantly enhanced DE development through mTOR suppression-induced augmentation of macrophage autophagy, while CQ significantly decreased DE development through suppression of macrophage autophagy.	Sirolimus	14-23	mechanistic target of rapamycin kinase	Rattus norvegicus	70-74
30185506-6	2018	Rapamycin restored LPS-induced up-regulation of EDN1, endothelin converting enzyme-1 (ECE1), and p-JNK in TSC1-knockdown mouse embryonic fibroblasts (MEFs).	Sirolimus	0-9	endothelin converting enzyme 1	Mus musculus	54-84
30185506-6	2018	Rapamycin restored LPS-induced up-regulation of EDN1, endothelin converting enzyme-1 (ECE1), and p-JNK in TSC1-knockdown mouse embryonic fibroblasts (MEFs).	Sirolimus	0-9	endothelin converting enzyme 1	Mus musculus	86-90
30185506-6	2018	Rapamycin restored LPS-induced up-regulation of EDN1, endothelin converting enzyme-1 (ECE1), and p-JNK in TSC1-knockdown mouse embryonic fibroblasts (MEFs).	Sirolimus	0-9	mitogen-activated protein kinase 8	Mus musculus	99-102
30132043-6	2018	Pharmacologic inhibition of mTOR signaling using rapamycin (20 nM), FK506 (5 nM), or 4EGI-1 (1 microM), and siRNA knockdown of mTOR, or the mTOR complex binding proteins, raptor or rictor, blocked PCB 95-induced dendritic growth.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Rattus norvegicus	28-32
29969175-6	2018	Also, our results suggest that mTORC1 pathway overactivation may function as a second hit event contributing to downregulation of the Reelin-DAB1 cascade in patient-derived NPCs, and that inhibition of mTORC1 by rapamycin attenuates Reelin-DAB1 signaling impairment.	Sirolimus	212-221	reelin	Homo sapiens	134-140
30144504-2	2018	The TSC1 and TSC2 genes encode proteins forming a complex (TSC), which is a major regulator and suppressor of mammalian target of rapamycin complex 1 (mTORC1), a signaling complex that promotes cell growth and proliferation.	Sirolimus	130-139	TSC complex subunit 2	Homo sapiens	13-17
29514215-8	2018	In addition, we found a defect in the ability of Cln7 ko MEFs to adapt to starvation conditions as shown by impaired mammalian target of rapamycin complex 1 reactivation, reduced autolysosome tubulation and increased perinuclear accumulation of autolysosomes compared with controls.	Sirolimus	137-146	major facilitator superfamily domain containing 8	Homo sapiens	49-53
29277549-5	2018	Pretreatment of the cells with rapamycin ameliorated oxidative stress, reduced the number of apoptotic cells induced by HG and caused the downstream effects of mTOR activation.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	160-164
29432811-3	2018	Rapamycin administration intraperitoneally markedly reduced clinical signs, total and OVA-specific IgE and IgG1/G2a ratio in serum, and conjunctival eosinophilic infiltration.	Sirolimus	0-9	LOC105243590	Mus musculus	107-111
29483302-7	2018	In tumor cells engineered to express NLS-IRS-1, the IRS-1/LC3 nuclear structures repress autophagy induced by either amino acid starvation or rapamycin treatment.	Sirolimus	142-151	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	58-61
29854093-7	2018	Blocking mTOR with rapamycin abolished the stimulatory effect of both L-Arg and SNP on protein synthesis and p70S6K phosphorylation.	Sirolimus	19-28	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	109-115
29755689-0	2018	A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.	Sirolimus	91-100	ALK receptor tyrosine kinase	Homo sapiens	45-48
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	ALK receptor tyrosine kinase	Homo sapiens	109-112
29755689-11	2018	Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin.	Sirolimus	0-9	ALK receptor tyrosine kinase	Homo sapiens	124-127
29277549-8	2018	mTOR inhibitor rapamycin treatment prevented these changes further alleviated albuminuria and improved renal function.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
30186415-10	2018	In addition, rapamycin downregulated the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 and MMP-9 in HUVECs.	Sirolimus	13-22	matrix metallopeptidase 9	Homo sapiens	135-140
29909290-1	2018	Regulated in development and DNA damage responses 1 (REDD1) is an inducible gene in response to various stresses, which functions as a negative regulator of the mammalian target of rapamycin protein kinase in complex 1.	Sirolimus	181-190	DNA damage inducible transcript 4	Homo sapiens	53-58
30107854-11	2018	The density of CD133+ renal stem-like cells was significantly increased in irradiated kidneys after rapamycin treatment.	Sirolimus	100-109	prominin 1	Mus musculus	15-20
28762191-8	2018	Finally, in the in vitro injury model, Rb1 treatment increased the viability of PC12 cells and suppressed apoptosis by inhibiting excessive autophagy, whereas stimulation of autophagy by rapamycin abolished the anti-apoptosis effect of Rb1.	Sirolimus	187-196	RB transcriptional corepressor 1	Rattus norvegicus	236-239
30107854-13	2018	CONCLUSIONS: These findings indicate that inhibition of mTORC1 signaling by rapamycin ameliorates irradiation-induced renal toxicity mediated by decreasing cellular apoptosis and increasing CD133+ renal stem-like cells.	Sirolimus	76-85	prominin 1	Mus musculus	190-195
29803175-10	2018	Rapamycin, an inhibitor of mTOR, reversed the effect of LPS on rat intestine epithelial cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	27-31
29556265-8	2018	The present study also demonstrated that the activation of autophagy with rapamycin led to an improvement in the AOPP-induced overexpression of kidney injury molecule 1 and neutrophil gelatinase-associated lipocalin, two biomarkers of RTEC injury, whereas inhibiting autophagy with chloroquine further increased their expression during AOPP treatment.	Sirolimus	74-83	hepatitis A virus cellular receptor 1	Homo sapiens	144-168
29556265-8	2018	The present study also demonstrated that the activation of autophagy with rapamycin led to an improvement in the AOPP-induced overexpression of kidney injury molecule 1 and neutrophil gelatinase-associated lipocalin, two biomarkers of RTEC injury, whereas inhibiting autophagy with chloroquine further increased their expression during AOPP treatment.	Sirolimus	74-83	lipocalin 2	Homo sapiens	173-215
29183718-6	2018	Heterologous SjPTC1 expression reversed the sensitivity of yeast ptc1 null mutants toward H2O2, ZnCl2, cisplatin, and rapamycin.	Sirolimus	118-127	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	65-69
29675586-0	2018	Rapamycin Alleviates Hormone Imbalance-Induced Chronic Nonbacterial Inflammation in Rat Prostate Through Activating Autophagy via the mTOR/ULK1/ATG13 Signaling Pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	134-138
29675586-9	2018	In addition to some histological changes in the prostate tissues, we found the levels of NF-kappaB and IL-1beta were significantly increased in the model group, along with significantly suppressed autophagy, whereas rapamycin could reverse these effects which involved in the mTOR/ULK1/ATG13 signaling pathway.	Sirolimus	216-225	mechanistic target of rapamycin kinase	Rattus norvegicus	276-280
30228949-8	2018	Furthermore, rapamycin uniquely enhanced the number and function of CD8+ effector and central memory T cells in a model of long-term contact hypersensitivity provided that rapamycin was present during the antigen sensitization phase.	Sirolimus	13-22	CD8a molecule	Homo sapiens	68-71
29343514-8	2018	Moreover, we found that TRPM2 modulates autophagy through a c-Jun N-terminal kinase (JNK)-dependent and mechanistic target of rapamycin-independent pathway.	Sirolimus	126-135	transient receptor potential cation channel subfamily M member 2	Homo sapiens	24-29
29072256-7	2018	Ox-LDL (100 mug/mL) time-dependently increased c-Fos levels in HUVECs, and pretreatment with rapamycin or rictor siRNA significantly decreased expression of c-Fos.	Sirolimus	93-102	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	47-52
29072256-7	2018	Ox-LDL (100 mug/mL) time-dependently increased c-Fos levels in HUVECs, and pretreatment with rapamycin or rictor siRNA significantly decreased expression of c-Fos.	Sirolimus	93-102	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	157-162
30016968-10	2018	Moreover, both rapamycin and trehalose attenuated the enhanced Ube2v1-mediated lung metastasis by inducing the autophagy pathway in an orthotropic mouse xenograft model of lung metastasis.	Sirolimus	15-24	ubiquitin-conjugating enzyme E2 variant 1	Mus musculus	63-69
29491408-6	2018	Rapamycin, shRNAs targeting raptor, or inhibition of S6 kinase significantly inhibited the expression of Nox4, resulting in attenuation of production of ROS in tuberin-downregulated proximal tubular epithelial cells.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	160-167
29449538-4	2018	Decreased eIF2alphaP in TSC2-deficient cells depends on reactive oxygen species (ROS) production and is associated with a reduced activity of the endoplasmic reticulum (ER)-resident kinase PERK owing to the hyper-activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	251-260	TSC complex subunit 2	Homo sapiens	24-28
29449538-4	2018	Decreased eIF2alphaP in TSC2-deficient cells depends on reactive oxygen species (ROS) production and is associated with a reduced activity of the endoplasmic reticulum (ER)-resident kinase PERK owing to the hyper-activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	251-260	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	189-193
29444251-9	2018	The mTOR inhibitor, rapamycin, suppressed phosphorylation of mTOR (P &lt; 0.01) and rS6 (P &lt; 0.01) with an increase in phosphorylation of rS6 in leucine-treated cultures observed when compared to control cultures (P &lt; 0.05).	Sirolimus	20-29	mechanistic target of rapamycin kinase	Equus caballus	4-8
29379118-3	2018	Here, we investigate the effects of PIP2 on Kv2.1 channels by applying exogenous PIP2 to the cytoplasmic face of excised membrane patches, activating muscarinic receptors (M1R), or depleting endogenous PIP2 using a rapamycin-translocated 5-phosphatase (FKBP-Inp54p).	Sirolimus	215-224	potassium voltage-gated channel subfamily B member 1	Homo sapiens	44-49
29375310-9	2017	In fact, rapamycin treatment had an adverse effect on sleep and social behavior in both control and Fmr1 KO mice.	Sirolimus	9-18	fragile X messenger ribonucleoprotein 1	Mus musculus	100-104
29337352-2	2018	Here, we report in mice that L-LTP failure induced by the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) inhibitor rapamycin is reversed by brain-specific genetic deletion of PKR-like ER kinase, PERK (PERK KO), a kinase for eukaryotic initiation factor 2alpha (eIF2alpha).	Sirolimus	92-101	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	217-221
29337352-2	2018	Here, we report in mice that L-LTP failure induced by the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) inhibitor rapamycin is reversed by brain-specific genetic deletion of PKR-like ER kinase, PERK (PERK KO), a kinase for eukaryotic initiation factor 2alpha (eIF2alpha).	Sirolimus	92-101	eukaryotic translation initiation factor 2A	Homo sapiens	277-286
29963174-10	2018	Rapamycin treatment also significantly enhanced autophagy in the 4 liver cancer cell lines and increased TRAP1 expression in HepG2, Hep3B2.1-7 and Sk-hep1 cells.	Sirolimus	0-9	TNF receptor associated protein 1	Homo sapiens	105-110
29963174-10	2018	Rapamycin treatment also significantly enhanced autophagy in the 4 liver cancer cell lines and increased TRAP1 expression in HepG2, Hep3B2.1-7 and Sk-hep1 cells.	Sirolimus	0-9	DNL-type zinc finger	Homo sapiens	150-154
29730892-9	2018	ATRA activated p70S6k1 in MSCs in vitro, which was completely inhibited by rapamycin.	Sirolimus	75-84	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	15-22
29996117-9	2018	Blocking mTOR by intrathecal infusion of rapamycin attenuated mechanical pain and cold hypersensitivity.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
30050390-6	2018	Results: Rapamycin alleviated the pathological damage of myocardial tissue, attenuated cardiac dysfunction (left ventricular ejection fraction (LVEF), p &lt; 0.05; fractional shortening (FS), p &lt; 0.05), and reduced HIF-1a expression (p &lt; 0.05).	Sirolimus	9-18	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	218-224
30050390-7	2018	Expectedly, rapamycin decreased the activity of the mTOR pathway in both sham-operated rats (p &lt; 0.0001) and CLP rats (p &lt; 0.01).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
30016763-12	2018	In addition, pS6, collagen I and collagen III protein expression was blocked by rapamycin.	Sirolimus	80-89	taste 2 receptor member 63 pseudogene	Homo sapiens	13-16
29195127-5	2018	Exposure with rapamycin enhanced the cytotoxicity of NK cells by upregulating the expression of IL-27 in UECC and IL-27 receptors (IL-27Rs: WSX-1 and gp130) on NK cells and further restricted the growth of UEC in Ishikawa-xenografted nude mice.	Sirolimus	14-23	interleukin 27	Mus musculus	96-101
29904395-0	2018	Rapamycin provides anti-epileptogenic effect in a rat model of post-traumatic epilepsy via deactivation of mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	107-111
27133527-9	2018	Rapamycin fully abolished PA or 5-HT-induced mTOR activation, which was more effective than sarpogrelate.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	45-49
29468175-9	2018	Rapamycin pre or postadministration inhibited the overactivation of mTOR pathway in ischemic penumbra.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	68-72
29468175-13	2018	mTOR inhibitor rapamycin significantly decreased the mTOR activation and infarct volume and subsequently improved neurological function.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
29468175-13	2018	mTOR inhibitor rapamycin significantly decreased the mTOR activation and infarct volume and subsequently improved neurological function.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	53-57
29579719-7	2018	Finally, we demonstrated that the restoration/preservation of autophagic-lysosomal degradation in senescent MEFs following rapamycin treatment correlated with attenuation of copper accumulation in these cells despite a further decrease in Atp7a levels.	Sirolimus	123-132	ATPase copper transporting alpha	Homo sapiens	239-244
28846543-1	2017	AIMS: Our aim was to report the long-term safety and efficacy of the biodegradable polymer-coated biolimus- eluting Nobori stent compared to the durable polymer-coated sirolimus-eluting CYPHER stent.	Sirolimus	168-177	LIM domain binding 3	Homo sapiens	186-192
29857512-6	2018	Meanwhile, the MMP-9 related signaling pathways, including Phosph-Protein Kinase B (P-AKT) and Phosph-mammalian Targets Of Rapamycin (P-mTOR) were decreased after a Salmonella treatment.	Sirolimus	123-132	matrix metallopeptidase 9	Homo sapiens	15-20
29240812-9	2017	In addition, vaspin increased the phosphorylation levels of mTOR and p70S6K, which was inhibited by rapamycin.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Rattus norvegicus	60-64
29170467-7	2017	We find that PIM3 repression is mediated by miR-33, an intronic microRNA encoded within the SREBP loci, the expression of which is decreased with rapamycin.	Sirolimus	146-155	proviral integration site 3	Mus musculus	13-17
29872406-9	2018	Further mechanistic studies revealed that TGC increased silent information regulator 1 (Sirt1) expression to reduce the phosphorylation of the mammalian target of rapamycin and its downstream effectors P70S6K and 4EBP1.	Sirolimus	163-172	sirtuin 1	Homo sapiens	56-86
29170467-7	2017	We find that PIM3 repression is mediated by miR-33, an intronic microRNA encoded within the SREBP loci, the expression of which is decreased with rapamycin.	Sirolimus	146-155	microRNA 33	Mus musculus	44-50
29872406-9	2018	Further mechanistic studies revealed that TGC increased silent information regulator 1 (Sirt1) expression to reduce the phosphorylation of the mammalian target of rapamycin and its downstream effectors P70S6K and 4EBP1.	Sirolimus	163-172	sirtuin 1	Homo sapiens	88-93
29764404-0	2018	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.	Sirolimus	96-105	TSC complex subunit 2	Homo sapiens	116-120
28220552-9	2017	Furthermore, when the mTOR inhibitor rapamycin was administered with ketamine to the HBdMECs, the expression of FSP-1 decreased significantly.	Sirolimus	37-46	S100 calcium binding protein A4	Homo sapiens	112-117
29736257-8	2017	Thus, rapamycin-mediated lifespan extension in Lmna-/- mice is in part due to the improvement of skeletal muscle function and can be phenocopied by reduced S6K1 activity, but not 4E-BP1 activation.	Sirolimus	6-15	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	156-160
29764404-10	2018	CONCLUSION: NGS on an EAML patient with an extraordinary response to sirolimus uncovered TSC2 inactivation as the mechanism for the response.	Sirolimus	69-78	TSC complex subunit 2	Homo sapiens	89-93
29757673-5	2018	Results indicated that both rapamycin and AZD8055 inhibited mTOR complex 1 (mTORC1)/70-kDa ribosomal protein S6 kinase signaling similarly, whereas mTORC1/eukaryotic translation initiation factor 4E-binding protein 1 signaling was greatly inhibited by AZD8055.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Rattus norvegicus	60-64
28919041-2	2017	We describe the engineering of a split-cAbl kinase (sKin-Abl) that is rapidly activated in cells with rapamycin and allows temporal, dose, and compartmentalization control.	Sirolimus	102-111	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	40-43
29447354-5	2018	We also reported that CREBRF-mTOR-autophagy pathway plays a vital role in regulating endometrial function, with a blockade of the mTOR by rapamycin demonstrating the regulatory function on prostaglandin (PGs) secretion and cell attachment in EECs.	Sirolimus	138-147	serine/threonine-protein kinase mTOR	Capra hircus	29-33
28669853-0	2017	Effect of sirolimus on arteriosclerosis induced by advanced glycation end products via inhibition of the ILK/mTOR pathway in kidney transplantation recipients.	Sirolimus	10-19	mechanistic target of rapamycin kinase	Rattus norvegicus	109-113
28922851-5	2017	Rapamycin treatment was found to reduce infarct size and behavioral deficits and, in GFAP+/HSF1+ zones, enhance alphaEnsa neuronal nuclear translocation and mitigate cell death, relative to controls.	Sirolimus	0-9	glial fibrillary acidic protein	Rattus norvegicus	85-89
28710231-6	2017	TSC2 negatively regulated EP3 expression via Rheb in a rapamycin-insensitive manner.	Sirolimus	55-64	TSC complex subunit 2	Homo sapiens	0-4
27660271-5	2017	Rapamycin administration caused a significant reduction of mTOR complex 1 phosphorylation at Ser2481 and a significant increase in levels of autophagy markers such as microtubule-associated protein-1 light chain-3 (LC3), beclin-1, sequestosome-1/p62, unc-51-like kinase 1 (ULK1).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	59-63
28626202-1	2017	BACKGROUND: Stent fracture (SF) and peri-stent contrast staining (PSS) after sirolimus-eluting stent implantation are reported to be risk factors of adverse events.	Sirolimus	77-86	perilipin 1	Homo sapiens	36-40
29085189-8	2017	When the intracellular pathway mTOR/S6k was inactivated by chronic treatment with rapamycin, rimonabant treatment was no longer able to stimulate the gastric secretion of Nucb2/nesfatin-1.	Sirolimus	82-91	mechanistic target of rapamycin kinase	Rattus norvegicus	31-35
29447354-5	2018	We also reported that CREBRF-mTOR-autophagy pathway plays a vital role in regulating endometrial function, with a blockade of the mTOR by rapamycin demonstrating the regulatory function on prostaglandin (PGs) secretion and cell attachment in EECs.	Sirolimus	138-147	serine/threonine-protein kinase mTOR	Capra hircus	130-134
29703175-6	2018	RESULTS: Gene and protein expression of tenascin-c and fibronectin of fibrotic fibroblasts were reduced by pirfenidone or rapamycin treatment.	Sirolimus	122-131	tenascin C	Homo sapiens	40-50
29444470-13	2018	In conclusion, sirolimus significantly improved hepatic inflammation and fibrosis accompanied by portal pressure reduction in cirrhotic rats, in which down-regulated mTOR/P70S6K and up-regulated eNOS expressions might play a role.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	166-170
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	CD8a molecule	Homo sapiens	58-61
29551338-19	2018	Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months.	Sirolimus	0-9	CD8a molecule	Homo sapiens	163-166
29619032-9	2018	Addition of rapamycin to CD28 superagonist-stimulated Treg led to a high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound TNFalpha.	Sirolimus	12-21	TNF receptor superfamily member 1B	Homo sapiens	87-92
29619032-9	2018	Addition of rapamycin to CD28 superagonist-stimulated Treg led to a high expression of TNFR2, the main TNFR expressed on Treg, and additional stimulation with a TNFR2 agonist enhanced the production of soluble as well as membrane-bound TNFalpha.	Sirolimus	12-21	TNF receptor superfamily member 1B	Homo sapiens	161-166
29540670-5	2018	Rapamycin, an mTOR inhibitor, restored myocardial apoptosis in the presence of beta1-AABs.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
29562463-0	2018	[Rapamycin affect the apoptosis of splenic CD4+CD25+ regulatory T cells of mouse severe aplastic anemia model].	Sirolimus	1-10	CD4 antigen	Mus musculus	43-46
29562463-0	2018	[Rapamycin affect the apoptosis of splenic CD4+CD25+ regulatory T cells of mouse severe aplastic anemia model].	Sirolimus	1-10	interleukin 2 receptor, alpha chain	Mus musculus	47-51
29562463-12	2018	On the contrary, RAPA-treated group exhibited CD4+ CD25+ Tregs with a reduction in apoptosis rate [(22.39+-3.71)%], Akt phosphorylation and Stat3 phosphorylation compared with the SAA group (P&lt;0.05, respectively).	Sirolimus	17-21	CD4 antigen	Mus musculus	46-49
29562463-12	2018	On the contrary, RAPA-treated group exhibited CD4+ CD25+ Tregs with a reduction in apoptosis rate [(22.39+-3.71)%], Akt phosphorylation and Stat3 phosphorylation compared with the SAA group (P&lt;0.05, respectively).	Sirolimus	17-21	interleukin 2 receptor, alpha chain	Mus musculus	51-55
29286127-7	2018	A transwell migration and invasion assays was also performed that demonstrated that autophagy activation by rapamycin enhanced TGF-beta2-stimulated RPE cell migration and invasion, and inhibition of autophagy reduced TGF-beta2-stimulated RPE cell migration and invasion.	Sirolimus	108-117	transforming growth factor beta 2	Homo sapiens	127-136
29472597-5	2018	During in vitro aging up to 12 h, upregulating autophagy with rapamycin or lithium chloride decreased activation susceptibility, cytoplasmic calcium, p62 contents, oxidative stress, caspase-3 activation and cytoplasmic fragmentation while increasing developmental competence, LC3-II contents, LC3-II/I ratio, mitochondrial membrane potential, spindle/chromosome integrity and normal cortical granule distribution.	Sirolimus	62-71	nucleoporin 62	Mus musculus	150-153
29472597-5	2018	During in vitro aging up to 12 h, upregulating autophagy with rapamycin or lithium chloride decreased activation susceptibility, cytoplasmic calcium, p62 contents, oxidative stress, caspase-3 activation and cytoplasmic fragmentation while increasing developmental competence, LC3-II contents, LC3-II/I ratio, mitochondrial membrane potential, spindle/chromosome integrity and normal cortical granule distribution.	Sirolimus	62-71	caspase 3	Mus musculus	182-191
29458386-10	2018	The median VEGF-D concentration decreased to 1609.4 pg/mL from 3075.6 pg/mL after sirolimus therapy (n = 41, p &lt; 0.001).	Sirolimus	82-91	vascular endothelial growth factor D	Homo sapiens	11-17
28812437-5	2017	We established a 3-dimensional collagen scaffold to examine the formation of VM and autophagy by GSCs, and found that rapamycin increased the number of VM and enhanced KDR/VEGFR-2 phosphorylation.	Sirolimus	118-127	kinase insert domain receptor	Homo sapiens	168-171
28812437-5	2017	We established a 3-dimensional collagen scaffold to examine the formation of VM and autophagy by GSCs, and found that rapamycin increased the number of VM and enhanced KDR/VEGFR-2 phosphorylation.	Sirolimus	118-127	kinase insert domain receptor	Homo sapiens	172-179
28685977-9	2017	The upregulation of Beclin-1 and PINK1 and the downregulation of caspase-3 and Cyt C extrapolate that rapamycin plays neuroprotective as well as anti-apoptotic role via interposition of both autophagy and mitophagy.	Sirolimus	102-111	PTEN induced kinase 1	Rattus norvegicus	33-38
28737825-0	2017	Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy/p62/Nrf2 pathway.	Sirolimus	15-24	nucleoporin 62	Mus musculus	173-176
28737825-6	2017	The rapamycin and SAMC combination activated antioxidant transcription expressions of Nrf2 and downstream gene NQO1.	Sirolimus	4-13	NAD(P)H dehydrogenase, quinone 1	Mus musculus	111-115
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	sequestosome 1	Homo sapiens	106-109
29152091-8	2017	The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1.	Sirolimus	19-28	sequestosome 1	Homo sapiens	110-116
28701309-10	2017	The abnormal SMC phenotype observed in the Arhgap18-/- mice can be partially rescued by pharmacological treatment with the mTORC1 inhibitor rapamycin, which reduces the synthetic and proinflammatory phenotype of Arhgap18-deficient SMC.	Sirolimus	140-149	Rho GTPase activating protein 18	Mus musculus	43-51
28701309-10	2017	The abnormal SMC phenotype observed in the Arhgap18-/- mice can be partially rescued by pharmacological treatment with the mTORC1 inhibitor rapamycin, which reduces the synthetic and proinflammatory phenotype of Arhgap18-deficient SMC.	Sirolimus	140-149	Rho GTPase activating protein 18	Mus musculus	212-220
29029388-3	2017	We discovered that the oncogenic miRNA, miR-21, is increased in Tsc2-deficient cells and, surprisingly, further increased by rapamycin.	Sirolimus	125-134	TSC complex subunit 2	Homo sapiens	64-68
29029388-6	2017	Tsc2-deficient cells" clonogenic and anchorage independent growth were reduced by ~50% (p&lt;0.01) and ~75% (p&lt;0.0001), respectively, and combined rapamycin treatment decreased soft agar growth by ~90% (p&lt;0.0001).	Sirolimus	150-159	TSC complex subunit 2	Homo sapiens	0-4
28810557-5	2017	Consequently, hyper phosphorylated Tau (pS199 or pS396) and upregulated mTOR activity were observed in SAMP8 when compared with SAMR1; however, 0.5 microM rapamycin administration significantly reduced the levels of phosphorylated Tau and p70S6K (pT389) in SAMP8 mice.	Sirolimus	155-164	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	239-245
27974549-11	2017	With the use of biologically relevant TSC2-mutant PDTXs, we demonstrated the therapeutic benefits of the hypersensitivity towards rapamycin treatment.	Sirolimus	130-139	TSC complex subunit 2	Homo sapiens	38-42
28665070-8	2017	In an ATP7A knock-out model, rapamycin treatment synergistically inhibited cell viability, wound healing, and invasion ability compared to rapamycin only.	Sirolimus	29-38	ATPase copper transporting alpha	Homo sapiens	6-11
28507054-8	2017	In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.	Sirolimus	13-22	solute carrier family 1 member 4	Homo sapiens	80-86
28507054-8	2017	In contrast, rapamycin was able to decrease the androgen-mediated expression of SLC1A4 and SLC1A5 independent of PTEN status, indicating that mTOR complex 1 (mTORC1) was needed for maximal AR-mediated glutamine uptake and prostate cancer cell growth.	Sirolimus	13-22	solute carrier family 1 member 5	Homo sapiens	91-97
28656223-0	2017	Rapamycin inhibits CaCl2-induced thoracic aortic aneurysm formation in rats through mTOR-mediated suppression of proinflammatory mediators.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	84-88
28656223-4	2017	Without pre-administering rapamycin, significantly enhanced phosphorylation of mTOR and expression of proinflammatory cytokines [i.e., tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and interleukin (IL)-1beta] were observed in the CaCl2-treated aortic segments 2 days post-treatment compared with the NaCl-treated segments.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Rattus norvegicus	79-83
29152062-3	2017	The combination of the PARP inhibitor olaparib and rapamycin synergistically inhibited cell proliferation in non-small cell lung cancer (NSCLC) cells, and even in triple negative breast cancer (TNBC) cells with BRCA1 mutations.	Sirolimus	51-60	BRCA1 DNA repair associated	Homo sapiens	211-216
28625574-6	2017	In half of the rats, an mTOR inhibitor, rapamycin was given for 2days before MCA occlusion.	Sirolimus	40-49	mechanistic target of rapamycin kinase	Rattus norvegicus	24-28
28365983-4	2017	An engineered domain inserted away from the active site responds to rapamycin to allosterically control activity of the PAK1 isoform.	Sirolimus	68-77	p21 (RAC1) activated kinase 1	Mus musculus	120-124
29444251-9	2018	The mTOR inhibitor, rapamycin, suppressed phosphorylation of mTOR (P &lt; 0.01) and rS6 (P &lt; 0.01) with an increase in phosphorylation of rS6 in leucine-treated cultures observed when compared to control cultures (P &lt; 0.05).	Sirolimus	20-29	mechanistic target of rapamycin kinase	Equus caballus	61-65
29439667-12	2018	Treatment of control siRNA glioma cells with rapamycin-induced autophagosome formation and increase in LC3-II level and caused a decrease in the expression of p62.	Sirolimus	45-54	nucleoporin 62	Homo sapiens	159-162
28488736-5	2018	p-p70S6K and Stra8 protein expressions decreased in post-natal testes after rapamycin treatment.	Sirolimus	76-85	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	2-8
29434788-7	2018	Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells.	Sirolimus	31-40	Cd4 molecule	Rattus norvegicus	177-180
29434788-7	2018	Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells.	Sirolimus	31-40	Cd4 molecule	Rattus norvegicus	189-192
29434788-7	2018	Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor gammat (RORgammat) level, increased FOXP3 level, reduced levels of CD4+IL-17+, CD4+ T and CD8+ T cells, and increased level of CD4+FOXP3+ cells.	Sirolimus	31-40	Cd4 molecule	Rattus norvegicus	189-192
29310109-15	2018	Moreover, long-term administration of sirolimus would up-regulate sCEACAM-1 level, while exert similar regulatory effects on Tim-3 and Gal-9 compared to tacrolimus.	Sirolimus	38-47	hepatitis A virus cellular receptor 2	Homo sapiens	125-130
29146131-3	2018	Although we have already confirmed that topical rapamycin treatment (an mTOR inhibitor) protects patients with TSC against macular hypopigmentation, the pathogenesis of such lesions remains poorly understood.	Sirolimus	48-57	TSC complex subunit 2	Homo sapiens	111-114
29146131-10	2018	Furthermore, depigmentation in TSC2-KD melanocytes was accelerated by inhibiting autophagy (ATG7-KD or bafilomycin A1-pretreatment) and was completely reversed by induction of autophagy via mTOR-dependent (rapamycin) or mTOR-independent (SMER28) exposure.	Sirolimus	206-215	TSC complex subunit 2	Homo sapiens	31-35
29445370-4	2017	Robustly expanded CD8+ Tregs displayed a specific gene signature, upregulated cytokines and expansion in the presence of rapamycin greatly improved proliferation and suppression.	Sirolimus	121-130	CD8a molecule	Homo sapiens	18-21
29339522-5	2018	Human skin TSC2+/- fibroblasts or LAM lung cells incubated short-term with isoproterenol (beta-agonist) showed a sirolimus-independent increase in phosphorylation of S6, a downstream effector of the mTOR pathway, and increased cell growth.	Sirolimus	113-122	TSC complex subunit 2	Homo sapiens	11-15
29176012-0	2018	Sirolimus therapy for congenital hyperinsulinism in an infant with a novel homozygous KCNJ11 mutation.	Sirolimus	0-9	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	86-92
29893708-1	2018	INTRODUCTION AND AIM: To investigate the effect of mTOR inhibitor Rapamycin combined with transcatheter arterial embolization (TAE) on the growth, metastasis, and prognosis of hepatocellular carcinoma (HCC) in rat model.	Sirolimus	66-75	mechanistic target of rapamycin kinase	Rattus norvegicus	51-55
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	84-94
29893708-6	2018	In addition, compared with rats in the Rapamycin + TAE group, N-cadherin, Vimentin, HIF-1alpha, VEGF, and MVD-CD34 were obviously enhanced, while E-cadherin was lowered in those TAE group, which were the complete opposite to the Rapamycin group.	Sirolimus	39-48	CD34 molecule	Rattus norvegicus	110-114
30257237-14	2018	The mTOR inhibitor rapamycin induced autophagy and decreased cardiomyocyte apoptosis, but the autophagy inhibitor 3-MA decreased autophagy and increased apoptosis at 3 h after exposure to hypoxia and H2O2.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
28808420-9	2017	Inhibition of mTOR with rapamycin ameliorated the damage and suppressed hyperglycemia-elevated p-MTOR, p-P70S6K and p-S6.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
28808420-9	2017	Inhibition of mTOR with rapamycin ameliorated the damage and suppressed hyperglycemia-elevated p-MTOR, p-P70S6K and p-S6.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	97-101
28903387-6	2017	Most importantly, rapamycin in combination with AG1295, a PDGFR inhibitor, significantly inhibited growth of TSC1/TSC2 complex-deficient cells in vitro and in vivo.	Sirolimus	18-27	TSC complex subunit 2	Homo sapiens	114-118
28672948-7	2017	In addition, EGCG had little effect on BMP-induced phosphorylation of p70 S6 kinase; however rapamycin, as an inhibitor of p70 S6 kinase, significantly suppressed osteoprotegerin release (P=0.007).	Sirolimus	93-102	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	163-178
28433555-5	2017	In contrast, sirolimus reduced the adhesion of leukocytes (CD45+) and bone marrow-derived progenitor cells (CD34+) to activated EC by down-regulating the adhesion molecules ICAM-1 and VCAM-1.	Sirolimus	13-22	intercellular adhesion molecule 1	Homo sapiens	173-179
28433555-6	2017	In addition, sirolimus treatment also significantly reduced the upregulation of ICAM-1 and VCAM-1 and the recruitment of monocytic cells (MOMA-2+) in neointimal lesions in vivo.	Sirolimus	13-22	intercellular adhesion molecule 1	Homo sapiens	80-86
28158917-7	2017	Further, to better understand the relationship between Notch signalling and autophagy in podocyte differentiation, rapamycin was added to enhance autophagy levels in DAPT-treated cells, and as a result, nephrin was recovered and DAPT-induced injury was ameliorated.	Sirolimus	115-124	nephrosis 1, nephrin	Mus musculus	203-210
28507282-10	2017	In addition, TP53 mutant cancer cells had elevation of RRM1 and RRM2, which was reduced by rapamycin.	Sirolimus	91-100	ribonucleotide reductase M2	Mus musculus	64-68
28533049-0	2018	Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.	Sirolimus	20-29	vascular endothelial growth factor D	Homo sapiens	39-75
28610619-7	2017	Activation of autophagic mechanisms with Rapamycin reduces the accumulation of p62 puncta in cells treated with patient conditioned medium.	Sirolimus	41-50	nucleoporin 62	Homo sapiens	79-82
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	mesoderm posterior 1	Mus musculus	104-109
28396518-6	2017	Additionally, rapamycin enhanced the expression of mesodermal and cardiac transcription factors such as Mesp1, Brachyury T, Eomes, Isl1, Gata4, Nkx2.5, Tbx5, and Mef2c.	Sirolimus	14-23	ISL1 transcription factor, LIM/homeodomain	Mus musculus	131-135
28396518-7	2017	Mechanistic studies showed that rapamycin inhibits Wnt/beta-catenin and Notch signaling but promotes the expression of fibroblast growth factor (Fgf8), Fgf10, and Nodal at early stage, and bone morphogenetic protein 2 (Bmp 2) at later stages.	Sirolimus	32-41	catenin (cadherin associated protein), beta 1	Mus musculus	55-67
28396518-7	2017	Mechanistic studies showed that rapamycin inhibits Wnt/beta-catenin and Notch signaling but promotes the expression of fibroblast growth factor (Fgf8), Fgf10, and Nodal at early stage, and bone morphogenetic protein 2 (Bmp 2) at later stages.	Sirolimus	32-41	fibroblast growth factor 8	Mus musculus	145-149
28396518-7	2017	Mechanistic studies showed that rapamycin inhibits Wnt/beta-catenin and Notch signaling but promotes the expression of fibroblast growth factor (Fgf8), Fgf10, and Nodal at early stage, and bone morphogenetic protein 2 (Bmp 2) at later stages.	Sirolimus	32-41	fibroblast growth factor 10	Mus musculus	152-157
28450107-6	2017	Co-immunoprecipitation (CoIP) demonstrated that LC3 co-immunoprecipitated with Smad3 and western blot showed that autophagy inducers, Rapamycin and Trehalose, could decrease the phosphorylation level of Smad3.	Sirolimus	134-143	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	48-51
28371119-5	2017	In wild-type (WT) mouse fibroblasts, rapamycin increased the levels of Nrf2, and this correlates with the activation of autophagy and a reduction in the induction of cell senescence, as measured by SA-beta-galactosidase (beta-gal) staining, senescence-associated secretory phenotype (SASP), and p16 and p21 molecular markers.	Sirolimus	37-46	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	303-306
28238805-7	2017	Interestingly, the LSD1 inhibitor, RN-1, and the mitophagy-inducing agent mammalian target of rapamycin (mTOR) inhibitor, sirolimus, increased RBC lifespan and reduced ROS accumulation in parallel with reducing mitochondria-retaining RBCs in the SCD mouse model.	Sirolimus	122-131	lysine demethylase 1A	Homo sapiens	19-23
28330873-11	2017	Rapamycin treatment increased FoxO3 activity as well as LC3 and ULK1 expressions in macrophages from AMPKalpha1-/- mice.	Sirolimus	0-9	forkhead box O3	Mus musculus	30-35
28469076-7	2017	Topical hydrocortisone, rapamycin, or Stat3 inhibitor XVIII prevents autoantibody-induced blistering in the PV passive transfer mouse model, correlating with increased epidermal DSG3 expression and decreased phospho-S727 Stat3.	Sirolimus	24-33	desmoglein 3	Mus musculus	178-182
28214587-9	2017	The inhibitory effect of PAQR3 knockdown on autophagy is abrogated by rapamycin treatment, indicating that PAQR3 modulates autophagy via its regulation on mTORC1 signaling.	Sirolimus	70-79	progestin and adipoQ receptor family member 3	Homo sapiens	25-30
28214587-9	2017	The inhibitory effect of PAQR3 knockdown on autophagy is abrogated by rapamycin treatment, indicating that PAQR3 modulates autophagy via its regulation on mTORC1 signaling.	Sirolimus	70-79	progestin and adipoQ receptor family member 3	Homo sapiens	107-112
28350133-7	2017	Furthermore, the level of p62 decreased when autophagy was induced by rapamycin, and increased when autophagy was inhibited by chloroquine (CQ), which indicated that LSS may serve an important role in inducing autophagy flux.	Sirolimus	70-79	nucleoporin 62	Homo sapiens	26-29
28729914-5	2017	Blocking mTOR using rapamycin attenuated upregulation of pro-inflammatory cytokines (namely IL-1beta, IL-6 and TNF-alpha), and Caspase-3, indicating cell apoptosis and also promoting the levels of vascular endothelial growth factor (VEGF) and its subtype receptor VEGFR-2 in the hippocampus.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
28199961-1	2017	We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	72-103
28199961-1	2017	We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	105-109
28533049-1	2018	BACKGROUND: Sirolimus reduces serum levels of vascular endothelial growth factor D (VEGF-D); the size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas; and stabilizes lung function in patients with lymphangioleiomyomatosis (LAM).	Sirolimus	12-21	vascular endothelial growth factor D	Homo sapiens	46-82
28533049-1	2018	BACKGROUND: Sirolimus reduces serum levels of vascular endothelial growth factor D (VEGF-D); the size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas; and stabilizes lung function in patients with lymphangioleiomyomatosis (LAM).	Sirolimus	12-21	vascular endothelial growth factor D	Homo sapiens	84-90
28533049-3	2018	RESULTS: Treatment with sirolimus stabilized FEV1 and diffusion capacity for carbon monoxide (Dlco) over a period of 4.5 +- 1.6 years, caused resolution of lymphatic disease, and reduced the size of angiomyolipomas and VEGF-D levels (3,720 +- 3,020 pg/mL to 945 +- 591 pg/mL; P &lt; .0001).	Sirolimus	24-33	vascular endothelial growth factor D	Homo sapiens	219-225
28533049-5	2018	Lower VEGF-D levels correlated with sirolimus therapy (P &lt; .001), but no significant relationship was observed between reduction in VEGF-D levels and FEV1 and Dlco during sirolimus therapy.	Sirolimus	36-45	vascular endothelial growth factor D	Homo sapiens	6-12
28533049-8	2018	CONCLUSIONS: Sirolimus therapy stabilizes lung function over many years of therapy while producing a sustained reduction in VEGF-D levels in patients with elevated levels preceding therapy.	Sirolimus	13-22	vascular endothelial growth factor D	Homo sapiens	124-130
29282029-10	2017	However, addition of rapamycin, an inhibitor of the mTOR signaling pathways, 1 h before addition of estradiol or insulin increased the pAkt/Akt ratio and FASN expression, and this effect was inhibited by addition of DHA 48 h before rapamycin.	Sirolimus	21-30	fatty acid synthase	Homo sapiens	154-158
28855451-0	2017	Impact of Dual Antiplatelet Therapy Beyond 1 Year on Clinical Outcomes of Patients With Stent Fracture or Peri-Stent Contrast Staining After Sirolimus-Eluting Stent Implantation.	Sirolimus	141-150	perilipin 1	Homo sapiens	106-110
28229367-0	2017	Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
28229367-0	2017	Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.	Sirolimus	30-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-64
28229367-8	2017	Rapamycin showed an inhibitory effect on P-S6 and P-gp expression 1 week after treatment in rats.	Sirolimus	0-9	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	50-54
28229367-12	2017	Inhibition of the mTOR pathway by rapamycin may be a potential therapeutic approach for pharmacoresistant epilepsy.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Rattus norvegicus	18-22
28333137-5	2017	MDSCs, especially CD11b+Ly6G+Ly6Clow G-MDSCs were recruited to the injured kidney following the interaction of CXCL1, CXCL2 and their receptor CXCR2 after inhibiting mTOR signal with rapamycin treatment.	Sirolimus	183-192	chemokine (C-X-C motif) receptor 2	Mus musculus	143-148
28333137-11	2017	Accordingly, both G-MDSCs and M-MDSCs presented downregulated runx1 gene expression after rapamycin treatment.	Sirolimus	90-99	runt related transcription factor 1	Mus musculus	62-67
28301940-4	2017	To test the strategy, we created chimeric proteins that generate Ca2+ signals upon stimulation with various extracellular stimuli (e.g., rapamycin, EDTA or extracellular free Ca2+).	Sirolimus	137-146	carbonic anhydrase 2	Homo sapiens	65-68
28855451-1	2017	BACKGROUND: Stent fracture (SF) and peri-stent contrast staining (PSS) after sirolimus-eluting stent (SES) implantation are considered to be related to very late stent thrombosis (VLST).	Sirolimus	77-86	perilipin 1	Homo sapiens	36-40
29233105-12	2017	Treatment with rapamycin or salidroside reversed hypoxia-induced PASMC proliferation and apoptosis resistance and further increased autophagy flux, autophagosome levels and the LC3II/LC3I ratio but decreased p62 expression.	Sirolimus	15-24	nucleoporin 62	Homo sapiens	208-211
28560583-2	2017	This study investigates the specificity and pharmacokinetics of 111In-bevacizumab binding to VEGF and its use for assessing response to anti-angiogenic therapy with rapamycin.	Sirolimus	165-174	vascular endothelial growth factor A	Mus musculus	93-97
27737727-10	2017	Furthermore, we found that mTOR/S6K signaling was required for chondrogenic differentiation of MSCs in chitosan film culture through rapamycin treatment and mTOR knockdown.	Sirolimus	133-142	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	27-35
28027414-7	2017	Upstream of p62, we found that BDNF triggered phosphorylation of mammalian target of rapamycin (mTOR) and its downstream mediator p70S6K; importantly, the mTOR inhibitor rapamycin reduced both BDNF-dependent p62 induction as well as 3-NP resistance.	Sirolimus	85-94	nucleoporin 62	Homo sapiens	12-15
28027414-7	2017	Upstream of p62, we found that BDNF triggered phosphorylation of mammalian target of rapamycin (mTOR) and its downstream mediator p70S6K; importantly, the mTOR inhibitor rapamycin reduced both BDNF-dependent p62 induction as well as 3-NP resistance.	Sirolimus	85-94	brain derived neurotrophic factor	Homo sapiens	31-35
28027414-7	2017	Upstream of p62, we found that BDNF triggered phosphorylation of mammalian target of rapamycin (mTOR) and its downstream mediator p70S6K; importantly, the mTOR inhibitor rapamycin reduced both BDNF-dependent p62 induction as well as 3-NP resistance.	Sirolimus	85-94	brain derived neurotrophic factor	Homo sapiens	193-197
28108221-10	2017	Rapamycin, a specific mTOR inhibitor, counteracted the Resv-induced cell enlargement (both cell diameter and area).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	22-26
27974437-2	2017	To gain information about potential partners of Arl1 and Ypt6 specifically in autophagy, we carried out a high copy number suppressor screen to identify genes that when overexpressed suppress the rapamycin sensitivity phenotype of arl1Delta and ypt6Delta strains at 37 .	Sirolimus	196-205	Rab family GTPase YPT6	Saccharomyces cerevisiae S288C	57-61
27909227-6	2017	In fasted mice, neither basal nor stimulated rates of protein synthesis were affected by castration despite lower phosphorylation of mechanistic target of rapamycin in complex 1 (mTORC1) substrates [p70S6K1 (Thr389) and 4E-BP1 (Ser65)].	Sirolimus	155-164	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	199-206
28094770-4	2017	In purified rCD4s from HIV-1-infected individuals on antiretroviral therapy, rapamycin treatment downregulated markers of toxicity, including proinflammatory cytokine release and cellular proliferation that were induced after potent T cell activation using alphaCD3/alphaCD28 antibodies.	Sirolimus	77-86	Cd4 molecule	Rattus norvegicus	12-16
28356986-9	2017	However, this hypoxia-induced increase in HIF-1alpha and CD44 protein and mRNA expression levels was inhibited by rapamycin.	Sirolimus	114-123	CD44 molecule (Indian blood group)	Homo sapiens	57-61
27974559-4	2017	In contrast, the number of memory CD4 T cells was increased in rapamycin-treated mice.	Sirolimus	63-72	CD4 antigen	Mus musculus	34-37
27279283-7	2017	The rapamycin treatment suppressed phosphorylated-p70S6K in the injured spinal cord that indicated inhibition of mTOR.	Sirolimus	4-13	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	50-56
28427080-1	2017	Backgroud/Aims: The aim of this study was to investigate the potential renoprotective effect of rapamycin on the autophagy of podocytes treated with the supernatant of mesangial cells cultured with aggregated IgA1 (aIgA1) from immunoglobulin A nephropathy (IgAN) patients.	Sirolimus	96-105	immunoglobulin heavy constant alpha 1	Homo sapiens	209-213
28560583-11	2017	CONCLUSIONS: 111In-bevacizumab accumulates specifically in VEGF-expressing tumours, and changes after rapamycin therapy reflect changes in VEGF expression.	Sirolimus	102-111	vascular endothelial growth factor A	Mus musculus	139-143
28965784-3	2017	Here, we discover a novel pathway of Jen1p endocytosis mediated by the alpha-arrestin Bul1p in response to the presence of cycloheximide or rapamycin, or prolonged growth in lactate.	Sirolimus	140-149	ubiquitin-ubiquitin ligase BUL1	Saccharomyces cerevisiae S288C	86-91
29358849-8	2017	In addition, overexpression of Mfn2 downregulated phorbol myristate acetate (PMA)/ionomycin-, rapamycin- and starvation-induced autophagy in Jurkat T cells.	Sirolimus	94-103	mitofusin 2	Homo sapiens	31-35
28864813-4	2017	Sequestration of FKBP12 by rapamycin or tacrolimus activates hepcidin both in vitro and in murine hepatocytes.	Sirolimus	27-36	hepcidin antimicrobial peptide	Mus musculus	61-69
28373901-11	2017	Rapamycin also attenuated Bax and increased Bcl-2/Bax ratio.	Sirolimus	0-9	BCL2-associated X protein	Mus musculus	26-29
28373901-11	2017	Rapamycin also attenuated Bax and increased Bcl-2/Bax ratio.	Sirolimus	0-9	BCL2-associated X protein	Mus musculus	50-53
31966350-0	2017	Anti-angiogenic effect of rapamycin in mouse oxygen-induced retinopathy is mediated through suppression of HIF-1alpha/VEGF pathway.	Sirolimus	26-35	vascular endothelial growth factor A	Mus musculus	118-122
27534900-4	2017	When autophagy was induced by rapamycin or inhibited by bafilomycin A1 in fetal liver cells, we observed a significant decrease in high ploidy megakaryocytes, a reduction of CD41 and CD61 co-expressing cells, and less proplatelet or platelet formation.	Sirolimus	30-39	integrin beta 3	Mus musculus	183-187
31966350-9	2017	RAPA inhibited HUVECs proliferation and retinal neovascularization by reducing protein and mRNA expressions of HIF-1alpha and VEGF.	Sirolimus	0-4	vascular endothelial growth factor A	Mus musculus	126-130
28123835-6	2016	Blocking mTOR by using rapamycin selectively enhanced activities of IL-6 and TNF-alpha signaling pathways, which was accompanied with an increase of Caspase-3, indicating cellular apoptosis and worsened learning performance.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
27371338-2	2016	Rapamycin inhibits mTOR activity, thereby preventing the phosphorylation of ribosomal protein S6, which is a downstream target of S6 kinase.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
27371338-2	2016	Rapamycin inhibits mTOR activity, thereby preventing the phosphorylation of ribosomal protein S6, which is a downstream target of S6 kinase.	Sirolimus	0-9	ribosomal protein S6	Rattus norvegicus	76-96
27933890-1	2016	Recent studies indicate that LRS may act as a leucine sensor for the mTORC1 pathway, potentially providing an alternative strategy to overcome rapamycin resistance in cancer treatments.	Sirolimus	143-152	leucyl-tRNA synthetase 1	Homo sapiens	29-32
31966350-10	2017	RAPA suppresses hypoxia-induced HUVECs cell proliferation and pathological ocular angiogenesis through a mechanism linked to the targeting of HIF-1alpha/VEGF signaling.	Sirolimus	0-4	vascular endothelial growth factor A	Mus musculus	153-157
27785978-1	2016	AIM: This work spotlights on fabrication of CD44-tropic, layer-by-layer (LbL) coated, liquid crystalline nanoparticles of rapamycin (Rap-LbL-LCNPs) to enhance its water solubility and enable its anticancer use.	Sirolimus	122-131	CD44 molecule (Indian blood group)	Homo sapiens	44-48
28765938-6	2017	Immunohistochemistry of mechanistic target of rapamycin (mTOR) and Ki67 in testes tissue, and western blotting of phosphorylated-p70S6K and p70S6K, supported the hypothesis that rapamycin causes sperm reduction through inhibiting proliferation of spermatogonia.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Rattus norvegicus	57-61
28993730-8	2017	However, targeting the altered biological pathways (mTOR, PDGFRB, FGF2, HDAC) guided identification of possibly beneficial treatment with a combination of sirolimus, thalidomide, sunitinib, and vorinostat.	Sirolimus	155-164	histone deacetylase 9	Homo sapiens	72-76
29113329-5	2017	Furthermore, autophagy stabilization by 3-methyladenine or rapamycin partially suppressed the effects of altered Bmal1 expression on cardiomyocyte survival.	Sirolimus	59-68	aryl hydrocarbon receptor nuclear translocator-like	Rattus norvegicus	113-118
28637240-1	2017	Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in either of two genes, TSC1 or TSC2, resulting in the constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	201-210	TSC complex subunit 2	Homo sapiens	127-131
28667702-4	2017	Hamartin-Tuberin complex is involved in the phosphoinositide 3-kinase-protein kinase B-mammalian target of rapamycin signal transduction pathway, and suppresses mammalian target of rapamycin complex 1 activity, which is a center for various functions.	Sirolimus	107-116	TSC complex subunit 2	Homo sapiens	9-16
28701348-5	2017	Persistent induction of DNA double-strand breaks or mTORC1 inhibition by rapamycin results in reduced levels of HMO1 mRNA, but only in the presence of Tor1p.	Sirolimus	73-82	Hmo1p	Saccharomyces cerevisiae S288C	112-116
28701348-5	2017	Persistent induction of DNA double-strand breaks or mTORC1 inhibition by rapamycin results in reduced levels of HMO1 mRNA, but only in the presence of Tor1p.	Sirolimus	73-82	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	151-156
28765952-9	2017	Rapamycin, an mTOR inhibitor, suppressed the expression and activity of mTOR and p70S6K, however enhanced expression of SIRT1, LXRalpha, and CCR7.	Sirolimus	0-9	sirtuin 1	Homo sapiens	120-125
28607148-8	2017	Rapamycin treatment reduced inflammatory lesions formed in the ears of Leishmania-infected C57BL/6 and Tlr3/7/9-/- mice, indicating that autophagy operates downstream of TLR signaling and is relevant for disease development in vivo Collectively, our results indicate that autophagy contributes to macrophage resistance to L. major replication, and mechanistically explain the previously described endosomal TLR-mediated resistance to L. major infection.	Sirolimus	0-9	toll-like receptor 9	Mus musculus	103-111
28801605-7	2017	Furthermore, we found that pretreatment with the mTOR inhibitor, rapamycin, significantly reduced the expression of the pro-apoptotic protein Bax.	Sirolimus	65-74	mechanistic target of rapamycin kinase	Rattus norvegicus	49-53
28550180-10	2017	Our study suggests the K475E mutation induces alteration in basal AMPK activity and results in a hypertrophy phenotype involving the mechanistic target of rapamycin signaling pathway, which can be reversed with rapamycin.NEW &amp; NOTEWORTHY We identified a novel, de novo PRKAG2 mutation (K475E) in the cystathionine beta-synthase 3 repeat, a region critical for AMP binding but with no previous reported mutation.	Sirolimus	155-164	protein kinase AMP-activated non-catalytic subunit gamma 2	Homo sapiens	273-279
28167236-5	2017	We have found that rapamycin activates the Nrf2 pathway to regulate cell cycle arrest, but not the production of SASP, which is regulated by a different pathway, probably involving the inhibition of MAPKAPK2.	Sirolimus	19-28	MAPK activated protein kinase 2	Homo sapiens	199-207
28475806-0	2017	Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	90-94
28475806-9	2017	CONCLUSIONS: Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the CA-JV shunt-induced PAH model in rats.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Rattus norvegicus	103-107
28244683-0	2017	Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.	Sirolimus	0-9	proliferating cell nuclear antigen	Mus musculus	137-143
28244683-5	2017	High-dose rapamycin significantly increased the lifespan, lowered the cystic index and kidney/body weight ratio and improved renal function in Vil-Cre;Pkd2f3/f3 mice in a time- and dose-dependent manner.	Sirolimus	10-19	villin 1	Mus musculus	143-146
28634253-14	2017	TNF-alpha-mediated induction of cleaved caspase-3 was downregulated by rapamycin, but upregulated by 3-MA, respectively.	Sirolimus	71-80	caspase 3	Mus musculus	40-49
28656223-7	2017	Further in vitro cell culture experiments using aortic smooth muscle cell (SMC) suggested that the inhibition of the mTOR signaling pathway by rapamycin could promote the differentiation of SMCs, as reflected by the reduced expression of S100A4 and osteopontin.	Sirolimus	143-152	mechanistic target of rapamycin kinase	Rattus norvegicus	117-121
28656223-7	2017	Further in vitro cell culture experiments using aortic smooth muscle cell (SMC) suggested that the inhibition of the mTOR signaling pathway by rapamycin could promote the differentiation of SMCs, as reflected by the reduced expression of S100A4 and osteopontin.	Sirolimus	143-152	S100 calcium-binding protein A4	Rattus norvegicus	238-244
28656223-8	2017	The present study indicated that the early enhanced mTOR signaling pathway in the TAA development and mTOR inhibitor rapamycin may inhibit CaCl2-induced TAA formation.	Sirolimus	117-126	mechanistic target of rapamycin kinase	Rattus norvegicus	102-106
28716920-7	2017	Systemic inhibition of VAMP3 and SNAP23 by rapamycin or periadventitial application of the endocytosis inhibitor dynasore ameliorates the disturbed flow-induced neointimal formation, whereas intraluminal overexpression of SNAP23 aggravates it.	Sirolimus	43-52	synaptosome associated protein 23	Homo sapiens	33-39
27558119-0	2017	Nine-year follow-up of progressive peri-stent contrast staining after Cypher sirolimus-eluting stent implantation: a case report.	Sirolimus	77-86	LIM domain binding 3	Homo sapiens	70-76
27558119-1	2017	A 62-year-old male underwent three percutaneous coronary interventions involving four bare metal stents and six Cypher sirolimus-eluting stents within 1 month.	Sirolimus	119-128	LIM domain binding 3	Homo sapiens	112-118
27714857-5	2017	However, rapamycin, a representative non-selective autophagy inducer, triggered autophagy in alpha-MSH-stimulated cells, which was characterized by a considerable decrease in p62, but it was unable to inhibit melanogenesis.	Sirolimus	9-18	nucleoporin 62	Homo sapiens	175-178
27665945-9	2016	Iotat was demonstrated that the combination is more efficient than the single use of substances, because subtherapeutic doses of rapamycin, when associated to FBP become effective, reducing cell proliferation, through a significant increase in the production of tiobarbituric acid reactive substances (TBARS), suggesting that this might be the cause of death by apoptosis.	Sirolimus	129-138	fructose-bisphosphatase 1	Homo sapiens	159-162
27569211-5	2016	IFNgamma signals were required in both hematopoietic and nonhematopoietic cells for rapamycin to optimally promote epidermal infiltration of gammadelta TCRmid T cells, as mediated by CXCR3-CXCL10 interactions, along with the antitumor effects of these cells.	Sirolimus	84-93	C-X-C motif chemokine ligand 10	Homo sapiens	189-195
27616194-5	2016	Rapamycin was found to inhibit the proliferation of Huh7 cells but not of HepG2 cells.	Sirolimus	0-9	MIR7-3 host gene	Homo sapiens	52-56
28904691-0	2017	IL-21 Augments Rapamycin in Expansion of Alpha Fetoprotein Antigen Specific Stem-Cell-like Memory T Cells in vitro.	Sirolimus	15-24	interleukin 21	Homo sapiens	0-5
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	38-47	MIR7-3 host gene	Homo sapiens	79-83
27616194-11	2016	Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells.	Sirolimus	279-288	MIR7-3 host gene	Homo sapiens	79-83
27466155-4	2016	In this study we showed that rapamycin treatment on RSV-infected murine bone marrow-derived DC (BMDC) decreases the frequency of CD8(+)CD44(high) T cells.	Sirolimus	29-38	CD8a molecule	Homo sapiens	129-132
28646232-2	2017	TS pathology is caused by mutations in tuberous sclerosis complex (TSC) genes and is associated with insulin resistance, decreased glycogen synthase kinase 3beta (GSK3beta) activity, activation of the mammalian target of rapamycin complex 1 (mTORC1), and subsequent increase in protein synthesis.	Sirolimus	221-230	TSC complex subunit 2	Homo sapiens	67-70
27310765-6	2016	While feeding the whitefly with 2 autophagy inhibitors (3-methyladenine and bafilomycin A1) and silencing the expression of Atg3 and Atg9 increased the viral load; autophagy activation via feeding of rapamycin notably decreased the amount of viral CP and DNA in the whitefly.	Sirolimus	200-209	autophagy related 3	Homo sapiens	124-128
27258186-3	2016	The results showed that the percentages of both CD19+CD24+CD38+TGF-beta1+ Bregs and CD19+CD24+CD38+IL-10+ Bregs to B cells were elevated by Sirolimus in PBMCs including B cells.	Sirolimus	140-149	interleukin 10	Homo sapiens	99-104
27258186-4	2016	Sirolimus significantly enhances the cytokine production of transforming growth factor-beta1 (TGF-beta1) and interleukin-10 (IL-10) in PBMCs with B cells, and the enhancement significantly decreased in PBMCs without B cells.	Sirolimus	0-9	interleukin 10	Homo sapiens	109-123
27258186-4	2016	Sirolimus significantly enhances the cytokine production of transforming growth factor-beta1 (TGF-beta1) and interleukin-10 (IL-10) in PBMCs with B cells, and the enhancement significantly decreased in PBMCs without B cells.	Sirolimus	0-9	interleukin 10	Homo sapiens	125-130
27258186-7	2016	The amplification of Tregs by Sirolimus was partially inhibited when either TGF-beta1 or IL-10 was neutralized, and it even disappeared when these two cytokines were both neutralized.	Sirolimus	30-39	interleukin 10	Homo sapiens	89-94
28489580-6	2017	Therefore, our results suggest that rapamycin negatively regulates macrophage activation by restricting a feedback loop of NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62/SQSTM1-dependent manners.	Sirolimus	36-45	sequestosome 1	Homo sapiens	187-190
28489580-6	2017	Therefore, our results suggest that rapamycin negatively regulates macrophage activation by restricting a feedback loop of NLRP3 inflammasome-p38 MAPK-NFkappaB pathways in autophagy- and p62/SQSTM1-dependent manners.	Sirolimus	36-45	sequestosome 1	Homo sapiens	191-197
29906075-3	2016	Herein we report the diagnostic and differential diagnostic value of serum VEGF-D in LAM patients and evaluate the change of serum VEGF-D levels before and after treatment with sirolimus.	Sirolimus	177-186	vascular endothelial growth factor D	Homo sapiens	131-137
28575052-8	2017	Treatment of hiPSC precursors with autophagy stimulators Rapamycin, Perifosine, or AT101 showed reduction in VCP pathology markers TDP-43, LC3-I/II and p62/SQSTM1.	Sirolimus	57-66	sequestosome 1	Homo sapiens	152-155
29906075-13	2016	Following a median of 12-month treatment with sirolimus, serum VEGF-D levels decreased from 3135.0+-909.4 pg/ml to 1731.8+-621.2 pg/ml and symptoms improved.	Sirolimus	46-55	vascular endothelial growth factor D	Homo sapiens	63-69
29906075-15	2016	Serum VEGF-D levels may be useful for diagnosis and differential diagnosis with high specificity and sensitivity as well as for following treatment response with sirolimus.	Sirolimus	162-171	vascular endothelial growth factor D	Homo sapiens	6-12
26374551-7	2016	However, much lower levels of phospho-mTOR, phospho-p70S6K, and AChE expression occurred in both brain regions of diabetic rats treated with rapamycin when compared with untreated ones.	Sirolimus	141-150	mechanistic target of rapamycin kinase	Rattus norvegicus	38-42
28575052-8	2017	Treatment of hiPSC precursors with autophagy stimulators Rapamycin, Perifosine, or AT101 showed reduction in VCP pathology markers TDP-43, LC3-I/II and p62/SQSTM1.	Sirolimus	57-66	sequestosome 1	Homo sapiens	156-162
28570161-11	2017	All patients who were taking sirolimus had a reduction in VEGF-D levels from baseline to the last visit, compared with only half of the patients who were not taking sirolimus.	Sirolimus	29-38	vascular endothelial growth factor D	Homo sapiens	58-64
27915965-7	2017	The mammalian target of rapamycin inhibitors everolimus and sirolimus are preferred due to their complementary mechanisms of action and favorable nephrotoxicity profile, which have opened the way for calcineurin inhibitor reduction/withdrawal in the early posttransplant period.	Sirolimus	60-69	calcineurin binding protein 1	Homo sapiens	200-221
28583549-6	2017	Glomerular mRNA expression profiling showed down-regulations of podocyte-related genes (Wilms tumor 1, synaptopodin, nephrin, CD2-associated protein, and podocin) and of transforming growth factor-beta (a marker of fibrosis) in sirolimus-treated mice.	Sirolimus	228-237	CD2-associated protein	Mus musculus	126-201
27343825-6	2016	Rapamycin treatment suppressed the effect of VPA on mTOR signaling and ameliorated the autistic-like behaviors of rats in our autism model.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
27610411-4	2016	Immunoprecipitation and immunofluorescence experiments confirmed that endogenous FKBP25 has a rapamycin-induced physical interaction with the FRB domain.	Sirolimus	94-103	FKBP prolyl isomerase 3	Homo sapiens	81-87
28404768-5	2017	AAV9 (adeno-associated virus 9)-mediated cardiac DJ-1 overexpression as well as pretreatment with the autophagy inducer rapamycin restored IPO-induced cardioprotection in diabetic rats, an effect accompanied by AMPK/mTOR activation and autophagy up-regulation.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Rattus norvegicus	216-220
28086065-11	2017	In addition, rapamycin suppressed cell apoptosis, and decreased Bax/Bcl-2 ratio and cleaved caspase-3 expression.	Sirolimus	13-22	BCL2-associated X protein	Mus musculus	64-67
28496990-6	2017	Inhibition of mTORC1 by rapamycin reduces T-cell expression of KIF13A and cell-surface M6PR, and increases T-cell survival in Listeria monocytogenes-infected mice.	Sirolimus	24-33	kinesin family member 13A	Mus musculus	63-69
28496990-6	2017	Inhibition of mTORC1 by rapamycin reduces T-cell expression of KIF13A and cell-surface M6PR, and increases T-cell survival in Listeria monocytogenes-infected mice.	Sirolimus	24-33	mannose-6-phosphate receptor, cation dependent	Mus musculus	87-91
28067204-0	2017	CD9 monoclonal antibody-conjugated PEGylated liposomes for targeted delivery of rapamycin in the treatment of cellular senescence.	Sirolimus	80-89	CD9 molecule	Homo sapiens	0-3
27423593-6	2016	Rapamycin and AZD8055 were also used to demonstrate the mTOR"s role on microglial polarization in vitro.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	56-60
27423593-8	2016	Rapamycin or AZD8055 markedly decreased the phosphorylation levels of mTOR and its substrates and the activation of microglia in vivo, and promoted the microglial polarization from M1 phenotype to M2 phenotype.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	70-74
27423593-10	2016	Our findings suggested that the rapamycin and AZD8055 could attenuate the development of EBI in this SAH model, possibly through inhibiting the activation of microglia by mTOR pathway.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Rattus norvegicus	171-175
27795990-1	2016	BACKGROUND: Due to lack of treatment options for early acute allograft dysfunction in the presence of tubular-interstitial injury without histological features of rejection, kidney transplant recipients are often treated with sirolimus-based therapy to prevent cumulative calcineurin inhibitor exposure and to prevent premature graft failure.	Sirolimus	226-235	calcineurin binding protein 1	Homo sapiens	272-293
27235551-9	2016	This effect could be reversed by rapamycin, an inhibitor of mTOR.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Rattus norvegicus	60-64
27935584-8	2017	Moreover, we showed that either knockdown of mTOR or inhibition of mTORC1 with rapamycin increases the expression of HMGCS2 in intestinal cells in vitro and in vivo, suggesting a possible cross-talk between mTOR and HMGCS2/betaHB signaling in intestinal cells.	Sirolimus	79-88	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2	Mus musculus	117-123
27935584-8	2017	Moreover, we showed that either knockdown of mTOR or inhibition of mTORC1 with rapamycin increases the expression of HMGCS2 in intestinal cells in vitro and in vivo, suggesting a possible cross-talk between mTOR and HMGCS2/betaHB signaling in intestinal cells.	Sirolimus	79-88	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2	Mus musculus	216-222
28027414-10	2017	In addition to suppressing p62 induction, rapamycin also partially suppressed BDNF-induced c-Jun expression, but c-Jun knockdown failed to affect mTOR activation.	Sirolimus	42-51	brain-derived neurotrophic factor	Rattus norvegicus	78-82
28367235-7	2017	Furthermore, MK-2206 increased the cytotoxicity of rapamycin in Tsc1-/- or Tsc2-/- MEFs.	Sirolimus	51-60	TSC complex subunit 2	Homo sapiens	75-79
28011640-8	2017	Consistent with an anti-apoptotic effect of autophagy, rapamycin-induced apoptosis and cytotoxicity were blocked in STAT1-deficient cells but restored in cells simultaneously exposed to the autophagy inhibitor ammonium chloride.	Sirolimus	55-64	signal transducer and activator of transcription 1	Homo sapiens	116-121
27725200-0	2017	Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates.	Sirolimus	95-104	intercellular adhesion molecule 1	Homo sapiens	63-69
27315465-0	2016	Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance.	Sirolimus	0-9	chemokine (C-C motif) ligand 4	Mus musculus	22-26
27315465-2	2016	The aim of the present study was to investigate the effect of rapamycin on immune responses in a carbon tetrachloride (CCl4)-induced murine liver fibrosis model.	Sirolimus	62-71	chemokine (C-C motif) ligand 4	Mus musculus	119-123
27315465-11	2016	Consequently, rapamycin treatment prevented the development of CCl4-induced hepatic fibrosis, which was shown by its histological appearances.	Sirolimus	14-23	chemokine (C-C motif) ligand 4	Mus musculus	63-67
27163719-7	2016	Moreover, the lost cell polarity labeled by F-actin and the absenced beta-catenin in RAPA-treated and 3-MA-treated cell membrane implied intracellular cytoskeleton alteration was induced by the activation and depression of autophagy.	Sirolimus	85-89	catenin beta 1	Gallus gallus	69-81
26526985-3	2016	It is associated with the mutation of two genes: TSC1 (hamartin) and TSC2 (tuberin), with the change in the functionality of the complex target of rapamycin (mTOR).	Sirolimus	147-156	TSC complex subunit 2	Homo sapiens	69-73
26526985-3	2016	It is associated with the mutation of two genes: TSC1 (hamartin) and TSC2 (tuberin), with the change in the functionality of the complex target of rapamycin (mTOR).	Sirolimus	147-156	TSC complex subunit 2	Homo sapiens	75-82
26975583-8	2016	Here, we show that inhibition of AMPK by compound C or by shRNA-mediated depletion of LKB1 reduces activation of autophagy by rapamycin in Tsc2-null cells.	Sirolimus	126-135	TSC complex subunit 2	Homo sapiens	139-143
26975583-11	2016	Finally, we show that p27-dependent activation of autophagy is involved in Tsc2-null cell survival under rapamycin treatment.	Sirolimus	105-114	TSC complex subunit 2	Homo sapiens	75-79
27253629-7	2016	To confirm nutrient regulation by rapamycin treatment, we checked the transcript levels of nutrient transporter genes (SLC2A2, SLC2A4, SLC6A14, and SLC7A1).	Sirolimus	34-43	solute carrier family 2 member 2	Homo sapiens	119-125
27253629-7	2016	To confirm nutrient regulation by rapamycin treatment, we checked the transcript levels of nutrient transporter genes (SLC2A2, SLC2A4, SLC6A14, and SLC7A1).	Sirolimus	34-43	solute carrier family 6 member 14	Homo sapiens	135-142
27253629-7	2016	To confirm nutrient regulation by rapamycin treatment, we checked the transcript levels of nutrient transporter genes (SLC2A2, SLC2A4, SLC6A14, and SLC7A1).	Sirolimus	34-43	solute carrier family 7 member 1	Homo sapiens	148-154
27888418-10	2017	Suppression of mTOR signaling pathway by rapamycin could promote BMSCs differentiation into osteoblast in DS.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
27913296-9	2017	Conversely, rapamycin inhibited S6K1 and rpS6 activation, and significantly improved insulin -stimulated activation of IRS-1 and MEK1/2 in KO mice.	Sirolimus	12-21	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	32-36
27737881-2	2017	Here, we studied the effects of the mTOR inhibitor rapamycin in mouse EL4 T-cell lymphoma.	Sirolimus	51-60	epilepsy 4	Mus musculus	70-73
27737881-6	2017	Low-dose (LD) rapamycin (75 mug/kg) increased potentially beneficial CD44hiCD62L+ CD8+ central memory T cells in EL4 challenge, but without clinical benefit.	Sirolimus	14-23	CD44 antigen	Mus musculus	69-73
27737881-6	2017	Low-dose (LD) rapamycin (75 mug/kg) increased potentially beneficial CD44hiCD62L+ CD8+ central memory T cells in EL4 challenge, but without clinical benefit.	Sirolimus	14-23	epilepsy 4	Mus musculus	113-116
27737881-8	2017	Instead, rapamycin upregulated EL4 IL2 receptor in vitro and in vivo, facilitating direct DD tumor cell killing.	Sirolimus	9-18	epilepsy 4	Mus musculus	31-34
27895122-6	2017	Specifically, growth under limiting potassium alters the activities of Npr1 and another TORC1 effector kinase, Sch9; hal4 hal5 and trk1 trk2 mutants display hypersensitivity to rapamycin, and reciprocally, TORC1 inhibition reduces potassium accumulation.	Sirolimus	177-186	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	71-75
27895122-6	2017	Specifically, growth under limiting potassium alters the activities of Npr1 and another TORC1 effector kinase, Sch9; hal4 hal5 and trk1 trk2 mutants display hypersensitivity to rapamycin, and reciprocally, TORC1 inhibition reduces potassium accumulation.	Sirolimus	177-186	serine/threonine protein kinase SAT4	Saccharomyces cerevisiae S288C	117-121
27895122-6	2017	Specifically, growth under limiting potassium alters the activities of Npr1 and another TORC1 effector kinase, Sch9; hal4 hal5 and trk1 trk2 mutants display hypersensitivity to rapamycin, and reciprocally, TORC1 inhibition reduces potassium accumulation.	Sirolimus	177-186	protein kinase HAL5	Saccharomyces cerevisiae S288C	122-126
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 2	Homo sapiens	27-31
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 2	Homo sapiens	32-36
27862655-7	2017	Because the product of the TSC2/Tsc2 gene (tuberin) together with hamartin, the product of another TSC gene (TSC1/Tsc1), suppresses mammalian/mechanistic target of rapamycin complex 1 (mTORC1), rapalogs have been used as therapeutic drugs for TSC.	Sirolimus	164-173	TSC complex subunit 2	Homo sapiens	43-50
28746918-10	2017	Histological analyses showed that low-dose RPM promoted wound healing, and enhanced the expression of IL-15 and IGF-1.	Sirolimus	43-46	interleukin 15	Mus musculus	102-107
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	71-74	interleukin 15	Mus musculus	83-88
28746918-12	2017	Instead, activation of the Akt/mTORC2 pathway was involved in low-dose RPM-induced IL-15 and IGF-1 production in epidermis, while high-dose RPM inhibited the expression of IL-15 and IGF-1 and the activity of mTORC1 and mTORC2 pathway.	Sirolimus	140-143	interleukin 15	Mus musculus	172-177
29224002-15	2017	The effects of U50,488H on PASMC autophagy were inhibited by AICAR, a selective AMPK agonist, or by rapamycin, a selective mTOR inhibitor.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Rattus norvegicus	123-127
26588882-0	2017	mTOR inhibition by rapamycin protects against deltamethrin-induced apoptosis in PC12 Cells.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
26721390-6	2017	We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E e4 transgenics.	Sirolimus	19-28	peptidylprolyl isomerase A	Mus musculus	72-85
27001230-1	2016	This study evaluates the association between the long noncoding RNA GAS5 levels and the anti-proliferative effect of the glucocorticoid (GC) methylprednisolone (MP) alone and in combination with rapamycin in peripheral blood mononuclear cells (PBMCs) obtained from healthy donors.	Sirolimus	195-204	growth arrest specific 5	Homo sapiens	68-72
27797139-4	2016	TSC is caused by the lack of functional Tsc1-Tsc2 complex, which serves as a major cellular inhibitor of mammalian Target of Rapamycin Complex 1 (mTORC1).	Sirolimus	125-134	TSC complex subunit 2	Homo sapiens	45-49
27001230-4	2016	Interestingly, when PBMCs were treated with the combination of rapamycin plus MP, the high levels of GAS5 observed for each drug in the MP poor responders group decreased in comparison with rapamycin (P value = 0.0134) or MP alone (P value = 0.0193).	Sirolimus	63-72	growth arrest specific 5	Homo sapiens	101-105
27181099-0	2016	A Novel Homozygous Mutation in the KCNJ11 Gene of a Neonate with Congenital Hyperinsulinism and Successful Management with Sirolimus.	Sirolimus	123-132	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	35-41
27035650-5	2016	However, rapamycin inhibited ID-induced thyroid blood flow and VEGF protein expression.	Sirolimus	9-18	vascular endothelial growth factor A	Mus musculus	63-67
27035650-6	2016	In the RET-PTC model, ID strongly increased the phosphorylation of p70S6K, whereas rapamycin completely inhibited the ID-induced increase in p70S6K phosphorylation, thyroid blood flow, and VEGF-A expression.	Sirolimus	83-92	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	141-147
27035650-6	2016	In the RET-PTC model, ID strongly increased the phosphorylation of p70S6K, whereas rapamycin completely inhibited the ID-induced increase in p70S6K phosphorylation, thyroid blood flow, and VEGF-A expression.	Sirolimus	83-92	vascular endothelial growth factor A	Mus musculus	189-195
27035650-7	2016	In vitro, although ID increased p70S6K phosphorylation, the ID-stimulated hypoxia-inducible factor/VEGF pathway was inhibited by rapamycin.	Sirolimus	129-138	vascular endothelial growth factor A	Mus musculus	99-103
27093550-12	2016	Thus, rapamycin shows an obvious protective effect on HG-induced EMT, by inhibiting the activation of Rho GTPases (RhoA, Rac1, and Cdc42).	Sirolimus	6-15	ras homolog family member A	Rattus norvegicus	102-113
27093550-12	2016	Thus, rapamycin shows an obvious protective effect on HG-induced EMT, by inhibiting the activation of Rho GTPases (RhoA, Rac1, and Cdc42).	Sirolimus	6-15	ras homolog family member A	Rattus norvegicus	115-119
27350635-0	2016	Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin.	Sirolimus	96-105	negative elongation factor complex member C/D	Homo sapiens	0-3
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 10	Homo sapiens	151-156
27350635-7	2016	RESULTS: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-gamma and TNF-alpha.	Sirolimus	107-116	interleukin 17A	Homo sapiens	172-177
27217700-13	2016	Rapamycin treatment significantly increased contractile force and myocardial localization of phosphorylated-mTOR and decreased cardiac TNF-alpha concentration compared to cirrhotic rats with no treatment.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	108-112
27217700-15	2016	Rapamycin normalized the inotropic effect and altered phosphorylated-mTOR expression and myocardial localization in cirrhotic rats.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	69-73
26566757-4	2016	Blocking spinal mTOR by using rapamycin significantly attenuated activities of PI3K signaling pathways as well as mechanical and thermal hyperalgesia.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	16-20
26769362-7	2016	The ability of PACAP to inhibit autophagy was also observed in an in vitro cell assay by the blocking of the p62-sequestration activity produced with the autophagy inducer rapamycin.	Sirolimus	172-181	nucleoporin 62	Homo sapiens	109-112
26526583-6	2016	Furthermore, we showed that ectopic expression of Sox2 in A549 cells was sufficient to render them more resistant to rapamycin treatment in vitro.	Sirolimus	117-126	SRY-box transcription factor 2	Homo sapiens	50-54
26526583-7	2016	These data suggested that rapamycin inhibited the function of lung CSCs via SOX2.	Sirolimus	26-35	SRY-box transcription factor 2	Homo sapiens	76-80
26984393-3	2016	Strengthening the significance of protein synthesis in dendritic spinogenesis, the translation blocker cyclohexamide and the mTOR inhibitor rapamycin reduce dendritic spine density, while a leucine supplement that increases protein synthesis ameliorates the dendritic spine defects caused by Vcp and Atl1 deficiencies.	Sirolimus	140-149	valosin containing protein	Mus musculus	292-295
26825372-7	2016	We also determined the effects on METH-induced autophagy and apoptosis after silencing DDIT4 expression with synthetic siRNA with or without pretreatment of a mTOR inhibitor rapamycin in cardiomyocytes using Western blot analysis, fluorescence microscopy and TUNEL staining.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Rattus norvegicus	159-163
26962683-8	2016	Blocking IL10R, p-AKT, p-mTOR, and p-STAT3 using specific inhibitors (IL10RB, LY294002, rapamycin, and cryptotanshinone, respectively) showed that IL10 inhibited autophagy via IL10Ralpha-mediated activation of STAT3 (the IL10R-STAT3 pathway) and by directly activating the AKT-mTOR pathway.	Sirolimus	88-97	interleukin 10 receptor subunit alpha	Homo sapiens	9-14
26910393-3	2016	Here we show that the transcription of miR-495 negatively correlates with the translation of ATG3 under nutrient-deprived or rapamycin-treated conditions.	Sirolimus	125-134	autophagy related 3	Homo sapiens	93-97
26901106-6	2016	The mTORC1 inhibitor rapamycin diminishes FBP enrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids.	Sirolimus	21-30	fructose-bisphosphatase 1	Homo sapiens	42-45
26756219-11	2016	Sirolimus, OSI-906, and their combination, blocked cell migration and invasion in HuH-7.	Sirolimus	0-9	MIR7-3 host gene	Homo sapiens	82-87
26903175-7	2016	The ras1, ras2 and tor1 mutants had a high-persister phenotype similar to wild-type biofilm and planktonic cells exposed to the TORC1 pathway inhibitor rapamycin.	Sirolimus	152-161	Ras family GTPase RAS1	Saccharomyces cerevisiae S288C	4-8
26903175-7	2016	The ras1, ras2 and tor1 mutants had a high-persister phenotype similar to wild-type biofilm and planktonic cells exposed to the TORC1 pathway inhibitor rapamycin.	Sirolimus	152-161	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	19-23
26437614-9	2016	Rapamycin treatment increased the frequency of mouse CD8 RSV-M282-90 pentamer-positive T cells and the frequency of RSV-specific memory T cells precursors.	Sirolimus	0-9	CD8a molecule	Homo sapiens	53-56
26659860-3	2016	In syncytiotrophoblasts, starvation, rapamycin, or punicalagin all decreased the expression of phosphorylated ribosomal protein S6, a downstream target of the mTOR kinase, and of the autophagy markers, LC3-II and p62.	Sirolimus	37-46	nucleoporin 62	Homo sapiens	213-216
26639426-4	2016	Here, we found that acute (within 2min) bath-application of rapamycin (0.5mugml(-1)) was able to depolarize the current-clamp baseline potentials significantly at postnatal day (P) 4, P10 in rats and P90 in mice (P&lt;0.05), and altered the membrane current/voltage (I/V) curves in an age-dependent manner.	Sirolimus	60-69	cellular inhibitor of PP2A	Homo sapiens	200-203
26639426-5	2016	Rapamycin not only increased the standard deviation or the peak amplitude of baseline membrane potential, but also increased the frequencies of spontaneous action potentials in more mature neurons (P10 and P90).	Sirolimus	0-9	cellular inhibitor of PP2A	Homo sapiens	206-209
26687947-9	2016	Interestingly, incubation with mTOR inhibitor rapamycin increased in the rate of LTR-positive autolysosomes in hepatocytes from KKAy mice and suppressed p62 accumulation in the liver from KKAy mice which correlated to an increase in the V-ATPase subunits expression.	Sirolimus	46-55	nucleoporin 62	Mus musculus	153-156
26702100-7	2016	Importantly, inhibition of mTORC1 signaling by rapamycin treatment aggravated the neurodegenerative phenotype in a TDP-43-depleted Drosophila model, whereas activation of mTORC1 signaling by PA treatment ameliorated the neurodegenerative phenotype.	Sirolimus	47-56	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	115-121
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	61-70	TIMP metallopeptidase inhibitor 2	Homo sapiens	239-285
26792606-1	2016	OBJECTIVE: To determine whether intramural administration of rapamycin (RPM)-loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase (TIMP)-2 and p27(kipl) in a coronary injury-stenosis model of minipigs.	Sirolimus	72-75	TIMP metallopeptidase inhibitor 2	Homo sapiens	239-285
26463951-9	2016	Early inhibition of mTOR by rapamycin improved long-term outcomes in rats.	Sirolimus	28-37	mechanistic target of rapamycin kinase	Rattus norvegicus	20-24
27776426-7	2016	Pretreatment of young SHRs with the mTOR inhibitor rapamycin blocked the antiautophagic and vasodilative effects of TSG.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Rattus norvegicus	36-40
27776426-8	2016	Moreover, TSG significantly activated Akt-mTOR signaling in HUVECs and reduced the autophagic levels in vitro, which were almost completely blocked by rapamycin.	Sirolimus	151-160	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
27050460-5	2016	Importantly, we found that modulation of MTOR activity by treatment with rapamycin and phosphatidic acid had strong effects on the neurodegenerative phenotypes of TBPH (Drosophila TARDBP)-depleted flies.	Sirolimus	73-82	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	163-167
27997905-7	2016	Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways.	Sirolimus	23-32	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
27997905-7	2016	Blocking mTOR by using rapamycin significantly attenuated activities of HIF-1alpha and VEGF signaling pathways.	Sirolimus	23-32	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	72-82
27825169-11	2016	In both in vitro and in vivo models, the combination of rapamycin with the MDM2 inhibitor, MI-319, demonstrated a synergistic inhibitory effect on rapamycin resistant cells.	Sirolimus	147-156	MDM2 proto-oncogene	Homo sapiens	75-79
26954224-3	2016	In the present study, we examined the effects of rapamycin, a specific inhibitor of mTORC1, on ELOVL1 expression and docosahexaenoic acid (DHA, C22:6 n-3) synthesis in bovine mammary epithelial cells (BMECs).	Sirolimus	49-58	ELOVL fatty acid elongase 1	Bos taurus	95-101
26954224-4	2016	We found that rapamycin decreased the relative abundance of ELOVL1 mRNA, ELOVL1 expression and the level of DHA in a time-dependent manner.	Sirolimus	14-23	ELOVL fatty acid elongase 1	Bos taurus	60-66
26954224-4	2016	We found that rapamycin decreased the relative abundance of ELOVL1 mRNA, ELOVL1 expression and the level of DHA in a time-dependent manner.	Sirolimus	14-23	ELOVL fatty acid elongase 1	Bos taurus	73-79
27555230-3	2016	In euvolemic anaesthetized rats, treatment with the mTOR inhibitor rapamycin increased blood pressure (121 +- 2 to 144 +- 3 mmHg; P&lt;.05), decreased glomerular filtration rate (GFR; 1.6 +- 0.3 to 0.5 +- 0.2 mL/min; P&lt;.05) and increased urinary sodium excretion (UNaV; 14 +- 1 to 109 +- 25 mmol/L per hour; P&lt;.05).	Sirolimus	67-76	mechanistic target of rapamycin kinase	Rattus norvegicus	52-56
27555230-4	2016	In rats subjected to IR, autophagy induction, p-mTOR expression and serum creatinine increased (1.9 +- 0.2 to 3 +- 0.3 mg/dL; P&lt;.05); treatment with rapamycin blunted p-mTOR expression but further increased autophagy induction and serum creatinine (3 +- 0.3 to 5 +- 0.6 mg/dL; P&lt;.05).	Sirolimus	152-161	mechanistic target of rapamycin kinase	Rattus norvegicus	48-52
27555230-4	2016	In rats subjected to IR, autophagy induction, p-mTOR expression and serum creatinine increased (1.9 +- 0.2 to 3 +- 0.3 mg/dL; P&lt;.05); treatment with rapamycin blunted p-mTOR expression but further increased autophagy induction and serum creatinine (3 +- 0.3 to 5 +- 0.6 mg/dL; P&lt;.05).	Sirolimus	152-161	mechanistic target of rapamycin kinase	Rattus norvegicus	172-176
27521838-9	2016	Notably, in the basal condition, Beclin-1 was more elevated in MHUASMCs than in FHUASMCs, and the difference disappeared after serum starvation and exposure to rapamycin.	Sirolimus	160-169	beclin 1	Homo sapiens	33-41
27780878-4	2016	Blocking mTOR by intrathecal infusion of rapamycin attenuated bladder hyperactivity and pain.	Sirolimus	41-50	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
27832632-6	2016	Autophagy inhibition by 3-MA or CQ, or by shRNA silencing of Agt-7 or Beclin-1 reduced the protective effects of starvation and rapamycin on H2O2-treated hTSCs.	Sirolimus	128-137	beclin 1	Homo sapiens	70-78
26875959-1	2016	Drug-eluting stents (DES) are widely used for the treatment of coronary artery disease, and a sirolimus-eluting stent (SES; Cypher) was the first DES introduced into clinical practice.	Sirolimus	94-103	LIM domain binding 3	Homo sapiens	124-130
26680373-10	2016	After transplantation with CB and rapamycin, donor-reactive Eomes(lo)CTLA4(hi) CD8+ T cells were reduced.	Sirolimus	34-43	eomesodermin	Homo sapiens	60-65
26680373-10	2016	After transplantation with CB and rapamycin, donor-reactive Eomes(lo)CTLA4(hi) CD8+ T cells were reduced.	Sirolimus	34-43	CD8a molecule	Homo sapiens	79-82
26636543-4	2015	Rapamycin exerts cytostatic effect on ERas tumor cells, thus causing a temporary and reversible cell cycle arrest, activation of non-selective autophagy not accompanied by cell death.	Sirolimus	0-9	ES cell expressed Ras	Homo sapiens	38-42
26132572-10	2015	When rapamycin was added to the vaginal fluid-PBMC co-incubation, p62 levels in samples from women with a malignant diagnosis decreased to 3.3 ng/ml, a level comparable to what was observed with the nonmalignant samples.	Sirolimus	5-14	nucleoporin 62	Homo sapiens	66-69
26449264-2	2015	This multi-organ disorder results from inactivating point mutations in either the TSC1 or the TSC2 genes and consequent activation of the canonical mammalian target of rapamycin complex 1 signalling (mTORC1) pathway.	Sirolimus	168-177	TSC complex subunit 2	Homo sapiens	94-98
26371515-5	2015	We further showed that Prp8 could regulate NES(AR) function using short hairpin RNA knockdown of Prp8 coupled with a rapamycin export assay in mammalian cells and knockdown of Prp8 could induce nuclear accumulation of GFP-tagged AR in PC3 cells.	Sirolimus	117-126	pre-mRNA processing factor 8	Homo sapiens	23-27
26681922-0	2015	Inhibition of mTOR Pathway by Rapamycin Reduces Brain Damage in Rats Subjected to Transient Forebrain Ischemia.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
26681922-4	2015	Inhibition of mTOR by rapamycin markedly reduced ischemia-induced damage; suppressed p-Akt, p-mTOR, p-P70S6K and p-S6 protein levels; decreased LC3-II and Beclin-1; and prevented cytochrome c release in the two structures.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
26681922-4	2015	Inhibition of mTOR by rapamycin markedly reduced ischemia-induced damage; suppressed p-Akt, p-mTOR, p-P70S6K and p-S6 protein levels; decreased LC3-II and Beclin-1; and prevented cytochrome c release in the two structures.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	94-98
26921303-5	2016	The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro.	Sirolimus	108-117	CD8a molecule	Homo sapiens	185-188
26921303-5	2016	The aim of this study was to evaluate the influence of the immunosuppressive drugs cyclosporine A (CsA) and rapamycin (RAPA) on the level, suppressor properties, and phenotype of human CD8(+)CD28(-) T cells in vitro.	Sirolimus	119-123	CD8a molecule	Homo sapiens	185-188
26921303-7	2016	It was observed that CD8(+)CD28(-) T cells from cultures with CsA or RAPA had similar suppressor properties to cells from control cultures, although the drugs influenced the expression of FOXP3.	Sirolimus	69-73	CD8a molecule	Homo sapiens	21-24
26517679-7	2015	Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib.	Sirolimus	42-51	EMAP like 4	Homo sapiens	110-114
26456737-5	2016	The amount of LC3, an important protein for the initiation of autophagosome formation and LAMP-1, a major constituent of the lysosomal membrane, underwent a dramatic and highly significant increase in control cultures challenged with rapamycin.	Sirolimus	234-243	lysosomal-associated membrane protein 1	Mus musculus	90-96
26517679-7	2015	Importantly, combinational treatment with rapamycin and crizotinib leads to synergistic anti-tumor effects on EML4-ALK+ NSCLC cells as well as on those resistant to crizotinib.	Sirolimus	42-51	ALK receptor tyrosine kinase	Homo sapiens	115-118
26597054-4	2015	PRL-3 also enhanced matrix metalloproteinase-2 secretion and cellular invasiveness via activation of mTOR, attributes which were sensitive to rapamycin treatment.	Sirolimus	142-151	matrix metallopeptidase 2	Mus musculus	20-46
27599409-7	2016	Pretreatment with rapamycin, an mTOR inhibitor, restored the abnormal mTOR/p70S6K signaling induced by surgery, attenuated the accumulation of Abeta and reduced the phosphorylation of tau protein.	Sirolimus	18-27	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	75-81
26540269-5	2015	Chronic systemic rapamycin treatment partially inhibited phosphorylation of a mechanistic target of rapamycin substrate in brain and stimulated LC3 cleavage, a marker of autophagic flux.	Sirolimus	17-26	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	144-147
27755955-5	2016	Western blot analysis showed that ICH led to a long-lasting increase of phosphorylated mTOR and this hyperactivation of mTOR was reduced by systemic administration of rapamycin.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Rattus norvegicus	87-91
26362858-0	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	Sirolimus	0-9	ribonuclease P/MRP subunit p14	Homo sapiens	19-22
27755955-5	2016	Western blot analysis showed that ICH led to a long-lasting increase of phosphorylated mTOR and this hyperactivation of mTOR was reduced by systemic administration of rapamycin.	Sirolimus	167-176	mechanistic target of rapamycin kinase	Rattus norvegicus	120-124
27493206-2	2016	The gene products hamartin and tuberin form the TSC complex that acts as GTPase-activating protein for Rheb and negatively regulates the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	157-166	TSC complex subunit 2	Homo sapiens	31-38
26363453-5	2015	Moreover, Atg5 knocking down could significantly increase the expression of MMP2, MMP9 and uPA in EPCs while rapamycin could decrease the expression of uPA and MMP9.	Sirolimus	109-118	matrix metallopeptidase 9	Homo sapiens	160-164
27549441-9	2016	Under rapamycin stress, PMA biosynthesis was obviously inhibited in a dose-dependent manner, and the transcription levels of TOR1, MCL, and DAT were also downregulated.	Sirolimus	6-15	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	125-129
26306048-6	2015	Moreover, rapamycin treatment in vivo reduced the skeletal muscle IRE1alpha activation in the Fyn-overexpressing transgenic mice.	Sirolimus	10-19	Fyn proto-oncogene	Mus musculus	94-97
27518575-3	2016	The in vitro studies showed that Tacrolimus exerted a more potent pro-apoptotic effect than Everolimus (Huh 7&gt;Hep 3B&gt;HepG2), being sirolimus only active in Hep3B cell line.	Sirolimus	137-146	MIR7-3 host gene	Homo sapiens	104-109
27564518-8	2016	Retinal MCs in HG treated with rapamycin (mTOR inhibitor) show autophagy machinery activation and reestablishment of cargo degradation, protecting cells from apoptosis (P &lt; 0.0001).	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	42-46
26622487-9	2015	Rapamycin affected the mTOR signaling pathway in rats following fracture, as indicated by the inhibition of the phosphorylation of ribosomal protein S6, a target of mTOR, and activation of microtubule-associated protein 2 light chain 3, a key marker of autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	23-27
27489506-0	2016	Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	95-99
27489506-7	2016	It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Rattus norvegicus	142-146
26061549-6	2015	Interestingly, the expression of Klotho, an antiaging gene that suppresses VC, was reduced in calcified vasculature, whereas rapamycin reversed membrane and secreted Klotho decline through mTOR inhibition.	Sirolimus	125-134	klotho	Homo sapiens	166-172
27489506-7	2016	It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings.	Sirolimus	150-159	mechanistic target of rapamycin kinase	Rattus norvegicus	142-146
27261605-8	2016	The treatment of mTOR inhibitor rapamycin prevented against the increase of cytokines expression and hippocampal neuron apoptosis induced by PTZ.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Rattus norvegicus	17-21
26426423-9	2015	Since our previous studies showed that modified tumor cell lysate (TCL)-pulsed, dendritic cell (DC)-based cancer vaccines can effectively suppress metastasis in mouse tumor models, we assessed whether such vaccines may help offset this rapamycin-promoted metastasis.	Sirolimus	236-245	ras homolog family member J	Mus musculus	67-70
26426423-10	2015	We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice.	Sirolimus	161-170	ras homolog family member J	Mus musculus	120-123
26426423-10	2015	We observed that shikonin efficiently induced ICD of 4T1 cells in culture, and DC vaccines pulsed with shikonin-treated TCL (SK-TCL-DC) significantly suppressed rapamycin-enhanced metastasis and Treg cell expansion in test mice.	Sirolimus	161-170	ras homolog family member J	Mus musculus	125-134
26382847-8	2015	Rapamycin induced the production of autophagosomes and diminished p62.	Sirolimus	0-9	nucleoporin 62	Mus musculus	66-69
27347023-7	2016	Furthermore, the serum level and protein expression of VEGF, and the MVD in the lesions of the RAPA-treated group were significantly reduced when compared with the other two groups.	Sirolimus	95-99	vascular endothelial growth factor A	Mus musculus	55-59
25943403-0	2015	Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC).	Sirolimus	49-58	TSC complex subunit 2	Homo sapiens	103-106
26202311-5	2015	We used a CCK-8 assay and western blotting to explore whether the stem cell biomarkers CD44 and SOX2 and the invasion protein MMP-2 could be suppressed by treatment with rapamycin in cultured primary NPC cells and secondary tumors in BALB/c nude mice.	Sirolimus	170-179	CD44 antigen	Mus musculus	87-91
26202311-5	2015	We used a CCK-8 assay and western blotting to explore whether the stem cell biomarkers CD44 and SOX2 and the invasion protein MMP-2 could be suppressed by treatment with rapamycin in cultured primary NPC cells and secondary tumors in BALB/c nude mice.	Sirolimus	170-179	SRY (sex determining region Y)-box 2	Mus musculus	96-100
26202311-5	2015	We used a CCK-8 assay and western blotting to explore whether the stem cell biomarkers CD44 and SOX2 and the invasion protein MMP-2 could be suppressed by treatment with rapamycin in cultured primary NPC cells and secondary tumors in BALB/c nude mice.	Sirolimus	170-179	matrix metallopeptidase 2	Mus musculus	126-131
26538632-7	2016	Kim-1 expression led to activation of the mammalian target of rapamycin (mTOR) pathway, and inhibition of this pathway with rapamycin increased survival.	Sirolimus	62-71	hepatitis A virus cellular receptor 1	Homo sapiens	0-5
26202311-6	2015	Interestingly, we found that rapamycin inhibited mTOR signaling in addition to simultaneously downregulating the expression of CD44, SOX2 and MMP-2 and that it affected cell growth and tumor size and weight both in vitro and in vivo.	Sirolimus	29-38	CD44 molecule (Indian blood group)	Homo sapiens	127-131
26202311-6	2015	Interestingly, we found that rapamycin inhibited mTOR signaling in addition to simultaneously downregulating the expression of CD44, SOX2 and MMP-2 and that it affected cell growth and tumor size and weight both in vitro and in vivo.	Sirolimus	29-38	SRY-box transcription factor 2	Homo sapiens	133-137
26239133-4	2015	Inhibition of mTOR by rapamycin was found to reduce primarily the immunoproteasome in both H9c2 cells in vitro and mouse heart in vivo, without significant effect on the constitutive proteasome and protein ubiquitination.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
26048361-9	2015	Phosphorylation of mTOR and S6K1 was similar in the two groups and equally reduced by rapamycin.	Sirolimus	86-95	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
27138352-6	2016	After treatment with rapamycin in podocytes, an autophagy inducer, VEGF activation was significantly abrogated and podocyte injury was ameliorated.	Sirolimus	21-30	vascular endothelial growth factor A	Mus musculus	67-71
26048361-10	2015	Thus, a rapamycin-sensitive, mTOR-dependent but S6K1-independent, signal led to enhanced oxidative metabolism in the Eker brain.	Sirolimus	8-17	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
26122844-6	2015	In animals vaccinated with CyaA-E7, rapamycin administration completely abolished recruitment of CD8+ T cells into TC-1 tumors along with the ability of the vaccine to reduce infiltration of T regulatory cells and myeloid-derived suppressor cells.	Sirolimus	36-45	CD8a molecule	Homo sapiens	97-100
26434594-9	2016	Overexpressed PAT4 is also able to promote rapamycin resistance in human embryonic kidney-293 cells.	Sirolimus	43-52	solute carrier family 36 member 4	Homo sapiens	14-18
26248290-4	2015	Thus, a suitable dose of rapamycin which can maintain the normal function of mTOR and has fewer side effects ideally should be identified.	Sirolimus	25-34	mechanistic target of rapamycin kinase	Rattus norvegicus	77-81
26248290-6	2015	Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	148-152
26248290-6	2015	Then we determined the dose of rapamycin by treating rats of 2 weeks of age with different doses of rapamycin for 3 days and detected its effect on mTOR pathway.	Sirolimus	100-109	mechanistic target of rapamycin kinase	Rattus norvegicus	148-152
26248290-14	2015	The expression of DCX was also significantly decreased in 1.0 and 3.0 mg/kg rapamycin-treated rats.	Sirolimus	76-85	doublecortin	Rattus norvegicus	18-21
26195783-6	2015	Amplification is completely repressed by rapamycin, an inhibitor of the nutrient-responsive TOR pathway; this effect is separable from growth rate and is mediated directly through Sir2, Hst3, and Hst4.	Sirolimus	41-50	NAD-dependent histone deacetylase HST4	Saccharomyces cerevisiae S288C	196-200
26004146-8	2015	The area of GFAP positive and the mean density of GFAP positive area in the dorsal horn of the ipsilateral side greatly increased in rapamycin-treated groups.	Sirolimus	133-142	glial fibrillary acidic protein	Rattus norvegicus	12-16
27103123-1	2016	PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation.	Sirolimus	9-18	kinase insert domain receptor	Homo sapiens	215-257
26004146-8	2015	The area of GFAP positive and the mean density of GFAP positive area in the dorsal horn of the ipsilateral side greatly increased in rapamycin-treated groups.	Sirolimus	133-142	glial fibrillary acidic protein	Rattus norvegicus	50-54
27103123-1	2016	PURPOSE: Sirolimus, an oral mTOR inhibitor, may complement the anti-angiogenic and anti-tumor activity of sunitinib, an oral small molecule inhibitor of multiple receptor tyrosine kinases, by vertical disruption of vascular epithelial growth factor receptor (VEGFR) signaling, by reducing the compensatory production of VEGF in sunitinib-treated patients and also by directly inhibiting tumor cell proliferation.	Sirolimus	9-18	kinase insert domain receptor	Homo sapiens	259-264
27368038-2	2016	Recent introduction of a newer-generation drug-eluting stent (DES) has significantly reduced the occurrence of stent thrombosis.The aim of this study was to evaluate the impact of CYP2C19 LOF alleles on clinical outcome in patients treated with the newer-generation DES.The effects of CYP2C19 genotypes were evaluated on clinical outcome of clopidogrel therapy in 2062 patients treated with percutaneous coronary intervention using either first-generation DES (sirolimus- and paclitaxel-eluting stent, n = 1349) or newer-generation DES (everolimus- and zotarolimus-eluting stent, n = 713).	Sirolimus	461-470	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	180-187
25929522-4	2015	Slight induction was observed for CYP2A6/2C9 mRNAs and CYP2A6 protein in the rapamycin-treated hepatocytes.	Sirolimus	77-86	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	34-40
25929522-4	2015	Slight induction was observed for CYP2A6/2C9 mRNAs and CYP2A6 protein in the rapamycin-treated hepatocytes.	Sirolimus	77-86	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	55-61
26170311-4	2015	Rapamycin interferes with viral entry of CCR5 (R5)-tropic HIV and with basal transcription of the HIV LTR, potently inhibiting replication of R5 HIV but not CXCR4 (X4)-tropic HIV in primary cells.	Sirolimus	0-9	C-C motif chemokine receptor 5	Homo sapiens	41-45
27105919-10	2016	Treatment with rapamycin, an inhibitor of mTOR signaling, together with Slc7a7 knockdown synergistically perturbed spaw expression, indicating an interaction between Slc7a7 and mTOR signaling affecting gene expression required for LR specification.	Sirolimus	15-24	Y+L amino acid transporter 1	Oryzias latipes	166-172
26170311-4	2015	Rapamycin interferes with viral entry of CCR5 (R5)-tropic HIV and with basal transcription of the HIV LTR, potently inhibiting replication of R5 HIV but not CXCR4 (X4)-tropic HIV in primary cells.	Sirolimus	0-9	C-X-C motif chemokine receptor 4	Homo sapiens	157-162
27050281-3	2016	Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.	Sirolimus	0-9	ATPase copper transporting alpha	Homo sapiens	80-83
27035541-8	2016	Both TRP and RAP increased the levels of IL-10.	Sirolimus	13-16	interleukin 10	Homo sapiens	41-46
25924882-14	2015	We conclude that the mTOR pathway in liver serves distinct physiological roles in the adult and fetus, with the latter representing a condition of rapamycin resistance.	Sirolimus	147-156	mechanistic target of rapamycin kinase	Rattus norvegicus	21-25
26873552-5	2016	Consistently, prenatal treatment with mTORC1 inhibitor rapamycin rescued the phenotype of Depdc5(-/-) embryos.	Sirolimus	55-64	DEP domain containing 5, GATOR1 subcomplex subunit	Rattus norvegicus	90-96
26142708-6	2015	Moreover, rapamycin treatment in vitro reduced the number of VGF+CD3+ cells in AD patients to control levels.	Sirolimus	10-19	VGF nerve growth factor inducible	Homo sapiens	61-64
27056891-6	2016	GNG7 knockdown reduces Rapamycin and starvation-induced autophagy.	Sirolimus	23-32	guanine nucleotide binding protein (G protein), gamma 7	Mus musculus	0-4
26037126-7	2015	Treatment with rapamycin increased survival, blocked breakdown of the blood-brain barrier and brain hemorrhaging, decreased the influx of both CD4(+) and CD8(+) T cells into the brain and the accumulation of parasitized red blood cells in the brain.	Sirolimus	15-24	CD8a molecule	Homo sapiens	154-157
27111854-8	2016	Rapamycin treatment led to the rapid accumulation of autophagic bodies and autophagy lysosomes, decreased p62 protein levels, and increased the ratio of microtubule-associated protein light chain 3 II (LC3-II) to LC3-I in hippocampal neurons through the mTOR signaling pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	254-258
25688987-13	2015	Rapamycin pre-treatment abolished the effects of increased p-mTOR and p-p70s6k expression exerted by lin28a overexpression.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	72-78
26946108-8	2016	Furthermore, the intrathecal administration of rapamycin, inhibiting the activity of mTOR, suppressed the phosphorylation of DRG Nav1.8, reduced the TTX-R current density, heightened the voltage threshold for activation and lowered the voltage threshold for inactivation and relieved mechanical hypersensitivity in diabetic rats.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Rattus norvegicus	85-89
25617592-9	2015	HNE-stimulated RPS6 phosphorylation was completely blocked using the mTOR inhibitor rapamycin.	Sirolimus	84-93	ribosomal protein S6	Rattus norvegicus	15-19
27358149-5	2016	Rapamycin promoted the expression of apoptosis-related genes Caspase3 and Caspase8 in the senile group, while 3-MA inhibited them in both the young and senile groups.	Sirolimus	0-9	caspase 3	Mus musculus	61-69
26822952-1	2016	BACKGROUND: Peri-stent contrast staining (PSS) after sirolimus-eluting stent implantation is associated with target lesion revascularization (TLR) and very late stent thrombosis.	Sirolimus	53-62	perilipin 1	Homo sapiens	12-16
26390657-4	2015	With the intervention of mammalian target of rapamycin mTOR inhibitor rapamycin (100 nmol x L(-1)) , the effect of blocking mTOR signaling pathway on autophagic inhibition of emodin was observed.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Rattus norvegicus	55-59
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	sequestosome 1	Homo sapiens	252-255
25884947-7	2015	Rapamycin-treated mice demonstrated significant improvement in muscle performance, quadriceps histological analysis, and rescue of ubiquitin, and TDP-43 pathology and defective autophagy as indicated by decreased protein expression levels of LC3-I/II, p62/SQSTM1, optineurin and inhibiting the mTORC1 substrates.	Sirolimus	0-9	sequestosome 1	Homo sapiens	256-262
25424831-13	2015	Treatment with the mTOR inhibitor rapamycin also diminished cellular proliferation, sprouting and AKT phosphorylation, but only in LM-LEC.	Sirolimus	34-43	C-C motif chemokine ligand 16	Homo sapiens	134-137
25903959-8	2015	The last 3 weeks with the conversion to sirolimus revealed high serum and urine NGAL contents but the CsA-evoked renal damage was substantially ameliorated, by reduced of connective tissue growth factor, mammalian target of rapamycin, nuclear factor-kappabeta1 protein expression.	Sirolimus	40-49	lipocalin 2	Homo sapiens	80-84
26738732-6	2016	Treatment of injured rats with the autophagy inducer rapamycin increased the number of autophagosomes and LC3-II expression while reducing the number of apoptotic cells at the lesion; this was associated with an upregulation of MBP and NF-200 expression and increased motor function recovery as compared to sham-operated rats and those that were subjected to crush injury but untreated.	Sirolimus	53-62	myelin basic protein	Rattus norvegicus	228-231
25739982-7	2015	Rapamycin suppressed 17beta-estradiol-induced Sertoli cell proliferation, appearing to act by reducing the abundance of SKP2, CCND1, and CCNE1 mRNA as well as RB and EMI1 protein.	Sirolimus	0-9	cyclin E1	Homo sapiens	137-142
25749036-9	2015	Furthermore, the expression of EMT regulating transcription factors, snail, slug and ZEB1, were also decreased markedly with rapamycin treatment.	Sirolimus	125-134	snail family transcriptional repressor 2	Homo sapiens	76-80
25749036-9	2015	Furthermore, the expression of EMT regulating transcription factors, snail, slug and ZEB1, were also decreased markedly with rapamycin treatment.	Sirolimus	125-134	zinc finger E-box binding homeobox 1	Homo sapiens	85-89
25729255-4	2015	A high concentration of rapamycin (10 microM) blocked both P70S6K and elF4E phosphorylation and inhibited cell proliferation in the KU-7-luc cells.	Sirolimus	24-33	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	59-65
25729255-7	2015	These findings suggest that both the mTOR pathway downstream of eIF4E and p70S6K can be successfully inhibited by high dose rapamycin only, and p70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression.	Sirolimus	124-133	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	74-80
25438952-0	2015	Rapamycin protects against apoptotic neuronal death and improves neurologic function after traumatic brain injury in mice via modulation of the mTOR-p53-Bax axis.	Sirolimus	0-9	BCL2-associated X protein	Mus musculus	153-156
25438952-9	2015	RESULTS: Rapamycin administration after TBI was associated with an increased number of neurons, decreased apoptosis index, and improved neurobehavioral function, which was potentially mediated by inactivation of the mTOR-p53-Bax axis.	Sirolimus	9-18	BCL2-associated X protein	Mus musculus	225-228
25582442-2	2015	This study aimed to determine whether a sirolimus (Sir)-based calcineurin inhibitor-sparing regimen is associated with a lower incidence of BK viremia.	Sirolimus	40-49	calcineurin binding protein 1	Homo sapiens	62-83
25534817-6	2015	Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice.	Sirolimus	178-187	fibrillin 1	Mus musculus	74-78
25534817-6	2015	Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice.	Sirolimus	178-187	interleukin 4 receptor, alpha	Mus musculus	88-97
25534817-6	2015	Collectively, this study identifies a previously unrecognized role of the FBN1/TGF-beta/IL4Ralpha/mTOR cascade in BMMSC lineage selection and provides experimental evidence that rapamycin treatment may provide an anabolic therapy for osteopenia in Fbn1(+/-) mice.	Sirolimus	178-187	fibrillin 1	Mus musculus	248-252
26378614-6	2015	C2-ceramide (C2), a PPP2A agonist, activated autophagy in GBA-silenced cells, while GBA knockdown-induced SNCA accumulation was reversed by C2 or rapamycin (an autophagy inducer), suggesting that PPP2A plays an important role in the GBA knockdown-mediated inhibition of autophagy.	Sirolimus	146-155	synuclein alpha	Rattus norvegicus	106-110
27113190-7	2016	CONCLUSION: The mechanism by which rapamycin inhibits the proliferation of valvular interstitial cells probably involves suppression of mTOR to lower S6 and P70S6K phosphorylation level but not direct regulation of the cell cycle.	Sirolimus	35-44	mechanistic target of rapamycin kinase	Rattus norvegicus	136-140
26749369-2	2016	Similar to other FKBPs, FK506 binding domain (FKBD) of hFKBP25 also binds to immunosuppressive drugs such as rapamycin and FK506, albeit with a lower affinity for the latter.	Sirolimus	109-118	FKBP prolyl isomerase 3	Homo sapiens	55-62
26302996-11	2015	Importantly, Rapa-imDC administration ameliorated airway obliteration symptoms and CD4+ and CD8+ T cell infiltration.	Sirolimus	13-17	Cd4 molecule	Rattus norvegicus	83-86
26623657-8	2015	Rapamycin also mediated an obvious increase in Dil-labeled ox-LDL (Dil-ox-LDL)/LC3 and Dil-ox-LDL/LAMP1 co-localization, which was inhibited by 3-methyladenine (3-MA), an autophagic inhibitor.	Sirolimus	0-9	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	79-82
26623657-9	2015	In addition, significant co-localization of LC3 and LAMP1 occurred in cells pretreated with rapamycin.	Sirolimus	92-101	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	44-47
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	eukaryotic translation initiation factor 2A	Homo sapiens	112-121
25653476-6	2015	Rapamycin attenuated PA-induced PERK and IRE1-associated UPR pathways, evidenced by decreased protein levels of eIF2alpha phosphorylation, ATF4, CHOP, and JNK phosphorylation.	Sirolimus	0-9	activating transcription factor 4	Homo sapiens	139-143
25034463-7	2015	We measured the activity of mammalian target of rapamycin (mTOR) in the pilocarpine rat model pretreated with the mTOR-specific inhibitor, rapamycin, and SB-399885 using western blotting.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Rattus norvegicus	114-118
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	Sirolimus	230-239	mechanistic target of rapamycin kinase	Rattus norvegicus	37-41
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	Sirolimus	230-239	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	Sirolimus	230-239	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	Sirolimus	230-239	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
26175092-5	2015	METHODS: Diabetic rats (6 weeks post-streptozotocin (STZ)) were treated with rapamycin to inhibit mTOR or vehicle for 2 additional weeks.	Sirolimus	77-86	mechanistic target of rapamycin kinase	Rattus norvegicus	98-102
26962683-8	2016	Blocking IL10R, p-AKT, p-mTOR, and p-STAT3 using specific inhibitors (IL10RB, LY294002, rapamycin, and cryptotanshinone, respectively) showed that IL10 inhibited autophagy via IL10Ralpha-mediated activation of STAT3 (the IL10R-STAT3 pathway) and by directly activating the AKT-mTOR pathway.	Sirolimus	88-97	interleukin 10	Homo sapiens	9-13
26936590-13	2016	Rapamycin induces an unfavorable, profibrotic imbalance between metalloproteinase-9 and its inhibitor, TIMP-1.	Sirolimus	0-9	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	103-109
27239444-3	2016	The phosphorylation of p70 S6 kinase, which indicates mTOR activation, was induced in the skin of rats fed a high-fat diet, but this abnormality was reversed by supplementation with rapamycin.	Sirolimus	182-191	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
26648565-13	2016	Treatment with rapamycin, an inhibitor of the mTOR/STAT3 signaling pathway had a similar effect to that of NogoA knockdown in the MPP+-treated PC12 cells.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	46-50
26648565-13	2016	Treatment with rapamycin, an inhibitor of the mTOR/STAT3 signaling pathway had a similar effect to that of NogoA knockdown in the MPP+-treated PC12 cells.	Sirolimus	15-24	reticulon 4	Rattus norvegicus	107-112
26814135-4	2016	Rapamycin-induced autophagy significantly increased the melanin index, tyrosinase activity and expression of several proteins linked to melanosome biogenesis, including microphthalmia transcription factor (MITF), pre-melanosome protein and tyrosinase, in Melan-a melanocytes.	Sirolimus	0-9	tyrosinase	Homo sapiens	71-81
26814135-4	2016	Rapamycin-induced autophagy significantly increased the melanin index, tyrosinase activity and expression of several proteins linked to melanosome biogenesis, including microphthalmia transcription factor (MITF), pre-melanosome protein and tyrosinase, in Melan-a melanocytes.	Sirolimus	0-9	tyrosinase	Homo sapiens	240-250
26426522-9	2016	CONCLUSIONS: mTOR inhibition by rapamycin restores corticosteroid sensitivity via inhibition of c-Jun expression, and thus mTOR is a potential novel therapeutic target for COPD.	Sirolimus	32-41	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	96-101
26578517-9	2016	Exposure of palmitate/BSA-treated cells to rapamycin normalized Miox expression and prevented Srebp1 nuclear translocation.	Sirolimus	43-52	myo-inositol oxygenase	Mus musculus	64-68
26578517-11	2016	Like rapamycin, srebp siRNA reduced Miox expression.	Sirolimus	5-14	myo-inositol oxygenase	Mus musculus	36-40
26734934-0	2016	Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	107-111
24703244-0	2014	Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells.	Sirolimus	55-64	growth arrest specific 5	Homo sapiens	8-12
25256739-0	2014	Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	12-16
26734934-9	2016	mTOR blockade by rapamycin profoundly ameliorated splenomegaly by limiting lymphocytes proliferation, angiogenesis, fibrogenesis and inflammation as well as decreasing portal pressure.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
27847820-6	2016	Furthermore, we demonstrated that neural differentiation in these iPS cells was accompanied by autophagy and that rapamycin promoted autophagy through degradation of mutant ATXN3 proteins in neurally differentiated spinocerebellar ataxia-3 human induced pluripotent stem cells (p < 0.05).	Sirolimus	114-123	ataxin 3	Homo sapiens	173-178
27825169-7	2016	RESULTS: Rapamycin treatment suppresses the expression of MDM2 and exogenous overexpression of MDM2 in A498 cells contributes to rapamycin resistance.	Sirolimus	9-18	MDM2 proto-oncogene	Homo sapiens	58-62
27825169-7	2016	RESULTS: Rapamycin treatment suppresses the expression of MDM2 and exogenous overexpression of MDM2 in A498 cells contributes to rapamycin resistance.	Sirolimus	9-18	MDM2 proto-oncogene	Homo sapiens	95-99
27825169-7	2016	RESULTS: Rapamycin treatment suppresses the expression of MDM2 and exogenous overexpression of MDM2 in A498 cells contributes to rapamycin resistance.	Sirolimus	129-138	MDM2 proto-oncogene	Homo sapiens	95-99
27825169-8	2016	By establishing a rapamycin resistant cell line, we observed that MDM2 was significantly upregulated in rapamycin resistant cells than that in rapamycin sensitive cells.	Sirolimus	18-27	MDM2 proto-oncogene	Homo sapiens	66-70
27825169-8	2016	By establishing a rapamycin resistant cell line, we observed that MDM2 was significantly upregulated in rapamycin resistant cells than that in rapamycin sensitive cells.	Sirolimus	104-113	MDM2 proto-oncogene	Homo sapiens	66-70
27825169-10	2016	Moreover, the inhibition of MDM2 by siMDM2 sensitizes A498 cells to rapamycin through the activation of p53.	Sirolimus	68-77	MDM2 proto-oncogene	Homo sapiens	28-32
26691904-2	2016	Treatment with the mTOR inhibitor rapamycin after status epilepticus reduces the development of epilepsy in a rat model.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
26462881-8	2016	An increase in the level of HDAC10 was also obtained when mTOR was inhibited by Rapamycin.	Sirolimus	80-89	histone deacetylase 10	Homo sapiens	28-34
26462881-9	2016	siRNA directed against HDAC10 abolished the effect of Rapamycin on cell viability and Ambra1 and Atg16L2 increased expression.	Sirolimus	54-63	histone deacetylase 10	Homo sapiens	23-29
27493704-10	2016	Rapamycin, an mTOR inhibitor, increased GRP78/BiP and EDC3 levels in a dose-dependent manner and subsequently resulted in a decrease in intracellular production of insulin.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
27493704-10	2016	Rapamycin, an mTOR inhibitor, increased GRP78/BiP and EDC3 levels in a dose-dependent manner and subsequently resulted in a decrease in intracellular production of insulin.	Sirolimus	0-9	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	40-45
27493704-10	2016	Rapamycin, an mTOR inhibitor, increased GRP78/BiP and EDC3 levels in a dose-dependent manner and subsequently resulted in a decrease in intracellular production of insulin.	Sirolimus	0-9	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	46-49
26782505-7	2015	Sirolimus-treated CD4+ T cell TGF-beta secretion increased 2.5X over control levels (P &lt; 0.01), but that of the cyclosporine group decreased marginally (P &gt; 0.05).	Sirolimus	0-9	CD4 antigen	Mus musculus	18-21
26782505-8	2015	The CD4+ cell proportion decreased significantly (41.25 vs 69.22%, P &lt; 0.01) and slightly (65.21 vs 69.22, P &gt; 0.05) in the cyclosporine and sirolimus groups, respectively.	Sirolimus	147-156	CD4 antigen	Mus musculus	4-7
26782505-10	2015	Overall, sirolimus promoted CD4+ CD25+ Treg cell proliferation and growth in vitro, whereas cyclosporin A inhibited proliferation.	Sirolimus	9-18	CD4 antigen	Mus musculus	28-31
26782505-10	2015	Overall, sirolimus promoted CD4+ CD25+ Treg cell proliferation and growth in vitro, whereas cyclosporin A inhibited proliferation.	Sirolimus	9-18	interleukin 2 receptor, alpha chain	Mus musculus	33-37
26782505-11	2015	Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo.	Sirolimus	0-9	CD4 antigen	Mus musculus	24-27
26782505-11	2015	Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo.	Sirolimus	0-9	interleukin 2 receptor, alpha chain	Mus musculus	29-33
26566676-7	2015	Akt-mediated downregulation of Mfn2 was via the mTORC1 pathway because this downregulation was blocked by rapamycin, and overexpression of wild-type, but not kinase-dead mTOR, caused Mfn2 downregulation.	Sirolimus	106-115	mitofusin 2	Homo sapiens	31-35
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	mechanistic target of rapamycin kinase	Rattus norvegicus	23-27
26397133-9	2015	Lung tumors harvested from mice exposed to rapamycin showed a significant decrease in p-mTOR, p-S6K1, PCNA and Bcl-xL as compared with controls in the early and late stage intervention studies.	Sirolimus	43-52	proliferating cell nuclear antigen	Mus musculus	102-106
26677273-1	2015	BACKGROUND: Sirolimus has provided the option for calcineurin inhibitor (CNI)-free immunosuppressive therapy in both solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT).	Sirolimus	12-21	calcineurin binding protein 1	Homo sapiens	50-71
24919871-5	2014	However, if the compounds were added to the cells 24 h before the viruses, GRA induced the production of an even higher amount of Beclin 1 and showed an improved antiviral effect; under these conditions, rapamycin was also able to exert a significant anti-HSV1 activity.	Sirolimus	204-213	beclin 1	Homo sapiens	130-138
25278019-4	2014	This orexin/GPCR-stimulated mTOR activation is sensitive to rapamycin, an inhibitor of mTOR complex 1 (mTORC1) but is independent of two well known mTORC1 activators, Erk and Akt.	Sirolimus	60-69	G protein-coupled bile acid receptor 1	Mus musculus	12-16
25241363-12	2014	Expressions of p-p70S6K, p-4EBP1, PCNA, and STRA8 decreased significantly in the rapamycin-treated group, where no difference was observed in VASA expression.	Sirolimus	81-90	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	17-23
25241363-12	2014	Expressions of p-p70S6K, p-4EBP1, PCNA, and STRA8 decreased significantly in the rapamycin-treated group, where no difference was observed in VASA expression.	Sirolimus	81-90	proliferating cell nuclear antigen	Mus musculus	34-38
24901414-11	2014	The mTOR inhibitor, rapamycin, significantly blocked these effects on escitalopram, paroxetine and tranylcypromine whereas fluoxetine, sertraline and imipramine effects were not affected.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
26693177-2	2015	The TSC1 and TSC2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	76-85	TSC complex subunit 2	Homo sapiens	13-17
25989700-0	2015	Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.	Sirolimus	0-9	CD8a molecule	Homo sapiens	54-57
25989700-3	2015	Using a murine model of latent viral infection, we observed that rapamycin treatment alone led to a significant increase in virus-specific CD8(+) T cells, as well as increased functionality of these cells, including the ability to make multiple cytokines, while CTLA4-Ig treatment alone significantly dampened the response and inhibited the generation of polyfunctional antigen-specific CD8(+) T cells.	Sirolimus	65-74	CD8a molecule	Homo sapiens	139-142
25989700-3	2015	Using a murine model of latent viral infection, we observed that rapamycin treatment alone led to a significant increase in virus-specific CD8(+) T cells, as well as increased functionality of these cells, including the ability to make multiple cytokines, while CTLA4-Ig treatment alone significantly dampened the response and inhibited the generation of polyfunctional antigen-specific CD8(+) T cells.	Sirolimus	65-74	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	262-267
24889758-2	2014	We have recently demonstrated that mTOR"s inhibition by rapamycin (started before seizure onset), permanently reduces the development of spontaneous absence seizures in WAG/Rij rats, an animal model of absence epilepsy; furthermore, mTOR phosphorylation was increased in adult WAG/Rij rats" cortex, but not other brain areas.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Rattus norvegicus	35-39
25989700-3	2015	Using a murine model of latent viral infection, we observed that rapamycin treatment alone led to a significant increase in virus-specific CD8(+) T cells, as well as increased functionality of these cells, including the ability to make multiple cytokines, while CTLA4-Ig treatment alone significantly dampened the response and inhibited the generation of polyfunctional antigen-specific CD8(+) T cells.	Sirolimus	65-74	CD8a molecule	Homo sapiens	387-390
24889758-2	2014	We have recently demonstrated that mTOR"s inhibition by rapamycin (started before seizure onset), permanently reduces the development of spontaneous absence seizures in WAG/Rij rats, an animal model of absence epilepsy; furthermore, mTOR phosphorylation was increased in adult WAG/Rij rats" cortex, but not other brain areas.	Sirolimus	56-65	mechanistic target of rapamycin kinase	Rattus norvegicus	233-237
25989700-4	2015	However, the addition of rapamycin to the CTLA4-Ig regimen was able to quantitatively and qualitatively restore the antigen-specific CD8(+) T cell response to the virus.	Sirolimus	25-34	CD8a molecule	Homo sapiens	133-136
26622487-9	2015	Rapamycin affected the mTOR signaling pathway in rats following fracture, as indicated by the inhibition of the phosphorylation of ribosomal protein S6, a target of mTOR, and activation of microtubule-associated protein 2 light chain 3, a key marker of autophagy.	Sirolimus	0-9	ribosomal protein S6	Rattus norvegicus	131-151
25349646-10	2014	While both starvation and rapamycin enhanced autophagy in Huh7 cells, only rapamycin increased autophagy in Hep3B cells.	Sirolimus	26-35	MIR7-3 host gene	Homo sapiens	58-62
26622487-9	2015	Rapamycin affected the mTOR signaling pathway in rats following fracture, as indicated by the inhibition of the phosphorylation of ribosomal protein S6, a target of mTOR, and activation of microtubule-associated protein 2 light chain 3, a key marker of autophagy.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	165-169
26224775-9	2015	Rats were pretreated with intrathecal injections of 20% DMSO (vehicle controls) or rapamycin (0.1 mM, 12 mul), a selective mTOR complex 1 inhibitor.	Sirolimus	83-92	mechanistic target of rapamycin kinase	Rattus norvegicus	123-127
25043732-6	2014	Systemic administration of a single low dose rapamycin (3mg/kg) led to enhanced neuronal activity in the amygdala analyzed by intracerebral electroencephalography and FOS protein expression 90min after drug injection.	Sirolimus	45-54	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-170
25257976-8	2014	RESULTS: Sirolimus significantly suppressed the LPS-induced expression of MCP-1, IL-8, RANTES, MIP-1alpha, and MIP-1beta in the THP-1 cells and human primary monocytes.	Sirolimus	9-18	C-C motif chemokine ligand 5	Homo sapiens	87-93
25257976-11	2014	CONCLUSION: Sirolimus downregulates the expression of chemokines in monocytes, including MCP-1, RANTES, IL-8, MIP-1alpha, and MIP-1beta, by inhibiting the NF-kappaB-p65 and MAPK-p38 signalling pathways.	Sirolimus	12-21	C-C motif chemokine ligand 5	Homo sapiens	96-102
26164831-8	2015	Rapamycin was administered to block mTOR activity.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	36-40
24794719-4	2014	Rapamycin increases the frequency of miniature excitatory postsynaptic currents and calcium transients of rat hippocampal primary neurons by a mechanism that involves the up regulation of SV2, a presynaptic vesicular protein linked to neurotransmitter release.	Sirolimus	0-9	synaptic vesicle glycoprotein 2a	Rattus norvegicus	188-191
25070853-3	2014	The mechanisms and signals that control the formation of tissue-resident memory CD8 T cells are poorly understood; however, one key regulator of memory CD8 T cell differentiation, mammalian target of rapamycin kinase, can be inhibited by rapamycin.	Sirolimus	200-209	CD8a molecule	Homo sapiens	80-83
25070853-3	2014	The mechanisms and signals that control the formation of tissue-resident memory CD8 T cells are poorly understood; however, one key regulator of memory CD8 T cell differentiation, mammalian target of rapamycin kinase, can be inhibited by rapamycin.	Sirolimus	200-209	CD8a molecule	Homo sapiens	152-155
26313913-3	2015	We report that rapamycin, an mTOR inhibitor, restored cardiac function in a passively beta1-AAB-immunized rat model with decreased cardiac function and myocardial autophagic flux.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
25149531-6	2014	In addition, cells treated with rapamycin showed a significant increase in p-Akt and a decrease in p-p70S6K that was associated with a decrease expression of vimentin and a slight increase expression in N-cadherin.	Sirolimus	32-41	cadherin 2	Homo sapiens	203-213
26349966-8	2015	Activation of PI3K by 740Y-P treatment leaded to upregulation of p-Akt, mTOR and MMP-9; inactivation of mTOR by Rapamycin treatment inhibited expression MMP-9 while activation of mTOR by l-Leucine treatment enhanced MMP-9 expression in Schisandrin B incubated cells.	Sirolimus	112-121	matrix metallopeptidase 9	Homo sapiens	153-158
26349966-8	2015	Activation of PI3K by 740Y-P treatment leaded to upregulation of p-Akt, mTOR and MMP-9; inactivation of mTOR by Rapamycin treatment inhibited expression MMP-9 while activation of mTOR by l-Leucine treatment enhanced MMP-9 expression in Schisandrin B incubated cells.	Sirolimus	112-121	matrix metallopeptidase 9	Homo sapiens	153-158
26006020-9	2015	Fibrin-cultured cells treated with rapamycin, the mTOR pathway inhibitor, had significantly decreased phospho-p70(s6k) and PDX-1 expression.	Sirolimus	35-44	annexin A6	Homo sapiens	110-113
25867817-7	2015	Flow cytometry results showed that the proportion of CD4(+) and CD8(+) T cells was significantly reduced, and the number of T regulatory cells increased in the spleen and lymph nodes in the iPSC-MSCs combined with the rapamycin group compared with the rapamycin-alone group.	Sirolimus	218-227	CD4 antigen	Mus musculus	53-56
26021876-8	2015	The expression of LC3 was enhanced in L5 DRG by rapamycin.	Sirolimus	48-57	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	18-21
26219339-4	2015	Our previous work demonstrated aberrant activation of mTORC1 signaling that led to ongoing clinical trials with rapamycin analogs for NF2 and sporadic meningioma patients.	Sirolimus	112-121	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	134-137
25349217-14	2015	However, rapamycin upregulated p27(Kip1) at least in part via AKT (also known as protein kinase B)/mTOR.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Rattus norvegicus	99-103
25836987-14	2015	Loss of mTOR regulation of NHE3 could mediate the development of diarrhea in patients undergoing rapamycin therapy.	Sirolimus	97-106	solute carrier family 9 member A3	Homo sapiens	27-31
26120832-5	2015	Rapamycin was used to treat rats as an mTOR inhibitor.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	39-43
26150775-8	2015	A single injection of sarcosine exhibited antidepressant-like effects in rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Rattus norvegicus	115-119
26150775-8	2015	A single injection of sarcosine exhibited antidepressant-like effects in rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment.	Sirolimus	190-199	mechanistic target of rapamycin kinase	Rattus norvegicus	175-179
26039212-5	2015	We targeted patients with advanced leukemia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54).	Sirolimus	51-60	calcineurin binding protein 1	Homo sapiens	68-89
25482130-8	2015	We also demonstrate that targeting LAT1 may be an efficient broad spectrum adjuvant approach to treat deadly T-cell malignancies as the molecule synergized with rapamycin, dexamethasone, doxorubicin, velcade and l-asparaginase to alter leukemic cell viability.	Sirolimus	161-170	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5	Mus musculus	35-39
26199613-4	2015	Rapamycin increased the levels of beta-catenin and brain-derived neurotrophic factor in the injured spinal cord, improved the pathological morphology at the injury site, reduced the loss of motor neurons, and promoted motor functional recovery in rats after spinal cord injury.	Sirolimus	0-9	brain-derived neurotrophic factor	Rattus norvegicus	51-84
25151963-9	2015	Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2.	Sirolimus	70-79	DNA damage inducible transcript 4	Homo sapiens	148-153
26060906-8	2015	Mutations in the TSC1 and TSC2 genes that cause tuberous sclerosis lead to hyperactivation of signaling via the mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	132-141	TSC complex subunit 2	Homo sapiens	26-30
25833958-9	2015	As co-administering Flt3L, rapamycin, and antigen blocked CD8(+) T-cell and antibody responses in models of gene and protein therapy, we conclude that the differential effect of rapamycin on DC subsets can be exploited for improved tolerance induction.	Sirolimus	27-36	CD8a molecule	Homo sapiens	58-61
25943884-8	2015	The optineurin level, RGC and axonal counts, and apoptosis in AAV2-E50K-GFP-injected rat eyes were averted to closer to normal limits after treatment with rapamycin, an autophagic enhancer.	Sirolimus	155-164	optineurin	Rattus norvegicus	4-14
25943884-11	2015	In addition, rapamycin is demonstrated to clear the accumulated mutant optineurin.	Sirolimus	13-22	optineurin	Rattus norvegicus	71-81
25866192-3	2015	Here we show that gene expression for several myogenic transcription factors including Myf5, Myog and Mef2c but not MyoD and myosin heavy chain isoforms decrease when C2C12 cells are treated with rapamycin, supporting a role for mTORC1 pathway during muscle development.	Sirolimus	196-205	myogenic factor 5	Mus musculus	87-91
24414276-1	2015	Human FKBP25, a nuclear protein, is a member of FK506 binding protein family (FKBP) and binds to immunosuppressive drugs such as FK506 and rapamycin.	Sirolimus	139-148	FKBP prolyl isomerase 3	Homo sapiens	6-12
25567352-2	2015	Merlin, the NF2 tumor suppressor, was identified as a negative regulator of mammalian target of rapamycin complex 1.	Sirolimus	96-105	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	0-6
25567352-2	2015	Merlin, the NF2 tumor suppressor, was identified as a negative regulator of mammalian target of rapamycin complex 1.	Sirolimus	96-105	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	12-15
25788687-3	2015	The present study focuses on Ube3A deficiency-induced alterations in signaling through the mechanistic target of rapamycin (mTOR) pathway in the cerebellum of the AS mouse model and on potential therapeutic applications of rapamycin.	Sirolimus	113-122	ubiquitin protein ligase E3A	Mus musculus	29-34
25794286-5	2015	Insulin signal transduction is mainly mediated via phosphoinositide 3-kinase (PI3K)/Akt, the target of rapamycin (TOR) and the extracellular signal-regulated kinase (ERK) pathways in vertebrates.	Sirolimus	103-112	phosphatidylinositol 3-kinase 60	Bombyx mori	51-76
25794286-5	2015	Insulin signal transduction is mainly mediated via phosphoinositide 3-kinase (PI3K)/Akt, the target of rapamycin (TOR) and the extracellular signal-regulated kinase (ERK) pathways in vertebrates.	Sirolimus	103-112	RAC serine/threonine-protein kinase	Bombyx mori	84-87
25277394-6	2015	Rapamycin abrogated the GLP-1R-dependent increase in pancreatic mass but had no effect on the robust induction of Reg3alpha and Reg3beta gene expression.	Sirolimus	0-9	glucagon-like peptide 1 receptor	Mus musculus	24-30
24984764-7	2014	Finally, a brief sirolimus treatment markedly prolonged RIPK3 null cardiac allograft survival in allogeneic BALB/c recipients as compared to WT C57BL/6 donor grafts (95 +- 5.8 vs. 24 +- 2.6 days, p &lt; 0.05).	Sirolimus	17-26	receptor interacting serine/threonine kinase 3	Homo sapiens	56-61
24769729-4	2014	Our previous studies have implicated autophagy in the survival of dormant ovarian cancer cells and have shown that ARHI is required for autophagy induced by starvation or rapamycin treatment.	Sirolimus	171-180	DIRAS family GTPase 3	Homo sapiens	115-119
24800850-7	2014	Phenotypic differences among hepatoma cell lines, specifically epithelial (HuH7 and HepG2) and mesenchymal (SNU-387 and SNU-449), correlated with the efficacy of rapamycin cotreatment, although rapamycin treatment did not affect cell phenotype.	Sirolimus	162-171	MIR7-3 host gene	Homo sapiens	75-79
25120315-1	2014	This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal function and histopathology in calcineurin inhibitor (CNI)-treated renal recipients with mild to moderate renal insufficiency.	Sirolimus	44-53	calcineurin binding protein 1	Homo sapiens	129-150
25120315-1	2014	This study was designed to evaluate whether sirolimus (SRL) conversion effectively improves renal function and histopathology in calcineurin inhibitor (CNI)-treated renal recipients with mild to moderate renal insufficiency.	Sirolimus	55-58	calcineurin binding protein 1	Homo sapiens	129-150
24637218-4	2014	In CD44-positive MDA-MB-468 cells, using HA as drug delivery carrier, the cell viability was significantly decreased compared to free rapamycin and CD44-blocked controls.	Sirolimus	134-143	CD44 molecule (Indian blood group)	Homo sapiens	3-7
24637218-6	2014	Moreover, in immunocompetent BALB/c mice bearing CD44-positive 4T1.2neu breast cancer, the rapamycin-loaded HA particles significantly improved animal survival, suppressed tumor growth and reduced the prevalence of lung metastasis.	Sirolimus	91-100	CD44 antigen	Mus musculus	49-53
24637218-7	2014	FROM THE CLINICAL EDITOR: This study demonstrates increased efficiency of rapamycin delivery and consequential treatment effects in a breast cancer model by hyaluronic acid - L-rapamycin conjugates with intrinsic tropism for CD44-positive cells.	Sirolimus	74-83	CD44 molecule (Indian blood group)	Homo sapiens	225-229
24913978-4	2014	We found that functional CD8 T cell and macrophage responses to both viral and intracellular bacterial pathogens were depressed in mice in vivo and in humans to phorbol ester and calcium ionophore stimulation in vitro in the face of low-dose Rapa treatment.	Sirolimus	242-246	CD8a molecule	Homo sapiens	25-28
24713582-4	2014	By using the mTOR inhibitor rapamycin, we show that SR-BI is down-regulated in human umbilical vein endothelial cells (HUVECs).	Sirolimus	28-37	scavenger receptor class B member 1	Homo sapiens	52-57
24713582-7	2014	The effects on cell migration could be counteracted by SR-BI overexpression, indicating that decreased SR-BI expression is in part responsible for the rapamycin-induced effects.	Sirolimus	151-160	scavenger receptor class B member 1	Homo sapiens	55-60
24713582-7	2014	The effects on cell migration could be counteracted by SR-BI overexpression, indicating that decreased SR-BI expression is in part responsible for the rapamycin-induced effects.	Sirolimus	151-160	scavenger receptor class B member 1	Homo sapiens	103-108
24713582-8	2014	We demonstrate that inhibition of mTOR leads to endothelial cell dysfunction and decreased SR-BI expression, which may contribute to atherogenesis during rapamycin treatment.	Sirolimus	154-163	scavenger receptor class B member 1	Homo sapiens	91-96
24604753-9	2014	Consistent with ROCK2 under-expression, microtubule acetylation was found to be increased with tuberin deficiency; this alteration was abrogated by rapamycin treatment and mimicked by HDAC6 inhibition.	Sirolimus	148-157	TSC complex subunit 2	Homo sapiens	95-102
24829408-3	2014	In this study, we injected rapamycin, a mTOR inhibitor, by the intracerebroventricular route 6 h after focal ischemic stroke in rats.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	40-44
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	BCL2 antagonist/killer 1	Homo sapiens	153-156
24901052-4	2014	The combination of mitomycin C and rapamycin inactivated p70 S6 ribosomal kinase (S6K1) and dephosphorylated Bad, leading to dissociation of Bcl-xL from Bak, which resulted in Bak oligomerization, mitochondria dysfunction and cytochrome c release.	Sirolimus	35-44	BCL2 antagonist/killer 1	Homo sapiens	176-179
24530860-7	2014	Attenuation of autophagosomal activity by 3-methyladenine increases DEPP protein levels while activation of autophagy by rapamycin reduced DEPP protein levels.	Sirolimus	121-130	DEPP1 autophagy regulator	Homo sapiens	139-143
24510654-2	2014	The present study investigates whether rapamycin, an inhibitor of the mTOR pathway, protects against N-methyl-D-aspartate (NMDA)-induced retinal neurotoxicity and whether the extracellular signal-regulated kinase (ERK) pathway contributes to this protective effect in rats.	Sirolimus	39-48	mechanistic target of rapamycin kinase	Rattus norvegicus	70-74
24831086-7	2014	Inhibition of S6 phosphorylation by rapamycin restores PARP sensitivity to resistant cells.	Sirolimus	36-45	poly (ADP-ribose) polymerase family, member 1	Mus musculus	55-59
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	fatty acid synthase	Homo sapiens	76-80
24866893-5	2014	The present study implicated the PI3K/AKT/mTOR pathway in the regulation of FASN expression in ER/HER2-positive breast cancer cells and demonstrated that rapamycin, an mTOR inhibitor, inhibited FASN expression.	Sirolimus	154-163	fatty acid synthase	Homo sapiens	194-198
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	184-213
24607296-6	2014	Interestingly, rapamycin pretreatment significantly suppressed light-induced ER stress and all three major branches of the unfolded protein response (UPR), including the RNA-dependent protein kinase-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) pathways both at the protein and mRNA levels.	Sirolimus	15-24	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	215-219
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	E74 like ETS transcription factor 1	Mus musculus	213-216
24607296-8	2014	Meanwhile, our results also revealed that rapamycin was able to remarkably inhibit the activation of mTOR and its downstream factors eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), p-4EBP1, p70, p-p70, and phosphorylated ribosomal protein S6 kinase (p-S6K) in the light-injured 661W cells.	Sirolimus	42-51	E74 like ETS transcription factor 1	Mus musculus	220-223
23996918-1	2014	OBJECTIVE: To evaluate the effects of the everolimus-eluting Xience /Promus  stent (EES) and the sirolimus-eluting Cypher  stent (SES) on intimal hyperplasia (IH) in diabetic patients.	Sirolimus	97-106	LIM domain binding 3	Homo sapiens	115-121
24375611-4	2014	This study clarified the effect of simvastatin on Akt/mTOR/p70 S6K and FoxO3a signalling pathways in rat CMECs following pretreated with rapamycin.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
24375611-8	2014	The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	134-138
24375611-8	2014	The data suggest that simvastatin inhibits rapamycin-induced CMECs dysfunction and apoptosis, probably through activation of PI3K/Akt/mTOR/p70 S6K and mTOR/FoxO3a signalling pathway in a sequential manner and this pathway may be important in some of the pleiotropic effects of statins.	Sirolimus	43-52	mechanistic target of rapamycin kinase	Rattus norvegicus	151-155
24683191-7	2014	DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +- 1.48%, rapamycin: 5.03 +- 0.66%; p &lt; 0.001).	Sirolimus	141-150	CD8a molecule	Homo sapiens	54-57
24683191-10	2014	IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +- 0.66%, HC: 2.29 +- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +- 0.79%, rapamycin: 2.22 +- 0.60%; p &lt; 0.001).	Sirolimus	131-140	interleukin 17A	Homo sapiens	0-5
24695395-9	2014	These effects were prevented by the presence of either melatonin (10 mmol/l) or the inhibitor of mTOR, rapamycin (10 mmol/l).	Sirolimus	103-112	mechanistic target of rapamycin kinase	Rattus norvegicus	97-101
24714658-1	2014	The TSC1-TSC2-TBC1D7 complex is an important negative regulator of the mechanistic target of rapamycin complex 1 that controls cell growth in response to environmental cues.	Sirolimus	93-102	TSC complex subunit 2	Homo sapiens	9-13
24514902-9	2014	Expression of the activated EGOC GTPase subunits Gtr1(GTP) and Gtr2(GDP) partially suppressed vps-c mutant rapamycin recovery defects, and this suppression was enhanced by increased amino acid concentrations.	Sirolimus	107-116	Gtr2p	Saccharomyces cerevisiae S288C	63-67
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	10-16
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	22-25
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	166-172
24414536-2	2014	Recently, merlin, the NF2 tumor suppressor, has been identified as a novel negative regulator of mammalian target of rapamycin complex 1 (mTORC1); functional loss of merlin was shown to result in elevated mTORC1 signaling in NF2-related tumors.	Sirolimus	117-126	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	225-228
24691473-6	2014	Treatment of those same cells used in the imatinib studies with rapamycin, an inhibitor of mTOR, resulted in elevated GPx-1 and GPx-4 protein levels independent of Bcr-Abl expression.	Sirolimus	64-73	glutathione peroxidase 1	Homo sapiens	118-123
24691473-6	2014	Treatment of those same cells used in the imatinib studies with rapamycin, an inhibitor of mTOR, resulted in elevated GPx-1 and GPx-4 protein levels independent of Bcr-Abl expression.	Sirolimus	64-73	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	164-171
24760501-10	2014	High rapamycin prevented an increase in SLC38A2/SNAT2 (P = 0.075) and SLC36A1/PAT1 (P &gt;= 0.06) mRNA abundance whereas both rapamycin doses prevented an increase in SLC7A5/LAT1 (P &gt;= 0.902) mRNA abundance.	Sirolimus	5-14	solute carrier family 38 member 2	Homo sapiens	40-47
24760501-10	2014	High rapamycin prevented an increase in SLC38A2/SNAT2 (P = 0.075) and SLC36A1/PAT1 (P &gt;= 0.06) mRNA abundance whereas both rapamycin doses prevented an increase in SLC7A5/LAT1 (P &gt;= 0.902) mRNA abundance.	Sirolimus	5-14	solute carrier family 38 member 2	Homo sapiens	48-53
25404086-0	2015	Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-beta signalling pathway in kidney transplant.	Sirolimus	49-58	calcineurin binding protein 1	Homo sapiens	20-41
25527453-7	2015	In KYO-1 cells where Akt is not constitutively active, Mnk inhibitors increase the sensitivity of cells to rapamycin, resulting in a more pronounced anti-proliferative activity.	Sirolimus	107-116	ATPase copper transporting alpha	Homo sapiens	55-58
24396066-4	2014	The Paip1-eIF3 interaction is impaired by the mTORC1 inhibitors, rapamycin and PP242.	Sirolimus	65-74	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	10-14
24445976-1	2014	OBJECTIVES: Erlotinib and Rapamycin are both in clinical use and experimental inhibition of their respective molecular targets, EGFR and mTORC1, has improved recovery from spinal cord injury.	Sirolimus	26-35	epidermal growth factor receptor	Rattus norvegicus	128-132
24445976-10	2014	In vitro studies confirmed that Erlotinib and Rapamycin both inhibit the EGFR-mTORC1 signaling pathway.	Sirolimus	46-55	epidermal growth factor receptor	Rattus norvegicus	73-77
25512609-9	2015	The TORC1-controlled transcriptional activators Gln3p, Gat1p, Rtg1p, and Rtg3p, but not Msn2p and Msn4p, were required for full induction of LDs by rapamycin.	Sirolimus	148-157	Rtg1p	Saccharomyces cerevisiae S288C	62-67
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	lysosomal acid lipase A	Mus musculus	23-26
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	integrin subunit alpha M	Homo sapiens	70-75
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	integrin subunit alpha M	Homo sapiens	95-100
24287405-5	2014	Rapamycin treatment of lal(-/-) mice stimulated a shift from immature CD11b(+)Ly6G(+) cells to CD11b(+) single-positive cells in marrow and tissues and partially reversed the increased cell proliferation, decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow CD11b(+)Ly6G(+) cells obtained from lal(-/-) mice.	Sirolimus	0-9	integrin subunit alpha M	Homo sapiens	95-100
24401275-3	2014	Targeted depletion of MAPK-interacting Ser/Thr kinase 1 (MNK1) sensitizes glioma cells to the mTORC1 inhibitor rapamycin through an indistinct mechanism.	Sirolimus	111-120	MAPK interacting serine/threonine kinase 1	Homo sapiens	22-55
24401275-3	2014	Targeted depletion of MAPK-interacting Ser/Thr kinase 1 (MNK1) sensitizes glioma cells to the mTORC1 inhibitor rapamycin through an indistinct mechanism.	Sirolimus	111-120	MAPK interacting serine/threonine kinase 1	Homo sapiens	57-61
25342595-5	2015	Here, we show that NH4Cl significantly inhibited rapamycin-induced autophagy in HCC cells through decreasing the levels of Beclin-1, autophagy-related protein 7 (ATG7), p62, and autophagosome marker LC3 and significantly decreased the level of phosphorylated SMAD2 in rapamycin-treated HCC cells.	Sirolimus	49-58	beclin 1	Homo sapiens	123-131
24395633-3	2014	Against this background, we report a dramatic response in a young patient with advanced HL refractory to the standard treatment who responded to the combination of a pan-histone deacetylase inhibitor (vorinostat, suberoylanilide hydroxamic acid, SAHA) and mammalian target of rapamycin (mTOR) inhibitor therapy (sirolimus,rapamume).	Sirolimus	312-321	histone deacetylase 9	Homo sapiens	170-189
25342595-5	2015	Here, we show that NH4Cl significantly inhibited rapamycin-induced autophagy in HCC cells through decreasing the levels of Beclin-1, autophagy-related protein 7 (ATG7), p62, and autophagosome marker LC3 and significantly decreased the level of phosphorylated SMAD2 in rapamycin-treated HCC cells.	Sirolimus	49-58	nucleoporin 62	Homo sapiens	169-172
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Rattus norvegicus	17-21
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Rattus norvegicus	95-99
25945415-9	2015	Consistent with observed sensitivity of S-phase cells to rapamycin, interfering with Gln utilization sensitized both MDA-MB-231 and Calu-1 K-Ras mutant cancer cells to the apoptotic effect of rapamycin.	Sirolimus	192-201	KRAS proto-oncogene, GTPase	Homo sapiens	139-144
26016899-5	2015	The use of a quantitative Real-Time-polymerase chain reaction ReTi-PCR technique and high performance liquid chromatography (HPLC) allowed us to determine the increase in gamma-globin mRNA expression and Hb F production in human erythroid cells treated with rapamycin.	Sirolimus	258-267	hemoglobin subunit gamma 1	Homo sapiens	171-183
24313960-7	2013	Both elevated mTOR-S6K signaling and enhanced LTP induced by BV injection were reversed by systemic injection of the mTOR inhibitor rapamycin (RAPA).	Sirolimus	132-141	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
24313960-7	2013	Both elevated mTOR-S6K signaling and enhanced LTP induced by BV injection were reversed by systemic injection of the mTOR inhibitor rapamycin (RAPA).	Sirolimus	132-141	mechanistic target of rapamycin kinase	Rattus norvegicus	117-121
24184927-4	2013	In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with the lysosomal protein marker LAMP2.	Sirolimus	91-100	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	182-185
24184927-4	2013	In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with the lysosomal protein marker LAMP2.	Sirolimus	91-100	sequestosome 1	Homo sapiens	193-199
24184927-4	2013	In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with the lysosomal protein marker LAMP2.	Sirolimus	91-100	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	280-283
24184927-4	2013	In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with the lysosomal protein marker LAMP2.	Sirolimus	91-100	lysosomal associated membrane protein 2	Homo sapiens	363-368
24238063-9	2013	A colocalization of GFP-LC3B and RFP-Lamp1 upon stimulation of rapamycin became obvious in transfected podocytes, which could be substantially blocked by nicotinamide, CD38 shRNA, and bafilomycin.	Sirolimus	63-72	tripartite motif-containing 27	Mus musculus	33-36
24238063-9	2013	A colocalization of GFP-LC3B and RFP-Lamp1 upon stimulation of rapamycin became obvious in transfected podocytes, which could be substantially blocked by nicotinamide, CD38 shRNA, and bafilomycin.	Sirolimus	63-72	lysosomal-associated membrane protein 1	Mus musculus	37-42
24238063-9	2013	A colocalization of GFP-LC3B and RFP-Lamp1 upon stimulation of rapamycin became obvious in transfected podocytes, which could be substantially blocked by nicotinamide, CD38 shRNA, and bafilomycin.	Sirolimus	63-72	CD38 antigen	Mus musculus	168-172
24238063-10	2013	Moreover, blockade of the CD38-mediated regulation by PPADS completely abolished rapamycin-induced fusion of APs with lysosomes.	Sirolimus	81-90	CD38 antigen	Mus musculus	26-30
23777415-7	2013	The mTOR inhibitor rapamycin abolished the long-term protective effects of IPostC.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
23777415-11	2013	The mTOR inhibitor rapamycin abolished the long-term protective effects of IPostC.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
24126911-0	2013	Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.	Sirolimus	0-9	dual specificity phosphatase 1	Mus musculus	18-70
24126911-0	2013	Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.	Sirolimus	0-9	dual specificity phosphatase 1	Mus musculus	72-77
24126911-4	2013	Low dose rapamycin led to a rapid activation of both AKT and ERK pathways with a subsequent increase in MKP-1 expression.	Sirolimus	9-18	dual specificity phosphatase 1	Mus musculus	104-109
24126911-5	2013	Rapamycin treatment led to phosphorylation of CREB, transcription factor 1 (ATF1), and ATF2, three transcription factors that bind to the cyclic AMP-responsive elements on the Mkp-1 promoter.	Sirolimus	0-9	dual specificity phosphatase 1	Mus musculus	176-181
24126911-8	2013	Using bone marrow-derived macrophages (BMDMs) derived from wild-type (WT) mice or mice deficient in AKT1 and AKT2 isoforms or BMDM from targeted deficiency in MEK1 and MEK2, we show that rapamycin treatment led to an increased MKP1 expression in BMDM from WT but failed to do so in BMDMs lacking the AKT1 isoform or MEK1 and MEK2.	Sirolimus	187-196	dual specificity phosphatase 1	Mus musculus	227-231
24123683-7	2013	However, the concurrent administration of rapamycin, with or without IL-2/anti-IL-2 Ab complexes, to the transplant recipients significantly improved Foxp3 stability in CD4 iTregs (and, to a lesser extent, CD8 iTregs), such that they remained detectable 12 wk after transfer.	Sirolimus	42-51	CD8a molecule	Homo sapiens	206-209
24078700-3	2013	In this study, we demonstrate that aging increases TORC2 signaling in murine CD4 T cells, a change blocked by long-term exposure to rapamycin, suggesting that functional defects may be the result of enhanced TORC2 function.	Sirolimus	132-141	CD4 antigen	Mus musculus	77-80
24090996-0	2013	Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.	Sirolimus	101-110	CD4 antigen	Mus musculus	43-46
24090996-9	2013	Rapamycin treatment selectively arrested more CD8(+)CD4(+) T-ALL cells at G0 phase of cell cycle.	Sirolimus	0-9	CD4 antigen	Mus musculus	52-55
24204783-2	2013	We found that rapamycin, at nM concentrations, increased phosphorylation of eukaryotic initiation factor (eIF) 2alpha in rapamycin-sensitive and estrogen-dependent MCF-7 cells, but had only a minimal effect on eIF2alpha phosphorylation in the rapamycin-insensitive triple-negative MDA-MB-231 cells.	Sirolimus	121-130	eukaryotic translation initiation factor 2A	Homo sapiens	106-117
24205354-5	2013	The best synergistic efficacy caused the highest decrease in cell viability due to combination of 50 nM LC3 shRNA plasmid transfection and 25 microM GST treatment in rapamycin-treated SK-N-BE2 cells while combination of 100 nM LC3 shRNA plasmid transfection and 25 microM GST treatment in rapamycin-treated IMR-32 cells.	Sirolimus	166-175	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	104-107
24205354-5	2013	The best synergistic efficacy caused the highest decrease in cell viability due to combination of 50 nM LC3 shRNA plasmid transfection and 25 microM GST treatment in rapamycin-treated SK-N-BE2 cells while combination of 100 nM LC3 shRNA plasmid transfection and 25 microM GST treatment in rapamycin-treated IMR-32 cells.	Sirolimus	166-175	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	227-230
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	74-77
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	beclin 1	Homo sapiens	233-241
24205354-6	2013	Quantitation of acidic vesicular organelles confirmed that combination of LC3 shRNA plasmid transfection and GST treatment prevented rapamycin-induced autophagy due to down regulation of autophagy promoting marker molecules (LC3 II, Beclin 1, TLR-4, and Myd88) and upregulation of autophagy inhibiting marker molecules (p62 and mTOR) in both cell lines.	Sirolimus	133-142	nucleoporin 62	Homo sapiens	320-323
26219309-9	2015	Although harmful to the control flies, administration of 400 muM rapamycin before the induction of dTDP overexpression can significantly reduce the number of neurons bearing dTDP (+) aggregates, as well as partially rescue the diminished lifespan and locomotive defects of the ALS-TDP flies.	Sirolimus	65-74	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	99-103
24146762-1	2013	BACKGROUND: Measures to prevent chronic calcineurin inhibitor (CNI) toxicity have included limiting exposure by switching to sirolimus (SIR).	Sirolimus	125-134	calcineurin binding protein 1	Homo sapiens	40-61
24116217-5	2013	The reduced mitochondrial respiration of icp55 deletion strains in glucose media requires the mitochondrial peptide transporter, Mdl1p, and was corrected by Tor1p inhibition with rapamycin.	Sirolimus	179-188	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	157-162
23928863-5	2013	We provide evidence that vascular progenitor cells treated with sirolimus resulted in an induction of their migration in both transwell and wound healing models, clearly mediated by CXCR4 activation.	Sirolimus	64-73	C-X-C motif chemokine receptor 4	Homo sapiens	182-187
23928863-10	2013	CONCLUSIONS: These findings provide direct evidence of sirolimus-induced progenitor cell migration and differentiation into SMC via CXCR4 and epidermal growth factor receptor/extracellular signal-regulated kinase/beta-catenin signal pathways, thus implicating a novel mechanism of restenosis formation after sirolimus-eluting stent treatment.	Sirolimus	55-64	C-X-C motif chemokine receptor 4	Homo sapiens	132-137
26219309-9	2015	Although harmful to the control flies, administration of 400 muM rapamycin before the induction of dTDP overexpression can significantly reduce the number of neurons bearing dTDP (+) aggregates, as well as partially rescue the diminished lifespan and locomotive defects of the ALS-TDP flies.	Sirolimus	65-74	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	174-178
26312014-6	2015	Rapamycin decreased mouse heart-to-body weight ratio, improved cardiac performance, and decreased phosphorylation of mTOR and downstream targets p70S6K and S6 in 10-day-old Ryr2ADA/ADA mice but did not extend longevity.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	145-151
26312014-6	2015	Rapamycin decreased mouse heart-to-body weight ratio, improved cardiac performance, and decreased phosphorylation of mTOR and downstream targets p70S6K and S6 in 10-day-old Ryr2ADA/ADA mice but did not extend longevity.	Sirolimus	0-9	ryanodine receptor 2, cardiac	Mus musculus	173-177
25185584-2	2015	The TSC protein complex inhibits the mammalian or mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	72-81	TSC complex subunit 2	Homo sapiens	4-7
25185584-5	2015	Using a high-throughput chemical screen in TSC2-deficient, patient-derived cells, we identified a series of molecules antagonized by rapamycin and therefore selective for cells with mTORC1 hyperactivity.	Sirolimus	133-142	TSC complex subunit 2	Homo sapiens	43-47
25187207-8	2015	Pretreatment with rapamycin for 4 days significantly slowed proliferation of GLUT1-selected cells, whereas propranolol pretreatment had no effect.	Sirolimus	18-27	solute carrier family 2 member 1	Homo sapiens	77-82
25801056-6	2015	Perifosine or rapamycin almost abolished the decrease of the Ces1d and Ces1e expression and the hydrolytic activity induced by the insulin in the primary mouse hepatocytes.	Sirolimus	14-23	carboxylesterase 1E	Mus musculus	71-76
25359003-6	2014	In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an alpha phase of 67.7 +- 6.9 h and a beta phase of 252.1 +- 54.9 h. These results suggest that rapamycin may be a necessary addition to Treg immunotherapy, and that tacrolimus may be deleterious to Treg integrity posttransfer.	Sirolimus	13-22	forkhead box P3	Macaca mulatta	62-67
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	269-275
25364403-3	2014	The current study demonstrates that rapamycin may enhance the chemopreventive effects of SFN on Caco-2 cells; this may be partially attributed to nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2)- and human pregnane X receptor (hPXR)-mediated UGT1A1, UGT1A8 and UGT1A10 induction.	Sirolimus	36-45	UDP glucuronosyltransferase family 1 member A8	Homo sapiens	277-283
25375091-3	2014	The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin.	Sirolimus	32-41	beclin 1	Homo sapiens	206-211
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	aurora kinase B	Homo sapiens	62-67
25193464-0	2014	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.	Sirolimus	133-142	polo like kinase 1	Homo sapiens	69-73
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	aurora kinase B	Homo sapiens	112-117
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	43-52	polo like kinase 1	Homo sapiens	119-123
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	aurora kinase B	Homo sapiens	112-117
25193464-4	2014	RNAi screens conducted in combination with rapamycin in multiple breast cancer cell lines identified six genes, AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 that when silenced, each enhanced the sensitivity of multiple breast cancer lines to rapamycin.	Sirolimus	242-251	polo like kinase 1	Homo sapiens	119-123
25193464-5	2014	Using selective pharmacological agents we confirmed that inhibition of AURKB or PLK1 synergizes with rapamycin.	Sirolimus	101-110	aurora kinase B	Homo sapiens	71-76
25411474-0	2014	A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.	Sirolimus	96-105	KRAS proto-oncogene, GTPase	Homo sapiens	26-30
25411474-7	2014	However, we found that rapamycin, in addition to inhibiting the mammalian target of rapamycin (mTOR) pathway, facilitated autophagy and prevented p62 accumulation-induced NF-kappaB activation and tumor cell proliferation.	Sirolimus	23-32	nucleoporin 62	Homo sapiens	146-149
25411474-8	2014	Overall, these results suggest that using lipophilic bisphosphonates in combination with rapamycin may provide an effective strategy for targeting lung adenocarcinomas harboring KRAS mutations.	Sirolimus	89-98	KRAS proto-oncogene, GTPase	Homo sapiens	178-182
25159322-5	2014	To determine if active CaMKKalpha expression stimulated muscle growth via increased mammalian target of rapamycin complex 1 (mTORC1) signaling and protein synthesis, [3H]phenylalanine incorporation into proteins was assessed with or without the mTORC1 inhibitor rapamycin.	Sirolimus	104-113	calcium/calmodulin dependent protein kinase kinase 1	Homo sapiens	23-33
25150927-8	2014	Treatment with rapamycin also significantly inhibited increased p62 protein levels induced by TNF.	Sirolimus	15-24	sequestosome 1	Homo sapiens	64-67
25243405-11	2014	Finally, we found that the effects of ICK or MOK knockdown on cilium length and IFT are suppressed by rapamycin treatment, suggesting that these effects require the mTORC1 pathway.	Sirolimus	102-111	ciliogenesis associated kinase 1	Mus musculus	38-41
24976516-9	2014	GFAP and mTOR expression in the rat spinal dorsal horn on post-surgical day 14 was enhanced by daily intrathecal injection of ADP, which was inhibited by rapamycin.	Sirolimus	154-163	glial fibrillary acidic protein	Rattus norvegicus	0-4
24976516-9	2014	GFAP and mTOR expression in the rat spinal dorsal horn on post-surgical day 14 was enhanced by daily intrathecal injection of ADP, which was inhibited by rapamycin.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Rattus norvegicus	9-13
25307036-10	2014	These findings suggest that sirolimus is more effective in improving GFR in patients without preexisting diabetes, and adequate MMF doses are needed for sirolimus conversion.	Sirolimus	28-37	Rap guanine nucleotide exchange factor 5	Homo sapiens	69-72
24682776-5	2014	Rapamycin restored abnormal mTOR/p70S6K signaling and attenuated the phosphorylation of tau protein in the hippocampus of diabetic mice.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	33-39
24682776-7	2014	These findings indicate that mTOR/p70S6K signaling pathway is hyperactive in the hippocampus of STZ-induced diabetic mice and inhibiting mTOR signaling with rapamycin prevents the DM-related cognitive deficits partly through attenuating the hyperphosphorylation of tau protein.	Sirolimus	157-166	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	34-40
24850187-9	2014	Down-regulation of bax and caspase-3 protein, and up-regulation of nephrin and podocin protein were observed in the glomeruli of diabetic mice after administration of rapamycin.	Sirolimus	167-176	BCL2-associated X protein	Mus musculus	19-22
24850187-9	2014	Down-regulation of bax and caspase-3 protein, and up-regulation of nephrin and podocin protein were observed in the glomeruli of diabetic mice after administration of rapamycin.	Sirolimus	167-176	caspase 3	Mus musculus	27-36
24850187-9	2014	Down-regulation of bax and caspase-3 protein, and up-regulation of nephrin and podocin protein were observed in the glomeruli of diabetic mice after administration of rapamycin.	Sirolimus	167-176	nephrosis 1, nephrin	Mus musculus	67-74
24850187-9	2014	Down-regulation of bax and caspase-3 protein, and up-regulation of nephrin and podocin protein were observed in the glomeruli of diabetic mice after administration of rapamycin.	Sirolimus	167-176	nephrosis 2, podocin	Mus musculus	79-86
24998444-6	2014	Rapamycin or FK506 treatments of the polyribosomes isolated from porcine brain, HeLa and K568 cells caused a residual release of the endogenous FKBP25, which suggests that the immunophilin also binds to some proteins via its PPIase cavity.	Sirolimus	0-9	FKBP prolyl isomerase 3	Homo sapiens	144-150
24998444-6	2014	Rapamycin or FK506 treatments of the polyribosomes isolated from porcine brain, HeLa and K568 cells caused a residual release of the endogenous FKBP25, which suggests that the immunophilin also binds to some proteins via its PPIase cavity.	Sirolimus	0-9	FKBP prolyl isomerase 3	Homo sapiens	225-231
24936056-5	2014	Notably, depletion/inhibition of PRCP/PREP destabilized IRS-1 in the cells treated with rapamycin, blocking the feedback activation PI3K/AKT.	Sirolimus	88-97	prolylcarboxypeptidase	Homo sapiens	33-37
24917666-0	2014	Rapamycin and interleukin-1beta impair brain-derived neurotrophic factor-dependent neuron survival by modulating autophagy.	Sirolimus	0-9	brain derived neurotrophic factor	Homo sapiens	39-72
24917666-4	2014	We report that mTOR activation is necessary for BDNF-dependent survival of primary rat hippocampal neurons, as either mTOR inhibition by rapamycin or genetic manipulation of the downstream molecule p70S6K specifically blocked BDNF rescue.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
24917666-4	2014	We report that mTOR activation is necessary for BDNF-dependent survival of primary rat hippocampal neurons, as either mTOR inhibition by rapamycin or genetic manipulation of the downstream molecule p70S6K specifically blocked BDNF rescue.	Sirolimus	137-146	brain-derived neurotrophic factor	Rattus norvegicus	48-52
24917666-4	2014	We report that mTOR activation is necessary for BDNF-dependent survival of primary rat hippocampal neurons, as either mTOR inhibition by rapamycin or genetic manipulation of the downstream molecule p70S6K specifically blocked BDNF rescue.	Sirolimus	137-146	mechanistic target of rapamycin kinase	Rattus norvegicus	118-122
24917666-7	2014	shRNA against the autophagic machinery Atg7 or Atg5 prolonged the survival of neurons co-treated with BDNF and rapamycin, suggesting that suppression of mTOR in BDNF-treated cells resulted in excessive autophagy.	Sirolimus	111-120	mechanistic target of rapamycin kinase	Rattus norvegicus	153-157
24917666-7	2014	shRNA against the autophagic machinery Atg7 or Atg5 prolonged the survival of neurons co-treated with BDNF and rapamycin, suggesting that suppression of mTOR in BDNF-treated cells resulted in excessive autophagy.	Sirolimus	111-120	brain-derived neurotrophic factor	Rattus norvegicus	161-165
24917666-8	2014	Finally, acting as a physiological analog of rapamycin, IL-1beta impaired BDNF signaling by way of inhibiting mTOR activation as follows: the cytokine induced caspase-independent neuronal death and accelerated autophagic flux in BDNF-treated cells.	Sirolimus	45-54	brain-derived neurotrophic factor	Rattus norvegicus	74-78
25071443-9	2014	Furthermore, the neuroprotective effect of miR-7 and miR-153 was alleviated when MPP(+) was co-administered with rapamycin.	Sirolimus	113-122	leukocyte immunoglobulin like receptor B1	Homo sapiens	43-48
24796670-9	2014	RESULTS: The rapamycin treatment significantly attenuated cisplatin-induced hearing loss, decreased oxidative stress, and alleviated the hair cell damage that was associated with the upregulation of the LC3-II/GAPDH ratio and increased Beclin-1 expression.	Sirolimus	13-22	glyceraldehyde-3-phosphate dehydrogenase	Rattus norvegicus	210-215
24901052-0	2014	Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1-Bad-Bak pathway in peritoneal carcinomatosis.	Sirolimus	0-9	BCL2 antagonist/killer 1	Homo sapiens	88-91
24889507-2	2014	Tsc1 and Tsc2 proteins form a complex that inhibits mammalian target of rapamycin complex 1 (mTORC1) signalling through Rheb-GTPase.	Sirolimus	72-81	TSC complex subunit 2	Homo sapiens	9-13
24631848-2	2014	These metabolic changes result in the development of both a spontaneous cardiac hypertrophy and increased phosphorylated S6 kinase (S6K), a substrate of the mechanistic target of rapamycin, mTOR.	Sirolimus	179-188	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	121-130
24631848-2	2014	These metabolic changes result in the development of both a spontaneous cardiac hypertrophy and increased phosphorylated S6 kinase (S6K), a substrate of the mechanistic target of rapamycin, mTOR.	Sirolimus	179-188	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	132-135
24631848-8	2014	Rapamycin completely blocked the enhanced ventricular S6K phosphorylation and cardiac hypertrophy and attenuated the expression of hypertrophy-associated fetal genes, including alpha-skeletal actin and B-type natriuretic peptide.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	54-57
24630239-9	2014	In contrast, rapamycin altered the expression of MMP1 gene at the transcriptional level through the JNK/c-Jun signaling pathway in those cells.	Sirolimus	13-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	104-109
24861463-10	2014	Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD.	Sirolimus	144-153	glucose-6-phosphate dehydrogenase	Homo sapiens	31-35
24861463-10	2014	Mechanistically, regulation of G6PD via AR in both hormone-sensitive and castration-resistant models of prostate cancer was abolished following rapamycin treatment, indicating that AR increased flux through the pentose phosphate pathway by the mammalian target of rapamycin (mTOR)-mediated upregulation of G6PD.	Sirolimus	144-153	glucose-6-phosphate dehydrogenase	Homo sapiens	306-310
24619883-0	2014	PPARgamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats.	Sirolimus	84-93	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
24619883-0	2014	PPARgamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Rattus norvegicus	63-67
24619883-1	2014	mTOR inhibition with rapamycin induces a diabetes-like syndrome characterized by severe glucose intolerance, hyperinsulinemia, and hypertriglyceridemia, which is due to increased hepatic glucose production as well as reduced skeletal muscle glucose uptake and adipose tissue PPARgamma activity.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
24619883-1	2014	mTOR inhibition with rapamycin induces a diabetes-like syndrome characterized by severe glucose intolerance, hyperinsulinemia, and hypertriglyceridemia, which is due to increased hepatic glucose production as well as reduced skeletal muscle glucose uptake and adipose tissue PPARgamma activity.	Sirolimus	21-30	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	275-284
24619883-9	2014	Our findings indicate that PPARgamma activation ameliorates some of the disturbances in glucose homeostasis and insulin action associated with chronic rapamycin treatment by reducing gluconeogenesis and insulin secretion and restoring muscle insulin signaling and glucose uptake.	Sirolimus	151-160	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	27-36
25049998-5	2014	Rapamycin treatment of aged IVM oocytes for 24 h also rescued aberrant spindle organization and chromosomal misalignment, blocked the decrease in the level of phosphorylated-p44/42 mitogen-activated protein kinase (MAPK), and increased the mRNA expression of cytoplasmic maturation factor genes (MOS, BMP15, GDF9, and CCNB1) compared with untreated, 24 h-aged IVM oocytes (p&lt;0.05).	Sirolimus	0-9	growth differentiation factor 9	Homo sapiens	308-312
24485875-10	2014	RESULTS: Our results indicate that sirolimus exerts prolonged suppression of lymphocyte proliferation and decreased interleukin 17A that lasts up to 48 h after drug withdrawal.	Sirolimus	35-44	interleukin 17A	Homo sapiens	116-131
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	CD8a molecule	Homo sapiens	69-72
24107844-6	2014	The number of circulating CD4(+)/CD25(high)/Foxp3(+)/CTLA4(+) Tregs, CD8(+)CD28(-) T cells, and HLA-G serum levels were higher in the rapamycin-treated group.	Sirolimus	134-143	major histocompatibility complex, class I, G	Homo sapiens	96-101
24107844-9	2014	Thus, rapamycin induces the upregulation of ILT3 and ILT4 on the DC surface, and this effect is associated with an increase in the number of Tregs and expansion of the CD8(+)CD28(-) T cell population.	Sirolimus	6-15	CD8a molecule	Homo sapiens	168-171
24414536-6	2014	Consistent with these results, in an NF2 patient with growing vestibular schwannomas, the rapalog sirolimus induced tumor growth arrest.	Sirolimus	98-107	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	37-40
24462935-8	2014	The inhibition of Beclin 1 by siRNAs significantly attenuated the expression of autophagy-related proteins and reduced HUVEC viability following OGD and rapamycin treatment.	Sirolimus	153-162	beclin 1	Homo sapiens	18-26
24602288-5	2014	METHODS: A rat ICH model was induced by intracerebral injection of collagenase IV into the striatum, and mTOR activation was inhibited by administration of rapamycin.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Rattus norvegicus	105-109
24602288-11	2014	Rapamycin treatment significantly improved the neurobehavioral deficit after ICH, increased the number of Tregs, increased levels of interleukin-10 and transforming growth factor-beta and reduced interferon-gamma both in peripheral blood and brain.	Sirolimus	0-9	interleukin 10	Homo sapiens	133-183
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	beclin 1	Homo sapiens	46-53
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	beclin 1	Homo sapiens	83-90
24587252-14	2014	Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1.	Sirolimus	120-129	beclin 1	Homo sapiens	83-90
24586612-4	2014	In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Rattus norvegicus	212-216
24057571-8	2014	Treatment with rapamycin, an mTOR inhibitor, MK2206, an Akt inhibitor, and BI-D1870, a RSK inhibitor, partially suppressed CdCl2-induced ATF4 expression.	Sirolimus	15-24	activating transcription factor 4	Homo sapiens	137-141
24345797-7	2014	Furthermore, pretreatment of HK-2 cells with rapamycin reduced the production of LCN2/NGAL and HAVCR1/KIM-1 and the level of apoptosis induced by urinary proteins.	Sirolimus	45-54	lipocalin 2	Homo sapiens	81-85
24345797-7	2014	Furthermore, pretreatment of HK-2 cells with rapamycin reduced the production of LCN2/NGAL and HAVCR1/KIM-1 and the level of apoptosis induced by urinary proteins.	Sirolimus	45-54	lipocalin 2	Homo sapiens	86-90
24345797-7	2014	Furthermore, pretreatment of HK-2 cells with rapamycin reduced the production of LCN2/NGAL and HAVCR1/KIM-1 and the level of apoptosis induced by urinary proteins.	Sirolimus	45-54	hepatitis A virus cellular receptor 1	Homo sapiens	95-101
24345797-7	2014	Furthermore, pretreatment of HK-2 cells with rapamycin reduced the production of LCN2/NGAL and HAVCR1/KIM-1 and the level of apoptosis induced by urinary proteins.	Sirolimus	45-54	hepatitis A virus cellular receptor 1	Homo sapiens	102-107
24395886-5	2014	Estradiol increased the expression of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in prostaglandin biosynthesis, which was also increased at baseline in TSC-deficient cells and was not affected by rapamycin treatment.	Sirolimus	202-211	TSC complex subunit 2	Homo sapiens	158-161
24404143-9	2014	mTOR blockade by rapamycin profoundly improved liver function by limiting inflammation, fibrosis and portal pressure.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Rattus norvegicus	0-4
24404143-10	2014	Rapamycin significantly inhibited the expressions of phosphorylated 70KD ribosomal protein S6 kinase (p-P70S6K) and phosphorylated ribosomal protein S6 (p-S6) but not p-AKT Ser473 relative to their total proteins in BDL-Ra rats.	Sirolimus	0-9	ribosomal protein S6	Rattus norvegicus	73-93
24404143-11	2014	Those results suggested that mTOR Complex 1 (mTORC1) rather than mTORC2 was inhibited by rapamycin.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
24404161-4	2014	HRES-1/Rab4 exhibited minimal baseline colocalization with LC3, which was enhanced 22-fold upon starvation or 6-fold upon rapamycin treatment.	Sirolimus	122-131	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	59-62
25495476-0	2014	RAB3GAP1 and RAB3GAP2 modulate basal and rapamycin-induced autophagy.	Sirolimus	41-50	RAB3 GTPase activating protein catalytic subunit 1	Homo sapiens	0-8
25495476-4	2014	Employing C. elegans and human primary fibroblasts, we show that RAB3GAP1 and RAB3GAP2, which are components of the TBC domain-free RAB3GAP complex, influence protein aggregation and affect autophagy at basal and rapamycin-induced conditions.	Sirolimus	213-222	RAB3 GTPase activating protein catalytic subunit 1	Homo sapiens	65-73
25495476-4	2014	Employing C. elegans and human primary fibroblasts, we show that RAB3GAP1 and RAB3GAP2, which are components of the TBC domain-free RAB3GAP complex, influence protein aggregation and affect autophagy at basal and rapamycin-induced conditions.	Sirolimus	213-222	TBC1 domain family member 1	Homo sapiens	116-119
25482947-10	2014	We found that rapamycin mimicked the effect of RPL11 depletion in terms of blunting the p53 response to nucleolar stress.	Sirolimus	14-23	ribosomal protein L11	Homo sapiens	47-52
24709185-4	2014	The purpose of this study was to examine the effects of rapamycin on bleomycin-induced pulmonary fibrosis in rats and the relation to the expression of metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1).	Sirolimus	56-65	matrix metallopeptidase 9	Rattus norvegicus	173-178
24709185-4	2014	The purpose of this study was to examine the effects of rapamycin on bleomycin-induced pulmonary fibrosis in rats and the relation to the expression of metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1).	Sirolimus	56-65	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	184-223
24717233-3	2014	Cypher sirolimus-eluting stent has been reported to accelerate atherosclerosis progression, but the influence of Endeavor zotarolimus-eluting stent (Endeavor-ZES) or Xience everolimus-eluting stent (Xience-EES) on atherosclerosis has not been clarified.	Sirolimus	7-16	LIM domain binding 3	Homo sapiens	0-6
24056904-0	2013	Inhibition of Orai1-mediated Ca(2+) entry is a key mechanism of the antiproliferative action of sirolimus in human arterial smooth muscle.	Sirolimus	96-105	ORAI calcium release-activated calcium modulator 1	Homo sapiens	14-19
24056904-8	2013	Analysis of the effects of sirolimus on cell proliferation and CREB activation in an in vitro model of arterial intervention using human aorta corroborated the ability of sirolimus to suppress stent implantation-induced CREB activation in human arteries.	Sirolimus	171-180	cAMP responsive element binding protein 1	Homo sapiens	63-67
24056904-8	2013	Analysis of the effects of sirolimus on cell proliferation and CREB activation in an in vitro model of arterial intervention using human aorta corroborated the ability of sirolimus to suppress stent implantation-induced CREB activation in human arteries.	Sirolimus	171-180	cAMP responsive element binding protein 1	Homo sapiens	220-224
24018049-7	2013	The recovery of mTORC1 signaling and the failure of Akt phosphorylation to do so in the REDD1 knockout cells were accompanied by a dramatic increase in caspase-3 cleavage and cell death, both of which were blocked by rapamycin.	Sirolimus	217-226	DNA damage inducible transcript 4	Homo sapiens	88-93
23942361-10	2013	The mTOR inhibitor rapamycin blocked the protective effects of both cAkt1 and cAkt3.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
24265670-7	2013	Rapamycin induced a general decrease in muscle of CD4 and CD8 T cells in lymphoid tissues, but spared B cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	50-53
24265670-8	2013	Among T cells, the frequency of Treg was increased in rapamycin treated mice in draining lymph nodes (16.9 +- 2.2% vs. 9.3 +- 1.4%, p&lt;0.001), which were mostly activated regulatory T cells (CD62L(low)CD44(high): 58.1 +- 5.78% vs. 33.1 +- 7%, treated vs. untreated, p&lt;0.001).	Sirolimus	54-63	CD44 antigen	Mus musculus	203-207
24244418-3	2013	As little as 30 min of RPM exposure resulted in increased expression of several genes responsible for cell motility, structure and integrity (beta-actin); control of cell growth, cell proliferation, cell differentiation and apoptosis (TGF-beta1, osteopontin); and cytoskeletal components such as microtubules (beta-tubulin) and intermediate filaments (vimentin).	Sirolimus	23-26	POTE ankyrin domain family member F	Homo sapiens	142-152
23947572-8	2013	Combined treatment of rapamycin with simvastatin but not with atorvastatin showed a synergistic growth-inhibitory effect on TSC2-null cells.	Sirolimus	22-31	TSC complex subunit 2	Homo sapiens	124-128
24001755-0	2013	Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
23585342-9	2013	In the presence of rapamycin, median p62 levels were 1.3 ng/mL (&lt;0.1-4.9) with pregnancy sera, when compared to 0.6 ng/mL (&lt;0.1-3.3) with control sera (P = .0191).	Sirolimus	19-28	nucleoporin 62	Homo sapiens	37-40
24204783-2	2013	We found that rapamycin, at nM concentrations, increased phosphorylation of eukaryotic initiation factor (eIF) 2alpha in rapamycin-sensitive and estrogen-dependent MCF-7 cells, but had only a minimal effect on eIF2alpha phosphorylation in the rapamycin-insensitive triple-negative MDA-MB-231 cells.	Sirolimus	14-23	eukaryotic translation initiation factor 2A	Homo sapiens	106-117
24194895-5	2013	Furthermore, the activation of p38 MAPK/ATF-2 signaling pathway was blocked by the p38 MAPK inhibitor SB253580, whereas adiponectin had a synergistic effect on the suppression of TOR/p70 S6 Kinase signaling pathway with the TOR inhibitor rapamycin.	Sirolimus	238-247	adapter molecule crk	Gallus gallus	31-34
24194895-5	2013	Furthermore, the activation of p38 MAPK/ATF-2 signaling pathway was blocked by the p38 MAPK inhibitor SB253580, whereas adiponectin had a synergistic effect on the suppression of TOR/p70 S6 Kinase signaling pathway with the TOR inhibitor rapamycin.	Sirolimus	238-247	adapter molecule crk	Gallus gallus	83-86
24194895-5	2013	Furthermore, the activation of p38 MAPK/ATF-2 signaling pathway was blocked by the p38 MAPK inhibitor SB253580, whereas adiponectin had a synergistic effect on the suppression of TOR/p70 S6 Kinase signaling pathway with the TOR inhibitor rapamycin.	Sirolimus	238-247	adiponectin, C1Q and collagen domain containing	Gallus gallus	120-131
24108003-7	2013	Interestingly, rapamycin, an inhibitor of MTOR, enhanced the expression of the autophagosomal marker LC3-II and GRP was localized within LC3-II-marked autophagosomes in vitro as well as in vivo, indicating autophagy-mediated degradation of GRP.	Sirolimus	15-24	gastrin releasing peptide	Homo sapiens	101-115
24108003-7	2013	Interestingly, rapamycin, an inhibitor of MTOR, enhanced the expression of the autophagosomal marker LC3-II and GRP was localized within LC3-II-marked autophagosomes in vitro as well as in vivo, indicating autophagy-mediated degradation of GRP.	Sirolimus	15-24	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	101-104
24108003-7	2013	Interestingly, rapamycin, an inhibitor of MTOR, enhanced the expression of the autophagosomal marker LC3-II and GRP was localized within LC3-II-marked autophagosomes in vitro as well as in vivo, indicating autophagy-mediated degradation of GRP.	Sirolimus	15-24	gastrin releasing peptide	Homo sapiens	112-115
19720745-4	2009	We find that one site, T1135, undergoes growth factor-responsive phosphorylation that is acutely sensitive to rapamycin and is phosphorylated downstream of mTORC1.	Sirolimus	110-119	CREB regulated transcription coactivator 1	Mus musculus	156-162
19771169-9	2009	By contrast, transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained inhibition of cell growth and no selective cell killing in starvation.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	39-45
19771169-9	2009	By contrast, transient exposure to the mTORC1 inhibitor rapamycin caused essentially irreversible mTORC1 inhibition, sustained inhibition of cell growth and no selective cell killing in starvation.	Sirolimus	56-65	CREB regulated transcription coactivator 1	Mus musculus	98-104
19484784-10	2009	Rapamycin increased cisplatin-induced apoptosis and stimulated expression of MSH2 and MSH6 in the cisplatin-treated cell lines.	Sirolimus	0-9	mutS homolog 2	Homo sapiens	77-81
19735104-6	2009	While one phosphoinositide 3-kinases (PI-3) kinase inhibitor, LY294002, completely blocked the effect of TGF-beta1 on SHARP-2 mRNA expression in LLC-PK1 cells at a low concentration, other inhibitors, including PD98059, staurosporine, AG490, wortmannin, okadaic acid and rapamycin, had no effect.	Sirolimus	271-280	transforming growth factor beta 1	Sus scrofa	105-114
19564418-1	2009	Rapamycin, a selective inhibitor of mTORC1 signaling, blocks terminal myoblast differentiation.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	36-42
19564418-4	2009	Importantly, downregulation of rictor inhibited TORC2 signaling without inhibiting mTORC1 signaling, suggesting that inhibition of mTORC1 by rapamycin may not be the cause of arrested differentiation.	Sirolimus	141-150	CREB regulated transcription coactivator 1	Mus musculus	131-137
19564418-7	2009	Rapamycin treatment prevented ROCK1 inactivation during differentiation, while suppression of ROCK1 activity during differentiation and myoblast fusion was restored through expression of AKT(S473D), even in the presence of rapamycin.	Sirolimus	0-9	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	30-35
19564418-7	2009	Rapamycin treatment prevented ROCK1 inactivation during differentiation, while suppression of ROCK1 activity during differentiation and myoblast fusion was restored through expression of AKT(S473D), even in the presence of rapamycin.	Sirolimus	223-232	Rho associated coiled-coil containing protein kinase 1	Homo sapiens	94-99
19684592-4	2009	4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants.	Sirolimus	48-57	thor	Drosophila melanogaster	0-5
19453998-0	2009	Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.	Sirolimus	12-21	forkhead box P3	Homo sapiens	53-58
19131641-3	2009	To examine these issues, we determined the effects of rapamycin-induced inhibition of mTORC1 on TLR2- and TLR4-induced neutrophil activation.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	86-92
19131641-3	2009	To examine these issues, we determined the effects of rapamycin-induced inhibition of mTORC1 on TLR2- and TLR4-induced neutrophil activation.	Sirolimus	54-63	toll-like receptor 2	Mus musculus	96-100
19443844-8	2009	Rapamycin decreased phosphorylation of both Akt and S6, suggesting that both the TORC1 and TORC2 pathways are impacted.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	91-96
19586661-3	2009	The immunosuppressive/anti-cancer agent rapamycin inhibits TORC1 function by disrupting the mTOR-raptor interaction.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Homo sapiens	59-64
19586661-3	2009	The immunosuppressive/anti-cancer agent rapamycin inhibits TORC1 function by disrupting the mTOR-raptor interaction.	Sirolimus	40-49	regulatory associated protein of MTOR complex 1	Homo sapiens	97-103
19541609-4	2009	Consistent with a central role for mTORC1 in these tumors, rapamycin as a single agent results in a dramatic suppression of preexisting GI polyps in LKB1+/- mice.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	35-41
19371739-9	2009	At 4 weeks after the surgery, re-endothelialization of the sirolimus-treated artery was significantly less than that of DMSO-treated one in the vehicle-treated mice as determined by the percentage of CD31-positive area (P&lt;0.05).	Sirolimus	59-68	platelet/endothelial cell adhesion molecule 1	Mus musculus	200-204
18841360-0	2009	Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.	Sirolimus	53-62	interleukin 2 receptor subunit alpha	Homo sapiens	19-23
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	65-69
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	178-182
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	178-182
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	mitogen-activated protein kinase kinase 1	Mus musculus	286-292
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	mitogen-activated protein kinase kinase 1	Mus musculus	286-292
19377293-6	2009	Knockout of either Sestrin2 or Dram reduced autophagy elicited by nutrient depletion, rapamycin, lithium or thapsigargin.	Sirolimus	86-95	sestrin 2	Homo sapiens	19-27
19245654-4	2009	Recent work has revealed that across eukaryotes mTOR orthologues are found in two biochemically distinct complexes and only one of those complexes (mTORC1 in mammals) is acutely sensitive to rapamycin and regulated by nutrients and AMPK.	Sirolimus	191-200	CREB regulated transcription coactivator 1	Mus musculus	148-154
19245654-4	2009	Recent work has revealed that across eukaryotes mTOR orthologues are found in two biochemically distinct complexes and only one of those complexes (mTORC1 in mammals) is acutely sensitive to rapamycin and regulated by nutrients and AMPK.	Sirolimus	191-200	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	232-236
19297407-3	2009	The gene products of TSC1 and TSC2, also known as hamartin and tuberin, respectively, form a physical and functional complex and inhibit the mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	182-188
19154728-7	2009	These results demonstrate that FKBP12 can be rate limiting for calcineurin inhibition at high tacrolimus concentrations and that the antagonism of sirolimus and everolimus on tacrolimus based immune suppression is mediated via saturation of FKBP12.	Sirolimus	147-156	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	241-247
19270529-9	2009	Since mTORC2 is likely more critical for survival signals in cancer cells, the recent findings suggest new strategies for enhancing the efficacy of rapamycin-based therapeutic approaches in cancer cells.	Sirolimus	148-157	CREB regulated transcription coactivator 2	Mus musculus	6-12
19151201-6	2009	RESULTS: Rapamycin inhibited the ability of anti-CD3 to revert disease without affecting the frequency/phenotype of T-cells.	Sirolimus	9-18	CD3 antigen, epsilon polypeptide	Mus musculus	49-52
19379082-4	2009	However, in recent preclinical studies a sustained exposure of cancer cells to rapamycin has been shown to inhibit the function of both mTORC1 and mTORC2 complexes.	Sirolimus	79-88	CREB regulated transcription coactivator 1	Mus musculus	136-142
19379082-4	2009	However, in recent preclinical studies a sustained exposure of cancer cells to rapamycin has been shown to inhibit the function of both mTORC1 and mTORC2 complexes.	Sirolimus	79-88	CREB regulated transcription coactivator 2	Mus musculus	147-153
19211835-8	2009	ULK1 is dephosphorylated by rapamycin treatment or starvation.	Sirolimus	28-37	unc-51 like autophagy activating kinase 1	Homo sapiens	0-4
19225151-6	2009	Inhibition of mTOR by rapamycin or leucine deprivation, the conditions that induce autophagy, leads to dephosphorylation of ULK1, ULK2, and Atg13 and activates ULK to phosphorylate FIP200.	Sirolimus	22-31	unc-51 like autophagy activating kinase 1	Homo sapiens	124-128
19225151-6	2009	Inhibition of mTOR by rapamycin or leucine deprivation, the conditions that induce autophagy, leads to dephosphorylation of ULK1, ULK2, and Atg13 and activates ULK to phosphorylate FIP200.	Sirolimus	22-31	unc-51 like autophagy activating kinase 2	Homo sapiens	130-134
19372588-3	2009	In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor reduction of cell proliferation.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	86-92
19141683-8	2009	Rapamycin treatment did not affect the rate of myofibrillar protein synthesis whether or not the mice received JA16 injections, although it eliminated the phosphorylation of S6K and rpS6.	Sirolimus	0-9	ribosomal protein S6	Mus musculus	182-186
19194827-2	2009	Here, we found that combination treatment with PD98059 and rapamycin suppressed the proliferation of CRC cells, induced apoptosis, arrested cell cycle, and reduced the incidence and volume of CRC in mice, as well as inhibited phosphorylation of mTOR and the MEK signal pathway components, of which the effects were more significant than single-drug treatments.	Sirolimus	59-68	midkine	Mus musculus	258-261
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	44-50
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	66-75	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	44-50
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	44-50
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-7	2009	Using S2481 phosphorylation as a marker for mTORC2 sensitivity to rapamycin, we find that mTORC2 formation is in fact rapamycin sensitive in several cancer cell lines in which it had been previously reported that mTORC2 assembly and function were rapamycin insensitive.	Sirolimus	118-127	CREB regulated transcription coactivator 2	Mus musculus	90-96
19244117-8	2009	Thus, phospho-S2481 on mTOR serves as a biomarker for intact mTORC2 and its sensitivity to rapamycin.	Sirolimus	91-100	CREB regulated transcription coactivator 2	Mus musculus	61-67
19250527-5	2009	In the tissue culture system, we detected significantly elevated Foxp3 expression and IL-10 production, as well as an increased percentage of Foxp3+ Tregs in nasal polyps after blocking the mTOR signaling pathway with rapamycin.	Sirolimus	218-227	forkhead box P3	Homo sapiens	142-147
19197153-2	2009	Rapamycin, an allosteric inhibitor of mTORC1, has been approved for treatment against renal cell carcinomas and is being evaluated for other cancers.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	38-44
19201859-2	2009	Treatment with rapamycin, which effectively controls disease activity, normalizes CD3/CD28-induced calcium fluxing but fails to influence MHP, suggesting that altered calcium fluxing is downstream or independent of mitochondrial dysfunction.	Sirolimus	15-24	CD28 molecule	Homo sapiens	86-90
19211884-6	2009	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	97-103
19211884-6	2009	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype.	Sirolimus	21-30	CREB regulated transcription coactivator 1	Mus musculus	261-267
19074679-9	2009	Therefore, other mTORC1 targets are more important in the inhibition by rapamycin of the rapid activation of protein synthesis and of cell growth.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	17-23
19234362-7	2009	Rapamycin, which is commonly used as a pharmacological tool to disrupt the FKBP12-RyR complex, decreased phenylephrine-induced contractions in RVD epididymal halves.	Sirolimus	0-9	ryanodine receptor 2	Rattus norvegicus	82-85
18722557-5	2009	Treatment of SLE patients with rapamycin improves disease activity, normalizes CD3/CD28-induced Ca(2+) fluxing but fails to affect MHP, suggesting that altered Ca(2+) fluxing is downstream or independent of mitochondrial dysfunction.	Sirolimus	31-40	CD28 molecule	Homo sapiens	83-87
18636076-0	2009	Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.	Sirolimus	0-9	huntingtin	Homo sapiens	96-106
19001278-6	2009	Of note, an increased XIAPlevel was evidenced during the blockade of the canonical cap-dependent translation by the mTOR inhibitor rapamycin, supporting the hypothesis of a functional IRES sequence in XIAP mRNA.	Sirolimus	131-140	X-linked inhibitor of apoptosis	Mus musculus	22-26
19200882-3	2009	mTORC1 activity is inhibited by rapamycin, a specific inhibitor of mTOR, whereas mTORC2 activity is resistant to short-term treatments with rapamycin.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	0-6
19242560-8	2009	Surprisingly, KIF5B depletion inhibited the rapamycin-induced accumulation of autophagosomes in MCF-7 cells.	Sirolimus	44-53	kinesin family member 5B	Homo sapiens	14-19
19115995-5	2008	The expression levels of PTEN- and P27kip1- mRNA were up-regulated, and the mTOR- and cyclinD1- mRNA were down-regulated in K562 cells after the cells transfected with wild type PTEN gene and treated with rapamycin.	Sirolimus	205-214	cyclin D1	Homo sapiens	86-94
18809972-4	2008	In contrast, eIF4E phosphorylation is low in PC3 and LNCaP cells with mutated PTEN and constitutively active AKT/mTOR pathway, but it can be strongly induced through inhibition of mTOR activity by rapamycin or serum depletion.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	255-260
19018001-4	2008	We found that rapamycin, which blocks mTORC1 and mTORC2 signaling, inhibited sCD40L-mediated transactivation of VEGF.	Sirolimus	14-23	CREB regulated transcription coactivator 1	Mus musculus	38-44
19018001-4	2008	We found that rapamycin, which blocks mTORC1 and mTORC2 signaling, inhibited sCD40L-mediated transactivation of VEGF.	Sirolimus	14-23	CREB regulated transcription coactivator 2	Mus musculus	49-55
19100906-10	2008	The Rapamune Maintenance Regimen study demonstrated that patients receiving sirolimus-based, CNI-free therapy after CsA withdrawal at 3 months showed a reduced incidence of malignancy at 5 years posttransplant, compared with those who continued on a regimen that included CsA.	Sirolimus	4-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	116-119
19100906-10	2008	The Rapamune Maintenance Regimen study demonstrated that patients receiving sirolimus-based, CNI-free therapy after CsA withdrawal at 3 months showed a reduced incidence of malignancy at 5 years posttransplant, compared with those who continued on a regimen that included CsA.	Sirolimus	4-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	272-275
19100906-10	2008	The Rapamune Maintenance Regimen study demonstrated that patients receiving sirolimus-based, CNI-free therapy after CsA withdrawal at 3 months showed a reduced incidence of malignancy at 5 years posttransplant, compared with those who continued on a regimen that included CsA.	Sirolimus	76-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	116-119
19100906-10	2008	The Rapamune Maintenance Regimen study demonstrated that patients receiving sirolimus-based, CNI-free therapy after CsA withdrawal at 3 months showed a reduced incidence of malignancy at 5 years posttransplant, compared with those who continued on a regimen that included CsA.	Sirolimus	76-85	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	272-275
19100909-7	2008	Mammalian TORC1 (mTORC1) is rapamycin sensitive and contains mTOR, raptor, and mLST8.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Homo sapiens	10-15
19100909-7	2008	Mammalian TORC1 (mTORC1) is rapamycin sensitive and contains mTOR, raptor, and mLST8.	Sirolimus	28-37	CREB regulated transcription coactivator 1	Mus musculus	17-23
18776922-6	2008	Inhibition of both mTORC1 and mTORC2 by rapamycin-induced apoptosis, whereas rapamycin-stimulation of AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2.	Sirolimus	40-49	CREB regulated transcription coactivator 1	Mus musculus	19-25
18776922-6	2008	Inhibition of both mTORC1 and mTORC2 by rapamycin-induced apoptosis, whereas rapamycin-stimulation of AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2.	Sirolimus	40-49	CREB regulated transcription coactivator 2	Mus musculus	30-36
18812319-2	2008	mTOR forms two functionally distinct complexes, termed the mTOR complex 1 (mTORC1) and 2 (mTORC2); only the former of which is inhibited by rapamycin.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	75-81
18812319-2	2008	mTOR forms two functionally distinct complexes, termed the mTOR complex 1 (mTORC1) and 2 (mTORC2); only the former of which is inhibited by rapamycin.	Sirolimus	140-149	CREB regulated transcription coactivator 2	Mus musculus	90-96
18651095-2	2008	TOR complex 1 (TORC1) is comprised of TOR, Raptor, and Lst8 and its activity is sensitive to inhibition by the macrolide antibiotic rapamycin.	Sirolimus	132-141	regulatory associated protein of MTOR complex 1	Homo sapiens	43-49
18361417-5	2008	Rapamycin was found to prevent dissociation of 4E-BP from the initiation factor eIF4E and to suppress correlatively a burst of global protein synthesis occurring at the G2/M transition.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
18662782-0	2008	Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A.	Sirolimus	56-65	interleukin 18	Mus musculus	23-28
18652845-0	2008	Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction.	Sirolimus	0-9	leukocyte immunoglobulin like receptor B2	Homo sapiens	61-65
18708346-7	2008	The hypothesis that NRP1 is degraded by autophagy is supported by the findings that its expression is lost rapidly in response to metabolic stress, prevented with 3-methyladenine and induced by rapamycin.	Sirolimus	194-203	neuropilin 1	Homo sapiens	20-24
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	CREB regulated transcription coactivator 1	Mus musculus	0-6
18621930-3	2008	Since mTORC1 regulates growth, we hypothesized that pharmacological inhibition of mTORC1 by rapamycin may reverse the phenotypic effects of c-MYC.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	6-12
18621930-3	2008	Since mTORC1 regulates growth, we hypothesized that pharmacological inhibition of mTORC1 by rapamycin may reverse the phenotypic effects of c-MYC.	Sirolimus	92-101	CREB regulated transcription coactivator 1	Mus musculus	82-88
18787409-4	2008	(2) The cancer-relevant activities emanating from increased Rheb depend on activation of mTORC1 and are sensitive to rapamycin.	Sirolimus	117-126	Ras homolog, mTORC1 binding	Homo sapiens	60-64
18722121-9	2008	CONCLUSIONS: We propose a unique mode of mTOR regulation in which RSK-mediated phosphorylation of Raptor regulates mTORC1 activity and thus suggest a means by which the Ras/MAPK pathway might promote rapamycin-sensitive signaling independently of the PI3K/Akt pathway.	Sirolimus	200-209	regulatory associated protein of MTOR complex 1	Homo sapiens	98-104
18722121-9	2008	CONCLUSIONS: We propose a unique mode of mTOR regulation in which RSK-mediated phosphorylation of Raptor regulates mTORC1 activity and thus suggest a means by which the Ras/MAPK pathway might promote rapamycin-sensitive signaling independently of the PI3K/Akt pathway.	Sirolimus	200-209	CREB regulated transcription coactivator 1	Mus musculus	115-121
18580968-7	2008	Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication.	Sirolimus	57-66	odorant binding protein 2A	Homo sapiens	110-113
18481161-0	2008	Use of sirolimus in IPEX and IPEX-like children.	Sirolimus	7-16	forkhead box P3	Homo sapiens	20-24
18481161-0	2008	Use of sirolimus in IPEX and IPEX-like children.	Sirolimus	7-16	forkhead box P3	Homo sapiens	29-33
18481161-3	2008	METHODS: We reviewed the effect of sirolimus use in our cohort of IPEX and IPEX-like patients (n = 7).	Sirolimus	35-44	forkhead box P3	Homo sapiens	66-70
18481161-3	2008	METHODS: We reviewed the effect of sirolimus use in our cohort of IPEX and IPEX-like patients (n = 7).	Sirolimus	35-44	forkhead box P3	Homo sapiens	75-79
18481161-11	2008	Our experience suggests that sirolimus is a clinically effective and safe therapeutic option in IPEX and IPEX-like patients.	Sirolimus	29-38	forkhead box P3	Homo sapiens	96-100
18481161-11	2008	Our experience suggests that sirolimus is a clinically effective and safe therapeutic option in IPEX and IPEX-like patients.	Sirolimus	29-38	forkhead box P3	Homo sapiens	105-109
18725988-6	2008	Significantly, pharmacological inhibition of the MAPK pathway enhanced the antitumoral effect of mTORC1 inhibition by rapamycin in cancer cells in vitro and in a xenograft mouse model.	Sirolimus	118-127	CREB regulated transcription coactivator 1	Mus musculus	97-103
18562319-7	2008	Importantly, knockdown of hnRNP A1 also renders quiescent Akt-containing cells sensitive to rapamycin-induced G(1) arrest.	Sirolimus	92-101	heterogeneous nuclear ribonucleoprotein A1	Homo sapiens	26-34
18701474-6	2008	Expression of wild-type eIF4E in rapamycin-treated E6/E7/hTert/HRas(V12) and U373 cells failed to rescue colony formation, although expression of wild-type S6K1 or rapamycin-resistant S6K1 in rapamycin-treated U373 and U251 provided partial rescue.	Sirolimus	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
18701474-6	2008	Expression of wild-type eIF4E in rapamycin-treated E6/E7/hTert/HRas(V12) and U373 cells failed to rescue colony formation, although expression of wild-type S6K1 or rapamycin-resistant S6K1 in rapamycin-treated U373 and U251 provided partial rescue.	Sirolimus	33-42	immunoglobulin lambda variable 2-8	Homo sapiens	63-71
18708578-7	2008	Notably, RHEB is highly expressed in some human lymphomas, resulting in mTORC1 activation and increased sensitivity to rapamycin and FTI.	Sirolimus	119-128	Ras homolog, mTORC1 binding	Homo sapiens	9-13
18418733-5	2008	Reporter mRNAs containing the Hsp90 or Hsp70 mRNAs" 5" untranslated region recapitulate these rapamycin-dependent translational characteristics, indicating this region regulates rapamycin-dependent translational sensitivity as well as heat shock preferential translation.	Sirolimus	94-103	Heat-shock-protein-70Ab	Drosophila melanogaster	39-44
18490075-8	2008	Potentially additive effects of bevacizumab plus rapamycin included reductions in vascular endothelial growth factor expression, cyclin D1, and cyclin B1.	Sirolimus	49-58	cyclin B1	Mus musculus	144-153
18667775-6	2008	Expressions of mTOR and eIF-4E mRNA or protein in CVB3-induced myocardial cells were significantly upregulated compared with the control group (P &lt; 0.05), and rapamycin (10 nmol/L) inhibited the upregulation (P &lt; 0.05).	Sirolimus	162-171	eukaryotic translation initiation factor 4E	Rattus norvegicus	24-30
18667775-7	2008	CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis.	Sirolimus	12-21	eukaryotic translation initiation factor 4E	Rattus norvegicus	67-73
18667775-7	2008	CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis.	Sirolimus	12-21	eukaryotic translation initiation factor 4E	Rattus norvegicus	129-135
18313267-6	2008	Addition of rapamycin to cultures containing IL-2 further increased the frequency and absolute number of functional CD4(+)CD25(+)FOXP3(+) Treg.	Sirolimus	12-21	forkhead box P3	Homo sapiens	129-134
17645504-13	2008	In the following study, we indicated that hypoxia-inducible factor (HIF)-1alpha inhibitor, rapamycin, could possibly prevent VM and phenotype transformation of SKOV3ip, reflected by down-regulating expression of CD31 and Factor VIII.	Sirolimus	91-100	platelet and endothelial cell adhesion molecule 1	Homo sapiens	212-216
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	35-41
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	Fc epsilon receptor Ia	Homo sapiens	82-93
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	111-117
18199701-4	2008	However, using a cellular model of HD, we found that rapamycin significantly decreased aggregation-prone polyglutamine (polyQ) and expanded huntingtin and its inclusion bodies (IB) in both autophagy-proficient and autophagy-deficient cells (by genetic knockout of the atg5 gene in mouse embryonic fibroblasts).	Sirolimus	53-62	autophagy related 5	Mus musculus	268-272
17647224-7	2008	Unlike free rapamycin that has shown little if any effect on the expression of maturation markers in immature DCs, PLGA encapsulated rapamycin decreased the expression of all maturation markers under the study, that is, MHC class II, CD86, and CD40, significantly.	Sirolimus	133-142	CD40 antigen	Mus musculus	244-248
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	hexose transporter HXT7	Saccharomyces cerevisiae S288C	193-198
17516572-4	2008	Western blot analysis shows that rapamycin treatment markedly reduced levels of cyclin A and D1 protein in both cell types.	Sirolimus	33-42	cyclin A2	Mus musculus	80-95
17684489-6	2008	In addition, the structures determined for the FRB-phosphatidic acid and FRB-HTS-1 complexes revealed a striking similarity between the conformations of buried portions of the ligands and that seen for the rapamycin backbone in contact with the domain.	Sirolimus	206-215	DENN domain containing 2B	Homo sapiens	77-82
17989609-7	2007	Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription.	Sirolimus	48-57	SREBF chaperone	Homo sapiens	83-87
17634255-5	2007	Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex.	Sirolimus	24-33	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	152-157
17634255-5	2007	Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex.	Sirolimus	24-33	eukaryotic translation initiation factor 4E	Rattus norvegicus	158-163
17634255-7	2007	Pretreatment with rapamycin completely prevented the feeding-induced phosphorylation of eIF4G(Ser(1108)), whereas the inhibitor only partially attenuated meal feeding-induced 70-kDa ribosomal protein S6 kinase1(Thr(389)) phosphorylation and extent of 4E-BP1 in the gamma-form.	Sirolimus	18-27	eukaryotic translation initiation factor 4 gamma 1	Rattus norvegicus	88-93
17606732-12	2007	Combined treatment of neuroblastoma cells and neuroblastoma-bearing mice with vinblastine and rapamycin induced the down-modulation of both vascular endothelial growth factor production and vascular endothelial growth factor receptor 2 expression.	Sirolimus	94-103	kinase insert domain protein receptor	Mus musculus	190-235
17549403-4	2007	IGF-I induction of myogenin protein was blocked by anti-IGF-IR monoclonal antibody alphaIR-3 and the mTOR-specific inhibitor rapamycin.	Sirolimus	125-134	myogenin	Homo sapiens	19-27
17466941-5	2007	Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), suppressed leucine-induced activation of p70 S6 kinase and 4E-BP1 and negated the stimulatory effect of leucine on HGF production.	Sirolimus	0-9	hepatocyte growth factor	Homo sapiens	180-183
17580150-0	2007	Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy.	Sirolimus	22-31	cellular communication network factor 2	Homo sapiens	47-78
17179228-0	2007	Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	29-35
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
17407584-8	2007	CONCLUSION: The sensitivity of HTLV-I transcription to rapamycin may be effected through an NF-kappaB-pathway associated with the rapamycin-sensitive mTORC1 cellular signalling network.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	150-156
17290308-4	2007	This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells.	Sirolimus	51-60	TSC complex subunit 1	Mus musculus	124-128
17245434-6	2007	In addition, there was a rapamycin/sirolimus-sensitive enhanced loading of ribosomes on preformed ROCK-1 mRNAs.	Sirolimus	25-34	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	98-104
17245434-6	2007	In addition, there was a rapamycin/sirolimus-sensitive enhanced loading of ribosomes on preformed ROCK-1 mRNAs.	Sirolimus	35-44	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	98-104
17245434-7	2007	Inhibition of mTOR by rapamycin abolished ROCK-1 synthesis in macrophages resulting in an inhibition of chemotaxis and phagocytosis.	Sirolimus	22-31	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	42-48
17210710-7	2007	Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC.	Sirolimus	95-104	cyclin D1	Homo sapiens	329-338
17210710-7	2007	Critical components in the translational machinery, such as phosphorylated mammalian target of rapamycin (mTOR) and its downstream targets, phosphorylated eukaryotic translation initiation factor and p70 S6 kinase, were up-regulated following NO treatment, and inhibition of mTOR with rapamycin attenuated NO induced increase of cyclin D1 and ODC.	Sirolimus	95-104	ornithine decarboxylase 1	Homo sapiens	343-346
17182569-0	2007	Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.	Sirolimus	97-106	interleukin 2 receptor subunit alpha	Homo sapiens	52-56
17182569-0	2007	Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin.	Sirolimus	97-106	forkhead box P3	Homo sapiens	57-62
17182569-3	2007	Human purified CD4(+)CD25(high) T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4(+)CD25(low) or CD4(+)CD25(-) T cells did not.	Sirolimus	146-155	interleukin 2 receptor subunit alpha	Homo sapiens	21-25
17182569-3	2007	Human purified CD4(+)CD25(high) T cell subsets stimulated via TCR and CD28 or by IL-2 survived and expanded up to 40-fold in the presence of 1 nM rapamycin, while CD4(+)CD25(low) or CD4(+)CD25(-) T cells did not.	Sirolimus	146-155	CD28 molecule	Homo sapiens	70-74
17182569-4	2007	The expanding pure populations of CD4(+)CD25(high) T cells were resistant to rapamycin-accelerated apoptosis.	Sirolimus	77-86	interleukin 2 receptor subunit alpha	Homo sapiens	40-44
17142730-0	2006	Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients.	Sirolimus	0-9	forkhead box P3	Homo sapiens	52-57
16702957-0	2006	Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.	Sirolimus	76-85	ZFP36 ring finger protein	Homo sapiens	0-15
16702957-0	2006	Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.	Sirolimus	76-85	cyclin D1	Homo sapiens	26-35
16845661-3	2006	The mTOR inhibitor, rapamycin (sirolimus), reduces disease severity in rodent models of TSC, and is currently in phase II clinical trials.	Sirolimus	20-29	TSC complex subunit 1	Mus musculus	88-91
16845661-3	2006	The mTOR inhibitor, rapamycin (sirolimus), reduces disease severity in rodent models of TSC, and is currently in phase II clinical trials.	Sirolimus	31-40	TSC complex subunit 1	Mus musculus	88-91
16936190-7	2006	Islets exposed to sirolimus for 24 h in culture displayed significantly diminished glucose-stimulated insulin release, coinciding with decreased pancreas duodenum homeobox-1 and GLUT2 expression in cultured islets.	Sirolimus	18-27	solute carrier family 2 (facilitated glucose transporter), member 2	Mus musculus	178-183
16825603-4	2006	Furthermore, cotreatment with rapamycin, a specific mTOR inhibitor, and troglitazone additively inhibited both p70S6K activity and protein synthesis, suggesting that the inhibitory effects of troglitazone are not mediated by mTOR.	Sirolimus	30-39	mechanistic target of rapamycin kinase	Bos taurus	52-56
16210336-6	2006	However, in contrast to CsA, rapamycin preserved the dominance of the potent CD27+ T(REG) subset over the CD27- T(REG) subset after alloantigen-driven expansion of CD4+ CD25+ T(REG)s in vitro.	Sirolimus	29-38	interleukin 2 receptor subunit alpha	Homo sapiens	169-173
16210336-7	2006	Accordingly, CD4+ CD25+ T(REG)s cultured in the presence of rapamycin displayed much stronger suppressive capacity than CD4+ CD25+ T(REG)s cultured in the presence of CsA.	Sirolimus	60-69	interleukin 2 receptor subunit alpha	Homo sapiens	18-22
16210336-8	2006	In addition, CD4+ CD25+ T(REG) cells cultured in the presence of rapamycin, but not CsA, were able to suppress ongoing alloimmune responses.	Sirolimus	65-74	interleukin 2 receptor subunit alpha	Homo sapiens	18-22
16322523-0	2006	The Saccharomyces cerevisiae phosphatase activator RRD1 is required to modulate gene expression in response to rapamycin exposure.	Sirolimus	111-120	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	51-55
16322523-1	2006	We show that mutants lacking either the phosphatase activator Rrd1 or the phosphatase Pph3 are resistant to rapamycin and that double mutants exhibit a synergistic response.	Sirolimus	108-117	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	62-66
16424043-0	2006	Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.	Sirolimus	122-131	cyclin D1	Homo sapiens	103-112
16424043-2	2006	A biochemical analysis of human mammary tumor cell lines indicated that rapamycin-induced antiproliferative effects correlated with down-regulation of cellular p21 levels and the levels of p21 in cyclin-dependent kinase (Cdk) 2 and 4 complexes.	Sirolimus	72-81	cyclin dependent kinase 2	Homo sapiens	196-233
17699197-11	2006	In patients with steroid-resistant FSGS, sirolimus reduced proteinuria and glomerular pore size and increased K(f) in patients with steroid-resistant FSGS.	Sirolimus	41-50	actinin alpha 4	Homo sapiens	35-39
17699197-11	2006	In patients with steroid-resistant FSGS, sirolimus reduced proteinuria and glomerular pore size and increased K(f) in patients with steroid-resistant FSGS.	Sirolimus	41-50	actinin alpha 4	Homo sapiens	150-154
16380505-10	2005	The mTOR antagonist, rapamycin, prevented foci formation of the A549/BMP-2 cells.	Sirolimus	21-30	bone morphogenetic protein 2	Homo sapiens	69-74
16242075-7	2005	Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E).	Sirolimus	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	162-205
16242075-7	2005	Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E).	Sirolimus	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	207-212
15994335-6	2005	Binding of FKBP12, calcineurin, and calmodulin to TRPC6 channels is blocked by the following: 1) inhibition of PKC; 2) mutation of the PKC phosphorylation site (Ser(7168/714)) in the channels; or 3) pretreatment with FK506 or rapamycin, immunosuppressants that directly bind FKBP12.	Sirolimus	226-235	calmodulin 1	Rattus norvegicus	36-46
16113783-4	2005	The aim of this study was to determine the effect of an immunosuppressant macrolide, rapamycin (Sirolimus), on the expression of TF and its inhibitor (TFPI) by monocytic cells (human blood mononuclear and THP-1 cells) and human aortic smooth muscle cells, in comparison with FK-506 and azithromycin.	Sirolimus	85-94	tissue factor pathway inhibitor	Homo sapiens	151-155
16113783-4	2005	The aim of this study was to determine the effect of an immunosuppressant macrolide, rapamycin (Sirolimus), on the expression of TF and its inhibitor (TFPI) by monocytic cells (human blood mononuclear and THP-1 cells) and human aortic smooth muscle cells, in comparison with FK-506 and azithromycin.	Sirolimus	96-105	tissue factor pathway inhibitor	Homo sapiens	151-155
16113783-8	2005	Rapamycin slightly inhibits TFPI induction by LPS in monocytic cells.	Sirolimus	0-9	tissue factor pathway inhibitor	Homo sapiens	28-32
15956968-6	2005	Iressa blocked ERK1/2 phosphorylation specifically in wt-VHL cells, whereas rapamycin inhibited phospho-RPS6 and 4E-BP1 irrespective of VHL.	Sirolimus	76-85	ribosomal protein S6	Homo sapiens	104-108
15788477-6	2005	The highly specific mTOR inhibitor rapamycin blocked UNX-increased phosphorylation of both rpS6 and 4E-BP1.	Sirolimus	35-44	ribosomal protein S6	Homo sapiens	91-106
15919492-10	2005	RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression.	Sirolimus	0-3	matrix metallopeptidase 9	Mus musculus	58-67
15919492-10	2005	RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression.	Sirolimus	0-3	tissue inhibitor of metalloproteinase 2	Mus musculus	147-153
15919492-12	2005	Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM.	Sirolimus	198-201	matrix metallopeptidase 9	Mus musculus	88-93
15919502-3	2005	The aim of this study was to retrospectively analyze a group of post-liver transplant patients who had been converted to rapamycin because of CNI-related neurotoxicity.	Sirolimus	121-130	5'-nucleotidase, cytosolic IA	Homo sapiens	142-145
15919502-6	2005	RESULTS: Seven patients were converted to rapamycin due to new-onset neurotoxicity or exacerbation of previous neurological symptoms secondary to CNI.	Sirolimus	42-51	5'-nucleotidase, cytosolic IA	Homo sapiens	146-149
15634685-0	2005	Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.	Sirolimus	123-132	cyclin D1	Homo sapiens	0-9
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	cyclin D1	Homo sapiens	26-35
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	zinc fingers and homeoboxes 2	Homo sapiens	135-138
15707399-4	2005	We studied the effects of the rapamycin derivative everolimus and the anti-CD25 monoclonal antibody basiliximab on the regulatory capacity of human CD4(+)CD25(+) cells in vitro.	Sirolimus	30-39	interleukin 2 receptor subunit alpha	Homo sapiens	154-158
15770593-15	2005	An important decrease in alfa -SMA expression by MC after rapamycin addition was observed.	Sirolimus	58-67	survival of motor neuron 1, telomeric	Homo sapiens	31-34
15770593-16	2005	In conclusion, rapamycin shows a mild protective effect on EMT, as it increases E-cadherin and decreases alfa -SMA expression.	Sirolimus	15-24	survival of motor neuron 1, telomeric	Homo sapiens	111-114
15383315-5	2004	Rapamycin inhibited proliferation of CD133(+) cells dose dependently at similar concentrations as hematopoietic Jurkat or HL-60 cells.	Sirolimus	0-9	prominin 1	Homo sapiens	37-42
15218033-9	2004	Overexpression of PP5, but not the PP2A catalytic subunit, blocked rapamycin-induced phosphorylation of c-Jun, and protected cells from rapamycin-induced apoptosis.	Sirolimus	67-76	protein phosphatase 5 catalytic subunit	Homo sapiens	18-21
15361291-11	2004	CONCLUSIONS: Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways can act as potent immunoregulatory cells in vitro, and prolong cardiac allograft survival after adoptive transfer in the presence of rapamycin therapy.	Sirolimus	233-242	CD40 antigen	Mus musculus	54-58
15233824-7	2004	The incidence of malignancy was significantly lower in patients receiving concentration-controlled SRL with elimination of CsA compared with those who remained on CsA + SRL.	Sirolimus	99-102	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	123-126
15150271-8	2004	Consistent with this, inhibition of B-Raf and p42/44 MAPK by Rheb was resistant to rapamycin in contrast to Rheb activation of S6 kinase, which is rapamycin-sensitive.	Sirolimus	83-92	Ras homolog, mTORC1 binding	Homo sapiens	61-65
15150271-8	2004	Consistent with this, inhibition of B-Raf and p42/44 MAPK by Rheb was resistant to rapamycin in contrast to Rheb activation of S6 kinase, which is rapamycin-sensitive.	Sirolimus	147-156	Ras homolog, mTORC1 binding	Homo sapiens	108-112
15190216-3	2004	Interestingly, lymphomas expressing Akt, but not those expressing Bcl-2 are sensitized to chemotherapy-induced apoptosis by the mTOR inhibitor rapamycin, an effect that is countered by eIF4E.	Sirolimus	143-152	eukaryotic translation initiation factor 4E	Homo sapiens	185-190
15239612-7	2004	SRL dosing suppressed CYP3A1/2 protein expression and catalytic activity, without affecting mRNA.	Sirolimus	0-3	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	22-30
15066126-6	2004	Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity.	Sirolimus	0-9	regulatory associated protein of MTOR complex 1	Homo sapiens	48-54
15066126-6	2004	Rapamycin diminished the recovery of endogenous raptor with endogenous or recombinant mTOR in vivo; this inhibition required the ability of mTOR to bind the FKBP12/rapamycin complex, but was independent of mTOR kinase activity.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Homo sapiens	157-163
15041732-10	2004	Furthermore, terminal deoxynucleotidyl transferase-mediated nick end labeling/CD31 double staining of orthotopic tumors demonstrated apoptotic endothelial cells with rapamycin treatment, which also occurred with human umbilical vein endothelial cells in vitro.	Sirolimus	166-175	platelet and endothelial cell adhesion molecule 1	Homo sapiens	78-82
14766396-1	2004	FKBP12 as an immunophilin that binds to two well-known immunosuppressive macrolides, FK506 and rapamycin, has attracted immense attention and its role in mediating the immunosuppressive functions of these macrolides has been extensively studied.	Sirolimus	95-104	FKBP prolyl isomerase 1A	Homo sapiens	0-6
14681687-0	2003	Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing"s sarcoma cell proliferation.	Sirolimus	0-9	EWS RNA binding protein 1	Homo sapiens	68-71
14638714-7	2003	RESULTS: The increases in MMP-2 and -14 that occur 24 hours after sustained mechanical stretching of TM cells were blocked by rapamycin.	Sirolimus	126-135	matrix metallopeptidase 2	Homo sapiens	26-39
14608357-10	2003	The distal peak of association is in RAPTOR (p150 target of rapamycin (TOR)-scaffold protein containing WD-repeats).	Sirolimus	60-69	regulatory associated protein of MTOR complex 1	Homo sapiens	37-43
14565935-4	2003	Here, we show that in contrast to CsA and FK506, rapamycin blocks activation-induced expression of the linker for activation of T cells (LAT), a signaling molecule critical for initiating TCR signaling.	Sirolimus	49-58	linker for activation of T cells	Homo sapiens	137-140
14565935-5	2003	Thus, whereas CsA and FK506 strongly enhanced TCR- and phorbol myristate acetate-induced LAT expression in T cells, rapamycin effectively inhibited activation-induced LAT expression.	Sirolimus	116-125	linker for activation of T cells	Homo sapiens	167-170
14565935-9	2003	Given the important role of LAT in initiating T cell activation, our data suggests that the effects of rapamycin, CsA and FK506 on T cell activation involve regulating early T cell signaling.	Sirolimus	103-112	linker for activation of T cells	Homo sapiens	28-31
12869588-5	2003	In Chinese hamster ovary cells transfected with pV1bR-green fluorescent protein (pV1bR-GFP), PMA increased V1bR-GFP protein levels when cap-mediated translation was inhibited by rapamycin.	Sirolimus	178-187	arginine vasopressin receptor 1B	Homo sapiens	49-53
12940738-5	2003	The splicing product MBP-His was detected by Western blotting and immunoprecipitation in cells treated with rapamycin or a nontoxic analogue thereof.	Sirolimus	108-117	myelin basic protein	Homo sapiens	21-24
14500340-6	2003	Moreover, short-term treatment of Tsc1+/- mice with rapamycin at 20 mg/kg led to some changes in tumor morphology and a reduction in serum VEGF levels.	Sirolimus	52-61	TSC complex subunit 1	Mus musculus	34-38
12676950-0	2003	Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2.	Sirolimus	0-9	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	48-52
12676950-4	2003	A cross-talk was suggested between the two pathways by rapamycin-induced translation of GCN4 mRNA.	Sirolimus	55-64	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	88-92
12676950-5	2003	Here we show that rapamycin causes an increase in phosphorylated eIF2alpha to translationally derepress GCN4.	Sirolimus	18-27	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	104-108
12719473-7	2003	Further, we show that a sublethal concentration of rapamycin mimics the Gap1p sorting defect of an lst8 mutant.	Sirolimus	51-60	TOR complex subunit LST8	Saccharomyces cerevisiae S288C	99-103
12631072-11	2003	Immunostaining of lung tissues for von Willebrand factor was minimal and circulating levels of VEGF-A and TGF-beta1 were lower in the rapamycin-treated mice compared to untreated or cyclosporine-treated mice.	Sirolimus	134-143	transforming growth factor, beta 1	Mus musculus	106-115
12469945-2	2002	In the present study, we developed a flow cytometric assay detecting intracellular IL-12 production by human CD14+ monocytes in order to assess the in vitro effects of widely used immunosuppressants, such as cyclosporine (CsA), sirolimus (SRL) and dexamethasone (DXM).	Sirolimus	228-237	CD14 molecule	Homo sapiens	109-113
12469945-2	2002	In the present study, we developed a flow cytometric assay detecting intracellular IL-12 production by human CD14+ monocytes in order to assess the in vitro effects of widely used immunosuppressants, such as cyclosporine (CsA), sirolimus (SRL) and dexamethasone (DXM).	Sirolimus	239-242	CD14 molecule	Homo sapiens	109-113
12036883-0	2002	Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway.	Sirolimus	10-19	CD28 molecule	Homo sapiens	51-55
12036883-6	2002	Treatment with rapamycin blocked IL-2 production after activation of human peripheral blood T cells with phorbol ester (PMA) and anti-CD28 (CsA-resistant pathway), whereas this drug did not have any effect on PMA plus ionomycin stimulation (CsA-sensitive pathway).	Sirolimus	15-24	CD28 molecule	Homo sapiens	134-138
11847216-0	2002	4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.	Sirolimus	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	40-71
11713209-8	2001	Rapamycin, an inhibitor of p70(S6K), a downstream effector of IRS-1 signaling, partially inhibits (but does not completely abrogate) the increase in Id2 gene expression.	Sirolimus	0-9	inhibitor of DNA binding 2	Mus musculus	149-152
11742267-0	2001	The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients.	Sirolimus	69-78	interleukin 5	Homo sapiens	134-138
11742267-0	2001	The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients.	Sirolimus	80-89	interleukin 5	Homo sapiens	134-138
11742267-1	2001	We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergen-sensitized atopic asthmatic individuals at physiologic concentrations.	Sirolimus	193-202	interleukin 5	Homo sapiens	310-314
11742267-1	2001	We have used an optimized, physiologically relevant in vitro assay system to show that in a concentration-dependent fashion the immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin), as well as the glucocorticoid dexamethasone, inhibit allergen-driven T-cell proliferation and IL-5 production in PBMCs from allergen-sensitized atopic asthmatic individuals at physiologic concentrations.	Sirolimus	204-213	interleukin 5	Homo sapiens	310-314
11602850-1	2001	BACKGROUND: Sirolimus (Rapamune, rapamycin, RAPA) is a potent immunosuppressive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials when added to an immunosuppression regimen of cyclosporine (CsA) and prednisone.	Sirolimus	12-21	transcriptional regulating factor 1	Homo sapiens	44-48
11573200-5	2001	Treatment of differentiating 3T3-L1 cells with rapamycin, starting on day 4, exerted potent negative effects on glycerol phosphate dehydrogenase activity, and triacylglycerol accumulation, as well as on the protein expression of adipogenic transcription factors, C/EBPalpha and PPARgamma.	Sirolimus	47-56	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	263-273
11573200-5	2001	Treatment of differentiating 3T3-L1 cells with rapamycin, starting on day 4, exerted potent negative effects on glycerol phosphate dehydrogenase activity, and triacylglycerol accumulation, as well as on the protein expression of adipogenic transcription factors, C/EBPalpha and PPARgamma.	Sirolimus	47-56	peroxisome proliferator activated receptor gamma	Mus musculus	278-287
11356843-4	2001	Rapamycin, a Tor protein inhibitor, like growth with a poor nitrogen source, promotes nuclear localization of Gln3p and Gat1p.	Sirolimus	0-9	Gat1p	Saccharomyces cerevisiae S288C	120-125
11399049-7	2001	Rapamycin, an inhibitor of p70 S6 kinase, completely inhibited the differentiation and suppressed the accumulation of HSP27 and alphaB-crystallin.	Sirolimus	0-9	crystallin, alpha B	Mus musculus	128-145
11245643-12	2001	FKBP12 is the receptor for Rapamycin (sirolimus), which in animal models reduced neointima formation.	Sirolimus	38-47	FKBP prolyl isomerase 1A	Homo sapiens	0-6
11096087-8	2001	The expression of APG14 is dependent on Gln3p; deletion of Gln3p severely reduced its induction by rapamycin, whereas depletion of Ure2p caused its constitutive expression.	Sirolimus	99-108	Atg14p	Saccharomyces cerevisiae S288C	18-23
11062058-4	2000	Physical interactions between the RyR and calcineurin were found in the CSMF in the presence of added 100 microM Ca(2+); however, the interactions were interrupted in the presence of 20 mM EGTA, 1 microM rapamycin or 1 microM FK506, suggesting that the interaction is Ca(2+)-dependent, and is mediated by FKBP12.6.	Sirolimus	204-213	ryanodine receptor 2	Rattus norvegicus	34-37
11062058-8	2000	Preincubation of cardiomyocytes with 20 microM rapamycin which dissociates FKBP12.6 from the RyR, evoked Ca(2+) oscillations, probably due to the leakiness of the RyR.	Sirolimus	47-56	ryanodine receptor 2	Rattus norvegicus	93-96
11062058-8	2000	Preincubation of cardiomyocytes with 20 microM rapamycin which dissociates FKBP12.6 from the RyR, evoked Ca(2+) oscillations, probably due to the leakiness of the RyR.	Sirolimus	47-56	ryanodine receptor 2	Rattus norvegicus	163-166
11023817-5	2000	Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Rattus norvegicus	246-251
10886809-4	2000	To preclude interference from maternally transferred transforming growth factor-beta1, cutaneous wounds were also made on the backs of 30-day-old transforming growth factor-beta1 null and littermate control mice treated with rapamycin, which extends their lifetime and suppresses the inflammatory response characteristic of the transforming growth factor-beta1 null mice.	Sirolimus	225-234	transforming growth factor, beta 1	Mus musculus	146-178
10886809-4	2000	To preclude interference from maternally transferred transforming growth factor-beta1, cutaneous wounds were also made on the backs of 30-day-old transforming growth factor-beta1 null and littermate control mice treated with rapamycin, which extends their lifetime and suppresses the inflammatory response characteristic of the transforming growth factor-beta1 null mice.	Sirolimus	225-234	transforming growth factor, beta 1	Mus musculus	146-178
10777621-3	2000	Using a chimeric TGF-beta receptor system, we have shown a specific enhancement of internalization when FKBP12 binding to the type I receptor was prevented with rapamycin.	Sirolimus	161-170	FKBP prolyl isomerase 1A	Homo sapiens	104-110
10778917-8	2000	RESULTS: Cyclosporin (1-5 microg/ml) and rapamycin (1.0-10 nM) but not FK-506 (5-10 nM) inhibited both iNOS and COX-2 expression at mRNA level which led to significant inhibition of NO and PGE2 production.	Sirolimus	41-50	cytochrome c oxidase II, mitochondrial	Mus musculus	112-117
10600478-3	1999	To delineate possible signaling pathways accounting for these gene expression, a subset of specific kinase inhibitors, SB203580, PD98059, rapamycin, LY294002, and Ro-32-0432, which inhibit p38 (HOG), MEK (MAPKK), S6 kinase, PI3 kinase, and protein kinase C (PKC), respectively, were employed.	Sirolimus	138-147	mitogen-activated protein kinase 14	Mus musculus	189-192
10480882-6	1999	In accordance with its inhibitory action on protein synthesis, activation of cyclin D1 and p21 proteins by growth factors is also blocked by preincubation with rapamycin.	Sirolimus	160-169	cyclin D1	Homo sapiens	77-86
10464278-9	1999	Rapamycin, an inhibitor of p70 S6 kinase activity, inhibited G-CSF-dependent proliferation of Trf-R(+) cells and increased fMLP-R expression on these cells.	Sirolimus	0-9	transferrin receptor	Homo sapiens	94-99
10437918-0	1999	The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin.	Sirolimus	79-88	GLI family zinc finger 1	Rattus norvegicus	24-27
10437918-3	1999	In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism.	Sirolimus	127-136	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	82-87
10217658-14	1999	CONCLUSIONS: Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27(kip1) and inhibition of the pRb phosphorylation within the vessel wall.	Sirolimus	13-22	RB transcriptional corepressor 1	Homo sapiens	186-189
10328886-6	1999	Experiments with wortmannin, LY294002, and rapamycin suggest that the peptide survival response is dependent on PI 3-kinase activity, but not p70 S6 kinase activity.	Sirolimus	43-52	peptidase inhibitor 3	Homo sapiens	112-116
10586201-4	1999	This study shows that concomitant therapy of RAPA and CsA produces strong synergistic interaction in prolonging renal allograft survival in mice when compared with monotherapy of RAPA or CsA.	Sirolimus	179-183	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	54-57
9806882-6	1998	The effects of insulin on the phosphorylation of these sites, and hence dissociation from eIF4E, are blocked by rapamycin.	Sirolimus	112-121	eukaryotic translation initiation factor 4E	Rattus norvegicus	90-95
9705862-4	1998	Rapamycin caused a significant increase in alkaline phosphatase (ALP) activity and in the expression of osteopontin and osteocalcin mRNAs.	Sirolimus	0-9	secreted phosphoprotein 1	Rattus norvegicus	104-115
9681677-1	1998	FcepsilonRI-mediated exocytosis of preformed mediators from mast cells and basophils (e.g. histamine, serotonin, beta-hexosaminidase) is sensitive to the immunosuppressants cyclosporin A and FK506 (IC50 200 and 4 nM, respectively) but not rapamycin.	Sirolimus	239-248	O-GlcNAcase	Rattus norvegicus	113-132
9545268-6	1998	Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo.	Sirolimus	19-28	FKBP prolyl isomerase 1A	Homo sapiens	78-84
9545268-6	1998	Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo.	Sirolimus	19-28	FKBP prolyl isomerase 1A	Homo sapiens	253-259
9730259-0	1998	Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide).	Sirolimus	102-111	CD3 antigen, epsilon polypeptide	Mus musculus	19-22
9237106-0	1997	Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and rapamycin.	Sirolimus	100-109	interleukin 5	Homo sapiens	13-17
9237106-9	1997	The inhibitory effect of RAP on PHA-induced IL-5 expression was more apparent at 12 and 24 h after stimulation than at earlier times.	Sirolimus	25-28	interleukin 5	Homo sapiens	44-48
9042337-5	1997	Only the phosphatidylinositol-3-kinase inhibitor, wortmannin, and the 70 kDa S6-kinase inhibitor, rapamycin, wholly or partially blocked the effects of insulin and IGF-I on protein synthesis.	Sirolimus	98-107	insulin-like growth factor 1	Mus musculus	164-169
8885238-7	1996	Rapamycin, an immunosuppressant that blocks TCR/CD3 signal transduction pathways and cdk2 activation, blocked telomerase induction.	Sirolimus	0-9	cyclin dependent kinase 2	Homo sapiens	85-89
8799169-3	1996	Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor.	Sirolimus	85-94	interleukin 2 receptor subunit alpha	Homo sapiens	141-146
8778023-6	1996	The hypersensitivity to rapamycin of BJAB cells thus reflects an unusual dependence on the intracellular signalling system targeted by the rapamycin-FKBP12 complex, and may provide a model system for elucidating the role played by this pathway in lymphocyte activation.	Sirolimus	24-33	FKBP prolyl isomerase 1A	Homo sapiens	149-155
8599949-7	1996	Thus, inactivation of eIF-4E is, at least in part, responsible for inhibition of cap-dependent translation in rapamycin-treated cells.	Sirolimus	110-119	eukaryotic translation initiation factor 4E	Homo sapiens	22-28
8521476-6	1995	We now report that calcineurin is physiologically associated with the IP3R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin.	Sirolimus	171-180	inositol 1,4,5-trisphosphate receptor type 3	Homo sapiens	70-74
7721872-10	1995	Using DNA binding gel mobility shift assay we demonstrated that rapamycin potently inhibited the binding of CREB/ATF transcription factors to CRE elements in the murine proximal PCNA promoter.	Sirolimus	64-73	glial cell line derived neurotrophic factor	Mus musculus	113-116
7536932-7	1995	Neutrophil activation by mast cell-derived FKBP12 is prevented by complexing FKBP12 with FK506 or rapamycin.	Sirolimus	98-107	FKBP prolyl isomerase 1A	Homo sapiens	43-49
7536932-9	1995	They further suggest a pathophysiological role for FKBP12 as a mediator in immediate or type I hypersensitivity and may have implications for novel therapeutic strategies in the treatment of allergic disorders with FK506 and rapamycin.	Sirolimus	225-234	FKBP prolyl isomerase 1A	Homo sapiens	51-57
7525596-9	1994	However, in cells carrying an fpr1 delta mutation (which confers resistance to rapamycin), overexpression from the GAL1 promoter of the C-terminal domain of Fpr3, but not full-length Fpr3, restored sensitivity to rapamycin.	Sirolimus	79-88	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	30-34
7525596-9	1994	However, in cells carrying an fpr1 delta mutation (which confers resistance to rapamycin), overexpression from the GAL1 promoter of the C-terminal domain of Fpr3, but not full-length Fpr3, restored sensitivity to rapamycin.	Sirolimus	79-88	peptidylprolyl isomerase FPR3	Saccharomyces cerevisiae S288C	157-161
7525596-9	1994	However, in cells carrying an fpr1 delta mutation (which confers resistance to rapamycin), overexpression from the GAL1 promoter of the C-terminal domain of Fpr3, but not full-length Fpr3, restored sensitivity to rapamycin.	Sirolimus	213-222	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	30-34
7525596-9	1994	However, in cells carrying an fpr1 delta mutation (which confers resistance to rapamycin), overexpression from the GAL1 promoter of the C-terminal domain of Fpr3, but not full-length Fpr3, restored sensitivity to rapamycin.	Sirolimus	213-222	galactokinase	Saccharomyces cerevisiae S288C	115-119
7525596-9	1994	However, in cells carrying an fpr1 delta mutation (which confers resistance to rapamycin), overexpression from the GAL1 promoter of the C-terminal domain of Fpr3, but not full-length Fpr3, restored sensitivity to rapamycin.	Sirolimus	213-222	peptidylprolyl isomerase FPR3	Saccharomyces cerevisiae S288C	157-161
7525596-11	1994	In fpr1 delta cells, the toxic effect of Fpr3 overproduction can be reversed by rapamycin.	Sirolimus	80-89	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	3-7
7525596-11	1994	In fpr1 delta cells, the toxic effect of Fpr3 overproduction can be reversed by rapamycin.	Sirolimus	80-89	peptidylprolyl isomerase FPR3	Saccharomyces cerevisiae S288C	41-45
7525596-12	1994	Overproduction of the NH2-terminal domain of Fpr3 is also growth inhibitory in normal cells and fpr1 delta mutants, but this toxicity is not ameliorated in fpr1 delta cells by rapamycin.	Sirolimus	176-185	peptidylprolyl isomerase FPR3	Saccharomyces cerevisiae S288C	45-49
7523138-4	1994	Activation of p70 S6 kinase through CD28 was inhibited by rapamycin.	Sirolimus	58-67	CD28 molecule	Homo sapiens	36-40
7514503-1	1994	FK506-binding protein (FKBP12) was originally identified as the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin.	Sirolimus	125-134	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	23-29
7514503-5	1994	FK506 or rapamycin, inhibitors of FKBP12 isomerase activity, reverse these stabilizing effects.	Sirolimus	9-18	FKBP prolyl isomerase 1A pseudogene 2	Homo sapiens	34-40
7693684-5	1993	Rapamycin antagonized the inhibitory effect of FK506 but not CsA, suggesting that FK506 and CsA may act through complex formation with distinct intracellular immunophilins.	Sirolimus	0-9	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	92-95
7689258-4	1993	Unexpectedly, rapamycin actually synergized with IL-4 in both the upregulation of CD23 expression and the down-regulation of the type II (p75) TNF receptor, while in the same B cell line, rapamycin simultaneously inhibited the IL-4-dependent production of TNF alpha and beta.	Sirolimus	14-23	Fc epsilon receptor II	Homo sapiens	82-86
7689258-4	1993	Unexpectedly, rapamycin actually synergized with IL-4 in both the upregulation of CD23 expression and the down-regulation of the type II (p75) TNF receptor, while in the same B cell line, rapamycin simultaneously inhibited the IL-4-dependent production of TNF alpha and beta.	Sirolimus	14-23	interleukin 2 receptor subunit beta	Homo sapiens	138-141
1930186-1	1991	FKBP-12 is the major T cell binding protein for the immunosuppressive drugs FK506 and rapamycin.	Sirolimus	86-95	FKBP prolyl isomerase 1A	Homo sapiens	0-7
1715094-4	1991	An FKBP-rapamycin complex is concluded to be the toxic agent because (i) strains that lack FKBP proline rotamase, encoded by FPR1, were viable and fully resistant to rapamycin and (ii) FK506 antagonized rapamycin toxicity in vivo.	Sirolimus	8-17	peptidylprolyl isomerase FPR1	Saccharomyces cerevisiae S288C	125-129
33942341-1	2021	AIMS: Tuberous sclerosis complex (TSC) is a genetic disorder associated with dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway.	Sirolimus	120-129	CREB regulated transcription coactivator 1	Mus musculus	141-147
33773987-7	2021	Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt.	Sirolimus	14-23	ribosomal protein S6	Homo sapiens	201-221
33761878-10	2021	The interaction of mitochondrial genotype (mtDNA) with rapamycin treatment identifies new links between mitochondria and the nutrient-sensing mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	142-148
33762334-5	2021	Adipocyte leptin was regulated by the mechanistic target of rapamycin complex 1 (mTORC1) and blocked by rapamycin.	Sirolimus	60-69	CREB regulated transcription coactivator 1	Mus musculus	81-87
32890589-2	2020	The rapamycin derivative ("rapalog") everolimus, which allosterically inhibits the mTOR pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (SRS) in individuals with tuberous sclerosis complex (TSC).	Sirolimus	4-13	TSC complex subunit 1	Mus musculus	237-240
33033115-3	2020	Recently, the mechanistic target of rapamycin complex 2 (mTORC2) was identified as an evolutionarily conserved Ras effector.	Sirolimus	36-45	CREB regulated transcription coactivator 2	Mus musculus	57-63
32796887-2	2020	Mammalian target of rapamycin complex 1 (mTORC1), a protein complex that contains the serine-threonine kinase mTOR, mediates signaling that underlies the control of cellular functions such as proliferation and autophagy by various external stimuli.	Sirolimus	20-29	CREB regulated transcription coactivator 1	Mus musculus	41-47
26220174-4	2015	To study the effects of mTORC1 activation on mitochondrial structure and function, mTORC1 was inhibited by treating Acsl1(T-/-) and littermate control mice with rapamycin or vehicle alone for 2 wk.	Sirolimus	161-170	CREB regulated transcription coactivator 1	Mus musculus	83-89
25574706-6	2015	Interestingly, inhibition of hypothalamic mTORC1 with rapamycin reversed the food intake- and body weight-lowering effects of ICV insulin.	Sirolimus	54-63	CREB regulated transcription coactivator 1	Mus musculus	42-48
25548282-10	2015	mTORC1 inhibition, by treatment with rapamycin, reversed changes in autophagic flux, and cell death induced by glucose/PA.	Sirolimus	37-46	CREB regulated transcription coactivator 1	Mus musculus	0-6
23888043-0	2013	mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin.	Sirolimus	72-81	CREB regulated transcription coactivator 1	Mus musculus	0-6
23888043-1	2013	The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) protein kinase promotes growth and is the target of rapamycin, a clinically useful drug that also prolongs life span in model organisms.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	54-60
23888043-2	2013	A persistent mystery is why the phosphorylation of many bona fide mTORC1 substrates is resistant to rapamycin.	Sirolimus	100-109	CREB regulated transcription coactivator 1	Mus musculus	66-72
23888043-4	2013	Slight modifications of the sites were sufficient to alter mTORC1 activity toward them in vitro and to cause concomitant changes within cells in their sensitivity to rapamycin and starvation.	Sirolimus	166-175	CREB regulated transcription coactivator 1	Mus musculus	59-65
34932133-9	2022	Of note, aripiprazole increased beta cell size (p<0.05) and mass (p<0.01) vs mice fed a control chow diet, along with activation of mechanistic target of rapamycin complex 1 (mTORC1)/S6 signalling, without preventing beta cell dysfunction.	Sirolimus	154-163	CREB regulated transcription coactivator 1	Mus musculus	175-181
34619135-7	2022	Inhibiting mTOR activity with rapamycin induces raptor and restores AKT activity, allowing beta-cells to gain proliferation capacity that are lost after HFD exposure.	Sirolimus	30-39	regulatory associated protein of MTOR complex 1	Homo sapiens	48-54
34974060-11	2022	Additionally, mTOR inhibitor rapamycin blocked these effects of GALNT4 overexpression on monocytes.	Sirolimus	29-38	polypeptide N-acetylgalactosaminyltransferase 4	Mus musculus	64-70
34968488-2	2022	Numerous previous studies have shown the role of central mammalian target of rapamycin complex 1 (mTORC1) signaling in depression.	Sirolimus	77-86	CREB regulated transcription coactivator 1	Mus musculus	98-104
34952616-19	2021	The levels of Rap1GAP were decreased after treating the cells with rapamycin to induce cell autophagy in HeLa and C33A cells.	Sirolimus	67-76	RAP1 GTPase activating protein	Homo sapiens	14-21
34941873-8	2021	Inhibition of mTORC1 by rapamycin rescues the hepatomegaly and liver dysfunction of lvh.	Sirolimus	24-33	CREB regulated transcription coactivator 1	Mus musculus	14-20
34949833-3	2022	Here, using a mouse model of acute infection with lymphocytic choriomeningitis virus (LCMV), we found that the serine/threonine kinase complex mammalian target of rapamycin complex 2 (mTORC2) is critical for the long-term persistence of virus-specific memory CD4+ T cells.	Sirolimus	163-172	CREB regulated transcription coactivator 2	Mus musculus	184-190
34839600-8	2021	After 30 min of culture, phosphorylation level of mammalian target of rapamycin complex 1 (mTORC1), p70 ribosomal protein S6 kinase (P70 S6k), and eIF4E-binding protein 1 (4E-BP1) were detected by Western blotting.	Sirolimus	70-79	CREB regulated transcription coactivator 1	Mus musculus	91-97
34959437-1	2021	The inhibition of the mammalian target of rapamycin complex 1 (mTORC1) by everolimus (RAD001) was recently shown to enhance the tumor uptake of radiolabeled minigastrin.	Sirolimus	42-51	CREB regulated transcription coactivator 1	Mus musculus	63-69
34878722-3	2022	Mechanistic target of rapamycin complex 1 (mTORC1) is known to control fundamental processes in ageing: inhibiting this signalling complex slows biological ageing, reduces age-related disease pathology, and increases lifespan in model organisms.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
33459974-6	2021	Moreover, several postnatal dietary interventions tested by the "Intervention Testing Program (ITP)" from the National Institute of Aging (NIA) have shown that while pharmacological interventions like rapamycin affect the IGF-1/insulin pathway and preferentially extend lifespan in females; dietary compounds that target other cellular pathways are effective only in male mice-indicating mutually exclusive sex-specific pathways.	Sirolimus	201-210	insulin-like growth factor 1	Mus musculus	222-227
34031457-6	2021	Pre-treatment with IGF-1 signal pathway specific inhibitors such as picropodophyllin, LY294002, and rapamycin attenuated EE induced myotube hypertrophy and MyHC isoform overexpression.	Sirolimus	100-109	insulin-like growth factor 1	Mus musculus	19-24
34023434-12	2021	The therapeutic effects of FGF-2 in the SAH + FGF-2+rapamycin group were weakened compared with that in the SAH + FGF-2+DMSO group.	Sirolimus	52-61	fibroblast growth factor 2	Rattus norvegicus	27-32
33756106-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) regulates metabolism and cell growth in response to nutrient, growth, and oncogenic signals.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33705959-11	2021	From the results of this study, NEAT1/hsa-miR-372-3p/AGPS/APOC4 axis plays a vital role in rapamycin-disruption of lipid homeostasis.	Sirolimus	91-100	alkylglycerone phosphate synthase	Homo sapiens	53-57
32799332-2	2021	We determined the mechanisms of ethanol-induced impaired phosphorylation of mechanistic target of rapamycin complex 1 (mTORC1) and AMP kinase (AMPK) with consequent dysregulated skeletal muscle protein homeostasis (balance between protein synthesis and breakdown).	Sirolimus	98-107	CREB regulated transcription coactivator 1	Mus musculus	119-125
33574130-2	2021	Although mechanistic target of rapamycin complex 1 (mTORC1) activation enhances MM cell growth, the mTORC1 inhibitor everolimus has shown limited efficacy in clinical trials of MM patients.	Sirolimus	31-40	CREB regulated transcription coactivator 1	Mus musculus	52-58
34027051-2	2021	Our recent study linked cyst(e)ine availability with glutathione peroxidase 4 (GPX4) protein synthesis and ferroptosis mitigation via a Rag-mechanistic target of rapamycin complex 1 (mTORC1) axis, and proposed that co-targeting mTORC1 and ferroptosis is a promising strategy for cancer therapy.	Sirolimus	162-171	CREB regulated transcription coactivator 1	Mus musculus	183-189
33919313-1	2021	Increased amino acid availability acutely stimulates protein synthesis partially via activation of mechanistic target of rapamycin complex 1 (mTORC1).	Sirolimus	121-130	CREB regulated transcription coactivator 1	Mus musculus	142-148
33863987-2	2021	LARS is also essential to sensitize the intracellular leucine concentration to the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	124-130
33846288-2	2021	Signaling by mammalian target of rapamycin complex 1 (mTORC1) plays a central role in the maintenance of skeletal muscle mass by regulating net protein balance; yet, its role in denervation-induced atrophy is unclear.	Sirolimus	33-42	CREB regulated transcription coactivator 1	Mus musculus	54-60
33897381-1	2021	Hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) due to mutations in genes along the PI3K-mTOR pathway and the GATOR1 complex causes a spectrum of neurodevelopmental disorders (termed mTORopathies) associated with malformation of cortical development and intractable epilepsy.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
33916918-8	2021	In vitro studies demonstrated that the effect of KP-Nano Rapa-loaded, in reducing the amount of the Phospo-Ser757-ULK1 protein through the inhibition of the mammalian target of rapamycin (mTOR), is comparable to that of the free drug.	Sirolimus	57-61	unc-51 like autophagy activating kinase 1	Homo sapiens	114-118
33398329-5	2021	We demonstrate that mTORC1 phosphorylates LARP1 in vitro and in vivo, activities that are efficiently inhibited by rapamycin and torin1.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	20-26
33398329-5	2021	We demonstrate that mTORC1 phosphorylates LARP1 in vitro and in vivo, activities that are efficiently inhibited by rapamycin and torin1.	Sirolimus	115-124	La ribonucleoprotein 1, translational regulator	Homo sapiens	42-47
33398329-6	2021	We uncover 26 rapamycin-sensitive phospho-serine and -threonine residues on LARP1 that are distributed in 7 clusters.	Sirolimus	14-23	La ribonucleoprotein 1, translational regulator	Homo sapiens	76-81
33398329-7	2021	Our data show that phosphorylation of a cluster of residues located proximally to the m7Gppp cap-binding DM15 region is particularly sensitive to rapamycin and regulates both the RNA-binding and the translation inhibitory activities of LARP1.	Sirolimus	146-155	La ribonucleoprotein 1, translational regulator	Homo sapiens	236-241
33987434-3	2021	Enhanced activity of mechanistic target of rapamycin complex 1 (mTORC1) is a hallmark of HCC promoted by hepatitis B virus (HBV) and hepatitis C virus (HCV).	Sirolimus	43-52	CREB regulated transcription coactivator 1	Mus musculus	64-70
33422633-4	2021	Hence, the present study aimed to better investigate these mechanisms, also considering a potential involvement of mammalian Target Of Rapamycin Complex1 (mTORC1)-ribosomal protein S6 Kinase beta1 (S6K1) pathway.	Sirolimus	135-144	CREB regulated transcription coactivator 1	Mus musculus	155-161
33597150-8	2021	PD1 upregulation is accentuated in the presence of rapamycin but prevented by tacrolimus.	Sirolimus	51-60	programmed cell death 1	Homo sapiens	0-3
33597150-9	2021	These data support a general theory of CoB-resistant cells as Ag-experienced, costimulation-independent cells and suggest a mechanism for the synergy of belatacept and rapamycin, with increased expression of the activation marker PD1 potentiating exhaustion of CoB-resistant cells.	Sirolimus	168-177	programmed cell death 1	Homo sapiens	230-233
33883257-3	2021	METHOD: In this study, we evaluated the roles of amino acids and the Rag complex in regulating mammalian target of rapamycin complex 1 (mTORC1) signaling in CD8+ TILs.	Sirolimus	115-124	CREB regulated transcription coactivator 1	Mus musculus	136-142
33865602-0	2021	Overexpression Prox1 in HemECs resembles Kaposiform hemangioendothelioma and cytotoxicity of sirolimus in vitro.	Sirolimus	93-102	prospero homeobox 1	Homo sapiens	15-20
33865602-10	2021	Sirolimus inhibited cell proliferation, promoted apoptosis and led to G1 phase arrest in Prox1+ HemECs.	Sirolimus	0-9	prospero homeobox 1	Homo sapiens	89-94
33723228-8	2021	We found that rapamycin effectively reduced the aggregation of TDP-43 in OPTN (E50K) mice and decreased the protein levels of p62/SQSTM1 and the autophagic marker LC3-II.	Sirolimus	14-23	sequestosome 1	Mus musculus	126-129
33723228-8	2021	We found that rapamycin effectively reduced the aggregation of TDP-43 in OPTN (E50K) mice and decreased the protein levels of p62/SQSTM1 and the autophagic marker LC3-II.	Sirolimus	14-23	sequestosome 1	Mus musculus	130-136
33710804-13	2021	CONCLUSIONS: SNORA23 exhibited antitumor effects in HCC and together with rapamycin, provided a promising therapeutic strategy for HCC treatment.	Sirolimus	74-83	HCC	Homo sapiens	131-134
33707434-5	2021	Mechanistically, we find that cyst(e)ine activates mechanistic/mammalian target of rapamycin complex 1 (mTORC1) and promotes GPX4 protein synthesis at least partly through the Rag-mTORC1-4EBP signaling axis.	Sirolimus	83-92	CREB regulated transcription coactivator 1	Mus musculus	104-110
33050984-6	2021	The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRalpha, CYP7A1, ABCG1, PPARgamma, ApoA1) in the liver.	Sirolimus	25-29	peroxisome proliferator activated receptor gamma	Mus musculus	184-193
33626233-4	2021	BC cell-intrinsic PD-L1 promoted mammalian target of rapamycin complex 1 (mTORC1) signals in vitro and augmented in vivo immune-independent cell growth and metastatic cancer spread, similar to effects we reported in melanoma and ovarian cancer.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	74-80
33626233-6	2021	BC cell-intrinsic PD-L1 also mediated chemotherapy resistance to the commonly used BC chemotherapy agents cis-platinum and gemcitabine and to the mTORC1 inhibitor, rapamycin.	Sirolimus	164-173	CREB regulated transcription coactivator 1	Mus musculus	146-152
33646118-1	2021	The mechanistic target of rapamycin complex 1 (mTORC1) stimulates a coordinated anabolic program in response to growth-promoting signals.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33660929-2	2021	In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor.	Sirolimus	183-192	CREB regulated transcription coactivator 1	Mus musculus	31-37
33650390-3	2021	Intensive research over the years has established deregulation of mam-malian target of rapamycin pathway in cancer.	Sirolimus	87-96	sarcoglycan gamma	Homo sapiens	66-69
33637808-10	2021	Therapeutic rapamycin treatment suppressed HIV-1 replication in tissue-derived CD11c+ DCs, while all selected drugs limited viral replication in CD4+ T cells.	Sirolimus	12-21	integrin subunit alpha X	Homo sapiens	79-84
33671526-4	2021	In particular, the activity of mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing signaling molecule, is hyperactivated in various organs of diabetic patients, which suggests the involvement of excessive mTORC1 activation in the pathogenesis of diabetes.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	74-80
33671526-4	2021	In particular, the activity of mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing signaling molecule, is hyperactivated in various organs of diabetic patients, which suggests the involvement of excessive mTORC1 activation in the pathogenesis of diabetes.	Sirolimus	53-62	CREB regulated transcription coactivator 1	Mus musculus	224-230
33482580-2	2021	Mutations in the TSC2 gene and loss of TSC2 promote cell growth by the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	91-100	CREB regulated transcription coactivator 1	Mus musculus	112-118
33498102-18	2021	The protein expression of Beclin1 in the tissue where the complete Freund"s adjuvant was injected of rats in BCG+rapamycin group was significantly higher than that of blank control group (P<0.05).	Sirolimus	113-122	beclin 1	Rattus norvegicus	26-33
33731662-3	2021	The role of RT-induced anabolic stimulation was investigated in tumor-bearing rats with the mTORC1 inhibitor rapamycin, and cross-sectional areas of skeletal muscle were evaluated to identify atrophy or hypertrophy.	Sirolimus	109-118	CREB regulated transcription coactivator 1	Mus musculus	92-98
33602225-2	2021	The E3 ubiquitin ligase RNF152 has been reported to regulate the activity of the mechanistic target of rapamycin complex 1 (mTORC1), induce autophagy and apoptosis.	Sirolimus	103-112	ring finger protein 152	Homo sapiens	24-30
33602225-2	2021	The E3 ubiquitin ligase RNF152 has been reported to regulate the activity of the mechanistic target of rapamycin complex 1 (mTORC1), induce autophagy and apoptosis.	Sirolimus	103-112	CREB regulated transcription coactivator 1	Mus musculus	124-130
33599151-6	2021	mTOR forms two protein complexes, mTORC1, which is sensitive to rapamycin and mTORC2, which is not directly inhibited by this drug.	Sirolimus	64-73	CREB regulated transcription coactivator 1	Mus musculus	34-40
33599151-7	2021	Rapamycin has facilitated the discovery of the various functions of mTORC1 in metabolism.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	68-74
33597177-4	2021	Notably, the rapamycin-sensitive mTORC1 pathway, rather than the rapamycin-insensitive mTORC2 pathway, was responsible for elevated activation of RIPK1, RIPK3, and MLKL in TSC1-deficient macrophages.	Sirolimus	13-22	CREB regulated transcription coactivator 1	Mus musculus	33-39
33593593-2	2021	It is tightly regulated by a suite of kinases responsive to nutrient status, including mammalian target of rapamycin complex 1 (mTORC1), AMP-activated protein kinase (AMPK), protein kinase C-alpha (PKCalpha), MAPK-activated protein kinases 2/3 (MAPKAPK2/3), Rho kinase 1 (ROCK1), c-Jun N-terminal kinase 1 (JNK), and Casein kinase 2 (CSNK2).	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	128-134
33744643-7	2021	A protein x citrulline interaction was observed for some plasma and muscle AA levels with a significant activation of mechanistic target of rapamycin complex 1 (mTORC1) signaling suggesting higher anabolism with the combination of citrulline and lactoserum.	Sirolimus	140-149	CREB regulated transcription coactivator 1	Mus musculus	161-167
33574709-2	2021	Inhibition of mTORC1 (mechanistic target of rapamycin complex 1) activity upon aspirin treatment has been reported in breast cancer cells harboring PI3KCA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation and is considered to account for anticancer action.	Sirolimus	44-53	CREB regulated transcription coactivator 1	Mus musculus	14-20
33277337-6	2021	mRNA expression analysis and differential proteomics on betaFurKO islets revealed activation of Activating Transcription Factor 4 (ATF4), which was mediated by mammalian target of rapamycin C1 (mTORC1).	Sirolimus	180-189	CREB regulated transcription coactivator 1	Mus musculus	194-200
33508145-13	2021	By inhibiting p53 alone or both mTORC1 and p53 with rapamycin and a p53 inhibitor, we elucidated that p53 acts downstream of mTORC1 and that mTORC1 thereby promotes odontoblast mineralization.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	125-131
33508145-13	2021	By inhibiting p53 alone or both mTORC1 and p53 with rapamycin and a p53 inhibitor, we elucidated that p53 acts downstream of mTORC1 and that mTORC1 thereby promotes odontoblast mineralization.	Sirolimus	52-61	CREB regulated transcription coactivator 1	Mus musculus	125-131
33225417-2	2021	Rapamycin Rapa, an inhibitor of mammalian target of rapamycin mTOR, has exhibited antitumor efficacy in a variety of malignant tumors.	Sirolimus	52-61	transcriptional regulating factor 1	Homo sapiens	0-4
33219627-4	2021	This may be related to Rapamycin inhibiting the phosphorylation of mTOR and affecting the expression of cell cycle-related genes (CDK2, CDK4, P27, CycleD1, and CycleD3).	Sirolimus	23-32	cyclin-dependent kinase 2	Bubalus bubalis	130-134
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	20-29	microtubule associated protein 1 light chain 3 beta	Homo sapiens	83-87
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	31-35	microtubule associated protein 1 light chain 3 beta	Homo sapiens	83-87
33340488-5	2021	Consequently, expression of the serine biosynthesis enzyme PHGDH was required for sensitivity to the mTORC1 inhibitor rapamycin in breast-cancer-derived lung tumors, but not in primary breast tumors.	Sirolimus	118-127	phosphoglycerate dehydrogenase	Homo sapiens	59-64
33340488-5	2021	Consequently, expression of the serine biosynthesis enzyme PHGDH was required for sensitivity to the mTORC1 inhibitor rapamycin in breast-cancer-derived lung tumors, but not in primary breast tumors.	Sirolimus	118-127	CREB regulated transcription coactivator 1	Mus musculus	101-107
33340489-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and proliferation by sensing fluctuations in environmental cues such as nutrients, growth factors, and energy levels.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
33542926-3	2021	To examine the role of mechanistic target of rapamycin complex 1 (mTORC1) on amino acid catabolism, mTORC1 was inactivated by rapamycin or shRNA targeting Raptor, versus activated by overexpressing Rheb or amino acids in human hepatocytes.	Sirolimus	45-54	CREB regulated transcription coactivator 1	Mus musculus	66-72
33542926-3	2021	To examine the role of mechanistic target of rapamycin complex 1 (mTORC1) on amino acid catabolism, mTORC1 was inactivated by rapamycin or shRNA targeting Raptor, versus activated by overexpressing Rheb or amino acids in human hepatocytes.	Sirolimus	126-135	CREB regulated transcription coactivator 1	Mus musculus	100-106
33519806-6	2020	Our data indicated that Arg1 haploinsufficiency promoted Abeta deposition, exacerbated some behavioral impairment, and decreased components of Ragulator-Rag complex involved in mechanistic target of rapamycin complex 1 (mTORC1) signaling and autophagy.	Sirolimus	199-208	arginase, liver	Mus musculus	24-28
33519806-6	2020	Our data indicated that Arg1 haploinsufficiency promoted Abeta deposition, exacerbated some behavioral impairment, and decreased components of Ragulator-Rag complex involved in mechanistic target of rapamycin complex 1 (mTORC1) signaling and autophagy.	Sirolimus	199-208	CREB regulated transcription coactivator 1	Mus musculus	220-226
33432187-1	2021	Rapid antidepressants are novel treatments for major depressive disorder (MDD) and work by blocking N-methyl-D-aspartate receptors (NMDARs), which, in turn, activate the protein synthesis pathway regulated by mechanistic/mammalian target of rapamycin complex 1 (mTORC1).	Sirolimus	241-250	CREB regulated transcription coactivator 1	Mus musculus	262-268
33485108-3	2021	According to a murine model, the expression level of the metabolic checkpoint kinase mechanistic target of Rapamycin complex 1 (mTORC1) in granulomas of sarcoidosis patients may be used as a clinical biomarker.	Sirolimus	107-116	CREB regulated transcription coactivator 1	Mus musculus	128-134
33398801-1	2021	Tuberous sclerosis complex (TSC) is a dominant autosomal genetic disorder caused by loss-of-function mutations in TSC1 and TSC2, which lead to constitutive activation of the mammalian target of rapamycin C1 (mTORC1) with its decoupling from regulatory inputs.	Sirolimus	194-203	CREB regulated transcription coactivator 1	Mus musculus	208-214
33539025-5	2021	These include mechanisms that were conserved during evolution but have gained special features in multicellular eukaryotes, such as pathways regulated by eukaryotic translation initiation factor 2 (eIF-2)-alpha kinase (GCN2, also named general control nonderepressible 2 kinase), 5"-adenosine monophosphate (AMP)-activated protein kinase (AMPK) and target of rapamycin (TOR).The interplay between IDO-1 and above-mentioned pathway seems to be highly context dependent.	Sirolimus	359-368	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	339-343
33052068-3	2021	The mechanistic target of rapamycin complex 1 (mTORC1) pathway integrates external and internal signals, including those by amino acids (AAs), to promote normal preimplantation development.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
32755490-5	2021	However, it has been hypothesised that mammalian target of rapamycin complex 1 (mTORC1) hyperactivation in the presence of amino acid overload contributes to reduced insulin-stimulated glucose uptake due to insulin receptor substrate (IRS) degradation and reduced Akt-AS160 activity.	Sirolimus	59-68	CREB regulated transcription coactivator 1	Mus musculus	80-86
31541182-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) regulates CD8+ T-cell differentiation and function.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
32838711-12	2021	In addition, H2O2 decreased the levels of Beclin1 and Atg5/12/16, which were reversed by rapamycin or melatonin.	Sirolimus	89-98	autophagy related 5	Mus musculus	54-64
32738450-13	2021	The mTOR inhibitor rapamycin significantly reduced hepatocarcinogenesis triggered by Tsc1 loss and p53 haploinsufficiency in vivo, as well as the biomarker Abcc4.	Sirolimus	19-28	TSC complex subunit 1	Mus musculus	85-89
33214245-6	2021	Functional studies using CRISPR-Cas9 gene-edited cells demonstrated a key role for the TSC2/RHEB axis in regulating TGF-beta1-induced mechanistic target of rapamycin complex 1 activation and collagen I deposition in mesenchymal cells reflecting IPF and other disease settings, including cancer-associated fibroblasts.	Sirolimus	156-165	Ras homolog, mTORC1 binding	Homo sapiens	92-96
33194193-0	2020	Sirolimus and MMF are insufficient immunosuppressants for regulation of the proliferation of CD133+EpCAM+ cell populations in HCC cell lines.	Sirolimus	0-9	prominin 1	Homo sapiens	93-98
33194193-4	2020	Sirolimus and MMF reduced the proliferation of Huh7 and HEP3B cells; however, the proportion of CD133+EpCAM+ was notably increased in treated Huh7 cells.	Sirolimus	0-9	prominin 1	Homo sapiens	96-101
33194193-5	2020	Sirolimus treatment alone resulted in G0-G1 cell cycle arrest at all doses in all Huh7 and CD133-EpCAM- populations; however, CD133+EpCAM+ populations showed only slight G1 arrest at higher doses only.	Sirolimus	0-9	prominin 1	Homo sapiens	91-96
33125102-3	2020	The present study thus aimed to investigate the effects of PTH(1-34) on the migration and adhesion of, and rictor/mammalian target of rapamycin complex 2 (mTORC2) signaling in BMSCs.	Sirolimus	134-143	CREB regulated transcription coactivator 2	Mus musculus	155-161
32848049-6	2020	Using Western blot analysis and AMP/ATP measurements, we found that simvastatin treatment blocked activation of mechanistic target of rapamycin complex 1 (mTORC1), activated AMP-activated protein kinase (AMPK) through increased intracellular AMP:ATP ratios, and favored nuclear translocation of transcription factor EB (TFEB).	Sirolimus	134-143	CREB regulated transcription coactivator 1	Mus musculus	155-161
32893874-4	2020	Rapamycin prevented contraction-induced muscle protein synthesis in Rictor mKO but not wild-type mice.	Sirolimus	0-9	RPTOR independent companion of MTOR, complex 2	Mus musculus	68-74
32893874-6	2020	Previous studies showed that the mechanistic target of rapamycin complex 1 (mTORC1) inhibition suppressed the early but not late muscle protein synthesis-response, while the inhibition of both mTORC1 and mTORC2 abolished both effects.	Sirolimus	55-64	CREB regulated transcription coactivator 1	Mus musculus	76-82
32893874-10	2020	Vehicle or the mTORC1 inhibitor rapamycin (1.5 mg/kg) was injected intraperitoneally 1 h before contraction.	Sirolimus	32-41	CREB regulated transcription coactivator 1	Mus musculus	15-21
32893874-12	2020	Rapamycin treatment in Rictor mKO prevented contraction-stimulated muscle protein synthesis.	Sirolimus	0-9	RPTOR independent companion of MTOR, complex 2	Mus musculus	23-29
32893874-14	2020	In rapamycin-treated Rictor mKO mice, the same mTORC1 signalling was blocked following contractions.	Sirolimus	3-12	RPTOR independent companion of MTOR, complex 2	Mus musculus	21-27
32893874-14	2020	In rapamycin-treated Rictor mKO mice, the same mTORC1 signalling was blocked following contractions.	Sirolimus	3-12	CREB regulated transcription coactivator 1	Mus musculus	47-53
32893874-15	2020	Our results indicate that although neither rapamycin-sensitive mTOR/mTORC1 nor mTORC2 regulates contraction-induced muscle protein synthesis, combined inhibition of rapamycin-sensitive mTOR/mTORC1 and mTORC2 synergistically inhibits contraction-induced muscle protein synthesis.	Sirolimus	165-174	CREB regulated transcription coactivator 1	Mus musculus	190-196
33329581-6	2020	In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells.	Sirolimus	45-54	forkhead box P3	Homo sapiens	100-105
33329581-6	2020	In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells.	Sirolimus	45-54	forkhead box P3	Homo sapiens	132-137
33329581-7	2020	Rapamycin induced IFN-gamma-producing T-bet+Foxp3lo cells accompanied with enhanced lipid metabolism, whereas 2DG induced IFN-gamma-non-producing T-bet+Foxp3hi cells.	Sirolimus	0-9	forkhead box P3	Homo sapiens	44-49
33257668-1	2020	The mechanistic target of rapamycin complex 1 (mTORC1) integrates growth, nutrient and energy status cues to control cell growth and metabolism.	Sirolimus	26-35	CREB regulated transcription coactivator 1	Mus musculus	47-53
33319180-2	2020	We show here that infusion of rapamycin (mTOR inhibitor) at reperfusion following ischemia reduced myocardial infarct size and apoptosis with restoration of cardiac function in type 1 diabetic rabbits.	Sirolimus	30-39	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	41-45
33319180-5	2020	Rapamycin inhibited mTORC1 and PTEN, but augmented mTORC2 with restoration of miRNA-302a under diabetic conditions.	Sirolimus	0-9	CREB regulated transcription coactivator 1	Mus musculus	20-26
33319180-5	2020	Rapamycin inhibited mTORC1 and PTEN, but augmented mTORC2 with restoration of miRNA-302a under diabetic conditions.	Sirolimus	0-9	CREB regulated transcription coactivator 2	Mus musculus	51-57
33319180-7	2020	We conclude that rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling.	Sirolimus	17-26	CREB regulated transcription coactivator 1	Mus musculus	106-112
33319180-7	2020	We conclude that rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling.	Sirolimus	17-26	CREB regulated transcription coactivator 2	Mus musculus	142-148
33324640-1	2020	Mechanistic Target of Rapamycin Complex 1 (mTORC1) serves as positive regulator of placental nutrient transport and mitochondrial respiration.	Sirolimus	22-31	CREB regulated transcription coactivator 1	Mus musculus	43-49
23787763-12	2013	Rapamycin in combination with Mino produced synergistic effects on LC3 conversion, reduction of the Akt/mTOR/p70S6K pathway, and glioma cell death.	Sirolimus	0-9	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	67-70
23787763-12	2013	Rapamycin in combination with Mino produced synergistic effects on LC3 conversion, reduction of the Akt/mTOR/p70S6K pathway, and glioma cell death.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	104-108
23806777-4	2013	Saline or rapamycin (mTOR inhibitor; 5mg/kg, i.p.)	Sirolimus	10-19	mechanistic target of rapamycin kinase	Mus musculus	21-25
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	forkhead box P3	Mus musculus	148-153
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	forkhead box P3	Mus musculus	148-153
23444145-0	2013	Rapamycin inhibits BMP-7-induced osteogenic and lipogenic marker expressions in fetal rat calvarial cells.	Sirolimus	0-9	bone morphogenetic protein 7	Rattus norvegicus	19-24
23863708-3	2013	The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals.	Sirolimus	93-102	mechanistic target of rapamycin kinase	Mus musculus	78-82
23829864-4	2013	The increase in GABAB receptor subunits was unaccompanied by a change in mRNA, but inhibition of mTOR by rapamycin blocked the increase in GABAB protein.	Sirolimus	105-114	mechanistic target of rapamycin kinase	Mus musculus	97-101
22890326-4	2013	Rapamycin increases epidermal Akt1 phosphorylation via inhibition of the mTOR complex 1-dependent regulation of insulin receptor substrate-1.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	112-140
23815869-8	2013	We found that rapamycin significantly reduced LEC proliferation and was correlated with decreased VEGFR-3 expression in both LEC, and in some HNSCC cell lines.	Sirolimus	14-23	FMS-like tyrosine kinase 4	Mus musculus	98-105
23520131-9	2013	The inflammatory responses in SNRK knockdown adipocytes can be partially attributable to defective mTORC1 signaling, since rapamycin treatment activates IKKbeta and induces lipolysis in adipocytes.	Sirolimus	123-132	inhibitor of kappaB kinase beta	Mus musculus	153-160
23566837-7	2013	Western blotting showed decreased expression of phosphorylated mTOR and phosphorylated p70S6K in the rapamycin-treated group, and increased the expression of both SIRT1 and SIRT6 compared to the control group (P&lt;0.05).	Sirolimus	101-110	ribosomal protein S6 kinase B1	Rattus norvegicus	87-93
23566837-7	2013	Western blotting showed decreased expression of phosphorylated mTOR and phosphorylated p70S6K in the rapamycin-treated group, and increased the expression of both SIRT1 and SIRT6 compared to the control group (P&lt;0.05).	Sirolimus	101-110	sirtuin 6	Rattus norvegicus	173-178
23762265-4	2013	Forced expression of miR-99a or rapamycin treatment blocked insulin-induced PKM2 and HIF-1alpha expression, and glucose consumption and lactate production.	Sirolimus	32-41	pyruvate kinase M1/2	Homo sapiens	76-80
23358238-4	2013	The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Mus musculus	59-63
23667480-0	2013	Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	40-43
23667480-0	2013	Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	63-66
23667480-3	2013	Here, we studied the effect of the autophagy inducing drug rapamycin on the progression of tau pathology in P301S mutant tau transgenic mice.	Sirolimus	59-68	microtubule associated protein tau	Homo sapiens	91-94
23667480-4	2013	Rapamycin treatment resulted in a significant reduction in cortical tau tangles, less tau hyperphosphorylation, and lowered levels of insoluble tau in the forebrain.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	68-71
23667480-4	2013	Rapamycin treatment resulted in a significant reduction in cortical tau tangles, less tau hyperphosphorylation, and lowered levels of insoluble tau in the forebrain.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	86-89
23667480-4	2013	Rapamycin treatment resulted in a significant reduction in cortical tau tangles, less tau hyperphosphorylation, and lowered levels of insoluble tau in the forebrain.	Sirolimus	0-9	microtubule associated protein tau	Homo sapiens	86-89
23667480-5	2013	The favourable effect of rapamycin on tau pathology was paralleled by a qualitative reduction in astrogliosis.	Sirolimus	25-34	microtubule associated protein tau	Homo sapiens	38-41
23667480-7	2013	We further noted an accumulation of the autophagy associated proteins p62 and LC3 in aged tangle bearing P301S mice that was lowered upon rapamycin treatment.	Sirolimus	138-147	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	78-81
23667480-8	2013	Thus, rapamycin treatment defers the progression of tau pathology in a tauopathy animal model and autophagy stimulation may constitute a therapeutic approach for patients suffering from tauopathies.	Sirolimus	6-15	microtubule associated protein tau	Homo sapiens	52-55
23470622-5	2013	Treatment with rapamycin (0.5 muM) or the Akt inhibitor, A-443654 (0.5 muM), reduced FCS-stimulated growth of PA-SMCs from MCT-PH rats to the level in control rats while inhibiting Akt, GSK3, and S6K activation.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Rattus norvegicus	196-199
23453973-6	2013	We then treated glucose-replete and -depleted cells with SB415286, U0126, LY294 and rapamycin to inhibit GSK3, MEK1/2, PI3K and mTOR, respectively.	Sirolimus	84-93	mitogen-activated protein kinase kinase 1	Homo sapiens	111-117
23434829-11	2013	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	Sirolimus	127-136	secreted phosphoprotein 1	Homo sapiens	26-29
23830390-3	2013	Our recent observation that rapamycin continues to inhibit S6K1 in the absence of either phosphorylation, together with the evidence that phosphorylation at activation loop may occur prior to that of hydrophobic motif raises serious questions about the proposed mechanism of rapamycin inhibition.	Sirolimus	28-37	ribosomal protein S6 kinase B1	Homo sapiens	59-63
23478407-8	2013	In a human-mouse chimeric model of allograft rejection, rapamycin pretreatment of human arterial allografts increased graft EC expression of PD-L1 and PD-L2 and reduced subsequent infiltration of allogeneic effector T cells into the artery intima and intimal expansion.	Sirolimus	56-65	CD274 molecule	Homo sapiens	141-146
23358973-6	2013	The tumor burden of SCC was reduced during the 2-year follow-up period in those receiving sirolimus (0.82 v 1.38 per year; HR, 0.51; 95% CI, 0.32 to 0.82; P = .006) if adjusted for the number of previous SCCs and age.	Sirolimus	90-99	serpin family B member 3	Homo sapiens	20-23
23283642-0	2013	Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.	Sirolimus	91-100	telomerase reverse transcriptase	Homo sapiens	17-22
23283642-7	2013	Perillyl alcohol or rapamycin caused rapid dissociation of the captured hTERT-mTOR-RAPTOR complex, establishing an additional mechanism by which these agents decrease telomerase activity.	Sirolimus	20-29	telomerase reverse transcriptase	Homo sapiens	72-77
23261705-4	2013	Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	Sirolimus	42-51	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	101-109
23261705-4	2013	Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6.	Sirolimus	42-51	ribosomal protein S6 kinase B1	Homo sapiens	111-118
23261705-6	2013	Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin.	Sirolimus	150-159	proliferating cell nuclear antigen	Homo sapiens	124-128
23108236-1	2013	The administration of rapamycin, an MTOR-dependent autophagy activator, for the treatment of neurodegenerative diseases has been tested in several animal models.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	36-40
23265586-12	2013	Inactivation of mTOR downstream signaling by rapamycin treatment inhibited S6K phosphorylation and abolished the stimulatory effect of IS on GLUT1 expression.	Sirolimus	45-54	ribosomal protein S6 kinase B1	Rattus norvegicus	75-78
23223314-1	2013	BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs).	Sirolimus	26-35	serpin family B member 3	Homo sapiens	196-199
23223314-9	2013	At 6 months, sirolimus conversion reduces new SCC/year, rate ratio 0.49 (95%CI: 0.15-1.63), P = 0.276.	Sirolimus	13-22	serpin family B member 3	Homo sapiens	46-49
23229928-0	2013	Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	93-97
23229928-10	2013	Significantly diminished expression of VEGF and VEGFR mRNA and protein was evident in the sirolimus group.	Sirolimus	90-99	vascular endothelial growth factor A	Rattus norvegicus	39-43
23229928-11	2013	In vitro, sirolimus reduced VEGF production by podocytes (P &lt; 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells.	Sirolimus	10-19	vascular endothelial growth factor A	Rattus norvegicus	28-32
23229928-11	2013	In vitro, sirolimus reduced VEGF production by podocytes (P &lt; 0.05) and inhibited VEGF-induced proliferation of podocytes, endothelial and mesangial cells.	Sirolimus	10-19	vascular endothelial growth factor A	Rattus norvegicus	85-89
23229928-13	2013	Sirolimus exhibits greater protection against vasculopathy but induces proteinuria; effects are likely to be related to inhibition of VEGF signalling.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	134-138
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	histone deacetylase 8	Homo sapiens	235-240
23273915-7	2013	Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1.	Sirolimus	72-81	ribosomal protein S6 kinase B1	Homo sapiens	125-129
23273915-7	2013	Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1.	Sirolimus	72-81	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	195-201
22391570-6	2013	Fatty-acid oxidation in response to S6K1 inactivation required the expression of the fatty-acid transporter carnitine palmitoyl transferase 1c, which was recently linked to rapamycin resistance in cancer.	Sirolimus	173-182	ribosomal protein S6 kinase B1	Homo sapiens	36-40
23184930-0	2013	Alterations in the Ure2 alphaCap domain elicit different GATA factor responses to rapamycin treatment and nitrogen limitation.	Sirolimus	82-91	glutaminyl-tRNA amidotransferase subunit QRSL1	Homo sapiens	57-61
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Sirolimus	208-217	peptidylprolyl isomerase A	Homo sapiens	19-23
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Sirolimus	208-217	solute carrier family 8 member A2	Homo sapiens	272-276
23224887-6	2013	Rapamycin reduces NCX2 and NCX3 transport activity but has no effect on their surface expression or total cell NCX protein expression suggesting that, although it shares a common receptor FKBP with FK506, its mode of action follows a different pathway.We are showing now that the large cytosolic loop of NCX1, NCX2, and NCX3 is involved in acquisition of immunosuppressive drug specificity: truncation of the large cytosolic loop of NCX1 renders the protein sensitive to FK506.	Sirolimus	0-9	solute carrier family 8 member A2	Homo sapiens	18-22
23229624-2	2013	As a result, mTOR inhibitors, such as rapamycin and its analogs, offer potential therapeutic avenues for these disorders.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Mus musculus	13-17
23331792-3	2013	We tested the hypothesis that the mTOR inhibitor rapamycin could inhibit neuroblastoma bone metastases through its action on OPG.	Sirolimus	49-58	mechanistic target of rapamycin kinase	Mus musculus	34-38
23437362-0	2013	Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.	Sirolimus	69-78	EPH receptor B2	Homo sapiens	30-33
23165214-0	2013	Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.	Sirolimus	0-9	B and T lymphocyte associated	Homo sapiens	73-77
23131564-3	2012	In cancer cells PIM kinases have been reported to produce resistance to mTOR inhibition by rapamycin.	Sirolimus	91-100	mechanistic target of rapamycin kinase	Mus musculus	72-76
23131564-5	2012	We therefore investigated how the PIM1 kinase modulates growth inhibitory effects of rapamycin in mouse aortic endothelial cells (MAEC).	Sirolimus	85-94	proviral integration site 1	Mus musculus	34-38
23131564-10	2012	Finally, overexpression of the nuclear localization mutant and the wildtype Pim1 resulted in complete resistance to growth inhibition by rapamycin.	Sirolimus	137-146	proviral integration site 1	Mus musculus	76-80
23131564-11	2012	Thus, mTOR inhibition-induced nuclear accumulation of PIM1 or expression of a nuclear C-terminal PIM1 truncation mutant is sufficient to increase endothelial cell proliferation, suggesting that nuclear localization of PIM1 is important for resistance of MAEC to rapamycin-mediated inhibition of proliferation.	Sirolimus	262-271	mechanistic target of rapamycin kinase	Mus musculus	6-10
23131564-11	2012	Thus, mTOR inhibition-induced nuclear accumulation of PIM1 or expression of a nuclear C-terminal PIM1 truncation mutant is sufficient to increase endothelial cell proliferation, suggesting that nuclear localization of PIM1 is important for resistance of MAEC to rapamycin-mediated inhibition of proliferation.	Sirolimus	262-271	proviral integration site 1	Mus musculus	97-101
23131564-11	2012	Thus, mTOR inhibition-induced nuclear accumulation of PIM1 or expression of a nuclear C-terminal PIM1 truncation mutant is sufficient to increase endothelial cell proliferation, suggesting that nuclear localization of PIM1 is important for resistance of MAEC to rapamycin-mediated inhibition of proliferation.	Sirolimus	262-271	proviral integration site 1	Mus musculus	97-101
22902867-7	2012	Western blot analysis revealed that hTERT protein levels decreased in response to perillyl alcohol or rapamycin.	Sirolimus	102-111	telomerase reverse transcriptase	Homo sapiens	36-41
22901235-1	2012	Rapamycin, an mTOR inhibitor and immunosuppressive agent in clinic, has protective effects on traumatic brain injury and neurodegenerative diseases.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	14-18
22985252-7	2012	We also found that mag-1-induced metastatic promotion could be abrogated by mTOR specific inhibitor, rapamycin.	Sirolimus	101-110	mechanistic target of rapamycin kinase	Mus musculus	76-80
22923157-3	2012	The apoptosis of prostate epithelial cancer cells LNCaP and PC3 was investigated upon treatment with the autophagy inhibitor 3-methyladenine and the autophagy inducer rapamycin, in combination with TNF-alpha.	Sirolimus	167-176	chromobox 8	Homo sapiens	60-63
22923157-7	2012	Conversely in PC3 but not in LNCaP cells, rapamycin stimulated TNF-alpha-dependent apoptosis; such effect was associated with reduced c-Flip promoter activity and FoxO3a activation.	Sirolimus	42-51	chromobox 8	Homo sapiens	14-17
22859856-2	2012	The mTOR inhibitors, such as rapamycin, ameliorate PKD in rodent models, but clinical trials have not shown benefit, possibly as a result of low tissue concentrations of rapamycin at clinically tolerable doses.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	4-8
22859856-2	2012	The mTOR inhibitors, such as rapamycin, ameliorate PKD in rodent models, but clinical trials have not shown benefit, possibly as a result of low tissue concentrations of rapamycin at clinically tolerable doses.	Sirolimus	170-179	mechanistic target of rapamycin kinase	Mus musculus	4-8
22863900-0	2012	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	53-59
22471963-6	2012	By taking advantage of the secondary inducible pluripotent stem (iPS) system, we demonstrate that either elevating the mTOR activity by Tsc2 shRNA knockdown or using high concentrations of rapamycin to completely block the mTOR activity in cells derived from iPS mice greatly impairs somatic cell reprogramming.	Sirolimus	189-198	mechanistic target of rapamycin kinase	Mus musculus	223-227
26894018-5	2012	mTOR inhibition with sirolimus or everolimus decreases cysts in most animal models of PKD including Pkd1 and Pkd2 gene deficient orthologous models of human disease.	Sirolimus	21-30	polycystin 1, transient receptor potential channel interacting	Homo sapiens	100-104
22343319-3	2012	Here, we utilized a murine model of post-transplantation cancer to examine the effect of a combination therapy (CNI + mTOR-inhibitor rapamycin) on allograft survival and renal cancer progression.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Mus musculus	118-122
22884327-0	2012	Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	70-74
22884327-4	2012	Systemic or intracerebral administration of the mTOR inhibitor rapamycin causes weight loss in old mice.	Sirolimus	63-72	mechanistic target of rapamycin kinase	Mus musculus	48-52
21631587-9	2012	In conclusion, EVR and SRL are both subject to an apically directed efflux mediated by P-gp.	Sirolimus	23-26	phosphoglycolate phosphatase	Homo sapiens	87-91
22613676-2	2012	Though the effects of rapamycin (RPM) and other immunosuppressant on the CD4(+)CD25(+)Foxp3(+) T regulatory cells (Tregs) were studied, their impact on Ag-specific Tregs during immune response was not well defined.	Sirolimus	33-36	forkhead box P3	Mus musculus	86-91
22837538-6	2012	At the cellular                     level, rapamycin decreases the number of myocytes with abnormal desmin                     accumulation and decreases the amount of desmin in both muscle and cardiac                     tissue of Lmna(-/-) mice.	Sirolimus	43-52	lamin A	Mus musculus	232-236
22837538-7	2012	In addition,                     inhibition of mTORC1 signaling with rapamycin improves defective                     autophagic-mediated degradation in                         Lmna(-/-) mice.	Sirolimus	69-78	lamin A	Mus musculus	177-181
24358826-1	2012	The recent development of mammalian target of rapamycin (mTOR) kinase domain inhibitors and genetic dissection of rapamycin-sensitive and -insensitive mTOR protein complexes (mTORC1 and mTORC2) have revealed that phosphorylation of the mTOR substrate 4E-BP1 on amino acids Thr37 and/or Thr46 represents a rapamycin-insensitive activity of mTORC1.	Sirolimus	46-55	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	251-257
22765013-3	2012	We have previously implicated platelet-derived growth factor-BB in TS-related tumorigenesis, thus providing a rationale for a combination of mTOR/PDGF blockade using rapamycin and imatinib.	Sirolimus	166-175	mechanistic target of rapamycin kinase	Mus musculus	141-145
22575459-8	2012	The notion that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK-AKT-mTOR pathway was further suggested by the finding that rapamycin completely abolished the effect of IGF-1 on the 10-pS Cl channels in the TAL.	Sirolimus	154-163	insulin-like growth factor 1	Rattus norvegicus	30-35
22575459-8	2012	The notion that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK-AKT-mTOR pathway was further suggested by the finding that rapamycin completely abolished the effect of IGF-1 on the 10-pS Cl channels in the TAL.	Sirolimus	154-163	insulin-like growth factor 1	Rattus norvegicus	199-204
22391948-12	2012	Ghrelin receptor antagonism and Ghsr1a knockout blocked the upregulation of JNK activity and downregulation of GLUT4 levels and translocation in the gastrocnemius muscle induced by rapamycin.	Sirolimus	181-190	growth hormone secretagogue receptor	Mus musculus	0-16
22391948-12	2012	Ghrelin receptor antagonism and Ghsr1a knockout blocked the upregulation of JNK activity and downregulation of GLUT4 levels and translocation in the gastrocnemius muscle induced by rapamycin.	Sirolimus	181-190	growth hormone secretagogue receptor	Mus musculus	32-38
21826653-7	2012	Conversely, the effect of T(3) on SREBP-1 level was enhanced by using rapamycin, mTOR-C1 inhibitor.	Sirolimus	70-79	sterol regulatory element binding transcription factor 1	Homo sapiens	34-41
22559167-7	2012	The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR.	Sirolimus	15-24	interferon alpha inducible protein 27	Homo sapiens	81-84
22426621-10	2012	Because both the Akt inhibitor MK-2206 and the mTOR inhibitor rapamycin provoked a strong diminution of PRL-induced synthesis of the two proteins, and because oleate induced phosphorylation of Akt, we concluded that, in the mammary epithelial cell line HC11, the PI3-kinase/Akt/mTOR signaling pathway strongly participates in beta-casein synthesis and is a main regulator of ADRP expression.	Sirolimus	62-71	mechanistic target of rapamycin kinase	Mus musculus	47-51
22364775-5	2012	Here we made fusion proteins of Stim1 and Orai1 with FRB and FKBP12 domains that associate in the presence of rapamycin.	Sirolimus	110-119	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	61-67
22314813-7	2012	Although rapamycin acutely inhibited mTOR complex 1 (mTORC1), the toxic effects of rapamycin were more closely correlated to the dissociation and inactivation of mTORC2 and the inhibition of PKB.	Sirolimus	83-92	protein tyrosine kinase 2 beta	Homo sapiens	191-194
22314813-10	2012	CONCLUSIONS/INTERPRETATION: This report provides evidence that rapamycin toxicity is mediated by the inactivation of mTORC2 and the inhibition of PKB and thus reveals the molecular basis of rapamycin toxicity and the essential role of mTORC2 in maintaining beta cell function and survival.	Sirolimus	63-72	protein tyrosine kinase 2 beta	Homo sapiens	146-149
22314813-10	2012	CONCLUSIONS/INTERPRETATION: This report provides evidence that rapamycin toxicity is mediated by the inactivation of mTORC2 and the inhibition of PKB and thus reveals the molecular basis of rapamycin toxicity and the essential role of mTORC2 in maintaining beta cell function and survival.	Sirolimus	190-199	protein tyrosine kinase 2 beta	Homo sapiens	146-149
22441016-1	2012	Sirolimus (rapamycin), an inhibitor of the mechanistic target of rapamycin (MTOR), was originally proposed as an immunosuppressant to prevent rejection of solid organ transplants.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Mus musculus	43-74
22441016-1	2012	Sirolimus (rapamycin), an inhibitor of the mechanistic target of rapamycin (MTOR), was originally proposed as an immunosuppressant to prevent rejection of solid organ transplants.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Mus musculus	76-80
22227406-11	2012	Rapamycin, a specific inhibitor of mammalian TOR signaling attenuated PTTH-stimulated phosphorylation of 4E-BP and S6K of the glands, and greatly inhibited PTTH-stimulated ecdysteroidogenesis.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	115-118
22364741-4	2012	As a part of this response, we found that the LAMMER kinase Kns1 is differentially expressed and hyperphosphorylated and accumulates in the nucleus after rapamycin treatment, whereupon it primes the phosphorylation of the RNA polymerase III subunit Rpc53 by a specific GSK-3 family member, Mck1.	Sirolimus	154-163	serine/threonine protein kinase RIM11	Saccharomyces cerevisiae S288C	269-274
22190165-11	2012	Sorafenib/rapamycin combination resulted in downregulation of pAkt, pmTOR, p-p70S6K, p4EBP1, pGSK3beta, Mcl1, and Bcl-Xl.	Sirolimus	10-19	ribosomal protein S6 kinase B1	Homo sapiens	77-83
22357207-8	2012	Ly294002 (a PI3K inhibitor) and rapamycin (an mTOR inhibitor) could prevent the regulatory effects of leptin on the proliferation and apoptosis of HCT-116 cells via abrogating leptin-mediated PI3K/Akt/mTOR pathway.	Sirolimus	32-41	leptin	Homo sapiens	176-182
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	69-78	BCL2 associated X, apoptosis regulator	Rattus norvegicus	235-238
22209856-3	2012	We show here that the strong reduction of caspase-3 activation after rapamycin was due, at least in part, to its effect on the intrinsic apoptotic mitochondrial pathway because after rapamycin treatment there was a marked reduction of Bax and Bad translocation to mitochondria, cytochrome c release, and caspase-3 activation.	Sirolimus	183-192	BCL2 associated X, apoptosis regulator	Rattus norvegicus	235-238
22173033-4	2012	The same effects are observed in     well-fed pins larvae that are mutant for pi3k (phosphatidylinositol 3-kinase) or     exposed to the TOR inhibitor rapamycin.	Sirolimus	151-160	Target of rapamycin	Drosophila melanogaster	137-140
22214188-8	2012	In contrast, the mTOR inhibitor rapamycin enhanced both COX-2 and mPGES-1 immunoreactivity and the release of PGE2 and PGD2.	Sirolimus	32-41	prostaglandin E synthase	Mus musculus	66-73
24116273-8	2012	The antigen-induced activation of S6K1 is inhibited by specific kinase inhibitors including mTOR, PI3K, PKC and Ca(2+)chelator inhibitor, while TNF-alpha mRNA level is reduced only by rapamycin treatment.	Sirolimus	184-193	ribosomal protein S6 kinase B1	Rattus norvegicus	34-38
22508056-8	2012	Inhibition of the gastric mTOR signaling by rapamycin attenuated the expression of gastric nesfatin-1/NUCB2 mRNA and protein in both lean and obese mice.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Mus musculus	26-30
21963787-5	2012	mTOR signaling was blocked by daily intraperitoneal injections of the pharmacologic inhibitor rapamycin (1.5 mg/kg).	Sirolimus	94-103	mechanistic target of rapamycin kinase	Mus musculus	0-4
21748792-10	2012	Inhibition of mTOR signaling by rapamycin in Nf1+/- OCLs abrogated abnormalities in cellular size and number.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	14-18
22984623-0	2012	The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
22937032-7	2012	Furthermore, small-interfering RNA-mediated knockdown of KLF2 strongly magnified the ability of rapamycin to induce TF and reduce eNOS accumulation in HUVECs.	Sirolimus	96-105	coagulation factor III, tissue factor	Homo sapiens	116-118
22685525-10	2012	Lastly, mediastinal lymph node re-stimulation experiments showed that treatment of rapamycin-naive T cells with ex vivo rapamycin decreased antigen-specific Th2 cytokine production, whereas prior exposure to in vivo rapamycin rendered T cells refractory to the suppressive effects of ex vivo rapamycin.	Sirolimus	83-92	heart and neural crest derivatives expressed 2	Mus musculus	157-160
22685525-10	2012	Lastly, mediastinal lymph node re-stimulation experiments showed that treatment of rapamycin-naive T cells with ex vivo rapamycin decreased antigen-specific Th2 cytokine production, whereas prior exposure to in vivo rapamycin rendered T cells refractory to the suppressive effects of ex vivo rapamycin.	Sirolimus	120-129	heart and neural crest derivatives expressed 2	Mus musculus	157-160
22662254-8	2012	In 3T3-L1 adipocytes, 11beta-HSD1 mRNA levels were down-regulated following induction of ER stress by tunicamycin but were up-regulated following inhibition of mTOR by rapamycin.	Sirolimus	168-177	mechanistic target of rapamycin kinase	Mus musculus	160-164
22470459-0	2012	Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	70-74
22470459-5	2012	Administration of rapamycin to unilateral ureteral obstruction (UUO) mice significantly suppressed the immunoreactivity of mTOR signaling, which decreased the inflammatory responses and ECM accumulation in the obstructed kidneys.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	123-127
21964931-9	2011	The use of small molecule inhibitors LY294002 or rapamycin to inhibit PI3K/Akt and p70(S6K) activities, respectively, resulted in diminished HIF-1alpha activation and subsequent VEGF expression.	Sirolimus	49-58	ribosomal protein S6 kinase B1	Homo sapiens	83-86
21890496-7	2011	This one dose of prenatal rapamycin treatment reduced hyperactivation of the mTOR pathway in the mutant brain without causing apparent pregnancy loss.	Sirolimus	26-35	mechanistic target of rapamycin kinase	Mus musculus	77-81
21890496-8	2011	Continued postnatal rapamycin beginning at day 8 extended the survival of these mice to a median of 12 days with complete suppression of hyperactive mTOR.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	149-153
21903885-4	2011	Treatment with the mTOR inhibitor rapamycin inhibits inflammation and AHR in allergic asthma models, but it is unclear if rapamycin can directly inhibit airway remodeling and AHR, or whether its therapeutic effects are entirely mediated through immunosuppression.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	19-23
21903885-8	2011	Rapamycin treatment prevented body weight loss, airway wall thickening, abnormal lung mechanics, and increases in airway resistance to methacholine after 3 wk of TGF-alpha induction.	Sirolimus	0-9	transforming growth factor alpha	Mus musculus	162-171
21903885-13	2011	Thus rapamycin reduced airway remodeling and AHR, demonstrating an important role for mTOR signaling in TGF-alpha-induced/EGF receptor-mediated reactive airway disease.	Sirolimus	5-14	transforming growth factor alpha	Mus musculus	104-113
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	Sirolimus	195-204	ribosomal protein S6 kinase B1	Homo sapiens	55-64
21885991-8	2011	Up4A-stimulated phosphorylation and kinase activity of S6 kinase (S6K) and Erk1/2 were inhibited by PD98059, whereas phosphorylation and kinase activity of S6K, but not Erk1/2, were inhibited by rapamycin.	Sirolimus	195-204	ribosomal protein S6 kinase B1	Homo sapiens	66-69
22021618-2	2011	Although inhibition of mTOR with rapamycin has potent immunosuppressive activity, mixed effects have been reported in OVA-induced models of allergic asthma.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	23-27
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Sirolimus	142-151	ribosomal protein S6 kinase B1	Homo sapiens	101-104
22071574-0	2011	High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.	Sirolimus	10-19	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	126-132
22071574-5	2011	We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1).	Sirolimus	55-64	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	184-208
22071574-5	2011	We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1).	Sirolimus	55-64	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	210-216
22071574-8	2011	In contrast with MDA-MB-231 cells, MCF-7 breast cancer cells survived rapamycin-induced suppression of 4E-BP1 phosphorylation.	Sirolimus	70-79	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	103-109
22071574-10	2011	This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E.	Sirolimus	48-57	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	156-162
21625955-4	2011	To gain insight into the molecular mechanism underlying hypoxia-induced liver metabolic adaptation, we treated a subset of mice with rapamycin (0.5 mg/kg/day) to inhibit mTOR postnatally.	Sirolimus	133-142	mechanistic target of rapamycin kinase	Mus musculus	170-174
22017876-6	2011	Biologically, DEPTOR accumulation upon betaTrCP knockdown inactivates mTORC1 and activates AKT in cancer cells to confer resistance to rapamycin and paclitaxel.	Sirolimus	135-144	beta-transducin repeat containing E3 ubiquitin protein ligase	Homo sapiens	39-47
22067655-3	2011	The results also demonstrated that inhibition of mTOR/p70S6K with rapamycin prevented the development of insulin resistance but had no effect on AMPK activity (Thr172 phosphorylation of its catalytic subunit).	Sirolimus	66-75	ribosomal protein S6 kinase B1	Rattus norvegicus	54-60
21876130-6	2011	To identify other rapamycin-resistant transcriptional outputs of mTOR, we compared the expression profiles of NIH 3T3 cells treated with rapamycin versus PP242.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Mus musculus	65-69
21857156-2	2011	Here, we show that pharmacological autophagy inducers like rapamycin, spermidine and resveratrol can reduce leptin concentrations in the serum of mice and that genetic inactivation of the leptin/leptin receptor system leads to an increase in autophagy in peripheral tissues including skeletal muscle, heart and liver.	Sirolimus	59-68	leptin	Mus musculus	108-114
21857156-2	2011	Here, we show that pharmacological autophagy inducers like rapamycin, spermidine and resveratrol can reduce leptin concentrations in the serum of mice and that genetic inactivation of the leptin/leptin receptor system leads to an increase in autophagy in peripheral tissues including skeletal muscle, heart and liver.	Sirolimus	59-68	leptin	Homo sapiens	188-194
21857156-2	2011	Here, we show that pharmacological autophagy inducers like rapamycin, spermidine and resveratrol can reduce leptin concentrations in the serum of mice and that genetic inactivation of the leptin/leptin receptor system leads to an increase in autophagy in peripheral tissues including skeletal muscle, heart and liver.	Sirolimus	59-68	leptin	Homo sapiens	188-194
21653236-6	2011	PGIS transcript was expressed only in RPM and TGEM macrophages and at an exceptionally low level, despite high metabolite production compared with other synthases.	Sirolimus	38-41	prostaglandin I2 (prostacyclin) synthase	Mus musculus	0-4
21984149-9	2011	The combination of IDA with rapamycin enhanced the expressions of Caspase 3, PARP, Caspase 8 and Caspase 9.	Sirolimus	28-37	caspase 9	Homo sapiens	97-106
21806970-3	2011	We have now shown that medium rich in branched-chain amino acids stimulates expression of the SREBP1c gene in cultured hepatocytes in a manner sensitive both to rapamycin, a pharmacological inhibitor of mTORC1, and to a short hairpin RNA (shRNA) specific for S6 kinase 1 (S6K1), a downstream effector of mTORC1.	Sirolimus	161-170	sterol regulatory element binding transcription factor 1	Mus musculus	94-101
21252047-6	2011	In the presence of rapamycin, a specific mTOR inhibitor, leptin and PDGF were no longer able to activate mTOR, and expression of VEGF was reduced, whereas HIF-1alpha abundance was not affected.	Sirolimus	19-28	leptin	Homo sapiens	57-63
21360661-3	2011	Rapamycin has been reported to be effective in the management of other conditions associated with PTEN mutation.	Sirolimus	0-9	phosphatase and tensin homolog	Homo sapiens	98-102
21659648-7	2011	Suppression of autophagy by 3-methyladenine increased, whereas enhancement of autophagy by rapamycin reduced the ability of a comparable level of mutant desmin overexpression to accumulate ubiquitinated proteins in NRVMs.	Sirolimus	91-100	desmin	Mus musculus	153-159
21730157-6	2011	We show the use of these BRET systems for ratiometric imaging of both cells in culture and deep-tissue small animal tumor models and validate their applicability for studying PPIs in mice in the context of rapamycin-induced FK506 binding protein 12 (FKBP12)-FKBP12 rapamycin binding domain (FRB) association.	Sirolimus	206-215	FK506 binding protein 1a	Mus musculus	224-248
21730157-6	2011	We show the use of these BRET systems for ratiometric imaging of both cells in culture and deep-tissue small animal tumor models and validate their applicability for studying PPIs in mice in the context of rapamycin-induced FK506 binding protein 12 (FKBP12)-FKBP12 rapamycin binding domain (FRB) association.	Sirolimus	206-215	FK506 binding protein 1a	Mus musculus	250-256
21730157-6	2011	We show the use of these BRET systems for ratiometric imaging of both cells in culture and deep-tissue small animal tumor models and validate their applicability for studying PPIs in mice in the context of rapamycin-induced FK506 binding protein 12 (FKBP12)-FKBP12 rapamycin binding domain (FRB) association.	Sirolimus	206-215	FK506 binding protein 1a	Mus musculus	258-264
21550972-9	2011	Furthermore, L-threonine induced phosphorylation of raptor and rictor binding to mTOR was completely inhibited by 24 h treatment with rapamycin (mTOR inhibitor); however, a 10 min treatment with rapamycin only partially inhibited rictor phosphorylation.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Mus musculus	81-85
21550972-9	2011	Furthermore, L-threonine induced phosphorylation of raptor and rictor binding to mTOR was completely inhibited by 24 h treatment with rapamycin (mTOR inhibitor); however, a 10 min treatment with rapamycin only partially inhibited rictor phosphorylation.	Sirolimus	134-143	mechanistic target of rapamycin kinase	Mus musculus	145-149
21550972-9	2011	Furthermore, L-threonine induced phosphorylation of raptor and rictor binding to mTOR was completely inhibited by 24 h treatment with rapamycin (mTOR inhibitor); however, a 10 min treatment with rapamycin only partially inhibited rictor phosphorylation.	Sirolimus	195-204	mechanistic target of rapamycin kinase	Mus musculus	81-85
21550972-9	2011	Furthermore, L-threonine induced phosphorylation of raptor and rictor binding to mTOR was completely inhibited by 24 h treatment with rapamycin (mTOR inhibitor); however, a 10 min treatment with rapamycin only partially inhibited rictor phosphorylation.	Sirolimus	195-204	mechanistic target of rapamycin kinase	Mus musculus	145-149
21593197-7	2011	Both CR and rapamycin decreased phosphorylation of mTOR, p70/S6K, and S6 ribosomal protein, but only CR decreased phosphorylation of Akt, GSK-3beta, extracellular signal regulated kinase/mitogen-activated protein kinase, and STAT3(TYR705).	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	51-55
21633171-2	2011	Mammalian TOR (mTOR) is thought to work through 2 independent complexes to regulate cell size and cell replication, and these 2 complexes show differential sensitivity to rapamycin.	Sirolimus	171-180	tortured	Mus musculus	10-13
21475253-6	2011	Interestingly, the mammalian target of rapamycin inhibitor rapamycin further suppresses the MM cell viability in combination with the Pim-2 silencing.	Sirolimus	39-48	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	134-139
21730367-6	2011	Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed  Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling.	Sirolimus	13-22	phosphatase and tensin homolog	Homo sapiens	223-227
21722526-7	2011	RESULTS: The expression of BTLA on T cells treated with various concentrations (10-1 000 ng/L) of RPM had no significant difference, while had significant difference (P&lt;0.01) by compared with RPM non-treatment group.	Sirolimus	98-101	B and T lymphocyte associated	Homo sapiens	27-31
21722526-7	2011	RESULTS: The expression of BTLA on T cells treated with various concentrations (10-1 000 ng/L) of RPM had no significant difference, while had significant difference (P&lt;0.01) by compared with RPM non-treatment group.	Sirolimus	195-198	B and T lymphocyte associated	Homo sapiens	27-31
21914363-21	2011	However RPM represses the cholangiocytes regeneration by inhibiting the STAT3 activation.	Sirolimus	8-11	signal transducer and activator of transcription 3	Rattus norvegicus	72-77
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	insulin-like growth factor I	Oryctolagus cuniculus	18-23
21651786-8	2011	We also show that IGF-1 increases the expression of leptin and reverses the Abeta42-induced attenuation in leptin expression via the activation of mTORC1 signaling as the mTORC1 inhibitor rapamycin completely precluded the IGF-1-induced increase in leptin expression.	Sirolimus	188-197	insulin-like growth factor I	Oryctolagus cuniculus	223-228
21472771-9	2011	Mutant GBA-induced SNCA accumulation could be pharmacologically reversed in D409V-expressing PC12-SNCA cells by rapamycin, an autophagy-inducer (<=40%; 10muM; p < 0.02).	Sirolimus	112-121	synuclein, alpha	Mus musculus	19-23
21073857-4	2011	Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells.	Sirolimus	0-9	transient receptor potential cation channel, subfamily M, member 7	Rattus norvegicus	202-207
21073857-5	2011	Both rapamycin and LY-294002 decreased EGF-induced Mg2+ influx.	Sirolimus	5-14	epidermal growth factor	Homo sapiens	39-42
21258412-5	2011	A careful examination of preclinical and clinical studies performed with rapamycin or derivatives thereof shows that although results are encouraging, we are only half way in the long and winding road to design rationale treatment targeted at the LKB1/AMPK/TSC/mTORC1 pathway.	Sirolimus	73-82	serine/threonine kinase 11	Homo sapiens	247-251
20936651-5	2011	IRS-1 (Ser302) phosphorylation was abolished by wortmannin and rapamycin, suggesting a feedback from the PI3K pathway on insulin signalling.	Sirolimus	63-72	insulin receptor substrate 1	Homo sapiens	0-5
21544240-9	2011	Treatment of aortas of old rats with resveratrol or rapamycin inhibited S6K1 activity, oxidative stress, and improved endothelial NO production.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Rattus norvegicus	72-76
21240477-7	2011	Remarkably, rapamycin resistance was found to affect specifically the mTORC1/eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) branch of the mTORC1 pathway in the presence of 50 mumol/l oleate.	Sirolimus	12-21	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	128-134
21289308-5	2011	In a murine bone marrow transplantation model, Evi1 leukemia showed modestly increased sensitivity to an mTOR inhibitor rapamycin.	Sirolimus	120-129	mechanistic target of rapamycin kinase	Mus musculus	105-109
21191105-7	2011	Pretreatment with the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 and the ERK inhibitor PD98059 blocked F prostanoid receptor signaling responses, whereas rapamycin blocked heightened p70S6K/eIF4G phosphorylation without influencing ERK1/2 phosphorylation.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	192-198
20821325-4	2011	In the present study, we tested the therapeutic effect of Rapamycin and its analog RAD001 on altered TRK-induced leukemia in a murine model.	Sirolimus	58-67	neurotrophic tyrosine kinase, receptor, type 1	Mus musculus	101-104
20821325-6	2011	Consistently, both mTOR and S6 proteins were strongly dephosphorylated in vitro and in vivo after treatment with Rapamycin or RAD001.	Sirolimus	113-122	mechanistic target of rapamycin kinase	Mus musculus	19-23
21339643-8	2011	The cardiac defects in LS/+ mice were completely reversed by treatment with rapamycin, an inhibitor of mTOR.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Mus musculus	103-107
21177869-5	2011	Treating cells with rapamycin or knockdown of mTOR using RNAi results in a marked decrease of PHLPP protein expression.	Sirolimus	20-29	PH domain and leucine rich repeat protein phosphatase 1	Homo sapiens	94-99
21177869-8	2011	In addition, depletion of 4E-BP1 expression by RNAi results in an increase of PHLPP expression and resistance to rapamycin-induced down-regulation.	Sirolimus	113-122	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	26-32
21177869-10	2011	Functionally, we show that rapamycin-mediated inhibition of PHLPP expression contributes to rapamycin resistance in colon cancer cells.	Sirolimus	27-36	PH domain and leucine rich repeat protein phosphatase 1	Homo sapiens	60-65
21062901-7	2011	The differences between Tsc1(GFAP1)CKO and Tsc2(GFAP1)CKO mice were correlated with higher levels of mammalian target of rapamycin (mTOR) activation in Tsc2(GFAP1)CKO mice and were reversed by the mTOR inhibitor, rapamycin.	Sirolimus	121-130	TSC complex subunit 2	Mus musculus	43-47
21115526-5	2011	With recent findings that deletion of the mTOR substrate S6K1 or exposure of mice to the mTOR inhibitor rapamycin result in lifespan extension, mTOR signalling has become a major focus of ageing research.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Mus musculus	89-93
21115526-5	2011	With recent findings that deletion of the mTOR substrate S6K1 or exposure of mice to the mTOR inhibitor rapamycin result in lifespan extension, mTOR signalling has become a major focus of ageing research.	Sirolimus	104-113	mechanistic target of rapamycin kinase	Mus musculus	89-93
21114628-6	2011	Chromatin immunoprecipitation assays showed that LPS enhanced the binding of Oct-2 to the iNOS and G-CSF promoters and that this effect was inhibited by pretreatment with rapamycin.	Sirolimus	171-180	colony stimulating factor 3	Homo sapiens	99-104
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	poly(A) binding protein cytoplasmic 1	Homo sapiens	22-26
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	ribosomal protein S6 kinase B1	Homo sapiens	201-208
20980505-5	2011	Instead, HCMV-induced PABP accumulation resulted from new protein synthesis and was sensitive to the mTORC1-selective inhibitor rapamycin, which interferes with phosphorylation of the mTORC1 substrate p70 S6K and the translational repressor 4E-BP1.	Sirolimus	128-137	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	241-247
21135252-9	2011	Moreover, silencing AIP4/Itch expression or inhibiting JNK mediated AIP4 activity abrogated the rapamycin-induced effects on cyclin D1 and c-MYC promoter activities.	Sirolimus	96-105	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	139-144
21135252-10	2011	Our findings support a role for the AKT-dependent regulation of AIP4/Itch activity in mediating the differential cyclin D1 and c-MYC transcriptional responses to rapamycin.	Sirolimus	162-171	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	127-132
21220493-10	2011	Following mithramycin exposure, UOK257-FLCN-null cells were mainly arrested and blocked in S and G(2)-M phases of the cell cycle and low dose of rapamycin (1 nmol/L) potentiated mithramycin sensitivity (1.5-fold in G(2)-M population and 2-fold in G(2)-M period time, 2xGI(50), 48 hours).	Sirolimus	145-154	folliculin	Homo sapiens	39-43
22219636-12	2011	Rapamycin successfully inhibited cell migration at concentrations of 10 ng/ml, 100 ng/ml, and 1,000 ng/ml for a treatment period of up to 8 h. Different concentrations of rapamycin induced the expression of VE-cadherin, inhibited vimentin and Twist expression in the endothelial cells, and inhibited endothelial cell secretion of MMP-2 and MMP-9.	Sirolimus	0-9	vimentin	Homo sapiens	230-238
22140576-7	2011	Intriguingly, two main drugs for drug-eluting stent, paclitaxel or rapamycin, significantly exaggerated thrombin-induced TF expression, which was also effectively blocked by the PPAR-gamma agonist in all cell types.	Sirolimus	67-76	coagulation factor III, tissue factor	Homo sapiens	121-123
20841502-9	2010	Furthermore, mTOR inhibition by rapamycin partially (42%) reduced the arginine-induced protein synthesis response and phosphorylation of mTOR and 4E-BP1.	Sirolimus	32-41	tortured	Mus musculus	137-152
20861085-5	2010	Interestingly, combination treatment with rapamycin and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, not only reduced the expression of NSC/progenitor markers more efficiently than single-agent treatment, but also increased the expression of betaIII-tubulin, a neuronal differentiation marker.	Sirolimus	42-51	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	68-97
21176352-8	2010	The cell growth inhibition rate in 50 nmol/L and 100 nmol/L rapamycin plus daunorubicin (DNR) group was more than that in DNR alone group (p &lt; 0.05), especially when DNR was added at 24 hours interval after RAP.	Sirolimus	60-69	LDL receptor related protein associated protein 1	Homo sapiens	210-213
21075311-5	2010	On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance.	Sirolimus	37-46	protein phosphatase 2 regulatory subunit Bbeta	Homo sapiens	11-18
21075311-5	2010	On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance.	Sirolimus	37-46	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	71-74
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	100-109	protein phosphatase 2 regulatory subunit Bbeta	Homo sapiens	16-23
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	100-109	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-121
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	150-159	protein phosphatase 2 regulatory subunit Bbeta	Homo sapiens	16-23
20933441-5	2010	DC-specific Pten targeting in vivo caused the expansion of CD8(+) and CD103(+) cDC numbers, which was reversible by rapamycin.	Sirolimus	116-125	phosphatase and tensin homolog	Homo sapiens	12-16
20622751-9	2010	The expression of insulin-like growth factor-II was significantly down-regulated, but the expression of Foxo1 was simultaneously inversely increased, and the translocation of Foxo1 from the cytoplasm to the nucleus was induced by rapamycin treatment.	Sirolimus	230-239	insulin-like growth factor 2	Mus musculus	18-47
20622751-9	2010	The expression of insulin-like growth factor-II was significantly down-regulated, but the expression of Foxo1 was simultaneously inversely increased, and the translocation of Foxo1 from the cytoplasm to the nucleus was induced by rapamycin treatment.	Sirolimus	230-239	forkhead box O1	Mus musculus	104-109
20622751-9	2010	The expression of insulin-like growth factor-II was significantly down-regulated, but the expression of Foxo1 was simultaneously inversely increased, and the translocation of Foxo1 from the cytoplasm to the nucleus was induced by rapamycin treatment.	Sirolimus	230-239	forkhead box O1	Mus musculus	175-180
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	59-65
20941752-5	2010	Moreover, pretreatment of cells with rapamycin, a specific p70S6K inhibitor, could inhibit silica-induced cell cycle alteration, AP-1 activation, and phosphorylation of p70S6K, but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	169-175
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	interleukin 4	Mus musculus	48-61
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	interleukin 4	Mus musculus	63-67
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	hemoglobin, beta adult major chain	Mus musculus	114-119
20135346-3	2010	As mTOR inhibition by rapamycin is associated with attenuation of negative feedback to IRS-1, rapamycin is known to increase activation of AKT, which may reduce its anti-neoplastic activity.	Sirolimus	22-31	insulin receptor substrate 1	Homo sapiens	87-92
20522007-8	2010	As a result of these studies, several signalling pathways including phosphatidylinositol 3-kinase (PI3K)/Akt and target of rapamycin (TOR), c-Jun N-terminal kinase (JNK) and bone morphogenetic protein (BMP) signalling, have been shown to be deregulated in models of proteinopathies, suggesting that two or more initiating events may trigger disease formation in an age-related manner.	Sirolimus	123-132	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	68-97
19856103-5	2010	RESULTS: Sirolimus significantly decreased liver cell apoptosis as well as tissue myeloperoxidase and malondialdehyde levels, but impaired postischemic liver regeneration.	Sirolimus	9-18	myeloperoxidase	Rattus norvegicus	82-97
20573703-4	2010	The GSC loss can be rescued by treatment with TORC1 inhibitor rapamycin, or by eliminating S6K, a TORC1 downstream effecter, suggesting that precocious differentiation of Tsc1/2 mutant GSC is due to hyperactivation of TORC1.	Sirolimus	62-71	Target of rapamycin	Drosophila melanogaster	46-51
20416302-11	2010	Inhibition of the mTOR pathway by rapamycin reduced formation of microadenomas and polyps in the Apcmin/+/Sigirr-/- mice.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	18-22
20416302-11	2010	Inhibition of the mTOR pathway by rapamycin reduced formation of microadenomas and polyps in the Apcmin/+/Sigirr-/- mice.	Sirolimus	34-43	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	106-112
20535152-0	2010	Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.	Sirolimus	107-116	signal transducer and activator of transcription 5A	Mus musculus	23-28
20535152-4	2010	To target Gab2-independent AKT/mTOR activation, we treated wild-type mice separately with rapamycin.	Sirolimus	90-99	growth factor receptor bound protein 2-associated protein 2	Mus musculus	10-14
20542014-0	2010	Rapamycin promotes beta-amyloid production via ADAM-10 inhibition.	Sirolimus	0-9	a disintegrin and metallopeptidase domain 10	Mus musculus	47-54
20542014-5	2010	We report that rapamycin (2.5muM), significantly increases Abeta generation in murine neuron-like cells (N2a) transfected with the human "Swedish" mutant amyloid precursor protein (APP).	Sirolimus	15-24	amyloid beta (A4) precursor protein	Mus musculus	59-64
20542014-9	2010	injected Tg2576 Abeta-overproducing transgenic mice with rapamycin (3mg/kg/day) for 2weeks.	Sirolimus	57-66	amyloid beta (A4) precursor protein	Mus musculus	16-21
20542014-10	2010	We found increased Abeta levels associated with decreased sAPP-alpha at an average rapamycin plasma concentration of 169.7+/-23.5ng/mL by high performance liquid chromatography (HPLC).	Sirolimus	83-92	amyloid beta (A4) precursor protein	Mus musculus	19-24
20670831-3	2010	Plasma membrane PIP(2) depletion by rapamycin-induced translocation of an inositol lipid 5-phosphatase or by a voltage-sensitive 5-phosphatase (VSP) suppresses Ca(V)1.2 and Ca(V)1.3 channel currents by approximately 35% and Ca(V)2.1 and Ca(V)2.2 currents by 29% and 55%, respectively.	Sirolimus	36-45	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	173-181
20444807-7	2010	Treatment with rapamycin, a specific inhibitor of the mTOR pathway, resulted in a significant reduction in the number and size of renal cysts and a decrease in the cystic index compared with untreated mutant animals, suggesting that dysregulation of this pathway in our model is mTOR-dependent.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	54-58
20444807-7	2010	Treatment with rapamycin, a specific inhibitor of the mTOR pathway, resulted in a significant reduction in the number and size of renal cysts and a decrease in the cystic index compared with untreated mutant animals, suggesting that dysregulation of this pathway in our model is mTOR-dependent.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Mus musculus	279-283
20452983-7	2010	Moreover, we demonstrate that glioma cells overexpressing PEA-15 show increased signs of autophagy in response to classical autophagic stimuli such as ionizing irradiation, serum deprivation, or rapamycin treatment.	Sirolimus	195-204	proliferation and apoptosis adaptor protein 15	Homo sapiens	58-64
20439463-4	2010	mTOR inhibitor rapamycin or NS5A knockdown blocked S6K1 and 4EBP1 phosphorylation increase in NS5A-Huh7 and HCV replicon cells, suggesting that NS5A specifically regulated mTOR activation.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	51-65
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	54-58
20382746-7	2010	The mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) inhibition with rapamycin inhibited IFN- and EGF-induced protein synthesis, suggesting that IFN-induced protein synthesis is modulated by mTOR/S6K1 activation.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	203-207
20219495-5	2010	In bovine retinal capillary endothelial cells (BRCECs), PEDF mRNA and protein expression was suppressed by insulin (22%) in a rapamycin-sensitive manner; wortmannin had no effect.	Sirolimus	126-135	insulin	Bos taurus	107-114
19815051-0	2010	The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.	Sirolimus	4-13	ribosomal protein S6 kinase B1	Homo sapiens	101-107
19959994-6	2010	Moreover, the knockout of IKK-beta suppressed the activation of autophagy by food deprivation or rapamycin injections in vivo, in mice.	Sirolimus	97-106	inhibitor of kappaB kinase beta	Mus musculus	26-34
19914305-0	2010	Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells.	Sirolimus	87-96	BCL2 like 11	Homo sapiens	0-3
19914305-10	2010	Gene silencing of Bim inhibited for the most part Dex-induced apoptosis and, to a large extent, apoptosis induced by Dex plus rapamycin.	Sirolimus	126-135	BCL2 like 11	Homo sapiens	18-21
19914305-11	2010	These results, taken together, indicate that Bim protein is the key mediator of apoptosis induced by Dex and also responsible for the potentiating effect of rapamycin, providing molecular criteria for the use of glucocorticoids combined with mTOR inhibitors in myeloma therapy.	Sirolimus	157-166	BCL2 like 11	Homo sapiens	45-48
19955083-11	2010	We determined that the protein product of GGC1 was stabilized in the presence of rapamycin, and the deletion of the GGC1 enhanced growth fitness in the presence of rapamycin.	Sirolimus	81-90	Ggc1p	Saccharomyces cerevisiae S288C	42-46
19955083-12	2010	A dynamic mRNA expression analysis of Deltaggc1 and wild-type cells treated with rapamycin revealed a key role for Ggc1p in the regulation of ribosome biogenesis and cell cycle progression under TOR control.	Sirolimus	81-90	Ggc1p	Saccharomyces cerevisiae S288C	115-120
20160148-2	2010	In the year 2000, TSC2 gene mutations were found in LAM cells; in 2001 the tuberous sclerosis complex (TSC) genes were discovered to regulate cell size in Drosophila via the kinase TOR (target of rapamycin); and in 2008 the results were published of a clinical trial of rapamycin, a specific inhibitor of TOR, in patients with TSC and LAM with renal angiomyolipomas.	Sirolimus	196-205	Target of rapamycin	Drosophila melanogaster	181-184
20236585-1	2010	OBJECTIVE: To evaluate the effects of rapamycin (RPM)-loaded poly (lactic-co- glycolic) acid (PLGA) nanoparticles (NPs) on the proliferation, distribution of cell cycle, and expression of p27 protein in human umbilical arterial vascular smooth muscle cell (HUASMC) in vitro.	Sirolimus	38-47	interferon alpha inducible protein 27	Homo sapiens	188-191
20236585-9	2010	Histologically, the expression of p27 were up-regulated in 500 microg/L RPM-PLGA NPs and 100 microg/L RPM treated group (all P &lt; 0.01 ) when compared with the control group.	Sirolimus	72-75	interferon alpha inducible protein 27	Homo sapiens	34-37
19845851-10	2010	Upon rapamycin and CCI-779 treatment, the phosphorylation level of mTOR and p70S6K in HCC cell lines was significantly reduced, indicating that both drugs can suppress mTOR activity in HCC cells.	Sirolimus	5-14	ribosomal protein S6 kinase B1	Homo sapiens	76-82
20389030-6	2010	By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002.	Sirolimus	114-123	vascular endothelial growth factor A	Rattus norvegicus	76-80
20389030-7	2010	For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway.	Sirolimus	4-13	vascular endothelial growth factor A	Rattus norvegicus	96-100
20389030-9	2010	In conclusion, our study points out to the complex regulation of VEGF synthesis and secretion in neoplastic GEP endocrine cells and suggests that the inhibition of VEGF production by octreotide and rapamycin may contribute to their therapeutic effects.	Sirolimus	198-207	vascular endothelial growth factor A	Rattus norvegicus	164-168
19923913-5	2009	Selective inhibition of the PI3K-AKT-mTOR pathway using pharmacologic inhibitors (LY294002, AKT inhibitor VIII, Rapamycin) significantly attenuated expression of p-AKT and p-70S6K, respectively and radiosensitized SKBR3 cells.	Sirolimus	112-121	ribosomal protein S6 kinase B1	Homo sapiens	172-179
20045915-4	2009	MEK inhibitor (PD98059), SAPK/p38 inhibitor (SB202190), and mTOR inhibitor (rapamycin) were used to respectively block MEK, SAPK/p38, and mTOR intracellular pathways or the phosphatase inhibitor (calyculin A) pretreatment before CCK treatment.	Sirolimus	76-85	mechanistic target of rapamycin kinase	Mus musculus	60-64
20045915-7	2009	MEK inhibitor PD98059 partially reversed the dephosphorylation of eEF2 induced by CCK, as did treatment p38 MAPK inhibitor SB202190, mTOR inhibitor rapamycin, and the phosphatase inhibitor calyculin A.	Sirolimus	148-157	eukaryotic translation elongation factor 2	Mus musculus	66-70
19797172-11	2009	Chromatin immunoprecipitation assay demonstrated sirolimus interferes with binding of PPARgamma to its response elements in heme oxygenase-1 promoter.	Sirolimus	49-58	heme oxygenase 1	Homo sapiens	124-140
19773438-4	2009	Here, using genetically engineered human prostate epithelial cells (PrEC), we show that MYC, a frequent target of genetic gain in prostate cancers, abrogates sensitivity to rapamycin by decreasing rapamycin-induced cytostasis and autophagy.	Sirolimus	173-182	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-91
19773438-4	2009	Here, using genetically engineered human prostate epithelial cells (PrEC), we show that MYC, a frequent target of genetic gain in prostate cancers, abrogates sensitivity to rapamycin by decreasing rapamycin-induced cytostasis and autophagy.	Sirolimus	197-206	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-91
19773438-7	2009	Suppression of 4EBP1 expression resulted in resensitization of MYC-expressing PrEC to rapamycin and increased autophagy.	Sirolimus	86-95	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	15-20
19773438-7	2009	Suppression of 4EBP1 expression resulted in resensitization of MYC-expressing PrEC to rapamycin and increased autophagy.	Sirolimus	86-95	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-66
19773438-8	2009	Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy.	Sirolimus	82-91	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	124-129
19789218-8	2009	CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor).	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	3-7
19789218-8	2009	CA-S6K1 overexpression reversed HIF-1alpha inhibition by rapamycin (a mammalian target of rapamycin/S6K1 inhibitor).	Sirolimus	57-66	ribosomal protein S6 kinase B1	Homo sapiens	100-104
19484784-10	2009	Rapamycin increased cisplatin-induced apoptosis and stimulated expression of MSH2 and MSH6 in the cisplatin-treated cell lines.	Sirolimus	0-9	mutS homolog 6	Homo sapiens	86-90
19996130-4	2009	We found that RAPA induced a time-dependent activation of MAPK (pERK1/2) and MEK1/2.	Sirolimus	14-18	mitogen-activated protein kinase kinase 1	Homo sapiens	77-83
19996130-5	2009	Inhibition of upstream kinase MEK1/2 by U0126 partially suppressed RAPA-induced ERK1/2 activation.	Sirolimus	67-71	mitogen-activated protein kinase kinase 1	Homo sapiens	30-36
19427311-4	2009	METHODS: Wild-type and CCK-null mice were fed protein-deficient chow for 4 days and then allowed to recover on control chow in the presence or absence of the mTOR inhibitor rapamycin.	Sirolimus	173-182	mechanistic target of rapamycin kinase	Mus musculus	158-162
19427311-8	2009	Administration of the mTOR inhibitor rapamycin decreased regrowth of the pancreas but did not affect digestive enzyme content or secretory capacity.	Sirolimus	37-46	mechanistic target of rapamycin kinase	Mus musculus	22-26
19647013-10	2009	By applying rapamycin, a specific pharmacological inhibitor of mTOR signaling, we found that the inhibition of mTOR could significantly prevent neuronal apoptosis induced by Paraquat.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	63-67
19647013-10	2009	By applying rapamycin, a specific pharmacological inhibitor of mTOR signaling, we found that the inhibition of mTOR could significantly prevent neuronal apoptosis induced by Paraquat.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Mus musculus	111-115
19564418-4	2009	Importantly, downregulation of rictor inhibited TORC2 signaling without inhibiting mTORC1 signaling, suggesting that inhibition of mTORC1 by rapamycin may not be the cause of arrested differentiation.	Sirolimus	141-150	RPTOR independent companion of MTOR complex 2	Homo sapiens	31-37
19564418-5	2009	In support of this, expression of a phosphomimetic mutant AKT(S473D) in rictor-deficient cells rescued myoblast fusion even in the presence of rapamycin.	Sirolimus	143-152	RPTOR independent companion of MTOR complex 2	Homo sapiens	72-78
19684592-4	2009	4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants.	Sirolimus	48-57	Target of rapamycin	Drosophila melanogaster	34-37
19684592-4	2009	4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants.	Sirolimus	48-57	PTEN-induced putative kinase 1	Drosophila melanogaster	102-107
19535330-4	2009	OGD-induced apoptosis was increased by the combined deletion of S6K1 and S6K2 genes, as well as by treatment with rapamycin that inhibits S6K1 activity by acting on the upstream regulator mTOR (mammalian target of rapamycin).	Sirolimus	114-123	ribosomal protein S6 kinase B1	Homo sapiens	138-142
19541609-6	2009	We demonstrate here that these polyps, and LKB1- and AMPK-deficient mouse embryonic fibroblasts, show dramatic up-regulation of the HIF-1alpha transcription factor and its downstream transcriptional targets in an rapamycin-suppressible manner.	Sirolimus	213-222	hypoxia inducible factor 1, alpha subunit	Mus musculus	132-142
19539216-1	2009	Previous studies have shown that adding sirolimus to a tacrolimus/mini-methotrexate regimen (Tac/Sir/MTX) as graft-versus-host disease (GVHD) prophylaxis produces low rates of acute GVHD (aGVHD) after reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT).	Sirolimus	40-49	metaxin 1	Homo sapiens	101-104
19470613-9	2009	We also demonstrate that a short-term treatment with the mTOR inhibitor rapamycin strongly suppresses the severity and the duration of the seizure activity.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Mus musculus	57-61
19107520-8	2009	CONCLUSISONS: Expression of mTOR and 4EBP1 characterize high-grade, high-stage endometrial adenocarcinomas and might be predictive markers of a response to rapamycin.	Sirolimus	156-165	tortured	Mus musculus	28-42
19415679-6	2009	The induction of stress either by glucose withdrawal or by treatment with rapamycin, stimulated degradation of proline and increased POX catalytic activity.	Sirolimus	74-83	proline dehydrogenase 1	Homo sapiens	133-136
19421190-3	2009	Effectiveness of the rapamycin dose and delivery was shown by the inhibition of insulin-stimulated phosphorylation of p70S6K, a marker of mTOR activity, in skeletal muscle.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Mus musculus	138-142
19421190-6	2009	Our study shows that rapamycin can prevent the late- but not the early-stage progression of renal pathology and deterioration of renal functional in this model of nephronophthisis, presumably by inhibiting mTOR activity.	Sirolimus	21-30	mechanistic target of rapamycin kinase	Mus musculus	206-210
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	ribosomal protein S6 kinase B1	Homo sapiens	262-266
19557637-6	2009	Because rapamycin targets the mammalian target of rapamycin (mTOR) pathway, we also used our cells to confirm that rapamycin modified the expression of mTOR and effectively suppressed the phosphorylation of two downstream effector molecules in the mTOR pathway, S6K1, and 4E-BP1.	Sirolimus	8-17	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	272-278
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Sirolimus	36-45	serpin family E member 1	Homo sapiens	109-114
19526041-5	2009	Rapamycin abrogated p70S6K phosphorylation in the left ventricle of sham rats and the noninfarcted left ventricle (NILV) of 1-week postmyocardial-infarcted (MI) rats.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	20-26
19229543-7	2009	RESULTS: Combination treatment with AZA and RPM inhibited the growth of HCT116 cells, induced apoptosis, arrested the cell cycle, and reduced the incidence and tumor volume of CRC in mice, as well as inhibited the phosphorylation of components of the mTOR signal transduction pathway.	Sirolimus	44-47	mechanistic target of rapamycin kinase	Mus musculus	251-255
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Mus musculus	67-71
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	mechanistic target of rapamycin kinase	Mus musculus	92-96
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	108-117	TSC complex subunit 2	Mus musculus	183-187
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	67-71
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	mechanistic target of rapamycin kinase	Mus musculus	92-96
19539245-6	2009	Investigation of this hypothesis in a TSC cell model revealed that mTOR suppression with an mTOR inhibitor, rapamycin (sirolimus), led to up-regulation of ERK/MAPK signaling in mouse Tsc2 knockout cells and that this augmented signaling was attenuated by concurrent administration of a MEK1/2 inhibitor, PD98059.	Sirolimus	119-128	TSC complex subunit 2	Mus musculus	183-187
19435901-0	2009	Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.	Sirolimus	0-9	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	68-73
19435901-0	2009	Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.	Sirolimus	0-9	transformation related protein 53, pseudogene	Mus musculus	78-81
19374031-6	2009	Gtr1p and Gtr2p are necessary for cells to acquire resistance to caffeine, rapamycin, and hydrogen peroxide.	Sirolimus	75-84	Rag GTPase GTR1	Saccharomyces cerevisiae S288C	0-5
19273591-6	2009	Epitasis analysis indicates that the mutation of SIT4 or TIP41, encoding a Tap42-interacting protein, abolishes the sensitivity of the ptc1 strain to rapamycin and caffeine.	Sirolimus	150-159	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	49-53
19273591-6	2009	Epitasis analysis indicates that the mutation of SIT4 or TIP41, encoding a Tap42-interacting protein, abolishes the sensitivity of the ptc1 strain to rapamycin and caffeine.	Sirolimus	150-159	Tap42p	Saccharomyces cerevisiae S288C	75-80
19273591-10	2009	The lack of Ptc1 partially abolishes the rapamycin-induced dephosphorylation of Tip41, which may further decrease Tap42 binding.	Sirolimus	41-50	Tap42p	Saccharomyces cerevisiae S288C	114-119
19414357-5	2009	Rapamycin resistance was reflected by reduced inhibition of p70S6K and S6RP phosphorylation in MCF10CA1a tumor cells, with RS6P showing the least response to rapamycin in the tumor cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	60-66
19211763-3	2009	However, although the mTOR inhibitor rapamycin suppressed VV-induced inactivation of 4E-BP1, it failed to inhibit eIF4F assembly.	Sirolimus	37-46	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	85-91
19373661-5	2009	Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax.	Sirolimus	13-22	caspase 9	Homo sapiens	46-55
19112174-1	2009	The 40 S ribosomal S6 kinase 1 (S6K1) acts downstream of mTOR (mammalian target of rapamycin) and is sensitive to inhibition by rapamycin.	Sirolimus	83-92	ribosomal protein S6 kinase A1	Homo sapiens	9-30
19112174-1	2009	The 40 S ribosomal S6 kinase 1 (S6K1) acts downstream of mTOR (mammalian target of rapamycin) and is sensitive to inhibition by rapamycin.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	32-36
19112174-5	2009	In this study, we report that overexpression of S6K1 endows breast cancer cells with a proliferative advantage in low serum conditions and enhanced sensitivity to rapamycin.	Sirolimus	163-172	ribosomal protein S6 kinase B1	Homo sapiens	48-52
19194827-2	2009	Here, we found that combination treatment with PD98059 and rapamycin suppressed the proliferation of CRC cells, induced apoptosis, arrested cell cycle, and reduced the incidence and volume of CRC in mice, as well as inhibited phosphorylation of mTOR and the MEK signal pathway components, of which the effects were more significant than single-drug treatments.	Sirolimus	59-68	mechanistic target of rapamycin kinase	Mus musculus	245-249
19223503-8	2009	The combination of rapamycin and UCN-01 synergistically inhibited the DLBCL cell proliferation by inducing G1 arrest as well as apoptosis by suppressing the phosphorylation of p70S6K/p85S6K and CDC2 expression.	Sirolimus	19-28	ribosomal protein S6 kinase B1	Homo sapiens	176-182
19223503-8	2009	The combination of rapamycin and UCN-01 synergistically inhibited the DLBCL cell proliferation by inducing G1 arrest as well as apoptosis by suppressing the phosphorylation of p70S6K/p85S6K and CDC2 expression.	Sirolimus	19-28	cyclin dependent kinase 1	Homo sapiens	194-198
18988195-8	2009	In addition, rapamycin (an mTOR inhibitor, 10(-8) M) blocked the ZnCl(2)-induced increase in [(3)H]-thymidine incorporation and cell cycle regulatory protein expression.	Sirolimus	13-22	mechanistic target of rapamycin kinase	Mus musculus	27-31
19197153-4	2009	In this review, we discuss the implications of a recent finding that showed differential inhibition of S6K1 and 4E-BP1 by rapamycin, leading to cell-type-specific repression of cap-dependent translation.	Sirolimus	122-131	ribosomal protein S6 kinase B1	Homo sapiens	103-118
19211884-6	2009	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype.	Sirolimus	21-30	phosphatase and tensin homolog	Homo sapiens	197-201
19211884-6	2009	Here, we report that rapamycin, a specific inhibitor of mammalian target of rapamycin complex 1 (mTORC1), can prevent and reverse neuronal hypertrophy, resulting in the amelioration of a subset of PTEN-associated abnormal behaviors, providing evidence that the mTORC1 pathway downstream of PTEN is critical for this complex phenotype.	Sirolimus	21-30	phosphatase and tensin homolog	Homo sapiens	290-294
19148492-11	2009	Rapamycin also down-regulated the activity of p70S6, pAkt and p-mTOR, but had no effect on pGSK-3beta, p44Erk, pCdc2, TSC1/2 or Hsp70 or Hsp90.	Sirolimus	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	137-142
19015262-0	2009	Rapamycin-induced Gln3 dephosphorylation is insufficient for nuclear localization: Sit4 and PP2A phosphatases are regulated and function differently.	Sirolimus	0-9	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	18-22
19015262-2	2009	Gln3 is cytoplasmic in cells cultured with repressive nitrogen sources (Gln) and nuclear with derepressive ones (Pro) or after treating Gln-grown cells with the Tor inhibitor, rapamycin (Rap).	Sirolimus	176-185	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	0-4
18758183-2	2009	P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel.	Sirolimus	157-166	interferon alpha inducible protein 27	Homo sapiens	0-3
19001278-6	2009	Of note, an increased XIAPlevel was evidenced during the blockade of the canonical cap-dependent translation by the mTOR inhibitor rapamycin, supporting the hypothesis of a functional IRES sequence in XIAP mRNA.	Sirolimus	131-140	mechanistic target of rapamycin kinase	Mus musculus	116-120
19139116-5	2009	Similar AKT-dependent regulation of rapamycin responsiveness was shown in a second myeloma model: the PTEN-null OPM-2 cell line transfected with wild-type PTEN.	Sirolimus	36-45	phosphatase and tensin homolog	Homo sapiens	102-106
19139116-5	2009	Similar AKT-dependent regulation of rapamycin responsiveness was shown in a second myeloma model: the PTEN-null OPM-2 cell line transfected with wild-type PTEN.	Sirolimus	36-45	phosphatase and tensin homolog	Homo sapiens	155-159
19139116-9	2009	Furthermore, the ERK inhibitor successfully sensitized myeloma cells to rapamycin in terms of down-regulated D-cyclin protein expression and G1 arrest.	Sirolimus	72-81	proliferating cell nuclear antigen	Homo sapiens	111-117
20066897-6	2009	p-mTOR and S6K expressions were significantly downregulated by rapamycin.	Sirolimus	63-72	ribosomal protein S6 kinase B1	Homo sapiens	11-14
20066897-8	2009	Combined cisplatin and rapamycin treatment resulted in significant downregulated p-mTOR and S6K expression, but no change in ERCC1 expression.	Sirolimus	23-32	ribosomal protein S6 kinase B1	Homo sapiens	92-95
19115995-5	2008	The expression levels of PTEN- and P27kip1- mRNA were up-regulated, and the mTOR- and cyclinD1- mRNA were down-regulated in K562 cells after the cells transfected with wild type PTEN gene and treated with rapamycin.	Sirolimus	205-214	phosphatase and tensin homolog	Homo sapiens	178-182
18789402-0	2008	Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation.	Sirolimus	0-9	toll like receptor 4	Homo sapiens	19-23
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	11-20	toll like receptor 4	Homo sapiens	34-38
18789402-6	2008	Therefore, rapamycin may abrogate TLR4-triggered tumor apoptosis resistance by inhibiting Akt/NF-kappaB pathways and Bcl-xL expression, providing experimental evidence for the anti-tumor effect of rapamycin.	Sirolimus	197-206	toll like receptor 4	Homo sapiens	34-38
19074906-8	2008	Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells.	Sirolimus	13-22	C-X-C motif chemokine receptor 6	Homo sapiens	177-182
19077306-12	2008	Pin1 inhibition greatly increased the sensitivity of Her2-positive breast cancer cells to the mTOR inhibitor Rapamycin, while it did not increase their sensitivity to Trastuzumab, suggesting that Pin1 might act on Her2 signaling.	Sirolimus	109-118	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	0-4
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	low density lipoprotein receptor	Homo sapiens	95-127
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	low density lipoprotein receptor	Homo sapiens	129-133
19180880-6	2008	Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta.	Sirolimus	0-9	low density lipoprotein receptor	Homo sapiens	66-70
18776140-8	2008	RESULTS: C75 and cerulenin increased phosphorylation of S6K1 and S6, and their anorexic action was reduced in rapamycin-treated rats and in S6K1(-/-) mice.	Sirolimus	110-119	ribosomal protein S6 kinase B1	Rattus norvegicus	56-60
19018001-9	2008	We found that the injection of CD40L transfectants, but not mock cells, resulted in VEGF expression and mediated a marked angiogenesis reaction, and this response was reduced in mice treated with rapamycin.	Sirolimus	196-205	CD40 ligand	Mus musculus	31-36
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	insulin-like growth factor 1	Rattus norvegicus	43-48
18652845-0	2008	Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction.	Sirolimus	0-9	leukocyte immunoglobulin like receptor B4	Homo sapiens	55-59
18931715-0	2008	[Sirolimus inhibits the expression of type I collagen and fibronectin in cultured renal cortical myofibroblasts].	Sirolimus	1-10	fibronectin 1	Rattus norvegicus	58-69
18663146-8	2008	We also observed that the oncogenic K-Ras-induced T-cell disease was responsive to rapamycin and inhibitors of the RAS/MAPK pathway.	Sirolimus	83-92	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	36-41
18616983-7	2008	The inhibitory effect of leucine, isoleucine or arginine on atrogin-1 mRNA level was reversed by rapamycin, although wortmannin did not reverse the effect.	Sirolimus	97-106	F-box protein 32	Mus musculus	60-69
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Sirolimus	0-9	angiopoietin 1	Rattus norvegicus	67-72
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Sirolimus	84-93	angiopoietin 1	Rattus norvegicus	158-162
18929866-12	2008	In a comparison of the control and CsA groups, mRNA expression of Ang1 was increased (P &lt; .05), and mRNA expression of Ang2 and Tie2 was decreased (P &lt; .05) in the rapamycin group at 8 and 12 weeks.	Sirolimus	170-179	angiopoietin 1	Rattus norvegicus	66-70
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	54-63	angiopoietin 1	Rattus norvegicus	92-96
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	167-176	angiopoietin 1	Rattus norvegicus	92-96
18621930-3	2008	Since mTORC1 regulates growth, we hypothesized that pharmacological inhibition of mTORC1 by rapamycin may reverse the phenotypic effects of c-MYC.	Sirolimus	92-101	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	140-145
18768852-7	2008	Skin gammadelta T cells treated with rapamycin are refractory to IL-2 stimulation and attempt to survive in the absence of cytokine and growth factor signaling by undergoing autophagy.	Sirolimus	37-46	interleukin 2	Mus musculus	65-69
18543252-9	2008	The mTOR inhibitor rapamycin did not block the formation of alpha4/PP2A-C in liver or hepatic cells, nor did it appear to modulate PP2A activity.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
18725989-3	2008	We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Mus musculus	73-77
18726521-10	2008	When the mTOR specific inhibitor Rapamycin was used, the first mitotic division of the mouse one-cell stage embryo was delayed.	Sirolimus	33-42	mechanistic target of rapamycin kinase	Mus musculus	9-13
18684977-3	2008	Only CD28 costimulation in the presence of rapamycin consistently generated Tregs that consistently suppressed xenogeneic graft-vs-host disease in immunodeficient mice.	Sirolimus	43-52	CD28 antigen	Mus musculus	5-9
18622277-9	2008	Tumor necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1beta production from the impure sirolimus group significantly decreased (P&lt;0.05).	Sirolimus	149-158	C-C motif chemokine ligand 2	Homo sapiens	48-78
18622277-9	2008	Tumor necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1beta production from the impure sirolimus group significantly decreased (P&lt;0.05).	Sirolimus	149-158	C-C motif chemokine ligand 4 like 2	Homo sapiens	84-121
18622277-10	2008	Furthermore, tumor necrosis factor-alpha and macrophage inflammatory protein-1beta production from sorted ductal cells significantly decreased in the sirolimus group (P&lt;0.05).	Sirolimus	150-159	C-C motif chemokine ligand 4 like 2	Homo sapiens	45-82
18332865-2	2008	Cells transfected with a mutant PTEN gene lacking both lipid and protein phosphatase activities were more resistant to doxorubicin than cells transfected with the PTEN mutant lacking lipid phosphatase activity indicating that the protein phosphatase activity of PTEN was also important in controlling the sensitivity to doxorubicin, while no difference was observed between the lipid (G129E) and lipid and protein (C124S) phosphatase PTEN mutants in terms of sensitivity to rapamycin.	Sirolimus	474-483	phosphatase and tensin homolog	Homo sapiens	32-36
18448283-10	2008	CONCLUSIONS: The increase in CETP activity and suppression in LPL activity following CsA and RAPA treatment observed in the present study may be associated with elevated LDL cholesterol levels and hypertriglyceridemia seen in patients administered these drugs.	Sirolimus	93-97	lipoprotein lipase	Homo sapiens	62-65
18283037-11	2008	Rapamycin cotreatment suppressed p70S6K1 hyperactivation and synergistically resensitized MCF-7/HER2-Lap10 cells to lapatinib (&gt;20-fold increase in lapatinib-induced cytotoxicity; CI(50) = 0.175 &lt; 1.0 = additivity).	Sirolimus	0-9	LAP	Homo sapiens	101-104
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	128-134
18354181-5	2008	Rapamycin, a specific inhibitor of mTORC1, selectively and completely blocked the FcepsilonRI- and Kit-induced mTORC1-dependent p70S6K phosphorylation and partially blocked the 4E-BP1 phosphorylation.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	177-183
18216782-5	2008	Rapamycin attenuated DC differentiation, HIF-1alpha expression, and its target gene expression in a dose-dependent manner along with downregulated interleukin-10 secretion.	Sirolimus	0-9	interleukin 10	Rattus norvegicus	147-161
18182482-7	2008	Sirolimus (rapamycin) had no effect on NCX2 and NCX3 protein expression, yet it reduced NCX2 and NCX3 transport activity.	Sirolimus	0-9	solute carrier family 8 member A2	Homo sapiens	88-92
18182482-7	2008	Sirolimus (rapamycin) had no effect on NCX2 and NCX3 protein expression, yet it reduced NCX2 and NCX3 transport activity.	Sirolimus	11-20	solute carrier family 8 member A2	Homo sapiens	88-92
18199701-4	2008	However, using a cellular model of HD, we found that rapamycin significantly decreased aggregation-prone polyglutamine (polyQ) and expanded huntingtin and its inclusion bodies (IB) in both autophagy-proficient and autophagy-deficient cells (by genetic knockout of the atg5 gene in mouse embryonic fibroblasts).	Sirolimus	53-62	huntingtin	Mus musculus	140-150
18191814-4	2008	By contrast, gefitinib inhibited in a fast and completely way p-EGFR and partially p-Akt while a 3 days-rapamycin exposure resulted in the inhibition of the expression of both mTor and p70S6K.	Sirolimus	104-113	ribosomal protein S6 kinase B1	Homo sapiens	185-191
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	glucose-induced degradation complex subunit VID28	Saccharomyces cerevisiae S288C	70-75
17986252-5	2008	Three members of the VID and GID gene families, VID30/GID1, GID2, and VID28/GID5 are needed for the rapamycin or nitrogen starvation-induced degradation of the high-affinity hexose transporter Hxt7p is shown here.	Sirolimus	100-109	glucose-induced degradation complex subunit VID28	Saccharomyces cerevisiae S288C	76-80
18374093-6	2008	Rapamycin treatment of islets resulted in reduced phosphorylation of p70s6k, a downstream effector molecule of mTOR and increased ERK1/2 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	69-75
18250445-6	2008	Long-term pretreatment with the mTOR inhibitor rapamycin significantly blocked both mTOR-raptor and mTOR-rictor complex formation.	Sirolimus	47-56	RPTOR independent companion of MTOR complex 2	Homo sapiens	105-111
18182245-0	2008	Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel.	Sirolimus	119-128	coagulation factor III, tissue factor	Homo sapiens	16-29
18182245-3	2008	This study examined the impact of rapamycin and paclitaxel on TF expression and compares the TF activity induction of both drugs and irradiation in SMCs.	Sirolimus	34-43	coagulation factor III, tissue factor	Homo sapiens	62-64
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Sirolimus	9-18	coagulation factor III, tissue factor	Homo sapiens	47-49
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Sirolimus	9-18	coagulation factor III, tissue factor	Homo sapiens	81-83
18182245-6	2008	RESULTS: Rapamycin or paclitaxel increased the TF mRNA expression 5-fold and the TF activity 4- to 6-fold with a maximum at 5 h. Irradiation induced TF activity 2- to 4-fold with a maximum at 7 days.	Sirolimus	9-18	coagulation factor III, tissue factor	Homo sapiens	81-83
18204792-6	2008	Similarly to primary tumors from TS patients, TSC2ang1 cells respond to rapamycin-induced mTOR inhibition.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Mus musculus	90-94
18182616-7	2008	BHD knockout mice and kidney cells isolated from BHD knockout and control mice were treated with the mTOR inhibitor rapamycin.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Mus musculus	101-105
17942753-6	2008	Pim 2-deficient B cells are readily protected from death by BLyS stimulation, but this protection is completely abrogated by treatment with the mTOR inhibitor rapamycin.	Sirolimus	159-168	Pim-2 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
18164202-5	2008	Specifically, we show that the mTOR inhibitor rapamycin potently suppresses the growth of aggressive NF1-associated malignancies in a genetically engineered murine model.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Mus musculus	31-35
18164202-5	2008	Specifically, we show that the mTOR inhibitor rapamycin potently suppresses the growth of aggressive NF1-associated malignancies in a genetically engineered murine model.	Sirolimus	46-55	neurofibromin 1	Mus musculus	101-104
18980674-1	2008	INTRODUCTION: Treatment with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be efficacious in the MRL/lpr and NZB x NZW F1 mouse models of lupus nephritis, indicating a critical role for the mTOR pathway in both models.	Sirolimus	29-38	mechanistic target of rapamycin kinase	Mus musculus	223-227
18156399-11	2008	Jejunal villi of the Rapa-treated group showed inactivation of p70(S6k) and a decrease in mucosal resistance (reflecting increased permeability), the latter of which was reversed by Arg.	Sirolimus	21-25	ribosomal protein S6 kinase B1	Homo sapiens	67-70
17969189-4	2007	Primary immunosuppression in both groups at the time of transplantation was tacrolimus, but more patients in the LAP group were on sirolimus at the time of hernia, while more patients in the OP group were on prednisone at the time of hernia repair.	Sirolimus	131-140	LAP	Homo sapiens	113-116
17940662-3	2007	Previous studies indicate that Arabidopsis thaliana TOR (AtTOR) activity is resistant to rapamycin whereas maize TOR (ZmTOR) is not, suggesting that plants might have different regulation mechanisms for this signal transduction pathway.	Sirolimus	89-98	Serine/threonine-protein kinase TOR	Zea mays	59-62
17940662-3	2007	Previous studies indicate that Arabidopsis thaliana TOR (AtTOR) activity is resistant to rapamycin whereas maize TOR (ZmTOR) is not, suggesting that plants might have different regulation mechanisms for this signal transduction pathway.	Sirolimus	89-98	Serine/threonine-protein kinase TOR	Zea mays	118-123
17940662-7	2007	Bioinformatic analyses indicated that maize FKBP12 and rapamycin form a functional structure capable of targeting the ZmTOR protein, similar to other non-plant eukaryotes, further supporting its regulation by rapamycin (in contrast with the rapamycin insensitivity of Arabidopsis thaliana) and the conservation of rapamycin regulation through plant evolution.	Sirolimus	55-64	Serine/threonine-protein kinase TOR	Zea mays	118-123
17940662-7	2007	Bioinformatic analyses indicated that maize FKBP12 and rapamycin form a functional structure capable of targeting the ZmTOR protein, similar to other non-plant eukaryotes, further supporting its regulation by rapamycin (in contrast with the rapamycin insensitivity of Arabidopsis thaliana) and the conservation of rapamycin regulation through plant evolution.	Sirolimus	209-218	Serine/threonine-protein kinase TOR	Zea mays	118-123
17940662-7	2007	Bioinformatic analyses indicated that maize FKBP12 and rapamycin form a functional structure capable of targeting the ZmTOR protein, similar to other non-plant eukaryotes, further supporting its regulation by rapamycin (in contrast with the rapamycin insensitivity of Arabidopsis thaliana) and the conservation of rapamycin regulation through plant evolution.	Sirolimus	209-218	Serine/threonine-protein kinase TOR	Zea mays	118-123
18005851-7	2007	The immunosuppressants rapamycin, cyclosporine A, and methylprednisolone significantly inhibited the expansion of regulatory T cells upon stimulation with alloantigen, whereas mycophenolic acid and the costimulatory blockers, anti-CD40L and CTLA4Ig, did not.	Sirolimus	23-32	CD40 ligand	Mus musculus	231-236
17989609-5	2007	RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells.	Sirolimus	9-18	low density lipoprotein receptor	Homo sapiens	29-67
17989609-5	2007	RESULTS: Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1beta in HepG2 cells.	Sirolimus	9-18	low density lipoprotein receptor	Homo sapiens	69-73
17989609-7	2007	Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription.	Sirolimus	48-57	low density lipoprotein receptor	Homo sapiens	174-178
17989609-11	2007	CONCLUSIONS: This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes.	Sirolimus	77-86	low density lipoprotein receptor	Homo sapiens	121-125
17707343-7	2007	Rapamycin-mediated rictor dephosphorylation is time and concentration dependent, and occurs at physiologically relevant rapamycin concentrations.	Sirolimus	120-129	RPTOR independent companion of MTOR complex 2	Homo sapiens	19-25
17706618-5	2007	Though RB1CC1 introduction enhanced neurite growth, RNAi-mediated knockdown of RB1CC1 or rapamycin treatment caused neurite atrophy and apoptosis due to mTOR signaling reduction in the differentiated Neuro-2a cells.	Sirolimus	89-98	mechanistic target of rapamycin kinase	Mus musculus	153-157
17603996-9	2007	Furthermore, decreases of p45 AUF1 and p42 and/or p40 AUF1 were observed in the polysomal fractions of BJAB cells in which translation of TOP mRNAs was selectively suppressed by rapamycin treatment.	Sirolimus	178-187	nucleoporin 43	Homo sapiens	39-42
17712719-6	2007	RESULTS: Only sirolimus, but not cyclosporine A, tacrolimus, mycophenolate mofetil, or azathioprine showed a slight inhibition of 11beta-HSD2 activity.	Sirolimus	14-23	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	130-141
17699716-8	2007	In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.	Sirolimus	126-135	mechanistic target of rapamycin kinase	Mus musculus	108-112
17699716-8	2007	In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.	Sirolimus	126-135	erb-b2 receptor tyrosine kinase 2	Mus musculus	162-167
17699716-8	2007	In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.	Sirolimus	126-135	erb-b2 receptor tyrosine kinase 2	Mus musculus	168-171
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	55-70
17517883-8	2007	Overexpressed PRAS40 suppressed the phosphorylation of S6K1 and 4E-BP1 at their rapamycin-sensitive phosphorylation sites, and reciprocally, overexpression of S6K1 or 4E-BP1 suppressed phosphorylation of PRAS40 (Ser(183)) and its binding to raptor.	Sirolimus	80-89	ribosomal protein S6 kinase B1	Homo sapiens	159-173
17525916-11	2007	Because rapamycin is capable of simultaneously binding both FRB and the chaperone, FK506-binding protein (FKBP), we next examined whether FKBP might contribute to the protection of FRB mutants.	Sirolimus	8-17	FK506 binding protein 1a	Mus musculus	83-104
17525916-11	2007	Because rapamycin is capable of simultaneously binding both FRB and the chaperone, FK506-binding protein (FKBP), we next examined whether FKBP might contribute to the protection of FRB mutants.	Sirolimus	8-17	FK506 binding protein 1a	Mus musculus	106-110
17478757-9	2007	CONCLUSIONS: Complete removal of FKBP12 and 12.6 from endothelial RyRs induces an intracellular Ca2+ leak which may contribute to the pathogenesis of endothelial dysfunction and hypertension caused by rapamycin or FK506.	Sirolimus	201-210	FK506 binding protein 1a	Mus musculus	33-39
17613438-0	2007	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.	Sirolimus	106-115	epidermal growth factor receptor	Mus musculus	78-82
17531780-4	2007	Sirolimus (Rapamycin), a new immunosuppressive agent, inhibits signal transduction and cell cycle progression after binding to FKBP12.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	127-133
17531780-4	2007	Sirolimus (Rapamycin), a new immunosuppressive agent, inhibits signal transduction and cell cycle progression after binding to FKBP12.	Sirolimus	11-20	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	127-133
17329620-11	2007	Rapamycin partially inhibited this increase in mTOR-mediated S6K phosphorylation and IRS-1 Ser312 and Ser636 phosphorylation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	61-64
17329620-11	2007	Rapamycin partially inhibited this increase in mTOR-mediated S6K phosphorylation and IRS-1 Ser312 and Ser636 phosphorylation.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	85-90
17329620-12	2007	In conclusion, rapamycin stimulates insulin-mediated glucose uptake in man under conditions known to activate the mTOR/S6K pathway.	Sirolimus	15-24	tortured	Mus musculus	114-122
17486044-5	2007	These SMERs, which seem to act either independently or downstream of the target of rapamycin, attenuated mutant huntingtin-fragment toxicity in Huntington"s disease cell and Drosophila melanogaster models, which suggests therapeutic potential.	Sirolimus	83-92	huntingtin	Drosophila melanogaster	112-122
17350953-1	2007	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	117-123
17351648-0	2007	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.	Sirolimus	0-9	forkhead box P3	Mus musculus	97-102
17351648-3	2007	Cyclosporine and rapamycin reduce the expansion of effector T cells by blocking interleukin (IL)-2, but signaling by IL-2 is pivotal for T(REG) homeostasis.	Sirolimus	17-26	interleukin 2	Mus musculus	80-98
17351648-8	2007	Prolonged rapamycin treatment allowed for thymic generation of CD4(+)FoxP3(+) T cells, whereas treatment with cyclosporine led to a reduced generation of these cells.	Sirolimus	10-19	forkhead box P3	Mus musculus	69-74
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Sirolimus	32-41	forkhead box P3	Mus musculus	85-90
17383120-6	2007	Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	59-62
17407584-0	2007	Rapamycin-induced inhibition of HTLV-I LTR activity is rescued by c-Myb.	Sirolimus	0-9	MYB proto-oncogene, transcription factor	Homo sapiens	66-71
17482291-4	2007	Wortmannin, SH-5, and rapamycin significantly blocked PDGF-stimulated induction of SphK1 mRNA and protein expression, indicating a regulatory role of the PI3K/AKT/mTOR pathway in SphK1 expression.	Sirolimus	22-31	sphingosine kinase 1	Homo sapiens	83-88
17482291-4	2007	Wortmannin, SH-5, and rapamycin significantly blocked PDGF-stimulated induction of SphK1 mRNA and protein expression, indicating a regulatory role of the PI3K/AKT/mTOR pathway in SphK1 expression.	Sirolimus	22-31	sphingosine kinase 1	Homo sapiens	179-184
17404113-2	2007	To test this, we did studies with rapamycin, an inhibitor of mTOR, in A/J mice that had been exposed to the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	61-65
17404113-7	2007	RESULTS: Rapamycin was administered on a daily (5 of 7 days) regimen beginning 26 weeks after NNK decreased tumor size, proliferative rate, and mTOR activity.	Sirolimus	9-18	mechanistic target of rapamycin kinase	Mus musculus	144-148
17327134-4	2007	Rapamycin treated cells failed to proliferate, expressed anergic T cell specific transcription factor genes egr-2 and egr-3 and showed diminished IFN-gamma production in response to Con A stimulation in vitro.	Sirolimus	0-9	early growth response 2	Mus musculus	108-113
17361185-8	2007	The aberrant mitotic phenotype of 14-3-3sigma-depleted cells can be rescued by forced expression of p58 PITSLRE or by extinguishing cap-dependent translation and increasing cap-independent translation during mitosis by using rapamycin.	Sirolimus	225-234	stratifin	Homo sapiens	34-45
17336708-5	2007	Long-term treatment with rapamycin was associated with marked inhibition of basal and stimulated phosphorylation of both AKT and P70(S6K), in parallel with regression of the dermal neoplasm.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	129-132
17336708-7	2007	Thus, monitoring P70(S6K) phosphorylation can help predict and monitor the biological effectiveness of rapamycin in renal transplant recipients with Kaposi sarcoma and possibly adjust the biologically active doses of the mTOR inhibitor.	Sirolimus	103-112	ribosomal protein S6 kinase B1	Homo sapiens	17-20
17290308-4	2007	This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells.	Sirolimus	51-60	mechanistic target of rapamycin kinase	Mus musculus	28-32
17290308-4	2007	This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells.	Sirolimus	51-60	platelet derived growth factor receptor, beta polypeptide	Mus musculus	70-75
17290308-4	2007	This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells.	Sirolimus	51-60	TSC complex subunit 2	Mus musculus	136-140
17302822-7	2007	Either SIC1 deletion or CLN3 overexpression results in non-cell-cycle-specific arrest upon rapamycin treatment and makes cells sensitive to a sublethal dose of rapamycin and to nutrient starvation.	Sirolimus	91-100	cyclin-dependent protein serine/threonine kinase inhibiting protein SIC1	Saccharomyces cerevisiae S288C	7-11
17302822-7	2007	Either SIC1 deletion or CLN3 overexpression results in non-cell-cycle-specific arrest upon rapamycin treatment and makes cells sensitive to a sublethal dose of rapamycin and to nutrient starvation.	Sirolimus	160-169	cyclin-dependent protein serine/threonine kinase inhibiting protein SIC1	Saccharomyces cerevisiae S288C	7-11
17302822-8	2007	In conclusion, our data indicate that Sic1 is involved in rapamycin-induced G1 arrest and that deregulated entrance into S phase severely decreases the ability of a cell to cope with starvation conditions induced by nutrient depletion or which are mimicked by rapamycin treatment.	Sirolimus	58-67	cyclin-dependent protein serine/threonine kinase inhibiting protein SIC1	Saccharomyces cerevisiae S288C	38-42
17164244-4	2007	Rapamycin, an inhibitor of mammalian target of rapamycin, and the MEK inhibitor PD98059 blocked the EtOH-induced phosphorylation of eEF2, whereas the p38 MAPK inhibitor SB202190 had no effect.	Sirolimus	0-9	eukaryotic translation elongation factor 2	Homo sapiens	132-136
17116308-2	2007	This scaffold, a fusion of three protein domains, FKBP12, FRB, and GST, presents a peptide linker region for target protein binding only in the absence of the small molecule Rapamycin or other non-immunosuppressive Rapamycin derivatives.	Sirolimus	215-224	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	50-56
17245434-7	2007	Inhibition of mTOR by rapamycin abolished ROCK-1 synthesis in macrophages resulting in an inhibition of chemotaxis and phagocytosis.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Mus musculus	14-18
16920414-8	2007	Local delivery of sirolimus during angioplasty attenuated the expression of structural proteins that included lamin A, vimentin, alpha-1-antitrypsin, and alpha-actin.	Sirolimus	18-27	vimentin	Homo sapiens	119-127
17200572-7	2007	When TOR is inactivated by rapamycin treatment or nitrogen starvation, downstream effectors of TOR such as the serine/threonine protein kinase NPR1 and the TAP42 interacting protein TIP41 are dephosphorylated in a SIT4-dependent manner.	Sirolimus	27-36	Tap42p	Saccharomyces cerevisiae S288C	156-161
17200572-7	2007	When TOR is inactivated by rapamycin treatment or nitrogen starvation, downstream effectors of TOR such as the serine/threonine protein kinase NPR1 and the TAP42 interacting protein TIP41 are dephosphorylated in a SIT4-dependent manner.	Sirolimus	27-36	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	214-218
17172981-6	2007	On the other hand, administration of AG490 (specific inhibitor for JAK2), fludarabine (specific inhibitor for STAT1) or rapamycin (specific inhibitor for STAT3) markedly suppressed HMGB1 expression.	Sirolimus	120-129	signal transducer and activator of transcription 3	Rattus norvegicus	154-159
17005563-5	2006	Because wortmannin largely phenocopies the effects of rapamycin (e.g. it triggers nuclear accumulation of Gln3p), it likely also inhibits the PI kinase-related, target of rapamycin (TOR) kinases.	Sirolimus	54-63	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	106-111
17142730-3	2006	We recently reported that rapamycin allows in vitro expansion of murine CD4+CD25+FoxP3+ Tregs, which preserve their suppressive function.	Sirolimus	26-35	forkhead box P3	Mus musculus	81-86
16455087-11	2006	Sirolimus decreased telomerase activity dose-dependently, which was accompanied with down-regulation of the catalytic subunit, telomerase reverse transcriptase (TERT).	Sirolimus	0-9	telomerase reverse transcriptase	Homo sapiens	161-165
16455087-12	2006	Furthermore, sirolimus up-regulated the cell cycle inhibitor p27(kip1).	Sirolimus	13-22	interferon alpha inducible protein 27	Homo sapiens	61-64
16455087-12	2006	Furthermore, sirolimus up-regulated the cell cycle inhibitor p27(kip1).	Sirolimus	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	65-69
17172843-2	2006	The key components mediating this dephosphorylation process are the Tap42-associated phosphatases, which become active upon rapamycin treatment.	Sirolimus	124-133	Tap42p	Saccharomyces cerevisiae S288C	68-73
17172843-4	2006	A recent report has provided evidence demonstrating a physical association of the Tap42-phosphatase complexes with TORC1, which is sensitive to rapamycin treatment or nutrient starvation.	Sirolimus	144-153	Tap42p	Saccharomyces cerevisiae S288C	82-87
17065572-8	2006	The suppression of p70S6 K by rapamycin did not influence cyclin D1 expression in PDGF-stimulated cells.	Sirolimus	30-39	ribosomal protein S6 kinase B1	Rattus norvegicus	19-26
16914544-0	2006	Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin.	Sirolimus	94-103	matrix metallopeptidase 1	Homo sapiens	27-32
16914544-7	2006	Conversely, the JNK inhibitor SP600125 inhibited rapamycin-induced MMP-1 gene transactivation and AP-1/DNA interactions.	Sirolimus	49-58	matrix metallopeptidase 1	Homo sapiens	67-72
16923813-2	2006	In budding yeast, Tor1p and Tor2p function as part of two distinct protein complexes, TORC1 and TORC2, where TORC1 is specifically inhibited by the antibiotic rapamycin.	Sirolimus	159-168	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	28-33
16702957-0	2006	Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling.	Sirolimus	76-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
16845661-3	2006	The mTOR inhibitor, rapamycin (sirolimus), reduces disease severity in rodent models of TSC, and is currently in phase II clinical trials.	Sirolimus	20-29	mechanistic target of rapamycin kinase	Mus musculus	4-8
16845661-3	2006	The mTOR inhibitor, rapamycin (sirolimus), reduces disease severity in rodent models of TSC, and is currently in phase II clinical trials.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Mus musculus	4-8
16864574-2	2006	In cells using ammonium or glutamine, the GATA transcription factor Gln3 is sequestered in the cytoplasm by Ure2 whereas it enters the nucleus after a shift to a nonpreferred nitrogen source like proline or upon addition of rapamycin, the TOR complex inhibitor.	Sirolimus	224-233	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	68-72
16874307-1	2006	In Saccharomyces cerevisiae, the Tap42-phosphatase complexes are major targets of the Tor kinases in the rapamycin-sensitive signaling pathway.	Sirolimus	105-114	Tap42p	Saccharomyces cerevisiae S288C	33-38
16899564-8	2006	PRL-induced phosphorylation of p70S6K and 4E-BP1 was inhibited by rapamycin, but not by okadaic acid (inhibitor of protein phosphatase, PP2A).	Sirolimus	66-75	ribosomal protein S6 kinase B1	Homo sapiens	31-48
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	37-46	interleukin 23 subunit alpha	Homo sapiens	172-177
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	37-46	interleukin 23 subunit alpha	Homo sapiens	192-197
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	37-46	interleukin 23 subunit alpha	Homo sapiens	192-197
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	ribosomal protein S6 kinase A1	Homo sapiens	61-82
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	ribosomal protein S6 kinase B1	Homo sapiens	84-88
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	interleukin 23 subunit alpha	Homo sapiens	172-177
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	interleukin 23 subunit alpha	Homo sapiens	192-197
16819968-4	2006	Blockade of the mammalian targets of rapamycin (mTOR)/70 kDa ribosomal S6 kinase 1 (S6K1) pathway by the specific inhibitor rapamycin greatly enhanced M. tbc-induced IL-12/IL-23 p40 (p40) and IL-23 p19 (p19) mRNA and IL-23 protein expression.	Sirolimus	124-133	interleukin 23 subunit alpha	Homo sapiens	192-197
16781309-5	2006	Epidermal growth factor inhibition by sirolimus is a plausible explanation for this acne.	Sirolimus	38-47	epidermal growth factor	Homo sapiens	0-23
16613881-5	2006	The camostat-induced increases in protein synthesis and 4E-BP1 and S6 phosphorylation were almost totally abolished by administration of the mTOR inhibitor rapamycin 1 h prior to camostat feeding.	Sirolimus	156-165	mechanistic target of rapamycin kinase	Mus musculus	141-145
16185698-6	2006	After 12 h incubation, rapamycin (0.001-10 microg/ml) induced IkappaB-alpha protein in niSMC, whereas in mSMC it stimulated IkappaB-alpha at much lower levels.	Sirolimus	23-32	NFKB inhibitor alpha	Rattus norvegicus	62-75
16185698-6	2006	After 12 h incubation, rapamycin (0.001-10 microg/ml) induced IkappaB-alpha protein in niSMC, whereas in mSMC it stimulated IkappaB-alpha at much lower levels.	Sirolimus	23-32	NFKB inhibitor alpha	Rattus norvegicus	124-137
16598206-8	2006	These effects were mostly mediated by mTOR as they were inhibited by rapamycin.	Sirolimus	69-78	mechanistic target of rapamycin kinase	Mus musculus	38-42
16539626-0	2006	Rapamycin attenuates liver graft injury in cirrhotic recipient--the significance of down-regulation of Rho-ROCK-VEGF pathway.	Sirolimus	0-9	vascular endothelial growth factor A	Rattus norvegicus	112-116
16539626-10	2006	In conclusion, rapamycin attenuated graft injury in a cirrhotic rat liver transplantation model by suppression of hepatic stellate cell activation, related to down-regulation of Rho-ROCK-VEGF pathway.	Sirolimus	15-24	vascular endothelial growth factor A	Rattus norvegicus	187-191
16497721-3	2006	We previously showed that rapamycin protects against mutant huntingtin-induced neurodegeneration in cell, fly and mouse models of Huntington"s disease [Ravikumar, B., Duden, R. and Rubinsztein, D.C. (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy.	Sirolimus	26-35	huntingtin	Drosophila melanogaster	60-70
16282343-3	2006	We show that phosphorylation of mTOR, p70S6K1, and 4E-BP1 was diminished in thrombopoietin-cultured human MKs after rapamycin treatment.	Sirolimus	116-125	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	51-57
16282343-4	2006	Rapamycin induced an inhibition in the G1/S transition and a decrease in the mean MK ploidy via a diminution of p21 and cyclin D3 occurring at a transcriptional level.	Sirolimus	0-9	H3 histone pseudogene 16	Homo sapiens	112-115
16364254-0	2006	Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	14-18
16364254-3	2006	Therefore, we examined the effect of mTOR signaling on diabetic renal hypertrophy by using the specific inhibitor for mTOR, rapamycin.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Mus musculus	118-122
16210336-6	2006	However, in contrast to CsA, rapamycin preserved the dominance of the potent CD27+ T(REG) subset over the CD27- T(REG) subset after alloantigen-driven expansion of CD4+ CD25+ T(REG)s in vitro.	Sirolimus	29-38	CD27 molecule	Homo sapiens	77-81
16210336-9	2006	This differential effect of rapamycin and CsA on the CD27+ T(REG) subset dominance may favor the use of rapamycin in tolerance-inducing strategies.	Sirolimus	28-37	CD27 molecule	Homo sapiens	53-57
16452206-4	2006	We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001.	Sirolimus	224-233	insulin receptor substrate 1	Homo sapiens	41-69
16424043-4	2006	Experiments using a novel cyclin D1-Cdk2 fusion protein or a kinase-dead mutant of the fusion protein indicated that reversal of rapamycin action required not only the formation of complexes with p21 and PCNA but also complex-associated kinase activity.	Sirolimus	129-138	proliferating cell nuclear antigen	Homo sapiens	26-32
16424043-4	2006	Experiments using a novel cyclin D1-Cdk2 fusion protein or a kinase-dead mutant of the fusion protein indicated that reversal of rapamycin action required not only the formation of complexes with p21 and PCNA but also complex-associated kinase activity.	Sirolimus	129-138	proliferating cell nuclear antigen	Homo sapiens	204-208
16139919-5	2005	In addition, TGF-beta1-induced ADAM12 up-regulation was blocked by the Frap/mTOR inhibitor rapamycin, which abrogated the phosphorylation of p70S6K.	Sirolimus	91-100	ribosomal protein S6 kinase B1	Homo sapiens	141-147
16255777-12	2005	As expected, rapamycin inhibited the phosphorylation of mTOR substrates, p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf activity.	Sirolimus	13-22	ribosomal protein S6 kinase B1	Homo sapiens	73-89
16242075-7	2005	Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E).	Sirolimus	39-48	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	148-153
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	Sirolimus	170-179	insulin receptor substrate 1	Homo sapiens	74-79
16172265-10	2005	FK-506 antagonized the effect of rapamycin on thrombin-induced TF expression.	Sirolimus	33-42	coagulation factor III, tissue factor	Homo sapiens	63-65
16172265-13	2005	CONCLUSIONS: Rapamycin, but not FK-506, enhances TF expression in HAECs but not in HAVSMCs.	Sirolimus	13-22	coagulation factor III, tissue factor	Homo sapiens	49-51
16014032-10	2005	We also found that LY294002 and rapamycin blocked Gas6-induced activation of the Akt/mTOR pathway and mesangial hypertrophy.	Sirolimus	32-41	growth arrest specific 6	Mus musculus	50-54
16014032-10	2005	We also found that LY294002 and rapamycin blocked Gas6-induced activation of the Akt/mTOR pathway and mesangial hypertrophy.	Sirolimus	32-41	mechanistic target of rapamycin kinase	Mus musculus	85-89
15763431-10	2005	Stx1 also induced hyperphosphorylation of 4E-BP1 and phosphorylation of S6Kinase; both effects were blocked by rapamycin.	Sirolimus	111-120	syntaxin 1A	Homo sapiens	0-4
15763431-10	2005	Stx1 also induced hyperphosphorylation of 4E-BP1 and phosphorylation of S6Kinase; both effects were blocked by rapamycin.	Sirolimus	111-120	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	42-48
16113783-0	2005	Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells.	Sirolimus	42-51	coagulation factor III, tissue factor	Homo sapiens	14-27
16113783-4	2005	The aim of this study was to determine the effect of an immunosuppressant macrolide, rapamycin (Sirolimus), on the expression of TF and its inhibitor (TFPI) by monocytic cells (human blood mononuclear and THP-1 cells) and human aortic smooth muscle cells, in comparison with FK-506 and azithromycin.	Sirolimus	85-94	coagulation factor III, tissue factor	Homo sapiens	129-131
16113783-4	2005	The aim of this study was to determine the effect of an immunosuppressant macrolide, rapamycin (Sirolimus), on the expression of TF and its inhibitor (TFPI) by monocytic cells (human blood mononuclear and THP-1 cells) and human aortic smooth muscle cells, in comparison with FK-506 and azithromycin.	Sirolimus	96-105	coagulation factor III, tissue factor	Homo sapiens	129-131
16113783-5	2005	In monocytic cells, rapamycin and FK-506 inhibited LPS-induced TF activity, antigen and mRNA expression through a transcriptional mechanism involving NF-kappaB.	Sirolimus	20-29	coagulation factor III, tissue factor	Homo sapiens	63-65
15671443-0	2005	Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.	Sirolimus	0-9	coagulation factor III, tissue factor	Homo sapiens	48-61
15671443-6	2005	In human umbilical vein endothelial cells vascular endothelial growth factor (VEGF)-induced tissue factor expression was strongly enhanced by rapamycin.	Sirolimus	142-151	coagulation factor III, tissue factor	Homo sapiens	92-105
15914125-10	2005	Significantly, rapamycin completely inhibited the phosphorylation of p70(S6K), an mTOR-regulated kinase implicated in the control of proliferation, but had no effect on collagen or total protein synthesis.	Sirolimus	15-24	ribosomal protein S6 kinase B1	Homo sapiens	73-76
15827164-3	2005	We show that mTOR is activated by expression of LMP2A in carcinoma cells, leading to wortmannin- and rapamycin-sensitive inhibition of the negative regulator of translation, eukaryotic initiation factor 4E-binding protein 1, and increased c-Myc protein translation.	Sirolimus	101-110	LMP2A	Human gammaherpesvirus 4	48-53
15827164-3	2005	We show that mTOR is activated by expression of LMP2A in carcinoma cells, leading to wortmannin- and rapamycin-sensitive inhibition of the negative regulator of translation, eukaryotic initiation factor 4E-binding protein 1, and increased c-Myc protein translation.	Sirolimus	101-110	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	239-244
15919492-1	2005	Because of its antiproliferative properties and its known effects on plasma lipids, we evaluated the mechanisms underlying the effect of rapamycin (RPM) on endothelial nitric oxide synthase (eNOS) and matrix metalloproteinases in Apo-E knockout mice.	Sirolimus	137-146	nitric oxide synthase 3, endothelial cell	Mus musculus	156-189
15919492-1	2005	Because of its antiproliferative properties and its known effects on plasma lipids, we evaluated the mechanisms underlying the effect of rapamycin (RPM) on endothelial nitric oxide synthase (eNOS) and matrix metalloproteinases in Apo-E knockout mice.	Sirolimus	148-151	nitric oxide synthase 3, endothelial cell	Mus musculus	156-189
15919492-10	2005	RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression.	Sirolimus	0-3	tissue inhibitor of metalloproteinase 3	Mus musculus	158-164
15833867-0	2005	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.	Sirolimus	28-37	protein tyrosine kinase 2 beta	Homo sapiens	115-131
15689491-4	2005	In this study, we investigate the mechanism underling rapamycin resistance associated with inactivation of PTPA in yeast.	Sirolimus	54-63	protein phosphatase 2 phosphatase activator	Homo sapiens	107-111
15783192-7	2005	The F36M substitution was reported to effect a homodimerization of the usually monomeric FKBP12 protein; however, addition of the small molecule ligand, rapamycin, or synthetic derivatives thereof leads to a dissociation of the dimer.	Sirolimus	153-162	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	89-95
15634685-0	2005	Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.	Sirolimus	123-132	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	14-19
15634685-6	2005	Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity.	Sirolimus	94-103	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Rattus norvegicus	19-23
15604215-11	2005	In vitro studies with rapamycin suggest that mTOR/S6K1 overactivation contributes to elevated serine phosphorylation of IRS-1, leading to impaired insulin signaling to Akt in liver and muscle of this dietary model of obesity.	Sirolimus	22-31	ribosomal protein S6 kinase B1	Rattus norvegicus	50-54
15625701-6	2005	In contrast, inhibition of MEK/ERK signaling with U0126 or of mTOR with rapamycin had no detectable effect on ES cell survival.	Sirolimus	72-81	mechanistic target of rapamycin kinase	Mus musculus	62-66
16895664-6	2005	The last developed immunosuppressant mTOR inhibitors, sirolimus and everolimus, effectively control the proliferation of various tumor cell lines, promote tumor cell apoptosis and inhibit metastatic tumor growth and angiogenesis in in vivo mouse models by affecting VEGF production and effect.	Sirolimus	54-63	mechanistic target of rapamycin kinase	Mus musculus	37-41
15671269-12	2005	Among the angiogenic factors, gene expression of substance P and hypoxia inducible factor (HIF)-1 alpha was inhibited by rapamycin earlier (1-3 days), with vascular endothelial growth factor (VEGFR)-1 gene expression being suppressed for the first 7 days in the corneal tissue.	Sirolimus	121-130	tachykinin 1	Mus musculus	49-60
15671269-12	2005	Among the angiogenic factors, gene expression of substance P and hypoxia inducible factor (HIF)-1 alpha was inhibited by rapamycin earlier (1-3 days), with vascular endothelial growth factor (VEGFR)-1 gene expression being suppressed for the first 7 days in the corneal tissue.	Sirolimus	121-130	hypoxia inducible factor 1, alpha subunit	Mus musculus	65-103
15671269-13	2005	The protein level of substance P and vascular endothelial growth factor (VEGF) was significantly decreased--more in mice treated with rapamycin than the control mice--as shown by ELISA assay of peripheral blood.	Sirolimus	134-143	tachykinin 1	Mus musculus	21-32
15537654-6	2005	In adenoviral-infected beta-cells expressing mTORDelta, the decrease in IRS-2 protein levels was also prevented by rapamycin or lactacystin, further indicating a proteasomal mediated degradation of IRS-2 mediated via mTOR-induced Ser/Thr phosphorylation of IRS-2.	Sirolimus	115-124	insulin receptor substrate 2	Homo sapiens	72-77
15537654-6	2005	In adenoviral-infected beta-cells expressing mTORDelta, the decrease in IRS-2 protein levels was also prevented by rapamycin or lactacystin, further indicating a proteasomal mediated degradation of IRS-2 mediated via mTOR-induced Ser/Thr phosphorylation of IRS-2.	Sirolimus	115-124	insulin receptor substrate 2	Homo sapiens	198-203
15537654-6	2005	In adenoviral-infected beta-cells expressing mTORDelta, the decrease in IRS-2 protein levels was also prevented by rapamycin or lactacystin, further indicating a proteasomal mediated degradation of IRS-2 mediated via mTOR-induced Ser/Thr phosphorylation of IRS-2.	Sirolimus	115-124	insulin receptor substrate 2	Homo sapiens	198-203
15585311-6	2005	We found that the number of CD8+ T(EM), as defined by CD3+CD45R0+CD8+CD27- phenotype, was significantly reduced in patients receiving a rapamycin-eluting stent as compared with basal values.	Sirolimus	136-145	CD27 molecule	Homo sapiens	69-73
15663199-8	2004	In addition, expression of Gal-1 involves interleukin (IL)-2-dependent signaling routes triggered by p70S6 kinase, as it could be inhibited by rapamycin.	Sirolimus	143-152	galectin 1	Homo sapiens	27-32
15686734-0	2004	Sirolimus upregulates aP2 expression in human monocytes and macrophages.	Sirolimus	0-9	fatty acid binding protein 4	Homo sapiens	22-25
15686734-5	2004	We found that aP2 messenger RNA (mRNA) was increased in human THP-1 cells after rapamycin treatment.	Sirolimus	80-89	fatty acid binding protein 4	Homo sapiens	14-17
15686734-6	2004	Exposure of human differentiated THP-1 cells to rapamycin led to a time- and dose-dependent induction of aP2 mRNA expression.	Sirolimus	48-57	fatty acid binding protein 4	Homo sapiens	105-108
15686734-7	2004	While aP2 expression was undetectable in undifferentiated THP-1 cells, aP2 was induced in these cells by rapamycin.	Sirolimus	105-114	fatty acid binding protein 4	Homo sapiens	71-74
15369799-4	2004	Rapamycin also induces PCNA translocation from the cytoplasm to the nucleus, an effect which is antagonized by okadaic acid, an inhibitor of type 2A protein phosphatases.	Sirolimus	0-9	proliferating cell nuclear antigen	Homo sapiens	23-27
15517874-6	2004	Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2.	Sirolimus	0-9	thymoma viral proto-oncogene 2	Mus musculus	231-235
15341530-8	2004	Serotonin application decreased eukaryotic elongation factor 2 phosphorylation in synaptosomes and in isolated neurites, and this was blocked by rapamycin.	Sirolimus	145-154	eukaryotic translation elongation factor 2	Homo sapiens	43-62
15210777-6	2004	However, blockade or genetic absence of CD28/CD154 costimulatory molecules rendered CD4(+) T cell-mediated rejection sensitive to rapamycin, and long term skin allograft survival can be readily induced by rapamycin in the absence of CD28/CD154 signals (&gt;100 days).	Sirolimus	130-139	CD28 antigen	Mus musculus	40-44
15210777-6	2004	However, blockade or genetic absence of CD28/CD154 costimulatory molecules rendered CD4(+) T cell-mediated rejection sensitive to rapamycin, and long term skin allograft survival can be readily induced by rapamycin in the absence of CD28/CD154 signals (&gt;100 days).	Sirolimus	130-139	CD40 ligand	Mus musculus	45-50
15210777-8	2004	We conclude that CD4(+) and CD8(+) T cells exhibit distinct sensitivity to growth factor blockade in transplant rejection, and CD28/CD154-independent rejection is sensitive to rapamycin and appears to be supported by OX40 costimulation.	Sirolimus	176-185	CD28 antigen	Mus musculus	127-131
15210777-8	2004	We conclude that CD4(+) and CD8(+) T cells exhibit distinct sensitivity to growth factor blockade in transplant rejection, and CD28/CD154-independent rejection is sensitive to rapamycin and appears to be supported by OX40 costimulation.	Sirolimus	176-185	CD40 ligand	Mus musculus	132-137
15184287-0	2004	Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.	Sirolimus	34-43	mechanistic target of rapamycin kinase	Mus musculus	14-18
15146184-5	2004	This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.	Sirolimus	77-86	huntingtin	Mus musculus	98-108
14990989-3	2004	Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR.	Sirolimus	154-163	ribosomal protein S6 kinase B1	Rattus norvegicus	42-48
14610086-6	2004	In isolated rat hepatocytes, both regulatory amino acids (RegAA) and insulin coordinately activated p70(S6k) phosphorylation, which was completely blocked by rapamycin, an mTOR inhibitor.	Sirolimus	158-167	ribosomal protein S6 kinase B1	Rattus norvegicus	104-107
15220530-6	2004	Loss of Cdh1 induces unscheduled accumulation of mitotic cyclins in G1, resulting in abrogation of G1 arrest caused by treatment with rapamycin, an inducer of p27Kip1.	Sirolimus	134-143	Cdh1p	Saccharomyces cerevisiae S288C	8-12
14625550-9	2003	High ABI in all cell lines was suppressed by mTOR inhibitors LY294002 and rapamycin.	Sirolimus	74-83	mechanistic target of rapamycin kinase	Mus musculus	45-49
14530907-7	2003	Additional inhibitors of phalloidin uptake mediated by SLC21A6 included the immunosuppressive drugs cyclosporin A, FK506, and rapamycin, whereas alpha-amanitin was only a weak inhibitor.	Sirolimus	126-135	solute carrier organic anion transporter family member 1B1	Homo sapiens	55-62
14561707-3	2003	Tsc2(-/-)TP53(-/-) cells, as well as tumors from Tsc2(+/-) mice, display an mTOR-activation signature with constitutive activation of S6K, which is reverted by treatment with rapamycin.	Sirolimus	175-184	TSC complex subunit 2	Mus musculus	0-4
14561707-3	2003	Tsc2(-/-)TP53(-/-) cells, as well as tumors from Tsc2(+/-) mice, display an mTOR-activation signature with constitutive activation of S6K, which is reverted by treatment with rapamycin.	Sirolimus	175-184	transformation related protein 53	Mus musculus	9-13
14561707-3	2003	Tsc2(-/-)TP53(-/-) cells, as well as tumors from Tsc2(+/-) mice, display an mTOR-activation signature with constitutive activation of S6K, which is reverted by treatment with rapamycin.	Sirolimus	175-184	mechanistic target of rapamycin kinase	Mus musculus	76-80
14561707-4	2003	Rapamycin also reverts a growth advantage of Tsc2(-/-)TP53(-/-) cells.	Sirolimus	0-9	TSC complex subunit 2	Mus musculus	45-49
14561707-4	2003	Rapamycin also reverts a growth advantage of Tsc2(-/-)TP53(-/-) cells.	Sirolimus	0-9	transformation related protein 53	Mus musculus	54-58
12967629-12	2003	Western blot analysis showed that wortmannin, at a dose of 0.6 mg/kg, and rapamycin, at a dose of 0.25 mg/kg, were sufficient to prevent phosphorylation of Akt and p70S6K, respectively, when the inhibitors were given prior to IPC.	Sirolimus	74-83	ribosomal protein S6 kinase beta-1	Oryctolagus cuniculus	164-170
12925703-6	2003	In contrast, a transcriptionally inactive mutant Foxo1 partially rescues inhibition of C2C12 differentiation mediated by wortmannin, but not by rapamycin, and is able to induce aggregation-independent myogenic conversion of teratocarcinoma cells.	Sirolimus	144-153	forkhead box O1	Mus musculus	49-54
12914928-4	2003	However, we recently found that the regulation of the IGFBP1 but not the PEPCK or G6Pase genes by insulin was sensitive to rapamycin, an inhibitor of mTOR.	Sirolimus	123-132	insulin like growth factor binding protein 1	Homo sapiens	54-60
12829920-7	2003	CONCLUSIONS: Sirolimus can be successfully combined with humanized mAb against CD80 and CD86.	Sirolimus	13-22	T-lymphocyte activation antigen CD80	Macaca fascicularis	79-83
12668683-8	2003	Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	43-47
12519199-0	2003	The product of the UTH1 gene, required for Bax-induced cell death in yeast, is involved in the response to rapamycin.	Sirolimus	107-116	SUN family protein UTH1	Saccharomyces cerevisiae S288C	19-23
12519199-6	2003	The absence of Uth1p was also found to induce resistance to rapamycin, a specific inducer of autophagy.	Sirolimus	60-69	SUN family protein UTH1	Saccharomyces cerevisiae S288C	15-20
12409674-7	2002	In contrast, rapamycin acted synergistically with anti-CD154 therapy in promoting long-term allograft survival.	Sirolimus	13-22	CD40 ligand	Mus musculus	55-60
12414688-6	2002	This effect was similar to those of FK506 and rapamycin, two drugs known to cause dissociation of FKBP12 from RyR.	Sirolimus	46-55	FK506 binding protein 1a	Mus musculus	98-104
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	ribosomal protein S6 kinase B1	Homo sapiens	148-154
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	ribosomal protein S6 kinase B1	Homo sapiens	251-257
12433206-3	2002	Rapamycin treatment induced a significant dephosphorylation and inactivation of p70S6k in all cancer cell lines, while wortmannin, a specific inhibitor of PI3-K, caused a mild dephosphorylation of p70S6k in AGS, MDA-MB-435S and MB-157.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	80-86
12433206-5	2002	Consistent with inhibitory effect of rapamycin on p70S6k activity, rapamycin inhibited [3H]-thymidine incorporation and increased the number of cells at G0/G1 phase.	Sirolimus	37-46	ribosomal protein S6 kinase B1	Homo sapiens	50-56
12192598-8	2002	Blockade of p70 S6K activation by rapamycin abrogated the IGF-II-mediated protection of cells to cisplatin-induced apoptosis.	Sirolimus	34-43	insulin-like growth factor 2	Mus musculus	58-64
12192598-9	2002	Furthermore, treatment of IGF-II-overexpressing Rh30 and CTR rhabdomyosarcoma cells with rapamycin restored sensitivity to cisplatin-induced apoptosis.	Sirolimus	89-98	insulin-like growth factor 2	Mus musculus	26-32
11923302-7	2002	(iii) In some instances, we can dissociate rapamycin-induced CIT2 expression from Mks1p function, i.e. rapamycin does not suppress Mks1p-mediated down-regulation of CIT2 expression.	Sirolimus	43-52	citrate (Si)-synthase CIT2	Saccharomyces cerevisiae S288C	61-65
12065239-10	2002	The immunosuppressant drug rapamycin inhibited proliferation of Nb2 cells in response to PRL or interleukin-2, but had no effect on Nb2-Sp cells.	Sirolimus	27-36	interleukin 2	Rattus norvegicus	96-109
12032184-2	2002	The aim of this study was to investigate in vitro the possible interaction of tacrolimus and sirolimus with motilin receptors in the rabbit antrum and duodenum.	Sirolimus	93-102	promotilin	Oryctolagus cuniculus	108-115
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Sirolimus	190-199	ribosomal protein S6 kinase B1	Homo sapiens	88-92
11914378-5	2002	Here we use phosphospecific antibodies to show that Thr(229) is fully phosphorylated in S6K1-E389D(3)E in the absence of mitogens and that regulation of S6K1-E389D(3)E activity by mitogens, rapamycin, or wortmannin parallels Ser(371) phosphorylation.	Sirolimus	190-199	ribosomal protein S6 kinase B1	Homo sapiens	153-157
12032842-8	2002	A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis.	Sirolimus	59-68	ribosomal protein S6 kinase B1	Homo sapiens	20-26
12051762-5	2002	Rapamycin prevented the reduction of IRS-1 protein levels and insulin-induced PKB Ser-473 phosphorylation with a partial normalization of insulin-induced glucose transport.	Sirolimus	0-9	insulin receptor substrate 1	Homo sapiens	37-42
11872747-7	2002	In contrast, IL-6-induced phosphorylation of 4E-BP1 was inhibited by rapamycin, wortmannin, and dominant negative AKT but ERK inhibitors had no effect, indicating ERK function was dispensable.	Sirolimus	69-78	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	45-51
11799119-5	2002	The TPA-stimulated phosphorylation of all these sites is sensitive to inhibitors of MEK and to the inhibitor of mTOR, rapamycin, indicating that inputs from both mTOR and MEK are required for the regulation of 4E-BP1 phosphorylation by TPA.	Sirolimus	118-127	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	210-216
11872661-3	2002	We found that sirolimus and IL-2 therapy of female NOD mice, beginning at age 10 weeks, was synergistic in preventing diabetes development, and disease prevention continued for 13 weeks after stopping sirolimus and IL-2 therapy.	Sirolimus	14-23	interleukin 2	Mus musculus	215-219
11872661-3	2002	We found that sirolimus and IL-2 therapy of female NOD mice, beginning at age 10 weeks, was synergistic in preventing diabetes development, and disease prevention continued for 13 weeks after stopping sirolimus and IL-2 therapy.	Sirolimus	201-210	interleukin 2	Mus musculus	28-32
11890899-4	2002	Rapamycin, an immunosuppressant that binds to FKBP, antagonized the effect of FK506.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	46-50
11834720-9	2002	Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor).	Sirolimus	149-158	vascular endothelial growth factor A	Rattus norvegicus	58-62
11882580-8	2002	PDGF-stimulated PC5 induction was inhibited by the PI3-kinase inhibitor wortmannin, and by rapamycin, an inhibitor of mTOR/p70(s6)-kinase (both P&lt;0.05).	Sirolimus	91-100	ribosomal protein S6 kinase B1	Rattus norvegicus	123-137
12362981-4	2002	The induction of leukemia cell differentiation in response to the analogs of vitamin D was inhibited by LY294002 (phosphatidylinositol 3-kinase inhibitor), PD98059 (inhibitor of MEK1,2, an upstream regulator of extracellular-signal regulated kinase) and rapamycin (p70S6K inhibitor) pointing out that activation of signal transduction pathways unrelated to nVDR is necessary for differentiation.	Sirolimus	254-263	mitogen-activated protein kinase kinase 1	Homo sapiens	178-184
11948686-2	2002	Inhibition of mTOR with rapamycin resulted in approximately 50% inhibition of the insulin-induced degradation of IRS-1.	Sirolimus	24-33	insulin receptor substrate 1	Homo sapiens	113-118
11713209-8	2001	Rapamycin, an inhibitor of p70(S6K), a downstream effector of IRS-1 signaling, partially inhibits (but does not completely abrogate) the increase in Id2 gene expression.	Sirolimus	0-9	insulin receptor substrate 1	Mus musculus	62-67
11739559-5	2001	IL-8 expression was attenuated more by the Src kinase inhibitor PP1 than by the p70s6k inhibitor rapamycin.	Sirolimus	97-106	ribosomal protein S6 kinase B1	Homo sapiens	80-86
11739804-4	2001	Overexpression of Tap42, a protein phosphatase regulatory subunit, restored pseudohyphal growth in cells exposed to rapamycin.	Sirolimus	116-125	Tap42p	Saccharomyces cerevisiae S288C	18-23
11739804-5	2001	The tap42-11 mutation compromised pseudohyphal differentiation and rendered it resistant to rapamycin.	Sirolimus	92-101	Tap42p	Saccharomyces cerevisiae S288C	4-9
11739804-6	2001	Cells lacking the Tap42-regulated protein phosphatase Sit4 exhibited a pseudohyphal growth defect and were markedly hypersensitive to rapamycin.	Sirolimus	134-143	Tap42p	Saccharomyces cerevisiae S288C	18-23
11739804-6	2001	Cells lacking the Tap42-regulated protein phosphatase Sit4 exhibited a pseudohyphal growth defect and were markedly hypersensitive to rapamycin.	Sirolimus	134-143	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	54-58
11792123-5	2001	The utilization of the inhibitors, wortmannin and LY294002, demonstrated a role for phosphatidylinositol 3-kinase (PI3K) whereas rapamycin demonstrated p70 S6-kinase (p70S6K) involvement in the production of IL-10 by these monocytes.	Sirolimus	129-138	ribosomal protein S6 kinase B1	Homo sapiens	152-165
11709727-4	2001	Wortmannin, LY294002, and rapamycin at concentrations that did not affect MAPK phosphorylation but substantially inhibited PI3K, Akt, and p70(S6K) significantly suppressed the soft agar growth of tumor cell lines that overexpress ErbB2 but not the growth of tumor lines with low ErbB2 expression.	Sirolimus	26-35	ribosomal protein S6 kinase B1	Homo sapiens	138-141
11402043-4	2001	Similarly, TNF significantly up-regulated PAI-1 synthesis when p70(S6K) phosphorylation was inhibited by rapamycin.	Sirolimus	105-114	serpin family E member 1	Homo sapiens	42-47
11402043-4	2001	Similarly, TNF significantly up-regulated PAI-1 synthesis when p70(S6K) phosphorylation was inhibited by rapamycin.	Sirolimus	105-114	ribosomal protein S6 kinase B1	Homo sapiens	63-66
11493700-4	2001	Rapamycin inhibited mitochondrial-based p70S6K, which prevented phosphorylation of Ser-136 on BAD and blocked cell survival induced by insulin-like growth factor 1 (IGF-1).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	40-46
11356843-4	2001	Rapamycin, a Tor protein inhibitor, like growth with a poor nitrogen source, promotes nuclear localization of Gln3p and Gat1p.	Sirolimus	0-9	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	110-115
11356843-5	2001	gln3 Delta and ure2 Delta mutants are partially resistant and hypersensitive to growth inhibition by rapamycin, respectively.	Sirolimus	101-110	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	0-4
11446769-8	2001	Furthermore, HGF and KGF increased the rate of corneal epithelial wound healing in an organ culture model, and wortmannin and rapamycin (the p70 S6K inhibitor) blocked corneal epithelial wound healing promoted by the growth factors.	Sirolimus	126-135	ribosomal protein S6 kinase B1	Homo sapiens	141-148
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	insulin receptor substrate 1	Homo sapiens	207-235
11438661-1	2001	A pathway sensitive to rapamycin, a selective inhibitor of mammalian target of rapamycin (mTOR), down-regulates effects of insulin such as activation of Akt (protein kinase B) via proteasomal degradation of insulin receptor substrate 1 (IRS-1).	Sirolimus	23-32	insulin receptor substrate 1	Homo sapiens	237-242
11438661-3	2001	After prolonged insulin stimulation, inhibition of the redistribution of IRS-1 by rapamycin resulted in increased levels of IRS-1 and the associated phosphatidylinositol (PI) 3-kinase in both the LDM and cytosol, whereas the proteasome inhibitor lactacystin increased the levels only in the cytosol.	Sirolimus	82-91	insulin receptor substrate 1	Homo sapiens	73-78
11438661-3	2001	After prolonged insulin stimulation, inhibition of the redistribution of IRS-1 by rapamycin resulted in increased levels of IRS-1 and the associated phosphatidylinositol (PI) 3-kinase in both the LDM and cytosol, whereas the proteasome inhibitor lactacystin increased the levels only in the cytosol.	Sirolimus	82-91	insulin receptor substrate 1	Homo sapiens	124-129
11369667-6	2001	A second type of CID, rapamycin, brings together one FKBP12 domain and one FRB domain, resulting in heterodimerization of the c-Kit(FKBP12) and Flt-3(FRB) fusions.	Sirolimus	22-31	FK506 binding protein 1a	Mus musculus	53-59
11369667-6	2001	A second type of CID, rapamycin, brings together one FKBP12 domain and one FRB domain, resulting in heterodimerization of the c-Kit(FKBP12) and Flt-3(FRB) fusions.	Sirolimus	22-31	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	126-131
11369667-6	2001	A second type of CID, rapamycin, brings together one FKBP12 domain and one FRB domain, resulting in heterodimerization of the c-Kit(FKBP12) and Flt-3(FRB) fusions.	Sirolimus	22-31	FK506 binding protein 1a	Mus musculus	132-138
11369667-7	2001	Ba/F3 cell growth was promoted not only by FK1012- or AP1510-induced homodimerization of the c-Kit(FKBP12) fusion (as reported previously), but also by rapamycin-induced c-Kit(FKBP12)-Flt-3(FRB) heterodimerization.	Sirolimus	152-161	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	170-175
11369667-7	2001	Ba/F3 cell growth was promoted not only by FK1012- or AP1510-induced homodimerization of the c-Kit(FKBP12) fusion (as reported previously), but also by rapamycin-induced c-Kit(FKBP12)-Flt-3(FRB) heterodimerization.	Sirolimus	152-161	FK506 binding protein 1a	Mus musculus	176-182
11096087-4	2001	When cells are starved from nitrogen nutrients or treated with rapamycin, however, Gln3p becomes translocated into the nucleus, thereby activating the expression of genes involved in nitrogen utilization and transport.	Sirolimus	63-72	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	83-88
11096087-8	2001	The expression of APG14 is dependent on Gln3p; deletion of Gln3p severely reduced its induction by rapamycin, whereas depletion of Ure2p caused its constitutive expression.	Sirolimus	99-108	nitrogen-responsive transcriptional regulator GLN3	Saccharomyces cerevisiae S288C	59-64
11222720-5	2001	RPMS interaction with CBF1 was demonstrated in a glutathione S-transferase (GST) affinity assay and by the ability of RPMS to alter the intracellular localization of a mutant CBF1.	Sirolimus	0-4	glutathione S-transferase kappa 1	Homo sapiens	76-79
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	187-193
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	ribosomal protein S6 kinase B1	Homo sapiens	199-212
11272147-1	2001	Recent findings have demonstrated that the branched-chain amino acid leucine can activate the translational regulators, phosphorylated heat- and acid-stable protein regulated by insulin (PHAS-I) and p70 S6 kinase (p70S6k), in an insulin-independent and rapamycin-sensitive manner through mammalian target of rapamycin (mTOR), although the mechanism for this activation is undefined.	Sirolimus	253-262	ribosomal protein S6 kinase B1	Homo sapiens	214-220
11228094-6	2001	The protective effect of IGF-1 was also blocked by rapamycin (an inhibitor of p70 S6 kinase).	Sirolimus	51-60	insulin-like growth factor 1	Rattus norvegicus	25-30
11400101-1	2001	Rapamycin was used as a medium additive to slow the progression of CRL 1606 hybridomas through the cell cycle, under the hypothesis that such a modulation might reduce cell death.	Sirolimus	0-9	interleukin 31 receptor A	Homo sapiens	67-70
11400101-3	2001	Rapamycin, an mTOR signaling inhibitor, immunosuppressant, and G1-phase arresting agent, was identified and tested for efficacy in restraining cell cycle progression in CRL 1606 hybridoma cultures.	Sirolimus	0-9	interleukin 31 receptor A	Homo sapiens	169-172
11027279-6	2000	The results showing cell cycle arrest in G(1) phase and down-regulation of the Tat2 protein seem to be similar to those observed upon treatment of cells with the immunosuppressive drug rapamycin.	Sirolimus	185-194	aromatic amino acid transmembrane transporter TAT2	Saccharomyces cerevisiae S288C	79-83
11023817-5	2000	Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	188-194
11023817-5	2000	Rapamycin, the inhibitor of mammalian target of rapamycin ("mTOR"), but not PD98059, the inhibitor of extracellular signal-regulated protein kinases ("ERK1/2"), induced similar effects on 4E-BP1 phosphorylation to ischaemia; nevertheless, 4E-BP1-eIF4E complex levels were higher in ischaemia than in rapamycin-treated cells.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	239-245
10998178-3	2000	Here, we report the cloning and characterization of a novel gene, termed FAP1, which confers resistance to rapamycin by competing with the drug for binding to FKBP12.	Sirolimus	107-116	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	159-165
10846175-7	2000	A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells.	Sirolimus	198-207	insulin receptor substrate 1	Mus musculus	10-15
10846175-7	2000	A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells.	Sirolimus	198-207	insulin receptor substrate 1	Mus musculus	178-183
10846175-7	2000	A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells.	Sirolimus	198-207	insulin receptor substrate 1	Mus musculus	178-183
10849422-5	2000	We now demonstrate that SCF activates phosphoinositide 3-kinase (PI3-K) and p70 S6 kinase (p70S6K) and that rapamycin, a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K, completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia.	Sirolimus	108-117	ribosomal protein S6 kinase B1	Homo sapiens	179-185
10849422-9	2000	Constitutively active v-AKT highly phosphorylated p70S6K, which was totally inhibited by rapamycin.	Sirolimus	89-98	ribosomal protein S6 kinase B1	Homo sapiens	50-56
10847581-5	2000	Adenovirus-mediated expression of a membrane-targeted form of the p110 subunit of phosphatidylinositol (PI) 3-kinase (p110CAAX) induced a mobility shift and degradation of IRS-1, both of which were inhibited by rapamycin.	Sirolimus	211-220	insulin receptor substrate 1	Homo sapiens	172-177
10771484-3	2000	Here we show that late tumor necrosis factor alpha gene expression is sensitive to rapamycin, implicating FKBP12-rapamycin-associated protein, a member of the DNA protein kinase family, as a signal transducer of ultraviolet-induced DNA damage.	Sirolimus	83-92	FK506 binding protein 1a	Mus musculus	106-112
10771484-5	2000	Immuno- precipitated FKBP12-rapamycin-associated protein was stimulated by ultraviolet-irradiated DNA to phosphorylate p53 in vitro, and in vivo rapamycin reduced ultraviolet induction of p53 by 20%.	Sirolimus	28-37	FK506 binding protein 1a	Mus musculus	21-27
10771484-5	2000	Immuno- precipitated FKBP12-rapamycin-associated protein was stimulated by ultraviolet-irradiated DNA to phosphorylate p53 in vitro, and in vivo rapamycin reduced ultraviolet induction of p53 by 20%.	Sirolimus	28-37	transformation related protein 53, pseudogene	Mus musculus	119-122
10771484-5	2000	Immuno- precipitated FKBP12-rapamycin-associated protein was stimulated by ultraviolet-irradiated DNA to phosphorylate p53 in vitro, and in vivo rapamycin reduced ultraviolet induction of p53 by 20%.	Sirolimus	28-37	transformation related protein 53, pseudogene	Mus musculus	188-191
10771484-6	2000	Rapamycin further inhibited the ultraviolet-induced phosphorylation of the FKBP12-rapamycin-associated protein downstream target kinase p70S6K.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	75-81
10749120-4	2000	LY294002 and rapamycin also inhibit growth factor- and mitogen-induced secretion of vascular endothelial growth factor, the product of a known HIF-1 target gene, thus linking the PI3K/PTEN/AKT/FRAP pathway, HIF-1, and tumor angiogenesis.	Sirolimus	13-22	phosphatase and tensin homolog	Homo sapiens	184-188
10710358-7	2000	Both FK-506 and rapamycin are known to target the immunophilin FKBP12.	Sirolimus	16-25	FK506 binding protein 1a	Mus musculus	50-69
10732978-7	2000	The approach described here has yielded modified rapamycin analogues (RP2 and RP3) as targets for biosynthesis by modified polyketide synthases.	Sirolimus	49-58	microtubule associated protein RP/EB family member 3	Homo sapiens	78-81
10579338-3	1999	Both LY 294002 [a phosphatidylinositol 3-kinase (PI3-K) inhibitor], and rapamycin [a blocker of activation of the serine/threonine p70 S6 kinase (p70S6K), a molecule downstream from PI3-K] completely reversed the IGF-1-induced stimulation of DNA synthesis.	Sirolimus	72-81	ribosomal protein S6 kinase B1	Rattus norvegicus	131-144
10490623-10	1999	Using rapamycin-inducible heterodimerization we show that c-Cbl is unable to associate with ErbB1 in a ErbB1-ErbB2 heterodimer most likely because ErbB2 is unable to phosphorylate the c-Cbl binding site on ErbB1.	Sirolimus	6-15	Cbl proto-oncogene	Homo sapiens	58-63
10480882-6	1999	In accordance with its inhibitory action on protein synthesis, activation of cyclin D1 and p21 proteins by growth factors is also blocked by preincubation with rapamycin.	Sirolimus	160-169	H3 histone pseudogene 16	Homo sapiens	91-94
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Homo sapiens	16-23
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	141-150	ribosomal protein S6 kinase B1	Homo sapiens	16-23
10480882-7	1999	Expression of a p70 S6K mutant partially resistant to rapamycin reverses the inhibitory effect of the drug on DNA synthesis, indicating that rapamycin action is via p70 S6K.	Sirolimus	141-150	ribosomal protein S6 kinase B1	Homo sapiens	165-172
10490848-4	1999	Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K.	Sirolimus	162-171	ribosomal protein S6 kinase B1	Homo sapiens	244-250
10464317-6	1999	Incubation of macrophages with wortmannin, LY294002, PD98059, SB203580, rapamycin, or antibodies against insulin receptors before insulin treatment and alpha(2)M* stimulation significantly reduced the insulin-augmented increase in IP(3) and [Ca(2+)](i) levels.	Sirolimus	72-81	alpha-2-macroglobulin	Homo sapiens	152-161
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	75-78
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10455142-3	1999	Comparison of sorbitol and rapamycin revealed that both agents inactivated S6K and caused dephosphorylation of Ser/Thr-Pro sites in the COOH terminus of S6K, including Thr(412), a residue essential to S6K regulation, as determined by phospho-specific antibodies.	Sirolimus	27-36	ribosomal protein S6 kinase B1	Homo sapiens	153-156
10373522-2	1999	PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	43-50
10217658-14	1999	CONCLUSIONS: Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27(kip1) and inhibition of the pRb phosphorylation within the vessel wall.	Sirolimus	13-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	158-162
10029080-3	1999	Here, we report that rapamycin, a specific inhibitor of mTOR kinase, induces G1 cell cycle arrest and apoptosis in two rhabdomyosarcoma cell lines (Rh1 and Rh30) under conditions of autocrine cell growth.	Sirolimus	21-30	Rh blood group D antigen	Homo sapiens	156-160
10029080-9	1999	Rh1 and Rh30 mTOR-rr clones were highly resistant (&gt;3000-fold) to both growth inhibition and apoptosis induced by rapamycin.	Sirolimus	117-126	Rh blood group D antigen	Homo sapiens	8-12
10029080-12	1999	However, in rapamycin-treated cultures, the response to IGF-I differed between the cell lines: Rh1 cells proliferated normally, whereas Rh30 cells remained arrested in G1 phase but viable.	Sirolimus	12-21	Rh blood group D antigen	Homo sapiens	136-140
10029080-14	1999	To examine the rate at which the mTOR pathway recovered, the ability of IGF-I to stimulate p70S6K activity was followed in cells treated for 1 h with rapamycin and then allowed to recover in medium containing &gt; or =100-fold excess of FK506 (to prevent rapamycin from rebinding to its cytosolic receptor FKBP-12).	Sirolimus	150-159	ribosomal protein S6 kinase B1	Homo sapiens	91-97
9895282-8	1999	However, inhibition of p70S6 kinase (p70(s6k)) with rapamycin or of mitogen-activated protein kinase (MAPK) with PD098059 does not preclude insulin effects on GLUT4 gene expression or glucose uptake.	Sirolimus	52-61	ribosomal protein S6 kinase B1	Homo sapiens	37-44
9774438-9	1998	In exploring the signaling pathway responsible for these effects, we find that rapamycin (25 nM) inhibits the ability of branched-chain amino acids to stimulate the phosphorylation of PHAS-I and p70(s6) kinase, suggesting that the mammalian target of rapamycin signaling pathway is involved.	Sirolimus	79-88	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	184-190
9657754-4	1998	Rapamycin treatment disrupts the association of PP2Ac/alpha4 in parallel with the inhibitory effect of lymphoid cell proliferation.	Sirolimus	0-9	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	48-53
9657754-7	1998	Introduction of the malpha4 cDNA into Jurkat cells or the increased association of PP2Ac/alpha4 by the culture with low serum concentration confers cells with rapamycin resistance.	Sirolimus	159-168	protein phosphatase 2 catalytic subunit alpha	Homo sapiens	83-88
9545268-6	1998	Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo.	Sirolimus	19-28	epidermal growth factor	Homo sapiens	123-126
9545268-6	1998	Finally, FK506 and rapamycin, which are known to block the PPIase activity of FKBP12, induced a significant stimulation of EGF receptor autophosphorylation in intact A431 cells suggesting suppression of EGF receptor autophosphorylation by intracellular FKBP12 in vivo.	Sirolimus	19-28	epidermal growth factor	Homo sapiens	203-206
9545305-7	1998	LIF-induced p70 S6 kinase activation, protein synthesis, and c-fos mRNA expression were inhibited by wortmannin and rapamycin.	Sirolimus	116-125	LIF interleukin 6 family cytokine	Homo sapiens	0-3
9531494-4	1998	CPPD crystals induced a robust, transient activation (peak activity at 2 min) of p70(S6K) that was fully inhibited by pretreatment with rapamycin.	Sirolimus	136-145	ribosomal protein S6 kinase B1	Homo sapiens	85-88
9497382-4	1998	Insulin lowers IGFBP-1 mRNA levels, inhibits IGFBP-1 promoter activity, and activates PKB/Akt in HepG2 hepatoma cells through a PI3K-dependent, rapamycin-insensitive mechanism.	Sirolimus	144-153	insulin like growth factor binding protein 1	Homo sapiens	15-22
9490004-4	1998	IGF-1-stimulated protein synthesis was also significantly inhibited by PD-098059, staurosporine, and rapamycin, but not by wortmannin, in cardiac myocytes.	Sirolimus	101-110	insulin-like growth factor 1	Rattus norvegicus	0-5
9546621-6	1998	Rapamycin, a specific inhibitor of the p70s6k isoform of S6 kinase, partially reduced the activation of S6 kinase activity by sodium selenate, indicating a role for this kinase in the overall activity of the S6 kinase in sodium selenate-treated cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	39-45
9546621-6	1998	Rapamycin, a specific inhibitor of the p70s6k isoform of S6 kinase, partially reduced the activation of S6 kinase activity by sodium selenate, indicating a role for this kinase in the overall activity of the S6 kinase in sodium selenate-treated cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	57-66
9546621-6	1998	Rapamycin, a specific inhibitor of the p70s6k isoform of S6 kinase, partially reduced the activation of S6 kinase activity by sodium selenate, indicating a role for this kinase in the overall activity of the S6 kinase in sodium selenate-treated cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	104-113
9546621-6	1998	Rapamycin, a specific inhibitor of the p70s6k isoform of S6 kinase, partially reduced the activation of S6 kinase activity by sodium selenate, indicating a role for this kinase in the overall activity of the S6 kinase in sodium selenate-treated cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	104-113
9441740-0	1997	Expression and chromosomal localization of the human alpha 4/IGBP1 gene, the structure of which is closely related to the yeast TAP42 protein of the rapamycin-sensitive signal transduction pathway.	Sirolimus	149-158	Tap42p	Saccharomyces cerevisiae S288C	128-133
9334222-1	1997	The proteins eIF-4E BP1 and p70 S6 kinase each undergo an insulin/mitogen-stimulated phosphorylation in situ that is partially inhibited by rapamycin.	Sirolimus	140-149	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	13-23
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	115-121
9334222-2	1997	Previous work has established that the protein known as mTOR/RAFT-1/FRAP is the target through which the rapamycin.FKBP12 complex acts to dephosphorylate/deactivate the p70 S6 kinase; thus, some mTOR mutants that have lost the ability to bind to the rapamycin.FKBP12 complex in vitro can protect the p70 S6 kinase against rapamycin-induced dephosphorylation/deactivation in situ.	Sirolimus	105-114	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	260-266
9334222-3	1997	We show herein that such mTOR mutants also protect eIF-4E BP1 against rapamycin-induced dephosphorylation, and for both p70 S6 kinase and eIF-4E BP1, such protection requires that the rapamycin-resistant mTOR variant retains an active catalytic domain.	Sirolimus	70-79	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	51-61
21528277-0	1997	Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	80-86
21528277-0	1997	Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	88-94
21528277-0	1997	Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70(S6K)) in human astrocytoma cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	100-103
9326417-8	1997	CONCLUSION: These data suggest that CTLA4-Ig may be effective clinically in combination with cyclosporine or sirolimus but offers no additional effectiveness in combination with antilymphocyte serum with or without donor-specific bone marrow.	Sirolimus	109-118	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	36-41
9242178-4	1997	PE stimulated the activity of p70S6K &gt; 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	30-36
9242178-4	1997	PE stimulated the activity of p70S6K &gt; 3-fold, and this increase was blocked by rapamycin, an immunosuppressant macrolide that selectively inhibits p70S6K.	Sirolimus	83-92	ribosomal protein S6 kinase B1	Homo sapiens	151-157
9211946-3	1997	Although the immunosuppressant, rapamycin, was found to stabilize the association of eIF4E with its negative regulator, 4E-BP1, this drug did not prevent the early effects of serum stimulation on the overall rate of translation, polysome formation, the phosphorylation status of eIF4E, or the recruitment of eIF4E into the eIF4F complex.	Sirolimus	32-41	eukaryotic translation initiation factor 4E	Mus musculus	85-90
9211946-3	1997	Although the immunosuppressant, rapamycin, was found to stabilize the association of eIF4E with its negative regulator, 4E-BP1, this drug did not prevent the early effects of serum stimulation on the overall rate of translation, polysome formation, the phosphorylation status of eIF4E, or the recruitment of eIF4E into the eIF4F complex.	Sirolimus	32-41	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	120-126
9211946-5	1997	Activation of the JNK/SAPK signaling pathway with anisomycin resulted in enhanced phosphorylation of eIF4E, which was prevented by either rapamycin or the highly specific p38 MAP kinase inhibitor, SB203580.	Sirolimus	138-147	eukaryotic translation initiation factor 4E	Mus musculus	101-106
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	85-98
9202301-6	1997	GM1 treatment stimulated another distinct signaling pathway leading to activation of p70 S6 kinase (p70s6k), and this was prevented by pretreatment with rapamycin.	Sirolimus	153-162	ribosomal protein S6 kinase B1	Homo sapiens	100-106
9182578-11	1997	Finally, we established that the IL2-activated Stat5a/b serine kinase is insensitive to several selective inhibitors of known IL2-stimulated kinases including MEK1/MEK2 (PD98059), mTOR (rapamycin), and phosphatidylinositol 3-kinase (wortmannin) as determined by phosphoamino acid and DNA binding analysis, thus suggesting that a yet-to-be-identified serine kinase mediates Stat5a/b activation.	Sirolimus	186-195	signal transducer and activator of transcription 5A	Homo sapiens	47-53
9175775-9	1997	Rapamycin, a selective inhibitor of p70S6K, and the casein kinase II inhibitor DRB blocked insulin-stimulated nuclear and cytosolic p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	132-138
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Sirolimus	71-74	interferon gamma	Rattus norvegicus	113-122
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Sirolimus	71-74	interleukin 2	Rattus norvegicus	138-142
9097913-7	1997	However, heart allografts from rat recipients treated with synergistic SRL/CsA doses displayed reduced levels of IFN-gamma (P &lt; 0.01), IL-2 (P &lt; 0.001) and IL-10 (P &lt; 0.001) mRNA.	Sirolimus	71-74	interleukin 10	Rattus norvegicus	162-167
8995241-5	1997	The pp70 S6 kinase (pp70S6K) inhibitor rapamycin (10(-8) M) was, however, less effective in blocking IGF-1 action.	Sirolimus	39-48	insulin-like growth factor 1	Rattus norvegicus	101-106
8943224-4	1996	In addition, LY294002 and rapamycin, a specific p70(S6)-kinase inhibitor, were found to independently stimulate tyrosinase expression, thus increasing melanin synthesis.	Sirolimus	26-35	ubiquitin associated and SH3 domain containing, B	Mus musculus	48-62
8943224-4	1996	In addition, LY294002 and rapamycin, a specific p70(S6)-kinase inhibitor, were found to independently stimulate tyrosinase expression, thus increasing melanin synthesis.	Sirolimus	26-35	tyrosinase	Mus musculus	112-122
8752154-0	1996	Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	32-38
8752154-3	1996	Rapamycin inhibited growth of H 69, H 345, and H 510 cells in liquid culture at similar concentrations to those required for inducing dephosphorylation of p70s6k.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	155-161
8752914-3	1996	Here, we analyzed the mechanism of inactivation of p70s6k by rapamycin using site-directed mutagenesis of the phosphate acceptor site.	Sirolimus	61-70	ribosomal protein S6 kinase B1	Rattus norvegicus	51-57
8752914-9	1996	Further, the residual activity of T229E-p70s6k was not affected by rapamycin, implying that rapamycin-induced inactivation of p70s6k may be caused by dephosphorylation or impaired phosphorylation of Thr229.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Rattus norvegicus	40-46
8752914-9	1996	Further, the residual activity of T229E-p70s6k was not affected by rapamycin, implying that rapamycin-induced inactivation of p70s6k may be caused by dephosphorylation or impaired phosphorylation of Thr229.	Sirolimus	92-101	ribosomal protein S6 kinase B1	Rattus norvegicus	126-132
8662507-1	1996	Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP).	Sirolimus	0-9	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	92-98
8621477-6	1996	Rapamycin completely blocked the activation of p70s6k by both agents.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	47-53
8603539-8	1996	Rapamycin, a macrolide immunosuppressant, inhibited completely growth factor-induced synovial fibroblast proliferation and P70S6k activation.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Homo sapiens	123-129
8603539-10	1996	Our data demonstrate that growth factor-mediated P70S6k activation is closely related to the growth of synovial fibroblast, and suggest the efficacy of rapamycin for controlling synovial hyperplasia in RA.	Sirolimus	152-161	ribosomal protein S6 kinase B1	Homo sapiens	49-55
8929823-8	1996	In contrast the Jab flux of 14C-RAPA using either PEG/DMA-RAPA or ethanol/FBS-RAPA as vehicle was highest and reached a maximal rate by 120 min, in contrast to the polysorbate/Phosal PEG-RAPA vehicle, which was significantly lower.	Sirolimus	32-36	suppressor of cytokine signaling 1	Homo sapiens	16-19
8599949-0	1996	Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.	Sirolimus	0-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	40-46
8599949-6	1996	The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation.	Sirolimus	4-13	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	81-87
8599949-6	1996	The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation.	Sirolimus	4-13	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	184-190
8599949-6	1996	The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation.	Sirolimus	128-137	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	81-87
8599949-6	1996	The rapamycin-FK506 binding protein complex is the effector of the inhibition of 4E-BP1 phosphorylation as excess of FK506 over rapamycin reversed the rapamycin-mediated inhibition of 4E-BP1 phosphorylation.	Sirolimus	128-137	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	184-190
7586215-9	1995	Rapamycin inhibited Ang II-induced activation of p70S6K in a dose-dependent manner, with an IC50 of 0.14 ng/mL (0.15 nmol/L).	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	49-55
7586215-11	1995	In contrast, a dose-dependent inhibition of p70S6K by rapamycin is very closely correlated with its inhibition of the Ang II-induced increase in protein synthesis.	Sirolimus	54-63	ribosomal protein S6 kinase B1	Rattus norvegicus	44-50
8521476-6	1995	We now report that calcineurin is physiologically associated with the IP3R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin.	Sirolimus	171-180	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	75-81
8521476-6	1995	We now report that calcineurin is physiologically associated with the IP3R-FKBP12 and RyR-FKBP12 receptor complexes and that this interaction can be disrupted by FK506 or rapamycin.	Sirolimus	171-180	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	90-96
7487901-7	1995	Rapamycin also failed to have any appreciable effect on stimulation of these parameters by insulin, although it did block the effect of insulin on p70S6K.	Sirolimus	0-9	ribosomal protein S6 kinase B1	Rattus norvegicus	147-153
7566093-5	1995	Translational activation is prevented by rapamycin and mimicked by anisomycin, which suggests that translation of the 6.0-kb mRNA is regulated by the p70S6k/85S6k kinase signalling pathway.	Sirolimus	41-50	ribosomal protein S6 kinase B1	Homo sapiens	150-156
7629182-7	1995	Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity.	Sirolimus	10-19	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	50-56
7721872-0	1995	Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte.	Sirolimus	0-9	interleukin 2	Mus musculus	29-42
7721872-8	1995	Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells.	Sirolimus	0-9	interleukin 2	Mus musculus	24-28
7721872-8	1995	Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells.	Sirolimus	0-9	interleukin 2	Mus musculus	89-93
7531689-3	1995	FKBP displays cis/trans-peptidyl-prolyl isomerase (PPIase) activity which is inhibited by FK-590 or rapamycin.	Sirolimus	100-109	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	0-4
7531689-3	1995	FKBP displays cis/trans-peptidyl-prolyl isomerase (PPIase) activity which is inhibited by FK-590 or rapamycin.	Sirolimus	100-109	FKBP prolyl isomerase 7	Homo sapiens	14-49
7531689-3	1995	FKBP displays cis/trans-peptidyl-prolyl isomerase (PPIase) activity which is inhibited by FK-590 or rapamycin.	Sirolimus	100-109	FKBP prolyl isomerase 7	Homo sapiens	51-57
7529995-3	1995	The existence of a slow cis-trans interconversion of an imidic bond in the inhibitor molecule during the course of the formation of the CsA-CyP18cy complex (where CyP18cy is human 18 kDa cytosolic CyP) prompted us to investigate the reaction of the peptidomacrolides FK506, ascomycin and rapamycin with two specific binding-proteins in more detail.	Sirolimus	288-297	peptidylprolyl isomerase G	Homo sapiens	140-143
7550452-2	1995	Significant IL-1 alpha was produced by EP-stimulated RPM from both C3H/OuJ and C3H/HeJ mouse strains.	Sirolimus	53-56	interleukin 1 alpha	Mus musculus	12-22
7528205-8	1994	We have found that a small fragment of wild-type yeast TOR2 spanning Ser1975 is capable of interacting with human FKBP12 in the presence of rapamycin, whereas an Arg1975 mutant fails to interact.	Sirolimus	140-149	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	55-59
7528205-8	1994	We have found that a small fragment of wild-type yeast TOR2 spanning Ser1975 is capable of interacting with human FKBP12 in the presence of rapamycin, whereas an Arg1975 mutant fails to interact.	Sirolimus	140-149	FKBP prolyl isomerase 1A pseudogene 1	Homo sapiens	114-120
7507316-6	1993	For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6.	Sirolimus	127-136	interleukin 3	Homo sapiens	208-212
8413204-6	1993	Genetic analysis indicated that the dominant mutations are nonallelic to mutations in RBP1 and define two genes, designated DRR1 and DRR2 (for dominant rapamycin resistance).	Sirolimus	152-161	Sgn1p	Saccharomyces cerevisiae S288C	86-90
8413204-6	1993	Genetic analysis indicated that the dominant mutations are nonallelic to mutations in RBP1 and define two genes, designated DRR1 and DRR2 (for dominant rapamycin resistance).	Sirolimus	152-161	phosphatidylinositol kinase-related protein kinase TOR2	Saccharomyces cerevisiae S288C	133-137
8344891-6	1993	Peptide maps reveal that rapamycin abolishes the activity of the overexpressed p70s6k through the dephosphorylation of a novel set of sites distinct from those associated with mitogenic activation.	Sirolimus	25-34	ribosomal protein S6 kinase B1	Homo sapiens	79-85
1716149-1	1991	FKBP-12, the major T-cell binding protein for the immunosuppressive agents FK506 and rapamycin, catalyzes the interconversion of the cis and trans rotamers of the peptidyl-prolyl amide bond of peptide and protein substrates.	Sirolimus	85-94	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	0-7
1987692-4	1991	Similarly, cyclosporine potentiated the inhibitory effects of rapamycin upon proliferation of IL-2 (CTLL-2) and IL-6 (MH60.BSF-2) lymphokine-dependent cell lines.	Sirolimus	62-71	interleukin 2	Mus musculus	94-98
33773987-7	2021	Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt.	Sirolimus	14-23	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	227-232
33761878-5	2021	Adult flies with the "native" and "disrupted" genotypes were re-fed following brief starvation, with or without exposure to rapamycin, the cognate inhibitor of the nutrient-sensing target of rapamycin (TOR).	Sirolimus	124-133	Target of rapamycin	Drosophila melanogaster	202-205
33762334-5	2021	Adipocyte leptin was regulated by the mechanistic target of rapamycin complex 1 (mTORC1) and blocked by rapamycin.	Sirolimus	60-69	leptin	Mus musculus	10-16
33762334-5	2021	Adipocyte leptin was regulated by the mechanistic target of rapamycin complex 1 (mTORC1) and blocked by rapamycin.	Sirolimus	104-113	leptin	Mus musculus	10-16
32890589-2	2020	The rapamycin derivative ("rapalog") everolimus, which allosterically inhibits the mTOR pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (SRS) in individuals with tuberous sclerosis complex (TSC).	Sirolimus	4-13	mechanistic target of rapamycin kinase	Mus musculus	83-87
33817078-7	2018	After IL-12 treatment, the expression of mTOR and its downstream signaling molecule S6 kinase, number of CD8+ Tem cells and interferon-gamma expression were significantly increased, while they were significantly decreased after treatment with rapamycin.	Sirolimus	243-252	mechanistic target of rapamycin kinase	Mus musculus	41-45
33817078-8	2018	Additionally, IL-12 treatment induced T-bet but inhibited Eomesodermin expression, while the opposite was seen when the mTOR pathway was blocked by rapamycin.	Sirolimus	148-157	mechanistic target of rapamycin kinase	Mus musculus	120-124
34958883-11	2022	Furthermore, Combined treatment can normalize the protein levels of two signal pathways in lung and heart tissue, where p-S6 or p-Akt significantly decreased compared to HO-3867 alone, or p-STAT3 significantly reduced compared to rapamycin alone.	Sirolimus	230-239	signal transducer and activator of transcription 3	Rattus norvegicus	190-195
34902496-6	2022	In both in vivo ISCI model in rats and in vitro OGD model in BV-2 cells, the PI3K/AKT/mTOR pathway showed to be inhibited, whereas the PI3K/AKT/mTOR pathway was further inhibited by mild hypothermia in ISCI rats or rapamycin treatment in OGD-stimulated BV-2 cells.	Sirolimus	215-224	mechanistic target of rapamycin kinase	Mus musculus	144-148
34935410-5	2022	Upon depletion of Sis1, cells become hypersensitive to rapamycin, a specific inhibitor of TORC1 kinase.	Sirolimus	55-64	type II HSP40 co-chaperone SIS1	Saccharomyces cerevisiae S288C	18-22
34849833-5	2021	One mutant, designated gal four throttle 1 (gft1) was identified as a recessive allele of hom3, encoding aspartokinase, and mutations in hom3 caused effects typical of inhibition of TORC1, including rapamycin sensitivity and enhanced nuclear localization of the TORC1-responsive transcription factor Gat1.	Sirolimus	199-208	aspartate kinase	Saccharomyces cerevisiae S288C	137-141
33554444-8	2021	Inhibition of mTOR with rapamycin blocked the effects of GPR39 overexpression on protein synthesis and repressed cardiac hypertrophy.	Sirolimus	24-33	G protein-coupled receptor 39	Homo sapiens	57-62
34024231-2	2021	Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the MTORC1 complex and increasing cellular clearance mechanisms.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	25-31
34024231-2	2021	Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the MTORC1 complex and increasing cellular clearance mechanisms.	Sirolimus	0-9	FK506 binding protein 1a	Mus musculus	32-38
34003967-4	2021	The results show that rapamycin increases parkin-mediated mitophagy and promotes fusion of mitophagosome and lysosome in the APP/PS1 mouse hippocampus.	Sirolimus	22-31	presenilin 1	Mus musculus	129-132
34003967-5	2021	Rapamycin enhances learning and memory viability, synaptic plasticity and the expression of synapse related proteins, and impedes Cytochrome C-mediated apoptosis, decreases oxidative status and recovers mitochondrial function in APP/PS1 mice.	Sirolimus	0-9	presenilin 1	Mus musculus	233-236
34003967-6	2021	The data suggest that rapamycin effectively alleviates AD-like behaviors and synaptic plasticity deficits in APP/PS1 mice, which is associated with enhanced mitophagy.	Sirolimus	22-31	presenilin 1	Mus musculus	113-116
34004440-8	2021	Inhibition of mTOR with rapamycin or knockdown of mTOR enhanced metformin"s suppression of hsBAFF-induced phosphorylation of S6K1, PTEN, Akt, and Erk1/2, as well as B-cell proliferation/viability.	Sirolimus	24-33	ribosomal protein S6 kinase B1	Homo sapiens	125-129
33328217-5	2021	By genetic and small molecule targeting of this pathway, we acutely sensitize KRASG12D models to rapamycin via suppression of c-MYC.	Sirolimus	97-106	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	126-131
33116044-10	2021	In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta.	Sirolimus	44-53	interleukin 1 alpha	Mus musculus	245-253
34027051-2	2021	Our recent study linked cyst(e)ine availability with glutathione peroxidase 4 (GPX4) protein synthesis and ferroptosis mitigation via a Rag-mechanistic target of rapamycin complex 1 (mTORC1) axis, and proposed that co-targeting mTORC1 and ferroptosis is a promising strategy for cancer therapy.	Sirolimus	162-171	glutathione peroxidase 4	Homo sapiens	53-77
34027051-2	2021	Our recent study linked cyst(e)ine availability with glutathione peroxidase 4 (GPX4) protein synthesis and ferroptosis mitigation via a Rag-mechanistic target of rapamycin complex 1 (mTORC1) axis, and proposed that co-targeting mTORC1 and ferroptosis is a promising strategy for cancer therapy.	Sirolimus	162-171	glutathione peroxidase 4	Homo sapiens	79-83
33959512-0	2021	Rapamycin Promotes ROS-Mediated Cell Death via Functional Inhibition of xCT Expression in Melanoma Under gamma-Irradiation.	Sirolimus	0-9	solute carrier family 7 member 11	Homo sapiens	72-75
33959512-10	2021	Moreover, the colocalized proportion of both xCT and LC3 in tumor tissues was elevated by the injection of rapamycin into tumoral regions.	Sirolimus	107-116	solute carrier family 7 member 11	Homo sapiens	45-48
33206174-5	2021	CHIR-124, a selective CHK1 inhibitor, impairs cell viability and induces remarkable synergistic lethality with mTOR inhibitor rapamycin in MYC-overexpressing cells.	Sirolimus	126-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	139-142
33206174-6	2021	Mechanistically, rapamycin inactivates carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase (CAD), the essential enzyme for the first three steps of de novo pyrimidine synthesis, and deteriorates CHIR-124-induced replicative stress.	Sirolimus	17-26	aconitate decarboxylase 1	Homo sapiens	122-125
33857309-8	2021	Compared to other calorie restriction mimetics such as metformin, rapamycin, resveratrol and NAD+ precursors, SGLT2 inhibitors appear to be the most promising in the treatment of ageing-related diseases, due to its regulation of multiple longevity pathways that closely resemble that achieved by calorie restriction, and their established efficacy in reduction in cardiovascular events and all-cause mortality.	Sirolimus	66-75	solute carrier family 5 member 2	Homo sapiens	110-115
33280021-9	2021	GRK4 overexpression in cardiomyocytes aggravated apoptosis, repressed autophagy, and decreased beclin-1 expression, which were partially rescued by the autophagy agonist rapamycin.	Sirolimus	170-179	beclin 1, autophagy related	Mus musculus	95-103
33530805-4	2021	Our recent study revealed: (i) the Far complex plays its localization-dependent roles, regulation of mitophagy and target of rapamycin complex 2 (TORC2) signaling, via the mitochondria- and endoplasmic reticulum (ER)-localized Far complexes, respectively; (ii) Ppg1 and Far11 form a subcomplex, and Ppg1 activity is required to assemble the sub- and core-Far complexes; (iii) association and dissociation between the Far complex and Atg32 are crucial determinants for mitophagy regulation.	Sirolimus	125-134	putative serine/threonine-protein kinase PPG1	Saccharomyces cerevisiae S288C	261-265
33530805-4	2021	Our recent study revealed: (i) the Far complex plays its localization-dependent roles, regulation of mitophagy and target of rapamycin complex 2 (TORC2) signaling, via the mitochondria- and endoplasmic reticulum (ER)-localized Far complexes, respectively; (ii) Ppg1 and Far11 form a subcomplex, and Ppg1 activity is required to assemble the sub- and core-Far complexes; (iii) association and dissociation between the Far complex and Atg32 are crucial determinants for mitophagy regulation.	Sirolimus	125-134	Far11p	Saccharomyces cerevisiae S288C	270-275
33530805-4	2021	Our recent study revealed: (i) the Far complex plays its localization-dependent roles, regulation of mitophagy and target of rapamycin complex 2 (TORC2) signaling, via the mitochondria- and endoplasmic reticulum (ER)-localized Far complexes, respectively; (ii) Ppg1 and Far11 form a subcomplex, and Ppg1 activity is required to assemble the sub- and core-Far complexes; (iii) association and dissociation between the Far complex and Atg32 are crucial determinants for mitophagy regulation.	Sirolimus	125-134	putative serine/threonine-protein kinase PPG1	Saccharomyces cerevisiae S288C	299-303
33530805-4	2021	Our recent study revealed: (i) the Far complex plays its localization-dependent roles, regulation of mitophagy and target of rapamycin complex 2 (TORC2) signaling, via the mitochondria- and endoplasmic reticulum (ER)-localized Far complexes, respectively; (ii) Ppg1 and Far11 form a subcomplex, and Ppg1 activity is required to assemble the sub- and core-Far complexes; (iii) association and dissociation between the Far complex and Atg32 are crucial determinants for mitophagy regulation.	Sirolimus	125-134	mitophagy protein ATG32	Saccharomyces cerevisiae S288C	433-438
33352257-6	2021	Further analysis indicated that a certain dosage of 3-MA and rapamycin decreased apoptosis and the caspase-3 expression, which suggested that As-induced autophagy regulated AML-12 cells apoptosis through the expressions of PI3K, mTOR, P62 and Bcl-2.	Sirolimus	61-70	mechanistic target of rapamycin kinase	Mus musculus	229-233
33865602-11	2021	The expression of p-mTOR, p-4EBP1, and p-P70S6K decreased and the ratio of LC-3 II/LC-3 I elevated after treatment of sirolimus.	Sirolimus	118-127	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	28-33
33865602-11	2021	The expression of p-mTOR, p-4EBP1, and p-P70S6K decreased and the ratio of LC-3 II/LC-3 I elevated after treatment of sirolimus.	Sirolimus	118-127	ribosomal protein S6 kinase B1	Homo sapiens	41-47
33687217-5	2021	Namely, a citrullinated multiepitope self-antigen (CitP) and rapamycin are incorporated into the nanoemulsions (NEs@CitP/Rapa), which are fabricated by a facial method using commercialized pharmaceutical excipients.	Sirolimus	61-70	transcriptional regulating factor 1	Mus musculus	121-125
33723228-8	2021	We found that rapamycin effectively reduced the aggregation of TDP-43 in OPTN (E50K) mice and decreased the protein levels of p62/SQSTM1 and the autophagic marker LC3-II.	Sirolimus	14-23	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	163-166
33710804-13	2021	CONCLUSIONS: SNORA23 exhibited antitumor effects in HCC and together with rapamycin, provided a promising therapeutic strategy for HCC treatment.	Sirolimus	74-83	small nucleolar RNA, H/ACA box 23	Homo sapiens	13-20
33693864-11	2021	Phosphorylated mammalian targets of rapamycin and AKT were downregulated, but phosphorylated adenosine monophosphate-activated protein kinase was upregulated in the HFD + MFGM group as compared to the HFD group (P < 0.05).	Sirolimus	36-45	milk fat globule EGF and factor V/VIII domain containing	Homo sapiens	171-175
33646885-8	2021	Rapamycin, an inhibitor of mTOR, reduced the BMP-4-stimulated p70 S6 kinase phosphorylation, and compound C, an inhibitor of BMP type I receptor, suppressed the SMAD1/5/8 phosphorylation stimulated by BMP-4.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	27-31
33050984-6	2021	The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRalpha, CYP7A1, ABCG1, PPARgamma, ApoA1) in the liver.	Sirolimus	25-29	ATP binding cassette subfamily G member 1	Mus musculus	177-182
33321182-6	2021	rDNA condensation after rapamycin treatment was compromised in cdc14-1 and top2-4 mutants.	Sirolimus	24-33	phosphoprotein phosphatase CDC14	Saccharomyces cerevisiae S288C	63-68
33626233-4	2021	BC cell-intrinsic PD-L1 promoted mammalian target of rapamycin complex 1 (mTORC1) signals in vitro and augmented in vivo immune-independent cell growth and metastatic cancer spread, similar to effects we reported in melanoma and ovarian cancer.	Sirolimus	53-62	CD274 molecule	Homo sapiens	18-23
33626233-6	2021	BC cell-intrinsic PD-L1 also mediated chemotherapy resistance to the commonly used BC chemotherapy agents cis-platinum and gemcitabine and to the mTORC1 inhibitor, rapamycin.	Sirolimus	164-173	CD274 molecule	Homo sapiens	18-23
33660929-2	2021	In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor.	Sirolimus	183-192	ribosomal protein S6 kinase B1	Homo sapiens	119-125
33660929-2	2021	In particular, mTOR complex 1 (mTORC1) promotes protein synthesis in ribosomes by activating the downstream effectors, p70S6K and 4EBP1, in skeletal muscle and is highly sensitive to rapamycin, an mTOR inhibitor.	Sirolimus	183-192	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	130-135
33632817-6	2021	Repopulation from zone 2 was driven by the insulin-like growth factor binding protein 2-mechanistic target of rapamycin-cyclin D1 (IGFBP2-mTOR-CCND1) axis.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Mus musculus	138-142
33708630-8	2021	These effects were significantly attenuated when PI3K or mTOR were inhibited by LY294002 or rapamycin, respectively.	Sirolimus	92-101	mechanistic target of rapamycin kinase	Mus musculus	57-61
33412209-9	2021	Furthermore, PDGF-BB-stimulated VSMC proliferation, migration and proliferating cell nuclear antigen (PCNA) expression were inhibited by U0126 and rapamycin.	Sirolimus	147-156	proliferating cell nuclear antigen	Homo sapiens	102-106
33508145-13	2021	By inhibiting p53 alone or both mTORC1 and p53 with rapamycin and a p53 inhibitor, we elucidated that p53 acts downstream of mTORC1 and that mTORC1 thereby promotes odontoblast mineralization.	Sirolimus	52-61	transformation related protein 53, pseudogene	Mus musculus	43-46
33508145-13	2021	By inhibiting p53 alone or both mTORC1 and p53 with rapamycin and a p53 inhibitor, we elucidated that p53 acts downstream of mTORC1 and that mTORC1 thereby promotes odontoblast mineralization.	Sirolimus	52-61	transformation related protein 53, pseudogene	Mus musculus	43-46
33508145-13	2021	By inhibiting p53 alone or both mTORC1 and p53 with rapamycin and a p53 inhibitor, we elucidated that p53 acts downstream of mTORC1 and that mTORC1 thereby promotes odontoblast mineralization.	Sirolimus	52-61	transformation related protein 53, pseudogene	Mus musculus	43-46
33099043-0	2021	Effective sirolimus treatment of two COPA syndrome patients.	Sirolimus	10-19	COPI coat complex subunit alpha	Homo sapiens	37-41
33225417-0	2021	Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/beta-catenin signaling and autophagy.	Sirolimus	0-9	glypican 3	Homo sapiens	73-83
33225417-0	2021	Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/beta-catenin signaling and autophagy.	Sirolimus	0-9	catenin beta 1	Homo sapiens	88-100
33225417-4	2021	The aim of this study is to investigate the mechanisms of rapamycin"s antitumor efficacy in relation to GPC3/Wnt/beta-catenin pathway and autophagy in LSCC.	Sirolimus	58-67	glypican 3	Homo sapiens	104-108
33225417-4	2021	The aim of this study is to investigate the mechanisms of rapamycin"s antitumor efficacy in relation to GPC3/Wnt/beta-catenin pathway and autophagy in LSCC.	Sirolimus	58-67	catenin beta 1	Homo sapiens	113-125
33225417-10	2021	RESULTS: Rapamycin could inhibit the SK-MES-1 cell proliferation in a concentration-dependent manner both in vitro and in vivo by decreasing the GPC3 expression and downregulating the glypican-3/Wnt/beta-catenin signaling pathway.	Sirolimus	9-18	glypican 3	Homo sapiens	145-149
33225417-10	2021	RESULTS: Rapamycin could inhibit the SK-MES-1 cell proliferation in a concentration-dependent manner both in vitro and in vivo by decreasing the GPC3 expression and downregulating the glypican-3/Wnt/beta-catenin signaling pathway.	Sirolimus	9-18	glypican 3	Homo sapiens	184-194
33225417-10	2021	RESULTS: Rapamycin could inhibit the SK-MES-1 cell proliferation in a concentration-dependent manner both in vitro and in vivo by decreasing the GPC3 expression and downregulating the glypican-3/Wnt/beta-catenin signaling pathway.	Sirolimus	9-18	catenin beta 1	Homo sapiens	199-211
33225417-12	2021	CONCLUSION: Rapamycin suppresses the growth of lung cancer through down-regulating glypican-3/Wnt/beta-catenin signaling, which mediates with activation of autophagy.	Sirolimus	12-21	glypican 3	Homo sapiens	83-93
33225417-12	2021	CONCLUSION: Rapamycin suppresses the growth of lung cancer through down-regulating glypican-3/Wnt/beta-catenin signaling, which mediates with activation of autophagy.	Sirolimus	12-21	catenin beta 1	Homo sapiens	98-110
33225417-13	2021	This study suggests GPC3 is a new promising target for rapamycin in the treatment of lung cancer.	Sirolimus	55-64	glypican 3	Homo sapiens	20-24
33509301-4	2021	METHODS: Here, we used bimolecular fluorescent complementation, rapamycin-dependent FKBP/FRB-tau interaction and transmission electron microscopy to prove the in vitro specificity of tau-proximity ligation assay (tau-PLA).	Sirolimus	64-73	FK506 binding protein 1a	Mus musculus	84-88
33509301-4	2021	METHODS: Here, we used bimolecular fluorescent complementation, rapamycin-dependent FKBP/FRB-tau interaction and transmission electron microscopy to prove the in vitro specificity of tau-proximity ligation assay (tau-PLA).	Sirolimus	64-73	microtubule associated protein tau	Homo sapiens	93-96
33509301-4	2021	METHODS: Here, we used bimolecular fluorescent complementation, rapamycin-dependent FKBP/FRB-tau interaction and transmission electron microscopy to prove the in vitro specificity of tau-proximity ligation assay (tau-PLA).	Sirolimus	64-73	microtubule associated protein tau	Homo sapiens	183-186
33509301-4	2021	METHODS: Here, we used bimolecular fluorescent complementation, rapamycin-dependent FKBP/FRB-tau interaction and transmission electron microscopy to prove the in vitro specificity of tau-proximity ligation assay (tau-PLA).	Sirolimus	64-73	microtubule associated protein tau	Homo sapiens	183-186
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	20-29	vimentin	Homo sapiens	89-97
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	31-35	vimentin	Homo sapiens	89-97
33479328-0	2021	Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin.	Sirolimus	99-108	vascular endothelial growth factor A	Rattus norvegicus	22-26
33479328-1	2021	Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells.	Sirolimus	44-53	vascular endothelial growth factor A	Rattus norvegicus	98-132
33479328-1	2021	Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells.	Sirolimus	44-53	vascular endothelial growth factor A	Rattus norvegicus	134-138
33479328-8	2021	In rat retina, rapamycin attenuates the diabetes-induced VEGF overexpression, and in cultured Muller cells and HRMECs, inhibits the hyperglycemia-induced boost ROS.	Sirolimus	15-24	vascular endothelial growth factor A	Rattus norvegicus	57-61
33472493-8	2021	More importantly, in vivo treatment of zebrafish with rapamycin, an autophagy activator that inhibits MAPK/JNK and MTORC1 signaling, stimulated autophagy in the lens and relieved the defects in organelle degradation, resulting in the mitigation of cataracts in gja8b mutant zebrafish.	Sirolimus	54-63	mitogen-activated protein kinase 8b	Danio rerio	107-110
33523960-0	2021	Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin.	Sirolimus	98-107	adiponectin receptor 1	Homo sapiens	0-22
33523960-6	2021	A transgenic mouse model expressing an ADIPOR1 variant displayed cardiomyopathy that recapitulated the cellular findings, and these features were rescued by rapamycin.	Sirolimus	157-166	adiponectin receptor 1	Mus musculus	39-46
33539025-5	2021	These include mechanisms that were conserved during evolution but have gained special features in multicellular eukaryotes, such as pathways regulated by eukaryotic translation initiation factor 2 (eIF-2)-alpha kinase (GCN2, also named general control nonderepressible 2 kinase), 5"-adenosine monophosphate (AMP)-activated protein kinase (AMPK) and target of rapamycin (TOR).The interplay between IDO-1 and above-mentioned pathway seems to be highly context dependent.	Sirolimus	359-368	indoleamine 2,3-dioxygenase 1	Homo sapiens	397-402
33162031-4	2021	The rapamycin treatment has been shown to inhibit the activation of mTOR signaling pathway in fresh thawed ovaries or in ovaries shortly grafted in the recipient mice.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Mus musculus	68-72
32838711-12	2021	In addition, H2O2 decreased the levels of Beclin1 and Atg5/12/16, which were reversed by rapamycin or melatonin.	Sirolimus	89-98	beclin 1, autophagy related	Mus musculus	42-49
32738450-13	2021	The mTOR inhibitor rapamycin significantly reduced hepatocarcinogenesis triggered by Tsc1 loss and p53 haploinsufficiency in vivo, as well as the biomarker Abcc4.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Mus musculus	4-8
32738450-13	2021	The mTOR inhibitor rapamycin significantly reduced hepatocarcinogenesis triggered by Tsc1 loss and p53 haploinsufficiency in vivo, as well as the biomarker Abcc4.	Sirolimus	19-28	transformation related protein 53, pseudogene	Mus musculus	99-102
33319976-6	2020	The downregulation of PFKFB4 can help inhibit the SRC3/Akt/mTOR pathway, leading autophagy to the direction of promoting apoptosis of tumor cells, which is induced by the collapse of tumor cellular homeostasis, while low dosages of rapamycin could decrease surgery-induced immune dysfunction.	Sirolimus	232-241	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	Homo sapiens	22-28
33318177-8	2020	Rapamycin-induced inhibition of mTOR robustly prevented glaucomatous neurodegeneration, supporting a damaging role for IOP-induced mTOR activation in perturbing metabolism and promoting glaucoma.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	32-36
33318177-8	2020	Rapamycin-induced inhibition of mTOR robustly prevented glaucomatous neurodegeneration, supporting a damaging role for IOP-induced mTOR activation in perturbing metabolism and promoting glaucoma.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Mus musculus	131-135
33333712-6	2020	Rapamycin, which modulated mRNA turnover by inhibiting the mTOR pathway, improved nucleotide pool imbalance in exosc2-/- zebrafish, resulting in prolonged survival and partial rescue of neuronal defects.	Sirolimus	0-9	exosome component 2	Danio rerio	111-117
33275600-9	2020	Furthermore, signaling downstream of EphA7 shifts during development, such that in vivo inhibition of mTOR by rapamycin in EphA7-mutant neurons ameliorates dendritic branching, but not dendritic spine phenotypes.	Sirolimus	110-119	mechanistic target of rapamycin kinase	Mus musculus	102-106
32666288-1	2020	Deregulated activity of protein kinase B/mammalian target of rapamycin complex-1 (Akt/mTORC1) incites crucial pathological characteristics of diabetic nephropathy.	Sirolimus	61-70	protein tyrosine kinase 2 beta	Homo sapiens	24-40
33329581-6	2020	In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells.	Sirolimus	45-54	T-box transcription factor 21	Homo sapiens	94-99
33329581-6	2020	In memory CD4+ cells of healthy donors, both rapamycin and 2-deoxy-D-glucose (2DG) suppressed T-bet+Foxp3- cells, and induced T-bet+Foxp3+(lo/hi) cells.	Sirolimus	45-54	T-box transcription factor 21	Homo sapiens	126-131
33329581-7	2020	Rapamycin induced IFN-gamma-producing T-bet+Foxp3lo cells accompanied with enhanced lipid metabolism, whereas 2DG induced IFN-gamma-non-producing T-bet+Foxp3hi cells.	Sirolimus	0-9	T-box transcription factor 21	Homo sapiens	38-43
33319180-5	2020	Rapamycin inhibited mTORC1 and PTEN, but augmented mTORC2 with restoration of miRNA-302a under diabetic conditions.	Sirolimus	0-9	phosphatase and tensin homolog	Homo sapiens	31-35
33319180-7	2020	We conclude that rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling.	Sirolimus	17-26	phosphatase and tensin homolog	Homo sapiens	97-101
33319180-7	2020	We conclude that rapamycin attenuates reperfusion injury in diabetic heart through inhibition of PTEN and mTORC1 with restoration of miR-302a-mTORC2 signaling.	Sirolimus	17-26	microRNA 302a	Homo sapiens	133-141
23787763-12	2013	Rapamycin in combination with Mino produced synergistic effects on LC3 conversion, reduction of the Akt/mTOR/p70S6K pathway, and glioma cell death.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	109-115
23827786-5	2013	Rapamycin, known as mTOR inhibitor, was used to inhibit the activation of mTOR, which prevented effectively high glucose-induced SREBP-1 up-regulation and lipogenesis in HKC cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	20-24
23827786-5	2013	Rapamycin, known as mTOR inhibitor, was used to inhibit the activation of mTOR, which prevented effectively high glucose-induced SREBP-1 up-regulation and lipogenesis in HKC cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	74-78
23242600-8	2013	However, combined use of rapamycin and all-trans retinoic acid abolishes IL-17 production and confers a specific chemokine receptor homing profile upon regulatory T cells.	Sirolimus	25-34	interleukin 17A	Homo sapiens	73-78
23242600-9	2013	The use of purified regulatory T-cell subpopulations provided direct evidence that rapamycin can confer an early selective advantage to CD45RA(+) regulatory T cells, while all-trans retinoic acid favors CD45RA(-) regulatory T-cell subset.	Sirolimus	83-92	protein tyrosine phosphatase receptor type C	Homo sapiens	136-140
23480027-7	2013	The therapeutic effects of sirolimus were associated with a down-regulation of pro-inflammatory cytokines tumour necrosis factor-alpha, IL-6 and IL-17A.	Sirolimus	27-36	interleukin 17A	Mus musculus	145-151
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	CD4 antigen	Mus musculus	85-88
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	interleukin 2 receptor, alpha chain	Mus musculus	90-94
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	CD4 antigen	Mus musculus	195-198
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	CD4 antigen	Mus musculus	85-88
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	interleukin 2 receptor, alpha chain	Mus musculus	90-94
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	CD4 antigen	Mus musculus	195-198
23480027-10	2013	Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells.	Sirolimus	16-25	CD4 antigen	Mus musculus	84-87
23480027-10	2013	Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells.	Sirolimus	16-25	interleukin 17A	Mus musculus	89-95
24159565-0	2013	Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.	Sirolimus	198-207	vascular endothelial growth factor D	Homo sapiens	6-12
24159565-3	2013	We used data from the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial to assess the usefulness of serum VEGF-D concentration as a marker of severity and therapeutic response to sirolimus in patients with lymphangioleiomyomatosis.	Sirolimus	216-225	vascular endothelial growth factor D	Homo sapiens	143-149
24159565-10	2013	Median serum VEGF-D concentrations were similar at baseline in the sirolimus and placebo groups, and fell from baseline at 6 and 12 months in the sirolimus group but remained roughly stable in the placebo group.	Sirolimus	67-76	vascular endothelial growth factor D	Homo sapiens	13-19
24159565-10	2013	Median serum VEGF-D concentrations were similar at baseline in the sirolimus and placebo groups, and fell from baseline at 6 and 12 months in the sirolimus group but remained roughly stable in the placebo group.	Sirolimus	146-155	vascular endothelial growth factor D	Homo sapiens	13-19
24159565-12	2013	In the sirolimus group, improvement in baseline-to-12-month FEV1 occurred in 15 of 23 (65%) VEGF-D responders (ie, those in whom baseline-to-12-month VEGF-D concentrations decreased by more than they did in any patients in the placebo group) and four of 15 (27%) VEGF-D non-responders (p=0 0448).	Sirolimus	7-16	vascular endothelial growth factor D	Homo sapiens	92-98
24159565-12	2013	In the sirolimus group, improvement in baseline-to-12-month FEV1 occurred in 15 of 23 (65%) VEGF-D responders (ie, those in whom baseline-to-12-month VEGF-D concentrations decreased by more than they did in any patients in the placebo group) and four of 15 (27%) VEGF-D non-responders (p=0 0448).	Sirolimus	7-16	vascular endothelial growth factor D	Homo sapiens	150-156
24159565-12	2013	In the sirolimus group, improvement in baseline-to-12-month FEV1 occurred in 15 of 23 (65%) VEGF-D responders (ie, those in whom baseline-to-12-month VEGF-D concentrations decreased by more than they did in any patients in the placebo group) and four of 15 (27%) VEGF-D non-responders (p=0 0448).	Sirolimus	7-16	vascular endothelial growth factor D	Homo sapiens	150-156
24159565-14	2013	Measurement of serum VEGF-D concentrations could inform the risk-benefit analysis of sirolimus therapy in patients with lymphangioleiomyomatosis and reduce the numbers of patients needed for clinical trials.	Sirolimus	85-94	vascular endothelial growth factor D	Homo sapiens	21-27
24252673-12	2013	CONCLUSIONS: Sirolimus can downregulate IL-2 expression and upregulate FoxP3 and IL-10 expression, thereby stimulating FoxP3+ Treg cells, suppressing immunopathological damage, and promoting epithelial repair in bile ducts.	Sirolimus	13-22	interleukin 10	Homo sapiens	81-86
23520131-9	2013	The inflammatory responses in SNRK knockdown adipocytes can be partially attributable to defective mTORC1 signaling, since rapamycin treatment activates IKKbeta and induces lipolysis in adipocytes.	Sirolimus	123-132	SNF related kinase	Mus musculus	30-34
23566837-0	2013	Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	110-114
23566837-7	2013	Western blotting showed decreased expression of phosphorylated mTOR and phosphorylated p70S6K in the rapamycin-treated group, and increased the expression of both SIRT1 and SIRT6 compared to the control group (P&lt;0.05).	Sirolimus	101-110	mechanistic target of rapamycin kinase	Rattus norvegicus	63-67
23532091-5	2013	METHODS: Cell proliferation in human uterine LMS cell lines, SKN and SK-UT-1, was assessed after exposure to rapamycin or curcumin.	Sirolimus	109-118	hedgehog acyltransferase	Homo sapiens	61-64
23532091-8	2013	RESULTS: Both rapamycin and curcumin potently inhibited SKN and SK-UT-1 cell proliferation in a dose-dependent manner.	Sirolimus	14-23	hedgehog acyltransferase	Homo sapiens	56-59
23608754-7	2013	GRP also attenuated rapamycin-induced formation of autophagosomes.	Sirolimus	20-29	gastrin releasing peptide	Homo sapiens	0-3
23696801-8	2013	Knock-down of DRAM1 robustly decreased rate of disappearance of induced autophagosomes, increased RFP-LC3 fluorescence dots and decreased the decline of LC3-II after withdraw of rapamycin, indicating DRAM1 promotes autophagy flux.	Sirolimus	178-187	DNA-damage regulated autophagy modulator 1	Rattus norvegicus	14-19
23696801-8	2013	Knock-down of DRAM1 robustly decreased rate of disappearance of induced autophagosomes, increased RFP-LC3 fluorescence dots and decreased the decline of LC3-II after withdraw of rapamycin, indicating DRAM1 promotes autophagy flux.	Sirolimus	178-187	DNA-damage regulated autophagy modulator 1	Rattus norvegicus	200-205
23667480-7	2013	We further noted an accumulation of the autophagy associated proteins p62 and LC3 in aged tangle bearing P301S mice that was lowered upon rapamycin treatment.	Sirolimus	138-147	nucleoporin 62	Mus musculus	70-73
23603979-11	2013	Macroautophagy inducer rapamycin increased the cell viability and reduced epoxomicin-induced alpha-synuclein accumulation.	Sirolimus	23-32	synuclein alpha	Rattus norvegicus	93-108
23439279-0	2013	Rapamycin-induced autophagy aggravates pathology and weakness in a mouse model of VCP-associated myopathy.	Sirolimus	0-9	valosin containing protein	Mus musculus	82-85
23493289-0	2013	Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency.	Sirolimus	0-9	elastin	Homo sapiens	97-104
23493289-2	2013	We investigated whether rapamycin, an inhibitor of the cell growth regulator mammalian target of rapamycin (mTOR) and effective against other SMC proliferative disorders, is of therapeutic benefit in experimental models of elastin deficiency.	Sirolimus	24-33	elastin	Homo sapiens	223-230
23493289-4	2013	Increased mTOR signaling was detected in elastin-deficient aortas of newborn pups that was inhibited by maternal administration of rapamycin.	Sirolimus	131-140	elastin	Homo sapiens	41-48
23426956-9	2013	Rapamycin enhanced rosuvastatin effect in inhibiting cell proliferation in TSC2(-/-) and TSC2(-/meth) ASM cells.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	75-79
23426956-9	2013	Rapamycin enhanced rosuvastatin effect in inhibiting cell proliferation in TSC2(-/-) and TSC2(-/meth) ASM cells.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	89-93
23726640-0	2013	Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.	Sirolimus	36-45	calcineurin binding protein 1	Homo sapiens	0-21
23426943-2	2013	To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4(+) Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy.	Sirolimus	82-91	negative elongation factor complex member C/D	Homo sapiens	119-122
23478407-8	2013	In a human-mouse chimeric model of allograft rejection, rapamycin pretreatment of human arterial allografts increased graft EC expression of PD-L1 and PD-L2 and reduced subsequent infiltration of allogeneic effector T cells into the artery intima and intimal expansion.	Sirolimus	56-65	programmed cell death 1 ligand 2	Homo sapiens	151-156
23663345-6	2013	SFN-induced LC3-II protein could be attenuated and enhanced by 3-MA and Rapa respectively.	Sirolimus	72-76	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	12-15
23265586-12	2013	Inactivation of mTOR downstream signaling by rapamycin treatment inhibited S6K phosphorylation and abolished the stimulatory effect of IS on GLUT1 expression.	Sirolimus	45-54	mechanistic target of rapamycin kinase	Rattus norvegicus	16-20
23223314-1	2013	BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs).	Sirolimus	26-35	calcineurin binding protein 1	Homo sapiens	41-62
23229928-1	2013	BACKGROUND: Use of the mTOR inhibitor (mTORi) sirolimus to replace calcineurin inhibitors in kidney transplantation has been associated with improved renal function but, in a proportion of cases, also with de novo or exacerbated proteinuria.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Rattus norvegicus	23-27
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	histone deacetylase 9	Homo sapiens	86-90
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	sirtuin 1	Homo sapiens	215-220
22729928-6	2013	When SSCs are exposed to the lifespan-enhancing drug rapamycin in vivo, the resultant HDAC gene expression patterns are opposite of those seen in the differentiating and aging SSCs, with increased Hdac2, Hdac6, and Sirt1 and decreased Hdac8, Hdac9, and Sirt4.	Sirolimus	53-62	histone deacetylase 9	Homo sapiens	242-247
23224887-4	2013	This suggests that CypA has a role in acquisition of function competence of NCX1 protein.Unlike CsA treatment, which affects the functional expression of all three mammalian NCX proteins similarly, FK506 and rapamycin treatment modulates only the functional expression of NCX2 and NCX3 proteins.	Sirolimus	208-217	T cell leukemia homeobox 2	Homo sapiens	76-79
23224887-6	2013	Rapamycin reduces NCX2 and NCX3 transport activity but has no effect on their surface expression or total cell NCX protein expression suggesting that, although it shares a common receptor FKBP with FK506, its mode of action follows a different pathway.We are showing now that the large cytosolic loop of NCX1, NCX2, and NCX3 is involved in acquisition of immunosuppressive drug specificity: truncation of the large cytosolic loop of NCX1 renders the protein sensitive to FK506.	Sirolimus	0-9	T cell leukemia homeobox 2	Homo sapiens	18-21
23182942-0	2013	Long-term efficacy of sirolimus-eluting stent for small vessel disease--subanalysis of Cypher Stent Japan Post-Marketing Surveillance Registry.	Sirolimus	22-31	LIM domain binding 3	Homo sapiens	87-93
23331792-0	2013	Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model.	Sirolimus	0-9	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	69-84
23331792-3	2013	We tested the hypothesis that the mTOR inhibitor rapamycin could inhibit neuroblastoma bone metastases through its action on OPG.	Sirolimus	49-58	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	125-128
23902989-3	2013	Expression of slow-twitch MHC isoforms was significantly increased in BO-rats with/without RAPA treatment, compared with controls, but the magnitude of the increase was much smaller in RAPA-treated BO-rats.	Sirolimus	185-189	major histocompatibility complex, class I, C	Homo sapiens	26-29
22901235-6	2012	In addition, rapamycin preconditioning decreased the production of NF-kappaB, TNF-alpha, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area.	Sirolimus	13-22	BCL2-associated X protein	Mus musculus	93-96
23207611-3	2012	We used a new model of experimental chronic pancreatitis to examine the effect of immune modulation with the mTOR-inhibitor rapamycin on clinical, chemical and histological parameters of chronic pancreatitis.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Rattus norvegicus	109-113
23195006-0	2012	High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.	Sirolimus	59-68	calcineurin binding protein 1	Homo sapiens	117-138
23073467-0	2012	Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.	Sirolimus	59-68	interleukin 10	Homo sapiens	26-31
22840496-7	2012	RESULTS: We observed that IL-22 induced significant proliferation of NHEK and FLS which was effectively inhibited by dual kinase (PI3K/mTOR) inhibitor, NVP-BEZ235 and specific mTOR inhibitor, Rapamycin.	Sirolimus	192-201	interleukin 22	Homo sapiens	26-31
22840496-8	2012	In NHEK and FLS, IL-22 significantly induced phosphorylation of Akt and mTOR which was effectively blocked by Rapamycin and NVP-BEZ235.	Sirolimus	110-119	interleukin 22	Homo sapiens	17-22
22859856-2	2012	The mTOR inhibitors, such as rapamycin, ameliorate PKD in rodent models, but clinical trials have not shown benefit, possibly as a result of low tissue concentrations of rapamycin at clinically tolerable doses.	Sirolimus	29-38	protein kinase D1	Mus musculus	51-54
22932872-7	2012	These behavioral improvements upon rapamycin treatment are accompanied by a decreased level of caspase-3 and a reduction of neuron loss in the forebrain of FTLD-U mice.	Sirolimus	35-44	caspase 3	Mus musculus	95-104
22787122-2	2012	Here we show that rapamycin-induced phosphorylation of Akt can occur in an IGF-1R-independent manner.	Sirolimus	18-27	insulin like growth factor 1 receptor	Homo sapiens	75-81
22787122-3	2012	Analysis of synovial sarcoma cell lines showed that either IGF-1R or the PDGF receptor alpha (PDGFRA) can mediate intrinsic resistance to rapamycin.	Sirolimus	138-147	insulin like growth factor 1 receptor	Homo sapiens	59-65
22343319-5	2012	Also, rapamycin inhibited CNI-induced over-expression of the angiogenic cytokine VEGF, and the chemokine receptor CXCR3 and its ligands in post-transplantation tumor tissues.	Sirolimus	6-15	vascular endothelial growth factor A	Mus musculus	81-85
21631587-1	2012	The mTOR inhibitors (ImTORs) sirolimus (SRL) and everolimus (EVR) have been increasingly used in renal transplantation as part of calcineurin inhibitor (CNI) sparing or avoidance regimens.	Sirolimus	29-38	calcineurin binding protein 1	Homo sapiens	130-151
22575222-6	2012	Restoration of autophagic signaling with rapamycin reduces organ damage in CaMKIV knockout mice to wild-type levels.	Sirolimus	41-50	calcium/calmodulin-dependent protein kinase IV	Mus musculus	75-81
22532572-3	2012	Hamartin and tuberin form a heterodimer that inhibits the mammalian target of rapamycin complex 1 (mTORC1) kinase, a major cellular regulator of protein translation, cell growth and proliferation.	Sirolimus	78-87	TSC complex subunit 2	Homo sapiens	13-20
22532572-6	2012	We hypothesized that low-dose rapamycin given prenatally and/or postnatally in a well-established neuroglial (Tsc2-hGFAP) model of TSC would rescue brain developmental defects.	Sirolimus	30-39	TSC complex subunit 2	Homo sapiens	110-114
22532572-6	2012	We hypothesized that low-dose rapamycin given prenatally and/or postnatally in a well-established neuroglial (Tsc2-hGFAP) model of TSC would rescue brain developmental defects.	Sirolimus	30-39	glial fibrillary acidic protein	Homo sapiens	115-120
22575459-8	2012	The notion that the effect of IGF-1 on the 10-pS Cl channels was induced by stimulation of PDK-AKT-mTOR pathway was further suggested by the finding that rapamycin completely abolished the effect of IGF-1 on the 10-pS Cl channels in the TAL.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Rattus norvegicus	99-103
22519596-11	2012	Rapamycin, an inhibitor of mTORC1, significantly reversed the suppressive effects of eIF2alpha on NF-kappaB.	Sirolimus	0-9	eukaryotic translation initiation factor 2A	Homo sapiens	85-94
22391948-12	2012	Ghrelin receptor antagonism and Ghsr1a knockout blocked the upregulation of JNK activity and downregulation of GLUT4 levels and translocation in the gastrocnemius muscle induced by rapamycin.	Sirolimus	181-190	mitogen-activated protein kinase 8	Mus musculus	76-79
21780151-1	2012	40-O -[2-Hydroxyethyl]rapamycin (RAD), a novel derivative of the immunosuppressive drug rapamycin, was analyzed for its immunomodulatory influence during the interaction of human monocyte-derived dendritic cells (moDC) with Aspergillus fumigatus.	Sirolimus	22-31	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	33-36
22398221-0	2012	Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin.	Sirolimus	89-98	GLI family zinc finger 1	Homo sapiens	0-3
22561310-10	2012	Rapamycin arrested MCs senescence induced by high glucose and prevented MCs senescence with serial cell culture passage, and meanwhile increased the SIRT1 expression and activity.	Sirolimus	0-9	sirtuin 1	Homo sapiens	149-154
22561310-12	2012	These findings provide support for the hypothesis that SIRT1 is required for the effects of rapamycin on high glucose-inducing MCs senescence.	Sirolimus	92-101	sirtuin 1	Homo sapiens	55-60
22426621-10	2012	Because both the Akt inhibitor MK-2206 and the mTOR inhibitor rapamycin provoked a strong diminution of PRL-induced synthesis of the two proteins, and because oleate induced phosphorylation of Akt, we concluded that, in the mammary epithelial cell line HC11, the PI3-kinase/Akt/mTOR signaling pathway strongly participates in beta-casein synthesis and is a main regulator of ADRP expression.	Sirolimus	62-71	prolactin	Mus musculus	104-107
22364775-0	2012	Effects of rapamycin-induced oligomerization of parvalbumin, Stim1 and Orai1 in puncta formation.	Sirolimus	11-20	parvalbumin	Homo sapiens	48-59
22364775-0	2012	Effects of rapamycin-induced oligomerization of parvalbumin, Stim1 and Orai1 in puncta formation.	Sirolimus	11-20	ORAI calcium release-activated calcium modulator 1	Homo sapiens	71-76
22364775-5	2012	Here we made fusion proteins of Stim1 and Orai1 with FRB and FKBP12 domains that associate in the presence of rapamycin.	Sirolimus	110-119	ORAI calcium release-activated calcium modulator 1	Homo sapiens	42-47
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	ORAI calcium release-activated calcium modulator 1	Homo sapiens	46-51
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	ORAI calcium release-activated calcium modulator 1	Homo sapiens	55-60
22364775-6	2012	Rapamycin-induced coupling of Stim1 to Stim1, Orai1 to Orai1 and Stim1 to Orai1 was found to be insufficient for puncta formation.	Sirolimus	0-9	ORAI calcium release-activated calcium modulator 1	Homo sapiens	55-60
22364775-7	2012	Rapamycin was then used to recruit the cytosolic Ca2+ buffer protein parvalbumin (Pav) to Stim1 in order to buffer the local cytosolic Ca2+ near the ER membrane.	Sirolimus	0-9	parvalbumin	Homo sapiens	69-80
22364775-7	2012	Rapamycin was then used to recruit the cytosolic Ca2+ buffer protein parvalbumin (Pav) to Stim1 in order to buffer the local cytosolic Ca2+ near the ER membrane.	Sirolimus	0-9	parvalbumin	Homo sapiens	82-85
22399302-4	2012	By fluorescence confocal microscopy, inactivation of mTOR with rapamycin promoted the nuclear translocation of unphosphorylated STAT1, but not that of a STAT1 mutant incapable of binding its nuclear import adaptor karyopherin-alpha1 (KPNA1).	Sirolimus	63-72	signal transducer and activator of transcription 1	Homo sapiens	128-133
22399302-5	2012	By immunoprecipitation, KPNA1 was physically associated with mTOR and STAT1 in a complex that translocated to the nucleus in response to rapamycin.	Sirolimus	137-146	signal transducer and activator of transcription 1	Homo sapiens	70-75
22424016-0	2012	Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.	Sirolimus	90-99	LIM domain binding 3	Homo sapiens	83-89
22302006-6	2012	Rapamycin treatment of BNIP3-expressing cells led to further increase in autophagosome number without affecting cell death.	Sirolimus	0-9	BCL2 interacting protein 3	Rattus norvegicus	23-28
22056209-1	2012	Our objective was to determine the effects of calcium salts of long-chain fatty acids (CLFAs) and rumen-protected methionine (RPM) on plasma concentrations of ghrelin, glucagon-like peptide-1 (7 to 36) amide, and pancreatic hormones in lactating cows.	Sirolimus	126-129	ghrelin and obestatin prepropeptide	Bos taurus	159-166
22056209-8	2012	Calcium salts of long-chain fatty acids increased plasma ghrelin concentration, and the ghrelin concentration with CLFAs plus RPM was the highest among the treatments.	Sirolimus	126-129	ghrelin and obestatin prepropeptide	Bos taurus	88-95
22123082-6	2012	An increase in phosphorylated-S6 (a downstream effector of mTOR) within intermediate grey neurons in Ex rats was blocked by Rapamycin treatment.	Sirolimus	124-133	mechanistic target of rapamycin kinase	Rattus norvegicus	59-63
22037516-0	2012	Inhibition of mTOR by rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
21871960-9	2012	Mevalonate, the product of HMG-CoA reductase enzymatic activity, AMPK siRNA or pharmacological inactivation of AMPK with compound C suppressed, while the inhibitors of Akt (10-DEBC hydrochloride) and mTOR (rapamycin) mimicked autophagy induction by simvastatin.	Sirolimus	206-215	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	111-115
22662254-8	2012	In 3T3-L1 adipocytes, 11beta-HSD1 mRNA levels were down-regulated following induction of ER stress by tunicamycin but were up-regulated following inhibition of mTOR by rapamycin.	Sirolimus	168-177	hydroxysteroid 11-beta dehydrogenase 1	Mus musculus	22-33
22094953-0	2011	Associations of ABCB1 3435C&gt;T and IL-10-1082G&gt;A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.	Sirolimus	83-92	interleukin 10	Homo sapiens	37-42
21924331-5	2011	Chromatin immunoprecipitation shows that Fhl1 localizes to the HMO1 promoter in an HMO1-dependent fashion and that it centers on a predicted Fhl1 site, and removal of the Fhl1 site in the HMO1 promoter attenuates the response to rapamycin.	Sirolimus	229-238	Fhl1p	Saccharomyces cerevisiae S288C	41-45
21911485-6	2011	Here, we show that both genetic and pharmacologic inhibition of SAPK2/p38 in glioblastoma multiforme cells significantly reduces rapamycin-induced IRES-mediated translation initiation of cyclin D1 and c-MYC, resulting in increased G(1) arrest in vitro and inhibition of tumor growth in xenografts.	Sirolimus	129-138	cyclin D1	Mus musculus	187-196
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Sirolimus	142-151	annexin A6	Homo sapiens	97-100
22017876-6	2011	Biologically, DEPTOR accumulation upon betaTrCP knockdown inactivates mTORC1 and activates AKT in cancer cells to confer resistance to rapamycin and paclitaxel.	Sirolimus	135-144	DEP domain containing MTOR interacting protein	Homo sapiens	14-20
22067655-3	2011	The results also demonstrated that inhibition of mTOR/p70S6K with rapamycin prevented the development of insulin resistance but had no effect on AMPK activity (Thr172 phosphorylation of its catalytic subunit).	Sirolimus	66-75	mechanistic target of rapamycin kinase	Rattus norvegicus	49-53
21742783-4	2011	Moreover, the tissue inhibitor of metalloproteases-3 (TIMP-3), a major regulator of angiogenesis, is significantly downregulated in aortic endothelial cells treated with CSE, acrolein, or rapamycin.	Sirolimus	188-197	TIMP metallopeptidase inhibitor 3	Homo sapiens	14-60
21336564-4	2011	Rapamycin potentiated differentiation of ATRA-treated NB4 cells, but the combination of rapamycin and LY 294002 inhibited the expression of CD11b in both ATRA- and phorbol myristate acetate (PMA)-stimulated cells more than PI3K inhibitor alone.	Sirolimus	88-97	integrin subunit alpha M	Homo sapiens	140-145
21806970-3	2011	We have now shown that medium rich in branched-chain amino acids stimulates expression of the SREBP1c gene in cultured hepatocytes in a manner sensitive both to rapamycin, a pharmacological inhibitor of mTORC1, and to a short hairpin RNA (shRNA) specific for S6 kinase 1 (S6K1), a downstream effector of mTORC1.	Sirolimus	161-170	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	259-270
21806970-3	2011	We have now shown that medium rich in branched-chain amino acids stimulates expression of the SREBP1c gene in cultured hepatocytes in a manner sensitive both to rapamycin, a pharmacological inhibitor of mTORC1, and to a short hairpin RNA (shRNA) specific for S6 kinase 1 (S6K1), a downstream effector of mTORC1.	Sirolimus	161-170	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	272-276
21784900-6	2011	The mTOR inhibitor rapamycin also protected glomeruli, demonstrating that calcium signaling has additional calcineurin-independent components.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
21399973-1	2011	FK506 binding protein 65 (FKBP65) belongs to a group of proteins termed immunophilins that have a high binding affinity to immunosuppressant drugs as FK506 (tacrolimus) and rapamycin (sirolimus).	Sirolimus	173-182	FKBP prolyl isomerase 10	Homo sapiens	0-24
21399973-1	2011	FK506 binding protein 65 (FKBP65) belongs to a group of proteins termed immunophilins that have a high binding affinity to immunosuppressant drugs as FK506 (tacrolimus) and rapamycin (sirolimus).	Sirolimus	173-182	FKBP prolyl isomerase 10	Homo sapiens	26-32
21399973-1	2011	FK506 binding protein 65 (FKBP65) belongs to a group of proteins termed immunophilins that have a high binding affinity to immunosuppressant drugs as FK506 (tacrolimus) and rapamycin (sirolimus).	Sirolimus	184-193	FKBP prolyl isomerase 10	Homo sapiens	0-24
21399973-1	2011	FK506 binding protein 65 (FKBP65) belongs to a group of proteins termed immunophilins that have a high binding affinity to immunosuppressant drugs as FK506 (tacrolimus) and rapamycin (sirolimus).	Sirolimus	184-193	FKBP prolyl isomerase 10	Homo sapiens	26-32
21600903-0	2011	Rapamycin (sirolimus) protects against hypoxic damage in primary heart cultures via Na+/Ca2+ exchanger activation.	Sirolimus	11-20	nascent polypeptide associated complex subunit alpha 2	Homo sapiens	84-91
21593197-7	2011	Both CR and rapamycin decreased phosphorylation of mTOR, p70/S6K, and S6 ribosomal protein, but only CR decreased phosphorylation of Akt, GSK-3beta, extracellular signal regulated kinase/mitogen-activated protein kinase, and STAT3(TYR705).	Sirolimus	12-21	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	57-64
21681844-9	2011	Interestingly, the inner cell mass, detected by immunostaining with POU5F1 (OCT3/4) after 3-MA or rapamycin treatment of embryos, was significantly increased compared to controls.	Sirolimus	98-107	POU domain, class 5, transcription factor 1	Mus musculus	68-74
21525000-4	2011	Short rapamycin treatment specifically inhibiting mTORC1 suppressed p70 but not p85 phosphorylation, suggesting that p85 might be directly activated by phosphatidic acid.	Sirolimus	6-15	annexin A6	Homo sapiens	68-71
21525000-4	2011	Short rapamycin treatment specifically inhibiting mTORC1 suppressed p70 but not p85 phosphorylation, suggesting that p85 might be directly activated by phosphatidic acid.	Sirolimus	6-15	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	117-120
21073857-4	2011	Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	98-102
21073857-4	2011	Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein without affecting TRPM7 expression in rat renal NRK-52E epithelial cells.	Sirolimus	0-9	transient receptor potential cation channel, subfamily M, member 6	Rattus norvegicus	170-175
20715103-5	2011	Simultaneous inhibition of VEGFR downstream effector mTOR using rapamycin 20 mg/kg q2dx5 did not statistically enhance tumor growth delay compared to single agent activities.	Sirolimus	64-73	kinase insert domain receptor	Homo sapiens	27-32
21385891-7	2011	Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3beta hyperphosphorylation in each sarcoma model.	Sirolimus	20-29	insulin like growth factor 1 receptor	Homo sapiens	38-43
21338459-0	2011	Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation.	Sirolimus	27-36	calcineurin binding protein 1	Homo sapiens	44-65
21572994-5	2011	The expression of IFN-gammainduced by IL-12 and IL-18 is sensitive to rapamycin and SB203580, indicating the possible involvement of mTOR and p38 MAP kinase, respectively, in this synergistic pathway.	Sirolimus	70-79	interleukin 18	Homo sapiens	48-53
21511183-5	2011	The ability of rapamycin to augment HP-induced memory was cell-intrinsic given that silencing mTOR in CD8+ T cells generated identical outcomes.	Sirolimus	15-24	CD8a molecule	Homo sapiens	102-105
21335533-4	2011	The sch9 hyperfilamentous phenotype was independent of Rim15 kinase and was recreated by inhibition of Tor1 kinase by rapamycin or caffeine in a wild-type strain, suggesting that Sch9 suppression requires Tor1.	Sirolimus	118-127	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	103-107
21289308-5	2011	In a murine bone marrow transplantation model, Evi1 leukemia showed modestly increased sensitivity to an mTOR inhibitor rapamycin.	Sirolimus	120-129	MDS1 and EVI1 complex locus	Mus musculus	47-51
21350938-7	2011	Rapamycin at low concentrations might be insufficient to initiate autophagosome formation in autophagy but Beclin-1 overexpression triggered additional processes downstream of mTOR during G(1) cell cycle arrest by rapamycin.	Sirolimus	214-223	beclin 1	Homo sapiens	107-115
21239712-9	2011	These results suggested that splenic CSF-1-dependent F4/80(hi)Mac-1(low) MPhis are a subpopulation of RPMs and regulate peripheral immune homeostasis.	Sirolimus	102-106	colony stimulating factor 1 (macrophage)	Mus musculus	37-42
21239712-9	2011	These results suggested that splenic CSF-1-dependent F4/80(hi)Mac-1(low) MPhis are a subpopulation of RPMs and regulate peripheral immune homeostasis.	Sirolimus	102-106	adhesion G protein-coupled receptor E1	Mus musculus	53-67
21062901-7	2011	The differences between Tsc1(GFAP1)CKO and Tsc2(GFAP1)CKO mice were correlated with higher levels of mammalian target of rapamycin (mTOR) activation in Tsc2(GFAP1)CKO mice and were reversed by the mTOR inhibitor, rapamycin.	Sirolimus	121-130	TSC complex subunit 2	Homo sapiens	152-156
21289215-7	2011	Pretreatment the cells with the mTOR inhibitor rapamycin reduced the number of apoptotic cells induced by HG and the downstream effects of mTOR activation noted above.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Rattus norvegicus	32-36
21289215-7	2011	Pretreatment the cells with the mTOR inhibitor rapamycin reduced the number of apoptotic cells induced by HG and the downstream effects of mTOR activation noted above.	Sirolimus	47-56	mechanistic target of rapamycin kinase	Rattus norvegicus	139-143
21084384-8	2011	These effects were counteracted by addition of glibenclamide, the action of which was blocked by the mTOR inhibitor rapamycin and the protein kinase A (PKA) inhibitor Rp-8-Br-cAMPs.	Sirolimus	116-125	mechanistic target of rapamycin kinase	Rattus norvegicus	101-105
20876686-7	2011	Despite the absence of internal ribosome entry site activity we demonstrate, using a dual reporter assay, that both the reported mdm2 5"-UTRs confer resistance to rapamycin relative to the 5"-UTR of beta-actin.	Sirolimus	163-172	MDM2 proto-oncogene	Homo sapiens	129-133
20876686-9	2011	Furthermore, extended exposure to rapamycin in the presence of serum increased the steady-state level of the endogenous MDM2 protein.	Sirolimus	34-43	MDM2 proto-oncogene	Homo sapiens	120-124
21034830-11	2011	However, Heme oxygenase-1(HO-1) was increased only in Rapamycin treatment.	Sirolimus	54-63	heme oxygenase 1	Rattus norvegicus	9-30
20854798-0	2011	Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin.	Sirolimus	112-121	matrix metallopeptidase 9	Rattus norvegicus	48-53
20854798-0	2011	Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin.	Sirolimus	112-121	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	54-60
20854798-0	2011	Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin.	Sirolimus	112-121	mechanistic target of rapamycin kinase	Rattus norvegicus	97-101
20854798-1	2011	The mTOR-inhibitor rapamycin is a potent drug used in many immunosuppressive and antiinflammatory therapeutic regimes.	Sirolimus	19-28	mechanistic target of rapamycin kinase	Rattus norvegicus	4-8
20854798-3	2011	In this study, we tested for possible modulatory effects of rapamycin on the cytokine-triggered matrix metalloproteinase 9 (MMP-9)/tissue inhibitor of metalloproteinase (TIMP)-1 protease-antiprotease system which is critically involved in renal inflammation and fibrosis.	Sirolimus	60-69	matrix metallopeptidase 9	Rattus norvegicus	96-122
20854798-3	2011	In this study, we tested for possible modulatory effects of rapamycin on the cytokine-triggered matrix metalloproteinase 9 (MMP-9)/tissue inhibitor of metalloproteinase (TIMP)-1 protease-antiprotease system which is critically involved in renal inflammation and fibrosis.	Sirolimus	60-69	matrix metallopeptidase 9	Rattus norvegicus	124-129
20854798-3	2011	In this study, we tested for possible modulatory effects of rapamycin on the cytokine-triggered matrix metalloproteinase 9 (MMP-9)/tissue inhibitor of metalloproteinase (TIMP)-1 protease-antiprotease system which is critically involved in renal inflammation and fibrosis.	Sirolimus	60-69	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	131-177
20854798-5	2011	The reduction in the extracellular MMP-9 content by rapamycin coincided with an attenuation in cytokine-induced steady-state MMP-9 mRNA levels.	Sirolimus	52-61	matrix metallopeptidase 9	Rattus norvegicus	35-40
20854798-5	2011	The reduction in the extracellular MMP-9 content by rapamycin coincided with an attenuation in cytokine-induced steady-state MMP-9 mRNA levels.	Sirolimus	52-61	matrix metallopeptidase 9	Rattus norvegicus	125-130
20854798-6	2011	Conversely, rapamycin caused a dose-dependent increase in cytokine-evoked TIMP-1 expression in a Smad binding element (SBE)-dependent manner.	Sirolimus	12-21	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	74-80
20854798-7	2011	Surprisingly, the attenuation of MMP-9 mRNA levels by rapamycin is accompanied by a potentiation of IL-1beta-induced MMP-9 promoter activity in which the stimulatory effects by rapamycin are mainly attributed to a proximal AP-1 binding site.	Sirolimus	54-63	matrix metallopeptidase 9	Rattus norvegicus	33-38
20854798-7	2011	Surprisingly, the attenuation of MMP-9 mRNA levels by rapamycin is accompanied by a potentiation of IL-1beta-induced MMP-9 promoter activity in which the stimulatory effects by rapamycin are mainly attributed to a proximal AP-1 binding site.	Sirolimus	177-186	matrix metallopeptidase 9	Rattus norvegicus	33-38
20854798-7	2011	Surprisingly, the attenuation of MMP-9 mRNA levels by rapamycin is accompanied by a potentiation of IL-1beta-induced MMP-9 promoter activity in which the stimulatory effects by rapamycin are mainly attributed to a proximal AP-1 binding site.	Sirolimus	177-186	matrix metallopeptidase 9	Rattus norvegicus	117-122
21439133-0	2011	Rapamycin generates graft-homing murine suppressor CD8(+) T cells that confer donor-specific graft protection.	Sirolimus	0-9	CD8a molecule	Homo sapiens	51-54
21439133-3	2011	In this study, we investigated the ability of short-term RPM treatment in promoting long-term acceptance (LTA) of MHC-mismatched skin allografts by generating a CD8(+) suppressor T-cell population.	Sirolimus	57-60	CD8a molecule	Homo sapiens	161-164
21439133-10	2011	Our data supported the notion that RPM-induced suppressor CD8(+) T cells home to the allograft and exert donor-specific graft protection.	Sirolimus	35-38	CD8a molecule	Homo sapiens	58-61
21597297-8	2011	In addition, rapamycin reduced wound lactate accumulation and enhanced MMP-2 protein expression, and both MMP-2 and MMP-9 activity.	Sirolimus	13-22	matrix metallopeptidase 2	Mus musculus	71-76
21597297-9	2011	At day 14, wound tensile strength and hydroxyproline content were significantly lower along with an increase in MMP-2 and MMP-9 activity in rapamycin-treated mice.	Sirolimus	140-149	matrix metallopeptidase 2	Mus musculus	112-117
21114628-6	2011	Chromatin immunoprecipitation assays showed that LPS enhanced the binding of Oct-2 to the iNOS and G-CSF promoters and that this effect was inhibited by pretreatment with rapamycin.	Sirolimus	171-180	POU class 2 homeobox 2	Homo sapiens	77-82
20801129-6	2011	Rapamycin, a specific mTOR inhibitor, did not alter insulin-induced Akt phosphorylation but significantly inhibited SVV expression (from 6.1+-0.3 to 3.0+-0.15, p&lt;0.05).	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	22-26
20615907-8	2011	RESULTS: Five out of 43 sirolimus-treated PCK rats, but none of the controls, died during the study.	Sirolimus	24-33	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	42-45
20615907-13	2011	Sirolimus-treated PCK rats showed only a minor inhibition of renal mTOR-specific phosphorylation of S6K.	Sirolimus	0-9	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	18-21
20615907-13	2011	Sirolimus-treated PCK rats showed only a minor inhibition of renal mTOR-specific phosphorylation of S6K.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
20615907-14	2011	Male PCK rats on sirolimus presented with increased concentrations of bile acids and bilirubin compared with controls (each P &lt; 0.05 at 12 weeks).	Sirolimus	17-26	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	5-8
21915260-0	2011	Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.	Sirolimus	29-38	vascular endothelial growth factor D	Homo sapiens	115-122
21915260-11	2011	A correlative biomarker study showed that serum VEGF-D levels are elevated at baseline, decrease with sirolimus treatment, and correlate with kidney angiomyolipoma size (Spearman correlation coefficient 0.54, p = 0.001, at baseline).	Sirolimus	102-111	vascular endothelial growth factor D	Homo sapiens	48-54
21611151-4	2011	RESULTS: Antigen-activated CD8(+) T cells treated with rapamycin gave rise to 5-fold more long-lived memory T cells in vivo than untreated control T cells.	Sirolimus	55-64	CD8a molecule	Homo sapiens	27-30
21217822-7	2010	Subcellular localization of endogenous FKH protein is shifted from predominantly cytoplasmic on a high-protein diet to a pronounced nuclear accumulation in animals with reduced levels of TOR or fed with rapamycin.	Sirolimus	203-212	fork head	Drosophila melanogaster	39-42
20868675-10	2010	Rapamycin (pharmacological inhibitor of mTOR) resulted in decrease in prolidase activity.	Sirolimus	0-9	peptidase D	Homo sapiens	70-79
20937815-5	2010	Here we show that rapamycin inhibited protein synthesis and activities of small GTPases (RhoA, Cdc42, and Rac1), crucial regulatory proteins for cell migration.	Sirolimus	18-27	Rac family small GTPase 1	Homo sapiens	106-110
21075311-5	2010	On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance.	Sirolimus	37-46	pyruvate dehydrogenase kinase 1	Homo sapiens	94-98
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	100-109	pyruvate dehydrogenase kinase 1	Homo sapiens	45-49
21075311-6	2010	Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization.	Sirolimus	100-109	pyruvate dehydrogenase kinase 1	Homo sapiens	81-85
20933441-5	2010	DC-specific Pten targeting in vivo caused the expansion of CD8(+) and CD103(+) cDC numbers, which was reversible by rapamycin.	Sirolimus	116-125	CD8a molecule	Homo sapiens	59-62
20840477-10	2010	In vitro, sirolimus downregulated nephrin expression by human podocytes.	Sirolimus	10-19	NPHS1 adhesion molecule, nephrin	Homo sapiens	34-41
20600853-6	2010	The mTor inhibitor, rapamycin, activates autophagy, prevents PDE4A4 from forming intracellular aggregates and triggers the loss of bound p62 from PDE4A4.	Sirolimus	20-29	sequestosome 1	Homo sapiens	137-140
20815021-1	2010	UNLABELLED: Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)-associated nephrotoxicity.	Sirolimus	12-21	calcineurin binding protein 1	Homo sapiens	129-150
20506342-6	2010	RESULTS: Treatment with rapamycin reduced skin fibrosis of TSK/+ mice and skin and lung fibrosis of bleomycin-induced SSc model mice.	Sirolimus	24-33	fibrillin 1	Mus musculus	59-62
20506342-7	2010	The production of fibrogenic cytokines, such as interleukin-4 (IL-4), IL-6, IL-17, and transforming growth factor beta1, was attenuated by rapamycin.	Sirolimus	139-148	interleukin 17A	Mus musculus	76-81
20506342-8	2010	Hypergammaglobulinemia and anti-topoisomerase I antibody production were also reduced by rapamycin treatment in TSK/+ mice.	Sirolimus	89-98	fibrillin 1	Mus musculus	112-115
20506342-10	2010	Rapamycin treatment inhibited proliferation and collagen production of TSK/+ mouse fibroblasts in a dose-dependent manner.	Sirolimus	0-9	fibrillin 1	Mus musculus	71-74
20506342-11	2010	CONCLUSION: This study is the first to show that rapamycin has a significant inhibitory effect on fibrosis in both TSK/+ and bleomycin-induced SSc model mice.	Sirolimus	49-58	fibrillin 1	Mus musculus	115-118
20725695-8	2010	A continuous fall in MMP-9 concentration was observed in SIR-G, with the greatest reduction at 4 weeks (-352.9 +/- 455 vs +395.2 +/- 377, P = 0.0004), while a positive variation was noted 4 weeks after sirolimus discontinuation (227 +/- 708 vs 406.2 +/- 472.1, P = 0.0958).	Sirolimus	202-211	matrix metallopeptidase 9	Homo sapiens	21-26
22187903-0	2010	[Long-term follow-up use of "cypher" sirolimus-eluting stents in patients with coronary heart disease after coronary artery bypass grafting with occlusive lesions of the coronary artery].	Sirolimus	37-46	LIM domain binding 3	Homo sapiens	29-35
20562737-1	2010	BACKGROUND: The aim of this study was to observe the effect of sirolimus (SRL) on calcineurin inhibitor (CNI)-induced nephrotoxicity in the aging process by using renal expression of KLOTHO, an antiaging gene.	Sirolimus	63-72	klotho	Mus musculus	183-189
20439463-4	2010	mTOR inhibitor rapamycin or NS5A knockdown blocked S6K1 and 4EBP1 phosphorylation increase in NS5A-Huh7 and HCV replicon cells, suggesting that NS5A specifically regulated mTOR activation.	Sirolimus	15-24	MIR7-3 host gene	Homo sapiens	99-103
20392814-4	2010	Here, we show that MTOR inhibition by rapamycin increases iodide uptake in TSH-stimulated PCCL3 thyroid cell line, although the effect of rapamycin was less pronounced than PI3K inhibition.	Sirolimus	38-47	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
20392814-4	2010	Here, we show that MTOR inhibition by rapamycin increases iodide uptake in TSH-stimulated PCCL3 thyroid cell line, although the effect of rapamycin was less pronounced than PI3K inhibition.	Sirolimus	138-147	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
20219495-5	2010	In bovine retinal capillary endothelial cells (BRCECs), PEDF mRNA and protein expression was suppressed by insulin (22%) in a rapamycin-sensitive manner; wortmannin had no effect.	Sirolimus	126-135	serpin family F member 1	Bos taurus	56-60
20074526-6	2010	Rapamycin could increase life span of weak insulin/Igf signaling (IIS) pathway mutants and of flies with life span maximized by dietary restriction, indicating additional mechanisms.	Sirolimus	0-9	Insulin-like receptor	Drosophila melanogaster	43-64
21063108-8	2010	Blocking mTOR signaling by either rapamycin or overexpression of its negative regulator tuberous sclerosis complex 1 (TSC1) or TSC2 attenuates the inhibitory effect of insulin on the transcription and translation of GOAT.	Sirolimus	34-43	serine/threonine-protein kinase mTOR	Capra hircus	9-13
21364612-5	2010	The knockdown or pharmacological inhibition of Sirtuin-1 enhanced the vulnerability of human cells to metabolic stress, unless they were stimulated to undergo autophagy by treatment with rapamycin or p53 inhibition.	Sirolimus	187-196	sirtuin 1	Homo sapiens	47-56
20389030-6	2010	By Western blotting analysis, we observed decreased intracellular levels of VEGF and HIF-1alpha under octreotide, rapamycin and LY294002.	Sirolimus	114-123	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	85-95
20389030-7	2010	For rapamycin and LY294002, this effect was likely mediated by the inhibition of the mTOR/HIF-1/VEGF pathway.	Sirolimus	4-13	mechanistic target of rapamycin kinase	Rattus norvegicus	85-89
19818818-5	2010	Similar to the action of the mTOR inhibitor rapamycin, dexamethasone (DEX), a synthetic glucocorticoid, also inhibited the mTOR signaling in the hypothalamic explants.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Rattus norvegicus	29-33
19818818-5	2010	Similar to the action of the mTOR inhibitor rapamycin, dexamethasone (DEX), a synthetic glucocorticoid, also inhibited the mTOR signaling in the hypothalamic explants.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Rattus norvegicus	123-127
19805410-13	2010	Deletion of the FPR1 or FAP1 gene abolishes the inhibitory effect of rapamycin on repair.	Sirolimus	69-78	Fap1p	Saccharomyces cerevisiae S288C	24-28
19864570-7	2009	In contrast, rapamycin enhanced the effects of beclin 1.	Sirolimus	13-22	beclin 1	Homo sapiens	47-55
19954658-7	2009	(3) On exposure to RAPA, the levels of p-mTOR, p-S6 and IFN-gamma in T cells in refractory/relapsed AA patients were significantly lower than those before the exposure (all P &lt; 0.05).	Sirolimus	19-23	taste 2 receptor member 63 pseudogene	Homo sapiens	47-51
19607806-4	2009	Treatment with the mTOR inhibitor, rapamycin, inhibited this CCL5-inducible proliferation.	Sirolimus	35-44	C-C motif chemokine ligand 5	Homo sapiens	61-65
19131641-8	2009	Administration of rapamycin also decreased the severity of lung injury after intratracheal LPS or PAM administration, as determined by diminished neutrophil accumulation in the lungs, reduced interstitial pulmonary edema, and diminished levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid.	Sirolimus	18-27	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	98-101
19622772-8	2009	Inhibition of mTOR in female Eker rats with the rapamycin analogue WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity, and size.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
19622772-8	2009	Inhibition of mTOR in female Eker rats with the rapamycin analogue WAY-129327 for 2 weeks decreased mTOR signaling and cell proliferation in tumors, and treatment for 4 months significantly decreased tumor incidence, multiplicity, and size.	Sirolimus	48-57	mechanistic target of rapamycin kinase	Rattus norvegicus	100-104
19586661-2	2009	mTOR signals via two complexes: TORC1, which contains the Regulatory Associated Protein of TOR (raptor), and TORC2, which contains the Rapamycin-insensitive Companion of TOR (rictor).	Sirolimus	135-144	CREB regulated transcription coactivator 2	Homo sapiens	109-114
19501260-0	2009	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.	Sirolimus	0-9	C-C motif chemokine receptor 5	Homo sapiens	99-103
19397913-8	2009	These morphological and biochemical changes were associated with marked activation of the key growth-promoting mTOR signalling pathway, whose pharmacological inhibition with rapamycin completely blocked cardiac hypertrophy induced by rosiglitazone.	Sirolimus	174-183	mechanistic target of rapamycin kinase	Rattus norvegicus	111-115
19421190-3	2009	Effectiveness of the rapamycin dose and delivery was shown by the inhibition of insulin-stimulated phosphorylation of p70S6K, a marker of mTOR activity, in skeletal muscle.	Sirolimus	21-30	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	118-124
19520256-0	2009	Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.	Sirolimus	0-9	sirtuin 1	Homo sapiens	68-77
19520256-5	2009	RESULTS: Treatment with paclitaxel, sirolimus, and everolimus significantly caused a senescent phenotype and PAI-1 up-regulation, associated with a decrease in endothelial nitric oxide synthase (eNOS) and Sirt1 expression.	Sirolimus	36-45	sirtuin 1	Homo sapiens	205-210
19520256-6	2009	Overexpression of Sirt1 or Sirt1 activation reversed the sirolimus- or everolimus-induced senescent phenotype.	Sirolimus	57-66	sirtuin 1	Homo sapiens	18-23
19520256-6	2009	Overexpression of Sirt1 or Sirt1 activation reversed the sirolimus- or everolimus-induced senescent phenotype.	Sirolimus	57-66	sirtuin 1	Homo sapiens	27-32
19520256-10	2009	CONCLUSIONS: Sirolimus and everolimus induce endothelial senescence involving down-regulation of Sirt1.	Sirolimus	13-22	sirtuin 1	Homo sapiens	97-102
19526041-7	2009	In the NILV of post-MI female rats, rapamycin inhibited the upregulation of eNOS.	Sirolimus	36-45	nitric oxide synthase 3	Rattus norvegicus	76-80
19208105-0	2009	Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.	Sirolimus	14-23	calcineurin binding protein 1	Homo sapiens	29-50
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	KRAS proto-oncogene, GTPase	Rattus norvegicus	61-64
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	KRAS proto-oncogene, GTPase	Rattus norvegicus	174-177
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	ATM serine/threonine kinase	Rattus norvegicus	194-197
19343784-8	2009	Dominant-negative PI3K plasmids attenuated arecoline-induced p21(WAF1), but not p-p53Ser15, at 24 h. Rapamycin attenuated arecoline-induced phosphrylated p-p53Ser15, but not p21(WAF1), at 24 h. ATM shRNA, but not dominant-negative PI3K plasmids, attenuated arecoline-induced p21(WAF1) gene transcription.	Sirolimus	101-110	KRAS proto-oncogene, GTPase	Rattus norvegicus	174-177
19539245-7	2009	When compared with monotherapy, combinatorial application of rapamycin and PD98059 had greater inhibitory effects on Tsc2 deficient cell proliferation, suggesting that combined suppression of mTOR and ERK/MAPK signaling pathways may have advantages over single mTOR inhibition in the treatment of TSC patients.	Sirolimus	61-70	TSC complex subunit 2	Homo sapiens	117-121
19509240-3	2009	We tested the hypothesis that IGF1R up-regulation mediates resistance to cancer therapeutics, evaluating the effects of IGF1R depletion on sensitivity to cytotoxic drugs, which are ineffective in RCC, and the mammalian target of rapamycin (mTOR) inhibitor rapamycin, analogues of which have clinical activity in this tumor.	Sirolimus	229-238	insulin like growth factor 1 receptor	Homo sapiens	30-35
19509240-11	2009	Administration of stabilized IGF1R siRNA was shown to sensitize CC-RCC xenografts to rapamycin in vivo.	Sirolimus	85-94	insulin like growth factor 1 receptor	Homo sapiens	29-34
19374031-6	2009	Gtr1p and Gtr2p are necessary for cells to acquire resistance to caffeine, rapamycin, and hydrogen peroxide.	Sirolimus	75-84	Gtr2p	Saccharomyces cerevisiae S288C	10-15
19406341-10	2009	The Endeavor stent and the sirolimus-eluting Cypher stent (Cordis, Johnson &amp; Johnson, Miami, Florida) had higher restenosis rates in patients with DM compared with those in patients without DM (RR: 1.77, 95% CI: 1.29 to 2.43 and RR: 1.25, 95% CI: 1.04 to 1.51).	Sirolimus	27-36	LIM domain binding 3	Homo sapiens	45-51
19273591-6	2009	Epitasis analysis indicates that the mutation of SIT4 or TIP41, encoding a Tap42-interacting protein, abolishes the sensitivity of the ptc1 strain to rapamycin and caffeine.	Sirolimus	150-159	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	135-139
19273591-10	2009	The lack of Ptc1 partially abolishes the rapamycin-induced dephosphorylation of Tip41, which may further decrease Tap42 binding.	Sirolimus	41-50	type 2C protein phosphatase PTC1	Saccharomyces cerevisiae S288C	12-16
19297407-3	2009	The gene products of TSC1 and TSC2, also known as hamartin and tuberin, respectively, form a physical and functional complex and inhibit the mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	161-170	TSC complex subunit 2	Homo sapiens	30-34
19297407-3	2009	The gene products of TSC1 and TSC2, also known as hamartin and tuberin, respectively, form a physical and functional complex and inhibit the mammalian target of rapamycin complex 1 (mTORC1) signaling.	Sirolimus	161-170	TSC complex subunit 2	Homo sapiens	63-70
19188906-8	2009	The increased Th1/Th2 ratio found in I/R livers after 2 h was reverted by immunosuppressants, which also amplified the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T lymphocytes at 24 h. The protective effects of both tacrolimus and sirolimus correlated well with a decreased ratio of proinflammatory to anti-inflammatory T lymphocytes, and with an increase in the Treg proportion.	Sirolimus	235-244	Cd4 molecule	Rattus norvegicus	133-136
19225151-6	2009	Inhibition of mTOR by rapamycin or leucine deprivation, the conditions that induce autophagy, leads to dephosphorylation of ULK1, ULK2, and Atg13 and activates ULK to phosphorylate FIP200.	Sirolimus	22-31	autophagy related 13	Homo sapiens	140-145
19225151-6	2009	Inhibition of mTOR by rapamycin or leucine deprivation, the conditions that induce autophagy, leads to dephosphorylation of ULK1, ULK2, and Atg13 and activates ULK to phosphorylate FIP200.	Sirolimus	22-31	RB1 inducible coiled-coil 1	Homo sapiens	181-187
19260835-0	2009	ID2-VEGF-related pathways in the pathogenesis of Kaposi"s sarcoma: a link disrupted by rapamycin.	Sirolimus	87-96	inhibitor of DNA binding 2	Homo sapiens	0-3
19166687-1	2009	The aim of the present study was to evaluate angiographic late luminal loss after the implantation of sirolimus-eluting Cypher stents and paclitaxel-eluting Taxus stents in patients with diabetes.	Sirolimus	102-111	LIM domain binding 3	Homo sapiens	120-126
19166687-11	2009	In conclusion, angiographic in-stent late luminal loss is significantly reduced in patients with diabetes by use of the sirolimus-eluting Cypher stent compared with the paclitaxel-eluting Taxus stent.	Sirolimus	120-129	LIM domain binding 3	Homo sapiens	138-144
19019941-8	2009	CONCLUSIONS: This study indicates that both RAPA and DEX inhibit the production of IL-17 and IFN-gamma by PBMCs.	Sirolimus	44-48	interleukin 17A	Homo sapiens	83-88
19019941-9	2009	RAPA is much stronger in inhibiting the production of IL-17 than DEX.	Sirolimus	0-4	interleukin 17A	Homo sapiens	54-59
19234362-7	2009	Rapamycin, which is commonly used as a pharmacological tool to disrupt the FKBP12-RyR complex, decreased phenylephrine-induced contractions in RVD epididymal halves.	Sirolimus	0-9	FKBP prolyl isomerase 1A	Rattus norvegicus	75-81
19187614-7	2009	In all the 15 patients, the calcineurin inhibitor was reduced down to one third of the original dosage after the rapamycin blood concentration became stable.	Sirolimus	113-122	calcineurin binding protein 1	Homo sapiens	28-49
19099400-2	2009	This is enhanced when combined with the immunosuppressive mTOR inhibitor sirolimus.	Sirolimus	73-82	mechanistic target of rapamycin kinase	Rattus norvegicus	58-62
19074906-8	2008	Furthermore, rapamycin not only drastically inhibited CXCL16-induced PCa cell invasion and growth but reduced secretion of IL-8 or VEGF levels and inhibited expression of other CXCR6 targets including CD44 and matrix metalloproteinase 3 in PCa cells.	Sirolimus	13-22	CD44 molecule (Indian blood group)	Homo sapiens	201-205
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	ATP binding cassette subfamily A member 1	Homo sapiens	139-174
19180880-3	2008	The effects of rapamycin on interleukin-1 beta (IL-1 beta)-induced mRNA and protein changes of low-density lipoprotein receptor (LDLR) and ATP-binding cassette transporter A1 (ABCA1) were assayed by quantitative real-time PCR and Western blot.	Sirolimus	15-24	ATP binding cassette subfamily A member 1	Homo sapiens	176-181
19180880-6	2008	Rapamycin dose-dependently suppressed the increased expression of LDLR induced by IL-1 beta and up-regulated the suppressed expression of ABCA1 caused by IL-1 beta.	Sirolimus	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	138-143
19018001-9	2008	We found that the injection of CD40L transfectants, but not mock cells, resulted in VEGF expression and mediated a marked angiogenesis reaction, and this response was reduced in mice treated with rapamycin.	Sirolimus	196-205	vascular endothelial growth factor A	Mus musculus	84-88
19105244-9	2008	Rapamycin also inhibited betacellulin- and IGF-I-induced entry of cells into S phase and 5"-Bromo-2"-deoxyuridine incorporation as well as the effect of betacellulin and IGF-I on cyclin D1 expression and nuclear exclusion of p21(Cip1) and p(27Kip1).	Sirolimus	0-9	betacellulin	Rattus norvegicus	25-37
18930138-8	2008	Minimization of calcineurin inhibitor exposure may be achieved with concurrent use of the more potent anti-proliferative agents mycophenolate mofetil and sirolimus.	Sirolimus	154-163	calcineurin binding protein 1	Homo sapiens	16-37
18652845-0	2008	Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction.	Sirolimus	0-9	leukocyte immunoglobulin like receptor B1	Homo sapiens	49-53
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	21-24
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	25-28
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	87-90
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	91-94
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	87-90
18832178-5	2008	mTORC1 activation by SF2/ASF bypasses upstream PI3K/Akt signaling and is essential for SF2/ASF-mediated transformation, as inhibition of mTOR by rapamycin blocked transformation by SF2/ASF in vitro and in vivo.	Sirolimus	145-154	serine and arginine rich splicing factor 1	Homo sapiens	91-94
18929849-14	2008	In conclusion, rapamycin-induced cytotoxicity was characterized by generation of ROS, which modulated Bak protein expression and mitochondrial dysfunction.	Sirolimus	15-24	BCL2 antagonist/killer 1	Homo sapiens	102-105
18929866-0	2008	Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.	Sirolimus	0-9	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	77-82
18929866-2	2008	This study of cardiac allografts investigated whether there is a difference between rapamycin and cyclosporine A (CsA) in the ability to affect expression of Ang1, Ang2, and Tie2 in rat renal allografts with chronic allograft nephropathy (CAN).	Sirolimus	84-93	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	164-168
18929866-12	2008	In a comparison of the control and CsA groups, mRNA expression of Ang1 was increased (P &lt; .05), and mRNA expression of Ang2 and Tie2 was decreased (P &lt; .05) in the rapamycin group at 8 and 12 weeks.	Sirolimus	170-179	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	122-126
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	54-63	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	98-102
18929866-14	2008	CONCLUSIONS: Our results show that compared with CsA, rapamycin modulates the expression of Ang1, Ang2, and Tie2 in rat renal allografts with CAN, which suggests that rapamycin may improve the long-term survival of renal allografts through its vasculoprotective properties.	Sirolimus	167-176	angiogenin, ribonuclease A family, member 2	Rattus norvegicus	98-102
18949710-9	2008	The analysis showed that the genes in the DCD pathway are aligned with those functionally influenced by the drugs sirolimus, LY-294002 and wortmannin.	Sirolimus	114-123	dermcidin	Homo sapiens	42-45
18562571-2	2008	Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity.	Sirolimus	46-55	calcineurin binding protein 1	Homo sapiens	0-21
18562571-2	2008	Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity.	Sirolimus	46-55	calcineurin binding protein 1	Homo sapiens	23-26
18562571-2	2008	Calcineurin inhibitor (CNI) withdrawal from a sirolimus-based immunosuppressive regimen may maximize the likelihood of long-term graft and patient survival by minimizing CNI-associated nephrotoxicity.	Sirolimus	46-55	calcineurin binding protein 1	Homo sapiens	170-173
18562571-3	2008	In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based CNI withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients.	Sirolimus	90-99	calcineurin binding protein 1	Homo sapiens	106-109
18562571-3	2008	In this study, a lifetime Markov model was created to compare the cost-effectiveness of a sirolimus-based CNI withdrawal regimen (sirolimus plus steroids) with other common CNI-containing regimens in adult de novo renal transplantation patients.	Sirolimus	130-139	calcineurin binding protein 1	Homo sapiens	106-109
18562571-6	2008	The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens.	Sirolimus	39-48	calcineurin binding protein 1	Homo sapiens	182-185
18562571-6	2008	The model suggests that treatment with sirolimus plus steroids is more efficacious and less costly than regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not only shows potential for long-term clinical benefits but also is expected to be cost-saving over a patient"s life compared with the most commonly prescribed CNI-containing regimens.	Sirolimus	39-48	calcineurin binding protein 1	Homo sapiens	182-185
18550700-5	2008	We found that rapamycin had no effect on DNA synthesis in major organs such as heart, intestine, and kidney in the fetal and early postnatal rat despite a marked attenuation in the phosphorylation of ribosomal protein S6.	Sirolimus	14-23	ribosomal protein S6	Rattus norvegicus	200-220
18672974-6	2008	Treatment with rapamycin resulted in a time-dependent decrease in phosphorylated mTOR expression and a lack of detectable phosphorylated p70S6 kinase.	Sirolimus	15-24	mechanistic target of rapamycin kinase	Canis lupus familiaris	81-85
18625027-0	2008	The MAP kinase-activated protein kinase Rck2p plays a role in rapamycin sensitivity in Saccharomyces cerevisiae and Candida albicans.	Sirolimus	62-71	serine/threonine protein kinase RCK2	Saccharomyces cerevisiae S288C	40-45
18625027-2	2008	In this study, we have demonstrated in both Saccharomyces cerevisiae and, the most medically important human fungal pathogen, Candida albicans that deletion of RCK2 renders cells sensitive to rapamycin, the inhibitor of target of rapamycin protein kinase controlling cell growth.	Sirolimus	192-201	serine/threonine protein kinase RCK2	Saccharomyces cerevisiae S288C	160-164
18480312-7	2008	A significant decrease in vascular endothelial growth factor-A and an increase in IL-6 were detected in kidneys of these rapamycin-treated mice.	Sirolimus	121-130	vascular endothelial growth factor A	Mus musculus	26-62
18510342-1	2008	Multivariate data analysis was applied to confocal Raman measurements on stents coated with the polymers and drug used in the CYPHER Sirolimus-eluting Coronary Stents.	Sirolimus	133-142	LIM domain binding 3	Homo sapiens	126-132
18398293-6	2008	Knocking down Beclin 1 markedly decreased the mitochondrial translocation of EGFR that was induced by rapamycin.	Sirolimus	102-111	beclin 1	Homo sapiens	14-22
18317669-0	2008	Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry.	Sirolimus	38-47	LIM domain binding 3	Homo sapiens	100-106
18486258-2	2008	We reported that sirolimus, an mTOR inhibitor, has antiangiogenic properties in HCC.	Sirolimus	17-26	mechanistic target of rapamycin kinase	Rattus norvegicus	31-35
18490075-8	2008	Potentially additive effects of bevacizumab plus rapamycin included reductions in vascular endothelial growth factor expression, cyclin D1, and cyclin B1.	Sirolimus	49-58	cyclin D1	Mus musculus	129-138
18612547-7	2008	Inhibition of this pathway with the specific mTOR inhibitor, rapamycin, markedly decreased cell migration induced by formation of TF-FVIIa-FXa complex.	Sirolimus	61-70	coagulation factor X	Homo sapiens	139-142
18667775-6	2008	Expressions of mTOR and eIF-4E mRNA or protein in CVB3-induced myocardial cells were significantly upregulated compared with the control group (P &lt; 0.05), and rapamycin (10 nmol/L) inhibited the upregulation (P &lt; 0.05).	Sirolimus	162-171	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
18667775-7	2008	CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Rattus norvegicus	58-62
18667775-7	2008	CONCLUSION: Rapamycin can downregulate the expressions of mTOR and eIF-4E in CVB3-induced myocardial cells, suggesting that mTOR/eIF-4E signal transduction may play an important role in viral myocarditis.	Sirolimus	12-21	mechanistic target of rapamycin kinase	Rattus norvegicus	124-128
17907241-4	2008	When rapamycin was encapsulated in the nanoparticle to maintain DCs in the immature state, ICAM-1 expression was down regulated.	Sirolimus	5-14	intercellular adhesion molecule 1	Homo sapiens	91-97
18337562-8	2008	Indeed, CCL5 initiated active translation of mRNA, shown by the increased presence of high-molecular-weight polysomes that were significantly reduced by rapamycin treatment.	Sirolimus	153-162	C-C motif chemokine ligand 5	Homo sapiens	8-12
18630505-5	2008	Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin).	Sirolimus	77-86	insulin like growth factor 1 receptor	Homo sapiens	14-19
18630505-8	2008	CONCLUSION: The combination of rapamycin or temsirolimus with alphaIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.	Sirolimus	31-40	insulin like growth factor 1 receptor	Homo sapiens	82-87
18630505-8	2008	CONCLUSION: The combination of rapamycin or temsirolimus with alphaIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.	Sirolimus	31-40	insulin like growth factor 1 receptor	Homo sapiens	219-224
18343366-6	2008	Autophagy induction by rapamycin decreases the extent of PI-induced inclusions and apoptosis in Huh7 and OUMS29 cells.	Sirolimus	23-32	MIR7-3 host gene	Homo sapiens	96-100
18216782-5	2008	Rapamycin attenuated DC differentiation, HIF-1alpha expression, and its target gene expression in a dose-dependent manner along with downregulated interleukin-10 secretion.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	41-51
18216782-9	2008	Rapamycin attenuates the hypoxic immune-inflammatory response through inhibition of the HIF-1alpha pathway.	Sirolimus	0-9	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	88-98
18064507-0	2008	Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry.	Sirolimus	0-9	LIM domain binding 3	Homo sapiens	25-31
18064507-0	2008	Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry.	Sirolimus	0-9	LIM domain binding 3	Homo sapiens	93-99
18005087-1	2008	The aim was to evaluate long-term graft survival and function after conversion to sirolimus (SRL) for chronic calcineurin inhibitor (CNI) toxicity and the predictive value of baseline proteinuria.	Sirolimus	82-91	calcineurin binding protein 1	Homo sapiens	110-131
18564143-14	2008	Rapamycin prevents angiogenesis in the mesenteric tissue and decreases the mesenteric blood flow in portal hypertensive mice, at least in part through an anti-VEGF activity and influence on the mTOR signalling pathway.	Sirolimus	0-9	vascular endothelial growth factor A	Mus musculus	159-163
18156399-11	2008	Jejunal villi of the Rapa-treated group showed inactivation of p70(S6k) and a decrease in mucosal resistance (reflecting increased permeability), the latter of which was reversed by Arg.	Sirolimus	21-25	annexin A6	Homo sapiens	63-66
18958173-10	2008	Exposure of TSC2(-/-) ASM cells to rapamycin reduced the proliferation rate, but only when added at plating time.	Sirolimus	35-44	TSC complex subunit 2	Homo sapiens	12-16
17669686-0	2007	Long-term clinical follow-up of sirolimus-eluting (CYPHER) coronary stents in the treatment of instent restenosis in an unselected population.	Sirolimus	32-41	LIM domain binding 3	Homo sapiens	51-57
17669686-1	2007	Randomised trials in a highly selected patient population have demonstrated a dramatic reduction in the incidence of in-stent restenosis (ISR) following implantation of sirolimus-eluting (S-E) Cypher coronary stents compared with bare metal stents (BMS).	Sirolimus	169-178	LIM domain binding 3	Homo sapiens	193-199
17919619-0	2007	Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	93-114
17906340-0	2007	Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study.	Sirolimus	11-20	LIM domain binding 3	Homo sapiens	29-35
17603996-9	2007	Furthermore, decreases of p45 AUF1 and p42 and/or p40 AUF1 were observed in the polysomal fractions of BJAB cells in which translation of TOP mRNAs was selectively suppressed by rapamycin treatment.	Sirolimus	178-187	heterogeneous nuclear ribonucleoprotein D	Homo sapiens	30-34
17603996-9	2007	Furthermore, decreases of p45 AUF1 and p42 and/or p40 AUF1 were observed in the polysomal fractions of BJAB cells in which translation of TOP mRNAs was selectively suppressed by rapamycin treatment.	Sirolimus	178-187	heterogeneous nuclear ribonucleoprotein D	Homo sapiens	54-58
17603109-4	2007	Loss of TOR1 restored the ability of the pmr1 strain to grow on media containing 2 mm MnCl2 and conferred wild type as well as the wild-type sensitivity to rapamycin.	Sirolimus	156-165	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	8-12
17700411-4	2007	We report a case in which in-stent restenosis of an overhanging stent had been treated with an also overhanging sirolimus-coated Cypher stent (Cordis Corporation, Roden, The Netherlands).	Sirolimus	112-121	LIM domain binding 3	Homo sapiens	129-135
17652906-1	2007	BACKGROUND: Outcomes after sirolimus-eluting stent (SES: Cypher) implantation remained to be elucidated in Japan.	Sirolimus	27-36	LIM domain binding 3	Homo sapiens	57-63
17690032-0	2007	Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	43-64
17634255-5	2007	Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
17634255-5	2007	Inhibition of mTOR with rapamycin decreased the association of rapamycin-associated TOR protein with mTOR and prevented the feeding-induced assembly of eIF4G-eIF4E complex.	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	101-105
17485501-0	2007	Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.	Sirolimus	0-9	C-C motif chemokine receptor 5	Homo sapiens	18-22
17565322-5	2007	Interestingly, induction of IL-21 was highly dependent on IL-2 (as in the presence of anti-IL-2, anti-IL-2R alpha-chain, and the immunosuppressive drugs cyclosporine A, tacrolimus, and rapamycin) the transcription of IL-21 was almost completely inhibited, whereas in the presence of exogenous IL-2 the mRNA expression of IL-21 was even more upregulated.	Sirolimus	185-194	interleukin 21	Homo sapiens	28-33
17350953-1	2007	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR) kinase.	Sirolimus	0-9	FKBP prolyl isomerase 3	Homo sapiens	90-115
17351648-0	2007	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	86-89
17351648-0	2007	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.	Sirolimus	0-9	interleukin 2 receptor, alpha chain	Mus musculus	91-95
17351648-8	2007	Prolonged rapamycin treatment allowed for thymic generation of CD4(+)FoxP3(+) T cells, whereas treatment with cyclosporine led to a reduced generation of these cells.	Sirolimus	10-19	CD4 antigen	Mus musculus	63-66
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Sirolimus	32-41	CD4 antigen	Mus musculus	79-82
17429314-10	2007	Consistently, the UGT2B7 genotype significantly influenced AcMPAG area under the curve (AUC0-9 h)/dose in patients on sirolimus at months 1 and 3 after transplant (P=0.04 for both).	Sirolimus	118-127	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	18-24
17401488-10	2007	Further development of effective calcineurin inhibitor-free regimens should exclude patients of black ethnicity and may need full-induction therapy, perhaps with depleting agents, and concentration-controlled use of sirolimus and MMF.	Sirolimus	216-225	calcineurin binding protein 1	Homo sapiens	33-54
17284292-3	2007	The aim of the present study was to test the effect of rapamycin on the bioelectrical activity and evoked field excitatory postsynaptic potentials (fEPSP) in CA1 area of hippocampal tissues and compare its effect with FK506, a calcineurin inhibitor agent.	Sirolimus	55-64	carbonic anhydrase 1	Homo sapiens	158-161
17327134-4	2007	Rapamycin treated cells failed to proliferate, expressed anergic T cell specific transcription factor genes egr-2 and egr-3 and showed diminished IFN-gamma production in response to Con A stimulation in vitro.	Sirolimus	0-9	early growth response 3	Mus musculus	118-123
17331841-5	2007	The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported.	Sirolimus	89-93	CD4 antigen	Mus musculus	20-23
17331841-5	2007	The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported.	Sirolimus	89-93	CD4 antigen	Mus musculus	31-34
17331841-5	2007	The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported.	Sirolimus	89-93	interleukin 2 receptor, alpha chain	Mus musculus	37-41
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	CD4 antigen	Mus musculus	21-24
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	interleukin 2 receptor, alpha chain	Mus musculus	27-31
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	CD4 antigen	Mus musculus	199-202
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	interleukin 2 receptor, alpha chain	Mus musculus	205-209
16920414-5	2007	Sirolimus also significantly reduced the deposition of elastin, collagen III and fibronectin within the vascular wall.	Sirolimus	0-9	elastin	Homo sapiens	55-62
17200572-7	2007	When TOR is inactivated by rapamycin treatment or nitrogen starvation, downstream effectors of TOR such as the serine/threonine protein kinase NPR1 and the TAP42 interacting protein TIP41 are dephosphorylated in a SIT4-dependent manner.	Sirolimus	27-36	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	143-147
17172981-6	2007	On the other hand, administration of AG490 (specific inhibitor for JAK2), fludarabine (specific inhibitor for STAT1) or rapamycin (specific inhibitor for STAT3) markedly suppressed HMGB1 expression.	Sirolimus	120-129	high mobility group box 1	Rattus norvegicus	181-186
17969375-0	2007	Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions.	Sirolimus	37-46	LIM domain binding 3	Homo sapiens	30-36
17077083-0	2006	Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway.	Sirolimus	103-112	TSC complex subunit 2	Homo sapiens	25-29
17142730-3	2006	We recently reported that rapamycin allows in vitro expansion of murine CD4+CD25+FoxP3+ Tregs, which preserve their suppressive function.	Sirolimus	26-35	CD4 antigen	Mus musculus	72-75
17175307-17	2006	We concluded that patients with early CAN who are switched to SRL and low-dose CsA have a significant attenuation of the rate of GFR declination when compared with patients who receive MMF or AZA addition.	Sirolimus	62-65	Rap guanine nucleotide exchange factor 5	Homo sapiens	129-132
16914544-6	2006	We determined that rapamycin efficiently activates AP-1-driven transcription by rapidly inducing c-jun/AP-1 phosphorylation with activation of the c-Jun N-terminal kinase (JNK) cascade, resulting in enhanced binding of AP-1.DNA complex formation and AP-1-dependent gene transactivation.	Sirolimus	19-28	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
16939628-5	2006	The ability of rapamycin to preferentially increase gamma-globin mRNA content and production of HbF in erythroid precursor cells from beta-thalassaemia patients is of great importance as this agent (also known as sirolimus or rapamune) is already in clinical use as an anti-rejection agent following kidney transplantation.	Sirolimus	15-24	hemoglobin subunit gamma 1	Homo sapiens	52-64
16923813-2	2006	In budding yeast, Tor1p and Tor2p function as part of two distinct protein complexes, TORC1 and TORC2, where TORC1 is specifically inhibited by the antibiotic rapamycin.	Sirolimus	159-168	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	18-23
16940348-6	2006	Amino acid starvation or rapamycin treatment, which upregulates autophagy, causes a redistribution of mAtg9 from the TGN to peripheral, endosomal membranes, which are positive for the autophagosomal marker GFP-LC3.	Sirolimus	25-34	autophagy related 9A	Mus musculus	102-107
16864948-0	2006	Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.	Sirolimus	76-85	LIM domain binding 3	Homo sapiens	101-107
16864948-1	2006	BACKGROUND: The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS).	Sirolimus	98-107	LIM domain binding 3	Homo sapiens	123-129
16881976-3	2006	This multicenter, nonrandomized study assessed the safety and effectiveness of the CYPHER sirolimus-eluting stent in reducing angiographic in-stent late loss in totally occluded native coronary arteries.	Sirolimus	90-99	LIM domain binding 3	Homo sapiens	83-89
16881976-4	2006	A total of 25 eligible patients were treated with the CYPHER sirolimus-eluting stent.	Sirolimus	61-70	LIM domain binding 3	Homo sapiens	54-60
16881976-13	2006	The CYPHER sirolimus-eluting stent was safe and effective in the treatment of CTO compared to historical data with bare metal stents.	Sirolimus	11-20	LIM domain binding 3	Homo sapiens	4-10
16730658-9	2006	The wild type serum and glucocorticoid inducible kinase SGK1 and the constitutively active (S422D)SGK1 similarly stimulated Ip, an effect again reversed by rapamycin.	Sirolimus	156-165	serum/glucocorticoid regulated kinase 1	Homo sapiens	56-60
16730658-9	2006	The wild type serum and glucocorticoid inducible kinase SGK1 and the constitutively active (S422D)SGK1 similarly stimulated Ip, an effect again reversed by rapamycin.	Sirolimus	156-165	serum/glucocorticoid regulated kinase 1	Homo sapiens	98-102
16613881-5	2006	The camostat-induced increases in protein synthesis and 4E-BP1 and S6 phosphorylation were almost totally abolished by administration of the mTOR inhibitor rapamycin 1 h prior to camostat feeding.	Sirolimus	156-165	proliferation-associated 2G4	Mus musculus	57-62
16797286-12	2006	CONCLUSION: Conversion from calcineurin inhibitor therapy to sirolimus in patients more than 1 year after transplantation with impaired organ function is feasible, safe, and associated with a trend toward improved renal function.	Sirolimus	61-70	calcineurin binding protein 1	Homo sapiens	28-49
16597691-2	2006	The effect of mTOR blockade by sirolimus (SRL) in diabetic kidney disease in rats was investigated.	Sirolimus	31-40	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
17407958-0	2006	[Use of "Cypher" sirolimus-eluting stents in coronary heart disease patients with different types of coronary arterial lesions].	Sirolimus	17-26	LIM domain binding 3	Homo sapiens	9-15
16282343-7	2006	Additional experiments performed in vitro with MKs from mutant mice showed that the decrease in mean ploidy level and the delay in MK differentiation in the presence of rapamycin were less pronounced in CdknIa (p21)-/- MKs than in CdknIa (p21)+/+ MKs.	Sirolimus	169-178	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	211-214
16282343-7	2006	Additional experiments performed in vitro with MKs from mutant mice showed that the decrease in mean ploidy level and the delay in MK differentiation in the presence of rapamycin were less pronounced in CdknIa (p21)-/- MKs than in CdknIa (p21)+/+ MKs.	Sirolimus	169-178	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	239-242
16221708-0	2006	Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).	Sirolimus	24-33	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
16487832-2	2006	Both DES elute compounds that inhibit the cell cycle, but at different stages: Cypher stents elute sirolimus, which induces G1 cell cycle inhibition, and Taxus stents release paclitaxel, which predominantly leads to M-phase arrest.	Sirolimus	99-108	LIM domain binding 3	Homo sapiens	79-85
16461044-5	2006	The percentages of CD8+ and CD4+ effector memory T cells, as defined by the CD3+CD45RO+CD27- phenotype, were significantly reduced in patients who received a sirolimus-eluting stent compared with the basal values.	Sirolimus	158-167	CD8a molecule	Homo sapiens	19-22
16461045-0	2006	Angiographic pattern of restenosis following implantation of overlapping sirolimus-eluting (Cypher) stents.	Sirolimus	73-82	LIM domain binding 3	Homo sapiens	92-98
16461045-1	2006	Sirolimus-eluting stents (Cypher) have been shown to reduce the frequency of neointimal hyperplasia and restenosis compared with bare metal stents.	Sirolimus	0-9	LIM domain binding 3	Homo sapiens	26-32
16477233-9	2006	Next to lowering precursor frequencies, rapamycin also inhibited T cell expansion by inducing apoptosis in divided alloreactive CD4+ and CD8+ T cells.	Sirolimus	40-49	CD8a molecule	Homo sapiens	137-140
16412252-12	2006	TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2.	Sirolimus	41-50	TSC complex subunit 2	Homo sapiens	5-9
16412252-12	2006	TSC1/TSC2 mutant cell lines administered Rapamycin blocked S6 phorphorylation and diminished the levels of HIF-1alpha to those observed in cell lines with wild type TSC1/TSC2.	Sirolimus	41-50	TSC complex subunit 2	Homo sapiens	170-174
16424043-4	2006	Experiments using a novel cyclin D1-Cdk2 fusion protein or a kinase-dead mutant of the fusion protein indicated that reversal of rapamycin action required not only the formation of complexes with p21 and PCNA but also complex-associated kinase activity.	Sirolimus	129-138	cyclin-dependent kinase 2	Mus musculus	36-40
16424043-6	2006	The rapamycin derivative RAD001 (everolimus) inhibited the growth of mouse mammary tumors, which correlated with the disruption of cyclin D1/Cdk2 complexes.	Sirolimus	4-13	cyclin D1	Mus musculus	131-140
16424043-6	2006	The rapamycin derivative RAD001 (everolimus) inhibited the growth of mouse mammary tumors, which correlated with the disruption of cyclin D1/Cdk2 complexes.	Sirolimus	4-13	cyclin-dependent kinase 2	Mus musculus	141-145
16273582-0	2006	Eosinophilic tissue response several weeks after sirolimus-eluting Cypher stent implantation within a bare metal stent in a coronary saphenous vein graft.	Sirolimus	49-58	LIM domain binding 3	Homo sapiens	67-73
17048977-12	2006	CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor.	Sirolimus	146-155	calcineurin binding protein 1	Homo sapiens	313-334
17048977-12	2006	CONCLUSION: This study presents an accurate population pharmacokinetic model showing the significant influence of the CYP3A5*1/*3 polymorphism on sirolimus apparent oral clearance, and a Bayesian estimator accurately predicting sirolimus pharmacokinetics in patients co-administered mycophenolate mofetil, but no calcineurin inhibitor.	Sirolimus	228-237	calcineurin binding protein 1	Homo sapiens	313-334
16364861-0	2005	Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.	Sirolimus	0-9	calcineurin binding protein 1	Homo sapiens	76-97
16394584-6	2005	Like the tor mutants, the las24 mutants were found to have a defect in cell wall integrity and to show sensitivity to rapamycin.	Sirolimus	118-127	ubiquitin-binding TORC1 subunit KOG1	Saccharomyces cerevisiae S288C	26-31
15994335-6	2005	Binding of FKBP12, calcineurin, and calmodulin to TRPC6 channels is blocked by the following: 1) inhibition of PKC; 2) mutation of the PKC phosphorylation site (Ser(7168/714)) in the channels; or 3) pretreatment with FK506 or rapamycin, immunosuppressants that directly bind FKBP12.	Sirolimus	226-235	FKBP prolyl isomerase 1A	Rattus norvegicus	11-17
15994335-6	2005	Binding of FKBP12, calcineurin, and calmodulin to TRPC6 channels is blocked by the following: 1) inhibition of PKC; 2) mutation of the PKC phosphorylation site (Ser(7168/714)) in the channels; or 3) pretreatment with FK506 or rapamycin, immunosuppressants that directly bind FKBP12.	Sirolimus	226-235	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	50-55
15973656-1	2005	Sirolimus-eluting stents (SESs; Cypher) have demonstrated a significant reduction in restenosis rates when compared to bare metal stents (BMSs).	Sirolimus	0-9	LIM domain binding 3	Homo sapiens	32-38
15769938-10	2005	Sirolimus overrode the suppression of cholesterol efflux and ABCA1 gene expression induced by the inflammatory cytokine IL-1beta.	Sirolimus	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	61-66
15989961-4	2005	Here, we describe the identification of a conserved member of the RagA subfamily of Ras-related GTPases, Gtr2, which acts in a vacuolar membrane-associated protein complex together with Ego1 and Ego3 to ensure proper exit from rapamycin-induced growth arrest.	Sirolimus	227-236	Gtr2p	Saccharomyces cerevisiae S288C	105-109
15989961-4	2005	Here, we describe the identification of a conserved member of the RagA subfamily of Ras-related GTPases, Gtr2, which acts in a vacuolar membrane-associated protein complex together with Ego1 and Ego3 to ensure proper exit from rapamycin-induced growth arrest.	Sirolimus	227-236	Slm4p	Saccharomyces cerevisiae S288C	195-199
15746082-0	2005	Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	30-33
15914125-10	2005	Significantly, rapamycin completely inhibited the phosphorylation of p70(S6K), an mTOR-regulated kinase implicated in the control of proliferation, but had no effect on collagen or total protein synthesis.	Sirolimus	15-24	annexin A6	Homo sapiens	69-72
15784722-1	2005	The mammalian target of rapamycin (mTOR) has recently been described to be constitutively activated in Bcr-Abl-transformed cells and to mediate rapamycin-induced inhibition of growth in respective cell lines.	Sirolimus	24-33	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	103-110
15784722-4	2005	Rapamycin dose dependently inhibited growth of primary CML cells obtained from patients with imatinib-responsive or imatinib-resistant disease as well as growth of Bcr-Abl-transformed imatinib-resistant cell lines.	Sirolimus	0-9	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	164-171
15784722-5	2005	Moreover, we observed potent cytoreductive effects of rapamycin in a patient with imatinib-resistant Bcr-Abl+ leukemia.	Sirolimus	54-63	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	101-108
15919492-10	2005	RPM treatment was associated with increased activation of pro-MMP-9, a significant decrease in MMP-2 tissue levels, and corresponding increases in TIMP-2 and TIMP-3 expression.	Sirolimus	0-3	matrix metallopeptidase 2	Mus musculus	95-100
15919492-12	2005	Alterations in eNOS expression, in addition to changes in MMP/TIMP ratios and MMP-2 and MMP-9 activation, may partially explain the changes observed in the aorta of treated Apo-E-/- mice induced by RPM.	Sirolimus	198-201	matrix metallopeptidase 2	Mus musculus	78-83
15919502-0	2005	Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.	Sirolimus	25-34	calcineurin binding protein 1	Homo sapiens	39-60
15849787-5	2005	Inhibition of the TOR kinase pathway by rapamycin treatment abolishes HXT1 glucose induction.	Sirolimus	40-49	hexose transporter HXT1	Saccharomyces cerevisiae S288C	70-74
15604215-9	2005	Inhibition of mTOR/S6K1 by rapamycin blunted insulin-induced Ser636/Ser639 phosphorylation of IRS-1, leading to a rapid (approximately 5 min) and persistent increase in IRS-1-associated phosphatidylinositol 3-kinase activity and Akt phosphorylation.	Sirolimus	27-36	mechanistic target of rapamycin kinase	Rattus norvegicus	14-18
15604215-11	2005	In vitro studies with rapamycin suggest that mTOR/S6K1 overactivation contributes to elevated serine phosphorylation of IRS-1, leading to impaired insulin signaling to Akt in liver and muscle of this dietary model of obesity.	Sirolimus	22-31	mechanistic target of rapamycin kinase	Rattus norvegicus	45-49
16895664-6	2005	The last developed immunosuppressant mTOR inhibitors, sirolimus and everolimus, effectively control the proliferation of various tumor cell lines, promote tumor cell apoptosis and inhibit metastatic tumor growth and angiogenesis in in vivo mouse models by affecting VEGF production and effect.	Sirolimus	54-63	vascular endothelial growth factor A	Mus musculus	266-270
15671269-13	2005	The protein level of substance P and vascular endothelial growth factor (VEGF) was significantly decreased--more in mice treated with rapamycin than the control mice--as shown by ELISA assay of peripheral blood.	Sirolimus	134-143	vascular endothelial growth factor A	Mus musculus	37-71
15671269-13	2005	The protein level of substance P and vascular endothelial growth factor (VEGF) was significantly decreased--more in mice treated with rapamycin than the control mice--as shown by ELISA assay of peripheral blood.	Sirolimus	134-143	vascular endothelial growth factor A	Mus musculus	73-77
15585311-6	2005	We found that the number of CD8+ T(EM), as defined by CD3+CD45R0+CD8+CD27- phenotype, was significantly reduced in patients receiving a rapamycin-eluting stent as compared with basal values.	Sirolimus	136-145	CD8a molecule	Homo sapiens	28-31
15585311-6	2005	We found that the number of CD8+ T(EM), as defined by CD3+CD45R0+CD8+CD27- phenotype, was significantly reduced in patients receiving a rapamycin-eluting stent as compared with basal values.	Sirolimus	136-145	CD8a molecule	Homo sapiens	65-68
15585311-9	2005	These findings suggest that rapamycin eluted from medicated coronary stents rapidly induce a redistribution of memory CD8+ T lymphocyte subsets, with a significant decrease of T(EM) and a corresponding increase of T(CM) increase circulating within the coronary sinus.	Sirolimus	28-37	CD8a molecule	Homo sapiens	118-121
15631539-14	2005	Multicentre and single-centre reports have demonstrated that both calcineurin inhibitor withdrawal and avoidance were possible when sirolimus was used in a concentration-controlled fashion, with low-dose corticosteroids and MMF.	Sirolimus	132-141	calcineurin binding protein 1	Homo sapiens	66-87
16243732-1	2005	OBJECTIVE: We examined our experience using the sirolimus eluting stents (Cypher) as an alternative to surgical revascularization in carefully selected cohort of patients undergoing multi-vessel percutaneous coronary intervention.	Sirolimus	48-57	LIM domain binding 3	Homo sapiens	74-80
15313464-6	2004	Fasted rats were treated with the mTOR inhibitor, rapamycin, prior to oral administration of leucine.	Sirolimus	50-59	mechanistic target of rapamycin kinase	Rattus norvegicus	34-38
15313464-7	2004	It was found that rapamycin severely attenuated leucine-induced signaling through mTOR in liver.	Sirolimus	18-27	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
15367229-2	2004	However, sirolimus can potentiate calcineurin inhibitor (CNI) nephrotoxicity by some still uncertain mechanisms.	Sirolimus	9-18	calcineurin binding protein 1	Homo sapiens	34-55
15339861-1	2004	Co-administration of the calcineurin inhibitor cyclosporine and the mTOR inhibitors sirolimus or everolimus increases the efficacy of immunosuppression after organ transplantation.	Sirolimus	84-93	mechanistic target of rapamycin kinase	Rattus norvegicus	68-72
15517874-6	2004	Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	59-65
15517874-6	2004	Rapamycin efficiently inhibited the activation of the mTOR-p70S6K pathway and the anchorage-independent growth of both 3T3-Akt cells, demonstrating the importance of the mTOR-p70S6K pathway for transformation by Akt1 as well as by Akt2.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	175-181
15218033-9	2004	Overexpression of PP5, but not the PP2A catalytic subunit, blocked rapamycin-induced phosphorylation of c-Jun, and protected cells from rapamycin-induced apoptosis.	Sirolimus	67-76	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	104-109
15297830-21	2004	In this experimental model rapamycin suppressed aneurysm expansion, decreased NF kappa B activation (a marker of inflammation), and decreased matrix metalloproteinase-9 levels.	Sirolimus	27-36	matrix metallopeptidase 9	Rattus norvegicus	142-168
15210777-6	2004	However, blockade or genetic absence of CD28/CD154 costimulatory molecules rendered CD4(+) T cell-mediated rejection sensitive to rapamycin, and long term skin allograft survival can be readily induced by rapamycin in the absence of CD28/CD154 signals (&gt;100 days).	Sirolimus	130-139	CD4 antigen	Mus musculus	84-87
15021902-6	2004	In contrast, inhibition of p70S6k with rapamycin did not show any inhibitory effects.	Sirolimus	39-48	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	27-33
15228089-0	2004	Glucose-induced binding of the polypyrimidine tract-binding protein (PTB) to the 3"-untranslated region of the insulin mRNA (ins-PRS) is inhibited by rapamycin.	Sirolimus	150-159	polypyrimidine tract binding protein 1	Rattus norvegicus	69-72
14990989-3	2004	Phosphorylated S6 protein, a substrate of p70S6K, was expressed in the early lesions in Eker rats, and this expression was suppressed by the treatment of rapamycin, an inhibitor of mTOR.	Sirolimus	154-163	mechanistic target of rapamycin kinase	Rattus norvegicus	181-185
15014039-0	2004	Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.	Sirolimus	55-64	thymidine phosphorylase	Mus musculus	79-102
14610086-6	2004	In isolated rat hepatocytes, both regulatory amino acids (RegAA) and insulin coordinately activated p70(S6k) phosphorylation, which was completely blocked by rapamycin, an mTOR inhibitor.	Sirolimus	158-167	mechanistic target of rapamycin kinase	Rattus norvegicus	172-176
14595104-4	2004	Rapamycin treatment also caused a decrease in the amount of Rrn3p-polymerase I complex, similar to stationary phase.	Sirolimus	0-9	rDNA-binding RNA polymerase I transcriptional factor	Saccharomyces cerevisiae S288C	60-65
14742978-0	2004	Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery.	Sirolimus	52-61	Cd4 molecule	Rattus norvegicus	29-32
14742978-0	2004	Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery.	Sirolimus	52-61	Cd4 molecule	Rattus norvegicus	87-90
14681687-0	2003	Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing"s sarcoma cell proliferation.	Sirolimus	0-9	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	72-77
14623952-2	2003	The mTOR inhibitor rapamycin can prevent forms of protein synthesis-dependent synaptic plasticity such as long-term facilitation in Aplysia and late-phase long-term potentiation (L-LTP) in the hippocampal CA1 region of rodents.	Sirolimus	19-28	carbonic anhydrase 1	Homo sapiens	205-208
14500340-5	2003	Rapamycin, a mTOR inhibitor, reduced the production of VEGF by Tsc1- and Tsc2-null fibroblasts to normal levels.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	73-77
14500340-6	2003	Moreover, short-term treatment of Tsc1+/- mice with rapamycin at 20 mg/kg led to some changes in tumor morphology and a reduction in serum VEGF levels.	Sirolimus	52-61	vascular endothelial growth factor A	Mus musculus	139-143
12676950-0	2003	Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2.	Sirolimus	0-9	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	125-129
12676950-5	2003	Here we show that rapamycin causes an increase in phosphorylated eIF2alpha to translationally derepress GCN4.	Sirolimus	18-27	eukaryotic translation initiation factor 2A	Homo sapiens	65-74
12676950-7	2003	It is thus suggested that rapamycin does not inhibit dephosphorylation of eIF2alpha but rather activates the kinase GCN2.	Sirolimus	26-35	serine/threonine-protein kinase GCN2	Saccharomyces cerevisiae S288C	116-120
12531798-7	2003	These novel findings have implications for RAPA-based therapy of chronic DC-triggered autoimmune diseases, transplant rejection, and hematologic malignancies with activating Flt3 mutations.	Sirolimus	43-47	FMS-like tyrosine kinase 3	Mus musculus	174-178
12752312-9	2003	Sirolimus treatment resulted in decreased expression of IL-12p40, IFN-gamma and IL-10 mRNA.	Sirolimus	0-9	interleukin 12b	Mus musculus	56-64
12692902-6	2003	As well, rapamycin, a p70 S6 kinase inhibitor, blocked the ATP-mediated proliferative response in NSCs.	Sirolimus	9-18	annexin A6	Homo sapiens	22-25
12866772-2	2003	From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson &amp; Johnson) appear to demonstrate a remarkable efficacy and safety in preventing restenosis.	Sirolimus	25-34	LIM domain binding 3	Homo sapiens	56-62
12647306-8	2003	Treatment of cells with rapamycin, an inhibitor of the mammalian target of mTOR, resulted in a 47% and a 53% decrease in the AP activity induced by OP-1 alone and by OP-1 plus IGF-I, respectively.	Sirolimus	24-33	bone morphogenetic protein 7	Homo sapiens	148-152
12647306-8	2003	Treatment of cells with rapamycin, an inhibitor of the mammalian target of mTOR, resulted in a 47% and a 53% decrease in the AP activity induced by OP-1 alone and by OP-1 plus IGF-I, respectively.	Sirolimus	24-33	bone morphogenetic protein 7	Homo sapiens	166-170
12631072-11	2003	Immunostaining of lung tissues for von Willebrand factor was minimal and circulating levels of VEGF-A and TGF-beta1 were lower in the rapamycin-treated mice compared to untreated or cyclosporine-treated mice.	Sirolimus	134-143	vascular endothelial growth factor A	Mus musculus	95-101
12504022-3	2002	Signaling pathways activated in response to rapamycin-induced nutrient limitation, DNA damage, and secretory pathway defects all require Maf1 in order to affect pol III transcriptional repression.	Sirolimus	44-53	RNA polymerase III-inhibiting protein MAF1	Saccharomyces cerevisiae S288C	137-141
12225947-4	2002	Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K.	Sirolimus	76-85	pyruvate dehydrogenase kinase 1	Homo sapiens	201-206
12231510-5	2002	CLIP-170 is phosphorylated in vivo at multiple sites, including rapamycin-sensitive and -insensitive sites, and is phosphorylated by FRAP in vitro at the rapamycin-sensitive sites.	Sirolimus	64-73	CAP-Gly domain containing linker protein 1	Homo sapiens	0-8
12235265-9	2002	Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused &gt;80% inhibition at 5 microM).	Sirolimus	35-44	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	69-83
12192598-8	2002	Blockade of p70 S6K activation by rapamycin abrogated the IGF-II-mediated protection of cells to cisplatin-induced apoptosis.	Sirolimus	34-43	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	12-19
12234280-3	2002	In two children who underwent living donor kidney transplantation for atypical HUS, we pre-emptively employed sirolimus in a calcineurin inhibitor-free immunosuppression regimen.	Sirolimus	110-119	calcineurin binding protein 1	Homo sapiens	125-146
12176411-0	2002	Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function.	Sirolimus	57-66	signal transducer and activator of transcription 4	Homo sapiens	30-35
11872747-9	2002	Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth.	Sirolimus	96-105	annexin A6	Homo sapiens	27-30
11834720-9	2002	Moreover, the stress-mediated induction of HIF-1alpha and VEGF was suppressed by gadolinium (a stretch-activated channel inhibitor), wortmannin, and rapamycin (a FRAP inhibitor).	Sirolimus	149-158	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	43-53
11882580-8	2002	PDGF-stimulated PC5 induction was inhibited by the PI3-kinase inhibitor wortmannin, and by rapamycin, an inhibitor of mTOR/p70(s6)-kinase (both P&lt;0.05).	Sirolimus	91-100	proprotein convertase subtilisin/kexin type 5	Rattus norvegicus	16-19
11591714-6	2001	Moreover, pretreatment with rapamycin, an inhibitor of p70 S6-K, inhibited UVB-induced activation of p70 S6-K, but UVB-induced activation of Akt did not change.	Sirolimus	28-37	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	55-63
11591714-6	2001	Moreover, pretreatment with rapamycin, an inhibitor of p70 S6-K, inhibited UVB-induced activation of p70 S6-K, but UVB-induced activation of Akt did not change.	Sirolimus	28-37	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	101-109
11713209-8	2001	Rapamycin, an inhibitor of p70(S6K), a downstream effector of IRS-1 signaling, partially inhibits (but does not completely abrogate) the increase in Id2 gene expression.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	27-34
11551912-2	2001	Here we have developed an in vitro assay to study nuclear export mediated by the C-terminal shuttle domain of Tap involving the rapamycin-induced attachment of this transport domain to a nuclear green fluorescent protein-containing reporter.	Sirolimus	128-137	nuclear RNA export factor 1	Homo sapiens	110-113
11606920-8	2001	OBJECTIVE: Based on this clinical observation and the observation that rapamycin, a chemically similar compound to tacrolimus, is known to inhibit signaling from the gli-1 oncogene, we examined keloids and scars for expression of Gli-1 protein.	Sirolimus	71-80	GLI family zinc finger 1	Homo sapiens	166-171
11606920-8	2001	OBJECTIVE: Based on this clinical observation and the observation that rapamycin, a chemically similar compound to tacrolimus, is known to inhibit signaling from the gli-1 oncogene, we examined keloids and scars for expression of Gli-1 protein.	Sirolimus	71-80	GLI family zinc finger 1	Homo sapiens	230-235
11544316-6	2001	Both FK506 and rapamycin efficiently inhibited proliferation of p18-null T cells.	Sirolimus	15-24	cyclin dependent kinase inhibitor 2C	Mus musculus	64-67
11406149-5	2001	The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD.	Sirolimus	157-166	Cd4 molecule	Rattus norvegicus	49-52
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	105-114	cyclin-dependent kinase inhibitor 1B	Mus musculus	69-72
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	105-114	cyclin-dependent kinase inhibitor 1B	Mus musculus	73-77
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	105-114	cyclin-dependent kinase inhibitor 1B	Mus musculus	142-145
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	105-114	cyclin-dependent kinase inhibitor 1B	Mus musculus	146-150
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	222-231	cyclin-dependent kinase inhibitor 1B	Mus musculus	142-145
11413088-3	2001	Previously, we showed that mixed embryonic fibroblasts obtained from p27(Kip1)(-/-) mice were relatively rapamycin-resistant, suggesting that p27(Kip1) plays an integral role in modulating the antiproliferative effects of rapamycin.	Sirolimus	222-231	cyclin-dependent kinase inhibitor 1B	Mus musculus	146-150
11413088-4	2001	We hypothesized that the antimigratory effect of rapamycin may also be mediated by p27(Kip1).	Sirolimus	49-58	cyclin-dependent kinase inhibitor 1B	Mus musculus	83-86
11413088-4	2001	We hypothesized that the antimigratory effect of rapamycin may also be mediated by p27(Kip1).	Sirolimus	49-58	cyclin-dependent kinase inhibitor 1B	Mus musculus	87-91
11413088-9	2001	CONCLUSIONS: Lack of p27(Kip1) reduces rapamycin-mediated inhibition of SMC migration.	Sirolimus	39-48	cyclin-dependent kinase inhibitor 1B	Mus musculus	21-24
11413088-9	2001	CONCLUSIONS: Lack of p27(Kip1) reduces rapamycin-mediated inhibition of SMC migration.	Sirolimus	39-48	cyclin-dependent kinase inhibitor 1B	Mus musculus	25-29
11399049-7	2001	Rapamycin, an inhibitor of p70 S6 kinase, completely inhibited the differentiation and suppressed the accumulation of HSP27 and alphaB-crystallin.	Sirolimus	0-9	heat shock protein 1	Mus musculus	118-123
11369667-6	2001	A second type of CID, rapamycin, brings together one FKBP12 domain and one FRB domain, resulting in heterodimerization of the c-Kit(FKBP12) and Flt-3(FRB) fusions.	Sirolimus	22-31	FMS-like tyrosine kinase 3	Mus musculus	144-149
11369667-7	2001	Ba/F3 cell growth was promoted not only by FK1012- or AP1510-induced homodimerization of the c-Kit(FKBP12) fusion (as reported previously), but also by rapamycin-induced c-Kit(FKBP12)-Flt-3(FRB) heterodimerization.	Sirolimus	152-161	FMS-like tyrosine kinase 3	Mus musculus	184-189
11406650-2	2001	Rapamycin treatment reportedly increases expression of p27, a cyclin-dependent kinase inhibitor.	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Mus musculus	55-58
11443573-3	2001	By inhibiting signal III, the mechanism of action and side effects of sirolimus (rapamycin) and its derivative RAD are distinct from other immunosuppressants.	Sirolimus	70-79	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	111-114
11443573-3	2001	By inhibiting signal III, the mechanism of action and side effects of sirolimus (rapamycin) and its derivative RAD are distinct from other immunosuppressants.	Sirolimus	81-90	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	111-114
11027279-7	2000	Although rapamycin treatment elicited the rapid dephosphorylation of Npr1 and induction of Gap1 expression, hydrostatic pressure did not affect the phosphorylation state of Npr1 and it decreased the level of Gap1 protein, suggesting that the pressure-sensing pathway may be independent of Npr1 function.	Sirolimus	9-18	serine/threonine protein kinase NPR1	Saccharomyces cerevisiae S288C	69-73
10934035-4	2000	Recruitment of an activated Rac1 protein to the cytoplasmic domain of an engineered membrane receptor by using rapamycin as a bridge induces ingestion of latex beads bound to the receptor.	Sirolimus	111-120	Rac family small GTPase 1	Homo sapiens	28-32
10998178-3	2000	Here, we report the cloning and characterization of a novel gene, termed FAP1, which confers resistance to rapamycin by competing with the drug for binding to FKBP12.	Sirolimus	107-116	Fap1p	Saccharomyces cerevisiae S288C	73-77
10998178-5	2000	We provide genetic and biochemical evidence that FAP1 interacts physically with FKBP12 in vivo and in vitro, and that it competes with rapamycin for interaction.	Sirolimus	135-144	Fap1p	Saccharomyces cerevisiae S288C	49-53
10846175-7	2000	A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells.	Sirolimus	198-207	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	20-27
10846175-7	2000	A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells.	Sirolimus	198-207	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	155-162
10849422-5	2000	We now demonstrate that SCF activates phosphoinositide 3-kinase (PI3-K) and p70 S6 kinase (p70S6K) and that rapamycin, a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K, completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia.	Sirolimus	108-117	KIT ligand	Homo sapiens	251-254
10849422-6	2000	SCF induced cyclin D3 expression and phosphorylation of the retinoblastoma protein through a pathway that is sensitive to both wortmannin and rapamycin.	Sirolimus	142-151	KIT ligand	Homo sapiens	0-3
10848587-10	2000	Targeted disruption of the EAP1 gene results in a temperature-sensitive phenotype and also confers partial resistance to growth inhibition by rapamycin.	Sirolimus	142-151	Eap1p	Saccharomyces cerevisiae S288C	27-31
10801327-2	2000	The extent to which insulin induces this response is potentiated by cycloheximide and blocked by pretreatment with rapamycin.	Sirolimus	115-124	Insulin-like receptor	Drosophila melanogaster	20-27
10660304-5	2000	We found that CNTF-induced phosphorylation of Ser727 was inhibited by the mTOR inhibitor rapamycin, but not by inhibitors of MAPK and protein kinase C (PKC) activation.	Sirolimus	89-98	ciliary neurotrophic factor	Homo sapiens	14-18
10551636-2	1999	RESULTS: RAD displayed a similar spectrum of side effects as observed with rapamycin, namely, an increased incidence of infection associated with the augmented immunosuppression and a dose-related occurrence of thrombocytopenia, hypercholesterolemia, and hypertriglyceridemia, particularly at the 7.5-mg dose.	Sirolimus	75-84	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	Homo sapiens	9-12
10529377-5	1999	Moreover, rapamycin reversed the Ca(2+) release induced by combined treatment with 3 mM caffeine and the PCoA-ACBP complex.	Sirolimus	10-19	acyl-CoA-binding protein	Oryctolagus cuniculus	110-114
10529377-7	1999	Under the above experimental conditions, rapamycin removed FKBP12 from the TC membranes, as revealed by Western blot analysis.	Sirolimus	41-50	peptidyl-prolyl cis-trans isomerase FKBP1A	Oryctolagus cuniculus	59-65
10480882-2	1999	We found that inhibitors of the p42/p44 MAPK pathway (PD98059) and the PI3K-p70 S6K pathway (wortmannin, Ly294002, and rapamycin) all block thymidine incorporation stimulated by fetal calf serum in the resting mouse endothelial cell line 1G11.	Sirolimus	119-128	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	76-83
10437918-0	1999	The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin.	Sirolimus	79-88	mechanistic target of rapamycin kinase	Rattus norvegicus	64-68
10437918-3	1999	In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Rattus norvegicus	146-150
10437918-3	1999	In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism.	Sirolimus	127-136	mechanistic target of rapamycin kinase	Rattus norvegicus	155-159
10217658-14	1999	CONCLUSIONS: Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27(kip1) and inhibition of the pRb phosphorylation within the vessel wall.	Sirolimus	13-22	cyclin dependent kinase inhibitor 3	Homo sapiens	149-153
9808344-9	1998	The inhibitory effect of SDZ ASM 981 was antagonized by rapamycin.	Sirolimus	56-65	H19, imprinted maternally expressed transcript (non-protein coding)	Rattus norvegicus	29-32
9721171-10	1998	Rapamycin inhibited basal protein synthesis and blocked the increase to all CCK concentrations.	Sirolimus	0-9	cholecystokinin	Rattus norvegicus	76-79
9721171-13	1998	Rapamycin and LY294002 eliminated this effect of CCK.	Sirolimus	0-9	cholecystokinin	Rattus norvegicus	49-52
9657754-4	1998	Rapamycin treatment disrupts the association of PP2Ac/alpha4 in parallel with the inhibitory effect of lymphoid cell proliferation.	Sirolimus	0-9	immunoglobulin binding protein 1	Homo sapiens	54-60
9657754-7	1998	Introduction of the malpha4 cDNA into Jurkat cells or the increased association of PP2Ac/alpha4 by the culture with low serum concentration confers cells with rapamycin resistance.	Sirolimus	159-168	immunoglobulin binding protein 1	Homo sapiens	21-27
9603954-0	1998	Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.	Sirolimus	0-9	cyclin D1	Mus musculus	73-82
9603954-3	1998	We now show that in serum-stimulated NIH 3T3 cells, rapamycin treatment delays the accumulation of cyclin D1 mRNA during progression through G1.	Sirolimus	52-61	cyclin D1	Mus musculus	99-108
9545305-7	1998	LIF-induced p70 S6 kinase activation, protein synthesis, and c-fos mRNA expression were inhibited by wortmannin and rapamycin.	Sirolimus	116-125	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-66
9528925-8	1998	Rapamycin which indirectly prevents activation of the p70 ribosomal protein-S6 kinase (p70S6k), suppressed IGFBP-5 induction.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	54-85
9528925-8	1998	Rapamycin which indirectly prevents activation of the p70 ribosomal protein-S6 kinase (p70S6k), suppressed IGFBP-5 induction.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	87-93
9541032-7	1998	Incubation of cells with 100 nM wortmannin or 30 ng/ml rapamycin prevented the dexamethasone-stimulated elevation of GLUT1 protein.	Sirolimus	55-64	solute carrier family 2 member 1	Homo sapiens	117-122
9441740-0	1997	Expression and chromosomal localization of the human alpha 4/IGBP1 gene, the structure of which is closely related to the yeast TAP42 protein of the rapamycin-sensitive signal transduction pathway.	Sirolimus	149-158	immunoglobulin binding protein 1	Homo sapiens	53-60
9441740-0	1997	Expression and chromosomal localization of the human alpha 4/IGBP1 gene, the structure of which is closely related to the yeast TAP42 protein of the rapamycin-sensitive signal transduction pathway.	Sirolimus	149-158	immunoglobulin binding protein 1	Homo sapiens	61-66
9367837-6	1997	Since p70 S6 kinase (p70S6K) is considered an important mediator of PI3K action in several experimental systems, the effect of rapamycin, which can lead to selective inhibition of p70S6K, was also investigated.	Sirolimus	127-136	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	180-186
9367837-7	1997	Rapamycin inhibited p70S6K activity and produced ODC inhibiting effects similar to those elicited by LY294002.	Sirolimus	0-9	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	20-26
9367837-7	1997	Rapamycin inhibited p70S6K activity and produced ODC inhibiting effects similar to those elicited by LY294002.	Sirolimus	0-9	ornithine decarboxylase, structural 1	Mus musculus	49-52
9211946-5	1997	Activation of the JNK/SAPK signaling pathway with anisomycin resulted in enhanced phosphorylation of eIF4E, which was prevented by either rapamycin or the highly specific p38 MAP kinase inhibitor, SB203580.	Sirolimus	138-147	mitogen-activated protein kinase 8	Mus musculus	18-26
9176016-10	1997	Mitogenic combinations of cAMP strongly stimulated the phosphorylation and activation of the serine/threonine kinase p70 S6 kinase, p70S6K, an effect that was inhibited by rapamycin.	Sirolimus	172-181	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	132-138
8943329-0	1996	Rapamycin resistance tied to defective regulation of p27Kip1.	Sirolimus	0-9	cyclin-dependent kinase inhibitor 1B	Mus musculus	53-60
8943329-3	1996	The antiproliferative effects of rapamycin are associated with prevention of mitogen-induced downregulation of the cyclin-dependent kinase inhibitor p27Kip1, suggesting that the latter may play an important role in the growth pathway targeted by rapamycin.	Sirolimus	33-42	cyclin-dependent kinase inhibitor 1B	Mus musculus	149-156
8943329-5	1996	Fibroblasts and T lymphocytes from mice with a targeted disruption of the p27Kip1 gene had impaired growth-inhibitory responses to rapamycin.	Sirolimus	131-140	cyclin-dependent kinase inhibitor 1B	Mus musculus	74-81
8943329-6	1996	These results suggest that the ability to regulate p27Kip1 levels is important for rapamycin to exert its antiproliferative effects.	Sirolimus	83-92	cyclin-dependent kinase inhibitor 1B	Mus musculus	51-58
8855259-9	1996	Consistent with this observation, analysis of total S6 kinase activity in fractionated Drosophila Schneider line 2 cell extracts reveals two peaks of activity, only one of which is rapamycin sensitive.	Sirolimus	181-190	Ribosomal protein S6 kinase	Drosophila melanogaster	52-61
8855259-10	1996	By employing a monospecific polyclonal antibody generated against Dp70s6k, we show that the cloned DP70s6k cDNA has identity with only the rapamycin sensitive peak, suggesting that this biological system would be useful in determining not only the mechanism of p70s6k activation, but also in elucidating the mechanism by which rapamycin acts to inhibit cell growth.	Sirolimus	139-148	Ribosomal protein S6 kinase	Drosophila melanogaster	99-106
8799169-3	1996	Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor.	Sirolimus	85-94	submaxillary gland androgen regulated protein 3A	Homo sapiens	40-56
8692927-11	1996	Like the mammalian and yeast FKBP13, the recombinant VfFKBP15 protein has rotamase activity that is inhibited by both FK506 and rapamycin with a Ki value of 30 nM and 0.9 nM, respectively, illustrating that VfFKBP15 binds rapamycin in preference over FK506.	Sirolimus	128-137	FKBP prolyl isomerase 2	Homo sapiens	29-35
7721872-0	1995	Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte.	Sirolimus	0-9	proliferating cell nuclear antigen	Mus musculus	51-85
7721872-7	1995	Analysis of nuclear proteins demonstrated that rapamycin selectively blocked the expression of proliferating cell nuclear antigen (PCNA), an obligate cofactor of DNA polymerase-delta, an important component for DNA replication.	Sirolimus	47-56	proliferating cell nuclear antigen	Mus musculus	95-129
7721872-7	1995	Analysis of nuclear proteins demonstrated that rapamycin selectively blocked the expression of proliferating cell nuclear antigen (PCNA), an obligate cofactor of DNA polymerase-delta, an important component for DNA replication.	Sirolimus	47-56	proliferating cell nuclear antigen	Mus musculus	131-135
7721872-8	1995	Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells.	Sirolimus	0-9	proliferating cell nuclear antigen	Mus musculus	37-41
7721872-10	1995	Using DNA binding gel mobility shift assay we demonstrated that rapamycin potently inhibited the binding of CREB/ATF transcription factors to CRE elements in the murine proximal PCNA promoter.	Sirolimus	64-73	proliferating cell nuclear antigen	Mus musculus	178-182
7540861-0	1995	Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin.	Sirolimus	77-86	CD5 antigen	Mus musculus	13-16
7540861-3	1995	We report that anti-mu induced CD5 expression on B-2 cells was inhibited by CsA as well as FK-520 and rapamycin.	Sirolimus	102-111	CD5 antigen	Mus musculus	31-34
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Sirolimus	184-193	CD4 antigen	Mus musculus	20-23
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Sirolimus	184-193	CD5 antigen	Mus musculus	134-137
8286755-7	1994	In these studies, we showed that RAPA administration can inhibit MHC class I-restricted CD8+ or class II-restricted CD4+ T-cell-mediated graft rejection without compromising recipient survival.	Sirolimus	33-37	CD8a molecule	Homo sapiens	88-91
8413204-6	1993	Genetic analysis indicated that the dominant mutations are nonallelic to mutations in RBP1 and define two genes, designated DRR1 and DRR2 (for dominant rapamycin resistance).	Sirolimus	152-161	phosphatidylinositol kinase-related protein kinase TOR1	Saccharomyces cerevisiae S288C	124-128
1709302-4	1991	The nature of this complex has implications for the mechanism of rotamase catalysis and for the biological actions of FK506 and rapamycin.	Sirolimus	128-137	FKBP prolyl isomerase 10	Homo sapiens	65-73
33773987-0	2021	Long-term effects of sirolimus on human skin TSC2-null fibroblast-like cells.	Sirolimus	21-30	TSC complex subunit 2	Homo sapiens	45-49
33773987-7	2021	Withdrawal of sirolimus from TSC2-/- cells resulted in a highly proliferative phenotype and caused cells to enter the S-phase of the cell cycle, with persistent phosphorylation of mTOR, p70 S6 kinase, ribosomal protein S6, and 4EBP1, decreased cyclin D kinase inhibitors and transient hyperactivation of Akt.	Sirolimus	14-23	TSC complex subunit 2	Homo sapiens	29-33
33773987-8	2021	Sirolimus modulated the estrogen- and autophagy-dependent volume of TSC2-/- cells.	Sirolimus	0-9	TSC complex subunit 2	Homo sapiens	68-72
33773987-9	2021	These results suggest that sirolimus may decrease the size of TSC tumors by reducing TSC2-/- cell volume, altering cell cycle and reprogramming TSC2-null cells.	Sirolimus	27-36	TSC complex subunit 2	Homo sapiens	85-89
33773987-9	2021	These results suggest that sirolimus may decrease the size of TSC tumors by reducing TSC2-/- cell volume, altering cell cycle and reprogramming TSC2-null cells.	Sirolimus	27-36	TSC complex subunit 2	Homo sapiens	144-148
33800526-10	2021	Additionally, co-treatment with OxyR with rapamycin intended to inhibit the mammalian target of rapamycin (mTOR) caused significantly lower levels of phospho-S6 ribosomal protein (pS6) and higher LC3-II expression, implying that OxyR-mediated autophagy was dependent on the mTOR pathway.	Sirolimus	42-51	taste 2 receptor member 63 pseudogene	Homo sapiens	180-183
33800526-10	2021	Additionally, co-treatment with OxyR with rapamycin intended to inhibit the mammalian target of rapamycin (mTOR) caused significantly lower levels of phospho-S6 ribosomal protein (pS6) and higher LC3-II expression, implying that OxyR-mediated autophagy was dependent on the mTOR pathway.	Sirolimus	42-51	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	196-199
34959219-10	2022	Rapamycin (autophagy activator) enhanced ROS levels and apoptosis in HG-treated RECs by activating autophagy, which was rescued by Drp1 knockdown.	Sirolimus	0-9	dynamin 1-like	Rattus norvegicus	131-135
34673129-0	2022	KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.	Sirolimus	42-51	lysine demethylase 1A	Homo sapiens	0-5
34673129-5	2022	Mechanistic studies demonstrated that KDM1A inhibition attenuated the activation of mTOR signaling cascade and abolished rapamycin induced feedback activation of Akt.	Sirolimus	121-130	lysine demethylase 1A	Homo sapiens	38-43
34673129-6	2022	RNA-seq analysis identified that KDM1A inhibition downregulated the expression of genes involved in rapamycin induced activation of Akt, including the mTORC2 complex.	Sirolimus	100-109	lysine demethylase 1A	Homo sapiens	33-38
34924000-8	2021	RESULTS: The ALP activity and the expression of RunX2 in fractured osteoblasts were significantly elevated, the apoptotic rate was suppressed by rapamycin, 60, and 80 muM beta-ecdysterone.	Sirolimus	145-154	ATHS	Homo sapiens	13-16
34895222-4	2021	Rapamycin (sirolimus) and everolimus are commercially available small molecule inhibitors that target mTOR and therefore may have anticancer activity in canine melanoma.	Sirolimus	0-9	mechanistic target of rapamycin kinase	Canis lupus familiaris	102-106
34895222-4	2021	Rapamycin (sirolimus) and everolimus are commercially available small molecule inhibitors that target mTOR and therefore may have anticancer activity in canine melanoma.	Sirolimus	11-20	mechanistic target of rapamycin kinase	Canis lupus familiaris	102-106
34895222-11	2021	Levels of phosphorylated mTOR were reduced by rapamycin and everolimus in all four cell lines, but activation of the downstream protein p70S6K was not consistently reduced by treatment in two of the cell lines.	Sirolimus	46-55	mechanistic target of rapamycin kinase	Canis lupus familiaris	25-29
34895222-13	2021	CONCLUSIONS: Inhibition of mTOR by rapalogs, such as rapamycin and everolimus combined with carboplatin chemotherapy may have activity in canine melanoma.	Sirolimus	53-62	mechanistic target of rapamycin kinase	Canis lupus familiaris	27-31
34024231-2	2021	Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the MTORC1 complex and increasing cellular clearance mechanisms.	Sirolimus	0-9	FK506 binding protein 5	Mus musculus	43-48
34024231-2	2021	Rapamycin interacts with FKBP1A/FKBP12 and FKBP5/FKBP51, inhibiting the MTORC1 complex and increasing cellular clearance mechanisms.	Sirolimus	0-9	FK506 binding protein 5	Mus musculus	49-55
34023781-2	2021	Nutrient depletion and inactivation of target of rapamycin complex 1 (TORC1) protein kinase elicit recruitment of the ESCRT-0 complex (Vps27-Hse1) onto vacuolar membranes and ESCRT-mediated microautophagy induction.	Sirolimus	49-58	ESCRT-0 subunit protein VPS27	Saccharomyces cerevisiae S288C	135-140
34023781-2	2021	Nutrient depletion and inactivation of target of rapamycin complex 1 (TORC1) protein kinase elicit recruitment of the ESCRT-0 complex (Vps27-Hse1) onto vacuolar membranes and ESCRT-mediated microautophagy induction.	Sirolimus	49-58	ESCRT-0 subunit protein HSE1	Saccharomyces cerevisiae S288C	141-145
34015361-5	2021	Treatment with rapamycin increased frequencies of monocytic myeloid-derived suppressor cells (M-MDSCs), augmented the immunosuppressive activity of M-MDSCs on T cells through indoleamine 2,3-dioxygenase pathway and shifted CD4+ T cells towards regulatory T cells in obese graft recipients.	Sirolimus	15-24	CD4 antigen	Mus musculus	223-226
33964457-4	2021	Using the RiD-receptors, we demonstrated that the rapamycin-mediated association of chimeric cytosolic kinase domains from the BRI1/BAK1 receptor/co-receptor, but not the BRI1/BRI1 or BAK1/BAK1 homodimer, is sufficient to activate downstream brassinosteroid signaling and physiological responses and that the engineered RiD-FLS2/BAK1 activates flagellin-22-mediated immune signaling and responses.	Sirolimus	50-59	BCL2 antagonist/killer 1	Homo sapiens	132-136
33705959-0	2021	NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder.	Sirolimus	42-51	nuclear paraspeckle assembly transcript 1	Homo sapiens	0-5
33705959-11	2021	From the results of this study, NEAT1/hsa-miR-372-3p/AGPS/APOC4 axis plays a vital role in rapamycin-disruption of lipid homeostasis.	Sirolimus	91-100	nuclear paraspeckle assembly transcript 1	Homo sapiens	32-37
33705959-11	2021	From the results of this study, NEAT1/hsa-miR-372-3p/AGPS/APOC4 axis plays a vital role in rapamycin-disruption of lipid homeostasis.	Sirolimus	91-100	apolipoprotein C4	Homo sapiens	58-63
33116044-10	2021	In addition, the clinical-mimicking dose of sirolimus reduced the thickness of the intestinal mucosal layer, increased the intestinal permeability, and enriched the circulating pro-inflammatory factors, including IL-12, IL-6, MCP-1, GM-CSF, and IL-1beta.	Sirolimus	44-53	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	233-239
33924998-5	2021	Additionally, the impact of rapamycin pre-treatment on the expression of the GluN2B subunit of NMDA receptor in the brain was assessed in adult rats.	Sirolimus	28-37	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	77-83
33924998-8	2021	Rapamycin prevented the neonatal effect of ethanol and normalized the GluN2B down-regulation in the hippocampus and the prefrontal cortex, as well as normalized this subunit"s up-regulation in the striatum of adult rats.	Sirolimus	0-9	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	70-76
33959512-7	2021	Rapamycin reduced the secretion of IL-4 in tumor cells as well as YM1 in macrophages.	Sirolimus	0-9	chitinase-like 3	Mus musculus	66-69
33959512-10	2021	Moreover, the colocalized proportion of both xCT and LC3 in tumor tissues was elevated by the injection of rapamycin into tumoral regions.	Sirolimus	107-116	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	53-56
33853774-7	2021	Kog1 regulates SNF1/AMPK activity and outputs and mediates a rapamycin-independent activation of the SNF1 targets Mig1 and Cat8.	Sirolimus	61-70	ubiquitin-binding TORC1 subunit KOG1	Saccharomyces cerevisiae S288C	0-4
33883257-3	2021	METHOD: In this study, we evaluated the roles of amino acids and the Rag complex in regulating mammalian target of rapamycin complex 1 (mTORC1) signaling in CD8+ TILs.	Sirolimus	115-124	CD8a molecule	Homo sapiens	157-160
33352257-6	2021	Further analysis indicated that a certain dosage of 3-MA and rapamycin decreased apoptosis and the caspase-3 expression, which suggested that As-induced autophagy regulated AML-12 cells apoptosis through the expressions of PI3K, mTOR, P62 and Bcl-2.	Sirolimus	61-70	caspase 3	Mus musculus	99-108
33352257-6	2021	Further analysis indicated that a certain dosage of 3-MA and rapamycin decreased apoptosis and the caspase-3 expression, which suggested that As-induced autophagy regulated AML-12 cells apoptosis through the expressions of PI3K, mTOR, P62 and Bcl-2.	Sirolimus	61-70	nucleoporin 62	Mus musculus	235-238
32945884-7	2021	This effect of protein restriction is mediated by the downregulation of the kinase activity of mammalian target of rapamycin complex 1; the latter suppresses PINK1 expression at the transcriptional level.	Sirolimus	115-124	PTEN induced kinase 1	Homo sapiens	158-163
33790644-10	2021	Notably, rapamycin increased the autophagy-related Beclin1 protein expression levels and the LC3 II/I ratio.	Sirolimus	9-18	beclin 1	Homo sapiens	51-58
33658088-2	2021	Mutations in the TSC1 or TSC2 genes have been reported to cause disruption in the TSC1-TSC2 intracellular protein complex, causing over-activation of the mammalian target of rapamycin protein complex.	Sirolimus	174-183	TSC complex subunit 2	Homo sapiens	25-29
33658088-2	2021	Mutations in the TSC1 or TSC2 genes have been reported to cause disruption in the TSC1-TSC2 intracellular protein complex, causing over-activation of the mammalian target of rapamycin protein complex.	Sirolimus	174-183	TSC complex subunit 2	Homo sapiens	87-91
33050984-6	2021	The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRalpha, CYP7A1, ABCG1, PPARgamma, ApoA1) in the liver.	Sirolimus	25-29	apolipoprotein A-I	Mus musculus	195-200
32342246-10	2021	The results of mechanism studies have shown that FTY720 notably repressed LPS-induced STAT1 activity, which was reactivated by rapamycin.	Sirolimus	127-136	signal transducer and activator of transcription 1	Homo sapiens	86-91
33423298-2	2021	Previous studies suggest a connection between the FA protein FANCD2 and the non-FA protein mechanistic target of rapamycin (mTOR).	Sirolimus	113-122	FA complementation group D2	Homo sapiens	61-67
33748286-6	2021	Furthermore, rapamycin reduced urinary protein-induced NGAL and KIM-1 secretion and cell growth inhibition, while chloroquine played the opposite effect, indicating that autophagy activation by ERK pathway was an adaptive response in the exposure to urinary proteins.	Sirolimus	13-22	lipocalin 2	Homo sapiens	55-59
33748286-6	2021	Furthermore, rapamycin reduced urinary protein-induced NGAL and KIM-1 secretion and cell growth inhibition, while chloroquine played the opposite effect, indicating that autophagy activation by ERK pathway was an adaptive response in the exposure to urinary proteins.	Sirolimus	13-22	hepatitis A virus cellular receptor 1	Homo sapiens	64-69
33632817-6	2021	Repopulation from zone 2 was driven by the insulin-like growth factor binding protein 2-mechanistic target of rapamycin-cyclin D1 (IGFBP2-mTOR-CCND1) axis.	Sirolimus	110-119	insulin-like growth factor binding protein 2	Mus musculus	43-87
33632817-6	2021	Repopulation from zone 2 was driven by the insulin-like growth factor binding protein 2-mechanistic target of rapamycin-cyclin D1 (IGFBP2-mTOR-CCND1) axis.	Sirolimus	110-119	cyclin D1	Mus musculus	120-129
33632817-6	2021	Repopulation from zone 2 was driven by the insulin-like growth factor binding protein 2-mechanistic target of rapamycin-cyclin D1 (IGFBP2-mTOR-CCND1) axis.	Sirolimus	110-119	insulin-like growth factor binding protein 2	Mus musculus	131-137
33632817-6	2021	Repopulation from zone 2 was driven by the insulin-like growth factor binding protein 2-mechanistic target of rapamycin-cyclin D1 (IGFBP2-mTOR-CCND1) axis.	Sirolimus	110-119	cyclin D1	Mus musculus	143-148
33482580-0	2021	Methionine controls insulin/mammalian target of rapamycin complex 1 activity by modulating tuberous sclerosis complex 2 stability.	Sirolimus	48-57	TSC complex subunit 2	Homo sapiens	91-119
33482580-2	2021	Mutations in the TSC2 gene and loss of TSC2 promote cell growth by the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	91-100	TSC complex subunit 2	Homo sapiens	17-21
33482580-2	2021	Mutations in the TSC2 gene and loss of TSC2 promote cell growth by the mammalian target of rapamycin complex 1 (mTORC1) activation.	Sirolimus	91-100	TSC complex subunit 2	Homo sapiens	39-43
33124043-9	2021	Our work suggests a universal role for MeJA-treatment of Arabidopsis in altering the DNA replication regulator CDC6, supporting conservation, across kingdoms, of cell cycle regulation, through the crosstalk between the target of rapamycin, mTOR, and JAs.	Sirolimus	229-238	cell division control 6	Arabidopsis thaliana	111-115
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	20-29	LDL receptor related protein 6	Homo sapiens	75-79
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	20-29	zinc finger E-box binding homeobox 1	Homo sapiens	103-107
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	31-35	LDL receptor related protein 6	Homo sapiens	75-79
33501755-9	2021	Autophagy revulsant rapamycin (RAPA) rescued the inhibitory effect of circ-LRP6 on LC3B, vimentin, and Zeb1.	Sirolimus	31-35	zinc finger E-box binding homeobox 1	Homo sapiens	103-107
33479328-0	2021	Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin.	Sirolimus	99-108	mechanistic target of rapamycin kinase	Rattus norvegicus	83-87
33479328-1	2021	Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells.	Sirolimus	44-53	mechanistic target of rapamycin kinase	Rattus norvegicus	28-32
33479328-6	2021	Treatment with rapamycin inhibited the diabetes-induced VEGF and GFAP increases.	Sirolimus	15-24	glial fibrillary acidic protein	Homo sapiens	65-69
33472493-8	2021	More importantly, in vivo treatment of zebrafish with rapamycin, an autophagy activator that inhibits MAPK/JNK and MTORC1 signaling, stimulated autophagy in the lens and relieved the defects in organelle degradation, resulting in the mitigation of cataracts in gja8b mutant zebrafish.	Sirolimus	54-63	origin recognition complex, subunit 1	Danio rerio	115-121
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Sirolimus	62-71	beclin 1	Homo sapiens	145-153
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Sirolimus	62-71	nucleoporin 62	Homo sapiens	196-199
33423318-6	2021	In macrophages in-vitro, budesonide and simvastatin inhibited rapamycin-induced autophagy as well as autophagic flux, with reduced expression of beclin-1 and LC3, but enhanced the accumulation of p62 and increased expression of IL-10, which itself further inhibited autophagy in macrophages.	Sirolimus	62-71	interleukin 10	Homo sapiens	228-233
33398801-1	2021	Tuberous sclerosis complex (TSC) is a dominant autosomal genetic disorder caused by loss-of-function mutations in TSC1 and TSC2, which lead to constitutive activation of the mammalian target of rapamycin C1 (mTORC1) with its decoupling from regulatory inputs.	Sirolimus	194-203	TSC complex subunit 2	Homo sapiens	123-127
33539025-5	2021	These include mechanisms that were conserved during evolution but have gained special features in multicellular eukaryotes, such as pathways regulated by eukaryotic translation initiation factor 2 (eIF-2)-alpha kinase (GCN2, also named general control nonderepressible 2 kinase), 5"-adenosine monophosphate (AMP)-activated protein kinase (AMPK) and target of rapamycin (TOR).The interplay between IDO-1 and above-mentioned pathway seems to be highly context dependent.	Sirolimus	359-368	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	219-223
33539025-5	2021	These include mechanisms that were conserved during evolution but have gained special features in multicellular eukaryotes, such as pathways regulated by eukaryotic translation initiation factor 2 (eIF-2)-alpha kinase (GCN2, also named general control nonderepressible 2 kinase), 5"-adenosine monophosphate (AMP)-activated protein kinase (AMPK) and target of rapamycin (TOR).The interplay between IDO-1 and above-mentioned pathway seems to be highly context dependent.	Sirolimus	359-368	eukaryotic translation initiation factor 2 alpha kinase 4	Homo sapiens	236-270
31541182-1	2021	Mechanistic target of rapamycin complex 1 (mTORC1) regulates CD8+ T-cell differentiation and function.	Sirolimus	22-31	CD8a molecule	Homo sapiens	61-64
33278711-14	2021	Rapamycin reduced both IL-12 and IL-10 secretions (p < 0.05).	Sirolimus	0-9	interleukin 10	Homo sapiens	33-38
32803763-8	2021	Finally, with mTOR inhibitor rapamycin, we confirmed that NEAT1 promoted glioma activity through mTOR signaling both in vitro and in vivo.	Sirolimus	29-38	nuclear paraspeckle assembly transcript 1	Homo sapiens	58-63
33099783-2	2021	A recent case report found that topical rapamycin (sirolimus) can improve FGFR3-induced epidermal nevi with AN features in children, specifically with Fitzpatrick skin type (FST) I/II, and we would like to expand these findings to skin plaques with extensive AN-like features in the FST IV/V adolescent population.	Sirolimus	40-49	fibroblast growth factor receptor 3	Homo sapiens	74-79
33099783-2	2021	A recent case report found that topical rapamycin (sirolimus) can improve FGFR3-induced epidermal nevi with AN features in children, specifically with Fitzpatrick skin type (FST) I/II, and we would like to expand these findings to skin plaques with extensive AN-like features in the FST IV/V adolescent population.	Sirolimus	51-60	fibroblast growth factor receptor 3	Homo sapiens	74-79
33099783-5	2021	Topical rapamycin should be considered as a treatment option for AN, particularly in FST IV/V adolescents with FGFR3-induced AN.	Sirolimus	8-17	fibroblast growth factor receptor 3	Homo sapiens	111-116
33214245-6	2021	Functional studies using CRISPR-Cas9 gene-edited cells demonstrated a key role for the TSC2/RHEB axis in regulating TGF-beta1-induced mechanistic target of rapamycin complex 1 activation and collagen I deposition in mesenchymal cells reflecting IPF and other disease settings, including cancer-associated fibroblasts.	Sirolimus	156-165	TSC complex subunit 2	Homo sapiens	87-91
33075479-8	2020	We observed that intracerebral-ventricular administration of the mTOR inhibitor rapamycin reduced immunoreactivity of phosphorylated S6, a downstream target of mTOR, in brain regions involved in fear extinction and eliminated the enhancement of fear extinction memory produced by acute exercise, without reducing voluntary exercise behavior or altering fear extinction in sedentary rats.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Rattus norvegicus	65-69
33075479-8	2020	We observed that intracerebral-ventricular administration of the mTOR inhibitor rapamycin reduced immunoreactivity of phosphorylated S6, a downstream target of mTOR, in brain regions involved in fear extinction and eliminated the enhancement of fear extinction memory produced by acute exercise, without reducing voluntary exercise behavior or altering fear extinction in sedentary rats.	Sirolimus	80-89	mechanistic target of rapamycin kinase	Rattus norvegicus	160-164